1 0 0 9746003 -DOCSTART- -X- -X- O

1 0 13 9746003 Inappropriate JJ B-NP O
2 14 17 9746003 use NN I-NP O
3 18 20 9746003 of IN B-PP O
4 21 34 9746003 carbamazepine NN B-NP B-Chemical
5 35 38 9746003 and CC I-NP O
6 39 49 9746003 vigabatrin NN I-NP B-Chemical
7 50 52 9746003 in IN B-PP O
8 53 60 9746003 typical JJ B-NP O
9 61 68 9746003 absence NN I-NP B-Disease
10 69 77 9746003 seizures NNS I-NP I-Disease
11 77 78 9746003 . . O O
12 79 92 9746003 Carbamazepine NN B-NP B-Chemical
13 93 96 9746003 and CC I-NP O
14 97 107 9746003 vigabatrin NN I-NP B-Chemical
15 108 111 9746003 are VBP B-VP O
16 112 127 9746003 contraindicated VBN I-VP O
17 128 130 9746003 in IN B-PP O
18 131 138 9746003 typical JJ B-NP O
19 139 146 9746003 absence NN I-NP B-Disease
20 147 155 9746003 seizures NNS I-NP I-Disease
21 155 156 9746003 . . O O

1 157 159 9746003 Of IN B-PP O
2 160 162 9746003 18 CD B-NP O
3 163 174 9746003 consecutive JJ I-NP O
4 175 184 9746003 referrals NNS I-NP O
5 185 187 9746003 of IN B-PP O
6 188 196 9746003 children NNS B-NP O
7 197 201 9746003 with IN B-PP O
8 202 211 9746003 resistant JJ B-NP O
9 212 219 9746003 typical JJ I-NP O
10 220 228 9746003 absences NNS I-NP O
11 229 233 9746003 only RB B-ADVP O
12 233 234 9746003 , , O O
13 235 240 9746003 eight CD B-NP O
14 241 245 9746003 were VBD B-VP O
15 246 257 9746003 erroneously RB I-VP O
16 258 265 9746003 treated VBN I-VP O
17 266 270 9746003 with IN B-PP O
18 271 284 9746003 carbamazepine NN B-NP B-Chemical
19 285 291 9746003 either CC B-PP O
20 292 294 9746003 as IN B-PP O
21 295 306 9746003 monotherapy NN B-NP O
22 307 309 9746003 or CC B-PP O
23 310 312 9746003 as IN B-PP O
24 313 315 9746003 an DT B-NP O
25 316 319 9746003 add NN I-NP O
26 319 320 9746003 - HYPH B-ADVP O
27 320 322 9746003 on RP I-ADVP O
28 322 323 9746003 . . O O

1 324 334 9746003 Vigabatrin NN B-NP B-Chemical
2 335 338 9746003 was VBD B-VP O
3 339 343 9746003 also RB I-VP O
4 344 348 9746003 used VBN I-VP O
5 349 351 9746003 in IN B-PP O
6 352 355 9746003 the DT B-NP O
7 356 365 9746003 treatment NN I-NP O
8 366 368 9746003 of IN B-PP O
9 369 372 9746003 two CD B-NP O
10 373 381 9746003 children NNS I-NP O
11 381 382 9746003 . . O O

1 383 392 9746003 Frequency NN B-NP O
2 393 395 9746003 of IN B-PP O
3 396 404 9746003 absences NNS B-NP O
4 405 414 9746003 increased VBD B-VP O
5 415 417 9746003 in IN B-PP O
6 418 422 9746003 four CD B-NP O
7 423 431 9746003 children NNS I-NP O
8 432 439 9746003 treated VBN B-VP O
9 440 444 9746003 with IN B-PP O
10 445 458 9746003 carbamazepine NN B-NP B-Chemical
11 459 462 9746003 and CC O O
12 463 466 9746003 two CD B-NP O
13 467 469 9746003 of IN B-PP O
14 470 475 9746003 these DT B-NP O
15 476 485 9746003 developed VBN I-NP O
16 486 495 9746003 myoclonic JJ I-NP B-Disease
17 496 501 9746003 jerks NNS I-NP I-Disease
18 501 502 9746003 , , O O
19 503 508 9746003 which WDT B-NP O
20 509 517 9746003 resolved VBD B-VP O
21 518 520 9746003 on IN B-PP O
22 521 531 9746003 withdrawal NN B-NP O
23 532 534 9746003 of IN B-PP O
24 535 548 9746003 carbamazepine NN B-NP B-Chemical
25 548 549 9746003 . . O O

1 550 558 9746003 Absences NNS B-NP O
2 559 563 9746003 were VBD B-VP O
3 564 574 9746003 aggravated VBN I-VP O
4 575 577 9746003 in IN B-PP O
5 578 582 9746003 both DT B-NP O
6 583 588 9746003 cases NNS I-NP O
7 589 594 9746003 where WRB B-ADVP O
8 595 605 9746003 vigabatrin NN B-NP B-Chemical
9 606 609 9746003 was VBD B-VP O
10 610 615 9746003 added VBN I-VP O
11 616 618 9746003 on RP B-PRT O
12 619 621 9746003 to TO B-PP O
13 622 632 9746003 concurrent JJ B-NP O
14 633 642 9746003 treatment NN I-NP O
15 642 643 9746003 . . O O

1 644 651 9746003 Optimal JJ B-NP O
2 652 659 9746003 control NN I-NP O
3 660 662 9746003 of IN B-PP O
4 663 666 9746003 the DT B-NP O
5 667 675 9746003 absences NNS I-NP O
6 676 679 9746003 was VBD B-VP O
7 680 688 9746003 achieved VBN I-VP O
8 689 693 9746003 with IN B-PP O
9 694 700 9746003 sodium NN B-NP B-Chemical
10 701 710 9746003 valproate NN I-NP I-Chemical
11 710 711 9746003 , , O O
12 712 723 9746003 lamotrigine NN B-NP B-Chemical
13 723 724 9746003 , , O O
14 725 727 9746003 or CC O O
15 728 740 9746003 ethosuximide NN B-NP B-Chemical
16 741 746 9746003 alone RB B-ADVP O
17 747 749 9746003 or CC O O
18 750 752 9746003 in IN B-PP O
19 753 764 9746003 combination NN B-NP O
20 764 765 9746003 . . O O

1 0 0 3719553 -DOCSTART- -X- -X- O

1 0 8 3719553 Allergic JJ B-NP B-Disease
2 9 17 3719553 reaction NN I-NP I-Disease
3 18 20 3719553 to TO B-PP O
4 21 22 3719553 5 CD B-NP B-Chemical
5 22 23 3719553 - HYPH I-NP I-Chemical
6 23 35 3719553 fluorouracil NN I-NP I-Chemical
7 36 44 3719553 infusion NN I-NP O
8 44 45 3719553 . . O O
9 46 48 3719553 An DT B-NP O
10 49 57 3719553 allergic JJ I-NP B-Disease
11 58 66 3719553 reaction NN I-NP I-Disease
12 67 77 3719553 consisting VBG B-VP O
13 78 80 3719553 of IN B-PP O
14 81 94 3719553 angioneurotic JJ B-NP B-Disease
15 95 100 3719553 edema NN I-NP I-Disease
16 101 110 3719553 secondary JJ B-ADJP O
17 111 113 3719553 to TO B-PP O
18 114 124 3719553 continuous JJ B-NP O
19 125 133 3719553 infusion NN I-NP O
20 134 135 3719553 5 CD I-NP B-Chemical
21 135 136 3719553 - HYPH I-NP I-Chemical
22 136 148 3719553 fluorouracil NN I-NP I-Chemical
23 149 157 3719553 occurred VBD B-VP O
24 158 160 3719553 in IN B-PP O
25 161 162 3719553 a DT B-NP O
26 163 170 3719553 patient NN I-NP O
27 171 175 3719553 with IN B-PP O
28 176 185 3719553 recurrent JJ B-NP O
29 186 195 3719553 carcinoma NN I-NP B-Disease
30 196 198 3719553 of IN B-PP I-Disease
31 199 202 3719553 the DT B-NP I-Disease
32 203 207 3719553 oral JJ I-NP I-Disease
33 208 214 3719553 cavity NN I-NP I-Disease
34 214 215 3719553 , , O O
35 216 225 3719553 cirrhosis NN B-NP B-Disease
36 225 226 3719553 , , O O
37 227 230 3719553 and CC O O
38 231 240 3719553 cisplatin NN B-NP B-Chemical
39 240 241 3719553 - HYPH O O
40 241 248 3719553 induced VBN B-NP O
41 249 257 3719553 impaired JJ I-NP B-Disease
42 258 263 3719553 renal JJ I-NP I-Disease
43 264 272 3719553 function NN I-NP I-Disease
44 272 273 3719553 . . O O

1 274 278 3719553 This DT B-NP O
2 279 287 3719553 reaction NN I-NP O
3 288 296 3719553 occurred VBD B-VP O
4 297 303 3719553 during IN B-PP O
5 304 307 3719553 the DT B-NP O
6 308 313 3719553 sixth JJ I-NP O
7 314 317 3719553 and CC I-NP O
8 318 325 3719553 seventh JJ I-NP O
9 326 333 3719553 courses NNS I-NP O
10 334 336 3719553 of IN B-PP O
11 337 347 3719553 infusional JJ B-NP O
12 348 360 3719553 chemotherapy NN I-NP O
13 360 361 3719553 . . O O

1 362 366 3719553 Oral JJ B-NP O
2 367 382 3719553 diphenhydramine NN I-NP B-Chemical
3 383 386 3719553 and CC I-NP O
4 387 397 3719553 prednisone NN I-NP B-Chemical
5 398 402 3719553 were VBD B-VP O
6 403 414 3719553 ineffective JJ B-ADJP O
7 415 417 3719553 in IN B-PP O
8 418 428 3719553 preventing VBG B-VP O
9 429 432 3719553 the DT B-NP O
10 433 443 3719553 recurrence NN I-NP O
11 444 446 3719553 of IN B-PP O
12 447 450 3719553 the DT B-NP O
13 451 459 3719553 allergic JJ I-NP B-Disease
14 460 468 3719553 reaction NN I-NP I-Disease
15 468 469 3719553 . . O O

1 470 484 3719553 Discontinuance NN B-NP O
2 485 487 3719553 of IN B-PP O
3 488 497 3719553 effective JJ B-NP O
4 498 510 3719553 chemotherapy NN I-NP O
5 511 513 3719553 in IN B-PP O
6 514 518 3719553 this DT B-NP O
7 519 526 3719553 patient NN I-NP O
8 527 533 3719553 during IN B-PP O
9 534 541 3719553 partial JJ B-NP O
10 542 551 3719553 remission NN I-NP O
11 552 560 3719553 resulted VBD B-VP O
12 561 563 3719553 in IN B-PP O
13 564 569 3719553 fatal JJ B-NP O
14 570 577 3719553 disease NN I-NP O
15 578 589 3719553 progression NN I-NP O
16 589 590 3719553 . . O O

1 0 0 9334596 -DOCSTART- -X- -X- O

1 0 9 9334596 Endocrine JJ B-NP O
2 10 19 9334596 screening NN I-NP O
3 20 22 9334596 in IN B-PP O
4 23 28 9334596 1,022 CD B-NP O
5 29 32 9334596 men NNS I-NP O
6 33 37 9334596 with IN B-PP O
7 38 46 9334596 erectile JJ B-NP B-Disease
8 47 58 9334596 dysfunction NN I-NP I-Disease
9 58 59 9334596 : : O O
10 60 68 9334596 clinical JJ B-NP O
11 69 81 9334596 significance NN I-NP O
12 82 85 9334596 and CC I-NP O
13 86 90 9334596 cost NN I-NP O
14 90 91 9334596 - HYPH B-NP O
15 91 100 9334596 effective JJ I-NP O
16 101 109 9334596 strategy NN I-NP O
17 109 110 9334596 . . I-NP O
18 111 118 9334596 PURPOSE NN I-NP O
19 118 119 9334596 : : O O
20 120 122 9334596 We PRP B-NP O
21 123 131 9334596 reviewed VBD B-VP O
22 132 135 9334596 the DT B-NP O
23 136 143 9334596 results NNS I-NP O
24 144 146 9334596 of IN B-PP O
25 147 152 9334596 serum NN B-NP O
26 153 165 9334596 testosterone NN I-NP B-Chemical
27 166 169 9334596 and CC O O
28 170 179 9334596 prolactin NN B-NP O
29 180 193 9334596 determination NN I-NP O
30 194 196 9334596 in IN B-PP O
31 197 202 9334596 1,022 CD B-NP O
32 203 211 9334596 patients NNS I-NP O
33 212 220 9334596 referred VBD B-VP O
34 221 228 9334596 because IN B-PP O
35 229 231 9334596 of IN I-PP O
36 232 240 9334596 erectile JJ B-NP B-Disease
37 241 252 9334596 dysfunction NN I-NP I-Disease
38 253 256 9334596 and CC O O
39 257 265 9334596 compared VBD B-VP O
40 266 269 9334596 the DT B-NP O
41 270 274 9334596 data NNS I-NP O
42 275 279 9334596 with IN B-PP O
43 280 287 9334596 history NN B-NP O
44 287 288 9334596 , , O O
45 289 296 9334596 results NNS B-NP O
46 297 299 9334596 of IN B-PP O
47 300 308 9334596 physical JJ B-NP O
48 309 320 9334596 examination NN I-NP O
49 320 321 9334596 , , O O
50 322 327 9334596 other JJ B-NP O
51 328 339 9334596 etiological JJ I-NP O
52 340 354 9334596 investigations NNS I-NP O
53 355 358 9334596 and CC I-NP O
54 359 366 9334596 effects NNS I-NP O
55 367 369 9334596 of IN B-PP O
56 370 379 9334596 endocrine JJ B-NP O
57 380 387 9334596 therapy NN I-NP O
58 388 390 9334596 to TO B-VP O
59 391 397 9334596 refine VB I-VP O
60 398 401 9334596 the DT B-NP O
61 402 407 9334596 rules NNS I-NP O
62 408 410 9334596 of IN B-PP O
63 411 415 9334596 cost NN B-NP O
64 415 416 9334596 - HYPH B-NP O
65 416 425 9334596 effective JJ I-NP O
66 426 435 9334596 endocrine JJ I-NP O
67 436 445 9334596 screening NN I-NP O
68 446 449 9334596 and CC O O
69 450 452 9334596 to TO B-VP O
70 453 461 9334596 pinpoint VB I-VP O
71 462 468 9334596 actual JJ B-NP O
72 469 483 9334596 responsibility NN I-NP O
73 484 487 9334596 for IN B-PP O
74 488 496 9334596 hormonal JJ B-NP O
75 497 510 9334596 abnormalities NNS I-NP O
76 510 511 9334596 . . O O

1 512 521 9334596 MATERIALS NNS B-NP O
2 522 525 9334596 AND CC I-NP O
3 526 533 9334596 METHODS NNS I-NP O
4 533 534 9334596 : : O O
5 535 547 9334596 Testosterone NN B-NP B-Chemical
6 548 551 9334596 and CC I-NP O
7 552 561 9334596 prolactin NN I-NP O
8 562 566 9334596 were VBD B-VP O
9 567 577 9334596 determined VBN I-VP O
10 578 580 9334596 by IN B-PP O
11 581 597 9334596 radioimmunoassay NN B-NP O
12 597 598 9334596 . . O O

1 599 604 9334596 Every DT B-NP O
2 605 612 9334596 patient NN I-NP O
3 613 616 9334596 was VBD B-VP O
4 617 625 9334596 screened VBN I-VP O
5 626 629 9334596 for IN B-PP O
6 630 642 9334596 testosterone NN B-NP B-Chemical
7 643 646 9334596 and CC O O
8 647 650 9334596 451 CD B-NP O
9 651 655 9334596 were VBD B-VP O
10 656 664 9334596 screened VBN I-VP O
11 665 668 9334596 for IN B-PP O
12 669 678 9334596 prolactin NN B-NP O
13 679 681 9334596 on IN B-PP O
14 682 685 9334596 the DT B-NP O
15 686 691 9334596 basis NN I-NP O
16 692 694 9334596 of IN B-PP O
17 695 698 9334596 low JJ B-NP B-Disease
18 699 705 9334596 sexual JJ I-NP I-Disease
19 706 712 9334596 desire NN I-NP I-Disease
20 712 713 9334596 , , O O
21 714 726 9334596 gynecomastia NN B-NP B-Disease
22 727 729 9334596 or CC O O
23 730 742 9334596 testosterone NN B-NP B-Chemical
24 743 747 9334596 less JJR B-NP O
25 748 752 9334596 than IN I-NP O
26 753 754 9334596 4 CD I-NP O
27 755 757 9334596 ng NN I-NP O
28 757 758 9334596 . . O O
29 758 759 9334596 / SYM B-NP O
30 759 761 9334596 ml NN I-NP O
31 761 762 9334596 . . O O

1 763 776 9334596 Determination NN B-NP O
2 777 780 9334596 was VBD B-VP O
3 781 789 9334596 repeated VBN I-VP O
4 790 792 9334596 in IN B-PP O
5 793 797 9334596 case NN B-NP O
6 798 800 9334596 of IN B-PP O
7 801 809 9334596 abnormal JJ B-NP O
8 810 815 9334596 first JJ I-NP O
9 816 823 9334596 results NNS I-NP O
10 823 824 9334596 . . O O

1 825 834 9334596 Prolactin NN B-NP O
2 835 842 9334596 results NNS I-NP O
3 843 847 9334596 were VBD B-VP O
4 848 856 9334596 compared VBN I-VP O
5 857 861 9334596 with IN B-PP O
6 862 867 9334596 those DT B-NP O
7 868 870 9334596 of IN B-PP O
8 871 872 9334596 a DT B-NP O
9 873 881 9334596 previous JJ I-NP O
10 882 890 9334596 personal JJ I-NP O
11 891 897 9334596 cohort NN I-NP O
12 898 900 9334596 of IN B-PP O
13 901 906 9334596 1,340 CD B-NP O
14 907 915 9334596 patients NNS I-NP O
15 916 920 9334596 with IN B-PP O
16 921 929 9334596 erectile JJ B-NP B-Disease
17 930 941 9334596 dysfunction NN I-NP I-Disease
18 942 945 9334596 and CC O O
19 946 956 9334596 systematic JJ B-NP O
20 957 966 9334596 prolactin NN I-NP O
21 967 980 9334596 determination NN I-NP O
22 980 981 9334596 . . O O

1 982 986 9334596 Main NNP B-NP O
2 987 995 9334596 clinical JJ I-NP O
3 996 1004 9334596 criteria NNS I-NP O
4 1005 1011 9334596 tested VBN B-VP O
5 1012 1021 9334596 regarding VBG B-PP O
6 1022 1032 9334596 efficiency NN B-NP O
7 1033 1035 9334596 in IN B-PP O
8 1036 1043 9334596 hormone NN B-NP O
9 1044 1057 9334596 determination NN I-NP O
10 1058 1062 9334596 were VBD B-VP O
11 1063 1066 9334596 low JJ B-NP B-Disease
12 1067 1073 9334596 sexual JJ I-NP I-Disease
13 1074 1080 9334596 desire NN I-NP I-Disease
14 1080 1081 9334596 , , O O
15 1082 1087 9334596 small JJ B-NP O
16 1088 1094 9334596 testes NNS I-NP O
17 1095 1098 9334596 and CC O O
18 1099 1111 9334596 gynecomastia NN B-NP B-Disease
19 1111 1112 9334596 . . O O

1 1113 1122 9334596 Endocrine JJ B-NP O
2 1123 1130 9334596 therapy NN I-NP O
3 1131 1140 9334596 consisted VBD B-VP O
4 1141 1143 9334596 of IN B-PP O
5 1144 1156 9334596 testosterone NN B-NP B-Chemical
6 1157 1166 9334596 heptylate NN I-NP I-Chemical
7 1167 1169 9334596 or CC O O
8 1170 1175 9334596 human JJ B-NP O
9 1176 1185 9334596 chorionic JJ I-NP O
10 1186 1198 9334596 gonadotropin NN I-NP O
11 1199 1202 9334596 for IN B-PP O
12 1203 1215 9334596 hypogonadism NN B-NP B-Disease
13 1216 1219 9334596 and CC I-NP O
14 1220 1233 9334596 bromocriptine NN I-NP B-Chemical
15 1234 1237 9334596 for IN B-PP O
16 1238 1256 9334596 hyperprolactinemia NN B-NP B-Disease
17 1256 1257 9334596 . . O O

1 1258 1265 9334596 RESULTS NNS B-NP O
2 1265 1266 9334596 : : O O
3 1267 1279 9334596 Testosterone NN B-NP B-Chemical
4 1280 1283 9334596 was VBD B-VP O
5 1284 1288 9334596 less JJR B-NP O
6 1289 1293 9334596 than IN I-NP O
7 1294 1295 9334596 3 CD I-NP O
8 1296 1298 9334596 ng NN I-NP O
9 1298 1299 9334596 . . O O
10 1299 1300 9334596 / SYM B-NP O
11 1300 1302 9334596 ml NN I-NP O
12 1302 1303 9334596 . . O O

1 1304 1306 9334596 in IN B-PP O
2 1307 1310 9334596 107 CD B-NP O
3 1311 1319 9334596 patients NNS I-NP O
4 1320 1323 9334596 but CC O O
5 1324 1330 9334596 normal JJ B-ADJP O
6 1331 1333 9334596 in IN B-PP O
7 1334 1337 9334596 40% NN B-NP O
8 1338 1340 9334596 at IN B-PP O
9 1341 1347 9334596 repeat NN B-NP O
10 1348 1361 9334596 determination NN I-NP O
11 1361 1362 9334596 . . O O

1 1363 1366 9334596 The DT B-NP O
2 1367 1377 9334596 prevalence NN I-NP O
3 1378 1380 9334596 of IN B-PP O
4 1381 1391 9334596 repeatedly RB B-NP O
5 1392 1395 9334596 low JJ I-NP O
6 1396 1408 9334596 testosterone NN I-NP B-Chemical
7 1409 1418 9334596 increased VBD B-VP O
8 1419 1423 9334596 with IN B-PP O
9 1424 1427 9334596 age NN B-NP O
10 1428 1429 9334596 ( ( O O
11 1429 1431 9334596 4% NN B-NP O
12 1432 1438 9334596 before IN B-PP O
13 1439 1442 9334596 age NN B-NP O
14 1443 1445 9334596 50 CD B-NP O
15 1446 1451 9334596 years NNS I-NP O
16 1452 1455 9334596 and CC O O
17 1456 1458 9334596 9% CD B-NP O
18 1459 1461 9334596 50 CD I-NP O
19 1462 1467 9334596 years NNS I-NP O
20 1468 1470 9334596 or CC O O
21 1471 1476 9334596 older JJR B-ADJP O
22 1476 1477 9334596 ) ) O O
23 1477 1478 9334596 . . O O

1 1479 1482 9334596 Two CD B-NP O
2 1483 1492 9334596 pituitary JJ I-NP B-Disease
3 1493 1499 9334596 tumors NNS I-NP I-Disease
4 1500 1504 9334596 were VBD B-VP O
5 1505 1515 9334596 discovered VBN I-VP O
6 1516 1521 9334596 after IN B-PP O
7 1522 1534 9334596 testosterone NN B-NP B-Chemical
8 1535 1548 9334596 determination NN I-NP O
9 1548 1549 9334596 . . O O

1 1550 1554 9334596 Most JJS B-NP O
2 1555 1557 9334596 of IN B-PP O
3 1558 1561 9334596 the DT B-NP O
4 1562 1567 9334596 other JJ I-NP O
5 1568 1571 9334596 low JJ I-NP O
6 1572 1584 9334596 testosterone NN I-NP B-Chemical
7 1585 1591 9334596 levels NNS I-NP O
8 1592 1598 9334596 seemed VBD B-VP O
9 1599 1601 9334596 to TO I-VP O
10 1602 1608 9334596 result VB I-VP O
11 1609 1613 9334596 from IN B-PP O
12 1614 1624 9334596 nonorganic JJ B-NP O
13 1625 1637 9334596 hypothalamic JJ I-NP B-Disease
14 1638 1649 9334596 dysfunction NN I-NP I-Disease
15 1650 1657 9334596 because IN B-PP O
16 1658 1660 9334596 of IN I-PP O
17 1661 1667 9334596 normal JJ B-NP O
18 1668 1673 9334596 serum NN I-NP O
19 1674 1685 9334596 luteinizing VBG B-VP O
20 1686 1693 9334596 hormone NN B-NP O
21 1694 1697 9334596 and CC I-NP O
22 1698 1707 9334596 prolactin NN I-NP O
23 1708 1711 9334596 and CC O O
24 1712 1714 9334596 to TO B-VP O
25 1715 1719 9334596 have VB I-VP O
26 1720 1724 9334596 only RB B-NP O
27 1725 1726 9334596 a DT I-NP O
28 1727 1732 9334596 small JJ I-NP O
29 1733 1737 9334596 role NN I-NP O
30 1738 1740 9334596 in IN B-PP O
31 1741 1749 9334596 erectile JJ B-NP B-Disease
32 1750 1761 9334596 dysfunction NN I-NP I-Disease
33 1762 1763 9334596 ( ( O O
34 1763 1771 9334596 definite JJ B-NP O
35 1772 1783 9334596 improvement NN I-NP O
36 1784 1786 9334596 in IN B-PP O
37 1787 1791 9334596 only RB B-NP O
38 1792 1794 9334596 16 CD I-NP O
39 1795 1797 9334596 of IN B-PP O
40 1798 1800 9334596 44 CD B-NP O
41 1801 1802 9334596 [ ( O O
42 1802 1805 9334596 36% NN B-NP O
43 1805 1806 9334596 ] ) O O
44 1807 1812 9334596 after IN B-PP O
45 1813 1821 9334596 androgen NN B-NP O
46 1822 1829 9334596 therapy NN I-NP O
47 1829 1830 9334596 , , O O
48 1831 1837 9334596 normal JJ B-NP O
49 1838 1845 9334596 morning NN I-NP O
50 1846 1848 9334596 or CC O O
51 1849 1858 9334596 nocturnal JJ B-NP O
52 1859 1868 9334596 erections NNS I-NP O
53 1869 1871 9334596 in IN B-PP O
54 1872 1875 9334596 30% CD B-NP O
55 1876 1879 9334596 and CC O O
56 1880 1888 9334596 definite JJ B-NP O
57 1889 1901 9334596 vasculogenic JJ I-NP O
58 1902 1915 9334596 contributions NNS I-NP O
59 1916 1918 9334596 in IN B-PP O
60 1919 1922 9334596 42% NN B-NP O
61 1922 1923 9334596 ) ) O O
62 1923 1924 9334596 . . O O

1 1925 1936 9334596 Determining VBG B-VP O
2 1937 1949 9334596 testosterone NN B-NP B-Chemical
3 1950 1954 9334596 only RB B-ADVP O
4 1955 1957 9334596 in IN B-PP O
5 1958 1963 9334596 cases NNS B-NP O
6 1964 1966 9334596 of IN B-PP O
7 1967 1970 9334596 low JJ B-NP B-Disease
8 1971 1977 9334596 sexual JJ I-NP I-Disease
9 1978 1984 9334596 desire NN I-NP I-Disease
10 1985 1987 9334596 or CC O O
11 1988 1996 9334596 abnormal JJ B-NP O
12 1997 2005 9334596 physical JJ I-NP O
13 2006 2017 9334596 examination NN I-NP O
14 2018 2023 9334596 would MD B-VP O
15 2024 2028 9334596 have VB I-VP O
16 2029 2035 9334596 missed VBN I-VP O
17 2036 2039 9334596 40% CD B-NP O
18 2040 2042 9334596 of IN B-PP O
19 2043 2046 9334596 the DT B-NP O
20 2047 2052 9334596 cases NNS I-NP O
21 2053 2057 9334596 with IN B-PP O
22 2058 2061 9334596 low JJ B-NP O
23 2062 2074 9334596 testosterone NN I-NP B-Chemical
24 2074 2075 9334596 , , O O
25 2076 2085 9334596 including VBG B-PP O
26 2086 2089 9334596 37% NN B-NP O
27 2090 2092 9334596 of IN B-PP O
28 2093 2098 9334596 those DT B-NP O
29 2099 2111 9334596 subsequently RB B-VP O
30 2112 2120 9334596 improved VBN I-VP O
31 2121 2123 9334596 by IN B-PP O
32 2124 2132 9334596 androgen NN B-NP O
33 2133 2140 9334596 therapy NN I-NP O
34 2140 2141 9334596 . . O O

1 2142 2151 9334596 Prolactin NN B-NP O
2 2152 2160 9334596 exceeded VBD B-VP O
3 2161 2163 9334596 20 CD B-NP O
4 2164 2166 9334596 ng NN I-NP O
5 2166 2167 9334596 . . O O
6 2167 2168 9334596 / SYM B-NP O
7 2168 2170 9334596 ml NN I-NP O
8 2170 2171 9334596 . . O O

1 2172 2174 9334596 in IN B-PP O
2 2175 2176 9334596 5 CD B-NP O
3 2177 2180 9334596 men NNS I-NP O
4 2181 2184 9334596 and CC O O
5 2185 2188 9334596 was VBD B-VP O
6 2189 2195 9334596 normal JJ B-ADJP O
7 2196 2198 9334596 in IN B-PP O
8 2199 2200 9334596 2 CD B-NP O
9 2201 2203 9334596 at IN B-PP O
10 2204 2210 9334596 repeat NN B-NP O
11 2211 2224 9334596 determination NN I-NP O
12 2224 2225 9334596 . . O O

1 2226 2230 9334596 Only RB B-NP O
2 2231 2232 9334596 1 CD I-NP O
3 2233 2245 9334596 prolactinoma NN I-NP B-Disease
4 2246 2249 9334596 was VBD B-VP O
5 2250 2260 9334596 discovered VBN I-VP O
6 2260 2261 9334596 . . O O

1 2262 2267 9334596 These DT B-NP O
2 2268 2272 9334596 data NNS I-NP O
3 2273 2276 9334596 are VBP B-VP O
4 2277 2282 9334596 lower JJR B-ADJP O
5 2283 2287 9334596 than IN B-PP O
6 2288 2293 9334596 those DT B-NP O
7 2294 2296 9334596 we PRP B-NP O
8 2297 2302 9334596 found VBD B-VP O
9 2303 2309 9334596 during IN B-PP O
10 2310 2313 9334596 the DT B-NP O
11 2314 2318 9334596 last JJ I-NP O
12 2319 2320 9334596 2 CD I-NP O
13 2321 2328 9334596 decades NNS I-NP O
14 2329 2330 9334596 ( ( O O
15 2330 2337 9334596 overall JJ B-NP O
16 2338 2347 9334596 prolactin NN I-NP O
17 2348 2355 9334596 greater JJR B-NP O
18 2356 2360 9334596 than IN I-NP O
19 2361 2363 9334596 20 CD I-NP O
20 2364 2366 9334596 ng NN I-NP O
21 2366 2367 9334596 . . O O
22 2367 2368 9334596 / SYM B-NP O
23 2368 2370 9334596 ml NN I-NP O
24 2370 2371 9334596 . . O O

1 2372 2374 9334596 in IN B-PP O
2 2375 2380 9334596 1.86% CD B-NP O
3 2381 2383 9334596 of IN B-PP O
4 2384 2389 9334596 1,821 CD B-NP O
5 2390 2398 9334596 patients NNS I-NP O
6 2398 2399 9334596 , , O O
7 2400 2413 9334596 prolactinomas NNS B-NP B-Disease
8 2414 2416 9334596 in IN B-PP O
9 2417 2418 9334596 7 CD B-NP O
10 2418 2419 9334596 , , I-NP O
11 2420 2425 9334596 0.38% CD I-NP O
12 2425 2426 9334596 ) ) O O
13 2426 2427 9334596 . . O O

1 2428 2441 9334596 Bromocriptine NN B-NP B-Chemical
2 2442 2445 9334596 was VBD B-VP O
3 2446 2456 9334596 definitely RB B-ADJP O
4 2457 2466 9334596 effective JJ I-ADJP O
5 2467 2469 9334596 in IN B-PP O
6 2470 2475 9334596 cases NNS B-NP O
7 2476 2480 9334596 with IN B-PP O
8 2481 2490 9334596 prolactin NN B-NP O
9 2491 2498 9334596 greater JJR B-ADJP O
10 2499 2503 9334596 than IN B-PP O
11 2504 2506 9334596 35 CD B-NP O
12 2507 2509 9334596 ng NN I-NP O
13 2509 2510 9334596 . . O O
14 2510 2511 9334596 / SYM B-NP O
15 2511 2513 9334596 ml NN I-NP O
16 2513 2514 9334596 . . O O

1 2515 2516 9334596 ( ( O O
2 2516 2517 9334596 8 CD B-NP O
3 2518 2520 9334596 of IN B-PP O
4 2521 2523 9334596 12 CD B-NP O
5 2524 2532 9334596 compared VBN B-VP O
6 2533 2535 9334596 to TO B-PP O
7 2536 2540 9334596 only RB B-NP O
8 2541 2542 9334596 9 CD I-NP O
9 2543 2545 9334596 of IN B-PP O
10 2546 2548 9334596 22 CD B-NP O
11 2549 2554 9334596 cases NNS I-NP O
12 2555 2559 9334596 with IN B-PP O
13 2560 2569 9334596 prolactin NN B-NP O
14 2570 2577 9334596 between IN B-PP O
15 2578 2580 9334596 20 CD B-NP O
16 2581 2584 9334596 and CC I-NP O
17 2585 2587 9334596 35 CD I-NP O
18 2588 2590 9334596 ng NN I-NP O
19 2590 2591 9334596 . . O O
20 2591 2592 9334596 / SYM B-NP O
21 2592 2594 9334596 ml NN I-NP O
22 2594 2595 9334596 . . O O
23 2595 2596 9334596 ) ) O O
24 2596 2597 9334596 . . O O

1 2598 2610 9334596 Testosterone NN B-NP B-Chemical
2 2611 2614 9334596 was VBD B-VP O
3 2615 2618 9334596 low JJ B-ADJP O
4 2619 2621 9334596 in IN B-PP O
5 2622 2626 9334596 less JJR B-NP O
6 2627 2631 9334596 than IN I-NP O
7 2632 2635 9334596 50% CD I-NP O
8 2636 2638 9334596 of IN B-PP O
9 2639 2644 9334596 cases NNS B-NP O
10 2645 2649 9334596 with IN B-PP O
11 2650 2659 9334596 prolactin NN B-NP O
12 2660 2667 9334596 greater JJR B-ADJP O
13 2668 2672 9334596 than IN B-PP O
14 2673 2675 9334596 35 CD B-NP O
15 2676 2678 9334596 ng NN I-NP O
16 2678 2679 9334596 . . O O
17 2679 2680 9334596 / SYM B-NP O
18 2680 2682 9334596 ml NN I-NP O
19 2682 2683 9334596 . . O O

1 2684 2695 9334596 CONCLUSIONS NNS B-NP O
2 2695 2696 9334596 : : O O
3 2697 2700 9334596 Low JJ B-NP O
4 2701 2712 9334596 prevalences NNS I-NP O
5 2713 2716 9334596 and CC I-NP O
6 2717 2724 9334596 effects NNS I-NP O
7 2725 2727 9334596 of IN B-PP O
8 2728 2731 9334596 low JJ B-NP O
9 2732 2744 9334596 testosterone NN I-NP B-Chemical
10 2745 2748 9334596 and CC O O
11 2749 2753 9334596 high JJ B-NP O
12 2754 2763 9334596 prolactin NN I-NP O
13 2764 2766 9334596 in IN B-PP O
14 2767 2775 9334596 erectile JJ B-NP B-Disease
15 2776 2787 9334596 dysfunction NN I-NP I-Disease
16 2788 2794 9334596 cannot MD B-VP O
17 2795 2802 9334596 justify VB I-VP O
18 2803 2808 9334596 their PRP$ B-NP O
19 2809 2816 9334596 routine JJ I-NP O
20 2817 2830 9334596 determination NN I-NP O
21 2830 2831 9334596 . . O O

1 2832 2839 9334596 However RB B-ADVP O
2 2839 2840 9334596 , , O O
3 2841 2845 9334596 cost NN B-NP O
4 2845 2846 9334596 - HYPH B-NP O
5 2846 2855 9334596 effective JJ I-NP O
6 2856 2865 9334596 screening NN I-NP O
7 2866 2876 9334596 strategies NNS I-NP O
8 2877 2888 9334596 recommended VBD B-VP O
9 2889 2891 9334596 so RB B-ADVP O
10 2892 2895 9334596 far RB I-ADVP O
11 2896 2902 9334596 missed VBN B-VP O
12 2903 2905 9334596 40 CD B-NP O
13 2906 2908 9334596 to TO B-PP O
14 2909 2912 9334596 50% CD B-NP O
15 2913 2915 9334596 of IN B-PP O
16 2916 2921 9334596 cases NNS B-NP O
17 2922 2930 9334596 improved VBN B-VP O
18 2931 2935 9334596 with IN B-PP O
19 2936 2945 9334596 endocrine JJ B-NP O
20 2946 2953 9334596 therapy NN I-NP O
21 2954 2957 9334596 and CC O O
22 2958 2961 9334596 the DT B-NP O
23 2962 2971 9334596 pituitary JJ I-NP B-Disease
24 2972 2978 9334596 tumors NNS I-NP I-Disease
25 2978 2979 9334596 . . O O

1 2980 2982 9334596 We PRP B-NP O
2 2983 2986 9334596 now RB B-ADVP O
3 2987 2995 9334596 advocate VBP B-VP O
4 2996 3000 9334596 that IN B-SBAR O
5 3001 3007 9334596 before IN B-PP O
6 3008 3011 9334596 age NN B-NP O
7 3012 3014 9334596 50 CD B-NP O
8 3015 3020 9334596 years NNS I-NP O
9 3021 3033 9334596 testosterone NN I-NP B-Chemical
10 3034 3036 9334596 be VB B-VP O
11 3037 3047 9334596 determined VBN I-VP O
12 3048 3052 9334596 only RB B-ADVP O
13 3053 3055 9334596 in IN B-PP O
14 3056 3061 9334596 cases NNS B-NP O
15 3062 3064 9334596 of IN B-PP O
16 3065 3068 9334596 low JJ B-NP B-Disease
17 3069 3075 9334596 sexual JJ I-NP I-Disease
18 3076 3082 9334596 desire NN I-NP I-Disease
19 3083 3086 9334596 and CC O O
20 3087 3095 9334596 abnormal JJ B-NP O
21 3096 3104 9334596 physical JJ I-NP O
22 3105 3116 9334596 examination NN I-NP O
23 3117 3120 9334596 but CC O O
24 3121 3125 9334596 that IN B-SBAR O
25 3126 3128 9334596 it PRP B-NP O
26 3129 3131 9334596 be VB B-VP O
27 3132 3140 9334596 measured VBN I-VP O
28 3141 3143 9334596 in IN B-PP O
29 3144 3147 9334596 all DT B-NP O
30 3148 3151 9334596 men NNS I-NP O
31 3152 3157 9334596 older JJR B-ADJP O
32 3158 3162 9334596 than IN B-PP O
33 3163 3165 9334596 50 CD B-NP O
34 3166 3171 9334596 years NNS I-NP O
35 3171 3172 9334596 . . O O

1 3173 3182 9334596 Prolactin NN B-NP O
2 3183 3189 9334596 should MD B-VP O
3 3190 3192 9334596 be VB I-VP O
4 3193 3203 9334596 determined VBN I-VP O
5 3204 3208 9334596 only RB B-ADVP O
6 3209 3211 9334596 in IN B-PP O
7 3212 3217 9334596 cases NNS B-NP O
8 3218 3220 9334596 of IN B-PP O
9 3221 3224 9334596 low JJ B-NP B-Disease
10 3225 3231 9334596 sexual JJ I-NP I-Disease
11 3232 3238 9334596 desire NN I-NP I-Disease
12 3238 3239 9334596 , , O O
13 3240 3252 9334596 gynecomastia NN B-NP B-Disease
14 3253 3256 9334596 and CC O O
15 3256 3257 9334596 / SYM B-NP O
16 3257 3259 9334596 or CC O O
17 3260 3272 9334596 testosterone NN B-NP B-Chemical
18 3273 3277 9334596 less JJR B-NP O
19 3278 3282 9334596 than IN I-NP O
20 3283 3284 9334596 4 CD I-NP O
21 3285 3287 9334596 ng NN I-NP O
22 3287 3288 9334596 . . O O
23 3288 3289 9334596 / SYM B-NP O
24 3289 3291 9334596 ml NN I-NP O
25 3291 3292 9334596 . . O O

1 0 0 9406968 -DOCSTART- -X- -X- O

1 0 12 9406968 Upregulation NN B-NP O
2 13 15 9406968 of IN B-PP O
3 16 19 9406968 the DT B-NP O
4 20 30 9406968 expression NN I-NP O
5 31 33 9406968 of IN B-PP O
6 34 45 9406968 vasopressin NN B-NP B-Chemical
7 46 50 9406968 gene NN I-NP O
8 51 53 9406968 in IN B-PP O
9 54 57 9406968 the DT B-NP O
10 58 73 9406968 paraventricular JJ I-NP O
11 74 77 9406968 and CC I-NP O
12 78 88 9406968 supraoptic JJ I-NP O
13 89 95 9406968 nuclei NNS I-NP O
14 96 98 9406968 of IN B-PP O
15 99 102 9406968 the DT B-NP O
16 103 110 9406968 lithium NN I-NP B-Chemical
17 110 111 9406968 - HYPH B-NP O
18 111 118 9406968 induced VBN I-NP O
19 119 127 9406968 diabetes NN I-NP B-Disease
20 128 137 9406968 insipidus NN I-NP I-Disease
21 138 141 9406968 rat NN I-NP O
22 141 142 9406968 . . O O
23 143 146 9406968 The DT B-NP O
24 147 157 9406968 expression NN I-NP O
25 158 160 9406968 of IN B-PP O
26 161 169 9406968 arginine NN B-NP B-Chemical
27 170 181 9406968 vasopressin NN I-NP I-Chemical
28 182 183 9406968 ( ( O O
29 183 186 9406968 AVP NN B-NP B-Chemical
30 186 187 9406968 ) ) O O
31 188 192 9406968 gene NN B-NP O
32 193 195 9406968 in IN B-PP O
33 196 199 9406968 the DT B-NP O
34 200 215 9406968 paraventricular JJ I-NP O
35 216 217 9406968 ( ( O O
36 217 220 9406968 PVN NN B-NP O
37 220 221 9406968 ) ) O O
38 222 225 9406968 and CC O O
39 226 236 9406968 supraoptic JJ B-NP O
40 237 243 9406968 nuclei NNS I-NP O
41 244 245 9406968 ( ( O O
42 245 248 9406968 SON NN B-NP O
43 248 249 9406968 ) ) O O
44 250 253 9406968 was VBD B-VP O
45 254 266 9406968 investigated VBN I-VP O
46 267 269 9406968 in IN B-PP O
47 270 274 9406968 rats NNS B-NP O
48 275 279 9406968 with IN B-PP O
49 280 287 9406968 lithium NN B-NP B-Chemical
50 288 289 9406968 ( ( O O
51 289 291 9406968 Li NN B-NP B-Chemical
52 291 292 9406968 ) ) O O
53 292 293 9406968 - HYPH B-NP O
54 293 300 9406968 induced VBN I-NP O
55 301 309 9406968 polyuria NN I-NP B-Disease
56 309 310 9406968 , , O O
57 311 316 9406968 using VBG B-VP O
58 317 319 9406968 in FW B-NP O
59 320 324 9406968 situ FW I-NP O
60 325 338 9406968 hybridization NN I-NP O
61 339 353 9406968 histochemistry NN I-NP O
62 354 357 9406968 and CC I-NP O
63 358 374 9406968 radioimmunoassay NN I-NP O
64 374 375 9406968 . . O O

1 376 379 9406968 The DT B-NP O
2 380 384 9406968 male JJ I-NP O
3 385 391 9406968 Wistar NNP I-NP O
4 392 396 9406968 rats NNS I-NP O
5 397 406 9406968 consuming VBG B-VP O
6 407 408 9406968 a DT B-NP O
7 409 413 9406968 diet NN I-NP O
8 414 418 9406968 that WDT B-NP O
9 419 428 9406968 contained VBD B-VP O
10 429 433 9406968 LiCl NN B-NP B-Chemical
11 434 435 9406968 ( ( O O
12 435 437 9406968 60 CD B-NP O
13 438 442 9406968 mmol NN I-NP O
14 442 443 9406968 / SYM B-NP O
15 443 445 9406968 kg NN I-NP O
16 445 446 9406968 ) ) O O
17 447 450 9406968 for IN B-PP O
18 451 452 9406968 4 CD B-NP O
19 453 458 9406968 weeks NNS I-NP O
20 459 468 9406968 developed VBD B-VP O
21 469 475 9406968 marked JJ B-NP O
22 476 484 9406968 polyuria NN I-NP B-Disease
23 484 485 9406968 . . O O

1 486 489 9406968 The DT B-NP O
2 490 492 9406968 Li NNP I-NP B-Chemical
3 492 493 9406968 - HYPH I-NP O
4 493 500 9406968 treated VBN I-NP O
5 501 505 9406968 rats NNS I-NP O
6 506 514 9406968 produced VBD B-VP O
7 515 516 9406968 a DT B-NP O
8 517 522 9406968 large JJ I-NP O
9 523 529 9406968 volume NN I-NP O
10 530 532 9406968 of IN B-PP O
11 533 542 9406968 hypotonic JJ B-NP O
12 543 548 9406968 urine NN I-NP O
13 549 553 9406968 with IN B-PP O
14 554 557 9406968 low JJ B-NP O
15 558 563 9406968 ionic JJ I-NP O
16 564 578 9406968 concentrations NNS I-NP O
17 578 579 9406968 . . O O

1 580 586 9406968 Plasma NN B-NP O
2 587 593 9406968 sodium NN I-NP B-Chemical
3 594 608 9406968 concentrations NNS I-NP O
4 609 613 9406968 were VBD B-VP O
5 614 619 9406968 found VBN I-VP O
6 620 622 9406968 to TO I-VP O
7 623 625 9406968 be VB I-VP O
8 626 634 9406968 slightly RB I-VP O
9 635 644 9406968 increased VBN I-VP O
10 645 647 9406968 in IN B-PP O
11 648 651 9406968 the DT B-NP O
12 652 654 9406968 Li NNP I-NP B-Chemical
13 654 655 9406968 - HYPH I-NP O
14 655 662 9406968 treated VBN I-NP O
15 663 667 9406968 rats NNS I-NP O
16 668 676 9406968 compared VBN B-PP O
17 677 681 9406968 with IN B-PP O
18 682 687 9406968 those DT B-NP O
19 688 690 9406968 in IN B-PP O
20 691 699 9406968 controls NNS B-NP O
21 699 700 9406968 . . O O

1 701 707 9406968 Plasma NN B-NP O
2 708 721 9406968 concentration NN I-NP O
3 722 724 9406968 of IN B-PP O
4 725 728 9406968 AVP NN B-NP B-Chemical
5 729 732 9406968 and CC I-NP O
6 733 744 9406968 transcripts NNS I-NP O
7 745 747 9406968 of IN B-PP O
8 748 751 9406968 AVP NN B-NP B-Chemical
9 752 756 9406968 gene NN I-NP O
10 757 759 9406968 in IN B-PP O
11 760 763 9406968 the DT B-NP O
12 764 767 9406968 PVN NN I-NP O
13 768 771 9406968 and CC I-NP O
14 772 775 9406968 SON NN I-NP O
15 776 780 9406968 were VBD B-VP O
16 781 794 9406968 significantly RB I-VP O
17 795 804 9406968 increased VBN I-VP O
18 805 807 9406968 in IN B-PP O
19 808 811 9406968 the DT B-NP O
20 812 814 9406968 Li NNP I-NP B-Chemical
21 814 815 9406968 - HYPH I-NP O
22 815 822 9406968 treated VBN I-NP O
23 823 827 9406968 rats NNS I-NP O
24 828 836 9406968 compared VBN B-PP O
25 837 841 9406968 with IN B-PP O
26 842 850 9406968 controls NNS B-NP O
27 850 851 9406968 . . O O

1 852 857 9406968 These DT B-NP O
2 858 865 9406968 results NNS I-NP O
3 866 873 9406968 suggest VBP B-VP O
4 874 878 9406968 that IN B-SBAR O
5 879 890 9406968 dehydration NN B-NP B-Disease
6 891 894 9406968 and CC O O
7 894 895 9406968 / SYM B-NP O
8 895 897 9406968 or CC O O
9 898 901 9406968 the DT B-NP O
10 902 912 9406968 activation NN I-NP O
11 913 915 9406968 of IN B-PP O
12 916 924 9406968 visceral JJ B-NP O
13 925 933 9406968 afferent JJ I-NP O
14 934 940 9406968 inputs NNS I-NP O
15 941 944 9406968 may MD B-VP O
16 945 955 9406968 contribute VB I-VP O
17 956 958 9406968 to TO B-PP O
18 959 962 9406968 the DT B-NP O
19 963 972 9406968 elevation NN I-NP O
20 973 975 9406968 of IN B-PP O
21 976 982 9406968 plasma NN B-NP O
22 983 986 9406968 AVP NN I-NP B-Chemical
23 987 990 9406968 and CC O O
24 991 994 9406968 the DT B-NP O
25 995 1007 9406968 upregulation NN I-NP O
26 1008 1010 9406968 of IN B-PP O
27 1011 1014 9406968 AVP NN B-NP B-Chemical
28 1015 1019 9406968 gene NN I-NP O
29 1020 1030 9406968 expression NN I-NP O
30 1031 1033 9406968 in IN B-PP O
31 1034 1037 9406968 the DT B-NP O
32 1038 1041 9406968 PVN NN I-NP O
33 1042 1045 9406968 and CC O O
34 1046 1049 9406968 the DT B-NP O
35 1050 1053 9406968 SON NN I-NP O
36 1054 1056 9406968 of IN B-PP O
37 1057 1060 9406968 the DT B-NP O
38 1061 1063 9406968 Li NNP I-NP B-Chemical
39 1063 1064 9406968 - HYPH B-NP O
40 1064 1071 9406968 induced VBN I-NP O
41 1072 1080 9406968 diabetes NN I-NP B-Disease
42 1081 1090 9406968 insipidus NN I-NP I-Disease
43 1091 1094 9406968 rat NN I-NP O
44 1094 1095 9406968 . . O O

1 0 0 354896 -DOCSTART- -X- -X- O

1 0 9 354896 Lidocaine NN B-NP B-Chemical
2 9 10 354896 - HYPH O O
3 10 17 354896 induced VBN B-NP O
4 18 25 354896 cardiac JJ I-NP B-Disease
5 26 34 354896 asystole NN I-NP I-Disease
6 34 35 354896 . . O O
7 36 47 354896 Intravenous JJ B-NP O
8 48 62 354896 administration NN I-NP O
9 63 65 354896 of IN B-PP O
10 66 67 354896 a DT B-NP O
11 68 74 354896 single JJ I-NP O
12 75 77 354896 50 CD I-NP O
13 77 78 354896 - HYPH I-NP O
14 78 80 354896 mg NN I-NP O
15 81 86 354896 bolus NN I-NP O
16 87 89 354896 of IN B-PP O
17 90 99 354896 lidocaine NN B-NP B-Chemical
18 100 102 354896 in IN B-PP O
19 103 104 354896 a DT B-NP O
20 105 107 354896 67 CD I-NP O
21 107 108 354896 - HYPH I-NP O
22 108 112 354896 year NN I-NP O
23 112 113 354896 - HYPH O O
24 113 116 354896 old JJ B-NP O
25 117 120 354896 man NN I-NP O
26 121 129 354896 resulted VBD B-VP O
27 130 132 354896 in IN B-PP O
28 133 141 354896 profound JJ B-NP O
29 142 152 354896 depression NN I-NP B-Disease
30 153 155 354896 of IN B-PP O
31 156 159 354896 the DT B-NP O
32 160 168 354896 activity NN I-NP O
33 169 171 354896 of IN B-PP O
34 172 175 354896 the DT B-NP O
35 176 186 354896 sinoatrial JJ I-NP O
36 187 190 354896 and CC I-NP O
37 191 207 354896 atrioventricular JJ I-NP O
38 208 213 354896 nodal JJ I-NP O
39 214 224 354896 pacemakers NNS I-NP O
40 224 225 354896 . . O O

1 226 229 354896 The DT B-NP O
2 230 237 354896 patient NN I-NP O
3 238 241 354896 had VBD B-VP O
4 242 244 354896 no DT B-NP O
5 245 253 354896 apparent JJ I-NP O
6 254 264 354896 associated VBN I-NP O
7 265 275 354896 conditions NNS I-NP O
8 276 281 354896 which WDT B-NP O
9 282 287 354896 might MD B-VP O
10 288 292 354896 have VB I-VP O
11 293 304 354896 predisposed VBN I-VP O
12 305 308 354896 him PRP B-NP O
13 309 311 354896 to TO B-PP O
14 312 315 354896 the DT B-NP O
15 316 327 354896 development NN I-NP O
16 328 330 354896 of IN B-PP O
17 331 347 354896 bradyarrhythmias NNS B-NP B-Disease
18 347 348 354896 ; : O O
19 349 352 354896 and CC O O
20 352 353 354896 , , O O
21 354 358 354896 thus RB B-ADVP O
22 358 359 354896 , , O O
23 360 364 354896 this DT B-NP O
24 365 373 354896 probably RB I-NP O
25 374 385 354896 represented VBN I-NP O
26 386 387 354896 a DT B-NP O
27 388 392 354896 true JJ I-NP O
28 393 405 354896 idiosyncrasy NN I-NP O
29 406 408 354896 to TO B-PP O
30 409 418 354896 lidocaine NN B-NP B-Chemical
31 418 419 354896 . . O O

1 0 0 6634932 -DOCSTART- -X- -X- O

1 0 10 6634932 Sublingual JJ B-NP O
2 11 21 6634932 absorption NN I-NP O
3 22 24 6634932 of IN B-PP O
4 25 28 6634932 the DT B-NP O
5 29 39 6634932 quaternary JJ I-NP B-Chemical
6 40 48 6634932 ammonium NN I-NP I-Chemical
7 49 63 6634932 antiarrhythmic JJ I-NP O
8 64 69 6634932 agent NN I-NP O
9 69 70 6634932 , , O O
10 71 73 6634932 UM NN B-NP B-Chemical
11 73 74 6634932 - HYPH B-NP I-Chemical
12 74 77 6634932 272 CD I-NP I-Chemical
13 77 78 6634932 . . I-NP O
14 79 81 6634932 UM NNP I-NP B-Chemical
15 81 82 6634932 - HYPH B-NP I-Chemical
16 82 85 6634932 272 CD I-NP I-Chemical
17 86 87 6634932 ( ( O O
18 87 90 6634932 N,N NN B-NP B-Chemical
19 90 91 6634932 - HYPH B-NP I-Chemical
20 91 110 6634932 dimethylpropranolol NN I-NP I-Chemical
21 110 111 6634932 ) ) O O
22 111 112 6634932 , , O O
23 113 114 6634932 a DT B-NP O
24 115 125 6634932 quaternary JJ I-NP O
25 126 140 6634932 antiarrhythmic JJ I-NP O
26 141 146 6634932 agent NN I-NP O
27 146 147 6634932 , , O O
28 148 151 6634932 was VBD B-VP O
29 152 164 6634932 administered VBN I-VP O
30 165 177 6634932 sublingually RB B-ADVP O
31 178 180 6634932 to TO B-PP O
32 181 185 6634932 dogs NNS B-NP O
33 186 190 6634932 with IN B-PP O
34 191 198 6634932 ouabain NN B-NP B-Chemical
35 198 199 6634932 - HYPH B-NP O
36 199 206 6634932 induced VBN I-NP O
37 207 218 6634932 ventricular JJ I-NP B-Disease
38 219 231 6634932 tachycardias NNS I-NP I-Disease
39 231 232 6634932 . . O O

1 233 237 6634932 Both CC O O
2 238 242 6634932 anti AFX O O
3 242 243 6634932 - HYPH B-NP O
4 243 253 6634932 arrhythmic JJ I-NP O
5 254 262 6634932 efficacy NN I-NP O
6 263 266 6634932 and CC I-NP O
7 267 282 6634932 bioavailability NN I-NP O
8 283 287 6634932 were VBD B-VP O
9 288 296 6634932 compared VBN I-VP O
10 297 299 6634932 to TO B-PP O
11 300 304 6634932 oral JJ B-NP O
12 305 309 6634932 drug NN I-NP O
13 309 310 6634932 . . O O

1 311 321 6634932 Sublingual JJ B-NP O
2 322 324 6634932 UM NN I-NP B-Chemical
3 324 325 6634932 - HYPH B-NP I-Chemical
4 325 328 6634932 272 CD I-NP I-Chemical
5 329 338 6634932 converted VBD B-VP O
6 339 350 6634932 ventricular JJ B-NP B-Disease
7 351 362 6634932 tachycardia NN I-NP I-Disease
8 363 365 6634932 to TO B-PP O
9 366 371 6634932 sinus NN B-NP O
10 372 378 6634932 rhythm NN I-NP O
11 379 381 6634932 in IN B-PP O
12 382 385 6634932 all DT B-NP O
13 386 387 6634932 5 CD I-NP O
14 388 392 6634932 dogs NNS I-NP O
15 392 393 6634932 . . O O

1 394 397 6634932 The DT B-NP O
2 398 402 6634932 area NN I-NP O
3 403 408 6634932 under IN B-PP O
4 409 412 6634932 the DT B-NP O
5 413 419 6634932 plasma NN I-NP O
6 420 433 6634932 concentration NN I-NP O
7 434 438 6634932 time NN I-NP O
8 439 444 6634932 curve NN I-NP O
9 445 447 6634932 at IN B-PP O
10 448 450 6634932 90 CD B-NP O
11 451 454 6634932 min NN I-NP O
12 455 458 6634932 was VBD B-VP O
13 459 460 6634932 4 CD B-NP O
14 460 461 6634932 - HYPH B-ADJP O
15 461 463 6634932 12 CD I-ADJP O
16 464 469 6634932 times NNS I-ADJP O
17 470 477 6634932 greater JJR I-ADJP O
18 478 482 6634932 than IN B-PP O
19 483 486 6634932 for IN B-PP O
20 487 491 6634932 oral JJ B-NP O
21 492 496 6634932 drug NN I-NP O
22 496 497 6634932 , , O O
23 498 508 6634932 suggesting VBG B-VP O
24 509 512 6634932 the DT B-NP O
25 513 522 6634932 existence NN I-NP O
26 523 525 6634932 of IN B-PP O
27 526 528 6634932 an DT B-NP O
28 529 539 6634932 absorption NN I-NP O
29 539 540 6634932 - HYPH O O
30 540 548 6634932 limiting VBG B-VP O
31 549 556 6634932 process NN B-NP O
32 557 559 6634932 in IN B-PP O
33 560 563 6634932 the DT B-NP O
34 564 573 6634932 intestine NN I-NP O
35 573 574 6634932 , , O O
36 575 578 6634932 and CC O O
37 579 588 6634932 providing VBG B-VP O
38 589 591 6634932 an DT B-NP O
39 592 601 6634932 alternate JJ I-NP O
40 602 606 6634932 form NN I-NP O
41 607 609 6634932 of IN B-PP O
42 610 624 6634932 administration NN B-NP O
43 625 628 6634932 for IN B-PP O
44 629 639 6634932 quaternary JJ B-NP O
45 640 645 6634932 drugs NNS I-NP O
46 645 646 6634932 . . O O

1 0 0 1468485 -DOCSTART- -X- -X- O

1 0 10 1468485 Hyperbaric JJ B-NP O
2 11 17 1468485 oxygen NN I-NP B-Chemical
3 18 25 1468485 therapy NN I-NP O
4 26 29 1468485 for IN B-PP O
5 30 37 1468485 control NN B-NP O
6 38 40 1468485 of IN B-PP O
7 41 52 1468485 intractable JJ B-NP O
8 53 69 1468485 cyclophosphamide NN I-NP B-Chemical
9 69 70 1468485 - HYPH O O
10 70 77 1468485 induced VBN B-NP O
11 78 89 1468485 hemorrhagic JJ I-NP B-Disease
12 90 98 1468485 cystitis NN I-NP I-Disease
13 98 99 1468485 . . O O
14 100 102 1468485 We PRP B-NP O
15 103 109 1468485 report VBP B-VP O
16 110 111 1468485 a DT B-NP O
17 112 116 1468485 case NN I-NP O
18 117 119 1468485 of IN B-PP O
19 120 131 1468485 intractable JJ B-NP O
20 132 143 1468485 hemorrhagic JJ I-NP B-Disease
21 144 152 1468485 cystitis NN I-NP I-Disease
22 153 156 1468485 due JJ B-ADJP O
23 157 159 1468485 to TO B-PP O
24 160 176 1468485 cyclophosphamide NN B-NP B-Chemical
25 177 184 1468485 therapy NN I-NP O
26 185 188 1468485 for IN B-PP O
27 189 198 1468485 Wegener's NNS B-NP B-Disease
28 199 213 1468485 granulomatosis NN I-NP I-Disease
29 213 214 1468485 . . O O

1 215 227 1468485 Conservative JJ B-NP O
2 228 237 1468485 treatment NN I-NP O
3 237 238 1468485 , , O O
4 239 248 1468485 including VBG B-PP O
5 249 256 1468485 bladder NN B-NP O
6 257 267 1468485 irrigation NN I-NP O
7 268 272 1468485 with IN B-PP O
8 273 286 1468485 physiological JJ B-NP O
9 287 293 1468485 saline NN I-NP O
10 294 297 1468485 and CC I-NP O
11 298 310 1468485 instillation NN I-NP O
12 311 313 1468485 of IN B-PP O
13 314 327 1468485 prostaglandin NN B-NP B-Chemical
14 328 330 1468485 F2 NN I-NP I-Chemical
15 331 336 1468485 alpha NN I-NP I-Chemical
16 336 337 1468485 , , O O
17 338 344 1468485 failed VBD B-VP O
18 345 347 1468485 to TO I-VP O
19 348 355 1468485 totally RB I-VP O
20 356 363 1468485 control VB I-VP O
21 364 374 1468485 hemorrhage NN B-NP B-Disease
22 374 375 1468485 . . O O

1 376 378 1468485 We PRP B-NP O
2 379 383 1468485 then RB B-ADVP O
3 384 388 1468485 used VBD B-VP O
4 389 399 1468485 hyperbaric JJ B-NP O
5 400 406 1468485 oxygen NN I-NP B-Chemical
6 407 409 1468485 at IN B-PP O
7 410 412 1468485 an DT B-NP O
8 413 421 1468485 absolute JJ I-NP O
9 422 430 1468485 pressure NN I-NP O
10 431 433 1468485 of IN B-PP O
11 434 435 1468485 2 CD B-NP O
12 436 439 1468485 atm NN I-NP O
13 439 440 1468485 , , O O
14 441 442 1468485 5 CD B-NP O
15 443 447 1468485 days NNS I-NP O
16 448 449 1468485 a DT B-NP O
17 450 454 1468485 week NN I-NP O
18 455 458 1468485 for IN B-PP O
19 459 460 1468485 8 CD B-NP O
20 461 472 1468485 consecutive JJ I-NP O
21 473 478 1468485 weeks NNS I-NP O
22 478 479 1468485 . . O O

1 480 483 1468485 The DT B-NP O
2 484 492 1468485 bleeding VBG I-NP B-Disease
3 493 499 1468485 ceased VBN B-VP O
4 500 510 1468485 completely RB B-ADVP O
5 511 513 1468485 by IN B-PP O
6 514 517 1468485 the DT B-NP O
7 518 521 1468485 end NN I-NP O
8 522 524 1468485 of IN B-PP O
9 525 534 1468485 treatment NN B-NP O
10 535 538 1468485 and CC O O
11 539 542 1468485 the DT B-NP O
12 543 550 1468485 patient NN I-NP O
13 551 559 1468485 remained VBD B-VP O
14 560 564 1468485 free JJ B-ADJP O
15 565 567 1468485 of IN B-PP O
16 568 577 1468485 hematuria NN B-NP B-Disease
17 578 588 1468485 thereafter RB B-ADVP O
18 588 589 1468485 . . O O

1 590 592 1468485 No DT B-NP O
2 593 597 1468485 side NN I-NP O
3 598 604 1468485 effect NN I-NP O
4 605 608 1468485 was VBD B-VP O
5 609 614 1468485 noted VBN I-VP O
6 615 621 1468485 during IN B-PP O
7 622 625 1468485 the DT B-NP O
8 626 632 1468485 course NN I-NP O
9 633 635 1468485 of IN B-PP O
10 636 643 1468485 therapy NN B-NP O
11 643 644 1468485 . . O O

1 645 647 1468485 In IN B-PP O
2 648 654 1468485 future NN B-NP O
3 654 655 1468485 , , O O
4 656 660 1468485 this DT B-NP O
5 661 665 1468485 form NN I-NP O
6 666 668 1468485 of IN B-PP O
7 669 676 1468485 therapy NN B-NP O
8 677 680 1468485 can MD B-VP O
9 681 686 1468485 offer VB I-VP O
10 687 688 1468485 a DT B-NP O
11 689 693 1468485 safe JJ I-NP O
12 694 705 1468485 alternative NN I-NP O
13 706 708 1468485 in IN B-PP O
14 709 712 1468485 the DT B-NP O
15 713 722 1468485 treatment NN I-NP O
16 723 725 1468485 of IN B-PP O
17 726 742 1468485 cyclophosphamide NN B-NP B-Chemical
18 742 743 1468485 - HYPH B-NP O
19 743 750 1468485 induced VBN I-NP O
20 751 762 1468485 hemorrhagic JJ I-NP B-Disease
21 763 771 1468485 cystitis NN I-NP I-Disease
22 771 772 1468485 . . O O

1 0 0 12921865 -DOCSTART- -X- -X- O

1 0 10 12921865 Protective JJ B-NP O
2 11 19 12921865 efficacy NN I-NP O
3 20 22 12921865 of IN B-PP O
4 23 34 12921865 neuroactive JJ B-NP O
5 35 43 12921865 steroids NNS I-NP B-Chemical
6 44 51 12921865 against IN B-PP O
7 52 59 12921865 cocaine NN B-NP B-Chemical
8 60 67 12921865 kindled VBD B-VP O
9 67 68 12921865 - HYPH B-NP O
10 68 76 12921865 seizures NNS I-NP B-Disease
11 77 79 12921865 in IN B-PP O
12 80 84 12921865 mice NNS B-NP O
13 84 85 12921865 . . O O
14 86 97 12921865 Neuroactive JJ B-NP O
15 98 106 12921865 steroids NNS I-NP B-Chemical
16 107 118 12921865 demonstrate VBP B-VP O
17 119 134 12921865 pharmacological JJ B-NP O
18 135 142 12921865 actions NNS I-NP O
19 143 147 12921865 that WDT B-NP O
20 148 152 12921865 have VBP B-VP O
21 153 162 12921865 relevance NN B-NP O
22 163 166 12921865 for IN B-PP O
23 167 168 12921865 a DT B-NP O
24 169 173 12921865 host NN I-NP O
25 174 176 12921865 of IN B-PP O
26 177 189 12921865 neurological JJ B-NP B-Disease
27 190 193 12921865 and CC I-NP I-Disease
28 194 205 12921865 psychiatric JJ I-NP I-Disease
29 206 215 12921865 disorders NNS I-NP I-Disease
30 215 216 12921865 . . O O

1 217 221 12921865 They PRP B-NP O
2 222 227 12921865 offer VBP B-VP O
3 228 238 12921865 protection NN B-NP O
4 239 246 12921865 against IN B-PP O
5 247 255 12921865 seizures NNS B-NP B-Disease
6 256 258 12921865 in IN B-PP O
7 259 260 12921865 a DT B-NP O
8 261 266 12921865 range NN I-NP O
9 267 269 12921865 of IN B-PP O
10 270 276 12921865 models NNS B-NP O
11 277 280 12921865 and CC O O
12 281 285 12921865 seem VBP B-VP O
13 286 288 12921865 to TO I-VP O
14 289 296 12921865 inhibit VB I-VP O
15 297 304 12921865 certain JJ B-NP O
16 305 311 12921865 stages NNS I-NP O
17 312 314 12921865 of IN B-PP O
18 315 319 12921865 drug NN B-NP B-Disease
19 320 330 12921865 dependence NN I-NP I-Disease
20 331 333 12921865 in IN B-PP O
21 334 345 12921865 preclinical JJ B-NP O
22 346 357 12921865 assessments NNS I-NP O
23 357 358 12921865 . . O O

1 359 362 12921865 The DT B-NP O
2 363 370 12921865 present JJ I-NP O
3 371 376 12921865 study NN I-NP O
4 377 380 12921865 was VBD B-VP O
5 381 389 12921865 designed VBN I-VP O
6 390 392 12921865 to TO B-VP O
7 393 401 12921865 evaluate VB I-VP O
8 402 405 12921865 two CD B-NP O
9 406 416 12921865 endogenous JJ I-NP O
10 417 420 12921865 and CC O O
11 421 424 12921865 one CD B-NP O
12 425 434 12921865 synthetic JJ I-NP O
13 435 446 12921865 neuroactive JJ I-NP O
14 447 454 12921865 steroid NN I-NP B-Chemical
15 455 459 12921865 that WDT B-NP O
16 460 470 12921865 positively RB B-ADVP O
17 471 479 12921865 modulate VBP B-VP O
18 480 483 12921865 the DT B-NP O
19 484 489 12921865 gamma SYM I-NP B-Chemical
20 489 490 12921865 - HYPH I-NP I-Chemical
21 490 502 12921865 aminobutyric JJ I-NP I-Chemical
22 503 507 12921865 acid NN I-NP I-Chemical
23 508 509 12921865 ( ( O O
24 509 516 12921865 GABA(A) NN B-NP B-Chemical
25 516 517 12921865 ) ) O O
26 518 526 12921865 receptor NN B-NP O
27 527 534 12921865 against IN B-PP O
28 535 538 12921865 the DT B-NP O
29 539 547 12921865 increase NN I-NP O
30 548 550 12921865 in IN B-PP O
31 551 562 12921865 sensitivity NN B-NP O
32 563 565 12921865 to TO B-PP O
33 566 569 12921865 the DT B-NP O
34 570 580 12921865 convulsant JJ I-NP O
35 581 588 12921865 effects NNS I-NP O
36 589 591 12921865 of IN B-PP O
37 592 599 12921865 cocaine NN B-NP B-Chemical
38 600 610 12921865 engendered VBN B-VP O
39 611 613 12921865 by IN B-PP O
40 614 622 12921865 repeated VBN B-NP O
41 623 630 12921865 cocaine NN I-NP B-Chemical
42 631 645 12921865 administration NN I-NP O
43 646 647 12921865 ( ( O O
44 647 654 12921865 seizure NN B-NP B-Disease
45 655 663 12921865 kindling NN I-NP O
46 663 664 12921865 ) ) O O
47 664 665 12921865 . . O O

1 666 682 12921865 Allopregnanolone NN B-NP B-Chemical
2 683 684 12921865 ( ( O O
3 684 690 12921865 3alpha NN B-NP B-Chemical
4 690 691 12921865 - HYPH B-NP I-Chemical
5 691 698 12921865 hydroxy NN I-NP I-Chemical
6 698 699 12921865 - HYPH B-NP I-Chemical
7 699 705 12921865 5alpha NN I-NP I-Chemical
8 705 706 12921865 - HYPH B-NP I-Chemical
9 706 713 12921865 pregnan NN I-NP I-Chemical
10 713 714 12921865 - HYPH B-NP I-Chemical
11 714 716 12921865 20 CD I-NP I-Chemical
12 716 717 12921865 - HYPH I-NP I-Chemical
13 717 720 12921865 one CD I-NP I-Chemical
14 720 721 12921865 ) ) O O
15 721 722 12921865 , , O O
16 723 735 12921865 pregnanolone NN B-NP B-Chemical
17 736 737 12921865 ( ( O O
18 737 743 12921865 3alpha NN B-NP B-Chemical
19 743 744 12921865 - HYPH B-NP I-Chemical
20 744 751 12921865 hydroxy NN I-NP I-Chemical
21 751 752 12921865 - HYPH B-NP I-Chemical
22 752 757 12921865 5beta NN I-NP I-Chemical
23 757 758 12921865 - HYPH B-NP I-Chemical
24 758 765 12921865 pregnan NN I-NP I-Chemical
25 765 766 12921865 - HYPH B-NP I-Chemical
26 766 768 12921865 20 CD I-NP I-Chemical
27 768 769 12921865 - HYPH I-NP I-Chemical
28 769 772 12921865 one CD I-NP I-Chemical
29 772 773 12921865 ) ) O O
30 774 777 12921865 and CC O O
31 778 788 12921865 ganaxolone NN B-NP B-Chemical
32 789 790 12921865 ( ( O O
33 790 791 12921865 a DT B-NP O
34 792 801 12921865 synthetic JJ I-NP O
35 802 812 12921865 derivative NN I-NP O
36 813 815 12921865 of IN B-PP O
37 816 832 12921865 allopregnanolone NN B-NP B-Chemical
38 833 839 12921865 3alpha NN I-NP B-Chemical
39 839 840 12921865 - HYPH B-NP I-Chemical
40 840 847 12921865 hydroxy NN I-NP I-Chemical
41 847 848 12921865 - HYPH B-NP I-Chemical
42 848 853 12921865 3beta NN I-NP I-Chemical
43 853 854 12921865 - HYPH B-NP I-Chemical
44 854 860 12921865 methyl NN I-NP I-Chemical
45 860 861 12921865 - HYPH B-NP I-Chemical
46 861 867 12921865 5alpha NN I-NP I-Chemical
47 867 868 12921865 - HYPH B-NP I-Chemical
48 868 875 12921865 pregnan NN I-NP I-Chemical
49 875 876 12921865 - HYPH B-NP I-Chemical
50 876 878 12921865 20 CD I-NP I-Chemical
51 878 879 12921865 - HYPH I-NP I-Chemical
52 879 882 12921865 one CD I-NP I-Chemical
53 882 883 12921865 ) ) O O
54 884 888 12921865 were VBD B-VP O
55 889 895 12921865 tested VBN I-VP O
56 896 899 12921865 for IN B-PP O
57 900 905 12921865 their PRP$ B-NP O
58 906 913 12921865 ability NN I-NP O
59 914 916 12921865 to TO B-VP O
60 917 925 12921865 suppress VB I-VP O
61 926 929 12921865 the DT B-NP O
62 930 940 12921865 expression NN I-NP O
63 941 942 12921865 ( ( O O
64 942 956 12921865 anticonvulsant JJ B-NP O
65 957 963 12921865 effect NN I-NP O
66 963 964 12921865 ) ) O O
67 965 968 12921865 and CC O O
68 969 980 12921865 development NN B-NP O
69 981 982 12921865 ( ( O O
70 982 999 12921865 antiepileptogenic JJ B-NP O
71 1000 1006 12921865 effect NN I-NP O
72 1006 1007 12921865 ) ) O O
73 1008 1010 12921865 of IN B-PP O
74 1011 1018 12921865 cocaine NN B-NP B-Chemical
75 1018 1019 12921865 - HYPH B-NP O
76 1019 1026 12921865 kindled VBN I-NP O
77 1027 1035 12921865 seizures NNS I-NP B-Disease
78 1036 1038 12921865 in IN B-PP O
79 1039 1043 12921865 male JJ B-NP O
80 1043 1044 12921865 , , I-NP O
81 1045 1050 12921865 Swiss JJ I-NP O
82 1050 1051 12921865 - HYPH I-NP O
83 1051 1058 12921865 Webster NN I-NP O
84 1059 1063 12921865 mice NNS I-NP O
85 1063 1064 12921865 . . O O

1 1065 1072 12921865 Kindled VBN B-NP O
2 1073 1081 12921865 seizures NNS I-NP B-Disease
3 1082 1086 12921865 were VBD B-VP O
4 1087 1094 12921865 induced VBN I-VP O
5 1095 1097 12921865 by IN B-PP O
6 1098 1103 12921865 daily JJ B-NP O
7 1104 1118 12921865 administration NN I-NP O
8 1119 1121 12921865 of IN B-PP O
9 1122 1124 12921865 60 CD B-NP O
10 1125 1127 12921865 mg NN I-NP O
11 1127 1128 12921865 / SYM B-NP O
12 1128 1130 12921865 kg NN I-NP O
13 1131 1138 12921865 cocaine NN I-NP B-Chemical
14 1139 1142 12921865 for IN B-PP O
15 1143 1144 12921865 5 CD B-NP O
16 1145 1149 12921865 days NNS I-NP O
17 1149 1150 12921865 . . O O

1 1151 1154 12921865 All DT B-NP O
2 1155 1157 12921865 of IN B-PP O
3 1158 1163 12921865 these DT B-NP O
4 1164 1172 12921865 positive JJ I-NP O
5 1173 1180 12921865 GABA(A) NN I-NP B-Chemical
6 1181 1191 12921865 modulators NNS I-NP O
7 1192 1202 12921865 suppressed VBD B-VP O
8 1203 1206 12921865 the DT B-NP O
9 1207 1217 12921865 expression NN I-NP O
10 1218 1220 12921865 of IN B-PP O
11 1221 1228 12921865 kindled JJ B-NP O
12 1229 1237 12921865 seizures NNS I-NP B-Disease
13 1237 1238 12921865 , , O O
14 1239 1246 12921865 whereas IN O O
15 1247 1251 12921865 only RB B-NP O
16 1252 1268 12921865 allopregnanolone NN I-NP B-Chemical
17 1269 1272 12921865 and CC I-NP O
18 1273 1283 12921865 ganaxolone NN I-NP B-Chemical
19 1284 1293 12921865 inhibited VBD B-VP O
20 1294 1297 12921865 the DT B-NP O
21 1298 1309 12921865 development NN I-NP O
22 1310 1312 12921865 of IN B-PP O
23 1313 1321 12921865 kindling NN B-NP O
24 1321 1322 12921865 . . O O

1 1323 1339 12921865 Allopregnanolone NN B-NP B-Chemical
2 1340 1343 12921865 and CC I-NP O
3 1344 1356 12921865 pregnanolone NN I-NP B-Chemical
4 1356 1357 12921865 , , B-NP O
5 1358 1361 12921865 but CC I-NP O
6 1362 1365 12921865 not RB I-NP O
7 1366 1376 12921865 ganaxolone NN B-NP B-Chemical
8 1376 1377 12921865 , , O O
9 1378 1382 12921865 also RB B-ADVP O
10 1383 1390 12921865 reduced VBD B-VP O
11 1391 1401 12921865 cumulative JJ B-NP O
12 1402 1411 12921865 lethality NN I-NP O
13 1412 1422 12921865 associated VBN B-VP O
14 1423 1427 12921865 with IN B-PP O
15 1428 1436 12921865 kindling NN B-NP O
16 1436 1437 12921865 . . O O

1 1438 1443 12921865 These DT B-NP O
2 1444 1452 12921865 findings NNS I-NP O
3 1453 1464 12921865 demonstrate VBP B-VP O
4 1465 1469 12921865 that IN B-SBAR O
5 1470 1474 12921865 some DT B-NP O
6 1475 1486 12921865 neuroactive JJ I-NP O
7 1487 1495 12921865 steroids NNS I-NP B-Chemical
8 1496 1505 12921865 attenuate VBP B-VP O
9 1506 1516 12921865 convulsant NN B-NP O
10 1517 1520 12921865 and CC O O
11 1521 1532 12921865 sensitizing VBG B-VP O
12 1533 1543 12921865 properties NNS B-NP O
13 1544 1546 12921865 of IN B-PP O
14 1547 1554 12921865 cocaine NN B-NP B-Chemical
15 1555 1558 12921865 and CC O O
16 1559 1562 12921865 add VB B-VP O
17 1563 1565 12921865 to TO B-PP O
18 1566 1567 12921865 a DT B-NP O
19 1568 1575 12921865 growing VBG I-NP O
20 1576 1586 12921865 literature NN I-NP O
21 1587 1589 12921865 on IN B-PP O
22 1590 1595 12921865 their PRP$ B-NP O
23 1596 1605 12921865 potential JJ I-NP O
24 1606 1609 12921865 use NN I-NP O
25 1610 1612 12921865 in IN B-PP O
26 1613 1616 12921865 the DT B-NP O
27 1617 1627 12921865 modulation NN I-NP O
28 1628 1630 12921865 of IN B-PP O
29 1631 1638 12921865 effects NNS B-NP O
30 1639 1641 12921865 of IN B-PP O
31 1642 1647 12921865 drugs NNS B-NP O
32 1648 1650 12921865 of IN B-PP O
33 1651 1656 12921865 abuse NN B-NP O
34 1656 1657 12921865 . . O O

1 0 0 2304736 -DOCSTART- -X- -X- O

1 0 8 2304736 Prazosin NN B-NP B-Chemical
2 8 9 2304736 - HYPH B-NP O
3 9 16 2304736 induced VBN I-NP O
4 17 23 2304736 stress NN I-NP B-Disease
5 24 36 2304736 incontinence NN I-NP I-Disease
6 36 37 2304736 . . O O
7 38 39 2304736 A DT B-NP O
8 40 44 2304736 case NN I-NP O
9 45 47 2304736 of IN B-PP O
10 48 55 2304736 genuine JJ B-NP O
11 56 62 2304736 stress NN I-NP B-Disease
12 63 75 2304736 incontinence NN I-NP I-Disease
13 76 79 2304736 due IN B-PP O
14 80 82 2304736 to TO B-PP O
15 83 91 2304736 prazosin NN B-NP B-Chemical
16 91 92 2304736 , , O O
17 93 94 2304736 a DT B-NP O
18 95 101 2304736 common JJ I-NP O
19 102 118 2304736 antihypertensive JJ I-NP O
20 119 123 2304736 drug NN I-NP O
21 123 124 2304736 , , O O
22 125 127 2304736 is VBZ B-VP O
23 128 137 2304736 presented VBN I-VP O
24 137 138 2304736 . . O O

1 139 147 2304736 Prazosin NN B-NP B-Chemical
2 148 154 2304736 exerts VBZ B-VP O
3 155 158 2304736 its PRP$ B-NP O
4 159 175 2304736 antihypertensive JJ I-NP O
5 176 183 2304736 effects NNS I-NP O
6 184 191 2304736 through IN B-PP O
7 192 206 2304736 vasodilatation NN B-NP O
8 207 213 2304736 caused VBN B-VP O
9 214 216 2304736 by IN B-PP O
10 217 226 2304736 selective JJ B-NP O
11 227 235 2304736 blockade NN I-NP O
12 236 238 2304736 of IN B-PP O
13 239 251 2304736 postsynaptic JJ B-NP O
14 252 257 2304736 alpha SYM I-NP O
15 257 258 2304736 - HYPH I-NP O
16 258 259 2304736 1 CD I-NP O
17 260 270 2304736 adrenergic JJ I-NP O
18 271 280 2304736 receptors NNS I-NP O
19 280 281 2304736 . . O O

1 282 284 2304736 As IN B-PP O
2 285 287 2304736 an DT B-NP O
3 288 293 2304736 alpha SYM I-NP O
4 293 294 2304736 - HYPH I-NP O
5 294 301 2304736 blocker NN B-NP O
6 301 302 2304736 , , O O
7 303 305 2304736 it PRP B-NP O
8 306 310 2304736 also RB B-ADVP O
9 311 317 2304736 exerts VBZ B-VP O
10 318 319 2304736 a DT B-NP O
11 320 331 2304736 significant JJ I-NP O
12 332 340 2304736 relaxant JJ I-NP O
13 341 347 2304736 effect NN I-NP O
14 348 350 2304736 on IN B-PP O
15 351 354 2304736 the DT B-NP O
16 355 362 2304736 bladder NN I-NP O
17 363 367 2304736 neck NN I-NP O
18 368 371 2304736 and CC I-NP O
19 372 379 2304736 urethra NN I-NP O
20 379 380 2304736 . . O O

1 381 384 2304736 The DT B-NP O
2 385 394 2304736 patient's NNS I-NP O
3 395 403 2304736 clinical JJ B-NP O
4 404 410 2304736 course NN I-NP O
5 411 413 2304736 is VBZ B-VP O
6 414 423 2304736 described VBN I-VP O
7 424 427 2304736 and CC I-VP O
8 428 438 2304736 correlated VBN I-VP O
9 439 443 2304736 with IN B-PP O
10 444 451 2304736 initial JJ B-NP O
11 452 462 2304736 urodynamic JJ I-NP O
12 463 470 2304736 studies NNS I-NP O
13 471 476 2304736 while IN B-SBAR O
14 477 479 2304736 on IN B-PP O
15 480 488 2304736 prazosin NN B-NP B-Chemical
16 489 492 2304736 and CC O O
17 493 503 2304736 subsequent JJ B-NP O
18 504 511 2304736 studies NNS I-NP O
19 512 517 2304736 while IN B-SBAR O
20 518 524 2304736 taking VBG B-VP O
21 525 534 2304736 verapamil NN B-NP B-Chemical
22 534 535 2304736 . . O O

1 536 539 2304736 Her PRP$ B-NP O
2 540 552 2304736 incontinence NN I-NP B-Disease
3 553 561 2304736 resolved VBN B-VP O
4 562 566 2304736 with IN B-PP O
5 567 570 2304736 the DT B-NP O
6 571 577 2304736 change NN I-NP O
7 578 580 2304736 of IN B-PP O
8 581 591 2304736 medication NN B-NP O
9 591 592 2304736 . . O O

1 593 596 2304736 The DT B-NP O
2 597 608 2304736 restoration NN I-NP O
3 609 611 2304736 of IN B-PP O
4 612 622 2304736 continence NN B-NP O
5 623 626 2304736 was VBD B-VP O
6 627 638 2304736 accompanied VBN I-VP O
7 639 641 2304736 by IN B-PP O
8 642 643 2304736 a DT B-NP O
9 644 655 2304736 substantial JJ I-NP O
10 656 660 2304736 rise NN I-NP O
11 661 663 2304736 in IN B-PP O
12 664 671 2304736 maximum JJ B-NP O
13 672 680 2304736 urethral JJ I-NP O
14 681 689 2304736 pressure NN I-NP O
15 689 690 2304736 , , O O
16 691 698 2304736 maximum JJ B-NP O
17 699 707 2304736 urethral JJ I-NP O
18 708 715 2304736 closure NN I-NP O
19 716 724 2304736 pressure NN I-NP O
20 724 725 2304736 , , O O
21 726 729 2304736 and CC O O
22 730 740 2304736 functional JJ B-NP O
23 741 749 2304736 urethral JJ I-NP O
24 750 756 2304736 length NN I-NP O
25 756 757 2304736 . . O O

1 758 766 2304736 Patients NNS B-NP O
2 767 770 2304736 who WP B-NP O
3 771 778 2304736 present VBP B-VP O
4 779 783 2304736 with IN B-PP O
5 784 790 2304736 stress NN B-NP B-Disease
6 791 803 2304736 incontinence NN I-NP I-Disease
7 804 809 2304736 while IN B-SBAR O
8 810 816 2304736 taking VBG B-VP O
9 817 825 2304736 prazosin NN B-NP B-Chemical
10 826 832 2304736 should MD B-VP O
11 833 839 2304736 change VB I-VP O
12 840 845 2304736 their PRP$ B-NP O
13 846 862 2304736 antihypertensive JJ I-NP O
14 863 873 2304736 medication NN I-NP O
15 874 880 2304736 before IN B-PP O
16 881 892 2304736 considering VBG B-VP O
17 893 900 2304736 surgery NN B-NP O
18 900 901 2304736 , , O O
19 902 909 2304736 because IN B-SBAR O
20 910 915 2304736 their PRP$ B-NP O
21 916 928 2304736 incontinence NN I-NP B-Disease
22 929 932 2304736 may MD B-VP O
23 933 940 2304736 resolve VB I-VP O
24 941 954 2304736 spontaneously RB B-ADVP O
25 955 959 2304736 with IN B-PP O
26 960 961 2304736 a DT B-NP O
27 962 968 2304736 change NN I-NP O
28 969 971 2304736 in IN B-PP O
29 972 976 2304736 drug NN B-NP O
30 977 984 2304736 therapy NN I-NP O
31 984 985 2304736 . . O O

1 0 0 4027862 -DOCSTART- -X- -X- O

1 0 11 4027862 Desipramine NN B-NP B-Chemical
2 11 12 4027862 - HYPH B-NP O
3 12 19 4027862 induced VBN I-NP O
4 20 28 4027862 delirium NN I-NP B-Disease
5 29 31 4027862 at IN B-PP O
6 32 33 4027862 " `` B-NP O
7 33 47 4027862 subtherapeutic JJ I-NP O
8 47 48 4027862 " '' I-NP O
9 49 63 4027862 concentrations NNS I-NP O
10 63 64 4027862 : : O O
11 65 66 4027862 a DT B-NP O
12 67 71 4027862 case NN I-NP O
13 72 78 4027862 report NN I-NP O
14 78 79 4027862 . . O O
15 80 82 4027862 An DT B-NP O
16 83 90 4027862 elderly JJ I-NP O
17 91 98 4027862 patient NN I-NP O
18 99 106 4027862 treated VBN B-VP O
19 107 111 4027862 with IN B-PP O
20 112 115 4027862 low JJ B-NP O
21 116 120 4027862 dose NN I-NP O
22 121 132 4027862 Desipramine NN I-NP B-Chemical
23 133 142 4027862 developed VBD B-VP O
24 143 144 4027862 a DT B-NP O
25 145 153 4027862 delirium NN I-NP B-Disease
26 154 159 4027862 while IN B-SBAR O
27 160 163 4027862 her PRP$ B-NP O
28 164 170 4027862 plasma NN I-NP O
29 171 176 4027862 level NN I-NP O
30 177 180 4027862 was VBD B-VP O
31 181 183 4027862 in IN B-PP O
32 184 187 4027862 the DT B-NP O
33 188 189 4027862 " `` I-NP O
34 189 203 4027862 subtherapeutic JJ I-NP O
35 203 204 4027862 " '' I-NP O
36 205 210 4027862 range NN I-NP O
37 210 211 4027862 . . O O

1 212 220 4027862 Delirium NNP B-NP B-Disease
2 220 221 4027862 , , O O
3 222 227 4027862 which WDT B-NP O
4 228 231 4027862 may MD B-VP O
5 232 234 4027862 be VB I-VP O
6 235 242 4027862 induced VBN I-VP O
7 243 245 4027862 by IN B-PP O
8 246 255 4027862 tricyclic JJ B-NP O
9 256 260 4027862 drug NN I-NP O
10 261 268 4027862 therapy NN I-NP O
11 269 271 4027862 in IN B-PP O
12 272 275 4027862 the DT B-NP O
13 276 283 4027862 elderly JJ I-NP O
14 283 284 4027862 , , O O
15 285 288 4027862 can MD B-VP O
16 289 291 4027862 be VB I-VP O
17 292 298 4027862 caused VBN I-VP O
18 299 301 4027862 by IN B-PP O
19 302 312 4027862 tricyclics NNS B-NP O
20 313 317 4027862 with IN B-PP O
21 318 321 4027862 low JJ B-NP O
22 322 337 4027862 anticholinergic JJ I-NP O
23 338 345 4027862 potency NN I-NP O
24 345 346 4027862 . . O O

1 347 358 4027862 Therapeutic JJ B-NP O
2 359 365 4027862 ranges NNS I-NP O
3 366 369 4027862 for IN B-PP O
4 370 385 4027862 antidepressants NNS B-NP B-Chemical
5 386 390 4027862 that WDT B-NP O
6 391 395 4027862 have VBP B-VP O
7 396 400 4027862 been VBN I-VP O
8 401 408 4027862 derived VBN I-VP O
9 409 413 4027862 from IN B-PP O
10 414 421 4027862 general JJ B-NP O
11 422 427 4027862 adult JJ I-NP O
12 428 438 4027862 population NN I-NP O
13 439 446 4027862 studies NNS I-NP O
14 447 450 4027862 may MD B-VP O
15 451 454 4027862 not RB I-VP O
16 455 457 4027862 be VB I-VP O
17 458 469 4027862 appropriate JJ B-ADJP O
18 470 473 4027862 for IN B-PP O
19 474 477 4027862 the DT B-NP O
20 478 485 4027862 elderly JJ I-NP O
21 485 486 4027862 . . O O

1 487 494 4027862 Further JJ B-NP O
2 495 502 4027862 studies NNS I-NP O
3 503 505 4027862 of IN B-PP O
4 506 518 4027862 specifically RB B-NP O
5 519 526 4027862 elderly JJ I-NP O
6 527 535 4027862 patients NNS I-NP O
7 536 539 4027862 are VBP B-VP O
8 540 543 4027862 now RB I-VP O
9 544 552 4027862 required VBN I-VP O
10 553 555 4027862 to TO I-VP O
11 556 565 4027862 establish VB I-VP O
12 566 571 4027862 safer JJR B-NP O
13 572 575 4027862 and CC I-NP O
14 576 580 4027862 more RBR I-NP O
15 581 592 4027862 appropriate JJ I-NP O
16 593 603 4027862 guidelines NNS I-NP O
17 604 607 4027862 for IN B-PP O
18 608 612 4027862 drug NN B-NP O
19 613 620 4027862 therapy NN I-NP O
20 620 621 4027862 . . O O

1 0 0 19300402 -DOCSTART- -X- -X- O

1 0 10 19300402 Bradykinin NN B-NP B-Chemical
2 11 20 19300402 receptors NNS I-NP O
3 21 32 19300402 antagonists NNS I-NP O
4 33 36 19300402 and CC O O
5 37 43 19300402 nitric JJ B-NP B-Chemical
6 44 49 19300402 oxide NN I-NP I-Chemical
7 50 58 19300402 synthase NN I-NP O
8 59 69 19300402 inhibitors NNS I-NP O
9 70 72 19300402 in IN B-PP O
10 73 84 19300402 vincristine NN B-NP B-Chemical
11 85 88 19300402 and CC I-NP O
12 89 103 19300402 streptozotocin NN I-NP B-Chemical
13 104 111 19300402 induced VBD B-VP O
14 112 124 19300402 hyperalgesia NN B-NP B-Disease
15 125 127 19300402 in IN B-PP O
16 128 140 19300402 chemotherapy NN B-NP O
17 141 144 19300402 and CC O O
18 145 153 19300402 diabetic JJ B-NP B-Disease
19 154 164 19300402 neuropathy JJ I-NP I-Disease
20 165 168 19300402 rat NN I-NP O
21 169 174 19300402 model NN I-NP O
22 174 175 19300402 . . I-NP O
23 176 183 19300402 PURPOSE NN I-NP O
24 183 184 19300402 : : O O
25 185 188 19300402 The DT B-NP O
26 189 198 19300402 influence NN I-NP O
27 199 201 19300402 of IN B-PP O
28 202 204 19300402 an DT B-NP O
29 205 217 19300402 irreversible JJ I-NP O
30 218 227 19300402 inhibitor NN I-NP O
31 228 230 19300402 of IN B-PP O
32 231 243 19300402 constitutive JJ B-NP O
33 244 246 19300402 NO NN I-NP B-Chemical
34 247 255 19300402 synthase NN I-NP O
35 256 257 19300402 ( ( O O
36 257 258 19300402 L NN B-NP O
37 258 259 19300402 - HYPH O O
38 259 264 19300402 NOArg NN B-NP O
39 264 265 19300402 ; : O O
40 266 269 19300402 1.0 CD B-NP O
41 270 272 19300402 mg NN I-NP O
42 272 273 19300402 / SYM B-NP O
43 273 275 19300402 kg NN I-NP O
44 276 278 19300402 ip NN I-NP O
45 278 279 19300402 ) ) O O
46 279 280 19300402 , , O O
47 281 282 19300402 a DT B-NP O
48 283 293 19300402 relatively RB I-NP O
49 294 303 19300402 selective JJ I-NP O
50 304 313 19300402 inhibitor NN I-NP O
51 314 316 19300402 of IN B-PP O
52 317 326 19300402 inducible JJ B-NP O
53 327 329 19300402 NO NN I-NP B-Chemical
54 330 338 19300402 synthase NN I-NP O
55 339 340 19300402 ( ( O O
56 340 341 19300402 L NN B-NP O
57 341 342 19300402 - HYPH O O
58 342 345 19300402 NIL NN B-NP O
59 345 346 19300402 ; : O O
60 347 350 19300402 1.0 CD B-NP O
61 351 353 19300402 mg NN I-NP O
62 353 354 19300402 / SYM B-NP O
63 354 356 19300402 kg NN I-NP O
64 357 359 19300402 ip NN I-NP O
65 359 360 19300402 ) ) O O
66 361 364 19300402 and CC O O
67 365 366 19300402 a DT B-NP O
68 367 377 19300402 relatively RB I-NP O
69 378 386 19300402 specific JJ I-NP O
70 387 396 19300402 inhibitor NN I-NP O
71 397 399 19300402 of IN B-PP O
72 400 408 19300402 neuronal JJ B-NP O
73 409 411 19300402 NO NN I-NP B-Chemical
74 412 420 19300402 synthase NN I-NP O
75 421 422 19300402 ( ( O O
76 422 423 19300402 7 CD B-NP O
77 423 424 19300402 - HYPH I-NP O
78 424 426 19300402 NI NN I-NP O
79 426 427 19300402 ; : O O
80 428 431 19300402 0.1 CD B-NP O
81 432 434 19300402 mg NN I-NP O
82 434 435 19300402 / SYM B-NP O
83 435 437 19300402 kg NN I-NP O
84 438 440 19300402 ip NN I-NP O
85 440 441 19300402 ) ) O O
86 441 442 19300402 , , O O
87 443 445 19300402 on IN B-PP O
88 446 462 19300402 antihyperalgesic JJ B-NP O
89 463 469 19300402 action NN I-NP O
90 470 472 19300402 of IN B-PP O
91 473 482 19300402 selective JJ B-NP O
92 483 494 19300402 antagonists NNS I-NP O
93 495 497 19300402 of IN B-PP O
94 498 500 19300402 B2 NN B-NP O
95 501 504 19300402 and CC I-NP O
96 505 507 19300402 B1 NN I-NP O
97 508 517 19300402 receptors NNS I-NP O
98 517 518 19300402 : : O O
99 519 520 19300402 D NN B-NP O
100 520 521 19300402 - HYPH B-NP O
101 521 524 19300402 Arg NN I-NP O
102 524 525 19300402 - HYPH B-NP O
103 525 537 19300402 [Hyp3,Thi5,D NN I-NP O
104 537 538 19300402 - HYPH O O
105 538 548 19300402 Tic7,Oic8] NN B-NP O
106 549 559 19300402 bradykinin NN I-NP B-Chemical
107 560 561 19300402 ( ( O O
108 561 564 19300402 HOE NN B-NP B-Chemical
109 565 568 19300402 140 CD I-NP I-Chemical
110 568 569 19300402 ; : O O
111 570 572 19300402 70 CD B-NP O
112 573 577 19300402 nmol NN I-NP O
113 577 578 19300402 / SYM I-NP O
114 578 580 19300402 kg NN I-NP O
115 581 583 19300402 ip NN I-NP O
116 583 584 19300402 ) ) O O
117 585 587 19300402 or CC O O
118 588 591 19300402 des VBZ B-VP B-Chemical
119 592 597 19300402 Arg10 NNP B-NP I-Chemical
120 598 601 19300402 HOE NNP I-NP I-Chemical
121 602 605 19300402 140 CD I-NP I-Chemical
122 606 607 19300402 ( ( O O
123 607 609 19300402 70 CD B-NP O
124 610 614 19300402 nmol NN I-NP O
125 614 615 19300402 / SYM B-NP O
126 615 617 19300402 kg NN I-NP O
127 618 620 19300402 ip NN I-NP O
128 620 621 19300402 ) ) O O
129 622 634 19300402 respectively RB B-ADVP O
130 634 635 19300402 , , O O
131 636 638 19300402 in IN B-PP O
132 639 644 19300402 model NN B-NP O
133 645 647 19300402 of IN B-PP O
134 648 656 19300402 diabetic JJ B-NP B-Disease
135 657 658 19300402 ( ( O I-Disease
136 658 672 19300402 streptozotocin NN B-NP I-Disease
137 672 673 19300402 - HYPH B-VP I-Disease
138 673 680 19300402 induced VBN I-VP I-Disease
139 680 681 19300402 ) ) O I-Disease
140 682 685 19300402 and CC O I-Disease
141 686 691 19300402 toxic JJ B-NP I-Disease
142 692 693 19300402 ( ( O I-Disease
143 693 704 19300402 vincristine NN B-NP I-Disease
144 704 705 19300402 - HYPH B-VP I-Disease
145 705 712 19300402 induced VBN I-VP I-Disease
146 712 713 19300402 ) ) O I-Disease
147 714 724 19300402 neuropathy NN B-NP I-Disease
148 725 728 19300402 was VBD B-VP O
149 729 741 19300402 investigated VBN I-VP O
150 741 742 19300402 . . O O

1 743 750 19300402 METHODS NNS B-NP O
2 750 751 19300402 : : O O
3 752 755 19300402 The DT B-NP O
4 756 763 19300402 changes NNS I-NP O
5 764 766 19300402 in IN B-PP O
6 767 771 19300402 pain NN B-NP B-Disease
7 772 782 19300402 thresholds NNS I-NP O
8 783 787 19300402 were VBD B-VP O
9 788 798 19300402 determined VBN I-VP O
10 799 804 19300402 using VBG B-VP O
11 805 815 19300402 mechanical JJ B-NP O
12 816 823 19300402 stimuli NNS I-NP O
13 823 824 19300402 - HYPH O O
14 824 825 19300402 - HYPH O O
15 825 828 19300402 the DT B-NP O
16 829 841 19300402 modification NN I-NP O
17 842 844 19300402 of IN B-PP O
18 845 848 19300402 the DT B-NP O
19 849 856 19300402 classic JJ I-NP O
20 857 860 19300402 paw NN I-NP O
21 861 871 19300402 withdrawal NN I-NP O
22 872 876 19300402 test NN I-NP O
23 877 886 19300402 described VBN B-VP O
24 887 889 19300402 by IN B-PP O
25 890 897 19300402 Randall NNP B-NP O
26 897 898 19300402 - HYPH I-NP O
27 898 905 19300402 Selitto NNP I-NP O
28 905 906 19300402 . . O O

1 907 914 19300402 RESULTS NNS B-NP O
2 914 915 19300402 : : O O
3 916 919 19300402 The DT B-NP O
4 920 927 19300402 results NNS I-NP O
5 928 930 19300402 of IN B-PP O
6 931 935 19300402 this DT B-NP O
7 936 941 19300402 paper NN I-NP O
8 942 949 19300402 confirm VBP B-VP O
9 950 954 19300402 that IN B-SBAR O
10 955 965 19300402 inhibition NN B-NP O
11 966 968 19300402 of IN B-PP O
12 969 979 19300402 bradykinin NN B-NP B-Chemical
13 980 989 19300402 receptors NNS I-NP O
14 990 993 19300402 and CC O O
15 994 1003 19300402 inducible JJ B-NP O
16 1004 1006 19300402 NO NN I-NP B-Chemical
17 1007 1015 19300402 synthase NN I-NP O
18 1016 1019 19300402 but CC B-CONJP O
19 1020 1023 19300402 not RB I-CONJP O
20 1024 1032 19300402 neuronal JJ B-NP O
21 1033 1035 19300402 NO NN I-NP B-Chemical
22 1036 1044 19300402 synthase NN I-NP O
23 1045 1053 19300402 activity NN I-NP O
24 1054 1061 19300402 reduces VBZ B-VP O
25 1062 1070 19300402 diabetic JJ B-NP B-Disease
26 1071 1083 19300402 hyperalgesia NN I-NP I-Disease
27 1083 1084 19300402 . . O O

1 1085 1097 19300402 Pretreatment NN B-NP O
2 1098 1102 19300402 with IN B-PP O
3 1103 1104 19300402 L NN B-NP O
4 1104 1105 19300402 - HYPH B-NP O
5 1105 1110 19300402 NOArg NN I-NP O
6 1111 1114 19300402 and CC I-NP O
7 1115 1116 19300402 L NN I-NP O
8 1116 1117 19300402 - HYPH O O
9 1117 1120 19300402 NIL NN B-NP O
10 1121 1124 19300402 but CC B-PP O
11 1125 1128 19300402 not RB B-NP O
12 1129 1130 19300402 7 CD I-NP O
13 1130 1131 19300402 - HYPH I-NP O
14 1131 1133 19300402 NI NN I-NP O
15 1133 1134 19300402 , , O O
16 1135 1148 19300402 significantly RB B-VP O
17 1149 1158 19300402 increases VBZ I-VP O
18 1159 1175 19300402 antihyperalgesic JJ B-NP O
19 1176 1184 19300402 activity NN I-NP O
20 1185 1189 19300402 both DT O O
21 1190 1193 19300402 HOE NN B-NP B-Chemical
22 1194 1197 19300402 140 CD I-NP I-Chemical
23 1198 1201 19300402 and CC O O
24 1202 1205 19300402 des VBZ B-VP B-Chemical
25 1206 1211 19300402 Arg10 NNP B-NP I-Chemical
26 1212 1215 19300402 HOE NNP I-NP I-Chemical
27 1216 1219 19300402 140 CD I-NP I-Chemical
28 1219 1220 19300402 . . O O

1 1221 1223 19300402 It PRP B-NP O
2 1224 1227 19300402 was VBD B-VP O
3 1228 1232 19300402 also RB I-VP O
4 1233 1238 19300402 shown VBN I-VP O
5 1239 1243 19300402 that IN B-SBAR O
6 1244 1248 19300402 both DT B-NP O
7 1249 1257 19300402 products NNS I-NP O
8 1258 1260 19300402 of IN B-PP O
9 1261 1270 19300402 inducible JJ B-NP O
10 1271 1273 19300402 NO NN I-NP B-Chemical
11 1274 1282 19300402 synthase NN I-NP O
12 1283 1286 19300402 and CC O O
13 1287 1295 19300402 neuronal JJ B-NP O
14 1296 1298 19300402 NO NN I-NP B-Chemical
15 1299 1307 19300402 synthase NN I-NP O
16 1308 1318 19300402 activation NN I-NP O
17 1319 1321 19300402 as RB B-CONJP O
18 1322 1326 19300402 well RB I-CONJP O
19 1327 1329 19300402 as IN I-CONJP O
20 1330 1340 19300402 bradykinin NN B-NP B-Chemical
21 1341 1344 19300402 are VBP B-VP O
22 1345 1353 19300402 involved VBN I-VP O
23 1354 1356 19300402 in IN B-PP O
24 1357 1369 19300402 hyperalgesia NN B-NP B-Disease
25 1370 1378 19300402 produced VBN B-VP O
26 1379 1381 19300402 by IN B-PP O
27 1382 1393 19300402 vincristine NN B-NP B-Chemical
28 1393 1394 19300402 . . O O

1 1395 1403 19300402 Moreover RB B-ADVP O
2 1403 1404 19300402 , , O O
3 1405 1406 19300402 L NN B-NP O
4 1406 1407 19300402 - HYPH I-NP O
5 1407 1412 19300402 NOArg NN I-NP O
6 1413 1416 19300402 and CC I-NP O
7 1417 1418 19300402 7 CD I-NP O
8 1418 1419 19300402 - HYPH I-NP O
9 1419 1421 19300402 NI NN I-NP O
10 1422 1425 19300402 but CC B-NP O
11 1426 1429 19300402 not RB I-NP O
12 1430 1431 19300402 L NN B-NP O
13 1431 1432 19300402 - HYPH O O
14 1432 1435 19300402 NIL NN B-NP O
15 1436 1445 19300402 intensify VBP B-VP O
16 1446 1462 19300402 antihyperalgesic JJ B-NP O
17 1463 1471 19300402 activity NN I-NP O
18 1472 1474 19300402 of IN B-PP O
19 1475 1478 19300402 HOE NN B-NP B-Chemical
20 1479 1482 19300402 140 CD I-NP I-Chemical
21 1483 1485 19300402 or CC O O
22 1486 1489 19300402 des AFX O B-Chemical
23 1489 1490 19300402 - HYPH O I-Chemical
24 1490 1498 19300402 Arg10HOE NN B-NP I-Chemical
25 1499 1502 19300402 140 CD I-NP I-Chemical
26 1503 1505 19300402 in IN B-PP O
27 1506 1511 19300402 toxic JJ B-NP B-Disease
28 1512 1522 19300402 neuropathy NN I-NP I-Disease
29 1522 1523 19300402 . . O O

1 1524 1535 19300402 CONCLUSIONS NNS B-NP O
2 1535 1536 19300402 : : O O
3 1537 1544 19300402 Results NNS B-NP O
4 1545 1547 19300402 of IN B-PP O
5 1548 1553 19300402 these DT B-NP O
6 1554 1561 19300402 studies NNS I-NP O
7 1562 1569 19300402 suggest VBP B-VP O
8 1570 1574 19300402 that IN B-SBAR O
9 1575 1577 19300402 B1 NN B-NP O
10 1578 1581 19300402 and CC I-NP O
11 1582 1584 19300402 B2 NN I-NP O
12 1585 1594 19300402 receptors NNS I-NP O
13 1595 1598 19300402 are VBP B-VP O
14 1599 1606 19300402 engaged VBN I-VP O
15 1607 1609 19300402 in IN B-PP O
16 1610 1622 19300402 transmission NN B-NP O
17 1623 1625 19300402 of IN B-PP O
18 1626 1637 19300402 nociceptive JJ B-NP O
19 1638 1645 19300402 stimuli NNS I-NP O
20 1646 1648 19300402 in IN B-PP O
21 1649 1653 19300402 both CC B-NP O
22 1654 1662 19300402 diabetic JJ I-NP B-Disease
23 1663 1666 19300402 and CC I-NP I-Disease
24 1667 1672 19300402 toxic JJ I-NP I-Disease
25 1673 1683 19300402 neuropathy NN I-NP I-Disease
26 1683 1684 19300402 . . O O

1 1685 1687 19300402 In IN B-PP O
2 1688 1702 19300402 streptozotocin NN B-NP B-Chemical
3 1702 1703 19300402 - HYPH B-NP O
4 1703 1710 19300402 induced VBN I-NP O
5 1711 1723 19300402 hyperalgesia NN I-NP B-Disease
6 1723 1724 19300402 , , O O
7 1725 1734 19300402 inducible JJ B-NP O
8 1735 1737 19300402 NO NN I-NP B-Chemical
9 1738 1746 19300402 synthase NN I-NP O
10 1747 1759 19300402 participates VBZ B-VP O
11 1760 1762 19300402 in IN B-PP O
12 1763 1777 19300402 pronociceptive JJ B-NP O
13 1778 1786 19300402 activity NN I-NP O
14 1787 1789 19300402 of IN B-PP O
15 1790 1800 19300402 bradykinin NN B-NP B-Chemical
16 1800 1801 19300402 , , O O
17 1802 1809 19300402 whereas IN O O
18 1810 1812 19300402 in IN B-PP O
19 1813 1824 19300402 vincristine NN B-NP B-Chemical
20 1824 1825 19300402 - HYPH B-NP O
21 1825 1832 19300402 induced VBN I-NP O
22 1833 1845 19300402 hyperalgesia NN I-NP B-Disease
23 1846 1856 19300402 bradykinin NN I-NP B-Chemical
24 1857 1863 19300402 seemed VBD B-VP O
25 1864 1866 19300402 to TO I-VP O
26 1867 1875 19300402 activate VB I-VP O
27 1876 1884 19300402 neuronal JJ B-NP O
28 1885 1887 19300402 NO NN I-NP B-Chemical
29 1888 1896 19300402 synthase NN I-NP O
30 1897 1904 19300402 pathway NN I-NP O
31 1904 1905 19300402 . . O O

1 1906 1915 19300402 Therefore RB B-ADVP O
2 1915 1916 19300402 , , O O
3 1917 1928 19300402 concomitant JJ B-NP O
4 1929 1943 19300402 administration NN I-NP O
5 1944 1946 19300402 of IN B-PP O
6 1947 1952 19300402 small JJ B-NP O
7 1953 1958 19300402 doses NNS I-NP O
8 1959 1961 19300402 of IN B-PP O
9 1962 1972 19300402 bradykinin NN B-NP B-Chemical
10 1973 1981 19300402 receptor NN I-NP O
11 1982 1993 19300402 antagonists NNS I-NP O
12 1994 1997 19300402 and CC O O
13 1998 2000 19300402 NO NN B-NP B-Chemical
14 2001 2009 19300402 synthase NN I-NP O
15 2010 2020 19300402 inhibitors NNS I-NP O
16 2021 2024 19300402 can MD B-VP O
17 2025 2027 19300402 be VB I-VP O
18 2028 2037 19300402 effective JJ B-ADJP O
19 2038 2040 19300402 in IN B-PP O
20 2041 2052 19300402 alleviation NN B-NP O
21 2053 2055 19300402 of IN B-PP O
22 2056 2067 19300402 neuropathic JJ B-NP B-Disease
23 2068 2072 19300402 pain NN I-NP I-Disease
24 2072 2073 19300402 , , O O
25 2074 2078 19300402 even RB B-ADVP O
26 2079 2081 19300402 in IN B-PP O
27 2082 2090 19300402 hospital NN B-NP O
28 2091 2095 19300402 care NN I-NP O
29 2095 2096 19300402 . . O O

1 0 0 12464714 -DOCSTART- -X- -X- O

1 0 9 12464714 Crossover NN B-NP O
2 10 20 12464714 comparison NN I-NP O
3 21 23 12464714 of IN B-PP O
4 24 32 12464714 efficacy NN B-NP O
5 33 36 12464714 and CC I-NP O
6 37 47 12464714 preference NN I-NP O
7 48 51 12464714 for IN B-PP O
8 52 63 12464714 rizatriptan NN B-NP B-Chemical
9 64 66 12464714 10 CD I-NP O
10 67 69 12464714 mg NN I-NP O
11 70 76 12464714 versus IN B-PP O
12 77 87 12464714 ergotamine NN B-NP B-Chemical
13 87 88 12464714 / SYM B-NP O
14 88 96 12464714 caffeine NN I-NP B-Chemical
15 97 99 12464714 in IN B-PP O
16 100 108 12464714 migraine NN B-NP B-Disease
17 108 109 12464714 . . O O
18 110 121 12464714 Rizatriptan NNP B-NP B-Chemical
19 122 124 12464714 is VBZ B-VP O
20 125 126 12464714 a DT B-NP O
21 127 136 12464714 selective JJ I-NP O
22 137 138 12464714 5 CD I-NP B-Chemical
23 138 139 12464714 - HYPH I-NP I-Chemical
24 139 144 12464714 HT(1B NN I-NP I-Chemical
25 144 145 12464714 / SYM B-NP O
26 145 147 12464714 1D NN I-NP O
27 147 148 12464714 ) ) O O
28 149 157 12464714 receptor NN B-NP O
29 158 165 12464714 agonist NN I-NP O
30 166 170 12464714 with IN B-PP O
31 171 176 12464714 rapid JJ B-NP O
32 177 181 12464714 oral JJ I-NP O
33 182 192 12464714 absorption NN I-NP O
34 193 196 12464714 and CC O O
35 197 202 12464714 early JJ B-NP O
36 203 208 12464714 onset NN I-NP O
37 209 211 12464714 of IN B-PP O
38 212 218 12464714 action NN B-NP O
39 219 221 12464714 in IN B-PP O
40 222 225 12464714 the DT B-NP O
41 226 231 12464714 acute JJ I-NP O
42 232 241 12464714 treatment NN I-NP O
43 242 244 12464714 of IN B-PP O
44 245 253 12464714 migraine NN B-NP B-Disease
45 253 254 12464714 . . O O

1 255 259 12464714 This DT B-NP O
2 260 270 12464714 randomized VBD B-VP O
3 271 277 12464714 double JJ B-NP O
4 277 278 12464714 - HYPH I-NP O
5 279 284 12464714 blind JJ I-NP O
6 285 294 12464714 crossover NN I-NP O
7 295 305 12464714 outpatient NN I-NP O
8 306 311 12464714 study NN I-NP O
9 312 320 12464714 assessed VBD B-VP O
10 321 324 12464714 the DT B-NP O
11 325 335 12464714 preference NN I-NP O
12 336 339 12464714 for IN B-PP O
13 340 341 12464714 1 CD B-NP O
14 342 353 12464714 rizatriptan NN I-NP B-Chemical
15 354 356 12464714 10 CD B-NP O
16 357 359 12464714 mg NN I-NP O
17 360 366 12464714 tablet NN I-NP O
18 367 369 12464714 to TO B-PP O
19 370 371 12464714 2 CD B-NP O
20 372 382 12464714 ergotamine NN I-NP B-Chemical
21 383 384 12464714 1 CD B-NP O
22 385 387 12464714 mg NN I-NP O
23 387 388 12464714 / SYM B-VP O
24 388 396 12464714 caffeine NN B-NP B-Chemical
25 397 400 12464714 100 CD I-NP O
26 401 403 12464714 mg NN I-NP O
27 404 411 12464714 tablets NNS I-NP O
28 412 414 12464714 in IN B-PP O
29 415 418 12464714 439 CD B-NP O
30 419 427 12464714 patients NNS I-NP O
31 428 436 12464714 treating VBG B-VP O
32 437 438 12464714 a DT B-NP O
33 439 445 12464714 single JJ I-NP O
34 446 454 12464714 migraine NN I-NP B-Disease
35 455 461 12464714 attack NN I-NP O
36 462 466 12464714 with IN B-PP O
37 467 471 12464714 each DT B-NP O
38 472 479 12464714 therapy NN I-NP O
39 479 480 12464714 . . O O

1 481 483 12464714 Of IN B-PP O
2 484 492 12464714 patients NNS B-NP O
3 493 503 12464714 expressing VBG B-VP O
4 504 505 12464714 a DT B-NP O
5 506 516 12464714 preference NN I-NP O
6 517 518 12464714 ( ( O O
7 518 523 12464714 89.1% NN B-NP O
8 523 524 12464714 ) ) O O
9 524 525 12464714 , , O O
10 526 530 12464714 more JJR B-NP O
11 531 535 12464714 than IN I-NP O
12 536 541 12464714 twice RB I-NP O
13 542 544 12464714 as RB I-NP O
14 545 549 12464714 many JJ I-NP O
15 550 559 12464714 preferred VBN I-NP O
16 560 571 12464714 rizatriptan NN I-NP B-Chemical
17 572 574 12464714 to TO B-PP O
18 575 585 12464714 ergotamine NN B-NP B-Chemical
19 585 586 12464714 / SYM O O
20 586 594 12464714 caffeine NN B-NP B-Chemical
21 595 596 12464714 ( ( O O
22 596 600 12464714 69.9 CD B-NP O
23 601 603 12464714 vs NNS I-NP O
24 603 604 12464714 . . O O
25 605 610 12464714 30.1% CD B-NP O
26 610 611 12464714 , , O O
27 612 613 12464714 p NN B-NP O
28 614 615 12464714 < SYM B-VP O
29 616 618 12464714 or CC O O
30 619 620 12464714 = SYM B-VP O
31 621 626 12464714 0.001 CD B-NP O
32 626 627 12464714 ) ) O O
33 627 628 12464714 . . O O

1 629 635 12464714 Faster NN B-NP O
2 636 642 12464714 relief NN I-NP O
3 643 645 12464714 of IN B-PP O
4 646 654 12464714 headache NN B-NP B-Disease
5 655 658 12464714 was VBD B-VP O
6 659 662 12464714 the DT B-NP O
7 663 667 12464714 most RBS I-NP O
8 668 677 12464714 important JJ I-NP O
9 678 684 12464714 reason NN I-NP O
10 685 688 12464714 for IN B-PP O
11 689 699 12464714 preference NN B-NP O
12 699 700 12464714 , , O O
13 701 706 12464714 cited VBN B-VP O
14 707 709 12464714 by IN B-PP O
15 710 715 12464714 67.3% CD B-NP O
16 716 718 12464714 of IN B-PP O
17 719 727 12464714 patients NNS B-NP O
18 728 738 12464714 preferring VBG B-VP O
19 739 750 12464714 rizatriptan NN B-NP B-Chemical
20 751 754 12464714 and CC O O
21 755 760 12464714 54.2% NN B-NP O
22 761 763 12464714 of IN B-PP O
23 764 772 12464714 patients NNS B-NP O
24 773 776 12464714 who WP B-NP O
25 777 786 12464714 preferred VBD B-VP O
26 787 797 12464714 ergotamine NN B-NP B-Chemical
27 797 798 12464714 / SYM B-NP O
28 798 806 12464714 caffeine NN I-NP B-Chemical
29 806 807 12464714 . . O O

1 808 811 12464714 The DT B-NP O
2 812 814 12464714 co AFX I-NP O
3 814 815 12464714 - HYPH I-NP O
4 815 822 12464714 primary JJ I-NP O
5 823 831 12464714 endpoint NN I-NP O
6 832 834 12464714 of IN B-PP O
7 835 840 12464714 being VBG B-VP O
8 841 845 12464714 pain NN B-NP B-Disease
9 846 850 12464714 free JJ B-ADJP O
10 851 853 12464714 at IN B-PP O
11 854 855 12464714 2 CD B-NP O
12 856 857 12464714 h NN I-NP O
13 858 861 12464714 was VBD B-VP O
14 862 866 12464714 also RB B-ADVP O
15 867 869 12464714 in IN B-PP O
16 870 875 12464714 favor NN B-NP O
17 876 878 12464714 of IN B-PP O
18 879 890 12464714 rizatriptan NN B-NP B-Chemical
19 890 891 12464714 . . O O

1 892 897 12464714 Forty CD B-NP O
2 897 898 12464714 - HYPH I-NP O
3 898 902 12464714 nine CD I-NP O
4 903 910 12464714 percent NN I-NP O
5 911 913 12464714 of IN B-PP O
6 914 922 12464714 patients NNS B-NP O
7 923 927 12464714 were VBD B-VP O
8 928 932 12464714 pain NN B-NP B-Disease
9 933 937 12464714 free JJ I-NP O
10 938 939 12464714 2 CD I-NP O
11 940 941 12464714 h NN I-NP O
12 942 947 12464714 after IN B-PP O
13 948 959 12464714 rizatriptan NN B-NP B-Chemical
14 959 960 12464714 , , O O
15 961 969 12464714 compared VBN B-PP O
16 970 974 12464714 with IN B-PP O
17 975 980 12464714 24.3% NN B-NP O
18 981 988 12464714 treated VBN B-VP O
19 989 993 12464714 with IN B-PP O
20 994 1004 12464714 ergotamine NN B-NP B-Chemical
21 1004 1005 12464714 / SYM O O
22 1005 1013 12464714 caffeine NN B-NP B-Chemical
23 1014 1015 12464714 ( ( O O
24 1015 1016 12464714 p NN B-NP O
25 1017 1018 12464714 < SYM B-VP O
26 1019 1021 12464714 or CC O O
27 1022 1023 12464714 = SYM B-VP O
28 1024 1029 12464714 0.001 CD B-NP O
29 1029 1030 12464714 ) ) O O
30 1030 1031 12464714 , , O O
31 1032 1043 12464714 rizatriptan NN B-NP B-Chemical
32 1044 1049 12464714 being VBG B-VP O
33 1050 1058 12464714 superior JJ B-ADJP O
34 1059 1065 12464714 within IN B-PP O
35 1066 1067 12464714 1 CD B-NP O
36 1068 1069 12464714 h NN I-NP O
37 1070 1072 12464714 of IN B-PP O
38 1073 1082 12464714 treatment NN B-NP O
39 1082 1083 12464714 . . O O

1 1084 1092 12464714 Headache NN B-NP B-Disease
2 1093 1099 12464714 relief NN I-NP O
3 1100 1102 12464714 at IN B-PP O
4 1103 1104 12464714 2 CD B-NP O
5 1105 1106 12464714 h NN I-NP O
6 1107 1110 12464714 was VBD B-VP O
7 1111 1116 12464714 75.9% CD B-NP O
8 1117 1120 12464714 for IN B-PP O
9 1121 1132 12464714 rizatriptan NN B-NP B-Chemical
10 1133 1136 12464714 and CC I-NP O
11 1137 1142 12464714 47.3% NN I-NP O
12 1143 1146 12464714 for IN B-PP O
13 1147 1157 12464714 ergotamine NN B-NP B-Chemical
14 1157 1158 12464714 / SYM O O
15 1158 1166 12464714 caffeine NN B-NP B-Chemical
16 1167 1168 12464714 ( ( O O
17 1168 1169 12464714 p NN B-NP O
18 1170 1171 12464714 < SYM B-VP O
19 1172 1174 12464714 or CC O O
20 1175 1176 12464714 = SYM B-VP O
21 1177 1182 12464714 0.001 CD B-NP O
22 1182 1183 12464714 ) ) O O
23 1183 1184 12464714 , , O O
24 1185 1189 12464714 with IN B-PP O
25 1190 1201 12464714 rizatriptan NN B-NP B-Chemical
26 1202 1207 12464714 being VBG B-VP O
27 1208 1216 12464714 superior JJ B-ADJP O
28 1217 1219 12464714 to TO B-PP O
29 1220 1230 12464714 ergotamine NN B-NP B-Chemical
30 1230 1231 12464714 / SYM B-NP O
31 1231 1239 12464714 caffeine NN I-NP B-Chemical
32 1240 1246 12464714 within IN B-PP O
33 1247 1249 12464714 30 CD B-NP O
34 1250 1253 12464714 min NN I-NP O
35 1254 1256 12464714 of IN B-PP O
36 1257 1263 12464714 dosing NN B-NP O
37 1263 1264 12464714 . . O O

1 1265 1271 12464714 Almost RB B-NP O
2 1272 1275 12464714 36% CD I-NP O
3 1276 1278 12464714 of IN B-PP O
4 1279 1287 12464714 patients NNS B-NP O
5 1288 1294 12464714 taking VBG B-VP O
6 1295 1306 12464714 rizatriptan NN B-NP B-Chemical
7 1307 1311 12464714 were VBD B-VP O
8 1312 1316 12464714 pain NN B-NP B-Disease
9 1317 1321 12464714 free JJ B-ADJP O
10 1322 1324 12464714 at IN B-PP O
11 1325 1326 12464714 2 CD B-NP O
12 1327 1328 12464714 h NN I-NP O
13 1329 1332 12464714 and CC O O
14 1333 1336 12464714 had VBD B-VP O
15 1337 1339 12464714 no DT B-NP O
16 1340 1350 12464714 recurrence NN I-NP O
17 1351 1353 12464714 or CC I-NP O
18 1354 1358 12464714 need NN I-NP O
19 1359 1362 12464714 for IN B-PP O
20 1363 1373 12464714 additional JJ B-NP O
21 1374 1384 12464714 medication NN I-NP O
22 1385 1391 12464714 within IN B-PP O
23 1392 1394 12464714 24 CD B-NP O
24 1395 1396 12464714 h NN I-NP O
25 1396 1397 12464714 , , O O
26 1398 1406 12464714 compared VBN B-PP O
27 1407 1409 12464714 to TO B-PP O
28 1410 1413 12464714 20% CD B-NP O
29 1414 1416 12464714 of IN B-PP O
30 1417 1425 12464714 patients NNS B-NP O
31 1426 1428 12464714 on IN B-PP O
32 1429 1439 12464714 ergotamine NN B-NP B-Chemical
33 1439 1440 12464714 / SYM O O
34 1440 1448 12464714 caffeine NN B-NP B-Chemical
35 1449 1450 12464714 ( ( O O
36 1450 1451 12464714 p NN B-NP O
37 1452 1453 12464714 < SYM B-VP O
38 1454 1456 12464714 or CC O O
39 1457 1458 12464714 = SYM B-VP O
40 1459 1464 12464714 0.001 CD B-NP O
41 1464 1465 12464714 ) ) O O
42 1465 1466 12464714 . . O O

1 1467 1478 12464714 Rizatriptan NN B-NP B-Chemical
2 1479 1482 12464714 was VBD B-VP O
3 1483 1487 12464714 also RB B-ADVP O
4 1488 1496 12464714 superior JJ B-ADJP O
5 1497 1499 12464714 to TO B-PP O
6 1500 1510 12464714 ergotamine NN B-NP B-Chemical
7 1510 1511 12464714 / SYM B-NP O
8 1511 1519 12464714 caffeine NN I-NP B-Chemical
9 1520 1522 12464714 in IN B-PP O
10 1523 1526 12464714 the DT B-NP O
11 1527 1538 12464714 proportions NNS I-NP O
12 1539 1541 12464714 of IN B-PP O
13 1542 1550 12464714 patients NNS B-NP O
14 1551 1555 12464714 with IN B-PP O
15 1556 1558 12464714 no DT B-NP O
16 1559 1565 12464714 nausea NN I-NP B-Disease
17 1565 1566 12464714 , , I-NP O
18 1567 1575 12464714 vomiting NN I-NP B-Disease
19 1575 1576 12464714 , , I-NP O
20 1577 1588 12464714 phonophobia NN I-NP B-Disease
21 1589 1591 12464714 or CC I-NP O
22 1592 1603 12464714 photophobia NN I-NP B-Disease
23 1604 1607 12464714 and CC B-PP O
24 1608 1611 12464714 for IN B-PP O
25 1612 1620 12464714 patients NNS B-NP O
26 1621 1625 12464714 with IN B-PP O
27 1626 1632 12464714 normal JJ B-NP O
28 1633 1641 12464714 function NN I-NP O
29 1642 1643 12464714 2 CD I-NP O
30 1644 1645 12464714 h NN I-NP O
31 1646 1651 12464714 after IN B-PP O
32 1652 1656 12464714 drug NN B-NP O
33 1657 1663 12464714 intake NN I-NP O
34 1664 1665 12464714 ( ( O O
35 1665 1666 12464714 p NN B-NP O
36 1667 1668 12464714 < SYM B-VP O
37 1669 1671 12464714 or CC O O
38 1672 1673 12464714 = SYM B-VP O
39 1674 1679 12464714 0.001 CD B-NP O
40 1679 1680 12464714 ) ) O O
41 1680 1681 12464714 . . O O

1 1682 1686 12464714 More JJR B-NP O
2 1687 1695 12464714 patients NNS I-NP O
3 1696 1700 12464714 were VBD B-VP O
4 1701 1702 12464714 ( ( O O
5 1702 1712 12464714 completely RB B-ADVP O
6 1712 1713 12464714 , , O O
7 1714 1718 12464714 very RB B-ADVP O
8 1719 1721 12464714 or CC I-ADVP O
9 1722 1730 12464714 somewhat RB I-ADVP O
10 1730 1731 12464714 ) ) O O
11 1732 1741 12464714 satisfied VBD B-VP O
12 1742 1743 12464714 2 CD B-NP O
13 1744 1745 12464714 h NN I-NP O
14 1746 1751 12464714 after IN B-PP O
15 1752 1761 12464714 treatment NN B-NP O
16 1762 1766 12464714 with IN B-PP O
17 1767 1778 12464714 rizatriptan NN B-NP B-Chemical
18 1779 1780 12464714 ( ( O O
19 1780 1785 12464714 69.8% CD B-NP O
20 1785 1786 12464714 ) ) O O
21 1787 1791 12464714 than IN B-PP O
22 1792 1794 12464714 at IN B-PP O
23 1795 1796 12464714 2 CD B-NP O
24 1797 1798 12464714 h NN I-NP O
25 1799 1804 12464714 after IN B-PP O
26 1805 1814 12464714 treatment NN B-NP O
27 1815 1819 12464714 with IN B-PP O
28 1820 1830 12464714 ergotamine NN B-NP B-Chemical
29 1830 1831 12464714 / SYM O O
30 1831 1839 12464714 caffeine NN B-NP B-Chemical
31 1840 1841 12464714 ( ( O O
32 1841 1846 12464714 38.6% NN B-NP O
33 1846 1847 12464714 , , O O
34 1848 1849 12464714 p NN B-NP O
35 1850 1851 12464714 < SYM B-VP O
36 1852 1854 12464714 or CC O O
37 1855 1856 12464714 = SYM B-VP O
38 1857 1862 12464714 0.001 CD B-NP O
39 1862 1863 12464714 ) ) O O
40 1863 1864 12464714 . . O O

1 1865 1875 12464714 Recurrence NN B-NP O
2 1876 1881 12464714 rates NNS I-NP O
3 1882 1886 12464714 were VBD B-VP O
4 1887 1892 12464714 31.4% CD B-NP O
5 1893 1897 12464714 with IN B-PP O
6 1898 1909 12464714 rizatriptan NN B-NP B-Chemical
7 1910 1913 12464714 and CC I-NP O
8 1914 1919 12464714 15.3% NN I-NP O
9 1920 1924 12464714 with IN B-PP O
10 1925 1935 12464714 ergotamine NN B-NP B-Chemical
11 1935 1936 12464714 / SYM B-NP O
12 1936 1944 12464714 caffeine NN I-NP B-Chemical
13 1944 1945 12464714 . . O O

1 1946 1950 12464714 Both DT B-NP O
2 1951 1957 12464714 active JJ I-NP O
3 1958 1968 12464714 treatments NNS I-NP O
4 1969 1973 12464714 were VBD B-VP O
5 1974 1978 12464714 well RB I-VP O
6 1979 1988 12464714 tolerated VBN I-VP O
7 1988 1989 12464714 . . O O

1 1990 1993 12464714 The DT B-NP O
2 1994 1998 12464714 most RBS I-NP O
3 1999 2005 12464714 common JJ I-NP O
4 2006 2013 12464714 adverse JJ I-NP O
5 2014 2020 12464714 events NNS I-NP O
6 2021 2022 12464714 ( ( O O
7 2022 2031 12464714 incidence NN B-NP O
8 2032 2033 12464714 > SYM B-VP O
9 2034 2036 12464714 or CC O O
10 2037 2038 12464714 = SYM B-VP O
11 2039 2041 12464714 5% CD B-NP O
12 2042 2044 12464714 in IN B-PP O
13 2045 2048 12464714 one CD B-NP O
14 2049 2054 12464714 group NN I-NP O
15 2054 2055 12464714 ) ) O O
16 2056 2061 12464714 after IN B-PP O
17 2062 2073 12464714 rizatriptan NN B-NP B-Chemical
18 2074 2077 12464714 and CC I-NP O
19 2078 2088 12464714 ergotamine NN I-NP B-Chemical
20 2088 2089 12464714 / SYM O O
21 2089 2097 12464714 caffeine NN B-NP B-Chemical
22 2097 2098 12464714 , , O O
23 2099 2111 12464714 respectively RB B-ADVP O
24 2111 2112 12464714 , , O O
25 2113 2117 12464714 were VBD B-VP O
26 2118 2127 12464714 dizziness NN B-NP B-Disease
27 2128 2129 12464714 ( ( O O
28 2129 2132 12464714 6.7 CD B-NP O
29 2133 2136 12464714 and CC I-NP O
30 2137 2141 12464714 5.3% CD I-NP O
31 2141 2142 12464714 ) ) O O
32 2142 2143 12464714 , , O O
33 2144 2150 12464714 nausea NN B-NP B-Disease
34 2151 2152 12464714 ( ( O O
35 2152 2155 12464714 4.2 CD B-NP O
36 2156 2159 12464714 and CC I-NP O
37 2160 2164 12464714 8.5% CD I-NP O
38 2164 2165 12464714 ) ) O O
39 2166 2169 12464714 and CC O O
40 2170 2180 12464714 somnolence NN B-NP B-Disease
41 2181 2182 12464714 ( ( O O
42 2182 2185 12464714 5.5 CD B-NP O
43 2186 2189 12464714 and CC I-NP O
44 2190 2194 12464714 2.3% CD I-NP O
45 2194 2195 12464714 ) ) O O
46 2195 2196 12464714 . . O O

1 0 0 7834920 -DOCSTART- -X- -X- O

1 0 10 7834920 Crescentic JJ B-NP O
2 11 21 7834920 fibrillary JJ I-NP O
3 22 40 7834920 glomerulonephritis NN I-NP B-Disease
4 41 51 7834920 associated VBN B-VP O
5 52 56 7834920 with IN B-PP O
6 57 69 7834920 intermittent JJ B-NP O
7 70 78 7834920 rifampin NN I-NP B-Chemical
8 79 86 7834920 therapy NN I-NP O
9 87 90 7834920 for IN B-PP O
10 91 100 7834920 pulmonary JJ B-NP B-Disease
11 101 113 7834920 tuberculosis NN I-NP I-Disease
12 113 114 7834920 . . O O
13 115 119 7834920 This DT B-NP O
14 120 124 7834920 case NN I-NP O
15 125 130 7834920 study NN I-NP O
16 131 138 7834920 reveals VBZ B-VP O
17 139 141 7834920 an DT B-NP O
18 142 149 7834920 unusual JJ I-NP O
19 150 157 7834920 finding NN I-NP O
20 158 160 7834920 of IN B-PP O
21 161 168 7834920 rapidly RB B-NP O
22 169 182 7834920 proliferative JJ I-NP O
23 183 193 7834920 crescentic JJ I-NP O
24 194 212 7834920 glomerulonephritis NN I-NP B-Disease
25 213 215 7834920 in IN B-PP O
26 216 217 7834920 a DT B-NP O
27 218 225 7834920 patient NN I-NP O
28 226 233 7834920 treated VBN B-VP O
29 234 238 7834920 with IN B-PP O
30 239 247 7834920 rifampin NN B-NP B-Chemical
31 248 251 7834920 who WP B-NP O
32 252 255 7834920 had VBD B-VP O
33 256 258 7834920 no DT B-NP O
34 259 264 7834920 other JJ I-NP O
35 265 277 7834920 identifiable JJ I-NP O
36 278 284 7834920 causes NNS I-NP O
37 285 288 7834920 for IN B-PP O
38 289 299 7834920 developing VBG B-VP O
39 300 304 7834920 this DT B-NP O
40 305 312 7834920 disease NN I-NP O
41 312 313 7834920 . . O O

1 314 318 7834920 This DT B-NP O
2 319 326 7834920 patient NN I-NP O
3 327 336 7834920 underwent VBD B-VP O
4 337 338 7834920 a DT B-NP O
5 339 341 7834920 10 CD I-NP O
6 341 342 7834920 - HYPH I-NP O
7 342 347 7834920 month NN I-NP O
8 348 355 7834920 regimen NN I-NP O
9 356 358 7834920 of IN B-PP O
10 359 367 7834920 rifampin NN B-NP B-Chemical
11 368 371 7834920 and CC I-NP O
12 372 381 7834920 isoniazid NN I-NP B-Chemical
13 382 385 7834920 for IN B-PP O
14 386 395 7834920 pulmonary JJ B-NP B-Disease
15 396 408 7834920 tuberculosis NN I-NP I-Disease
16 409 412 7834920 and CC O O
17 413 416 7834920 was VBD B-VP O
18 417 427 7834920 discovered VBN I-VP O
19 428 430 7834920 to TO I-VP O
20 431 435 7834920 have VB I-VP O
21 436 445 7834920 developed VBN I-VP O
22 446 451 7834920 signs NNS B-NP O
23 452 454 7834920 of IN B-PP O
24 455 461 7834920 severe JJ B-NP O
25 462 467 7834920 renal JJ I-NP B-Disease
26 468 475 7834920 failure NN I-NP I-Disease
27 476 480 7834920 five CD B-NP O
28 481 486 7834920 weeks NNS I-NP O
29 487 492 7834920 after IN B-PP O
30 493 503 7834920 completion NN B-NP O
31 504 506 7834920 of IN B-PP O
32 507 514 7834920 therapy NN B-NP O
33 514 515 7834920 . . O O

1 516 521 7834920 Renal JJ B-NP O
2 522 528 7834920 biopsy NN I-NP O
3 529 537 7834920 revealed VBD B-VP O
4 538 544 7834920 severe JJ B-NP O
5 545 563 7834920 glomerulonephritis NN I-NP B-Disease
6 564 568 7834920 with IN B-PP O
7 569 578 7834920 crescents NNS B-NP O
8 578 579 7834920 , , O O
9 580 588 7834920 electron NN B-NP O
10 589 594 7834920 dense JJ I-NP O
11 595 604 7834920 fibrillar JJ I-NP O
12 605 613 7834920 deposits NNS I-NP O
13 614 617 7834920 and CC O O
14 618 626 7834920 moderate JJ B-NP O
15 627 638 7834920 lymphocytic JJ I-NP O
16 639 651 7834920 interstitial JJ I-NP O
17 652 662 7834920 infiltrate NN I-NP O
18 662 663 7834920 . . O O

1 664 669 7834920 Other JJ B-NP O
2 670 678 7834920 possible JJ I-NP O
3 679 685 7834920 causes NNS I-NP O
4 686 688 7834920 of IN B-PP O
5 689 696 7834920 rapidly RB B-NP O
6 697 708 7834920 progressive JJ I-NP O
7 709 727 7834920 glomerulonephritis NN I-NP B-Disease
8 728 732 7834920 were VBD B-VP O
9 733 745 7834920 investigated VBN I-VP O
10 746 749 7834920 and CC O O
11 750 755 7834920 ruled VBN B-VP O
12 756 759 7834920 out RP B-PRT O
13 759 760 7834920 . . O O

1 761 765 7834920 This DT B-NP O
2 766 772 7834920 report NN I-NP O
3 773 782 7834920 documents VBZ B-VP O
4 783 786 7834920 the DT B-NP O
5 787 794 7834920 unusual JJ I-NP O
6 795 805 7834920 occurrence NN I-NP O
7 806 808 7834920 of IN B-PP O
8 809 816 7834920 rapidly RB B-NP O
9 817 828 7834920 progressive JJ I-NP O
10 829 847 7834920 glomerulonephritis NN I-NP B-Disease
11 848 852 7834920 with IN B-PP O
12 853 862 7834920 crescents NNS B-NP O
13 863 866 7834920 and CC O O
14 867 876 7834920 fibrillar JJ B-NP O
15 877 895 7834920 glomerulonephritis NN I-NP B-Disease
16 896 898 7834920 in IN B-PP O
17 899 900 7834920 a DT B-NP O
18 901 908 7834920 patient NN I-NP O
19 909 916 7834920 treated VBN B-VP O
20 917 921 7834920 with IN B-PP O
21 922 930 7834920 rifampin NN B-NP B-Chemical
22 930 931 7834920 . . O O

1 0 0 11379838 -DOCSTART- -X- -X- O

1 0 14 11379838 Antidepressant NN B-NP B-Chemical
2 14 15 11379838 - HYPH B-PP O
3 15 22 11379838 induced VBN B-NP O
4 23 28 11379838 mania NN I-NP B-Disease
5 29 31 11379838 in IN B-PP O
6 32 39 11379838 bipolar JJ B-NP B-Disease
7 40 48 11379838 patients NNS I-NP O
8 48 49 11379838 : : O O
9 50 64 11379838 identification NN B-NP O
10 65 67 11379838 of IN B-PP O
11 68 72 11379838 risk NN B-NP O
12 73 80 11379838 factors NNS I-NP O
13 80 81 11379838 . . O O
14 82 92 11379838 BACKGROUND NN B-NP O
15 92 93 11379838 : : O O
16 94 102 11379838 Concerns NNS B-NP O
17 103 108 11379838 about IN B-PP O
18 109 117 11379838 possible JJ B-NP O
19 118 123 11379838 risks NNS I-NP O
20 124 126 11379838 of IN B-PP O
21 127 136 11379838 switching VBG B-VP O
22 137 139 11379838 to TO B-PP O
23 140 145 11379838 mania NN B-NP B-Disease
24 146 156 11379838 associated VBN B-VP O
25 157 161 11379838 with IN B-PP O
26 162 177 11379838 antidepressants NNS B-NP B-Chemical
27 178 186 11379838 continue VBP B-VP O
28 187 189 11379838 to TO I-VP O
29 190 199 11379838 interfere VB I-VP O
30 200 204 11379838 with IN B-PP O
31 205 208 11379838 the DT B-NP O
32 209 222 11379838 establishment NN I-NP O
33 223 225 11379838 of IN B-PP O
34 226 228 11379838 an DT B-NP O
35 229 236 11379838 optimal JJ I-NP O
36 237 246 11379838 treatment NN I-NP O
37 247 255 11379838 paradigm NN I-NP O
38 256 259 11379838 for IN B-PP O
39 260 267 11379838 bipolar JJ B-NP B-Disease
40 268 278 11379838 depression NN I-NP I-Disease
41 278 279 11379838 . . O O

1 280 286 11379838 METHOD NN B-NP O
2 286 287 11379838 : : O O
3 288 291 11379838 The DT B-NP O
4 292 300 11379838 response NN I-NP O
5 301 303 11379838 of IN B-PP O
6 304 306 11379838 44 CD B-NP O
7 307 315 11379838 patients NNS I-NP O
8 316 323 11379838 meeting VBG B-VP O
9 324 327 11379838 DSM NN B-NP O
10 327 328 11379838 - HYPH O O
11 328 330 11379838 IV CD B-NP O
12 331 339 11379838 criteria NNS I-NP O
13 340 343 11379838 for IN B-PP O
14 344 351 11379838 bipolar JJ B-NP B-Disease
15 352 360 11379838 disorder NN I-NP I-Disease
16 361 363 11379838 to TO B-PP O
17 364 376 11379838 naturalistic JJ B-NP O
18 377 386 11379838 treatment NN I-NP O
19 387 390 11379838 was VBD B-VP O
20 391 399 11379838 assessed VBN I-VP O
21 400 403 11379838 for IN B-PP O
22 404 406 11379838 at IN B-NP O
23 407 412 11379838 least JJS I-NP O
24 413 414 11379838 6 CD I-NP O
25 415 420 11379838 weeks NNS I-NP O
26 421 426 11379838 using VBG B-VP O
27 427 430 11379838 the DT B-NP O
28 431 441 11379838 Montgomery NNP I-NP O
29 441 442 11379838 - HYPH I-NP O
30 442 448 11379838 Asberg NNP I-NP O
31 449 459 11379838 Depression NNP I-NP O
32 460 466 11379838 Rating NNP I-NP O
33 467 472 11379838 Scale NNP I-NP O
34 473 476 11379838 and CC O O
35 477 480 11379838 the DT B-NP O
36 481 485 11379838 Bech NNP I-NP O
37 485 486 11379838 - HYPH I-NP O
38 486 495 11379838 Rafaelson NNP I-NP O
39 496 501 11379838 Mania NNP I-NP O
40 502 508 11379838 Rating NNP I-NP O
41 509 514 11379838 Scale NNP I-NP O
42 514 515 11379838 . . O O

1 516 524 11379838 Patients NNS B-NP O
2 525 528 11379838 who WP B-NP O
3 529 540 11379838 experienced VBD B-VP O
4 541 542 11379838 a DT B-NP O
5 543 548 11379838 manic JJ I-NP B-Disease
6 549 551 11379838 or CC I-NP O
7 552 561 11379838 hypomanic JJ I-NP B-Disease
8 562 568 11379838 switch NN I-NP O
9 569 573 11379838 were VBD B-VP O
10 574 582 11379838 compared VBN I-VP O
11 583 587 11379838 with IN B-PP O
12 588 593 11379838 those DT B-NP O
13 594 597 11379838 who WP B-NP O
14 598 601 11379838 did VBD B-VP O
15 602 605 11379838 not RB O O
16 606 608 11379838 on IN B-PP O
17 609 616 11379838 several JJ B-NP O
18 617 626 11379838 variables NNS I-NP O
19 627 636 11379838 including VBG B-PP O
20 637 640 11379838 age NN B-NP O
21 640 641 11379838 , , O O
22 642 645 11379838 sex NN B-NP O
23 645 646 11379838 , , O O
24 647 656 11379838 diagnosis NN B-NP O
25 657 658 11379838 ( ( O O
26 658 661 11379838 DSM NN B-NP B-Disease
27 661 662 11379838 - HYPH O I-Disease
28 662 664 11379838 IV CD B-NP I-Disease
29 665 672 11379838 bipolar JJ I-NP I-Disease
30 673 674 11379838 I NN I-NP I-Disease
31 675 677 11379838 vs NNS I-NP O
32 677 678 11379838 . . O O
33 679 686 11379838 bipolar JJ B-NP B-Disease
34 687 689 11379838 II NN I-NP I-Disease
35 689 690 11379838 ) ) O O
36 690 691 11379838 , , O O
37 692 698 11379838 number NN B-NP O
38 699 701 11379838 of IN B-PP O
39 702 710 11379838 previous JJ B-NP O
40 711 716 11379838 manic JJ I-NP B-Disease
41 717 725 11379838 episodes NNS I-NP O
42 725 726 11379838 , , O O
43 727 731 11379838 type NN B-NP O
44 732 734 11379838 of IN B-PP O
45 735 749 11379838 antidepressant NN B-NP B-Chemical
46 750 757 11379838 therapy NN I-NP O
47 758 762 11379838 used VBN B-VP O
48 763 764 11379838 ( ( O O
49 764 781 11379838 electroconvulsive JJ B-NP O
50 782 789 11379838 therapy NN I-NP O
51 790 792 11379838 vs NNS I-NP O
52 792 793 11379838 . . O O
53 794 808 11379838 antidepressant JJ B-NP B-Chemical
54 809 814 11379838 drugs NNS I-NP O
55 815 818 11379838 and CC O O
56 818 819 11379838 , , O O
57 820 824 11379838 more RBR B-ADVP O
58 825 837 11379838 particularly RB I-ADVP O
59 837 838 11379838 , , O O
60 839 848 11379838 selective JJ B-NP O
61 849 858 11379838 serotonin NN I-NP B-Chemical
62 859 867 11379838 reuptake NN I-NP I-Chemical
63 868 878 11379838 inhibitors NNS I-NP I-Chemical
64 879 880 11379838 [ ( O O
65 880 885 11379838 SSRIs NNS B-NP B-Chemical
66 885 886 11379838 ] ) O O
67 886 887 11379838 ) ) O O
68 887 888 11379838 , , O O
69 889 892 11379838 use NN B-NP O
70 893 896 11379838 and CC I-NP O
71 897 901 11379838 type NN I-NP O
72 902 904 11379838 of IN B-PP O
73 905 909 11379838 mood NN B-NP O
74 910 921 11379838 stabilizers NNS I-NP O
75 922 923 11379838 ( ( O O
76 923 930 11379838 lithium NN B-NP B-Chemical
77 931 933 11379838 vs NNS I-NP O
78 933 934 11379838 . . O O
79 935 950 11379838 anticonvulsants NNS B-NP O
80 950 951 11379838 ) ) O O
81 951 952 11379838 , , O O
82 953 956 11379838 and CC O O
83 957 968 11379838 temperament NN B-NP O
84 969 971 11379838 of IN B-PP O
85 972 975 11379838 the DT B-NP O
86 976 983 11379838 patient NN I-NP O
87 983 984 11379838 , , O O
88 985 993 11379838 assessed VBN B-VP O
89 994 1000 11379838 during IN B-PP O
90 1001 1002 11379838 a DT B-NP O
91 1003 1014 11379838 normothymic JJ I-NP O
92 1015 1021 11379838 period NN I-NP O
93 1022 1027 11379838 using VBG B-VP O
94 1028 1031 11379838 the DT B-NP O
95 1032 1043 11379838 hyperthymia NN I-NP O
96 1044 1053 11379838 component NN I-NP O
97 1054 1056 11379838 of IN B-PP O
98 1057 1060 11379838 the DT B-NP O
99 1061 1065 11379838 Semi NN I-NP O
100 1065 1066 11379838 - HYPH O O
101 1066 1076 11379838 structured VBN B-VP O
102 1077 1086 11379838 Affective JJ B-NP O
103 1087 1098 11379838 Temperament NNP I-NP O
104 1099 1108 11379838 Interview NNP I-NP O
105 1108 1109 11379838 . . O O

1 1110 1117 11379838 RESULTS NNS B-NP O
2 1117 1118 11379838 : : O O
3 1119 1127 11379838 Switches NNS B-NP O
4 1128 1130 11379838 to TO B-PP O
5 1131 1140 11379838 hypomania NN B-NP B-Disease
6 1141 1143 11379838 or CC I-NP O
7 1144 1149 11379838 mania NN I-NP B-Disease
8 1150 1158 11379838 occurred VBD B-VP O
9 1159 1161 11379838 in IN B-PP O
10 1162 1165 11379838 27% CD B-NP O
11 1166 1168 11379838 of IN B-PP O
12 1169 1172 11379838 all DT B-NP O
13 1173 1181 11379838 patients NNS I-NP O
14 1182 1183 11379838 ( ( O O
15 1183 1184 11379838 N NN B-NP O
16 1185 1186 11379838 = SYM B-VP O
17 1187 1189 11379838 12 CD B-NP O
18 1189 1190 11379838 ) ) O O
19 1191 1192 11379838 ( ( O O
20 1192 1195 11379838 and CC O O
21 1196 1198 11379838 in IN B-PP O
22 1199 1202 11379838 24% NN B-NP O
23 1203 1205 11379838 of IN B-PP O
24 1206 1209 11379838 the DT B-NP O
25 1210 1218 11379838 subgroup NN I-NP O
26 1219 1221 11379838 of IN B-PP O
27 1222 1230 11379838 patients NNS B-NP O
28 1231 1238 11379838 treated VBN B-VP O
29 1239 1243 11379838 with IN B-PP O
30 1244 1249 11379838 SSRIs NNS B-NP B-Chemical
31 1250 1251 11379838 [ ( O O
32 1251 1252 11379838 8 CD B-NP O
33 1252 1253 11379838 / SYM I-NP O
34 1253 1255 11379838 33 CD I-NP O
35 1255 1256 11379838 ] ) O O
36 1256 1257 11379838 ) ) O O
37 1257 1258 11379838 ; : O O
38 1259 1262 11379838 16% CD B-NP O
39 1263 1264 11379838 ( ( O O
40 1264 1265 11379838 N NN B-NP O
41 1266 1267 11379838 = SYM B-VP O
42 1268 1269 11379838 7 CD B-NP O
43 1269 1270 11379838 ) ) O O
44 1271 1282 11379838 experienced VBD B-VP O
45 1283 1288 11379838 manic JJ B-NP B-Disease
46 1289 1297 11379838 episodes NNS I-NP O
47 1297 1298 11379838 , , O O
48 1299 1302 11379838 and CC O O
49 1303 1306 11379838 11% NN B-NP O
50 1307 1308 11379838 ( ( O O
51 1308 1309 11379838 N NN B-NP O
52 1310 1311 11379838 = SYM B-VP O
53 1312 1313 11379838 5 CD B-NP O
54 1313 1314 11379838 ) ) O O
55 1315 1326 11379838 experienced VBD B-VP O
56 1327 1336 11379838 hypomanic JJ B-NP B-Disease
57 1337 1345 11379838 episodes NNS I-NP O
58 1345 1346 11379838 . . O O

1 1347 1350 11379838 Sex NN B-NP O
2 1350 1351 11379838 , , O O
3 1352 1355 11379838 age NN B-NP O
4 1355 1356 11379838 , , O O
5 1357 1366 11379838 diagnosis NN B-NP O
6 1367 1368 11379838 ( ( O O
7 1368 1375 11379838 bipolar JJ B-NP B-Disease
8 1376 1377 11379838 I NN I-NP I-Disease
9 1378 1380 11379838 vs NNS I-NP O
10 1380 1381 11379838 . . O O
11 1382 1389 11379838 bipolar JJ B-NP B-Disease
12 1390 1392 11379838 II NN I-NP I-Disease
13 1392 1393 11379838 ) ) O O
14 1393 1394 11379838 , , O O
15 1395 1398 11379838 and CC O O
16 1399 1409 11379838 additional JJ B-NP O
17 1410 1419 11379838 treatment NN I-NP O
18 1420 1423 11379838 did VBD B-VP O
19 1424 1427 11379838 not RB I-VP O
20 1428 1434 11379838 affect VB I-VP O
21 1435 1438 11379838 the DT B-NP O
22 1439 1443 11379838 risk NN I-NP O
23 1444 1446 11379838 of IN B-PP O
24 1447 1456 11379838 switching NN B-NP O
25 1456 1457 11379838 . . O O

1 1458 1461 11379838 The DT B-NP O
2 1462 1471 11379838 incidence NN I-NP O
3 1472 1474 11379838 of IN B-PP O
4 1475 1479 11379838 mood NN B-NP O
5 1480 1488 11379838 switches NNS I-NP O
6 1489 1495 11379838 seemed VBD B-VP O
7 1496 1499 11379838 not RB O O
8 1500 1502 11379838 to TO B-VP O
9 1503 1509 11379838 differ VB I-VP O
10 1510 1517 11379838 between IN B-PP O
11 1518 1526 11379838 patients NNS B-NP O
12 1527 1536 11379838 receiving VBG B-VP O
13 1537 1539 11379838 an DT B-NP O
14 1540 1554 11379838 anticonvulsant NN I-NP O
15 1555 1558 11379838 and CC O O
16 1559 1564 11379838 those DT B-NP O
17 1565 1574 11379838 receiving VBG B-VP O
18 1575 1577 11379838 no DT B-NP O
19 1578 1582 11379838 mood NN I-NP O
20 1583 1593 11379838 stabilizer NN I-NP O
21 1593 1594 11379838 . . O O

1 1595 1597 11379838 In IN B-PP O
2 1598 1606 11379838 contrast NN B-NP O
3 1606 1607 11379838 , , O O
4 1608 1612 11379838 mood NN B-NP O
5 1613 1621 11379838 switches NNS I-NP O
6 1622 1626 11379838 were VBD B-VP O
7 1627 1631 11379838 less RBR B-ADJP O
8 1632 1640 11379838 frequent JJ I-ADJP O
9 1641 1643 11379838 in IN B-PP O
10 1644 1652 11379838 patients NNS B-NP O
11 1653 1662 11379838 receiving VBG B-VP O
12 1663 1670 11379838 lithium NN B-NP B-Chemical
13 1671 1672 11379838 ( ( O O
14 1672 1675 11379838 15% CD B-NP O
15 1675 1676 11379838 , , I-NP O
16 1677 1678 11379838 4 CD I-NP O
17 1678 1679 11379838 / SYM B-NP O
18 1679 1681 11379838 26 CD I-NP O
19 1681 1682 11379838 ) ) O O
20 1683 1687 11379838 than IN B-PP O
21 1688 1690 11379838 in IN B-PP O
22 1691 1699 11379838 patients NNS B-NP O
23 1700 1703 11379838 not RB B-VP O
24 1704 1711 11379838 treated VBN I-VP O
25 1712 1716 11379838 with IN B-PP O
26 1717 1724 11379838 lithium NN B-NP B-Chemical
27 1725 1726 11379838 ( ( O O
28 1726 1729 11379838 44% CD B-NP O
29 1729 1730 11379838 , , O O
30 1731 1732 11379838 8 CD B-NP O
31 1732 1733 11379838 / SYM I-NP O
32 1733 1735 11379838 18 CD I-NP O
33 1735 1736 11379838 ; : O O
34 1737 1738 11379838 p NN B-NP O
35 1739 1740 11379838 = SYM B-VP O
36 1741 1744 11379838 .04 CD B-NP O
37 1744 1745 11379838 ) ) O O
38 1745 1746 11379838 . . O O

1 1747 1750 11379838 The DT B-NP O
2 1751 1757 11379838 number NN I-NP O
3 1758 1760 11379838 of IN B-PP O
4 1761 1769 11379838 previous JJ B-NP O
5 1770 1775 11379838 manic JJ I-NP B-Disease
6 1776 1784 11379838 episodes NNS I-NP O
7 1785 1788 11379838 did VBD B-VP O
8 1789 1792 11379838 not RB I-VP O
9 1793 1799 11379838 affect VB I-VP O
10 1800 1803 11379838 the DT B-NP O
11 1804 1815 11379838 probability NN I-NP O
12 1816 1818 11379838 of IN B-PP O
13 1819 1828 11379838 switching NN B-NP O
14 1828 1829 11379838 , , O O
15 1830 1837 11379838 whereas IN O O
16 1838 1839 11379838 a DT B-NP O
17 1840 1844 11379838 high JJ I-NP O
18 1845 1850 11379838 score NN I-NP O
19 1851 1853 11379838 on IN B-PP O
20 1854 1857 11379838 the DT B-NP O
21 1858 1869 11379838 hyperthymia NN I-NP O
22 1870 1879 11379838 component NN I-NP O
23 1880 1882 11379838 of IN B-PP O
24 1883 1886 11379838 the DT B-NP O
25 1887 1901 11379838 Semistructured JJ I-NP O
26 1902 1911 11379838 Affective JJ I-NP O
27 1912 1923 11379838 Temperament NN I-NP O
28 1924 1933 11379838 Interview NN I-NP O
29 1934 1937 11379838 was VBD B-VP O
30 1938 1948 11379838 associated VBN I-VP O
31 1949 1953 11379838 with IN B-PP O
32 1954 1955 11379838 a DT B-NP O
33 1956 1963 11379838 greater JJR I-NP O
34 1964 1968 11379838 risk NN I-NP O
35 1969 1971 11379838 of IN B-PP O
36 1972 1981 11379838 switching NN B-NP O
37 1982 1983 11379838 ( ( O O
38 1983 1984 11379838 p NN B-NP O
39 1985 1986 11379838 = SYM B-VP O
40 1987 1991 11379838 .008 CD B-NP O
41 1991 1992 11379838 ) ) O O
42 1992 1993 11379838 . . O O

1 1994 2004 11379838 CONCLUSION NN B-NP O
2 2004 2005 11379838 : : O O
3 2006 2009 11379838 The DT B-NP O
4 2010 2019 11379838 frequency NN I-NP O
5 2020 2022 11379838 of IN B-PP O
6 2023 2027 11379838 mood NN B-NP O
7 2028 2037 11379838 switching NN I-NP O
8 2038 2048 11379838 associated VBN B-VP O
9 2049 2053 11379838 with IN B-PP O
10 2054 2059 11379838 acute JJ B-NP O
11 2060 2074 11379838 antidepressant NN I-NP B-Chemical
12 2075 2082 11379838 therapy NN I-NP O
13 2083 2086 11379838 may MD B-VP O
14 2087 2089 11379838 be VB I-VP O
15 2090 2097 11379838 reduced VBN I-VP O
16 2098 2100 11379838 by IN B-PP O
17 2101 2108 11379838 lithium NN B-NP B-Chemical
18 2109 2118 11379838 treatment NN I-NP O
19 2118 2119 11379838 . . O O

1 2120 2130 11379838 Particular JJ B-NP O
2 2131 2140 11379838 attention NN I-NP O
3 2141 2147 11379838 should MD B-VP O
4 2148 2150 11379838 be VB I-VP O
5 2151 2155 11379838 paid VBN I-VP O
6 2156 2158 11379838 to TO B-PP O
7 2159 2167 11379838 patients NNS B-NP O
8 2168 2172 11379838 with IN B-PP O
9 2173 2174 11379838 a DT B-NP O
10 2175 2186 11379838 hyperthymic JJ I-NP O
11 2187 2198 11379838 temperament NN I-NP O
12 2198 2199 11379838 , , O O
13 2200 2203 11379838 who WP B-NP O
14 2204 2208 11379838 have VBP B-VP O
15 2209 2210 11379838 a DT B-NP O
16 2211 2218 11379838 greater JJR I-NP O
17 2219 2223 11379838 risk NN I-NP O
18 2224 2226 11379838 of IN B-PP O
19 2227 2231 11379838 mood NN B-NP O
20 2232 2240 11379838 switches NNS I-NP O
21 2240 2241 11379838 . . O O

1 0 0 1664218 -DOCSTART- -X- -X- O

1 0 5 1664218 Phase NN B-NP O
2 6 8 1664218 II CD I-NP O
3 9 14 1664218 study NN I-NP O
4 15 17 1664218 of IN B-PP O
5 18 21 1664218 the DT B-NP O
6 22 31 1664218 amsacrine NN I-NP B-Chemical
7 32 40 1664218 analogue NN I-NP O
8 41 43 1664218 CI NN I-NP B-Chemical
9 43 44 1664218 - HYPH O I-Chemical
10 44 47 1664218 921 CD B-NP I-Chemical
11 48 49 1664218 ( ( O O
12 49 52 1664218 NSC NN B-NP B-Chemical
13 53 59 1664218 343499 CD I-NP I-Chemical
14 59 60 1664218 ) ) O O
15 61 63 1664218 in IN B-PP O
16 64 67 1664218 non AFX B-NP B-Disease
17 67 68 1664218 - HYPH I-NP I-Disease
18 68 73 1664218 small JJ B-NP I-Disease
19 74 78 1664218 cell NN I-NP I-Disease
20 79 83 1664218 lung NN I-NP I-Disease
21 84 90 1664218 cancer NN I-NP I-Disease
22 90 91 1664218 . . B-NP O
23 92 94 1664218 CI NN I-NP B-Chemical
24 94 95 1664218 - HYPH B-NP I-Chemical
25 95 98 1664218 921 CD I-NP I-Chemical
26 99 100 1664218 ( ( O O
27 100 103 1664218 NSC NNP B-NP B-Chemical
28 104 110 1664218 343499 CD I-NP I-Chemical
29 110 111 1664218 ; : O O
30 112 113 1664218 9 CD B-NP B-Chemical
31 113 114 1664218 - HYPH I-NP I-Chemical
32 114 117 1664218 [[2 CD I-NP I-Chemical
33 117 118 1664218 - HYPH I-NP I-Chemical
34 118 125 1664218 methoxy NN I-NP I-Chemical
35 125 126 1664218 - HYPH B-NP I-Chemical
36 126 127 1664218 4 CD I-NP I-Chemical
37 127 128 1664218 - HYPH O I-Chemical
38 128 165 1664218 [(methylsulphonyl)amino]phenyl]amino] SYM B-NP I-Chemical
39 166 167 1664218 - HYPH B-NP I-Chemical
40 167 170 1664218 N,5 NN I-NP I-Chemical
41 170 171 1664218 - HYPH B-NP I-Chemical
42 171 179 1664218 dimethyl NN I-NP I-Chemical
43 179 180 1664218 - HYPH B-NP I-Chemical
44 181 182 1664218 4 CD I-NP I-Chemical
45 182 183 1664218 - HYPH I-NP I-Chemical
46 183 202 1664218 acridinecarboxamide NN I-NP I-Chemical
47 202 203 1664218 ) ) O O
48 204 206 1664218 is VBZ B-VP O
49 207 208 1664218 a DT B-NP O
50 209 222 1664218 topoisomerase NN I-NP O
51 223 225 1664218 II CD I-NP O
52 226 232 1664218 poison NN I-NP O
53 233 237 1664218 with IN B-PP O
54 238 242 1664218 high JJ B-NP O
55 243 255 1664218 experimental JJ I-NP O
56 256 266 1664218 antitumour JJ I-NP O
57 267 275 1664218 activity NN I-NP O
58 275 276 1664218 . . O O

1 277 279 1664218 It PRP B-NP O
2 280 283 1664218 was VBD B-VP O
3 284 296 1664218 administered VBN I-VP O
4 297 299 1664218 by IN B-PP O
5 300 302 1664218 15 CD B-NP O
6 303 306 1664218 min NN I-NP O
7 307 315 1664218 infusion NN I-NP O
8 316 318 1664218 to TO B-PP O
9 319 321 1664218 16 CD B-NP O
10 322 331 1664218 evaluable JJ I-NP O
11 332 340 1664218 patients NNS I-NP O
12 341 345 1664218 with IN B-PP O
13 346 349 1664218 non AFX O B-Disease
14 349 350 1664218 - HYPH O I-Disease
15 350 355 1664218 small JJ B-NP I-Disease
16 356 360 1664218 cell NN I-NP I-Disease
17 361 365 1664218 lung NN I-NP I-Disease
18 366 372 1664218 cancer NN I-NP I-Disease
19 373 374 1664218 ( ( O O
20 374 379 1664218 NSCLC NN B-NP B-Disease
21 379 380 1664218 ) ) O O
22 381 382 1664218 ( ( O O
23 382 383 1664218 7 CD B-NP O
24 384 388 1664218 with IN B-PP O
25 389 391 1664218 no DT B-NP O
26 392 397 1664218 prior JJ I-NP O
27 398 407 1664218 treatment NN I-NP O
28 407 408 1664218 , , O O
29 409 410 1664218 9 CD B-NP O
30 411 419 1664218 patients NNS I-NP O
31 420 422 1664218 in IN B-PP O
32 423 430 1664218 relapse NN B-NP O
33 431 440 1664218 following VBG B-PP O
34 441 448 1664218 surgery NN B-NP O
35 448 449 1664218 / SYM B-NP O
36 449 461 1664218 radiotherapy NN I-NP O
37 461 462 1664218 ) ) O O
38 463 465 1664218 at IN B-PP O
39 466 467 1664218 a DT B-NP O
40 468 472 1664218 dose NN I-NP O
41 473 474 1664218 ( ( O O
42 474 477 1664218 648 CD B-NP O
43 478 480 1664218 mg NN I-NP O
44 480 481 1664218 / SYM B-NP O
45 481 483 1664218 m2 NN I-NP O
46 484 491 1664218 divided VBN B-VP O
47 492 496 1664218 over IN B-PP O
48 497 498 1664218 3 CD B-NP O
49 499 503 1664218 days NNS I-NP O
50 503 504 1664218 , , O O
51 505 513 1664218 repeated VBD B-VP O
52 514 519 1664218 every DT B-NP O
53 520 521 1664218 3 CD I-NP O
54 522 527 1664218 weeks NNS I-NP O
55 527 528 1664218 ) ) O O
56 529 539 1664218 determined VBN B-VP O
57 540 542 1664218 by IN B-PP O
58 543 548 1664218 phase NN B-NP O
59 549 550 1664218 I CD I-NP O
60 551 556 1664218 trial NN I-NP O
61 556 557 1664218 . . O O

1 558 566 1664218 Patients NNS B-NP O
2 567 570 1664218 had VBD B-VP O
3 571 572 1664218 a DT B-NP O
4 573 579 1664218 median JJ I-NP O
5 580 591 1664218 performance NN I-NP O
6 592 598 1664218 status NN I-NP O
7 599 601 1664218 of IN B-PP O
8 602 603 1664218 1 CD B-NP O
9 604 605 1664218 ( ( O O
10 605 608 1664218 WHO NN B-NP O
11 608 609 1664218 ) ) O O
12 609 610 1664218 , , O O
13 611 614 1664218 and CC O O
14 615 621 1664218 median JJ B-NP O
15 622 625 1664218 age NN I-NP O
16 626 628 1664218 of IN B-PP O
17 629 631 1664218 61 CD B-NP O
18 632 637 1664218 years NNS I-NP O
19 637 638 1664218 . . O O

1 639 642 1664218 The DT B-NP O
2 643 652 1664218 histology NN I-NP O
3 653 662 1664218 comprised VBD B-VP O
4 663 671 1664218 squamous JJ B-NP B-Disease
5 672 681 1664218 carcinoma NN I-NP I-Disease
6 682 683 1664218 ( ( O O
7 683 685 1664218 11 CD B-NP O
8 685 686 1664218 ) ) O O
9 686 687 1664218 , , O O
10 688 702 1664218 adenocarcinoma NN B-NP B-Disease
11 703 704 1664218 ( ( O O
12 704 705 1664218 1 CD B-NP O
13 705 706 1664218 ) ) O O
14 706 707 1664218 , , O O
15 708 713 1664218 mixed VBN B-NP O
16 714 723 1664218 histology NN I-NP O
17 724 725 1664218 ( ( O O
18 725 726 1664218 2 CD B-NP O
19 726 727 1664218 ) ) O O
20 727 728 1664218 , , O O
21 729 737 1664218 bronchio AFX O B-Disease
22 737 738 1664218 - HYPH O I-Disease
23 738 746 1664218 alveolar JJ B-NP I-Disease
24 747 756 1664218 carcinoma NN I-NP I-Disease
25 757 758 1664218 ( ( O O
26 758 759 1664218 1 CD B-NP O
27 759 760 1664218 ) ) O O
28 761 764 1664218 and CC O O
29 765 770 1664218 large JJ B-NP O
30 771 775 1664218 cell NN I-NP O
31 776 792 1664218 undifferentiated JJ I-NP B-Disease
32 793 802 1664218 carcinoma NN I-NP I-Disease
33 803 804 1664218 ( ( O O
34 804 805 1664218 1 CD B-NP O
35 805 806 1664218 ) ) O O
36 806 807 1664218 . . O O

1 808 819 1664218 Neutropenia NNP B-NP B-Disease
2 820 825 1664218 grade NN I-NP O
3 826 833 1664218 greater JJR B-ADJP O
4 834 838 1664218 than IN B-PP O
5 839 841 1664218 or CC O O
6 842 847 1664218 equal JJ B-ADJP O
7 848 850 1664218 to TO B-PP O
8 851 852 1664218 3 CD B-NP O
9 853 856 1664218 was VBD B-VP O
10 857 861 1664218 seen VBN I-VP O
11 862 864 1664218 in IN B-PP O
12 865 867 1664218 15 CD B-NP O
13 868 876 1664218 patients NNS I-NP O
14 876 877 1664218 , , O O
15 878 888 1664218 infections NNS B-NP B-Disease
16 889 893 1664218 with IN B-PP O
17 894 902 1664218 recovery NN B-NP O
18 903 905 1664218 in IN B-PP O
19 906 907 1664218 3 CD B-NP O
20 907 908 1664218 , , O O
21 909 912 1664218 and CC O O
22 913 918 1664218 grand JJ B-NP O
23 919 922 1664218 mal JJ I-NP O
24 923 931 1664218 seizures NNS I-NP B-Disease
25 932 934 1664218 in IN B-PP O
26 935 936 1664218 1 CD B-NP O
27 937 944 1664218 patient NN I-NP O
28 944 945 1664218 . . O O

1 946 951 1664218 Grade NN B-NP O
2 952 956 1664218 less JJR B-ADJP O
3 957 961 1664218 than IN B-PP O
4 962 964 1664218 or CC O O
5 965 970 1664218 equal JJ B-ADJP O
6 971 973 1664218 to TO B-PP O
7 974 975 1664218 2 CD B-NP O
8 976 982 1664218 nausea NN I-NP B-Disease
9 983 986 1664218 and CC I-NP O
10 987 995 1664218 vomiting NN I-NP B-Disease
11 996 1004 1664218 occurred VBD B-VP O
12 1005 1007 1664218 in IN B-PP O
13 1008 1011 1664218 66% CD B-NP O
14 1012 1019 1664218 courses NNS I-NP O
15 1020 1023 1664218 and CC I-NP O
16 1024 1033 1664218 phlebitis NN I-NP B-Disease
17 1034 1036 1664218 in IN B-PP O
18 1037 1040 1664218 the DT B-NP O
19 1041 1049 1664218 infusion NN I-NP O
20 1050 1053 1664218 arm NN I-NP O
21 1054 1056 1664218 in IN B-PP O
22 1057 1060 1664218 37% NN B-NP O
23 1060 1061 1664218 . . O O

1 1062 1063 1664218 1 CD B-NP O
2 1064 1071 1664218 patient NN I-NP O
3 1072 1076 1664218 with IN B-PP O
4 1077 1085 1664218 squamous JJ B-NP B-Disease
5 1086 1090 1664218 cell NN I-NP I-Disease
6 1091 1100 1664218 carcinoma NN I-NP I-Disease
7 1101 1109 1664218 achieved VBD B-VP O
8 1110 1111 1664218 a DT B-NP O
9 1112 1119 1664218 partial JJ I-NP O
10 1120 1128 1664218 response NN I-NP O
11 1129 1136 1664218 lasting VBG B-VP O
12 1137 1138 1664218 5 CD B-NP O
13 1139 1145 1664218 months NNS I-NP O
14 1145 1146 1664218 . . O O

1 1147 1154 1664218 Further JJ B-NP O
2 1155 1162 1664218 testing NN I-NP O
3 1163 1165 1664218 in IN B-PP O
4 1166 1170 1664218 this DT B-NP O
5 1171 1174 1664218 and CC O O
6 1175 1180 1664218 other JJ B-NP O
7 1181 1187 1664218 tumour NN I-NP B-Disease
8 1188 1193 1664218 types NNS I-NP O
9 1194 1199 1664218 using VBG B-VP O
10 1200 1208 1664218 multiple JJ B-NP O
11 1209 1214 1664218 daily JJ I-NP O
12 1215 1224 1664218 schedules NNS I-NP O
13 1225 1227 1664218 is VBZ B-VP O
14 1228 1237 1664218 warranted VBN I-VP O
15 1237 1238 1664218 . . O O

1 0 0 19803309 -DOCSTART- -X- -X- O

1 0 14 19803309 Anaesthetists' NN B-NP O
2 15 24 19803309 nightmare NN I-NP O
3 24 25 19803309 : : O O
4 26 34 19803309 masseter NN B-NP B-Disease
5 35 40 19803309 spasm NN I-NP I-Disease
6 41 46 19803309 after IN B-PP O
7 47 56 19803309 induction NN B-NP O
8 57 59 19803309 in IN B-PP O
9 60 62 19803309 an DT B-NP O
10 63 74 19803309 undiagnosed JJ I-NP O
11 75 79 19803309 case NN I-NP O
12 80 82 19803309 of IN B-PP O
13 83 91 19803309 myotonia NN B-NP B-Disease
14 92 101 19803309 congenita NN I-NP I-Disease
15 101 102 19803309 . . O O
16 103 105 19803309 We PRP B-NP O
17 106 112 19803309 report VBP B-VP O
18 113 115 19803309 an DT B-NP O
19 116 127 19803309 undiagnosed JJ I-NP O
20 128 132 19803309 case NN I-NP O
21 133 135 19803309 of IN B-PP O
22 136 144 19803309 myotonia NN B-NP B-Disease
23 145 154 19803309 congenita NN I-NP I-Disease
24 155 157 19803309 in IN B-PP O
25 158 159 19803309 a DT B-NP O
26 160 162 19803309 24 CD I-NP O
27 162 163 19803309 - HYPH I-NP O
28 163 167 19803309 year NN I-NP O
29 167 168 19803309 - HYPH O O
30 168 171 19803309 old JJ B-NP O
31 172 182 19803309 previously RB I-NP O
32 183 190 19803309 healthy JJ I-NP O
33 191 203 19803309 primigravida NN I-NP O
34 203 204 19803309 , , O O
35 205 208 19803309 who WP B-NP O
36 209 218 19803309 developed VBD B-VP O
37 219 223 19803309 life NN B-NP O
38 224 235 19803309 threatening JJ I-NP O
39 236 244 19803309 masseter NN I-NP B-Disease
40 245 250 19803309 spasm NN I-NP I-Disease
41 251 260 19803309 following VBG B-PP O
42 261 262 19803309 a DT B-NP O
43 263 271 19803309 standard JJ I-NP O
44 272 276 19803309 dose NN I-NP O
45 277 279 19803309 of IN B-PP O
46 280 291 19803309 intravenous JJ B-NP O
47 292 305 19803309 suxamethonium NN I-NP B-Chemical
48 306 309 19803309 for IN B-PP O
49 310 319 19803309 induction NN B-NP O
50 320 322 19803309 of IN B-PP O
51 323 334 19803309 anaesthesia NN B-NP O
52 334 335 19803309 . . O O

1 336 343 19803309 Neither CC O O
2 344 347 19803309 the DT B-NP O
3 348 355 19803309 patient NN I-NP O
4 356 359 19803309 nor CC O O
5 360 363 19803309 the DT B-NP O
6 364 376 19803309 anaesthetist NN I-NP O
7 377 380 19803309 was VBD B-VP O
8 381 386 19803309 aware JJ B-ADJP O
9 387 389 19803309 of IN B-PP O
10 390 393 19803309 the DT B-NP O
11 394 403 19803309 diagnosis NN I-NP O
12 404 410 19803309 before IN B-PP O
13 411 415 19803309 this DT B-NP O
14 416 427 19803309 potentially RB I-NP O
15 428 434 19803309 lethal JJ I-NP O
16 435 447 19803309 complication NN I-NP O
17 448 456 19803309 occurred VBD B-VP O
18 456 457 19803309 . . O O

1 0 0 9672936 -DOCSTART- -X- -X- O

1 0 9 9672936 Pethidine NN B-NP B-Chemical
2 9 10 9672936 - HYPH B-PP O
3 10 20 9672936 associated VBN B-NP O
4 21 28 9672936 seizure NN I-NP B-Disease
5 29 31 9672936 in IN B-PP O
6 32 33 9672936 a DT B-NP O
7 34 41 9672936 healthy JJ I-NP O
8 42 52 9672936 adolescent JJ I-NP O
9 53 62 9672936 receiving VBG I-NP O
10 63 72 9672936 pethidine NN I-NP B-Chemical
11 73 76 9672936 for IN B-PP O
12 77 90 9672936 postoperative JJ B-NP B-Disease
13 91 95 9672936 pain NN I-NP I-Disease
14 96 103 9672936 control NN I-NP O
15 103 104 9672936 . . O O
16 105 106 9672936 A DT B-NP O
17 107 114 9672936 healthy JJ I-NP O
18 115 117 9672936 17 CD I-NP O
19 117 118 9672936 - HYPH I-NP O
20 118 122 9672936 year NN I-NP O
21 122 123 9672936 - HYPH B-NP O
22 123 126 9672936 old JJ I-NP O
23 127 131 9672936 male JJ I-NP O
24 132 140 9672936 received VBN I-NP O
25 141 149 9672936 standard JJ I-NP O
26 150 162 9672936 intermittent JJ I-NP O
27 163 168 9672936 doses NNS I-NP O
28 169 171 9672936 of IN B-PP O
29 172 181 9672936 pethidine NN B-NP B-Chemical
30 182 185 9672936 via IN B-PP O
31 186 187 9672936 a DT B-NP O
32 188 195 9672936 patient NN I-NP O
33 195 196 9672936 - HYPH O O
34 196 206 9672936 controlled VBN B-VP O
35 207 216 9672936 analgesia NN B-NP O
36 217 218 9672936 ( ( O O
37 218 221 9672936 PCA NN B-NP O
38 221 222 9672936 ) ) O O
39 223 227 9672936 pump NN B-NP O
40 228 231 9672936 for IN B-PP O
41 232 242 9672936 management NN B-NP O
42 243 245 9672936 of IN B-PP O
43 246 259 9672936 postoperative JJ B-NP B-Disease
44 260 264 9672936 pain NN I-NP I-Disease
45 265 272 9672936 control NN I-NP O
46 272 273 9672936 . . O O

1 274 280 9672936 Twenty CD B-NP O
2 280 281 9672936 - HYPH I-NP O
3 281 286 9672936 three CD I-NP O
4 287 288 9672936 h NN I-NP O
5 289 304 9672936 postoperatively RB B-ADVP O
6 305 307 9672936 he PRP B-NP O
7 308 317 9672936 developed VBD B-VP O
8 318 319 9672936 a DT B-NP O
9 320 325 9672936 brief JJ I-NP O
10 326 330 9672936 self NN I-NP O
11 330 331 9672936 - HYPH B-VP O
12 331 338 9672936 limited VBN B-NP O
13 339 346 9672936 seizure NN I-NP B-Disease
14 346 347 9672936 . . O O

1 348 352 9672936 Both CC O O
2 353 359 9672936 plasma NN B-NP O
3 360 369 9672936 pethidine NN I-NP B-Chemical
4 370 373 9672936 and CC O O
5 374 386 9672936 norpethidine NN B-NP B-Chemical
6 387 391 9672936 were VBD B-VP O
7 392 400 9672936 elevated VBN I-VP O
8 401 403 9672936 in IN B-PP O
9 404 407 9672936 the DT B-NP O
10 408 413 9672936 range NN I-NP O
11 414 424 9672936 associated VBN B-VP O
12 425 429 9672936 with IN B-PP O
13 430 438 9672936 clinical JJ B-NP O
14 439 453 9672936 manifestations NNS I-NP O
15 454 456 9672936 of IN B-PP O
16 457 464 9672936 central JJ B-NP O
17 465 472 9672936 nervous JJ I-NP O
18 473 479 9672936 system NN I-NP O
19 480 490 9672936 excitation NN I-NP O
20 490 491 9672936 . . O O

1 492 494 9672936 No DT B-NP O
2 495 500 9672936 other JJ I-NP O
3 501 505 9672936 risk NN I-NP O
4 506 513 9672936 factors NNS I-NP O
5 514 517 9672936 for IN B-PP O
6 518 521 9672936 CNS NN B-NP O
7 522 530 9672936 toxicity NN I-NP B-Disease
8 531 535 9672936 were VBD B-VP O
9 536 546 9672936 identified VBN I-VP O
10 546 547 9672936 . . O O

1 548 552 9672936 This DT B-NP O
2 553 559 9672936 method NN I-NP O
3 560 567 9672936 allowed VBD B-VP O
4 568 576 9672936 frequent JJ B-NP O
5 577 581 9672936 self AFX I-NP O
6 581 582 9672936 - HYPH I-NP O
7 582 588 9672936 dosing NN B-NP O
8 589 591 9672936 of IN B-PP O
9 592 601 9672936 pethidine NN B-NP B-Chemical
10 602 604 9672936 at IN B-PP O
11 605 610 9672936 short JJ B-NP O
12 611 615 9672936 time NN I-NP O
13 616 625 9672936 intervals NNS I-NP O
14 626 629 9672936 and CC O O
15 630 635 9672936 rapid JJ B-NP O
16 636 648 9672936 accumulation NN I-NP O
17 649 651 9672936 of IN B-PP O
18 652 661 9672936 pethidine NN B-NP B-Chemical
19 662 665 9672936 and CC I-NP O
20 666 678 9672936 norpethidine NN I-NP B-Chemical
21 678 679 9672936 . . O O

1 680 683 9672936 The DT B-NP O
2 684 691 9672936 routine JJ I-NP O
3 692 695 9672936 use NN I-NP O
4 696 698 9672936 of IN B-PP O
5 699 708 9672936 pethidine NN B-NP B-Chemical
6 709 712 9672936 via IN B-PP O
7 713 716 9672936 PCA NN B-NP O
8 717 721 9672936 even RB B-ADVP O
9 722 725 9672936 for IN B-PP O
10 726 727 9672936 a DT B-NP O
11 728 733 9672936 brief JJ I-NP O
12 734 747 9672936 postoperative JJ I-NP O
13 748 757 9672936 analgesia NN I-NP O
14 758 764 9672936 should MD B-VP O
15 765 767 9672936 be VB I-VP O
16 768 780 9672936 reconsidered VBN I-VP O
17 780 781 9672936 . . O O

1 0 0 15863244 -DOCSTART- -X- -X- O

1 0 10 15863244 Comparison NN B-NP O
2 11 13 15863244 of IN B-PP O
3 14 27 15863244 developmental JJ B-NP O
4 28 36 15863244 toxicity NN I-NP B-Disease
5 37 39 15863244 of IN B-PP O
6 40 49 15863244 selective JJ B-NP O
7 50 53 15863244 and CC O O
8 54 57 15863244 non AFX O O
9 57 58 15863244 - HYPH O O
10 58 67 15863244 selective JJ B-NP O
11 68 82 15863244 cyclooxygenase NN I-NP O
12 82 83 15863244 - HYPH O O
13 83 84 15863244 2 CD B-NP O
14 85 95 15863244 inhibitors NNS I-NP O
15 96 98 15863244 in IN B-PP O
16 99 102 15863244 CRL NN B-NP O
17 102 103 15863244 : : O O
18 103 111 15863244 (WI)WUBR NNP B-NP O
19 112 118 15863244 Wistar NNP I-NP O
20 119 123 15863244 rats NNS I-NP O
21 123 124 15863244 - SYM B-NP O
22 124 125 15863244 - HYPH I-NP O
23 125 128 15863244 DFU NN I-NP B-Chemical
24 129 132 15863244 and CC I-NP O
25 133 142 15863244 piroxicam NN I-NP B-Chemical
26 143 148 15863244 study NN I-NP O
27 148 149 15863244 . . I-NP O
28 150 160 15863244 BACKGROUND NN I-NP O
29 160 161 15863244 : : O O
30 162 176 15863244 Cyclooxygenase NN B-NP O
31 177 178 15863244 ( ( O O
32 178 181 15863244 COX NN B-NP O
33 181 182 15863244 ) ) O O
34 183 193 15863244 inhibitors NNS B-NP O
35 194 197 15863244 are VBP B-VP O
36 198 201 15863244 one CD B-NP O
37 202 204 15863244 of IN B-PP O
38 205 208 15863244 the DT O O
39 209 213 15863244 most RBS B-ADVP O
40 214 219 15863244 often RB I-ADVP O
41 220 228 15863244 ingested VBN B-VP O
42 229 234 15863244 drugs NNS B-NP O
43 235 241 15863244 during IN B-PP O
44 242 251 15863244 pregnancy NN B-NP O
45 251 252 15863244 . . O O

1 253 259 15863244 Unlike IN B-PP O
2 260 267 15863244 general JJ B-NP O
3 268 276 15863244 toxicity NN I-NP B-Disease
4 277 281 15863244 data NNS I-NP O
5 281 282 15863244 , , O O
6 283 288 15863244 their PRP$ B-NP O
7 289 297 15863244 prenatal JJ I-NP O
8 298 303 15863244 toxic JJ I-NP O
9 304 311 15863244 effects NNS I-NP O
10 312 316 15863244 were VBD B-VP O
11 317 320 15863244 not RB I-VP O
12 321 332 15863244 extensively RB I-VP O
13 333 340 15863244 studied VBN I-VP O
14 341 347 15863244 before RB B-ADVP O
15 347 348 15863244 . . O O

1 349 352 15863244 The DT B-NP O
2 353 356 15863244 aim NN I-NP O
3 357 359 15863244 of IN B-PP O
4 360 363 15863244 the DT B-NP O
5 364 374 15863244 experiment NN I-NP O
6 375 378 15863244 was VBD B-VP O
7 379 381 15863244 to TO B-VP O
8 382 390 15863244 evaluate VB I-VP O
9 391 394 15863244 the DT B-NP O
10 395 408 15863244 developmental JJ I-NP O
11 409 417 15863244 toxicity NN I-NP B-Disease
12 418 420 15863244 of IN B-PP O
13 421 424 15863244 the DT B-NP O
14 425 428 15863244 non AFX I-NP O
15 428 429 15863244 - HYPH I-NP O
16 429 438 15863244 selective JJ I-NP O
17 439 440 15863244 ( ( O O
18 440 449 15863244 piroxicam NN B-NP B-Chemical
19 449 450 15863244 ) ) O O
20 451 454 15863244 and CC O O
21 455 464 15863244 selective JJ B-NP O
22 465 466 15863244 ( ( O O
23 466 469 15863244 DFU NN B-NP B-Chemical
24 469 470 15863244 ; : O O
25 471 474 15863244 5,5 CD B-NP B-Chemical
26 474 475 15863244 - HYPH I-NP I-Chemical
27 475 483 15863244 dimethyl NN I-NP I-Chemical
28 483 484 15863244 - HYPH B-NP I-Chemical
29 484 485 15863244 3 CD I-NP I-Chemical
30 485 486 15863244 - HYPH I-NP I-Chemical
31 486 488 15863244 (3 CD I-NP I-Chemical
32 488 489 15863244 - HYPH I-NP I-Chemical
33 489 502 15863244 fluorophenyl) NN I-NP I-Chemical
34 502 503 15863244 - HYPH B-NP I-Chemical
35 503 504 15863244 4 CD I-NP I-Chemical
36 504 505 15863244 - HYPH I-NP I-Chemical
37 505 507 15863244 (4 CD I-NP I-Chemical
38 507 508 15863244 - HYPH I-NP I-Chemical
39 508 524 15863244 methylsulphonyl) NN I-NP I-Chemical
40 525 531 15863244 phenyl NN I-NP I-Chemical
41 531 532 15863244 - HYPH B-NP I-Chemical
42 532 537 15863244 2(5H) NN I-NP I-Chemical
43 537 538 15863244 - HYPH B-NP I-Chemical
44 538 545 15863244 furanon NN I-NP I-Chemical
45 545 546 15863244 ) ) O O
46 547 550 15863244 COX NN B-NP O
47 550 551 15863244 - HYPH O O
48 551 552 15863244 2 CD B-NP O
49 553 563 15863244 inhibitors NNS I-NP O
50 563 564 15863244 . . O O

1 565 572 15863244 METHODS NNS B-NP O
2 572 573 15863244 : : O O
3 574 579 15863244 Drugs NNS B-NP O
4 580 584 15863244 were VBD B-VP O
5 585 595 15863244 separately RB B-ADVP O
6 595 596 15863244 , , O O
7 597 603 15863244 orally RB B-ADVP O
8 604 608 15863244 once RB I-ADVP O
9 609 614 15863244 daily RB B-ADVP O
10 615 620 15863244 dosed VBN B-VP O
11 621 623 15863244 to TO B-PP O
12 624 632 15863244 pregnant JJ B-NP O
13 633 637 15863244 rats NNS I-NP O
14 638 642 15863244 from IN B-PP O
15 643 646 15863244 day NN B-NP O
16 647 648 15863244 8 CD I-NP O
17 649 651 15863244 to TO I-NP O
18 652 654 15863244 21 CD I-NP O
19 655 656 15863244 ( ( O O
20 656 659 15863244 GD1 NN B-NP O
21 659 660 15863244 = SYM B-VP O
22 660 664 15863244 plug NN B-NP O
23 665 668 15863244 day NN I-NP O
24 668 669 15863244 ) ) O O
25 669 670 15863244 . . O O

1 671 676 15863244 Doses NNS B-NP O
2 677 681 15863244 were VBD B-VP O
3 682 685 15863244 set VBN I-VP O
4 686 688 15863244 at IN B-PP O
5 689 692 15863244 0.3 CD B-NP O
6 692 693 15863244 , , I-NP O
7 694 697 15863244 3.0 CD I-NP O
8 698 701 15863244 and CC I-NP O
9 702 708 15863244 30.0mg CD I-NP O
10 708 709 15863244 / SYM I-NP O
11 709 711 15863244 kg NN I-NP O
12 712 715 15863244 for IN B-PP O
13 716 725 15863244 piroxicam NN B-NP B-Chemical
14 726 729 15863244 and CC O O
15 730 733 15863244 0.2 CD B-NP O
16 733 734 15863244 , , I-NP O
17 735 738 15863244 2.0 CD I-NP O
18 739 742 15863244 and CC I-NP O
19 743 749 15863244 20.0mg CD I-NP O
20 749 750 15863244 / SYM I-NP O
21 750 752 15863244 kg NN I-NP O
22 753 756 15863244 for IN B-PP O
23 757 760 15863244 DFU NN B-NP B-Chemical
24 760 761 15863244 . . O O

1 762 769 15863244 Fetuses NNS B-NP O
2 770 774 15863244 were VBD B-VP O
3 775 784 15863244 delivered VBN I-VP O
4 785 787 15863244 on IN B-PP O
5 788 790 15863244 GD NN B-NP O
6 791 793 15863244 21 CD I-NP O
7 794 797 15863244 and CC O O
8 798 807 15863244 routinely RB B-VP O
9 808 816 15863244 examined VBN I-VP O
10 816 817 15863244 . . O O

1 818 831 15863244 Comprehensive JJ B-NP O
2 832 840 15863244 clinical JJ I-NP O
3 841 844 15863244 and CC I-NP O
4 845 858 15863244 developmental JJ I-NP O
5 859 871 15863244 measurements NNS I-NP O
6 872 876 15863244 were VBD B-VP O
7 877 881 15863244 done VBN I-VP O
8 881 882 15863244 . . O O

1 883 886 15863244 The DT B-NP O
2 887 893 15863244 pooled JJ I-NP O
3 894 905 15863244 statistical JJ I-NP O
4 906 914 15863244 analysis NN I-NP O
5 915 918 15863244 for IN B-PP O
6 919 930 15863244 ventricular JJ B-NP B-Disease
7 931 937 15863244 septal JJ I-NP I-Disease
8 938 939 15863244 ( ( O I-Disease
9 939 942 15863244 VSD NN B-NP I-Disease
10 942 943 15863244 ) ) O I-Disease
11 944 947 15863244 and CC O I-Disease
12 948 955 15863244 midline NN B-NP I-Disease
13 956 957 15863244 ( ( O I-Disease
14 957 959 15863244 MD NN B-NP I-Disease
15 959 960 15863244 ) ) O I-Disease
16 961 968 15863244 defects NNS B-NP I-Disease
17 969 972 15863244 was VBD B-VP O
18 973 982 15863244 performed VBN I-VP O
19 983 986 15863244 for IN B-PP O
20 987 990 15863244 rat NN B-NP O
21 991 998 15863244 fetuses NNS I-NP O
22 999 1006 15863244 exposed VBN B-VP O
23 1007 1009 15863244 to TO B-PP O
24 1010 1019 15863244 piroxicam NN B-NP B-Chemical
25 1019 1020 15863244 , , O O
26 1021 1030 15863244 selective JJ B-ADJP O
27 1031 1034 15863244 and CC O O
28 1035 1038 15863244 non AFX O O
29 1038 1039 15863244 - HYPH O O
30 1039 1048 15863244 selective JJ B-NP O
31 1049 1052 15863244 COX NN I-NP O
32 1052 1053 15863244 - HYPH B-NP O
33 1053 1054 15863244 2 CD I-NP O
34 1055 1064 15863244 inhibitor NN I-NP O
35 1065 1070 15863244 based VBN B-PP O
36 1071 1073 15863244 on IN B-PP O
37 1074 1081 15863244 present JJ B-NP O
38 1082 1085 15863244 and CC I-NP O
39 1086 1094 15863244 historic JJ I-NP O
40 1095 1099 15863244 data NNS I-NP O
41 1099 1100 15863244 . . O O

1 1101 1108 15863244 RESULTS NNS B-NP O
2 1108 1109 15863244 : : O O
3 1110 1118 15863244 Maternal JJ B-NP O
4 1119 1127 15863244 toxicity NN I-NP B-Disease
5 1127 1128 15863244 , , O O
6 1129 1141 15863244 intrauterine JJ B-NP B-Disease
7 1142 1148 15863244 growth NN I-NP I-Disease
8 1149 1160 15863244 retardation NN I-NP I-Disease
9 1160 1161 15863244 , , O O
10 1162 1165 15863244 and CC O O
11 1166 1174 15863244 increase NN B-NP B-Disease
12 1175 1177 15863244 of IN B-PP I-Disease
13 1178 1186 15863244 external JJ B-NP I-Disease
14 1187 1190 15863244 and CC I-NP I-Disease
15 1191 1199 15863244 skeletal JJ I-NP I-Disease
16 1200 1210 15863244 variations NNS I-NP I-Disease
17 1211 1215 15863244 were VBD B-VP O
18 1216 1221 15863244 found VBN I-VP O
19 1222 1224 15863244 in IN B-PP O
20 1225 1229 15863244 rats NNS B-NP O
21 1230 1237 15863244 treated VBN B-VP O
22 1238 1242 15863244 with IN B-PP O
23 1243 1246 15863244 the DT B-NP O
24 1247 1254 15863244 highest JJS I-NP O
25 1255 1259 15863244 dose NN I-NP O
26 1260 1262 15863244 of IN B-PP O
27 1263 1272 15863244 piroxicam NN B-NP B-Chemical
28 1272 1273 15863244 . . O O

1 1274 1282 15863244 Decrease NN B-NP O
2 1283 1285 15863244 of IN B-PP O
3 1286 1291 15863244 fetal JJ B-NP O
4 1292 1298 15863244 length NN I-NP O
5 1299 1302 15863244 was VBD B-VP O
6 1303 1306 15863244 the DT B-NP O
7 1307 1311 15863244 only JJ I-NP O
8 1312 1317 15863244 signs NNS I-NP O
9 1318 1320 15863244 of IN B-PP O
10 1321 1324 15863244 the DT B-NP O
11 1325 1328 15863244 DFU NN I-NP B-Chemical
12 1329 1342 15863244 developmental JJ I-NP O
13 1343 1351 15863244 toxicity NN I-NP B-Disease
14 1352 1360 15863244 observed VBN B-VP O
15 1361 1363 15863244 in IN B-PP O
16 1364 1368 15863244 pups NNS B-NP O
17 1369 1376 15863244 exposed VBN B-VP O
18 1377 1379 15863244 to TO B-PP O
19 1380 1383 15863244 the DT B-NP O
20 1384 1391 15863244 highest JJS I-NP O
21 1392 1400 15863244 compound NN I-NP O
22 1401 1405 15863244 dose NN I-NP O
23 1405 1406 15863244 . . O O

1 1407 1411 15863244 Lack NN B-NP O
2 1412 1414 15863244 of IN B-PP O
3 1415 1429 15863244 teratogenicity NN B-NP O
4 1430 1433 15863244 was VBD B-VP O
5 1434 1439 15863244 found VBN I-VP O
6 1440 1442 15863244 in IN B-PP O
7 1443 1452 15863244 piroxicam NN B-NP B-Chemical
8 1453 1456 15863244 and CC I-NP O
9 1457 1460 15863244 DFU NN I-NP B-Chemical
10 1460 1461 15863244 - HYPH B-NP O
11 1461 1468 15863244 exposed VBN I-NP O
12 1469 1475 15863244 groups NNS I-NP O
13 1475 1476 15863244 . . O O

1 1477 1485 15863244 Prenatal JJ B-NP O
2 1486 1494 15863244 exposure NN I-NP O
3 1495 1497 15863244 to TO B-PP O
4 1498 1501 15863244 non AFX B-NP O
5 1501 1502 15863244 - HYPH I-NP O
6 1502 1511 15863244 selective JJ I-NP O
7 1512 1515 15863244 COX NN I-NP O
8 1516 1526 15863244 inhibitors NNS I-NP O
9 1527 1536 15863244 increases VBZ B-VP O
10 1537 1540 15863244 the DT B-NP O
11 1541 1545 15863244 risk NN I-NP O
12 1546 1548 15863244 of IN B-PP O
13 1549 1552 15863244 VSD NN B-NP O
14 1553 1556 15863244 and CC I-NP O
15 1557 1559 15863244 MD NN I-NP O
16 1560 1564 15863244 when WRB B-ADVP O
17 1565 1573 15863244 compared VBN B-VP O
18 1574 1576 15863244 to TO B-PP O
19 1577 1585 15863244 historic JJ B-NP O
20 1586 1593 15863244 control NN I-NP O
21 1594 1597 15863244 but CC B-PP O
22 1598 1601 15863244 not RB B-PP O
23 1602 1606 15863244 with IN I-PP O
24 1607 1616 15863244 selective JJ B-NP O
25 1617 1620 15863244 COX NN I-NP O
26 1620 1621 15863244 - HYPH B-NP O
27 1621 1622 15863244 2 CD I-NP O
28 1623 1633 15863244 inhibitors NNS I-NP O
29 1633 1634 15863244 . . O O

1 1635 1645 15863244 CONCLUSION NN B-NP O
2 1645 1646 15863244 : : O O
3 1647 1651 15863244 Both CC O O
4 1652 1661 15863244 selective JJ O O
5 1662 1665 15863244 and CC O O
6 1666 1669 15863244 non AFX O O
7 1669 1670 15863244 - HYPH O O
8 1670 1679 15863244 selective JJ B-NP O
9 1680 1683 15863244 COX NN I-NP O
10 1683 1684 15863244 - HYPH B-NP O
11 1684 1685 15863244 2 CD I-NP O
12 1686 1696 15863244 inhibitors NNS I-NP O
13 1697 1701 15863244 were VBD B-VP O
14 1702 1707 15863244 toxic JJ B-ADJP O
15 1708 1711 15863244 for IN B-PP O
16 1712 1716 15863244 rats NNS B-NP O
17 1717 1724 15863244 fetuses NNS I-NP O
18 1725 1729 15863244 when WRB B-ADVP O
19 1730 1742 15863244 administered VBN B-VP O
20 1743 1745 15863244 in IN B-PP O
21 1746 1749 15863244 the DT B-NP O
22 1750 1757 15863244 highest JJS I-NP O
23 1758 1762 15863244 dose NN I-NP O
24 1762 1763 15863244 . . O O

1 1764 1770 15863244 Unlike IN B-PP O
2 1771 1774 15863244 DFU NN B-NP B-Chemical
3 1774 1775 15863244 , , O O
4 1776 1785 15863244 piroxicam NN B-NP B-Chemical
5 1786 1789 15863244 was VBD B-VP O
6 1790 1794 15863244 also RB B-ADVP O
7 1795 1801 15863244 highly RB B-ADJP O
8 1802 1807 15863244 toxic JJ I-ADJP O
9 1808 1810 15863244 to TO B-PP O
10 1811 1814 15863244 the DT B-NP O
11 1815 1819 15863244 dams NNS I-NP O
12 1819 1820 15863244 . . O O

1 1821 1829 15863244 Prenatal JJ B-NP O
2 1830 1838 15863244 exposure NN I-NP O
3 1839 1841 15863244 to TO B-PP O
4 1842 1851 15863244 selective JJ B-NP O
5 1852 1855 15863244 COX NN I-NP O
6 1855 1856 15863244 - HYPH O O
7 1856 1857 15863244 2 CD B-NP O
8 1858 1868 15863244 inhibitors NNS I-NP O
9 1869 1873 15863244 does VBZ B-VP O
10 1874 1877 15863244 not RB I-VP O
11 1878 1886 15863244 increase VB I-VP O
12 1887 1890 15863244 the DT B-NP O
13 1891 1895 15863244 risk NN I-NP O
14 1896 1898 15863244 of IN B-PP O
15 1899 1910 15863244 ventricular JJ B-NP B-Disease
16 1911 1917 15863244 septal JJ I-NP I-Disease
17 1918 1921 15863244 and CC I-NP I-Disease
18 1922 1929 15863244 midline NN I-NP I-Disease
19 1930 1937 15863244 defects NNS I-NP I-Disease
20 1938 1940 15863244 in IN B-PP O
21 1941 1944 15863244 rat NN B-NP O
22 1945 1949 15863244 when WRB B-ADVP O
23 1950 1958 15863244 compared VBN B-VP O
24 1959 1961 15863244 to TO B-PP O
25 1962 1965 15863244 non AFX B-NP O
26 1965 1966 15863244 - HYPH I-NP O
27 1966 1975 15863244 selective JJ B-NP O
28 1976 1981 15863244 drugs NNS I-NP O
29 1982 1985 15863244 and CC O O
30 1986 1994 15863244 historic JJ B-NP O
31 1995 2002 15863244 control NN I-NP O
32 2002 2003 15863244 . . O O

1 0 0 18020536 -DOCSTART- -X- -X- O

1 0 12 18020536 Associations NNS B-NP O
2 13 20 18020536 between IN B-PP O
3 21 24 18020536 use NN B-NP O
4 25 27 18020536 of IN B-PP O
5 28 43 18020536 benzodiazepines NNS B-NP B-Chemical
6 44 46 18020536 or CC O O
7 47 54 18020536 related VBN B-NP O
8 55 60 18020536 drugs NNS I-NP O
9 61 64 18020536 and CC I-NP O
10 65 71 18020536 health NN I-NP O
11 71 72 18020536 , , O O
12 73 81 18020536 physical JJ B-NP O
13 82 91 18020536 abilities NNS I-NP O
14 92 95 18020536 and CC O O
15 96 105 18020536 cognitive JJ B-NP O
16 106 114 18020536 function NN I-NP O
17 114 115 18020536 : : O O
18 116 117 18020536 a DT B-NP O
19 118 121 18020536 non AFX I-NP O
20 121 122 18020536 - HYPH I-NP O
21 122 132 18020536 randomised VBN I-NP O
22 133 141 18020536 clinical JJ I-NP O
23 142 147 18020536 study NN I-NP O
24 148 150 18020536 in IN B-PP O
25 151 154 18020536 the DT B-NP O
26 155 162 18020536 elderly JJ I-NP O
27 162 163 18020536 . . I-NP O
28 164 173 18020536 OBJECTIVE NN I-NP O
29 173 174 18020536 : : O O
30 175 177 18020536 To TO B-VP O
31 178 186 18020536 describe VB I-VP O
32 187 199 18020536 associations NNS B-NP O
33 200 207 18020536 between IN B-PP O
34 208 211 18020536 the DT B-NP O
35 212 215 18020536 use NN I-NP O
36 216 218 18020536 of IN B-PP O
37 219 234 18020536 benzodiazepines NNS B-NP B-Chemical
38 235 237 18020536 or CC O O
39 238 245 18020536 related VBN B-NP O
40 246 251 18020536 drugs NNS I-NP O
41 252 253 18020536 ( ( O O
42 253 257 18020536 BZDs NNS B-NP B-Chemical
43 257 258 18020536 / SYM B-NP O
44 258 261 18020536 RDs NNS I-NP O
45 261 262 18020536 ) ) O O
46 263 266 18020536 and CC O O
47 267 273 18020536 health NN B-NP O
48 273 274 18020536 , , O O
49 275 285 18020536 functional JJ B-NP O
50 286 295 18020536 abilities NNS I-NP O
51 296 299 18020536 and CC O O
52 300 309 18020536 cognitive JJ B-NP O
53 310 318 18020536 function NN I-NP O
54 319 321 18020536 in IN B-PP O
55 322 325 18020536 the DT B-NP O
56 326 333 18020536 elderly JJ I-NP O
57 333 334 18020536 . . O O

1 335 342 18020536 METHODS NNS B-NP O
2 342 343 18020536 : : O O
3 344 345 18020536 A DT B-NP O
4 346 349 18020536 non AFX I-NP O
5 349 350 18020536 - HYPH B-VP O
6 350 360 18020536 randomised VBN I-VP O
7 361 369 18020536 clinical JJ B-NP O
8 370 375 18020536 study NN I-NP O
9 376 378 18020536 of IN B-PP O
10 379 387 18020536 patients NNS B-NP O
11 388 392 18020536 aged JJ B-ADJP O
12 393 394 18020536 > SYM B-NP O
13 395 397 18020536 or CC O O
14 398 399 18020536 = SYM B-VP O
15 399 401 18020536 65 CD B-NP O
16 402 407 18020536 years NNS I-NP O
17 408 416 18020536 admitted VBN B-VP O
18 417 419 18020536 to TO B-PP O
19 420 425 18020536 acute JJ B-NP O
20 426 434 18020536 hospital NN I-NP O
21 435 440 18020536 wards NNS I-NP O
22 441 447 18020536 during IN B-PP O
23 448 449 18020536 1 CD B-NP O
24 450 455 18020536 month NN I-NP O
25 455 456 18020536 . . O O

1 457 460 18020536 164 CD B-NP O
2 461 469 18020536 patients NNS I-NP O
3 470 471 18020536 ( ( O O
4 471 475 18020536 mean JJ B-NP O
5 476 479 18020536 age NN I-NP O
6 480 481 18020536 + SYM O O
7 481 482 18020536 / SYM O O
8 482 483 18020536 - HYPH O O
9 484 492 18020536 standard JJ B-NP O
10 493 502 18020536 deviation NN I-NP O
11 503 504 18020536 [ ( O O
12 504 506 18020536 SD NN B-NP O
13 506 507 18020536 ] ) O O
14 508 512 18020536 81.6 CD B-NP O
15 513 514 18020536 + SYM O O
16 514 515 18020536 / SYM O O
17 515 516 18020536 - SYM O O
18 517 520 18020536 6.8 CD B-NP O
19 521 526 18020536 years NNS I-NP O
20 526 527 18020536 ) ) O O
21 528 532 18020536 were VBD B-VP O
22 533 541 18020536 admitted VBN I-VP O
23 541 542 18020536 . . O O

1 543 545 18020536 Of IN B-PP O
2 546 551 18020536 these DT B-NP O
3 551 552 18020536 , , O O
4 553 559 18020536 nearly RB B-NP O
5 560 564 18020536 half NN I-NP O
6 565 566 18020536 ( ( O O
7 566 567 18020536 n NN B-NP O
8 568 569 18020536 = SYM B-VP O
9 570 572 18020536 78 CD B-NP O
10 572 573 18020536 ) ) O O
11 574 577 18020536 had VBD B-VP O
12 578 582 18020536 used VBN I-VP O
13 583 587 18020536 BZDs NNS B-NP B-Chemical
14 587 588 18020536 / SYM O O
15 588 591 18020536 RDs NNS B-NP O
16 592 598 18020536 before IN B-PP O
17 599 608 18020536 admission NN B-NP O
18 608 609 18020536 , , O O
19 610 613 18020536 and CC O O
20 614 617 18020536 the DT B-NP O
21 618 627 18020536 remainder NN I-NP O
22 628 629 18020536 ( ( O O
23 629 630 18020536 n NN B-NP O
24 631 632 18020536 = SYM B-VP O
25 633 635 18020536 86 CD B-NP O
26 635 636 18020536 ) ) O O
27 637 641 18020536 were VBD B-VP O
28 642 645 18020536 non AFX B-ADJP O
29 645 646 18020536 - HYPH B-NP O
30 646 651 18020536 users NNS I-NP O
31 651 652 18020536 . . O O

1 653 662 18020536 Cognitive JJ B-NP O
2 663 670 18020536 ability NN I-NP O
3 671 674 18020536 was VBD B-VP O
4 675 683 18020536 assessed VBN I-VP O
5 684 686 18020536 by IN B-PP O
6 687 690 18020536 the DT B-NP O
7 691 695 18020536 Mini NNP I-NP O
8 695 696 18020536 - HYPH I-NP O
9 696 702 18020536 Mental NNP I-NP O
10 703 708 18020536 State NNP I-NP O
11 709 720 18020536 Examination NNP I-NP O
12 721 722 18020536 ( ( O O
13 722 726 18020536 MMSE NN B-NP O
14 726 727 18020536 ) ) O O
15 727 728 18020536 . . O O

1 729 737 18020536 Patients NNS B-NP O
2 738 745 18020536 scoring VBG B-VP O
3 746 747 18020536 > SYM B-NP O
4 748 750 18020536 or CC O O
5 751 752 18020536 = SYM B-VP O
6 752 754 18020536 20 CD B-NP O
7 755 759 18020536 MMSE NN I-NP O
8 760 763 18020536 sum NN I-NP O
9 764 770 18020536 points NNS I-NP O
10 771 775 18020536 were VBD B-VP O
11 776 787 18020536 interviewed VBN I-VP O
12 788 789 18020536 ( ( O O
13 789 790 18020536 n NN B-NP O
14 791 792 18020536 = SYM B-VP O
15 793 795 18020536 79 CD B-NP O
16 795 796 18020536 ) ) O O
17 797 800 18020536 and CC O O
18 801 811 18020536 questioned VBD B-VP O
19 812 821 18020536 regarding VBG I-VP O
20 822 830 18020536 symptoms NNS B-NP O
21 831 834 18020536 and CC O O
22 835 845 18020536 functional JJ B-NP O
23 846 855 18020536 abilities NNS I-NP O
24 856 862 18020536 during IN B-PP O
25 863 866 18020536 the DT B-NP O
26 867 871 18020536 week NN I-NP O
27 872 877 18020536 prior RB B-ADVP O
28 878 880 18020536 to TO B-PP O
29 881 890 18020536 admission NN B-NP O
30 890 891 18020536 . . O O

1 892 896 18020536 Data NNS B-NP O
2 897 899 18020536 on IN B-PP O
3 900 903 18020536 use NN B-NP O
4 904 906 18020536 of IN B-PP O
5 907 911 18020536 BZDs NNS B-NP B-Chemical
6 911 912 18020536 / SYM B-VP O
7 912 915 18020536 RDs NNS B-NP O
8 916 922 18020536 before IN B-PP O
9 923 932 18020536 admission NN B-NP O
10 932 933 18020536 , , O O
11 934 941 18020536 current JJ B-NP O
12 942 953 18020536 medications NNS I-NP O
13 954 957 18020536 and CC O O
14 958 967 18020536 discharge NN B-NP O
15 968 977 18020536 diagnoses NNS I-NP O
16 978 982 18020536 were VBD B-VP O
17 983 992 18020536 collected VBN I-VP O
18 993 997 18020536 from IN B-PP O
19 998 1005 18020536 medical JJ B-NP O
20 1006 1013 18020536 records NNS I-NP O
21 1013 1014 18020536 . . O O

1 1015 1021 18020536 Health NNP B-NP O
2 1021 1022 18020536 , , O O
3 1023 1031 18020536 physical JJ B-NP O
4 1032 1041 18020536 abilities NNS I-NP O
5 1042 1045 18020536 and CC O O
6 1046 1055 18020536 cognitive JJ B-NP O
7 1056 1064 18020536 function NN I-NP O
8 1065 1069 18020536 were VBD B-VP O
9 1070 1078 18020536 compared VBN I-VP O
10 1079 1086 18020536 between IN B-PP O
11 1087 1090 18020536 BZD NN B-NP O
12 1090 1091 18020536 / SYM I-NP O
13 1091 1093 18020536 RD NN I-NP O
14 1094 1099 18020536 users NNS I-NP O
15 1100 1103 18020536 and CC O O
16 1104 1107 18020536 non AFX B-NP O
17 1107 1108 18020536 - HYPH I-NP O
18 1108 1113 18020536 users NNS I-NP O
19 1113 1114 18020536 , , O O
20 1115 1118 18020536 and CC O O
21 1119 1130 18020536 adjustments NNS B-NP O
22 1131 1135 18020536 were VBD B-VP O
23 1136 1140 18020536 made VBN I-VP O
24 1141 1144 18020536 for IN B-PP O
25 1145 1156 18020536 confounding VBG B-VP O
26 1157 1166 18020536 variables NNS B-NP O
27 1166 1167 18020536 . . O O

1 1168 1171 18020536 The DT B-NP O
2 1172 1180 18020536 residual JJ I-NP O
3 1181 1186 18020536 serum NN I-NP O
4 1187 1201 18020536 concentrations NNS I-NP O
5 1202 1204 18020536 of IN B-PP O
6 1205 1213 18020536 oxazepam NN B-NP B-Chemical
7 1213 1214 18020536 , , O O
8 1215 1224 18020536 temazepam NN B-NP B-Chemical
9 1225 1228 18020536 and CC I-NP O
10 1229 1238 18020536 zopiclone NN I-NP B-Chemical
11 1239 1243 18020536 were VBD B-VP O
12 1244 1252 18020536 analysed VBN I-VP O
13 1252 1253 18020536 . . O O

1 1254 1261 18020536 RESULTS NNS B-NP O
2 1261 1262 18020536 : : O O
3 1263 1266 18020536 The DT B-NP O
4 1267 1271 18020536 mean NN I-NP O
5 1272 1273 18020536 + SYM B-VP O
6 1273 1274 18020536 / SYM B-NP O
7 1274 1275 18020536 - HYPH B-NP O
8 1276 1278 18020536 SD NN I-NP O
9 1279 1287 18020536 duration NN I-NP O
10 1288 1290 18020536 of IN B-PP O
11 1291 1294 18020536 BZD NN B-NP O
12 1294 1295 18020536 / SYM I-NP O
13 1295 1297 18020536 RD NN I-NP O
14 1298 1301 18020536 use NN I-NP O
15 1302 1305 18020536 was VBD B-VP O
16 1306 1307 18020536 7 CD B-NP O
17 1308 1309 18020536 + SYM B-NP O
18 1309 1310 18020536 / SYM I-NP O
19 1310 1311 18020536 - SYM I-NP O
20 1312 1313 18020536 7 CD B-NP O
21 1314 1319 18020536 years NNS I-NP O
22 1320 1321 18020536 ( ( O O
23 1321 1326 18020536 range NN B-NP O
24 1327 1328 18020536 1 CD I-NP O
25 1328 1329 18020536 - HYPH B-NP O
26 1329 1331 18020536 31 CD I-NP O
27 1331 1332 18020536 ) ) O O
28 1332 1333 18020536 . . O O

1 1334 1337 18020536 Two CD B-NP O
2 1338 1340 18020536 or CC I-NP O
3 1341 1346 18020536 three CD I-NP O
4 1347 1351 18020536 BZDs NNS I-NP B-Chemical
5 1351 1352 18020536 / SYM I-NP O
6 1352 1355 18020536 RDs NNS I-NP O
7 1356 1360 18020536 were VBD B-VP O
8 1361 1374 18020536 concomitantly RB I-VP O
9 1375 1380 18020536 taken VBN I-VP O
10 1381 1383 18020536 by IN B-PP O
11 1384 1387 18020536 26% CD B-NP O
12 1388 1390 18020536 of IN B-PP O
13 1391 1396 18020536 users NNS B-NP O
14 1397 1398 18020536 ( ( O O
15 1398 1399 18020536 n NN B-NP O
16 1400 1401 18020536 = SYM B-VP O
17 1402 1404 18020536 20 CD B-NP O
18 1404 1405 18020536 ) ) O O
19 1405 1406 18020536 . . O O

1 1407 1411 18020536 Long JJ B-NP O
2 1411 1412 18020536 - HYPH I-NP O
3 1412 1416 18020536 term NN I-NP O
4 1417 1420 18020536 use NN I-NP O
5 1421 1423 18020536 of IN B-PP O
6 1424 1429 18020536 these DT B-NP O
7 1430 1435 18020536 drugs NNS I-NP O
8 1436 1439 18020536 was VBD B-VP O
9 1440 1450 18020536 associated VBN I-VP O
10 1451 1455 18020536 with IN B-PP O
11 1456 1462 18020536 female JJ B-NP O
12 1463 1466 18020536 sex NN I-NP O
13 1467 1470 18020536 and CC I-NP O
14 1471 1474 18020536 use NN I-NP O
15 1475 1477 18020536 of IN B-PP O
16 1478 1479 18020536 a DT B-NP O
17 1480 1486 18020536 higher JJR I-NP O
18 1487 1493 18020536 number NN I-NP O
19 1494 1496 18020536 of IN B-PP O
20 1497 1502 18020536 drugs NNS B-NP O
21 1503 1507 18020536 with IN B-PP O
22 1508 1515 18020536 effects NNS B-NP O
23 1516 1518 18020536 on IN B-PP O
24 1519 1522 18020536 the DT B-NP O
25 1523 1526 18020536 CNS NN I-NP O
26 1526 1527 18020536 , , O O
27 1528 1533 18020536 which WDT B-NP O
28 1534 1540 18020536 tended VBD B-VP O
29 1541 1543 18020536 to TO I-VP O
30 1544 1546 18020536 be VB I-VP O
31 1547 1554 18020536 related VBN I-VP O
32 1555 1557 18020536 to TO B-PP O
33 1558 1567 18020536 diagnosed VBN B-NP O
34 1568 1576 18020536 dementia NN I-NP B-Disease
35 1576 1577 18020536 . . O O

1 1578 1583 18020536 After IN B-PP O
2 1584 1594 18020536 adjustment NN B-NP O
3 1595 1598 18020536 for IN B-PP O
4 1599 1604 18020536 these DT B-NP O
5 1605 1614 18020536 variables NNS I-NP O
6 1615 1617 18020536 as IN B-PP O
7 1618 1629 18020536 confounders NNS B-NP O
8 1629 1630 18020536 , , O O
9 1631 1634 18020536 use NN B-NP O
10 1635 1637 18020536 of IN B-PP O
11 1638 1642 18020536 BZDs NNS B-NP B-Chemical
12 1642 1643 18020536 / SYM B-NP O
13 1643 1646 18020536 RDs NNS I-NP O
14 1647 1650 18020536 was VBD B-VP O
15 1651 1654 18020536 not RB I-VP O
16 1655 1665 18020536 associated VBN I-VP O
17 1666 1670 18020536 with IN B-PP O
18 1671 1680 18020536 cognitive JJ B-NP O
19 1681 1689 18020536 function NN I-NP O
20 1690 1692 18020536 as IN B-SBAR O
21 1693 1701 18020536 measured VBN B-VP O
22 1702 1704 18020536 by IN B-PP O
23 1705 1708 18020536 the DT B-NP O
24 1709 1713 18020536 MMSE NN I-NP O
25 1713 1714 18020536 . . O O

1 1715 1722 18020536 However RB B-ADVP O
2 1722 1723 18020536 , , O O
3 1724 1727 18020536 use NN B-NP O
4 1728 1730 18020536 of IN B-PP O
5 1731 1735 18020536 BZDs NNS B-NP B-Chemical
6 1735 1736 18020536 / SYM B-NP O
7 1736 1739 18020536 RDs NNS I-NP O
8 1740 1743 18020536 was VBD B-VP O
9 1744 1754 18020536 associated VBN I-VP O
10 1755 1759 18020536 with IN B-PP O
11 1760 1769 18020536 dizziness NN B-NP B-Disease
12 1769 1770 18020536 , , O O
13 1771 1780 18020536 inability NN B-NP B-Disease
14 1781 1783 18020536 to TO B-VP I-Disease
15 1784 1789 18020536 sleep VB I-VP I-Disease
16 1790 1795 18020536 after IN B-PP O
17 1796 1803 18020536 awaking VBG B-VP O
18 1804 1806 18020536 at IN B-PP O
19 1807 1812 18020536 night NN B-NP O
20 1813 1816 18020536 and CC I-NP O
21 1817 1826 18020536 tiredness NN I-NP B-Disease
22 1827 1829 18020536 in IN B-PP O
23 1830 1833 18020536 the DT B-NP O
24 1834 1842 18020536 mornings NNS I-NP O
25 1843 1849 18020536 during IN B-PP O
26 1850 1853 18020536 the DT B-NP O
27 1854 1858 18020536 week NN I-NP O
28 1859 1864 18020536 prior RB B-ADVP O
29 1865 1867 18020536 to TO B-PP O
30 1868 1877 18020536 admission NN B-NP O
31 1878 1881 18020536 and CC O O
32 1882 1886 18020536 with IN B-PP O
33 1887 1895 18020536 stronger JJR B-NP O
34 1896 1906 18020536 depressive JJ I-NP B-Disease
35 1907 1915 18020536 symptoms NNS I-NP I-Disease
36 1916 1924 18020536 measured VBN B-VP O
37 1925 1927 18020536 at IN B-PP O
38 1928 1931 18020536 the DT B-NP O
39 1932 1941 18020536 beginning NN I-NP O
40 1942 1944 18020536 of IN B-PP O
41 1945 1948 18020536 the DT B-NP O
42 1949 1957 18020536 hospital NN I-NP O
43 1958 1962 18020536 stay NN I-NP O
44 1962 1963 18020536 . . O O

1 1964 1967 18020536 Use NN B-NP O
2 1968 1970 18020536 of IN B-PP O
3 1971 1975 18020536 BZDs NNS B-NP B-Chemical
4 1975 1976 18020536 / SYM B-NP O
5 1976 1979 18020536 RDs NNS I-NP O
6 1980 1986 18020536 tended VBD B-VP O
7 1987 1989 18020536 to TO I-VP O
8 1990 1992 18020536 be VB I-VP O
9 1993 2003 18020536 associated VBN I-VP O
10 2004 2008 18020536 with IN B-PP O
11 2009 2010 18020536 a DT B-NP O
12 2011 2018 18020536 reduced VBN I-NP O
13 2019 2026 18020536 ability NN I-NP O
14 2027 2029 18020536 to TO B-VP O
15 2030 2034 18020536 walk VB I-VP O
16 2035 2038 18020536 and CC O O
17 2039 2046 18020536 shorter JJR B-NP O
18 2047 2052 18020536 night NN I-NP O
19 2052 2053 18020536 - HYPH B-NP O
20 2053 2057 18020536 time NN I-NP O
21 2058 2063 18020536 sleep NN I-NP O
22 2064 2070 18020536 during IN B-PP O
23 2071 2074 18020536 the DT B-NP O
24 2075 2079 18020536 week NN I-NP O
25 2080 2085 18020536 prior RB B-ADVP O
26 2086 2088 18020536 to TO B-PP O
27 2089 2098 18020536 admission NN B-NP O
28 2098 2099 18020536 . . O O

1 2100 2101 18020536 A DT B-NP O
2 2102 2108 18020536 higher JJR I-NP O
3 2109 2117 18020536 residual JJ I-NP O
4 2118 2123 18020536 serum NN I-NP O
5 2124 2137 18020536 concentration NN I-NP O
6 2138 2140 18020536 of IN B-PP O
7 2141 2150 18020536 temazepam NN B-NP B-Chemical
8 2151 2161 18020536 correlated VBD B-VP O
9 2162 2166 18020536 with IN B-PP O
10 2167 2168 18020536 a DT B-NP O
11 2169 2174 18020536 lower JJR I-NP O
12 2175 2179 18020536 MMSE NN I-NP O
13 2180 2183 18020536 sum NN I-NP O
14 2184 2189 18020536 score NN I-NP O
15 2190 2195 18020536 after IN B-PP O
16 2196 2206 18020536 adjustment NN B-NP O
17 2207 2210 18020536 for IN B-PP O
18 2211 2222 18020536 confounding VBG B-VP O
19 2223 2232 18020536 variables NNS B-NP O
20 2232 2233 18020536 . . O O

1 2234 2245 18020536 CONCLUSIONS NNS B-NP O
2 2245 2246 18020536 : : O O
3 2247 2251 18020536 Long JJ B-NP O
4 2251 2252 18020536 - HYPH I-NP O
5 2252 2256 18020536 term NN I-NP O
6 2257 2260 18020536 use NN I-NP O
7 2261 2264 18020536 and CC O O
8 2265 2276 18020536 concomitant JJ B-NP O
9 2277 2280 18020536 use NN I-NP O
10 2281 2283 18020536 of IN B-PP O
11 2284 2288 18020536 more JJR B-NP O
12 2289 2293 18020536 than IN I-NP O
13 2294 2297 18020536 one CD I-NP O
14 2298 2301 18020536 BZD NN I-NP O
15 2301 2302 18020536 / SYM B-NP O
16 2302 2304 18020536 RD NN I-NP O
17 2305 2309 18020536 were VBD B-VP O
18 2310 2316 18020536 common JJ B-ADJP O
19 2317 2319 18020536 in IN B-PP O
20 2320 2327 18020536 elderly JJ B-NP O
21 2328 2336 18020536 patients NNS I-NP O
22 2337 2349 18020536 hospitalised VBD B-VP O
23 2350 2357 18020536 because IN B-PP O
24 2358 2360 18020536 of IN I-PP O
25 2361 2366 18020536 acute JJ B-NP O
26 2367 2376 18020536 illnesses NNS I-NP O
27 2376 2377 18020536 . . O O

1 2378 2382 18020536 Long JJ B-NP O
2 2382 2383 18020536 - HYPH I-NP O
3 2383 2387 18020536 term NN I-NP O
4 2388 2391 18020536 use NN I-NP O
5 2392 2395 18020536 was VBD B-VP O
6 2396 2406 18020536 associated VBN I-VP O
7 2407 2411 18020536 with IN B-PP O
8 2412 2419 18020536 daytime NN B-NP O
9 2420 2423 18020536 and CC I-NP O
10 2424 2429 18020536 night NN I-NP O
11 2429 2430 18020536 - HYPH O O
12 2430 2434 18020536 time NN B-NP O
13 2435 2443 18020536 symptoms NNS I-NP O
14 2444 2454 18020536 indicative JJ B-ADJP O
15 2455 2457 18020536 of IN B-PP O
16 2458 2464 18020536 poorer JJR B-NP O
17 2465 2471 18020536 health NN I-NP O
18 2472 2475 18020536 and CC O O
19 2476 2487 18020536 potentially RB B-VP O
20 2488 2494 18020536 caused VBN I-VP O
21 2495 2497 18020536 by IN B-PP O
22 2498 2501 18020536 the DT B-NP O
23 2502 2509 18020536 adverse JJ I-NP O
24 2510 2517 18020536 effects NNS I-NP O
25 2518 2520 18020536 of IN B-PP O
26 2521 2526 18020536 these DT B-NP O
27 2527 2532 18020536 drugs NNS I-NP O
28 2532 2533 18020536 . . O O

1 0 0 16740173 -DOCSTART- -X- -X- O

1 0 4 16740173 Case NN B-NP O
2 5 11 16740173 report NN I-NP O
3 11 12 16740173 : : O O
4 13 18 16740173 acute JJ B-NP O
5 19 32 16740173 unintentional JJ I-NP O
6 33 42 16740173 carbachol NN I-NP B-Chemical
7 43 55 16740173 intoxication NN I-NP O
8 55 56 16740173 . . I-NP O
9 57 69 16740173 INTRODUCTION NN I-NP O
10 69 70 16740173 : : O O
11 71 84 16740173 Intoxications NNS B-NP O
12 85 89 16740173 with IN B-PP O
13 90 99 16740173 carbachol NN B-NP B-Chemical
14 99 100 16740173 , , O O
15 101 102 16740173 a DT B-NP O
16 103 113 16740173 muscarinic JJ I-NP O
17 114 125 16740173 cholinergic JJ I-NP O
18 126 134 16740173 receptor NN I-NP O
19 135 142 16740173 agonist NN I-NP O
20 143 146 16740173 are VBP B-VP O
21 147 151 16740173 rare JJ B-ADJP O
22 151 152 16740173 . . O O

1 153 155 16740173 We PRP B-NP O
2 156 162 16740173 report VBP B-VP O
3 163 165 16740173 an DT B-NP O
4 166 177 16740173 interesting JJ I-NP O
5 178 182 16740173 case NN I-NP O
6 183 196 16740173 investigating VBG B-VP O
7 197 198 16740173 a DT O O
8 199 200 16740173 ( ( O O
9 200 204 16740173 near IN O O
10 204 205 16740173 ) ) O O
11 206 211 16740173 fatal JJ B-NP O
12 212 221 16740173 poisoning NN I-NP B-Disease
13 221 222 16740173 . . O O

1 223 230 16740173 METHODS NNS B-NP O
2 230 231 16740173 : : O O
3 232 235 16740173 The DT B-NP O
4 236 239 16740173 son NN I-NP O
5 240 242 16740173 of IN B-PP O
6 243 245 16740173 an DT B-NP O
7 246 248 16740173 84 CD I-NP O
8 248 249 16740173 - HYPH I-NP O
9 249 253 16740173 year NN I-NP O
10 253 254 16740173 - HYPH O O
11 254 257 16740173 old JJ B-NP O
12 258 262 16740173 male NN I-NP O
13 263 273 16740173 discovered VBD B-VP O
14 274 275 16740173 a DT B-NP O
15 276 285 16740173 newspaper NN I-NP O
16 286 292 16740173 report NN I-NP O
17 293 300 16740173 stating VBG B-VP O
18 301 309 16740173 clinical JJ B-NP O
19 310 317 16740173 success NN I-NP O
20 318 322 16740173 with IN B-PP O
21 323 328 16740173 plant NN B-NP O
22 329 337 16740173 extracts NNS I-NP O
23 338 340 16740173 in IN B-PP O
24 341 352 16740173 Alzheimer's NNP B-NP B-Disease
25 353 360 16740173 disease NN I-NP I-Disease
26 360 361 16740173 . . O O

1 362 365 16740173 The DT B-NP O
2 366 370 16740173 mode NN I-NP O
3 371 373 16740173 of IN B-PP O
4 374 380 16740173 action NN B-NP O
5 381 384 16740173 was VBD B-VP O
6 385 389 16740173 said VBN I-VP O
7 390 392 16740173 to TO I-VP O
8 393 395 16740173 be VB I-VP O
9 396 406 16740173 comparable JJ B-ADJP O
10 407 409 16740173 to TO B-PP O
11 410 414 16740173 that DT B-NP O
12 415 417 16740173 of IN B-PP O
13 418 421 16740173 the DT B-NP O
14 422 431 16740173 synthetic JJ I-NP O
15 432 440 16740173 compound NN I-NP O
16 441 442 16740173 ' `` I-NP O
17 442 456 16740173 carbamylcholin NN I-NP B-Chemical
18 456 457 16740173 ' '' O O
19 457 458 16740173 ; : O O
20 459 463 16740173 that DT B-NP O
21 464 466 16740173 is VBZ B-VP O
22 466 467 16740173 , , O O
23 468 477 16740173 carbachol NN B-NP B-Chemical
24 477 478 16740173 . . O O

1 479 481 16740173 He PRP B-NP O
2 482 488 16740173 bought VBD B-VP O
3 489 491 16740173 25 CD B-NP O
4 492 493 16740173 g NN I-NP O
5 494 496 16740173 of IN B-PP O
6 497 506 16740173 carbachol NN B-NP B-Chemical
7 507 509 16740173 as IN B-PP O
8 510 514 16740173 pure JJ B-NP O
9 515 524 16740173 substance NN I-NP O
10 525 527 16740173 in IN B-PP O
11 528 529 16740173 a DT B-NP O
12 530 538 16740173 pharmacy NN I-NP O
13 538 539 16740173 , , O O
14 540 543 16740173 and CC O O
15 544 547 16740173 the DT B-NP O
16 548 554 16740173 father NN I-NP O
17 555 558 16740173 was VBD B-VP O
18 559 571 16740173 administered VBN I-VP O
19 572 575 16740173 400 CD B-NP O
20 576 578 16740173 to TO I-NP O
21 579 582 16740173 500 CD I-NP O
22 583 585 16740173 mg NN I-NP O
23 585 586 16740173 . . O O

1 587 596 16740173 Carbachol NN B-NP B-Chemical
2 597 611 16740173 concentrations NNS I-NP O
3 612 614 16740173 in IN B-PP O
4 615 620 16740173 serum NN B-NP O
5 621 624 16740173 and CC I-NP O
6 625 630 16740173 urine NN I-NP O
7 631 633 16740173 on IN B-PP O
8 634 637 16740173 day NN B-NP O
9 638 639 16740173 1 CD I-NP O
10 640 643 16740173 and CC I-NP O
11 644 645 16740173 2 CD I-NP O
12 646 648 16740173 of IN B-PP O
13 649 657 16740173 hospital NN B-NP O
14 658 667 16740173 admission NN I-NP O
15 668 672 16740173 were VBD B-VP O
16 673 681 16740173 analysed VBN I-VP O
17 682 684 16740173 by IN B-PP O
18 685 689 16740173 HPLC NN B-NP O
19 689 690 16740173 - HYPH I-NP O
20 690 694 16740173 mass NN I-NP O
21 695 707 16740173 spectrometry NN I-NP O
22 707 708 16740173 . . O O

1 709 716 16740173 RESULTS NNS B-NP O
2 716 717 16740173 : : O O
3 718 725 16740173 Minutes NNS B-NP O
4 726 731 16740173 after IN B-SBAR O
5 732 736 16740173 oral JJ B-NP O
6 737 751 16740173 administration NN I-NP O
7 751 752 16740173 , , O O
8 753 756 16740173 the DT B-NP O
9 757 764 16740173 patient NN I-NP O
10 765 774 16740173 developed VBD B-VP O
11 775 781 16740173 nausea NN B-NP B-Disease
12 781 782 16740173 , , I-NP O
13 783 791 16740173 sweating NN I-NP O
14 792 795 16740173 and CC I-NP O
15 796 807 16740173 hypotension NN I-NP B-Disease
16 807 808 16740173 , , O O
17 809 812 16740173 and CC O O
18 813 820 16740173 finally RB B-VP O
19 821 830 16740173 collapsed VBD I-VP O
20 830 831 16740173 . . O O

1 832 843 16740173 Bradycardia NNP B-NP B-Disease
2 843 844 16740173 , , O O
3 845 856 16740173 cholinergic JJ B-NP O
4 857 865 16740173 symptoms NNS I-NP O
5 866 869 16740173 and CC O O
6 870 878 16740173 asystole NN B-NP B-Disease
7 879 887 16740173 occurred VBD B-VP O
8 887 888 16740173 . . O O

1 889 896 16740173 Initial JJ B-NP O
2 897 912 16740173 cardiopulmonary JJ I-NP O
3 913 926 16740173 resuscitation NN I-NP O
4 927 930 16740173 and CC O O
5 931 940 16740173 immediate JJ B-NP O
6 941 950 16740173 treatment NN I-NP O
7 951 955 16740173 with IN B-PP O
8 956 966 16740173 adrenaline NN B-NP B-Chemical
9 967 968 16740173 ( ( O O
10 968 979 16740173 epinephrine NN B-NP B-Chemical
11 979 980 16740173 ) ) O O
12 980 981 16740173 , , O O
13 982 990 16740173 atropine NN B-NP B-Chemical
14 991 994 16740173 and CC I-NP O
15 995 1005 16740173 furosemide NN I-NP B-Chemical
16 1006 1009 16740173 was VBD B-VP O
17 1010 1020 16740173 successful JJ B-ADJP O
18 1020 1021 16740173 . . O O

1 1022 1024 16740173 On IN B-PP O
2 1025 1033 16740173 hospital NN B-NP O
3 1034 1043 16740173 admission NN I-NP O
4 1043 1044 16740173 , , O O
5 1045 1050 16740173 blood NN B-NP O
6 1051 1059 16740173 pressure NN I-NP O
7 1060 1062 16740173 of IN B-PP O
8 1063 1066 16740173 the DT B-NP O
9 1067 1076 16740173 intubated JJ I-NP O
10 1076 1077 16740173 , , I-NP O
11 1078 1093 16740173 bradyarrhythmic JJ I-NP O
12 1094 1101 16740173 patient NN I-NP O
13 1102 1105 16740173 was VBD B-VP O
14 1106 1109 16740173 100 CD B-NP O
15 1109 1110 16740173 / SYM I-NP O
16 1110 1112 16740173 65 CD I-NP O
17 1113 1117 16740173 mmHg NN I-NP O
18 1117 1118 16740173 . . O O

1 1119 1126 16740173 Further JJ B-NP O
2 1127 1132 16740173 signs NNS I-NP O
3 1133 1137 16740173 were VBD B-VP O
4 1138 1151 16740173 hyperhidrosis NN B-NP B-Disease
5 1151 1152 16740173 , , O O
6 1153 1168 16740173 hypersalivation NN B-NP B-Disease
7 1168 1169 16740173 , , O O
8 1170 1183 16740173 bronchorrhoea NN B-NP B-Disease
9 1183 1184 16740173 , , O O
10 1185 1188 16740173 and CC O O
11 1189 1195 16740173 severe JJ B-NP O
12 1196 1202 16740173 miosis NN I-NP B-Disease
13 1202 1203 16740173 ; : O O
14 1204 1207 16740173 the DT B-NP O
15 1208 1228 16740173 electrocardiographic JJ I-NP O
16 1229 1236 16740173 finding NN I-NP O
17 1237 1240 16740173 was VBD B-VP O
18 1241 1246 16740173 atrio AFX B-ADJP B-Disease
19 1246 1247 16740173 - HYPH B-NP I-Disease
20 1247 1258 16740173 ventricular JJ I-NP I-Disease
21 1259 1271 16740173 dissociation NN I-NP I-Disease
22 1271 1272 16740173 . . O O

1 1273 1277 16740173 High JJ B-NP O
2 1278 1283 16740173 doses NNS I-NP O
3 1284 1286 16740173 of IN B-PP O
4 1287 1295 16740173 atropine NN B-NP B-Chemical
5 1296 1297 16740173 ( ( O O
6 1297 1299 16740173 up RB B-NP O
7 1300 1302 16740173 to TO I-NP O
8 1303 1305 16740173 50 CD I-NP O
9 1306 1308 16740173 mg NN I-NP O
10 1309 1312 16740173 per IN B-PP O
11 1313 1315 16740173 24 CD B-NP O
12 1316 1321 16740173 hours NNS I-NP O
13 1321 1322 16740173 ) ) O O
14 1322 1323 16740173 , , O O
15 1324 1334 16740173 adrenaline NN B-NP B-Chemical
16 1335 1338 16740173 and CC I-NP O
17 1339 1347 16740173 dopamine NN I-NP B-Chemical
18 1348 1352 16740173 were VBD B-VP O
19 1353 1362 16740173 necessary JJ B-ADJP O
20 1362 1363 16740173 . . O O

1 1364 1367 16740173 The DT B-NP O
2 1368 1375 16740173 patient NN I-NP O
3 1376 1379 16740173 was VBD B-VP O
4 1380 1389 16740173 extubated VBN I-VP O
5 1390 1391 16740173 1 CD B-NP O
6 1392 1396 16740173 week NN I-NP O
7 1397 1402 16740173 later RB B-ADVP O
8 1402 1403 16740173 . . O O

1 1404 1411 16740173 However RB B-ADVP O
2 1411 1412 16740173 , , O O
3 1413 1422 16740173 increased VBN B-NP O
4 1423 1431 16740173 dyspnoea NN I-NP B-Disease
5 1432 1435 16740173 and CC I-NP O
6 1436 1448 16740173 bronchospasm NN I-NP B-Disease
7 1449 1461 16740173 necessitated VBD B-VP O
8 1462 1474 16740173 reintubation NN B-NP O
9 1474 1475 16740173 . . O O

1 1476 1487 16740173 Respiratory JJ B-NP B-Disease
2 1488 1501 16740173 insufficiency NN I-NP I-Disease
3 1502 1505 16740173 was VBD B-VP O
4 1506 1513 16740173 further RBR I-VP O
5 1514 1522 16740173 worsened VBN I-VP O
6 1523 1525 16740173 by IN B-PP O
7 1526 1533 16740173 Proteus NNP B-NP B-Disease
8 1534 1543 16740173 mirabilis NN I-NP I-Disease
9 1544 1553 16740173 infection NN I-NP I-Disease
10 1554 1557 16740173 and CC O O
11 1558 1564 16740173 severe JJ B-NP O
12 1565 1584 16740173 bronchoconstriction NN I-NP O
13 1584 1585 16740173 . . O O

1 1586 1589 16740173 One CD B-NP O
2 1590 1594 16740173 week NN I-NP O
3 1595 1600 16740173 later RB B-ADVP O
4 1600 1601 16740173 , , O O
5 1602 1605 16740173 the DT B-NP O
6 1606 1613 16740173 patient NN I-NP O
7 1614 1617 16740173 was VBD B-VP O
8 1618 1623 16740173 again RB I-VP O
9 1624 1633 16740173 extubated VBN I-VP O
10 1634 1637 16740173 and CC O O
11 1638 1639 16740173 3 CD B-NP O
12 1640 1644 16740173 days NNS I-NP O
13 1645 1650 16740173 later RB B-ADVP O
14 1651 1654 16740173 was VBD B-VP O
15 1655 1666 16740173 transferred VBN I-VP O
16 1667 1669 16740173 to TO B-PP O
17 1670 1671 16740173 a DT B-NP O
18 1672 1682 16740173 peripheral JJ I-NP O
19 1683 1687 16740173 ward NN I-NP O
20 1687 1688 16740173 . . O O

1 1689 1691 16740173 On IN B-PP O
2 1692 1695 16740173 the DT B-NP O
3 1696 1700 16740173 next JJ I-NP O
4 1701 1704 16740173 day NN I-NP O
5 1705 1707 16740173 he PRP B-NP O
6 1708 1712 16740173 died VBD B-VP O
7 1712 1713 16740173 , , O O
8 1714 1722 16740173 probably RB B-ADVP O
9 1723 1725 16740173 as IN B-PP O
10 1726 1727 16740173 a DT B-NP O
11 1728 1734 16740173 result NN I-NP O
12 1735 1737 16740173 of IN B-PP O
13 1738 1743 16740173 heart NN B-NP B-Disease
14 1744 1751 16740173 failure NN I-NP I-Disease
15 1751 1752 16740173 . . O O

1 1753 1758 16740173 Serum NN B-NP O
2 1759 1766 16740173 samples NNS I-NP O
3 1767 1771 16740173 from IN B-PP O
4 1772 1775 16740173 the DT B-NP O
5 1776 1781 16740173 first JJ I-NP O
6 1782 1785 16740173 and CC I-NP O
7 1786 1792 16740173 second JJ I-NP O
8 1793 1797 16740173 days NNS I-NP O
9 1798 1807 16740173 contained VBD B-VP O
10 1808 1811 16740173 3.6 CD B-NP O
11 1812 1815 16740173 and CC I-NP O
12 1816 1819 16740173 1.9 CD I-NP O
13 1820 1822 16740173 mg NN I-NP O
14 1822 1823 16740173 / SYM B-NP O
15 1823 1824 16740173 l NN I-NP O
16 1825 1834 16740173 carbachol NN I-NP B-Chemical
17 1834 1835 16740173 , , O O
18 1836 1848 16740173 respectively RB B-ADVP O
19 1848 1849 16740173 . . O O

1 1850 1853 16740173 The DT B-NP O
2 1854 1867 16740173 corresponding VBG I-NP O
3 1868 1873 16740173 urine NN I-NP O
4 1874 1888 16740173 concentrations NNS I-NP O
5 1889 1897 16740173 amounted VBD B-VP O
6 1898 1900 16740173 to TO B-PP O
7 1901 1904 16740173 374 CD B-NP O
8 1905 1908 16740173 and CC I-NP O
9 1909 1912 16740173 554 CD I-NP O
10 1913 1915 16740173 mg NN I-NP O
11 1915 1916 16740173 / SYM B-NP O
12 1916 1917 16740173 l NN I-NP O
13 1917 1918 16740173 . . O O

1 1919 1929 16740173 CONCLUSION NN B-NP O
2 1929 1930 16740173 : : O O
3 1931 1935 16740173 This DT B-NP O
4 1936 1940 16740173 case NN I-NP O
5 1941 1948 16740173 started VBD B-VP O
6 1949 1953 16740173 with IN B-PP O
7 1954 1955 16740173 a DT B-NP O
8 1956 1961 16740173 media NNS I-NP O
9 1962 1968 16740173 report NN I-NP O
10 1969 1971 16740173 in IN B-PP O
11 1972 1973 16740173 a DT B-NP O
12 1974 1981 16740173 popular JJ I-NP O
13 1982 1991 16740173 newspaper NN I-NP O
14 1991 1992 16740173 , , O O
15 1993 2002 16740173 initiated VBN B-VP O
16 2003 2005 16740173 by IN B-PP O
17 2006 2015 16740173 published VBN B-VP O
18 2015 2016 16740173 , , O O
19 2017 2021 16740173 peer NN B-NP O
20 2021 2022 16740173 - HYPH O O
21 2022 2030 16740173 reviewed VBN B-VP O
22 2031 2039 16740173 research NN B-NP O
23 2040 2042 16740173 on IN B-PP O
24 2043 2050 16740173 herbals NNS B-NP O
25 2050 2051 16740173 , , O O
26 2052 2055 16740173 and CC O O
27 2056 2064 16740173 involved VBN B-VP O
28 2065 2070 16740173 human JJ B-NP O
29 2071 2078 16740173 failure NN I-NP O
30 2079 2081 16740173 in IN B-PP O
31 2082 2083 16740173 a DT B-NP O
32 2084 2088 16740173 case NN I-NP O
33 2089 2096 16740173 history NN I-NP O
34 2096 2097 16740173 , , O O
35 2098 2105 16740173 medical JJ B-NP O
36 2106 2117 16740173 examination NN I-NP O
37 2118 2121 16740173 and CC O O
38 2122 2130 16740173 clinical JJ B-NP O
39 2131 2140 16740173 treatment NN I-NP O
40 2140 2141 16740173 . . O O

1 2142 2145 16740173 For IN B-PP O
2 2146 2149 16740173 the DT B-NP O
3 2150 2155 16740173 first JJ I-NP O
4 2156 2160 16740173 time NN I-NP O
5 2160 2161 16740173 , , O O
6 2162 2164 16740173 an DT B-NP O
7 2165 2175 16740173 analytical JJ I-NP O
8 2176 2182 16740173 method NN I-NP O
9 2183 2186 16740173 for IN B-PP O
10 2187 2190 16740173 the DT B-NP O
11 2191 2204 16740173 determination NN I-NP O
12 2205 2207 16740173 of IN B-PP O
13 2208 2217 16740173 carbachol NN B-NP B-Chemical
14 2218 2220 16740173 in IN B-PP O
15 2221 2227 16740173 plasma NN B-NP O
16 2228 2231 16740173 and CC I-NP O
17 2232 2237 16740173 urine NN I-NP O
18 2238 2241 16740173 has VBZ B-VP O
19 2242 2246 16740173 been VBN I-VP O
20 2247 2256 16740173 developed VBN I-VP O
21 2256 2257 16740173 . . O O

1 2258 2261 16740173 The DT B-NP O
2 2262 2270 16740173 analysed VBN I-NP O
3 2271 2280 16740173 carbachol NN I-NP B-Chemical
4 2281 2294 16740173 concentration NN I-NP O
5 2295 2303 16740173 exceeded VBD B-VP O
6 2304 2307 16740173 the DT B-NP O
7 2308 2316 16740173 supposed VBN I-NP O
8 2317 2322 16740173 serum NN I-NP O
9 2323 2328 16740173 level NN I-NP O
10 2329 2338 16740173 resulting VBG B-VP O
11 2339 2343 16740173 from IN B-PP O
12 2344 2345 16740173 a DT B-NP O
13 2346 2357 16740173 therapeutic JJ I-NP O
14 2358 2362 16740173 dose NN I-NP O
15 2363 2365 16740173 by IN B-PP O
16 2366 2367 16740173 a DT B-NP O
17 2368 2374 16740173 factor NN I-NP O
18 2375 2377 16740173 of IN B-PP O
19 2378 2381 16740173 130 CD B-NP O
20 2382 2384 16740173 to TO B-PP O
21 2385 2388 16740173 260 CD B-NP O
22 2388 2389 16740173 . . O O

1 2390 2400 16740173 Especially RB B-ADVP O
2 2401 2403 16740173 in IN B-PP O
3 2404 2407 16740173 old JJ B-NP O
4 2408 2416 16740173 patients NNS I-NP O
5 2416 2417 16740173 , , O O
6 2418 2430 16740173 intensivists NNS B-NP O
7 2431 2437 16740173 should MD B-VP O
8 2438 2446 16740173 consider VB I-VP O
9 2447 2460 16740173 intoxications NNS B-NP O
10 2461 2462 16740173 ( ( O O
11 2462 2466 16740173 with IN B-PP O
12 2467 2479 16740173 cholinergics NNS B-NP O
13 2479 2480 16740173 ) ) O O
14 2481 2483 16740173 as IN B-PP O
15 2484 2485 16740173 a DT B-NP O
16 2486 2491 16740173 cause NN I-NP O
17 2492 2494 16740173 of IN B-PP O
18 2495 2500 16740173 acute JJ B-NP B-Disease
19 2501 2515 16740173 cardiovascular JJ I-NP I-Disease
20 2516 2523 16740173 failure NN I-NP I-Disease
21 2523 2524 16740173 . . O O

1 0 0 20722491 -DOCSTART- -X- -X- O

1 0 6 20722491 Safety NN B-NP O
2 7 9 20722491 of IN B-PP O
3 10 22 20722491 capecitabine NN B-NP B-Chemical
4 22 23 20722491 : : O O
5 24 25 20722491 a DT B-NP O
6 26 32 20722491 review NN I-NP O
7 32 33 20722491 . . I-NP O
8 34 44 20722491 IMPORTANCE NN I-NP O
9 45 47 20722491 OF IN B-PP O
10 48 51 20722491 THE DT B-NP O
11 52 57 20722491 FIELD NN I-NP O
12 57 58 20722491 : : O O
13 59 76 20722491 Fluoropyrimidines NNS B-NP B-Chemical
14 76 77 20722491 , , O O
15 78 80 20722491 in IN B-PP O
16 81 91 20722491 particular JJ B-NP O
17 92 93 20722491 5 CD I-NP B-Chemical
18 93 94 20722491 - HYPH I-NP I-Chemical
19 94 106 20722491 fluorouracil NN I-NP I-Chemical
20 107 108 20722491 ( ( O O
21 108 109 20722491 5 CD B-NP B-Chemical
22 109 110 20722491 - HYPH I-NP I-Chemical
23 110 112 20722491 FU NN I-NP I-Chemical
24 112 113 20722491 ) ) O O
25 113 114 20722491 , , O O
26 115 119 20722491 have VBP B-VP O
27 120 124 20722491 been VBN I-VP O
28 125 128 20722491 the DT B-NP O
29 129 137 20722491 mainstay NN I-NP O
30 138 140 20722491 of IN B-PP O
31 141 150 20722491 treatment NN B-NP O
32 151 154 20722491 for IN B-PP O
33 155 162 20722491 several JJ B-NP O
34 163 168 20722491 solid JJ I-NP O
35 169 175 20722491 tumors NNS I-NP B-Disease
36 175 176 20722491 , , O O
37 177 186 20722491 including VBG B-PP O
38 187 197 20722491 colorectal JJ B-NP B-Disease
39 197 198 20722491 , , I-NP I-Disease
40 199 205 20722491 breast NN I-NP I-Disease
41 206 209 20722491 and CC I-NP I-Disease
42 210 214 20722491 head NN I-NP I-Disease
43 215 218 20722491 and CC I-NP I-Disease
44 219 223 20722491 neck NN I-NP I-Disease
45 224 231 20722491 cancers NNS I-NP I-Disease
46 231 232 20722491 , , O O
47 233 236 20722491 for IN B-PP O
48 237 238 20722491 > JJR B-NP O
49 239 241 20722491 40 CD I-NP O
50 242 247 20722491 years NNS I-NP O
51 247 248 20722491 . . O O

1 249 254 20722491 AREAS NNP B-NP O
2 255 262 20722491 COVERED NNP I-NP O
3 263 265 20722491 IN NNP I-NP O
4 266 270 20722491 THIS NNP I-NP O
5 271 277 20722491 REVIEW NNP I-NP O
6 277 278 20722491 : : O O
7 279 283 20722491 This DT B-NP O
8 284 291 20722491 article NN I-NP O
9 292 299 20722491 reviews VBZ B-VP O
10 300 303 20722491 the DT B-NP O
11 304 316 20722491 pharmacology NN I-NP O
12 317 320 20722491 and CC I-NP O
13 321 329 20722491 efficacy NN I-NP O
14 330 332 20722491 of IN B-PP O
15 333 345 20722491 capecitabine NN B-NP B-Chemical
16 346 350 20722491 with IN B-PP O
17 351 352 20722491 a DT B-NP O
18 353 360 20722491 special JJ I-NP O
19 361 369 20722491 emphasis NN I-NP O
20 370 372 20722491 on IN B-PP O
21 373 376 20722491 its PRP$ B-NP O
22 377 383 20722491 safety NN I-NP O
23 383 384 20722491 . . O O

1 385 389 20722491 WHAT WDT B-NP O
2 390 393 20722491 THE DT B-NP O
3 394 400 20722491 READER NN I-NP O
4 401 405 20722491 WILL NN I-NP O
5 406 410 20722491 GAIN NN I-NP O
6 410 411 20722491 : : O O
7 412 415 20722491 The DT B-NP O
8 416 422 20722491 reader NN I-NP O
9 423 427 20722491 will MD B-VP O
10 428 432 20722491 gain VB I-VP O
11 433 439 20722491 better JJR B-NP O
12 440 447 20722491 insight NN I-NP O
13 448 452 20722491 into IN B-PP O
14 453 456 20722491 the DT B-NP O
15 457 463 20722491 safety NN I-NP O
16 464 466 20722491 of IN B-PP O
17 467 479 20722491 capecitabine NN B-NP B-Chemical
18 480 482 20722491 in IN B-PP O
19 483 490 20722491 special JJ B-NP O
20 491 502 20722491 populations NNS I-NP O
21 503 507 20722491 such JJ B-PP O
22 508 510 20722491 as IN I-PP O
23 511 519 20722491 patients NNS B-NP O
24 520 524 20722491 with IN B-PP O
25 525 533 20722491 advanced JJ B-NP O
26 534 537 20722491 age NN I-NP O
27 537 538 20722491 , , O O
28 539 544 20722491 renal JJ B-NP B-Disease
29 545 548 20722491 and CC I-NP I-Disease
30 549 555 20722491 kidney NN I-NP I-Disease
31 556 563 20722491 disease NN I-NP I-Disease
32 563 564 20722491 . . O O

1 565 567 20722491 We PRP B-NP O
2 568 572 20722491 also RB B-ADVP O
3 573 580 20722491 explore VBP B-VP O
4 581 590 20722491 different JJ B-NP O
5 591 597 20722491 dosing NN I-NP O
6 598 601 20722491 and CC O O
7 602 611 20722491 schedules NNS B-NP O
8 612 614 20722491 of IN B-PP O
9 615 627 20722491 capecitabine NN B-NP B-Chemical
10 628 642 20722491 administration NN I-NP O
11 642 643 20722491 . . O O

1 644 648 20722491 TAKE NN B-NP O
2 649 653 20722491 HOME NN I-NP O
3 654 661 20722491 MESSAGE NN I-NP O
4 661 662 20722491 : : O O
5 663 675 20722491 Capecitabine NN B-NP B-Chemical
6 676 678 20722491 is VBZ B-VP O
7 679 681 20722491 an DT B-NP O
8 682 686 20722491 oral JJ I-NP O
9 687 694 20722491 prodrug NN I-NP O
10 695 697 20722491 of IN B-PP O
11 698 699 20722491 5 CD B-NP B-Chemical
12 699 700 20722491 - HYPH I-NP I-Chemical
13 700 702 20722491 FU NN I-NP I-Chemical
14 703 706 20722491 and CC O O
15 707 710 20722491 was VBD B-VP O
16 711 720 20722491 developed VBN I-VP O
17 721 723 20722491 to TO I-VP O
18 724 731 20722491 fulfill VB I-VP O
19 732 735 20722491 the DT B-NP O
20 736 740 20722491 need NN I-NP O
21 741 744 20722491 for IN B-PP O
22 745 746 20722491 a DT B-NP O
23 747 751 20722491 more RBR I-NP O
24 752 762 20722491 convenient JJ I-NP O
25 763 770 20722491 therapy NN I-NP O
26 771 774 20722491 and CC O O
27 775 782 20722491 provide VBP B-VP O
28 783 785 20722491 an DT B-NP O
29 786 794 20722491 improved VBN I-NP O
30 795 801 20722491 safety NN I-NP O
31 801 802 20722491 / SYM I-NP O
32 802 810 20722491 efficacy NN I-NP O
33 811 818 20722491 profile NN I-NP O
34 818 819 20722491 . . O O

1 820 822 20722491 It PRP B-NP O
2 823 826 20722491 has VBZ B-VP O
3 827 832 20722491 shown VBN I-VP O
4 833 842 20722491 promising JJ B-NP O
5 843 850 20722491 results NNS I-NP O
6 851 856 20722491 alone RB B-ADVP O
7 857 859 20722491 or CC O O
8 860 862 20722491 in IN B-PP O
9 863 874 20722491 combination NN B-NP O
10 875 879 20722491 with IN B-PP O
11 880 885 20722491 other JJ B-NP O
12 886 902 20722491 chemotherapeutic JJ I-NP O
13 903 909 20722491 agents NNS I-NP O
14 910 912 20722491 in IN B-PP O
15 913 923 20722491 colorectal JJ B-NP B-Disease
16 923 924 20722491 , , I-NP I-Disease
17 925 931 20722491 breast NN I-NP I-Disease
18 931 932 20722491 , , I-NP I-Disease
19 933 951 20722491 pancreaticobiliary JJ I-NP I-Disease
20 951 952 20722491 , , I-NP I-Disease
21 953 960 20722491 gastric JJ I-NP I-Disease
22 960 961 20722491 , , I-NP I-Disease
23 962 967 20722491 renal JJ I-NP I-Disease
24 968 972 20722491 cell NN I-NP I-Disease
25 973 976 20722491 and CC O I-Disease
26 977 981 20722491 head NN B-NP I-Disease
27 982 985 20722491 and CC O I-Disease
28 986 990 20722491 neck NN B-NP I-Disease
29 991 998 20722491 cancers NNS I-NP I-Disease
30 998 999 20722491 . . O O

1 1000 1003 20722491 The DT B-NP O
2 1004 1008 20722491 most RBS I-NP O
3 1009 1017 20722491 commonly RB I-NP O
4 1018 1026 20722491 reported VBN I-NP O
5 1027 1032 20722491 toxic JJ I-NP O
6 1033 1040 20722491 effects NNS I-NP O
7 1041 1043 20722491 of IN B-PP O
8 1044 1056 20722491 capecitabine NN B-NP B-Chemical
9 1057 1060 20722491 are VBP B-VP O
10 1061 1069 20722491 diarrhea NN B-NP B-Disease
11 1069 1070 20722491 , , O O
12 1071 1077 20722491 nausea NN B-NP B-Disease
13 1077 1078 20722491 , , O O
14 1079 1087 20722491 vomiting NN B-NP B-Disease
15 1087 1088 20722491 , , O O
16 1089 1099 20722491 stomatitis NN B-NP B-Disease
17 1100 1103 20722491 and CC I-NP O
18 1104 1108 20722491 hand NN I-NP B-Disease
19 1108 1109 20722491 - HYPH B-NP I-Disease
20 1109 1113 20722491 foot NN I-NP I-Disease
21 1114 1122 20722491 syndrome NN I-NP I-Disease
22 1122 1123 20722491 . . O O

1 1124 1136 20722491 Capecitabine NNP B-NP B-Chemical
2 1137 1140 20722491 has VBZ B-VP O
3 1141 1142 20722491 a DT B-NP O
4 1143 1147 20722491 well RB I-NP O
5 1147 1148 20722491 - HYPH I-NP O
6 1148 1159 20722491 established VBN I-NP O
7 1160 1166 20722491 safety NN I-NP O
8 1167 1174 20722491 profile NN I-NP O
9 1175 1178 20722491 and CC O O
10 1179 1182 20722491 can MD B-VP O
11 1183 1185 20722491 be VB I-VP O
12 1186 1191 20722491 given VBN I-VP O
13 1192 1198 20722491 safely RB B-ADVP O
14 1199 1201 20722491 to TO B-PP O
15 1202 1210 20722491 patients NNS B-NP O
16 1211 1215 20722491 with IN B-PP O
17 1216 1224 20722491 advanced JJ B-NP O
18 1225 1228 20722491 age NN I-NP O
19 1228 1229 20722491 , , O O
20 1230 1237 20722491 hepatic JJ B-NP B-Disease
21 1238 1241 20722491 and CC I-NP I-Disease
22 1242 1247 20722491 renal JJ I-NP I-Disease
23 1248 1260 20722491 dysfunctions NNS I-NP I-Disease
24 1260 1261 20722491 . . O O

1 0 0 3125768 -DOCSTART- -X- -X- O

1 0 12 3125768 Intracranial JJ B-NP O
2 13 21 3125768 pressure NN I-NP O
3 22 31 3125768 increases VBZ B-VP O
4 32 38 3125768 during IN B-PP O
5 39 49 3125768 alfentanil NN B-NP B-Chemical
6 49 50 3125768 - HYPH B-NP O
7 50 57 3125768 induced VBN I-NP O
8 58 66 3125768 rigidity NN I-NP B-Disease
9 66 67 3125768 . . O O
10 68 80 3125768 Intracranial JJ B-NP O
11 81 89 3125768 pressure NN I-NP O
12 90 91 3125768 ( ( O O
13 91 94 3125768 ICP NN B-NP O
14 94 95 3125768 ) ) O O
15 96 99 3125768 was VBD B-VP O
16 100 108 3125768 measured VBN I-VP O
17 109 115 3125768 during IN B-PP O
18 116 126 3125768 alfentanil NN B-NP B-Chemical
19 126 127 3125768 - HYPH B-NP O
20 127 134 3125768 induced VBN I-NP O
21 135 143 3125768 rigidity NN I-NP B-Disease
22 144 146 3125768 in IN B-PP O
23 147 151 3125768 rats NNS B-NP O
24 151 152 3125768 . . O O

1 153 156 3125768 Ten CD B-NP O
2 157 161 3125768 rats NNS I-NP O
3 162 165 3125768 had VBD B-VP O
4 166 174 3125768 arterial JJ B-NP O
5 174 175 3125768 , , I-NP O
6 176 183 3125768 central JJ I-NP O
7 184 190 3125768 venous JJ I-NP O
8 191 192 3125768 ( ( O O
9 192 195 3125768 CVP NN B-NP O
10 195 196 3125768 ) ) O O
11 196 197 3125768 , , O O
12 198 201 3125768 and CC O O
13 202 210 3125768 subdural JJ B-NP O
14 211 219 3125768 cannulae NNS I-NP O
15 220 228 3125768 inserted VBN B-VP O
16 229 234 3125768 under IN B-PP O
17 235 244 3125768 halothane NN B-NP B-Chemical
18 245 255 3125768 anesthesia NN I-NP O
19 255 256 3125768 . . O O

1 257 260 3125768 The DT B-NP O
2 261 268 3125768 animals NNS I-NP O
3 269 273 3125768 were VBD B-VP O
4 274 286 3125768 mechanically RB I-VP O
5 287 297 3125768 ventilated VBN I-VP O
6 298 300 3125768 to TO I-VP O
7 301 308 3125768 achieve VB I-VP O
8 309 320 3125768 normocarbia NN B-NP O
9 321 322 3125768 ( ( O O
10 322 326 3125768 PCO2 NN B-NP O
11 327 328 3125768 = SYM B-VP O
12 329 331 3125768 42 CD B-NP O
13 332 333 3125768 + SYM O O
14 333 334 3125768 / SYM O O
15 334 335 3125768 - SYM O O
16 336 337 3125768 1 CD B-NP O
17 338 342 3125768 mmHg NN I-NP O
18 342 343 3125768 , , O O
19 344 348 3125768 mean NN B-NP O
20 349 350 3125768 + SYM O O
21 350 351 3125768 / SYM O O
22 351 352 3125768 - HYPH O O
23 353 355 3125768 SE NN B-NP O
24 355 356 3125768 ) ) O O
25 356 357 3125768 . . O O

1 358 367 3125768 Following VBG B-PP O
2 368 383 3125768 instrumentation NN B-NP O
3 383 384 3125768 , , O O
4 385 394 3125768 halothane NN B-NP B-Chemical
5 395 398 3125768 was VBD B-VP O
6 399 411 3125768 discontinued VBN I-VP O
7 412 415 3125768 and CC O O
8 416 426 3125768 alfentanil NN B-NP B-Chemical
9 427 428 3125768 ( ( O O
10 428 431 3125768 125 CD B-NP O
11 432 434 3125768 mu NN I-NP O
12 434 435 3125768 / SYM B-NP O
13 435 437 3125768 kg NN I-NP O
14 437 438 3125768 ) ) O O
15 439 451 3125768 administered VBN B-NP O
16 452 454 3125768 iv NN I-NP O
17 455 461 3125768 during IN B-PP O
18 462 471 3125768 emergence NN B-NP O
19 472 476 3125768 from IN B-PP O
20 477 486 3125768 halothane NN B-NP B-Chemical
21 487 497 3125768 anesthesia NN I-NP O
22 497 498 3125768 . . O O

1 499 501 3125768 In IN B-PP O
2 502 505 3125768 the DT B-NP O
3 506 510 3125768 five CD I-NP O
4 511 515 3125768 rats NNS I-NP O
5 516 520 3125768 that WDT B-NP O
6 521 530 3125768 developed VBD B-VP O
7 531 538 3125768 somatic JJ B-NP B-Disease
8 539 547 3125768 rigidity NN I-NP I-Disease
9 547 548 3125768 , , I-NP O
10 549 552 3125768 ICP NN I-NP O
11 553 556 3125768 and CC I-NP O
12 557 560 3125768 CVP NN I-NP O
13 561 570 3125768 increased VBD B-VP O
14 571 584 3125768 significantly RB B-ADVP O
15 585 590 3125768 above IN B-PP O
16 591 599 3125768 baseline NN B-NP O
17 600 601 3125768 ( ( O O
18 601 606 3125768 delta SYM B-NP O
19 607 610 3125768 ICP NN B-NP O
20 611 614 3125768 7.5 CD I-NP O
21 615 616 3125768 + SYM O O
22 616 617 3125768 / SYM O O
23 617 618 3125768 - SYM O O
24 619 622 3125768 1.0 CD B-NP O
25 623 627 3125768 mmHg NN I-NP O
26 627 628 3125768 , , O O
27 629 634 3125768 delta SYM O O
28 635 638 3125768 CVP NN B-NP O
29 639 642 3125768 5.9 CD I-NP O
30 643 644 3125768 + SYM O O
31 644 645 3125768 / SYM O O
32 645 646 3125768 - SYM O O
33 647 650 3125768 1.3 CD B-NP O
34 651 655 3125768 mmHg NN I-NP O
35 655 656 3125768 ) ) O O
36 656 657 3125768 . . O O

1 658 663 3125768 These DT B-NP O
2 664 673 3125768 variables NNS I-NP O
3 674 682 3125768 returned VBD B-VP O
4 683 685 3125768 to TO B-PP O
5 686 694 3125768 baseline NN B-NP O
6 695 699 3125768 when WRB B-ADVP O
7 700 708 3125768 rigidity NN B-NP B-Disease
8 709 712 3125768 was VBD B-VP O
9 713 722 3125768 abolished VBN I-VP O
10 723 727 3125768 with IN B-PP O
11 728 738 3125768 metocurine NN B-NP B-Chemical
12 738 739 3125768 . . O O

1 740 742 3125768 In IN B-PP O
2 743 747 3125768 five CD B-NP O
3 748 752 3125768 rats NNS I-NP O
4 753 757 3125768 that WDT B-NP O
5 758 761 3125768 did VBD B-VP O
6 762 765 3125768 not RB I-VP O
7 766 772 3125768 become VBN I-VP O
8 773 778 3125768 rigid JJ B-NP O
9 778 779 3125768 , , I-NP O
10 780 783 3125768 ICP NN I-NP O
11 784 787 3125768 and CC I-NP O
12 788 791 3125768 CVP NN I-NP O
13 792 795 3125768 did VBD B-VP O
14 796 799 3125768 not RB I-VP O
15 800 806 3125768 change VB I-VP O
16 807 816 3125768 following VBG B-PP O
17 817 827 3125768 alfentanil NN B-NP B-Chemical
18 827 828 3125768 . . O O

1 829 834 3125768 These DT B-NP O
2 835 847 3125768 observations NNS I-NP O
3 848 855 3125768 suggest VBP B-VP O
4 856 860 3125768 that IN B-SBAR O
5 861 869 3125768 rigidity NN B-NP B-Disease
6 870 876 3125768 should MD B-VP O
7 877 879 3125768 be VB I-VP O
8 880 889 3125768 prevented VBN I-VP O
9 890 894 3125768 when WRB B-ADVP O
10 895 905 3125768 alfentanil NN B-NP B-Chemical
11 905 906 3125768 , , O O
12 907 910 3125768 and CC O O
13 910 911 3125768 , , O O
14 912 922 3125768 presumably RB B-ADVP O
15 922 923 3125768 , , O O
16 924 929 3125768 other JJ B-NP O
17 930 937 3125768 opiates NNS I-NP O
18 937 938 3125768 , , O O
19 939 942 3125768 are VBP B-VP O
20 943 947 3125768 used VBN I-VP O
21 948 950 3125768 in IN B-PP O
22 951 954 3125768 the DT B-NP O
23 955 965 3125768 anesthetic JJ I-NP O
24 966 976 3125768 management NN I-NP O
25 977 979 3125768 of IN B-PP O
26 980 988 3125768 patients NNS B-NP O
27 989 993 3125768 with IN B-PP O
28 994 997 3125768 ICP NN B-NP O
29 998 1006 3125768 problems NNS I-NP O
30 1006 1007 3125768 . . O O

1 0 0 1130930 -DOCSTART- -X- -X- O

1 0 14 1130930 Nephrotoxicity NN B-NP B-Disease
2 15 17 1130930 of IN B-PP O
3 18 26 1130930 combined VBN B-NP O
4 27 38 1130930 cephalothin JJ I-NP B-Chemical
5 38 39 1130930 - HYPH I-NP O
6 39 49 1130930 gentamicin NN I-NP B-Chemical
7 50 57 1130930 regimen NN I-NP O
8 57 58 1130930 . . O O
9 59 62 1130930 Two CD B-NP O
10 63 71 1130930 patients NNS I-NP O
11 72 81 1130930 developed VBD B-VP O
12 82 87 1130930 acute JJ B-NP B-Disease
13 88 95 1130930 tubular JJ I-NP I-Disease
14 96 104 1130930 necrosis NN I-NP I-Disease
15 104 105 1130930 , , O O
16 106 119 1130930 characterized VBN B-VP O
17 120 130 1130930 clinically RB B-ADVP O
18 131 133 1130930 by IN B-PP O
19 134 139 1130930 acute JJ B-NP O
20 140 148 1130930 oliguric JJ I-NP B-Disease
21 149 154 1130930 renal JJ I-NP I-Disease
22 155 162 1130930 failure NN I-NP I-Disease
23 162 163 1130930 , , O O
24 164 169 1130930 while IN B-SBAR O
25 170 174 1130930 they PRP B-NP O
26 175 179 1130930 were VBD B-VP O
27 180 189 1130930 receiving VBG I-VP O
28 190 191 1130930 a DT B-NP O
29 192 203 1130930 combination NN I-NP O
30 204 206 1130930 of IN B-PP O
31 207 218 1130930 cephalothin JJ B-NP B-Chemical
32 219 225 1130930 sodium NN I-NP I-Chemical
33 226 229 1130930 and CC I-NP O
34 230 240 1130930 gentamicin NN I-NP B-Chemical
35 241 248 1130930 sulfate NN I-NP I-Chemical
36 249 256 1130930 therapy NN I-NP O
37 256 257 1130930 . . O O

1 258 266 1130930 Patients NNS B-NP O
2 267 270 1130930 who WP B-NP O
3 271 274 1130930 are VBP B-VP O
4 275 280 1130930 given VBN I-VP O
5 281 285 1130930 this DT B-NP O
6 286 290 1130930 drug NN I-NP O
7 291 298 1130930 regimen NN I-NP O
8 299 305 1130930 should MD B-VP O
9 306 308 1130930 be VB I-VP O
10 309 317 1130930 observed VBN I-VP O
11 318 322 1130930 very RB B-ADVP O
12 323 332 1130930 carefully RB I-ADVP O
13 333 336 1130930 for IN B-PP O
14 337 342 1130930 early JJ B-NP O
15 343 348 1130930 signs NNS I-NP O
16 349 351 1130930 of IN B-PP O
17 352 366 1130930 nephrotoxicity NN B-NP B-Disease
18 366 367 1130930 . . O O

1 368 372 1130930 High JJ B-NP O
2 373 378 1130930 doses NNS I-NP O
3 379 381 1130930 of IN B-PP O
4 382 386 1130930 this DT B-NP O
5 387 397 1130930 antibiotic JJ I-NP O
6 398 409 1130930 combination NN I-NP O
7 410 416 1130930 should MD B-VP O
8 417 419 1130930 be VB I-VP O
9 420 427 1130930 avoided VBN I-VP O
10 428 438 1130930 especially RB B-ADVP O
11 439 441 1130930 in IN B-PP O
12 442 449 1130930 elderly JJ B-NP O
13 450 458 1130930 patients NNS I-NP O
14 458 459 1130930 . . O O

1 460 468 1130930 Patients NNS B-NP O
2 469 473 1130930 with IN B-PP O
3 474 479 1130930 renal JJ B-NP B-Disease
4 480 493 1130930 insufficiency NN I-NP I-Disease
5 494 500 1130930 should MD B-VP O
6 501 504 1130930 not RB I-VP O
7 505 507 1130930 be VB I-VP O
8 508 513 1130930 given VBN I-VP O
9 514 518 1130930 this DT B-NP O
10 519 526 1130930 regimen NN I-NP O
11 526 527 1130930 . . O O

1 0 0 8423889 -DOCSTART- -X- -X- O

1 0 8 8423889 Increase NN B-NP O
2 9 11 8423889 of IN B-PP O
3 12 21 8423889 Parkinson NNP B-NP B-Disease
4 22 32 8423889 disability NN I-NP I-Disease
5 33 38 8423889 after IN B-PP O
6 39 49 8423889 fluoxetine NN B-NP B-Chemical
7 50 60 8423889 medication NN I-NP O
8 60 61 8423889 . . I-NP O
9 62 72 8423889 Depression NN I-NP B-Disease
10 73 75 8423889 is VBZ B-VP O
11 76 77 8423889 a DT B-NP O
12 78 83 8423889 major JJ I-NP O
13 84 92 8423889 clinical JJ I-NP O
14 93 100 8423889 feature NN I-NP O
15 101 103 8423889 of IN B-PP O
16 104 115 8423889 Parkinson's NNP B-NP B-Disease
17 116 123 8423889 disease NN I-NP I-Disease
18 123 124 8423889 . . O O

1 125 127 8423889 We PRP B-NP O
2 128 134 8423889 report VBP B-VP O
3 135 138 8423889 the DT B-NP O
4 139 148 8423889 increased VBN I-NP O
5 149 155 8423889 amount NN I-NP O
6 156 158 8423889 of IN B-PP O
7 159 164 8423889 motor NN B-NP B-Disease
8 165 175 8423889 disability NN I-NP I-Disease
9 176 178 8423889 in IN B-PP O
10 179 183 8423889 four CD B-NP O
11 184 192 8423889 patients NNS I-NP O
12 193 197 8423889 with IN B-PP O
13 198 208 8423889 idiopathic JJ B-NP B-Disease
14 209 220 8423889 Parkinson's NNPS I-NP I-Disease
15 221 228 8423889 disease NN I-NP I-Disease
16 229 234 8423889 after IN B-PP O
17 235 243 8423889 exposure NN B-NP O
18 244 246 8423889 to TO B-PP O
19 247 250 8423889 the DT B-NP O
20 251 265 8423889 antidepressant NN I-NP B-Chemical
21 266 276 8423889 fluoxetine NN I-NP B-Chemical
22 276 277 8423889 . . O O

1 278 281 8423889 The DT B-NP O
2 282 293 8423889 possibility NN I-NP O
3 294 296 8423889 of IN B-PP O
4 297 298 8423889 a DT B-NP O
5 299 309 8423889 clinically RB I-NP O
6 310 318 8423889 relevant JJ I-NP O
7 319 327 8423889 dopamine NN I-NP B-Chemical
8 327 328 8423889 - HYPH B-NP O
9 328 340 8423889 antagonistic JJ I-NP O
10 341 349 8423889 capacity NN I-NP O
11 350 352 8423889 of IN B-PP O
12 353 363 8423889 fluoxetine NN B-NP B-Chemical
13 364 366 8423889 in IN B-PP O
14 367 378 8423889 Parkinson's NNP B-NP B-Disease
15 379 386 8423889 disease NN I-NP I-Disease
16 387 395 8423889 patients NNS I-NP O
17 396 400 8423889 must MD B-VP O
18 401 403 8423889 be VB I-VP O
19 404 414 8423889 considered VBN I-VP O
20 414 415 8423889 . . O O

1 0 0 8595686 -DOCSTART- -X- -X- O

1 0 11 8595686 Thiopentone NN B-NP B-Chemical
2 12 24 8595686 pretreatment NN I-NP O
3 25 28 8595686 for IN B-PP O
4 29 37 8595686 propofol NN B-NP B-Chemical
5 38 47 8595686 injection NN I-NP O
6 48 52 8595686 pain NN I-NP B-Disease
7 53 55 8595686 in IN B-PP O
8 56 66 8595686 ambulatory JJ B-NP O
9 67 75 8595686 patients NNS I-NP O
10 75 76 8595686 . . O O
11 77 81 8595686 This DT B-NP O
12 82 87 8595686 study NN I-NP O
13 88 100 8595686 investigated VBD B-VP O
14 101 109 8595686 propofol NN B-NP B-Chemical
15 110 119 8595686 injection NN I-NP O
16 120 124 8595686 pain NN I-NP B-Disease
17 125 127 8595686 in IN B-PP O
18 128 136 8595686 patients NNS B-NP O
19 137 147 8595686 undergoing VBG B-VP O
20 148 158 8595686 ambulatory JJ B-NP O
21 159 170 8595686 anaesthesia NN I-NP O
22 170 171 8595686 . . O O

1 172 174 8595686 In IN B-PP O
2 175 176 8595686 a DT B-NP O
3 177 187 8595686 randomized VBN I-NP O
4 187 188 8595686 , , I-NP O
5 189 195 8595686 double JJ I-NP O
6 195 196 8595686 - HYPH I-NP O
7 196 201 8595686 blind JJ I-NP O
8 202 207 8595686 trial NN I-NP O
9 207 208 8595686 , , O O
10 209 211 8595686 90 CD B-NP O
11 212 217 8595686 women NNS I-NP O
12 218 222 8595686 were VBD B-VP O
13 223 232 8595686 allocated VBN I-VP O
14 233 235 8595686 to TO I-VP O
15 236 243 8595686 receive VB I-VP O
16 244 247 8595686 one CD B-NP O
17 248 250 8595686 of IN B-PP O
18 251 256 8595686 three CD B-NP O
19 257 267 8595686 treatments NNS I-NP O
20 268 273 8595686 prior RB B-ADVP O
21 274 276 8595686 to TO B-PP O
22 277 286 8595686 induction NN B-NP O
23 287 289 8595686 of IN B-PP O
24 290 301 8595686 anaesthesia NN B-NP O
25 302 306 8595686 with IN B-PP O
26 307 315 8595686 propofol NN B-NP B-Chemical
27 315 316 8595686 . . O O

1 317 325 8595686 Patients NNS B-NP O
2 326 328 8595686 in IN B-PP O
3 329 334 8595686 Group NN B-NP O
4 335 336 8595686 C NN I-NP O
5 337 345 8595686 received VBD B-VP O
6 346 347 8595686 2 CD B-NP O
7 348 350 8595686 ml NN I-NP O
8 351 357 8595686 normal JJ I-NP O
9 358 364 8595686 saline NN I-NP O
10 364 365 8595686 , , O O
11 366 371 8595686 Group NNP B-NP O
12 372 373 8595686 L NNP I-NP O
13 373 374 8595686 , , O O
14 375 376 8595686 2 CD B-NP O
15 377 379 8595686 ml NN I-NP O
16 379 380 8595686 , , O O
17 381 390 8595686 lidocaine NN B-NP B-Chemical
18 391 393 8595686 2% NN I-NP O
19 394 395 8595686 ( ( O O
20 395 397 8595686 40 CD B-NP O
21 398 400 8595686 mg NN I-NP O
22 400 401 8595686 ) ) O O
23 402 405 8595686 and CC O O
24 406 411 8595686 Group NNP B-NP O
25 412 413 8595686 T NNP I-NP O
26 413 414 8595686 , , O O
27 415 416 8595686 2 CD B-NP O
28 417 419 8595686 ml NN I-NP O
29 420 431 8595686 thiopentone NN I-NP B-Chemical
30 432 436 8595686 2.5% CD I-NP O
31 437 438 8595686 ( ( O O
32 438 440 8595686 50 CD B-NP O
33 441 443 8595686 mg NN I-NP O
34 443 444 8595686 ) ) O O
35 444 445 8595686 . . O O

1 446 452 8595686 Venous JJ B-NP O
2 453 463 8595686 discomfort NN I-NP O
3 464 467 8595686 was VBD B-VP O
4 468 476 8595686 assessed VBN I-VP O
5 477 481 8595686 with IN B-PP O
6 482 483 8595686 a DT B-NP O
7 484 490 8595686 visual JJ I-NP O
8 491 499 8595686 analogue NN I-NP O
9 500 505 8595686 scale NN I-NP O
10 506 507 8595686 ( ( O O
11 507 510 8595686 VAS NN B-NP O
12 510 511 8595686 ) ) O O
13 512 513 8595686 5 CD B-NP O
14 513 514 8595686 - HYPH I-NP O
15 514 516 8595686 15 CD I-NP O
16 517 520 8595686 sec NN I-NP O
17 521 526 8595686 after IN B-PP O
18 527 537 8595686 commencing VBG B-VP O
19 538 546 8595686 propofol NN B-NP B-Chemical
20 547 561 8595686 administration NN I-NP O
21 562 567 8595686 using VBG B-VP O
22 568 570 8595686 an DT B-NP O
23 571 579 8595686 infusion NN I-NP O
24 580 584 8595686 pump NN I-NP O
25 585 586 8595686 ( ( O O
26 586 590 8595686 rate NN B-NP O
27 591 595 8595686 1000 CD I-NP O
28 596 609 8595686 micrograms.kg NN I-NP O
29 609 610 8595686 - HYPH B-NP O
30 610 615 8595686 1.min NN I-NP O
31 615 616 8595686 - HYPH B-NP O
32 616 617 8595686 1 CD I-NP O
33 617 618 8595686 ) ) O O
34 618 619 8595686 . . O O

1 620 624 8595686 Loss NN B-NP B-Disease
2 625 627 8595686 of IN B-PP I-Disease
3 628 641 8595686 consciousness NN B-NP I-Disease
4 642 650 8595686 occurred VBD B-VP O
5 651 653 8595686 in IN B-PP O
6 654 656 8595686 60 CD B-NP O
7 656 657 8595686 - HYPH I-NP O
8 657 659 8595686 90 CD I-NP O
9 660 663 8595686 sec NN I-NP O
10 663 664 8595686 . . O O

1 665 671 8595686 Visual JJ B-NP O
2 672 680 8595686 analogue NN I-NP O
3 681 687 8595686 scores NNS I-NP O
4 688 689 8595686 ( ( O O
5 689 693 8595686 mean NN B-NP O
6 694 695 8595686 + SYM O O
7 695 696 8595686 / SYM B-NP O
8 696 697 8595686 - HYPH B-NP O
9 698 700 8595686 SD NN I-NP O
10 700 701 8595686 ) ) O O
11 702 708 8595686 during IN B-PP O
12 709 718 8595686 induction NN B-NP O
13 719 723 8595686 were VBD B-VP O
14 724 729 8595686 lower JJR B-ADJP O
15 730 732 8595686 in IN B-PP O
16 733 739 8595686 Groups NNS B-NP O
17 740 741 8595686 L NN I-NP O
18 742 743 8595686 ( ( O O
19 743 746 8595686 3.3 CD B-NP O
20 747 748 8595686 + SYM O O
21 748 749 8595686 / SYM B-NP O
22 749 750 8595686 - SYM B-NP O
23 751 754 8595686 2.5 CD I-NP O
24 754 755 8595686 ) ) O O
25 756 759 8595686 and CC O O
26 760 761 8595686 T NN B-NP O
27 762 763 8595686 ( ( O O
28 763 766 8595686 4.1 CD B-NP O
29 767 768 8595686 + SYM O O
30 768 769 8595686 / SYM O O
31 769 770 8595686 - SYM O O
32 771 774 8595686 2.7 CD B-NP O
33 774 775 8595686 ) ) O O
34 776 780 8595686 than IN B-PP O
35 781 783 8595686 in IN B-PP O
36 784 789 8595686 Group NN B-NP O
37 790 791 8595686 C NN I-NP O
38 792 793 8595686 ( ( O O
39 793 796 8595686 5.6 CD B-NP O
40 797 798 8595686 + SYM O O
41 798 799 8595686 / SYM O O
42 799 800 8595686 - SYM O O
43 801 804 8595686 2.3 CD B-NP O
44 804 805 8595686 ) ) O O
45 805 806 8595686 ; : O O
46 807 808 8595686 P NN B-NP O
47 809 810 8595686 = SYM B-VP O
48 811 817 8595686 0.0031 CD B-NP O
49 817 818 8595686 . . O O

1 819 822 8595686 The DT B-NP O
2 823 832 8595686 incidence NN I-NP O
3 833 835 8595686 of IN B-PP O
4 836 842 8595686 venous JJ B-NP O
5 843 853 8595686 discomfort NN I-NP O
6 854 857 8595686 was VBD B-VP O
7 858 863 8595686 lower JJR B-ADJP O
8 864 866 8595686 in IN B-PP O
9 867 872 8595686 Group NN B-NP O
10 873 874 8595686 L NN I-NP O
11 875 876 8595686 ( ( O O
12 876 881 8595686 76.6% CD B-NP O
13 881 882 8595686 ; : O O
14 883 884 8595686 P NN B-NP O
15 885 886 8595686 < SYM B-NP O
16 887 891 8595686 0.05 CD I-NP O
17 891 892 8595686 ) ) O O
18 893 897 8595686 than IN B-PP O
19 898 900 8595686 in IN B-PP O
20 901 906 8595686 Group NN B-NP O
21 907 908 8595686 C NN I-NP O
22 909 910 8595686 ( ( O O
23 910 914 8595686 100% CD B-NP O
24 914 915 8595686 ) ) O O
25 916 919 8595686 but CC O O
26 920 923 8595686 not RB B-ADJP O
27 924 933 8595686 different JJ I-ADJP O
28 934 938 8595686 from IN B-PP O
29 939 944 8595686 Group NN B-NP O
30 945 946 8595686 T NN I-NP O
31 947 948 8595686 ( ( O O
32 948 951 8595686 90% CD B-NP O
33 951 952 8595686 ) ) O O
34 952 953 8595686 . . O O

1 954 957 8595686 The DT B-NP O
2 958 961 8595686 VAS NNP I-NP O
3 962 968 8595686 scores NNS I-NP O
4 969 972 8595686 for IN B-PP O
5 973 979 8595686 recall NN B-NP O
6 980 982 8595686 of IN B-PP O
7 983 987 8595686 pain NN B-NP B-Disease
8 988 990 8595686 in IN B-PP O
9 991 994 8595686 the DT B-NP O
10 995 1003 8595686 recovery NN I-NP O
11 1004 1008 8595686 room NN I-NP O
12 1009 1013 8595686 were VBD B-VP O
13 1014 1024 8595686 correlated VBN I-VP O
14 1025 1029 8595686 with IN B-PP O
15 1030 1033 8595686 the DT B-NP O
16 1034 1037 8595686 VAS NNP I-NP O
17 1038 1044 8595686 scores NNS I-NP O
18 1045 1051 8595686 during IN B-PP O
19 1052 1061 8595686 induction NN B-NP O
20 1062 1063 8595686 ( ( O O
21 1063 1064 8595686 r NN B-NP O
22 1065 1066 8595686 = SYM B-VP O
23 1067 1073 8595686 0.7045 CD B-NP O
24 1073 1074 8595686 ; : O O
25 1075 1076 8595686 P NN B-NP O
26 1077 1078 8595686 < SYM B-NP O
27 1079 1085 8595686 0.0001 CD I-NP O
28 1085 1086 8595686 ) ) O O
29 1086 1087 8595686 . . O O

1 1088 1096 8595686 Recovery NN B-NP O
2 1097 1101 8595686 room NN I-NP O
3 1102 1111 8595686 discharge NN I-NP O
4 1112 1117 8595686 times NNS I-NP O
5 1118 1122 8595686 were VBD B-VP O
6 1123 1130 8595686 similar JJ B-ADJP O
7 1130 1131 8595686 : : O O
8 1132 1133 8595686 C NN B-NP O
9 1134 1135 8595686 ( ( O O
10 1135 1139 8595686 75.9 CD B-NP O
11 1140 1141 8595686 + SYM O O
12 1141 1142 8595686 / SYM O O
13 1142 1143 8595686 - SYM O O
14 1144 1148 8595686 19.4 CD B-NP O
15 1149 1152 8595686 min NN I-NP O
16 1152 1153 8595686 ) ) O O
17 1153 1154 8595686 ; : O O
18 1155 1156 8595686 L NN B-NP O
19 1157 1161 8595686 73.6 CD I-NP O
20 1162 1163 8595686 + SYM O O
21 1163 1164 8595686 / SYM O O
22 1164 1165 8595686 - SYM O O
23 1166 1170 8595686 21.6 CD B-NP O
24 1171 1174 8595686 min NN I-NP O
25 1174 1175 8595686 ) ) O O
26 1175 1176 8595686 ; : O O
27 1177 1178 8595686 T NN B-NP O
28 1179 1180 8595686 ( ( O O
29 1180 1184 8595686 77.1 CD B-NP O
30 1185 1186 8595686 + SYM O O
31 1186 1187 8595686 / SYM O O
32 1187 1188 8595686 - SYM O O
33 1189 1193 8595686 18.9 CD B-NP O
34 1194 1197 8595686 min NN I-NP O
35 1197 1198 8595686 ) ) O O
36 1198 1199 8595686 . . O O

1 1200 1209 8595686 Assessing VBG B-VP O
2 1210 1215 8595686 their PRP$ B-NP O
3 1216 1223 8595686 overall JJ I-NP O
4 1224 1236 8595686 satisfaction NN I-NP O
5 1236 1237 8595686 , , O O
6 1238 1243 8595686 89.7% NN B-NP O
7 1244 1249 8595686 would MD B-VP O
8 1250 1256 8595686 choose VB I-VP O
9 1257 1265 8595686 propofol NN B-NP B-Chemical
10 1266 1277 8595686 anaesthesia NN I-NP O
11 1278 1283 8595686 again RB B-ADVP O
12 1283 1284 8595686 . . O O

1 1285 1287 8595686 We PRP B-NP O
2 1288 1296 8595686 conclude VBP B-VP O
3 1297 1301 8595686 that IN B-SBAR O
4 1302 1311 8595686 lidocaine NN B-NP B-Chemical
5 1312 1319 8595686 reduces VBZ B-VP O
6 1320 1323 8595686 the DT B-NP O
7 1324 1333 8595686 incidence NN I-NP O
8 1334 1337 8595686 and CC I-NP O
9 1338 1346 8595686 severity NN I-NP O
10 1347 1349 8595686 of IN B-PP O
11 1350 1358 8595686 propofol NN B-NP B-Chemical
12 1359 1368 8595686 injection NN I-NP O
13 1369 1373 8595686 pain NN I-NP B-Disease
14 1374 1376 8595686 in IN B-PP O
15 1377 1387 8595686 ambulatory JJ B-NP O
16 1388 1396 8595686 patients NNS I-NP O
17 1397 1404 8595686 whereas IN B-PP O
18 1405 1416 8595686 thiopentone NN B-NP B-Chemical
19 1417 1421 8595686 only RB B-ADVP O
20 1422 1429 8595686 reduces VBZ B-VP O
21 1430 1433 8595686 its PRP$ B-NP O
22 1434 1442 8595686 severity NN I-NP O
23 1442 1443 8595686 . . O O

1 0 0 2484011 -DOCSTART- -X- -X- O

1 0 5 2484011 Mouse NN B-NP O
2 6 12 2484011 strain NN I-NP O
3 12 13 2484011 - HYPH B-NP O
4 13 22 2484011 dependent JJ I-NP O
5 23 29 2484011 effect NN I-NP O
6 30 32 2484011 of IN B-PP O
7 33 43 2484011 amantadine NN B-NP B-Chemical
8 44 46 2484011 on IN B-PP O
9 47 55 2484011 motility NN B-NP O
10 56 59 2484011 and CC I-NP O
11 60 65 2484011 brain NN I-NP O
12 66 74 2484011 biogenic JJ I-NP O
13 75 81 2484011 amines NNS I-NP B-Chemical
14 81 82 2484011 . . O O
15 83 86 2484011 The DT B-NP O
16 87 93 2484011 effect NN I-NP O
17 94 96 2484011 of IN B-PP O
18 97 107 2484011 amantadine NN B-NP B-Chemical
19 108 121 2484011 hydrochloride NN I-NP I-Chemical
20 121 122 2484011 , , O O
21 123 131 2484011 injected VBN B-NP O
22 132 135 2484011 i.p NN I-NP O
23 135 136 2484011 . . O O

1 137 139 2484011 in IN B-PP O
2 140 141 2484011 6 CD B-NP O
3 142 152 2484011 increments NNS I-NP O
4 153 155 2484011 of IN B-PP O
5 156 159 2484011 100 CD B-NP O
6 160 162 2484011 mg NN I-NP O
7 162 163 2484011 / SYM I-NP O
8 163 165 2484011 kg NN I-NP O
9 166 170 2484011 each DT B-NP O
10 171 175 2484011 over IN I-NP O
11 176 178 2484011 30 CD I-NP O
12 179 181 2484011 hr NN I-NP O
13 181 182 2484011 , , O O
14 183 185 2484011 on IN B-PP O
15 186 191 2484011 mouse NN B-NP O
16 192 200 2484011 motility NN I-NP O
17 201 204 2484011 and CC O O
18 205 210 2484011 whole JJ B-NP O
19 211 216 2484011 brain NN I-NP O
20 217 224 2484011 content NN I-NP O
21 225 227 2484011 of IN B-PP O
22 228 236 2484011 selected VBN B-NP O
23 237 245 2484011 biogenic JJ I-NP O
24 246 252 2484011 amines NNS I-NP B-Chemical
25 253 256 2484011 and CC O O
26 257 262 2484011 major JJ B-NP O
27 263 274 2484011 metabolites NNS I-NP O
28 275 278 2484011 was VBD B-VP O
29 279 286 2484011 studied VBN I-VP O
30 287 289 2484011 in IN B-PP O
31 290 291 2484011 4 CD B-NP O
32 292 299 2484011 strains NNS I-NP O
33 300 302 2484011 of IN B-PP O
34 303 307 2484011 mice NNS B-NP O
35 307 308 2484011 . . O O

1 309 314 2484011 These DT B-NP O
2 315 319 2484011 were VBD B-VP O
3 320 323 2484011 the DT B-NP O
4 324 330 2484011 albino JJ I-NP O
5 331 338 2484011 Sprague NNP I-NP O
6 338 339 2484011 - HYPH I-NP O
7 339 345 2484011 Dawley NNP I-NP O
8 346 349 2484011 ICR NN I-NP O
9 350 353 2484011 and CC I-NP O
10 354 358 2484011 BALB NN I-NP O
11 358 359 2484011 / SYM B-NP O
12 359 360 2484011 C NN I-NP O
13 360 361 2484011 , , O O
14 362 365 2484011 the DT B-NP O
15 366 371 2484011 black JJ I-NP O
16 372 377 2484011 C57BL NN I-NP O
17 377 378 2484011 / SYM B-NP O
18 378 379 2484011 6 CD B-NP O
19 380 383 2484011 and CC O O
20 384 387 2484011 the DT B-NP O
21 388 393 2484011 brown VBN I-NP O
22 394 397 2484011 CDF NN I-NP O
23 397 398 2484011 - HYPH I-NP O
24 398 399 2484011 I NN I-NP O
25 400 405 2484011 mouse NN I-NP O
26 406 413 2484011 strains NNS I-NP O
27 413 414 2484011 . . O O

1 415 425 2484011 Amantadine NN B-NP B-Chemical
2 426 435 2484011 treatment NN I-NP O
3 436 444 2484011 produced VBD B-VP O
4 445 446 2484011 a DT B-NP O
5 447 455 2484011 biphasic JJ I-NP O
6 456 462 2484011 effect NN I-NP O
7 463 465 2484011 on IN B-PP O
8 466 471 2484011 mouse NN B-NP O
9 472 480 2484011 motility NN I-NP O
10 480 481 2484011 . . O O

1 482 485 2484011 The DT B-NP O
2 486 493 2484011 initial JJ I-NP O
3 494 498 2484011 dose NN I-NP O
4 499 501 2484011 of IN B-PP O
5 502 512 2484011 amantadine NN B-NP B-Chemical
6 513 522 2484011 depressed VBD B-VP B-Disease
7 523 532 2484011 locomotor NN B-NP O
8 533 541 2484011 activity NN I-NP O
9 542 544 2484011 in IN B-PP O
10 545 548 2484011 all DT B-NP O
11 549 554 2484011 mouse NN I-NP O
12 555 562 2484011 strains NNS I-NP O
13 563 570 2484011 studied VBN B-VP O
14 571 575 2484011 with IN B-PP O
15 576 579 2484011 the DT B-NP O
16 580 584 2484011 BALB NN I-NP O
17 584 585 2484011 / SYM B-VP O
18 585 586 2484011 C NN B-NP O
19 587 591 2484011 mice NNS I-NP O
20 592 597 2484011 being VBG B-VP O
21 598 601 2484011 the DT B-NP O
22 602 606 2484011 most RBS I-NP O
23 607 616 2484011 sensitive JJ I-NP O
24 616 617 2484011 . . O O

1 618 628 2484011 Subsequent JJ B-NP O
2 629 639 2484011 amantadine NN I-NP B-Chemical
3 640 650 2484011 treatments NNS I-NP O
4 651 659 2484011 produced VBD B-VP O
5 660 671 2484011 enhancement NN B-NP O
6 672 674 2484011 of IN B-PP O
7 675 683 2484011 motility NN B-NP O
8 684 688 2484011 from IN B-PP O
9 689 702 2484011 corresponding VBG B-VP O
10 703 710 2484011 control NN B-NP O
11 711 713 2484011 in IN B-PP O
12 714 717 2484011 all DT B-NP O
13 718 723 2484011 mouse NN I-NP O
14 724 731 2484011 strains NNS I-NP O
15 732 736 2484011 with IN B-PP O
16 737 740 2484011 the DT B-NP O
17 741 745 2484011 BALB NN I-NP O
18 745 746 2484011 / SYM B-VP O
19 746 747 2484011 C NN B-NP O
20 748 752 2484011 mice NNS I-NP O
21 753 758 2484011 being VBG B-VP O
22 759 762 2484011 the DT B-NP O
23 763 768 2484011 least JJS I-NP O
24 769 778 2484011 sensitive JJ I-NP O
25 778 779 2484011 . . O O

1 780 783 2484011 The DT B-NP O
2 784 793 2484011 locomotor NN I-NP O
3 794 802 2484011 activity NN I-NP O
4 803 806 2484011 was VBD B-VP O
5 807 816 2484011 decreased VBN I-VP O
6 817 821 2484011 from IN B-PP O
7 822 835 2484011 corresponding VBG B-VP O
8 836 844 2484011 controls NNS B-NP O
9 845 847 2484011 in IN B-PP O
10 848 851 2484011 all DT B-NP O
11 852 859 2484011 strains NNS I-NP O
12 860 867 2484011 studied VBN B-VP O
13 867 868 2484011 , , O O
14 869 875 2484011 except IN B-PP O
15 876 879 2484011 for IN B-PP O
16 880 883 2484011 the DT B-NP O
17 884 887 2484011 ICR NN I-NP O
18 888 892 2484011 mice NNS I-NP O
19 892 893 2484011 , , O O
20 894 900 2484011 during IN B-PP O
21 901 903 2484011 an DT B-NP O
22 904 913 2484011 overnight JJ I-NP O
23 914 918 2484011 drug NN I-NP O
24 918 919 2484011 - HYPH B-NP O
25 919 923 2484011 free JJ I-NP O
26 924 930 2484011 period NN I-NP O
27 931 940 2484011 following VBG B-PP O
28 941 944 2484011 the DT B-NP O
29 945 951 2484011 fourth JJ I-NP O
30 952 962 2484011 amantadine NN I-NP B-Chemical
31 963 972 2484011 treatment NN I-NP O
32 972 973 2484011 . . O O

1 974 990 2484011 Readministration NN B-NP O
2 991 993 2484011 of IN B-PP O
3 994 1004 2484011 amantadine NN B-NP B-Chemical
4 1004 1005 2484011 , , O O
5 1006 1011 2484011 after IN B-PP O
6 1012 1013 2484011 a DT B-NP O
7 1014 1018 2484011 drug NN I-NP O
8 1018 1019 2484011 - HYPH O O
9 1019 1023 2484011 free JJ B-NP O
10 1024 1033 2484011 overnight JJ I-NP O
11 1034 1040 2484011 period NN I-NP O
12 1040 1041 2484011 , , O O
13 1042 1051 2484011 increased VBD B-VP O
14 1052 1060 2484011 motility NN B-NP O
15 1061 1065 2484011 from IN B-PP O
16 1066 1076 2484011 respective JJ B-NP O
17 1077 1083 2484011 saline NN I-NP O
18 1084 1091 2484011 control NN I-NP O
19 1092 1094 2484011 in IN B-PP O
20 1095 1098 2484011 all DT B-NP O
21 1099 1106 2484011 strains NNS I-NP O
22 1107 1111 2484011 with IN B-PP O
23 1112 1121 2484011 exception NN B-NP O
24 1122 1124 2484011 of IN B-PP O
25 1125 1128 2484011 the DT B-NP O
26 1129 1133 2484011 BALB NN I-NP O
27 1133 1134 2484011 / SYM B-NP O
28 1134 1135 2484011 C NN I-NP O
29 1136 1140 2484011 mice NNS I-NP O
30 1141 1146 2484011 where WRB B-ADVP O
31 1147 1158 2484011 suppression NN B-NP B-Disease
32 1159 1161 2484011 of IN B-PP I-Disease
33 1162 1170 2484011 motility NN B-NP I-Disease
34 1171 1179 2484011 occurred VBD B-VP O
35 1179 1180 2484011 . . O O

1 1181 1190 2484011 Treatment NN B-NP O
2 1191 1195 2484011 with IN B-PP O
3 1196 1206 2484011 amantadine NN B-NP B-Chemical
4 1207 1210 2484011 did VBD B-VP O
5 1211 1214 2484011 not RB I-VP O
6 1215 1220 2484011 alter VB I-VP O
7 1221 1226 2484011 whole JJ B-NP O
8 1227 1232 2484011 brain NN I-NP O
9 1233 1241 2484011 dopamine NN I-NP B-Chemical
10 1242 1248 2484011 levels NNS I-NP O
11 1249 1252 2484011 but CC O O
12 1253 1262 2484011 decreased VBD B-VP O
13 1263 1266 2484011 the DT B-NP O
14 1267 1274 2484011 amounts NNS I-NP O
15 1275 1277 2484011 of IN B-PP O
16 1278 1281 2484011 3,4 CD B-NP B-Chemical
17 1281 1282 2484011 - HYPH I-NP I-Chemical
18 1282 1303 2484011 dihydroxyphenylacetic JJ I-NP I-Chemical
19 1304 1308 2484011 acid NN I-NP I-Chemical
20 1309 1311 2484011 in IN B-PP O
21 1312 1315 2484011 the DT B-NP O
22 1316 1320 2484011 BALB NN I-NP O
23 1320 1321 2484011 / SYM B-NP O
24 1321 1322 2484011 C NN I-NP O
25 1323 1327 2484011 mice NNS I-NP O
26 1328 1336 2484011 compared VBN B-VP O
27 1337 1339 2484011 to TO B-PP O
28 1340 1346 2484011 saline NN B-NP O
29 1347 1354 2484011 control NN I-NP O
30 1354 1355 2484011 . . O O

1 1356 1366 2484011 Conversely RB B-ADVP O
2 1366 1367 2484011 , , O O
3 1368 1373 2484011 brain NN B-NP O
4 1374 1389 2484011 normetanephrine NN I-NP B-Chemical
5 1390 1403 2484011 concentration NN I-NP O
6 1404 1407 2484011 was VBD B-VP O
7 1408 1417 2484011 increased VBN I-VP O
8 1418 1422 2484011 from IN B-PP O
9 1423 1429 2484011 saline NN B-NP O
10 1430 1437 2484011 control NN I-NP O
11 1438 1440 2484011 by IN B-PP O
12 1441 1451 2484011 amantadine NN B-NP B-Chemical
13 1452 1454 2484011 in IN B-PP O
14 1455 1458 2484011 the DT B-NP O
15 1459 1463 2484011 BALB NN I-NP O
16 1463 1464 2484011 / SYM B-NP O
17 1464 1465 2484011 C NN I-NP O
18 1466 1470 2484011 mice NNS I-NP O
19 1470 1471 2484011 . . O O

1 1472 1475 2484011 The DT B-NP O
2 1476 1483 2484011 results NNS I-NP O
3 1484 1491 2484011 suggest VBP B-VP O
4 1492 1493 2484011 a DT B-NP O
5 1494 1500 2484011 strain NN I-NP O
6 1500 1501 2484011 - HYPH B-NP O
7 1501 1510 2484011 dependent JJ I-NP O
8 1511 1517 2484011 effect NN I-NP O
9 1518 1520 2484011 of IN B-PP O
10 1521 1531 2484011 amantadine NN B-NP B-Chemical
11 1532 1534 2484011 on IN B-PP O
12 1535 1543 2484011 motility NN B-NP O
13 1544 1547 2484011 and CC O O
14 1548 1556 2484011 indicate VBP B-VP O
15 1557 1558 2484011 a DT B-NP O
16 1559 1571 2484011 differential JJ I-NP O
17 1572 1580 2484011 response NN I-NP O
18 1581 1583 2484011 to TO B-PP O
19 1584 1587 2484011 the DT B-NP O
20 1588 1593 2484011 acute JJ I-NP O
21 1594 1597 2484011 and CC I-NP O
22 1598 1606 2484011 multiple JJ I-NP O
23 1607 1611 2484011 dose NN I-NP O
24 1612 1620 2484011 regimens NNS I-NP O
25 1621 1625 2484011 used VBN B-VP O
26 1625 1626 2484011 . . O O

1 1627 1630 2484011 The DT B-NP O
2 1631 1635 2484011 BALB NN I-NP O
3 1635 1636 2484011 / SYM I-NP O
4 1636 1637 2484011 C NN I-NP O
5 1638 1643 2484011 mouse NN I-NP O
6 1644 1647 2484011 was VBD B-VP O
7 1648 1651 2484011 the DT B-NP O
8 1652 1656 2484011 most RBS I-NP O
9 1657 1666 2484011 sensitive JJ I-NP O
10 1667 1673 2484011 strain NN I-NP O
11 1674 1677 2484011 and CC O O
12 1678 1683 2484011 could MD B-VP O
13 1684 1689 2484011 serve VB I-VP O
14 1690 1692 2484011 as IN B-PP O
15 1693 1696 2484011 the DT B-NP O
16 1697 1703 2484011 strain NN I-NP O
17 1704 1706 2484011 of IN B-PP O
18 1707 1713 2484011 choice NN B-NP O
19 1714 1717 2484011 for IN B-PP O
20 1718 1728 2484011 evaluating VBG B-VP O
21 1729 1732 2484011 the DT B-NP O
22 1733 1737 2484011 side NN I-NP O
23 1738 1745 2484011 effects NNS I-NP O
24 1746 1748 2484011 of IN B-PP O
25 1749 1759 2484011 amantadine NN B-NP B-Chemical
26 1759 1760 2484011 . . O O

1 1761 1764 2484011 The DT B-NP O
2 1765 1776 2484011 biochemical JJ I-NP O
3 1777 1784 2484011 results NNS I-NP O
4 1785 1787 2484011 of IN B-PP O
5 1788 1793 2484011 brain NN B-NP O
6 1794 1802 2484011 biogenic JJ I-NP O
7 1803 1809 2484011 amines NNS I-NP B-Chemical
8 1810 1812 2484011 of IN B-PP O
9 1813 1817 2484011 BALB NN B-NP O
10 1817 1818 2484011 / SYM I-NP O
11 1818 1819 2484011 C NN I-NP O
12 1820 1825 2484011 mouse NN I-NP O
13 1826 1832 2484011 strain NN I-NP O
14 1833 1840 2484011 suggest VBP B-VP O
15 1841 1842 2484011 a DT B-NP O
16 1843 1851 2484011 probable JJ I-NP O
17 1852 1860 2484011 decrease NN I-NP O
18 1861 1863 2484011 of IN B-PP O
19 1864 1877 2484011 catecholamine NN B-NP B-Chemical
20 1878 1886 2484011 turnover NN I-NP O
21 1887 1891 2484011 rate NN I-NP O
22 1892 1895 2484011 and CC O O
23 1895 1896 2484011 / SYM B-NP O
24 1896 1898 2484011 or CC O O
25 1899 1909 2484011 metabolism NN B-NP O
26 1910 1912 2484011 by IN B-PP O
27 1913 1922 2484011 monoamine NN B-NP O
28 1923 1930 2484011 oxidase NN I-NP O
29 1931 1934 2484011 and CC O O
30 1935 1936 2484011 a DT B-NP O
31 1937 1946 2484011 resulting VBG I-NP O
32 1947 1955 2484011 increase NN I-NP O
33 1956 1958 2484011 in IN B-PP O
34 1959 1960 2484011 O NN B-NP O
35 1960 1961 2484011 - HYPH B-NP O
36 1961 1972 2484011 methylation NN I-NP O
37 1973 1975 2484011 of IN B-PP O
38 1976 1990 2484011 norepinephrine NN B-NP B-Chemical
39 1991 1996 2484011 which WDT B-NP O
40 1997 2000 2484011 may MD B-VP O
41 2001 2008 2484011 account VB I-VP O
42 2009 2012 2484011 for IN B-PP O
43 2013 2014 2484011 a DT B-NP O
44 2015 2025 2484011 behavioral JJ I-NP B-Disease
45 2026 2036 2484011 depression NN I-NP I-Disease
46 2037 2043 2484011 caused VBN B-VP O
47 2044 2046 2484011 by IN B-PP O
48 2047 2057 2484011 amantadine NN B-NP B-Chemical
49 2058 2060 2484011 in IN B-PP O
50 2061 2064 2484011 the DT B-NP O
51 2065 2069 2484011 BALB NN I-NP O
52 2069 2070 2484011 / SYM B-NP O
53 2070 2071 2484011 C NN I-NP O
54 2072 2076 2484011 mice NNS I-NP O
55 2076 2077 2484011 . . O O

1 0 0 9245658 -DOCSTART- -X- -X- O

1 0 3 9245658 The DT B-NP O
2 4 8 9245658 role NN I-NP O
3 9 11 9245658 of IN B-PP O
4 12 20 9245658 nicotine NN B-NP B-Chemical
5 21 23 9245658 in IN B-PP O
6 24 31 9245658 smoking NN B-NP O
7 31 32 9245658 - HYPH O O
8 32 39 9245658 related VBN B-NP O
9 40 54 9245658 cardiovascular JJ I-NP B-Disease
10 55 62 9245658 disease NN I-NP I-Disease
11 62 63 9245658 . . O O
12 64 72 9245658 Nicotine NN B-NP B-Chemical
13 73 82 9245658 activates VBZ B-VP O
14 83 86 9245658 the DT B-NP O
15 87 98 9245658 sympathetic JJ I-NP O
16 99 106 9245658 nervous JJ I-NP O
17 107 113 9245658 system NN I-NP O
18 114 117 9245658 and CC B-PP O
19 118 120 9245658 in IN B-PP O
20 121 125 9245658 this DT B-NP O
21 126 129 9245658 way NN I-NP O
22 130 135 9245658 could MD B-VP O
23 136 146 9245658 contribute VB I-VP O
24 147 149 9245658 to TO B-PP O
25 150 164 9245658 cardiovascular JJ B-NP B-Disease
26 165 172 9245658 disease NN I-NP I-Disease
27 172 173 9245658 . . O O

1 174 180 9245658 Animal NN B-NP O
2 181 188 9245658 studies NNS I-NP O
3 189 192 9245658 and CC O O
4 193 204 9245658 mechanistic JJ B-NP O
5 205 212 9245658 studies NNS I-NP O
6 213 221 9245658 indicate VBP B-VP O
7 222 226 9245658 that IN B-SBAR O
8 227 235 9245658 nicotine NN B-NP B-Chemical
9 236 241 9245658 could MD B-VP O
10 242 246 9245658 play VB I-VP O
11 247 248 9245658 a DT B-NP O
12 249 253 9245658 role NN I-NP O
13 254 256 9245658 in IN B-PP O
14 257 269 9245658 accelerating VBG B-NP O
15 270 285 9245658 atherosclerosis NN I-NP B-Disease
16 285 286 9245658 , , O O
17 287 290 9245658 but CC O O
18 291 299 9245658 evidence NN B-NP O
19 300 305 9245658 among IN B-PP O
20 306 312 9245658 humans NNS B-NP O
21 313 315 9245658 is VBZ B-VP O
22 316 319 9245658 too RB B-ADJP O
23 320 330 9245658 inadequate JJ I-ADJP O
24 331 333 9245658 to TO B-VP O
25 334 336 9245658 be VB I-VP O
26 337 347 9245658 definitive JJ B-ADJP O
27 348 353 9245658 about IN B-PP O
28 354 358 9245658 such JJ B-NP O
29 359 361 9245658 an DT I-NP O
30 362 368 9245658 effect NN I-NP O
31 368 369 9245658 . . O O

1 370 376 9245658 Almost RB B-ADVP O
2 377 386 9245658 certainly RB I-ADVP O
3 386 387 9245658 , , O O
4 388 396 9245658 nicotine NN B-NP B-Chemical
5 397 400 9245658 via IN B-PP O
6 401 404 9245658 its PRP$ B-NP O
7 405 416 9245658 hemodynamic JJ I-NP O
8 417 424 9245658 effects NNS I-NP O
9 425 436 9245658 contributes VBZ B-VP O
10 437 439 9245658 to TO B-PP O
11 440 445 9245658 acute JJ B-NP O
12 446 460 9245658 cardiovascular JJ I-NP O
13 461 467 9245658 events NNS I-NP O
14 467 468 9245658 , , O O
15 469 477 9245658 although IN B-SBAR O
16 478 485 9245658 current JJ B-NP O
17 486 494 9245658 evidence NN I-NP O
18 495 503 9245658 suggests VBZ B-VP O
19 504 508 9245658 that IN B-SBAR O
20 509 512 9245658 the DT B-NP O
21 513 520 9245658 effects NNS I-NP O
22 521 523 9245658 of IN B-PP O
23 524 532 9245658 nicotine NN B-NP B-Chemical
24 533 536 9245658 are VBP B-VP O
25 537 541 9245658 much RB B-ADJP O
26 542 546 9245658 less RBR I-ADJP O
27 547 556 9245658 important JJ I-ADJP O
28 557 561 9245658 than IN B-SBAR O
29 562 565 9245658 are VBP B-VP O
30 566 569 9245658 the DT B-NP O
31 570 583 9245658 prothrombotic JJ I-NP O
32 584 591 9245658 effects NNS I-NP O
33 592 594 9245658 of IN B-PP O
34 595 604 9245658 cigarette NN B-NP O
35 605 612 9245658 smoking NN I-NP O
36 613 615 9245658 or CC O O
37 616 619 9245658 the DT B-NP O
38 620 627 9245658 effects NNS I-NP O
39 628 630 9245658 of IN B-PP O
40 631 637 9245658 carbon NN B-NP B-Chemical
41 638 646 9245658 monoxide NN I-NP I-Chemical
42 646 647 9245658 . . O O

1 648 656 9245658 Nicotine NN B-NP B-Chemical
2 657 661 9245658 does VBZ B-VP O
3 662 665 9245658 not RB I-VP O
4 666 672 9245658 appear VB I-VP O
5 673 675 9245658 to TO I-VP O
6 676 683 9245658 enhance VB I-VP O
7 684 694 9245658 thrombosis NN B-NP B-Disease
8 695 700 9245658 among IN B-PP O
9 701 707 9245658 humans NNS B-NP O
10 707 708 9245658 . . O O

1 709 717 9245658 Clinical JJ B-NP O
2 718 725 9245658 studies NNS I-NP O
3 726 728 9245658 of IN B-PP O
4 729 733 9245658 pipe NN B-NP O
5 734 741 9245658 smokers NNS I-NP O
6 742 745 9245658 and CC O O
7 746 752 9245658 people NNS B-NP O
8 753 758 9245658 using VBG B-VP O
9 759 770 9245658 transdermal JJ B-NP O
10 771 779 9245658 nicotine NN I-NP B-Chemical
11 780 787 9245658 support VBP B-VP O
12 788 791 9245658 the DT B-NP O
13 792 796 9245658 idea NN I-NP O
14 797 801 9245658 that IN B-SBAR O
15 802 808 9245658 toxins NNS B-NP O
16 809 814 9245658 other JJ B-ADJP O
17 815 819 9245658 than IN B-PP O
18 820 828 9245658 nicotine NN B-NP B-Chemical
19 829 832 9245658 are VBP B-VP O
20 833 836 9245658 the DT B-NP O
21 837 841 9245658 most RBS I-NP O
22 842 851 9245658 important JJ I-NP O
23 852 858 9245658 causes NNS I-NP O
24 859 861 9245658 of IN B-PP O
25 862 867 9245658 acute JJ B-NP O
26 868 882 9245658 cardiovascular JJ I-NP O
27 883 889 9245658 events NNS I-NP O
28 889 890 9245658 . . O O

1 891 898 9245658 Finally RB B-ADVP O
2 898 899 9245658 , , O O
3 900 903 9245658 the DT B-NP O
4 904 908 9245658 dose NN I-NP O
5 909 917 9245658 response NN I-NP O
6 918 921 9245658 for IN B-PP O
7 922 936 9245658 cardiovascular JJ B-NP O
8 937 943 9245658 events NNS I-NP O
9 944 946 9245658 of IN B-PP O
10 947 955 9245658 nicotine NN B-NP B-Chemical
11 956 963 9245658 appears VBZ B-VP O
12 964 966 9245658 to TO I-VP O
13 967 969 9245658 be VB I-VP O
14 970 974 9245658 flat JJ B-ADJP O
15 974 975 9245658 , , O O
16 976 986 9245658 suggesting VBG B-VP O
17 987 991 9245658 that IN B-SBAR O
18 992 994 9245658 if IN B-SBAR O
19 995 1003 9245658 nicotine NN B-NP B-Chemical
20 1004 1006 9245658 is VBZ B-VP O
21 1007 1015 9245658 involved VBN I-VP O
22 1015 1016 9245658 , , O O
23 1017 1024 9245658 adverse JJ B-NP O
24 1025 1032 9245658 effects NNS I-NP O
25 1033 1038 9245658 might MD B-VP O
26 1039 1041 9245658 be VB I-VP O
27 1042 1046 9245658 seen VBN I-VP O
28 1047 1051 9245658 with IN B-PP O
29 1052 1062 9245658 relatively RB B-NP O
30 1063 1066 9245658 low JJ I-NP O
31 1066 1067 9245658 - HYPH I-NP O
32 1067 1072 9245658 level NN I-NP O
33 1073 1082 9245658 cigarette NN I-NP O
34 1083 1092 9245658 exposures NNS I-NP O
35 1092 1093 9245658 . . O O

1 0 0 18726058 -DOCSTART- -X- -X- O

1 0 7 18726058 Adverse JJ B-NP O
2 8 15 18726058 effects NNS I-NP O
3 16 18 18726058 of IN B-PP O
4 19 26 18726058 topical JJ B-NP O
5 27 37 18726058 papaverine NN I-NP B-Chemical
6 38 40 18726058 on IN B-PP O
7 41 49 18726058 auditory JJ B-NP O
8 50 55 18726058 nerve NN I-NP O
9 56 64 18726058 function NN I-NP O
10 64 65 18726058 . . I-NP O
11 66 76 18726058 BACKGROUND NN I-NP O
12 76 77 18726058 : : O O
13 78 88 18726058 Papaverine NN B-NP B-Chemical
14 89 102 18726058 hydrochloride NN I-NP I-Chemical
15 103 105 18726058 is VBZ B-VP O
16 106 107 18726058 a DT B-NP O
17 108 114 18726058 direct JJ I-NP O
18 114 115 18726058 - HYPH I-NP O
19 115 121 18726058 acting VBG I-NP O
20 122 133 18726058 vasodilator NN I-NP O
21 134 138 18726058 used VBN B-VP O
22 139 141 18726058 to TO B-VP O
23 142 148 18726058 manage VB I-VP O
24 149 158 18726058 vasospasm NN B-NP B-Disease
25 159 165 18726058 during IN B-PP O
26 166 173 18726058 various JJ B-NP O
27 174 187 18726058 neurosurgical JJ I-NP O
28 188 198 18726058 operations NNS I-NP O
29 198 199 18726058 . . O O

1 200 209 18726058 Transient JJ B-NP O
2 210 217 18726058 cranial JJ I-NP B-Disease
3 218 223 18726058 nerve NN I-NP I-Disease
4 224 235 18726058 dysfunction NN I-NP I-Disease
5 236 239 18726058 has VBZ B-VP O
6 240 244 18726058 been VBN I-VP O
7 245 254 18726058 described VBN I-VP O
8 255 257 18726058 in IN B-PP O
9 258 259 18726058 a DT B-NP O
10 260 263 18726058 few JJ I-NP O
11 264 269 18726058 cases NNS I-NP O
12 270 274 18726058 with IN B-PP O
13 275 282 18726058 topical JJ B-NP O
14 283 293 18726058 papaverine NN I-NP B-Chemical
15 293 294 18726058 . . O O

1 295 299 18726058 This DT B-NP O
2 300 305 18726058 study NN I-NP O
3 306 314 18726058 supports VBZ B-VP O
4 315 323 18726058 previous JJ B-NP O
5 324 331 18726058 reports NNS I-NP O
6 332 335 18726058 and CC O O
7 336 344 18726058 provides VBZ B-VP O
8 345 363 18726058 neurophysiological JJ B-NP O
9 364 372 18726058 evidence NN I-NP O
10 373 375 18726058 of IN B-PP O
11 376 378 18726058 an DT B-NP O
12 379 386 18726058 adverse JJ I-NP O
13 387 393 18726058 effect NN I-NP O
14 394 396 18726058 on IN B-PP O
15 397 400 18726058 the DT B-NP O
16 401 409 18726058 auditory JJ I-NP O
17 410 415 18726058 nerve NN I-NP O
18 415 416 18726058 . . O O

1 417 424 18726058 METHODS NNS B-NP O
2 424 425 18726058 : : O O
3 426 428 18726058 We PRP B-NP O
4 429 438 18726058 conducted VBD B-VP O
5 439 440 18726058 a DT B-NP O
6 441 454 18726058 retrospective JJ I-NP O
7 455 461 18726058 review NN I-NP O
8 462 464 18726058 of IN B-PP O
9 465 467 18726058 70 CD B-NP O
10 468 479 18726058 consecutive JJ I-NP O
11 480 493 18726058 microvascular JJ I-NP O
12 494 507 18726058 decompression NN I-NP O
13 508 518 18726058 operations NNS I-NP O
14 519 522 18726058 and CC O O
15 523 530 18726058 studied VBN B-VP O
16 531 536 18726058 those DT B-NP O
17 537 545 18726058 patients NNS I-NP O
18 546 549 18726058 who WP B-NP O
19 550 558 18726058 received VBD B-VP O
20 559 566 18726058 topical JJ B-NP O
21 567 577 18726058 papaverine NN I-NP B-Chemical
22 578 581 18726058 for IN B-PP O
23 582 591 18726058 vasospasm NN B-NP B-Disease
24 591 592 18726058 . . O O

1 593 600 18726058 Topical JJ B-NP O
2 601 611 18726058 papaverine NN I-NP B-Chemical
3 612 615 18726058 was VBD B-VP O
4 616 620 18726058 used VBN I-VP O
5 621 623 18726058 as IN B-PP O
6 624 625 18726058 a DT B-NP O
7 626 632 18726058 direct JJ I-NP O
8 633 644 18726058 therapeutic JJ I-NP O
9 645 651 18726058 action NN I-NP O
10 652 654 18726058 to TO B-VP O
11 655 661 18726058 manage VB I-VP O
12 662 671 18726058 vasospasm NN B-NP B-Disease
13 672 674 18726058 in IN B-PP O
14 675 676 18726058 a DT B-NP O
15 677 682 18726058 total NN I-NP O
16 683 685 18726058 of IN B-PP O
17 686 688 18726058 11 CD B-NP O
18 689 697 18726058 patients NNS I-NP O
19 697 698 18726058 . . O O

1 699 702 18726058 The DT B-NP O
2 703 709 18726058 timing NN I-NP O
3 710 712 18726058 of IN B-PP O
4 713 723 18726058 papaverine NN B-NP B-Chemical
5 724 735 18726058 application NN I-NP O
6 736 739 18726058 and CC O O
7 740 747 18726058 ongoing JJ B-NP O
8 748 757 18726058 operative JJ I-NP O
9 758 764 18726058 events NNS I-NP O
10 765 768 18726058 was VBD B-VP O
11 769 777 18726058 reviewed VBN I-VP O
12 778 786 18726058 relative JJ B-ADVP O
13 787 789 18726058 to TO B-PP O
14 790 797 18726058 changes NNS B-NP O
15 798 800 18726058 in IN B-PP O
16 801 819 18726058 neurophysiological JJ B-NP O
17 820 830 18726058 recordings NNS I-NP O
18 830 831 18726058 . . O O

1 832 841 18726058 Brainstem NN B-NP O
2 842 850 18726058 auditory JJ I-NP O
3 851 857 18726058 evoked JJ I-NP O
4 858 868 18726058 potentials NNS I-NP O
5 869 870 18726058 ( ( O O
6 870 875 18726058 BAEPs NNS B-NP O
7 875 876 18726058 ) ) O O
8 877 881 18726058 were VBD B-VP O
9 882 891 18726058 routinely RB I-VP O
10 892 896 18726058 used VBN I-VP O
11 897 899 18726058 to TO B-VP O
12 900 907 18726058 monitor VB I-VP O
13 908 916 18726058 cochlear JJ B-NP O
14 917 922 18726058 nerve NN I-NP O
15 923 931 18726058 function NN I-NP O
16 932 938 18726058 during IN B-PP O
17 939 944 18726058 these DT B-NP O
18 945 955 18726058 operations NNS I-NP O
19 955 956 18726058 . . O O

1 957 965 18726058 FINDINGS NNS B-NP O
2 965 966 18726058 : : O O
3 967 968 18726058 A DT B-NP O
4 969 977 18726058 temporal JJ I-NP O
5 978 990 18726058 relationship NN I-NP O
6 991 994 18726058 was VBD B-VP O
7 995 1000 18726058 found VBN I-VP O
8 1001 1008 18726058 between IN B-PP O
9 1009 1016 18726058 topical JJ B-NP O
10 1017 1027 18726058 papaverine NN I-NP B-Chemical
11 1028 1031 18726058 and CC I-NP O
12 1032 1036 18726058 BAEP NN I-NP O
13 1037 1044 18726058 changes NNS I-NP O
14 1045 1052 18726058 leading VBG B-VP O
15 1053 1055 18726058 to TO B-PP O
16 1056 1064 18726058 complete JJ B-NP O
17 1065 1073 18726058 waveform NN I-NP O
18 1074 1078 18726058 loss NN I-NP O
19 1078 1079 18726058 . . O O

1 1080 1083 18726058 The DT B-NP O
2 1084 1091 18726058 average JJ I-NP O
3 1092 1100 18726058 temporal JJ I-NP O
4 1101 1106 18726058 delay NN I-NP O
5 1107 1114 18726058 between IN B-PP O
6 1115 1125 18726058 papaverine NN B-NP B-Chemical
7 1126 1129 18726058 and CC O O
8 1130 1133 18726058 the DT B-NP O
9 1134 1139 18726058 onset NN I-NP O
10 1140 1142 18726058 of IN B-PP O
11 1143 1145 18726058 an DT B-NP O
12 1146 1153 18726058 adverse JJ I-NP O
13 1154 1158 18726058 BAEP NN I-NP O
14 1159 1165 18726058 change NN I-NP O
15 1166 1169 18726058 was VBD B-VP O
16 1170 1171 18726058 5 CD B-NP O
17 1172 1175 18726058 min NN I-NP O
18 1175 1176 18726058 . . O O

1 1177 1179 18726058 In IN B-PP O
2 1180 1182 18726058 10 CD B-NP O
3 1183 1185 18726058 of IN B-PP O
4 1186 1188 18726058 11 CD B-NP O
5 1189 1197 18726058 patients NNS I-NP O
6 1197 1198 18726058 , , O O
7 1199 1203 18726058 BAEP NN B-NP O
8 1204 1209 18726058 waves VBZ B-VP O
9 1210 1212 18726058 II CD B-NP O
10 1212 1213 18726058 / SYM I-NP O
11 1213 1216 18726058 III CD I-NP O
12 1216 1217 18726058 - HYPH I-NP O
13 1217 1218 18726058 V NN I-NP O
14 1219 1229 18726058 completely RB B-ADVP O
15 1230 1241 18726058 disappeared VBD B-VP O
16 1242 1248 18726058 within IN B-PP O
17 1249 1250 18726058 2 CD B-NP O
18 1251 1253 18726058 to TO I-NP O
19 1254 1256 18726058 25 CD I-NP O
20 1257 1260 18726058 min NN I-NP O
21 1261 1266 18726058 after IN B-PP O
22 1267 1277 18726058 papaverine NN B-NP B-Chemical
23 1277 1278 18726058 . . O O

1 1279 1284 18726058 Eight CD B-NP O
2 1285 1287 18726058 of IN B-PP O
3 1288 1293 18726058 these DT B-NP O
4 1294 1296 18726058 10 CD I-NP O
5 1297 1305 18726058 patients NNS I-NP O
6 1306 1309 18726058 had VBD B-VP O
7 1310 1318 18726058 complete JJ B-NP O
8 1319 1323 18726058 loss NN I-NP O
9 1324 1326 18726058 of IN B-PP O
10 1327 1331 18726058 BAEP NN B-NP O
11 1332 1341 18726058 waveforms NNS I-NP O
12 1342 1348 18726058 within IN B-PP O
13 1349 1351 18726058 10 CD B-NP O
14 1352 1355 18726058 min NN I-NP O
15 1355 1356 18726058 . . O O

1 1357 1360 18726058 One CD B-NP O
2 1361 1368 18726058 patient NN I-NP O
3 1369 1375 18726058 showed VBD B-VP O
4 1376 1378 18726058 no DT B-NP O
5 1379 1387 18726058 recovery NN I-NP O
6 1388 1390 18726058 of IN B-PP O
7 1391 1396 18726058 later JJ B-NP O
8 1397 1402 18726058 waves NNS I-NP O
9 1403 1406 18726058 and CC O O
10 1407 1408 18726058 a DT B-NP O
11 1409 1416 18726058 delayed VBN I-NP O
12 1417 1425 18726058 profound JJ I-NP O
13 1426 1439 18726058 sensorineural JJ I-NP B-Disease
14 1440 1447 18726058 hearing NN I-NP I-Disease
15 1448 1452 18726058 loss NN I-NP I-Disease
16 1452 1453 18726058 . . O O

1 1454 1457 18726058 The DT B-NP O
2 1458 1465 18726058 average JJ I-NP O
3 1466 1474 18726058 recovery NN I-NP O
4 1475 1479 18726058 time NN I-NP O
5 1480 1482 18726058 of IN B-PP O
6 1483 1487 18726058 BAEP NN B-NP O
7 1488 1497 18726058 waveforms NNS I-NP O
8 1498 1500 18726058 to TO B-PP O
9 1501 1504 18726058 pre AFX B-NP O
10 1504 1505 18726058 - HYPH I-NP O
11 1505 1515 18726058 papaverine NN I-NP B-Chemical
12 1516 1524 18726058 baseline NN I-NP O
13 1525 1531 18726058 values NNS I-NP O
14 1532 1535 18726058 was VBD B-VP O
15 1536 1538 18726058 39 CD B-NP O
16 1539 1542 18726058 min NN I-NP O
17 1542 1543 18726058 . . O O

1 1544 1555 18726058 CONCLUSIONS NNS B-NP O
2 1555 1556 18726058 : : O O
3 1557 1564 18726058 Topical JJ B-NP O
4 1565 1575 18726058 papaverine NN I-NP B-Chemical
5 1576 1579 18726058 for IN B-PP O
6 1580 1583 18726058 the DT B-NP O
7 1584 1593 18726058 treatment NN I-NP O
8 1594 1596 18726058 of IN B-PP O
9 1597 1606 18726058 vasospasm NN B-NP B-Disease
10 1607 1610 18726058 was VBD B-VP O
11 1611 1621 18726058 associated VBN I-VP O
12 1622 1626 18726058 with IN B-PP O
13 1627 1630 18726058 the DT B-NP O
14 1631 1636 18726058 onset NN I-NP O
15 1637 1639 18726058 of IN B-PP O
16 1640 1641 18726058 a DT B-NP O
17 1642 1651 18726058 transient JJ I-NP O
18 1652 1663 18726058 disturbance NN I-NP O
19 1664 1666 18726058 in IN B-PP O
20 1667 1685 18726058 neurophysiological JJ B-NP O
21 1686 1694 18726058 function NN I-NP O
22 1695 1697 18726058 of IN B-PP O
23 1698 1701 18726058 the DT B-NP O
24 1702 1711 18726058 ascending VBG I-NP O
25 1712 1720 18726058 auditory JJ I-NP O
26 1721 1730 18726058 brainstem NN I-NP O
27 1731 1738 18726058 pathway NN I-NP O
28 1738 1739 18726058 . . O O

1 1740 1743 18726058 The DT B-NP O
2 1744 1752 18726058 complete JJ I-NP O
3 1753 1766 18726058 disappearance NN I-NP O
4 1767 1769 18726058 of IN B-PP O
5 1770 1774 18726058 BAEP NN B-NP O
6 1775 1784 18726058 waveforms NNS I-NP O
7 1785 1789 18726058 with IN B-PP O
8 1790 1791 18726058 a DT B-NP O
9 1792 1802 18726058 consistent JJ I-NP O
10 1803 1811 18726058 temporal JJ I-NP O
11 1812 1817 18726058 delay NN I-NP O
12 1818 1826 18726058 suggests VBZ B-VP O
13 1827 1828 18726058 a DT B-NP O
14 1829 1837 18726058 possible JJ I-NP O
15 1838 1845 18726058 adverse JJ I-NP B-Disease
16 1846 1852 18726058 effect NN I-NP I-Disease
17 1853 1855 18726058 on IN B-PP I-Disease
18 1856 1859 18726058 the DT B-NP I-Disease
19 1860 1868 18726058 proximal JJ I-NP I-Disease
20 1869 1875 18726058 eighth JJ I-NP I-Disease
21 1876 1881 18726058 nerve NN I-NP I-Disease
22 1881 1882 18726058 . . O O

1 1883 1898 18726058 Recommendations NNS B-NP O
2 1899 1901 18726058 to TO B-VP O
3 1902 1907 18726058 avoid VB I-VP O
4 1908 1917 18726058 potential JJ B-NP O
5 1918 1925 18726058 cranial JJ I-NP B-Disease
6 1926 1931 18726058 nerve NN I-NP I-Disease
7 1932 1940 18726058 deficits NNS I-NP I-Disease
8 1941 1945 18726058 from IN B-PP O
9 1946 1956 18726058 papaverine NN B-NP B-Chemical
10 1957 1960 18726058 are VBP B-VP O
11 1961 1969 18726058 provided VBN I-VP O
12 1969 1970 18726058 . . O O

1 0 0 3780846 -DOCSTART- -X- -X- O

1 0 2 3780846 On IN B-PP O
2 3 6 3780846 the DT B-NP O
3 7 17 3780846 mechanisms NNS I-NP O
4 18 20 3780846 of IN B-PP O
5 21 24 3780846 the DT B-NP O
6 25 36 3780846 development NN I-NP O
7 37 39 3780846 of IN B-PP O
8 40 49 3780846 tolerance NN B-NP O
9 50 52 3780846 to TO B-PP O
10 53 56 3780846 the DT B-NP O
11 57 65 3780846 muscular JJ I-NP B-Disease
12 66 74 3780846 rigidity NN I-NP I-Disease
13 75 83 3780846 produced VBN B-VP O
14 84 86 3780846 by IN B-PP O
15 87 95 3780846 morphine NN B-NP B-Chemical
16 96 98 3780846 in IN B-PP O
17 99 103 3780846 rats NNS B-NP O
18 103 104 3780846 . . O O
19 105 108 3780846 The DT B-NP O
20 109 120 3780846 development NN I-NP O
21 121 123 3780846 of IN B-PP O
22 124 133 3780846 tolerance NN B-NP O
23 134 136 3780846 to TO B-PP O
24 137 140 3780846 the DT B-NP O
25 141 149 3780846 muscular JJ I-NP B-Disease
26 150 158 3780846 rigidity NN I-NP I-Disease
27 159 167 3780846 produced VBN B-VP O
28 168 170 3780846 by IN B-PP O
29 171 179 3780846 morphine NN B-NP B-Chemical
30 180 183 3780846 was VBD B-VP O
31 184 191 3780846 studied VBN I-VP O
32 192 194 3780846 in IN B-PP O
33 195 199 3780846 rats NNS B-NP O
34 199 200 3780846 . . O O

1 201 207 3780846 Saline NN B-NP O
2 207 208 3780846 - HYPH B-NP O
3 208 218 3780846 pretreated VBN I-NP O
4 219 227 3780846 controls NNS I-NP O
5 228 233 3780846 given VBN B-VP O
6 234 235 3780846 a DT B-NP O
7 236 240 3780846 test NN I-NP O
8 241 245 3780846 dose NN I-NP O
9 246 248 3780846 of IN B-PP O
10 249 257 3780846 morphine NN B-NP B-Chemical
11 258 259 3780846 ( ( O O
12 259 261 3780846 20 CD B-NP O
13 262 264 3780846 mg NN I-NP O
14 264 265 3780846 / SYM O O
15 265 267 3780846 kg NN B-NP O
16 268 271 3780846 i.p NN I-NP O
17 271 272 3780846 . . O O
18 272 273 3780846 ) ) O O
19 274 280 3780846 showed VBD B-VP O
20 281 282 3780846 a DT B-NP O
21 283 293 3780846 pronounced JJ I-NP O
22 294 302 3780846 rigidity NN I-NP B-Disease
23 303 311 3780846 recorded VBN B-VP O
24 312 314 3780846 as IN B-PP O
25 315 320 3780846 tonic JJ B-NP O
26 321 329 3780846 activity NN I-NP O
27 330 332 3780846 in IN B-PP O
28 333 336 3780846 the DT B-NP O
29 337 351 3780846 electromyogram NN I-NP O
30 351 352 3780846 . . O O

1 353 357 3780846 Rats NNS B-NP O
2 358 365 3780846 treated VBN B-VP O
3 366 369 3780846 for IN B-PP O
4 370 372 3780846 11 CD B-NP O
5 373 377 3780846 days NNS I-NP O
6 378 382 3780846 with IN B-PP O
7 383 391 3780846 morphine NN B-NP B-Chemical
8 392 395 3780846 and CC O O
9 396 405 3780846 withdrawn VBN B-VP O
10 406 409 3780846 for IN B-PP O
11 410 412 3780846 36 CD B-NP O
12 412 413 3780846 - HYPH I-NP O
13 413 415 3780846 40 CD I-NP O
14 416 417 3780846 h NN I-NP O
15 418 424 3780846 showed VBD B-VP O
16 425 436 3780846 differences NNS B-NP O
17 437 439 3780846 in IN B-PP O
18 440 443 3780846 the DT B-NP O
19 444 455 3780846 development NN I-NP O
20 456 458 3780846 of IN B-PP O
21 459 468 3780846 tolerance NN B-NP O
22 468 469 3780846 : : O O
23 470 475 3780846 about IN B-NP O
24 476 480 3780846 half NN I-NP O
25 481 483 3780846 of IN B-PP O
26 484 487 3780846 the DT B-NP O
27 488 495 3780846 animals NNS I-NP O
28 496 502 3780846 showed VBD B-VP O
29 503 504 3780846 a DT B-NP O
30 505 513 3780846 rigidity NN I-NP B-Disease
31 514 519 3780846 after IN B-PP O
32 520 523 3780846 the DT B-NP O
33 524 528 3780846 test NN I-NP O
34 529 533 3780846 dose NN I-NP O
35 534 536 3780846 of IN B-PP O
36 537 545 3780846 morphine NN B-NP B-Chemical
37 546 550 3780846 that WDT B-NP O
38 551 554 3780846 was VBD B-VP O
39 555 558 3780846 not RB O O
40 559 572 3780846 significantly RB B-ADJP O
41 573 577 3780846 less JJR I-ADJP O
42 578 582 3780846 than IN B-PP O
43 583 585 3780846 in IN B-PP O
44 586 589 3780846 the DT B-NP O
45 590 598 3780846 controls NNS I-NP O
46 599 602 3780846 and CC O O
47 603 607 3780846 were VBD B-VP O
48 608 616 3780846 akinetic JJ B-ADJP B-Disease
49 617 618 3780846 ( ( O O
50 618 619 3780846 A NN B-NP O
51 620 625 3780846 group NN I-NP O
52 625 626 3780846 ) ) O O
53 626 627 3780846 . . O O

1 628 631 3780846 The DT B-NP O
2 632 637 3780846 other JJ I-NP O
3 638 642 3780846 rats NNS I-NP O
4 643 649 3780846 showed VBD B-VP O
5 650 651 3780846 a DT B-NP O
6 652 658 3780846 strong JJ I-NP O
7 659 667 3780846 decrease NN I-NP O
8 668 670 3780846 in IN B-PP O
9 671 674 3780846 the DT B-NP O
10 675 683 3780846 rigidity NN I-NP B-Disease
11 684 687 3780846 and CC O O
12 688 691 3780846 the DT B-NP O
13 692 702 3780846 occurrence NN I-NP O
14 703 705 3780846 of IN B-PP O
15 706 717 3780846 stereotyped JJ B-NP O
16 718 719 3780846 ( ( O O
17 719 720 3780846 S NN B-NP O
18 720 721 3780846 ) ) O O
19 722 729 3780846 licking NN B-NP O
20 730 733 3780846 and CC O O
21 733 734 3780846 / SYM B-NP O
22 734 736 3780846 or CC O O
23 737 744 3780846 gnawing VBG B-VP O
24 745 747 3780846 in IN B-PP O
25 748 756 3780846 presence NN B-NP O
26 757 759 3780846 of IN B-PP O
27 760 768 3780846 akinetic JJ B-NP B-Disease
28 769 771 3780846 or CC I-NP O
29 772 784 3780846 hyperkinetic JJ I-NP B-Disease
30 785 786 3780846 ( ( O O
31 786 787 3780846 K NN B-NP O
32 787 788 3780846 ) ) O O
33 789 798 3780846 behaviour NN B-NP O
34 799 800 3780846 ( ( O O
35 800 802 3780846 AS NN B-NP O
36 802 803 3780846 / SYM B-NP O
37 803 805 3780846 KS NN I-NP O
38 806 811 3780846 group NN I-NP O
39 811 812 3780846 ) ) O O
40 812 813 3780846 , , O O
41 814 824 3780846 suggesting VBG B-VP O
42 825 830 3780846 signs NNS B-NP O
43 831 833 3780846 of IN B-PP O
44 834 846 3780846 dopaminergic JJ B-NP O
45 847 857 3780846 activation NN I-NP O
46 857 858 3780846 . . O O

1 859 862 3780846 The DT B-NP O
2 863 871 3780846 rigidity NN I-NP B-Disease
3 872 875 3780846 was VBD B-VP O
4 876 888 3780846 considerably RB I-VP O
5 889 898 3780846 decreased VBN I-VP O
6 899 901 3780846 in IN B-PP O
7 902 906 3780846 both DT B-NP O
8 907 913 3780846 groups NNS I-NP O
9 914 919 3780846 after IN B-PP O
10 920 922 3780846 20 CD B-NP O
11 923 927 3780846 days NNS I-NP O
12 927 928 3780846 ' POS B-NP O
13 929 938 3780846 treatment NN I-NP O
14 938 939 3780846 . . O O

1 940 942 3780846 In IN B-PP O
2 943 944 3780846 a DT B-NP O
3 945 952 3780846 further JJ I-NP O
4 953 959 3780846 series NN I-NP O
5 960 962 3780846 of IN B-PP O
6 963 974 3780846 experiments NNS B-NP O
7 974 975 3780846 , , O O
8 976 987 3780846 haloperidol NN B-NP B-Chemical
9 988 989 3780846 ( ( O O
10 989 992 3780846 0.2 CD B-NP O
11 993 995 3780846 mg NN I-NP O
12 995 996 3780846 / SYM B-NP O
13 996 998 3780846 kg NN I-NP O
14 999 1002 3780846 i.p NN I-NP O
15 1002 1003 3780846 . . O O
16 1003 1004 3780846 ) ) O O
17 1005 1008 3780846 was VBD B-VP O
18 1009 1013 3780846 used VBN I-VP O
19 1014 1016 3780846 in IN B-SBAR O
20 1017 1022 3780846 order NN O O
21 1023 1025 3780846 to TO B-VP O
22 1026 1031 3780846 block VB I-VP O
23 1032 1035 3780846 the DT B-NP O
24 1036 1048 3780846 dopaminergic JJ I-NP O
25 1049 1059 3780846 activation NN I-NP O
26 1060 1063 3780846 and CC O O
27 1064 1066 3780846 to TO B-VP O
28 1067 1075 3780846 estimate VB I-VP O
29 1076 1079 3780846 the DT B-NP O
30 1080 1084 3780846 real JJ I-NP O
31 1085 1091 3780846 degree NN I-NP O
32 1092 1094 3780846 of IN B-PP O
33 1095 1098 3780846 the DT B-NP O
34 1099 1108 3780846 tolerance NN I-NP O
35 1109 1111 3780846 to TO B-PP O
36 1112 1115 3780846 the DT B-NP O
37 1116 1124 3780846 rigidity NN I-NP B-Disease
38 1125 1132 3780846 without IN B-PP O
39 1133 1136 3780846 any DT B-NP O
40 1137 1149 3780846 dopaminergic JJ I-NP O
41 1150 1162 3780846 interference NN I-NP O
42 1162 1163 3780846 . . O O

1 1164 1175 3780846 Haloperidol NN B-NP B-Chemical
2 1176 1184 3780846 enhanced VBD B-VP O
3 1185 1188 3780846 the DT B-NP O
4 1189 1197 3780846 rigidity NN I-NP B-Disease
5 1198 1200 3780846 in IN B-PP O
6 1201 1204 3780846 the DT B-NP O
7 1205 1206 3780846 A NN I-NP O
8 1207 1212 3780846 group NN I-NP O
9 1212 1213 3780846 . . O O

1 1214 1221 3780846 However RB B-ADVP O
2 1221 1222 3780846 , , O O
3 1223 1226 3780846 the DT B-NP O
4 1227 1232 3780846 level NN I-NP O
5 1233 1235 3780846 in IN B-PP O
6 1236 1239 3780846 the DT B-NP O
7 1240 1242 3780846 AS NN I-NP O
8 1242 1243 3780846 / SYM B-NP O
9 1243 1245 3780846 KS NN I-NP O
10 1246 1251 3780846 group NN I-NP O
11 1252 1260 3780846 remained VBD B-VP O
12 1261 1273 3780846 considerably RB B-ADJP O
13 1274 1279 3780846 lower JJR I-ADJP O
14 1280 1284 3780846 than IN B-PP O
15 1285 1287 3780846 in IN B-PP O
16 1288 1291 3780846 the DT B-NP O
17 1292 1293 3780846 A NN I-NP O
18 1294 1299 3780846 group NN I-NP O
19 1299 1300 3780846 . . O O

1 1301 1304 3780846 The DT B-NP O
2 1305 1312 3780846 results NNS I-NP O
3 1313 1320 3780846 suggest VBP B-VP O
4 1321 1325 3780846 that IN B-SBAR O
5 1326 1334 3780846 rigidity NN B-NP B-Disease
6 1334 1335 3780846 , , O O
7 1336 1341 3780846 which WDT B-NP O
8 1342 1344 3780846 is VBZ B-VP O
9 1345 1352 3780846 assumed VBN I-VP O
10 1353 1355 3780846 to TO I-VP O
11 1356 1358 3780846 be VB I-VP O
12 1359 1362 3780846 due IN B-PP O
13 1363 1365 3780846 to TO B-PP O
14 1366 1368 3780846 an DT B-NP O
15 1369 1375 3780846 action NN I-NP O
16 1376 1378 3780846 of IN B-PP O
17 1379 1387 3780846 morphine NN B-NP B-Chemical
18 1388 1390 3780846 in IN B-PP O
19 1391 1394 3780846 the DT B-NP O
20 1395 1403 3780846 striatum NN I-NP O
21 1403 1404 3780846 , , O O
22 1405 1408 3780846 can MD B-VP O
23 1409 1411 3780846 be VB I-VP O
24 1412 1423 3780846 antagonized VBN I-VP O
25 1424 1426 3780846 by IN B-PP O
26 1427 1434 3780846 another DT B-NP O
27 1435 1442 3780846 process NN I-NP O
28 1443 1450 3780846 leading VBG B-VP O
29 1451 1453 3780846 to TO B-PP O
30 1454 1466 3780846 dopaminergic JJ B-NP O
31 1467 1477 3780846 activation NN I-NP O
32 1478 1480 3780846 in IN B-PP O
33 1481 1484 3780846 the DT B-NP O
34 1485 1493 3780846 striatum NN I-NP O
35 1493 1494 3780846 . . O O

1 1495 1507 3780846 Nevertheless RB B-ADVP O
2 1507 1508 3780846 , , O O
3 1509 1514 3780846 there EX B-NP O
4 1515 1521 3780846 occurs VBZ B-VP O
5 1522 1526 3780846 some DT B-NP O
6 1527 1531 3780846 real JJ I-NP O
7 1532 1541 3780846 tolerance NN I-NP O
8 1542 1544 3780846 to TO B-PP O
9 1545 1549 3780846 this DT B-NP O
10 1550 1556 3780846 effect NN I-NP O
11 1556 1557 3780846 . . O O

1 1558 1561 3780846 The DT B-NP O
2 1562 1567 3780846 rapid JJ I-NP O
3 1568 1580 3780846 alternations NNS I-NP O
4 1581 1583 3780846 of IN B-PP O
5 1584 1592 3780846 rigidity NN B-NP B-Disease
6 1593 1596 3780846 and CC O O
7 1597 1600 3780846 the DT B-NP O
8 1601 1606 3780846 signs NNS I-NP O
9 1607 1609 3780846 of IN B-PP O
10 1610 1622 3780846 dopaminergic JJ B-NP O
11 1623 1633 3780846 activation NN I-NP O
12 1634 1642 3780846 observed VBN B-VP O
13 1643 1645 3780846 in IN B-PP O
14 1646 1649 3780846 the DT B-NP O
15 1650 1657 3780846 animals NNS I-NP O
16 1658 1660 3780846 of IN B-PP O
17 1661 1664 3780846 the DT B-NP O
18 1665 1667 3780846 AS NN I-NP O
19 1667 1668 3780846 / SYM B-NP O
20 1668 1670 3780846 KS NN I-NP O
21 1671 1676 3780846 group NN I-NP O
22 1677 1682 3780846 might MD B-VP O
23 1683 1685 3780846 be VB I-VP O
24 1686 1689 3780846 due JJ B-ADVP O
25 1690 1692 3780846 to TO B-PP O
26 1693 1698 3780846 rapid JJ B-NP O
27 1699 1705 3780846 shifts NNS I-NP O
28 1706 1708 3780846 in IN B-PP O
29 1709 1712 3780846 the DT B-NP O
30 1713 1725 3780846 predominance NN I-NP O
31 1726 1728 3780846 of IN B-PP O
32 1729 1736 3780846 various JJ B-NP O
33 1737 1739 3780846 DA NN I-NP O
34 1739 1740 3780846 - HYPH B-NP O
35 1740 1750 3780846 innervated VBN I-NP O
36 1751 1761 3780846 structures NNS I-NP O
37 1761 1762 3780846 . . O O

1 0 0 9721172 -DOCSTART- -X- -X- O

1 0 4 9721172 Drug NN B-NP O
2 4 5 9721172 - HYPH O O
3 5 15 9721172 associated VBN B-NP O
4 16 21 9721172 acute JJ I-NP O
5 21 22 9721172 - HYPH I-NP O
6 22 27 9721172 onset NN I-NP O
7 28 37 9721172 vanishing VBG B-VP B-Disease
8 38 42 9721172 bile NN B-NP I-Disease
9 43 47 9721172 duct NN I-NP I-Disease
10 48 51 9721172 and CC O O
11 52 59 9721172 Stevens NNP B-NP B-Disease
12 59 60 9721172 - HYPH B-NP I-Disease
13 60 67 9721172 Johnson NNP I-NP I-Disease
14 68 77 9721172 syndromes NNS I-NP I-Disease
15 78 80 9721172 in IN B-PP O
16 81 82 9721172 a DT B-NP O
17 83 88 9721172 child NN I-NP O
18 88 89 9721172 . . I-NP O
19 90 95 9721172 Acute JJ I-NP O
20 96 105 9721172 vanishing VBG I-NP B-Disease
21 106 110 9721172 bile NN I-NP I-Disease
22 111 115 9721172 duct NN I-NP I-Disease
23 116 124 9721172 syndrome NN I-NP O
24 125 127 9721172 is VBZ B-VP O
25 128 129 9721172 a DT B-NP O
26 130 134 9721172 rare JJ I-NP O
27 135 138 9721172 but CC I-NP O
28 139 150 9721172 established JJ I-NP O
29 151 156 9721172 cause NN I-NP O
30 157 159 9721172 of IN B-PP O
31 160 171 9721172 progressive JJ B-NP O
32 172 183 9721172 cholestasis NN I-NP B-Disease
33 184 186 9721172 in IN B-PP O
34 187 193 9721172 adults NNS B-NP O
35 193 194 9721172 , , O O
36 195 197 9721172 is VBZ B-VP O
37 198 202 9721172 most RBS B-ADVP O
38 203 208 9721172 often RB I-ADVP O
39 209 213 9721172 drug NN B-NP O
40 214 216 9721172 or CC I-NP O
41 217 222 9721172 toxin NN I-NP O
42 223 230 9721172 related VBN B-ADJP O
43 230 231 9721172 , , O O
44 232 235 9721172 and CC O O
45 236 238 9721172 is VBZ B-VP O
46 239 241 9721172 of IN B-PP O
47 242 249 9721172 unknown JJ B-NP O
48 250 262 9721172 pathogenesis NN I-NP O
49 262 263 9721172 . . O O

1 264 266 9721172 It PRP B-NP O
2 267 270 9721172 has VBZ B-VP O
3 271 274 9721172 not RB I-VP O
4 275 279 9721172 been VBN I-VP O
5 280 288 9721172 reported VBN I-VP O
6 289 299 9721172 previously RB B-ADVP O
7 300 302 9721172 in IN B-PP O
8 303 311 9721172 children NNS B-NP O
9 311 312 9721172 . . O O

1 313 320 9721172 Stevens NNP B-NP B-Disease
2 320 321 9721172 - HYPH I-NP I-Disease
3 321 328 9721172 Johnson NNP I-NP I-Disease
4 329 337 9721172 syndrome NN I-NP I-Disease
5 338 340 9721172 is VBZ B-VP O
6 341 342 9721172 a DT B-NP O
7 343 347 9721172 well RB I-NP O
8 347 348 9721172 - HYPH I-NP O
9 348 358 9721172 recognized VBN B-VP O
10 359 365 9721172 immune JJ B-NP O
11 366 373 9721172 complex NN I-NP O
12 373 374 9721172 - HYPH B-VP O
13 374 382 9721172 mediated VBN B-NP O
14 383 399 9721172 hypersensitivity NN I-NP B-Disease
15 400 408 9721172 reaction NN I-NP O
16 409 413 9721172 that WDT B-NP O
17 414 421 9721172 affects VBZ B-VP O
18 422 425 9721172 all DT B-NP O
19 426 429 9721172 age NN I-NP O
20 430 436 9721172 groups NNS I-NP O
21 436 437 9721172 , , O O
22 438 440 9721172 is VBZ B-VP O
23 441 445 9721172 drug NN B-NP O
24 446 448 9721172 or CC I-NP O
25 449 458 9721172 infection NN I-NP B-Disease
26 459 466 9721172 induced VBD B-VP O
27 466 467 9721172 , , O O
28 468 471 9721172 and CC O O
29 472 475 9721172 has VBZ B-VP O
30 476 483 9721172 classic JJ B-NP O
31 484 492 9721172 systemic JJ I-NP O
32 492 493 9721172 , , I-NP O
33 494 501 9721172 mucosal JJ I-NP O
34 501 502 9721172 , , O O
35 503 506 9721172 and CC O O
36 507 519 9721172 dermatologic JJ B-NP O
37 520 534 9721172 manifestations NNS I-NP O
38 534 535 9721172 . . O O

1 536 537 9721172 A DT B-NP O
2 538 548 9721172 previously RB I-NP O
3 549 556 9721172 healthy JJ I-NP O
4 557 562 9721172 child NN I-NP O
5 563 566 9721172 who WP B-NP O
6 567 576 9721172 developed VBD B-VP O
7 577 582 9721172 acute JJ B-NP O
8 582 583 9721172 , , I-NP O
9 584 590 9721172 severe JJ I-NP O
10 590 591 9721172 , , I-NP O
11 592 599 9721172 rapidly RB I-NP O
12 600 611 9721172 progressive JJ I-NP O
13 612 621 9721172 vanishing VBG I-NP B-Disease
14 622 626 9721172 bile NN I-NP I-Disease
15 627 631 9721172 duct NN I-NP I-Disease
16 632 640 9721172 syndrome NN I-NP I-Disease
17 641 648 9721172 shortly RB B-ADVP O
18 649 654 9721172 after IN B-PP O
19 655 662 9721172 Stevens NNP B-NP B-Disease
20 662 663 9721172 - HYPH I-NP I-Disease
21 663 670 9721172 Johnson NNP I-NP I-Disease
22 671 679 9721172 syndrome NN I-NP I-Disease
23 680 682 9721172 is VBZ B-VP O
24 683 692 9721172 described VBN I-VP O
25 692 693 9721172 ; : O O
26 694 698 9721172 this DT B-NP O
27 699 702 9721172 was VBD B-VP O
28 703 713 9721172 temporally RB I-VP O
29 714 724 9721172 associated VBN I-VP O
30 725 729 9721172 with IN B-PP O
31 730 739 9721172 ibuprofen NN B-NP B-Chemical
32 740 743 9721172 use NN I-NP O
33 743 744 9721172 . . O O

1 745 752 9721172 Despite IN B-PP O
2 753 760 9721172 therapy NN B-NP O
3 761 765 9721172 with IN B-PP O
4 766 781 9721172 ursodeoxycholic JJ B-NP B-Chemical
5 782 786 9721172 acid NN I-NP I-Chemical
6 786 787 9721172 , , O O
7 788 798 9721172 prednisone NN B-NP B-Chemical
8 798 799 9721172 , , O O
9 800 803 9721172 and CC O O
10 804 808 9721172 then RB B-ADVP O
11 809 819 9721172 tacrolimus NN B-NP B-Chemical
12 819 820 9721172 , , O O
13 821 824 9721172 her PRP$ B-NP O
14 825 836 9721172 cholestatic JJ I-NP B-Disease
15 837 844 9721172 disease NN I-NP I-Disease
16 845 848 9721172 was VBD B-VP O
17 849 860 9721172 unrelenting VBG I-VP O
18 860 861 9721172 , , O O
19 862 866 9721172 with IN B-PP O
20 867 876 9721172 cirrhosis NN B-NP B-Disease
21 877 882 9721172 shown VBN B-VP O
22 883 885 9721172 by IN B-PP O
23 886 892 9721172 biopsy NN B-NP O
24 893 894 9721172 6 CD B-NP O
25 895 901 9721172 months NNS I-NP O
26 902 907 9721172 after IN B-PP O
27 908 920 9721172 presentation NN B-NP O
28 920 921 9721172 . . O O

1 922 926 9721172 This DT B-NP O
2 927 931 9721172 case NN I-NP O
3 932 941 9721172 documents NNS I-NP O
4 942 947 9721172 acute JJ B-NP O
5 948 952 9721172 drug NN I-NP O
6 952 953 9721172 - HYPH B-VP O
7 953 960 9721172 related VBN I-VP O
8 961 970 9721172 vanishing VBG B-VP B-Disease
9 971 975 9721172 bile NN B-NP I-Disease
10 976 980 9721172 duct NN I-NP I-Disease
11 981 989 9721172 syndrome NN I-NP I-Disease
12 990 992 9721172 in IN B-PP O
13 993 996 9721172 the DT B-NP O
14 997 1006 9721172 pediatric JJ I-NP O
15 1007 1010 9721172 age NN I-NP O
16 1011 1016 9721172 group NN I-NP O
17 1017 1020 9721172 and CC O O
18 1021 1029 9721172 suggests VBZ B-VP O
19 1030 1036 9721172 shared VBN I-VP O
20 1037 1043 9721172 immune JJ B-NP O
21 1044 1054 9721172 mechanisms NNS I-NP O
22 1055 1057 9721172 in IN B-PP O
23 1058 1061 9721172 the DT B-NP O
24 1062 1074 9721172 pathogenesis NN I-NP O
25 1075 1077 9721172 of IN B-PP O
26 1078 1082 9721172 both CC O O
27 1083 1090 9721172 Stevens NNP B-NP B-Disease
28 1090 1091 9721172 - HYPH I-NP I-Disease
29 1091 1098 9721172 Johnson NNP I-NP I-Disease
30 1099 1107 9721172 syndrome NN I-NP I-Disease
31 1108 1111 9721172 and CC O O
32 1112 1121 9721172 vanishing VBG B-VP B-Disease
33 1122 1126 9721172 bile NN B-NP I-Disease
34 1127 1131 9721172 duct NN I-NP I-Disease
35 1132 1140 9721172 syndrome NN I-NP I-Disease
36 1140 1141 9721172 . . O O

1 0 0 17042910 -DOCSTART- -X- -X- O

1 0 4 17042910 Anti AFX B-NP O
2 4 5 17042910 - HYPH I-NP O
3 5 12 17042910 oxidant JJ B-NP O
4 13 20 17042910 effects NNS I-NP O
5 21 23 17042910 of IN B-PP O
6 24 36 17042910 atorvastatin NN B-NP B-Chemical
7 37 39 17042910 in IN B-PP O
8 40 53 17042910 dexamethasone NN B-NP B-Chemical
9 53 54 17042910 - HYPH B-NP O
10 54 61 17042910 induced VBN I-NP O
11 62 74 17042910 hypertension NN I-NP B-Disease
12 75 77 17042910 in IN B-PP O
13 78 81 17042910 the DT B-NP O
14 82 85 17042910 rat NN I-NP O
15 85 86 17042910 . . B-NP O
16 87 88 17042910 1 CD I-NP O
17 88 89 17042910 . . O O

1 90 103 17042910 Dexamethasone NN B-NP B-Chemical
2 104 105 17042910 ( ( O O
3 105 108 17042910 Dex NN B-NP B-Chemical
4 108 109 17042910 ) ) O O
5 109 110 17042910 - HYPH B-NP O
6 110 117 17042910 induced VBN I-NP O
7 118 130 17042910 hypertension NN I-NP B-Disease
8 131 133 17042910 is VBZ B-VP O
9 134 147 17042910 characterized VBN I-VP O
10 148 150 17042910 by IN B-PP O
11 151 162 17042910 endothelial JJ B-NP O
12 163 174 17042910 dysfunction NN I-NP O
13 175 185 17042910 associated VBN B-VP O
14 186 190 17042910 with IN B-PP O
15 191 197 17042910 nitric JJ B-NP B-Chemical
16 198 203 17042910 oxide NN I-NP I-Chemical
17 204 205 17042910 ( ( O O
18 205 207 17042910 NO NN B-NP B-Chemical
19 207 208 17042910 ) ) O O
20 209 219 17042910 deficiency NN B-NP O
21 220 223 17042910 and CC O O
22 224 233 17042910 increased VBN B-NP O
23 234 244 17042910 superoxide NN I-NP B-Chemical
24 245 246 17042910 ( ( O O
25 246 248 17042910 O2 NN B-NP B-Chemical
26 248 249 17042910 - HYPH O I-Chemical
27 249 250 17042910 ) ) O O
28 251 261 17042910 production NN B-NP O
29 261 262 17042910 . . O O

1 263 275 17042910 Atorvastatin NN B-NP B-Chemical
2 276 277 17042910 ( ( O O
3 277 280 17042910 Ato NN B-NP B-Chemical
4 280 281 17042910 ) ) O O
5 282 291 17042910 possesses VBZ B-VP O
6 292 303 17042910 pleiotropic JJ B-NP O
7 304 314 17042910 properties NNS I-NP O
8 315 319 17042910 that WDT B-NP O
9 320 324 17042910 have VBP B-VP O
10 325 329 17042910 been VBN I-VP O
11 330 338 17042910 reported VBN I-VP O
12 339 341 17042910 to TO I-VP O
13 342 349 17042910 improve VB I-VP O
14 350 361 17042910 endothelial JJ B-NP O
15 362 370 17042910 function NN I-NP O
16 371 378 17042910 through IN B-PP O
17 379 388 17042910 increased VBN B-NP O
18 389 401 17042910 availability NN I-NP O
19 402 404 17042910 of IN B-PP O
20 405 407 17042910 NO NN B-NP B-Chemical
21 408 411 17042910 and CC O O
22 412 419 17042910 reduced VBN B-NP O
23 420 422 17042910 O2 NN I-NP B-Chemical
24 422 423 17042910 - HYPH B-NP I-Chemical
25 424 434 17042910 production NN I-NP O
26 435 437 17042910 in IN B-PP O
27 438 445 17042910 various JJ B-NP O
28 446 451 17042910 forms NNS I-NP O
29 452 454 17042910 of IN B-PP O
30 455 467 17042910 hypertension NN B-NP B-Disease
31 467 468 17042910 . . O O

1 469 471 17042910 In IN B-PP O
2 472 475 17042910 the DT B-NP O
3 476 483 17042910 present JJ I-NP O
4 484 489 17042910 study NN I-NP O
5 489 490 17042910 , , O O
6 491 493 17042910 we PRP B-NP O
7 494 506 17042910 investigated VBD B-VP O
8 507 514 17042910 whether IN B-SBAR O
9 515 517 17042910 50 CD B-NP O
10 518 520 17042910 mg NN I-NP O
11 520 521 17042910 / SYM B-NP O
12 521 523 17042910 kg NN I-NP O
13 524 527 17042910 per IN B-PP O
14 528 531 17042910 day NN B-NP O
15 531 532 17042910 , , O O
16 533 536 17042910 p.o FW B-NP O
17 536 537 17042910 . . O O
18 537 538 17042910 , , O O
19 539 542 17042910 Ato NNP B-NP B-Chemical
20 543 548 17042910 could MD B-VP O
21 549 556 17042910 prevent VB I-VP O
22 557 568 17042910 endothelial JJ B-NP O
23 569 571 17042910 NO NN I-NP B-Chemical
24 572 580 17042910 synthase NN I-NP O
25 581 582 17042910 ( ( O O
26 582 586 17042910 eNOS NN B-NP O
27 586 587 17042910 ) ) O O
28 588 602 17042910 downregulation NN B-NP O
29 603 606 17042910 and CC O O
30 607 610 17042910 the DT B-NP O
31 611 619 17042910 increase NN I-NP O
32 620 622 17042910 in IN B-PP O
33 623 625 17042910 O2 NN B-NP B-Chemical
34 625 626 17042910 - HYPH B-ADJP I-Chemical
35 627 629 17042910 in IN B-PP O
36 630 637 17042910 Sprague NNP B-NP O
37 637 638 17042910 - HYPH I-NP O
38 638 644 17042910 Dawley NNP I-NP O
39 645 646 17042910 ( ( O O
40 646 648 17042910 SD NNP B-NP O
41 648 649 17042910 ) ) O O
42 650 654 17042910 rats NNS B-NP O
43 654 655 17042910 , , O O
44 656 663 17042910 thereby RB B-VP O
45 664 672 17042910 reducing VBG I-VP O
46 673 678 17042910 blood NN B-NP O
47 679 687 17042910 pressure NN I-NP O
48 687 688 17042910 . . O O

1 689 690 17042910 2 LS B-LST O
2 690 691 17042910 . . O O

1 692 696 17042910 Male JJ B-NP O
2 697 699 17042910 SD NN I-NP O
3 700 704 17042910 rats NNS I-NP O
4 705 706 17042910 ( ( O O
5 706 707 17042910 n NN B-NP O
6 708 709 17042910 = SYM B-VP O
7 710 712 17042910 30 CD B-NP O
8 712 713 17042910 ) ) O O
9 714 718 17042910 were VBD B-VP O
10 719 726 17042910 treated VBN I-VP O
11 727 731 17042910 with IN B-PP O
12 732 735 17042910 Ato NNP B-NP B-Chemical
13 736 737 17042910 ( ( O O
14 737 739 17042910 50 CD B-NP O
15 740 742 17042910 mg NN I-NP O
16 742 743 17042910 / SYM B-NP O
17 743 745 17042910 kg NN I-NP O
18 746 749 17042910 per IN B-PP O
19 750 753 17042910 day NN B-NP O
20 754 756 17042910 in IN B-PP O
21 757 765 17042910 drinking NN B-NP O
22 766 771 17042910 water NN I-NP O
23 771 772 17042910 ) ) O O
24 773 775 17042910 or CC O O
25 776 779 17042910 tap NN B-NP O
26 780 785 17042910 water NN I-NP O
27 786 789 17042910 for IN B-PP O
28 790 792 17042910 15 CD B-NP O
29 793 797 17042910 days NNS I-NP O
30 797 798 17042910 . . O O

1 799 812 17042910 Dexamethasone NN B-NP B-Chemical
2 813 814 17042910 ( ( O O
3 814 816 17042910 10 CD B-NP O
4 817 823 17042910 microg NN I-NP O
5 823 824 17042910 / SYM B-NP O
6 824 826 17042910 kg NN I-NP O
7 827 830 17042910 per IN B-PP O
8 831 834 17042910 day NN B-NP O
9 834 835 17042910 , , O O
10 836 839 17042910 s.c NN B-NP O
11 839 840 17042910 . . O O
12 840 841 17042910 ) ) O O
13 842 844 17042910 or CC O O
14 845 851 17042910 saline NN B-NP O
15 852 855 17042910 was VBD B-VP O
16 856 863 17042910 started VBN I-VP O
17 864 869 17042910 after IN B-PP O
18 870 871 17042910 4 CD B-NP O
19 872 876 17042910 days NNS I-NP O
20 877 879 17042910 in IN B-PP O
21 880 883 17042910 Ato NNP B-NP B-Chemical
22 883 884 17042910 - HYPH O O
23 884 891 17042910 treated VBN B-VP O
24 892 895 17042910 and CC O O
25 896 899 17042910 non AFX O O
26 899 900 17042910 - HYPH O O
27 900 907 17042910 treated VBN B-NP O
28 908 912 17042910 rats NNS I-NP O
29 913 916 17042910 and CC O O
30 917 926 17042910 continued VBN B-VP O
31 927 930 17042910 for IN B-PP O
32 931 933 17042910 11 CD B-NP O
33 933 934 17042910 - HYPH I-NP O
34 934 936 17042910 13 CD I-NP O
35 937 941 17042910 days NNS I-NP O
36 941 942 17042910 . . O O

1 943 951 17042910 Systolic JJ B-NP O
2 952 957 17042910 blood NN I-NP O
3 958 966 17042910 pressure NN I-NP O
4 967 968 17042910 ( ( O O
5 968 971 17042910 SBP NN B-NP O
6 971 972 17042910 ) ) O O
7 973 976 17042910 was VBD B-VP O
8 977 985 17042910 measured VBN I-VP O
9 986 988 17042910 on IN B-PP O
10 989 998 17042910 alternate JJ B-NP O
11 999 1003 17042910 days NNS I-NP O
12 1004 1009 17042910 using VBG B-VP O
13 1010 1013 17042910 the DT B-NP O
14 1014 1018 17042910 tail NN I-NP O
15 1018 1019 17042910 - HYPH I-NP O
16 1019 1023 17042910 cuff NN I-NP O
17 1024 1030 17042910 method NN I-NP O
18 1030 1031 17042910 . . O O

1 1032 1043 17042910 Endothelial JJ B-NP O
2 1044 1052 17042910 function NN I-NP O
3 1053 1056 17042910 was VBD B-VP O
4 1057 1065 17042910 assessed VBN I-VP O
5 1066 1068 17042910 by IN B-PP O
6 1069 1082 17042910 acetylcholine NN B-NP B-Chemical
7 1082 1083 17042910 - HYPH B-NP O
8 1083 1090 17042910 induced VBN I-NP O
9 1091 1105 17042910 vasorelaxation NN I-NP O
10 1106 1109 17042910 and CC I-NP O
11 1110 1123 17042910 phenylephrine NN I-NP B-Chemical
12 1123 1124 17042910 - HYPH B-NP O
13 1124 1131 17042910 induced VBN I-NP O
14 1132 1148 17042910 vasoconstriction NN I-NP O
15 1149 1151 17042910 in IN B-PP O
16 1152 1158 17042910 aortic JJ B-NP O
17 1159 1167 17042910 segments NNS I-NP O
18 1167 1168 17042910 . . O O

1 1169 1177 17042910 Vascular JJ B-NP O
2 1178 1182 17042910 eNOS NN I-NP O
3 1183 1187 17042910 mRNA NN I-NP O
4 1188 1191 17042910 was VBD B-VP O
5 1192 1200 17042910 assessed VBN I-VP O
6 1201 1203 17042910 by IN B-PP O
7 1204 1208 17042910 semi AFX B-NP O
8 1208 1209 17042910 - HYPH I-NP O
9 1209 1221 17042910 quantitative JJ I-NP O
10 1222 1229 17042910 reverse JJ I-NP O
11 1230 1243 17042910 transcription NN I-NP O
12 1243 1244 17042910 - HYPH B-NP O
13 1244 1254 17042910 polymerase NN I-NP O
14 1255 1260 17042910 chain NN I-NP O
15 1261 1269 17042910 reaction NN I-NP O
16 1269 1270 17042910 . . O O

1 1271 1272 17042910 3 LS B-LST O
2 1272 1273 17042910 . . O O

1 1274 1276 17042910 In IN B-PP O
2 1277 1281 17042910 rats NNS B-NP O
3 1282 1289 17042910 treated VBN B-VP O
4 1290 1294 17042910 with IN B-PP O
5 1295 1298 17042910 Dex NN B-NP B-Chemical
6 1299 1304 17042910 alone RB B-ADVP O
7 1304 1305 17042910 , , O O
8 1306 1309 17042910 SBP NN B-NP O
9 1310 1313 17042910 was VBD B-VP O
10 1314 1323 17042910 increased VBN I-VP O
11 1324 1328 17042910 from IN B-PP O
12 1329 1332 17042910 109 CD B-NP O
13 1333 1334 17042910 + SYM B-ADJP O
14 1334 1335 17042910 / SYM O O
15 1335 1336 17042910 - SYM O O
16 1337 1338 17042910 2 CD B-NP O
17 1339 1341 17042910 to TO B-PP O
18 1342 1345 17042910 133 CD B-NP O
19 1346 1347 17042910 + SYM O O
20 1347 1348 17042910 / SYM O O
21 1348 1349 17042910 - SYM O O
22 1350 1351 17042910 2 CD B-NP O
23 1352 1356 17042910 mmHg NN I-NP O
24 1357 1359 17042910 on IN B-PP O
25 1360 1364 17042910 Days NNS B-NP O
26 1365 1366 17042910 4 CD B-NP O
27 1367 1370 17042910 and CC O O
28 1371 1374 17042910 Day NN B-NP O
29 1375 1377 17042910 14 CD I-NP O
30 1377 1378 17042910 , , O O
31 1379 1391 17042910 respectively RB B-ADVP O
32 1392 1393 17042910 ( ( O O
33 1393 1394 17042910 P NN B-NP O
34 1395 1396 17042910 < SYM O O
35 1397 1402 17042910 0.001 CD B-NP O
36 1402 1403 17042910 ) ) O O
37 1403 1404 17042910 . . O O

1 1405 1407 17042910 In IN B-PP O
2 1408 1411 17042910 the DT B-NP O
3 1412 1415 17042910 Ato NNP I-NP B-Chemical
4 1416 1417 17042910 + CC I-NP O
5 1418 1421 17042910 Dex NNP I-NP B-Chemical
6 1422 1427 17042910 group NN I-NP O
7 1427 1428 17042910 , , O O
8 1429 1432 17042910 SBP NN B-NP O
9 1433 1436 17042910 was VBD B-VP O
10 1437 1446 17042910 increased VBN I-VP O
11 1447 1451 17042910 from IN B-PP O
12 1452 1455 17042910 113 CD B-NP O
13 1456 1457 17042910 + SYM B-ADJP O
14 1457 1458 17042910 / SYM O O
15 1458 1459 17042910 - SYM O O
16 1460 1461 17042910 2 CD B-NP O
17 1462 1464 17042910 to TO B-PP O
18 1465 1468 17042910 119 CD B-NP O
19 1469 1470 17042910 + SYM O O
20 1470 1471 17042910 / SYM O O
21 1471 1472 17042910 - SYM O O
22 1473 1474 17042910 2 CD B-NP O
23 1475 1479 17042910 mmHg NN I-NP O
24 1480 1482 17042910 on IN B-PP O
25 1483 1487 17042910 Days NNS B-NP O
26 1488 1489 17042910 4 CD B-NP O
27 1490 1492 17042910 to TO B-PP O
28 1493 1495 17042910 14 CD B-NP O
29 1495 1496 17042910 , , O O
30 1497 1509 17042910 respectively RB B-ADVP O
31 1510 1511 17042910 ( ( O O
32 1511 1512 17042910 P NN B-NP O
33 1513 1514 17042910 < SYM O O
34 1515 1520 17042910 0.001 CD B-NP O
35 1520 1521 17042910 ) ) O O
36 1521 1522 17042910 , , O O
37 1523 1526 17042910 but CC O O
38 1527 1530 17042910 was VBD B-VP O
39 1531 1544 17042910 significantly RB B-ADJP O
40 1545 1550 17042910 lower JJR I-ADJP O
41 1551 1555 17042910 than IN B-PP O
42 1556 1559 17042910 SBP NN B-NP O
43 1560 1562 17042910 in IN B-PP O
44 1563 1566 17042910 the DT B-NP O
45 1567 1572 17042910 group NN I-NP O
46 1573 1580 17042910 treated VBN B-VP O
47 1581 1585 17042910 with IN B-PP O
48 1586 1589 17042910 Dex NN B-NP B-Chemical
49 1590 1595 17042910 alone RB B-ADVP O
50 1596 1597 17042910 ( ( O O
51 1597 1598 17042910 P NN B-NP O
52 1599 1600 17042910 < SYM O O
53 1601 1605 17042910 0.05 CD B-NP O
54 1605 1606 17042910 ) ) O O
55 1606 1607 17042910 . . O O

1 1608 1619 17042910 Endothelial JJ B-NP O
2 1619 1620 17042910 - HYPH I-NP O
3 1620 1629 17042910 dependent JJ I-NP O
4 1630 1640 17042910 relaxation NN I-NP O
5 1641 1644 17042910 and CC I-NP O
6 1645 1649 17042910 eNOS NN I-NP O
7 1650 1654 17042910 mRNA NN I-NP O
8 1655 1665 17042910 expression NN I-NP O
9 1666 1670 17042910 were VBD B-VP O
10 1671 1678 17042910 greater JJR B-ADJP O
11 1679 1681 17042910 in IN B-PP O
12 1682 1685 17042910 the DT B-NP O
13 1686 1689 17042910 Dex NNP I-NP B-Chemical
14 1690 1691 17042910 + SYM I-NP O
15 1692 1695 17042910 Ato NNP I-NP B-Chemical
16 1696 1701 17042910 group NN I-NP O
17 1702 1706 17042910 than IN B-PP O
18 1707 1709 17042910 in IN B-PP O
19 1710 1713 17042910 the DT B-NP O
20 1714 1717 17042910 Dex NN I-NP B-Chemical
21 1718 1722 17042910 only RB B-NP O
22 1723 1728 17042910 group NN I-NP O
23 1729 1730 17042910 ( ( O O
24 1730 1731 17042910 P NN B-NP O
25 1732 1733 17042910 < JJR B-NP O
26 1734 1738 17042910 0.05 CD I-NP O
27 1739 1742 17042910 and CC O O
28 1743 1744 17042910 P NN B-NP O
29 1745 1746 17042910 < SYM O O
30 1747 1753 17042910 0.0001 CD B-NP O
31 1753 1754 17042910 , , O O
32 1755 1767 17042910 respectively RB B-ADVP O
33 1767 1768 17042910 ) ) O O
34 1768 1769 17042910 . . O O

1 1770 1776 17042910 Aortic JJ B-NP O
2 1777 1787 17042910 superoxide NN I-NP B-Chemical
3 1788 1798 17042910 production NN I-NP O
4 1799 1802 17042910 was VBD B-VP O
5 1803 1808 17042910 lower JJR B-ADJP O
6 1809 1811 17042910 in IN B-PP O
7 1812 1815 17042910 the DT B-NP O
8 1816 1819 17042910 Dex NNP I-NP B-Chemical
9 1820 1821 17042910 + SYM I-NP O
10 1822 1825 17042910 Ato NNP I-NP B-Chemical
11 1826 1831 17042910 group NN I-NP O
12 1832 1840 17042910 compared VBN B-PP O
13 1841 1845 17042910 with IN B-PP O
14 1846 1849 17042910 the DT B-NP O
15 1850 1855 17042910 group NN I-NP O
16 1856 1863 17042910 treated VBN B-VP O
17 1864 1868 17042910 with IN B-PP O
18 1869 1872 17042910 Dex NN B-NP B-Chemical
19 1873 1878 17042910 alone RB B-ADVP O
20 1879 1880 17042910 ( ( O O
21 1880 1881 17042910 P NN B-NP O
22 1882 1883 17042910 < SYM O O
23 1884 1890 17042910 0.0001 CD B-NP O
24 1890 1891 17042910 ) ) O O
25 1891 1892 17042910 . . O O

1 1893 1894 17042910 4 LS B-LST O
2 1894 1895 17042910 . . O O

1 1896 1905 17042910 Treatment NN B-NP O
2 1906 1910 17042910 with IN B-PP O
3 1911 1914 17042910 Ato NNP B-NP B-Chemical
4 1915 1923 17042910 improved VBD B-VP O
5 1924 1935 17042910 endothelial JJ B-NP O
6 1936 1944 17042910 function NN I-NP O
7 1944 1945 17042910 , , O O
8 1946 1953 17042910 reduced VBD B-VP O
9 1954 1964 17042910 superoxide NN B-NP B-Chemical
10 1965 1975 17042910 production NN I-NP O
11 1976 1979 17042910 and CC O O
12 1980 1987 17042910 reduced VBN B-NP O
13 1988 1991 17042910 SBP NN I-NP O
14 1992 1994 17042910 in IN B-PP O
15 1995 1998 17042910 Dex NN B-NP B-Chemical
16 1998 1999 17042910 - HYPH O O
17 1999 2006 17042910 treated VBN B-NP O
18 2007 2009 17042910 SD NN I-NP O
19 2010 2014 17042910 rats NNS I-NP O
20 2014 2015 17042910 . . O O

1 0 0 17612891 -DOCSTART- -X- -X- O

1 0 5 17612891 Acute JJ B-NP O
2 6 17 17612891 myocarditis NN I-NP B-Disease
3 18 28 17612891 associated VBN B-VP O
4 29 33 17612891 with IN B-PP O
5 34 43 17612891 clozapine NN B-NP B-Chemical
6 43 44 17612891 . . O O
7 45 54 17612891 OBJECTIVE NN B-NP O
8 54 55 17612891 : : O O
9 56 57 17612891 A DT B-NP O
10 58 62 17612891 case NN I-NP O
11 63 65 17612891 of IN B-PP O
12 66 71 17612891 acute JJ B-NP O
13 72 83 17612891 myocarditis NN I-NP B-Disease
14 84 94 17612891 associated VBN B-VP O
15 95 99 17612891 with IN B-PP O
16 100 103 17612891 the DT B-NP O
17 104 116 17612891 commencement NN I-NP O
18 117 119 17612891 of IN B-PP O
19 120 129 17612891 clozapine NN B-NP B-Chemical
20 130 132 17612891 is VBZ B-VP O
21 133 142 17612891 described VBN I-VP O
22 142 143 17612891 , , O O
23 144 156 17612891 highlighting VBG B-VP O
24 157 160 17612891 the DT B-NP O
25 161 166 17612891 onset NN I-NP O
26 166 167 17612891 , , O O
27 168 174 17612891 course NN B-NP O
28 175 178 17612891 and CC O O
29 179 187 17612891 possible JJ B-NP O
30 188 200 17612891 contributing VBG I-NP O
31 201 208 17612891 factors NNS I-NP O
32 208 209 17612891 . . O O

1 210 215 17612891 There EX B-NP O
2 216 218 17612891 is VBZ B-VP O
3 219 221 17612891 an DT B-NP O
4 222 228 17612891 urgent JJ I-NP O
5 229 233 17612891 need NN I-NP O
6 234 236 17612891 to TO B-VP O
7 237 242 17612891 raise VB I-VP O
8 243 252 17612891 awareness NN B-NP O
9 253 258 17612891 about IN B-PP O
10 259 263 17612891 this DT B-NP O
11 264 275 17612891 potentially RB I-NP O
12 276 281 17612891 fatal JJ I-NP O
13 282 294 17612891 complication NN I-NP O
14 295 297 17612891 of IN B-PP O
15 298 307 17612891 clozapine NN B-NP B-Chemical
16 308 311 17612891 use NN I-NP O
17 311 312 17612891 . . O O

1 313 320 17612891 RESULTS NNS B-NP O
2 320 321 17612891 : : O O
3 322 323 17612891 A DT B-NP O
4 324 326 17612891 20 CD I-NP O
5 326 327 17612891 - HYPH I-NP O
6 327 331 17612891 year NN I-NP O
7 331 332 17612891 - HYPH O O
8 332 335 17612891 old JJ B-NP O
9 336 340 17612891 male NN I-NP O
10 341 345 17612891 with IN B-PP O
11 346 359 17612891 schizophrenia NN B-NP B-Disease
12 360 369 17612891 developed VBD B-VP O
13 370 371 17612891 a DT B-NP O
14 372 378 17612891 sudden JJ I-NP O
15 379 384 17612891 onset NN I-NP O
16 385 387 17612891 of IN B-PP O
17 388 399 17612891 myocarditis NN B-NP B-Disease
18 400 405 17612891 after IN B-PP O
19 406 418 17612891 commencement NN B-NP O
20 419 421 17612891 of IN B-PP O
21 422 431 17612891 clozapine NN B-NP B-Chemical
22 431 432 17612891 . . O O

1 433 436 17612891 The DT B-NP O
2 437 444 17612891 patient NN I-NP O
3 445 454 17612891 recovered VBD B-VP O
4 455 459 17612891 with IN B-PP O
5 460 469 17612891 intensive JJ B-NP O
6 470 477 17612891 medical JJ I-NP O
7 478 485 17612891 support NN I-NP O
8 485 486 17612891 . . O O

1 487 490 17612891 The DT B-NP O
2 491 499 17612891 symptoms NNS I-NP O
3 500 508 17612891 occurred VBD B-VP O
4 509 515 17612891 around RB B-NP O
5 516 517 17612891 2 CD I-NP O
6 518 523 17612891 weeks NNS I-NP O
7 524 529 17612891 after IN B-PP O
8 530 538 17612891 starting VBG B-VP O
9 539 548 17612891 clozapine NN B-NP B-Chemical
10 549 551 17612891 in IN B-PP O
11 552 554 17612891 an DT B-NP O
12 555 564 17612891 inpatient NN I-NP O
13 565 572 17612891 setting NN I-NP O
14 572 573 17612891 . . O O

1 574 582 17612891 Possible JJ B-NP O
2 583 595 17612891 contributing VBG I-NP O
3 596 603 17612891 factors NNS I-NP O
4 604 607 17612891 may MD B-VP O
5 608 612 17612891 have VB I-VP O
6 613 617 17612891 been VBN I-VP O
7 618 629 17612891 concomitant JJ B-NP O
8 630 644 17612891 antidepressant NN I-NP B-Chemical
9 645 648 17612891 use NN I-NP O
10 649 652 17612891 and CC O O
11 653 665 17612891 unaccustomed JJ B-NP O
12 666 674 17612891 physical JJ I-NP O
13 675 683 17612891 activity NN I-NP O
14 683 684 17612891 . . O O

1 685 696 17612891 CONCLUSIONS NNS B-NP O
2 696 697 17612891 : : O O
3 698 709 17612891 Myocarditis NN B-NP B-Disease
4 710 712 17612891 is VBZ B-VP O
5 713 715 17612891 an DT B-NP O
6 716 728 17612891 increasingly RB I-NP O
7 729 739 17612891 recognized VBN I-NP O
8 740 752 17612891 complication NN I-NP O
9 753 763 17612891 associated VBN B-VP O
10 764 768 17612891 with IN B-PP O
11 769 772 17612891 the DT B-NP O
12 773 776 17612891 use NN I-NP O
13 777 779 17612891 of IN B-PP O
14 780 789 17612891 clozapine NN B-NP B-Chemical
15 789 790 17612891 . . O O

1 791 793 17612891 It PRP B-NP O
2 794 797 17612891 can MD B-VP O
3 798 800 17612891 be VB I-VP O
4 801 806 17612891 fatal JJ B-ADJP O
5 807 809 17612891 if IN B-SBAR O
6 810 813 17612891 not RB O O
7 814 824 17612891 recognized VBN B-VP O
8 825 828 17612891 and CC I-VP O
9 829 836 17612891 treated VBN I-VP O
10 837 842 17612891 early RB B-ADVP O
11 842 843 17612891 . . O O

1 844 855 17612891 Considering VBG B-VP O
2 856 860 17612891 that DT B-NP O
3 861 870 17612891 clozapine NN I-NP B-Chemical
4 871 878 17612891 remains VBZ B-VP O
5 879 882 17612891 the DT B-NP O
6 883 887 17612891 gold JJ I-NP O
7 888 896 17612891 standard NN I-NP O
8 897 899 17612891 in IN B-PP O
9 900 909 17612891 treatment NN B-NP O
10 910 912 17612891 of IN B-PP O
11 913 922 17612891 resistant JJ B-NP O
12 923 932 17612891 psychosis NN I-NP B-Disease
13 932 933 17612891 , , O O
14 934 939 17612891 there EX B-NP O
15 940 942 17612891 is VBZ B-VP O
16 943 945 17612891 an DT B-NP O
17 946 952 17612891 urgent JJ I-NP O
18 953 957 17612891 need NN I-NP O
19 958 960 17612891 to TO B-VP O
20 961 966 17612891 raise VB I-VP O
21 967 976 17612891 awareness NN B-NP O
22 977 982 17612891 among IN B-PP O
23 983 990 17612891 medical JJ B-NP O
24 991 994 17612891 and CC I-NP O
25 995 1006 17612891 paramedical JJ I-NP O
26 1007 1012 17612891 staff NN I-NP O
27 1013 1021 17612891 involved VBN B-VP O
28 1022 1024 17612891 in IN B-PP O
29 1025 1028 17612891 the DT B-NP O
30 1029 1033 17612891 care NN I-NP O
31 1034 1036 17612891 of IN B-PP O
32 1037 1042 17612891 these DT B-NP O
33 1043 1051 17612891 patients NNS I-NP O
34 1051 1052 17612891 . . O O

1 1053 1058 17612891 There EX B-NP O
2 1059 1062 17612891 are VBP B-VP O
3 1063 1067 17612891 also RB B-ADVP O
4 1068 1080 17612891 implications NNS B-NP O
5 1081 1084 17612891 for IN B-PP O
6 1085 1100 17612891 recommendations NNS B-NP O
7 1101 1104 17612891 and CC I-NP O
8 1105 1116 17612891 regulations NNS I-NP O
9 1117 1126 17612891 regarding VBG B-VP O
10 1127 1130 17612891 the DT B-NP O
11 1131 1134 17612891 use NN I-NP O
12 1135 1137 17612891 of IN B-PP O
13 1138 1147 17612891 clozapine NN B-NP B-Chemical
14 1147 1148 17612891 . . O O

1 0 0 18004067 -DOCSTART- -X- -X- O

1 0 5 18004067 Acute JJ B-NP B-Disease
2 6 11 18004067 liver NN I-NP I-Disease
3 12 19 18004067 failure NN I-NP I-Disease
4 20 22 18004067 in IN B-PP O
5 23 26 18004067 two CD B-NP O
6 27 35 18004067 patients NNS I-NP O
7 36 40 18004067 with IN B-PP O
8 41 48 18004067 regular JJ B-NP O
9 49 56 18004067 alcohol NN I-NP B-Chemical
10 57 68 18004067 consumption NN I-NP O
11 69 78 18004067 ingesting VBG B-VP O
12 79 90 18004067 paracetamol NN B-NP B-Chemical
13 91 93 18004067 at IN B-PP O
14 94 105 18004067 therapeutic JJ B-NP O
15 106 112 18004067 dosage NN I-NP O
16 112 113 18004067 . . I-NP O
17 114 124 18004067 BACKGROUND NN I-NP O
18 124 125 18004067 : : O O
19 126 129 18004067 The DT B-NP O
20 130 138 18004067 possible JJ I-NP O
21 139 143 18004067 role NN I-NP O
22 144 146 18004067 of IN B-PP O
23 147 154 18004067 alcohol NN B-NP B-Chemical
24 155 157 18004067 in IN B-PP O
25 158 161 18004067 the DT B-NP O
26 162 173 18004067 development NN I-NP O
27 174 176 18004067 of IN B-PP O
28 177 191 18004067 hepatotoxicity NN B-NP B-Disease
29 192 202 18004067 associated VBN B-VP O
30 203 207 18004067 with IN B-PP O
31 208 219 18004067 therapeutic JJ B-NP O
32 220 225 18004067 doses NNS I-NP O
33 226 228 18004067 of IN B-PP O
34 229 240 18004067 paracetamol NN B-NP B-Chemical
35 241 242 18004067 ( ( O O
36 242 255 18004067 acetaminophen NN B-NP B-Chemical
37 255 256 18004067 ) ) O O
38 257 259 18004067 is VBZ B-VP O
39 260 269 18004067 currently RB I-VP O
40 270 277 18004067 debated VBN I-VP O
41 277 278 18004067 . . O O

1 279 283 18004067 CASE NN B-NP O
2 284 290 18004067 REPORT NN I-NP O
3 290 291 18004067 : : O O
4 292 294 18004067 We PRP B-NP O
5 295 303 18004067 describe VBP B-VP O
6 304 305 18004067 2 CD B-NP O
7 306 314 18004067 patients NNS I-NP O
8 315 318 18004067 who WP B-NP O
9 319 323 18004067 were VBD B-VP O
10 324 331 18004067 regular JJ B-NP O
11 332 341 18004067 consumers NNS I-NP O
12 342 344 18004067 of IN B-PP O
13 345 352 18004067 alcohol NN B-NP B-Chemical
14 353 356 18004067 and CC O O
15 357 360 18004067 who WP B-NP O
16 361 370 18004067 developed VBD B-VP O
17 371 376 18004067 liver NN B-NP B-Disease
18 377 384 18004067 failure NN I-NP I-Disease
19 385 391 18004067 within IN B-PP O
20 392 393 18004067 3 CD B-NP O
21 393 394 18004067 - HYPH I-NP O
22 394 395 18004067 5 CD I-NP O
23 396 400 18004067 days NNS I-NP O
24 401 406 18004067 after IN B-PP O
25 407 422 18004067 hospitalization NN B-NP O
26 423 426 18004067 and CC O O
27 427 435 18004067 stopping VBG B-VP O
28 436 443 18004067 alcohol NN B-NP B-Chemical
29 444 455 18004067 consumption NN I-NP O
30 456 461 18004067 while IN B-SBAR O
31 462 467 18004067 being VBG B-VP O
32 468 475 18004067 treated VBN I-VP O
33 476 480 18004067 with IN B-PP O
34 481 482 18004067 4 CD B-NP O
35 483 484 18004067 g NN I-NP O
36 485 496 18004067 paracetamol NN I-NP B-Chemical
37 496 497 18004067 / SYM B-NP O
38 497 500 18004067 day NN I-NP O
39 500 501 18004067 . . O O

1 502 503 18004067 A DT B-NP O
2 504 515 18004067 paracetamol NN I-NP B-Chemical
3 516 521 18004067 serum NN I-NP O
4 522 527 18004067 level NN I-NP O
5 528 536 18004067 obtained VBN B-VP O
6 537 539 18004067 in IN B-PP O
7 540 543 18004067 one CD B-NP O
8 544 546 18004067 of IN B-PP O
9 547 552 18004067 these DT B-NP O
10 553 561 18004067 patients NNS I-NP O
11 562 565 18004067 was VBD B-VP O
12 566 569 18004067 not RB O O
13 570 572 18004067 in IN B-PP O
14 573 576 18004067 the DT B-NP O
15 577 582 18004067 toxic JJ I-NP O
16 583 588 18004067 range NN I-NP O
17 588 589 18004067 . . O O

1 590 598 18004067 Possible JJ B-NP O
2 599 603 18004067 risk NN I-NP O
3 604 611 18004067 factors NNS I-NP O
4 612 615 18004067 for IN B-PP O
5 616 619 18004067 the DT B-NP O
6 620 631 18004067 development NN I-NP O
7 632 634 18004067 of IN B-PP O
8 635 649 18004067 hepatotoxicity NN B-NP B-Disease
9 650 652 18004067 in IN B-PP O
10 653 661 18004067 patients NNS B-NP O
11 662 669 18004067 treated VBN B-VP O
12 670 674 18004067 with IN B-PP O
13 675 686 18004067 therapeutic JJ B-NP O
14 687 692 18004067 doses NNS I-NP O
15 693 695 18004067 of IN B-PP O
16 696 707 18004067 paracetamol NN B-NP B-Chemical
17 708 711 18004067 are VBP B-VP O
18 712 721 18004067 discussed VBN I-VP O
19 721 722 18004067 . . O O

1 723 733 18004067 CONCLUSION NN B-NP O
2 733 734 18004067 : : O O
3 735 737 18004067 In IN B-PP O
4 738 746 18004067 patients NNS B-NP O
5 747 751 18004067 with IN B-PP O
6 752 756 18004067 risk NN B-NP O
7 757 764 18004067 factors NNS I-NP O
8 764 765 18004067 , , O O
9 766 770 18004067 e.g. FW B-NP O

1 771 778 18004067 regular JJ B-NP O
2 779 790 18004067 consumption NN I-NP O
3 791 793 18004067 of IN B-PP O
4 794 801 18004067 alcohol NN B-NP B-Chemical
5 801 802 18004067 , , O O
6 803 808 18004067 liver NN B-NP B-Disease
7 809 816 18004067 failure NN I-NP I-Disease
8 817 819 18004067 is VBZ B-VP O
9 820 828 18004067 possible JJ B-ADJP O
10 829 833 18004067 when WRB B-ADVP O
11 834 845 18004067 therapeutic JJ B-NP O
12 846 851 18004067 doses NNS I-NP O
13 852 855 18004067 are VBP B-VP O
14 856 864 18004067 ingested VBN I-VP O
15 864 865 18004067 . . O O

1 866 868 18004067 We PRP B-NP O
2 869 876 18004067 propose VBP B-VP O
3 877 881 18004067 that IN B-SBAR O
4 882 885 18004067 the DT B-NP O
5 886 897 18004067 paracetamol NN I-NP B-Chemical
6 898 902 18004067 dose NN I-NP O
7 903 909 18004067 should MD B-VP O
8 910 913 18004067 not RB I-VP O
9 914 920 18004067 exceed VB I-VP O
10 921 922 18004067 2 CD B-NP O
11 923 924 18004067 g NN I-NP O
12 924 925 18004067 / SYM B-NP O
13 925 928 18004067 day NN I-NP O
14 929 931 18004067 in IN B-PP O
15 932 936 18004067 such JJ B-NP O
16 937 945 18004067 patients NNS I-NP O
17 946 949 18004067 and CC O O
18 950 954 18004067 that IN B-SBAR O
19 955 960 18004067 their PRP$ B-NP O
20 961 966 18004067 liver NN I-NP O
21 967 975 18004067 function NN I-NP O
22 976 982 18004067 should MD B-VP O
23 983 985 18004067 be VB I-VP O
24 986 995 18004067 monitored VBN I-VP O
25 996 1003 18004067 closely RB B-ADVP O
26 1004 1009 18004067 while IN B-SBAR O
27 1010 1015 18004067 being VBG B-VP O
28 1016 1023 18004067 treated VBN I-VP O
29 1024 1028 18004067 with IN B-PP O
30 1029 1040 18004067 paracetamol NN B-NP B-Chemical
31 1040 1041 18004067 . . O O

1 0 0 2071257 -DOCSTART- -X- -X- O

1 0 6 2071257 Effect NN B-NP O
2 7 9 2071257 of IN B-PP O
3 10 11 2071257 L NN B-NP B-Chemical
4 11 12 2071257 - HYPH O I-Chemical
5 12 17 2071257 alpha SYM B-NP I-Chemical
6 17 18 2071257 - HYPH B-NP I-Chemical
7 18 26 2071257 glyceryl NN I-NP I-Chemical
8 26 27 2071257 - HYPH O I-Chemical
9 27 44 2071257 phosphorylcholine NN B-NP I-Chemical
10 45 47 2071257 on IN B-PP O
11 48 55 2071257 amnesia NN B-NP B-Disease
12 56 62 2071257 caused VBN B-VP O
13 63 65 2071257 by IN B-PP O
14 66 77 2071257 scopolamine NN B-NP B-Chemical
15 77 78 2071257 . . O O
16 79 82 2071257 The DT B-NP O
17 83 90 2071257 present JJ I-NP O
18 91 96 2071257 study NN I-NP O
19 97 100 2071257 was VBD B-VP O
20 101 108 2071257 carried VBN I-VP O
21 109 112 2071257 out RP B-PRT O
22 113 115 2071257 to TO B-VP O
23 116 120 2071257 test VB I-VP O
24 121 124 2071257 the DT B-NP O
25 125 132 2071257 effects NNS I-NP O
26 133 135 2071257 of IN B-PP O
27 136 137 2071257 L NN B-NP B-Chemical
28 137 138 2071257 - HYPH O I-Chemical
29 138 143 2071257 alpha SYM O I-Chemical
30 143 144 2071257 - HYPH O I-Chemical
31 144 169 2071257 glycerylphosphorylcholine NN B-NP I-Chemical
32 170 171 2071257 ( ( O O
33 171 172 2071257 L NN B-NP B-Chemical
34 172 173 2071257 - HYPH O I-Chemical
35 173 178 2071257 alpha SYM O I-Chemical
36 178 179 2071257 - HYPH O I-Chemical
37 179 182 2071257 GFC NN B-NP I-Chemical
38 182 183 2071257 ) ) O O
39 184 186 2071257 on IN B-PP O
40 187 193 2071257 memory NN B-NP B-Disease
41 194 204 2071257 impairment NN I-NP I-Disease
42 205 212 2071257 induced VBN B-VP O
43 213 215 2071257 by IN B-PP O
44 216 227 2071257 scopolamine NN B-NP B-Chemical
45 228 230 2071257 in IN B-PP O
46 231 234 2071257 man NN B-NP O
47 234 235 2071257 . . O O

1 236 242 2071257 Thirty CD B-NP O
2 242 243 2071257 - HYPH I-NP O
3 243 246 2071257 two CD I-NP O
4 247 254 2071257 healthy JJ I-NP O
5 255 260 2071257 young JJ I-NP O
6 261 271 2071257 volunteers NNS I-NP O
7 272 276 2071257 were VBD B-VP O
8 277 285 2071257 randomly RB I-VP O
9 286 295 2071257 allocated VBN I-VP O
10 296 298 2071257 to TO B-PP O
11 299 303 2071257 four CD B-NP O
12 304 313 2071257 different JJ I-NP O
13 314 320 2071257 groups NNS I-NP O
14 320 321 2071257 . . O O

1 322 326 2071257 They PRP B-NP O
2 327 331 2071257 were VBD B-VP O
3 332 337 2071257 given VBN I-VP O
4 338 339 2071257 a DT B-NP O
5 340 343 2071257 ten CD I-NP O
6 344 347 2071257 day NN I-NP O
7 348 360 2071257 pretreatment NN I-NP O
8 361 365 2071257 with IN B-PP O
9 366 372 2071257 either CC O O
10 373 374 2071257 L NN B-NP B-Chemical
11 374 375 2071257 - HYPH B-NP I-Chemical
12 375 380 2071257 alpha SYM I-NP I-Chemical
13 380 381 2071257 - HYPH I-NP I-Chemical
14 381 384 2071257 GFC NN I-NP I-Chemical
15 385 387 2071257 or CC I-NP O
16 388 395 2071257 placebo NN I-NP O
17 395 396 2071257 , , O O
18 397 400 2071257 p.o NN B-NP O
19 400 401 2071257 . NN I-NP O
20 401 402 2071257 , , O O
21 403 406 2071257 and CC O O
22 407 409 2071257 on IN B-PP O
23 410 413 2071257 the DT B-NP O
24 414 422 2071257 eleventh JJ I-NP O
25 423 426 2071257 day NN I-NP O
26 427 433 2071257 either CC O O
27 434 445 2071257 scopolamine NN B-NP B-Chemical
28 446 448 2071257 or CC O O
29 449 456 2071257 placebo NN B-NP O
30 456 457 2071257 , , O O
31 458 461 2071257 i.m RB B-ADVP O
32 461 462 2071257 . . O O

1 463 469 2071257 Before IN B-NP O
2 470 473 2071257 and CC I-NP O
3 474 477 2071257 0.5 CD I-NP O
4 477 478 2071257 , , I-NP O
5 479 480 2071257 1 CD I-NP O
6 480 481 2071257 , , I-NP O
7 482 483 2071257 2 CD I-NP O
8 483 484 2071257 , , I-NP O
9 485 486 2071257 3 CD I-NP O
10 486 487 2071257 , , O O
11 488 491 2071257 and CC O O
12 492 493 2071257 6 CD B-NP O
13 494 495 2071257 h NN I-NP O
14 496 501 2071257 after IN B-PP O
15 502 511 2071257 injection NN B-NP O
16 512 515 2071257 the DT B-NP O
17 516 524 2071257 subjects NNS I-NP O
18 525 529 2071257 were VBD B-VP O
19 530 535 2071257 given VBN I-VP O
20 536 545 2071257 attention NN B-NP O
21 546 549 2071257 and CC O O
22 550 558 2071257 mnemonic JJ B-NP O
23 559 564 2071257 tests NNS I-NP O
24 564 565 2071257 . . O O

1 566 569 2071257 The DT B-NP O
2 570 578 2071257 findings NNS I-NP O
3 579 581 2071257 of IN B-PP O
4 582 586 2071257 this DT B-NP O
5 587 592 2071257 study NN I-NP O
6 593 601 2071257 indicate VBP B-VP O
7 602 606 2071257 that IN B-SBAR O
8 607 610 2071257 the DT B-NP O
9 611 615 2071257 drug NN I-NP O
10 616 618 2071257 is VBZ B-VP O
11 619 623 2071257 able JJ B-ADJP O
12 624 626 2071257 to TO B-VP O
13 627 637 2071257 antagonize VB I-VP O
14 638 648 2071257 impairment NN B-NP B-Disease
15 649 651 2071257 of IN B-PP I-Disease
16 652 661 2071257 attention NN B-NP I-Disease
17 662 665 2071257 and CC I-NP I-Disease
18 666 672 2071257 memory NN I-NP I-Disease
19 673 680 2071257 induced VBN B-VP O
20 681 683 2071257 by IN B-PP O
21 684 695 2071257 scopolamine NN B-NP B-Chemical
22 695 696 2071257 . . O O

1 0 0 8092427 -DOCSTART- -X- -X- O

1 0 9 8092427 Immediate JJ B-NP O
2 10 18 8092427 allergic JJ I-NP B-Disease
3 19 28 8092427 reactions NNS I-NP I-Disease
4 29 31 8092427 to TO B-PP O
5 32 43 8092427 amoxicillin NN B-NP B-Chemical
6 43 44 8092427 . . O O
7 45 46 8092427 A DT B-NP O
8 47 52 8092427 large JJ I-NP O
9 53 58 8092427 group NN I-NP O
10 59 61 8092427 of IN B-PP O
11 62 70 8092427 patients NNS B-NP O
12 71 75 8092427 with IN B-PP O
13 76 85 8092427 suspected VBN B-NP O
14 86 94 8092427 allergic JJ I-NP B-Disease
15 95 104 8092427 reactions NNS I-NP I-Disease
16 105 107 8092427 to TO B-PP O
17 108 112 8092427 beta SYM B-NP B-Chemical
18 112 113 8092427 - HYPH B-NP I-Chemical
19 113 119 8092427 lactam NN I-NP I-Chemical
20 120 131 8092427 antibiotics NNS I-NP O
21 132 135 8092427 was VBD B-VP O
22 136 145 8092427 evaluated VBN I-VP O
23 145 146 8092427 . . O O

1 147 148 8092427 A DT B-NP O
2 149 157 8092427 detailed JJ I-NP O
3 158 166 8092427 clinical JJ I-NP O
4 167 174 8092427 history NN I-NP O
5 174 175 8092427 , , O O
6 176 184 8092427 together RB B-ADVP O
7 185 189 8092427 with IN B-PP O
8 190 194 8092427 skin NN B-NP O
9 195 200 8092427 tests NNS I-NP O
10 200 201 8092427 , , O O
11 202 206 8092427 RAST NN B-NP O
12 207 208 8092427 ( ( O O
13 208 227 8092427 radioallergosorbent JJ B-NP O
14 228 232 8092427 test NN I-NP O
15 232 233 8092427 ) ) O O
16 233 234 8092427 , , O O
17 235 238 8092427 and CC O O
18 239 249 8092427 controlled VBN B-NP O
19 250 259 8092427 challenge NN I-NP O
20 260 265 8092427 tests NNS I-NP O
21 265 266 8092427 , , O O
22 267 270 8092427 was VBD B-VP O
23 271 275 8092427 used VBN I-VP O
24 276 278 8092427 to TO B-VP O
25 279 288 8092427 establish VB I-VP O
26 289 296 8092427 whether IN B-SBAR O
27 297 305 8092427 patients NNS B-NP O
28 306 314 8092427 allergic JJ B-ADJP B-Disease
29 315 317 8092427 to TO B-PP O
30 318 322 8092427 beta SYM B-NP B-Chemical
31 322 323 8092427 - HYPH B-NP I-Chemical
32 323 329 8092427 lactam NN I-NP I-Chemical
33 330 341 8092427 antibiotics NNS I-NP O
34 342 345 8092427 had VBD B-VP O
35 346 355 8092427 selective JJ B-NP O
36 356 365 8092427 immediate JJ I-NP O
37 366 374 8092427 allergic JJ I-NP B-Disease
38 375 384 8092427 responses NNS I-NP O
39 385 387 8092427 to TO B-PP O
40 388 399 8092427 amoxicillin NN B-NP B-Chemical
41 400 401 8092427 ( ( O O
42 401 403 8092427 AX NN B-NP B-Chemical
43 403 404 8092427 ) ) O O
44 405 407 8092427 or CC O O
45 408 412 8092427 were VBD B-VP O
46 413 418 8092427 cross AFX B-ADJP O
47 418 419 8092427 - HYPH O O
48 419 427 8092427 reacting VBG B-VP O
49 428 432 8092427 with IN B-PP O
50 433 438 8092427 other JJ B-NP O
51 439 449 8092427 penicillin NN I-NP B-Chemical
52 450 461 8092427 derivatives NNS I-NP O
53 461 462 8092427 . . O O

1 463 467 8092427 Skin NN B-NP O
2 468 473 8092427 tests NNS I-NP O
3 474 478 8092427 were VBD B-VP O
4 479 488 8092427 performed VBN I-VP O
5 489 493 8092427 with IN B-PP O
6 494 511 8092427 benzylpenicilloyl NN B-NP B-Chemical
7 511 512 8092427 - HYPH B-NP I-Chemical
8 512 516 8092427 poly NN I-NP I-Chemical
9 516 517 8092427 - HYPH B-NP I-Chemical
10 517 518 8092427 L NN I-NP I-Chemical
11 518 519 8092427 - HYPH O I-Chemical
12 519 525 8092427 lysine NN B-NP I-Chemical
13 526 527 8092427 ( ( O O
14 527 530 8092427 BPO NN B-NP B-Chemical
15 530 531 8092427 - HYPH B-NP I-Chemical
16 531 534 8092427 PLL NN I-NP I-Chemical
17 534 535 8092427 ) ) O O
18 535 536 8092427 , , O O
19 537 555 8092427 benzylpenicilloate NN B-NP B-Chemical
20 555 556 8092427 , , O O
21 557 573 8092427 benzylpenicillin NN B-NP B-Chemical
22 574 575 8092427 ( ( O O
23 575 577 8092427 PG NN B-NP B-Chemical
24 577 578 8092427 ) ) O O
25 578 579 8092427 , , O O
26 580 590 8092427 ampicillin NN B-NP B-Chemical
27 591 592 8092427 ( ( O O
28 592 595 8092427 AMP NN B-NP B-Chemical
29 595 596 8092427 ) ) O O
30 596 597 8092427 , , O O
31 598 601 8092427 and CC O O
32 602 604 8092427 AX NNP B-NP B-Chemical
33 604 605 8092427 . . O O

1 606 610 8092427 RAST NN B-NP O
2 611 614 8092427 for IN B-PP O
3 615 618 8092427 BPO NN B-NP B-Chemical
4 618 619 8092427 - HYPH B-NP I-Chemical
5 619 622 8092427 PLL NN I-NP I-Chemical
6 623 626 8092427 and CC I-NP O
7 627 629 8092427 AX NN I-NP B-Chemical
8 629 630 8092427 - HYPH B-NP O
9 630 633 8092427 PLL NN I-NP O
10 634 637 8092427 was VBD B-VP O
11 638 642 8092427 done VBN I-VP O
12 642 643 8092427 . . O O

1 644 648 8092427 When WRB B-ADVP O
2 649 653 8092427 both CC O O
3 654 658 8092427 skin NN B-NP O
4 659 663 8092427 test NN I-NP O
5 664 667 8092427 and CC O O
6 668 672 8092427 RAST NN B-NP O
7 673 676 8092427 for IN B-PP O
8 677 680 8092427 BPO NN B-NP B-Chemical
9 681 685 8092427 were VBD B-VP O
10 686 694 8092427 negative JJ B-NP O
11 694 695 8092427 , , I-NP O
12 696 702 8092427 single JJ I-NP O
13 702 703 8092427 - HYPH I-NP O
14 703 708 8092427 blind JJ I-NP O
15 708 709 8092427 , , I-NP O
16 710 717 8092427 placebo NN I-NP O
17 717 718 8092427 - HYPH I-NP O
18 718 728 8092427 controlled VBN B-NP O
19 729 738 8092427 challenge NN I-NP O
20 739 744 8092427 tests NNS I-NP O
21 745 749 8092427 were VBD B-VP O
22 750 754 8092427 done VBN I-VP O
23 755 757 8092427 to TO B-VP O
24 758 764 8092427 ensure VB I-VP O
25 765 774 8092427 tolerance NN B-NP O
26 775 777 8092427 of IN B-PP O
27 778 780 8092427 PG NN B-NP B-Chemical
28 781 783 8092427 or CC I-NP O
29 784 795 8092427 sensitivity NN I-NP O
30 796 798 8092427 to TO B-PP O
31 799 801 8092427 AX NN B-NP B-Chemical
32 801 802 8092427 . . O O

1 803 804 8092427 A DT B-NP O
2 805 810 8092427 total NN I-NP O
3 811 813 8092427 of IN B-PP O
4 814 817 8092427 177 CD B-NP O
5 818 826 8092427 patients NNS I-NP O
6 827 831 8092427 were VBD B-VP O
7 832 841 8092427 diagnosed VBN I-VP O
8 842 844 8092427 as IN B-PP O
9 845 853 8092427 allergic JJ B-ADJP B-Disease
10 854 856 8092427 to TO B-PP O
11 857 861 8092427 beta SYM B-NP B-Chemical
12 861 862 8092427 - HYPH B-NP I-Chemical
13 862 868 8092427 lactam NN I-NP I-Chemical
14 869 880 8092427 antibiotics NNS I-NP O
15 880 881 8092427 . . O O

1 882 884 8092427 We PRP B-NP O
2 885 893 8092427 selected VBD B-VP O
3 894 897 8092427 the DT B-NP O
4 898 900 8092427 54 CD I-NP O
5 901 902 8092427 ( ( O O
6 902 907 8092427 30.5% CD B-NP O
7 907 908 8092427 ) ) O O
8 909 914 8092427 cases NNS B-NP O
9 915 917 8092427 of IN B-PP O
10 918 927 8092427 immediate JJ B-NP O
11 928 930 8092427 AX NN I-NP B-Chemical
12 931 938 8092427 allergy NN I-NP B-Disease
13 939 943 8092427 with IN B-PP O
14 944 948 8092427 good JJ B-NP O
15 949 958 8092427 tolerance NN I-NP O
16 959 961 8092427 of IN B-PP O
17 962 964 8092427 PG NN B-NP B-Chemical
18 964 965 8092427 . . O O

1 966 977 8092427 Anaphylaxis NN B-NP B-Disease
2 978 981 8092427 was VBD B-VP O
3 982 986 8092427 seen VBN I-VP O
4 987 989 8092427 in IN B-PP O
5 990 992 8092427 37 CD B-NP O
6 993 1001 8092427 patients NNS I-NP O
7 1002 1003 8092427 ( ( O O
8 1003 1006 8092427 69% NN B-NP O
9 1006 1007 8092427 ) ) O O
10 1007 1008 8092427 , , O O
11 1009 1012 8092427 the DT B-NP O
12 1013 1018 8092427 other JJ I-NP O
13 1019 1021 8092427 17 CD I-NP O
14 1022 1023 8092427 ( ( O O
15 1023 1026 8092427 31% NN B-NP O
16 1026 1027 8092427 ) ) O O
17 1028 1034 8092427 having VBG B-VP O
18 1035 1044 8092427 urticaria NN B-NP B-Disease
19 1045 1048 8092427 and CC O O
20 1048 1049 8092427 / SYM B-NP O
21 1049 1051 8092427 or CC O O
22 1052 1062 8092427 angioedema NN B-NP B-Disease
23 1062 1063 8092427 . . O O

1 1064 1067 8092427 All PDT B-NP O
2 1068 1071 8092427 the DT I-NP O
3 1072 1080 8092427 patients NNS I-NP O
4 1081 1085 8092427 were VBD B-VP O
5 1086 1090 8092427 skin NN B-NP O
6 1091 1095 8092427 test NN I-NP O
7 1096 1104 8092427 negative JJ B-ADJP O
8 1105 1107 8092427 to TO B-PP O
9 1108 1111 8092427 BPO NN B-NP B-Chemical
10 1111 1112 8092427 ; : O O
11 1113 1115 8092427 49 CD B-NP O
12 1116 1118 8092427 of IN B-PP O
13 1119 1121 8092427 51 CD B-NP O
14 1122 1123 8092427 ( ( O O
15 1123 1126 8092427 96% NN B-NP O
16 1126 1127 8092427 ) ) O O
17 1128 1132 8092427 were VBD B-VP O
18 1133 1137 8092427 also RB B-ADVP O
19 1138 1146 8092427 negative JJ B-ADJP O
20 1147 1149 8092427 to TO B-PP O
21 1150 1153 8092427 MDM NN B-NP B-Disease
22 1153 1154 8092427 , , O O
23 1155 1158 8092427 and CC O O
24 1159 1161 8092427 44 CD B-NP O
25 1162 1164 8092427 of IN B-PP O
26 1165 1167 8092427 46 CD B-NP O
27 1168 1169 8092427 ( ( O O
28 1169 1172 8092427 96% CD B-NP O
29 1172 1173 8092427 ) ) O O
30 1174 1176 8092427 to TO B-PP O
31 1177 1179 8092427 PG NN B-NP B-Chemical
32 1179 1180 8092427 . . O O

1 1181 1185 8092427 Skin NN B-NP O
2 1186 1191 8092427 tests NNS I-NP O
3 1192 1196 8092427 with IN B-PP O
4 1197 1199 8092427 AX NN B-NP B-Chemical
5 1200 1204 8092427 were VBD B-VP O
6 1205 1213 8092427 positive JJ B-ADJP O
7 1214 1216 8092427 in IN B-PP O
8 1217 1219 8092427 34 CD B-NP O
9 1220 1221 8092427 ( ( O O
10 1221 1224 8092427 63% CD B-NP O
11 1224 1225 8092427 ) ) O O
12 1226 1234 8092427 patients NNS B-NP O
13 1234 1235 8092427 . . O O

1 1236 1240 8092427 RAST NN B-NP O
2 1241 1244 8092427 was VBD B-VP O
3 1245 1253 8092427 positive JJ B-ADJP O
4 1254 1257 8092427 for IN B-PP O
5 1258 1260 8092427 AX NN B-NP B-Chemical
6 1261 1263 8092427 in IN B-PP O
7 1264 1266 8092427 22 CD B-NP O
8 1267 1275 8092427 patients NNS I-NP O
9 1276 1277 8092427 ( ( O O
10 1277 1280 8092427 41% NN B-NP O
11 1280 1281 8092427 ) ) O O
12 1282 1285 8092427 and CC O O
13 1286 1288 8092427 to TO B-PP O
14 1289 1292 8092427 BPO NN B-NP B-Chemical
15 1293 1295 8092427 in IN B-PP O
16 1296 1300 8092427 just RB B-NP O
17 1301 1302 8092427 5 CD I-NP O
18 1303 1304 8092427 ( ( O O
19 1304 1306 8092427 9% CD B-NP O
20 1306 1307 8092427 ) ) O O
21 1307 1308 8092427 . . O O

1 1309 1313 8092427 None NN B-NP O
2 1314 1316 8092427 of IN B-PP O
3 1317 1320 8092427 the DT B-NP O
4 1321 1325 8092427 sera NNS I-NP O
5 1326 1330 8092427 with IN B-PP O
6 1331 1339 8092427 negative JJ B-NP O
7 1340 1344 8092427 RAST NN I-NP O
8 1345 1348 8092427 for IN B-PP O
9 1349 1351 8092427 AX NN B-NP B-Chemical
10 1352 1356 8092427 were VBD B-VP O
11 1357 1365 8092427 positive JJ B-ADJP O
12 1366 1368 8092427 to TO B-PP O
13 1369 1372 8092427 BPO NN B-NP B-Chemical
14 1372 1373 8092427 . . O O

1 1374 1383 8092427 Challenge NN B-NP O
2 1384 1389 8092427 tests NNS I-NP O
3 1390 1394 8092427 with IN B-PP O
4 1395 1397 8092427 AX NN B-NP B-Chemical
5 1398 1402 8092427 were VBD B-VP O
6 1403 1412 8092427 performed VBN I-VP O
7 1413 1415 8092427 in IN B-PP O
8 1416 1418 8092427 23 CD B-NP O
9 1419 1427 8092427 subjects NNS I-NP O
10 1428 1429 8092427 ( ( O O
11 1429 1432 8092427 43% CD B-NP O
12 1432 1433 8092427 ) ) O O
13 1434 1436 8092427 to TO B-VP O
14 1437 1446 8092427 establish VB I-VP O
15 1447 1450 8092427 the DT B-NP O
16 1451 1460 8092427 diagnosis NN I-NP O
17 1461 1463 8092427 of IN B-PP O
18 1464 1473 8092427 immediate JJ B-NP O
19 1474 1482 8092427 allergic JJ I-NP B-Disease
20 1483 1491 8092427 reaction NN I-NP I-Disease
21 1492 1494 8092427 to TO B-PP O
22 1495 1497 8092427 AX NN B-NP B-Chemical
23 1497 1498 8092427 , , O O
24 1499 1502 8092427 and CC O O
25 1503 1505 8092427 in IN B-PP O
26 1506 1508 8092427 15 CD B-NP O
27 1509 1514 8092427 cases NNS I-NP O
28 1515 1516 8092427 ( ( O O
29 1516 1519 8092427 28% CD B-NP O
30 1519 1520 8092427 ) ) O O
31 1521 1525 8092427 both CC O O
32 1526 1530 8092427 skin NN B-NP O
33 1531 1535 8092427 test NN I-NP O
34 1536 1539 8092427 and CC O O
35 1540 1544 8092427 RAST NN B-NP O
36 1545 1548 8092427 for IN B-PP O
37 1549 1551 8092427 AX NN B-NP B-Chemical
38 1552 1556 8092427 were VBD B-VP O
39 1557 1565 8092427 negative JJ B-ADJP O
40 1565 1566 8092427 . . O O

1 1567 1569 8092427 PG NN B-NP B-Chemical
2 1570 1573 8092427 was VBD B-VP O
3 1574 1578 8092427 well RB I-VP O
4 1579 1588 8092427 tolerated VBN I-VP O
5 1589 1591 8092427 by IN B-PP O
6 1592 1595 8092427 all DT B-NP O
7 1596 1598 8092427 54 CD I-NP O
8 1599 1607 8092427 patients NNS I-NP O
9 1607 1608 8092427 . . O O

1 1609 1611 8092427 We PRP B-NP O
2 1612 1620 8092427 describe VBP B-VP O
3 1621 1624 8092427 the DT B-NP O
4 1625 1632 8092427 largest JJS I-NP O
5 1633 1638 8092427 group NN I-NP O
6 1639 1641 8092427 of IN B-PP O
7 1642 1644 8092427 AX NN B-NP B-Chemical
8 1644 1645 8092427 - HYPH B-NP O
9 1645 1653 8092427 allergic JJ I-NP B-Disease
10 1654 1662 8092427 patients NNS I-NP O
11 1663 1666 8092427 who WP B-NP O
12 1667 1671 8092427 have VBP B-VP O
13 1672 1681 8092427 tolerated VBN I-VP O
14 1682 1684 8092427 PG NN B-NP B-Chemical
15 1685 1693 8092427 reported VBN B-VP O
16 1694 1696 8092427 so RB B-ADVP O
17 1697 1700 8092427 far RB I-ADVP O
18 1700 1701 8092427 . . O O

1 1702 1711 8092427 Diagnosis NN B-NP O
2 1712 1714 8092427 of IN B-PP O
3 1715 1720 8092427 these DT B-NP O
4 1721 1729 8092427 patients NNS I-NP O
5 1730 1733 8092427 can MD B-VP O
6 1734 1736 8092427 be VB I-VP O
7 1737 1745 8092427 achieved VBN I-VP O
8 1746 1750 8092427 only RB B-ADVP O
9 1751 1753 8092427 if IN B-SBAR O
10 1754 1762 8092427 specific JJ B-NP O
11 1763 1765 8092427 AX NN I-NP B-Chemical
12 1765 1766 8092427 - HYPH B-NP O
13 1766 1773 8092427 related VBN I-NP O
14 1774 1782 8092427 reagents NNS I-NP O
15 1783 1786 8092427 are VBP B-VP O
16 1787 1795 8092427 employed VBN I-VP O
17 1795 1796 8092427 . . O O

1 1797 1804 8092427 Further JJ B-NP O
2 1805 1812 8092427 studies NNS I-NP O
3 1813 1816 8092427 are VBP B-VP O
4 1817 1826 8092427 necessary JJ B-ADJP O
5 1827 1829 8092427 to TO B-VP O
6 1830 1839 8092427 determine VB I-VP O
7 1840 1843 8092427 the DT B-NP O
8 1844 1849 8092427 exact JJ I-NP O
9 1850 1856 8092427 extent NN I-NP O
10 1857 1859 8092427 of IN B-PP O
11 1860 1864 8092427 this DT B-NP O
12 1865 1872 8092427 problem NN I-NP O
13 1873 1876 8092427 and CC O O
14 1877 1879 8092427 to TO B-VP O
15 1880 1887 8092427 improve VB I-VP O
16 1888 1891 8092427 the DT B-NP O
17 1892 1900 8092427 efficacy NN I-NP O
18 1901 1903 8092427 of IN B-PP O
19 1904 1914 8092427 diagnostic JJ B-NP O
20 1915 1922 8092427 methods NNS I-NP O
21 1922 1923 8092427 . . O O

1 0 0 3970039 -DOCSTART- -X- -X- O

1 0 9 3970039 Incidence NN B-NP O
2 10 12 3970039 of IN B-PP O
3 13 22 3970039 neoplasms NNS B-NP B-Disease
4 23 25 3970039 in IN B-PP O
5 26 34 3970039 patients NNS B-NP O
6 35 39 3970039 with IN B-PP O
7 40 50 3970039 rheumatoid JJ B-NP B-Disease
8 51 60 3970039 arthritis NN I-NP I-Disease
9 61 68 3970039 exposed VBN B-VP O
10 69 71 3970039 to TO B-PP O
11 72 81 3970039 different JJ B-NP O
12 82 91 3970039 treatment NN I-NP O
13 92 100 3970039 regimens NNS I-NP O
14 100 101 3970039 . . O O
15 102 119 3970039 Immunosuppressive JJ B-NP O
16 120 125 3970039 drugs NNS I-NP O
17 126 130 3970039 have VBP B-VP O
18 131 135 3970039 been VBN I-VP O
19 136 140 3970039 used VBN I-VP O
20 141 147 3970039 during IN B-PP O
21 148 151 3970039 the DT B-NP O
22 152 156 3970039 last JJ I-NP O
23 157 159 3970039 30 CD I-NP O
24 160 165 3970039 years NNS I-NP O
25 166 168 3970039 in IN B-PP O
26 169 178 3970039 treatment NN B-NP O
27 179 181 3970039 of IN B-PP O
28 182 190 3970039 patients NNS B-NP O
29 191 195 3970039 with IN B-PP O
30 196 202 3970039 severe JJ B-NP O
31 203 213 3970039 rheumatoid JJ I-NP B-Disease
32 214 223 3970039 arthritis NN I-NP I-Disease
33 223 224 3970039 . . O O

1 225 228 3970039 The DT B-NP O
2 229 234 3970039 drugs NNS I-NP O
3 235 243 3970039 commonly RB B-VP O
4 244 248 3970039 used VBN I-VP O
5 249 252 3970039 are VBP B-VP O
6 253 269 3970039 cyclophosphamide NN B-NP B-Chemical
7 270 273 3970039 and CC O O
8 274 286 3970039 chlorambucil NN B-NP B-Chemical
9 287 288 3970039 ( ( O O
10 288 298 3970039 alkylating VBG B-NP B-Chemical
11 299 305 3970039 agents NNS I-NP I-Chemical
12 305 306 3970039 ) ) O O
13 306 307 3970039 , , O O
14 308 320 3970039 azathioprine NN B-NP B-Chemical
15 321 322 3970039 ( ( O O
16 322 328 3970039 purine NN B-NP B-Chemical
17 329 337 3970039 analogue NN I-NP O
18 337 338 3970039 ) ) O O
19 338 339 3970039 , , O O
20 340 343 3970039 and CC O O
21 344 356 3970039 methotrexate NN B-NP B-Chemical
22 357 358 3970039 ( ( O O
23 358 363 3970039 folic JJ B-NP B-Chemical
24 364 368 3970039 acid NN I-NP I-Chemical
25 369 377 3970039 analogue NN I-NP O
26 377 378 3970039 ) ) O O
27 378 379 3970039 . . O O

1 380 385 3970039 There EX B-NP O
2 386 388 3970039 is VBZ B-VP O
3 389 397 3970039 evidence NN B-NP O
4 398 402 3970039 that IN B-SBAR O
5 403 406 3970039 all DT B-NP O
6 407 411 3970039 four CD I-NP O
7 412 429 3970039 immunosuppressive JJ I-NP O
8 430 435 3970039 drugs NNS I-NP O
9 436 439 3970039 can MD B-VP O
10 440 446 3970039 reduce VB I-VP O
11 447 456 3970039 synovitis NN B-NP B-Disease
12 456 457 3970039 , , O O
13 458 461 3970039 but CC O O
14 462 469 3970039 disease NN B-NP O
15 470 478 3970039 activity NN I-NP O
16 479 485 3970039 almost RB B-ADVP O
17 486 492 3970039 always RB I-ADVP O
18 493 499 3970039 recurs VBZ B-VP O
19 500 505 3970039 after IN B-SBAR O
20 506 513 3970039 therapy NN B-NP O
21 514 516 3970039 is VBZ B-VP O
22 517 524 3970039 stopped VBN I-VP O
23 524 525 3970039 . . O O

1 526 531 3970039 Since IN B-SBAR O
2 532 539 3970039 adverse JJ B-NP O
3 540 549 3970039 reactions NNS I-NP O
4 550 553 3970039 are VBP B-VP O
5 554 562 3970039 frequent JJ B-ADJP O
6 562 563 3970039 , , O O
7 564 568 3970039 less JJR B-NP O
8 569 573 3970039 than IN I-NP O
9 574 576 3970039 50 CD I-NP O
10 577 584 3970039 percent NN I-NP O
11 585 587 3970039 of IN B-PP O
12 588 596 3970039 patients NNS B-NP O
13 597 600 3970039 are VBP B-VP O
14 601 605 3970039 able JJ B-ADJP O
15 606 608 3970039 to TO B-VP O
16 609 617 3970039 continue VB I-VP O
17 618 619 3970039 a DT B-NP O
18 620 630 3970039 particular JJ I-NP O
19 631 635 3970039 drug NN I-NP O
20 636 639 3970039 for IN B-PP O
21 640 644 3970039 more JJR B-NP O
22 645 649 3970039 than IN I-NP O
23 650 653 3970039 one CD I-NP O
24 654 658 3970039 year NN I-NP O
25 658 659 3970039 . . O O

1 660 665 3970039 Since IN B-SBAR O
2 666 668 3970039 it PRP B-NP O
3 669 674 3970039 takes VBZ B-VP O
4 675 680 3970039 three CD B-NP O
5 681 683 3970039 to TO I-NP O
6 684 686 3970039 12 CD I-NP O
7 687 693 3970039 months NNS I-NP O
8 694 696 3970039 to TO B-VP O
9 697 704 3970039 achieve VB I-VP O
10 705 712 3970039 maximal JJ B-NP O
11 713 720 3970039 effects NNS I-NP O
12 720 721 3970039 , , O O
13 722 727 3970039 those DT B-NP O
14 728 736 3970039 patients NNS I-NP O
15 737 740 3970039 who WP B-NP O
16 741 744 3970039 are VBP B-VP O
17 745 751 3970039 unable JJ B-ADJP O
18 752 754 3970039 to TO B-VP O
19 755 763 3970039 continue VB I-VP O
20 764 767 3970039 the DT B-NP O
21 768 772 3970039 drug NN I-NP O
22 773 780 3970039 receive VB B-VP O
23 781 787 3970039 little JJ B-NP O
24 788 795 3970039 benefit NN I-NP O
25 796 800 3970039 from IN B-PP O
26 801 803 3970039 it PRP B-NP O
27 803 804 3970039 . . O O

1 805 813 3970039 Patients NNS B-NP O
2 814 821 3970039 treated VBN B-VP O
3 822 826 3970039 with IN B-PP O
4 827 837 3970039 alkylating VBG B-NP B-Chemical
5 838 844 3970039 agents NNS I-NP I-Chemical
6 845 849 3970039 have VBP B-VP O
7 850 852 3970039 an DT B-NP O
8 853 862 3970039 increased VBN I-NP O
9 863 867 3970039 risk NN I-NP O
10 868 870 3970039 of IN B-PP O
11 871 882 3970039 development NN B-NP O
12 883 885 3970039 of IN B-PP O
13 886 891 3970039 acute JJ B-NP B-Disease
14 892 906 3970039 nonlymphocytic JJ I-NP I-Disease
15 907 915 3970039 leukemia NN I-NP I-Disease
16 915 916 3970039 , , O O
17 917 920 3970039 and CC O O
18 921 925 3970039 both DT B-NP O
19 926 936 3970039 alkylating VBG I-NP B-Chemical
20 937 943 3970039 agents NNS I-NP I-Chemical
21 944 947 3970039 and CC O O
22 948 960 3970039 azathioprine NN B-NP B-Chemical
23 961 964 3970039 are VBP B-VP O
24 965 975 3970039 associated VBN I-VP O
25 976 980 3970039 with IN B-PP O
26 981 984 3970039 the DT B-NP O
27 985 996 3970039 development NN I-NP O
28 997 999 3970039 of IN B-PP O
29 1000 1003 3970039 non AFX B-NP B-Disease
30 1003 1004 3970039 - HYPH I-NP I-Disease
31 1004 1013 3970039 Hodgkin's NNS I-NP I-Disease
32 1014 1022 3970039 lymphoma NN I-NP I-Disease
33 1022 1023 3970039 . . O O

1 1024 1040 3970039 Cyclophosphamide NN B-NP B-Chemical
2 1041 1048 3970039 therapy NN I-NP O
3 1049 1058 3970039 increases VBZ B-VP O
4 1059 1062 3970039 the DT B-NP O
5 1063 1067 3970039 risk NN I-NP O
6 1068 1070 3970039 of IN B-PP O
7 1071 1080 3970039 carcinoma NN B-NP B-Disease
8 1081 1083 3970039 of IN B-PP I-Disease
9 1084 1087 3970039 the DT B-NP I-Disease
10 1088 1095 3970039 bladder NN I-NP I-Disease
11 1095 1096 3970039 . . O O

1 1097 1102 3970039 There EX B-NP O
2 1103 1107 3970039 have VBP B-VP O
3 1108 1112 3970039 been VBN I-VP O
4 1113 1120 3970039 several JJ B-NP O
5 1121 1125 3970039 long JJ I-NP O
6 1125 1126 3970039 - HYPH I-NP O
7 1126 1130 3970039 term NN I-NP O
8 1131 1138 3970039 studies NNS I-NP O
9 1139 1141 3970039 of IN B-PP O
10 1142 1150 3970039 patients NNS B-NP O
11 1151 1155 3970039 with IN B-PP O
12 1156 1166 3970039 rheumatoid JJ B-NP B-Disease
13 1167 1176 3970039 arthritis NN I-NP I-Disease
14 1177 1184 3970039 treated VBN B-VP O
15 1185 1189 3970039 with IN B-PP O
16 1190 1202 3970039 azathioprine NN B-NP B-Chemical
17 1203 1206 3970039 and CC I-NP O
18 1207 1223 3970039 cyclophosphamide NN I-NP B-Chemical
19 1224 1227 3970039 and CC O O
20 1228 1231 3970039 the DT B-NP O
21 1232 1241 3970039 incidence NN I-NP O
22 1242 1244 3970039 of IN B-PP O
23 1245 1249 3970039 most JJS B-NP O
24 1250 1252 3970039 of IN B-PP O
25 1253 1256 3970039 the DT B-NP O
26 1257 1263 3970039 common JJ I-NP O
27 1264 1271 3970039 cancers NNS I-NP B-Disease
28 1272 1274 3970039 is VBZ B-VP O
29 1275 1278 3970039 not RB I-VP O
30 1279 1288 3970039 increased VBN I-VP O
31 1288 1289 3970039 . . O O

1 1290 1294 3970039 Data NNS B-NP O
2 1295 1297 3970039 on IN B-PP O
3 1298 1301 3970039 the DT B-NP O
4 1302 1310 3970039 possible JJ I-NP O
5 1311 1320 3970039 increased VBN I-NP O
6 1321 1325 3970039 risk NN I-NP O
7 1326 1328 3970039 of IN B-PP O
8 1329 1339 3970039 malignancy NN B-NP B-Disease
9 1340 1342 3970039 in IN B-PP O
10 1343 1353 3970039 rheumatoid JJ B-NP B-Disease
11 1354 1363 3970039 arthritis NN I-NP I-Disease
12 1364 1367 3970039 are VBP B-VP O
13 1368 1373 3970039 still RB I-VP O
14 1374 1379 3970039 being VBG I-VP O
15 1380 1389 3970039 collected VBN I-VP O
16 1389 1390 3970039 , , O O
17 1391 1394 3970039 and CC O O
18 1395 1400 3970039 until IN B-SBAR O
19 1401 1408 3970039 further JJ B-NP O
20 1409 1420 3970039 information NN I-NP O
21 1421 1423 3970039 is VBZ B-VP O
22 1424 1433 3970039 available JJ B-ADJP O
23 1433 1434 3970039 , , O O
24 1435 1438 3970039 the DT B-NP O
25 1439 1442 3970039 use NN I-NP O
26 1443 1445 3970039 of IN B-PP O
27 1446 1463 3970039 immunosuppressive JJ B-NP O
28 1464 1469 3970039 drugs NNS I-NP O
29 1469 1470 3970039 , , O O
30 1471 1483 3970039 particularly RB B-ADVP O
31 1484 1494 3970039 alkylating VBG B-VP B-Chemical
32 1495 1501 3970039 agents NNS B-NP I-Chemical
33 1501 1502 3970039 , , O O
34 1503 1505 3970039 in IN B-PP O
35 1506 1509 3970039 the DT B-NP O
36 1510 1519 3970039 treatment NN I-NP O
37 1520 1522 3970039 of IN B-PP O
38 1523 1533 3970039 rheumatoid JJ B-NP B-Disease
39 1534 1543 3970039 arthritis NN I-NP I-Disease
40 1544 1550 3970039 should MD B-VP O
41 1551 1553 3970039 be VB I-VP O
42 1554 1562 3970039 reserved VBN I-VP O
43 1563 1566 3970039 for IN B-PP O
44 1567 1575 3970039 patients NNS B-NP O
45 1576 1580 3970039 with IN B-PP O
46 1581 1587 3970039 severe JJ B-NP O
47 1588 1599 3970039 progressive JJ I-NP O
48 1600 1607 3970039 disease NN I-NP O
49 1608 1610 3970039 or CC O O
50 1611 1615 3970039 life NN B-NP O
51 1615 1616 3970039 - HYPH O O
52 1616 1627 3970039 threatening VBG B-VP O
53 1628 1641 3970039 complications NNS B-NP O
54 1641 1642 3970039 . . O O

1 0 0 18410508 -DOCSTART- -X- -X- O

1 0 15 18410508 Methamphetamine NN B-NP B-Chemical
2 15 16 18410508 - HYPH B-PP O
3 16 23 18410508 induced VBN B-NP O
4 24 37 18410508 neurotoxicity NN I-NP B-Disease
5 38 41 18410508 and CC O O
6 42 52 18410508 microglial JJ B-NP O
7 53 63 18410508 activation NN I-NP O
8 64 67 18410508 are VBP B-VP O
9 68 71 18410508 not RB I-VP O
10 72 80 18410508 mediated VBN I-VP O
11 81 83 18410508 by IN B-PP O
12 84 95 18410508 fractalkine NN B-NP O
13 96 104 18410508 receptor NN I-NP O
14 105 114 18410508 signaling NN I-NP O
15 114 115 18410508 . . O O
16 116 131 18410508 Methamphetamine NN B-NP B-Chemical
17 132 133 18410508 ( ( O O
18 133 137 18410508 METH NN B-NP B-Chemical
19 137 138 18410508 ) ) O O
20 139 146 18410508 damages NNS B-NP O
21 147 155 18410508 dopamine NN I-NP B-Chemical
22 156 157 18410508 ( ( O O
23 157 159 18410508 DA NN B-NP B-Chemical
24 159 160 18410508 ) ) O O
25 161 166 18410508 nerve NN B-NP O
26 167 174 18410508 endings NNS I-NP O
27 175 177 18410508 by IN B-PP O
28 178 179 18410508 a DT B-NP O
29 180 187 18410508 process NN I-NP O
30 188 192 18410508 that WDT B-NP O
31 193 196 18410508 has VBZ B-VP O
32 197 201 18410508 been VBN I-VP O
33 202 208 18410508 linked VBN I-VP O
34 209 211 18410508 to TO B-PP O
35 212 222 18410508 microglial JJ B-NP O
36 223 233 18410508 activation NN I-NP O
37 234 237 18410508 but CC O O
38 238 241 18410508 the DT B-NP O
39 242 251 18410508 signaling NN I-NP O
40 252 260 18410508 pathways NNS I-NP O
41 261 265 18410508 that WDT B-NP O
42 266 273 18410508 mediate VBP B-VP O
43 274 278 18410508 this DT B-NP O
44 279 287 18410508 response NN I-NP O
45 288 292 18410508 have VBP B-VP O
46 293 296 18410508 not RB I-VP O
47 297 300 18410508 yet RB I-VP O
48 301 305 18410508 been VBN I-VP O
49 306 316 18410508 delineated VBN I-VP O
50 316 317 18410508 . . O O

1 318 325 18410508 Cardona NNP B-NP O
2 326 328 18410508 et FW I-NP O
3 329 332 18410508 al. FW I-NP O
4 333 334 18410508 [ ( O O
5 334 337 18410508 Nat NNP B-NP O
6 337 338 18410508 . . O O

1 339 347 18410508 Neurosci NNP B-NP O
2 347 348 18410508 . . I-NP O
3 349 350 18410508 9 CD I-NP O
4 351 352 18410508 ( ( O O
5 352 356 18410508 2006 CD B-NP O
6 356 357 18410508 ) ) O O
7 357 358 18410508 , , O O
8 359 362 18410508 917 CD B-NP O
9 362 363 18410508 ] ) O O
10 364 372 18410508 recently RB B-ADVP O
11 373 383 18410508 identified VBD B-VP O
12 384 387 18410508 the DT B-NP O
13 388 398 18410508 microglial JJ I-NP O
14 398 399 18410508 - HYPH I-NP O
15 399 407 18410508 specific JJ I-NP O
16 408 419 18410508 fractalkine NN I-NP O
17 420 428 18410508 receptor NN I-NP O
18 429 430 18410508 ( ( O O
19 430 436 18410508 CX3CR1 NN B-NP O
20 436 437 18410508 ) ) O O
21 438 440 18410508 as IN B-PP O
22 441 443 18410508 an DT B-NP O
23 444 453 18410508 important JJ I-NP O
24 454 462 18410508 mediator NN I-NP O
25 463 465 18410508 of IN B-PP O
26 466 470 18410508 MPTP NN B-NP B-Chemical
27 470 471 18410508 - HYPH B-NP O
28 471 478 18410508 induced VBN I-NP O
29 479 496 18410508 neurodegeneration NN I-NP B-Disease
30 497 499 18410508 of IN B-PP O
31 500 502 18410508 DA NN B-NP B-Chemical
32 503 510 18410508 neurons NNS I-NP O
33 510 511 18410508 . . O O

1 512 519 18410508 Because IN B-SBAR O
2 520 523 18410508 the DT B-NP O
3 524 527 18410508 CNS NN I-NP B-Disease
4 528 534 18410508 damage NN I-NP I-Disease
5 535 541 18410508 caused VBN B-VP O
6 542 544 18410508 by IN B-PP O
7 545 549 18410508 METH NN B-NP B-Chemical
8 550 553 18410508 and CC I-NP O
9 554 558 18410508 MPTP NN I-NP B-Chemical
10 559 561 18410508 is VBZ B-VP O
11 562 568 18410508 highly RB B-ADJP O
12 569 578 18410508 selective JJ I-ADJP O
13 579 582 18410508 for IN B-PP O
14 583 586 18410508 the DT B-NP O
15 587 589 18410508 DA NN I-NP B-Chemical
16 590 598 18410508 neuronal JJ I-NP O
17 599 605 18410508 system NN I-NP O
18 606 608 18410508 in IN B-PP O
19 609 614 18410508 mouse NN B-NP O
20 615 621 18410508 models NNS I-NP O
21 622 624 18410508 of IN B-PP O
22 625 638 18410508 neurotoxicity NN B-NP B-Disease
23 638 639 18410508 , , O O
24 640 642 18410508 we PRP B-NP O
25 643 655 18410508 hypothesized VBD B-VP O
26 656 660 18410508 that IN B-SBAR O
27 661 664 18410508 the DT B-NP O
28 665 671 18410508 CX3CR1 NN I-NP O
29 672 677 18410508 plays VBZ B-VP O
30 678 679 18410508 a DT B-NP O
31 680 684 18410508 role NN I-NP O
32 685 687 18410508 in IN B-PP O
33 688 692 18410508 METH NN B-NP B-Chemical
34 692 693 18410508 - HYPH B-NP O
35 693 700 18410508 induced VBN I-NP O
36 701 714 18410508 neurotoxicity NN I-NP B-Disease
37 715 718 18410508 and CC O O
38 719 729 18410508 microglial JJ B-NP O
39 730 740 18410508 activation NN I-NP O
40 740 741 18410508 . . O O

1 742 746 18410508 Mice NNS B-NP O
2 747 749 18410508 in IN B-PP O
3 750 755 18410508 which WDT B-NP O
4 756 759 18410508 the DT B-NP O
5 760 766 18410508 CX3CR1 NN I-NP O
6 767 771 18410508 gene NN I-NP O
7 772 775 18410508 has VBZ B-VP O
8 776 780 18410508 been VBN I-VP O
9 781 788 18410508 deleted VBN I-VP O
10 789 792 18410508 and CC O O
11 793 801 18410508 replaced VBN B-VP O
12 802 806 18410508 with IN B-PP O
13 807 808 18410508 a DT B-NP O
14 809 813 18410508 cDNA NN I-NP O
15 814 822 18410508 encoding NN I-NP O
16 823 831 18410508 enhanced VBD B-VP O
17 832 837 18410508 green JJ B-NP O
18 838 849 18410508 fluorescent JJ I-NP O
19 850 857 18410508 protein NN I-NP O
20 858 859 18410508 ( ( O O
21 859 863 18410508 eGFP NN B-NP O
22 863 864 18410508 ) ) O O
23 865 869 18410508 were VBD B-VP O
24 870 877 18410508 treated VBN I-VP O
25 878 882 18410508 with IN B-PP O
26 883 887 18410508 METH NN B-NP B-Chemical
27 888 891 18410508 and CC O O
28 892 900 18410508 examined VBN B-VP O
29 901 904 18410508 for IN B-PP O
30 905 913 18410508 striatal JJ B-NP O
31 914 927 18410508 neurotoxicity NN I-NP B-Disease
32 927 928 18410508 . . O O

1 929 933 18410508 METH NN B-NP B-Chemical
2 934 942 18410508 depleted VBD B-VP O
3 943 945 18410508 DA NNP B-NP B-Chemical
4 945 946 18410508 , , O O
5 947 953 18410508 caused VBD B-VP O
6 954 964 18410508 microglial JJ B-NP O
7 965 975 18410508 activation NN I-NP O
8 975 976 18410508 , , O O
9 977 980 18410508 and CC O O
10 981 990 18410508 increased VBD B-VP O
11 991 995 18410508 body NN B-NP O
12 996 1007 18410508 temperature NN I-NP O
13 1008 1010 18410508 in IN B-PP O
14 1011 1017 18410508 CX3CR1 NN B-NP O
15 1018 1026 18410508 knockout NN I-NP O
16 1027 1031 18410508 mice NNS I-NP O
17 1032 1034 18410508 to TO B-PP O
18 1035 1038 18410508 the DT B-NP O
19 1039 1043 18410508 same JJ I-NP O
20 1044 1050 18410508 extent NN I-NP O
21 1051 1054 18410508 and CC O O
22 1055 1059 18410508 over IN B-PP O
23 1060 1063 18410508 the DT B-NP O
24 1064 1068 18410508 same JJ I-NP O
25 1069 1073 18410508 time NN I-NP O
26 1074 1080 18410508 course NN I-NP O
27 1081 1085 18410508 seen VBN B-VP O
28 1086 1088 18410508 in IN B-PP O
29 1089 1093 18410508 wild JJ B-NP O
30 1093 1094 18410508 - HYPH I-NP O
31 1094 1098 18410508 type NN I-NP O
32 1099 1107 18410508 controls NNS I-NP O
33 1107 1108 18410508 . . O O

1 1109 1112 18410508 The DT B-NP O
2 1113 1120 18410508 effects NNS I-NP O
3 1121 1123 18410508 of IN B-PP O
4 1124 1128 18410508 METH NN B-NP B-Chemical
5 1129 1131 18410508 in IN B-PP O
6 1132 1138 18410508 CX3CR1 NN B-NP O
7 1139 1147 18410508 knockout NN I-NP O
8 1148 1152 18410508 mice NNS I-NP O
9 1153 1157 18410508 were VBD B-VP O
10 1158 1161 18410508 not RB O O
11 1162 1168 18410508 gender NN B-NP O
12 1168 1169 18410508 - HYPH B-ADJP O
13 1169 1178 18410508 dependent JJ I-ADJP O
14 1179 1182 18410508 and CC O O
15 1183 1186 18410508 did VBD B-VP O
16 1187 1190 18410508 not RB I-VP O
17 1191 1197 18410508 extend VB I-VP O
18 1198 1204 18410508 beyond IN B-PP O
19 1205 1208 18410508 the DT B-NP O
20 1209 1217 18410508 striatum NN I-NP O
21 1217 1218 18410508 . . O O

1 1219 1227 18410508 Striatal JJ B-NP O
2 1228 1237 18410508 microglia NNS I-NP O
3 1238 1248 18410508 expressing VBG B-VP O
4 1249 1253 18410508 eGFP NN B-NP O
5 1254 1268 18410508 constitutively RB B-VP O
6 1269 1273 18410508 show VBP I-VP O
7 1274 1287 18410508 morphological JJ B-NP O
8 1288 1295 18410508 changes NNS I-NP O
9 1296 1301 18410508 after IN B-PP O
10 1302 1306 18410508 METH NN B-NP B-Chemical
11 1307 1311 18410508 that WDT B-NP O
12 1312 1315 18410508 are VBP B-VP O
13 1316 1330 18410508 characteristic JJ B-ADJP O
14 1331 1333 18410508 of IN B-PP O
15 1334 1344 18410508 activation NN B-NP O
16 1344 1345 18410508 . . O O

1 1346 1350 18410508 This DT B-NP O
2 1351 1359 18410508 response NN I-NP O
3 1360 1363 18410508 was VBD B-VP O
4 1364 1374 18410508 restricted JJ B-ADJP O
5 1375 1377 18410508 to TO B-PP O
6 1378 1381 18410508 the DT B-NP O
7 1382 1390 18410508 striatum NN I-NP O
8 1391 1394 18410508 and CC O O
9 1395 1405 18410508 contrasted VBN B-VP O
10 1406 1413 18410508 sharply RB B-ADVP O
11 1414 1418 18410508 with IN B-PP O
12 1419 1431 18410508 unresponsive JJ B-NP O
13 1432 1436 18410508 eGFP NN I-NP O
14 1436 1437 18410508 - HYPH B-NP O
15 1437 1446 18410508 microglia NN I-NP O
16 1447 1449 18410508 in IN B-PP O
17 1450 1461 18410508 surrounding VBG B-VP O
18 1462 1467 18410508 brain NN B-NP O
19 1468 1473 18410508 areas NNS I-NP O
20 1474 1478 18410508 that WDT B-NP O
21 1479 1482 18410508 are VBP B-VP O
22 1483 1486 18410508 not RB I-VP O
23 1487 1494 18410508 damaged VBN I-VP O
24 1495 1497 18410508 by IN B-PP O
25 1498 1502 18410508 METH NN B-NP B-Chemical
26 1502 1503 18410508 . . O O

1 1504 1506 18410508 We PRP B-NP O
2 1507 1515 18410508 conclude VBP B-VP O
3 1516 1520 18410508 from IN B-PP O
4 1521 1526 18410508 these DT B-NP O
5 1527 1534 18410508 studies NNS I-NP O
6 1535 1539 18410508 that IN B-NP O
7 1540 1546 18410508 CX3CR1 NN B-NP O
8 1547 1556 18410508 signaling NN I-NP O
9 1557 1561 18410508 does VBZ B-VP O
10 1562 1565 18410508 not RB I-VP O
11 1566 1574 18410508 modulate VB I-VP O
12 1575 1579 18410508 METH NN B-NP B-Chemical
13 1580 1593 18410508 neurotoxicity NN I-NP B-Disease
14 1594 1596 18410508 or CC O O
15 1597 1607 18410508 microglial JJ B-NP O
16 1608 1618 18410508 activation NN I-NP O
17 1618 1619 18410508 . . O O

1 1620 1631 18410508 Furthermore RB B-ADVP O
2 1631 1632 18410508 , , O O
3 1633 1635 18410508 it PRP B-NP O
4 1636 1643 18410508 appears VBZ B-VP O
5 1644 1648 18410508 that IN B-SBAR O
6 1649 1657 18410508 striatal JJ B-NP O
7 1657 1658 18410508 - HYPH I-NP O
8 1658 1666 18410508 resident JJ I-NP O
9 1667 1676 18410508 microglia NNS I-NP O
10 1677 1684 18410508 respond VBP B-VP O
11 1685 1687 18410508 to TO B-PP O
12 1688 1692 18410508 METH NN B-NP B-Chemical
13 1693 1697 18410508 with IN B-PP O
14 1698 1700 18410508 an DT B-NP O
15 1701 1711 18410508 activation NN I-NP O
16 1712 1719 18410508 cascade NN I-NP O
17 1720 1723 18410508 and CC O O
18 1724 1728 18410508 then RB B-VP O
19 1729 1735 18410508 return VB I-VP O
20 1736 1738 18410508 to TO B-PP O
21 1739 1740 18410508 a DT B-NP O
22 1741 1750 18410508 surveying VBG I-NP O
23 1751 1756 18410508 state NN I-NP O
24 1757 1764 18410508 without IN B-PP O
25 1765 1775 18410508 undergoing VBG B-VP O
26 1776 1785 18410508 apoptosis NN B-NP O
27 1786 1788 18410508 or CC I-NP O
28 1789 1798 18410508 migration NN I-NP O
29 1798 1799 18410508 . . O O

1 0 0 12084448 -DOCSTART- -X- -X- O

1 0 10 12084448 Ifosfamide NN B-NP B-Chemical
2 11 25 12084448 encephalopathy NN I-NP B-Disease
3 26 36 12084448 presenting VBG B-VP O
4 37 41 12084448 with IN B-PP O
5 42 51 12084448 asterixis NN B-NP B-Disease
6 51 52 12084448 . . O O
7 53 56 12084448 CNS NN B-NP O
8 57 62 12084448 toxic JJ I-NP O
9 63 70 12084448 effects NNS I-NP O
10 71 73 12084448 of IN B-PP O
11 74 77 12084448 the DT B-NP O
12 78 92 12084448 antineoplastic JJ I-NP O
13 93 98 12084448 agent NN I-NP O
14 99 109 12084448 ifosfamide NN I-NP B-Chemical
15 110 111 12084448 ( ( O O
16 111 114 12084448 IFX NN B-NP B-Chemical
17 114 115 12084448 ) ) O O
18 116 119 12084448 are VBP B-VP O
19 120 128 12084448 frequent JJ B-ADJP O
20 129 132 12084448 and CC O O
21 133 140 12084448 include VBP B-VP O
22 141 142 12084448 a DT B-NP O
23 143 150 12084448 variety NN I-NP O
24 151 153 12084448 of IN B-PP O
25 154 166 12084448 neurological JJ B-NP O
26 167 175 12084448 symptoms NNS I-NP O
27 176 180 12084448 that WDT B-NP O
28 181 184 12084448 can MD B-VP O
29 185 190 12084448 limit VB I-VP O
30 191 195 12084448 drug NN B-NP O
31 196 199 12084448 use NN I-NP O
32 199 200 12084448 . . O O

1 201 203 12084448 We PRP B-NP O
2 204 210 12084448 report VBP B-VP O
3 211 212 12084448 a DT B-NP O
4 213 217 12084448 case NN I-NP O
5 218 220 12084448 of IN B-PP O
6 221 222 12084448 a DT B-NP O
7 223 225 12084448 51 CD I-NP O
8 225 226 12084448 - HYPH I-NP O
9 226 230 12084448 year NN I-NP O
10 230 231 12084448 - HYPH B-NP O
11 231 234 12084448 old JJ I-NP O
12 235 238 12084448 man NN I-NP O
13 239 242 12084448 who WP B-NP O
14 243 252 12084448 developed VBD B-VP O
15 253 259 12084448 severe JJ B-ADJP O
16 259 260 12084448 , , O O
17 261 270 12084448 disabling VBG B-VP O
18 271 279 12084448 negative JJ B-NP O
19 280 289 12084448 myoclonus NN I-NP B-Disease
20 290 292 12084448 of IN B-PP O
21 293 296 12084448 the DT B-NP O
22 297 302 12084448 upper JJ I-NP O
23 303 306 12084448 and CC I-NP O
24 307 312 12084448 lower JJR I-NP O
25 313 324 12084448 extremities NNS I-NP O
26 325 330 12084448 after IN B-PP O
27 331 334 12084448 the DT B-NP O
28 335 343 12084448 infusion NN I-NP O
29 344 346 12084448 of IN B-PP O
30 347 357 12084448 ifosfamide NN B-NP B-Chemical
31 358 361 12084448 for IN B-PP O
32 362 374 12084448 plasmacytoma NN B-NP B-Disease
33 374 375 12084448 . . O O

1 376 378 12084448 He PRP B-NP O
2 379 382 12084448 was VBD B-VP O
3 383 388 12084448 awake NN B-NP O
4 388 389 12084448 , , O O
5 390 398 12084448 revealed VBD B-VP O
6 399 401 12084448 no DT B-NP O
7 402 409 12084448 changes NNS I-NP O
8 410 412 12084448 of IN B-PP O
9 413 419 12084448 mental JJ B-NP O
10 420 426 12084448 status NN I-NP O
11 427 430 12084448 and CC B-PP O
12 431 433 12084448 at IN B-PP O
13 434 438 12084448 rest NN B-NP O
14 439 444 12084448 there EX B-NP O
15 445 449 12084448 were VBD B-VP O
16 450 452 12084448 no DT B-NP O
17 453 460 12084448 further JJ I-NP O
18 461 466 12084448 motor NN I-NP O
19 467 475 12084448 symptoms NNS I-NP O
20 475 476 12084448 . . O O

1 477 484 12084448 Cranial JJ B-NP O
2 485 493 12084448 magnetic JJ I-NP O
3 494 503 12084448 resonance NN I-NP O
4 504 511 12084448 imaging NN I-NP O
5 512 515 12084448 and CC O O
6 516 525 12084448 extensive JJ B-NP O
7 526 536 12084448 laboratory NN I-NP O
8 537 544 12084448 studies NNS I-NP O
9 545 551 12084448 failed VBD B-VP O
10 552 554 12084448 to TO I-VP O
11 555 561 12084448 reveal VB I-VP O
12 562 572 12084448 structural JJ B-NP B-Disease
13 573 580 12084448 lesions NNS I-NP I-Disease
14 581 583 12084448 of IN B-PP I-Disease
15 584 587 12084448 the DT B-NP I-Disease
16 588 593 12084448 brain NN I-NP I-Disease
17 594 597 12084448 and CC I-NP O
18 598 607 12084448 metabolic JJ I-NP B-Disease
19 608 621 12084448 abnormalities NNS I-NP I-Disease
20 621 622 12084448 . . O O

1 623 625 12084448 An DT B-NP O
2 626 646 12084448 electroencephalogram NN I-NP O
3 647 653 12084448 showed VBD B-VP O
4 654 664 12084448 continuous JJ B-ADJP O
5 664 665 12084448 , , O O
6 666 677 12084448 generalized VBN B-VP O
7 678 687 12084448 irregular JJ B-NP O
8 688 695 12084448 slowing NN I-NP O
9 696 700 12084448 with IN B-PP O
10 701 708 12084448 admixed VBN B-NP O
11 709 717 12084448 periodic JJ I-NP O
12 718 727 12084448 triphasic JJ I-NP O
13 728 733 12084448 waves NNS I-NP O
14 734 744 12084448 indicating VBG B-VP O
15 745 756 12084448 symptomatic JJ B-NP O
16 757 771 12084448 encephalopathy NN I-NP B-Disease
17 771 772 12084448 . . O O

1 773 776 12084448 The DT B-NP O
2 777 791 12084448 administration NN I-NP O
3 792 794 12084448 of IN B-PP O
4 795 805 12084448 ifosfamide NN B-NP B-Chemical
5 806 809 12084448 was VBD B-VP O
6 810 822 12084448 discontinued VBN I-VP O
7 823 826 12084448 and CC O O
8 827 833 12084448 within IN B-PP O
9 834 836 12084448 12 CD B-NP O
10 837 838 12084448 h NN I-NP O
11 839 842 12084448 the DT B-NP O
12 843 852 12084448 asterixis NN I-NP B-Disease
13 853 861 12084448 resolved VBD B-VP O
14 862 872 12084448 completely RB B-ADVP O
15 872 873 12084448 . . O O

1 874 876 12084448 In IN B-PP O
2 877 880 12084448 the DT B-NP O
3 881 888 12084448 patient NN I-NP O
4 889 898 12084448 described VBN B-VP O
5 898 899 12084448 , , O O
6 900 903 12084448 the DT B-NP O
7 904 912 12084448 presence NN I-NP O
8 913 915 12084448 of IN B-PP O
9 916 925 12084448 asterixis NN B-NP B-Disease
10 926 932 12084448 during IN B-PP O
11 933 941 12084448 infusion NN B-NP O
12 942 944 12084448 of IN B-PP O
13 945 955 12084448 ifosfamide NN B-NP B-Chemical
14 955 956 12084448 , , O O
15 957 963 12084448 normal JJ B-NP O
16 964 974 12084448 laboratory NN I-NP O
17 975 983 12084448 findings NNS I-NP O
18 984 987 12084448 and CC O O
19 988 995 12084448 imaging NN B-NP O
20 996 1003 12084448 studies NNS I-NP O
21 1004 1007 12084448 and CC O O
22 1008 1011 12084448 the DT B-NP O
23 1012 1022 12084448 resolution NN I-NP O
24 1023 1025 12084448 of IN B-PP O
25 1026 1034 12084448 symptoms NNS B-NP O
26 1035 1044 12084448 following VBG B-PP O
27 1045 1048 12084448 the DT B-NP O
28 1049 1064 12084448 discontinuation NN I-NP O
29 1065 1067 12084448 of IN B-PP O
30 1068 1071 12084448 the DT B-NP O
31 1072 1076 12084448 drug NN I-NP O
32 1077 1084 12084448 suggest VBP B-VP O
33 1085 1089 12084448 that IN B-SBAR O
34 1090 1098 12084448 negative JJ B-NP O
35 1099 1108 12084448 myoclonus NN I-NP B-Disease
36 1109 1111 12084448 is VBZ B-VP O
37 1112 1122 12084448 associated VBN I-VP O
38 1123 1127 12084448 with IN B-PP O
39 1128 1131 12084448 the DT B-NP O
40 1132 1135 12084448 use NN I-NP O
41 1136 1138 12084448 of IN B-PP O
42 1139 1142 12084448 IFX NN B-NP B-Chemical
43 1142 1143 12084448 . . O O

1 0 0 9523805 -DOCSTART- -X- -X- O

1 0 9 9523805 Transient JJ B-NP B-Disease
2 10 20 9523805 neurologic JJ I-NP I-Disease
3 21 29 9523805 symptoms NNS I-NP I-Disease
4 30 35 9523805 after IN B-PP O
5 36 42 9523805 spinal JJ B-NP O
6 43 53 9523805 anesthesia NN I-NP O
7 53 54 9523805 : : O O
8 55 56 9523805 a DT B-NP O
9 57 62 9523805 lower JJR I-NP O
10 63 72 9523805 incidence NN I-NP O
11 73 77 9523805 with IN B-PP O
12 78 88 9523805 prilocaine NN B-NP B-Chemical
13 89 92 9523805 and CC I-NP O
14 93 104 9523805 bupivacaine NN I-NP B-Chemical
15 105 109 9523805 than IN B-PP O
16 110 114 9523805 with IN B-PP O
17 115 124 9523805 lidocaine NN B-NP B-Chemical
18 124 125 9523805 . . O O
19 126 136 9523805 BACKGROUND NN B-NP O
20 136 137 9523805 : : O O
21 138 144 9523805 Recent JJ B-NP O
22 145 153 9523805 evidence NN I-NP O
23 154 162 9523805 suggests VBZ B-VP O
24 163 167 9523805 that IN B-SBAR O
25 168 177 9523805 transient JJ B-NP B-Disease
26 178 188 9523805 neurologic JJ I-NP I-Disease
27 189 197 9523805 symptoms NNS I-NP I-Disease
28 198 199 9523805 ( ( O O
29 199 203 9523805 TNSs NNS B-NP B-Disease
30 203 204 9523805 ) ) O O
31 205 215 9523805 frequently RB B-ADVP O
32 216 222 9523805 follow VBP B-VP O
33 223 232 9523805 lidocaine NN B-NP B-Chemical
34 233 239 9523805 spinal JJ I-NP O
35 240 250 9523805 anesthesia NN I-NP O
36 251 254 9523805 but CC O O
37 255 258 9523805 are VBP B-VP O
38 259 269 9523805 infrequent JJ B-ADJP O
39 270 274 9523805 with IN B-PP O
40 275 286 9523805 bupivacaine NN B-NP B-Chemical
41 286 287 9523805 . . O O

1 288 295 9523805 However RB B-ADVP O
2 295 296 9523805 , , O O
3 297 311 9523805 identification NN B-NP O
4 312 314 9523805 of IN B-PP O
5 315 316 9523805 a DT B-NP O
6 317 322 9523805 short JJ I-NP O
7 322 323 9523805 - HYPH I-NP O
8 323 329 9523805 acting VBG B-VP O
9 330 335 9523805 local JJ B-NP O
10 336 346 9523805 anesthetic NN I-NP O
11 347 349 9523805 to TO B-VP O
12 350 360 9523805 substitute VB I-VP O
13 361 364 9523805 for IN B-PP O
14 365 374 9523805 lidocaine NN B-NP B-Chemical
15 375 378 9523805 for IN B-PP O
16 379 384 9523805 brief JJ B-NP O
17 385 393 9523805 surgical JJ I-NP O
18 394 404 9523805 procedures NNS I-NP O
19 405 412 9523805 remains VBZ B-VP O
20 413 415 9523805 an DT B-NP O
21 416 425 9523805 important JJ I-NP O
22 426 430 9523805 goal NN I-NP O
23 430 431 9523805 . . O O

1 432 442 9523805 Prilocaine NN B-NP B-Chemical
2 443 445 9523805 is VBZ B-VP O
3 446 448 9523805 an DT B-NP O
4 449 454 9523805 amide NN I-NP O
5 455 460 9523805 local JJ I-NP O
6 461 471 9523805 anesthetic NN I-NP O
7 472 476 9523805 with IN B-PP O
8 477 478 9523805 a DT B-NP O
9 479 487 9523805 duration NN I-NP O
10 488 490 9523805 of IN B-PP O
11 491 497 9523805 action NN B-NP O
12 498 505 9523805 similar JJ B-ADJP O
13 506 508 9523805 to TO B-PP O
14 509 513 9523805 that DT B-NP O
15 514 516 9523805 of IN B-PP O
16 517 526 9523805 lidocaine NN B-NP B-Chemical
17 526 527 9523805 . . O O

1 528 539 9523805 Accordingly RB B-ADVP O
2 539 540 9523805 , , O O
3 541 544 9523805 the DT B-NP O
4 545 552 9523805 present JJ I-NP O
5 552 553 9523805 , , I-NP O
6 554 565 9523805 prospective JJ I-NP O
7 566 572 9523805 double JJ I-NP O
8 572 573 9523805 - HYPH I-NP O
9 573 578 9523805 blind JJ I-NP O
10 579 584 9523805 study NN I-NP O
11 585 593 9523805 compares VBZ B-VP O
12 594 604 9523805 prilocaine NN B-NP B-Chemical
13 605 609 9523805 with IN B-PP O
14 610 619 9523805 lidocaine NN B-NP B-Chemical
15 620 623 9523805 and CC I-NP O
16 624 635 9523805 bupivacaine NN I-NP B-Chemical
17 636 640 9523805 with IN B-PP O
18 641 648 9523805 respect NN B-NP O
19 649 651 9523805 to TO B-PP O
20 652 660 9523805 duration NN B-NP O
21 661 663 9523805 of IN B-PP O
22 664 670 9523805 action NN B-NP O
23 671 674 9523805 and CC O O
24 675 683 9523805 relative JJ B-NP O
25 684 688 9523805 risk NN I-NP O
26 689 691 9523805 of IN B-PP O
27 692 696 9523805 TNSs NNS B-NP B-Disease
28 696 697 9523805 . . O O

1 698 705 9523805 METHODS NNS B-NP O
2 705 706 9523805 : : O O
3 707 713 9523805 Ninety CD B-NP O
4 714 722 9523805 patients NNS I-NP O
5 723 733 9523805 classified VBN B-VP O
6 734 736 9523805 as IN B-PP O
7 737 745 9523805 American NNP B-NP O
8 746 753 9523805 Society NNP I-NP O
9 754 756 9523805 of IN B-PP O
10 757 774 9523805 Anesthesiologists NNPS B-NP O
11 775 783 9523805 physical JJ I-NP O
12 784 790 9523805 status NN I-NP O
13 791 792 9523805 I CD B-NP O
14 793 795 9523805 or CC I-NP O
15 796 798 9523805 II CD I-NP O
16 799 802 9523805 who WP B-NP O
17 803 807 9523805 were VBD B-VP O
18 808 817 9523805 scheduled VBN I-VP O
19 818 821 9523805 for IN B-PP O
20 822 827 9523805 short JJ B-NP O
21 828 839 9523805 gynecologic JJ I-NP O
22 840 850 9523805 procedures NNS I-NP O
23 851 856 9523805 under IN B-PP O
24 857 863 9523805 spinal JJ B-NP O
25 864 874 9523805 anesthesia NN I-NP O
26 875 879 9523805 were VBD B-VP O
27 880 888 9523805 randomly RB I-VP O
28 889 898 9523805 allocated VBN I-VP O
29 899 901 9523805 to TO I-VP O
30 902 909 9523805 receive VB I-VP O
31 910 913 9523805 2.5 CD B-NP O
32 914 916 9523805 ml NN I-NP O
33 917 919 9523805 2% NN I-NP O
34 920 929 9523805 lidocaine NN I-NP B-Chemical
35 930 932 9523805 in IN B-PP O
36 933 937 9523805 7.5% CD B-NP O
37 938 945 9523805 glucose NN I-NP B-Chemical
38 945 946 9523805 , , O O
39 947 949 9523805 2% NN B-NP O
40 950 960 9523805 prilocaine NN I-NP B-Chemical
41 961 963 9523805 in IN B-PP O
42 964 968 9523805 7.5% CD B-NP O
43 969 976 9523805 glucose NN I-NP B-Chemical
44 976 977 9523805 , , O O
45 978 980 9523805 or CC O O
46 981 985 9523805 0.5% CD B-NP O
47 986 997 9523805 bupivacaine NN I-NP B-Chemical
48 998 1000 9523805 in IN B-PP O
49 1001 1005 9523805 7.5% CD B-NP O
50 1006 1013 9523805 glucose NN I-NP B-Chemical
51 1013 1014 9523805 . . O O

1 1015 1018 9523805 All DT B-NP O
2 1019 1028 9523805 solutions NNS I-NP O
3 1029 1033 9523805 were VBD B-VP O
4 1034 1042 9523805 provided VBN I-VP O
5 1043 1045 9523805 in IN B-PP O
6 1046 1053 9523805 blinded JJ B-NP O
7 1054 1059 9523805 vials NNS I-NP O
8 1060 1062 9523805 by IN B-PP O
9 1063 1066 9523805 the DT B-NP O
10 1067 1075 9523805 hospital NN I-NP O
11 1076 1084 9523805 pharmacy NN I-NP O
12 1084 1085 9523805 . . O O

1 1086 1093 9523805 Details NNS B-NP O
2 1094 1096 9523805 of IN B-PP O
3 1097 1103 9523805 spinal JJ B-NP O
4 1104 1112 9523805 puncture NN I-NP O
5 1112 1113 9523805 , , O O
6 1114 1123 9523805 extension NN B-NP O
7 1124 1127 9523805 and CC I-NP O
8 1128 1138 9523805 regression NN I-NP O
9 1139 1141 9523805 of IN B-PP O
10 1142 1148 9523805 spinal JJ B-NP O
11 1149 1154 9523805 block NN I-NP O
12 1154 1155 9523805 , , O O
13 1156 1159 9523805 and CC O O
14 1160 1163 9523805 the DT B-NP O
15 1164 1169 9523805 times NNS I-NP O
16 1170 1172 9523805 to TO B-VP O
17 1173 1178 9523805 reach VB I-VP O
18 1179 1188 9523805 discharge NN B-NP O
19 1189 1197 9523805 criteria NNS I-NP O
20 1198 1202 9523805 were VBD B-VP O
21 1203 1208 9523805 noted VBN I-VP O
22 1208 1209 9523805 . . O O

1 1210 1212 9523805 In IN B-PP O
2 1213 1216 9523805 the DT B-NP O
3 1217 1224 9523805 evening NN I-NP O
4 1225 1227 9523805 of IN B-PP O
5 1228 1241 9523805 postoperative JJ B-NP O
6 1242 1245 9523805 day NN I-NP O
7 1246 1247 9523805 1 CD I-NP O
8 1247 1248 9523805 , , O O
9 1249 1257 9523805 patients NNS B-NP O
10 1258 1262 9523805 were VBD B-VP O
11 1263 1272 9523805 evaluated VBN I-VP O
12 1273 1276 9523805 for IN B-PP O
13 1277 1281 9523805 TNSs NNS B-NP B-Disease
14 1282 1284 9523805 by IN B-PP O
15 1285 1286 9523805 a DT B-NP O
16 1287 1296 9523805 physician NN I-NP O
17 1297 1304 9523805 unaware JJ B-ADJP O
18 1305 1307 9523805 of IN B-PP O
19 1308 1311 9523805 the DT B-NP O
20 1312 1316 9523805 drug NN I-NP O
21 1317 1329 9523805 administered VBN B-VP O
22 1330 1333 9523805 and CC O O
23 1334 1337 9523805 the DT B-NP O
24 1338 1345 9523805 details NNS I-NP O
25 1346 1348 9523805 of IN B-PP O
26 1349 1352 9523805 the DT B-NP O
27 1353 1363 9523805 anesthetic JJ I-NP O
28 1364 1373 9523805 procedure NN I-NP O
29 1373 1374 9523805 . . O O

1 1375 1382 9523805 RESULTS NNS B-NP O
2 1382 1383 9523805 : : O O
3 1384 1388 9523805 Nine CD B-NP O
4 1389 1391 9523805 of IN B-PP O
5 1392 1394 9523805 30 CD B-NP O
6 1395 1403 9523805 patients NNS I-NP O
7 1404 1413 9523805 receiving VBG B-VP O
8 1414 1423 9523805 lidocaine NN B-NP B-Chemical
9 1424 1435 9523805 experienced JJ I-NP O
10 1436 1440 9523805 TNSs NNS I-NP B-Disease
11 1440 1441 9523805 , , O O
12 1442 1443 9523805 1 CD B-NP O
13 1444 1446 9523805 of IN B-PP O
14 1447 1449 9523805 30 CD B-NP O
15 1450 1458 9523805 patients NNS I-NP O
16 1459 1468 9523805 receiving VBG B-VP O
17 1469 1479 9523805 prilocaine NN B-NP B-Chemical
18 1480 1481 9523805 ( ( O O
19 1481 1482 9523805 P NN B-NP O
20 1483 1484 9523805 = SYM B-VP O
21 1485 1489 9523805 0.03 CD B-NP O
22 1489 1490 9523805 ) ) O O
23 1491 1494 9523805 had VBD B-VP O
24 1495 1499 9523805 them PRP B-NP O
25 1499 1500 9523805 , , O O
26 1501 1504 9523805 and CC O O
27 1505 1509 9523805 none NN B-NP O
28 1510 1512 9523805 of IN B-PP O
29 1513 1515 9523805 30 CD B-NP O
30 1516 1524 9523805 patients NNS I-NP O
31 1525 1534 9523805 receiving VBG B-VP O
32 1535 1546 9523805 bupivacaine NN B-NP B-Chemical
33 1547 1550 9523805 had VBD B-VP O
34 1551 1555 9523805 TNSs NNS B-NP B-Disease
35 1555 1556 9523805 . . O O

1 1557 1562 9523805 Times NNS B-NP O
2 1563 1565 9523805 to TO B-VP O
3 1566 1574 9523805 ambulate VB I-VP O
4 1575 1578 9523805 and CC O O
5 1579 1581 9523805 to TO B-PP O
6 1582 1586 9523805 void NN B-NP O
7 1587 1591 9523805 were VBD B-VP O
8 1592 1599 9523805 similar JJ B-ADJP O
9 1600 1605 9523805 after IN B-PP O
10 1606 1615 9523805 lidocaine NN B-NP B-Chemical
11 1616 1619 9523805 and CC O O
12 1620 1630 9523805 prilocaine NN B-NP B-Chemical
13 1631 1632 9523805 ( ( O O
14 1632 1635 9523805 150 CD B-NP O
15 1636 1638 9523805 vs NNS I-NP O
16 1638 1639 9523805 . . O O
17 1640 1643 9523805 165 CD B-NP O
18 1644 1647 9523805 min NN I-NP O
19 1648 1651 9523805 and CC O O
20 1652 1655 9523805 238 CD B-NP O
21 1656 1658 9523805 vs NNS I-NP O
22 1658 1659 9523805 . . O O
23 1660 1663 9523805 253 CD B-NP O
24 1664 1667 9523805 min NN I-NP O
25 1667 1668 9523805 , , O O
26 1669 1681 9523805 respectively RB B-ADVP O
27 1681 1682 9523805 ) ) O O
28 1683 1686 9523805 but CC O O
29 1687 1696 9523805 prolonged VBD B-VP O
30 1697 1702 9523805 after IN B-PP O
31 1703 1714 9523805 bupivacaine NN B-NP B-Chemical
32 1715 1716 9523805 ( ( O O
33 1716 1719 9523805 200 CD B-NP O
34 1720 1723 9523805 and CC I-NP O
35 1724 1727 9523805 299 CD I-NP O
36 1728 1731 9523805 min NN I-NP O
37 1731 1732 9523805 , , O O
38 1733 1745 9523805 respectively RB B-ADVP O
39 1745 1746 9523805 ; : O O
40 1747 1748 9523805 P NN B-NP O
41 1749 1750 9523805 < SYM B-NP O
42 1751 1755 9523805 0.05 CD I-NP O
43 1755 1756 9523805 ) ) O O
44 1756 1757 9523805 . . O O

1 1758 1769 9523805 CONCLUSIONS NNS B-NP O
2 1769 1770 9523805 : : O O
3 1771 1781 9523805 Prilocaine NN B-NP B-Chemical
4 1782 1785 9523805 may MD B-VP O
5 1786 1788 9523805 be VB I-VP O
6 1789 1799 9523805 preferable JJ B-ADJP O
7 1800 1802 9523805 to TO B-PP O
8 1803 1812 9523805 lidocaine NN B-NP B-Chemical
9 1813 1816 9523805 for IN B-PP O
10 1817 1822 9523805 short JJ B-NP O
11 1823 1831 9523805 surgical JJ I-NP O
12 1832 1842 9523805 procedures NNS I-NP O
13 1843 1850 9523805 because IN B-SBAR O
14 1851 1853 9523805 it PRP B-NP O
15 1854 1857 9523805 has VBZ B-VP O
16 1858 1859 9523805 a DT B-NP O
17 1860 1867 9523805 similar JJ I-NP O
18 1868 1876 9523805 duration NN I-NP O
19 1877 1879 9523805 of IN B-PP O
20 1880 1886 9523805 action NN B-NP O
21 1887 1890 9523805 but CC O O
22 1891 1892 9523805 a DT B-NP O
23 1893 1898 9523805 lower JJR I-NP O
24 1899 1908 9523805 incidence NN I-NP O
25 1909 1911 9523805 of IN B-PP O
26 1912 1916 9523805 TNSs NNS B-NP B-Disease
27 1916 1917 9523805 . . O O

1 0 0 11135224 -DOCSTART- -X- -X- O

1 0 10 11135224 Paclitaxel NN B-NP B-Chemical
2 10 11 11135224 , , O O
3 12 21 11135224 cisplatin NN B-NP B-Chemical
4 21 22 11135224 , , O O
5 23 26 11135224 and CC O O
6 27 38 11135224 gemcitabine NN B-NP B-Chemical
7 39 50 11135224 combination NN I-NP O
8 51 63 11135224 chemotherapy NN I-NP O
9 64 70 11135224 within IN B-PP O
10 71 72 11135224 a DT B-NP O
11 73 90 11135224 multidisciplinary JJ I-NP O
12 91 102 11135224 therapeutic JJ I-NP O
13 103 111 11135224 approach NN I-NP O
14 112 114 11135224 in IN B-PP O
15 115 125 11135224 metastatic JJ B-NP O
16 126 134 11135224 nonsmall JJ I-NP B-Disease
17 135 139 11135224 cell NN I-NP I-Disease
18 140 144 11135224 lung NN I-NP I-Disease
19 145 154 11135224 carcinoma NN I-NP I-Disease
20 154 155 11135224 . . I-NP O
21 156 166 11135224 BACKGROUND NN I-NP O
22 166 167 11135224 : : O O
23 168 177 11135224 Cisplatin NN B-NP B-Chemical
24 177 178 11135224 - HYPH O O
25 178 183 11135224 based VBN B-NP O
26 184 196 11135224 chemotherapy NN I-NP O
27 197 209 11135224 combinations NNS I-NP O
28 210 217 11135224 improve VBP B-VP O
29 218 225 11135224 quality NN B-NP O
30 226 228 11135224 of IN B-PP O
31 229 233 11135224 life NN B-NP O
32 234 237 11135224 and CC I-NP O
33 238 246 11135224 survival NN I-NP O
34 247 249 11135224 in IN B-PP O
35 250 258 11135224 advanced VBN B-NP O
36 259 267 11135224 nonsmall JJ I-NP B-Disease
37 268 272 11135224 cell NN I-NP I-Disease
38 273 277 11135224 lung NN I-NP I-Disease
39 278 287 11135224 carcinoma NN I-NP I-Disease
40 288 289 11135224 ( ( O O
41 289 294 11135224 NSCLC NN B-NP B-Disease
42 294 295 11135224 ) ) O O
43 295 296 11135224 . . O O

1 297 300 11135224 The DT B-NP O
2 301 310 11135224 emergence NN I-NP O
3 311 313 11135224 of IN B-PP O
4 314 317 11135224 new JJ B-NP O
5 318 324 11135224 active JJ I-NP O
6 325 330 11135224 drugs NNS I-NP O
7 331 336 11135224 might MD B-VP O
8 337 346 11135224 translate VB I-VP O
9 347 351 11135224 into IN B-PP O
10 352 356 11135224 more RBR B-NP O
11 357 366 11135224 effective JJ I-NP O
12 367 375 11135224 regimens NNS I-NP O
13 376 379 11135224 for IN B-PP O
14 380 383 11135224 the DT B-NP O
15 384 393 11135224 treatment NN I-NP O
16 394 396 11135224 of IN B-PP O
17 397 401 11135224 this DT B-NP O
18 402 409 11135224 disease NN I-NP O
19 409 410 11135224 . . O O

1 411 418 11135224 METHODS NNS B-NP O
2 418 419 11135224 : : O O
3 420 423 11135224 The DT B-NP O
4 424 433 11135224 objective NN I-NP O
5 434 436 11135224 of IN B-PP O
6 437 441 11135224 this DT B-NP O
7 442 447 11135224 study NN I-NP O
8 448 451 11135224 was VBD B-VP O
9 452 454 11135224 to TO B-VP O
10 455 464 11135224 determine VB I-VP O
11 465 468 11135224 the DT B-NP O
12 469 480 11135224 feasibility NN I-NP O
13 480 481 11135224 , , O O
14 482 490 11135224 response NN B-NP O
15 491 495 11135224 rate NN I-NP O
16 495 496 11135224 , , O O
17 497 500 11135224 and CC O O
18 501 509 11135224 toxicity NN B-NP B-Disease
19 510 512 11135224 of IN B-PP O
20 513 514 11135224 a DT B-NP O
21 515 525 11135224 paclitaxel NN I-NP B-Chemical
22 525 526 11135224 , , O O
23 527 536 11135224 cisplatin NN B-NP B-Chemical
24 536 537 11135224 , , O O
25 538 541 11135224 and CC O O
26 542 553 11135224 gemcitabine NN B-NP B-Chemical
27 554 565 11135224 combination NN I-NP O
28 566 568 11135224 to TO B-VP O
29 569 574 11135224 treat VB I-VP O
30 575 585 11135224 metastatic JJ B-NP O
31 586 591 11135224 NSCLC NN I-NP B-Disease
32 591 592 11135224 . . O O

1 593 599 11135224 Thirty CD B-NP O
2 599 600 11135224 - HYPH I-NP O
3 600 604 11135224 five CD I-NP O
4 605 616 11135224 consecutive JJ I-NP O
5 617 629 11135224 chemotherapy NN I-NP O
6 629 630 11135224 - HYPH O O
7 630 635 11135224 naive JJ B-NP O
8 636 644 11135224 patients NNS I-NP O
9 645 649 11135224 with IN B-PP O
10 650 655 11135224 Stage NN B-NP O
11 656 658 11135224 IV CD I-NP O
12 659 664 11135224 NSCLC NN I-NP B-Disease
13 665 668 11135224 and CC O O
14 669 671 11135224 an DT B-NP O
15 672 679 11135224 Eastern NNP I-NP O
16 680 691 11135224 Cooperative NNP I-NP O
17 692 700 11135224 Oncology NNP I-NP O
18 701 706 11135224 Group NNP I-NP O
19 707 718 11135224 performance NN I-NP O
20 719 725 11135224 status NN I-NP O
21 726 728 11135224 of IN B-PP O
22 729 730 11135224 0 CD B-NP O
23 730 731 11135224 - HYPH I-NP O
24 731 732 11135224 2 CD I-NP O
25 733 737 11135224 were VBD B-VP O
26 738 745 11135224 treated VBN I-VP O
27 746 750 11135224 with IN B-PP O
28 751 752 11135224 a DT B-NP O
29 753 764 11135224 combination NN I-NP O
30 765 767 11135224 of IN B-PP O
31 768 778 11135224 paclitaxel NN B-NP B-Chemical
32 779 780 11135224 ( ( O O
33 780 783 11135224 135 CD B-NP O
34 784 786 11135224 mg NN I-NP O
35 786 787 11135224 / SYM B-NP O
36 787 791 11135224 m(2) NN I-NP O
37 792 797 11135224 given VBN B-VP O
38 798 811 11135224 intravenously RB B-ADVP O
39 812 814 11135224 in IN B-PP O
40 815 816 11135224 3 CD B-NP O
41 817 822 11135224 hours NNS I-NP O
42 822 823 11135224 ) ) O O
43 824 826 11135224 on IN B-PP O
44 827 830 11135224 Day NN B-NP O
45 831 832 11135224 1 CD I-NP O
46 832 833 11135224 , , O O
47 834 843 11135224 cisplatin NN B-NP B-Chemical
48 844 845 11135224 ( ( O O
49 845 848 11135224 120 CD B-NP O
50 849 851 11135224 mg NN I-NP O
51 851 852 11135224 / SYM B-NP O
52 852 856 11135224 m(2) NN I-NP O
53 857 862 11135224 given VBN B-VP O
54 863 876 11135224 intravenously RB B-ADVP O
55 877 879 11135224 in IN B-PP O
56 880 881 11135224 6 CD B-NP O
57 882 887 11135224 hours NNS I-NP O
58 887 888 11135224 ) ) O O
59 889 891 11135224 on IN B-PP O
60 892 895 11135224 Day NN B-NP O
61 896 897 11135224 1 CD I-NP O
62 897 898 11135224 , , O O
63 899 902 11135224 and CC O O
64 903 914 11135224 gemcitabine NN B-NP B-Chemical
65 915 916 11135224 ( ( O O
66 916 919 11135224 800 CD B-NP O
67 920 922 11135224 mg NN I-NP O
68 922 923 11135224 / SYM B-NP O
69 923 927 11135224 m(2) NN I-NP O
70 928 933 11135224 given VBN B-VP O
71 934 947 11135224 intravenously RB B-ADVP O
72 948 950 11135224 in IN B-PP O
73 951 953 11135224 30 CD B-NP O
74 954 961 11135224 minutes NNS I-NP O
75 961 962 11135224 ) ) O O
76 963 965 11135224 on IN B-PP O
77 966 970 11135224 Days NNS B-NP O
78 971 972 11135224 1 CD I-NP O
79 973 976 11135224 and CC I-NP O
80 977 978 11135224 8 CD I-NP O
81 978 979 11135224 , , O O
82 980 985 11135224 every DT B-NP O
83 986 987 11135224 4 CD I-NP O
84 988 993 11135224 weeks NNS I-NP O
85 993 994 11135224 . . O O

1 995 1003 11135224 Although IN B-SBAR O
2 1004 1014 11135224 responding VBG B-VP O
3 1015 1023 11135224 patients NNS B-NP O
4 1024 1028 11135224 were VBD B-VP O
5 1029 1038 11135224 scheduled VBN I-VP O
6 1039 1041 11135224 to TO I-VP O
7 1042 1049 11135224 receive VB I-VP O
8 1050 1063 11135224 consolidation NN B-NP O
9 1064 1076 11135224 radiotherapy NN I-NP O
10 1077 1080 11135224 and CC O O
11 1081 1083 11135224 24 CD B-NP O
12 1084 1092 11135224 patients NNS I-NP O
13 1093 1101 11135224 received VBD B-VP O
14 1102 1112 11135224 preplanned VBN I-VP O
15 1113 1119 11135224 second JJ B-NP O
16 1119 1120 11135224 - HYPH I-NP O
17 1120 1124 11135224 line NN I-NP O
18 1125 1137 11135224 chemotherapy NN I-NP O
19 1138 1143 11135224 after IN B-PP O
20 1144 1151 11135224 disease NN B-NP O
21 1152 1163 11135224 progression NN I-NP O
22 1163 1164 11135224 , , O O
23 1165 1168 11135224 the DT B-NP O
24 1169 1177 11135224 response NN I-NP O
25 1178 1181 11135224 and CC I-NP O
26 1182 1190 11135224 toxicity NN I-NP B-Disease
27 1191 1196 11135224 rates NNS I-NP O
28 1197 1205 11135224 reported VBN B-VP O
29 1206 1211 11135224 refer VBP B-VP O
30 1212 1216 11135224 only RB B-ADVP O
31 1217 1219 11135224 to TO B-PP O
32 1220 1223 11135224 the DT B-NP O
33 1224 1236 11135224 chemotherapy NN I-NP O
34 1237 1244 11135224 regimen NN I-NP O
35 1245 1250 11135224 given VBN B-VP O
36 1250 1251 11135224 . . O O

1 1252 1259 11135224 RESULTS NNS B-NP O
2 1259 1260 11135224 : : O O
3 1261 1264 11135224 All PDT B-NP O
4 1265 1268 11135224 the DT I-NP O
5 1269 1277 11135224 patients NNS I-NP O
6 1278 1282 11135224 were VBD B-VP O
7 1283 1291 11135224 examined VBN I-VP O
8 1292 1295 11135224 for IN B-PP O
9 1296 1304 11135224 toxicity NN B-NP B-Disease
10 1304 1305 11135224 ; : O O
11 1306 1308 11135224 34 CD B-NP O
12 1309 1313 11135224 were VBD B-VP O
13 1314 1324 11135224 examinable JJ B-ADJP O
14 1325 1328 11135224 for IN B-PP O
15 1329 1337 11135224 response NN B-NP O
16 1337 1338 11135224 . . O O

1 1339 1341 11135224 An DT B-NP O
2 1342 1351 11135224 objective JJ I-NP O
3 1352 1360 11135224 response NN I-NP O
4 1361 1364 11135224 was VBD B-VP O
5 1365 1373 11135224 observed VBN I-VP O
6 1374 1376 11135224 in IN B-PP O
7 1377 1382 11135224 73.5% CD B-NP O
8 1383 1385 11135224 of IN B-PP O
9 1386 1389 11135224 the DT B-NP O
10 1390 1398 11135224 patients NNS I-NP O
11 1399 1400 11135224 ( ( O O
12 1400 1403 11135224 95% CD B-NP O
13 1404 1414 11135224 confidence NN I-NP O
14 1415 1423 11135224 interval NN I-NP O
15 1424 1425 11135224 [ ( O O
16 1425 1427 11135224 CI NN B-NP O
17 1427 1428 11135224 ] ) O O
18 1428 1429 11135224 , , O O
19 1430 1434 11135224 55.6 CD B-NP O
20 1434 1435 11135224 - HYPH I-NP O
21 1435 1440 11135224 87.1% NN I-NP O
22 1440 1441 11135224 ) ) O O
23 1441 1442 11135224 , , O O
24 1443 1452 11135224 including VBG B-PP O
25 1453 1454 11135224 4 CD B-NP O
26 1455 1463 11135224 complete JJ I-NP O
27 1464 1473 11135224 responses NNS I-NP O
28 1474 1475 11135224 ( ( O O
29 1475 1480 11135224 11.7% CD B-NP O
30 1480 1481 11135224 ) ) O O
31 1481 1482 11135224 . . O O

1 1483 1492 11135224 According VBG B-PP O
2 1493 1495 11135224 to TO B-PP O
3 1496 1505 11135224 intention NN B-NP O
4 1505 1506 11135224 - HYPH B-ADJP O
5 1506 1508 11135224 to TO B-PP O
6 1508 1509 11135224 - HYPH B-NP O
7 1509 1514 11135224 treat NN I-NP O
8 1514 1515 11135224 , , O O
9 1516 1519 11135224 the DT B-NP O
10 1520 1527 11135224 overall JJ I-NP O
11 1528 1536 11135224 response NN I-NP O
12 1537 1541 11135224 rate NN I-NP O
13 1542 1545 11135224 was VBD B-VP O
14 1546 1551 11135224 71.4% CD B-NP O
15 1552 1553 11135224 ( ( O O
16 1553 1556 11135224 95% CD B-NP O
17 1557 1559 11135224 CI NN I-NP O
18 1559 1560 11135224 , , O O
19 1561 1563 11135224 53 CD B-NP O
20 1563 1564 11135224 . . O O

1 1565 1566 11135224 7 CD B-NP O
2 1566 1567 11135224 - HYPH I-NP O
3 1567 1572 11135224 85.4% CD I-NP O
4 1572 1573 11135224 ) ) O O
5 1573 1574 11135224 . . O O

1 1575 1580 11135224 After IN B-PP O
2 1581 1584 11135224 154 CD B-NP O
3 1585 1592 11135224 courses NNS I-NP O
4 1593 1595 11135224 of IN B-PP O
5 1596 1603 11135224 therapy NN B-NP O
6 1603 1604 11135224 , , O O
7 1605 1608 11135224 the DT B-NP O
8 1609 1615 11135224 median JJ I-NP O
9 1616 1620 11135224 dose NN I-NP O
10 1621 1630 11135224 intensity NN I-NP O
11 1631 1634 11135224 was VBD B-VP O
12 1635 1638 11135224 131 CD B-NP O
13 1639 1641 11135224 mg NN I-NP O
14 1641 1642 11135224 / SYM B-NP O
15 1642 1646 11135224 m(2) NN I-NP O
16 1647 1650 11135224 for IN B-PP O
17 1651 1661 11135224 paclitaxel NN B-NP B-Chemical
18 1662 1663 11135224 ( ( O O
19 1663 1668 11135224 97.3% CD B-NP O
20 1668 1669 11135224 ) ) O O
21 1669 1670 11135224 , , O O
22 1671 1674 11135224 117 CD B-NP O
23 1675 1677 11135224 mg NN I-NP O
24 1677 1678 11135224 / SYM B-NP O
25 1678 1682 11135224 m(2) NN I-NP O
26 1683 1686 11135224 for IN B-PP O
27 1687 1696 11135224 cisplatin NN B-NP B-Chemical
28 1697 1698 11135224 ( ( O O
29 1698 1703 11135224 97.3% CD B-NP O
30 1703 1704 11135224 ) ) O O
31 1704 1705 11135224 , , O O
32 1706 1709 11135224 and CC O O
33 1710 1714 11135224 1378 CD B-NP O
34 1715 1717 11135224 mg NN I-NP O
35 1717 1718 11135224 / SYM B-NP O
36 1718 1722 11135224 m(2) NN I-NP O
37 1723 1726 11135224 for IN B-PP O
38 1727 1738 11135224 gemcitabine NN B-NP B-Chemical
39 1739 1740 11135224 ( ( O O
40 1740 1745 11135224 86.2% CD B-NP O
41 1745 1746 11135224 ) ) O O
42 1746 1747 11135224 . . O O

1 1748 1753 11135224 World NNP B-NP O
2 1754 1760 11135224 Health NNP I-NP O
3 1761 1773 11135224 Organization NNP I-NP O
4 1774 1779 11135224 Grade NNP I-NP O
5 1780 1781 11135224 3 CD I-NP O
6 1781 1782 11135224 - HYPH I-NP O
7 1782 1783 11135224 4 CD I-NP O
8 1784 1795 11135224 neutropenia NN I-NP B-Disease
9 1796 1799 11135224 and CC I-NP O
10 1800 1816 11135224 thrombocytopenia NN I-NP B-Disease
11 1817 1825 11135224 occurred VBD B-VP O
12 1826 1828 11135224 in IN B-PP O
13 1829 1834 11135224 39.9% NN B-NP O
14 1835 1838 11135224 and CC O O
15 1839 1844 11135224 11.4% NN B-NP O
16 1845 1847 11135224 of IN B-PP O
17 1848 1856 11135224 patients NNS B-NP O
18 1856 1857 11135224 , , O O
19 1858 1870 11135224 respectively RB B-ADVP O
20 1870 1871 11135224 . . O O

1 1872 1877 11135224 There EX B-NP O
2 1878 1881 11135224 was VBD B-VP O
3 1882 1885 11135224 one CD B-NP O
4 1886 1895 11135224 treatment NN I-NP O
5 1895 1896 11135224 - HYPH B-NP O
6 1896 1903 11135224 related VBN I-NP O
7 1904 1909 11135224 death NN I-NP B-Disease
8 1909 1910 11135224 . . O O

1 1911 1925 11135224 Nonhematologic JJ B-NP O
2 1926 1936 11135224 toxicities NNS I-NP B-Disease
3 1937 1941 11135224 were VBD B-VP O
4 1942 1946 11135224 mild JJ B-ADJP O
5 1946 1947 11135224 . . O O

1 1948 1953 11135224 After IN B-PP O
2 1954 1955 11135224 a DT B-NP O
3 1956 1962 11135224 median JJ I-NP O
4 1963 1969 11135224 follow VB I-NP O
5 1969 1970 11135224 - HYPH B-VP O
6 1970 1972 11135224 up RP B-PRT O
7 1973 1975 11135224 of IN B-PP O
8 1976 1978 11135224 22 CD B-NP O
9 1979 1985 11135224 months NNS I-NP O
10 1985 1986 11135224 , , O O
11 1987 1990 11135224 the DT B-NP O
12 1991 1997 11135224 median JJ I-NP O
13 1998 2009 11135224 progression NN I-NP O
14 2010 2014 11135224 free JJ I-NP O
15 2015 2023 11135224 survival NN I-NP O
16 2024 2028 11135224 rate NN I-NP O
17 2029 2032 11135224 was VBD B-VP O
18 2033 2034 11135224 7 CD B-NP O
19 2035 2041 11135224 months NNS I-NP O
20 2041 2042 11135224 , , O O
21 2043 2046 11135224 and CC O O
22 2047 2050 11135224 the DT B-NP O
23 2051 2057 11135224 median JJ I-NP O
24 2058 2066 11135224 survival NN I-NP O
25 2067 2071 11135224 time NN I-NP O
26 2072 2075 11135224 was VBD B-VP O
27 2076 2078 11135224 16 CD B-NP O
28 2079 2085 11135224 months NNS I-NP O
29 2085 2086 11135224 . . O O

1 2087 2098 11135224 CONCLUSIONS NNS B-NP O
2 2098 2099 11135224 : : O O
3 2100 2103 11135224 The DT B-NP O
4 2104 2115 11135224 combination NN I-NP O
5 2116 2118 11135224 of IN B-PP O
6 2119 2129 11135224 paclitaxel NN B-NP B-Chemical
7 2129 2130 11135224 , , O O
8 2131 2140 11135224 cisplatin NN B-NP B-Chemical
9 2140 2141 11135224 , , O O
10 2142 2145 11135224 and CC O O
11 2146 2157 11135224 gemcitabine NN B-NP B-Chemical
12 2158 2160 11135224 is VBZ B-VP O
13 2161 2165 11135224 well RB I-VP O
14 2166 2175 11135224 tolerated VBN I-VP O
15 2176 2179 11135224 and CC O O
16 2180 2185 11135224 shows VBZ B-VP O
17 2186 2190 11135224 high JJ B-NP O
18 2191 2199 11135224 activity NN I-NP O
19 2200 2202 11135224 in IN B-PP O
20 2203 2213 11135224 metastatic JJ B-NP O
21 2214 2219 11135224 NSCLC NN I-NP B-Disease
22 2219 2220 11135224 . . O O

1 2221 2225 11135224 This DT B-NP O
2 2226 2235 11135224 treatment NN I-NP O
3 2236 2242 11135224 merits VBZ B-VP O
4 2243 2250 11135224 further JJR B-NP O
5 2251 2261 11135224 comparison NN I-NP O
6 2262 2266 11135224 with IN B-PP O
7 2267 2272 11135224 other JJ B-NP O
8 2273 2282 11135224 cisplatin NN I-NP B-Chemical
9 2282 2283 11135224 - HYPH B-NP O
10 2283 2288 11135224 based VBN I-NP O
11 2289 2297 11135224 regimens NNS I-NP O
12 2297 2298 11135224 . . O O

1 0 0 19346865 -DOCSTART- -X- -X- O

1 0 10 19346865 Reversible JJ B-NP O
2 11 19 19346865 inferior JJ I-NP B-Disease
3 20 30 19346865 colliculus NN I-NP I-Disease
4 31 37 19346865 lesion NN I-NP I-Disease
5 38 40 19346865 in IN B-PP O
6 41 54 19346865 metronidazole NN B-NP B-Chemical
7 54 55 19346865 - HYPH B-NP O
8 55 62 19346865 induced VBN I-NP O
9 63 77 19346865 encephalopathy NN I-NP B-Disease
10 77 78 19346865 : : O O
11 79 87 19346865 magnetic JJ B-NP O
12 88 97 19346865 resonance NN I-NP O
13 98 106 19346865 findings NNS I-NP O
14 107 109 19346865 on IN B-PP O
15 110 119 19346865 diffusion NN B-NP O
16 119 120 19346865 - HYPH O O
17 120 128 19346865 weighted VBN B-VP O
18 129 132 19346865 and CC O O
19 133 138 19346865 fluid NN B-NP O
20 139 149 19346865 attenuated VBD B-VP O
21 150 159 19346865 inversion NN B-NP O
22 160 168 19346865 recovery NN I-NP O
23 169 176 19346865 imaging NN I-NP O
24 176 177 19346865 . . I-NP O
25 178 187 19346865 OBJECTIVE NN I-NP O
26 187 188 19346865 : : O O
27 189 193 19346865 This DT B-NP O
28 194 196 19346865 is VBZ B-VP O
29 197 199 19346865 to TO B-VP O
30 200 207 19346865 present VB I-VP O
31 208 218 19346865 reversible JJ B-NP O
32 219 227 19346865 inferior JJ I-NP B-Disease
33 228 238 19346865 colliculus NN I-NP I-Disease
34 239 246 19346865 lesions NNS I-NP I-Disease
35 247 249 19346865 in IN B-PP O
36 250 263 19346865 metronidazole NN B-NP B-Chemical
37 263 264 19346865 - HYPH B-NP O
38 264 271 19346865 induced VBN I-NP O
39 272 286 19346865 encephalopathy NN I-NP B-Disease
40 286 287 19346865 , , O O
41 288 290 19346865 to TO B-VP O
42 291 296 19346865 focus VB I-VP O
43 297 299 19346865 on IN B-PP O
44 300 303 19346865 the DT B-NP O
45 304 313 19346865 diffusion NN I-NP O
46 313 314 19346865 - HYPH O O
47 314 322 19346865 weighted VBN B-VP O
48 323 330 19346865 imaging NN B-NP O
49 331 332 19346865 ( ( O O
50 332 335 19346865 DWI NN B-NP O
51 335 336 19346865 ) ) O O
52 337 340 19346865 and CC O O
53 341 346 19346865 fluid NN B-NP O
54 347 357 19346865 attenuated VBD B-VP O
55 358 367 19346865 inversion NN B-NP O
56 368 376 19346865 recovery NN I-NP O
57 377 378 19346865 ( ( O O
58 378 383 19346865 FLAIR NN B-NP O
59 383 384 19346865 ) ) O O
60 385 392 19346865 imaging NN B-NP O
61 392 393 19346865 . . O O

1 394 403 19346865 MATERIALS NNS B-NP O
2 404 407 19346865 AND CC I-NP O
3 408 415 19346865 METHODS NNS I-NP O
4 415 416 19346865 : : O O
5 417 421 19346865 From IN B-PP O
6 422 430 19346865 November NNP B-NP O
7 431 435 19346865 2005 CD I-NP O
8 436 438 19346865 to TO B-PP O
9 439 448 19346865 September NNP B-NP O
10 449 453 19346865 2007 CD I-NP O
11 453 454 19346865 , , O O
12 455 456 19346865 8 CD B-NP O
13 457 465 19346865 patients NNS I-NP O
14 466 467 19346865 ( ( O O
15 467 468 19346865 5 CD B-NP O
16 469 472 19346865 men NNS I-NP O
17 473 476 19346865 and CC O O
18 477 478 19346865 3 CD B-NP O
19 479 484 19346865 women NNS I-NP O
20 484 485 19346865 ) ) O O
21 486 490 19346865 were VBD B-VP O
22 491 500 19346865 diagnosed VBN I-VP O
23 501 503 19346865 as IN B-PP O
24 504 510 19346865 having VBG B-VP O
25 511 524 19346865 metronidazole NN B-NP B-Chemical
26 524 525 19346865 - HYPH B-PP O
27 525 532 19346865 induced VBN B-NP O
28 533 547 19346865 encephalopathy NN I-NP B-Disease
29 548 549 19346865 ( ( O O
30 549 552 19346865 age NN B-NP O
31 553 558 19346865 range NN I-NP O
32 558 559 19346865 ; : O O
33 560 562 19346865 43 CD B-NP O
34 562 563 19346865 - HYPH I-NP O
35 563 565 19346865 78 CD I-NP O
36 566 571 19346865 years NNS I-NP O
37 571 572 19346865 ) ) O O
38 572 573 19346865 . . O O

1 574 578 19346865 They PRP B-NP O
2 579 582 19346865 had VBD B-VP O
3 583 587 19346865 been VBN I-VP O
4 588 594 19346865 taking VBG I-VP O
5 595 608 19346865 metronidazole NN B-NP B-Chemical
6 609 610 19346865 ( ( O O
7 610 615 19346865 total JJ B-NP O
8 616 622 19346865 dosage NN I-NP O
9 622 623 19346865 , , O O
10 624 626 19346865 45 CD B-NP O
11 626 627 19346865 - HYPH I-NP O
12 627 630 19346865 120 CD I-NP O
13 631 632 19346865 g NN I-NP O
14 632 633 19346865 ; : O O
15 634 642 19346865 duration NN B-NP O
16 642 643 19346865 , , O O
17 644 646 19346865 30 CD B-NP O
18 647 651 19346865 days NNS I-NP O
19 652 654 19346865 to TO B-PP O
20 655 656 19346865 2 CD B-NP O
21 657 663 19346865 months NNS I-NP O
22 663 664 19346865 ) ) O O
23 665 667 19346865 to TO B-VP O
24 668 673 19346865 treat VB I-VP O
25 674 677 19346865 the DT B-NP O
26 678 687 19346865 infection NN I-NP B-Disease
27 688 690 19346865 in IN B-PP O
28 691 698 19346865 various JJ B-NP O
29 699 705 19346865 organs NNS I-NP O
30 705 706 19346865 . . O O

1 707 714 19346865 Initial JJ B-NP O
2 715 720 19346865 brain NN I-NP O
3 721 729 19346865 magnetic JJ I-NP O
4 730 739 19346865 resonance NN I-NP O
5 740 747 19346865 imaging NN I-NP O
6 748 749 19346865 ( ( O O
7 749 752 19346865 MRI NN B-NP O
8 752 753 19346865 ) ) O O
9 754 758 19346865 were VBD B-VP O
10 759 767 19346865 obtained VBN I-VP O
11 768 773 19346865 after IN B-PP O
12 774 777 19346865 the DT B-NP O
13 778 793 19346865 hospitalization NN I-NP O
14 793 794 19346865 , , O O
15 795 804 19346865 including VBG B-PP O
16 805 808 19346865 DWI NN B-NP O
17 809 810 19346865 ( ( O O
18 810 811 19346865 8 CD B-NP O
19 811 812 19346865 / SYM I-NP O
20 812 813 19346865 8 CD I-NP O
21 813 814 19346865 ) ) O O
22 814 815 19346865 , , O O
23 816 824 19346865 apparent JJ B-NP O
24 825 834 19346865 diffusion NN I-NP O
25 835 846 19346865 coefficient NN I-NP O
26 847 848 19346865 ( ( O O
27 848 851 19346865 ADC NN B-NP O
28 851 852 19346865 ) ) O O
29 853 856 19346865 map NN B-NP O
30 857 858 19346865 ( ( O O
31 858 859 19346865 4 CD B-NP O
32 859 860 19346865 / SYM I-NP O
33 860 861 19346865 8 CD I-NP O
34 861 862 19346865 ) ) O O
35 862 863 19346865 , , O O
36 864 869 19346865 FLAIR NN B-NP O
37 870 871 19346865 ( ( O O
38 871 872 19346865 7 CD B-NP O
39 872 873 19346865 / SYM O O
40 873 874 19346865 8 CD B-NP O
41 874 875 19346865 ) ) O O
42 875 876 19346865 , , O O
43 877 880 19346865 and CC O O
44 881 883 19346865 T2 NN B-NP O
45 883 884 19346865 - HYPH O O
46 884 892 19346865 weighted VBN B-NP O
47 893 898 19346865 image NN I-NP O
48 899 900 19346865 ( ( O O
49 900 901 19346865 8 CD B-NP O
50 901 902 19346865 / SYM I-NP O
51 902 903 19346865 8 CD I-NP O
52 903 904 19346865 ) ) O O
53 904 905 19346865 . . O O

1 906 912 19346865 Follow VB B-VP O
2 912 913 19346865 - HYPH O O
3 913 915 19346865 up RP B-PRT O
4 916 920 19346865 MRIs NNS B-NP O
5 921 925 19346865 were VBD B-VP O
6 926 935 19346865 performed VBN I-VP O
7 936 938 19346865 on IN B-PP O
8 939 940 19346865 5 CD B-NP O
9 941 949 19346865 patients NNS I-NP O
10 950 954 19346865 from IN B-PP O
11 955 960 19346865 third JJ B-ADJP O
12 961 963 19346865 to TO B-PP O
13 964 968 19346865 14th JJ B-NP O
14 969 973 19346865 days NNS I-NP O
15 974 979 19346865 after IN B-PP O
16 980 995 19346865 discontinuation NN B-NP O
17 996 998 19346865 of IN B-PP O
18 999 1012 19346865 metronidazole NN B-NP B-Chemical
19 1013 1027 19346865 administration NN I-NP O
20 1027 1028 19346865 . . O O

1 1029 1037 19346865 Findings NNS B-NP O
2 1038 1040 19346865 of IN B-PP O
3 1041 1048 19346865 initial JJ B-NP O
4 1049 1052 19346865 and CC O O
5 1053 1059 19346865 follow VB B-VP O
6 1059 1060 19346865 - HYPH O O
7 1060 1062 19346865 up RP B-PRT O
8 1063 1067 19346865 MRIs NNS B-NP O
9 1068 1072 19346865 were VBD B-VP O
10 1073 1088 19346865 retrospectively RB I-VP O
11 1089 1098 19346865 evaluated VBN I-VP O
12 1099 1101 19346865 by IN B-PP O
13 1102 1103 19346865 2 CD B-NP O
14 1104 1121 19346865 neuroradiologists NNS I-NP O
15 1122 1124 19346865 by IN B-PP O
16 1125 1134 19346865 consensus NN B-NP O
17 1134 1135 19346865 , , O O
18 1136 1138 19346865 to TO B-VP O
19 1139 1146 19346865 analyze VB I-VP O
20 1147 1150 19346865 the DT B-NP O
21 1151 1159 19346865 presence NN I-NP O
22 1160 1162 19346865 of IN B-PP O
23 1163 1171 19346865 abnormal JJ B-NP O
24 1172 1178 19346865 signal NN I-NP O
25 1179 1190 19346865 intensities NNS I-NP O
26 1190 1191 19346865 , , O O
27 1192 1197 19346865 their PRP$ B-NP O
28 1198 1207 19346865 locations NNS I-NP O
29 1207 1208 19346865 , , O O
30 1209 1212 19346865 and CC O O
31 1213 1219 19346865 signal NN B-NP O
32 1220 1227 19346865 changes NNS I-NP O
33 1228 1230 19346865 on IN B-PP O
34 1231 1237 19346865 follow VB B-VP O
35 1237 1238 19346865 - HYPH O O
36 1238 1240 19346865 up RP B-PRT O
37 1241 1247 19346865 images NNS B-NP O
38 1247 1248 19346865 . . O O

1 1249 1256 19346865 RESULTS NNS B-NP O
2 1256 1257 19346865 : : O O
3 1258 1265 19346865 Initial JJ B-NP O
4 1266 1270 19346865 MRIs NNS I-NP O
5 1271 1277 19346865 showed VBD B-VP O
6 1278 1286 19346865 abnormal JJ B-NP O
7 1287 1291 19346865 high JJ I-NP O
8 1292 1298 19346865 signal NN I-NP O
9 1299 1310 19346865 intensities NNS I-NP O
10 1311 1313 19346865 on IN B-PP O
11 1314 1317 19346865 DWI NN B-NP O
12 1318 1321 19346865 and CC I-NP O
13 1322 1327 19346865 FLAIR NN I-NP O
14 1328 1329 19346865 ( ( O O
15 1329 1331 19346865 or CC O O
16 1332 1334 19346865 T2 NN B-NP O
17 1334 1335 19346865 - HYPH O O
18 1335 1343 19346865 weighted VBN B-NP O
19 1344 1349 19346865 image NN I-NP O
20 1349 1350 19346865 ) ) O O
21 1351 1353 19346865 at IN B-PP O
22 1354 1357 19346865 the DT B-NP O
23 1358 1365 19346865 dentate NN I-NP O
24 1366 1373 19346865 nucleus NN I-NP O
25 1374 1375 19346865 ( ( O O
26 1375 1376 19346865 8 CD B-NP O
27 1376 1377 19346865 / SYM I-NP O
28 1377 1378 19346865 8 CD I-NP O
29 1378 1379 19346865 ) ) O O
30 1379 1380 19346865 , , O O
31 1381 1389 19346865 inferior JJ B-NP O
32 1390 1400 19346865 colliculus NN I-NP O
33 1401 1402 19346865 ( ( O O
34 1402 1403 19346865 6 CD B-NP O
35 1403 1404 19346865 / SYM I-NP O
36 1404 1405 19346865 8 CD I-NP O
37 1405 1406 19346865 ) ) O O
38 1406 1407 19346865 , , O O
39 1408 1414 19346865 corpus NN B-NP O
40 1415 1423 19346865 callosum NN I-NP O
41 1424 1425 19346865 ( ( O O
42 1425 1426 19346865 2 CD B-NP O
43 1426 1427 19346865 / SYM O O
44 1427 1428 19346865 8 CD B-NP O
45 1428 1429 19346865 ) ) O O
46 1429 1430 19346865 , , O O
47 1431 1435 19346865 pons NNS B-NP O
48 1436 1437 19346865 ( ( O O
49 1437 1438 19346865 2 CD B-NP O
50 1438 1439 19346865 / SYM I-NP O
51 1439 1440 19346865 8 CD I-NP O
52 1440 1441 19346865 ) ) O O
53 1441 1442 19346865 , , O O
54 1443 1450 19346865 medulla NN B-NP O
55 1451 1452 19346865 ( ( O O
56 1452 1453 19346865 1 CD B-NP O
57 1453 1454 19346865 / SYM O O
58 1454 1455 19346865 8 CD O O
59 1455 1456 19346865 ) ) O O
60 1456 1457 19346865 , , O O
61 1458 1461 19346865 and CC O O
62 1462 1471 19346865 bilateral JJ B-NP O
63 1472 1480 19346865 cerebral JJ I-NP O
64 1481 1486 19346865 white JJ I-NP O
65 1487 1493 19346865 matter NN I-NP O
66 1494 1495 19346865 ( ( O O
67 1495 1496 19346865 1 CD B-NP O
68 1496 1497 19346865 / SYM O O
69 1497 1498 19346865 8 CD O O
70 1498 1499 19346865 ) ) O O
71 1499 1500 19346865 . . O O

1 1501 1505 19346865 High JJ B-NP O
2 1505 1506 19346865 - HYPH I-NP O
3 1506 1512 19346865 signal NN I-NP O
4 1513 1522 19346865 intensity NN I-NP O
5 1523 1530 19346865 lesions NNS I-NP O
6 1531 1533 19346865 on IN B-PP O
7 1534 1537 19346865 DWI NN B-NP O
8 1538 1544 19346865 tended VBD B-VP O
9 1545 1547 19346865 to TO I-VP O
10 1548 1552 19346865 show VB I-VP O
11 1553 1556 19346865 low JJ B-NP O
12 1557 1563 19346865 signal NN I-NP O
13 1564 1573 19346865 intensity NN I-NP O
14 1574 1576 19346865 on IN B-PP O
15 1577 1580 19346865 ADC NN B-NP O
16 1581 1584 19346865 map NN I-NP O
17 1585 1586 19346865 ( ( O O
18 1586 1587 19346865 3 CD B-NP O
19 1587 1588 19346865 / SYM I-NP O
20 1588 1589 19346865 4 CD I-NP O
21 1589 1590 19346865 ) ) O O
22 1590 1591 19346865 , , O O
23 1592 1595 19346865 but CC O O
24 1596 1598 19346865 in IN B-PP O
25 1599 1602 19346865 one CD B-NP O
26 1603 1610 19346865 patient NN I-NP O
27 1610 1611 19346865 , , O O
28 1612 1616 19346865 high JJ B-NP O
29 1617 1623 19346865 signal NN I-NP O
30 1624 1633 19346865 intensity NN I-NP O
31 1634 1637 19346865 was VBD B-VP O
32 1638 1643 19346865 shown VBN I-VP O
33 1644 1646 19346865 at IN B-PP O
34 1647 1656 19346865 bilateral JJ B-NP O
35 1657 1664 19346865 dentate NN I-NP O
36 1665 1671 19346865 nuclei NNS I-NP O
37 1672 1674 19346865 on IN B-PP O
38 1675 1678 19346865 not RB B-CONJP O
39 1679 1683 19346865 only RB I-CONJP O
40 1684 1687 19346865 DWI NN B-NP O
41 1688 1691 19346865 but CC B-CONJP O
42 1692 1696 19346865 also RB I-CONJP O
43 1697 1700 19346865 ADC NN B-NP O
44 1701 1704 19346865 map NN I-NP O
45 1704 1705 19346865 . . O O

1 1706 1709 19346865 All PDT B-NP O
2 1710 1713 19346865 the DT I-NP O
3 1714 1721 19346865 lesions NNS I-NP O
4 1722 1724 19346865 in IN B-PP O
5 1725 1732 19346865 dentate NN B-NP O
6 1732 1733 19346865 , , O O
7 1734 1742 19346865 inferior JJ B-NP O
8 1743 1753 19346865 colliculus NN I-NP O
9 1753 1754 19346865 , , O O
10 1755 1759 19346865 pons NNS B-NP O
11 1759 1760 19346865 , , O O
12 1761 1764 19346865 and CC O O
13 1765 1773 19346865 medullas NNS B-NP O
14 1774 1777 19346865 had VBD B-VP O
15 1778 1782 19346865 been VBN I-VP O
16 1783 1791 19346865 resolved VBN I-VP O
17 1792 1802 19346865 completely RB B-ADVP O
18 1803 1805 19346865 on IN B-PP O
19 1806 1812 19346865 follow VB B-VP O
20 1812 1813 19346865 - HYPH O O
21 1813 1815 19346865 up RP B-PRT O
22 1816 1820 19346865 MRIs NNS B-NP O
23 1821 1823 19346865 in IN B-PP O
24 1824 1825 19346865 5 CD B-NP O
25 1826 1834 19346865 patients NNS I-NP O
26 1834 1835 19346865 , , O O
27 1836 1839 19346865 but CC O O
28 1840 1842 19346865 in IN B-PP O
29 1843 1844 19346865 1 CD B-NP O
30 1845 1852 19346865 patient NN I-NP O
31 1853 1855 19346865 of IN B-PP O
32 1856 1860 19346865 them PRP B-NP O
33 1860 1861 19346865 , , O O
34 1862 1868 19346865 corpus VBZ B-VP O
35 1869 1877 19346865 callosal JJ B-NP B-Disease
36 1878 1884 19346865 lesion NN I-NP I-Disease
37 1885 1894 19346865 persisted VBD B-VP O
38 1894 1895 19346865 . . O O

1 1896 1907 19346865 CONCLUSIONS NNS B-NP O
2 1907 1908 19346865 : : O O
3 1909 1919 19346865 Reversible JJ B-NP O
4 1920 1928 19346865 inferior JJ I-NP B-Disease
5 1929 1939 19346865 colliculus NN I-NP I-Disease
6 1940 1947 19346865 lesions NNS I-NP I-Disease
7 1948 1953 19346865 could MD B-VP O
8 1954 1956 19346865 be VB I-VP O
9 1957 1967 19346865 considered VBN I-VP O
10 1968 1970 19346865 as IN B-SBAR O
11 1971 1974 19346865 the DT B-NP O
12 1975 1989 19346865 characteristic NN I-NP O
13 1990 1993 19346865 for IN B-PP O
14 1994 2007 19346865 metronidazole NN B-NP B-Chemical
15 2007 2008 19346865 - HYPH B-NP O
16 2008 2015 19346865 induced VBN I-NP O
17 2016 2030 19346865 encephalopathy NN I-NP B-Disease
18 2030 2031 19346865 , , O O
19 2032 2036 19346865 next JJ B-ADVP O
20 2037 2039 19346865 to TO B-PP O
21 2040 2043 19346865 the DT B-NP O
22 2044 2051 19346865 dentate NN I-NP O
23 2052 2059 19346865 nucleus NN I-NP O
24 2060 2071 19346865 involvement NN I-NP O
25 2071 2072 19346865 . . O O

1 0 0 2224762 -DOCSTART- -X- -X- O

1 0 1 2224762 A DT B-NP O
2 2 7 2224762 phase NN I-NP O
3 8 9 2224762 I CD I-NP O
4 10 15 2224762 study NN I-NP O
5 16 18 2224762 of IN B-PP O
6 19 21 2224762 4' CD B-NP B-Chemical
7 21 22 2224762 - HYPH I-NP I-Chemical
8 22 23 2224762 0 CD I-NP I-Chemical
9 23 24 2224762 - HYPH I-NP I-Chemical
10 24 51 2224762 tetrahydropyranyladriamycin NN I-NP I-Chemical
11 51 52 2224762 . . O O

1 53 61 2224762 Clinical JJ B-NP O
2 62 74 2224762 pharmacology NN I-NP O
3 75 78 2224762 and CC I-NP O
4 79 95 2224762 pharmacokinetics NNS I-NP O
5 95 96 2224762 . . O O
6 97 98 2224762 A DT B-NP O
7 99 104 2224762 Phase NN I-NP O
8 105 106 2224762 I CD I-NP O
9 107 112 2224762 study NN I-NP O
10 113 115 2224762 of IN B-PP O
11 116 127 2224762 intravenous JJ B-NP O
12 128 132 2224762 (IV) NN I-NP O
13 133 138 2224762 bolus NN I-NP O
14 139 141 2224762 4' CD I-NP B-Chemical
15 141 142 2224762 - HYPH I-NP I-Chemical
16 142 143 2224762 0 CD I-NP I-Chemical
17 143 144 2224762 - HYPH I-NP I-Chemical
18 144 171 2224762 tetrahydropyranyladriamycin NN I-NP I-Chemical
19 172 173 2224762 ( ( O O
20 173 184 2224762 Pirarubicin NN B-NP B-Chemical
21 184 185 2224762 ) ) O O
22 186 189 2224762 was VBD B-VP O
23 190 194 2224762 done VBN I-VP O
24 195 197 2224762 in IN B-PP O
25 198 200 2224762 55 CD B-NP O
26 201 209 2224762 patients NNS I-NP O
27 210 212 2224762 in IN B-PP O
28 213 217 2224762 good JJ B-NP O
29 218 229 2224762 performance NN I-NP O
30 230 236 2224762 status NN I-NP O
31 237 241 2224762 with IN B-PP O
32 242 252 2224762 refractory JJ B-NP O
33 253 259 2224762 tumors NNS I-NP B-Disease
34 259 260 2224762 . . O O

1 261 267 2224762 Twenty CD B-NP O
2 267 268 2224762 - HYPH I-NP O
3 268 271 2224762 six CD I-NP O
4 272 275 2224762 had VBD B-VP O
5 276 283 2224762 minimal JJ B-NP O
6 284 289 2224762 prior JJ I-NP O
7 290 297 2224762 therapy NN I-NP O
8 298 299 2224762 ( ( O O
9 299 303 2224762 good JJ B-NP O
10 304 308 2224762 risk NN I-NP O
11 308 309 2224762 ) ) O O
12 309 310 2224762 , , O O
13 311 313 2224762 23 CD B-NP O
14 314 317 2224762 had VBD B-VP O
15 318 327 2224762 extensive JJ B-NP O
16 328 333 2224762 prior JJ I-NP O
17 334 341 2224762 therapy NN I-NP O
18 342 343 2224762 ( ( O O
19 343 347 2224762 poor JJ B-NP O
20 348 352 2224762 risk NN I-NP O
21 352 353 2224762 ) ) O O
22 353 354 2224762 , , O O
23 355 358 2224762 and CC O O
24 359 362 2224762 six CD B-NP O
25 363 366 2224762 had VBD B-VP O
26 367 372 2224762 renal JJ B-ADJP B-Disease
27 373 376 2224762 and CC O I-Disease
28 376 377 2224762 / SYM B-NP I-Disease
29 377 379 2224762 or CC O I-Disease
30 380 387 2224762 hepatic JJ B-NP I-Disease
31 388 399 2224762 dysfunction NN I-NP I-Disease
32 399 400 2224762 . . O O

1 401 402 2224762 A DT B-NP O
2 403 408 2224762 total NN I-NP O
3 409 411 2224762 of IN B-PP O
4 412 415 2224762 167 CD B-NP O
5 416 423 2224762 courses NNS I-NP O
6 424 426 2224762 at IN B-PP O
7 427 432 2224762 doses NNS B-NP O
8 433 435 2224762 of IN B-PP O
9 436 438 2224762 15 CD B-NP O
10 439 441 2224762 to TO I-NP O
11 442 444 2224762 70 CD I-NP O
12 445 447 2224762 mg NN I-NP O
13 447 448 2224762 / SYM I-NP O
14 448 450 2224762 m2 NN I-NP O
15 451 455 2224762 were VBD B-VP O
16 456 465 2224762 evaluable JJ B-ADJP O
17 465 466 2224762 . . O O

1 467 474 2224762 Maximum JJ B-NP O
2 475 484 2224762 tolerated VBN I-NP O
3 485 489 2224762 dose NN I-NP O
4 490 492 2224762 in IN B-PP O
5 493 497 2224762 good JJ B-NP O
6 497 498 2224762 - HYPH I-NP O
7 498 502 2224762 risk NN B-NP O
8 503 511 2224762 patients NNS I-NP O
9 512 515 2224762 was VBD B-VP O
10 516 518 2224762 70 CD B-NP O
11 519 521 2224762 mg NN I-NP O
12 521 522 2224762 / SYM B-NP O
13 522 524 2224762 m2 NN I-NP O
14 524 525 2224762 , , O O
15 526 529 2224762 and CC O O
16 530 532 2224762 in IN B-PP O
17 533 537 2224762 poor JJ B-NP O
18 537 538 2224762 - HYPH I-NP O
19 538 542 2224762 risk NN I-NP O
20 543 551 2224762 patients NNS I-NP O
21 551 552 2224762 , , O O
22 553 555 2224762 60 CD B-NP O
23 556 558 2224762 mg NN I-NP O
24 558 559 2224762 / SYM B-NP O
25 559 561 2224762 m2 NN I-NP O
26 561 562 2224762 . . O O

1 563 566 2224762 The DT B-NP O
2 567 571 2224762 dose NN I-NP O
3 571 572 2224762 - HYPH O O
4 572 580 2224762 limiting VBG B-VP O
5 581 586 2224762 toxic JJ B-NP O
6 587 593 2224762 effect NN I-NP O
7 594 597 2224762 was VBD B-VP O
8 598 607 2224762 transient JJ B-NP O
9 608 621 2224762 noncumulative JJ I-NP O
10 622 638 2224762 granulocytopenia NN I-NP B-Disease
11 638 639 2224762 . . O O

1 640 651 2224762 Granulocyte NN B-NP O
2 652 657 2224762 nadir NN I-NP O
3 658 661 2224762 was VBD B-VP O
4 662 664 2224762 on IN B-PP O
5 665 668 2224762 day NN B-NP O
6 669 671 2224762 14 CD I-NP O
7 672 673 2224762 ( ( O O
8 673 678 2224762 range NN B-NP O
9 678 679 2224762 , , O O
10 680 681 2224762 4 CD B-NP O
11 681 682 2224762 - HYPH I-NP O
12 682 684 2224762 22 CD I-NP O
13 684 685 2224762 ) ) O O
14 685 686 2224762 . . O O

1 687 691 2224762 Less RBR B-NP O
2 692 700 2224762 frequent JJ I-NP O
3 701 706 2224762 toxic JJ I-NP O
4 707 714 2224762 effects NNS I-NP O
5 715 723 2224762 included VBD B-VP O
6 724 740 2224762 thrombocytopenia NN B-NP B-Disease
7 740 741 2224762 , , O O
8 742 748 2224762 anemia NN B-NP B-Disease
9 748 749 2224762 , , O O
10 750 756 2224762 nausea NN B-NP B-Disease
11 756 757 2224762 , , O O
12 758 762 2224762 mild JJ B-NP O
13 763 771 2224762 alopecia NN I-NP B-Disease
14 771 772 2224762 , , O O
15 773 782 2224762 phlebitis NN B-NP B-Disease
16 782 783 2224762 , , O O
17 784 787 2224762 and CC O O
18 788 797 2224762 mucositis NN B-NP B-Disease
19 797 798 2224762 . . O O

1 799 815 2224762 Myelosuppression NN B-NP B-Disease
2 816 819 2224762 was VBD B-VP O
3 820 824 2224762 more JJR B-ADJP O
4 825 827 2224762 in IN B-PP O
5 828 836 2224762 patients NNS B-NP O
6 837 841 2224762 with IN B-PP O
7 842 849 2224762 hepatic JJ B-NP B-Disease
8 850 861 2224762 dysfunction NN I-NP I-Disease
9 861 862 2224762 . . O O

1 863 878 2224762 Pharmacokinetic JJ B-NP O
2 879 887 2224762 analyses NNS I-NP O
3 888 890 2224762 in IN B-PP O
4 891 893 2224762 21 CD B-NP O
5 894 902 2224762 patients NNS I-NP O
6 903 911 2224762 revealed VBD B-VP O
7 912 923 2224762 Pirarubicin NN B-NP B-Chemical
8 924 930 2224762 plasma NN I-NP O
9 931 932 2224762 T NN I-NP O
10 933 934 2224762 1 CD I-NP O
11 934 935 2224762 / SYM I-NP O
12 935 936 2224762 2 CD I-NP O
13 937 942 2224762 alpha SYM O O
14 943 944 2224762 ( ( O O
15 944 945 2224762 + SYM B-NP O
16 945 946 2224762 / SYM O O
17 946 947 2224762 - HYPH B-NP O
18 948 950 2224762 SE NN I-NP O
19 950 951 2224762 ) ) O O
20 952 954 2224762 of IN B-PP O
21 955 958 2224762 2.5 CD B-NP O
22 959 960 2224762 + SYM O O
23 960 961 2224762 / SYM O O
24 961 962 2224762 - SYM B-NP O
25 963 967 2224762 0.85 CD B-NP O
26 968 975 2224762 minutes NNS I-NP O
27 975 976 2224762 , , O O
28 977 978 2224762 T NN B-NP O
29 979 983 2224762 beta SYM B-NP O
30 984 985 2224762 1 CD I-NP O
31 985 986 2224762 / SYM I-NP O
32 986 987 2224762 2 CD I-NP O
33 988 990 2224762 of IN B-PP O
34 991 995 2224762 25.6 CD B-NP O
35 996 997 2224762 + SYM O O
36 997 998 2224762 / SYM O O
37 998 999 2224762 - SYM B-NP O
38 1000 1003 2224762 6.5 CD B-NP O
39 1004 1011 2224762 minutes NNS I-NP O
40 1011 1012 2224762 , , O O
41 1013 1016 2224762 and CC O O
42 1017 1018 2224762 T NN B-NP O
43 1019 1020 2224762 1 CD I-NP O
44 1020 1021 2224762 / SYM I-NP O
45 1021 1022 2224762 2 CD I-NP O
46 1023 1028 2224762 gamma NN I-NP O
47 1029 1031 2224762 of IN B-PP O
48 1032 1036 2224762 23.6 CD B-NP O
49 1037 1038 2224762 + SYM B-NP O
50 1038 1039 2224762 / SYM B-NP O
51 1039 1040 2224762 - SYM B-VP O
52 1041 1044 2224762 7.6 CD B-NP O
53 1045 1050 2224762 hours NNS I-NP O
54 1050 1051 2224762 . . O O

1 1052 1055 2224762 The DT B-NP O
2 1056 1060 2224762 area NN I-NP O
3 1061 1066 2224762 under IN B-PP O
4 1067 1070 2224762 the DT B-NP O
5 1071 1076 2224762 curve NN I-NP O
6 1077 1080 2224762 was VBD B-VP O
7 1081 1084 2224762 537 CD B-NP O
8 1085 1086 2224762 + SYM O O
9 1086 1087 2224762 / SYM O O
10 1087 1088 2224762 - SYM O O
11 1089 1092 2224762 149 CD B-NP O
12 1093 1095 2224762 ng NN I-NP O
13 1095 1096 2224762 / SYM B-NP O
14 1096 1098 2224762 ml NN I-NP O
15 1099 1100 2224762 x SYM I-NP O
16 1101 1106 2224762 hours NNS I-NP O
17 1106 1107 2224762 , , O O
18 1108 1114 2224762 volume NN B-NP O
19 1115 1117 2224762 of IN B-PP O
20 1118 1130 2224762 distribution NN B-NP O
21 1131 1132 2224762 ( ( O O
22 1132 1134 2224762 Vd NN B-NP O
23 1134 1135 2224762 ) ) O O
24 1136 1140 2224762 3504 CD B-NP O
25 1141 1142 2224762 + SYM O O
26 1142 1143 2224762 / SYM O O
27 1143 1144 2224762 - SYM O O
28 1145 1148 2224762 644 CD B-NP O
29 1149 1150 2224762 l NN I-NP O
30 1150 1151 2224762 / SYM B-NP O
31 1151 1153 2224762 m2 NN I-NP O
32 1153 1154 2224762 , , O O
33 1155 1158 2224762 and CC O O
34 1159 1164 2224762 total JJ B-NP O
35 1165 1174 2224762 clearance NN I-NP O
36 1175 1176 2224762 ( ( O O
37 1176 1179 2224762 ClT NN B-NP O
38 1179 1180 2224762 ) ) O O
39 1181 1184 2224762 was VBD B-VP O
40 1185 1188 2224762 204 CD B-NP O
41 1189 1190 2224762 + SYM O O
42 1191 1195 2224762 39.3 CD B-NP O
43 1196 1197 2224762 l NN I-NP O
44 1197 1198 2224762 / SYM B-NP O
45 1198 1202 2224762 hour NN I-NP O
46 1202 1203 2224762 / SYM I-NP O
47 1203 1205 2224762 m2 NN I-NP O
48 1205 1206 2224762 . . O O

1 1207 1219 2224762 Adriamycinol NN B-NP B-Chemical
2 1219 1220 2224762 , , O O
3 1221 1232 2224762 doxorubicin NN B-NP B-Chemical
4 1232 1233 2224762 , , O O
5 1234 1247 2224762 adriamycinone NN B-NP B-Chemical
6 1247 1248 2224762 , , O O
7 1249 1252 2224762 and CC O O
8 1253 1282 2224762 tetrahydropyranyladriamycinol NN B-NP B-Chemical
9 1283 1287 2224762 were VBD B-VP O
10 1288 1291 2224762 the DT B-NP O
11 1292 1303 2224762 metabolites NNS I-NP O
12 1304 1312 2224762 detected VBN B-VP O
13 1313 1315 2224762 in IN B-PP O
14 1316 1322 2224762 plasma NN B-NP O
15 1323 1326 2224762 and CC O O
16 1327 1330 2224762 the DT B-NP O
17 1331 1337 2224762 amount NN I-NP O
18 1338 1340 2224762 of IN B-PP O
19 1341 1352 2224762 doxorubicin NN B-NP B-Chemical
20 1353 1356 2224762 was VBD B-VP O
21 1357 1361 2224762 less JJR B-ADJP O
22 1362 1366 2224762 than IN B-PP O
23 1367 1369 2224762 or CC O O
24 1370 1375 2224762 equal JJ B-ADJP O
25 1376 1378 2224762 to TO B-PP O
26 1379 1382 2224762 10% CD B-NP O
27 1383 1385 2224762 of IN B-PP O
28 1386 1389 2224762 the DT B-NP O
29 1390 1395 2224762 total JJ I-NP O
30 1396 1407 2224762 metabolites NNS I-NP O
31 1407 1408 2224762 . . O O

1 1409 1416 2224762 Urinary JJ B-NP O
2 1417 1426 2224762 excretion NN I-NP O
3 1427 1429 2224762 of IN B-PP O
4 1430 1441 2224762 Pirarubicin NN B-NP B-Chemical
5 1442 1444 2224762 in IN B-PP O
6 1445 1448 2224762 the DT B-NP O
7 1449 1454 2224762 first JJ I-NP O
8 1455 1457 2224762 24 CD I-NP O
9 1458 1463 2224762 hours NNS I-NP O
10 1464 1467 2224762 was VBD B-VP O
11 1468 1472 2224762 less JJR B-ADJP O
12 1473 1477 2224762 than IN B-PP O
13 1478 1480 2224762 or CC O O
14 1481 1486 2224762 equal JJ B-ADJP O
15 1487 1489 2224762 to TO B-PP O
16 1490 1493 2224762 10% CD B-NP O
17 1493 1494 2224762 . . O O

1 1495 1503 2224762 Activity NN B-NP O
2 1504 1507 2224762 was VBD B-VP O
3 1508 1513 2224762 noted VBN I-VP O
4 1514 1516 2224762 in IN B-PP O
5 1517 1529 2224762 mesothelioma NN B-NP B-Disease
6 1529 1530 2224762 , , O O
7 1531 1545 2224762 leiomyosarcoma NN B-NP B-Disease
8 1545 1546 2224762 , , O O
9 1547 1550 2224762 and CC O O
10 1551 1556 2224762 basal JJ B-NP B-Disease
11 1557 1561 2224762 cell NN I-NP I-Disease
12 1562 1571 2224762 carcinoma NN I-NP I-Disease
13 1571 1572 2224762 . . O O

1 1573 1576 2224762 The DT B-NP O
2 1577 1588 2224762 recommended VBN I-NP O
3 1589 1597 2224762 starting NN I-NP O
4 1598 1602 2224762 dose NN I-NP O
5 1603 1606 2224762 for IN B-PP O
6 1607 1612 2224762 Phase NN B-NP O
7 1613 1615 2224762 II CD I-NP O
8 1616 1622 2224762 trials NNS I-NP O
9 1623 1625 2224762 is VBZ B-VP O
10 1626 1628 2224762 60 CD B-NP O
11 1629 1631 2224762 mg NN I-NP O
12 1631 1632 2224762 / SYM B-NP O
13 1632 1634 2224762 m2 NN B-NP O
14 1635 1637 2224762 IV CD I-NP O
15 1638 1643 2224762 bolus NN I-NP O
16 1644 1649 2224762 every DT B-NP O
17 1650 1651 2224762 3 CD I-NP O
18 1652 1657 2224762 weeks NNS I-NP O
19 1657 1658 2224762 . . O O

1 0 0 15338796 -DOCSTART- -X- -X- O

1 0 6 15338796 Tremor NN B-NP B-Disease
2 7 11 15338796 side NN I-NP O
3 12 19 15338796 effects NNS I-NP O
4 20 22 15338796 of IN B-PP O
5 23 33 15338796 salbutamol NN B-NP B-Chemical
6 33 34 15338796 , , O O
7 35 45 15338796 quantified VBN B-VP O
8 46 48 15338796 by IN B-PP O
9 49 50 15338796 a DT B-NP O
10 51 56 15338796 laser NN I-NP O
11 57 64 15338796 pointer NN I-NP O
12 65 74 15338796 technique NN I-NP O
13 74 75 15338796 . . I-NP O
14 76 85 15338796 OBJECTIVE NN I-NP O
15 85 86 15338796 : : O O
16 87 89 15338796 To TO B-VP O
17 90 95 15338796 study VB I-VP O
18 96 102 15338796 tremor NN B-NP B-Disease
19 103 107 15338796 side NN I-NP O
20 108 115 15338796 effects NNS I-NP O
21 116 118 15338796 of IN B-PP O
22 119 129 15338796 salbutamol NN B-NP B-Chemical
23 130 132 15338796 an DT B-NP O
24 133 139 15338796 easily RB I-NP O
25 140 150 15338796 applicable JJ I-NP O
26 150 151 15338796 , , I-NP O
27 152 157 15338796 quick JJ I-NP O
28 158 161 15338796 and CC I-NP O
29 162 165 15338796 low JJ I-NP O
30 165 166 15338796 - HYPH I-NP O
31 166 172 15338796 priced VBN I-NP O
32 173 179 15338796 method NN I-NP O
33 180 182 15338796 is VBZ B-VP O
34 183 189 15338796 needed VBN I-VP O
35 189 190 15338796 . . O O

1 191 192 15338796 A DT B-NP O
2 193 196 15338796 new JJ I-NP O
3 197 203 15338796 method NN I-NP O
4 204 209 15338796 using VBG B-VP O
5 210 211 15338796 a DT B-NP O
6 212 224 15338796 commercially RB I-NP O
7 225 234 15338796 available JJ B-ADJP O
8 234 235 15338796 , , O O
9 236 239 15338796 pen NN B-NP O
10 239 240 15338796 - HYPH B-VP O
11 240 246 15338796 shaped VBN B-NP O
12 247 252 15338796 laser NN I-NP O
13 253 260 15338796 pointer NN I-NP O
14 261 264 15338796 was VBD B-VP O
15 265 274 15338796 developed VBN I-VP O
16 274 275 15338796 . . O O

1 276 279 15338796 Aim NN B-NP O
2 280 282 15338796 of IN B-PP O
3 283 286 15338796 the DT B-NP O
4 287 292 15338796 study NN I-NP O
5 293 296 15338796 was VBD B-VP O
6 297 299 15338796 to TO B-VP O
7 300 309 15338796 determine VB I-VP O
8 310 321 15338796 sensitivity NN B-NP O
9 321 322 15338796 , , O O
10 323 338 15338796 reproducibility NN B-NP O
11 338 339 15338796 , , O O
12 340 349 15338796 reference NN B-NP O
13 350 356 15338796 values NNS I-NP O
14 357 360 15338796 and CC O O
15 361 364 15338796 the DT B-NP O
16 365 374 15338796 agreement NN I-NP O
17 375 379 15338796 with IN B-PP O
18 380 381 15338796 a DT B-NP O
19 382 395 15338796 questionnaire NN I-NP O
20 395 396 15338796 . . O O

1 397 404 15338796 METHODS NNS B-NP O
2 404 405 15338796 : : O O
3 406 412 15338796 Tremor NN B-NP B-Disease
4 413 416 15338796 was VBD B-VP O
5 417 425 15338796 measured VBN I-VP O
6 426 431 15338796 using VBG B-VP O
7 432 433 15338796 a DT B-NP O
8 434 439 15338796 laser NN I-NP O
9 440 447 15338796 pointer NN I-NP O
10 448 457 15338796 technique NN I-NP O
11 457 458 15338796 . . O O

1 459 461 15338796 To TO B-VP O
2 462 471 15338796 determine VB I-VP O
3 472 483 15338796 sensitivity NN B-NP O
4 484 486 15338796 we PRP B-NP O
5 487 495 15338796 assessed VBD B-VP O
6 496 502 15338796 tremor NN B-NP B-Disease
7 503 505 15338796 in IN B-PP O
8 506 508 15338796 44 CD B-NP O
9 509 517 15338796 patients NNS I-NP O
10 518 522 15338796 with IN B-PP O
11 523 534 15338796 obstructive JJ B-NP B-Disease
12 535 539 15338796 lung NN I-NP I-Disease
13 540 547 15338796 disease NN I-NP I-Disease
14 548 553 15338796 after IN B-PP O
15 554 568 15338796 administration NN B-NP O
16 569 571 15338796 of IN B-PP O
17 572 582 15338796 cumulative JJ B-NP O
18 583 588 15338796 doses NNS I-NP O
19 589 591 15338796 of IN B-PP O
20 592 602 15338796 salbutamol NN B-NP B-Chemical
21 602 603 15338796 . . O O

1 604 612 15338796 Subjects NNS B-NP O
2 613 617 15338796 were VBD B-VP O
3 618 623 15338796 asked VBN I-VP O
4 624 626 15338796 to TO B-VP O
5 627 630 15338796 aim VB I-VP O
6 631 633 15338796 at IN B-PP O
7 634 637 15338796 the DT B-NP O
8 638 644 15338796 centre NN I-NP O
9 645 647 15338796 of IN B-PP O
10 648 649 15338796 a DT B-NP O
11 650 656 15338796 target NN I-NP O
12 656 657 15338796 , , O O
13 658 668 15338796 subdivided VBN B-VP O
14 669 671 15338796 in IN B-PP O
15 672 682 15338796 concentric JJ B-NP O
16 683 690 15338796 circles NNS I-NP O
17 690 691 15338796 , , O O
18 692 696 15338796 from IN B-PP O
19 697 698 15338796 5 CD B-NP O
20 699 700 15338796 m NN I-NP O
21 701 709 15338796 distance NN I-NP O
22 709 710 15338796 . . O O

1 711 714 15338796 The DT B-NP O
2 715 721 15338796 circle NN I-NP O
3 722 724 15338796 in IN B-PP O
4 725 730 15338796 which WDT B-NP O
5 731 734 15338796 the DT B-NP O
6 735 746 15338796 participant NN I-NP O
7 747 756 15338796 succeeded VBD B-VP O
8 757 759 15338796 to TO B-PP O
9 760 763 15338796 aim NN B-NP O
10 764 767 15338796 was VBD B-VP O
11 768 776 15338796 recorded VBN I-VP O
12 777 779 15338796 in IN B-PP O
13 780 791 15338796 millimetres NNS B-NP O
14 792 798 15338796 radius NN I-NP O
15 798 799 15338796 . . O O

1 800 802 15338796 In IN B-PP O
2 803 810 15338796 another DT B-NP O
3 811 817 15338796 series NN I-NP O
4 818 820 15338796 of IN B-PP O
5 821 833 15338796 measurements NNS B-NP O
6 833 834 15338796 , , O O
7 835 850 15338796 reproducibility NN B-NP O
8 851 854 15338796 and CC I-NP O
9 855 864 15338796 reference NN I-NP O
10 865 871 15338796 values NNS I-NP O
11 872 874 15338796 of IN B-PP O
12 875 878 15338796 the DT B-NP O
13 879 885 15338796 tremor NN I-NP B-Disease
14 886 889 15338796 was VBD B-VP O
15 890 898 15338796 assessed VBN I-VP O
16 899 901 15338796 in IN B-PP O
17 902 904 15338796 65 CD B-NP O
18 905 912 15338796 healthy JJ I-NP O
19 913 921 15338796 subjects NNS I-NP O
20 922 924 15338796 in IN B-PP O
21 925 930 15338796 three CD B-NP O
22 931 939 15338796 sessions NNS I-NP O
23 939 940 15338796 , , O O
24 941 943 15338796 at IN B-PP O
25 944 945 15338796 9 CD B-NP O
26 946 949 15338796 a.m RB I-NP O
27 949 950 15338796 . . O O
28 950 951 15338796 , , O O
29 952 953 15338796 4 CD B-NP O
30 954 957 15338796 p.m RB I-NP O
31 957 958 15338796 . . O O

1 959 962 15338796 and CC O O
2 963 964 15338796 9 CD B-NP O
3 965 968 15338796 a.m NN I-NP O
4 968 969 15338796 . NN I-NP O
5 969 970 15338796 , , O O
6 971 983 15338796 respectively RB B-ADVP O
7 983 984 15338796 , , O O
8 985 986 15338796 1 CD B-NP O
9 987 991 15338796 week NN I-NP O
10 992 997 15338796 later RB B-ADVP O
11 997 998 15338796 . . O O

1 999 1007 15338796 Postural JJ B-NP O
2 1008 1014 15338796 tremor NN I-NP B-Disease
3 1015 1018 15338796 was VBD B-VP O
4 1019 1027 15338796 measured VBN I-VP O
5 1028 1032 15338796 with IN B-PP O
6 1033 1036 15338796 the DT B-NP O
7 1037 1040 15338796 arm NN I-NP O
8 1041 1053 15338796 horizontally RB B-ADVP O
9 1054 1066 15338796 outstretched VBD B-VP O
10 1067 1071 15338796 rest NN B-NP O
11 1072 1078 15338796 tremor NN I-NP B-Disease
12 1079 1083 15338796 with IN B-PP O
13 1084 1087 15338796 the DT B-NP O
14 1088 1091 15338796 arm NN I-NP O
15 1092 1101 15338796 supported VBN B-VP O
16 1102 1104 15338796 by IN B-PP O
17 1105 1107 15338796 an DT B-NP O
18 1108 1115 15338796 armrest NN I-NP O
19 1116 1119 15338796 and CC O O
20 1120 1127 15338796 finally RB B-ADVP O
21 1128 1134 15338796 tremor NN B-NP B-Disease
22 1135 1138 15338796 was VBD B-VP O
23 1139 1147 15338796 measured VBN I-VP O
24 1148 1153 15338796 after IN B-PP O
25 1154 1161 15338796 holding VBG B-VP O
26 1162 1163 15338796 a DT B-NP O
27 1164 1165 15338796 2 CD I-NP O
28 1165 1166 15338796 - HYPH I-NP O
29 1166 1168 15338796 kg NN I-NP O
30 1169 1175 15338796 weight NN I-NP O
31 1176 1181 15338796 until IN B-PP O
32 1182 1192 15338796 exhaustion NN B-NP O
33 1192 1193 15338796 . . O O

1 1194 1199 15338796 Inter AFX B-NP O
2 1199 1200 15338796 - HYPH I-NP O
3 1200 1208 15338796 observer NN I-NP O
4 1209 1220 15338796 variability NN I-NP O
5 1221 1224 15338796 was VBD B-VP O
6 1225 1233 15338796 measured VBN I-VP O
7 1234 1236 15338796 in IN B-PP O
8 1237 1238 15338796 a DT B-NP O
9 1239 1245 15338796 series NN I-NP O
10 1246 1248 15338796 of IN B-PP O
11 1249 1251 15338796 10 CD B-NP O
12 1252 1259 15338796 healthy JJ I-NP O
13 1260 1268 15338796 subjects NNS I-NP O
14 1268 1269 15338796 . . O O

1 1270 1276 15338796 Tremor NN B-NP B-Disease
2 1277 1280 15338796 was VBD B-VP O
3 1281 1289 15338796 measured VBN I-VP O
4 1290 1304 15338796 simultaneously RB B-ADVP O
5 1305 1307 15338796 by IN B-PP O
6 1308 1311 15338796 two CD B-NP O
7 1312 1323 15338796 independent JJ I-NP O
8 1324 1333 15338796 observers NNS I-NP O
9 1333 1334 15338796 . . O O

1 1335 1342 15338796 RESULTS NNS B-NP O
2 1342 1343 15338796 : : O O
3 1344 1354 15338796 Salbutamol NN B-NP B-Chemical
4 1355 1368 15338796 significantly RB B-ADVP O
5 1369 1378 15338796 increased VBD B-VP O
6 1379 1385 15338796 tremor NN B-NP B-Disease
7 1386 1394 15338796 severity NN I-NP O
8 1395 1397 15338796 in IN B-PP O
9 1398 1406 15338796 patients NNS B-NP O
10 1407 1409 15338796 in IN B-PP O
11 1410 1411 15338796 a DT B-NP O
12 1412 1416 15338796 dose NN I-NP O
13 1416 1417 15338796 - HYPH I-NP O
14 1417 1426 15338796 dependent JJ I-NP O
15 1427 1430 15338796 way NN I-NP O
16 1430 1431 15338796 . . O O

1 1432 1438 15338796 Within IN B-PP O
2 1439 1446 15338796 healthy JJ B-NP O
3 1447 1453 15338796 adults NNS I-NP O
4 1454 1456 15338796 no DT B-NP O
5 1457 1460 15338796 age NN I-NP O
6 1460 1461 15338796 - HYPH B-NP O
7 1461 1471 15338796 dependency NN I-NP O
8 1472 1477 15338796 could MD B-VP O
9 1478 1480 15338796 be VB I-VP O
10 1481 1486 15338796 found VBN I-VP O
11 1487 1488 15338796 ( ( O O
12 1488 1489 15338796 b NN B-NP O
13 1490 1491 15338796 = SYM B-VP O
14 1492 1497 15338796 0.262 CD B-NP O
15 1498 1500 15338796 mm NN I-NP O
16 1500 1501 15338796 / SYM B-NP O
17 1501 1505 15338796 year NN I-NP O
18 1505 1506 15338796 ; : O O
19 1507 1508 15338796 P NN B-NP O
20 1509 1510 15338796 = SYM B-VP O
21 1511 1515 15338796 0.72 CD B-NP O
22 1515 1516 15338796 ) ) O O
23 1516 1517 15338796 . . O O

1 1518 1523 15338796 There EX B-NP O
2 1524 1527 15338796 was VBD B-VP O
3 1528 1530 15338796 no DT B-NP O
4 1531 1540 15338796 agreement NN I-NP O
5 1541 1548 15338796 between IN B-PP O
6 1549 1552 15338796 the DT B-NP O
7 1553 1566 15338796 questionnaire NN I-NP O
8 1567 1570 15338796 and CC I-NP O
9 1571 1577 15338796 tremor NN I-NP B-Disease
10 1578 1586 15338796 severity NN I-NP O
11 1587 1588 15338796 ( ( O O
12 1588 1589 15338796 r NN B-NP O
13 1590 1591 15338796 = SYM B-VP O
14 1592 1597 15338796 0.093 CD B-NP O
15 1597 1598 15338796 ; : O O
16 1599 1600 15338796 P NN B-NP O
17 1601 1602 15338796 = SYM B-VP O
18 1603 1607 15338796 0.53 CD B-NP O
19 1607 1608 15338796 ) ) O O
20 1608 1609 15338796 . . O O

1 1610 1618 15338796 Postural JJ B-NP O
2 1619 1625 15338796 tremor NN I-NP B-Disease
3 1626 1632 15338796 showed VBD B-VP O
4 1633 1635 15338796 no DT B-NP O
5 1636 1647 15338796 significant JJ I-NP O
6 1648 1658 15338796 difference NN I-NP O
7 1659 1666 15338796 between IN B-PP O
8 1667 1670 15338796 the DT B-NP O
9 1671 1676 15338796 first JJ I-NP O
10 1677 1680 15338796 and CC I-NP O
11 1681 1686 15338796 third JJ I-NP O
12 1687 1694 15338796 session NN I-NP O
13 1695 1696 15338796 ( ( O O
14 1696 1697 15338796 P NN B-NP O
15 1698 1699 15338796 = SYM B-VP O
16 1700 1704 15338796 0.07 CD B-NP O
17 1704 1705 15338796 ) ) O O
18 1705 1706 15338796 . . O O

1 1707 1714 15338796 Support NN B-NP O
2 1715 1717 15338796 of IN B-PP O
3 1718 1721 15338796 the DT B-NP O
4 1722 1725 15338796 arm NN I-NP O
5 1726 1735 15338796 decreased VBD B-VP O
6 1736 1742 15338796 tremor NN B-NP B-Disease
7 1743 1751 15338796 severity NN I-NP O
8 1751 1752 15338796 , , O O
9 1753 1763 15338796 exhaustion NN B-NP O
10 1764 1773 15338796 increased VBD B-VP O
11 1774 1780 15338796 tremor NN B-NP B-Disease
12 1781 1789 15338796 severity NN I-NP O
13 1790 1803 15338796 significantly RB B-ADVP O
14 1803 1804 15338796 . . O O

1 1805 1806 15338796 A DT B-NP O
2 1807 1811 15338796 good JJ I-NP O
3 1812 1821 15338796 agreement NN I-NP O
4 1822 1825 15338796 was VBD B-VP O
5 1826 1831 15338796 found VBN I-VP O
6 1832 1839 15338796 between IN B-PP O
7 1840 1843 15338796 two CD B-NP O
8 1844 1855 15338796 independent JJ I-NP O
9 1856 1865 15338796 observers NNS I-NP O
10 1866 1867 15338796 ( ( O O
11 1867 1877 15338796 interclass NN B-NP O
12 1878 1889 15338796 correlation NN I-NP O
13 1890 1901 15338796 coefficient JJ B-NP O
14 1902 1906 15338796 0.72 CD I-NP O
15 1906 1907 15338796 ) ) O O
16 1907 1908 15338796 . . O O

1 1909 1919 15338796 DISCUSSION NN B-NP O
2 1919 1920 15338796 : : O O
3 1921 1932 15338796 Quantifying VBG B-VP O
4 1933 1939 15338796 tremor NN B-NP B-Disease
5 1940 1942 15338796 by IN B-PP O
6 1943 1948 15338796 using VBG B-VP O
7 1949 1951 15338796 an DT B-NP O
8 1952 1963 15338796 inexpensive JJ I-NP O
9 1964 1969 15338796 laser NN I-NP O
10 1970 1977 15338796 pointer NN I-NP O
11 1978 1980 15338796 is VBZ B-VP O
12 1980 1981 15338796 , , O O
13 1982 1986 15338796 with IN B-PP O
14 1987 1990 15338796 the DT B-NP O
15 1991 2000 15338796 exception NN I-NP O
16 2001 2003 15338796 of IN B-PP O
17 2004 2012 15338796 children NNS B-NP O
18 2013 2014 15338796 ( ( O O
19 2014 2015 15338796 < SYM B-NP O
20 2015 2017 15338796 12 CD B-NP O
21 2018 2023 15338796 years NNS I-NP O
22 2023 2024 15338796 ) ) O O
23 2025 2026 15338796 a DT B-NP O
24 2027 2036 15338796 sensitive JJ I-NP O
25 2037 2040 15338796 and CC I-NP O
26 2041 2053 15338796 reproducible JJ I-NP O
27 2054 2060 15338796 method NN I-NP O
28 2060 2061 15338796 . . O O

1 0 0 2522601 -DOCSTART- -X- -X- O

1 0 16 2522601 Hypersensitivity NN B-NP B-Disease
2 17 19 2522601 to TO B-PP O
3 20 33 2522601 carbamazepine NN B-NP B-Chemical
4 34 44 2522601 presenting VBG B-VP O
5 45 49 2522601 with IN B-PP O
6 50 51 2522601 a DT B-NP O
7 52 61 2522601 leukemoid JJ I-NP B-Disease
8 62 70 2522601 reaction NN I-NP I-Disease
9 70 71 2522601 , , O O
10 72 84 2522601 eosinophilia NN B-NP B-Disease
11 84 85 2522601 , , O O
12 86 98 2522601 erythroderma NN B-NP B-Disease
13 98 99 2522601 , , O O
14 100 103 2522601 and CC O O
15 104 109 2522601 renal JJ B-NP B-Disease
16 110 117 2522601 failure NN I-NP I-Disease
17 117 118 2522601 . . O O
18 119 121 2522601 We PRP B-NP O
19 122 128 2522601 report VBP B-VP O
20 129 130 2522601 a DT B-NP O
21 131 138 2522601 patient NN I-NP O
22 139 141 2522601 in IN B-PP O
23 142 146 2522601 whom WP B-NP O
24 147 163 2522601 hypersensitivity NN B-NP B-Disease
25 164 166 2522601 to TO B-PP O
26 167 180 2522601 carbamazepine NN B-NP B-Chemical
27 181 190 2522601 presented VBD B-VP O
28 191 195 2522601 with IN B-PP O
29 196 207 2522601 generalized VBN B-NP O
30 208 220 2522601 erythroderma NN I-NP B-Disease
31 220 221 2522601 , , O O
32 222 223 2522601 a DT B-NP O
33 224 230 2522601 severe JJ I-NP O
34 231 240 2522601 leukemoid JJ I-NP B-Disease
35 241 249 2522601 reaction NN I-NP I-Disease
36 249 250 2522601 , , O O
37 251 263 2522601 eosinophilia NN B-NP B-Disease
38 263 264 2522601 , , O O
39 265 277 2522601 hyponatremia NN B-NP B-Disease
40 277 278 2522601 , , O O
41 279 282 2522601 and CC O O
42 283 288 2522601 renal JJ B-NP B-Disease
43 289 296 2522601 failure NN I-NP I-Disease
44 296 297 2522601 . . O O

1 298 302 2522601 This DT B-NP O
2 303 305 2522601 is VBZ B-VP O
3 306 309 2522601 the DT B-NP O
4 310 315 2522601 first JJ I-NP O
5 316 322 2522601 report NN I-NP O
6 323 325 2522601 of IN B-PP O
7 326 330 2522601 such JJ B-NP O
8 331 333 2522601 an DT I-NP O
9 334 341 2522601 unusual JJ I-NP O
10 342 350 2522601 reaction NN I-NP O
11 351 353 2522601 to TO B-PP O
12 354 367 2522601 carbamazepine NN B-NP B-Chemical
13 367 368 2522601 . . O O

1 0 0 19759529 -DOCSTART- -X- -X- O

1 0 3 19759529 The DT B-NP O
2 4 11 19759529 glycine NN I-NP B-Chemical
3 12 23 19759529 transporter NN I-NP O
4 23 24 19759529 - HYPH B-NP O
5 24 25 19759529 1 CD I-NP O
6 26 35 19759529 inhibitor NN I-NP O
7 36 45 19759529 SSR103800 NN I-NP B-Chemical
8 46 54 19759529 displays VBZ B-VP O
9 55 56 19759529 a DT B-NP O
10 57 66 19759529 selective JJ I-NP O
11 67 70 19759529 and CC I-NP O
12 71 79 19759529 specific JJ I-NP O
13 80 93 19759529 antipsychotic JJ I-NP O
14 93 94 19759529 - HYPH I-NP O
15 94 98 19759529 like JJ I-NP O
16 99 106 19759529 profile NN I-NP O
17 107 109 19759529 in IN B-PP O
18 110 116 19759529 normal JJ B-NP O
19 117 120 19759529 and CC I-NP O
20 121 131 19759529 transgenic JJ I-NP O
21 132 136 19759529 mice NNS I-NP O
22 136 137 19759529 . . O O
23 138 151 19759529 Schizophrenia NNP B-NP B-Disease
24 152 155 19759529 has VBZ B-VP O
25 156 160 19759529 been VBN I-VP O
26 161 170 19759529 initially RB I-VP O
27 171 181 19759529 associated VBN I-VP O
28 182 186 19759529 with IN B-PP O
29 187 198 19759529 dysfunction NN B-NP O
30 199 201 19759529 in IN B-PP O
31 202 210 19759529 dopamine NN B-NP B-Chemical
32 211 228 19759529 neurotransmission NN I-NP O
33 228 229 19759529 . . O O

1 230 237 19759529 However RB B-ADVP O
2 237 238 19759529 , , O O
3 239 242 19759529 the DT B-NP O
4 243 254 19759529 observation NN I-NP O
5 255 259 19759529 that IN B-SBAR O
6 260 271 19759529 antagonists NNS B-NP O
7 272 274 19759529 of IN B-PP O
8 275 278 19759529 the DT B-NP O
9 279 288 19759529 glutamate NN I-NP B-Chemical
10 289 290 19759529 N NN I-NP B-Chemical
11 290 291 19759529 - HYPH B-NP I-Chemical
12 291 297 19759529 methyl NN I-NP I-Chemical
13 297 298 19759529 - HYPH B-NP I-Chemical
14 298 299 19759529 D NN I-NP I-Chemical
15 299 300 19759529 - HYPH B-NP I-Chemical
16 300 309 19759529 aspartate NN I-NP I-Chemical
17 310 311 19759529 ( ( O O
18 311 315 19759529 NMDA NN B-NP B-Chemical
19 315 316 19759529 ) ) O O
20 317 325 19759529 receptor NN B-NP O
21 326 333 19759529 produce VBP B-VP O
22 334 347 19759529 schizophrenic JJ B-NP B-Disease
23 347 348 19759529 - HYPH I-NP O
24 348 352 19759529 like JJ I-NP O
25 353 361 19759529 symptoms NNS I-NP O
26 362 364 19759529 in IN B-PP O
27 365 371 19759529 humans NNS B-NP O
28 372 375 19759529 has VBZ B-VP O
29 376 379 19759529 led VBN I-VP O
30 380 382 19759529 to TO B-PP O
31 383 386 19759529 the DT B-NP O
32 387 391 19759529 idea NN I-NP O
33 392 394 19759529 of IN B-PP O
34 395 396 19759529 a DT B-NP O
35 397 411 19759529 dysfunctioning NN I-NP O
36 412 414 19759529 of IN B-PP O
37 415 418 19759529 the DT B-NP O
38 419 432 19759529 glutamatergic JJ I-NP O
39 433 439 19759529 system NN I-NP O
40 440 443 19759529 via IN B-PP O
41 444 447 19759529 its PRP$ B-NP O
42 448 452 19759529 NMDA NN I-NP B-Chemical
43 453 461 19759529 receptor NN I-NP O
44 461 462 19759529 . . O O

1 463 465 19759529 As IN B-PP O
2 466 467 19759529 a DT B-NP O
3 468 474 19759529 result NN I-NP O
4 474 475 19759529 , , O O
5 476 481 19759529 there EX B-NP O
6 482 484 19759529 is VBZ B-VP O
7 485 486 19759529 a DT B-NP O
8 487 494 19759529 growing VBG I-NP O
9 495 503 19759529 interest NN I-NP O
10 504 506 19759529 in IN B-PP O
11 507 510 19759529 the DT B-NP O
12 511 522 19759529 development NN I-NP O
13 523 525 19759529 of IN B-PP O
14 526 541 19759529 pharmacological JJ B-NP O
15 542 548 19759529 agents NNS I-NP O
16 549 553 19759529 with IN B-PP O
17 554 563 19759529 potential JJ B-NP O
18 564 577 19759529 antipsychotic JJ I-NP O
19 578 588 19759529 properties NNS I-NP O
20 589 593 19759529 that WDT B-NP O
21 594 601 19759529 enhance VBP B-VP O
22 602 605 19759529 the DT B-NP O
23 606 614 19759529 activity NN I-NP O
24 615 617 19759529 of IN B-PP O
25 618 621 19759529 the DT B-NP O
26 622 635 19759529 glutamatergic JJ I-NP O
27 636 642 19759529 system NN I-NP O
28 643 646 19759529 via IN B-PP O
29 647 648 19759529 a DT B-NP O
30 649 659 19759529 modulation NN I-NP O
31 660 662 19759529 of IN B-PP O
32 663 666 19759529 the DT B-NP O
33 667 671 19759529 NMDA NN I-NP B-Chemical
34 672 680 19759529 receptor NN I-NP O
35 680 681 19759529 . . O O

1 682 687 19759529 Among IN B-PP O
2 688 692 19759529 them PRP B-NP O
3 693 696 19759529 are VBP B-VP O
4 697 704 19759529 glycine NN B-NP B-Chemical
5 705 716 19759529 transporter NN I-NP O
6 716 717 19759529 - HYPH B-NP O
7 717 718 19759529 1 CD I-NP O
8 719 720 19759529 ( ( O O
9 720 725 19759529 GlyT1 NN B-NP O
10 725 726 19759529 ) ) O O
11 727 737 19759529 inhibitors NNS B-NP O
12 738 742 19759529 such JJ B-PP O
13 743 745 19759529 as IN I-PP O
14 746 755 19759529 SSR103800 NN B-NP B-Chemical
15 755 756 19759529 , , O O
16 757 762 19759529 which WDT B-NP O
17 763 773 19759529 indirectly RB B-ADVP O
18 774 781 19759529 enhance VBP B-VP O
19 782 786 19759529 NMDA NN B-NP B-Chemical
20 787 795 19759529 receptor NN I-NP O
21 796 804 19759529 function NN I-NP O
22 805 807 19759529 by IN B-PP O
23 808 818 19759529 increasing VBG B-VP O
24 819 822 19759529 the DT B-NP O
25 823 830 19759529 glycine NN I-NP B-Chemical
26 831 832 19759529 ( ( O O
27 832 833 19759529 a DT B-NP O
28 834 836 19759529 co AFX I-NP O
29 836 837 19759529 - HYPH I-NP O
30 837 844 19759529 agonist NN I-NP O
31 845 848 19759529 for IN B-PP O
32 849 852 19759529 the DT B-NP O
33 853 857 19759529 NMDA NN I-NP B-Chemical
34 858 866 19759529 receptor NN I-NP O
35 866 867 19759529 ) ) O O
36 868 874 19759529 levels NNS B-NP O
37 875 877 19759529 in IN B-PP O
38 878 881 19759529 the DT B-NP O
39 882 889 19759529 synapse NN I-NP O
40 889 890 19759529 . . O O

1 891 895 19759529 This DT B-NP O
2 896 901 19759529 study NN I-NP O
3 902 907 19759529 aimed VBN B-VP O
4 908 910 19759529 at IN B-PP O
5 911 924 19759529 investigating VBG B-VP O
6 925 928 19759529 the DT B-NP O
7 929 938 19759529 potential JJ I-NP O
8 939 952 19759529 antipsychotic JJ I-NP O
9 952 953 19759529 - HYPH I-NP O
10 953 957 19759529 like JJ I-NP O
11 958 968 19759529 properties NNS I-NP O
12 969 971 19759529 of IN B-PP O
13 972 981 19759529 SSR103800 NN B-NP B-Chemical
14 981 982 19759529 , , O O
15 983 987 19759529 with IN B-PP O
16 988 989 19759529 a DT B-NP O
17 990 1000 19759529 particular JJ I-NP O
18 1001 1006 19759529 focus NN I-NP O
19 1007 1009 19759529 on IN B-PP O
20 1010 1016 19759529 models NNS B-NP O
21 1017 1019 19759529 of IN B-PP O
22 1020 1033 19759529 hyperactivity NN B-NP B-Disease
23 1033 1034 19759529 , , O O
24 1035 1044 19759529 involving VBG B-VP O
25 1045 1051 19759529 either CC O O
26 1052 1056 19759529 drug NN B-NP O
27 1057 1066 19759529 challenge NN I-NP O
28 1067 1068 19759529 ( ( O O
29 1068 1070 19759529 ie FW B-NP O
30 1070 1071 19759529 , , I-NP O
31 1072 1083 19759529 amphetamine NN I-NP B-Chemical
32 1084 1087 19759529 and CC I-NP O
33 1088 1090 19759529 MK NN I-NP B-Chemical
34 1090 1091 19759529 - HYPH B-NP I-Chemical
35 1091 1094 19759529 801 CD I-NP I-Chemical
36 1094 1095 19759529 ) ) O O
37 1096 1098 19759529 or CC O O
38 1099 1109 19759529 transgenic JJ B-NP O
39 1110 1114 19759529 mice NNS I-NP O
40 1115 1116 19759529 ( ( O O
41 1116 1118 19759529 ie FW B-NP O
42 1118 1119 19759529 , , O O
43 1120 1124 19759529 NMDA NN B-NP B-Chemical
44 1125 1132 19759529 Nr1(neo NN I-NP O
45 1132 1133 19759529 - HYPH O O
46 1133 1134 19759529 / SYM B-NP O
47 1134 1135 19759529 - SYM B-NP O
48 1135 1136 19759529 ) ) O O
49 1137 1140 19759529 and CC O O
50 1141 1145 19759529 DAT( NN B-NP O
51 1145 1146 19759529 - HYPH O O
52 1146 1147 19759529 / SYM O O
53 1147 1148 19759529 - SYM O O
54 1148 1149 19759529 ) ) O O
55 1149 1150 19759529 ) ) O O
56 1150 1151 19759529 . . O O

1 1152 1159 19759529 Results NNS B-NP O
2 1160 1166 19759529 showed VBD B-VP O
3 1167 1171 19759529 that IN B-SBAR O
4 1172 1181 19759529 SSR103800 NN B-NP B-Chemical
5 1182 1183 19759529 ( ( O O
6 1183 1185 19759529 10 CD B-NP O
7 1185 1186 19759529 - HYPH I-NP O
8 1186 1188 19759529 30 CD I-NP O
9 1189 1191 19759529 mg NN I-NP O
10 1191 1192 19759529 / SYM B-NP O
11 1192 1194 19759529 kg NN I-NP O
12 1195 1198 19759529 p.o NN I-NP O
13 1198 1199 19759529 . . O O
14 1199 1200 19759529 ) ) O O
15 1201 1208 19759529 blocked VBD B-VP O
16 1209 1222 19759529 hyperactivity NN B-NP B-Disease
17 1223 1230 19759529 induced VBN B-VP O
18 1231 1233 19759529 by IN B-PP O
19 1234 1237 19759529 the DT B-NP O
20 1238 1241 19759529 non AFX I-NP O
21 1241 1242 19759529 - HYPH I-NP O
22 1242 1253 19759529 competitive JJ I-NP O
23 1254 1258 19759529 NMDA NN I-NP B-Chemical
24 1259 1267 19759529 receptor NN I-NP O
25 1268 1278 19759529 antagonist NN I-NP O
26 1278 1279 19759529 , , O O
27 1280 1282 19759529 MK NN B-NP B-Chemical
28 1282 1283 19759529 - HYPH B-NP I-Chemical
29 1283 1286 19759529 801 CD I-NP I-Chemical
30 1287 1290 19759529 and CC O O
31 1291 1300 19759529 partially RB B-VP O
32 1301 1309 19759529 reversed VBD I-VP O
33 1310 1321 19759529 spontaneous JJ B-NP O
34 1322 1335 19759529 hyperactivity NN I-NP B-Disease
35 1336 1338 19759529 of IN B-PP O
36 1339 1343 19759529 NMDA NN B-NP B-Chemical
37 1344 1351 19759529 Nr1(neo NN I-NP O
38 1351 1352 19759529 - HYPH O O
39 1352 1353 19759529 / SYM O O
40 1353 1354 19759529 - SYM O O
41 1354 1355 19759529 ) ) O O
42 1356 1360 19759529 mice NNS B-NP O
43 1360 1361 19759529 . . O O

1 1362 1364 19759529 In IN B-PP O
2 1365 1373 19759529 contrast NN B-NP O
3 1373 1374 19759529 , , O O
4 1375 1384 19759529 SSR103800 NN B-NP B-Chemical
5 1385 1391 19759529 failed VBD B-VP O
6 1392 1394 19759529 to TO I-VP O
7 1395 1401 19759529 affect VB I-VP O
8 1402 1415 19759529 hyperactivity NN B-NP B-Disease
9 1416 1423 19759529 induced VBN B-VP O
10 1424 1426 19759529 by IN B-PP O
11 1427 1438 19759529 amphetamine NN B-NP B-Chemical
12 1439 1441 19759529 or CC O O
13 1442 1451 19759529 naturally RB B-VP O
14 1452 1460 19759529 observed VBN I-VP O
15 1461 1463 19759529 in IN B-PP O
16 1464 1472 19759529 dopamine NN B-NP B-Chemical
17 1473 1484 19759529 transporter NN I-NP O
18 1485 1486 19759529 ( ( O O
19 1486 1490 19759529 DAT( NN B-NP O
20 1490 1491 19759529 - HYPH O O
21 1491 1492 19759529 / SYM O O
22 1492 1493 19759529 - SYM O O
23 1493 1494 19759529 ) ) O O
24 1494 1495 19759529 ) ) O O
25 1496 1504 19759529 knockout JJ B-NP O
26 1505 1509 19759529 mice NNS I-NP O
27 1510 1511 19759529 ( ( O O
28 1511 1513 19759529 10 CD B-NP O
29 1513 1514 19759529 - HYPH I-NP O
30 1514 1516 19759529 30 CD I-NP O
31 1517 1519 19759529 mg NN I-NP O
32 1519 1520 19759529 / SYM B-NP O
33 1520 1522 19759529 kg NN I-NP O
34 1523 1526 19759529 p.o NN I-NP O
35 1526 1527 19759529 . . O O
36 1527 1528 19759529 ) ) O O
37 1528 1529 19759529 . . O O

1 1530 1541 19759529 Importantly RB B-ADVP O
2 1541 1542 19759529 , , O O
3 1543 1547 19759529 both DT O O
4 1548 1557 19759529 classical JJ O O
5 1558 1559 19759529 ( ( O O
6 1559 1570 19759529 haloperidol NN B-NP B-Chemical
7 1570 1571 19759529 ) ) O O
8 1572 1575 19759529 and CC O O
9 1576 1584 19759529 atypical JJ B-NP O
10 1585 1586 19759529 ( ( O O
11 1586 1596 19759529 olanzapine NN B-NP B-Chemical
12 1596 1597 19759529 , , O O
13 1598 1607 19759529 clozapine NN B-NP B-Chemical
14 1608 1611 19759529 and CC O O
15 1612 1624 19759529 aripiprazole NN B-NP B-Chemical
16 1624 1625 19759529 ) ) O O
17 1626 1640 19759529 antipsychotics NNS B-NP O
18 1641 1645 19759529 were VBD B-VP O
19 1646 1655 19759529 effective JJ B-ADJP O
20 1656 1658 19759529 in IN B-PP O
21 1659 1662 19759529 all PDT B-NP O
22 1663 1668 19759529 these DT I-NP O
23 1669 1675 19759529 models NNS I-NP O
24 1676 1678 19759529 of IN B-PP O
25 1679 1692 19759529 hyperactivity NN B-NP B-Disease
26 1692 1693 19759529 . . O O

1 1694 1701 19759529 However RB B-ADVP O
2 1701 1702 19759529 , , O O
3 1703 1709 19759529 unlike IN B-PP O
4 1710 1715 19759529 these DT B-NP O
5 1716 1722 19759529 latter JJ I-NP O
6 1722 1723 19759529 , , O O
7 1724 1733 19759529 SSR103800 NN B-NP B-Chemical
8 1734 1737 19759529 did VBD B-VP O
9 1738 1741 19759529 not RB I-VP O
10 1742 1749 19759529 produce VB I-VP O
11 1750 1759 19759529 catalepsy NN B-NP B-Disease
12 1760 1761 19759529 ( ( O O
13 1761 1770 19759529 retention NN B-NP O
14 1771 1773 19759529 on IN B-PP O
15 1774 1777 19759529 the DT B-NP O
16 1778 1781 19759529 bar NN I-NP O
17 1782 1786 19759529 test NN I-NP O
18 1786 1787 19759529 ) ) O O
19 1788 1790 19759529 up IN B-NP O
20 1791 1793 19759529 to TO I-NP O
21 1794 1796 19759529 30 CD I-NP O
22 1797 1799 19759529 mg NN I-NP O
23 1799 1800 19759529 / SYM B-NP O
24 1800 1802 19759529 kg NN I-NP O
25 1803 1806 19759529 p.o NN I-NP O
26 1806 1807 19759529 . . O O

1 1808 1816 19759529 Together RB B-ADVP O
2 1817 1822 19759529 these DT B-NP O
3 1823 1831 19759529 findings NNS I-NP O
4 1832 1836 19759529 show VBP B-VP O
5 1837 1841 19759529 that IN B-SBAR O
6 1842 1845 19759529 the DT B-NP O
7 1846 1851 19759529 GlyT1 NN I-NP O
8 1852 1861 19759529 inhibitor NN I-NP O
9 1861 1862 19759529 , , O O
10 1863 1872 19759529 SSR103800 NN B-NP B-Chemical
11 1872 1873 19759529 , , O O
12 1874 1882 19759529 produces VBZ B-VP O
13 1883 1896 19759529 antipsychotic JJ B-NP O
14 1896 1897 19759529 - HYPH I-NP O
15 1897 1901 19759529 like JJ I-NP O
16 1902 1909 19759529 effects NNS I-NP O
17 1909 1910 19759529 , , O O
18 1911 1916 19759529 which WDT B-NP O
19 1917 1923 19759529 differ VBP B-VP O
20 1924 1928 19759529 from IN B-PP O
21 1929 1934 19759529 those DT B-NP O
22 1935 1943 19759529 observed VBN B-VP O
23 1944 1948 19759529 with IN B-PP O
24 1949 1958 19759529 compounds NNS B-NP O
25 1959 1968 19759529 primarily RB B-VP O
26 1969 1978 19759529 targeting VBG I-VP O
27 1979 1982 19759529 the DT B-NP O
28 1983 1995 19759529 dopaminergic JJ I-NP O
29 1996 2002 19759529 system NN I-NP O
30 2002 2003 19759529 , , O O
31 2004 2007 19759529 and CC O O
32 2008 2011 19759529 has VBZ B-VP O
33 2012 2013 19759529 a DT B-NP O
34 2014 2021 19759529 reduced VBN I-NP O
35 2022 2026 19759529 side NN I-NP O
36 2026 2027 19759529 - HYPH I-NP O
37 2027 2033 19759529 effect NN I-NP O
38 2034 2043 19759529 potential NN I-NP O
39 2044 2046 19759529 as IN B-PP O
40 2047 2055 19759529 compared VBN B-PP O
41 2056 2060 19759529 with IN B-PP O
42 2061 2066 19759529 these DT B-NP O
43 2067 2073 19759529 latter JJ I-NP O
44 2074 2079 19759529 drugs NNS I-NP O
45 2079 2080 19759529 . . O O

1 0 0 11961407 -DOCSTART- -X- -X- O

1 0 6 11961407 GLEPP1 NN B-NP O
2 7 15 11961407 receptor NN I-NP O
3 16 24 11961407 tyrosine NN I-NP B-Chemical
4 25 36 11961407 phosphatase NN I-NP O
5 37 38 11961407 ( ( O O
6 38 43 11961407 Ptpro NN B-NP O
7 43 44 11961407 ) ) O O
8 45 47 11961407 in IN B-PP O
9 48 51 11961407 rat NN B-NP O
10 52 55 11961407 PAN NN I-NP B-Chemical
11 56 65 11961407 nephrosis NN I-NP B-Disease
12 65 66 11961407 . . O O

1 67 68 11961407 A DT B-NP O
2 69 75 11961407 marker NN I-NP O
3 76 78 11961407 of IN B-PP O
4 79 84 11961407 acute JJ B-NP O
5 85 93 11961407 podocyte NN I-NP O
6 94 100 11961407 injury NN I-NP O
7 100 101 11961407 . . O O
8 102 112 11961407 Glomerular JJ B-NP O
9 113 123 11961407 epithelial JJ I-NP O
10 124 131 11961407 protein NN I-NP O
11 132 133 11961407 1 CD I-NP O
12 134 135 11961407 ( ( O O
13 135 141 11961407 GLEPP1 NN B-NP O
14 141 142 11961407 ) ) O O
15 143 145 11961407 is VBZ B-VP O
16 146 147 11961407 a DT B-NP O
17 148 156 11961407 podocyte NN I-NP O
18 157 165 11961407 receptor NN I-NP O
19 166 174 11961407 membrane NN I-NP O
20 175 182 11961407 protein NN I-NP O
21 183 191 11961407 tyrosine NN I-NP B-Chemical
22 192 203 11961407 phosphatase NN I-NP O
23 204 211 11961407 located JJ B-ADJP O
24 212 214 11961407 on IN B-PP O
25 215 218 11961407 the DT B-NP O
26 219 225 11961407 apical JJ I-NP O
27 226 230 11961407 cell NN I-NP O
28 231 239 11961407 membrane NN I-NP O
29 240 242 11961407 of IN B-PP O
30 243 251 11961407 visceral JJ B-NP O
31 252 262 11961407 glomerular JJ I-NP O
32 263 273 11961407 epithelial JJ I-NP O
33 274 278 11961407 cell NN I-NP O
34 279 282 11961407 and CC I-NP O
35 283 287 11961407 foot NN I-NP O
36 288 297 11961407 processes NNS I-NP O
37 297 298 11961407 . . O O

1 299 303 11961407 This DT B-NP O
2 304 312 11961407 receptor NN I-NP O
3 313 318 11961407 plays VBZ B-VP O
4 319 320 11961407 a DT B-NP O
5 321 325 11961407 role NN I-NP O
6 326 328 11961407 in IN B-PP O
7 329 339 11961407 regulating VBG B-VP O
8 340 343 11961407 the DT B-NP O
9 344 353 11961407 structure NN I-NP O
10 354 357 11961407 and CC I-NP O
11 358 366 11961407 function NN I-NP O
12 367 369 11961407 of IN B-PP O
13 370 378 11961407 podocyte NN B-NP O
14 379 383 11961407 foot NN I-NP O
15 384 391 11961407 process NN I-NP O
16 391 392 11961407 . . O O

1 393 395 11961407 To TO B-VP O
2 396 402 11961407 better RBR I-VP O
3 403 413 11961407 understand VB I-VP O
4 414 417 11961407 the DT B-NP O
5 418 425 11961407 utility NN I-NP O
6 426 428 11961407 of IN B-PP O
7 429 435 11961407 GLEPP1 NN B-NP O
8 436 438 11961407 as IN B-PP O
9 439 440 11961407 a DT B-NP O
10 441 447 11961407 marker NN I-NP O
11 448 450 11961407 of IN B-PP O
12 451 461 11961407 glomerular JJ B-NP B-Disease
13 462 468 11961407 injury NN I-NP I-Disease
14 468 469 11961407 , , O O
15 470 473 11961407 the DT B-NP O
16 474 480 11961407 amount NN I-NP O
17 481 484 11961407 and CC I-NP O
18 485 497 11961407 distribution NN I-NP O
19 498 500 11961407 of IN B-PP O
20 501 507 11961407 GLEPP1 NN B-NP O
21 508 515 11961407 protein NN I-NP O
22 516 519 11961407 and CC O O
23 520 524 11961407 mRNA NN B-NP O
24 525 529 11961407 were VBD B-VP O
25 530 538 11961407 examined VBN I-VP O
26 539 541 11961407 by IN B-PP O
27 542 562 11961407 immunohistochemistry NN B-NP O
28 562 563 11961407 , , O O
29 564 571 11961407 Western NN B-NP O
30 572 576 11961407 blot NN I-NP O
31 577 580 11961407 and CC O O
32 581 586 11961407 RNase NN B-NP O
33 587 597 11961407 protection NN I-NP O
34 598 603 11961407 assay NN I-NP O
35 604 606 11961407 in IN B-PP O
36 607 608 11961407 a DT B-NP O
37 609 614 11961407 model NN I-NP O
38 615 617 11961407 of IN B-PP O
39 618 626 11961407 podocyte NN B-NP O
40 627 633 11961407 injury NN I-NP O
41 634 636 11961407 in IN B-PP O
42 637 640 11961407 the DT B-NP O
43 641 644 11961407 rat NN I-NP O
44 644 645 11961407 . . O O

1 646 655 11961407 Puromycin NN B-NP B-Chemical
2 656 671 11961407 aminonucleoside NN I-NP I-Chemical
3 672 681 11961407 nephrosis NN I-NP B-Disease
4 682 685 11961407 was VBD B-VP O
5 686 693 11961407 induced VBN I-VP O
6 694 696 11961407 by IN B-PP O
7 697 703 11961407 single JJ B-NP O
8 704 719 11961407 intraperitoneal JJ I-NP O
9 720 729 11961407 injection NN I-NP O
10 730 732 11961407 of IN B-PP O
11 733 742 11961407 puromycin NN B-NP B-Chemical
12 743 758 11961407 aminonucleoside NN I-NP I-Chemical
13 759 760 11961407 ( ( O O
14 760 763 11961407 PAN NN B-NP B-Chemical
15 763 764 11961407 , , O O
16 765 767 11961407 20 CD B-NP O
17 768 770 11961407 mg NN I-NP O
18 770 771 11961407 / SYM B-NP O
19 771 775 11961407 100g NN I-NP O
20 776 778 11961407 BW NN I-NP O
21 778 779 11961407 ) ) O O
22 779 780 11961407 . . O O

1 781 788 11961407 Tissues NNS B-NP O
2 789 793 11961407 were VBD B-VP O
3 794 802 11961407 analyzed VBN I-VP O
4 803 805 11961407 at IN B-PP O
5 806 807 11961407 0 CD B-NP O
6 807 808 11961407 , , I-NP O
7 809 810 11961407 5 CD I-NP O
8 810 811 11961407 , , I-NP O
9 812 813 11961407 7 CD I-NP O
10 813 814 11961407 , , I-NP O
11 815 817 11961407 11 CD I-NP O
12 817 818 11961407 , , I-NP O
13 819 821 11961407 21 CD I-NP O
14 821 822 11961407 , , I-NP O
15 823 825 11961407 45 CD I-NP O
16 825 826 11961407 , , I-NP O
17 827 829 11961407 80 CD I-NP O
18 830 833 11961407 and CC I-NP O
19 834 837 11961407 126 CD I-NP O
20 838 842 11961407 days NNS I-NP O
21 843 848 11961407 after IN B-PP O
22 849 852 11961407 PAN NN B-NP B-Chemical
23 853 862 11961407 injection NN I-NP O
24 863 865 11961407 so RB B-SBAR O
25 866 868 11961407 as IN I-SBAR O
26 869 871 11961407 to TO B-VP O
27 872 879 11961407 include VB I-VP O
28 880 884 11961407 both CC O O
29 885 888 11961407 the DT B-NP O
30 889 894 11961407 acute JJ I-NP O
31 895 900 11961407 phase NN I-NP O
32 901 903 11961407 of IN B-PP O
33 904 915 11961407 proteinuria NN B-NP B-Disease
34 916 926 11961407 associated VBN B-VP O
35 927 931 11961407 with IN B-PP O
36 932 936 11961407 foot NN B-NP O
37 937 944 11961407 process NN I-NP O
38 945 955 11961407 effacement NN I-NP O
39 956 957 11961407 ( ( O O
40 957 961 11961407 days NNS B-NP O
41 962 963 11961407 5 CD B-NP O
42 963 964 11961407 - HYPH I-NP O
43 964 966 11961407 11 CD I-NP O
44 966 967 11961407 ) ) O O
45 968 971 11961407 and CC O O
46 972 975 11961407 the DT B-NP O
47 976 983 11961407 chronic JJ I-NP O
48 984 989 11961407 phase NN I-NP O
49 990 992 11961407 of IN B-PP O
50 993 1004 11961407 proteinuria NN B-NP B-Disease
51 1005 1015 11961407 associated VBN B-VP O
52 1016 1020 11961407 with IN B-PP O
53 1021 1039 11961407 glomerulosclerosis NN B-NP B-Disease
54 1040 1041 11961407 ( ( O O
55 1041 1045 11961407 days NNS B-NP O
56 1046 1048 11961407 45 CD B-NP O
57 1048 1049 11961407 - HYPH I-NP O
58 1049 1052 11961407 126 CD I-NP O
59 1052 1053 11961407 ) ) O O
60 1053 1054 11961407 . . O O

1 1055 1057 11961407 At IN B-PP O
2 1058 1061 11961407 day NN B-NP O
3 1062 1063 11961407 5 CD I-NP O
4 1063 1064 11961407 , , O O
5 1065 1071 11961407 GLEPP1 NN B-NP O
6 1072 1079 11961407 protein NN I-NP O
7 1080 1083 11961407 and CC O O
8 1084 1088 11961407 mRNA NN B-NP O
9 1089 1093 11961407 were VBD B-VP O
10 1094 1101 11961407 reduced VBN I-VP O
11 1102 1106 11961407 from IN B-PP O
12 1107 1110 11961407 the DT B-NP O
13 1111 1117 11961407 normal JJ I-NP O
14 1118 1123 11961407 range NN I-NP O
15 1124 1125 11961407 ( ( O O
16 1125 1130 11961407 265.2 CD B-NP O
17 1131 1132 11961407 + SYM O O
18 1132 1133 11961407 / SYM O O
19 1133 1134 11961407 - SYM O O
20 1135 1139 11961407 79.6 CD B-NP O
21 1140 1141 11961407 x SYM I-NP O
22 1142 1147 11961407 10(6) CD I-NP O
23 1148 1153 11961407 moles NNS I-NP O
24 1153 1154 11961407 / SYM B-NP O
25 1154 1164 11961407 glomerulus NN B-NP O
26 1165 1168 11961407 and CC O O
27 1169 1173 11961407 100% NN B-NP O
28 1173 1174 11961407 ) ) O O
29 1175 1177 11961407 to TO B-PP O
30 1178 1181 11961407 15% CD B-NP O
31 1182 1184 11961407 of IN B-PP O
32 1185 1191 11961407 normal JJ B-NP O
33 1192 1193 11961407 ( ( O O
34 1193 1197 11961407 41.8 CD B-NP O
35 1198 1199 11961407 + SYM O O
36 1199 1200 11961407 / SYM O O
37 1200 1201 11961407 - SYM O O
38 1202 1205 11961407 4.8 CD B-NP O
39 1206 1207 11961407 x SYM I-NP O
40 1208 1213 11961407 10(6) CD I-NP O
41 1214 1219 11961407 moles NNS I-NP O
42 1219 1220 11961407 / SYM B-NP O
43 1220 1230 11961407 glomerulus NN I-NP O
44 1230 1231 11961407 , , O O
45 1232 1233 11961407 p NN B-NP O
46 1234 1235 11961407 < SYM B-NP O
47 1236 1241 11961407 0.005 CD I-NP O
48 1241 1242 11961407 ) ) O O
49 1242 1243 11961407 . . O O

1 1244 1248 11961407 This DT B-NP O
2 1249 1257 11961407 occurred VBD B-VP O
3 1258 1260 11961407 in IN B-PP O
4 1261 1272 11961407 association NN B-NP O
5 1273 1277 11961407 with IN B-PP O
6 1278 1280 11961407 an DT B-NP O
7 1281 1289 11961407 increase NN I-NP O
8 1290 1292 11961407 in IN B-PP O
9 1293 1300 11961407 urinary JJ B-NP O
10 1301 1308 11961407 protein NN I-NP O
11 1309 1316 11961407 content NN I-NP O
12 1317 1321 11961407 from IN B-PP O
13 1322 1325 11961407 1.8 CD B-NP O
14 1326 1327 11961407 + SYM B-ADJP O
15 1327 1328 11961407 / SYM O O
16 1328 1329 11961407 - SYM O O
17 1330 1331 11961407 1 CD B-NP O
18 1332 1334 11961407 to TO B-PP O
19 1335 1339 11961407 99.0 CD B-NP O
20 1340 1341 11961407 + SYM O O
21 1341 1342 11961407 / SYM O O
22 1342 1343 11961407 - SYM O O
23 1344 1346 11961407 61 CD B-NP O
24 1347 1349 11961407 mg NN I-NP O
25 1349 1350 11961407 / SYM B-NP O
26 1350 1353 11961407 day NN I-NP O
27 1354 1355 11961407 ( ( O O
28 1355 1356 11961407 p NN B-NP O
29 1357 1358 11961407 < SYM O O
30 1359 1364 11961407 0.001 CD B-NP O
31 1364 1365 11961407 ) ) O O
32 1365 1366 11961407 . . O O

1 1367 1369 11961407 In IN B-PP O
2 1370 1378 11961407 contrast NN B-NP O
3 1378 1379 11961407 , , O O
4 1380 1391 11961407 podocalyxin NN B-NP O
5 1392 1395 11961407 did VBD B-VP O
6 1396 1399 11961407 not RB I-VP O
7 1400 1406 11961407 change VB I-VP O
8 1407 1420 11961407 significantly RB B-ADVP O
9 1421 1423 11961407 at IN B-PP O
10 1424 1428 11961407 this DT B-NP O
11 1429 1433 11961407 time NN I-NP O
12 1433 1434 11961407 . . O O

1 1435 1437 11961407 By IN B-PP O
2 1438 1441 11961407 day NN B-NP O
3 1442 1444 11961407 11 CD I-NP O
4 1444 1445 11961407 , , O O
5 1446 1452 11961407 GLEPP1 NN B-NP O
6 1453 1460 11961407 protein NN I-NP O
7 1461 1464 11961407 and CC O O
8 1465 1469 11961407 mRNA NN B-NP O
9 1470 1473 11961407 had VBD B-VP O
10 1474 1479 11961407 begun VBN I-VP O
11 1480 1482 11961407 to TO I-VP O
12 1483 1489 11961407 return VB I-VP O
13 1490 1497 11961407 towards IN B-PP O
14 1498 1506 11961407 baseline NN B-NP O
15 1506 1507 11961407 . . O O

1 1508 1510 11961407 By IN B-PP O
2 1511 1514 11961407 day NN B-NP O
3 1515 1517 11961407 45 CD I-NP O
4 1517 1518 11961407 - HYPH B-NP O
5 1518 1521 11961407 126 CD I-NP O
6 1521 1522 11961407 , , O O
7 1523 1525 11961407 at IN B-PP O
8 1526 1527 11961407 a DT B-NP O
9 1528 1532 11961407 time NN I-NP O
10 1533 1537 11961407 when WRB B-ADVP O
11 1538 1548 11961407 glomerular JJ B-NP O
12 1549 1557 11961407 scarring NN I-NP O
13 1558 1561 11961407 was VBD B-VP O
14 1562 1569 11961407 present JJ B-ADJP O
15 1569 1570 11961407 , , O O
16 1571 1577 11961407 GLEPP1 NN B-NP O
17 1578 1581 11961407 was VBD B-VP O
18 1582 1588 11961407 absent JJ B-ADJP O
19 1589 1593 11961407 from IN B-PP O
20 1594 1612 11961407 glomerulosclerotic JJ B-NP O
21 1613 1618 11961407 areas NNS I-NP O
22 1619 1627 11961407 although IN B-SBAR O
23 1628 1631 11961407 the DT B-NP O
24 1632 1637 11961407 total JJ I-NP O
25 1638 1648 11961407 glomerular JJ I-NP O
26 1649 1656 11961407 content NN I-NP O
27 1657 1659 11961407 of IN B-PP O
28 1660 1666 11961407 GLEPP1 NN B-NP O
29 1667 1670 11961407 was VBD B-VP O
30 1671 1674 11961407 not RB O O
31 1675 1684 11961407 different JJ B-ADJP O
32 1685 1689 11961407 from IN B-PP O
33 1690 1696 11961407 normal JJ B-ADJP O
34 1696 1697 11961407 . . O O

1 1698 1700 11961407 We PRP B-NP O
2 1701 1709 11961407 conclude VBP B-VP O
3 1710 1714 11961407 that IN B-SBAR O
4 1715 1721 11961407 GLEPP1 NN B-NP O
5 1722 1732 11961407 expression NN I-NP O
6 1732 1733 11961407 , , O O
7 1734 1740 11961407 unlike IN B-PP O
8 1741 1752 11961407 podocalyxin NN B-NP O
9 1752 1753 11961407 , , O O
10 1754 1762 11961407 reflects VBZ B-VP O
11 1763 1771 11961407 podocyte NN B-NP O
12 1772 1778 11961407 injury NN I-NP O
13 1779 1786 11961407 induced VBN B-VP O
14 1787 1789 11961407 by IN B-PP O
15 1790 1793 11961407 PAN NN B-NP B-Chemical
16 1793 1794 11961407 . . O O

1 1795 1801 11961407 GLEPP1 NN B-NP O
2 1802 1812 11961407 expression NN I-NP O
3 1813 1816 11961407 may MD B-VP O
4 1817 1819 11961407 be VB I-VP O
5 1820 1821 11961407 a DT B-NP O
6 1822 1828 11961407 useful JJ I-NP O
7 1829 1835 11961407 marker NN I-NP O
8 1836 1838 11961407 of IN B-PP O
9 1839 1847 11961407 podocyte NN B-NP O
10 1848 1854 11961407 injury NN I-NP O
11 1854 1855 11961407 . . O O

1 0 0 16181582 -DOCSTART- -X- -X- O

1 0 9 16181582 Valproate NN B-NP B-Chemical
2 9 10 16181582 - HYPH B-PP O
3 10 17 16181582 induced VBN B-NP O
4 18 32 16181582 encephalopathy NN I-NP B-Disease
5 32 33 16181582 . . B-NP O
6 34 43 16181582 Valproate NN I-NP B-Chemical
7 43 44 16181582 - HYPH B-NP O
8 44 51 16181582 induced VBN I-NP O
9 52 66 16181582 encephalopathy NN I-NP B-Disease
10 67 69 16181582 is VBZ B-VP O
11 70 71 16181582 a DT B-NP O
12 72 76 16181582 rare JJ I-NP O
13 77 85 16181582 syndrome NN I-NP O
14 86 90 16181582 that WDT B-NP O
15 91 94 16181582 may MD B-VP O
16 95 103 16181582 manifest VB I-VP O
17 104 106 16181582 in IN B-PP O
18 107 116 16181582 otherwise RB B-NP O
19 117 123 16181582 normal JJ I-NP O
20 124 133 16181582 epileptic JJ I-NP B-Disease
21 134 145 16181582 individuals NNS I-NP O
22 145 146 16181582 . . O O

1 147 149 16181582 It PRP B-NP O
2 150 153 16181582 may MD B-VP O
3 154 158 16181582 even RB B-ADJP O
4 159 166 16181582 present JJ I-ADJP O
5 167 169 16181582 in IN B-PP O
6 170 178 16181582 patients NNS B-NP O
7 179 182 16181582 who WP B-NP O
8 183 187 16181582 have VBP B-VP O
9 188 197 16181582 tolerated VBN I-VP O
10 198 202 16181582 this DT B-NP O
11 203 211 16181582 medicine NN I-NP O
12 212 216 16181582 well RB B-ADVP O
13 217 219 16181582 in IN B-PP O
14 220 223 16181582 the DT B-NP O
15 224 228 16181582 past NN I-NP O
16 228 229 16181582 . . O O

1 230 232 16181582 It PRP B-NP O
2 233 235 16181582 is VBZ B-VP O
3 236 243 16181582 usually RB I-VP O
4 244 247 16181582 but CC I-VP O
5 248 251 16181582 not RB I-VP O
6 252 263 16181582 necessarily RB I-VP O
7 264 274 16181582 associated VBN I-VP O
8 275 279 16181582 with IN B-PP O
9 280 294 16181582 hyperammonemia NN B-NP B-Disease
10 294 295 16181582 . . O O

1 296 299 16181582 The DT B-NP O
2 300 303 16181582 EEG NN I-NP O
3 304 309 16181582 shows VBZ B-VP O
4 310 324 16181582 characteristic JJ B-NP O
5 325 334 16181582 triphasic JJ I-NP O
6 335 340 16181582 waves NNS I-NP O
7 341 343 16181582 in IN B-PP O
8 344 348 16181582 most JJS B-NP O
9 349 357 16181582 patients NNS I-NP O
10 358 362 16181582 with IN B-PP O
11 363 367 16181582 this DT B-NP O
12 368 380 16181582 complication NN I-NP O
13 380 381 16181582 . . O O

1 382 383 16181582 A DT B-NP O
2 384 388 16181582 case NN I-NP O
3 389 391 16181582 of IN B-PP O
4 392 401 16181582 valproate NN B-NP B-Chemical
5 401 402 16181582 - HYPH B-NP O
6 402 409 16181582 induced VBN I-NP O
7 410 424 16181582 encephalopathy NN I-NP B-Disease
8 425 427 16181582 is VBZ B-VP O
9 428 437 16181582 presented VBN I-VP O
10 437 438 16181582 . . O O

1 439 442 16181582 The DT B-NP O
2 443 451 16181582 problems NNS I-NP O
3 452 454 16181582 in IN B-PP O
4 455 465 16181582 diagnosing VBG B-VP O
5 466 470 16181582 this DT B-NP O
6 471 480 16181582 condition NN I-NP O
7 481 484 16181582 are VBP B-VP O
8 485 497 16181582 subsequently RB I-VP O
9 498 507 16181582 discussed VBN I-VP O
10 507 508 16181582 . . O O

1 0 0 16298782 -DOCSTART- -X- -X- O

1 0 5 16298782 Nitro AFX B-NP B-Chemical
2 5 6 16298782 - HYPH I-NP I-Chemical
3 6 7 16298782 L NN I-NP I-Chemical
4 7 8 16298782 - HYPH I-NP I-Chemical
5 8 16 16298782 arginine NN I-NP I-Chemical
6 17 23 16298782 methyl NN I-NP I-Chemical
7 24 29 16298782 ester NN I-NP I-Chemical
8 29 30 16298782 : : O O
9 31 32 16298782 a DT B-NP O
10 33 42 16298782 potential JJ I-NP O
11 43 52 16298782 protector NN I-NP O
12 53 60 16298782 against IN B-PP O
13 61 71 16298782 gentamicin NN B-NP B-Chemical
14 72 83 16298782 ototoxicity NN I-NP B-Disease
15 83 84 16298782 . . O O
16 85 88 16298782 The DT B-NP O
17 89 95 16298782 nitric JJ I-NP B-Chemical
18 96 101 16298782 oxide NN I-NP I-Chemical
19 102 103 16298782 ( ( O O
20 103 105 16298782 NO NN B-NP B-Chemical
21 105 106 16298782 ) ) O O
22 107 116 16298782 inhibitor NN B-NP O
23 117 122 16298782 nitro NN I-NP B-Chemical
24 122 123 16298782 - HYPH B-NP I-Chemical
25 123 124 16298782 L NN I-NP I-Chemical
26 124 125 16298782 - HYPH B-NP I-Chemical
27 125 133 16298782 arginine NN I-NP I-Chemical
28 134 140 16298782 methyl NN I-NP I-Chemical
29 141 146 16298782 ester NN I-NP I-Chemical
30 147 148 16298782 ( ( O O
31 148 149 16298782 L NN B-NP B-Chemical
32 149 150 16298782 - HYPH O I-Chemical
33 150 154 16298782 NAME NN B-NP I-Chemical
34 154 155 16298782 ) ) O O
35 156 159 16298782 may MD B-VP O
36 160 163 16298782 act VB I-VP O
37 164 166 16298782 as IN B-PP O
38 167 169 16298782 an DT B-NP O
39 170 183 16298782 otoprotectant NN I-NP O
40 184 191 16298782 against IN B-PP O
41 192 196 16298782 high JJ B-NP B-Disease
42 196 197 16298782 - HYPH I-NP I-Disease
43 197 206 16298782 frequency NN I-NP I-Disease
44 207 214 16298782 hearing NN I-NP I-Disease
45 215 219 16298782 loss NN I-NP I-Disease
46 220 226 16298782 caused VBN B-VP O
47 227 229 16298782 by IN B-PP O
48 230 240 16298782 gentamicin NN B-NP B-Chemical
49 240 241 16298782 , , O O
50 242 245 16298782 but CC O O
51 246 253 16298782 further JJ B-NP O
52 254 261 16298782 studies NNS I-NP O
53 262 265 16298782 are VBP B-VP O
54 266 272 16298782 needed VBN I-VP O
55 273 275 16298782 to TO B-VP O
56 276 283 16298782 confirm VB I-VP O
57 284 303 16298782 this.Aminoglycoside NN B-NP B-Chemical
58 304 315 16298782 antibiotics NNS I-NP O
59 316 319 16298782 are VBP B-VP O
60 320 325 16298782 still RB I-VP O
61 326 332 16298782 widely RB I-VP O
62 333 337 16298782 used VBN I-VP O
63 338 340 16298782 by IN B-PP O
64 341 347 16298782 virtue NN B-NP O
65 348 350 16298782 of IN B-PP O
66 351 356 16298782 their PRP$ B-NP O
67 357 365 16298782 efficacy NN I-NP O
68 366 369 16298782 and CC I-NP O
69 370 373 16298782 low JJ I-NP O
70 374 378 16298782 cost NN I-NP O
71 378 379 16298782 . . O O

1 380 385 16298782 Their PRP$ B-NP O
2 386 397 16298782 ototoxicity NN I-NP B-Disease
3 398 400 16298782 is VBZ B-VP O
4 401 402 16298782 a DT B-NP O
5 403 410 16298782 serious JJ I-NP O
6 411 417 16298782 health NN I-NP O
7 418 425 16298782 problem NN I-NP O
8 426 429 16298782 and CC O O
9 429 430 16298782 , , O O
10 431 433 16298782 as IN B-SBAR O
11 434 439 16298782 their PRP$ B-NP O
12 440 448 16298782 ototoxic JJ I-NP B-Disease
13 449 458 16298782 mechanism NN I-NP O
14 459 467 16298782 involves VBZ B-VP O
15 468 471 16298782 the DT B-NP O
16 472 482 16298782 production NN I-NP O
17 483 485 16298782 of IN B-PP O
18 486 488 16298782 NO NN B-NP B-Chemical
19 488 489 16298782 , , O O
20 490 492 16298782 we PRP B-NP O
21 493 497 16298782 need VBP B-VP O
22 498 500 16298782 to TO I-VP O
23 501 507 16298782 assess VB I-VP O
24 508 511 16298782 the DT B-NP O
25 512 515 16298782 use NN I-NP O
26 516 518 16298782 of IN B-PP O
27 519 521 16298782 NO NN B-NP B-Chemical
28 522 532 16298782 inhibitors NNS I-NP O
29 533 536 16298782 for IN B-PP O
30 537 540 16298782 the DT B-NP O
31 541 551 16298782 prevention NN I-NP O
32 552 554 16298782 of IN B-PP O
33 555 569 16298782 aminoglycoside NN B-NP B-Chemical
34 569 570 16298782 - HYPH B-NP O
35 570 577 16298782 induced VBN I-NP O
36 578 591 16298782 sensorineural JJ I-NP B-Disease
37 592 599 16298782 hearing NN I-NP I-Disease
38 600 604 16298782 loss NN I-NP I-Disease
39 604 605 16298782 . . O O

1 606 608 16298782 In IN B-PP O
2 609 613 16298782 this DT B-NP O
3 614 626 16298782 experimental JJ I-NP O
4 627 632 16298782 study NN I-NP O
5 633 635 16298782 we PRP B-NP O
6 636 640 16298782 used VBD B-VP O
7 641 643 16298782 30 CD B-NP O
8 644 651 16298782 Sprague NNP I-NP O
9 651 652 16298782 - HYPH I-NP O
10 652 658 16298782 Dawley NNP I-NP O
11 659 663 16298782 rats NNS I-NP O
12 663 664 16298782 , , O O
13 665 667 16298782 27 CD B-NP O
14 668 670 16298782 of IN B-PP O
15 671 676 16298782 which WDT B-NP O
16 677 680 16298782 had VBD B-VP O
17 681 691 16298782 gentamicin NN B-NP B-Chemical
18 692 701 16298782 instilled VBN B-VP O
19 702 706 16298782 into IN B-PP O
20 707 710 16298782 the DT B-NP O
21 711 717 16298782 middle JJ I-NP O
22 718 721 16298782 ear NN I-NP O
23 721 722 16298782 . . O O

1 723 726 16298782 The DT B-NP O
2 727 740 16298782 otoprotectant JJ I-NP O
3 741 742 16298782 L NN I-NP B-Chemical
4 742 743 16298782 - HYPH O I-Chemical
5 743 747 16298782 NAME NN B-NP I-Chemical
6 748 751 16298782 was VBD B-VP O
7 752 764 16298782 administered VBN I-VP O
8 765 774 16298782 topically RB B-ADVP O
9 775 777 16298782 to TO B-PP O
10 778 780 16298782 12 CD B-NP O
11 780 781 16298782 / SYM O O
12 781 783 16298782 27 CD B-NP O
13 784 791 16298782 animals NNS I-NP O
14 791 792 16298782 . . O O

1 793 796 16298782 Its PRP$ B-NP O
2 797 803 16298782 effect NN I-NP O
3 804 807 16298782 was VBD B-VP O
4 808 818 16298782 determined VBN I-VP O
5 819 821 16298782 in IN B-PP O
6 822 827 16298782 terms NNS B-NP O
7 828 830 16298782 of IN B-PP O
8 831 842 16298782 attenuation NN B-NP O
9 843 845 16298782 of IN B-PP O
10 846 853 16298782 hearing NN B-NP B-Disease
11 854 858 16298782 loss NN I-NP I-Disease
12 858 859 16298782 , , O O
13 860 868 16298782 measured VBN B-VP O
14 869 871 16298782 by IN B-PP O
15 872 878 16298782 shifts NNS B-NP O
16 879 881 16298782 in IN B-PP O
17 882 885 16298782 the DT B-NP O
18 886 894 16298782 auditory JJ I-NP O
19 895 904 16298782 brainstem NN I-NP O
20 905 913 16298782 response NN I-NP O
21 914 923 16298782 threshold NN I-NP O
22 923 924 16298782 . . O O

1 925 926 16298782 L NN B-NP B-Chemical
2 926 927 16298782 - HYPH O I-Chemical
3 927 931 16298782 NAME NN B-NP I-Chemical
4 932 939 16298782 reduced VBD B-VP O
5 940 950 16298782 gentamicin NN B-NP B-Chemical
6 950 951 16298782 - HYPH B-NP O
7 951 958 16298782 induced VBN I-NP O
8 959 966 16298782 hearing NN I-NP B-Disease
9 967 971 16298782 loss NN I-NP I-Disease
10 972 974 16298782 in IN B-PP O
11 975 978 16298782 the DT B-NP O
12 979 983 16298782 high JJ I-NP O
13 983 984 16298782 - HYPH I-NP O
14 984 993 16298782 frequency NN I-NP O
15 994 999 16298782 range NN I-NP O
16 999 1000 16298782 , , O O
17 1001 1004 16298782 but CC O O
18 1005 1009 16298782 gave VBD B-VP O
19 1010 1012 16298782 no DT B-NP O
20 1013 1023 16298782 protection NN I-NP O
21 1024 1026 16298782 in IN B-PP O
22 1027 1030 16298782 the DT B-NP O
23 1031 1037 16298782 middle JJ I-NP O
24 1038 1040 16298782 or CC I-NP O
25 1041 1044 16298782 low JJ I-NP O
26 1045 1056 16298782 frequencies NNS I-NP O
27 1056 1057 16298782 . . O O

1 0 0 8437969 -DOCSTART- -X- -X- O

1 0 5 8437969 Sinus NN B-NP B-Disease
2 6 12 8437969 arrest NN I-NP I-Disease
3 13 23 8437969 associated VBN B-VP O
4 24 28 8437969 with IN B-PP O
5 29 39 8437969 continuous JJ B-NP O
6 39 40 8437969 - HYPH I-NP O
7 40 48 8437969 infusion NN I-NP O
8 49 59 8437969 cimetidine NN I-NP B-Chemical
9 59 60 8437969 . . O O
10 61 64 8437969 The DT B-NP O
11 65 79 8437969 administration NN I-NP O
12 80 82 8437969 of IN B-PP O
13 83 95 8437969 intermittent JJ B-NP O
14 96 107 8437969 intravenous JJ I-NP O
15 108 117 8437969 infusions NNS I-NP O
16 118 120 8437969 of IN B-PP O
17 121 131 8437969 cimetidine NN B-NP B-Chemical
18 132 134 8437969 is VBZ B-VP O
19 135 147 8437969 infrequently RB I-VP O
20 148 158 8437969 associated VBN I-VP O
21 159 163 8437969 with IN B-PP O
22 164 167 8437969 the DT B-NP O
23 168 179 8437969 development NN I-NP O
24 180 182 8437969 of IN B-PP O
25 183 199 8437969 bradyarrhythmias NNS B-NP B-Disease
26 199 200 8437969 . . O O

1 201 202 8437969 A DT B-NP O
2 203 205 8437969 40 CD I-NP O
3 205 206 8437969 - HYPH I-NP O
4 206 210 8437969 year NN I-NP O
5 210 211 8437969 - HYPH O O
6 211 214 8437969 old JJ B-NP O
7 215 218 8437969 man NN I-NP O
8 219 223 8437969 with IN B-PP O
9 224 232 8437969 leukemia NN B-NP B-Disease
10 233 236 8437969 and CC O O
11 237 239 8437969 no DT B-NP O
12 240 247 8437969 history NN I-NP O
13 248 250 8437969 of IN B-PP O
14 251 258 8437969 cardiac JJ B-NP B-Disease
15 259 266 8437969 disease NN I-NP I-Disease
16 267 276 8437969 developed VBD B-VP O
17 277 286 8437969 recurrent JJ B-NP O
18 286 287 8437969 , , I-NP O
19 288 293 8437969 brief JJ I-NP O
20 294 302 8437969 episodes NNS I-NP O
21 303 305 8437969 of IN B-PP O
22 306 314 8437969 apparent JJ B-NP O
23 315 320 8437969 sinus NN I-NP B-Disease
24 321 327 8437969 arrest NN I-NP I-Disease
25 328 333 8437969 while IN B-SBAR O
26 334 343 8437969 receiving VBG B-VP O
27 344 354 8437969 continuous JJ B-NP O
28 354 355 8437969 - HYPH I-NP O
29 355 363 8437969 infusion NN I-NP O
30 364 374 8437969 cimetidine NN I-NP B-Chemical
31 375 377 8437969 50 CD I-NP O
32 378 380 8437969 mg NN I-NP O
33 380 381 8437969 / SYM B-NP O
34 381 385 8437969 hour NN I-NP O
35 385 386 8437969 . . O O

1 387 390 8437969 The DT B-NP O
2 391 402 8437969 arrhythmias NNS I-NP B-Disease
3 403 407 8437969 were VBD B-VP O
4 408 418 8437969 temporally RB B-ADJP O
5 419 426 8437969 related VBN I-ADJP O
6 427 429 8437969 to TO B-PP O
7 430 440 8437969 cimetidine NN B-NP B-Chemical
8 441 455 8437969 administration NN I-NP O
9 455 456 8437969 , , O O
10 457 468 8437969 disappeared VBD B-VP O
11 469 474 8437969 after IN B-PP O
12 475 486 8437969 dechallenge NN B-NP O
13 486 487 8437969 , , O O
14 488 491 8437969 and CC O O
15 492 495 8437969 did VBD B-VP O
16 496 499 8437969 not RB I-VP O
17 500 505 8437969 recur VB I-VP O
18 506 512 8437969 during IN B-PP O
19 513 523 8437969 ranitidine NN B-NP B-Chemical
20 524 533 8437969 treatment NN I-NP O
21 533 534 8437969 . . O O

1 535 539 8437969 This DT B-NP O
2 540 542 8437969 is VBZ B-VP O
3 543 546 8437969 the DT B-NP O
4 547 552 8437969 first JJ I-NP O
5 553 561 8437969 reported VBN I-NP O
6 562 566 8437969 case NN I-NP O
7 567 569 8437969 of IN B-PP O
8 570 575 8437969 sinus NN B-NP B-Disease
9 576 582 8437969 arrest NN I-NP I-Disease
10 583 593 8437969 associated VBN B-VP O
11 594 598 8437969 with IN B-PP O
12 599 609 8437969 continuous JJ B-NP O
13 609 610 8437969 - HYPH I-NP O
14 610 618 8437969 infusion NN I-NP O
15 619 629 8437969 cimetidine NN I-NP B-Chemical
16 629 630 8437969 . . O O

1 0 0 26094 -DOCSTART- -X- -X- O

1 0 16 26094 Antihypertensive JJ B-NP O
2 17 22 26094 drugs NNS I-NP O
3 23 26 26094 and CC I-NP O
4 27 37 26094 depression NN I-NP B-Disease
5 37 38 26094 : : O O
6 39 40 26094 a DT B-NP O
7 41 52 26094 reappraisal NN I-NP O
8 52 53 26094 . . O O
9 54 60 26094 Eighty CD B-NP O
10 60 61 26094 - HYPH I-NP O
11 61 65 26094 nine CD I-NP O
12 66 69 26094 new JJ I-NP O
13 70 78 26094 referral JJ I-NP O
14 79 91 26094 hypertensive JJ I-NP B-Disease
15 92 95 26094 out RP B-PRT O
16 95 96 26094 - HYPH B-NP O
17 96 104 26094 patients NNS I-NP O
18 105 108 26094 and CC O O
19 109 111 26094 46 CD B-NP O
20 112 115 26094 new JJ I-NP O
21 116 124 26094 referral JJ I-NP O
22 125 128 26094 non AFX I-NP O
23 128 129 26094 - HYPH I-NP O
24 129 141 26094 hypertensive JJ I-NP B-Disease
25 142 153 26094 chronically RB B-VP O
26 154 164 26094 physically RB I-VP O
27 165 168 26094 ill VB I-VP O
28 169 172 26094 out RP B-PRT O
29 172 173 26094 - HYPH B-NP O
30 173 181 26094 patients NNS I-NP O
31 182 191 26094 completed VBD B-VP O
32 192 193 26094 a DT B-NP O
33 194 198 26094 mood NN I-NP O
34 199 205 26094 rating NN I-NP O
35 206 211 26094 scale NN I-NP O
36 212 214 26094 at IN B-PP O
37 215 222 26094 regular JJ B-NP O
38 223 232 26094 intervals NNS I-NP O
39 233 236 26094 for IN B-PP O
40 237 240 26094 one CD B-NP O
41 241 245 26094 year NN I-NP O
42 245 246 26094 . . O O

1 247 250 26094 The DT B-NP O
2 251 258 26094 results NNS I-NP O
3 259 265 26094 showed VBD B-VP O
4 266 267 26094 a DT B-NP O
5 268 272 26094 high JJ I-NP O
6 273 283 26094 prevalence NN I-NP O
7 284 286 26094 of IN B-PP O
8 287 297 26094 depression NN B-NP B-Disease
9 298 300 26094 in IN B-PP O
10 301 305 26094 both DT B-NP O
11 306 312 26094 groups NNS I-NP O
12 313 315 26094 of IN B-PP O
13 316 324 26094 patients NNS B-NP O
14 324 325 26094 , , O O
15 326 330 26094 with IN B-PP O
16 331 333 26094 no DT B-NP O
17 334 347 26094 preponderance NN I-NP O
18 348 350 26094 in IN B-PP O
19 351 354 26094 the DT B-NP O
20 355 367 26094 hypertensive JJ I-NP B-Disease
21 368 373 26094 group NN I-NP O
22 373 374 26094 . . O O

1 375 387 26094 Hypertensive JJ B-NP B-Disease
2 388 396 26094 patients NNS I-NP O
3 397 401 26094 with IN B-PP O
4 402 413 26094 psychiatric JJ B-NP B-Disease
5 414 423 26094 histories NNS I-NP O
6 424 427 26094 had VBD B-VP O
7 428 429 26094 a DT B-NP O
8 430 436 26094 higher JJR I-NP O
9 437 447 26094 prevalence NN I-NP O
10 448 450 26094 of IN B-PP O
11 451 461 26094 depression NN B-NP B-Disease
12 462 466 26094 than IN B-PP O
13 467 470 26094 the DT B-NP O
14 471 481 26094 comparison NN I-NP O
15 482 490 26094 patients NNS I-NP O
16 490 491 26094 . . O O

1 492 496 26094 This DT B-NP O
2 497 500 26094 was VBD B-VP O
3 501 510 26094 accounted VBN I-VP O
4 511 514 26094 for IN B-PP O
5 515 517 26094 by IN B-PP O
6 518 519 26094 a DT B-NP O
7 520 531 26094 significant JJ I-NP O
8 532 538 26094 number NN I-NP O
9 539 541 26094 of IN B-PP O
10 542 553 26094 depressions NNS B-NP B-Disease
11 554 563 26094 occurring VBG B-VP O
12 564 566 26094 in IN B-PP O
13 567 573 26094 methyl NN B-NP B-Chemical
14 574 578 26094 dopa NN I-NP I-Chemical
15 579 586 26094 treated VBN B-VP O
16 587 595 26094 patients NNS B-NP O
17 596 600 26094 with IN B-PP O
18 601 612 26094 psychiatric JJ B-NP B-Disease
19 613 622 26094 histories NNS I-NP O
20 622 623 26094 . . O O

1 0 0 3076126 -DOCSTART- -X- -X- O

1 0 3 3076126 HMG NN B-NP O
2 4 7 3076126 CoA NN I-NP O
3 8 17 3076126 reductase NN I-NP O
4 18 28 3076126 inhibitors NNS I-NP O
5 28 29 3076126 . . O O

1 30 37 3076126 Current JJ B-NP O
2 38 46 3076126 clinical JJ I-NP O
3 47 57 3076126 experience NN I-NP O
4 57 58 3076126 . . O O
5 59 69 3076126 Lovastatin NN B-NP B-Chemical
6 70 73 3076126 and CC I-NP O
7 74 85 3076126 simvastatin NN I-NP B-Chemical
8 86 89 3076126 are VBP B-VP O
9 90 93 3076126 the DT B-NP O
10 94 95 3076126 2 CD I-NP O
11 96 100 3076126 best JJS I-NP O
12 100 101 3076126 - HYPH I-NP O
13 101 106 3076126 known VBN I-NP O
14 107 114 3076126 members NNS I-NP O
15 115 117 3076126 of IN B-PP O
16 118 121 3076126 the DT B-NP O
17 122 127 3076126 class NN I-NP O
18 128 130 3076126 of IN B-PP O
19 131 145 3076126 hypolipidaemic JJ B-NP O
20 146 152 3076126 agents NNS I-NP O
21 153 158 3076126 known VBN B-VP O
22 159 161 3076126 as IN B-PP O
23 162 165 3076126 HMG NN B-NP O
24 166 169 3076126 CoA NN I-NP O
25 170 179 3076126 reductase NN I-NP O
26 180 190 3076126 inhibitors NNS I-NP O
27 190 191 3076126 . . O O

1 192 200 3076126 Clinical JJ B-NP O
2 201 211 3076126 experience NN I-NP O
3 212 216 3076126 with IN B-PP O
4 217 227 3076126 lovastatin NN B-NP B-Chemical
5 228 236 3076126 includes VBZ B-VP O
6 237 241 3076126 over IN B-NP O
7 242 246 3076126 5000 CD I-NP O
8 247 255 3076126 patients NNS I-NP O
9 255 256 3076126 , , O O
10 257 260 3076126 700 CD B-NP O
11 261 263 3076126 of IN B-PP O
12 264 268 3076126 whom WP B-NP O
13 269 273 3076126 have VBP B-VP O
14 274 278 3076126 been VBN I-VP O
15 279 286 3076126 treated VBN I-VP O
16 287 290 3076126 for IN B-PP O
17 291 292 3076126 2 CD B-NP O
18 293 298 3076126 years NNS I-NP O
19 299 301 3076126 or CC I-NP O
20 302 306 3076126 more JJR I-NP O
21 306 307 3076126 , , O O
22 308 311 3076126 and CC O O
23 312 322 3076126 experience NN B-NP O
24 323 327 3076126 with IN B-PP O
25 328 339 3076126 simvastatin NN B-NP B-Chemical
26 340 348 3076126 includes VBZ B-VP O
27 349 353 3076126 over IN B-NP O
28 354 358 3076126 3500 CD I-NP O
29 359 367 3076126 patients NNS I-NP O
30 367 368 3076126 , , O O
31 369 371 3076126 of IN B-PP O
32 372 376 3076126 whom WP B-NP O
33 377 380 3076126 350 CD B-NP O
34 381 385 3076126 have VBP B-VP O
35 386 390 3076126 been VBN I-VP O
36 391 398 3076126 treated VBN I-VP O
37 399 402 3076126 for IN B-PP O
38 403 405 3076126 18 CD B-NP O
39 406 412 3076126 months NNS I-NP O
40 413 415 3076126 or CC I-NP O
41 416 420 3076126 more JJR I-NP O
42 420 421 3076126 . . O O

1 422 432 3076126 Lovastatin NN B-NP B-Chemical
2 433 436 3076126 has VBZ B-VP O
3 437 441 3076126 been VBN I-VP O
4 442 450 3076126 marketed VBN I-VP O
5 451 453 3076126 in IN B-PP O
6 454 457 3076126 the DT B-NP O
7 458 464 3076126 United NNP I-NP O
8 465 471 3076126 States NNPS I-NP O
9 472 475 3076126 for IN B-PP O
10 476 480 3076126 over IN B-NP O
11 481 482 3076126 6 CD I-NP O
12 483 489 3076126 months NNS I-NP O
13 489 490 3076126 . . O O

1 491 495 3076126 Both DT B-NP O
2 496 502 3076126 agents NNS I-NP O
3 503 507 3076126 show VBP B-VP O
4 508 519 3076126 substantial JJ B-NP O
5 520 528 3076126 clinical JJ I-NP O
6 529 537 3076126 efficacy NN I-NP O
7 537 538 3076126 , , O O
8 539 543 3076126 with IN B-PP O
9 544 554 3076126 reductions NNS B-NP O
10 555 557 3076126 in IN B-PP O
11 558 563 3076126 total JJ B-NP O
12 564 575 3076126 cholesterol NN I-NP B-Chemical
13 576 578 3076126 of IN B-PP O
14 579 583 3076126 over IN B-NP O
15 584 587 3076126 30% CD I-NP O
16 588 591 3076126 and CC O O
17 592 594 3076126 in IN B-PP O
18 595 598 3076126 LDL NN B-NP O
19 598 599 3076126 - HYPH B-NP O
20 599 610 3076126 cholesterol NN I-NP B-Chemical
21 611 613 3076126 of IN B-PP O
22 614 617 3076126 40% NN B-NP O
23 618 620 3076126 in IN B-PP O
24 621 629 3076126 clinical JJ B-NP O
25 630 637 3076126 studies NNS I-NP O
26 637 638 3076126 . . O O

1 639 645 3076126 Modest JJ B-NP O
2 646 655 3076126 increases NNS I-NP O
3 656 658 3076126 in IN B-PP O
4 659 662 3076126 HDL NN B-NP O
5 662 663 3076126 - HYPH B-NP O
6 663 674 3076126 cholesterol NN I-NP B-Chemical
7 675 681 3076126 levels NNS I-NP O
8 682 684 3076126 of IN B-PP O
9 685 690 3076126 about IN B-NP O
10 691 694 3076126 10% CD I-NP O
11 695 698 3076126 are VBP B-VP O
12 699 703 3076126 also RB I-VP O
13 704 712 3076126 reported VBN I-VP O
14 712 713 3076126 . . O O

1 714 722 3076126 Clinical JJ B-NP O
2 723 735 3076126 tolerability NN I-NP O
3 736 738 3076126 of IN B-PP O
4 739 743 3076126 both DT B-NP O
5 744 750 3076126 agents NNS I-NP O
6 751 754 3076126 has VBZ B-VP O
7 755 759 3076126 been VBN I-VP O
8 760 764 3076126 good JJ B-ADJP O
9 764 765 3076126 , , O O
10 766 770 3076126 with IN B-PP O
11 771 776 3076126 fewer JJR B-NP O
12 777 781 3076126 than IN I-NP O
13 782 784 3076126 3% CD I-NP O
14 785 787 3076126 of IN B-PP O
15 788 796 3076126 patients NNS B-NP O
16 797 806 3076126 withdrawn VBN B-VP O
17 807 811 3076126 from IN B-PP O
18 812 821 3076126 treatment NN B-NP O
19 822 829 3076126 because IN B-PP O
20 830 832 3076126 of IN I-PP O
21 833 841 3076126 clinical JJ B-NP O
22 842 849 3076126 adverse JJ I-NP O
23 850 861 3076126 experiences NNS I-NP O
24 861 862 3076126 . . O O

1 863 879 3076126 Ophthalmological JJ B-NP O
2 880 892 3076126 examinations NNS I-NP O
3 893 895 3076126 in IN B-PP O
4 896 900 3076126 over IN B-NP O
5 901 905 3076126 1100 CD I-NP O
6 906 914 3076126 patients NNS I-NP O
7 915 922 3076126 treated VBN B-VP O
8 923 927 3076126 with IN B-PP O
9 928 931 3076126 one CD B-NP O
10 932 934 3076126 or CC O O
11 935 938 3076126 the DT B-NP O
12 939 944 3076126 other JJ I-NP O
13 945 950 3076126 agent NN I-NP O
14 951 955 3076126 have VBP B-VP O
15 956 964 3076126 revealed VBN I-VP O
16 965 967 3076126 no DT B-NP O
17 968 976 3076126 evidence NN I-NP O
18 977 979 3076126 of IN B-PP O
19 980 991 3076126 significant JJ B-NP O
20 992 997 3076126 short JJ I-NP O
21 998 1002 3076126 term NN I-NP O
22 1003 1004 3076126 ( ( O O
23 1004 1006 3076126 up RB B-NP O
24 1007 1009 3076126 to TO I-NP O
25 1010 1011 3076126 2 CD I-NP O
26 1012 1017 3076126 years NNS I-NP O
27 1017 1018 3076126 ) ) O O
28 1019 1033 3076126 cataractogenic JJ B-NP O
29 1034 1043 3076126 potential NN I-NP O
30 1043 1044 3076126 . . O O

1 1045 1048 3076126 One CD B-NP O
2 1049 1051 3076126 to TO B-PP O
3 1052 1054 3076126 2% CD B-NP O
4 1055 1057 3076126 of IN B-PP O
5 1058 1066 3076126 patients NNS B-NP O
6 1067 1071 3076126 have VBP B-VP O
7 1072 1082 3076126 elevations NNS B-NP O
8 1083 1085 3076126 of IN B-PP O
9 1086 1091 3076126 serum NN B-NP O
10 1092 1105 3076126 transaminases NNS I-NP O
11 1106 1108 3076126 to TO B-PP O
12 1109 1116 3076126 greater JJR B-NP O
13 1117 1121 3076126 than IN I-NP O
14 1122 1123 3076126 3 CD I-NP O
15 1124 1129 3076126 times NNS I-NP O
16 1130 1133 3076126 the DT I-NP O
17 1134 1139 3076126 upper JJ I-NP O
18 1140 1145 3076126 limit NN I-NP O
19 1146 1148 3076126 of IN B-PP O
20 1149 1155 3076126 normal JJ B-NP O
21 1155 1156 3076126 . . O O

1 1157 1162 3076126 These DT B-NP O
2 1163 1171 3076126 episodes NNS I-NP O
3 1172 1175 3076126 are VBP B-VP O
4 1176 1188 3076126 asymptomatic JJ B-ADJP O
5 1189 1192 3076126 and CC I-ADJP O
6 1193 1203 3076126 reversible JJ I-ADJP O
7 1204 1208 3076126 when WRB B-ADVP O
8 1209 1216 3076126 therapy NN B-NP O
9 1217 1219 3076126 is VBZ B-VP O
10 1220 1232 3076126 discontinued VBN I-VP O
11 1232 1233 3076126 . . O O

1 1234 1239 3076126 Minor JJ B-NP O
2 1240 1250 3076126 elevations NNS I-NP O
3 1251 1253 3076126 of IN B-PP O
4 1254 1262 3076126 creatine NN B-NP B-Chemical
5 1263 1269 3076126 kinase NN I-NP O
6 1270 1276 3076126 levels NNS I-NP O
7 1277 1280 3076126 are VBP B-VP O
8 1281 1289 3076126 reported VBN I-VP O
9 1290 1292 3076126 in IN B-PP O
10 1293 1298 3076126 about RB B-NP O
11 1299 1301 3076126 5% CD I-NP O
12 1302 1304 3076126 of IN B-PP O
13 1305 1313 3076126 patients NNS B-NP O
14 1313 1314 3076126 . . O O

1 1315 1323 3076126 Myopathy NN B-NP B-Disease
2 1323 1324 3076126 , , O O
3 1325 1335 3076126 associated VBN B-VP O
4 1336 1338 3076126 in IN B-PP O
5 1339 1343 3076126 some DT B-NP O
6 1344 1349 3076126 cases NNS I-NP O
7 1350 1354 3076126 with IN B-PP O
8 1355 1368 3076126 myoglobinuria NN B-NP B-Disease
9 1368 1369 3076126 , , O O
10 1370 1373 3076126 and CC O O
11 1374 1376 3076126 in IN B-PP O
12 1377 1378 3076126 2 CD B-NP O
13 1379 1384 3076126 cases NNS I-NP O
14 1385 1389 3076126 with IN B-PP O
15 1390 1399 3076126 transient JJ B-NP O
16 1400 1405 3076126 renal JJ I-NP B-Disease
17 1406 1413 3076126 failure NN I-NP I-Disease
18 1413 1414 3076126 , , O O
19 1415 1418 3076126 has VBZ B-VP O
20 1419 1423 3076126 been VBN I-VP O
21 1424 1430 3076126 rarely RB I-VP O
22 1431 1439 3076126 reported VBN I-VP O
23 1440 1444 3076126 with IN B-PP O
24 1445 1455 3076126 lovastatin NN B-NP B-Chemical
25 1455 1456 3076126 , , O O
26 1457 1467 3076126 especially RB B-ADVP O
27 1468 1470 3076126 in IN B-PP O
28 1471 1479 3076126 patients NNS B-NP O
29 1480 1493 3076126 concomitantly RB B-VP O
30 1494 1501 3076126 treated VBN I-VP O
31 1502 1506 3076126 with IN B-PP O
32 1507 1518 3076126 cyclosporin NN B-NP B-Chemical
33 1518 1519 3076126 , , I-NP O
34 1520 1531 3076126 gemfibrozil NN I-NP B-Chemical
35 1532 1534 3076126 or CC I-NP O
36 1535 1541 3076126 niacin NN I-NP B-Chemical
37 1541 1542 3076126 . . O O

1 1543 1553 3076126 Lovastatin NN B-NP B-Chemical
2 1554 1557 3076126 and CC I-NP O
3 1558 1569 3076126 simvastatin NN I-NP B-Chemical
4 1570 1573 3076126 are VBP B-VP O
5 1574 1578 3076126 both DT O O
6 1579 1588 3076126 effective JJ B-ADJP O
7 1589 1592 3076126 and CC O O
8 1593 1597 3076126 well RB B-ADJP O
9 1597 1598 3076126 - HYPH I-ADJP O
10 1598 1607 3076126 tolerated VBN B-NP O
11 1608 1614 3076126 agents NNS I-NP O
12 1615 1618 3076126 for IN B-PP O
13 1619 1627 3076126 lowering VBG B-VP O
14 1628 1636 3076126 elevated JJ B-NP O
15 1637 1643 3076126 levels NNS I-NP O
16 1644 1646 3076126 of IN B-PP O
17 1647 1652 3076126 serum NN B-NP O
18 1653 1664 3076126 cholesterol NN I-NP B-Chemical
19 1664 1665 3076126 . . O O

1 1666 1668 3076126 As IN B-SBAR O
2 1669 1674 3076126 wider JJR B-NP O
3 1675 1678 3076126 use NN I-NP O
4 1679 1687 3076126 confirms VBZ B-VP O
5 1688 1693 3076126 their PRP$ B-NP O
6 1694 1700 3076126 safety NN I-NP O
7 1701 1708 3076126 profile NN I-NP O
8 1708 1709 3076126 , , O O
9 1710 1714 3076126 they PRP B-NP O
10 1715 1719 3076126 will MD B-VP O
11 1720 1724 3076126 gain VB I-VP O
12 1725 1735 3076126 increasing VBG B-NP O
13 1736 1746 3076126 importance NN I-NP O
14 1747 1749 3076126 in IN B-PP O
15 1750 1753 3076126 the DT B-NP O
16 1754 1765 3076126 therapeutic JJ I-NP O
17 1766 1774 3076126 approach NN I-NP O
18 1775 1777 3076126 to TO B-PP O
19 1778 1799 3076126 hypercholesterolaemia NN B-NP B-Disease
20 1800 1803 3076126 and CC O O
21 1804 1807 3076126 its PRP$ B-NP O
22 1808 1820 3076126 consequences NNS I-NP O
23 1820 1821 3076126 . . O O

1 0 0 3341566 -DOCSTART- -X- -X- O

1 0 8 3341566 Systolic JJ B-NP O
2 9 17 3341566 pressure NN I-NP O
3 18 27 3341566 variation NN I-NP O
4 28 30 3341566 is VBZ B-VP O
5 31 38 3341566 greater JJR B-ADJP O
6 39 45 3341566 during IN B-PP O
7 46 56 3341566 hemorrhage NN B-NP B-Disease
8 57 61 3341566 than IN B-PP O
9 62 68 3341566 during IN B-PP O
10 69 75 3341566 sodium NN B-NP B-Chemical
11 76 89 3341566 nitroprusside NN I-NP I-Chemical
12 89 90 3341566 - HYPH B-NP O
13 90 97 3341566 induced VBN I-NP O
14 98 109 3341566 hypotension NN I-NP B-Disease
15 110 112 3341566 in IN B-PP O
16 113 123 3341566 ventilated VBN B-NP O
17 124 128 3341566 dogs NNS I-NP O
18 128 129 3341566 . . O O
19 130 133 3341566 The DT B-NP O
20 134 142 3341566 systolic JJ I-NP O
21 143 151 3341566 pressure NN I-NP O
22 152 161 3341566 variation NN I-NP O
23 162 163 3341566 ( ( O O
24 163 166 3341566 SPV NN B-NP O
25 166 167 3341566 ) ) O O
26 167 168 3341566 , , O O
27 169 174 3341566 which WDT B-NP O
28 175 177 3341566 is VBZ B-VP O
29 178 181 3341566 the DT B-NP O
30 182 192 3341566 difference NN I-NP O
31 193 200 3341566 between IN B-PP O
32 201 204 3341566 the DT B-NP O
33 205 212 3341566 maximal JJ I-NP O
34 213 216 3341566 and CC I-NP O
35 217 224 3341566 minimal JJ I-NP O
36 225 231 3341566 values NNS I-NP O
37 232 234 3341566 of IN B-PP O
38 235 238 3341566 the DT B-NP O
39 239 247 3341566 systolic JJ I-NP O
40 248 253 3341566 blood NN I-NP O
41 254 262 3341566 pressure NN I-NP O
42 263 264 3341566 ( ( O O
43 264 267 3341566 SBP NN B-NP O
44 267 268 3341566 ) ) O O
45 269 274 3341566 after IN B-PP O
46 275 278 3341566 one CD B-NP O
47 279 287 3341566 positive JJ I-NP O
48 287 288 3341566 - HYPH I-NP O
49 288 296 3341566 pressure NN I-NP O
50 297 303 3341566 breath NN I-NP O
51 303 304 3341566 , , O O
52 305 308 3341566 was VBD B-VP O
53 309 316 3341566 studied VBN I-VP O
54 317 319 3341566 in IN B-PP O
55 320 330 3341566 ventilated VBN B-NP O
56 331 335 3341566 dogs NNS I-NP O
57 336 345 3341566 subjected VBN B-VP O
58 346 348 3341566 to TO B-PP O
59 349 360 3341566 hypotension NN B-NP B-Disease
60 360 361 3341566 . . O O

1 362 366 3341566 Mean JJ B-NP O
2 367 375 3341566 arterial JJ I-NP O
3 376 384 3341566 pressure NN I-NP O
4 385 388 3341566 was VBD B-VP O
5 389 398 3341566 decreased VBN I-VP O
6 399 401 3341566 to TO B-PP O
7 402 404 3341566 50 CD B-NP O
8 405 407 3341566 mm NN I-NP O
9 408 410 3341566 Hg NN I-NP O
10 411 414 3341566 for IN B-PP O
11 415 417 3341566 30 CD B-NP O
12 418 425 3341566 minutes NNS I-NP O
13 426 432 3341566 either CC B-PP O
14 433 435 3341566 by IN B-PP O
15 436 446 3341566 hemorrhage NN B-NP B-Disease
16 447 448 3341566 ( ( O O
17 448 451 3341566 HEM NN B-NP B-Disease
18 451 452 3341566 , , O O
19 453 454 3341566 n NN B-NP O
20 455 456 3341566 = SYM B-VP O
21 457 458 3341566 7 CD B-NP O
22 458 459 3341566 ) ) O O
23 460 462 3341566 or CC O O
24 463 465 3341566 by IN B-PP O
25 466 476 3341566 continuous JJ B-NP O
26 477 485 3341566 infusion NN I-NP O
27 486 488 3341566 of IN B-PP O
28 489 495 3341566 sodium NN B-NP B-Chemical
29 496 509 3341566 nitroprusside NN I-NP I-Chemical
30 510 511 3341566 ( ( O O
31 511 514 3341566 SNP NN B-NP B-Chemical
32 514 515 3341566 , , O O
33 516 517 3341566 n NN B-NP O
34 518 519 3341566 = SYM B-VP O
35 520 521 3341566 7 CD B-NP O
36 521 522 3341566 ) ) O O
37 522 523 3341566 . . O O

1 524 530 3341566 During IN B-PP O
2 531 534 3341566 HEM NN B-NP B-Disease
3 534 535 3341566 - HYPH B-NP O
4 535 542 3341566 induced VBN I-NP O
5 543 554 3341566 hypotension NN I-NP B-Disease
6 555 558 3341566 the DT B-NP O
7 559 566 3341566 cardiac JJ I-NP O
8 567 573 3341566 output NN I-NP O
9 574 577 3341566 was VBD B-VP O
10 578 591 3341566 significantly RB B-ADJP O
11 592 597 3341566 lower JJR B-NP O
12 598 601 3341566 and CC I-NP O
13 602 610 3341566 systemic JJ I-NP O
14 611 619 3341566 vascular JJ I-NP O
15 620 630 3341566 resistance NN I-NP O
16 631 637 3341566 higher JJR B-ADJP O
17 638 646 3341566 compared VBN B-PP O
18 647 651 3341566 with IN B-PP O
19 652 656 3341566 that DT B-NP O
20 657 659 3341566 in IN B-PP O
21 660 663 3341566 the DT B-NP O
22 664 667 3341566 SNP NN I-NP B-Chemical
23 668 673 3341566 group NN I-NP O
24 673 674 3341566 . . O O

1 675 678 3341566 The DT B-NP O
2 679 687 3341566 systemic JJ I-NP O
3 687 688 3341566 , , I-NP O
4 689 696 3341566 central JJ I-NP O
5 697 703 3341566 venous JJ I-NP O
6 703 704 3341566 , , I-NP O
7 705 714 3341566 pulmonary JJ I-NP O
8 715 724 3341566 capillary JJ I-NP O
9 725 730 3341566 wedge NN I-NP O
10 731 740 3341566 pressures NNS I-NP O
11 740 741 3341566 , , O O
12 742 745 3341566 and CC O O
13 746 751 3341566 heart NN B-NP O
14 752 757 3341566 rates NNS I-NP O
15 757 758 3341566 , , O O
16 759 763 3341566 were VBD B-VP O
17 764 771 3341566 similar JJ B-ADJP O
18 772 774 3341566 in IN B-PP O
19 775 778 3341566 the DT B-NP O
20 779 782 3341566 two CD I-NP O
21 783 789 3341566 groups NNS I-NP O
22 789 790 3341566 . . O O

1 791 799 3341566 Analysis NN B-NP O
2 800 802 3341566 of IN B-PP O
3 803 806 3341566 the DT B-NP O
4 807 818 3341566 respiratory JJ I-NP O
5 819 826 3341566 changes NNS I-NP O
6 827 829 3341566 in IN B-PP O
7 830 833 3341566 the DT B-NP O
8 834 842 3341566 arterial JJ I-NP O
9 843 851 3341566 pressure NN I-NP O
10 852 860 3341566 waveform NN I-NP O
11 861 868 3341566 enabled VBD B-VP O
12 869 884 3341566 differentiation NN B-NP O
13 885 892 3341566 between IN B-PP O
14 893 896 3341566 the DT B-NP O
15 897 900 3341566 two CD I-NP O
16 901 907 3341566 groups NNS I-NP O
17 907 908 3341566 . . O O

1 909 912 3341566 The DT B-NP O
2 913 916 3341566 SPV NN I-NP O
3 917 923 3341566 during IN B-PP O
4 924 935 3341566 hypotension NN B-NP B-Disease
5 936 939 3341566 was VBD B-VP O
6 940 944 3341566 15.7 CD B-NP O
7 945 946 3341566 + SYM O O
8 946 947 3341566 / SYM O O
9 947 948 3341566 - SYM O O
10 949 952 3341566 6.7 CD B-NP O
11 953 955 3341566 mm NN I-NP O
12 956 958 3341566 Hg NN I-NP O
13 959 961 3341566 in IN B-PP O
14 962 965 3341566 the DT B-NP O
15 966 969 3341566 HEM NN I-NP B-Disease
16 970 975 3341566 group NN I-NP O
17 975 976 3341566 , , O O
18 977 985 3341566 compared VBN B-PP O
19 986 990 3341566 with IN B-PP O
20 991 994 3341566 9.1 CD B-NP O
21 995 996 3341566 + SYM O O
22 996 997 3341566 / SYM O O
23 997 998 3341566 - SYM O O
24 999 1002 3341566 2.0 CD B-NP O
25 1003 1005 3341566 mm NN I-NP O
26 1006 1008 3341566 Hg NN I-NP O
27 1009 1011 3341566 in IN B-PP O
28 1012 1015 3341566 the DT B-NP O
29 1016 1019 3341566 SNP NN I-NP B-Chemical
30 1020 1025 3341566 group NN I-NP O
31 1026 1027 3341566 ( ( O O
32 1027 1028 3341566 P NN B-NP O
33 1029 1033 3341566 less JJR B-ADJP O
34 1034 1038 3341566 than IN B-PP O
35 1039 1043 3341566 0.02 CD B-NP O
36 1043 1044 3341566 ) ) O O
37 1044 1045 3341566 . . O O

1 1046 1049 3341566 The DT B-NP O
2 1050 1055 3341566 delta SYM I-NP O
3 1056 1060 3341566 down RP B-PRT O
4 1060 1061 3341566 , , O O
5 1062 1067 3341566 which WDT B-NP O
6 1068 1070 3341566 is VBZ B-VP O
7 1071 1074 3341566 the DT B-NP O
8 1075 1082 3341566 measure NN I-NP O
9 1083 1085 3341566 of IN B-PP O
10 1086 1094 3341566 decrease NN B-NP O
11 1095 1097 3341566 of IN B-PP O
12 1098 1101 3341566 SBP NN B-NP O
13 1102 1107 3341566 after IN B-PP O
14 1108 1109 3341566 a DT B-NP O
15 1110 1120 3341566 mechanical JJ I-NP O
16 1121 1127 3341566 breath NN I-NP O
17 1127 1128 3341566 , , O O
18 1129 1132 3341566 was VBD B-VP O
19 1133 1137 3341566 20.3 CD B-NP O
20 1138 1139 3341566 + SYM O O
21 1139 1140 3341566 / SYM O O
22 1140 1141 3341566 - SYM B-NP O
23 1142 1145 3341566 8.4 CD B-NP O
24 1146 1149 3341566 and CC I-NP O
25 1150 1154 3341566 10.1 CD I-NP O
26 1155 1156 3341566 + SYM O O
27 1156 1157 3341566 / SYM O O
28 1157 1158 3341566 - SYM O O
29 1159 1162 3341566 3.8 CD B-NP O
30 1163 1165 3341566 mm NN I-NP O
31 1166 1168 3341566 Hg NN I-NP O
32 1169 1171 3341566 in IN B-PP O
33 1172 1175 3341566 the DT B-NP O
34 1176 1179 3341566 HEM NN I-NP B-Disease
35 1180 1183 3341566 and CC I-NP O
36 1184 1187 3341566 SNP NN I-NP B-Chemical
37 1188 1194 3341566 groups NNS I-NP O
38 1194 1195 3341566 , , O O
39 1196 1208 3341566 respectively RB B-ADVP O
40 1208 1209 3341566 , , O O
41 1210 1216 3341566 during IN B-PP O
42 1217 1228 3341566 hypotension NN B-NP B-Disease
43 1229 1230 3341566 ( ( O O
44 1230 1231 3341566 P NN B-NP O
45 1232 1236 3341566 less JJR B-ADJP O
46 1237 1241 3341566 than IN B-PP O
47 1242 1246 3341566 0.02 CD B-NP O
48 1246 1247 3341566 ) ) O O
49 1247 1248 3341566 . . O O

1 1249 1251 3341566 It PRP B-NP O
2 1252 1254 3341566 is VBZ B-VP O
3 1255 1264 3341566 concluded VBN I-VP O
4 1265 1269 3341566 that IN B-SBAR O
5 1270 1279 3341566 increases NNS B-NP O
6 1280 1282 3341566 in IN B-PP O
7 1283 1286 3341566 the DT B-NP O
8 1287 1290 3341566 SPV NN I-NP O
9 1291 1294 3341566 and CC O O
10 1295 1298 3341566 the DT B-NP O
11 1299 1304 3341566 delta SYM I-NP O
12 1305 1309 3341566 down RP B-PRT O
13 1310 1313 3341566 are VBP B-VP O
14 1314 1328 3341566 characteristic JJ B-ADJP O
15 1329 1331 3341566 of IN B-PP O
16 1332 1333 3341566 a DT B-NP O
17 1334 1345 3341566 hypotensive JJ I-NP B-Disease
18 1346 1351 3341566 state NN I-NP O
19 1352 1355 3341566 due JJ B-PP O
20 1356 1358 3341566 to TO B-PP O
21 1359 1360 3341566 a DT B-NP O
22 1361 1372 3341566 predominant JJ I-NP O
23 1373 1381 3341566 decrease NN I-NP O
24 1382 1384 3341566 in IN B-PP O
25 1385 1392 3341566 preload NN B-NP O
26 1392 1393 3341566 . . O O

1 1394 1398 3341566 They PRP B-NP O
2 1399 1402 3341566 are VBP B-VP O
3 1403 1407 3341566 thus RB B-ADJP O
4 1408 1412 3341566 more RBR I-ADJP O
5 1413 1422 3341566 important JJ I-ADJP O
6 1423 1429 3341566 during IN B-PP O
7 1430 1438 3341566 absolute JJ B-NP O
8 1439 1450 3341566 hypovolemia NN I-NP B-Disease
9 1451 1455 3341566 than IN B-PP O
10 1456 1462 3341566 during IN B-PP O
11 1463 1473 3341566 deliberate JJ B-NP O
12 1474 1485 3341566 hypotension NN I-NP B-Disease
13 1485 1486 3341566 . . O O

1 0 0 19356307 -DOCSTART- -X- -X- O

1 0 10 19356307 Components NNS B-NP O
2 11 13 19356307 of IN B-PP O
3 14 19 19356307 lemon NN B-NP O
4 20 29 19356307 essential JJ I-NP O
5 30 33 19356307 oil NN I-NP O
6 34 43 19356307 attenuate NN I-NP O
7 44 52 19356307 dementia NN I-NP B-Disease
8 53 60 19356307 induced VBN B-VP O
9 61 63 19356307 by IN B-PP O
10 64 75 19356307 scopolamine NN B-NP B-Chemical
11 75 76 19356307 . . O O
12 77 80 19356307 The DT B-NP O
13 81 85 19356307 anti AFX I-NP O
14 85 86 19356307 - HYPH I-NP O
15 86 94 19356307 dementia NN I-NP B-Disease
16 95 102 19356307 effects NNS I-NP O
17 103 105 19356307 of IN B-PP O
18 106 107 19356307 s AFX B-NP B-Chemical
19 107 108 19356307 - HYPH I-NP I-Chemical
20 108 116 19356307 limonene NN I-NP I-Chemical
21 117 120 19356307 and CC O O
22 121 122 19356307 s AFX B-NP B-Chemical
23 122 123 19356307 - HYPH I-NP I-Chemical
24 123 131 19356307 perillyl NN I-NP I-Chemical
25 132 139 19356307 alcohol NN I-NP I-Chemical
26 140 144 19356307 were VBD B-VP O
27 145 153 19356307 observed VBN I-VP O
28 154 159 19356307 using VBG B-VP O
29 160 163 19356307 the DT B-NP O
30 164 171 19356307 passive JJ I-NP O
31 172 181 19356307 avoidance NN I-NP O
32 182 186 19356307 test NN I-NP O
33 187 188 19356307 ( ( O O
34 188 190 19356307 PA NN B-NP O
35 190 191 19356307 ) ) O O
36 192 195 19356307 and CC O O
37 196 199 19356307 the DT B-NP O
38 200 204 19356307 open JJ I-NP O
39 205 210 19356307 field NN I-NP O
40 211 222 19356307 habituation NN I-NP O
41 223 227 19356307 test NN I-NP O
42 228 229 19356307 ( ( O O
43 229 232 19356307 OFH NN B-NP O
44 232 233 19356307 ) ) O O
45 233 234 19356307 . . O O

1 235 240 19356307 These DT B-NP O
2 241 246 19356307 lemon JJ I-NP O
3 247 256 19356307 essential JJ I-NP O
4 257 261 19356307 oils NNS I-NP O
5 262 268 19356307 showed VBD B-VP O
6 269 275 19356307 strong JJ B-NP O
7 276 283 19356307 ability NN I-NP O
8 284 286 19356307 to TO B-VP O
9 287 294 19356307 improve VB I-VP O
10 295 301 19356307 memory NN B-NP B-Disease
11 302 310 19356307 impaired VBN B-VP I-Disease
12 311 313 19356307 by IN B-PP O
13 314 325 19356307 scopolamine NN B-NP B-Chemical
14 325 326 19356307 ; : O O
15 327 334 19356307 however RB B-ADVP O
16 334 335 19356307 , , O O
17 336 337 19356307 s AFX B-NP B-Chemical
18 337 338 19356307 - HYPH I-NP I-Chemical
19 338 346 19356307 perillyl NN I-NP I-Chemical
20 347 354 19356307 alcohol NN I-NP I-Chemical
21 355 363 19356307 relieved VBD B-VP O
22 364 367 19356307 the DT B-NP O
23 368 375 19356307 deficit NN I-NP B-Disease
24 376 378 19356307 of IN B-PP I-Disease
25 379 390 19356307 associative JJ B-NP I-Disease
26 391 397 19356307 memory NN I-NP I-Disease
27 398 400 19356307 in IN B-PP O
28 401 403 19356307 PA NN B-NP O
29 404 408 19356307 only RB B-ADVP O
30 408 409 19356307 , , O O
31 410 413 19356307 and CC O O
32 414 417 19356307 did VBD B-VP O
33 418 421 19356307 not RB I-VP O
34 422 429 19356307 improve VB I-VP O
35 430 433 19356307 non AFX B-NP O
36 433 434 19356307 - HYPH I-NP O
37 434 445 19356307 associative JJ B-NP O
38 446 452 19356307 memory NN I-NP O
39 453 466 19356307 significantly RB B-ADVP O
40 467 469 19356307 in IN B-PP O
41 470 473 19356307 OFH NN B-NP O
42 473 474 19356307 . . O O

1 475 483 19356307 Analysis NN B-NP O
2 484 486 19356307 of IN B-PP O
3 487 503 19356307 neurotransmitter NN B-NP O
4 504 517 19356307 concentration NN I-NP O
5 518 520 19356307 in IN B-PP O
6 521 525 19356307 some DT B-NP O
7 526 531 19356307 brain NN I-NP O
8 532 539 19356307 regions NNS I-NP O
9 540 542 19356307 on IN B-PP O
10 543 546 19356307 the DT B-NP O
11 547 551 19356307 test NN I-NP O
12 552 555 19356307 day NN I-NP O
13 556 562 19356307 showed VBD B-VP O
14 563 567 19356307 that IN B-SBAR O
15 568 576 19356307 dopamine NN B-NP B-Chemical
16 577 590 19356307 concentration NN I-NP O
17 591 593 19356307 of IN B-PP O
18 594 597 19356307 the DT B-NP O
19 598 605 19356307 vehicle NN I-NP O
20 605 606 19356307 / SYM B-NP O
21 606 617 19356307 scopolamine NN I-NP B-Chemical
22 618 623 19356307 group NN I-NP O
23 624 627 19356307 was VBD B-VP O
24 628 641 19356307 significantly RB B-ADJP O
25 642 647 19356307 lower JJR I-ADJP O
26 648 652 19356307 than IN B-PP O
27 653 657 19356307 that DT B-NP O
28 658 660 19356307 of IN B-PP O
29 661 664 19356307 the DT B-NP O
30 665 672 19356307 vehicle NN I-NP O
31 672 673 19356307 / SYM I-NP O
32 673 680 19356307 vehicle NN I-NP O
33 681 686 19356307 group NN I-NP O
34 686 687 19356307 , , O O
35 688 691 19356307 but CC O O
36 692 696 19356307 this DT B-NP O
37 697 707 19356307 phenomenon NN I-NP O
38 708 711 19356307 was VBD B-VP O
39 712 720 19356307 reversed VBN I-VP O
40 721 725 19356307 when WRB B-ADVP O
41 726 727 19356307 s AFX O B-Chemical
42 727 728 19356307 - HYPH O I-Chemical
43 728 736 19356307 limonene NN B-NP I-Chemical
44 737 739 19356307 or CC O O
45 740 741 19356307 s AFX B-NP B-Chemical
46 741 742 19356307 - HYPH I-NP I-Chemical
47 742 750 19356307 perillyl NN I-NP I-Chemical
48 751 758 19356307 alcohol NN I-NP I-Chemical
49 759 763 19356307 were VBD B-VP O
50 764 776 19356307 administered VBN I-VP O
51 777 783 19356307 before IN B-PP O
52 784 787 19356307 the DT B-NP O
53 788 797 19356307 injection NN I-NP O
54 798 800 19356307 of IN B-PP O
55 801 812 19356307 scopolamine NN B-NP B-Chemical
56 812 813 19356307 . . O O

1 814 828 19356307 Simultaneously RB B-ADVP O
2 828 829 19356307 , , O O
3 830 832 19356307 we PRP B-NP O
4 833 838 19356307 found VBD B-VP O
5 839 843 19356307 that IN B-SBAR O
6 844 849 19356307 these DT B-NP O
7 850 853 19356307 two CD I-NP O
8 854 859 19356307 lemon NN I-NP O
9 860 869 19356307 essential JJ I-NP O
10 870 873 19356307 oil NN I-NP O
11 874 884 19356307 components NNS I-NP O
12 885 890 19356307 could MD B-VP O
13 891 898 19356307 inhibit VB I-VP O
14 899 919 19356307 acetylcholinesterase NN B-NP O
15 920 928 19356307 activity NN I-NP O
16 929 931 19356307 in FW B-ADVP O
17 932 937 19356307 vitro FW I-ADVP O
18 938 943 19356307 using VBG B-VP O
19 944 947 19356307 the DT B-NP O
20 948 954 19356307 Ellman NNP I-NP O
21 955 961 19356307 method NN I-NP O
22 961 962 19356307 . . O O

1 0 0 8996652 -DOCSTART- -X- -X- O

1 0 4 8996652 Risk NN B-NP O
2 5 12 8996652 factors NNS I-NP O
3 13 15 8996652 of IN B-PP O
4 16 29 8996652 sensorineural JJ B-NP B-Disease
5 30 37 8996652 hearing NN I-NP I-Disease
6 38 42 8996652 loss NN I-NP I-Disease
7 43 45 8996652 in IN B-PP O
8 46 53 8996652 preterm JJ B-NP O
9 54 61 8996652 infants NNS I-NP O
10 61 62 8996652 . . O O
11 63 68 8996652 Among IN B-PP O
12 69 72 8996652 547 CD B-NP O
13 73 80 8996652 preterm JJ I-NP O
14 81 88 8996652 infants NNS I-NP O
15 89 91 8996652 of IN B-PP O
16 92 93 8996652 < SYM B-NP O
17 94 96 8996652 or CC O O
18 97 98 8996652 = SYM B-VP O
19 99 101 8996652 34 CD B-NP O
20 102 107 8996652 weeks NNS I-NP O
21 108 117 8996652 gestation NN I-NP O
22 118 122 8996652 born VBN B-VP O
23 123 130 8996652 between IN B-PP O
24 131 135 8996652 1987 CD B-NP O
25 136 139 8996652 and CC I-NP O
26 140 144 8996652 1991 CD I-NP O
27 144 145 8996652 , , O O
28 146 147 8996652 8 CD B-NP O
29 148 156 8996652 children NNS I-NP O
30 157 158 8996652 ( ( O O
31 158 163 8996652 1.46% CD B-NP O
32 163 164 8996652 ) ) O O
33 165 174 8996652 developed VBD B-VP O
34 175 181 8996652 severe JJ B-NP O
35 182 193 8996652 progressive JJ I-NP O
36 194 197 8996652 and CC I-NP O
37 198 207 8996652 bilateral JJ I-NP O
38 208 221 8996652 sensorineural JJ I-NP B-Disease
39 222 229 8996652 hearing NN I-NP I-Disease
40 230 234 8996652 loss NN I-NP I-Disease
41 234 235 8996652 . . O O

1 236 245 8996652 Perinatal JJ B-NP O
2 246 250 8996652 risk NN I-NP O
3 251 258 8996652 factors NNS I-NP O
4 259 261 8996652 of IN B-PP O
5 262 269 8996652 infants NNS B-NP O
6 270 274 8996652 with IN B-PP O
7 275 282 8996652 hearing NN B-NP B-Disease
8 283 287 8996652 loss NN I-NP I-Disease
9 288 292 8996652 were VBD B-VP O
10 293 301 8996652 compared VBN I-VP O
11 302 306 8996652 with IN B-PP O
12 307 312 8996652 those DT B-NP O
13 313 315 8996652 of IN B-PP O
14 316 319 8996652 two CD B-NP O
15 320 327 8996652 control NN I-NP O
16 328 334 8996652 groups NNS I-NP O
17 335 342 8996652 matched VBN B-VP O
18 343 346 8996652 for IN B-PP O
19 347 356 8996652 gestation NN B-NP O
20 357 360 8996652 and CC I-NP O
21 361 366 8996652 birth NN I-NP O
22 367 373 8996652 weight NN I-NP O
23 374 377 8996652 and CC B-PP O
24 378 381 8996652 for IN B-PP O
25 382 391 8996652 perinatal JJ B-NP O
26 392 405 8996652 complications NNS I-NP O
27 405 406 8996652 . . O O

1 407 410 8996652 Our PRP$ B-NP O
2 411 423 8996652 observations NNS I-NP O
3 424 436 8996652 demonstrated VBD B-VP O
4 437 439 8996652 an DT B-NP O
5 440 451 8996652 association NN I-NP O
6 452 454 8996652 of IN B-PP O
7 455 462 8996652 hearing NN B-NP B-Disease
8 463 467 8996652 loss NN I-NP I-Disease
9 468 472 8996652 with IN B-PP O
10 473 474 8996652 a DT B-NP O
11 475 481 8996652 higher JJR I-NP O
12 482 491 8996652 incidence NN I-NP O
13 492 494 8996652 of IN B-PP O
14 495 504 8996652 perinatal JJ B-NP O
15 505 518 8996652 complications NNS I-NP O
16 518 519 8996652 . . O O

1 520 531 8996652 Ototoxicity NN B-NP B-Disease
2 532 540 8996652 appeared VBD B-VP O
3 541 548 8996652 closely RB B-ADJP O
4 549 556 8996652 related JJ I-ADJP O
5 557 559 8996652 to TO B-PP O
6 560 561 8996652 a DT B-NP O
7 562 571 8996652 prolonged VBN I-NP O
8 572 586 8996652 administration NN I-NP O
9 587 590 8996652 and CC O O
10 591 597 8996652 higher JJR B-NP O
11 598 603 8996652 total JJ I-NP O
12 604 608 8996652 dose NN I-NP O
13 609 611 8996652 of IN B-PP O
14 612 620 8996652 ototoxic JJ B-NP B-Disease
15 621 626 8996652 drugs NNS I-NP O
16 626 627 8996652 , , O O
17 628 640 8996652 particularly RB B-ADVP O
18 641 656 8996652 aminoglycosides IN B-ADVP B-Chemical
19 657 660 8996652 and CC O O
20 661 671 8996652 furosemide NN B-NP B-Chemical
21 671 672 8996652 . . O O

1 673 680 8996652 Finally RB B-ADVP O
2 680 681 8996652 , , O O
3 682 684 8996652 we PRP B-NP O
4 685 693 8996652 strongly RB B-ADVP O
5 694 703 8996652 recommend VBP B-VP O
6 704 706 8996652 to TO B-PP O
7 707 720 8996652 prospectively RB B-VP O
8 721 724 8996652 and CC I-VP O
9 725 734 8996652 regularly RB I-VP O
10 735 742 8996652 perform VB I-VP O
11 743 753 8996652 audiologic JJ B-NP O
12 754 764 8996652 assessment NN I-NP O
13 765 767 8996652 in IN B-PP O
14 768 772 8996652 sick JJ B-NP O
15 773 780 8996652 preterm JJ I-NP O
16 781 789 8996652 children NNS I-NP O
17 790 792 8996652 as IN B-PP O
18 793 800 8996652 hearing NN B-NP B-Disease
19 801 805 8996652 loss NN I-NP I-Disease
20 806 808 8996652 is VBZ B-VP O
21 809 811 8996652 of IN B-PP O
22 812 819 8996652 delayed VBN B-NP O
23 820 825 8996652 onset NN I-NP O
24 826 829 8996652 and CC O O
25 830 832 8996652 in IN B-PP O
26 833 837 8996652 most JJS B-NP O
27 838 843 8996652 cases NNS I-NP O
28 844 853 8996652 bilateral JJ B-ADJP O
29 854 857 8996652 and CC I-ADJP O
30 858 864 8996652 severe JJ I-ADJP O
31 864 865 8996652 . . O O

1 0 0 2070391 -DOCSTART- -X- -X- O

1 0 9 2070391 Reduction NN B-NP O
2 10 12 2070391 in IN B-PP O
3 13 22 2070391 injection NN B-NP O
4 23 27 2070391 pain NN I-NP B-Disease
5 28 33 2070391 using VBG B-VP O
6 34 42 2070391 buffered VBN B-NP O
7 43 52 2070391 lidocaine NN I-NP B-Chemical
8 53 55 2070391 as IN B-PP O
9 56 57 2070391 a DT B-NP O
10 58 63 2070391 local JJ I-NP O
11 64 74 2070391 anesthetic NN I-NP O
12 75 81 2070391 before IN B-PP O
13 82 89 2070391 cardiac JJ B-NP O
14 90 105 2070391 catheterization NN I-NP O
15 105 106 2070391 . . O O
16 107 115 2070391 Previous JJ B-NP O
17 116 123 2070391 reports NNS I-NP O
18 124 128 2070391 have VBP B-VP O
19 129 138 2070391 suggested VBN I-VP O
20 139 143 2070391 that IN B-SBAR O
21 144 148 2070391 pain NN B-NP B-Disease
22 149 159 2070391 associated VBN B-VP O
23 160 164 2070391 with IN B-PP O
24 165 168 2070391 the DT B-NP O
25 169 178 2070391 injection NN I-NP O
26 179 181 2070391 of IN B-PP O
27 182 191 2070391 lidocaine NN B-NP B-Chemical
28 192 194 2070391 is VBZ B-VP O
29 195 202 2070391 related JJ B-ADJP O
30 203 205 2070391 to TO B-PP O
31 206 209 2070391 the DT B-NP O
32 210 216 2070391 acidic JJ I-NP O
33 217 219 2070391 pH NN I-NP O
34 220 222 2070391 of IN B-PP O
35 223 226 2070391 the DT B-NP O
36 227 235 2070391 solution NN I-NP O
37 235 236 2070391 . . O O

1 237 239 2070391 To TO B-VP O
2 240 249 2070391 determine VB I-VP O
3 250 252 2070391 if IN B-SBAR O
4 253 256 2070391 the DT B-NP O
5 257 265 2070391 addition NN I-NP O
6 266 268 2070391 of IN B-PP O
7 269 270 2070391 a DT B-NP O
8 271 280 2070391 buffering NN I-NP O
9 281 289 2070391 solution NN I-NP O
10 290 292 2070391 to TO B-VP O
11 293 299 2070391 adjust VB I-VP O
12 300 303 2070391 the DT B-NP O
13 304 306 2070391 pH NN I-NP O
14 307 309 2070391 of IN B-PP O
15 310 319 2070391 lidocaine NN B-NP B-Chemical
16 320 324 2070391 into IN B-PP O
17 325 328 2070391 the DT B-NP O
18 329 340 2070391 physiologic JJ I-NP O
19 341 346 2070391 range NN I-NP O
20 347 352 2070391 would MD B-VP O
21 353 359 2070391 reduce VB I-VP O
22 360 364 2070391 pain NN B-NP B-Disease
23 365 371 2070391 during IN B-PP O
24 372 381 2070391 injection NN B-NP O
25 381 382 2070391 , , O O
26 383 385 2070391 we PRP B-NP O
27 386 395 2070391 performed VBD B-VP O
28 396 397 2070391 a DT B-NP O
29 398 405 2070391 blinded VBN I-NP O
30 406 416 2070391 randomized VBN I-NP O
31 417 422 2070391 study NN I-NP O
32 423 425 2070391 in IN B-PP O
33 426 434 2070391 patients NNS B-NP O
34 435 445 2070391 undergoing VBG B-VP O
35 446 453 2070391 cardiac JJ B-NP O
36 454 469 2070391 catheterization NN I-NP O
37 469 470 2070391 . . O O

1 471 477 2070391 Twenty CD B-NP O
2 478 486 2070391 patients NNS I-NP O
3 487 491 2070391 were VBD B-VP O
4 492 497 2070391 asked VBN I-VP O
5 498 500 2070391 to TO B-VP O
6 501 509 2070391 quantify VB I-VP O
7 510 513 2070391 the DT B-NP O
8 514 522 2070391 severity NN I-NP O
9 523 525 2070391 of IN B-PP O
10 526 530 2070391 pain NN B-NP B-Disease
11 531 536 2070391 after IN B-PP O
12 537 546 2070391 receiving VBG B-VP O
13 547 555 2070391 standard JJ B-NP O
14 556 565 2070391 lidocaine NN I-NP B-Chemical
15 566 568 2070391 in IN B-PP O
16 569 572 2070391 one CD B-NP O
17 573 580 2070391 femoral JJ I-NP O
18 581 585 2070391 area NN I-NP O
19 586 589 2070391 and CC O O
20 590 598 2070391 buffered VBN B-NP O
21 599 608 2070391 lidocaine NN I-NP B-Chemical
22 609 611 2070391 in IN B-PP O
23 612 615 2070391 the DT B-NP O
24 616 624 2070391 opposite JJ I-NP O
25 625 632 2070391 femoral JJ I-NP O
26 633 637 2070391 area NN I-NP O
27 637 638 2070391 . . O O

1 639 642 2070391 The DT B-NP O
2 643 647 2070391 mean JJ I-NP O
3 648 652 2070391 pain NN I-NP B-Disease
4 653 658 2070391 score NN I-NP O
5 659 662 2070391 for IN B-PP O
6 663 671 2070391 buffered VBN B-NP O
7 672 681 2070391 lidocaine NN I-NP B-Chemical
8 682 685 2070391 was VBD B-VP O
9 686 699 2070391 significantly RB B-ADJP O
10 700 705 2070391 lower JJR I-ADJP O
11 706 710 2070391 than IN B-PP O
12 711 714 2070391 the DT B-NP O
13 715 719 2070391 mean JJ I-NP O
14 720 725 2070391 score NN I-NP O
15 726 729 2070391 for IN B-PP O
16 730 738 2070391 standard JJ B-NP O
17 739 748 2070391 lidocaine NN I-NP B-Chemical
18 749 750 2070391 ( ( O O
19 750 753 2070391 2.7 CD B-NP O
20 754 755 2070391 + SYM O O
21 755 756 2070391 / SYM O O
22 756 757 2070391 - SYM O O
23 758 761 2070391 1.9 CD B-NP O
24 762 764 2070391 vs NNS I-NP O
25 764 765 2070391 . . O O
26 766 769 2070391 3.8 CD B-NP O
27 770 771 2070391 + SYM O O
28 771 772 2070391 / SYM O O
29 772 773 2070391 - SYM O O
30 774 777 2070391 2.2 CD B-NP O
31 777 778 2070391 , , O O
32 779 780 2070391 P NN B-NP O
33 781 782 2070391 = SYM B-VP O
34 783 787 2070391 0.03 CD B-NP O
35 787 788 2070391 ) ) O O
36 788 789 2070391 . . O O

1 790 793 2070391 The DT B-NP O
2 794 796 2070391 pH NN I-NP O
3 797 807 2070391 adjustment NN I-NP O
4 808 810 2070391 of IN B-PP O
5 811 819 2070391 standard JJ B-NP O
6 820 829 2070391 lidocaine NN I-NP B-Chemical
7 830 833 2070391 can MD B-VP O
8 834 836 2070391 be VB I-VP O
9 837 849 2070391 accomplished VBN I-VP O
10 850 856 2070391 easily RB B-ADVP O
11 857 859 2070391 in IN B-PP O
12 860 863 2070391 the DT B-NP O
13 864 879 2070391 catheterization NN I-NP O
14 880 890 2070391 laboratory NN I-NP O
15 891 897 2070391 before IN B-PP O
16 898 907 2070391 injection NN B-NP O
17 908 911 2070391 and CC O O
18 912 919 2070391 results VBZ B-VP O
19 920 922 2070391 in IN B-PP O
20 923 924 2070391 a DT B-NP O
21 925 934 2070391 reduction NN I-NP O
22 935 937 2070391 of IN B-PP O
23 938 941 2070391 the DT B-NP O
24 942 946 2070391 pain NN I-NP B-Disease
25 947 956 2070391 occurring VBG B-VP O
26 957 963 2070391 during IN B-PP O
27 964 967 2070391 the DT B-NP O
28 968 980 2070391 infiltration NN I-NP O
29 981 983 2070391 of IN B-PP O
30 984 991 2070391 tissues NNS B-NP O
31 991 992 2070391 . . O O

1 0 0 2096243 -DOCSTART- -X- -X- O

1 0 8 2096243 Carmofur NN B-NP B-Chemical
2 8 9 2096243 - HYPH O O
3 9 16 2096243 induced VBN B-NP O
4 17 24 2096243 organic JJ I-NP B-Disease
5 25 31 2096243 mental JJ I-NP I-Disease
6 32 41 2096243 disorders NNS I-NP I-Disease
7 41 42 2096243 . . O O
8 43 50 2096243 Organic JJ B-NP B-Disease
9 51 57 2096243 mental JJ I-NP I-Disease
10 58 66 2096243 disorder NN I-NP I-Disease
11 67 70 2096243 was VBD B-VP O
12 71 79 2096243 observed VBN I-VP O
13 80 82 2096243 in IN B-PP O
14 83 84 2096243 a DT B-NP O
15 85 87 2096243 29 CD I-NP O
16 87 88 2096243 - HYPH I-NP O
17 88 92 2096243 year NN I-NP O
18 92 93 2096243 - HYPH O O
19 93 96 2096243 old JJ B-NP O
20 97 103 2096243 female NN I-NP O
21 104 106 2096243 in IN B-PP O
22 107 110 2096243 the DT B-NP O
23 111 121 2096243 prognostic JJ I-NP O
24 122 128 2096243 period NN I-NP O
25 129 134 2096243 after IN B-PP O
26 135 138 2096243 the DT B-NP O
27 139 144 2096243 onset NN I-NP O
28 145 147 2096243 of IN B-PP O
29 148 156 2096243 carmofur NN B-NP B-Chemical
30 156 157 2096243 - HYPH B-NP O
31 157 164 2096243 induced VBN I-NP O
32 165 184 2096243 leukoencephalopathy NN I-NP B-Disease
33 184 185 2096243 . . O O

1 186 194 2096243 Symptoms NNS B-NP O
2 195 199 2096243 such JJ B-PP O
3 200 202 2096243 as IN I-PP O
4 203 211 2096243 euphoria NN B-NP O
5 211 212 2096243 , , O O
6 213 222 2096243 emotional JJ B-NP O
7 223 231 2096243 lability NN I-NP O
8 232 235 2096243 and CC O O
9 236 243 2096243 puerile JJ B-NP O
10 244 252 2096243 attitude NN I-NP O
11 253 258 2096243 noted VBN B-VP O
12 259 261 2096243 in IN B-PP O
13 262 265 2096243 the DT B-NP O
14 266 273 2096243 patient NN I-NP O
15 274 278 2096243 were VBD B-VP O
16 279 288 2096243 diagnosed VBN I-VP O
17 289 291 2096243 as IN B-PP O
18 292 299 2096243 organic JJ B-NP B-Disease
19 300 311 2096243 personality NN I-NP I-Disease
20 312 320 2096243 syndrome NN I-NP I-Disease
21 321 330 2096243 according VBG B-PP O
22 331 333 2096243 to TO B-PP O
23 334 337 2096243 the DT B-NP O
24 338 346 2096243 criteria NNS I-NP O
25 347 354 2096243 defined VBN B-VP O
26 355 357 2096243 in IN B-PP O
27 358 361 2096243 the DT B-NP O
28 362 365 2096243 DSM NN I-NP O
29 365 366 2096243 - HYPH B-NP O
30 366 369 2096243 III CD I-NP O
31 369 370 2096243 - HYPH I-NP O
32 370 371 2096243 R NN I-NP O
33 371 372 2096243 . . O O

1 373 375 2096243 It PRP B-NP O
2 376 378 2096243 is VBZ B-VP O
3 379 387 2096243 referred VBN I-VP O
4 388 390 2096243 to TO B-PP O
5 391 393 2096243 as IN B-PP O
6 394 395 2096243 a DT B-NP O
7 396 403 2096243 frontal JJ I-NP B-Disease
8 404 408 2096243 lobe NN I-NP I-Disease
9 409 417 2096243 syndrome NN I-NP I-Disease
10 417 418 2096243 . . O O

1 419 424 2096243 Brain NN B-NP O
2 425 427 2096243 CT NN I-NP O
3 428 436 2096243 revealed VBD B-VP O
4 437 438 2096243 a DT B-NP O
5 439 454 2096243 periventricular JJ I-NP O
6 455 458 2096243 low JJ I-NP O
7 459 466 2096243 density NN I-NP O
8 467 471 2096243 area NN I-NP O
9 472 474 2096243 in IN B-PP O
10 475 478 2096243 the DT B-NP O
11 479 486 2096243 frontal JJ I-NP O
12 487 492 2096243 white JJ I-NP O
13 493 499 2096243 matter NN I-NP O
14 500 503 2096243 and CC O O
15 504 512 2096243 moderate JJ B-NP O
16 513 523 2096243 dilatation NN I-NP O
17 524 526 2096243 of IN B-PP O
18 527 530 2096243 the DT B-NP O
19 531 538 2096243 lateral JJ I-NP O
20 539 549 2096243 ventricles NNS I-NP O
21 550 560 2096243 especially RB B-ADVP O
22 561 563 2096243 at IN B-PP O
23 564 567 2096243 the DT B-NP O
24 568 577 2096243 bilateral JJ I-NP O
25 578 586 2096243 anterior JJ I-NP O
26 587 592 2096243 horns NNS I-NP O
27 592 593 2096243 . . O O

1 594 606 2096243 Consequently RB B-ADVP O
2 606 607 2096243 , , O O
3 608 616 2096243 carmofur NN B-NP B-Chemical
4 616 617 2096243 - HYPH B-VP O
5 617 624 2096243 induced VBN B-NP O
6 625 644 2096243 leukoencephalopathy NN I-NP B-Disease
7 645 648 2096243 may MD B-VP O
8 649 659 2096243 uncommonly RB I-VP O
9 660 666 2096243 result VB I-VP O
10 667 669 2096243 in IN B-PP O
11 670 677 2096243 organic JJ B-NP B-Disease
12 678 689 2096243 personality NN I-NP I-Disease
13 690 698 2096243 syndrome NN I-NP I-Disease
14 699 701 2096243 in IN B-PP O
15 702 705 2096243 the DT B-NP O
16 706 714 2096243 residual JJ I-NP O
17 715 720 2096243 state NN I-NP O
18 720 721 2096243 . . O O

1 722 724 2096243 It PRP B-NP O
2 725 728 2096243 may MD B-VP O
3 729 731 2096243 be VB I-VP O
4 732 742 2096243 attributed VBN I-VP O
5 743 745 2096243 to TO B-PP O
6 746 749 2096243 the DT B-NP O
7 750 760 2096243 structural JJ I-NP B-Disease
8 761 767 2096243 damage NN I-NP I-Disease
9 768 770 2096243 to TO B-PP I-Disease
10 771 774 2096243 the DT B-NP I-Disease
11 775 782 2096243 frontal JJ I-NP I-Disease
12 783 787 2096243 lobe NN I-NP I-Disease
13 787 788 2096243 . . O O

1 0 0 15458908 -DOCSTART- -X- -X- O

1 0 6 15458908 Safety NN B-NP O
2 7 10 15458908 and CC O O
3 11 18 15458908 adverse JJ B-NP O
4 19 26 15458908 effects NNS I-NP O
5 27 37 15458908 associated VBN B-VP O
6 38 42 15458908 with IN B-PP O
7 43 53 15458908 raloxifene NN B-NP B-Chemical
8 53 54 15458908 : : O O
9 55 63 15458908 multiple JJ B-NP O
10 64 72 15458908 outcomes NNS I-NP O
11 73 75 15458908 of IN B-PP O
12 76 86 15458908 raloxifene NN B-NP B-Chemical
13 87 97 15458908 evaluation NN I-NP O
14 97 98 15458908 . . I-NP O
15 99 108 15458908 OBJECTIVE NN I-NP O
16 108 109 15458908 : : O O
17 110 112 15458908 To TO B-VP O
18 113 120 15458908 examine VB I-VP O
19 121 124 15458908 the DT B-NP O
20 125 131 15458908 effect NN I-NP O
21 132 134 15458908 of IN B-PP O
22 135 145 15458908 raloxifene NN B-NP B-Chemical
23 146 148 15458908 on IN B-PP O
24 149 154 15458908 major JJ B-NP O
25 155 162 15458908 adverse JJ I-NP O
26 163 169 15458908 events NNS I-NP O
27 170 174 15458908 that WDT B-NP O
28 175 180 15458908 occur VBP B-VP O
29 181 185 15458908 with IN B-PP O
30 186 200 15458908 postmenopausal JJ B-NP O
31 201 209 15458908 estrogen NN I-NP B-Chemical
32 210 217 15458908 therapy NN I-NP O
33 218 220 15458908 or CC I-NP O
34 221 230 15458908 tamoxifen NN I-NP B-Chemical
35 230 231 15458908 . . O O

1 232 239 15458908 METHODS NNS B-NP O
2 239 240 15458908 : : O O
3 241 244 15458908 The DT B-NP O
4 245 253 15458908 Multiple JJ I-NP O
5 254 262 15458908 Outcomes NNP I-NP O
6 263 265 15458908 of IN B-PP O
7 266 276 15458908 Raloxifene NNP B-NP B-Chemical
8 277 287 15458908 Evaluation NNP I-NP O
9 287 288 15458908 , , O O
10 289 290 15458908 a DT B-NP O
11 291 302 15458908 multicenter NN I-NP O
12 302 303 15458908 , , O O
13 304 314 15458908 randomized VBN B-NP O
14 314 315 15458908 , , I-NP O
15 316 322 15458908 double JJ I-NP O
16 322 323 15458908 - HYPH I-NP O
17 323 328 15458908 blind JJ I-NP O
18 329 334 15458908 trial NN I-NP O
19 334 335 15458908 , , O O
20 336 344 15458908 enrolled VBD B-VP O
21 345 350 15458908 7,705 CD B-NP O
22 351 365 15458908 postmenopausal JJ I-NP O
23 366 371 15458908 women NNS I-NP O
24 372 376 15458908 with IN B-PP O
25 377 389 15458908 osteoporosis NN B-NP B-Disease
26 389 390 15458908 . . O O

1 391 396 15458908 Women NNS B-NP O
2 397 401 15458908 were VBD B-VP O
3 402 410 15458908 randomly RB I-VP O
4 411 419 15458908 assigned VBN I-VP O
5 420 422 15458908 to TO B-PP O
6 423 433 15458908 raloxifene NN B-NP B-Chemical
7 434 436 15458908 60 CD I-NP O
8 437 439 15458908 mg NN I-NP O
9 439 440 15458908 / SYM B-NP O
10 440 441 15458908 d NN I-NP O
11 442 444 15458908 or CC O O
12 445 448 15458908 120 CD B-NP O
13 449 451 15458908 mg NN I-NP O
14 451 452 15458908 / SYM B-NP O
15 452 453 15458908 d NN B-NP O
16 454 456 15458908 or CC I-NP O
17 457 464 15458908 placebo NN I-NP O
18 464 465 15458908 . . O O

1 466 474 15458908 Outcomes NNS B-NP O
2 475 483 15458908 included VBD B-VP O
3 484 490 15458908 venous JJ B-NP B-Disease
4 491 506 15458908 thromboembolism NN I-NP I-Disease
5 506 507 15458908 , , O O
6 508 517 15458908 cataracts NNS B-NP B-Disease
7 517 518 15458908 , , O O
8 519 530 15458908 gallbladder NN B-NP B-Disease
9 531 538 15458908 disease NN I-NP I-Disease
10 538 539 15458908 , , O O
11 540 543 15458908 and CC O O
12 544 555 15458908 endometrial JJ B-NP B-Disease
13 556 567 15458908 hyperplasia NN I-NP I-Disease
14 568 570 15458908 or CC I-NP I-Disease
15 571 577 15458908 cancer NN I-NP I-Disease
16 577 578 15458908 . . O O

1 579 586 15458908 RESULTS NNS B-NP O
2 586 587 15458908 : : O O
3 588 594 15458908 During IN B-PP O
4 595 596 15458908 a DT B-NP O
5 597 601 15458908 mean JJ I-NP O
6 602 608 15458908 follow VB B-VP O
7 608 609 15458908 - HYPH O O
8 609 611 15458908 up RP B-PRT O
9 612 614 15458908 of IN B-PP O
10 615 618 15458908 3.3 CD B-NP O
11 619 624 15458908 years NNS I-NP O
12 624 625 15458908 , , O O
13 626 636 15458908 raloxifene NN B-NP B-Chemical
14 637 640 15458908 was VBD B-VP O
15 641 651 15458908 associated VBN I-VP O
16 652 656 15458908 with IN B-PP O
17 657 659 15458908 an DT B-NP O
18 660 669 15458908 increased VBN I-NP O
19 670 674 15458908 risk NN I-NP O
20 675 678 15458908 for IN B-PP O
21 679 685 15458908 venous JJ B-NP B-Disease
22 686 701 15458908 thromboembolism NN I-NP I-Disease
23 702 703 15458908 ( ( O O
24 703 711 15458908 relative JJ B-NP O
25 712 716 15458908 risk NN I-NP O
26 717 718 15458908 [ ( O O
27 718 720 15458908 RR NN B-NP O
28 720 721 15458908 ] ) O O
29 722 725 15458908 2.1 CD B-NP O
30 725 726 15458908 ; : O O
31 727 730 15458908 95% CD B-NP O
32 731 741 15458908 confidence NN I-NP O
33 742 750 15458908 interval NN I-NP O
34 751 752 15458908 [ ( O O
35 752 754 15458908 CI NN B-NP O
36 754 755 15458908 ] ) O O
37 756 759 15458908 1.2 CD B-NP O
38 759 760 15458908 - HYPH I-NP O
39 760 763 15458908 3.8 CD I-NP O
40 763 764 15458908 ) ) O O
41 764 765 15458908 . . O O

1 766 769 15458908 The DT B-NP O
2 770 776 15458908 excess JJ I-NP O
3 777 782 15458908 event NN I-NP O
4 783 787 15458908 rate NN I-NP O
5 788 791 15458908 was VBD B-VP O
6 792 795 15458908 1.8 CD B-NP O
7 796 799 15458908 per IN B-PP O
8 800 805 15458908 1,000 CD B-NP O
9 806 811 15458908 woman NN I-NP O
10 811 812 15458908 - HYPH B-NP O
11 812 817 15458908 years NNS I-NP O
12 818 819 15458908 ( ( O O
13 819 822 15458908 95% CD B-NP O
14 823 825 15458908 CI NN I-NP O
15 826 827 15458908 - HYPH B-NP O
16 827 830 15458908 0.5 CD I-NP O
17 830 831 15458908 - HYPH I-NP O
18 831 834 15458908 4.1 CD I-NP O
19 834 835 15458908 ) ) O O
20 835 836 15458908 , , O O
21 837 840 15458908 and CC O O
22 841 844 15458908 the DT B-NP O
23 845 851 15458908 number NN I-NP O
24 852 858 15458908 needed VBN B-VP O
25 859 861 15458908 to TO B-VP O
26 862 867 15458908 treat VB I-VP O
27 868 870 15458908 to TO I-VP O
28 871 876 15458908 cause VB I-VP O
29 877 878 15458908 1 CD B-NP O
30 879 884 15458908 event NN I-NP O
31 885 888 15458908 was VBD B-VP O
32 889 892 15458908 170 CD B-NP O
33 893 894 15458908 ( ( O O
34 894 897 15458908 95% CD B-NP O
35 898 900 15458908 CI NN I-NP O
36 901 904 15458908 100 CD B-NP O
37 904 905 15458908 - HYPH I-NP O
38 905 908 15458908 582 CD I-NP O
39 908 909 15458908 ) ) O O
40 910 914 15458908 over IN B-PP O
41 915 918 15458908 3.3 CD B-NP O
42 919 924 15458908 years NNS I-NP O
43 924 925 15458908 . . O O

1 926 930 15458908 Risk NN B-NP O
2 931 933 15458908 in IN B-PP O
3 934 937 15458908 the DT B-NP O
4 938 948 15458908 raloxifene NN I-NP B-Chemical
5 949 954 15458908 group NN I-NP O
6 955 958 15458908 was VBD B-VP O
7 959 965 15458908 higher JJR B-ADJP O
8 966 970 15458908 than IN B-PP O
9 971 973 15458908 in IN B-PP O
10 974 977 15458908 the DT B-NP O
11 978 985 15458908 placebo NN I-NP O
12 986 991 15458908 group NN I-NP O
13 992 995 15458908 for IN B-PP O
14 996 999 15458908 the DT B-NP O
15 1000 1005 15458908 first JJ I-NP O
16 1006 1007 15458908 2 CD I-NP O
17 1008 1013 15458908 years NNS I-NP O
18 1013 1014 15458908 , , O O
19 1015 1018 15458908 but CC O O
20 1019 1028 15458908 decreased VBD B-VP O
21 1029 1031 15458908 to TO B-PP O
22 1032 1037 15458908 about IN B-NP O
23 1038 1041 15458908 the DT I-NP O
24 1042 1046 15458908 same JJ I-NP O
25 1047 1051 15458908 rate NN I-NP O
26 1052 1054 15458908 as IN B-PP O
27 1055 1057 15458908 in IN B-PP O
28 1058 1061 15458908 the DT B-NP O
29 1062 1069 15458908 placebo NN I-NP O
30 1070 1075 15458908 group NN I-NP O
31 1076 1086 15458908 thereafter RB B-ADVP O
32 1086 1087 15458908 . . O O

1 1088 1098 15458908 Raloxifene NN B-NP B-Chemical
2 1099 1102 15458908 did VBD B-VP O
3 1103 1106 15458908 not RB I-VP O
4 1107 1115 15458908 increase VB I-VP O
5 1116 1120 15458908 risk NN B-NP O
6 1121 1124 15458908 for IN B-PP O
7 1125 1134 15458908 cataracts NNS B-NP B-Disease
8 1135 1136 15458908 ( ( O O
9 1136 1138 15458908 RR NN B-NP O
10 1139 1142 15458908 0.9 CD I-NP O
11 1142 1143 15458908 ; : O O
12 1144 1147 15458908 95% CD B-NP O
13 1148 1150 15458908 CI NN I-NP O
14 1151 1154 15458908 0.8 CD B-NP O
15 1154 1155 15458908 - HYPH I-NP O
16 1155 1158 15458908 1.1 CD I-NP O
17 1158 1159 15458908 ) ) O O
18 1159 1160 15458908 , , O O
19 1161 1172 15458908 gallbladder NN B-NP B-Disease
20 1173 1180 15458908 disease NN I-NP I-Disease
21 1181 1182 15458908 ( ( O O
22 1182 1184 15458908 RR NN B-NP O
23 1185 1188 15458908 1.0 CD I-NP O
24 1188 1189 15458908 ; : O O
25 1190 1193 15458908 95% CD B-NP O
26 1194 1196 15458908 CI NN I-NP O
27 1197 1200 15458908 0.7 CD B-NP O
28 1200 1201 15458908 - HYPH I-NP O
29 1201 1204 15458908 1.3 CD I-NP O
30 1204 1205 15458908 ) ) O O
31 1205 1206 15458908 , , O O
32 1207 1218 15458908 endometrial JJ B-NP B-Disease
33 1219 1230 15458908 hyperplasia NN I-NP I-Disease
34 1231 1232 15458908 ( ( O O
35 1232 1234 15458908 RR NN B-NP O
36 1235 1238 15458908 1.3 CD I-NP O
37 1238 1239 15458908 ; : O O
38 1240 1243 15458908 95% CD B-NP O
39 1244 1246 15458908 CI NN I-NP O
40 1247 1250 15458908 0.4 CD B-NP O
41 1250 1251 15458908 - HYPH I-NP O
42 1251 1254 15458908 5.1 CD I-NP O
43 1254 1255 15458908 ) ) O O
44 1255 1256 15458908 , , O O
45 1257 1259 15458908 or CC O O
46 1260 1271 15458908 endometrial JJ B-NP B-Disease
47 1272 1278 15458908 cancer NN I-NP I-Disease
48 1279 1280 15458908 ( ( O O
49 1280 1282 15458908 RR NN B-NP O
50 1283 1286 15458908 0.9 CD I-NP O
51 1286 1287 15458908 ; : O O
52 1288 1291 15458908 95% CD B-NP O
53 1292 1294 15458908 CI NN I-NP O
54 1295 1298 15458908 0.3 CD B-NP O
55 1298 1299 15458908 - HYPH I-NP O
56 1299 1302 15458908 2.7 CD I-NP O
57 1302 1303 15458908 ) ) O O
58 1303 1304 15458908 . . O O

1 1305 1315 15458908 CONCLUSION NN B-NP O
2 1315 1316 15458908 : : O O
3 1317 1327 15458908 Raloxifene NN B-NP B-Chemical
4 1328 1331 15458908 was VBD B-VP O
5 1332 1342 15458908 associated VBN I-VP O
6 1343 1347 15458908 with IN B-PP O
7 1348 1350 15458908 an DT B-NP O
8 1351 1360 15458908 increased VBN I-NP O
9 1361 1365 15458908 risk NN I-NP O
10 1366 1369 15458908 for IN B-PP O
11 1370 1376 15458908 venous JJ B-NP B-Disease
12 1377 1392 15458908 thromboembolism NN I-NP I-Disease
13 1392 1393 15458908 , , O O
14 1394 1397 15458908 but CC O O
15 1398 1403 15458908 there EX B-NP O
16 1404 1407 15458908 was VBD B-VP O
17 1408 1410 15458908 no DT B-NP O
18 1411 1420 15458908 increased VBN I-NP O
19 1421 1425 15458908 risk NN I-NP O
20 1426 1429 15458908 for IN B-PP O
21 1430 1439 15458908 cataracts NNS B-NP B-Disease
22 1439 1440 15458908 , , O O
23 1441 1452 15458908 gallbladder NN B-NP B-Disease
24 1453 1460 15458908 disease NN I-NP I-Disease
25 1460 1461 15458908 , , O O
26 1462 1473 15458908 endometrial JJ B-NP B-Disease
27 1474 1485 15458908 hyperplasia NN I-NP I-Disease
28 1485 1486 15458908 , , O O
29 1487 1489 15458908 or CC O O
30 1490 1501 15458908 endometrial JJ B-NP B-Disease
31 1502 1508 15458908 cancer NN I-NP I-Disease
32 1508 1509 15458908 . . O O

1 1510 1515 15458908 LEVEL NN B-NP O
2 1516 1518 15458908 OF IN B-PP O
3 1519 1527 15458908 EVIDENCE NN B-NP O
4 1527 1528 15458908 : : O O
5 1529 1530 15458908 I PRP B-NP O

1 0 0 11263551 -DOCSTART- -X- -X- O

1 0 11 11263551 Calcineurin NN B-NP O
2 11 12 11263551 - HYPH I-NP O
3 12 21 11263551 inhibitor NN I-NP O
4 22 29 11263551 induced VBN I-NP O
5 30 34 11263551 pain NN I-NP B-Disease
6 35 43 11263551 syndrome NN I-NP O
7 44 45 11263551 ( ( O O
8 45 49 11263551 CIPS NN B-NP B-Disease
9 49 50 11263551 ) ) O O
10 50 51 11263551 : : O O
11 52 53 11263551 a DT B-NP O
12 54 60 11263551 severe JJ I-NP O
13 61 70 11263551 disabling VBG I-NP O
14 71 83 11263551 complication NN I-NP O
15 84 89 11263551 after IN B-PP O
16 90 95 11263551 organ NN B-NP O
17 96 111 11263551 transplantation NN I-NP O
18 111 112 11263551 . . O O
19 113 117 11263551 Bone NN B-NP O
20 118 122 11263551 pain NN I-NP B-Disease
21 123 128 11263551 after IN B-SBAR O
22 129 144 11263551 transplantation NN B-NP O
23 145 147 11263551 is VBZ B-VP O
24 148 149 11263551 a DT B-NP O
25 150 158 11263551 frequent JJ I-NP O
26 159 171 11263551 complication NN I-NP O
27 172 176 11263551 that WDT B-NP O
28 177 180 11263551 can MD B-VP O
29 181 183 11263551 be VB I-VP O
30 184 190 11263551 caused VBN I-VP O
31 191 193 11263551 by IN B-PP O
32 194 201 11263551 several JJ B-NP O
33 202 210 11263551 diseases NNS I-NP O
34 210 211 11263551 . . O O

1 212 221 11263551 Treatment NN B-NP O
2 222 232 11263551 strategies NNS I-NP O
3 233 239 11263551 depend VBP B-VP O
4 240 242 11263551 on IN B-PP O
5 243 246 11263551 the DT B-NP O
6 247 254 11263551 correct JJ I-NP O
7 255 264 11263551 diagnosis NN I-NP O
8 265 267 11263551 of IN B-PP O
9 268 271 11263551 the DT B-NP O
10 272 276 11263551 pain NN I-NP B-Disease
11 276 277 11263551 . . O O

1 278 282 11263551 Nine CD B-NP O
2 283 291 11263551 patients NNS I-NP O
3 292 296 11263551 with IN B-PP O
4 297 303 11263551 severe JJ B-NP O
5 304 308 11263551 pain NN I-NP B-Disease
6 309 311 11263551 in IN B-PP O
7 312 317 11263551 their PRP$ B-NP O
8 318 322 11263551 feet NNS I-NP O
9 322 323 11263551 , , O O
10 324 329 11263551 which WDT B-NP O
11 330 333 11263551 was VBD B-VP O
12 334 344 11263551 registered VBN I-VP O
13 345 350 11263551 after IN B-PP O
14 351 366 11263551 transplantation NN B-NP O
15 366 367 11263551 , , O O
16 368 372 11263551 were VBD B-VP O
17 373 385 11263551 investigated VBN I-VP O
18 385 386 11263551 . . O O

1 387 391 11263551 Bone NN B-NP O
2 392 397 11263551 scans NNS I-NP O
3 398 404 11263551 showed VBD B-VP O
4 405 407 11263551 an DT B-NP O
5 408 417 11263551 increased VBN I-NP O
6 418 424 11263551 tracer NN I-NP O
7 425 431 11263551 uptake NN I-NP O
8 432 434 11263551 of IN B-PP O
9 435 438 11263551 the DT B-NP O
10 439 443 11263551 foot NN I-NP O
11 444 449 11263551 bones NNS I-NP O
12 449 450 11263551 . . O O

1 451 459 11263551 Magnetic JJ B-NP O
2 460 469 11263551 resonance NN I-NP O
3 470 477 11263551 imaging NN I-NP O
4 478 490 11263551 demonstrated VBD B-VP O
5 491 495 11263551 bone NN B-NP B-Disease
6 496 502 11263551 marrow NN I-NP I-Disease
7 503 509 11263551 oedema NN I-NP I-Disease
8 510 512 11263551 in IN B-PP O
9 513 516 11263551 the DT B-NP O
10 517 524 11263551 painful JJ I-NP O
11 525 530 11263551 bones NNS I-NP O
12 530 531 11263551 . . O O

1 532 536 11263551 Pain NN B-NP B-Disease
2 537 540 11263551 was VBD B-VP O
3 541 544 11263551 not RB I-VP O
4 545 554 11263551 explained VBN I-VP O
5 555 557 11263551 by IN B-PP O
6 558 563 11263551 other JJ B-NP O
7 564 572 11263551 diseases NNS I-NP O
8 573 580 11263551 causing VBG B-VP O
9 581 585 11263551 foot NN B-NP O
10 586 590 11263551 pain NN I-NP B-Disease
11 590 591 11263551 , , O O
12 592 596 11263551 like IN B-PP O
13 597 603 11263551 reflex NN B-NP B-Disease
14 604 615 11263551 sympathetic JJ I-NP I-Disease
15 616 625 11263551 dystrophy NN I-NP I-Disease
16 625 626 11263551 , , O O
17 627 641 11263551 polyneuropathy NN B-NP B-Disease
18 641 642 11263551 , , O O
19 643 651 11263551 Morton's NNP B-NP B-Disease
20 652 661 11263551 neuralgia NN I-NP I-Disease
21 661 662 11263551 , , O O
22 663 667 11263551 gout NN B-NP B-Disease
23 667 668 11263551 , , O O
24 669 681 11263551 osteoporosis NN B-NP B-Disease
25 681 682 11263551 , , O O
26 683 692 11263551 avascular JJ B-NP B-Disease
27 693 701 11263551 necrosis NN I-NP I-Disease
28 701 702 11263551 , , O O
29 703 715 11263551 intermittent JJ B-NP B-Disease
30 716 728 11263551 claudication NN I-NP I-Disease
31 728 729 11263551 , , O O
32 730 741 11263551 orthopaedic JJ B-NP O
33 742 746 11263551 foot NN I-NP B-Disease
34 747 758 11263551 deformities NNS I-NP I-Disease
35 758 759 11263551 , , O O
36 760 766 11263551 stress NN B-NP B-Disease
37 767 776 11263551 fractures NNS I-NP I-Disease
38 776 777 11263551 , , O O
39 778 781 11263551 and CC O O
40 782 801 11263551 hyperparathyroidism NN B-NP B-Disease
41 801 802 11263551 . . O O

1 803 806 11263551 The DT B-NP O
2 807 816 11263551 reduction NN I-NP O
3 817 819 11263551 of IN B-PP O
4 820 832 11263551 cyclosporine NN B-NP B-Chemical
5 832 833 11263551 - HYPH B-NP O
6 834 836 11263551 or CC O O
7 837 847 11263551 tacrolimus NN B-NP B-Chemical
8 848 854 11263551 trough NN I-NP O
9 855 861 11263551 levels NNS I-NP O
10 862 865 11263551 and CC O O
11 866 869 11263551 the DT B-NP O
12 870 884 11263551 administration NN I-NP O
13 885 887 11263551 of IN B-PP O
14 888 895 11263551 calcium NN B-NP B-Chemical
15 896 903 11263551 channel NN I-NP O
16 904 912 11263551 blockers NNS I-NP O
17 913 916 11263551 led VBD B-VP O
18 917 919 11263551 to TO B-PP O
19 920 926 11263551 relief NN B-NP O
20 927 929 11263551 of IN B-PP O
21 930 934 11263551 pain NN B-NP B-Disease
22 934 935 11263551 . . O O

1 936 939 11263551 The DT B-NP O
2 940 951 11263551 Calcineurin NN I-NP O
3 951 952 11263551 - HYPH I-NP O
4 952 961 11263551 inhibitor NN I-NP O
5 962 969 11263551 Induced VBN I-NP O
6 970 974 11263551 Pain NN I-NP B-Disease
7 975 983 11263551 Syndrome NN I-NP O
8 984 985 11263551 ( ( O O
9 985 989 11263551 CIPS NN B-NP B-Disease
10 989 990 11263551 ) ) O O
11 991 993 11263551 is VBZ B-VP O
12 994 995 11263551 a DT B-NP O
13 996 1000 11263551 rare JJ I-NP O
14 1001 1004 11263551 but CC I-NP O
15 1005 1011 11263551 severe JJ I-NP O
16 1012 1016 11263551 side NN I-NP O
17 1017 1023 11263551 effect NN I-NP O
18 1024 1026 11263551 of IN B-PP O
19 1027 1039 11263551 cyclosporine NN B-NP B-Chemical
20 1040 1042 11263551 or CC I-NP O
21 1043 1053 11263551 tacrolimus NN I-NP B-Chemical
22 1054 1057 11263551 and CC O O
23 1058 1060 11263551 is VBZ B-VP O
24 1061 1071 11263551 accurately RB I-VP O
25 1072 1081 11263551 diagnosed VBN I-VP O
26 1082 1084 11263551 by IN B-PP O
27 1085 1088 11263551 its PRP$ B-NP O
28 1089 1096 11263551 typical JJ I-NP O
29 1097 1109 11263551 presentation NN I-NP O
30 1109 1110 11263551 , , O O
31 1111 1119 11263551 magnetic JJ B-NP O
32 1120 1129 11263551 resonance NN I-NP O
33 1130 1137 11263551 imaging NN I-NP O
34 1138 1141 11263551 and CC I-NP O
35 1142 1146 11263551 bone NN I-NP O
36 1147 1152 11263551 scans NNS I-NP O
37 1152 1153 11263551 . . O O

1 1154 1163 11263551 Incorrect JJ B-NP O
2 1164 1173 11263551 diagnosis NN I-NP O
3 1174 1176 11263551 of IN B-PP O
4 1177 1180 11263551 the DT B-NP O
5 1181 1189 11263551 syndrome NN I-NP O
6 1190 1194 11263551 will MD B-VP O
7 1195 1199 11263551 lead VB I-VP O
8 1200 1202 11263551 to TO B-PP O
9 1203 1204 11263551 a DT B-NP O
10 1205 1216 11263551 significant JJ I-NP O
11 1217 1226 11263551 reduction NN I-NP O
12 1227 1229 11263551 of IN B-PP O
13 1230 1234 11263551 life NN B-NP O
14 1235 1242 11263551 quality NN I-NP O
15 1243 1245 11263551 in IN B-PP O
16 1246 1254 11263551 patients NNS B-NP O
17 1255 1264 11263551 suffering VBG B-VP O
18 1265 1269 11263551 from IN B-PP O
19 1270 1274 11263551 CIPS NNP B-NP B-Disease
20 1274 1275 11263551 . . O O

1 0 0 18442015 -DOCSTART- -X- -X- O

1 0 10 18442015 Protective JJ B-NP O
2 11 17 18442015 effect NN I-NP O
3 18 20 18442015 of IN B-PP O
4 21 30 18442015 verapamil NN B-NP B-Chemical
5 31 33 18442015 on IN B-PP O
6 34 41 18442015 gastric JJ B-NP B-Disease
7 42 53 18442015 hemorrhagic JJ I-NP I-Disease
8 54 60 18442015 ulcers NNS I-NP B-Disease
9 61 63 18442015 in IN B-PP O
10 64 70 18442015 severe JJ B-NP O
11 71 86 18442015 atherosclerotic JJ I-NP B-Disease
12 87 91 18442015 rats NNS I-NP O
13 91 92 18442015 . . O O
14 93 100 18442015 Studies NNS B-NP O
15 101 111 18442015 concerning VBG B-VP O
16 112 116 18442015 with IN B-PP O
17 117 129 18442015 pathogenesis NN B-NP O
18 130 132 18442015 of IN B-PP O
19 133 140 18442015 gastric JJ B-NP B-Disease
20 141 151 18442015 hemorrhage NN I-NP I-Disease
21 152 155 18442015 and CC O O
22 156 163 18442015 mucosal JJ B-NP O
23 164 174 18442015 ulceration NN I-NP O
24 175 183 18442015 produced VBN B-VP O
25 184 186 18442015 in IN B-PP O
26 187 202 18442015 atherosclerotic JJ B-NP B-Disease
27 203 207 18442015 rats NNS I-NP O
28 208 211 18442015 are VBP B-VP O
29 212 219 18442015 lacking VBG I-VP O
30 219 220 18442015 . . O O

1 221 224 18442015 The DT B-NP O
2 225 228 18442015 aim NN I-NP O
3 229 231 18442015 of IN B-PP O
4 232 236 18442015 this DT B-NP O
5 237 242 18442015 study NN I-NP O
6 243 245 18442015 is VBZ B-VP O
7 246 248 18442015 to TO B-VP O
8 249 256 18442015 examine VB I-VP O
9 257 260 18442015 the DT B-NP O
10 261 265 18442015 role NN I-NP O
11 266 268 18442015 of IN B-PP O
12 269 276 18442015 gastric JJ B-NP O
13 277 281 18442015 acid NN I-NP O
14 282 286 18442015 back RB B-ADVP O
15 286 287 18442015 - HYPH B-NP O
16 287 296 18442015 diffusion NN I-NP O
17 296 297 18442015 , , O O
18 298 302 18442015 mast NN B-NP O
19 303 307 18442015 cell NN I-NP O
20 308 317 18442015 histamine NN I-NP B-Chemical
21 318 325 18442015 release NN I-NP O
22 325 326 18442015 , , O O
23 327 332 18442015 lipid NN B-NP O
24 333 341 18442015 peroxide NN I-NP O
25 342 343 18442015 ( ( O O
26 343 346 18442015 LPO NN B-NP O
27 346 347 18442015 ) ) O O
28 348 358 18442015 generation NN B-NP O
29 359 362 18442015 and CC O O
30 363 370 18442015 mucosal JJ B-NP O
31 371 384 18442015 microvascular JJ I-NP O
32 385 397 18442015 permeability NN I-NP O
33 398 400 18442015 in IN B-PP O
34 401 411 18442015 modulating VBG B-VP O
35 412 419 18442015 gastric JJ B-NP B-Disease
36 420 430 18442015 hemorrhage NN I-NP I-Disease
37 431 434 18442015 and CC I-NP O
38 435 440 18442015 ulcer NN I-NP B-Disease
39 441 443 18442015 in IN B-PP O
40 444 448 18442015 rats NNS B-NP O
41 449 453 18442015 with IN B-PP O
42 454 469 18442015 atherosclerosis NN B-NP B-Disease
43 470 477 18442015 induced VBN B-VP O
44 478 480 18442015 by IN B-PP O
45 481 497 18442015 coadministration NN B-NP O
46 498 500 18442015 of IN B-PP O
47 501 508 18442015 vitamin NN B-NP B-Chemical
48 509 511 18442015 D2 NN I-NP I-Chemical
49 512 515 18442015 and CC I-NP O
50 516 527 18442015 cholesterol NN I-NP B-Chemical
51 527 528 18442015 . . O O

1 529 541 18442015 Additionally RB B-ADVP O
2 541 542 18442015 , , O O
3 543 546 18442015 the DT B-NP O
4 547 557 18442015 protective JJ I-NP O
5 558 564 18442015 effect NN I-NP O
6 565 567 18442015 of IN B-PP O
7 568 577 18442015 verapamil NN B-NP B-Chemical
8 578 580 18442015 on IN B-PP O
9 581 585 18442015 this DT B-NP O
10 586 591 18442015 ulcer NN I-NP B-Disease
11 592 597 18442015 model NN I-NP O
12 598 601 18442015 was VBD B-VP O
13 602 611 18442015 evaluated VBN I-VP O
14 611 612 18442015 . . O O

1 613 617 18442015 Male JJ B-NP O
2 618 624 18442015 Wistar NNP I-NP O
3 625 629 18442015 rats NNS I-NP O
4 630 634 18442015 were VBD B-VP O
5 635 645 18442015 challenged VBN I-VP O
6 646 662 18442015 intragastrically RB B-ADJP O
7 663 667 18442015 once RB I-ADJP O
8 668 673 18442015 daily JJ I-ADJP O
9 674 677 18442015 for IN B-PP O
10 678 679 18442015 9 CD B-NP O
11 680 684 18442015 days NNS I-NP O
12 685 689 18442015 with IN B-PP O
13 690 693 18442015 1.0 CD B-NP O
14 694 696 18442015 ml NN I-NP O
15 696 697 18442015 / SYM B-NP O
16 697 699 18442015 kg NN I-NP O
17 700 702 18442015 of IN B-PP O
18 703 707 18442015 corn NN B-NP O
19 708 711 18442015 oil NN I-NP O
20 712 722 18442015 containing VBG B-VP O
21 723 730 18442015 vitamin NN B-NP B-Chemical
22 731 733 18442015 D2 NN I-NP I-Chemical
23 734 737 18442015 and CC O O
24 738 749 18442015 cholesterol NN B-NP B-Chemical
25 750 752 18442015 to TO B-VP O
26 753 759 18442015 induce VB I-VP O
27 760 775 18442015 atherosclerosis NN B-NP B-Disease
28 775 776 18442015 . . O O

1 777 784 18442015 Control NN B-NP O
2 785 789 18442015 rats NNS I-NP O
3 790 798 18442015 received VBD B-VP O
4 799 803 18442015 corn NN B-NP O
5 804 807 18442015 oil NN I-NP O
6 808 812 18442015 only RB B-ADVP O
7 812 813 18442015 . . O O

1 814 819 18442015 After IN B-PP O
2 820 827 18442015 gastric JJ B-NP O
3 828 835 18442015 surgery NN I-NP O
4 835 836 18442015 , , O O
5 837 840 18442015 rat NN B-NP O
6 841 849 18442015 stomachs NNS I-NP O
7 850 854 18442015 were VBD B-VP O
8 855 864 18442015 irrigated VBN I-VP O
9 865 868 18442015 for IN B-PP O
10 869 870 18442015 3 CD B-NP O
11 871 872 18442015 h NN I-NP O
12 873 877 18442015 with IN B-PP O
13 878 884 18442015 either CC O O
14 885 894 18442015 simulated VBN B-VP O
15 895 902 18442015 gastric JJ B-NP O
16 903 908 18442015 juice NN I-NP O
17 909 911 18442015 or CC O O
18 912 918 18442015 normal JJ B-NP O
19 919 925 18442015 saline NN I-NP O
20 925 926 18442015 . . O O

1 927 934 18442015 Gastric JJ B-NP O
2 935 939 18442015 acid NN I-NP O
3 940 944 18442015 back RB B-ADVP O
4 944 945 18442015 - HYPH B-NP O
5 945 954 18442015 diffusion NN I-NP O
6 954 955 18442015 , , O O
7 956 963 18442015 mucosal JJ B-NP O
8 964 967 18442015 LPO NN I-NP O
9 968 978 18442015 generation NN I-NP O
10 978 979 18442015 , , O O
11 980 989 18442015 histamine NN B-NP B-Chemical
12 990 1003 18442015 concentration NN I-NP O
13 1003 1004 18442015 , , O O
14 1005 1018 18442015 microvascular JJ B-NP O
15 1019 1031 18442015 permeability NN I-NP O
16 1031 1032 18442015 , , O O
17 1033 1040 18442015 luminal JJ B-NP B-Chemical
18 1041 1051 18442015 hemoglobin NN I-NP O
19 1052 1059 18442015 content NN I-NP O
20 1060 1063 18442015 and CC I-NP O
21 1064 1069 18442015 ulcer NN I-NP B-Disease
22 1070 1075 18442015 areas NNS I-NP O
23 1076 1080 18442015 were VBD B-VP O
24 1081 1091 18442015 determined VBN I-VP O
25 1091 1092 18442015 . . O O

1 1093 1101 18442015 Elevated JJ B-NP O
2 1102 1117 18442015 atherosclerotic JJ I-NP B-Disease
3 1118 1128 18442015 parameters NNS I-NP O
4 1128 1129 18442015 , , O O
5 1130 1134 18442015 such JJ B-PP O
6 1135 1137 18442015 as IN I-PP O
7 1138 1143 18442015 serum NN B-NP O
8 1144 1151 18442015 calcium NN I-NP B-Chemical
9 1151 1152 18442015 , , O O
10 1153 1158 18442015 total JJ B-NP O
11 1159 1170 18442015 cholesterol NN I-NP B-Chemical
12 1171 1174 18442015 and CC O O
13 1175 1178 18442015 low JJ B-NP O
14 1178 1179 18442015 - HYPH I-NP O
15 1179 1186 18442015 density NN I-NP O
16 1187 1198 18442015 lipoprotein NN I-NP O
17 1199 1212 18442015 concentration NN I-NP O
18 1213 1217 18442015 were VBD B-VP O
19 1218 1226 18442015 obtained VBN I-VP O
20 1227 1229 18442015 in IN B-PP O
21 1230 1245 18442015 atherosclerotic JJ B-NP B-Disease
22 1246 1250 18442015 rats NNS I-NP O
23 1250 1251 18442015 . . O O

1 1252 1258 18442015 Severe JJ B-NP O
2 1259 1266 18442015 gastric JJ I-NP O
3 1267 1273 18442015 ulcers NNS I-NP B-Disease
4 1274 1285 18442015 accompanied VBN B-VP O
5 1286 1290 18442015 with IN B-PP O
6 1291 1300 18442015 increased VBN B-NP O
7 1301 1312 18442015 ulcerogenic JJ I-NP O
8 1313 1320 18442015 factors NNS I-NP O
9 1320 1321 18442015 , , O O
10 1322 1331 18442015 including VBG B-PP O
11 1332 1339 18442015 gastric JJ B-NP O
12 1340 1344 18442015 acid NN I-NP O
13 1345 1349 18442015 back RB B-ADVP O
14 1349 1350 18442015 - HYPH B-NP O
15 1350 1359 18442015 diffusion NN I-NP O
16 1359 1360 18442015 , , O O
17 1361 1370 18442015 histamine NN B-NP B-Chemical
18 1371 1378 18442015 release NN I-NP O
19 1378 1379 18442015 , , O O
20 1380 1383 18442015 LPO NN B-NP O
21 1384 1394 18442015 generation NN I-NP O
22 1395 1398 18442015 and CC O O
23 1399 1406 18442015 luminal JJ B-NP B-Chemical
24 1407 1417 18442015 hemoglobin NN I-NP O
25 1418 1425 18442015 content NN I-NP O
26 1426 1430 18442015 were VBD B-VP O
27 1431 1435 18442015 also RB I-VP O
28 1436 1444 18442015 observed VBN I-VP O
29 1445 1447 18442015 in IN B-PP O
30 1448 1453 18442015 these DT B-NP O
31 1454 1458 18442015 rats NNS I-NP O
32 1458 1459 18442015 . . O O

1 1460 1468 18442015 Moreover RB B-ADVP O
2 1468 1469 18442015 , , O O
3 1470 1471 18442015 a DT B-NP O
4 1472 1480 18442015 positive JJ I-NP O
5 1481 1492 18442015 correlation NN I-NP O
6 1493 1495 18442015 of IN B-PP O
7 1496 1505 18442015 histamine NN B-NP B-Chemical
8 1506 1508 18442015 to TO B-PP O
9 1509 1516 18442015 gastric JJ B-NP B-Disease
10 1517 1527 18442015 hemorrhage NN I-NP I-Disease
11 1528 1531 18442015 and CC B-PP O
12 1532 1534 18442015 to TO B-PP O
13 1535 1540 18442015 ulcer NN B-NP B-Disease
14 1541 1544 18442015 was VBD B-VP O
15 1545 1550 18442015 found VBN I-VP O
16 1551 1553 18442015 in IN B-PP O
17 1554 1559 18442015 those DT B-NP O
18 1560 1575 18442015 atherosclerotic JJ I-NP B-Disease
19 1576 1580 18442015 rats NNS I-NP O
20 1580 1581 18442015 . . O O

1 1582 1586 18442015 This DT B-NP O
2 1587 1598 18442015 hemorrhagic JJ I-NP B-Disease
3 1599 1604 18442015 ulcer NN I-NP B-Disease
4 1605 1608 18442015 and CC O O
5 1609 1616 18442015 various JJ B-NP O
6 1617 1628 18442015 ulcerogenic JJ I-NP O
7 1629 1639 18442015 parameters NNS I-NP O
8 1640 1644 18442015 were VBD B-VP O
9 1645 1649 18442015 dose NN B-NP O
10 1649 1650 18442015 - HYPH O O
11 1650 1661 18442015 dependently RB B-VP O
12 1662 1673 18442015 ameliorated VBN I-VP O
13 1674 1676 18442015 by IN B-PP O
14 1677 1682 18442015 daily JJ B-NP O
15 1683 1695 18442015 intragastric JJ I-NP O
16 1696 1705 18442015 verapamil NN I-NP B-Chemical
17 1705 1706 18442015 . . O O

1 1707 1722 18442015 Atherosclerosis NN B-NP B-Disease
2 1723 1728 18442015 could MD B-VP O
3 1729 1736 18442015 produce VB I-VP O
4 1737 1744 18442015 gastric JJ B-NP B-Disease
5 1745 1756 18442015 hemorrhagic JJ I-NP I-Disease
6 1757 1762 18442015 ulcer NN I-NP B-Disease
7 1763 1766 18442015 via IN B-PP O
8 1767 1778 18442015 aggravation NN B-NP O
9 1779 1781 18442015 of IN B-PP O
10 1782 1789 18442015 gastric JJ B-NP O
11 1790 1794 18442015 acid NN I-NP O
12 1795 1799 18442015 back RB B-ADVP O
13 1799 1800 18442015 - HYPH B-NP O
14 1800 1809 18442015 diffusion NN I-NP O
15 1809 1810 18442015 , , O O
16 1811 1814 18442015 LPO NN B-NP O
17 1815 1825 18442015 generation NN I-NP O
18 1825 1826 18442015 , , O O
19 1827 1836 18442015 histamine NN B-NP B-Chemical
20 1837 1844 18442015 release NN I-NP O
21 1845 1848 18442015 and CC O O
22 1849 1862 18442015 microvascular JJ B-NP O
23 1863 1875 18442015 permeability NN I-NP O
24 1876 1880 18442015 that WDT B-NP O
25 1881 1886 18442015 could MD B-VP O
26 1887 1889 18442015 be VB I-VP O
27 1890 1901 18442015 ameliorated VBN I-VP O
28 1902 1904 18442015 by IN B-PP O
29 1905 1914 18442015 verapamil NN B-NP B-Chemical
30 1915 1917 18442015 in IN B-PP O
31 1918 1922 18442015 rats NNS B-NP O
32 1922 1923 18442015 . . O O

1 0 0 2670794 -DOCSTART- -X- -X- O

1 0 7 2670794 Effects NNS B-NP O
2 8 10 2670794 of IN B-PP O
3 11 13 2670794 an DT B-NP O
4 14 23 2670794 inhibitor NN I-NP O
5 24 26 2670794 of IN B-PP O
6 27 38 2670794 angiotensin NN B-NP B-Chemical
7 39 49 2670794 converting VBG B-VP O
8 50 56 2670794 enzyme NN B-NP O
9 57 58 2670794 ( ( O O
10 58 67 2670794 Captopril NNP B-NP B-Chemical
11 67 68 2670794 ) ) O O
12 69 71 2670794 on IN B-PP O
13 72 81 2670794 pulmonary JJ B-NP B-Disease
14 82 85 2670794 and CC I-NP I-Disease
15 86 91 2670794 renal JJ I-NP I-Disease
16 92 105 2670794 insufficiency NN I-NP I-Disease
17 106 109 2670794 due JJ B-PP O
18 110 112 2670794 to TO B-PP O
19 113 126 2670794 intravascular JJ B-NP B-Disease
20 127 138 2670794 coagulation NN I-NP I-Disease
21 139 141 2670794 in IN B-PP O
22 142 145 2670794 the DT B-NP O
23 146 149 2670794 rat NN I-NP O
24 149 150 2670794 . . I-NP O
25 151 160 2670794 Induction NN I-NP O
26 161 163 2670794 of IN B-PP O
27 164 177 2670794 intravascular JJ B-NP B-Disease
28 178 189 2670794 coagulation NN I-NP I-Disease
29 190 193 2670794 and CC I-NP O
30 194 204 2670794 inhibition NN I-NP O
31 205 207 2670794 of IN B-PP O
32 208 220 2670794 fibrinolysis NN B-NP O
33 221 223 2670794 by IN B-PP O
34 224 233 2670794 injection NN B-NP O
35 234 236 2670794 of IN B-PP O
36 237 245 2670794 thrombin NN B-NP O
37 246 249 2670794 and CC O O
38 250 260 2670794 tranexamic JJ B-NP B-Chemical
39 261 265 2670794 acid NN I-NP I-Chemical
40 266 267 2670794 ( ( O O
41 267 271 2670794 AMCA NN B-NP B-Chemical
42 271 272 2670794 ) ) O O
43 273 275 2670794 in IN B-PP O
44 276 279 2670794 the DT B-NP O
45 280 283 2670794 rat NN I-NP O
46 284 289 2670794 gives VBZ B-VP O
47 290 294 2670794 rise NN B-NP O
48 295 297 2670794 to TO B-PP O
49 298 307 2670794 pulmonary JJ B-NP B-Disease
50 308 311 2670794 and CC I-NP I-Disease
51 312 317 2670794 renal JJ I-NP I-Disease
52 318 331 2670794 insufficiency NN I-NP I-Disease
53 332 342 2670794 resembling VBG B-VP O
54 343 347 2670794 that IN B-SBAR O
55 348 357 2670794 occurring VBG B-VP O
56 358 363 2670794 after IN B-PP O
57 364 370 2670794 trauma NN B-NP B-Disease
58 371 373 2670794 or CC I-NP O
59 374 380 2670794 sepsis NN I-NP B-Disease
60 381 383 2670794 in IN B-PP O
61 384 387 2670794 man NN B-NP O
62 387 388 2670794 . . O O

1 389 398 2670794 Injection NN B-NP O
2 399 401 2670794 of IN B-PP O
3 402 411 2670794 Captopril NNP B-NP B-Chemical
4 412 413 2670794 ( ( O O
5 413 414 2670794 1 CD B-NP O
6 415 417 2670794 mg NN I-NP O
7 417 418 2670794 / SYM B-NP O
8 418 420 2670794 kg NN I-NP O
9 420 421 2670794 ) ) O O
10 421 422 2670794 , , O O
11 423 425 2670794 an DT B-NP O
12 426 435 2670794 inhibitor NN I-NP O
13 436 438 2670794 of IN B-PP O
14 439 450 2670794 angiotensin NN B-NP B-Chemical
15 451 461 2670794 converting VBG B-VP O
16 462 468 2670794 enzyme NN B-NP O
17 469 470 2670794 ( ( O O
18 470 473 2670794 ACE NN B-NP O
19 473 474 2670794 ) ) O O
20 474 475 2670794 , , O O
21 476 483 2670794 reduced VBD B-VP O
22 484 488 2670794 both CC O O
23 489 498 2670794 pulmonary JJ B-NP B-Disease
24 499 502 2670794 and CC I-NP I-Disease
25 503 508 2670794 renal JJ I-NP I-Disease
26 509 522 2670794 insufficiency NN I-NP I-Disease
27 523 525 2670794 in IN B-PP O
28 526 530 2670794 this DT B-NP O
29 531 534 2670794 rat NN I-NP O
30 535 540 2670794 model NN I-NP O
31 540 541 2670794 . . O O

1 542 545 2670794 The DT B-NP O
2 546 550 2670794 lung NN I-NP O
3 551 558 2670794 weights NNS I-NP O
4 559 563 2670794 were VBD B-VP O
5 564 569 2670794 lower JJR B-ADJP O
6 570 573 2670794 and CC O O
7 574 578 2670794 PaO2 NN B-NP O
8 579 582 2670794 was VBD B-VP O
9 583 591 2670794 improved VBN I-VP O
10 592 594 2670794 in IN B-PP O
11 595 599 2670794 rats NNS B-NP O
12 600 605 2670794 given VBN B-VP O
13 606 610 2670794 this DT B-NP O
14 611 617 2670794 enzyme NN I-NP O
15 617 618 2670794 - HYPH O O
16 618 626 2670794 blocking VBG B-VP O
17 627 632 2670794 agent NN B-NP O
18 632 633 2670794 . . O O

1 634 637 2670794 The DT B-NP O
2 638 646 2670794 contents NNS I-NP O
3 647 649 2670794 of IN B-PP O
4 650 657 2670794 albumin NN B-NP O
5 658 660 2670794 in IN B-PP O
6 661 664 2670794 the DT B-NP O
7 665 670 2670794 lungs NNS I-NP O
8 671 675 2670794 were VBD B-VP O
9 676 679 2670794 not RB I-VP O
10 680 687 2670794 changed VBN I-VP O
11 687 688 2670794 , , O O
12 689 699 2670794 indicating VBG B-VP O
13 700 704 2670794 that IN B-SBAR O
14 705 714 2670794 Captopril NNP B-NP B-Chemical
15 715 718 2670794 did VBD B-VP O
16 719 722 2670794 not RB I-VP O
17 723 732 2670794 influence VB I-VP O
18 733 736 2670794 the DT B-NP O
19 737 750 2670794 extravasation NN I-NP O
20 751 753 2670794 of IN B-PP O
21 754 761 2670794 protein NN B-NP O
22 761 762 2670794 . . O O

1 763 768 2670794 Renal JJ B-NP B-Disease
2 769 775 2670794 damage NN I-NP I-Disease
3 776 778 2670794 as IN B-SBAR O
4 779 788 2670794 reflected VBN B-VP O
5 789 791 2670794 by IN B-PP O
6 792 794 2670794 an DT B-NP O
7 795 803 2670794 increase NN I-NP O
8 804 806 2670794 in IN B-PP O
9 807 812 2670794 serum NN B-NP O
10 813 817 2670794 urea NN I-NP B-Chemical
11 818 821 2670794 and CC B-PP O
12 822 824 2670794 in IN B-PP O
13 825 831 2670794 kidney NN B-NP O
14 832 838 2670794 weight NN I-NP O
15 839 842 2670794 was VBD B-VP O
16 843 852 2670794 prevented VBN I-VP O
17 853 855 2670794 by IN B-PP O
18 856 865 2670794 Captopril NNP B-NP B-Chemical
19 865 866 2670794 . . O O

1 867 870 2670794 The DT B-NP O
2 871 877 2670794 amount NN I-NP O
3 878 880 2670794 of IN B-PP O
4 881 887 2670794 fibrin NN B-NP O
5 888 890 2670794 in IN B-PP O
6 891 894 2670794 the DT B-NP O
7 895 902 2670794 kidneys NNS I-NP O
8 903 906 2670794 was VBD B-VP O
9 907 911 2670794 also RB B-ADVP O
10 912 924 2670794 considerably RB B-ADJP O
11 925 930 2670794 lower JJR I-ADJP O
12 931 935 2670794 than IN B-PP O
13 936 938 2670794 in IN B-PP O
14 939 946 2670794 animals NNS B-NP O
15 947 952 2670794 which WDT B-NP O
16 953 961 2670794 received VBD B-VP O
17 962 970 2670794 thrombin NN B-NP O
18 971 974 2670794 and CC I-NP O
19 975 979 2670794 AMCA NN I-NP B-Chemical
20 980 985 2670794 alone RB B-ADVP O
21 985 986 2670794 . . O O

1 987 989 2670794 It PRP B-NP O
2 990 992 2670794 is VBZ B-VP O
3 993 1002 2670794 suggested VBN I-VP O
4 1003 1007 2670794 that IN B-SBAR O
5 1008 1011 2670794 the DT B-NP O
6 1012 1019 2670794 effects NNS I-NP O
7 1020 1022 2670794 of IN B-PP O
8 1023 1032 2670794 Captopril NNP B-NP B-Chemical
9 1033 1035 2670794 on IN B-PP O
10 1036 1039 2670794 the DT B-NP O
11 1040 1045 2670794 lungs NNS I-NP O
12 1046 1049 2670794 may MD B-VP O
13 1050 1052 2670794 be VB I-VP O
14 1053 1065 2670794 attributable JJ B-ADJP O
15 1066 1068 2670794 to TO B-PP O
16 1069 1070 2670794 a DT B-NP O
17 1071 1083 2670794 vasodilatory JJ I-NP O
18 1084 1090 2670794 effect NN I-NP O
19 1091 1094 2670794 due JJ B-PP O
20 1095 1097 2670794 to TO B-PP O
21 1098 1099 2670794 a DT B-NP O
22 1100 1109 2670794 reduction NN I-NP O
23 1110 1112 2670794 in IN B-PP O
24 1113 1116 2670794 the DT B-NP O
25 1117 1128 2670794 circulating VBG I-NP O
26 1129 1134 2670794 level NN I-NP O
27 1135 1137 2670794 of IN B-PP O
28 1138 1150 2670794 Angiotension NN B-NP B-Chemical
29 1151 1153 2670794 II CD I-NP I-Chemical
30 1154 1157 2670794 and CC O O
31 1158 1160 2670794 an DT B-NP O
32 1161 1169 2670794 increase NN I-NP O
33 1170 1172 2670794 in IN B-PP O
34 1173 1185 2670794 prostacyclin NN B-NP B-Chemical
35 1186 1187 2670794 ( ( O O
36 1187 1196 2670794 secondary JJ B-ADJP O
37 1197 1199 2670794 to TO B-PP O
38 1200 1202 2670794 an DT B-NP O
39 1203 1211 2670794 increase NN I-NP O
40 1212 1214 2670794 in IN B-PP O
41 1215 1225 2670794 bradykinin NN B-NP B-Chemical
42 1225 1226 2670794 ) ) O O
43 1226 1227 2670794 . . O O

1 1228 1237 2670794 Captopril NNP B-NP B-Chemical
2 1238 1241 2670794 may MD B-VP O
3 1241 1242 2670794 , , O O
4 1243 1245 2670794 by IN B-PP O
5 1246 1249 2670794 the DT B-NP O
6 1250 1254 2670794 same JJ I-NP O
7 1255 1264 2670794 mechanism NN I-NP O
8 1264 1265 2670794 , , O O
9 1266 1272 2670794 reduce VBP B-VP O
10 1273 1276 2670794 the DT B-NP O
11 1277 1285 2670794 increase NN I-NP O
12 1286 1288 2670794 in IN B-PP O
13 1289 1299 2670794 glomerular JJ B-NP O
14 1300 1310 2670794 filtration NN I-NP O
15 1311 1315 2670794 that WDT B-NP O
16 1316 1318 2670794 is VBZ B-VP O
17 1319 1324 2670794 known VBN I-VP O
18 1325 1327 2670794 to TO B-VP O
19 1328 1333 2670794 occur VB I-VP O
20 1334 1339 2670794 after IN B-PP O
21 1340 1342 2670794 an DT B-NP O
22 1343 1352 2670794 injection NN I-NP O
23 1353 1355 2670794 of IN B-PP O
24 1356 1364 2670794 thrombin NN B-NP O
25 1364 1365 2670794 , , O O
26 1366 1373 2670794 thereby RB B-VP O
27 1374 1385 2670794 diminishing VBG I-VP O
28 1386 1389 2670794 the DT B-NP O
29 1390 1401 2670794 aggregation NN I-NP O
30 1402 1404 2670794 of IN B-PP O
31 1405 1411 2670794 fibrin NN B-NP O
32 1412 1420 2670794 monomers NNS I-NP O
33 1421 1423 2670794 in IN B-PP O
34 1424 1427 2670794 the DT B-NP O
35 1428 1437 2670794 glomeruli NNS I-NP O
36 1437 1438 2670794 , , O O
37 1439 1443 2670794 with IN B-PP O
38 1444 1447 2670794 the DT B-NP O
39 1448 1454 2670794 result NN I-NP O
40 1455 1459 2670794 that IN B-SBAR O
41 1460 1464 2670794 less JJR B-NP O
42 1465 1471 2670794 fibrin NN I-NP O
43 1472 1476 2670794 will MD B-VP O
44 1477 1479 2670794 be VB I-VP O
45 1480 1489 2670794 deposited VBN I-VP O
46 1490 1493 2670794 and CC O O
47 1494 1498 2670794 thus RB O O
48 1499 1503 2670794 less JJR B-NP O
49 1504 1510 2670794 kidney NN I-NP B-Disease
50 1511 1517 2670794 damage NN I-NP I-Disease
51 1518 1522 2670794 will MD B-VP O
52 1523 1525 2670794 be VB I-VP O
53 1526 1534 2670794 produced VBN I-VP O
54 1534 1535 2670794 . . O O

1 0 0 19884587 -DOCSTART- -X- -X- O

1 0 13 19884587 Antibacterial JJ B-NP O
2 14 24 19884587 medication NN I-NP O
3 25 28 19884587 use NN I-NP O
4 29 35 19884587 during IN B-PP O
5 36 45 19884587 pregnancy NN B-NP O
6 46 49 19884587 and CC O O
7 50 54 19884587 risk NN B-NP O
8 55 57 19884587 of IN B-PP O
9 58 63 19884587 birth NN B-NP B-Disease
10 64 71 19884587 defects NNS I-NP I-Disease
11 71 72 19884587 : : O O
12 73 81 19884587 National NNP B-NP O
13 82 87 19884587 Birth NNP I-NP B-Disease
14 88 95 19884587 Defects NNPS I-NP I-Disease
15 96 106 19884587 Prevention NNP I-NP O
16 107 112 19884587 Study NNP I-NP O
17 112 113 19884587 . . I-NP O
18 114 123 19884587 OBJECTIVE NNP I-NP O
19 123 124 19884587 : : O O
20 125 127 19884587 To TO B-VP O
21 128 136 19884587 estimate VB I-VP O
22 137 140 19884587 the DT B-NP O
23 141 152 19884587 association NN I-NP O
24 153 160 19884587 between IN B-PP O
25 161 174 19884587 antibacterial JJ B-NP O
26 175 186 19884587 medications NNS I-NP O
27 187 190 19884587 and CC O O
28 191 199 19884587 selected VBN B-NP O
29 200 205 19884587 birth NN I-NP B-Disease
30 206 213 19884587 defects NNS I-NP I-Disease
31 213 214 19884587 . . O O

1 215 221 19884587 DESIGN NN B-NP O
2 221 222 19884587 , , O O
3 223 230 19884587 SETTING NN B-NP O
4 230 231 19884587 , , O O
5 232 235 19884587 AND CC O O
6 236 248 19884587 PARTICIPANTS NNS B-NP O
7 248 249 19884587 : : O O
8 250 260 19884587 Population NN B-NP O
9 260 261 19884587 - HYPH B-NP O
10 261 266 19884587 based VBN I-NP O
11 266 267 19884587 , , I-NP O
12 268 277 19884587 multisite JJ I-NP O
13 277 278 19884587 , , I-NP O
14 279 283 19884587 case NN I-NP O
15 283 284 19884587 - HYPH I-NP O
16 284 291 19884587 control NN I-NP O
17 292 297 19884587 study NN I-NP O
18 298 300 19884587 of IN B-PP O
19 301 306 19884587 women NNS B-NP O
20 307 310 19884587 who WP B-NP O
21 311 314 19884587 had VBD B-VP O
22 315 326 19884587 pregnancies NNS B-NP O
23 327 335 19884587 affected VBN B-VP O
24 336 338 19884587 by IN B-PP O
25 339 340 19884587 1 CD B-NP O
26 341 343 19884587 of IN B-PP O
27 344 348 19884587 more JJR B-NP O
28 349 353 19884587 than IN I-NP O
29 354 356 19884587 30 CD I-NP O
30 357 365 19884587 eligible JJ I-NP O
31 366 371 19884587 major JJ I-NP O
32 372 377 19884587 birth NN I-NP B-Disease
33 378 385 19884587 defects NNS I-NP I-Disease
34 386 396 19884587 identified VBN B-VP O
35 397 400 19884587 via IN B-PP O
36 401 406 19884587 birth NN B-NP B-Disease
37 407 413 19884587 defect NN I-NP I-Disease
38 414 426 19884587 surveillance NN I-NP O
39 427 435 19884587 programs NNS I-NP O
40 436 438 19884587 in IN B-PP O
41 439 441 19884587 10 CD B-NP O
42 442 448 19884587 states NNS I-NP O
43 449 450 19884587 ( ( O O
44 450 451 19884587 n NN B-NP O
45 452 453 19884587 = SYM B-VP O
46 454 456 19884587 13 CD B-NP O
47 457 460 19884587 155 CD I-NP O
48 460 461 19884587 ) ) O O
49 462 465 19884587 and CC O O
50 466 473 19884587 control NN B-NP O
51 474 479 19884587 women NNS I-NP O
52 480 488 19884587 randomly RB B-VP O
53 489 497 19884587 selected VBN I-VP O
54 498 502 19884587 from IN B-PP O
55 503 506 19884587 the DT B-NP O
56 507 511 19884587 same JJ I-NP O
57 512 524 19884587 geographical JJ I-NP O
58 525 532 19884587 regions NNS I-NP O
59 533 534 19884587 ( ( O O
60 534 535 19884587 n NN B-NP O
61 536 537 19884587 = SYM B-VP O
62 538 542 19884587 4941 CD B-NP O
63 542 543 19884587 ) ) O O
64 543 544 19884587 . . O O

1 545 549 19884587 MAIN NN B-NP O
2 550 558 19884587 EXPOSURE NN I-NP O
3 558 559 19884587 : : O O
4 560 568 19884587 Reported VBN B-VP O
5 569 577 19884587 maternal JJ B-NP O
6 578 581 19884587 use NN I-NP O
7 582 584 19884587 of IN B-PP O
8 585 599 19884587 antibacterials NNS B-NP O
9 600 601 19884587 ( ( O O
10 601 602 19884587 1 CD B-NP O
11 603 608 19884587 month NN I-NP O
12 609 615 19884587 before IN B-PP O
13 616 625 19884587 pregnancy NN B-NP O
14 626 633 19884587 through IN B-PP O
15 634 637 19884587 the DT B-NP O
16 638 641 19884587 end NN I-NP O
17 642 644 19884587 of IN B-PP O
18 645 648 19884587 the DT B-NP O
19 649 654 19884587 first JJ I-NP O
20 655 664 19884587 trimester NN I-NP O
21 664 665 19884587 ) ) O O
22 665 666 19884587 . . O O

1 667 671 19884587 MAIN NNP B-NP O
2 672 679 19884587 OUTCOME NNP I-NP O
3 680 687 19884587 MEASURE NNP I-NP O
4 687 688 19884587 : : O O
5 689 693 19884587 Odds NNS B-NP O
6 694 700 19884587 ratios NNS I-NP O
7 701 702 19884587 ( ( O O
8 702 705 19884587 ORs NNS B-NP O
9 705 706 19884587 ) ) O O
10 707 716 19884587 measuring VBG B-VP O
11 717 720 19884587 the DT B-NP O
12 721 732 19884587 association NN I-NP O
13 733 740 19884587 between IN B-PP O
14 741 754 19884587 antibacterial JJ B-NP O
15 755 758 19884587 use NN I-NP O
16 759 762 19884587 and CC O O
17 763 771 19884587 selected VBN B-NP O
18 772 777 19884587 birth NN I-NP B-Disease
19 778 785 19884587 defects NNS I-NP I-Disease
20 786 794 19884587 adjusted VBN B-VP O
21 795 798 19884587 for IN B-PP O
22 799 808 19884587 potential JJ B-NP O
23 809 820 19884587 confounders NNS I-NP O
24 820 821 19884587 . . O O

1 822 829 19884587 RESULTS NNS B-NP O
2 829 830 19884587 : : O O
3 831 834 19884587 The DT B-NP O
4 835 843 19884587 reported VBN I-NP O
5 844 847 19884587 use NN I-NP O
6 848 850 19884587 of IN B-PP O
7 851 865 19884587 antibacterials NNS B-NP O
8 866 875 19884587 increased VBD B-VP O
9 876 882 19884587 during IN B-PP O
10 883 892 19884587 pregnancy NN B-NP O
11 892 893 19884587 , , O O
12 894 901 19884587 peaking VBG B-VP O
13 902 908 19884587 during IN B-PP O
14 909 912 19884587 the DT B-NP O
15 913 918 19884587 third JJ I-NP O
16 919 924 19884587 month NN I-NP O
17 924 925 19884587 . . O O

1 926 938 19884587 Sulfonamides NNS B-NP B-Chemical
2 939 943 19884587 were VBD B-VP O
3 944 954 19884587 associated VBN I-VP O
4 955 959 19884587 with IN B-PP O
5 960 971 19884587 anencephaly RB O B-Disease
6 972 973 19884587 ( ( O O
7 973 981 19884587 adjusted VBN B-NP O
8 982 984 19884587 OR NN I-NP O
9 985 986 19884587 [ ( O O
10 986 989 19884587 AOR NN B-NP O
11 989 990 19884587 ] ) O O
12 991 992 19884587 = SYM B-VP O
13 993 996 19884587 3.4 CD B-NP O
14 996 997 19884587 ; : O O
15 998 1001 19884587 95% CD B-NP O
16 1002 1012 19884587 confidence NN I-NP O
17 1013 1021 19884587 interval NN I-NP O
18 1022 1023 19884587 [ ( O O
19 1023 1025 19884587 CI NN B-NP O
20 1025 1026 19884587 ] ) O O
21 1026 1027 19884587 , , O O
22 1028 1031 19884587 1.3 CD B-NP O
23 1031 1032 19884587 - HYPH I-NP O
24 1032 1035 19884587 8.8 CD I-NP O
25 1035 1036 19884587 ) ) O O
26 1036 1037 19884587 , , O O
27 1038 1049 19884587 hypoplastic JJ B-NP B-Disease
28 1050 1054 19884587 left JJ I-NP I-Disease
29 1055 1060 19884587 heart NN I-NP I-Disease
30 1061 1069 19884587 syndrome NN I-NP I-Disease
31 1070 1071 19884587 ( ( O O
32 1071 1074 19884587 AOR NN B-NP O
33 1075 1076 19884587 = SYM B-VP O
34 1077 1080 19884587 3.2 CD B-NP O
35 1080 1081 19884587 ; : O O
36 1082 1085 19884587 95% CD B-NP O
37 1086 1088 19884587 CI NN I-NP O
38 1088 1089 19884587 , , O O
39 1090 1093 19884587 1.3 CD B-NP O
40 1093 1094 19884587 - HYPH I-NP O
41 1094 1097 19884587 7.6 CD I-NP O
42 1097 1098 19884587 ) ) O O
43 1098 1099 19884587 , , O O
44 1100 1111 19884587 coarctation NN B-NP B-Disease
45 1112 1114 19884587 of IN B-PP I-Disease
46 1115 1118 19884587 the DT B-NP I-Disease
47 1119 1124 19884587 aorta NN I-NP I-Disease
48 1125 1126 19884587 ( ( O O
49 1126 1129 19884587 AOR NN B-NP O
50 1130 1131 19884587 = SYM B-VP O
51 1132 1135 19884587 2.7 CD B-NP O
52 1135 1136 19884587 ; : O O
53 1137 1140 19884587 95% CD B-NP O
54 1141 1143 19884587 CI NN I-NP O
55 1143 1144 19884587 , , O O
56 1145 1148 19884587 1.3 CD B-NP O
57 1148 1149 19884587 - HYPH I-NP O
58 1149 1152 19884587 5.6 CD I-NP O
59 1152 1153 19884587 ) ) O O
60 1153 1154 19884587 , , O O
61 1155 1162 19884587 choanal JJ B-NP B-Disease
62 1163 1170 19884587 atresia NN I-NP I-Disease
63 1171 1172 19884587 ( ( O O
64 1172 1175 19884587 AOR NN B-NP O
65 1176 1177 19884587 = SYM B-VP O
66 1178 1181 19884587 8.0 CD B-NP O
67 1181 1182 19884587 ; : O O
68 1183 1186 19884587 95% CD B-NP O
69 1187 1189 19884587 CI NN I-NP O
70 1189 1190 19884587 , , O O
71 1191 1194 19884587 2.7 CD B-NP O
72 1194 1195 19884587 - HYPH I-NP O
73 1195 1199 19884587 23.5 CD I-NP O
74 1199 1200 19884587 ) ) O O
75 1200 1201 19884587 , , O O
76 1202 1212 19884587 transverse JJ B-NP B-Disease
77 1213 1217 19884587 limb NN I-NP I-Disease
78 1218 1228 19884587 deficiency NN I-NP I-Disease
79 1229 1230 19884587 ( ( O O
80 1230 1233 19884587 AOR NN B-NP O
81 1234 1235 19884587 = SYM B-VP O
82 1236 1239 19884587 2.5 CD B-NP O
83 1239 1240 19884587 ; : O O
84 1241 1244 19884587 95% CD B-NP O
85 1245 1247 19884587 CI NN I-NP O
86 1247 1248 19884587 , , O O
87 1249 1252 19884587 1.0 CD B-NP O
88 1252 1253 19884587 - HYPH I-NP O
89 1253 1256 19884587 5.9 CD I-NP O
90 1256 1257 19884587 ) ) O O
91 1257 1258 19884587 , , O O
92 1259 1262 19884587 and CC O O
93 1263 1276 19884587 diaphragmatic JJ B-NP B-Disease
94 1277 1283 19884587 hernia NN I-NP I-Disease
95 1284 1285 19884587 ( ( O O
96 1285 1288 19884587 AOR NN B-NP O
97 1289 1290 19884587 = SYM B-VP O
98 1291 1294 19884587 2.4 CD B-NP O
99 1294 1295 19884587 ; : O O
100 1296 1299 19884587 95% CD B-NP O
101 1300 1302 19884587 CI NN I-NP O
102 1302 1303 19884587 , , O O
103 1304 1307 19884587 1.1 CD B-NP O
104 1307 1308 19884587 - HYPH I-NP O
105 1308 1311 19884587 5.4 CD I-NP O
106 1311 1312 19884587 ) ) O O
107 1312 1313 19884587 . . O O

1 1314 1329 19884587 Nitrofurantoins NNS B-NP B-Chemical
2 1330 1334 19884587 were VBD B-VP O
3 1335 1345 19884587 associated VBN I-VP O
4 1346 1350 19884587 with IN B-PP O
5 1351 1363 19884587 anophthalmia NN B-NP B-Disease
6 1364 1366 19884587 or CC I-NP O
7 1367 1381 19884587 microphthalmos NNS I-NP B-Disease
8 1382 1383 19884587 ( ( O O
9 1383 1386 19884587 AOR NN B-NP O
10 1387 1388 19884587 = SYM B-VP O
11 1389 1392 19884587 3.7 CD B-NP O
12 1392 1393 19884587 ; : O O
13 1394 1397 19884587 95% CD B-NP O
14 1398 1400 19884587 CI NN I-NP O
15 1400 1401 19884587 , , O O
16 1402 1405 19884587 1.1 CD B-NP O
17 1405 1406 19884587 - HYPH I-NP O
18 1406 1410 19884587 12.2 CD I-NP O
19 1410 1411 19884587 ) ) O O
20 1411 1412 19884587 , , O O
21 1413 1424 19884587 hypoplastic JJ B-NP B-Disease
22 1425 1429 19884587 left JJ I-NP I-Disease
23 1430 1435 19884587 heart NN I-NP I-Disease
24 1436 1444 19884587 syndrome NN I-NP I-Disease
25 1445 1446 19884587 ( ( O O
26 1446 1449 19884587 AOR NN B-NP O
27 1450 1451 19884587 = SYM B-VP O
28 1452 1455 19884587 4.2 CD B-NP O
29 1455 1456 19884587 ; : O O
30 1457 1460 19884587 95% CD B-NP O
31 1461 1463 19884587 CI NN I-NP O
32 1463 1464 19884587 , , O O
33 1465 1468 19884587 1.9 CD B-NP O
34 1468 1469 19884587 - HYPH I-NP O
35 1469 1472 19884587 9.1 CD I-NP O
36 1472 1473 19884587 ) ) O O
37 1473 1474 19884587 , , O O
38 1475 1481 19884587 atrial JJ B-NP B-Disease
39 1482 1488 19884587 septal JJ I-NP I-Disease
40 1489 1496 19884587 defects NNS I-NP I-Disease
41 1497 1498 19884587 ( ( O O
42 1498 1501 19884587 AOR NN B-NP O
43 1502 1503 19884587 = SYM B-VP O
44 1504 1507 19884587 1.9 CD B-NP O
45 1507 1508 19884587 ; : O O
46 1509 1512 19884587 95% CD B-NP O
47 1513 1515 19884587 CI NN I-NP O
48 1515 1516 19884587 , , O O
49 1517 1520 19884587 1.1 CD B-NP O
50 1520 1521 19884587 - HYPH I-NP O
51 1521 1524 19884587 3.4 CD I-NP O
52 1524 1525 19884587 ) ) O O
53 1525 1526 19884587 , , O O
54 1527 1530 19884587 and CC O O
55 1531 1536 19884587 cleft NN B-NP B-Disease
56 1537 1540 19884587 lip NN I-NP I-Disease
57 1541 1545 19884587 with IN B-PP O
58 1546 1551 19884587 cleft NN B-NP B-Disease
59 1552 1558 19884587 palate NN I-NP I-Disease
60 1559 1560 19884587 ( ( O O
61 1560 1563 19884587 AOR NN B-NP O
62 1564 1565 19884587 = SYM B-VP O
63 1566 1569 19884587 2.1 CD B-NP O
64 1569 1570 19884587 ; : O O
65 1571 1574 19884587 95% CD B-NP O
66 1575 1577 19884587 CI NN I-NP O
67 1577 1578 19884587 , , O O
68 1579 1582 19884587 1.2 CD B-NP O
69 1582 1583 19884587 - HYPH I-NP O
70 1583 1586 19884587 3.9 CD I-NP O
71 1586 1587 19884587 ) ) O O
72 1587 1588 19884587 . . O O

1 1589 1594 19884587 Other JJ B-NP O
2 1595 1608 19884587 antibacterial JJ I-NP O
3 1609 1615 19884587 agents NNS I-NP O
4 1616 1620 19884587 that WDT B-NP O
5 1621 1627 19884587 showed VBD B-VP O
6 1628 1640 19884587 associations NNS B-NP O
7 1641 1649 19884587 included VBD B-VP O
8 1650 1663 19884587 erythromycins NNS B-NP B-Chemical
9 1664 1665 19884587 ( ( O O
10 1665 1666 19884587 2 CD B-NP O
11 1667 1674 19884587 defects NNS I-NP O
12 1674 1675 19884587 ) ) O O
13 1675 1676 19884587 , , O O
14 1677 1688 19884587 penicillins NNS B-NP B-Chemical
15 1689 1690 19884587 ( ( O O
16 1690 1691 19884587 1 CD B-NP O
17 1692 1698 19884587 defect NN I-NP O
18 1698 1699 19884587 ) ) O O
19 1699 1700 19884587 , , O O
20 1701 1715 19884587 cephalosporins NNS B-NP B-Chemical
21 1716 1717 19884587 ( ( O O
22 1717 1718 19884587 1 CD B-NP O
23 1719 1725 19884587 defect NN I-NP O
24 1725 1726 19884587 ) ) O O
25 1726 1727 19884587 , , O O
26 1728 1731 19884587 and CC O O
27 1732 1742 19884587 quinolones NNS B-NP B-Chemical
28 1743 1744 19884587 ( ( O O
29 1744 1745 19884587 1 CD B-NP O
30 1746 1752 19884587 defect NN I-NP O
31 1752 1753 19884587 ) ) O O
32 1753 1754 19884587 . . O O

1 1755 1766 19884587 CONCLUSIONS NNS B-NP O
2 1766 1767 19884587 : : O O
3 1768 1780 19884587 Reassuringly RB B-ADVP O
4 1780 1781 19884587 , , O O
5 1782 1793 19884587 penicillins NNS B-NP B-Chemical
6 1793 1794 19884587 , , O O
7 1795 1808 19884587 erythromycins NNS B-NP B-Chemical
8 1808 1809 19884587 , , O O
9 1810 1813 19884587 and CC O O
10 1814 1828 19884587 cephalosporins NNS B-NP B-Chemical
11 1828 1829 19884587 , , O O
12 1830 1838 19884587 although IN B-SBAR O
13 1839 1843 19884587 used VBN B-VP O
14 1844 1852 19884587 commonly RB B-ADVP O
15 1853 1855 19884587 by IN B-PP O
16 1856 1864 19884587 pregnant JJ B-NP O
17 1865 1870 19884587 women NNS I-NP O
18 1870 1871 19884587 , , O O
19 1872 1876 19884587 were VBD B-VP O
20 1877 1880 19884587 not RB I-VP O
21 1881 1891 19884587 associated VBN I-VP O
22 1892 1896 19884587 with IN B-PP O
23 1897 1901 19884587 many JJ B-NP O
24 1902 1907 19884587 birth NN I-NP B-Disease
25 1908 1915 19884587 defects NNS I-NP I-Disease
26 1915 1916 19884587 . . O O

1 1917 1929 19884587 Sulfonamides NNS B-NP B-Chemical
2 1930 1933 19884587 and CC I-NP O
3 1934 1949 19884587 nitrofurantoins NNS I-NP B-Chemical
4 1950 1954 19884587 were VBD B-VP O
5 1955 1965 19884587 associated VBN I-VP O
6 1966 1970 19884587 with IN B-PP O
7 1971 1978 19884587 several JJ B-NP O
8 1979 1984 19884587 birth NN I-NP B-Disease
9 1985 1992 19884587 defects NNS I-NP I-Disease
10 1992 1993 19884587 , , O O
11 1994 2004 19884587 indicating VBG B-VP O
12 2005 2006 19884587 a DT B-NP O
13 2007 2011 19884587 need NN I-NP O
14 2012 2015 19884587 for IN B-PP O
15 2016 2026 19884587 additional JJ B-NP O
16 2027 2035 19884587 scrutiny NN I-NP O
17 2035 2036 19884587 . . O O

1 0 0 12483326 -DOCSTART- -X- -X- O

1 0 6 12483326 Severe JJ B-NP O
2 7 13 12483326 ocular JJ I-NP B-Disease
3 14 17 12483326 and CC I-NP I-Disease
4 18 25 12483326 orbital JJ I-NP I-Disease
5 26 34 12483326 toxicity NN I-NP I-Disease
6 35 40 12483326 after IN B-PP O
7 41 53 12483326 intracarotid JJ B-NP O
8 54 63 12483326 injection NN I-NP O
9 64 66 12483326 of IN B-PP O
10 67 78 12483326 carboplatin NN B-NP B-Chemical
11 79 82 12483326 for IN B-PP O
12 83 92 12483326 recurrent JJ B-NP O
13 93 106 12483326 glioblastomas NNS I-NP B-Disease
14 106 107 12483326 . . O O
15 108 118 12483326 BACKGROUND NN B-NP O
16 118 119 12483326 : : O O
17 120 132 12483326 Glioblastoma NN B-NP B-Disease
18 133 135 12483326 is VBZ B-VP O
19 136 137 12483326 a DT B-NP O
20 138 147 12483326 malignant JJ I-NP B-Disease
21 148 153 12483326 tumor NN I-NP I-Disease
22 154 158 12483326 that WDT B-NP O
23 159 165 12483326 occurs VBZ B-VP O
24 166 168 12483326 in IN B-PP O
25 169 172 12483326 the DT B-NP O
26 173 181 12483326 cerebrum NN I-NP O
27 182 188 12483326 during IN B-PP O
28 189 198 12483326 adulthood NN B-NP O
29 198 199 12483326 . . O O

1 200 204 12483326 With IN B-PP O
2 205 212 12483326 current JJ B-NP O
3 213 222 12483326 treatment NN I-NP O
4 223 231 12483326 regimens NNS I-NP O
5 232 241 12483326 including VBG B-PP O
6 242 250 12483326 combined VBN B-NP O
7 251 258 12483326 surgery NN I-NP O
8 258 259 12483326 , , I-NP O
9 260 269 12483326 radiation NN I-NP O
10 270 273 12483326 and CC I-NP O
11 274 286 12483326 chemotherapy NN I-NP O
12 286 287 12483326 , , O O
13 288 291 12483326 the DT B-NP O
14 292 299 12483326 average JJ I-NP O
15 300 304 12483326 life NN I-NP O
16 305 315 12483326 expectancy NN I-NP O
17 316 318 12483326 of IN B-PP O
18 319 322 12483326 the DT B-NP O
19 323 331 12483326 patients NNS I-NP O
20 332 334 12483326 is VBZ B-VP O
21 335 342 12483326 limited VBN I-VP O
22 343 345 12483326 to TO B-PP O
23 346 359 12483326 approximately RB B-NP O
24 360 361 12483326 1 CD I-NP O
25 362 366 12483326 year NN I-NP O
26 366 367 12483326 . . O O

1 368 377 12483326 Therefore RB B-ADVP O
2 377 378 12483326 , , O O
3 379 387 12483326 patients NNS B-NP O
4 388 392 12483326 with IN B-PP O
5 393 405 12483326 glioblastoma NN B-NP B-Disease
6 406 415 12483326 sometimes RB B-ADVP O
7 416 420 12483326 have VBP B-VP O
8 421 433 12483326 intracarotid JJ B-NP O
9 434 443 12483326 injection NN I-NP O
10 444 446 12483326 of IN B-PP O
11 447 461 12483326 carcinostatics NNS B-NP O
12 462 467 12483326 added VBN B-VP O
13 468 470 12483326 to TO B-PP O
14 471 474 12483326 the DT B-NP O
15 475 484 12483326 treatment NN I-NP O
16 485 492 12483326 regimen NN I-NP O
17 492 493 12483326 . . O O

1 494 503 12483326 Generally RB B-ADVP O
2 503 504 12483326 , , O O
3 505 516 12483326 carboplatin NN B-NP B-Chemical
4 517 519 12483326 is VBZ B-VP O
5 520 524 12483326 said VBN I-VP O
6 525 527 12483326 to TO I-VP O
7 528 532 12483326 have VB I-VP O
8 533 539 12483326 milder JJR B-NP O
9 540 544 12483326 side NN I-NP O
10 545 552 12483326 effects NNS I-NP O
11 553 557 12483326 than IN B-PP O
12 558 567 12483326 cisplatin NN B-NP B-Chemical
13 567 568 12483326 , , O O
14 569 574 12483326 whose WP$ B-NP O
15 575 581 12483326 ocular JJ I-NP B-Disease
16 582 585 12483326 and CC I-NP I-Disease
17 586 593 12483326 orbital JJ I-NP I-Disease
18 594 602 12483326 toxicity NN I-NP I-Disease
19 603 606 12483326 are VBP B-VP O
20 607 611 12483326 well RB B-ADJP O
21 612 617 12483326 known VBN I-ADJP O
22 617 618 12483326 . . O O

1 619 626 12483326 However RB B-ADVP O
2 626 627 12483326 , , O O
3 628 630 12483326 we PRP B-NP O
4 631 642 12483326 experienced VBD B-VP O
5 643 644 12483326 a DT B-NP O
6 645 649 12483326 case NN I-NP O
7 650 652 12483326 of IN B-PP O
8 653 659 12483326 severe JJ B-NP O
9 660 666 12483326 ocular JJ I-NP B-Disease
10 667 670 12483326 and CC I-NP I-Disease
11 671 678 12483326 orbital JJ I-NP I-Disease
12 679 687 12483326 toxicity NN I-NP I-Disease
13 688 693 12483326 after IN B-PP O
14 694 706 12483326 intracarotid JJ B-NP O
15 707 716 12483326 injection NN I-NP O
16 717 719 12483326 of IN B-PP O
17 720 731 12483326 carboplatin NN B-NP B-Chemical
18 731 732 12483326 , , O O
19 733 738 12483326 which WDT B-NP O
20 739 741 12483326 is VBZ B-VP O
21 742 754 12483326 infrequently RB I-VP O
22 755 763 12483326 reported VBN I-VP O
23 763 764 12483326 . . O O

1 765 769 12483326 CASE NN B-NP O
2 769 770 12483326 : : O O
3 771 772 12483326 A DT B-NP O
4 773 775 12483326 58 CD I-NP O
5 775 776 12483326 - HYPH I-NP O
6 776 780 12483326 year NN I-NP O
7 780 781 12483326 - HYPH O O
8 781 784 12483326 old JJ B-NP O
9 785 788 12483326 man NN I-NP O
10 789 797 12483326 received VBD B-VP O
11 798 800 12483326 an DT B-NP O
12 801 813 12483326 intracarotid JJ I-NP O
13 814 823 12483326 injection NN I-NP O
14 824 826 12483326 of IN B-PP O
15 827 838 12483326 carboplatin NN B-NP B-Chemical
16 839 842 12483326 for IN B-PP O
17 843 852 12483326 recurrent JJ B-NP O
18 853 866 12483326 glioblastomas NNS I-NP B-Disease
19 867 869 12483326 in IN B-PP O
20 870 873 12483326 his PRP$ B-NP O
21 874 878 12483326 left JJ I-NP O
22 879 887 12483326 temporal JJ I-NP O
23 888 892 12483326 lobe NN I-NP O
24 892 893 12483326 . . O O

1 894 896 12483326 He PRP B-NP O
2 897 907 12483326 complained VBD B-VP O
3 908 910 12483326 of IN B-PP O
4 911 915 12483326 pain NN B-NP B-Disease
5 916 919 12483326 and CC O I-Disease
6 920 926 12483326 visual JJ B-NP I-Disease
7 927 938 12483326 disturbance NN I-NP I-Disease
8 939 941 12483326 in IN B-PP I-Disease
9 942 945 12483326 the DT B-NP I-Disease
10 946 957 12483326 ipsilateral JJ I-NP I-Disease
11 958 961 12483326 eye NN I-NP I-Disease
12 962 964 12483326 30 CD I-NP O
13 965 966 12483326 h NN I-NP O
14 967 972 12483326 after IN B-PP O
15 973 976 12483326 the DT B-NP O
16 977 986 12483326 injection NN I-NP O
17 986 987 12483326 . . O O

1 988 995 12483326 Various JJ B-NP O
2 996 1002 12483326 ocular JJ I-NP O
3 1003 1011 12483326 symptoms NNS I-NP O
4 1012 1015 12483326 and CC I-NP O
5 1016 1024 12483326 findings NNS I-NP O
6 1025 1031 12483326 caused VBN B-VP O
7 1032 1034 12483326 by IN B-PP O
8 1035 1046 12483326 carboplatin NN B-NP B-Chemical
9 1047 1055 12483326 toxicity NN I-NP B-Disease
10 1056 1060 12483326 were VBD B-VP O
11 1061 1065 12483326 seen VBN I-VP O
12 1065 1066 12483326 . . O O

1 1067 1074 12483326 RESULTS NNS B-NP O
2 1074 1075 12483326 : : O O
3 1076 1078 12483326 He PRP B-NP O
4 1079 1082 12483326 was VBD B-VP O
5 1083 1090 12483326 treated VBN I-VP O
6 1091 1095 12483326 with IN B-PP O
7 1096 1107 12483326 intravenous JJ B-NP O
8 1108 1122 12483326 administration NN I-NP O
9 1123 1125 12483326 of IN B-PP O
10 1126 1141 12483326 corticosteroids NNS B-NP O
11 1142 1145 12483326 and CC O O
12 1146 1154 12483326 glycerin NN B-NP B-Chemical
13 1155 1158 12483326 for IN B-PP O
14 1159 1160 12483326 6 CD B-NP O
15 1161 1165 12483326 days NNS I-NP O
16 1166 1171 12483326 after IN B-PP O
17 1172 1175 12483326 the DT B-NP O
18 1176 1185 12483326 injection NN I-NP O
19 1185 1186 12483326 . . O O

1 1187 1195 12483326 Although IN B-SBAR O
2 1196 1199 12483326 the DT B-NP O
3 1200 1211 12483326 intraocular JJ I-NP O
4 1212 1220 12483326 pressure NN I-NP O
5 1221 1230 12483326 elevation NN I-NP O
6 1231 1237 12483326 caused VBN B-VP O
7 1238 1240 12483326 by IN B-PP O
8 1241 1250 12483326 secondary JJ B-NP O
9 1251 1256 12483326 acute JJ I-NP O
10 1257 1262 12483326 angle JJ I-NP O
11 1262 1263 12483326 - HYPH I-NP O
12 1263 1270 12483326 closure NN I-NP O
13 1271 1279 12483326 glaucoma NN I-NP B-Disease
14 1280 1289 12483326 decreased VBD B-VP O
15 1290 1293 12483326 and CC O O
16 1294 1300 12483326 ocular JJ B-NP B-Disease
17 1301 1305 12483326 pain NN I-NP I-Disease
18 1306 1316 12483326 diminished VBD B-VP O
19 1316 1317 12483326 , , O O
20 1318 1328 12483326 inexorable JJ B-NP O
21 1329 1340 12483326 papilledema NN I-NP B-Disease
22 1341 1344 12483326 and CC O O
23 1345 1354 12483326 exudative JJ B-NP O
24 1355 1362 12483326 retinal JJ I-NP B-Disease
25 1363 1373 12483326 detachment NN I-NP I-Disease
26 1374 1383 12483326 continued VBN B-VP O
27 1384 1387 12483326 for IN B-PP O
28 1388 1389 12483326 3 CD B-NP O
29 1390 1395 12483326 weeks NNS I-NP O
30 1395 1396 12483326 . . O O

1 1397 1404 12483326 Finally RB B-ADVP O
2 1404 1405 12483326 , , O O
3 1406 1407 12483326 6 CD B-NP O
4 1408 1413 12483326 weeks NNS I-NP O
5 1414 1419 12483326 later RB B-ADVP O
6 1419 1420 12483326 , , O O
7 1421 1428 12483326 diffuse JJ B-NP O
8 1429 1442 12483326 chorioretinal JJ I-NP B-Disease
9 1443 1450 12483326 atrophy NN I-NP I-Disease
10 1451 1455 12483326 with IN B-PP O
11 1456 1461 12483326 optic JJ B-NP B-Disease
12 1462 1469 12483326 atrophy NN I-NP I-Disease
13 1470 1478 12483326 occurred VBD B-VP O
14 1479 1482 12483326 and CC O O
15 1483 1486 12483326 the DT B-NP O
16 1487 1493 12483326 vision NN I-NP O
17 1494 1496 12483326 in IN B-PP O
18 1497 1500 12483326 his PRP$ B-NP O
19 1501 1505 12483326 left JJ I-NP O
20 1506 1509 12483326 eye NN I-NP O
21 1510 1513 12483326 was VBD B-VP O
22 1514 1518 12483326 lost VBN I-VP O
23 1518 1519 12483326 . . O O

1 1520 1530 12483326 CONCLUSION NN B-NP O
2 1530 1531 12483326 : : O O
3 1532 1536 12483326 When WRB B-ADVP O
4 1537 1547 12483326 performing VBG B-VP O
5 1548 1560 12483326 intracarotid JJ B-NP O
6 1561 1570 12483326 injection NN I-NP O
7 1571 1573 12483326 of IN B-PP O
8 1574 1585 12483326 carboplatin NN B-NP B-Chemical
9 1585 1586 12483326 , , O O
10 1587 1589 12483326 we PRP B-NP O
11 1590 1594 12483326 must MD B-VP O
12 1595 1597 12483326 be VB I-VP O
13 1598 1603 12483326 aware JJ B-ADJP O
14 1604 1606 12483326 of IN B-PP O
15 1607 1610 12483326 its PRP$ B-NP O
16 1611 1622 12483326 potentially RB I-NP O
17 1623 1631 12483326 blinding VBG I-NP O
18 1632 1638 12483326 ocular JJ B-NP B-Disease
19 1639 1647 12483326 toxicity NN I-NP I-Disease
20 1647 1648 12483326 . . O O

1 1649 1651 12483326 It PRP B-NP O
2 1652 1654 12483326 is VBZ B-VP O
3 1655 1666 12483326 recommended VBN I-VP O
4 1667 1671 12483326 that IN B-SBAR O
5 1672 1679 12483326 further JJ B-NP O
6 1680 1687 12483326 studies NNS I-NP O
7 1688 1691 12483326 and CC I-NP O
8 1692 1706 12483326 investigations NNS I-NP O
9 1707 1710 12483326 are VBP B-VP O
10 1711 1721 12483326 undertaken VBN I-VP O
11 1722 1724 12483326 in IN B-PP O
12 1725 1728 12483326 the DT B-NP O
13 1729 1735 12483326 effort NN I-NP O
14 1736 1738 12483326 to TO B-VP O
15 1739 1747 12483326 minimize VB I-VP O
16 1748 1752 12483326 such JJ B-NP O
17 1753 1759 12483326 severe JJ I-NP O
18 1760 1764 12483326 side NN I-NP O
19 1765 1772 12483326 effects NNS I-NP O
20 1772 1773 12483326 . . O O

1 0 0 17439425 -DOCSTART- -X- -X- O

1 0 4 17439425 Role NN B-NP O
2 5 7 17439425 of IN B-PP O
3 8 16 17439425 xanthine NN B-NP B-Chemical
4 17 24 17439425 oxidase NN I-NP O
5 25 27 17439425 in IN B-PP O
6 28 41 17439425 dexamethasone NN B-NP B-Chemical
7 41 42 17439425 - HYPH B-NP O
8 42 49 17439425 induced VBN I-NP O
9 50 62 17439425 hypertension NN I-NP B-Disease
10 63 65 17439425 in IN B-PP O
11 66 70 17439425 rats NNS B-NP O
12 70 71 17439425 . . O O
13 72 73 17439425 1 CD B-NP O
14 73 74 17439425 . . O O

1 75 89 17439425 Glucocorticoid NN B-NP O
2 89 90 17439425 - HYPH B-PP O
3 90 97 17439425 induced VBN B-NP O
4 98 110 17439425 hypertension NN I-NP B-Disease
5 111 112 17439425 ( ( O O
6 112 114 17439425 GC NN B-NP O
7 114 115 17439425 - HYPH B-NP O
8 115 117 17439425 HT NN I-NP B-Disease
9 117 118 17439425 ) ) O O
10 119 121 17439425 in IN B-PP O
11 122 125 17439425 the DT B-NP O
12 126 129 17439425 rat NN I-NP O
13 130 132 17439425 is VBZ B-VP O
14 133 143 17439425 associated VBN I-VP O
15 144 148 17439425 with IN B-PP O
16 149 155 17439425 nitric JJ B-NP B-Chemical
17 156 161 17439425 oxide NN I-NP I-Chemical
18 161 162 17439425 - HYPH B-NP O
19 162 167 17439425 redox NN I-NP O
20 168 177 17439425 imbalance NN I-NP O
21 177 178 17439425 . . O O

1 179 180 17439425 2 LS B-LST O
2 180 181 17439425 . . O O

1 182 184 17439425 We PRP B-NP O
2 185 192 17439425 studied VBD B-VP O
3 193 196 17439425 the DT B-NP O
4 197 201 17439425 role NN I-NP O
5 202 204 17439425 of IN B-PP O
6 205 213 17439425 xanthine NN B-NP B-Chemical
7 214 221 17439425 oxidase NN I-NP O
8 222 223 17439425 ( ( O O
9 223 225 17439425 XO NN B-NP O
10 225 226 17439425 ) ) O O
11 226 227 17439425 , , O O
12 228 233 17439425 which WDT B-NP O
13 234 236 17439425 is VBZ B-VP O
14 237 247 17439425 implicated VBN I-VP O
15 248 250 17439425 in IN B-PP O
16 251 254 17439425 the DT B-NP O
17 255 265 17439425 production NN I-NP O
18 266 268 17439425 of IN B-PP O
19 269 277 17439425 reactive JJ B-NP O
20 278 284 17439425 oxygen NN I-NP O
21 285 292 17439425 species NNS I-NP O
22 292 293 17439425 , , O O
23 294 296 17439425 in IN B-PP O
24 297 310 17439425 dexamethasone NN B-NP B-Chemical
25 310 311 17439425 - HYPH B-NP O
26 311 318 17439425 induced VBN I-NP O
27 319 331 17439425 hypertension NN I-NP B-Disease
28 332 333 17439425 ( ( O O
29 333 336 17439425 dex NN B-NP B-Chemical
30 336 337 17439425 - HYPH B-NP O
31 337 339 17439425 HT NN I-NP B-Disease
32 339 340 17439425 ) ) O O
33 340 341 17439425 . . O O
34 342 343 17439425 3 CD B-NP O
35 343 344 17439425 . . O O

1 345 351 17439425 Thirty CD B-NP O
2 352 356 17439425 male JJ I-NP O
3 357 364 17439425 Sprague NNP I-NP O
4 364 365 17439425 - HYPH I-NP O
5 365 371 17439425 Dawley NNP I-NP O
6 372 376 17439425 rats NNS I-NP O
7 377 381 17439425 were VBD B-VP O
8 382 389 17439425 divided VBN I-VP O
9 390 398 17439425 randomly RB B-ADVP O
10 399 403 17439425 into IN B-PP O
11 404 408 17439425 four CD B-NP O
12 409 418 17439425 treatment NN I-NP O
13 419 425 17439425 groups NNS I-NP O
14 425 426 17439425 : : O O
15 427 433 17439425 saline NN B-NP O
16 433 434 17439425 , , O O
17 435 448 17439425 dexamethasone NN B-NP B-Chemical
18 449 450 17439425 ( ( O O
19 450 453 17439425 dex NN B-NP B-Chemical
20 453 454 17439425 ) ) O O
21 454 455 17439425 , , O O
22 456 467 17439425 allopurinol NN B-NP B-Chemical
23 468 472 17439425 plus CC O O
24 473 479 17439425 saline NN B-NP O
25 479 480 17439425 , , O O
26 481 484 17439425 and CC O O
27 485 496 17439425 allopurinol NN B-NP B-Chemical
28 497 501 17439425 plus CC I-NP O
29 502 505 17439425 dex NN I-NP B-Chemical
30 505 506 17439425 . . O O

1 507 508 17439425 4 LS B-LST O
2 508 509 17439425 . . O O

1 510 518 17439425 Systolic JJ B-NP O
2 519 524 17439425 blood NN I-NP O
3 525 534 17439425 pressures NNS I-NP O
4 535 536 17439425 ( ( O O
5 536 539 17439425 SBP NN B-NP O
6 539 540 17439425 ) ) O O
7 541 544 17439425 and CC O O
8 545 556 17439425 bodyweights NNS B-NP O
9 557 561 17439425 were VBD B-VP O
10 562 570 17439425 recorded VBN I-VP O
11 571 575 17439425 each DT B-NP O
12 576 585 17439425 alternate JJ I-NP O
13 586 589 17439425 day NN I-NP O
14 589 590 17439425 . . O O

1 591 597 17439425 Thymus NN B-NP O
2 598 604 17439425 weight NN I-NP O
3 605 608 17439425 was VBD B-VP O
4 609 613 17439425 used VBN I-VP O
5 614 616 17439425 as IN B-PP O
6 617 618 17439425 a DT B-NP O
7 619 625 17439425 marker NN I-NP O
8 626 628 17439425 of IN B-PP O
9 629 643 17439425 glucocorticoid NN B-NP O
10 644 652 17439425 activity NN I-NP O
11 652 653 17439425 , , O O
12 654 657 17439425 and CC O O
13 658 663 17439425 serum NN B-NP O
14 664 669 17439425 urate NN I-NP B-Chemical
15 670 672 17439425 to TO B-VP O
16 673 679 17439425 assess VB I-VP O
17 680 682 17439425 XO NN B-NP O
18 683 693 17439425 inhibition NN I-NP O
19 693 694 17439425 . . O O

1 695 696 17439425 5 LS B-LST O
2 696 697 17439425 . . O O

1 698 701 17439425 Dex NN B-NP B-Chemical
2 702 711 17439425 increased VBD B-VP B-Disease
3 712 715 17439425 SBP NN B-NP I-Disease
4 716 717 17439425 ( ( O O
5 717 720 17439425 110 CD B-NP O
6 721 722 17439425 + SYM O O
7 722 723 17439425 / SYM O O
8 723 724 17439425 - SYM B-NP O
9 725 726 17439425 2 CD I-NP O
10 726 727 17439425 - HYPH I-NP O
11 727 730 17439425 126 CD I-NP O
12 731 732 17439425 + SYM O O
13 732 733 17439425 / SYM O O
14 733 734 17439425 - SYM O O
15 735 736 17439425 3 CD B-NP O
16 737 741 17439425 mmHg NN I-NP O
17 741 742 17439425 ; : O O
18 743 744 17439425 P NN B-NP O
19 745 746 17439425 < SYM B-NP O
20 747 752 17439425 0.001 CD I-NP O
21 752 753 17439425 ) ) O O
22 754 757 17439425 and CC O O
23 758 767 17439425 decreased VBD B-VP B-Disease
24 768 774 17439425 thymus NN B-NP I-Disease
25 775 776 17439425 ( ( O I-Disease
26 776 777 17439425 P NN B-NP I-Disease
27 778 779 17439425 < SYM O I-Disease
28 780 785 17439425 0.001 CD B-NP I-Disease
29 785 786 17439425 ) ) O I-Disease
30 787 790 17439425 and CC O I-Disease
31 791 802 17439425 bodyweights NNS B-NP I-Disease
32 803 804 17439425 ( ( O O
33 804 805 17439425 P NN B-NP O
34 805 806 17439425 " '' O O
35 807 808 17439425 < SYM B-NP O
36 809 813 17439425 0.01 CD I-NP O
37 813 814 17439425 ) ) O O
38 814 815 17439425 . . O O

1 816 827 17439425 Allopurinol NN B-NP B-Chemical
2 828 837 17439425 decreased VBD B-VP O
3 838 843 17439425 serum NN B-NP O
4 844 849 17439425 urate NN I-NP B-Chemical
5 850 854 17439425 from IN B-PP O
6 855 857 17439425 76 CD B-NP O
7 858 859 17439425 + SYM B-ADJP O
8 859 860 17439425 / SYM O O
9 860 861 17439425 - SYM B-NP O
10 862 863 17439425 5 CD B-NP O
11 864 866 17439425 to TO I-NP O
12 867 869 17439425 30 CD I-NP O
13 870 871 17439425 + SYM O O
14 871 872 17439425 / SYM O O
15 872 873 17439425 - SYM O O
16 874 875 17439425 3 CD B-NP O
17 876 884 17439425 micromol NN I-NP O
18 884 885 17439425 / SYM B-NP O
19 885 886 17439425 L NN B-NP O
20 887 888 17439425 ( ( O O
21 888 889 17439425 P NN B-NP O
22 890 891 17439425 < SYM O O
23 892 897 17439425 0.001 CD B-NP O
24 897 898 17439425 ) ) O O
25 899 901 17439425 in IN B-PP O
26 902 908 17439425 saline NN B-NP O
27 909 912 17439425 and CC B-PP O
28 913 917 17439425 from IN B-PP O
29 918 920 17439425 84 CD B-NP O
30 921 922 17439425 + SYM B-ADJP O
31 922 923 17439425 / SYM O O
32 923 924 17439425 - SYM O O
33 925 927 17439425 13 CD B-NP O
34 928 930 17439425 to TO B-PP O
35 931 933 17439425 28 CD B-NP O
36 934 935 17439425 + SYM O O
37 935 936 17439425 / SYM O O
38 936 937 17439425 - SYM O O
39 938 939 17439425 2 CD B-NP O
40 940 948 17439425 micromol NN I-NP O
41 948 949 17439425 / SYM B-NP O
42 949 950 17439425 L NN I-NP O
43 951 953 17439425 in IN B-PP O
44 954 957 17439425 dex NN B-NP B-Chemical
45 957 958 17439425 - HYPH O O
46 958 965 17439425 treated VBN B-VP O
47 966 967 17439425 ( ( O O
48 967 968 17439425 P NN B-NP O
49 969 970 17439425 < SYM O O
50 971 975 17439425 0.01 CD O O
51 975 976 17439425 ) ) O O
52 977 983 17439425 groups NNS B-NP O
53 983 984 17439425 . . O O

1 985 986 17439425 6 CD B-NP O
2 986 987 17439425 . . O O

1 988 999 17439425 Allopurinol NN B-NP B-Chemical
2 1000 1003 17439425 did VBD B-VP O
3 1004 1007 17439425 not RB I-VP O
4 1008 1015 17439425 prevent VB I-VP O
5 1016 1019 17439425 dex NN B-NP B-Chemical
6 1019 1020 17439425 - HYPH B-NP O
7 1020 1022 17439425 HT NN I-NP B-Disease
8 1022 1023 17439425 . . O O

1 1024 1028 17439425 This DT B-NP O
2 1028 1029 17439425 , , O O
3 1030 1038 17439425 together RB B-ADVP O
4 1039 1043 17439425 with IN B-PP O
5 1044 1047 17439425 our PRP$ B-NP O
6 1048 1056 17439425 previous JJ I-NP O
7 1057 1065 17439425 findings NNS I-NP O
8 1066 1070 17439425 that IN B-SBAR O
9 1071 1082 17439425 allopurinol NN B-NP B-Chemical
10 1083 1089 17439425 failed VBD B-VP O
11 1090 1092 17439425 to TO I-VP O
12 1093 1100 17439425 prevent VB I-VP O
13 1101 1121 17439425 adrenocorticotrophic JJ B-NP O
14 1122 1129 17439425 hormone NN I-NP O
15 1130 1137 17439425 induced VBD B-VP O
16 1138 1150 17439425 hypertension NN B-NP B-Disease
17 1150 1151 17439425 , , O O
18 1152 1160 17439425 suggests VBZ B-VP O
19 1161 1165 17439425 that IN B-SBAR O
20 1166 1168 17439425 XO NN B-NP O
21 1169 1177 17439425 activity NN I-NP O
22 1178 1180 17439425 is VBZ B-VP O
23 1181 1184 17439425 not RB O O
24 1185 1186 17439425 a DT B-NP O
25 1187 1192 17439425 major JJ I-NP O
26 1193 1204 17439425 determinant NN I-NP O
27 1205 1207 17439425 of IN B-PP O
28 1208 1210 17439425 GC NN B-NP O
29 1210 1211 17439425 - HYPH B-NP O
30 1211 1213 17439425 HT NN I-NP B-Disease
31 1214 1216 17439425 in IN B-PP O
32 1217 1220 17439425 the DT B-NP O
33 1221 1224 17439425 rat NN I-NP O
34 1224 1225 17439425 . . O O

1 0 0 16867021 -DOCSTART- -X- -X- O

1 0 13 16867021 Antipsychotic JJ B-NP O
2 13 14 16867021 - HYPH I-NP O
3 14 18 16867021 like JJ I-NP O
4 19 26 16867021 profile NN I-NP O
5 27 29 16867021 of IN B-PP O
6 30 42 16867021 thioperamide NN B-NP B-Chemical
7 42 43 16867021 , , O O
8 44 45 16867021 a DT B-NP O
9 46 55 16867021 selective JJ I-NP O
10 56 58 16867021 H3 NN I-NP O
11 58 59 16867021 - HYPH B-NP O
12 59 67 16867021 receptor NN I-NP O
13 68 78 16867021 antagonist NN I-NP O
14 79 81 16867021 in IN B-PP O
15 82 86 16867021 mice NNS B-NP O
16 86 87 16867021 . . O O
17 88 100 16867021 Experimental JJ B-NP O
18 101 104 16867021 and CC I-NP O
19 105 113 16867021 clinical JJ I-NP O
20 114 122 16867021 evidence NN I-NP O
21 123 129 16867021 points VBZ B-VP O
22 130 132 16867021 to TO B-PP O
23 133 134 16867021 a DT B-NP O
24 135 139 16867021 role NN I-NP O
25 140 142 16867021 of IN B-PP O
26 143 150 16867021 central JJ B-NP O
27 151 164 16867021 histaminergic JJ I-NP O
28 165 171 16867021 system NN I-NP O
29 172 174 16867021 in IN B-PP O
30 175 178 16867021 the DT B-NP O
31 179 191 16867021 pathogenesis NN I-NP O
32 192 194 16867021 of IN B-PP O
33 195 208 16867021 schizophrenia NN B-NP B-Disease
34 208 209 16867021 . . O O

1 210 213 16867021 The DT B-NP O
2 214 221 16867021 present JJ I-NP O
3 222 227 16867021 study NN I-NP O
4 228 231 16867021 was VBD B-VP O
5 232 240 16867021 designed VBN I-VP O
6 241 243 16867021 to TO B-VP O
7 244 249 16867021 study VB I-VP O
8 250 253 16867021 the DT B-NP O
9 254 260 16867021 effect NN I-NP O
10 261 263 16867021 of IN B-PP O
11 264 273 16867021 histamine NN B-NP B-Chemical
12 274 278 16867021 H(3) NN I-NP O
13 278 279 16867021 - HYPH B-NP O
14 279 287 16867021 receptor NN I-NP O
15 288 295 16867021 ligands NNS I-NP O
16 296 298 16867021 on IN B-PP O
17 299 310 16867021 neuroleptic JJ B-NP O
18 310 311 16867021 - HYPH I-NP O
19 311 318 16867021 induced VBN I-NP O
20 319 328 16867021 catalepsy NN I-NP B-Disease
21 328 329 16867021 , , O O
22 330 341 16867021 apomorphine NN B-NP B-Chemical
23 341 342 16867021 - HYPH B-VP O
24 342 349 16867021 induced VBN I-VP O
25 350 358 16867021 climbing VBG B-VP O
26 359 367 16867021 behavior NN B-NP O
27 368 371 16867021 and CC I-NP O
28 372 383 16867021 amphetamine NN I-NP B-Chemical
29 383 384 16867021 - HYPH B-NP O
30 384 391 16867021 induced VBN I-NP O
31 392 401 16867021 locomotor NN I-NP O
32 402 412 16867021 activities NNS I-NP O
33 413 415 16867021 in IN B-PP O
34 416 420 16867021 mice NNS B-NP O
35 420 421 16867021 . . O O

1 422 431 16867021 Catalepsy NN B-NP B-Disease
2 432 435 16867021 was VBD B-VP O
3 436 443 16867021 induced VBN I-VP O
4 444 446 16867021 by IN B-PP O
5 447 458 16867021 haloperidol NN B-NP B-Chemical
6 459 460 16867021 ( ( O O
7 460 461 16867021 2 CD B-NP O
8 462 464 16867021 mg NN I-NP O
9 464 465 16867021 / SYM B-NP O
10 465 467 16867021 kg NN I-NP O
11 468 471 16867021 p.o NN I-NP O
12 471 472 16867021 . . O O
13 472 473 16867021 ) ) O O
14 473 474 16867021 , , O O
15 475 480 16867021 while IN B-SBAR O
16 481 492 16867021 apomorphine NN B-NP B-Chemical
17 493 494 16867021 ( ( O O
18 494 497 16867021 1.5 CD B-NP O
19 498 500 16867021 mg NN I-NP O
20 500 501 16867021 / SYM B-NP O
21 501 503 16867021 kg NN I-NP O
22 504 507 16867021 s.c NN I-NP O
23 507 508 16867021 . . O O
24 508 509 16867021 ) ) O O
25 510 513 16867021 and CC O O
26 514 525 16867021 amphetamine NN B-NP B-Chemical
27 526 527 16867021 ( ( O O
28 527 528 16867021 2 CD B-NP O
29 529 531 16867021 mg NN I-NP O
30 531 532 16867021 / SYM B-NP O
31 532 534 16867021 kg NN I-NP O
32 535 538 16867021 s.c NN I-NP O
33 538 539 16867021 . . O O
34 539 540 16867021 ) ) O O
35 541 545 16867021 were VBD B-VP O
36 546 550 16867021 used VBN I-VP O
37 551 554 16867021 for IN B-PP O
38 555 563 16867021 studying VBG B-VP O
39 564 572 16867021 climbing VBG I-VP O
40 573 581 16867021 behavior NN B-NP O
41 582 585 16867021 and CC I-NP O
42 586 595 16867021 locomotor NN I-NP O
43 596 606 16867021 activities NNS I-NP O
44 606 607 16867021 , , O O
45 608 620 16867021 respectively RB B-ADVP O
46 620 621 16867021 . . O O

1 622 625 16867021 (R) LS B-LST B-Chemical
2 625 626 16867021 - HYPH O I-Chemical
3 626 631 16867021 alpha SYM O I-Chemical
4 631 632 16867021 - HYPH O I-Chemical
5 632 647 16867021 methylhistamine NN B-NP I-Chemical
6 648 649 16867021 ( ( O O
7 649 653 16867021 RAMH NN B-NP B-Chemical
8 653 654 16867021 ) ) O O
9 655 656 16867021 ( ( O O
10 656 657 16867021 5 CD B-NP O
11 658 664 16867021 microg NN I-NP O
12 665 670 16867021 i.c.v NN I-NP O
13 670 671 16867021 . . O O
14 671 672 16867021 ) ) O O
15 673 676 16867021 and CC O O
16 677 689 16867021 thioperamide NN B-NP B-Chemical
17 690 691 16867021 ( ( O O
18 691 694 16867021 THP NN B-NP B-Chemical
19 694 695 16867021 ) ) O O
20 696 697 16867021 ( ( O O
21 697 699 16867021 15 CD B-NP O
22 700 702 16867021 mg NN I-NP O
23 702 703 16867021 / SYM O O
24 703 705 16867021 kg NN B-NP O
25 706 709 16867021 i.p NN I-NP O
26 709 710 16867021 . . O O
27 710 711 16867021 ) ) O O
28 711 712 16867021 , , O O
29 713 716 16867021 per FW B-ADVP O
30 717 719 16867021 se FW I-ADVP O
31 720 723 16867021 did VBD B-VP O
32 724 727 16867021 not RB I-VP O
33 728 733 16867021 cause VB I-VP O
34 734 743 16867021 catalepsy NN B-NP B-Disease
35 743 744 16867021 . . O O

1 745 759 16867021 Administration NN B-NP O
2 760 762 16867021 of IN B-PP O
3 763 766 16867021 THP NN B-NP B-Chemical
4 767 768 16867021 ( ( O O
5 768 772 16867021 3.75 CD B-NP O
6 772 773 16867021 , , I-NP O
7 774 777 16867021 7.5 CD I-NP O
8 778 781 16867021 and CC I-NP O
9 782 784 16867021 15 CD I-NP O
10 785 787 16867021 mg NN I-NP O
11 787 788 16867021 / SYM I-NP O
12 788 790 16867021 kg NN I-NP O
13 791 794 16867021 i.p NN I-NP O
14 794 795 16867021 . . O O
15 795 796 16867021 ) ) O O
16 797 798 16867021 1 CD B-NP O
17 799 800 16867021 h NN I-NP O
18 801 806 16867021 prior JJ B-ADJP O
19 807 809 16867021 to TO B-PP O
20 810 821 16867021 haloperidol NN B-NP B-Chemical
21 822 830 16867021 resulted VBD B-VP O
22 831 833 16867021 in IN B-PP O
23 834 835 16867021 a DT B-NP O
24 836 840 16867021 dose NN I-NP O
25 840 841 16867021 - HYPH B-NP O
26 841 850 16867021 dependent JJ I-NP O
27 851 859 16867021 increase NN I-NP O
28 860 862 16867021 in IN B-PP O
29 863 866 16867021 the DT B-NP O
30 867 876 16867021 catalepsy NN I-NP B-Disease
31 877 882 16867021 times NNS I-NP O
32 883 884 16867021 ( ( O O
33 884 885 16867021 P NN B-NP O
34 886 887 16867021 < SYM O O
35 888 892 16867021 0.05 CD B-NP O
36 892 893 16867021 ) ) O O
37 893 894 16867021 . . O O

1 895 902 16867021 However RB B-ADVP O
2 902 903 16867021 , , O O
3 904 916 16867021 pretreatment NN B-NP O
4 917 921 16867021 with IN B-PP O
5 922 926 16867021 RAMH NN B-NP B-Chemical
6 927 940 16867021 significantly RB B-ADVP O
7 941 949 16867021 reversed VBD B-VP O
8 950 954 16867021 such PDT B-NP O
9 955 957 16867021 an DT I-NP O
10 958 964 16867021 effect NN I-NP O
11 965 967 16867021 of IN B-PP O
12 968 971 16867021 THP NN B-NP B-Chemical
13 972 973 16867021 ( ( O O
14 973 975 16867021 15 CD B-NP O
15 976 978 16867021 mg NN I-NP O
16 978 979 16867021 / SYM O O
17 979 981 16867021 kg NN B-NP O
18 982 985 16867021 i.p NN I-NP O
19 985 986 16867021 . . O O
20 986 987 16867021 ) ) O O
21 987 988 16867021 . . O O

1 989 993 16867021 RAMH NN B-NP B-Chemical
2 994 997 16867021 per FW B-ADVP O
3 998 1000 16867021 se FW I-ADVP O
4 1001 1007 16867021 showed VBD B-VP O
5 1008 1019 16867021 significant JJ B-NP O
6 1020 1029 16867021 reduction NN I-NP O
7 1030 1032 16867021 in IN B-PP O
8 1033 1042 16867021 locomotor NN B-NP O
9 1043 1047 16867021 time NN I-NP O
10 1047 1048 16867021 , , O O
11 1049 1057 16867021 distance NN B-NP O
12 1058 1066 16867021 traveled VBN B-VP O
13 1067 1070 16867021 and CC O O
14 1071 1078 16867021 average JJ B-NP O
15 1079 1084 16867021 speed NN I-NP O
16 1085 1088 16867021 but CC O O
17 1089 1092 16867021 THP NN B-NP B-Chemical
18 1093 1094 16867021 ( ( O O
19 1094 1096 16867021 15 CD B-NP O
20 1097 1099 16867021 mg NN I-NP O
21 1099 1100 16867021 / SYM O O
22 1100 1102 16867021 kg NN B-NP O
23 1103 1106 16867021 i.p NN I-NP O
24 1106 1107 16867021 . . O O
25 1107 1108 16867021 ) ) O O
26 1109 1112 16867021 per FW B-NP O
27 1113 1115 16867021 se FW I-NP O
28 1116 1119 16867021 had VBD B-VP O
29 1120 1122 16867021 no DT B-NP O
30 1123 1129 16867021 effect NN I-NP O
31 1130 1132 16867021 on IN B-PP O
32 1133 1138 16867021 these DT B-NP O
33 1139 1149 16867021 parameters NNS I-NP O
34 1149 1150 16867021 . . O O

1 1151 1153 16867021 On IN B-PP O
2 1154 1165 16867021 amphetamine NN B-NP B-Chemical
3 1165 1166 16867021 - HYPH B-NP O
4 1166 1173 16867021 induced VBN I-NP O
5 1174 1187 16867021 hyperactivity NN I-NP B-Disease
6 1187 1188 16867021 , , O O
7 1189 1192 16867021 THP NN B-NP B-Chemical
8 1193 1194 16867021 ( ( O O
9 1194 1198 16867021 3.75 CD B-NP O
10 1199 1202 16867021 and CC I-NP O
11 1203 1206 16867021 7.5 CD I-NP O
12 1207 1209 16867021 mg NN I-NP O
13 1209 1210 16867021 / SYM B-NP O
14 1210 1212 16867021 kg NN I-NP O
15 1213 1216 16867021 i.p NN I-NP O
16 1216 1217 16867021 . . O O
17 1217 1218 16867021 ) ) O O
18 1219 1226 16867021 reduced VBD B-VP O
19 1227 1236 16867021 locomotor NN B-NP O
20 1237 1241 16867021 time NN I-NP O
21 1241 1242 16867021 , , O O
22 1243 1251 16867021 distance NN B-NP O
23 1252 1260 16867021 traveled VBN B-VP O
24 1261 1264 16867021 and CC O O
25 1265 1272 16867021 average JJ B-NP O
26 1273 1278 16867021 speed NN I-NP O
27 1279 1280 16867021 ( ( O O
28 1280 1281 16867021 P NN B-NP O
29 1282 1283 16867021 < SYM O O
30 1284 1288 16867021 0.05 CD B-NP O
31 1288 1289 16867021 ) ) O O
32 1289 1290 16867021 . . O O

1 1291 1303 16867021 Pretreatment NN B-NP O
2 1304 1308 16867021 with IN B-PP O
3 1309 1313 16867021 RAMH NN B-NP B-Chemical
4 1314 1315 16867021 ( ( O O
5 1315 1316 16867021 5 CD B-NP O
6 1317 1323 16867021 microg NN I-NP O
7 1324 1329 16867021 i.c.v NN I-NP O
8 1329 1330 16867021 . . O O
9 1330 1331 16867021 ) ) O O
10 1332 1337 16867021 could MD B-VP O
11 1338 1347 16867021 partially RB I-VP O
12 1348 1355 16867021 reverse VB I-VP O
13 1356 1360 16867021 such JJ B-NP O
14 1361 1368 16867021 effects NNS I-NP O
15 1369 1371 16867021 of IN B-PP O
16 1372 1375 16867021 THP NN B-NP B-Chemical
17 1376 1377 16867021 ( ( O O
18 1377 1381 16867021 3.75 CD B-NP O
19 1382 1384 16867021 mg NN I-NP O
20 1384 1385 16867021 / SYM B-NP O
21 1385 1387 16867021 kg NN I-NP O
22 1388 1391 16867021 i.p NN I-NP O
23 1391 1392 16867021 . . O O
24 1392 1393 16867021 ) ) O O
25 1393 1394 16867021 . . O O

1 1395 1403 16867021 Climbing VBG B-VP O
2 1404 1412 16867021 behavior NN B-NP O
3 1413 1420 16867021 induced VBN B-VP O
4 1421 1423 16867021 by IN B-PP O
5 1424 1435 16867021 apomorphine NN B-NP B-Chemical
6 1436 1439 16867021 was VBD B-VP O
7 1440 1447 16867021 reduced VBN I-VP O
8 1448 1450 16867021 in IN B-PP O
9 1451 1458 16867021 animals NNS B-NP O
10 1459 1466 16867021 treated VBN B-VP O
11 1467 1471 16867021 with IN B-PP O
12 1472 1475 16867021 THP NN B-NP B-Chemical
13 1475 1476 16867021 . . O O

1 1477 1481 16867021 Such PDT B-NP O
2 1482 1484 16867021 an DT I-NP O
3 1485 1491 16867021 effect NN I-NP O
4 1492 1495 16867021 was VBD B-VP O
5 1495 1496 16867021 , , O O
6 1497 1504 16867021 however RB B-ADVP O
7 1504 1505 16867021 , , O O
8 1506 1514 16867021 reversed VBN B-VP O
9 1515 1517 16867021 in IN B-PP O
10 1518 1526 16867021 presence NN B-NP O
11 1527 1529 16867021 of IN B-PP O
12 1530 1534 16867021 RAMH NN B-NP B-Chemical
13 1534 1535 16867021 . . O O

1 1536 1539 16867021 THP NN B-NP B-Chemical
2 1540 1549 16867021 exhibited VBD B-VP O
3 1550 1552 16867021 an DT B-NP O
4 1553 1566 16867021 antipsychotic JJ I-NP O
5 1566 1567 16867021 - HYPH I-NP O
6 1567 1571 16867021 like JJ I-NP O
7 1572 1579 16867021 profile NN I-NP O
8 1580 1582 16867021 by IN B-PP O
9 1583 1595 16867021 potentiating VBG B-VP O
10 1596 1607 16867021 haloperidol NN B-NP B-Chemical
11 1607 1608 16867021 - HYPH B-NP O
12 1608 1615 16867021 induced VBN I-NP O
13 1616 1625 16867021 catalepsy NN I-NP B-Disease
14 1625 1626 16867021 , , O O
15 1627 1635 16867021 reducing VBG B-VP O
16 1636 1647 16867021 amphetamine NN B-NP B-Chemical
17 1647 1648 16867021 - HYPH O O
18 1648 1655 16867021 induced VBN B-NP O
19 1656 1669 16867021 hyperactivity NN I-NP B-Disease
20 1670 1673 16867021 and CC O O
21 1674 1682 16867021 reducing VBG B-VP O
22 1683 1694 16867021 apomorphine NN B-NP B-Chemical
23 1694 1695 16867021 - HYPH O O
24 1695 1702 16867021 induced VBN B-NP O
25 1703 1711 16867021 climbing NN I-NP O
26 1712 1714 16867021 in IN B-PP O
27 1715 1719 16867021 mice NNS B-NP O
28 1719 1720 16867021 . . O O

1 1721 1725 16867021 Such JJ B-NP O
2 1726 1733 16867021 effects NNS I-NP O
3 1734 1736 16867021 of IN B-PP O
4 1737 1740 16867021 THP NN B-NP B-Chemical
5 1741 1745 16867021 were VBD B-VP O
6 1746 1754 16867021 reversed VBN I-VP O
7 1755 1757 16867021 by IN B-PP O
8 1758 1762 16867021 RAMH NN B-NP B-Chemical
9 1763 1773 16867021 indicating VBG B-VP O
10 1774 1777 16867021 the DT B-NP O
11 1778 1789 16867021 involvement NN I-NP O
12 1790 1792 16867021 of IN B-PP O
13 1793 1802 16867021 histamine NN B-NP B-Chemical
14 1803 1807 16867021 H(3) NN I-NP O
15 1807 1808 16867021 - HYPH B-NP O
16 1808 1817 16867021 receptors NNS I-NP O
17 1817 1818 16867021 . . O O

1 1819 1827 16867021 Findings NNS B-NP O
2 1828 1835 16867021 suggest VBP B-VP O
3 1836 1837 16867021 a DT B-NP O
4 1838 1847 16867021 potential NN I-NP O
5 1848 1851 16867021 for IN B-PP O
6 1852 1856 16867021 H(3) NN B-NP O
7 1856 1857 16867021 - HYPH I-NP O
8 1857 1865 16867021 receptor NN I-NP O
9 1866 1877 16867021 antagonists NNS I-NP O
10 1878 1880 16867021 in IN B-PP O
11 1881 1890 16867021 improving VBG B-VP O
12 1891 1894 16867021 the DT B-NP O
13 1895 1905 16867021 refractory JJ I-NP O
14 1906 1911 16867021 cases NNS I-NP O
15 1912 1914 16867021 of IN B-PP O
16 1915 1928 16867021 schizophrenia NN B-NP B-Disease
17 1928 1929 16867021 . . O O

1 0 0 16938416 -DOCSTART- -X- -X- O

1 0 4 16938416 High JJ B-NP O
2 4 5 16938416 - HYPH I-NP O
3 5 9 16938416 dose NN I-NP O
4 10 22 16938416 testosterone NN I-NP B-Chemical
5 23 25 16938416 is VBZ B-VP O
6 26 36 16938416 associated VBN I-VP O
7 37 41 16938416 with IN B-PP O
8 42 57 16938416 atherosclerosis NN B-NP B-Disease
9 58 60 16938416 in IN B-PP O
10 61 75 16938416 postmenopausal JJ B-NP O
11 76 81 16938416 women NNS I-NP O
12 81 82 16938416 . . O O
13 83 93 16938416 OBJECTIVES NNS B-NP O
14 93 94 16938416 : : O O
15 95 97 16938416 To TO B-VP O
16 98 103 16938416 study VB I-VP O
17 104 107 16938416 the DT B-NP O
18 108 112 16938416 long JJ I-NP O
19 112 113 16938416 - HYPH I-NP O
20 113 117 16938416 term NN I-NP O
21 118 125 16938416 effects NNS I-NP O
22 126 128 16938416 of IN B-PP O
23 129 137 16938416 androgen NN B-NP O
24 138 147 16938416 treatment NN I-NP O
25 148 150 16938416 on IN B-PP O
26 151 166 16938416 atherosclerosis NN B-NP B-Disease
27 167 169 16938416 in IN B-PP O
28 170 184 16938416 postmenopausal JJ B-NP O
29 185 190 16938416 women NNS I-NP O
30 190 191 16938416 . . O O

1 192 199 16938416 METHODS NNS B-NP O
2 199 200 16938416 : : O O
3 201 203 16938416 In IN B-PP O
4 204 205 16938416 a DT B-NP O
5 206 216 16938416 population NN I-NP O
6 216 217 16938416 - HYPH O O
7 217 222 16938416 based VBN B-NP O
8 223 228 16938416 study NN I-NP O
9 229 231 16938416 in IN B-PP O
10 232 235 16938416 513 CD B-NP O
11 236 245 16938416 naturally RB I-NP O
12 246 260 16938416 postmenopausal JJ I-NP O
13 261 266 16938416 women NNS I-NP O
14 267 271 16938416 aged VBN B-VP O
15 272 274 16938416 54 CD B-NP O
16 274 275 16938416 - HYPH I-NP O
17 275 277 16938416 67 CD I-NP O
18 278 283 16938416 years NNS I-NP O
19 283 284 16938416 , , O O
20 285 287 16938416 we PRP B-NP O
21 288 295 16938416 studied VBD B-VP O
22 296 299 16938416 the DT B-NP O
23 300 311 16938416 association NN I-NP O
24 312 319 16938416 between IN B-PP O
25 320 324 16938416 self NN B-NP O
26 324 325 16938416 - HYPH B-VP O
27 325 333 16938416 reported VBN I-VP O
28 334 349 16938416 intramuscularly RB B-NP O
29 350 362 16938416 administered VBN I-NP O
30 363 367 16938416 high JJ I-NP O
31 367 368 16938416 - HYPH I-NP O
32 368 372 16938416 dose NN I-NP O
33 373 381 16938416 estrogen NN I-NP B-Chemical
34 381 382 16938416 - HYPH O O
35 382 394 16938416 testosterone NN B-NP B-Chemical
36 395 402 16938416 therapy NN I-NP O
37 403 404 16938416 ( ( O O
38 404 413 16938416 estradiol NN B-NP B-Chemical
39 413 414 16938416 - HYPH B-NP I-Chemical
40 415 418 16938416 and CC I-NP I-Chemical
41 419 431 16938416 testosterone NN I-NP I-Chemical
42 432 438 16938416 esters NNS I-NP I-Chemical
43 438 439 16938416 ) ) O O
44 440 443 16938416 and CC O O
45 444 450 16938416 aortic JJ B-NP O
46 451 466 16938416 atherosclerosis NN I-NP B-Disease
47 466 467 16938416 . . O O

1 468 474 16938416 Aortic JJ B-NP O
2 475 490 16938416 atherosclerosis NN I-NP B-Disease
3 491 494 16938416 was VBD B-VP O
4 495 504 16938416 diagnosed VBN I-VP O
5 505 507 16938416 by IN B-PP O
6 508 520 16938416 radiographic JJ B-NP O
7 521 530 16938416 detection NN I-NP O
8 531 533 16938416 of IN B-PP O
9 534 543 16938416 calcified VBN B-NP O
10 544 552 16938416 deposits NNS I-NP O
11 553 555 16938416 in IN B-PP O
12 556 559 16938416 the DT B-NP O
13 560 569 16938416 abdominal JJ I-NP O
14 570 575 16938416 aorta NN I-NP O
15 575 576 16938416 , , O O
16 577 582 16938416 which WDT B-NP O
17 583 587 16938416 have VBP B-VP O
18 588 592 16938416 been VBN I-VP O
19 593 598 16938416 shown VBN I-VP O
20 599 601 16938416 to TO I-VP O
21 602 609 16938416 reflect VB I-VP O
22 610 616 16938416 intima NN B-NP O
23 617 632 16938416 atherosclerosis NN I-NP B-Disease
24 632 633 16938416 . . O O

1 634 641 16938416 Hormone NN B-NP O
2 642 649 16938416 therapy NN I-NP O
3 650 655 16938416 users NNS I-NP O
4 656 660 16938416 were VBD B-VP O
5 661 669 16938416 compared VBN I-VP O
6 670 674 16938416 with IN B-PP O
7 675 680 16938416 never JJ B-NP O
8 681 686 16938416 users NNS I-NP O
9 686 687 16938416 . . O O

1 688 695 16938416 RESULTS NNS B-NP O
2 695 696 16938416 : : O O
3 697 710 16938416 Intramuscular JJ B-NP O
4 711 718 16938416 hormone NN I-NP O
5 719 726 16938416 therapy NN I-NP O
6 727 730 16938416 use NN I-NP O
7 731 734 16938416 for IN B-PP O
8 735 736 16938416 1 CD B-NP O
9 737 741 16938416 year NN I-NP O
10 742 744 16938416 or CC I-NP O
11 745 751 16938416 longer NN I-NP O
12 752 755 16938416 was VBD B-VP O
13 756 764 16938416 reported VBN I-VP O
14 765 767 16938416 by IN B-PP O
15 768 770 16938416 25 CD B-NP O
16 771 776 16938416 women NNS I-NP O
17 776 777 16938416 . . O O

1 778 780 16938416 In IN B-PP O
2 781 787 16938416 almost RB B-NP O
3 788 792 16938416 half NN I-NP O
4 793 795 16938416 of IN B-PP O
5 796 801 16938416 these DT B-NP O
6 802 807 16938416 women NNS I-NP O
7 808 814 16938416 severe VBP B-VP O
8 815 830 16938416 atherosclerosis NN B-NP B-Disease
9 831 833 16938416 of IN B-PP O
10 834 837 16938416 the DT B-NP O
11 838 843 16938416 aorta NN I-NP O
12 844 847 16938416 was VBD B-VP O
13 848 855 16938416 present JJ B-ADJP O
14 856 857 16938416 ( ( O O
15 857 858 16938416 n NN B-NP O
16 858 859 16938416 = SYM B-VP O
17 859 861 16938416 11 CD B-NP O
18 861 862 16938416 ) ) O O
19 862 863 16938416 , , O O
20 864 869 16938416 while IN B-SBAR O
21 870 872 16938416 in IN B-PP O
22 873 878 16938416 women NNS B-NP O
23 879 886 16938416 without IN B-PP O
24 887 894 16938416 hormone NN B-NP O
25 895 898 16938416 use NN I-NP O
26 899 905 16938416 severe JJ I-NP O
27 906 921 16938416 atherosclerosis NN I-NP B-Disease
28 922 924 16938416 of IN B-PP O
29 925 928 16938416 the DT B-NP O
30 929 934 16938416 aorta NN I-NP O
31 935 938 16938416 was VBD B-VP O
32 939 946 16938416 present JJ B-ADJP O
33 947 949 16938416 in IN B-PP O
34 950 954 16938416 less JJR B-NP O
35 955 959 16938416 than IN I-NP O
36 960 963 16938416 20% CD I-NP O
37 964 965 16938416 ( ( O O
38 965 967 16938416 OR NN B-NP O
39 968 971 16938416 3.1 CD I-NP O
40 971 972 16938416 ; : O O
41 973 976 16938416 95% CD B-NP O
42 977 979 16938416 CI NN I-NP O
43 979 980 16938416 , , O O
44 981 984 16938416 1.1 CD B-NP O
45 984 985 16938416 - HYPH I-NP O
46 985 988 16938416 8.5 CD I-NP O
47 988 989 16938416 , , O O
48 990 998 16938416 adjusted VBN B-VP O
49 999 1002 16938416 for IN B-PP O
50 1003 1006 16938416 age NN B-NP O
51 1006 1007 16938416 , , O O
52 1008 1013 16938416 years NNS B-NP O
53 1014 1019 16938416 since IN B-PP O
54 1020 1029 16938416 menopause NN B-NP O
55 1029 1030 16938416 , , O O
56 1031 1038 16938416 smoking NN B-NP O
57 1038 1039 16938416 , , O O
58 1040 1043 16938416 and CC O O
59 1044 1048 16938416 body NN B-NP O
60 1049 1053 16938416 mass NN I-NP O
61 1054 1059 16938416 index NN I-NP O
62 1059 1060 16938416 ) ) O O
63 1060 1061 16938416 . . O O

1 1062 1065 16938416 The DT B-NP O
2 1066 1077 16938416 association NN I-NP O
3 1078 1086 16938416 remained VBD B-VP O
4 1087 1092 16938416 after IN B-PP O
5 1093 1103 16938416 additional JJ B-NP O
6 1104 1114 16938416 adjustment NN I-NP O
7 1115 1118 16938416 for IN B-PP O
8 1119 1127 16938416 diabetes NN B-NP B-Disease
9 1127 1128 16938416 , , O O
10 1129 1140 16938416 cholesterol NN B-NP B-Chemical
11 1141 1146 16938416 level NN I-NP O
12 1146 1147 16938416 , , O O
13 1148 1156 16938416 systolic JJ B-NP O
14 1157 1162 16938416 blood NN I-NP O
15 1163 1171 16938416 pressure NN I-NP O
16 1171 1172 16938416 , , O O
17 1173 1175 16938416 or CC O O
18 1176 1183 16938416 alcohol NN B-NP B-Chemical
19 1184 1187 16938416 use NN I-NP O
20 1187 1188 16938416 . . O O

1 1189 1191 16938416 No DT B-NP O
2 1192 1203 16938416 association NN I-NP O
3 1204 1207 16938416 was VBD B-VP O
4 1208 1213 16938416 found VBN I-VP O
5 1214 1217 16938416 for IN B-PP O
6 1218 1225 16938416 hormone NN B-NP O
7 1226 1229 16938416 use NN I-NP O
8 1230 1234 16938416 less JJR B-NP O
9 1235 1239 16938416 than IN I-NP O
10 1240 1241 16938416 1 CD I-NP O
11 1242 1246 16938416 year NN I-NP O
12 1246 1247 16938416 . . O O

1 1248 1258 16938416 CONCLUSION NN B-NP O
2 1258 1259 16938416 : : O O
3 1260 1263 16938416 Our PRP$ B-NP O
4 1264 1271 16938416 results NNS I-NP O
5 1272 1279 16938416 suggest VBP B-VP O
6 1280 1284 16938416 that IN B-SBAR O
7 1285 1289 16938416 high JJ B-NP O
8 1289 1290 16938416 - HYPH I-NP O
9 1290 1294 16938416 dose NN I-NP O
10 1295 1307 16938416 testosterone NN I-NP B-Chemical
11 1308 1315 16938416 therapy NN I-NP O
12 1316 1319 16938416 may MD B-VP O
13 1320 1329 16938416 adversely RB I-VP O
14 1330 1336 16938416 affect VB I-VP O
15 1337 1352 16938416 atherosclerosis NN B-NP B-Disease
16 1353 1355 16938416 in IN B-PP O
17 1356 1370 16938416 postmenopausal JJ B-NP O
18 1371 1376 16938416 women NNS I-NP O
19 1377 1380 16938416 and CC O O
20 1381 1389 16938416 indicate VBP B-VP O
21 1390 1394 16938416 that IN B-SBAR O
22 1395 1403 16938416 androgen NN B-NP O
23 1404 1415 16938416 replacement NN I-NP O
24 1416 1418 16938416 in IN B-PP O
25 1419 1424 16938416 these DT B-NP O
26 1425 1430 16938416 women NNS I-NP O
27 1431 1434 16938416 may MD B-VP O
28 1435 1438 16938416 not RB I-VP O
29 1439 1441 16938416 be VB I-VP O
30 1442 1450 16938416 harmless JJ B-ADJP O
31 1450 1451 16938416 . . O O

1 0 0 2578334 -DOCSTART- -X- -X- O

1 0 1 2578334 5 CD B-NP B-Chemical
2 1 2 2578334 - HYPH I-NP I-Chemical
3 2 13 2578334 azacytidine NN I-NP I-Chemical
4 14 25 2578334 potentiates VBZ B-VP O
5 26 36 2578334 initiation NN B-NP B-Disease
6 37 44 2578334 induced VBN B-VP I-Disease
7 45 47 2578334 by IN B-PP I-Disease
8 48 59 2578334 carcinogens NNS B-NP I-Disease
9 60 62 2578334 in IN B-PP O
10 63 66 2578334 rat NN B-NP O
11 67 72 2578334 liver NN I-NP O
12 72 73 2578334 . . O O
13 74 76 2578334 To TO B-VP O
14 77 81 2578334 test VB I-VP O
15 82 85 2578334 the DT B-NP O
16 86 94 2578334 validity NN I-NP O
17 95 97 2578334 of IN B-PP O
18 98 101 2578334 the DT B-NP O
19 102 112 2578334 hypothesis NN I-NP O
20 113 117 2578334 that IN B-SBAR O
21 118 133 2578334 hypomethylation NN B-NP O
22 134 136 2578334 of IN B-PP O
23 137 140 2578334 DNA NN B-NP O
24 141 146 2578334 plays VBZ B-VP O
25 147 149 2578334 an DT B-NP O
26 150 159 2578334 important JJ I-NP O
27 160 164 2578334 role NN I-NP O
28 165 167 2578334 in IN B-PP O
29 168 171 2578334 the DT B-NP O
30 172 182 2578334 initiation NN I-NP B-Disease
31 183 185 2578334 of IN B-PP I-Disease
32 186 198 2578334 carcinogenic JJ B-NP I-Disease
33 199 206 2578334 process NN I-NP I-Disease
34 206 207 2578334 , , O O
35 208 209 2578334 5 CD B-NP B-Chemical
36 209 210 2578334 - HYPH I-NP I-Chemical
37 210 221 2578334 azacytidine NN I-NP I-Chemical
38 222 223 2578334 ( ( O O
39 223 224 2578334 5 CD B-NP B-Chemical
40 224 225 2578334 - HYPH I-NP I-Chemical
41 225 228 2578334 AzC NN I-NP I-Chemical
42 228 229 2578334 ) ) O O
43 230 231 2578334 ( ( O O
44 231 233 2578334 10 CD B-NP O
45 234 236 2578334 mg NN I-NP O
46 236 237 2578334 / SYM B-NP O
47 237 239 2578334 kg NN I-NP O
48 239 240 2578334 ) ) O O
49 240 241 2578334 , , O O
50 242 244 2578334 an DT B-NP O
51 245 254 2578334 inhibitor NN I-NP O
52 255 257 2578334 of IN B-PP O
53 258 261 2578334 DNA NN B-NP O
54 262 273 2578334 methylation NN I-NP O
55 273 274 2578334 , , O O
56 275 278 2578334 was VBD B-VP O
57 279 284 2578334 given VBN I-VP O
58 285 287 2578334 to TO B-PP O
59 288 292 2578334 rats NNS B-NP O
60 293 299 2578334 during IN B-PP O
61 300 303 2578334 the DT B-NP O
62 304 309 2578334 phase NN I-NP O
63 310 312 2578334 of IN B-PP O
64 313 319 2578334 repair NN B-NP O
65 320 329 2578334 synthesis NN I-NP O
66 330 337 2578334 induced VBN B-VP O
67 338 340 2578334 by IN B-PP O
68 341 344 2578334 the DT B-NP O
69 345 350 2578334 three CD I-NP O
70 351 362 2578334 carcinogens NNS I-NP O
71 362 363 2578334 , , O O
72 364 372 2578334 benzo[a] NN B-NP B-Chemical
73 372 373 2578334 - HYPH O I-Chemical
74 373 379 2578334 pyrene NN B-NP I-Chemical
75 380 381 2578334 ( ( O O
76 381 384 2578334 200 CD B-NP O
77 385 387 2578334 mg NN I-NP O
78 387 388 2578334 / SYM B-NP O
79 388 390 2578334 kg NN I-NP O
80 390 391 2578334 ) ) O O
81 391 392 2578334 , , O O
82 393 394 2578334 N NN B-NP B-Chemical
83 394 395 2578334 - HYPH B-NP I-Chemical
84 395 401 2578334 methyl NN I-NP I-Chemical
85 401 402 2578334 - HYPH B-NP I-Chemical
86 402 403 2578334 N NN I-NP I-Chemical
87 403 404 2578334 - HYPH B-NP I-Chemical
88 404 415 2578334 nitrosourea NN I-NP I-Chemical
89 416 417 2578334 ( ( O O
90 417 419 2578334 60 CD B-NP O
91 420 422 2578334 mg NN I-NP O
92 422 423 2578334 / SYM B-NP O
93 423 425 2578334 kg NN I-NP O
94 425 426 2578334 ) ) O O
95 427 430 2578334 and CC O O
96 431 434 2578334 1,2 CD B-NP B-Chemical
97 434 435 2578334 - HYPH I-NP I-Chemical
98 435 452 2578334 dimethylhydrazine NN I-NP I-Chemical
99 453 454 2578334 ( ( O O
100 454 457 2578334 1,2 CD B-NP B-Chemical
101 457 458 2578334 - HYPH I-NP I-Chemical
102 458 461 2578334 DMH NN I-NP I-Chemical
103 461 462 2578334 ) ) O O
104 463 464 2578334 ( ( O O
105 464 467 2578334 100 CD B-NP O
106 468 470 2578334 mg NN I-NP O
107 470 471 2578334 / SYM B-NP O
108 471 473 2578334 kg NN I-NP O
109 473 474 2578334 ) ) O O
110 474 475 2578334 . . O O

1 476 479 2578334 The DT B-NP O
2 480 489 2578334 initiated VBN I-NP O
3 490 501 2578334 hepatocytes NNS I-NP O
4 502 504 2578334 in IN B-PP O
5 505 508 2578334 the DT B-NP O
6 509 514 2578334 liver NN I-NP O
7 515 519 2578334 were VBD B-VP O
8 520 527 2578334 assayed VBN I-VP O
9 528 530 2578334 as IN B-PP O
10 531 534 2578334 the DT B-NP O
11 535 540 2578334 gamma SYM I-NP O
12 540 541 2578334 - HYPH I-NP O
13 541 560 2578334 glutamyltransferase NN I-NP O
14 561 562 2578334 ( ( O O
15 562 567 2578334 gamma SYM B-NP O
16 567 568 2578334 - HYPH I-NP O
17 568 570 2578334 GT NN I-NP O
18 570 571 2578334 ) ) I-NP O
19 572 580 2578334 positive JJ I-NP O
20 581 585 2578334 foci NNS I-NP O
21 586 592 2578334 formed VBN B-VP O
22 593 602 2578334 following VBG B-PP O
23 603 604 2578334 a DT B-NP O
24 605 606 2578334 2 CD I-NP O
25 606 607 2578334 - HYPH I-NP O
26 607 611 2578334 week NN I-NP O
27 612 621 2578334 selection NN I-NP O
28 622 629 2578334 regimen NN I-NP O
29 630 640 2578334 consisting VBG B-VP O
30 641 643 2578334 of IN B-PP O
31 644 651 2578334 dietary JJ B-NP O
32 652 657 2578334 0.02% CD I-NP O
33 658 659 2578334 2 CD I-NP B-Chemical
34 659 660 2578334 - HYPH I-NP I-Chemical
35 660 679 2578334 acetylaminofluorene NN I-NP I-Chemical
36 680 687 2578334 coupled VBN B-VP O
37 688 692 2578334 with IN B-PP O
38 693 694 2578334 a DT B-NP O
39 695 705 2578334 necrogenic JJ I-NP O
40 706 710 2578334 dose NN I-NP O
41 711 713 2578334 of IN B-PP O
42 714 718 2578334 CCl4 NN B-NP B-Chemical
43 718 719 2578334 . . O O

1 720 723 2578334 The DT B-NP O
2 724 731 2578334 results NNS I-NP O
3 732 740 2578334 obtained VBN B-VP O
4 741 749 2578334 indicate VBP B-VP O
5 750 754 2578334 that IN B-SBAR O
6 755 759 2578334 with IN B-PP O
7 760 763 2578334 all DT B-NP O
8 764 769 2578334 three CD I-NP O
9 770 781 2578334 carcinogens NNS I-NP O
10 781 782 2578334 , , O O
11 783 797 2578334 administration NN B-NP O
12 798 800 2578334 of IN B-PP O
13 801 802 2578334 5 CD B-NP B-Chemical
14 802 803 2578334 - HYPH I-NP I-Chemical
15 803 806 2578334 AzC NN I-NP I-Chemical
16 807 813 2578334 during IN B-PP O
17 814 820 2578334 repair NN B-NP O
18 821 830 2578334 synthesis NN I-NP O
19 831 840 2578334 increased VBD B-VP O
20 841 844 2578334 the DT B-NP O
21 845 854 2578334 incidence NN I-NP O
22 855 857 2578334 of IN B-PP O
23 858 867 2578334 initiated VBN B-NP O
24 868 879 2578334 hepatocytes NNS I-NP O
25 879 880 2578334 , , O O
26 881 884 2578334 for IN B-PP O
27 885 892 2578334 example NN B-NP O
28 893 895 2578334 10 CD I-NP O
29 895 896 2578334 - HYPH I-NP O
30 896 898 2578334 20 CD I-NP O
31 899 903 2578334 foci NNS I-NP O
32 903 904 2578334 / SYM B-NP O
33 904 907 2578334 cm2 NN I-NP O
34 908 910 2578334 in IN B-PP O
35 911 912 2578334 5 CD B-NP B-Chemical
36 912 913 2578334 - HYPH I-NP I-Chemical
37 913 916 2578334 AzC NN I-NP I-Chemical
38 917 920 2578334 and CC I-NP O
39 921 931 2578334 carcinogen NN I-NP O
40 931 932 2578334 - HYPH B-NP O
41 932 939 2578334 treated VBN I-NP O
42 940 944 2578334 rats NNS I-NP O
43 945 953 2578334 compared VBN B-PP O
44 954 958 2578334 with IN B-PP O
45 959 960 2578334 3 CD B-NP O
46 960 961 2578334 - HYPH I-NP O
47 961 962 2578334 5 CD I-NP O
48 963 967 2578334 foci NNS I-NP O
49 967 968 2578334 / SYM B-NP O
50 968 971 2578334 cm2 NN I-NP O
51 972 974 2578334 in IN B-PP O
52 975 979 2578334 rats NNS B-NP O
53 980 987 2578334 treated VBN B-VP O
54 988 992 2578334 with IN B-PP O
55 993 1003 2578334 carcinogen NN B-NP O
56 1004 1008 2578334 only RB B-ADVP O
57 1008 1009 2578334 . . O O

1 1010 1024 2578334 Administration NN B-NP O
2 1025 1027 2578334 of IN B-PP O
3 1028 1032 2578334 [3H] NN B-NP B-Chemical
4 1032 1033 2578334 - HYPH B-NP I-Chemical
5 1033 1034 2578334 5 CD I-NP I-Chemical
6 1034 1035 2578334 - HYPH I-NP I-Chemical
7 1035 1051 2578334 azadeoxycytidine NN I-NP I-Chemical
8 1052 1058 2578334 during IN B-PP O
9 1059 1062 2578334 the DT B-NP O
10 1063 1069 2578334 repair NN I-NP O
11 1070 1079 2578334 synthesis NN I-NP O
12 1080 1087 2578334 induced VBN B-VP O
13 1088 1090 2578334 by IN B-PP O
14 1091 1094 2578334 1,2 CD B-NP B-Chemical
15 1094 1095 2578334 - HYPH I-NP I-Chemical
16 1095 1098 2578334 DMH NN I-NP I-Chemical
17 1099 1106 2578334 further RB B-ADVP O
18 1107 1113 2578334 showed VBD B-VP O
19 1114 1118 2578334 that IN B-SBAR O
20 1119 1124 2578334 0.019 CD B-NP O
21 1125 1128 2578334 mol NN I-NP O
22 1129 1130 2578334 % NN I-NP O
23 1131 1133 2578334 of IN B-PP O
24 1134 1142 2578334 cytosine NN B-NP B-Chemical
25 1143 1151 2578334 residues NNS I-NP O
26 1152 1154 2578334 in IN B-PP O
27 1155 1158 2578334 DNA NN B-NP O
28 1159 1163 2578334 were VBD B-VP O
29 1164 1175 2578334 substituted VBN I-VP O
30 1176 1178 2578334 by IN B-PP O
31 1179 1182 2578334 the DT B-NP O
32 1183 1191 2578334 analogue NN I-NP O
33 1191 1192 2578334 , , O O
34 1193 1203 2578334 indicating VBG B-VP O
35 1204 1208 2578334 that IN B-SBAR O
36 1209 1222 2578334 incorporation NN B-NP O
37 1223 1225 2578334 of IN B-PP O
38 1226 1227 2578334 5 CD B-NP B-Chemical
39 1227 1228 2578334 - HYPH I-NP I-Chemical
40 1228 1231 2578334 AzC NN I-NP I-Chemical
41 1232 1238 2578334 occurs VBZ B-VP O
42 1239 1245 2578334 during IN B-PP O
43 1246 1252 2578334 repair NN B-NP O
44 1253 1262 2578334 synthesis NN I-NP O
45 1262 1263 2578334 . . O O

1 1264 1266 2578334 In IN B-PP O
2 1267 1270 2578334 the DT B-NP O
3 1271 1278 2578334 absence NN I-NP O
4 1279 1281 2578334 of IN B-PP O
5 1282 1285 2578334 the DT B-NP O
6 1286 1296 2578334 carcinogen NN I-NP O
7 1296 1297 2578334 , , O O
8 1298 1299 2578334 5 CD B-NP B-Chemical
9 1299 1300 2578334 - HYPH I-NP I-Chemical
10 1300 1303 2578334 AzC NN I-NP I-Chemical
11 1304 1309 2578334 given VBN B-VP O
12 1310 1315 2578334 after IN B-PP O
13 1316 1317 2578334 a DT B-NP O
14 1318 1321 2578334 two CD I-NP O
15 1322 1328 2578334 thirds NNS I-NP O
16 1329 1336 2578334 partial JJ I-NP O
17 1337 1348 2578334 hepatectomy NN I-NP O
18 1348 1349 2578334 , , O O
19 1350 1354 2578334 when WRB B-ADVP O
20 1355 1358 2578334 its PRP$ B-NP O
21 1359 1372 2578334 incorporation NN I-NP O
22 1373 1379 2578334 should MD B-VP O
23 1380 1382 2578334 be VB I-VP O
24 1383 1390 2578334 maximum JJ B-ADJP O
25 1390 1391 2578334 , , O O
26 1392 1398 2578334 failed VBD B-VP O
27 1399 1401 2578334 to TO I-VP O
28 1402 1408 2578334 induce VB I-VP O
29 1409 1412 2578334 any DT B-NP O
30 1413 1418 2578334 gamma SYM I-NP O
31 1418 1419 2578334 - HYPH I-NP O
32 1419 1421 2578334 GT NN I-NP O
33 1422 1430 2578334 positive JJ I-NP O
34 1431 1435 2578334 foci NNS I-NP O
35 1435 1436 2578334 . . O O

1 1437 1440 2578334 The DT B-NP O
2 1441 1448 2578334 results NNS I-NP O
3 1449 1456 2578334 suggest VBP B-VP O
4 1457 1461 2578334 that IN B-SBAR O
5 1462 1477 2578334 hypomethylation NN B-NP O
6 1478 1480 2578334 of IN B-PP O
7 1481 1484 2578334 DNA NN B-NP O
8 1485 1488 2578334 per FW B-ADVP O
9 1489 1491 2578334 se FW I-ADVP O
10 1492 1495 2578334 may MD B-VP O
11 1496 1499 2578334 not RB I-VP O
12 1500 1502 2578334 be VB I-VP O
13 1503 1513 2578334 sufficient JJ B-ADJP O
14 1514 1517 2578334 for IN B-PP O
15 1518 1528 2578334 initiation NN B-NP O
16 1528 1529 2578334 . . O O

1 1530 1537 2578334 Perhaps RB B-ADVP O
2 1538 1541 2578334 two CD B-NP O
3 1542 1548 2578334 events NNS I-NP O
4 1549 1554 2578334 might MD B-VP O
5 1555 1557 2578334 be VB I-VP O
6 1558 1567 2578334 necessary JJ B-ADJP O
7 1568 1571 2578334 for IN B-PP O
8 1572 1582 2578334 initiation NN B-NP O
9 1582 1583 2578334 , , O O
10 1584 1587 2578334 the DT B-NP O
11 1588 1593 2578334 first JJ I-NP O
12 1594 1600 2578334 caused VBN B-VP O
13 1601 1603 2578334 by IN B-PP O
14 1604 1607 2578334 the DT B-NP O
15 1608 1618 2578334 carcinogen NN I-NP O
16 1619 1622 2578334 and CC O O
17 1623 1624 2578334 a DT B-NP O
18 1625 1631 2578334 second JJ I-NP O
19 1632 1641 2578334 involving VBG I-NP O
20 1642 1657 2578334 hypomethylation NN I-NP O
21 1658 1660 2578334 of IN B-PP O
22 1661 1664 2578334 DNA NN B-NP O
23 1664 1665 2578334 . . O O

1 0 0 20477932 -DOCSTART- -X- -X- O

1 0 7 20477932 Cocaine NN B-NP B-Chemical
2 8 14 20477932 causes VBZ B-VP O
3 15 21 20477932 memory NN B-NP B-Disease
4 22 25 20477932 and CC I-NP I-Disease
5 26 34 20477932 learning NN I-NP I-Disease
6 35 46 20477932 impairments NNS I-NP I-Disease
7 47 49 20477932 in IN B-PP O
8 50 54 20477932 rats NNS B-NP O
9 54 55 20477932 : : O O
10 56 67 20477932 involvement NN B-NP O
11 68 70 20477932 of IN B-PP O
12 71 78 20477932 nuclear JJ B-NP O
13 79 85 20477932 factor NN I-NP O
14 86 91 20477932 kappa NN I-NP O
15 92 93 20477932 B NN I-NP O
16 94 97 20477932 and CC O O
17 98 107 20477932 oxidative JJ B-NP O
18 108 114 20477932 stress NN I-NP O
19 114 115 20477932 , , O O
20 116 119 20477932 and CC O O
21 120 130 20477932 prevention NN B-NP O
22 131 133 20477932 by IN B-PP O
23 134 144 20477932 topiramate NN B-NP B-Chemical
24 144 145 20477932 . . O O
25 146 155 20477932 Different JJ B-NP O
26 156 166 20477932 mechanisms NNS I-NP O
27 167 171 20477932 have VBP B-VP O
28 172 176 20477932 been VBN I-VP O
29 177 186 20477932 suggested VBN I-VP O
30 187 190 20477932 for IN B-PP O
31 191 198 20477932 cocaine NN B-NP B-Chemical
32 199 207 20477932 toxicity NN I-NP B-Disease
33 208 217 20477932 including VBG B-PP O
34 218 220 20477932 an DT B-NP O
35 221 229 20477932 increase NN I-NP O
36 230 232 20477932 in IN B-PP O
37 233 242 20477932 oxidative JJ B-NP O
38 243 249 20477932 stress NN I-NP O
39 250 253 20477932 but CC O O
40 254 257 20477932 the DT B-NP O
41 258 269 20477932 association NN I-NP O
42 270 277 20477932 between IN B-PP O
43 278 287 20477932 oxidative JJ B-NP O
44 288 294 20477932 status NN I-NP O
45 295 297 20477932 in IN B-PP O
46 298 301 20477932 the DT B-NP O
47 302 307 20477932 brain NN I-NP O
48 308 311 20477932 and CC I-NP O
49 312 319 20477932 cocaine NN I-NP B-Chemical
50 320 327 20477932 induced VBN B-VP O
51 327 328 20477932 - HYPH B-NP O
52 328 337 20477932 behaviour NN I-NP O
53 338 340 20477932 is VBZ B-VP O
54 341 347 20477932 poorly RB B-ADJP O
55 348 358 20477932 understood VBN I-ADJP O
56 358 359 20477932 . . O O

1 360 367 20477932 Nuclear JJ B-NP O
2 368 374 20477932 factor NN I-NP O
3 375 380 20477932 kappa NN I-NP O
4 381 382 20477932 B NN I-NP O
5 383 384 20477932 ( ( O O
6 384 392 20477932 NFkappaB NN B-NP O
7 392 393 20477932 ) ) O O
8 394 396 20477932 is VBZ B-VP O
9 397 398 20477932 a DT B-NP O
10 399 405 20477932 sensor NN I-NP O
11 406 408 20477932 of IN B-PP O
12 409 418 20477932 oxidative JJ B-NP O
13 419 425 20477932 stress NN I-NP O
14 426 429 20477932 and CC O O
15 430 442 20477932 participates VBZ B-VP O
16 443 445 20477932 in IN B-PP O
17 446 452 20477932 memory NN B-NP O
18 453 462 20477932 formation NN I-NP O
19 463 467 20477932 that WDT B-NP O
20 468 473 20477932 could MD B-VP O
21 474 476 20477932 be VB I-VP O
22 477 485 20477932 involved VBN I-VP O
23 486 488 20477932 in IN B-PP O
24 489 493 20477932 drug NN B-NP O
25 494 502 20477932 toxicity NN I-NP B-Disease
26 503 506 20477932 and CC O O
27 507 516 20477932 addiction NN B-NP O
28 517 527 20477932 mechanisms NNS I-NP O
29 527 528 20477932 . . O O

1 529 538 20477932 Therefore RB B-NP O
2 539 547 20477932 NFkappaB NN I-NP O
3 548 556 20477932 activity NN I-NP O
4 556 557 20477932 , , O O
5 558 567 20477932 oxidative JJ B-NP O
6 568 574 20477932 stress NN I-NP O
7 574 575 20477932 , , O O
8 576 584 20477932 neuronal JJ B-NP O
9 585 591 20477932 nitric JJ I-NP B-Chemical
10 592 597 20477932 oxide NN I-NP I-Chemical
11 598 606 20477932 synthase NN I-NP O
12 607 608 20477932 ( ( O O
13 608 612 20477932 nNOS NN B-NP O
14 612 613 20477932 ) ) O O
15 614 622 20477932 activity NN B-NP O
16 622 623 20477932 , , O O
17 624 631 20477932 spatial JJ B-NP O
18 632 640 20477932 learning NN I-NP O
19 641 644 20477932 and CC I-NP O
20 645 651 20477932 memory NN I-NP O
21 652 654 20477932 as RB B-CONJP O
22 655 659 20477932 well RB I-CONJP O
23 660 662 20477932 as IN I-CONJP O
24 663 666 20477932 the DT B-NP O
25 667 673 20477932 effect NN I-NP O
26 674 676 20477932 of IN B-PP O
27 677 687 20477932 topiramate NN B-NP B-Chemical
28 687 688 20477932 , , O O
29 689 690 20477932 a DT B-NP O
30 691 701 20477932 previously RB I-NP O
31 702 710 20477932 proposed VBN I-NP O
32 711 718 20477932 therapy NN I-NP O
33 719 722 20477932 for IN B-PP O
34 723 730 20477932 cocaine NN B-NP B-Disease
35 731 740 20477932 addiction NN I-NP I-Disease
36 740 741 20477932 , , O O
37 742 746 20477932 were VBD B-VP O
38 747 756 20477932 evaluated VBN I-VP O
39 757 759 20477932 in IN B-PP O
40 760 762 20477932 an DT B-NP O
41 763 775 20477932 experimental JJ I-NP O
42 776 781 20477932 model NN I-NP O
43 782 784 20477932 of IN B-PP O
44 785 792 20477932 cocaine NN B-NP B-Chemical
45 793 807 20477932 administration NN I-NP O
46 808 810 20477932 in IN B-PP O
47 811 815 20477932 rats NNS B-NP O
48 815 816 20477932 . . O O

1 817 825 20477932 NFkappaB NN B-NP O
2 826 834 20477932 activity NN I-NP O
3 835 838 20477932 was VBD B-VP O
4 839 848 20477932 decreased VBN I-VP O
5 849 851 20477932 in IN B-PP O
6 852 855 20477932 the DT B-NP O
7 856 863 20477932 frontal JJ I-NP O
8 864 870 20477932 cortex NN I-NP O
9 871 873 20477932 of IN B-PP O
10 874 881 20477932 cocaine NN B-NP B-Chemical
11 882 889 20477932 treated VBN I-NP O
12 890 894 20477932 rats NNS I-NP O
13 894 895 20477932 , , O O
14 896 898 20477932 as RB B-CONJP O
15 899 903 20477932 well RB I-CONJP O
16 904 906 20477932 as IN I-CONJP O
17 907 910 20477932 GSH NN B-NP B-Chemical
18 911 924 20477932 concentration NN I-NP O
19 925 928 20477932 and CC O O
20 929 940 20477932 glutathione NN B-NP B-Chemical
21 941 951 20477932 peroxidase NN I-NP O
22 952 960 20477932 activity NN I-NP O
23 961 963 20477932 in IN B-PP O
24 964 967 20477932 the DT B-NP O
25 968 979 20477932 hippocampus NN I-NP O
26 979 980 20477932 , , O O
27 981 988 20477932 whereas IN O O
28 989 993 20477932 nNOS NN B-NP O
29 994 1002 20477932 activity NN I-NP O
30 1003 1005 20477932 in IN B-PP O
31 1006 1009 20477932 the DT B-NP O
32 1010 1021 20477932 hippocampus NN I-NP O
33 1022 1025 20477932 was VBD B-VP O
34 1026 1035 20477932 increased VBN I-VP O
35 1035 1036 20477932 . . O O

1 1037 1043 20477932 Memory NN B-NP O
2 1044 1053 20477932 retrieval NN I-NP O
3 1054 1056 20477932 of IN B-PP O
4 1057 1068 20477932 experiences NNS B-NP O
5 1069 1077 20477932 acquired VBN B-VP O
6 1078 1083 20477932 prior RB B-ADVP O
7 1084 1086 20477932 to TO B-PP O
8 1087 1094 20477932 cocaine NN B-NP B-Chemical
9 1095 1109 20477932 administration NN I-NP O
10 1110 1113 20477932 was VBD B-VP O
11 1114 1122 20477932 impaired JJ B-ADJP O
12 1123 1126 20477932 and CC O O
13 1127 1137 20477932 negatively RB B-VP O
14 1138 1148 20477932 correlated VBD I-VP O
15 1149 1153 20477932 with IN B-PP O
16 1154 1162 20477932 NFkappaB NN B-NP O
17 1163 1171 20477932 activity NN I-NP O
18 1172 1174 20477932 in IN B-PP O
19 1175 1178 20477932 the DT B-NP O
20 1179 1186 20477932 frontal JJ I-NP O
21 1187 1193 20477932 cortex NN I-NP O
22 1193 1194 20477932 . . O O

1 1195 1197 20477932 In IN B-PP O
2 1198 1206 20477932 contrast NN B-NP O
3 1206 1207 20477932 , , O O
4 1208 1216 20477932 learning VBG B-VP O
5 1217 1219 20477932 of IN B-PP O
6 1220 1223 20477932 new JJ B-NP O
7 1224 1229 20477932 tasks NNS I-NP O
8 1230 1233 20477932 was VBD B-VP O
9 1234 1242 20477932 enhanced VBN I-VP O
10 1243 1246 20477932 and CC O O
11 1247 1257 20477932 correlated VBN B-VP O
12 1258 1262 20477932 with IN B-PP O
13 1263 1266 20477932 the DT B-NP O
14 1267 1275 20477932 increase NN I-NP O
15 1276 1278 20477932 of IN B-PP O
16 1279 1283 20477932 nNOS NN B-NP O
17 1284 1292 20477932 activity NN I-NP O
18 1293 1296 20477932 and CC O O
19 1297 1300 20477932 the DT B-NP O
20 1301 1309 20477932 decrease NN I-NP O
21 1310 1312 20477932 of IN B-PP O
22 1313 1324 20477932 glutathione NN B-NP B-Chemical
23 1325 1335 20477932 peroxidase NN I-NP O
24 1335 1336 20477932 . . O O

1 1337 1342 20477932 These DT B-NP O
2 1343 1350 20477932 results NNS I-NP O
3 1351 1358 20477932 provide VBP B-VP O
4 1359 1367 20477932 evidence NN B-NP O
5 1368 1371 20477932 for IN B-PP O
6 1372 1373 20477932 a DT B-NP O
7 1374 1382 20477932 possible JJ I-NP O
8 1383 1394 20477932 mechanistic JJ I-NP O
9 1395 1399 20477932 role NN I-NP O
10 1400 1402 20477932 of IN B-PP O
11 1403 1412 20477932 oxidative JJ B-NP O
12 1413 1416 20477932 and CC I-NP O
13 1417 1428 20477932 nitrosative JJ I-NP O
14 1429 1435 20477932 stress NN I-NP O
15 1436 1439 20477932 and CC I-NP O
16 1440 1448 20477932 NFkappaB NN I-NP O
17 1449 1451 20477932 in IN B-PP O
18 1452 1455 20477932 the DT B-NP O
19 1456 1467 20477932 alterations NNS I-NP O
20 1468 1475 20477932 induced VBN B-VP O
21 1476 1478 20477932 by IN B-PP O
22 1479 1486 20477932 cocaine NN B-NP B-Chemical
23 1486 1487 20477932 . . O O

1 1488 1498 20477932 Topiramate NN B-NP B-Chemical
2 1499 1508 20477932 prevented VBD B-VP O
3 1509 1512 20477932 all PDT B-NP O
4 1513 1516 20477932 the DT I-NP O
5 1517 1528 20477932 alterations NNS I-NP O
6 1529 1537 20477932 observed VBN B-VP O
7 1537 1538 20477932 , , O O
8 1539 1546 20477932 showing VBG B-VP O
9 1547 1552 20477932 novel JJ B-NP O
10 1553 1568 20477932 neuroprotective JJ I-NP O
11 1569 1579 20477932 properties NNS I-NP O
12 1579 1580 20477932 . . O O

1 0 0 18417364 -DOCSTART- -X- -X- O

1 0 8 18417364 Nicotine NN B-NP B-Chemical
2 8 9 18417364 - HYPH B-NP O
3 9 16 18417364 induced VBN I-NP O
4 17 26 18417364 nystagmus NN I-NP B-Disease
5 27 37 18417364 correlates VBZ B-VP O
6 38 42 18417364 with IN B-PP O
7 43 53 18417364 midpontine JJ B-NP O
8 54 64 18417364 activation NN I-NP O
9 64 65 18417364 . . O O
10 66 69 18417364 The DT B-NP O
11 70 84 18417364 pathomechanism NN I-NP O
12 85 87 18417364 of IN B-PP O
13 88 96 18417364 nicotine NN B-NP B-Chemical
14 96 97 18417364 - HYPH B-NP O
15 97 104 18417364 induced VBN I-NP O
16 105 114 18417364 nystagmus NN I-NP B-Disease
17 115 116 18417364 ( ( O O
18 116 119 18417364 NIN NN B-NP B-Disease
19 119 120 18417364 ) ) O O
20 121 123 18417364 is VBZ B-VP O
21 124 131 18417364 unknown JJ B-ADJP O
22 131 132 18417364 . . O O

1 133 136 18417364 The DT B-NP O
2 137 140 18417364 aim NN I-NP O
3 141 143 18417364 of IN B-PP O
4 144 148 18417364 this DT B-NP O
5 149 154 18417364 study NN I-NP O
6 155 158 18417364 was VBD B-VP O
7 159 161 18417364 to TO B-VP O
8 162 171 18417364 delineate VB I-VP O
9 172 177 18417364 brain NN B-NP O
10 178 188 18417364 structures NNS I-NP O
11 189 193 18417364 that WDT B-NP O
12 194 197 18417364 are VBP B-VP O
13 198 206 18417364 involved VBN I-VP O
14 207 209 18417364 in IN B-PP O
15 210 213 18417364 NIN NN B-NP B-Disease
16 214 224 18417364 generation NN I-NP O
17 224 225 18417364 . . O O

1 226 231 18417364 Eight CD B-NP O
2 232 239 18417364 healthy JJ I-NP O
3 240 250 18417364 volunteers NNS I-NP O
4 251 258 18417364 inhaled VBD B-VP O
5 259 267 18417364 nicotine NN B-NP B-Chemical
6 268 270 18417364 in IN B-PP O
7 271 279 18417364 darkness NN B-NP O
8 280 286 18417364 during IN B-PP O
9 287 288 18417364 a DT B-NP O
10 289 299 18417364 functional JJ I-NP O
11 300 308 18417364 magnetic JJ I-NP O
12 309 318 18417364 resonance NN I-NP O
13 319 326 18417364 imaging NN I-NP O
14 327 328 18417364 ( ( O O
15 328 332 18417364 fMRI NN B-NP O
16 332 333 18417364 ) ) O O
17 334 344 18417364 experiment NN B-NP O
18 344 345 18417364 ; : O O
19 346 349 18417364 eye NN B-NP O
20 350 359 18417364 movements NNS I-NP O
21 360 364 18417364 were VBD B-VP O
22 365 375 18417364 registered VBN I-VP O
23 376 381 18417364 using VBG B-VP O
24 382 387 18417364 video AFX B-NP O
25 387 388 18417364 - HYPH I-NP O
26 388 399 18417364 oculography NN I-NP O
27 399 400 18417364 . . O O

1 401 404 18417364 NIN NN B-NP B-Disease
2 405 415 18417364 correlated VBD B-VP O
3 416 420 18417364 with IN B-PP O
4 421 426 18417364 blood NN B-NP O
5 427 433 18417364 oxygen NN I-NP B-Chemical
6 434 439 18417364 level NN I-NP O
7 439 440 18417364 - HYPH B-NP O
8 440 449 18417364 dependent JJ I-NP O
9 450 451 18417364 ( ( O O
10 451 455 18417364 BOLD NN B-NP O
11 455 456 18417364 ) ) O O
12 457 465 18417364 activity NN B-NP O
13 466 472 18417364 levels NNS I-NP O
14 473 475 18417364 in IN B-PP O
15 476 477 18417364 a DT B-NP O
16 478 488 18417364 midpontine JJ I-NP O
17 489 493 18417364 site NN I-NP O
18 494 496 18417364 in IN B-PP O
19 497 500 18417364 the DT B-NP O
20 501 510 18417364 posterior JJ I-NP O
21 511 516 18417364 basis NN I-NP O
22 517 523 18417364 pontis NN I-NP O
23 523 524 18417364 . . O O

1 525 528 18417364 NIN NN B-NP B-Disease
2 528 529 18417364 - HYPH B-NP O
3 529 536 18417364 induced VBN I-NP O
4 537 547 18417364 midpontine NN I-NP O
5 548 558 18417364 activation NN I-NP O
6 559 562 18417364 may MD B-VP O
7 563 573 18417364 correspond VB I-VP O
8 574 576 18417364 to TO B-PP O
9 577 587 18417364 activation NN B-NP O
10 588 590 18417364 of IN B-PP O
11 591 594 18417364 the DT B-NP O
12 595 606 18417364 dorsomedial JJ I-NP O
13 607 614 18417364 pontine NN I-NP O
14 615 621 18417364 nuclei NNS I-NP O
15 622 625 18417364 and CC O O
16 626 629 18417364 the DT B-NP O
17 630 637 18417364 nucleus NN I-NP O
18 638 649 18417364 reticularis NN I-NP O
19 650 658 18417364 tegmenti NN I-NP O
20 659 665 18417364 pontis NN I-NP O
21 665 666 18417364 , , O O
22 667 677 18417364 structures NNS B-NP O
23 678 683 18417364 known VBN B-VP O
24 684 686 18417364 to TO B-VP O
25 687 698 18417364 participate VB I-VP O
26 699 701 18417364 in IN B-PP O
27 702 705 18417364 the DT B-NP O
28 706 716 18417364 generation NN I-NP O
29 717 719 18417364 of IN B-PP O
30 720 736 18417364 multidirectional JJ B-NP O
31 737 745 18417364 saccades NNS I-NP O
32 746 749 18417364 and CC O O
33 750 756 18417364 smooth JJ B-NP O
34 757 764 18417364 pursuit NN I-NP O
35 765 768 18417364 eye NN I-NP O
36 769 778 18417364 movements NNS I-NP O
37 778 779 18417364 . . O O

1 0 0 2924746 -DOCSTART- -X- -X- O

1 0 7 2924746 Chronic JJ B-NP O
2 8 21 2924746 carbamazepine NN I-NP B-Chemical
3 22 31 2924746 treatment NN I-NP O
4 32 34 2924746 in IN B-PP O
5 35 38 2924746 the DT B-NP O
6 39 42 2924746 rat NN I-NP O
7 42 43 2924746 : : O O
8 44 52 2924746 efficacy NN B-NP O
9 52 53 2924746 , , O O
10 54 62 2924746 toxicity NN B-NP B-Disease
11 62 63 2924746 , , O O
12 64 67 2924746 and CC O O
13 68 74 2924746 effect NN B-NP O
14 75 77 2924746 on IN B-PP O
15 78 84 2924746 plasma NN B-NP O
16 85 88 2924746 and CC I-NP O
17 89 95 2924746 tissue NN I-NP O
18 96 102 2924746 folate NN I-NP B-Chemical
19 103 117 2924746 concentrations NNS I-NP O
20 117 118 2924746 . . O O
21 119 125 2924746 Folate JJ B-NP B-Chemical
22 126 135 2924746 depletion NN I-NP O
23 136 139 2924746 has VBZ B-VP O
24 140 145 2924746 often RB I-VP O
25 146 150 2924746 been VBN I-VP O
26 151 152 2924746 a DT B-NP O
27 153 160 2924746 problem NN I-NP O
28 161 163 2924746 in IN B-PP O
29 164 171 2924746 chronic JJ B-NP O
30 172 185 2924746 antiepileptic JJ I-NP O
31 186 190 2924746 drug NN I-NP O
32 191 192 2924746 ( ( O O
33 192 195 2924746 AED NN B-NP O
34 195 196 2924746 ) ) O O
35 197 204 2924746 therapy NN B-NP O
36 204 205 2924746 . . O O

1 206 219 2924746 Carbamazepine NN B-NP B-Chemical
2 220 221 2924746 ( ( O O
3 221 224 2924746 CBZ NN B-NP B-Chemical
4 224 225 2924746 ) ) O O
5 225 226 2924746 , , O O
6 227 228 2924746 a DT B-NP O
7 229 237 2924746 commonly RB I-NP O
8 238 242 2924746 used VBN I-NP O
9 243 246 2924746 AED NN I-NP O
10 246 247 2924746 , , O O
11 248 251 2924746 has VBZ B-VP O
12 252 256 2924746 been VBN I-VP O
13 257 267 2924746 implicated VBN I-VP O
14 268 270 2924746 in IN B-PP O
15 271 275 2924746 some DT B-NP O
16 276 284 2924746 clinical JJ I-NP O
17 285 292 2924746 studies NNS I-NP O
18 292 293 2924746 . . O O

1 294 295 2924746 A DT B-NP O
2 296 299 2924746 rat NN I-NP O
3 300 305 2924746 model NN I-NP O
4 306 309 2924746 was VBD B-VP O
5 310 319 2924746 developed VBN I-VP O
6 320 322 2924746 to TO I-VP O
7 323 330 2924746 examine VB I-VP O
8 331 334 2924746 the DT B-NP O
9 335 342 2924746 effects NNS I-NP O
10 343 345 2924746 of IN B-PP O
11 346 353 2924746 chronic JJ B-NP O
12 354 357 2924746 CBZ NN I-NP B-Chemical
13 358 367 2924746 treatment NN I-NP O
14 368 370 2924746 on IN B-PP O
15 371 377 2924746 folate JJ B-NP B-Chemical
16 378 392 2924746 concentrations NNS I-NP O
17 393 395 2924746 in IN B-PP O
18 396 399 2924746 the DT B-NP O
19 400 403 2924746 rat NN I-NP O
20 403 404 2924746 . . O O

1 405 407 2924746 In IN B-PP O
2 408 411 2924746 the DT B-NP O
3 412 418 2924746 course NN I-NP O
4 419 421 2924746 of IN B-PP O
5 422 432 2924746 developing VBG B-VP O
6 433 437 2924746 this DT B-NP O
7 438 443 2924746 model NN I-NP O
8 443 444 2924746 , , O O
9 445 446 2924746 a DT B-NP O
10 447 453 2924746 common JJ I-NP O
11 454 461 2924746 vehicle NN I-NP O
12 461 462 2924746 , , O O
13 463 472 2924746 propylene NN B-NP B-Chemical
14 473 479 2924746 glycol NN I-NP I-Chemical
15 479 480 2924746 , , O O
16 481 483 2924746 by IN B-PP O
17 484 490 2924746 itself PRP B-NP O
18 491 493 2924746 in IN B-PP O
19 494 498 2924746 high JJ B-NP O
20 499 504 2924746 doses NNS I-NP O
21 504 505 2924746 , , O O
22 506 509 2924746 was VBD B-VP O
23 510 515 2924746 found VBN I-VP O
24 516 518 2924746 to TO I-VP O
25 519 526 2924746 exhibit VB I-VP O
26 527 537 2924746 protective JJ B-NP O
27 538 548 2924746 properties NNS I-NP O
28 549 556 2924746 against IN B-PP O
29 557 564 2924746 induced VBN B-NP O
30 565 573 2924746 seizures NNS I-NP B-Disease
31 574 577 2924746 and CC O O
32 578 587 2924746 inhibited VBD B-VP O
33 588 594 2924746 weight NN B-NP B-Disease
34 595 599 2924746 gain NN I-NP I-Disease
35 599 600 2924746 . . O O

1 601 609 2924746 Seizures NNS B-NP B-Disease
2 610 617 2924746 induced VBN B-VP O
3 618 620 2924746 by IN B-PP O
4 621 638 2924746 hexafluorodiethyl NN B-NP B-Chemical
5 639 644 2924746 ether NN I-NP I-Chemical
6 645 646 2924746 ( ( O O
7 646 650 2924746 HFDE NN B-NP B-Chemical
8 650 651 2924746 ) ) O O
9 652 656 2924746 were VBD B-VP O
10 657 661 2924746 also RB I-VP O
11 662 667 2924746 found VBN I-VP O
12 668 670 2924746 to TO I-VP O
13 671 673 2924746 be VB I-VP O
14 674 675 2924746 a DT B-NP O
15 676 680 2924746 more RBR I-NP O
16 681 690 2924746 sensitive JJ I-NP O
17 691 698 2924746 measure NN I-NP O
18 699 701 2924746 of IN B-PP O
19 702 712 2924746 protection NN B-NP O
20 713 715 2924746 by IN B-PP O
21 716 719 2924746 CBZ NN B-NP B-Chemical
22 720 724 2924746 than IN B-PP O
23 725 733 2924746 seizures NNS B-NP B-Disease
24 734 741 2924746 induced VBN B-VP O
25 742 744 2924746 by IN B-PP O
26 745 752 2924746 maximal JJ B-NP O
27 753 765 2924746 electroshock NN I-NP O
28 766 767 2924746 ( ( O O
29 767 770 2924746 MES NN B-NP O
30 770 771 2924746 ) ) O O
31 771 772 2924746 . . O O

1 773 777 2924746 Oral JJ B-NP O
2 778 792 2924746 administration NN I-NP O
3 793 795 2924746 of IN B-PP O
4 796 799 2924746 CBZ NN B-NP B-Chemical
5 800 802 2924746 as IN B-PP O
6 803 805 2924746 an DT B-NP O
7 806 813 2924746 aqueous JJ I-NP O
8 814 824 2924746 suspension NN I-NP O
9 825 830 2924746 every DT B-NP O
10 831 832 2924746 8 CD I-NP O
11 833 834 2924746 h NN I-NP O
12 835 837 2924746 at IN B-PP O
13 838 839 2924746 a DT B-NP O
14 840 844 2924746 dose NN I-NP O
15 845 847 2924746 of IN B-PP O
16 848 851 2924746 250 CD B-NP O
17 852 854 2924746 mg NN I-NP O
18 854 855 2924746 / SYM B-NP O
19 855 857 2924746 kg NN I-NP O
20 858 861 2924746 was VBD B-VP O
21 862 874 2924746 continuously RB B-ADJP O
22 875 885 2924746 protective JJ I-ADJP O
23 886 893 2924746 against IN B-PP O
24 894 898 2924746 HFDE NN B-NP B-Chemical
25 898 899 2924746 - HYPH B-NP O
26 899 906 2924746 induced VBN I-NP O
27 907 915 2924746 seizures NNS I-NP B-Disease
28 916 919 2924746 and CC O O
29 920 923 2924746 was VBD B-VP O
30 924 933 2924746 minimally RB B-ADJP O
31 934 939 2924746 toxic JJ I-ADJP O
32 940 942 2924746 as IN B-SBAR O
33 943 951 2924746 measured VBN B-VP O
34 952 954 2924746 by IN B-PP O
35 955 961 2924746 weight NN B-NP B-Disease
36 962 966 2924746 gain NN I-NP I-Disease
37 967 971 2924746 over IN B-PP O
38 972 973 2924746 8 CD B-NP O
39 974 979 2924746 weeks NNS I-NP O
40 980 982 2924746 of IN B-PP O
41 983 992 2924746 treatment NN B-NP O
42 992 993 2924746 . . O O

1 994 997 2924746 The DT B-NP O
2 998 1001 2924746 CBZ NN I-NP B-Chemical
3 1002 1008 2924746 levels NNS I-NP O
4 1009 1017 2924746 measured VBN B-VP O
5 1018 1020 2924746 in IN B-PP O
6 1021 1027 2924746 plasma NN B-NP O
7 1028 1031 2924746 and CC I-NP O
8 1032 1037 2924746 brain NN I-NP O
9 1038 1040 2924746 of IN B-PP O
10 1041 1046 2924746 these DT B-NP O
11 1047 1054 2924746 animals NNS I-NP O
12 1054 1055 2924746 , , O O
13 1056 1063 2924746 however RB B-ADVP O
14 1063 1064 2924746 , , O O
15 1065 1069 2924746 were VBD B-VP O
16 1070 1075 2924746 below IN B-PP O
17 1076 1081 2924746 those DT B-NP O
18 1082 1090 2924746 normally RB B-VP O
19 1091 1101 2924746 considered VBN I-VP O
20 1102 1112 2924746 protective JJ B-ADJP O
21 1112 1113 2924746 . . O O

1 1114 1118 2924746 This DT B-NP O
2 1119 1128 2924746 treatment NN I-NP O
3 1129 1133 2924746 with IN B-PP O
4 1134 1137 2924746 CBZ NN B-NP B-Chemical
5 1138 1141 2924746 had VBD B-VP O
6 1142 1144 2924746 no DT B-NP O
7 1145 1153 2924746 apparent JJ I-NP O
8 1154 1161 2924746 adverse JJ I-NP O
9 1162 1168 2924746 effect NN I-NP O
10 1169 1171 2924746 on IN B-PP O
11 1172 1178 2924746 folate JJ B-NP B-Chemical
12 1179 1193 2924746 concentrations NNS I-NP O
13 1194 1196 2924746 in IN B-PP O
14 1197 1200 2924746 the DT B-NP O
15 1201 1204 2924746 rat NN I-NP O
16 1204 1205 2924746 , , O O
17 1206 1209 2924746 and CC O O
18 1209 1210 2924746 , , O O
19 1211 1217 2924746 indeed RB B-ADVP O
20 1217 1218 2924746 , , O O
21 1219 1222 2924746 the DT B-NP O
22 1223 1229 2924746 folate JJ I-NP B-Chemical
23 1230 1243 2924746 concentration NN I-NP O
24 1244 1253 2924746 increased VBD B-VP O
25 1254 1256 2924746 in IN B-PP O
26 1257 1262 2924746 liver NN B-NP O
27 1263 1268 2924746 after IN B-PP O
28 1269 1270 2924746 6 CD B-NP O
29 1271 1276 2924746 weeks NNS I-NP O
30 1277 1279 2924746 of IN B-PP O
31 1280 1289 2924746 treatment NN B-NP O
32 1290 1293 2924746 and CC B-PP O
33 1294 1296 2924746 in IN B-PP O
34 1297 1303 2924746 plasma NN B-NP O
35 1304 1306 2924746 at IN B-PP O
36 1307 1308 2924746 8 CD B-NP O
37 1309 1314 2924746 weeks NNS I-NP O
38 1315 1317 2924746 of IN B-PP O
39 1318 1327 2924746 treatment NN B-NP O
40 1327 1328 2924746 . . O O

1 0 0 3615541 -DOCSTART- -X- -X- O

1 0 8 3615541 Regional JJ B-NP O
2 9 21 3615541 localization NN I-NP O
3 22 24 3615541 of IN B-PP O
4 25 28 3615541 the DT B-NP O
5 29 39 3615541 antagonism NN I-NP O
6 40 42 3615541 of IN B-PP O
7 43 54 3615541 amphetamine NN B-NP B-Chemical
8 54 55 3615541 - HYPH B-NP O
9 55 62 3615541 induced VBN I-NP O
10 63 76 3615541 hyperactivity NN I-NP B-Disease
11 77 79 3615541 by IN B-PP O
12 80 93 3615541 intracerebral JJ B-NP O
13 94 104 3615541 calcitonin NN I-NP B-Chemical
14 105 115 3615541 injections NNS I-NP O
15 115 116 3615541 . . O O
16 117 127 3615541 Calcitonin NN B-NP B-Chemical
17 128 137 3615541 receptors NNS I-NP O
18 138 141 3615541 are VBP B-VP O
19 142 147 3615541 found VBN I-VP O
20 148 150 3615541 in IN B-PP O
21 151 154 3615541 the DT B-NP O
22 155 160 3615541 brain NN I-NP O
23 160 161 3615541 , , O O
24 162 165 3615541 and CC O O
25 166 179 3615541 intracerebral JJ B-NP O
26 180 189 3615541 infusions NNS I-NP O
27 190 192 3615541 of IN B-PP O
28 193 203 3615541 calcitonin NN B-NP B-Chemical
29 204 207 3615541 can MD B-VP O
30 208 215 3615541 produce VB I-VP O
31 216 226 3615541 behavioral JJ B-NP O
32 227 234 3615541 effects NNS I-NP O
33 234 235 3615541 . . O O

1 236 241 3615541 Among IN B-PP O
2 242 247 3615541 these DT B-NP O
3 248 258 3615541 behavioral JJ I-NP O
4 259 266 3615541 effects NNS I-NP O
5 267 270 3615541 are VBP B-VP O
6 271 280 3615541 decreases NNS B-NP O
7 281 283 3615541 in IN B-PP O
8 284 288 3615541 food NN B-NP O
9 289 295 3615541 intake NN I-NP O
10 296 299 3615541 and CC O O
11 300 309 3615541 decreases VBZ B-VP O
12 310 312 3615541 in IN B-PP O
13 313 324 3615541 amphetamine NN B-NP B-Chemical
14 324 325 3615541 - HYPH B-NP O
15 325 332 3615541 induced VBN I-NP O
16 333 342 3615541 locomotor NN I-NP O
17 343 351 3615541 activity NN I-NP O
18 351 352 3615541 . . O O

1 353 355 3615541 In IN B-PP O
2 356 364 3615541 previous JJ B-NP O
3 365 376 3615541 experiments NNS I-NP O
4 377 379 3615541 we PRP B-NP O
5 380 385 3615541 found VBD B-VP O
6 386 390 3615541 that IN B-SBAR O
7 391 400 3615541 decreases NNS B-NP O
8 401 403 3615541 in IN B-PP O
9 404 408 3615541 food NN B-NP O
10 409 415 3615541 intake NN I-NP O
11 416 420 3615541 were VBD B-VP O
12 421 428 3615541 induced VBN I-VP O
13 429 431 3615541 by IN B-PP O
14 432 437 3615541 local JJ B-NP O
15 438 452 3615541 administration NN I-NP O
16 453 455 3615541 of IN B-PP O
17 456 466 3615541 calcitonin NN B-NP B-Chemical
18 467 471 3615541 into IN B-PP O
19 472 479 3615541 several JJ B-NP O
20 480 492 3615541 hypothalamic JJ I-NP O
21 493 498 3615541 sites NNS I-NP O
22 499 502 3615541 and CC B-PP O
23 503 507 3615541 into IN B-PP O
24 508 511 3615541 the DT B-NP O
25 512 519 3615541 nucleus NN I-NP O
26 520 529 3615541 accumbens NN I-NP O
27 529 530 3615541 . . O O

1 531 533 3615541 In IN B-PP O
2 534 537 3615541 the DT B-NP O
3 538 545 3615541 present JJ I-NP O
4 546 556 3615541 experiment NN I-NP O
5 557 567 3615541 calcitonin NN I-NP B-Chemical
6 568 577 3615541 decreased VBD B-VP O
7 578 587 3615541 locomotor NN B-NP O
8 588 596 3615541 activity NN I-NP O
9 597 601 3615541 when WRB B-ADVP O
10 602 609 3615541 locally RB B-VP O
11 610 618 3615541 injected VBN I-VP O
12 619 623 3615541 into IN B-PP O
13 624 627 3615541 the DT B-NP O
14 628 632 3615541 same JJ I-NP O
15 633 638 3615541 sites NNS I-NP O
16 639 644 3615541 where WRB B-ADVP O
17 645 647 3615541 it PRP B-NP O
18 648 657 3615541 decreases VBZ B-VP O
19 658 662 3615541 food NN B-NP O
20 663 669 3615541 intake NN I-NP O
21 669 670 3615541 . . O O

1 671 674 3615541 The DT B-NP O
2 675 680 3615541 areas NNS I-NP O
3 681 686 3615541 where WRB B-ADVP O
4 687 697 3615541 calcitonin NN B-NP B-Chemical
5 698 700 3615541 is VBZ B-VP O
6 701 705 3615541 most RBS B-ADJP O
7 706 715 3615541 effective JJ I-ADJP O
8 716 718 3615541 in IN B-PP O
9 719 729 3615541 decreasing VBG B-VP O
10 730 739 3615541 locomotor NN B-NP O
11 740 748 3615541 activity NN I-NP O
12 749 752 3615541 are VBP B-VP O
13 753 760 3615541 located JJ B-ADJP O
14 761 763 3615541 in IN B-PP O
15 764 767 3615541 the DT B-NP O
16 768 780 3615541 hypothalamus NN I-NP O
17 781 784 3615541 and CC I-NP O
18 785 792 3615541 nucleus NN I-NP O
19 793 802 3615541 accumbens NNS I-NP O
20 802 803 3615541 , , O O
21 804 814 3615541 suggesting VBG B-VP O
22 815 819 3615541 that IN B-SBAR O
23 820 825 3615541 these DT B-NP O
24 826 831 3615541 areas NNS I-NP O
25 832 835 3615541 are VBP B-VP O
26 836 839 3615541 the DT B-NP O
27 840 845 3615541 major JJ I-NP O
28 846 851 3615541 sites NNS I-NP O
29 852 854 3615541 of IN B-PP O
30 855 861 3615541 action NN B-NP O
31 862 864 3615541 of IN B-PP O
32 865 875 3615541 calcitonin NN B-NP B-Chemical
33 876 878 3615541 in IN B-PP O
34 879 889 3615541 inhibiting VBG B-VP O
35 890 901 3615541 amphetamine NN B-NP B-Chemical
36 901 902 3615541 - HYPH B-NP O
37 902 909 3615541 induced VBN I-NP O
38 910 919 3615541 locomotor NN I-NP O
39 920 928 3615541 activity NN I-NP O
40 928 929 3615541 . . O O

1 0 0 17879945 -DOCSTART- -X- -X- O

1 0 8 17879945 Estrogen NN B-NP O
2 9 17 17879945 prevents VBZ B-VP O
3 18 29 17879945 cholesteryl NN B-NP B-Chemical
4 30 35 17879945 ester NN I-NP I-Chemical
5 36 48 17879945 accumulation NN I-NP O
6 49 51 17879945 in IN B-PP O
7 52 63 17879945 macrophages NNS B-NP O
8 64 71 17879945 induced VBN B-VP O
9 72 74 17879945 by IN B-PP O
10 75 78 17879945 the DT B-NP O
11 79 82 17879945 HIV NN I-NP O
12 83 91 17879945 protease NN I-NP O
13 92 101 17879945 inhibitor NN I-NP O
14 102 111 17879945 ritonavir NN I-NP B-Chemical
15 111 112 17879945 . . O O
16 113 124 17879945 Individuals NNS B-NP O
17 125 129 17879945 with IN B-PP O
18 130 133 17879945 HIV NN B-NP O
19 134 137 17879945 can MD B-VP O
20 138 141 17879945 now RB I-VP O
21 142 146 17879945 live VB I-VP O
22 147 151 17879945 long JJ B-NP O
23 152 157 17879945 lives NNS I-NP O
24 158 162 17879945 with IN B-PP O
25 163 167 17879945 drug NN B-NP O
26 168 175 17879945 therapy NN I-NP O
27 176 180 17879945 that WDT B-NP O
28 181 186 17879945 often RB B-ADVP O
29 187 195 17879945 includes VBZ B-VP O
30 196 204 17879945 protease NN B-NP O
31 205 215 17879945 inhibitors NNS I-NP O
32 216 220 17879945 such JJ B-PP O
33 221 223 17879945 as IN I-PP O
34 224 233 17879945 ritonavir NN B-NP B-Chemical
35 233 234 17879945 . . O O

1 235 239 17879945 Many JJ B-NP O
2 240 248 17879945 patients NNS I-NP O
3 248 249 17879945 , , O O
4 250 257 17879945 however RB B-ADVP O
5 257 258 17879945 , , O O
6 259 266 17879945 develop VBP B-VP O
7 267 275 17879945 negative JJ B-NP O
8 276 280 17879945 long JJ I-NP O
9 280 281 17879945 - HYPH I-NP O
10 281 285 17879945 term NN I-NP O
11 286 290 17879945 side NN I-NP O
12 291 298 17879945 effects NNS I-NP O
13 299 303 17879945 such JJ B-PP O
14 304 306 17879945 as IN I-PP O
15 307 316 17879945 premature JJ B-NP B-Disease
16 317 332 17879945 atherosclerosis NN I-NP I-Disease
17 332 333 17879945 . . O O

1 334 336 17879945 We PRP B-NP O
2 337 341 17879945 have VBP B-VP O
3 342 352 17879945 previously RB I-VP O
4 353 365 17879945 demonstrated VBN I-VP O
5 366 370 17879945 that IN B-SBAR O
6 371 380 17879945 ritonavir NN B-NP B-Chemical
7 381 390 17879945 treatment NN I-NP O
8 391 400 17879945 increases VBZ B-VP O
9 401 416 17879945 atherosclerotic JJ B-NP B-Disease
10 417 423 17879945 lesion NN I-NP I-Disease
11 424 433 17879945 formation NN I-NP O
12 434 436 17879945 in IN B-PP O
13 437 441 17879945 male JJ B-NP O
14 442 446 17879945 mice NNS I-NP O
15 447 449 17879945 to TO B-PP O
16 450 451 17879945 a DT B-NP O
17 452 459 17879945 greater JJR I-NP O
18 460 466 17879945 extent NN I-NP O
19 467 471 17879945 than IN B-PP O
20 472 474 17879945 in IN B-PP O
21 475 481 17879945 female JJ B-NP O
22 482 486 17879945 mice NNS I-NP O
23 486 487 17879945 . . O O

1 488 499 17879945 Furthermore RB B-ADVP O
2 499 500 17879945 , , O O
3 501 511 17879945 peripheral JJ B-NP O
4 512 517 17879945 blood NN I-NP O
5 518 527 17879945 monocytes NNS I-NP O
6 528 536 17879945 isolated VBN B-VP O
7 537 541 17879945 from IN B-PP O
8 542 551 17879945 ritonavir NN B-NP B-Chemical
9 551 552 17879945 - HYPH B-NP O
10 552 559 17879945 treated VBN I-NP O
11 560 567 17879945 females NNS I-NP O
12 568 571 17879945 had VBD B-VP O
13 572 576 17879945 less JJR B-NP O
14 577 588 17879945 cholesteryl NN I-NP B-Chemical
15 589 594 17879945 ester NN I-NP I-Chemical
16 595 607 17879945 accumulation NN I-NP O
17 607 608 17879945 . . O O

1 609 611 17879945 In IN B-PP O
2 612 615 17879945 the DT B-NP O
3 616 623 17879945 present JJ I-NP O
4 624 629 17879945 study NN I-NP O
5 629 630 17879945 , , O O
6 631 633 17879945 we PRP B-NP O
7 634 638 17879945 have VBP B-VP O
8 639 651 17879945 investigated VBN I-VP O
9 652 655 17879945 the DT B-NP O
10 656 665 17879945 molecular JJ I-NP O
11 666 676 17879945 mechanisms NNS I-NP O
12 677 679 17879945 by IN B-PP O
13 680 685 17879945 which WDT B-NP O
14 686 692 17879945 female JJ B-NP O
15 693 701 17879945 hormones NNS I-NP O
16 702 711 17879945 influence VBP B-VP O
17 712 723 17879945 cholesterol NN B-NP B-Chemical
18 724 734 17879945 metabolism NN I-NP O
19 735 737 17879945 in IN B-PP O
20 738 749 17879945 macrophages NNS B-NP O
21 750 752 17879945 in IN B-PP O
22 753 761 17879945 response NN B-NP O
23 762 764 17879945 to TO B-PP O
24 765 768 17879945 the DT B-NP O
25 769 772 17879945 HIV NN I-NP O
26 773 781 17879945 protease NN I-NP O
27 782 791 17879945 inhibitor NN I-NP O
28 792 801 17879945 ritonavir NN I-NP B-Chemical
29 801 802 17879945 . . O O

1 803 805 17879945 We PRP B-NP O
2 806 810 17879945 have VBP B-VP O
3 811 819 17879945 utilized VBN I-VP O
4 820 823 17879945 the DT B-NP O
5 824 829 17879945 human JJ I-NP O
6 830 838 17879945 monocyte NN I-NP O
7 839 843 17879945 cell NN I-NP O
8 844 848 17879945 line NN I-NP O
9 848 849 17879945 , , O O
10 850 853 17879945 THP NN B-NP O
11 853 854 17879945 - HYPH B-NP O
12 854 855 17879945 1 CD I-NP O
13 856 858 17879945 as IN B-PP O
14 859 860 17879945 a DT B-NP O
15 861 866 17879945 model NN I-NP O
16 867 869 17879945 to TO B-VP O
17 870 877 17879945 address VB I-VP O
18 878 882 17879945 this DT B-NP O
19 883 891 17879945 question NN I-NP O
20 891 892 17879945 . . O O

1 893 900 17879945 Briefly RB B-ADVP O
2 900 901 17879945 , , O O
3 902 907 17879945 cells NNS B-NP O
4 908 912 17879945 were VBD B-VP O
5 913 927 17879945 differentiated VBN I-VP O
6 928 931 17879945 for IN B-PP O
7 932 934 17879945 72 CD B-NP O
8 935 936 17879945 h NN I-NP O
9 937 941 17879945 with IN B-PP O
10 942 945 17879945 100 CD B-NP O
11 946 948 17879945 nM NN I-NP O
12 949 952 17879945 PMA NN I-NP O
13 953 955 17879945 to TO B-VP O
14 956 962 17879945 obtain VB I-VP O
15 963 964 17879945 a DT B-NP O
16 965 975 17879945 macrophage NN I-NP O
17 975 976 17879945 - HYPH B-NP O
18 976 980 17879945 like JJ I-NP O
19 981 990 17879945 phenotype NN I-NP O
20 991 993 17879945 in IN B-PP O
21 994 997 17879945 the DT B-NP O
22 998 1006 17879945 presence NN I-NP O
23 1007 1009 17879945 or CC I-NP O
24 1010 1017 17879945 absence NN I-NP O
25 1018 1020 17879945 of IN B-PP O
26 1021 1022 17879945 1 CD B-NP O
27 1023 1025 17879945 nM NN I-NP O
28 1026 1032 17879945 17beta NN I-NP B-Chemical
29 1032 1033 17879945 - HYPH O I-Chemical
30 1033 1042 17879945 estradiol NN B-NP I-Chemical
31 1043 1044 17879945 ( ( O O
32 1044 1046 17879945 E2 NN B-NP B-Chemical
33 1046 1047 17879945 ) ) O O
34 1047 1048 17879945 , , O O
35 1049 1052 17879945 100 CD B-NP O
36 1053 1055 17879945 nM NN I-NP O
37 1056 1068 17879945 progesterone NN I-NP B-Chemical
38 1069 1071 17879945 or CC O O
39 1072 1079 17879945 vehicle NN B-NP O
40 1080 1081 17879945 ( ( O O
41 1081 1086 17879945 0.01% CD B-NP O
42 1087 1094 17879945 ethanol NN I-NP B-Chemical
43 1094 1095 17879945 ) ) O O
44 1095 1096 17879945 . . O O

1 1097 1102 17879945 Cells NNS B-NP O
2 1103 1107 17879945 were VBD B-VP O
3 1108 1112 17879945 then RB I-VP O
4 1113 1120 17879945 treated VBN I-VP O
5 1121 1125 17879945 with IN B-PP O
6 1126 1128 17879945 30 CD B-NP O
7 1129 1131 17879945 ng NN I-NP O
8 1131 1132 17879945 / SYM O O
9 1132 1134 17879945 ml NN B-NP O
10 1135 1144 17879945 ritonavir NN I-NP B-Chemical
11 1145 1147 17879945 or CC I-NP O
12 1148 1155 17879945 vehicle NN I-NP O
13 1156 1158 17879945 in IN B-PP O
14 1159 1162 17879945 the DT I-PP O
15 1163 1171 17879945 presence NN I-PP O
16 1172 1174 17879945 of IN I-PP O
17 1175 1185 17879945 aggregated JJ B-NP O
18 1186 1189 17879945 LDL NN I-NP O
19 1190 1193 17879945 for IN B-PP O
20 1194 1196 17879945 24 CD B-NP O
21 1197 1198 17879945 h NN I-NP O
22 1198 1199 17879945 . . O O

1 1200 1204 17879945 Cell NN B-NP O
2 1205 1213 17879945 extracts NNS I-NP O
3 1214 1218 17879945 were VBD B-VP O
4 1219 1228 17879945 harvested VBN I-VP O
5 1228 1229 17879945 , , O O
6 1230 1233 17879945 and CC O O
7 1234 1239 17879945 lipid NN B-NP O
8 1240 1242 17879945 or CC O O
9 1243 1248 17879945 total JJ B-NP O
10 1249 1252 17879945 RNA NN I-NP O
11 1253 1256 17879945 was VBD B-VP O
12 1257 1265 17879945 isolated VBN I-VP O
13 1265 1266 17879945 . . O O

1 1267 1269 17879945 E2 NN B-NP B-Chemical
2 1270 1279 17879945 decreased VBD B-VP O
3 1280 1283 17879945 the DT B-NP O
4 1284 1296 17879945 accumulation NN I-NP O
5 1297 1299 17879945 of IN B-PP O
6 1300 1311 17879945 cholesteryl NN B-NP B-Chemical
7 1312 1318 17879945 esters NNS I-NP I-Chemical
8 1319 1321 17879945 in IN B-PP O
9 1322 1333 17879945 macrophages NNS B-NP O
10 1334 1343 17879945 following VBG B-PP O
11 1344 1353 17879945 ritonavir NN B-NP B-Chemical
12 1354 1363 17879945 treatment NN I-NP O
13 1363 1364 17879945 . . O O

1 1365 1374 17879945 Ritonavir NN B-NP B-Chemical
2 1375 1384 17879945 increased VBD B-VP O
3 1385 1388 17879945 the DT B-NP O
4 1389 1399 17879945 expression NN I-NP O
5 1400 1402 17879945 of IN B-PP O
6 1403 1406 17879945 the DT B-NP O
7 1407 1416 17879945 scavenger NN I-NP O
8 1417 1425 17879945 receptor NN I-NP O
9 1425 1426 17879945 , , O O
10 1427 1431 17879945 CD36 NN B-NP O
11 1432 1436 17879945 mRNA NN I-NP O
12 1436 1437 17879945 , , O O
13 1438 1449 17879945 responsible JJ B-ADJP O
14 1450 1453 17879945 for IN B-PP O
15 1454 1457 17879945 the DT B-NP O
16 1458 1464 17879945 uptake NN I-NP O
17 1465 1467 17879945 of IN B-PP O
18 1468 1471 17879945 LDL NN B-NP O
19 1471 1472 17879945 . . O O

1 1473 1485 17879945 Additionally RB B-ADVP O
2 1485 1486 17879945 , , O O
3 1487 1496 17879945 ritonavir NN B-NP B-Chemical
4 1497 1506 17879945 treatment NN I-NP O
5 1507 1518 17879945 selectively RB B-ADVP O
6 1519 1528 17879945 increased VBD B-VP O
7 1529 1532 17879945 the DT B-NP O
8 1533 1541 17879945 relative JJ I-NP O
9 1542 1548 17879945 levels NNS I-NP O
10 1549 1551 17879945 of IN B-PP O
11 1552 1561 17879945 PPARgamma NN B-NP O
12 1562 1566 17879945 mRNA NN I-NP O
13 1566 1567 17879945 , , O O
14 1568 1569 17879945 a DT B-NP O
15 1570 1583 17879945 transcription NN I-NP O
16 1584 1590 17879945 factor NN I-NP O
17 1591 1602 17879945 responsible JJ B-ADJP O
18 1603 1606 17879945 for IN B-PP O
19 1607 1610 17879945 the DT B-NP O
20 1611 1621 17879945 regulation NN I-NP O
21 1622 1624 17879945 of IN B-PP O
22 1625 1629 17879945 CD36 NN B-NP O
23 1630 1634 17879945 mRNA NN I-NP O
24 1635 1645 17879945 expression NN I-NP O
25 1645 1646 17879945 . . O O

1 1647 1656 17879945 Treatment NN B-NP O
2 1657 1661 17879945 with IN B-PP O
3 1662 1664 17879945 E2 NN B-NP B-Chemical
4 1664 1665 17879945 , , O O
5 1666 1673 17879945 however RB B-ADVP O
6 1673 1674 17879945 , , O O
7 1675 1681 17879945 failed VBD B-VP O
8 1682 1684 17879945 to TO I-VP O
9 1685 1692 17879945 prevent VB I-VP O
10 1693 1698 17879945 these DT B-NP O
11 1699 1708 17879945 increases NNS I-NP O
12 1709 1711 17879945 at IN B-PP O
13 1712 1715 17879945 the DT B-NP O
14 1716 1720 17879945 mRNA NN I-NP O
15 1721 1726 17879945 level NN I-NP O
16 1726 1727 17879945 . . O O

1 1728 1730 17879945 E2 NN B-NP B-Chemical
2 1731 1734 17879945 did VBD B-VP O
3 1734 1735 17879945 , , O O
4 1736 1743 17879945 however RB B-ADVP O
5 1743 1744 17879945 , , O O
6 1745 1758 17879945 significantly RB B-ADVP O
7 1759 1767 17879945 suppress VBP B-VP O
8 1768 1772 17879945 CD36 NN B-NP O
9 1773 1780 17879945 protein NN I-NP O
10 1781 1787 17879945 levels NNS I-NP O
11 1788 1790 17879945 as IN B-SBAR O
12 1791 1799 17879945 measured VBN B-VP O
13 1800 1802 17879945 by IN B-PP O
14 1803 1814 17879945 fluorescent JJ B-NP O
15 1815 1834 17879945 immunocytochemistry NN I-NP O
16 1834 1835 17879945 . . O O

1 1836 1840 17879945 This DT B-NP O
2 1841 1845 17879945 data NNS I-NP O
3 1846 1854 17879945 suggests VBZ B-VP O
4 1855 1859 17879945 that IN B-SBAR O
5 1860 1862 17879945 E2 NN B-NP B-Chemical
6 1863 1871 17879945 modifies VBZ B-VP O
7 1872 1875 17879945 the DT B-NP O
8 1876 1886 17879945 expression NN I-NP O
9 1887 1889 17879945 of IN B-PP O
10 1890 1894 17879945 CD36 NN B-NP O
11 1895 1897 17879945 at IN B-PP O
12 1898 1901 17879945 the DT B-NP O
13 1902 1907 17879945 level NN I-NP O
14 1908 1910 17879945 of IN B-PP O
15 1911 1918 17879945 protein NN B-NP O
16 1919 1929 17879945 expression NN I-NP O
17 1930 1932 17879945 in IN B-PP O
18 1933 1941 17879945 monocyte NN B-NP O
19 1941 1942 17879945 - HYPH O O
20 1942 1949 17879945 derived VBN B-VP O
21 1950 1961 17879945 macrophages NNS B-NP O
22 1962 1971 17879945 resulting VBG B-VP O
23 1972 1974 17879945 in IN B-PP O
24 1975 1982 17879945 reduced VBN B-NP O
25 1983 1994 17879945 cholesteryl NN I-NP B-Chemical
26 1995 2000 17879945 ester NN I-NP I-Chemical
27 2001 2013 17879945 accumulation NN I-NP O
28 2014 2023 17879945 following VBG B-PP O
29 2024 2033 17879945 ritonavir NN B-NP B-Chemical
30 2034 2043 17879945 treatment NN I-NP O
31 2043 2044 17879945 . . O O

1 0 0 20098969 -DOCSTART- -X- -X- O

1 0 4 20098969 Oral JJ B-NP O
2 5 19 20098969 manifestations NNS I-NP O
3 20 22 20098969 of IN B-PP O
4 23 24 20098969 " `` O O
5 24 28 20098969 meth NN B-NP B-Disease
6 29 34 20098969 mouth NN I-NP I-Disease
7 34 35 20098969 " '' O O
8 35 36 20098969 : : O O
9 37 38 20098969 a DT B-NP O
10 39 43 20098969 case NN I-NP O
11 44 50 20098969 report NN I-NP O
12 50 51 20098969 . . I-NP O
13 52 55 20098969 AIM NN I-NP O
14 55 56 20098969 : : O O
15 57 60 20098969 The DT B-NP O
16 61 64 20098969 aim NN I-NP O
17 65 67 20098969 of IN B-PP O
18 68 71 20098969 the DT B-NP O
19 72 85 20098969 documentation NN I-NP O
20 86 88 20098969 of IN B-PP O
21 89 93 20098969 this DT B-NP O
22 94 102 20098969 clinical JJ I-NP O
23 103 107 20098969 case NN I-NP O
24 108 110 20098969 is VBZ B-VP O
25 111 113 20098969 to TO B-VP O
26 114 118 20098969 make VB I-VP O
27 119 129 20098969 clinicians NNS B-NP O
28 130 135 20098969 aware JJ B-ADJP O
29 136 138 20098969 of IN B-PP O
30 139 140 20098969 " `` O O
31 140 144 20098969 meth NN B-NP B-Disease
32 145 150 20098969 mouth NN I-NP I-Disease
33 150 151 20098969 " '' O O
34 152 155 20098969 and CC O O
35 156 159 20098969 the DT B-NP O
36 160 167 20098969 medical JJ I-NP O
37 168 173 20098969 risks NNS I-NP O
38 174 184 20098969 associated VBN B-VP O
39 185 189 20098969 with IN B-PP O
40 190 194 20098969 this DT B-NP O
41 195 202 20098969 serious JJ I-NP O
42 203 212 20098969 condition NN I-NP O
43 212 213 20098969 . . O O

1 214 224 20098969 BACKGROUND NN B-NP O
2 224 225 20098969 : : O O
3 226 241 20098969 Methamphetamine NN B-NP B-Chemical
4 242 244 20098969 is VBZ B-VP O
5 245 246 20098969 a DT B-NP O
6 247 251 20098969 very RB I-NP O
7 252 261 20098969 addictive JJ I-NP O
8 261 262 20098969 , , I-NP O
9 263 271 20098969 powerful JJ I-NP O
10 272 281 20098969 stimulant NN I-NP O
11 282 286 20098969 that WDT B-NP O
12 287 296 20098969 increases VBZ B-VP O
13 297 308 20098969 wakefulness NN B-NP O
14 309 312 20098969 and CC O O
15 313 321 20098969 physical JJ B-NP O
16 322 330 20098969 activity NN I-NP O
17 331 334 20098969 and CC O O
18 335 338 20098969 can MD B-VP O
19 339 346 20098969 produce VB I-VP O
20 347 352 20098969 other JJ B-NP O
21 353 360 20098969 effects NNS I-NP O
22 361 365 20098969 such JJ B-PP O
23 366 368 20098969 as IN I-PP O
24 369 376 20098969 cardiac JJ B-NP B-Disease
25 377 389 20098969 dysrhythmias NNS I-NP I-Disease
26 389 390 20098969 , , O O
27 391 403 20098969 hypertension NN B-NP B-Disease
28 403 404 20098969 , , O O
29 405 419 20098969 hallucinations NNS B-NP B-Disease
30 419 420 20098969 , , O O
31 421 424 20098969 and CC O O
32 425 432 20098969 violent JJ B-NP B-Disease
33 433 441 20098969 behavior NN I-NP I-Disease
34 441 442 20098969 . . O O

1 443 449 20098969 Dental JJ B-NP O
2 450 458 20098969 patients NNS I-NP O
3 459 466 20098969 abusing VBG B-VP O
4 467 482 20098969 methamphetamine NN B-NP B-Chemical
5 483 486 20098969 can MD B-VP O
6 487 494 20098969 present VB I-VP O
7 495 499 20098969 with IN B-PP O
8 500 504 20098969 poor JJ B-NP O
9 505 509 20098969 oral JJ I-NP O
10 510 517 20098969 hygiene NN I-NP O
11 517 518 20098969 , , O O
12 519 529 20098969 xerostomia NN B-NP B-Disease
13 529 530 20098969 , , O O
14 531 538 20098969 rampant JJ B-NP O
15 539 545 20098969 caries NNS I-NP B-Disease
16 546 547 20098969 ( ( O O
17 547 548 20098969 " `` O O
18 548 552 20098969 meth NN B-NP B-Disease
19 553 558 20098969 mouth NN I-NP I-Disease
20 558 559 20098969 " '' O O
21 559 560 20098969 ) ) O O
22 560 561 20098969 , , O O
23 562 565 20098969 and CC O O
24 566 575 20098969 excessive JJ B-NP O
25 576 581 20098969 tooth NN I-NP B-Disease
26 582 586 20098969 wear NN I-NP I-Disease
27 586 587 20098969 . . O O

1 588 592 20098969 Oral JJ B-NP O
2 593 607 20098969 rehabilitation NN I-NP O
3 608 610 20098969 of IN B-PP O
4 611 619 20098969 patients NNS B-NP O
5 620 625 20098969 using VBG B-VP O
6 626 641 20098969 methamphetamine NN B-NP B-Chemical
7 642 645 20098969 can MD B-VP O
8 646 648 20098969 be VB I-VP O
9 649 660 20098969 challenging JJ B-ADJP O
10 660 661 20098969 . . O O

1 662 666 20098969 CASE NN B-NP O
2 667 678 20098969 DESCRIPTION NN I-NP O
3 678 679 20098969 : : O O
4 680 681 20098969 A DT B-NP O
5 682 684 20098969 30 CD I-NP O
6 684 685 20098969 - HYPH I-NP O
7 685 689 20098969 year NN I-NP O
8 689 690 20098969 - HYPH O O
9 690 693 20098969 old JJ B-NP O
10 694 703 20098969 Caucasian JJ I-NP O
11 704 709 20098969 woman NN I-NP O
12 710 719 20098969 presented VBD B-VP O
13 720 724 20098969 with IN B-PP O
14 725 731 20098969 dental JJ B-NP O
15 732 736 20098969 pain NN I-NP B-Disease
16 736 737 20098969 , , O O
17 738 741 20098969 bad JJ B-NP B-Disease
18 742 748 20098969 breath NN I-NP I-Disease
19 748 749 20098969 , , O O
20 750 753 20098969 and CC O O
21 754 758 20098969 self NN B-NP O
22 758 759 20098969 - HYPH B-VP O
23 759 767 20098969 reported VBN B-NP O
24 768 772 20098969 poor JJ I-NP O
25 773 782 20098969 esthetics NNS I-NP O
26 782 783 20098969 . . O O

1 784 785 20098969 A DT B-NP O
2 786 799 20098969 comprehensive JJ I-NP O
3 800 811 20098969 examination NN I-NP O
4 812 821 20098969 including VBG B-PP O
5 822 825 20098969 her PRP$ B-NP O
6 826 833 20098969 medical JJ I-NP O
7 834 841 20098969 history NN I-NP O
8 841 842 20098969 , , O O
9 843 852 20098969 panoramic JJ B-NP O
10 853 863 20098969 radiograph NN I-NP O
11 863 864 20098969 , , O O
12 865 868 20098969 and CC O O
13 869 878 20098969 intraoral JJ B-NP O
14 879 890 20098969 examination NN I-NP O
15 891 899 20098969 revealed VBD B-VP O
16 900 902 20098969 19 CD B-NP O
17 903 910 20098969 carious JJ I-NP B-Disease
18 911 918 20098969 lesions NNS I-NP I-Disease
19 918 919 20098969 , , O O
20 920 925 20098969 which WDT B-NP O
21 926 928 20098969 is VBZ B-VP O
22 929 932 20098969 not RB O O
23 933 937 20098969 very RB B-ADJP O
24 938 944 20098969 common JJ I-ADJP O
25 945 948 20098969 for IN B-PP O
26 949 950 20098969 a DT B-NP O
27 951 958 20098969 healthy JJ I-NP O
28 959 964 20098969 adult NN I-NP O
29 964 965 20098969 . . O O

1 966 969 20098969 She PRP B-NP O
2 970 978 20098969 reported VBD B-VP O
3 979 982 20098969 her PRP$ B-NP O
4 983 986 20098969 use NN I-NP O
5 987 989 20098969 of IN B-PP O
6 990 1005 20098969 methamphetamine NN B-NP B-Chemical
7 1006 1009 20098969 for IN B-PP O
8 1010 1014 20098969 five CD B-NP O
9 1015 1020 20098969 years NNS I-NP O
10 1021 1024 20098969 and CC O O
11 1025 1028 20098969 had VBD B-VP O
12 1029 1032 20098969 not RB I-VP O
13 1033 1044 20098969 experienced VBN I-VP O
14 1045 1048 20098969 any DT B-NP O
15 1049 1054 20098969 major JJ I-NP O
16 1055 1062 20098969 carious JJ I-NP B-Disease
17 1063 1071 20098969 episodes NNS I-NP I-Disease
18 1072 1078 20098969 before IN B-SBAR O
19 1079 1082 20098969 she PRP B-NP O
20 1083 1090 20098969 started VBD B-VP O
21 1091 1096 20098969 using VBG I-VP O
22 1097 1100 20098969 the DT B-NP O
23 1101 1105 20098969 drug NN I-NP O
24 1105 1106 20098969 . . O O

1 1107 1114 20098969 SUMMARY NN B-NP O
2 1114 1115 20098969 : : O O
3 1116 1119 20098969 The DT B-NP O
4 1120 1129 20098969 patient's NNS I-NP O
5 1130 1137 20098969 medical JJ B-NP O
6 1138 1141 20098969 and CC I-NP O
7 1142 1148 20098969 dental JJ I-NP O
8 1149 1158 20098969 histories NNS I-NP O
9 1159 1164 20098969 along IN B-PP O
10 1165 1169 20098969 with IN B-PP O
11 1170 1182 20098969 radiographic JJ B-NP O
12 1183 1186 20098969 and CC I-NP O
13 1187 1195 20098969 clinical JJ I-NP O
14 1196 1204 20098969 findings NNS I-NP O
15 1205 1209 20098969 lead VBP B-VP O
16 1210 1212 20098969 to TO B-PP O
17 1213 1214 20098969 a DT B-NP O
18 1215 1224 20098969 diagnosis NN I-NP O
19 1225 1227 20098969 of IN B-PP O
20 1228 1229 20098969 " `` O O
21 1229 1233 20098969 meth NN B-NP B-Disease
22 1234 1239 20098969 mouth NN I-NP I-Disease
23 1239 1240 20098969 . . O O
24 1240 1241 20098969 " '' O O
25 1242 1250 20098969 Although IN B-SBAR O
26 1251 1256 20098969 three CD B-NP O
27 1257 1266 20098969 different JJ I-NP O
28 1267 1273 20098969 dental JJ I-NP O
29 1274 1283 20098969 treatment NN I-NP O
30 1284 1294 20098969 modalities NNS I-NP O
31 1295 1296 20098969 ( ( O O
32 1296 1302 20098969 either CC O O
33 1303 1315 20098969 conventional JJ O O
34 1316 1318 20098969 or CC O O
35 1319 1326 20098969 implant NN B-NP O
36 1326 1327 20098969 - HYPH B-VP O
37 1327 1336 20098969 supported VBN I-VP O
38 1336 1337 20098969 ) ) O O
39 1338 1342 20098969 have VBP B-VP O
40 1343 1347 20098969 been VBN I-VP O
41 1348 1355 20098969 offered VBN I-VP O
42 1356 1358 20098969 to TO B-PP O
43 1359 1362 20098969 the DT B-NP O
44 1363 1370 20098969 patient NN I-NP O
45 1371 1376 20098969 since IN B-PP O
46 1377 1383 20098969 August NNP B-NP O
47 1384 1388 20098969 2007 CD I-NP O
48 1388 1389 20098969 , , O O
49 1390 1393 20098969 the DT B-NP O
50 1394 1401 20098969 patient NN I-NP O
51 1402 1405 20098969 has VBZ B-VP O
52 1406 1409 20098969 yet RB I-VP O
53 1410 1412 20098969 to TO I-VP O
54 1413 1421 20098969 initiate VB I-VP O
55 1422 1425 20098969 any DT B-NP O
56 1426 1435 20098969 treatment NN I-NP O
57 1435 1436 20098969 . . O O

1 1437 1445 20098969 CLINICAL JJ B-NP O
2 1446 1458 20098969 SIGNIFICANCE NN I-NP O
3 1458 1459 20098969 : : O O
4 1460 1464 20098969 This DT B-NP O
5 1465 1473 20098969 clinical JJ I-NP O
6 1474 1478 20098969 case NN I-NP O
7 1479 1486 20098969 showing VBG B-VP O
8 1487 1491 20098969 oral JJ B-NP O
9 1492 1506 20098969 manifestations NNS I-NP O
10 1507 1509 20098969 of IN B-PP O
11 1510 1514 20098969 meth NN B-NP B-Disease
12 1515 1520 20098969 mouth NN I-NP I-Disease
13 1521 1524 20098969 was VBD B-VP O
14 1525 1534 20098969 presented VBN I-VP O
15 1535 1537 20098969 to TO I-VP O
16 1538 1542 20098969 help VB I-VP O
17 1543 1549 20098969 dental JJ B-NP O
18 1550 1563 20098969 practitioners NNS I-NP O
19 1564 1573 20098969 recognize VBP B-VP O
20 1574 1577 20098969 and CC I-VP O
21 1578 1584 20098969 manage VBP I-VP O
22 1585 1593 20098969 patients NNS B-NP O
23 1594 1597 20098969 who WP B-NP O
24 1598 1601 20098969 may MD B-VP O
25 1602 1604 20098969 be VB I-VP O
26 1605 1612 20098969 abusing VBG I-VP O
27 1613 1629 20098969 methamphetamines NNS B-NP B-Chemical
28 1629 1630 20098969 . . O O

1 1631 1637 20098969 Dental JJ B-NP O
2 1638 1651 20098969 practitioners NNS I-NP O
3 1652 1656 20098969 also RB B-ADVP O
4 1657 1660 20098969 may MD B-VP O
5 1661 1663 20098969 be VB I-VP O
6 1664 1673 20098969 skeptical JJ B-ADJP O
7 1674 1679 20098969 about IN B-PP O
8 1680 1683 20098969 the DT B-NP O
9 1684 1695 20098969 reliability NN I-NP O
10 1696 1698 20098969 of IN B-PP O
11 1699 1710 20098969 appointment NN B-NP O
12 1711 1718 20098969 keeping NN I-NP O
13 1719 1721 20098969 by IN B-PP O
14 1722 1727 20098969 these DT B-NP O
15 1728 1736 20098969 patients NNS I-NP O
16 1736 1737 20098969 , , O O
17 1738 1740 20098969 as IN B-SBAR O
18 1741 1745 20098969 they PRP B-NP O
19 1746 1756 20098969 frequently RB B-ADVP O
20 1757 1761 20098969 miss VBP B-VP O
21 1762 1767 20098969 their PRP$ B-NP O
22 1768 1780 20098969 appointments NNS I-NP O
23 1781 1788 20098969 without IN B-PP O
24 1789 1799 20098969 reasonable JJ B-NP O
25 1800 1813 20098969 justification NN I-NP O
26 1813 1814 20098969 . . O O

1 0 0 2870085 -DOCSTART- -X- -X- O

1 0 9 2870085 Flestolol NN B-NP B-Chemical
2 9 10 2870085 : : O O
3 11 13 2870085 an DT B-NP O
4 14 19 2870085 ultra AFX I-NP O
5 19 20 2870085 - HYPH I-NP O
6 20 25 2870085 short JJ I-NP O
7 25 26 2870085 - HYPH I-NP O
8 26 32 2870085 acting VBG B-VP O
9 33 37 2870085 beta SYM B-NP O
10 37 38 2870085 - HYPH B-NP O
11 38 48 2870085 adrenergic JJ I-NP O
12 49 57 2870085 blocking VBG I-NP O
13 58 63 2870085 agent NN I-NP O
14 63 64 2870085 . . O O
15 65 74 2870085 Flestolol NN B-NP B-Chemical
16 75 76 2870085 ( ( O O
17 76 79 2870085 ACC NN B-NP B-Chemical
18 79 80 2870085 - HYPH B-NP I-Chemical
19 80 84 2870085 9089 CD I-NP I-Chemical
20 84 85 2870085 ) ) O O
21 86 88 2870085 is VBZ B-VP O
22 89 90 2870085 a DT B-NP O
23 91 103 2870085 nonselective JJ I-NP O
24 103 104 2870085 , , I-NP O
25 105 116 2870085 competitive JJ I-NP O
26 116 117 2870085 , , O O
27 118 123 2870085 ultra AFX O O
28 123 124 2870085 - HYPH O O
29 124 129 2870085 short JJ B-ADJP O
30 129 130 2870085 - HYPH O O
31 130 136 2870085 acting VBG B-VP O
32 137 141 2870085 beta SYM B-NP O
33 141 142 2870085 - HYPH B-NP O
34 142 152 2870085 adrenergic JJ I-NP O
35 153 161 2870085 blocking VBG I-NP O
36 162 167 2870085 agent NN I-NP O
37 167 168 2870085 , , O O
38 169 176 2870085 without IN B-PP O
39 177 180 2870085 any DT B-NP O
40 181 190 2870085 intrinsic JJ I-NP O
41 191 206 2870085 sympathomimetic JJ I-NP O
42 207 215 2870085 activity NN I-NP O
43 215 216 2870085 . . O O

1 217 226 2870085 Flestolol NN B-NP B-Chemical
2 227 229 2870085 is VBZ B-VP O
3 230 241 2870085 metabolized VBN I-VP O
4 242 244 2870085 by IN B-PP O
5 245 251 2870085 plasma NN B-NP O
6 252 261 2870085 esterases NNS I-NP O
7 262 265 2870085 and CC O O
8 266 269 2870085 has VBZ B-VP O
9 270 272 2870085 an DT B-NP O
10 273 284 2870085 elimination NN I-NP O
11 285 289 2870085 half NN I-NP O
12 289 290 2870085 - HYPH I-NP O
13 290 294 2870085 life NN I-NP O
14 295 297 2870085 of IN B-PP O
15 298 311 2870085 approximately RB B-NP O
16 312 315 2870085 6.5 CD I-NP O
17 316 323 2870085 minutes NNS I-NP O
18 323 324 2870085 . . O O

1 325 329 2870085 This DT B-NP O
2 330 335 2870085 agent NN I-NP O
3 336 339 2870085 was VBD B-VP O
4 340 344 2870085 well RB I-VP O
5 345 354 2870085 tolerated VBN I-VP O
6 355 357 2870085 in IN B-PP O
7 358 365 2870085 healthy JJ B-NP O
8 366 376 2870085 volunteers NNS I-NP O
9 377 379 2870085 at IN B-PP O
10 380 385 2870085 doses NNS B-NP O
11 386 388 2870085 up RB B-NP O
12 389 391 2870085 to TO I-NP O
13 392 395 2870085 100 CD I-NP O
14 396 406 2870085 micrograms NNS I-NP O
15 406 407 2870085 / SYM B-NP O
16 407 409 2870085 kg NN I-NP O
17 409 410 2870085 / SYM B-NP O
18 410 413 2870085 min NN I-NP O
19 413 414 2870085 . . O O

1 415 417 2870085 In IN B-PP O
2 418 422 2870085 long JJ B-NP O
3 422 423 2870085 - HYPH I-NP O
4 423 427 2870085 term NN I-NP O
5 428 436 2870085 infusion NN I-NP O
6 437 444 2870085 studies NNS I-NP O
7 444 445 2870085 , , O O
8 446 455 2870085 flestolol NN B-NP B-Chemical
9 456 459 2870085 was VBD B-VP O
10 460 464 2870085 well RB I-VP O
11 465 474 2870085 tolerated VBN I-VP O
12 475 477 2870085 at IN B-PP O
13 478 481 2870085 the DT B-NP O
14 482 491 2870085 effective JJ I-NP O
15 492 496 2870085 beta SYM O O
16 496 497 2870085 - HYPH O O
17 497 505 2870085 blocking VBG B-VP O
18 506 510 2870085 dose NN B-NP O
19 511 512 2870085 ( ( O O
20 512 513 2870085 5 CD B-NP O
21 514 524 2870085 micrograms NNS I-NP O
22 524 525 2870085 / SYM B-NP O
23 525 527 2870085 kg NN I-NP O
24 527 528 2870085 / SYM B-NP O
25 528 531 2870085 min NN I-NP O
26 531 532 2870085 ) ) O O
27 533 536 2870085 for IN B-PP O
28 537 539 2870085 up RB B-NP O
29 540 542 2870085 to TO I-NP O
30 543 548 2870085 seven CD I-NP O
31 549 553 2870085 days NNS I-NP O
32 553 554 2870085 . . O O

1 555 564 2870085 Flestolol NN B-NP B-Chemical
2 565 570 2870085 blood NN I-NP O
3 571 585 2870085 concentrations NNS I-NP O
4 586 595 2870085 increased VBD B-VP O
5 596 604 2870085 linearly RB B-ADVP O
6 605 609 2870085 with IN B-PP O
7 610 620 2870085 increasing VBG B-NP O
8 621 625 2870085 dose NN I-NP O
9 626 629 2870085 and CC I-NP O
10 630 634 2870085 good JJ I-NP O
11 635 646 2870085 correlation NN I-NP O
12 647 653 2870085 exists VBZ B-VP O
13 654 661 2870085 between IN B-PP O
14 662 667 2870085 blood NN B-NP O
15 668 682 2870085 concentrations NNS I-NP O
16 683 685 2870085 of IN B-PP O
17 686 695 2870085 flestolol NN B-NP B-Chemical
18 696 699 2870085 and CC O O
19 700 704 2870085 beta SYM B-NP O
20 704 705 2870085 - HYPH B-NP O
21 705 715 2870085 adrenergic JJ I-NP O
22 716 724 2870085 blockade NN I-NP O
23 724 725 2870085 . . O O

1 726 735 2870085 Flestolol NN B-NP B-Chemical
2 736 744 2870085 produced VBD B-VP O
3 745 746 2870085 a DT B-NP O
4 747 751 2870085 dose NN I-NP O
5 751 752 2870085 - HYPH B-NP O
6 752 761 2870085 dependent JJ I-NP O
7 762 773 2870085 attenuation NN I-NP O
8 774 776 2870085 of IN B-PP O
9 777 790 2870085 isoproterenol NN B-NP B-Chemical
10 790 791 2870085 - HYPH B-NP O
11 791 798 2870085 induced VBN I-NP O
12 799 810 2870085 tachycardia NN I-NP B-Disease
13 810 811 2870085 . . O O

1 812 830 2870085 Electrophysiologic JJ B-NP O
2 831 834 2870085 and CC I-NP O
3 835 846 2870085 hemodynamic JJ I-NP O
4 847 854 2870085 effects NNS I-NP O
5 855 857 2870085 of IN B-PP O
6 858 867 2870085 flestolol NN B-NP B-Chemical
7 868 871 2870085 are VBP B-VP O
8 872 879 2870085 similar JJ B-ADJP O
9 880 882 2870085 to TO B-PP O
10 883 888 2870085 those DT B-NP O
11 889 891 2870085 of IN B-PP O
12 892 897 2870085 other JJ B-NP O
13 898 902 2870085 beta NN I-NP O
14 903 911 2870085 blockers NNS I-NP O
15 911 912 2870085 . . O O

1 913 915 2870085 In IN B-PP O
2 916 924 2870085 contrast NN B-NP O
3 925 929 2870085 with IN B-PP O
4 930 935 2870085 other JJ B-NP O
5 936 940 2870085 beta NN I-NP O
6 941 949 2870085 blockers NNS I-NP O
7 949 950 2870085 , , O O
8 951 960 2870085 flestolol NN B-NP B-Chemical
9 960 961 2870085 - HYPH B-NP O
10 961 968 2870085 induced VBN I-NP O
11 969 976 2870085 effects NNS I-NP O
12 977 984 2870085 reverse VBP B-VP O
13 985 992 2870085 rapidly RB B-ADVP O
14 993 994 2870085 ( ( O O
15 994 1000 2870085 within IN B-PP O
16 1001 1003 2870085 30 CD B-NP O
17 1004 1011 2870085 minutes NNS I-NP O
18 1011 1012 2870085 ) ) O O
19 1013 1022 2870085 following VBG B-PP O
20 1023 1038 2870085 discontinuation NN B-NP O
21 1039 1046 2870085 because IN B-PP O
22 1047 1049 2870085 of IN I-PP O
23 1050 1053 2870085 its PRP$ B-NP O
24 1054 1059 2870085 short JJ I-NP O
25 1060 1064 2870085 half NN I-NP O
26 1064 1065 2870085 - HYPH I-NP O
27 1065 1069 2870085 life NN I-NP O
28 1069 1070 2870085 . . O O

1 1071 1080 2870085 Flestolol NN B-NP B-Chemical
2 1081 1092 2870085 effectively RB B-ADVP O
3 1093 1100 2870085 reduced VBD B-VP O
4 1101 1106 2870085 heart NN B-NP O
5 1107 1111 2870085 rate NN I-NP O
6 1112 1114 2870085 in IN B-PP O
7 1115 1123 2870085 patients NNS B-NP O
8 1124 1128 2870085 with IN B-PP O
9 1129 1145 2870085 supraventricular JJ B-NP B-Disease
10 1146 1161 2870085 tachyarrhythmia NN I-NP I-Disease
11 1161 1162 2870085 . . O O

1 1163 1165 2870085 In IN B-PP O
2 1166 1174 2870085 patients NNS B-NP O
3 1175 1179 2870085 with IN B-PP O
4 1180 1188 2870085 unstable JJ B-NP B-Disease
5 1189 1195 2870085 angina NN I-NP I-Disease
6 1195 1196 2870085 , , O O
7 1197 1206 2870085 flestolol NN B-NP B-Chemical
8 1207 1215 2870085 infusion NN I-NP O
9 1216 1219 2870085 was VBD B-VP O
10 1220 1225 2870085 found VBN I-VP O
11 1226 1228 2870085 to TO I-VP O
12 1229 1231 2870085 be VB I-VP O
13 1232 1236 2870085 safe JJ B-ADJP O
14 1237 1240 2870085 and CC I-ADJP O
15 1241 1250 2870085 effective JJ I-ADJP O
16 1251 1253 2870085 in IN B-PP O
17 1254 1265 2870085 controlling VBG B-VP O
18 1266 1271 2870085 chest NN B-NP B-Disease
19 1272 1276 2870085 pain NN I-NP I-Disease
20 1276 1277 2870085 . . O O

1 1278 1280 2870085 It PRP B-NP O
2 1281 1283 2870085 is VBZ B-VP O
3 1284 1293 2870085 concluded VBN I-VP O
4 1294 1298 2870085 that IN B-SBAR O
5 1299 1308 2870085 flestolol NN B-NP B-Chemical
6 1309 1311 2870085 is VBZ B-VP O
7 1312 1313 2870085 a DT B-NP O
8 1314 1320 2870085 potent JJ I-NP O
9 1320 1321 2870085 , , O O
10 1322 1326 2870085 well RB B-ADVP O
11 1326 1327 2870085 - HYPH B-NP O
12 1327 1336 2870085 tolerated VBN B-VP O
13 1336 1337 2870085 , , O O
14 1338 1343 2870085 ultra AFX B-NP O
15 1343 1344 2870085 - HYPH I-NP O
16 1344 1349 2870085 short JJ B-ADJP O
17 1349 1350 2870085 - HYPH O O
18 1350 1356 2870085 acting VBG B-VP O
19 1357 1361 2870085 beta SYM B-NP O
20 1361 1362 2870085 - HYPH B-NP O
21 1362 1372 2870085 adrenergic JJ I-NP O
22 1373 1381 2870085 blocking VBG I-NP O
23 1382 1387 2870085 agent NN I-NP O
24 1387 1388 2870085 . . O O

1 1389 1392 2870085 Use NN B-NP O
2 1393 1395 2870085 of IN B-PP O
3 1396 1405 2870085 flestolol NN B-NP B-Chemical
4 1406 1408 2870085 in IN B-PP O
5 1409 1412 2870085 the DT B-NP O
6 1413 1421 2870085 critical JJ I-NP O
7 1422 1426 2870085 care NN I-NP O
8 1427 1434 2870085 setting NN I-NP O
9 1435 1437 2870085 is VBZ B-VP O
10 1438 1447 2870085 currently RB I-VP O
11 1448 1458 2870085 undergoing VBG I-VP O
12 1459 1472 2870085 investigation NN B-NP O
13 1472 1473 2870085 . . O O

1 0 0 19767176 -DOCSTART- -X- -X- O

1 0 11 19767176 Pyrrolidine NN B-NP B-Chemical
2 12 27 19767176 dithiocarbamate NN I-NP I-Chemical
3 28 36 19767176 protects VBZ B-VP O
4 37 40 19767176 the DT B-NP O
5 41 49 19767176 piriform JJ I-NP O
6 50 56 19767176 cortex NN I-NP O
7 57 59 19767176 in IN B-PP O
8 60 63 19767176 the DT B-NP O
9 64 75 19767176 pilocarpine NN I-NP B-Chemical
10 76 82 19767176 status NN I-NP B-Disease
11 83 94 19767176 epilepticus NN I-NP I-Disease
12 95 100 19767176 model NN I-NP O
13 100 101 19767176 . . O O
14 102 113 19767176 Pyrrolidine NN B-NP B-Chemical
15 114 129 19767176 dithiocarbamate NN I-NP I-Chemical
16 130 131 19767176 ( ( O O
17 131 135 19767176 PDTC NN B-NP B-Chemical
18 135 136 19767176 ) ) O O
19 137 140 19767176 has VBZ B-VP O
20 141 142 19767176 a DT B-NP O
21 143 147 19767176 dual JJ I-NP O
22 148 157 19767176 mechanism NN I-NP O
23 158 160 19767176 of IN B-PP O
24 161 167 19767176 action NN B-NP O
25 168 170 19767176 as IN B-PP O
26 171 173 19767176 an DT B-NP O
27 174 185 19767176 antioxidant NN I-NP O
28 186 189 19767176 and CC O O
29 190 192 19767176 an DT B-NP O
30 193 202 19767176 inhibitor NN I-NP O
31 203 205 19767176 of IN B-PP O
32 206 209 19767176 the DT B-NP O
33 210 223 19767176 transcription NN I-NP O
34 224 230 19767176 factor NN I-NP O
35 231 236 19767176 kappa NN I-NP O
36 236 237 19767176 - HYPH O O
37 237 241 19767176 beta SYM B-NP O
38 241 242 19767176 . . O O

1 243 247 19767176 Both CC O O
2 247 248 19767176 , , O O
3 249 259 19767176 production NN B-NP O
4 260 262 19767176 of IN B-PP O
5 263 271 19767176 reactive JJ B-NP O
6 272 278 19767176 oxygen NN I-NP B-Chemical
7 279 286 19767176 species NNS I-NP O
8 287 289 19767176 as RB B-CONJP O
9 290 294 19767176 well RB I-CONJP O
10 295 297 19767176 as IN I-CONJP O
11 298 308 19767176 activation NN B-NP O
12 309 311 19767176 of IN B-PP O
13 312 314 19767176 NF NN B-NP O
14 314 315 19767176 - HYPH B-NP O
15 315 321 19767176 kappaB NN I-NP O
16 322 326 19767176 have VBP B-VP O
17 327 331 19767176 been VBN I-VP O
18 332 342 19767176 implicated VBN I-VP O
19 343 345 19767176 in IN B-PP O
20 346 352 19767176 severe JJ B-NP O
21 353 361 19767176 neuronal JJ I-NP B-Disease
22 362 368 19767176 damage NN I-NP I-Disease
23 369 371 19767176 in IN B-PP O
24 372 381 19767176 different JJ B-NP O
25 382 385 19767176 sub AFX I-NP O
26 385 386 19767176 - HYPH I-NP O
27 386 393 19767176 regions NNS I-NP O
28 394 396 19767176 of IN B-PP O
29 397 400 19767176 the DT B-NP O
30 401 412 19767176 hippocampus NN I-NP O
31 413 415 19767176 as RB B-CONJP O
32 416 420 19767176 well RB I-CONJP O
33 421 423 19767176 as IN I-CONJP O
34 424 426 19767176 in IN B-PP O
35 427 430 19767176 the DT B-NP O
36 431 442 19767176 surrounding VBG I-NP O
37 443 451 19767176 cortices NNS I-NP O
38 451 452 19767176 . . O O

1 453 456 19767176 The DT B-NP O
2 457 463 19767176 effect NN I-NP O
3 464 466 19767176 of IN B-PP O
4 467 471 19767176 PDTC NN B-NP B-Chemical
5 472 474 19767176 on IN B-PP O
6 475 481 19767176 status NN B-NP B-Disease
7 482 493 19767176 epilepticus NN I-NP I-Disease
8 493 494 19767176 - HYPH B-VP O
9 494 504 19767176 associated VBN B-NP O
10 505 509 19767176 cell NN I-NP O
11 510 514 19767176 loss NN I-NP O
12 515 517 19767176 in IN B-PP O
13 518 521 19767176 the DT B-NP O
14 522 533 19767176 hippocampus NN I-NP O
15 534 537 19767176 and CC I-NP O
16 538 546 19767176 piriform NN I-NP O
17 547 553 19767176 cortex NN I-NP O
18 554 557 19767176 was VBD B-VP O
19 558 567 19767176 evaluated VBN I-VP O
20 568 570 19767176 in IN B-PP O
21 571 574 19767176 the DT B-NP O
22 575 578 19767176 rat NN I-NP O
23 579 591 19767176 fractionated VBD B-VP O
24 592 603 19767176 pilocarpine NN B-NP B-Chemical
25 604 609 19767176 model NN I-NP O
26 609 610 19767176 . . O O

1 611 620 19767176 Treatment NN B-NP O
2 621 625 19767176 with IN B-PP O
3 626 629 19767176 150 CD B-NP O
4 630 632 19767176 mg NN I-NP O
5 632 633 19767176 / SYM B-NP O
6 633 635 19767176 kg NN I-NP O
7 636 640 19767176 PDTC NN I-NP B-Chemical
8 641 647 19767176 before IN B-PP O
9 648 651 19767176 and CC O O
10 652 661 19767176 following VBG B-PP O
11 662 668 19767176 status NN B-NP B-Disease
12 669 680 19767176 epilepticus NN I-NP I-Disease
13 681 694 19767176 significantly RB B-ADVP O
14 695 704 19767176 increased VBD B-VP O
15 705 708 19767176 the DT B-NP O
16 709 718 19767176 mortality NN I-NP O
17 719 723 19767176 rate NN I-NP O
18 724 726 19767176 to TO B-PP O
19 727 731 19767176 100% CD B-NP O
20 731 732 19767176 . . O O

1 733 747 19767176 Administration NN B-NP O
2 748 750 19767176 of IN B-PP O
3 751 753 19767176 50 CD B-NP O
4 754 756 19767176 mg NN I-NP O
5 756 757 19767176 / SYM B-NP O
6 757 759 19767176 kg NN B-NP O
7 760 764 19767176 PDTC NN I-NP B-Chemical
8 765 766 19767176 ( ( O O
9 766 769 19767176 low JJ B-NP O
10 769 770 19767176 - HYPH I-NP O
11 770 774 19767176 dose NN I-NP O
12 774 775 19767176 ) ) O O
13 776 779 19767176 did VBD B-VP O
14 780 783 19767176 not RB I-VP O
15 784 789 19767176 exert VB I-VP O
16 790 795 19767176 major JJ B-NP O
17 796 803 19767176 effects NNS I-NP O
18 804 806 19767176 on IN B-PP O
19 807 810 19767176 the DT B-NP O
20 811 822 19767176 development NN I-NP O
21 823 825 19767176 of IN B-PP O
22 826 827 19767176 a DT B-NP O
23 828 834 19767176 status NN I-NP B-Disease
24 835 846 19767176 epilepticus NN I-NP I-Disease
25 847 849 19767176 or CC O O
26 850 853 19767176 the DT B-NP O
27 854 863 19767176 mortality NN I-NP O
28 864 868 19767176 rate NN I-NP O
29 868 869 19767176 . . O O

1 870 872 19767176 In IN B-PP O
2 873 880 19767176 vehicle NN B-NP O
3 880 881 19767176 - HYPH B-NP O
4 881 888 19767176 treated VBN I-NP O
5 889 893 19767176 rats NNS I-NP O
6 893 894 19767176 , , O O
7 895 901 19767176 status NN B-NP B-Disease
8 902 913 19767176 epilepticus NN I-NP I-Disease
9 914 920 19767176 caused VBD B-VP O
10 921 931 19767176 pronounced JJ B-NP O
11 932 940 19767176 neuronal JJ I-NP B-Disease
12 941 947 19767176 damage NN I-NP I-Disease
13 948 950 19767176 in IN B-PP O
14 951 954 19767176 the DT B-NP O
15 955 963 19767176 piriform NN I-NP O
16 964 970 19767176 cortex NN I-NP O
17 971 981 19767176 comprising VBG B-VP O
18 982 986 19767176 both CC O O
19 987 996 19767176 pyramidal JJ B-NP O
20 997 1002 19767176 cells NNS I-NP O
21 1003 1006 19767176 and CC I-NP O
22 1007 1019 19767176 interneurons NNS I-NP O
23 1019 1020 19767176 . . O O

1 1021 1024 19767176 Low JJ B-NP O
2 1024 1025 19767176 - HYPH I-NP O
3 1025 1029 19767176 dose NN I-NP O
4 1030 1034 19767176 PDTC NN I-NP B-Chemical
5 1035 1044 19767176 treatment NN I-NP O
6 1045 1051 19767176 almost RB B-VP O
7 1052 1062 19767176 completely RB I-VP O
8 1063 1072 19767176 protected VBN I-VP O
9 1073 1077 19767176 from IN B-PP O
10 1078 1085 19767176 lesions NNS B-NP O
11 1086 1088 19767176 in IN B-PP O
12 1089 1092 19767176 the DT B-NP O
13 1093 1101 19767176 piriform NN I-NP O
14 1102 1108 19767176 cortex NN I-NP O
15 1108 1109 19767176 . . O O

1 1110 1111 19767176 A DT B-NP O
2 1112 1123 19767176 significant JJ I-NP O
3 1124 1132 19767176 decrease NN I-NP O
4 1133 1135 19767176 in IN B-PP O
5 1136 1144 19767176 neuronal JJ B-NP O
6 1145 1152 19767176 density NN I-NP O
7 1153 1155 19767176 of IN B-PP O
8 1156 1159 19767176 the DT B-NP O
9 1160 1171 19767176 hippocampal JJ I-NP O
10 1172 1177 19767176 hilar JJ I-NP O
11 1178 1187 19767176 formation NN I-NP O
12 1188 1191 19767176 was VBD B-VP O
13 1192 1202 19767176 identified VBN I-VP O
14 1203 1205 19767176 in IN B-PP O
15 1206 1213 19767176 vehicle NN B-NP O
16 1213 1214 19767176 - HYPH B-NP O
17 1215 1218 19767176 and CC I-NP O
18 1219 1223 19767176 PDTC NN I-NP B-Chemical
19 1223 1224 19767176 - HYPH O O
20 1224 1231 19767176 treated VBN B-NP O
21 1232 1236 19767176 rats NNS I-NP O
22 1237 1246 19767176 following VBG B-PP O
23 1247 1253 19767176 status NN B-NP B-Disease
24 1254 1265 19767176 epilepticus NN I-NP I-Disease
25 1265 1266 19767176 . . O O

1 1267 1269 19767176 In IN B-PP O
2 1270 1280 19767176 conclusion NN B-NP O
3 1280 1281 19767176 , , O O
4 1282 1285 19767176 the DT B-NP O
5 1286 1288 19767176 NF NN I-NP O
6 1288 1289 19767176 - HYPH B-NP O
7 1289 1295 19767176 kappaB NN I-NP O
8 1296 1305 19767176 inhibitor NN I-NP O
9 1306 1309 19767176 and CC O O
10 1310 1321 19767176 antioxidant JJ B-NP O
11 1322 1326 19767176 PDTC NN I-NP B-Chemical
12 1327 1336 19767176 protected VBD B-VP O
13 1337 1340 19767176 the DT B-NP O
14 1341 1349 19767176 piriform NN I-NP O
15 1350 1356 19767176 cortex NN I-NP O
16 1356 1357 19767176 , , O O
17 1358 1365 19767176 whereas IN O O
18 1366 1368 19767176 it PRP B-NP O
19 1369 1372 19767176 did VBD B-VP O
20 1373 1376 19767176 not RB I-VP O
21 1377 1383 19767176 affect VB I-VP O
22 1384 1389 19767176 hilar JJ B-NP O
23 1390 1398 19767176 neuronal JJ I-NP B-Disease
24 1399 1403 19767176 loss NN I-NP I-Disease
25 1403 1404 19767176 . . O O

1 1405 1410 19767176 These DT B-NP O
2 1411 1415 19767176 data NNS I-NP O
3 1416 1421 19767176 might MD B-VP O
4 1422 1430 19767176 indicate VB I-VP O
5 1431 1435 19767176 that IN B-SBAR O
6 1436 1439 19767176 the DT B-NP O
7 1440 1450 19767176 generation NN I-NP O
8 1451 1453 19767176 of IN B-PP O
9 1454 1462 19767176 reactive JJ B-NP O
10 1463 1469 19767176 oxygen NN I-NP B-Chemical
11 1470 1477 19767176 species NNS I-NP O
12 1478 1481 19767176 and CC O O
13 1482 1492 19767176 activation NN B-NP O
14 1493 1495 19767176 of IN B-PP O
15 1496 1498 19767176 NF NN B-NP O
16 1498 1499 19767176 - HYPH B-NP O
17 1499 1505 19767176 kappaB NN I-NP O
18 1506 1511 19767176 plays VBZ B-VP O
19 1512 1513 19767176 a DT B-NP O
20 1514 1518 19767176 more RBR I-NP O
21 1519 1526 19767176 central JJ I-NP O
22 1527 1531 19767176 role NN I-NP O
23 1532 1534 19767176 in IN B-PP O
24 1535 1542 19767176 seizure NN B-NP B-Disease
25 1542 1543 19767176 - HYPH O O
26 1543 1553 19767176 associated VBN B-NP O
27 1554 1562 19767176 neuronal JJ I-NP B-Disease
28 1563 1569 19767176 damage NN I-NP I-Disease
29 1570 1572 19767176 in IN B-PP O
30 1573 1576 19767176 the DT B-NP O
31 1577 1585 19767176 temporal JJ I-NP O
32 1586 1592 19767176 cortex NN I-NP O
33 1593 1595 19767176 as IN B-SBAR O
34 1596 1604 19767176 compared VBN B-PP O
35 1605 1607 19767176 to TO B-PP O
36 1608 1611 19767176 the DT B-NP O
37 1612 1623 19767176 hippocampal JJ I-NP O
38 1624 1629 19767176 hilus NN I-NP O
39 1629 1630 19767176 . . O O

1 1631 1638 19767176 However RB B-ADVP O
2 1638 1639 19767176 , , O O
3 1640 1646 19767176 future JJ B-NP O
4 1647 1661 19767176 investigations NNS I-NP O
5 1662 1665 19767176 are VBP B-VP O
6 1666 1675 19767176 necessary JJ B-ADJP O
7 1676 1678 19767176 to TO B-VP O
8 1679 1686 19767176 exactly RB I-VP O
9 1687 1694 19767176 analyze VB I-VP O
10 1695 1698 19767176 the DT B-NP O
11 1699 1710 19767176 biochemical JJ I-NP O
12 1711 1721 19767176 mechanisms NNS I-NP O
13 1722 1724 19767176 by IN B-PP O
14 1725 1730 19767176 which WDT B-NP O
15 1731 1735 19767176 PDTC NN B-NP B-Chemical
16 1736 1743 19767176 exerted VBD B-VP O
17 1744 1747 19767176 its PRP$ B-NP O
18 1748 1758 19767176 beneficial JJ I-NP O
19 1759 1766 19767176 effects NNS I-NP O
20 1767 1769 19767176 in IN B-PP O
21 1770 1773 19767176 the DT B-NP O
22 1774 1782 19767176 piriform NN I-NP O
23 1783 1789 19767176 cortex NN I-NP O
24 1789 1790 19767176 . . O O

1 0 0 19058010 -DOCSTART- -X- -X- O

1 0 6 19058010 Effect NN B-NP O
2 7 9 19058010 of IN B-PP O
3 10 15 19058010 green JJ B-NP B-Chemical
4 16 19 19058010 tea NN I-NP I-Chemical
5 20 23 19058010 and CC I-NP O
6 24 31 19058010 vitamin NN I-NP B-Chemical
7 32 33 19058010 E NN I-NP I-Chemical
8 34 45 19058010 combination NN I-NP O
9 46 48 19058010 in IN B-PP O
10 49 62 19058010 isoproterenol NN B-NP B-Chemical
11 63 70 19058010 induced VBD B-VP O
12 71 81 19058010 myocardial JJ B-NP B-Disease
13 82 92 19058010 infarction NN I-NP I-Disease
14 93 95 19058010 in IN B-PP O
15 96 100 19058010 rats NNS B-NP O
16 100 101 19058010 . . O O
17 102 105 19058010 The DT B-NP O
18 106 113 19058010 present JJ I-NP O
19 114 119 19058010 study NN I-NP O
20 120 123 19058010 was VBD B-VP O
21 124 129 19058010 aimed VBN I-VP O
22 130 132 19058010 to TO I-VP O
23 133 144 19058010 investigate VB I-VP O
24 145 148 19058010 the DT B-NP O
25 149 157 19058010 combined VBN I-NP O
26 158 165 19058010 effects NNS I-NP O
27 166 168 19058010 of IN B-PP O
28 169 174 19058010 green JJ B-NP B-Chemical
29 175 178 19058010 tea NN I-NP I-Chemical
30 179 182 19058010 and CC I-NP O
31 183 190 19058010 vitamin NN I-NP B-Chemical
32 191 192 19058010 E NN I-NP I-Chemical
33 193 195 19058010 on IN B-PP O
34 196 201 19058010 heart NN B-NP O
35 202 208 19058010 weight NN I-NP O
36 208 209 19058010 , , O O
37 210 214 19058010 body NN B-NP O
38 215 221 19058010 weight NN I-NP O
39 221 222 19058010 , , O O
40 223 228 19058010 serum NN B-NP O
41 229 235 19058010 marker NN I-NP O
42 236 243 19058010 enzymes NNS I-NP O
43 243 244 19058010 , , O O
44 245 250 19058010 lipid NN B-NP O
45 251 263 19058010 peroxidation NN I-NP O
46 263 264 19058010 , , O O
47 265 275 19058010 endogenous JJ B-NP O
48 276 288 19058010 antioxidants NNS I-NP O
49 289 292 19058010 and CC O O
50 293 301 19058010 membrane NN B-NP O
51 302 307 19058010 bound VBD B-VP O
52 308 315 19058010 ATPases NNS B-NP O
53 316 318 19058010 in IN B-PP O
54 319 332 19058010 isoproterenol NN B-NP B-Chemical
55 333 334 19058010 ( ( O O
56 334 337 19058010 ISO NN B-NP B-Chemical
57 337 338 19058010 ) ) O O
58 338 339 19058010 - HYPH O O
59 339 346 19058010 induced VBN B-NP O
60 347 357 19058010 myocardial JJ I-NP B-Disease
61 358 368 19058010 infarction NN I-NP I-Disease
62 369 371 19058010 in IN B-PP O
63 372 376 19058010 rats NNS B-NP O
64 376 377 19058010 . . O O

1 378 383 19058010 Adult JJ B-NP O
2 384 388 19058010 male JJ I-NP O
3 389 395 19058010 albino NN I-NP O
4 396 400 19058010 rats NNS I-NP O
5 400 401 19058010 , , O O
6 402 409 19058010 treated VBN B-VP O
7 410 414 19058010 with IN B-PP O
8 415 418 19058010 ISO NN B-NP B-Chemical
9 419 420 19058010 ( ( O O
10 420 423 19058010 200 CD B-NP O
11 424 426 19058010 mg NN I-NP O
12 426 427 19058010 / SYM B-NP O
13 427 429 19058010 kg NN I-NP O
14 429 430 19058010 , , O O
15 431 434 19058010 s.c NN B-NP O
16 434 435 19058010 . . O O
17 435 436 19058010 ) ) O O
18 437 440 19058010 for IN B-PP O
19 441 442 19058010 2 CD B-NP O
20 443 447 19058010 days NNS I-NP O
21 448 450 19058010 at IN B-PP O
22 451 453 19058010 an DT B-NP O
23 454 462 19058010 interval NN I-NP O
24 463 465 19058010 of IN B-PP O
25 466 468 19058010 24 CD B-NP O
26 469 470 19058010 h NN I-NP O
27 471 477 19058010 caused VBD B-VP O
28 478 479 19058010 a DT O O
29 480 491 19058010 significant JJ O O
30 492 493 19058010 ( ( O O
31 493 494 19058010 P NN O O
32 494 495 19058010 < SYM O O
33 495 499 19058010 0.05 CD O O
34 499 500 19058010 ) ) O O
35 501 510 19058010 elevation NN B-NP O
36 511 513 19058010 of IN B-PP O
37 514 519 19058010 heart NN B-NP O
38 520 526 19058010 weight NN I-NP O
39 526 527 19058010 , , O O
40 528 533 19058010 serum NN B-NP O
41 534 540 19058010 marker NN I-NP O
42 541 548 19058010 enzymes NNS I-NP O
43 548 549 19058010 , , O O
44 550 555 19058010 lipid NN B-NP O
45 556 568 19058010 peroxidation NN I-NP O
46 569 572 19058010 and CC I-NP O
47 573 575 19058010 Ca NN I-NP B-Chemical
48 575 576 19058010 + SYM B-NP O
49 576 577 19058010 2 CD I-NP O
50 578 584 19058010 ATPase NN I-NP O
51 585 590 19058010 level NN I-NP O
52 591 598 19058010 whereas IN B-SBAR O
53 599 604 19058010 there EX B-NP O
54 605 608 19058010 was VBD B-VP O
55 609 610 19058010 a DT O O
56 611 622 19058010 significant JJ O O
57 623 624 19058010 ( ( O O
58 624 625 19058010 P NN O O
59 625 626 19058010 < SYM O O
60 626 630 19058010 0.05 CD O O
61 630 631 19058010 ) ) O O
62 632 640 19058010 decrease NN B-NP O
63 641 643 19058010 in IN B-PP O
64 644 648 19058010 body NN B-NP O
65 649 655 19058010 weight NN I-NP O
66 655 656 19058010 , , O O
67 657 667 19058010 endogenous JJ B-NP O
68 668 680 19058010 antioxidants NNS I-NP O
69 680 681 19058010 , , O O
70 682 685 19058010 Na+ NN B-NP B-Chemical
71 685 686 19058010 / SYM I-NP O
72 687 689 19058010 K+ NN I-NP B-Chemical
73 690 696 19058010 ATPase NN I-NP O
74 697 700 19058010 and CC I-NP O
75 701 703 19058010 Mg NN I-NP B-Chemical
76 703 704 19058010 + SYM B-NP O
77 704 705 19058010 2 CD I-NP O
78 706 712 19058010 ATPase NN I-NP O
79 713 719 19058010 levels NNS I-NP O
80 719 720 19058010 . . O O

1 721 735 19058010 Administration NN B-NP O
2 736 738 19058010 of IN B-PP O
3 739 744 19058010 green JJ B-NP B-Chemical
4 745 748 19058010 tea NN I-NP I-Chemical
5 749 750 19058010 ( ( O O
6 750 753 19058010 100 CD B-NP O
7 754 756 19058010 mg NN I-NP O
8 756 757 19058010 / SYM B-NP O
9 757 759 19058010 kg NN I-NP O
10 759 760 19058010 / SYM B-NP O
11 760 763 19058010 day NN I-NP O
12 763 764 19058010 , , O O
13 765 768 19058010 p.o FW B-NP O
14 768 769 19058010 . . O O
15 769 770 19058010 ) ) O O
16 771 774 19058010 and CC O O
17 775 782 19058010 vitamin NN B-NP B-Chemical
18 783 784 19058010 E NN I-NP I-Chemical
19 785 786 19058010 ( ( O O
20 786 789 19058010 100 CD B-NP O
21 790 792 19058010 mg NN I-NP O
22 792 793 19058010 / SYM B-NP O
23 793 795 19058010 kg NN I-NP O
24 795 796 19058010 / SYM B-NP O
25 796 799 19058010 day NN I-NP O
26 799 800 19058010 , , O O
27 801 804 19058010 p.o FW B-NP O
28 804 805 19058010 . . O O
29 805 806 19058010 ) ) O O
30 807 815 19058010 together RB B-ADVP O
31 816 819 19058010 for IN B-PP O
32 820 822 19058010 30 CD B-NP O
33 823 834 19058010 consecutive JJ I-NP O
34 835 839 19058010 days NNS I-NP O
35 840 843 19058010 and CC O O
36 844 854 19058010 challenged VBD B-VP O
37 855 859 19058010 with IN B-PP O
38 860 863 19058010 ISO NN B-NP B-Chemical
39 864 866 19058010 on IN B-PP O
40 867 870 19058010 the DT B-NP O
41 871 874 19058010 day NN I-NP O
42 875 879 19058010 29th JJ B-ADJP O
43 880 883 19058010 and CC I-ADJP O
44 884 888 19058010 30th JJ I-ADJP O
45 888 889 19058010 , , O O
46 890 896 19058010 showed VBD B-VP O
47 897 898 19058010 a DT B-NP O
48 899 910 19058010 significant JJ I-NP O
49 911 912 19058010 ( ( O O
50 912 913 19058010 P NN O O
51 913 914 19058010 < SYM O O
52 914 918 19058010 0.05 CD O O
53 918 919 19058010 ) ) O O
54 920 928 19058010 decrease NN B-NP O
55 929 931 19058010 in IN B-PP O
56 932 937 19058010 heart NN B-NP O
57 938 944 19058010 weight NN I-NP O
58 944 945 19058010 , , O O
59 946 951 19058010 serum NN B-NP O
60 952 958 19058010 marker NN I-NP O
61 959 966 19058010 enzymes NNS I-NP O
62 966 967 19058010 , , O O
63 968 973 19058010 lipid NN B-NP O
64 974 986 19058010 peroxidation NN I-NP O
65 986 987 19058010 , , O O
66 988 990 19058010 Ca NN B-NP B-Chemical
67 990 991 19058010 + SYM O O
68 991 992 19058010 2 CD B-NP O
69 993 999 19058010 ATPase NN I-NP O
70 1000 1003 19058010 and CC O O
71 1004 1005 19058010 a DT B-NP O
72 1006 1017 19058010 significant JJ I-NP O
73 1018 1026 19058010 increase NN I-NP O
74 1027 1029 19058010 in IN B-PP O
75 1030 1033 19058010 the DT B-NP O
76 1034 1038 19058010 body NN I-NP O
77 1039 1045 19058010 weight NN I-NP O
78 1045 1046 19058010 , , O O
79 1047 1057 19058010 endogenous JJ B-NP O
80 1058 1070 19058010 antioxidants NNS I-NP O
81 1070 1071 19058010 , , O O
82 1072 1075 19058010 Na+ NN B-NP B-Chemical
83 1075 1076 19058010 / SYM I-NP O
84 1076 1078 19058010 K+ NN I-NP B-Chemical
85 1079 1085 19058010 ATPase NN I-NP O
86 1086 1089 19058010 and CC I-NP O
87 1090 1092 19058010 Mg NN I-NP B-Chemical
88 1092 1093 19058010 + SYM B-NP O
89 1093 1094 19058010 2 CD B-NP O
90 1095 1101 19058010 ATPase NN I-NP O
91 1102 1106 19058010 when WRB B-ADVP O
92 1107 1115 19058010 compared VBN B-PP O
93 1116 1120 19058010 with IN B-PP O
94 1121 1124 19058010 ISO NN B-NP B-Chemical
95 1125 1132 19058010 treated JJ I-NP O
96 1133 1138 19058010 group NN I-NP O
97 1139 1142 19058010 and CC O O
98 1143 1148 19058010 green JJ B-NP B-Chemical
99 1149 1152 19058010 tea NN I-NP I-Chemical
100 1153 1155 19058010 or CC I-NP O
101 1156 1163 19058010 vitamin NN I-NP B-Chemical
102 1164 1165 19058010 E NN I-NP I-Chemical
103 1166 1171 19058010 alone RB B-NP O
104 1172 1179 19058010 treated VBN I-NP O
105 1180 1186 19058010 groups NNS I-NP O
106 1186 1187 19058010 . . O O

1 1188 1193 19058010 These DT B-NP O
2 1194 1202 19058010 findings NNS I-NP O
3 1203 1211 19058010 indicate VBP B-VP O
4 1212 1215 19058010 the DT B-NP O
5 1216 1227 19058010 synergistic JJ I-NP O
6 1228 1238 19058010 protective JJ I-NP O
7 1239 1245 19058010 effect NN I-NP O
8 1246 1248 19058010 of IN B-PP O
9 1249 1254 19058010 green JJ B-NP B-Chemical
10 1255 1258 19058010 tea NN I-NP I-Chemical
11 1259 1262 19058010 and CC I-NP O
12 1263 1270 19058010 vitamin NN I-NP B-Chemical
13 1271 1272 19058010 E NN I-NP I-Chemical
14 1273 1279 19058010 during IN B-PP O
15 1280 1283 19058010 ISO NN B-NP B-Chemical
16 1284 1291 19058010 induced VBD B-VP O
17 1292 1302 19058010 myocardial JJ B-NP B-Disease
18 1303 1313 19058010 infarction NN I-NP I-Disease
19 1314 1316 19058010 in IN B-PP O
20 1317 1321 19058010 rats NNS B-NP O
21 1321 1322 19058010 . . O O

1 0 0 6503301 -DOCSTART- -X- -X- O

1 0 4 6503301 Veno AFX B-NP B-Disease
2 4 5 6503301 - HYPH I-NP I-Disease
3 5 14 6503301 occlusive JJ B-NP I-Disease
4 15 20 6503301 liver NN I-NP I-Disease
5 21 28 6503301 disease NN I-NP I-Disease
6 29 34 6503301 after IN B-PP O
7 35 46 6503301 dacarbazine NN B-NP B-Chemical
8 47 54 6503301 therapy NN I-NP O
9 55 56 6503301 ( ( O O
10 56 60 6503301 DTIC NN B-NP B-Chemical
11 60 61 6503301 ) ) O O
12 62 65 6503301 for IN B-PP O
13 66 74 6503301 melanoma NN B-NP B-Disease
14 74 75 6503301 . . O O
15 76 77 6503301 A DT B-NP O
16 78 82 6503301 case NN I-NP O
17 83 85 6503301 of IN B-PP O
18 86 90 6503301 veno AFX B-NP B-Disease
19 90 91 6503301 - HYPH I-NP I-Disease
20 91 100 6503301 occlusive JJ I-NP I-Disease
21 101 108 6503301 disease NN I-NP I-Disease
22 109 111 6503301 of IN B-PP I-Disease
23 112 115 6503301 the DT B-NP I-Disease
24 116 121 6503301 liver NN I-NP I-Disease
25 122 126 6503301 with IN B-PP O
26 127 132 6503301 fatal JJ B-NP O
27 133 140 6503301 outcome NN I-NP O
28 141 146 6503301 after IN B-PP O
29 147 158 6503301 dacarbazine NN B-NP B-Chemical
30 159 160 6503301 ( ( O O
31 160 164 6503301 DTIC NN B-NP B-Chemical
32 164 165 6503301 ) ) O O
33 166 173 6503301 therapy NN B-NP O
34 174 177 6503301 for IN B-PP O
35 178 186 6503301 melanoma NN B-NP B-Disease
36 187 189 6503301 is VBZ B-VP O
37 190 198 6503301 reported VBN I-VP O
38 198 199 6503301 . . O O

1 200 205 6503301 There EX B-NP O
2 206 209 6503301 was VBD B-VP O
3 210 211 6503301 a DT B-NP O
4 212 221 6503301 fulminant JJ I-NP O
5 222 230 6503301 clinical JJ I-NP O
6 231 237 6503301 course NN I-NP O
7 238 242 6503301 from IN B-PP O
8 243 248 6503301 start NN B-NP O
9 249 251 6503301 of IN B-PP O
10 252 260 6503301 symptoms NNS B-NP O
11 261 266 6503301 until IN B-PP O
12 267 272 6503301 death NN B-NP B-Disease
13 272 273 6503301 . . O O

1 274 276 6503301 At IN B-PP O
2 277 284 6503301 autopsy NN B-NP O
3 285 288 6503301 the DT B-NP O
4 289 294 6503301 liver NN I-NP O
5 295 298 6503301 was VBD B-VP O
6 299 307 6503301 enlarged VBN I-VP O
7 308 311 6503301 and CC O O
8 312 316 6503301 firm NN B-NP O
9 317 321 6503301 with IN B-PP O
10 322 327 6503301 signs NNS B-NP O
11 328 330 6503301 of IN B-PP O
12 331 337 6503301 venous JJ B-NP B-Disease
13 338 348 6503301 congestion NN I-NP I-Disease
14 348 349 6503301 . . O O

1 350 355 6503301 Small JJ B-NP O
2 355 356 6503301 - HYPH I-NP O
3 357 360 6503301 and CC I-NP O
4 361 367 6503301 medium NN I-NP O
5 367 368 6503301 - HYPH B-VP O
6 368 373 6503301 sized VBN B-NP O
7 374 381 6503301 hepatic JJ I-NP O
8 382 387 6503301 veins NNS I-NP O
9 388 392 6503301 were VBD B-VP O
10 393 400 6503301 blocked VBN I-VP O
11 401 403 6503301 by IN B-PP O
12 404 414 6503301 thrombosis NN B-NP B-Disease
13 414 415 6503301 . . O O

1 416 428 6503301 Eosinophilic JJ B-NP O
2 429 442 6503301 infiltrations NNS I-NP O
3 443 447 6503301 were VBD B-VP O
4 448 453 6503301 found VBN I-VP O
5 454 460 6503301 around IN B-PP O
6 461 464 6503301 the DT B-NP O
7 465 472 6503301 vessels NNS I-NP O
8 472 473 6503301 . . O O

1 474 483 6503301 Published VBN B-NP O
2 484 489 6503301 cases NNS I-NP O
3 490 494 6503301 from IN B-PP O
4 495 498 6503301 the DT B-NP O
5 499 509 6503301 literature NN I-NP O
6 510 513 6503301 are VBP B-VP O
7 514 522 6503301 reviewed VBN I-VP O
8 523 526 6503301 and CC O O
9 527 536 6503301 pertinent JJ B-NP O
10 537 545 6503301 features NNS I-NP O
11 546 555 6503301 discussed VBN B-VP O
12 555 556 6503301 . . O O

1 0 0 3412544 -DOCSTART- -X- -X- O

1 0 4 3412544 Does NNP B-NP O
2 5 16 3412544 paracetamol NN I-NP B-Chemical
3 17 22 3412544 cause VBP B-VP O
4 23 33 3412544 urothelial JJ B-NP B-Disease
5 34 40 3412544 cancer NN I-NP I-Disease
6 41 43 3412544 or CC O O
7 44 49 3412544 renal JJ B-NP B-Disease
8 50 59 3412544 papillary JJ I-NP I-Disease
9 60 68 3412544 necrosis NN I-NP I-Disease
10 68 69 3412544 ? . O O
11 70 73 3412544 The DT B-NP O
12 74 78 3412544 risk NN I-NP O
13 79 81 3412544 of IN B-PP O
14 82 92 3412544 developing VBG B-VP O
15 93 98 3412544 renal JJ B-NP B-Disease
16 99 108 3412544 papillary JJ I-NP I-Disease
17 109 117 3412544 necrosis NN I-NP I-Disease
18 118 120 3412544 or CC I-NP O
19 121 127 3412544 cancer NN I-NP B-Disease
20 128 130 3412544 of IN B-PP I-Disease
21 131 134 3412544 the DT B-NP I-Disease
22 135 140 3412544 renal JJ I-NP I-Disease
23 141 147 3412544 pelvis NN I-NP I-Disease
24 147 148 3412544 , , I-NP I-Disease
25 149 155 3412544 ureter NN I-NP I-Disease
26 156 158 3412544 or CC I-NP I-Disease
27 159 166 3412544 bladder NN I-NP I-Disease
28 167 177 3412544 associated VBN B-VP O
29 178 182 3412544 with IN B-PP O
30 183 194 3412544 consumption NN B-NP O
31 195 197 3412544 of IN B-PP O
32 198 204 3412544 either CC O O
33 205 215 3412544 phenacetin NN B-NP B-Chemical
34 216 218 3412544 or CC I-NP O
35 219 230 3412544 paracetamol NN I-NP B-Chemical
36 231 234 3412544 was VBD B-VP O
37 235 245 3412544 calculated VBN I-VP O
38 246 250 3412544 from IN B-PP O
39 251 255 3412544 data NNS B-NP O
40 256 264 3412544 acquired VBN B-VP O
41 265 267 3412544 by IN B-PP O
42 268 281 3412544 questionnaire NN B-NP O
43 282 286 3412544 from IN B-PP O
44 287 290 3412544 381 CD B-NP O
45 291 296 3412544 cases NNS I-NP O
46 297 300 3412544 and CC O O
47 301 304 3412544 808 CD B-NP O
48 305 313 3412544 controls NNS I-NP O
49 313 314 3412544 . . O O

1 315 318 3412544 The DT B-NP O
2 319 323 3412544 risk NN I-NP O
3 324 326 3412544 of IN B-PP O
4 327 332 3412544 renal JJ B-NP B-Disease
5 333 342 3412544 papillary JJ I-NP I-Disease
6 343 351 3412544 necrosis NN I-NP I-Disease
7 352 355 3412544 was VBD B-VP O
8 356 365 3412544 increased VBN I-VP O
9 366 372 3412544 nearly RB B-NP O
10 373 375 3412544 20 CD I-NP O
11 375 376 3412544 - HYPH B-VP O
12 376 380 3412544 fold RB B-ADVP O
13 381 383 3412544 by IN B-PP O
14 384 395 3412544 consumption NN B-NP O
15 396 398 3412544 of IN B-PP O
16 399 409 3412544 phenacetin NN B-NP B-Chemical
17 409 410 3412544 , , O O
18 411 416 3412544 which WDT B-NP O
19 417 421 3412544 also RB B-ADVP O
20 422 431 3412544 increased VBD B-VP O
21 432 435 3412544 the DT B-NP O
22 436 440 3412544 risk NN I-NP O
23 441 444 3412544 for IN B-PP O
24 445 451 3412544 cancer NN B-NP B-Disease
25 452 454 3412544 of IN B-PP I-Disease
26 455 458 3412544 the DT B-NP I-Disease
27 459 464 3412544 renal JJ I-NP I-Disease
28 465 471 3412544 pelvis NN I-NP I-Disease
29 472 475 3412544 and CC I-NP I-Disease
30 476 483 3412544 bladder NN I-NP I-Disease
31 484 487 3412544 but CC B-PP O
32 488 491 3412544 not RB B-PP O
33 492 495 3412544 for IN I-PP O
34 496 504 3412544 ureteric JJ B-NP B-Disease
35 505 511 3412544 cancer NN I-NP I-Disease
36 511 512 3412544 . . O O

1 513 515 3412544 By IN B-PP O
2 516 524 3412544 contrast NN B-NP O
3 524 525 3412544 , , O O
4 526 528 3412544 we PRP B-NP O
5 529 533 3412544 were VBD B-VP O
6 534 540 3412544 unable JJ B-ADJP O
7 541 543 3412544 to TO B-VP O
8 544 556 3412544 substantiate VB I-VP O
9 557 559 3412544 an DT B-NP O
10 560 569 3412544 increased VBN I-NP O
11 570 574 3412544 risk NN I-NP O
12 575 579 3412544 from IN B-PP O
13 580 591 3412544 paracetamol NN B-NP B-Chemical
14 592 603 3412544 consumption NN I-NP O
15 604 607 3412544 for IN B-PP O
16 608 613 3412544 renal JJ B-NP B-Disease
17 614 623 3412544 papillary JJ I-NP I-Disease
18 624 632 3412544 necrosis NN I-NP I-Disease
19 633 635 3412544 or CC O O
20 636 639 3412544 any DT B-NP O
21 640 642 3412544 of IN B-PP O
22 643 648 3412544 these DT B-NP O
23 649 656 3412544 cancers NNS I-NP B-Disease
24 657 665 3412544 although IN B-SBAR O
25 666 671 3412544 there EX B-NP O
26 672 675 3412544 was VBD B-VP O
27 676 677 3412544 a DT B-NP O
28 678 688 3412544 suggestion NN I-NP O
29 689 691 3412544 of IN B-PP O
30 692 694 3412544 an DT B-NP O
31 695 706 3412544 association NN I-NP O
32 707 711 3412544 with IN B-PP O
33 712 718 3412544 cancer NN B-NP B-Disease
34 719 721 3412544 of IN B-PP I-Disease
35 722 725 3412544 the DT B-NP I-Disease
36 726 732 3412544 ureter NN I-NP I-Disease
37 732 733 3412544 . . O O

1 0 0 1527456 -DOCSTART- -X- -X- O

1 0 9 1527456 Treatment NN B-NP O
2 10 12 1527456 of IN B-PP O
3 13 21 1527456 tinnitus NN B-NP B-Disease
4 22 24 1527456 by IN B-PP O
5 25 38 1527456 intratympanic JJ B-NP O
6 39 51 1527456 instillation NN I-NP O
7 52 54 1527456 of IN B-PP O
8 55 65 1527456 lignocaine NN B-NP B-Chemical
9 66 67 1527456 ( ( O O
10 67 76 1527456 lidocaine NN B-NP B-Chemical
11 76 77 1527456 ) ) O O
12 78 79 1527456 2 CD B-NP O
13 80 83 1527456 per IN B-PP O
14 84 88 1527456 cent NN B-NP O
15 89 96 1527456 through IN B-PP O
16 97 108 1527456 ventilation NN B-NP O
17 109 114 1527456 tubes NNS I-NP O
18 114 115 1527456 . . O O
19 116 126 1527456 Idiopathic JJ B-NP B-Disease
20 127 137 1527456 subjective JJ I-NP I-Disease
21 138 146 1527456 tinnitus NN I-NP I-Disease
22 147 148 1527456 ( ( O O
23 148 151 1527456 IST NN B-NP B-Disease
24 151 152 1527456 ) ) O O
25 153 155 1527456 is VBZ B-VP O
26 156 159 1527456 one CD B-NP O
27 160 162 1527456 of IN B-PP O
28 163 166 1527456 the DT B-NP O
29 167 171 1527456 most RBS I-NP O
30 172 179 1527456 obscure JJ I-NP O
31 180 190 1527456 otological JJ I-NP O
32 191 202 1527456 pathologies NNS I-NP O
33 202 203 1527456 . . O O

1 204 208 1527456 This DT B-NP O
2 209 214 1527456 paper NN I-NP O
3 215 223 1527456 presents VBZ B-VP O
4 224 227 1527456 the DT B-NP O
5 228 235 1527456 results NNS I-NP O
6 236 238 1527456 of IN B-PP O
7 239 247 1527456 treating VBG B-VP O
8 248 251 1527456 IST NN B-NP B-Disease
9 252 254 1527456 by IN B-PP O
10 255 268 1527456 intratympanic JJ B-NP O
11 269 281 1527456 instillation NN I-NP O
12 282 284 1527456 of IN B-PP O
13 285 295 1527456 lignocaine NN B-NP B-Chemical
14 296 297 1527456 ( ( O O
15 297 306 1527456 lidocaine NN B-NP B-Chemical
16 306 307 1527456 ) ) O O
17 308 309 1527456 2 CD B-NP O
18 310 313 1527456 per IN B-PP O
19 314 318 1527456 cent NN B-NP O
20 319 326 1527456 through IN B-PP O
21 327 328 1527456 a DT B-NP O
22 329 336 1527456 grommet NN I-NP O
23 336 337 1527456 , , O O
24 338 341 1527456 for IN B-PP O
25 342 346 1527456 five CD B-NP O
26 347 353 1527456 weekly JJ I-NP O
27 354 361 1527456 courses NNS I-NP O
28 361 362 1527456 . . O O

1 363 368 1527456 Fifty CD B-NP O
2 368 369 1527456 - HYPH I-NP O
3 369 372 1527456 two CD B-NP O
4 373 381 1527456 patients NNS I-NP O
5 382 391 1527456 suffering VBG B-VP O
6 392 396 1527456 from IN B-PP O
7 397 408 1527456 intractable JJ B-NP O
8 409 417 1527456 tinnitus NN I-NP B-Disease
9 418 425 1527456 entered VBD B-VP O
10 426 430 1527456 this DT B-NP O
11 431 442 1527456 therapeutic JJ I-NP O
12 443 448 1527456 trial NN I-NP O
13 448 449 1527456 , , O O
14 450 453 1527456 but CC O O
15 454 458 1527456 only RB B-NP O
16 459 463 1527456 nine CD I-NP O
17 464 472 1527456 finished VBD B-VP O
18 473 476 1527456 all DT B-NP O
19 477 481 1527456 five CD I-NP O
20 482 489 1527456 courses NNS I-NP O
21 489 490 1527456 . . O O

1 491 493 1527456 In IN B-PP O
2 494 497 1527456 one CD B-NP O
3 498 505 1527456 patient NN I-NP O
4 505 506 1527456 , , O O
5 507 510 1527456 the DT B-NP O
6 511 519 1527456 tinnitus NN I-NP B-Disease
7 520 523 1527456 was VBD B-VP O
8 524 530 1527456 almost RB I-VP O
9 531 541 1527456 completely RB I-VP O
10 542 551 1527456 abolished VBN I-VP O
11 551 552 1527456 , , O O
12 553 556 1527456 but CC O O
13 557 559 1527456 in IN B-PP O
14 560 563 1527456 all PDT B-NP O
15 564 567 1527456 the DT I-NP O
16 568 572 1527456 nine CD I-NP O
17 573 581 1527456 patients NNS I-NP O
18 582 585 1527456 the DT B-NP O
19 586 599 1527456 decompensated VBN I-NP O
20 600 608 1527456 tinnitus NN I-NP B-Disease
21 609 616 1527456 changed VBD B-VP O
22 617 619 1527456 to TO B-PP O
23 620 621 1527456 a DT B-NP O
24 622 633 1527456 compensated VBN I-NP O
25 634 637 1527456 one NN I-NP O
26 637 638 1527456 . . O O

1 639 641 1527456 We PRP B-NP O
2 642 649 1527456 suggest VBP B-VP O
3 650 654 1527456 this DT B-NP O
4 655 659 1527456 mode NN I-NP O
5 660 662 1527456 of IN B-PP O
6 663 672 1527456 treatment NN B-NP O
7 673 676 1527456 for IN B-PP O
8 677 685 1527456 patients NNS B-NP O
9 686 690 1527456 that WDT B-NP O
10 691 695 1527456 were VBD B-VP O
11 696 706 1527456 previously RB I-VP O
12 707 714 1527456 treated VBN I-VP O
13 715 717 1527456 by IN B-PP O
14 718 723 1527456 drugs NNS B-NP O
15 723 724 1527456 , , O O
16 725 736 1527456 acupuncture NN B-NP O
17 737 740 1527456 and CC I-NP O
18 741 752 1527456 biofeedback NN I-NP O
19 752 753 1527456 , , O O
20 754 758 1527456 with IN B-PP O
21 759 772 1527456 disappointing JJ B-NP O
22 773 780 1527456 results NNS I-NP O
23 780 781 1527456 . . O O

1 782 790 1527456 Patients NNS B-NP O
2 791 797 1527456 should MD B-VP O
3 798 800 1527456 be VB I-VP O
4 801 807 1527456 warned VBN I-VP O
5 808 813 1527456 about IN B-PP O
6 814 817 1527456 the DT B-NP O
7 818 822 1527456 side NN I-NP O
8 823 830 1527456 effects NNS I-NP O
9 831 833 1527456 of IN B-PP O
10 834 841 1527456 vertigo NN B-NP B-Disease
11 842 845 1527456 and CC I-NP O
12 846 854 1527456 vomiting NN I-NP B-Disease
13 854 855 1527456 , , O O
14 856 861 1527456 which WDT B-NP O
15 862 870 1527456 subsides VBZ B-VP O
16 871 880 1527456 gradually RB B-ADVP O
17 881 885 1527456 with IN B-PP O
18 886 891 1527456 every DT B-NP O
19 892 895 1527456 new JJ I-NP O
20 896 908 1527456 instillation NN I-NP O
21 908 909 1527456 , , O O
22 910 913 1527456 and CC O O
23 914 918 1527456 that IN B-SBAR O
24 919 922 1527456 the DT B-NP O
25 923 931 1527456 tinnitus NN I-NP B-Disease
26 932 935 1527456 may MD B-VP O
27 936 939 1527456 not RB I-VP O
28 940 949 1527456 disappear VB I-VP O
29 950 953 1527456 but CC O O
30 954 958 1527456 will MD B-VP O
31 959 961 1527456 be VB I-VP O
32 962 972 1527456 alleviated VBN I-VP O
33 972 973 1527456 , , O O
34 974 982 1527456 enabling VBG B-VP O
35 983 987 1527456 them PRP B-NP O
36 988 990 1527456 to TO B-VP O
37 991 995 1527456 cope VB I-VP O
38 996 1000 1527456 more RBR B-ADVP O
39 1001 1007 1527456 easily RB I-ADVP O
40 1008 1012 1527456 with IN B-PP O
41 1013 1016 1527456 the DT B-NP O
42 1017 1024 1527456 disease NN I-NP O
43 1025 1028 1527456 and CC O O
44 1029 1033 1527456 lead VBP B-VP O
45 1034 1035 1527456 a DT B-NP O
46 1036 1040 1527456 more RBR I-NP O
47 1041 1047 1527456 normal JJ I-NP O
48 1048 1052 1527456 life NN I-NP O
49 1052 1053 1527456 . . O O

1 0 0 2312209 -DOCSTART- -X- -X- O

1 0 10 2312209 Myocardial JJ B-NP B-Disease
2 11 21 2312209 infarction NN I-NP I-Disease
3 22 31 2312209 following VBG B-PP O
4 32 42 2312209 sublingual JJ B-NP O
5 43 57 2312209 administration NN I-NP O
6 58 60 2312209 of IN B-PP O
7 61 71 2312209 isosorbide NN B-NP B-Chemical
8 72 81 2312209 dinitrate NN I-NP I-Chemical
9 81 82 2312209 . . O O
10 83 84 2312209 A DT B-NP O
11 85 87 2312209 78 CD I-NP O
12 87 88 2312209 - HYPH I-NP O
13 88 92 2312209 year NN I-NP O
14 92 93 2312209 - HYPH B-VP O
15 93 96 2312209 old JJ B-ADJP O
16 97 101 2312209 with IN B-PP O
17 102 108 2312209 healed VBN B-NP O
18 109 115 2312209 septal JJ I-NP O
19 116 124 2312209 necrosis NN I-NP B-Disease
20 125 133 2312209 suffered VBD B-VP O
21 134 135 2312209 a DT B-NP O
22 136 145 2312209 recurrent JJ I-NP O
23 146 156 2312209 myocardial JJ I-NP B-Disease
24 157 167 2312209 infarction NN I-NP I-Disease
25 168 170 2312209 of IN B-PP O
26 171 174 2312209 the DT B-NP O
27 175 183 2312209 anterior JJ I-NP O
28 184 188 2312209 wall NN I-NP O
29 189 198 2312209 following VBG B-PP O
30 199 202 2312209 the DT B-NP O
31 203 217 2312209 administration NN I-NP O
32 218 220 2312209 of IN B-PP O
33 221 231 2312209 isosorbide NN B-NP B-Chemical
34 232 241 2312209 dinitrate NN I-NP I-Chemical
35 242 243 2312209 5 CD I-NP O
36 244 246 2312209 mg NN I-NP O
37 247 259 2312209 sublingually RB B-ADVP O
38 259 260 2312209 . . O O

1 261 266 2312209 After IN B-PP O
2 267 276 2312209 detailing VBG B-VP O
3 277 280 2312209 the DT B-NP O
4 281 287 2312209 course NN I-NP O
5 288 290 2312209 of IN B-PP O
6 291 297 2312209 events NNS B-NP O
7 297 298 2312209 , , O O
8 299 301 2312209 we PRP B-NP O
9 302 309 2312209 discuss VBP B-VP O
10 310 313 2312209 the DT B-NP O
11 314 318 2312209 role NN I-NP O
12 319 321 2312209 of IN B-PP O
13 322 333 2312209 paradoxical JJ B-NP O
14 334 342 2312209 coronary JJ I-NP O
15 343 348 2312209 spasm NN I-NP B-Disease
16 349 352 2312209 and CC I-NP O
17 353 364 2312209 hypotension NN I-NP B-Disease
18 364 365 2312209 - HYPH O O
19 365 373 2312209 mediated VBN B-VP O
20 374 384 2312209 myocardial JJ B-NP B-Disease
21 385 393 2312209 ischemia NN I-NP I-Disease
22 394 403 2312209 occurring VBG B-VP O
23 404 414 2312209 downstream RB B-ADVP O
24 415 417 2312209 to TO B-PP O
25 418 429 2312209 significant JJ B-NP O
26 430 438 2312209 coronary JJ I-NP B-Disease
27 439 447 2312209 arterial JJ I-NP I-Disease
28 448 456 2312209 stenosis NN I-NP I-Disease
29 457 459 2312209 in IN B-PP O
30 460 463 2312209 the DT B-NP O
31 464 479 2312209 pathophysiology NN I-NP O
32 480 482 2312209 of IN B-PP O
33 483 488 2312209 acute JJ B-NP B-Disease
34 489 497 2312209 coronary JJ I-NP I-Disease
35 498 511 2312209 insufficiency NN I-NP I-Disease
36 511 512 2312209 . . O O

1 0 0 11007689 -DOCSTART- -X- -X- O

1 0 12 11007689 Cyclosporine NN B-NP B-Chemical
2 13 16 11007689 and CC I-NP O
3 17 27 11007689 tacrolimus NN I-NP B-Chemical
4 27 28 11007689 - HYPH O O
5 28 38 11007689 associated VBN B-VP O
6 39 49 11007689 thrombotic JJ B-NP B-Disease
7 50 65 11007689 microangiopathy NN I-NP I-Disease
8 65 66 11007689 . . O O
9 67 70 11007689 The DT B-NP O
10 71 82 11007689 development NN I-NP O
11 83 85 11007689 of IN B-PP O
12 86 96 11007689 thrombotic JJ B-NP B-Disease
13 97 112 11007689 microangiopathy NN I-NP I-Disease
14 113 114 11007689 ( ( O O
15 114 117 11007689 TMA NN B-NP B-Disease
16 117 118 11007689 ) ) O O
17 119 129 11007689 associated VBN B-VP O
18 130 134 11007689 with IN B-PP O
19 135 138 11007689 the DT B-NP O
20 139 142 11007689 use NN I-NP O
21 143 145 11007689 of IN B-PP O
22 146 158 11007689 cyclosporine NN B-NP B-Chemical
23 159 162 11007689 has VBZ B-VP O
24 163 167 11007689 been VBN I-VP O
25 168 172 11007689 well RB I-VP O
26 173 183 11007689 documented VBN I-VP O
27 183 184 11007689 . . O O

1 185 195 11007689 Treatments NNS B-NP O
2 196 200 11007689 have VBP B-VP O
3 201 209 11007689 included VBN I-VP O
4 210 225 11007689 discontinuation NN B-NP O
5 226 228 11007689 or CC I-NP O
6 229 238 11007689 reduction NN I-NP O
7 239 241 11007689 of IN B-PP O
8 242 254 11007689 cyclosporine NN B-NP B-Chemical
9 255 259 11007689 dose NN I-NP O
10 260 264 11007689 with IN B-PP O
11 265 267 11007689 or CC B-PP O
12 268 275 11007689 without IN B-PP O
13 276 286 11007689 concurrent JJ B-NP O
14 287 293 11007689 plasma NN I-NP O
15 294 302 11007689 exchange NN I-NP O
16 302 303 11007689 , , O O
17 304 310 11007689 plasma NN B-NP O
18 311 319 11007689 infusion NN I-NP O
19 319 320 11007689 , , O O
20 321 336 11007689 anticoagulation NN B-NP O
21 336 337 11007689 , , O O
22 338 341 11007689 and CC O O
23 342 353 11007689 intravenous JJ B-NP O
24 354 368 11007689 immunoglobulin NN I-NP O
25 369 370 11007689 G NN I-NP O
26 371 379 11007689 infusion NN I-NP O
27 379 380 11007689 . . O O

1 381 388 11007689 However RB B-ADVP O
2 388 389 11007689 , , O O
3 390 393 11007689 for IN B-PP O
4 394 404 11007689 recipients NNS B-NP O
5 405 407 11007689 of IN B-PP O
6 408 413 11007689 organ NN B-NP O
7 414 429 11007689 transplantation NN I-NP O
8 429 430 11007689 , , O O
9 431 439 11007689 removing VBG B-VP O
10 440 443 11007689 the DT B-NP O
11 444 452 11007689 inciting VBG I-NP O
12 453 458 11007689 agent NN I-NP O
13 459 461 11007689 is VBZ B-VP O
14 462 465 11007689 not RB O O
15 466 473 11007689 without IN B-PP O
16 474 477 11007689 the DT B-NP O
17 478 487 11007689 attendant JJ I-NP O
18 488 492 11007689 risk NN I-NP O
19 493 495 11007689 of IN B-PP O
20 496 509 11007689 precipitating VBG B-VP O
21 510 515 11007689 acute JJ B-NP O
22 516 525 11007689 rejection NN I-NP O
23 526 529 11007689 and CC I-NP O
24 530 535 11007689 graft NN I-NP O
25 536 540 11007689 loss NN I-NP O
26 540 541 11007689 . . O O

1 542 545 11007689 The DT B-NP O
2 546 550 11007689 last JJ I-NP O
3 551 557 11007689 decade NN I-NP O
4 558 561 11007689 has VBZ B-VP O
5 562 566 11007689 seen VBN I-VP O
6 567 570 11007689 the DT B-NP O
7 571 580 11007689 emergence NN I-NP O
8 581 583 11007689 of IN B-PP O
9 584 594 11007689 tacrolimus NN B-NP B-Chemical
10 595 597 11007689 as IN B-PP O
11 598 599 11007689 a DT B-NP O
12 600 606 11007689 potent JJ I-NP O
13 607 624 11007689 immunosuppressive JJ I-NP O
14 625 630 11007689 agent NN I-NP O
15 631 635 11007689 with IN B-PP O
16 636 646 11007689 mechanisms NNS B-NP O
17 647 649 11007689 of IN B-PP O
18 650 656 11007689 action NN B-NP O
19 657 666 11007689 virtually RB B-ADJP O
20 667 676 11007689 identical JJ I-ADJP O
21 677 679 11007689 to TO B-PP O
22 680 685 11007689 those DT B-NP O
23 686 688 11007689 of IN B-PP O
24 689 701 11007689 cyclosporine NN B-NP B-Chemical
25 701 702 11007689 . . O O

1 703 705 11007689 As IN B-PP O
2 706 707 11007689 a DT B-NP O
3 708 714 11007689 result NN I-NP O
4 714 715 11007689 , , O O
5 716 725 11007689 switching VBG B-VP O
6 726 728 11007689 to TO B-PP O
7 729 739 11007689 tacrolimus NN B-NP B-Chemical
8 740 743 11007689 has VBZ B-VP O
9 744 748 11007689 been VBN I-VP O
10 749 757 11007689 reported VBN I-VP O
11 758 760 11007689 to TO I-VP O
12 761 763 11007689 be VB I-VP O
13 764 765 11007689 a DT B-NP O
14 766 772 11007689 viable JJ I-NP O
15 773 784 11007689 therapeutic JJ I-NP O
16 785 791 11007689 option NN I-NP O
17 792 794 11007689 in IN B-PP O
18 795 798 11007689 the DT B-NP O
19 799 806 11007689 setting NN I-NP O
20 807 809 11007689 of IN B-PP O
21 810 822 11007689 cyclosporine NN B-NP B-Chemical
22 822 823 11007689 - HYPH B-NP O
23 823 830 11007689 induced VBN I-NP O
24 831 834 11007689 TMA NN I-NP B-Disease
25 834 835 11007689 . . O O

1 836 840 11007689 With IN B-PP O
2 841 844 11007689 the DT B-NP O
3 845 849 11007689 more RBR I-NP O
4 850 860 11007689 widespread JJ I-NP O
5 861 872 11007689 application NN I-NP O
6 873 875 11007689 of IN B-PP O
7 876 886 11007689 tacrolimus NN B-NP B-Chemical
8 887 889 11007689 in IN B-PP O
9 890 895 11007689 organ NN B-NP O
10 896 911 11007689 transplantation NN I-NP O
11 911 912 11007689 , , O O
12 913 923 11007689 tacrolimus NN B-NP B-Chemical
13 923 924 11007689 - HYPH B-VP O
14 924 934 11007689 associated VBN B-NP O
15 935 938 11007689 TMA NN I-NP B-Disease
16 939 942 11007689 has VBZ B-VP O
17 943 947 11007689 also RB I-VP O
18 948 952 11007689 been VBN I-VP O
19 953 963 11007689 recognized VBN I-VP O
20 963 964 11007689 . . O O

1 965 972 11007689 However RB B-ADVP O
2 972 973 11007689 , , O O
3 974 984 11007689 literature NN B-NP O
4 985 994 11007689 regarding VBG B-VP O
5 995 998 11007689 the DT B-NP O
6 999 1008 11007689 incidence NN I-NP O
7 1009 1011 11007689 of IN B-PP O
8 1012 1015 11007689 the DT B-NP O
9 1016 1026 11007689 recurrence NN I-NP O
10 1027 1029 11007689 of IN B-PP O
11 1030 1033 11007689 TMA NN B-NP B-Disease
12 1034 1036 11007689 in IN B-PP O
13 1037 1045 11007689 patients NNS B-NP O
14 1046 1053 11007689 exposed VBN B-VP O
15 1054 1066 11007689 sequentially RB B-ADVP O
16 1067 1069 11007689 to TO B-PP O
17 1070 1082 11007689 cyclosporine NN B-NP B-Chemical
18 1083 1086 11007689 and CC I-NP O
19 1087 1097 11007689 tacrolimus NN I-NP B-Chemical
20 1098 1100 11007689 is VBZ B-VP O
21 1101 1108 11007689 limited VBN B-ADJP O
22 1108 1109 11007689 . . O O

1 1110 1112 11007689 We PRP B-NP O
2 1113 1119 11007689 report VBP B-VP O
3 1120 1121 11007689 a DT B-NP O
4 1122 1126 11007689 case NN I-NP O
5 1127 1129 11007689 of IN B-PP O
6 1130 1131 11007689 a DT B-NP O
7 1132 1138 11007689 living VBG I-NP O
8 1139 1144 11007689 donor NN I-NP O
9 1145 1150 11007689 renal JJ I-NP O
10 1151 1161 11007689 transplant NN I-NP O
11 1162 1171 11007689 recipient NN I-NP O
12 1172 1175 11007689 who WP B-NP O
13 1176 1185 11007689 developed VBD B-VP O
14 1186 1198 11007689 cyclosporine NN B-NP B-Chemical
15 1198 1199 11007689 - HYPH B-NP O
16 1199 1206 11007689 induced VBN I-NP O
17 1207 1210 11007689 TMA NN I-NP B-Disease
18 1211 1215 11007689 that WDT B-NP O
19 1216 1225 11007689 responded VBD B-VP O
20 1226 1228 11007689 to TO B-PP O
21 1229 1232 11007689 the DT B-NP O
22 1233 1243 11007689 withdrawal NN I-NP O
23 1244 1246 11007689 of IN B-PP O
24 1247 1259 11007689 cyclosporine NN B-NP B-Chemical
25 1260 1262 11007689 in IN B-PP O
26 1263 1274 11007689 conjunction NN B-NP O
27 1275 1279 11007689 with IN B-PP O
28 1280 1294 11007689 plasmapheresis NN B-NP O
29 1295 1298 11007689 and CC O O
30 1299 1304 11007689 fresh JJ B-NP O
31 1305 1311 11007689 frozen JJ I-NP O
32 1312 1318 11007689 plasma NN I-NP O
33 1319 1330 11007689 replacement NN I-NP O
34 1331 1338 11007689 therapy NN I-NP O
35 1338 1339 11007689 . . O O

1 1340 1352 11007689 Introduction NN B-NP O
2 1353 1355 11007689 of IN B-PP O
3 1356 1366 11007689 tacrolimus NN B-NP B-Chemical
4 1367 1369 11007689 as IN B-PP O
5 1370 1372 11007689 an DT B-NP O
6 1373 1384 11007689 alternative JJ I-NP O
7 1385 1402 11007689 immunosuppressive JJ I-NP O
8 1403 1408 11007689 agent NN I-NP O
9 1409 1417 11007689 resulted VBD B-VP O
10 1418 1420 11007689 in IN B-PP O
11 1421 1424 11007689 the DT B-NP O
12 1425 1435 11007689 recurrence NN I-NP O
13 1436 1438 11007689 of IN B-PP O
14 1439 1442 11007689 TMA NN B-NP B-Disease
15 1443 1446 11007689 and CC O O
16 1447 1450 11007689 the DT B-NP O
17 1451 1461 11007689 subsequent JJ I-NP O
18 1462 1466 11007689 loss NN I-NP O
19 1467 1469 11007689 of IN B-PP O
20 1470 1473 11007689 the DT B-NP O
21 1474 1479 11007689 renal JJ I-NP O
22 1480 1489 11007689 allograft NN I-NP O
23 1489 1490 11007689 . . O O

1 1491 1499 11007689 Patients NNS B-NP O
2 1500 1503 11007689 who WP B-NP O
3 1504 1507 11007689 are VBP B-VP O
4 1508 1516 11007689 switched VBN I-VP O
5 1517 1521 11007689 from IN B-PP O
6 1522 1534 11007689 cyclosporine NN B-NP B-Chemical
7 1535 1537 11007689 to TO B-PP O
8 1538 1548 11007689 tacrolimus NN B-NP B-Chemical
9 1549 1551 11007689 or CC I-NP O
10 1552 1556 11007689 vice NN I-NP O
11 1557 1562 11007689 versa NN I-NP O
12 1563 1569 11007689 should MD B-VP O
13 1570 1572 11007689 be VB I-VP O
14 1573 1580 11007689 closely RB I-VP O
15 1581 1590 11007689 monitored VBN I-VP O
16 1591 1594 11007689 for IN B-PP O
17 1595 1598 11007689 the DT B-NP O
18 1599 1604 11007689 signs NNS I-NP O
19 1605 1608 11007689 and CC I-NP O
20 1609 1617 11007689 symptoms NNS I-NP O
21 1618 1620 11007689 of IN B-PP O
22 1621 1630 11007689 recurrent JJ B-NP O
23 1631 1634 11007689 TMA NN I-NP B-Disease
24 1634 1635 11007689 . . O O

1 0 0 18752389 -DOCSTART- -X- -X- O

1 0 11 18752389 Simvastatin NN B-NP B-Chemical
2 11 12 18752389 - HYPH B-NP I-Chemical
3 12 21 18752389 ezetimibe NN I-NP I-Chemical
4 21 22 18752389 - HYPH O O
5 22 29 18752389 induced VBN B-NP O
6 30 37 18752389 hepatic JJ I-NP B-Disease
7 38 45 18752389 failure NN I-NP I-Disease
8 46 59 18752389 necessitating VBG B-VP O
9 60 65 18752389 liver NN B-NP O
10 66 81 18752389 transplantation NN I-NP O
11 81 82 18752389 . . O O
12 83 91 18752389 Abstract NNP B-NP O
13 92 97 18752389 Serum NNP I-NP O
14 98 114 18752389 aminotransferase NN I-NP O
15 115 125 18752389 elevations NNS I-NP O
16 126 129 18752389 are VBP B-VP O
17 130 131 18752389 a DT B-NP O
18 132 140 18752389 commonly RB I-NP O
19 141 146 18752389 known VBN I-NP O
20 147 154 18752389 adverse JJ I-NP O
21 155 161 18752389 effect NN I-NP O
22 162 164 18752389 of IN B-PP O
23 165 166 18752389 3 CD B-NP O
24 166 167 18752389 - HYPH I-NP O
25 167 174 18752389 hydroxy NN I-NP O
26 174 175 18752389 - HYPH B-NP O
27 175 176 18752389 3 CD I-NP O
28 176 177 18752389 - HYPH I-NP O
29 177 191 18752389 methylglutaryl NN I-NP O
30 192 200 18752389 coenzyme NN I-NP O
31 201 202 18752389 A NN I-NP O
32 203 212 18752389 reductase NN I-NP O
33 213 222 18752389 inhibitor NN I-NP O
34 223 224 18752389 ( ( O O
35 224 230 18752389 statin NN B-NP B-Chemical
36 230 231 18752389 ) ) O O
37 232 239 18752389 therapy NN B-NP O
38 239 240 18752389 . . O O

1 241 248 18752389 However RB B-ADVP O
2 248 249 18752389 , , O O
3 250 261 18752389 hepatotoxic JJ B-NP B-Disease
4 262 268 18752389 events NNS I-NP O
5 269 273 18752389 have VBP B-VP O
6 274 277 18752389 not RB I-VP O
7 278 282 18752389 been VBN I-VP O
8 283 289 18752389 widely RB I-VP O
9 290 299 18752389 published VBN I-VP O
10 300 304 18752389 with IN B-PP O
11 305 314 18752389 ezetimibe NN B-NP B-Chemical
12 315 317 18752389 or CC O O
13 318 321 18752389 the DT B-NP O
14 322 333 18752389 combination NN I-NP O
15 334 339 18752389 agent NN I-NP O
16 340 351 18752389 simvastatin NN I-NP B-Chemical
17 351 352 18752389 - HYPH B-NP I-Chemical
18 352 361 18752389 ezetimibe NN I-NP I-Chemical
19 361 362 18752389 . . O O

1 363 365 18752389 We PRP B-NP O
2 366 374 18752389 describe VBP B-VP O
3 375 376 18752389 a DT B-NP O
4 377 379 18752389 70 CD I-NP O
5 379 380 18752389 - HYPH I-NP O
6 380 384 18752389 year NN I-NP O
7 384 385 18752389 - HYPH O O
8 385 388 18752389 old JJ B-NP O
9 389 397 18752389 Hispanic JJ I-NP O
10 398 403 18752389 woman NN I-NP O
11 404 407 18752389 who WP B-NP O
12 408 417 18752389 developed VBD B-VP O
13 418 427 18752389 fulminant JJ B-NP B-Disease
14 428 435 18752389 hepatic JJ I-NP I-Disease
15 436 443 18752389 failure NN I-NP I-Disease
16 444 457 18752389 necessitating VBG B-VP O
17 458 463 18752389 liver NN B-NP O
18 464 479 18752389 transplantation NN I-NP O
19 480 482 18752389 10 CD B-NP O
20 483 488 18752389 weeks NNS I-NP O
21 489 494 18752389 after IN B-PP O
22 495 505 18752389 conversion NN B-NP O
23 506 510 18752389 from IN B-PP O
24 511 522 18752389 simvastatin NN B-NP B-Chemical
25 523 525 18752389 40 CD I-NP O
26 526 528 18752389 mg NN I-NP O
27 528 529 18752389 / SYM B-NP O
28 529 532 18752389 day NN I-NP O
29 533 535 18752389 to TO B-PP O
30 536 547 18752389 simvastatin NN B-NP B-Chemical
31 548 550 18752389 10 CD I-NP I-Chemical
32 551 553 18752389 mg NN I-NP I-Chemical
33 553 554 18752389 - HYPH O I-Chemical
34 554 563 18752389 ezetimibe NN B-NP I-Chemical
35 564 566 18752389 40 CD I-NP I-Chemical
36 567 569 18752389 mg NN I-NP I-Chemical
37 569 570 18752389 / SYM B-NP O
38 570 573 18752389 day NN I-NP O
39 573 574 18752389 . . O O

1 575 578 18752389 The DT B-NP O
2 579 588 18752389 patient's NNS I-NP O
3 589 594 18752389 lipid NN I-NP O
4 595 600 18752389 panel NN I-NP O
5 601 604 18752389 had VBD B-VP O
6 605 609 18752389 been VBN I-VP O
7 610 620 18752389 maintained VBN I-VP O
8 621 625 18752389 with IN B-PP O
9 626 637 18752389 simvastatin NN B-NP B-Chemical
10 638 641 18752389 for IN B-PP O
11 642 644 18752389 18 CD B-NP O
12 645 651 18752389 months NNS I-NP O
13 652 658 18752389 before IN B-SBAR O
14 659 662 18752389 the DT B-NP O
15 663 673 18752389 conversion NN I-NP O
16 674 681 18752389 without IN B-PP O
17 682 690 18752389 evidence NN B-NP O
18 691 693 18752389 of IN B-PP O
19 694 708 18752389 hepatotoxicity NN B-NP B-Disease
20 708 709 18752389 . . O O

1 710 711 18752389 A DT B-NP O
2 712 719 18752389 routine JJ I-NP O
3 720 730 18752389 laboratory NN I-NP O
4 731 735 18752389 work VB B-VP O
5 735 736 18752389 - HYPH O O
6 736 738 18752389 up RP B-PRT O
7 739 741 18752389 10 CD B-NP O
8 742 747 18752389 weeks NNS I-NP O
9 748 753 18752389 after IN B-SBAR O
10 754 764 18752389 conversion NN B-NP O
11 765 773 18752389 revealed VBD B-VP O
12 774 782 18752389 elevated JJ B-NP O
13 783 788 18752389 serum NN I-NP O
14 789 805 18752389 aminotransferase NN I-NP O
15 806 812 18752389 levels NNS I-NP O
16 812 813 18752389 . . O O

1 814 834 18752389 Simvastatinezetimibe NN B-NP B-Chemical
2 835 838 18752389 and CC I-NP O
3 839 851 18752389 escitalopram NN I-NP B-Chemical
4 852 853 18752389 ( ( O O
5 853 858 18752389 which WDT B-NP O
6 859 862 18752389 she PRP B-NP O
7 863 866 18752389 was VBD B-VP O
8 867 873 18752389 taking VBG I-VP O
9 874 877 18752389 for IN B-PP O
10 878 888 18752389 depression NN B-NP B-Disease
11 888 889 18752389 ) ) O O
12 890 894 18752389 were VBD B-VP O
13 895 907 18752389 discontinued VBN I-VP O
14 907 908 18752389 , , O O
15 909 912 18752389 and CC O O
16 913 918 18752389 other JJ B-NP O
17 919 928 18752389 potential JJ I-NP O
18 929 935 18752389 causes NNS I-NP O
19 936 938 18752389 of IN B-PP O
20 939 953 18752389 hepatotoxicity NN B-NP B-Disease
21 954 958 18752389 were VBD B-VP O
22 959 967 18752389 excluded VBN I-VP O
23 967 968 18752389 . . O O

1 969 970 18752389 A DT B-NP O
2 971 977 18752389 repeat NN I-NP O
3 978 982 18752389 work VB B-VP O
4 982 983 18752389 - HYPH O O
5 983 985 18752389 up RP B-PRT O
6 986 994 18752389 revealed VBD B-VP O
7 995 1002 18752389 further JJ B-NP O
8 1003 1013 18752389 elevations NNS I-NP O
9 1014 1016 18752389 in IN B-PP O
10 1017 1033 18752389 aminotransferase NN B-NP O
11 1034 1040 18752389 levels NNS I-NP O
12 1040 1041 18752389 , , O O
13 1042 1045 18752389 and CC O O
14 1046 1051 18752389 liver NN B-NP O
15 1052 1058 18752389 biopsy NN I-NP O
16 1059 1067 18752389 revealed VBD B-VP O
17 1068 1076 18752389 evidence NN B-NP O
18 1077 1079 18752389 of IN B-PP O
19 1080 1088 18752389 moderate JJ B-NP O
20 1088 1089 18752389 - HYPH I-NP O
21 1089 1091 18752389 to TO B-PP O
22 1091 1092 18752389 - HYPH B-NP O
23 1092 1098 18752389 severe JJ I-NP O
24 1099 1103 18752389 drug NN I-NP B-Disease
25 1104 1112 18752389 toxicity NN I-NP I-Disease
26 1112 1113 18752389 . . O O

1 1114 1117 18752389 She PRP B-NP O
2 1118 1127 18752389 underwent VBD B-VP O
3 1128 1133 18752389 liver NN B-NP O
4 1134 1149 18752389 transplantation NN I-NP O
5 1150 1154 18752389 with IN B-PP O
6 1155 1157 18752389 an DT B-NP O
7 1158 1168 18752389 uneventful JJ I-NP O
8 1169 1182 18752389 postoperative JJ I-NP O
9 1183 1189 18752389 course NN I-NP O
10 1189 1190 18752389 . . O O

1 1191 1194 18752389 Her PRP$ B-NP O
2 1195 1211 18752389 aminotransferase NN I-NP O
3 1212 1218 18752389 levels NNS I-NP O
4 1219 1227 18752389 returned VBD B-VP O
5 1228 1230 18752389 to TO B-PP O
6 1231 1237 18752389 normal JJ B-NP O
7 1238 1240 18752389 by IN B-PP O
8 1241 1254 18752389 postoperative JJ B-NP O
9 1255 1258 18752389 day NN I-NP O
10 1259 1261 18752389 23 CD I-NP O
11 1261 1262 18752389 , , O O
12 1263 1266 18752389 and CC O O
13 1267 1270 18752389 her PRP B-NP O
14 1271 1272 18752389 2 CD I-NP O
15 1272 1273 18752389 - HYPH I-NP O
16 1273 1277 18752389 year NN I-NP O
17 1278 1284 18752389 follow VB B-VP O
18 1284 1285 18752389 - HYPH O O
19 1285 1287 18752389 up RP B-PRT O
20 1288 1294 18752389 showed VBD B-VP O
21 1295 1297 18752389 no DT B-NP O
22 1298 1305 18752389 adverse JJ I-NP O
23 1306 1312 18752389 events NNS I-NP O
24 1312 1313 18752389 . . O O

1 1314 1323 18752389 Ezetimibe NNP B-NP B-Chemical
2 1324 1333 18752389 undergoes VBZ B-VP O
3 1334 1343 18752389 extensive JJ B-NP O
4 1344 1359 18752389 glucuronidation NN I-NP O
5 1360 1362 18752389 by IN B-PP O
6 1363 1370 18752389 uridine NN B-NP B-Chemical
7 1371 1382 18752389 diphosphate NN I-NP I-Chemical
8 1383 1407 18752389 glucoronosyltransferases NNS I-NP O
9 1408 1409 18752389 ( ( O O
10 1409 1412 18752389 UGT NN B-NP O
11 1412 1413 18752389 ) ) O O
12 1414 1416 18752389 in IN B-PP O
13 1417 1420 18752389 the DT B-NP O
14 1421 1430 18752389 intestine NN I-NP O
15 1431 1434 18752389 and CC I-NP O
16 1435 1440 18752389 liver NN I-NP O
17 1441 1444 18752389 and CC O O
18 1445 1448 18752389 may MD B-VP O
19 1449 1453 18752389 have VB I-VP O
20 1454 1463 18752389 inhibited VBN I-VP O
21 1464 1467 18752389 the DT B-NP O
22 1468 1483 18752389 glucuronidation NN I-NP O
23 1484 1486 18752389 of IN B-PP O
24 1487 1498 18752389 simvastatin NN B-NP B-Chemical
25 1499 1506 18752389 hydroxy NN I-NP I-Chemical
26 1507 1511 18752389 acid NN I-NP I-Chemical
27 1511 1512 18752389 , , O O
28 1513 1522 18752389 resulting VBG B-VP O
29 1523 1525 18752389 in IN B-PP O
30 1526 1535 18752389 increased VBN B-NP O
31 1536 1547 18752389 simvastatin NN I-NP B-Chemical
32 1548 1556 18752389 exposure NN I-NP O
33 1557 1560 18752389 and CC O O
34 1561 1571 18752389 subsequent JJ B-NP O
35 1572 1586 18752389 hepatotoxicity NN I-NP B-Disease
36 1586 1587 18752389 . . O O

1 1588 1590 18752389 To TO B-PP O
2 1591 1594 18752389 our PRP$ B-NP O
3 1595 1604 18752389 knowledge NN I-NP O
4 1604 1605 18752389 , , O O
5 1606 1610 18752389 this DT B-NP O
6 1611 1613 18752389 is VBZ B-VP O
7 1614 1617 18752389 the DT B-NP O
8 1618 1623 18752389 first JJ I-NP O
9 1624 1628 18752389 case NN I-NP O
10 1629 1635 18752389 report NN I-NP O
11 1636 1638 18752389 of IN B-PP O
12 1639 1650 18752389 simvastatin NN B-NP B-Chemical
13 1650 1651 18752389 - HYPH B-NP I-Chemical
14 1651 1660 18752389 ezetimibe NN I-NP I-Chemical
15 1660 1661 18752389 - HYPH O O
16 1661 1668 18752389 induced VBN B-NP O
17 1669 1674 18752389 liver NN I-NP B-Disease
18 1675 1682 18752389 failure NN I-NP I-Disease
19 1683 1687 18752389 that WDT B-NP O
20 1688 1696 18752389 resulted VBD B-VP O
21 1697 1699 18752389 in IN B-PP O
22 1700 1705 18752389 liver NN B-NP O
23 1706 1721 18752389 transplantation NN I-NP O
24 1721 1722 18752389 . . O O

1 1723 1725 18752389 We PRP B-NP O
2 1726 1735 18752389 postulate VBP B-VP O
3 1736 1740 18752389 that IN B-SBAR O
4 1741 1744 18752389 the DT B-NP O
5 1745 1754 18752389 mechanism NN I-NP O
6 1755 1757 18752389 of IN B-PP O
7 1758 1761 18752389 the DT B-NP O
8 1762 1782 18752389 simvastatinezetimibe NN I-NP B-Chemical
9 1782 1783 18752389 - HYPH B-NP O
10 1783 1790 18752389 induced VBN I-NP O
11 1791 1805 18752389 hepatotoxicity NN I-NP B-Disease
12 1806 1808 18752389 is VBZ B-VP O
13 1809 1812 18752389 the DT B-NP O
14 1813 1822 18752389 increased VBN I-NP O
15 1823 1834 18752389 simvastatin NN I-NP B-Chemical
16 1835 1843 18752389 exposure NN I-NP O
17 1844 1846 18752389 by IN B-PP O
18 1847 1856 18752389 ezetimibe NN B-NP B-Chemical
19 1857 1867 18752389 inhibition NN I-NP O
20 1868 1870 18752389 of IN B-PP O
21 1871 1874 18752389 UGT NN B-NP O
22 1875 1882 18752389 enzymes NNS I-NP O
23 1882 1883 18752389 . . O O

1 1884 1894 18752389 Clinicians NNS B-NP O
2 1895 1901 18752389 should MD B-VP O
3 1902 1904 18752389 be VB I-VP O
4 1905 1910 18752389 aware JJ B-ADJP O
5 1911 1913 18752389 of IN B-PP O
6 1914 1923 18752389 potential JJ B-NP O
7 1924 1938 18752389 hepatotoxicity NN I-NP B-Disease
8 1939 1943 18752389 with IN B-PP O
9 1944 1955 18752389 simvastatin NN B-NP B-Chemical
10 1955 1956 18752389 - HYPH B-NP I-Chemical
11 1956 1965 18752389 ezetimibe NN I-NP I-Chemical
12 1966 1976 18752389 especially RB B-ADVP O
13 1977 1979 18752389 in IN B-PP O
14 1980 1987 18752389 elderly JJ B-NP O
15 1988 1996 18752389 patients NNS I-NP O
16 1997 2000 18752389 and CC O O
17 2001 2007 18752389 should MD B-VP O
18 2008 2017 18752389 carefully RB I-VP O
19 2018 2025 18752389 monitor VB I-VP O
20 2026 2031 18752389 serum NN B-NP O
21 2032 2048 18752389 aminotransferase NN I-NP O
22 2049 2055 18752389 levels NNS I-NP O
23 2056 2060 18752389 when WRB B-ADVP O
24 2061 2069 18752389 starting VBG B-VP O
25 2070 2077 18752389 therapy NN B-NP O
26 2078 2081 18752389 and CC O O
27 2082 2091 18752389 titrating VBG B-VP O
28 2092 2095 18752389 the DT B-NP O
29 2096 2102 18752389 dosage NN I-NP O
30 2102 2103 18752389 . . O O

1 0 0 20470218 -DOCSTART- -X- -X- O

1 0 7 20470218 Central JJ B-NP B-Disease
2 8 15 20470218 nervous JJ I-NP I-Disease
3 16 22 20470218 system NN I-NP I-Disease
4 23 36 20470218 complications NNS I-NP I-Disease
5 37 43 20470218 during IN B-PP O
6 44 53 20470218 treatment NN B-NP O
7 54 56 20470218 of IN B-PP O
8 57 62 20470218 acute JJ B-NP B-Disease
9 63 76 20470218 lymphoblastic JJ I-NP I-Disease
10 77 85 20470218 leukemia NN I-NP I-Disease
11 86 88 20470218 in IN B-PP O
12 89 90 20470218 a DT B-NP O
13 91 97 20470218 single JJ I-NP O
14 98 107 20470218 pediatric JJ I-NP O
15 108 119 20470218 institution NN I-NP O
16 119 120 20470218 . . O O
17 121 128 20470218 Central JJ B-NP B-Disease
18 129 136 20470218 nervous JJ I-NP I-Disease
19 137 143 20470218 system NN I-NP I-Disease
20 144 145 20470218 ( ( O I-Disease
21 145 148 20470218 CNS NN B-NP I-Disease
22 148 149 20470218 ) ) O I-Disease
23 150 163 20470218 complications NNS B-NP I-Disease
24 164 170 20470218 during IN B-PP O
25 171 180 20470218 treatment NN B-NP O
26 181 183 20470218 of IN B-PP O
27 184 193 20470218 childhood NN B-NP O
28 194 199 20470218 acute JJ I-NP B-Disease
29 200 213 20470218 lymphoblastic JJ I-NP I-Disease
30 214 222 20470218 leukemia NN I-NP I-Disease
31 223 224 20470218 ( ( O O
32 224 227 20470218 ALL NN B-NP B-Disease
33 227 228 20470218 ) ) O O
34 229 235 20470218 remain VBP B-VP O
35 236 237 20470218 a DT B-NP O
36 238 249 20470218 challenging JJ I-NP O
37 250 258 20470218 clinical JJ I-NP O
38 259 266 20470218 problem NN I-NP O
39 266 267 20470218 . . O O

1 268 275 20470218 Outcome DT B-NP O
2 276 287 20470218 improvement NN I-NP O
3 288 292 20470218 with IN B-PP O
4 293 297 20470218 more RBR B-NP O
5 298 307 20470218 intensive JJ I-NP O
6 308 320 20470218 chemotherapy NN I-NP O
7 321 324 20470218 has VBZ B-VP O
8 325 338 20470218 significantly RB I-VP O
9 339 348 20470218 increased VBN I-VP O
10 349 352 20470218 the DT B-NP O
11 353 362 20470218 incidence NN I-NP O
12 363 366 20470218 and CC I-NP O
13 367 375 20470218 severity NN I-NP O
14 376 378 20470218 of IN B-PP O
15 379 386 20470218 adverse JJ B-NP O
16 387 393 20470218 events NNS I-NP O
17 393 394 20470218 . . O O

1 395 399 20470218 This DT B-NP O
2 400 405 20470218 study NN I-NP O
3 406 414 20470218 analyzed VBD B-VP O
4 415 418 20470218 the DT B-NP O
5 419 428 20470218 incidence NN I-NP O
6 429 431 20470218 of IN B-PP O
7 432 444 20470218 neurological JJ B-NP B-Disease
8 445 458 20470218 complications NNS I-NP I-Disease
9 459 465 20470218 during IN B-PP O
10 466 469 20470218 ALL NN B-NP B-Disease
11 470 479 20470218 treatment NN I-NP O
12 480 482 20470218 in IN B-PP O
13 483 484 20470218 a DT B-NP O
14 485 491 20470218 single JJ I-NP O
15 492 501 20470218 pediatric JJ I-NP O
16 502 513 20470218 institution NN I-NP O
17 513 514 20470218 , , O O
18 515 523 20470218 focusing VBG B-VP O
19 524 526 20470218 on IN B-PP O
20 527 535 20470218 clinical JJ B-NP O
21 535 536 20470218 , , I-NP O
22 537 549 20470218 radiological JJ I-NP O
23 549 550 20470218 , , O O
24 551 554 20470218 and CC O O
25 555 575 20470218 electrophysiological JJ B-NP O
26 576 584 20470218 findings NNS I-NP O
27 584 585 20470218 . . O O

1 586 595 20470218 Exclusion NN B-NP O
2 596 604 20470218 criteria NNS I-NP O
3 605 613 20470218 included VBD B-VP O
4 614 617 20470218 CNS NN B-NP O
5 618 626 20470218 leukemic JJ I-NP B-Disease
6 627 639 20470218 infiltration NN I-NP I-Disease
7 640 642 20470218 at IN B-PP O
8 643 652 20470218 diagnosis NN B-NP O
9 652 653 20470218 , , O O
10 654 661 20470218 therapy NN B-NP O
11 661 662 20470218 - HYPH O O
12 662 669 20470218 related VBN B-NP O
13 670 680 20470218 peripheral JJ I-NP B-Disease
14 681 691 20470218 neuropathy NN I-NP I-Disease
15 691 692 20470218 , , O O
16 693 697 20470218 late JJ B-NP O
17 697 698 20470218 - HYPH I-NP O
18 698 703 20470218 onset NN I-NP O
19 704 718 20470218 encephalopathy NN I-NP B-Disease
20 718 719 20470218 , , O O
21 720 722 20470218 or CC O O
22 723 727 20470218 long JJ B-NP O
23 727 728 20470218 - HYPH I-NP O
24 728 732 20470218 term NN I-NP O
25 733 747 20470218 neurocognitive JJ I-NP B-Disease
26 748 755 20470218 defects NNS I-NP I-Disease
27 755 756 20470218 . . O O

1 757 763 20470218 During IN B-PP O
2 764 765 20470218 a DT B-NP O
3 766 767 20470218 9 CD I-NP O
4 767 768 20470218 - HYPH I-NP O
5 768 772 20470218 year NN I-NP O
6 773 779 20470218 period NN I-NP O
7 779 780 20470218 , , O O
8 781 783 20470218 we PRP B-NP O
9 784 799 20470218 retrospectively RB B-ADVP O
10 800 809 20470218 collected VBD B-VP O
11 810 812 20470218 27 CD B-NP O
12 813 825 20470218 neurological JJ I-NP O
13 826 832 20470218 events NNS I-NP O
14 833 834 20470218 ( ( O O
15 834 837 20470218 11% NN B-NP O
16 837 838 20470218 ) ) O O
17 839 841 20470218 in IN B-PP O
18 842 844 20470218 as RB B-NP O
19 845 849 20470218 many JJ I-NP O
20 850 858 20470218 patients NNS I-NP O
21 858 859 20470218 , , O O
22 860 864 20470218 from IN B-PP O
23 865 868 20470218 253 CD B-NP O
24 869 877 20470218 children NNS I-NP O
25 878 886 20470218 enrolled VBN B-VP O
26 887 889 20470218 in IN B-PP O
27 890 893 20470218 the DT B-NP O
28 894 897 20470218 ALL NN I-NP B-Disease
29 898 903 20470218 front NN I-NP O
30 903 904 20470218 - HYPH B-NP O
31 904 908 20470218 line NN I-NP O
32 909 917 20470218 protocol NN I-NP O
33 917 918 20470218 . . O O

1 919 922 20470218 CNS NN B-NP O
2 923 936 20470218 complications NNS I-NP O
3 937 945 20470218 included VBD B-VP O
4 946 955 20470218 posterior JJ B-NP O
5 956 966 20470218 reversible JJ I-NP O
6 967 986 20470218 leukoencephalopathy NN I-NP B-Disease
7 987 995 20470218 syndrome NN I-NP O
8 996 997 20470218 ( ( O O
9 997 998 20470218 n NN B-NP O
10 999 1000 20470218 = SYM B-VP O
11 1001 1003 20470218 10 CD B-NP O
12 1003 1004 20470218 ) ) O O
13 1004 1005 20470218 , , O O
14 1006 1012 20470218 stroke NN B-NP B-Disease
15 1013 1014 20470218 ( ( O O
16 1014 1015 20470218 n NN B-NP O
17 1016 1017 20470218 = SYM B-VP O
18 1018 1019 20470218 5 CD B-NP O
19 1019 1020 20470218 ) ) O O
20 1020 1021 20470218 , , O O
21 1022 1030 20470218 temporal JJ B-NP B-Disease
22 1031 1035 20470218 lobe NN I-NP I-Disease
23 1036 1044 20470218 epilepsy NN I-NP I-Disease
24 1045 1046 20470218 ( ( O O
25 1046 1047 20470218 n NN B-NP O
26 1048 1049 20470218 = SYM B-VP O
27 1050 1051 20470218 2 CD B-NP O
28 1051 1052 20470218 ) ) O O
29 1052 1053 20470218 , , O O
30 1054 1058 20470218 high JJ B-NP O
31 1058 1059 20470218 - HYPH I-NP O
32 1059 1063 20470218 dose NN I-NP O
33 1064 1076 20470218 methotrexate NN I-NP B-Chemical
34 1077 1085 20470218 toxicity NN I-NP B-Disease
35 1086 1087 20470218 ( ( O O
36 1087 1088 20470218 n NN B-NP O
37 1089 1090 20470218 = SYM B-VP O
38 1091 1092 20470218 2 CD B-NP O
39 1092 1093 20470218 ) ) O O
40 1093 1094 20470218 , , O O
41 1095 1103 20470218 syndrome NN B-NP O
42 1104 1106 20470218 of IN B-PP O
43 1107 1120 20470218 inappropriate JJ B-NP B-Disease
44 1121 1133 20470218 antidiuretic JJ I-NP I-Disease
45 1134 1141 20470218 hormone NN I-NP I-Disease
46 1142 1151 20470218 secretion NN I-NP I-Disease
47 1152 1153 20470218 ( ( O O
48 1153 1154 20470218 n NN B-NP O
49 1155 1156 20470218 = SYM B-VP O
50 1157 1158 20470218 1 CD B-NP O
51 1158 1159 20470218 ) ) O O
52 1159 1160 20470218 , , O O
53 1161 1164 20470218 and CC O O
54 1165 1170 20470218 other JJ B-NP O
55 1171 1183 20470218 unclassified JJ I-NP O
56 1184 1190 20470218 events NNS I-NP O
57 1191 1192 20470218 ( ( O O
58 1192 1193 20470218 n NN B-NP O
59 1194 1195 20470218 = SYM B-VP O
60 1196 1197 20470218 7 CD B-NP O
61 1197 1198 20470218 ) ) O O
62 1198 1199 20470218 . . O O

1 1200 1202 20470218 In IN B-PP O
2 1203 1213 20470218 conclusion NN B-NP O
3 1213 1214 20470218 , , O O
4 1215 1218 20470218 CNS NN B-NP O
5 1219 1232 20470218 complications NNS I-NP O
6 1233 1236 20470218 are VBP B-VP O
7 1237 1245 20470218 frequent JJ B-NP O
8 1246 1252 20470218 events NNS I-NP O
9 1253 1259 20470218 during IN B-PP O
10 1260 1263 20470218 ALL NN B-NP B-Disease
11 1264 1271 20470218 therapy NN I-NP O
12 1271 1272 20470218 , , O O
13 1273 1276 20470218 and CC O O
14 1277 1284 20470218 require VB B-VP O
15 1285 1290 20470218 rapid JJ B-NP O
16 1291 1300 20470218 detection NN I-NP O
17 1301 1304 20470218 and CC O O
18 1305 1311 20470218 prompt JJ B-NP O
19 1312 1321 20470218 treatment NN I-NP O
20 1322 1324 20470218 to TO B-VP O
21 1325 1330 20470218 limit VB I-VP O
22 1331 1340 20470218 permanent JJ B-NP O
23 1341 1347 20470218 damage NN I-NP O
24 1347 1348 20470218 . . O O

1 0 0 11147747 -DOCSTART- -X- -X- O

1 0 12 11147747 Serotonergic JJ B-NP B-Chemical
2 13 28 11147747 antidepressants NNS I-NP I-Chemical
3 29 32 11147747 and CC O O
4 33 40 11147747 urinary JJ B-NP B-Disease
5 41 53 11147747 incontinence NN I-NP I-Disease
6 53 54 11147747 . . O O
7 55 59 11147747 Many JJ B-NP O
8 60 63 11147747 new JJ I-NP O
9 64 76 11147747 serotonergic JJ I-NP B-Chemical
10 77 92 11147747 antidepressants NNS I-NP I-Chemical
11 93 97 11147747 have VBP B-VP O
12 98 102 11147747 been VBN I-VP O
13 103 113 11147747 introduced VBN I-VP O
14 114 118 11147747 over IN B-PP O
15 119 122 11147747 the DT B-NP O
16 123 127 11147747 past JJ I-NP O
17 128 134 11147747 decade NN I-NP O
18 134 135 11147747 . . O O

1 136 144 11147747 Although IN B-SBAR O
2 145 152 11147747 urinary JJ B-NP B-Disease
3 153 165 11147747 incontinence NN I-NP I-Disease
4 166 168 11147747 is VBZ B-VP O
5 169 175 11147747 listed VBN I-VP O
6 176 178 11147747 as IN B-PP O
7 179 182 11147747 one CD B-NP O
8 183 187 11147747 side NN I-NP O
9 188 194 11147747 effect NN I-NP O
10 195 197 11147747 of IN B-PP O
11 198 203 11147747 these DT B-NP O
12 204 209 11147747 drugs NNS I-NP O
13 210 212 11147747 in IN B-PP O
14 213 218 11147747 their PRP$ B-NP O
15 219 226 11147747 package NN I-NP O
16 227 234 11147747 inserts VBZ B-VP O
17 235 240 11147747 there EX B-NP O
18 241 243 11147747 is VBZ B-VP O
19 244 248 11147747 only RB B-NP O
20 249 252 11147747 one CD I-NP O
21 253 259 11147747 report NN I-NP O
22 260 262 11147747 in IN B-PP O
23 263 266 11147747 the DT B-NP O
24 267 277 11147747 literature NN I-NP O
25 277 278 11147747 . . O O

1 279 283 11147747 This DT B-NP O
2 284 292 11147747 concerns VBZ B-VP O
3 293 294 11147747 2 CD B-NP O
4 295 299 11147747 male JJ I-NP O
5 300 308 11147747 patients NNS I-NP O
6 309 312 11147747 who WP B-NP O
7 313 324 11147747 experienced VBD B-VP O
8 325 337 11147747 incontinence NN B-NP B-Disease
9 338 343 11147747 while IN B-SBAR O
10 344 350 11147747 taking VBG B-VP O
11 351 362 11147747 venlafaxine NN B-NP B-Chemical
12 362 363 11147747 . . O O

1 364 366 11147747 In IN B-PP O
2 367 370 11147747 the DT B-NP O
3 371 378 11147747 present JJ I-NP O
4 379 384 11147747 paper NN I-NP O
5 385 388 11147747 the DT B-NP O
6 389 396 11147747 authors NNS I-NP O
7 397 405 11147747 describe VBP B-VP O
8 406 407 11147747 2 CD B-NP O
9 408 414 11147747 female JJ I-NP O
10 415 423 11147747 patients NNS I-NP O
11 424 427 11147747 who WP B-NP O
12 428 437 11147747 developed VBD B-VP O
13 438 450 11147747 incontinence NN B-NP B-Disease
14 451 460 11147747 secondary JJ B-ADJP O
15 461 463 11147747 to TO B-PP O
16 464 467 11147747 the DT B-NP O
17 468 477 11147747 selective JJ I-NP O
18 478 487 11147747 serotonin NN I-NP B-Chemical
19 488 496 11147747 reuptake NN I-NP O
20 497 507 11147747 inhibitors NNS I-NP O
21 508 518 11147747 paroxetine NN I-NP B-Chemical
22 519 522 11147747 and CC I-NP O
23 523 533 11147747 sertraline NN I-NP B-Chemical
24 533 534 11147747 , , O O
25 535 537 11147747 as RB B-CONJP O
26 538 542 11147747 well RB I-CONJP O
27 543 545 11147747 as IN I-CONJP O
28 546 547 11147747 a DT B-NP O
29 548 553 11147747 third JJ I-NP O
30 554 557 11147747 who WP B-NP O
31 558 567 11147747 developed VBD B-VP O
32 568 572 11147747 this DT B-NP O
33 573 577 11147747 side NN I-NP O
34 578 584 11147747 effect NN I-NP O
35 585 587 11147747 on IN B-PP O
36 588 599 11147747 venlafaxine NN B-NP B-Chemical
37 599 600 11147747 . . O O

1 601 603 11147747 In IN B-PP O
2 604 605 11147747 2 CD B-NP O
3 606 608 11147747 of IN B-PP O
4 609 612 11147747 the DT B-NP O
5 613 614 11147747 3 CD I-NP O
6 615 620 11147747 cases NNS I-NP O
7 621 624 11147747 the DT B-NP O
8 625 633 11147747 patients NNS I-NP O
9 634 638 11147747 were VBD B-VP O
10 639 643 11147747 also RB I-VP O
11 644 650 11147747 taking VBG I-VP O
12 651 658 11147747 lithium NN B-NP B-Chemical
13 659 668 11147747 carbonate NN I-NP I-Chemical
14 669 672 11147747 and CC O O
15 673 677 11147747 beta SYM O O
16 677 678 11147747 - HYPH O O
17 678 686 11147747 blockers NNS B-NP O
18 686 687 11147747 , , O O
19 688 692 11147747 both DT B-NP O
20 693 695 11147747 of IN B-PP O
21 696 701 11147747 which WDT B-NP O
22 702 707 11147747 could MD B-VP O
23 708 712 11147747 have VB I-VP O
24 713 724 11147747 contributed VBN I-VP O
25 725 727 11147747 to TO B-PP O
26 728 731 11147747 the DT B-NP O
27 732 744 11147747 incontinence NN I-NP B-Disease
28 744 745 11147747 . . O O

1 746 752 11147747 Animal JJ B-NP O
2 753 760 11147747 studies NNS I-NP O
3 761 768 11147747 suggest VBP B-VP O
4 769 773 11147747 that IN B-SBAR O
5 774 786 11147747 incontinence NN B-NP B-Disease
6 787 796 11147747 secondary JJ B-ADJP O
7 797 799 11147747 to TO B-PP O
8 800 812 11147747 serotonergic JJ B-NP B-Chemical
9 813 828 11147747 antidepressants NNS I-NP I-Chemical
10 829 834 11147747 could MD B-VP O
11 835 837 11147747 be VB I-VP O
12 838 846 11147747 mediated VBN I-VP O
13 847 849 11147747 by IN B-PP O
14 850 853 11147747 the DT B-NP O
15 854 858 11147747 5HT4 NN I-NP O
16 859 868 11147747 receptors NNS I-NP O
17 869 874 11147747 found VBN B-VP O
18 875 877 11147747 on IN B-PP O
19 878 881 11147747 the DT B-NP O
20 882 889 11147747 bladder NN I-NP O
21 889 890 11147747 . . O O

1 891 898 11147747 Further JJ B-NP O
2 899 907 11147747 research NN I-NP O
3 908 910 11147747 is VBZ B-VP O
4 911 917 11147747 needed VBN I-VP O
5 918 920 11147747 to TO B-VP O
6 921 930 11147747 delineate VB I-VP O
7 931 934 11147747 the DT B-NP O
8 935 944 11147747 frequency NN I-NP O
9 945 947 11147747 of IN B-PP O
10 948 952 11147747 this DT B-NP O
11 953 962 11147747 troubling JJ I-NP O
12 963 967 11147747 side NN I-NP O
13 968 974 11147747 effect NN I-NP O
14 975 978 11147747 and CC O O
15 979 982 11147747 how WRB B-ADVP O
16 983 987 11147747 best JJS O O
17 988 990 11147747 to TO B-VP O
18 991 996 11147747 treat VB I-VP O
19 997 999 11147747 it PRP B-NP O
20 999 1000 11147747 . . O O

1 0 0 15325671 -DOCSTART- -X- -X- O

1 0 7 15325671 Cardiac JJ B-NP B-Disease
2 8 16 15325671 toxicity NN I-NP I-Disease
3 17 25 15325671 observed VBN B-VP O
4 26 28 15325671 in IN B-PP O
5 29 40 15325671 association NN B-NP O
6 41 45 15325671 with IN B-PP O
7 46 50 15325671 high JJ B-NP O
8 50 51 15325671 - HYPH I-NP O
9 51 55 15325671 dose NN I-NP O
10 56 72 15325671 cyclophosphamide NN I-NP B-Chemical
11 72 73 15325671 - HYPH B-VP O
12 73 78 15325671 based VBN B-NP O
13 79 91 15325671 chemotherapy NN I-NP O
14 92 95 15325671 for IN B-PP O
15 96 106 15325671 metastatic JJ B-NP O
16 107 113 15325671 breast NN I-NP B-Disease
17 114 120 15325671 cancer NN I-NP I-Disease
18 120 121 15325671 . . I-NP O
19 122 134 15325671 INTRODUCTION NN I-NP O
20 134 135 15325671 : : O O
21 136 152 15325671 Cyclophosphamide NN B-NP B-Chemical
22 153 155 15325671 is VBZ B-VP O
23 156 158 15325671 an DT B-NP O
24 159 169 15325671 alkylating VBG I-NP O
25 170 175 15325671 agent NN I-NP O
26 176 181 15325671 given VBN B-VP O
27 182 192 15325671 frequently RB B-ADVP O
28 193 195 15325671 as IN B-PP O
29 196 197 15325671 a DT B-NP O
30 198 207 15325671 component NN I-NP O
31 208 210 15325671 of IN B-PP O
32 211 215 15325671 many JJ B-NP O
33 216 228 15325671 conditioning VBG I-NP O
34 229 237 15325671 regimens NNS I-NP O
35 237 238 15325671 . . O O

1 239 241 15325671 In IN B-PP O
2 242 246 15325671 high JJ B-NP O
3 247 252 15325671 doses NNS I-NP O
4 252 253 15325671 , , O O
5 254 257 15325671 its PRP$ B-NP O
6 258 274 15325671 nonhematological JJ I-NP O
7 275 279 15325671 dose NN I-NP O
8 279 280 15325671 - HYPH O O
9 280 288 15325671 limiting VBG B-VP O
10 289 297 15325671 toxicity NN B-NP B-Disease
11 298 300 15325671 is VBZ B-VP O
12 301 315 15325671 cardiomyopathy NN B-NP B-Disease
13 315 316 15325671 . . O O

1 317 322 15325671 STUDY NN B-NP O
2 323 329 15325671 DESIGN NN I-NP O
3 329 330 15325671 : : O O
4 331 333 15325671 We PRP B-NP O
5 334 342 15325671 combined VBD B-VP O
6 343 353 15325671 paclitaxel NN B-NP B-Chemical
7 353 354 15325671 , , O O
8 355 364 15325671 melphalan NN B-NP B-Chemical
9 365 368 15325671 and CC O O
10 369 373 15325671 high JJ B-NP O
11 373 374 15325671 - HYPH I-NP O
12 374 378 15325671 dose NN I-NP O
13 379 395 15325671 cyclophosphamide NN I-NP B-Chemical
14 395 396 15325671 , , O O
15 397 405 15325671 thiotepa NN B-NP B-Chemical
16 405 406 15325671 , , O O
17 407 410 15325671 and CC O O
18 411 422 15325671 carboplatin NN B-NP B-Chemical
19 423 425 15325671 in IN B-PP O
20 426 427 15325671 a DT B-NP O
21 428 434 15325671 triple JJ I-NP O
22 435 445 15325671 sequential JJ I-NP O
23 446 450 15325671 high JJ I-NP O
24 450 451 15325671 - HYPH I-NP O
25 451 455 15325671 dose NN I-NP O
26 456 463 15325671 regimen NN I-NP O
27 464 467 15325671 for IN B-PP O
28 468 476 15325671 patients NNS B-NP O
29 477 481 15325671 with IN B-PP O
30 482 492 15325671 metastatic JJ B-NP O
31 493 499 15325671 breast NN I-NP B-Disease
32 500 506 15325671 cancer NN I-NP I-Disease
33 506 507 15325671 . . O O

1 508 516 15325671 Analysis NN B-NP O
2 517 520 15325671 was VBD B-VP O
3 521 530 15325671 performed VBN I-VP O
4 531 533 15325671 on IN B-PP O
5 534 536 15325671 61 CD B-NP O
6 537 542 15325671 women NNS I-NP O
7 543 547 15325671 with IN B-PP O
8 548 560 15325671 chemotherapy NN B-NP O
9 560 561 15325671 - HYPH B-NP O
10 561 571 15325671 responsive JJ I-NP O
11 572 582 15325671 metastatic JJ I-NP O
12 583 589 15325671 breast NN I-NP B-Disease
13 590 596 15325671 cancer NN I-NP I-Disease
14 597 606 15325671 receiving VBG B-VP O
15 607 609 15325671 96 CD B-NP O
16 609 610 15325671 - HYPH I-NP O
17 610 611 15325671 h NN I-NP O
18 612 622 15325671 infusional JJ I-NP O
19 623 639 15325671 cyclophosphamide NN I-NP B-Chemical
20 640 642 15325671 as IN B-PP O
21 643 647 15325671 part NN B-NP O
22 648 650 15325671 of IN B-PP O
23 651 652 15325671 a DT B-NP O
24 653 659 15325671 triple JJ I-NP O
25 660 670 15325671 sequential JJ I-NP O
26 671 675 15325671 high JJ I-NP O
27 675 676 15325671 - HYPH I-NP O
28 676 680 15325671 dose NN I-NP O
29 681 688 15325671 regimen NN I-NP O
30 689 691 15325671 to TO B-VP O
31 692 698 15325671 assess VB I-VP O
32 699 710 15325671 association NN B-NP O
33 711 718 15325671 between IN B-PP O
34 719 727 15325671 presence NN B-NP O
35 728 730 15325671 of IN B-PP O
36 731 745 15325671 peritransplant NN B-NP O
37 746 756 15325671 congestive JJ I-NP B-Disease
38 757 762 15325671 heart NN I-NP I-Disease
39 763 770 15325671 failure NN I-NP I-Disease
40 771 772 15325671 ( ( O O
41 772 775 15325671 CHF NN B-NP B-Disease
42 775 776 15325671 ) ) O O
43 777 780 15325671 and CC O O
44 781 784 15325671 the DT B-NP O
45 785 794 15325671 following VBG I-NP O
46 795 807 15325671 pretreatment NN I-NP O
47 808 823 15325671 characteristics NNS I-NP O
48 823 824 15325671 : : O O
49 825 833 15325671 presence NN B-NP O
50 834 836 15325671 of IN B-PP O
51 837 854 15325671 electrocardiogram NN B-NP O
52 855 856 15325671 ( ( O O
53 856 859 15325671 EKG NN B-NP O
54 859 860 15325671 ) ) O O
55 861 874 15325671 abnormalities NNS B-NP O
56 874 875 15325671 , , O O
57 876 879 15325671 age NN B-NP O
58 879 880 15325671 , , O O
59 881 893 15325671 hypertension NN B-NP B-Disease
60 893 894 15325671 , , O O
61 895 900 15325671 prior JJ B-NP O
62 901 908 15325671 cardiac JJ I-NP O
63 909 916 15325671 history NN I-NP O
64 916 917 15325671 , , O O
65 918 925 15325671 smoking NN B-NP O
66 925 926 15325671 , , O O
67 927 935 15325671 diabetes NN B-NP B-Disease
68 936 944 15325671 mellitus NN I-NP I-Disease
69 944 945 15325671 , , O O
70 946 951 15325671 prior JJ B-NP O
71 952 955 15325671 use NN I-NP O
72 956 958 15325671 of IN B-PP O
73 959 973 15325671 anthracyclines NNS B-NP B-Chemical
74 973 974 15325671 , , O O
75 975 978 15325671 and CC O O
76 979 983 15325671 left JJ B-NP O
77 983 984 15325671 - HYPH I-NP O
78 984 989 15325671 sided JJ I-NP O
79 990 995 15325671 chest NN I-NP O
80 996 1007 15325671 irradiation NN I-NP O
81 1007 1008 15325671 . . O O

1 1009 1016 15325671 RESULTS NNS B-NP O
2 1016 1017 15325671 : : O O
3 1018 1021 15325671 Six CD B-NP O
4 1022 1024 15325671 of IN B-PP O
5 1025 1027 15325671 61 CD B-NP O
6 1028 1033 15325671 women NNS I-NP O
7 1034 1035 15325671 ( ( O O
8 1035 1038 15325671 10% CD B-NP O
9 1038 1039 15325671 ) ) O O
10 1040 1049 15325671 developed VBD B-VP O
11 1050 1060 15325671 clinically RB B-NP O
12 1061 1071 15325671 reversible JJ I-NP O
13 1072 1077 15325671 grade NN I-NP O
14 1078 1079 15325671 3 CD I-NP O
15 1080 1083 15325671 CHF NN I-NP B-Disease
16 1084 1093 15325671 following VBG B-PP O
17 1094 1104 15325671 infusional JJ B-NP O
18 1105 1121 15325671 cyclophosphamide NN I-NP B-Chemical
19 1122 1126 15325671 with IN B-PP O
20 1127 1128 15325671 a DT B-NP O
21 1129 1135 15325671 median JJ I-NP O
22 1136 1143 15325671 percent NN I-NP O
23 1144 1151 15325671 decline NN I-NP O
24 1152 1154 15325671 in IN B-PP O
25 1155 1163 15325671 ejection NN B-NP O
26 1164 1172 15325671 fraction NN I-NP O
27 1173 1175 15325671 of IN B-PP O
28 1176 1179 15325671 31% NN B-NP O
29 1179 1180 15325671 . . O O

1 1181 1190 15325671 Incidence NN B-NP O
2 1191 1193 15325671 of IN B-PP O
3 1194 1203 15325671 transient JJ B-NP O
4 1204 1220 15325671 cyclophosphamide NN I-NP B-Chemical
5 1220 1221 15325671 - HYPH O O
6 1221 1228 15325671 related VBN B-VP O
7 1229 1236 15325671 cardiac JJ B-NP B-Disease
8 1237 1245 15325671 toxicity NN I-NP I-Disease
9 1246 1247 15325671 ( ( O O
10 1247 1250 15325671 10% CD B-NP O
11 1250 1251 15325671 ) ) O O
12 1252 1254 15325671 is VBZ B-VP O
13 1255 1265 15325671 comparable JJ B-ADJP O
14 1266 1268 15325671 to TO B-PP O
15 1269 1277 15325671 previous JJ B-NP O
16 1278 1286 15325671 recorded VBN I-NP O
17 1287 1297 15325671 literature NN I-NP O
18 1297 1298 15325671 . . O O

1 1299 1304 15325671 Older JJR B-NP O
2 1305 1308 15325671 age NN I-NP O
3 1309 1312 15325671 was VBD B-VP O
4 1313 1326 15325671 significantly RB I-VP O
5 1327 1337 15325671 correlated VBN I-VP O
6 1338 1342 15325671 with IN B-PP O
7 1343 1346 15325671 the DT B-NP O
8 1347 1350 15325671 CHF NN I-NP B-Disease
9 1351 1362 15325671 development NN I-NP O
10 1362 1363 15325671 ; : O O
11 1364 1368 15325671 with IN B-PP O
12 1369 1375 15325671 median JJ B-NP O
13 1376 1380 15325671 ages NNS I-NP O
14 1381 1384 15325671 for IN B-PP O
15 1385 1388 15325671 the DT B-NP O
16 1389 1395 15325671 entire JJ I-NP O
17 1396 1401 15325671 group NN I-NP O
18 1402 1405 15325671 and CC B-PP O
19 1406 1409 15325671 for IN B-PP O
20 1410 1418 15325671 patients NNS B-NP O
21 1419 1429 15325671 developing VBG B-VP O
22 1430 1433 15325671 CHF NN B-NP B-Disease
23 1434 1436 15325671 of IN B-PP O
24 1437 1439 15325671 45 CD B-NP O
25 1440 1443 15325671 and CC I-NP O
26 1444 1446 15325671 59 CD I-NP O
27 1446 1447 15325671 , , O O
28 1448 1460 15325671 respectively RB B-ADVP O
29 1460 1461 15325671 . . O O

1 1462 1464 15325671 No DT B-NP O
2 1465 1476 15325671 association NN I-NP O
3 1477 1480 15325671 was VBD B-VP O
4 1481 1486 15325671 found VBN I-VP O
5 1487 1491 15325671 with IN B-PP O
6 1492 1497 15325671 other JJ B-NP O
7 1498 1510 15325671 pretreatment NN I-NP O
8 1511 1526 15325671 characteristics NNS I-NP O
9 1526 1527 15325671 . . O O

1 1528 1539 15325671 CONCLUSIONS NNS B-NP O
2 1539 1540 15325671 : : O O
3 1541 1543 15325671 As IN B-PP O
4 1544 1545 15325671 a DT B-NP O
5 1546 1552 15325671 result NN I-NP O
6 1553 1555 15325671 of IN B-PP O
7 1556 1561 15325671 these DT B-NP O
8 1562 1570 15325671 findings NNS I-NP O
9 1570 1571 15325671 , , O O
10 1572 1583 15325671 oncologists NNS B-NP O
11 1584 1590 15325671 should MD B-VP O
12 1591 1600 15325671 carefully RB I-VP O
13 1601 1608 15325671 monitor VB I-VP O
14 1609 1614 15325671 fluid NN B-NP O
15 1615 1622 15325671 balance NN I-NP O
16 1623 1625 15325671 in IN B-PP O
17 1626 1631 15325671 older JJR B-NP O
18 1632 1640 15325671 patients NNS I-NP O
19 1640 1641 15325671 . . O O

1 1642 1649 15325671 Routine NN B-NP O
2 1650 1653 15325671 EKG NN I-NP O
3 1654 1664 15325671 monitoring NN I-NP O
4 1665 1671 15325671 during IN B-PP O
5 1672 1682 15325671 infusional JJ B-NP O
6 1683 1699 15325671 cyclophosphamide NN I-NP B-Chemical
7 1700 1703 15325671 did VBD B-VP O
8 1704 1707 15325671 not RB I-VP O
9 1708 1715 15325671 predict VB I-VP O
10 1716 1719 15325671 CHF NN B-NP B-Disease
11 1720 1731 15325671 development NN I-NP O
12 1731 1732 15325671 . . O O

1 0 0 7988234 -DOCSTART- -X- -X- O

1 0 10 7988234 Angioedema NN B-NP B-Disease
2 11 20 7988234 following VBG B-PP O
3 21 24 7988234 the DT B-NP O
4 25 36 7988234 intravenous JJ I-NP O
5 37 51 7988234 administration NN I-NP O
6 52 54 7988234 of IN B-PP O
7 55 65 7988234 metoprolol NN B-NP B-Chemical
8 65 66 7988234 . . O O
9 67 68 7988234 A DT B-NP O
10 69 71 7988234 72 CD I-NP O
11 71 72 7988234 - HYPH I-NP O
12 72 76 7988234 year NN I-NP O
13 76 77 7988234 - HYPH O O
14 77 80 7988234 old JJ B-NP O
15 81 86 7988234 woman NN I-NP O
16 87 90 7988234 was VBD B-VP O
17 91 99 7988234 admitted VBN I-VP O
18 100 102 7988234 to TO B-PP O
19 103 106 7988234 the DT B-NP O
20 107 115 7988234 hospital NN I-NP O
21 116 120 7988234 with IN B-PP O
22 121 122 7988234 " `` O O
23 122 127 7988234 flash NN B-NP O
24 127 128 7988234 " '' O O
25 129 138 7988234 pulmonary JJ B-NP B-Disease
26 139 144 7988234 edema NN I-NP I-Disease
27 144 145 7988234 , , O O
28 146 154 7988234 preceded VBN B-VP O
29 155 157 7988234 by IN B-PP O
30 158 163 7988234 chest NN B-NP B-Disease
31 164 168 7988234 pain NN I-NP I-Disease
32 168 169 7988234 , , O O
33 170 179 7988234 requiring VBG B-VP O
34 180 190 7988234 intubation NN B-NP O
35 190 191 7988234 . . O O

1 192 195 7988234 Her PRP$ B-NP O
2 196 203 7988234 medical JJ I-NP O
3 204 211 7988234 history NN I-NP O
4 212 220 7988234 included VBD B-VP O
5 221 229 7988234 coronary JJ B-NP B-Disease
6 230 236 7988234 artery NN I-NP I-Disease
7 237 244 7988234 disease NN I-NP I-Disease
8 245 249 7988234 with IN B-PP O
9 250 258 7988234 previous JJ B-NP O
10 259 269 7988234 myocardial JJ I-NP B-Disease
11 270 281 7988234 infarctions NNS I-NP I-Disease
12 281 282 7988234 , , O O
13 283 295 7988234 hypertension NN B-NP B-Disease
14 295 296 7988234 , , O O
15 297 300 7988234 and CC O O
16 301 309 7988234 diabetes NN B-NP B-Disease
17 310 318 7988234 mellitus NN I-NP I-Disease
18 318 319 7988234 . . O O

1 320 321 7988234 A DT B-NP O
2 322 329 7988234 history NN I-NP O
3 330 332 7988234 of IN B-PP O
4 333 343 7988234 angioedema NN B-NP B-Disease
5 344 353 7988234 secondary JJ B-ADJP O
6 354 356 7988234 to TO B-PP O
7 357 367 7988234 lisinopril NN B-NP B-Chemical
8 368 375 7988234 therapy NN I-NP O
9 376 379 7988234 was VBD B-VP O
10 380 388 7988234 elicited VBN I-VP O
11 388 389 7988234 . . O O

1 390 397 7988234 Current JJ B-NP O
2 398 409 7988234 medications NNS I-NP O
3 410 413 7988234 did VBD B-VP O
4 414 417 7988234 not RB I-VP O
5 418 425 7988234 include VB I-VP O
6 426 437 7988234 angiotensin NN B-NP B-Chemical
7 437 438 7988234 - HYPH O O
8 438 448 7988234 converting VBG B-VP O
9 449 455 7988234 enzyme NN B-NP O
10 456 466 7988234 inhibitors NNS I-NP O
11 467 469 7988234 or CC O O
12 470 474 7988234 beta SYM B-NP O
13 474 475 7988234 - HYPH B-VP O
14 475 483 7988234 blockers NNS B-NP O
15 483 484 7988234 . . O O

1 485 488 7988234 She PRP B-NP O
2 489 492 7988234 had VBD B-VP O
3 493 495 7988234 no DT B-NP O
4 496 504 7988234 previous JJ I-NP O
5 505 509 7988234 beta SYM I-NP O
6 509 510 7988234 - HYPH I-NP O
7 510 518 7988234 blocking VBG B-VP O
8 519 523 7988234 drug NN B-NP O
9 524 532 7988234 exposure NN I-NP O
10 532 533 7988234 . . O O

1 534 540 7988234 During IN B-PP O
2 541 544 7988234 the DT B-NP O
3 545 550 7988234 first JJ I-NP O
4 551 554 7988234 day NN I-NP O
5 555 557 7988234 of IN B-PP O
6 558 573 7988234 hospitalization NN B-NP O
7 574 575 7988234 ( ( O O
8 575 580 7988234 while IN B-SBAR O
9 581 590 7988234 intubated VBN B-VP O
10 590 591 7988234 ) ) O O
11 591 592 7988234 , , O O
12 593 604 7988234 intravenous JJ B-NP O
13 605 615 7988234 metoprolol NN I-NP B-Chemical
14 616 619 7988234 was VBD B-VP O
15 620 625 7988234 given VBN I-VP O
16 625 626 7988234 , , O O
17 627 636 7988234 resulting VBG B-VP O
18 637 639 7988234 in IN B-PP O
19 640 646 7988234 severe JJ B-NP O
20 647 657 7988234 angioedema NN I-NP B-Disease
21 657 658 7988234 . . O O

1 659 662 7988234 The DT B-NP O
2 663 673 7988234 angioedema NN I-NP B-Disease
3 674 682 7988234 resolved VBN B-VP O
4 683 688 7988234 after IN B-PP O
5 689 696 7988234 therapy NN B-NP O
6 697 701 7988234 with IN B-PP O
7 702 713 7988234 intravenous JJ B-NP O
8 714 722 7988234 steroids NNS I-NP B-Chemical
9 723 726 7988234 and CC O O
10 727 742 7988234 diphenhydramine NN B-NP B-Chemical
11 743 756 7988234 hydrochloride NN I-NP O
12 756 757 7988234 . . O O

1 0 0 12596116 -DOCSTART- -X- -X- O

1 0 10 12596116 Octreotide NN B-NP B-Chemical
2 10 11 12596116 - HYPH B-NP O
3 11 18 12596116 induced VBN I-NP O
4 19 28 12596116 hypoxemia NN I-NP B-Disease
5 29 32 12596116 and CC I-NP O
6 33 42 12596116 pulmonary JJ I-NP B-Disease
7 43 55 12596116 hypertension NN I-NP I-Disease
8 56 58 12596116 in IN B-PP O
9 59 68 12596116 premature JJ B-NP O
10 69 77 12596116 neonates NNS I-NP O
11 77 78 12596116 . . O O
12 79 82 12596116 The DT B-NP O
13 83 90 12596116 authors NNS I-NP O
14 91 97 12596116 report VBP B-VP O
15 98 99 12596116 2 CD B-NP O
16 100 105 12596116 cases NNS I-NP O
17 106 108 12596116 of IN B-PP O
18 109 118 12596116 premature JJ B-NP O
19 119 127 12596116 neonates NNS I-NP O
20 128 131 12596116 who WP B-NP O
21 132 135 12596116 had VBD B-VP O
22 136 151 12596116 enterocutaneous JJ B-NP O
23 152 159 12596116 fistula NN I-NP B-Disease
24 160 172 12596116 complicating VBG B-VP O
25 173 184 12596116 necrotizing VBG B-NP B-Disease
26 185 198 12596116 enterocolitis NN I-NP I-Disease
27 198 199 12596116 . . O O

1 200 209 12596116 Pulmonary JJ B-NP B-Disease
2 210 222 12596116 hypertension NN I-NP I-Disease
3 223 232 12596116 developed VBN B-VP O
4 233 238 12596116 after IN B-PP O
5 239 253 12596116 administration NN B-NP O
6 254 256 12596116 of IN B-PP O
7 257 258 12596116 a DT B-NP O
8 259 271 12596116 somatostatin NN I-NP O
9 272 280 12596116 analogue NN I-NP O
10 280 281 12596116 , , O O
11 282 292 12596116 octreotide NN B-NP B-Chemical
12 292 293 12596116 , , O O
13 294 296 12596116 to TO B-VP O
14 297 304 12596116 enhance VB I-VP O
15 305 315 12596116 resolution NN B-NP O
16 316 318 12596116 of IN B-PP O
17 319 322 12596116 the DT B-NP O
18 323 330 12596116 fistula NN I-NP B-Disease
19 330 331 12596116 . . O O

1 332 335 12596116 The DT B-NP O
2 336 343 12596116 authors NNS I-NP O
3 344 351 12596116 discuss VBP B-VP O
4 352 355 12596116 the DT B-NP O
5 356 365 12596116 mechanism NN I-NP O
6 366 368 12596116 of IN B-PP O
7 369 372 12596116 the DT B-NP O
8 373 383 12596116 occurrence NN I-NP O
9 384 386 12596116 of IN B-PP O
10 387 391 12596116 this DT B-NP O
11 392 404 12596116 complication NN I-NP O
12 405 408 12596116 and CC O O
13 409 418 12596116 recommend VB B-VP O
14 419 426 12596116 caution NN B-NP O
15 427 429 12596116 of IN B-PP O
16 430 433 12596116 its PRP$ B-NP O
17 434 437 12596116 use NN I-NP O
18 438 440 12596116 in IN B-PP O
19 441 445 12596116 high JJ B-NP O
20 445 446 12596116 - HYPH I-NP O
21 446 450 12596116 risk NN I-NP O
22 451 460 12596116 premature JJ I-NP O
23 461 469 12596116 neonates NNS I-NP O
24 469 470 12596116 . . O O

1 0 0 2696505 -DOCSTART- -X- -X- O

1 0 1 2696505 A DT B-NP O
2 2 12 2696505 randomized VBN I-NP O
3 13 23 2696505 comparison NN I-NP O
4 24 26 2696505 of IN B-PP O
5 27 36 2696505 labetalol NN B-NP B-Chemical
6 37 40 2696505 and CC I-NP O
7 41 54 2696505 nitroprusside NN I-NP B-Chemical
8 55 58 2696505 for IN B-PP O
9 59 66 2696505 induced VBN B-NP O
10 67 78 2696505 hypotension NN I-NP B-Disease
11 78 79 2696505 . . O O
12 80 82 2696505 In IN B-PP O
13 83 84 2696505 a DT B-NP O
14 85 95 2696505 randomized VBN I-NP O
15 96 101 2696505 study NN I-NP O
16 101 102 2696505 , , O O
17 103 112 2696505 labetalol NN B-NP B-Chemical
18 112 113 2696505 - HYPH B-NP O
19 113 120 2696505 induced VBN I-NP O
20 121 132 2696505 hypotension NN I-NP B-Disease
21 133 136 2696505 and CC I-NP O
22 137 150 2696505 nitroprusside NN I-NP B-Chemical
23 150 151 2696505 - HYPH B-NP O
24 151 158 2696505 induced VBN I-NP O
25 159 170 2696505 hypotension NN I-NP B-Disease
26 171 175 2696505 were VBD B-VP O
27 176 184 2696505 compared VBN I-VP O
28 185 187 2696505 in IN B-PP O
29 188 190 2696505 20 CD B-NP O
30 191 199 2696505 patients NNS I-NP O
31 200 201 2696505 ( ( O O
32 201 203 2696505 10 CD B-NP O
33 204 206 2696505 in IN B-PP O
34 207 211 2696505 each DT B-NP O
35 212 217 2696505 group NN I-NP O
36 217 218 2696505 ) ) O O
37 219 228 2696505 scheduled VBN B-VP O
38 229 232 2696505 for IN B-PP O
39 233 238 2696505 major JJ B-NP O
40 239 249 2696505 orthopedic JJ I-NP O
41 250 260 2696505 procedures NNS I-NP O
42 260 261 2696505 . . O O

1 262 266 2696505 Each DT B-NP O
2 267 274 2696505 patient NN I-NP O
3 275 278 2696505 was VBD B-VP O
4 279 288 2696505 subjected VBN I-VP O
5 289 291 2696505 to TO B-PP O
6 292 294 2696505 an DT B-NP O
7 295 304 2696505 identical JJ I-NP O
8 305 315 2696505 anesthetic JJ I-NP O
9 316 324 2696505 protocol NN I-NP O
10 325 328 2696505 and CC O O
11 329 336 2696505 similar JJ B-NP O
12 337 341 2696505 drug NN I-NP O
13 341 342 2696505 - HYPH B-NP O
14 342 349 2696505 induced VBN I-NP O
15 350 360 2696505 reductions NNS I-NP B-Disease
16 361 363 2696505 in IN B-PP I-Disease
17 364 368 2696505 mean JJ B-NP I-Disease
18 369 377 2696505 arterial JJ I-NP I-Disease
19 378 383 2696505 blood NN I-NP I-Disease
20 384 392 2696505 pressure NN I-NP I-Disease
21 393 394 2696505 ( ( O O
22 394 396 2696505 BP NN B-NP O
23 396 397 2696505 ) ) O O
24 398 399 2696505 ( ( O O
25 399 401 2696505 50 CD B-NP O
26 402 404 2696505 to TO O O
27 405 407 2696505 55 CD B-NP O
28 408 412 2696505 mmHg NN I-NP O
29 412 413 2696505 ) ) O O
30 413 414 2696505 . . O O

1 415 428 2696505 Nitroprusside NN B-NP O
2 429 437 2696505 infusion NN I-NP O
3 438 441 2696505 was VBD B-VP O
4 442 452 2696505 associated VBN I-VP O
5 453 457 2696505 with IN B-PP O
6 458 459 2696505 a DT B-NP O
7 460 471 2696505 significant JJ I-NP O
8 472 473 2696505 ( ( O O
9 473 474 2696505 p NN B-NP O
10 475 479 2696505 less JJR B-ADJP O
11 480 484 2696505 than IN B-PP O
12 485 489 2696505 0.05 CD B-NP O
13 489 490 2696505 ) ) O O
14 491 499 2696505 increase NN B-NP B-Disease
15 500 502 2696505 in IN B-PP I-Disease
16 503 508 2696505 heart NN B-NP I-Disease
17 509 513 2696505 rate NN I-NP I-Disease
18 514 517 2696505 and CC O I-Disease
19 518 525 2696505 cardiac JJ B-NP I-Disease
20 526 532 2696505 output NN I-NP I-Disease
21 532 533 2696505 ; : O O
22 534 541 2696505 rebound NN B-NP O
23 542 554 2696505 hypertension NN I-NP B-Disease
24 555 558 2696505 was VBD B-VP O
25 559 567 2696505 observed VBN I-VP O
26 568 570 2696505 in IN B-PP O
27 571 576 2696505 three CD B-NP O
28 577 585 2696505 patients NNS I-NP O
29 586 591 2696505 after IN B-PP O
30 592 607 2696505 discontinuation NN B-NP O
31 608 610 2696505 of IN B-PP O
32 611 624 2696505 nitroprusside NN B-NP B-Chemical
33 624 625 2696505 . . O O

1 626 635 2696505 Labetalol NN B-NP B-Chemical
2 636 650 2696505 administration NN I-NP O
3 651 654 2696505 was VBD B-VP O
4 655 658 2696505 not RB I-VP O
5 659 669 2696505 associated VBN I-VP O
6 670 674 2696505 with IN B-PP O
7 675 678 2696505 any DT B-NP O
8 679 681 2696505 of IN B-PP O
9 682 687 2696505 these DT B-NP O
10 688 696 2696505 findings NNS I-NP O
11 696 697 2696505 . . O O

1 698 706 2696505 Arterial JJ B-NP O
2 707 710 2696505 PO2 NN I-NP B-Chemical
3 711 720 2696505 decreased VBD B-VP O
4 721 723 2696505 in IN B-PP O
5 724 728 2696505 both DT B-NP O
6 729 735 2696505 groups NNS I-NP O
7 735 736 2696505 . . O O

1 737 739 2696505 It PRP B-NP O
2 740 743 2696505 was VBD B-VP O
3 744 753 2696505 concluded VBN I-VP O
4 754 758 2696505 that IN B-SBAR O
5 759 768 2696505 labetalol NN B-NP B-Chemical
6 769 775 2696505 offers VBZ B-VP O
7 776 786 2696505 advantages NNS B-NP O
8 787 791 2696505 over IN B-PP O
9 792 805 2696505 nitroprusside NN B-NP B-Chemical
10 805 806 2696505 . . O O

1 0 0 12615818 -DOCSTART- -X- -X- O

1 0 3 12615818 The DT B-NP O
2 4 8 12615818 risk NN I-NP O
3 9 11 12615818 of IN B-PP O
4 12 18 12615818 venous JJ B-NP B-Disease
5 19 34 12615818 thromboembolism NN I-NP I-Disease
6 35 37 12615818 in IN B-PP O
7 38 43 12615818 women NNS B-NP O
8 44 54 12615818 prescribed VBD B-VP O
9 55 66 12615818 cyproterone NN B-NP B-Chemical
10 67 74 12615818 acetate NN I-NP I-Chemical
11 75 77 12615818 in IN B-PP O
12 78 89 12615818 combination NN B-NP O
13 90 94 12615818 with IN B-PP O
14 95 102 12615818 ethinyl NN B-NP B-Chemical
15 103 112 12615818 estradiol NN I-NP I-Chemical
16 112 113 12615818 : : O O
17 114 115 12615818 a DT B-NP O
18 116 122 12615818 nested JJ I-NP O
19 123 129 12615818 cohort JJ I-NP O
20 130 138 12615818 analysis NN I-NP O
21 139 142 12615818 and CC I-NP O
22 143 147 12615818 case NN I-NP O
23 147 148 12615818 - HYPH B-NP O
24 148 155 12615818 control NN I-NP O
25 156 161 12615818 study NN I-NP O
26 161 162 12615818 . . I-NP O
27 163 173 12615818 BACKGROUND NN I-NP O
28 173 174 12615818 : : O O
29 175 186 12615818 Cyproterone NN B-NP B-Chemical
30 187 194 12615818 acetate NN I-NP I-Chemical
31 195 203 12615818 combined VBN B-VP O
32 204 208 12615818 with IN B-PP O
33 209 216 12615818 ethinyl NN B-NP B-Chemical
34 217 226 12615818 estradiol NN I-NP I-Chemical
35 227 228 12615818 ( ( O O
36 228 231 12615818 CPA NN B-NP B-Chemical
37 231 232 12615818 / SYM B-NP O
38 232 234 12615818 EE NN I-NP B-Chemical
39 234 235 12615818 ) ) O O
40 236 238 12615818 is VBZ B-VP O
41 239 247 12615818 licensed VBN I-VP O
42 248 250 12615818 in IN B-PP O
43 251 254 12615818 the DT B-NP O
44 255 257 12615818 UK NNP I-NP O
45 258 261 12615818 for IN B-PP O
46 262 265 12615818 the DT B-NP O
47 266 275 12615818 treatment NN I-NP O
48 276 278 12615818 of IN B-PP O
49 279 284 12615818 women NNS B-NP O
50 285 289 12615818 with IN B-PP O
51 290 294 12615818 acne NN B-NP B-Disease
52 295 298 12615818 and CC I-NP O
53 299 308 12615818 hirsutism NN I-NP B-Disease
54 309 312 12615818 and CC O O
55 313 315 12615818 is VBZ B-VP O
56 316 320 12615818 also RB B-ADVP O
57 321 322 12615818 a DT B-NP O
58 323 332 12615818 treatment NN I-NP O
59 333 339 12615818 option NN I-NP O
60 340 343 12615818 for IN B-PP O
61 344 354 12615818 polycystic JJ B-NP B-Disease
62 355 360 12615818 ovary NN I-NP I-Disease
63 361 369 12615818 syndrome NN I-NP I-Disease
64 370 371 12615818 ( ( O O
65 371 375 12615818 PCOS NN B-NP B-Disease
66 375 376 12615818 ) ) O O
67 376 377 12615818 . . O O

1 378 386 12615818 Previous JJ B-NP O
2 387 394 12615818 studies NNS I-NP O
3 395 399 12615818 have VBP B-VP O
4 400 412 12615818 demonstrated VBN I-VP O
5 413 415 12615818 an DT B-NP O
6 416 425 12615818 increased VBN I-NP O
7 426 430 12615818 risk NN I-NP O
8 431 433 12615818 of IN B-PP O
9 434 440 12615818 venous JJ B-NP B-Disease
10 441 456 12615818 thromboembolism NN I-NP I-Disease
11 457 458 12615818 ( ( O O
12 458 461 12615818 VTE NN B-NP B-Disease
13 461 462 12615818 ) ) O O
14 463 473 12615818 associated VBN B-VP O
15 474 478 12615818 with IN B-PP O
16 479 482 12615818 CPA NN B-NP B-Chemical
17 482 483 12615818 / SYM B-NP O
18 483 485 12615818 EE NN I-NP B-Chemical
19 486 494 12615818 compared VBN B-PP O
20 495 499 12615818 with IN B-PP O
21 500 512 12615818 conventional JJ B-NP O
22 513 521 12615818 combined JJ I-NP O
23 522 526 12615818 oral JJ I-NP B-Chemical
24 527 541 12615818 contraceptives NNS I-NP I-Chemical
25 542 543 12615818 ( ( O O
26 543 547 12615818 COCs NNS B-NP O
27 547 548 12615818 ) ) O O
28 548 549 12615818 . . O O

1 550 552 12615818 We PRP B-NP O
2 553 560 12615818 believe VBP B-VP O
3 561 564 12615818 the DT B-NP O
4 565 572 12615818 results NNS I-NP O
5 573 575 12615818 of IN B-PP O
6 576 581 12615818 those DT B-NP O
7 582 589 12615818 studies NNS I-NP O
8 590 593 12615818 may MD B-VP O
9 594 598 12615818 have VB I-VP O
10 599 603 12615818 been VBN I-VP O
11 604 612 12615818 affected VBN I-VP O
12 613 615 12615818 by IN B-PP O
13 616 624 12615818 residual JJ B-NP O
14 625 636 12615818 confounding NN I-NP O
15 636 637 12615818 . . O O

1 638 645 12615818 METHODS NNS B-NP O
2 645 646 12615818 : : O O
3 647 652 12615818 Using VBG B-VP O
4 653 656 12615818 the DT B-NP O
5 657 664 12615818 General NNP I-NP O
6 665 673 12615818 Practice NNP I-NP O
7 674 682 12615818 Research NNP I-NP O
8 683 691 12615818 Database NNP I-NP O
9 692 694 12615818 we PRP B-NP O
10 695 704 12615818 conducted VBD B-VP O
11 705 706 12615818 a DT B-NP O
12 707 713 12615818 cohort JJ I-NP O
13 714 722 12615818 analysis NN I-NP O
14 723 726 12615818 and CC I-NP O
15 727 731 12615818 case NN I-NP O
16 731 732 12615818 - HYPH B-NP O
17 732 739 12615818 control NN I-NP O
18 740 745 12615818 study NN I-NP O
19 746 752 12615818 nested VBD B-VP O
20 753 759 12615818 within IN B-PP O
21 760 761 12615818 a DT B-NP O
22 762 772 12615818 population NN I-NP O
23 773 775 12615818 of IN B-PP O
24 776 781 12615818 women NNS B-NP O
25 782 786 12615818 aged JJ B-ADJP O
26 787 794 12615818 between IN B-PP O
27 795 797 12615818 15 CD B-NP O
28 798 801 12615818 and CC I-NP O
29 802 804 12615818 39 CD I-NP O
30 805 810 12615818 years NNS I-NP O
31 811 815 12615818 with IN B-PP O
32 816 820 12615818 acne NN B-NP B-Disease
33 820 821 12615818 , , O O
34 822 831 12615818 hirsutism NN B-NP B-Disease
35 832 834 12615818 or CC O O
36 835 839 12615818 PCOS NN B-NP B-Disease
37 840 842 12615818 to TO B-VP O
38 843 851 12615818 estimate VB I-VP O
39 852 855 12615818 the DT B-NP O
40 856 860 12615818 risk NN I-NP O
41 861 863 12615818 of IN B-PP O
42 864 867 12615818 VTE NN B-NP B-Disease
43 868 878 12615818 associated VBN B-VP O
44 879 883 12615818 with IN B-PP O
45 884 887 12615818 CPA NN B-NP B-Chemical
46 887 888 12615818 / SYM I-NP O
47 888 890 12615818 EE NN I-NP B-Chemical
48 890 891 12615818 . . O O

1 892 899 12615818 RESULTS NNS B-NP O
2 899 900 12615818 : : O O
3 901 904 12615818 The DT B-NP O
4 905 908 12615818 age NN I-NP O
5 908 909 12615818 - HYPH B-VP O
6 909 917 12615818 adjusted VBN B-NP O
7 918 927 12615818 incidence NN I-NP O
8 928 932 12615818 rate NN I-NP O
9 933 938 12615818 ratio NN I-NP O
10 939 942 12615818 for IN B-PP O
11 943 946 12615818 CPA NN B-NP B-Chemical
12 946 947 12615818 / SYM B-NP O
13 947 949 12615818 EE NN I-NP B-Chemical
14 950 956 12615818 versus IN B-PP O
15 957 969 12615818 conventional JJ B-NP O
16 970 974 12615818 COCs NNS I-NP O
17 975 978 12615818 was VBD B-VP O
18 979 983 12615818 2.20 CD B-NP O
19 984 985 12615818 [ ( O O
20 985 988 12615818 95% CD B-NP O
21 989 999 12615818 confidence NN I-NP O
22 1000 1008 12615818 interval NN I-NP O
23 1009 1010 12615818 ( ( O O
24 1010 1012 12615818 CI NN B-NP O
25 1012 1013 12615818 ) ) O O
26 1014 1018 12615818 1.35 CD B-NP O
27 1018 1019 12615818 - HYPH I-NP O
28 1019 1023 12615818 3.58 CD I-NP O
29 1023 1024 12615818 ] ) O O
30 1024 1025 12615818 . . O O

1 1026 1031 12615818 Using VBG B-VP O
2 1032 1034 12615818 as IN B-PP O
3 1035 1038 12615818 the DT B-NP O
4 1039 1048 12615818 reference NN I-NP O
5 1049 1054 12615818 group NN I-NP O
6 1055 1060 12615818 women NNS I-NP O
7 1061 1064 12615818 who WP B-NP O
8 1065 1069 12615818 were VBD B-VP O
9 1070 1073 12615818 not RB I-VP O
10 1074 1079 12615818 using VBG I-VP O
11 1080 1084 12615818 oral JJ B-NP O
12 1085 1098 12615818 contraception NN I-NP O
13 1098 1099 12615818 , , O O
14 1100 1103 12615818 had VBD B-VP O
15 1104 1106 12615818 no DT B-NP O
16 1107 1113 12615818 recent JJ I-NP O
17 1114 1123 12615818 pregnancy NN I-NP O
18 1124 1126 12615818 or CC I-NP O
19 1127 1137 12615818 menopausal JJ I-NP O
20 1138 1146 12615818 symptoms NNS I-NP O
21 1146 1147 12615818 , , O O
22 1148 1151 12615818 the DT B-NP O
23 1152 1156 12615818 case NN I-NP O
24 1156 1157 12615818 - HYPH B-NP O
25 1157 1164 12615818 control NN I-NP O
26 1165 1173 12615818 analysis NN I-NP O
27 1174 1178 12615818 gave VBD B-VP O
28 1179 1181 12615818 an DT B-NP O
29 1182 1190 12615818 adjusted VBN I-NP O
30 1191 1195 12615818 odds NNS I-NP O
31 1196 1201 12615818 ratio NN I-NP O
32 1202 1203 12615818 ( ( O O
33 1203 1210 12615818 OR(adj) NN B-NP O
34 1210 1211 12615818 ) ) O O
35 1212 1214 12615818 of IN B-PP O
36 1215 1219 12615818 7.44 CD B-NP O
37 1220 1221 12615818 ( ( O O
38 1221 1224 12615818 95% CD B-NP O
39 1225 1227 12615818 CI NN I-NP O
40 1228 1232 12615818 3.67 CD B-NP O
41 1232 1233 12615818 - HYPH I-NP O
42 1233 1238 12615818 15.08 CD I-NP O
43 1238 1239 12615818 ) ) O O
44 1240 1243 12615818 for IN B-PP O
45 1244 1247 12615818 CPA NN B-NP B-Chemical
46 1247 1248 12615818 / SYM I-NP O
47 1248 1250 12615818 EE NN I-NP B-Chemical
48 1251 1254 12615818 use NN I-NP O
49 1255 1263 12615818 compared VBN B-PP O
50 1264 1268 12615818 with IN B-PP O
51 1269 1271 12615818 an DT B-NP O
52 1272 1279 12615818 OR(adj) NN I-NP O
53 1280 1282 12615818 of IN B-PP O
54 1283 1287 12615818 2.58 CD B-NP O
55 1288 1289 12615818 ( ( O O
56 1289 1292 12615818 95% CD B-NP O
57 1293 1295 12615818 CI NN I-NP O
58 1296 1300 12615818 1.60 CD B-NP O
59 1300 1301 12615818 - HYPH I-NP O
60 1301 1305 12615818 4.18 CD I-NP O
61 1305 1306 12615818 ) ) O O
62 1307 1310 12615818 for IN B-PP O
63 1311 1314 12615818 use NN B-NP O
64 1315 1317 12615818 of IN B-PP O
65 1318 1330 12615818 conventional JJ B-NP O
66 1331 1335 12615818 COCs NNS I-NP O
67 1335 1336 12615818 . . O O

1 1337 1348 12615818 CONCLUSIONS NNS B-NP O
2 1348 1349 12615818 : : O O
3 1350 1352 12615818 We PRP B-NP O
4 1353 1357 12615818 have VBP B-VP O
5 1358 1370 12615818 demonstrated VBN I-VP O
6 1371 1373 12615818 an DT B-NP O
7 1374 1383 12615818 increased VBN I-NP O
8 1384 1388 12615818 risk NN I-NP O
9 1389 1391 12615818 of IN B-PP O
10 1392 1395 12615818 VTE NN B-NP B-Disease
11 1396 1406 12615818 associated VBN B-VP O
12 1407 1411 12615818 with IN B-PP O
13 1412 1415 12615818 the DT B-NP O
14 1416 1419 12615818 use NN I-NP O
15 1420 1422 12615818 of IN B-PP O
16 1423 1426 12615818 CPA NN B-NP B-Chemical
17 1426 1427 12615818 / SYM B-NP O
18 1427 1429 12615818 EE NN I-NP B-Chemical
19 1430 1432 12615818 in IN B-PP O
20 1433 1438 12615818 women NNS B-NP O
21 1439 1443 12615818 with IN B-PP O
22 1444 1448 12615818 acne NN B-NP B-Disease
23 1448 1449 12615818 , , I-NP O
24 1450 1459 12615818 hirsutism NN I-NP B-Disease
25 1460 1462 12615818 or CC I-NP O
26 1463 1467 12615818 PCOS NN I-NP B-Disease
27 1468 1476 12615818 although IN B-SBAR O
28 1477 1485 12615818 residual JJ B-NP O
29 1486 1497 12615818 confounding NN I-NP O
30 1498 1500 12615818 by IN B-PP O
31 1501 1511 12615818 indication NN B-NP O
32 1512 1518 12615818 cannot MD B-VP O
33 1519 1521 12615818 be VB I-VP O
34 1522 1530 12615818 excluded VBN I-VP O
35 1530 1531 12615818 . . O O

1 0 0 3187073 -DOCSTART- -X- -X- O

1 0 7 3187073 Adverse JJ B-NP O
2 8 15 3187073 cardiac JJ I-NP O
3 16 23 3187073 effects NNS I-NP O
4 24 30 3187073 during IN B-PP O
5 31 40 3187073 induction NN B-NP O
6 41 53 3187073 chemotherapy NN I-NP O
7 54 63 3187073 treatment NN I-NP O
8 64 68 3187073 with IN B-PP O
9 69 72 3187073 cis NN B-NP B-Chemical
10 72 73 3187073 - HYPH B-NP I-Chemical
11 73 79 3187073 platin NN I-NP I-Chemical
12 80 83 3187073 and CC O O
13 84 85 3187073 5 CD B-NP B-Chemical
14 85 86 3187073 - HYPH I-NP I-Chemical
15 86 98 3187073 fluorouracil NN I-NP I-Chemical
16 98 99 3187073 . . I-NP O
17 100 108 3187073 Survival NN I-NP O
18 109 112 3187073 for IN B-PP O
19 113 121 3187073 patients NNS B-NP O
20 122 126 3187073 with IN B-PP O
21 127 135 3187073 advanced VBN B-NP O
22 136 140 3187073 head NN I-NP B-Disease
23 141 144 3187073 and CC I-NP I-Disease
24 145 149 3187073 neck NN I-NP I-Disease
25 150 159 3187073 carcinoma NN I-NP I-Disease
26 160 163 3187073 and CC O O
27 164 174 3187073 esophageal JJ B-NP B-Disease
28 175 184 3187073 carcinoma NN I-NP I-Disease
29 185 187 3187073 is VBZ B-VP O
30 188 192 3187073 poor JJ B-ADJP O
31 193 197 3187073 with IN B-PP O
32 198 210 3187073 radiotherapy NN B-NP O
33 211 214 3187073 and CC O O
34 214 215 3187073 / SYM B-NP O
35 215 217 3187073 or CC O O
36 218 225 3187073 surgery NN B-NP O
37 225 226 3187073 . . O O

1 227 236 3187073 Obviously RB B-ADVP O
2 236 237 3187073 , , O O
3 238 243 3187073 there EX B-NP O
4 244 246 3187073 is VBZ B-VP O
5 247 248 3187073 a DT B-NP O
6 249 253 3187073 need NN I-NP O
7 254 257 3187073 for IN B-PP O
8 258 267 3187073 effective JJ B-NP O
9 268 280 3187073 chemotherapy NN I-NP O
10 280 281 3187073 . . O O

1 282 284 3187073 In IN B-PP O
2 285 288 3187073 the DT B-NP O
3 289 296 3187073 present JJ I-NP O
4 297 302 3187073 study NN I-NP O
5 302 303 3187073 , , O O
6 304 307 3187073 cis NN B-NP B-Chemical
7 307 308 3187073 - HYPH O I-Chemical
8 308 314 3187073 platin NN B-NP I-Chemical
9 315 316 3187073 ( ( O O
10 316 318 3187073 80 CD B-NP O
11 318 319 3187073 - HYPH I-NP O
12 319 322 3187073 120 CD I-NP O
13 323 325 3187073 mg NN I-NP O
14 325 326 3187073 / SYM B-NP O
15 326 331 3187073 m2BSA NN I-NP O
16 331 332 3187073 ) ) O O
17 333 336 3187073 and CC O O
18 337 338 3187073 5 CD B-NP B-Chemical
19 338 339 3187073 - HYPH I-NP I-Chemical
20 339 341 3187073 FU NN I-NP I-Chemical
21 342 343 3187073 ( ( O O
22 343 347 3187073 1000 CD B-NP O
23 348 350 3187073 mg NN I-NP O
24 350 351 3187073 / SYM B-NP O
25 351 356 3187073 m2BSA NN I-NP O
26 357 362 3187073 daily RB B-ADVP O
27 363 365 3187073 as IN B-PP O
28 366 367 3187073 a DT B-NP O
29 368 378 3187073 continuous JJ I-NP O
30 379 387 3187073 infusion NN I-NP O
31 388 394 3187073 during IN B-PP O
32 395 396 3187073 5 CD B-NP O
33 397 401 3187073 days NNS I-NP O
34 401 402 3187073 ) ) O O
35 403 407 3187073 were VBD B-VP O
36 408 413 3187073 given VBN I-VP O
37 414 416 3187073 to TO B-PP O
38 417 419 3187073 76 CD B-NP O
39 420 428 3187073 patients NNS I-NP O
40 429 435 3187073 before IN B-PP O
41 436 448 3187073 radiotherapy NN B-NP O
42 449 452 3187073 and CC I-NP O
43 453 460 3187073 surgery NN I-NP O
44 460 461 3187073 . . O O

1 462 465 3187073 The DT B-NP O
2 466 469 3187073 aim NN I-NP O
3 470 472 3187073 of IN B-PP O
4 473 476 3187073 the DT B-NP O
5 477 482 3187073 study NN I-NP O
6 483 486 3187073 was VBD B-VP O
7 487 489 3187073 to TO B-VP O
8 490 497 3187073 clarify VB I-VP O
9 498 501 3187073 the DT B-NP O
10 502 511 3187073 incidence NN I-NP O
11 512 515 3187073 and CC I-NP O
12 516 524 3187073 severity NN I-NP O
13 525 527 3187073 of IN B-PP O
14 528 535 3187073 adverse JJ B-NP O
15 536 543 3187073 cardiac JJ I-NP O
16 544 551 3187073 effects NNS I-NP O
17 552 554 3187073 to TO B-PP O
18 555 559 3187073 this DT B-NP O
19 560 569 3187073 treatment NN I-NP O
20 569 570 3187073 . . O O

1 571 577 3187073 Before IN B-PP O
2 578 587 3187073 treatment NN B-NP O
3 588 591 3187073 all DT B-NP O
4 592 600 3187073 patients NNS I-NP O
5 601 604 3187073 had VBD B-VP O
6 605 606 3187073 a DT B-NP O
7 607 614 3187073 cardiac JJ I-NP O
8 615 625 3187073 evaluation NN I-NP O
9 626 629 3187073 and CC B-PP O
10 630 636 3187073 during IN B-PP O
11 637 646 3187073 treatment NN B-NP O
12 647 653 3187073 serial JJ I-NP O
13 654 657 3187073 ECG NN I-NP O
14 658 668 3187073 recordings NNS I-NP O
15 669 673 3187073 were VBD B-VP O
16 674 683 3187073 performed VBN I-VP O
17 683 684 3187073 . . O O

1 685 687 3187073 In IN B-PP O
2 688 691 3187073 the DT B-NP O
3 692 695 3187073 pre AFX I-NP O
4 695 696 3187073 - HYPH I-NP O
5 696 705 3187073 treatment NN I-NP O
6 706 716 3187073 evaluation NN I-NP O
7 716 717 3187073 , , O O
8 718 723 3187073 signs NNS B-NP O
9 724 726 3187073 of IN B-PP O
10 727 741 3187073 cardiovascular JJ B-NP B-Disease
11 742 749 3187073 disease NN I-NP I-Disease
12 750 754 3187073 were VBD B-VP O
13 755 760 3187073 found VBN I-VP O
14 761 763 3187073 in IN B-PP O
15 764 766 3187073 33 CD B-NP O
16 767 775 3187073 patients NNS I-NP O
17 776 777 3187073 ( ( O O
18 777 780 3187073 43% CD B-NP O
19 780 781 3187073 ) ) O O
20 781 782 3187073 . . O O

1 783 789 3187073 During IN B-PP O
2 790 799 3187073 treatment NN B-NP O
3 799 800 3187073 , , O O
4 801 808 3187073 adverse JJ B-NP O
5 809 816 3187073 cardiac JJ I-NP O
6 817 824 3187073 effects NNS I-NP O
7 825 829 3187073 were VBD B-VP O
8 830 838 3187073 observed VBN I-VP O
9 839 841 3187073 in IN B-PP O
10 842 844 3187073 14 CD B-NP O
11 845 853 3187073 patients NNS I-NP O
12 854 855 3187073 ( ( O O
13 855 858 3187073 18% CD B-NP O
14 858 859 3187073 ) ) O O
15 859 860 3187073 . . O O

1 861 864 3187073 The DT B-NP O
2 865 869 3187073 mean JJ I-NP O
3 870 873 3187073 age NN I-NP O
4 874 876 3187073 of IN B-PP O
5 877 882 3187073 these DT B-NP O
6 883 891 3187073 patients NNS I-NP O
7 892 895 3187073 was VBD B-VP O
8 896 899 3187073 the DT B-NP O
9 900 904 3187073 same JJ I-NP O
10 905 907 3187073 as IN B-PP O
11 908 911 3187073 for IN B-PP O
12 912 915 3187073 the DT B-NP O
13 916 922 3187073 entire JJ I-NP O
14 923 928 3187073 group NN I-NP O
15 928 929 3187073 , , O O
16 930 932 3187073 64 CD B-NP O
17 933 938 3187073 years NNS I-NP O
18 938 939 3187073 . . O O

1 940 943 3187073 The DT B-NP O
2 944 953 3187073 incidence NN I-NP O
3 954 956 3187073 of IN B-PP O
4 957 971 3187073 cardiotoxicity NN B-NP B-Disease
5 972 975 3187073 was VBD B-VP O
6 976 979 3187073 not RB O O
7 980 986 3187073 higher JJR B-ADJP O
8 987 989 3187073 in IN B-PP O
9 990 998 3187073 patients NNS B-NP O
10 999 1003 3187073 with IN B-PP O
11 1004 1009 3187073 signs NNS B-NP O
12 1010 1012 3187073 of IN B-PP O
13 1013 1027 3187073 cardiovascular JJ B-NP B-Disease
14 1028 1035 3187073 disease NN I-NP I-Disease
15 1036 1040 3187073 than IN B-PP O
16 1041 1043 3187073 in IN B-PP O
17 1044 1049 3187073 those DT B-NP O
18 1050 1057 3187073 without IN B-PP O
19 1058 1060 3187073 in IN B-PP O
20 1061 1064 3187073 the DT B-NP O
21 1065 1068 3187073 pre AFX I-NP O
22 1068 1069 3187073 - HYPH I-NP O
23 1069 1078 3187073 treatment NN I-NP O
24 1079 1089 3187073 evaluation NN I-NP O
25 1089 1090 3187073 . . O O

1 1091 1094 3187073 The DT B-NP O
2 1095 1099 3187073 most RBS I-NP O
3 1100 1106 3187073 common JJ I-NP O
4 1107 1112 3187073 signs NNS I-NP O
5 1113 1115 3187073 of IN B-PP O
6 1116 1130 3187073 cardiotoxicity NN B-NP B-Disease
7 1131 1135 3187073 were VBD B-VP O
8 1136 1141 3187073 chest NN B-NP B-Disease
9 1142 1146 3187073 pain NN I-NP I-Disease
10 1146 1147 3187073 , , O O
11 1148 1150 3187073 ST NN B-NP O
12 1150 1151 3187073 - HYPH I-NP O
13 1151 1152 3187073 T NN I-NP O
14 1153 1157 3187073 wave NN I-NP O
15 1158 1165 3187073 changes NNS I-NP O
16 1166 1169 3187073 and CC O O
17 1170 1176 3187073 atrial JJ B-NP B-Disease
18 1177 1189 3187073 fibrillation NN I-NP I-Disease
19 1189 1190 3187073 . . O O

1 1191 1195 3187073 This DT B-NP O
2 1196 1199 3187073 was VBD B-VP O
3 1200 1208 3187073 followed VBN I-VP O
4 1209 1211 3187073 by IN B-PP O
5 1212 1223 3187073 ventricular JJ B-NP B-Disease
6 1224 1236 3187073 fibrillation NN I-NP I-Disease
7 1237 1239 3187073 in IN B-PP O
8 1240 1243 3187073 one CD B-NP O
9 1244 1251 3187073 patient NN I-NP O
10 1252 1255 3187073 and CC O O
11 1256 1262 3187073 sudden JJ B-NP B-Disease
12 1263 1268 3187073 death NN I-NP I-Disease
13 1269 1271 3187073 in IN B-PP O
14 1272 1279 3187073 another DT B-NP O
15 1279 1280 3187073 . . O O

1 1281 1283 3187073 It PRP B-NP O
2 1284 1286 3187073 is VBZ B-VP O
3 1287 1296 3187073 concluded VBN I-VP O
4 1297 1301 3187073 that IN B-SBAR O
5 1302 1310 3187073 patients NNS B-NP O
6 1311 1313 3187073 on IN B-PP O
7 1314 1315 3187073 5 CD B-NP B-Chemical
8 1315 1316 3187073 - HYPH I-NP I-Chemical
9 1316 1318 3187073 FU NN I-NP I-Chemical
10 1319 1328 3187073 treatment NN I-NP O
11 1329 1335 3187073 should MD B-VP O
12 1336 1338 3187073 be VB I-VP O
13 1339 1344 3187073 under IN B-PP O
14 1345 1350 3187073 close JJ B-NP O
15 1351 1362 3187073 supervision NN I-NP O
16 1363 1366 3187073 and CC O O
17 1367 1371 3187073 that IN B-SBAR O
18 1372 1375 3187073 the DT B-NP O
19 1376 1385 3187073 treatment NN I-NP O
20 1386 1392 3187073 should MD B-VP O
21 1393 1395 3187073 be VB I-VP O
22 1396 1408 3187073 discontinued VBN I-VP O
23 1409 1411 3187073 if IN B-SBAR O
24 1412 1417 3187073 chest NN B-NP B-Disease
25 1418 1422 3187073 pain NN I-NP I-Disease
26 1423 1425 3187073 or CC I-NP O
27 1426 1441 3187073 tachyarrhythmia NN I-NP B-Disease
28 1442 1444 3187073 is VBZ B-VP O
29 1445 1453 3187073 observed VBN I-VP O
30 1453 1454 3187073 . . O O

1 0 0 11581460 -DOCSTART- -X- -X- O

1 0 7 11581460 Bladder NN B-NP O
2 8 17 11581460 retention NN I-NP B-Disease
3 18 20 11581460 of IN B-PP I-Disease
4 21 26 11581460 urine NN B-NP I-Disease
5 27 29 11581460 as IN B-PP O
6 30 31 11581460 a DT B-NP O
7 32 38 11581460 result NN I-NP O
8 39 41 11581460 of IN B-PP O
9 42 52 11581460 continuous JJ B-NP O
10 53 64 11581460 intravenous JJ I-NP O
11 65 73 11581460 infusion NN I-NP O
12 74 76 11581460 of IN B-PP O
13 77 85 11581460 fentanyl NN B-NP B-Chemical
14 85 86 11581460 : : O O
15 87 88 11581460 2 CD B-NP O
16 89 93 11581460 case NN I-NP O
17 94 101 11581460 reports NNS I-NP O
18 101 102 11581460 . . O O
19 103 111 11581460 Sedation NN B-NP O
20 112 115 11581460 has VBZ B-VP O
21 116 120 11581460 been VBN I-VP O
22 121 129 11581460 commonly RB I-VP O
23 130 134 11581460 used VBN I-VP O
24 135 137 11581460 in IN B-PP O
25 138 141 11581460 the DT B-NP O
26 142 149 11581460 neonate NN I-NP O
27 150 152 11581460 to TO B-VP O
28 153 161 11581460 decrease VB I-VP O
29 162 165 11581460 the DT B-NP O
30 166 172 11581460 stress NN I-NP O
31 173 176 11581460 and CC I-NP O
32 177 181 11581460 pain NN I-NP B-Disease
33 182 186 11581460 from IN B-PP O
34 187 190 11581460 the DT B-NP O
35 191 198 11581460 noxious JJ I-NP O
36 199 206 11581460 stimuli NNS I-NP O
37 207 210 11581460 and CC O O
38 211 219 11581460 invasive JJ B-NP O
39 220 230 11581460 procedures NNS I-NP O
40 231 233 11581460 in IN B-PP O
41 234 237 11581460 the DT B-NP O
42 238 246 11581460 neonatal JJ I-NP O
43 247 256 11581460 intensive JJ I-NP O
44 257 261 11581460 care NN I-NP O
45 262 266 11581460 unit NN I-NP O
46 266 267 11581460 , , O O
47 268 270 11581460 as RB B-CONJP O
48 271 275 11581460 well RB I-CONJP O
49 276 278 11581460 as IN I-CONJP O
50 279 281 11581460 to TO B-VP O
51 282 292 11581460 facilitate VB I-VP O
52 293 302 11581460 synchrony NN B-NP O
53 303 310 11581460 between IN B-PP O
54 311 321 11581460 ventilator NN B-NP O
55 322 325 11581460 and CC O O
56 326 337 11581460 spontaneous JJ B-NP O
57 338 345 11581460 breaths NNS I-NP O
58 345 346 11581460 . . O O

1 347 355 11581460 Fentanyl NN B-NP B-Chemical
2 355 356 11581460 , , O O
3 357 359 11581460 an DT B-NP O
4 360 366 11581460 opioid JJ I-NP O
5 367 376 11581460 analgesic NN I-NP O
6 376 377 11581460 , , O O
7 378 380 11581460 is VBZ B-VP O
8 381 391 11581460 frequently RB I-VP O
9 392 396 11581460 used VBN I-VP O
10 397 399 11581460 in IN B-PP O
11 400 403 11581460 the DT B-NP O
12 404 412 11581460 neonatal JJ I-NP O
13 413 422 11581460 intensive JJ I-NP O
14 423 427 11581460 care NN I-NP O
15 428 432 11581460 unit NN I-NP O
16 433 440 11581460 setting VBG B-VP O
17 441 444 11581460 for IN B-PP O
18 445 450 11581460 these DT B-NP O
19 451 455 11581460 very JJ I-NP O
20 456 464 11581460 purposes NNS I-NP O
21 464 465 11581460 . . O O

1 466 473 11581460 Various NNP B-NP O
2 474 482 11581460 reported VBD B-VP O
3 483 487 11581460 side NN B-NP O
4 488 495 11581460 effects NNS I-NP O
5 496 498 11581460 of IN B-PP O
6 499 507 11581460 fentanyl NN B-NP B-Chemical
7 508 522 11581460 administration NN I-NP O
8 523 530 11581460 include VBP B-VP O
9 531 536 11581460 chest NN B-NP B-Disease
10 537 541 11581460 wall NN I-NP I-Disease
11 542 550 11581460 rigidity NN I-NP I-Disease
12 550 551 11581460 , , O O
13 552 563 11581460 hypotension NN B-NP B-Disease
14 563 564 11581460 , , O O
15 565 576 11581460 respiratory JJ B-NP B-Disease
16 577 587 11581460 depression NN I-NP I-Disease
17 587 588 11581460 , , O O
18 589 592 11581460 and CC O O
19 593 604 11581460 bradycardia NN B-NP B-Disease
20 604 605 11581460 . . O O

1 606 610 11581460 Here RB B-ADVP O
2 610 611 11581460 , , O O
3 612 613 11581460 2 CD B-NP O
4 614 619 11581460 cases NNS I-NP O
5 620 622 11581460 of IN B-PP O
6 623 630 11581460 urinary JJ B-NP B-Disease
7 631 638 11581460 bladder NN I-NP I-Disease
8 639 648 11581460 retention NN I-NP I-Disease
9 649 656 11581460 leading VBG B-VP O
10 657 659 11581460 to TO B-PP O
11 660 665 11581460 renal JJ B-NP O
12 666 679 11581460 pelvocalyceal JJ I-NP O
13 680 690 11581460 dilatation NN I-NP O
14 691 700 11581460 mimicking VBG B-VP O
15 701 715 11581460 hydronephrosis NN B-NP B-Disease
16 716 718 11581460 as IN B-PP O
17 719 720 11581460 a DT B-NP O
18 721 727 11581460 result NN I-NP O
19 728 730 11581460 of IN B-PP O
20 731 741 11581460 continuous JJ B-NP O
21 742 750 11581460 infusion NN I-NP O
22 751 753 11581460 of IN B-PP O
23 754 762 11581460 fentanyl NN B-NP B-Chemical
24 763 766 11581460 are VBP B-VP O
25 767 775 11581460 reported VBN I-VP O
26 775 776 11581460 . . O O

1 0 0 18081909 -DOCSTART- -X- -X- O

1 0 14 18081909 Encephalopathy NN B-NP B-Disease
2 15 22 18081909 induced VBN B-VP O
3 23 25 18081909 by IN B-PP O
4 26 39 18081909 levetiracetam NN B-NP B-Chemical
5 40 45 18081909 added VBN B-VP O
6 46 48 18081909 to TO I-VP O
7 49 58 18081909 valproate VB I-VP B-Chemical
8 58 59 18081909 . . O O
9 60 70 18081909 BACKGROUND NN B-NP O
10 70 71 18081909 : : O O
11 72 74 18081909 We PRP B-NP O
12 75 81 18081909 report VBP B-VP O
13 82 84 18081909 on IN B-PP O
14 85 88 18081909 the DT B-NP O
15 89 102 18081909 manifestation NN I-NP O
16 103 105 18081909 of IN B-PP O
17 106 107 18081909 a DT B-NP O
18 108 121 18081909 levetiracetam NN I-NP B-Chemical
19 122 123 18081909 ( ( O O
20 123 126 18081909 LEV NN B-NP B-Chemical
21 126 127 18081909 ) ) O O
22 127 128 18081909 - HYPH B-NP O
23 128 135 18081909 induced VBN I-NP O
24 136 150 18081909 encephalopathy NN I-NP B-Disease
25 150 151 18081909 . . O O

1 152 160 18081909 FINDINGS NNS B-NP O
2 160 161 18081909 : : O O
3 162 163 18081909 A DT B-NP O
4 164 166 18081909 28 CD I-NP O
5 166 167 18081909 - HYPH I-NP O
6 167 171 18081909 year NN I-NP O
7 171 172 18081909 - HYPH O O
8 172 175 18081909 old JJ B-NP O
9 176 179 18081909 man NN I-NP O
10 180 189 18081909 suffering VBG B-VP O
11 190 194 18081909 from IN B-PP O
12 195 205 18081909 idiopathic JJ B-NP B-Disease
13 206 214 18081909 epilepsy NN I-NP I-Disease
14 215 219 18081909 with IN B-PP O
15 220 231 18081909 generalized VBN B-NP O
16 232 240 18081909 seizures NNS I-NP B-Disease
17 241 244 18081909 was VBD B-VP O
18 245 252 18081909 treated VBN I-VP O
19 253 257 18081909 with IN B-PP O
20 258 261 18081909 LEV NN B-NP B-Chemical
21 262 263 18081909 ( ( O O
22 263 267 18081909 3000 CD B-NP O
23 268 270 18081909 mg NN I-NP O
24 270 271 18081909 ) ) O O
25 272 277 18081909 added VBN B-VP O
26 278 280 18081909 to TO B-PP O
27 281 290 18081909 valproate NN B-NP B-Chemical
28 291 292 18081909 ( ( O O
29 292 295 18081909 VPA NN B-NP B-Chemical
30 295 296 18081909 ) ) O O
31 297 298 18081909 ( ( O O
32 298 302 18081909 2000 CD B-NP O
33 303 305 18081909 mg NN I-NP O
34 305 306 18081909 ) ) O O
35 306 307 18081909 . . O O

1 308 317 18081909 Frequency NN B-NP O
2 318 320 18081909 of IN B-PP O
3 321 332 18081909 generalized VBN B-NP O
4 333 338 18081909 tonic JJ I-NP B-Disease
5 338 339 18081909 - HYPH I-NP I-Disease
6 339 345 18081909 clonic JJ I-NP I-Disease
7 346 354 18081909 seizures NNS I-NP I-Disease
8 355 364 18081909 increased VBD B-VP O
9 365 369 18081909 from IN B-PP O
10 370 373 18081909 one CD B-NP O
11 374 377 18081909 per IN B-PP O
12 378 379 18081909 6 CD B-NP O
13 380 386 18081909 months NNS I-NP O
14 387 389 18081909 to TO B-PP O
15 390 393 18081909 two CD B-NP O
16 394 397 18081909 per IN B-PP O
17 398 403 18081909 month NN B-NP O
18 403 404 18081909 . . O O

1 405 423 18081909 Neuropsychological JJ B-NP O
2 424 431 18081909 testing NN I-NP O
3 432 438 18081909 showed VBD B-VP O
4 439 447 18081909 impaired JJ B-NP B-Disease
5 448 452 18081909 word NN I-NP I-Disease
6 453 460 18081909 fluency NN I-NP I-Disease
7 460 461 18081909 , , O I-Disease
8 462 473 18081909 psychomotor NN B-NP I-Disease
9 474 479 18081909 speed NN I-NP I-Disease
10 480 483 18081909 and CC O I-Disease
11 484 491 18081909 working VBG B-NP I-Disease
12 492 498 18081909 memory NN I-NP I-Disease
13 498 499 18081909 . . O O

1 500 503 18081909 The DT B-NP O
2 504 514 18081909 interictal JJ I-NP O
3 515 535 18081909 electroencephalogram NN I-NP O
4 536 537 18081909 ( ( O O
5 537 540 18081909 EEG NN B-NP O
6 540 541 18081909 ) ) O O
7 542 548 18081909 showed VBD B-VP O
8 549 550 18081909 a DT B-NP O
9 551 562 18081909 generalized VBN I-NP O
10 563 570 18081909 slowing VBG B-VP O
11 571 573 18081909 to TO B-PP O
12 574 575 18081909 5 CD B-NP O
13 576 579 18081909 per IN B-PP O
14 580 586 18081909 second JJ B-NP O
15 587 592 18081909 theta NN I-NP O
16 593 600 18081909 rhythms NNS I-NP O
17 601 605 18081909 with IN B-PP O
18 606 615 18081909 bilateral JJ B-NP O
19 616 627 18081909 generalized VBN I-NP O
20 628 632 18081909 high JJ I-NP O
21 632 633 18081909 - HYPH I-NP O
22 633 642 18081909 amplitude NN I-NP O
23 643 653 18081909 discharges NNS I-NP O
24 653 654 18081909 . . O O

1 655 662 18081909 OUTCOME NN B-NP O
2 662 663 18081909 : : O O
3 664 673 18081909 Following VBG B-VP O
4 674 689 18081909 discontinuation NN B-NP O
5 690 692 18081909 of IN B-PP O
6 693 696 18081909 LEV NN B-NP B-Chemical
7 696 697 18081909 , , O O
8 698 701 18081909 EEG NN B-NP O
9 702 705 18081909 and CC O O
10 706 724 18081909 neuropsychological JJ B-NP O
11 725 733 18081909 findings NNS I-NP O
12 734 742 18081909 improved VBN B-VP O
13 743 746 18081909 and CC O O
14 747 754 18081909 seizure NN B-NP B-Disease
15 755 764 18081909 frequency NN I-NP O
16 765 774 18081909 decreased VBD B-VP O
17 774 775 18081909 . . O O

1 0 0 1720453 -DOCSTART- -X- -X- O

1 0 4 1720453 Long JJ B-NP O
2 4 5 1720453 - HYPH I-NP O
3 5 9 1720453 term NN I-NP O
4 10 16 1720453 follow VB B-VP O
5 16 17 1720453 - HYPH O O
6 17 19 1720453 up RP B-PRT O
7 20 22 1720453 of IN B-PP O
8 23 33 1720453 ifosfamide NN B-NP B-Chemical
9 34 39 1720453 renal JJ I-NP B-Disease
10 40 48 1720453 toxicity NN I-NP I-Disease
11 49 51 1720453 in IN B-PP O
12 52 60 1720453 children NNS B-NP O
13 61 68 1720453 treated VBN B-VP O
14 69 72 1720453 for IN B-PP O
15 73 82 1720453 malignant JJ B-NP B-Disease
16 83 94 1720453 mesenchymal JJ I-NP I-Disease
17 95 101 1720453 tumors NNS I-NP I-Disease
18 101 102 1720453 : : O O
19 103 105 1720453 an DT B-NP O
20 106 119 1720453 International NNP I-NP O
21 120 127 1720453 Society NNP I-NP O
22 128 130 1720453 of IN B-PP O
23 131 140 1720453 Pediatric NNP B-NP O
24 141 149 1720453 Oncology NNP I-NP O
25 150 156 1720453 report NN I-NP O
26 156 157 1720453 . . O O
27 158 161 1720453 The DT B-NP O
28 162 167 1720453 renal JJ I-NP O
29 168 176 1720453 function NN I-NP O
30 177 179 1720453 of IN B-PP O
31 180 182 1720453 74 CD B-NP O
32 183 191 1720453 children NNS I-NP O
33 192 196 1720453 with IN B-PP O
34 197 206 1720453 malignant JJ B-NP B-Disease
35 207 218 1720453 mesenchymal JJ I-NP I-Disease
36 219 225 1720453 tumors NNS I-NP I-Disease
37 226 228 1720453 in IN B-PP O
38 229 237 1720453 complete JJ B-NP O
39 238 247 1720453 remission NN I-NP O
40 248 251 1720453 and CC O O
41 252 255 1720453 who WP B-NP O
42 256 260 1720453 have VBP B-VP O
43 261 269 1720453 received VBN I-VP O
44 270 273 1720453 the DT B-NP O
45 274 278 1720453 same JJ I-NP O
46 279 289 1720453 ifosfamide NN I-NP B-Chemical
47 290 302 1720453 chemotherapy NN I-NP O
48 303 311 1720453 protocol NN I-NP O
49 312 313 1720453 ( ( O O
50 313 326 1720453 International NNP B-NP O
51 327 334 1720453 Society NNP I-NP O
52 335 337 1720453 of IN B-PP O
53 338 347 1720453 Pediatric NNP B-NP O
54 348 356 1720453 Oncology NNP I-NP O
55 357 366 1720453 Malignant NNP I-NP B-Disease
56 367 378 1720453 Mesenchymal NNP I-NP I-Disease
57 379 384 1720453 Tumor NNP I-NP I-Disease
58 385 390 1720453 Study NNP I-NP O
59 391 393 1720453 84 CD I-NP O
60 394 395 1720453 [ ( B-NP O
61 395 399 1720453 SIOP NN I-NP O
62 400 403 1720453 MMT NN I-NP O
63 404 406 1720453 84 CD I-NP O
64 406 407 1720453 ] ) O O
65 407 408 1720453 ) ) O O
66 409 413 1720453 were VBD B-VP O
67 414 421 1720453 studied VBN I-VP O
68 422 423 1720453 1 CD B-NP O
69 424 428 1720453 year NN I-NP O
70 429 434 1720453 after IN B-PP O
71 435 438 1720453 the DT B-NP O
72 439 449 1720453 completion NN I-NP O
73 450 452 1720453 of IN B-PP O
74 453 462 1720453 treatment NN B-NP O
75 462 463 1720453 . . O O

1 464 469 1720453 Total JJ B-NP O
2 470 480 1720453 cumulative JJ I-NP O
3 481 486 1720453 doses NNS I-NP O
4 487 491 1720453 were VBD B-VP O
5 492 494 1720453 36 CD B-NP O
6 495 497 1720453 or CC I-NP O
7 498 500 1720453 60 CD I-NP O
8 501 502 1720453 g NN I-NP O
9 502 503 1720453 / SYM B-NP O
10 503 505 1720453 m2 NN I-NP O
11 506 508 1720453 of IN B-PP O
12 509 519 1720453 ifosfamide NN B-NP B-Chemical
13 520 521 1720453 ( ( O O
14 521 524 1720453 six CD B-NP O
15 525 527 1720453 or CC I-NP O
16 528 530 1720453 10 CD I-NP O
17 531 537 1720453 cycles NNS I-NP O
18 538 540 1720453 of IN B-PP O
19 541 551 1720453 ifosfamide NN B-NP B-Chemical
20 551 552 1720453 , , O I-Chemical
21 553 564 1720453 vincristine NN B-NP I-Chemical
22 564 565 1720453 , , O I-Chemical
23 566 569 1720453 and CC O I-Chemical
24 570 582 1720453 dactinomycin NN B-NP I-Chemical
25 583 584 1720453 [ ( O O
26 584 587 1720453 IVA NN B-NP B-Chemical
27 587 588 1720453 ] ) O O
28 588 589 1720453 ) ) O O
29 589 590 1720453 . . O O

1 591 595 1720453 None NN B-NP O
2 596 598 1720453 of IN B-PP O
3 599 603 1720453 them PRP B-NP O
4 604 607 1720453 had VBD B-VP O
5 608 616 1720453 received VBN I-VP O
6 617 626 1720453 cisplatin NN B-NP B-Chemical
7 627 639 1720453 chemotherapy NN I-NP O
8 639 640 1720453 . . O O

1 641 645 1720453 Ages NNS B-NP O
2 646 652 1720453 ranged VBD B-VP O
3 653 657 1720453 from IN B-PP O
4 658 659 1720453 4 CD B-NP O
5 660 666 1720453 months NNS I-NP O
6 667 669 1720453 to TO B-PP O
7 670 672 1720453 17 CD B-NP O
8 673 678 1720453 years NNS I-NP O
9 678 679 1720453 ; : O O
10 680 682 1720453 58 CD B-NP O
11 683 691 1720453 patients NNS I-NP O
12 692 696 1720453 were VBD B-VP O
13 697 702 1720453 males NNS B-NP O
14 703 706 1720453 and CC O O
15 707 709 1720453 42 CD B-NP O
16 710 717 1720453 females NNS I-NP O
17 717 718 1720453 . . O O

1 719 722 1720453 The DT B-NP O
2 723 727 1720453 most RBS I-NP O
3 728 734 1720453 common JJ I-NP O
4 735 742 1720453 primary JJ I-NP O
5 743 748 1720453 tumor NN I-NP B-Disease
6 749 753 1720453 site NN I-NP O
7 754 757 1720453 was VBD B-VP O
8 758 761 1720453 the DT B-NP O
9 762 766 1720453 head NN I-NP O
10 767 770 1720453 and CC I-NP O
11 771 775 1720453 neck NN I-NP O
12 775 776 1720453 . . O O

1 777 782 1720453 Renal JJ B-NP O
2 783 791 1720453 function NN I-NP O
3 792 795 1720453 was VBD B-VP O
4 796 808 1720453 investigated VBN I-VP O
5 809 811 1720453 by IN B-PP O
6 812 821 1720453 measuring VBG B-VP O
7 822 828 1720453 plasma NN B-NP O
8 829 832 1720453 and CC O O
9 833 840 1720453 urinary JJ B-NP O
10 841 853 1720453 electrolytes NNS I-NP O
11 853 854 1720453 , , O O
12 855 865 1720453 glucosuria NN B-NP B-Disease
13 865 866 1720453 , , O O
14 867 878 1720453 proteinuria NN B-NP B-Disease
15 878 879 1720453 , , O O
16 880 893 1720453 aminoaciduria NN B-NP B-Disease
17 893 894 1720453 , , O O
18 895 902 1720453 urinary JJ B-NP O
19 903 905 1720453 pH NN I-NP O
20 905 906 1720453 , , O O
21 907 917 1720453 osmolarity NN B-NP O
22 917 918 1720453 , , O O
23 919 929 1720453 creatinine NN B-NP B-Chemical
24 930 939 1720453 clearance NN I-NP O
25 939 940 1720453 , , O O
26 941 950 1720453 phosphate NN B-NP B-Chemical
27 951 958 1720453 tubular JJ I-NP O
28 959 971 1720453 reabsorption NN I-NP O
29 971 972 1720453 , , O O
30 973 977 1720453 beta NN B-NP O
31 978 979 1720453 2 CD I-NP O
32 980 997 1720453 microglobulinuria NNS I-NP O
33 997 998 1720453 , , O O
34 999 1002 1720453 and CC O O
35 1003 1014 1720453 lysozymuria NN B-NP O
36 1014 1015 1720453 . . O O

1 1016 1021 1720453 Fifty CD B-NP O
2 1021 1022 1720453 - HYPH I-NP O
3 1022 1027 1720453 eight CD B-NP O
4 1028 1036 1720453 patients NNS I-NP O
5 1037 1038 1720453 ( ( O O
6 1038 1041 1720453 78% NN B-NP O
7 1041 1042 1720453 ) ) O O
8 1043 1046 1720453 had VBD B-VP O
9 1047 1053 1720453 normal JJ B-NP O
10 1054 1059 1720453 renal JJ I-NP O
11 1060 1065 1720453 tests NNS I-NP O
12 1065 1066 1720453 , , O O
13 1067 1074 1720453 whereas IN O O
14 1075 1077 1720453 16 CD B-NP O
15 1078 1086 1720453 patients NNS I-NP O
16 1087 1088 1720453 ( ( O O
17 1088 1091 1720453 22% NN B-NP O
18 1091 1092 1720453 ) ) O O
19 1093 1096 1720453 had VBD B-VP O
20 1097 1102 1720453 renal JJ B-NP B-Disease
21 1103 1116 1720453 abnormalities NNS I-NP I-Disease
22 1116 1117 1720453 . . O O

1 1118 1121 1720453 Two CD B-NP O
2 1122 1129 1720453 subsets NNS I-NP O
3 1130 1132 1720453 of IN B-PP O
4 1133 1141 1720453 patients NNS B-NP O
5 1142 1146 1720453 were VBD B-VP O
6 1147 1157 1720453 identified VBN I-VP O
7 1158 1162 1720453 from IN B-PP O
8 1163 1167 1720453 this DT B-NP O
9 1168 1174 1720453 latter JJ I-NP O
10 1175 1180 1720453 group NN I-NP O
11 1180 1181 1720453 : : O O
12 1182 1185 1720453 the DT B-NP O
13 1186 1191 1720453 first JJ I-NP O
14 1192 1200 1720453 included VBD B-VP O
15 1201 1205 1720453 four CD B-NP O
16 1206 1214 1720453 patients NNS I-NP O
17 1215 1216 1720453 ( ( O O
18 1216 1218 1720453 5% CD B-NP O
19 1219 1221 1720453 of IN B-PP O
20 1222 1225 1720453 the DT B-NP O
21 1226 1231 1720453 total JJ I-NP O
22 1232 1242 1720453 population NN I-NP O
23 1242 1243 1720453 ) ) O O
24 1244 1247 1720453 who WP B-NP O
25 1248 1257 1720453 developed VBD B-VP O
26 1258 1263 1720453 major JJ B-NP O
27 1264 1272 1720453 toxicity NN I-NP B-Disease
28 1273 1282 1720453 resulting VBG B-VP O
29 1283 1285 1720453 in IN B-PP O
30 1286 1295 1720453 Fanconi's NNS B-NP B-Disease
31 1296 1304 1720453 syndrome NN I-NP I-Disease
32 1305 1306 1720453 ( ( O O
33 1306 1310 1720453 TDFS NN B-NP B-Disease
34 1310 1311 1720453 ) ) O O
35 1311 1312 1720453 ; : O O
36 1313 1316 1720453 and CC O O
37 1317 1320 1720453 the DT B-NP O
38 1321 1327 1720453 second JJ I-NP O
39 1328 1333 1720453 group NN I-NP O
40 1334 1342 1720453 included VBD B-VP O
41 1343 1347 1720453 five CD B-NP O
42 1348 1356 1720453 patients NNS I-NP O
43 1357 1361 1720453 with IN B-PP O
44 1362 1370 1720453 elevated VBN B-NP O
45 1371 1375 1720453 beta SYM I-NP O
46 1376 1377 1720453 2 CD I-NP O
47 1378 1395 1720453 microglobulinuria NNS I-NP O
48 1396 1399 1720453 and CC O O
49 1400 1403 1720453 low JJ B-NP O
50 1404 1413 1720453 phosphate NN I-NP B-Chemical
51 1414 1426 1720453 reabsorption NN I-NP O
52 1426 1427 1720453 . . O O

1 1428 1431 1720453 The DT B-NP O
2 1432 1441 1720453 remaining VBG I-NP O
3 1442 1447 1720453 seven CD I-NP O
4 1448 1456 1720453 patients NNS I-NP O
5 1457 1460 1720453 had VBD B-VP O
6 1461 1469 1720453 isolated VBN I-VP O
7 1470 1474 1720453 beta SYM B-NP O
8 1475 1476 1720453 2 CD I-NP O
9 1477 1494 1720453 microglobulinuria NNS I-NP O
10 1494 1495 1720453 . . O O

1 1496 1502 1720453 Severe JJ B-NP O
2 1503 1511 1720453 toxicity NN I-NP B-Disease
3 1512 1515 1720453 was VBD B-VP O
4 1516 1526 1720453 correlated VBN I-VP O
5 1527 1531 1720453 with IN B-PP O
6 1532 1535 1720453 the DT B-NP O
7 1536 1542 1720453 higher JJR I-NP O
8 1543 1553 1720453 cumulative JJ I-NP O
9 1554 1558 1720453 dose NN I-NP O
10 1559 1561 1720453 of IN B-PP O
11 1562 1564 1720453 60 CD B-NP O
12 1565 1566 1720453 g NN I-NP O
13 1566 1567 1720453 / SYM B-NP O
14 1567 1569 1720453 m2 NN I-NP O
15 1570 1572 1720453 of IN B-PP O
16 1573 1583 1720453 ifosfamide NN B-NP B-Chemical
17 1583 1584 1720453 , , O O
18 1585 1586 1720453 a DT B-NP O
19 1587 1594 1720453 younger JJR I-NP O
20 1595 1598 1720453 age NN I-NP O
21 1599 1600 1720453 ( ( O O
22 1600 1604 1720453 less JJR B-NP O
23 1605 1609 1720453 than IN I-NP O
24 1610 1611 1720453 2 CD I-NP O
25 1612 1613 1720453 1 CD I-NP O
26 1613 1614 1720453 / SYM B-NP O
27 1614 1615 1720453 2 CD B-NP O
28 1616 1621 1720453 years NNS I-NP O
29 1622 1625 1720453 old JJ B-ADJP O
30 1625 1626 1720453 ) ) O O
31 1626 1627 1720453 , , O O
32 1628 1631 1720453 and CC O O
33 1632 1633 1720453 a DT B-NP O
34 1634 1646 1720453 predominance NN I-NP O
35 1647 1649 1720453 of IN B-PP O
36 1650 1665 1720453 vesicoprostatic JJ B-NP O
37 1666 1671 1720453 tumor NN I-NP B-Disease
38 1672 1683 1720453 involvement NN I-NP O
39 1683 1684 1720453 . . O O

1 1685 1689 1720453 This DT B-NP O
2 1690 1693 1720453 low JJ I-NP O
3 1694 1704 1720453 percentage NN I-NP O
4 1705 1706 1720453 ( ( O O
5 1706 1708 1720453 5% NN B-NP O
6 1708 1709 1720453 ) ) O O
7 1710 1712 1720453 of IN B-PP O
8 1713 1717 1720453 TDFS NN B-NP O
9 1718 1722 1720453 must MD B-VP O
10 1723 1725 1720453 be VB I-VP O
11 1726 1735 1720453 evaluated VBN I-VP O
12 1736 1740 1720453 with IN B-PP O
13 1741 1748 1720453 respect NN B-NP O
14 1749 1751 1720453 to TO B-PP O
15 1752 1755 1720453 the DT B-NP O
16 1756 1764 1720453 efficacy NN I-NP O
17 1765 1767 1720453 of IN B-PP O
18 1768 1778 1720453 ifosfamide NN B-NP B-Chemical
19 1779 1781 1720453 in IN B-PP O
20 1782 1785 1720453 the DT B-NP O
21 1786 1795 1720453 treatment NN I-NP O
22 1796 1798 1720453 of IN B-PP O
23 1799 1810 1720453 mesenchymal JJ B-NP B-Disease
24 1811 1817 1720453 tumors NNS I-NP I-Disease
25 1818 1820 1720453 in IN B-PP O
26 1821 1829 1720453 children NNS B-NP O
27 1829 1830 1720453 . . O O

1 0 0 424937 -DOCSTART- -X- -X- O

1 0 8 424937 Patterns NNS B-NP O
2 9 11 424937 of IN B-PP O
3 12 19 424937 hepatic JJ B-NP B-Disease
4 20 26 424937 injury NN I-NP I-Disease
5 27 34 424937 induced VBN B-VP O
6 35 37 424937 by IN B-PP O
7 38 48 424937 methyldopa NN B-NP B-Chemical
8 48 49 424937 . . O O
9 50 56 424937 Twelve CD B-NP O
10 57 65 424937 patients NNS I-NP O
11 66 70 424937 with IN B-PP O
12 71 76 424937 liver NN B-NP B-Disease
13 77 84 424937 disease NN I-NP I-Disease
14 85 92 424937 related VBN B-VP O
15 93 95 424937 to TO B-PP O
16 96 106 424937 methyldopa NN B-NP B-Chemical
17 107 111 424937 were VBD B-VP O
18 112 116 424937 seen VBN I-VP O
19 117 124 424937 between IN B-PP O
20 125 129 424937 1967 CD B-NP O
21 130 133 424937 and CC I-NP O
22 134 138 424937 1977 CD I-NP O
23 138 139 424937 . . O O

1 140 147 424937 Illness NN B-NP O
2 148 156 424937 occurred VBD B-VP O
3 157 163 424937 within IN B-PP O
4 164 165 424937 1 CD B-NP O
5 165 166 424937 - HYPH B-NP O
6 166 167 424937 - SYM I-NP O
7 167 168 424937 9 CD I-NP O
8 169 174 424937 weeks NNS I-NP O
9 175 177 424937 of IN B-PP O
10 178 190 424937 commencement NN B-NP O
11 191 193 424937 of IN B-PP O
12 194 201 424937 therapy NN B-NP O
13 202 204 424937 in IN B-PP O
14 205 206 424937 9 CD B-NP O
15 207 215 424937 patients NNS I-NP O
16 215 216 424937 , , O O
17 217 220 424937 the DT B-NP O
18 221 230 424937 remaining VBG I-NP O
19 231 232 424937 3 CD I-NP O
20 233 241 424937 patients NNS I-NP O
21 242 248 424937 having VBG B-VP O
22 249 257 424937 received VBN I-VP O
23 258 261 424937 the DT B-NP O
24 262 266 424937 drug NN I-NP O
25 267 270 424937 for IN B-PP O
26 271 273 424937 13 CD B-NP O
27 274 280 424937 months NNS I-NP O
28 280 281 424937 , , O O
29 282 284 424937 15 CD B-NP O
30 285 291 424937 months NNS I-NP O
31 292 295 424937 and CC O O
32 296 297 424937 7 CD B-NP O
33 298 303 424937 years NNS I-NP O
34 304 310 424937 before IN B-PP O
35 311 323 424937 experiencing VBG B-VP O
36 324 332 424937 symptoms NNS B-NP O
37 332 333 424937 . . O O

1 334 342 424937 Jaundice NN B-NP B-Disease
2 343 347 424937 with IN B-PP O
3 348 354 424937 tender NN B-NP O
4 355 367 424937 hepatomegaly NN I-NP B-Disease
5 367 368 424937 , , O O
6 369 376 424937 usually RB B-VP O
7 377 385 424937 preceded VBN I-VP O
8 386 388 424937 by IN B-PP O
9 389 397 424937 symptoms NNS B-NP O
10 398 400 424937 of IN B-PP O
11 401 408 424937 malaise NN B-NP O
12 408 409 424937 , , I-NP O
13 410 418 424937 anorexia NN I-NP B-Disease
14 418 419 424937 , , I-NP O
15 420 426 424937 nausea NN I-NP B-Disease
16 427 430 424937 and CC I-NP O
17 431 439 424937 vomiting NN I-NP B-Disease
18 439 440 424937 , , O O
19 441 444 424937 and CC O O
20 445 455 424937 associated VBN B-VP O
21 456 460 424937 with IN B-PP O
22 461 466 424937 upper JJ B-NP O
23 467 476 424937 abdominal JJ I-NP B-Disease
24 477 481 424937 pain NN I-NP I-Disease
25 481 482 424937 , , O O
26 483 486 424937 was VBD B-VP O
27 487 489 424937 an DT B-NP O
28 490 500 424937 invariable JJ I-NP O
29 501 508 424937 finding NN I-NP O
30 509 511 424937 in IN B-PP O
31 512 515 424937 all DT B-NP O
32 516 524 424937 patients NNS I-NP O
33 524 525 424937 . . O O

1 526 537 424937 Biochemical JJ B-NP O
2 538 543 424937 liver NN I-NP O
3 544 552 424937 function NN I-NP O
4 553 558 424937 tests NNS I-NP O
5 559 568 424937 indicated VBD B-VP O
6 569 583 424937 hepatocellular JJ B-NP O
7 584 592 424937 necrosis NN I-NP B-Disease
8 593 596 424937 and CC O O
9 597 607 424937 correlated VBD B-VP O
10 608 612 424937 with IN B-PP O
11 613 630 424937 histopathological JJ B-NP O
12 631 639 424937 evidence NN I-NP O
13 640 642 424937 of IN B-PP O
14 643 650 424937 hepatic JJ B-NP B-Disease
15 651 657 424937 injury NN I-NP I-Disease
16 657 658 424937 , , O O
17 659 662 424937 the DT B-NP O
18 663 671 424937 spectrum NN I-NP O
19 672 674 424937 of IN B-PP O
20 675 680 424937 which WDT B-NP O
21 681 687 424937 ranged VBD B-VP O
22 688 692 424937 from IN B-PP O
23 693 698 424937 fatty JJ B-NP B-Disease
24 699 705 424937 change NN I-NP I-Disease
25 706 709 424937 and CC O O
26 710 715 424937 focal JJ B-NP O
27 716 730 424937 hepatocellular JJ I-NP O
28 731 739 424937 necrosis NN I-NP B-Disease
29 740 742 424937 to TO B-PP O
30 743 750 424937 massive JJ B-NP B-Disease
31 751 758 424937 hepatic JJ I-NP I-Disease
32 759 767 424937 necrosis NN I-NP I-Disease
33 767 768 424937 . . O O

1 769 773 424937 Most JJS B-NP O
2 774 782 424937 patients NNS I-NP O
3 783 789 424937 showed VBD B-VP O
4 790 798 424937 moderate JJ B-ADJP O
5 799 801 424937 to TO B-PP O
6 802 808 424937 severe JJ B-NP O
7 809 814 424937 acute JJ I-NP B-Disease
8 815 824 424937 hepatitis NN I-NP I-Disease
9 825 827 424937 or CC O O
10 828 835 424937 chronic JJ B-NP B-Disease
11 836 842 424937 active JJ I-NP I-Disease
12 843 852 424937 hepatitis NN I-NP I-Disease
13 853 857 424937 with IN B-PP O
14 858 868 424937 associated VBN B-NP O
15 869 880 424937 cholestasis NN I-NP B-Disease
16 880 881 424937 . . O O

1 882 885 424937 The DT B-NP O
2 886 890 424937 drug NN I-NP O
3 891 894 424937 was VBD B-VP O
4 895 904 424937 withdrawn VBN I-VP O
5 905 907 424937 on IN B-PP O
6 908 920 424937 presentation NN B-NP O
7 921 923 424937 to TO B-PP O
8 924 932 424937 hospital NN B-NP O
9 933 935 424937 in IN B-PP O
10 936 938 424937 11 CD B-NP O
11 939 947 424937 patients NNS I-NP O
12 947 948 424937 , , O O
13 949 953 424937 with IN B-PP O
14 954 959 424937 rapid JJ B-NP O
15 960 968 424937 clinical JJ I-NP O
16 969 980 424937 improvement NN I-NP O
17 981 983 424937 in IN B-PP O
18 984 985 424937 9 CD B-NP O
19 985 986 424937 . . O O

1 987 990 424937 One CD B-NP O
2 991 998 424937 patient NN I-NP O
3 999 1003 424937 died VBD B-VP O
4 1003 1004 424937 , , O O
5 1005 1011 424937 having VBG B-VP O
6 1012 1021 424937 presented VBN I-VP O
7 1022 1024 424937 in IN B-PP O
8 1025 1032 424937 hepatic JJ B-NP B-Disease
9 1033 1040 424937 failure NN I-NP I-Disease
10 1040 1041 424937 , , O O
11 1042 1045 424937 and CC O O
12 1046 1053 424937 another DT B-NP O
13 1053 1054 424937 , , O O
14 1055 1058 424937 who WP B-NP O
15 1059 1062 424937 had VBD B-VP O
16 1063 1067 424937 been VBN I-VP O
17 1068 1074 424937 taking VBG I-VP O
18 1075 1085 424937 methyldopa NN B-NP B-Chemical
19 1086 1089 424937 for IN B-PP O
20 1090 1091 424937 7 CD B-NP O
21 1092 1097 424937 years NNS I-NP O
22 1097 1098 424937 , , O O
23 1099 1105 424937 showed VBD B-VP O
24 1106 1112 424937 slower JJR B-NP O
25 1113 1121 424937 clinical JJ I-NP O
26 1122 1125 424937 and CC I-NP O
27 1126 1137 424937 biochemical JJ I-NP O
28 1138 1148 424937 resolution NN I-NP O
29 1149 1153 424937 over IN B-PP O
30 1154 1155 424937 a DT B-NP O
31 1156 1162 424937 period NN I-NP O
32 1163 1165 424937 of IN B-PP O
33 1166 1173 424937 several JJ B-NP O
34 1174 1180 424937 months NNS I-NP O
35 1180 1181 424937 . . O O

1 1182 1185 424937 The DT B-NP O
2 1186 1195 424937 remaining VBG I-NP O
3 1196 1203 424937 patient NN I-NP O
4 1204 1206 424937 in IN B-PP O
5 1207 1210 424937 the DT B-NP O
6 1211 1217 424937 series NN I-NP O
7 1218 1227 424937 developed VBD B-VP O
8 1228 1237 424937 fulminant JJ B-NP B-Disease
9 1238 1247 424937 hepatitis NN I-NP I-Disease
10 1248 1252 424937 when WRB B-ADVP O
11 1253 1256 424937 the DT B-NP O
12 1257 1261 424937 drug NN I-NP O
13 1262 1265 424937 was VBD B-VP O
14 1266 1278 424937 accidentally RB I-VP O
15 1279 1290 424937 recommenced VBN I-VP O
16 1291 1292 424937 1 CD B-NP O
17 1293 1297 424937 year NN I-NP O
18 1298 1303 424937 after IN B-PP O
19 1304 1305 424937 a DT B-NP O
20 1306 1311 424937 prior JJ I-NP O
21 1312 1319 424937 episode NN I-NP O
22 1320 1322 424937 of IN B-PP O
23 1323 1333 424937 methyldopa NN B-NP B-Chemical
24 1333 1334 424937 - HYPH B-NP O
25 1334 1341 424937 induced VBN I-NP O
26 1342 1351 424937 hepatitis NN I-NP B-Disease
27 1351 1352 424937 . . O O

1 1353 1355 424937 In IN B-PP O
2 1356 1360 424937 this DT B-NP O
3 1361 1367 424937 latter JJ I-NP O
4 1368 1375 424937 patient NN I-NP O
5 1375 1376 424937 , , O O
6 1377 1380 424937 and CC O O
7 1381 1383 424937 in IN B-PP O
8 1384 1385 424937 2 CD B-NP O
9 1386 1392 424937 others NNS I-NP O
10 1392 1393 424937 , , O O
11 1394 1397 424937 the DT B-NP O
12 1398 1404 424937 causal JJ I-NP O
13 1405 1417 424937 relationship NN I-NP O
14 1418 1425 424937 between IN B-PP O
15 1426 1436 424937 methyldopa NN B-NP B-Chemical
16 1437 1440 424937 and CC O O
17 1441 1448 424937 hepatic JJ B-NP B-Disease
18 1449 1460 424937 dysfunction NN I-NP I-Disease
19 1461 1464 424937 was VBD B-VP O
20 1465 1471 424937 proved VBN I-VP O
21 1472 1476 424937 with IN B-PP O
22 1477 1480 424937 the DT B-NP O
23 1481 1491 424937 recurrence NN I-NP O
24 1492 1494 424937 of IN B-PP O
25 1495 1504 424937 hepatitis NN B-NP B-Disease
26 1505 1511 424937 within IN B-PP O
27 1512 1513 424937 2 CD B-NP O
28 1514 1519 424937 weeks NNS I-NP O
29 1520 1522 424937 of IN B-PP O
30 1523 1525 424937 re AFX B-NP O
31 1525 1526 424937 - HYPH I-NP O
32 1526 1534 424937 exposure NN I-NP O
33 1535 1537 424937 to TO B-PP O
34 1538 1541 424937 the DT B-NP O
35 1542 1546 424937 drug NN I-NP O
36 1546 1547 424937 . . O O

1 0 0 20084309 -DOCSTART- -X- -X- O

1 0 6 20084309 Safety NN B-NP O
2 7 9 20084309 of IN B-PP O
3 10 25 20084309 transesophageal JJ B-NP O
4 26 42 20084309 echocardiography NN I-NP O
5 43 45 20084309 in IN B-PP O
6 46 52 20084309 adults NNS B-NP O
7 52 53 20084309 : : O O
8 54 59 20084309 study NN B-NP O
9 60 62 20084309 in IN B-PP O
10 63 64 20084309 a DT B-NP O
11 65 82 20084309 multidisciplinary JJ I-NP O
12 83 91 20084309 hospital NN I-NP O
13 91 92 20084309 . . I-NP O
14 93 103 20084309 BACKGROUND NN I-NP O
15 103 104 20084309 : : O O
16 105 108 20084309 TEE NN B-NP O
17 109 111 20084309 is VBZ B-VP O
18 112 113 20084309 a DT B-NP O
19 114 118 20084309 semi AFX I-NP O
20 118 119 20084309 - HYPH I-NP O
21 119 127 20084309 invasive JJ I-NP O
22 128 132 20084309 tool NN I-NP O
23 133 140 20084309 broadly RB B-VP O
24 141 145 20084309 used VBN I-VP O
25 146 149 20084309 and CC O O
26 150 153 20084309 its PRP$ B-NP O
27 154 165 20084309 utilization NN I-NP O
28 166 176 20084309 associated VBN B-VP O
29 177 179 20084309 to TO B-PP O
30 180 189 20084309 sedatives NNS B-NP O
31 190 195 20084309 drugs NNS I-NP O
32 196 201 20084309 might MD B-VP O
33 202 204 20084309 to TO I-VP O
34 205 211 20084309 affect VB I-VP O
35 212 215 20084309 the DT B-NP O
36 216 225 20084309 procedure NN I-NP O
37 226 232 20084309 safety NN I-NP O
38 232 233 20084309 . . O O

1 234 243 20084309 OBJECTIVE NN B-NP O
2 243 244 20084309 : : O O
3 245 247 20084309 to TO B-VP O
4 248 255 20084309 analyze VB I-VP O
5 256 263 20084309 aspects NNS B-NP O
6 264 266 20084309 of IN B-PP O
7 267 270 20084309 TEE NN B-NP O
8 271 277 20084309 safety NN I-NP O
9 278 288 20084309 associated VBN B-VP O
10 289 291 20084309 to TO B-PP O
11 292 295 20084309 the DT B-NP O
12 296 299 20084309 use NN I-NP O
13 300 302 20084309 of IN B-PP O
14 303 312 20084309 Midazolan NN B-NP B-Chemical
15 313 314 20084309 ( ( O O
16 314 316 20084309 MZ NN B-NP B-Chemical
17 316 317 20084309 ) ) O O
18 318 321 20084309 and CC O O
19 322 332 20084309 Flumazenil NN B-NP B-Chemical
20 333 334 20084309 ( ( O O
21 334 336 20084309 FL NN B-NP B-Chemical
22 336 337 20084309 ) ) O O
23 338 341 20084309 and CC O O
24 342 345 20084309 the DT B-NP O
25 346 355 20084309 influence NN I-NP O
26 356 358 20084309 of IN B-PP O
27 359 362 20084309 the DT B-NP O
28 363 371 20084309 clinical JJ I-NP O
29 372 381 20084309 variables NNS I-NP O
30 382 384 20084309 on IN B-PP O
31 385 388 20084309 the DT B-NP O
32 389 394 20084309 event NN I-NP O
33 395 399 20084309 rate NN I-NP O
34 399 400 20084309 . . O O

1 401 407 20084309 METHOD NN B-NP O
2 407 408 20084309 : : O O
3 409 420 20084309 prospective JJ B-NP O
4 421 426 20084309 study NN I-NP O
5 427 431 20084309 with IN B-PP O
6 432 435 20084309 137 CD B-NP O
7 436 444 20084309 patients NNS I-NP O
8 445 449 20084309 that WDT B-NP O
9 450 459 20084309 underwent VBD B-VP O
10 460 463 20084309 TEE NN B-NP O
11 464 468 20084309 with IN B-PP O
12 469 471 20084309 MZ NN B-NP B-Chemical
13 472 482 20084309 associated VBN B-VP O
14 483 485 20084309 to TO B-PP O
15 486 494 20084309 moderate JJ B-NP O
16 495 503 20084309 sedation NN I-NP O
17 503 504 20084309 . . O O

1 505 507 20084309 We PRP B-NP O
2 508 516 20084309 analyzed VBD B-VP O
3 517 520 20084309 the DT B-NP O
4 521 530 20084309 following JJ I-NP O
5 531 537 20084309 events NNS I-NP O
6 537 538 20084309 : : O O
7 539 552 20084309 complications NNS B-NP O
8 553 560 20084309 related VBN B-VP O
9 561 565 20084309 with IN B-PP O
10 566 569 20084309 the DT B-NP O
11 570 577 20084309 topical JJ I-NP O
12 578 588 20084309 anesthesia NN I-NP O
13 588 589 20084309 , , O O
14 590 594 20084309 with IN B-PP O
15 595 597 20084309 MZ NN B-NP B-Chemical
16 598 601 20084309 use NN I-NP O
17 602 605 20084309 and CC B-PP O
18 606 610 20084309 with IN B-PP O
19 611 614 20084309 the DT B-NP O
20 615 624 20084309 procedure NN I-NP O
21 624 625 20084309 . . O O

1 626 629 20084309 Uni NNP B-NP O
2 629 630 20084309 - : O O
3 631 634 20084309 and CC O O
4 635 647 20084309 multivariate JJ B-NP O
5 648 656 20084309 analyses NNS I-NP O
6 657 661 20084309 were VBD B-VP O
7 662 666 20084309 used VBN I-VP O
8 667 669 20084309 to TO B-VP O
9 670 674 20084309 test VB I-VP O
10 675 678 20084309 the DT B-NP O
11 679 688 20084309 influence NN I-NP O
12 689 691 20084309 of IN B-PP O
13 692 695 20084309 the DT B-NP O
14 696 704 20084309 clinical JJ I-NP O
15 705 714 20084309 variables NNS I-NP O
16 714 715 20084309 : : O O
17 716 719 20084309 age NN B-NP O
18 719 720 20084309 , , O O
19 721 724 20084309 sex NN B-NP O
20 724 725 20084309 , , O O
21 726 732 20084309 stroke NN B-NP B-Disease
22 732 733 20084309 , , O O
23 734 748 20084309 myocardiopathy NN B-NP B-Disease
24 749 750 20084309 ( ( O O
25 750 752 20084309 MP NN B-NP B-Disease
26 752 753 20084309 ) ) O O
27 753 754 20084309 , , O O
28 755 763 20084309 duration NN B-NP O
29 764 766 20084309 of IN B-PP O
30 767 770 20084309 the DT B-NP O
31 771 775 20084309 test NN I-NP O
32 775 776 20084309 , , O O
33 777 783 20084309 mitral JJ B-NP B-Disease
34 784 797 20084309 regurgitation NN I-NP I-Disease
35 798 799 20084309 ( ( O O
36 799 801 20084309 MR NN B-NP B-Disease
37 801 802 20084309 ) ) O O
38 803 806 20084309 and CC O O
39 807 810 20084309 the DT B-NP O
40 811 813 20084309 MZ NN I-NP B-Chemical
41 814 818 20084309 dose NN I-NP O
42 818 819 20084309 . . O O

1 820 827 20084309 RESULTS NNS B-NP O
2 827 828 20084309 : : O O
3 829 832 20084309 All DT B-NP O
4 833 841 20084309 patients NNS I-NP O
5 842 843 20084309 ( ( O O
6 843 846 20084309 65+ SYM B-NP O
7 846 847 20084309 / SYM B-NP O
8 847 848 20084309 - SYM B-VP O
9 848 850 20084309 16 CD B-NP O
10 851 854 20084309 yrs NNS I-NP O
11 854 855 20084309 ; : O O
12 856 859 20084309 58% CD B-NP O
13 860 865 20084309 males NNS I-NP O
14 865 866 20084309 ) ) O O
15 867 875 20084309 finished VBD B-VP O
16 876 879 20084309 the DT B-NP O
17 880 891 20084309 examination NN I-NP O
18 891 892 20084309 . . O O

1 893 896 20084309 The DT B-NP O
2 897 901 20084309 mean JJ I-NP O
3 902 907 20084309 doses NNS I-NP O
4 908 910 20084309 of IN B-PP O
5 911 913 20084309 MZ NN B-NP B-Chemical
6 914 917 20084309 and CC I-NP O
7 918 920 20084309 FL NN I-NP B-Chemical
8 921 925 20084309 were VBD B-VP O
9 926 930 20084309 4.3+ JJ B-ADJP O
10 930 931 20084309 / SYM O O
11 931 932 20084309 - SYM O O
12 932 935 20084309 1.9 CD B-NP O
13 936 938 20084309 mg NN I-NP O
14 939 942 20084309 and CC O O
15 943 948 20084309 0.28+ JJ B-NP O
16 948 949 20084309 / SYM I-NP O
17 949 950 20084309 - SYM I-NP O
18 950 953 20084309 0.2 CD I-NP O
19 954 956 20084309 mg NN I-NP O
20 956 957 20084309 , , O O
21 958 970 20084309 respectively RB B-ADVP O
22 970 971 20084309 . . O O

1 972 975 20084309 The DT B-NP O
2 976 984 20084309 duration NN I-NP O
3 985 987 20084309 of IN B-PP O
4 988 991 20084309 the DT B-NP O
5 992 1003 20084309 examination NN I-NP O
6 1004 1007 20084309 and CC O O
7 1008 1011 20084309 the DT B-NP O
8 1012 1016 20084309 mean JJ I-NP O
9 1017 1025 20084309 ejection NN I-NP O
10 1026 1034 20084309 fraction NN I-NP O
11 1035 1036 20084309 ( ( O O
12 1036 1038 20084309 EF NN B-NP O
13 1038 1039 20084309 ) ) O O
14 1040 1044 20084309 were VBD B-VP O
15 1045 1050 20084309 16.4+ JJ B-ADJP O
16 1050 1051 20084309 / SYM B-NP O
17 1051 1052 20084309 - SYM B-VP O
18 1052 1055 20084309 6.1 CD B-NP O
19 1056 1063 20084309 minutes NNS I-NP O
20 1064 1067 20084309 and CC O O
21 1068 1071 20084309 60+ JJ B-NP O
22 1071 1072 20084309 / SYM I-NP O
23 1072 1073 20084309 - SYM I-NP O
24 1073 1075 20084309 9% CD B-NP O
25 1075 1076 20084309 , , O O
26 1077 1089 20084309 respectively RB B-ADVP O
27 1089 1090 20084309 . . O O

1 1091 1095 20084309 Mild JJ B-NP O
2 1096 1103 20084309 hypoxia NN I-NP B-Disease
3 1104 1105 20084309 ( ( O O
4 1105 1108 20084309 SO2 NN B-NP O
5 1108 1109 20084309 < SYM B-NP O
6 1109 1112 20084309 90% CD I-NP O
7 1112 1113 20084309 ) ) O O
8 1114 1117 20084309 was VBD B-VP O
9 1118 1121 20084309 the DT B-NP O
10 1122 1126 20084309 most RBS I-NP O
11 1127 1133 20084309 common JJ I-NP O
12 1134 1139 20084309 event NN I-NP O
13 1140 1141 20084309 ( ( O O
14 1141 1143 20084309 11 CD B-NP O
15 1144 1152 20084309 patients NNS I-NP O
16 1152 1153 20084309 ) ) O O
17 1153 1154 20084309 ; : O O
18 1155 1156 20084309 3 CD B-NP O
19 1157 1165 20084309 patients NNS I-NP O
20 1166 1167 20084309 ( ( O O
21 1167 1169 20084309 2% NN B-NP O
22 1169 1170 20084309 ) ) O O
23 1171 1180 20084309 presented VBD B-VP O
24 1181 1190 20084309 transient JJ B-NP O
25 1191 1198 20084309 hypoxia NN I-NP B-Disease
26 1199 1202 20084309 due JJ B-PP O
27 1203 1205 20084309 to TO B-PP O
28 1206 1211 20084309 upper JJ B-NP O
29 1212 1218 20084309 airway NN I-NP B-Disease
30 1219 1230 20084309 obstruction NN I-NP I-Disease
31 1231 1233 20084309 by IN B-PP O
32 1234 1239 20084309 probe NN B-NP O
33 1240 1252 20084309 introduction NN I-NP O
34 1253 1256 20084309 and CC O O
35 1257 1258 20084309 8 CD B-NP O
36 1259 1260 20084309 ( ( O O
37 1260 1264 20084309 5.8% NN B-NP O
38 1264 1265 20084309 ) ) O O
39 1266 1269 20084309 due IN B-PP O
40 1270 1272 20084309 to TO B-PP O
41 1273 1280 20084309 hypoxia NN B-NP B-Disease
42 1281 1287 20084309 caused VBN B-VP O
43 1288 1290 20084309 by IN B-PP O
44 1291 1293 20084309 MZ NN B-NP B-Chemical
45 1294 1297 20084309 use NN I-NP O
46 1297 1298 20084309 . . O O

1 1299 1308 20084309 Transient JJ B-NP O
2 1309 1320 20084309 hypotension NN I-NP B-Disease
3 1321 1322 20084309 ( ( O O
4 1322 1325 20084309 SAP NN B-NP O
5 1325 1326 20084309 < SYM B-NP O
6 1326 1332 20084309 90mmHg NN I-NP O
7 1332 1333 20084309 ) ) O O
8 1334 1342 20084309 occurred VBD B-VP O
9 1343 1345 20084309 in IN B-PP O
10 1346 1347 20084309 1 CD B-NP O
11 1348 1355 20084309 patient NN I-NP O
12 1356 1357 20084309 ( ( O O
13 1357 1361 20084309 0.7% CD B-NP O
14 1361 1362 20084309 ) ) O O
15 1362 1363 20084309 . . O O

1 1364 1367 20084309 The DT B-NP O
2 1368 1380 20084309 multivariate JJ I-NP O
3 1381 1389 20084309 analysis NN I-NP O
4 1390 1396 20084309 showed VBD B-VP O
5 1397 1401 20084309 that IN B-SBAR O
6 1402 1408 20084309 severe JJ B-NP O
7 1409 1411 20084309 MR NN I-NP B-Disease
8 1411 1412 20084309 , , O O
9 1413 1415 20084309 MP NN B-NP B-Disease
10 1416 1417 20084309 ( ( O O
11 1417 1419 20084309 EF NN B-NP O
12 1419 1420 20084309 < SYM O O
13 1420 1423 20084309 45% CD B-NP O
14 1423 1424 20084309 ) ) O O
15 1425 1428 20084309 and CC O O
16 1429 1433 20084309 high JJ B-NP O
17 1434 1439 20084309 doses NNS I-NP O
18 1440 1442 20084309 of IN B-PP O
19 1443 1445 20084309 MZ NN B-NP B-Chemical
20 1446 1447 20084309 ( ( O O
21 1447 1448 20084309 > SYM B-NP O
22 1448 1451 20084309 5mg NN I-NP O
23 1451 1452 20084309 ) ) O O
24 1453 1457 20084309 were VBD B-VP O
25 1458 1468 20084309 associated VBN I-VP O
26 1469 1473 20084309 with IN B-PP O
27 1474 1480 20084309 events NNS B-NP O
28 1481 1482 20084309 ( ( O O
29 1482 1483 20084309 p NN B-NP O
30 1483 1484 20084309 < SYM O O
31 1484 1489 20084309 0.001 CD B-NP O
32 1489 1490 20084309 ) ) O O
33 1490 1491 20084309 . . O O

1 1492 1495 20084309 The DT B-NP O
2 1496 1498 20084309 EF NN I-NP O
3 1499 1502 20084309 was VBD B-VP O
4 1503 1506 20084309 40% CD B-NP O
5 1506 1507 20084309 , , O O
6 1508 1510 20084309 in IN B-PP O
7 1511 1514 20084309 the DT B-NP O
8 1515 1520 20084309 group NN I-NP O
9 1521 1525 20084309 with IN B-PP O
10 1526 1528 20084309 MP NN B-NP B-Disease
11 1529 1532 20084309 and CC I-NP O
12 1533 1536 20084309 44% NN I-NP O
13 1537 1539 20084309 in IN B-PP O
14 1540 1543 20084309 the DT B-NP O
15 1544 1549 20084309 group NN I-NP O
16 1550 1554 20084309 with IN B-PP O
17 1555 1561 20084309 severe JJ B-NP O
18 1562 1564 20084309 MR NN I-NP B-Disease
19 1565 1568 20084309 and CC O O
20 1569 1571 20084309 it PRP B-NP O
21 1572 1575 20084309 can MD B-VP O
22 1576 1578 20084309 be VB I-VP O
23 1579 1580 20084309 a DT B-NP O
24 1581 1587 20084309 factor NN I-NP O
25 1588 1598 20084309 associated VBN B-VP O
26 1599 1603 20084309 with IN B-PP O
27 1604 1612 20084309 clinical JJ B-NP O
28 1613 1619 20084309 events NNS I-NP O
29 1620 1622 20084309 in IN B-PP O
30 1623 1626 20084309 the DT B-NP O
31 1627 1631 20084309 last JJ I-NP O
32 1632 1637 20084309 group NN I-NP O
33 1637 1638 20084309 . . O O

1 1639 1649 20084309 CONCLUSION NN B-NP O
2 1649 1650 20084309 : : O O
3 1651 1654 20084309 TEE NN B-NP O
4 1655 1659 20084309 with IN B-PP O
5 1660 1668 20084309 sedation NN B-NP O
6 1669 1677 20084309 presents VBZ B-VP O
7 1678 1679 20084309 a DT B-NP O
8 1680 1683 20084309 low JJ I-NP O
9 1684 1688 20084309 rate NN I-NP O
10 1689 1691 20084309 of IN B-PP O
11 1692 1698 20084309 events NNS B-NP O
12 1698 1699 20084309 . . O O

1 1700 1705 20084309 There EX B-NP O
2 1706 1710 20084309 were VBD B-VP O
3 1711 1713 20084309 no DT B-NP O
4 1714 1720 20084309 severe JJ I-NP O
5 1721 1727 20084309 events NNS I-NP O
6 1728 1731 20084309 and CC O O
7 1732 1737 20084309 there EX B-NP O
8 1738 1741 20084309 was VBD B-VP O
9 1742 1744 20084309 no DT B-NP O
10 1745 1749 20084309 need NN I-NP O
11 1750 1752 20084309 to TO B-VP O
12 1753 1762 20084309 interrupt VB I-VP O
13 1763 1766 20084309 the DT B-NP O
14 1767 1779 20084309 examinations NNS I-NP O
15 1779 1780 20084309 . . O O

1 0 0 7444978 -DOCSTART- -X- -X- O

1 0 3 7444978 Age NN B-NP O
2 3 4 7444978 - HYPH I-NP O
3 4 13 7444978 dependent JJ I-NP O
4 14 25 7444978 sensitivity NN I-NP O
5 26 28 7444978 of IN B-PP O
6 29 32 7444978 the DT B-NP O
7 33 36 7444978 rat NN I-NP O
8 37 39 7444978 to TO B-PP O
9 40 50 7444978 neurotoxic JJ B-NP B-Disease
10 51 58 7444978 effects NNS I-NP O
11 59 61 7444978 of IN B-PP O
12 62 74 7444978 streptomycin NN B-NP B-Chemical
13 74 75 7444978 . . O O
14 76 88 7444978 Streptomycin NN B-NP B-Chemical
15 89 96 7444978 sulfate NN I-NP O
16 97 98 7444978 ( ( O O
17 98 101 7444978 300 CD B-NP O
18 102 104 7444978 mg NN I-NP O
19 104 105 7444978 / SYM B-NP O
20 105 107 7444978 kg NN I-NP O
21 108 111 7444978 s.c NN I-NP O
22 111 112 7444978 . . O O
23 112 113 7444978 ) ) O O
24 114 117 7444978 was VBD B-VP O
25 118 126 7444978 injected VBN I-VP O
26 127 130 7444978 for IN B-PP O
27 131 138 7444978 various JJ B-NP O
28 139 146 7444978 periods NNS I-NP O
29 147 151 7444978 into IN B-PP O
30 152 163 7444978 preweanling VBG B-NP O
31 164 168 7444978 rats NNS I-NP O
32 169 172 7444978 and CC B-PP O
33 173 176 7444978 for IN B-PP O
34 177 178 7444978 3 CD B-NP O
35 179 184 7444978 weeks NNS I-NP O
36 185 189 7444978 into IN B-PP O
37 190 198 7444978 weanling VBG B-VP O
38 199 203 7444978 rats NNS B-NP O
39 203 204 7444978 . . O O

1 205 214 7444978 Beginning VBG B-VP O
2 215 217 7444978 at IN B-PP O
3 218 219 7444978 8 CD B-NP O
4 220 224 7444978 days NNS I-NP O
5 225 227 7444978 of IN B-PP O
6 228 231 7444978 age NN B-NP O
7 231 232 7444978 , , O O
8 233 237 7444978 body NN B-NP O
9 238 246 7444978 movement NN I-NP O
10 247 250 7444978 and CC I-NP O
11 251 258 7444978 hearing NN I-NP O
12 259 263 7444978 were VBD B-VP O
13 264 272 7444978 examined VBN I-VP O
14 273 276 7444978 for IN B-PP O
15 277 278 7444978 6 CD B-NP O
16 279 282 7444978 and CC O O
17 283 285 7444978 up RB B-NP O
18 286 288 7444978 to TO I-NP O
19 289 291 7444978 17 CD I-NP O
20 292 297 7444978 weeks NNS I-NP O
21 297 298 7444978 , , O O
22 299 311 7444978 respectively RB B-ADVP O
23 311 312 7444978 . . O O

1 313 321 7444978 Abnormal JJ B-NP B-Disease
2 322 331 7444978 movements NNS I-NP I-Disease
3 332 335 7444978 and CC I-NP O
4 336 344 7444978 deafness NN I-NP B-Disease
5 345 353 7444978 occurred VBD B-VP O
6 354 358 7444978 only RB B-ADVP O
7 359 361 7444978 in IN B-PP O
8 362 366 7444978 rats NNS B-NP O
9 367 374 7444978 treated VBN B-VP O
10 375 381 7444978 during IN B-PP O
11 382 385 7444978 the DT B-NP O
12 386 396 7444978 preweaning JJ I-NP O
13 397 403 7444978 period NN I-NP O
14 403 404 7444978 ; : O O
15 405 411 7444978 within IN B-PP O
16 412 416 7444978 this DT B-NP O
17 417 423 7444978 period NN I-NP O
18 424 427 7444978 the DT B-NP O
19 428 436 7444978 greatest JJS I-NP O
20 437 450 7444978 sensitivities NNS I-NP O
21 451 454 7444978 for IN B-PP O
22 455 460 7444978 these DT B-NP O
23 461 474 7444978 abnormalities NNS I-NP O
24 475 483 7444978 occurred VBD B-VP O
25 484 488 7444978 from IN B-PP O
26 489 490 7444978 2 CD B-NP O
27 491 493 7444978 to TO B-PP O
28 494 496 7444978 11 CD B-NP O
29 496 497 7444978 - : O O
30 497 499 7444978 17 CD B-NP O
31 500 503 7444978 and CC I-NP O
32 504 505 7444978 5 CD I-NP O
33 506 508 7444978 to TO I-NP O
34 509 511 7444978 11 CD I-NP O
35 512 516 7444978 days NNS I-NP O
36 517 519 7444978 of IN B-PP O
37 520 523 7444978 age NN B-NP O
38 523 524 7444978 , , O O
39 525 537 7444978 respectively RB B-ADVP O
40 537 538 7444978 , , O O
41 539 549 7444978 indicating VBG B-VP O
42 550 554 7444978 that IN B-SBAR O
43 555 558 7444978 the DT B-NP O
44 559 566 7444978 cochlea NN I-NP O
45 567 569 7444978 is VBZ B-VP O
46 570 574 7444978 more RBR B-ADJP O
47 575 584 7444978 sensitive JJ I-ADJP O
48 585 587 7444978 to TO B-PP O
49 588 600 7444978 streptomycin NN B-NP B-Chemical
50 601 605 7444978 than IN B-PP O
51 606 609 7444978 the DT B-NP O
52 610 614 7444978 site NN I-NP O
53 615 616 7444978 ( ( O O
54 616 626 7444978 vestibular JJ B-ADJP O
55 627 629 7444978 or CC I-ADJP O
56 630 637 7444978 central JJ I-ADJP O
57 637 638 7444978 ) ) O O
58 639 650 7444978 responsible JJ B-ADJP O
59 651 654 7444978 for IN B-PP O
60 655 658 7444978 the DT B-NP O
61 659 670 7444978 dyskinesias NNS I-NP B-Disease
62 670 671 7444978 . . O O

1 0 0 6861444 -DOCSTART- -X- -X- O

1 0 5 6861444 Blood NN B-NP O
2 6 14 6861444 pressure NN I-NP O
3 15 23 6861444 response NN I-NP O
4 24 26 6861444 to TO B-PP O
5 27 34 6861444 chronic JJ B-NP O
6 35 38 6861444 low JJ I-NP O
7 38 39 6861444 - HYPH I-NP O
8 39 43 6861444 dose NN I-NP O
9 44 54 6861444 intrarenal JJ I-NP O
10 55 68 6861444 noradrenaline NN I-NP B-Chemical
11 69 77 6861444 infusion NN I-NP O
12 78 80 6861444 in IN B-PP O
13 81 90 6861444 conscious JJ B-NP O
14 91 95 6861444 rats NNS I-NP O
15 95 96 6861444 . . O O
16 97 103 6861444 Sodium NN B-NP B-Chemical
17 104 112 6861444 chloride NN I-NP I-Chemical
18 113 121 6861444 solution NN I-NP O
19 122 123 6861444 ( ( O O
20 123 127 6861444 0.9% CD B-NP O
21 127 128 6861444 ) ) O O
22 129 131 6861444 or CC O O
23 132 145 6861444 noradrenaline NN B-NP B-Chemical
24 146 148 6861444 in IN B-PP O
25 149 154 6861444 doses NNS B-NP O
26 155 157 6861444 of IN B-PP O
27 158 159 6861444 4 CD B-NP O
28 159 160 6861444 , , I-NP O
29 161 163 6861444 12 CD I-NP O
30 164 167 6861444 and CC I-NP O
31 168 170 6861444 36 CD I-NP O
32 171 181 6861444 micrograms NNS I-NP O
33 182 183 6861444 h NN I-NP O
34 183 184 6861444 - HYPH B-NP O
35 184 185 6861444 1 CD I-NP O
36 186 188 6861444 kg NN I-NP O
37 188 189 6861444 - HYPH B-NP O
38 189 190 6861444 1 CD I-NP O
39 191 194 6861444 was VBD B-VP O
40 195 202 6861444 infused VBN I-VP O
41 203 206 6861444 for IN B-PP O
42 207 211 6861444 five CD B-NP O
43 212 223 6861444 consecutive JJ I-NP O
44 224 228 6861444 days NNS I-NP O
45 228 229 6861444 , , O O
46 230 236 6861444 either CC O O
47 237 249 6861444 intrarenally RB B-ADVP O
48 250 251 6861444 ( ( O O
49 251 253 6861444 by IN B-PP O
50 254 255 6861444 a DT B-NP O
51 256 259 6861444 new JJ I-NP O
52 260 269 6861444 technique NN I-NP O
53 269 270 6861444 ) ) O O
54 271 273 6861444 or CC O O
55 274 287 6861444 intravenously RB B-ADVP O
56 288 292 6861444 into IN B-PP O
57 293 297 6861444 rats NNS B-NP O
58 298 302 6861444 with IN B-PP O
59 303 306 6861444 one CD B-NP O
60 307 313 6861444 kidney NN I-NP O
61 314 321 6861444 removed VBN B-VP O
62 321 322 6861444 . . O O

1 323 333 6861444 Intrarenal JJ B-NP O
2 334 342 6861444 infusion NN I-NP O
3 343 345 6861444 of IN B-PP O
4 346 359 6861444 noradrenaline NN B-NP B-Chemical
5 360 366 6861444 caused VBD B-VP O
6 367 379 6861444 hypertension NN B-NP B-Disease
7 380 382 6861444 at IN B-PP O
8 383 388 6861444 doses NNS B-NP O
9 389 394 6861444 which WDT B-NP O
10 395 398 6861444 did VBD B-VP O
11 399 402 6861444 not RB I-VP O
12 403 405 6861444 do VB I-VP O
13 406 408 6861444 so RB B-ADVP O
14 409 413 6861444 when WRB B-ADVP O
15 414 421 6861444 infused VBN B-VP O
16 422 435 6861444 intravenously RB B-ADVP O
17 435 436 6861444 . . O O

1 437 447 6861444 Intrarenal JJ B-ADJP O
2 448 456 6861444 compared VBN B-PP O
3 457 461 6861444 with IN B-PP O
4 462 473 6861444 intravenous JJ B-NP O
5 474 482 6861444 infusion NN I-NP O
6 483 485 6861444 of IN B-PP O
7 486 499 6861444 noradrenaline NN B-NP B-Chemical
8 500 506 6861444 caused VBD B-VP O
9 507 513 6861444 higher JJR B-NP O
10 514 520 6861444 plasma NN I-NP O
11 521 534 6861444 noradrenaline NN I-NP B-Chemical
12 535 549 6861444 concentrations NNS I-NP O
13 550 553 6861444 and CC O O
14 554 555 6861444 a DT B-NP O
15 556 561 6861444 shift NN I-NP O
16 562 564 6861444 of IN B-PP O
17 565 568 6861444 the DT B-NP O
18 569 575 6861444 plasma NN I-NP O
19 576 589 6861444 noradrenaline NN I-NP B-Chemical
20 590 603 6861444 concentration NN I-NP O
21 603 604 6861444 - HYPH B-NP O
22 604 609 6861444 blood NN I-NP O
23 610 618 6861444 pressure NN I-NP O
24 619 625 6861444 effect NN I-NP O
25 626 631 6861444 curve NN I-NP O
26 632 639 6861444 towards IN B-PP O
27 640 645 6861444 lower JJR B-NP O
28 646 652 6861444 plasma NN I-NP O
29 653 666 6861444 noradrenaline NN I-NP B-Chemical
30 667 673 6861444 levels NNS I-NP O
31 673 674 6861444 . . O O

1 675 680 6861444 These DT B-NP O
2 681 688 6861444 results NNS I-NP O
3 689 696 6861444 suggest VBP B-VP O
4 697 701 6861444 that IN B-SBAR O
5 702 714 6861444 hypertension NN B-NP B-Disease
6 715 720 6861444 after IN B-PP O
7 721 728 6861444 chronic JJ B-NP O
8 729 739 6861444 intrarenal JJ I-NP O
9 740 753 6861444 noradrenaline NN I-NP B-Chemical
10 754 762 6861444 infusion NN I-NP O
11 763 765 6861444 is VBZ B-VP O
12 766 774 6861444 produced VBN I-VP O
13 775 777 6861444 by IN B-PP O
14 778 788 6861444 relatively RB B-NP O
15 789 795 6861444 higher JJR I-NP O
16 796 802 6861444 levels NNS I-NP O
17 803 805 6861444 of IN B-PP O
18 806 817 6861444 circulating VBG B-VP O
19 818 831 6861444 noradrenaline NN B-NP B-Chemical
20 832 835 6861444 and CC B-PP O
21 836 838 6861444 by IN B-PP O
22 839 849 6861444 triggering NN B-NP O
23 850 852 6861444 of IN B-PP O
24 853 855 6861444 an DT B-NP O
25 856 866 6861444 additional JJ I-NP O
26 867 877 6861444 intrarenal JJ I-NP O
27 878 885 6861444 pressor NN I-NP O
28 886 895 6861444 mechanism NN I-NP O
29 895 896 6861444 . . O O

1 0 0 3564823 -DOCSTART- -X- -X- O

1 0 4 3564823 Drug NN B-NP O
2 4 5 3564823 - HYPH O O
3 5 12 3564823 induced VBN B-NP O
4 13 21 3564823 arterial JJ I-NP O
5 22 27 3564823 spasm NN I-NP B-Disease
6 28 36 3564823 relieved VBN B-VP O
7 37 39 3564823 by IN B-PP O
8 40 49 3564823 lidocaine NN B-NP B-Chemical
9 49 50 3564823 . . O O

1 51 55 3564823 Case NN B-NP O
2 56 62 3564823 report NN I-NP O
3 62 63 3564823 . . O O
4 64 73 3564823 Following VBG B-VP O
5 74 79 3564823 major JJ B-NP O
6 80 92 3564823 intracranial JJ I-NP O
7 93 100 3564823 surgery NN I-NP O
8 101 103 3564823 in IN B-PP O
9 104 105 3564823 a DT B-NP O
10 106 108 3564823 35 CD I-NP O
11 108 109 3564823 - HYPH I-NP O
12 109 113 3564823 year NN I-NP O
13 113 114 3564823 - HYPH O O
14 114 117 3564823 old JJ B-NP O
15 118 121 3564823 man NN I-NP O
16 121 122 3564823 , , O O
17 123 129 3564823 sodium NN B-NP B-Chemical
18 130 139 3564823 pentothal NN I-NP I-Chemical
19 140 143 3564823 was VBD B-VP O
20 144 157 3564823 intravenously RB I-VP O
21 158 165 3564823 infused VBN I-VP O
22 166 168 3564823 to TO I-VP O
23 169 177 3564823 minimize VB I-VP O
24 178 186 3564823 cerebral JJ B-NP B-Disease
25 187 196 3564823 ischaemia NN I-NP I-Disease
26 196 197 3564823 . . O O

1 198 205 3564823 Intense JJ B-NP O
2 206 215 3564823 vasospasm NN I-NP B-Disease
3 216 220 3564823 with IN B-PP O
4 221 231 3564823 threatened VBN B-NP O
5 232 240 3564823 gangrene NN I-NP B-Disease
6 241 246 3564823 arose VBD B-VP O
7 247 249 3564823 in IN B-PP O
8 250 253 3564823 the DT B-NP O
9 254 257 3564823 arm NN I-NP O
10 258 262 3564823 used VBN B-VP O
11 263 266 3564823 for IN B-PP O
12 267 270 3564823 the DT B-NP O
13 271 279 3564823 infusion NN I-NP O
14 279 280 3564823 . . O O

1 281 286 3564823 Since IN B-SBAR O
2 287 290 3564823 the DT B-NP O
3 291 298 3564823 cranial JJ I-NP O
4 299 308 3564823 condition NN I-NP O
5 309 318 3564823 precluded VBD B-VP O
6 319 322 3564823 use NN B-NP O
7 323 325 3564823 of IN B-PP O
8 326 330 3564823 more JJR B-NP O
9 331 336 3564823 usual JJ I-NP O
10 337 344 3564823 methods NNS I-NP O
11 344 345 3564823 , , O O
12 346 355 3564823 lidocaine NN B-NP B-Chemical
13 356 359 3564823 was VBD B-VP O
14 360 365 3564823 given VBN I-VP O
15 366 371 3564823 intra AFX O O
16 371 372 3564823 - HYPH O O
17 372 382 3564823 arterially RB B-ADVP O
18 382 383 3564823 , , O O
19 384 388 3564823 with IN B-PP O
20 389 396 3564823 careful JJ B-NP O
21 397 411 3564823 cardiovascular JJ I-NP O
22 412 422 3564823 monitoring NN I-NP O
23 422 423 3564823 , , O O
24 424 426 3564823 to TO B-VP O
25 427 437 3564823 counteract VB I-VP O
26 438 441 3564823 the DT B-NP O
27 442 451 3564823 vasospasm NN I-NP B-Disease
28 451 452 3564823 . . O O

1 453 456 3564823 The DT B-NP O
2 457 466 3564823 treatment NN I-NP O
3 467 470 3564823 was VBD B-VP O
4 471 478 3564823 rapidly RB B-ADJP O
5 479 489 3564823 successful JJ I-ADJP O
6 489 490 3564823 . . O O

1 0 0 6308277 -DOCSTART- -X- -X- O

1 0 9 6308277 Reduction NN B-NP O
2 10 12 6308277 in IN B-PP O
3 13 21 6308277 caffeine NN B-NP B-Chemical
4 22 30 6308277 toxicity NN I-NP B-Disease
5 31 33 6308277 by IN B-PP O
6 34 47 6308277 acetaminophen NN B-NP B-Chemical
7 47 48 6308277 . . O O
8 49 50 6308277 A DT B-NP O
9 51 58 6308277 patient NN I-NP O
10 59 62 6308277 who WP B-NP O
11 63 72 6308277 allegedly RB B-ADVP O
12 73 81 6308277 consumed VBD B-VP O
13 82 85 6308277 100 CD B-NP O
14 86 93 6308277 tablets NNS I-NP O
15 94 96 6308277 of IN B-PP O
16 97 99 6308277 an DT B-NP O
17 100 104 6308277 over IN I-NP O
18 104 105 6308277 - HYPH I-NP O
19 105 108 6308277 the DT B-NP O
20 108 109 6308277 - HYPH I-NP O
21 109 116 6308277 counter NN I-NP O
22 117 126 6308277 analgesic JJ I-NP O
23 127 137 6308277 containing VBG I-NP O
24 138 144 6308277 sodium NN I-NP B-Chemical
25 145 161 6308277 acetylsalicylate NN I-NP I-Chemical
26 161 162 6308277 , , O O
27 163 171 6308277 caffeine NN B-NP B-Chemical
28 171 172 6308277 , , O O
29 173 176 6308277 and CC O O
30 177 190 6308277 acetaminophen NN B-NP B-Chemical
31 191 200 6308277 displayed VBD B-VP O
32 201 203 6308277 no DT B-NP O
33 204 215 6308277 significant JJ I-NP O
34 216 219 6308277 CNS NN I-NP O
35 220 231 6308277 stimulation NN I-NP O
36 232 239 6308277 despite IN B-PP O
37 240 243 6308277 the DT B-NP O
38 244 252 6308277 presence NN I-NP O
39 253 255 6308277 of IN B-PP O
40 256 259 6308277 175 CD B-NP O
41 260 270 6308277 micrograms NNS I-NP O
42 271 273 6308277 of IN B-PP O
43 274 282 6308277 caffeine NN B-NP B-Chemical
44 283 286 6308277 per IN B-PP O
45 287 289 6308277 mL NN B-NP O
46 290 292 6308277 of IN B-PP O
47 293 298 6308277 serum NN B-NP O
48 298 299 6308277 . . O O

1 300 307 6308277 Because IN B-SBAR O
2 308 319 6308277 salicylates NNS B-NP O
3 320 324 6308277 have VBP B-VP O
4 325 329 6308277 been VBN I-VP O
5 330 338 6308277 reported VBN I-VP O
6 339 341 6308277 to TO I-VP O
7 342 349 6308277 augment VB I-VP O
8 350 353 6308277 the DT B-NP O
9 354 365 6308277 stimulatory JJ I-NP O
10 366 373 6308277 effects NNS I-NP O
11 374 376 6308277 of IN B-PP O
12 377 385 6308277 caffeine NN B-NP B-Chemical
13 386 388 6308277 on IN B-PP O
14 389 392 6308277 the DT B-NP O
15 393 396 6308277 CNS NN I-NP O
16 396 397 6308277 , , O O
17 398 407 6308277 attention NN B-NP O
18 408 411 6308277 was VBD B-VP O
19 412 419 6308277 focused VBN I-VP O
20 420 422 6308277 on IN B-PP O
21 423 426 6308277 the DT B-NP O
22 427 438 6308277 possibility NN I-NP O
23 439 443 6308277 that IN B-SBAR O
24 444 447 6308277 the DT B-NP O
25 448 456 6308277 presence NN I-NP O
26 457 459 6308277 of IN B-PP O
27 460 473 6308277 acetaminophen NN B-NP B-Chemical
28 474 475 6308277 ( ( O O
29 475 477 6308277 52 CD B-NP O
30 478 488 6308277 micrograms NNS I-NP O
31 488 489 6308277 / SYM B-NP O
32 489 491 6308277 mL NN I-NP O
33 491 492 6308277 ) ) O O
34 493 500 6308277 reduced VBD B-VP O
35 501 504 6308277 the DT B-NP O
36 505 508 6308277 CNS NN I-NP O
37 509 517 6308277 toxicity NN I-NP B-Disease
38 518 520 6308277 of IN B-PP O
39 521 529 6308277 caffeine NN B-NP B-Chemical
40 529 530 6308277 . . O O

1 531 538 6308277 Studies NNS B-NP O
2 539 541 6308277 in IN B-PP O
3 542 545 6308277 DBA NN B-NP O
4 545 546 6308277 / SYM B-NP O
5 546 548 6308277 2J NN I-NP O
6 549 553 6308277 mice NNS I-NP O
7 554 560 6308277 showed VBD B-VP O
8 561 565 6308277 that IN B-SBAR O
9 565 566 6308277 : : O O
10 567 568 6308277 1 LS B-LST O
11 568 569 6308277 ) ) O O
12 570 582 6308277 pretreatment NN B-NP O
13 583 587 6308277 with IN B-PP O
14 588 601 6308277 acetaminophen NN B-NP B-Chemical
15 602 603 6308277 ( ( O O
16 603 606 6308277 100 CD B-NP O
17 607 609 6308277 mg NN I-NP O
18 609 610 6308277 / SYM B-NP O
19 610 612 6308277 kg NN I-NP O
20 612 613 6308277 ) ) O O
21 614 623 6308277 increased VBD B-VP O
22 624 627 6308277 the DT B-NP O
23 628 636 6308277 interval NN I-NP O
24 637 644 6308277 between IN B-PP O
25 645 648 6308277 the DT B-NP O
26 649 663 6308277 administration NN I-NP O
27 664 666 6308277 of IN B-PP O
28 667 675 6308277 caffeine NN B-NP B-Chemical
29 676 677 6308277 ( ( O O
30 677 680 6308277 300 CD B-NP O
31 681 683 6308277 to TO O O
32 684 687 6308277 450 CD B-NP O
33 688 690 6308277 mg NN I-NP O
34 690 691 6308277 / SYM B-NP O
35 691 693 6308277 kg NN I-NP O
36 694 696 6308277 IP NN I-NP O
37 696 697 6308277 ) ) O O
38 698 701 6308277 and CC O O
39 702 705 6308277 the DT B-NP O
40 706 711 6308277 onset NN I-NP O
41 712 714 6308277 of IN B-PP O
42 715 720 6308277 fatal JJ B-NP O
43 721 732 6308277 convulsions NNS I-NP B-Disease
44 733 735 6308277 by IN B-PP O
45 736 737 6308277 a DT B-NP O
46 738 744 6308277 factor NN I-NP O
47 745 747 6308277 of IN B-PP O
48 748 753 6308277 about IN B-NP O
49 754 757 6308277 two CD I-NP O
50 757 758 6308277 ; : O O
51 759 762 6308277 and CC O O
52 763 764 6308277 2 LS B-LST O
53 764 765 6308277 ) ) O O
54 766 778 6308277 pretreatment NN B-NP O
55 779 783 6308277 with IN B-PP O
56 784 797 6308277 acetaminophen NN B-NP B-Chemical
57 798 799 6308277 ( ( O O
58 799 801 6308277 75 CD B-NP O
59 802 804 6308277 mg NN I-NP O
60 804 805 6308277 / SYM B-NP O
61 805 807 6308277 kg NN I-NP O
62 807 808 6308277 ) ) O O
63 809 816 6308277 reduced VBD B-VP O
64 817 820 6308277 the DT B-NP O
65 821 830 6308277 incidence NN I-NP O
66 831 833 6308277 of IN B-PP O
67 834 844 6308277 audiogenic JJ B-NP O
68 845 853 6308277 seizures NNS I-NP B-Disease
69 854 862 6308277 produced VBN B-VP O
70 863 865 6308277 in IN B-PP O
71 866 869 6308277 the DT B-NP O
72 870 878 6308277 presence NN I-NP O
73 879 881 6308277 of IN B-PP O
74 882 890 6308277 caffeine NN B-NP B-Chemical
75 891 892 6308277 ( ( O O
76 892 896 6308277 12.5 CD B-NP O
77 897 899 6308277 to TO O O
78 900 902 6308277 75 CD B-NP O
79 903 905 6308277 mg NN I-NP O
80 905 906 6308277 / SYM B-NP O
81 906 908 6308277 kg NN I-NP O
82 909 911 6308277 IP NN I-NP O
83 911 912 6308277 ) ) O O
84 912 913 6308277 . . O O

1 914 917 6308277 The DT B-NP O
2 918 927 6308277 frequency NN I-NP O
3 928 930 6308277 of IN B-PP O
4 931 936 6308277 sound NN B-NP O
5 936 937 6308277 - HYPH B-NP O
6 937 944 6308277 induced VBN I-NP O
7 945 953 6308277 seizures NNS I-NP B-Disease
8 954 959 6308277 after IN B-PP O
9 960 964 6308277 12.5 CD B-NP O
10 965 967 6308277 or CC I-NP O
11 968 970 6308277 25 CD I-NP O
12 971 973 6308277 mg NN I-NP O
13 973 974 6308277 / SYM B-NP O
14 974 976 6308277 kg NN I-NP O
15 977 985 6308277 caffeine NN I-NP B-Chemical
16 986 989 6308277 was VBD B-VP O
17 990 997 6308277 reduced VBN I-VP O
18 998 1002 6308277 from IN B-PP O
19 1003 1005 6308277 50 CD B-NP O
20 1006 1008 6308277 to TO B-PP O
21 1009 1011 6308277 5% CD B-NP O
22 1012 1014 6308277 by IN B-PP O
23 1015 1028 6308277 acetaminophen NN B-NP B-Chemical
24 1028 1029 6308277 . . O O

1 1030 1032 6308277 In IN B-PP O
2 1033 1036 6308277 the DT B-NP O
3 1037 1044 6308277 absence NN I-NP O
4 1045 1047 6308277 of IN B-PP O
5 1048 1056 6308277 caffeine NN B-NP B-Chemical
6 1056 1057 6308277 , , O O
7 1058 1071 6308277 acetaminophen NN B-NP B-Chemical
8 1072 1073 6308277 ( ( O O
9 1073 1075 6308277 up RB B-NP O
10 1076 1078 6308277 to TO I-NP O
11 1079 1082 6308277 300 CD I-NP O
12 1083 1085 6308277 mg NN I-NP O
13 1085 1086 6308277 / SYM B-NP O
14 1086 1088 6308277 kg NN I-NP O
15 1088 1089 6308277 ) ) O O
16 1090 1093 6308277 did VBD B-VP O
17 1094 1097 6308277 not RB I-VP O
18 1098 1104 6308277 modify VB I-VP O
19 1105 1108 6308277 the DT B-NP O
20 1109 1117 6308277 seizures NNS I-NP B-Disease
21 1118 1125 6308277 induced VBN B-VP O
22 1126 1128 6308277 by IN B-PP O
23 1129 1136 6308277 maximal JJ B-NP O
24 1137 1149 6308277 electroshock NN I-NP O
25 1150 1153 6308277 and CC O O
26 1154 1157 6308277 did VBD B-VP O
27 1158 1161 6308277 not RB I-VP O
28 1162 1167 6308277 alter VB I-VP O
29 1168 1171 6308277 the DT B-NP O
30 1172 1182 6308277 convulsant JJ I-NP O
31 1183 1187 6308277 dose NN I-NP O
32 1188 1190 6308277 of IN B-PP O
33 1191 1208 6308277 pentylenetetrezol NN B-NP B-Chemical
34 1209 1211 6308277 in IN B-PP O
35 1212 1216 6308277 mice NNS B-NP O
36 1217 1218 6308277 ( ( O O
37 1218 1223 6308277 tests NNS B-NP O
38 1224 1233 6308277 performed VBN B-VP O
39 1234 1236 6308277 by IN B-PP O
40 1237 1240 6308277 the DT B-NP O
41 1241 1255 6308277 Anticonvulsant NNP I-NP O
42 1256 1265 6308277 Screening NNP I-NP O
43 1266 1273 6308277 Project NNP I-NP O
44 1274 1276 6308277 of IN B-PP O
45 1277 1283 6308277 NINCDS NN B-NP O
46 1283 1284 6308277 ) ) O O
47 1284 1285 6308277 . . O O

1 1286 1299 6308277 Acetaminophen NN B-NP B-Chemical
2 1300 1301 6308277 ( ( O O
3 1301 1303 6308277 up RB B-NP O
4 1304 1306 6308277 to TO I-NP O
5 1307 1310 6308277 150 CD I-NP O
6 1311 1321 6308277 micrograms NNS I-NP O
7 1321 1322 6308277 / SYM B-NP O
8 1322 1324 6308277 mL NN I-NP O
9 1324 1325 6308277 ) ) O O
10 1326 1329 6308277 did VBD B-VP O
11 1330 1333 6308277 not RB I-VP O
12 1334 1340 6308277 retard VB I-VP O
13 1341 1344 6308277 the DT B-NP O
14 1345 1358 6308277 incorporation NN I-NP O
15 1359 1361 6308277 of IN B-PP O
16 1362 1373 6308277 radioactive JJ B-NP O
17 1374 1383 6308277 adenosine NN I-NP B-Chemical
18 1384 1388 6308277 into IN B-PP O
19 1389 1392 6308277 ATP NN B-NP B-Chemical
20 1393 1395 6308277 in IN B-PP O
21 1396 1402 6308277 slices NNS B-NP O
22 1403 1405 6308277 of IN B-PP O
23 1406 1409 6308277 rat NN B-NP O
24 1410 1418 6308277 cerebral JJ I-NP O
25 1419 1425 6308277 cortex NN I-NP O
26 1425 1426 6308277 . . O O

1 1427 1431 6308277 Thus RB B-ADVP O
2 1432 1435 6308277 the DT B-NP O
3 1436 1445 6308277 mechanism NN I-NP O
4 1446 1448 6308277 by IN B-PP O
5 1449 1454 6308277 which WDT B-NP O
6 1455 1468 6308277 acetaminophen NN B-NP B-Chemical
7 1469 1480 6308277 antagonizes VBZ B-VP O
8 1481 1484 6308277 the DT B-NP O
9 1485 1492 6308277 actions NNS I-NP O
10 1493 1495 6308277 of IN B-PP O
11 1496 1504 6308277 caffeine NN B-NP B-Chemical
12 1505 1507 6308277 in IN B-PP O
13 1508 1511 6308277 the DT B-NP O
14 1512 1515 6308277 CNS NN I-NP O
15 1516 1523 6308277 remains VBZ B-VP O
16 1524 1531 6308277 unknown JJ B-ADJP O
17 1531 1532 6308277 . . O O

1 0 0 11928786 -DOCSTART- -X- -X- O

1 0 9 11928786 Bupropion NN B-NP B-Chemical
2 10 11 11928786 ( ( O O
3 11 16 11928786 Zyban NN B-NP B-Chemical
4 16 17 11928786 ) ) O O
5 18 26 11928786 toxicity NN B-NP B-Disease
6 26 27 11928786 . . I-NP O
7 28 37 11928786 Bupropion NN I-NP B-Chemical
8 38 40 11928786 is VBZ B-VP O
9 41 42 11928786 a DT B-NP O
10 43 53 11928786 monocyclic JJ I-NP O
11 54 68 11928786 antidepressant NN I-NP B-Chemical
12 69 81 11928786 structurally RB B-ADJP O
13 82 89 11928786 related JJ I-ADJP O
14 90 92 11928786 to TO B-PP O
15 93 104 11928786 amphetamine NN B-NP B-Chemical
16 104 105 11928786 . . O O

1 106 111 11928786 Zyban NNP B-NP B-Chemical
2 111 112 11928786 , , O O
3 113 114 11928786 a DT B-NP O
4 115 124 11928786 sustained JJ I-NP O
5 124 125 11928786 - HYPH I-NP O
6 125 132 11928786 release NN I-NP O
7 133 144 11928786 formulation NN I-NP O
8 145 147 11928786 of IN B-PP O
9 148 157 11928786 bupropion NN B-NP B-Chemical
10 158 171 11928786 hydrochloride NN I-NP I-Chemical
11 171 172 11928786 , , O O
12 173 176 11928786 was VBD B-VP O
13 177 185 11928786 recently RB I-VP O
14 186 194 11928786 released VBN I-VP O
15 195 197 11928786 in IN B-PP O
16 198 205 11928786 Ireland NNP B-NP O
17 205 206 11928786 , , O O
18 207 209 11928786 as IN B-PP O
19 210 211 11928786 a DT B-NP O
20 212 219 11928786 smoking NN I-NP O
21 220 229 11928786 cessation NN I-NP O
22 230 233 11928786 aid NN I-NP O
23 233 234 11928786 . . O O

1 235 237 11928786 In IN B-PP O
2 238 241 11928786 the DT B-NP O
3 242 249 11928786 initial JJ I-NP O
4 250 251 11928786 6 CD I-NP O
5 252 258 11928786 months NNS I-NP O
6 259 264 11928786 since IN B-SBAR O
7 265 269 11928786 it's NNS B-NP O
8 270 282 11928786 introduction NN I-NP O
9 282 283 11928786 , , O O
10 284 286 11928786 12 CD B-NP O
11 287 295 11928786 overdose JJ I-NP B-Disease
12 296 301 11928786 cases NNS I-NP O
13 302 306 11928786 have VBP B-VP O
14 307 311 11928786 been VBN I-VP O
15 312 320 11928786 reported VBN I-VP O
16 321 323 11928786 to TO B-PP O
17 324 327 11928786 The DT B-NP O
18 328 336 11928786 National NNP I-NP O
19 337 344 11928786 Poisons NNP I-NP O
20 345 356 11928786 Information NNP I-NP O
21 357 363 11928786 Centre NNP I-NP O
22 363 364 11928786 . . I-NP O
23 365 366 11928786 8 CD I-NP O
24 367 375 11928786 patients NNS I-NP O
25 376 385 11928786 developed VBD B-VP O
26 386 394 11928786 symptoms NNS B-NP O
27 395 397 11928786 of IN B-PP O
28 398 406 11928786 toxicity NN B-NP B-Disease
29 406 407 11928786 . . O O

1 408 414 11928786 Common JJ B-NP O
2 415 423 11928786 features NNS I-NP O
3 424 432 11928786 included VBD B-VP O
4 433 444 11928786 tachycardia NN B-NP B-Disease
5 444 445 11928786 , , I-NP O
6 446 456 11928786 drowsiness NN I-NP O
7 456 457 11928786 , , I-NP O
8 458 472 11928786 hallucinations NNS I-NP B-Disease
9 473 476 11928786 and CC I-NP O
10 477 488 11928786 convulsions NNS I-NP B-Disease
11 488 489 11928786 . . O O

1 490 493 11928786 Two CD B-NP O
2 494 502 11928786 patients NNS I-NP O
3 503 512 11928786 developed VBD B-VP O
4 513 519 11928786 severe JJ B-NP O
5 520 527 11928786 cardiac JJ I-NP B-Disease
6 528 539 11928786 arrhythmias NNS I-NP I-Disease
7 539 540 11928786 , , O O
8 541 550 11928786 including VBG B-PP O
9 551 554 11928786 one CD B-NP O
10 555 562 11928786 patient NN I-NP O
11 563 566 11928786 who WP B-NP O
12 567 570 11928786 was VBD B-VP O
13 571 583 11928786 resuscitated VBN I-VP O
14 584 593 11928786 following VBG B-PP O
15 594 595 11928786 a DT B-NP O
16 596 603 11928786 cardiac JJ I-NP B-Disease
17 604 610 11928786 arrest NN I-NP I-Disease
18 610 611 11928786 . . O O

1 612 615 11928786 All DT B-NP O
2 616 624 11928786 patients NNS I-NP O
3 625 634 11928786 recovered VBD B-VP O
4 635 642 11928786 without IN B-PP O
5 643 651 11928786 sequelae NNS B-NP O
6 651 652 11928786 . . O O

1 653 655 11928786 We PRP B-NP O
2 656 662 11928786 report VBP B-VP O
3 663 664 11928786 a DT B-NP O
4 665 669 11928786 case NN I-NP O
5 670 672 11928786 of IN B-PP O
6 673 674 11928786 a DT B-NP O
7 675 677 11928786 31 CD I-NP O
8 678 682 11928786 year NN I-NP O
9 683 686 11928786 old JJ I-NP O
10 687 693 11928786 female NN I-NP O
11 694 697 11928786 who WP B-NP O
12 698 706 11928786 required VBD B-VP O
13 707 716 11928786 admission NN B-NP O
14 717 719 11928786 to TO B-PP O
15 720 723 11928786 the DT B-NP O
16 724 733 11928786 Intensive JJ I-NP O
17 734 738 11928786 Care NNP I-NP O
18 739 743 11928786 Unit NNP I-NP O
19 744 747 11928786 for IN B-PP O
20 748 759 11928786 ventilation NN B-NP O
21 760 763 11928786 and CC O O
22 764 768 11928786 full JJ B-NP O
23 769 779 11928786 supportive JJ I-NP O
24 780 787 11928786 therapy NN I-NP O
25 787 788 11928786 , , O O
26 789 798 11928786 following VBG B-PP O
27 799 808 11928786 ingestion NN B-NP O
28 809 811 11928786 of IN B-PP O
29 812 817 11928786 13.5g NN B-NP O
30 818 827 11928786 bupropion NN I-NP B-Chemical
31 827 828 11928786 . . O O

1 829 838 11928786 Recurrent JJ B-NP O
2 839 847 11928786 seizures NNS I-NP B-Disease
3 848 852 11928786 were VBD B-VP O
4 853 860 11928786 treated VBN I-VP O
5 861 865 11928786 with IN B-PP O
6 866 874 11928786 diazepam NN B-NP B-Chemical
7 875 878 11928786 and CC O O
8 879 884 11928786 broad JJ B-NP O
9 885 892 11928786 complex JJ I-NP O
10 893 904 11928786 tachycardia NN I-NP B-Disease
11 905 908 11928786 was VBD B-VP O
12 909 921 11928786 successfully RB I-VP O
13 922 929 11928786 treated VBN I-VP O
14 930 934 11928786 with IN B-PP O
15 935 944 11928786 adenosine NN B-NP B-Chemical
16 944 945 11928786 . . O O

1 946 951 11928786 Zyban NNP B-NP B-Chemical
2 952 958 11928786 caused VBD B-VP O
3 959 970 11928786 significant JJ B-NP O
4 971 983 11928786 neurological JJ I-NP B-Disease
5 984 987 11928786 and CC I-NP I-Disease
6 988 1002 11928786 cardiovascular JJ I-NP I-Disease
7 1003 1011 11928786 toxicity NN I-NP I-Disease
8 1012 1014 11928786 in IN B-PP O
9 1015 1023 11928786 overdose NN B-NP B-Disease
10 1023 1024 11928786 . . O O

1 1025 1028 11928786 The DT B-NP O
2 1029 1038 11928786 potential JJ I-NP O
3 1039 1044 11928786 toxic JJ I-NP O
4 1045 1052 11928786 effects NNS I-NP O
5 1053 1059 11928786 should MD B-VP O
6 1060 1062 11928786 be VB I-VP O
7 1063 1073 11928786 considered VBN I-VP O
8 1074 1078 11928786 when WRB B-ADVP O
9 1079 1090 11928786 prescribing VBG B-VP O
10 1091 1093 11928786 it PRP B-NP O
11 1094 1096 11928786 as IN B-PP O
12 1097 1098 11928786 a DT B-NP O
13 1099 1106 11928786 smoking NN I-NP O
14 1107 1116 11928786 cessation NN I-NP O
15 1117 1120 11928786 aid NN I-NP O
16 1120 1121 11928786 . . O O

1 0 0 7053303 -DOCSTART- -X- -X- O

1 0 3 7053303 Age NN B-NP O
2 4 7 7053303 and CC I-NP O
3 8 13 7053303 renal JJ I-NP O
4 14 23 7053303 clearance NN I-NP O
5 24 26 7053303 of IN B-PP O
6 27 37 7053303 cimetidine NN B-NP B-Chemical
7 37 38 7053303 . . O O
8 39 41 7053303 In IN B-PP O
9 42 44 7053303 35 CD B-NP O
10 45 53 7053303 patients NNS I-NP O
11 54 55 7053303 ( ( O O
12 55 59 7053303 ages NNS B-NP O
13 60 62 7053303 20 CD B-NP O
14 63 65 7053303 to TO I-NP O
15 66 68 7053303 86 CD I-NP O
16 69 71 7053303 yr NN I-NP O
17 71 72 7053303 ) ) O O
18 73 82 7053303 receiving VBG B-VP O
19 83 93 7053303 cimetidine NN B-NP B-Chemical
20 94 109 7053303 therapeutically RB B-NP O
21 110 113 7053303 two CD I-NP O
22 114 119 7053303 serum NN I-NP O
23 120 127 7053303 samples NNS I-NP O
24 128 131 7053303 and CC O O
25 132 135 7053303 all DT B-NP O
26 136 141 7053303 urine NN I-NP O
27 142 148 7053303 formed VBN B-VP O
28 149 151 7053303 in IN B-PP O
29 152 155 7053303 the DT B-NP O
30 156 163 7053303 interim NN I-NP O
31 164 168 7053303 were VBD B-VP O
32 169 178 7053303 collected VBN I-VP O
33 179 182 7053303 for IN B-PP O
34 183 191 7053303 analysis NN B-NP O
35 192 194 7053303 of IN B-PP O
36 195 205 7053303 cimetidine NN B-NP B-Chemical
37 206 208 7053303 by IN B-PP O
38 209 213 7053303 high JJ B-NP O
39 213 214 7053303 - HYPH I-NP O
40 214 222 7053303 pressure NN I-NP O
41 223 229 7053303 liquid NN I-NP O
42 230 244 7053303 chromatography NN I-NP O
43 245 248 7053303 and CC B-PP O
44 249 252 7053303 for IN B-PP O
45 253 263 7053303 creatinine NN B-NP B-Chemical
46 263 264 7053303 . . O O

1 265 275 7053303 Cimetidine NN B-NP B-Chemical
2 276 285 7053303 clearance NN I-NP O
3 286 295 7053303 decreased VBD B-VP O
4 296 300 7053303 with IN B-PP O
5 301 304 7053303 age NN B-NP O
6 304 305 7053303 . . O O

1 306 309 7053303 The DT B-NP O
2 310 322 7053303 extrapolated VBN I-NP O
3 323 324 7053303 6 CD I-NP O
4 324 325 7053303 - HYPH I-NP O
5 325 327 7053303 hr NN I-NP O
6 328 333 7053303 serum NN I-NP O
7 334 347 7053303 concentration NN I-NP O
8 348 350 7053303 of IN B-PP O
9 351 361 7053303 cimetidine NN B-NP B-Chemical
10 362 365 7053303 per IN B-PP O
11 366 370 7053303 unit NN B-NP O
12 371 375 7053303 dose NN I-NP O
13 375 376 7053303 , , O O
14 377 382 7053303 after IN B-PP O
15 383 394 7053303 intravenous JJ B-NP O
16 395 405 7053303 cimetidine NN I-NP B-Chemical
17 405 406 7053303 , , O O
18 407 416 7053303 increased VBD B-VP O
19 417 421 7053303 with IN B-PP O
20 422 425 7053303 age NN B-NP O
21 426 428 7053303 of IN B-PP O
22 429 432 7053303 the DT B-NP O
23 433 441 7053303 patients NNS I-NP O
24 441 442 7053303 . . O O

1 443 446 7053303 The DT B-NP O
2 447 452 7053303 ratio NN I-NP O
3 453 455 7053303 of IN B-PP O
4 456 466 7053303 cimetidine NN B-NP B-Chemical
5 467 476 7053303 clearance NN I-NP O
6 477 479 7053303 to TO B-PP O
7 480 490 7053303 creatinine NN B-NP B-Chemical
8 491 500 7053303 clearance NN I-NP O
9 501 502 7053303 ( ( O O
10 502 504 7053303 Rc NN B-NP O
11 504 505 7053303 ) ) O O
12 506 514 7053303 averaged VBD B-VP O
13 515 518 7053303 4.8 CD B-NP O
14 519 520 7053303 + SYM O O
15 520 521 7053303 / SYM O O
16 521 522 7053303 - SYM O O
17 523 526 7053303 2.0 CD B-NP O
18 526 527 7053303 , , O O
19 528 538 7053303 indicating VBG B-VP O
20 539 542 7053303 net JJ B-NP O
21 543 550 7053303 tubular JJ I-NP O
22 551 560 7053303 secretion NN I-NP O
23 561 564 7053303 for IN B-PP O
24 565 575 7053303 cimetidine NN B-NP B-Chemical
25 575 576 7053303 . . O O

1 577 579 7053303 Rc NN B-NP O
2 580 586 7053303 seemed VBD B-VP O
3 587 589 7053303 to TO I-VP O
4 590 592 7053303 be VB I-VP O
5 593 604 7053303 independent JJ B-ADJP O
6 605 607 7053303 of IN B-PP O
7 608 611 7053303 age NN B-NP O
8 612 615 7053303 and CC O O
9 616 625 7053303 decreased VBD B-VP O
10 626 630 7053303 with IN B-PP O
11 631 641 7053303 increasing VBG B-NP O
12 642 647 7053303 serum NN I-NP O
13 648 661 7053303 concentration NN I-NP O
14 662 664 7053303 of IN B-PP O
15 665 675 7053303 cimetidine NN B-NP B-Chemical
16 675 676 7053303 , , O O
17 677 687 7053303 suggesting VBG B-VP O
18 688 692 7053303 that IN B-SBAR O
19 693 702 7053303 secretion NN B-NP O
20 703 705 7053303 of IN B-PP O
21 706 716 7053303 cimetidine NN B-NP B-Chemical
22 717 719 7053303 is VBZ B-VP O
23 720 721 7053303 a DT B-NP O
24 722 731 7053303 saturable JJ I-NP O
25 732 739 7053303 process NN I-NP O
26 739 740 7053303 . . O O

1 741 746 7053303 There EX B-NP O
2 747 750 7053303 was VBD B-VP O
3 751 755 7053303 only RB B-NP O
4 756 759 7053303 one CD I-NP O
5 760 764 7053303 case NN I-NP O
6 765 767 7053303 of IN B-PP O
7 768 776 7053303 dementia NN B-NP B-Disease
8 777 785 7053303 possibly RB B-ADVP O
9 786 789 7053303 due IN B-PP O
10 790 792 7053303 to TO B-PP O
11 793 803 7053303 cimetidine NN B-NP B-Chemical
12 804 805 7053303 ( ( O O
13 805 809 7053303 with IN B-PP O
14 810 811 7053303 a DT B-NP O
15 812 816 7053303 drug NN I-NP O
16 817 822 7053303 level NN I-NP O
17 823 825 7053303 of IN B-PP O
18 826 829 7053303 1.9 CD B-NP O
19 830 839 7053303 microgram NN I-NP O
20 839 840 7053303 / SYM B-NP O
21 840 842 7053303 ml NN B-NP O
22 843 844 7053303 6 CD I-NP O
23 845 847 7053303 hr NN I-NP O
24 848 853 7053303 after IN B-PP O
25 854 855 7053303 a DT B-NP O
26 856 860 7053303 dose NN I-NP O
27 860 861 7053303 ) ) O O
28 862 864 7053303 in IN B-PP O
29 865 866 7053303 a DT B-NP O
30 867 872 7053303 group NN I-NP O
31 873 875 7053303 of IN B-PP O
32 876 878 7053303 13 CD B-NP O
33 879 887 7053303 patients NNS I-NP O
34 888 895 7053303 without IN B-PP O
35 896 901 7053303 liver NN B-NP B-Disease
36 902 904 7053303 or CC I-NP I-Disease
37 905 911 7053303 kidney NN I-NP I-Disease
38 912 919 7053303 disease NN I-NP I-Disease
39 920 923 7053303 who WP B-NP O
40 924 927 7053303 had VBD B-VP O
41 928 938 7053303 cimetidine NN B-NP B-Chemical
42 939 945 7053303 levels NNS I-NP O
43 946 951 7053303 above IN B-PP O
44 952 956 7053303 1.25 CD B-NP O
45 957 966 7053303 microgram NN I-NP O
46 966 967 7053303 / SYM B-NP O
47 967 969 7053303 ml NN I-NP O
48 969 970 7053303 . . O O

1 971 975 7053303 Thus RB B-ADVP O
2 975 976 7053303 , , O O
3 977 981 7053303 high JJ B-NP O
4 982 992 7053303 cimetidine NN I-NP B-Chemical
5 993 999 7053303 levels NNS I-NP O
6 1000 1005 7053303 alone RB B-ADVP O
7 1006 1008 7053303 do VBP B-VP O
8 1009 1012 7053303 not RB I-VP O
9 1013 1019 7053303 always RB I-VP O
10 1020 1026 7053303 induce VB I-VP O
11 1027 1035 7053303 dementia NN B-NP B-Disease
12 1035 1036 7053303 . . O O

1 0 0 7468724 -DOCSTART- -X- -X- O

1 0 14 7468724 Cardiovascular JJ B-NP B-Disease
2 15 28 7468724 complications NNS I-NP I-Disease
3 29 39 7468724 associated VBN B-VP O
4 40 44 7468724 with IN B-PP O
5 45 56 7468724 terbutaline NN B-NP B-Chemical
6 57 66 7468724 treatment NN I-NP O
7 67 70 7468724 for IN B-PP O
8 71 78 7468724 preterm JJ B-NP B-Disease
9 79 84 7468724 labor NN I-NP I-Disease
10 84 85 7468724 . . O O
11 86 92 7468724 Severe JJ B-NP O
12 93 107 7468724 cardiovascular JJ I-NP B-Disease
13 108 121 7468724 complications NNS I-NP I-Disease
14 122 130 7468724 occurred VBD B-VP O
15 131 133 7468724 in IN B-PP O
16 134 139 7468724 eight CD B-NP O
17 140 142 7468724 of IN B-PP O
18 143 146 7468724 160 CD B-NP O
19 147 155 7468724 patients NNS I-NP O
20 156 163 7468724 treated VBN B-VP O
21 164 168 7468724 with IN B-PP O
22 169 180 7468724 terbutaline NN B-NP B-Chemical
23 181 184 7468724 for IN B-PP O
24 185 192 7468724 preterm JJ B-NP B-Disease
25 193 198 7468724 labor NN I-NP I-Disease
26 198 199 7468724 . . O O

1 200 210 7468724 Associated VBN B-NP O
2 211 225 7468724 corticosteroid NN I-NP O
3 226 233 7468724 therapy NN I-NP O
4 234 237 7468724 and CC I-NP O
5 238 242 7468724 twin NN I-NP O
6 243 253 7468724 gestations NNS I-NP O
7 254 260 7468724 appear VBP B-VP O
8 261 263 7468724 to TO I-VP O
9 264 266 7468724 be VB I-VP O
10 267 279 7468724 predisposing VBG I-VP O
11 280 287 7468724 factors NNS B-NP O
12 287 288 7468724 . . O O

1 289 298 7468724 Potential JJ B-NP O
2 299 309 7468724 mechanisms NNS I-NP O
3 310 312 7468724 of IN B-PP O
4 313 316 7468724 the DT B-NP O
5 317 332 7468724 pathophysiology NN I-NP O
6 333 336 7468724 are VBP B-VP O
7 337 344 7468724 briefly RB I-VP O
8 345 354 7468724 discussed VBN I-VP O
9 354 355 7468724 . . O O

1 0 0 8643971 -DOCSTART- -X- -X- O

1 0 1 8643971 A DT B-NP O
2 2 7 8643971 phase NN I-NP O
3 8 9 8643971 I CD I-NP O
4 9 10 8643971 / SYM I-NP O
5 10 12 8643971 II CD I-NP O
6 13 18 8643971 study NN I-NP O
7 19 21 8643971 of IN B-PP O
8 22 32 8643971 paclitaxel NN B-NP B-Chemical
9 33 37 8643971 plus CC I-NP O
10 38 47 8643971 cisplatin NN I-NP B-Chemical
11 48 50 8643971 as IN B-PP O
12 51 56 8643971 first JJ B-NP O
13 56 57 8643971 - HYPH I-NP O
14 57 61 8643971 line NN I-NP O
15 62 69 8643971 therapy NN I-NP O
16 70 73 8643971 for IN B-PP O
17 74 78 8643971 head NN B-NP B-Disease
18 79 82 8643971 and CC I-NP I-Disease
19 83 87 8643971 neck NN I-NP I-Disease
20 88 95 8643971 cancers NNS I-NP I-Disease
21 95 96 8643971 : : O O
22 97 108 8643971 preliminary JJ B-NP O
23 109 116 8643971 results NNS I-NP O
24 116 117 8643971 . . O O
25 118 126 8643971 Improved VBD B-VP O
26 127 135 8643971 outcomes NNS B-NP O
27 136 141 8643971 among IN B-PP O
28 142 150 8643971 patients NNS B-NP O
29 151 155 8643971 with IN B-PP O
30 156 160 8643971 head NN B-NP B-Disease
31 161 164 8643971 and CC I-NP I-Disease
32 165 169 8643971 neck NN I-NP I-Disease
33 170 180 8643971 carcinomas NNS I-NP I-Disease
34 181 188 8643971 require VBP B-VP O
35 189 203 8643971 investigations NNS B-NP O
36 204 206 8643971 of IN B-PP O
37 207 210 8643971 new JJ B-NP O
38 211 216 8643971 drugs NNS I-NP O
39 217 220 8643971 for IN B-PP O
40 221 230 8643971 induction NN B-NP O
41 231 238 8643971 therapy NN I-NP O
42 238 239 8643971 . . O O

1 240 251 8643971 Preliminary JJ B-NP O
2 252 259 8643971 results NNS I-NP O
3 260 262 8643971 of IN B-PP O
4 263 265 8643971 an DT B-NP O
5 266 273 8643971 Eastern NNP I-NP O
6 274 285 8643971 Cooperative NNP I-NP O
7 286 294 8643971 Oncology NNP I-NP O
8 295 300 8643971 Group NNP I-NP O
9 301 306 8643971 study NN I-NP O
10 307 309 8643971 of IN B-PP O
11 310 316 8643971 single JJ B-NP O
12 316 317 8643971 - HYPH I-NP O
13 317 322 8643971 agent NN I-NP O
14 323 333 8643971 paclitaxel NN I-NP B-Chemical
15 334 335 8643971 ( ( O O
16 335 340 8643971 Taxol NN B-NP B-Chemical
17 340 341 8643971 ; : O O
18 342 349 8643971 Bristol NNP B-NP O
19 349 350 8643971 - : O O
20 350 355 8643971 Myers NNP B-NP O
21 356 362 8643971 Squibb NNP I-NP O
22 363 370 8643971 Company NNP I-NP O
23 370 371 8643971 , , O O
24 372 381 8643971 Princeton NNP B-NP O
25 381 382 8643971 , , O O
26 383 385 8643971 NJ NNP B-NP O
27 385 386 8643971 ) ) O O
28 387 395 8643971 reported VBD B-VP O
29 396 397 8643971 a DT B-NP O
30 398 401 8643971 37% NN I-NP O
31 402 410 8643971 response NN I-NP O
32 411 415 8643971 rate NN I-NP O
33 416 418 8643971 in IN B-PP O
34 419 427 8643971 patients NNS B-NP O
35 428 432 8643971 with IN B-PP O
36 433 437 8643971 head NN B-NP B-Disease
37 438 441 8643971 and CC O I-Disease
38 442 446 8643971 neck NN B-NP I-Disease
39 447 453 8643971 cancer NN I-NP I-Disease
40 453 454 8643971 , , O O
41 455 458 8643971 and CC O O
42 459 462 8643971 the DT B-NP O
43 463 473 8643971 paclitaxel NN I-NP B-Chemical
44 473 474 8643971 / SYM B-NP O
45 474 483 8643971 cisplatin NN I-NP B-Chemical
46 484 495 8643971 combination NN I-NP O
47 496 499 8643971 has VBZ B-VP O
48 500 504 8643971 been VBN I-VP O
49 505 509 8643971 used VBN I-VP O
50 510 522 8643971 successfully RB B-ADVP O
51 523 526 8643971 and CC O O
52 527 530 8643971 has VBZ B-VP O
53 531 544 8643971 significantly RB I-VP O
54 545 553 8643971 improved VBN I-VP O
55 554 560 8643971 median JJ B-NP O
56 561 569 8643971 response NN I-NP O
57 570 578 8643971 duration NN I-NP O
58 579 581 8643971 in IN B-PP O
59 582 589 8643971 ovarian JJ B-NP B-Disease
60 590 596 8643971 cancer NN I-NP I-Disease
61 597 605 8643971 patients NNS I-NP O
62 605 606 8643971 . . O O

1 607 609 8643971 We PRP B-NP O
2 610 619 8643971 initiated VBD B-VP O
3 620 621 8643971 a DT B-NP O
4 622 627 8643971 phase NN I-NP O
5 628 629 8643971 I CD I-NP O
6 629 630 8643971 / SYM I-NP O
7 630 632 8643971 II CD I-NP O
8 633 638 8643971 trial NN I-NP O
9 639 641 8643971 to TO B-VP O
10 642 651 8643971 determine VB I-VP O
11 652 655 8643971 the DT B-NP O
12 656 664 8643971 response NN I-NP O
13 665 668 8643971 and CC I-NP O
14 669 677 8643971 toxicity NN I-NP B-Disease
15 678 680 8643971 of IN B-PP O
16 681 691 8643971 escalating VBG B-VP O
17 692 702 8643971 paclitaxel NN B-NP B-Chemical
18 703 708 8643971 doses NNS I-NP O
19 709 717 8643971 combined VBN B-VP O
20 718 722 8643971 with IN B-PP O
21 723 728 8643971 fixed VBN B-NP O
22 728 729 8643971 - HYPH I-NP O
23 729 733 8643971 dose NN I-NP O
24 734 743 8643971 cisplatin NN I-NP B-Chemical
25 744 748 8643971 with IN B-PP O
26 749 760 8643971 granulocyte NN B-NP O
27 761 767 8643971 colony NN I-NP O
28 767 768 8643971 - HYPH O O
29 768 779 8643971 stimulating VBG B-VP O
30 780 786 8643971 factor NN B-NP O
31 787 794 8643971 support NN I-NP O
32 795 797 8643971 in IN B-PP O
33 798 806 8643971 patients NNS B-NP O
34 807 811 8643971 with IN B-PP O
35 812 821 8643971 untreated JJ B-NP O
36 822 829 8643971 locally RB I-NP O
37 830 838 8643971 advanced JJ I-NP O
38 839 849 8643971 inoperable JJ I-NP O
39 850 854 8643971 head NN I-NP B-Disease
40 855 858 8643971 and CC I-NP I-Disease
41 859 863 8643971 neck NN I-NP I-Disease
42 864 873 8643971 carcinoma NN I-NP I-Disease
43 873 874 8643971 . . O O

1 875 877 8643971 To TO B-PP O
2 878 882 8643971 date NN B-NP O
3 882 883 8643971 , , O O
4 884 886 8643971 23 CD B-NP O
5 887 890 8643971 men NNS I-NP O
6 891 895 8643971 with IN B-PP O
7 896 897 8643971 a DT B-NP O
8 898 904 8643971 median JJ I-NP O
9 905 908 8643971 age NN I-NP O
10 909 911 8643971 of IN B-PP O
11 912 914 8643971 50 CD B-NP O
12 915 920 8643971 years NNS I-NP O
13 921 924 8643971 and CC O O
14 925 929 8643971 good JJ B-NP O
15 930 941 8643971 performance NN I-NP O
16 942 948 8643971 status NN I-NP O
17 949 953 8643971 have VBP B-VP O
18 954 961 8643971 entered VBN I-VP O
19 962 965 8643971 the DT B-NP O
20 966 971 8643971 trial NN I-NP O
21 971 972 8643971 . . O O

1 973 980 8643971 Primary JJ B-NP O
2 981 986 8643971 tumor NN I-NP B-Disease
3 987 992 8643971 sites NNS I-NP O
4 993 997 8643971 were VBD B-VP O
5 998 1008 8643971 oropharynx NN B-NP O
6 1008 1009 8643971 , , O O
7 1010 1012 8643971 10 CD B-NP O
8 1013 1021 8643971 patients NNS I-NP O
9 1021 1022 8643971 ; : O O
10 1023 1034 8643971 hypopharynx NN B-NP O
11 1034 1035 8643971 , , O O
12 1036 1040 8643971 four CD B-NP O
13 1040 1041 8643971 ; : O O
14 1042 1048 8643971 larynx NN B-NP O
15 1048 1049 8643971 , , O O
16 1050 1053 8643971 two CD B-NP O
17 1053 1054 8643971 ; : O O
18 1055 1059 8643971 oral JJ B-NP O
19 1060 1066 8643971 cavity NN I-NP O
20 1066 1067 8643971 , , O O
21 1068 1073 8643971 three CD B-NP O
22 1073 1074 8643971 ; : O O
23 1075 1082 8643971 unknown JJ B-NP O
24 1083 1090 8643971 primary JJ I-NP O
25 1090 1091 8643971 , , O O
26 1092 1095 8643971 two CD B-NP O
27 1095 1096 8643971 ; : O O
28 1097 1100 8643971 and CC O O
29 1101 1106 8643971 nasal JJ B-NP O
30 1107 1113 8643971 cavity NN I-NP O
31 1114 1117 8643971 and CC I-NP O
32 1118 1125 8643971 parotid NN I-NP O
33 1126 1131 8643971 gland NN I-NP O
34 1131 1132 8643971 , , O O
35 1133 1136 8643971 one CD B-NP O
36 1137 1141 8643971 each DT B-NP O
37 1141 1142 8643971 . . O O

1 1143 1145 8643971 Of IN B-PP O
2 1146 1148 8643971 20 CD B-NP O
3 1149 1157 8643971 patients NNS I-NP O
4 1158 1167 8643971 evaluable JJ B-ADJP O
5 1168 1171 8643971 for IN B-PP O
6 1172 1180 8643971 toxicity NN B-NP B-Disease
7 1180 1181 8643971 , , O O
8 1182 1186 8643971 four CD B-NP O
9 1187 1190 8643971 had VBD B-VP O
10 1191 1196 8643971 stage NN B-NP O
11 1197 1200 8643971 III CD B-NP O
12 1201 1204 8643971 and CC I-NP O
13 1205 1207 8643971 16 CD I-NP O
14 1208 1211 8643971 had VBD B-VP O
15 1212 1217 8643971 stage NN B-NP O
16 1218 1220 8643971 IV CD I-NP O
17 1221 1228 8643971 disease NN I-NP O
18 1228 1229 8643971 . . O O

1 1230 1239 8643971 Treatment NN B-NP O
2 1239 1240 8643971 , , O O
3 1241 1246 8643971 given VBN B-PP O
4 1247 1252 8643971 every DT B-NP O
5 1253 1255 8643971 21 CD I-NP O
6 1256 1260 8643971 days NNS I-NP O
7 1261 1264 8643971 for IN B-PP O
8 1265 1266 8643971 a DT B-NP O
9 1267 1274 8643971 maximum NN I-NP O
10 1275 1277 8643971 of IN B-PP O
11 1278 1283 8643971 three CD B-NP O
12 1284 1290 8643971 cycles NNS I-NP O
13 1290 1291 8643971 , , O O
14 1292 1301 8643971 consisted VBD B-VP O
15 1302 1304 8643971 of IN B-PP O
16 1305 1315 8643971 paclitaxel NN B-NP B-Chemical
17 1316 1318 8643971 by IN B-PP O
18 1319 1320 8643971 3 CD B-NP O
19 1320 1321 8643971 - HYPH I-NP O
20 1321 1325 8643971 hour NN I-NP O
21 1326 1334 8643971 infusion NN I-NP O
22 1335 1343 8643971 followed VBD B-VP O
23 1344 1347 8643971 the DT B-NP O
24 1348 1352 8643971 next JJ I-NP O
25 1353 1356 8643971 day NN I-NP O
26 1357 1359 8643971 by IN B-PP O
27 1360 1361 8643971 a DT B-NP O
28 1362 1367 8643971 fixed VBN I-NP O
29 1368 1372 8643971 dose NN I-NP O
30 1373 1375 8643971 of IN B-PP O
31 1376 1385 8643971 cisplatin NN B-NP B-Chemical
32 1386 1387 8643971 ( ( O O
33 1387 1389 8643971 75 CD B-NP O
34 1390 1392 8643971 mg NN I-NP O
35 1392 1393 8643971 / SYM B-NP O
36 1393 1395 8643971 m2 NN I-NP O
37 1395 1396 8643971 ) ) O O
38 1396 1397 8643971 . . O O

1 1398 1401 8643971 The DT B-NP O
2 1402 1406 8643971 dose NN I-NP O
3 1407 1413 8643971 levels NNS I-NP O
4 1414 1425 8643971 incorporate JJ B-ADJP O
5 1426 1436 8643971 escalating VBG B-VP O
6 1437 1447 8643971 paclitaxel NN B-NP B-Chemical
7 1448 1453 8643971 doses NNS I-NP O
8 1453 1454 8643971 , , O O
9 1455 1458 8643971 and CC O O
10 1459 1471 8643971 intrapatient JJ B-NP O
11 1472 1483 8643971 escalations NNS I-NP O
12 1484 1490 8643971 within IN B-PP O
13 1491 1492 8643971 a DT B-NP O
14 1493 1498 8643971 given VBN I-NP O
15 1499 1503 8643971 dose NN I-NP O
16 1504 1509 8643971 level NN I-NP O
17 1510 1513 8643971 are VBP B-VP O
18 1514 1523 8643971 permitted VBN I-VP O
19 1524 1526 8643971 if IN B-SBAR O
20 1527 1535 8643971 toxicity NN B-NP B-Disease
21 1536 1543 8643971 permits NNS I-NP O
22 1543 1544 8643971 . . O O

1 1545 1547 8643971 At IN B-PP O
2 1548 1551 8643971 the DT B-NP O
3 1552 1556 8643971 time NN I-NP O
4 1557 1559 8643971 of IN B-PP O
5 1560 1564 8643971 this DT B-NP O
6 1565 1572 8643971 writing NN I-NP O
7 1572 1573 8643971 , , I-NP O
8 1574 1578 8643971 dose NN I-NP O
9 1579 1584 8643971 level NN I-NP O
10 1585 1586 8643971 4 CD I-NP O
11 1587 1588 8643971 ( ( O O
12 1588 1591 8643971 260 CD B-NP O
13 1591 1592 8643971 , , I-NP O
14 1593 1596 8643971 270 CD I-NP O
15 1596 1597 8643971 , , O O
16 1598 1601 8643971 and CC O O
17 1602 1605 8643971 280 CD B-NP O
18 1606 1608 8643971 mg NN I-NP O
19 1608 1609 8643971 / SYM B-NP O
20 1609 1611 8643971 m2 NN I-NP O
21 1611 1612 8643971 ) ) O O
22 1613 1615 8643971 is VBZ B-VP O
23 1616 1621 8643971 being VBG I-VP O
24 1622 1631 8643971 evaluated VBN I-VP O
25 1631 1632 8643971 ; : O O
26 1633 1638 8643971 three CD B-NP O
27 1639 1647 8643971 patients NNS I-NP O
28 1648 1652 8643971 from IN B-PP O
29 1653 1657 8643971 this DT B-NP O
30 1658 1663 8643971 level NN I-NP O
31 1664 1667 8643971 are VBP B-VP O
32 1668 1677 8643971 evaluable JJ B-ADJP O
33 1677 1678 8643971 . . O O

1 1679 1683 8643971 With IN B-PP O
2 1684 1694 8643971 paclitaxel NN B-NP B-Chemical
3 1695 1700 8643971 doses NNS I-NP O
4 1701 1703 8643971 of IN B-PP O
5 1704 1707 8643971 200 CD B-NP O
6 1708 1710 8643971 mg NN I-NP O
7 1710 1711 8643971 / SYM B-NP O
8 1711 1713 8643971 m2 NN I-NP O
9 1714 1717 8643971 and CC O O
10 1718 1724 8643971 higher JJR B-NP O
11 1724 1725 8643971 , , I-NP O
12 1726 1737 8643971 granulocyte NN I-NP O
13 1738 1744 8643971 colony NN I-NP O
14 1744 1745 8643971 - HYPH O O
15 1745 1756 8643971 stimulating VBG B-VP O
16 1757 1763 8643971 factor NN B-NP O
17 1764 1765 8643971 5 CD B-NP O
18 1766 1776 8643971 micrograms NNS I-NP O
19 1776 1777 8643971 / SYM B-NP O
20 1777 1779 8643971 kg NN I-NP O
21 1779 1780 8643971 / SYM B-NP O
22 1780 1781 8643971 d NN I-NP O
23 1782 1784 8643971 is VBZ B-VP O
24 1785 1790 8643971 given VBN I-VP O
25 1791 1792 8643971 ( ( O O
26 1792 1796 8643971 days NNS B-NP O
27 1797 1798 8643971 4 CD B-NP O
28 1799 1806 8643971 through IN B-PP O
29 1807 1809 8643971 12 CD B-NP O
30 1809 1810 8643971 ) ) O O
31 1810 1811 8643971 . . O O

1 1812 1814 8643971 Of IN B-PP O
2 1815 1817 8643971 18 CD B-NP O
3 1818 1826 8643971 patients NNS I-NP O
4 1827 1836 8643971 evaluable JJ B-ADJP O
5 1837 1840 8643971 for IN B-PP O
6 1841 1849 8643971 response NN B-NP O
7 1849 1850 8643971 , , O O
8 1851 1856 8643971 seven CD B-NP O
9 1857 1858 8643971 ( ( O O
10 1858 1861 8643971 39% NN B-NP O
11 1861 1862 8643971 ) ) O O
12 1863 1871 8643971 achieved VBD B-VP O
13 1872 1873 8643971 a DT B-NP O
14 1874 1882 8643971 complete JJ I-NP O
15 1883 1891 8643971 response NN I-NP O
16 1892 1895 8643971 and CC O O
17 1896 1899 8643971 six CD B-NP O
18 1900 1901 8643971 ( ( O O
19 1901 1904 8643971 33% NN B-NP O
20 1904 1905 8643971 ) ) O O
21 1906 1914 8643971 achieved VBD B-VP O
22 1915 1916 8643971 a DT B-NP O
23 1917 1924 8643971 partial JJ I-NP O
24 1925 1933 8643971 response NN I-NP O
25 1933 1934 8643971 . . O O

1 1935 1940 8643971 Three CD B-NP O
2 1941 1949 8643971 patients NNS I-NP O
3 1950 1953 8643971 had VBD B-VP O
4 1954 1956 8643971 no DT B-NP O
5 1957 1963 8643971 change NN I-NP O
6 1964 1967 8643971 and CC I-NP O
7 1968 1975 8643971 disease NN I-NP O
8 1976 1986 8643971 progressed VBD B-VP O
9 1987 1989 8643971 in IN B-PP O
10 1990 1993 8643971 two CD B-NP O
11 1993 1994 8643971 . . O O

1 1995 1998 8643971 The DT B-NP O
2 1999 2006 8643971 overall JJ I-NP O
3 2007 2015 8643971 response NN I-NP O
4 2016 2020 8643971 rate NN I-NP O
5 2021 2023 8643971 is VBZ B-VP O
6 2024 2027 8643971 72% CD B-NP O
7 2027 2028 8643971 . . O O

1 2029 2035 8643971 Eleven CD B-NP O
2 2036 2046 8643971 responding VBG I-NP O
3 2047 2055 8643971 patients NNS I-NP O
4 2056 2059 8643971 had VBD B-VP O
5 2060 2070 8643971 subsequent JJ B-NP O
6 2071 2078 8643971 surgery NN I-NP O
7 2078 2079 8643971 / SYM B-NP O
8 2079 2091 8643971 radiotherapy NN B-NP O
9 2092 2094 8643971 or CC O O
10 2095 2102 8643971 radical JJ B-NP O
11 2103 2115 8643971 radiotherapy NN I-NP O
12 2115 2116 8643971 . . O O

1 2117 2120 8643971 Two CD B-NP O
2 2121 2131 8643971 pathologic JJ I-NP O
3 2132 2140 8643971 complete JJ I-NP O
4 2141 2150 8643971 responses NNS I-NP O
5 2151 2155 8643971 were VBD B-VP O
6 2156 2164 8643971 observed VBN I-VP O
7 2165 2167 8643971 in IN B-PP O
8 2168 2176 8643971 patients NNS B-NP O
9 2177 2180 8643971 who WP B-NP O
10 2181 2184 8643971 had VBD B-VP O
11 2185 2193 8643971 achieved VBN I-VP O
12 2194 2202 8643971 clinical JJ B-NP O
13 2203 2211 8643971 complete JJ I-NP O
14 2212 2221 8643971 responses NNS I-NP O
15 2221 2222 8643971 . . O O

1 2223 2231 8643971 Alopecia NNP B-NP B-Disease
2 2231 2232 8643971 , , O O
3 2233 2245 8643971 paresthesias NNS B-NP B-Disease
4 2245 2246 8643971 , , O O
5 2247 2250 8643971 and CC O O
6 2251 2262 8643971 arthralgias NNS B-NP B-Disease
7 2262 2263 8643971 / SYM B-NP O
8 2263 2271 8643971 myalgias NNS I-NP B-Disease
9 2272 2276 8643971 have VBP B-VP O
10 2277 2285 8643971 occurred VBN I-VP O
11 2286 2296 8643971 frequently RB B-ADVP O
12 2296 2297 8643971 , , O O
13 2298 2301 8643971 but CC O O
14 2302 2306 8643971 with IN B-PP O
15 2307 2310 8643971 one CD B-NP O
16 2311 2320 8643971 exception NN I-NP O
17 2321 2322 8643971 ( ( O O
18 2322 2323 8643971 a DT B-NP O
19 2324 2329 8643971 grade NN I-NP O
20 2330 2331 8643971 3 CD I-NP O
21 2332 2339 8643971 myalgia NN I-NP B-Disease
22 2339 2340 8643971 ) ) O O
23 2341 2345 8643971 they PRP B-NP O
24 2346 2350 8643971 have VBP B-VP O
25 2351 2355 8643971 been VBN I-VP O
26 2356 2361 8643971 grade NN B-NP O
27 2362 2363 8643971 1 CD I-NP O
28 2364 2366 8643971 or CC I-NP O
29 2367 2368 8643971 2 CD I-NP O
30 2368 2369 8643971 . . O O

1 2370 2372 8643971 No DT B-NP O
2 2373 2377 8643971 dose NN I-NP O
3 2377 2378 8643971 - HYPH O O
4 2378 2386 8643971 limiting VBG B-VP O
5 2387 2398 8643971 hematologic JJ B-NP O
6 2399 2407 8643971 toxicity NN I-NP B-Disease
7 2408 2411 8643971 has VBZ B-VP O
8 2412 2416 8643971 been VBN I-VP O
9 2417 2421 8643971 seen VBN I-VP O
10 2421 2422 8643971 . . O O

1 2423 2433 8643971 Paclitaxel NN B-NP B-Chemical
2 2433 2434 8643971 / SYM I-NP O
3 2434 2443 8643971 cisplatin NN I-NP B-Chemical
4 2444 2446 8643971 is VBZ B-VP O
5 2447 2449 8643971 an DT B-NP O
6 2450 2459 8643971 effective JJ I-NP O
7 2460 2465 8643971 first JJ I-NP O
8 2465 2466 8643971 - HYPH I-NP O
9 2466 2470 8643971 line NN I-NP O
10 2471 2478 8643971 regimen NN I-NP O
11 2479 2482 8643971 for IN B-PP O
12 2483 2497 8643971 locoregionally RB B-NP O
13 2498 2506 8643971 advanced JJ I-NP O
14 2507 2511 8643971 head NN I-NP B-Disease
15 2512 2515 8643971 and CC I-NP I-Disease
16 2516 2520 8643971 neck NN I-NP I-Disease
17 2521 2527 8643971 cancer NN I-NP I-Disease
18 2528 2531 8643971 and CC O O
19 2532 2541 8643971 continued JJ B-NP O
20 2542 2547 8643971 study NN I-NP O
21 2548 2550 8643971 is VBZ B-VP O
22 2551 2560 8643971 warranted VBN I-VP O
23 2560 2561 8643971 . . O O

1 2562 2569 8643971 Results NNS B-NP O
2 2570 2574 8643971 thus RB B-ADVP O
3 2575 2578 8643971 far RB B-VP O
4 2579 2586 8643971 suggest VBP I-VP O
5 2587 2589 8643971 no DT B-NP O
6 2590 2594 8643971 dose NN I-NP O
7 2594 2595 8643971 - HYPH B-NP O
8 2595 2603 8643971 response NN I-NP O
9 2604 2610 8643971 effect NN I-NP O
10 2611 2614 8643971 for IN B-PP O
11 2615 2625 8643971 paclitaxel NN B-NP B-Chemical
12 2626 2631 8643971 doses NNS I-NP O
13 2632 2637 8643971 above IN B-PP O
14 2638 2641 8643971 200 CD B-NP O
15 2642 2644 8643971 mg NN I-NP O
16 2644 2645 8643971 / SYM B-NP O
17 2645 2647 8643971 m2 NN I-NP O
18 2647 2648 8643971 . . O O

1 0 0 9401499 -DOCSTART- -X- -X- O

1 0 11 9401499 Ticlopidine NN B-NP B-Chemical
2 11 12 9401499 - HYPH O O
3 12 19 9401499 induced VBN B-NP O
4 20 28 9401499 aplastic JJ I-NP B-Disease
5 29 35 9401499 anemia NN I-NP I-Disease
6 35 36 9401499 : : O O
7 37 43 9401499 report NN B-NP O
8 44 46 9401499 of IN B-PP O
9 47 52 9401499 three CD B-NP O
10 53 60 9401499 Chinese JJ I-NP O
11 61 69 9401499 patients NNS I-NP O
12 70 73 9401499 and CC O O
13 74 80 9401499 review NN B-NP O
14 81 83 9401499 of IN B-PP O
15 84 87 9401499 the DT B-NP O
16 88 98 9401499 literature NN I-NP O
17 98 99 9401499 . . O O
18 100 102 9401499 In IN B-PP O
19 103 107 9401499 this DT B-NP O
20 108 113 9401499 study NN I-NP O
21 113 114 9401499 , , O O
22 115 120 9401499 three CD B-NP O
23 121 128 9401499 Chinese JJ I-NP O
24 129 137 9401499 patients NNS I-NP O
25 138 142 9401499 with IN B-PP O
26 143 154 9401499 ticlopidine NN B-NP B-Chemical
27 154 155 9401499 - HYPH B-NP O
28 155 162 9401499 induced VBN I-NP O
29 163 171 9401499 aplastic JJ I-NP B-Disease
30 172 178 9401499 anemia NN I-NP I-Disease
31 179 183 9401499 were VBD B-VP O
32 184 192 9401499 reported VBN I-VP O
33 193 196 9401499 and CC O O
34 197 204 9401499 another DT B-NP O
35 205 207 9401499 13 CD I-NP O
36 208 216 9401499 patients NNS I-NP O
37 217 219 9401499 in IN B-PP O
38 220 223 9401499 the DT B-NP O
39 224 231 9401499 English JJ I-NP O
40 232 242 9401499 literature NN I-NP O
41 243 247 9401499 were VBD B-VP O
42 248 256 9401499 reviewed VBN I-VP O
43 256 257 9401499 . . O O

1 258 260 9401499 We PRP B-NP O
2 261 270 9401499 attempted VBD B-VP O
3 271 273 9401499 to TO I-VP O
4 274 278 9401499 find VB I-VP O
5 279 289 9401499 underlying JJ B-NP O
6 290 302 9401499 similarities NNS I-NP O
7 302 303 9401499 , , O O
8 304 312 9401499 evaluate VBP B-VP O
9 313 316 9401499 the DT B-NP O
10 317 321 9401499 risk NN I-NP O
11 322 329 9401499 factors NNS I-NP O
12 329 330 9401499 , , O O
13 331 334 9401499 and CC O O
14 335 343 9401499 identify VB B-VP O
15 344 355 9401499 appropriate JJ B-NP O
16 356 365 9401499 treatment NN I-NP O
17 366 369 9401499 for IN B-PP O
18 370 374 9401499 this DT B-NP O
19 375 387 9401499 complication NN I-NP O
20 387 388 9401499 . . O O

1 389 392 9401499 All DT B-NP O
2 393 396 9401499 but IN B-PP O
3 397 400 9401499 one CD B-NP O
4 401 403 9401499 of IN B-PP O
5 404 407 9401499 the DT B-NP O
6 408 416 9401499 patients NNS I-NP O
7 417 421 9401499 were VBD B-VP O
8 422 426 9401499 over IN B-PP O
9 427 429 9401499 60 CD B-NP O
10 430 435 9401499 years NNS I-NP O
11 436 439 9401499 old JJ B-ADJP O
12 439 440 9401499 , , O O
13 441 444 9401499 and CC O O
14 445 448 9401499 the DT B-NP O
15 449 450 9401499 6 CD I-NP O
16 451 454 9401499 who WP B-NP O
17 455 459 9401499 died VBD B-VP O
18 460 464 9401499 were VBD B-VP O
19 465 468 9401499 all DT O O
20 469 474 9401499 older JJR B-ADJP O
21 475 479 9401499 than IN B-PP O
22 480 482 9401499 65 CD B-NP O
23 482 483 9401499 . . O O

1 484 493 9401499 Therefore RB B-ADVP O
2 493 494 9401499 , , O O
3 495 498 9401499 old JJ B-NP O
4 499 502 9401499 age NN I-NP O
5 503 506 9401499 may MD B-VP O
6 507 509 9401499 be VB I-VP O
7 510 511 9401499 a DT B-NP O
8 512 516 9401499 risk NN I-NP O
9 517 523 9401499 factor NN I-NP O
10 524 527 9401499 for IN B-PP O
11 528 538 9401499 developing VBG B-VP O
12 539 543 9401499 this DT B-NP O
13 544 556 9401499 complication NN I-NP O
14 556 557 9401499 . . O O

1 558 573 9401499 Agranulocytosis NN B-NP B-Disease
2 574 582 9401499 occurred VBD B-VP O
3 583 584 9401499 3 CD B-NP O
4 584 585 9401499 - HYPH I-NP O
5 585 587 9401499 20 CD I-NP O
6 588 593 9401499 weeks NNS I-NP O
7 594 599 9401499 after IN B-PP O
8 600 610 9401499 initiation NN B-NP O
9 611 613 9401499 of IN B-PP O
10 614 625 9401499 ticlopidine NN B-NP B-Chemical
11 625 626 9401499 , , O O
12 627 629 9401499 so RB B-NP O
13 630 638 9401499 frequent JJ I-NP O
14 639 650 9401499 examination NN I-NP O
15 651 653 9401499 of IN B-PP O
16 654 659 9401499 white JJ B-NP O
17 660 664 9401499 cell NN I-NP O
18 665 670 9401499 count NN I-NP O
19 671 677 9401499 during IN B-PP O
20 678 687 9401499 treatment NN B-NP O
21 688 690 9401499 is VBZ B-VP O
22 691 702 9401499 recommended VBN I-VP O
23 702 703 9401499 . . O O

1 704 709 9401499 There EX B-NP O
2 710 716 9401499 seemed VBD B-VP O
3 717 719 9401499 to TO I-VP O
4 720 722 9401499 be VB I-VP O
5 723 725 9401499 no DT B-NP O
6 726 732 9401499 direct JJ I-NP O
7 733 744 9401499 correlation NN I-NP O
8 745 752 9401499 between IN B-PP O
9 753 756 9401499 the DT B-NP O
10 757 761 9401499 dose NN I-NP O
11 762 764 9401499 or CC I-NP O
12 765 773 9401499 duration NN I-NP O
13 774 778 9401499 used VBN B-VP O
14 779 782 9401499 and CC O O
15 783 786 9401499 the DT B-NP O
16 787 795 9401499 severity NN I-NP O
17 796 798 9401499 of IN B-PP O
18 799 803 9401499 bone NN B-NP B-Disease
19 804 810 9401499 marrow NN I-NP I-Disease
20 811 822 9401499 suppression NN I-NP I-Disease
21 822 823 9401499 . . O O

1 824 833 9401499 Treatment NN B-NP O
2 834 837 9401499 for IN B-PP O
3 838 849 9401499 ticlopidine NN B-NP B-Chemical
4 849 850 9401499 - HYPH B-NP O
5 850 857 9401499 induced VBN I-NP O
6 858 866 9401499 aplastic JJ I-NP B-Disease
7 867 873 9401499 anemia NN I-NP I-Disease
8 874 878 9401499 with IN B-PP O
9 879 885 9401499 colony NN B-NP O
10 885 886 9401499 - HYPH O O
11 886 897 9401499 stimulating VBG B-VP O
12 898 905 9401499 factors NNS B-NP O
13 906 912 9401499 seemed VBD B-VP O
14 913 915 9401499 to TO I-VP O
15 916 920 9401499 have VB I-VP O
16 921 927 9401499 little JJ B-NP O
17 928 934 9401499 effect NN I-NP O
18 934 935 9401499 . . O O

1 936 939 9401499 The DT B-NP O
2 940 944 9401499 fact NN I-NP O
3 945 949 9401499 that IN B-SBAR O
4 950 951 9401499 5 CD B-NP O
5 952 954 9401499 of IN B-PP O
6 955 958 9401499 the DT B-NP O
7 959 960 9401499 6 CD I-NP O
8 961 969 9401499 patients NNS I-NP O
9 970 973 9401499 who WP B-NP O
10 974 982 9401499 received VBD B-VP O
11 983 993 9401499 concurrent JJ B-NP O
12 994 1001 9401499 calcium NN I-NP B-Chemical
13 1002 1009 9401499 channel NN I-NP O
14 1010 1018 9401499 blockers NNS I-NP O
15 1019 1023 9401499 died VBD B-VP O
16 1023 1024 9401499 , , O O
17 1025 1031 9401499 should MD B-VP O
18 1032 1037 9401499 alert VB I-VP O
19 1038 1048 9401499 clinicians NNS B-NP O
20 1049 1051 9401499 to TO B-VP O
21 1052 1054 9401499 be VB I-VP O
22 1055 1059 9401499 more RBR B-ADJP O
23 1060 1068 9401499 cautious JJ I-ADJP O
24 1069 1073 9401499 when WRB B-ADVP O
25 1074 1079 9401499 using VBG B-VP O
26 1080 1085 9401499 these DT B-NP O
27 1086 1089 9401499 two CD I-NP O
28 1090 1095 9401499 drugs NNS I-NP O
29 1096 1110 9401499 simultaneously RB B-ADVP O
30 1110 1111 9401499 . . O O

1 0 0 2234245 -DOCSTART- -X- -X- O

1 0 6 2234245 Ocular JJ B-NP B-Disease
2 7 10 2234245 and CC I-NP I-Disease
3 11 19 2234245 auditory JJ I-NP I-Disease
4 20 28 2234245 toxicity NN I-NP I-Disease
5 29 31 2234245 in IN B-PP O
6 32 44 2234245 hemodialyzed VBN B-NP O
7 45 53 2234245 patients NNS I-NP O
8 54 63 2234245 receiving VBG B-VP O
9 64 79 2234245 desferrioxamine NN B-NP B-Chemical
10 79 80 2234245 . . O O
11 81 87 2234245 During IN B-PP O
12 88 90 2234245 an DT B-NP O
13 91 93 2234245 18 CD I-NP O
14 93 94 2234245 - HYPH I-NP O
15 94 99 2234245 month NN I-NP O
16 100 106 2234245 period NN I-NP O
17 107 109 2234245 of IN B-PP O
18 110 115 2234245 study NN B-NP O
19 116 118 2234245 41 CD I-NP O
20 119 131 2234245 hemodialyzed VBN B-VP O
21 132 140 2234245 patients NNS B-NP O
22 141 150 2234245 receiving VBG B-VP O
23 151 166 2234245 desferrioxamine NN B-NP B-Chemical
24 167 168 2234245 ( ( O O
25 168 170 2234245 10 CD B-NP O
26 170 171 2234245 - HYPH I-NP O
27 171 173 2234245 40 CD I-NP O
28 174 176 2234245 mg NN I-NP O
29 176 177 2234245 / SYM O O
30 177 179 2234245 kg NN B-NP O
31 180 182 2234245 BW NN I-NP O
32 182 183 2234245 / SYM B-VP O
33 183 184 2234245 3 CD B-NP O
34 185 190 2234245 times NNS I-NP O
35 191 197 2234245 weekly RB B-ADVP O
36 197 198 2234245 ) ) O O
37 199 202 2234245 for IN B-PP O
38 203 206 2234245 the DT B-NP O
39 207 212 2234245 first JJ I-NP O
40 213 217 2234245 time NN I-NP O
41 218 222 2234245 were VBD B-VP O
42 223 232 2234245 monitored VBN I-VP O
43 233 236 2234245 for IN B-PP O
44 237 246 2234245 detection NN B-NP O
45 247 249 2234245 of IN B-PP O
46 250 261 2234245 audiovisual JJ B-NP B-Disease
47 262 270 2234245 toxicity NN I-NP I-Disease
48 270 271 2234245 . . O O

1 272 273 2234245 6 CD B-NP O
2 274 282 2234245 patients NNS I-NP O
3 283 292 2234245 presented VBD B-VP O
4 293 301 2234245 clinical JJ B-NP O
5 302 310 2234245 symptoms NNS I-NP O
6 311 313 2234245 of IN B-PP O
7 314 320 2234245 visual JJ B-NP B-Disease
8 321 323 2234245 or CC I-NP I-Disease
9 324 332 2234245 auditory JJ I-NP I-Disease
10 333 341 2234245 toxicity NN I-NP I-Disease
11 341 342 2234245 . . O O

1 343 351 2234245 Moreover RB B-ADVP O
2 351 352 2234245 , , O O
3 353 361 2234245 detailed VBD B-VP O
4 362 376 2234245 ophthalmologic JJ B-NP O
5 377 380 2234245 and CC I-NP O
6 381 391 2234245 audiologic JJ I-NP O
7 392 399 2234245 studies NNS I-NP O
8 400 409 2234245 disclosed VBD B-VP O
9 410 423 2234245 abnormalities NNS B-NP O
10 424 426 2234245 in IN B-PP O
11 427 428 2234245 7 CD B-NP O
12 429 433 2234245 more JJR I-NP O
13 434 446 2234245 asymptomatic JJ I-NP O
14 447 455 2234245 patients NNS I-NP O
15 455 456 2234245 . . O O

1 457 463 2234245 Visual JJ B-NP B-Disease
2 464 472 2234245 toxicity NN I-NP I-Disease
3 473 476 2234245 was VBD B-VP O
4 477 479 2234245 of IN B-PP O
5 480 487 2234245 retinal JJ B-NP O
6 488 494 2234245 origin NN I-NP O
7 495 498 2234245 and CC O O
8 499 502 2234245 was VBD B-VP O
9 503 516 2234245 characterized VBN I-VP O
10 517 519 2234245 by IN B-PP O
11 520 521 2234245 a DT B-NP O
12 522 528 2234245 tritan NN I-NP O
13 528 529 2234245 - HYPH I-NP O
14 529 533 2234245 type NN I-NP O
15 534 548 2234245 dyschromatopsy NN I-NP B-Disease
16 548 549 2234245 , , O O
17 550 559 2234245 sometimes RB B-VP O
18 560 570 2234245 associated VBN I-VP O
19 571 575 2234245 with IN B-PP O
20 576 577 2234245 a DT B-NP B-Disease
21 578 582 2234245 loss NN I-NP I-Disease
22 583 585 2234245 of IN B-PP I-Disease
23 586 592 2234245 visual JJ B-NP I-Disease
24 593 599 2234245 acuity NN I-NP I-Disease
25 600 603 2234245 and CC O O
26 604 614 2234245 pigmentary JJ B-NP B-Disease
27 615 622 2234245 retinal JJ I-NP I-Disease
28 623 631 2234245 deposits NNS I-NP I-Disease
29 631 632 2234245 . . O O

1 633 641 2234245 Auditory JJ B-NP B-Disease
2 642 650 2234245 toxicity NN I-NP I-Disease
3 651 654 2234245 was VBD B-VP O
4 655 668 2234245 characterized VBN I-VP O
5 669 671 2234245 by IN B-PP O
6 672 673 2234245 a DT B-NP O
7 674 677 2234245 mid NN I-NP O
8 677 678 2234245 - HYPH B-ADVP O
9 679 681 2234245 to TO B-PP O
10 682 686 2234245 high JJ B-NP O
11 686 687 2234245 - HYPH I-NP O
12 687 696 2234245 frequency NN I-NP O
13 697 711 2234245 neurosensorial JJ I-NP B-Disease
14 712 719 2234245 hearing NN I-NP I-Disease
15 720 724 2234245 loss NN I-NP I-Disease
16 725 728 2234245 and CC O O
17 729 732 2234245 the DT B-NP O
18 733 739 2234245 lesion NN I-NP O
19 740 743 2234245 was VBD B-VP O
20 744 746 2234245 of IN B-PP O
21 747 750 2234245 the DT B-NP O
22 751 759 2234245 cochlear JJ I-NP O
23 760 764 2234245 type NN I-NP O
24 764 765 2234245 . . O O

1 766 781 2234245 Desferrioxamine NN B-NP B-Chemical
2 782 792 2234245 withdrawal NN I-NP O
3 793 801 2234245 resulted VBD B-VP O
4 802 804 2234245 in IN B-PP O
5 805 806 2234245 a DT B-NP O
6 807 815 2234245 complete JJ I-NP O
7 816 824 2234245 recovery NN I-NP O
8 825 827 2234245 of IN B-PP O
9 828 834 2234245 visual JJ B-NP O
10 835 843 2234245 function NN I-NP O
11 844 846 2234245 in IN B-PP O
12 847 848 2234245 1 CD B-NP O
13 849 856 2234245 patient NN I-NP O
14 857 860 2234245 and CC O O
15 861 868 2234245 partial JJ B-NP O
16 869 877 2234245 recovery NN I-NP O
17 878 880 2234245 in IN B-PP O
18 881 882 2234245 3 CD B-NP O
19 882 883 2234245 , , O O
20 884 887 2234245 and CC O O
21 888 889 2234245 a DT B-NP O
22 890 898 2234245 complete JJ I-NP O
23 899 907 2234245 reversal NN I-NP O
24 908 910 2234245 of IN B-PP O
25 911 918 2234245 hearing NN B-NP B-Disease
26 919 923 2234245 loss NN I-NP I-Disease
27 924 926 2234245 in IN B-PP O
28 927 928 2234245 3 CD B-NP O
29 929 937 2234245 patients NNS I-NP O
30 938 941 2234245 and CC O O
31 942 949 2234245 partial JJ B-NP O
32 950 958 2234245 recovery NN I-NP O
33 959 961 2234245 in IN B-PP O
34 962 963 2234245 3 CD B-NP O
35 963 964 2234245 . . O O

1 965 969 2234245 This DT B-NP O
2 970 978 2234245 toxicity NN I-NP B-Disease
3 979 987 2234245 appeared VBD B-VP O
4 988 990 2234245 in IN B-PP O
5 991 999 2234245 patients NNS B-NP O
6 1000 1009 2234245 receiving VBG B-VP O
7 1010 1013 2234245 the DT B-NP O
8 1014 1020 2234245 higher JJR I-NP O
9 1021 1026 2234245 doses NNS I-NP O
10 1027 1029 2234245 of IN B-PP O
11 1030 1045 2234245 desferrioxamine NN B-NP B-Chemical
12 1046 1048 2234245 or CC O O
13 1049 1058 2234245 coincided VBD B-VP O
14 1059 1063 2234245 with IN B-PP O
15 1064 1067 2234245 the DT B-NP O
16 1068 1081 2234245 normalization NN I-NP O
17 1082 1084 2234245 of IN B-PP O
18 1085 1093 2234245 ferritin NN B-NP O
19 1094 1096 2234245 or CC I-NP O
20 1097 1106 2234245 aluminium NN I-NP B-Chemical
21 1107 1112 2234245 serum NN I-NP O
22 1113 1119 2234245 levels NNS I-NP O
23 1119 1120 2234245 . . O O

1 1121 1124 2234245 The DT B-NP O
2 1125 1129 2234245 data NNS I-NP O
3 1130 1138 2234245 indicate VBP B-VP O
4 1139 1143 2234245 that IN B-SBAR O
5 1144 1155 2234245 audiovisual JJ B-NP B-Disease
6 1156 1164 2234245 toxicity NN I-NP I-Disease
7 1165 1167 2234245 is VBZ B-VP O
8 1168 1171 2234245 not RB O O
9 1172 1174 2234245 an DT B-NP O
10 1175 1185 2234245 infrequent JJ I-NP O
11 1186 1198 2234245 complication NN I-NP O
12 1199 1201 2234245 in IN B-PP O
13 1202 1214 2234245 hemodialyzed VBN B-NP O
14 1215 1223 2234245 patients NNS I-NP O
15 1224 1233 2234245 receiving VBG B-VP O
16 1234 1249 2234245 desferrioxamine NN B-NP B-Chemical
17 1249 1250 2234245 . . O O

1 1251 1261 2234245 Periodical JJ B-NP O
2 1262 1273 2234245 audiovisual JJ I-NP O
3 1274 1284 2234245 monitoring NN I-NP O
4 1285 1291 2234245 should MD B-VP O
5 1292 1294 2234245 be VB I-VP O
6 1295 1304 2234245 performed VBN I-VP O
7 1305 1307 2234245 on IN B-PP O
8 1308 1320 2234245 hemodialyzed VBN B-NP O
9 1321 1329 2234245 patients NNS I-NP O
10 1330 1339 2234245 receiving VBG B-VP O
11 1340 1343 2234245 the DT B-NP O
12 1344 1348 2234245 drug NN I-NP O
13 1349 1351 2234245 in IN B-SBAR O
14 1352 1357 2234245 order NN O O
15 1358 1360 2234245 to TO B-VP O
16 1361 1367 2234245 detect VB I-VP O
17 1368 1375 2234245 adverse JJ B-NP O
18 1376 1383 2234245 effects NNS I-NP O
19 1384 1386 2234245 as RB B-ADVP O
20 1387 1392 2234245 early RB I-ADVP O
21 1393 1395 2234245 as IN B-PP O
22 1396 1404 2234245 possible JJ B-ADJP O
23 1404 1405 2234245 . . O O

1 0 0 18308784 -DOCSTART- -X- -X- O

1 0 11 18308784 Ginsenoside NN B-NP B-Chemical
2 12 15 18308784 Rg1 NN I-NP I-Chemical
3 16 24 18308784 restores VBZ B-VP O
4 25 28 18308784 the DT B-NP O
5 29 39 18308784 impairment NN I-NP B-Disease
6 40 42 18308784 of IN B-PP I-Disease
7 43 51 18308784 learning NN B-NP I-Disease
8 52 59 18308784 induced VBN B-VP O
9 60 62 18308784 by IN B-PP O
10 63 70 18308784 chronic JJ B-NP O
11 71 79 18308784 morphine NN I-NP B-Chemical
12 80 94 18308784 administration NN I-NP O
13 95 97 18308784 in IN B-PP O
14 98 102 18308784 rats NNS B-NP O
15 102 103 18308784 . . O O
16 104 107 18308784 Rg1 NN B-NP B-Chemical
17 107 108 18308784 , , O O
18 109 111 18308784 as IN B-PP O
19 112 113 18308784 a DT B-NP O
20 114 125 18308784 ginsenoside NN I-NP B-Chemical
21 126 135 18308784 extracted VBN B-VP O
22 136 140 18308784 from IN B-PP O
23 141 146 18308784 Panax NN B-NP O
24 147 154 18308784 ginseng NN I-NP O
25 154 155 18308784 , , O O
26 156 161 18308784 could MD B-VP O
27 162 172 18308784 ameliorate VB I-VP O
28 173 180 18308784 spatial JJ B-NP O
29 181 189 18308784 learning NN I-NP B-Disease
30 190 200 18308784 impairment NN I-NP I-Disease
31 200 201 18308784 . . O O

1 202 210 18308784 Previous JJ B-NP O
2 211 218 18308784 studies NNS I-NP O
3 219 223 18308784 have VBP B-VP O
4 224 236 18308784 demonstrated VBN I-VP O
5 237 241 18308784 that IN B-SBAR O
6 242 245 18308784 Rg1 NN B-NP B-Chemical
7 246 251 18308784 might MD B-VP O
8 252 254 18308784 be VB I-VP O
9 255 256 18308784 a DT B-NP O
10 257 263 18308784 useful JJ I-NP O
11 264 269 18308784 agent NN I-NP O
12 270 273 18308784 for IN B-PP O
13 274 277 18308784 the DT B-NP O
14 278 288 18308784 prevention NN I-NP O
15 289 292 18308784 and CC I-NP O
16 293 302 18308784 treatment NN I-NP O
17 303 305 18308784 of IN B-PP O
18 306 309 18308784 the DT B-NP O
19 310 317 18308784 adverse JJ I-NP O
20 318 325 18308784 effects NNS I-NP O
21 326 328 18308784 of IN B-PP O
22 329 337 18308784 morphine NN B-NP B-Chemical
23 337 338 18308784 . . O O

1 339 342 18308784 The DT B-NP O
2 343 346 18308784 aim NN I-NP O
3 347 349 18308784 of IN B-PP O
4 350 354 18308784 this DT B-NP O
5 355 360 18308784 study NN I-NP O
6 361 364 18308784 was VBD B-VP O
7 365 367 18308784 to TO B-VP O
8 368 379 18308784 investigate VB I-VP O
9 380 383 18308784 the DT B-NP O
10 384 390 18308784 effect NN I-NP O
11 391 393 18308784 of IN B-PP O
12 394 397 18308784 Rg1 NN B-NP B-Chemical
13 398 400 18308784 on IN B-PP O
14 401 409 18308784 learning VBG B-VP B-Disease
15 410 420 18308784 impairment NN B-NP I-Disease
16 421 423 18308784 by IN B-PP O
17 424 431 18308784 chronic JJ B-NP O
18 432 440 18308784 morphine NN I-NP B-Chemical
19 441 455 18308784 administration NN I-NP O
20 456 459 18308784 and CC O O
21 460 463 18308784 the DT B-NP O
22 464 473 18308784 mechanism NN I-NP O
23 474 485 18308784 responsible JJ B-ADJP O
24 486 489 18308784 for IN B-PP O
25 490 494 18308784 this DT B-NP O
26 495 501 18308784 effect NN I-NP O
27 501 502 18308784 . . O O

1 503 507 18308784 Male JJ B-NP O
2 508 512 18308784 rats NNS I-NP O
3 513 517 18308784 were VBD B-VP O
4 518 532 18308784 subcutaneously RB I-VP O
5 533 541 18308784 injected VBN I-VP O
6 542 546 18308784 with IN B-PP O
7 547 555 18308784 morphine NN B-NP B-Chemical
8 556 557 18308784 ( ( O O
9 557 559 18308784 10 CD B-NP O
10 560 562 18308784 mg NN I-NP O
11 562 563 18308784 / SYM B-NP O
12 563 565 18308784 kg NN I-NP O
13 565 566 18308784 ) ) O O
14 567 572 18308784 twice RB B-NP O
15 573 574 18308784 a DT I-NP O
16 575 578 18308784 day NN I-NP O
17 579 581 18308784 at IN B-PP O
18 582 584 18308784 12 CD B-NP O
19 585 589 18308784 hour NN I-NP O
20 590 599 18308784 intervals NNS I-NP O
21 600 603 18308784 for IN B-PP O
22 604 606 18308784 10 CD B-NP O
23 607 611 18308784 days NNS I-NP O
24 611 612 18308784 , , O O
25 613 616 18308784 and CC O O
26 617 620 18308784 Rg1 NN B-NP B-Chemical
27 621 622 18308784 ( ( O O
28 622 624 18308784 30 CD B-NP O
29 625 627 18308784 mg NN I-NP O
30 627 628 18308784 / SYM B-NP O
31 628 630 18308784 kg NN I-NP O
32 630 631 18308784 ) ) O O
33 632 635 18308784 was VBD B-VP O
34 636 653 18308784 intraperitoneally RB I-VP O
35 654 662 18308784 injected VBN I-VP O
36 663 664 18308784 2 CD B-NP O
37 665 670 18308784 hours NNS I-NP O
38 671 676 18308784 after IN B-PP O
39 677 680 18308784 the DT B-NP O
40 681 687 18308784 second JJ I-NP O
41 688 697 18308784 injection NN I-NP O
42 698 700 18308784 of IN B-PP O
43 701 709 18308784 morphine NN B-NP B-Chemical
44 710 714 18308784 once RB O O
45 715 716 18308784 a DT B-NP O
46 717 720 18308784 day NN I-NP O
47 721 724 18308784 for IN B-PP O
48 725 727 18308784 10 CD B-NP O
49 728 732 18308784 days NNS I-NP O
50 732 733 18308784 . . O O

1 734 741 18308784 Spatial JJ B-NP O
2 742 750 18308784 learning NN I-NP O
3 751 759 18308784 capacity NN I-NP O
4 760 763 18308784 was VBD B-VP O
5 764 772 18308784 assessed VBN I-VP O
6 773 775 18308784 in IN B-PP O
7 776 779 18308784 the DT B-NP O
8 780 786 18308784 Morris NNP I-NP O
9 787 792 18308784 water NN I-NP O
10 793 797 18308784 maze NN I-NP O
11 797 798 18308784 . . O O

1 799 802 18308784 The DT B-NP O
2 803 810 18308784 results NNS I-NP O
3 811 817 18308784 showed VBD B-VP O
4 818 822 18308784 that IN B-SBAR O
5 823 827 18308784 rats NNS B-NP O
6 828 835 18308784 treated VBN B-VP O
7 836 840 18308784 with IN B-PP O
8 841 849 18308784 Morphine NN B-NP B-Chemical
9 849 850 18308784 / SYM B-NP O
10 850 853 18308784 Rg1 NN I-NP B-Chemical
11 854 863 18308784 decreased VBD B-VP O
12 864 870 18308784 escape NN B-NP O
13 871 878 18308784 latency NN I-NP O
14 879 882 18308784 and CC O O
15 883 892 18308784 increased VBD B-VP O
16 893 896 18308784 the DT B-NP O
17 897 901 18308784 time NN I-NP O
18 902 907 18308784 spent VBN B-VP O
19 908 910 18308784 in IN B-PP O
20 911 919 18308784 platform NN B-NP O
21 920 928 18308784 quadrant NN I-NP O
22 929 932 18308784 and CC O O
23 933 941 18308784 entering VBG B-VP O
24 942 951 18308784 frequency NN B-NP O
25 951 952 18308784 . . O O

1 953 955 18308784 By IN B-PP O
2 956 968 18308784 implantation NN B-NP O
3 969 971 18308784 of IN B-PP O
4 972 982 18308784 electrodes NNS B-NP O
5 983 986 18308784 and CC O O
6 987 1007 18308784 electrophysiological JJ B-NP O
7 1008 1017 18308784 recording NN I-NP O
8 1018 1020 18308784 in FW B-ADVP O
9 1021 1025 18308784 vivo FW I-ADVP O
10 1025 1026 18308784 , , O O
11 1027 1030 18308784 the DT B-NP O
12 1031 1038 18308784 results NNS I-NP O
13 1039 1045 18308784 showed VBD B-VP O
14 1046 1050 18308784 that IN B-SBAR O
15 1051 1054 18308784 Rg1 NN B-NP B-Chemical
16 1055 1063 18308784 restored VBD B-VP O
17 1064 1067 18308784 the DT B-NP O
18 1068 1072 18308784 long JJ I-NP O
19 1072 1073 18308784 - HYPH I-NP O
20 1073 1077 18308784 term NN I-NP O
21 1078 1090 18308784 potentiation NN I-NP O
22 1091 1092 18308784 ( ( O O
23 1092 1095 18308784 LTP NN B-NP O
24 1095 1096 18308784 ) ) O O
25 1097 1105 18308784 impaired VBN B-VP O
26 1106 1108 18308784 by IN B-PP O
27 1109 1117 18308784 morphine NN B-NP B-Chemical
28 1118 1120 18308784 in IN B-PP O
29 1121 1125 18308784 both CC O O
30 1126 1132 18308784 freely RB B-VP O
31 1133 1139 18308784 moving VBG I-VP O
32 1140 1143 18308784 and CC O O
33 1144 1157 18308784 anaesthetised VBN B-NP O
34 1158 1162 18308784 rats NNS I-NP O
35 1162 1163 18308784 . . O O

1 1164 1167 18308784 The DT B-NP O
2 1168 1188 18308784 electrophysiological JJ I-NP O
3 1189 1198 18308784 recording NN I-NP O
4 1199 1201 18308784 in FW B-ADVP O
5 1202 1207 18308784 vitro FW I-ADVP O
6 1208 1214 18308784 showed VBD B-VP O
7 1215 1219 18308784 that IN B-SBAR O
8 1220 1223 18308784 Rg1 NN B-NP B-Chemical
9 1224 1232 18308784 restored VBD B-VP O
10 1233 1236 18308784 the DT B-NP O
11 1237 1240 18308784 LTP NN I-NP O
12 1241 1243 18308784 in IN B-PP O
13 1244 1250 18308784 slices NNS B-NP O
14 1251 1255 18308784 from IN B-PP O
15 1256 1259 18308784 the DT B-NP O
16 1260 1264 18308784 rats NNS I-NP O
17 1265 1272 18308784 treated VBN B-VP O
18 1273 1277 18308784 with IN B-PP O
19 1278 1286 18308784 morphine NN B-NP B-Chemical
20 1286 1287 18308784 , , O O
21 1288 1291 18308784 but CC O O
22 1292 1295 18308784 not RB O O
23 1296 1303 18308784 changed VBD B-VP O
24 1304 1307 18308784 LTP NN B-NP O
25 1308 1310 18308784 in IN B-PP O
26 1311 1314 18308784 the DT B-NP O
27 1315 1321 18308784 slices NNS I-NP O
28 1322 1326 18308784 from IN B-PP O
29 1327 1333 18308784 normal JJ B-NP O
30 1334 1340 18308784 saline NN I-NP O
31 1340 1341 18308784 - HYPH B-VP O
32 1342 1344 18308784 or CC O O
33 1345 1353 18308784 morphine NN B-NP B-Chemical
34 1353 1354 18308784 / SYM B-NP O
35 1354 1357 18308784 Rg1 NN I-NP B-Chemical
36 1357 1358 18308784 - HYPH B-NP O
37 1358 1365 18308784 treated VBN I-NP O
38 1366 1370 18308784 rats NNS I-NP O
39 1370 1371 18308784 ; : O O
40 1372 1376 18308784 this DT B-NP O
41 1377 1388 18308784 restoration NN I-NP O
42 1389 1394 18308784 could MD B-VP O
43 1395 1397 18308784 be VB I-VP O
44 1398 1407 18308784 inhibited VBN I-VP O
45 1408 1410 18308784 by IN B-PP O
46 1411 1412 18308784 N NN B-NP B-Chemical
47 1412 1413 18308784 - HYPH B-NP I-Chemical
48 1413 1419 18308784 methyl NN I-NP I-Chemical
49 1419 1420 18308784 - HYPH B-NP I-Chemical
50 1420 1421 18308784 D NN I-NP I-Chemical
51 1421 1422 18308784 - HYPH O I-Chemical
52 1422 1431 18308784 aspartate NN B-NP I-Chemical
53 1432 1433 18308784 ( ( O O
54 1433 1437 18308784 NMDA NN B-NP B-Chemical
55 1437 1438 18308784 ) ) O O
56 1439 1447 18308784 receptor NN B-NP O
57 1448 1458 18308784 antagonist NN I-NP O
58 1459 1464 18308784 MK801 NN I-NP B-Chemical
59 1464 1465 18308784 . . O O

1 1466 1468 18308784 We PRP B-NP O
2 1469 1477 18308784 conclude VBP B-VP O
3 1478 1482 18308784 that IN B-SBAR O
4 1483 1486 18308784 Rg1 NN B-NP B-Chemical
5 1487 1490 18308784 may MD B-VP O
6 1491 1504 18308784 significantly RB I-VP O
7 1505 1512 18308784 improve VB I-VP O
8 1513 1516 18308784 the DT B-NP O
9 1517 1524 18308784 spatial JJ I-NP O
10 1525 1533 18308784 learning NN I-NP O
11 1534 1542 18308784 capacity NN I-NP O
12 1543 1551 18308784 impaired VBN B-VP O
13 1552 1554 18308784 by IN B-PP O
14 1555 1561 18308784 chonic JJ B-NP O
15 1562 1570 18308784 morphine NN I-NP B-Chemical
16 1571 1585 18308784 administration NN I-NP O
17 1586 1589 18308784 and CC O O
18 1590 1597 18308784 restore VB B-VP O
19 1598 1601 18308784 the DT B-NP O
20 1602 1610 18308784 morphine NN I-NP B-Chemical
21 1610 1611 18308784 - HYPH B-VP O
22 1611 1620 18308784 inhibited VBN B-NP O
23 1621 1624 18308784 LTP NN I-NP O
24 1624 1625 18308784 . . O O

1 1626 1630 18308784 This DT B-NP O
2 1631 1637 18308784 effect NN I-NP O
3 1638 1640 18308784 is VBZ B-VP O
4 1641 1645 18308784 NMDA NN B-NP B-Chemical
5 1646 1654 18308784 receptor NN I-NP O
6 1655 1664 18308784 dependent JJ B-ADJP O
7 1664 1665 18308784 . . O O

1 0 0 3503576 -DOCSTART- -X- -X- O

1 0 6 3503576 Serial JJ B-NP O
2 7 14 3503576 studies NNS I-NP O
3 15 17 3503576 of IN B-PP O
4 18 26 3503576 auditory JJ B-NP B-Disease
5 27 40 3503576 neurotoxicity NN I-NP I-Disease
6 41 43 3503576 in IN B-PP O
7 44 52 3503576 patients NNS B-NP O
8 53 62 3503576 receiving VBG B-VP O
9 63 75 3503576 deferoxamine NN B-NP B-Chemical
10 76 83 3503576 therapy NN I-NP O
11 83 84 3503576 . . O O
12 85 91 3503576 Visual JJ B-NP B-Disease
13 92 95 3503576 and CC I-NP I-Disease
14 96 104 3503576 auditory JJ I-NP I-Disease
15 105 118 3503576 neurotoxicity NN I-NP I-Disease
16 119 122 3503576 was VBD B-VP O
17 123 133 3503576 previously RB I-VP O
18 134 144 3503576 documented VBN I-VP O
19 145 147 3503576 in IN B-PP O
20 148 150 3503576 42 CD B-NP O
21 151 153 3503576 of IN B-PP O
22 154 156 3503576 89 CD B-NP O
23 157 165 3503576 patients NNS I-NP O
24 166 170 3503576 with IN B-PP O
25 171 182 3503576 transfusion NN B-NP O
26 182 183 3503576 - HYPH B-NP O
27 183 192 3503576 dependent JJ I-NP O
28 193 199 3503576 anemia NN I-NP B-Disease
29 200 203 3503576 who WP B-NP O
30 204 208 3503576 were VBD B-VP O
31 209 218 3503576 receiving VBG I-VP O
32 219 223 3503576 iron NN B-NP B-Chemical
33 224 233 3503576 chelation NN I-NP O
34 234 241 3503576 therapy NN I-NP O
35 242 246 3503576 with IN B-PP O
36 247 252 3503576 daily JJ B-NP O
37 253 265 3503576 subcutaneous JJ I-NP O
38 266 278 3503576 deferoxamine NN I-NP B-Chemical
39 278 279 3503576 . . O O

1 280 286 3503576 Twenty CD B-NP O
2 286 287 3503576 - HYPH I-NP O
3 287 290 3503576 two CD B-NP O
4 291 299 3503576 patients NNS I-NP O
5 300 302 3503576 in IN B-PP O
6 303 306 3503576 the DT B-NP O
7 307 315 3503576 affected VBN I-NP O
8 316 321 3503576 group NN I-NP O
9 322 325 3503576 had VBD B-VP O
10 326 334 3503576 abnormal JJ B-NP B-Disease
11 335 345 3503576 audiograms NNS I-NP I-Disease
12 346 350 3503576 with IN B-PP I-Disease
13 351 359 3503576 deficits NNS B-NP I-Disease
14 360 366 3503576 mostly RB B-ADVP I-Disease
15 367 369 3503576 in IN B-PP I-Disease
16 370 373 3503576 the DT B-NP I-Disease
17 374 378 3503576 high JJ I-NP I-Disease
18 379 388 3503576 frequency NN I-NP I-Disease
19 389 394 3503576 range NN I-NP I-Disease
20 395 397 3503576 of IN B-PP I-Disease
21 398 403 3503576 4,000 CD B-NP I-Disease
22 404 406 3503576 to TO I-NP I-Disease
23 407 412 3503576 8,000 CD I-NP I-Disease
24 413 415 3503576 Hz NN I-NP I-Disease
25 416 419 3503576 and CC B-PP O
26 420 422 3503576 in IN B-PP O
27 423 426 3503576 the DT B-NP O
28 427 434 3503576 hearing NN I-NP O
29 435 444 3503576 threshold NN I-NP O
30 445 451 3503576 levels NNS I-NP O
31 452 454 3503576 of IN B-PP O
32 455 457 3503576 30 CD B-NP O
33 458 460 3503576 to TO I-NP O
34 461 464 3503576 100 CD I-NP O
35 465 473 3503576 decibels NNS I-NP O
36 473 474 3503576 . . O O

1 475 479 3503576 When WRB B-ADVP O
2 480 492 3503576 deferoxamine NN B-NP B-Chemical
3 493 500 3503576 therapy NN I-NP O
4 501 504 3503576 was VBD B-VP O
5 505 517 3503576 discontinued VBN I-VP O
6 518 521 3503576 and CC O O
7 522 528 3503576 serial JJ B-NP O
8 529 536 3503576 studies NNS I-NP O
9 537 541 3503576 were VBD B-VP O
10 542 551 3503576 performed VBN I-VP O
11 551 552 3503576 , , O O
12 553 563 3503576 audiograms NNS B-NP O
13 564 566 3503576 in IN B-PP O
14 567 572 3503576 seven CD B-NP O
15 573 578 3503576 cases NNS I-NP O
16 579 587 3503576 reverted VBD B-VP O
17 588 590 3503576 to TO B-PP O
18 591 597 3503576 normal JJ B-ADJP O
19 598 600 3503576 or CC O O
20 601 605 3503576 near RB B-ADJP O
21 606 612 3503576 normal JJ I-ADJP O
22 613 619 3503576 within IN B-PP O
23 620 623 3503576 two CD B-NP O
24 624 626 3503576 to TO I-NP O
25 627 632 3503576 three CD I-NP O
26 633 638 3503576 weeks NNS I-NP O
27 638 639 3503576 , , O O
28 640 643 3503576 and CC O O
29 644 648 3503576 nine CD B-NP O
30 649 651 3503576 of IN B-PP O
31 652 654 3503576 13 CD B-NP O
32 655 663 3503576 patients NNS I-NP O
33 664 668 3503576 with IN B-PP O
34 669 677 3503576 symptoms NNS B-NP O
35 678 684 3503576 became VBD B-VP O
36 685 697 3503576 asymptomatic JJ B-ADJP O
37 697 698 3503576 . . O O

1 699 709 3503576 Audiograms NNS B-NP O
2 710 714 3503576 from IN B-PP O
3 715 717 3503576 15 CD B-NP O
4 718 726 3503576 patients NNS I-NP O
5 727 735 3503576 remained VBD B-VP O
6 736 744 3503576 abnormal JJ B-ADJP O
7 745 748 3503576 and CC O O
8 749 753 3503576 four CD B-NP O
9 754 762 3503576 patients NNS I-NP O
10 763 771 3503576 required VBD B-VP O
11 772 779 3503576 hearing NN B-NP O
12 780 784 3503576 aids NNS I-NP O
13 785 792 3503576 because IN B-PP O
14 793 795 3503576 of IN I-PP O
15 796 805 3503576 permanent JJ B-NP B-Disease
16 806 816 3503576 disability NN I-NP I-Disease
17 816 817 3503576 . . O O

1 818 823 3503576 Since IN B-PP O
2 824 826 3503576 18 CD B-NP O
3 827 829 3503576 of IN B-PP O
4 830 833 3503576 the DT B-NP O
5 834 836 3503576 22 CD I-NP O
6 837 845 3503576 patients NNS I-NP O
7 846 850 3503576 were VBD B-VP O
8 851 860 3503576 initially RB I-VP O
9 861 870 3503576 receiving VBG I-VP O
10 871 883 3503576 deferoxamine NN B-NP B-Chemical
11 884 889 3503576 doses NNS I-NP O
12 890 892 3503576 in IN B-PP O
13 893 899 3503576 excess NN B-NP O
14 900 902 3503576 of IN B-PP O
15 903 906 3503576 the DT B-NP O
16 907 915 3503576 commonly RB I-NP O
17 916 927 3503576 recommended VBN I-NP O
18 928 930 3503576 50 CD I-NP O
19 931 933 3503576 mg NN I-NP O
20 933 934 3503576 / SYM B-NP O
21 934 936 3503576 kg NN I-NP O
22 937 940 3503576 per IN B-PP O
23 941 945 3503576 dose NN B-NP O
24 945 946 3503576 , , O O
25 947 954 3503576 therapy NN B-NP O
26 955 958 3503576 was VBD B-VP O
27 959 968 3503576 restarted VBN I-VP O
28 969 973 3503576 with IN B-PP O
29 974 979 3503576 lower JJR B-NP O
30 980 985 3503576 doses NNS I-NP O
31 985 986 3503576 , , O O
32 987 994 3503576 usually RB B-ADVP O
33 995 997 3503576 50 CD B-NP O
34 998 1000 3503576 mg NN I-NP O
35 1000 1001 3503576 / SYM B-NP O
36 1001 1003 3503576 kg NN I-NP O
37 1004 1007 3503576 per IN B-PP O
38 1008 1012 3503576 dose NN B-NP O
39 1013 1015 3503576 or CC O O
40 1016 1020 3503576 less JJR B-NP O
41 1021 1030 3503576 depending VBG B-PP O
42 1031 1033 3503576 on IN B-PP O
43 1034 1037 3503576 the DT B-NP O
44 1038 1044 3503576 degree NN I-NP O
45 1045 1047 3503576 of IN B-PP O
46 1048 1056 3503576 auditory JJ B-NP B-Disease
47 1057 1068 3503576 abnormality NN I-NP I-Disease
48 1068 1069 3503576 , , O O
49 1070 1073 3503576 and CC O O
50 1074 1078 3503576 with IN B-PP O
51 1079 1082 3503576 the DT B-NP O
52 1083 1092 3503576 exception NN I-NP O
53 1093 1095 3503576 of IN B-PP O
54 1096 1099 3503576 two CD B-NP O
55 1100 1105 3503576 cases NNS I-NP O
56 1106 1108 3503576 no DT B-NP O
57 1109 1116 3503576 further JJ I-NP O
58 1117 1125 3503576 toxicity NN I-NP B-Disease
59 1126 1129 3503576 was VBD B-VP O
60 1130 1142 3503576 demonstrated VBN I-VP O
61 1142 1143 3503576 . . O O

1 1144 1152 3503576 Auditory JJ B-NP O
2 1153 1166 3503576 deterioration NN I-NP O
3 1167 1170 3503576 and CC I-NP O
4 1171 1182 3503576 improvement NN I-NP O
5 1182 1183 3503576 , , O O
6 1184 1196 3503576 demonstrated VBD B-VP O
7 1197 1205 3503576 serially RB B-ADVP O
8 1206 1208 3503576 in IN B-PP O
9 1209 1219 3503576 individual JJ B-NP O
10 1220 1228 3503576 patients NNS I-NP O
11 1229 1238 3503576 receiving VBG B-VP O
12 1239 1242 3503576 and CC O O
13 1243 1246 3503576 not RB B-VP O
14 1247 1256 3503576 receiving VBG I-VP O
15 1257 1269 3503576 deferoxamine NN B-NP B-Chemical
16 1269 1270 3503576 , , O O
17 1271 1283 3503576 respectively RB B-ADVP O
18 1283 1284 3503576 , , O O
19 1285 1293 3503576 provided VBN B-PP O
20 1294 1304 3503576 convincing VBG B-VP O
21 1305 1313 3503576 evidence NN B-NP O
22 1314 1317 3503576 for IN B-PP O
23 1318 1319 3503576 a DT B-NP O
24 1320 1325 3503576 cause NN I-NP O
25 1325 1326 3503576 - HYPH B-NP O
26 1326 1329 3503576 and CC I-NP O
27 1329 1330 3503576 - HYPH I-NP O
28 1330 1336 3503576 effect NN I-NP O
29 1337 1345 3503576 relation NN I-NP O
30 1346 1353 3503576 between IN B-PP O
31 1354 1366 3503576 deferoxamine NN B-NP B-Chemical
32 1367 1381 3503576 administration NN I-NP O
33 1382 1385 3503576 and CC I-NP O
34 1386 1397 3503576 ototoxicity NN I-NP B-Disease
35 1397 1398 3503576 . . O O

1 1399 1404 3503576 Based VBN B-PP O
2 1405 1407 3503576 on IN B-PP O
3 1408 1413 3503576 these DT B-NP O
4 1414 1418 3503576 data NNS I-NP O
5 1418 1419 3503576 , , O O
6 1420 1421 3503576 a DT B-NP O
7 1422 1426 3503576 plan NN I-NP O
8 1427 1429 3503576 of IN B-PP O
9 1430 1440 3503576 management NN B-NP O
10 1441 1444 3503576 was VBD B-VP O
11 1445 1454 3503576 developed VBN I-VP O
12 1455 1459 3503576 that WDT B-NP O
13 1460 1466 3503576 allows VBZ B-VP O
14 1467 1476 3503576 effective JJ B-NP O
15 1477 1480 3503576 yet RB I-NP O
16 1481 1485 3503576 safe JJ I-NP O
17 1486 1500 3503576 administration NN I-NP O
18 1501 1503 3503576 of IN B-PP O
19 1504 1516 3503576 deferoxamine NN B-NP B-Chemical
20 1516 1517 3503576 . . O O

1 1518 1519 3503576 A DT B-NP O
2 1520 1524 3503576 dose NN I-NP O
3 1525 1527 3503576 of IN B-PP O
4 1528 1530 3503576 50 CD B-NP O
5 1531 1533 3503576 mg NN I-NP O
6 1533 1534 3503576 / SYM B-NP O
7 1534 1536 3503576 kg NN I-NP O
8 1537 1539 3503576 is VBZ B-VP O
9 1540 1551 3503576 recommended VBN I-VP O
10 1552 1554 3503576 in IN B-PP O
11 1555 1560 3503576 those DT B-NP O
12 1561 1568 3503576 without IN B-PP O
13 1569 1578 3503576 audiogram NN B-NP O
14 1579 1592 3503576 abnormalities NNS I-NP O
15 1592 1593 3503576 . . O O

1 1594 1598 3503576 With IN B-PP O
2 1599 1603 3503576 mild JJ B-NP O
3 1604 1612 3503576 toxicity NN I-NP B-Disease
4 1612 1613 3503576 , , O O
5 1614 1615 3503576 a DT B-NP O
6 1616 1625 3503576 reduction NN I-NP O
7 1626 1628 3503576 to TO B-PP O
8 1629 1631 3503576 30 CD B-NP O
9 1632 1634 3503576 or CC I-NP O
10 1635 1637 3503576 40 CD I-NP O
11 1638 1640 3503576 mg NN I-NP O
12 1640 1641 3503576 / SYM B-NP O
13 1641 1643 3503576 kg NN I-NP O
14 1644 1647 3503576 per IN B-PP O
15 1648 1652 3503576 dose NN B-NP O
16 1653 1659 3503576 should MD B-VP O
17 1660 1666 3503576 result VB I-VP O
18 1667 1669 3503576 in IN B-PP O
19 1670 1671 3503576 a DT B-NP O
20 1672 1680 3503576 reversal NN I-NP O
21 1681 1683 3503576 of IN B-PP O
22 1684 1687 3503576 the DT B-NP O
23 1688 1696 3503576 abnormal JJ I-NP O
24 1697 1704 3503576 results NNS I-NP O
25 1705 1707 3503576 to TO B-PP O
26 1708 1714 3503576 normal JJ B-ADJP O
27 1715 1721 3503576 within IN B-PP O
28 1722 1726 3503576 four CD B-NP O
29 1727 1732 3503576 weeks NNS I-NP O
30 1732 1733 3503576 . . O O

1 1734 1742 3503576 Moderate JJ B-NP O
2 1743 1756 3503576 abnormalities NNS I-NP O
3 1757 1764 3503576 require VBP B-VP O
4 1765 1766 3503576 a DT B-NP O
5 1767 1776 3503576 reduction NN I-NP O
6 1777 1779 3503576 of IN B-PP O
7 1780 1792 3503576 deferoxamine NN B-NP B-Chemical
8 1793 1795 3503576 to TO B-PP O
9 1796 1798 3503576 25 CD B-NP O
10 1799 1801 3503576 mg NN I-NP O
11 1801 1802 3503576 / SYM B-NP O
12 1802 1804 3503576 kg NN I-NP O
13 1805 1808 3503576 per IN B-PP O
14 1809 1813 3503576 dose NN B-NP O
15 1814 1818 3503576 with IN B-PP O
16 1819 1826 3503576 careful JJ B-NP O
17 1827 1837 3503576 monitoring NN I-NP O
18 1837 1838 3503576 . . O O

1 1839 1841 3503576 In IN B-PP O
2 1842 1847 3503576 those DT B-NP O
3 1848 1852 3503576 with IN B-PP O
4 1853 1861 3503576 symptoms NNS B-NP O
5 1862 1864 3503576 of IN B-PP O
6 1865 1872 3503576 hearing NN B-NP B-Disease
7 1873 1877 3503576 loss NN I-NP I-Disease
8 1877 1878 3503576 , , O O
9 1879 1882 3503576 the DT B-NP O
10 1883 1887 3503576 drug NN I-NP O
11 1888 1894 3503576 should MD B-VP O
12 1895 1897 3503576 be VB I-VP O
13 1898 1905 3503576 stopped VBN I-VP O
14 1906 1909 3503576 for IN B-PP O
15 1910 1914 3503576 four CD B-NP O
16 1915 1920 3503576 weeks NNS I-NP O
17 1920 1921 3503576 , , O O
18 1922 1925 3503576 and CC O O
19 1926 1930 3503576 when WRB B-ADVP O
20 1931 1934 3503576 the DT B-NP O
21 1935 1944 3503576 audiogram NN I-NP O
22 1945 1947 3503576 is VBZ B-VP O
23 1948 1954 3503576 stable JJ B-ADJP O
24 1955 1957 3503576 or CC I-ADJP O
25 1958 1966 3503576 improved JJ I-ADJP O
26 1966 1967 3503576 , , O O
27 1968 1975 3503576 therapy NN B-NP O
28 1976 1982 3503576 should MD B-VP O
29 1983 1985 3503576 be VB I-VP O
30 1986 1995 3503576 restarted VBN I-VP O
31 1996 1998 3503576 at IN B-PP O
32 1999 2001 3503576 10 CD B-NP O
33 2002 2004 3503576 to TO I-NP O
34 2005 2007 3503576 25 CD I-NP O
35 2008 2010 3503576 mg NN I-NP O
36 2010 2011 3503576 / SYM I-NP O
37 2011 2013 3503576 kg NN I-NP O
38 2014 2017 3503576 per IN B-PP O
39 2018 2022 3503576 dose NN B-NP O
40 2022 2023 3503576 . . O O

1 2024 2030 3503576 Serial JJ B-NP O
2 2031 2041 3503576 audiograms NNS I-NP O
3 2042 2048 3503576 should MD B-VP O
4 2049 2051 3503576 be VB I-VP O
5 2052 2061 3503576 performed VBN I-VP O
6 2062 2067 3503576 every DT B-NP O
7 2068 2071 3503576 six CD I-NP O
8 2072 2078 3503576 months NNS I-NP O
9 2079 2081 3503576 in IN B-PP O
10 2082 2087 3503576 those DT B-NP O
11 2088 2095 3503576 without IN B-PP O
12 2096 2104 3503576 problems NNS B-NP O
13 2105 2108 3503576 and CC O O
14 2109 2113 3503576 more RBR B-ADVP O
15 2114 2124 3503576 frequently RB I-ADVP O
16 2125 2127 3503576 in IN B-PP O
17 2128 2133 3503576 young JJ B-NP O
18 2134 2142 3503576 patients NNS I-NP O
19 2143 2147 3503576 with IN B-PP O
20 2148 2154 3503576 normal JJ B-NP O
21 2155 2160 3503576 serum NN I-NP O
22 2161 2169 3503576 ferritin NN I-NP O
23 2170 2176 3503576 values NNS I-NP O
24 2177 2180 3503576 and CC B-PP O
25 2181 2183 3503576 in IN B-PP O
26 2184 2189 3503576 those DT B-NP O
27 2190 2194 3503576 with IN B-PP O
28 2195 2203 3503576 auditory JJ B-NP B-Disease
29 2204 2215 3503576 dysfunction NN I-NP I-Disease
30 2215 2216 3503576 . . O O

1 0 0 1085609 -DOCSTART- -X- -X- O

1 0 8 1085609 Neonatal JJ B-NP O
2 9 19 1085609 pyridoxine NN I-NP B-Chemical
3 20 30 1085609 responsive JJ I-NP O
4 31 42 1085609 convulsions NNS I-NP B-Disease
5 43 46 1085609 due JJ B-ADJP O
6 47 49 1085609 to TO B-PP O
7 50 59 1085609 isoniazid NN B-NP B-Chemical
8 60 67 1085609 therapy NN I-NP O
9 67 68 1085609 . . O O
10 69 70 1085609 A DT B-NP O
11 71 73 1085609 17 CD I-NP O
12 73 74 1085609 - HYPH I-NP O
13 74 77 1085609 day NN I-NP O
14 77 78 1085609 - HYPH O O
15 78 81 1085609 old JJ B-NP O
16 82 88 1085609 infant NN I-NP O
17 89 91 1085609 on IN B-PP O
18 92 101 1085609 isoniazid NN B-NP B-Chemical
19 102 109 1085609 therapy NN I-NP O
20 110 112 1085609 13 CD I-NP O
21 113 115 1085609 mg NN I-NP O
22 115 116 1085609 / SYM B-NP O
23 116 118 1085609 kg NN I-NP O
24 119 124 1085609 daily RB B-ADVP O
25 125 129 1085609 from IN B-PP O
26 130 135 1085609 birth NN B-NP O
27 136 143 1085609 because IN B-PP O
28 144 146 1085609 of IN I-PP O
29 147 155 1085609 maternal JJ B-NP O
30 156 168 1085609 tuberculosis NN I-NP B-Disease
31 169 172 1085609 was VBD B-VP O
32 173 181 1085609 admitted VBN I-VP O
33 182 187 1085609 after IN B-PP O
34 188 189 1085609 4 CD B-NP O
35 190 194 1085609 days NNS I-NP O
36 195 197 1085609 of IN B-PP O
37 198 204 1085609 clonic JJ B-NP B-Disease
38 205 209 1085609 fits NNS I-NP I-Disease
39 209 210 1085609 . . O O

1 211 213 1085609 No DT B-NP O
2 214 224 1085609 underlying VBG I-NP O
3 225 234 1085609 infective JJ I-NP O
4 235 237 1085609 or CC I-NP O
5 238 249 1085609 biochemical JJ I-NP O
6 250 255 1085609 cause NN I-NP O
7 256 261 1085609 could MD B-VP O
8 262 264 1085609 be VB I-VP O
9 265 270 1085609 found VBN I-VP O
10 270 271 1085609 . . O O

1 272 275 1085609 The DT B-NP O
2 276 280 1085609 fits NNS I-NP B-Disease
3 281 287 1085609 ceased VBD B-VP O
4 288 294 1085609 within IN B-PP O
5 295 296 1085609 4 CD B-NP O
6 297 302 1085609 hours NNS I-NP O
7 303 305 1085609 of IN B-PP O
8 306 319 1085609 administering VBG B-VP O
9 320 333 1085609 intramuscular JJ B-NP O
10 334 344 1085609 pyridoxine NN I-NP B-Chemical
11 344 345 1085609 , , O O
12 346 356 1085609 suggesting VBG B-VP O
13 357 359 1085609 an DT B-NP O
14 360 369 1085609 aetiology NN I-NP O
15 370 372 1085609 of IN B-PP O
16 373 383 1085609 pyridoxine NN B-NP B-Chemical
17 384 394 1085609 deficiency NN I-NP O
18 395 404 1085609 secondary JJ B-ADJP O
19 405 407 1085609 to TO B-PP O
20 408 417 1085609 isoniazid NN B-NP B-Chemical
21 418 428 1085609 medication NN I-NP O
22 428 429 1085609 . . O O

1 0 0 8387218 -DOCSTART- -X- -X- O

1 0 3 8387218 The DT B-NP O
2 4 7 8387218 use NN I-NP O
3 8 11 8387218 and CC I-NP O
4 12 20 8387218 toxicity NN I-NP B-Disease
5 21 23 8387218 of IN B-PP O
6 24 34 8387218 didanosine NN B-NP B-Chemical
7 35 36 8387218 ( ( O O
8 36 39 8387218 ddI NN B-NP B-Chemical
9 39 40 8387218 ) ) O O
10 41 43 8387218 in IN B-PP O
11 44 47 8387218 HIV NN B-NP B-Disease
12 48 56 8387218 antibody NN I-NP I-Disease
13 56 57 8387218 - HYPH B-NP I-Disease
14 57 65 8387218 positive JJ I-NP I-Disease
15 66 77 8387218 individuals NNS I-NP O
16 78 88 8387218 intolerant JJ B-ADJP O
17 89 91 8387218 to TO B-PP O
18 92 102 8387218 zidovudine NN B-NP B-Chemical
19 103 104 8387218 ( ( O O
20 104 107 8387218 AZT NN B-NP B-Chemical
21 107 108 8387218 ) ) O O
22 109 112 8387218 One CD B-NP O
23 113 120 8387218 hundred CD I-NP O
24 121 124 8387218 and CC I-NP O
25 125 130 8387218 fifty CD I-NP O
26 130 131 8387218 - HYPH O O
27 131 134 8387218 one CD B-NP O
28 135 143 8387218 patients NNS I-NP O
29 144 154 8387218 intolerant JJ B-ADJP O
30 155 157 8387218 to TO B-PP O
31 158 168 8387218 zidovudine NN B-NP B-Chemical
32 169 170 8387218 ( ( O O
33 170 173 8387218 AZT NN B-NP B-Chemical
34 173 174 8387218 ) ) O O
35 175 183 8387218 received VBD B-VP O
36 184 194 8387218 didanosine NN B-NP B-Chemical
37 195 196 8387218 ( ( O O
38 196 199 8387218 ddI NN B-NP B-Chemical
39 199 200 8387218 ) ) O O
40 201 203 8387218 to TO B-PP O
41 204 205 8387218 a DT B-NP O
42 206 213 8387218 maximum NN I-NP O
43 214 218 8387218 dose NN I-NP O
44 219 221 8387218 of IN B-PP O
45 222 226 8387218 12.5 CD B-NP O
46 227 229 8387218 mg NN I-NP O
47 229 230 8387218 / SYM B-NP O
48 230 232 8387218 kg NN I-NP O
49 232 233 8387218 / SYM B-NP O
50 233 236 8387218 day NN I-NP O
51 236 237 8387218 . . O O

1 238 245 8387218 Patient NN B-NP O
2 246 254 8387218 response NN I-NP O
3 255 258 8387218 was VBD B-VP O
4 259 267 8387218 assessed VBN I-VP O
5 268 273 8387218 using VBG B-VP O
6 274 281 8387218 changes NNS B-NP O
7 282 284 8387218 in IN B-PP O
8 285 289 8387218 CD4+ JJ B-NP O
9 290 300 8387218 lymphocyte NN I-NP O
10 301 307 8387218 subset NN I-NP O
11 308 313 8387218 count NN I-NP O
12 313 314 8387218 , , O O
13 315 318 8387218 HIV NN B-NP O
14 319 322 8387218 p24 NN I-NP O
15 323 330 8387218 antigen NN I-NP O
16 330 331 8387218 , , O O
17 332 338 8387218 weight NN B-NP O
18 338 339 8387218 , , O O
19 340 343 8387218 and CC O O
20 344 351 8387218 quality NN B-NP O
21 352 354 8387218 of IN B-PP O
22 355 359 8387218 life NN B-NP O
23 359 360 8387218 . . O O

1 361 368 8387218 Seventy CD B-NP O
2 369 377 8387218 patients NNS I-NP O
3 378 387 8387218 developed VBD B-VP O
4 388 393 8387218 major JJ B-NP O
5 394 407 8387218 opportunistic JJ I-NP B-Disease
6 408 418 8387218 infections NNS I-NP I-Disease
7 419 425 8387218 whilst IN B-PP O
8 426 428 8387218 on IN B-PP O
9 429 436 8387218 therapy NN B-NP O
10 436 437 8387218 ; : O O
11 438 442 8387218 this DT B-NP O
12 443 446 8387218 was VBD B-VP O
13 447 450 8387218 the DT B-NP O
14 451 456 8387218 first JJ I-NP O
15 457 461 8387218 AIDS NNP I-NP B-Disease
16 462 471 8387218 diagnosis NN I-NP O
17 472 474 8387218 in IN B-PP O
18 475 477 8387218 17 CD B-NP O
19 477 478 8387218 . . O O

1 479 483 8387218 Only RB B-NP O
2 484 489 8387218 minor JJ I-NP O
3 490 497 8387218 changes NNS I-NP O
4 498 500 8387218 in IN B-PP O
5 501 505 8387218 CD4+ JJ B-NP O
6 506 516 8387218 lymphocyte NN I-NP O
7 517 523 8387218 subset NN I-NP O
8 524 529 8387218 count NN I-NP O
9 530 534 8387218 were VBD B-VP O
10 535 543 8387218 observed VBN I-VP O
11 544 546 8387218 in IN B-PP O
12 547 551 8387218 AIDS NN B-NP B-Disease
13 552 560 8387218 patients NNS I-NP O
14 560 561 8387218 , , O O
15 562 570 8387218 although IN B-SBAR O
16 571 572 8387218 a DT B-NP O
17 573 577 8387218 more RBR I-NP O
18 578 589 8387218 significant JJ I-NP O
19 590 594 8387218 rise NN I-NP O
20 595 603 8387218 occurred VBD B-VP O
21 604 606 8387218 in IN B-PP O
22 607 612 8387218 those DT B-NP O
23 613 617 8387218 with IN B-PP O
24 618 625 8387218 earlier JJR B-NP O
25 626 632 8387218 stages NNS I-NP O
26 633 635 8387218 of IN B-PP O
27 636 643 8387218 disease NN B-NP O
28 643 644 8387218 . . O O

1 645 647 8387218 Of IN B-PP O
2 648 653 8387218 those DT B-NP O
3 654 662 8387218 positive JJ B-ADJP O
4 663 666 8387218 for IN B-PP O
5 667 670 8387218 p24 NN B-NP O
6 671 678 8387218 antigen NN I-NP O
7 679 681 8387218 at IN B-PP O
8 682 685 8387218 the DT B-NP O
9 686 698 8387218 commencement NN I-NP O
10 699 701 8387218 of IN B-PP O
11 702 705 8387218 the DT B-NP O
12 706 711 8387218 study NN I-NP O
13 712 715 8387218 67% NN I-NP O
14 716 722 8387218 showed VBD B-VP O
15 723 724 8387218 a DT B-NP O
16 725 733 8387218 positive JJ I-NP O
17 734 742 8387218 response NN I-NP O
18 742 743 8387218 , , O O
19 744 747 8387218 and CC O O
20 748 752 8387218 this DT B-NP O
21 753 756 8387218 was VBD B-VP O
22 757 761 8387218 most RBS B-ADVP O
23 762 768 8387218 likely RB I-ADVP O
24 769 771 8387218 in IN B-PP O
25 772 777 8387218 those DT B-NP O
26 778 782 8387218 with IN B-PP O
27 783 787 8387218 CD4+ JJ B-NP O
28 788 798 8387218 lymphocyte NN I-NP O
29 799 805 8387218 subset NN I-NP O
30 806 812 8387218 counts NNS I-NP O
31 813 818 8387218 above IN B-PP O
32 819 822 8387218 100 CD B-NP O
33 823 826 8387218 mm3 NN I-NP O
34 826 827 8387218 . . O O

1 828 829 8387218 A DT B-NP O
2 830 838 8387218 positive JJ I-NP O
3 839 845 8387218 weight NN I-NP O
4 846 854 8387218 response NN I-NP O
5 855 858 8387218 was VBD B-VP O
6 859 863 8387218 seen VBN I-VP O
7 864 866 8387218 in IN B-PP O
8 867 870 8387218 16% NN B-NP O
9 871 873 8387218 of IN B-PP O
10 874 882 8387218 patients NNS B-NP O
11 882 883 8387218 . . O O

1 884 888 8387218 Most JJS B-NP O
2 889 897 8387218 patients NNS I-NP O
3 898 904 8387218 showed VBD B-VP O
4 905 916 8387218 improvement NN B-NP O
5 917 919 8387218 in IN B-PP O
6 920 930 8387218 individual JJ B-NP O
7 931 941 8387218 parameters NNS I-NP O
8 942 945 8387218 and CC O O
9 946 952 8387218 global JJ B-NP O
10 953 958 8387218 score NN I-NP O
11 959 961 8387218 of IN B-PP O
12 962 969 8387218 quality NN B-NP O
13 970 972 8387218 of IN B-PP O
14 973 977 8387218 life NN B-NP O
15 977 978 8387218 . . O O

1 979 986 8387218 Adverse JJ B-NP O
2 987 996 8387218 reactions NNS I-NP O
3 997 1005 8387218 possibly RB B-ADJP O
4 1006 1018 8387218 attributable JJ I-ADJP O
5 1019 1021 8387218 to TO B-PP O
6 1022 1032 8387218 didanosine NN B-NP B-Chemical
7 1033 1037 8387218 were VBD B-VP O
8 1038 1044 8387218 common JJ B-ADJP O
9 1044 1045 8387218 . . O O

1 1046 1049 8387218 The DT B-NP O
2 1050 1054 8387218 most RBS I-NP O
3 1055 1061 8387218 common JJ I-NP O
4 1062 1066 8387218 side NN I-NP O
5 1066 1067 8387218 - HYPH B-NP O
6 1067 1073 8387218 effect NN I-NP O
7 1074 1077 8387218 was VBD B-VP O
8 1078 1087 8387218 diarrhoea NN B-NP B-Disease
9 1087 1088 8387218 , , O O
10 1089 1094 8387218 which WDT B-NP O
11 1095 1103 8387218 resulted VBD B-VP O
12 1104 1106 8387218 in IN B-PP O
13 1107 1116 8387218 cessation NN B-NP O
14 1117 1119 8387218 of IN B-PP O
15 1120 1127 8387218 therapy NN B-NP O
16 1128 1130 8387218 in IN B-PP O
17 1131 1133 8387218 19 CD B-NP O
18 1134 1145 8387218 individuals NNS I-NP O
19 1145 1146 8387218 . . O O

1 1147 1157 8387218 Peripheral JJ B-NP B-Disease
2 1158 1168 8387218 neuropathy NN I-NP I-Disease
3 1169 1177 8387218 occurred VBD B-VP O
4 1178 1180 8387218 in IN B-PP O
5 1181 1183 8387218 12 CD B-NP O
6 1184 1192 8387218 patients NNS I-NP O
7 1193 1196 8387218 and CC O O
8 1197 1209 8387218 pancreatitis NN B-NP B-Disease
9 1210 1212 8387218 in IN B-PP O
10 1213 1216 8387218 six CD B-NP O
11 1216 1217 8387218 . . O O

1 1218 1226 8387218 Thirteen CD B-NP O
2 1227 1235 8387218 patients NNS I-NP O
3 1236 1245 8387218 developed VBD B-VP O
4 1246 1247 8387218 a DT B-NP O
5 1248 1254 8387218 raised VBN I-NP O
6 1255 1260 8387218 serum NN I-NP O
7 1261 1268 8387218 amylase NN I-NP O
8 1269 1276 8387218 without IN B-PP O
9 1277 1286 8387218 abdominal JJ B-NP B-Disease
10 1287 1291 8387218 pain NN I-NP I-Disease
11 1291 1292 8387218 . . O O

1 1293 1298 8387218 Seven CD B-NP O
2 1299 1307 8387218 patients NNS I-NP O
3 1308 1317 8387218 developed VBD B-VP O
4 1318 1325 8387218 glucose NN B-NP B-Disease
5 1326 1335 8387218 tolerance NN I-NP I-Disease
6 1336 1342 8387218 curves NNS I-NP I-Disease
7 1343 1357 8387218 characteristic JJ B-ADJP O
8 1358 1360 8387218 of IN B-PP O
9 1361 1369 8387218 diabetes NN B-NP B-Disease
10 1370 1373 8387218 but CC O O
11 1374 1379 8387218 these DT B-NP O
12 1380 1384 8387218 were VBD B-VP O
13 1385 1389 8387218 mild JJ B-ADJP O
14 1389 1390 8387218 , , O O
15 1391 1394 8387218 did VBD B-VP O
16 1395 1398 8387218 not RB I-VP O
17 1399 1406 8387218 require VB I-VP O
18 1407 1416 8387218 treatment NN B-NP O
19 1417 1420 8387218 and CC O O
20 1421 1429 8387218 returned VBD B-VP O
21 1430 1432 8387218 to TO B-PP O
22 1433 1439 8387218 normal JJ B-ADJP O
23 1440 1442 8387218 on IN B-PP O
24 1443 1450 8387218 ceasing VBG B-VP O
25 1451 1461 8387218 didanosine NN B-NP B-Chemical
26 1461 1462 8387218 . . O O

1 0 0 10342929 -DOCSTART- -X- -X- O

1 0 10 10342929 Angioedema NN B-NP B-Disease
2 11 14 10342929 due JJ B-ADJP O
3 15 17 10342929 to TO B-PP O
4 18 21 10342929 ACE NN B-NP B-Chemical
5 22 32 10342929 inhibitors NNS I-NP I-Chemical
6 32 33 10342929 : : O O
7 34 40 10342929 common JJ B-ADJP O
8 41 44 10342929 and CC O O
9 45 57 10342929 inadequately RB B-ADJP O
10 58 67 10342929 diagnosed VBN I-ADJP O
11 67 68 10342929 . . O O
12 69 72 10342929 The DT B-NP O
13 73 82 10342929 estimated VBN I-NP O
14 83 92 10342929 incidence NN I-NP O
15 93 95 10342929 of IN B-PP O
16 96 106 10342929 angioedema NN B-NP B-Disease
17 107 113 10342929 during IN B-PP O
18 114 125 10342929 angiotensin NN B-NP B-Chemical
19 125 126 10342929 - HYPH O I-Chemical
20 126 136 10342929 converting VBG B-VP I-Chemical
21 137 143 10342929 enzyme NN B-NP I-Chemical
22 144 145 10342929 ( ( O I-Chemical
23 145 148 10342929 ACE NN B-NP I-Chemical
24 148 149 10342929 ) ) O I-Chemical
25 150 159 10342929 inhibitor NN B-NP I-Chemical
26 160 169 10342929 treatment NN I-NP O
27 170 172 10342929 is VBZ B-VP O
28 173 180 10342929 between IN B-NP O
29 181 182 10342929 1 CD I-NP O
30 183 186 10342929 and CC I-NP O
31 187 188 10342929 7 CD I-NP O
32 189 192 10342929 per IN B-PP O
33 193 201 10342929 thousand CD B-NP O
34 202 210 10342929 patients NNS I-NP O
35 210 211 10342929 . . O O

1 212 216 10342929 This DT B-NP O
2 217 228 10342929 potentially RB I-NP O
3 229 236 10342929 serious JJ I-NP O
4 237 244 10342929 adverse JJ I-NP O
5 245 251 10342929 effect NN I-NP O
6 252 254 10342929 is VBZ B-VP O
7 255 260 10342929 often RB I-VP O
8 261 269 10342929 preceded VBN I-VP O
9 270 272 10342929 by IN B-PP O
10 273 278 10342929 minor JJ B-NP O
11 279 293 10342929 manifestations NNS I-NP O
12 294 298 10342929 that WDT B-NP O
13 299 302 10342929 may MD B-VP O
14 303 308 10342929 serve VB I-VP O
15 309 311 10342929 as IN B-PP O
16 312 313 10342929 a DT B-NP O
17 314 321 10342929 warning NN I-NP O
18 321 322 10342929 . . O O

1 0 0 1009330 -DOCSTART- -X- -X- O

1 0 7 1009330 Further JJ B-NP O
2 8 15 1009330 studies NNS I-NP O
3 16 18 1009330 on IN B-PP O
4 19 26 1009330 effects NNS B-NP O
5 27 29 1009330 of IN B-PP O
6 30 40 1009330 irrigation NN B-NP O
7 41 50 1009330 solutions NNS I-NP O
8 51 53 1009330 on IN B-PP O
9 54 57 1009330 rat NN B-NP O
10 58 66 1009330 bladders NNS I-NP O
11 66 67 1009330 . . O O
12 68 75 1009330 Further JJ B-NP O
13 76 83 1009330 studies NNS I-NP O
14 84 86 1009330 on IN B-PP O
15 87 90 1009330 the DT B-NP O
16 91 98 1009330 effects NNS I-NP O
17 99 101 1009330 of IN B-PP O
18 102 109 1009330 certain JJ B-NP O
19 110 120 1009330 irrigating VBG I-NP O
20 121 127 1009330 fluids NNS I-NP O
21 128 130 1009330 on IN B-PP O
22 131 134 1009330 the DT B-NP O
23 135 138 1009330 rat NN I-NP O
24 139 146 1009330 bladder NN I-NP O
25 147 150 1009330 for IN B-PP O
26 151 153 1009330 18 CD B-NP O
27 154 159 1009330 hours NNS I-NP O
28 160 163 1009330 are VBP B-VP O
29 164 172 1009330 reported VBN I-VP O
30 172 173 1009330 . . O O

1 174 177 1009330 The DT B-NP O
2 178 185 1009330 results NNS I-NP O
3 186 190 1009330 have VBP B-VP O
4 191 196 1009330 shown VBN I-VP O
5 197 201 1009330 that IN B-SBAR O
6 202 205 1009330 the DT B-NP O
7 206 217 1009330 degradation NN I-NP O
8 218 225 1009330 product NN I-NP O
9 226 227 1009330 p NN I-NP B-Chemical
10 227 228 1009330 - HYPH B-NP I-Chemical
11 228 242 1009330 choloroaniline NN I-NP I-Chemical
12 243 245 1009330 is VBZ B-VP O
13 246 249 1009330 not RB O O
14 250 251 1009330 a DT B-NP O
15 252 263 1009330 significant JJ I-NP O
16 264 270 1009330 factor NN I-NP O
17 271 273 1009330 in IN B-PP O
18 274 287 1009330 chlorhexidine NN B-NP B-Chemical
19 287 288 1009330 - HYPH B-NP I-Chemical
20 288 299 1009330 digluconate NN I-NP I-Chemical
21 300 310 1009330 associated VBN B-VP O
22 311 318 1009330 erosive JJ B-NP O
23 319 327 1009330 cystitis NN I-NP B-Disease
24 327 328 1009330 . . O O

1 329 330 1009330 A DT B-NP O
2 331 335 1009330 high JJ I-NP O
3 336 346 1009330 percentage NN I-NP O
4 347 349 1009330 of IN B-PP O
5 350 359 1009330 kanamycin NN B-NP B-Chemical
6 359 360 1009330 - HYPH B-NP O
7 360 368 1009330 colistin NN I-NP B-Chemical
8 369 372 1009330 and CC I-NP O
9 373 381 1009330 povidone NN I-NP B-Chemical
10 381 382 1009330 - HYPH B-NP I-Chemical
11 382 388 1009330 iodine NN I-NP I-Chemical
12 389 400 1009330 irrigations NNS I-NP O
13 401 405 1009330 were VBD B-VP O
14 406 416 1009330 associated VBN I-VP O
15 417 421 1009330 with IN B-PP O
16 422 429 1009330 erosive JJ B-NP O
17 430 438 1009330 cystitis NN I-NP B-Disease
18 439 442 1009330 and CC O O
19 443 452 1009330 suggested VBD B-VP O
20 453 454 1009330 a DT B-NP O
21 455 463 1009330 possible JJ I-NP O
22 464 476 1009330 complication NN I-NP O
23 477 481 1009330 with IN B-PP O
24 482 487 1009330 human JJ B-NP O
25 488 493 1009330 usage NN I-NP O
26 493 494 1009330 . . O O

1 495 506 1009330 Picloxydine NN B-NP B-Chemical
2 507 518 1009330 irrigations NNS I-NP O
3 519 527 1009330 appeared VBD B-VP O
4 528 530 1009330 to TO I-VP O
5 531 535 1009330 have VB I-VP O
6 536 537 1009330 a DT B-NP O
7 538 543 1009330 lower JJR I-NP O
8 544 553 1009330 incidence NN I-NP O
9 554 556 1009330 of IN B-PP O
10 557 564 1009330 erosive JJ B-NP O
11 565 573 1009330 cystitis NN I-NP B-Disease
12 574 577 1009330 but CC O O
13 578 585 1009330 further JJ B-NP O
14 586 593 1009330 studies NNS I-NP O
15 594 599 1009330 would MD B-VP O
16 600 604 1009330 have VB I-VP O
17 605 607 1009330 to TO I-VP O
18 608 610 1009330 be VB I-VP O
19 611 620 1009330 performed VBN I-VP O
20 621 627 1009330 before IN B-SBAR O
21 628 630 1009330 it PRP B-NP O
22 631 636 1009330 could MD B-VP O
23 637 639 1009330 be VB I-VP O
24 640 651 1009330 recommended VBN I-VP O
25 652 655 1009330 for IN B-PP O
26 656 659 1009330 use NN B-NP O
27 660 662 1009330 in IN B-PP O
28 663 673 1009330 urological JJ B-NP O
29 674 684 1009330 procedures NNS I-NP O
30 684 685 1009330 . . O O

1 0 0 12589964 -DOCSTART- -X- -X- O

1 0 10 12589964 Evaluation NN B-NP O
2 11 13 12589964 of IN B-PP O
3 14 21 12589964 cardiac JJ B-NP O
4 22 30 12589964 troponin NN I-NP O
5 31 32 12589964 I CD I-NP O
6 33 36 12589964 and CC I-NP O
7 37 38 12589964 T NN I-NP O
8 39 45 12589964 levels NNS I-NP O
9 46 48 12589964 as IN B-PP O
10 49 56 12589964 markers NNS B-NP O
11 57 59 12589964 of IN B-PP O
12 60 70 12589964 myocardial JJ B-NP B-Disease
13 71 77 12589964 damage NN I-NP I-Disease
14 78 80 12589964 in IN B-PP O
15 81 92 12589964 doxorubicin NN B-NP B-Chemical
16 92 93 12589964 - HYPH B-NP O
17 93 100 12589964 induced VBN I-NP O
18 101 115 12589964 cardiomyopathy NN I-NP B-Disease
19 116 120 12589964 rats NNS I-NP O
20 120 121 12589964 , , O O
21 122 125 12589964 and CC O O
22 126 131 12589964 their PRP$ B-NP O
23 132 144 12589964 relationship NN I-NP O
24 145 149 12589964 with IN B-PP O
25 150 167 12589964 echocardiographic JJ B-NP O
26 168 171 12589964 and CC I-NP O
27 172 184 12589964 histological JJ I-NP O
28 185 193 12589964 findings NNS I-NP O
29 193 194 12589964 . . I-NP O
30 195 205 12589964 BACKGROUND NN I-NP O
31 205 206 12589964 : : O O
32 207 214 12589964 Cardiac JJ B-NP O
33 215 224 12589964 troponins NNS I-NP O
34 225 226 12589964 I NN I-NP O
35 227 228 12589964 ( ( O O
36 228 232 12589964 cTnI NN B-NP O
37 232 233 12589964 ) ) O O
38 234 237 12589964 and CC O O
39 238 239 12589964 T NN B-NP O
40 240 241 12589964 ( ( O O
41 241 245 12589964 cTnT NN B-NP O
42 245 246 12589964 ) ) O O
43 247 251 12589964 have VBP B-VP O
44 252 256 12589964 been VBN I-VP O
45 257 262 12589964 shown VBN I-VP O
46 263 265 12589964 to TO I-VP O
47 266 268 12589964 be VB I-VP O
48 269 275 12589964 highly RB B-NP O
49 276 285 12589964 sensitive JJ I-NP O
50 286 289 12589964 and CC I-NP O
51 290 298 12589964 specific JJ I-NP O
52 299 306 12589964 markers NNS I-NP O
53 307 309 12589964 of IN B-PP O
54 310 320 12589964 myocardial JJ B-NP B-Disease
55 321 325 12589964 cell NN I-NP I-Disease
56 326 332 12589964 injury NN I-NP I-Disease
57 332 333 12589964 . . O O

1 334 336 12589964 We PRP B-NP O
2 337 349 12589964 investigated VBD B-VP O
3 350 353 12589964 the DT B-NP O
4 354 364 12589964 diagnostic JJ I-NP O
5 365 370 12589964 value NN I-NP O
6 371 373 12589964 of IN B-PP O
7 374 378 12589964 cTnI NN B-NP O
8 379 382 12589964 and CC I-NP O
9 383 387 12589964 cTnT NN I-NP O
10 388 391 12589964 for IN B-PP O
11 392 395 12589964 the DT B-NP O
12 396 405 12589964 diagnosis NN I-NP O
13 406 408 12589964 of IN B-PP O
14 409 419 12589964 myocardial JJ B-NP B-Disease
15 420 426 12589964 damage NN I-NP I-Disease
16 427 429 12589964 in IN B-PP O
17 430 431 12589964 a DT B-NP O
18 432 435 12589964 rat NN I-NP O
19 436 441 12589964 model NN I-NP O
20 442 444 12589964 of IN B-PP O
21 445 456 12589964 doxorubicin NN B-NP B-Chemical
22 457 458 12589964 ( ( O O
23 458 461 12589964 DOX NN B-NP B-Chemical
24 461 462 12589964 ) ) O O
25 462 463 12589964 - HYPH B-NP O
26 463 470 12589964 induced VBN I-NP O
27 471 485 12589964 cardiomyopathy NN I-NP B-Disease
28 485 486 12589964 , , O O
29 487 490 12589964 and CC O O
30 491 493 12589964 we PRP B-NP O
31 494 502 12589964 examined VBD B-VP O
32 503 506 12589964 the DT B-NP O
33 507 519 12589964 relationship NN I-NP O
34 520 527 12589964 between IN B-PP O
35 528 534 12589964 serial JJ B-NP O
36 535 539 12589964 cTnI NN I-NP O
37 540 543 12589964 and CC I-NP O
38 544 548 12589964 cTnT NN I-NP O
39 549 553 12589964 with IN B-PP O
40 554 557 12589964 the DT B-NP O
41 558 569 12589964 development NN I-NP O
42 570 572 12589964 of IN B-PP O
43 573 580 12589964 cardiac JJ B-NP B-Disease
44 581 590 12589964 disorders NNS I-NP I-Disease
45 591 600 12589964 monitored VBN B-VP O
46 601 603 12589964 by IN B-PP O
47 604 620 12589964 echocardiography NN B-NP O
48 621 624 12589964 and CC O O
49 625 637 12589964 histological JJ B-NP O
50 638 650 12589964 examinations NNS I-NP O
51 651 653 12589964 in IN B-PP O
52 654 658 12589964 this DT B-NP O
53 659 664 12589964 model NN I-NP O
54 664 665 12589964 . . O O

1 666 673 12589964 METHODS NNS B-NP O
2 673 674 12589964 : : O O
3 675 681 12589964 Thirty CD B-NP O
4 681 682 12589964 - HYPH I-NP O
5 682 686 12589964 five CD I-NP O
6 687 693 12589964 Wistar NNP I-NP O
7 694 698 12589964 rats NNS I-NP O
8 699 703 12589964 were VBD B-VP O
9 704 709 12589964 given VBN I-VP O
10 710 713 12589964 1.5 CD B-NP O
11 714 716 12589964 mg NN I-NP O
12 716 717 12589964 / SYM B-NP O
13 717 719 12589964 kg NN I-NP O
14 720 723 12589964 DOX NN I-NP B-Chemical
15 723 724 12589964 , , O O
16 725 728 12589964 i.v JJ B-NP O
17 728 729 12589964 . NN I-NP O
18 729 730 12589964 , , O O
19 731 737 12589964 weekly RB B-ADVP O
20 738 741 12589964 for IN B-PP O
21 742 744 12589964 up RB B-NP O
22 745 747 12589964 to TO I-NP O
23 748 749 12589964 8 CD I-NP O
24 750 755 12589964 weeks NNS I-NP O
25 756 759 12589964 for IN B-PP O
26 760 761 12589964 a DT B-NP O
27 762 767 12589964 total JJ I-NP O
28 768 778 12589964 cumulative JJ I-NP O
29 779 783 12589964 dose NN I-NP O
30 784 786 12589964 of IN B-PP O
31 787 789 12589964 12 CD B-NP O
32 790 792 12589964 mg NN I-NP O
33 792 793 12589964 / SYM B-NP O
34 793 795 12589964 kg NN I-NP O
35 796 798 12589964 BW NN I-NP O
36 798 799 12589964 . . O O

1 800 803 12589964 Ten CD B-NP O
2 804 808 12589964 rats NNS I-NP O
3 809 817 12589964 received VBD B-VP O
4 818 824 12589964 saline NN B-NP O
5 825 827 12589964 as IN B-PP O
6 828 829 12589964 a DT B-NP O
7 830 837 12589964 control NN I-NP O
8 838 843 12589964 group NN I-NP O
9 843 844 12589964 . . O O

1 845 849 12589964 cTnI NN B-NP O
2 850 853 12589964 was VBD B-VP O
3 854 862 12589964 measured VBN I-VP O
4 863 867 12589964 with IN B-PP O
5 868 874 12589964 Access NN B-NP O
6 874 875 12589964 ( ( O O
7 875 876 12589964 R NN B-NP O
8 876 877 12589964 ) ) O O
9 878 879 12589964 ( ( O O
10 879 881 12589964 ng NN B-NP O
11 881 882 12589964 / SYM B-NP O
12 882 884 12589964 ml NN I-NP O
13 884 885 12589964 ) ) O O
14 886 889 12589964 and CC O O
15 890 891 12589964 a DT B-NP O
16 892 900 12589964 research NN I-NP O
17 901 912 12589964 immunoassay NN I-NP O
18 913 914 12589964 ( ( O O
19 914 916 12589964 pg NN B-NP O
20 916 917 12589964 / SYM O O
21 917 919 12589964 ml NN B-NP O
22 919 920 12589964 ) ) O O
23 920 921 12589964 , , O O
24 922 925 12589964 and CC O O
25 926 934 12589964 compared VBN B-PP O
26 935 939 12589964 with IN B-PP O
27 940 944 12589964 cTnT NN B-NP O
28 944 945 12589964 , , O O
29 946 948 12589964 CK NN B-NP O
30 948 949 12589964 - HYPH I-NP O
31 949 951 12589964 MB NN I-NP O
32 952 956 12589964 mass NN I-NP O
33 957 960 12589964 and CC I-NP O
34 961 963 12589964 CK NN I-NP O
35 963 964 12589964 . . O O

1 965 967 12589964 By IN B-PP O
2 968 973 12589964 using VBG B-VP O
3 974 987 12589964 transthoracic JJ B-NP O
4 988 1004 12589964 echocardiography NN I-NP O
5 1004 1005 12589964 , , O O
6 1006 1014 12589964 anterior JJ B-NP O
7 1015 1018 12589964 and CC I-NP O
8 1019 1028 12589964 posterior JJ I-NP O
9 1029 1033 12589964 wall NN I-NP O
10 1034 1043 12589964 thickness NN I-NP O
11 1043 1044 12589964 , , O O
12 1045 1047 12589964 LV NN B-NP O
13 1048 1057 12589964 diameters NNS I-NP O
14 1058 1061 12589964 and CC O O
15 1062 1064 12589964 LV NN B-NP O
16 1065 1075 12589964 fractional JJ I-NP O
17 1076 1086 12589964 shortening NN I-NP O
18 1087 1088 12589964 ( ( O O
19 1088 1090 12589964 FS NN B-NP O
20 1090 1091 12589964 ) ) O O
21 1092 1096 12589964 were VBD B-VP O
22 1097 1105 12589964 measured VBN I-VP O
23 1106 1108 12589964 in IN B-PP O
24 1109 1112 12589964 all DT B-NP O
25 1113 1117 12589964 rats NNS I-NP O
26 1118 1124 12589964 before IN B-PP O
27 1125 1128 12589964 DOX NN B-NP B-Chemical
28 1129 1131 12589964 or CC I-NP O
29 1132 1138 12589964 saline NN I-NP O
30 1138 1139 12589964 , , B-PP O
31 1140 1143 12589964 and CC I-PP O
32 1144 1146 12589964 at IN B-PP O
33 1147 1152 12589964 weeks NNS B-NP O
34 1153 1154 12589964 6 CD B-NP O
35 1155 1158 12589964 and CC I-NP O
36 1159 1160 12589964 9 CD I-NP O
37 1161 1166 12589964 after IN B-PP O
38 1167 1176 12589964 treatment NN B-NP O
39 1177 1179 12589964 in IN B-PP O
40 1180 1183 12589964 all DT B-NP O
41 1184 1193 12589964 surviving VBG I-NP O
42 1194 1198 12589964 rats NNS I-NP O
43 1198 1199 12589964 . . O O

1 1200 1209 12589964 Histology NN B-NP O
2 1210 1213 12589964 was VBD B-VP O
3 1214 1223 12589964 performed VBN I-VP O
4 1224 1226 12589964 in IN B-PP O
5 1227 1230 12589964 DOX NN B-NP B-Chemical
6 1230 1231 12589964 - HYPH B-NP O
7 1231 1235 12589964 rats NNS I-NP O
8 1236 1238 12589964 at IN B-PP O
9 1239 1240 12589964 6 CD B-NP O
10 1241 1244 12589964 and CC I-NP O
11 1245 1246 12589964 9 CD I-NP O
12 1247 1252 12589964 weeks NNS I-NP O
13 1253 1258 12589964 after IN B-PP O
14 1259 1262 12589964 the DT B-NP O
15 1263 1267 12589964 last JJ I-NP O
16 1268 1271 12589964 DOX NN I-NP B-Chemical
17 1272 1276 12589964 dose NN I-NP O
18 1277 1280 12589964 and CC B-PP O
19 1281 1283 12589964 in IN B-PP O
20 1284 1287 12589964 all DT B-NP O
21 1288 1296 12589964 controls NNS I-NP O
22 1296 1297 12589964 . . O O

1 1298 1305 12589964 RESULTS NNS B-NP O
2 1305 1306 12589964 : : O O
3 1307 1315 12589964 Eighteen CD B-NP O
4 1316 1318 12589964 of IN B-PP O
5 1319 1322 12589964 the DT B-NP O
6 1323 1326 12589964 DOX NN I-NP B-Chemical
7 1327 1331 12589964 rats NNS I-NP O
8 1332 1336 12589964 died VBD B-VP O
9 1337 1348 12589964 prematurely RB B-ADVP O
10 1349 1351 12589964 of IN B-PP O
11 1352 1359 12589964 general JJ B-NP O
12 1360 1368 12589964 toxicity NN I-NP B-Disease
13 1369 1375 12589964 during IN B-PP O
14 1376 1379 12589964 the DT B-NP O
15 1380 1381 12589964 9 CD I-NP O
16 1381 1382 12589964 - HYPH I-NP O
17 1382 1386 12589964 week NN I-NP O
18 1387 1393 12589964 period NN I-NP O
19 1393 1394 12589964 . . O O

1 1395 1398 12589964 End NN B-NP O
2 1398 1399 12589964 - HYPH O O
3 1399 1408 12589964 diastolic JJ O O
4 1409 1410 12589964 ( ( O O
5 1410 1412 12589964 ED JJ B-ADJP O
6 1412 1413 12589964 ) ) O O
7 1414 1417 12589964 and CC O O
8 1418 1421 12589964 end NN B-ADJP O
9 1421 1422 12589964 - HYPH I-ADJP O
10 1422 1430 12589964 systolic JJ I-ADJP O
11 1431 1432 12589964 ( ( O O
12 1432 1434 12589964 ES NN B-NP O
13 1434 1435 12589964 ) ) O O
14 1436 1438 12589964 LV NN B-NP O
15 1439 1448 12589964 diameters NNS I-NP O
16 1448 1449 12589964 / SYM O O
17 1449 1451 12589964 BW NN B-NP O
18 1452 1465 12589964 significantly RB B-ADVP O
19 1466 1475 12589964 increased VBD B-VP O
20 1475 1476 12589964 , , O O
21 1477 1484 12589964 whereas IN O O
22 1485 1487 12589964 LV NN B-NP O
23 1488 1490 12589964 FS NN I-NP O
24 1491 1494 12589964 was VBD B-VP O
25 1495 1504 12589964 decreased VBN I-VP O
26 1505 1510 12589964 after IN B-PP O
27 1511 1512 12589964 9 CD B-NP O
28 1513 1518 12589964 weeks NNS I-NP O
29 1519 1521 12589964 in IN B-PP O
30 1522 1525 12589964 the DT B-NP O
31 1526 1529 12589964 DOX NN I-NP B-Chemical
32 1530 1535 12589964 group NN I-NP O
33 1536 1537 12589964 ( ( O O
34 1537 1538 12589964 p NN B-NP O
35 1538 1539 12589964 < SYM O O
36 1539 1544 12589964 0.001 CD B-NP O
37 1544 1545 12589964 ) ) O O
38 1545 1546 12589964 . . O O

1 1547 1552 12589964 These DT B-NP O
2 1553 1563 12589964 parameters NNS I-NP O
3 1564 1572 12589964 remained VBD B-VP O
4 1573 1582 12589964 unchanged JJ B-ADJP O
5 1583 1585 12589964 in IN B-PP O
6 1586 1594 12589964 controls NNS B-NP O
7 1594 1595 12589964 . . O O

1 1596 1608 12589964 Histological JJ B-NP O
2 1609 1619 12589964 evaluation NN I-NP O
3 1620 1622 12589964 of IN B-PP O
4 1623 1629 12589964 hearts NNS B-NP O
5 1630 1634 12589964 from IN B-PP O
6 1635 1638 12589964 all DT B-NP O
7 1639 1643 12589964 rats NNS I-NP O
8 1644 1649 12589964 given VBN B-VP O
9 1650 1653 12589964 DOX NN B-NP B-Chemical
10 1654 1662 12589964 revealed VBD B-VP O
11 1663 1674 12589964 significant JJ B-NP O
12 1675 1681 12589964 slight JJ I-NP O
13 1682 1689 12589964 degrees NNS I-NP O
14 1690 1692 12589964 of IN B-PP O
15 1693 1705 12589964 perivascular JJ B-NP O
16 1706 1709 12589964 and CC I-NP O
17 1710 1722 12589964 interstitial JJ I-NP O
18 1723 1731 12589964 fibrosis NN I-NP B-Disease
19 1731 1732 12589964 . . O O

1 1733 1735 12589964 In IN B-PP O
2 1736 1737 12589964 7 CD B-NP O
3 1738 1740 12589964 of IN B-PP O
4 1741 1744 12589964 the DT B-NP O
5 1745 1747 12589964 18 CD I-NP O
6 1748 1752 12589964 rats NNS I-NP O
7 1752 1753 12589964 , , O O
8 1754 1766 12589964 degeneration NN B-NP O
9 1767 1770 12589964 and CC I-NP O
10 1771 1778 12589964 myocyte NN I-NP O
11 1779 1792 12589964 vacuolisation NN I-NP O
12 1793 1797 12589964 were VBD B-VP O
13 1798 1803 12589964 found VBN I-VP O
14 1803 1804 12589964 . . O O

1 1805 1809 12589964 Only RB B-NP O
2 1810 1814 12589964 five CD I-NP O
3 1815 1817 12589964 of IN B-PP O
4 1818 1821 12589964 the DT B-NP O
5 1822 1830 12589964 controls NNS I-NP O
6 1831 1840 12589964 exhibited VBD B-VP O
7 1841 1849 12589964 evidence NN B-NP O
8 1850 1852 12589964 of IN B-PP O
9 1853 1857 12589964 very RB B-NP O
10 1858 1864 12589964 slight JJ I-NP O
11 1865 1877 12589964 perivascular JJ I-NP O
12 1878 1886 12589964 fibrosis NN I-NP B-Disease
13 1886 1887 12589964 . . O O

1 1888 1889 12589964 A DT B-NP O
2 1890 1901 12589964 significant JJ I-NP O
3 1902 1906 12589964 rise NN I-NP O
4 1907 1909 12589964 in IN B-PP O
5 1910 1914 12589964 cTnT NN B-NP O
6 1915 1918 12589964 was VBD B-VP O
7 1919 1924 12589964 found VBN I-VP O
8 1925 1927 12589964 in IN B-PP O
9 1928 1931 12589964 DOX NN B-NP B-Chemical
10 1932 1936 12589964 rats NNS I-NP O
11 1937 1942 12589964 after IN B-PP O
12 1943 1953 12589964 cumulative JJ B-NP O
13 1954 1959 12589964 doses NNS I-NP O
14 1960 1962 12589964 of IN B-PP O
15 1963 1966 12589964 7.5 CD B-NP O
16 1967 1970 12589964 and CC I-NP O
17 1971 1973 12589964 12 CD I-NP O
18 1974 1976 12589964 mg NN I-NP O
19 1976 1977 12589964 / SYM B-NP O
20 1977 1979 12589964 kg NN I-NP O
21 1980 1982 12589964 in IN B-PP O
22 1983 1993 12589964 comparison NN B-NP O
23 1994 1998 12589964 with IN B-PP O
24 1999 2007 12589964 baseline NN B-NP O
25 2008 2009 12589964 ( ( O O
26 2009 2010 12589964 p NN B-NP O
27 2010 2011 12589964 < SYM O O
28 2011 2015 12589964 0.05 CD B-NP O
29 2015 2016 12589964 ) ) O O
30 2016 2017 12589964 . . O O

1 2018 2022 12589964 cTnT NN B-NP O
2 2023 2028 12589964 found VBN B-VP O
3 2029 2031 12589964 in IN B-PP O
4 2032 2036 12589964 rats NNS B-NP O
5 2037 2042 12589964 after IN B-PP O
6 2043 2045 12589964 12 CD B-NP O
7 2046 2048 12589964 mg NN I-NP O
8 2048 2049 12589964 / SYM B-NP O
9 2049 2051 12589964 kg NN I-NP O
10 2052 2056 12589964 were VBD B-VP O
11 2057 2070 12589964 significantly RB B-ADJP O
12 2071 2078 12589964 greater JJR I-ADJP O
13 2079 2083 12589964 than IN B-PP O
14 2084 2088 12589964 that DT B-NP O
15 2089 2094 12589964 found VBN B-VP O
16 2095 2100 12589964 after IN B-PP O
17 2101 2104 12589964 7.5 CD B-NP O
18 2105 2107 12589964 mg NN I-NP O
19 2107 2108 12589964 / SYM B-NP O
20 2108 2110 12589964 kg NN I-NP O
21 2111 2114 12589964 DOX NN I-NP B-Chemical
22 2114 2115 12589964 . . O O

1 2116 2123 12589964 Maximal JJ B-NP O
2 2124 2128 12589964 cTnI NN I-NP O
3 2129 2130 12589964 ( ( O O
4 2130 2132 12589964 pg NN B-NP O
5 2132 2133 12589964 / SYM B-NP O
6 2133 2135 12589964 ml NN I-NP O
7 2135 2136 12589964 ) ) O O
8 2137 2140 12589964 and CC O O
9 2141 2145 12589964 cTnT NN B-NP O
10 2146 2152 12589964 levels NNS I-NP O
11 2153 2157 12589964 were VBD B-VP O
12 2158 2171 12589964 significantly RB I-VP O
13 2172 2181 12589964 increased VBN I-VP O
14 2182 2184 12589964 in IN B-PP O
15 2185 2188 12589964 DOX NN B-NP B-Chemical
16 2189 2193 12589964 rats NNS I-NP O
17 2194 2202 12589964 compared VBN B-PP O
18 2203 2207 12589964 with IN B-PP O
19 2208 2216 12589964 controls NNS B-NP O
20 2217 2218 12589964 ( ( O O
21 2218 2219 12589964 p NN B-NP O
22 2219 2220 12589964 = SYM B-VP O
23 2220 2225 12589964 0.006 CD B-NP O
24 2225 2226 12589964 , , O O
25 2227 2232 12589964 0.007 CD B-NP O
26 2232 2233 12589964 ) ) O O
27 2233 2234 12589964 . . O O

1 2235 2239 12589964 cTnI NN B-NP O
2 2240 2241 12589964 ( ( O O
3 2241 2243 12589964 ng NN B-NP O
4 2243 2244 12589964 / SYM O O
5 2244 2246 12589964 ml NN B-NP O
6 2246 2247 12589964 ) ) O O
7 2247 2248 12589964 , , O O
8 2249 2251 12589964 CK NN B-NP O
9 2251 2252 12589964 - HYPH B-NP O
10 2252 2254 12589964 MB NN I-NP O
11 2255 2259 12589964 mass NN I-NP O
12 2260 2263 12589964 and CC I-NP O
13 2264 2266 12589964 CK NN I-NP O
14 2267 2275 12589964 remained VBD B-VP O
15 2276 2285 12589964 unchanged JJ B-ADJP O
16 2286 2288 12589964 in IN B-PP O
17 2289 2292 12589964 DOX NN B-NP B-Chemical
18 2293 2297 12589964 rats NNS I-NP O
19 2298 2306 12589964 compared VBN B-PP O
20 2307 2311 12589964 with IN B-PP O
21 2312 2320 12589964 controls NNS B-NP O
22 2320 2321 12589964 . . O O

1 2322 2325 12589964 All DT B-NP O
2 2326 2333 12589964 markers NNS I-NP O
3 2334 2342 12589964 remained VBD B-VP O
4 2343 2349 12589964 stable JJ B-ADJP O
5 2350 2352 12589964 in IN B-PP O
6 2353 2361 12589964 controls NNS B-NP O
7 2361 2362 12589964 . . O O

1 2363 2371 12589964 Analysis NN B-NP O
2 2372 2374 12589964 of IN B-PP O
3 2375 2379 12589964 data NNS B-NP O
4 2380 2388 12589964 revealed VBD B-VP O
5 2389 2390 12589964 a DT B-NP O
6 2391 2402 12589964 significant JJ I-NP O
7 2403 2414 12589964 correlation NN I-NP O
8 2415 2422 12589964 between IN B-PP O
9 2423 2430 12589964 maximal JJ B-NP O
10 2431 2435 12589964 cTnT NN I-NP O
11 2436 2439 12589964 and CC I-NP O
12 2440 2442 12589964 ED NN I-NP O
13 2443 2446 12589964 and CC I-NP O
14 2447 2449 12589964 ES NN I-NP O
15 2450 2452 12589964 LV NN I-NP O
16 2453 2462 12589964 diameters NNS I-NP O
17 2462 2463 12589964 / SYM O O
18 2463 2465 12589964 BW NN B-NP O
19 2466 2467 12589964 ( ( O O
20 2467 2468 12589964 r NN B-NP O
21 2468 2469 12589964 = JJ B-NP O
22 2469 2473 12589964 0.81 CD I-NP O
23 2474 2477 12589964 and CC I-NP O
24 2478 2482 12589964 0.65 CD I-NP O
25 2482 2483 12589964 ; : O O
26 2484 2485 12589964 p NN B-NP O
27 2485 2486 12589964 < SYM B-NP O
28 2486 2492 12589964 0.0001 CD I-NP O
29 2492 2493 12589964 ) ) O O
30 2493 2494 12589964 . . O O

1 2495 2496 12589964 A DT B-NP O
2 2497 2508 12589964 significant JJ I-NP O
3 2509 2521 12589964 relationship NN I-NP O
4 2522 2525 12589964 was VBD B-VP O
5 2526 2534 12589964 observed VBN I-VP O
6 2535 2542 12589964 between IN B-PP O
7 2543 2550 12589964 maximal JJ B-NP O
8 2551 2555 12589964 cTnT NN I-NP O
9 2556 2559 12589964 and CC O O
10 2560 2563 12589964 the DT B-NP O
11 2564 2570 12589964 extent NN I-NP O
12 2571 2573 12589964 of IN B-PP O
13 2574 2584 12589964 myocardial JJ B-NP O
14 2585 2598 12589964 morphological JJ I-NP O
15 2599 2606 12589964 changes NNS I-NP O
16 2606 2607 12589964 , , B-PP O
17 2608 2611 12589964 and CC I-PP O
18 2612 2619 12589964 between IN B-PP O
19 2620 2622 12589964 LV NN B-NP O
20 2623 2632 12589964 diameters NNS I-NP O
21 2632 2633 12589964 / SYM B-NP O
22 2633 2635 12589964 BW NN I-NP O
23 2636 2639 12589964 and CC O O
24 2640 2652 12589964 histological JJ B-NP O
25 2653 2661 12589964 findings NNS I-NP O
26 2661 2662 12589964 . . O O

1 2663 2674 12589964 CONCLUSIONS NNS B-NP O
2 2674 2675 12589964 : : O O
3 2676 2681 12589964 Among IN B-PP O
4 2682 2689 12589964 markers NNS B-NP O
5 2690 2692 12589964 of IN B-PP O
6 2693 2701 12589964 ischemic JJ B-NP B-Disease
7 2702 2708 12589964 injury NN I-NP I-Disease
8 2709 2714 12589964 after IN B-PP O
9 2715 2718 12589964 DOX NN B-NP B-Chemical
10 2719 2721 12589964 in IN B-PP O
11 2722 2726 12589964 rats NNS B-NP O
12 2726 2727 12589964 , , O O
13 2728 2732 12589964 cTnT NN B-NP O
14 2733 2739 12589964 showed VBD B-VP O
15 2740 2743 12589964 the DT B-NP O
16 2744 2752 12589964 greatest JJS I-NP O
17 2753 2760 12589964 ability NN I-NP O
18 2761 2763 12589964 to TO B-VP O
19 2764 2770 12589964 detect VB I-VP O
20 2771 2781 12589964 myocardial JJ B-NP B-Disease
21 2782 2788 12589964 damage NN I-NP I-Disease
22 2789 2797 12589964 assessed VBN B-VP O
23 2798 2800 12589964 by IN B-PP O
24 2801 2818 12589964 echocardiographic JJ B-NP O
25 2819 2828 12589964 detection NN I-NP O
26 2829 2832 12589964 and CC O O
27 2833 2845 12589964 histological JJ B-NP O
28 2846 2853 12589964 changes NNS I-NP O
29 2853 2854 12589964 . . O O

1 2855 2863 12589964 Although IN B-SBAR O
2 2864 2869 12589964 there EX B-NP O
3 2870 2873 12589964 was VBD B-VP O
4 2874 2875 12589964 a DT B-NP O
5 2876 2887 12589964 discrepancy NN I-NP O
6 2888 2895 12589964 between IN B-PP O
7 2896 2899 12589964 the DT B-NP O
8 2900 2906 12589964 amount NN I-NP O
9 2907 2909 12589964 of IN B-PP O
10 2910 2914 12589964 cTnI NN B-NP O
11 2915 2918 12589964 and CC I-NP O
12 2919 2923 12589964 cTnT NN I-NP O
13 2924 2929 12589964 after IN B-PP O
14 2930 2933 12589964 DOX NN B-NP B-Chemical
15 2933 2934 12589964 , , O O
16 2935 2943 12589964 probably RB B-ADVP O
17 2944 2947 12589964 due IN B-PP O
18 2948 2950 12589964 to TO B-PP O
19 2951 2964 12589964 heterogeneity NN B-NP O
20 2965 2967 12589964 in IN B-PP O
21 2968 2973 12589964 cross AFX B-NP O
22 2973 2974 12589964 - HYPH I-NP O
23 2974 2986 12589964 reactivities NNS I-NP O
24 2987 2989 12589964 of IN B-PP O
25 2990 2994 12589964 mAbs NNS B-NP O
26 2995 2997 12589964 to TO B-PP O
27 2998 3005 12589964 various JJ B-NP O
28 3006 3010 12589964 cTnI NN I-NP O
29 3011 3014 12589964 and CC I-NP O
30 3015 3019 12589964 cTnT NN I-NP O
31 3020 3025 12589964 forms NNS I-NP O
32 3025 3026 12589964 , , O O
33 3027 3029 12589964 it PRP B-NP O
34 3030 3032 12589964 is VBZ B-VP O
35 3033 3039 12589964 likely JJ B-ADJP O
36 3040 3044 12589964 that IN B-SBAR O
37 3045 3049 12589964 cTnT NN B-NP O
38 3050 3052 12589964 in IN B-PP O
39 3053 3057 12589964 rats NNS B-NP O
40 3058 3063 12589964 after IN B-SBAR O
41 3064 3067 12589964 DOX NN B-NP B-Chemical
42 3068 3077 12589964 indicates VBZ B-VP O
43 3078 3082 12589964 cell NN B-NP O
44 3083 3089 12589964 damage NN I-NP O
45 3090 3100 12589964 determined VBN B-VP O
46 3101 3103 12589964 by IN B-PP O
47 3104 3107 12589964 the DT B-NP O
48 3108 3117 12589964 magnitude NN I-NP O
49 3118 3120 12589964 of IN B-PP O
50 3121 3127 12589964 injury NN B-NP O
51 3128 3135 12589964 induced VBN B-VP O
52 3136 3139 12589964 and CC O O
53 3140 3144 12589964 that IN B-SBAR O
54 3145 3149 12589964 cTnT NN B-NP O
55 3150 3156 12589964 should MD B-VP O
56 3157 3159 12589964 be VB I-VP O
57 3160 3161 12589964 a DT B-NP O
58 3162 3168 12589964 useful JJ I-NP O
59 3169 3175 12589964 marker NN I-NP O
60 3176 3179 12589964 for IN B-PP O
61 3180 3183 12589964 the DT B-NP O
62 3184 3194 12589964 prediction NN I-NP O
63 3195 3197 12589964 of IN B-PP O
64 3198 3212 12589964 experimentally RB B-NP O
65 3213 3220 12589964 induced VBN I-NP O
66 3221 3235 12589964 cardiotoxicity NN I-NP B-Disease
67 3236 3239 12589964 and CC O O
68 3240 3248 12589964 possibly RB B-ADVP O
69 3249 3252 12589964 for IN B-PP O
70 3253 3269 12589964 cardioprotective JJ B-NP O
71 3270 3281 12589964 experiments NNS I-NP O
72 3281 3282 12589964 . . O O

1 0 0 12627929 -DOCSTART- -X- -X- O

1 0 9 12627929 Increased VBN B-NP O
2 10 19 12627929 frequency NN I-NP O
3 20 22 12627929 of IN B-PP O
4 23 29 12627929 venous JJ B-NP B-Disease
5 30 45 12627929 thromboembolism NN I-NP I-Disease
6 46 50 12627929 with IN B-PP O
7 51 54 12627929 the DT B-NP O
8 55 66 12627929 combination NN I-NP O
9 67 69 12627929 of IN B-PP O
10 70 79 12627929 docetaxel NN B-NP B-Chemical
11 80 83 12627929 and CC I-NP O
12 84 95 12627929 thalidomide NN I-NP B-Chemical
13 96 98 12627929 in IN B-PP O
14 99 107 12627929 patients NNS B-NP O
15 108 112 12627929 with IN B-PP O
16 113 123 12627929 metastatic JJ B-NP O
17 124 132 12627929 androgen NN I-NP O
18 132 133 12627929 - HYPH B-NP O
19 133 144 12627929 independent JJ I-NP O
20 145 153 12627929 prostate NN I-NP B-Disease
21 154 160 12627929 cancer NN I-NP I-Disease
22 160 161 12627929 . . O O
23 162 167 12627929 STUDY NN B-NP O
24 168 177 12627929 OBJECTIVE NN I-NP O
25 177 178 12627929 : : O O
26 179 181 12627929 To TO B-VP O
27 182 190 12627929 evaluate VB I-VP O
28 191 194 12627929 the DT B-NP O
29 195 204 12627929 frequency NN I-NP O
30 205 207 12627929 of IN B-PP O
31 208 214 12627929 venous JJ B-NP B-Disease
32 215 230 12627929 thromboembolism NN I-NP I-Disease
33 231 232 12627929 ( ( O O
34 232 235 12627929 VTE NN B-NP B-Disease
35 235 236 12627929 ) ) O O
36 237 239 12627929 in IN B-PP O
37 240 248 12627929 patients NNS B-NP O
38 249 253 12627929 with IN B-PP O
39 254 262 12627929 advanced VBN B-NP O
40 263 271 12627929 androgen NN I-NP O
41 271 272 12627929 - HYPH B-NP O
42 272 283 12627929 independent JJ I-NP O
43 284 292 12627929 prostate NN I-NP B-Disease
44 293 299 12627929 cancer NN I-NP I-Disease
45 300 303 12627929 who WP B-NP O
46 304 308 12627929 were VBD B-VP O
47 309 316 12627929 treated VBN I-VP O
48 317 321 12627929 with IN B-PP O
49 322 331 12627929 docetaxel NN B-NP B-Chemical
50 332 337 12627929 alone RB B-ADVP O
51 338 340 12627929 or CC O O
52 341 343 12627929 in IN B-PP O
53 344 355 12627929 combination NN B-NP O
54 356 360 12627929 with IN B-PP O
55 361 372 12627929 thalidomide NN B-NP B-Chemical
56 372 373 12627929 . . O O

1 374 380 12627929 DESIGN NN B-NP O
2 380 381 12627929 : : O O
3 382 395 12627929 Retrospective JJ B-NP O
4 396 404 12627929 analysis NN I-NP O
5 405 407 12627929 of IN B-PP O
6 408 409 12627929 a DT B-NP O
7 410 420 12627929 randomized VBN I-NP O
8 421 426 12627929 phase NN I-NP O
9 427 429 12627929 II CD I-NP O
10 430 435 12627929 trial NN I-NP O
11 435 436 12627929 . . O O

1 437 444 12627929 SETTING NN B-NP O
2 444 445 12627929 : : O O
3 446 454 12627929 National NNP B-NP O
4 455 465 12627929 Institutes NNPS I-NP O
5 466 468 12627929 of IN B-PP O
6 469 475 12627929 Health NNP B-NP O
7 476 484 12627929 clinical JJ B-NP O
8 485 493 12627929 research NN I-NP O
9 494 500 12627929 center NN I-NP O
10 500 501 12627929 . . O O

1 502 510 12627929 PATIENTS NNS B-NP O
2 510 511 12627929 : : O O
3 512 519 12627929 Seventy CD B-NP O
4 520 523 12627929 men NNS I-NP O
5 523 524 12627929 , , O O
6 525 529 12627929 aged VBN B-VP O
7 530 532 12627929 50 CD B-NP O
8 532 533 12627929 - HYPH I-NP O
9 533 535 12627929 80 CD I-NP O
10 536 541 12627929 years NNS I-NP O
11 541 542 12627929 , , O O
12 543 547 12627929 with IN B-PP O
13 548 556 12627929 advanced VBN B-NP O
14 557 565 12627929 androgen NN I-NP O
15 565 566 12627929 - HYPH B-NP O
16 566 577 12627929 independent JJ I-NP O
17 578 586 12627929 prostate NN I-NP B-Disease
18 587 593 12627929 cancer NN I-NP I-Disease
19 593 594 12627929 . . O O

1 595 607 12627929 INTERVENTION NN B-NP O
2 607 608 12627929 : : O O
3 609 613 12627929 Each DT B-NP O
4 614 621 12627929 patient NN I-NP O
5 622 630 12627929 received VBD B-VP O
6 631 637 12627929 either CC O O
7 638 649 12627929 intravenous JJ B-NP O
8 650 659 12627929 docetaxel NN I-NP B-Chemical
9 660 662 12627929 30 CD I-NP O
10 663 665 12627929 mg NN I-NP O
11 665 666 12627929 / SYM B-NP O
12 666 668 12627929 m2 NN I-NP O
13 668 669 12627929 / SYM B-NP O
14 669 673 12627929 week NN I-NP O
15 674 677 12627929 for IN B-PP O
16 678 679 12627929 3 CD B-NP O
17 680 691 12627929 consecutive JJ I-NP O
18 692 697 12627929 weeks NNS I-NP O
19 697 698 12627929 , , O O
20 699 707 12627929 followed VBN B-VP O
21 708 710 12627929 by IN B-PP O
22 711 712 12627929 1 CD B-NP O
23 713 717 12627929 week NN I-NP O
24 718 721 12627929 off RB B-ADVP O
25 721 722 12627929 , , O O
26 723 725 12627929 or CC O O
27 726 729 12627929 the DT B-NP O
28 730 741 12627929 combination NN I-NP O
29 742 744 12627929 of IN B-PP O
30 745 755 12627929 continuous JJ B-NP O
31 756 760 12627929 oral JJ I-NP O
32 761 772 12627929 thalidomide NN I-NP B-Chemical
33 773 776 12627929 200 CD I-NP O
34 777 779 12627929 mg NN I-NP O
35 780 785 12627929 every DT B-NP O
36 786 793 12627929 evening NN I-NP O
37 794 798 12627929 plus CC O O
38 799 802 12627929 the DT B-NP O
39 803 807 12627929 same JJ I-NP O
40 808 817 12627929 docetaxel NN I-NP B-Chemical
41 818 825 12627929 regimen NN I-NP O
42 825 826 12627929 . . O O

1 827 831 12627929 This DT B-NP O
2 832 833 12627929 4 CD I-NP O
3 833 834 12627929 - HYPH I-NP O
4 834 838 12627929 week NN I-NP O
5 839 844 12627929 cycle NN I-NP O
6 845 848 12627929 was VBD B-VP O
7 849 857 12627929 repeated VBN I-VP O
8 858 863 12627929 until IN B-SBAR O
9 864 869 12627929 there EX B-NP O
10 870 873 12627929 was VBD B-VP O
11 874 882 12627929 evidence NN B-NP O
12 883 885 12627929 of IN B-PP O
13 886 895 12627929 excessive JJ B-NP O
14 896 904 12627929 toxicity NN I-NP B-Disease
15 905 907 12627929 or CC I-NP O
16 908 915 12627929 disease NN I-NP O
17 916 927 12627929 progression NN I-NP O
18 927 928 12627929 . . O O

1 929 941 12627929 MEASUREMENTS NNS B-NP O
2 942 945 12627929 AND CC I-NP O
3 946 950 12627929 MAIN NN I-NP O
4 951 958 12627929 RESULTS NNS I-NP O
5 958 959 12627929 : : O O
6 960 964 12627929 None NN B-NP O
7 965 967 12627929 of IN B-PP O
8 968 970 12627929 23 CD B-NP O
9 971 979 12627929 patients NNS I-NP O
10 980 983 12627929 who WP B-NP O
11 984 992 12627929 received VBD B-VP O
12 993 1002 12627929 docetaxel NN B-NP B-Chemical
13 1003 1008 12627929 alone RB B-ADVP O
14 1009 1018 12627929 developed VBD B-VP O
15 1019 1022 12627929 VTE NNP B-NP B-Disease
16 1022 1023 12627929 , , O O
17 1024 1031 12627929 whereas IN O O
18 1032 1033 12627929 9 CD B-NP O
19 1034 1036 12627929 of IN B-PP O
20 1037 1039 12627929 47 CD B-NP O
21 1040 1048 12627929 patients NNS I-NP O
22 1049 1050 12627929 ( ( O O
23 1050 1053 12627929 19% CD B-NP O
24 1053 1054 12627929 ) ) O O
25 1055 1058 12627929 who WP B-NP O
26 1059 1067 12627929 received VBD B-VP O
27 1068 1077 12627929 docetaxel NN B-NP B-Chemical
28 1078 1082 12627929 plus CC I-NP O
29 1083 1094 12627929 thalidomide NN I-NP B-Chemical
30 1095 1104 12627929 developed VBD B-VP O
31 1105 1108 12627929 VTE NN B-NP B-Disease
32 1109 1110 12627929 ( ( O O
33 1110 1111 12627929 p NN B-NP O
34 1111 1112 12627929 = SYM B-VP O
35 1112 1117 12627929 0.025 CD B-NP O
36 1117 1118 12627929 ) ) O O
37 1118 1119 12627929 . . O O

1 1120 1130 12627929 CONCLUSION NN B-NP O
2 1130 1131 12627929 : : O O
3 1132 1135 12627929 The DT B-NP O
4 1136 1144 12627929 addition NN I-NP O
5 1145 1147 12627929 of IN B-PP O
6 1148 1159 12627929 thalidomide NN B-NP B-Chemical
7 1160 1162 12627929 to TO B-PP O
8 1163 1172 12627929 docetaxel NN B-NP B-Chemical
9 1173 1175 12627929 in IN B-PP O
10 1176 1179 12627929 the DT B-NP O
11 1180 1189 12627929 treatment NN I-NP O
12 1190 1192 12627929 of IN B-PP O
13 1193 1201 12627929 prostate NN B-NP B-Disease
14 1202 1208 12627929 cancer NN I-NP I-Disease
15 1209 1222 12627929 significantly RB B-ADVP O
16 1223 1232 12627929 increases VBZ B-VP O
17 1233 1236 12627929 the DT B-NP O
18 1237 1246 12627929 frequency NN I-NP O
19 1247 1249 12627929 of IN B-PP O
20 1250 1253 12627929 VTE NN B-NP B-Disease
21 1253 1254 12627929 . . O O

1 1255 1265 12627929 Clinicians NNS B-NP O
2 1266 1272 12627929 should MD B-VP O
3 1273 1275 12627929 be VB I-VP O
4 1276 1281 12627929 aware JJ B-ADJP O
5 1282 1284 12627929 of IN B-PP O
6 1285 1289 12627929 this DT B-NP O
7 1290 1299 12627929 potential JJ I-NP O
8 1300 1312 12627929 complication NN I-NP O
9 1313 1317 12627929 when WRB B-ADVP O
10 1318 1324 12627929 adding VBG B-VP O
11 1325 1336 12627929 thalidomide NN B-NP B-Chemical
12 1337 1339 12627929 to TO B-PP O
13 1340 1356 12627929 chemotherapeutic JJ B-NP O
14 1357 1365 12627929 regimens NNS I-NP O
15 1365 1366 12627929 . . O O

1 0 0 1601297 -DOCSTART- -X- -X- O

1 0 20 1601297 Electrocardiographic JJ B-NP O
2 21 29 1601297 evidence NN I-NP O
3 30 32 1601297 of IN B-PP O
4 33 43 1601297 myocardial JJ B-NP B-Disease
5 44 50 1601297 injury NN I-NP I-Disease
6 51 53 1601297 in IN B-PP O
7 54 69 1601297 psychiatrically RB B-NP O
8 70 82 1601297 hospitalized VBN I-NP O
9 83 90 1601297 cocaine NN I-NP B-Chemical
10 91 98 1601297 abusers NNS I-NP O
11 98 99 1601297 . . O O
12 100 103 1601297 The DT B-NP O
13 104 122 1601297 electrocardiograms NNS I-NP O
14 123 124 1601297 ( ( O O
15 124 127 1601297 ECG NN B-NP O
16 127 128 1601297 ) ) O O
17 129 131 1601297 of IN B-PP O
18 132 134 1601297 99 CD B-NP O
19 135 142 1601297 cocaine NN I-NP B-Chemical
20 142 143 1601297 - HYPH O O
21 143 150 1601297 abusing VBG B-VP O
22 151 159 1601297 patients NNS B-NP O
23 160 164 1601297 were VBD B-VP O
24 165 173 1601297 compared VBN I-VP O
25 174 178 1601297 with IN B-PP O
26 179 182 1601297 the DT B-NP O
27 183 187 1601297 ECGs NNS I-NP O
28 188 190 1601297 of IN B-PP O
29 191 193 1601297 50 CD B-NP O
30 194 207 1601297 schizophrenic JJ I-NP B-Disease
31 208 216 1601297 controls NNS I-NP O
32 216 217 1601297 . . O O

1 218 224 1601297 Eleven CD B-NP O
2 225 227 1601297 of IN B-PP O
3 228 231 1601297 the DT B-NP O
4 232 239 1601297 cocaine NN I-NP B-Chemical
5 240 247 1601297 abusers NNS I-NP O
6 248 251 1601297 and CC O O
7 252 256 1601297 none NN B-NP O
8 257 259 1601297 of IN B-PP O
9 260 263 1601297 the DT B-NP O
10 264 272 1601297 controls NNS I-NP O
11 273 276 1601297 had VBD B-VP O
12 277 280 1601297 ECG NN B-NP O
13 281 289 1601297 evidence NN I-NP O
14 290 292 1601297 of IN B-PP O
15 293 304 1601297 significant JJ B-NP O
16 305 315 1601297 myocardial JJ I-NP B-Disease
17 316 322 1601297 injury NN I-NP I-Disease
18 323 330 1601297 defined VBN B-VP O
19 331 333 1601297 as IN B-PP O
20 334 344 1601297 myocardial JJ B-NP B-Disease
21 345 355 1601297 infarction NN I-NP I-Disease
22 355 356 1601297 , , O O
23 357 365 1601297 ischemia NN B-NP B-Disease
24 365 366 1601297 , , O O
25 367 370 1601297 and CC O O
26 371 377 1601297 bundle NN B-NP B-Disease
27 378 384 1601297 branch NN I-NP I-Disease
28 385 390 1601297 block NN I-NP I-Disease
29 390 391 1601297 . . O O

1 0 0 17919553 -DOCSTART- -X- -X- O

1 0 5 17919553 Acute JJ B-NP O
2 6 15 17919553 hepatitis NN I-NP B-Disease
3 16 22 17919553 attack NN I-NP O
4 23 28 17919553 after IN B-PP O
5 29 37 17919553 exposure NN B-NP O
6 38 40 17919553 to TO B-PP O
7 41 54 17919553 telithromycin NN B-NP B-Chemical
8 54 55 17919553 . . I-NP O
9 56 68 17919553 INTRODUCTION NN I-NP O
10 68 69 17919553 : : O O
11 70 80 17919553 Antibiotic JJ B-NP O
12 80 81 17919553 - HYPH I-NP O
13 81 91 17919553 associated VBN I-NP O
14 92 106 17919553 hepatotoxicity NN I-NP B-Disease
15 107 109 17919553 is VBZ B-VP O
16 110 114 17919553 rare JJ B-ADJP O
17 114 115 17919553 . . O O

1 116 120 17919553 With IN B-PP O
2 121 131 17919553 widespread JJ B-NP O
3 132 135 17919553 use NN I-NP O
4 136 138 17919553 of IN B-PP O
5 139 152 17919553 antimicrobial JJ B-NP O
6 153 159 17919553 agents NNS I-NP O
7 159 160 17919553 , , O O
8 161 168 17919553 however RB B-ADVP O
9 168 169 17919553 , , O O
10 170 177 17919553 hepatic JJ B-NP B-Disease
11 178 184 17919553 injury NN I-NP I-Disease
12 185 191 17919553 occurs VBZ B-VP O
13 192 202 17919553 frequently RB B-ADVP O
14 202 203 17919553 , , O O
15 204 207 17919553 and CC O O
16 208 213 17919553 among IN B-PP O
17 214 221 17919553 adverse JJ B-NP B-Disease
18 222 226 17919553 drug NN I-NP I-Disease
19 227 236 17919553 reactions NNS I-NP I-Disease
20 236 237 17919553 , , O O
21 238 251 17919553 idiosyncratic JJ B-NP O
22 252 261 17919553 reactions NNS I-NP O
23 262 265 17919553 are VBP B-VP O
24 266 269 17919553 the DT B-NP O
25 270 274 17919553 most RBS I-NP O
26 275 282 17919553 serious JJ I-NP O
27 282 283 17919553 . . O O

1 284 288 17919553 CASE NN B-NP O
2 289 296 17919553 SUMMARY NN I-NP O
3 296 297 17919553 : : O O
4 298 299 17919553 A DT B-NP O
5 300 302 17919553 25 CD I-NP O
6 302 303 17919553 - HYPH I-NP O
7 303 307 17919553 year NN I-NP O
8 307 308 17919553 - HYPH O O
9 308 311 17919553 old JJ B-NP O
10 312 316 17919553 male JJ I-NP O
11 317 324 17919553 patient NN I-NP O
12 324 325 17919553 , , O O
13 326 330 17919553 with IN B-PP O
14 331 332 17919553 a DT B-NP O
15 333 339 17919553 height NN I-NP O
16 340 342 17919553 of IN B-PP O
17 343 346 17919553 175 CD B-NP O
18 347 349 17919553 cm NN I-NP O
19 350 353 17919553 and CC I-NP O
20 354 360 17919553 weight NN I-NP O
21 361 363 17919553 of IN B-PP O
22 364 366 17919553 72 CD B-NP O
23 367 369 17919553 kg NN I-NP O
24 370 379 17919553 presented VBN B-VP O
25 380 382 17919553 to TO B-PP O
26 383 390 17919553 Marmara NNP B-NP O
27 391 401 17919553 University NNP I-NP O
28 402 410 17919553 Hospital NNP I-NP O
29 411 420 17919553 Emergency NNP I-NP O
30 421 431 17919553 Department NNP I-NP O
31 431 432 17919553 , , O O
32 433 441 17919553 Istanbul NNP B-NP O
33 441 442 17919553 , , O O
34 443 449 17919553 Turkey NNP B-NP O
35 449 450 17919553 , , O O
36 451 455 17919553 with IN B-PP O
37 456 457 17919553 5 CD B-NP O
38 458 462 17919553 days NNS I-NP O
39 462 463 17919553 ' POS B-NP O
40 464 471 17919553 history NN I-NP O
41 472 474 17919553 of IN B-PP O
42 475 483 17919553 jaundice NN B-NP B-Disease
43 483 484 17919553 , , O O
44 485 492 17919553 malaise NN B-NP O
45 492 493 17919553 , , O O
46 494 500 17919553 nausea NN B-NP B-Disease
47 500 501 17919553 , , O O
48 502 505 17919553 and CC O O
49 506 514 17919553 vomiting NN B-NP B-Disease
50 514 515 17919553 . . O O

1 516 518 17919553 He PRP B-NP O
2 519 522 17919553 had VBD B-VP O
3 523 527 17919553 been VBN I-VP O
4 528 538 17919553 prescribed VBN I-VP O
5 539 552 17919553 telithromycin NN B-NP B-Chemical
6 553 556 17919553 400 CD I-NP O
7 557 559 17919553 mg NN I-NP O
8 559 560 17919553 / SYM B-NP O
9 560 561 17919553 d NN B-NP O
10 562 564 17919553 PO NN I-NP O
11 565 567 17919553 to TO B-VP O
12 568 573 17919553 treat VB I-VP O
13 574 576 17919553 an DT B-NP O
14 577 582 17919553 upper JJ I-NP B-Disease
15 583 594 17919553 respiratory JJ I-NP I-Disease
16 595 600 17919553 tract NN I-NP I-Disease
17 601 610 17919553 infection NN I-NP I-Disease
18 611 612 17919553 7 CD B-NP O
19 613 617 17919553 days NNS I-NP O
20 618 623 17919553 prior RB B-ADVP O
21 623 624 17919553 . . O O

1 625 634 17919553 Admission NN B-NP O
2 635 645 17919553 laboratory NN I-NP O
3 646 651 17919553 tests NNS I-NP O
4 652 656 17919553 were VBD B-VP O
5 657 659 17919553 as IN B-SBAR O
6 660 667 17919553 follows VBZ B-VP O
7 667 668 17919553 : : O O
8 669 676 17919553 alanine NN B-NP B-Chemical
9 677 693 17919553 aminotransferase NN I-NP O
10 693 694 17919553 , , O O
11 695 697 17919553 67 CD B-NP O
12 698 699 17919553 U NN I-NP O
13 699 700 17919553 / SYM B-NP O
14 700 701 17919553 L NN B-NP O
15 702 703 17919553 ( ( O O
16 703 712 17919553 reference NN B-NP O
17 713 718 17919553 range NN I-NP O
18 718 719 17919553 , , O O
19 720 722 17919553 10 CD B-NP O
20 722 723 17919553 - HYPH I-NP O
21 723 725 17919553 37 CD I-NP O
22 726 727 17919553 U NN I-NP O
23 727 728 17919553 / SYM B-NP O
24 728 729 17919553 L NN I-NP O
25 729 730 17919553 ) ) O O
26 730 731 17919553 ; : O O
27 732 741 17919553 aspartate NN B-NP B-Chemical
28 742 758 17919553 aminotransferase NN I-NP O
29 758 759 17919553 , , O O
30 760 762 17919553 98 CD B-NP O
31 763 764 17919553 U NN I-NP O
32 764 765 17919553 / SYM B-NP O
33 765 766 17919553 L NN I-NP O
34 767 768 17919553 ( ( O O
35 768 770 17919553 10 CD B-NP O
36 770 771 17919553 - HYPH I-NP O
37 771 773 17919553 40 CD I-NP O
38 774 775 17919553 U NN I-NP O
39 775 776 17919553 / SYM B-NP O
40 776 777 17919553 L NN I-NP O
41 777 778 17919553 ) ) O O
42 778 779 17919553 ; : O O
43 780 788 17919553 alkaline NN B-NP O
44 789 800 17919553 phosphatase NN I-NP O
45 800 801 17919553 , , O O
46 802 805 17919553 513 CD B-NP O
47 806 807 17919553 U NN I-NP O
48 807 808 17919553 / SYM B-NP O
49 808 809 17919553 L NN B-NP O
50 810 811 17919553 ( ( O O
51 811 812 17919553 0 CD B-NP O
52 812 813 17919553 - HYPH I-NP O
53 813 816 17919553 270 CD I-NP O
54 817 818 17919553 U NN I-NP O
55 818 819 17919553 / SYM B-NP O
56 819 820 17919553 L NN I-NP O
57 820 821 17919553 ) ) O O
58 821 822 17919553 ; : O O
59 823 828 17919553 gamma SYM B-NP O
60 828 829 17919553 - HYPH I-NP O
61 829 848 17919553 glutamyltransferase NN I-NP O
62 848 849 17919553 , , O O
63 850 852 17919553 32 CD B-NP O
64 853 854 17919553 U NN I-NP O
65 854 855 17919553 / SYM B-NP O
66 855 856 17919553 L NN I-NP O
67 857 858 17919553 ( ( O O
68 858 859 17919553 7 CD B-NP O
69 859 860 17919553 - HYPH I-NP O
70 860 862 17919553 49 CD I-NP O
71 863 864 17919553 U NN I-NP O
72 864 865 17919553 / SYM B-NP O
73 865 866 17919553 L NN I-NP O
74 866 867 17919553 ) ) O O
75 867 868 17919553 ; : O O
76 869 876 17919553 amylase NN B-NP O
77 876 877 17919553 , , O O
78 878 880 17919553 46 CD B-NP O
79 881 882 17919553 U NN I-NP O
80 882 883 17919553 / SYM B-NP O
81 883 884 17919553 L NN I-NP O
82 885 886 17919553 ( ( O O
83 886 887 17919553 0 CD B-NP O
84 887 888 17919553 - HYPH I-NP O
85 888 891 17919553 220 CD I-NP O
86 892 893 17919553 U NN I-NP O
87 893 894 17919553 / SYM B-NP O
88 894 895 17919553 L NN I-NP O
89 895 896 17919553 ) ) O O
90 896 897 17919553 ; : O O
91 898 903 17919553 total JJ B-NP O
92 904 913 17919553 bilirubin NN I-NP B-Chemical
93 913 914 17919553 , , O O
94 915 919 17919553 20.1 CD B-NP O
95 920 922 17919553 mg NN I-NP O
96 922 923 17919553 / SYM B-NP O
97 923 925 17919553 dL NN B-NP O
98 926 927 17919553 ( ( O O
99 927 930 17919553 0.2 CD B-NP O
100 930 931 17919553 - HYPH I-NP O
101 931 934 17919553 1.0 CD I-NP O
102 935 937 17919553 mg NN I-NP O
103 937 938 17919553 / SYM B-NP O
104 938 940 17919553 dL NN I-NP O
105 940 941 17919553 ) ) O O
106 941 942 17919553 ; : O O
107 943 949 17919553 direct JJ B-NP O
108 950 959 17919553 bilirubin NN I-NP B-Chemical
109 959 960 17919553 , , O O
110 961 965 17919553 14.8 CD B-NP O
111 966 968 17919553 mg NN I-NP O
112 968 969 17919553 / SYM B-NP O
113 969 971 17919553 dL NN B-NP O
114 972 973 17919553 ( ( O O
115 973 974 17919553 0 CD B-NP O
116 974 975 17919553 - HYPH I-NP O
117 975 978 17919553 0.3 CD I-NP O
118 979 981 17919553 mg NN I-NP O
119 981 982 17919553 / SYM B-NP O
120 982 984 17919553 dL NN I-NP O
121 984 985 17919553 ) ) O O
122 985 986 17919553 ; : O O
123 987 990 17919553 and CC O O
124 991 998 17919553 albumin NN B-NP O
125 998 999 17919553 , , O O
126 1000 1003 17919553 4.7 CD B-NP O
127 1004 1006 17919553 mg NN I-NP O
128 1006 1007 17919553 / SYM B-NP O
129 1007 1009 17919553 dL NN B-NP O
130 1010 1011 17919553 ( ( O O
131 1011 1014 17919553 3.5 CD B-NP O
132 1014 1015 17919553 - HYPH I-NP O
133 1015 1018 17919553 5.4 CD I-NP O
134 1019 1021 17919553 mg NN I-NP O
135 1021 1022 17919553 / SYM B-NP O
136 1022 1024 17919553 dL NN I-NP O
137 1024 1025 17919553 ) ) O O
138 1025 1026 17919553 . . O O

1 1027 1029 17919553 No DT B-NP O
2 1030 1035 17919553 toxin NN I-NP O
3 1035 1036 17919553 , , O O
4 1037 1044 17919553 alcohol NN B-NP B-Chemical
5 1044 1045 17919553 , , O O
6 1046 1048 17919553 or CC O O
7 1049 1054 17919553 other JJ B-NP O
8 1055 1060 17919553 drugs NNS I-NP O
9 1061 1065 17919553 were VBD B-VP O
10 1066 1074 17919553 reported VBN I-VP O
11 1074 1075 17919553 . . O O

1 1076 1079 17919553 The DT B-NP O
2 1080 1087 17919553 patient NN I-NP O
3 1088 1091 17919553 had VBD B-VP O
4 1092 1100 17919553 suffered VBN I-VP O
5 1101 1102 17919553 a DT B-NP O
6 1103 1111 17919553 previous JJ I-NP O
7 1112 1119 17919553 episode NN I-NP O
8 1120 1122 17919553 of IN B-PP O
9 1123 1124 17919553 " `` O O
10 1124 1129 17919553 acute JJ B-NP O
11 1130 1139 17919553 hepatitis NN I-NP B-Disease
12 1140 1142 17919553 of IN B-PP O
13 1143 1150 17919553 unknown JJ B-NP O
14 1151 1157 17919553 origin NN I-NP O
15 1157 1158 17919553 , , O O
16 1158 1159 17919553 " '' O O
17 1160 1164 17919553 that WDT B-NP O
18 1165 1173 17919553 occurred VBD B-VP O
19 1174 1179 17919553 after IN B-PP O
20 1180 1193 17919553 telithromycin NN B-NP B-Chemical
21 1194 1199 17919553 usage NN I-NP O
22 1199 1200 17919553 . . O O

1 1201 1205 17919553 Both DT B-NP O
2 1206 1215 17919553 incidents NNS I-NP O
3 1216 1224 17919553 occurred VBD B-VP O
4 1225 1231 17919553 within IN B-PP O
5 1232 1233 17919553 a DT B-NP O
6 1234 1238 17919553 year NN I-NP O
7 1238 1239 17919553 . . O O

1 1240 1250 17919553 DISCUSSION NN B-NP O
2 1250 1251 17919553 : : O O
3 1252 1265 17919553 Telithromycin NN B-NP B-Chemical
4 1266 1268 17919553 is VBZ B-VP O
5 1269 1272 17919553 the DT B-NP O
6 1273 1278 17919553 first JJ I-NP O
7 1279 1281 17919553 of IN B-PP O
8 1282 1285 17919553 the DT B-NP O
9 1286 1294 17919553 ketolide NN I-NP O
10 1295 1309 17919553 antibacterials NNS I-NP O
11 1310 1312 17919553 to TO B-VP O
12 1313 1320 17919553 receive VB I-VP O
13 1321 1323 17919553 US NNP B-NP O
14 1324 1328 17919553 Food NNP I-NP O
15 1329 1332 17919553 and CC I-NP O
16 1333 1337 17919553 Drug NNP I-NP O
17 1338 1352 17919553 Administration NNP I-NP O
18 1353 1361 17919553 approval NN I-NP O
19 1362 1365 17919553 for IN B-PP O
20 1366 1374 17919553 clinical JJ B-NP O
21 1375 1378 17919553 use NN I-NP O
22 1378 1379 17919553 . . O O

1 1380 1382 17919553 It PRP B-NP O
2 1383 1386 17919553 has VBZ B-VP O
3 1387 1391 17919553 been VBN I-VP O
4 1392 1402 17919553 associated VBN I-VP O
5 1403 1407 17919553 with IN B-PP O
6 1408 1418 17919553 infrequent JJ B-NP O
7 1419 1422 17919553 and CC I-NP O
8 1423 1430 17919553 usually RB I-NP O
9 1431 1441 17919553 reversible JJ I-NP O
10 1442 1448 17919553 severe JJ I-NP O
11 1449 1456 17919553 hepatic JJ I-NP B-Disease
12 1457 1468 17919553 dysfunction NN I-NP I-Disease
13 1468 1469 17919553 . . O O

1 1470 1475 17919553 Based VBN B-PP O
2 1476 1478 17919553 on IN B-PP O
3 1479 1480 17919553 a DT B-NP O
4 1481 1486 17919553 score NN I-NP O
5 1487 1489 17919553 of IN B-PP O
6 1490 1491 17919553 8 CD B-NP O
7 1492 1494 17919553 on IN B-PP O
8 1495 1498 17919553 the DT B-NP O
9 1499 1506 17919553 Naranjo NNP I-NP O
10 1507 1514 17919553 adverse JJ I-NP B-Disease
11 1515 1519 17919553 drug NN I-NP I-Disease
12 1520 1528 17919553 reaction NN I-NP I-Disease
13 1529 1540 17919553 probability NN I-NP O
14 1541 1546 17919553 scale NN I-NP O
15 1546 1547 17919553 , , O O
16 1548 1561 17919553 telithromycin NN B-NP B-Chemical
17 1562 1565 17919553 was VBD B-VP O
18 1566 1569 17919553 the DT B-NP O
19 1570 1578 17919553 probable JJ I-NP O
20 1579 1584 17919553 cause NN I-NP O
21 1585 1587 17919553 of IN B-PP O
22 1588 1593 17919553 acute JJ B-NP O
23 1594 1603 17919553 hepatitis NN I-NP B-Disease
24 1604 1606 17919553 in IN B-PP O
25 1607 1611 17919553 this DT B-NP O
26 1612 1619 17919553 patient NN I-NP O
27 1619 1620 17919553 , , O O
28 1621 1624 17919553 and CC O O
29 1625 1637 17919553 pathological JJ B-NP O
30 1638 1646 17919553 findings NNS I-NP O
31 1647 1656 17919553 suggested VBD B-VP O
32 1657 1661 17919553 drug NN B-NP O
33 1661 1662 17919553 - HYPH O O
34 1662 1669 17919553 induced VBN B-NP O
35 1670 1675 17919553 toxic JJ I-NP B-Disease
36 1676 1685 17919553 hepatitis NN I-NP I-Disease
37 1685 1686 17919553 . . O O

1 1687 1697 17919553 Recurrence NN B-NP O
2 1698 1700 17919553 of IN B-PP O
3 1701 1710 17919553 hepatitis NN B-NP B-Disease
4 1711 1717 17919553 attack NN I-NP O
5 1718 1723 17919553 might MD B-VP O
6 1724 1728 17919553 have VB I-VP O
7 1729 1733 17919553 been VBN I-VP O
8 1734 1741 17919553 avoided VBN I-VP O
9 1742 1744 17919553 if IN B-SBAR O
10 1745 1748 17919553 the DT B-NP O
11 1749 1756 17919553 initial JJ I-NP O
12 1757 1765 17919553 incident NN I-NP O
13 1766 1769 17919553 had VBD B-VP O
14 1770 1774 17919553 been VBN I-VP O
15 1775 1787 17919553 communicated VBN I-VP O
16 1788 1790 17919553 to TO B-PP O
17 1791 1794 17919553 the DT B-NP O
18 1795 1804 17919553 attending VBG I-NP O
19 1805 1814 17919553 physician NN I-NP O
20 1815 1818 17919553 who WP B-NP O
21 1819 1829 17919553 prescribed VBD B-VP O
22 1830 1843 17919553 telithromycin NN B-NP B-Chemical
23 1844 1847 17919553 the DT B-NP O
24 1848 1854 17919553 second JJ I-NP O
25 1855 1859 17919553 time NN I-NP O
26 1859 1860 17919553 . . O O

1 1861 1871 17919553 CONCLUSION NN B-NP O
2 1871 1872 17919553 : : O O
3 1873 1877 17919553 Here RB B-ADVP O
4 1878 1880 17919553 we PRP B-NP O
5 1881 1887 17919553 report VBP B-VP O
6 1888 1889 17919553 a DT B-NP O
7 1890 1894 17919553 case NN I-NP O
8 1895 1897 17919553 of IN B-PP O
9 1898 1903 17919553 acute JJ B-NP O
10 1904 1913 17919553 hepatitis NN I-NP B-Disease
11 1914 1922 17919553 probably RB B-VP O
12 1923 1933 17919553 associated VBN I-VP O
13 1934 1938 17919553 with IN B-PP O
14 1939 1942 17919553 the DT B-NP O
15 1943 1957 17919553 administration NN I-NP O
16 1958 1960 17919553 of IN B-PP O
17 1961 1974 17919553 telithromycin NN B-NP B-Chemical
18 1974 1975 17919553 . . O O

1 0 0 12695819 -DOCSTART- -X- -X- O

1 0 2 12695819 MR NN B-NP O
2 3 10 12695819 imaging NN I-NP O
3 11 15 12695819 with IN B-PP O
4 16 28 12695819 quantitative JJ B-NP O
5 29 38 12695819 diffusion NN I-NP O
6 39 46 12695819 mapping NN I-NP O
7 47 49 12695819 of IN B-PP O
8 50 60 12695819 tacrolimus NN B-NP B-Chemical
9 60 61 12695819 - HYPH B-NP O
10 61 68 12695819 induced VBN I-NP O
11 69 82 12695819 neurotoxicity NN I-NP B-Disease
12 83 85 12695819 in IN B-PP O
13 86 91 12695819 organ NN B-NP O
14 92 102 12695819 transplant NN I-NP O
15 103 111 12695819 patients NNS I-NP O
16 111 112 12695819 . . O O
17 113 116 12695819 Our PRP$ B-NP O
18 117 126 12695819 objective NN I-NP O
19 127 130 12695819 was VBD B-VP O
20 131 133 12695819 to TO B-VP O
21 134 145 12695819 investigate VB I-VP O
22 146 151 12695819 brain NN B-NP O
23 152 154 12695819 MR NN I-NP O
24 155 162 12695819 imaging NN I-NP O
25 163 171 12695819 findings NNS I-NP O
26 172 175 12695819 and CC O O
27 176 179 12695819 the DT B-NP O
28 180 187 12695819 utility NN I-NP O
29 188 190 12695819 of IN B-PP O
30 191 200 12695819 diffusion NN B-NP O
31 200 201 12695819 - HYPH O O
32 201 209 12695819 weighted VBN B-VP O
33 210 211 12695819 ( ( O O
34 211 213 12695819 DW NN B-NP O
35 213 214 12695819 ) ) O O
36 215 222 12695819 imaging NN B-NP O
37 223 225 12695819 in IN B-PP O
38 226 231 12695819 organ NN B-NP O
39 232 242 12695819 transplant NN I-NP O
40 243 251 12695819 patients NNS I-NP O
41 252 255 12695819 who WP B-NP O
42 256 265 12695819 developed VBD B-VP O
43 266 276 12695819 neurologic JJ B-NP O
44 277 285 12695819 symptoms NNS I-NP O
45 286 292 12695819 during IN B-PP O
46 293 303 12695819 tacrolimus NN B-NP B-Chemical
47 304 311 12695819 therapy NN I-NP O
48 311 312 12695819 . . O O

1 313 318 12695819 Brain NN B-NP O
2 319 321 12695819 MR NN I-NP O
3 322 329 12695819 studies NNS I-NP O
4 329 330 12695819 , , O O
5 331 340 12695819 including VBG B-PP O
6 341 343 12695819 DW NN B-NP O
7 344 351 12695819 imaging NN I-NP O
8 351 352 12695819 , , O O
9 353 357 12695819 were VBD B-VP O
10 358 371 12695819 prospectively RB I-VP O
11 372 381 12695819 performed VBN I-VP O
12 382 384 12695819 in IN B-PP O
13 385 387 12695819 14 CD B-NP O
14 388 393 12695819 organ NN I-NP O
15 394 404 12695819 transplant NN I-NP O
16 405 413 12695819 patients NNS I-NP O
17 414 423 12695819 receiving VBG B-VP O
18 424 434 12695819 tacrolimus NN B-NP B-Chemical
19 435 438 12695819 who WP B-NP O
20 439 448 12695819 developed VBD B-VP O
21 449 459 12695819 neurologic JJ B-NP B-Disease
22 460 473 12695819 complications NNS I-NP I-Disease
23 473 474 12695819 . . O O

1 475 477 12695819 In IN B-PP O
2 478 482 12695819 each DT B-NP O
3 483 490 12695819 patient NN I-NP O
4 491 494 12695819 who WP B-NP O
5 495 498 12695819 had VBD B-VP O
6 499 512 12695819 abnormalities NNS B-NP O
7 513 515 12695819 on IN B-PP O
8 516 519 12695819 the DT B-NP O
9 520 527 12695819 initial JJ I-NP O
10 528 530 12695819 MR NN I-NP O
11 531 536 12695819 study NN I-NP O
12 536 537 12695819 , , O O
13 538 539 12695819 a DT B-NP O
14 540 546 12695819 follow VB I-NP O
15 546 547 12695819 - HYPH O O
16 547 549 12695819 up RP B-PRT O
17 550 552 12695819 MR NN B-NP O
18 553 558 12695819 study NN I-NP O
19 559 562 12695819 was VBD B-VP O
20 563 572 12695819 performed VBN I-VP O
21 573 574 12695819 1 CD B-NP O
22 575 580 12695819 month NN I-NP O
23 581 586 12695819 later RB B-ADVP O
24 586 587 12695819 . . O O

1 588 596 12695819 Apparent JJ B-NP O
2 597 606 12695819 diffusion NN I-NP O
3 607 618 12695819 coefficient NN I-NP O
4 619 620 12695819 ( ( O O
5 620 623 12695819 ADC NN B-NP O
6 623 624 12695819 ) ) O O
7 625 631 12695819 values NNS B-NP O
8 632 634 12695819 on IN B-PP O
9 635 638 12695819 the DT B-NP O
10 639 646 12695819 initial JJ I-NP O
11 647 649 12695819 MR NN I-NP O
12 650 655 12695819 study NN I-NP O
13 656 660 12695819 were VBD B-VP O
14 661 671 12695819 correlated VBN I-VP O
15 672 676 12695819 with IN B-PP O
16 677 690 12695819 reversibility NN B-NP O
17 691 693 12695819 of IN B-PP O
18 694 697 12695819 the DT B-NP O
19 698 705 12695819 lesions NNS I-NP O
20 705 706 12695819 . . O O

1 707 709 12695819 Of IN B-PP O
2 710 713 12695819 the DT B-NP O
3 714 716 12695819 14 CD I-NP O
4 717 725 12695819 patients NNS I-NP O
5 725 726 12695819 , , O O
6 727 728 12695819 5 CD B-NP O
7 729 730 12695819 ( ( O O
8 730 735 12695819 35.7% NN B-NP O
9 735 736 12695819 ) ) O O
10 737 740 12695819 had VBD B-VP O
11 741 746 12695819 white JJ B-NP B-Disease
12 747 753 12695819 matter NN I-NP I-Disease
13 754 767 12695819 abnormalities NNS I-NP I-Disease
14 767 768 12695819 , , O O
15 769 770 12695819 1 CD B-NP O
16 771 772 12695819 ( ( O O
17 772 776 12695819 7.1% NN B-NP O
18 776 777 12695819 ) ) O O
19 778 781 12695819 had VBD B-VP O
20 782 791 12695819 putaminal JJ B-NP B-Disease
21 792 802 12695819 hemorrhage NN I-NP I-Disease
22 802 803 12695819 , , O O
23 804 807 12695819 and CC O O
24 808 809 12695819 8 CD B-NP O
25 810 811 12695819 ( ( O O
26 811 816 12695819 57.1% NN B-NP O
27 816 817 12695819 ) ) O O
28 818 821 12695819 had VBD B-VP O
29 822 828 12695819 normal JJ B-NP O
30 829 837 12695819 findings NNS I-NP O
31 838 840 12695819 on IN B-PP O
32 841 848 12695819 initial JJ B-NP O
33 849 851 12695819 MR NN I-NP O
34 852 858 12695819 images NNS I-NP O
35 858 859 12695819 . . O O

1 860 865 12695819 Among IN B-PP O
2 866 869 12695819 the DT B-NP O
3 870 871 12695819 5 CD I-NP O
4 872 880 12695819 patients NNS I-NP O
5 881 885 12695819 with IN B-PP O
6 886 891 12695819 white JJ B-NP B-Disease
7 892 898 12695819 matter NN I-NP I-Disease
8 899 912 12695819 abnormalities NNS I-NP I-Disease
9 912 913 12695819 , , O O
10 914 915 12695819 4 CD B-NP O
11 916 924 12695819 patients NNS I-NP O
12 925 926 12695819 ( ( O O
13 926 931 12695819 80.0% NN B-NP O
14 931 932 12695819 ) ) O O
15 933 939 12695819 showed VBD B-VP O
16 940 946 12695819 higher JJR B-ADVP O
17 947 951 12695819 than IN B-PP O
18 952 958 12695819 normal JJ B-NP O
19 959 962 12695819 ADC NN I-NP O
20 963 969 12695819 values NNS I-NP O
21 970 972 12695819 on IN B-PP O
22 973 980 12695819 initial JJ B-NP O
23 981 983 12695819 MR NN I-NP O
24 984 990 12695819 images NNS I-NP O
25 990 991 12695819 , , O O
26 992 995 12695819 and CC O O
27 996 999 12695819 all DT B-NP O
28 1000 1006 12695819 showed VBD B-VP O
29 1007 1015 12695819 complete JJ B-NP O
30 1016 1026 12695819 resolution NN I-NP O
31 1027 1029 12695819 on IN B-PP O
32 1030 1036 12695819 follow VB B-VP O
33 1036 1037 12695819 - HYPH O O
34 1037 1039 12695819 up RP B-PRT O
35 1040 1046 12695819 images NNS B-NP O
36 1046 1047 12695819 . . O O

1 1048 1051 12695819 The DT B-NP O
2 1052 1061 12695819 remaining VBG I-NP O
3 1062 1063 12695819 1 CD I-NP O
4 1064 1071 12695819 patient NN I-NP O
5 1072 1073 12695819 ( ( O O
6 1073 1078 12695819 20.0% NN B-NP O
7 1078 1079 12695819 ) ) O O
8 1080 1086 12695819 showed VBD B-VP O
9 1087 1092 12695819 lower JJR B-ADVP O
10 1093 1097 12695819 than IN B-PP O
11 1098 1104 12695819 normal JJ B-NP O
12 1105 1108 12695819 ADC NN I-NP O
13 1109 1114 12695819 value NN I-NP O
14 1115 1118 12695819 and CC O O
15 1119 1125 12695819 showed VBD B-VP O
16 1126 1136 12695819 incomplete JJ B-NP O
17 1137 1147 12695819 resolution NN I-NP O
18 1148 1152 12695819 with IN B-PP O
19 1153 1161 12695819 cortical JJ B-NP B-Disease
20 1162 1169 12695819 laminar JJ I-NP I-Disease
21 1170 1178 12695819 necrosis NN I-NP I-Disease
22 1178 1179 12695819 . . O O

1 1180 1189 12695819 Diffusion NN B-NP O
2 1189 1190 12695819 - HYPH B-PP O
3 1190 1198 12695819 weighted VBN B-NP O
4 1199 1206 12695819 imaging NN I-NP O
5 1207 1210 12695819 may MD B-VP O
6 1211 1213 12695819 be VB I-VP O
7 1214 1220 12695819 useful JJ B-ADJP O
8 1221 1223 12695819 in IN B-PP O
9 1224 1234 12695819 predicting VBG B-VP O
10 1235 1238 12695819 the DT B-NP O
11 1239 1247 12695819 outcomes NNS I-NP O
12 1248 1250 12695819 of IN B-PP O
13 1251 1254 12695819 the DT B-NP O
14 1255 1262 12695819 lesions NNS I-NP O
15 1263 1265 12695819 of IN B-PP O
16 1266 1276 12695819 tacrolimus NN B-NP B-Chemical
17 1276 1277 12695819 - HYPH B-NP O
18 1277 1284 12695819 induced VBN I-NP O
19 1285 1298 12695819 neurotoxicity NN I-NP B-Disease
20 1298 1299 12695819 . . O O

1 0 0 1919871 -DOCSTART- -X- -X- O

1 0 12 1919871 Irreversible JJ B-NP O
2 13 19 1919871 damage NN I-NP O
3 20 22 1919871 to TO B-PP O
4 23 26 1919871 the DT B-NP O
5 27 36 1919871 medullary JJ I-NP O
6 37 49 1919871 interstitium NN I-NP O
7 50 52 1919871 in IN B-PP O
8 53 65 1919871 experimental JJ B-NP O
9 66 75 1919871 analgesic JJ I-NP O
10 76 87 1919871 nephropathy NN I-NP B-Disease
11 88 90 1919871 in IN B-PP O
12 91 95 1919871 F344 NN B-NP O
13 96 100 1919871 rats NNS I-NP O
14 100 101 1919871 . . O O
15 102 107 1919871 Renal JJ B-NP B-Disease
16 108 117 1919871 papillary JJ I-NP I-Disease
17 118 126 1919871 necrosis NN I-NP I-Disease
18 127 128 1919871 ( ( O O
19 128 131 1919871 RPN NN B-NP B-Disease
20 131 132 1919871 ) ) O O
21 133 136 1919871 and CC O O
22 137 138 1919871 a DT B-NP O
23 139 148 1919871 decreased VBN I-NP O
24 149 156 1919871 urinary JJ I-NP O
25 157 170 1919871 concentrating VBG I-NP O
26 171 178 1919871 ability NN I-NP O
27 179 188 1919871 developed VBN B-VP O
28 189 195 1919871 during IN B-PP O
29 196 206 1919871 continuous JJ B-NP O
30 207 211 1919871 long JJ I-NP O
31 211 212 1919871 - HYPH I-NP O
32 212 216 1919871 term NN I-NP O
33 217 226 1919871 treatment NN I-NP O
34 227 231 1919871 with IN B-PP O
35 232 239 1919871 aspirin NN B-NP B-Chemical
36 240 243 1919871 and CC I-NP O
37 244 255 1919871 paracetamol NN I-NP B-Chemical
38 256 258 1919871 in IN B-PP O
39 259 265 1919871 female JJ B-NP O
40 266 273 1919871 Fischer NNP I-NP O
41 274 277 1919871 344 CD I-NP O
42 278 282 1919871 rats NNS I-NP O
43 282 283 1919871 . . O O

1 284 289 1919871 Renal JJ B-NP O
2 290 299 1919871 structure NN I-NP O
3 300 303 1919871 and CC O O
4 304 317 1919871 concentrating VBG B-NP O
5 318 325 1919871 ability NN I-NP O
6 326 330 1919871 were VBD B-VP O
7 331 339 1919871 examined VBN I-VP O
8 340 345 1919871 after IN B-PP O
9 346 347 1919871 a DT B-NP O
10 348 356 1919871 recovery NN I-NP O
11 357 363 1919871 period NN I-NP O
12 364 366 1919871 of IN B-PP O
13 367 369 1919871 up IN B-NP O
14 370 372 1919871 to TO I-NP O
15 373 375 1919871 18 CD I-NP O
16 376 381 1919871 weeks NNS I-NP O
17 381 382 1919871 , , O O
18 383 387 1919871 when WRB B-ADVP O
19 388 390 1919871 no DT B-NP O
20 391 401 1919871 analgesics NNS I-NP O
21 402 406 1919871 were VBD B-VP O
22 407 412 1919871 given VBN I-VP O
23 412 413 1919871 , , O O
24 414 416 1919871 to TO B-VP O
25 417 428 1919871 investigate VB I-VP O
26 429 436 1919871 whether IN B-SBAR O
27 437 440 1919871 the DT B-NP O
28 441 450 1919871 analgesic JJ I-NP O
29 450 451 1919871 - HYPH I-NP O
30 451 458 1919871 induced VBN I-NP O
31 459 466 1919871 changes NNS I-NP O
32 467 471 1919871 were VBD B-VP O
33 472 482 1919871 reversible JJ B-ADJP O
34 482 483 1919871 . . O O

1 484 489 1919871 There EX B-NP O
2 490 493 1919871 was VBD B-VP O
3 494 496 1919871 no DT B-NP O
4 497 505 1919871 evidence NN I-NP O
5 506 508 1919871 of IN B-PP O
6 509 515 1919871 repair NN B-NP O
7 516 518 1919871 to TO B-PP O
8 519 522 1919871 the DT B-NP O
9 523 530 1919871 damaged VBN I-NP O
10 531 540 1919871 medullary JJ I-NP O
11 541 553 1919871 interstitial JJ I-NP O
12 554 560 1919871 matrix NN I-NP O
13 560 561 1919871 , , O O
14 562 564 1919871 or CC O O
15 565 578 1919871 proliferation NN B-NP O
16 579 581 1919871 of IN B-PP O
17 582 591 1919871 remaining VBG B-NP O
18 592 601 1919871 undamaged JJ I-NP O
19 602 606 1919871 type NN I-NP O
20 607 608 1919871 1 CD I-NP O
21 609 618 1919871 medullary JJ I-NP O
22 619 631 1919871 interstitial JJ I-NP O
23 632 637 1919871 cells NNS I-NP O
24 638 643 1919871 after IN B-PP O
25 644 647 1919871 the DT B-NP O
26 648 656 1919871 recovery NN I-NP O
27 657 663 1919871 period NN I-NP O
28 664 673 1919871 following VBG B-PP O
29 674 683 1919871 analgesic JJ B-NP O
30 684 693 1919871 treatment NN I-NP O
31 693 694 1919871 . . O O

1 695 698 1919871 The DT B-NP O
2 699 707 1919871 recovery NN I-NP O
3 708 710 1919871 of IN B-PP O
4 711 718 1919871 urinary JJ B-NP O
5 719 732 1919871 concentrating VBG I-NP O
6 733 740 1919871 ability NN I-NP O
7 741 744 1919871 was VBD B-VP O
8 745 752 1919871 related VBN I-VP O
9 753 755 1919871 to TO B-PP O
10 756 759 1919871 the DT B-NP O
11 760 766 1919871 length NN I-NP O
12 767 769 1919871 of IN B-PP O
13 770 779 1919871 analgesic JJ B-NP O
14 780 789 1919871 treatment NN I-NP O
15 790 793 1919871 and CC O O
16 794 797 1919871 the DT B-NP O
17 798 804 1919871 extent NN I-NP O
18 805 807 1919871 of IN B-PP O
19 808 811 1919871 the DT B-NP O
20 812 821 1919871 resulting VBG I-NP O
21 822 827 1919871 inner JJ I-NP O
22 828 837 1919871 medullary JJ I-NP O
23 838 848 1919871 structural JJ I-NP O
24 849 855 1919871 damage NN I-NP O
25 855 856 1919871 . . O O

1 857 863 1919871 During IN B-PP O
2 864 867 1919871 the DT B-NP O
3 868 873 1919871 early JJ I-NP O
4 874 880 1919871 stages NNS I-NP O
5 881 883 1919871 of IN B-PP O
6 884 893 1919871 analgesic JJ B-NP O
7 894 903 1919871 treatment NN I-NP O
8 903 904 1919871 , , O O
9 905 908 1919871 the DT B-NP O
10 909 916 1919871 changes NNS I-NP O
11 917 919 1919871 in IN B-PP O
12 920 927 1919871 urinary JJ B-NP O
13 928 941 1919871 concentrating VBG I-NP O
14 942 949 1919871 ability NN I-NP O
15 950 954 1919871 were VBD B-VP O
16 955 965 1919871 reversible JJ B-ADJP O
17 965 966 1919871 , , O O
18 967 970 1919871 but CC O O
19 971 976 1919871 after IN B-PP O
20 977 986 1919871 prolonged JJ B-NP O
21 987 996 1919871 analgesic JJ I-NP O
22 997 1006 1919871 treatment NN I-NP O
23 1006 1007 1919871 , , O O
24 1008 1015 1919871 maximum JJ B-NP O
25 1016 1023 1919871 urinary JJ I-NP O
26 1024 1037 1919871 concentrating VBG I-NP O
27 1038 1045 1919871 ability NN I-NP O
28 1046 1052 1919871 failed VBD B-VP O
29 1053 1055 1919871 to TO I-VP O
30 1056 1063 1919871 recover VB I-VP O
31 1063 1064 1919871 . . O O

1 1065 1069 1919871 This DT B-NP O
2 1070 1075 1919871 study NN I-NP O
3 1076 1081 1919871 shows VBZ B-VP O
4 1082 1086 1919871 that IN B-SBAR O
5 1087 1096 1919871 prolonged JJ B-NP O
6 1097 1106 1919871 analgesic JJ I-NP O
7 1107 1116 1919871 treatment NN I-NP O
8 1117 1119 1919871 in IN B-PP O
9 1120 1127 1919871 Fischer NNP B-NP O
10 1128 1131 1919871 344 CD I-NP O
11 1132 1136 1919871 rats NNS I-NP O
12 1137 1143 1919871 causes VBZ B-VP O
13 1144 1155 1919871 progressive JJ B-NP O
14 1156 1159 1919871 and CC I-NP O
15 1160 1172 1919871 irreversible JJ I-NP O
16 1173 1179 1919871 damage NN I-NP O
17 1180 1182 1919871 to TO B-PP O
18 1183 1186 1919871 the DT B-NP O
19 1187 1199 1919871 interstitial JJ I-NP O
20 1200 1206 1919871 matrix NN I-NP O
21 1207 1210 1919871 and CC I-NP O
22 1211 1215 1919871 type NN I-NP O
23 1216 1217 1919871 1 CD I-NP O
24 1218 1230 1919871 interstitial JJ I-NP O
25 1231 1236 1919871 cells NNS I-NP O
26 1237 1244 1919871 leading VBG B-VP O
27 1245 1247 1919871 to TO B-PP O
28 1248 1251 1919871 RPN NN B-NP B-Disease
29 1251 1252 1919871 . . O O

1 1253 1256 1919871 The DT B-NP O
2 1257 1267 1919871 associated VBN I-NP O
3 1268 1275 1919871 urinary JJ I-NP O
4 1276 1289 1919871 concentrating VBG I-NP O
5 1290 1296 1919871 defect NN I-NP O
6 1297 1299 1919871 is VBZ B-VP O
7 1300 1310 1919871 reversible JJ B-ADJP O
8 1311 1315 1919871 only RB B-ADVP O
9 1316 1322 1919871 during IN B-PP O
10 1323 1326 1919871 the DT B-NP O
11 1327 1332 1919871 early JJ I-NP O
12 1333 1339 1919871 stages NNS I-NP O
13 1340 1342 1919871 of IN B-PP O
14 1343 1353 1919871 structural JJ B-NP O
15 1354 1360 1919871 damage NN I-NP O
16 1361 1363 1919871 to TO B-PP O
17 1364 1367 1919871 the DT B-NP O
18 1368 1373 1919871 inner JJ I-NP O
19 1374 1381 1919871 medulla NN I-NP O
20 1381 1382 1919871 . . O O

1 0 0 12574103 -DOCSTART- -X- -X- O

1 0 8 12574103 Prenatal JJ B-NP O
2 9 22 12574103 dexamethasone NN I-NP B-Chemical
3 23 31 12574103 programs NNS I-NP O
4 32 44 12574103 hypertension NN I-NP B-Disease
5 45 48 12574103 and CC O O
6 49 54 12574103 renal JJ B-NP B-Disease
7 55 61 12574103 injury NN I-NP I-Disease
8 62 64 12574103 in IN B-PP O
9 65 68 12574103 the DT B-NP O
10 69 72 12574103 rat NN I-NP O
11 72 73 12574103 . . I-NP O
12 74 87 12574103 Dexamethasone NN I-NP O
13 88 90 12574103 is VBZ B-VP O
14 91 101 12574103 frequently RB I-VP O
15 102 114 12574103 administered VBN I-VP O
16 115 117 12574103 to TO B-PP O
17 118 121 12574103 the DT B-NP O
18 122 132 12574103 developing VBG I-NP O
19 133 138 12574103 fetus NN I-NP O
20 139 141 12574103 to TO B-VP O
21 142 152 12574103 accelerate VB I-VP O
22 153 162 12574103 pulmonary JJ B-NP O
23 163 174 12574103 development NN I-NP O
24 174 175 12574103 . . O O

1 176 179 12574103 The DT B-NP O
2 180 187 12574103 purpose NN I-NP O
3 188 190 12574103 of IN B-PP O
4 191 194 12574103 the DT B-NP O
5 195 202 12574103 present JJ I-NP O
6 203 208 12574103 study NN I-NP O
7 209 212 12574103 was VBD B-VP O
8 213 215 12574103 to TO B-VP O
9 216 225 12574103 determine VB I-VP O
10 226 228 12574103 if IN B-SBAR O
11 229 237 12574103 prenatal JJ B-NP O
12 238 251 12574103 dexamethasone NN I-NP B-Chemical
13 252 262 12574103 programmed VBD B-VP O
14 263 264 12574103 a DT B-NP O
15 265 276 12574103 progressive JJ I-NP O
16 277 285 12574103 increase NN I-NP B-Disease
17 286 288 12574103 in IN B-PP I-Disease
18 289 294 12574103 blood NN B-NP I-Disease
19 295 303 12574103 pressure NN I-NP I-Disease
20 304 307 12574103 and CC O O
21 308 313 12574103 renal JJ B-NP B-Disease
22 314 320 12574103 injury NN I-NP I-Disease
23 321 323 12574103 in IN B-PP O
24 324 328 12574103 rats NNS B-NP O
25 328 329 12574103 . . O O

1 330 338 12574103 Pregnant JJ B-NP O
2 339 343 12574103 rats NNS I-NP O
3 344 348 12574103 were VBD B-VP O
4 349 354 12574103 given VBN I-VP O
5 355 361 12574103 either CC O O
6 362 369 12574103 vehicle NN B-NP O
7 370 372 12574103 or CC O O
8 373 374 12574103 2 CD B-NP O
9 375 380 12574103 daily JJ I-NP O
10 381 396 12574103 intraperitoneal JJ I-NP O
11 397 407 12574103 injections NNS I-NP O
12 408 410 12574103 of IN B-PP O
13 411 424 12574103 dexamethasone NN B-NP B-Chemical
14 425 426 12574103 ( ( O O
15 426 429 12574103 0.2 CD B-NP O
16 430 432 12574103 mg NN I-NP O
17 432 433 12574103 / SYM B-NP O
18 433 435 12574103 kg NN I-NP O
19 436 440 12574103 body NN I-NP O
20 441 447 12574103 weight NN I-NP O
21 447 448 12574103 ) ) O O
22 449 451 12574103 on IN B-PP O
23 452 463 12574103 gestational JJ B-NP O
24 464 468 12574103 days NNS I-NP O
25 469 471 12574103 11 CD B-NP O
26 472 475 12574103 and CC I-NP O
27 476 478 12574103 12 CD I-NP O
28 478 479 12574103 , , I-NP O
29 480 482 12574103 13 CD I-NP O
30 483 486 12574103 and CC I-NP O
31 487 489 12574103 14 CD I-NP O
32 489 490 12574103 , , I-NP O
33 491 493 12574103 15 CD I-NP O
34 494 497 12574103 and CC I-NP O
35 498 500 12574103 16 CD I-NP O
36 500 501 12574103 , , I-NP O
37 502 504 12574103 17 CD I-NP O
38 505 508 12574103 and CC I-NP O
39 509 511 12574103 18 CD I-NP O
40 511 512 12574103 , , O O
41 513 515 12574103 or CC O O
42 516 518 12574103 19 CD B-NP O
43 519 522 12574103 and CC I-NP O
44 523 525 12574103 20 CD I-NP O
45 525 526 12574103 . . O O

1 527 536 12574103 Offspring NN B-NP O
2 537 539 12574103 of IN B-PP O
3 540 544 12574103 rats NNS B-NP O
4 545 557 12574103 administered VBN B-NP O
5 558 571 12574103 dexamethasone NN I-NP B-Chemical
6 572 574 12574103 on IN B-PP O
7 575 579 12574103 days NNS B-NP O
8 580 582 12574103 15 CD I-NP O
9 583 586 12574103 and CC I-NP O
10 587 589 12574103 16 CD I-NP O
11 590 599 12574103 gestation NN I-NP O
12 600 603 12574103 had VBD B-VP O
13 604 605 12574103 a DT B-NP O
14 606 609 12574103 20% JJ I-NP O
15 610 619 12574103 reduction NN I-NP B-Disease
16 620 622 12574103 in IN B-PP I-Disease
17 623 633 12574103 glomerular JJ B-NP I-Disease
18 634 640 12574103 number NN I-NP I-Disease
19 641 649 12574103 compared VBN B-PP O
20 650 654 12574103 with IN B-PP O
21 655 662 12574103 control NN B-NP O
22 663 665 12574103 at IN B-PP O
23 666 667 12574103 6 CD B-NP O
24 668 670 12574103 to TO I-NP O
25 671 672 12574103 9 CD I-NP O
26 673 679 12574103 months NNS I-NP O
27 680 682 12574103 of IN B-PP O
28 683 686 12574103 age NN B-NP O
29 687 688 12574103 ( ( O O
30 688 690 12574103 22 CD B-NP O
31 691 695 12574103 527+ SYM O O
32 695 696 12574103 / SYM O O
33 696 697 12574103 - SYM O O
34 697 700 12574103 509 CD B-NP O
35 701 707 12574103 versus IN B-PP O
36 708 710 12574103 28 CD B-NP O
37 711 715 12574103 050+ SYM O O
38 715 716 12574103 / SYM O O
39 716 717 12574103 - SYM O O
40 717 720 12574103 561 CD B-NP O
41 720 721 12574103 , , O O
42 722 723 12574103 P NN B-NP O
43 723 724 12574103 < SYM B-NP O
44 724 728 12574103 0.05 CD I-NP O
45 728 729 12574103 ) ) O O
46 729 730 12574103 , , O O
47 731 736 12574103 which WDT B-NP O
48 737 740 12574103 was VBD B-VP O
49 741 751 12574103 comparable JJ B-ADJP O
50 752 754 12574103 to TO B-PP O
51 755 758 12574103 the DT B-NP O
52 759 766 12574103 percent NN I-NP O
53 767 776 12574103 reduction NN I-NP O
54 777 779 12574103 in IN B-PP O
55 780 789 12574103 glomeruli NNS B-NP O
56 790 798 12574103 measured VBN B-VP O
57 799 801 12574103 at IN B-PP O
58 802 803 12574103 3 CD B-NP O
59 804 809 12574103 weeks NNS I-NP O
60 810 812 12574103 of IN B-PP O
61 813 816 12574103 age NN B-NP O
62 816 817 12574103 . . O O

1 818 821 12574103 Six CD B-NP O
2 821 822 12574103 - HYPH I-NP O
3 823 825 12574103 to TO B-PP O
4 826 827 12574103 9 CD B-NP O
5 827 828 12574103 - HYPH I-NP O
6 828 833 12574103 month NN I-NP O
7 834 837 12574103 old JJ I-NP O
8 838 842 12574103 rats NNS I-NP O
9 843 852 12574103 receiving VBG B-VP O
10 853 861 12574103 prenatal JJ B-NP O
11 862 875 12574103 dexamethasone NN I-NP B-Chemical
12 876 878 12574103 on IN B-PP O
13 879 883 12574103 days NNS B-NP O
14 884 886 12574103 17 CD B-NP O
15 887 890 12574103 and CC I-NP O
16 891 893 12574103 18 CD I-NP O
17 894 896 12574103 of IN B-PP O
18 897 906 12574103 gestation NN B-NP O
19 907 910 12574103 had VBD B-VP O
20 911 912 12574103 a DT B-NP O
21 913 916 12574103 17% NN I-NP O
22 917 926 12574103 reduction NN I-NP O
23 927 929 12574103 in IN B-PP O
24 930 939 12574103 glomeruli NNS B-NP O
25 940 941 12574103 ( ( O O
26 941 943 12574103 23 CD B-NP O
27 944 948 12574103 380+ SYM O O
28 948 949 12574103 / SYM O O
29 949 950 12574103 - SYM O O
30 950 953 12574103 587 CD B-NP O
31 953 954 12574103 ) ) O O
32 955 963 12574103 compared VBN B-PP O
33 964 968 12574103 with IN B-PP O
34 969 976 12574103 control NN B-NP O
35 977 981 12574103 rats NNS I-NP O
36 982 983 12574103 ( ( O O
37 983 984 12574103 P NN B-NP O
38 984 985 12574103 < SYM O O
39 985 989 12574103 0.05 CD B-NP O
40 989 990 12574103 ) ) O O
41 990 991 12574103 . . O O

1 992 996 12574103 Male JJ B-NP O
2 997 1001 12574103 rats NNS I-NP O
3 1002 1006 12574103 that WDT B-NP O
4 1007 1015 12574103 received VBD B-VP O
5 1016 1024 12574103 prenatal JJ B-NP O
6 1025 1038 12574103 dexamethasone NN I-NP B-Chemical
7 1039 1041 12574103 on IN B-PP O
8 1042 1046 12574103 days NNS B-NP O
9 1047 1049 12574103 15 CD I-NP O
10 1050 1053 12574103 and CC I-NP O
11 1054 1056 12574103 16 CD I-NP O
12 1056 1057 12574103 , , I-NP O
13 1058 1060 12574103 17 CD I-NP O
14 1061 1064 12574103 and CC I-NP O
15 1065 1067 12574103 18 CD I-NP O
16 1067 1068 12574103 , , O O
17 1069 1072 12574103 and CC O O
18 1073 1075 12574103 13 CD B-NP O
19 1076 1079 12574103 and CC I-NP O
20 1080 1082 12574103 14 CD I-NP O
21 1083 1085 12574103 of IN B-PP O
22 1086 1095 12574103 gestation NN B-NP O
23 1096 1099 12574103 had VBD B-VP O
24 1100 1108 12574103 elevated VBN I-VP B-Disease
25 1109 1114 12574103 blood NN B-NP I-Disease
26 1115 1124 12574103 pressures NNS I-NP I-Disease
27 1125 1127 12574103 at IN B-PP O
28 1128 1129 12574103 6 CD B-NP O
29 1130 1136 12574103 months NNS I-NP O
30 1137 1139 12574103 of IN B-PP O
31 1140 1143 12574103 age NN B-NP O
32 1143 1144 12574103 ; : O O
33 1145 1148 12574103 the DT B-NP O
34 1149 1155 12574103 latter JJ I-NP O
35 1156 1161 12574103 group NN I-NP O
36 1162 1165 12574103 did VBD B-VP O
37 1166 1169 12574103 not RB I-VP O
38 1170 1174 12574103 have VB I-VP O
39 1175 1176 12574103 a DT B-NP O
40 1177 1186 12574103 reduction NN I-NP B-Disease
41 1187 1189 12574103 in IN B-PP I-Disease
42 1190 1200 12574103 glomerular JJ B-NP I-Disease
43 1201 1207 12574103 number NN I-NP I-Disease
44 1207 1208 12574103 . . O O

1 1209 1214 12574103 Adult JJ B-NP O
2 1215 1219 12574103 rats NNS I-NP O
3 1220 1225 12574103 given VBN B-NP O
4 1226 1239 12574103 dexamethasone NN I-NP B-Chemical
5 1240 1242 12574103 on IN B-PP O
6 1243 1247 12574103 days NNS B-NP O
7 1248 1250 12574103 15 CD I-NP O
8 1251 1254 12574103 and CC I-NP O
9 1255 1257 12574103 16 CD I-NP O
10 1258 1260 12574103 of IN B-PP O
11 1261 1270 12574103 gestation NN B-NP O
12 1271 1274 12574103 had VBD B-VP O
13 1275 1279 12574103 more RBR B-ADJP O
14 1280 1289 12574103 glomeruli JJ I-ADJP O
15 1290 1294 12574103 with IN B-PP O
16 1295 1313 12574103 glomerulosclerosis NN B-NP B-Disease
17 1314 1318 12574103 than IN B-PP O
18 1319 1326 12574103 control NN B-NP O
19 1327 1331 12574103 rats NNS I-NP O
20 1331 1332 12574103 . . O O

1 1333 1337 12574103 This DT B-NP O
2 1338 1343 12574103 study NN I-NP O
3 1344 1349 12574103 shows VBZ B-VP O
4 1350 1354 12574103 that IN B-SBAR O
5 1355 1363 12574103 prenatal JJ B-NP O
6 1364 1377 12574103 dexamethasone NN I-NP B-Chemical
7 1378 1380 12574103 in IN B-PP O
8 1381 1385 12574103 rats NNS B-NP O
9 1386 1393 12574103 results VBZ B-VP O
10 1394 1396 12574103 in IN B-PP O
11 1397 1398 12574103 a DT B-NP O
12 1399 1408 12574103 reduction NN I-NP B-Disease
13 1409 1411 12574103 in IN B-PP I-Disease
14 1412 1422 12574103 glomerular JJ B-NP I-Disease
15 1423 1429 12574103 number NN I-NP I-Disease
16 1429 1430 12574103 , , O O
17 1431 1449 12574103 glomerulosclerosis NN B-NP B-Disease
18 1449 1450 12574103 , , O O
19 1451 1454 12574103 and CC O O
20 1455 1467 12574103 hypertension NN B-NP B-Disease
21 1468 1472 12574103 when WRB B-ADVP O
22 1473 1485 12574103 administered VBN B-VP O
23 1486 1488 12574103 at IN B-PP O
24 1489 1497 12574103 specific JJ B-NP O
25 1498 1504 12574103 points NNS I-NP O
26 1505 1511 12574103 during IN B-PP O
27 1512 1521 12574103 gestation NN B-NP O
28 1521 1522 12574103 . . O O

1 1523 1535 12574103 Hypertension NN B-NP B-Disease
2 1536 1539 12574103 was VBD B-VP O
3 1540 1548 12574103 observed VBN I-VP O
4 1549 1551 12574103 in IN B-PP O
5 1552 1559 12574103 animals NNS B-NP O
6 1560 1564 12574103 that WDT B-NP O
7 1565 1568 12574103 had VBD B-VP O
8 1569 1570 12574103 a DT B-NP O
9 1571 1580 12574103 reduction NN I-NP O
10 1581 1583 12574103 in IN B-PP O
11 1584 1593 12574103 glomeruli NNS B-NP O
12 1594 1596 12574103 as RB B-CONJP O
13 1597 1601 12574103 well RB I-CONJP O
14 1602 1604 12574103 as IN I-CONJP O
15 1605 1607 12574103 in IN B-PP O
16 1608 1609 12574103 a DT B-NP O
17 1610 1615 12574103 group NN I-NP O
18 1616 1620 12574103 that WDT B-NP O
19 1621 1624 12574103 did VBD B-VP O
20 1625 1628 12574103 not RB I-VP O
21 1629 1633 12574103 have VB I-VP O
22 1634 1635 12574103 a DT B-NP O
23 1636 1645 12574103 reduction NN I-NP B-Disease
24 1646 1648 12574103 in IN B-PP I-Disease
25 1649 1659 12574103 glomerular JJ B-NP I-Disease
26 1660 1666 12574103 number NN I-NP I-Disease
27 1666 1667 12574103 , , O O
28 1668 1678 12574103 suggesting VBG B-VP O
29 1679 1683 12574103 that IN B-SBAR O
30 1684 1685 12574103 a DT B-NP O
31 1686 1695 12574103 reduction NN I-NP B-Disease
32 1696 1698 12574103 in IN B-PP I-Disease
33 1699 1709 12574103 glomerular JJ B-NP I-Disease
34 1710 1716 12574103 number NN I-NP I-Disease
35 1717 1719 12574103 is VBZ B-VP O
36 1720 1723 12574103 not RB O O
37 1724 1727 12574103 the DT B-NP O
38 1728 1732 12574103 sole JJ I-NP O
39 1733 1738 12574103 cause NN I-NP O
40 1739 1742 12574103 for IN B-PP O
41 1743 1746 12574103 the DT B-NP O
42 1747 1758 12574103 development NN I-NP O
43 1759 1761 12574103 of IN B-PP O
44 1762 1774 12574103 hypertension NN B-NP B-Disease
45 1774 1775 12574103 . . O O

1 0 0 17608141 -DOCSTART- -X- -X- O

1 0 11 17608141 Attenuation NN B-NP O
2 12 14 17608141 of IN B-PP O
3 15 30 17608141 methamphetamine NN B-NP B-Chemical
4 30 31 17608141 - HYPH B-NP O
5 31 38 17608141 induced VBN I-NP O
6 39 52 17608141 nigrostriatal JJ I-NP O
7 53 65 17608141 dopaminergic JJ I-NP O
8 66 79 17608141 neurotoxicity NN I-NP B-Disease
9 80 82 17608141 in IN B-PP O
10 83 87 17608141 mice NNS B-NP O
11 88 90 17608141 by IN B-PP O
12 91 109 17608141 lipopolysaccharide NN B-NP B-Chemical
13 110 122 17608141 pretreatment NN I-NP O
14 122 123 17608141 . . O O
15 124 137 17608141 Immunological JJ B-NP O
16 138 148 17608141 activation NN I-NP O
17 149 152 17608141 has VBZ B-VP O
18 153 157 17608141 been VBN I-VP O
19 158 166 17608141 proposed VBN I-VP O
20 167 169 17608141 to TO I-VP O
21 170 174 17608141 play VB I-VP O
22 175 176 17608141 a DT B-NP O
23 177 181 17608141 role NN I-NP O
24 182 184 17608141 in IN B-PP O
25 185 200 17608141 methamphetamine NN B-NP B-Chemical
26 200 201 17608141 - HYPH B-NP O
27 201 208 17608141 induced VBN I-NP O
28 209 221 17608141 dopaminergic JJ I-NP B-Disease
29 222 230 17608141 terminal JJ I-NP I-Disease
30 231 237 17608141 damage NN I-NP I-Disease
31 237 238 17608141 . . O O

1 239 241 17608141 In IN B-PP O
2 242 246 17608141 this DT B-NP O
3 247 252 17608141 study NN I-NP O
4 252 253 17608141 , , O O
5 254 256 17608141 we PRP B-NP O
6 257 265 17608141 examined VBD B-VP O
7 266 269 17608141 the DT B-NP O
8 270 275 17608141 roles NNS I-NP O
9 276 278 17608141 of IN B-PP O
10 279 297 17608141 lipopolysaccharide NN B-NP B-Chemical
11 297 298 17608141 , , O O
12 299 300 17608141 a DT B-NP O
13 301 304 17608141 pro AFX I-NP O
14 304 305 17608141 - HYPH I-NP O
15 305 317 17608141 inflammatory JJ I-NP O
16 318 321 17608141 and CC I-NP O
17 322 334 17608141 inflammatory JJ I-NP O
18 335 341 17608141 factor NN I-NP O
19 341 342 17608141 , , O O
20 343 352 17608141 treatment NN B-NP O
21 353 355 17608141 in IN B-PP O
22 356 366 17608141 modulating VBG B-VP O
23 367 370 17608141 the DT B-NP O
24 371 386 17608141 methamphetamine NN I-NP B-Chemical
25 386 387 17608141 - HYPH O O
26 387 394 17608141 induced VBN B-NP O
27 395 408 17608141 nigrostriatal JJ I-NP O
28 409 417 17608141 dopamine NN I-NP B-Chemical
29 418 431 17608141 neurotoxicity NN I-NP B-Disease
30 431 432 17608141 . . O O

1 433 451 17608141 Lipopolysaccharide NN B-NP B-Chemical
2 452 464 17608141 pretreatment NN I-NP O
3 465 468 17608141 did VBD B-VP O
4 469 472 17608141 not RB I-VP O
5 473 479 17608141 affect VB I-VP O
6 480 483 17608141 the DT B-NP O
7 484 489 17608141 basal JJ I-NP O
8 490 494 17608141 body NN I-NP O
9 495 506 17608141 temperature NN I-NP O
10 507 509 17608141 or CC I-NP O
11 510 525 17608141 methamphetamine NN I-NP B-Chemical
12 525 526 17608141 - HYPH O O
13 526 534 17608141 elicited VBN B-NP O
14 535 547 17608141 hyperthermia NN I-NP B-Disease
15 548 553 17608141 three CD B-NP O
16 554 558 17608141 days NNS I-NP O
17 559 564 17608141 later RB B-ADVP O
18 564 565 17608141 . . O O

1 566 570 17608141 Such JJ B-NP O
2 571 579 17608141 systemic JJ I-NP O
3 580 598 17608141 lipopolysaccharide NN I-NP B-Chemical
4 599 608 17608141 treatment NN I-NP O
5 609 618 17608141 mitigated VBD B-VP O
6 619 634 17608141 methamphetamine NN B-NP B-Chemical
7 634 635 17608141 - HYPH O O
8 635 642 17608141 induced VBN B-NP O
9 643 651 17608141 striatal JJ I-NP O
10 652 660 17608141 dopamine NN I-NP B-Chemical
11 661 664 17608141 and CC O O
12 665 668 17608141 3,4 CD B-NP B-Chemical
13 668 669 17608141 - HYPH I-NP I-Chemical
14 669 690 17608141 dihydroxyphenylacetic JJ I-NP I-Chemical
15 691 695 17608141 acid NN I-NP I-Chemical
16 696 706 17608141 depletions NNS I-NP O
17 707 709 17608141 in IN B-PP O
18 710 711 17608141 a DT B-NP O
19 712 716 17608141 dose NN I-NP O
20 716 717 17608141 - HYPH B-NP O
21 717 726 17608141 dependent JJ I-NP O
22 727 733 17608141 manner NN I-NP O
23 733 734 17608141 . . O O

1 735 737 17608141 As IN B-SBAR O
2 738 741 17608141 the DT B-NP O
3 742 746 17608141 most RBS I-NP O
4 747 753 17608141 potent JJ I-NP O
5 754 758 17608141 dose NN I-NP O
6 759 760 17608141 ( ( O O
7 760 761 17608141 1 CD B-NP O
8 762 764 17608141 mg NN I-NP O
9 764 765 17608141 / SYM B-NP O
10 765 767 17608141 kg NN I-NP O
11 767 768 17608141 ) ) O O
12 769 771 17608141 of IN B-PP O
13 772 790 17608141 lipopolysaccharide NN B-NP B-Chemical
14 791 794 17608141 was VBD B-VP O
15 795 807 17608141 administered VBN I-VP O
16 808 811 17608141 two CD B-NP O
17 812 817 17608141 weeks NNS I-NP O
18 817 818 17608141 , , O O
19 819 822 17608141 one CD B-NP O
20 823 826 17608141 day NN I-NP O
21 827 833 17608141 before IN B-PP O
22 834 836 17608141 or CC I-PP O
23 837 842 17608141 after IN I-PP O
24 843 846 17608141 the DT B-NP O
25 847 862 17608141 methamphetamine NN I-NP B-Chemical
26 863 869 17608141 dosing NN I-NP O
27 870 877 17608141 regimen NN I-NP O
28 877 878 17608141 , , O O
29 879 894 17608141 methamphetamine NN B-NP B-Chemical
30 894 895 17608141 - HYPH O O
31 895 902 17608141 induced VBN B-NP O
32 903 911 17608141 striatal JJ I-NP O
33 912 920 17608141 dopamine NN I-NP B-Chemical
34 921 924 17608141 and CC O O
35 925 928 17608141 3,4 CD B-NP B-Chemical
36 928 929 17608141 - HYPH I-NP I-Chemical
37 929 950 17608141 dihydroxyphenylacetic JJ I-NP I-Chemical
38 951 955 17608141 acid NN I-NP I-Chemical
39 956 966 17608141 depletions NNS I-NP O
40 967 975 17608141 remained VBD B-VP O
41 976 985 17608141 unaltered JJ B-ADJP O
42 985 986 17608141 . . O O

1 987 995 17608141 Moreover RB B-ADVP O
2 995 996 17608141 , , O O
3 997 1005 17608141 systemic JJ B-NP O
4 1006 1024 17608141 lipopolysaccharide NN I-NP B-Chemical
5 1025 1037 17608141 pretreatment NN I-NP O
6 1038 1039 17608141 ( ( O O
7 1039 1040 17608141 1 CD B-NP O
8 1041 1043 17608141 mg NN I-NP O
9 1043 1044 17608141 / SYM B-NP O
10 1044 1046 17608141 kg NN I-NP O
11 1046 1047 17608141 ) ) O O
12 1048 1058 17608141 attenuated VBD B-VP O
13 1059 1064 17608141 local JJ B-NP O
14 1065 1080 17608141 methamphetamine NN I-NP B-Chemical
15 1081 1089 17608141 infusion NN I-NP O
16 1089 1090 17608141 - HYPH B-NP O
17 1090 1098 17608141 produced VBN I-NP O
18 1099 1107 17608141 dopamine NN I-NP B-Chemical
19 1108 1111 17608141 and CC I-NP O
20 1112 1115 17608141 3,4 CD I-NP B-Chemical
21 1115 1116 17608141 - HYPH I-NP I-Chemical
22 1116 1137 17608141 dihydroxyphenylacetic JJ I-NP I-Chemical
23 1138 1142 17608141 acid NN I-NP I-Chemical
24 1143 1153 17608141 depletions NNS I-NP O
25 1154 1156 17608141 in IN B-PP O
26 1157 1160 17608141 the DT B-NP O
27 1161 1169 17608141 striatum NN I-NP O
28 1169 1170 17608141 , , O O
29 1171 1181 17608141 indicating VBG B-VP O
30 1182 1186 17608141 that IN B-SBAR O
31 1187 1190 17608141 the DT B-NP O
32 1191 1201 17608141 protective JJ I-NP O
33 1202 1208 17608141 effect NN I-NP O
34 1209 1211 17608141 of IN B-PP O
35 1212 1230 17608141 lipopolysaccharide NN B-NP B-Chemical
36 1231 1233 17608141 is VBZ B-VP O
37 1234 1238 17608141 less RBR B-ADJP O
38 1239 1245 17608141 likely JJ I-ADJP O
39 1246 1249 17608141 due IN B-PP O
40 1250 1252 17608141 to TO B-PP O
41 1253 1264 17608141 interrupted JJ B-NP O
42 1265 1275 17608141 peripheral JJ I-NP O
43 1276 1288 17608141 distribution NN I-NP O
44 1289 1291 17608141 or CC I-NP O
45 1292 1302 17608141 metabolism NN I-NP O
46 1303 1305 17608141 of IN B-PP O
47 1306 1321 17608141 methamphetamine NN B-NP B-Chemical
48 1321 1322 17608141 . . O O

1 1323 1325 17608141 We PRP B-NP O
2 1326 1335 17608141 concluded VBD B-VP O
3 1336 1337 17608141 a DT B-NP O
4 1338 1346 17608141 critical JJ I-NP O
5 1347 1351 17608141 time NN I-NP O
6 1352 1358 17608141 window NN I-NP O
7 1359 1362 17608141 for IN B-PP O
8 1363 1371 17608141 systemic JJ B-NP O
9 1372 1390 17608141 lipopolysaccharide NN I-NP B-Chemical
10 1391 1403 17608141 pretreatment NN I-NP O
11 1404 1406 17608141 in IN B-PP O
12 1407 1415 17608141 exerting VBG B-VP O
13 1416 1425 17608141 effective JJ B-NP O
14 1426 1436 17608141 protection NN I-NP O
15 1437 1444 17608141 against IN B-PP O
16 1445 1460 17608141 methamphetamine NN B-NP B-Chemical
17 1460 1461 17608141 - HYPH B-NP O
18 1461 1468 17608141 induced VBN I-NP O
19 1469 1482 17608141 nigrostriatal JJ I-NP O
20 1483 1491 17608141 dopamine NN I-NP B-Chemical
21 1492 1505 17608141 neurotoxicity NN I-NP B-Disease
22 1505 1506 17608141 . . O O

1 0 0 7265370 -DOCSTART- -X- -X- O

1 0 11 7265370 Triamterene NN B-NP B-Chemical
2 12 27 7265370 nephrolithiasis NN I-NP B-Disease
3 28 40 7265370 complicating VBG B-VP O
4 41 48 7265370 dyazide NN B-NP B-Chemical
5 49 56 7265370 therapy NN I-NP O
6 56 57 7265370 . . O O
7 58 59 7265370 A DT B-NP O
8 60 64 7265370 case NN I-NP O
9 65 67 7265370 of IN B-PP O
10 68 79 7265370 triamterene NN B-NP B-Chemical
11 80 95 7265370 nephrolithiasis NN I-NP B-Disease
12 96 98 7265370 is VBZ B-VP O
13 99 107 7265370 reported VBN I-VP O
14 108 110 7265370 in IN B-PP O
15 111 112 7265370 a DT B-NP O
16 113 116 7265370 man NN I-NP O
17 117 122 7265370 after IN B-PP O
18 123 124 7265370 4 CD B-NP O
19 125 130 7265370 years NNS I-NP O
20 131 133 7265370 of IN B-PP O
21 134 153 7265370 hydrochlorothiazide NN B-NP B-Chemical
22 153 154 7265370 - HYPH B-NP I-Chemical
23 154 165 7265370 triamterene NN I-NP I-Chemical
24 166 173 7265370 therapy NN I-NP O
25 174 177 7265370 for IN B-PP O
26 178 190 7265370 hypertension NN B-NP B-Disease
27 190 191 7265370 . . O O

1 192 195 7265370 The DT B-NP O
2 196 201 7265370 stone NN I-NP O
3 202 208 7265370 passed VBD B-VP O
4 209 222 7265370 spontaneously RB B-ADVP O
5 223 226 7265370 and CC O O
6 227 230 7265370 was VBD B-VP O
7 231 236 7265370 found VBN I-VP O
8 237 239 7265370 to TO I-VP O
9 240 247 7265370 contain VB I-VP O
10 248 249 7265370 a DT B-NP O
11 250 261 7265370 triamterene NN I-NP B-Chemical
12 262 272 7265370 metabolite NN I-NP O
13 273 280 7265370 admixed VBN B-VP O
14 281 285 7265370 with IN B-PP O
15 286 290 7265370 uric JJ B-NP B-Chemical
16 291 295 7265370 acid NN I-NP I-Chemical
17 296 301 7265370 salts NNS I-NP I-Chemical
18 301 302 7265370 . . O O

1 303 310 7265370 Factors NNS B-NP O
2 311 320 7265370 affecting VBG B-VP O
3 321 332 7265370 triamterene NN B-NP B-Chemical
4 333 348 7265370 nephrolithiasis NN I-NP B-Disease
5 349 352 7265370 are VBP B-VP O
6 353 362 7265370 discussed VBN I-VP O
7 363 366 7265370 and CC O O
8 367 368 7265370 2 CD B-NP O
9 369 379 7265370 previously RB I-NP O
10 380 388 7265370 reported VBN I-NP O
11 389 394 7265370 cases NNS I-NP O
12 395 398 7265370 are VBP B-VP O
13 399 407 7265370 reviewed VBN I-VP O
14 407 408 7265370 . . O O

1 0 0 20667451 -DOCSTART- -X- -X- O

1 0 8 20667451 Curcumin NN B-NP B-Chemical
2 9 20 20667451 ameliorates VBZ B-VP O
3 21 30 20667451 cognitive JJ B-NP B-Disease
4 31 42 20667451 dysfunction NN I-NP I-Disease
5 43 46 20667451 and CC O O
6 47 56 20667451 oxidative JJ B-NP O
7 57 63 20667451 damage NN I-NP O
8 64 66 20667451 in IN B-PP O
9 67 81 20667451 phenobarbitone NN B-NP B-Chemical
10 82 85 20667451 and CC I-NP O
11 86 99 20667451 carbamazepine NN I-NP B-Chemical
12 100 112 20667451 administered VBN I-NP O
13 113 117 20667451 rats NNS I-NP O
14 117 118 20667451 . . O O
15 119 122 20667451 The DT B-NP O
16 123 136 20667451 antiepileptic JJ I-NP O
17 137 142 20667451 drugs NNS I-NP O
18 142 143 20667451 , , I-NP O
19 144 158 20667451 phenobarbitone NN I-NP B-Chemical
20 159 162 20667451 and CC I-NP O
21 163 176 20667451 carbamazepine NN I-NP B-Chemical
22 177 180 20667451 are VBP B-VP O
23 181 185 20667451 well RB I-VP O
24 186 191 20667451 known VBN I-VP O
25 192 194 20667451 to TO B-VP O
26 195 200 20667451 cause VB I-VP O
27 201 210 20667451 cognitive JJ B-NP B-Disease
28 211 221 20667451 impairment NN I-NP I-Disease
29 222 224 20667451 on IN B-PP O
30 225 232 20667451 chronic JJ B-NP O
31 233 236 20667451 use NN I-NP O
32 236 237 20667451 . . O O

1 238 241 20667451 The DT B-NP O
2 242 250 20667451 increase NN I-NP O
3 251 253 20667451 in IN B-PP O
4 254 258 20667451 free JJ B-NP O
5 259 266 20667451 radical NN I-NP O
6 267 277 20667451 generation NN I-NP O
7 278 281 20667451 has VBZ B-VP O
8 282 286 20667451 been VBN I-VP O
9 287 297 20667451 implicated VBN I-VP O
10 298 300 20667451 as IN B-PP O
11 301 304 20667451 one CD B-NP O
12 305 307 20667451 of IN B-PP O
13 308 311 20667451 the DT B-NP O
14 312 321 20667451 important JJ I-NP O
15 322 332 20667451 mechanisms NNS I-NP O
16 333 335 20667451 of IN B-PP O
17 336 345 20667451 cognitive JJ B-NP B-Disease
18 346 356 20667451 impairment NN I-NP I-Disease
19 357 359 20667451 by IN B-PP O
20 360 373 20667451 antiepileptic JJ B-NP O
21 374 379 20667451 drugs NNS I-NP O
22 379 380 20667451 . . O O

1 381 389 20667451 Curcumin NN B-NP B-Chemical
2 390 393 20667451 has VBZ B-VP O
3 394 399 20667451 shown VBN I-VP O
4 400 411 20667451 antioxidant JJ B-ADJP O
5 411 412 20667451 , , O O
6 413 417 20667451 anti AFX O O
7 417 418 20667451 - HYPH O O
8 418 430 20667451 inflammatory JJ B-ADJP O
9 431 434 20667451 and CC O O
10 435 440 20667451 neuro AFX B-NP O
11 440 441 20667451 - HYPH I-NP O
12 441 451 20667451 protective JJ I-NP O
13 452 462 20667451 properties NNS I-NP O
14 462 463 20667451 . . O O

1 464 473 20667451 Therefore RB B-ADVP O
2 473 474 20667451 , , O O
3 475 478 20667451 the DT B-NP O
4 479 486 20667451 present JJ I-NP O
5 487 492 20667451 study NN I-NP O
6 493 496 20667451 was VBD B-VP O
7 497 504 20667451 carried VBN I-VP O
8 505 508 20667451 out RP B-PRT O
9 509 511 20667451 to TO B-VP O
10 512 523 20667451 investigate VB I-VP O
11 524 527 20667451 the DT B-NP O
12 528 534 20667451 effect NN I-NP O
13 535 537 20667451 of IN B-PP O
14 538 545 20667451 chronic JJ B-NP O
15 546 554 20667451 curcumin NN I-NP B-Chemical
16 555 569 20667451 administration NN I-NP O
17 570 572 20667451 on IN B-PP O
18 573 587 20667451 phenobarbitone NN B-NP B-Chemical
19 587 588 20667451 - HYPH B-NP O
20 589 592 20667451 and CC I-NP O
21 593 606 20667451 carbamazepine NN I-NP B-Chemical
22 606 607 20667451 - HYPH O O
23 607 614 20667451 induced VBN B-NP O
24 615 624 20667451 cognitive JJ I-NP B-Disease
25 625 635 20667451 impairment NN I-NP I-Disease
26 636 639 20667451 and CC O O
27 640 649 20667451 oxidative JJ B-NP O
28 650 656 20667451 stress NN I-NP O
29 657 659 20667451 in IN B-PP O
30 660 664 20667451 rats NNS B-NP O
31 664 665 20667451 . . O O

1 666 681 20667451 Pharmacokinetic JJ B-NP O
2 682 694 20667451 interactions NNS I-NP O
3 695 697 20667451 of IN B-PP O
4 698 706 20667451 curcumin NN B-NP B-Chemical
5 707 711 20667451 with IN B-PP O
6 712 726 20667451 phenobarbitone NN B-NP B-Chemical
7 727 730 20667451 and CC I-NP O
8 731 744 20667451 carbamazepine NN I-NP B-Chemical
9 745 749 20667451 were VBD B-VP O
10 750 754 20667451 also RB I-VP O
11 755 762 20667451 studied VBN I-VP O
12 762 763 20667451 . . O O

1 764 771 20667451 Vehicle NN B-NP O
2 771 772 20667451 / SYM I-NP O
3 772 777 20667451 drugs NNS I-NP O
4 778 782 20667451 were VBD B-VP O
5 783 795 20667451 administered VBN I-VP O
6 796 801 20667451 daily RB B-ADVP O
7 802 805 20667451 for IN B-PP O
8 806 812 20667451 21days NNS B-NP O
9 813 815 20667451 to TO B-PP O
10 816 820 20667451 male JJ B-NP O
11 821 827 20667451 Wistar NNP I-NP O
12 828 832 20667451 rats NNS I-NP O
13 832 833 20667451 . . O O

1 834 841 20667451 Passive JJ B-NP O
2 842 851 20667451 avoidance NN I-NP O
3 852 860 20667451 paradigm NN I-NP O
4 861 864 20667451 and CC O O
5 865 873 20667451 elevated VBN B-VP O
6 874 878 20667451 plus CC O O
7 879 883 20667451 maze NN B-NP O
8 884 888 20667451 test NN I-NP O
9 889 893 20667451 were VBD B-VP O
10 894 898 20667451 used VBN I-VP O
11 899 901 20667451 to TO B-VP O
12 902 908 20667451 assess VB I-VP O
13 909 918 20667451 cognitive JJ B-NP O
14 919 927 20667451 function NN I-NP O
15 927 928 20667451 . . O O

1 929 931 20667451 At IN B-PP O
2 932 935 20667451 the DT B-NP O
3 936 939 20667451 end NN I-NP O
4 940 942 20667451 of IN B-PP O
5 943 948 20667451 study NN B-NP O
6 949 955 20667451 period NN I-NP O
7 955 956 20667451 , , O O
8 957 962 20667451 serum NN B-NP O
9 963 977 20667451 phenobarbitone NN I-NP B-Chemical
10 978 981 20667451 and CC I-NP O
11 982 995 20667451 carbamazepine NN I-NP B-Chemical
12 995 996 20667451 , , O O
13 997 1002 20667451 whole JJ B-NP O
14 1003 1008 20667451 brain NN I-NP O
15 1009 1024 20667451 malondialdehyde NN I-NP B-Chemical
16 1025 1028 20667451 and CC O O
17 1029 1036 20667451 reduced VBN B-NP O
18 1037 1048 20667451 glutathione NN I-NP B-Chemical
19 1049 1055 20667451 levels NNS I-NP O
20 1056 1060 20667451 were VBD B-VP O
21 1061 1070 20667451 estimated VBN I-VP O
22 1070 1071 20667451 . . O O

1 1072 1075 20667451 The DT B-NP O
2 1076 1090 20667451 administration NN I-NP O
3 1091 1093 20667451 of IN B-PP O
4 1094 1108 20667451 phenobarbitone NN B-NP B-Chemical
5 1109 1112 20667451 and CC I-NP O
6 1113 1126 20667451 carbamazepine NN I-NP B-Chemical
7 1127 1130 20667451 for IN B-PP O
8 1131 1137 20667451 21days NNS B-NP O
9 1138 1144 20667451 caused VBD B-VP O
10 1145 1146 20667451 a DT B-NP O
11 1147 1158 20667451 significant JJ I-NP O
12 1159 1169 20667451 impairment NN I-NP B-Disease
13 1170 1172 20667451 of IN B-PP I-Disease
14 1173 1181 20667451 learning NN B-NP I-Disease
15 1182 1185 20667451 and CC I-NP I-Disease
16 1186 1192 20667451 memory NN I-NP I-Disease
17 1193 1195 20667451 as RB B-CONJP O
18 1196 1200 20667451 well RB I-CONJP O
19 1201 1203 20667451 as IN I-CONJP O
20 1204 1206 20667451 an DT B-NP O
21 1207 1216 20667451 increased VBN I-NP O
22 1217 1226 20667451 oxidative JJ I-NP O
23 1227 1233 20667451 stress NN I-NP O
24 1233 1234 20667451 . . O O

1 1235 1246 20667451 Concomitant JJ B-NP O
2 1247 1255 20667451 curcumin NN I-NP B-Chemical
3 1256 1270 20667451 administration NN I-NP O
4 1271 1280 20667451 prevented VBD B-VP O
5 1281 1284 20667451 the DT B-NP O
6 1285 1294 20667451 cognitive JJ I-NP B-Disease
7 1295 1305 20667451 impairment NN I-NP I-Disease
8 1306 1309 20667451 and CC O O
9 1310 1319 20667451 decreased VBD B-VP O
10 1320 1323 20667451 the DT B-NP O
11 1324 1333 20667451 increased VBN I-NP O
12 1334 1343 20667451 oxidative JJ I-NP O
13 1344 1350 20667451 stress NN I-NP O
14 1351 1358 20667451 induced VBN B-VP O
15 1359 1361 20667451 by IN B-PP O
16 1362 1367 20667451 these DT B-NP O
17 1368 1381 20667451 antiepileptic JJ I-NP O
18 1382 1387 20667451 drugs NNS I-NP O
19 1387 1388 20667451 . . O O

1 1389 1397 20667451 Curcumin NN B-NP B-Chemical
2 1398 1400 20667451 co AFX O O
3 1400 1401 20667451 - HYPH O O
4 1401 1415 20667451 administration NN B-NP O
5 1416 1419 20667451 did VBD B-VP O
6 1420 1423 20667451 not RB I-VP O
7 1424 1429 20667451 cause VB I-VP O
8 1430 1433 20667451 any DT B-NP O
9 1434 1445 20667451 significant JJ I-NP O
10 1446 1456 20667451 alteration NN I-NP O
11 1457 1459 20667451 in IN B-PP O
12 1460 1463 20667451 the DT B-NP O
13 1464 1469 20667451 serum NN I-NP O
14 1470 1484 20667451 concentrations NNS I-NP O
15 1485 1487 20667451 of IN B-PP O
16 1488 1492 20667451 both DT B-NP O
17 1493 1507 20667451 phenobarbitone NN I-NP B-Chemical
18 1508 1510 20667451 as RB B-CONJP O
19 1511 1515 20667451 well RB I-CONJP O
20 1516 1518 20667451 as IN I-CONJP O
21 1519 1532 20667451 carbamazepine NN B-NP B-Chemical
22 1532 1533 20667451 . . O O

1 1534 1539 20667451 These DT B-NP O
2 1540 1547 20667451 results NNS I-NP O
3 1548 1552 20667451 show VBP B-VP O
4 1553 1557 20667451 that IN B-SBAR O
5 1558 1566 20667451 curcumin NN B-NP B-Chemical
6 1567 1570 20667451 has VBZ B-VP O
7 1571 1581 20667451 beneficial JJ B-NP O
8 1582 1588 20667451 effect NN I-NP O
9 1589 1591 20667451 in IN B-PP O
10 1592 1602 20667451 mitigating VBG B-VP O
11 1603 1606 20667451 the DT B-NP O
12 1607 1620 20667451 deterioration NN I-NP B-Disease
13 1621 1623 20667451 of IN B-PP I-Disease
14 1624 1633 20667451 cognitive JJ B-NP I-Disease
15 1634 1643 20667451 functions NNS I-NP I-Disease
16 1644 1647 20667451 and CC O O
17 1648 1657 20667451 oxidative JJ B-NP O
18 1658 1664 20667451 damage NN I-NP O
19 1665 1667 20667451 in IN B-PP O
20 1668 1672 20667451 rats NNS B-NP O
21 1673 1680 20667451 treated VBN B-VP O
22 1681 1685 20667451 with IN B-PP O
23 1686 1700 20667451 phenobarbitone NN B-NP B-Chemical
24 1701 1704 20667451 and CC I-NP O
25 1705 1718 20667451 carbamazepine NN I-NP B-Chemical
26 1719 1726 20667451 without IN B-PP O
27 1727 1740 20667451 significantly RB B-VP O
28 1741 1749 20667451 altering VBG I-VP O
29 1750 1755 20667451 their PRP$ B-NP O
30 1756 1761 20667451 serum NN I-NP O
31 1762 1776 20667451 concentrations NNS I-NP O
32 1776 1777 20667451 . . O O

1 1778 1781 20667451 The DT B-NP O
2 1782 1790 20667451 findings NNS I-NP O
3 1791 1798 20667451 suggest VBP B-VP O
4 1799 1803 20667451 that IN B-SBAR O
5 1804 1812 20667451 curcumin NN B-NP B-Chemical
6 1813 1816 20667451 can MD B-VP O
7 1817 1819 20667451 be VB I-VP O
8 1820 1830 20667451 considered VBN I-VP O
9 1831 1833 20667451 as IN B-PP O
10 1834 1835 20667451 a DT B-NP O
11 1836 1845 20667451 potential JJ I-NP O
12 1846 1850 20667451 safe JJ I-NP O
13 1851 1854 20667451 and CC I-NP O
14 1855 1864 20667451 effective JJ I-NP O
15 1865 1873 20667451 adjuvant JJ I-NP O
16 1874 1876 20667451 to TO B-PP O
17 1877 1891 20667451 phenobarbitone NN B-NP B-Chemical
18 1892 1895 20667451 and CC I-NP O
19 1896 1909 20667451 carbamazepine NN I-NP B-Chemical
20 1910 1917 20667451 therapy NN I-NP O
21 1918 1920 20667451 in IN B-PP O
22 1921 1931 20667451 preventing VBG B-VP O
23 1932 1941 20667451 cognitive JJ B-NP B-Disease
24 1942 1952 20667451 impairment NN I-NP I-Disease
25 1953 1963 20667451 associated VBN B-VP O
26 1964 1968 20667451 with IN B-PP O
27 1969 1974 20667451 these DT B-NP O
28 1975 1980 20667451 drugs NNS I-NP O
29 1980 1981 20667451 . . O O

1 0 0 12584269 -DOCSTART- -X- -X- O

1 0 6 12584269 Kidney NN B-NP O
2 7 15 12584269 function NN I-NP O
3 16 19 12584269 and CC I-NP O
4 20 30 12584269 morphology NN I-NP O
5 31 36 12584269 after IN B-PP O
6 37 42 12584269 short JJ B-NP O
7 42 43 12584269 - HYPH I-NP O
8 43 47 12584269 term NN I-NP O
9 48 59 12584269 combination NN I-NP O
10 60 67 12584269 therapy NN I-NP O
11 68 72 12584269 with IN B-PP O
12 73 85 12584269 cyclosporine NN B-NP B-Chemical
13 86 87 12584269 A NN I-NP I-Chemical
14 87 88 12584269 , , O O
15 89 99 12584269 tacrolimus NN B-NP B-Chemical
16 100 103 12584269 and CC I-NP O
17 104 113 12584269 sirolimus NN I-NP B-Chemical
18 114 116 12584269 in IN B-PP O
19 117 120 12584269 the DT B-NP O
20 121 124 12584269 rat NN I-NP O
21 124 125 12584269 . . I-NP O
22 126 136 12584269 BACKGROUND NN I-NP O
23 136 137 12584269 : : O O
24 138 147 12584269 Sirolimus NN B-NP B-Chemical
25 148 149 12584269 ( ( O O
26 149 152 12584269 SRL NN B-NP B-Chemical
27 152 153 12584269 ) ) O O
28 154 157 12584269 may MD B-VP O
29 158 168 12584269 supplement VB I-VP O
30 169 180 12584269 calcineurin NN B-NP O
31 181 191 12584269 inhibitors NNS I-NP O
32 192 194 12584269 in IN B-PP O
33 195 203 12584269 clinical JJ B-NP O
34 204 209 12584269 organ NN I-NP O
35 210 225 12584269 transplantation NN I-NP O
36 225 226 12584269 . . O O

1 227 232 12584269 These DT B-NP O
2 233 236 12584269 are VBP B-VP O
3 237 248 12584269 nephrotoxic JJ B-ADJP B-Disease
4 248 249 12584269 , , O O
5 250 253 12584269 but CC O O
6 254 257 12584269 SRL NN B-NP B-Chemical
7 258 263 12584269 seems VBZ B-VP O
8 264 266 12584269 to TO I-VP O
9 267 270 12584269 act VB I-VP O
10 271 282 12584269 differently RB B-ADVP O
11 283 293 12584269 displaying VBG B-VP O
12 294 298 12584269 only RB B-NP O
13 299 304 12584269 minor JJ I-NP O
14 305 316 12584269 nephrotoxic JJ I-NP B-Disease
15 317 324 12584269 effects NNS I-NP O
16 324 325 12584269 , , O O
17 326 334 12584269 although IN B-SBAR O
18 335 339 12584269 this DT B-NP O
19 340 348 12584269 question NN I-NP O
20 349 351 12584269 is VBZ B-VP O
21 352 357 12584269 still RB B-ADVP O
22 358 362 12584269 open JJ B-ADJP O
23 362 363 12584269 . . O O

1 364 366 12584269 In IN B-PP O
2 367 368 12584269 a DT B-NP O
3 369 375 12584269 number NN I-NP O
4 376 378 12584269 of IN B-PP O
5 379 388 12584269 treatment NN B-NP O
6 389 398 12584269 protocols NNS I-NP O
7 399 404 12584269 where WRB B-ADVP O
8 405 408 12584269 SRL NN B-NP B-Chemical
9 409 412 12584269 was VBD B-VP O
10 413 421 12584269 combined VBN I-VP O
11 422 426 12584269 with IN B-PP O
12 427 428 12584269 a DT B-NP O
13 429 440 12584269 calcineurin NN I-NP O
14 441 450 12584269 inhibitor NN I-NP O
15 451 462 12584269 indications NNS I-NP O
16 463 465 12584269 of IN B-PP O
17 466 467 12584269 a DT B-NP O
18 468 479 12584269 synergistic JJ I-NP O
19 480 491 12584269 nephrotoxic JJ I-NP B-Disease
20 492 498 12584269 effect NN I-NP O
21 499 503 12584269 were VBD B-VP O
22 504 513 12584269 described VBN I-VP O
23 513 514 12584269 . . O O

1 515 518 12584269 The DT B-NP O
2 519 522 12584269 aim NN I-NP O
3 523 525 12584269 of IN B-PP O
4 526 530 12584269 this DT B-NP O
5 531 536 12584269 study NN I-NP O
6 537 540 12584269 was VBD B-VP O
7 541 543 12584269 to TO B-VP O
8 544 551 12584269 examine VB I-VP O
9 552 559 12584269 further RBR B-ADVP O
10 560 563 12584269 the DT B-NP O
11 564 569 12584269 renal JJ I-NP O
12 570 578 12584269 function NN I-NP O
13 578 579 12584269 , , O O
14 580 589 12584269 including VBG B-PP O
15 590 603 12584269 morphological JJ B-NP O
16 604 612 12584269 analysis NN I-NP O
17 613 615 12584269 of IN B-PP O
18 616 619 12584269 the DT B-NP O
19 620 627 12584269 kidneys NNS I-NP O
20 628 630 12584269 of IN B-PP O
21 631 635 12584269 male JJ B-NP O
22 636 643 12584269 Sprague NNP I-NP O
23 643 644 12584269 - HYPH I-NP O
24 644 650 12584269 Dawley NNP I-NP O
25 651 655 12584269 rats NNS I-NP O
26 656 663 12584269 treated VBN B-VP O
27 664 668 12584269 with IN B-PP O
28 669 675 12584269 either CC O O
29 676 688 12584269 cyclosporine NN B-NP B-Chemical
30 689 690 12584269 A NN I-NP I-Chemical
31 691 692 12584269 ( ( O O
32 692 695 12584269 CsA NN B-NP B-Chemical
33 695 696 12584269 ) ) O O
34 696 697 12584269 , , O O
35 698 708 12584269 tacrolimus NN B-NP B-Chemical
36 709 710 12584269 ( ( O O
37 710 715 12584269 FK506 NN B-NP B-Chemical
38 715 716 12584269 ) ) O O
39 717 719 12584269 or CC O O
40 720 723 12584269 SRL NN B-NP B-Chemical
41 724 726 12584269 as IN B-PP O
42 727 740 12584269 monotherapies NNS B-NP O
43 741 743 12584269 or CC B-PP O
44 744 746 12584269 in IN B-PP O
45 747 756 12584269 different JJ B-NP O
46 757 769 12584269 combinations NNS I-NP O
47 769 770 12584269 . . O O

1 771 778 12584269 METHODS NNS B-NP O
2 778 779 12584269 : : O O
3 780 783 12584269 For IN B-PP O
4 784 785 12584269 a DT B-NP O
5 786 792 12584269 period NN I-NP O
6 793 795 12584269 of IN B-PP O
7 796 797 12584269 2 CD B-NP O
8 798 803 12584269 weeks NNS I-NP O
9 803 804 12584269 , , O O
10 805 808 12584269 CsA NN B-NP B-Chemical
11 809 811 12584269 15 CD I-NP O
12 812 814 12584269 mg NN I-NP O
13 814 815 12584269 / SYM B-NP O
14 815 817 12584269 kg NN I-NP O
15 817 818 12584269 / SYM B-NP O
16 818 821 12584269 day NN I-NP O
17 822 823 12584269 ( ( O O
18 823 828 12584269 given VBN B-VP O
19 829 835 12584269 orally RB B-ADVP O
20 835 836 12584269 ) ) O O
21 836 837 12584269 , , O O
22 838 843 12584269 FK506 NN B-NP B-Chemical
23 844 847 12584269 3.0 CD I-NP O
24 848 850 12584269 mg NN I-NP O
25 850 851 12584269 / SYM B-NP O
26 851 853 12584269 kg NN I-NP O
27 853 854 12584269 / SYM B-NP O
28 854 857 12584269 day NN I-NP O
29 858 859 12584269 ( ( O O
30 859 864 12584269 given VBN B-VP O
31 865 871 12584269 orally RB B-ADVP O
32 871 872 12584269 ) ) O O
33 873 875 12584269 or CC O O
34 876 879 12584269 SRL NN B-NP B-Chemical
35 880 883 12584269 0.4 CD I-NP O
36 884 886 12584269 mg NN I-NP O
37 886 887 12584269 / SYM B-NP O
38 887 889 12584269 kg NN I-NP O
39 889 890 12584269 / SYM B-NP O
40 890 893 12584269 day NN I-NP O
41 894 895 12584269 ( ( O O
42 895 900 12584269 given VBN B-VP O
43 901 918 12584269 intraperitoneally RB B-ADVP O
44 918 919 12584269 ) ) O O
45 920 923 12584269 was VBD B-VP O
46 924 936 12584269 administered VBN I-VP O
47 937 941 12584269 once RB B-ADVP O
48 942 943 12584269 a DT B-NP O
49 944 947 12584269 day NN I-NP O
50 948 950 12584269 as IN B-PP O
51 951 956 12584269 these DT B-NP O
52 957 962 12584269 doses NNS I-NP O
53 963 967 12584269 have VBP B-VP O
54 968 975 12584269 earlier RBR I-VP O
55 976 980 12584269 been VBN I-VP O
56 981 986 12584269 found VBN I-VP O
57 987 989 12584269 to TO I-VP O
58 990 997 12584269 achieve VB I-VP O
59 998 999 12584269 a DT B-NP O
60 1000 1011 12584269 significant JJ I-NP O
61 1012 1029 12584269 immunosuppressive JJ I-NP O
62 1030 1036 12584269 effect NN I-NP O
63 1037 1039 12584269 in IN B-PP O
64 1040 1047 12584269 Sprague NNP B-NP O
65 1047 1048 12584269 - HYPH I-NP O
66 1048 1054 12584269 Dawley NNP I-NP O
67 1055 1059 12584269 rats NNS I-NP O
68 1059 1060 12584269 . . O O

1 1061 1063 12584269 In IN B-PP O
2 1064 1067 12584269 the DT B-NP O
3 1068 1069 12584269 ' `` I-NP O
4 1069 1078 12584269 conscious JJ I-NP O
5 1079 1091 12584269 catheterized VBN I-NP O
6 1092 1095 12584269 rat NN I-NP O
7 1095 1096 12584269 ' '' I-NP O
8 1097 1102 12584269 model NN I-NP O
9 1102 1103 12584269 , , O O
10 1104 1107 12584269 the DT B-NP O
11 1108 1118 12584269 glomerular JJ I-NP O
12 1119 1129 12584269 filtration NN I-NP O
13 1130 1134 12584269 rate NN I-NP O
14 1135 1136 12584269 ( ( O O
15 1136 1139 12584269 GFR NN B-NP O
16 1139 1140 12584269 ) ) O O
17 1141 1144 12584269 was VBD B-VP O
18 1145 1153 12584269 measured VBN I-VP O
19 1154 1156 12584269 as IN B-PP O
20 1157 1160 12584269 the DT B-NP O
21 1161 1170 12584269 clearance NN I-NP O
22 1171 1173 12584269 of IN B-PP O
23 1174 1182 12584269 Cr(EDTA) NN B-NP O
24 1182 1183 12584269 . . O O

1 1184 1187 12584269 The DT B-NP O
2 1188 1201 12584269 morphological JJ I-NP O
3 1202 1210 12584269 analysis NN I-NP O
4 1211 1213 12584269 of IN B-PP O
5 1214 1217 12584269 the DT B-NP O
6 1218 1225 12584269 kidneys NNS I-NP O
7 1226 1234 12584269 included VBD B-VP O
8 1235 1236 12584269 a DT B-NP O
9 1237 1241 12584269 semi AFX I-NP O
10 1241 1242 12584269 - HYPH I-NP O
11 1242 1254 12584269 quantitative JJ I-NP O
12 1255 1262 12584269 scoring NN I-NP O
13 1263 1269 12584269 system NN I-NP O
14 1270 1279 12584269 analysing VBG B-VP O
15 1280 1283 12584269 the DT B-NP O
16 1284 1290 12584269 degree NN I-NP O
17 1291 1293 12584269 of IN B-PP O
18 1294 1301 12584269 striped VBN B-NP O
19 1302 1310 12584269 fibrosis NN I-NP B-Disease
20 1310 1311 12584269 , , O O
21 1312 1323 12584269 subcapsular JJ B-NP O
22 1324 1332 12584269 fibrosis NN I-NP B-Disease
23 1333 1336 12584269 and CC O O
24 1337 1340 12584269 the DT B-NP O
25 1341 1347 12584269 number NN I-NP O
26 1348 1350 12584269 of IN B-PP O
27 1351 1361 12584269 basophilic JJ B-NP O
28 1362 1369 12584269 tubules NNS I-NP O
29 1369 1370 12584269 , , O O
30 1371 1375 12584269 plus CC B-PP O
31 1376 1378 12584269 an DT B-NP O
32 1379 1389 12584269 additional JJ I-NP O
33 1390 1403 12584269 stereological JJ I-NP O
34 1404 1412 12584269 analysis NN I-NP O
35 1413 1415 12584269 of IN B-PP O
36 1416 1419 12584269 the DT B-NP O
37 1420 1425 12584269 total JJ I-NP O
38 1426 1431 12584269 grade NN I-NP O
39 1432 1434 12584269 of IN B-PP O
40 1435 1443 12584269 fibrosis NN B-NP B-Disease
41 1444 1446 12584269 in IN B-PP O
42 1447 1450 12584269 the DT B-NP O
43 1451 1457 12584269 cortex NN I-NP O
44 1458 1465 12584269 stained VBD B-VP O
45 1466 1470 12584269 with IN B-PP O
46 1471 1477 12584269 Sirius NNP B-NP O
47 1478 1481 12584269 Red NNP I-NP O
48 1481 1482 12584269 . . O O

1 1483 1490 12584269 RESULTS NNS B-NP O
2 1490 1491 12584269 : : O O
3 1492 1495 12584269 CsA NN B-NP B-Chemical
4 1495 1496 12584269 , , I-NP O
5 1497 1502 12584269 FK506 NN I-NP B-Chemical
6 1503 1506 12584269 and CC I-NP O
7 1507 1510 12584269 SRL NN I-NP B-Chemical
8 1511 1514 12584269 all RB B-ADVP O
9 1515 1528 12584269 significantly RB I-ADVP O
10 1529 1538 12584269 decreased VBD B-VP O
11 1539 1542 12584269 the DT B-NP O
12 1543 1546 12584269 GFR NN I-NP O
13 1546 1547 12584269 . . O O

1 1548 1549 12584269 A DT B-NP O
2 1550 1557 12584269 further JJ I-NP O
3 1558 1571 12584269 deterioration NN I-NP O
4 1572 1575 12584269 was VBD B-VP O
5 1576 1580 12584269 seen VBN I-VP O
6 1581 1585 12584269 when WRB B-ADVP O
7 1586 1589 12584269 CsA NN B-NP B-Chemical
8 1590 1593 12584269 was VBD B-VP O
9 1594 1602 12584269 combined VBN I-VP O
10 1603 1607 12584269 with IN B-PP O
11 1608 1614 12584269 either CC O O
12 1615 1620 12584269 FK506 NN B-NP B-Chemical
13 1621 1623 12584269 or CC O O
14 1624 1627 12584269 SRL NN B-NP B-Chemical
15 1627 1628 12584269 , , O O
16 1629 1636 12584269 whereas IN O O
17 1637 1640 12584269 the DT B-NP O
18 1641 1644 12584269 GFR NN I-NP O
19 1645 1653 12584269 remained VBD B-VP O
20 1654 1663 12584269 unchanged JJ B-ADJP O
21 1664 1666 12584269 in IN B-PP O
22 1667 1670 12584269 the DT B-NP O
23 1671 1676 12584269 group NN I-NP O
24 1677 1684 12584269 treated VBN B-VP O
25 1685 1689 12584269 with IN B-PP O
26 1690 1695 12584269 FK506 NN B-NP B-Chemical
27 1696 1700 12584269 plus CC O O
28 1701 1704 12584269 SRL NN B-NP B-Chemical
29 1705 1709 12584269 when WRB B-ADVP O
30 1710 1718 12584269 compared VBN B-PP O
31 1719 1723 12584269 with IN B-PP O
32 1724 1733 12584269 treatment NN B-NP O
33 1734 1738 12584269 with IN B-PP O
34 1739 1742 12584269 any DT B-NP O
35 1743 1745 12584269 of IN B-PP O
36 1746 1749 12584269 the DT B-NP O
37 1750 1756 12584269 single JJ I-NP O
38 1757 1767 12584269 substances NNS I-NP O
39 1767 1768 12584269 . . O O

1 1769 1772 12584269 The DT B-NP O
2 1773 1786 12584269 morphological JJ I-NP O
3 1787 1794 12584269 changes NNS I-NP O
4 1795 1804 12584269 presented VBD B-VP O
5 1805 1806 12584269 a DT B-NP O
6 1807 1814 12584269 similar JJ I-NP O
7 1815 1822 12584269 pattern NN I-NP O
8 1822 1823 12584269 . . O O

1 1824 1827 12584269 The DT B-NP O
2 1828 1832 12584269 semi AFX I-NP O
3 1832 1833 12584269 - HYPH I-NP O
4 1833 1845 12584269 quantitative JJ I-NP O
5 1846 1853 12584269 scoring NN I-NP O
6 1854 1857 12584269 was VBD B-VP O
7 1858 1871 12584269 significantly RB B-ADJP O
8 1872 1877 12584269 worst JJS I-ADJP O
9 1878 1880 12584269 in IN B-PP O
10 1881 1884 12584269 the DT B-NP O
11 1885 1890 12584269 group NN I-NP O
12 1891 1898 12584269 treated VBN B-VP O
13 1899 1903 12584269 with IN B-PP O
14 1904 1907 12584269 CsA NN B-NP B-Chemical
15 1908 1912 12584269 plus CC O O
16 1913 1916 12584269 SRL NN B-NP B-Chemical
17 1917 1918 12584269 ( ( O O
18 1918 1919 12584269 P NN B-NP O
19 1919 1920 12584269 < SYM O O
20 1920 1925 12584269 0.001 CD B-NP O
21 1926 1934 12584269 compared VBN B-PP O
22 1935 1939 12584269 with IN B-PP O
23 1940 1948 12584269 controls NNS B-NP O
24 1948 1949 12584269 ) ) O O
25 1950 1953 12584269 and CC O O
26 1954 1957 12584269 the DT B-NP O
27 1958 1966 12584269 analysis NN I-NP O
28 1967 1969 12584269 of IN B-PP O
29 1970 1973 12584269 the DT B-NP O
30 1974 1979 12584269 total JJ I-NP O
31 1980 1985 12584269 grade NN I-NP O
32 1986 1988 12584269 of IN B-PP O
33 1989 1997 12584269 fibrosis NN B-NP B-Disease
34 1998 2002 12584269 also RB B-ADVP O
35 2003 2009 12584269 showed VBD B-VP O
36 2010 2013 12584269 the DT B-NP O
37 2014 2021 12584269 highest JJS I-NP O
38 2022 2032 12584269 proportion NN I-NP O
39 2033 2035 12584269 in IN B-PP O
40 2036 2039 12584269 the DT B-NP O
41 2040 2044 12584269 same JJ I-NP O
42 2045 2050 12584269 group NN I-NP O
43 2051 2054 12584269 and CC O O
44 2055 2058 12584269 was VBD B-VP O
45 2059 2072 12584269 significantly RB B-ADJP O
46 2073 2082 12584269 different JJ I-ADJP O
47 2083 2087 12584269 from IN B-PP O
48 2088 2096 12584269 controls NNS B-NP O
49 2097 2098 12584269 ( ( O O
50 2098 2099 12584269 P NN B-NP O
51 2099 2100 12584269 < JJR B-NP O
52 2100 2104 12584269 0.02 CD I-NP O
53 2104 2105 12584269 ) ) O O
54 2105 2106 12584269 . . O O

1 2107 2110 12584269 The DT B-NP O
2 2111 2116 12584269 FK506 NN I-NP B-Chemical
3 2117 2121 12584269 plus CC I-NP O
4 2122 2125 12584269 SRL NN I-NP B-Chemical
5 2126 2137 12584269 combination NN I-NP O
6 2138 2144 12584269 showed VBD B-VP O
7 2145 2149 12584269 only RB B-NP O
8 2150 2151 12584269 a DT I-NP O
9 2152 2162 12584269 marginally RB I-NP O
10 2163 2169 12584269 higher JJR I-NP O
11 2170 2176 12584269 degree NN I-NP O
12 2177 2179 12584269 of IN B-PP O
13 2180 2188 12584269 fibrosis NN B-NP B-Disease
14 2189 2191 12584269 as IN B-PP O
15 2192 2200 12584269 compared VBN B-PP O
16 2201 2205 12584269 with IN B-PP O
17 2206 2214 12584269 controls NNS B-NP O
18 2215 2216 12584269 ( ( O O
19 2216 2217 12584269 P NN B-NP O
20 2217 2218 12584269 = SYM B-VP O
21 2218 2222 12584269 0.05 CD B-NP O
22 2222 2223 12584269 ) ) O O
23 2223 2224 12584269 . . O O

1 2225 2235 12584269 CONCLUSION NN B-NP O
2 2235 2236 12584269 : : O O
3 2237 2241 12584269 This DT B-NP O
4 2242 2245 12584269 rat NN I-NP O
5 2246 2251 12584269 study NN I-NP O
6 2252 2264 12584269 demonstrated VBD B-VP O
7 2265 2266 12584269 a DT B-NP O
8 2267 2278 12584269 synergistic JJ I-NP O
9 2279 2290 12584269 nephrotoxic JJ I-NP B-Disease
10 2291 2297 12584269 effect NN I-NP O
11 2298 2300 12584269 of IN B-PP O
12 2301 2304 12584269 CsA NN B-NP B-Chemical
13 2305 2309 12584269 plus CC I-NP O
14 2310 2313 12584269 SRL NN B-NP B-Chemical
15 2313 2314 12584269 , , O O
16 2315 2322 12584269 whereas IN O O
17 2323 2328 12584269 FK506 NN B-NP B-Chemical
18 2329 2333 12584269 plus CC O O
19 2334 2337 12584269 SRL NN B-NP B-Chemical
20 2338 2341 12584269 was VBD B-VP O
21 2342 2348 12584269 better RBR B-ADJP O
22 2349 2358 12584269 tolerated VBN I-ADJP O
23 2358 2359 12584269 . . O O

1 0 0 3358181 -DOCSTART- -X- -X- O

1 0 11 3358181 Ventricular JJ B-NP B-Disease
2 12 28 3358181 tachyarrhythmias NNS I-NP I-Disease
3 29 35 3358181 during IN B-PP O
4 36 44 3358181 cesarean JJ B-NP O
5 45 52 3358181 section NN I-NP O
6 53 58 3358181 after IN B-PP O
7 59 68 3358181 ritodrine NN B-NP B-Chemical
8 69 76 3358181 therapy NN I-NP O
9 76 77 3358181 : : O O
10 78 89 3358181 interaction NN B-NP O
11 90 94 3358181 with IN B-PP O
12 95 106 3358181 anesthetics NNS B-NP O
13 106 107 3358181 . . O O
14 108 112 3358181 This DT B-NP O
15 113 117 3358181 case NN I-NP O
16 118 129 3358181 illustrates VBZ B-VP O
17 130 134 3358181 that IN B-SBAR O
18 135 143 3358181 patients NNS B-NP O
19 144 153 3358181 receiving VBG B-VP O
20 154 163 3358181 ritodrine NN B-NP B-Chemical
21 164 167 3358181 for IN B-PP O
22 168 175 3358181 preterm JJ B-NP B-Disease
23 176 181 3358181 labor NN I-NP I-Disease
24 182 185 3358181 may MD B-VP O
25 186 190 3358181 risk VB I-VP O
26 191 203 3358181 interactions NNS B-NP O
27 204 211 3358181 between IN B-PP O
28 212 215 3358181 the DT B-NP O
29 216 224 3358181 residual JJ I-NP O
30 225 236 3358181 betamimetic JJ I-NP O
31 237 244 3358181 effects NNS I-NP O
32 245 247 3358181 of IN B-PP O
33 248 257 3358181 ritodrine NN B-NP B-Chemical
34 258 261 3358181 and CC O O
35 262 265 3358181 the DT B-NP O
36 266 273 3358181 effects NNS I-NP O
37 274 276 3358181 of IN B-PP O
38 277 288 3358181 anesthetics NNS B-NP O
39 289 295 3358181 during IN B-PP O
40 296 304 3358181 cesarean JJ B-NP O
41 305 312 3358181 section NN I-NP O
42 312 313 3358181 . . O O

1 314 318 3358181 Such JJ B-NP O
2 319 331 3358181 interactions NNS I-NP O
3 332 335 3358181 may MD B-VP O
4 336 342 3358181 result VB I-VP O
5 343 345 3358181 in IN B-PP O
6 346 353 3358181 serious JJ B-NP O
7 354 368 3358181 cardiovascular JJ I-NP B-Disease
8 369 382 3358181 complications NNS I-NP I-Disease
9 383 387 3358181 even RB B-ADVP O
10 388 393 3358181 after IN B-PP O
11 394 403 3358181 cessation NN B-NP O
12 404 406 3358181 of IN B-PP O
13 407 409 3358181 an DT B-NP O
14 410 418 3358181 infusion NN I-NP O
15 419 421 3358181 of IN B-PP O
16 422 431 3358181 ritodrine NN B-NP B-Chemical
17 431 432 3358181 . . O O

1 433 445 3358181 Preoperative JJ B-NP O
2 446 456 3358181 assessment NN I-NP O
3 457 463 3358181 should MD B-VP O
4 464 469 3358181 focus VB I-VP O
5 470 472 3358181 on IN B-PP O
6 473 487 3358181 cardiovascular JJ B-NP O
7 488 494 3358181 status NN I-NP O
8 495 498 3358181 and CC O O
9 499 504 3358181 serum NN B-NP O
10 505 514 3358181 potassium NN I-NP B-Chemical
11 515 520 3358181 level NN I-NP O
12 520 521 3358181 . . O O

1 522 530 3358181 Delaying VBG B-VP O
2 531 540 3358181 induction NN B-NP O
3 541 543 3358181 of IN B-PP O
4 544 554 3358181 anesthesia NN B-NP O
5 555 561 3358181 should MD B-VP O
6 562 564 3358181 be VB I-VP O
7 565 575 3358181 considered VBN I-VP O
8 576 584 3358181 whenever WRB B-ADJP O
9 585 593 3358181 possible JJ I-ADJP O
10 593 594 3358181 . . O O

1 595 602 3358181 Careful JJ B-NP O
2 603 608 3358181 fluid NN I-NP O
3 609 623 3358181 administration NN I-NP O
4 624 627 3358181 and CC O O
5 628 636 3358181 cautious JJ B-NP O
6 637 640 3358181 use NN I-NP O
7 641 643 3358181 of IN B-PP O
8 644 652 3358181 titrated VBN B-NP O
9 653 658 3358181 doses NNS I-NP O
10 659 661 3358181 of IN B-PP O
11 662 671 3358181 ephedrine NN B-NP B-Chemical
12 672 675 3358181 are VBP B-VP O
13 676 683 3358181 advised VBN I-VP O
14 683 684 3358181 . . O O

1 685 690 3358181 After IN B-PP O
2 691 699 3358181 delivery NN B-NP O
3 700 702 3358181 of IN B-PP O
4 703 706 3358181 the DT B-NP O
5 707 713 3358181 infant NN I-NP O
6 713 714 3358181 , , O O
7 715 720 3358181 there EX B-NP O
8 721 727 3358181 should MD B-VP O
9 728 730 3358181 be VB I-VP O
10 731 733 3358181 no DT B-NP O
11 734 750 3358181 contraindication NN I-NP O
12 751 753 3358181 to TO B-PP O
13 754 757 3358181 the DT B-NP O
14 758 761 3358181 use NN I-NP O
15 762 764 3358181 of IN B-PP O
16 765 767 3358181 an DT B-NP O
17 768 773 3358181 alpha SYM I-NP O
18 773 774 3358181 - HYPH I-NP O
19 774 784 3358181 adrenergic JJ I-NP O
20 785 796 3358181 vasopressor NN I-NP O
21 797 801 3358181 such JJ B-PP O
22 802 804 3358181 as IN I-PP O
23 805 818 3358181 phenylephrine NN B-NP B-Chemical
24 819 821 3358181 to TO B-VP O
25 822 827 3358181 treat VB I-VP O
26 828 839 3358181 hypotensive JJ B-NP B-Disease
27 840 848 3358181 patients NNS I-NP O
28 849 853 3358181 with IN B-PP O
29 854 865 3358181 tachycardia NN B-NP B-Disease
30 865 866 3358181 . . O O

1 0 0 15957009 -DOCSTART- -X- -X- O

1 0 3 15957009 The DT B-NP O
2 4 13 15957009 selective JJ I-NP O
3 14 15 15957009 5 CD I-NP O
4 15 16 15957009 - HYPH I-NP O
5 16 19 15957009 HT6 NN I-NP O
6 20 28 15957009 receptor NN I-NP O
7 29 39 15957009 antagonist NN I-NP O
8 40 49 15957009 Ro4368554 NN I-NP B-Chemical
9 50 58 15957009 restores VBZ B-VP O
10 59 65 15957009 memory NN B-NP O
11 66 77 15957009 performance NN I-NP O
12 78 80 15957009 in IN B-PP O
13 81 92 15957009 cholinergic JJ B-NP O
14 93 96 15957009 and CC I-NP O
15 97 109 15957009 serotonergic JJ I-NP O
16 110 116 15957009 models NNS I-NP O
17 117 119 15957009 of IN B-PP O
18 120 126 15957009 memory NN B-NP B-Disease
19 127 137 15957009 deficiency NN I-NP I-Disease
20 138 140 15957009 in IN B-PP O
21 141 144 15957009 the DT B-NP O
22 145 148 15957009 rat NN I-NP O
23 148 149 15957009 . . O O
24 150 161 15957009 Antagonists NNS B-NP O
25 162 164 15957009 at IN B-PP O
26 165 174 15957009 serotonin NN B-NP B-Chemical
27 175 179 15957009 type NN I-NP O
28 180 181 15957009 6 CD I-NP O
29 182 183 15957009 ( ( O O
30 183 184 15957009 5 CD B-NP B-Chemical
31 184 185 15957009 - HYPH I-NP I-Chemical
32 185 190 15957009 HT(6) NN I-NP I-Chemical
33 190 191 15957009 ) ) O O
34 192 201 15957009 receptors NNS B-NP O
35 202 206 15957009 show VBP B-VP O
36 207 215 15957009 activity NN B-NP O
37 216 218 15957009 in IN B-PP O
38 219 225 15957009 models NNS B-NP O
39 226 228 15957009 of IN B-PP O
40 229 237 15957009 learning NN B-NP O
41 238 241 15957009 and CC I-NP O
42 242 248 15957009 memory NN I-NP O
43 248 249 15957009 . . O O

1 250 258 15957009 Although IN B-SBAR O
2 259 262 15957009 the DT B-NP O
3 263 273 15957009 underlying VBG I-NP O
4 274 283 15957009 mechanism NN I-NP O
5 283 284 15957009 ( ( I-NP O
6 284 285 15957009 s NNS I-NP O
7 285 286 15957009 ) ) O O
8 287 290 15957009 are VBP B-VP O
9 291 294 15957009 not RB I-VP O
10 295 299 15957009 well RB I-VP O
11 300 310 15957009 understood VBN I-VP O
12 310 311 15957009 , , O O
13 312 317 15957009 these DT B-NP O
14 318 325 15957009 effects NNS I-NP O
15 326 329 15957009 may MD B-VP O
16 330 337 15957009 involve VB I-VP O
17 338 340 15957009 an DT B-NP O
18 341 349 15957009 increase NN I-NP O
19 350 352 15957009 in IN B-PP O
20 353 366 15957009 acetylcholine NN B-NP B-Chemical
21 367 368 15957009 ( ( O O
22 368 371 15957009 ACh NN B-NP B-Chemical
23 371 372 15957009 ) ) O O
24 373 379 15957009 levels NNS B-NP O
25 379 380 15957009 . . O O

1 381 384 15957009 The DT B-NP O
2 385 392 15957009 present JJ I-NP O
3 393 398 15957009 study NN I-NP O
4 399 405 15957009 sought VBD B-VP O
5 406 408 15957009 to TO I-VP O
6 409 421 15957009 characterize VB I-VP O
7 422 425 15957009 the DT B-NP O
8 426 435 15957009 cognitive JJ I-NP O
9 435 436 15957009 - HYPH I-NP O
10 436 445 15957009 enhancing VBG I-NP O
11 446 453 15957009 effects NNS I-NP O
12 454 456 15957009 of IN B-PP O
13 457 460 15957009 the DT B-NP O
14 461 462 15957009 5 CD I-NP B-Chemical
15 462 463 15957009 - HYPH I-NP I-Chemical
16 463 468 15957009 HT(6) NN I-NP I-Chemical
17 469 479 15957009 antagonist NN I-NP O
18 480 489 15957009 Ro4368554 NN I-NP B-Chemical
19 490 491 15957009 ( ( O O
20 491 492 15957009 3 CD B-NP B-Chemical
21 492 493 15957009 - HYPH I-NP I-Chemical
22 493 508 15957009 benzenesulfonyl NN I-NP I-Chemical
23 508 509 15957009 - HYPH B-NP I-Chemical
24 509 510 15957009 7 CD I-NP I-Chemical
25 510 511 15957009 - HYPH I-NP I-Chemical
26 511 513 15957009 (4 CD I-NP I-Chemical
27 513 514 15957009 - HYPH I-NP I-Chemical
28 514 520 15957009 methyl NN I-NP I-Chemical
29 520 521 15957009 - HYPH B-NP I-Chemical
30 521 530 15957009 piperazin NN I-NP I-Chemical
31 530 531 15957009 - HYPH B-NP I-Chemical
32 531 532 15957009 1 CD I-NP I-Chemical
33 532 533 15957009 - HYPH I-NP I-Chemical
34 533 538 15957009 yl)1H NN I-NP I-Chemical
35 538 539 15957009 - HYPH I-NP I-Chemical
36 539 545 15957009 indole NN I-NP I-Chemical
37 545 546 15957009 ) ) O O
38 547 549 15957009 in IN B-PP O
39 550 551 15957009 a DT B-NP O
40 552 555 15957009 rat NN I-NP O
41 556 562 15957009 object NN I-NP O
42 563 574 15957009 recognition NN I-NP O
43 575 579 15957009 task NN I-NP O
44 580 589 15957009 employing VBG B-VP O
45 590 591 15957009 a DT B-NP O
46 592 603 15957009 cholinergic JJ I-NP O
47 604 605 15957009 ( ( O O
48 605 616 15957009 scopolamine NN B-NP B-Chemical
49 617 629 15957009 pretreatment NN I-NP O
50 629 630 15957009 ) ) O O
51 631 634 15957009 and CC O O
52 635 636 15957009 a DT B-NP O
53 637 649 15957009 serotonergic JJ I-NP O
54 649 650 15957009 - HYPH I-NP O
55 651 652 15957009 ( ( O O
56 652 662 15957009 tryptophan NN B-NP B-Chemical
57 663 664 15957009 ( ( O O
58 664 667 15957009 TRP NN B-NP B-Chemical
59 667 668 15957009 ) ) O O
60 669 678 15957009 depletion NN B-NP O
61 678 679 15957009 ) ) O O
62 680 689 15957009 deficient JJ B-NP O
63 690 695 15957009 model NN I-NP O
64 695 696 15957009 , , O O
65 697 700 15957009 and CC O O
66 701 709 15957009 compared VBD B-VP O
67 710 713 15957009 its PRP$ B-NP O
68 714 721 15957009 pattern NN I-NP O
69 722 724 15957009 of IN B-PP O
70 725 731 15957009 action NN B-NP O
71 732 736 15957009 with IN B-PP O
72 737 741 15957009 that DT B-NP O
73 742 744 15957009 of IN B-PP O
74 745 748 15957009 the DT B-NP O
75 749 769 15957009 acetylcholinesterase NN I-NP O
76 770 779 15957009 inhibitor NN I-NP O
77 780 791 15957009 metrifonate NN I-NP B-Chemical
78 791 792 15957009 . . O O

1 793 800 15957009 Initial JJ B-NP O
2 801 808 15957009 testing NN I-NP O
3 809 811 15957009 in IN B-PP O
4 812 813 15957009 a DT B-NP O
5 814 818 15957009 time NN I-NP O
6 818 819 15957009 - HYPH B-NP O
7 819 828 15957009 dependent JJ I-NP O
8 829 839 15957009 forgetting VBG I-NP O
9 840 844 15957009 task NN I-NP O
10 845 854 15957009 employing VBG B-VP O
11 855 856 15957009 a DT B-NP O
12 857 859 15957009 24 CD I-NP O
13 859 860 15957009 - HYPH I-NP O
14 860 861 15957009 h NN I-NP O
15 862 867 15957009 delay NN I-NP O
16 868 875 15957009 between IN B-PP O
17 876 884 15957009 training NN B-NP O
18 885 888 15957009 and CC I-NP O
19 889 896 15957009 testing NN I-NP O
20 897 903 15957009 showed VBD B-VP O
21 904 908 15957009 that IN B-SBAR O
22 909 920 15957009 metrifonate NN B-NP B-Chemical
23 921 929 15957009 improved VBD B-VP O
24 930 936 15957009 object NN B-NP O
25 937 948 15957009 recognition NN I-NP O
26 949 950 15957009 ( ( O O
27 950 952 15957009 at IN B-PP O
28 953 955 15957009 10 CD B-NP O
29 956 959 15957009 and CC I-NP O
30 960 962 15957009 30 CD I-NP O
31 963 965 15957009 mg NN I-NP O
32 965 966 15957009 / SYM B-NP O
33 966 968 15957009 kg NN I-NP O
34 968 969 15957009 , , O O
35 970 973 15957009 p.o FW B-NP O
36 973 974 15957009 . . O O
37 974 975 15957009 ) ) O O
38 975 976 15957009 , , O O
39 977 984 15957009 whereas IN O O
40 985 994 15957009 Ro4368554 NN B-NP B-Chemical
41 995 998 15957009 was VBD B-VP O
42 999 1007 15957009 inactive JJ B-ADJP O
43 1007 1008 15957009 . . O O

1 1009 1013 15957009 Both CC O O
2 1013 1014 15957009 , , O O
3 1015 1024 15957009 Ro4368554 NN B-NP B-Chemical
4 1025 1026 15957009 ( ( O O
5 1026 1027 15957009 3 CD B-NP O
6 1028 1031 15957009 and CC I-NP O
7 1032 1034 15957009 10 CD I-NP O
8 1035 1037 15957009 mg NN I-NP O
9 1037 1038 15957009 / SYM I-NP O
10 1038 1040 15957009 kg NN I-NP O
11 1040 1041 15957009 , , O O
12 1042 1059 15957009 intraperitoneally RB B-ADVP O
13 1060 1061 15957009 ( ( O O
14 1061 1064 15957009 i.p JJ O O
15 1064 1065 15957009 . . O O
16 1065 1066 15957009 ) ) O O
17 1066 1067 15957009 ) ) O O
18 1068 1071 15957009 and CC O O
19 1072 1083 15957009 metrifonate NN B-NP B-Chemical
20 1084 1085 15957009 ( ( O O
21 1085 1087 15957009 10 CD B-NP O
22 1088 1090 15957009 mg NN I-NP O
23 1090 1091 15957009 / SYM O O
24 1091 1093 15957009 kg NN B-NP O
25 1093 1094 15957009 , , O O
26 1095 1098 15957009 p.o NN B-NP O
27 1098 1099 15957009 . NN I-NP O
28 1099 1100 15957009 , , O O
29 1101 1113 15957009 respectively RB B-ADVP O
30 1113 1114 15957009 ) ) O O
31 1115 1123 15957009 reversed VBD B-VP O
32 1124 1130 15957009 memory NN B-NP B-Disease
33 1131 1139 15957009 deficits NNS I-NP I-Disease
34 1140 1147 15957009 induced VBN B-VP O
35 1148 1150 15957009 by IN B-PP O
36 1151 1162 15957009 scopolamine NN B-NP B-Chemical
37 1163 1166 15957009 and CC O O
38 1167 1170 15957009 TRP NN B-NP B-Chemical
39 1171 1180 15957009 depletion NN I-NP O
40 1181 1182 15957009 ( ( O O
41 1182 1184 15957009 10 CD B-NP O
42 1185 1187 15957009 mg NN I-NP O
43 1187 1188 15957009 / SYM B-NP O
44 1188 1190 15957009 kg NN I-NP O
45 1190 1191 15957009 , , O O
46 1192 1195 15957009 i.p JJ B-NP O
47 1195 1196 15957009 . NN I-NP O
48 1196 1197 15957009 , , O O
49 1198 1201 15957009 and CC O O
50 1202 1203 15957009 3 CD B-NP O
51 1204 1206 15957009 mg NN I-NP O
52 1206 1207 15957009 / SYM O O
53 1207 1209 15957009 kg NN B-NP O
54 1209 1210 15957009 , , O O
55 1211 1214 15957009 p.o NN B-NP O
56 1214 1215 15957009 . NN I-NP O
57 1215 1216 15957009 , , O O
58 1217 1229 15957009 respectively RB B-ADVP O
59 1229 1230 15957009 ) ) O O
60 1230 1231 15957009 . . O O

1 1232 1234 15957009 In IN B-PP O
2 1235 1245 15957009 conclusion NN B-NP O
3 1245 1246 15957009 , , O O
4 1247 1255 15957009 although IN B-SBAR O
5 1256 1265 15957009 Ro4368554 NN B-NP B-Chemical
6 1266 1269 15957009 did VBD B-VP O
7 1270 1273 15957009 not RB I-VP O
8 1274 1281 15957009 improve VB I-VP O
9 1282 1283 15957009 a DT B-NP O
10 1284 1288 15957009 time NN I-NP O
11 1288 1289 15957009 - HYPH B-NP O
12 1289 1296 15957009 related VBN I-NP O
13 1297 1306 15957009 retention NN I-NP O
14 1307 1314 15957009 deficit NN I-NP O
15 1314 1315 15957009 , , O O
16 1316 1318 15957009 it PRP B-NP O
17 1319 1327 15957009 reversed VBD B-VP O
18 1328 1329 15957009 a DT B-NP O
19 1330 1341 15957009 cholinergic JJ I-NP O
20 1342 1345 15957009 and CC O O
21 1346 1347 15957009 a DT B-NP O
22 1348 1360 15957009 serotonergic JJ I-NP O
23 1361 1367 15957009 memory NN I-NP B-Disease
24 1368 1375 15957009 deficit NN I-NP I-Disease
25 1375 1376 15957009 , , O O
26 1377 1387 15957009 suggesting VBG B-VP O
27 1388 1392 15957009 that IN B-SBAR O
28 1393 1397 15957009 both DT B-NP O
29 1398 1408 15957009 mechanisms NNS I-NP O
30 1409 1412 15957009 may MD B-VP O
31 1413 1415 15957009 be VB I-VP O
32 1416 1424 15957009 involved VBN I-VP O
33 1425 1427 15957009 in IN B-PP O
34 1428 1431 15957009 the DT B-NP O
35 1432 1444 15957009 facilitation NN I-NP O
36 1445 1447 15957009 of IN B-PP O
37 1448 1454 15957009 object NN B-NP O
38 1455 1461 15957009 memory NN I-NP O
39 1462 1464 15957009 by IN B-PP O
40 1465 1474 15957009 Ro4368554 NN B-NP B-Chemical
41 1475 1478 15957009 and CC O O
42 1478 1479 15957009 , , O O
43 1480 1488 15957009 possibly RB B-ADVP O
44 1488 1489 15957009 , , O O
45 1490 1495 15957009 other JJ B-NP O
46 1496 1497 15957009 5 CD I-NP B-Chemical
47 1497 1498 15957009 - HYPH I-NP I-Chemical
48 1498 1503 15957009 HT(6) NN I-NP I-Chemical
49 1504 1512 15957009 receptor NN I-NP O
50 1513 1524 15957009 antagonists NNS I-NP O
51 1524 1525 15957009 . . O O

1 0 0 12757899 -DOCSTART- -X- -X- O

1 0 9 12757899 Estradiol NN B-NP B-Chemical
2 10 17 12757899 reduces VBZ B-VP O
3 18 25 12757899 seizure NN B-NP B-Disease
4 25 26 12757899 - HYPH O O
5 26 33 12757899 induced VBN B-NP O
6 34 45 12757899 hippocampal JJ I-NP B-Disease
7 46 52 12757899 injury NN I-NP I-Disease
8 53 55 12757899 in IN B-PP O
9 56 70 12757899 ovariectomized VBN B-NP O
10 71 77 12757899 female JJ I-NP O
11 78 81 12757899 but CC B-PP O
12 82 85 12757899 not RB B-PP O
13 86 88 12757899 in IN I-PP O
14 89 93 12757899 male JJ B-NP O
15 94 98 12757899 rats NNS I-NP O
16 98 99 12757899 . . O O
17 100 109 12757899 Estrogens NNS B-NP O
18 110 117 12757899 protect VBP B-VP O
19 118 132 12757899 ovariectomized VBN I-VP O
20 133 137 12757899 rats NNS B-NP O
21 138 142 12757899 from IN B-PP O
22 143 154 12757899 hippocampal JJ B-NP B-Disease
23 155 161 12757899 injury NN I-NP I-Disease
24 162 169 12757899 induced VBN B-VP O
25 170 172 12757899 by IN B-PP O
26 173 179 12757899 kainic JJ B-NP B-Chemical
27 180 184 12757899 acid NN I-NP I-Chemical
28 184 185 12757899 - HYPH B-NP O
29 185 192 12757899 induced VBN I-NP O
30 193 199 12757899 status NN I-NP B-Disease
31 200 211 12757899 epilepticus NN I-NP I-Disease
32 212 213 12757899 ( ( O O
33 213 215 12757899 SE NN B-NP B-Disease
34 215 216 12757899 ) ) O O
35 216 217 12757899 . . O O

1 218 220 12757899 We PRP B-NP O
2 221 229 12757899 compared VBD B-VP O
3 230 233 12757899 the DT B-NP O
4 234 241 12757899 effects NNS I-NP O
5 242 244 12757899 of IN B-PP O
6 245 251 12757899 17beta NN B-NP B-Chemical
7 251 252 12757899 - HYPH B-NP I-Chemical
8 252 261 12757899 estradiol NN I-NP I-Chemical
9 262 264 12757899 in IN B-PP O
10 265 270 12757899 adult JJ B-NP O
11 271 275 12757899 male JJ I-NP O
12 276 279 12757899 and CC I-NP O
13 280 294 12757899 ovariectomized VBN I-NP O
14 295 301 12757899 female JJ I-NP O
15 302 306 12757899 rats NNS I-NP O
16 307 316 12757899 subjected VBN B-VP O
17 317 319 12757899 to TO B-PP O
18 320 327 12757899 lithium NN B-NP B-Chemical
19 327 328 12757899 - HYPH B-NP O
20 328 339 12757899 pilocarpine NN I-NP B-Chemical
21 339 340 12757899 - HYPH B-NP O
22 340 347 12757899 induced VBN I-NP O
23 348 350 12757899 SE NN I-NP B-Disease
24 350 351 12757899 . . O O

1 352 356 12757899 Rats NNS B-NP O
2 357 365 12757899 received VBD B-VP O
3 366 378 12757899 subcutaneous JJ B-NP O
4 379 389 12757899 injections NNS I-NP O
5 390 392 12757899 of IN B-PP O
6 393 399 12757899 17beta NN B-NP B-Chemical
7 399 400 12757899 - HYPH B-NP I-Chemical
8 400 409 12757899 estradiol NN I-NP I-Chemical
9 410 411 12757899 ( ( O O
10 411 412 12757899 2 CD B-NP O
11 413 419 12757899 microg NN I-NP O
12 419 420 12757899 / SYM B-NP O
13 420 423 12757899 rat NN I-NP O
14 423 424 12757899 ) ) O O
15 425 427 12757899 or CC O O
16 428 431 12757899 oil NN B-NP O
17 432 436 12757899 once RB B-ADVP O
18 437 442 12757899 daily RB I-ADVP O
19 443 446 12757899 for IN B-PP O
20 447 451 12757899 four CD B-NP O
21 452 463 12757899 consecutive JJ I-NP O
22 464 468 12757899 days NNS I-NP O
23 468 469 12757899 . . O O

1 470 472 12757899 SE NN B-NP B-Disease
2 473 476 12757899 was VBD B-VP O
3 477 484 12757899 induced VBN I-VP O
4 485 487 12757899 20 CD B-NP O
5 488 489 12757899 h NN I-NP O
6 490 499 12757899 following VBG B-PP O
7 500 503 12757899 the DT B-NP O
8 504 510 12757899 second JJ I-NP O
9 511 520 12757899 injection NN I-NP O
10 521 524 12757899 and CC O O
11 525 535 12757899 terminated VBN B-VP O
12 536 537 12757899 3 CD B-NP O
13 538 539 12757899 h NN I-NP O
14 540 545 12757899 later RB B-ADVP O
15 545 546 12757899 . . O O

1 547 550 12757899 The DT B-NP O
2 551 557 12757899 extent NN I-NP O
3 558 560 12757899 of IN B-PP O
4 561 567 12757899 silver NN B-NP B-Chemical
5 567 568 12757899 - HYPH B-NP O
6 568 575 12757899 stained VBN I-NP O
7 576 579 12757899 CA3 NN I-NP O
8 580 583 12757899 and CC I-NP O
9 584 587 12757899 CA1 NN I-NP O
10 588 599 12757899 hippocampal JJ I-NP O
11 600 607 12757899 neurons NNS I-NP O
12 608 611 12757899 was VBD B-VP O
13 612 621 12757899 evaluated VBN I-VP O
14 622 623 12757899 2 CD B-NP O
15 624 628 12757899 days NNS I-NP O
16 629 634 12757899 after IN B-PP O
17 635 637 12757899 SE NN B-NP B-Disease
18 637 638 12757899 . . O O
19 639 645 12757899 17beta NN B-NP B-Chemical
20 645 646 12757899 - HYPH O I-Chemical
21 646 655 12757899 Estradiol NN B-NP I-Chemical
22 656 659 12757899 did VBD B-VP O
23 660 663 12757899 not RB I-VP O
24 664 669 12757899 alter VB I-VP O
25 670 673 12757899 the DT B-NP O
26 674 679 12757899 onset NN I-NP O
27 680 682 12757899 of IN B-PP O
28 683 688 12757899 first JJ B-NP O
29 689 695 12757899 clonus NN I-NP O
30 696 698 12757899 in IN B-PP O
31 699 713 12757899 ovariectomized VBN B-NP O
32 714 718 12757899 rats NNS I-NP O
33 719 722 12757899 but CC O O
34 723 734 12757899 accelerated VBD B-VP O
35 735 737 12757899 it PRP B-NP O
36 738 740 12757899 in IN B-PP O
37 741 746 12757899 males NNS B-NP O
38 746 747 12757899 . . O O

1 748 754 12757899 17beta NN B-NP B-Chemical
2 754 755 12757899 - HYPH I-NP I-Chemical
3 755 764 12757899 Estradiol NN I-NP I-Chemical
4 765 772 12757899 reduced VBD B-VP O
5 773 776 12757899 the DT B-NP O
6 777 789 12757899 argyrophilic JJ I-NP O
7 790 797 12757899 neurons NNS I-NP O
8 798 800 12757899 in IN B-PP O
9 801 804 12757899 the DT B-NP O
10 805 808 12757899 CA1 NN I-NP O
11 809 812 12757899 and CC I-NP O
12 813 816 12757899 CA3 NN I-NP O
13 816 817 12757899 - HYPH I-NP O
14 817 818 12757899 C NN I-NP O
15 819 826 12757899 sectors NNS I-NP O
16 827 829 12757899 of IN B-PP O
17 830 844 12757899 ovariectomized VBN B-NP O
18 845 849 12757899 rats NNS I-NP O
19 849 850 12757899 . . O O

1 851 853 12757899 In IN B-PP O
2 854 859 12757899 males NNS B-NP O
3 859 860 12757899 , , O O
4 861 870 12757899 estradiol NN B-NP B-Chemical
5 871 880 12757899 increased VBD B-VP O
6 881 884 12757899 the DT B-NP O
7 885 890 12757899 total JJ I-NP O
8 891 897 12757899 damage NN I-NP O
9 898 903 12757899 score NN I-NP O
10 903 904 12757899 . . O O

1 905 910 12757899 These DT B-NP O
2 911 919 12757899 findings NNS I-NP O
3 920 927 12757899 suggest VBP B-VP O
4 928 932 12757899 that IN B-SBAR O
5 933 936 12757899 the DT B-NP O
6 937 944 12757899 effects NNS I-NP O
7 945 947 12757899 of IN B-PP O
8 948 957 12757899 estradiol NN B-NP B-Chemical
9 958 960 12757899 on IN B-PP O
10 961 968 12757899 seizure NN B-NP B-Disease
11 969 978 12757899 threshold NN I-NP O
12 979 982 12757899 and CC I-NP O
13 983 989 12757899 damage NN I-NP O
14 990 993 12757899 may MD B-VP O
15 994 996 12757899 be VB I-VP O
16 997 1004 12757899 altered VBN I-VP O
17 1005 1007 12757899 by IN B-PP O
18 1008 1011 12757899 sex NN B-NP O
19 1011 1012 12757899 - HYPH B-NP O
20 1012 1019 12757899 related VBN I-NP O
21 1020 1031 12757899 differences NNS I-NP O
22 1032 1034 12757899 in IN B-PP O
23 1035 1038 12757899 the DT B-NP O
24 1039 1047 12757899 hormonal JJ I-NP O
25 1048 1059 12757899 environment NN I-NP O
26 1059 1060 12757899 . . O O

1 0 0 7930386 -DOCSTART- -X- -X- O

1 0 12 7930386 Clomipramine NN B-NP B-Chemical
2 12 13 7930386 - HYPH B-NP O
3 13 20 7930386 induced VBN I-NP O
4 21 26 7930386 sleep NN I-NP B-Disease
5 27 38 7930386 disturbance NN I-NP I-Disease
6 39 43 7930386 does VBZ B-VP O
7 44 47 7930386 not RB I-VP O
8 48 54 7930386 impair VB I-VP O
9 55 58 7930386 its PRP$ B-NP O
10 59 68 7930386 prolactin NN I-NP O
11 68 69 7930386 - HYPH O O
12 69 78 7930386 releasing VBG B-VP O
13 79 85 7930386 action NN B-NP O
14 85 86 7930386 . . O O
15 87 90 7930386 The DT B-NP O
16 91 98 7930386 present JJ I-NP O
17 99 104 7930386 study NN I-NP O
18 105 108 7930386 was VBD B-VP O
19 109 119 7930386 undertaken VBN I-VP O
20 120 122 7930386 to TO I-VP O
21 123 130 7930386 examine VB I-VP O
22 131 134 7930386 the DT B-NP O
23 135 139 7930386 role NN I-NP O
24 140 142 7930386 of IN B-PP O
25 143 148 7930386 sleep NN B-NP B-Disease
26 149 160 7930386 disturbance NN I-NP I-Disease
27 160 161 7930386 , , O O
28 162 169 7930386 induced VBN B-VP O
29 170 172 7930386 by IN B-PP O
30 173 185 7930386 clomipramine NN B-NP B-Chemical
31 186 200 7930386 administration NN I-NP O
32 200 201 7930386 , , O O
33 202 204 7930386 on IN B-PP O
34 205 208 7930386 the DT B-NP O
35 209 218 7930386 secretory JJ I-NP O
36 219 223 7930386 rate NN I-NP O
37 224 226 7930386 of IN B-PP O
38 227 236 7930386 prolactin NN B-NP O
39 237 238 7930386 ( ( O O
40 238 241 7930386 PRL NN B-NP O
41 241 242 7930386 ) ) O O
42 243 245 7930386 in IN B-PP O
43 246 254 7930386 addition NN B-NP O
44 255 257 7930386 to TO B-PP O
45 258 261 7930386 the DT B-NP O
46 262 268 7930386 direct JJ I-NP O
47 269 273 7930386 drug NN I-NP O
48 274 280 7930386 effect NN I-NP O
49 280 281 7930386 . . O O

1 282 285 7930386 Two CD B-NP O
2 286 292 7930386 groups NNS I-NP O
3 293 295 7930386 of IN B-PP O
4 296 302 7930386 supine NN B-NP O
5 303 311 7930386 subjects NNS I-NP O
6 312 316 7930386 were VBD B-VP O
7 317 324 7930386 studied VBN I-VP O
8 325 330 7930386 under IN B-PP O
9 331 338 7930386 placebo NN B-NP O
10 338 339 7930386 - HYPH B-NP O
11 339 349 7930386 controlled VBN I-NP O
12 350 360 7930386 conditions NNS I-NP O
13 360 361 7930386 , , O O
14 362 365 7930386 one CD B-NP O
15 366 372 7930386 during IN B-PP O
16 373 376 7930386 the DT B-NP O
17 377 382 7930386 night NN I-NP O
18 382 383 7930386 , , O O
19 384 388 7930386 when WRB B-ADVP O
20 389 397 7930386 sleeping VBG B-VP O
21 398 399 7930386 ( ( O O
22 399 400 7930386 n NN B-NP O
23 401 402 7930386 = SYM B-VP O
24 403 404 7930386 7 CD B-NP O
25 404 405 7930386 ) ) O O
26 406 409 7930386 and CC O O
27 410 413 7930386 the DT B-NP O
28 414 419 7930386 other JJ I-NP O
29 420 422 7930386 at IN B-PP O
30 423 430 7930386 daytime NN B-NP O
31 430 431 7930386 , , O O
32 432 436 7930386 when WRB B-ADVP O
33 437 442 7930386 awake NN B-NP O
34 443 444 7930386 ( ( O O
35 444 445 7930386 n NN B-NP O
36 446 447 7930386 = SYM B-VP O
37 448 449 7930386 6 CD B-NP O
38 449 450 7930386 ) ) O O
39 450 451 7930386 . . O O

1 452 456 7930386 Each DT B-NP O
2 457 464 7930386 subject NN I-NP O
3 465 473 7930386 received VBD B-VP O
4 474 475 7930386 a DT B-NP O
5 476 482 7930386 single JJ I-NP O
6 483 485 7930386 50 CD I-NP O
7 486 488 7930386 mg NN I-NP O
8 489 493 7930386 dose NN I-NP O
9 494 496 7930386 of IN B-PP O
10 497 509 7930386 clomipramine NN B-NP B-Chemical
11 510 515 7930386 given VBN B-VP O
12 516 522 7930386 orally RB B-NP O
13 523 524 7930386 2 CD I-NP O
14 525 530 7930386 hours NNS I-NP O
15 531 537 7930386 before IN B-PP O
16 538 543 7930386 blood NN B-NP O
17 544 554 7930386 collection NN I-NP O
18 554 555 7930386 . . O O

1 556 562 7930386 Plasma NN B-NP O
2 563 566 7930386 PRL NN I-NP O
3 567 581 7930386 concentrations NNS I-NP O
4 582 586 7930386 were VBD B-VP O
5 587 595 7930386 analysed VBN I-VP O
6 596 598 7930386 at IN B-PP O
7 599 601 7930386 10 CD B-NP O
8 602 605 7930386 min NN I-NP O
9 606 615 7930386 intervals NNS I-NP O
10 616 619 7930386 and CC O O
11 620 630 7930386 underlying VBG B-VP O
12 631 640 7930386 secretory JJ B-NP O
13 641 646 7930386 rates NNS I-NP O
14 647 657 7930386 calculated VBN B-VP O
15 658 660 7930386 by IN B-PP O
16 661 662 7930386 a DT B-NP O
17 663 676 7930386 deconvolution NN I-NP O
18 677 686 7930386 procedure NN I-NP O
19 686 687 7930386 . . O O

1 688 691 7930386 For IN B-PP O
2 692 696 7930386 both DT B-NP O
3 697 708 7930386 experiments NNS I-NP O
4 709 712 7930386 the DT B-NP O
5 713 717 7930386 drug NN I-NP O
6 718 724 7930386 intake NN I-NP O
7 725 728 7930386 led VBD B-VP O
8 729 731 7930386 to TO B-PP O
9 732 743 7930386 significant JJ B-NP O
10 744 753 7930386 increases NNS I-NP O
11 754 756 7930386 in IN B-PP O
12 757 760 7930386 PRL NN B-NP O
13 761 770 7930386 secretion NN I-NP O
14 770 771 7930386 , , O O
15 772 778 7930386 acting VBG B-VP O
16 779 793 7930386 preferentially RB B-ADVP O
17 794 796 7930386 on IN B-PP O
18 797 802 7930386 tonic JJ B-NP O
19 803 812 7930386 secretion NN I-NP O
20 813 815 7930386 as IN B-PP O
21 816 821 7930386 pulse NN B-NP O
22 822 831 7930386 amplitude NN I-NP O
23 832 835 7930386 and CC O O
24 836 845 7930386 frequency NN B-NP O
25 846 849 7930386 did VBD B-VP O
26 850 853 7930386 not RB I-VP O
27 854 860 7930386 differ VB I-VP O
28 861 874 7930386 significantly RB B-ADVP O
29 875 879 7930386 from IN B-PP O
30 880 893 7930386 corresponding VBG B-VP O
31 894 901 7930386 control NN B-NP O
32 902 908 7930386 values NNS I-NP O
33 908 909 7930386 . . O O

1 910 916 7930386 During IN B-PP O
2 917 920 7930386 the DT B-NP O
3 921 926 7930386 night NN I-NP O
4 927 939 7930386 clomipramine NN I-NP B-Chemical
5 940 949 7930386 ingestion NN I-NP O
6 950 957 7930386 altered VBD B-VP O
7 958 961 7930386 the DT B-NP O
8 962 970 7930386 complete JJ I-NP O
9 971 976 7930386 sleep NN I-NP O
10 977 989 7930386 architecture NN I-NP O
11 990 992 7930386 in IN B-PP O
12 993 997 7930386 that IN B-NP O
13 998 1000 7930386 it PRP B-NP O
14 1001 1011 7930386 suppressed VBD B-VP O
15 1012 1015 7930386 REM NN B-NP O
16 1016 1021 7930386 sleep NN I-NP O
17 1022 1025 7930386 and CC O O
18 1026 1029 7930386 the DT B-NP O
19 1030 1035 7930386 sleep JJ I-NP O
20 1036 1042 7930386 cycles NNS I-NP O
21 1043 1046 7930386 and CC O O
22 1047 1054 7930386 induced VBD B-VP O
23 1055 1064 7930386 increased VBN B-NP O
24 1065 1076 7930386 wakefulness NN I-NP O
25 1076 1077 7930386 . . O O

1 1078 1080 7930386 As IN B-SBAR O
2 1081 1084 7930386 the DT B-NP O
3 1085 1093 7930386 relative JJ I-NP O
4 1094 1102 7930386 increase NN I-NP O
5 1103 1105 7930386 in IN B-PP O
6 1106 1109 7930386 PRL NN B-NP O
7 1110 1119 7930386 secretion NN I-NP O
8 1120 1129 7930386 expressed VBN B-VP O
9 1130 1132 7930386 as IN B-PP O
10 1133 1134 7930386 a DT B-NP O
11 1135 1145 7930386 percentage NN I-NP O
12 1146 1148 7930386 of IN B-PP O
13 1149 1152 7930386 the DT B-NP O
14 1153 1157 7930386 mean NN I-NP O
15 1158 1161 7930386 did VBD B-VP O
16 1162 1165 7930386 not RB I-VP O
17 1166 1179 7930386 significantly RB I-VP O
18 1180 1186 7930386 differ VB I-VP O
19 1187 1194 7930386 between IN B-PP O
20 1195 1198 7930386 the DT B-NP O
21 1199 1204 7930386 night NN I-NP O
22 1205 1208 7930386 and CC I-NP O
23 1209 1212 7930386 day NN I-NP O
24 1213 1217 7930386 time NN I-NP O
25 1218 1225 7930386 studies NNS I-NP O
26 1226 1227 7930386 ( ( O O
27 1227 1229 7930386 46 CD B-NP O
28 1230 1231 7930386 + SYM O O
29 1231 1232 7930386 / SYM O O
30 1232 1233 7930386 - SYM O O
31 1234 1237 7930386 19% CD B-NP O
32 1238 1240 7930386 vs IN I-NP O
33 1241 1243 7930386 34 CD I-NP O
34 1244 1245 7930386 + SYM O O
35 1245 1246 7930386 / SYM O O
36 1246 1247 7930386 - SYM O O
37 1248 1251 7930386 10% CD B-NP O
38 1251 1252 7930386 ) ) O O
39 1252 1253 7930386 , , O O
40 1254 1256 7930386 it PRP B-NP O
41 1257 1260 7930386 can MD B-VP O
42 1261 1263 7930386 be VB I-VP O
43 1264 1273 7930386 concluded VBN I-VP O
44 1274 1278 7930386 that IN B-SBAR O
45 1279 1282 7930386 the DT B-NP O
46 1283 1291 7930386 observed VBN I-NP O
47 1292 1297 7930386 sleep NN I-NP B-Disease
48 1298 1309 7930386 disturbance NN I-NP I-Disease
49 1310 1313 7930386 did VBD B-VP O
50 1314 1317 7930386 not RB I-VP O
51 1318 1327 7930386 interfere VB I-VP O
52 1328 1332 7930386 with IN B-PP O
53 1333 1336 7930386 the DT B-NP O
54 1337 1341 7930386 drug NN I-NP O
55 1342 1348 7930386 action NN I-NP O
56 1349 1352 7930386 per FW B-ADVP O
57 1353 1355 7930386 se FW I-ADVP O
58 1355 1356 7930386 . . O O

1 1357 1360 7930386 The DT B-NP O
2 1361 1369 7930386 presence NN I-NP O
3 1370 1372 7930386 of IN B-PP O
4 1373 1376 7930386 REM NN B-NP O
5 1377 1382 7930386 sleep NN I-NP O
6 1383 1386 7930386 was VBD B-VP O
7 1387 1392 7930386 shown VBN I-VP O
8 1393 1396 7930386 not RB O O
9 1397 1399 7930386 to TO B-VP O
10 1400 1402 7930386 be VB I-VP O
11 1403 1404 7930386 a DT B-NP O
12 1405 1416 7930386 determining VBG I-NP O
13 1417 1423 7930386 factor NN I-NP O
14 1424 1430 7930386 either CC B-PP O
15 1431 1434 7930386 for IN B-PP O
16 1435 1444 7930386 secretory JJ B-NP O
17 1445 1450 7930386 pulse NN I-NP O
18 1451 1460 7930386 amplitude NN I-NP O
19 1461 1464 7930386 and CC I-NP O
20 1465 1474 7930386 frequency NN I-NP O
21 1474 1475 7930386 , , O O
22 1476 1478 7930386 as IN B-SBAR O
23 1478 1479 7930386 , , O O
24 1480 1483 7930386 for IN B-PP O
25 1484 1488 7930386 both DT B-NP O
26 1488 1489 7930386 , , O O
27 1490 1494 7930386 mean JJ B-NP O
28 1495 1504 7930386 nocturnal JJ I-NP O
29 1505 1511 7930386 values NNS I-NP O
30 1512 1516 7930386 were VBD B-VP O
31 1517 1524 7930386 similar JJ B-ADJP O
32 1525 1529 7930386 with IN B-PP O
33 1530 1533 7930386 and CC O O
34 1534 1541 7930386 without IN B-PP O
35 1542 1547 7930386 prior JJ B-NP O
36 1548 1560 7930386 clomipramine NN I-NP B-Chemical
37 1561 1570 7930386 ingestion NN I-NP O
38 1570 1571 7930386 . . O O

1 0 0 18791946 -DOCSTART- -X- -X- O

1 0 6 18791946 Severe JJ B-NP O
2 7 23 18791946 thrombocytopenia NN I-NP B-Disease
3 24 27 18791946 and CC O O
4 28 38 18791946 haemolytic JJ B-NP B-Disease
5 39 46 18791946 anaemia NN I-NP I-Disease
6 47 57 18791946 associated VBN B-VP O
7 58 62 18791946 with IN B-PP O
8 63 76 18791946 ciprofloxacin NN B-NP B-Chemical
9 76 77 18791946 : : O O
10 78 79 18791946 a DT B-NP O
11 80 84 18791946 case NN I-NP O
12 85 91 18791946 report NN I-NP O
13 92 96 18791946 with IN B-PP O
14 97 102 18791946 fatal JJ B-NP O
15 103 110 18791946 outcome NN I-NP O
16 110 111 18791946 . . O O
17 112 126 18791946 Haematological JJ B-NP O
18 127 134 18791946 adverse JJ I-NP O
19 135 144 18791946 reactions NNS I-NP O
20 145 155 18791946 associated VBN B-VP O
21 156 160 18791946 with IN B-PP O
22 161 166 18791946 fatal JJ B-NP O
23 167 174 18791946 outcome NN I-NP O
24 175 178 18791946 are VBP B-VP O
25 179 183 18791946 rare JJ B-ADJP O
26 184 190 18791946 during IN B-PP O
27 191 200 18791946 treatment NN B-NP O
28 201 205 18791946 with IN B-PP O
29 206 219 18791946 ciprofloxacin NN B-NP B-Chemical
30 219 220 18791946 . . O O

1 221 222 18791946 A DT B-NP O
2 223 225 18791946 30 CD I-NP O
3 225 226 18791946 - HYPH I-NP O
4 226 230 18791946 year NN I-NP O
5 231 234 18791946 old JJ I-NP O
6 235 244 18791946 Caucasian JJ I-NP O
7 245 248 18791946 man NN I-NP O
8 249 257 18791946 reported VBN B-VP O
9 258 262 18791946 with IN B-PP O
10 263 272 18791946 abdominal JJ B-NP B-Disease
11 273 277 18791946 pain NN I-NP I-Disease
12 278 281 18791946 and CC I-NP O
13 282 290 18791946 jaundice NN I-NP B-Disease
14 291 296 18791946 after IN B-PP O
15 297 298 18791946 3 CD B-NP O
16 298 299 18791946 - HYPH I-NP O
17 299 302 18791946 day NN I-NP O
18 303 317 18791946 administration NN I-NP O
19 318 320 18791946 of IN B-PP O
20 321 325 18791946 oral JJ B-NP O
21 326 339 18791946 ciprofloxacin NN I-NP B-Chemical
22 340 343 18791946 for IN B-PP O
23 344 345 18791946 a DT B-NP O
24 346 353 18791946 suspect NN I-NP O
25 354 356 18791946 of IN B-PP O
26 357 364 18791946 urinary JJ B-NP B-Disease
27 365 370 18791946 tract NN I-NP I-Disease
28 371 380 18791946 infection NN I-NP I-Disease
29 380 381 18791946 . . O O

1 382 390 18791946 Clinical JJ B-NP O
2 391 402 18791946 evaluations NNS I-NP O
3 403 412 18791946 suggested VBD B-VP O
4 413 415 18791946 an DT B-NP O
5 416 423 18791946 initial JJ I-NP O
6 424 433 18791946 diagnosis NN I-NP O
7 434 436 18791946 of IN B-PP O
8 437 443 18791946 severe JJ B-NP O
9 444 460 18791946 thrombocytopenia NN I-NP B-Disease
10 461 464 18791946 and CC I-NP O
11 465 475 18791946 haemolysis NN I-NP B-Disease
12 475 476 18791946 . . O O

1 477 480 18791946 The DT B-NP O
2 481 488 18791946 patient NN I-NP O
3 489 502 18791946 progressively RB B-ADVP O
4 503 512 18791946 developed VBD B-VP O
5 513 522 18791946 petechiae NN B-NP B-Disease
6 523 526 18791946 and CC I-NP O
7 527 534 18791946 purpura NN I-NP B-Disease
8 535 537 18791946 on IN B-PP O
9 538 544 18791946 thorax NN B-NP O
10 545 548 18791946 and CC O O
11 549 554 18791946 lower JJR B-NP O
12 555 560 18791946 limbs NNS I-NP O
13 560 561 18791946 . . O O

1 562 569 18791946 Despite IN B-PP O
2 570 585 18791946 pharmacological JJ B-NP O
3 586 589 18791946 and CC I-NP O
4 590 600 18791946 supportive JJ I-NP O
5 601 614 18791946 interventions NNS I-NP O
6 614 615 18791946 , , O O
7 616 626 18791946 laboratory NN B-NP O
8 627 637 18791946 parameters NNS I-NP O
9 638 646 18791946 worsened VBD B-VP O
10 647 650 18791946 and CC O O
11 651 654 18791946 the DT B-NP O
12 655 662 18791946 patient NN I-NP O
13 663 667 18791946 died VBD B-VP O
14 668 670 18791946 17 CD B-NP O
15 671 676 18791946 hours NNS I-NP O
16 677 682 18791946 after IN B-PP O
17 683 692 18791946 admission NN B-NP O
18 692 693 18791946 . . O O

1 694 696 18791946 An DT B-NP O
2 697 705 18791946 accurate JJ I-NP O
3 706 713 18791946 autopsy NN I-NP O
4 714 722 18791946 revealed VBD B-VP O
5 723 727 18791946 most JJS B-NP O
6 728 734 18791946 organs NNS I-NP O
7 735 739 18791946 with IN B-PP O
8 740 747 18791946 diffuse JJ B-NP O
9 748 757 18791946 petechial JJ I-NP O
10 758 770 18791946 haemorrhages NNS I-NP B-Disease
11 770 771 18791946 . . O O

1 772 774 18791946 No DT B-NP O
2 775 780 18791946 signs NNS I-NP O
3 781 783 18791946 of IN B-PP O
4 784 788 18791946 bone NN B-NP B-Disease
5 789 795 18791946 marrow NN I-NP I-Disease
6 796 806 18791946 depression NN I-NP I-Disease
7 807 811 18791946 were VBD B-VP O
8 812 817 18791946 found VBN I-VP O
9 817 818 18791946 . . O O

1 819 821 18791946 No DT B-NP O
2 822 829 18791946 thrombi NN I-NP B-Disease
3 830 832 18791946 or CC I-NP O
4 833 838 18791946 signs NNS I-NP O
5 839 841 18791946 of IN B-PP O
6 842 859 18791946 microangiopathies NNS B-NP B-Disease
7 860 864 18791946 were VBD B-VP O
8 865 873 18791946 observed VBN I-VP O
9 874 876 18791946 in IN B-PP O
10 877 885 18791946 arterial JJ B-NP O
11 886 893 18791946 vessels NNS I-NP O
12 893 894 18791946 . . O O

1 895 900 18791946 Blood NN B-NP O
2 901 904 18791946 and CC I-NP O
3 905 910 18791946 urine NN I-NP O
4 911 919 18791946 cultures NNS I-NP O
5 920 923 18791946 did VBD B-VP O
6 924 927 18791946 not RB I-VP O
7 928 932 18791946 show VB I-VP O
8 933 936 18791946 any DT B-NP O
9 937 946 18791946 bacterial JJ I-NP O
10 947 953 18791946 growth NN I-NP O
11 953 954 18791946 . . O O

1 955 959 18791946 This DT B-NP O
2 960 964 18791946 case NN I-NP O
3 965 971 18791946 report NN I-NP O
4 972 977 18791946 shows VBZ B-VP O
5 978 982 18791946 that IN B-SBAR O
6 983 996 18791946 ciprofloxacin NN B-NP B-Chemical
7 997 1000 18791946 may MD B-VP O
8 1001 1012 18791946 precipitate VB I-VP O
9 1013 1017 18791946 life NN B-NP O
10 1017 1018 18791946 - HYPH O O
11 1018 1029 18791946 threatening VBG B-VP O
12 1030 1046 18791946 thrombocytopenia NN B-NP B-Disease
13 1047 1050 18791946 and CC O O
14 1051 1061 18791946 haemolytic JJ B-NP B-Disease
15 1062 1069 18791946 anaemia NN I-NP I-Disease
16 1069 1070 18791946 , , O O
17 1071 1075 18791946 even RB B-ADVP O
18 1076 1078 18791946 in IN B-PP O
19 1079 1082 18791946 the DT B-NP O
20 1083 1088 18791946 early JJ I-NP O
21 1089 1095 18791946 phases NNS I-NP O
22 1096 1098 18791946 of IN B-PP O
23 1099 1108 18791946 treatment NN B-NP O
24 1109 1112 18791946 and CC O O
25 1113 1120 18791946 without IN B-PP O
26 1121 1129 18791946 apparent JJ B-NP O
27 1130 1138 18791946 previous JJ I-NP O
28 1139 1148 18791946 exposures NNS I-NP O
29 1148 1149 18791946 . . O O

1 0 0 869641 -DOCSTART- -X- -X- O

1 0 9 869641 Mediation NN B-NP O
2 10 12 869641 of IN B-PP O
3 13 21 869641 enhanced VBN B-NP O
4 22 28 869641 reflex NN I-NP O
5 29 34 869641 vagal JJ I-NP O
6 35 46 869641 bradycardia NN I-NP B-Disease
7 47 49 869641 by IN B-PP O
8 50 51 869641 L NN B-NP B-Chemical
9 51 52 869641 - HYPH O I-Chemical
10 52 56 869641 dopa NN B-NP I-Chemical
11 57 60 869641 via IN B-PP O
12 61 68 869641 central JJ B-NP O
13 69 77 869641 dopamine NN I-NP B-Chemical
14 78 87 869641 formation NN I-NP O
15 88 90 869641 in IN B-PP O
16 91 95 869641 dogs NNS B-NP O
17 95 96 869641 . . O O
18 97 98 869641 L NN B-NP B-Chemical
19 98 99 869641 - HYPH O I-Chemical
20 99 103 869641 Dopa NN B-NP I-Chemical
21 104 105 869641 ( ( O O
22 105 106 869641 5 CD B-NP O
23 107 109 869641 mg NN I-NP O
24 109 110 869641 / SYM B-NP O
25 110 112 869641 kg NN I-NP O
26 113 116 869641 i.v JJ B-ADJP O
27 116 117 869641 . . O O
28 117 118 869641 ) ) O O
29 119 128 869641 decreased VBD B-VP O
30 129 134 869641 blood NN B-NP O
31 135 143 869641 pressure NN I-NP O
32 144 147 869641 and CC I-NP O
33 148 153 869641 heart NN I-NP O
34 154 158 869641 rate NN I-NP O
35 159 164 869641 after IN B-PP O
36 165 178 869641 extracerebral JJ B-NP O
37 179 192 869641 decarboxylase NN I-NP O
38 193 203 869641 inhibition NN I-NP O
39 204 208 869641 with IN B-PP O
40 209 211 869641 MK NN B-NP B-Chemical
41 211 212 869641 - HYPH O I-Chemical
42 212 215 869641 486 CD B-NP I-Chemical
43 216 217 869641 ( ( O O
44 217 219 869641 25 CD B-NP O
45 220 222 869641 mg NN I-NP O
46 222 223 869641 / SYM B-NP O
47 223 225 869641 kg NN I-NP O
48 226 229 869641 i.v JJ B-ADJP O
49 229 230 869641 . . O O
50 230 231 869641 ) ) O O
51 232 234 869641 in IN B-PP O
52 235 246 869641 anesthetize NN B-NP O
53 247 250 869641 MAO NN I-NP B-Chemical
54 250 251 869641 - HYPH B-NP O
55 251 260 869641 inhibited VBN I-NP O
56 261 265 869641 dogs NNS I-NP O
57 265 266 869641 . . O O

1 267 269 869641 In IN B-PP O
2 270 278 869641 addition NN B-NP O
3 278 279 869641 , , O O
4 280 286 869641 reflex NN B-NP O
5 287 298 869641 bradycardia NN I-NP B-Disease
6 299 305 869641 caused VBN B-VP O
7 306 308 869641 by IN B-PP O
8 309 317 869641 injected VBN B-NP O
9 318 332 869641 norepinephrine NN I-NP B-Chemical
10 333 336 869641 was VBD B-VP O
11 337 350 869641 significantly RB I-VP O
12 351 359 869641 enhanced VBN I-VP O
13 360 362 869641 by IN B-PP O
14 363 364 869641 L NN B-NP B-Chemical
15 364 365 869641 - HYPH B-NP I-Chemical
16 365 369 869641 dopa NN I-NP I-Chemical
17 369 370 869641 , , O O
18 371 373 869641 DL NN B-NP B-Chemical
19 373 374 869641 - HYPH O I-Chemical
20 374 379 869641 Threo AFX O I-Chemical
21 379 380 869641 - HYPH O I-Chemical
22 380 401 869641 dihydroxyphenylserine NN B-NP I-Chemical
23 402 405 869641 had VBD B-VP O
24 406 408 869641 no DT B-NP O
25 409 415 869641 effect NN I-NP O
26 416 418 869641 on IN B-PP O
27 419 424 869641 blood NN B-NP O
28 425 433 869641 pressure NN I-NP O
29 433 434 869641 , , O O
30 435 440 869641 heart NN B-NP O
31 441 445 869641 rate NN I-NP O
32 446 448 869641 or CC I-NP O
33 449 455 869641 reflex NN I-NP O
34 456 465 869641 responses NNS I-NP O
35 466 468 869641 to TO B-PP O
36 469 483 869641 norepinephrine NN B-NP B-Chemical
37 483 484 869641 . . O O

1 485 488 869641 FLA NN B-NP B-Chemical
2 488 489 869641 - HYPH O I-Chemical
3 489 491 869641 63 CD B-NP I-Chemical
4 491 492 869641 , , O O
5 493 494 869641 a DT B-NP O
6 495 503 869641 dopamine NN I-NP B-Chemical
7 503 504 869641 - HYPH B-NP O
8 504 508 869641 beta SYM I-NP O
9 508 509 869641 - HYPH I-NP O
10 509 516 869641 oxidase NN I-NP O
11 517 526 869641 inhibitor NN I-NP O
12 526 527 869641 , , O O
13 528 531 869641 did VBD B-VP O
14 532 535 869641 not RB I-VP O
15 536 540 869641 have VB I-VP O
16 541 544 869641 any DT B-NP O
17 545 551 869641 effect NN I-NP O
18 552 554 869641 on IN B-PP O
19 555 558 869641 the DT B-NP O
20 559 570 869641 hypotension NN I-NP B-Disease
21 570 571 869641 , , I-NP O
22 572 583 869641 bradycardia NN I-NP B-Disease
23 584 586 869641 or CC I-NP O
24 587 593 869641 reflex NN I-NP O
25 593 594 869641 - HYPH O O
26 594 603 869641 enhancing VBG B-VP O
27 604 610 869641 effect NN B-NP O
28 611 613 869641 of IN B-PP O
29 614 615 869641 L NN B-NP B-Chemical
30 615 616 869641 - HYPH I-NP I-Chemical
31 616 620 869641 dopa NN B-NP I-Chemical
32 620 621 869641 . . O O

1 622 630 869641 Pimozide NNP B-NP B-Chemical
2 631 634 869641 did VBD B-VP O
3 635 638 869641 not RB I-VP O
4 639 645 869641 affect VB I-VP O
5 646 649 869641 the DT B-NP O
6 650 657 869641 actions NNS I-NP O
7 658 660 869641 of IN B-PP O
8 661 662 869641 L NN B-NP B-Chemical
9 662 663 869641 - HYPH O I-Chemical
10 663 667 869641 dopa NN B-NP I-Chemical
11 668 670 869641 on IN B-PP O
12 671 676 869641 blood NN B-NP O
13 677 685 869641 pressure NN I-NP O
14 686 689 869641 and CC I-NP O
15 690 695 869641 heart NN I-NP O
16 696 700 869641 rate NN I-NP O
17 701 704 869641 but CC O O
18 705 715 869641 completely RB B-VP O
19 716 723 869641 blocked VBD I-VP O
20 724 727 869641 the DT B-NP O
21 728 739 869641 enhancement NN I-NP O
22 740 742 869641 of IN B-PP O
23 743 751 869641 reflexes NNS B-NP O
24 751 752 869641 . . O O

1 753 760 869641 Removal NN B-NP O
2 761 763 869641 of IN B-PP O
3 764 767 869641 the DT B-NP O
4 768 775 869641 carotid NN I-NP O
5 776 783 869641 sinuses NNS I-NP O
6 784 790 869641 caused VBD B-VP O
7 791 793 869641 an DT B-NP O
8 794 803 869641 elevation NN I-NP O
9 804 809 869641 blood NN I-NP O
10 810 818 869641 pressure NN I-NP O
11 819 822 869641 and CC I-NP O
12 823 828 869641 heart NN I-NP O
13 829 833 869641 rate NN I-NP O
14 834 837 869641 and CC O O
15 838 847 869641 abolished VBD B-VP O
16 848 851 869641 the DT B-NP O
17 852 860 869641 negative JJ I-NP O
18 861 873 869641 chronotropic JJ I-NP O
19 874 880 869641 effect NN I-NP O
20 881 883 869641 of IN B-PP O
21 884 898 869641 norepinephrine NN B-NP B-Chemical
22 898 899 869641 . . O O

1 900 907 869641 However RB B-ADVP O
2 907 908 869641 , , O O
3 909 910 869641 L NN B-NP B-Chemical
4 910 911 869641 - HYPH O I-Chemical
5 911 915 869641 dopa NN B-NP I-Chemical
6 916 924 869641 restored VBD B-VP O
7 925 928 869641 the DT B-NP O
8 929 940 869641 bradycardia NN I-NP B-Disease
9 941 947 869641 caused VBN B-VP O
10 948 950 869641 by IN B-PP O
11 951 965 869641 norepinephrine NN B-NP B-Chemical
12 966 968 869641 in IN B-PP O
13 969 977 869641 addition NN B-NP O
14 978 980 869641 to TO B-PP O
15 981 991 869641 decreasing VBG B-VP O
16 992 997 869641 blood NN B-NP O
17 998 1006 869641 pressure NN I-NP O
18 1007 1010 869641 and CC O O
19 1011 1016 869641 heart NN B-NP O
20 1017 1021 869641 rate NN I-NP O
21 1021 1022 869641 . . O O

1 1023 1024 869641 5 CD B-NP B-Chemical
2 1024 1025 869641 - HYPH I-NP I-Chemical
3 1025 1028 869641 HTP NN I-NP I-Chemical
4 1029 1030 869641 ( ( O O
5 1030 1031 869641 5 CD B-NP O
6 1032 1034 869641 mg NN I-NP O
7 1034 1035 869641 / SYM B-NP O
8 1035 1037 869641 kg NN I-NP O
9 1038 1041 869641 i.v JJ B-ADJP O
10 1041 1042 869641 . . O O
11 1042 1043 869641 ) ) O O
12 1044 1053 869641 decreased VBD B-VP O
13 1054 1059 869641 blood NN B-NP O
14 1060 1068 869641 pressure NN I-NP O
15 1069 1072 869641 and CC I-NP O
16 1073 1078 869641 heart NN I-NP O
17 1079 1083 869641 rate NN I-NP O
18 1084 1087 869641 and CC O O
19 1088 1097 869641 decreased VBD B-VP O
20 1098 1101 869641 the DT B-NP O
21 1102 1108 869641 reflex NN I-NP O
22 1109 1120 869641 bradycardia NN I-NP B-Disease
23 1121 1123 869641 to TO B-PP O
24 1124 1138 869641 norepinephrine NN B-NP B-Chemical
25 1138 1139 869641 . . O O

1 1140 1142 869641 It PRP B-NP O
2 1143 1145 869641 is VBZ B-VP O
3 1146 1155 869641 concluded VBN I-VP O
4 1156 1160 869641 that IN B-SBAR O
5 1161 1162 869641 L NN B-NP B-Chemical
6 1162 1163 869641 - HYPH O I-Chemical
7 1163 1167 869641 dopa NN B-NP I-Chemical
8 1168 1176 869641 enhances VBZ B-VP O
9 1177 1183 869641 reflex NN B-NP O
10 1184 1195 869641 bradycardia NN I-NP B-Disease
11 1196 1203 869641 through IN B-PP O
12 1204 1211 869641 central JJ B-NP O
13 1212 1217 869641 alpha SYM I-NP O
14 1217 1218 869641 - HYPH I-NP O
15 1218 1226 869641 receptor NN I-NP O
16 1227 1238 869641 stimulation NN I-NP O
17 1238 1239 869641 . . O O

1 1240 1251 869641 Furthermore RB B-ADVP O
2 1251 1252 869641 , , O O
3 1253 1256 869641 the DT B-NP O
4 1257 1264 869641 effects NNS I-NP O
5 1265 1268 869641 are VBP B-VP O
6 1269 1277 869641 mediated VBN I-VP O
7 1278 1285 869641 through IN B-PP O
8 1286 1294 869641 dopamine NN B-NP B-Chemical
9 1295 1301 869641 rather RB B-CONJP O
10 1302 1306 869641 than IN I-CONJP O
11 1307 1321 869641 norepinephrine NN B-NP B-Chemical
12 1322 1325 869641 and CC O O
13 1326 1328 869641 do VBP B-VP O
14 1329 1332 869641 not RB I-VP O
15 1333 1340 869641 require VB I-VP O
16 1341 1344 869641 the DT B-NP O
17 1345 1352 869641 carotid NN I-NP O
18 1353 1358 869641 sinus NN I-NP O
19 1359 1372 869641 baroreceptors NNS I-NP O
20 1372 1373 869641 . . O O

1 0 0 8302922 -DOCSTART- -X- -X- O

1 0 8 8302922 Epidural JJ B-NP O
2 9 14 8302922 blood NN I-NP O
3 15 19 8302922 flow NN I-NP O
4 20 26 8302922 during IN B-PP O
5 27 40 8302922 prostaglandin NN B-NP B-Chemical
6 41 43 8302922 E1 NN I-NP I-Chemical
7 44 46 8302922 or CC I-NP O
8 47 59 8302922 trimethaphan NN I-NP B-Chemical
9 60 67 8302922 induced VBD B-VP O
10 68 79 8302922 hypotension NN B-NP B-Disease
11 79 80 8302922 . . O O
12 81 83 8302922 To TO B-VP O
13 84 92 8302922 evaluate VB I-VP O
14 93 96 8302922 the DT B-NP O
15 97 103 8302922 effect NN I-NP O
16 104 106 8302922 of IN B-PP O
17 107 120 8302922 prostaglandin NN B-NP B-Chemical
18 121 123 8302922 E1 NN I-NP I-Chemical
19 124 125 8302922 ( ( O O
20 125 129 8302922 PGE1 NN B-NP B-Chemical
21 129 130 8302922 ) ) O O
22 131 133 8302922 or CC O O
23 134 146 8302922 trimethaphan NN B-NP B-Chemical
24 147 148 8302922 ( ( O O
25 148 151 8302922 TMP NN B-NP B-Chemical
26 151 152 8302922 ) ) O O
27 153 160 8302922 induced VBD B-VP O
28 161 172 8302922 hypotension NN B-NP B-Disease
29 173 175 8302922 on IN B-PP O
30 176 184 8302922 epidural JJ B-NP O
31 185 190 8302922 blood NN I-NP O
32 191 195 8302922 flow NN I-NP O
33 196 197 8302922 ( ( O O
34 197 200 8302922 EBF NN B-NP O
35 200 201 8302922 ) ) O O
36 202 208 8302922 during IN B-PP O
37 209 215 8302922 spinal JJ B-NP O
38 216 223 8302922 surgery NN I-NP O
39 223 224 8302922 , , O O
40 225 228 8302922 EBF NN B-NP O
41 229 232 8302922 was VBD B-VP O
42 233 241 8302922 measured VBN I-VP O
43 242 247 8302922 using VBG B-VP O
44 248 251 8302922 the DT B-NP O
45 252 256 8302922 heat NN I-NP O
46 257 266 8302922 clearance NN I-NP O
47 267 273 8302922 method NN I-NP O
48 274 276 8302922 in IN B-PP O
49 277 279 8302922 30 CD B-NP O
50 280 288 8302922 patients NNS I-NP O
51 289 292 8302922 who WP B-NP O
52 293 302 8302922 underwent VBD B-VP O
53 303 310 8302922 postero AFX B-ADVP O
54 310 311 8302922 - HYPH B-NP O
55 311 318 8302922 lateral JJ I-NP O
56 319 328 8302922 interbody NN I-NP O
57 329 335 8302922 fusion NN I-NP O
58 336 341 8302922 under IN B-PP O
59 342 352 8302922 isoflurane NN B-NP B-Chemical
60 353 364 8302922 anaesthesia NN I-NP O
61 364 365 8302922 . . O O

1 366 368 8302922 An DT B-NP O
2 369 376 8302922 initial JJ I-NP O
3 377 381 8302922 dose NN I-NP O
4 382 384 8302922 of IN B-PP O
5 385 388 8302922 0.1 CD B-NP O
6 389 401 8302922 microgram.kg NN I-NP O
7 401 402 8302922 - HYPH B-NP O
8 402 407 8302922 1.min NN I-NP O
9 407 408 8302922 - HYPH B-NP O
10 408 409 8302922 1 CD I-NP O
11 410 412 8302922 of IN B-PP O
12 413 417 8302922 PGE1 NN B-NP B-Chemical
13 418 419 8302922 ( ( O O
14 419 421 8302922 15 CD B-NP O
15 422 430 8302922 patients NNS I-NP O
16 430 431 8302922 ) ) O O
17 431 432 8302922 , , O O
18 433 435 8302922 or CC O O
19 436 438 8302922 10 CD B-NP O
20 439 452 8302922 micrograms.kg NN I-NP O
21 452 453 8302922 - HYPH B-NP O
22 453 458 8302922 1.min NN I-NP O
23 458 459 8302922 - HYPH B-NP O
24 459 460 8302922 1 CD I-NP O
25 461 463 8302922 of IN B-PP O
26 464 467 8302922 TMP NN B-NP B-Chemical
27 468 469 8302922 ( ( O O
28 469 471 8302922 15 CD B-NP O
29 472 480 8302922 patients NNS I-NP O
30 480 481 8302922 ) ) O O
31 482 485 8302922 was VBD B-VP O
32 486 498 8302922 administered VBN I-VP O
33 499 512 8302922 intravenously RB B-ADVP O
34 513 518 8302922 after IN B-PP O
35 519 522 8302922 the DT B-NP O
36 523 528 8302922 dural JJ I-NP O
37 529 536 8302922 opening NN I-NP O
38 537 540 8302922 and CC O O
39 541 544 8302922 the DT B-NP O
40 545 549 8302922 dose NN I-NP O
41 550 553 8302922 was VBD B-VP O
42 554 562 8302922 adjusted VBN I-VP O
43 563 565 8302922 to TO B-VP O
44 566 574 8302922 maintain VB I-VP O
45 575 578 8302922 the DT B-NP O
46 579 583 8302922 mean JJ I-NP O
47 584 592 8302922 arterial JJ I-NP O
48 593 598 8302922 blood NN I-NP O
49 599 607 8302922 pressure NN I-NP O
50 608 609 8302922 ( ( O O
51 609 612 8302922 MAP NN B-NP O
52 612 613 8302922 ) ) O O
53 614 616 8302922 at IN B-PP O
54 617 622 8302922 about RB B-NP O
55 623 625 8302922 60 CD I-NP O
56 626 630 8302922 mmHg NN I-NP O
57 630 631 8302922 . . O O

1 632 635 8302922 The DT B-NP O
2 636 647 8302922 hypotensive JJ I-NP B-Disease
3 648 652 8302922 drug NN I-NP O
4 653 656 8302922 was VBD B-VP O
5 657 669 8302922 discontinued VBN I-VP O
6 670 672 8302922 at IN B-PP O
7 673 676 8302922 the DT B-NP O
8 677 687 8302922 completion NN I-NP O
9 688 690 8302922 of IN B-PP O
10 691 694 8302922 the DT B-NP O
11 695 704 8302922 operative JJ I-NP O
12 705 714 8302922 procedure NN I-NP O
13 714 715 8302922 . . O O

1 716 721 8302922 After IN B-PP O
2 722 730 8302922 starting VBG B-VP O
3 731 735 8302922 PGE1 NN B-NP B-Chemical
4 736 738 8302922 or CC I-NP O
5 739 742 8302922 TMP NN I-NP B-Chemical
6 742 743 8302922 , , I-NP O
7 744 747 8302922 MAP NN I-NP O
8 748 751 8302922 and CC I-NP O
9 752 756 8302922 rate NN I-NP O
10 757 765 8302922 pressure NN I-NP O
11 766 773 8302922 product NN I-NP O
12 774 775 8302922 ( ( O O
13 775 778 8302922 RPP NN B-NP O
14 778 779 8302922 ) ) O O
15 780 789 8302922 decreased VBD B-VP O
16 790 803 8302922 significantly RB B-ADVP O
17 804 812 8302922 compared VBN B-PP O
18 813 817 8302922 with IN B-PP O
19 818 829 8302922 preinfusion NN B-NP O
20 830 836 8302922 values NNS I-NP O
21 837 838 8302922 ( ( O O
22 838 839 8302922 P NN B-NP O
23 840 841 8302922 < SYM O O
24 842 846 8302922 0.01 CD B-NP O
25 846 847 8302922 ) ) O O
26 847 848 8302922 , , O O
27 849 852 8302922 and CC O O
28 853 856 8302922 the DT B-NP O
29 857 863 8302922 degree NN I-NP O
30 864 866 8302922 of IN B-PP O
31 867 878 8302922 hypotension NN B-NP B-Disease
32 879 882 8302922 due JJ B-ADJP O
33 883 885 8302922 to TO B-PP O
34 886 890 8302922 PGE1 NN B-NP B-Chemical
35 891 899 8302922 remained VBD B-VP O
36 900 908 8302922 constant JJ B-ADJP O
37 909 914 8302922 until IN B-SBAR O
38 915 917 8302922 60 CD B-NP O
39 918 921 8302922 min NN I-NP O
40 922 927 8302922 after IN B-PP O
41 928 931 8302922 its PRP$ B-NP O
42 932 947 8302922 discontinuation NN I-NP O
43 947 948 8302922 . . O O

1 949 954 8302922 Heart NN B-NP O
2 955 959 8302922 rate NN I-NP O
3 960 961 8302922 ( ( O O
4 961 963 8302922 HR NN B-NP O
5 963 964 8302922 ) ) O O
6 965 968 8302922 did VBD B-VP O
7 969 972 8302922 not RB I-VP O
8 973 979 8302922 change VB I-VP O
9 980 982 8302922 in IN B-PP O
10 983 989 8302922 either DT B-NP O
11 990 995 8302922 group NN I-NP O
12 995 996 8302922 . . O O

1 997 1001 8302922 EBFF NN B-NP O
2 1002 1005 8302922 did VBD B-VP O
3 1006 1009 8302922 not RB I-VP O
4 1010 1016 8302922 change VB I-VP O
5 1017 1023 8302922 during IN B-PP O
6 1024 1028 8302922 PGE1 NN B-NP B-Chemical
7 1029 1037 8302922 infusion NN I-NP O
8 1038 1045 8302922 whereas IN B-ADVP O
9 1046 1048 8302922 in IN B-PP O
10 1049 1052 8302922 the DT B-NP O
11 1053 1056 8302922 TMP NN I-NP B-Chemical
12 1057 1062 8302922 group NN I-NP O
13 1062 1063 8302922 , , O O
14 1064 1067 8302922 EBF NN B-NP O
15 1068 1077 8302922 decreased VBD B-VP O
16 1078 1091 8302922 significantly RB B-ADVP O
17 1092 1094 8302922 at IN B-PP O
18 1095 1097 8302922 30 CD B-NP O
19 1098 1101 8302922 and CC I-NP O
20 1102 1104 8302922 60 CD I-NP O
21 1105 1108 8302922 min NN I-NP O
22 1109 1114 8302922 after IN B-PP O
23 1115 1118 8302922 the DT B-NP O
24 1119 1124 8302922 start NN I-NP O
25 1125 1127 8302922 of IN B-PP O
26 1128 1131 8302922 TMP NN B-NP B-Chemical
27 1132 1133 8302922 ( ( O O
28 1133 1144 8302922 preinfusion NN B-NP O
29 1144 1145 8302922 : : O O
30 1146 1150 8302922 45.9 CD B-NP O
31 1151 1152 8302922 + SYM O O
32 1152 1153 8302922 / SYM O O
33 1153 1154 8302922 - SYM O O
34 1155 1159 8302922 13.9 CD B-NP O
35 1160 1162 8302922 ml NN I-NP O
36 1162 1163 8302922 / SYM B-NP O
37 1163 1167 8302922 100g NN I-NP O
38 1167 1168 8302922 / SYM I-NP O
39 1168 1171 8302922 min NN I-NP O
40 1171 1172 8302922 . . O O

1 1173 1175 8302922 30 CD B-NP O
2 1176 1179 8302922 min NN I-NP O
3 1179 1180 8302922 : : O O
4 1181 1185 8302922 32.3 CD B-NP O
5 1186 1187 8302922 + SYM O O
6 1187 1188 8302922 / SYM O O
7 1188 1189 8302922 - SYM O O
8 1190 1193 8302922 9.9 CD B-NP O
9 1194 1196 8302922 ml NN I-NP O
10 1196 1197 8302922 / SYM B-NP O
11 1197 1200 8302922 100 CD B-NP O
12 1201 1202 8302922 g NN I-NP O
13 1202 1203 8302922 / SYM B-NP O
14 1203 1206 8302922 min NN B-NP O
15 1207 1208 8302922 ( ( O O
16 1208 1209 8302922 P NN B-NP O
17 1210 1211 8302922 < SYM O O
18 1212 1216 8302922 0.05 CD B-NP O
19 1216 1217 8302922 ) ) O O
20 1217 1218 8302922 . . O O

1 1219 1221 8302922 60 CD B-NP O
2 1222 1225 8302922 min NN I-NP O
3 1225 1226 8302922 : : O O
4 1227 1229 8302922 30 CD B-NP O
5 1230 1231 8302922 + SYM O O
6 1231 1232 8302922 / SYM O O
7 1232 1233 8302922 - SYM O O
8 1234 1237 8302922 7.5 CD B-NP O
9 1238 1240 8302922 ml NN I-NP O
10 1240 1241 8302922 / SYM B-NP O
11 1241 1244 8302922 100 CD B-NP O
12 1245 1246 8302922 g NN I-NP O
13 1246 1247 8302922 / SYM B-NP O
14 1247 1250 8302922 min NN B-NP O
15 1251 1252 8302922 ( ( O O
16 1252 1253 8302922 P NN B-NP O
17 1254 1255 8302922 < SYM O O
18 1256 1260 8302922 0.05 CD B-NP O
19 1260 1261 8302922 ) ) O O
20 1261 1262 8302922 ) ) O O
21 1262 1263 8302922 . . O O

1 1264 1269 8302922 These DT B-NP O
2 1270 1277 8302922 results NNS I-NP O
3 1278 1285 8302922 suggest VBP B-VP O
4 1286 1290 8302922 that IN B-SBAR O
5 1291 1295 8302922 PGE1 NN B-NP B-Chemical
6 1296 1299 8302922 may MD B-VP O
7 1300 1302 8302922 be VB I-VP O
8 1303 1313 8302922 preferable JJ B-ADJP O
9 1314 1316 8302922 to TO B-PP O
10 1317 1320 8302922 TMP NN B-NP B-Chemical
11 1321 1324 8302922 for IN B-PP O
12 1325 1336 8302922 hypotensive JJ B-NP B-Disease
13 1337 1348 8302922 anaesthesia NN I-NP O
14 1349 1351 8302922 in IN B-PP O
15 1352 1358 8302922 spinal JJ B-NP O
16 1359 1366 8302922 surgery NN I-NP O
17 1367 1374 8302922 because IN B-SBAR O
18 1375 1378 8302922 TMP NN B-NP B-Chemical
19 1379 1388 8302922 decreased VBD B-VP O
20 1389 1392 8302922 EBF NN B-NP O
21 1392 1393 8302922 . . O O

1 0 0 7420681 -DOCSTART- -X- -X- O

1 0 8 7420681 Clinical JJ B-NP O
2 9 23 7420681 nephrotoxicity NN I-NP B-Disease
3 24 26 7420681 of IN B-PP O
4 27 37 7420681 tobramycin NN B-NP B-Chemical
5 38 41 7420681 and CC I-NP O
6 42 52 7420681 gentamicin NN I-NP B-Chemical
7 52 53 7420681 . . O O

1 54 55 7420681 A DT B-NP O
2 56 67 7420681 prospective JJ I-NP O
3 68 73 7420681 study NN I-NP O
4 73 74 7420681 . . O O
5 75 81 7420681 Nearly RB B-NP O
6 82 85 7420681 3.2 CD I-NP O
7 86 93 7420681 million CD I-NP O
8 94 100 7420681 people NNS I-NP O
9 101 103 7420681 in IN B-PP O
10 104 108 7420681 this DT B-NP O
11 109 116 7420681 country NN I-NP O
12 117 124 7420681 receive VBP B-VP O
13 125 139 7420681 aminoglycoside NN B-NP B-Chemical
14 140 151 7420681 antibiotics NNS I-NP O
15 152 160 7420681 annually RB B-ADVP O
16 160 161 7420681 . . O O

1 162 172 7420681 Gentamicin NN B-NP B-Chemical
2 173 180 7420681 sulfate NN I-NP I-Chemical
3 181 184 7420681 and CC O O
4 185 195 7420681 tobramycin NN B-NP B-Chemical
5 196 203 7420681 sulfate NN I-NP I-Chemical
6 204 212 7420681 continue VBP B-VP O
7 213 215 7420681 to TO I-VP O
8 216 227 7420681 demonstrate VB I-VP O
9 228 239 7420681 ototoxicity NN B-NP B-Disease
10 240 243 7420681 and CC I-NP O
11 244 258 7420681 nephrotoxicity NN I-NP B-Disease
12 259 261 7420681 in IN B-PP O
13 262 266 7420681 both CC B-NP O
14 267 273 7420681 animal JJ I-NP O
15 274 277 7420681 and CC I-NP O
16 278 286 7420681 clinical JJ I-NP O
17 287 294 7420681 studies NNS I-NP O
18 294 295 7420681 . . O O

1 296 298 7420681 In IN B-PP O
2 299 303 7420681 this DT B-NP O
3 304 309 7420681 study NN I-NP O
4 309 310 7420681 , , O O
5 311 313 7420681 62 CD B-NP O
6 314 322 7420681 patients NNS I-NP O
7 323 327 7420681 with IN B-PP O
8 328 337 7420681 confirmed VBN B-NP O
9 338 345 7420681 initial JJ I-NP O
10 346 352 7420681 normal JJ I-NP O
11 353 358 7420681 renal JJ I-NP O
12 359 367 7420681 function NN I-NP O
13 368 371 7420681 and CC O O
14 372 379 7420681 treated VBN B-VP O
15 380 384 7420681 with IN B-PP O
16 385 386 7420681 2 CD B-NP O
17 387 389 7420681 to TO I-NP O
18 390 391 7420681 5 CD I-NP O
19 392 394 7420681 mg NN I-NP O
20 394 395 7420681 / SYM B-NP O
21 395 397 7420681 kg NN I-NP O
22 397 398 7420681 / SYM B-NP O
23 398 401 7420681 day NN I-NP O
24 402 404 7420681 of IN B-PP O
25 405 415 7420681 gentamicin NN B-NP B-Chemical
26 416 423 7420681 sulfate NN I-NP I-Chemical
27 424 426 7420681 or CC O O
28 427 437 7420681 tobramycin NN B-NP B-Chemical
29 438 445 7420681 sulfate NN I-NP I-Chemical
30 446 449 7420681 for IN B-PP O
31 450 451 7420681 a DT B-NP O
32 452 459 7420681 minimum NN I-NP O
33 460 462 7420681 of IN B-PP O
34 463 468 7420681 seven CD B-NP O
35 469 473 7420681 days NNS I-NP O
36 474 478 7420681 were VBD B-VP O
37 479 487 7420681 followed VBN I-VP O
38 488 490 7420681 up RP B-PRT O
39 491 504 7420681 prospectively RB B-ADVP O
40 505 508 7420681 for IN B-PP O
41 509 512 7420681 the DT B-NP O
42 513 524 7420681 development NN I-NP O
43 525 527 7420681 of IN B-PP O
44 528 542 7420681 aminoglycoside NN B-NP B-Chemical
45 542 543 7420681 - HYPH O O
46 543 550 7420681 related VBN B-NP O
47 551 556 7420681 renal JJ I-NP B-Disease
48 557 564 7420681 failure NN I-NP I-Disease
49 564 565 7420681 , , O O
50 566 573 7420681 defined VBN B-VP O
51 574 576 7420681 as IN B-PP O
52 577 579 7420681 at IN B-ADVP O
53 580 585 7420681 least JJS I-ADVP O
54 586 587 7420681 a DT B-NP O
55 588 591 7420681 one CD I-NP O
56 591 592 7420681 - HYPH I-NP O
57 592 597 7420681 third JJ I-NP O
58 598 607 7420681 reduction NN I-NP O
59 608 610 7420681 in IN B-PP O
60 611 616 7420681 renal JJ B-NP O
61 617 625 7420681 function NN I-NP O
62 625 626 7420681 . . O O

1 627 629 7420681 In IN B-PP O
2 630 635 7420681 these DT B-NP O
3 636 638 7420681 62 CD I-NP O
4 639 647 7420681 patients NNS I-NP O
5 647 648 7420681 , , O O
6 649 651 7420681 no DT B-NP O
7 652 657 7420681 other JJ I-NP O
8 658 664 7420681 causes NNS I-NP O
9 665 668 7420681 for IN B-PP O
10 669 674 7420681 renal JJ B-NP B-Disease
11 675 682 7420681 failure NN I-NP I-Disease
12 683 688 7420681 could MD B-VP O
13 689 691 7420681 be VB I-VP O
14 692 702 7420681 identified VBN I-VP O
15 702 703 7420681 . . O O

1 704 708 7420681 Five CD B-NP O
2 709 711 7420681 of IN B-PP O
3 712 714 7420681 33 CD B-NP O
4 715 716 7420681 ( ( O O
5 716 719 7420681 15% NN B-NP O
6 719 720 7420681 ) ) O O
7 721 723 7420681 of IN B-PP O
8 724 727 7420681 the DT B-NP O
9 728 738 7420681 tobramycin NN I-NP B-Chemical
10 738 739 7420681 - HYPH B-NP O
11 739 746 7420681 treated VBN I-NP O
12 747 755 7420681 patients NNS I-NP O
13 756 759 7420681 and CC O O
14 760 762 7420681 16 CD B-NP O
15 763 765 7420681 of IN B-PP O
16 766 768 7420681 29 CD B-NP O
17 769 770 7420681 ( ( O O
18 770 775 7420681 55.2% NN B-NP O
19 775 776 7420681 ) ) O O
20 777 779 7420681 of IN B-PP O
21 780 783 7420681 the DT B-NP O
22 784 794 7420681 gentamicin NN I-NP B-Chemical
23 794 795 7420681 - HYPH B-NP O
24 795 802 7420681 treated VBN I-NP O
25 803 811 7420681 patients NNS I-NP O
26 812 815 7420681 had VBD B-VP O
27 816 821 7420681 renal JJ B-NP B-Disease
28 822 829 7420681 failure NN I-NP I-Disease
29 829 830 7420681 . . O O

1 831 835 7420681 Thus RB B-ADVP O
2 835 836 7420681 , , O O
3 837 847 7420681 gentamicin NN B-NP B-Chemical
4 848 851 7420681 was VBD B-VP O
5 852 862 7420681 associated VBN I-VP O
6 863 867 7420681 with IN B-PP O
7 868 873 7420681 renal JJ B-NP B-Disease
8 874 881 7420681 failure NN I-NP I-Disease
9 882 886 7420681 more JJR B-NP O
10 887 891 7420681 than IN I-NP O
11 892 897 7420681 three CD I-NP O
12 898 903 7420681 times NNS I-NP O
13 904 906 7420681 as RB I-NP O
14 907 912 7420681 often RB I-NP O
15 913 915 7420681 as IN I-NP O
16 916 919 7420681 was VBD B-VP O
17 920 930 7420681 tobramycin NN B-NP B-Chemical
18 930 931 7420681 . . O O

1 0 0 2440413 -DOCSTART- -X- -X- O

1 0 12 2440413 Differential JJ B-NP O
2 13 20 2440413 effects NNS I-NP O
3 21 23 2440413 of IN B-PP O
4 24 29 2440413 gamma SYM O B-Chemical
5 29 30 2440413 - HYPH O I-Chemical
6 30 51 2440413 hexachlorocyclohexane NN B-NP I-Chemical
7 52 53 2440413 ( ( O O
8 53 60 2440413 lindane NN B-NP B-Chemical
9 60 61 2440413 ) ) O O
10 62 64 2440413 on IN B-PP O
11 65 82 2440413 pharmacologically RB B-NP O
12 82 83 2440413 - HYPH I-NP O
13 83 90 2440413 induced VBN I-NP O
14 91 99 2440413 seizures NNS I-NP B-Disease
15 99 100 2440413 . . O O
16 101 106 2440413 Gamma NN B-NP B-Chemical
17 106 107 2440413 - HYPH B-NP I-Chemical
18 107 128 2440413 hexachlorocyclohexane NN I-NP I-Chemical
19 129 130 2440413 ( ( O O
20 130 135 2440413 gamma SYM O B-Chemical
21 135 136 2440413 - HYPH O I-Chemical
22 136 139 2440413 HCH NN B-NP I-Chemical
23 139 140 2440413 ) ) O O
24 140 141 2440413 , , O O
25 142 145 2440413 the DT B-NP O
26 146 152 2440413 active JJ I-NP O
27 153 163 2440413 ingredient NN I-NP O
28 164 166 2440413 of IN B-PP O
29 167 170 2440413 the DT B-NP O
30 171 182 2440413 insecticide NN I-NP O
31 183 190 2440413 lindane NN I-NP B-Chemical
32 190 191 2440413 , , O O
33 192 195 2440413 has VBZ B-VP O
34 196 200 2440413 been VBN I-VP O
35 201 206 2440413 shown VBN I-VP O
36 207 209 2440413 to TO I-VP O
37 210 218 2440413 decrease VB I-VP O
38 219 226 2440413 seizure NN B-NP B-Disease
39 227 236 2440413 threshold NN I-NP O
40 237 239 2440413 to TO B-PP O
41 240 255 2440413 pentylenetrazol NN B-NP O
42 256 257 2440413 ( ( O O
43 257 260 2440413 PTZ NN B-NP B-Chemical
44 260 261 2440413 ) ) O O
45 262 263 2440413 3 CD B-NP O
46 264 265 2440413 h NN I-NP O
47 266 271 2440413 after IN B-PP O
48 272 280 2440413 exposure NN B-NP O
49 281 283 2440413 to TO B-PP O
50 284 289 2440413 gamma SYM B-NP B-Chemical
51 289 290 2440413 - HYPH B-NP I-Chemical
52 290 293 2440413 HCH NN I-NP I-Chemical
53 294 297 2440413 and CC O O
54 298 308 2440413 conversely RB B-VP O
55 309 317 2440413 increase VBP I-VP O
56 318 327 2440413 threshold NN B-NP O
57 328 330 2440413 to TO B-PP O
58 331 334 2440413 PTZ NN B-NP B-Chemical
59 334 335 2440413 - HYPH B-NP O
60 335 342 2440413 induced VBN I-NP O
61 343 351 2440413 seizures NNS I-NP B-Disease
62 352 354 2440413 24 CD B-NP O
63 355 356 2440413 h NN I-NP O
64 357 362 2440413 after IN B-PP O
65 363 371 2440413 exposure NN B-NP O
66 372 374 2440413 to TO B-PP O
67 375 380 2440413 gamma SYM B-NP B-Chemical
68 380 381 2440413 - HYPH B-NP I-Chemical
69 381 384 2440413 HCH NN I-NP I-Chemical
70 385 386 2440413 ( ( O O
71 386 393 2440413 Vohland NNP B-NP O
72 394 396 2440413 et FW I-NP O
73 397 400 2440413 al. FW I-NP O
74 401 405 2440413 1981 CD I-NP O
75 405 406 2440413 ) ) O O
76 406 407 2440413 . . O O

1 408 410 2440413 In IN B-PP O
2 411 415 2440413 this DT B-NP O
3 416 421 2440413 study NN I-NP O
4 421 422 2440413 , , O O
5 423 426 2440413 the DT B-NP O
6 427 435 2440413 severity NN I-NP O
7 436 438 2440413 of IN B-PP O
8 439 447 2440413 response NN B-NP O
9 448 450 2440413 to TO B-PP O
10 451 456 2440413 other JJ B-NP O
11 457 464 2440413 seizure NN I-NP B-Disease
12 464 465 2440413 - HYPH B-VP O
13 465 473 2440413 inducing VBG B-NP O
14 474 480 2440413 agents NNS I-NP O
15 481 484 2440413 was VBD B-VP O
16 485 491 2440413 tested VBN I-VP O
17 492 494 2440413 in IN B-PP O
18 495 499 2440413 mice NNS B-NP O
19 500 501 2440413 1 CD I-NP O
20 502 505 2440413 and CC I-NP O
21 506 508 2440413 24 CD I-NP O
22 509 510 2440413 h NN I-NP O
23 511 516 2440413 after IN B-SBAR O
24 517 532 2440413 intraperitoneal JJ B-NP O
25 533 547 2440413 administration NN I-NP O
26 548 550 2440413 of IN B-PP O
27 551 553 2440413 80 CD B-NP O
28 554 556 2440413 mg NN I-NP O
29 556 557 2440413 / SYM B-NP O
30 557 559 2440413 kg NN I-NP O
31 560 565 2440413 gamma SYM O B-Chemical
32 565 566 2440413 - HYPH O I-Chemical
33 566 569 2440413 HCH NN B-NP I-Chemical
34 569 570 2440413 . . O O

1 571 574 2440413 One CD B-NP O
2 575 579 2440413 hour NN I-NP O
3 580 585 2440413 after IN B-SBAR O
4 586 589 2440413 the DT B-NP O
5 590 604 2440413 administration NN I-NP O
6 605 607 2440413 of IN B-PP O
7 608 613 2440413 gamma SYM B-NP B-Chemical
8 613 614 2440413 - HYPH O I-Chemical
9 614 617 2440413 HCH NN B-NP I-Chemical
10 617 618 2440413 , , O O
11 619 622 2440413 the DT B-NP O
12 623 631 2440413 activity NN I-NP O
13 632 634 2440413 of IN B-PP O
14 635 642 2440413 seizure NN B-NP B-Disease
15 642 643 2440413 - HYPH O O
16 643 651 2440413 inducing VBG B-NP O
17 652 658 2440413 agents NNS I-NP O
18 659 662 2440413 was VBD B-VP O
19 663 672 2440413 increased VBN I-VP O
20 672 673 2440413 , , O O
21 674 684 2440413 regardless RB B-ADVP O
22 685 687 2440413 of IN B-PP O
23 688 693 2440413 their PRP$ B-NP O
24 694 703 2440413 mechanism NN I-NP O
25 703 704 2440413 , , O O
26 705 710 2440413 while IN B-SBAR O
27 711 713 2440413 24 CD B-NP O
28 714 715 2440413 h NN I-NP O
29 716 721 2440413 after IN B-PP O
30 722 727 2440413 gamma SYM B-NP B-Chemical
31 727 728 2440413 - HYPH B-NP I-Chemical
32 728 731 2440413 HCH NN I-NP I-Chemical
33 732 733 2440413 a DT B-NP O
34 734 746 2440413 differential JJ I-NP O
35 747 755 2440413 response NN I-NP O
36 756 759 2440413 was VBD B-VP O
37 760 768 2440413 observed VBN I-VP O
38 768 769 2440413 . . O O

1 770 777 2440413 Seizure NN B-NP B-Disease
2 778 786 2440413 activity NN I-NP O
3 787 790 2440413 due IN B-PP O
4 791 793 2440413 to TO B-PP O
5 794 797 2440413 PTZ NN B-NP B-Chemical
6 798 801 2440413 and CC I-NP O
7 802 812 2440413 picrotoxin NN I-NP B-Chemical
8 813 814 2440413 ( ( O O
9 814 817 2440413 PTX NN B-NP B-Chemical
10 817 818 2440413 ) ) O O
11 819 822 2440413 was VBD B-VP O
12 823 836 2440413 significantly RB I-VP O
13 837 846 2440413 decreased VBN I-VP O
14 846 847 2440413 ; : O O
15 848 855 2440413 however RB B-ADVP O
16 855 856 2440413 , , O O
17 857 864 2440413 seizure NN B-NP B-Disease
18 865 873 2440413 activity NN I-NP O
19 874 877 2440413 due IN B-PP O
20 878 880 2440413 to TO B-PP O
21 881 882 2440413 3 CD B-NP B-Chemical
22 882 883 2440413 - HYPH I-NP I-Chemical
23 883 900 2440413 mercaptopropionic JJ I-NP I-Chemical
24 901 905 2440413 acid NN I-NP I-Chemical
25 906 907 2440413 ( ( O O
26 907 910 2440413 MPA NN B-NP B-Chemical
27 910 911 2440413 ) ) O O
28 911 912 2440413 , , O O
29 913 924 2440413 bicuculline NN B-NP B-Chemical
30 925 926 2440413 ( ( O O
31 926 929 2440413 BCC NN B-NP B-Chemical
32 929 930 2440413 ) ) O O
33 930 931 2440413 , , O O
34 932 938 2440413 methyl NN B-NP B-Chemical
35 939 942 2440413 6,7 CD I-NP I-Chemical
36 942 943 2440413 - HYPH I-NP I-Chemical
37 943 952 2440413 dimethoxy NN I-NP I-Chemical
38 952 953 2440413 - HYPH B-NP I-Chemical
39 953 954 2440413 4 CD I-NP I-Chemical
40 954 955 2440413 - HYPH I-NP I-Chemical
41 955 960 2440413 ethyl NN I-NP I-Chemical
42 960 961 2440413 - HYPH B-NP I-Chemical
43 961 962 2440413 B NN I-NP I-Chemical
44 962 963 2440413 - HYPH O I-Chemical
45 963 972 2440413 carboline NN B-NP I-Chemical
46 972 973 2440413 - HYPH B-NP I-Chemical
47 973 974 2440413 3 CD I-NP I-Chemical
48 974 975 2440413 - HYPH I-NP I-Chemical
49 975 986 2440413 carboxylate NN I-NP I-Chemical
50 987 988 2440413 ( ( O O
51 988 992 2440413 DMCM NN B-NP B-Chemical
52 992 993 2440413 ) ) O O
53 993 994 2440413 , , O O
54 995 997 2440413 or CC O O
55 998 1008 2440413 strychnine NN B-NP B-Chemical
56 1009 1010 2440413 ( ( O O
57 1010 1013 2440413 STR NN B-NP B-Chemical
58 1013 1014 2440413 ) ) O O
59 1015 1018 2440413 was VBD B-VP O
60 1019 1022 2440413 not RB O O
61 1023 1032 2440413 different JJ B-ADJP O
62 1033 1037 2440413 from IN B-PP O
63 1038 1045 2440413 control NN B-NP O
64 1045 1046 2440413 . . O O

1 1047 1049 2440413 In FW B-ADVP O
2 1050 1055 2440413 vitro FW I-ADVP O
3 1055 1056 2440413 , , O O
4 1057 1062 2440413 gamma SYM B-NP B-Chemical
5 1062 1063 2440413 - HYPH I-NP I-Chemical
6 1063 1066 2440413 HCH NN I-NP I-Chemical
7 1066 1067 2440413 , , I-NP O
8 1068 1085 2440413 pentylenetetrazol NN I-NP B-Chemical
9 1086 1089 2440413 and CC I-NP O
10 1090 1100 2440413 picrotoxin NN I-NP B-Chemical
11 1101 1105 2440413 were VBD B-VP O
12 1106 1111 2440413 shown VBN I-VP O
13 1112 1114 2440413 to TO I-VP O
14 1115 1122 2440413 inhibit VB I-VP O
15 1123 1125 2440413 3H NN B-NP B-Chemical
16 1125 1126 2440413 - HYPH B-NP I-Chemical
17 1126 1130 2440413 TBOB NN I-NP I-Chemical
18 1131 1138 2440413 binding NN I-NP O
19 1139 1141 2440413 in IN B-PP O
20 1142 1147 2440413 mouse NN B-NP O
21 1148 1153 2440413 whole JJ I-NP O
22 1154 1159 2440413 brain NN I-NP O
23 1159 1160 2440413 , , O O
24 1161 1165 2440413 with IN B-PP O
25 1166 1170 2440413 IC50 NN B-NP O
26 1171 1177 2440413 values NNS I-NP O
27 1178 1180 2440413 of IN B-PP O
28 1181 1184 2440413 4.6 CD B-NP O
29 1184 1185 2440413 , , I-NP O
30 1186 1189 2440413 404 CD I-NP O
31 1190 1193 2440413 and CC I-NP O
32 1194 1197 2440413 9.4 CD I-NP O
33 1198 1204 2440413 microM NN I-NP O
34 1204 1205 2440413 , , O O
35 1206 1218 2440413 respectively RB B-ADVP O
36 1218 1219 2440413 . . O O

1 1220 1223 2440413 MPA NN B-NP B-Chemical
2 1223 1224 2440413 , , O O
3 1225 1228 2440413 BCC NN B-NP B-Chemical
4 1228 1229 2440413 , , O O
5 1230 1234 2440413 DMCM NN B-NP B-Chemical
6 1234 1235 2440413 , , O O
7 1236 1239 2440413 and CC O O
8 1240 1243 2440413 STR NN B-NP B-Chemical
9 1244 1250 2440413 showed VBD B-VP O
10 1251 1253 2440413 no DT B-NP O
11 1254 1264 2440413 inhibition NN I-NP O
12 1265 1267 2440413 of IN B-PP O
13 1268 1270 2440413 3H NN B-NP B-Chemical
14 1270 1271 2440413 - HYPH B-NP I-Chemical
15 1271 1275 2440413 TBOB NN I-NP I-Chemical
16 1276 1277 2440413 ( ( O O
17 1277 1278 2440413 t NN B-NP B-Chemical
18 1278 1279 2440413 - HYPH B-NP I-Chemical
19 1279 1284 2440413 butyl NN I-NP I-Chemical
20 1285 1292 2440413 bicyclo AFX O I-Chemical
21 1292 1293 2440413 - HYPH B-NP I-Chemical
22 1293 1306 2440413 orthobenzoate NN I-NP I-Chemical
23 1306 1307 2440413 ) ) O O
24 1308 1315 2440413 binding NN B-NP O
25 1316 1318 2440413 at IN B-PP O
26 1319 1333 2440413 concentrations NNS B-NP O
27 1334 1336 2440413 of IN B-PP O
28 1337 1340 2440413 100 CD B-NP O
29 1341 1347 2440413 micron NN I-NP O
30 1347 1348 2440413 . . O O

1 1349 1352 2440413 The DT B-NP O
2 1353 1368 2440413 pharmacological JJ I-NP O
3 1369 1378 2440413 challenge NN I-NP O
4 1379 1383 2440413 data NNS I-NP O
5 1384 1391 2440413 suggest VBP B-VP O
6 1392 1396 2440413 that IN B-SBAR O
7 1397 1406 2440413 tolerance NN B-NP O
8 1407 1410 2440413 may MD B-VP O
9 1411 1416 2440413 occur VB I-VP O
10 1417 1419 2440413 to TO B-PP O
11 1420 1427 2440413 seizure NN B-NP B-Disease
12 1428 1436 2440413 activity NN I-NP O
13 1437 1444 2440413 induced VBN B-VP O
14 1445 1447 2440413 by IN B-PP O
15 1448 1451 2440413 PTZ NN B-NP B-Chemical
16 1452 1455 2440413 and CC I-NP O
17 1456 1459 2440413 PTX NN I-NP B-Chemical
18 1460 1462 2440413 24 CD I-NP O
19 1463 1464 2440413 h NN I-NP O
20 1465 1470 2440413 after IN B-PP O
21 1471 1476 2440413 gamma SYM B-NP B-Chemical
22 1476 1477 2440413 - HYPH B-NP I-Chemical
23 1477 1480 2440413 HCH NN I-NP I-Chemical
24 1480 1481 2440413 , , O O
25 1482 1487 2440413 since IN B-SBAR O
26 1488 1491 2440413 the DT B-NP O
27 1492 1500 2440413 response NN I-NP O
28 1501 1503 2440413 to TO B-PP O
29 1504 1508 2440413 only RB B-NP O
30 1509 1514 2440413 these DT I-NP O
31 1515 1518 2440413 two CD I-NP O
32 1519 1526 2440413 seizure NN I-NP B-Disease
33 1526 1527 2440413 - HYPH B-VP O
34 1527 1535 2440413 inducing VBG B-NP O
35 1536 1542 2440413 agents NNS I-NP O
36 1543 1545 2440413 is VBZ B-VP O
37 1546 1555 2440413 decreased VBN I-VP O
38 1555 1556 2440413 . . O O

1 1557 1560 2440413 The DT B-NP O
2 1561 1563 2440413 in FW I-NP O
3 1564 1569 2440413 vitro FW I-NP O
4 1570 1574 2440413 data NNS I-NP O
5 1575 1582 2440413 suggest VBP B-VP O
6 1583 1587 2440413 that IN B-SBAR O
7 1588 1591 2440413 the DT B-NP O
8 1592 1596 2440413 site NN I-NP O
9 1597 1608 2440413 responsible JJ B-ADJP O
10 1609 1612 2440413 for IN B-PP O
11 1613 1616 2440413 the DT B-NP O
12 1617 1625 2440413 decrease NN I-NP O
13 1626 1628 2440413 in IN B-PP O
14 1629 1636 2440413 seizure NN B-NP B-Disease
15 1637 1645 2440413 activity NN I-NP O
16 1646 1648 2440413 24 CD B-NP O
17 1649 1650 2440413 h NN I-NP O
18 1651 1656 2440413 after IN B-PP O
19 1657 1662 2440413 gamma SYM O B-Chemical
20 1662 1663 2440413 - HYPH O I-Chemical
21 1663 1666 2440413 HCH NN B-NP I-Chemical
22 1667 1670 2440413 may MD B-VP O
23 1671 1673 2440413 be VB I-VP O
24 1674 1677 2440413 the DT B-NP O
25 1678 1682 2440413 GABA NN I-NP B-Chemical
26 1682 1683 2440413 - HYPH O O
27 1683 1684 2440413 A NN B-NP O
28 1685 1693 2440413 receptor NN I-NP O
29 1693 1694 2440413 - HYPH B-VP O
30 1694 1700 2440413 linked VBN B-NP O
31 1701 1709 2440413 chloride NN I-NP O
32 1710 1717 2440413 channel NN I-NP O
33 1717 1718 2440413 . . O O

1 0 0 18809400 -DOCSTART- -X- -X- O

1 0 5 18809400 Alpha NN B-NP B-Chemical
2 5 6 18809400 - HYPH I-NP I-Chemical
3 6 12 18809400 lipoic JJ I-NP I-Chemical
4 13 17 18809400 acid NN I-NP I-Chemical
5 18 26 18809400 prevents VBZ B-VP O
6 27 40 18809400 mitochondrial JJ B-NP B-Disease
7 41 47 18809400 damage NN I-NP I-Disease
8 48 51 18809400 and CC I-NP O
9 52 65 18809400 neurotoxicity NN I-NP B-Disease
10 66 68 18809400 in IN B-PP O
11 69 81 18809400 experimental JJ B-NP O
12 82 94 18809400 chemotherapy NN I-NP O
13 95 105 18809400 neuropathy NN I-NP B-Disease
14 105 106 18809400 . . O O
15 107 110 18809400 The DT B-NP O
16 111 116 18809400 study NN I-NP O
17 117 129 18809400 investigates VBZ B-VP O
18 130 132 18809400 if IN B-SBAR O
19 133 138 18809400 alpha SYM B-NP B-Chemical
20 138 139 18809400 - HYPH B-VP I-Chemical
21 139 145 18809400 lipoic JJ B-NP I-Chemical
22 146 150 18809400 acid NN I-NP I-Chemical
23 151 153 18809400 is VBZ B-VP O
24 154 169 18809400 neuroprotective JJ B-ADJP O
25 170 177 18809400 against IN B-PP O
26 178 190 18809400 chemotherapy NN B-NP O
27 191 198 18809400 induced VBD B-VP O
28 199 212 18809400 neurotoxicity NN B-NP B-Disease
29 212 213 18809400 , , O O
30 214 216 18809400 if IN B-SBAR O
31 217 230 18809400 mitochondrial JJ B-NP B-Disease
32 231 237 18809400 damage NN I-NP I-Disease
33 238 243 18809400 plays VBZ B-VP O
34 244 245 18809400 a DT B-NP O
35 246 254 18809400 critical JJ I-NP O
36 255 259 18809400 role NN I-NP O
37 260 262 18809400 in IN B-PP O
38 263 268 18809400 toxic JJ B-NP B-Disease
39 269 286 18809400 neurodegenerative JJ I-NP I-Disease
40 287 294 18809400 cascade NN I-NP I-Disease
41 294 295 18809400 , , O O
42 296 299 18809400 and CC O O
43 300 302 18809400 if IN B-SBAR O
44 303 318 18809400 neuroprotective JJ B-NP O
45 319 326 18809400 effects NNS I-NP O
46 327 329 18809400 of IN B-PP O
47 330 335 18809400 alpha SYM B-NP B-Chemical
48 335 336 18809400 - HYPH B-NP I-Chemical
49 336 342 18809400 lipoic JJ I-NP I-Chemical
50 343 347 18809400 acid NN I-NP I-Chemical
51 348 354 18809400 depend VBP B-VP O
52 355 357 18809400 on IN B-PP O
53 358 370 18809400 mitochondria NNS B-NP O
54 371 381 18809400 protection NN I-NP O
55 381 382 18809400 . . O O

1 383 385 18809400 We PRP B-NP O
2 386 390 18809400 used VBD B-VP O
3 391 393 18809400 an DT B-NP O
4 394 396 18809400 in FW I-NP O
5 397 402 18809400 vitro FW I-NP O
6 403 408 18809400 model NN I-NP O
7 409 411 18809400 of IN B-PP O
8 412 424 18809400 chemotherapy NN B-NP O
9 425 432 18809400 induced JJ I-NP O
10 433 443 18809400 peripheral JJ I-NP B-Disease
11 444 454 18809400 neuropathy NN I-NP I-Disease
12 455 459 18809400 that WDT B-NP O
13 460 467 18809400 closely RB B-ADVP O
14 468 473 18809400 mimic VBP B-VP O
15 474 477 18809400 the DT B-NP O
16 478 480 18809400 in FW I-NP O
17 481 485 18809400 vivo FW I-NP O
18 486 495 18809400 condition NN I-NP O
19 496 498 18809400 by IN B-PP O
20 499 507 18809400 exposing VBG B-VP O
21 508 515 18809400 primary JJ B-NP O
22 516 524 18809400 cultures NNS I-NP O
23 525 527 18809400 of IN B-PP O
24 528 534 18809400 dorsal JJ B-NP O
25 535 539 18809400 root NN I-NP O
26 540 548 18809400 ganglion NN I-NP O
27 549 550 18809400 ( ( O O
28 550 553 18809400 DRG NN B-NP O
29 553 554 18809400 ) ) O O
30 555 562 18809400 sensory JJ B-NP O
31 563 570 18809400 neurons NNS I-NP O
32 571 573 18809400 to TO B-PP O
33 574 584 18809400 paclitaxel NN B-NP B-Chemical
34 585 588 18809400 and CC I-NP O
35 589 598 18809400 cisplatin NN I-NP B-Chemical
36 598 599 18809400 , , O O
37 600 603 18809400 two CD B-NP O
38 604 610 18809400 widely RB I-NP O
39 611 615 18809400 used VBN I-NP O
40 616 619 18809400 and CC O O
41 620 626 18809400 highly RB B-NP O
42 627 636 18809400 effective JJ I-NP O
43 637 653 18809400 chemotherapeutic JJ I-NP O
44 654 659 18809400 drugs NNS I-NP O
45 659 660 18809400 . . O O

1 661 665 18809400 This DT B-NP O
2 666 674 18809400 approach NN I-NP O
3 675 682 18809400 allowed VBD B-VP O
4 683 696 18809400 investigating VBG I-VP O
5 697 700 18809400 the DT B-NP O
6 701 709 18809400 efficacy NN I-NP O
7 710 712 18809400 of IN B-PP O
8 713 718 18809400 alpha SYM B-NP B-Chemical
9 718 719 18809400 - HYPH O I-Chemical
10 719 725 18809400 lipoic JJ B-NP I-Chemical
11 726 730 18809400 acid NN I-NP I-Chemical
12 731 733 18809400 in IN B-PP O
13 734 744 18809400 preventing VBG B-VP O
14 745 751 18809400 axonal JJ B-NP B-Disease
15 752 758 18809400 damage NN I-NP I-Disease
16 759 762 18809400 and CC I-NP O
17 763 772 18809400 apoptosis NN I-NP O
18 773 776 18809400 and CC O O
19 777 780 18809400 the DT B-NP O
20 781 789 18809400 function NN I-NP O
21 790 793 18809400 and CC I-NP O
22 794 809 18809400 ultrastructural JJ I-NP O
23 810 820 18809400 morphology NN I-NP O
24 821 823 18809400 of IN B-PP O
25 824 836 18809400 mitochondria NNS B-NP O
26 837 842 18809400 after IN B-PP O
27 843 851 18809400 exposure NN B-NP O
28 852 854 18809400 to TO B-PP O
29 855 860 18809400 toxic JJ B-NP O
30 861 867 18809400 agents NNS I-NP O
31 868 871 18809400 and CC O O
32 872 877 18809400 alpha SYM B-NP B-Chemical
33 877 878 18809400 - HYPH O I-Chemical
34 878 884 18809400 lipoic JJ B-NP I-Chemical
35 885 889 18809400 acid NN I-NP I-Chemical
36 889 890 18809400 . . O O

1 891 894 18809400 Our PRP$ B-NP O
2 895 902 18809400 results NNS I-NP O
3 903 914 18809400 demonstrate VBP B-VP O
4 915 919 18809400 that IN B-SBAR O
5 920 924 18809400 both CC O O
6 925 934 18809400 cisplatin NN B-NP B-Chemical
7 935 938 18809400 and CC I-NP O
8 939 949 18809400 paclitaxel NN I-NP B-Chemical
9 950 955 18809400 cause VBP B-VP O
10 956 961 18809400 early JJ B-NP O
11 962 975 18809400 mitochondrial JJ I-NP B-Disease
12 976 986 18809400 impairment NN I-NP I-Disease
13 987 991 18809400 with IN B-PP O
14 992 996 18809400 loss NN B-NP O
15 997 999 18809400 of IN B-PP O
16 1000 1008 18809400 membrane NN B-NP O
17 1009 1018 18809400 potential NN I-NP O
18 1019 1022 18809400 and CC O O
19 1023 1032 18809400 induction NN B-NP O
20 1033 1035 18809400 of IN B-PP O
21 1036 1046 18809400 autophagic JJ B-NP O
22 1047 1055 18809400 vacuoles NNS I-NP O
23 1056 1058 18809400 in IN B-PP O
24 1059 1066 18809400 neurons NNS B-NP O
25 1066 1067 18809400 . . O O

1 1068 1073 18809400 Alpha NN B-NP B-Chemical
2 1073 1074 18809400 - HYPH I-NP I-Chemical
3 1074 1080 18809400 lipoic JJ I-NP I-Chemical
4 1081 1085 18809400 acid NN I-NP I-Chemical
5 1086 1092 18809400 exerts VBZ B-VP O
6 1093 1108 18809400 neuroprotective JJ B-NP O
7 1109 1116 18809400 effects NNS I-NP O
8 1117 1124 18809400 against IN B-PP O
9 1125 1137 18809400 chemotherapy NN B-NP O
10 1138 1145 18809400 induced VBD B-VP O
11 1146 1159 18809400 neurotoxicity NN B-NP B-Disease
12 1160 1162 18809400 in IN B-PP O
13 1163 1170 18809400 sensory JJ B-NP O
14 1171 1178 18809400 neurons NNS I-NP O
15 1178 1179 18809400 : : O O
16 1180 1182 18809400 it PRP B-NP O
17 1183 1190 18809400 rescues VBZ B-VP O
18 1191 1194 18809400 the DT B-NP O
19 1195 1208 18809400 mitochondrial JJ I-NP B-Disease
20 1209 1217 18809400 toxicity NN I-NP I-Disease
21 1218 1221 18809400 and CC O O
22 1222 1229 18809400 induces VBZ B-VP O
23 1230 1233 18809400 the DT B-NP O
24 1234 1244 18809400 expression NN I-NP O
25 1245 1247 18809400 of IN B-PP O
26 1248 1256 18809400 frataxin NN B-NP O
27 1256 1257 18809400 , , O O
28 1258 1260 18809400 an DT B-NP O
29 1261 1270 18809400 essential JJ I-NP O
30 1271 1284 18809400 mitochondrial JJ I-NP O
31 1285 1292 18809400 protein NN I-NP O
32 1293 1297 18809400 with IN B-PP O
33 1298 1302 18809400 anti AFX B-NP O
34 1302 1303 18809400 - HYPH I-NP O
35 1303 1310 18809400 oxidant JJ I-NP O
36 1311 1314 18809400 and CC I-NP O
37 1315 1324 18809400 chaperone NN I-NP O
38 1325 1335 18809400 properties NNS I-NP O
39 1335 1336 18809400 . . O O

1 1337 1339 18809400 In IN B-PP O
2 1340 1350 18809400 conclusion NN B-NP O
3 1351 1364 18809400 mitochondrial JJ I-NP B-Disease
4 1365 1373 18809400 toxicity NN I-NP I-Disease
5 1374 1376 18809400 is VBZ B-VP O
6 1377 1379 18809400 an DT B-NP O
7 1380 1385 18809400 early JJ I-NP O
8 1386 1392 18809400 common JJ I-NP O
9 1393 1398 18809400 event NN I-NP O
10 1399 1403 18809400 both CC B-PP O
11 1404 1406 18809400 in IN B-PP O
12 1407 1417 18809400 paclitaxel NN B-NP B-Chemical
13 1418 1421 18809400 and CC I-NP O
14 1422 1431 18809400 cisplatin NN I-NP B-Chemical
15 1432 1439 18809400 induced VBD B-VP O
16 1440 1453 18809400 neurotoxicity NN B-NP B-Disease
17 1453 1454 18809400 . . O O

1 1455 1460 18809400 Alpha NN B-NP B-Chemical
2 1460 1461 18809400 - HYPH I-NP I-Chemical
3 1461 1467 18809400 lipoic JJ I-NP I-Chemical
4 1468 1472 18809400 acid NN I-NP I-Chemical
5 1473 1481 18809400 protects VBZ B-VP O
6 1482 1489 18809400 sensory JJ B-NP O
7 1490 1497 18809400 neurons NNS I-NP O
8 1498 1505 18809400 through IN B-PP O
9 1506 1509 18809400 its PRP$ B-NP O
10 1510 1514 18809400 anti AFX I-NP O
11 1514 1515 18809400 - HYPH I-NP O
12 1515 1522 18809400 oxidant JJ I-NP O
13 1523 1526 18809400 and CC I-NP O
14 1527 1540 18809400 mitochondrial JJ I-NP O
15 1541 1551 18809400 regulatory JJ I-NP O
16 1552 1561 18809400 functions NNS I-NP O
17 1561 1562 18809400 , , O O
18 1563 1571 18809400 possibly RB B-ADVP O
19 1572 1580 18809400 inducing VBG B-VP O
20 1581 1584 18809400 the DT B-NP O
21 1585 1595 18809400 expression NN I-NP O
22 1596 1598 18809400 of IN B-PP O
23 1599 1607 18809400 frataxin NN B-NP O
24 1607 1608 18809400 . . O O

1 1609 1614 18809400 These DT B-NP O
2 1615 1623 18809400 findings NNS I-NP O
3 1624 1631 18809400 suggest VBP B-VP O
4 1632 1636 18809400 that IN B-SBAR O
5 1637 1642 18809400 alpha SYM B-NP B-Chemical
6 1642 1643 18809400 - HYPH B-VP I-Chemical
7 1643 1649 18809400 lipoic JJ B-NP I-Chemical
8 1650 1654 18809400 acid NN I-NP I-Chemical
9 1655 1660 18809400 might MD B-VP O
10 1661 1667 18809400 reduce VB I-VP O
11 1668 1671 18809400 the DT B-NP O
12 1672 1676 18809400 risk NN I-NP O
13 1677 1679 18809400 of IN B-PP O
14 1680 1690 18809400 developing VBG B-VP O
15 1691 1701 18809400 peripheral JJ B-NP B-Disease
16 1702 1707 18809400 nerve NN I-NP I-Disease
17 1708 1716 18809400 toxicity NN I-NP I-Disease
18 1717 1719 18809400 in IN B-PP O
19 1720 1728 18809400 patients NNS B-NP O
20 1729 1739 18809400 undergoing VBG B-VP O
21 1740 1752 18809400 chemotherapy NN B-NP O
22 1753 1756 18809400 and CC O O
23 1757 1766 18809400 encourage VB B-VP O
24 1767 1774 18809400 further JJ B-NP O
25 1775 1787 18809400 confirmatory JJ I-NP O
26 1788 1796 18809400 clinical JJ I-NP O
27 1797 1803 18809400 trials NNS I-NP O
28 1803 1804 18809400 . . O O

1 0 0 9088814 -DOCSTART- -X- -X- O

1 0 8 9088814 Combined VBN B-NP O
2 9 16 9088814 effects NNS I-NP O
3 17 19 9088814 of IN B-PP O
4 20 29 9088814 prolonged VBN B-NP O
5 30 43 9088814 prostaglandin NN I-NP B-Chemical
6 44 46 9088814 E1 NN I-NP I-Chemical
7 46 47 9088814 - HYPH B-NP O
8 47 54 9088814 induced VBN I-NP O
9 55 66 9088814 hypotension NN I-NP B-Disease
10 67 70 9088814 and CC I-NP O
11 71 84 9088814 haemodilution NN I-NP B-Disease
12 85 87 9088814 on IN B-PP O
13 88 93 9088814 human JJ B-NP O
14 94 101 9088814 hepatic JJ I-NP O
15 102 110 9088814 function NN I-NP O
16 110 111 9088814 . . O O
17 112 120 9088814 Combined VBN B-NP O
18 121 128 9088814 effects NNS I-NP O
19 129 131 9088814 of IN B-PP O
20 132 141 9088814 prolonged VBN B-NP O
21 142 155 9088814 prostaglandin NN I-NP B-Chemical
22 156 158 9088814 E1 NN I-NP I-Chemical
23 159 160 9088814 ( ( O O
24 160 164 9088814 PGE1 NN B-NP B-Chemical
25 164 165 9088814 ) ) O O
26 165 166 9088814 - HYPH B-NP O
27 166 173 9088814 induced VBN I-NP O
28 174 185 9088814 hypotension NN I-NP B-Disease
29 186 189 9088814 and CC I-NP O
30 190 203 9088814 haemodilution NN I-NP B-Disease
31 204 206 9088814 on IN B-PP O
32 207 214 9088814 hepatic JJ B-NP O
33 215 223 9088814 function NN I-NP O
34 224 228 9088814 were VBD B-VP O
35 229 236 9088814 studied VBN I-VP O
36 237 239 9088814 in IN B-PP O
37 240 242 9088814 30 CD B-NP O
38 243 251 9088814 patients NNS I-NP O
39 252 262 9088814 undergoing VBG B-VP O
40 263 266 9088814 hip NN B-NP O
41 267 274 9088814 surgery NN I-NP O
42 274 275 9088814 . . O O

1 276 279 9088814 The DT B-NP O
2 280 288 9088814 patients NNS I-NP O
3 289 293 9088814 were VBD B-VP O
4 294 302 9088814 randomly RB I-VP O
5 303 312 9088814 allocated VBN I-VP O
6 313 315 9088814 to TO B-PP O
7 316 319 9088814 one CD B-NP O
8 320 322 9088814 of IN B-PP O
9 323 328 9088814 three CD B-NP O
10 329 335 9088814 groups NNS I-NP O
11 335 336 9088814 ; : O O
12 337 342 9088814 those DT B-NP O
13 343 345 9088814 in IN B-PP O
14 346 351 9088814 group NN B-NP O
15 352 353 9088814 A NN I-NP O
16 354 355 9088814 ( ( O O
17 355 356 9088814 n NN B-NP O
18 357 358 9088814 = SYM B-VP O
19 359 361 9088814 10 CD B-NP O
20 361 362 9088814 ) ) O O
21 363 367 9088814 were VBD B-VP O
22 368 377 9088814 subjected VBN I-VP O
23 378 380 9088814 to TO B-PP O
24 381 391 9088814 controlled VBN B-NP O
25 392 403 9088814 hypotension NN I-NP B-Disease
26 404 409 9088814 alone RB B-ADVP O
27 409 410 9088814 , , O O
28 411 416 9088814 those DT B-NP O
29 417 419 9088814 in IN B-PP O
30 420 425 9088814 group NN B-NP O
31 426 427 9088814 B NN I-NP O
32 428 429 9088814 ( ( O O
33 429 430 9088814 n NN B-NP O
34 431 432 9088814 = SYM B-VP O
35 433 435 9088814 10 CD B-NP O
36 435 436 9088814 ) ) O O
37 437 439 9088814 to TO B-PP O
38 440 453 9088814 haemodilution NN B-NP B-Disease
39 454 459 9088814 alone RB B-ADVP O
40 460 463 9088814 and CC O O
41 464 469 9088814 those DT B-NP O
42 470 472 9088814 in IN B-PP O
43 473 478 9088814 group NN B-NP O
44 479 480 9088814 C NN I-NP O
45 481 482 9088814 ( ( O O
46 482 483 9088814 n NN B-NP O
47 484 485 9088814 = SYM B-VP O
48 486 488 9088814 10 CD B-NP O
49 488 489 9088814 ) ) O O
50 490 492 9088814 to TO B-PP O
51 493 497 9088814 both CC O O
52 498 508 9088814 controlled JJ B-NP O
53 509 520 9088814 hypotension NN I-NP B-Disease
54 521 524 9088814 and CC I-NP O
55 525 538 9088814 haemodilution NN I-NP B-Disease
56 538 539 9088814 . . O O

1 540 553 9088814 Haemodilution NN B-NP B-Disease
2 554 556 9088814 in IN B-PP O
3 557 563 9088814 groups NNS B-NP O
4 564 565 9088814 B NN B-NP O
5 566 569 9088814 and CC O O
6 570 571 9088814 C NN B-NP O
7 572 575 9088814 was VBD B-VP O
8 576 584 9088814 produced VBN I-VP O
9 585 587 9088814 by IN B-PP O
10 588 599 9088814 withdrawing VBG B-VP O
11 600 613 9088814 approximately RB B-NP O
12 614 618 9088814 1000 CD I-NP O
13 619 621 9088814 mL NN I-NP O
14 622 624 9088814 of IN B-PP O
15 625 630 9088814 blood NN B-NP O
16 631 634 9088814 and CC O O
17 635 644 9088814 replacing VBG B-VP O
18 645 647 9088814 it PRP B-NP O
19 648 652 9088814 with IN B-PP O
20 653 656 9088814 the DT B-NP O
21 657 661 9088814 same JJ I-NP O
22 662 668 9088814 amount NN I-NP O
23 669 671 9088814 of IN B-PP O
24 672 679 9088814 dextran NN B-NP B-Chemical
25 680 688 9088814 solution NN I-NP O
26 688 689 9088814 , , O O
27 690 693 9088814 and CC O O
28 694 699 9088814 final JJ B-NP O
29 700 711 9088814 haematocrit NN I-NP O
30 712 718 9088814 values NNS I-NP O
31 719 723 9088814 were VBD B-VP O
32 724 726 9088814 21 CD B-NP O
33 727 729 9088814 or CC I-NP O
34 730 733 9088814 22% CD I-NP O
35 733 734 9088814 . . O O

1 735 745 9088814 Controlled VBN B-NP O
2 746 757 9088814 hypotension NN I-NP B-Disease
3 758 760 9088814 in IN B-PP O
4 761 767 9088814 groups NNS B-NP O
5 768 769 9088814 A NN I-NP O
6 770 773 9088814 and CC I-NP O
7 774 775 9088814 C NN I-NP O
8 776 779 9088814 was VBD B-VP O
9 780 787 9088814 induced VBN I-VP O
10 788 792 9088814 with IN B-PP O
11 793 797 9088814 PGE1 NN B-NP B-Chemical
12 798 800 9088814 to TO B-VP O
13 801 809 9088814 maintain VB I-VP O
14 810 814 9088814 mean JJ B-NP O
15 815 823 9088814 arterial JJ I-NP O
16 824 829 9088814 blood NN I-NP O
17 830 838 9088814 pressure NN I-NP O
18 839 841 9088814 at IN B-PP O
19 842 844 9088814 55 CD B-NP O
20 845 849 9088814 mmHg NN I-NP O
21 850 853 9088814 for IN B-PP O
22 854 857 9088814 180 CD B-NP O
23 858 861 9088814 min NN I-NP O
24 861 862 9088814 . . O O

1 863 875 9088814 Measurements NNS B-NP O
2 876 884 9088814 included VBD B-VP O
3 885 893 9088814 arterial JJ B-NP O
4 894 900 9088814 ketone NN I-NP O
5 901 905 9088814 body NN I-NP O
6 906 911 9088814 ratio NN I-NP O
7 912 913 9088814 ( ( O O
8 913 917 9088814 AKBR NN B-NP O
9 917 918 9088814 , , O O
10 919 924 9088814 aceto AFX B-NP B-Chemical
11 924 925 9088814 - HYPH I-NP I-Chemical
12 925 932 9088814 acetate NN I-NP I-Chemical
13 932 933 9088814 / SYM B-NP O
14 933 934 9088814 3 CD I-NP B-Chemical
15 934 935 9088814 - HYPH I-NP I-Chemical
16 935 950 9088814 hydroxybutyrate NN I-NP I-Chemical
17 950 951 9088814 ) ) O O
18 952 955 9088814 and CC O O
19 956 964 9088814 clinical JJ B-NP O
20 965 972 9088814 hepatic JJ I-NP O
21 973 981 9088814 function NN I-NP O
22 982 992 9088814 parameters NNS I-NP O
23 992 993 9088814 . . O O

1 994 998 9088814 AKBR NN B-NP O
2 999 1002 9088814 and CC I-NP O
3 1003 1013 9088814 biological JJ I-NP O
4 1014 1021 9088814 hepatic JJ I-NP O
5 1022 1030 9088814 function NN I-NP O
6 1031 1036 9088814 tests NNS I-NP O
7 1037 1043 9088814 showed VBD B-VP O
8 1044 1046 9088814 no DT B-NP O
9 1047 1053 9088814 change NN I-NP O
10 1054 1064 9088814 throughout IN B-PP O
11 1065 1068 9088814 the DT B-NP O
12 1069 1073 9088814 time NN I-NP O
13 1074 1080 9088814 course NN I-NP O
14 1081 1083 9088814 in IN B-PP O
15 1084 1090 9088814 groups NNS B-NP O
16 1091 1092 9088814 A NN I-NP O
17 1093 1096 9088814 and CC I-NP O
18 1097 1098 9088814 B NN I-NP O
19 1098 1099 9088814 . . O O

1 1100 1102 9088814 In IN B-PP O
2 1103 1108 9088814 group NN B-NP O
3 1109 1110 9088814 C NN I-NP O
4 1110 1111 9088814 , , O O
5 1112 1116 9088814 AKBR NN B-NP O
6 1117 1123 9088814 showed VBD B-VP O
7 1124 1125 9088814 a DT B-NP O
8 1126 1137 9088814 significant JJ I-NP O
9 1138 1146 9088814 decrease NN I-NP O
10 1147 1149 9088814 at IN B-PP O
11 1150 1153 9088814 120 CD B-NP O
12 1154 1157 9088814 min NN I-NP O
13 1158 1159 9088814 ( ( O O
14 1159 1160 9088814 - SYM B-NP O
15 1160 1163 9088814 40% CD I-NP O
16 1163 1164 9088814 ) ) O O
17 1165 1168 9088814 and CC O O
18 1169 1171 9088814 at IN B-PP O
19 1172 1175 9088814 180 CD B-NP O
20 1176 1179 9088814 min NN I-NP O
21 1180 1181 9088814 ( ( O O
22 1181 1182 9088814 - SYM B-NP O
23 1182 1185 9088814 49% CD I-NP O
24 1185 1186 9088814 ) ) O O
25 1187 1192 9088814 after IN B-PP O
26 1193 1196 9088814 the DT B-NP O
27 1197 1202 9088814 start NN I-NP O
28 1203 1205 9088814 of IN B-PP O
29 1206 1217 9088814 hypotension NN B-NP B-Disease
30 1218 1221 9088814 and CC B-PP O
31 1222 1224 9088814 at IN B-PP O
32 1225 1227 9088814 60 CD B-NP O
33 1228 1231 9088814 min NN I-NP O
34 1232 1233 9088814 ( ( O O
35 1233 1234 9088814 - SYM B-NP O
36 1234 1237 9088814 32% CD I-NP O
37 1237 1238 9088814 ) ) O O
38 1239 1244 9088814 after IN B-PP O
39 1245 1253 9088814 recovery NN B-NP O
40 1254 1256 9088814 of IN B-PP O
41 1257 1269 9088814 normotension NN B-NP O
42 1269 1270 9088814 , , O O
43 1271 1274 9088814 and CC O O
44 1275 1279 9088814 SGOT NN B-NP O
45 1279 1280 9088814 , , O O
46 1281 1285 9088814 SGPT NN B-NP O
47 1285 1286 9088814 , , O O
48 1287 1290 9088814 LDH NN B-NP O
49 1291 1294 9088814 and CC O O
50 1295 1300 9088814 total JJ B-NP O
51 1301 1310 9088814 bilirubin NN I-NP B-Chemical
52 1311 1317 9088814 showed VBD B-VP O
53 1318 1329 9088814 significant JJ B-NP O
54 1330 1339 9088814 increases NNS I-NP O
55 1340 1345 9088814 after IN B-PP O
56 1346 1355 9088814 operation NN B-NP O
57 1355 1356 9088814 . . O O

1 1357 1360 9088814 The DT B-NP O
2 1361 1368 9088814 results NNS I-NP O
3 1369 1376 9088814 suggest VBP B-VP O
4 1377 1381 9088814 that IN B-SBAR O
5 1382 1383 9088814 a DT B-NP O
6 1384 1393 9088814 prolonged VBN I-NP O
7 1394 1405 9088814 combination NN I-NP O
8 1406 1408 9088814 of IN B-PP O
9 1409 1413 9088814 more JJR B-NP O
10 1414 1418 9088814 than IN I-NP O
11 1419 1422 9088814 120 CD I-NP O
12 1423 1426 9088814 min NN I-NP O
13 1427 1429 9088814 of IN B-PP O
14 1430 1434 9088814 PGE1 NN B-NP B-Chemical
15 1434 1435 9088814 - HYPH B-NP O
16 1435 1442 9088814 induced VBN I-NP O
17 1443 1454 9088814 hypotension NN I-NP B-Disease
18 1455 1458 9088814 and CC I-NP O
19 1459 1467 9088814 moderate JJ I-NP O
20 1468 1481 9088814 haemodilution NN I-NP B-Disease
21 1482 1487 9088814 would MD B-VP O
22 1488 1493 9088814 cause VB I-VP O
23 1494 1504 9088814 impairment NN B-NP B-Disease
24 1505 1507 9088814 of IN B-PP I-Disease
25 1508 1515 9088814 hepatic JJ B-NP I-Disease
26 1516 1524 9088814 function NN I-NP I-Disease
27 1524 1525 9088814 . . O O

1 0 0 10406016 -DOCSTART- -X- -X- O

1 0 6 10406016 Effect NN B-NP O
2 7 9 10406016 of IN B-PP O
3 10 18 10406016 fucoidan NN B-NP B-Chemical
4 19 28 10406016 treatment NN I-NP O
5 29 31 10406016 on IN B-PP O
6 32 43 10406016 collagenase NN B-NP O
7 43 44 10406016 - HYPH B-NP O
8 44 51 10406016 induced VBN I-NP O
9 52 65 10406016 intracerebral JJ I-NP B-Disease
10 66 76 10406016 hemorrhage NN I-NP I-Disease
11 77 79 10406016 in IN B-PP O
12 80 84 10406016 rats NNS B-NP O
13 84 85 10406016 . . O O
14 86 98 10406016 Inflammatory JJ B-NP O
15 99 104 10406016 cells NNS I-NP O
16 105 108 10406016 are VBP B-VP O
17 109 119 10406016 postulated VBN I-VP O
18 120 122 10406016 to TO I-VP O
19 123 130 10406016 mediate VB I-VP O
20 131 135 10406016 some DT B-NP O
21 136 138 10406016 of IN B-PP O
22 139 142 10406016 the DT B-NP O
23 143 148 10406016 brain NN I-NP B-Disease
24 149 155 10406016 damage NN I-NP I-Disease
25 156 165 10406016 following VBG B-PP O
26 166 174 10406016 ischemic JJ B-NP B-Disease
27 175 181 10406016 stroke NN I-NP I-Disease
28 181 182 10406016 . . O O

1 183 196 10406016 Intracerebral JJ B-NP B-Disease
2 197 207 10406016 hemorrhage NN I-NP I-Disease
3 208 210 10406016 is VBZ B-VP O
4 211 221 10406016 associated VBN I-VP O
5 222 226 10406016 with IN B-PP O
6 227 231 10406016 more JJR B-NP O
7 232 244 10406016 inflammation NN I-NP B-Disease
8 245 249 10406016 than IN B-PP O
9 250 258 10406016 ischemic JJ B-NP B-Disease
10 259 265 10406016 stroke NN I-NP I-Disease
11 265 266 10406016 . . O O

1 267 269 10406016 We PRP B-NP O
2 270 276 10406016 tested VBD B-VP O
3 277 280 10406016 the DT B-NP O
4 281 289 10406016 sulfated JJ I-NP O
5 290 304 10406016 polysaccharide NN I-NP O
6 305 313 10406016 fucoidan NN I-NP B-Chemical
7 313 314 10406016 , , O O
8 315 320 10406016 which WDT B-NP O
9 321 324 10406016 has VBZ B-VP O
10 325 329 10406016 been VBN I-VP O
11 330 338 10406016 reported VBN I-VP O
12 339 341 10406016 to TO I-VP O
13 342 348 10406016 reduce VB I-VP O
14 349 361 10406016 inflammatory JJ B-NP O
15 362 367 10406016 brain NN I-NP B-Disease
16 368 374 10406016 damage NN I-NP I-Disease
17 374 375 10406016 , , O O
18 376 378 10406016 in IN B-PP O
19 379 380 10406016 a DT B-NP O
20 381 384 10406016 rat NN I-NP O
21 385 390 10406016 model NN I-NP O
22 391 393 10406016 of IN B-PP O
23 394 407 10406016 intracerebral JJ B-NP B-Disease
24 408 418 10406016 hemorrhage NN I-NP I-Disease
25 419 426 10406016 induced VBN B-VP O
26 427 429 10406016 by IN B-PP O
27 430 439 10406016 injection NN B-NP O
28 440 442 10406016 of IN B-PP O
29 443 452 10406016 bacterial JJ B-NP O
30 453 464 10406016 collagenase NN I-NP O
31 465 469 10406016 into IN B-PP O
32 470 473 10406016 the DT B-NP O
33 474 481 10406016 caudate JJ I-NP O
34 482 489 10406016 nucleus NN I-NP O
35 489 490 10406016 . . O O

1 491 495 10406016 Rats NNS B-NP O
2 496 500 10406016 were VBD B-VP O
3 501 508 10406016 treated VBN I-VP O
4 509 513 10406016 with IN B-PP O
5 514 519 10406016 seven CD B-NP O
6 520 523 10406016 day NN I-NP O
7 524 535 10406016 intravenous JJ I-NP O
8 536 544 10406016 infusion NN I-NP O
9 545 547 10406016 of IN B-PP O
10 548 556 10406016 fucoidan NN B-NP B-Chemical
11 557 558 10406016 ( ( O O
12 558 560 10406016 30 CD B-NP O
13 561 571 10406016 micrograms NNS I-NP O
14 572 573 10406016 h NN I-NP O
15 573 574 10406016 - HYPH B-NP O
16 574 575 10406016 1 CD I-NP O
17 575 576 10406016 ) ) O O
18 577 579 10406016 or CC O O
19 580 587 10406016 vehicle NN B-NP O
20 587 588 10406016 . . O O

1 589 592 10406016 The DT B-NP O
2 593 601 10406016 hematoma NN I-NP B-Disease
3 602 605 10406016 was VBD B-VP O
4 606 614 10406016 assessed VBN I-VP O
5 615 617 10406016 in FW B-ADVP O
6 618 622 10406016 vivo FW I-ADVP O
7 623 625 10406016 by IN B-PP O
8 626 634 10406016 magnetic JJ B-NP O
9 635 644 10406016 resonance NN I-NP O
10 645 652 10406016 imaging NN I-NP O
11 652 653 10406016 . . O O

1 654 659 10406016 Motor NNP B-NP O
2 660 668 10406016 behavior NN I-NP O
3 668 669 10406016 , , O O
4 670 677 10406016 passive JJ B-NP O
5 678 687 10406016 avoidance NN I-NP O
6 687 688 10406016 , , O O
7 689 692 10406016 and CC O O
8 693 700 10406016 skilled VBD B-VP O
9 701 709 10406016 forelimb NN B-NP O
10 710 718 10406016 function NN I-NP O
11 719 723 10406016 were VBD B-VP O
12 724 730 10406016 tested VBN I-VP O
13 731 741 10406016 repeatedly RB B-ADVP O
14 742 745 10406016 for IN B-PP O
15 746 749 10406016 six CD B-NP O
16 750 755 10406016 weeks NNS I-NP O
17 755 756 10406016 . . O O

1 757 765 10406016 Fucoidan NN B-NP B-Chemical
2 765 766 10406016 - HYPH B-NP O
3 766 773 10406016 treated VBN I-NP O
4 774 778 10406016 rats NNS I-NP O
5 779 788 10406016 exhibited VBD B-VP O
6 789 797 10406016 evidence NN B-NP O
7 798 800 10406016 of IN B-PP O
8 801 809 10406016 impaired JJ B-NP B-Disease
9 810 815 10406016 blood NN I-NP I-Disease
10 816 824 10406016 clotting NN I-NP I-Disease
11 825 828 10406016 and CC I-NP O
12 829 841 10406016 hemodilution NN I-NP B-Disease
13 841 842 10406016 , , O O
14 843 846 10406016 had VBD B-VP O
15 847 853 10406016 larger JJR B-NP O
16 854 863 10406016 hematomas NNS I-NP B-Disease
17 863 864 10406016 , , O O
18 865 868 10406016 and CC O O
19 869 875 10406016 tended VBD B-VP O
20 876 878 10406016 to TO I-VP O
21 879 883 10406016 have VB I-VP O
22 884 888 10406016 less JJR B-NP O
23 889 901 10406016 inflammation NN I-NP B-Disease
24 902 904 10406016 in IN B-PP O
25 905 908 10406016 the DT B-NP O
26 909 917 10406016 vicinity NN I-NP O
27 918 920 10406016 of IN B-PP O
28 921 924 10406016 the DT B-NP O
29 925 933 10406016 hematoma NN I-NP B-Disease
30 934 939 10406016 after IN B-PP O
31 940 945 10406016 three CD B-NP O
32 946 950 10406016 days NNS I-NP O
33 950 951 10406016 . . O O

1 952 956 10406016 They PRP B-NP O
2 957 963 10406016 showed VBD B-VP O
3 964 977 10406016 significantly RB B-NP O
4 978 982 10406016 more RBR I-NP O
5 983 988 10406016 rapid JJ I-NP O
6 989 1000 10406016 improvement NN I-NP O
7 1001 1003 10406016 of IN B-PP O
8 1004 1009 10406016 motor NN B-NP O
9 1010 1018 10406016 function NN I-NP O
10 1019 1021 10406016 in IN B-PP O
11 1022 1025 10406016 the DT B-NP O
12 1026 1031 10406016 first JJ I-NP O
13 1032 1036 10406016 week NN I-NP O
14 1037 1046 10406016 following VBG B-PP O
15 1047 1057 10406016 hemorrhage NN B-NP B-Disease
16 1058 1061 10406016 and CC O O
17 1062 1068 10406016 better JJR B-NP O
18 1069 1075 10406016 memory NN I-NP O
19 1076 1085 10406016 retention NN I-NP O
20 1086 1088 10406016 in IN B-PP O
21 1089 1092 10406016 the DT B-NP O
22 1093 1100 10406016 passive JJ I-NP O
23 1101 1110 10406016 avoidance NN I-NP O
24 1111 1115 10406016 test NN I-NP O
25 1115 1116 10406016 . . O O

1 1117 1122 10406016 Acute JJ B-NP O
2 1123 1128 10406016 white JJ I-NP B-Disease
3 1129 1135 10406016 matter NN I-NP I-Disease
4 1136 1141 10406016 edema NN I-NP I-Disease
5 1142 1145 10406016 and CC O O
6 1146 1154 10406016 eventual JJ B-NP O
7 1155 1163 10406016 neuronal JJ I-NP B-Disease
8 1164 1168 10406016 loss NN I-NP I-Disease
9 1169 1171 10406016 in IN B-PP O
10 1172 1175 10406016 the DT B-NP O
11 1176 1184 10406016 striatum NN I-NP O
12 1185 1193 10406016 adjacent JJ B-ADJP O
13 1194 1196 10406016 to TO B-PP O
14 1197 1200 10406016 the DT B-NP O
15 1201 1209 10406016 hematoma NN I-NP B-Disease
16 1210 1213 10406016 did VBD B-VP O
17 1214 1217 10406016 not RB I-VP O
18 1218 1224 10406016 differ VB I-VP O
19 1225 1232 10406016 between IN B-PP O
20 1233 1236 10406016 the DT B-NP O
21 1237 1240 10406016 two CD I-NP O
22 1241 1247 10406016 groups NNS I-NP O
23 1247 1248 10406016 . . O O

1 1249 1262 10406016 Investigation NN B-NP O
2 1263 1265 10406016 of IN B-PP O
3 1266 1270 10406016 more RBR B-NP O
4 1271 1279 10406016 specific JJ I-NP O
5 1280 1284 10406016 anti AFX I-NP O
6 1284 1285 10406016 - HYPH I-NP O
7 1285 1297 10406016 inflammatory JJ I-NP O
8 1298 1304 10406016 agents NNS I-NP O
9 1305 1308 10406016 and CC O O
10 1309 1321 10406016 hemodiluting VBG B-NP O
11 1322 1328 10406016 agents NNS I-NP O
12 1329 1332 10406016 are VBP B-VP O
13 1333 1342 10406016 warranted VBN I-VP O
14 1343 1345 10406016 in IN B-PP O
15 1346 1359 10406016 intracerebral JJ B-NP B-Disease
16 1360 1370 10406016 hemorrhage NN I-NP I-Disease
17 1370 1371 10406016 . . O O

1 0 0 17344566 -DOCSTART- -X- -X- O

1 0 11 17344566 Simvastatin NN B-NP B-Chemical
2 11 12 17344566 - HYPH O O
3 12 19 17344566 induced VBN B-NP O
4 20 29 17344566 bilateral JJ I-NP O
5 30 33 17344566 leg NN I-NP O
6 34 45 17344566 compartment NN I-NP B-Disease
7 46 54 17344566 syndrome NN I-NP I-Disease
8 55 58 17344566 and CC I-NP O
9 59 70 17344566 myonecrosis NN I-NP B-Disease
10 71 81 17344566 associated VBN B-VP O
11 82 86 17344566 with IN B-PP O
12 87 101 17344566 hypothyroidism NN B-NP B-Disease
13 101 102 17344566 . . O O
14 103 104 17344566 A DT B-NP O
15 105 107 17344566 54 CD I-NP O
16 107 108 17344566 - HYPH I-NP O
17 108 112 17344566 year NN I-NP O
18 112 113 17344566 - HYPH O O
19 113 116 17344566 old JJ B-NP O
20 117 128 17344566 hypothyroid NN I-NP B-Disease
21 129 133 17344566 male JJ B-NP O
22 134 140 17344566 taking VBG I-NP O
23 141 150 17344566 thyroxine NN I-NP B-Chemical
24 151 154 17344566 and CC I-NP O
25 155 166 17344566 simvastatin NN I-NP B-Chemical
26 167 176 17344566 presented VBD B-VP O
27 177 181 17344566 with IN B-PP O
28 182 191 17344566 bilateral JJ B-NP O
29 192 195 17344566 leg NN I-NP O
30 196 207 17344566 compartment NN I-NP B-Disease
31 208 216 17344566 syndrome NN I-NP I-Disease
32 217 220 17344566 and CC I-NP O
33 221 232 17344566 myonecrosis NN I-NP B-Disease
34 232 233 17344566 . . O O

1 234 240 17344566 Urgent JJ B-NP O
2 241 253 17344566 fasciotomies NNS I-NP O
3 254 258 17344566 were VBD B-VP O
4 259 268 17344566 performed VBN I-VP O
5 269 272 17344566 and CC O O
6 273 276 17344566 the DT B-NP O
7 277 284 17344566 patient NN I-NP O
8 285 289 17344566 made VBD B-VP O
9 290 292 17344566 an DT B-NP O
10 293 303 17344566 uneventful JJ I-NP O
11 304 312 17344566 recovery NN I-NP O
12 313 317 17344566 with IN B-PP O
13 318 321 17344566 the DT B-NP O
14 322 332 17344566 withdrawal NN I-NP O
15 333 335 17344566 of IN B-PP O
16 336 347 17344566 simvastatin NN B-NP B-Chemical
17 347 348 17344566 . . O O

1 349 351 17344566 It PRP B-NP O
2 352 354 17344566 is VBZ B-VP O
3 355 361 17344566 likely JJ B-ADJP O
4 362 366 17344566 that IN B-SBAR O
5 367 371 17344566 this DT B-NP O
6 372 384 17344566 complication NN I-NP O
7 385 389 17344566 will MD B-VP O
8 390 392 17344566 be VB I-VP O
9 393 397 17344566 seen VBN I-VP O
10 398 402 17344566 more RBR B-ADVP O
11 403 408 17344566 often RB I-ADVP O
12 409 413 17344566 with IN B-PP O
13 414 417 17344566 the DT B-NP O
14 418 427 17344566 increased VBN I-NP O
15 428 437 17344566 worldwide JJ I-NP O
16 438 441 17344566 use NN I-NP O
17 442 444 17344566 of IN B-PP O
18 445 449 17344566 this DT B-NP O
19 450 454 17344566 drug NN I-NP O
20 455 458 17344566 and CC O O
21 459 462 17344566 its PRP$ B-NP O
22 463 471 17344566 approval NN I-NP O
23 472 475 17344566 for IN B-PP O
24 476 479 17344566 all DT B-NP O
25 480 493 17344566 arteriopathic JJ I-NP B-Disease
26 494 502 17344566 patients NNS I-NP O
27 502 503 17344566 . . O O

1 0 0 16274958 -DOCSTART- -X- -X- O

1 0 9 16274958 Recurrent JJ B-NP O
2 10 19 16274958 dysphonia NN I-NP B-Disease
3 20 23 16274958 and CC I-NP O
4 24 33 16274958 acitretin NN I-NP B-Chemical
5 33 34 16274958 . . O O
6 35 37 16274958 We PRP B-NP O
7 38 44 16274958 report VBP B-VP O
8 45 48 16274958 the DT B-NP O
9 49 53 16274958 case NN I-NP O
10 54 56 16274958 of IN B-PP O
11 57 58 16274958 a DT B-NP O
12 59 64 16274958 woman NN I-NP O
13 65 76 16274958 complaining VBG B-VP O
14 77 79 16274958 of IN B-PP O
15 80 89 16274958 dysphonia NN B-NP B-Disease
16 90 95 16274958 while IN B-SBAR O
17 96 99 16274958 she PRP B-NP O
18 100 103 16274958 was VBD B-VP O
19 104 111 16274958 treated VBN I-VP O
20 112 114 16274958 by IN B-PP O
21 115 124 16274958 acitretin NN B-NP B-Chemical
22 124 125 16274958 . . O O

1 126 129 16274958 Her PRP$ B-NP O
2 130 138 16274958 symptoms NNS I-NP O
3 139 146 16274958 totally RB B-VP O
4 147 156 16274958 regressed VBN I-VP O
5 157 162 16274958 after IN B-PP O
6 163 167 16274958 drug NN B-NP O
7 168 178 16274958 withdrawal NN I-NP O
8 179 182 16274958 and CC O O
9 183 193 16274958 reappeared VBD B-VP O
10 194 198 16274958 when WRB B-ADVP O
11 199 208 16274958 acitretin NN B-NP B-Chemical
12 209 212 16274958 was VBD B-VP O
13 213 225 16274958 reintroduced VBN I-VP O
14 225 226 16274958 . . O O

1 227 229 16274958 To TO B-PP O
2 230 233 16274958 our PRP$ B-NP O
3 234 243 16274958 knowledge NN I-NP O
4 243 244 16274958 , , O O
5 245 249 16274958 this DT B-NP O
6 250 252 16274958 is VBZ B-VP O
7 253 256 16274958 the DT B-NP O
8 257 262 16274958 first JJ I-NP O
9 263 267 16274958 case NN I-NP O
10 268 270 16274958 of IN B-PP O
11 271 280 16274958 acitretin NN B-NP B-Chemical
12 280 281 16274958 - HYPH B-NP O
13 281 288 16274958 induced VBN I-NP O
14 289 298 16274958 dysphonia NN I-NP B-Disease
15 298 299 16274958 . . O O

1 300 304 16274958 This DT B-NP O
2 305 311 16274958 effect NN I-NP O
3 312 315 16274958 may MD B-VP O
4 316 318 16274958 be VB I-VP O
5 319 326 16274958 related JJ B-ADJP O
6 327 329 16274958 to TO B-PP O
7 330 333 16274958 the DT B-NP O
8 334 349 16274958 pharmacological JJ I-NP O
9 350 356 16274958 effect NN I-NP O
10 357 359 16274958 of IN B-PP O
11 360 364 16274958 this DT B-NP O
12 365 369 16274958 drug NN I-NP O
13 370 372 16274958 on IN B-PP O
14 373 379 16274958 mucous JJ B-NP O
15 380 389 16274958 membranes NNS I-NP O
16 389 390 16274958 . . O O

1 0 0 7881871 -DOCSTART- -X- -X- O

1 0 4 7881871 Time NN B-NP O
2 5 11 7881871 course NN I-NP O
3 12 14 7881871 of IN B-PP O
4 15 20 7881871 lipid NN B-NP O
5 21 33 7881871 peroxidation NN I-NP O
6 34 36 7881871 in IN B-PP O
7 37 46 7881871 puromycin NN B-NP B-Chemical
8 47 62 7881871 aminonucleoside NN I-NP I-Chemical
9 62 63 7881871 - HYPH B-NP O
10 63 70 7881871 induced VBN I-NP O
11 71 82 7881871 nephropathy NN I-NP B-Disease
12 82 83 7881871 . . O O
13 84 92 7881871 Reactive JJ B-NP O
14 93 99 7881871 oxygen NN I-NP B-Chemical
15 100 107 7881871 species NNS I-NP O
16 108 112 7881871 have VBP B-VP O
17 113 117 7881871 been VBN I-VP O
18 118 128 7881871 implicated VBN I-VP O
19 129 131 7881871 in IN B-PP O
20 132 135 7881871 the DT B-NP O
21 136 148 7881871 pathogenesis NN I-NP O
22 149 151 7881871 of IN B-PP O
23 152 157 7881871 acute JJ B-NP O
24 158 167 7881871 puromycin NN I-NP B-Chemical
25 168 183 7881871 aminonucleoside NN I-NP I-Chemical
26 184 185 7881871 ( ( O O
27 185 188 7881871 PAN NN B-NP B-Chemical
28 188 189 7881871 ) ) O O
29 189 190 7881871 - HYPH B-NP O
30 190 197 7881871 induced VBN I-NP O
31 198 209 7881871 nephropathy NN I-NP B-Disease
32 209 210 7881871 , , O O
33 211 215 7881871 with IN B-PP O
34 216 228 7881871 antioxidants NNS B-NP O
35 229 242 7881871 significantly RB B-VP O
36 243 251 7881871 reducing VBG I-VP O
37 252 255 7881871 the DT B-NP O
38 256 267 7881871 proteinuria NN I-NP B-Disease
39 267 268 7881871 . . O O

1 269 272 7881871 The DT B-NP O
2 273 281 7881871 temporal JJ I-NP O
3 282 294 7881871 relationship NN I-NP O
4 295 302 7881871 between IN B-PP O
5 303 308 7881871 lipid NN B-NP O
6 309 321 7881871 peroxidation NN I-NP O
7 322 324 7881871 in IN B-PP O
8 325 328 7881871 the DT B-NP O
9 329 335 7881871 kidney NN I-NP O
10 336 339 7881871 and CC I-NP O
11 340 351 7881871 proteinuria NN I-NP B-Disease
12 352 355 7881871 was VBD B-VP O
13 356 364 7881871 examined VBN I-VP O
14 365 367 7881871 in IN B-PP O
15 368 372 7881871 this DT B-NP O
16 373 378 7881871 study NN I-NP O
17 378 379 7881871 . . O O

1 380 384 7881871 Rats NNS B-NP O
2 385 389 7881871 were VBD B-VP O
3 390 397 7881871 treated VBN I-VP O
4 398 402 7881871 with IN B-PP O
5 403 404 7881871 a DT B-NP O
6 405 411 7881871 single JJ I-NP O
7 412 414 7881871 IV CD I-NP O
8 415 424 7881871 injection NN I-NP O
9 425 427 7881871 of IN B-PP O
10 428 437 7881871 puromycin NN B-NP B-Chemical
11 438 453 7881871 aminonucleoside NN I-NP I-Chemical
12 453 454 7881871 , , O O
13 455 456 7881871 ( ( O O
14 456 459 7881871 PAN NNP B-NP B-Chemical
15 459 460 7881871 , , O O
16 461 464 7881871 7.5 CD B-NP O
17 465 467 7881871 mg NN I-NP O
18 467 468 7881871 / SYM B-NP O
19 468 470 7881871 kg NN I-NP O
20 470 471 7881871 ) ) O O
21 472 475 7881871 and CC O O
22 476 478 7881871 24 CD B-NP O
23 479 483 7881871 hour NN I-NP O
24 484 489 7881871 urine NN I-NP O
25 490 497 7881871 samples NNS I-NP O
26 498 502 7881871 were VBD B-VP O
27 503 511 7881871 obtained VBN I-VP O
28 512 517 7881871 prior RB B-ADVP O
29 518 520 7881871 to TO B-VP O
30 521 530 7881871 sacrifice VB I-VP O
31 531 533 7881871 on IN B-PP O
32 534 538 7881871 days NNS B-NP O
33 539 556 7881871 3,5,7,10,17,27,41 CD B-NP O
34 557 558 7881871 ( ( O O
35 558 559 7881871 N NN B-NP O
36 560 561 7881871 = SYM B-VP O
37 562 563 7881871 5 CD B-NP O
38 563 564 7881871 - HYPH I-NP O
39 564 566 7881871 10 CD I-NP O
40 567 570 7881871 per IN B-PP O
41 571 576 7881871 group NN B-NP O
42 576 577 7881871 ) ) O O
43 577 578 7881871 . . O O

1 579 582 7881871 The DT B-NP O
2 583 590 7881871 kidneys NNS I-NP O
3 591 595 7881871 were VBD B-VP O
4 596 603 7881871 removed VBN I-VP O
5 603 604 7881871 , , O O
6 605 612 7881871 flushed VBN B-VP O
7 613 617 7881871 with IN B-PP O
8 618 621 7881871 ice NN B-NP O
9 622 626 7881871 cold JJ I-NP O
10 627 631 7881871 TRIS NN I-NP O
11 632 638 7881871 buffer NN I-NP O
12 638 639 7881871 . . O O

1 640 646 7881871 Kidney NN B-NP O
2 647 655 7881871 cortices NNS I-NP O
3 656 660 7881871 from IN B-PP O
4 661 665 7881871 each DT B-NP O
5 666 672 7881871 animal NN I-NP O
6 673 677 7881871 were VBD B-VP O
7 678 682 7881871 used VBN I-VP O
8 683 685 7881871 to TO B-VP O
9 686 693 7881871 prepare VB I-VP O
10 694 705 7881871 homogenates NNS B-NP O
11 705 706 7881871 . . O O

1 707 713 7881871 Tissue NN B-NP O
2 714 719 7881871 lipid NN I-NP O
3 720 732 7881871 peroxidation NN I-NP O
4 733 736 7881871 was VBD B-VP O
5 737 745 7881871 measured VBN I-VP O
6 746 748 7881871 in IN B-PP O
7 749 754 7881871 whole JJ B-NP O
8 755 766 7881871 homogenates NNS I-NP O
9 767 769 7881871 as RB B-CONJP O
10 770 774 7881871 well RB I-CONJP O
11 775 777 7881871 as IN I-CONJP O
12 778 780 7881871 in IN B-PP O
13 781 786 7881871 lipid NN B-NP O
14 787 795 7881871 extracts NNS I-NP O
15 796 800 7881871 from IN B-PP O
16 801 812 7881871 homogenates NNS B-NP O
17 813 815 7881871 as IN B-PP O
18 816 830 7881871 thiobarbituric JJ B-NP B-Chemical
19 831 835 7881871 acid NN I-NP I-Chemical
20 836 844 7881871 reactive JJ I-NP O
21 845 855 7881871 substances NNS I-NP O
22 855 856 7881871 . . O O

1 857 868 7881871 Proteinuria NNP B-NP B-Disease
2 869 872 7881871 was VBD B-VP O
3 873 880 7881871 evident JJ B-ADJP O
4 881 883 7881871 at IN B-PP O
5 884 887 7881871 day NN B-NP O
6 888 889 7881871 5 CD I-NP O
7 889 890 7881871 , , O O
8 891 897 7881871 peaked VBD B-VP O
9 898 900 7881871 at IN B-PP O
10 901 904 7881871 day NN B-NP O
11 905 906 7881871 7 CD I-NP O
12 907 910 7881871 and CC O O
13 911 920 7881871 persisted VBD B-VP O
14 921 923 7881871 to TO B-PP O
15 924 927 7881871 day NN B-NP O
16 928 930 7881871 27 CD I-NP O
17 930 931 7881871 . . O O

1 932 937 7881871 Lipid NN B-NP O
2 938 950 7881871 peroxidation NN I-NP O
3 951 953 7881871 in IN B-PP O
4 954 965 7881871 homogenates NNS B-NP O
5 966 969 7881871 was VBD B-VP O
6 970 977 7881871 maximal JJ B-ADJP O
7 978 980 7881871 at IN B-PP O
8 981 984 7881871 day NN B-NP O
9 985 986 7881871 3 CD I-NP O
10 987 990 7881871 and CC O O
11 991 999 7881871 declined VBD B-VP O
12 1000 1007 7881871 rapidly RB B-ADVP O
13 1008 1010 7881871 to TO B-PP O
14 1011 1018 7881871 control NN B-NP O
15 1019 1025 7881871 levels NNS I-NP O
16 1026 1028 7881871 by IN B-PP O
17 1029 1032 7881871 day NN B-NP O
18 1033 1035 7881871 17 CD I-NP O
19 1035 1036 7881871 . . O O

1 1037 1041 7881871 This DT B-NP O
2 1042 1047 7881871 study NN I-NP O
3 1048 1056 7881871 supports VBZ B-VP O
4 1057 1060 7881871 the DT B-NP O
5 1061 1065 7881871 role NN I-NP O
6 1066 1068 7881871 of IN B-PP O
7 1069 1074 7881871 lipid NN B-NP O
8 1075 1087 7881871 peroxidation NN I-NP O
9 1088 1090 7881871 in IN B-PP O
10 1091 1100 7881871 mediating VBG B-VP O
11 1101 1104 7881871 the DT B-NP O
12 1105 1116 7881871 proteinuric JJ I-NP B-Disease
13 1117 1123 7881871 injury NN I-NP I-Disease
14 1124 1126 7881871 in IN B-PP O
15 1127 1130 7881871 PAN NN B-NP B-Chemical
16 1131 1142 7881871 nephropathy NN I-NP B-Disease
17 1142 1143 7881871 . . O O

1 0 0 9812111 -DOCSTART- -X- -X- O

1 0 1 9812111 A DT B-NP O
2 2 12 9812111 randomized VBN I-NP O
3 12 13 9812111 , , I-NP O
4 14 21 9812111 placebo NN I-NP O
5 21 22 9812111 - HYPH I-NP O
6 22 32 9812111 controlled VBN B-NP O
7 33 37 9812111 dose NN I-NP O
8 37 38 9812111 - HYPH B-NP O
9 38 48 9812111 comparison NN I-NP O
10 49 54 9812111 trial NN I-NP O
11 55 57 9812111 of IN B-PP O
12 58 69 9812111 haloperidol NN B-NP B-Chemical
13 70 73 9812111 for IN B-PP O
14 74 83 9812111 psychosis NN B-NP B-Disease
15 84 87 9812111 and CC O O
16 88 98 9812111 disruptive JJ B-NP B-Disease
17 99 108 9812111 behaviors NNS I-NP I-Disease
18 109 111 9812111 in IN B-PP O
19 112 123 9812111 Alzheimer's NNP B-NP B-Disease
20 124 131 9812111 disease NN I-NP I-Disease
21 131 132 9812111 . . O O
22 133 142 9812111 OBJECTIVE NN B-NP O
23 142 143 9812111 : : O O
24 144 147 9812111 The DT B-NP O
25 148 152 9812111 goal NN I-NP O
26 153 155 9812111 of IN B-PP O
27 156 160 9812111 this DT B-NP O
28 161 166 9812111 study NN I-NP O
29 167 170 9812111 was VBD B-VP O
30 171 173 9812111 to TO B-VP O
31 174 181 9812111 compare VB I-VP O
32 182 185 9812111 the DT B-NP O
33 186 194 9812111 efficacy NN I-NP O
34 195 198 9812111 and CC I-NP O
35 199 203 9812111 side NN I-NP O
36 204 211 9812111 effects NNS I-NP O
37 212 214 9812111 of IN B-PP O
38 215 218 9812111 two CD B-NP O
39 219 224 9812111 doses NNS I-NP O
40 225 227 9812111 of IN B-PP O
41 228 239 9812111 haloperidol NN B-NP B-Chemical
42 240 243 9812111 and CC I-NP O
43 244 251 9812111 placebo NN I-NP O
44 252 254 9812111 in IN B-PP O
45 255 258 9812111 the DT B-NP O
46 259 268 9812111 treatment NN I-NP O
47 269 271 9812111 of IN B-PP O
48 272 281 9812111 psychosis NN B-NP B-Disease
49 282 285 9812111 and CC O O
50 286 296 9812111 disruptive JJ B-NP B-Disease
51 297 306 9812111 behaviors NNS I-NP I-Disease
52 307 309 9812111 in IN B-PP O
53 310 318 9812111 patients NNS B-NP O
54 319 323 9812111 with IN B-PP O
55 324 335 9812111 Alzheimer's NNS B-NP B-Disease
56 336 343 9812111 disease NN I-NP I-Disease
57 343 344 9812111 . . O O

1 345 351 9812111 METHOD NN B-NP O
2 351 352 9812111 : : O O
3 353 355 9812111 In IN B-PP O
4 356 357 9812111 a DT B-NP O
5 358 359 9812111 6 CD I-NP O
6 359 360 9812111 - HYPH I-NP O
7 360 364 9812111 week NN I-NP O
8 365 371 9812111 random JJ I-NP O
9 371 372 9812111 - HYPH I-NP O
10 372 382 9812111 assignment NN I-NP O
11 382 383 9812111 , , O O
12 384 390 9812111 double JJ B-NP O
13 390 391 9812111 - HYPH I-NP O
14 391 396 9812111 blind JJ I-NP O
15 396 397 9812111 , , I-NP O
16 398 405 9812111 placebo NN I-NP O
17 405 406 9812111 - HYPH I-NP O
18 406 416 9812111 controlled VBN B-VP O
19 417 422 9812111 trial NN B-NP O
20 423 424 9812111 ( ( O O
21 424 429 9812111 phase NN B-NP O
22 430 431 9812111 A NN I-NP O
23 431 432 9812111 ) ) O O
24 432 433 9812111 , , O O
25 434 445 9812111 haloperidol NN B-NP B-Chemical
26 445 446 9812111 , , O O
27 447 448 9812111 2 CD B-NP O
28 448 449 9812111 - HYPH I-NP O
29 449 450 9812111 3 CD I-NP O
30 451 453 9812111 mg NN I-NP O
31 453 454 9812111 / SYM B-NP O
32 454 457 9812111 day NN I-NP O
33 458 459 9812111 ( ( O O
34 459 467 9812111 standard JJ B-NP O
35 468 472 9812111 dose NN I-NP O
36 472 473 9812111 ) ) O O
37 473 474 9812111 , , O O
38 475 478 9812111 and CC O O
39 479 490 9812111 haloperidol NN B-NP B-Chemical
40 490 491 9812111 , , O O
41 492 496 9812111 0.50 CD B-NP O
42 496 497 9812111 - HYPH I-NP O
43 497 501 9812111 0.75 CD I-NP O
44 502 504 9812111 mg NN I-NP O
45 504 505 9812111 / SYM B-NP O
46 505 508 9812111 day NN I-NP O
47 509 510 9812111 ( ( O O
48 510 513 9812111 low JJ B-NP O
49 514 518 9812111 dose NN I-NP O
50 518 519 9812111 ) ) O O
51 519 520 9812111 , , O O
52 521 525 9812111 were VBD B-VP O
53 526 534 9812111 compared VBN I-VP O
54 535 537 9812111 in IN B-PP O
55 538 540 9812111 71 CD B-NP O
56 541 552 9812111 outpatients NNS I-NP O
57 553 557 9812111 with IN B-PP O
58 558 569 9812111 Alzheimer's NNS B-NP B-Disease
59 570 577 9812111 disease NN I-NP I-Disease
60 577 578 9812111 . . O O

1 579 582 9812111 For IN B-PP O
2 583 586 9812111 the DT B-NP O
3 587 597 9812111 subsequent JJ I-NP O
4 598 599 9812111 6 CD I-NP O
5 599 600 9812111 - HYPH I-NP O
6 600 604 9812111 week NN I-NP O
7 605 611 9812111 double JJ I-NP O
8 611 612 9812111 - HYPH I-NP O
9 612 617 9812111 blind JJ I-NP O
10 618 627 9812111 crossover NN I-NP O
11 628 633 9812111 phase NN I-NP O
12 634 635 9812111 ( ( O O
13 635 640 9812111 phase NN B-NP O
14 641 642 9812111 B NN I-NP O
15 642 643 9812111 ) ) O O
16 643 644 9812111 , , O O
17 645 653 9812111 patients NNS B-NP O
18 654 660 9812111 taking VBG B-VP O
19 661 669 9812111 standard JJ B-NP O
20 669 670 9812111 - HYPH I-NP O
21 671 673 9812111 or CC I-NP O
22 674 677 9812111 low JJ I-NP O
23 677 678 9812111 - HYPH I-NP O
24 678 682 9812111 dose NN I-NP O
25 683 694 9812111 haloperidol NN I-NP B-Chemical
26 695 699 9812111 were VBD B-VP O
27 700 708 9812111 switched VBN I-VP O
28 709 711 9812111 to TO B-PP O
29 712 719 9812111 placebo NN B-NP O
30 719 720 9812111 , , O O
31 721 724 9812111 and CC O O
32 725 733 9812111 patients NNS B-NP O
33 734 740 9812111 taking VBG B-VP O
34 741 748 9812111 placebo NN B-NP O
35 749 753 9812111 were VBD B-VP O
36 754 762 9812111 randomly RB I-VP O
37 763 771 9812111 assigned VBN I-VP O
38 772 774 9812111 to TO B-PP O
39 775 783 9812111 standard JJ B-NP O
40 783 784 9812111 - HYPH I-NP O
41 785 787 9812111 or CC I-NP O
42 788 791 9812111 low JJ I-NP O
43 791 792 9812111 - HYPH I-NP O
44 792 796 9812111 dose NN I-NP O
45 797 808 9812111 haloperidol NN I-NP B-Chemical
46 808 809 9812111 . . O O

1 810 817 9812111 RESULTS NNS B-NP O
2 817 818 9812111 : : O O
3 819 822 9812111 For IN B-PP O
4 823 826 9812111 the DT B-NP O
5 827 829 9812111 60 CD I-NP O
6 830 838 9812111 patients NNS I-NP O
7 839 842 9812111 who WP B-NP O
8 843 852 9812111 completed VBD B-VP O
9 853 858 9812111 phase NN B-NP O
10 859 860 9812111 A NN I-NP O
11 860 861 9812111 , , O O
12 862 870 9812111 standard JJ B-NP O
13 870 871 9812111 - HYPH I-NP O
14 871 875 9812111 dose NN I-NP O
15 876 887 9812111 haloperidol NN I-NP B-Chemical
16 888 891 9812111 was VBD B-VP O
17 892 903 9812111 efficacious JJ B-ADJP O
18 904 907 9812111 and CC I-ADJP O
19 908 916 9812111 superior JJ I-ADJP O
20 917 919 9812111 to TO B-PP O
21 920 924 9812111 both CC O O
22 925 928 9812111 low JJ B-NP O
23 928 929 9812111 - HYPH I-NP O
24 929 933 9812111 dose NN I-NP O
25 934 945 9812111 haloperidol NN I-NP B-Chemical
26 946 949 9812111 and CC I-NP O
27 950 957 9812111 placebo NN I-NP O
28 958 961 9812111 for IN B-PP O
29 962 968 9812111 scores NNS B-NP O
30 969 971 9812111 on IN B-PP O
31 972 975 9812111 the DT B-NP O
32 976 981 9812111 Brief NNP I-NP O
33 982 993 9812111 Psychiatric NNP I-NP O
34 994 1000 9812111 Rating NNP I-NP O
35 1001 1006 9812111 Scale NNP I-NP O
36 1007 1016 9812111 psychosis NN I-NP B-Disease
37 1017 1023 9812111 factor NN I-NP O
38 1024 1027 9812111 and CC B-PP O
39 1028 1030 9812111 on IN B-PP O
40 1031 1042 9812111 psychomotor NN B-NP B-Disease
41 1043 1052 9812111 agitation NN I-NP I-Disease
42 1052 1053 9812111 . . O O

1 1054 1062 9812111 Response NN B-NP O
2 1063 1068 9812111 rates NNS I-NP O
3 1069 1078 9812111 according VBG B-PP O
4 1079 1081 9812111 to TO B-PP O
5 1082 1087 9812111 three CD B-NP O
6 1088 1092 9812111 sets NNS I-NP O
7 1093 1095 9812111 of IN B-PP O
8 1096 1104 9812111 criteria NNS B-NP O
9 1105 1109 9812111 were VBD B-VP O
10 1110 1117 9812111 greater JJR B-ADJP O
11 1118 1122 9812111 with IN B-PP O
12 1123 1126 9812111 the DT B-NP O
13 1127 1135 9812111 standard JJ I-NP O
14 1136 1140 9812111 dose NN I-NP O
15 1141 1142 9812111 ( ( O O
16 1142 1145 9812111 55% NN B-NP O
17 1145 1146 9812111 - HYPH B-NP O
18 1146 1149 9812111 60% NN I-NP O
19 1149 1150 9812111 ) ) O O
20 1151 1155 9812111 than IN B-PP O
21 1156 1159 9812111 the DT B-NP O
22 1160 1163 9812111 low JJ I-NP O
23 1164 1168 9812111 dose NN I-NP O
24 1169 1170 9812111 ( ( O O
25 1170 1173 9812111 25% NN B-NP O
26 1173 1174 9812111 - HYPH B-NP O
27 1174 1177 9812111 35% NN I-NP O
28 1177 1178 9812111 ) ) O O
29 1179 1182 9812111 and CC O O
30 1183 1190 9812111 placebo NN B-NP O
31 1191 1192 9812111 ( ( O O
32 1192 1195 9812111 25% CD B-NP O
33 1195 1196 9812111 - HYPH O O
34 1196 1199 9812111 30% CD B-NP O
35 1199 1200 9812111 ) ) O O
36 1200 1201 9812111 . . O O

1 1202 1205 9812111 The DT B-NP O
2 1206 1215 9812111 advantage NN I-NP O
3 1216 1218 9812111 of IN B-PP O
4 1219 1227 9812111 standard JJ B-NP O
5 1228 1232 9812111 dose NN I-NP O
6 1233 1237 9812111 over IN B-PP O
7 1238 1241 9812111 low JJ B-NP O
8 1242 1246 9812111 dose NN I-NP O
9 1247 1250 9812111 was VBD B-VP O
10 1251 1261 9812111 replicated VBN I-VP O
11 1262 1264 9812111 in IN B-PP O
12 1265 1270 9812111 phase NN B-NP O
13 1271 1272 9812111 B NN I-NP O
14 1272 1273 9812111 . . O O

1 1274 1276 9812111 In IN B-PP O
2 1277 1282 9812111 phase NN B-NP O
3 1283 1284 9812111 A NN I-NP O
4 1284 1285 9812111 , , O O
5 1286 1300 9812111 extrapyramidal JJ B-NP B-Disease
6 1301 1306 9812111 signs NNS I-NP I-Disease
7 1307 1313 9812111 tended VBD B-VP O
8 1314 1316 9812111 to TO I-VP O
9 1317 1319 9812111 be VB I-VP O
10 1320 1327 9812111 greater JJR B-ADJP O
11 1328 1332 9812111 with IN B-PP O
12 1333 1336 9812111 the DT B-NP O
13 1337 1345 9812111 standard JJ I-NP O
14 1346 1350 9812111 dose NN I-NP O
15 1351 1355 9812111 than IN B-PP O
16 1356 1358 9812111 in IN B-PP O
17 1359 1362 9812111 the DT B-NP O
18 1363 1368 9812111 other JJ I-NP O
19 1369 1372 9812111 two CD I-NP O
20 1373 1383 9812111 conditions NNS I-NP O
21 1383 1384 9812111 , , O O
22 1385 1394 9812111 primarily RB B-ADVP O
23 1395 1402 9812111 because IN B-PP O
24 1403 1405 9812111 of IN I-PP O
25 1406 1407 9812111 a DT B-NP O
26 1408 1416 9812111 subgroup NN I-NP O
27 1417 1418 9812111 ( ( O O
28 1418 1421 9812111 20% CD B-NP O
29 1421 1422 9812111 ) ) O O
30 1423 1426 9812111 who WP B-NP O
31 1427 1436 9812111 developed VBD B-VP O
32 1437 1445 9812111 moderate JJ B-ADJP O
33 1446 1448 9812111 to TO B-PP O
34 1449 1455 9812111 severe JJ B-NP O
35 1456 1461 9812111 signs NNS I-NP O
36 1461 1462 9812111 . . O O

1 1463 1466 9812111 Low JJ B-NP O
2 1466 1467 9812111 - HYPH I-NP O
3 1467 1471 9812111 dose NN I-NP O
4 1472 1483 9812111 haloperidol NN I-NP B-Chemical
5 1484 1487 9812111 did VBD B-VP O
6 1488 1491 9812111 not RB I-VP O
7 1492 1498 9812111 differ VB I-VP O
8 1499 1503 9812111 from IN B-PP O
9 1504 1511 9812111 placebo NN B-NP O
10 1512 1514 9812111 on IN B-PP O
11 1515 1518 9812111 any DT B-NP O
12 1519 1526 9812111 measure NN I-NP O
13 1527 1529 9812111 of IN B-PP O
14 1530 1538 9812111 efficacy NN B-NP O
15 1539 1541 9812111 or CC I-NP O
16 1542 1546 9812111 side NN I-NP O
17 1547 1554 9812111 effects NNS I-NP O
18 1554 1555 9812111 . . O O

1 1556 1567 9812111 CONCLUSIONS NNS B-NP O
2 1567 1568 9812111 : : O O
3 1569 1572 9812111 The DT B-NP O
4 1573 1580 9812111 results NNS I-NP O
5 1581 1590 9812111 indicated VBD B-VP O
6 1591 1592 9812111 a DT B-NP O
7 1593 1602 9812111 favorable JJ I-NP O
8 1603 1614 9812111 therapeutic JJ I-NP O
9 1615 1622 9812111 profile NN I-NP O
10 1623 1626 9812111 for IN B-PP O
11 1627 1638 9812111 haloperidol NN B-NP B-Chemical
12 1639 1641 9812111 in IN B-PP O
13 1642 1647 9812111 doses NNS B-NP O
14 1648 1650 9812111 of IN B-PP O
15 1651 1652 9812111 2 CD B-NP O
16 1652 1653 9812111 - HYPH I-NP O
17 1653 1654 9812111 3 CD I-NP O
18 1655 1657 9812111 mg NN I-NP O
19 1657 1658 9812111 / SYM B-NP O
20 1658 1661 9812111 day NN I-NP O
21 1661 1662 9812111 , , O O
22 1663 1671 9812111 although IN B-SBAR O
23 1672 1673 9812111 a DT B-NP O
24 1674 1682 9812111 subgroup NN I-NP O
25 1683 1692 9812111 developed VBD B-VP O
26 1693 1701 9812111 moderate JJ B-ADJP O
27 1702 1704 9812111 to TO B-PP O
28 1705 1711 9812111 severe JJ B-NP O
29 1712 1726 9812111 extrapyramidal JJ I-NP B-Disease
30 1727 1732 9812111 signs NNS I-NP I-Disease
31 1732 1733 9812111 . . O O

1 1734 1735 9812111 A DT B-NP O
2 1736 1744 9812111 starting VBG I-NP O
3 1745 1749 9812111 dose NN I-NP O
4 1750 1752 9812111 of IN B-PP O
5 1753 1754 9812111 1 CD B-NP O
6 1755 1757 9812111 mg NN I-NP O
7 1757 1758 9812111 / SYM B-NP O
8 1758 1761 9812111 day NN I-NP O
9 1762 1766 9812111 with IN B-PP O
10 1767 1774 9812111 gradual JJ B-NP O
11 1774 1775 9812111 , , I-NP O
12 1776 1782 9812111 upward JJ I-NP O
13 1783 1787 9812111 dose NN I-NP O
14 1788 1797 9812111 titration NN I-NP O
15 1798 1800 9812111 is VBZ B-VP O
16 1801 1812 9812111 recommended VBN I-VP O
17 1812 1813 9812111 . . O O

1 1814 1817 9812111 The DT B-NP O
2 1818 1824 9812111 narrow JJ I-NP O
3 1825 1836 9812111 therapeutic JJ I-NP O
4 1837 1843 9812111 window NN I-NP O
5 1844 1852 9812111 observed VBN B-VP O
6 1853 1857 9812111 with IN B-PP O
7 1858 1869 9812111 haloperidol NN B-NP B-Chemical
8 1870 1873 9812111 may MD B-VP O
9 1874 1878 9812111 also RB I-VP O
10 1879 1884 9812111 apply VB I-VP O
11 1885 1887 9812111 to TO B-PP O
12 1888 1893 9812111 other JJ B-NP O
13 1894 1906 9812111 neuroleptics NNS I-NP O
14 1907 1911 9812111 used VBN B-VP O
15 1912 1914 9812111 in IN B-PP O
16 1915 1926 9812111 Alzheimer's NNP B-NP B-Disease
17 1927 1934 9812111 disease NN I-NP I-Disease
18 1935 1943 9812111 patients NNS I-NP O
19 1944 1948 9812111 with IN B-PP O
20 1949 1958 9812111 psychosis NN B-NP B-Disease
21 1959 1962 9812111 and CC O O
22 1963 1973 9812111 disruptive JJ B-NP B-Disease
23 1974 1983 9812111 behaviors NNS I-NP I-Disease
24 1983 1984 9812111 . . O O

1 0 0 10091617 -DOCSTART- -X- -X- O

1 0 10 10091617 Selegiline NN B-NP B-Chemical
2 10 11 10091617 - HYPH O O
3 11 18 10091617 induced VBN B-NP O
4 19 27 10091617 postural JJ I-NP B-Disease
5 28 39 10091617 hypotension NN I-NP I-Disease
6 40 42 10091617 in IN B-PP O
7 43 54 10091617 Parkinson's NNS B-NP B-Disease
8 55 62 10091617 disease NN I-NP I-Disease
9 62 63 10091617 : : O O
10 64 65 10091617 a DT B-NP O
11 66 78 10091617 longitudinal JJ I-NP O
12 79 84 10091617 study NN I-NP O
13 85 87 10091617 on IN B-PP O
14 88 91 10091617 the DT B-NP O
15 92 99 10091617 effects NNS I-NP O
16 100 102 10091617 of IN B-PP O
17 103 107 10091617 drug NN B-NP O
18 108 118 10091617 withdrawal NN I-NP O
19 118 119 10091617 . . O O
20 120 130 10091617 OBJECTIVES NNS B-NP O
21 130 131 10091617 : : O O
22 132 135 10091617 The DT B-NP O
23 136 142 10091617 United NNP I-NP O
24 143 150 10091617 Kingdom NNP I-NP O
25 151 162 10091617 Parkinson's NNP I-NP B-Disease
26 163 170 10091617 Disease NNP I-NP I-Disease
27 171 179 10091617 Research NNP I-NP O
28 180 185 10091617 Group NNP I-NP O
29 186 187 10091617 ( ( O O
30 187 193 10091617 UKPDRG NNP O O
31 193 194 10091617 ) ) O O
32 195 200 10091617 trial NN B-NP O
33 201 206 10091617 found VBD B-VP O
34 207 209 10091617 an DT B-NP O
35 210 219 10091617 increased VBN I-NP O
36 220 229 10091617 mortality NN I-NP O
37 230 232 10091617 in IN B-PP O
38 233 241 10091617 patients NNS B-NP O
39 242 246 10091617 with IN B-PP O
40 247 258 10091617 Parkinson's NNS B-NP B-Disease
41 259 266 10091617 disease NN B-NP I-Disease
42 267 268 10091617 ( ( O O
43 268 270 10091617 PD NN B-NP B-Disease
44 270 271 10091617 ) ) O O
45 272 282 10091617 randomized VBD B-VP O
46 283 285 10091617 to TO I-VP O
47 286 293 10091617 receive VB I-VP O
48 294 296 10091617 10 CD B-NP O
49 297 299 10091617 mg NN I-NP O
50 300 310 10091617 selegiline NN I-NP B-Chemical
51 311 314 10091617 per IN B-PP O
52 315 318 10091617 day NN B-NP O
53 319 322 10091617 and CC O O
54 323 324 10091617 L NN B-NP B-Chemical
55 324 325 10091617 - HYPH O I-Chemical
56 325 329 10091617 dopa NN B-NP I-Chemical
57 330 338 10091617 compared VBN B-PP O
58 339 343 10091617 with IN B-PP O
59 344 349 10091617 those DT B-NP O
60 350 356 10091617 taking VBG I-NP O
61 357 358 10091617 L NN I-NP B-Chemical
62 358 359 10091617 - HYPH B-NP I-Chemical
63 359 363 10091617 dopa NN I-NP I-Chemical
64 364 369 10091617 alone RB B-ADVP O
65 369 370 10091617 . . O O

1 371 379 10091617 Recently RB B-ADVP O
2 379 380 10091617 , , O O
3 381 383 10091617 we PRP B-NP O
4 384 389 10091617 found VBD B-VP O
5 390 394 10091617 that IN B-SBAR O
6 395 402 10091617 therapy NN B-NP O
7 403 407 10091617 with IN B-PP O
8 408 418 10091617 selegiline NN B-NP B-Chemical
9 419 422 10091617 and CC I-NP O
10 423 424 10091617 L NN I-NP B-Chemical
11 424 425 10091617 - HYPH B-NP I-Chemical
12 425 429 10091617 dopa NN I-NP I-Chemical
13 430 433 10091617 was VBD B-VP O
14 434 444 10091617 associated VBN I-VP O
15 445 449 10091617 with IN B-PP O
16 450 459 10091617 selective JJ B-NP O
17 460 468 10091617 systolic JJ I-NP B-Disease
18 469 480 10091617 orthostatic JJ I-NP I-Disease
19 481 492 10091617 hypotension NN I-NP I-Disease
20 493 498 10091617 which WDT B-NP O
21 499 502 10091617 was VBD B-VP O
22 503 512 10091617 abolished VBN I-VP O
23 513 515 10091617 by IN B-PP O
24 516 526 10091617 withdrawal NN B-NP O
25 527 529 10091617 of IN B-PP O
26 530 540 10091617 selegiline NN B-NP B-Chemical
27 540 541 10091617 . . O O

1 542 546 10091617 This DT B-NP O
2 547 555 10091617 unwanted JJ I-NP O
3 556 562 10091617 effect NN I-NP O
4 563 565 10091617 on IN B-PP O
5 566 574 10091617 postural JJ B-NP O
6 575 580 10091617 blood NN I-NP O
7 581 589 10091617 pressure NN I-NP O
8 590 593 10091617 was VBD B-VP O
9 594 597 10091617 not RB O O
10 598 601 10091617 the DT B-NP O
11 602 608 10091617 result NN I-NP O
12 609 611 10091617 of IN B-PP O
13 612 622 10091617 underlying VBG B-VP O
14 623 632 10091617 autonomic JJ B-NP O
15 633 640 10091617 failure NN I-NP O
16 640 641 10091617 . . O O

1 642 645 10091617 The DT B-NP O
2 646 650 10091617 aims NNS I-NP O
3 651 653 10091617 of IN B-PP O
4 654 658 10091617 this DT B-NP O
5 659 664 10091617 study NN I-NP O
6 665 669 10091617 were VBD B-VP O
7 670 672 10091617 to TO I-VP O
8 673 680 10091617 confirm VB I-VP O
9 681 684 10091617 our PRP$ B-NP O
10 685 693 10091617 previous JJ I-NP O
11 694 702 10091617 findings NNS I-NP O
12 703 705 10091617 in IN B-PP O
13 706 707 10091617 a DT B-NP O
14 708 716 10091617 separate JJ I-NP O
15 717 723 10091617 cohort NN I-NP O
16 724 726 10091617 of IN B-PP O
17 727 735 10091617 patients NNS B-NP O
18 736 739 10091617 and CC O O
19 740 742 10091617 to TO B-VP O
20 743 752 10091617 determine VB I-VP O
21 753 756 10091617 the DT B-NP O
22 757 761 10091617 time NN I-NP O
23 762 768 10091617 course NN I-NP O
24 769 771 10091617 of IN B-PP O
25 772 775 10091617 the DT B-NP O
26 776 790 10091617 cardiovascular JJ I-NP O
27 791 803 10091617 consequences NNS I-NP O
28 804 806 10091617 of IN B-PP O
29 807 815 10091617 stopping VBG B-VP O
30 816 826 10091617 selegiline NN B-NP B-Chemical
31 827 829 10091617 in IN B-PP O
32 830 833 10091617 the DT B-NP O
33 834 845 10091617 expectation NN I-NP O
34 846 850 10091617 that IN B-SBAR O
35 851 855 10091617 this DT B-NP O
36 856 861 10091617 might MD B-VP O
37 862 866 10091617 shed VB I-VP O
38 867 872 10091617 light NN B-NP O
39 873 875 10091617 on IN B-PP O
40 876 879 10091617 the DT B-NP O
41 880 890 10091617 mechanisms NNS I-NP O
42 891 893 10091617 by IN B-PP O
43 894 899 10091617 which WDT B-NP O
44 900 903 10091617 the DT B-NP O
45 904 908 10091617 drug NN I-NP O
46 909 915 10091617 causes VBZ B-VP O
47 916 927 10091617 orthostatic JJ B-NP B-Disease
48 928 939 10091617 hypotension NN I-NP I-Disease
49 939 940 10091617 . . O O

1 941 948 10091617 METHODS NNS B-NP O
2 948 949 10091617 : : O O
3 950 953 10091617 The DT B-NP O
4 954 968 10091617 cardiovascular JJ I-NP O
5 969 978 10091617 responses NNS I-NP O
6 979 981 10091617 to TO B-VP O
7 982 990 10091617 standing VB I-VP O
8 991 994 10091617 and CC I-VP O
9 995 999 10091617 head VB I-VP O
10 999 1000 10091617 - HYPH O O
11 1000 1002 10091617 up RP B-PRT O
12 1003 1007 10091617 tilt NN B-NP O
13 1008 1012 10091617 were VBD B-VP O
14 1013 1020 10091617 studied VBN I-VP O
15 1021 1031 10091617 repeatedly RB B-ADVP O
16 1032 1034 10091617 in IN B-PP O
17 1035 1037 10091617 PD NN B-NP B-Disease
18 1038 1046 10091617 patients NNS I-NP O
19 1047 1056 10091617 receiving VBG B-VP O
20 1057 1067 10091617 selegiline NN B-NP B-Chemical
21 1068 1071 10091617 and CC B-PP O
22 1072 1074 10091617 as IN B-PP O
23 1075 1078 10091617 the DT B-NP O
24 1079 1083 10091617 drug NN I-NP O
25 1084 1087 10091617 was VBD B-VP O
26 1088 1097 10091617 withdrawn VBN I-VP O
27 1097 1098 10091617 . . O O

1 1099 1106 10091617 RESULTS NNS B-NP O
2 1106 1107 10091617 : : O O
3 1108 1112 10091617 Head VB B-VP O
4 1112 1113 10091617 - HYPH O O
5 1113 1115 10091617 up RP B-PRT O
6 1116 1120 10091617 tilt NN B-NP O
7 1121 1127 10091617 caused VBD B-VP O
8 1128 1136 10091617 systolic JJ B-NP B-Disease
9 1137 1148 10091617 orthostatic JJ I-NP I-Disease
10 1149 1160 10091617 hypotension NN I-NP I-Disease
11 1161 1166 10091617 which WDT B-NP O
12 1167 1170 10091617 was VBD B-VP O
13 1171 1177 10091617 marked VBN I-VP O
14 1178 1180 10091617 in IN B-PP O
15 1181 1184 10091617 six CD B-NP O
16 1185 1187 10091617 of IN I-NP O
17 1188 1190 10091617 20 CD I-NP O
18 1191 1193 10091617 PD NN I-NP B-Disease
19 1194 1202 10091617 patients NNS I-NP O
20 1203 1205 10091617 on IN B-PP O
21 1206 1216 10091617 selegiline NN B-NP B-Chemical
22 1216 1217 10091617 , , O O
23 1218 1221 10091617 one CD B-NP O
24 1222 1224 10091617 of IN B-PP O
25 1225 1229 10091617 whom WP B-NP O
26 1230 1234 10091617 lost VBD B-VP O
27 1235 1248 10091617 consciousness NN B-NP O
28 1249 1253 10091617 with IN B-PP O
29 1254 1266 10091617 unrecordable JJ B-NP O
30 1267 1272 10091617 blood NN I-NP O
31 1273 1282 10091617 pressures NNS I-NP O
32 1282 1283 10091617 . . O O

1 1284 1285 10091617 A DT B-NP O
2 1286 1292 10091617 lesser JJR I-NP O
3 1293 1299 10091617 degree NN I-NP O
4 1300 1302 10091617 of IN B-PP O
5 1303 1314 10091617 orthostatic JJ B-NP B-Disease
6 1315 1326 10091617 hypotension NN I-NP I-Disease
7 1327 1335 10091617 occurred VBD B-VP O
8 1336 1340 10091617 with IN B-PP O
9 1341 1349 10091617 standing NN B-NP O
10 1349 1350 10091617 . . O O

1 1351 1362 10091617 Orthostatic JJ B-NP B-Disease
2 1363 1374 10091617 hypotension NN I-NP I-Disease
3 1375 1378 10091617 was VBD B-VP O
4 1379 1390 10091617 ameliorated VBN I-VP O
5 1391 1392 10091617 4 CD B-NP O
6 1393 1397 10091617 days NNS I-NP O
7 1398 1403 10091617 after IN B-PP O
8 1404 1414 10091617 withdrawal NN B-NP O
9 1415 1417 10091617 of IN B-PP O
10 1418 1428 10091617 selegiline NN B-NP B-Chemical
11 1429 1432 10091617 and CC O O
12 1433 1440 10091617 totally RB B-VP O
13 1441 1450 10091617 abolished VBD I-VP O
14 1451 1452 10091617 7 CD B-NP O
15 1453 1457 10091617 days NNS I-NP O
16 1458 1463 10091617 after IN B-PP O
17 1464 1479 10091617 discontinuation NN B-NP O
18 1480 1482 10091617 of IN B-PP O
19 1483 1486 10091617 the DT B-NP O
20 1487 1491 10091617 drug NN I-NP O
21 1491 1492 10091617 . . O O

1 1493 1501 10091617 Stopping VBG B-VP O
2 1502 1512 10091617 selegiline NN B-NP B-Chemical
3 1513 1517 10091617 also RB B-ADVP O
4 1518 1531 10091617 significantly RB B-VP O
5 1532 1539 10091617 reduced VBD I-VP B-Disease
6 1540 1543 10091617 the DT B-NP I-Disease
7 1544 1550 10091617 supine NN I-NP I-Disease
8 1551 1559 10091617 systolic JJ I-NP I-Disease
9 1560 1563 10091617 and CC I-NP I-Disease
10 1564 1573 10091617 diastolic JJ I-NP I-Disease
11 1574 1579 10091617 blood NN I-NP I-Disease
12 1580 1589 10091617 pressures NNS I-NP I-Disease
13 1590 1600 10091617 consistent JJ B-ADJP O
14 1601 1605 10091617 with IN B-PP O
15 1606 1607 10091617 a DT B-NP O
16 1608 1618 10091617 previously RB I-NP O
17 1619 1630 10091617 undescribed JJ I-NP O
18 1631 1637 10091617 supine NN I-NP O
19 1638 1645 10091617 pressor NN I-NP O
20 1646 1652 10091617 action NN I-NP O
21 1652 1653 10091617 . . O O

1 1654 1664 10091617 CONCLUSION NN B-NP O
2 1664 1665 10091617 : : O O
3 1666 1670 10091617 This DT B-NP O
4 1671 1676 10091617 study NN I-NP O
5 1677 1685 10091617 confirms VBZ B-VP O
6 1686 1689 10091617 our PRP$ B-NP O
7 1690 1698 10091617 previous JJ I-NP O
8 1699 1706 10091617 finding NN I-NP O
9 1707 1711 10091617 that IN B-SBAR O
10 1712 1722 10091617 selegiline NN B-NP B-Chemical
11 1723 1725 10091617 in IN B-PP O
12 1726 1737 10091617 combination NN B-NP O
13 1738 1742 10091617 with IN B-PP O
14 1743 1744 10091617 L NN B-NP B-Chemical
15 1744 1745 10091617 - HYPH O I-Chemical
16 1745 1749 10091617 dopa NN B-NP I-Chemical
17 1750 1752 10091617 is VBZ B-VP O
18 1753 1763 10091617 associated VBN I-VP O
19 1764 1768 10091617 with IN B-PP O
20 1769 1778 10091617 selective JJ B-NP O
21 1779 1790 10091617 orthostatic JJ I-NP B-Disease
22 1791 1802 10091617 hypotension NN I-NP I-Disease
23 1802 1803 10091617 . . O O

1 1804 1807 10091617 The DT B-NP O
2 1808 1821 10091617 possibilities NNS I-NP O
3 1822 1826 10091617 that IN B-SBAR O
4 1827 1832 10091617 these DT B-NP O
5 1833 1847 10091617 cardiovascular JJ I-NP O
6 1848 1856 10091617 findings NNS I-NP O
7 1857 1862 10091617 might MD B-VP O
8 1863 1865 10091617 be VB I-VP O
9 1866 1869 10091617 the DT B-NP O
10 1870 1876 10091617 result NN I-NP O
11 1877 1879 10091617 of IN B-PP O
12 1880 1883 10091617 non AFX B-NP O
13 1883 1884 10091617 - HYPH I-NP O
14 1884 1893 10091617 selective JJ I-NP O
15 1894 1904 10091617 inhibition NN I-NP O
16 1905 1907 10091617 of IN B-PP O
17 1908 1917 10091617 monoamine NN B-NP O
18 1918 1925 10091617 oxidase NN I-NP O
19 1926 1928 10091617 or CC B-PP O
20 1929 1931 10091617 of IN B-PP O
21 1932 1943 10091617 amphetamine NN B-NP B-Chemical
22 1944 1947 10091617 and CC I-NP O
23 1948 1962 10091617 metamphetamine NN I-NP B-Chemical
24 1963 1966 10091617 are VBP B-VP O
25 1967 1976 10091617 discussed VBN I-VP O
26 1976 1977 10091617 . . O O

1 0 0 9869257 -DOCSTART- -X- -X- O

1 0 6 9869257 Memory NN B-NP O
2 7 19 9869257 facilitation NN I-NP O
3 20 23 9869257 and CC I-NP O
4 24 35 9869257 stimulation NN I-NP O
5 36 38 9869257 of IN B-PP O
6 39 49 9869257 endogenous JJ B-NP O
7 50 55 9869257 nerve NN I-NP O
8 56 62 9869257 growth NN I-NP O
9 63 69 9869257 factor NN I-NP O
10 70 79 9869257 synthesis NN I-NP O
11 80 82 9869257 by IN B-PP O
12 83 86 9869257 the DT B-NP O
13 87 100 9869257 acetylcholine NN I-NP B-Chemical
14 101 109 9869257 releaser NN I-NP O
15 110 112 9869257 PG NN I-NP B-Chemical
16 112 113 9869257 - HYPH B-NP I-Chemical
17 113 114 9869257 9 CD I-NP I-Chemical
18 114 115 9869257 . . O O
19 116 119 9869257 The DT B-NP O
20 120 127 9869257 effects NNS I-NP O
21 128 130 9869257 of IN B-PP O
22 131 133 9869257 PG NN B-NP B-Chemical
23 133 134 9869257 - HYPH B-NP I-Chemical
24 134 135 9869257 9 CD I-NP I-Chemical
25 136 137 9869257 ( ( O O
26 137 143 9869257 3alpha NN B-NP B-Chemical
27 143 144 9869257 - HYPH O I-Chemical
28 144 150 9869257 tropyl NN B-NP I-Chemical
29 151 152 9869257 2 CD I-NP I-Chemical
30 152 153 9869257 - HYPH I-NP I-Chemical
31 153 155 9869257 (p NN I-NP I-Chemical
32 155 156 9869257 - HYPH I-NP I-Chemical
33 156 178 9869257 bromophenyl)propionate NN I-NP I-Chemical
34 178 179 9869257 ) ) O O
35 179 180 9869257 , , O O
36 181 184 9869257 the DT B-NP O
37 185 198 9869257 acetylcholine NN I-NP B-Chemical
38 199 207 9869257 releaser NN I-NP O
39 207 208 9869257 , , O O
40 209 211 9869257 on IN B-PP O
41 212 218 9869257 memory NN B-NP O
42 219 228 9869257 processes NNS I-NP O
43 229 232 9869257 and CC O O
44 233 238 9869257 nerve NN B-NP O
45 239 245 9869257 growth NN I-NP O
46 246 252 9869257 factor NN I-NP O
47 253 254 9869257 ( ( O O
48 254 257 9869257 NGF NN B-NP O
49 257 258 9869257 ) ) O O
50 259 268 9869257 synthesis NN B-NP O
51 269 273 9869257 were VBD B-VP O
52 274 283 9869257 evaluated VBN I-VP O
53 283 284 9869257 . . O O

1 285 287 9869257 In IN B-PP O
2 288 291 9869257 the DT B-NP O
3 292 297 9869257 mouse NN I-NP O
4 298 305 9869257 passive JJ I-NP O
5 305 306 9869257 - HYPH I-NP O
6 306 315 9869257 avoidance NN I-NP O
7 316 320 9869257 test NN I-NP O
8 320 321 9869257 , , O O
9 322 324 9869257 PG NN B-NP B-Chemical
10 324 325 9869257 - HYPH O I-Chemical
11 325 326 9869257 9 CD B-NP I-Chemical
12 327 328 9869257 ( NN I-NP O
13 328 330 9869257 10 CD B-NP O
14 330 331 9869257 - HYPH I-NP O
15 331 333 9869257 30 CD I-NP O
16 334 336 9869257 mg NN I-NP O
17 336 337 9869257 / SYM B-NP O
18 337 339 9869257 kg NN I-NP O
19 339 340 9869257 , , O O
20 341 344 9869257 i.p NN B-NP O
21 344 345 9869257 . . O O
22 345 346 9869257 ) ) O O
23 346 347 9869257 , , O O
24 348 360 9869257 administered VBN B-VP O
25 361 363 9869257 20 CD B-NP O
26 364 367 9869257 min NN I-NP O
27 368 374 9869257 before IN B-PP O
28 375 378 9869257 the DT B-NP O
29 379 387 9869257 training NN I-NP O
30 388 395 9869257 session NN I-NP O
31 395 396 9869257 , , O O
32 397 406 9869257 prevented VBD B-VP O
33 407 414 9869257 amnesia NN B-NP B-Disease
34 415 422 9869257 induced VBN B-VP O
35 423 425 9869257 by IN B-PP O
36 426 430 9869257 both CC O O
37 431 434 9869257 the DT B-NP O
38 435 438 9869257 non JJ I-NP O
39 439 448 9869257 selective JJ I-NP O
40 449 463 9869257 antimuscarinic JJ I-NP O
41 464 468 9869257 drug NN I-NP O
42 469 480 9869257 scopolamine NN I-NP B-Chemical
43 481 484 9869257 and CC O O
44 485 488 9869257 the DT B-NP O
45 489 491 9869257 M1 NN I-NP O
46 491 492 9869257 - HYPH B-NP O
47 492 501 9869257 selective JJ I-NP O
48 502 512 9869257 antagonist NN I-NP O
49 513 514 9869257 S NN I-NP B-Chemical
50 514 515 9869257 - HYPH O I-Chemical
51 515 516 9869257 ( ( O I-Chemical
52 516 517 9869257 - SYM O I-Chemical
53 517 518 9869257 ) ) O I-Chemical
54 518 519 9869257 - HYPH B-NP I-Chemical
55 519 521 9869257 ET NN I-NP I-Chemical
56 521 522 9869257 - SYM B-NP I-Chemical
57 522 525 9869257 126 CD B-NP I-Chemical
58 525 526 9869257 . . O O

1 527 529 9869257 In IN B-PP O
2 530 533 9869257 the DT B-NP O
3 534 538 9869257 same JJ I-NP O
4 539 551 9869257 experimental JJ I-NP O
5 552 562 9869257 conditions NNS I-NP O
6 562 563 9869257 , , O O
7 564 566 9869257 PG NN B-NP B-Chemical
8 566 567 9869257 - HYPH O I-Chemical
9 567 568 9869257 9 CD B-NP I-Chemical
10 569 570 9869257 ( ( O O
11 570 571 9869257 5 CD B-NP O
12 571 572 9869257 - HYPH I-NP O
13 572 574 9869257 20 CD I-NP O
14 575 581 9869257 microg NN I-NP O
15 582 585 9869257 per IN B-PP O
16 586 591 9869257 mouse NN B-NP O
17 591 592 9869257 , , O O
18 593 598 9869257 i.c.v NN B-NP O
19 598 599 9869257 . . O O
20 599 600 9869257 ) ) O O
21 601 604 9869257 was VBD B-VP O
22 605 609 9869257 also RB B-ADVP O
23 610 614 9869257 able JJ B-ADJP O
24 615 617 9869257 to TO B-VP O
25 618 625 9869257 prevent VB I-VP O
26 626 639 9869257 antimuscarine NN B-NP O
27 639 640 9869257 - HYPH B-NP O
28 640 647 9869257 induced VBN I-NP O
29 648 655 9869257 amnesia NN I-NP B-Disease
30 655 656 9869257 , , O O
31 657 670 9869257 demonstrating VBG B-VP O
32 671 672 9869257 a DT B-NP O
33 673 680 9869257 central JJ I-NP O
34 681 693 9869257 localization NN I-NP O
35 694 696 9869257 of IN B-PP O
36 697 700 9869257 the DT B-NP O
37 701 709 9869257 activity NN I-NP O
38 709 710 9869257 . . O O

1 711 713 9869257 At IN B-PP O
2 714 717 9869257 the DT B-NP O
3 718 725 9869257 highest JJS I-NP O
4 726 735 9869257 effective JJ I-NP O
5 736 741 9869257 doses NNS I-NP O
6 741 742 9869257 , , O O
7 743 745 9869257 PG NN B-NP B-Chemical
8 745 746 9869257 - HYPH O I-Chemical
9 746 747 9869257 9 CD B-NP I-Chemical
10 748 751 9869257 did VBD B-VP O
11 752 755 9869257 not RB I-VP O
12 756 763 9869257 produce VB I-VP O
13 764 767 9869257 any DT B-NP O
14 768 778 9869257 collateral JJ I-NP O
15 779 787 9869257 symptoms NNS I-NP O
16 788 790 9869257 as IN B-SBAR O
17 791 799 9869257 revealed VBN B-VP O
18 800 802 9869257 by IN B-PP O
19 803 806 9869257 the DT B-NP O
20 807 812 9869257 Irwin NNP I-NP O
21 813 817 9869257 test NN I-NP O
22 817 818 9869257 , , O O
23 819 822 9869257 and CC O O
24 823 825 9869257 it PRP B-NP O
25 826 829 9869257 did VBD B-VP O
26 830 833 9869257 not RB I-VP O
27 834 840 9869257 modify VB I-VP O
28 841 852 9869257 spontaneous JJ B-NP O
29 853 861 9869257 motility NN I-NP O
30 862 865 9869257 and CC I-NP O
31 866 876 9869257 inspection NN I-NP O
32 877 885 9869257 activity NN I-NP O
33 885 886 9869257 , , O O
34 887 889 9869257 as IN B-SBAR O
35 890 898 9869257 revealed VBN B-VP O
36 899 901 9869257 by IN B-PP O
37 902 905 9869257 the DT B-NP O
38 906 910 9869257 hole NN I-NP O
39 910 911 9869257 - HYPH I-NP O
40 911 916 9869257 board NN I-NP O
41 917 921 9869257 test NN I-NP O
42 921 922 9869257 . . O O

1 923 925 9869257 PG NN B-NP B-Chemical
2 925 926 9869257 - HYPH B-NP I-Chemical
3 926 927 9869257 9 CD I-NP I-Chemical
4 928 931 9869257 was VBD B-VP O
5 932 936 9869257 also RB B-ADVP O
6 937 941 9869257 able JJ B-ADJP O
7 942 944 9869257 to TO B-VP O
8 945 953 9869257 increase VB I-VP O
9 954 957 9869257 the DT B-NP O
10 958 964 9869257 amount NN I-NP O
11 965 967 9869257 of IN B-PP O
12 968 971 9869257 NGF NN B-NP O
13 972 980 9869257 secreted VBN B-VP O
14 981 983 9869257 in FW B-ADVP O
15 984 989 9869257 vitro FW I-ADVP O
16 990 992 9869257 by IN B-PP O
17 993 1003 9869257 astrocytes NNS B-NP O
18 1004 1006 9869257 in IN B-PP O
19 1007 1008 9869257 a DT B-NP O
20 1009 1013 9869257 dose NN I-NP O
21 1013 1014 9869257 - HYPH B-NP O
22 1014 1023 9869257 dependent JJ I-NP O
23 1024 1030 9869257 manner NN I-NP O
24 1030 1031 9869257 . . O O

1 1032 1035 9869257 The DT B-NP O
2 1036 1043 9869257 maximal JJ I-NP O
3 1044 1047 9869257 NGF NN I-NP O
4 1048 1056 9869257 contents NNS I-NP O
5 1057 1065 9869257 obtained VBN B-VP O
6 1066 1068 9869257 by IN B-PP O
7 1069 1071 9869257 PG NN B-NP B-Chemical
8 1071 1072 9869257 - HYPH O I-Chemical
9 1072 1073 9869257 9 CD B-NP I-Chemical
10 1074 1078 9869257 were VBD B-VP O
11 1079 1083 9869257 17.6 CD B-NP O
12 1083 1084 9869257 - HYPH B-ADVP O
13 1084 1088 9869257 fold RB B-ADVP O
14 1089 1091 9869257 of IN B-PP O
15 1092 1095 9869257 the DT B-NP O
16 1096 1103 9869257 control NN I-NP O
17 1104 1109 9869257 value NN I-NP O
18 1109 1110 9869257 . . O O

1 1111 1117 9869257 During IN B-PP O
2 1118 1125 9869257 culture NN B-NP O
3 1125 1126 9869257 , , O O
4 1127 1129 9869257 no DT B-NP O
5 1130 1143 9869257 morphological JJ I-NP O
6 1144 1151 9869257 changes NNS I-NP O
7 1152 1156 9869257 were VBD B-VP O
8 1157 1162 9869257 found VBN I-VP O
9 1163 1165 9869257 at IN B-PP O
10 1166 1175 9869257 effective JJ B-NP O
11 1176 1190 9869257 concentrations NNS I-NP O
12 1191 1193 9869257 of IN B-PP O
13 1194 1196 9869257 PG NN B-NP B-Chemical
14 1196 1197 9869257 - HYPH B-NP I-Chemical
15 1197 1198 9869257 9 CD I-NP I-Chemical
16 1198 1199 9869257 . . O O

1 1200 1203 9869257 The DT B-NP O
2 1204 1211 9869257 current JJ I-NP O
3 1212 1216 9869257 work NN I-NP O
4 1217 1226 9869257 indicates VBZ B-VP O
5 1227 1230 9869257 the DT B-NP O
6 1231 1238 9869257 ability NN I-NP O
7 1239 1241 9869257 of IN B-PP O
8 1242 1244 9869257 PG NN B-NP B-Chemical
9 1244 1245 9869257 - HYPH O I-Chemical
10 1245 1246 9869257 9 CD B-NP I-Chemical
11 1247 1249 9869257 to TO B-VP O
12 1250 1256 9869257 induce VB I-VP O
13 1257 1267 9869257 beneficial JJ B-NP O
14 1268 1275 9869257 effects NNS I-NP O
15 1276 1278 9869257 on IN B-PP O
16 1279 1288 9869257 cognitive JJ B-NP O
17 1289 1298 9869257 processes NNS I-NP O
18 1299 1302 9869257 and CC O O
19 1303 1312 9869257 stimulate VBP B-VP O
20 1313 1321 9869257 activity NN B-NP O
21 1322 1324 9869257 of IN B-PP O
22 1325 1328 9869257 NGF NN B-NP O
23 1329 1338 9869257 synthesis NN I-NP O
24 1339 1341 9869257 in IN B-PP O
25 1342 1352 9869257 astroglial JJ B-NP O
26 1353 1358 9869257 cells NNS I-NP O
27 1358 1359 9869257 . . O O

1 1360 1369 9869257 Therefore RB B-ADVP O
2 1369 1370 9869257 , , O O
3 1371 1373 9869257 PG NN B-NP B-Chemical
4 1373 1374 9869257 - HYPH O I-Chemical
5 1374 1375 9869257 9 CD B-NP I-Chemical
6 1376 1381 9869257 could MD B-VP O
7 1382 1391 9869257 represent VB I-VP O
8 1392 1393 9869257 a DT B-NP O
9 1394 1403 9869257 potential JJ I-NP O
10 1404 1410 9869257 useful JJ I-NP O
11 1411 1415 9869257 drug NN I-NP O
12 1416 1420 9869257 able JJ B-ADJP O
13 1421 1423 9869257 to TO B-VP O
14 1424 1431 9869257 improve VB I-VP O
15 1432 1435 9869257 the DT B-NP O
16 1436 1444 9869257 function NN I-NP O
17 1445 1447 9869257 of IN B-PP O
18 1448 1456 9869257 impaired JJ B-NP O
19 1457 1466 9869257 cognitive JJ I-NP O
20 1467 1476 9869257 processes NNS I-NP O
21 1476 1477 9869257 . . O O

1 0 0 6209318 -DOCSTART- -X- -X- O

1 0 13 6209318 International JJ B-NP O
2 14 24 6209318 mexiletine NN I-NP B-Chemical
3 25 28 6209318 and CC I-NP O
4 29 36 6209318 placebo NN I-NP O
5 37 51 6209318 antiarrhythmic JJ I-NP O
6 52 60 6209318 coronary JJ I-NP O
7 61 66 6209318 trial NN I-NP O
8 66 67 6209318 : : O O
9 68 69 6209318 I LS B-LST O
10 69 70 6209318 . . O O

1 71 77 6209318 Report NN B-NP O
2 78 80 6209318 on IN B-PP O
3 81 91 6209318 arrhythmia NN B-NP B-Disease
4 92 95 6209318 and CC O O
5 96 101 6209318 other JJ B-NP O
6 102 110 6209318 findings NNS I-NP O
7 110 111 6209318 . . O O

1 112 118 6209318 Impact NNP B-NP O
2 119 127 6209318 Research NNP I-NP O
3 128 133 6209318 Group NNP I-NP O
4 133 134 6209318 . . O O
5 135 138 6209318 The DT B-NP O
6 139 153 6209318 antiarrhythmic JJ I-NP O
7 154 161 6209318 effects NNS I-NP O
8 162 164 6209318 of IN B-PP O
9 165 168 6209318 the DT B-NP O
10 169 178 6209318 sustained JJ I-NP O
11 179 186 6209318 release NN I-NP O
12 187 191 6209318 form NN I-NP O
13 192 194 6209318 of IN B-PP O
14 195 205 6209318 mexiletine NN B-NP B-Chemical
15 206 207 6209318 ( ( O O
16 207 214 6209318 Mexitil NN B-NP B-Chemical
17 214 215 6209318 - HYPH B-NP I-Chemical
18 215 225 6209318 Perlongets NNPS I-NP I-Chemical
19 225 226 6209318 ) ) O O
20 227 231 6209318 were VBD B-VP O
21 232 241 6209318 evaluated VBN I-VP O
22 242 244 6209318 in IN B-PP O
23 245 246 6209318 a DT B-NP O
24 247 253 6209318 double JJ I-NP O
25 253 254 6209318 - HYPH I-NP O
26 254 259 6209318 blind JJ I-NP O
27 260 267 6209318 placebo NN I-NP O
28 268 273 6209318 trial NN I-NP O
29 274 276 6209318 in IN B-PP O
30 277 280 6209318 630 CD B-NP O
31 281 289 6209318 patients NNS I-NP O
32 290 294 6209318 with IN B-PP O
33 295 301 6209318 recent JJ B-NP O
34 302 312 6209318 documented VBN I-NP O
35 313 323 6209318 myocardial JJ I-NP B-Disease
36 324 334 6209318 infarction NN I-NP I-Disease
37 334 335 6209318 . . O O

1 336 339 6209318 The DT B-NP O
2 340 347 6209318 primary JJ I-NP O
3 348 356 6209318 response NN I-NP O
4 357 365 6209318 variable JJ I-NP O
5 366 369 6209318 was VBD B-VP O
6 370 375 6209318 based VBN I-VP O
7 376 378 6209318 on IN B-PP O
8 379 386 6209318 central JJ B-NP O
9 387 394 6209318 reading NN I-NP O
10 395 397 6209318 of IN B-PP O
11 398 400 6209318 24 CD B-NP O
12 401 405 6209318 hour NN I-NP O
13 406 416 6209318 ambulatory JJ I-NP O
14 417 437 6209318 electrocardiographic JJ I-NP O
15 438 448 6209318 recordings NNS I-NP O
16 449 452 6209318 and CC O O
17 453 456 6209318 was VBD B-VP O
18 457 464 6209318 defined VBN I-VP O
19 465 467 6209318 as IN B-PP O
20 468 471 6209318 the DT B-NP O
21 472 482 6209318 occurrence NN I-NP O
22 483 485 6209318 of IN B-PP O
23 486 488 6209318 30 CD B-NP O
24 489 491 6209318 or CC I-NP O
25 492 496 6209318 more JJR I-NP O
26 497 503 6209318 single JJ I-NP O
27 504 513 6209318 premature JJ I-NP O
28 514 525 6209318 ventricular JJ I-NP O
29 526 535 6209318 complexes NNS I-NP O
30 536 538 6209318 in IN B-PP O
31 539 542 6209318 any DT B-NP O
32 543 546 6209318 two CD I-NP O
33 547 558 6209318 consecutive JJ I-NP O
34 559 561 6209318 30 CD I-NP O
35 562 568 6209318 minute NN I-NP O
36 569 575 6209318 blocks NNS I-NP O
37 576 578 6209318 or CC O O
38 579 582 6209318 one CD B-NP O
39 583 585 6209318 or CC I-NP O
40 586 590 6209318 more JJR I-NP O
41 591 595 6209318 runs NNS I-NP O
42 596 598 6209318 of IN B-PP O
43 599 602 6209318 two CD B-NP O
44 603 605 6209318 or CC I-NP O
45 606 610 6209318 more JJR I-NP O
46 611 620 6209318 premature JJ I-NP O
47 621 632 6209318 ventricular JJ I-NP O
48 633 642 6209318 complexes NNS I-NP O
49 643 645 6209318 in IN B-PP O
50 646 649 6209318 the DT B-NP O
51 650 656 6209318 entire JJ I-NP O
52 657 659 6209318 24 CD I-NP O
53 660 664 6209318 hour NN I-NP O
54 665 685 6209318 electrocardiographic JJ I-NP O
55 686 695 6209318 recording NN I-NP O
56 695 696 6209318 . . O O

1 697 702 6209318 Large JJ B-NP O
2 703 714 6209318 differences NNS I-NP O
3 714 715 6209318 , , O O
4 716 724 6209318 regarded VBN B-VP O
5 725 727 6209318 as IN B-PP O
6 728 741 6209318 statistically RB B-ADJP O
7 742 753 6209318 significant JJ I-ADJP O
8 753 754 6209318 , , O O
9 755 762 6209318 between IN B-PP O
10 763 766 6209318 the DT B-NP O
11 767 777 6209318 mexiletine NN I-NP B-Chemical
12 778 781 6209318 and CC I-NP O
13 782 789 6209318 placebo NN I-NP O
14 790 796 6209318 groups NNS I-NP O
15 797 801 6209318 were VBD B-VP O
16 802 807 6209318 noted VBN I-VP O
17 808 810 6209318 in IN B-PP O
18 811 815 6209318 that DT B-NP O
19 816 819 6209318 end NN I-NP O
20 820 825 6209318 point NN I-NP O
21 826 828 6209318 at IN B-PP O
22 829 835 6209318 months NNS B-NP O
23 836 837 6209318 1 CD I-NP O
24 838 841 6209318 and CC I-NP O
25 842 843 6209318 4 CD I-NP O
26 843 844 6209318 , , O O
27 845 848 6209318 but CC O O
28 849 853 6209318 only RB B-NP O
29 854 860 6209318 trends NNS I-NP O
30 861 865 6209318 were VBD B-VP O
31 866 874 6209318 observed VBN I-VP O
32 875 877 6209318 at IN B-PP O
33 878 883 6209318 month NN B-NP O
34 884 886 6209318 12 CD I-NP O
35 886 887 6209318 . . O O

1 888 893 6209318 These DT B-NP O
2 894 905 6209318 differences NNS I-NP O
3 906 910 6209318 were VBD B-VP O
4 911 919 6209318 observed VBN I-VP O
5 920 924 6209318 even RB B-SBAR O
6 925 931 6209318 though IN I-SBAR O
7 932 935 6209318 the DT B-NP O
8 936 941 6209318 serum NN I-NP O
9 942 952 6209318 mexiletine NN I-NP B-Chemical
10 953 959 6209318 levels NNS I-NP O
11 960 968 6209318 obtained VBN B-VP O
12 969 971 6209318 in IN B-PP O
13 972 976 6209318 this DT B-NP O
14 977 982 6209318 study NN I-NP O
15 983 987 6209318 were VBD B-VP O
16 988 997 6209318 generally RB B-ADJP O
17 998 1003 6209318 lower JJR I-ADJP O
18 1004 1008 6209318 than IN B-PP O
19 1009 1014 6209318 those DT B-NP O
20 1015 1023 6209318 observed VBN B-VP O
21 1024 1026 6209318 in IN B-PP O
22 1027 1034 6209318 studies NNS B-NP O
23 1035 1039 6209318 that WDT B-NP O
24 1040 1044 6209318 have VBP B-VP O
25 1045 1049 6209318 used VBN I-VP O
26 1050 1053 6209318 the DT B-NP O
27 1054 1061 6209318 regular JJ I-NP O
28 1062 1066 6209318 form NN I-NP O
29 1067 1069 6209318 of IN B-PP O
30 1070 1073 6209318 the DT B-NP O
31 1074 1078 6209318 drug NN I-NP O
32 1078 1079 6209318 . . O O

1 1080 1085 6209318 There EX B-NP O
2 1086 1090 6209318 were VBD B-VP O
3 1091 1095 6209318 more JJR B-NP O
4 1096 1102 6209318 deaths NNS I-NP B-Disease
5 1103 1105 6209318 in IN B-PP O
6 1106 1109 6209318 the DT B-NP O
7 1110 1120 6209318 mexiletine NN I-NP B-Chemical
8 1121 1126 6209318 group NN I-NP O
9 1127 1128 6209318 ( ( O O
10 1128 1132 6209318 7.6% NN B-NP O
11 1132 1133 6209318 ) ) O O
12 1134 1138 6209318 than IN B-PP O
13 1139 1141 6209318 in IN B-PP O
14 1142 1145 6209318 the DT B-NP O
15 1146 1153 6209318 placebo NN I-NP O
16 1154 1159 6209318 group NN I-NP O
17 1160 1161 6209318 ( ( O O
18 1161 1165 6209318 4.8% NN B-NP O
19 1165 1166 6209318 ) ) O O
20 1166 1167 6209318 ; : O O
21 1168 1171 6209318 the DT B-NP O
22 1172 1182 6209318 difference NN I-NP O
23 1183 1186 6209318 was VBD B-VP O
24 1187 1190 6209318 not RB O O
25 1191 1204 6209318 statistically RB B-ADJP O
26 1205 1216 6209318 significant JJ I-ADJP O
27 1216 1217 6209318 . . O O

1 1218 1221 6209318 The DT B-NP O
2 1222 1231 6209318 incidence NN I-NP O
3 1232 1234 6209318 of IN B-PP O
4 1235 1243 6209318 coronary JJ B-NP O
5 1244 1250 6209318 events NNS I-NP O
6 1251 1254 6209318 was VBD B-VP O
7 1255 1262 6209318 similar JJ B-ADJP O
8 1263 1265 6209318 in IN B-PP O
9 1266 1270 6209318 both DT B-NP O
10 1271 1277 6209318 groups NNS I-NP O
11 1277 1278 6209318 . . O O

1 1279 1289 6209318 Previously RB B-NP O
2 1290 1300 6209318 recognized VBN I-NP O
3 1301 1305 6209318 side NN I-NP O
4 1306 1313 6209318 effects NNS I-NP O
5 1313 1314 6209318 , , O O
6 1315 1327 6209318 particularly RB B-NP O
7 1328 1334 6209318 tremor NN I-NP B-Disease
8 1335 1338 6209318 and CC O O
9 1339 1355 6209318 gastrointestinal JJ B-NP B-Disease
10 1356 1364 6209318 problems NNS I-NP I-Disease
11 1364 1365 6209318 , , O O
12 1366 1370 6209318 were VBD B-VP O
13 1371 1375 6209318 more RBR B-ADJP O
14 1376 1384 6209318 frequent JJ I-ADJP O
15 1385 1387 6209318 in IN B-PP O
16 1388 1391 6209318 the DT B-NP O
17 1392 1402 6209318 mexiletine NN I-NP B-Chemical
18 1403 1408 6209318 group NN I-NP O
19 1409 1413 6209318 than IN B-PP O
20 1414 1416 6209318 in IN B-PP O
21 1417 1420 6209318 the DT B-NP O
22 1421 1428 6209318 placebo NN I-NP O
23 1429 1434 6209318 group NN I-NP O
24 1434 1435 6209318 . . O O

1 0 0 11569530 -DOCSTART- -X- -X- O

1 0 15 11569530 Pharmacokinetic JJ B-NP O
2 15 16 11569530 / SYM I-NP O
3 16 31 11569530 pharmacodynamic JJ I-NP O
4 32 42 11569530 assessment NN I-NP O
5 43 45 11569530 of IN B-PP O
6 46 49 11569530 the DT B-NP O
7 50 57 11569530 effects NNS I-NP O
8 58 60 11569530 of IN B-PP O
9 61 66 11569530 E4031 NN B-NP B-Chemical
10 66 67 11569530 , , O O
11 68 77 11569530 cisapride NN B-NP B-Chemical
12 77 78 11569530 , , O O
13 79 90 11569530 terfenadine NN B-NP B-Chemical
14 91 94 11569530 and CC I-NP O
15 95 105 11569530 terodiline NN I-NP B-Chemical
16 106 108 11569530 on IN B-PP O
17 109 119 11569530 monophasic JJ B-NP O
18 120 126 11569530 action NN I-NP O
19 127 136 11569530 potential NN I-NP O
20 137 145 11569530 duration NN I-NP O
21 146 148 11569530 in IN B-PP O
22 149 152 11569530 dog NN B-NP O
23 152 153 11569530 . . O O
24 154 155 11569530 1 CD B-NP O
25 155 156 11569530 . . O O

1 157 165 11569530 Torsades NNS B-NP B-Disease
2 166 168 11569530 de FW I-NP I-Disease
3 169 176 11569530 pointes FW I-NP I-Disease
4 177 178 11569530 ( ( O O
5 178 181 11569530 TDP NN B-NP B-Disease
6 181 182 11569530 ) ) O O
7 183 185 11569530 is VBZ B-VP O
8 186 187 11569530 a DT B-NP O
9 188 199 11569530 potentially RB I-NP O
10 200 205 11569530 fatal JJ I-NP O
11 206 217 11569530 ventricular JJ I-NP B-Disease
12 218 229 11569530 tachycardia NN I-NP I-Disease
13 230 240 11569530 associated VBN B-VP O
14 241 245 11569530 with IN B-PP O
15 246 255 11569530 increases NNS B-NP O
16 256 258 11569530 in IN B-PP O
17 259 261 11569530 QT NN B-NP O
18 262 270 11569530 interval NN I-NP O
19 271 274 11569530 and CC O O
20 275 285 11569530 monophasic JJ B-NP O
21 286 292 11569530 action NN I-NP O
22 293 302 11569530 potential NN I-NP O
23 303 311 11569530 duration NN I-NP O
24 312 313 11569530 ( ( O O
25 313 317 11569530 MAPD NN B-NP O
26 317 318 11569530 ) ) O O
27 318 319 11569530 . . O O

1 320 323 11569530 TDP NN B-NP B-Disease
2 324 326 11569530 is VBZ B-VP O
3 327 328 11569530 a DT B-NP O
4 329 333 11569530 side NN I-NP O
5 333 334 11569530 - HYPH I-NP O
6 334 340 11569530 effect NN I-NP O
7 341 345 11569530 that WDT B-NP O
8 346 349 11569530 has VBZ B-VP O
9 350 353 11569530 led VBN I-VP O
10 354 356 11569530 to TO B-PP O
11 357 367 11569530 withdrawal NN B-NP O
12 368 370 11569530 of IN B-PP O
13 371 378 11569530 several JJ B-NP O
14 379 384 11569530 drugs NNS I-NP O
15 385 389 11569530 from IN B-PP O
16 390 393 11569530 the DT B-NP O
17 394 400 11569530 market NN I-NP O
18 401 402 11569530 ( ( O O
19 402 406 11569530 e.g. FW B-NP O
20 407 418 11569530 terfenadine NN I-NP B-Chemical
21 419 422 11569530 and CC O O
22 423 433 11569530 terodiline NN B-NP B-Chemical
23 433 434 11569530 ) ) O O
24 434 435 11569530 . . O O

1 436 437 11569530 2 LS B-LST O
2 437 438 11569530 . . O O

1 439 442 11569530 The DT B-NP O
2 443 452 11569530 potential NN I-NP O
3 453 455 11569530 of IN B-PP O
4 456 465 11569530 compounds NNS B-NP O
5 466 468 11569530 to TO B-VP O
6 469 474 11569530 cause VB I-VP O
7 475 478 11569530 TDP NN B-NP B-Disease
8 479 482 11569530 was VBD B-VP O
9 483 492 11569530 evaluated VBN I-VP O
10 493 495 11569530 by IN B-PP O
11 496 506 11569530 monitoring VBG B-VP O
12 507 512 11569530 their PRP$ B-NP O
13 513 520 11569530 effects NNS I-NP O
14 521 523 11569530 on IN B-PP O
15 524 528 11569530 MAPD NN B-NP O
16 529 531 11569530 in IN B-PP O
17 532 535 11569530 dog NN B-NP O
18 535 536 11569530 . . O O

1 537 541 11569530 Four CD B-NP O
2 542 551 11569530 compounds NNS I-NP O
3 552 557 11569530 known VBN B-VP O
4 558 560 11569530 to TO B-VP O
5 561 569 11569530 increase VB I-VP O
6 570 572 11569530 QT NN B-NP O
7 573 581 11569530 interval NN I-NP O
8 582 585 11569530 and CC O O
9 586 591 11569530 cause NN B-NP O
10 592 595 11569530 TDP NN I-NP B-Disease
11 596 600 11569530 were VBD B-VP O
12 601 613 11569530 investigated VBN I-VP O
13 613 614 11569530 : : O O
14 615 626 11569530 terfenadine NN B-NP B-Chemical
15 626 627 11569530 , , I-NP O
16 628 638 11569530 terodiline NN I-NP B-Chemical
17 638 639 11569530 , , I-NP O
18 640 649 11569530 cisapride NN I-NP B-Chemical
19 650 653 11569530 and CC I-NP O
20 654 659 11569530 E4031 NN I-NP B-Chemical
21 659 660 11569530 . . O O

1 661 663 11569530 On IN B-PP O
2 664 667 11569530 the DT B-NP O
3 668 673 11569530 basis NN I-NP O
4 674 678 11569530 that IN B-SBAR O
5 679 683 11569530 only RB B-NP O
6 684 688 11569530 free JJ I-NP O
7 689 693 11569530 drug NN I-NP O
8 694 696 11569530 in IN B-PP O
9 697 700 11569530 the DT B-NP O
10 701 709 11569530 systemic JJ I-NP O
11 710 721 11569530 circulation NN I-NP O
12 722 726 11569530 will MD B-VP O
13 727 733 11569530 elicit VB I-VP O
14 734 735 11569530 a DT B-NP O
15 736 751 11569530 pharmacological JJ I-NP O
16 752 760 11569530 response NN I-NP O
17 761 767 11569530 target NN I-NP O
18 767 768 11569530 , , O O
19 769 773 11569530 free JJ B-NP O
20 774 788 11569530 concentrations NNS I-NP O
21 789 791 11569530 in IN B-PP O
22 792 798 11569530 plasma NN B-NP O
23 799 803 11569530 were VBD B-VP O
24 804 812 11569530 selected VBN I-VP O
25 813 815 11569530 to TO I-VP O
26 816 821 11569530 mimic VB I-VP O
27 822 825 11569530 the DT B-NP O
28 826 830 11569530 free JJ I-NP O
29 831 835 11569530 drug NN I-NP O
30 836 845 11569530 exposures NNS I-NP O
31 846 848 11569530 in IN B-PP O
32 849 852 11569530 man NN B-NP O
33 852 853 11569530 . . O O

1 854 862 11569530 Infusion NN B-NP O
2 863 871 11569530 regimens NNS I-NP O
3 872 876 11569530 were VBD B-VP O
4 877 885 11569530 designed VBN I-VP O
5 886 890 11569530 that WDT B-NP O
6 891 898 11569530 rapidly RB B-ADVP O
7 899 907 11569530 achieved VBD B-VP O
8 908 911 11569530 and CC O O
9 912 922 11569530 maintained VBD B-VP O
10 923 929 11569530 target NN B-NP O
11 929 930 11569530 - HYPH O O
12 930 934 11569530 free JJ B-NP O
13 935 949 11569530 concentrations NNS I-NP O
14 950 952 11569530 of IN B-PP O
15 953 958 11569530 these DT B-NP O
16 959 964 11569530 drugs NNS I-NP O
17 965 967 11569530 in IN B-PP O
18 968 974 11569530 plasma NN B-NP O
19 975 978 11569530 and CC I-NP O
20 979 983 11569530 data NNS I-NP O
21 984 986 11569530 on IN B-PP O
22 987 990 11569530 the DT B-NP O
23 991 1003 11569530 relationship NN I-NP O
24 1004 1011 11569530 between IN B-PP O
25 1012 1016 11569530 free JJ B-NP O
26 1017 1030 11569530 concentration NN I-NP O
27 1031 1034 11569530 and CC I-NP O
28 1035 1042 11569530 changes NNS I-NP O
29 1043 1045 11569530 in IN B-PP O
30 1046 1050 11569530 MAPD NN B-NP O
31 1051 1055 11569530 were VBD B-VP O
32 1056 1064 11569530 obtained VBN I-VP O
33 1065 1068 11569530 for IN B-PP O
34 1069 1074 11569530 these DT B-NP O
35 1075 1084 11569530 compounds NNS I-NP O
36 1084 1085 11569530 . . O O

1 1086 1087 11569530 3 LS B-LST O
2 1087 1088 11569530 . . O O

1 1089 1094 11569530 These DT B-NP O
2 1095 1099 11569530 data NNS I-NP O
3 1100 1108 11569530 indicate VBP B-VP O
4 1109 1113 11569530 that IN B-SBAR O
5 1114 1117 11569530 the DT B-NP O
6 1118 1122 11569530 free JJ I-NP O
7 1123 1127 11569530 ED50 NN I-NP O
8 1128 1130 11569530 in IN B-PP O
9 1131 1137 11569530 plasma NN B-NP O
10 1138 1141 11569530 for IN B-PP O
11 1142 1153 11569530 terfenadine NN B-NP B-Chemical
12 1154 1155 11569530 ( ( O O
13 1155 1158 11569530 1.9 CD B-NP O
14 1159 1161 11569530 nM NN I-NP O
15 1161 1162 11569530 ) ) O O
16 1162 1163 11569530 , , O O
17 1164 1174 11569530 terodiline NN B-NP B-Chemical
18 1175 1176 11569530 ( ( O O
19 1176 1178 11569530 76 CD B-NP O
20 1179 1181 11569530 nM NN I-NP O
21 1181 1182 11569530 ) ) O O
22 1182 1183 11569530 , , O O
23 1184 1193 11569530 cisapride NN B-NP B-Chemical
24 1194 1195 11569530 ( ( O O
25 1195 1197 11569530 11 CD B-NP O
26 1198 1200 11569530 nM NN I-NP O
27 1200 1201 11569530 ) ) O O
28 1202 1205 11569530 and CC O O
29 1206 1211 11569530 E4031 NN B-NP B-Chemical
30 1212 1213 11569530 ( ( O O
31 1213 1216 11569530 1.9 CD B-NP O
32 1217 1219 11569530 nM NN I-NP O
33 1219 1220 11569530 ) ) O O
34 1221 1228 11569530 closely RB B-ADVP O
35 1229 1238 11569530 correlate VBP B-VP O
36 1239 1243 11569530 with IN B-PP O
37 1244 1247 11569530 the DT B-NP O
38 1248 1252 11569530 free JJ I-NP O
39 1253 1266 11569530 concentration NN I-NP O
40 1267 1269 11569530 in IN B-PP O
41 1270 1273 11569530 man NN B-NP O
42 1274 1281 11569530 causing VBG B-VP O
43 1282 1284 11569530 QT NN B-NP O
44 1285 1292 11569530 effects NNS I-NP O
45 1292 1293 11569530 . . O O

1 1294 1297 11569530 For IN B-PP O
2 1298 1307 11569530 compounds NNS B-NP O
3 1308 1312 11569530 that WDT B-NP O
4 1313 1317 11569530 have VBP B-VP O
5 1318 1323 11569530 shown VBN I-VP O
6 1324 1327 11569530 TDP NN B-NP B-Disease
7 1328 1330 11569530 in IN B-PP O
8 1331 1334 11569530 the DT B-NP O
9 1335 1341 11569530 clinic NN I-NP O
10 1342 1343 11569530 ( ( O O
11 1343 1354 11569530 terfenadine NN B-NP B-Chemical
12 1354 1355 11569530 , , O O
13 1356 1366 11569530 terodiline NN B-NP B-Chemical
14 1366 1367 11569530 , , O O
15 1368 1377 11569530 cisapride NN B-NP B-Chemical
16 1377 1378 11569530 ) ) O O
17 1379 1384 11569530 there EX B-NP O
18 1385 1387 11569530 is VBZ B-VP O
19 1388 1394 11569530 little JJ B-NP O
20 1395 1410 11569530 differentiation NN I-NP O
21 1411 1418 11569530 between IN B-PP O
22 1419 1422 11569530 the DT B-NP O
23 1423 1426 11569530 dog NN I-NP O
24 1427 1431 11569530 ED50 NN I-NP O
25 1432 1435 11569530 and CC O O
26 1436 1439 11569530 the DT B-NP O
27 1440 1451 11569530 efficacious JJ I-NP O
28 1452 1456 11569530 free JJ I-NP O
29 1457 1463 11569530 plasma NN I-NP O
30 1464 1478 11569530 concentrations NNS I-NP O
31 1479 1481 11569530 in IN B-PP O
32 1482 1485 11569530 man NN B-NP O
33 1486 1487 11569530 ( ( O O
34 1487 1488 11569530 < SYM B-NP O
35 1489 1491 11569530 10 CD I-NP O
36 1491 1492 11569530 - HYPH O O
37 1492 1496 11569530 fold RB B-ADVP O
38 1496 1497 11569530 ) ) O O
39 1498 1508 11569530 reflecting VBG B-VP O
40 1509 1514 11569530 their PRP$ B-NP O
41 1515 1522 11569530 limited VBN I-NP O
42 1523 1529 11569530 safety NN I-NP O
43 1530 1537 11569530 margins NNS I-NP O
44 1537 1538 11569530 . . O O

1 1539 1544 11569530 These DT B-NP O
2 1545 1549 11569530 data NNS I-NP O
3 1550 1559 11569530 underline VBP B-VP O
4 1560 1563 11569530 the DT B-NP O
5 1564 1568 11569530 need NN I-NP O
6 1569 1571 11569530 to TO B-VP O
7 1572 1580 11569530 maximize VB I-VP O
8 1581 1584 11569530 the DT B-NP O
9 1585 1596 11569530 therapeutic JJ I-NP O
10 1597 1602 11569530 ratio NN I-NP O
11 1603 1607 11569530 with IN B-PP O
12 1608 1615 11569530 respect NN B-NP O
13 1616 1618 11569530 to TO B-PP O
14 1619 1622 11569530 TDP NN B-NP B-Disease
15 1623 1625 11569530 in IN B-PP O
16 1626 1635 11569530 potential JJ B-NP O
17 1636 1647 11569530 development NN I-NP O
18 1648 1658 11569530 candidates NNS I-NP O
19 1659 1662 11569530 and CC O O
20 1663 1666 11569530 the DT B-NP O
21 1667 1677 11569530 importance NN I-NP O
22 1678 1680 11569530 of IN B-PP O
23 1681 1686 11569530 using VBG B-VP O
24 1687 1691 11569530 free JJ B-NP O
25 1692 1696 11569530 drug NN I-NP O
26 1697 1711 11569530 concentrations NNS I-NP O
27 1712 1714 11569530 in IN B-PP O
28 1715 1730 11569530 pharmacokinetic JJ B-NP O
29 1730 1731 11569530 / SYM I-NP O
30 1731 1746 11569530 pharmacodynamic JJ I-NP O
31 1747 1754 11569530 studies NNS I-NP O
32 1754 1755 11569530 . . O O

1 0 0 3629586 -DOCSTART- -X- -X- O

1 0 3 3629586 The DT B-NP O
2 4 15 3629586 hematologic JJ I-NP O
3 16 23 3629586 effects NNS I-NP O
4 24 26 3629586 of IN B-PP O
5 27 36 3629586 cefonicid NN B-NP B-Chemical
6 37 40 3629586 and CC I-NP O
7 41 51 3629586 cefazedone NN I-NP B-Chemical
8 52 54 3629586 in IN B-PP O
9 55 58 3629586 the DT B-NP O
10 59 62 3629586 dog NN I-NP O
11 62 63 3629586 : : O O
12 64 65 3629586 a DT B-NP O
13 66 75 3629586 potential JJ I-NP O
14 76 81 3629586 model NN I-NP O
15 82 84 3629586 of IN B-PP O
16 85 98 3629586 cephalosporin NN B-NP B-Chemical
17 99 113 3629586 hematotoxicity NN I-NP B-Disease
18 114 116 3629586 in IN B-PP O
19 117 120 3629586 man NN B-NP O
20 120 121 3629586 . . O O
21 122 135 3629586 Cephalosporin NN B-NP B-Chemical
22 136 147 3629586 antibiotics NNS I-NP O
23 148 153 3629586 cause VBP B-VP O
24 154 155 3629586 a DT B-NP O
25 156 163 3629586 variety NN I-NP O
26 164 166 3629586 of IN B-PP O
27 167 178 3629586 hematologic JJ B-NP B-Disease
28 179 191 3629586 disturbances NNS I-NP I-Disease
29 192 194 3629586 in IN B-PP O
30 195 198 3629586 man NN B-NP O
31 198 199 3629586 , , O O
32 200 203 3629586 the DT B-NP O
33 204 216 3629586 pathogeneses NNS I-NP O
34 217 220 3629586 and CC I-NP O
35 221 236 3629586 hematopathology NN I-NP O
36 237 239 3629586 of IN B-PP O
37 240 245 3629586 which WDT B-NP O
38 246 252 3629586 remain VBP B-VP O
39 253 259 3629586 poorly RB B-ADJP O
40 260 273 3629586 characterized VBN I-ADJP O
41 273 274 3629586 . . O O

1 275 280 3629586 There EX B-NP O
2 281 283 3629586 is VBZ B-VP O
3 284 285 3629586 a DT B-NP O
4 286 290 3629586 need NN I-NP O
5 291 294 3629586 for IN B-PP O
6 295 296 3629586 a DT B-NP O
7 297 301 3629586 well RB I-NP O
8 301 302 3629586 - HYPH I-NP O
9 302 309 3629586 defined VBN I-NP O
10 310 316 3629586 animal NN I-NP O
11 317 322 3629586 model NN I-NP O
12 323 325 3629586 in IN B-PP O
13 326 331 3629586 which WDT B-NP O
14 332 337 3629586 these DT B-NP O
15 338 343 3629586 blood NN I-NP B-Disease
16 344 354 3629586 dyscrasias NNS I-NP I-Disease
17 355 358 3629586 can MD B-VP O
18 359 361 3629586 be VB I-VP O
19 362 369 3629586 studied VBN I-VP O
20 369 370 3629586 . . O O

1 371 373 3629586 In IN B-PP O
2 374 378 3629586 four CD B-NP O
3 379 387 3629586 subacute JJ I-NP O
4 388 396 3629586 toxicity NN I-NP B-Disease
5 397 404 3629586 studies NNS I-NP O
6 404 405 3629586 , , O O
7 406 409 3629586 the DT B-NP O
8 410 421 3629586 intravenous JJ I-NP O
9 422 436 3629586 administration NN I-NP O
10 437 439 3629586 of IN B-PP O
11 440 449 3629586 cefonicid NN B-NP B-Chemical
12 450 452 3629586 or CC I-NP O
13 453 463 3629586 cefazedone NN I-NP B-Chemical
14 464 466 3629586 to TO B-PP O
15 467 473 3629586 beagle NN B-NP O
16 474 478 3629586 dogs NNS I-NP O
17 479 485 3629586 caused VBD B-VP O
18 486 487 3629586 a DT B-NP O
19 488 492 3629586 dose NN I-NP O
20 492 493 3629586 - HYPH B-NP O
21 493 502 3629586 dependent JJ I-NP O
22 503 512 3629586 incidence NN I-NP O
23 513 515 3629586 of IN B-PP O
24 516 522 3629586 anemia NN B-NP B-Disease
25 522 523 3629586 , , O O
26 524 535 3629586 neutropenia NN B-NP B-Disease
27 535 536 3629586 , , O O
28 537 540 3629586 and CC O O
29 541 557 3629586 thrombocytopenia NN B-NP B-Disease
30 558 563 3629586 after IN B-PP O
31 564 565 3629586 1 CD B-NP O
32 565 566 3629586 - HYPH I-NP O
33 566 567 3629586 3 CD I-NP O
34 568 574 3629586 months NNS I-NP O
35 575 577 3629586 of IN B-PP O
36 578 587 3629586 treatment NN B-NP O
37 587 588 3629586 . . O O

1 589 590 3629586 A DT B-NP O
2 591 606 3629586 nonregenerative JJ I-NP O
3 607 613 3629586 anemia NN I-NP B-Disease
4 614 617 3629586 was VBD B-VP O
5 618 621 3629586 the DT B-NP O
6 622 626 3629586 most RBS I-NP O
7 627 639 3629586 compromising JJ I-NP O
8 640 642 3629586 of IN B-PP O
9 643 646 3629586 the DT B-NP O
10 647 657 3629586 cytopenias NNS I-NP B-Disease
11 658 661 3629586 and CC O O
12 662 670 3629586 occurred VBD B-VP O
13 671 673 3629586 in IN B-PP O
14 674 687 3629586 approximately RB B-NP O
15 688 691 3629586 50% CD I-NP O
16 692 694 3629586 of IN B-PP O
17 695 699 3629586 dogs NNS B-NP O
18 700 709 3629586 receiving VBG B-VP O
19 710 713 3629586 400 CD B-NP O
20 713 714 3629586 - HYPH I-NP O
21 714 717 3629586 500 CD I-NP O
22 718 720 3629586 mg NN I-NP O
23 720 721 3629586 / SYM O O
24 721 723 3629586 kg NN B-NP O
25 724 733 3629586 cefonicid NN I-NP B-Chemical
26 734 736 3629586 or CC O O
27 737 740 3629586 540 CD B-NP O
28 740 741 3629586 - HYPH I-NP O
29 741 744 3629586 840 CD I-NP O
30 745 747 3629586 mg NN I-NP O
31 747 748 3629586 / SYM B-NP O
32 748 750 3629586 kg NN I-NP O
33 751 761 3629586 cefazedone NN I-NP B-Chemical
34 761 762 3629586 . . O O

1 763 766 3629586 All DT B-NP O
2 767 772 3629586 three CD I-NP O
3 773 783 3629586 cytopenias NNS I-NP B-Disease
4 784 788 3629586 were VBD B-VP O
5 789 799 3629586 completely RB B-ADJP O
6 800 810 3629586 reversible JJ I-ADJP O
7 811 820 3629586 following VBG B-PP O
8 821 830 3629586 cessation NN B-NP O
9 831 833 3629586 of IN B-PP O
10 834 843 3629586 treatment NN B-NP O
11 843 844 3629586 ; : O O
12 845 848 3629586 the DT B-NP O
13 849 853 3629586 time NN I-NP O
14 854 862 3629586 required VBN B-VP O
15 863 866 3629586 for IN B-PP O
16 867 875 3629586 recovery NN B-NP O
17 876 878 3629586 of IN B-PP O
18 879 882 3629586 the DT B-NP O
19 883 891 3629586 erythron NN I-NP O
20 892 893 3629586 ( ( O O
21 893 906 3629586 approximately RB B-NP O
22 907 908 3629586 1 CD I-NP O
23 909 914 3629586 month NN I-NP O
24 914 915 3629586 ) ) O O
25 916 919 3629586 was VBD B-VP O
26 920 932 3629586 considerably RB B-ADVP O
27 933 939 3629586 longer RBR I-ADVP O
28 940 944 3629586 than IN B-PP O
29 945 949 3629586 that DT B-NP O
30 950 952 3629586 of IN B-PP O
31 953 956 3629586 the DT B-NP O
32 957 969 3629586 granulocytes NNS I-NP O
33 970 973 3629586 and CC I-NP O
34 974 983 3629586 platelets NNS I-NP O
35 984 985 3629586 ( ( O O
36 985 990 3629586 hours NNS B-NP O
37 991 993 3629586 to TO B-PP O
38 994 995 3629586 a DT B-NP O
39 996 999 3629586 few JJ I-NP O
40 1000 1004 3629586 days NNS I-NP O
41 1004 1005 3629586 ) ) O O
42 1005 1006 3629586 . . O O

1 1007 1011 3629586 Upon IN B-PP O
2 1012 1023 3629586 rechallenge NN B-NP O
3 1024 1028 3629586 with IN B-PP O
4 1029 1035 3629586 either CC O O
5 1036 1049 3629586 cephalosporin NN B-NP B-Chemical
6 1049 1050 3629586 , , O O
7 1051 1054 3629586 the DT B-NP O
8 1055 1066 3629586 hematologic JJ I-NP B-Disease
9 1067 1075 3629586 syndrome NN I-NP I-Disease
10 1076 1079 3629586 was VBD B-VP O
11 1080 1090 3629586 reproduced VBN I-VP O
12 1091 1093 3629586 in IN B-PP O
13 1094 1098 3629586 most JJS B-NP O
14 1099 1103 3629586 dogs NNS I-NP O
15 1104 1110 3629586 tested VBN B-VP O
16 1110 1111 3629586 ; : O O
17 1112 1121 3629586 cefonicid NN B-NP B-Chemical
18 1122 1123 3629586 ( ( O O
19 1123 1126 3629586 but CC O O
20 1127 1130 3629586 not RB O O
21 1131 1141 3629586 cefazedone NN B-NP B-Chemical
22 1141 1142 3629586 ) ) O O
23 1142 1143 3629586 - HYPH B-NP O
24 1143 1150 3629586 treated VBN I-NP O
25 1151 1155 3629586 dogs NNS I-NP O
26 1156 1162 3629586 showed VBD B-VP O
27 1163 1164 3629586 a DT B-NP O
28 1165 1178 3629586 substantially RB I-NP O
29 1179 1186 3629586 reduced VBN I-NP O
30 1187 1196 3629586 induction NN I-NP O
31 1197 1203 3629586 period NN I-NP O
32 1204 1205 3629586 ( ( O O
33 1205 1207 3629586 15 CD B-NP O
34 1208 1209 3629586 + SYM O O
35 1209 1210 3629586 / SYM O O
36 1210 1211 3629586 - SYM O O
37 1212 1213 3629586 5 CD B-NP O
38 1214 1218 3629586 days NNS I-NP O
39 1218 1219 3629586 ) ) O O
40 1220 1228 3629586 compared VBN B-VP O
41 1229 1231 3629586 to TO B-PP O
42 1232 1236 3629586 that DT B-NP O
43 1237 1239 3629586 of IN B-PP O
44 1240 1243 3629586 the DT B-NP O
45 1244 1249 3629586 first JJ I-NP O
46 1250 1258 3629586 exposure NN I-NP O
47 1259 1261 3629586 to TO B-PP O
48 1262 1265 3629586 the DT B-NP O
49 1266 1270 3629586 drug NN I-NP O
50 1271 1272 3629586 ( ( O O
51 1272 1274 3629586 61 CD B-NP O
52 1275 1276 3629586 + SYM O O
53 1276 1277 3629586 / SYM O O
54 1277 1278 3629586 - SYM O O
55 1279 1281 3629586 24 CD B-NP O
56 1282 1286 3629586 days NNS I-NP O
57 1286 1287 3629586 ) ) O O
58 1287 1288 3629586 . . O O

1 1289 1293 3629586 This DT B-NP O
2 1294 1305 3629586 observation NN I-NP O
3 1305 1306 3629586 , , O O
4 1307 1312 3629586 along IN B-PP O
5 1313 1317 3629586 with IN B-PP O
6 1318 1321 3629586 the DT B-NP O
7 1322 1327 3629586 rapid JJ I-NP O
8 1328 1332 3629586 rate NN I-NP O
9 1333 1335 3629586 of IN B-PP O
10 1336 1343 3629586 decline NN B-NP O
11 1344 1346 3629586 in IN B-PP O
12 1347 1350 3629586 red JJ B-NP O
13 1351 1355 3629586 cell NN I-NP O
14 1356 1360 3629586 mass NN I-NP O
15 1361 1371 3629586 parameters NNS I-NP O
16 1372 1374 3629586 of IN B-PP O
17 1375 1383 3629586 affected VBN B-NP O
18 1384 1388 3629586 dogs NNS I-NP O
19 1388 1389 3629586 , , O O
20 1390 1398 3629586 suggests VBZ B-VP O
21 1399 1403 3629586 that IN B-SBAR O
22 1404 1405 3629586 a DT B-NP O
23 1406 1415 3629586 hemolytic JJ I-NP B-Disease
24 1416 1425 3629586 component NN I-NP O
25 1426 1437 3629586 complicated VBD B-VP O
26 1438 1441 3629586 the DT B-NP O
27 1442 1445 3629586 red JJ I-NP O
28 1446 1450 3629586 cell NN I-NP O
29 1451 1461 3629586 production NN I-NP O
30 1462 1469 3629586 problem NN I-NP O
31 1470 1473 3629586 and CC O O
32 1474 1478 3629586 that IN B-SBAR O
33 1479 1487 3629586 multiple JJ B-NP O
34 1488 1499 3629586 toxicologic JJ I-NP O
35 1500 1510 3629586 mechanisms NNS I-NP O
36 1511 1522 3629586 contributed VBD B-VP O
37 1523 1525 3629586 to TO B-PP O
38 1526 1529 3629586 the DT B-NP O
39 1530 1539 3629586 cytopenia NN I-NP B-Disease
40 1539 1540 3629586 . . O O

1 1541 1543 3629586 We PRP B-NP O
2 1544 1552 3629586 conclude VBP B-VP O
3 1553 1557 3629586 that IN B-SBAR O
4 1558 1561 3629586 the DT B-NP O
5 1562 1576 3629586 administration NN I-NP O
6 1577 1579 3629586 of IN B-PP O
7 1580 1584 3629586 high JJ B-NP O
8 1585 1590 3629586 doses NNS I-NP O
9 1591 1593 3629586 of IN B-PP O
10 1594 1603 3629586 cefonicid NN B-NP B-Chemical
11 1604 1606 3629586 or CC I-NP O
12 1607 1617 3629586 cefazedone NN I-NP B-Chemical
13 1618 1620 3629586 to TO B-PP O
14 1621 1625 3629586 dogs NNS B-NP O
15 1626 1629 3629586 can MD B-VP O
16 1630 1636 3629586 induce VB I-VP O
17 1637 1651 3629586 hematotoxicity NN B-NP B-Disease
18 1652 1659 3629586 similar JJ B-ADJP O
19 1660 1662 3629586 to TO B-PP O
20 1663 1666 3629586 the DT B-NP O
21 1667 1680 3629586 cephalosporin NN I-NP B-Chemical
22 1680 1681 3629586 - HYPH B-NP O
23 1681 1688 3629586 induced VBN I-NP O
24 1689 1694 3629586 blood NN I-NP B-Disease
25 1695 1705 3629586 dyscrasias NNS I-NP I-Disease
26 1706 1715 3629586 described VBN B-VP O
27 1716 1718 3629586 in IN B-PP O
28 1719 1722 3629586 man NN B-NP O
29 1723 1726 3629586 and CC O O
30 1727 1731 3629586 thus RB B-VP O
31 1732 1740 3629586 provides VBZ I-VP O
32 1741 1742 3629586 a DT B-NP O
33 1743 1749 3629586 useful JJ I-NP O
34 1750 1755 3629586 model NN I-NP O
35 1756 1759 3629586 for IN B-PP O
36 1760 1768 3629586 studying VBG B-VP O
37 1769 1772 3629586 the DT B-NP O
38 1773 1783 3629586 mechanisms NNS I-NP O
39 1784 1786 3629586 of IN B-PP O
40 1787 1792 3629586 these DT B-NP O
41 1793 1802 3629586 disorders NNS I-NP O
42 1802 1803 3629586 . . O O

1 0 0 15233872 -DOCSTART- -X- -X- O

1 0 16 15233872 Cardioprotective JJ B-NP O
2 17 23 15233872 effect NN I-NP O
3 24 26 15233872 of IN B-PP O
4 27 35 15233872 tincture NN B-NP B-Chemical
5 36 38 15233872 of IN B-PP I-Chemical
6 39 48 15233872 Crataegus NNP B-NP I-Chemical
7 49 51 15233872 on IN B-PP O
8 52 65 15233872 isoproterenol NN B-NP B-Chemical
9 65 66 15233872 - HYPH B-NP O
10 66 73 15233872 induced VBN I-NP O
11 74 84 15233872 myocardial JJ I-NP B-Disease
12 85 95 15233872 infarction NN I-NP I-Disease
13 96 98 15233872 in IN B-PP O
14 99 103 15233872 rats NNS B-NP O
15 103 104 15233872 . . O O
16 105 113 15233872 Tincture NNP B-NP B-Chemical
17 114 116 15233872 of IN B-PP I-Chemical
18 117 126 15233872 Crataegus NNP B-NP I-Chemical
19 127 128 15233872 ( ( O O
20 128 131 15233872 TCR NN B-NP B-Chemical
21 131 132 15233872 ) ) O O
22 132 133 15233872 , , O O
23 134 136 15233872 an DT B-NP O
24 137 146 15233872 alcoholic JJ I-NP B-Chemical
25 147 154 15233872 extract NN I-NP I-Chemical
26 155 157 15233872 of IN B-PP I-Chemical
27 158 161 15233872 the DT B-NP I-Chemical
28 162 169 15233872 berries NNS I-NP I-Chemical
29 170 172 15233872 of IN B-PP I-Chemical
30 173 181 15233872 hawthorn NN B-NP I-Chemical
31 182 183 15233872 ( ( O O
32 183 192 15233872 Crataegus NNP B-NP B-Chemical
33 193 202 15233872 oxycantha NN I-NP I-Chemical
34 202 203 15233872 ) ) O O
35 203 204 15233872 , , O O
36 205 207 15233872 is VBZ B-VP O
37 208 212 15233872 used VBN I-VP O
38 213 215 15233872 in IN B-PP O
39 216 222 15233872 herbal JJ B-NP O
40 223 226 15233872 and CC I-NP O
41 227 238 15233872 homeopathic JJ I-NP O
42 239 247 15233872 medicine NN I-NP O
43 247 248 15233872 . . O O

1 249 252 15233872 The DT B-NP O
2 253 260 15233872 present JJ I-NP O
3 261 266 15233872 study NN I-NP O
4 267 270 15233872 was VBD B-VP O
5 271 275 15233872 done VBN I-VP O
6 276 278 15233872 to TO I-VP O
7 279 290 15233872 investigate VB I-VP O
8 291 294 15233872 the DT B-NP O
9 295 305 15233872 protective JJ I-NP O
10 306 312 15233872 effect NN I-NP O
11 313 315 15233872 of IN B-PP O
12 316 319 15233872 TCR NN B-NP B-Chemical
13 320 322 15233872 on IN B-PP O
14 323 337 15233872 experimentally RB B-NP O
15 338 345 15233872 induced VBN I-NP O
16 346 356 15233872 myocardial JJ I-NP B-Disease
17 357 367 15233872 infarction NN I-NP I-Disease
18 368 370 15233872 in IN B-PP O
19 371 375 15233872 rats NNS B-NP O
20 375 376 15233872 . . O O

1 377 389 15233872 Pretreatment NN B-NP O
2 390 392 15233872 of IN B-PP O
3 393 396 15233872 TCR NN B-NP B-Chemical
4 396 397 15233872 , , O O
5 398 400 15233872 at IN B-PP O
6 401 402 15233872 a DT B-NP O
7 403 407 15233872 dose NN I-NP O
8 408 410 15233872 of IN B-PP O
9 411 414 15233872 0.5 CD B-NP O
10 415 417 15233872 mL NN I-NP O
11 417 418 15233872 / SYM B-NP O
12 418 421 15233872 100 CD B-NP O
13 422 423 15233872 g NN I-NP O
14 424 434 15233872 bodyweight NN I-NP O
15 435 438 15233872 per IN B-PP O
16 439 442 15233872 day NN B-NP O
17 442 443 15233872 , , O O
18 444 450 15233872 orally RB B-ADVP O
19 451 454 15233872 for IN B-PP O
20 455 457 15233872 30 CD B-NP O
21 458 462 15233872 days NNS I-NP O
22 462 463 15233872 , , O O
23 464 473 15233872 prevented VBD B-VP O
24 474 477 15233872 the DT B-NP O
25 478 486 15233872 increase NN I-NP O
26 487 489 15233872 in IN B-PP O
27 490 495 15233872 lipid NN B-NP O
28 496 508 15233872 peroxidation NN I-NP O
29 509 512 15233872 and CC I-NP O
30 513 521 15233872 activity NN I-NP O
31 522 524 15233872 of IN B-PP O
32 525 531 15233872 marker NN B-NP O
33 532 539 15233872 enzymes NNS I-NP O
34 540 548 15233872 observed VBN B-VP O
35 549 551 15233872 in IN B-PP O
36 552 565 15233872 isoproterenol NN B-NP B-Chemical
37 565 566 15233872 - HYPH B-NP O
38 566 573 15233872 induced VBN I-NP O
39 574 578 15233872 rats NNS I-NP O
40 579 580 15233872 ( ( O O
41 580 582 15233872 85 CD B-NP O
42 583 585 15233872 mg NN I-NP O
43 586 589 15233872 kg( AFX B-NP O
44 589 590 15233872 - HYPH I-NP O
45 590 592 15233872 1) CD I-NP O
46 593 594 15233872 s NN I-NP O
47 594 595 15233872 . . O O

1 596 597 15233872 c NN B-NP O
2 597 598 15233872 . . O O

1 599 602 15233872 for IN B-PP O
2 603 604 15233872 2 CD B-NP O
3 605 609 15233872 days NNS I-NP O
4 610 612 15233872 at IN B-PP O
5 613 615 15233872 an DT B-NP O
6 616 624 15233872 interval NN I-NP O
7 625 627 15233872 of IN B-PP O
8 628 630 15233872 24 CD B-NP O
9 631 632 15233872 h NN I-NP O
10 632 633 15233872 ) ) O O
11 633 634 15233872 . . O O

1 635 638 15233872 TCR NN B-NP B-Chemical
2 639 648 15233872 prevented VBD B-VP O
3 649 652 15233872 the DT B-NP O
4 653 666 15233872 isoproterenol NN I-NP B-Chemical
5 666 667 15233872 - HYPH B-NP O
6 667 674 15233872 induced VBN I-NP O
7 675 683 15233872 decrease NN I-NP O
8 684 686 15233872 in IN B-PP O
9 687 698 15233872 antioxidant JJ B-NP O
10 699 706 15233872 enzymes NNS I-NP O
11 707 709 15233872 in IN B-PP O
12 710 713 15233872 the DT B-NP O
13 714 719 15233872 heart NN I-NP O
14 720 723 15233872 and CC O O
15 724 733 15233872 increased VBD B-VP O
16 734 737 15233872 the DT B-NP O
17 738 742 15233872 rate NN I-NP O
18 743 745 15233872 of IN B-PP O
19 746 749 15233872 ADP NN B-NP B-Chemical
20 749 750 15233872 - HYPH B-NP O
21 750 760 15233872 stimulated VBN I-NP O
22 761 767 15233872 oxygen NN I-NP B-Chemical
23 768 774 15233872 uptake NN I-NP O
24 775 778 15233872 and CC O O
25 779 790 15233872 respiratory JJ B-NP O
26 791 799 15233872 coupling NN I-NP O
27 800 805 15233872 ratio NN I-NP O
28 805 806 15233872 . . O O

1 807 810 15233872 TCR NN B-NP B-Chemical
2 811 820 15233872 protected VBD B-VP O
3 821 828 15233872 against IN B-PP O
4 829 841 15233872 pathological JJ B-NP O
5 842 849 15233872 changes NNS I-NP O
6 850 857 15233872 induced VBN B-VP O
7 858 860 15233872 by IN B-PP O
8 861 874 15233872 isoproterenol NN B-NP B-Chemical
9 875 877 15233872 in IN B-PP O
10 878 881 15233872 rat NN B-NP O
11 882 887 15233872 heart NN I-NP O
12 887 888 15233872 . . O O

1 889 892 15233872 The DT B-NP O
2 893 900 15233872 results NNS I-NP O
3 901 905 15233872 show VBP B-VP O
4 906 910 15233872 that IN B-SBAR O
5 911 923 15233872 pretreatment NN B-NP O
6 924 928 15233872 with IN B-PP O
7 929 932 15233872 TCR NN B-NP B-Chemical
8 933 936 15233872 may MD B-VP O
9 937 939 15233872 be VB I-VP O
10 940 946 15233872 useful JJ B-ADJP O
11 947 949 15233872 in IN B-PP O
12 950 960 15233872 preventing VBG B-VP O
13 961 964 15233872 the DT B-NP O
14 965 971 15233872 damage NN I-NP O
15 972 979 15233872 induced VBN B-VP O
16 980 982 15233872 by IN B-PP O
17 983 996 15233872 isoproterenol NN B-NP B-Chemical
18 997 999 15233872 in IN B-PP O
19 1000 1003 15233872 rat NN B-NP O
20 1004 1009 15233872 heart NN I-NP O
21 1009 1010 15233872 . . O O

1 0 0 150790 -DOCSTART- -X- -X- O

1 0 1 150790 A DT B-NP O
2 2 12 150790 pyridoxine NN I-NP B-Chemical
3 12 13 150790 - HYPH B-NP O
4 13 22 150790 dependent JJ I-NP O
5 23 33 150790 behavioral JJ I-NP B-Disease
6 34 42 150790 disorder NN I-NP I-Disease
7 43 51 150790 unmasked JJ B-ADJP O
8 52 54 150790 by IN B-PP O
9 55 64 150790 isoniazid NN B-NP B-Chemical
10 64 65 150790 . . O O
11 66 67 150790 A NN B-NP O
12 68 69 150790 3 CD I-NP O
13 69 70 150790 - HYPH I-NP O
14 70 74 150790 year NN I-NP O
15 74 75 150790 - HYPH O O
16 75 78 150790 old JJ B-NP O
17 79 83 150790 girl NN I-NP O
18 84 87 150790 had VBD B-VP O
19 88 98 150790 behavioral JJ B-NP B-Disease
20 99 112 150790 deterioration NN I-NP I-Disease
21 112 113 150790 , , O O
22 114 118 150790 with IN B-PP O
23 119 131 150790 hyperkinesis NN B-NP B-Disease
24 131 132 150790 , , O O
25 133 145 150790 irritability NN B-NP B-Disease
26 145 146 150790 , , O O
27 147 150 150790 and CC O O
28 151 159 150790 sleeping VBG B-VP B-Disease
29 160 172 150790 difficulties NNS B-NP I-Disease
30 173 178 150790 after IN B-PP O
31 179 182 150790 the DT B-NP O
32 183 194 150790 therapeutic JJ I-NP O
33 195 209 150790 administration NN I-NP O
34 210 212 150790 of IN B-PP O
35 213 222 150790 isoniazid NN B-NP B-Chemical
36 222 223 150790 . . O O

1 224 227 150790 The DT B-NP O
2 228 242 150790 administration NN I-NP O
3 243 245 150790 of IN B-PP O
4 246 259 150790 pharmacologic JJ B-NP O
5 260 265 150790 doses NNS I-NP O
6 266 268 150790 of IN B-PP O
7 269 279 150790 pyridoxine NN B-NP B-Chemical
8 280 293 150790 hydrochloride NN I-NP I-Chemical
9 294 297 150790 led VBD B-VP O
10 298 300 150790 to TO B-PP O
11 301 302 150790 a DT B-NP O
12 303 316 150790 disappearance NN I-NP O
13 317 319 150790 of IN B-PP O
14 320 328 150790 symptoms NNS B-NP O
15 328 329 150790 . . O O

1 330 335 150790 After IN B-PP O
2 336 349 150790 discontinuing VBG B-VP O
3 350 359 150790 isoniazid NN B-NP B-Chemical
4 360 367 150790 therapy NN I-NP O
5 368 369 150790 a DT B-NP O
6 370 377 150790 similar JJ I-NP O
7 378 385 150790 pattern NN I-NP O
8 386 388 150790 of IN B-PP O
9 389 397 150790 behavior NN B-NP O
10 398 401 150790 was VBD B-VP O
11 402 407 150790 noted VBN I-VP O
12 408 412 150790 that WDT B-NP O
13 413 416 150790 was VBD B-VP O
14 417 427 150790 controlled VBN I-VP O
15 428 430 150790 by IN B-PP O
16 431 441 150790 pyridoxine NN B-NP B-Chemical
17 441 442 150790 . . O O

1 443 444 150790 A DT B-NP O
2 445 452 150790 placebo NN I-NP O
3 453 456 150790 had VBD B-VP O
4 457 459 150790 no DT B-NP O
5 460 466 150790 effect NN I-NP O
6 466 467 150790 , , O O
7 468 471 150790 but CC O O
8 472 483 150790 niacinamide NN B-NP B-Chemical
9 484 487 150790 was VBD B-VP O
10 488 490 150790 as RB B-ADJP O
11 491 500 150790 effective JJ I-ADJP O
12 501 503 150790 as IN B-PP O
13 504 514 150790 pyridoxine NN B-NP B-Chemical
14 514 515 150790 . . O O

1 516 524 150790 Periodic JJ B-NP O
2 525 535 150790 withdrawal NN I-NP O
3 536 538 150790 of IN B-PP O
4 539 549 150790 pyridoxine NN B-NP B-Chemical
5 550 553 150790 was VBD B-VP O
6 554 564 150790 associated VBN I-VP O
7 565 569 150790 with IN B-PP O
8 570 576 150790 return NN B-NP O
9 577 579 150790 of IN B-PP O
10 580 583 150790 the DT B-NP O
11 584 596 150790 hyperkinesis NN I-NP B-Disease
12 596 597 150790 . . O O

1 598 601 150790 The DT B-NP O
2 602 607 150790 level NN I-NP O
3 608 610 150790 of IN B-PP O
4 611 620 150790 pyridoxal NN B-NP B-Chemical
5 621 623 150790 in IN B-PP O
6 624 627 150790 the DT B-NP O
7 628 633 150790 blood NN I-NP O
8 634 637 150790 was VBD B-VP O
9 638 644 150790 normal JJ B-ADJP O
10 645 651 150790 during IN B-PP O
11 652 655 150790 the DT B-NP O
12 656 663 150790 periods NNS I-NP O
13 664 666 150790 of IN B-PP O
14 667 674 150790 relapse NN B-NP O
15 674 675 150790 . . O O

1 676 685 150790 Metabolic JJ B-NP O
2 686 693 150790 studies NNS I-NP O
3 694 703 150790 suggested VBD B-VP O
4 704 705 150790 a DT B-NP O
5 706 711 150790 block NN I-NP O
6 712 714 150790 in IN B-PP O
7 715 718 150790 the DT B-NP O
8 719 729 150790 kynurenine NN I-NP B-Chemical
9 730 737 150790 pathway NN I-NP O
10 738 740 150790 of IN B-PP O
11 741 751 150790 tryptophan NN B-NP B-Chemical
12 752 762 150790 metabolism NN I-NP O
13 762 763 150790 . . O O

1 764 767 150790 The DT B-NP O
2 768 775 150790 patient NN I-NP O
3 776 779 150790 has VBZ B-VP O
4 780 784 150790 been VBN I-VP O
5 785 793 150790 followed VBN I-VP O
6 794 797 150790 for IN B-PP O
7 798 801 150790 six CD B-NP O
8 802 807 150790 years NNS I-NP O
9 808 811 150790 and CC O O
10 812 815 150790 has VBZ B-VP O
11 816 824 150790 required VBN I-VP O
12 825 838 150790 pharmacologic JJ B-NP O
13 839 844 150790 doses NNS I-NP O
14 845 847 150790 of IN B-PP O
15 848 858 150790 pyridoxine NN B-NP B-Chemical
16 859 861 150790 to TO B-VP O
17 862 869 150790 control VB I-VP O
18 870 873 150790 her PRP$ B-NP O
19 874 882 150790 behavior NN I-NP O
20 882 883 150790 . . O O

1 0 0 9862868 -DOCSTART- -X- -X- O

1 0 9 9862868 Different JJ B-NP O
2 10 17 9862868 lobular JJ I-NP O
3 18 31 9862868 distributions NNS I-NP O
4 32 34 9862868 of IN B-PP O
5 35 42 9862868 altered JJ B-NP O
6 43 53 9862868 hepatocyte NN I-NP O
7 54 59 9862868 tight JJ I-NP O
8 60 69 9862868 junctions NNS I-NP O
9 70 72 9862868 in IN B-PP O
10 73 76 9862868 rat NN B-NP O
11 77 83 9862868 models NNS I-NP O
12 84 86 9862868 of IN B-PP O
13 87 99 9862868 intrahepatic JJ B-NP B-Disease
14 100 103 9862868 and CC I-NP I-Disease
15 104 116 9862868 extrahepatic JJ I-NP I-Disease
16 117 128 9862868 cholestasis NN I-NP I-Disease
17 128 129 9862868 . . I-NP O
18 130 140 9862868 Hepatocyte NN I-NP O
19 141 146 9862868 tight JJ I-NP O
20 147 156 9862868 junctions NNS I-NP O
21 157 158 9862868 ( ( O O
22 158 161 9862868 TJs NNS B-NP O
23 161 162 9862868 ) ) O O
24 162 163 9862868 , , O O
25 164 167 9862868 the DT B-NP O
26 168 172 9862868 only RB I-NP O
27 173 186 9862868 intercellular JJ I-NP O
28 187 194 9862868 barrier NN I-NP O
29 195 202 9862868 between IN B-PP O
30 203 206 9862868 the DT B-NP O
31 207 217 9862868 sinusoidal JJ I-NP O
32 218 221 9862868 and CC O O
33 222 225 9862868 the DT B-NP O
34 226 237 9862868 canalicular JJ I-NP O
35 238 244 9862868 spaces NNS I-NP O
36 244 245 9862868 , , O O
37 246 250 9862868 play VBP B-VP O
38 251 252 9862868 a DT B-NP O
39 253 256 9862868 key JJ I-NP O
40 257 261 9862868 role NN I-NP O
41 262 264 9862868 in IN B-PP O
42 265 269 9862868 bile NN B-NP O
43 270 279 9862868 formation NN I-NP O
44 279 280 9862868 . . O O

1 281 289 9862868 Although IN B-SBAR O
2 290 300 9862868 hepatocyte NN B-NP O
3 301 304 9862868 TJs NNS I-NP O
4 305 308 9862868 are VBP B-VP O
5 309 317 9862868 impaired JJ B-ADJP O
6 318 320 9862868 in IN B-PP O
7 321 332 9862868 cholestasis NN B-NP B-Disease
8 332 333 9862868 , , O O
9 334 342 9862868 attempts VBZ B-VP O
10 343 345 9862868 to TO I-VP O
11 346 354 9862868 localize VB I-VP O
12 355 358 9862868 the DT B-NP O
13 359 366 9862868 precise JJ I-NP O
14 367 371 9862868 site NN I-NP O
15 372 374 9862868 of IN B-PP O
16 375 385 9862868 hepatocyte NN B-NP O
17 386 388 9862868 TJ NN I-NP O
18 389 395 9862868 damage NN I-NP O
19 396 398 9862868 by IN B-PP O
20 399 405 9862868 freeze NN B-NP O
21 405 406 9862868 - HYPH B-NP O
22 406 414 9862868 fracture NN I-NP O
23 415 423 9862868 electron NN I-NP O
24 424 434 9862868 microscopy NN I-NP O
25 435 439 9862868 have VBP B-VP O
26 440 448 9862868 produced VBN I-VP O
27 449 456 9862868 limited JJ B-NP O
28 457 468 9862868 information NN I-NP O
29 468 469 9862868 . . O O

1 470 478 9862868 Recently RB B-ADVP O
2 478 479 9862868 , , O O
3 480 487 9862868 several JJ B-NP O
4 488 490 9862868 TJ NN I-NP O
5 490 491 9862868 - HYPH B-NP O
6 491 501 9862868 associated VBN I-NP O
7 502 510 9862868 proteins NNS I-NP O
8 511 515 9862868 like IN B-PP O
9 516 518 9862868 ZO NN B-NP O
10 518 519 9862868 - HYPH B-NP O
11 519 520 9862868 1 CD I-NP O
12 521 524 9862868 and CC I-NP O
13 525 528 9862868 7H6 CD I-NP O
14 529 533 9862868 have VBP B-VP O
15 534 538 9862868 been VBN I-VP O
16 539 549 9862868 identified VBN I-VP O
17 550 553 9862868 and CC O O
18 554 567 9862868 characterized VBN B-VP O
19 567 568 9862868 . . O O

1 569 587 9862868 Immunolocalization NN B-NP O
2 588 590 9862868 of IN B-PP O
3 591 594 9862868 7H6 NN B-NP O
4 595 602 9862868 appears VBZ B-VP O
5 603 605 9862868 to TO I-VP O
6 606 613 9862868 closely RB I-VP O
7 614 623 9862868 correlate VB I-VP O
8 624 628 9862868 with IN B-PP O
9 629 641 9862868 paracellular JJ B-NP O
10 642 654 9862868 permeability NN I-NP O
11 654 655 9862868 . . O O

1 656 658 9862868 We PRP B-NP O
2 659 663 9862868 used VBD B-VP O
3 664 667 9862868 rat NN B-NP O
4 668 674 9862868 models NNS I-NP O
5 675 677 9862868 of IN B-PP O
6 678 690 9862868 intrahepatic JJ B-NP B-Disease
7 691 702 9862868 cholestasis NN I-NP I-Disease
8 703 705 9862868 by IN B-PP O
9 706 713 9862868 ethinyl NN B-NP B-Chemical
10 714 723 9862868 estradiol NN I-NP I-Chemical
11 724 725 9862868 ( ( O O
12 725 727 9862868 EE NN B-NP B-Chemical
13 727 728 9862868 ) ) O O
14 729 738 9862868 treatment NN B-NP O
15 739 742 9862868 and CC O O
16 743 755 9862868 extrahepatic JJ B-NP B-Disease
17 756 767 9862868 cholestasis NN I-NP I-Disease
18 768 770 9862868 by IN B-PP O
19 771 775 9862868 bile NN B-NP O
20 776 780 9862868 duct NN I-NP O
21 781 789 9862868 ligation NN I-NP O
22 790 791 9862868 ( ( O O
23 791 794 9862868 BDL NN B-NP O
24 794 795 9862868 ) ) O O
25 796 798 9862868 to TO B-VP O
26 799 808 9862868 precisely RB I-VP O
27 809 818 9862868 determine VB I-VP O
28 819 822 9862868 the DT B-NP O
29 823 827 9862868 site NN I-NP O
30 828 830 9862868 of IN B-PP O
31 831 833 9862868 TJ NN B-NP O
32 834 840 9862868 damage NN I-NP O
33 840 841 9862868 . . O O

1 842 853 9862868 Alterations NNS B-NP O
2 854 856 9862868 in IN B-PP O
3 857 867 9862868 hepatocyte NN B-NP O
4 868 871 9862868 TJs NNS I-NP O
5 872 876 9862868 were VBD B-VP O
6 877 885 9862868 assessed VBN I-VP O
7 886 888 9862868 by IN B-PP O
8 889 895 9862868 double JJ B-NP O
9 895 896 9862868 - HYPH I-NP O
10 896 910 9862868 immunolabeling NN I-NP O
11 911 914 9862868 for IN B-PP O
12 915 918 9862868 7H6 NN B-NP O
13 919 922 9862868 and CC I-NP O
14 923 925 9862868 ZO NN I-NP O
15 925 926 9862868 - HYPH B-NP O
16 926 927 9862868 1 CD I-NP O
17 928 933 9862868 using VBG B-VP O
18 934 935 9862868 a DT B-NP O
19 936 944 9862868 confocal JJ I-NP O
20 945 950 9862868 laser NN I-NP O
21 951 959 9862868 scanning NN I-NP O
22 960 970 9862868 microscope NN I-NP O
23 970 971 9862868 . . O O

1 972 974 9862868 In IN B-PP O
2 975 982 9862868 control NN B-NP O
3 983 987 9862868 rats NNS I-NP O
4 987 988 9862868 , , O O
5 989 1003 9862868 immunostaining NN B-NP O
6 1004 1007 9862868 for IN B-PP O
7 1008 1011 9862868 7H6 NN B-NP O
8 1012 1015 9862868 and CC I-NP O
9 1016 1018 9862868 ZO NN I-NP O
10 1018 1019 9862868 - HYPH B-NP O
11 1019 1020 9862868 1 CD I-NP O
12 1021 1032 9862868 colocalized VBD B-VP O
13 1033 1035 9862868 to TO I-VP O
14 1036 1043 9862868 outline VB I-VP O
15 1044 1048 9862868 bile NN B-NP O
16 1049 1059 9862868 canaliculi NNS I-NP O
17 1060 1062 9862868 in IN B-PP O
18 1063 1064 9862868 a DT B-NP O
19 1065 1075 9862868 continuous JJ I-NP O
20 1076 1083 9862868 fashion NN I-NP O
21 1083 1084 9862868 . . O O

1 1085 1087 9862868 In IN B-PP O
2 1088 1096 9862868 contrast NN B-NP O
3 1096 1097 9862868 , , O O
4 1098 1101 9862868 7H6 NN B-NP O
5 1102 1105 9862868 and CC I-NP O
6 1106 1108 9862868 ZO NN I-NP O
7 1108 1109 9862868 - HYPH B-NP O
8 1109 1110 9862868 1 CD I-NP O
9 1111 1125 9862868 immunostaining NN I-NP O
10 1126 1129 9862868 was VBD B-VP O
11 1130 1134 9862868 more RBR B-ADJP O
12 1135 1148 9862868 discontinuous JJ I-ADJP O
13 1148 1149 9862868 , , O O
14 1150 1159 9862868 outlining VBG B-VP O
15 1160 1163 9862868 the DT B-NP O
16 1164 1168 9862868 bile NN I-NP O
17 1169 1179 9862868 canaliculi NNS I-NP O
18 1180 1185 9862868 after IN B-PP O
19 1186 1189 9862868 BDL NN B-NP O
20 1189 1190 9862868 . . O O

1 1191 1205 9862868 Immunostaining NN B-NP O
2 1206 1209 9862868 for IN B-PP O
3 1210 1213 9862868 7H6 NN B-NP O
4 1213 1214 9862868 , , O O
5 1215 1218 9862868 not RB B-NP O
6 1219 1221 9862868 ZO NN I-NP O
7 1221 1222 9862868 - HYPH B-NP O
8 1222 1223 9862868 1 CD I-NP O
9 1223 1224 9862868 , , O O
10 1225 1234 9862868 decreased VBN B-VP O
11 1235 1238 9862868 and CC O O
12 1239 1252 9862868 predominantly RB B-VP O
13 1253 1261 9862868 appeared VBD I-VP O
14 1262 1264 9862868 as IN B-PP O
15 1265 1273 9862868 discrete JJ B-NP O
16 1274 1281 9862868 signals NNS I-NP O
17 1282 1284 9862868 in IN B-PP O
18 1285 1288 9862868 the DT B-NP O
19 1289 1302 9862868 submembranous JJ I-NP O
20 1303 1312 9862868 cytoplasm NN I-NP O
21 1313 1315 9862868 of IN B-PP O
22 1316 1326 9862868 periportal JJ B-NP O
23 1327 1338 9862868 hepatocytes NNS I-NP O
24 1339 1344 9862868 after IN B-PP O
25 1345 1348 9862868 BDL NN B-NP O
26 1348 1349 9862868 . . O O

1 1350 1355 9862868 After IN B-PP O
2 1356 1358 9862868 EE NN B-NP B-Chemical
3 1359 1368 9862868 treatment NN I-NP O
4 1368 1369 9862868 , , O O
5 1370 1377 9862868 changes NNS B-NP O
6 1378 1380 9862868 in IN B-PP O
7 1381 1395 9862868 immunostaining NN B-NP O
8 1396 1399 9862868 for IN B-PP O
9 1400 1403 9862868 7H6 NN B-NP O
10 1404 1407 9862868 and CC I-NP O
11 1408 1410 9862868 ZO NN I-NP O
12 1410 1411 9862868 - HYPH B-NP O
13 1411 1412 9862868 1 CD I-NP O
14 1413 1417 9862868 were VBD B-VP O
15 1418 1425 9862868 similar JJ B-ADJP O
16 1426 1428 9862868 to TO B-PP O
17 1429 1434 9862868 those DT B-NP O
18 1435 1439 9862868 seen VBN B-VP O
19 1440 1442 9862868 in IN B-PP O
20 1443 1453 9862868 periportal JJ B-NP O
21 1454 1465 9862868 hepatocytes NNS I-NP O
22 1466 1471 9862868 after IN B-PP O
23 1472 1475 9862868 BDL NN B-NP O
24 1475 1476 9862868 , , O O
25 1477 1480 9862868 but CC O O
26 1481 1492 9862868 distributed VBD B-VP O
27 1493 1497 9862868 more RBR B-ADVP O
28 1498 1507 9862868 diffusely RB I-ADVP O
29 1508 1518 9862868 throughout IN B-PP O
30 1519 1522 9862868 the DT B-NP O
31 1523 1529 9862868 lobule NN I-NP O
32 1529 1530 9862868 . . O O

1 1531 1535 9862868 This DT B-NP O
2 1536 1541 9862868 study NN I-NP O
3 1542 1544 9862868 is VBZ B-VP O
4 1545 1548 9862868 the DT B-NP O
5 1549 1554 9862868 first JJ I-NP O
6 1555 1557 9862868 to TO B-VP O
7 1558 1569 9862868 demonstrate VB I-VP O
8 1570 1574 9862868 that IN B-SBAR O
9 1575 1585 9862868 impairment NN B-NP O
10 1586 1588 9862868 of IN B-PP O
11 1589 1599 9862868 hepatocyte NN B-NP O
12 1600 1603 9862868 TJs NNS I-NP O
13 1604 1610 9862868 occurs VBZ B-VP O
14 1611 1625 9862868 heterogenously RB B-ADVP O
15 1626 1628 9862868 in IN B-PP O
16 1629 1632 9862868 the DT B-NP O
17 1633 1638 9862868 liver NN I-NP O
18 1639 1645 9862868 lobule NN I-NP O
19 1646 1651 9862868 after IN B-PP O
20 1652 1655 9862868 BDL NN B-NP O
21 1656 1659 9862868 and CC O O
22 1660 1668 9862868 suggests VBZ B-VP O
23 1669 1673 9862868 that IN B-SBAR O
24 1674 1677 9862868 BDL NN B-NP O
25 1678 1681 9862868 and CC I-NP O
26 1682 1684 9862868 EE NN I-NP B-Chemical
27 1685 1695 9862868 treatments NNS I-NP O
28 1696 1703 9862868 produce VBP B-VP O
29 1704 1713 9862868 different JJ B-NP O
30 1714 1721 9862868 lobular JJ I-NP O
31 1722 1735 9862868 distributions NNS I-NP O
32 1736 1738 9862868 of IN B-PP O
33 1739 1748 9862868 increased VBN B-NP O
34 1749 1761 9862868 paracellular JJ I-NP O
35 1762 1774 9862868 permeability NN I-NP O
36 1774 1775 9862868 . . O O

1 0 0 230316 -DOCSTART- -X- -X- O

1 0 13 230316 Neurotoxicity NN B-NP B-Disease
2 14 16 230316 of IN B-PP O
3 17 28 230316 halogenated VBN B-NP B-Chemical
4 29 46 230316 hydroxyquinolines NNS I-NP I-Chemical
5 46 47 230316 : : O O
6 48 56 230316 clinical JJ B-NP O
7 57 65 230316 analysis NN I-NP O
8 66 68 230316 of IN B-PP O
9 69 74 230316 cases NNS B-NP O
10 75 83 230316 reported VBN B-VP O
11 84 91 230316 outside IN B-PP O
12 92 97 230316 Japan NNP B-NP O
13 97 98 230316 . . I-NP O
14 99 101 230316 An NNP I-NP O
15 102 110 230316 analysis NN I-NP O
16 111 113 230316 is VBZ B-VP O
17 114 123 230316 presented VBN I-VP O
18 124 126 230316 of IN B-PP O
19 127 130 230316 220 CD B-NP O
20 131 136 230316 cases NNS I-NP O
21 137 139 230316 of IN B-PP O
22 140 148 230316 possible JJ B-NP O
23 149 159 230316 neurotoxic JJ I-NP B-Disease
24 160 169 230316 reactions NNS I-NP O
25 170 172 230316 to TO B-PP O
26 173 184 230316 halogenated VBN B-NP B-Chemical
27 185 202 230316 hydroxyquinolines NNS I-NP I-Chemical
28 203 211 230316 reported VBN B-VP O
29 212 216 230316 from IN B-PP O
30 217 224 230316 outside IN B-PP O
31 225 230 230316 Japan NNP B-NP O
32 230 231 230316 . . O O

1 232 234 230316 In IN B-PP O
2 235 237 230316 80 CD B-NP O
3 238 243 230316 cases NNS I-NP O
4 244 256 230316 insufficient JJ B-NP O
5 257 268 230316 information NN I-NP O
6 269 272 230316 was VBD B-VP O
7 273 282 230316 available JJ B-ADJP O
8 283 286 230316 for IN B-PP O
9 287 295 230316 adequate JJ B-NP O
10 296 303 230316 comment NN I-NP O
11 304 307 230316 and CC O O
12 308 310 230316 in IN B-PP O
13 311 313 230316 29 CD B-NP O
14 314 315 230316 a DT B-NP O
15 316 328 230316 relationship NN I-NP O
16 329 331 230316 to TO B-PP O
17 332 335 230316 the DT B-NP O
18 336 350 230316 administration NN I-NP O
19 351 353 230316 of IN B-PP O
20 354 364 230316 clioquinol NN B-NP B-Chemical
21 365 370 230316 could MD B-VP O
22 371 373 230316 be VB I-VP O
23 374 382 230316 excluded VBN I-VP O
24 382 383 230316 . . O O

1 384 386 230316 Of IN B-PP O
2 387 390 230316 the DT B-NP O
3 391 400 230316 remainder NN I-NP O
4 400 401 230316 , , O O
5 402 403 230316 a DT B-NP O
6 404 416 230316 relationship NN I-NP O
7 417 419 230316 to TO B-PP O
8 420 430 230316 clioquinol NN B-NP B-Chemical
9 431 434 230316 was VBD B-VP O
10 435 445 230316 considered VBN I-VP O
11 446 454 230316 probable JJ B-ADJP O
12 455 457 230316 in IN B-PP O
13 458 460 230316 42 CD B-NP O
14 461 464 230316 and CC O O
15 465 473 230316 possible JJ B-ADJP O
16 474 476 230316 in IN B-PP O
17 477 479 230316 69 CD B-NP O
18 480 485 230316 cases NNS I-NP O
19 485 486 230316 . . O O

1 487 489 230316 In IN B-PP O
2 490 493 230316 six CD B-NP O
3 494 496 230316 of IN B-PP O
4 497 500 230316 the DT B-NP O
5 501 509 230316 probable JJ I-NP O
6 510 515 230316 cases NNS I-NP O
7 516 519 230316 the DT B-NP O
8 520 532 230316 neurological JJ I-NP B-Disease
9 533 544 230316 disturbance NN I-NP I-Disease
10 545 554 230316 consisted VBD B-VP O
11 555 557 230316 of IN B-PP O
12 558 560 230316 an DT B-NP O
13 561 566 230316 acute JJ I-NP O
14 567 577 230316 reversible JJ I-NP O
15 578 592 230316 encephalopathy NN I-NP B-Disease
16 593 600 230316 usually RB B-ADVP O
17 601 608 230316 related VBN B-VP O
18 609 611 230316 to TO B-PP O
19 612 615 230316 the DT B-NP O
20 616 625 230316 ingestion NN I-NP O
21 626 628 230316 of IN B-PP O
22 629 630 230316 a DT B-NP O
23 631 635 230316 high JJ I-NP O
24 636 640 230316 dose NN I-NP O
25 641 643 230316 of IN B-PP O
26 644 654 230316 clioquinol NN B-NP B-Chemical
27 655 659 230316 over IN B-PP O
28 660 661 230316 a DT B-NP O
29 662 667 230316 short JJ I-NP O
30 668 674 230316 period NN I-NP O
31 674 675 230316 . . O O

1 676 679 230316 The DT B-NP O
2 680 684 230316 most RBS I-NP O
3 685 691 230316 common JJ I-NP O
4 692 705 230316 manifestation NN I-NP O
5 705 706 230316 , , O O
6 707 715 230316 observed VBN B-VP O
7 716 718 230316 in IN B-PP O
8 719 721 230316 15 CD B-NP O
9 722 729 230316 further JJ I-NP O
10 730 735 230316 cases NNS I-NP O
11 735 736 230316 , , O O
12 737 740 230316 was VBD B-VP O
13 741 749 230316 isolated VBN I-VP O
14 750 755 230316 optic JJ B-NP B-Disease
15 756 763 230316 atrophy NN I-NP I-Disease
16 763 764 230316 . . O O

1 765 769 230316 This DT B-NP O
2 770 773 230316 was VBD B-VP O
3 774 778 230316 most RBS I-VP O
4 779 789 230316 frequently RB I-VP O
5 790 795 230316 found VBN I-VP O
6 796 798 230316 in IN B-PP O
7 799 807 230316 children NNS B-NP O
8 807 808 230316 , , O O
9 809 813 230316 many DT B-NP O
10 814 816 230316 of IN B-PP O
11 817 821 230316 whom WP B-NP O
12 822 825 230316 had VBD B-VP O
13 826 834 230316 received VBN I-VP O
14 835 845 230316 clioquinol NN B-NP B-Chemical
15 846 848 230316 as IN B-PP O
16 849 858 230316 treatment NN B-NP O
17 859 862 230316 for IN B-PP O
18 863 877 230316 acrodermatitis NN B-NP B-Disease
19 878 891 230316 enteropathica NN I-NP I-Disease
20 891 892 230316 . . O O

1 893 895 230316 In IN B-PP O
2 896 899 230316 the DT B-NP O
3 900 909 230316 remaining VBG I-NP O
4 910 915 230316 cases NNS I-NP O
5 915 916 230316 , , O O
6 917 918 230316 a DT B-NP O
7 919 930 230316 combination NN I-NP O
8 931 933 230316 of IN B-PP O
9 934 944 230316 myelopathy JJ B-NP B-Disease
10 944 945 230316 , , I-NP O
11 946 952 230316 visual JJ I-NP B-Disease
12 953 964 230316 disturbance NN I-NP I-Disease
13 964 965 230316 , , O O
14 966 969 230316 and CC O O
15 970 980 230316 peripheral JJ B-NP B-Disease
16 981 991 230316 neuropathy NN I-NP I-Disease
17 992 995 230316 was VBD B-VP O
18 996 999 230316 the DT B-NP O
19 1000 1004 230316 most RBS I-NP O
20 1005 1011 230316 common JJ I-NP O
21 1012 1025 230316 manifestation NN I-NP O
22 1025 1026 230316 . . O O

1 1027 1035 230316 Isolated VBN B-NP O
2 1036 1046 230316 myelopathy JJ I-NP B-Disease
3 1047 1049 230316 or CC I-NP O
4 1050 1060 230316 peripheral JJ I-NP B-Disease
5 1061 1071 230316 neuropathy NN I-NP I-Disease
6 1071 1072 230316 , , O O
7 1073 1075 230316 or CC O O
8 1076 1081 230316 these DT B-NP O
9 1082 1096 230316 manifestations NNS I-NP O
10 1097 1106 230316 occurring VBG B-VP O
11 1107 1115 230316 together RB B-ADVP O
12 1115 1116 230316 , , O O
13 1117 1121 230316 were VBD B-VP O
14 1122 1132 230316 infrequent JJ B-ADJP O
15 1132 1133 230316 . . O O

1 1134 1137 230316 The DT B-NP O
2 1138 1143 230316 onset NN I-NP O
3 1144 1146 230316 of IN B-PP O
4 1147 1150 230316 all DT B-NP O
5 1151 1165 230316 manifestations NNS I-NP O
6 1166 1167 230316 ( ( O O
7 1167 1173 230316 except IN B-PP O
8 1174 1179 230316 toxic JJ B-NP O
9 1180 1194 230316 encephalopathy NN I-NP B-Disease
10 1194 1195 230316 ) ) O O
11 1196 1199 230316 was VBD B-VP O
12 1200 1207 230316 usually RB B-ADVP O
13 1208 1216 230316 subacute JJ B-ADJP O
14 1216 1217 230316 , , O O
15 1218 1222 230316 with IN B-PP O
16 1223 1233 230316 subsequent JJ B-NP O
17 1234 1241 230316 partial JJ I-NP O
18 1242 1250 230316 recovery NN I-NP O
19 1250 1251 230316 . . O O

1 1252 1257 230316 Older JJR B-NP O
2 1258 1266 230316 subjects NNS I-NP O
3 1267 1273 230316 tended VBD B-VP O
4 1274 1276 230316 to TO I-VP O
5 1277 1284 230316 display VB I-VP O
6 1285 1289 230316 more RBR B-NP O
7 1290 1294 230316 side JJ I-NP O
8 1295 1302 230316 effects NNS I-NP O
9 1302 1303 230316 . . O O

1 1304 1307 230316 The DT B-NP O
2 1308 1312 230316 full JJ I-NP O
3 1313 1321 230316 syndrome NN I-NP O
4 1322 1324 230316 of IN B-PP O
5 1325 1333 230316 subacute JJ B-NP O
6 1334 1339 230316 myelo AFX I-NP B-Disease
7 1339 1340 230316 - HYPH I-NP I-Disease
8 1340 1345 230316 optic JJ I-NP I-Disease
9 1346 1356 230316 neuropathy NN I-NP I-Disease
10 1357 1360 230316 was VBD B-VP O
11 1361 1365 230316 more RBR B-ADJP O
12 1366 1374 230316 frequent JJ I-ADJP O
13 1375 1377 230316 in IN B-PP O
14 1378 1383 230316 women NNS B-NP O
15 1383 1384 230316 , , O O
16 1385 1388 230316 but CC O O
17 1389 1393 230316 they PRP B-NP O
18 1394 1400 230316 tended VBD B-VP O
19 1401 1403 230316 to TO I-VP O
20 1404 1408 230316 have VB I-VP O
21 1409 1414 230316 taken VBN I-VP O
22 1415 1422 230316 greater JJR B-NP O
23 1423 1433 230316 quantities NNS I-NP O
24 1434 1436 230316 of IN B-PP O
25 1437 1440 230316 the DT B-NP O
26 1441 1445 230316 drug NN I-NP O
27 1445 1446 230316 . . O O

1 0 0 18951540 -DOCSTART- -X- -X- O

1 0 10 18951540 Repetitive JJ B-NP O
2 11 23 18951540 transcranial JJ I-NP O
3 24 32 18951540 magnetic JJ I-NP O
4 33 44 18951540 stimulation NN I-NP O
5 45 48 18951540 for IN B-PP O
6 49 57 18951540 levodopa NN B-NP B-Chemical
7 57 58 18951540 - HYPH B-NP O
8 58 65 18951540 induced VBN I-NP O
9 66 77 18951540 dyskinesias NNS I-NP B-Disease
10 78 80 18951540 in IN B-PP O
11 81 92 18951540 Parkinson's NNS B-NP B-Disease
12 93 100 18951540 disease NN I-NP I-Disease
13 100 101 18951540 . . O O
14 102 104 18951540 In IN B-PP O
15 105 106 18951540 a DT B-NP O
16 107 114 18951540 placebo NN I-NP O
17 114 115 18951540 - HYPH B-VP O
18 115 125 18951540 controlled VBN I-VP O
19 125 126 18951540 , , O O
20 127 133 18951540 single JJ B-NP O
21 133 134 18951540 - HYPH I-NP O
22 134 141 18951540 blinded VBN B-VP O
23 141 142 18951540 , , O O
24 143 152 18951540 crossover NN B-NP O
25 153 158 18951540 study NN I-NP O
26 158 159 18951540 , , O O
27 160 162 18951540 we PRP B-NP O
28 163 171 18951540 assessed VBD B-VP O
29 172 175 18951540 the DT B-NP O
30 176 182 18951540 effect NN I-NP O
31 183 185 18951540 of IN B-PP O
32 186 187 18951540 " `` B-NP O
33 187 191 18951540 real JJ I-NP O
34 191 192 18951540 " '' I-NP O
35 193 203 18951540 repetitive JJ I-NP O
36 204 216 18951540 transcranial JJ I-NP O
37 217 225 18951540 magnetic JJ I-NP O
38 226 237 18951540 stimulation NN I-NP O
39 238 239 18951540 ( ( O O
40 239 243 18951540 rTMS NN B-NP O
41 243 244 18951540 ) ) O O
42 245 251 18951540 versus IN B-PP O
43 252 253 18951540 " `` B-NP O
44 253 257 18951540 sham NN I-NP O
45 257 258 18951540 " '' I-NP O
46 259 263 18951540 rTMS NN I-NP O
47 264 265 18951540 ( ( O O
48 265 272 18951540 placebo NN B-NP O
49 272 273 18951540 ) ) O O
50 274 276 18951540 on IN B-PP O
51 277 281 18951540 peak NN B-NP O
52 282 286 18951540 dose NN I-NP O
53 287 298 18951540 dyskinesias NNS I-NP B-Disease
54 299 301 18951540 in IN B-PP O
55 302 310 18951540 patients NNS B-NP O
56 311 315 18951540 with IN B-PP O
57 316 327 18951540 Parkinson's NNS B-NP B-Disease
58 328 335 18951540 disease NN B-NP I-Disease
59 336 337 18951540 ( ( O O
60 337 339 18951540 PD NN B-NP B-Disease
61 339 340 18951540 ) ) O O
62 340 341 18951540 . . O O

1 342 345 18951540 Ten CD B-NP O
2 346 354 18951540 patients NNS I-NP O
3 355 359 18951540 with IN B-PP O
4 360 362 18951540 PD NN B-NP B-Disease
5 363 366 18951540 and CC O O
6 367 376 18951540 prominent JJ B-NP O
7 377 388 18951540 dyskinesias NNS I-NP B-Disease
8 389 392 18951540 had VBD B-VP O
9 393 397 18951540 rTMS NN B-NP O
10 398 399 18951540 ( ( O O
11 399 404 18951540 1,800 CD B-NP O
12 405 411 18951540 pulses NNS I-NP O
13 411 412 18951540 ; : O O
14 413 414 18951540 1 CD B-NP O
15 415 417 18951540 Hz NN I-NP O
16 418 422 18951540 rate NN I-NP O
17 422 423 18951540 ) ) O O
18 424 433 18951540 delivered VBN B-VP O
19 434 438 18951540 over IN B-PP O
20 439 442 18951540 the DT B-NP O
21 443 448 18951540 motor NN I-NP O
22 449 455 18951540 cortex NN I-NP O
23 456 459 18951540 for IN B-PP O
24 460 461 18951540 4 CD B-NP O
25 462 473 18951540 consecutive JJ I-NP O
26 474 478 18951540 days NNS I-NP O
27 479 484 18951540 twice RB B-ADVP O
28 484 485 18951540 , , O O
29 486 490 18951540 once RB B-ADVP O
30 491 495 18951540 real JJ B-NP O
31 496 503 18951540 stimuli NNS I-NP O
32 504 507 18951540 and CC O O
33 508 512 18951540 once RB B-ADVP O
34 513 517 18951540 sham NN B-NP O
35 518 529 18951540 stimulation NN I-NP O
36 530 534 18951540 were VBD B-VP O
37 535 539 18951540 used VBN I-VP O
38 539 540 18951540 ; : O O
39 541 552 18951540 evaluations NNS B-NP O
40 553 557 18951540 were VBD B-VP O
41 558 562 18951540 done VBN I-VP O
42 563 565 18951540 at IN B-PP O
43 566 569 18951540 the DT B-NP O
44 570 578 18951540 baseline NN I-NP O
45 579 582 18951540 and CC I-NP O
46 583 584 18951540 1 CD I-NP O
47 585 588 18951540 day NN I-NP O
48 589 594 18951540 after IN B-PP O
49 595 598 18951540 the DT B-NP O
50 599 602 18951540 end NN I-NP O
51 603 605 18951540 of IN B-PP O
52 606 610 18951540 each DT B-NP O
53 611 613 18951540 of IN B-PP O
54 614 617 18951540 the DT B-NP O
55 618 627 18951540 treatment NN I-NP O
56 628 634 18951540 series NN I-NP O
57 634 635 18951540 . . O O

1 636 642 18951540 Direct JJ B-NP O
2 643 653 18951540 comparison NN I-NP O
3 654 661 18951540 between IN B-PP O
4 662 666 18951540 sham NN B-NP O
5 667 670 18951540 and CC O O
6 671 675 18951540 real JJ B-NP O
7 676 680 18951540 rTMS NN I-NP O
8 681 688 18951540 effects NNS I-NP O
9 689 695 18951540 showed VBD B-VP O
10 696 698 18951540 no DT B-NP O
11 699 710 18951540 significant JJ I-NP O
12 711 721 18951540 difference NN I-NP O
13 722 724 18951540 in IN B-PP O
14 725 734 18951540 clinician NN B-NP O
15 734 735 18951540 - HYPH B-NP O
16 735 743 18951540 assessed VBN I-NP O
17 744 754 18951540 dyskinesia NN I-NP B-Disease
18 755 763 18951540 severity NN I-NP O
19 763 764 18951540 . . O O

1 765 772 18951540 However RB B-ADVP O
2 772 773 18951540 , , O O
3 774 784 18951540 comparison NN B-NP O
4 785 789 18951540 with IN B-PP O
5 790 793 18951540 the DT B-NP O
6 794 802 18951540 baseline NN I-NP O
7 803 809 18951540 showed VBD B-VP O
8 810 815 18951540 small JJ B-NP O
9 816 819 18951540 but CC I-NP O
10 820 831 18951540 significant JJ I-NP O
11 832 841 18951540 reduction NN I-NP O
12 842 844 18951540 in IN B-PP O
13 845 855 18951540 dyskinesia NN B-NP B-Disease
14 856 864 18951540 severity NN I-NP O
15 865 874 18951540 following VBG B-PP O
16 875 879 18951540 real JJ B-NP O
17 880 884 18951540 rTMS NN I-NP O
18 885 888 18951540 but CC B-NP O
19 889 892 18951540 not RB I-NP O
20 893 900 18951540 placebo NN B-NP O
21 900 901 18951540 . . O O

1 902 905 18951540 The DT B-NP O
2 906 911 18951540 major JJ I-NP O
3 912 918 18951540 effect NN I-NP O
4 919 922 18951540 was VBD B-VP O
5 923 925 18951540 on IN B-PP O
6 926 934 18951540 dystonia NN B-NP B-Disease
7 935 943 18951540 subscore NN I-NP O
8 943 944 18951540 . . O O

1 945 954 18951540 Similarly RB B-ADVP O
2 954 955 18951540 , , O O
3 956 958 18951540 in IN B-PP O
4 959 966 18951540 patient NN B-NP O
5 967 974 18951540 diaries NNS I-NP O
6 974 975 18951540 , , O O
7 976 984 18951540 although IN B-SBAR O
8 985 989 18951540 both DT B-NP O
9 990 1000 18951540 treatments NNS I-NP O
10 1001 1007 18951540 caused VBD B-VP O
11 1008 1017 18951540 reduction NN B-NP O
12 1018 1020 18951540 in IN B-PP O
13 1021 1031 18951540 subjective JJ B-NP O
14 1032 1042 18951540 dyskinesia NN I-NP B-Disease
15 1043 1049 18951540 scores NNS I-NP O
16 1050 1056 18951540 during IN B-PP O
17 1057 1060 18951540 the DT B-NP O
18 1061 1065 18951540 days NNS I-NP O
19 1066 1068 18951540 of IN B-PP O
20 1069 1081 18951540 intervention NN B-NP O
21 1081 1082 18951540 , , O O
22 1083 1086 18951540 the DT B-NP O
23 1087 1093 18951540 effect NN I-NP O
24 1094 1097 18951540 was VBD B-VP O
25 1098 1107 18951540 sustained JJ B-ADJP O
26 1108 1111 18951540 for IN B-PP O
27 1112 1113 18951540 3 CD B-NP O
28 1114 1118 18951540 days NNS I-NP O
29 1119 1124 18951540 after IN B-PP O
30 1125 1128 18951540 the DT B-NP O
31 1129 1141 18951540 intervention NN I-NP O
32 1142 1145 18951540 for IN B-PP O
33 1146 1149 18951540 the DT B-NP O
34 1150 1154 18951540 real JJ I-NP O
35 1155 1159 18951540 rTMS NN I-NP O
36 1160 1164 18951540 only RB B-ADVP O
37 1164 1165 18951540 . . O O

1 1166 1175 18951540 Following VBG B-PP O
2 1176 1180 18951540 rTMS NN B-NP O
3 1180 1181 18951540 , , O O
4 1182 1184 18951540 no DT B-NP O
5 1185 1189 18951540 side NN I-NP O
6 1190 1197 18951540 effects NNS I-NP O
7 1198 1201 18951540 and CC O O
8 1202 1204 18951540 no DT B-NP O
9 1205 1212 18951540 adverse JJ I-NP O
10 1213 1220 18951540 effects NNS I-NP O
11 1221 1223 18951540 on IN B-PP O
12 1224 1229 18951540 motor NN B-NP O
13 1230 1238 18951540 function NN I-NP O
14 1239 1242 18951540 and CC I-NP O
15 1243 1245 18951540 PD NN I-NP B-Disease
16 1246 1254 18951540 symptoms NNS I-NP O
17 1255 1259 18951540 were VBD B-VP O
18 1260 1265 18951540 noted VBN I-VP O
19 1265 1266 18951540 . . O O

1 1267 1270 18951540 The DT B-NP O
2 1271 1278 18951540 results NNS I-NP O
3 1279 1286 18951540 suggest VBP B-VP O
4 1287 1290 18951540 the DT B-NP O
5 1291 1300 18951540 existence NN I-NP O
6 1301 1303 18951540 of IN B-PP O
7 1304 1312 18951540 residual JJ B-NP O
8 1313 1323 18951540 beneficial JJ I-NP O
9 1324 1332 18951540 clinical JJ I-NP O
10 1333 1345 18951540 aftereffects NNS I-NP O
11 1346 1348 18951540 of IN B-PP O
12 1349 1360 18951540 consecutive JJ B-NP O
13 1361 1366 18951540 daily JJ I-NP O
14 1367 1379 18951540 applications NNS I-NP O
15 1380 1382 18951540 of IN B-PP O
16 1383 1386 18951540 low JJ B-NP O
17 1386 1387 18951540 - HYPH I-NP O
18 1387 1396 18951540 frequency NN I-NP O
19 1397 1401 18951540 rTMS NN I-NP O
20 1402 1404 18951540 on IN B-PP O
21 1405 1416 18951540 dyskinesias NNS B-NP B-Disease
22 1417 1419 18951540 in IN B-PP O
23 1420 1422 18951540 PD NN B-NP B-Disease
24 1422 1423 18951540 . . O O

1 1424 1427 18951540 The DT B-NP O
2 1428 1435 18951540 effects NNS I-NP O
3 1436 1439 18951540 may MD B-VP O
4 1440 1442 18951540 be VB I-VP O
5 1443 1450 18951540 further RBR B-ADJP O
6 1451 1460 18951540 exploited VBN I-ADJP O
7 1461 1464 18951540 for IN B-PP O
8 1465 1474 18951540 potential JJ B-NP O
9 1475 1486 18951540 therapeutic JJ I-NP O
10 1487 1491 18951540 uses NNS I-NP O
11 1491 1492 18951540 . . O O

1 0 0 7890216 -DOCSTART- -X- -X- O

1 0 11 7890216 Composition NN B-NP O
2 12 14 7890216 of IN B-PP O
3 15 19 7890216 gall NN B-NP B-Disease
4 20 27 7890216 bladder NN I-NP I-Disease
5 28 34 7890216 stones NNS I-NP I-Disease
6 35 45 7890216 associated VBN B-VP O
7 46 50 7890216 with IN B-PP O
8 51 61 7890216 octreotide NN B-NP B-Chemical
9 61 62 7890216 : : O O
10 63 71 7890216 response NN B-NP O
11 72 74 7890216 to TO B-PP O
12 75 79 7890216 oral JJ B-NP O
13 80 95 7890216 ursodeoxycholic JJ I-NP B-Chemical
14 96 100 7890216 acid NN I-NP I-Chemical
15 100 101 7890216 . . I-NP O
16 102 112 7890216 Octreotide NN I-NP B-Chemical
17 112 113 7890216 , , O O
18 114 116 7890216 an DT B-NP O
19 117 126 7890216 effective JJ I-NP O
20 127 136 7890216 treatment NN I-NP O
21 137 140 7890216 for IN B-PP O
22 141 151 7890216 acromegaly RB B-NP B-Disease
23 151 152 7890216 , , O O
24 153 160 7890216 induces VBZ B-VP O
25 161 165 7890216 gall NN B-NP B-Disease
26 166 173 7890216 bladder NN I-NP I-Disease
27 174 180 7890216 stones NNS I-NP I-Disease
28 181 183 7890216 in IN B-PP O
29 184 186 7890216 13 CD B-NP O
30 186 187 7890216 - HYPH O O
31 187 190 7890216 60% CD B-NP O
32 191 193 7890216 of IN B-PP O
33 194 202 7890216 patients NNS B-NP O
34 202 203 7890216 . . O O

1 204 211 7890216 Because IN B-SBAR O
2 212 221 7890216 knowledge NN B-NP O
3 222 224 7890216 of IN B-PP O
4 225 230 7890216 stone NN B-NP O
5 231 242 7890216 composition NN I-NP O
6 243 245 7890216 is VBZ B-VP O
7 246 255 7890216 essential JJ B-ADJP O
8 256 259 7890216 for IN B-PP O
9 260 267 7890216 studies NNS B-NP O
10 268 270 7890216 of IN B-PP O
11 271 276 7890216 their PRP$ B-NP O
12 277 289 7890216 pathogenesis NN I-NP O
13 289 290 7890216 , , O O
14 291 300 7890216 treatment NN B-NP O
15 300 301 7890216 , , O O
16 302 305 7890216 and CC O O
17 306 316 7890216 prevention NN B-NP O
18 316 317 7890216 , , O O
19 318 322 7890216 this DT B-NP O
20 323 326 7890216 was VBD B-VP O
21 327 339 7890216 investigated VBN I-VP O
22 340 342 7890216 by IN B-PP O
23 343 349 7890216 direct JJ B-NP O
24 350 353 7890216 and CC I-NP O
25 354 362 7890216 indirect JJ I-NP O
26 363 370 7890216 methods NNS I-NP O
27 371 373 7890216 in IN B-PP O
28 374 376 7890216 14 CD B-NP O
29 377 387 7890216 octreotide NN I-NP B-Chemical
30 388 395 7890216 treated VBN B-VP O
31 396 407 7890216 acromegalic JJ B-NP B-Disease
32 408 416 7890216 patients NNS I-NP O
33 417 421 7890216 with IN B-PP O
34 422 426 7890216 gall NN B-NP B-Disease
35 427 433 7890216 stones NNS I-NP I-Disease
36 433 434 7890216 . . O O

1 435 443 7890216 Chemical JJ B-NP O
2 444 452 7890216 analysis NN I-NP O
3 453 455 7890216 of IN B-PP O
4 456 460 7890216 gall NN B-NP B-Disease
5 461 467 7890216 stones NNS I-NP I-Disease
6 468 477 7890216 retrieved VBD B-VP O
7 478 480 7890216 at IN B-PP O
8 481 496 7890216 cholecystectomy NN B-NP O
9 497 501 7890216 from IN B-PP O
10 502 505 7890216 two CD B-NP O
11 506 514 7890216 patients NNS I-NP O
12 514 515 7890216 , , O O
13 516 522 7890216 showed VBD B-VP O
14 523 527 7890216 that IN B-SBAR O
15 528 532 7890216 they PRP B-NP O
16 533 542 7890216 contained VBD B-VP O
17 543 546 7890216 71% CD B-NP O
18 547 550 7890216 and CC I-NP O
19 551 554 7890216 87% CD I-NP O
20 555 566 7890216 cholesterol NN I-NP B-Chemical
21 567 569 7890216 by IN B-PP O
22 570 576 7890216 weight NN B-NP O
23 576 577 7890216 . . O O

1 578 580 7890216 In IN B-PP O
2 581 584 7890216 the DT B-NP O
3 585 594 7890216 remaining VBG I-NP O
4 595 597 7890216 12 CD I-NP O
5 598 606 7890216 patients NNS I-NP O
6 606 607 7890216 , , O O
7 608 617 7890216 localised JJ B-NP O
8 618 626 7890216 computed VBN I-NP O
9 627 637 7890216 tomography NN I-NP O
10 638 640 7890216 of IN B-PP O
11 641 644 7890216 the DT B-NP O
12 645 649 7890216 gall NN I-NP O
13 650 657 7890216 bladder NN I-NP O
14 658 664 7890216 showed VBD B-VP O
15 665 669 7890216 that IN B-SBAR O
16 670 675 7890216 eight CD B-NP O
17 676 679 7890216 had VBD B-VP O
18 680 686 7890216 stones NNS B-NP O
19 687 691 7890216 with IN B-PP O
20 692 699 7890216 maximum JJ B-NP O
21 700 711 7890216 attenuation NN I-NP O
22 712 718 7890216 scores NNS I-NP O
23 719 721 7890216 of IN B-PP O
24 722 723 7890216 < SYM B-NP O
25 724 727 7890216 100 CD I-NP O
26 728 738 7890216 Hounsfield NNP I-NP O
27 739 744 7890216 units NNS I-NP O
28 745 746 7890216 ( ( O O
29 746 752 7890216 values NNS B-NP O
30 753 755 7890216 of IN B-PP O
31 756 757 7890216 < SYM B-NP O
32 758 761 7890216 100 CD I-NP O
33 762 764 7890216 HU NN I-NP O
34 765 772 7890216 predict VBP B-VP O
35 773 784 7890216 cholesterol NN B-NP B-Chemical
36 785 789 7890216 rich JJ I-NP O
37 789 790 7890216 , , I-NP O
38 791 802 7890216 dissolvable JJ I-NP O
39 803 809 7890216 stones NNS I-NP O
40 809 810 7890216 ) ) O O
41 810 811 7890216 . . O O

1 812 816 7890216 Gall NN B-NP O
2 817 824 7890216 bladder NN I-NP O
3 825 829 7890216 bile NN I-NP O
4 830 833 7890216 was VBD B-VP O
5 834 842 7890216 obtained VBN I-VP O
6 843 845 7890216 by IN B-PP O
7 846 856 7890216 ultrasound JJ B-NP O
8 857 863 7890216 guided VBN I-NP O
9 863 864 7890216 , , I-NP O
10 865 869 7890216 fine JJ I-NP O
11 870 876 7890216 needle NN I-NP O
12 877 885 7890216 puncture NN I-NP O
13 886 890 7890216 from IN B-PP O
14 891 894 7890216 six CD B-NP O
15 895 903 7890216 patients NNS I-NP O
16 903 904 7890216 . . O O

1 905 908 7890216 All DT B-NP O
2 909 912 7890216 six CD I-NP O
3 913 921 7890216 patients NNS I-NP O
4 922 925 7890216 had VBD B-VP O
5 926 940 7890216 supersaturated VBN I-VP O
6 941 945 7890216 bile NN B-NP O
7 946 947 7890216 ( ( O O
8 947 951 7890216 mean NN B-NP O
9 952 953 7890216 ( ( O O
10 953 956 7890216 SEM NN B-NP O
11 956 957 7890216 ) ) O O
12 958 969 7890216 cholesterol NN B-NP B-Chemical
13 970 980 7890216 saturation NN I-NP O
14 981 986 7890216 index NN I-NP O
15 987 989 7890216 of IN B-PP O
16 990 994 7890216 1.19 CD B-NP O
17 995 996 7890216 ( ( O O
18 996 1000 7890216 0.08 CD B-NP O
19 1000 1001 7890216 ) ) O O
20 1002 1003 7890216 ( ( O O
21 1003 1008 7890216 range NN B-NP O
22 1009 1013 7890216 1.01 CD I-NP O
23 1013 1014 7890216 - HYPH B-NP O
24 1014 1018 7890216 1.53 CD I-NP O
25 1018 1019 7890216 ) ) O O
26 1019 1020 7890216 ) ) O O
27 1021 1024 7890216 and CC O O
28 1025 1028 7890216 all DT B-NP O
29 1029 1032 7890216 had VBD B-VP O
30 1033 1043 7890216 abnormally RB B-NP O
31 1044 1049 7890216 rapid JJ I-NP O
32 1050 1061 7890216 cholesterol NN I-NP B-Chemical
33 1062 1074 7890216 microcrystal NN I-NP O
34 1075 1085 7890216 nucleation NN I-NP O
35 1086 1091 7890216 times NNS I-NP O
36 1092 1093 7890216 ( ( O O
37 1093 1094 7890216 < SYM B-NP O
38 1095 1096 7890216 4 CD B-NP O
39 1097 1101 7890216 days NNS I-NP O
40 1102 1103 7890216 ( ( O O
41 1103 1108 7890216 range NN B-NP O
42 1109 1110 7890216 1 CD I-NP O
43 1110 1111 7890216 - HYPH B-NP O
44 1111 1112 7890216 4 CD I-NP O
45 1112 1113 7890216 ) ) O O
46 1113 1114 7890216 ) ) O O
47 1114 1115 7890216 , , O O
48 1116 1122 7890216 whilst IN B-ADVP O
49 1123 1125 7890216 in IN B-PP O
50 1126 1130 7890216 four CD B-NP O
51 1130 1131 7890216 , , O O
52 1132 1135 7890216 the DT B-NP O
53 1136 1140 7890216 bile NN I-NP O
54 1141 1150 7890216 contained VBD B-VP O
55 1151 1162 7890216 cholesterol NN B-NP B-Chemical
56 1163 1176 7890216 microcrystals NNS I-NP O
57 1177 1188 7890216 immediately RB B-ADVP O
58 1189 1194 7890216 after IN B-PP O
59 1195 1203 7890216 sampling VBG B-VP O
60 1203 1204 7890216 . . O O

1 1205 1207 7890216 Of IN B-PP O
2 1208 1211 7890216 the DT B-NP O
3 1212 1214 7890216 12 CD I-NP O
4 1215 1223 7890216 patients NNS I-NP O
5 1224 1234 7890216 considered VBN B-VP O
6 1235 1238 7890216 for IN B-PP O
7 1239 1243 7890216 oral JJ B-NP O
8 1244 1259 7890216 ursodeoxycholic JJ I-NP B-Chemical
9 1260 1264 7890216 acid NN I-NP I-Chemical
10 1265 1266 7890216 ( ( O O
11 1266 1270 7890216 UDCA NN B-NP B-Chemical
12 1270 1271 7890216 ) ) O O
13 1272 1281 7890216 treatment NN B-NP O
14 1281 1282 7890216 , , O O
15 1283 1286 7890216 two CD B-NP O
16 1287 1290 7890216 had VBD B-VP O
17 1291 1292 7890216 a DT B-NP O
18 1293 1300 7890216 blocked VBN I-NP O
19 1301 1307 7890216 cystic JJ I-NP O
20 1308 1312 7890216 duct NN I-NP O
21 1313 1316 7890216 and CC O O
22 1317 1321 7890216 were VBD B-VP O
23 1322 1325 7890216 not RB I-VP O
24 1326 1333 7890216 started VBN I-VP O
25 1334 1336 7890216 on IN B-PP O
26 1337 1341 7890216 UDCA NN B-NP B-Chemical
27 1342 1347 7890216 while IN B-SBAR O
28 1348 1351 7890216 one CD B-NP O
29 1352 1355 7890216 was VBD B-VP O
30 1356 1360 7890216 lost VBN I-VP O
31 1361 1363 7890216 to TO I-VP O
32 1364 1370 7890216 follow VB I-VP O
33 1371 1373 7890216 up RP B-PRT O
34 1373 1374 7890216 . . O O

1 1375 1380 7890216 After IN B-PP O
2 1381 1384 7890216 one CD B-NP O
3 1385 1389 7890216 year NN I-NP O
4 1390 1392 7890216 of IN B-PP O
5 1393 1402 7890216 treatment NN B-NP O
6 1402 1403 7890216 , , O O
7 1404 1408 7890216 five CD B-NP O
8 1409 1411 7890216 of IN B-PP O
9 1412 1415 7890216 the DT B-NP O
10 1416 1425 7890216 remaining VBG I-NP O
11 1426 1430 7890216 nine CD I-NP O
12 1431 1439 7890216 patients NNS I-NP O
13 1440 1446 7890216 showed VBD B-VP O
14 1447 1453 7890216 either CC O O
15 1454 1461 7890216 partial JJ O O
16 1462 1463 7890216 ( ( O O
17 1463 1464 7890216 n NN B-NP O
18 1465 1466 7890216 = SYM B-VP O
19 1467 1468 7890216 3 CD B-NP O
20 1468 1469 7890216 ) ) O O
21 1470 1472 7890216 or CC O O
22 1473 1481 7890216 complete JJ B-NP O
23 1482 1483 7890216 ( ( O O
24 1483 1484 7890216 n NN B-NP O
25 1485 1486 7890216 = SYM B-VP O
26 1487 1488 7890216 2 CD B-NP O
27 1488 1489 7890216 ) ) O O
28 1490 1494 7890216 gall NN B-NP B-Disease
29 1495 1500 7890216 stone NN I-NP I-Disease
30 1501 1512 7890216 dissolution NN I-NP O
31 1512 1513 7890216 , , O O
32 1514 1524 7890216 suggesting VBG B-VP O
33 1525 1529 7890216 that IN B-SBAR O
34 1530 1535 7890216 their PRP$ B-NP O
35 1536 1542 7890216 stones NNS I-NP O
36 1543 1547 7890216 were VBD B-VP O
37 1548 1559 7890216 cholesterol NN B-ADJP B-Chemical
38 1560 1564 7890216 rich JJ I-ADJP O
39 1564 1565 7890216 . . O O

1 1566 1570 7890216 This DT B-NP O
2 1571 1582 7890216 corresponds VBZ B-VP O
3 1582 1583 7890216 , , O O
4 1584 1586 7890216 by IN B-PP O
5 1587 1596 7890216 actuarial JJ B-ADJP O
6 1597 1598 7890216 ( ( O O
7 1598 1602 7890216 life NN B-NP O
8 1603 1608 7890216 table NN I-NP O
9 1608 1609 7890216 ) ) O O
10 1610 1618 7890216 analysis NN B-NP O
11 1618 1619 7890216 , , O O
12 1620 1622 7890216 to TO B-PP O
13 1623 1624 7890216 a DT B-NP O
14 1625 1633 7890216 combined JJ I-NP O
15 1634 1638 7890216 gall NN I-NP B-Disease
16 1639 1644 7890216 stone NN I-NP I-Disease
17 1645 1656 7890216 dissolution NN I-NP O
18 1657 1661 7890216 rate NN I-NP O
19 1662 1664 7890216 of IN B-PP O
20 1665 1669 7890216 58.3 CD B-NP O
21 1670 1671 7890216 ( ( O O
22 1671 1676 7890216 15.9% NN B-NP O
23 1676 1677 7890216 ) ) O O
24 1677 1678 7890216 . . O O

1 1679 1681 7890216 In IN B-PP O
2 1682 1692 7890216 conclusion NN B-NP O
3 1692 1693 7890216 , , O O
4 1694 1704 7890216 octreotide NN B-NP B-Chemical
5 1705 1712 7890216 induced VBD B-VP O
6 1713 1717 7890216 gall NN B-NP B-Disease
7 1718 1724 7890216 stones NNS I-NP I-Disease
8 1725 1728 7890216 are VBP B-VP O
9 1729 1738 7890216 generally RB B-ADVP O
10 1739 1744 7890216 small JJ B-NP O
11 1744 1745 7890216 , , I-NP O
12 1746 1754 7890216 multiple JJ I-NP O
13 1754 1755 7890216 , , O O
14 1756 1759 7890216 and CC O O
15 1760 1771 7890216 cholesterol NN B-NP B-Chemical
16 1772 1776 7890216 rich JJ B-ADJP O
17 1777 1785 7890216 although IN B-SBAR O
18 1785 1786 7890216 , , O O
19 1787 1789 7890216 in IN B-PP O
20 1790 1796 7890216 common JJ B-ADJP O
21 1797 1801 7890216 with IN B-PP O
22 1802 1813 7890216 spontaneous JJ B-NP O
23 1814 1818 7890216 gall NN I-NP B-Disease
24 1819 1824 7890216 stone NN I-NP I-Disease
25 1825 1832 7890216 disease NN I-NP I-Disease
26 1832 1833 7890216 , , O O
27 1834 1836 7890216 at IN B-PP O
28 1837 1849 7890216 presentation NN B-NP O
29 1850 1854 7890216 some DT B-NP O
30 1855 1863 7890216 patients NNS I-NP O
31 1864 1868 7890216 will MD B-VP O
32 1869 1873 7890216 have VB I-VP O
33 1874 1875 7890216 a DT B-NP O
34 1876 1883 7890216 blocked VBN I-NP O
35 1884 1890 7890216 cystic JJ I-NP O
36 1891 1895 7890216 duct NN I-NP O
37 1896 1899 7890216 and CC O O
38 1900 1904 7890216 some DT B-NP O
39 1905 1909 7890216 gall JJ I-NP B-Disease
40 1910 1916 7890216 stones NNS I-NP I-Disease
41 1917 1927 7890216 containing VBG B-VP O
42 1928 1935 7890216 calcium NN B-NP B-Chemical
43 1935 1936 7890216 . . O O

1 0 0 10365197 -DOCSTART- -X- -X- O

1 0 7 10365197 Cocaine NN B-NP B-Chemical
2 7 8 10365197 - HYPH B-NP O
3 8 15 10365197 induced VBN I-NP O
4 16 20 10365197 mood NN I-NP B-Disease
5 21 29 10365197 disorder NN I-NP I-Disease
6 29 30 10365197 : : O O
7 31 41 10365197 prevalence NN B-NP O
8 42 47 10365197 rates NNS I-NP O
9 48 51 10365197 and CC O O
10 52 63 10365197 psychiatric JJ B-NP B-Disease
11 64 72 10365197 symptoms NNS I-NP O
12 73 75 10365197 in IN B-PP O
13 76 78 10365197 an DT B-NP O
14 79 89 10365197 outpatient NN I-NP O
15 90 97 10365197 cocaine NN I-NP B-Chemical
16 97 98 10365197 - HYPH B-NP O
17 98 107 10365197 dependent JJ I-NP O
18 108 114 10365197 sample NN I-NP O
19 114 115 10365197 . . O O
20 116 120 10365197 This DT B-NP O
21 121 126 10365197 paper NN I-NP O
22 127 135 10365197 attempts VBZ B-VP O
23 136 138 10365197 to TO I-VP O
24 139 146 10365197 examine VB I-VP O
25 147 150 10365197 and CC I-VP O
26 151 158 10365197 compare VB I-VP O
27 159 169 10365197 prevalence NN B-NP O
28 170 175 10365197 rates NNS I-NP O
29 176 179 10365197 and CC O O
30 180 187 10365197 symptom NN B-NP O
31 188 196 10365197 patterns NNS I-NP O
32 197 199 10365197 of IN B-PP O
33 200 203 10365197 DSM NN B-NP O
34 204 213 10365197 substance NN I-NP O
35 213 214 10365197 - HYPH B-VP O
36 214 221 10365197 induced VBN B-NP O
37 222 225 10365197 and CC I-NP O
38 226 231 10365197 other JJ I-NP O
39 232 236 10365197 mood NN I-NP B-Disease
40 237 246 10365197 disorders NNS I-NP I-Disease
41 246 247 10365197 . . O O

1 248 251 10365197 243 CD B-NP O
2 252 259 10365197 cocaine NN I-NP B-Chemical
3 259 260 10365197 - HYPH B-NP O
4 260 269 10365197 dependent JJ I-NP O
5 270 281 10365197 outpatients NNS I-NP O
6 282 286 10365197 with IN B-PP O
7 287 294 10365197 cocaine NN B-NP B-Chemical
8 294 295 10365197 - HYPH B-NP O
9 295 302 10365197 induced VBN I-NP O
10 303 307 10365197 mood NN I-NP B-Disease
11 308 316 10365197 disorder NN I-NP I-Disease
12 317 318 10365197 ( ( O O
13 318 322 10365197 CIMD NN B-NP B-Disease
14 322 323 10365197 ) ) O O
15 323 324 10365197 , , O O
16 325 330 10365197 other JJ B-NP O
17 331 335 10365197 mood NN I-NP B-Disease
18 336 345 10365197 disorders NNS I-NP I-Disease
19 345 346 10365197 , , O O
20 347 349 10365197 or CC O O
21 350 352 10365197 no DT B-NP O
22 353 357 10365197 mood NN I-NP B-Disease
23 358 366 10365197 disorder NN I-NP I-Disease
24 367 371 10365197 were VBD B-VP O
25 372 380 10365197 compared VBN I-VP O
26 381 383 10365197 on IN B-PP O
27 384 392 10365197 measures NNS B-NP O
28 393 395 10365197 of IN B-PP O
29 396 407 10365197 psychiatric JJ B-NP B-Disease
30 408 416 10365197 symptoms NNS I-NP O
31 416 417 10365197 . . O O

1 418 421 10365197 The DT B-NP O
2 422 432 10365197 prevalence NN I-NP O
3 433 437 10365197 rate NN I-NP O
4 438 441 10365197 for IN B-PP O
5 442 446 10365197 CIMD NN B-NP B-Disease
6 447 450 10365197 was VBD B-VP O
7 451 454 10365197 12% CD B-NP O
8 455 457 10365197 at IN B-PP O
9 458 466 10365197 baseline NN B-NP O
10 466 467 10365197 . . O O

1 468 480 10365197 Introduction NN B-NP O
2 481 483 10365197 of IN B-PP O
3 484 487 10365197 the DT B-NP O
4 488 491 10365197 DSM NN I-NP O
5 491 492 10365197 - HYPH O O
6 492 494 10365197 IV CD B-NP O
7 495 504 10365197 diagnosis NN I-NP O
8 505 507 10365197 of IN B-PP O
9 508 512 10365197 CIMD NN B-NP B-Disease
10 513 516 10365197 did VBD B-VP O
11 517 520 10365197 not RB I-VP O
12 521 534 10365197 substantially RB I-VP O
13 535 541 10365197 affect VB I-VP O
14 542 547 10365197 rates NNS B-NP O
15 548 550 10365197 of IN B-PP O
16 551 554 10365197 the DT B-NP O
17 555 560 10365197 other JJ I-NP O
18 561 571 10365197 depressive JJ I-NP B-Disease
19 572 581 10365197 disorders NNS I-NP I-Disease
20 581 582 10365197 . . O O

1 583 591 10365197 Patients NNS B-NP O
2 592 596 10365197 with IN B-PP O
3 597 601 10365197 CIMD NN B-NP B-Disease
4 602 605 10365197 had VBD B-VP O
5 606 613 10365197 symptom NN B-NP O
6 614 622 10365197 severity NN I-NP O
7 623 629 10365197 levels NNS I-NP O
8 630 637 10365197 between IN B-PP O
9 638 643 10365197 those DT B-NP O
10 644 646 10365197 of IN B-PP O
11 647 655 10365197 patients NNS B-NP O
12 656 660 10365197 with IN B-PP O
13 661 664 10365197 and CC I-PP O
14 665 672 10365197 without IN I-PP O
15 673 674 10365197 a DT B-NP O
16 675 679 10365197 mood NN I-NP B-Disease
17 680 688 10365197 disorder NN I-NP I-Disease
18 688 689 10365197 . . O O

1 690 695 10365197 These DT B-NP O
2 696 704 10365197 findings NNS I-NP O
3 705 712 10365197 suggest VBP B-VP O
4 713 717 10365197 some DT B-NP O
5 718 726 10365197 validity NN I-NP O
6 727 730 10365197 for IN B-PP O
7 731 734 10365197 the DT B-NP O
8 735 738 10365197 new JJ I-NP O
9 739 742 10365197 DSM NN I-NP O
10 742 743 10365197 - HYPH O O
11 743 745 10365197 IV CD B-NP O
12 746 755 10365197 diagnosis NN I-NP O
13 756 758 10365197 of IN B-PP O
14 759 763 10365197 CIMD NN B-NP B-Disease
15 763 764 10365197 , , O O
16 765 768 10365197 but CC B-CONJP O
17 769 773 10365197 also RB I-CONJP O
18 774 781 10365197 suggest VBP B-VP O
19 782 786 10365197 that IN B-SBAR O
20 787 789 10365197 it PRP B-NP O
21 790 798 10365197 requires VBZ B-VP O
22 799 806 10365197 further JJ B-NP O
23 807 820 10365197 specification NN I-NP O
24 821 824 10365197 and CC I-NP O
25 825 836 10365197 replication NN I-NP O
26 836 837 10365197 . . O O

1 0 0 6727060 -DOCSTART- -X- -X- O

1 0 1 6727060 A DT B-NP O
2 2 6 6727060 case NN I-NP O
3 7 9 6727060 of IN B-PP O
4 10 17 6727060 tardive JJ B-NP B-Disease
5 18 28 6727060 dyskinesia NN I-NP I-Disease
6 29 35 6727060 caused VBN B-VP O
7 36 38 6727060 by IN B-PP O
8 39 53 6727060 metoclopramide NN B-NP B-Chemical
9 53 54 6727060 . . O O
10 55 63 6727060 Abnormal JJ B-NP B-Disease
11 64 75 6727060 involuntary JJ I-NP I-Disease
12 76 85 6727060 movements NNS I-NP I-Disease
13 86 94 6727060 appeared VBD B-VP O
14 95 97 6727060 in IN B-PP O
15 98 101 6727060 the DT B-NP O
16 102 107 6727060 mouth NN I-NP O
17 107 108 6727060 , , I-NP O
18 109 115 6727060 tongue NN I-NP O
19 115 116 6727060 , , I-NP O
20 117 121 6727060 neck NN I-NP O
21 122 125 6727060 and CC I-NP O
22 126 133 6727060 abdomen NN I-NP O
23 134 136 6727060 of IN B-PP O
24 137 138 6727060 a DT B-NP O
25 139 141 6727060 64 CD I-NP O
26 141 142 6727060 - HYPH I-NP O
27 142 146 6727060 year NN I-NP O
28 146 147 6727060 - HYPH O O
29 147 150 6727060 old JJ B-NP O
30 151 155 6727060 male JJ I-NP O
31 156 163 6727060 patient NN I-NP O
32 164 169 6727060 after IN B-SBAR O
33 170 172 6727060 he PRP B-NP O
34 173 177 6727060 took VBD B-VP O
35 178 192 6727060 metoclopramide NN B-NP B-Chemical
36 193 196 6727060 for IN B-PP O
37 197 213 6727060 gastrointestinal JJ B-NP B-Disease
38 214 222 6727060 disorder NN I-NP I-Disease
39 223 225 6727060 in IN B-PP O
40 226 227 6727060 a DT B-NP O
41 228 235 6727060 regimen NN I-NP O
42 236 238 6727060 of IN B-PP O
43 239 241 6727060 30 CD B-NP O
44 242 244 6727060 mg NN I-NP O
45 245 248 6727060 per IN B-PP O
46 249 252 6727060 day NN B-NP O
47 253 256 6727060 for IN B-PP O
48 257 258 6727060 a DT B-NP O
49 259 264 6727060 total NN I-NP O
50 265 267 6727060 of IN B-PP O
51 268 273 6727060 about IN B-NP O
52 274 277 6727060 260 CD I-NP O
53 278 282 6727060 days NNS I-NP O
54 282 283 6727060 . . O O

1 284 287 6727060 The DT B-NP O
2 288 296 6727060 symptoms NNS I-NP O
3 297 308 6727060 exacerbated VBN B-VP O
4 309 311 6727060 to TO B-PP O
5 312 313 6727060 a DT B-NP O
6 314 321 6727060 maximum NN I-NP O
7 322 324 6727060 in IN B-PP O
8 325 326 6727060 a DT B-NP O
9 327 332 6727060 month NN I-NP O
10 332 333 6727060 . . O O

1 334 338 6727060 When WRB B-ADVP O
2 339 342 6727060 the DT B-NP O
3 343 357 6727060 metoclopramide NN I-NP B-Chemical
4 358 372 6727060 administration NN I-NP O
5 373 376 6727060 was VBD B-VP O
6 377 389 6727060 discontinued VBN I-VP O
7 389 390 6727060 , , O O
8 391 394 6727060 the DT B-NP O
9 395 403 6727060 abnormal JJ I-NP B-Disease
10 404 413 6727060 movements NNS I-NP I-Disease
11 414 423 6727060 gradually RB B-ADVP O
12 424 432 6727060 improved VBD B-VP O
13 433 435 6727060 to TO B-PP O
14 436 437 6727060 a DT B-NP O
15 438 450 6727060 considerable JJ I-NP O
16 451 457 6727060 extent NN I-NP O
17 457 458 6727060 . . O O

1 459 468 6727060 Attention NN B-NP O
2 469 471 6727060 to TO B-PP O
3 472 475 6727060 the DT B-NP O
4 476 484 6727060 possible JJ I-NP O
5 485 494 6727060 induction NN I-NP O
6 495 497 6727060 of IN B-PP O
7 498 506 6727060 specific JJ B-NP O
8 507 514 6727060 tardive JJ I-NP B-Disease
9 515 525 6727060 dyskinesia NN I-NP I-Disease
10 526 528 6727060 is VBZ B-VP O
11 529 535 6727060 called VBN I-VP O
12 536 539 6727060 for IN B-PP O
13 540 542 6727060 in IN B-PP O
14 543 546 6727060 the DT B-NP O
15 547 550 6727060 use NN I-NP O
16 551 553 6727060 of IN B-PP O
17 554 558 6727060 this DT B-NP O
18 559 563 6727060 drug NN I-NP O
19 563 564 6727060 . . O O

1 0 0 11419773 -DOCSTART- -X- -X- O

1 0 8 11419773 Caffeine NN B-NP B-Chemical
2 8 9 11419773 - HYPH O O
3 9 16 11419773 induced VBN B-NP O
4 17 24 11419773 cardiac JJ I-NP B-Disease
5 25 35 11419773 arrhythmia NN I-NP I-Disease
6 35 36 11419773 : : O O
7 37 39 11419773 an DT B-NP O
8 40 52 11419773 unrecognised JJ I-NP O
9 53 59 11419773 danger NN I-NP O
10 60 62 11419773 of IN B-PP O
11 63 73 11419773 healthfood NN B-NP O
12 74 82 11419773 products NNS I-NP O
13 82 83 11419773 . . O O
14 84 86 11419773 We PRP B-NP O
15 87 95 11419773 describe VBP B-VP O
16 96 97 11419773 a DT B-NP O
17 98 100 11419773 25 CD I-NP O
18 100 101 11419773 - HYPH I-NP O
19 101 105 11419773 year NN I-NP O
20 105 106 11419773 - HYPH O O
21 106 109 11419773 old JJ B-NP O
22 110 115 11419773 woman NN I-NP O
23 116 120 11419773 with IN B-PP O
24 121 124 11419773 pre AFX B-NP O
25 124 125 11419773 - HYPH B-VP O
26 125 133 11419773 existing VBG B-NP O
27 134 140 11419773 mitral JJ I-NP B-Disease
28 141 146 11419773 valve NN I-NP I-Disease
29 147 155 11419773 prolapse NN I-NP I-Disease
30 156 159 11419773 who WP B-NP O
31 160 169 11419773 developed VBD B-VP O
32 170 181 11419773 intractable JJ B-NP O
33 182 193 11419773 ventricular JJ I-NP B-Disease
34 194 206 11419773 fibrillation NN I-NP I-Disease
35 207 212 11419773 after IN B-PP O
36 213 222 11419773 consuming VBG B-VP O
37 223 224 11419773 a DT B-NP O
38 225 226 11419773 " `` I-NP O
39 226 233 11419773 natural JJ I-NP O
40 234 240 11419773 energy NN I-NP O
41 240 241 11419773 " `` O O
42 242 249 11419773 guarana NN B-NP O
43 250 256 11419773 health NN I-NP O
44 257 262 11419773 drink NN I-NP O
45 263 273 11419773 containing VBG B-VP O
46 274 275 11419773 a DT B-NP O
47 276 280 11419773 high JJ I-NP O
48 281 294 11419773 concentration NN I-NP O
49 295 297 11419773 of IN B-PP O
50 298 306 11419773 caffeine NN B-NP B-Chemical
51 306 307 11419773 . . O O

1 308 312 11419773 This DT B-NP O
2 313 317 11419773 case NN I-NP O
3 318 328 11419773 highlights VBZ B-VP O
4 329 332 11419773 the DT B-NP O
5 333 337 11419773 need NN I-NP O
6 338 341 11419773 for IN B-PP O
7 342 350 11419773 adequate JJ B-NP O
8 351 360 11419773 labelling NN I-NP O
9 361 364 11419773 and CC O O
10 365 375 11419773 regulation NN B-NP O
11 376 378 11419773 of IN B-PP O
12 379 383 11419773 such JJ B-NP O
13 384 392 11419773 products NNS I-NP O
14 392 393 11419773 . . O O

1 0 0 15275829 -DOCSTART- -X- -X- O

1 0 3 15275829 The DT B-NP O
2 4 10 15275829 alpha3 NN I-NP O
3 11 14 15275829 and CC I-NP O
4 15 20 15275829 beta4 NN I-NP O
5 21 30 15275829 nicotinic JJ I-NP O
6 31 44 15275829 acetylcholine NN I-NP B-Chemical
7 45 53 15275829 receptor NN I-NP O
8 54 62 15275829 subunits NNS I-NP O
9 63 66 15275829 are VBP B-VP O
10 67 76 15275829 necessary JJ B-ADJP O
11 77 80 15275829 for IN B-PP O
12 81 89 15275829 nicotine NN B-NP B-Chemical
13 89 90 15275829 - HYPH B-NP O
14 90 97 15275829 induced VBN I-NP O
15 98 106 15275829 seizures NNS I-NP B-Disease
16 107 110 15275829 and CC I-NP O
17 111 125 15275829 hypolocomotion NN I-NP B-Disease
18 126 128 15275829 in IN B-PP O
19 129 133 15275829 mice NNS B-NP O
20 133 134 15275829 . . O O
21 135 142 15275829 Binding NN B-NP O
22 143 145 15275829 of IN B-PP O
23 146 154 15275829 nicotine NN B-NP B-Chemical
24 155 157 15275829 to TO B-PP O
25 158 167 15275829 nicotinic JJ B-NP O
26 168 181 15275829 acetylcholine NN I-NP B-Chemical
27 182 191 15275829 receptors NNS I-NP O
28 192 193 15275829 ( ( O O
29 193 199 15275829 nAChRs NNS B-NP O
30 199 200 15275829 ) ) O O
31 201 208 15275829 elicits VBZ B-VP O
32 209 210 15275829 a DT B-NP O
33 211 217 15275829 series NN I-NP O
34 218 220 15275829 of IN B-PP O
35 221 225 15275829 dose NN B-NP O
36 225 226 15275829 - HYPH B-NP O
37 226 235 15275829 dependent JJ I-NP O
38 236 245 15275829 behaviors NNS I-NP O
39 246 250 15275829 that WDT B-NP O
40 251 253 15275829 go VBP B-VP O
41 254 258 15275829 from IN B-PP O
42 259 266 15275829 altered VBN B-NP O
43 267 278 15275829 exploration NN I-NP O
44 278 279 15275829 , , O O
45 280 288 15275829 sedation NN B-NP O
46 288 289 15275829 , , O O
47 290 293 15275829 and CC O O
48 294 301 15275829 tremors NNS B-NP B-Disease
49 301 302 15275829 , , O O
50 303 305 15275829 to TO B-PP O
51 306 314 15275829 seizures NNS B-NP B-Disease
52 315 318 15275829 and CC I-NP O
53 319 324 15275829 death NN I-NP B-Disease
54 324 325 15275829 . . O O

1 326 332 15275829 nAChRs NNS B-NP O
2 333 336 15275829 are VBP B-VP O
3 337 347 15275829 pentameric JJ B-NP O
4 348 351 15275829 ion NN I-NP O
5 352 360 15275829 channels NNS I-NP O
6 361 368 15275829 usually RB B-VP O
7 369 377 15275829 composed VBN I-VP O
8 378 380 15275829 of IN B-PP O
9 381 386 15275829 alpha NN B-NP O
10 387 390 15275829 and CC O O
11 391 395 15275829 beta NN B-NP O
12 396 404 15275829 subunits NNS I-NP O
13 404 405 15275829 . . O O

1 406 407 15275829 A DT B-NP O
2 408 412 15275829 gene NN I-NP O
3 413 420 15275829 cluster NN I-NP O
4 421 430 15275829 comprises VBZ B-VP O
5 431 434 15275829 the DT B-NP O
6 435 441 15275829 alpha3 NN I-NP O
7 441 442 15275829 , , I-NP O
8 443 449 15275829 alpha5 NN I-NP O
9 450 453 15275829 and CC I-NP O
10 454 459 15275829 beta4 NN I-NP O
11 460 468 15275829 subunits NNS I-NP O
12 468 469 15275829 , , O O
13 470 475 15275829 which WDT B-NP O
14 476 486 15275829 coassemble VBP B-VP O
15 487 489 15275829 to TO I-VP O
16 490 494 15275829 form VB I-VP O
17 495 505 15275829 functional JJ B-NP O
18 506 515 15275829 receptors NNS I-NP O
19 515 516 15275829 . . O O

1 517 519 15275829 We PRP B-NP O
2 520 528 15275829 examined VBD B-VP O
3 529 532 15275829 the DT B-NP O
4 533 537 15275829 role NN I-NP O
5 538 540 15275829 of IN B-PP O
6 541 544 15275829 the DT B-NP O
7 545 550 15275829 beta4 NN I-NP O
8 551 559 15275829 subunits NNS I-NP O
9 560 562 15275829 in IN B-PP O
10 563 571 15275829 nicotine NN B-NP B-Chemical
11 571 572 15275829 - HYPH B-NP O
12 572 579 15275829 induced VBN I-NP O
13 580 588 15275829 seizures NNS I-NP B-Disease
14 589 592 15275829 and CC I-NP O
15 593 607 15275829 hypolocomotion NN I-NP B-Disease
16 608 610 15275829 in IN B-PP O
17 611 616 15275829 beta4 NN B-NP O
18 617 627 15275829 homozygous JJ I-NP O
19 628 632 15275829 null NN I-NP O
20 633 634 15275829 ( ( O O
21 634 639 15275829 beta4 NN B-NP O
22 640 641 15275829 - HYPH O O
23 641 642 15275829 / SYM B-NP O
24 642 643 15275829 - SYM B-NP O
25 643 644 15275829 ) ) O O
26 645 648 15275829 and CC O O
27 649 655 15275829 alpha3 NN B-NP O
28 656 668 15275829 heterozygous JJ B-ADJP O
29 669 670 15275829 ( ( O O
30 670 671 15275829 + SYM O O
31 671 672 15275829 / SYM O O
32 672 673 15275829 - SYM O O
33 673 674 15275829 ) ) O O
34 675 679 15275829 mice NNS B-NP O
35 679 680 15275829 . . O O

1 681 686 15275829 beta4 NN B-NP O
2 687 688 15275829 - HYPH B-NP O
3 688 689 15275829 / SYM I-NP O
4 689 690 15275829 - HYPH I-NP O
5 691 695 15275829 mice NNS I-NP O
6 696 700 15275829 were VBD B-VP O
7 701 705 15275829 less RBR B-ADJP O
8 706 715 15275829 sensitive JJ I-ADJP O
9 716 718 15275829 to TO B-PP O
10 719 722 15275829 the DT B-NP O
11 723 730 15275829 effects NNS I-NP O
12 731 733 15275829 of IN B-PP O
13 734 742 15275829 nicotine NN B-NP B-Chemical
14 743 747 15275829 both CC B-PP O
15 748 750 15275829 at IN B-PP O
16 751 754 15275829 low JJ B-NP O
17 755 760 15275829 doses NNS I-NP O
18 760 761 15275829 , , O O
19 762 770 15275829 measured VBN B-VP O
20 771 773 15275829 as IN B-PP O
21 774 783 15275829 decreased VBN B-NP O
22 784 795 15275829 exploration NN I-NP O
23 796 798 15275829 in IN B-PP O
24 799 801 15275829 an DT B-NP O
25 802 806 15275829 open JJ I-NP O
26 807 812 15275829 field NN I-NP O
27 812 813 15275829 , , B-PP O
28 814 817 15275829 and CC I-PP O
29 818 820 15275829 at IN B-PP O
30 821 825 15275829 high JJ B-NP O
31 826 831 15275829 doses NNS I-NP O
32 831 832 15275829 , , O O
33 833 841 15275829 measured VBN B-VP O
34 842 844 15275829 as IN B-PP O
35 845 856 15275829 sensitivity NN B-NP O
36 857 859 15275829 to TO B-PP O
37 860 868 15275829 nicotine NN B-NP B-Chemical
38 868 869 15275829 - HYPH B-NP O
39 869 876 15275829 induced VBN I-NP O
40 877 885 15275829 seizures NNS I-NP B-Disease
41 885 886 15275829 . . O O

1 887 892 15275829 Using VBG B-VP O
2 893 895 15275829 in FW B-NP O
3 896 900 15275829 situ FW I-NP O
4 901 914 15275829 hybridization NN I-NP O
5 915 921 15275829 probes NNS I-NP O
6 922 925 15275829 for IN B-PP O
7 926 929 15275829 the DT B-NP O
8 930 936 15275829 alpha3 NN I-NP O
9 937 940 15275829 and CC I-NP O
10 941 947 15275829 alpha5 NN I-NP O
11 948 956 15275829 subunits NNS I-NP O
12 956 957 15275829 , , O O
13 958 960 15275829 we PRP B-NP O
14 961 967 15275829 showed VBD B-VP O
15 968 972 15275829 that IN B-SBAR O
16 973 979 15275829 alpha5 NN B-NP O
17 980 984 15275829 mRNA NN I-NP O
18 985 991 15275829 levels NNS I-NP O
19 992 995 15275829 are VBP B-VP O
20 996 1005 15275829 unchanged JJ B-ADJP O
21 1005 1006 15275829 , , O O
22 1007 1014 15275829 whereas IN O O
23 1015 1021 15275829 alpha3 NN B-NP O
24 1022 1026 15275829 mRNA NN I-NP O
25 1027 1033 15275829 levels NNS I-NP O
26 1034 1037 15275829 are VBP B-VP O
27 1038 1049 15275829 selectively RB I-VP O
28 1050 1059 15275829 decreased VBN I-VP O
29 1060 1062 15275829 in IN B-PP O
30 1063 1066 15275829 the DT B-NP O
31 1067 1073 15275829 mitral JJ I-NP O
32 1074 1078 15275829 cell NN I-NP O
33 1079 1084 15275829 layer NN I-NP O
34 1085 1087 15275829 of IN B-PP O
35 1088 1091 15275829 the DT B-NP O
36 1092 1101 15275829 olfactory JJ I-NP O
37 1102 1106 15275829 bulb NN I-NP O
38 1106 1107 15275829 , , O O
39 1108 1111 15275829 and CC O O
40 1112 1115 15275829 the DT B-NP O
41 1116 1124 15275829 inferior JJ I-NP O
42 1125 1128 15275829 and CC O O
43 1129 1132 15275829 the DT B-NP O
44 1133 1141 15275829 superior JJ I-NP O
45 1142 1152 15275829 colliculus NN I-NP O
46 1153 1155 15275829 of IN B-PP O
47 1156 1161 15275829 beta4 NN B-NP O
48 1162 1163 15275829 - HYPH O O
49 1163 1164 15275829 / SYM O O
50 1164 1165 15275829 - HYPH O O
51 1166 1172 15275829 brains NNS B-NP O
52 1172 1173 15275829 . . O O

1 1174 1180 15275829 alpha3 NN B-NP O
2 1181 1182 15275829 + SYM B-NP O
3 1182 1183 15275829 / SYM B-VP O
4 1183 1184 15275829 - HYPH B-ADVP O
5 1185 1189 15275829 mice NNS B-NP O
6 1190 1194 15275829 were VBD B-VP O
7 1195 1204 15275829 partially RB B-ADJP O
8 1205 1214 15275829 resistant JJ I-ADJP O
9 1215 1217 15275829 to TO B-PP O
10 1218 1226 15275829 nicotine NN B-NP B-Chemical
11 1226 1227 15275829 - HYPH B-NP O
12 1227 1234 15275829 induced VBN I-NP O
13 1235 1243 15275829 seizures NNS I-NP B-Disease
14 1244 1248 15275829 when WRB B-ADVP O
15 1249 1257 15275829 compared VBN B-VP O
16 1258 1260 15275829 to TO B-PP O
17 1261 1265 15275829 wild JJ B-NP O
18 1265 1266 15275829 - HYPH I-NP O
19 1266 1270 15275829 type NN I-NP O
20 1271 1282 15275829 littermates NNS I-NP O
21 1282 1283 15275829 . . O O

1 1284 1288 15275829 mRNA NN B-NP O
2 1289 1295 15275829 levels NNS I-NP O
3 1296 1299 15275829 for IN B-PP O
4 1300 1303 15275829 the DT B-NP O
5 1304 1310 15275829 alpha5 NN I-NP O
6 1311 1314 15275829 and CC O O
7 1315 1318 15275829 the DT B-NP O
8 1319 1324 15275829 beta4 NN I-NP O
9 1325 1333 15275829 subunits NNS I-NP O
10 1334 1338 15275829 were VBD B-VP O
11 1339 1348 15275829 unchanged JJ B-ADJP O
12 1349 1351 15275829 in IN B-PP O
13 1352 1358 15275829 alpha3 NN B-NP O
14 1359 1360 15275829 + SYM B-NP O
15 1360 1361 15275829 / SYM B-VP O
16 1361 1362 15275829 - HYPH B-ADVP O
17 1363 1369 15275829 brains NNS B-NP O
18 1369 1370 15275829 . . O O

1 1371 1379 15275829 Together RB B-ADVP O
2 1379 1380 15275829 , , O O
3 1381 1386 15275829 these DT B-NP O
4 1387 1394 15275829 results NNS I-NP O
5 1395 1402 15275829 suggest VBP B-VP O
6 1403 1407 15275829 that IN B-SBAR O
7 1408 1411 15275829 the DT B-NP O
8 1412 1417 15275829 beta4 NN I-NP O
9 1418 1421 15275829 and CC O O
10 1422 1425 15275829 the DT B-NP O
11 1426 1432 15275829 alpha3 NN I-NP O
12 1433 1441 15275829 subunits NNS I-NP O
13 1442 1445 15275829 are VBP B-VP O
14 1446 1455 15275829 mediators NNS B-NP O
15 1456 1458 15275829 of IN B-PP O
16 1459 1467 15275829 nicotine NN B-NP B-Chemical
17 1467 1468 15275829 - HYPH B-NP O
18 1468 1475 15275829 induced VBN I-NP O
19 1476 1484 15275829 seizures NNS I-NP B-Disease
20 1485 1488 15275829 and CC I-NP O
21 1489 1503 15275829 hypolocomotion NN I-NP B-Disease
22 1503 1504 15275829 . . O O

1 0 0 12684739 -DOCSTART- -X- -X- O

1 0 3 12684739 Sub NN B-NP O
2 3 4 12684739 - HYPH I-NP O
3 4 11 12684739 chronic JJ I-NP O
4 12 15 12684739 low JJ I-NP O
5 16 20 12684739 dose NN I-NP O
6 21 26 12684739 gamma SYM O B-Chemical
7 26 27 12684739 - HYPH O I-Chemical
8 27 32 12684739 vinyl NN B-NP I-Chemical
9 33 37 12684739 GABA NN I-NP I-Chemical
10 38 39 12684739 ( ( O O
11 39 49 12684739 vigabatrin NN B-NP B-Chemical
12 49 50 12684739 ) ) O O
13 51 59 12684739 inhibits VBZ B-VP O
14 60 67 12684739 cocaine NN B-NP B-Chemical
15 67 68 12684739 - HYPH B-NP O
16 68 75 12684739 induced VBN I-NP O
17 76 85 12684739 increases NNS I-NP O
18 86 88 12684739 in IN B-PP O
19 89 96 12684739 nucleus NN B-NP O
20 97 106 12684739 accumbens NN I-NP O
21 107 115 12684739 dopamine NN I-NP B-Chemical
22 115 116 12684739 . . I-NP O
23 117 126 12684739 RATIONALE NN I-NP O
24 126 127 12684739 : : O O
25 128 133 12684739 gamma SYM O B-Chemical
26 133 134 12684739 - HYPH O I-Chemical
27 134 139 12684739 Vinyl NN B-NP I-Chemical
28 140 144 12684739 GABA NN I-NP I-Chemical
29 145 146 12684739 ( ( O O
30 146 149 12684739 GVG NN B-NP B-Chemical
31 149 150 12684739 ) ) O O
32 151 163 12684739 irreversibly RB B-ADVP O
33 164 172 12684739 inhibits VBZ B-VP O
34 173 177 12684739 GABA NN B-NP B-Chemical
35 177 178 12684739 - HYPH I-NP O
36 178 190 12684739 transaminase NN I-NP O
37 190 191 12684739 . . O O

1 192 196 12684739 This DT B-NP O
2 197 200 12684739 non AFX I-NP O
3 200 201 12684739 - HYPH I-NP O
4 201 209 12684739 receptor NN I-NP O
5 210 218 12684739 mediated VBN I-NP O
6 219 229 12684739 inhibition NN I-NP O
7 230 238 12684739 requires VBZ B-VP O
8 239 241 12684739 de FW B-NP O
9 242 246 12684739 novo FW I-NP O
10 247 256 12684739 synthesis NN I-NP O
11 257 260 12684739 for IN B-PP O
12 261 272 12684739 restoration NN B-NP O
13 273 275 12684739 of IN B-PP O
14 276 286 12684739 functional JJ B-NP O
15 287 291 12684739 GABA NN I-NP B-Chemical
16 292 302 12684739 catabolism NN I-NP O
17 302 303 12684739 . . O O

1 304 314 12684739 OBJECTIVES NNS B-NP O
2 314 315 12684739 : : O O
3 316 321 12684739 Given VBN B-VP O
4 322 325 12684739 its PRP$ B-NP O
5 326 337 12684739 preclinical JJ I-NP O
6 338 345 12684739 success NN I-NP O
7 346 349 12684739 for IN B-PP O
8 350 358 12684739 treating VBG B-VP O
9 359 368 12684739 substance NN B-NP B-Disease
10 369 374 12684739 abuse NN I-NP I-Disease
11 375 378 12684739 and CC O O
12 379 382 12684739 the DT B-NP O
13 383 392 12684739 increased VBN I-NP O
14 393 397 12684739 risk NN I-NP O
15 398 400 12684739 of IN B-PP O
16 401 407 12684739 visual JJ B-NP B-Disease
17 408 413 12684739 field NN I-NP I-Disease
18 414 421 12684739 defects NNS I-NP I-Disease
19 422 423 12684739 ( ( O O
20 423 426 12684739 VFD NN B-NP B-Disease
21 426 427 12684739 ) ) O O
22 428 438 12684739 associated VBN B-VP O
23 439 443 12684739 with IN B-PP O
24 444 454 12684739 cumulative JJ B-NP O
25 455 463 12684739 lifetime NN I-NP O
26 464 472 12684739 exposure NN I-NP O
27 472 473 12684739 , , O O
28 474 476 12684739 we PRP B-NP O
29 477 485 12684739 explored VBD B-VP O
30 486 489 12684739 the DT B-NP O
31 490 497 12684739 effects NNS I-NP O
32 498 500 12684739 of IN B-PP O
33 501 504 12684739 sub AFX B-NP O
34 504 505 12684739 - HYPH I-NP O
35 505 512 12684739 chronic JJ I-NP O
36 513 516 12684739 low JJ I-NP O
37 517 521 12684739 dose NN I-NP O
38 522 525 12684739 GVG NN I-NP B-Chemical
39 526 528 12684739 on IN B-PP O
40 529 536 12684739 cocaine NN B-NP B-Chemical
41 536 537 12684739 - HYPH B-NP O
42 537 544 12684739 induced VBN I-NP O
43 545 554 12684739 increases NNS I-NP O
44 555 557 12684739 in IN B-PP O
45 558 565 12684739 nucleus NN B-NP O
46 566 575 12684739 accumbens NN I-NP O
47 576 577 12684739 ( ( O O
48 577 581 12684739 NAcc NN B-NP O
49 581 582 12684739 ) ) O O
50 583 591 12684739 dopamine NN B-NP B-Chemical
51 592 593 12684739 ( ( O O
52 593 595 12684739 DA NN B-NP B-Chemical
53 595 596 12684739 ) ) O O
54 596 597 12684739 . . O O

1 598 605 12684739 METHODS NNS B-NP O
2 605 606 12684739 : : O O
3 607 612 12684739 Using VBG B-VP O
4 613 615 12684739 in FW B-NP O
5 616 620 12684739 vivo FW I-NP O
6 621 634 12684739 microdialysis NN I-NP O
7 634 635 12684739 , , O O
8 636 638 12684739 we PRP B-NP O
9 639 647 12684739 compared VBD B-VP O
10 648 653 12684739 acute JJ B-NP O
11 654 662 12684739 exposure NN I-NP O
12 663 664 12684739 ( ( O O
13 664 667 12684739 450 CD B-NP O
14 668 670 12684739 mg NN I-NP O
15 670 671 12684739 / SYM B-NP O
16 671 673 12684739 kg NN I-NP O
17 673 674 12684739 ) ) O O
18 675 677 12684739 to TO B-PP O
19 678 680 12684739 an DT B-NP O
20 681 690 12684739 identical JJ I-NP O
21 691 694 12684739 sub AFX I-NP O
22 694 695 12684739 - HYPH I-NP O
23 695 702 12684739 chronic JJ I-NP O
24 703 711 12684739 exposure NN I-NP O
25 712 713 12684739 ( ( O O
26 713 716 12684739 150 CD B-NP O
27 717 719 12684739 mg NN I-NP O
28 719 720 12684739 / SYM B-NP O
29 720 722 12684739 kg NN I-NP O
30 723 726 12684739 per IN B-PP O
31 727 730 12684739 day NN B-NP O
32 731 734 12684739 for IN B-PP O
33 735 736 12684739 3 CD B-NP O
34 737 741 12684739 days NNS I-NP O
35 741 742 12684739 ) ) O O
36 742 743 12684739 , , O O
37 744 752 12684739 followed VBN B-VP O
38 753 755 12684739 by IN B-PP O
39 756 757 12684739 1 CD B-NP O
40 757 758 12684739 - HYPH B-VP O
41 759 761 12684739 or CC B-NP O
42 762 763 12684739 3 CD I-NP O
43 763 764 12684739 - HYPH I-NP O
44 764 767 12684739 day NN I-NP O
45 768 775 12684739 washout NN I-NP O
46 775 776 12684739 . . O O

1 777 784 12684739 Finally RB B-ADVP O
2 784 785 12684739 , , O O
3 786 788 12684739 we PRP B-NP O
4 789 797 12684739 examined VBD B-VP O
5 798 801 12684739 the DT B-NP O
6 802 805 12684739 low JJ I-NP O
7 806 810 12684739 dose NN I-NP O
8 811 813 12684739 of IN B-PP O
9 814 817 12684739 150 CD B-NP O
10 818 820 12684739 mg NN I-NP O
11 820 821 12684739 / SYM B-NP O
12 821 823 12684739 kg NN I-NP O
13 824 825 12684739 ( ( O O
14 825 827 12684739 50 CD B-NP O
15 828 830 12684739 mg NN I-NP O
16 830 831 12684739 / SYM B-NP O
17 831 833 12684739 kg NN I-NP O
18 834 837 12684739 per IN B-PP O
19 838 841 12684739 day NN B-NP O
20 841 842 12684739 ) ) O O
21 843 848 12684739 using VBG B-VP O
22 849 850 12684739 a DT B-NP O
23 851 858 12684739 similar JJ I-NP O
24 859 866 12684739 washout NN I-NP O
25 867 873 12684739 period NN I-NP O
26 873 874 12684739 . . O O

1 875 882 12684739 RESULTS NNS B-NP O
2 882 883 12684739 : : O O
3 884 887 12684739 Sub NN B-NP O
4 887 888 12684739 - HYPH B-NP O
5 888 895 12684739 chronic JJ I-NP O
6 896 899 12684739 GVG NN I-NP B-Chemical
7 900 908 12684739 exposure NN I-NP O
8 909 918 12684739 inhibited VBD B-VP O
9 919 922 12684739 the DT B-NP O
10 923 929 12684739 effect NN I-NP O
11 930 932 12684739 of IN B-PP O
12 933 940 12684739 cocaine NN B-NP B-Chemical
13 941 944 12684739 for IN B-PP O
14 945 946 12684739 3 CD B-NP O
15 947 951 12684739 days NNS I-NP O
16 951 952 12684739 , , O O
17 953 958 12684739 which WDT B-NP O
18 959 967 12684739 exceeded VBD B-VP O
19 968 970 12684739 in IN B-PP O
20 971 980 12684739 magnitude NN B-NP O
21 981 984 12684739 and CC I-NP O
22 985 993 12684739 duration NN I-NP O
23 994 997 12684739 the DT B-NP O
24 998 1007 12684739 identical JJ I-NP O
25 1008 1013 12684739 acute JJ I-NP O
26 1014 1018 12684739 dose NN I-NP O
27 1018 1019 12684739 . . O O

1 1020 1031 12684739 CONCLUSIONS NNS B-NP O
2 1031 1032 12684739 : : O O
3 1033 1036 12684739 Sub NN B-NP O
4 1036 1037 12684739 - HYPH B-NP O
5 1037 1044 12684739 chronic JJ I-NP O
6 1045 1048 12684739 low JJ I-NP O
7 1049 1053 12684739 dose NN I-NP O
8 1054 1057 12684739 GVG NN I-NP B-Chemical
9 1058 1069 12684739 potentiates VBZ B-VP O
10 1070 1073 12684739 and CC I-VP O
11 1074 1081 12684739 extends VBZ I-VP O
12 1082 1085 12684739 the DT B-NP O
13 1086 1096 12684739 inhibition NN I-NP O
14 1097 1099 12684739 of IN B-PP O
15 1100 1107 12684739 cocaine NN B-NP B-Chemical
16 1107 1108 12684739 - HYPH B-NP O
17 1108 1115 12684739 induced VBN I-NP O
18 1116 1125 12684739 increases NNS I-NP O
19 1126 1128 12684739 in IN B-PP O
20 1129 1137 12684739 dopamine NN B-NP B-Chemical
21 1137 1138 12684739 , , O O
22 1139 1150 12684739 effectively RB B-VP O
23 1151 1159 12684739 reducing VBG I-VP O
24 1160 1170 12684739 cumulative JJ B-NP O
25 1171 1180 12684739 exposures NNS I-NP O
26 1181 1184 12684739 and CC O O
27 1185 1188 12684739 the DT B-NP O
28 1189 1193 12684739 risk NN I-NP O
29 1194 1197 12684739 for IN B-PP O
30 1198 1202 12684739 VFDS NN B-NP O
31 1202 1203 12684739 . . O O

1 0 0 9100294 -DOCSTART- -X- -X- O

1 0 14 9100294 Cardiovascular JJ B-NP B-Disease
2 15 26 9100294 alterations NNS I-NP I-Disease
3 27 29 9100294 in IN B-PP O
4 30 33 9100294 rat NN B-NP O
5 34 41 9100294 fetuses NNS I-NP O
6 42 49 9100294 exposed VBN B-VP O
7 50 52 9100294 to TO B-PP O
8 53 60 9100294 calcium NN B-NP B-Chemical
9 61 68 9100294 channel NN I-NP O
10 69 77 9100294 blockers NNS I-NP O
11 77 78 9100294 . . O O
12 79 90 9100294 Preclinical JJ B-NP O
13 91 102 9100294 toxicologic JJ I-NP O
14 103 116 9100294 investigation NN I-NP O
15 117 126 9100294 suggested VBD B-VP O
16 127 131 9100294 that IN B-SBAR O
17 132 133 9100294 a DT B-NP O
18 134 137 9100294 new JJ I-NP O
19 138 145 9100294 calcium NN I-NP B-Chemical
20 146 153 9100294 channel NN I-NP O
21 154 161 9100294 blocker NN I-NP O
22 161 162 9100294 , , O O
23 163 165 9100294 Ro NN B-NP B-Chemical
24 166 168 9100294 40 CD I-NP I-Chemical
25 168 169 9100294 - HYPH I-NP I-Chemical
26 169 173 9100294 5967 CD I-NP I-Chemical
27 173 174 9100294 , , O O
28 175 182 9100294 induced VBD B-VP O
29 183 197 9100294 cardiovascular JJ B-NP B-Disease
30 198 209 9100294 alterations NNS I-NP I-Disease
31 210 212 9100294 in IN B-PP O
32 213 216 9100294 rat NN B-NP O
33 217 224 9100294 fetuses NNS I-NP O
34 225 232 9100294 exposed VBN B-VP O
35 233 235 9100294 to TO B-PP O
36 236 240 9100294 this DT B-NP O
37 241 246 9100294 agent NN I-NP O
38 247 253 9100294 during IN B-PP O
39 254 267 9100294 organogenesis NN B-NP O
40 267 268 9100294 . . O O

1 269 272 9100294 The DT B-NP O
2 273 280 9100294 present JJ I-NP O
3 281 286 9100294 study NN I-NP O
4 287 290 9100294 was VBD B-VP O
5 291 299 9100294 designed VBN I-VP O
6 300 302 9100294 to TO B-VP O
7 303 314 9100294 investigate VB I-VP O
8 315 318 9100294 the DT B-NP O
9 319 329 9100294 hypothesis NN I-NP O
10 330 334 9100294 that IN B-SBAR O
11 335 342 9100294 calcium NN B-NP B-Chemical
12 343 350 9100294 channel NN I-NP O
13 351 359 9100294 blockers NNS I-NP O
14 360 362 9100294 in IN B-PP O
15 363 370 9100294 general JJ B-NP O
16 371 377 9100294 induce VBP B-VP O
17 378 392 9100294 cardiovascular JJ B-NP B-Disease
18 393 406 9100294 malformations NNS I-NP I-Disease
19 407 417 9100294 indicating VBG B-VP O
20 418 419 9100294 a DT B-NP O
21 420 433 9100294 pharmacologic JJ I-NP O
22 434 439 9100294 class NN I-NP O
23 440 446 9100294 effect NN I-NP O
24 446 447 9100294 . . O O

1 448 450 9100294 We PRP B-NP O
2 451 458 9100294 studied VBD B-VP O
3 459 464 9100294 three CD B-NP O
4 465 472 9100294 calcium NN I-NP B-Chemical
5 473 480 9100294 channel NN I-NP O
6 481 489 9100294 blockers NNS I-NP O
7 490 492 9100294 of IN B-PP O
8 493 502 9100294 different JJ B-NP O
9 503 512 9100294 structure NN I-NP O
10 512 513 9100294 , , O O
11 514 524 9100294 nifedipine NN B-NP B-Chemical
12 524 525 9100294 , , O O
13 526 535 9100294 diltiazem NN B-NP B-Chemical
14 535 536 9100294 , , O O
15 537 540 9100294 and CC O O
16 541 550 9100294 verapamil NN B-NP B-Chemical
17 550 551 9100294 , , O O
18 552 557 9100294 along IN B-PP O
19 558 562 9100294 with IN B-PP O
20 563 566 9100294 the DT B-NP O
21 567 570 9100294 new JJ I-NP O
22 571 576 9100294 agent NN I-NP O
23 576 577 9100294 . . O O

1 578 586 9100294 Pregnant JJ B-NP O
2 587 591 9100294 rats NNS I-NP O
3 592 596 9100294 were VBD B-VP O
4 597 609 9100294 administered VBN I-VP O
5 610 613 9100294 one CD B-NP O
6 614 616 9100294 of IN B-PP O
7 617 622 9100294 these DT B-NP O
8 623 630 9100294 calcium NN I-NP B-Chemical
9 631 638 9100294 channel NN I-NP O
10 639 647 9100294 blockers NNS I-NP O
11 648 654 9100294 during IN B-PP O
12 655 658 9100294 the DT B-NP O
13 659 665 9100294 period NN I-NP O
14 666 668 9100294 of IN B-PP O
15 669 676 9100294 cardiac JJ B-NP O
16 677 690 9100294 morphogenesis NN I-NP O
17 691 694 9100294 and CC O O
18 695 698 9100294 the DT B-NP O
19 699 708 9100294 offspring NN I-NP O
20 709 717 9100294 examined VBN B-VP O
21 718 720 9100294 on IN B-PP O
22 721 724 9100294 day NN B-NP O
23 725 727 9100294 20 CD I-NP O
24 728 730 9100294 of IN B-PP O
25 731 740 9100294 gestation NN B-NP O
26 741 744 9100294 for IN B-PP O
27 745 759 9100294 cardiovascular JJ B-NP B-Disease
28 760 773 9100294 malformations NNS I-NP I-Disease
29 773 774 9100294 . . O O

1 775 776 9100294 A DT B-NP O
2 777 780 9100294 low JJ I-NP O
3 781 790 9100294 incidence NN I-NP O
4 791 793 9100294 of IN B-PP O
5 794 808 9100294 cardiovascular JJ B-NP B-Disease
6 809 822 9100294 malformations NNS I-NP I-Disease
7 823 826 9100294 was VBD B-VP O
8 827 835 9100294 observed VBN I-VP O
9 836 841 9100294 after IN B-PP O
10 842 850 9100294 exposure NN B-NP O
11 851 853 9100294 to TO B-PP O
12 854 858 9100294 each DT B-NP O
13 859 861 9100294 of IN B-PP O
14 862 865 9100294 the DT B-NP O
15 866 870 9100294 four CD I-NP O
16 871 878 9100294 calcium NN I-NP B-Chemical
17 879 886 9100294 channel NN I-NP O
18 887 895 9100294 blockers NNS I-NP O
19 895 896 9100294 , , O O
20 897 900 9100294 but CC O O
21 901 905 9100294 this DT B-NP O
22 906 915 9100294 incidence NN I-NP O
23 916 919 9100294 was VBD B-VP O
24 920 933 9100294 statistically RB B-ADJP O
25 934 945 9100294 significant JJ I-ADJP O
26 946 950 9100294 only RB B-ADVP O
27 951 954 9100294 for IN B-PP O
28 955 964 9100294 verapamil NN B-NP B-Chemical
29 965 968 9100294 and CC I-NP O
30 969 979 9100294 nifedipine NN I-NP B-Chemical
31 979 980 9100294 . . O O

1 981 984 9100294 All DT B-NP O
2 985 989 9100294 four CD I-NP O
3 990 996 9100294 agents NNS I-NP O
4 997 1001 9100294 were VBD B-VP O
5 1002 1012 9100294 associated VBN I-VP O
6 1013 1017 9100294 with IN B-PP O
7 1018 1024 9100294 aortic JJ B-NP O
8 1025 1029 9100294 arch NN I-NP O
9 1030 1039 9100294 branching NN I-NP O
10 1040 1048 9100294 variants NNS I-NP O
11 1048 1049 9100294 , , O O
12 1050 1058 9100294 although IN B-SBAR O
13 1059 1072 9100294 significantly RB B-ADJP O
14 1073 1082 9100294 increased VBN I-ADJP O
15 1083 1087 9100294 only RB B-ADVP O
16 1088 1091 9100294 for IN B-PP O
17 1092 1094 9100294 Ro NN B-NP B-Chemical
18 1095 1097 9100294 40 CD I-NP I-Chemical
19 1097 1098 9100294 - HYPH I-NP I-Chemical
20 1098 1102 9100294 5967 CD I-NP I-Chemical
21 1103 1106 9100294 and CC I-NP O
22 1107 1116 9100294 verapamil NN I-NP B-Chemical
23 1116 1117 9100294 . . O O

1 0 0 7234705 -DOCSTART- -X- -X- O

1 0 12 7234705 Procainamide NN B-NP B-Chemical
2 12 13 7234705 - HYPH O O
3 13 20 7234705 induced VBN B-NP O
4 21 33 7234705 polymorphous JJ I-NP O
5 34 45 7234705 ventricular JJ I-NP B-Disease
6 46 57 7234705 tachycardia NN I-NP I-Disease
7 57 58 7234705 . . O O
8 59 64 7234705 Seven CD B-NP O
9 65 70 7234705 cases NNS I-NP O
10 71 73 7234705 of IN B-PP O
11 74 86 7234705 procainamide NN B-NP B-Chemical
12 86 87 7234705 - HYPH B-NP O
13 87 94 7234705 induced VBN I-NP O
14 95 107 7234705 polymorphous JJ I-NP O
15 108 119 7234705 ventricular JJ I-NP B-Disease
16 120 131 7234705 tachycardia NN I-NP I-Disease
17 132 135 7234705 are VBP B-VP O
18 136 145 7234705 presented VBN I-VP O
19 145 146 7234705 . . O O

1 147 149 7234705 In IN B-PP O
2 150 154 7234705 four CD B-NP O
3 155 163 7234705 patients NNS I-NP O
4 163 164 7234705 , , O O
5 165 177 7234705 polymorphous JJ B-NP O
6 178 189 7234705 ventricular JJ I-NP B-Disease
7 190 201 7234705 tachycardia NN I-NP I-Disease
8 202 210 7234705 appeared VBD B-VP O
9 211 216 7234705 after IN B-SBAR O
10 217 228 7234705 intravenous JJ B-NP O
11 229 243 7234705 administration NN I-NP O
12 244 246 7234705 of IN B-PP O
13 247 250 7234705 200 CD B-NP O
14 251 253 7234705 to TO I-NP O
15 254 257 7234705 400 CD I-NP O
16 258 260 7234705 mg NN I-NP O
17 261 263 7234705 of IN B-PP O
18 264 276 7234705 procainamide NN B-NP B-Chemical
19 277 280 7234705 for IN B-PP O
20 281 284 7234705 the DT B-NP O
21 285 294 7234705 treatment NN I-NP O
22 295 297 7234705 of IN B-PP O
23 298 307 7234705 sustained JJ B-NP O
24 308 319 7234705 ventricular JJ I-NP B-Disease
25 320 331 7234705 tachycardia NN I-NP I-Disease
26 331 332 7234705 . . O O

1 333 335 7234705 In IN B-PP O
2 336 339 7234705 the DT B-NP O
3 340 349 7234705 remaining VBG I-NP O
4 350 355 7234705 three CD I-NP O
5 356 364 7234705 patients NNS I-NP O
6 364 365 7234705 , , O O
7 366 378 7234705 procainamide NN B-NP B-Chemical
8 379 382 7234705 was VBD B-VP O
9 383 395 7234705 administered VBN I-VP O
10 396 402 7234705 orally RB B-ADVP O
11 403 406 7234705 for IN B-PP O
12 407 416 7234705 treatment NN B-NP O
13 417 419 7234705 of IN B-PP O
14 420 427 7234705 chronic JJ B-NP O
15 428 437 7234705 premature JJ I-NP B-Disease
16 438 449 7234705 ventricular JJ I-NP I-Disease
17 450 462 7234705 contractions NNS I-NP I-Disease
18 463 465 7234705 or CC O O
19 466 472 7234705 atrial JJ B-NP B-Disease
20 473 480 7234705 flutter NN I-NP I-Disease
21 480 481 7234705 . . O O

1 482 487 7234705 These DT B-NP O
2 488 496 7234705 patients NNS I-NP O
3 497 500 7234705 had VBD B-VP O
4 501 502 7234705 Q NN B-NP B-Disease
5 502 503 7234705 - HYPH I-NP I-Disease
6 503 504 7234705 T NN I-NP I-Disease
7 505 517 7234705 prolongation NN I-NP I-Disease
8 518 521 7234705 and CC O O
9 522 531 7234705 recurrent JJ B-NP O
10 532 539 7234705 syncope NN I-NP B-Disease
11 540 543 7234705 due JJ B-PP O
12 544 546 7234705 to TO B-PP O
13 547 559 7234705 polymorphous JJ B-NP O
14 560 571 7234705 ventricular JJ I-NP B-Disease
15 572 583 7234705 tachycardia NN I-NP I-Disease
16 583 584 7234705 . . O O

1 585 587 7234705 In IN B-PP O
2 588 592 7234705 four CD B-NP O
3 593 601 7234705 patients NNS I-NP O
4 601 602 7234705 , , O O
5 603 606 7234705 the DT B-NP O
6 607 617 7234705 arrhythmia NN I-NP B-Disease
7 618 621 7234705 was VBD B-VP O
8 622 629 7234705 rapidly RB I-VP O
9 630 639 7234705 diagnosed VBN I-VP O
10 640 643 7234705 and CC O O
11 644 651 7234705 treated VBN B-VP O
12 652 656 7234705 with IN B-PP O
13 657 670 7234705 disappearance NN B-NP O
14 671 673 7234705 of IN B-PP O
15 674 681 7234705 further JJ B-NP O
16 682 690 7234705 episodes NNS I-NP O
17 691 693 7234705 of IN B-PP O
18 694 697 7234705 the DT B-NP O
19 698 708 7234705 arrhythmia NN I-NP B-Disease
20 708 709 7234705 . . O O

1 710 712 7234705 In IN B-PP O
2 713 716 7234705 two CD B-NP O
3 717 725 7234705 patients NNS I-NP O
4 725 726 7234705 , , O O
5 727 730 7234705 the DT B-NP O
6 731 741 7234705 arrhythmia NN I-NP B-Disease
7 742 753 7234705 degenerated VBD B-VP O
8 754 758 7234705 into IN B-PP O
9 759 771 7234705 irreversible JJ B-NP O
10 772 783 7234705 ventricular JJ I-NP B-Disease
11 784 796 7234705 fibrillation NN I-NP I-Disease
12 797 800 7234705 and CC O O
13 801 805 7234705 both DT B-NP O
14 806 814 7234705 patients NNS I-NP O
15 815 819 7234705 died VBD B-VP O
16 819 820 7234705 . . O O

1 821 823 7234705 In IN B-PP O
2 824 827 7234705 the DT B-NP O
3 828 835 7234705 seventh JJ I-NP O
4 836 843 7234705 patient NN I-NP O
5 843 844 7234705 , , O O
6 845 846 7234705 a DT B-NP O
7 847 856 7234705 permanent JJ I-NP O
8 857 868 7234705 ventricular JJ I-NP O
9 869 878 7234705 pacemaker NN I-NP O
10 879 882 7234705 was VBD B-VP O
11 883 891 7234705 inserted VBN I-VP O
12 892 895 7234705 and CC O O
13 895 896 7234705 , , O O
14 897 904 7234705 despite IN B-PP O
15 905 917 7234705 continuation NN B-NP O
16 918 920 7234705 of IN B-PP O
17 921 933 7234705 procainamide NN B-NP B-Chemical
18 934 941 7234705 therapy NN I-NP O
19 941 942 7234705 , , O O
20 943 955 7234705 polymorphous JJ B-NP O
21 956 967 7234705 ventricular JJ I-NP B-Disease
22 968 979 7234705 tachycardia NN I-NP I-Disease
23 980 983 7234705 did VBD B-VP O
24 984 987 7234705 not RB I-VP O
25 988 995 7234705 reoccur VB I-VP O
26 995 996 7234705 . . O O

1 997 1002 7234705 These DT B-NP O
2 1003 1008 7234705 seven CD I-NP O
3 1009 1014 7234705 cases NNS I-NP O
4 1015 1026 7234705 demonstrate VBP B-VP O
5 1027 1031 7234705 that IN B-SBAR O
6 1032 1044 7234705 procainamide NN B-NP B-Chemical
7 1045 1048 7234705 can MD B-VP O
8 1049 1056 7234705 produce VB I-VP O
9 1057 1059 7234705 an DT B-NP O
10 1060 1068 7234705 acquired VBN I-NP O
11 1069 1078 7234705 prolonged VBN I-NP B-Disease
12 1079 1080 7234705 Q NN I-NP I-Disease
13 1080 1081 7234705 - HYPH I-NP I-Disease
14 1081 1082 7234705 T NN I-NP I-Disease
15 1083 1091 7234705 syndrome NN I-NP I-Disease
16 1092 1096 7234705 with IN B-PP O
17 1097 1109 7234705 polymorphous JJ B-NP O
18 1110 1121 7234705 ventricular JJ I-NP B-Disease
19 1122 1133 7234705 tachycardia NN I-NP I-Disease
20 1133 1134 7234705 . . O O

1 0 0 16904497 -DOCSTART- -X- -X- O

1 0 5 16904497 Cauda NNP B-NP B-Disease
2 6 12 16904497 equina NNP I-NP I-Disease
3 13 21 16904497 syndrome NN I-NP I-Disease
4 22 27 16904497 after IN B-PP O
5 28 36 16904497 epidural JJ B-NP O
6 37 44 16904497 steroid NN I-NP B-Chemical
7 45 54 16904497 injection NN I-NP O
8 54 55 16904497 : : O O
9 56 57 16904497 a DT B-NP O
10 58 62 16904497 case NN I-NP O
11 63 69 16904497 report NN I-NP O
12 69 70 16904497 . . I-NP O
13 71 80 16904497 OBJECTIVE NN I-NP O
14 80 81 16904497 : : O O
15 82 94 16904497 Conventional JJ B-NP O
16 95 104 16904497 treatment NN I-NP O
17 105 112 16904497 methods NNS I-NP O
18 113 115 16904497 of IN B-PP O
19 116 127 16904497 lumbusacral JJ B-NP O
20 128 141 16904497 radiculopathy NN I-NP B-Disease
21 142 145 16904497 are VBP B-VP O
22 146 154 16904497 physical JJ B-NP O
23 155 162 16904497 therapy NN I-NP O
24 162 163 16904497 , , O O
25 164 172 16904497 epidural JJ B-NP O
26 173 180 16904497 steroid NN I-NP B-Chemical
27 181 191 16904497 injections NNS I-NP O
28 191 192 16904497 , , O O
29 193 197 16904497 oral JJ B-NP O
30 198 209 16904497 medications NNS I-NP O
31 209 210 16904497 , , O O
32 211 214 16904497 and CC O O
33 215 221 16904497 spinal JJ B-NP O
34 222 234 16904497 manipulative JJ I-NP O
35 235 242 16904497 therapy NN I-NP O
36 242 243 16904497 . . O O

1 244 249 16904497 Cauda NNP B-NP B-Disease
2 250 256 16904497 equina NNP I-NP I-Disease
3 257 265 16904497 syndrome NN I-NP I-Disease
4 266 268 16904497 is VBZ B-VP O
5 269 270 16904497 a DT B-NP O
6 271 275 16904497 rare JJ I-NP O
7 276 288 16904497 complication NN I-NP O
8 289 291 16904497 of IN B-PP O
9 292 300 16904497 epidural JJ B-NP O
10 301 311 16904497 anesthesia NN I-NP O
11 311 312 16904497 . . O O

1 313 316 16904497 The DT B-NP O
2 317 326 16904497 following VBG I-NP O
3 327 331 16904497 case NN I-NP O
4 332 334 16904497 is VBZ B-VP O
5 335 336 16904497 a DT B-NP O
6 337 343 16904497 report NN I-NP O
7 344 346 16904497 of IN B-PP O
8 347 352 16904497 cauda NN B-NP B-Disease
9 353 359 16904497 equina NN I-NP I-Disease
10 360 368 16904497 syndrome NN I-NP I-Disease
11 369 377 16904497 possibly RB B-VP O
12 378 384 16904497 caused VBN I-VP O
13 385 387 16904497 by IN B-PP O
14 388 396 16904497 epidural JJ B-NP O
15 397 406 16904497 injection NN I-NP O
16 407 409 16904497 of IN B-PP O
17 410 423 16904497 triamcinolone NN B-NP B-Chemical
18 424 427 16904497 and CC I-NP O
19 428 439 16904497 bupivacaine NN I-NP B-Chemical
20 439 440 16904497 . . O O

1 441 449 16904497 CLINICAL JJ B-NP O
2 450 458 16904497 FEATURES NNS I-NP O
3 458 459 16904497 : : O O
4 460 461 16904497 A DT B-NP O
5 462 464 16904497 50 CD I-NP O
6 464 465 16904497 - HYPH I-NP O
7 465 469 16904497 year NN I-NP O
8 469 470 16904497 - HYPH O O
9 470 473 16904497 old JJ B-NP O
10 474 479 16904497 woman NN I-NP O
11 480 484 16904497 with IN B-PP O
12 485 488 16904497 low JJ B-NP B-Disease
13 489 493 16904497 back NN I-NP I-Disease
14 494 497 16904497 and CC O I-Disease
15 498 503 16904497 right JJ B-NP I-Disease
16 504 507 16904497 leg NN I-NP I-Disease
17 508 512 16904497 pain NN I-NP I-Disease
18 513 516 16904497 was VBD B-VP O
19 517 526 16904497 scheduled VBN I-VP O
20 527 530 16904497 for IN B-PP O
21 531 539 16904497 epidural JJ B-NP O
22 540 547 16904497 steroid NN I-NP B-Chemical
23 548 557 16904497 injection NN I-NP O
24 557 558 16904497 . . O O

1 559 571 16904497 INTERVENTION NN B-NP O
2 572 575 16904497 AND CC I-NP O
3 576 583 16904497 OUTCOME NN I-NP O
4 583 584 16904497 : : O O
5 585 587 16904497 An DT B-NP O
6 588 590 16904497 18 CD I-NP O
7 590 591 16904497 - HYPH I-NP O
8 591 596 16904497 gauge NN I-NP O
9 597 602 16904497 Touhy NN I-NP O
10 603 609 16904497 needle NN I-NP O
11 610 613 16904497 was VBD B-VP O
12 614 622 16904497 inserted VBN I-VP O
13 623 628 16904497 until IN B-PP O
14 629 633 16904497 loss NN B-NP O
15 634 636 16904497 of IN B-PP O
16 637 647 16904497 resistance NN B-NP O
17 648 656 16904497 occurred VBD B-VP O
18 657 659 16904497 at IN B-PP O
19 660 663 16904497 the DT B-NP O
20 664 666 16904497 L4 NN I-NP O
21 666 667 16904497 - HYPH I-NP O
22 667 668 16904497 5 CD I-NP O
23 669 674 16904497 level NN I-NP O
24 674 675 16904497 . . O O

1 676 682 16904497 Spread NN B-NP O
2 683 685 16904497 of IN B-PP O
3 686 689 16904497 the DT B-NP O
4 690 698 16904497 contrast NN I-NP O
5 699 705 16904497 medium NN I-NP O
6 706 712 16904497 within IN B-PP O
7 713 716 16904497 the DT B-NP O
8 717 725 16904497 epidural JJ I-NP O
9 726 731 16904497 space NN I-NP O
10 732 735 16904497 was VBD B-VP O
11 736 746 16904497 determined VBN I-VP O
12 747 749 16904497 by IN B-PP O
13 750 762 16904497 radiographic JJ B-NP O
14 763 770 16904497 imaging NN I-NP O
15 770 771 16904497 . . O O

1 772 777 16904497 After IN B-PP O
2 778 787 16904497 verifying VBG B-VP O
3 788 791 16904497 the DT B-NP O
4 792 800 16904497 epidural JJ I-NP O
5 801 806 16904497 space NN I-NP O
6 806 807 16904497 , , O O
7 808 819 16904497 bupivacaine NN B-NP B-Chemical
8 820 823 16904497 and CC I-NP O
9 824 837 16904497 triamcinolone NN I-NP B-Chemical
10 838 847 16904497 diacetate NN I-NP I-Chemical
11 848 852 16904497 were VBD B-VP O
12 853 861 16904497 injected VBN I-VP O
13 861 862 16904497 . . O O

1 863 868 16904497 After IN B-PP O
2 869 872 16904497 the DT B-NP O
3 873 882 16904497 injection NN I-NP O
4 882 883 16904497 , , O O
5 884 889 16904497 there EX B-NP O
6 890 893 16904497 was VBD B-VP O
7 894 895 16904497 a DT B-NP O
8 896 905 16904497 reduction NN I-NP O
9 906 908 16904497 in IN B-PP O
10 909 918 16904497 radicular JJ B-NP O
11 919 927 16904497 symptoms NNS I-NP O
12 927 928 16904497 . . O O

1 929 934 16904497 Three CD B-NP O
2 935 940 16904497 hours NNS I-NP O
3 941 946 16904497 later RB B-ADVP O
4 946 947 16904497 , , O O
5 948 951 16904497 she PRP B-NP O
6 952 962 16904497 complained VBD B-VP O
7 963 965 16904497 of IN B-PP O
8 966 974 16904497 perineal JJ B-NP O
9 975 983 16904497 numbness NN I-NP B-Disease
10 984 987 16904497 and CC O O
11 988 993 16904497 lower JJR B-NP B-Disease
12 994 1003 16904497 extremity NN I-NP I-Disease
13 1004 1012 16904497 weakness NN I-NP I-Disease
14 1012 1013 16904497 . . O O

1 1014 1017 16904497 The DT B-NP O
2 1018 1028 16904497 neurologic JJ I-NP O
3 1029 1039 16904497 evaluation NN I-NP O
4 1040 1048 16904497 revealed VBD B-VP O
5 1049 1053 16904497 loss NN B-NP B-Disease
6 1054 1056 16904497 of IN B-PP I-Disease
7 1057 1066 16904497 sensation NN B-NP I-Disease
8 1067 1069 16904497 in IN B-PP O
9 1070 1073 16904497 the DT B-NP O
10 1074 1080 16904497 saddle JJ I-NP O
11 1081 1085 16904497 area NN I-NP O
12 1086 1089 16904497 and CC O O
13 1090 1096 16904497 medial JJ B-NP O
14 1097 1103 16904497 aspect NN I-NP O
15 1104 1106 16904497 of IN B-PP O
16 1107 1110 16904497 her PRP$ B-NP O
17 1111 1116 16904497 right JJ I-NP O
18 1117 1120 16904497 leg NN I-NP O
19 1120 1121 16904497 . . O O

1 1122 1127 16904497 There EX B-NP O
2 1128 1131 16904497 was VBD B-VP O
3 1132 1133 16904497 a DT B-NP O
4 1134 1142 16904497 decrease NN I-NP O
5 1143 1145 16904497 in IN B-PP O
6 1146 1149 16904497 the DT B-NP O
7 1150 1160 16904497 perception NN I-NP O
8 1161 1163 16904497 of IN B-PP O
9 1164 1172 16904497 pinprick NN B-NP O
10 1173 1177 16904497 test NN I-NP O
11 1177 1178 16904497 . . O O

1 1179 1183 16904497 Deep JJ B-NP O
2 1183 1184 16904497 - HYPH I-NP O
3 1184 1190 16904497 tendon NN I-NP O
4 1191 1199 16904497 reflexes NNS I-NP O
5 1200 1204 16904497 were VBD B-VP O
6 1205 1214 16904497 decreased VBN I-VP O
7 1215 1225 16904497 especially RB B-ADVP O
8 1226 1228 16904497 in IN B-PP O
9 1229 1232 16904497 the DT B-NP O
10 1233 1238 16904497 right JJ I-NP O
11 1239 1242 16904497 leg NN I-NP O
12 1242 1243 16904497 . . O O

1 1244 1247 16904497 She PRP B-NP O
2 1248 1251 16904497 was VBD B-VP O
3 1252 1258 16904497 unable JJ B-ADJP O
4 1259 1261 16904497 to TO B-VP O
5 1262 1269 16904497 urinate VB I-VP O
6 1269 1270 16904497 . . O O

1 1271 1274 16904497 The DT B-NP O
2 1275 1284 16904497 patient's NNS I-NP O
3 1285 1293 16904497 symptoms NNS I-NP O
4 1294 1302 16904497 improved VBD B-VP O
5 1303 1311 16904497 slightly RB B-ADVP O
6 1312 1316 16904497 over IN B-PP O
7 1317 1320 16904497 the DT B-NP O
8 1321 1325 16904497 next JJ I-NP O
9 1326 1329 16904497 few JJ I-NP O
10 1330 1335 16904497 hours NNS I-NP O
11 1335 1336 16904497 . . O O

1 1337 1340 16904497 She PRP B-NP O
2 1341 1344 16904497 had VBD B-VP O
3 1345 1346 16904497 a DT B-NP O
4 1347 1354 16904497 gradual JJ I-NP O
5 1355 1361 16904497 return NN I-NP O
6 1362 1364 16904497 of IN B-PP O
7 1365 1370 16904497 motor NN B-NP O
8 1371 1379 16904497 function NN I-NP O
9 1380 1383 16904497 and CC I-NP O
10 1384 1391 16904497 ability NN I-NP O
11 1392 1394 16904497 of IN B-PP O
12 1395 1402 16904497 feeling NN B-NP O
13 1403 1408 16904497 Foley NNP I-NP O
14 1409 1417 16904497 catheter NN I-NP O
15 1417 1418 16904497 . . O O

1 1419 1422 16904497 All DT B-NP O
2 1423 1425 16904497 of IN B-PP O
3 1426 1429 16904497 the DT B-NP O
4 1430 1438 16904497 symptoms NNS I-NP O
5 1439 1443 16904497 were VBD B-VP O
6 1444 1454 16904497 completely RB I-VP O
7 1455 1463 16904497 resolved VBN I-VP O
8 1464 1468 16904497 over IN B-PP O
9 1469 1472 16904497 the DT B-NP O
10 1473 1477 16904497 next JJ I-NP O
11 1478 1479 16904497 8 CD I-NP O
12 1480 1485 16904497 hours NNS I-NP O
13 1485 1486 16904497 . . O O

1 1487 1497 16904497 CONCLUSION NN B-NP O
2 1497 1498 16904497 : : O O
3 1499 1512 16904497 Complications NNS B-NP O
4 1513 1523 16904497 associated VBN B-VP O
5 1524 1528 16904497 with IN B-PP O
6 1529 1537 16904497 epidural JJ B-NP O
7 1538 1545 16904497 steroid NN I-NP B-Chemical
8 1546 1556 16904497 injections NNS I-NP O
9 1557 1560 16904497 are VBP B-VP O
10 1561 1565 16904497 rare JJ B-ADJP O
11 1565 1566 16904497 . . O O

1 1567 1575 16904497 Clinical JJ B-NP O
2 1576 1587 16904497 examination NN I-NP O
3 1588 1591 16904497 and CC O O
4 1592 1601 16904497 continued JJ B-NP O
5 1602 1611 16904497 vigilance NN I-NP O
6 1612 1615 16904497 for IN B-PP O
7 1616 1626 16904497 neurologic JJ B-NP B-Disease
8 1627 1640 16904497 deterioration NN I-NP I-Disease
9 1641 1646 16904497 after IN B-PP O
10 1647 1655 16904497 epidural JJ B-NP O
11 1656 1663 16904497 steroid NN I-NP B-Chemical
12 1664 1674 16904497 injections NNS I-NP O
13 1675 1677 16904497 is VBZ B-VP O
14 1678 1687 16904497 important JJ B-ADJP O
15 1687 1688 16904497 . . O O

1 0 0 10683478 -DOCSTART- -X- -X- O

1 0 4 10683478 Test NN B-NP O
2 5 15 10683478 conditions NNS I-NP O
3 16 25 10683478 influence VBP B-VP O
4 26 29 10683478 the DT B-NP O
5 30 38 10683478 response NN I-NP O
6 39 41 10683478 to TO B-PP O
7 42 43 10683478 a DT B-NP O
8 44 48 10683478 drug NN I-NP O
9 49 58 10683478 challenge NN I-NP O
10 59 61 10683478 in IN B-PP O
11 62 69 10683478 rodents NNS B-NP O
12 69 70 10683478 . . O O
13 71 76 10683478 These DT B-NP O
14 77 84 10683478 studies NNS I-NP O
15 85 89 10683478 were VBD B-VP O
16 90 99 10683478 conducted VBN I-VP O
17 100 102 10683478 to TO B-VP O
18 103 110 10683478 examine VB I-VP O
19 111 114 10683478 the DT B-NP O
20 115 127 10683478 differential JJ I-NP O
21 128 136 10683478 response NN I-NP O
22 137 139 10683478 to TO B-PP O
23 140 141 10683478 a DT B-NP O
24 142 146 10683478 drug NN I-NP O
25 147 156 10683478 challenge NN I-NP O
26 157 162 10683478 under IN B-PP O
27 163 169 10683478 varied JJ B-NP O
28 170 182 10683478 experimental JJ I-NP O
29 183 187 10683478 test NN I-NP O
30 188 198 10683478 conditions NNS I-NP O
31 199 208 10683478 routinely RB B-VP O
32 209 217 10683478 employed VBN I-VP O
33 218 220 10683478 to TO B-VP O
34 221 226 10683478 study VB I-VP O
35 227 231 10683478 drug NN B-NP O
36 231 232 10683478 - HYPH B-NP O
37 232 239 10683478 induced VBN I-NP O
38 240 250 10683478 behavioral NN I-NP O
39 251 254 10683478 and CC I-NP O
40 255 273 10683478 neurophysiological JJ I-NP O
41 274 283 10683478 responses NNS I-NP O
42 284 286 10683478 in IN B-PP O
43 287 294 10683478 rodents NNS B-NP O
44 294 295 10683478 . . O O

1 296 307 10683478 Apomorphine NN B-NP B-Chemical
2 307 308 10683478 , , O O
3 309 310 10683478 a DT B-NP O
4 311 323 10683478 nonselective JJ I-NP O
5 324 332 10683478 dopamine NN I-NP B-Chemical
6 333 340 10683478 agonist NN I-NP I-Chemical
7 340 341 10683478 , , O O
8 342 345 10683478 was VBD B-VP O
9 346 354 10683478 selected VBN I-VP O
10 355 358 10683478 due JJ B-ADJP O
11 359 361 10683478 to TO B-PP O
12 362 365 10683478 its PRP$ B-NP O
13 366 374 10683478 biphasic JJ I-NP O
14 375 385 10683478 behavioral JJ I-NP O
15 386 393 10683478 effects NNS I-NP O
16 393 394 10683478 , , O O
17 395 398 10683478 its PRP$ B-NP O
18 399 406 10683478 ability NN I-NP O
19 407 409 10683478 to TO B-VP O
20 410 416 10683478 induce VB I-VP O
21 417 428 10683478 hypothermia NN B-NP B-Disease
22 428 429 10683478 , , O O
23 430 433 10683478 and CC O O
24 434 436 10683478 to TO B-VP O
25 437 444 10683478 produce VB I-VP O
26 445 453 10683478 distinct JJ B-NP O
27 454 461 10683478 changes NNS I-NP O
28 462 464 10683478 to TO B-PP O
29 465 473 10683478 dopamine NN B-NP B-Chemical
30 474 482 10683478 turnover NN I-NP O
31 483 485 10683478 in IN B-PP O
32 486 489 10683478 the DT B-NP O
33 490 496 10683478 rodent NN I-NP O
34 497 502 10683478 brain NN I-NP O
35 502 503 10683478 . . O O

1 504 508 10683478 From IN B-PP O
2 509 513 10683478 such JJ B-NP O
3 514 525 10683478 experiments NNS I-NP O
4 526 531 10683478 there EX B-NP O
5 532 534 10683478 is VBZ B-VP O
6 535 543 10683478 evidence NN B-NP O
7 544 548 10683478 that IN B-SBAR O
8 549 565 10683478 characterization NN B-NP O
9 566 569 10683478 and CC I-NP O
10 570 579 10683478 detection NN I-NP O
11 580 582 10683478 of IN B-PP O
12 583 594 10683478 apomorphine NN B-NP B-Chemical
13 594 595 10683478 - HYPH B-NP O
14 595 602 10683478 induced VBN I-NP O
15 603 611 10683478 activity NN I-NP O
16 612 614 10683478 in IN B-PP O
17 615 622 10683478 rodents NNS B-NP O
18 623 633 10683478 critically RB B-ADVP O
19 634 641 10683478 depends VBZ B-VP O
20 642 646 10683478 upon IN B-PP O
21 647 650 10683478 the DT B-NP O
22 651 655 10683478 test NN I-NP O
23 656 666 10683478 conditions NNS I-NP O
24 667 675 10683478 employed VBN B-VP O
25 675 676 10683478 . . O O

1 677 679 10683478 In IN B-PP O
2 680 684 10683478 rats NNS B-NP O
3 684 685 10683478 , , O O
4 686 695 10683478 detection NN B-NP O
5 696 698 10683478 of IN B-PP O
6 699 710 10683478 apomorphine NN B-NP B-Chemical
7 710 711 10683478 - HYPH B-NP O
8 711 718 10683478 induced VBN I-NP O
9 719 732 10683478 hyperactivity NN I-NP B-Disease
10 733 736 10683478 was VBD B-VP O
11 737 748 10683478 facilitated VBN I-VP O
12 749 751 10683478 by IN B-PP O
13 752 753 10683478 a DT B-NP O
14 754 760 10683478 period NN I-NP O
15 761 763 10683478 of IN B-PP O
16 764 779 10683478 acclimatization NN B-NP O
17 780 782 10683478 to TO B-PP O
18 783 786 10683478 the DT B-NP O
19 787 791 10683478 test NN I-NP O
20 792 802 10683478 conditions NNS I-NP O
21 802 803 10683478 . . O O

1 804 812 10683478 Moreover RB B-ADVP O
2 812 813 10683478 , , O O
3 814 818 10683478 test NN B-NP O
4 819 829 10683478 conditions NNS I-NP O
5 830 833 10683478 can MD B-VP O
6 834 840 10683478 impact VB I-VP O
7 841 845 10683478 upon IN B-PP O
8 846 851 10683478 other JJ B-NP O
9 852 865 10683478 physiological JJ I-NP O
10 866 875 10683478 responses NNS I-NP O
11 876 878 10683478 to TO B-PP O
12 879 890 10683478 apomorphine NN B-NP B-Chemical
13 891 895 10683478 such JJ B-PP O
14 896 898 10683478 as IN I-PP O
15 899 903 10683478 drug NN B-NP O
16 903 904 10683478 - HYPH B-NP O
17 904 911 10683478 induced VBN I-NP O
18 912 923 10683478 hypothermia NN I-NP B-Disease
19 923 924 10683478 . . O O

1 925 927 10683478 In IN B-PP O
2 928 932 10683478 mice NNS B-NP O
3 932 933 10683478 , , O O
4 934 945 10683478 apomorphine NN B-NP B-Chemical
5 946 954 10683478 produced VBD B-VP O
6 955 968 10683478 qualitatively RB B-NP O
7 969 978 10683478 different JJ I-NP O
8 979 988 10683478 responses NNS I-NP O
9 989 994 10683478 under IN B-PP O
10 995 1000 10683478 novel JJ B-NP O
11 1001 1011 10683478 conditions NNS I-NP O
12 1012 1016 10683478 when WRB B-ADVP O
13 1017 1025 10683478 compared VBN B-PP O
14 1026 1028 10683478 to TO B-PP O
15 1029 1034 10683478 those DT B-NP O
16 1035 1044 10683478 behaviors NNS I-NP O
17 1045 1053 10683478 elicited VBN B-VP O
18 1054 1056 10683478 in IN B-PP O
19 1057 1060 10683478 the DT B-NP O
20 1061 1065 10683478 home NN I-NP O
21 1066 1070 10683478 test NN I-NP O
22 1071 1075 10683478 cage NN I-NP O
23 1075 1076 10683478 . . O O

1 1077 1081 10683478 Drug NN B-NP O
2 1081 1082 10683478 - HYPH O O
3 1082 1089 10683478 induced VBN B-NP O
4 1090 1095 10683478 gross JJ I-NP O
5 1096 1104 10683478 activity NN I-NP O
6 1105 1111 10683478 counts NNS I-NP O
7 1112 1116 10683478 were VBD B-VP O
8 1117 1126 10683478 increased VBN I-VP O
9 1127 1129 10683478 in IN B-PP O
10 1130 1133 10683478 the DT B-NP O
11 1134 1139 10683478 novel JJ I-NP O
12 1140 1151 10683478 exploratory NN I-NP O
13 1152 1155 10683478 box NN I-NP O
14 1156 1160 10683478 only RB B-ADVP O
15 1160 1161 10683478 , , O O
16 1162 1167 10683478 while IN B-SBAR O
17 1168 1176 10683478 measures NNS B-NP O
18 1177 1179 10683478 of IN B-PP O
19 1180 1191 10683478 stereotypic JJ B-NP O
20 1192 1200 10683478 behavior NN I-NP O
21 1201 1205 10683478 were VBD B-VP O
22 1206 1213 10683478 similar JJ B-ADJP O
23 1214 1216 10683478 in IN B-PP O
24 1217 1221 10683478 both DT B-NP O
25 1221 1222 10683478 . . O O

1 1223 1225 10683478 By IN B-PP O
2 1226 1234 10683478 contrast NN B-NP O
3 1234 1235 10683478 , , O O
4 1236 1247 10683478 apomorphine NN B-NP B-Chemical
5 1247 1248 10683478 - HYPH B-VP O
6 1248 1255 10683478 induced VBN B-NP O
7 1256 1266 10683478 locomotion NN I-NP O
8 1267 1270 10683478 was VBD B-VP O
9 1271 1275 10683478 more RBR B-ADJP O
10 1276 1285 10683478 prominent JJ I-ADJP O
11 1286 1288 10683478 in IN B-PP O
12 1289 1292 10683478 the DT B-NP O
13 1293 1298 10683478 novel JJ I-NP O
14 1299 1310 10683478 exploratory NN I-NP O
15 1311 1314 10683478 box NN I-NP O
16 1314 1315 10683478 . . O O

1 1316 1324 10683478 Dopamine NN B-NP B-Chemical
2 1325 1333 10683478 turnover NN I-NP O
3 1334 1340 10683478 ratios NNS I-NP O
4 1341 1342 10683478 ( ( O O
5 1342 1347 10683478 DOPAC NN B-NP B-Chemical
6 1347 1348 10683478 : : O O
7 1348 1350 10683478 DA NN B-NP B-Chemical
8 1351 1354 10683478 and CC I-NP O
9 1355 1358 10683478 HVA NN I-NP B-Chemical
10 1358 1359 10683478 : : O O
11 1359 1361 10683478 DA NN B-NP B-Chemical
12 1361 1362 10683478 ) ) O O
13 1363 1367 10683478 were VBD B-VP O
14 1368 1373 10683478 found VBN I-VP O
15 1374 1376 10683478 to TO I-VP O
16 1377 1379 10683478 be VB I-VP O
17 1380 1385 10683478 lower JJR B-ADJP O
18 1386 1388 10683478 in IN B-PP O
19 1389 1394 10683478 those DT B-NP O
20 1395 1402 10683478 animals NNS I-NP O
21 1403 1410 10683478 exposed VBN B-VP O
22 1411 1413 10683478 to TO B-PP O
23 1414 1417 10683478 the DT B-NP O
24 1418 1429 10683478 exploratory NN I-NP O
25 1430 1433 10683478 box NN I-NP O
26 1434 1438 10683478 when WRB B-ADVP O
27 1439 1447 10683478 compared VBN B-VP O
28 1448 1450 10683478 to TO B-PP O
29 1451 1456 10683478 their PRP$ B-NP O
30 1457 1461 10683478 home NN I-NP O
31 1462 1466 10683478 cage NN I-NP O
32 1467 1479 10683478 counterparts NNS I-NP O
33 1479 1480 10683478 . . O O

1 1481 1488 10683478 However RB B-ADVP O
2 1488 1489 10683478 , , O O
3 1490 1501 10683478 apomorphine NN B-NP B-Chemical
4 1501 1502 10683478 - HYPH B-NP O
5 1502 1509 10683478 induced VBN I-NP O
6 1510 1520 10683478 reductions NNS I-NP O
7 1521 1523 10683478 in IN B-PP O
8 1524 1532 10683478 striatal JJ B-NP O
9 1533 1541 10683478 dopamine NN I-NP B-Chemical
10 1542 1550 10683478 turnover NN I-NP O
11 1551 1555 10683478 were VBD B-VP O
12 1556 1564 10683478 detected VBN I-VP O
13 1565 1567 10683478 in IN B-PP O
14 1568 1572 10683478 both CC B-NP O
15 1573 1578 10683478 novel JJ I-NP O
16 1579 1582 10683478 and CC I-NP O
17 1583 1587 10683478 home NN I-NP O
18 1588 1592 10683478 cage NN I-NP O
19 1593 1605 10683478 environments NNS I-NP O
20 1605 1606 10683478 . . O O

1 1607 1610 10683478 The DT B-NP O
2 1611 1623 10683478 implications NNS I-NP O
3 1624 1626 10683478 of IN B-PP O
4 1627 1632 10683478 these DT B-NP O
5 1633 1641 10683478 findings NNS I-NP O
6 1642 1645 10683478 are VBP B-VP O
7 1646 1655 10683478 discussed VBN I-VP O
8 1656 1660 10683478 with IN B-PP O
9 1661 1671 10683478 particular JJ B-NP O
10 1672 1680 10683478 emphasis NN I-NP O
11 1681 1685 10683478 upon IN B-PP O
12 1686 1696 10683478 conducting VBG B-VP O
13 1697 1718 10683478 psychopharmacological JJ B-NP O
14 1719 1728 10683478 challenge NN I-NP O
15 1729 1734 10683478 tests NNS I-NP O
16 1735 1737 10683478 in IN B-PP O
17 1738 1745 10683478 rodents NNS B-NP O
18 1745 1746 10683478 . . O O

1 0 0 18329269 -DOCSTART- -X- -X- O

1 0 9 18329269 Synthesis NN B-NP O
2 10 12 18329269 of IN B-PP O
3 13 14 18329269 N NN B-NP B-Chemical
4 14 15 18329269 - HYPH B-NP I-Chemical
5 15 26 18329269 pyrimidinyl NN I-NP I-Chemical
6 26 27 18329269 - HYPH B-NP I-Chemical
7 27 28 18329269 2 CD I-NP I-Chemical
8 28 29 18329269 - HYPH I-NP I-Chemical
9 29 46 18329269 phenoxyacetamides NNS I-NP I-Chemical
10 47 49 18329269 as IN B-PP O
11 50 59 18329269 adenosine NN B-NP B-Chemical
12 60 63 18329269 A2A NN I-NP O
13 64 72 18329269 receptor NN I-NP O
14 73 84 18329269 antagonists NNS I-NP O
15 84 85 18329269 . . O O
16 86 87 18329269 A DT B-NP O
17 88 94 18329269 series NN I-NP O
18 95 97 18329269 of IN B-PP O
19 98 99 18329269 N NN B-NP B-Chemical
20 99 100 18329269 - HYPH B-NP I-Chemical
21 100 111 18329269 pyrimidinyl NN I-NP I-Chemical
22 111 112 18329269 - HYPH B-NP I-Chemical
23 112 113 18329269 2 CD I-NP I-Chemical
24 113 114 18329269 - HYPH I-NP I-Chemical
25 114 130 18329269 phenoxyacetamide NN I-NP I-Chemical
26 131 140 18329269 adenosine NN I-NP B-Chemical
27 141 146 18329269 A(2A) NN I-NP O
28 147 158 18329269 antagonists NNS I-NP O
29 159 161 18329269 is VBZ B-VP O
30 162 171 18329269 described VBN I-VP O
31 171 172 18329269 . . O O

1 173 176 18329269 SAR NN B-NP O
2 177 184 18329269 studies NNS I-NP O
3 185 188 18329269 led VBD B-VP O
4 189 191 18329269 to TO B-PP O
5 192 200 18329269 compound NN B-NP O
6 201 203 18329269 14 CD I-NP O
7 204 208 18329269 with IN B-PP O
8 209 218 18329269 excellent JJ B-NP O
9 219 226 18329269 potency NN I-NP O
10 227 228 18329269 ( ( O O
11 228 232 18329269 K(i) NN B-NP O
12 233 234 18329269 = SYM B-VP O
13 235 238 18329269 0.4 CD B-NP O
14 239 241 18329269 nM NN I-NP O
15 241 242 18329269 ) ) O O
16 242 243 18329269 , , O O
17 244 255 18329269 selectivity NN B-NP O
18 256 257 18329269 ( ( O O
19 257 261 18329269 A(1) NN B-NP O
20 261 262 18329269 / SYM B-NP O
21 262 267 18329269 A(2A) NN I-NP O
22 268 269 18329269 > SYM O O
23 270 273 18329269 100 CD B-NP O
24 273 274 18329269 ) ) O O
25 274 275 18329269 , , O O
26 276 279 18329269 and CC O O
27 280 288 18329269 efficacy NN B-NP O
28 289 290 18329269 ( ( O O
29 290 293 18329269 MED NN B-NP O
30 294 296 18329269 10 CD I-NP O
31 297 299 18329269 mg NN I-NP O
32 299 300 18329269 / SYM B-NP O
33 300 302 18329269 kg NN I-NP O
34 303 306 18329269 p.o NN I-NP O
35 306 307 18329269 . . O O
36 307 308 18329269 ) ) O O
37 309 311 18329269 in IN B-PP O
38 312 315 18329269 the DT B-NP O
39 316 319 18329269 rat NN I-NP O
40 320 331 18329269 haloperidol NN I-NP B-Chemical
41 331 332 18329269 - HYPH B-NP O
42 332 339 18329269 induced VBN I-NP O
43 340 349 18329269 catalepsy NN I-NP B-Disease
44 350 355 18329269 model NN I-NP O
45 356 359 18329269 for IN B-PP O
46 360 371 18329269 Parkinson's NNP B-NP B-Disease
47 372 379 18329269 disease NN I-NP I-Disease
48 379 380 18329269 . . O O

1 0 0 21029050 -DOCSTART- -X- -X- O

1 0 21 21029050 Butyrylcholinesterase NN B-NP O
2 22 26 21029050 gene NN I-NP O
3 27 36 21029050 mutations NNS I-NP O
4 37 39 21029050 in IN B-PP O
5 40 48 21029050 patients NNS B-NP O
6 49 53 21029050 with IN B-PP O
7 54 63 21029050 prolonged JJ B-NP O
8 64 69 21029050 apnea NN I-NP B-Disease
9 70 75 21029050 after IN B-PP O
10 76 91 21029050 succinylcholine NN B-NP B-Chemical
11 92 95 21029050 for IN B-PP O
12 96 113 21029050 electroconvulsive JJ B-NP O
13 114 121 21029050 therapy NN I-NP O
14 121 122 21029050 . . I-NP O
15 123 133 21029050 BACKGROUND NN I-NP O
16 133 134 21029050 : : O O
17 135 143 21029050 patients NNS B-NP O
18 144 154 21029050 undergoing VBG B-VP O
19 155 172 21029050 electroconvulsive JJ B-NP O
20 173 180 21029050 therapy NN I-NP O
21 181 182 21029050 ( ( O O
22 182 185 21029050 ECT NN B-NP O
23 185 186 21029050 ) ) O O
24 187 192 21029050 often RB B-ADVP O
25 193 200 21029050 receive VBP B-VP O
26 201 216 21029050 succinylcholine NN B-NP B-Chemical
27 217 219 21029050 as IN B-PP O
28 220 224 21029050 part NN B-NP O
29 225 227 21029050 of IN B-PP O
30 228 231 21029050 the DT B-NP O
31 232 242 21029050 anesthetic JJ I-NP O
32 243 252 21029050 procedure NN I-NP O
33 252 253 21029050 . . O O

1 254 257 21029050 The DT B-NP O
2 258 266 21029050 duration NN I-NP O
3 267 269 21029050 of IN B-PP O
4 270 276 21029050 action NN B-NP O
5 277 280 21029050 may MD B-VP O
6 281 283 21029050 be VB I-VP O
7 284 293 21029050 prolonged VBN I-VP O
8 294 296 21029050 in IN B-PP O
9 297 305 21029050 patients NNS B-NP O
10 306 310 21029050 with IN B-PP O
11 311 318 21029050 genetic JJ B-NP O
12 319 327 21029050 variants NNS I-NP O
13 328 330 21029050 of IN B-PP O
14 331 334 21029050 the DT B-NP O
15 335 356 21029050 butyrylcholinesterase NN I-NP O
16 357 363 21029050 enzyme NN I-NP O
17 364 365 21029050 ( ( O O
18 365 369 21029050 BChE NN B-NP O
19 369 370 21029050 ) ) O O
20 370 371 21029050 , , O O
21 372 375 21029050 the DT B-NP O
22 376 380 21029050 most RBS I-NP O
23 381 387 21029050 common JJ I-NP O
24 388 393 21029050 being VBG B-VP O
25 394 397 21029050 the DT B-NP O
26 398 399 21029050 K NN I-NP O
27 399 400 21029050 - HYPH B-ADJP O
28 401 404 21029050 and CC O O
29 405 408 21029050 the DT B-NP O
30 409 410 21029050 A NN I-NP O
31 410 411 21029050 - HYPH I-NP O
32 411 419 21029050 variants NNS I-NP O
33 419 420 21029050 . . O O

1 421 424 21029050 The DT B-NP O
2 425 428 21029050 aim NN I-NP O
3 429 431 21029050 of IN B-PP O
4 432 435 21029050 the DT B-NP O
5 436 441 21029050 study NN I-NP O
6 442 445 21029050 was VBD B-VP O
7 446 448 21029050 to TO B-VP O
8 449 455 21029050 assess VB I-VP O
9 456 459 21029050 the DT B-NP O
10 460 468 21029050 clinical JJ I-NP O
11 469 481 21029050 significance NN I-NP O
12 482 484 21029050 of IN B-PP O
13 485 492 21029050 genetic JJ B-NP O
14 493 501 21029050 variants NNS I-NP O
15 502 504 21029050 in IN B-PP O
16 505 526 21029050 butyrylcholinesterase NN B-NP O
17 527 531 21029050 gene NN I-NP O
18 532 533 21029050 ( ( O O
19 533 537 21029050 BCHE NN B-NP O
20 537 538 21029050 ) ) O O
21 539 541 21029050 in IN B-PP O
22 542 550 21029050 patients NNS B-NP O
23 551 555 21029050 with IN B-PP O
24 556 557 21029050 a DT B-NP O
25 558 567 21029050 suspected VBN I-NP O
26 568 577 21029050 prolonged VBN I-NP O
27 578 586 21029050 duration NN I-NP O
28 587 589 21029050 of IN B-PP O
29 590 596 21029050 action NN B-NP O
30 597 599 21029050 of IN B-PP O
31 600 615 21029050 succinylcholine NN B-NP B-Chemical
32 616 621 21029050 after IN B-PP O
33 622 625 21029050 ECT NN B-NP O
34 625 626 21029050 . . O O

1 627 634 21029050 METHODS NNS B-NP O
2 634 635 21029050 : : O O
3 636 637 21029050 a DT B-NP O
4 638 643 21029050 total NN I-NP O
5 644 646 21029050 of IN B-PP O
6 647 649 21029050 13 CD B-NP O
7 650 658 21029050 patients NNS I-NP O
8 659 663 21029050 were VBD B-VP O
9 664 672 21029050 referred VBN I-VP O
10 673 675 21029050 to TO B-PP O
11 676 679 21029050 the DT B-NP O
12 680 686 21029050 Danish NNP I-NP O
13 687 701 21029050 Cholinesterase NNP I-NP O
14 702 710 21029050 Research NNP I-NP O
15 711 715 21029050 Unit NNP I-NP O
16 716 721 21029050 after IN B-PP O
17 722 725 21029050 ECT NN B-NP O
18 726 732 21029050 during IN B-PP O
19 733 735 21029050 38 CD B-NP O
20 736 742 21029050 months NNS I-NP O
21 742 743 21029050 . . O O

1 744 746 21029050 We PRP B-NP O
2 747 757 21029050 determined VBD B-VP O
3 758 761 21029050 the DT B-NP O
4 762 766 21029050 BChE NN I-NP O
5 767 775 21029050 activity NN I-NP O
6 776 779 21029050 and CC O O
7 780 783 21029050 the DT B-NP O
8 784 788 21029050 BCHE NN I-NP O
9 789 797 21029050 genotype NN I-NP O
10 798 803 21029050 using VBG B-VP O
11 804 813 21029050 molecular JJ B-NP O
12 814 821 21029050 genetic JJ I-NP O
13 822 829 21029050 methods NNS I-NP O
14 829 830 21029050 , , O O
15 831 834 21029050 the DT B-NP O
16 835 843 21029050 duration NN I-NP O
17 844 846 21029050 of IN B-PP O
18 847 852 21029050 apnea NN B-NP B-Disease
19 852 853 21029050 , , O O
20 854 858 21029050 time NN B-NP O
21 859 861 21029050 to TO B-PP O
22 862 872 21029050 sufficient JJ B-NP O
23 873 884 21029050 spontaneous JJ I-NP O
24 885 896 21029050 ventilation NN I-NP O
25 897 900 21029050 and CC O O
26 901 908 21029050 whether IN B-SBAR O
27 909 922 21029050 neuromuscular JJ B-NP O
28 923 933 21029050 monitoring NN I-NP O
29 934 937 21029050 was VBD B-VP O
30 938 942 21029050 used VBN I-VP O
31 942 943 21029050 . . O O

1 944 947 21029050 The DT B-NP O
2 948 956 21029050 duration NN I-NP O
3 957 959 21029050 of IN B-PP O
4 960 965 21029050 apnea NN B-NP B-Disease
5 966 969 21029050 was VBD B-VP O
6 970 978 21029050 compared VBN I-VP O
7 979 983 21029050 with IN B-PP O
8 984 993 21029050 published VBN B-NP O
9 994 998 21029050 data NNS I-NP O
10 999 1001 21029050 on IN B-PP O
11 1002 1008 21029050 normal JJ B-NP O
12 1009 1017 21029050 subjects NNS I-NP O
13 1017 1018 21029050 . . O O

1 1019 1026 21029050 RESULTS NNS B-NP O
2 1026 1027 21029050 : : O O
3 1028 1030 21029050 in IN B-PP O
4 1031 1033 21029050 11 CD B-NP O
5 1034 1042 21029050 patients NNS I-NP O
6 1042 1043 21029050 , , O O
7 1044 1053 21029050 mutations NNS B-NP O
8 1054 1058 21029050 were VBD B-VP O
9 1059 1064 21029050 found VBN I-VP O
10 1065 1067 21029050 in IN B-PP O
11 1068 1071 21029050 the DT B-NP O
12 1072 1076 21029050 BCHE NN I-NP O
13 1077 1081 21029050 gene NN I-NP O
14 1081 1082 21029050 , , O O
15 1083 1086 21029050 the DT B-NP O
16 1087 1088 21029050 K NN I-NP O
17 1088 1089 21029050 - HYPH B-NP O
18 1089 1096 21029050 variant NN I-NP O
19 1097 1102 21029050 being VBG B-VP O
20 1103 1106 21029050 the DT B-NP O
21 1107 1111 21029050 most RBS I-NP O
22 1112 1120 21029050 frequent JJ I-NP O
23 1120 1121 21029050 . . O O

1 1122 1125 21029050 The DT B-NP O
2 1126 1134 21029050 duration NN I-NP O
3 1135 1137 21029050 of IN B-PP O
4 1138 1143 21029050 apnea NN B-NP B-Disease
5 1144 1147 21029050 was VBD B-VP O
6 1148 1149 21029050 5 CD B-NP O
7 1149 1150 21029050 - HYPH I-NP O
8 1150 1152 21029050 15 CD I-NP O
9 1153 1156 21029050 min NN I-NP O
10 1157 1165 21029050 compared VBN B-PP O
11 1166 1170 21029050 with IN B-PP O
12 1171 1172 21029050 3 CD B-NP O
13 1172 1173 21029050 - HYPH I-NP O
14 1173 1176 21029050 5.3 CD I-NP O
15 1177 1180 21029050 min NN I-NP O
16 1181 1185 21029050 from IN B-PP O
17 1186 1189 21029050 the DT B-NP O
18 1190 1200 21029050 literature NN I-NP O
19 1200 1201 21029050 . . O O

1 1202 1208 21029050 Severe JJ B-NP O
2 1209 1217 21029050 distress NN I-NP O
3 1218 1221 21029050 was VBD B-VP O
4 1222 1227 21029050 noted VBN I-VP O
5 1228 1230 21029050 in IN B-PP O
6 1231 1234 21029050 the DT B-NP O
7 1235 1243 21029050 recovery NN I-NP O
8 1244 1249 21029050 phase NN I-NP O
9 1250 1252 21029050 in IN B-PP O
10 1253 1256 21029050 two CD B-NP O
11 1257 1265 21029050 patients NNS I-NP O
12 1265 1266 21029050 . . O O

1 1267 1280 21029050 Neuromuscular JJ B-NP O
2 1281 1291 21029050 monitoring NN I-NP O
3 1292 1295 21029050 was VBD B-VP O
4 1296 1300 21029050 used VBN I-VP O
5 1301 1303 21029050 in IN B-PP O
6 1304 1307 21029050 two CD B-NP O
7 1308 1316 21029050 patients NNS I-NP O
8 1316 1317 21029050 . . O O

1 1318 1328 21029050 CONCLUSION NN B-NP O
2 1328 1329 21029050 : : O O
3 1330 1336 21029050 eleven CD B-NP O
4 1337 1339 21029050 of IN B-PP O
5 1340 1342 21029050 13 CD B-NP O
6 1343 1351 21029050 patients NNS I-NP O
7 1352 1356 21029050 with IN B-PP O
8 1357 1358 21029050 a DT B-NP O
9 1359 1368 21029050 prolonged JJ I-NP O
10 1369 1377 21029050 duration NN I-NP O
11 1378 1380 21029050 of IN B-PP O
12 1381 1387 21029050 action NN B-NP O
13 1388 1390 21029050 of IN B-PP O
14 1391 1406 21029050 succinylcholine NN B-NP B-Chemical
15 1407 1410 21029050 had VBD B-VP O
16 1411 1420 21029050 mutations NNS B-NP O
17 1421 1423 21029050 in IN B-PP O
18 1424 1428 21029050 BCHE NN B-NP O
19 1428 1429 21029050 , , O O
20 1430 1440 21029050 indicating VBG B-VP O
21 1441 1445 21029050 that IN B-SBAR O
22 1446 1450 21029050 this DT B-NP O
23 1451 1453 21029050 is VBZ B-VP O
24 1454 1457 21029050 the DT B-NP O
25 1458 1466 21029050 possible JJ I-NP O
26 1467 1473 21029050 reason NN I-NP O
27 1474 1477 21029050 for IN B-PP O
28 1478 1479 21029050 a DT B-NP O
29 1480 1489 21029050 prolonged JJ I-NP O
30 1490 1496 21029050 period NN I-NP O
31 1497 1499 21029050 of IN B-PP O
32 1500 1505 21029050 apnea NN B-NP B-Disease
33 1505 1506 21029050 . . O O

1 1507 1509 21029050 We PRP B-NP O
2 1510 1519 21029050 recommend VBP B-VP O
3 1520 1529 21029050 objective JJ B-NP O
4 1530 1543 21029050 neuromuscular JJ I-NP O
5 1544 1554 21029050 monitoring NN I-NP O
6 1555 1561 21029050 during IN B-PP O
7 1562 1565 21029050 the DT B-NP O
8 1566 1571 21029050 first JJ I-NP O
9 1572 1575 21029050 ECT NN I-NP O
10 1575 1576 21029050 . . O O

1 0 0 11532387 -DOCSTART- -X- -X- O

1 0 10 11532387 Withdrawal NN B-NP B-Disease
2 10 11 11532387 - HYPH I-NP I-Disease
3 11 19 11532387 emergent JJ I-NP I-Disease
4 20 26 11532387 rabbit NN I-NP I-Disease
5 27 35 11532387 syndrome NN I-NP I-Disease
6 36 42 11532387 during IN B-PP O
7 43 47 11532387 dose NN B-NP O
8 48 57 11532387 reduction NN I-NP O
9 58 60 11532387 of IN B-PP O
10 61 72 11532387 risperidone NN B-NP B-Chemical
11 72 73 11532387 . . O O
12 74 80 11532387 Rabbit NN B-NP B-Disease
13 81 89 11532387 syndrome NN I-NP I-Disease
14 90 91 11532387 ( ( O O
15 91 93 11532387 RS NN B-NP B-Disease
16 93 94 11532387 ) ) O O
17 95 97 11532387 is VBZ B-VP O
18 98 99 11532387 a DT B-NP O
19 100 104 11532387 rare JJ I-NP O
20 105 119 11532387 extrapyramidal JJ I-NP O
21 120 124 11532387 side NN I-NP O
22 125 131 11532387 effect NN I-NP O
23 132 138 11532387 caused VBN B-VP O
24 139 141 11532387 by IN B-PP O
25 142 151 11532387 prolonged JJ B-NP O
26 152 163 11532387 neuroleptic JJ I-NP O
27 164 174 11532387 medication NN I-NP O
28 174 175 11532387 . . O O

1 176 180 11532387 Here RB B-ADVP O
2 181 183 11532387 we PRP B-NP O
3 184 191 11532387 present VBP B-VP O
4 192 193 11532387 a DT B-NP O
5 194 198 11532387 case NN I-NP O
6 199 201 11532387 of IN B-PP O
7 202 212 11532387 withdrawal NN B-NP B-Disease
8 212 213 11532387 - HYPH B-NP I-Disease
9 213 221 11532387 emergent JJ I-NP I-Disease
10 222 224 11532387 RS NN I-NP I-Disease
11 224 225 11532387 , , O O
12 226 231 11532387 which WDT B-NP O
13 232 234 11532387 is VBZ B-VP O
14 235 238 11532387 the DT B-NP O
15 239 244 11532387 first JJ I-NP O
16 245 247 11532387 of IN B-PP O
17 248 251 11532387 its PRP$ B-NP O
18 252 256 11532387 kind NN I-NP O
19 257 259 11532387 to TO B-VP O
20 260 262 11532387 be VB I-VP O
21 263 271 11532387 reported VBN I-VP O
22 271 272 11532387 . . O O

1 273 276 11532387 The DT B-NP O
2 277 284 11532387 patient NN I-NP O
3 285 294 11532387 developed VBD B-VP O
4 295 297 11532387 RS NN B-NP B-Disease
5 298 304 11532387 during IN B-PP O
6 305 309 11532387 dose NN B-NP O
7 310 319 11532387 reduction NN I-NP O
8 320 322 11532387 of IN B-PP O
9 323 334 11532387 risperidone NN B-NP B-Chemical
10 334 335 11532387 . . O O

1 336 339 11532387 The DT B-NP O
2 340 347 11532387 symptom NN I-NP O
3 348 351 11532387 was VBD B-VP O
4 352 359 11532387 treated VBN I-VP O
5 360 372 11532387 successfully RB B-ADVP O
6 373 377 11532387 with IN B-PP O
7 378 393 11532387 trihexyphenidyl NN B-NP B-Chemical
8 394 409 11532387 anticholinergic JJ I-NP O
9 410 417 11532387 therapy NN I-NP O
10 417 418 11532387 . . O O

1 419 422 11532387 The DT B-NP O
2 423 433 11532387 underlying VBG I-NP O
3 434 443 11532387 mechanism NN I-NP O
4 444 446 11532387 of IN B-PP O
5 447 457 11532387 withdrawal NN B-NP B-Disease
6 457 458 11532387 - HYPH B-NP I-Disease
7 458 466 11532387 emergent JJ I-NP I-Disease
8 467 469 11532387 RS NN I-NP I-Disease
9 470 472 11532387 in IN B-PP O
10 473 476 11532387 the DT B-NP O
11 477 484 11532387 present JJ I-NP O
12 485 489 11532387 case NN I-NP O
13 490 493 11532387 may MD B-VP O
14 494 498 11532387 have VB I-VP O
15 499 503 11532387 been VBN I-VP O
16 504 511 11532387 related VBN I-VP O
17 512 514 11532387 to TO B-PP O
18 515 518 11532387 the DT B-NP O
19 519 534 11532387 pharmacological JJ I-NP O
20 535 542 11532387 profile NN I-NP O
21 543 545 11532387 of IN B-PP O
22 546 557 11532387 risperidone NN B-NP B-Chemical
23 557 558 11532387 , , O O
24 559 560 11532387 a DT B-NP O
25 561 570 11532387 serotonin NN I-NP B-Chemical
26 570 571 11532387 - HYPH I-NP O
27 571 579 11532387 dopamine NN I-NP B-Chemical
28 580 590 11532387 antagonist NN I-NP O
29 590 591 11532387 , , O O
30 592 602 11532387 suggesting VBG B-VP O
31 603 606 11532387 the DT B-NP O
32 607 623 11532387 pathophysiologic JJ I-NP O
33 624 633 11532387 influence NN I-NP O
34 634 636 11532387 of IN B-PP O
35 637 640 11532387 the DT B-NP O
36 641 650 11532387 serotonin NN I-NP B-Chemical
37 651 657 11532387 system NN I-NP O
38 658 660 11532387 in IN B-PP O
39 661 664 11532387 the DT B-NP O
40 665 676 11532387 development NN I-NP O
41 677 679 11532387 of IN B-PP O
42 680 682 11532387 RS NN B-NP B-Disease
43 682 683 11532387 . . O O

1 0 0 9754849 -DOCSTART- -X- -X- O

1 0 14 9754849 Choreoathetoid JJ B-NP B-Disease
2 15 24 9754849 movements NNS I-NP I-Disease
3 25 35 9754849 associated VBN B-VP O
4 36 40 9754849 with IN B-PP O
5 41 46 9754849 rapid JJ B-NP O
6 47 57 9754849 adjustment NN I-NP O
7 58 60 9754849 to TO B-PP O
8 61 70 9754849 methadone NN B-NP B-Chemical
9 70 71 9754849 . . O O
10 72 84 9754849 Choreatiform NNP B-NP B-Disease
11 85 98 9754849 hyperkinesias NNS I-NP I-Disease
12 99 102 9754849 are VBP B-VP O
13 103 108 9754849 known VBN I-VP O
14 109 111 9754849 to TO I-VP O
15 112 114 9754849 be VB I-VP O
16 115 125 9754849 occasional JJ B-NP O
17 126 134 9754849 movement NN I-NP B-Disease
18 135 148 9754849 abnormalities NNS I-NP I-Disease
19 149 155 9754849 during IN B-PP O
20 156 169 9754849 intoxications NNS B-NP O
21 170 174 9754849 with IN B-PP O
22 175 182 9754849 cocaine NN B-NP B-Chemical
23 183 186 9754849 but CC B-NP O
24 187 190 9754849 not RB I-NP O
25 191 198 9754849 opiates NNS B-NP O
26 198 199 9754849 . . O O

1 200 204 9754849 This DT B-NP O
2 205 207 9754849 is VBZ B-VP O
3 208 209 9754849 a DT B-NP O
4 210 214 9754849 case NN I-NP O
5 215 221 9754849 report NN I-NP O
6 222 224 9754849 of IN B-PP O
7 225 233 9754849 euphoria NN B-NP O
8 234 237 9754849 and CC O O
9 238 252 9754849 choreoathetoid JJ B-NP B-Disease
10 253 262 9754849 movements NNS I-NP I-Disease
11 263 267 9754849 both CC O O
12 268 279 9754849 transiently RB B-VP O
13 280 287 9754849 induced VBN I-VP O
14 288 290 9754849 by IN B-PP O
15 291 296 9754849 rapid JJ B-NP O
16 297 307 9754849 adjustment NN I-NP O
17 308 310 9754849 to TO B-PP O
18 311 314 9754849 the DT B-NP O
19 315 324 9754849 selective JJ I-NP O
20 325 327 9754849 mu SYM I-NP O
21 327 328 9754849 - HYPH I-NP O
22 328 334 9754849 opioid JJ I-NP O
23 335 343 9754849 receptor NN I-NP O
24 344 351 9754849 agonist NN I-NP O
25 352 361 9754849 methadone NN I-NP B-Chemical
26 362 364 9754849 in IN B-PP O
27 365 367 9754849 an DT B-NP O
28 368 377 9754849 inpatient NN I-NP O
29 378 388 9754849 previously RB B-NP O
30 389 396 9754849 abusing VBG I-NP O
31 397 404 9754849 heroine NN I-NP B-Chemical
32 405 408 9754849 and CC I-NP O
33 409 416 9754849 cocaine NN I-NP B-Chemical
34 416 417 9754849 . . O O

1 418 420 9754849 In IN B-PP O
2 421 429 9754849 addition NN B-NP O
3 429 430 9754849 , , O O
4 431 436 9754849 minor JJ B-NP O
5 437 440 9754849 EEG NN I-NP O
6 441 454 9754849 abnormalities NNS I-NP O
7 455 463 9754849 occurred VBD B-VP O
8 463 464 9754849 . . O O

1 465 473 9754849 Possible JJ B-NP O
2 474 484 9754849 underlying VBG I-NP O
3 485 500 9754849 neurobiological JJ I-NP O
4 501 510 9754849 phenomena NNS I-NP O
5 511 514 9754849 are VBP B-VP O
6 515 524 9754849 discussed VBN I-VP O
7 524 525 9754849 . . O O

1 0 0 1592014 -DOCSTART- -X- -X- O

1 0 8 1592014 Seizures NNS B-NP B-Disease
2 9 16 1592014 induced VBN B-VP O
3 17 19 1592014 by IN B-PP O
4 20 23 1592014 the DT B-NP O
5 24 31 1592014 cocaine NN I-NP B-Chemical
6 32 42 1592014 metabolite NN I-NP O
7 43 58 1592014 benzoylecgonine NN I-NP B-Chemical
8 59 61 1592014 in IN B-PP O
9 62 66 1592014 rats NNS B-NP O
10 66 67 1592014 . . O O
11 68 71 1592014 The DT B-NP O
12 72 76 1592014 half JJ I-NP O
13 76 77 1592014 - HYPH I-NP O
14 77 81 1592014 life NN I-NP O
15 82 83 1592014 ( ( O O
16 83 85 1592014 t1 NN B-NP O
17 85 86 1592014 / SYM O O
18 86 87 1592014 2 CD B-NP O
19 87 88 1592014 ) ) O O
20 89 91 1592014 of IN B-PP O
21 92 99 1592014 cocaine NN B-NP B-Chemical
22 100 102 1592014 is VBZ B-VP O
23 103 113 1592014 relatively RB B-ADJP O
24 114 119 1592014 short JJ I-ADJP O
25 119 120 1592014 , , O O
26 121 124 1592014 but CC O O
27 125 129 1592014 some DT B-NP O
28 130 132 1592014 of IN B-PP O
29 133 136 1592014 the DT B-NP O
30 137 149 1592014 consequences NNS I-NP O
31 150 152 1592014 of IN B-PP O
32 153 156 1592014 its PRP$ B-NP O
33 157 160 1592014 use NN I-NP O
34 160 161 1592014 , , O O
35 162 166 1592014 such JJ B-PP O
36 167 169 1592014 as IN I-PP O
37 170 178 1592014 seizures NNS B-NP B-Disease
38 179 182 1592014 and CC I-NP O
39 183 190 1592014 strokes NNS I-NP B-Disease
40 190 191 1592014 , , O O
41 192 195 1592014 can MD B-VP O
42 196 201 1592014 occur VB I-VP O
43 202 207 1592014 hours NNS B-NP O
44 208 213 1592014 after IN B-PP O
45 214 222 1592014 exposure NN B-NP O
46 222 223 1592014 . . O O

1 224 228 1592014 This DT B-NP O
2 229 232 1592014 led VBD B-VP O
3 233 235 1592014 us PRP B-NP O
4 236 238 1592014 to TO B-VP O
5 239 250 1592014 hypothesize VB I-VP O
6 251 255 1592014 that IN B-SBAR O
7 256 257 1592014 a DT B-NP O
8 258 268 1592014 metabolite NN I-NP O
9 269 271 1592014 of IN B-PP O
10 272 279 1592014 cocaine NN B-NP B-Chemical
11 280 283 1592014 may MD B-VP O
12 284 286 1592014 be VB I-VP O
13 287 298 1592014 responsible JJ B-ADJP O
14 299 302 1592014 for IN B-PP O
15 303 307 1592014 some DT B-NP O
16 308 310 1592014 of IN B-PP O
17 311 316 1592014 those DT B-NP O
18 317 324 1592014 delayed VBN I-NP O
19 325 333 1592014 sequelae NNS I-NP O
20 333 334 1592014 . . O O

1 335 337 1592014 We PRP B-NP O
2 338 347 1592014 evaluated VBD B-VP O
3 348 351 1592014 the DT B-NP O
4 352 361 1592014 potential NN I-NP O
5 362 364 1592014 of IN B-PP O
6 365 368 1592014 the DT B-NP O
7 369 374 1592014 major JJ I-NP O
8 375 385 1592014 metabolite NN I-NP O
9 386 388 1592014 of IN B-PP O
10 389 396 1592014 cocaine NN B-NP B-Chemical
11 396 397 1592014 , , O O
12 398 413 1592014 benzoylecgonine NN B-NP B-Chemical
13 414 415 1592014 ( ( O O
14 415 417 1592014 BE NN B-NP B-Chemical
15 417 418 1592014 ) ) O O
16 418 419 1592014 , , O O
17 420 422 1592014 to TO B-VP O
18 423 428 1592014 cause VB I-VP O
19 429 437 1592014 seizures NNS B-NP B-Disease
20 437 438 1592014 . . O O

1 439 442 1592014 Two CD B-NP O
2 443 451 1592014 separate JJ I-NP O
3 452 461 1592014 equimolar JJ I-NP O
4 462 467 1592014 doses NNS I-NP O
5 468 469 1592014 ( ( O O
6 469 472 1592014 0.2 CD B-NP O
7 473 476 1592014 and CC I-NP O
8 477 480 1592014 0.4 CD I-NP O
9 481 486 1592014 mumol NN I-NP O
10 486 487 1592014 ) ) O O
11 488 490 1592014 of IN B-PP O
12 491 497 1592014 either CC O O
13 498 505 1592014 cocaine NN B-NP B-Chemical
14 506 508 1592014 or CC I-NP O
15 509 511 1592014 BE NN I-NP B-Chemical
16 512 516 1592014 were VBD B-VP O
17 517 525 1592014 injected VBN I-VP O
18 526 539 1592014 ventricularly RB B-ADVP O
19 540 542 1592014 in IN B-PP O
20 543 557 1592014 unanesthetized JJ B-NP O
21 558 566 1592014 juvenile JJ I-NP O
22 567 571 1592014 rats NNS I-NP O
23 571 572 1592014 . . O O

1 573 580 1592014 Treated VBN B-NP O
2 581 585 1592014 rats NNS I-NP O
3 586 590 1592014 were VBD B-VP O
4 591 595 1592014 then RB I-VP O
5 596 605 1592014 evaluated VBN I-VP O
6 606 609 1592014 for IN B-PP O
7 610 619 1592014 incidence NN B-NP O
8 619 620 1592014 , , O O
9 621 628 1592014 latency NN B-NP O
10 628 629 1592014 , , O O
11 630 633 1592014 and CC O O
12 634 641 1592014 seizure NN B-NP B-Disease
13 642 649 1592014 pattern NN I-NP O
14 650 652 1592014 or CC B-PP O
15 653 656 1592014 for IN B-PP O
16 657 666 1592014 locomotor NN B-NP O
17 667 675 1592014 activity NN I-NP O
18 676 678 1592014 in IN B-PP O
19 679 686 1592014 animals NNS B-NP O
20 687 694 1592014 without IN B-PP O
21 695 703 1592014 seizures NNS B-NP B-Disease
22 703 704 1592014 . . O O

1 705 707 1592014 BE NN B-NP B-Chemical
2 707 708 1592014 - HYPH B-NP O
3 708 715 1592014 Induced VBN I-NP O
4 716 724 1592014 seizures NNS I-NP B-Disease
5 725 733 1592014 occurred VBD B-VP O
6 734 738 1592014 more RBR B-ADVP O
7 739 749 1592014 frequently RB I-ADVP O
8 750 753 1592014 and CC O O
9 754 757 1592014 had VBD B-VP O
10 758 771 1592014 significantly RB B-NP O
11 772 778 1592014 longer JJR I-NP O
12 779 788 1592014 latencies NNS I-NP O
13 789 793 1592014 than IN B-PP O
14 794 799 1592014 those DT B-NP O
15 800 807 1592014 induced VBN B-VP O
16 808 810 1592014 by IN B-PP O
17 811 820 1592014 equimolar JJ B-NP O
18 821 828 1592014 amounts NNS I-NP O
19 829 831 1592014 of IN B-PP O
20 832 839 1592014 cocaine NN B-NP B-Chemical
21 839 840 1592014 . . O O

1 841 848 1592014 Whereas IN B-PP O
2 849 856 1592014 cocaine NN B-NP B-Chemical
3 856 857 1592014 - HYPH B-NP O
4 857 864 1592014 induced VBN I-NP O
5 865 873 1592014 seizures NNS I-NP B-Disease
6 874 878 1592014 were VBD B-VP O
7 879 883 1592014 best RBS I-VP O
8 884 897 1592014 characterized VBN I-VP O
9 898 900 1592014 as IN B-PP O
10 901 906 1592014 brief NN B-NP O
11 906 907 1592014 , , O O
12 908 919 1592014 generalized VBN B-VP O
13 919 920 1592014 , , O O
14 921 924 1592014 and CC O O
15 925 930 1592014 tonic JJ B-ADJP O
16 931 934 1592014 and CC O O
17 935 943 1592014 resulted VBD B-VP O
18 944 946 1592014 in IN B-PP O
19 947 952 1592014 death NN B-NP B-Disease
20 952 953 1592014 , , O O
21 954 959 1592014 those DT B-NP O
22 960 967 1592014 induced VBN B-VP O
23 968 970 1592014 by IN B-PP O
24 971 973 1592014 BE NN B-NP B-Chemical
25 974 978 1592014 were VBD B-VP O
26 979 988 1592014 prolonged JJ B-ADJP O
27 988 989 1592014 , , O O
28 990 995 1592014 often RB B-ADVP O
29 996 1004 1592014 multiple JJ B-ADJP O
30 1005 1008 1592014 and CC O O
31 1009 1014 1592014 mixed JJ B-ADJP O
32 1015 1017 1592014 in IN B-PP O
33 1018 1022 1592014 type NN B-NP O
34 1022 1023 1592014 , , O O
35 1024 1027 1592014 and CC O O
36 1028 1034 1592014 rarely RB B-VP O
37 1035 1043 1592014 resulted VBD I-VP O
38 1044 1046 1592014 in IN B-PP O
39 1047 1052 1592014 death NN B-NP B-Disease
40 1052 1053 1592014 . . O O

1 1054 1064 1592014 Electrical JJ B-NP O
2 1065 1075 1592014 recordings NNS I-NP O
3 1076 1080 1592014 from IN B-PP O
4 1081 1084 1592014 the DT B-NP O
5 1085 1096 1592014 hippocampus NN I-NP O
6 1097 1103 1592014 showed VBD B-VP O
7 1104 1105 1592014 a DT B-NP O
8 1106 1114 1592014 rhythmic JJ I-NP O
9 1115 1126 1592014 progression NN I-NP O
10 1127 1129 1592014 in IN B-PP O
11 1130 1133 1592014 EEG NN B-NP O
12 1134 1143 1592014 frequency NN I-NP O
13 1144 1147 1592014 and CC I-NP O
14 1148 1155 1592014 voltage NN I-NP O
15 1156 1160 1592014 with IN B-PP O
16 1161 1169 1592014 clinical JJ B-NP O
17 1170 1177 1592014 seizure NN I-NP B-Disease
18 1178 1188 1592014 expression NN I-NP O
19 1188 1189 1592014 . . O O

1 1190 1192 1592014 BE NN B-NP B-Chemical
2 1192 1193 1592014 - HYPH B-NP O
3 1193 1201 1592014 Injected VBN I-NP O
4 1202 1206 1592014 rats NNS I-NP O
5 1207 1211 1592014 that WDT B-NP O
6 1212 1215 1592014 did VBD B-VP O
7 1216 1219 1592014 not RB I-VP O
8 1220 1224 1592014 have VB I-VP O
9 1225 1233 1592014 seizures NNS B-NP B-Disease
10 1234 1237 1592014 had VBD B-VP O
11 1238 1251 1592014 significantly RB B-NP O
12 1252 1256 1592014 more RBR I-NP O
13 1257 1266 1592014 locomotor JJ I-NP O
14 1267 1275 1592014 activity NN I-NP O
15 1276 1280 1592014 than IN B-PP O
16 1281 1288 1592014 cocaine NN B-NP B-Chemical
17 1288 1289 1592014 - HYPH B-NP O
18 1289 1297 1592014 injected VBN I-NP O
19 1298 1305 1592014 animals NNS I-NP O
20 1306 1313 1592014 without IN B-PP O
21 1314 1322 1592014 seizures NNS B-NP B-Disease
22 1322 1323 1592014 . . O O

1 1324 1327 1592014 The DT B-NP O
2 1328 1335 1592014 finding NN I-NP O
3 1336 1340 1592014 that IN B-SBAR O
4 1341 1348 1592014 cocaine NN B-NP B-Chemical
5 1348 1349 1592014 - HYPH B-NP O
6 1350 1353 1592014 and CC I-NP O
7 1354 1356 1592014 BE NN I-NP B-Chemical
8 1356 1357 1592014 - HYPH O O
9 1357 1364 1592014 induced VBN B-NP O
10 1365 1373 1592014 seizures NNS I-NP B-Disease
11 1374 1380 1592014 differ VBP B-VP O
12 1381 1383 1592014 in IN B-PP O
13 1384 1391 1592014 several JJ B-NP O
14 1392 1400 1592014 respects NNS I-NP O
15 1401 1409 1592014 suggests VBZ B-VP O
16 1410 1414 1592014 more JJR B-NP O
17 1415 1419 1592014 than IN I-NP O
18 1420 1423 1592014 one CD I-NP O
19 1424 1433 1592014 mechanism NN I-NP O
20 1434 1437 1592014 for IN B-PP O
21 1438 1445 1592014 cocaine NN B-NP B-Chemical
22 1445 1446 1592014 - HYPH B-NP O
23 1446 1453 1592014 induced VBN I-NP O
24 1454 1462 1592014 seizures NNS I-NP B-Disease
25 1463 1466 1592014 and CC O O
26 1467 1477 1592014 emphasizes VBZ B-VP O
27 1478 1481 1592014 the DT B-NP O
28 1482 1492 1592014 importance NN I-NP O
29 1493 1495 1592014 of IN B-PP O
30 1496 1497 1592014 a DT B-NP O
31 1498 1505 1592014 cocaine NN I-NP B-Chemical
32 1506 1516 1592014 metabolite NN I-NP O
33 1516 1517 1592014 , , O O
34 1518 1520 1592014 BE NN B-NP B-Chemical
35 1520 1521 1592014 . . O O

1 0 0 2266990 -DOCSTART- -X- -X- O

1 0 10 2266990 Randomized VBN B-VP O
2 10 11 2266990 , , O O
3 12 18 2266990 double JJ B-NP O
4 18 19 2266990 - HYPH I-NP O
5 19 24 2266990 blind JJ I-NP O
6 25 30 2266990 trial NN I-NP O
7 31 33 2266990 of IN B-PP O
8 34 42 2266990 mazindol NN B-NP B-Chemical
9 43 45 2266990 in IN B-PP O
10 46 54 2266990 Duchenne NNP B-NP B-Disease
11 55 64 2266990 dystrophy NN I-NP I-Disease
12 64 65 2266990 . . O O
13 66 71 2266990 There EX B-NP O
14 72 74 2266990 is VBZ B-VP O
15 75 83 2266990 evidence NN B-NP O
16 84 88 2266990 that IN B-SBAR O
17 89 95 2266990 growth NN B-NP O
18 96 103 2266990 hormone NN I-NP O
19 104 107 2266990 may MD B-VP O
20 108 110 2266990 be VB I-VP O
21 111 118 2266990 related JJ B-ADJP O
22 119 121 2266990 to TO B-PP O
23 122 125 2266990 the DT B-NP O
24 126 137 2266990 progression NN I-NP O
25 138 140 2266990 of IN B-PP O
26 141 149 2266990 weakness NN B-NP B-Disease
27 150 152 2266990 in IN B-PP O
28 153 161 2266990 Duchenne NNP B-NP B-Disease
29 162 171 2266990 dystrophy NN I-NP I-Disease
30 171 172 2266990 . . O O

1 173 175 2266990 We PRP B-NP O
2 176 185 2266990 conducted VBD B-VP O
3 186 187 2266990 a DT B-NP O
4 188 190 2266990 12 CD I-NP O
5 190 191 2266990 - HYPH I-NP O
6 191 196 2266990 month NN I-NP O
7 197 207 2266990 controlled VBD B-VP O
8 208 213 2266990 trial NN B-NP O
9 214 216 2266990 of IN B-PP O
10 217 225 2266990 mazindol NN B-NP B-Chemical
11 225 226 2266990 , , O O
12 227 228 2266990 a DT B-NP O
13 229 237 2266990 putative JJ I-NP O
14 238 244 2266990 growth NN I-NP O
15 245 252 2266990 hormone NN I-NP O
16 253 262 2266990 secretion NN I-NP O
17 263 272 2266990 inhibitor NN I-NP O
18 272 273 2266990 , , O O
19 274 276 2266990 in IN B-PP O
20 277 279 2266990 83 CD B-NP O
21 280 284 2266990 boys NNS I-NP O
22 285 289 2266990 with IN B-PP O
23 290 298 2266990 Duchenne JJ B-NP B-Disease
24 299 308 2266990 dystrophy NN I-NP I-Disease
25 308 309 2266990 . . O O

1 310 316 2266990 Muscle NN B-NP O
2 317 325 2266990 strength NN I-NP O
3 325 326 2266990 , , O O
4 327 339 2266990 contractures NNS B-NP O
5 339 340 2266990 , , O O
6 341 351 2266990 functional JJ B-NP O
7 352 359 2266990 ability NN I-NP O
8 360 363 2266990 and CC O O
9 364 373 2266990 pulmonary JJ B-NP O
10 374 382 2266990 function NN I-NP O
11 383 387 2266990 were VBD B-VP O
12 388 394 2266990 tested VBN I-VP O
13 395 397 2266990 at IN B-PP O
14 398 406 2266990 baseline NN B-NP O
15 406 407 2266990 , , O O
16 408 411 2266990 and CC O O
17 412 413 2266990 6 CD B-NP O
18 414 417 2266990 and CC I-NP O
19 418 420 2266990 12 CD I-NP O
20 421 427 2266990 months NNS I-NP O
21 428 433 2266990 after IN B-PP O
22 434 443 2266990 treatment NN B-NP O
23 444 448 2266990 with IN B-PP O
24 449 457 2266990 mazindol NN B-NP B-Chemical
25 458 459 2266990 ( ( O O
26 459 460 2266990 3 CD B-NP O
27 461 463 2266990 mg NN I-NP O
28 463 464 2266990 / SYM B-NP O
29 464 465 2266990 d NN I-NP O
30 465 466 2266990 ) ) O O
31 467 469 2266990 or CC O O
32 470 477 2266990 placebo NN B-NP O
33 477 478 2266990 . . O O

1 479 482 2266990 The DT B-NP O
2 483 488 2266990 study NN I-NP O
3 489 492 2266990 was VBD B-VP O
4 493 501 2266990 designed VBN I-VP O
5 502 504 2266990 to TO I-VP O
6 505 509 2266990 have VB I-VP O
7 510 511 2266990 a DT B-NP O
8 512 517 2266990 power NN I-NP O
9 518 520 2266990 of IN B-PP O
10 521 528 2266990 greater JJR B-NP O
11 529 533 2266990 than IN I-NP O
12 534 538 2266990 0.90 CD I-NP O
13 539 541 2266990 to TO B-VP O
14 542 548 2266990 detect VB I-VP O
15 549 550 2266990 a DT B-NP O
16 551 558 2266990 slowing NN I-NP O
17 559 561 2266990 to TO B-PP O
18 562 565 2266990 25% CD B-NP O
19 566 568 2266990 of IN B-PP O
20 569 572 2266990 the DT B-NP O
21 573 581 2266990 expected VBN I-NP O
22 582 586 2266990 rate NN I-NP O
23 587 589 2266990 of IN B-PP O
24 590 601 2266990 progression NN B-NP O
25 602 604 2266990 of IN B-PP O
26 605 613 2266990 weakness NN B-NP B-Disease
27 614 616 2266990 at IN B-PP O
28 617 618 2266990 P NN B-NP O
29 619 623 2266990 less JJR B-ADJP O
30 624 628 2266990 than IN B-PP O
31 629 633 2266990 0.05 CD B-NP O
32 633 634 2266990 . . O O

1 635 643 2266990 Mazindol NN B-NP B-Chemical
2 644 647 2266990 did VBD B-VP O
3 648 651 2266990 not RB I-VP O
4 652 659 2266990 benefit VB I-VP O
5 660 668 2266990 strength NN B-NP O
6 669 671 2266990 at IN B-PP O
7 672 675 2266990 any DT B-NP O
8 676 681 2266990 point NN I-NP O
9 682 684 2266990 in IN B-PP O
10 685 688 2266990 the DT B-NP O
11 689 694 2266990 study NN I-NP O
12 694 695 2266990 . . O O

1 696 700 2266990 Side NN B-NP O
2 701 708 2266990 effects NNS I-NP O
3 709 721 2266990 attributable JJ B-ADJP O
4 722 724 2266990 to TO B-PP O
5 725 733 2266990 mazindol NN B-NP B-Chemical
6 734 742 2266990 included VBD B-VP O
7 743 752 2266990 decreased VBN B-NP B-Disease
8 753 761 2266990 appetite NN I-NP I-Disease
9 762 763 2266990 ( ( O O
10 763 766 2266990 36% CD B-NP O
11 766 767 2266990 ) ) O O
12 767 768 2266990 , , O O
13 769 772 2266990 dry JJ B-NP B-Disease
14 773 778 2266990 mouth NN I-NP I-Disease
15 779 780 2266990 ( ( O O
16 780 783 2266990 10% CD B-NP O
17 783 784 2266990 ) ) O O
18 784 785 2266990 , , O O
19 786 796 2266990 behavioral JJ B-NP O
20 797 803 2266990 change NN I-NP O
21 804 805 2266990 ( ( O O
22 805 808 2266990 22% NN B-NP O
23 808 809 2266990 ) ) O O
24 809 810 2266990 , , O O
25 811 814 2266990 and CC O O
26 815 831 2266990 gastrointestinal JJ B-NP B-Disease
27 832 840 2266990 symptoms NNS I-NP I-Disease
28 841 842 2266990 ( ( O O
29 842 845 2266990 18% NN B-NP O
30 845 846 2266990 ) ) O O
31 846 847 2266990 ; : O O
32 848 856 2266990 mazindol NN B-NP B-Chemical
33 857 863 2266990 dosage NN I-NP O
34 864 867 2266990 was VBD B-VP O
35 868 875 2266990 reduced VBN I-VP O
36 876 878 2266990 in IN B-PP O
37 879 882 2266990 43% CD B-NP O
38 883 885 2266990 of IN B-PP O
39 886 894 2266990 patients NNS B-NP O
40 894 895 2266990 . . O O

1 896 899 2266990 The DT B-NP O
2 900 906 2266990 effect NN I-NP O
3 907 909 2266990 of IN B-PP O
4 910 918 2266990 mazindol NN B-NP B-Chemical
5 919 921 2266990 on IN B-PP O
6 922 924 2266990 GH NN B-NP O
7 925 934 2266990 secretion NN I-NP O
8 935 938 2266990 was VBD B-VP O
9 939 948 2266990 estimated VBN I-VP O
10 949 959 2266990 indirectly RB B-ADVP O
11 960 962 2266990 by IN B-PP O
12 963 972 2266990 comparing VBG B-VP O
13 973 976 2266990 the DT B-NP O
14 977 991 2266990 postabsorptive JJ I-NP O
15 992 995 2266990 IGF NN I-NP O
16 995 996 2266990 - HYPH B-NP O
17 996 997 2266990 I NN I-NP O
18 998 1004 2266990 levels NNS I-NP O
19 1005 1013 2266990 obtained VBN B-VP O
20 1014 1023 2266990 following VBG B-PP O
21 1024 1025 2266990 3 CD B-NP O
22 1025 1026 2266990 , , I-NP O
23 1027 1028 2266990 6 CD I-NP O
24 1028 1029 2266990 , , I-NP O
25 1030 1031 2266990 9 CD I-NP O
26 1031 1032 2266990 , , O O
27 1033 1036 2266990 and CC O O
28 1037 1039 2266990 12 CD B-NP O
29 1040 1046 2266990 months NNS I-NP O
30 1047 1049 2266990 in IN B-PP O
31 1050 1053 2266990 the DT B-NP O
32 1054 1062 2266990 mazindol NN I-NP B-Chemical
33 1063 1070 2266990 treated VBN B-VP O
34 1071 1073 2266990 to TO B-PP O
35 1074 1079 2266990 those DT B-NP O
36 1080 1082 2266990 in IN B-PP O
37 1083 1086 2266990 the DT B-NP O
38 1087 1094 2266990 placebo NN I-NP O
39 1095 1101 2266990 groups NNS I-NP O
40 1101 1102 2266990 . . O O

1 1103 1111 2266990 Although IN B-SBAR O
2 1112 1120 2266990 mazindol NN B-NP B-Chemical
3 1120 1121 2266990 - HYPH B-NP O
4 1121 1128 2266990 treated VBN I-NP O
5 1129 1137 2266990 patients NNS I-NP O
6 1138 1144 2266990 gained VBD B-VP O
7 1145 1149 2266990 less JJR B-NP O
8 1150 1156 2266990 weight NN I-NP O
9 1157 1160 2266990 and CC I-NP O
10 1161 1167 2266990 height NN I-NP O
11 1168 1172 2266990 than IN B-PP O
12 1173 1180 2266990 placebo NN B-NP O
13 1180 1181 2266990 - HYPH B-NP O
14 1181 1188 2266990 treated VBN I-NP O
15 1189 1197 2266990 patients NNS I-NP O
16 1197 1198 2266990 , , O O
17 1199 1201 2266990 no DT B-NP O
18 1202 1213 2266990 significant JJ I-NP O
19 1214 1220 2266990 effect NN I-NP O
20 1221 1223 2266990 on IN B-PP O
21 1224 1227 2266990 IGF NN B-NP O
22 1227 1228 2266990 - HYPH I-NP O
23 1228 1229 2266990 I NN I-NP O
24 1230 1236 2266990 levels NNS I-NP O
25 1237 1240 2266990 was VBD B-VP O
26 1241 1249 2266990 observed VBN I-VP O
27 1249 1250 2266990 . . O O

1 1251 1259 2266990 Mazindol NN B-NP B-Chemical
2 1260 1265 2266990 doses NNS I-NP O
3 1266 1269 2266990 not RB O O
4 1270 1274 2266990 slow VB B-VP O
5 1275 1278 2266990 the DT B-NP O
6 1279 1290 2266990 progression NN I-NP O
7 1291 1293 2266990 of IN B-PP O
8 1294 1302 2266990 weakness NN B-NP B-Disease
9 1303 1305 2266990 in IN B-PP O
10 1306 1314 2266990 Duchenne NNP B-NP B-Disease
11 1315 1324 2266990 dystrophy NN I-NP I-Disease
12 1324 1325 2266990 . . O O

1 0 0 10579464 -DOCSTART- -X- -X- O

1 0 1 10579464 A DT B-NP O
2 2 11 10579464 selective JJ I-NP O
3 12 20 10579464 dopamine NN I-NP B-Chemical
4 21 23 10579464 D4 NN I-NP O
5 24 32 10579464 receptor NN I-NP O
6 33 43 10579464 antagonist NN I-NP O
7 43 44 10579464 , , O O
8 45 52 10579464 NRA0160 NN B-NP B-Chemical
9 52 53 10579464 : : O O
10 54 55 10579464 a DT B-NP O
11 56 67 10579464 preclinical JJ I-NP O
12 68 88 10579464 neuropharmacological JJ I-NP O
13 89 96 10579464 profile NN I-NP O
14 96 97 10579464 . . I-NP O
15 98 105 10579464 NRA0160 NN I-NP B-Chemical
16 105 106 10579464 , , O O
17 107 108 10579464 5 CD B-NP B-Chemical
18 109 110 10579464 - HYPH O I-Chemical
19 111 112 10579464 [ ( B-NP I-Chemical
20 112 113 10579464 2 CD I-NP I-Chemical
21 113 114 10579464 - HYPH I-NP I-Chemical
22 115 116 10579464 ( ( O I-Chemical
23 117 118 10579464 4 CD B-NP I-Chemical
24 118 119 10579464 - HYPH O I-Chemical
25 120 121 10579464 ( ( O I-Chemical
26 122 123 10579464 3 CD B-NP I-Chemical
27 124 125 10579464 - HYPH I-NP I-Chemical
28 126 143 10579464 fluorobenzylidene NN I-NP I-Chemical
29 143 144 10579464 ) ) O I-Chemical
30 145 154 10579464 piperidin NN B-NP I-Chemical
31 154 155 10579464 - HYPH B-NP I-Chemical
32 155 156 10579464 1 CD I-NP I-Chemical
33 156 157 10579464 - HYPH I-NP I-Chemical
34 157 159 10579464 yl NN I-NP I-Chemical
35 159 160 10579464 ) ) O I-Chemical
36 161 166 10579464 ethyl NN B-NP I-Chemical
37 166 167 10579464 ] ) O I-Chemical
38 168 169 10579464 - HYPH B-NP I-Chemical
39 170 171 10579464 4 CD I-NP I-Chemical
40 172 173 10579464 - HYPH I-NP I-Chemical
41 173 175 10579464 (4 CD I-NP I-Chemical
42 175 176 10579464 - HYPH I-NP I-Chemical
43 176 189 10579464 fluorophenyl) NN I-NP I-Chemical
44 190 198 10579464 thiazole NN I-NP I-Chemical
45 198 199 10579464 - HYPH B-NP I-Chemical
46 199 200 10579464 2 CD I-NP I-Chemical
47 200 201 10579464 - HYPH I-NP I-Chemical
48 201 212 10579464 carboxamide NN I-NP I-Chemical
49 212 213 10579464 , , O O
50 214 217 10579464 has VBZ B-VP O
51 218 219 10579464 a DT B-NP O
52 220 224 10579464 high JJ I-NP O
53 225 233 10579464 affinity NN I-NP O
54 234 237 10579464 for IN B-PP O
55 238 243 10579464 human JJ B-NP O
56 244 250 10579464 cloned VBN I-NP O
57 251 259 10579464 dopamine NN I-NP B-Chemical
58 260 264 10579464 D4.2 NN I-NP O
59 264 265 10579464 , , I-NP O
60 266 270 10579464 D4.4 NN I-NP O
61 271 274 10579464 and CC I-NP O
62 275 279 10579464 D4.7 NN I-NP O
63 280 289 10579464 receptors NNS I-NP O
64 289 290 10579464 , , O O
65 291 295 10579464 with IN B-PP O
66 296 298 10579464 Ki NN B-NP O
67 299 305 10579464 values NNS I-NP O
68 306 308 10579464 of IN B-PP O
69 309 312 10579464 0.5 CD B-NP O
70 312 313 10579464 , , I-NP O
71 314 317 10579464 0.9 CD I-NP O
72 318 321 10579464 and CC I-NP O
73 322 325 10579464 2.7 CD I-NP O
74 326 328 10579464 nM NN I-NP O
75 328 329 10579464 , , O O
76 330 342 10579464 respectively RB B-ADVP O
77 342 343 10579464 . . O O

1 344 351 10579464 NRA0160 NN B-NP B-Chemical
2 352 354 10579464 is VBZ B-VP O
3 355 359 10579464 over IN B-PP O
4 360 370 10579464 20,000fold RB B-NP O
5 371 375 10579464 more RBR I-NP O
6 376 382 10579464 potent JJ I-NP O
7 383 385 10579464 at IN B-PP O
8 386 389 10579464 the DT B-NP O
9 390 398 10579464 dopamine NN I-NP B-Chemical
10 399 403 10579464 D4.2 NN I-NP O
11 404 412 10579464 receptor NN I-NP O
12 413 421 10579464 compared VBN B-PP O
13 422 426 10579464 with IN B-PP O
14 427 430 10579464 the DT B-NP O
15 431 436 10579464 human JJ I-NP O
16 437 443 10579464 cloned VBN I-NP O
17 444 452 10579464 dopamine NN I-NP B-Chemical
18 453 456 10579464 D2L NN I-NP O
19 457 465 10579464 receptor NN I-NP O
20 465 466 10579464 . . O O

1 467 474 10579464 NRA0160 NN B-NP B-Chemical
2 475 478 10579464 has VBZ B-VP O
3 479 489 10579464 negligible JJ B-NP O
4 490 498 10579464 affinity NN I-NP O
5 499 502 10579464 for IN B-PP O
6 503 506 10579464 the DT B-NP O
7 507 512 10579464 human JJ I-NP O
8 513 519 10579464 cloned VBN I-NP O
9 520 528 10579464 dopamine NN I-NP B-Chemical
10 529 531 10579464 D3 NN I-NP O
11 532 540 10579464 receptor NN I-NP O
12 541 542 10579464 ( ( O O
13 542 544 10579464 Ki NN B-NP O
14 544 545 10579464 = SYM B-VP O
15 545 547 10579464 39 CD B-NP O
16 548 550 10579464 nM NN I-NP O
17 550 551 10579464 ) ) O O
18 551 552 10579464 , , O O
19 553 556 10579464 rat NN B-NP O
20 557 566 10579464 serotonin NN I-NP B-Chemical
21 567 569 10579464 (5 CD I-NP B-Chemical
22 569 570 10579464 - HYPH I-NP I-Chemical
23 570 575 10579464 HT)2A NN I-NP I-Chemical
24 576 585 10579464 receptors NNS I-NP O
25 586 587 10579464 ( ( O O
26 587 589 10579464 Ki NN B-NP O
27 589 590 10579464 = SYM B-VP O
28 590 593 10579464 180 CD B-NP O
29 594 596 10579464 nM NN I-NP O
30 596 597 10579464 ) ) O O
31 598 601 10579464 and CC O O
32 602 605 10579464 rat NN B-NP O
33 606 612 10579464 alpha1 NN I-NP O
34 613 625 10579464 adrenoceptor NN I-NP O
35 626 627 10579464 ( ( O O
36 627 629 10579464 Ki NN B-NP O
37 629 630 10579464 = SYM B-VP O
38 630 633 10579464 237 CD B-NP O
39 634 636 10579464 nM NN I-NP O
40 636 637 10579464 ) ) O O
41 637 638 10579464 . . O O

1 639 646 10579464 NRA0160 NN B-NP B-Chemical
2 647 650 10579464 and CC I-NP O
3 651 660 10579464 clozapine NN I-NP B-Chemical
4 661 672 10579464 antagonized VBD B-VP O
5 673 682 10579464 locomotor NN B-NP O
6 683 696 10579464 hyperactivity NN I-NP B-Disease
7 697 704 10579464 induced VBN B-VP O
8 705 707 10579464 by IN B-PP O
9 708 723 10579464 methamphetamine NN B-NP B-Chemical
10 724 725 10579464 ( ( O O
11 725 728 10579464 MAP NN B-NP B-Chemical
12 728 729 10579464 ) ) O O
13 730 732 10579464 in IN B-PP O
14 733 737 10579464 mice NNS B-NP O
15 737 738 10579464 . . O O

1 739 746 10579464 NRA0160 NN B-NP B-Chemical
2 747 750 10579464 and CC I-NP O
3 751 760 10579464 clozapine NN I-NP B-Chemical
4 761 772 10579464 antagonized VBD B-VP O
5 773 776 10579464 MAP NN B-NP B-Chemical
6 776 777 10579464 - HYPH B-NP O
7 777 784 10579464 induced VBN I-NP O
8 785 796 10579464 stereotyped VBN I-NP O
9 797 805 10579464 behavior NN I-NP O
10 806 808 10579464 in IN B-PP O
11 809 813 10579464 mice NNS B-NP O
12 813 814 10579464 , , O O
13 815 823 10579464 although IN B-SBAR O
14 824 829 10579464 their PRP$ B-NP O
15 830 837 10579464 effects NNS I-NP O
16 838 841 10579464 did VBD B-VP O
17 842 845 10579464 not RB I-VP O
18 846 852 10579464 exceed VB I-VP O
19 853 856 10579464 50% CD B-NP O
20 857 867 10579464 inhibition NN I-NP O
21 867 868 10579464 , , O O
22 869 873 10579464 even RB B-ADVP O
23 874 876 10579464 at IN B-PP O
24 877 880 10579464 the DT B-NP O
25 881 888 10579464 highest JJS I-NP O
26 889 893 10579464 dose NN I-NP O
27 894 899 10579464 given VBN B-VP O
28 899 900 10579464 . . O O

1 901 908 10579464 NRA0160 NN B-NP B-Chemical
2 909 912 10579464 and CC I-NP O
3 913 922 10579464 clozapine NN I-NP B-Chemical
4 923 936 10579464 significantly RB B-ADVP O
5 937 944 10579464 induced VBD B-VP O
6 945 954 10579464 catalepsy NN B-NP B-Disease
7 955 957 10579464 in IN B-PP O
8 958 962 10579464 rats NNS B-NP O
9 962 963 10579464 , , O O
10 964 972 10579464 although IN B-SBAR O
11 973 978 10579464 their PRP$ B-NP O
12 979 986 10579464 effects NNS I-NP O
13 987 990 10579464 did VBD B-VP O
14 991 994 10579464 not RB I-VP O
15 995 1001 10579464 exceed VB I-VP O
16 1002 1005 10579464 50% CD B-NP O
17 1006 1015 10579464 induction NN I-NP O
18 1016 1020 10579464 even RB B-ADVP O
19 1021 1023 10579464 at IN B-PP O
20 1024 1027 10579464 the DT B-NP O
21 1028 1035 10579464 highest JJS I-NP O
22 1036 1040 10579464 dose NN I-NP O
23 1041 1046 10579464 given VBN B-VP O
24 1046 1047 10579464 . . O O

1 1048 1055 10579464 NRA0160 NN B-NP B-Chemical
2 1056 1059 10579464 and CC I-NP O
3 1060 1069 10579464 clozapine NN I-NP B-Chemical
4 1070 1083 10579464 significantly RB B-ADVP O
5 1084 1092 10579464 reversed VBD B-VP O
6 1093 1096 10579464 the DT B-NP O
7 1097 1107 10579464 disruption NN I-NP O
8 1108 1110 10579464 of IN B-PP O
9 1111 1119 10579464 prepulse NN B-NP O
10 1120 1130 10579464 inhibition NN I-NP O
11 1131 1132 10579464 ( ( O O
12 1132 1135 10579464 PPI NN B-NP O
13 1135 1136 10579464 ) ) O O
14 1137 1139 10579464 in IN B-PP O
15 1140 1144 10579464 rats NNS B-NP O
16 1145 1153 10579464 produced VBN B-VP O
17 1154 1156 10579464 by IN B-PP O
18 1157 1168 10579464 apomorphine NN B-NP B-Chemical
19 1168 1169 10579464 . . O O

1 1170 1177 10579464 NRA0160 NN B-NP B-Chemical
2 1178 1181 10579464 and CC I-NP O
3 1182 1191 10579464 clozapine NN I-NP B-Chemical
4 1192 1205 10579464 significantly RB B-ADVP O
5 1206 1215 10579464 shortened VBD B-VP O
6 1216 1219 10579464 the DT B-NP O
7 1220 1233 10579464 phencyclidine NN I-NP B-Chemical
8 1234 1235 10579464 ( ( O O
9 1235 1238 10579464 PCP NN B-NP B-Chemical
10 1238 1239 10579464 ) ) O O
11 1239 1240 10579464 - HYPH O O
12 1240 1247 10579464 induced VBN B-VP O
13 1248 1257 10579464 prolonged VBN I-VP O
14 1258 1266 10579464 swimming VBG B-VP O
15 1267 1274 10579464 latency NN B-NP O
16 1275 1277 10579464 in IN B-PP O
17 1278 1282 10579464 rats NNS B-NP O
18 1283 1285 10579464 in IN B-PP O
19 1286 1287 10579464 a DT B-NP O
20 1288 1293 10579464 water NN I-NP O
21 1294 1298 10579464 maze NN I-NP O
22 1299 1303 10579464 task NN I-NP O
23 1303 1304 10579464 . . O O

1 1305 1310 10579464 These DT B-NP O
2 1311 1319 10579464 findings NNS I-NP O
3 1320 1327 10579464 suggest VBP B-VP O
4 1328 1332 10579464 that IN B-SBAR O
5 1333 1340 10579464 NRA0160 NN B-NP B-Chemical
6 1341 1344 10579464 may MD B-VP O
7 1345 1349 10579464 have VB I-VP O
8 1350 1356 10579464 unique JJ B-NP O
9 1357 1370 10579464 antipsychotic JJ I-NP O
10 1371 1381 10579464 activities NNS I-NP O
11 1382 1389 10579464 without IN B-PP O
12 1390 1393 10579464 the DT B-NP O
13 1394 1403 10579464 liability NN I-NP O
14 1404 1406 10579464 of IN B-PP O
15 1407 1412 10579464 motor NN B-NP O
16 1413 1417 10579464 side NN I-NP O
17 1418 1425 10579464 effects NNS I-NP O
18 1426 1433 10579464 typical JJ B-ADJP O
19 1434 1436 10579464 of IN B-PP O
20 1437 1446 10579464 classical JJ B-NP O
21 1447 1461 10579464 antipsychotics NNS I-NP O
22 1461 1462 10579464 . . O O

1 0 0 7453952 -DOCSTART- -X- -X- O

1 0 11 7453952 Attenuation NN B-NP O
2 12 14 7453952 of IN B-PP O
3 15 18 7453952 the DT B-NP O
4 19 26 7453952 lithium NN I-NP B-Chemical
5 26 27 7453952 - HYPH B-VP O
6 27 34 7453952 induced VBN B-NP O
7 35 43 7453952 diabetes NN I-NP B-Disease
8 43 44 7453952 - HYPH B-NP I-Disease
9 44 53 7453952 insipidus NN I-NP I-Disease
10 53 54 7453952 - HYPH B-NP I-Disease
11 54 58 7453952 like JJ I-NP I-Disease
12 59 67 7453952 syndrome NN I-NP I-Disease
13 68 70 7453952 by IN B-PP O
14 71 80 7453952 amiloride NN B-NP B-Chemical
15 81 83 7453952 in IN B-PP O
16 84 88 7453952 rats NNS B-NP O
17 88 89 7453952 . . O O
18 90 93 7453952 The DT B-NP O
19 94 100 7453952 effect NN I-NP O
20 101 103 7453952 of IN B-PP O
21 104 113 7453952 amiloride NN B-NP B-Chemical
22 114 116 7453952 on IN B-PP O
23 117 124 7453952 lithium NN B-NP B-Chemical
24 124 125 7453952 - HYPH B-NP O
25 125 132 7453952 induced VBN I-NP O
26 133 143 7453952 polydipsia NN I-NP B-Disease
27 144 147 7453952 and CC I-NP O
28 148 156 7453952 polyuria NN I-NP B-Disease
29 157 160 7453952 and CC B-PP O
30 161 163 7453952 on IN B-PP O
31 164 167 7453952 the DT B-NP O
32 168 175 7453952 lithium NN I-NP B-Chemical
33 176 189 7453952 concentration NN I-NP O
34 190 192 7453952 in IN B-PP O
35 193 196 7453952 the DT B-NP O
36 197 203 7453952 plasma NN I-NP O
37 203 204 7453952 , , I-NP O
38 205 210 7453952 brain NN I-NP O
39 210 211 7453952 , , I-NP O
40 212 218 7453952 kidney NN I-NP O
41 218 219 7453952 , , I-NP O
42 220 227 7453952 thyroid NN I-NP O
43 228 231 7453952 and CC I-NP O
44 232 235 7453952 red JJ I-NP O
45 236 241 7453952 blood NN I-NP O
46 242 247 7453952 cells NNS I-NP O
47 248 251 7453952 was VBD B-VP O
48 252 264 7453952 investigated VBN I-VP O
49 265 267 7453952 in IN B-PP O
50 268 272 7453952 rats NNS B-NP O
51 272 273 7453952 , , O O
52 274 285 7453952 chronically RB B-VP O
53 286 293 7453952 treated VBN I-VP O
54 294 298 7453952 with IN B-PP O
55 299 303 7453952 LiCl NN B-NP B-Chemical
56 303 304 7453952 . . O O

1 305 314 7453952 Amiloride NN B-NP B-Chemical
2 315 322 7453952 reduced VBD B-VP O
3 323 326 7453952 the DT B-NP O
4 327 335 7453952 drinking NN I-NP O
5 336 339 7453952 and CC I-NP O
6 340 345 7453952 urine NN I-NP O
7 346 352 7453952 volume NN I-NP O
8 353 355 7453952 of IN B-PP O
9 356 360 7453952 rats NNS B-NP O
10 361 363 7453952 in IN B-PP O
11 364 366 7453952 an DT B-NP O
12 367 372 7453952 acute JJ I-NP O
13 373 374 7453952 ( ( O O
14 374 375 7453952 6 CD B-NP O
15 376 378 7453952 or CC I-NP O
16 379 381 7453952 12 CD I-NP O
17 382 383 7453952 h NN I-NP O
18 383 384 7453952 ) ) O O
19 385 388 7453952 and CC O O
20 389 390 7453952 a DT B-NP O
21 391 399 7453952 subacute JJ I-NP O
22 400 401 7453952 ( ( O O
23 401 402 7453952 3 CD B-NP O
24 403 407 7453952 days NNS I-NP O
25 407 408 7453952 ) ) O O
26 409 419 7453952 experiment NN B-NP O
27 419 420 7453952 . . O O

1 421 422 7453952 6 CD B-NP O
2 423 424 7453952 h NN I-NP O
3 425 430 7453952 after IN B-PP O
4 431 434 7453952 the DT B-NP O
5 435 449 7453952 administration NN I-NP O
6 450 452 7453952 of IN B-PP O
7 453 462 7453952 amiloride NN B-NP B-Chemical
8 462 463 7453952 , , O O
9 464 465 7453952 a DT B-NP O
10 466 475 7453952 reduction NN I-NP O
11 476 479 7453952 was VBD B-VP O
12 480 488 7453952 observed VBN I-VP O
13 489 491 7453952 in IN B-PP O
14 492 495 7453952 the DT B-NP O
15 496 503 7453952 lithium NN I-NP B-Chemical
16 504 511 7453952 content NN I-NP O
17 512 514 7453952 of IN B-PP O
18 515 518 7453952 the DT B-NP O
19 519 524 7453952 renal JJ I-NP O
20 525 532 7453952 medulla NN I-NP O
21 533 536 7453952 but CC B-PP O
22 537 540 7453952 not RB B-PP O
23 541 543 7453952 in IN I-PP O
24 544 547 7453952 the DT B-NP O
25 548 553 7453952 other JJ I-NP O
26 554 560 7453952 organs NNS I-NP O
27 561 568 7453952 studied VBN B-VP O
28 568 569 7453952 . . O O

1 570 572 7453952 At IN B-PP O
2 573 575 7453952 12 CD B-NP O
3 576 577 7453952 h NN I-NP O
4 577 578 7453952 , , O O
5 579 582 7453952 all PDT B-NP O
6 583 586 7453952 the DT I-NP O
7 587 594 7453952 tissues NNS I-NP O
8 595 601 7453952 showed VBD B-VP O
9 602 603 7453952 a DT B-NP O
10 604 610 7453952 slight JJ I-NP O
11 611 619 7453952 increase NN I-NP O
12 620 622 7453952 in IN B-PP O
13 623 630 7453952 lithium NN B-NP B-Chemical
14 631 637 7453952 levels NNS I-NP O
15 637 638 7453952 . . O O

1 639 644 7453952 After IN B-PP O
2 645 646 7453952 3 CD B-NP O
3 647 651 7453952 days NNS I-NP O
4 652 654 7453952 of IN B-PP O
5 655 663 7453952 combined JJ B-NP O
6 664 673 7453952 treatment NN I-NP O
7 673 674 7453952 , , O O
8 675 676 7453952 a DT B-NP O
9 677 683 7453952 marked JJ I-NP O
10 684 693 7453952 elevation NN I-NP O
11 694 696 7453952 in IN B-PP O
12 697 703 7453952 plasma NN B-NP O
13 704 707 7453952 and CC I-NP O
14 708 714 7453952 tissue NN I-NP O
15 715 722 7453952 lithium NN I-NP B-Chemical
16 723 729 7453952 levels NNS I-NP O
17 730 741 7453952 accompanied VBD B-VP O
18 742 743 7453952 a DT B-NP O
19 744 753 7453952 reduction NN I-NP O
20 754 756 7453952 in IN B-PP O
21 757 762 7453952 water NN B-NP O
22 763 769 7453952 intake NN I-NP O
23 769 770 7453952 . . O O

1 771 773 7453952 In IN B-PP O
2 774 777 7453952 all PDT B-NP O
3 778 781 7453952 the DT I-NP O
4 782 793 7453952 experiments NNS I-NP O
5 793 794 7453952 , , O O
6 795 798 7453952 the DT B-NP O
7 799 810 7453952 attenuation NN I-NP O
8 811 813 7453952 of IN B-PP O
9 814 817 7453952 the DT B-NP O
10 818 825 7453952 lithium NN I-NP B-Chemical
11 825 826 7453952 - HYPH B-VP O
12 826 833 7453952 induced VBN B-NP O
13 834 842 7453952 diabetes NN I-NP B-Disease
14 842 843 7453952 - HYPH B-NP I-Disease
15 843 852 7453952 insipidus NN I-NP I-Disease
16 852 853 7453952 - HYPH B-NP I-Disease
17 853 857 7453952 like JJ I-NP I-Disease
18 858 866 7453952 syndrome NN I-NP I-Disease
19 867 869 7453952 by IN B-PP O
20 870 879 7453952 amiloride NN B-NP B-Chemical
21 880 883 7453952 was VBD B-VP O
22 884 895 7453952 accompanied VBN I-VP O
23 896 898 7453952 by IN B-PP O
24 899 900 7453952 a DT B-NP O
25 901 910 7453952 reduction NN I-NP O
26 911 913 7453952 of IN B-PP O
27 914 917 7453952 the DT B-NP O
28 918 923 7453952 ratio NN I-NP O
29 924 931 7453952 between IN B-PP O
30 932 935 7453952 the DT B-NP O
31 936 943 7453952 lithium NN I-NP B-Chemical
32 944 957 7453952 concentration NN I-NP O
33 958 960 7453952 in IN B-PP O
34 961 964 7453952 the DT B-NP O
35 965 970 7453952 renal JJ I-NP O
36 971 978 7453952 medulla NN I-NP O
37 979 982 7453952 and CC O O
38 983 986 7453952 its PRP$ B-NP O
39 987 993 7453952 levels NNS I-NP O
40 994 996 7453952 in IN B-PP O
41 997 1000 7453952 the DT B-NP O
42 1001 1006 7453952 blood NN I-NP O
43 1007 1010 7453952 and CC O O
44 1011 1013 7453952 an DT B-NP O
45 1014 1023 7453952 elevation NN I-NP O
46 1024 1026 7453952 in IN B-PP O
47 1027 1030 7453952 the DT B-NP O
48 1031 1037 7453952 plasma NN I-NP O
49 1038 1047 7453952 potassium NN I-NP B-Chemical
50 1048 1053 7453952 level NN I-NP O
51 1053 1054 7453952 . . O O

1 1055 1057 7453952 It PRP B-NP O
2 1058 1060 7453952 is VBZ B-VP O
3 1061 1070 7453952 concluded VBN I-VP O
4 1071 1075 7453952 that IN B-SBAR O
5 1076 1081 7453952 acute JJ B-NP O
6 1082 1091 7453952 amiloride NN I-NP B-Chemical
7 1092 1106 7453952 administration NN I-NP O
8 1107 1109 7453952 to TO B-PP O
9 1110 1117 7453952 lithium NN B-NP B-Chemical
10 1117 1118 7453952 - HYPH B-NP O
11 1118 1125 7453952 treated VBN I-NP O
12 1126 1134 7453952 patients NNS I-NP O
13 1135 1144 7453952 suffering VBG B-VP O
14 1145 1149 7453952 from IN B-PP O
15 1150 1160 7453952 polydipsia NN B-NP B-Disease
16 1161 1164 7453952 and CC I-NP O
17 1165 1173 7453952 polyuria NN I-NP B-Disease
18 1174 1179 7453952 might MD B-VP O
19 1180 1187 7453952 relieve VB I-VP O
20 1188 1193 7453952 these DT B-NP O
21 1194 1202 7453952 patients NNS I-NP O
22 1203 1206 7453952 but CC O O
23 1207 1216 7453952 prolonged VBD B-VP O
24 1217 1226 7453952 amiloride NN B-NP B-Chemical
25 1227 1242 7453952 supplementation NN I-NP O
26 1243 1248 7453952 would MD B-VP O
27 1249 1255 7453952 result VB I-VP O
28 1256 1258 7453952 in IN B-PP O
29 1259 1267 7453952 elevated JJ B-NP O
30 1268 1275 7453952 lithium NN I-NP B-Chemical
31 1276 1282 7453952 levels NNS I-NP O
32 1283 1286 7453952 and CC O O
33 1287 1292 7453952 might MD B-VP O
34 1293 1295 7453952 be VB I-VP O
35 1296 1305 7453952 hazardous JJ B-ADJP O
36 1305 1306 7453952 . . O O

1 0 0 18996674 -DOCSTART- -X- -X- O

1 0 14 18996674 Intracavernous JJ B-NP O
2 15 26 18996674 epinephrine NN I-NP B-Chemical
3 26 27 18996674 : : O O
4 28 29 18996674 a DT B-NP O
5 30 39 18996674 minimally RB I-NP O
6 40 48 18996674 invasive JJ I-NP O
7 49 58 18996674 treatment NN I-NP O
8 59 62 18996674 for IN B-PP O
9 63 71 18996674 priapism NN B-NP B-Disease
10 72 74 18996674 in IN B-PP O
11 75 78 18996674 the DT B-NP O
12 79 88 18996674 emergency NN I-NP O
13 89 99 18996674 department NN I-NP O
14 99 100 18996674 . . I-NP O
15 101 109 18996674 Priapism NN I-NP B-Disease
16 110 112 18996674 is VBZ B-VP O
17 113 116 18996674 the DT B-NP O
18 117 126 18996674 prolonged VBN I-NP O
19 127 135 18996674 erection NN I-NP O
20 136 138 18996674 of IN B-PP O
21 139 142 18996674 the DT B-NP O
22 143 148 18996674 penis NN I-NP O
23 149 151 18996674 in IN B-PP O
24 152 155 18996674 the DT B-NP O
25 156 163 18996674 absence NN I-NP O
26 164 166 18996674 of IN B-PP O
27 167 173 18996674 sexual JJ B-NP O
28 174 181 18996674 arousal NN I-NP O
29 181 182 18996674 . . O O

1 183 184 18996674 A DT B-NP O
2 185 187 18996674 45 CD I-NP O
3 187 188 18996674 - HYPH I-NP O
4 188 192 18996674 year NN I-NP O
5 192 193 18996674 - HYPH O O
6 193 196 18996674 old JJ B-NP O
7 197 200 18996674 man NN I-NP O
8 200 201 18996674 , , O O
9 202 204 18996674 an DT B-NP O
10 205 213 18996674 admitted VBN I-NP O
11 214 222 18996674 frequent JJ I-NP O
12 223 230 18996674 cocaine NN I-NP B-Chemical
13 231 235 18996674 user NN I-NP O
14 235 236 18996674 , , O O
15 237 246 18996674 presented VBN B-VP O
16 247 249 18996674 to TO B-PP O
17 250 253 18996674 the DT B-NP O
18 254 263 18996674 Emergency NNP I-NP O
19 264 274 18996674 Department NNP I-NP O
20 275 276 18996674 ( ( O O
21 276 278 18996674 ED VBN B-VP O
22 278 279 18996674 ) ) O O
23 280 282 18996674 on IN B-PP O
24 283 286 18996674 two CD B-NP O
25 287 295 18996674 separate JJ I-NP O
26 296 305 18996674 occasions NNS I-NP O
27 306 310 18996674 with IN B-PP O
28 311 312 18996674 a DT B-NP O
29 313 320 18996674 history NN I-NP O
30 321 323 18996674 of IN B-PP O
31 324 332 18996674 priapism NN B-NP B-Disease
32 333 338 18996674 after IN B-PP O
33 339 346 18996674 cocaine NN B-NP B-Chemical
34 347 350 18996674 use NN I-NP O
35 350 351 18996674 . . O O

1 352 355 18996674 The DT B-NP O
2 356 366 18996674 management NN I-NP O
3 367 374 18996674 options NNS I-NP O
4 375 377 18996674 in IN B-PP O
5 378 381 18996674 the DT B-NP O
6 382 384 18996674 ED NNP I-NP O
7 384 385 18996674 , , O O
8 386 388 18996674 as IN B-SBAR O
9 389 400 18996674 exemplified VBN B-VP O
10 401 403 18996674 by IN B-PP O
11 404 408 18996674 four CD B-NP O
12 409 419 18996674 individual JJ I-NP O
13 420 424 18996674 case NN I-NP O
14 425 432 18996674 reports NNS I-NP O
15 432 433 18996674 , , O O
16 434 436 18996674 in IN B-PP O
17 437 447 18996674 particular JJ B-ADJP O
18 448 451 18996674 the DT B-NP O
19 452 455 18996674 use NN I-NP O
20 456 458 18996674 of IN B-PP O
21 459 460 18996674 a DT B-NP O
22 461 470 18996674 minimally RB I-NP O
23 471 479 18996674 invasive JJ I-NP O
24 480 486 18996674 method NN I-NP O
25 487 489 18996674 of IN B-PP O
26 490 503 18996674 intracorporal JJ B-NP O
27 504 515 18996674 epinephrine NN I-NP B-Chemical
28 516 528 18996674 instillation NN I-NP O
29 528 529 18996674 , , O O
30 530 533 18996674 are VBP B-VP O
31 534 543 18996674 discussed VBN I-VP O
32 543 544 18996674 . . O O

1 0 0 18439803 -DOCSTART- -X- -X- O

1 0 5 18439803 Acute JJ B-NP O
2 6 13 18439803 effects NNS I-NP O
3 14 16 18439803 of IN B-PP O
4 17 18 18439803 N NN B-NP B-Chemical
5 18 19 18439803 - HYPH B-NP I-Chemical
6 19 21 18439803 (2 CD I-NP I-Chemical
7 21 22 18439803 - HYPH I-NP I-Chemical
8 22 42 18439803 propylpentanoyl)urea NN I-NP I-Chemical
9 43 45 18439803 on IN B-PP O
10 46 57 18439803 hippocampal JJ B-NP O
11 58 63 18439803 amino JJ I-NP B-Chemical
12 64 68 18439803 acid NN I-NP I-Chemical
13 69 86 18439803 neurotransmitters NNS I-NP O
14 87 89 18439803 in IN B-PP O
15 90 101 18439803 pilocarpine NN B-NP B-Chemical
16 101 102 18439803 - HYPH B-NP O
17 102 109 18439803 induced VBN I-NP O
18 110 117 18439803 seizure NN I-NP B-Disease
19 118 120 18439803 in IN B-PP O
20 121 125 18439803 rats NNS B-NP O
21 125 126 18439803 . . O O
22 127 130 18439803 The DT B-NP O
23 131 138 18439803 present JJ I-NP O
24 139 144 18439803 study NN I-NP O
25 145 150 18439803 aimed VBD B-VP O
26 151 153 18439803 to TO I-VP O
27 154 165 18439803 investigate VB I-VP O
28 166 169 18439803 the DT B-NP O
29 170 184 18439803 anticonvulsant JJ I-NP O
30 185 193 18439803 activity NN I-NP O
31 194 196 18439803 as RB B-CONJP O
32 197 201 18439803 well RB I-CONJP O
33 202 204 18439803 as IN I-CONJP O
34 205 208 18439803 the DT B-NP O
35 209 216 18439803 effects NNS I-NP O
36 217 219 18439803 on IN B-PP O
37 220 223 18439803 the DT B-NP O
38 224 229 18439803 level NN I-NP O
39 230 232 18439803 of IN B-PP O
40 233 244 18439803 hippocampal JJ B-NP O
41 245 250 18439803 amino JJ I-NP B-Chemical
42 251 255 18439803 acid NN I-NP I-Chemical
43 256 273 18439803 neurotransmitters NNS I-NP O
44 274 275 18439803 ( ( O O
45 275 284 18439803 glutamate NN B-NP B-Chemical
46 284 285 18439803 , , O O
47 286 295 18439803 aspartate NN B-NP B-Chemical
48 295 296 18439803 , , O O
49 297 304 18439803 glycine NN B-NP B-Chemical
50 305 308 18439803 and CC O O
51 309 313 18439803 GABA NN B-NP B-Chemical
52 313 314 18439803 ) ) O O
53 315 317 18439803 of IN B-PP O
54 318 319 18439803 N NN B-NP B-Chemical
55 319 320 18439803 - HYPH B-NP I-Chemical
56 320 322 18439803 (2 CD I-NP I-Chemical
57 322 323 18439803 - HYPH I-NP I-Chemical
58 323 343 18439803 propylpentanoyl)urea NN I-NP I-Chemical
59 344 345 18439803 ( ( O O
60 345 348 18439803 VPU NN B-NP B-Chemical
61 348 349 18439803 ) ) O O
62 350 352 18439803 in IN B-PP O
63 353 363 18439803 comparison NN B-NP O
64 364 366 18439803 to TO B-PP O
65 367 370 18439803 its PRP$ B-NP O
66 371 377 18439803 parent NN I-NP O
67 378 386 18439803 compound NN I-NP O
68 386 387 18439803 , , O O
69 388 396 18439803 valproic JJ B-NP B-Chemical
70 397 401 18439803 acid NN I-NP I-Chemical
71 402 403 18439803 ( ( O O
72 403 406 18439803 VPA NN B-NP B-Chemical
73 406 407 18439803 ) ) O O
74 407 408 18439803 . . O O

1 409 412 18439803 VPU NN B-NP B-Chemical
2 413 416 18439803 was VBD B-VP O
3 417 421 18439803 more RBR B-ADJP O
4 422 428 18439803 potent JJ I-ADJP O
5 429 433 18439803 than IN B-PP O
6 434 437 18439803 VPA NN B-NP B-Chemical
7 437 438 18439803 , , O O
8 439 449 18439803 exhibiting VBG B-VP O
9 450 453 18439803 the DT B-NP O
10 454 460 18439803 median JJ I-NP O
11 461 470 18439803 effective JJ I-NP O
12 471 475 18439803 dose NN I-NP O
13 476 477 18439803 ( ( O O
14 477 483 18439803 ED(50) NN B-NP O
15 483 484 18439803 ) ) O O
16 485 487 18439803 of IN B-PP O
17 488 490 18439803 49 CD B-NP O
18 491 493 18439803 mg NN I-NP O
19 493 494 18439803 / SYM B-NP O
20 494 496 18439803 kg NN I-NP O
21 497 499 18439803 in IN B-PP O
22 500 510 18439803 protecting VBG B-VP O
23 511 515 18439803 rats NNS B-NP O
24 516 523 18439803 against IN B-PP O
25 524 535 18439803 pilocarpine NN B-NP B-Chemical
26 535 536 18439803 - HYPH B-NP O
27 536 543 18439803 induced VBN I-NP O
28 544 551 18439803 seizure NN I-NP B-Disease
29 552 559 18439803 whereas IN B-PP O
30 560 563 18439803 the DT B-NP O
31 564 577 18439803 corresponding JJ I-NP O
32 578 583 18439803 value NN I-NP O
33 584 587 18439803 for IN B-PP O
34 588 591 18439803 VPA NN B-NP B-Chemical
35 592 595 18439803 was VBD B-VP O
36 596 599 18439803 322 CD B-NP O
37 600 602 18439803 mg NN I-NP O
38 602 603 18439803 / SYM B-NP O
39 603 605 18439803 kg NN I-NP O
40 605 606 18439803 . . O O

1 607 609 18439803 In FW B-NP O
2 610 614 18439803 vivo FW I-NP O
3 615 628 18439803 microdialysis NN I-NP O
4 629 641 18439803 demonstrated VBD B-VP O
5 642 646 18439803 that IN B-SBAR O
6 647 649 18439803 an DT B-NP O
7 650 665 18439803 intraperitoneal JJ I-NP O
8 666 680 18439803 administration NN I-NP O
9 681 683 18439803 of IN B-PP O
10 684 695 18439803 pilocarpine NN B-NP B-Chemical
11 696 703 18439803 induced VBD B-VP O
12 704 705 18439803 a DT B-NP O
13 706 716 18439803 pronounced JJ I-NP O
14 717 726 18439803 increment NN I-NP O
15 727 729 18439803 of IN B-PP O
16 730 741 18439803 hippocampal JJ B-NP O
17 742 751 18439803 glutamate NN I-NP B-Chemical
18 752 755 18439803 and CC I-NP O
19 756 765 18439803 aspartate NN I-NP B-Chemical
20 766 773 18439803 whereas IN B-PP O
21 774 776 18439803 no DT B-NP O
22 777 788 18439803 significant JJ I-NP O
23 789 795 18439803 change NN I-NP O
24 796 799 18439803 was VBD B-VP O
25 800 808 18439803 observed VBN I-VP O
26 809 811 18439803 on IN B-PP O
27 812 815 18439803 the DT B-NP O
28 816 821 18439803 level NN I-NP O
29 822 824 18439803 of IN B-PP O
30 825 832 18439803 glycine NN B-NP B-Chemical
31 833 836 18439803 and CC I-NP O
32 837 841 18439803 GABA NN I-NP B-Chemical
33 841 842 18439803 . . O O

1 843 855 18439803 Pretreatment NN B-NP O
2 856 860 18439803 with IN B-PP O
3 861 867 18439803 either CC O O
4 868 871 18439803 VPU NN B-NP B-Chemical
5 872 873 18439803 ( ( O O
6 873 875 18439803 50 CD B-NP O
7 876 879 18439803 and CC I-NP O
8 880 883 18439803 100 CD I-NP O
9 884 886 18439803 mg NN I-NP O
10 886 887 18439803 / SYM B-NP O
11 887 889 18439803 kg NN I-NP O
12 889 890 18439803 ) ) O O
13 891 893 18439803 or CC O O
14 894 897 18439803 VPA NN B-NP B-Chemical
15 898 899 18439803 ( ( O O
16 899 902 18439803 300 CD B-NP O
17 903 906 18439803 and CC I-NP O
18 907 910 18439803 600 CD I-NP O
19 911 913 18439803 mg NN I-NP O
20 913 914 18439803 / SYM B-NP O
21 914 916 18439803 kg NN I-NP O
22 916 917 18439803 ) ) O O
23 918 928 18439803 completely RB B-ADVP O
24 929 938 18439803 abolished VBD B-VP O
25 939 950 18439803 pilocarpine NN B-NP B-Chemical
26 950 951 18439803 - HYPH B-NP O
27 951 957 18439803 evoked VBN I-NP O
28 958 967 18439803 increases NNS I-NP O
29 968 970 18439803 in IN B-PP O
30 971 984 18439803 extracellular JJ B-NP O
31 985 994 18439803 glutamate NN I-NP B-Chemical
32 995 998 18439803 and CC I-NP O
33 999 1008 18439803 aspartate NN I-NP B-Chemical
34 1008 1009 18439803 . . O O

1 1010 1012 18439803 In IN B-PP O
2 1013 1021 18439803 addition NN B-NP O
3 1021 1022 18439803 , , O O
4 1023 1024 18439803 a DT B-NP O
5 1025 1038 18439803 statistically RB I-NP O
6 1039 1050 18439803 significant JJ I-NP O
7 1051 1060 18439803 reduction NN I-NP O
8 1061 1064 18439803 was VBD B-VP O
9 1065 1069 18439803 also RB I-VP O
10 1070 1078 18439803 observed VBN I-VP O
11 1079 1081 18439803 on IN B-PP O
12 1082 1085 18439803 the DT B-NP O
13 1086 1091 18439803 level NN I-NP O
14 1092 1094 18439803 of IN B-PP O
15 1095 1099 18439803 GABA NN B-NP B-Chemical
16 1100 1103 18439803 and CC I-NP O
17 1104 1111 18439803 glycine NN I-NP B-Chemical
18 1112 1115 18439803 but CC O O
19 1116 1120 18439803 less JJR B-NP O
20 1121 1125 18439803 than IN B-PP O
21 1126 1127 18439803 a DT B-NP O
22 1128 1135 18439803 drastic JJ I-NP O
23 1136 1145 18439803 reduction NN I-NP O
24 1146 1148 18439803 of IN B-PP O
25 1149 1158 18439803 glutamate NN B-NP B-Chemical
26 1159 1162 18439803 and CC I-NP O
27 1163 1172 18439803 aspartate NN I-NP B-Chemical
28 1173 1178 18439803 level NN I-NP O
29 1178 1179 18439803 . . O O

1 1180 1185 18439803 Based VBN B-PP O
2 1186 1188 18439803 on IN B-PP O
3 1189 1192 18439803 the DT B-NP O
4 1193 1200 18439803 finding NN I-NP O
5 1201 1205 18439803 that IN B-SBAR O
6 1206 1209 18439803 VPU NN B-NP B-Chemical
7 1210 1213 18439803 and CC I-NP O
8 1214 1217 18439803 VPA NN I-NP B-Chemical
9 1218 1223 18439803 could MD B-VP O
10 1224 1231 18439803 protect VB I-VP O
11 1232 1235 18439803 the DT B-NP O
12 1236 1243 18439803 animals NNS I-NP O
13 1244 1251 18439803 against IN B-PP O
14 1252 1263 18439803 pilocarpine NN B-NP B-Chemical
15 1263 1264 18439803 - HYPH B-NP O
16 1264 1271 18439803 induced VBN I-NP O
17 1272 1279 18439803 seizure NN I-NP B-Disease
18 1280 1282 18439803 it PRP B-NP O
19 1283 1285 18439803 is VBZ B-VP O
20 1286 1295 18439803 suggested VBN I-VP O
21 1296 1300 18439803 that IN B-SBAR O
22 1301 1304 18439803 the DT B-NP O
23 1305 1314 18439803 reduction NN I-NP O
24 1315 1317 18439803 of IN B-PP O
25 1318 1328 18439803 inhibitory JJ B-NP O
26 1329 1334 18439803 amino JJ I-NP B-Chemical
27 1335 1339 18439803 acid NN I-NP I-Chemical
28 1340 1357 18439803 neurotransmitters NNS I-NP O
29 1358 1361 18439803 was VBD B-VP O
30 1362 1375 18439803 comparatively RB B-ADJP O
31 1376 1381 18439803 minor JJ I-ADJP O
32 1382 1385 18439803 and CC O O
33 1386 1392 18439803 offset VBN B-VP O
34 1393 1395 18439803 by IN B-PP O
35 1396 1397 18439803 a DT B-NP O
36 1398 1408 18439803 pronounced JJ I-NP O
37 1409 1418 18439803 reduction NN I-NP O
38 1419 1421 18439803 of IN B-PP O
39 1422 1431 18439803 glutamate NN B-NP B-Chemical
40 1432 1435 18439803 and CC I-NP O
41 1436 1445 18439803 aspartate NN I-NP B-Chemical
42 1445 1446 18439803 . . O O

1 1447 1456 18439803 Therefore RB B-ADVP O
2 1456 1457 18439803 , , O O
3 1458 1462 18439803 like IN B-PP O
4 1463 1466 18439803 VPA NN B-NP B-Chemical
5 1466 1467 18439803 , , O O
6 1468 1471 18439803 the DT B-NP O
7 1472 1479 18439803 finding NN I-NP O
8 1480 1484 18439803 that IN B-SBAR O
9 1485 1488 18439803 VPU NN B-NP B-Chemical
10 1489 1494 18439803 could MD B-VP O
11 1495 1506 18439803 drastically RB I-VP O
12 1507 1513 18439803 reduce VB I-VP O
13 1514 1525 18439803 pilocarpine NN B-NP B-Chemical
14 1525 1526 18439803 - HYPH B-NP O
15 1526 1533 18439803 induced VBN I-NP O
16 1534 1543 18439803 increases NNS I-NP O
17 1544 1546 18439803 in IN B-PP O
18 1547 1556 18439803 glutamate NN B-NP B-Chemical
19 1557 1560 18439803 and CC I-NP O
20 1561 1570 18439803 aspartate NN I-NP B-Chemical
21 1571 1577 18439803 should MD B-VP O
22 1578 1585 18439803 account VB I-VP O
23 1585 1586 18439803 , , O O
24 1587 1589 18439803 at IN B-ADVP O
25 1590 1595 18439803 least JJS I-ADVP O
26 1596 1602 18439803 partly RB B-ADVP O
27 1602 1603 18439803 , , O O
28 1604 1607 18439803 for IN B-PP O
29 1608 1611 18439803 its PRP$ B-NP O
30 1612 1626 18439803 anticonvulsant JJ I-NP O
31 1627 1635 18439803 activity NN I-NP O
32 1636 1644 18439803 observed VBN B-VP O
33 1645 1647 18439803 in IN B-PP O
34 1648 1659 18439803 pilocarpine NN B-NP B-Chemical
35 1659 1660 18439803 - HYPH B-NP O
36 1660 1667 18439803 induced VBN I-NP O
37 1668 1675 18439803 seizure NN I-NP B-Disease
38 1676 1678 18439803 in IN B-PP O
39 1679 1691 18439803 experimental JJ B-NP O
40 1692 1699 18439803 animals NNS I-NP O
41 1699 1700 18439803 . . O O

1 1701 1705 18439803 Some DT B-NP O
2 1706 1711 18439803 other JJ I-NP O
3 1712 1721 18439803 mechanism NN I-NP O
4 1722 1726 18439803 than IN B-PP O
5 1727 1732 18439803 those DT B-NP O
6 1733 1738 18439803 being VBG B-VP O
7 1739 1747 18439803 reported VBN I-VP O
8 1748 1754 18439803 herein RB B-ADVP O
9 1755 1761 18439803 should MD B-VP O
10 1762 1764 18439803 be VB I-VP O
11 1765 1772 18439803 further RBR B-ADJP O
12 1773 1785 18439803 investigated VBN I-ADJP O
13 1785 1786 18439803 . . O O

1 0 0 7292072 -DOCSTART- -X- -X- O

1 0 7 7292072 Variant JJ B-NP O
2 8 19 7292072 ventricular JJ I-NP B-Disease
3 20 31 7292072 tachycardia NN I-NP I-Disease
4 32 34 7292072 in IN B-PP O
5 35 46 7292072 desipramine NN B-NP B-Chemical
6 47 55 7292072 toxicity NN I-NP B-Disease
7 55 56 7292072 . . O O
8 57 59 7292072 We PRP B-NP O
9 60 66 7292072 report VBP B-VP O
10 67 68 7292072 a DT B-NP O
11 69 73 7292072 case NN I-NP O
12 74 76 7292072 of IN B-PP O
13 77 84 7292072 variant JJ B-NP O
14 85 96 7292072 ventricular JJ I-NP B-Disease
15 97 108 7292072 tachycardia NN I-NP I-Disease
16 109 116 7292072 induced VBN B-VP O
17 117 119 7292072 by IN B-PP O
18 120 131 7292072 desipramine NN B-NP B-Chemical
19 132 140 7292072 toxicity NN I-NP B-Disease
20 140 141 7292072 . . O O

1 142 149 7292072 Unusual JJ B-NP O
2 150 158 7292072 features NNS I-NP O
3 159 161 7292072 of IN B-PP O
4 162 165 7292072 the DT B-NP O
5 166 176 7292072 arrhythmia NN I-NP B-Disease
6 177 180 7292072 are VBP B-VP O
7 181 191 7292072 repetitive JJ B-NP O
8 192 197 7292072 group NN I-NP O
9 198 205 7292072 beating NN I-NP O
10 205 206 7292072 , , O O
11 207 218 7292072 progressive JJ B-NP O
12 219 229 7292072 shortening NN I-NP O
13 230 232 7292072 of IN B-PP O
14 233 236 7292072 the DT B-NP O
15 237 238 7292072 R NN I-NP O
16 238 239 7292072 - HYPH B-NP O
17 239 240 7292072 R NN I-NP O
18 241 249 7292072 interval NN I-NP O
19 249 250 7292072 , , O O
20 251 262 7292072 progressive JJ B-NP O
21 263 271 7292072 widening NN I-NP O
22 272 274 7292072 of IN B-PP O
23 275 278 7292072 the DT B-NP O
24 279 282 7292072 QRS NN I-NP O
25 283 290 7292072 complex NN I-NP O
26 291 295 7292072 with IN B-PP O
27 296 304 7292072 eventual JJ B-NP O
28 305 312 7292072 failure NN I-NP O
29 313 315 7292072 of IN B-PP O
30 316 332 7292072 intraventricular JJ B-NP O
31 333 343 7292072 conduction NN I-NP O
32 343 344 7292072 , , O O
33 345 348 7292072 and CC O O
34 349 356 7292072 changes NNS B-NP O
35 357 359 7292072 in IN B-PP O
36 360 369 7292072 direction NN B-NP O
37 370 372 7292072 of IN B-PP O
38 373 376 7292072 the DT B-NP O
39 377 380 7292072 QRS NNP I-NP O
40 381 385 7292072 axis NN I-NP O
41 385 386 7292072 . . O O

1 387 398 7292072 Recognition NN B-NP O
2 399 401 7292072 of IN B-PP O
3 402 409 7292072 variant JJ B-NP O
4 410 421 7292072 ventricular JJ I-NP B-Disease
5 422 433 7292072 tachycardia NN I-NP I-Disease
6 434 436 7292072 is VBZ B-VP O
7 437 446 7292072 important JJ B-ADJP O
8 447 454 7292072 because IN B-SBAR O
9 455 462 7292072 therapy NN B-NP O
10 463 470 7292072 differs VBZ B-VP O
11 471 475 7292072 from IN B-PP O
12 476 480 7292072 that DT B-NP O
13 481 483 7292072 of IN B-PP O
14 484 491 7292072 classic JJ B-NP O
15 492 503 7292072 ventricular JJ I-NP B-Disease
16 504 515 7292072 tachycardia NN I-NP I-Disease
17 515 516 7292072 . . O O

1 0 0 1786266 -DOCSTART- -X- -X- O

1 0 6 1786266 Rabbit NN B-NP B-Disease
2 7 15 1786266 syndrome NN I-NP I-Disease
3 15 16 1786266 , , O O
4 17 31 1786266 antidepressant NN B-NP B-Chemical
5 32 35 1786266 use NN I-NP O
6 35 36 1786266 , , O O
7 37 40 1786266 and CC O O
8 41 49 1786266 cerebral JJ B-NP O
9 50 59 1786266 perfusion NN I-NP O
10 60 65 1786266 SPECT NN I-NP O
11 66 70 1786266 scan NN I-NP O
12 71 79 1786266 findings NNS I-NP O
13 79 80 1786266 . . O O
14 81 84 1786266 The DT B-NP O
15 85 91 1786266 rabbit NN I-NP B-Disease
16 92 100 1786266 syndrome NN I-NP I-Disease
17 101 103 1786266 is VBZ B-VP O
18 104 106 1786266 an DT B-NP O
19 107 121 1786266 extrapyramidal JJ I-NP O
20 122 126 1786266 side NN I-NP O
21 127 133 1786266 effect NN I-NP O
22 134 144 1786266 associated VBN B-VP O
23 145 149 1786266 with IN B-PP O
24 150 157 1786266 chronic JJ B-NP O
25 158 169 1786266 neuroleptic JJ I-NP O
26 170 177 1786266 therapy NN I-NP O
27 177 178 1786266 . . O O

1 179 182 1786266 Its PRP$ B-NP O
2 183 193 1786266 occurrence NN I-NP O
3 194 196 1786266 in IN B-PP O
4 197 198 1786266 a DT B-NP O
5 199 206 1786266 patient NN I-NP O
6 207 212 1786266 being VBG B-VP O
7 213 220 1786266 treated VBN I-VP O
8 221 225 1786266 with IN B-PP O
9 226 236 1786266 imipramine NN B-NP B-Chemical
10 237 239 1786266 is VBZ B-VP O
11 240 249 1786266 described VBN I-VP O
12 249 250 1786266 , , O O
13 251 263 1786266 representing VBG B-VP O
14 264 267 1786266 the DT B-NP O
15 268 273 1786266 first JJ I-NP O
16 274 282 1786266 reported VBN I-NP O
17 283 287 1786266 case NN I-NP O
18 288 290 1786266 of IN B-PP O
19 291 295 1786266 this DT B-NP O
20 296 304 1786266 syndrome NN I-NP O
21 305 307 1786266 in IN B-PP O
22 308 319 1786266 conjunction NN B-NP O
23 320 324 1786266 with IN B-PP O
24 325 340 1786266 antidepressants NNS B-NP B-Chemical
25 340 341 1786266 . . O O

1 342 350 1786266 Repeated VBN B-NP O
2 351 359 1786266 cerebral JJ I-NP O
3 360 369 1786266 perfusion NN I-NP O
4 370 375 1786266 SPECT NN I-NP O
5 376 381 1786266 scans NNS I-NP O
6 382 390 1786266 revealed VBD B-VP O
7 391 400 1786266 decreased VBN I-VP B-Disease
8 401 406 1786266 basal JJ B-NP I-Disease
9 407 414 1786266 ganglia NN I-NP I-Disease
10 415 424 1786266 perfusion NN I-NP I-Disease
11 425 430 1786266 while IN B-SBAR O
12 431 434 1786266 the DT B-NP O
13 435 443 1786266 movement NN I-NP B-Disease
14 444 452 1786266 disorder NN I-NP I-Disease
15 453 456 1786266 was VBD B-VP O
16 457 464 1786266 present JJ B-ADJP O
17 464 465 1786266 , , O O
18 466 469 1786266 and CC O O
19 470 471 1786266 a DT B-NP O
20 472 478 1786266 return NN I-NP O
21 479 481 1786266 to TO B-PP O
22 482 488 1786266 normal JJ B-NP O
23 489 498 1786266 perfusion NN I-NP O
24 499 503 1786266 when WRB B-ADVP O
25 504 507 1786266 the DT B-NP O
26 508 514 1786266 rabbit NN I-NP B-Disease
27 515 523 1786266 syndrome NN I-NP I-Disease
28 524 532 1786266 resolved VBN B-VP O
29 532 533 1786266 . . O O

1 0 0 14765563 -DOCSTART- -X- -X- O

1 0 5 14765563 Risks NNS B-NP O
2 6 8 14765563 of IN B-PP O
3 9 12 14765563 the DT B-NP O
4 13 24 14765563 consumption NN I-NP O
5 25 27 14765563 of IN B-PP O
6 28 37 14765563 beverages NNS B-NP O
7 38 48 14765563 containing VBG B-VP O
8 49 56 14765563 quinine NN B-NP B-Chemical
9 56 57 14765563 . . O O
10 58 66 14765563 Although IN B-SBAR O
11 67 70 14765563 the DT B-NP O
12 71 77 14765563 United NNP I-NP O
13 78 84 14765563 States NNPS I-NP O
14 85 89 14765563 Food NNP I-NP O
15 90 93 14765563 and CC I-NP O
16 94 98 14765563 Drug NNP I-NP O
17 99 113 14765563 Administration NNP I-NP O
18 114 120 14765563 banned VBD B-VP O
19 121 124 14765563 its PRP$ B-NP O
20 125 128 14765563 use NN I-NP O
21 129 132 14765563 for IN B-PP O
22 133 142 14765563 nocturnal JJ B-NP B-Disease
23 143 146 14765563 leg NN I-NP I-Disease
24 147 153 14765563 cramps NNS I-NP I-Disease
25 154 157 14765563 due JJ B-ADJP O
26 158 160 14765563 to TO B-PP O
27 161 165 14765563 lack NN B-NP O
28 166 168 14765563 of IN B-PP O
29 169 175 14765563 safety NN B-NP O
30 176 179 14765563 and CC I-NP O
31 180 188 14765563 efficacy NN I-NP O
32 188 189 14765563 , , O O
33 190 197 14765563 quinine NN B-NP B-Chemical
34 198 200 14765563 is VBZ B-VP O
35 201 207 14765563 widely RB B-ADJP O
36 208 217 14765563 available JJ I-ADJP O
37 218 220 14765563 in IN B-PP O
38 221 230 14765563 beverages NNS B-NP O
39 231 240 14765563 including VBG B-PP O
40 241 246 14765563 tonic JJ B-NP O
41 247 252 14765563 water NN I-NP O
42 253 256 14765563 and CC O O
43 257 263 14765563 bitter JJ B-NP O
44 264 269 14765563 lemon NN I-NP O
45 269 270 14765563 . . O O

1 271 279 14765563 Numerous JJ B-NP O
2 280 289 14765563 anecdotal JJ I-NP O
3 290 297 14765563 reports NNS I-NP O
4 298 305 14765563 suggest VBP B-VP O
5 306 310 14765563 that IN B-SBAR O
6 311 319 14765563 products NNS B-NP O
7 320 330 14765563 containing VBG B-VP O
8 331 338 14765563 quinine NN B-NP B-Chemical
9 339 342 14765563 may MD B-VP O
10 343 350 14765563 produce VB I-VP O
11 351 363 14765563 neurological JJ B-NP B-Disease
12 364 377 14765563 complications NNS I-NP I-Disease
13 377 378 14765563 , , O O
14 379 388 14765563 including VBG B-PP O
15 389 398 14765563 confusion NN B-NP B-Disease
16 398 399 14765563 , , O O
17 400 407 14765563 altered VBN B-NP O
18 408 414 14765563 mental JJ I-NP O
19 415 421 14765563 status NN I-NP O
20 421 422 14765563 , , O O
21 423 431 14765563 seizures NNS B-NP B-Disease
22 431 432 14765563 , , O O
23 433 436 14765563 and CC O O
24 437 441 14765563 coma NN B-NP B-Disease
25 441 442 14765563 , , O O
26 443 455 14765563 particularly RB B-ADVP O
27 456 458 14765563 in IN B-PP O
28 459 464 14765563 older JJR B-NP O
29 465 470 14765563 women NNS I-NP O
30 470 471 14765563 . . O O

1 472 485 14765563 Psychologists NNS B-NP O
2 486 490 14765563 need VBP B-VP O
3 491 493 14765563 to TO I-VP O
4 494 501 14765563 inquire VB I-VP O
5 502 507 14765563 about IN B-PP O
6 508 519 14765563 consumption NN B-NP O
7 520 522 14765563 of IN B-PP O
8 523 530 14765563 quinine NN B-NP B-Chemical
9 530 531 14765563 - HYPH O O
10 531 541 14765563 containing VBG B-VP O
11 542 551 14765563 beverages NNS B-NP O
12 552 554 14765563 as IN B-PP O
13 555 559 14765563 part NN B-NP O
14 560 562 14765563 of IN B-PP O
15 563 565 14765563 an DT B-NP O
16 566 576 14765563 evaluation NN I-NP O
17 577 584 14765563 process NN I-NP O
18 584 585 14765563 . . O O

1 0 0 12707296 -DOCSTART- -X- -X- O

1 0 1 12707296 L NN B-NP B-Chemical
2 1 2 12707296 - HYPH I-NP I-Chemical
3 2 10 12707296 arginine NN I-NP I-Chemical
4 11 20 12707296 transport NN I-NP O
5 21 23 12707296 in IN B-PP O
6 24 30 12707296 humans NNS B-NP O
7 31 35 12707296 with IN B-PP O
8 36 44 12707296 cortisol NN B-NP B-Chemical
9 44 45 12707296 - HYPH B-NP O
10 45 52 12707296 induced VBN I-NP O
11 53 65 12707296 hypertension NN I-NP B-Disease
12 65 66 12707296 . . O O
13 67 68 12707296 A DT B-NP O
14 69 78 12707296 deficient JJ I-NP O
15 79 80 12707296 L NN I-NP B-Chemical
16 80 81 12707296 - HYPH B-NP I-Chemical
17 81 89 12707296 arginine NN I-NP I-Chemical
18 89 90 12707296 - HYPH I-NP O
19 90 96 12707296 nitric JJ I-NP B-Chemical
20 97 102 12707296 oxide NN I-NP I-Chemical
21 103 109 12707296 system NN I-NP O
22 110 112 12707296 is VBZ B-VP O
23 113 123 12707296 implicated VBN I-VP O
24 124 126 12707296 in IN B-PP O
25 127 135 12707296 cortisol NN B-NP B-Chemical
26 135 136 12707296 - HYPH B-NP O
27 136 143 12707296 induced VBN I-NP O
28 144 156 12707296 hypertension NN I-NP B-Disease
29 156 157 12707296 . . O O

1 158 160 12707296 We PRP B-NP O
2 161 172 12707296 investigate VBP B-VP O
3 173 180 12707296 whether IN B-SBAR O
4 181 194 12707296 abnormalities NNS B-NP O
5 195 197 12707296 in IN B-PP O
6 198 199 12707296 L NN B-NP B-Chemical
7 199 200 12707296 - HYPH B-NP I-Chemical
8 200 208 12707296 arginine NN I-NP I-Chemical
9 209 215 12707296 uptake NN I-NP O
10 216 226 12707296 contribute VBP B-VP O
11 227 229 12707296 to TO B-PP O
12 230 234 12707296 this DT B-NP O
13 235 245 12707296 deficiency NN I-NP O
14 245 246 12707296 . . O O

1 247 252 12707296 Eight CD B-NP O
2 253 260 12707296 healthy JJ I-NP O
3 261 264 12707296 men NNS I-NP O
4 265 269 12707296 were VBD B-VP O
5 270 279 12707296 recruited VBN I-VP O
6 279 280 12707296 . . O O

1 281 295 12707296 Hydrocortisone NN B-NP B-Chemical
2 296 303 12707296 acetate NN I-NP I-Chemical
3 304 305 12707296 ( ( O O
4 305 307 12707296 50 CD B-NP O
5 308 310 12707296 mg NN I-NP O
6 310 311 12707296 ) ) O O
7 312 315 12707296 was VBD B-VP O
8 316 321 12707296 given VBN I-VP O
9 322 328 12707296 orally RB B-ADVP O
10 329 334 12707296 every DT B-NP O
11 335 336 12707296 6 CD I-NP O
12 337 342 12707296 hours NNS I-NP O
13 343 346 12707296 for IN B-PP O
14 347 349 12707296 24 CD B-NP O
15 350 355 12707296 hours NNS I-NP O
16 356 361 12707296 after IN B-PP O
17 362 363 12707296 a DT B-NP O
18 364 365 12707296 5 CD I-NP O
19 365 366 12707296 - HYPH I-NP O
20 366 369 12707296 day NN I-NP O
21 370 375 12707296 fixed VBN B-VP O
22 375 376 12707296 - HYPH B-NP O
23 376 380 12707296 salt NN I-NP O
24 381 385 12707296 diet NN I-NP O
25 386 387 12707296 ( ( O O
26 387 390 12707296 150 CD B-NP O
27 391 395 12707296 mmol NN I-NP O
28 395 396 12707296 / SYM B-NP O
29 396 397 12707296 d NN I-NP O
30 397 398 12707296 ) ) O O
31 398 399 12707296 . . O O

1 400 409 12707296 Crossover NN B-NP O
2 410 417 12707296 studies NNS I-NP O
3 418 422 12707296 were VBD B-VP O
4 423 432 12707296 performed VBN I-VP O
5 433 434 12707296 2 CD B-NP O
6 435 440 12707296 weeks NNS I-NP O
7 441 446 12707296 apart RB B-ADVP O
8 446 447 12707296 . . O O

1 448 454 12707296 Thirty CD B-NP O
2 455 466 12707296 milliliters NNS I-NP O
3 467 469 12707296 of IN B-PP O
4 470 475 12707296 blood NN B-NP O
5 476 479 12707296 was VBD B-VP O
6 480 488 12707296 obtained VBN I-VP O
7 489 492 12707296 for IN B-PP O
8 493 502 12707296 isolation NN B-NP O
9 503 505 12707296 of IN B-PP O
10 506 516 12707296 peripheral JJ B-NP O
11 517 522 12707296 blood NN I-NP O
12 523 534 12707296 mononuclear JJ I-NP O
13 535 540 12707296 cells NNS I-NP O
14 541 546 12707296 after IN B-PP O
15 547 551 12707296 each DT B-NP O
16 552 561 12707296 treatment NN I-NP O
17 562 568 12707296 period NN I-NP O
18 568 569 12707296 . . O O

1 570 571 12707296 L NN B-NP B-Chemical
2 571 572 12707296 - HYPH I-NP I-Chemical
3 572 580 12707296 arginine NN I-NP I-Chemical
4 581 587 12707296 uptake NN I-NP O
5 588 591 12707296 was VBD B-VP O
6 592 600 12707296 assessed VBN I-VP O
7 601 603 12707296 in IN B-PP O
8 604 615 12707296 mononuclear JJ B-NP O
9 616 621 12707296 cells NNS I-NP O
10 622 631 12707296 incubated VBN B-VP O
11 632 636 12707296 with IN B-PP O
12 637 638 12707296 L NN B-NP B-Chemical
13 638 639 12707296 - HYPH O I-Chemical
14 639 647 12707296 arginine NN B-NP I-Chemical
15 648 649 12707296 ( ( O O
16 649 650 12707296 1 CD B-NP O
17 651 653 12707296 to TO O O
18 654 657 12707296 300 CD B-NP O
19 658 666 12707296 micromol NN I-NP O
20 666 667 12707296 / SYM B-NP O
21 667 668 12707296 L NN I-NP O
22 668 669 12707296 ) ) O O
23 669 670 12707296 , , O O
24 671 684 12707296 incorporating VBG B-VP O
25 685 688 12707296 100 CD B-NP O
26 689 693 12707296 nmol NN I-NP O
27 693 694 12707296 / SYM O O
28 694 695 12707296 L NN B-NP O
29 696 700 12707296 [3H] NN I-NP B-Chemical
30 700 701 12707296 - HYPH B-NP I-Chemical
31 701 702 12707296 l NN I-NP I-Chemical
32 702 703 12707296 - HYPH B-NP I-Chemical
33 703 711 12707296 arginine NN I-NP I-Chemical
34 712 715 12707296 for IN B-PP O
35 716 717 12707296 a DT B-NP O
36 718 724 12707296 period NN I-NP O
37 725 727 12707296 of IN B-PP O
38 728 729 12707296 5 CD B-NP O
39 730 737 12707296 minutes NNS I-NP O
40 738 740 12707296 at IN B-PP O
41 741 743 12707296 37 CD B-NP O
42 744 751 12707296 degrees NNS I-NP O
43 752 753 12707296 C JJ B-ADJP O
44 753 754 12707296 . . O O

1 755 762 12707296 Forearm NN B-NP O
2 763 767 12707296 [3H] NN I-NP B-Chemical
3 767 768 12707296 - HYPH B-NP I-Chemical
4 768 769 12707296 L NN I-NP I-Chemical
5 769 770 12707296 - HYPH B-NP I-Chemical
6 770 778 12707296 arginine NN I-NP I-Chemical
7 779 789 12707296 extraction NN I-NP O
8 790 793 12707296 was VBD B-VP O
9 794 804 12707296 calculated VBN I-VP O
10 805 810 12707296 after IN B-PP O
11 811 819 12707296 infusion NN B-NP O
12 820 822 12707296 of IN B-PP O
13 823 827 12707296 [3H] NN B-NP B-Chemical
14 827 828 12707296 - HYPH B-NP I-Chemical
15 828 829 12707296 L NN I-NP I-Chemical
16 829 830 12707296 - HYPH O I-Chemical
17 830 838 12707296 arginine NN B-NP I-Chemical
18 839 843 12707296 into IN B-PP O
19 844 847 12707296 the DT B-NP O
20 848 856 12707296 brachial JJ I-NP O
21 857 863 12707296 artery NN I-NP O
22 864 866 12707296 at IN B-PP O
23 867 868 12707296 a DT B-NP O
24 869 873 12707296 rate NN I-NP O
25 874 876 12707296 of IN B-PP O
26 877 880 12707296 100 CD B-NP O
27 881 884 12707296 nCi NN I-NP O
28 884 885 12707296 / SYM B-NP O
29 885 888 12707296 min NN I-NP O
30 889 892 12707296 for IN B-PP O
31 893 895 12707296 80 CD B-NP O
32 896 903 12707296 minutes NNS I-NP O
33 903 904 12707296 . . O O

1 905 909 12707296 Deep JJ B-NP O
2 910 917 12707296 forearm NN I-NP O
3 918 924 12707296 venous JJ I-NP O
4 925 932 12707296 samples NNS I-NP O
5 933 937 12707296 were VBD B-VP O
6 938 947 12707296 collected VBN I-VP O
7 948 951 12707296 for IN B-PP O
8 952 965 12707296 determination NN B-NP O
9 966 968 12707296 of IN B-PP O
10 969 970 12707296 L NN B-NP B-Chemical
11 970 971 12707296 - HYPH B-NP I-Chemical
12 971 979 12707296 arginine NN I-NP I-Chemical
13 980 990 12707296 extraction NN I-NP O
14 990 991 12707296 . . O O

1 992 998 12707296 Plasma NN B-NP O
2 999 1007 12707296 cortisol NN I-NP B-Chemical
3 1008 1022 12707296 concentrations NNS I-NP O
4 1023 1027 12707296 were VBD B-VP O
5 1028 1041 12707296 significantly RB I-VP O
6 1042 1048 12707296 raised VBN I-VP O
7 1049 1055 12707296 during IN B-PP O
8 1056 1059 12707296 the DT B-NP O
9 1060 1066 12707296 active JJ I-NP O
10 1067 1072 12707296 phase NN I-NP O
11 1073 1074 12707296 ( ( O O
12 1074 1078 12707296 323+ SYM B-NP O
13 1078 1079 12707296 / SYM O O
14 1079 1080 12707296 - SYM O O
15 1080 1082 12707296 43 CD B-NP O
16 1083 1085 12707296 to TO B-PP O
17 1086 1091 12707296 1082+ CD B-NP O
18 1091 1092 12707296 / SYM O O
19 1092 1093 12707296 - SYM O O
20 1093 1096 12707296 245 CD B-NP O
21 1097 1101 12707296 mmol NN I-NP O
22 1101 1102 12707296 / SYM O O
23 1102 1103 12707296 L NN B-NP O
24 1103 1104 12707296 , , O O
25 1105 1106 12707296 P NN B-NP O
26 1106 1107 12707296 < SYM B-NP O
27 1107 1111 12707296 0.05 CD I-NP O
28 1111 1112 12707296 ) ) O O
29 1112 1113 12707296 . . O O

1 1114 1122 12707296 Systolic JJ B-NP O
2 1123 1128 12707296 blood NN I-NP O
3 1129 1137 12707296 pressure NN I-NP O
4 1138 1141 12707296 was VBD B-VP O
5 1142 1150 12707296 elevated VBN I-VP O
6 1151 1153 12707296 by IN B-PP O
7 1154 1156 12707296 an DT B-NP O
8 1157 1164 12707296 average NN I-NP O
9 1165 1167 12707296 of IN B-PP O
10 1168 1169 12707296 7 CD B-NP O
11 1170 1172 12707296 mm NN I-NP O
12 1173 1175 12707296 Hg NN I-NP O
13 1175 1176 12707296 . . O O

1 1177 1184 12707296 Neither CC O O
2 1185 1186 12707296 L NN B-NP B-Chemical
3 1186 1187 12707296 - HYPH I-NP I-Chemical
4 1187 1195 12707296 arginine NN I-NP I-Chemical
5 1196 1205 12707296 transport NN I-NP O
6 1206 1210 12707296 into IN B-PP O
7 1211 1222 12707296 mononuclear JJ B-NP O
8 1223 1228 12707296 cells NNS I-NP O
9 1229 1230 12707296 ( ( O O
10 1230 1237 12707296 placebo NN B-NP O
11 1238 1240 12707296 vs IN B-PP O
12 1241 1247 12707296 active JJ B-NP O
13 1247 1248 12707296 , , I-NP O
14 1249 1254 12707296 26.3+ JJ I-NP O
15 1254 1255 12707296 / SYM I-NP O
16 1255 1256 12707296 - SYM I-NP O
17 1256 1259 12707296 3.6 CD I-NP O
18 1260 1262 12707296 vs IN B-PP O
19 1263 1268 12707296 29.0+ JJ B-NP O
20 1268 1269 12707296 / SYM I-NP O
21 1269 1270 12707296 - SYM I-NP O
22 1270 1273 12707296 2.1 CD B-NP O
23 1274 1278 12707296 pmol NN I-NP O
24 1278 1279 12707296 / SYM B-NP O
25 1279 1281 12707296 10 CD I-NP O
26 1282 1285 12707296 000 CD I-NP O
27 1286 1291 12707296 cells NNS I-NP O
28 1292 1295 12707296 per IN B-PP O
29 1296 1297 12707296 5 CD B-NP O
30 1298 1305 12707296 minutes NNS I-NP O
31 1305 1306 12707296 , , O O
32 1307 1319 12707296 respectively RB B-ADVP O
33 1319 1320 12707296 , , O O
34 1321 1323 12707296 at IN B-PP O
35 1324 1326 12707296 an DT B-NP O
36 1327 1328 12707296 l NN I-NP B-Chemical
37 1328 1329 12707296 - HYPH I-NP I-Chemical
38 1329 1337 12707296 arginine NN I-NP I-Chemical
39 1338 1351 12707296 concentration NN I-NP O
40 1352 1354 12707296 of IN B-PP O
41 1355 1358 12707296 300 CD B-NP O
42 1359 1367 12707296 micromol NN I-NP O
43 1367 1368 12707296 / SYM B-NP O
44 1368 1369 12707296 L NN I-NP O
45 1369 1370 12707296 ) ) O O
46 1371 1374 12707296 nor CC O O
47 1375 1376 12707296 L NN B-NP B-Chemical
48 1376 1377 12707296 - HYPH I-NP I-Chemical
49 1377 1385 12707296 arginine NN I-NP I-Chemical
50 1386 1396 12707296 extraction NN I-NP O
51 1397 1399 12707296 in IN B-PP O
52 1400 1403 12707296 the DT B-NP O
53 1404 1411 12707296 forearm NN I-NP O
54 1412 1413 12707296 ( ( O O
55 1413 1415 12707296 at IN B-PP O
56 1416 1418 12707296 80 CD B-NP O
57 1419 1426 12707296 minutes NNS I-NP O
58 1426 1427 12707296 , , O O
59 1428 1435 12707296 placebo NN B-NP O
60 1436 1438 12707296 vs IN B-PP O
61 1439 1445 12707296 active JJ B-ADJP O
62 1445 1446 12707296 , , O O
63 1447 1448 12707296 1 CD B-NP O
64 1449 1452 12707296 868 CD I-NP O
65 1453 1457 12707296 904+ SYM O O
66 1457 1458 12707296 / SYM O O
67 1458 1459 12707296 - SYM O O
68 1459 1462 12707296 434 CD B-NP O
69 1463 1466 12707296 962 CD I-NP O
70 1467 1469 12707296 vs IN B-PP O
71 1470 1471 12707296 2 CD B-NP O
72 1472 1475 12707296 013 CD I-NP O
73 1476 1480 12707296 910+ SYM B-NP O
74 1480 1481 12707296 / SYM B-NP O
75 1481 1482 12707296 - SYM B-VP O
76 1482 1485 12707296 770 CD B-NP O
77 1486 1489 12707296 619 CD I-NP O
78 1490 1505 12707296 disintegrations NNS I-NP O
79 1506 1509 12707296 per IN B-PP O
80 1510 1516 12707296 minute NN B-NP O
81 1516 1517 12707296 ) ) O O
82 1518 1521 12707296 was VBD B-VP O
83 1522 1530 12707296 affected VBN I-VP O
84 1531 1533 12707296 by IN B-PP O
85 1534 1542 12707296 cortisol NN B-NP B-Chemical
86 1543 1552 12707296 treatment NN I-NP O
87 1552 1553 12707296 ; : O O
88 1554 1556 12707296 ie FW B-NP O
89 1556 1557 12707296 , , O O
90 1558 1562 12707296 that IN B-SBAR O
91 1563 1564 12707296 L NN B-NP B-Chemical
92 1564 1565 12707296 - HYPH B-NP I-Chemical
93 1565 1573 12707296 arginine NN I-NP I-Chemical
94 1574 1580 12707296 uptake NN I-NP O
95 1581 1583 12707296 is VBZ B-VP O
96 1584 1587 12707296 not RB I-VP O
97 1588 1596 12707296 affected VBN I-VP O
98 1597 1599 12707296 by IN B-PP O
99 1600 1605 12707296 short JJ B-NP O
100 1605 1606 12707296 - HYPH I-NP O
101 1606 1610 12707296 term NN I-NP O
102 1611 1619 12707296 cortisol NN I-NP B-Chemical
103 1620 1629 12707296 treatment NN I-NP O
104 1629 1630 12707296 . . O O

1 1631 1633 12707296 We PRP B-NP O
2 1634 1642 12707296 conclude VBP B-VP O
3 1643 1647 12707296 that IN B-SBAR O
4 1648 1656 12707296 cortisol NN B-NP B-Chemical
5 1656 1657 12707296 - HYPH B-NP O
6 1657 1664 12707296 induced VBN I-NP O
7 1665 1674 12707296 increases NNS I-NP B-Disease
8 1675 1677 12707296 in IN B-PP I-Disease
9 1678 1683 12707296 blood NN B-NP I-Disease
10 1684 1692 12707296 pressure NN I-NP I-Disease
11 1693 1696 12707296 are VBP B-VP O
12 1697 1700 12707296 not RB I-VP O
13 1701 1711 12707296 associated VBN I-VP O
14 1712 1716 12707296 with IN B-PP O
15 1717 1730 12707296 abnormalities NNS B-NP O
16 1731 1733 12707296 in IN B-PP O
17 1734 1737 12707296 the DT B-NP O
18 1738 1739 12707296 l NN I-NP B-Chemical
19 1739 1740 12707296 - HYPH I-NP I-Chemical
20 1740 1748 12707296 arginine NN I-NP I-Chemical
21 1749 1758 12707296 transport NN I-NP O
22 1759 1765 12707296 system NN I-NP O
23 1765 1766 12707296 . . O O

1 0 0 2572625 -DOCSTART- -X- -X- O

1 0 11 2572625 Clotiazepam NN B-NP B-Chemical
2 11 12 2572625 - HYPH O O
3 12 19 2572625 induced VBN B-NP O
4 20 25 2572625 acute JJ I-NP O
5 26 35 2572625 hepatitis NN I-NP B-Disease
6 35 36 2572625 . . O O
7 37 39 2572625 We PRP B-NP O
8 40 46 2572625 report VBP B-VP O
9 47 50 2572625 the DT B-NP O
10 51 55 2572625 case NN I-NP O
11 56 58 2572625 of IN B-PP O
12 59 60 2572625 a DT B-NP O
13 61 68 2572625 patient NN I-NP O
14 69 72 2572625 who WP B-NP O
15 73 82 2572625 developed VBD B-VP O
16 83 88 2572625 acute JJ B-NP O
17 89 98 2572625 hepatitis NN I-NP B-Disease
18 99 103 2572625 with IN B-PP O
19 104 113 2572625 extensive JJ B-NP B-Disease
20 114 128 2572625 hepatocellular JJ I-NP I-Disease
21 129 137 2572625 necrosis NN I-NP I-Disease
22 137 138 2572625 , , O O
23 139 140 2572625 7 CD B-NP O
24 141 147 2572625 months NNS I-NP O
25 148 153 2572625 after IN B-SBAR O
26 154 157 2572625 the DT B-NP O
27 158 163 2572625 onset NN I-NP O
28 164 166 2572625 of IN B-PP O
29 167 181 2572625 administration NN B-NP O
30 182 184 2572625 of IN B-PP O
31 185 196 2572625 clotiazepam NN B-NP B-Chemical
32 196 197 2572625 , , O O
33 198 199 2572625 a DT B-NP O
34 200 215 2572625 thienodiazepine NN I-NP B-Chemical
35 216 226 2572625 derivative NN I-NP O
36 226 227 2572625 . . O O

1 228 239 2572625 Clotiazepam NN B-NP B-Chemical
2 240 250 2572625 withdrawal NN I-NP O
3 251 254 2572625 was VBD B-VP O
4 255 263 2572625 followed VBN I-VP O
5 264 266 2572625 by IN B-PP O
6 267 273 2572625 prompt JJ B-NP O
7 274 282 2572625 recovery NN I-NP O
8 282 283 2572625 . . O O

1 284 287 2572625 The DT B-NP O
2 288 302 2572625 administration NN I-NP O
3 303 305 2572625 of IN B-PP O
4 306 313 2572625 several JJ B-NP O
5 314 329 2572625 benzodiazepines NNS I-NP B-Chemical
6 329 330 2572625 , , O O
7 331 341 2572625 chemically RB B-VP O
8 342 349 2572625 related VBN I-VP O
9 350 352 2572625 to TO B-PP O
10 353 364 2572625 clotiazepam NN B-NP B-Chemical
11 364 365 2572625 , , O O
12 366 369 2572625 did VBD B-VP O
13 370 373 2572625 not RB I-VP O
14 374 383 2572625 interfere VB I-VP O
15 384 388 2572625 with IN B-PP O
16 389 397 2572625 recovery NN B-NP O
17 398 401 2572625 and CC O O
18 402 405 2572625 did VBD B-VP O
19 406 409 2572625 not RB I-VP O
20 410 416 2572625 induce VB I-VP O
21 417 420 2572625 any DT B-NP O
22 421 428 2572625 relapse NN I-NP O
23 429 431 2572625 of IN B-PP O
24 432 441 2572625 hepatitis NN B-NP B-Disease
25 441 442 2572625 . . O O

1 443 447 2572625 This DT B-NP O
2 448 459 2572625 observation NN I-NP O
3 460 465 2572625 shows VBZ B-VP O
4 466 470 2572625 that IN B-SBAR O
5 471 482 2572625 clotiazepam NN B-NP B-Chemical
6 483 486 2572625 can MD B-VP O
7 487 493 2572625 induce VB I-VP O
8 494 499 2572625 acute JJ B-NP O
9 500 509 2572625 hepatitis NN I-NP B-Disease
10 510 513 2572625 and CC O O
11 514 522 2572625 suggests VBZ B-VP O
12 523 527 2572625 that IN B-SBAR O
13 528 533 2572625 there EX B-NP O
14 534 536 2572625 is VBZ B-VP O
15 537 539 2572625 no DT B-NP O
16 540 545 2572625 cross JJ I-NP O
17 546 560 2572625 hepatotoxicity NN I-NP B-Disease
18 561 568 2572625 between IN B-PP O
19 569 580 2572625 clotiazepam NN B-NP B-Chemical
20 581 584 2572625 and CC O O
21 585 592 2572625 several JJ B-NP O
22 593 608 2572625 benzodiazepines NNS I-NP B-Chemical
23 608 609 2572625 . . O O

1 0 0 17241784 -DOCSTART- -X- -X- O

1 0 11 17241784 Progressive JJ B-NP O
2 12 20 17241784 myopathy NN I-NP B-Disease
3 21 25 17241784 with IN B-PP O
4 26 28 17241784 up RB B-ADVP O
5 28 29 17241784 - HYPH O O
6 29 39 17241784 regulation NN B-NP O
7 40 42 17241784 of IN B-PP O
8 43 46 17241784 MHC NN B-NP O
9 46 47 17241784 - HYPH B-NP O
10 47 48 17241784 I NN I-NP O
11 49 59 17241784 associated VBN B-VP O
12 60 64 17241784 with IN B-PP O
13 65 71 17241784 statin NN B-NP B-Chemical
14 72 79 17241784 therapy NN I-NP O
15 79 80 17241784 . . I-NP O
16 81 88 17241784 Statins NNPS I-NP B-Chemical
17 89 92 17241784 can MD B-VP O
18 93 98 17241784 cause VB I-VP O
19 99 100 17241784 a DT B-NP O
20 101 112 17241784 necrotizing VBG I-NP O
21 113 121 17241784 myopathy NN I-NP B-Disease
22 122 125 17241784 and CC I-NP O
23 126 138 17241784 hyperCKaemia NN I-NP B-Disease
24 139 144 17241784 which WDT B-NP O
25 145 147 17241784 is VBZ B-VP O
26 148 158 17241784 reversible JJ B-ADJP O
27 159 161 17241784 on IN B-PP O
28 162 171 17241784 cessation NN B-NP O
29 172 174 17241784 of IN B-PP O
30 175 178 17241784 the DT B-NP O
31 179 183 17241784 drug NN I-NP O
32 183 184 17241784 . . O O

1 185 189 17241784 What WP B-NP O
2 190 192 17241784 is VBZ B-VP O
3 193 197 17241784 less RBR I-VP O
4 198 202 17241784 well RB I-VP O
5 203 208 17241784 known VBN I-VP O
6 209 211 17241784 is VBZ B-VP O
7 212 213 17241784 a DT B-NP O
8 214 224 17241784 phenomenon NN I-NP O
9 225 232 17241784 whereby WRB B-ADVP O
10 233 240 17241784 statins NNS B-NP B-Chemical
11 241 244 17241784 may MD B-VP O
12 245 251 17241784 induce VB I-VP O
13 252 253 17241784 a DT B-NP O
14 254 262 17241784 myopathy NN I-NP B-Disease
15 262 263 17241784 , , O O
16 264 269 17241784 which WDT B-NP O
17 270 278 17241784 persists VBZ B-VP O
18 279 281 17241784 or CC O O
19 282 285 17241784 may MD B-VP O
20 286 294 17241784 progress VB I-VP O
21 295 300 17241784 after IN B-PP O
22 301 309 17241784 stopping VBG B-VP O
23 310 313 17241784 the DT B-NP O
24 314 318 17241784 drug NN I-NP O
25 318 319 17241784 . . O O

1 320 322 17241784 We PRP B-NP O
2 323 335 17241784 investigated VBD B-VP O
3 336 339 17241784 the DT B-NP O
4 340 346 17241784 muscle NN I-NP O
5 347 356 17241784 pathology NN I-NP O
6 357 359 17241784 in IN B-PP O
7 360 361 17241784 8 CD B-NP O
8 362 366 17241784 such JJ I-NP O
9 367 372 17241784 cases NNS I-NP O
10 372 373 17241784 . . O O

1 374 377 17241784 All DT B-NP O
2 378 381 17241784 had VBD B-VP O
3 382 390 17241784 myofibre NN B-NP O
4 391 399 17241784 necrosis NN I-NP B-Disease
5 400 403 17241784 but CC O O
6 404 408 17241784 only RB B-NP O
7 409 410 17241784 3 CD I-NP O
8 411 414 17241784 had VBD B-VP O
9 415 417 17241784 an DT B-NP O
10 418 430 17241784 inflammatory JJ I-NP O
11 431 441 17241784 infiltrate NN I-NP O
12 441 442 17241784 . . O O

1 443 445 17241784 In IN B-PP O
2 446 449 17241784 all DT B-NP O
3 450 455 17241784 cases NNS I-NP O
4 456 461 17241784 there EX B-NP O
5 462 465 17241784 was VBD B-VP O
6 466 473 17241784 diffuse JJ B-ADJP O
7 474 476 17241784 or CC I-ADJP O
8 477 487 17241784 multifocal JJ I-ADJP O
9 488 490 17241784 up RB B-ADVP O
10 490 491 17241784 - HYPH O O
11 491 501 17241784 regulation NN B-NP O
12 502 504 17241784 of IN B-PP O
13 505 508 17241784 MHC NN B-NP O
14 508 509 17241784 - HYPH I-NP O
15 509 510 17241784 I NN I-NP O
16 511 521 17241784 expression NN I-NP O
17 522 526 17241784 even RB B-ADVP O
18 527 529 17241784 in IN B-PP O
19 530 533 17241784 non AFX B-NP O
20 533 534 17241784 - HYPH I-NP O
21 534 542 17241784 necrotic JJ I-NP B-Disease
22 543 549 17241784 fibres NNS I-NP O
23 549 550 17241784 . . O O

1 551 562 17241784 Progressive JJ B-NP O
2 563 574 17241784 improvement NN I-NP O
3 575 583 17241784 occurred VBD B-VP O
4 584 586 17241784 in IN B-PP O
5 587 588 17241784 7 CD B-NP O
6 589 594 17241784 cases NNS I-NP O
7 595 600 17241784 after IN B-PP O
8 601 613 17241784 commencement NN B-NP O
9 614 616 17241784 of IN B-PP O
10 617 629 17241784 prednisolone NN B-NP B-Chemical
11 630 633 17241784 and CC I-NP O
12 634 646 17241784 methotrexate NN I-NP B-Chemical
13 646 647 17241784 , , O O
14 648 651 17241784 and CC O O
15 652 654 17241784 in IN B-PP O
16 655 658 17241784 one CD B-NP O
17 659 663 17241784 case NN I-NP O
18 664 677 17241784 spontaneously RB B-ADVP O
19 677 678 17241784 . . O O

1 679 684 17241784 These DT B-NP O
2 685 697 17241784 observations NNS I-NP O
3 698 705 17241784 suggest VBP B-VP O
4 706 710 17241784 that IN B-SBAR O
5 711 718 17241784 statins NNS B-NP B-Chemical
6 719 722 17241784 may MD B-VP O
7 723 731 17241784 initiate VB I-VP O
8 732 734 17241784 an DT B-NP O
9 735 741 17241784 immune JJ I-NP O
10 741 742 17241784 - HYPH I-NP O
11 742 750 17241784 mediated VBN I-NP O
12 751 759 17241784 myopathy NN I-NP B-Disease
13 760 764 17241784 that WDT B-NP O
14 765 773 17241784 persists VBZ B-VP O
15 774 779 17241784 after IN B-PP O
16 780 790 17241784 withdrawal NN B-NP O
17 791 793 17241784 of IN B-PP O
18 794 797 17241784 the DT B-NP O
19 798 802 17241784 drug NN I-NP O
20 803 806 17241784 and CC O O
21 807 815 17241784 responds VBZ B-VP O
22 816 818 17241784 to TO B-PP O
23 819 836 17241784 immunosuppressive JJ B-NP O
24 837 844 17241784 therapy NN I-NP O
25 844 845 17241784 . . O O

1 846 849 17241784 The DT B-NP O
2 850 859 17241784 mechanism NN I-NP O
3 860 862 17241784 of IN B-PP O
4 863 867 17241784 this DT B-NP O
5 868 876 17241784 myopathy NN I-NP B-Disease
6 877 879 17241784 is VBZ B-VP O
7 880 889 17241784 uncertain JJ B-ADJP O
8 890 893 17241784 but CC O O
9 894 897 17241784 may MD B-VP O
10 898 905 17241784 involve VB I-VP O
11 906 909 17241784 the DT B-NP O
12 910 919 17241784 induction NN I-NP O
13 920 922 17241784 by IN B-PP O
14 923 930 17241784 statins NNS B-NP B-Chemical
15 931 933 17241784 of IN B-PP O
16 934 936 17241784 an DT B-NP O
17 937 948 17241784 endoplasmic JJ I-NP O
18 949 958 17241784 reticulum NN I-NP O
19 959 965 17241784 stress NN I-NP O
20 966 974 17241784 response NN I-NP O
21 975 979 17241784 with IN B-PP O
22 980 990 17241784 associated VBN B-VP O
23 991 993 17241784 up RB B-ADVP O
24 993 994 17241784 - HYPH O O
25 994 1004 17241784 regulation NN B-NP O
26 1005 1007 17241784 of IN B-PP O
27 1008 1011 17241784 MHC NN B-NP O
28 1011 1012 17241784 - HYPH I-NP O
29 1012 1013 17241784 I NN I-NP O
30 1014 1024 17241784 expression NN I-NP O
31 1025 1028 17241784 and CC O O
32 1029 1036 17241784 antigen NN B-NP O
33 1037 1049 17241784 presentation NN I-NP O
34 1050 1052 17241784 by IN B-PP O
35 1053 1059 17241784 muscle NN B-NP O
36 1060 1066 17241784 fibres NNS I-NP O
37 1066 1067 17241784 . . O O

1 0 0 3985451 -DOCSTART- -X- -X- O

1 0 8 3985451 Warfarin NN B-NP B-Chemical
2 8 9 3985451 - HYPH B-NP O
3 9 16 3985451 induced VBN I-NP O
4 17 26 3985451 iliopsoas NNS I-NP O
5 27 37 3985451 hemorrhage NN I-NP B-Disease
6 38 42 3985451 with IN B-PP O
7 43 53 3985451 subsequent JJ B-NP O
8 54 61 3985451 femoral JJ I-NP B-Disease
9 62 67 3985451 nerve NN I-NP I-Disease
10 68 73 3985451 palsy NN I-NP I-Disease
11 73 74 3985451 . . O O
12 75 77 3985451 We PRP B-NP O
13 78 85 3985451 present VBP B-VP O
14 86 89 3985451 the DT B-NP O
15 90 94 3985451 case NN I-NP O
16 95 97 3985451 of IN B-PP O
17 98 99 3985451 a DT B-NP O
18 100 102 3985451 28 CD I-NP O
19 102 103 3985451 - HYPH I-NP O
20 103 107 3985451 year NN I-NP O
21 107 108 3985451 - HYPH O O
22 108 111 3985451 old JJ B-NP O
23 112 115 3985451 man NN I-NP O
24 116 118 3985451 on IN B-PP O
25 119 126 3985451 chronic JJ B-NP O
26 127 135 3985451 warfarin NN I-NP B-Chemical
27 136 143 3985451 therapy NN I-NP O
28 144 147 3985451 who WP B-NP O
29 148 157 3985451 sustained VBD B-VP O
30 158 159 3985451 a DT B-NP O
31 160 165 3985451 minor JJ I-NP O
32 166 172 3985451 muscle NN I-NP B-Disease
33 173 177 3985451 tear NN I-NP I-Disease
34 178 181 3985451 and CC O O
35 182 191 3985451 developed VBD B-VP O
36 192 202 3985451 increasing VBG I-VP O
37 203 207 3985451 pain NN B-NP B-Disease
38 208 211 3985451 and CC O O
39 212 213 3985451 a DT B-NP O
40 214 221 3985451 flexure NN I-NP O
41 222 233 3985451 contracture NN I-NP B-Disease
42 234 236 3985451 of IN B-PP O
43 237 240 3985451 the DT B-NP O
44 241 246 3985451 right JJ I-NP O
45 247 250 3985451 hip NN I-NP O
46 250 251 3985451 . . O O

1 252 260 3985451 Surgical JJ B-NP O
2 261 272 3985451 exploration NN I-NP O
3 273 281 3985451 revealed VBD B-VP O
4 282 284 3985451 an DT B-NP O
5 285 294 3985451 iliopsoas JJ I-NP O
6 295 303 3985451 hematoma NN I-NP B-Disease
7 304 307 3985451 and CC O O
8 308 315 3985451 femoral JJ B-NP O
9 316 321 3985451 nerve NN I-NP B-Disease
10 322 332 3985451 entrapment NN I-NP I-Disease
11 332 333 3985451 , , O O
12 334 343 3985451 resulting VBG B-VP O
13 344 346 3985451 in IN B-PP O
14 347 348 3985451 a DT B-NP O
15 349 356 3985451 femoral JJ I-NP B-Disease
16 357 362 3985451 nerve NN I-NP I-Disease
17 363 368 3985451 palsy NN I-NP I-Disease
18 369 372 3985451 and CC O O
19 373 380 3985451 partial JJ B-NP B-Disease
20 381 385 3985451 loss NN I-NP I-Disease
21 386 388 3985451 of IN B-PP I-Disease
22 389 399 3985451 quadriceps NNS B-NP I-Disease
23 400 409 3985451 functions NNS I-NP I-Disease
24 409 410 3985451 . . O O

1 411 424 3985451 Anticoagulant NN B-NP O
2 424 425 3985451 - HYPH O O
3 425 432 3985451 induced VBN B-NP O
4 433 440 3985451 femoral JJ I-NP B-Disease
5 441 446 3985451 nerve NN I-NP I-Disease
6 447 452 3985451 palsy NN I-NP I-Disease
7 453 463 3985451 represents VBZ B-VP O
8 464 467 3985451 the DT B-NP O
9 468 472 3985451 most RBS I-NP O
10 473 479 3985451 common JJ I-NP O
11 480 484 3985451 form NN I-NP O
12 485 487 3985451 of IN B-PP O
13 488 496 3985451 warfarin NN B-NP B-Chemical
14 496 497 3985451 - HYPH B-NP O
15 497 504 3985451 induced VBN I-NP O
16 505 515 3985451 peripheral JJ I-NP B-Disease
17 516 526 3985451 neuropathy NN I-NP I-Disease
18 526 527 3985451 ; : O O
19 528 530 3985451 it PRP B-NP O
20 531 533 3985451 is VBZ B-VP O
21 534 547 3985451 characterized VBN I-VP O
22 548 550 3985451 by IN B-PP O
23 551 557 3985451 severe JJ B-NP O
24 558 562 3985451 pain NN I-NP B-Disease
25 563 565 3985451 in IN B-PP O
26 566 569 3985451 the DT B-NP O
27 570 578 3985451 inguinal JJ I-NP O
28 579 585 3985451 region NN I-NP O
29 585 586 3985451 , , O O
30 587 594 3985451 varying VBG B-VP O
31 595 602 3985451 degrees NNS B-NP O
32 603 605 3985451 of IN B-PP O
33 606 611 3985451 motor NN B-NP B-Disease
34 612 615 3985451 and CC O I-Disease
35 616 623 3985451 sensory JJ B-NP I-Disease
36 624 634 3985451 impairment NN I-NP I-Disease
37 634 635 3985451 , , O O
38 636 639 3985451 and CC O O
39 640 647 3985451 flexure NN B-NP O
40 648 659 3985451 contracture NN I-NP B-Disease
41 660 662 3985451 of IN B-PP O
42 663 666 3985451 the DT B-NP O
43 667 675 3985451 involved VBN I-NP O
44 676 685 3985451 extremity NN I-NP O
45 685 686 3985451 . . O O

1 0 0 567256 -DOCSTART- -X- -X- O

1 0 12 567256 Angiosarcoma NN B-NP B-Disease
2 13 15 567256 of IN B-PP I-Disease
3 16 19 567256 the DT B-NP I-Disease
4 20 25 567256 liver NN I-NP I-Disease
5 26 36 567256 associated VBN B-VP O
6 37 41 567256 with IN B-PP O
7 42 60 567256 diethylstilbestrol NN B-NP B-Chemical
8 60 61 567256 . . O O
9 62 74 567256 Angiosarcoma NN B-NP B-Disease
10 75 77 567256 of IN B-PP I-Disease
11 78 81 567256 the DT B-NP I-Disease
12 82 87 567256 liver NN I-NP I-Disease
13 88 96 567256 occurred VBD B-VP O
14 97 99 567256 in IN B-PP O
15 100 101 567256 a DT B-NP O
16 102 104 567256 76 CD I-NP O
17 104 105 567256 - HYPH I-NP O
18 105 109 567256 year NN I-NP O
19 109 110 567256 - HYPH B-NP O
20 110 113 567256 old JJ I-NP O
21 114 117 567256 man NN I-NP O
22 118 121 567256 who WP B-NP O
23 122 125 567256 had VBD B-VP O
24 126 130 567256 been VBN I-VP O
25 131 138 567256 treated VBN I-VP O
26 139 142 567256 for IN B-PP O
27 143 144 567256 a DT B-NP O
28 145 149 567256 well RB I-NP O
29 149 150 567256 - HYPH I-NP O
30 150 164 567256 differentiated VBN I-NP O
31 165 179 567256 adenocarcinoma NN I-NP B-Disease
32 180 182 567256 of IN B-PP I-Disease
33 183 186 567256 the DT B-NP I-Disease
34 187 192 567256 liver NN I-NP I-Disease
35 193 197 567256 with IN B-PP O
36 198 216 567256 diethylstilbestrol NN B-NP B-Chemical
37 217 220 567256 for IN B-PP O
38 221 223 567256 13 CD B-NP O
39 224 229 567256 years NNS I-NP O
40 229 230 567256 . . O O

1 231 243 567256 Angiosarcoma NN B-NP B-Disease
2 244 247 567256 was VBD B-VP O
3 248 252 567256 also RB B-ADVP O
4 253 260 567256 present JJ B-ADJP O
5 261 267 567256 within IN B-PP O
6 268 277 567256 pulmonary JJ B-NP O
7 278 281 567256 and CC I-NP O
8 282 287 567256 renal JJ I-NP O
9 288 296 567256 arteries NNS I-NP O
10 296 297 567256 . . O O

1 298 301 567256 The DT B-NP O
2 302 313 567256 possibility NN I-NP O
3 314 318 567256 that IN B-SBAR O
4 319 322 567256 the DT B-NP O
5 323 336 567256 intraarterial JJ I-NP B-Disease
6 337 344 567256 lesions NNS I-NP I-Disease
7 345 350 567256 might MD B-VP O
8 351 360 567256 represent VB I-VP O
9 361 372 567256 independent JJ B-NP O
10 373 380 567256 primary JJ I-NP O
11 381 387 567256 tumors NNS I-NP B-Disease
12 388 390 567256 is VBZ B-VP O
13 391 401 567256 considered VBN I-VP O
14 401 402 567256 . . O O

1 0 0 15649445 -DOCSTART- -X- -X- O

1 0 5 15649445 Acute JJ B-NP O
2 6 15 15649445 reserpine NN I-NP B-Chemical
3 16 19 15649445 and CC O O
4 20 30 15649445 subchronic JJ B-NP O
5 31 42 15649445 haloperidol NN I-NP B-Chemical
6 43 53 15649445 treatments NNS I-NP O
7 54 60 15649445 change VBP B-VP O
8 61 73 15649445 synaptosomal JJ B-NP O
9 74 79 15649445 brain NN I-NP O
10 80 89 15649445 glutamate NN I-NP B-Chemical
11 90 96 15649445 uptake NN I-NP O
12 97 100 15649445 and CC O O
13 101 107 15649445 elicit VB B-VP O
14 108 117 15649445 orofacial JJ B-NP B-Disease
15 118 128 15649445 dyskinesia NN I-NP I-Disease
16 129 131 15649445 in IN B-PP O
17 132 136 15649445 rats NNS B-NP O
18 136 137 15649445 . . O O
19 138 147 15649445 Reserpine NN B-NP B-Chemical
20 147 148 15649445 - HYPH B-NP O
21 149 152 15649445 and CC I-NP O
22 153 164 15649445 haloperidol NN I-NP B-Chemical
23 164 165 15649445 - HYPH O O
24 165 172 15649445 induced VBN B-NP O
25 173 182 15649445 orofacial JJ I-NP B-Disease
26 183 193 15649445 dyskinesia NN I-NP I-Disease
27 194 197 15649445 are VBP B-VP O
28 198 206 15649445 putative JJ B-NP O
29 207 213 15649445 animal NN I-NP O
30 214 220 15649445 models NNS I-NP O
31 221 223 15649445 of IN B-PP O
32 224 231 15649445 tardive NN B-NP B-Disease
33 232 242 15649445 dyskinesia NN I-NP I-Disease
34 243 244 15649445 ( ( O O
35 244 246 15649445 TD NN B-NP B-Disease
36 246 247 15649445 ) ) O O
37 248 253 15649445 whose WP$ B-NP O
38 254 269 15649445 pathophysiology NN I-NP O
39 270 273 15649445 has VBZ B-VP O
40 274 278 15649445 been VBN I-VP O
41 279 286 15649445 related VBN I-VP O
42 287 289 15649445 to TO B-PP O
43 290 294 15649445 free JJ B-NP O
44 295 302 15649445 radical NN I-NP O
45 303 313 15649445 generation NN I-NP O
46 314 317 15649445 and CC O O
47 318 327 15649445 oxidative JJ B-NP O
48 328 334 15649445 stress NN I-NP O
49 334 335 15649445 . . O O

1 336 338 15649445 In IN B-PP O
2 339 342 15649445 the DT B-NP O
3 343 350 15649445 present JJ I-NP O
4 351 356 15649445 study NN I-NP O
5 356 357 15649445 , , O O
6 358 361 15649445 the DT B-NP O
7 362 369 15649445 authors NNS I-NP O
8 370 377 15649445 induced VBD B-VP O
9 378 387 15649445 orofacial JJ B-NP B-Disease
10 388 398 15649445 dyskinesia NN I-NP I-Disease
11 399 401 15649445 by IN B-PP O
12 402 407 15649445 acute JJ B-NP O
13 408 417 15649445 reserpine NN I-NP B-Chemical
14 418 421 15649445 and CC O O
15 422 432 15649445 subchronic JJ B-NP O
16 433 444 15649445 haloperidol NN I-NP B-Chemical
17 445 459 15649445 administration NN I-NP O
18 460 462 15649445 to TO B-PP O
19 463 467 15649445 rats NNS B-NP O
20 467 468 15649445 . . O O

1 469 478 15649445 Reserpine NN B-NP B-Chemical
2 479 488 15649445 injection NN I-NP O
3 489 490 15649445 ( ( O O
4 490 493 15649445 one CD B-NP O
5 494 498 15649445 dose NN I-NP O
6 499 501 15649445 of IN B-PP O
7 502 503 15649445 1 CD B-NP O
8 504 506 15649445 mg NN I-NP O
9 506 507 15649445 / SYM B-NP O
10 507 509 15649445 kg NN I-NP O
11 510 513 15649445 s.c NN I-NP O
12 513 514 15649445 . . O O
13 514 515 15649445 ) ) O O
14 516 521 15649445 every DT B-NP O
15 522 527 15649445 other JJ I-NP O
16 528 531 15649445 day NN I-NP O
17 532 535 15649445 for IN B-PP O
18 536 537 15649445 3 CD B-NP O
19 538 542 15649445 days NNS I-NP O
20 543 549 15649445 caused VBD B-VP O
21 550 551 15649445 a DT B-NP O
22 552 563 15649445 significant JJ I-NP O
23 564 572 15649445 increase NN I-NP O
24 573 575 15649445 in IN B-PP O
25 576 583 15649445 vacuous JJ B-NP O
26 584 591 15649445 chewing NN I-NP O
27 591 592 15649445 , , O O
28 593 599 15649445 tongue NN B-NP O
29 600 610 15649445 protrusion NN I-NP O
30 611 614 15649445 and CC I-NP O
31 615 623 15649445 duration NN I-NP O
32 624 626 15649445 of IN B-PP O
33 627 633 15649445 facial JJ B-NP O
34 634 643 15649445 twitching NN I-NP O
35 643 644 15649445 , , O O
36 645 653 15649445 compared VBN B-PP O
37 654 656 15649445 to TO B-PP O
38 657 660 15649445 the DT B-NP O
39 661 668 15649445 control NN I-NP O
40 668 669 15649445 . . O O

1 670 681 15649445 Haloperidol NN B-NP B-Chemical
2 682 696 15649445 administration NN I-NP O
3 697 698 15649445 ( ( O O
4 698 701 15649445 one CD B-NP O
5 702 706 15649445 dose NN I-NP O
6 707 709 15649445 of IN B-PP O
7 710 712 15649445 12 CD B-NP O
8 713 715 15649445 mg NN I-NP O
9 715 716 15649445 / SYM B-NP O
10 716 718 15649445 kg NN I-NP O
11 719 723 15649445 once RB B-ADVP O
12 724 725 15649445 a DT B-NP O
13 726 730 15649445 week NN I-NP O
14 731 734 15649445 s.c NN I-NP O
15 734 735 15649445 . . O O
16 735 736 15649445 ) ) O O
17 737 740 15649445 for IN B-PP O
18 741 742 15649445 4 CD B-NP O
19 743 748 15649445 weeks NNS I-NP O
20 749 755 15649445 caused VBD B-VP O
21 756 758 15649445 an DT B-NP O
22 759 767 15649445 increase NN I-NP O
23 768 770 15649445 in IN B-PP O
24 771 778 15649445 vacuous JJ B-NP O
25 779 786 15649445 chewing NN I-NP O
26 786 787 15649445 , , O O
27 788 794 15649445 tongue NN B-NP O
28 795 805 15649445 protrusion NN I-NP O
29 806 809 15649445 and CC I-NP O
30 810 818 15649445 duration NN I-NP O
31 819 821 15649445 of IN B-PP O
32 822 828 15649445 facial JJ B-NP O
33 829 838 15649445 twitching NN I-NP O
34 839 847 15649445 observed VBN B-VP O
35 848 850 15649445 in IN B-PP O
36 851 855 15649445 four CD B-NP O
37 856 862 15649445 weekly JJ I-NP O
38 863 874 15649445 evaluations NNS I-NP O
39 874 875 15649445 . . O O

1 876 881 15649445 After IN B-PP O
2 882 885 15649445 the DT B-NP O
3 886 896 15649445 treatments NNS I-NP O
4 897 900 15649445 and CC O O
5 901 911 15649445 behavioral JJ B-NP O
6 912 923 15649445 observation NN I-NP O
7 923 924 15649445 , , O O
8 925 934 15649445 glutamate NN B-NP B-Chemical
9 935 941 15649445 uptake NN I-NP O
10 942 944 15649445 by IN B-PP O
11 945 953 15649445 segments NNS B-NP O
12 954 956 15649445 of IN B-PP O
13 957 960 15649445 the DT B-NP O
14 961 966 15649445 brain NN I-NP O
15 967 970 15649445 was VBD B-VP O
16 971 979 15649445 analyzed VBN I-VP O
17 979 980 15649445 . . O O

1 981 982 15649445 A DT B-NP O
2 983 992 15649445 decreased VBN I-NP O
3 993 1002 15649445 glutamate NN I-NP B-Chemical
4 1003 1009 15649445 uptake NN I-NP O
5 1010 1013 15649445 was VBD B-VP O
6 1014 1022 15649445 observed VBN I-VP O
7 1023 1025 15649445 in IN B-PP O
8 1026 1029 15649445 the DT B-NP O
9 1030 1041 15649445 subcortical JJ I-NP O
10 1042 1047 15649445 parts NNS I-NP O
11 1048 1050 15649445 of IN B-PP O
12 1051 1058 15649445 animals NNS B-NP O
13 1059 1066 15649445 treated VBN B-VP O
14 1067 1071 15649445 with IN B-PP O
15 1072 1081 15649445 reserpine NN B-NP B-Chemical
16 1082 1085 15649445 and CC I-NP O
17 1086 1097 15649445 haloperidol NN I-NP B-Chemical
18 1097 1098 15649445 , , O O
19 1099 1107 15649445 compared VBN B-PP O
20 1108 1110 15649445 to TO B-PP O
21 1111 1114 15649445 the DT B-NP O
22 1115 1122 15649445 control NN I-NP O
23 1122 1123 15649445 . . O O

1 1124 1135 15649445 Importantly RB B-ADVP O
2 1135 1136 15649445 , , O O
3 1137 1138 15649445 a DT B-NP O
4 1139 1147 15649445 decrease NN I-NP O
5 1148 1150 15649445 in IN B-PP O
6 1151 1160 15649445 glutamate NN B-NP B-Chemical
7 1161 1167 15649445 uptake NN I-NP O
8 1168 1178 15649445 correlates VBZ B-VP O
9 1179 1189 15649445 negatively RB B-ADVP O
10 1190 1194 15649445 with IN B-PP O
11 1195 1197 15649445 an DT B-NP O
12 1198 1206 15649445 increase NN I-NP O
13 1207 1209 15649445 in IN B-PP O
14 1210 1213 15649445 the DT B-NP O
15 1214 1223 15649445 incidence NN I-NP O
16 1224 1226 15649445 of IN B-PP O
17 1227 1236 15649445 orofacial JJ B-NP B-Disease
18 1237 1247 15649445 diskinesia NN I-NP I-Disease
19 1247 1248 15649445 . . O O

1 1249 1254 15649445 These DT B-NP O
2 1255 1262 15649445 results NNS I-NP O
3 1263 1271 15649445 indicate VBP B-VP O
4 1272 1276 15649445 that IN B-SBAR O
5 1277 1282 15649445 early JJ B-NP O
6 1283 1290 15649445 changes NNS I-NP O
7 1291 1293 15649445 in IN B-PP O
8 1294 1303 15649445 glutamate NN B-NP B-Chemical
9 1304 1313 15649445 transport NN I-NP O
10 1314 1317 15649445 may MD B-VP O
11 1318 1320 15649445 be VB I-VP O
12 1321 1328 15649445 related JJ B-ADJP O
13 1329 1331 15649445 to TO B-PP O
14 1332 1335 15649445 the DT B-NP O
15 1336 1347 15649445 development NN I-NP O
16 1348 1350 15649445 of IN B-PP O
17 1351 1358 15649445 vacuous JJ B-NP O
18 1359 1366 15649445 chewing NN I-NP O
19 1367 1376 15649445 movements NNS I-NP O
20 1377 1379 15649445 in IN B-PP O
21 1380 1384 15649445 rats NNS B-NP O
22 1384 1385 15649445 . . O O

1 0 0 16858720 -DOCSTART- -X- -X- O

1 0 8 16858720 Cerebral JJ B-NP B-Disease
2 9 20 16858720 haemorrhage NN I-NP I-Disease
3 21 28 16858720 induced VBN B-VP O
4 29 31 16858720 by IN B-PP O
5 32 40 16858720 warfarin NN B-NP B-Chemical
6 41 42 16858720 - HYPH O O
7 43 46 16858720 the DT B-NP O
8 47 56 16858720 influence NN I-NP O
9 57 59 16858720 of IN B-PP O
10 60 64 16858720 drug NN B-NP O
11 64 65 16858720 - HYPH I-NP O
12 65 69 16858720 drug NN I-NP O
13 70 82 16858720 interactions NNS I-NP O
14 82 83 16858720 . . I-NP O
15 84 91 16858720 PURPOSE NN I-NP O
16 91 92 16858720 : : O O
17 93 95 16858720 To TO B-VP O
18 96 104 16858720 evaluate VB I-VP O
19 105 108 16858720 the DT B-NP O
20 109 118 16858720 frequency NN I-NP O
21 118 119 16858720 , , I-NP O
22 120 128 16858720 severity NN I-NP O
23 129 132 16858720 and CC I-NP O
24 133 147 16858720 preventability NN I-NP O
25 148 150 16858720 of IN B-PP O
26 151 159 16858720 warfarin NN B-NP B-Chemical
27 159 160 16858720 - HYPH O O
28 160 167 16858720 induced VBN B-NP O
29 168 176 16858720 cerebral JJ I-NP B-Disease
30 177 189 16858720 haemorrhages NNS I-NP I-Disease
31 190 193 16858720 due JJ B-ADJP O
32 194 196 16858720 to TO B-PP O
33 197 205 16858720 warfarin NN B-NP B-Chemical
34 206 209 16858720 and CC I-NP O
35 210 218 16858720 warfarin NN I-NP B-Chemical
36 218 219 16858720 - HYPH B-NP O
37 219 223 16858720 drug NN I-NP O
38 224 236 16858720 interactions NNS I-NP O
39 237 239 16858720 in IN B-PP O
40 240 248 16858720 patients NNS B-NP O
41 249 255 16858720 living VBG B-VP O
42 256 258 16858720 in IN B-PP O
43 259 262 16858720 the DT B-NP O
44 263 269 16858720 county NN I-NP O
45 270 272 16858720 of IN B-PP O
46 273 279 16858720 Osterg NNP B-NP O
47 281 286 16858720 tland NNP I-NP O
48 286 287 16858720 , , O O
49 288 294 16858720 Sweden NNP B-NP O
50 294 295 16858720 . . O O

1 296 303 16858720 METHODS NNS B-NP O
2 303 304 16858720 : : O O
3 305 308 16858720 All DT B-NP O
4 309 317 16858720 patients NNS I-NP O
5 318 322 16858720 with IN B-PP O
6 323 324 16858720 a DT B-NP O
7 325 334 16858720 diagnosed VBN I-NP O
8 335 343 16858720 cerebral JJ I-NP B-Disease
9 344 355 16858720 haemorrhage NN I-NP I-Disease
10 356 358 16858720 at IN B-PP O
11 359 364 16858720 three CD B-NP O
12 365 374 16858720 hospitals NNS I-NP O
13 375 381 16858720 during IN B-PP O
14 382 385 16858720 the DT B-NP O
15 386 392 16858720 period NN I-NP O
16 393 397 16858720 2000 CD I-NP O
17 397 398 16858720 - HYPH I-NP O
18 398 402 16858720 2002 CD I-NP O
19 403 407 16858720 were VBD B-VP O
20 408 418 16858720 identified VBN I-VP O
21 418 419 16858720 . . O O

1 420 427 16858720 Medical JJ B-NP O
2 428 435 16858720 records NNS I-NP O
3 436 440 16858720 were VBD B-VP O
4 441 448 16858720 studied VBN I-VP O
5 449 464 16858720 retrospectively RB B-ADVP O
6 465 467 16858720 to TO B-VP O
7 468 476 16858720 evaluate VB I-VP O
8 477 484 16858720 whether IN B-SBAR O
9 485 493 16858720 warfarin NN B-NP B-Chemical
10 494 497 16858720 and CC I-NP O
11 498 506 16858720 warfarin NN I-NP B-Chemical
12 506 507 16858720 - HYPH O O
13 507 511 16858720 drug NN B-NP O
14 512 524 16858720 interactions NNS I-NP O
15 525 530 16858720 could MD B-VP O
16 531 535 16858720 have VB I-VP O
17 536 542 16858720 caused VBN I-VP O
18 543 546 16858720 the DT B-NP O
19 547 555 16858720 cerebral JJ I-NP B-Disease
20 556 567 16858720 haemorrhage NN I-NP I-Disease
21 567 568 16858720 . . O O

1 569 572 16858720 The DT B-NP O
2 573 583 16858720 proportion NN I-NP O
3 584 586 16858720 of IN B-PP O
4 587 595 16858720 possibly RB B-NP O
5 596 605 16858720 avoidable JJ I-NP O
6 606 611 16858720 cases NNS I-NP O
7 612 615 16858720 due JJ B-ADJP O
8 616 618 16858720 to TO B-PP O
9 619 623 16858720 drug NN B-NP O
10 624 636 16858720 interactions NNS I-NP O
11 637 640 16858720 was VBD B-VP O
12 641 650 16858720 estimated VBN I-VP O
13 650 651 16858720 . . O O

1 652 659 16858720 RESULTS NNS B-NP O
2 659 660 16858720 : : O O
3 661 666 16858720 Among IN B-PP O
4 667 670 16858720 593 CD B-NP O
5 671 679 16858720 patients NNS I-NP O
6 680 684 16858720 with IN B-PP O
7 685 693 16858720 cerebral JJ B-NP B-Disease
8 694 705 16858720 haemorrhage NN I-NP I-Disease
9 705 706 16858720 , , O O
10 707 709 16858720 59 CD B-NP O
11 710 711 16858720 ( ( O O
12 711 714 16858720 10% CD B-NP O
13 714 715 16858720 ) ) O O
14 716 720 16858720 were VBD B-VP O
15 721 729 16858720 assessed VBN I-VP O
16 730 732 16858720 as IN B-SBAR O
17 733 740 16858720 related VBN B-VP O
18 741 743 16858720 to TO B-PP O
19 744 752 16858720 warfarin NN B-NP B-Chemical
20 753 762 16858720 treatment NN I-NP O
21 762 763 16858720 . . O O

1 764 768 16858720 This DT B-NP O
2 769 774 16858720 imply VBP B-VP O
3 775 777 16858720 an DT B-NP O
4 778 787 16858720 incidence NN I-NP O
5 788 790 16858720 of IN B-PP O
6 791 794 16858720 1.7 CD B-NP O
7 794 795 16858720 / SYM I-NP O
8 795 802 16858720 100,000 CD I-NP O
9 803 812 16858720 treatment NN I-NP O
10 813 818 16858720 years NNS I-NP O
11 818 819 16858720 . . O O

1 820 822 16858720 Of IN B-PP O
2 823 826 16858720 the DT B-NP O
3 827 829 16858720 59 CD I-NP O
4 830 835 16858720 cases NNS I-NP O
5 835 836 16858720 , , O O
6 837 839 16858720 26 CD B-NP O
7 840 841 16858720 ( ( O O
8 841 844 16858720 44% NN B-NP O
9 844 845 16858720 ) ) O O
10 846 849 16858720 had VBD B-VP O
11 850 851 16858720 a DT B-NP O
12 852 857 16858720 fatal JJ I-NP O
13 858 865 16858720 outcome NN I-NP O
14 865 866 16858720 , , O O
15 867 875 16858720 compared VBN B-PP O
16 876 878 16858720 to TO B-PP O
17 879 882 16858720 136 CD B-NP O
18 883 884 16858720 ( ( O O
19 884 887 16858720 25% NN B-NP O
20 887 888 16858720 ) ) O O
21 889 894 16858720 among IN B-PP O
22 895 898 16858720 the DT B-NP O
23 899 902 16858720 non AFX I-NP O
24 902 903 16858720 - HYPH I-NP O
25 903 911 16858720 warfarin NN B-NP B-Chemical
26 912 920 16858720 patients NNS I-NP O
27 921 922 16858720 ( ( O O
28 922 923 16858720 p NN B-NP O
29 924 925 16858720 < SYM O O
30 926 930 16858720 0.01 CD B-NP O
31 930 931 16858720 ) ) O O
32 931 932 16858720 . . O O

1 933 934 16858720 A DT B-NP O
2 935 943 16858720 warfarin NN I-NP B-Chemical
3 943 944 16858720 - HYPH I-NP O
4 944 948 16858720 drug NN I-NP O
5 949 960 16858720 interaction NN I-NP O
6 961 966 16858720 could MD B-VP O
7 967 971 16858720 have VB I-VP O
8 972 983 16858720 contributed VBN I-VP O
9 984 986 16858720 to TO B-PP O
10 987 990 16858720 the DT B-NP O
11 991 1002 16858720 haemorrhage NN I-NP B-Disease
12 1003 1005 16858720 in IN B-PP O
13 1006 1008 16858720 24 CD B-NP O
14 1009 1010 16858720 ( ( O O
15 1010 1013 16858720 41% NN B-NP O
16 1013 1014 16858720 ) ) O O
17 1015 1017 16858720 of IN B-PP O
18 1018 1021 16858720 the DT B-NP O
19 1022 1030 16858720 warfarin NN I-NP B-Chemical
20 1031 1039 16858720 patients NNS I-NP O
21 1040 1043 16858720 and CC O O
22 1044 1046 16858720 in IN B-PP O
23 1047 1048 16858720 7 CD B-NP O
24 1049 1051 16858720 of IN B-PP O
25 1052 1057 16858720 these DT B-NP O
26 1058 1059 16858720 ( ( O O
27 1059 1062 16858720 12% NN O O
28 1062 1063 16858720 ) ) O O
29 1064 1067 16858720 the DT B-NP O
30 1068 1076 16858720 bleeding VBG I-NP B-Disease
31 1077 1089 16858720 complication NN I-NP O
32 1090 1093 16858720 was VBD B-VP O
33 1094 1104 16858720 considered VBN I-VP O
34 1105 1110 16858720 being VBG B-VP O
35 1111 1119 16858720 possible JJ B-ADJP O
36 1120 1122 16858720 to TO B-VP O
37 1123 1128 16858720 avoid VB I-VP O
38 1128 1129 16858720 . . O O

1 1130 1141 16858720 CONCLUSIONS NNS B-NP O
2 1141 1142 16858720 : : O O
3 1143 1151 16858720 Warfarin NN B-NP B-Chemical
4 1151 1152 16858720 - HYPH O O
5 1152 1159 16858720 induced VBN B-NP O
6 1160 1168 16858720 cerebral JJ I-NP B-Disease
7 1169 1181 16858720 haemorrhages NNS I-NP I-Disease
8 1182 1185 16858720 are VBP B-VP O
9 1186 1187 16858720 a DT B-NP O
10 1188 1193 16858720 major JJ I-NP O
11 1194 1202 16858720 clinical JJ I-NP O
12 1203 1210 16858720 problem NN I-NP O
13 1211 1215 16858720 with IN B-PP O
14 1216 1217 16858720 a DT B-NP O
15 1218 1222 16858720 high JJ I-NP O
16 1223 1231 16858720 fatality NN I-NP O
17 1232 1236 16858720 rate NN I-NP O
18 1236 1237 16858720 . . O O

1 1238 1244 16858720 Almost RB B-NP O
2 1245 1249 16858720 half NN I-NP O
3 1250 1252 16858720 of IN B-PP O
4 1253 1256 16858720 the DT B-NP O
5 1257 1262 16858720 cases NNS I-NP O
6 1263 1266 16858720 was VBD B-VP O
7 1267 1274 16858720 related VBN B-ADJP O
8 1275 1277 16858720 to TO B-PP O
9 1278 1279 16858720 a DT B-NP O
10 1280 1288 16858720 warfarin NN I-NP B-Chemical
11 1288 1289 16858720 - HYPH B-NP O
12 1289 1293 16858720 drug NN I-NP O
13 1294 1305 16858720 interaction NN I-NP O
14 1305 1306 16858720 . . O O

1 1307 1308 16858720 A DT B-NP O
2 1309 1320 16858720 significant JJ I-NP O
3 1321 1331 16858720 proportion NN I-NP O
4 1332 1334 16858720 of IN B-PP O
5 1335 1343 16858720 warfarin NN B-NP B-Chemical
6 1343 1344 16858720 - HYPH O O
7 1344 1351 16858720 related VBN B-NP O
8 1352 1360 16858720 cerebral JJ I-NP B-Disease
9 1361 1373 16858720 haemorrhages NNS I-NP I-Disease
10 1374 1379 16858720 might MD B-VP O
11 1380 1384 16858720 have VB I-VP O
12 1385 1389 16858720 been VBN I-VP O
13 1390 1399 16858720 prevented VBN I-VP O
14 1400 1402 16858720 if IN B-SBAR O
15 1403 1410 16858720 greater JJR B-NP O
16 1411 1418 16858720 caution NN I-NP O
17 1419 1422 16858720 had VBD B-VP O
18 1423 1427 16858720 been VBN I-VP O
19 1428 1433 16858720 taken VBN I-VP O
20 1434 1438 16858720 when WRB B-ADVP O
21 1439 1450 16858720 prescribing VBG B-VP O
22 1451 1456 16858720 drugs NNS B-NP O
23 1457 1462 16858720 known VBN B-VP O
24 1463 1465 16858720 to TO B-VP O
25 1466 1474 16858720 interact VB I-VP O
26 1475 1479 16858720 with IN B-PP O
27 1480 1488 16858720 warfarin NN B-NP B-Chemical
28 1488 1489 16858720 . . O O

1 0 0 11027905 -DOCSTART- -X- -X- O

1 0 9 11027905 Analgesic JJ B-NP O
2 10 16 11027905 effect NN I-NP O
3 17 19 11027905 of IN B-PP O
4 20 31 11027905 intravenous JJ B-NP O
5 32 40 11027905 ketamine NN I-NP B-Chemical
6 41 43 11027905 in IN B-PP O
7 44 50 11027905 cancer NN B-NP B-Disease
8 51 59 11027905 patients NNS I-NP O
9 60 62 11027905 on IN B-PP O
10 63 71 11027905 morphine NN B-NP B-Chemical
11 72 79 11027905 therapy NN I-NP O
12 79 80 11027905 : : O O
13 81 82 11027905 a DT B-NP O
14 83 93 11027905 randomized VBN I-NP O
15 93 94 11027905 , , I-NP O
16 95 105 11027905 controlled VBN I-NP O
17 105 106 11027905 , , I-NP O
18 107 113 11027905 double JJ I-NP O
19 113 114 11027905 - HYPH I-NP O
20 114 119 11027905 blind JJ I-NP O
21 119 120 11027905 , , I-NP O
22 121 130 11027905 crossover JJ I-NP O
23 130 131 11027905 , , I-NP O
24 132 138 11027905 double JJ I-NP O
25 138 139 11027905 - HYPH I-NP O
26 139 143 11027905 dose NN I-NP O
27 144 149 11027905 study NN I-NP O
28 149 150 11027905 . . O O
29 151 155 11027905 Pain NNP B-NP B-Disease
30 156 159 11027905 not RB O O
31 160 170 11027905 responsive JJ B-ADJP O
32 171 173 11027905 to TO B-PP O
33 174 182 11027905 morphine NN B-NP B-Chemical
34 183 185 11027905 is VBZ B-VP O
35 186 191 11027905 often RB B-ADVP O
36 192 203 11027905 problematic JJ B-ADJP O
37 203 204 11027905 . . O O

1 205 211 11027905 Animal NN B-NP O
2 212 215 11027905 and CC O O
3 216 224 11027905 clinical JJ B-NP O
4 225 232 11027905 studies NNS I-NP O
5 233 237 11027905 have VBP B-VP O
6 238 247 11027905 suggested VBN I-VP O
7 248 252 11027905 that IN B-SBAR O
8 253 254 11027905 N NN B-NP B-Chemical
9 254 255 11027905 - HYPH B-NP I-Chemical
10 255 261 11027905 methyl NN I-NP I-Chemical
11 261 262 11027905 - HYPH B-NP I-Chemical
12 262 263 11027905 D NN I-NP I-Chemical
13 263 264 11027905 - HYPH O I-Chemical
14 264 273 11027905 aspartate NN B-NP I-Chemical
15 274 275 11027905 ( ( O O
16 275 279 11027905 NMDA NN B-NP B-Chemical
17 279 280 11027905 ) ) O O
18 281 292 11027905 antagonists NNS B-NP O
19 292 293 11027905 , , O O
20 294 298 11027905 such JJ B-PP O
21 299 301 11027905 as IN I-PP O
22 302 310 11027905 ketamine NN B-NP B-Chemical
23 310 311 11027905 , , O O
24 312 315 11027905 may MD B-VP O
25 316 318 11027905 be VB I-VP O
26 319 328 11027905 effective JJ B-ADJP O
27 329 331 11027905 in IN B-PP O
28 332 341 11027905 improving VBG B-VP O
29 342 348 11027905 opioid JJ B-NP O
30 349 358 11027905 analgesia NN I-NP O
31 359 361 11027905 in IN B-PP O
32 362 371 11027905 difficult JJ B-NP O
33 372 376 11027905 pain NN I-NP B-Disease
34 377 386 11027905 syndromes NNS I-NP O
35 386 387 11027905 , , O O
36 388 392 11027905 such JJ B-PP O
37 393 395 11027905 as IN I-PP O
38 396 407 11027905 neuropathic JJ B-NP B-Disease
39 408 412 11027905 pain NN I-NP I-Disease
40 412 413 11027905 . . O O

1 414 415 11027905 A DT B-NP O
2 416 420 11027905 slow JJ I-NP O
3 421 426 11027905 bolus NN I-NP O
4 427 429 11027905 of IN B-PP O
5 430 441 11027905 subhypnotic JJ B-NP O
6 442 447 11027905 doses NNS I-NP O
7 448 450 11027905 of IN B-PP O
8 451 459 11027905 ketamine NN B-NP B-Chemical
9 460 461 11027905 ( ( O O
10 461 465 11027905 0.25 CD B-NP O
11 466 468 11027905 mg NN I-NP O
12 468 469 11027905 / SYM B-NP O
13 469 471 11027905 kg NN B-NP O
14 472 474 11027905 or CC O O
15 475 479 11027905 0.50 CD B-NP O
16 480 482 11027905 mg NN I-NP O
17 482 483 11027905 / SYM B-NP O
18 483 485 11027905 kg NN I-NP O
19 485 486 11027905 ) ) O O
20 487 490 11027905 was VBD B-VP O
21 491 496 11027905 given VBN I-VP O
22 497 499 11027905 to TO B-PP O
23 500 502 11027905 10 CD B-NP O
24 503 509 11027905 cancer NN I-NP B-Disease
25 510 518 11027905 patients NNS I-NP O
26 519 524 11027905 whose WP$ B-NP O
27 525 529 11027905 pain NN I-NP B-Disease
28 530 533 11027905 was VBD B-VP O
29 534 544 11027905 unrelieved JJ B-ADJP O
30 545 547 11027905 by IN B-PP O
31 548 556 11027905 morphine NN B-NP B-Chemical
32 557 559 11027905 in IN B-PP O
33 560 561 11027905 a DT B-NP O
34 562 572 11027905 randomized VBN I-NP O
35 572 573 11027905 , , I-NP O
36 574 580 11027905 double JJ I-NP O
37 580 581 11027905 - HYPH I-NP O
38 581 586 11027905 blind JJ I-NP O
39 586 587 11027905 , , I-NP O
40 588 597 11027905 crossover JJ I-NP O
41 597 598 11027905 , , I-NP O
42 599 605 11027905 double JJ I-NP O
43 605 606 11027905 - HYPH I-NP O
44 606 610 11027905 dose NN I-NP O
45 611 616 11027905 study NN I-NP O
46 616 617 11027905 . . O O

1 618 622 11027905 Pain NN B-NP B-Disease
2 623 632 11027905 intensity NN I-NP O
3 633 635 11027905 on IN B-PP O
4 636 637 11027905 a DT B-NP O
5 638 639 11027905 0 CD I-NP O
6 640 642 11027905 to TO I-NP O
7 643 645 11027905 10 CD I-NP O
8 646 655 11027905 numerical JJ I-NP O
9 656 661 11027905 scale NN I-NP O
10 661 662 11027905 ; : O O
11 663 669 11027905 nausea NN B-NP B-Disease
12 670 673 11027905 and CC I-NP O
13 674 682 11027905 vomiting NN I-NP B-Disease
14 682 683 11027905 , , O O
15 684 694 11027905 drowsiness NN B-NP O
16 694 695 11027905 , , O O
17 696 705 11027905 confusion NN B-NP B-Disease
18 705 706 11027905 , , O O
19 707 710 11027905 and CC O O
20 711 714 11027905 dry JJ B-NP B-Disease
21 715 720 11027905 mouth NN I-NP I-Disease
22 720 721 11027905 , , O O
23 722 727 11027905 using VBG B-VP O
24 728 729 11027905 a DT B-NP O
25 730 735 11027905 scale NN I-NP O
26 736 740 11027905 from IN B-PP O
27 741 742 11027905 0 CD B-NP O
28 743 745 11027905 to TO B-PP O
29 746 747 11027905 3 CD B-NP O
30 748 749 11027905 ( ( O O
31 749 752 11027905 not RB O O
32 753 755 11027905 at IN B-ADVP O
33 756 759 11027905 all DT I-ADVP O
34 759 760 11027905 , , O O
35 761 767 11027905 slight JJ B-ADJP O
36 767 768 11027905 , , O O
37 769 770 11027905 a DT B-NP O
38 771 774 11027905 lot NN I-NP O
39 774 775 11027905 , , O O
40 776 781 11027905 awful JJ B-ADJP O
41 781 782 11027905 ) ) O O
42 782 783 11027905 ; : O O
43 784 788 11027905 Mini NNP B-NP O
44 788 789 11027905 - : O O
45 789 795 11027905 Mental NNP B-NP O
46 796 801 11027905 State NNP I-NP O
47 802 813 11027905 Examination NNP I-NP O
48 814 815 11027905 ( ( O O
49 815 819 11027905 MMSE NN B-NP O
50 819 820 11027905 ) ) O O
51 821 822 11027905 ( ( O O
52 822 823 11027905 0 CD B-NP O
53 823 824 11027905 - HYPH I-NP O
54 824 826 11027905 30 CD I-NP O
55 826 827 11027905 ) ) O O
56 827 828 11027905 ; : O O
57 829 832 11027905 and CC O O
58 833 841 11027905 arterial JJ B-NP O
59 842 850 11027905 pressure NN I-NP O
60 851 855 11027905 were VBD B-VP O
61 856 864 11027905 recorded VBN I-VP O
62 865 871 11027905 before IN B-PP O
63 872 886 11027905 administration NN B-NP O
64 887 889 11027905 of IN B-PP O
65 890 895 11027905 drugs NNS B-NP O
66 896 897 11027905 ( ( O O
67 897 899 11027905 T0 NN B-NP O
68 899 900 11027905 ) ) O O
69 901 904 11027905 and CC O O
70 905 910 11027905 after IN B-PP O
71 911 913 11027905 30 CD B-NP O
72 914 921 11027905 minutes NNS I-NP O
73 922 923 11027905 ( ( O O
74 923 926 11027905 T30 NN B-NP O
75 926 927 11027905 ) ) O O
76 927 928 11027905 , , O O
77 929 931 11027905 60 CD B-NP O
78 932 939 11027905 minutes NNS I-NP O
79 940 941 11027905 ( ( O O
80 941 944 11027905 T60 NN B-NP O
81 944 945 11027905 ) ) O O
82 945 946 11027905 , , O O
83 947 950 11027905 120 CD B-NP O
84 951 958 11027905 minutes NNS I-NP O
85 959 960 11027905 ( ( O O
86 960 964 11027905 T120 NN B-NP O
87 964 965 11027905 ) ) O O
88 965 966 11027905 , , O O
89 967 970 11027905 and CC O O
90 971 974 11027905 180 CD B-NP O
91 975 982 11027905 minutes NNS I-NP O
92 983 984 11027905 ( ( O O
93 984 988 11027905 T180 NN B-NP O
94 988 989 11027905 ) ) O O
95 989 990 11027905 . . O O

1 991 999 11027905 Ketamine NN B-NP B-Chemical
2 999 1000 11027905 , , O O
3 1001 1004 11027905 but CC O O
4 1005 1008 11027905 not RB O O
5 1009 1015 11027905 saline NN B-NP O
6 1016 1024 11027905 solution NN I-NP O
7 1024 1025 11027905 , , O O
8 1026 1039 11027905 significantly RB B-VP O
9 1040 1047 11027905 reduced VBD I-VP O
10 1048 1051 11027905 the DT B-NP O
11 1052 1056 11027905 pain NN I-NP B-Disease
12 1057 1066 11027905 intensity NN I-NP O
13 1067 1069 11027905 in IN B-PP O
14 1070 1076 11027905 almost RB B-NP O
15 1077 1080 11027905 all PDT I-NP O
16 1081 1084 11027905 the DT I-NP O
17 1085 1093 11027905 patients NNS I-NP O
18 1094 1096 11027905 at IN B-PP O
19 1097 1101 11027905 both DT B-NP O
20 1102 1107 11027905 doses NNS I-NP O
21 1107 1108 11027905 . . O O

1 1109 1113 11027905 This DT B-NP O
2 1114 1120 11027905 effect NN I-NP O
3 1121 1124 11027905 was VBD B-VP O
4 1125 1129 11027905 more RBR B-ADJP O
5 1130 1138 11027905 relevant JJ I-ADJP O
6 1139 1141 11027905 in IN B-PP O
7 1142 1150 11027905 patients NNS B-NP O
8 1151 1158 11027905 treated VBN B-VP O
9 1159 1163 11027905 with IN B-PP O
10 1164 1170 11027905 higher JJR B-NP O
11 1171 1176 11027905 doses NNS I-NP O
12 1176 1177 11027905 . . O O

1 1178 1192 11027905 Hallucinations NNS B-NP B-Disease
2 1193 1201 11027905 occurred VBD B-VP O
3 1202 1204 11027905 in IN B-PP O
4 1205 1206 11027905 4 CD B-NP O
5 1207 1215 11027905 patients NNS I-NP O
6 1215 1216 11027905 , , O O
7 1217 1220 11027905 and CC O O
8 1221 1223 11027905 an DT B-NP O
9 1224 1234 11027905 unpleasant JJ I-NP O
10 1235 1244 11027905 sensation NN I-NP O
11 1245 1246 11027905 ( ( O O
12 1246 1247 11027905 " `` O O
13 1247 1252 11027905 empty JJ B-NP O
14 1253 1257 11027905 head NN I-NP O
15 1257 1258 11027905 " '' O O
16 1258 1259 11027905 ) ) O O
17 1260 1263 11027905 was VBD B-VP O
18 1264 1268 11027905 also RB I-VP O
19 1269 1277 11027905 reported VBN I-VP O
20 1278 1280 11027905 by IN B-PP O
21 1281 1282 11027905 2 CD B-NP O
22 1283 1291 11027905 patients NNS I-NP O
23 1291 1292 11027905 . . O O

1 1293 1298 11027905 These DT B-NP O
2 1299 1307 11027905 episodes NNS I-NP O
3 1308 1316 11027905 reversed VBD B-VP O
4 1317 1322 11027905 after IN B-SBAR O
5 1323 1326 11027905 the DT B-NP O
6 1327 1341 11027905 administration NN I-NP O
7 1342 1344 11027905 of IN B-PP O
8 1345 1353 11027905 diazepam NN B-NP B-Chemical
9 1354 1355 11027905 1 CD I-NP O
10 1356 1358 11027905 mg NN I-NP O
11 1359 1372 11027905 intravenously RB B-ADVP O
12 1372 1373 11027905 . . O O

1 1374 1385 11027905 Significant JJ B-NP O
2 1386 1395 11027905 increases NNS I-NP O
3 1396 1398 11027905 in IN B-PP O
4 1399 1409 11027905 drowsiness NN B-NP O
5 1410 1414 11027905 were VBD B-VP O
6 1415 1423 11027905 reported VBN I-VP O
7 1424 1426 11027905 in IN B-PP O
8 1427 1435 11027905 patients NNS B-NP O
9 1436 1443 11027905 treated VBN B-VP O
10 1444 1448 11027905 with IN B-PP O
11 1449 1457 11027905 ketamine NN B-NP B-Chemical
12 1458 1460 11027905 in IN B-PP O
13 1461 1465 11027905 both CC O O
14 1466 1472 11027905 groups NNS B-NP O
15 1473 1476 11027905 and CC O O
16 1477 1481 11027905 were VBD B-VP O
17 1482 1486 11027905 more RBR B-ADJP O
18 1487 1493 11027905 marked JJ I-ADJP O
19 1494 1498 11027905 with IN B-PP O
20 1499 1507 11027905 ketamine NN B-NP B-Chemical
21 1508 1512 11027905 0.50 CD I-NP O
22 1513 1515 11027905 mg NN I-NP O
23 1515 1516 11027905 / SYM B-NP O
24 1516 1518 11027905 kg NN I-NP O
25 1518 1519 11027905 . . O O

1 1520 1521 11027905 A DT B-NP O
2 1522 1533 11027905 significant JJ I-NP O
3 1534 1544 11027905 difference NN I-NP O
4 1545 1547 11027905 in IN B-PP O
5 1548 1552 11027905 MMSE NN B-NP O
6 1553 1556 11027905 was VBD B-VP O
7 1557 1565 11027905 observed VBN I-VP O
8 1566 1568 11027905 at IN B-PP O
9 1569 1572 11027905 T30 NN B-NP O
10 1573 1575 11027905 in IN B-PP O
11 1576 1584 11027905 patients NNS B-NP O
12 1585 1588 11027905 who WP B-NP O
13 1589 1597 11027905 received VBD B-VP O
14 1598 1602 11027905 0.50 CD B-NP O
15 1603 1605 11027905 mg NN I-NP O
16 1605 1606 11027905 / SYM B-NP O
17 1606 1608 11027905 kg NN I-NP O
18 1609 1611 11027905 of IN B-PP O
19 1612 1620 11027905 ketamine NN B-NP B-Chemical
20 1620 1621 11027905 . . O O

1 1622 1630 11027905 Ketamine NN B-NP B-Chemical
2 1631 1634 11027905 can MD B-VP O
3 1635 1642 11027905 improve VB I-VP O
4 1643 1651 11027905 morphine NN B-NP B-Chemical
5 1652 1661 11027905 analgesia NN I-NP O
6 1662 1664 11027905 in IN B-PP O
7 1665 1674 11027905 difficult JJ B-NP O
8 1675 1679 11027905 pain NN I-NP B-Disease
9 1680 1689 11027905 syndromes NNS I-NP O
10 1689 1690 11027905 , , O O
11 1691 1695 11027905 such JJ B-PP O
12 1696 1698 11027905 as IN I-PP O
13 1699 1710 11027905 neuropathic JJ B-NP B-Disease
14 1711 1715 11027905 pain NN I-NP I-Disease
15 1715 1716 11027905 . . O O

1 1717 1724 11027905 However RB B-ADVP O
2 1724 1725 11027905 , , O O
3 1726 1729 11027905 the DT B-NP O
4 1730 1740 11027905 occurrence NN I-NP O
5 1741 1743 11027905 of IN B-PP O
6 1744 1751 11027905 central JJ B-NP O
7 1752 1759 11027905 adverse JJ I-NP O
8 1760 1767 11027905 effects NNS I-NP O
9 1768 1774 11027905 should MD B-VP O
10 1775 1777 11027905 be VB I-VP O
11 1778 1783 11027905 taken VBN I-VP O
12 1784 1788 11027905 into IN B-PP O
13 1789 1796 11027905 account NN B-NP O
14 1796 1797 11027905 , , O O
15 1798 1808 11027905 especially RB B-ADVP O
16 1809 1813 11027905 when WRB B-ADVP O
17 1814 1819 11027905 using VBG B-VP O
18 1820 1826 11027905 higher JJR B-NP O
19 1827 1832 11027905 doses NNS I-NP O
20 1832 1833 11027905 . . O O

1 1834 1838 11027905 This DT B-NP O
2 1839 1850 11027905 observation NN I-NP O
3 1851 1857 11027905 should MD B-VP O
4 1858 1860 11027905 be VB I-VP O
5 1861 1867 11027905 tested VBN I-VP O
6 1868 1870 11027905 in IN B-PP O
7 1871 1878 11027905 studies NNS B-NP O
8 1879 1881 11027905 of IN B-PP O
9 1882 1891 11027905 prolonged VBN B-NP O
10 1892 1900 11027905 ketamine NN I-NP B-Chemical
11 1901 1915 11027905 administration NN I-NP O
12 1915 1916 11027905 . . O O

1 0 0 15859940 -DOCSTART- -X- -X- O

1 0 6 15859940 Causes NNS B-NP O
2 7 9 15859940 of IN B-PP O
3 10 15 15859940 acute JJ B-NP O
4 16 26 15859940 thrombotic JJ I-NP B-Disease
5 27 42 15859940 microangiopathy NN I-NP I-Disease
6 43 45 15859940 in IN B-PP O
7 46 54 15859940 patients NNS B-NP O
8 55 64 15859940 receiving VBG B-VP O
9 65 71 15859940 kidney NN B-NP O
10 72 87 15859940 transplantation NN I-NP O
11 87 88 15859940 . . I-NP O
12 89 99 15859940 OBJECTIVES NN I-NP O
13 99 100 15859940 : : O O
14 101 111 15859940 Thrombotic JJ B-NP B-Disease
15 112 127 15859940 microangiopathy NN I-NP I-Disease
16 128 130 15859940 is VBZ B-VP O
17 131 132 15859940 a DT B-NP O
18 133 137 15859940 well RB I-NP O
19 137 138 15859940 - HYPH I-NP O
20 138 143 15859940 known VBN I-NP O
21 144 151 15859940 problem NN I-NP O
22 152 154 15859940 in IN B-PP O
23 155 163 15859940 patients NNS B-NP O
24 164 173 15859940 following VBG B-PP O
25 174 179 15859940 renal JJ B-NP O
26 180 195 15859940 transplantation NN I-NP O
27 195 196 15859940 . . O O

1 197 199 15859940 In IN B-PP O
2 200 209 15859940 postrenal JJ B-NP O
3 210 225 15859940 transplantation NN I-NP O
4 225 226 15859940 , , O O
5 227 237 15859940 thrombotic JJ B-NP B-Disease
6 238 253 15859940 microangiopathy NN I-NP I-Disease
7 254 256 15859940 is VBZ B-VP O
8 257 262 15859940 often RB B-ADVP O
9 263 264 15859940 a DT B-NP O
10 265 275 15859940 reflection NN I-NP O
11 276 278 15859940 of IN B-PP O
12 279 288 15859940 hemolytic JJ B-NP B-Disease
13 289 295 15859940 uremic JJ I-NP I-Disease
14 296 304 15859940 syndrome NN I-NP I-Disease
15 304 305 15859940 . . O O

1 306 308 15859940 We PRP B-NP O
2 309 314 15859940 aimed VBD B-VP O
3 315 317 15859940 to TO I-VP O
4 318 327 15859940 determine VB I-VP O
5 328 331 15859940 the DT B-NP O
6 332 338 15859940 causes NNS I-NP O
7 339 341 15859940 of IN B-PP O
8 342 352 15859940 thrombotic JJ B-NP B-Disease
9 353 368 15859940 microangiopathy NN I-NP I-Disease
10 369 371 15859940 in IN B-PP O
11 372 373 15859940 a DT B-NP O
12 374 384 15859940 population NN I-NP O
13 385 387 15859940 of IN B-PP O
14 388 393 15859940 renal JJ B-NP O
15 394 409 15859940 transplantation NN I-NP O
16 410 420 15859940 recipients NNS I-NP O
17 421 424 15859940 and CC O O
18 425 432 15859940 discuss VBP B-VP O
19 433 436 15859940 the DT B-NP O
20 437 447 15859940 literature NN I-NP O
21 447 448 15859940 . . O O

1 449 458 15859940 MATERIALS NNS B-NP O
2 459 462 15859940 AND CC I-NP O
3 463 470 15859940 METHODS NNS I-NP O
4 470 471 15859940 : : O O
5 472 474 15859940 We PRP B-NP O
6 475 487 15859940 investigated VBD B-VP O
7 488 491 15859940 the DT B-NP O
8 492 498 15859940 causes NNS I-NP O
9 499 501 15859940 of IN B-PP O
10 502 512 15859940 thrombotic JJ B-NP B-Disease
11 513 528 15859940 microangiopathy NN I-NP I-Disease
12 529 535 15859940 during IN B-PP O
13 536 537 15859940 a DT B-NP O
14 538 539 15859940 1 CD I-NP O
15 539 540 15859940 - HYPH I-NP O
16 540 544 15859940 year NN I-NP O
17 545 551 15859940 period NN I-NP O
18 551 552 15859940 , , O O
19 553 557 15859940 from IN B-PP O
20 558 562 15859940 June NNP B-NP O
21 563 567 15859940 2003 CD I-NP O
22 568 570 15859940 to TO B-PP O
23 571 575 15859940 June NNP B-NP O
24 576 580 15859940 2004 CD I-NP O
25 580 581 15859940 , , O O
26 582 584 15859940 at IN B-PP O
27 585 588 15859940 the DT B-NP O
28 589 593 15859940 King NNP I-NP O
29 594 599 15859940 Fahad NNP I-NP O
30 600 608 15859940 National NNP I-NP O
31 609 614 15859940 Guard NNP I-NP O
32 615 623 15859940 Hospital NNP I-NP O
33 624 626 15859940 in IN B-PP O
34 627 633 15859940 Riyadh NNP B-NP O
35 633 634 15859940 , , O O
36 635 640 15859940 Saudi NNP B-NP O
37 641 647 15859940 Arabia NNP I-NP O
38 647 648 15859940 , , O O
39 649 651 15859940 by IN B-PP O
40 652 661 15859940 reviewing VBG B-VP O
41 662 665 15859940 the DT B-NP O
42 666 672 15859940 slides NNS I-NP O
43 673 675 15859940 of IN B-PP O
44 676 679 15859940 all DT B-NP O
45 680 690 15859940 transplant NN I-NP O
46 691 699 15859940 biopsies NNS I-NP O
47 700 701 15859940 ( ( O O
48 701 702 15859940 n NN B-NP O
49 702 703 15859940 = SYM B-VP O
50 703 705 15859940 25 CD B-NP O
51 705 706 15859940 ) ) O O
52 707 716 15859940 performed VBN B-VP O
53 717 723 15859940 during IN B-PP O
54 724 728 15859940 this DT B-NP O
55 729 737 15859940 interval NN I-NP O
56 737 738 15859940 . . O O

1 739 742 15859940 Pre NN B-NP O
2 742 743 15859940 - HYPH I-NP O
3 744 747 15859940 and CC I-NP O
4 748 762 15859940 posttransplant NN I-NP O
5 763 776 15859940 crossmatching NN I-NP O
6 777 780 15859940 was VBD B-VP O
7 781 785 15859940 done VBN I-VP O
8 786 790 15859940 when WRB B-ADVP O
9 791 799 15859940 possible JJ B-ADJP O
10 799 800 15859940 . . O O

1 801 808 15859940 RESULTS NNS B-NP O
2 808 809 15859940 : : O O
3 810 814 15859940 Five CD B-NP O
4 815 820 15859940 cases NNS I-NP O
5 821 823 15859940 of IN B-PP O
6 824 834 15859940 thrombotic JJ B-NP B-Disease
7 835 850 15859940 microangiopathy NN I-NP I-Disease
8 851 855 15859940 were VBD B-VP O
9 856 861 15859940 found VBN I-VP O
10 861 862 15859940 . . O O

1 863 868 15859940 Three CD B-NP O
2 869 871 15859940 of IN B-PP O
3 872 877 15859940 these DT B-NP O
4 878 883 15859940 cases NNS I-NP O
5 884 888 15859940 were VBD B-VP O
6 889 893 15859940 from IN B-PP O
7 894 897 15859940 the DT B-NP O
8 898 900 15859940 25 CD I-NP O
9 901 917 15859940 transplantations NNS I-NP O
10 918 927 15859940 performed VBN B-VP O
11 928 930 15859940 at IN B-PP O
12 931 935 15859940 King NNP B-NP O
13 936 941 15859940 Fahad NNP I-NP O
14 942 950 15859940 National NNP I-NP O
15 951 956 15859940 Guard NNP I-NP O
16 957 965 15859940 Hospital NNP I-NP O
17 965 966 15859940 , , O O
18 967 972 15859940 while IN B-SBAR O
19 973 976 15859940 the DT B-NP O
20 977 982 15859940 other JJ I-NP O
21 983 984 15859940 2 CD I-NP O
22 985 1001 15859940 transplantations NNS I-NP O
23 1002 1005 15859940 had VBD B-VP O
24 1006 1010 15859940 been VBN I-VP O
25 1011 1020 15859940 performed VBN I-VP O
26 1021 1027 15859940 abroad RB B-ADVP O
27 1028 1031 15859940 and CC O O
28 1032 1036 15859940 were VBD B-VP O
29 1037 1045 15859940 referred VBN I-VP O
30 1046 1048 15859940 to TO B-PP O
31 1049 1051 15859940 us PRP B-NP O
32 1052 1055 15859940 for IN B-PP O
33 1056 1062 15859940 follow VB B-VP O
34 1062 1063 15859940 - HYPH B-PRT O
35 1063 1065 15859940 up RP B-PRT O
36 1065 1066 15859940 . . O O

1 1067 1072 15859940 Three CD B-NP O
2 1073 1078 15859940 cases NNS I-NP O
3 1079 1083 15859940 were VBD B-VP O
4 1084 1091 15859940 related VBN I-VP O
5 1092 1094 15859940 to TO B-PP O
6 1095 1107 15859940 cyclosporine NN B-NP B-Chemical
7 1107 1108 15859940 , , O O
8 1109 1112 15859940 and CC O O
9 1113 1114 15859940 1 CD B-NP O
10 1115 1119 15859940 case NN I-NP O
11 1120 1123 15859940 was VBD B-VP O
12 1124 1133 15859940 secondary JJ B-ADJP O
13 1134 1136 15859940 to TO B-PP O
14 1137 1141 15859940 both CC O O
15 1142 1154 15859940 cyclosporine NN B-NP B-Chemical
16 1155 1158 15859940 and CC I-NP O
17 1159 1169 15859940 tacrolimus NN I-NP B-Chemical
18 1169 1170 15859940 . . O O

1 1171 1174 15859940 The DT B-NP O
2 1175 1180 15859940 fifth JJ I-NP O
3 1181 1185 15859940 case NN I-NP O
4 1186 1189 15859940 had VBD B-VP O
5 1190 1198 15859940 features NNS B-NP O
6 1199 1201 15859940 of IN B-PP O
7 1202 1212 15859940 thrombotic JJ B-NP B-Disease
8 1213 1228 15859940 microangiopathy NN I-NP I-Disease
9 1229 1236 15859940 related VBN B-VP O
10 1237 1239 15859940 to TO B-PP O
11 1240 1242 15859940 an DT B-NP O
12 1243 1259 15859940 antiphospholipid JJ I-NP B-Disease
13 1260 1268 15859940 syndrome NN I-NP I-Disease
14 1269 1271 15859940 in IN B-PP O
15 1272 1273 15859940 a DT B-NP O
16 1274 1281 15859940 patient NN I-NP O
17 1282 1286 15859940 with IN B-PP O
18 1287 1295 15859940 systemic JJ B-NP B-Disease
19 1296 1301 15859940 lupus NN I-NP I-Disease
20 1302 1315 15859940 erythematosus NN I-NP I-Disease
21 1315 1316 15859940 . . O O

1 1317 1328 15859940 CONCLUSIONS NNS B-NP O
2 1328 1329 15859940 : : O O
3 1330 1332 15859940 In IN B-PP O
4 1333 1336 15859940 the DT B-NP O
5 1337 1347 15859940 literature NN I-NP O
6 1347 1348 15859940 , , O O
7 1349 1352 15859940 the DT B-NP O
8 1353 1357 15859940 most JJS I-NP O
9 1357 1358 15859940 - HYPH I-NP O
10 1358 1366 15859940 frequent JJ I-NP O
11 1367 1372 15859940 cause NN I-NP O
12 1373 1375 15859940 of IN B-PP O
13 1376 1385 15859940 hemolytic JJ B-NP B-Disease
14 1386 1392 15859940 uremic JJ I-NP I-Disease
15 1393 1401 15859940 syndrome NN I-NP I-Disease
16 1402 1404 15859940 in IN B-PP O
17 1405 1413 15859940 patients NNS B-NP O
18 1414 1423 15859940 following VBG B-PP O
19 1424 1429 15859940 renal JJ B-NP O
20 1430 1445 15859940 transplantation NN I-NP O
21 1446 1448 15859940 is VBZ B-VP O
22 1449 1459 15859940 recurrence NN B-NP O
23 1460 1462 15859940 of IN B-PP O
24 1463 1466 15859940 the DT B-NP O
25 1467 1476 15859940 hemolytic JJ I-NP B-Disease
26 1477 1483 15859940 uremic JJ I-NP I-Disease
27 1484 1492 15859940 syndrome NN I-NP I-Disease
28 1492 1493 15859940 . . O O

1 1494 1499 15859940 Other JJ B-NP O
2 1500 1506 15859940 causes NNS I-NP O
3 1507 1514 15859940 include VBP B-VP O
4 1515 1519 15859940 drug NN B-NP O
5 1519 1520 15859940 - HYPH O O
6 1520 1527 15859940 related VBN B-ADJP O
7 1528 1529 15859940 ( ( O O
8 1529 1541 15859940 cyclosporine NN B-NP B-Chemical
9 1541 1542 15859940 , , O O
10 1543 1553 15859940 tacrolimus NN B-NP B-Chemical
11 1553 1554 15859940 ) ) O O
12 1555 1563 15859940 toxicity NN B-NP B-Disease
13 1563 1564 15859940 , , O O
14 1565 1577 15859940 procoagulant JJ B-NP O
15 1578 1584 15859940 status NN I-NP O
16 1584 1585 15859940 , , O O
17 1586 1589 15859940 and CC O O
18 1590 1598 15859940 antibody NN B-NP O
19 1598 1599 15859940 - HYPH O O
20 1599 1607 15859940 mediated VBN B-NP O
21 1608 1617 15859940 rejection NN I-NP O
22 1617 1618 15859940 . . O O

1 1619 1621 15859940 We PRP B-NP O
2 1622 1627 15859940 found VBD B-VP O
3 1628 1632 15859940 that IN B-SBAR O
4 1633 1636 15859940 the DT B-NP O
5 1637 1641 15859940 most JJS I-NP O
6 1641 1642 15859940 - HYPH I-NP O
7 1642 1650 15859940 frequent JJ I-NP O
8 1651 1656 15859940 cause NN I-NP O
9 1657 1659 15859940 of IN B-PP O
10 1660 1670 15859940 thrombotic JJ B-NP B-Disease
11 1671 1686 15859940 microangiopathy NN I-NP I-Disease
12 1687 1690 15859940 was VBD B-VP O
13 1691 1695 15859940 drug NN B-NP O
14 1696 1703 15859940 related VBN B-ADJP O
15 1703 1704 15859940 , , O O
16 1705 1714 15859940 secondary JJ B-ADJP O
17 1715 1721 15859940 mainly RB I-ADJP O
18 1722 1724 15859940 to TO B-PP O
19 1725 1737 15859940 cyclosporine NN B-NP B-Chemical
20 1737 1738 15859940 . . O O

1 1739 1741 15859940 In IN B-PP O
2 1742 1745 15859940 the DT B-NP O
3 1746 1753 15859940 current JJ I-NP O
4 1754 1759 15859940 study NN I-NP O
5 1759 1760 15859940 , , O O
6 1761 1764 15859940 the DT B-NP O
7 1765 1774 15859940 frequency NN I-NP O
8 1775 1777 15859940 of IN B-PP O
9 1778 1788 15859940 thrombotic JJ B-NP B-Disease
10 1789 1804 15859940 microangiopathy NN I-NP I-Disease
11 1805 1808 15859940 was VBD B-VP O
12 1809 1816 15859940 similar JJ B-ADJP O
13 1817 1819 15859940 to TO B-PP O
14 1820 1823 15859940 the DT B-NP O
15 1824 1834 15859940 percentage NN I-NP O
16 1835 1843 15859940 reported VBN B-VP O
17 1844 1846 15859940 in IN B-PP O
18 1847 1850 15859940 the DT B-NP O
19 1851 1861 15859940 literature NN I-NP O
20 1862 1863 15859940 ( ( O O
21 1863 1866 15859940 20% CD B-NP O
22 1866 1867 15859940 ) ) O O
23 1867 1868 15859940 . . O O

1 0 0 4008111 -DOCSTART- -X- -X- O

1 0 10 4008111 Amiodarone NN B-NP B-Chemical
2 10 11 4008111 - HYPH O O
3 11 18 4008111 induced VBN B-NP O
4 19 29 4008111 sinoatrial JJ I-NP B-Disease
5 30 35 4008111 block NN I-NP I-Disease
6 35 36 4008111 . . O O
7 37 39 4008111 We PRP B-NP O
8 40 48 4008111 observed VBD B-VP O
9 49 59 4008111 sinoatrial JJ B-NP B-Disease
10 60 65 4008111 block NN I-NP I-Disease
11 66 69 4008111 due JJ B-PP O
12 70 72 4008111 to TO B-PP O
13 73 80 4008111 chronic JJ B-NP O
14 81 91 4008111 amiodarone NN I-NP B-Chemical
15 92 106 4008111 administration NN I-NP O
16 107 109 4008111 in IN B-PP O
17 110 111 4008111 a DT B-NP O
18 112 113 4008111 5 CD I-NP O
19 113 114 4008111 - HYPH I-NP O
20 114 118 4008111 year NN I-NP O
21 118 119 4008111 - HYPH O O
22 119 122 4008111 old JJ B-NP O
23 123 126 4008111 boy NN I-NP O
24 127 131 4008111 with IN B-PP O
25 132 139 4008111 primary JJ B-NP B-Disease
26 140 154 4008111 cardiomyopathy NN I-NP I-Disease
27 154 155 4008111 , , O O
28 156 161 4008111 Wolff NNP B-NP B-Disease
29 161 162 4008111 - HYPH B-NP I-Disease
30 162 171 4008111 Parkinson NNP I-NP I-Disease
31 171 172 4008111 - HYPH I-NP I-Disease
32 172 177 4008111 White NNP I-NP I-Disease
33 178 186 4008111 syndrome NN I-NP I-Disease
34 187 190 4008111 and CC I-NP O
35 191 207 4008111 supraventricular JJ I-NP B-Disease
36 208 219 4008111 tachycardia NN I-NP I-Disease
37 219 220 4008111 . . O O

1 221 230 4008111 Reduction NN B-NP O
2 231 233 4008111 in IN B-PP O
3 234 237 4008111 the DT B-NP O
4 238 244 4008111 dosage NN I-NP O
5 245 247 4008111 of IN B-PP O
6 248 258 4008111 amiodarone NN B-NP B-Chemical
7 259 267 4008111 resulted VBD B-VP O
8 268 270 4008111 in IN B-PP O
9 271 274 4008111 the DT B-NP O
10 275 288 4008111 disappearance NN I-NP O
11 289 291 4008111 of IN B-PP O
12 292 295 4008111 the DT B-NP O
13 296 306 4008111 sinoatrial JJ I-NP B-Disease
14 307 312 4008111 block NN I-NP I-Disease
15 313 316 4008111 and CC O O
16 317 320 4008111 the DT B-NP O
17 321 332 4008111 persistence NN I-NP O
18 333 335 4008111 of IN B-PP O
19 336 348 4008111 asymptomatic JJ B-NP O
20 349 354 4008111 sinus NN I-NP B-Disease
21 355 366 4008111 bradycardia NN I-NP I-Disease
22 366 367 4008111 . . O O

1 0 0 12369736 -DOCSTART- -X- -X- O

1 0 7 12369736 Effects NNS B-NP O
2 8 10 12369736 of IN B-PP O
3 11 12 12369736 5 CD B-NP O
4 12 13 12369736 - HYPH I-NP O
5 13 17 12369736 HT1B NN I-NP O
6 18 26 12369736 receptor NN I-NP O
7 27 34 12369736 ligands NNS I-NP O
8 35 48 12369736 microinjected VBN B-VP O
9 49 53 12369736 into IN B-PP O
10 54 57 12369736 the DT B-NP O
11 58 66 12369736 accumbal JJ I-NP O
12 67 72 12369736 shell NN I-NP O
13 73 75 12369736 or CC I-NP O
14 76 80 12369736 core NN I-NP O
15 81 83 12369736 on IN B-PP O
16 84 87 12369736 the DT B-NP O
17 88 95 12369736 cocaine NN I-NP B-Chemical
18 95 96 12369736 - HYPH B-NP O
19 96 103 12369736 induced VBN I-NP O
20 104 113 12369736 locomotor NN I-NP B-Disease
21 114 127 12369736 hyperactivity NN I-NP I-Disease
22 128 130 12369736 in IN B-PP O
23 131 135 12369736 rats NNS B-NP O
24 135 136 12369736 . . O O
25 137 140 12369736 The DT B-NP O
26 141 148 12369736 present JJ I-NP O
27 149 154 12369736 study NN I-NP O
28 155 158 12369736 was VBD B-VP O
29 159 167 12369736 designed VBN I-VP O
30 168 170 12369736 to TO B-VP O
31 171 178 12369736 examine VB I-VP O
32 179 182 12369736 the DT B-NP O
33 183 189 12369736 effect NN I-NP O
34 190 192 12369736 of IN B-PP O
35 193 194 12369736 5 CD B-NP O
36 194 195 12369736 - HYPH I-NP O
37 195 199 12369736 HT1B NN I-NP O
38 200 208 12369736 receptor NN I-NP O
39 209 216 12369736 ligands NNS I-NP O
40 217 230 12369736 microinjected VBN B-VP O
41 231 235 12369736 into IN B-PP O
42 236 239 12369736 the DT B-NP O
43 240 250 12369736 subregions NNS I-NP O
44 251 253 12369736 of IN B-PP O
45 254 257 12369736 the DT B-NP O
46 258 265 12369736 nucleus NN I-NP O
47 266 275 12369736 accumbens NN I-NP O
48 276 277 12369736 ( ( O O
49 277 280 12369736 the DT B-NP O
50 281 286 12369736 shell NN I-NP O
51 287 290 12369736 and CC O O
52 291 294 12369736 the DT B-NP O
53 295 299 12369736 core NN I-NP O
54 299 300 12369736 ) ) O O
55 301 303 12369736 on IN B-PP O
56 304 307 12369736 the DT B-NP O
57 308 317 12369736 locomotor JJ I-NP B-Disease
58 318 331 12369736 hyperactivity NN I-NP I-Disease
59 332 339 12369736 induced VBN B-VP O
60 340 342 12369736 by IN B-PP O
61 343 350 12369736 cocaine NN B-NP B-Chemical
62 351 353 12369736 in IN B-PP O
63 354 358 12369736 rats NNS B-NP O
64 358 359 12369736 . . O O

1 360 364 12369736 Male JJ B-NP O
2 365 371 12369736 Wistar NNP I-NP O
3 372 376 12369736 rats NNS I-NP O
4 377 381 12369736 were VBD B-VP O
5 382 391 12369736 implanted VBN I-VP O
6 392 403 12369736 bilaterally RB B-ADVP O
7 404 408 12369736 with IN B-PP O
8 409 417 12369736 cannulae NNS B-NP O
9 418 422 12369736 into IN B-PP O
10 423 426 12369736 the DT B-NP O
11 427 436 12369736 accumbens NNS I-NP O
12 437 442 12369736 shell NN I-NP O
13 443 445 12369736 or CC I-NP O
14 446 450 12369736 core NN I-NP O
15 450 451 12369736 , , O O
16 452 455 12369736 and CC O O
17 456 460 12369736 then RB O O
18 461 465 12369736 were VBD B-VP O
19 466 473 12369736 locally RB I-VP O
20 474 482 12369736 injected VBN I-VP O
21 483 487 12369736 with IN B-PP O
22 488 490 12369736 GR NN B-NP B-Chemical
23 491 496 12369736 55562 CD I-NP I-Chemical
24 497 498 12369736 ( ( O O
25 498 500 12369736 an DT B-NP O
26 501 511 12369736 antagonist NN I-NP O
27 512 514 12369736 of IN B-PP O
28 515 516 12369736 5 CD B-NP O
29 516 517 12369736 - HYPH I-NP O
30 517 521 12369736 HT1B NN I-NP O
31 522 531 12369736 receptors NNS I-NP O
32 531 532 12369736 ) ) O O
33 533 535 12369736 or CC O O
34 536 538 12369736 CP NN B-NP B-Chemical
35 539 544 12369736 93129 CD I-NP I-Chemical
36 545 546 12369736 ( ( O O
37 546 548 12369736 an DT B-NP O
38 549 556 12369736 agonist NN I-NP O
39 557 559 12369736 of IN B-PP O
40 560 561 12369736 5 CD B-NP O
41 561 562 12369736 - HYPH I-NP O
42 562 566 12369736 HT1B NN I-NP O
43 567 576 12369736 receptors NNS I-NP O
44 576 577 12369736 ) ) O O
45 577 578 12369736 . . O O

1 579 584 12369736 Given VBN B-VP O
2 585 590 12369736 alone RB B-ADVP O
3 591 593 12369736 to TO B-PP O
4 594 597 12369736 any DT B-NP O
5 598 606 12369736 accumbal JJ I-NP O
6 607 616 12369736 subregion NN I-NP O
7 616 617 12369736 , , O O
8 618 620 12369736 GR NN B-NP B-Chemical
9 621 626 12369736 55562 CD I-NP I-Chemical
10 627 628 12369736 ( ( O O
11 628 631 12369736 0.1 CD B-NP O
12 631 632 12369736 - HYPH I-NP O
13 632 634 12369736 10 CD I-NP O
14 635 641 12369736 microg NN I-NP O
15 641 642 12369736 / SYM I-NP O
16 642 646 12369736 side NN I-NP O
17 646 647 12369736 ) ) O O
18 648 650 12369736 or CC O O
19 651 653 12369736 CP NN B-NP B-Chemical
20 654 659 12369736 93129 CD I-NP I-Chemical
21 660 661 12369736 ( ( O O
22 661 664 12369736 0.1 CD B-NP O
23 664 665 12369736 - HYPH I-NP O
24 665 667 12369736 10 CD I-NP O
25 668 674 12369736 microg NN I-NP O
26 674 675 12369736 / SYM I-NP O
27 675 679 12369736 side NN I-NP O
28 679 680 12369736 ) ) O O
29 681 684 12369736 did VBD B-VP O
30 685 688 12369736 not RB I-VP O
31 689 695 12369736 change VB I-VP O
32 696 701 12369736 basal JJ B-NP O
33 702 711 12369736 locomotor NN I-NP O
34 712 720 12369736 activity NN I-NP O
35 720 721 12369736 . . O O

1 722 730 12369736 Systemic JJ B-NP O
2 731 738 12369736 cocaine NN I-NP B-Chemical
3 739 740 12369736 ( ( O O
4 740 742 12369736 10 CD B-NP O
5 743 745 12369736 mg NN I-NP O
6 745 746 12369736 / SYM B-NP O
7 746 748 12369736 kg NN I-NP O
8 748 749 12369736 ) ) O O
9 750 763 12369736 significantly RB B-ADVP O
10 764 773 12369736 increased VBD B-VP O
11 774 777 12369736 the DT B-NP O
12 778 787 12369736 locomotor NN I-NP O
13 788 796 12369736 activity NN I-NP O
14 797 799 12369736 of IN B-PP O
15 800 804 12369736 rats NNS B-NP O
16 804 805 12369736 . . O O

1 806 808 12369736 GR NN B-NP B-Chemical
2 809 814 12369736 55562 CD I-NP I-Chemical
3 815 816 12369736 ( ( O O
4 816 819 12369736 0.1 CD B-NP O
5 819 820 12369736 - HYPH I-NP O
6 820 822 12369736 10 CD I-NP O
7 823 829 12369736 microg NN I-NP O
8 829 830 12369736 / SYM I-NP O
9 830 834 12369736 side NN I-NP O
10 834 835 12369736 ) ) O O
11 835 836 12369736 , , O O
12 837 849 12369736 administered VBN B-VP O
13 850 855 12369736 intra AFX O O
14 855 856 12369736 - HYPH O O
15 856 865 12369736 accumbens VBZ B-VP O
16 866 871 12369736 shell NN B-NP O
17 872 877 12369736 prior JJ B-ADJP O
18 878 880 12369736 to TO B-PP O
19 881 888 12369736 cocaine NN B-NP B-Chemical
20 888 889 12369736 , , O O
21 890 894 12369736 dose NN B-NP O
22 894 895 12369736 - HYPH B-NP O
23 895 906 12369736 dependently RB B-ADVP O
24 907 917 12369736 attenuated VBD B-VP O
25 918 921 12369736 the DT B-NP O
26 922 937 12369736 psychostimulant NN I-NP O
27 937 938 12369736 - HYPH B-NP O
28 938 945 12369736 induced VBN I-NP O
29 946 955 12369736 locomotor NN I-NP B-Disease
30 956 969 12369736 hyperactivity NN I-NP I-Disease
31 969 970 12369736 . . O O

1 971 975 12369736 Such JJ B-NP O
2 976 987 12369736 attenuation NN I-NP O
3 988 991 12369736 was VBD B-VP O
4 992 995 12369736 not RB I-VP O
5 996 1001 12369736 found VBN I-VP O
6 1002 1004 12369736 in IN B-PP O
7 1005 1012 12369736 animals NNS B-NP O
8 1013 1018 12369736 which WDT B-NP O
9 1019 1022 12369736 had VBD B-VP O
10 1023 1027 12369736 been VBN I-VP O
11 1028 1036 12369736 injected VBN I-VP O
12 1037 1041 12369736 with IN B-PP O
13 1042 1044 12369736 GR NN B-NP B-Chemical
14 1045 1050 12369736 55562 CD I-NP I-Chemical
15 1051 1055 12369736 into IN B-PP O
16 1056 1059 12369736 the DT B-NP O
17 1060 1069 12369736 accumbens NNS I-NP O
18 1070 1074 12369736 core NN I-NP O
19 1074 1075 12369736 . . O O

1 1076 1080 12369736 When WRB B-ADVP O
2 1081 1089 12369736 injected VBN B-VP O
3 1090 1094 12369736 into IN B-PP O
4 1095 1098 12369736 the DT B-NP O
5 1099 1108 12369736 accumbens NNS I-NP O
6 1109 1114 12369736 shell NN I-NP O
7 1115 1116 12369736 ( ( O O
8 1116 1119 12369736 but CC B-CONJP O
9 1120 1123 12369736 not RB I-CONJP O
10 1124 1127 12369736 the DT B-NP O
11 1128 1132 12369736 core NN I-NP O
12 1132 1133 12369736 ) ) O O
13 1134 1140 12369736 before IN B-PP O
14 1141 1148 12369736 cocaine NN B-NP B-Chemical
15 1148 1149 12369736 , , O O
16 1150 1152 12369736 CP NN B-NP B-Chemical
17 1153 1158 12369736 93129 CD I-NP I-Chemical
18 1159 1160 12369736 ( ( O O
19 1160 1163 12369736 0.1 CD B-NP O
20 1163 1164 12369736 - HYPH I-NP O
21 1164 1166 12369736 10 CD I-NP O
22 1167 1173 12369736 microg NN I-NP O
23 1173 1174 12369736 / SYM I-NP O
24 1174 1178 12369736 side NN I-NP O
25 1178 1179 12369736 ) ) O O
26 1180 1188 12369736 enhanced VBD B-VP O
27 1189 1192 12369736 the DT B-NP O
28 1193 1202 12369736 locomotor JJ I-NP O
29 1203 1211 12369736 response NN I-NP O
30 1212 1214 12369736 to TO B-PP O
31 1215 1222 12369736 cocaine NN B-NP B-Chemical
32 1222 1223 12369736 ; : O O
33 1224 1227 12369736 the DT B-NP O
34 1228 1235 12369736 maximum NN I-NP O
35 1236 1242 12369736 effect NN I-NP O
36 1243 1248 12369736 being VBG B-VP O
37 1249 1257 12369736 observed VBN I-VP O
38 1258 1263 12369736 after IN B-PP O
39 1264 1266 12369736 10 CD B-NP O
40 1267 1273 12369736 microg NN I-NP O
41 1273 1274 12369736 / SYM I-NP O
42 1274 1278 12369736 side NN I-NP O
43 1279 1281 12369736 of IN B-PP O
44 1282 1285 12369736 the DT B-NP O
45 1286 1293 12369736 agonist NN I-NP O
46 1293 1294 12369736 . . O O

1 1295 1298 12369736 The DT B-NP O
2 1299 1304 12369736 later JJ I-NP O
3 1305 1316 12369736 enhancement NN I-NP O
4 1317 1320 12369736 was VBD B-VP O
5 1321 1331 12369736 attenuated VBN I-VP O
6 1332 1337 12369736 after IN B-PP O
7 1338 1343 12369736 intra AFX B-NP O
8 1343 1344 12369736 - HYPH B-NP O
9 1344 1353 12369736 accumbens VBZ B-VP O
10 1354 1359 12369736 shell NN B-NP O
11 1360 1369 12369736 treatment NN I-NP O
12 1370 1374 12369736 with IN B-PP O
13 1375 1377 12369736 GR NN B-NP B-Chemical
14 1378 1383 12369736 55562 CD I-NP I-Chemical
15 1384 1385 12369736 ( ( O O
16 1385 1386 12369736 1 CD B-NP O
17 1387 1393 12369736 microg NN I-NP O
18 1393 1394 12369736 / SYM B-NP O
19 1394 1398 12369736 side NN I-NP O
20 1398 1399 12369736 ) ) O O
21 1399 1400 12369736 . . O O

1 1401 1404 12369736 Our PRP$ B-NP O
2 1405 1413 12369736 findings NNS I-NP O
3 1414 1422 12369736 indicate VBP B-VP O
4 1423 1427 12369736 that IN B-SBAR O
5 1428 1435 12369736 cocaine NN B-NP B-Chemical
6 1436 1443 12369736 induced JJ I-NP O
7 1444 1459 12369736 hyperlocomotion NN I-NP B-Disease
8 1460 1462 12369736 is VBZ B-VP O
9 1463 1471 12369736 modified VBN I-VP O
10 1472 1474 12369736 by IN B-PP O
11 1475 1476 12369736 5 CD B-NP O
12 1476 1477 12369736 - HYPH I-NP O
13 1477 1481 12369736 HT1B NN I-NP O
14 1482 1490 12369736 receptor NN I-NP O
15 1491 1498 12369736 ligands NNS I-NP O
16 1499 1512 12369736 microinjected VBN B-VP O
17 1513 1517 12369736 into IN B-PP O
18 1518 1521 12369736 the DT B-NP O
19 1522 1531 12369736 accumbens NNS I-NP O
20 1532 1537 12369736 shell NN I-NP O
21 1537 1538 12369736 , , B-NP O
22 1539 1542 12369736 but CC I-NP O
23 1543 1546 12369736 not RB I-NP O
24 1547 1551 12369736 core NN B-NP O
25 1551 1552 12369736 , , O O
26 1553 1557 12369736 this DT B-NP O
27 1558 1570 12369736 modification NN I-NP O
28 1571 1581 12369736 consisting VBG B-VP O
29 1582 1584 12369736 in IN B-PP O
30 1585 1595 12369736 inhibitory JJ B-NP O
31 1596 1599 12369736 and CC I-NP O
32 1600 1612 12369736 facilitatory JJ I-NP O
33 1613 1620 12369736 effects NNS I-NP O
34 1621 1623 12369736 of IN B-PP O
35 1624 1627 12369736 the DT B-NP O
36 1628 1629 12369736 5 CD I-NP O
37 1629 1630 12369736 - HYPH I-NP O
38 1630 1634 12369736 HT1B NN I-NP O
39 1635 1643 12369736 receptor NN I-NP O
40 1644 1654 12369736 antagonist NN I-NP O
41 1655 1656 12369736 ( ( O O
42 1656 1658 12369736 GR NN B-NP B-Chemical
43 1659 1664 12369736 55562 CD I-NP I-Chemical
44 1664 1665 12369736 ) ) O O
45 1666 1669 12369736 and CC O O
46 1670 1677 12369736 agonist NN B-NP O
47 1678 1679 12369736 ( ( O O
48 1679 1681 12369736 CP NN B-NP B-Chemical
49 1682 1687 12369736 93129 CD I-NP I-Chemical
50 1687 1688 12369736 ) ) O O
51 1688 1689 12369736 , , O O
52 1690 1702 12369736 respectively RB B-ADVP O
53 1702 1703 12369736 . . O O

1 1704 1706 12369736 In IN B-PP O
2 1707 1712 12369736 other JJ B-NP O
3 1713 1718 12369736 words NNS I-NP O
4 1718 1719 12369736 , , O O
5 1720 1723 12369736 the DT B-NP O
6 1724 1731 12369736 present JJ I-NP O
7 1732 1739 12369736 results NNS I-NP O
8 1740 1747 12369736 suggest VBP B-VP O
9 1748 1752 12369736 that IN B-SBAR O
10 1753 1756 12369736 the DT B-NP O
11 1757 1765 12369736 accumbal JJ I-NP O
12 1766 1771 12369736 shell NN I-NP O
13 1772 1773 12369736 5 CD I-NP O
14 1773 1774 12369736 - HYPH I-NP O
15 1774 1778 12369736 HT1B NN I-NP O
16 1779 1788 12369736 receptors NNS I-NP O
17 1789 1793 12369736 play VBP B-VP O
18 1794 1795 12369736 a DT B-NP O
19 1796 1806 12369736 permissive JJ I-NP O
20 1807 1811 12369736 role NN I-NP O
21 1812 1814 12369736 in IN B-PP O
22 1815 1818 12369736 the DT B-NP O
23 1819 1830 12369736 behavioural JJ I-NP O
24 1831 1839 12369736 response NN I-NP O
25 1840 1842 12369736 to TO B-PP O
26 1843 1846 12369736 the DT B-NP O
27 1847 1862 12369736 psychostimulant NN I-NP O
28 1862 1863 12369736 . . O O

1 0 0 7919560 -DOCSTART- -X- -X- O

1 0 8 7919560 Erythema NN B-NP B-Disease
2 9 19 7919560 multiforme JJ I-NP I-Disease
3 20 23 7919560 and CC I-NP O
4 24 40 7919560 hypersensitivity NN I-NP B-Disease
5 41 52 7919560 myocarditis NN I-NP I-Disease
6 53 59 7919560 caused VBN B-VP O
7 60 62 7919560 by IN B-PP O
8 63 73 7919560 ampicillin NN B-NP B-Chemical
9 73 74 7919560 . . O O
10 75 84 7919560 OBJECTIVE NN B-NP O
11 84 85 7919560 : : O O
12 86 88 7919560 To TO B-VP O
13 89 95 7919560 report VB I-VP O
14 96 97 7919560 a DT B-NP O
15 98 102 7919560 case NN I-NP O
16 103 105 7919560 of IN B-PP O
17 106 114 7919560 erythema NN B-NP B-Disease
18 115 125 7919560 multiforme NN I-NP I-Disease
19 126 129 7919560 and CC O O
20 130 146 7919560 hypersensitivity NN B-NP B-Disease
21 147 158 7919560 myocarditis NN I-NP I-Disease
22 159 165 7919560 caused VBN B-VP O
23 166 168 7919560 by IN B-PP O
24 169 179 7919560 ampicillin NN B-NP B-Chemical
25 179 180 7919560 . . O O

1 181 185 7919560 CASE NN B-NP O
2 186 193 7919560 SUMMARY NN I-NP O
3 193 194 7919560 : : O O
4 195 196 7919560 A DT B-NP O
5 197 199 7919560 13 CD I-NP O
6 199 200 7919560 - HYPH I-NP O
7 200 204 7919560 year NN I-NP O
8 204 205 7919560 - HYPH O O
9 205 208 7919560 old JJ B-NP O
10 209 212 7919560 boy NN I-NP O
11 213 216 7919560 was VBD B-VP O
12 217 224 7919560 treated VBN I-VP O
13 225 229 7919560 with IN B-PP O
14 230 240 7919560 ampicillin NN B-NP B-Chemical
15 241 244 7919560 and CC I-NP O
16 245 255 7919560 gentamicin NN I-NP B-Chemical
17 256 263 7919560 because IN B-PP O
18 264 266 7919560 of IN I-PP O
19 267 276 7919560 suspected VBN B-NP O
20 277 287 7919560 septicemia NN I-NP B-Disease
21 287 288 7919560 . . O O

1 289 300 7919560 Medications NNS B-NP O
2 301 305 7919560 were VBD B-VP O
3 306 318 7919560 discontinued VBN I-VP O
4 319 323 7919560 when WRB B-ADVP O
5 324 332 7919560 erythema NN B-NP B-Disease
6 333 343 7919560 multiforme JJ I-NP I-Disease
7 344 347 7919560 and CC I-NP O
8 348 358 7919560 congestive JJ I-NP B-Disease
9 359 364 7919560 heart NN I-NP I-Disease
10 365 372 7919560 failure NN I-NP I-Disease
11 373 379 7919560 caused VBN B-VP O
12 380 382 7919560 by IN B-PP O
13 383 394 7919560 myocarditis NN B-NP B-Disease
14 395 403 7919560 occurred VBD B-VP O
15 403 404 7919560 . . O O

1 405 408 7919560 The DT B-NP O
2 409 416 7919560 patient NN I-NP O
3 417 420 7919560 was VBD B-VP O
4 421 428 7919560 treated VBN I-VP O
5 429 433 7919560 with IN B-PP O
6 434 452 7919560 methylprednisolone NN B-NP B-Chemical
7 453 456 7919560 and CC O O
8 457 466 7919560 gradually RB B-VP O
9 467 475 7919560 improved VBN I-VP O
10 475 476 7919560 . . O O

1 477 487 7919560 Macrophage NN B-NP O
2 487 488 7919560 - HYPH I-NP O
3 488 497 7919560 migration NN I-NP O
4 498 508 7919560 inhibition NN I-NP O
5 509 510 7919560 ( ( O O
6 510 513 7919560 MIF NN B-NP O
7 513 514 7919560 ) ) O O
8 515 519 7919560 test NN B-NP O
9 520 524 7919560 with IN B-PP O
10 525 535 7919560 ampicillin NN B-NP B-Chemical
11 536 539 7919560 was VBD B-VP O
12 540 548 7919560 positive JJ B-ADJP O
13 548 549 7919560 . . O O

1 550 560 7919560 DISCUSSION NN B-NP O
2 560 561 7919560 : : O O
3 562 567 7919560 After IN B-PP O
4 568 572 7919560 most JJS B-NP O
5 573 583 7919560 infections NNS I-NP B-Disease
6 584 591 7919560 causing VBG B-VP O
7 592 600 7919560 erythema NN B-NP B-Disease
8 601 611 7919560 multiforme JJ I-NP I-Disease
9 612 615 7919560 and CC O O
10 616 627 7919560 myocarditis NN B-NP B-Disease
11 628 632 7919560 were VBD B-VP O
12 633 638 7919560 ruled VBN I-VP O
13 639 642 7919560 out RP B-PRT O
14 642 643 7919560 , , O O
15 644 645 7919560 a DT B-NP O
16 646 650 7919560 drug NN I-NP B-Disease
17 650 651 7919560 - HYPH O I-Disease
18 651 658 7919560 induced VBN B-NP I-Disease
19 659 667 7919560 allergic JJ I-NP I-Disease
20 668 676 7919560 reaction NN I-NP I-Disease
21 677 680 7919560 was VBD B-VP O
22 681 690 7919560 suspected VBN I-VP O
23 690 691 7919560 . . O O

1 692 700 7919560 Positive JJ B-NP O
2 701 704 7919560 MIF NN I-NP O
3 705 709 7919560 test NN I-NP O
4 710 713 7919560 for IN B-PP O
5 714 724 7919560 ampicillin NN B-NP B-Chemical
6 725 731 7919560 showed VBD B-VP O
7 732 745 7919560 sensitization NN B-NP O
8 746 748 7919560 of IN B-PP O
9 749 752 7919560 the DT B-NP O
10 753 762 7919560 patient's NNS I-NP O
11 763 774 7919560 lymphocytes NNS I-NP O
12 775 777 7919560 to TO B-PP O
13 778 788 7919560 ampicillin NN B-NP B-Chemical
14 788 789 7919560 . . O O

1 790 801 7919560 CONCLUSIONS NNS B-NP O
2 801 802 7919560 : : O O
3 803 819 7919560 Hypersensitivity NN B-NP B-Disease
4 820 831 7919560 myocarditis NN I-NP I-Disease
5 832 834 7919560 is VBZ B-VP O
6 835 836 7919560 a DT B-NP O
7 837 841 7919560 rare JJ I-NP O
8 842 845 7919560 and CC I-NP O
9 846 855 7919560 dangerous JJ I-NP O
10 856 869 7919560 manifestation NN I-NP O
11 870 872 7919560 of IN B-PP O
12 873 880 7919560 allergy NN B-NP B-Disease
13 881 883 7919560 to TO B-PP O
14 884 895 7919560 penicillins NNS B-NP B-Chemical
15 895 896 7919560 . . O O

1 0 0 10704919 -DOCSTART- -X- -X- O

1 0 9 10704919 Hemolysis NN B-NP B-Disease
2 10 12 10704919 of IN B-PP O
3 13 18 10704919 human JJ B-NP O
4 19 31 10704919 erythrocytes NNS I-NP O
5 32 39 10704919 induced VBN B-VP O
6 40 42 10704919 by IN B-PP O
7 43 52 10704919 tamoxifen NN B-NP B-Chemical
8 53 55 10704919 is VBZ B-VP O
9 56 63 10704919 related VBN I-VP O
10 64 66 10704919 to TO B-PP O
11 67 77 10704919 disruption NN B-NP O
12 78 80 10704919 of IN B-PP O
13 81 89 10704919 membrane NN B-NP O
14 90 99 10704919 structure NN I-NP O
15 99 100 10704919 . . O O
16 101 110 10704919 Tamoxifen NN B-NP B-Chemical
17 111 112 10704919 ( ( O O
18 112 115 10704919 TAM NN B-NP B-Chemical
19 115 116 10704919 ) ) O O
20 116 117 10704919 , , O O
21 118 121 10704919 the DT B-NP O
22 122 136 10704919 antiestrogenic JJ I-NP O
23 137 141 10704919 drug NN I-NP O
24 142 146 10704919 most RBS B-VP O
25 147 153 10704919 widely RB I-VP O
26 154 164 10704919 prescribed VBN I-VP O
27 165 167 10704919 in IN B-PP O
28 168 171 10704919 the DT B-NP O
29 172 184 10704919 chemotherapy NN I-NP O
30 185 187 10704919 of IN B-PP O
31 188 194 10704919 breast NN B-NP B-Disease
32 195 201 10704919 cancer NN I-NP I-Disease
33 201 202 10704919 , , O O
34 203 210 10704919 induces VBZ B-VP O
35 211 218 10704919 changes NNS B-NP O
36 219 221 10704919 in IN B-PP O
37 222 228 10704919 normal JJ B-NP O
38 229 236 10704919 discoid JJ I-NP O
39 237 242 10704919 shape NN I-NP O
40 243 245 10704919 of IN B-PP O
41 246 258 10704919 erythrocytes NNS B-NP O
42 259 262 10704919 and CC O O
43 263 272 10704919 hemolytic JJ B-NP B-Disease
44 273 279 10704919 anemia NN I-NP I-Disease
45 279 280 10704919 . . O O

1 281 285 10704919 This DT B-NP O
2 286 290 10704919 work NN I-NP O
3 291 300 10704919 evaluates VBZ B-VP O
4 301 304 10704919 the DT B-NP O
5 305 312 10704919 effects NNS I-NP O
6 313 315 10704919 of IN B-PP O
7 316 319 10704919 TAM NN B-NP B-Chemical
8 320 322 10704919 on IN B-PP O
9 323 331 10704919 isolated VBN B-NP O
10 332 337 10704919 human JJ I-NP O
11 338 350 10704919 erythrocytes NNS I-NP O
12 350 351 10704919 , , O O
13 352 362 10704919 attempting VBG B-VP O
14 363 365 10704919 to TO I-VP O
15 366 374 10704919 identify VB I-VP O
16 375 378 10704919 the DT B-NP O
17 379 389 10704919 underlying VBG I-NP O
18 390 400 10704919 mechanisms NNS I-NP O
19 401 403 10704919 on IN B-PP O
20 404 407 10704919 TAM NN B-NP B-Chemical
21 407 408 10704919 - HYPH B-NP O
22 408 415 10704919 induced VBN I-NP O
23 416 425 10704919 hemolytic JJ I-NP B-Disease
24 426 432 10704919 anemia NN I-NP I-Disease
25 433 436 10704919 and CC O O
26 437 440 10704919 the DT B-NP O
27 441 452 10704919 involvement NN I-NP O
28 453 455 10704919 of IN B-PP O
29 456 468 10704919 biomembranes NNS B-NP O
30 469 471 10704919 in IN B-PP O
31 472 475 10704919 its PRP$ B-NP O
32 476 486 10704919 cytostatic JJ I-NP O
33 487 493 10704919 action NN I-NP O
34 494 504 10704919 mechanisms NNS I-NP O
35 504 505 10704919 . . O O

1 506 509 10704919 TAM NN B-NP B-Chemical
2 510 517 10704919 induces VBZ B-VP O
3 518 527 10704919 hemolysis NN B-NP B-Disease
4 528 530 10704919 of IN B-PP O
5 531 543 10704919 erythrocytes NNS B-NP O
6 544 546 10704919 as IN B-PP O
7 547 548 10704919 a DT B-NP O
8 549 557 10704919 function NN I-NP O
9 558 560 10704919 of IN B-PP O
10 561 574 10704919 concentration NN B-NP O
11 574 575 10704919 . . O O

1 576 579 10704919 The DT B-NP O
2 580 589 10704919 extension NN I-NP O
3 590 592 10704919 of IN B-PP O
4 593 602 10704919 hemolysis NN B-NP B-Disease
5 603 605 10704919 is VBZ B-VP O
6 606 614 10704919 variable JJ B-ADJP O
7 615 619 10704919 with IN B-PP O
8 620 631 10704919 erythrocyte NN B-NP O
9 632 639 10704919 samples NNS I-NP O
10 639 640 10704919 , , O O
11 641 644 10704919 but CC O O
12 645 649 10704919 12.5 CD B-NP O
13 650 656 10704919 microM NN I-NP O
14 657 660 10704919 TAM NN I-NP B-Chemical
15 661 668 10704919 induces VBZ B-VP O
16 669 674 10704919 total JJ B-NP O
17 675 684 10704919 hemolysis NN I-NP B-Disease
18 685 687 10704919 of IN B-PP O
19 688 691 10704919 all DT B-NP O
20 692 698 10704919 tested VBN I-NP O
21 699 710 10704919 suspensions NNS I-NP O
22 710 711 10704919 . . O O

1 712 719 10704919 Despite IN B-PP O
2 720 728 10704919 inducing VBG B-VP O
3 729 738 10704919 extensive JJ B-NP O
4 739 750 10704919 erythrocyte NN I-NP O
5 751 756 10704919 lysis NN I-NP O
6 756 757 10704919 , , O O
7 758 761 10704919 TAM NN B-NP B-Chemical
8 762 766 10704919 does VBZ B-VP O
9 767 770 10704919 not RB I-VP O
10 771 776 10704919 shift VB I-VP O
11 777 780 10704919 the DT B-NP O
12 781 788 10704919 osmotic JJ I-NP O
13 789 798 10704919 fragility NN I-NP O
14 799 805 10704919 curves NNS I-NP O
15 806 808 10704919 of IN B-PP O
16 809 821 10704919 erythrocytes NNS B-NP O
17 821 822 10704919 . . O O

1 823 826 10704919 The DT B-NP O
2 827 836 10704919 hemolytic JJ I-NP B-Disease
3 837 843 10704919 effect NN I-NP O
4 844 846 10704919 of IN B-PP O
5 847 850 10704919 TAM NN B-NP B-Chemical
6 851 853 10704919 is VBZ B-VP O
7 854 863 10704919 prevented VBN I-VP O
8 864 866 10704919 by IN B-PP O
9 867 870 10704919 low JJ B-NP O
10 871 885 10704919 concentrations NNS I-NP O
11 886 888 10704919 of IN B-PP O
12 889 894 10704919 alpha SYM O B-Chemical
13 894 895 10704919 - HYPH O I-Chemical
14 895 905 10704919 tocopherol NN B-NP I-Chemical
15 906 907 10704919 ( ( O O
16 907 912 10704919 alpha SYM O B-Chemical
17 912 913 10704919 - HYPH O I-Chemical
18 913 914 10704919 T NN B-NP I-Chemical
19 914 915 10704919 ) ) O O
20 916 919 10704919 and CC O O
21 920 925 10704919 alpha SYM O B-Chemical
22 925 926 10704919 - HYPH O I-Chemical
23 926 936 10704919 tocopherol NN B-NP I-Chemical
24 937 944 10704919 acetate NN I-NP I-Chemical
25 945 946 10704919 ( ( O O
26 946 951 10704919 alpha SYM O B-Chemical
27 951 952 10704919 - HYPH O I-Chemical
28 952 955 10704919 TAc NN B-NP I-Chemical
29 955 956 10704919 ) ) O O
30 957 958 10704919 ( ( O O
31 958 969 10704919 inactivated VBN B-VP O
32 970 980 10704919 functional JJ B-NP O
33 981 989 10704919 hydroxyl NN I-NP B-Chemical
34 989 990 10704919 ) ) O O
35 991 1001 10704919 indicating VBG B-VP O
36 1002 1006 10704919 that IN B-SBAR O
37 1007 1010 10704919 TAM NN B-NP B-Chemical
38 1010 1011 10704919 - HYPH B-NP O
39 1011 1018 10704919 induced VBN I-NP O
40 1019 1028 10704919 hemolysis NN I-NP B-Disease
41 1029 1031 10704919 is VBZ B-VP O
42 1032 1035 10704919 not RB O O
43 1036 1043 10704919 related JJ B-ADJP O
44 1044 1046 10704919 to TO B-PP O
45 1047 1056 10704919 oxidative JJ B-NP O
46 1057 1065 10704919 membrane NN I-NP O
47 1066 1072 10704919 damage NN I-NP O
48 1072 1073 10704919 . . O O

1 1074 1078 10704919 This DT B-NP O
2 1079 1082 10704919 was VBD B-VP O
3 1083 1090 10704919 further RB I-VP O
4 1091 1100 10704919 evidenced VBN I-VP O
5 1101 1103 10704919 by IN B-PP O
6 1104 1111 10704919 absence NN B-NP O
7 1112 1114 10704919 of IN B-PP O
8 1115 1121 10704919 oxygen NN B-NP B-Chemical
9 1122 1133 10704919 consumption NN I-NP O
10 1134 1137 10704919 and CC O O
11 1138 1148 10704919 hemoglobin NN B-NP O
12 1149 1158 10704919 oxidation NN I-NP O
13 1159 1163 10704919 both CC O O
14 1164 1174 10704919 determined VBN B-VP O
15 1175 1177 10704919 in IN B-PP O
16 1178 1186 10704919 parallel NN B-NP O
17 1187 1191 10704919 with IN B-PP O
18 1192 1195 10704919 TAM NN B-NP B-Chemical
19 1195 1196 10704919 - HYPH B-NP O
20 1196 1203 10704919 induced VBN I-NP O
21 1204 1213 10704919 hemolysis NN I-NP B-Disease
22 1213 1214 10704919 . . O O

1 1215 1226 10704919 Furthermore RB B-ADVP O
2 1226 1227 10704919 , , O O
3 1228 1230 10704919 it PRP B-NP O
4 1231 1234 10704919 was VBD B-VP O
5 1235 1243 10704919 observed VBN I-VP O
6 1244 1248 10704919 that IN B-SBAR O
7 1249 1252 10704919 TAM NN B-NP B-Chemical
8 1253 1261 10704919 inhibits VBZ B-VP O
9 1262 1265 10704919 the DT B-NP O
10 1266 1278 10704919 peroxidation NN I-NP O
11 1279 1281 10704919 of IN B-PP O
12 1282 1287 10704919 human JJ B-NP O
13 1288 1300 10704919 erythrocytes NNS I-NP O
14 1301 1308 10704919 induced VBN B-VP O
15 1309 1311 10704919 by IN B-PP O
16 1312 1316 10704919 AAPH NN B-NP B-Chemical
17 1316 1317 10704919 , , O O
18 1318 1322 10704919 thus RB B-ADVP O
19 1323 1329 10704919 ruling VBG B-VP O
20 1330 1333 10704919 out RP B-PRT O
21 1334 1337 10704919 TAM NN B-NP B-Chemical
22 1337 1338 10704919 - HYPH B-NP O
23 1338 1345 10704919 induced VBN I-NP O
24 1346 1350 10704919 cell NN I-NP O
25 1351 1360 10704919 oxidative JJ I-NP O
26 1361 1367 10704919 stress NN I-NP O
27 1367 1368 10704919 . . O O

1 1369 1378 10704919 Hemolysis NN B-NP B-Disease
2 1379 1385 10704919 caused VBN B-VP O
3 1386 1388 10704919 by IN B-PP O
4 1389 1392 10704919 TAM NN B-NP B-Chemical
5 1393 1396 10704919 was VBD B-VP O
6 1397 1400 10704919 not RB I-VP O
7 1401 1409 10704919 preceded VBN I-VP O
8 1410 1412 10704919 by IN B-PP O
9 1413 1416 10704919 the DT B-NP O
10 1417 1424 10704919 leakage NN I-NP O
11 1425 1427 10704919 of IN B-PP O
12 1428 1432 10704919 K(+) NN B-NP B-Chemical
13 1433 1437 10704919 from IN B-PP O
14 1438 1441 10704919 the DT B-NP O
15 1442 1447 10704919 cells NNS I-NP O
16 1447 1448 10704919 , , O O
17 1449 1453 10704919 also RB B-ADVP O
18 1454 1463 10704919 excluding VBG B-VP O
19 1464 1465 10704919 a DT B-NP O
20 1466 1473 10704919 colloid JJ I-NP O
21 1473 1474 10704919 - HYPH I-NP O
22 1474 1481 10704919 osmotic JJ I-NP O
23 1482 1486 10704919 type NN I-NP O
24 1487 1496 10704919 mechanism NN I-NP O
25 1497 1499 10704919 of IN B-PP O
26 1500 1509 10704919 hemolysis NN B-NP B-Disease
27 1509 1510 10704919 , , O O
28 1511 1520 10704919 according VBG B-PP O
29 1521 1523 10704919 to TO B-PP O
30 1524 1527 10704919 the DT B-NP O
31 1528 1535 10704919 effects NNS I-NP O
32 1536 1538 10704919 on IN B-PP O
33 1539 1546 10704919 osmotic JJ B-NP O
34 1547 1556 10704919 fragility NN I-NP O
35 1557 1563 10704919 curves NNS I-NP O
36 1563 1564 10704919 . . O O

1 1565 1572 10704919 However RB B-ADVP O
2 1572 1573 10704919 , , O O
3 1574 1577 10704919 TAM NN B-NP B-Chemical
4 1578 1585 10704919 induces VBZ B-VP O
5 1586 1593 10704919 release NN B-NP O
6 1594 1596 10704919 of IN B-PP O
7 1597 1607 10704919 peripheral JJ B-NP O
8 1608 1616 10704919 proteins NNS I-NP O
9 1617 1619 10704919 of IN B-PP O
10 1620 1628 10704919 membrane NN B-NP O
11 1628 1629 10704919 - HYPH B-NP O
12 1629 1641 10704919 cytoskeleton NN I-NP O
13 1642 1645 10704919 and CC I-NP O
14 1646 1653 10704919 cytosol NN I-NP O
15 1654 1662 10704919 proteins NNS I-NP O
16 1663 1674 10704919 essentially RB B-ADVP O
17 1675 1680 10704919 bound VBD B-VP O
18 1681 1683 10704919 to TO B-PP O
19 1684 1688 10704919 band NN B-NP O
20 1689 1690 10704919 3 CD I-NP O
21 1690 1691 10704919 . . O O

1 1692 1698 10704919 Either CC O O
2 1699 1704 10704919 alpha SYM O B-Chemical
3 1704 1705 10704919 - HYPH O I-Chemical
4 1705 1706 10704919 T NN B-NP I-Chemical
5 1707 1709 10704919 or CC O O
6 1710 1715 10704919 alpha SYM O B-Chemical
7 1715 1716 10704919 - HYPH O I-Chemical
8 1716 1719 10704919 TAc NN B-NP I-Chemical
9 1720 1729 10704919 increases VBZ B-VP O
10 1730 1738 10704919 membrane NN B-NP O
11 1739 1746 10704919 packing NN I-NP O
12 1747 1750 10704919 and CC O O
13 1751 1759 10704919 prevents VBZ B-VP O
14 1760 1763 10704919 TAM NN B-NP B-Chemical
15 1764 1773 10704919 partition NN I-NP O
16 1774 1778 10704919 into IN B-PP O
17 1779 1784 10704919 model NN B-NP O
18 1785 1794 10704919 membranes NNS I-NP O
19 1794 1795 10704919 . . O O

1 1796 1801 10704919 These DT B-NP O
2 1802 1809 10704919 effects NNS I-NP O
3 1810 1817 10704919 suggest VBP B-VP O
4 1818 1822 10704919 that IN B-SBAR O
5 1823 1826 10704919 the DT B-NP O
6 1827 1837 10704919 protection NN I-NP O
7 1838 1842 10704919 from IN B-PP O
8 1843 1852 10704919 hemolysis NN B-NP B-Disease
9 1853 1855 10704919 by IN B-PP O
10 1856 1867 10704919 tocopherols NNS B-NP B-Chemical
11 1868 1870 10704919 is VBZ B-VP O
12 1871 1878 10704919 related JJ B-ADJP O
13 1879 1881 10704919 to TO B-PP O
14 1882 1883 10704919 a DT B-NP O
15 1884 1893 10704919 decreased VBN I-NP O
16 1894 1897 10704919 TAM NN I-NP B-Chemical
17 1898 1911 10704919 incorporation NN I-NP O
18 1912 1914 10704919 in IN B-PP O
19 1915 1924 10704919 condensed VBN B-NP O
20 1925 1934 10704919 membranes NNS I-NP O
21 1935 1938 10704919 and CC O O
22 1939 1942 10704919 the DT B-NP O
23 1943 1953 10704919 structural JJ I-NP O
24 1954 1960 10704919 damage NN I-NP O
25 1961 1963 10704919 of IN B-PP O
26 1964 1967 10704919 the DT B-NP O
27 1968 1979 10704919 erythrocyte NN I-NP O
28 1980 1988 10704919 membrane NN I-NP O
29 1989 1991 10704919 is VBZ B-VP O
30 1992 2004 10704919 consequently RB I-VP O
31 2005 2012 10704919 avoided VBN I-VP O
32 2012 2013 10704919 . . O O

1 2014 2023 10704919 Therefore RB B-ADVP O
2 2023 2024 10704919 , , O O
3 2025 2028 10704919 TAM NN B-NP B-Chemical
4 2028 2029 10704919 - HYPH B-NP O
5 2029 2036 10704919 induced VBN I-NP O
6 2037 2046 10704919 hemolysis NN I-NP B-Disease
7 2047 2054 10704919 results VBZ B-VP O
8 2055 2059 10704919 from IN B-PP O
9 2060 2061 10704919 a DT B-NP O
10 2062 2072 10704919 structural JJ I-NP O
11 2073 2085 10704919 perturbation NN I-NP O
12 2086 2088 10704919 of IN B-PP O
13 2089 2092 10704919 red JJ B-NP O
14 2093 2097 10704919 cell NN I-NP O
15 2098 2106 10704919 membrane NN I-NP O
16 2106 2107 10704919 , , O O
17 2108 2115 10704919 leading VBG B-VP O
18 2116 2118 10704919 to TO B-PP O
19 2119 2126 10704919 changes NNS B-NP O
20 2127 2129 10704919 in IN B-PP O
21 2130 2133 10704919 the DT B-NP O
22 2134 2143 10704919 framework NN I-NP O
23 2144 2146 10704919 of IN B-PP O
24 2147 2150 10704919 the DT B-NP O
25 2151 2162 10704919 erythrocyte NN I-NP O
26 2163 2171 10704919 membrane NN I-NP O
27 2172 2175 10704919 and CC O O
28 2176 2179 10704919 its PRP$ B-NP O
29 2180 2192 10704919 cytoskeleton NN I-NP O
30 2193 2199 10704919 caused VBN B-VP O
31 2200 2202 10704919 by IN B-PP O
32 2203 2206 10704919 its PRP$ B-NP O
33 2207 2211 10704919 high JJ I-NP O
34 2212 2221 10704919 partition NN I-NP O
35 2222 2224 10704919 in IN B-PP O
36 2225 2228 10704919 the DT B-NP O
37 2229 2237 10704919 membrane NN I-NP O
38 2237 2238 10704919 . . O O

1 2239 2244 10704919 These DT B-NP O
2 2245 2252 10704919 defects NNS I-NP O
3 2253 2260 10704919 explain VBP B-VP O
4 2261 2264 10704919 the DT B-NP O
5 2265 2273 10704919 abnormal JJ I-NP O
6 2274 2285 10704919 erythrocyte NN I-NP O
7 2286 2291 10704919 shape NN I-NP O
8 2292 2295 10704919 and CC O O
9 2296 2305 10704919 decreased VBD B-VP O
10 2306 2316 10704919 mechanical JJ B-NP O
11 2317 2326 10704919 stability NN I-NP O
12 2327 2335 10704919 promoted VBN B-VP O
13 2336 2338 10704919 by IN B-PP O
14 2339 2342 10704919 TAM NN B-NP B-Chemical
15 2342 2343 10704919 , , O O
16 2344 2353 10704919 resulting VBG B-VP O
17 2354 2356 10704919 in IN B-PP O
18 2357 2366 10704919 hemolytic JJ B-NP B-Disease
19 2367 2373 10704919 anemia NN I-NP I-Disease
20 2373 2374 10704919 . . O O

1 2375 2387 10704919 Additionally RB B-ADVP O
2 2387 2388 10704919 , , O O
3 2389 2394 10704919 since IN B-SBAR O
4 2395 2403 10704919 membrane NN B-NP O
5 2404 2411 10704919 leakage NN I-NP O
6 2412 2414 10704919 is VBZ B-VP O
7 2415 2416 10704919 a DT B-NP O
8 2417 2422 10704919 final JJ I-NP O
9 2423 2428 10704919 stage NN I-NP O
10 2429 2431 10704919 of IN B-PP O
11 2432 2444 10704919 cytotoxicity NN B-NP O
12 2444 2445 10704919 , , O O
13 2446 2449 10704919 the DT B-NP O
14 2450 2460 10704919 disruption NN I-NP O
15 2461 2463 10704919 of IN B-PP O
16 2464 2467 10704919 the DT B-NP O
17 2468 2478 10704919 structural JJ I-NP O
18 2479 2494 10704919 characteristics NNS I-NP O
19 2495 2497 10704919 of IN B-PP O
20 2498 2510 10704919 biomembranes NNS B-NP O
21 2511 2513 10704919 by IN B-PP O
22 2514 2517 10704919 TAM NN B-NP B-Chemical
23 2518 2521 10704919 may MD B-VP O
24 2522 2532 10704919 contribute VB I-VP O
25 2533 2535 10704919 to TO B-PP O
26 2536 2539 10704919 the DT B-NP O
27 2540 2548 10704919 multiple JJ I-NP O
28 2549 2559 10704919 mechanisms NNS I-NP O
29 2560 2562 10704919 of IN B-PP O
30 2563 2566 10704919 its PRP$ B-NP O
31 2567 2577 10704919 anticancer JJ I-NP O
32 2578 2584 10704919 action NN I-NP O
33 2584 2585 10704919 . . O O

1 0 0 17437408 -DOCSTART- -X- -X- O

1 0 12 17437408 Upregulation NN B-NP O
2 13 15 17437408 of IN B-PP O
3 16 21 17437408 brain NN B-NP O
4 22 32 17437408 expression NN I-NP O
5 33 35 17437408 of IN B-PP O
6 36 37 17437408 P NN B-NP O
7 37 38 17437408 - HYPH B-NP O
8 38 50 17437408 glycoprotein NN I-NP O
9 51 53 17437408 in IN B-PP O
10 54 58 17437408 MRP2 NN B-NP O
11 58 59 17437408 - HYPH B-NP O
12 59 68 17437408 deficient JJ I-NP O
13 69 72 17437408 TR( NN I-NP O
14 72 73 17437408 - HYPH O O
15 73 74 17437408 ) ) O O
16 75 79 17437408 rats NNS B-NP O
17 80 89 17437408 resembles VBZ B-VP O
18 90 97 17437408 seizure NN B-NP B-Disease
19 97 98 17437408 - HYPH O O
20 98 105 17437408 induced VBN B-VP O
21 106 108 17437408 up RB B-ADVP O
22 108 109 17437408 - HYPH B-NP O
23 109 119 17437408 regulation NN I-NP O
24 120 122 17437408 of IN B-PP O
25 123 127 17437408 this DT B-NP O
26 128 132 17437408 drug NN I-NP O
27 133 139 17437408 efflux NN I-NP O
28 140 151 17437408 transporter NN I-NP O
29 152 154 17437408 in IN B-PP O
30 155 161 17437408 normal JJ B-NP O
31 162 166 17437408 rats NNS I-NP O
32 166 167 17437408 . . O O
33 168 175 17437408 PURPOSE NN B-NP O
34 175 176 17437408 : : O O
35 177 180 17437408 The DT B-NP O
36 181 190 17437408 multidrug JJ I-NP O
37 191 201 17437408 resistance NN I-NP O
38 202 209 17437408 protein NN I-NP O
39 210 211 17437408 2 CD I-NP O
40 212 213 17437408 ( ( O O
41 213 217 17437408 MRP2 NN B-NP O
42 217 218 17437408 ) ) O O
43 219 221 17437408 is VBZ B-VP O
44 222 223 17437408 a DT B-NP O
45 224 228 17437408 drug NN I-NP O
46 229 235 17437408 efflux NN I-NP O
47 236 247 17437408 transporter NN I-NP O
48 248 252 17437408 that WDT B-NP O
49 253 255 17437408 is VBZ B-VP O
50 256 265 17437408 expressed VBN I-VP O
51 266 279 17437408 predominantly RB B-ADVP O
52 280 282 17437408 at IN B-PP O
53 283 286 17437408 the DT B-NP O
54 287 293 17437408 apical JJ I-NP O
55 294 300 17437408 domain NN I-NP O
56 301 303 17437408 of IN B-PP O
57 304 315 17437408 hepatocytes NNS B-NP O
58 316 319 17437408 but CC O O
59 320 325 17437408 seems VBZ B-VP O
60 326 330 17437408 also RB B-ADVP O
61 331 333 17437408 to TO B-VP O
62 334 336 17437408 be VB I-VP O
63 337 346 17437408 expressed VBN I-VP O
64 347 349 17437408 at IN B-PP O
65 350 353 17437408 the DT B-NP O
66 354 360 17437408 apical JJ I-NP O
67 361 369 17437408 membrane NN I-NP O
68 370 372 17437408 of IN B-PP O
69 373 378 17437408 brain NN B-NP O
70 379 388 17437408 capillary JJ I-NP O
71 389 400 17437408 endothelial JJ I-NP O
72 401 406 17437408 cells NNS I-NP O
73 407 411 17437408 that WDT B-NP O
74 412 416 17437408 form VBP B-VP O
75 417 420 17437408 the DT B-NP O
76 421 426 17437408 blood NN I-NP O
77 426 427 17437408 - HYPH I-NP O
78 427 432 17437408 brain NN I-NP O
79 433 440 17437408 barrier NN I-NP O
80 441 442 17437408 ( ( O O
81 442 445 17437408 BBB NN B-NP O
82 445 446 17437408 ) ) O O
83 446 447 17437408 . . O O

1 448 452 17437408 MRP2 NN B-NP O
2 453 455 17437408 is VBZ B-VP O
3 456 462 17437408 absent JJ B-ADJP O
4 463 465 17437408 in IN B-PP O
5 466 469 17437408 the DT B-NP O
6 470 479 17437408 transport NN I-NP O
7 479 480 17437408 - HYPH B-NP O
8 480 489 17437408 deficient JJ I-NP O
9 490 491 17437408 ( ( O O
10 491 494 17437408 TR( NN B-NP O
11 494 495 17437408 - HYPH O O
12 495 496 17437408 ) ) O O
13 496 497 17437408 ) ) O O
14 498 504 17437408 Wistar NNP B-NP O
15 505 508 17437408 rat NN I-NP O
16 509 515 17437408 mutant NN I-NP O
17 515 516 17437408 , , O O
18 517 519 17437408 so IN B-SBAR O
19 520 524 17437408 that IN I-SBAR O
20 525 529 17437408 this DT B-NP O
21 530 533 17437408 rat NN I-NP O
22 534 540 17437408 strain NN I-NP O
23 541 544 17437408 was VBD B-VP O
24 545 549 17437408 very RB B-ADJP O
25 550 557 17437408 helpful JJ I-ADJP O
26 558 560 17437408 in IN B-PP O
27 561 569 17437408 defining VBG B-VP O
28 570 580 17437408 substrates NNS B-NP O
29 581 583 17437408 of IN B-PP O
30 584 588 17437408 MRP2 NN B-NP O
31 589 591 17437408 by IN B-PP O
32 592 601 17437408 comparing VBG B-VP O
33 602 608 17437408 tissue NN B-NP O
34 609 623 17437408 concentrations NNS I-NP O
35 624 626 17437408 or CC O O
36 627 637 17437408 functional JJ B-NP O
37 638 648 17437408 activities NNS I-NP O
38 649 651 17437408 of IN B-PP O
39 652 661 17437408 compounds NNS B-NP O
40 662 664 17437408 in IN B-PP O
41 665 669 17437408 MRP2 NN B-NP O
42 669 670 17437408 - HYPH B-NP O
43 670 679 17437408 deficient JJ I-NP O
44 680 684 17437408 rats NNS I-NP O
45 685 689 17437408 with IN B-PP O
46 690 695 17437408 those DT B-NP O
47 696 698 17437408 in IN B-PP O
48 699 708 17437408 transport NN B-NP O
49 708 709 17437408 - HYPH B-NP O
50 709 718 17437408 competent JJ I-NP O
51 719 725 17437408 Wistar NNP I-NP O
52 726 730 17437408 rats NNS I-NP O
53 730 731 17437408 . . O O

1 732 734 17437408 By IN B-PP O
2 735 740 17437408 using VBG B-VP O
3 741 745 17437408 this DT B-NP O
4 746 754 17437408 strategy NN I-NP O
5 755 757 17437408 to TO B-VP O
6 758 763 17437408 study VB I-VP O
7 764 767 17437408 the DT B-NP O
8 768 779 17437408 involvement NN I-NP O
9 780 782 17437408 of IN B-PP O
10 783 787 17437408 MRP2 NN B-NP O
11 788 790 17437408 in IN B-PP O
12 791 796 17437408 brain NN B-NP O
13 797 803 17437408 access NN I-NP O
14 804 806 17437408 of IN B-PP O
15 807 820 17437408 antiepileptic JJ B-NP O
16 821 826 17437408 drugs NNS I-NP O
17 827 828 17437408 ( ( O O
18 828 832 17437408 AEDs NNS B-NP O
19 832 833 17437408 ) ) O O
20 833 834 17437408 , , O O
21 835 837 17437408 we PRP B-NP O
22 838 846 17437408 recently RB B-ADVP O
23 847 855 17437408 reported VBD B-VP O
24 856 860 17437408 that IN B-SBAR O
25 861 870 17437408 phenytoin NN B-NP B-Chemical
26 871 873 17437408 is VBZ B-VP O
27 874 875 17437408 a DT B-NP O
28 876 885 17437408 substrate NN I-NP O
29 886 889 17437408 for IN B-PP O
30 890 894 17437408 MRP2 NN B-NP O
31 895 897 17437408 in IN B-PP O
32 898 901 17437408 the DT B-NP O
33 902 905 17437408 BBB NNP I-NP O
34 905 906 17437408 . . O O

1 907 914 17437408 However RB B-ADVP O
2 914 915 17437408 , , O O
3 916 919 17437408 one CD B-NP O
4 920 928 17437408 drawback NN I-NP O
5 929 931 17437408 of IN B-PP O
6 932 936 17437408 such JJ B-NP O
7 937 944 17437408 studies NNS I-NP O
8 945 947 17437408 in IN B-PP O
9 948 959 17437408 genetically RB B-NP O
10 960 969 17437408 deficient JJ I-NP O
11 970 974 17437408 rats NNS I-NP O
12 975 977 17437408 is VBZ B-VP O
13 978 981 17437408 the DT B-NP O
14 982 986 17437408 fact NN I-NP O
15 987 991 17437408 that IN B-SBAR O
16 992 1004 17437408 compensatory JJ B-NP O
17 1005 1012 17437408 changes NNS I-NP O
18 1013 1017 17437408 with IN B-PP O
19 1018 1030 17437408 upregulation NN B-NP O
20 1031 1033 17437408 of IN B-PP O
21 1034 1039 17437408 other JJ B-NP O
22 1040 1052 17437408 transporters NNS I-NP O
23 1053 1056 17437408 can MD B-VP O
24 1057 1062 17437408 occur VB I-VP O
25 1062 1063 17437408 . . O O

1 1064 1068 17437408 This DT B-NP O
2 1069 1077 17437408 prompted VBD B-VP O
3 1078 1080 17437408 us PRP B-NP O
4 1081 1083 17437408 to TO B-VP O
5 1084 1089 17437408 study VB I-VP O
6 1090 1093 17437408 the DT B-NP O
7 1094 1099 17437408 brain NN I-NP O
8 1100 1110 17437408 expression NN I-NP O
9 1111 1113 17437408 of IN B-PP O
10 1114 1115 17437408 P NN B-NP O
11 1115 1116 17437408 - HYPH O O
12 1116 1128 17437408 glycoprotein NN B-NP O
13 1129 1130 17437408 ( ( O O
14 1130 1133 17437408 Pgp NN B-NP O
15 1133 1134 17437408 ) ) O O
16 1134 1135 17437408 , , O O
17 1136 1137 17437408 a DT B-NP O
18 1138 1143 17437408 major JJ I-NP O
19 1144 1148 17437408 drug NN I-NP O
20 1149 1155 17437408 efflux NN I-NP O
21 1156 1167 17437408 transporter NN I-NP O
22 1168 1170 17437408 in IN B-PP O
23 1171 1175 17437408 many JJ B-NP O
24 1176 1183 17437408 tissues NNS I-NP O
25 1183 1184 17437408 , , O O
26 1185 1194 17437408 including VBG B-PP O
27 1195 1198 17437408 the DT B-NP O
28 1199 1202 17437408 BBB NNP I-NP O
29 1202 1203 17437408 , , O O
30 1204 1206 17437408 in IN B-PP O
31 1207 1210 17437408 TR( NN B-NP O
32 1210 1211 17437408 - HYPH O O
33 1211 1212 17437408 ) ) O O
34 1213 1217 17437408 rats NNS B-NP O
35 1218 1226 17437408 compared VBN B-PP O
36 1227 1231 17437408 with IN B-PP O
37 1232 1241 17437408 nonmutant JJ O O
38 1242 1243 17437408 ( ( O O
39 1243 1247 17437408 wild JJ B-NP O
40 1247 1248 17437408 - HYPH I-NP O
41 1248 1252 17437408 type NN I-NP O
42 1252 1253 17437408 ) ) I-NP O
43 1254 1260 17437408 Wistar NNP I-NP O
44 1261 1265 17437408 rats NNS I-NP O
45 1265 1266 17437408 . . O O

1 1267 1274 17437408 METHODS NNS B-NP O
2 1274 1275 17437408 : : O O
3 1276 1279 17437408 The DT B-NP O
4 1280 1290 17437408 expression NN I-NP O
5 1291 1293 17437408 of IN B-PP O
6 1294 1298 17437408 MRP2 NN B-NP O
7 1299 1302 17437408 and CC I-NP O
8 1303 1306 17437408 Pgp NN I-NP O
9 1307 1309 17437408 in IN B-PP O
10 1310 1315 17437408 brain NN B-NP O
11 1316 1319 17437408 and CC I-NP O
12 1320 1325 17437408 liver NN I-NP O
13 1326 1334 17437408 sections NNS I-NP O
14 1335 1337 17437408 of IN B-PP O
15 1338 1341 17437408 TR( NN B-NP O
16 1341 1342 17437408 - HYPH O O
17 1342 1343 17437408 ) ) O O
18 1344 1348 17437408 rats NNS B-NP O
19 1349 1352 17437408 and CC O O
20 1353 1359 17437408 normal JJ B-NP O
21 1360 1366 17437408 Wistar NNP I-NP O
22 1367 1371 17437408 rats NNS I-NP O
23 1372 1375 17437408 was VBD B-VP O
24 1376 1386 17437408 determined VBN I-VP O
25 1387 1391 17437408 with IN B-PP O
26 1392 1412 17437408 immunohistochemistry NN B-NP O
27 1412 1413 17437408 , , O O
28 1414 1416 17437408 by IN B-PP O
29 1417 1422 17437408 using VBG B-VP O
30 1423 1424 17437408 a DT B-NP O
31 1425 1430 17437408 novel JJ I-NP O
32 1430 1431 17437408 , , I-NP O
33 1432 1438 17437408 highly RB I-NP O
34 1439 1448 17437408 selective JJ I-NP O
35 1449 1459 17437408 monoclonal JJ I-NP O
36 1460 1464 17437408 MRP2 NN I-NP O
37 1465 1473 17437408 antibody NN I-NP O
38 1474 1477 17437408 and CC O O
39 1478 1481 17437408 the DT B-NP O
40 1482 1492 17437408 monoclonal JJ I-NP O
41 1493 1496 17437408 Pgp NN I-NP O
42 1497 1505 17437408 antibody NN I-NP O
43 1506 1510 17437408 C219 NN I-NP O
44 1510 1511 17437408 , , O O
45 1512 1524 17437408 respectively RB B-ADVP O
46 1524 1525 17437408 . . O O

1 1526 1533 17437408 RESULTS NNS B-NP O
2 1533 1534 17437408 : : O O
3 1535 1553 17437408 Immunofluorescence NN B-NP O
4 1554 1562 17437408 staining NN I-NP O
5 1563 1567 17437408 with IN B-PP O
6 1568 1571 17437408 the DT B-NP O
7 1572 1576 17437408 MRP2 NN I-NP O
8 1577 1585 17437408 antibody NN I-NP O
9 1586 1589 17437408 was VBD B-VP O
10 1590 1595 17437408 found VBN I-VP O
11 1596 1598 17437408 to TO I-VP O
12 1599 1604 17437408 label VB I-VP O
13 1605 1606 17437408 a DT B-NP O
14 1607 1611 17437408 high JJ I-NP O
15 1612 1618 17437408 number NN I-NP O
16 1619 1621 17437408 of IN B-PP O
17 1622 1634 17437408 microvessels NNS B-NP O
18 1635 1645 17437408 throughout IN B-PP O
19 1646 1649 17437408 the DT B-NP O
20 1650 1655 17437408 brain NN I-NP O
21 1656 1658 17437408 in IN B-PP O
22 1659 1665 17437408 normal JJ B-NP O
23 1666 1672 17437408 Wistar NNP I-NP O
24 1673 1677 17437408 rats NNS I-NP O
25 1677 1678 17437408 , , O O
26 1679 1686 17437408 whereas IN O O
27 1687 1691 17437408 such JJ B-NP O
28 1692 1700 17437408 labeling NN I-NP O
29 1701 1704 17437408 was VBD B-VP O
30 1705 1711 17437408 absent JJ B-ADJP O
31 1712 1714 17437408 in IN B-PP O
32 1715 1718 17437408 TR( NNP B-NP O
33 1718 1719 17437408 - HYPH O O
34 1719 1720 17437408 ) ) O O
35 1721 1725 17437408 rats NNS B-NP O
36 1725 1726 17437408 . . O O

1 1727 1730 17437408 TR( ( O O
2 1730 1731 17437408 - HYPH O O
3 1731 1732 17437408 ) ) O O
4 1733 1737 17437408 rats NNS B-NP O
5 1738 1747 17437408 exhibited VBD B-VP O
6 1748 1749 17437408 a DT B-NP O
7 1750 1761 17437408 significant JJ I-NP O
8 1762 1764 17437408 up RB B-ADVP O
9 1764 1765 17437408 - HYPH O O
10 1765 1775 17437408 regulation NN B-NP O
11 1776 1778 17437408 of IN B-PP O
12 1779 1782 17437408 Pgp NN B-NP O
13 1783 1785 17437408 in IN B-PP O
14 1786 1791 17437408 brain NN B-NP O
15 1792 1801 17437408 capillary JJ I-NP O
16 1802 1813 17437408 endothelial JJ I-NP O
17 1814 1819 17437408 cells NNS I-NP O
18 1820 1828 17437408 compared VBN B-PP O
19 1829 1833 17437408 with IN B-PP O
20 1834 1838 17437408 wild JJ B-NP O
21 1838 1839 17437408 - HYPH I-NP O
22 1839 1843 17437408 type NN I-NP O
23 1844 1852 17437408 controls NNS I-NP O
24 1852 1853 17437408 . . O O

1 1854 1856 17437408 No DT B-NP O
2 1857 1861 17437408 such JJ I-NP O
3 1862 1869 17437408 obvious JJ I-NP O
4 1870 1882 17437408 upregulation NN I-NP O
5 1883 1885 17437408 of IN B-PP O
6 1886 1889 17437408 Pgp NN B-NP O
7 1890 1893 17437408 was VBD B-VP O
8 1894 1902 17437408 observed VBN I-VP O
9 1903 1905 17437408 in IN B-PP O
10 1906 1911 17437408 liver NN B-NP O
11 1912 1920 17437408 sections NNS I-NP O
12 1920 1921 17437408 . . O O

1 1922 1923 17437408 A DT B-NP O
2 1924 1934 17437408 comparable JJ I-NP O
3 1935 1949 17437408 overexpression NN I-NP O
4 1950 1952 17437408 of IN B-PP O
5 1953 1956 17437408 Pgp NN B-NP O
6 1957 1959 17437408 in IN B-PP O
7 1960 1963 17437408 the DT B-NP O
8 1964 1967 17437408 BBB NN I-NP O
9 1968 1971 17437408 was VBD B-VP O
10 1972 1980 17437408 obtained VBN I-VP O
11 1981 1986 17437408 after IN B-PP O
12 1987 1998 17437408 pilocarpine NN B-NP B-Chemical
13 1998 1999 17437408 - HYPH B-NP O
14 1999 2006 17437408 induced VBN I-NP O
15 2007 2015 17437408 seizures NNS I-NP B-Disease
16 2016 2018 17437408 in IN B-PP O
17 2019 2023 17437408 wild JJ B-NP O
18 2023 2024 17437408 - HYPH I-NP O
19 2024 2028 17437408 type NN I-NP O
20 2029 2035 17437408 Wistar NNP I-NP O
21 2036 2040 17437408 rats NNS I-NP O
22 2040 2041 17437408 . . O O

1 2042 2053 17437408 Experiments NNS B-NP O
2 2054 2058 17437408 with IN B-PP O
3 2059 2067 17437408 systemic JJ B-NP O
4 2068 2082 17437408 administration NN I-NP O
5 2083 2085 17437408 of IN B-PP O
6 2086 2089 17437408 the DT B-NP O
7 2090 2093 17437408 Pgp NN I-NP O
8 2094 2103 17437408 substrate NN I-NP O
9 2104 2117 17437408 phenobarbital NN I-NP B-Chemical
10 2118 2121 17437408 and CC O O
11 2122 2125 17437408 the DT B-NP O
12 2126 2135 17437408 selective JJ I-NP O
13 2136 2139 17437408 Pgp NN I-NP O
14 2140 2149 17437408 inhibitor NN I-NP O
15 2150 2160 17437408 tariquidar NN I-NP B-Chemical
16 2161 2163 17437408 in IN B-PP O
17 2164 2167 17437408 TR( NN B-NP O
18 2167 2168 17437408 - HYPH O O
19 2168 2169 17437408 ) ) O O
20 2170 2174 17437408 rats NNS B-NP O
21 2175 2188 17437408 substantiated VBD B-VP O
22 2189 2193 17437408 that IN B-SBAR O
23 2194 2197 17437408 Pgp NN B-NP O
24 2198 2200 17437408 is VBZ B-VP O
25 2201 2211 17437408 functional JJ B-ADJP O
26 2212 2215 17437408 and CC O O
27 2216 2227 17437408 compensates NNS B-NP O
28 2228 2231 17437408 for IN B-PP O
29 2232 2235 17437408 the DT B-NP O
30 2236 2240 17437408 lack NN I-NP O
31 2241 2243 17437408 of IN B-PP O
32 2244 2248 17437408 MRP2 NN B-NP O
33 2249 2251 17437408 in IN B-PP O
34 2252 2255 17437408 the DT B-NP O
35 2256 2259 17437408 BBB NNP I-NP O
36 2259 2260 17437408 . . O O

1 2261 2272 17437408 CONCLUSIONS NNS B-NP O
2 2272 2273 17437408 : : O O
3 2274 2277 17437408 The DT B-NP O
4 2278 2282 17437408 data NNS I-NP O
5 2283 2285 17437408 on IN B-PP O
6 2286 2289 17437408 TR( NN B-NP O
7 2289 2290 17437408 - HYPH O O
8 2290 2291 17437408 ) ) O O
9 2292 2296 17437408 rats NNS B-NP O
10 2297 2305 17437408 indicate VBP B-VP O
11 2306 2310 17437408 that IN B-SBAR O
12 2311 2314 17437408 Pgp NN B-NP O
13 2315 2320 17437408 plays VBZ B-VP O
14 2321 2323 17437408 an DT B-NP O
15 2324 2333 17437408 important JJ I-NP O
16 2334 2338 17437408 role NN I-NP O
17 2339 2341 17437408 in IN B-PP O
18 2342 2345 17437408 the DT B-NP O
19 2346 2358 17437408 compensation NN I-NP O
20 2359 2361 17437408 of IN B-PP O
21 2362 2366 17437408 MRP2 NN B-NP O
22 2367 2377 17437408 deficiency NN I-NP O
23 2378 2380 17437408 in IN B-PP O
24 2381 2384 17437408 the DT B-NP O
25 2385 2388 17437408 BBB NNP I-NP O
26 2388 2389 17437408 . . O O

1 2390 2397 17437408 Because IN B-SBAR O
2 2398 2402 17437408 such PDT B-NP O
3 2403 2404 17437408 a DT I-NP O
4 2405 2417 17437408 compensatory JJ I-NP O
5 2418 2427 17437408 mechanism NN I-NP O
6 2428 2432 17437408 most RBS B-ADVP O
7 2433 2439 17437408 likely RB I-ADVP O
8 2440 2446 17437408 occurs VBZ B-VP O
9 2447 2449 17437408 to TO I-VP O
10 2450 2456 17437408 reduce VB I-VP O
11 2457 2463 17437408 injury NN B-NP B-Disease
12 2464 2466 17437408 to TO B-PP I-Disease
13 2467 2470 17437408 the DT B-NP I-Disease
14 2471 2476 17437408 brain NN I-NP I-Disease
15 2477 2481 17437408 from IN B-PP O
16 2482 2491 17437408 cytotoxic JJ B-NP O
17 2492 2501 17437408 compounds NNS I-NP O
18 2501 2502 17437408 , , O O
19 2503 2506 17437408 the DT B-NP O
20 2507 2514 17437408 present JJ I-NP O
21 2515 2519 17437408 data NNS I-NP O
22 2520 2532 17437408 substantiate VBP B-VP O
23 2533 2536 17437408 the DT B-NP O
24 2537 2544 17437408 concept NN I-NP O
25 2545 2549 17437408 that IN B-SBAR O
26 2550 2554 17437408 MRP2 NN B-NP O
27 2555 2563 17437408 performs VBZ B-VP O
28 2564 2565 17437408 a DT B-NP O
29 2566 2576 17437408 protective JJ I-NP O
30 2577 2581 17437408 role NN I-NP O
31 2582 2584 17437408 in IN B-PP O
32 2585 2588 17437408 the DT B-NP O
33 2589 2592 17437408 BBB NNP I-NP O
34 2592 2593 17437408 . . O O

1 2594 2605 17437408 Furthermore RB B-ADVP O
2 2605 2606 17437408 , , O O
3 2607 2610 17437408 our PRP$ B-NP O
4 2611 2615 17437408 data NNS I-NP O
5 2616 2623 17437408 suggest VBP B-VP O
6 2624 2628 17437408 that IN B-SBAR O
7 2629 2632 17437408 TR( NN B-NP O
8 2632 2633 17437408 - HYPH O O
9 2633 2634 17437408 ) ) O O
10 2635 2639 17437408 rats NNS B-NP O
11 2640 2643 17437408 are VBP B-VP O
12 2644 2646 17437408 an DT B-NP O
13 2647 2658 17437408 interesting JJ I-NP O
14 2659 2663 17437408 tool NN I-NP O
15 2664 2666 17437408 to TO B-VP O
16 2667 2672 17437408 study VB I-VP O
17 2673 2685 17437408 consequences NNS B-NP O
18 2686 2688 17437408 of IN B-PP O
19 2689 2703 17437408 overexpression NN B-NP O
20 2704 2706 17437408 of IN B-PP O
21 2707 2710 17437408 Pgp NN B-NP O
22 2711 2713 17437408 in IN B-PP O
23 2714 2717 17437408 the DT B-NP O
24 2718 2721 17437408 BBB NN I-NP O
25 2722 2724 17437408 on IN B-PP O
26 2725 2731 17437408 access NN B-NP O
27 2732 2734 17437408 of IN B-PP O
28 2735 2740 17437408 drugs NNS B-NP O
29 2741 2743 17437408 in IN B-PP O
30 2744 2747 17437408 the DT B-NP O
31 2748 2753 17437408 brain NN I-NP O
32 2753 2754 17437408 , , O O
33 2755 2762 17437408 without IN B-PP O
34 2763 2766 17437408 the DT B-NP O
35 2767 2771 17437408 need NN I-NP O
36 2772 2774 17437408 of IN B-PP O
37 2775 2783 17437408 inducing VBG B-VP O
38 2784 2792 17437408 seizures NNS B-NP B-Disease
39 2793 2795 17437408 or CC O O
40 2796 2801 17437408 other JJ B-NP O
41 2802 2805 17437408 Pgp NN I-NP O
42 2805 2806 17437408 - HYPH B-NP O
43 2806 2815 17437408 enhancing VBG B-VP O
44 2816 2822 17437408 events NNS B-NP O
45 2823 2826 17437408 for IN B-PP O
46 2827 2831 17437408 this DT B-NP O
47 2832 2839 17437408 purpose NN I-NP O
48 2839 2840 17437408 . . O O

1 0 0 19657887 -DOCSTART- -X- -X- O

1 0 10 19657887 Disulfiram NN B-NP B-Chemical
2 10 11 19657887 - HYPH I-NP O
3 11 15 19657887 like JJ I-NP O
4 16 24 19657887 syndrome NN I-NP O
5 25 30 19657887 after IN B-PP O
6 31 39 19657887 hydrogen NN B-NP B-Chemical
7 40 49 19657887 cyanamide NN I-NP I-Chemical
8 50 62 19657887 professional JJ I-NP O
9 63 67 19657887 skin NN I-NP O
10 68 76 19657887 exposure NN I-NP O
11 76 77 19657887 : : O O
12 78 81 19657887 two CD B-NP O
13 82 86 19657887 case NN I-NP O
14 87 94 19657887 reports NNS I-NP O
15 95 97 19657887 in IN B-PP O
16 98 104 19657887 France NNP B-NP O
17 104 105 19657887 . . I-NP O
18 106 114 19657887 Hydrogen NN I-NP B-Chemical
19 115 124 19657887 cyanamide NN I-NP I-Chemical
20 125 127 19657887 is VBZ B-VP O
21 128 129 19657887 a DT B-NP O
22 130 135 19657887 plant NN I-NP O
23 136 142 19657887 growth NN I-NP O
24 143 152 19657887 regulator NN I-NP O
25 153 157 19657887 used VBN B-VP O
26 158 160 19657887 in IN B-PP O
27 161 172 19657887 agriculture NN B-NP O
28 173 175 19657887 to TO B-VP O
29 176 182 19657887 induce VB I-VP O
30 183 186 19657887 bud NN B-NP O
31 187 192 19657887 break NN I-NP O
32 193 195 19657887 in IN B-PP O
33 196 201 19657887 fruit NN B-NP O
34 202 207 19657887 trees NNS I-NP O
35 207 208 19657887 . . O O

1 209 216 19657887 Contact NN B-NP O
2 217 221 19657887 with IN B-PP O
3 222 225 19657887 the DT B-NP O
4 226 230 19657887 skin NN I-NP O
5 231 234 19657887 can MD B-VP O
6 235 241 19657887 result VB I-VP O
7 242 244 19657887 in IN B-PP O
8 245 257 19657887 percutaneous JJ B-NP O
9 258 268 19657887 absorption NN I-NP O
10 269 271 19657887 of IN B-PP O
11 272 275 19657887 the DT B-NP O
12 276 285 19657887 substance NN I-NP O
13 286 290 19657887 that WDT B-NP O
14 291 299 19657887 inhibits VBZ B-VP O
15 300 308 19657887 aldehyde NN B-NP B-Chemical
16 309 322 19657887 dehydrogenase NN I-NP O
17 323 326 19657887 and CC O O
18 327 330 19657887 can MD B-VP O
19 331 337 19657887 induce VB I-VP O
20 338 350 19657887 acetaldehyde NN B-NP B-Chemical
21 351 359 19657887 syndrome NN I-NP O
22 360 362 19657887 in IN B-PP O
23 363 367 19657887 case NN B-NP O
24 368 370 19657887 of IN B-PP O
25 371 378 19657887 alcohol NN B-NP B-Chemical
26 379 382 19657887 use NN I-NP O
27 382 383 19657887 . . O O

1 384 387 19657887 The DT B-NP O
2 388 395 19657887 purpose NN I-NP O
3 396 398 19657887 of IN B-PP O
4 399 403 19657887 this DT B-NP O
5 404 410 19657887 report NN I-NP O
6 411 413 19657887 is VBZ B-VP O
7 414 416 19657887 to TO B-VP O
8 417 425 19657887 describe VB I-VP O
9 426 429 19657887 two CD B-NP O
10 430 435 19657887 cases NNS I-NP O
11 436 438 19657887 of IN B-PP O
12 439 440 19657887 a DT B-NP O
13 441 451 19657887 disulfiram NN I-NP B-Chemical
14 451 452 19657887 - HYPH B-NP O
15 452 456 19657887 like JJ I-NP O
16 457 465 19657887 syndrome NN I-NP O
17 466 475 19657887 following VBG B-PP O
18 476 488 19657887 occupational JJ B-NP O
19 489 497 19657887 exposure NN I-NP O
20 498 500 19657887 to TO B-PP O
21 501 509 19657887 hydrogen NN B-NP B-Chemical
22 510 519 19657887 cyanamide NN I-NP I-Chemical
23 519 520 19657887 . . O O

1 521 524 19657887 The DT B-NP O
2 525 530 19657887 first JJ I-NP O
3 531 535 19657887 case NN I-NP O
4 536 544 19657887 involved VBD B-VP O
5 545 546 19657887 a DT B-NP O
6 547 549 19657887 59 CD I-NP O
7 549 550 19657887 - HYPH I-NP O
8 550 554 19657887 year NN I-NP O
9 554 555 19657887 - HYPH B-NP O
10 555 558 19657887 old JJ I-NP O
11 559 562 19657887 man NN I-NP O
12 563 566 19657887 who WP B-NP O
13 567 571 19657887 used VBD B-VP O
14 572 578 19657887 Dormex NNP B-NP B-Chemical
15 578 579 19657887 , , O O
16 580 585 19657887 which WDT B-NP O
17 586 594 19657887 contains VBZ B-VP O
18 595 603 19657887 hydrogen NN B-NP B-Chemical
19 604 613 19657887 cyanamide NN I-NP I-Chemical
20 613 614 19657887 , , O O
21 615 622 19657887 without IN B-PP O
22 623 633 19657887 protection NN B-NP O
23 634 639 19657887 after IN B-PP O
24 640 649 19657887 consuming VBG B-VP O
25 650 651 19657887 a DT B-NP O
26 652 657 19657887 large JJ I-NP O
27 658 664 19657887 amount NN I-NP O
28 665 667 19657887 of IN B-PP O
29 668 675 19657887 alcohol NN B-NP B-Chemical
30 676 682 19657887 during IN B-PP O
31 683 684 19657887 a DT B-NP O
32 685 689 19657887 meal NN I-NP O
33 689 690 19657887 . . O O

1 691 693 19657887 In IN B-PP O
2 694 698 19657887 less JJR B-NP O
3 699 703 19657887 than IN I-NP O
4 704 705 19657887 1 CD I-NP O
5 706 710 19657887 hour NN I-NP O
6 711 716 19657887 after IN B-PP O
7 717 720 19657887 the DT B-NP O
8 721 730 19657887 ingestion NN I-NP O
9 731 733 19657887 of IN B-PP O
10 734 741 19657887 alcohol NN B-NP B-Chemical
11 741 742 19657887 , , O O
12 743 745 19657887 he PRP B-NP O
13 746 755 19657887 developed VBD B-VP O
14 756 763 19657887 malaise NN B-NP O
15 764 768 19657887 with IN B-PP O
16 769 777 19657887 flushing NN B-NP B-Disease
17 778 780 19657887 of IN B-PP I-Disease
18 781 784 19657887 the DT B-NP I-Disease
19 785 789 19657887 face NN I-NP I-Disease
20 789 790 19657887 , , O O
21 791 802 19657887 tachycardia NN B-NP B-Disease
22 802 803 19657887 , , O O
23 804 807 19657887 and CC O O
24 808 815 19657887 dyspnea NN B-NP B-Disease
25 815 816 19657887 . . O O

1 817 831 19657887 Manifestations NNS B-NP O
2 832 841 19657887 regressed VBD B-VP O
3 842 855 19657887 spontaneously RB B-ADVP O
4 856 861 19657887 under IN B-PP O
5 862 874 19657887 surveillance NN B-NP O
6 875 877 19657887 in IN B-PP O
7 878 881 19657887 the DT B-NP O
8 882 890 19657887 hospital NN I-NP O
9 890 891 19657887 . . O O

1 892 895 19657887 The DT B-NP O
2 896 902 19657887 second JJ I-NP O
3 903 907 19657887 case NN I-NP O
4 908 916 19657887 occurred VBD B-VP O
5 917 919 19657887 in IN B-PP O
6 920 921 19657887 a DT B-NP O
7 922 924 19657887 55 CD I-NP O
8 924 925 19657887 - HYPH I-NP O
9 925 929 19657887 year NN I-NP O
10 929 930 19657887 - HYPH O O
11 930 933 19657887 old JJ B-NP O
12 934 940 19657887 farmer NN I-NP O
13 941 950 19657887 following VBG B-PP O
14 951 960 19657887 cutaneous JJ B-NP O
15 961 968 19657887 contact NN I-NP O
16 969 973 19657887 with IN B-PP O
17 974 980 19657887 Dormex NNP B-NP B-Chemical
18 980 981 19657887 . . O O

1 982 986 19657887 Five CD B-NP O
2 987 992 19657887 hours NNS I-NP O
3 993 998 19657887 after IN B-PP O
4 999 1007 19657887 exposure NN B-NP O
5 1007 1008 19657887 , , O O
6 1009 1011 19657887 he PRP B-NP O
7 1012 1021 19657887 developed VBD B-VP O
8 1022 1032 19657887 disulfiram NN B-NP B-Chemical
9 1032 1033 19657887 - HYPH B-NP O
10 1033 1037 19657887 like JJ I-NP O
11 1038 1046 19657887 syndrome NN I-NP O
12 1047 1051 19657887 with IN B-PP O
13 1052 1060 19657887 flushing NN B-NP B-Disease
14 1060 1061 19657887 , , O O
15 1062 1073 19657887 tachycardia NN B-NP B-Disease
16 1073 1074 19657887 , , O O
17 1075 1078 19657887 and CC O O
18 1079 1087 19657887 arterial JJ B-NP B-Disease
19 1088 1099 19657887 hypotension NN I-NP I-Disease
20 1100 1105 19657887 after IN B-PP O
21 1106 1115 19657887 consuming VBG B-VP O
22 1116 1121 19657887 three CD B-NP O
23 1122 1129 19657887 glasses NNS I-NP O
24 1130 1132 19657887 of IN B-PP O
25 1133 1137 19657887 wine NN B-NP O
26 1137 1138 19657887 . . O O

1 1139 1142 19657887 The DT B-NP O
2 1143 1150 19657887 patient NN I-NP O
3 1151 1160 19657887 recovered VBD B-VP O
4 1161 1174 19657887 spontaneously RB B-ADVP O
5 1175 1177 19657887 in IN B-PP O
6 1178 1179 19657887 3 CD B-NP O
7 1180 1185 19657887 hours NNS I-NP O
8 1186 1191 19657887 under IN B-PP O
9 1192 1204 19657887 surveillance NN B-NP O
10 1205 1207 19657887 in IN B-PP O
11 1208 1211 19657887 the DT B-NP O
12 1212 1220 19657887 hospital NN I-NP O
13 1220 1221 19657887 . . O O

1 1222 1227 19657887 These DT B-NP O
2 1228 1233 19657887 cases NNS I-NP O
3 1234 1241 19657887 confirm VBP B-VP O
4 1242 1245 19657887 the DT B-NP O
5 1246 1255 19657887 necessity NN I-NP O
6 1256 1258 19657887 of IN B-PP O
7 1259 1267 19657887 avoiding VBG B-VP O
8 1268 1275 19657887 alcohol NN B-NP B-Chemical
9 1276 1287 19657887 consumption NN I-NP O
10 1288 1290 19657887 as IN B-SBAR O
11 1291 1302 19657887 recommended VBN B-VP O
12 1303 1305 19657887 in IN B-PP O
13 1306 1309 19657887 the DT B-NP O
14 1310 1322 19657887 instructions NNS I-NP O
15 1323 1326 19657887 for IN B-PP O
16 1327 1330 19657887 use NN B-NP O
17 1331 1333 19657887 of IN B-PP O
18 1334 1340 19657887 Dormex NNP B-NP B-Chemical
19 1341 1344 19657887 and CC B-PP O
20 1345 1347 19657887 of IN B-PP O
21 1348 1358 19657887 preventing VBG B-VP O
22 1359 1368 19657887 cutaneous JJ B-NP O
23 1369 1376 19657887 contact NN I-NP O
24 1377 1383 19657887 during IN B-PP O
25 1384 1387 19657887 use NN B-NP O
26 1387 1388 19657887 . . O O

1 0 0 3496378 -DOCSTART- -X- -X- O

1 0 9 3496378 Prolonged JJ B-NP O
2 10 21 3496378 cholestasis NN I-NP B-Disease
3 22 27 3496378 after IN B-PP O
4 28 42 3496378 troleandomycin NN B-NP B-Chemical
5 42 43 3496378 - HYPH B-NP O
6 43 50 3496378 induced VBN I-NP O
7 51 56 3496378 acute JJ I-NP O
8 57 66 3496378 hepatitis NN I-NP B-Disease
9 66 67 3496378 . . O O
10 68 70 3496378 We PRP B-NP O
11 71 77 3496378 report VBP B-VP O
12 78 81 3496378 the DT B-NP O
13 82 86 3496378 case NN I-NP O
14 87 89 3496378 of IN B-PP O
15 90 91 3496378 a DT B-NP O
16 92 99 3496378 patient NN I-NP O
17 100 102 3496378 in IN B-PP O
18 103 107 3496378 whom WP B-NP O
19 108 122 3496378 troleandomycin NN I-NP B-Chemical
20 122 123 3496378 - HYPH B-NP O
21 123 130 3496378 induced VBN I-NP O
22 131 140 3496378 hepatitis NN I-NP B-Disease
23 141 144 3496378 was VBD B-VP O
24 145 153 3496378 followed VBN I-VP O
25 154 156 3496378 by IN B-PP O
26 157 166 3496378 prolonged JJ B-NP O
27 167 176 3496378 anicteric JJ I-NP O
28 177 188 3496378 cholestasis NN I-NP B-Disease
29 188 189 3496378 . . O O

1 190 198 3496378 Jaundice NNP B-NP B-Disease
2 199 207 3496378 occurred VBD B-VP O
3 208 213 3496378 after IN B-PP O
4 214 228 3496378 administration NN B-NP O
5 229 231 3496378 of IN B-PP O
6 232 246 3496378 troleandomycin NN B-NP B-Chemical
7 247 250 3496378 for IN B-PP O
8 251 252 3496378 7 CD B-NP O
9 253 257 3496378 days NNS I-NP O
10 258 261 3496378 and CC O O
11 262 265 3496378 was VBD B-VP O
12 266 276 3496378 associated VBN I-VP O
13 277 281 3496378 with IN B-PP O
14 282 299 3496378 hypereosinophilia NN B-NP B-Disease
15 299 300 3496378 . . O O

1 301 309 3496378 Jaundice NNP B-NP B-Disease
2 310 321 3496378 disappeared VBD B-VP O
3 322 328 3496378 within IN B-PP O
4 329 330 3496378 3 CD B-NP O
5 331 337 3496378 months NNS I-NP O
6 338 341 3496378 but CC O O
7 342 345 3496378 was VBD B-VP O
8 346 354 3496378 followed VBN I-VP O
9 355 357 3496378 by IN B-PP O
10 358 367 3496378 prolonged JJ B-NP O
11 368 377 3496378 anicteric JJ I-NP O
12 378 389 3496378 cholestasis NN I-NP B-Disease
13 390 396 3496378 marked VBN B-VP O
14 397 399 3496378 by IN B-PP O
15 400 408 3496378 pruritus NN B-NP B-Disease
16 409 412 3496378 and CC O O
17 413 417 3496378 high JJ B-NP O
18 418 424 3496378 levels NNS I-NP O
19 425 427 3496378 of IN B-PP O
20 428 436 3496378 alkaline NN B-NP O
21 437 448 3496378 phosphatase NN I-NP O
22 449 452 3496378 and CC I-NP O
23 453 477 3496378 gammaglutamyltransferase NN I-NP O
24 478 488 3496378 activities NNS I-NP O
25 488 489 3496378 . . O O

1 490 497 3496378 Finally RB B-ADVP O
2 497 498 3496378 , , O O
3 499 507 3496378 pruritus NN B-NP B-Disease
4 508 519 3496378 disappeared VBD B-VP O
5 520 526 3496378 within IN B-PP O
6 527 529 3496378 19 CD B-NP O
7 530 536 3496378 months NNS I-NP O
8 536 537 3496378 , , O O
9 538 541 3496378 and CC O O
10 542 547 3496378 liver NN B-NP O
11 548 553 3496378 tests NNS I-NP O
12 554 562 3496378 returned VBD B-VP O
13 563 565 3496378 to TO B-PP O
14 566 572 3496378 normal JJ B-NP O
15 573 575 3496378 27 CD I-NP O
16 576 582 3496378 months NNS I-NP O
17 583 588 3496378 after IN B-SBAR O
18 589 592 3496378 the DT B-NP O
19 593 598 3496378 onset NN I-NP O
20 599 601 3496378 of IN B-PP O
21 602 611 3496378 hepatitis NN B-NP B-Disease
22 611 612 3496378 . . O O

1 613 617 3496378 This DT B-NP O
2 618 629 3496378 observation NN I-NP O
3 630 642 3496378 demonstrates VBZ B-VP O
4 643 647 3496378 that IN B-SBAR O
5 648 657 3496378 prolonged VBN B-NP O
6 658 669 3496378 cholestasis NN I-NP B-Disease
7 670 673 3496378 can MD B-VP O
8 674 680 3496378 follow VB I-VP O
9 681 695 3496378 troleandomycin NN B-NP B-Chemical
10 695 696 3496378 - HYPH O O
11 696 703 3496378 induced VBN B-NP O
12 704 709 3496378 acute JJ I-NP O
13 710 719 3496378 hepatitis NN I-NP B-Disease
14 719 720 3496378 . . O O

1 0 0 7449470 -DOCSTART- -X- -X- O

1 0 4 7449470 Late RB B-ADVP O
2 4 5 7449470 , , O O
3 6 10 7449470 late JJ B-NP O
4 11 22 7449470 doxorubicin NN I-NP B-Chemical
5 23 37 7449470 cardiotoxicity NN I-NP B-Disease
6 37 38 7449470 . . O O
7 39 46 7449470 Cardiac JJ B-NP B-Disease
8 47 55 7449470 toxicity NN I-NP I-Disease
9 56 58 7449470 is VBZ B-VP O
10 59 60 7449470 a DT B-NP O
11 61 66 7449470 major JJ I-NP O
12 67 79 7449470 complication NN I-NP O
13 80 85 7449470 which WDT B-NP O
14 86 92 7449470 limits VBZ B-VP O
15 93 96 7449470 the DT B-NP O
16 97 100 7449470 use NN I-NP O
17 101 103 7449470 of IN B-PP O
18 104 114 7449470 adriamycin NN B-NP B-Chemical
19 115 117 7449470 as IN B-PP O
20 118 119 7449470 a DT B-NP O
21 120 136 7449470 chemotherapeutic JJ I-NP O
22 137 142 7449470 agent NN I-NP O
23 142 143 7449470 . . O O

1 144 158 7449470 Cardiomyopathy NNP B-NP B-Disease
2 159 161 7449470 is VBZ B-VP O
3 162 170 7449470 frequent JJ B-ADJP O
4 171 175 7449470 when WRB B-ADVP O
5 176 179 7449470 the DT B-NP O
6 180 185 7449470 total JJ I-NP O
7 186 190 7449470 dose NN I-NP O
8 191 198 7449470 exceeds VBZ B-VP O
9 199 202 7449470 600 CD B-NP O
10 203 205 7449470 mg NN I-NP O
11 205 206 7449470 / SYM B-NP O
12 206 208 7449470 m2 NN I-NP O
13 209 212 7449470 and CC O O
14 213 219 7449470 occurs VBZ B-VP O
15 220 226 7449470 within IN B-PP O
16 227 230 7449470 one CD B-NP O
17 231 233 7449470 to TO I-NP O
18 234 237 7449470 six CD I-NP O
19 238 244 7449470 months NNS I-NP O
20 245 250 7449470 after IN B-PP O
21 251 260 7449470 cessation NN B-NP O
22 261 263 7449470 of IN B-PP O
23 264 271 7449470 therapy NN B-NP O
24 271 272 7449470 . . O O

1 273 274 7449470 A DT B-NP O
2 275 282 7449470 patient NN I-NP O
3 283 285 7449470 is VBZ B-VP O
4 286 294 7449470 reported VBN I-VP O
5 295 298 7449470 who WP B-NP O
6 299 308 7449470 developed VBD B-VP O
7 309 320 7449470 progressive JJ B-NP O
8 321 335 7449470 cardiomyopathy NN I-NP B-Disease
9 336 339 7449470 two CD B-NP O
10 340 343 7449470 and CC I-NP O
11 344 347 7449470 one CD I-NP O
12 347 348 7449470 - HYPH I-NP O
13 348 352 7449470 half NN I-NP O
14 353 358 7449470 years NNS I-NP O
15 359 364 7449470 after IN B-PP O
16 365 374 7449470 receiving VBG B-VP O
17 375 378 7449470 580 CD B-NP O
18 379 381 7449470 mg NN I-NP O
19 381 382 7449470 / SYM B-NP O
20 382 384 7449470 m2 NN I-NP O
21 385 390 7449470 which WDT B-NP O
22 391 401 7449470 apparently RB B-ADVP O
23 402 412 7449470 represents VBZ B-VP O
24 413 417 7449470 late JJ B-NP O
25 417 418 7449470 , , I-NP O
26 419 423 7449470 late JJ I-NP O
27 424 438 7449470 cardiotoxicity NN I-NP B-Disease
28 438 439 7449470 . . O O

1 0 0 12905102 -DOCSTART- -X- -X- O

1 0 8 12905102 Delirium NN B-NP B-Disease
2 9 15 12905102 during IN B-PP O
3 16 25 12905102 clozapine NN B-NP B-Chemical
4 26 35 12905102 treatment NN I-NP O
5 35 36 12905102 : : O O
6 37 46 12905102 incidence NN B-NP O
7 47 50 12905102 and CC O O
8 51 61 12905102 associated VBN B-VP O
9 62 66 12905102 risk NN B-NP O
10 67 74 12905102 factors NNS I-NP O
11 74 75 12905102 . . B-NP O
12 76 86 12905102 BACKGROUND NN I-NP O
13 86 87 12905102 : : O O
14 88 97 12905102 Incidence NN B-NP O
15 98 101 12905102 and CC I-NP O
16 102 106 12905102 risk NN I-NP O
17 107 114 12905102 factors NNS I-NP O
18 115 118 12905102 for IN B-PP O
19 119 127 12905102 delirium NN B-NP B-Disease
20 128 134 12905102 during IN B-PP O
21 135 144 12905102 clozapine NN B-NP B-Chemical
22 145 154 12905102 treatment NN I-NP O
23 155 162 12905102 require VBP B-VP O
24 163 170 12905102 further JJR B-NP O
25 171 184 12905102 clarification NN I-NP O
26 184 185 12905102 . . O O

1 186 193 12905102 METHODS NNS B-NP O
2 193 194 12905102 : : O O
3 195 197 12905102 We PRP B-NP O
4 198 202 12905102 used VBD B-VP O
5 203 215 12905102 computerized JJ B-NP O
6 216 224 12905102 pharmacy NN I-NP O
7 225 232 12905102 records NNS I-NP O
8 233 235 12905102 to TO B-VP O
9 236 244 12905102 identify VB I-VP O
10 245 248 12905102 all DT B-NP O
11 249 254 12905102 adult JJ I-NP O
12 255 266 12905102 psychiatric JJ I-NP B-Disease
13 267 277 12905102 inpatients NNS I-NP O
14 278 285 12905102 treated VBN B-VP O
15 286 290 12905102 with IN B-PP O
16 291 300 12905102 clozapine NN B-NP B-Chemical
17 301 302 12905102 ( ( O O
18 302 306 12905102 1995 CD B-NP O
19 306 307 12905102 - HYPH O O
20 307 309 12905102 96 CD B-NP O
21 309 310 12905102 ) ) O O
22 310 311 12905102 , , O O
23 312 320 12905102 reviewed VBD B-VP O
24 321 326 12905102 their PRP$ B-NP O
25 327 334 12905102 medical JJ I-NP O
26 335 342 12905102 records NNS I-NP O
27 343 345 12905102 to TO B-VP O
28 346 351 12905102 score VB I-VP O
29 352 361 12905102 incidence NN B-NP O
30 362 365 12905102 and CC I-NP O
31 366 374 12905102 severity NN I-NP O
32 375 377 12905102 of IN B-PP O
33 378 386 12905102 delirium NN B-NP B-Disease
34 386 387 12905102 , , O O
35 388 391 12905102 and CC O O
36 392 398 12905102 tested VBN B-VP O
37 399 411 12905102 associations NNS B-NP O
38 412 416 12905102 with IN B-PP O
39 417 426 12905102 potential JJ B-NP O
40 427 431 12905102 risk NN I-NP O
41 432 439 12905102 factors NNS I-NP O
42 439 440 12905102 . . O O

1 441 448 12905102 RESULTS NNS B-NP O
2 448 449 12905102 : : O O
3 450 458 12905102 Subjects NNS B-NP O
4 459 460 12905102 ( ( O O
5 460 461 12905102 n NN B-NP O
6 462 463 12905102 = SYM B-VP O
7 464 467 12905102 139 CD B-NP O
8 467 468 12905102 ) ) O O
9 469 473 12905102 were VBD B-VP O
10 474 476 12905102 72 CD B-NP O
11 477 482 12905102 women NNS I-NP O
12 483 486 12905102 and CC O O
13 487 489 12905102 67 CD B-NP O
14 490 493 12905102 men NNS I-NP O
15 493 494 12905102 , , O O
16 495 499 12905102 aged VBN B-VP O
17 500 504 12905102 40.8 CD B-NP O
18 505 506 12905102 + SYM O O
19 506 507 12905102 / SYM O O
20 507 508 12905102 - SYM O O
21 509 513 12905102 12.1 CD B-NP O
22 514 519 12905102 years NNS I-NP O
23 519 520 12905102 , , O O
24 521 533 12905102 hospitalized VBN B-VP O
25 534 537 12905102 for IN B-PP O
26 538 542 12905102 24.9 CD B-NP O
27 543 544 12905102 + SYM O O
28 544 545 12905102 / SYM O O
29 545 546 12905102 - SYM B-NP O
30 547 551 12905102 23.3 CD B-NP O
31 552 556 12905102 days NNS I-NP O
32 556 557 12905102 , , O O
33 558 561 12905102 and CC O O
34 562 567 12905102 given VBN B-VP O
35 568 577 12905102 clozapine NN B-NP B-Chemical
36 577 578 12905102 , , O O
37 579 588 12905102 gradually RB B-ADVP O
38 589 598 12905102 increased VBD B-VP O
39 599 601 12905102 to TO B-PP O
40 602 604 12905102 an DT B-NP O
41 605 612 12905102 average JJ I-NP O
42 613 618 12905102 daily JJ I-NP O
43 619 623 12905102 dose NN I-NP O
44 624 626 12905102 of IN B-PP O
45 627 630 12905102 282 CD B-NP O
46 631 632 12905102 + SYM O O
47 632 633 12905102 / SYM O O
48 633 634 12905102 - SYM O O
49 635 638 12905102 203 CD B-NP O
50 639 641 12905102 mg NN I-NP O
51 642 643 12905102 ( ( O O
52 643 647 12905102 3.45 CD B-NP O
53 648 649 12905102 + SYM O O
54 649 650 12905102 / SYM O O
55 650 651 12905102 - SYM O O
56 652 656 12905102 2.45 CD B-NP O
57 657 659 12905102 mg NN I-NP O
58 659 660 12905102 / SYM B-NP O
59 660 662 12905102 kg NN I-NP O
60 662 663 12905102 ) ) O O
61 664 667 12905102 for IN B-PP O
62 668 672 12905102 18.9 CD B-NP O
63 673 674 12905102 + SYM O O
64 674 675 12905102 / SYM O O
65 675 676 12905102 - SYM B-NP O
66 677 681 12905102 16.4 CD B-NP O
67 682 686 12905102 days NNS I-NP O
68 686 687 12905102 . . O O

1 688 696 12905102 Delirium NN B-NP B-Disease
2 697 700 12905102 was VBD B-VP O
3 701 710 12905102 diagnosed VBN I-VP O
4 711 713 12905102 in IN B-PP O
5 714 716 12905102 14 CD B-NP O
6 717 718 12905102 ( ( O O
7 718 722 12905102 10.1 CD B-NP O
8 723 724 12905102 % NN I-NP O
9 725 734 12905102 incidence NN I-NP O
10 734 735 12905102 , , O O
11 736 738 12905102 or CC O O
12 739 743 12905102 1.48 CD B-NP O
13 744 749 12905102 cases NNS I-NP O
14 749 750 12905102 / SYM B-NP O
15 750 756 12905102 person NN I-NP O
16 756 757 12905102 - HYPH B-NP O
17 757 762 12905102 years NNS I-NP O
18 763 765 12905102 of IN B-PP O
19 766 774 12905102 exposure NN B-NP O
20 774 775 12905102 ) ) O O
21 775 776 12905102 ; : O O
22 777 781 12905102 71.4 CD B-NP O
23 782 783 12905102 % NN I-NP O
24 784 786 12905102 of IN B-PP O
25 787 792 12905102 cases NNS B-NP O
26 793 797 12905102 were VBD B-VP O
27 798 806 12905102 moderate JJ B-ADJP O
28 807 809 12905102 or CC I-ADJP O
29 810 816 12905102 severe JJ I-ADJP O
30 816 817 12905102 . . O O

1 818 828 12905102 Associated VBN B-NP O
2 829 836 12905102 factors NNS I-NP O
3 837 841 12905102 were VBD B-VP O
4 842 844 12905102 co AFX O O
5 844 845 12905102 - HYPH O O
6 845 854 12905102 treatment NN B-NP O
7 855 859 12905102 with IN B-PP O
8 860 865 12905102 other JJ B-NP O
9 866 875 12905102 centrally RB I-NP O
10 876 890 12905102 antimuscarinic JJ I-NP O
11 891 897 12905102 agents NNS I-NP O
12 897 898 12905102 , , O O
13 899 903 12905102 poor JJ B-NP O
14 904 912 12905102 clinical JJ I-NP O
15 913 920 12905102 outcome NN I-NP O
16 920 921 12905102 , , O O
17 922 927 12905102 older JJR B-NP O
18 928 931 12905102 age NN I-NP O
19 931 932 12905102 , , O O
20 933 936 12905102 and CC O O
21 937 943 12905102 longer JJR B-NP O
22 944 959 12905102 hospitalization NN I-NP O
23 960 961 12905102 ( ( O O
24 961 963 12905102 by IN B-PP O
25 964 968 12905102 17.5 CD B-NP O
26 969 973 12905102 days NNS I-NP O
27 973 974 12905102 , , O O
28 975 985 12905102 increasing VBG B-VP O
29 986 990 12905102 cost NN B-NP O
30 990 991 12905102 ) ) O O
31 991 992 12905102 ; : O O
32 993 996 12905102 sex NN B-NP O
33 996 997 12905102 , , I-NP O
34 998 1007 12905102 diagnosis NN I-NP O
35 1008 1010 12905102 or CC I-NP O
36 1011 1018 12905102 medical JJ I-NP O
37 1019 1021 12905102 co AFX O O
38 1021 1022 12905102 - HYPH O O
39 1022 1031 12905102 morbidity NN B-NP O
40 1031 1032 12905102 , , O O
41 1033 1036 12905102 and CC O O
42 1037 1042 12905102 daily JJ B-NP O
43 1043 1052 12905102 clozapine NN I-NP B-Chemical
44 1053 1057 12905102 dose NN I-NP O
45 1057 1058 12905102 , , O O
46 1059 1064 12905102 which WDT B-NP O
47 1065 1069 12905102 fell VBD B-VP O
48 1070 1074 12905102 with IN B-PP O
49 1075 1078 12905102 age NN B-NP O
50 1078 1079 12905102 , , O O
51 1080 1084 12905102 were VBD B-VP O
52 1085 1094 12905102 unrelated JJ B-ADJP O
53 1094 1095 12905102 . . O O

1 1096 1107 12905102 CONCLUSIONS NNS B-NP O
2 1107 1108 12905102 : : O O
3 1109 1117 12905102 Delirium NN B-NP B-Disease
4 1118 1121 12905102 was VBD B-VP O
5 1122 1127 12905102 found VBN I-VP O
6 1128 1130 12905102 in IN B-PP O
7 1131 1133 12905102 10 CD B-NP O
8 1134 1135 12905102 % NN I-NP O
9 1136 1138 12905102 of IN B-PP O
10 1139 1148 12905102 clozapine NN B-NP B-Chemical
11 1148 1149 12905102 - HYPH B-NP O
12 1149 1156 12905102 treated VBN I-NP O
13 1157 1167 12905102 inpatients NNS I-NP O
14 1167 1168 12905102 , , O O
15 1169 1181 12905102 particularly RB B-ADVP O
16 1182 1184 12905102 in IN B-PP O
17 1185 1190 12905102 older JJR B-NP O
18 1191 1199 12905102 patients NNS I-NP O
19 1200 1207 12905102 exposed VBN B-VP O
20 1208 1210 12905102 to TO B-PP O
21 1211 1216 12905102 other JJ B-NP O
22 1217 1224 12905102 central JJ I-NP O
23 1225 1241 12905102 anticholinergics NNS I-NP O
24 1241 1242 12905102 . . O O

1 1243 1251 12905102 Delirium NN B-NP B-Disease
2 1252 1255 12905102 was VBD B-VP O
3 1256 1270 12905102 inconsistently RB I-VP O
4 1271 1281 12905102 recognized VBN I-VP O
5 1282 1292 12905102 clinically RB B-ADVP O
6 1293 1295 12905102 in IN B-PP O
7 1296 1302 12905102 milder JJR B-NP O
8 1303 1308 12905102 cases NNS I-NP O
9 1309 1312 12905102 and CC O O
10 1313 1316 12905102 was VBD B-VP O
11 1317 1327 12905102 associated VBN I-VP O
12 1328 1332 12905102 with IN B-PP O
13 1333 1342 12905102 increased VBN B-NP O
14 1343 1349 12905102 length NN I-NP O
15 1349 1350 12905102 - HYPH B-NP O
16 1350 1352 12905102 of IN B-PP O
17 1352 1353 12905102 - HYPH B-NP O
18 1353 1357 12905102 stay NN I-NP O
19 1358 1361 12905102 and CC O O
20 1362 1368 12905102 higher JJR B-NP O
21 1369 1374 12905102 costs NNS I-NP O
22 1374 1375 12905102 , , O O
23 1376 1379 12905102 and CC O O
24 1380 1388 12905102 inferior JJ B-NP O
25 1389 1397 12905102 clinical JJ I-NP O
26 1398 1405 12905102 outcome NN I-NP O
27 1405 1406 12905102 . . O O

1 0 0 15602202 -DOCSTART- -X- -X- O

1 0 9 15602202 Recurrent JJ B-NP O
2 10 15 15602202 acute JJ I-NP O
3 16 28 15602202 interstitial JJ I-NP B-Disease
4 29 38 15602202 nephritis NN I-NP I-Disease
5 39 46 15602202 induced VBN B-VP O
6 47 49 15602202 by IN B-PP O
7 50 62 15602202 azithromycin NN B-NP B-Chemical
8 62 63 15602202 . . O O
9 64 65 15602202 A NN B-NP O
10 66 68 15602202 14 CD I-NP O
11 68 69 15602202 - HYPH I-NP O
12 69 73 15602202 year NN I-NP O
13 73 74 15602202 - HYPH O O
14 74 77 15602202 old JJ B-NP O
15 78 82 15602202 girl NN I-NP O
16 83 85 15602202 is VBZ B-VP O
17 86 94 15602202 reported VBN I-VP O
18 95 99 15602202 with IN B-PP O
19 100 109 15602202 recurrent JJ B-NP O
20 109 110 15602202 , , I-NP O
21 111 123 15602202 azithromycin NN I-NP B-Chemical
22 123 124 15602202 - HYPH I-NP O
23 124 131 15602202 induced VBN I-NP O
24 131 132 15602202 , , I-NP O
25 133 138 15602202 acute JJ I-NP O
26 139 151 15602202 interstitial JJ I-NP B-Disease
27 152 161 15602202 nephritis NN I-NP I-Disease
28 161 162 15602202 . . O O

1 163 166 15602202 The DT B-NP O
2 167 173 15602202 second JJ I-NP O
3 174 181 15602202 episode NN I-NP O
4 182 185 15602202 was VBD B-VP O
5 186 190 15602202 more RBR B-ADJP O
6 191 197 15602202 severe JJ I-ADJP O
7 198 202 15602202 than IN B-PP O
8 203 206 15602202 the DT B-NP O
9 207 212 15602202 first JJ I-NP O
10 212 213 15602202 ; : O O
11 214 217 15602202 and CC O O
12 218 226 15602202 although IN B-SBAR O
13 227 231 15602202 both DT B-NP O
14 232 236 15602202 were VBD B-VP O
15 237 244 15602202 treated VBN I-VP O
16 245 249 15602202 with IN B-PP O
17 250 259 15602202 intensive JJ B-NP O
18 260 274 15602202 corticosteroid NN I-NP O
19 275 282 15602202 therapy NN I-NP O
20 282 283 15602202 , , O O
21 284 289 15602202 renal JJ B-NP O
22 290 298 15602202 function NN I-NP O
23 299 307 15602202 remained VBD B-VP O
24 308 316 15602202 impaired JJ B-ADJP O
25 316 317 15602202 . . O O

1 318 326 15602202 Although IN B-SBAR O
2 327 331 15602202 most JJS B-NP O
3 332 337 15602202 cases NNS I-NP O
4 338 340 15602202 of IN B-PP O
5 341 351 15602202 antibiotic NN B-NP O
6 352 359 15602202 induced VBD B-VP O
7 360 365 15602202 acute JJ B-NP O
8 366 378 15602202 interstitial JJ I-NP B-Disease
9 379 388 15602202 nephritis NN I-NP I-Disease
10 389 392 15602202 are VBP B-VP O
11 393 399 15602202 benign JJ B-ADJP O
12 400 403 15602202 and CC O O
13 404 408 15602202 self AFX B-VP O
14 408 409 15602202 - HYPH I-VP O
15 409 416 15602202 limited VBN I-VP O
16 416 417 15602202 , , O O
17 418 422 15602202 some DT B-NP O
18 423 431 15602202 patients NNS I-NP O
19 432 435 15602202 are VBP B-VP O
20 436 438 15602202 at IN B-PP O
21 439 443 15602202 risk NN B-NP O
22 444 447 15602202 for IN B-PP O
23 448 457 15602202 permanent JJ B-NP O
24 458 463 15602202 renal JJ I-NP B-Disease
25 464 470 15602202 injury NN I-NP I-Disease
26 470 471 15602202 . . O O

1 0 0 17532790 -DOCSTART- -X- -X- O

1 0 9 17532790 Proteomic JJ B-NP O
2 10 18 17532790 analysis NN I-NP O
3 19 21 17532790 of IN B-PP O
4 22 30 17532790 striatal JJ B-NP O
5 31 39 17532790 proteins NNS I-NP O
6 40 42 17532790 in IN B-PP O
7 43 46 17532790 the DT B-NP O
8 47 50 17532790 rat NN I-NP O
9 51 56 17532790 model NN I-NP O
10 57 59 17532790 of IN B-PP O
11 60 61 17532790 L NN B-NP B-Chemical
12 61 62 17532790 - HYPH B-NP I-Chemical
13 62 66 17532790 DOPA NN I-NP I-Chemical
14 66 67 17532790 - HYPH B-NP O
15 67 74 17532790 induced VBN I-NP O
16 75 85 17532790 dyskinesia NN I-NP B-Disease
17 85 86 17532790 . . I-NP O
18 87 88 17532790 L NN I-NP B-Chemical
19 88 89 17532790 - HYPH B-NP I-Chemical
20 89 93 17532790 DOPA NN I-NP I-Chemical
21 93 94 17532790 - HYPH O O
22 94 101 17532790 induced VBN B-NP O
23 102 112 17532790 dyskinesia NN I-NP B-Disease
24 113 114 17532790 ( ( O O
25 114 117 17532790 LID NN B-NP B-Disease
26 117 118 17532790 ) ) O O
27 119 121 17532790 is VBZ B-VP O
28 122 127 17532790 among IN B-PP O
29 128 131 17532790 the DT B-NP O
30 132 137 17532790 motor NN I-NP O
31 138 151 17532790 complications NNS I-NP O
32 152 156 17532790 that WDT B-NP O
33 157 162 17532790 arise VBP B-VP O
34 163 165 17532790 in IN B-PP O
35 166 177 17532790 Parkinson's NNS B-NP B-Disease
36 178 185 17532790 disease NN B-NP I-Disease
37 186 187 17532790 ( ( O O
38 187 189 17532790 PD NN B-NP B-Disease
39 189 190 17532790 ) ) O O
40 191 199 17532790 patients NNS B-NP O
41 200 205 17532790 after IN B-PP O
42 206 207 17532790 a DT B-NP O
43 208 217 17532790 prolonged VBN I-NP O
44 218 227 17532790 treatment NN I-NP O
45 228 232 17532790 with IN B-PP O
46 233 234 17532790 L NN B-NP B-Chemical
47 234 235 17532790 - HYPH B-NP I-Chemical
48 235 239 17532790 DOPA NN I-NP I-Chemical
49 239 240 17532790 . . O O

1 241 243 17532790 To TO B-PP O
2 244 248 17532790 this DT B-NP O
3 249 252 17532790 day NN I-NP O
4 252 253 17532790 , , O O
5 254 267 17532790 transcriptome NN B-NP O
6 268 276 17532790 analysis NN I-NP O
7 277 280 17532790 has VBZ B-VP O
8 281 285 17532790 been VBN I-VP O
9 286 295 17532790 performed VBN I-VP O
10 296 298 17532790 in IN B-PP O
11 299 300 17532790 a DT B-NP O
12 301 304 17532790 rat NN I-NP O
13 305 310 17532790 model NN I-NP O
14 311 313 17532790 of IN B-PP O
15 314 317 17532790 LID NN B-NP B-Disease
16 318 319 17532790 [ ( O O
17 319 328 17532790 Neurobiol NN B-NP O
18 328 329 17532790 . . O O

1 330 333 17532790 Dis NNP B-NP O
2 333 334 17532790 . NN I-NP O
3 334 335 17532790 , , O O
4 336 338 17532790 17 CD B-NP O
5 339 340 17532790 ( ( O O
6 340 344 17532790 2004 CD B-NP O
7 344 345 17532790 ) ) O O
8 345 346 17532790 , , O O
9 347 350 17532790 219 CD B-NP O
10 350 351 17532790 ] ) O O
11 352 355 17532790 but CC O O
12 356 367 17532790 information NN B-NP O
13 368 377 17532790 regarding VBG B-VP O
14 378 381 17532790 the DT B-NP O
15 382 390 17532790 proteome NN I-NP O
16 391 393 17532790 is VBZ B-VP O
17 394 399 17532790 still RB I-VP O
18 400 407 17532790 lacking VBG I-VP O
19 407 408 17532790 . . O O

1 409 411 17532790 In IN B-PP O
2 412 415 17532790 the DT B-NP O
3 416 423 17532790 present JJ I-NP O
4 424 429 17532790 study NN I-NP O
5 429 430 17532790 , , O O
6 431 433 17532790 we PRP B-NP O
7 434 446 17532790 investigated VBD B-VP O
8 447 450 17532790 the DT B-NP O
9 451 458 17532790 changes NNS I-NP O
10 459 468 17532790 occurring VBG B-VP O
11 469 471 17532790 at IN B-PP O
12 472 475 17532790 the DT B-NP O
13 476 483 17532790 protein NN I-NP O
14 484 489 17532790 level NN I-NP O
15 490 492 17532790 in IN B-PP O
16 493 501 17532790 striatal JJ B-NP O
17 502 509 17532790 samples NNS I-NP O
18 510 518 17532790 obtained VBN B-VP O
19 519 523 17532790 from IN B-PP O
20 524 527 17532790 the DT B-NP O
21 528 540 17532790 unilaterally RB I-NP O
22 541 542 17532790 6 CD I-NP B-Chemical
23 542 543 17532790 - HYPH I-NP I-Chemical
24 543 558 17532790 hydroxydopamine NN I-NP I-Chemical
25 558 559 17532790 - HYPH I-NP O
26 559 565 17532790 lesion NN I-NP O
27 566 569 17532790 rat NN I-NP O
28 570 575 17532790 model NN I-NP O
29 576 578 17532790 of IN B-PP O
30 579 581 17532790 PD NN B-NP B-Disease
31 582 589 17532790 treated VBN B-VP O
32 590 594 17532790 with IN B-PP O
33 595 601 17532790 saline NN B-NP O
34 601 602 17532790 , , O O
35 603 604 17532790 L NN B-NP B-Chemical
36 604 605 17532790 - HYPH B-NP I-Chemical
37 605 609 17532790 DOPA NN I-NP I-Chemical
38 610 612 17532790 or CC I-NP O
39 613 626 17532790 bromocriptine NN I-NP B-Chemical
40 627 632 17532790 using VBG B-VP O
41 633 636 17532790 two CD B-NP O
42 636 637 17532790 - HYPH I-NP O
43 637 648 17532790 dimensional JJ I-NP O
44 649 659 17532790 difference NN I-NP O
45 660 663 17532790 gel NN I-NP O
46 664 679 17532790 electrophoresis NN I-NP O
47 680 683 17532790 and CC O O
48 684 688 17532790 mass NN B-NP O
49 689 701 17532790 spectrometry NN I-NP O
50 702 703 17532790 ( ( O O
51 703 705 17532790 MS NN B-NP O
52 705 706 17532790 ) ) O O
53 706 707 17532790 . . O O

1 708 712 17532790 Rats NNS B-NP O
2 713 720 17532790 treated VBN B-VP O
3 721 725 17532790 with IN B-PP O
4 726 727 17532790 L NN B-NP B-Chemical
5 727 728 17532790 - HYPH B-NP I-Chemical
6 728 732 17532790 DOPA NN I-NP I-Chemical
7 733 737 17532790 were VBD B-VP O
8 738 747 17532790 allocated VBN I-VP O
9 748 750 17532790 to TO B-PP O
10 751 754 17532790 two CD B-NP O
11 755 761 17532790 groups NNS I-NP O
12 762 767 17532790 based VBN B-PP O
13 768 770 17532790 on IN B-PP O
14 771 774 17532790 the DT B-NP O
15 775 783 17532790 presence NN I-NP O
16 784 786 17532790 or CC I-NP O
17 787 794 17532790 absence NN I-NP O
18 795 797 17532790 of IN B-PP O
19 798 801 17532790 LID NN B-NP B-Disease
20 801 802 17532790 . . O O

1 803 808 17532790 Among IN B-PP O
2 809 812 17532790 the DT B-NP O
3 813 817 17532790 2000 CD I-NP O
4 818 823 17532790 spots NNS I-NP O
5 824 832 17532790 compared VBN B-VP O
6 833 836 17532790 for IN B-PP O
7 837 848 17532790 statistical JJ B-NP O
8 849 859 17532790 difference NN I-NP O
9 859 860 17532790 , , O O
10 861 863 17532790 67 CD B-NP O
11 864 869 17532790 spots NNS I-NP O
12 870 874 17532790 were VBD B-VP O
13 875 888 17532790 significantly RB I-VP O
14 889 896 17532790 changed VBN I-VP O
15 897 899 17532790 in IN B-PP O
16 900 909 17532790 abundance NN B-NP O
17 910 913 17532790 and CC O O
18 914 924 17532790 identified VBN B-VP O
19 925 930 17532790 using VBG B-VP O
20 931 937 17532790 matrix NN B-NP O
21 937 938 17532790 - HYPH I-NP O
22 938 946 17532790 assisted VBN I-NP O
23 947 952 17532790 laser NN I-NP O
24 953 963 17532790 desorption NN I-NP O
25 963 964 17532790 / SYM B-VP O
26 964 974 17532790 ionization NN B-NP O
27 975 979 17532790 time NN I-NP O
28 979 980 17532790 - HYPH B-NP O
29 980 982 17532790 of IN B-PP O
30 982 983 17532790 - HYPH B-NP O
31 983 989 17532790 flight NN I-NP O
32 990 992 17532790 MS NN I-NP O
33 992 993 17532790 , , O O
34 994 1005 17532790 atmospheric JJ B-NP O
35 1006 1014 17532790 pressure NN I-NP O
36 1015 1021 17532790 matrix NN I-NP O
37 1021 1022 17532790 - HYPH B-VP O
38 1022 1030 17532790 assisted VBN B-NP O
39 1031 1036 17532790 laser NN I-NP O
40 1037 1047 17532790 desorption NN I-NP O
41 1047 1048 17532790 / SYM B-NP O
42 1048 1058 17532790 ionization NN I-NP O
43 1059 1062 17532790 and CC I-NP O
44 1063 1067 17532790 HPLC NN I-NP O
45 1068 1075 17532790 coupled VBN B-VP O
46 1076 1082 17532790 tandem JJ B-NP O
47 1083 1085 17532790 MS NN I-NP O
48 1086 1087 17532790 ( ( O O
49 1087 1089 17532790 LC NN B-NP O
50 1089 1090 17532790 / SYM B-NP O
51 1090 1092 17532790 MS NN I-NP O
52 1092 1093 17532790 / SYM I-NP O
53 1093 1095 17532790 MS NN I-NP O
54 1095 1096 17532790 ) ) O O
55 1096 1097 17532790 . . O O

1 1098 1101 17532790 Out IN B-PP O
2 1102 1104 17532790 of IN B-PP O
3 1105 1110 17532790 these DT B-NP O
4 1111 1113 17532790 67 CD I-NP O
5 1114 1122 17532790 proteins NNS I-NP O
6 1122 1123 17532790 , , O O
7 1124 1127 17532790 LID NNP B-NP B-Disease
8 1128 1141 17532790 significantly RB B-ADVP O
9 1142 1149 17532790 changed VBD B-VP O
10 1150 1153 17532790 the DT B-NP O
11 1154 1164 17532790 expression NN I-NP O
12 1165 1170 17532790 level NN I-NP O
13 1171 1173 17532790 of IN B-PP O
14 1174 1178 17532790 five CD B-NP O
15 1179 1187 17532790 proteins NNS I-NP O
16 1187 1188 17532790 : : O O
17 1189 1198 17532790 alphabeta NN B-NP O
18 1198 1199 17532790 - HYPH B-NP O
19 1199 1208 17532790 crystalin NN I-NP O
20 1208 1209 17532790 , , O O
21 1210 1215 17532790 gamma SYM O O
22 1215 1216 17532790 - HYPH O O
23 1216 1223 17532790 enolase NN B-NP O
24 1223 1224 17532790 , , O O
25 1225 1239 17532790 guanidoacetate NN B-NP O
26 1240 1257 17532790 methyltransferase NN I-NP O
27 1257 1258 17532790 , , O O
28 1259 1267 17532790 vinculin NN B-NP O
29 1267 1268 17532790 , , O O
30 1269 1272 17532790 and CC O O
31 1273 1283 17532790 proteasome NN B-NP O
32 1284 1289 17532790 alpha SYM B-NP O
33 1289 1290 17532790 - SYM B-VP O
34 1290 1291 17532790 2 CD B-NP O
35 1292 1299 17532790 subunit NN I-NP O
36 1299 1300 17532790 . . O O

1 1301 1314 17532790 Complementary JJ B-NP O
2 1315 1325 17532790 techniques NNS I-NP O
3 1326 1330 17532790 such JJ B-PP O
4 1331 1333 17532790 as IN I-PP O
5 1334 1341 17532790 western JJ B-NP O
6 1342 1356 17532790 immunoblotting NN I-NP O
7 1357 1360 17532790 and CC I-NP O
8 1361 1381 17532790 immunohistochemistry NN I-NP O
9 1382 1386 17532790 were VBD B-VP O
10 1387 1396 17532790 performed VBN I-VP O
11 1397 1399 17532790 to TO B-VP O
12 1400 1411 17532790 investigate VB I-VP O
13 1412 1415 17532790 the DT B-NP O
14 1416 1424 17532790 validity NN I-NP O
15 1425 1427 17532790 of IN B-PP O
16 1428 1431 17532790 the DT B-NP O
17 1432 1436 17532790 data NNS I-NP O
18 1437 1445 17532790 obtained VBN B-VP O
19 1446 1451 17532790 using VBG B-VP O
20 1452 1455 17532790 the DT B-NP O
21 1456 1465 17532790 proteomic JJ I-NP O
22 1466 1474 17532790 approach NN I-NP O
23 1474 1475 17532790 . . O O

1 1476 1478 17532790 In IN B-PP O
2 1479 1489 17532790 conclusion NN B-NP O
3 1489 1490 17532790 , , O O
4 1491 1495 17532790 this DT B-NP O
5 1496 1501 17532790 study NN I-NP O
6 1502 1510 17532790 provides VBZ B-VP O
7 1511 1514 17532790 new JJ B-NP O
8 1515 1523 17532790 insights NNS I-NP O
9 1524 1528 17532790 into IN B-PP O
10 1529 1532 17532790 the DT B-NP O
11 1533 1540 17532790 protein NN I-NP O
12 1541 1548 17532790 changes NNS I-NP O
13 1549 1558 17532790 occurring VBG B-VP O
14 1559 1561 17532790 in IN B-PP O
15 1562 1565 17532790 LID NNP B-NP B-Disease
16 1565 1566 17532790 . . O O

1 0 0 3192036 -DOCSTART- -X- -X- O

1 0 5 3192036 Death NN B-NP B-Disease
2 6 10 3192036 from IN B-PP O
3 11 23 3192036 chemotherapy NN B-NP O
4 24 26 3192036 in IN B-PP O
5 27 38 3192036 gestational JJ B-NP B-Disease
6 39 52 3192036 trophoblastic JJ I-NP I-Disease
7 53 60 3192036 disease NN I-NP I-Disease
8 60 61 3192036 . . O O
9 62 70 3192036 Multiple JJ B-NP O
10 71 80 3192036 cytotoxic JJ I-NP O
11 81 85 3192036 drug NN I-NP O
12 86 100 3192036 administration NN I-NP O
13 101 103 3192036 is VBZ B-VP O
14 104 107 3192036 the DT B-NP O
15 108 117 3192036 generally RB I-NP O
16 118 126 3192036 accepted VBN I-NP O
17 127 136 3192036 treatment NN I-NP O
18 137 139 3192036 of IN B-PP O
19 140 148 3192036 patients NNS B-NP O
20 149 153 3192036 with IN B-PP O
21 154 155 3192036 a DT B-NP O
22 156 160 3192036 high JJ I-NP O
23 160 161 3192036 - HYPH I-NP O
24 161 165 3192036 risk NN I-NP O
25 166 171 3192036 stage NN I-NP O
26 172 174 3192036 of IN B-PP O
27 175 190 3192036 choriocarcinoma NN B-NP B-Disease
28 190 191 3192036 . . O O

1 192 197 3192036 Based VBN B-PP O
2 198 200 3192036 on IN B-PP O
3 201 205 3192036 this DT B-NP O
4 206 215 3192036 principle NN I-NP O
5 216 217 3192036 a DT B-NP O
6 218 220 3192036 27 CD I-NP O
7 220 221 3192036 - HYPH I-NP O
8 221 225 3192036 year NN I-NP O
9 226 229 3192036 old JJ I-NP O
10 230 235 3192036 woman NN I-NP O
11 235 236 3192036 , , O O
12 237 247 3192036 classified VBN B-VP O
13 248 250 3192036 as IN B-PP O
14 251 256 3192036 being VBG B-VP O
15 257 259 3192036 in IN B-PP O
16 260 263 3192036 the DT B-NP O
17 264 268 3192036 high JJ I-NP O
18 268 269 3192036 - HYPH I-NP O
19 269 273 3192036 risk NN I-NP O
20 274 279 3192036 group NN I-NP O
21 280 281 3192036 ( ( O O
22 281 290 3192036 Goldstein NNP B-NP O
23 291 294 3192036 and CC I-NP O
24 295 304 3192036 Berkowitz NNP I-NP O
25 305 310 3192036 score NN I-NP O
26 310 311 3192036 : : O O
27 312 314 3192036 11 CD B-NP O
28 314 315 3192036 ) ) O O
29 315 316 3192036 , , O O
30 317 320 3192036 was VBD B-VP O
31 321 328 3192036 treated VBN I-VP O
32 329 333 3192036 with IN B-PP O
33 334 342 3192036 multiple JJ B-NP O
34 343 352 3192036 cytotoxic JJ I-NP O
35 353 358 3192036 drugs NNS I-NP O
36 358 359 3192036 . . O O

1 360 363 3192036 The DT B-NP O
2 364 372 3192036 multiple JJ I-NP O
3 373 377 3192036 drug NN I-NP O
4 378 384 3192036 schema NN I-NP O
5 385 394 3192036 consisted VBD B-VP O
6 395 397 3192036 of IN B-PP O
7 397 398 3192036 : : O O
8 399 408 3192036 Etoposide NN B-NP B-Chemical
9 409 415 3192036 16.213 CD I-NP O
10 415 416 3192036 , , O O
11 417 429 3192036 Methotrexate NN B-NP B-Chemical
12 429 430 3192036 , , O O
13 431 447 3192036 Cyclophosphamide NN B-NP B-Chemical
14 447 448 3192036 , , O O
15 449 458 3192036 Actomycin NN B-NP B-Chemical
16 458 459 3192036 - HYPH B-NP I-Chemical
17 459 460 3192036 D NN I-NP I-Chemical
18 460 461 3192036 , , O O
19 462 465 3192036 and CC O O
20 466 475 3192036 Cisplatin NN B-NP B-Chemical
21 475 476 3192036 . . O O

1 477 479 3192036 On IN B-PP O
2 480 483 3192036 the DT B-NP O
3 484 489 3192036 first JJ I-NP O
4 490 493 3192036 day NN I-NP O
5 494 496 3192036 of IN B-PP O
6 497 500 3192036 the DT B-NP O
7 501 509 3192036 schedule NN I-NP O
8 509 510 3192036 , , O O
9 511 519 3192036 moderate JJ B-NP O
10 520 524 3192036 high JJ I-NP O
11 525 530 3192036 doses NNS I-NP O
12 531 533 3192036 of IN B-PP O
13 534 546 3192036 Methotrexate NN B-NP B-Chemical
14 546 547 3192036 , , I-NP O
15 548 557 3192036 Etoposide NN I-NP B-Chemical
16 558 561 3192036 and CC I-NP O
17 562 578 3192036 Cyclophosphamide NN I-NP B-Chemical
18 579 583 3192036 were VBD B-VP O
19 584 596 3192036 administered VBN I-VP O
20 596 597 3192036 . . O O

1 598 604 3192036 Within IN B-PP O
2 605 606 3192036 8 CD B-NP O
3 607 612 3192036 hours NNS I-NP O
4 613 618 3192036 after IN B-PP O
5 619 629 3192036 initiation NN B-NP O
6 630 632 3192036 of IN B-PP O
7 633 640 3192036 therapy NN B-NP O
8 641 644 3192036 the DT B-NP O
9 645 652 3192036 patient NN I-NP O
10 653 657 3192036 died VBD B-VP O
11 658 662 3192036 with IN B-PP O
12 663 664 3192036 a DT B-NP O
13 665 673 3192036 clinical JJ I-NP O
14 674 681 3192036 picture NN I-NP O
15 682 692 3192036 resembling VBG B-VP O
16 693 700 3192036 massive JJ B-NP O
17 701 710 3192036 pulmonary JJ I-NP B-Disease
18 711 722 3192036 obstruction NN I-NP I-Disease
19 723 726 3192036 due JJ B-PP O
20 727 729 3192036 to TO B-PP O
21 730 746 3192036 choriocarcinomic JJ B-NP O
22 747 753 3192036 tissue NN I-NP O
23 754 759 3192036 plugs NNS I-NP O
24 759 760 3192036 , , O O
25 761 769 3192036 probably RB B-ADVP O
26 770 781 3192036 originating VBG B-VP O
27 782 786 3192036 from IN B-PP O
28 787 790 3192036 the DT B-NP O
29 791 797 3192036 uterus NN I-NP O
30 797 798 3192036 . . O O

1 799 808 3192036 Formation NN B-NP O
2 809 811 3192036 of IN B-PP O
3 812 817 3192036 these DT B-NP O
4 818 823 3192036 plugs NNS I-NP O
5 824 827 3192036 was VBD B-VP O
6 828 836 3192036 probably RB B-ADVP O
7 837 840 3192036 due JJ B-ADJP O
8 841 843 3192036 to TO B-PP O
9 844 853 3192036 extensive JJ B-NP O
10 854 859 3192036 tumor NN I-NP B-Disease
11 860 868 3192036 necrosis NN I-NP B-Disease
12 869 871 3192036 at IN B-PP O
13 872 875 3192036 the DT B-NP O
14 876 881 3192036 level NN I-NP O
15 882 884 3192036 of IN B-PP O
16 885 888 3192036 the DT B-NP O
17 889 894 3192036 walls NNS I-NP O
18 895 897 3192036 of IN B-PP O
19 898 901 3192036 the DT B-NP O
20 902 907 3192036 major JJ I-NP O
21 908 915 3192036 uterine JJ I-NP O
22 916 921 3192036 veins NNS I-NP O
23 921 922 3192036 , , O O
24 923 928 3192036 which WDT B-NP O
25 929 937 3192036 resulted VBD B-VP O
26 938 940 3192036 in IN B-PP O
27 941 943 3192036 an DT B-NP O
28 944 948 3192036 open JJ I-NP O
29 949 957 3192036 exchange NN I-NP O
30 958 960 3192036 of IN B-PP O
31 961 966 3192036 tumor NN B-NP B-Disease
32 967 972 3192036 plugs NNS I-NP O
33 973 975 3192036 to TO B-PP O
34 976 979 3192036 the DT B-NP O
35 980 988 3192036 vascular JJ I-NP O
36 989 995 3192036 spaces NNS I-NP O
37 995 996 3192036 ; : O O
38 997 1005 3192036 decrease NN B-NP O
39 1006 1008 3192036 in IN B-PP O
40 1009 1014 3192036 tumor NN B-NP B-Disease
41 1015 1021 3192036 tissue NN I-NP O
42 1022 1031 3192036 coherence NN I-NP O
43 1032 1041 3192036 secondary JJ B-ADJP O
44 1042 1044 3192036 to TO B-PP O
45 1045 1057 3192036 chemotherapy NN B-NP O
46 1058 1061 3192036 may MD B-VP O
47 1062 1066 3192036 have VB I-VP O
48 1067 1074 3192036 further RBR I-VP O
49 1075 1086 3192036 contributed VBN I-VP O
50 1087 1089 3192036 to TO B-PP O
51 1090 1093 3192036 the DT B-NP O
52 1094 1103 3192036 formation NN I-NP O
53 1104 1106 3192036 of IN B-PP O
54 1107 1112 3192036 tumor NN B-NP B-Disease
55 1113 1119 3192036 emboli NNS I-NP O
56 1119 1120 3192036 . . O O

1 1121 1123 3192036 In IN B-PP O
2 1124 1128 3192036 view NN B-NP O
3 1129 1131 3192036 of IN B-PP O
4 1132 1135 3192036 the DT B-NP O
5 1136 1141 3192036 close JJ I-NP O
6 1142 1146 3192036 time NN I-NP O
7 1147 1158 3192036 association NN I-NP O
8 1159 1166 3192036 between IN B-PP O
9 1167 1170 3192036 the DT B-NP O
10 1171 1176 3192036 start NN I-NP O
11 1177 1179 3192036 of IN B-PP O
12 1180 1192 3192036 chemotherapy NN B-NP O
13 1193 1196 3192036 and CC O O
14 1197 1200 3192036 the DT B-NP O
15 1201 1206 3192036 acute JJ I-NP O
16 1207 1212 3192036 onset NN I-NP O
17 1213 1215 3192036 of IN B-PP O
18 1216 1223 3192036 massive JJ B-NP O
19 1224 1232 3192036 embolism NN I-NP B-Disease
20 1233 1238 3192036 other JJ I-NP O
21 1239 1251 3192036 explanations NNS I-NP O
22 1251 1252 3192036 , , O O
23 1253 1257 3192036 such JJ B-PP O
24 1258 1260 3192036 as IN I-PP O
25 1261 1272 3192036 spontaneous JJ B-NP O
26 1273 1281 3192036 necrosis NN I-NP B-Disease
27 1281 1282 3192036 , , O O
28 1283 1287 3192036 must MD B-VP O
29 1288 1290 3192036 be VB I-VP O
30 1291 1301 3192036 considered VBN I-VP O
31 1302 1306 3192036 less RBR B-ADJP O
32 1307 1313 3192036 likely JJ I-ADJP O
33 1313 1314 3192036 . . O O

1 1315 1323 3192036 Patients NNS B-NP O
2 1324 1328 3192036 with IN B-PP O
3 1329 1334 3192036 large JJ B-NP O
4 1335 1341 3192036 pelvic JJ I-NP B-Disease
5 1342 1347 3192036 tumor NN I-NP I-Disease
6 1348 1353 3192036 loads NNS I-NP O
7 1354 1357 3192036 are VBP B-VP O
8 1357 1358 3192036 , , O O
9 1359 1368 3192036 according VBG B-PP O
10 1369 1371 3192036 to TO B-PP O
11 1372 1380 3192036 existing VBG B-NP O
12 1381 1396 3192036 classifications NNS I-NP O
13 1396 1397 3192036 , , O O
14 1398 1400 3192036 at IN B-PP O
15 1401 1405 3192036 high JJ B-NP O
16 1406 1410 3192036 risk NN I-NP O
17 1411 1413 3192036 to TO B-VP O
18 1414 1417 3192036 die VB I-VP O
19 1418 1421 3192036 and CC O O
20 1422 1424 3192036 to TO B-VP O
21 1425 1432 3192036 develop VB I-VP O
22 1433 1437 3192036 drug NN B-NP O
23 1438 1448 3192036 resistance NN I-NP O
24 1448 1449 3192036 . . O O

1 1450 1465 3192036 Notwithstanding IN B-PP O
2 1466 1471 3192036 these DT B-NP O
3 1472 1477 3192036 facts NNS I-NP O
4 1478 1481 3192036 our PRP$ B-NP O
5 1482 1490 3192036 findings NNS I-NP O
6 1491 1498 3192036 suggest VBP B-VP O
7 1499 1503 3192036 that IN B-SBAR O
8 1504 1509 3192036 these DT B-NP O
9 1510 1518 3192036 patients NNS I-NP O
10 1519 1524 3192036 might MD B-VP O
11 1525 1532 3192036 benefit VB I-VP O
12 1533 1537 3192036 from IN B-PP O
13 1538 1548 3192036 relatively RB B-NP O
14 1549 1553 3192036 mild JJ I-NP O
15 1554 1561 3192036 initial JJ I-NP O
16 1562 1571 3192036 treatment NN I-NP O
17 1571 1572 3192036 , , O O
18 1573 1583 3192036 especially RB B-ADJP O
19 1584 1588 3192036 true JJ I-ADJP O
20 1589 1592 3192036 for IN B-PP O
21 1593 1601 3192036 patients NNS B-NP O
22 1602 1605 3192036 not RB B-VP O
23 1606 1616 3192036 previously RB I-VP O
24 1617 1624 3192036 exposed VBN I-VP O
25 1625 1627 3192036 to TO B-PP O
26 1628 1632 3192036 this DT B-NP O
27 1633 1637 3192036 drug NN I-NP O
28 1637 1638 3192036 . . O O

1 1639 1644 3192036 Close JJ B-NP O
2 1645 1656 3192036 observation NN I-NP O
3 1657 1659 3192036 of IN B-PP O
4 1660 1663 3192036 the DT B-NP O
5 1664 1672 3192036 response NN I-NP O
6 1673 1679 3192036 status NN I-NP O
7 1680 1684 3192036 both CC O O
8 1685 1695 3192036 clinically RB B-ADVP O
9 1696 1699 3192036 and CC O O
10 1700 1704 3192036 with IN B-PP O
11 1705 1709 3192036 beta SYM B-NP O
12 1709 1710 3192036 - HYPH O O
13 1710 1713 3192036 hCG NN B-NP O
14 1714 1720 3192036 values NNS I-NP O
15 1721 1724 3192036 may MD B-VP O
16 1725 1733 3192036 indicate VB I-VP O
17 1734 1741 3192036 whether IN B-SBAR O
18 1742 1745 3192036 and CC O O
19 1746 1750 3192036 when WRB B-ADVP O
20 1751 1755 3192036 more RBR B-NP O
21 1756 1765 3192036 agressive JJ I-NP O
22 1766 1777 3192036 combination NN I-NP O
23 1778 1790 3192036 chemotherapy NN I-NP O
24 1791 1797 3192036 should MD B-VP O
25 1798 1800 3192036 be VB I-VP O
26 1801 1818 3192036 started.(ABSTRACT NN B-NP O
27 1819 1828 3192036 TRUNCATED VBN B-VP O
28 1829 1831 3192036 AT IN B-PP O
29 1832 1835 3192036 250 CD B-NP O
30 1836 1841 3192036 WORDS NNS I-NP O
31 1841 1842 3192036 ) ) O O

1 0 0 9766615 -DOCSTART- -X- -X- O

1 0 7 9766615 Adverse JJ B-NP O
2 8 15 9766615 effects NNS I-NP O
3 16 18 9766615 of IN B-PP O
4 19 22 9766615 the DT B-NP O
5 23 31 9766615 atypical JJ I-NP O
6 32 46 9766615 antipsychotics NNS I-NP O
7 46 47 9766615 . . O O

1 48 61 9766615 Collaborative JJ B-NP O
2 62 69 9766615 Working NNP I-NP O
3 70 75 9766615 Group NNP I-NP O
4 76 78 9766615 on IN B-PP O
5 79 87 9766615 Clinical NNP B-NP O
6 88 93 9766615 Trial NNP I-NP O
7 94 105 9766615 Evaluations NNP I-NP O
8 105 106 9766615 . . I-NP O
9 107 114 9766615 Adverse JJ I-NP O
10 115 122 9766615 effects NNS I-NP O
11 123 125 9766615 of IN B-PP O
12 126 140 9766615 antipsychotics NNS B-NP O
13 141 146 9766615 often RB B-ADVP O
14 147 151 9766615 lead VBP B-VP O
15 152 154 9766615 to TO B-PP O
16 155 168 9766615 noncompliance NN B-NP O
17 168 169 9766615 . . O O

1 170 174 9766615 Thus RB B-ADVP O
2 174 175 9766615 , , O O
3 176 186 9766615 clinicians NNS B-NP O
4 187 193 9766615 should MD B-VP O
5 194 201 9766615 address VB I-VP O
6 202 210 9766615 patients NNS B-NP O
7 210 211 9766615 ' POS B-NP O
8 212 220 9766615 concerns NNS I-NP O
9 221 226 9766615 about IN B-PP O
10 227 234 9766615 adverse JJ B-NP O
11 235 242 9766615 effects NNS I-NP O
12 243 246 9766615 and CC O O
13 247 254 9766615 attempt NN B-NP O
14 255 257 9766615 to TO B-VP O
15 258 264 9766615 choose VB I-VP O
16 265 276 9766615 medications NNS B-NP O
17 277 281 9766615 that WDT B-NP O
18 282 286 9766615 will MD B-VP O
19 287 294 9766615 improve VB I-VP O
20 295 300 9766615 their PRP$ B-NP O
21 301 309 9766615 patients NNS I-NP O
22 309 310 9766615 ' POS B-NP O
23 311 318 9766615 quality NN I-NP O
24 319 321 9766615 of IN B-PP O
25 322 326 9766615 life NN B-NP O
26 327 329 9766615 as RB B-CONJP O
27 330 334 9766615 well RB I-CONJP O
28 335 337 9766615 as IN I-CONJP O
29 338 345 9766615 overall JJ B-NP O
30 346 352 9766615 health NN I-NP O
31 352 353 9766615 . . O O

1 354 357 9766615 The DT B-NP O
2 358 362 9766615 side NN I-NP O
3 363 369 9766615 effect NN I-NP O
4 370 378 9766615 profiles NNS I-NP O
5 379 381 9766615 of IN B-PP O
6 382 385 9766615 the DT B-NP O
7 386 394 9766615 atypical JJ I-NP O
8 395 409 9766615 antipsychotics NNS I-NP O
9 410 413 9766615 are VBP B-VP O
10 414 418 9766615 more RBR B-ADJP O
11 419 431 9766615 advantageous JJ I-ADJP O
12 432 436 9766615 than IN B-PP O
13 437 442 9766615 those DT B-NP O
14 443 445 9766615 of IN B-PP O
15 446 449 9766615 the DT B-NP O
16 450 462 9766615 conventional JJ I-NP O
17 463 475 9766615 neuroleptics NNS I-NP O
18 475 476 9766615 . . O O

1 477 489 9766615 Conventional JJ B-NP O
2 490 496 9766615 agents NNS I-NP O
3 497 500 9766615 are VBP B-VP O
4 501 511 9766615 associated VBN I-VP O
5 512 516 9766615 with IN B-PP O
6 517 525 9766615 unwanted JJ B-NP O
7 526 533 9766615 central JJ I-NP O
8 534 541 9766615 nervous JJ I-NP O
9 542 548 9766615 system NN I-NP O
10 549 556 9766615 effects NNS I-NP O
11 556 557 9766615 , , O O
12 558 567 9766615 including VBG B-PP O
13 568 582 9766615 extrapyramidal JJ B-NP B-Disease
14 583 591 9766615 symptoms NNS I-NP I-Disease
15 592 593 9766615 ( ( O O
16 593 596 9766615 EPS NNS B-NP B-Disease
17 596 597 9766615 ) ) O O
18 597 598 9766615 , , O O
19 599 606 9766615 tardive JJ B-NP B-Disease
20 607 617 9766615 dyskinesia NN I-NP I-Disease
21 617 618 9766615 , , O O
22 619 627 9766615 sedation NN B-NP O
23 627 628 9766615 , , O O
24 629 632 9766615 and CC O O
25 633 641 9766615 possible JJ B-NP O
26 642 652 9766615 impairment NN I-NP O
27 653 655 9766615 of IN B-PP O
28 656 660 9766615 some DT B-NP O
29 661 670 9766615 cognitive JJ I-NP O
30 671 679 9766615 measures NNS I-NP O
31 679 680 9766615 , , O O
32 681 683 9766615 as RB B-CONJP O
33 684 688 9766615 well RB I-CONJP O
34 689 691 9766615 as IN I-CONJP O
35 692 699 9766615 cardiac JJ B-NP O
36 700 707 9766615 effects NNS I-NP O
37 707 708 9766615 , , O O
38 709 720 9766615 orthostatic JJ B-NP B-Disease
39 721 732 9766615 hypotension NN I-NP I-Disease
40 732 733 9766615 , , O O
41 734 741 9766615 hepatic JJ B-NP O
42 742 749 9766615 changes NNS I-NP O
43 749 750 9766615 , , O O
44 751 766 9766615 anticholinergic JJ B-NP O
45 767 771 9766615 side NN I-NP O
46 772 779 9766615 effects NNS I-NP O
47 779 780 9766615 , , O O
48 781 787 9766615 sexual JJ B-NP B-Disease
49 788 799 9766615 dysfunction NN I-NP I-Disease
50 799 800 9766615 , , O O
51 801 804 9766615 and CC O O
52 805 811 9766615 weight NN B-NP B-Disease
53 812 816 9766615 gain NN I-NP I-Disease
54 816 817 9766615 . . O O

1 818 821 9766615 The DT B-NP O
2 822 827 9766615 newer JJR I-NP O
3 828 836 9766615 atypical JJ I-NP O
4 837 843 9766615 agents NNS I-NP O
5 844 848 9766615 have VBP B-VP O
6 849 850 9766615 a DT B-NP O
7 851 856 9766615 lower JJR I-NP O
8 857 861 9766615 risk NN I-NP O
9 862 864 9766615 of IN B-PP O
10 865 868 9766615 EPS NNP B-NP B-Disease
11 868 869 9766615 , , O O
12 870 873 9766615 but CC O O
13 874 877 9766615 are VBP B-VP O
14 878 888 9766615 associated VBN I-VP O
15 889 891 9766615 in IN B-PP O
16 892 899 9766615 varying VBG B-NP O
17 900 907 9766615 degrees NNS I-NP O
18 908 912 9766615 with IN B-PP O
19 913 921 9766615 sedation NN B-NP O
20 921 922 9766615 , , O O
21 923 937 9766615 cardiovascular JJ B-NP O
22 938 945 9766615 effects NNS I-NP O
23 945 946 9766615 , , O O
24 947 962 9766615 anticholinergic JJ B-NP O
25 963 970 9766615 effects NNS I-NP O
26 970 971 9766615 , , O O
27 972 978 9766615 weight NN B-NP B-Disease
28 979 983 9766615 gain NN I-NP I-Disease
29 983 984 9766615 , , O O
30 985 991 9766615 sexual JJ B-NP B-Disease
31 992 1003 9766615 dysfunction NN I-NP I-Disease
32 1003 1004 9766615 , , O O
33 1005 1012 9766615 hepatic JJ B-NP O
34 1013 1020 9766615 effects NNS I-NP O
35 1020 1021 9766615 , , O O
36 1022 1029 9766615 lowered VBD B-VP O
37 1030 1037 9766615 seizure NN B-NP B-Disease
38 1038 1047 9766615 threshold NN I-NP O
39 1048 1049 9766615 ( ( O O
40 1049 1058 9766615 primarily RB B-NP O
41 1059 1068 9766615 clozapine NN I-NP B-Chemical
42 1068 1069 9766615 ) ) O O
43 1069 1070 9766615 , , O O
44 1071 1074 9766615 and CC O O
45 1075 1090 9766615 agranulocytosis NN B-NP B-Disease
46 1091 1092 9766615 ( ( O O
47 1092 1101 9766615 clozapine NN B-NP B-Chemical
48 1102 1106 9766615 only RB B-ADVP O
49 1106 1107 9766615 ) ) O O
50 1107 1108 9766615 . . O O

1 1109 1114 9766615 Since IN B-SBAR O
2 1115 1118 9766615 the DT B-NP O
3 1119 1128 9766615 incidence NN I-NP O
4 1129 1132 9766615 and CC I-NP O
5 1133 1141 9766615 severity NN I-NP O
6 1142 1144 9766615 of IN B-PP O
7 1145 1153 9766615 specific JJ B-NP O
8 1154 1161 9766615 adverse JJ I-NP O
9 1162 1169 9766615 effects NNS I-NP O
10 1170 1176 9766615 differ VBP B-VP O
11 1177 1182 9766615 among IN B-PP O
12 1183 1186 9766615 the DT B-NP O
13 1187 1194 9766615 various JJ I-NP O
14 1195 1204 9766615 atypicals NNS I-NP O
15 1204 1205 9766615 , , O O
16 1206 1209 9766615 the DT B-NP O
17 1210 1219 9766615 clinician NN I-NP O
18 1220 1226 9766615 should MD B-VP O
19 1227 1236 9766615 carefully RB I-VP O
20 1237 1245 9766615 consider VB I-VP O
21 1246 1251 9766615 which WDT B-NP O
22 1252 1256 9766615 side NN B-NP O
23 1257 1264 9766615 effects NNS I-NP O
24 1265 1268 9766615 are VBP B-VP O
25 1269 1273 9766615 most RBS B-ADJP O
26 1274 1280 9766615 likely JJ I-ADJP O
27 1281 1283 9766615 to TO B-VP O
28 1284 1288 9766615 lead VB I-VP O
29 1289 1291 9766615 to TO B-PP O
30 1292 1295 9766615 the DT B-NP O
31 1296 1308 9766615 individual's NNS I-NP O
32 1309 1324 9766615 dissatisfaction NN I-NP O
33 1325 1328 9766615 and CC I-NP O
34 1329 1342 9766615 noncompliance NN I-NP O
35 1343 1349 9766615 before IN B-PP O
36 1350 1358 9766615 choosing VBG B-VP O
37 1359 1361 9766615 an DT B-NP O
38 1362 1375 9766615 antipsychotic JJ I-NP O
39 1376 1379 9766615 for IN B-PP O
40 1380 1381 9766615 a DT B-NP O
41 1382 1392 9766615 particular JJ I-NP O
42 1393 1400 9766615 patient NN I-NP O
43 1400 1401 9766615 . . O O

1 0 0 1616457 -DOCSTART- -X- -X- O

1 0 8 1616457 Learning NN B-NP O
2 9 11 1616457 of IN B-PP O
3 12 16 1616457 rats NNS B-NP O
4 17 22 1616457 under IN B-PP O
5 23 30 1616457 amnesia NN B-NP B-Disease
6 31 37 1616457 caused VBN B-VP O
7 38 40 1616457 by IN B-PP O
8 41 54 1616457 pentobarbital NN B-NP B-Chemical
9 54 55 1616457 . . O O
10 56 67 1616457 Dissociated VBN B-NP O
11 68 76 1616457 learning NN I-NP O
12 77 79 1616457 of IN B-PP O
13 80 84 1616457 rats NNS B-NP O
14 85 87 1616457 in IN B-PP O
15 88 91 1616457 the DT B-NP O
16 92 98 1616457 normal JJ I-NP O
17 99 104 1616457 state NN I-NP O
18 105 108 1616457 and CC O O
19 109 112 1616457 the DT B-NP O
20 113 118 1616457 state NN I-NP O
21 119 121 1616457 of IN B-PP O
22 122 129 1616457 amnesia NN B-NP B-Disease
23 130 138 1616457 produced VBN B-VP O
24 139 141 1616457 by IN B-PP O
25 142 155 1616457 pentobarbital NN B-NP B-Chemical
26 156 157 1616457 ( ( O O
27 157 159 1616457 15 CD B-NP O
28 160 162 1616457 mg NN I-NP O
29 162 163 1616457 / SYM B-NP O
30 163 165 1616457 kg NN I-NP O
31 165 166 1616457 , , O O
32 167 169 1616457 ip JJ B-ADJP O
33 169 170 1616457 ) ) O O
34 171 174 1616457 was VBD B-VP O
35 175 182 1616457 carried VBN I-VP O
36 183 186 1616457 out RP B-PRT O
37 186 187 1616457 . . O O

1 188 192 1616457 Rats NNS B-NP O
2 193 197 1616457 were VBD B-VP O
3 198 205 1616457 trained VBN I-VP O
4 206 208 1616457 to TO I-VP O
5 209 217 1616457 approach VB I-VP O
6 218 219 1616457 a DT B-NP O
7 220 225 1616457 shelf NN I-NP O
8 226 231 1616457 where WRB B-ADVP O
9 232 236 1616457 they PRP B-NP O
10 237 245 1616457 received VBD B-VP O
11 246 250 1616457 food NN B-NP O
12 251 264 1616457 reinforcement NN I-NP O
13 264 265 1616457 . . O O

1 266 268 1616457 In IN B-PP O
2 269 274 1616457 Group NN B-NP O
3 275 276 1616457 1 CD I-NP O
4 277 280 1616457 the DT B-NP O
5 281 285 1616457 rats NNS I-NP O
6 286 290 1616457 were VBD B-VP O
7 291 298 1616457 trained VBN I-VP O
8 299 304 1616457 under IN B-PP O
9 305 308 1616457 the DT B-NP O
10 309 318 1616457 influence NN I-NP O
11 319 321 1616457 of IN B-PP O
12 322 335 1616457 pentobarbital NN B-NP B-Chemical
13 336 338 1616457 to TO B-VP O
14 339 342 1616457 run VB I-VP O
15 343 345 1616457 to TO B-PP O
16 346 349 1616457 the DT B-NP O
17 350 354 1616457 same JJ I-NP O
18 355 360 1616457 shelf NN I-NP O
19 361 363 1616457 as IN B-PP O
20 364 366 1616457 in IN B-PP O
21 367 370 1616457 the DT B-NP O
22 371 377 1616457 normal JJ I-NP O
23 378 383 1616457 state NN I-NP O
24 383 384 1616457 . . O O

1 385 387 1616457 In IN B-PP O
2 388 393 1616457 Group NN B-NP O
3 394 395 1616457 2 CD I-NP O
4 396 399 1616457 the DT B-NP O
5 400 404 1616457 rats NNS I-NP O
6 405 409 1616457 were VBD B-VP O
7 410 417 1616457 trained VBN I-VP O
8 418 420 1616457 to TO I-VP O
9 421 429 1616457 approach VB I-VP O
10 430 439 1616457 different JJ B-NP O
11 440 447 1616457 shelves NNS I-NP O
12 448 450 1616457 in IN B-PP O
13 451 460 1616457 different JJ B-NP O
14 461 465 1616457 drug NN I-NP O
15 466 472 1616457 states NNS I-NP O
16 472 473 1616457 . . O O

1 474 476 1616457 It PRP B-NP O
2 477 480 1616457 was VBD B-VP O
3 481 486 1616457 shown VBN I-VP O
4 487 491 1616457 that IN B-SBAR O
5 492 498 1616457 memory NN B-NP B-Disease
6 499 511 1616457 dissociation NN I-NP I-Disease
7 512 520 1616457 occurred VBD B-VP O
8 521 523 1616457 in IN B-PP O
9 524 528 1616457 both DT B-NP O
10 529 535 1616457 groups NNS I-NP O
11 535 536 1616457 . . O O

1 537 548 1616457 Differences NNS B-NP O
2 549 551 1616457 in IN B-PP O
3 552 555 1616457 the DT B-NP O
4 556 566 1616457 parameters NNS I-NP O
5 567 569 1616457 of IN B-PP O
6 570 578 1616457 training NN B-NP O
7 579 584 1616457 under IN B-PP O
8 585 588 1616457 the DT B-NP O
9 589 598 1616457 influence NN I-NP O
10 599 601 1616457 of IN B-PP O
11 602 615 1616457 pentobarbital NN B-NP B-Chemical
12 616 623 1616457 between IN B-PP O
13 624 630 1616457 Groups NNS B-NP O
14 631 632 1616457 1 CD I-NP O
15 633 636 1616457 and CC I-NP O
16 637 638 1616457 2 CD I-NP O
17 639 643 1616457 were VBD B-VP O
18 644 652 1616457 revealed VBN I-VP O
19 652 653 1616457 . . O O

1 654 659 1616457 These DT B-NP O
2 660 668 1616457 findings NNS I-NP O
3 669 673 1616457 show VBP B-VP O
4 674 678 1616457 that IN B-SBAR O
5 679 682 1616457 the DT B-NP O
6 683 688 1616457 brain NN I-NP O
7 688 689 1616457 - HYPH O O
8 689 700 1616457 dissociated VBN B-NP O
9 701 706 1616457 state NN I-NP O
10 707 714 1616457 induced VBN B-VP O
11 715 717 1616457 by IN B-PP O
12 718 731 1616457 pentobarbital NN B-NP B-Chemical
13 732 734 1616457 is VBZ B-VP O
14 735 741 1616457 formed VBN I-VP O
15 742 746 1616457 with IN B-PP O
16 747 750 1616457 the DT B-NP O
17 751 764 1616457 participation NN I-NP O
18 765 767 1616457 of IN B-PP O
19 768 771 1616457 the DT B-NP O
20 772 782 1616457 mechanisms NNS I-NP O
21 783 785 1616457 of IN B-PP O
22 786 797 1616457 information NN B-NP O
23 798 808 1616457 perception NN I-NP O
24 808 809 1616457 . . O O

1 0 0 18703024 -DOCSTART- -X- -X- O

1 0 8 18703024 Prenatal JJ B-NP O
2 9 16 18703024 protein NN I-NP O
3 17 28 18703024 deprivation NN I-NP O
4 29 35 18703024 alters VBZ B-VP O
5 36 44 18703024 dopamine NN B-NP B-Chemical
6 44 45 18703024 - HYPH B-NP O
7 45 53 18703024 mediated VBN I-NP O
8 54 63 18703024 behaviors NNS I-NP O
9 64 67 18703024 and CC O O
10 68 80 18703024 dopaminergic JJ B-NP O
11 81 84 18703024 and CC I-NP O
12 85 98 18703024 glutamatergic JJ I-NP O
13 99 107 18703024 receptor NN I-NP O
14 108 115 18703024 binding NN I-NP O
15 115 116 18703024 . . O O
16 117 132 18703024 Epidemiological JJ B-NP O
17 133 141 18703024 evidence NN I-NP O
18 142 151 18703024 indicates VBZ B-VP O
19 152 156 18703024 that IN B-SBAR O
20 157 165 18703024 prenatal JJ B-NP O
21 166 177 18703024 nutritional JJ I-NP O
22 178 189 18703024 deprivation NN I-NP O
23 190 193 18703024 may MD B-VP O
24 194 202 18703024 increase VB I-VP O
25 203 206 18703024 the DT B-NP O
26 207 211 18703024 risk NN I-NP O
27 212 214 18703024 of IN B-PP O
28 215 228 18703024 schizophrenia NN B-NP B-Disease
29 228 229 18703024 . . O O

1 230 233 18703024 The DT B-NP O
2 234 238 18703024 goal NN I-NP O
3 239 241 18703024 of IN B-PP O
4 242 247 18703024 these DT B-NP O
5 248 255 18703024 studies NNS I-NP O
6 256 259 18703024 was VBD B-VP O
7 260 262 18703024 to TO I-VP O
8 263 266 18703024 use VB I-VP O
9 267 269 18703024 an DT B-NP O
10 270 276 18703024 animal NN I-NP O
11 277 282 18703024 model NN I-NP O
12 283 285 18703024 to TO B-VP O
13 286 293 18703024 examine VB I-VP O
14 294 297 18703024 the DT B-NP O
15 298 305 18703024 effects NNS I-NP O
16 306 308 18703024 of IN B-PP O
17 309 317 18703024 prenatal JJ B-NP O
18 318 325 18703024 protein NN I-NP O
19 326 337 18703024 deprivation NN I-NP O
20 338 340 18703024 on IN B-PP O
21 341 350 18703024 behaviors NNS B-NP O
22 351 354 18703024 and CC O O
23 355 363 18703024 receptor NN B-NP O
24 364 371 18703024 binding NN I-NP O
25 372 376 18703024 with IN B-PP O
26 377 386 18703024 relevance NN B-NP O
27 387 389 18703024 to TO B-PP O
28 390 403 18703024 schizophrenia NN B-NP B-Disease
29 403 404 18703024 . . O O

1 405 407 18703024 We PRP B-NP O
2 408 414 18703024 report VBP B-VP O
3 415 419 18703024 that IN B-SBAR O
4 420 430 18703024 prenatally RB B-NP O
5 431 438 18703024 protein NN I-NP O
6 439 447 18703024 deprived VBN B-VP O
7 448 449 18703024 ( ( O O
8 449 451 18703024 PD NN B-NP O
9 451 452 18703024 ) ) O O
10 453 459 18703024 female JJ B-NP O
11 460 464 18703024 rats NNS I-NP O
12 465 471 18703024 showed VBD B-VP O
13 472 474 18703024 an DT B-NP O
14 475 484 18703024 increased VBN I-NP O
15 485 496 18703024 stereotypic JJ I-NP O
16 497 505 18703024 response NN I-NP O
17 506 508 18703024 to TO B-PP O
18 509 520 18703024 apomorphine NN B-NP B-Chemical
19 521 524 18703024 and CC O O
20 525 527 18703024 an DT B-NP O
21 528 537 18703024 increased VBN I-NP O
22 538 547 18703024 locomotor NN I-NP O
23 548 556 18703024 response NN I-NP O
24 557 559 18703024 to TO B-PP O
25 560 571 18703024 amphetamine NN B-NP B-Chemical
26 572 574 18703024 in IN B-PP O
27 575 584 18703024 adulthood NN B-NP O
28 584 585 18703024 . . O O

1 586 591 18703024 These DT B-NP O
2 592 603 18703024 differences NNS I-NP O
3 604 608 18703024 were VBD B-VP O
4 609 612 18703024 not RB I-VP O
5 613 621 18703024 observed VBN I-VP O
6 622 628 18703024 during IN B-PP O
7 629 636 18703024 puberty NN B-NP O
8 636 637 18703024 . . O O

1 638 640 18703024 No DT B-NP O
2 641 648 18703024 changes NNS I-NP O
3 649 651 18703024 in IN B-PP O
4 652 663 18703024 haloperidol NN B-NP B-Chemical
5 663 664 18703024 - HYPH B-NP O
6 664 671 18703024 induced VBN I-NP O
7 672 681 18703024 catalepsy NN I-NP B-Disease
8 682 684 18703024 or CC I-NP O
9 685 687 18703024 MK NN I-NP B-Chemical
10 687 688 18703024 - HYPH B-NP I-Chemical
11 688 691 18703024 801 CD I-NP I-Chemical
12 691 692 18703024 - HYPH I-NP O
13 692 699 18703024 induced VBN I-NP O
14 700 710 18703024 locomotion NN I-NP O
15 711 715 18703024 were VBD B-VP O
16 716 720 18703024 seen VBN I-VP O
17 721 730 18703024 following VBG B-PP O
18 731 733 18703024 PD NN B-NP O
19 733 734 18703024 . . O O

1 735 737 18703024 In IN B-PP O
2 738 746 18703024 addition NN B-NP O
3 746 747 18703024 , , O O
4 748 750 18703024 PD NN B-NP O
5 751 757 18703024 female JJ I-NP O
6 758 762 18703024 rats NNS I-NP O
7 763 769 18703024 showed VBD B-VP O
8 770 779 18703024 increased VBN B-NP O
9 780 784 18703024 (3)H NN I-NP B-Chemical
10 784 785 18703024 - HYPH B-NP O
11 785 787 18703024 MK NN I-NP B-Chemical
12 787 788 18703024 - HYPH I-NP I-Chemical
13 788 791 18703024 801 CD I-NP I-Chemical
14 792 799 18703024 binding NN I-NP O
15 800 802 18703024 in IN B-PP O
16 803 806 18703024 the DT B-NP O
17 807 815 18703024 striatum NN I-NP O
18 816 819 18703024 and CC I-NP O
19 820 831 18703024 hippocampus NN I-NP O
20 831 832 18703024 , , B-PP O
21 833 836 18703024 but CC I-PP O
22 837 840 18703024 not RB B-PP O
23 841 843 18703024 in IN I-PP O
24 844 847 18703024 the DT B-NP O
25 848 854 18703024 cortex NN I-NP O
26 854 855 18703024 . . O O

1 856 858 18703024 PD NN B-NP O
2 859 865 18703024 female JJ I-NP O
3 866 870 18703024 rats NNS I-NP O
4 871 875 18703024 also RB B-ADVP O
5 876 882 18703024 showed VBD B-VP O
6 883 892 18703024 increased VBN B-NP O
7 893 897 18703024 (3)H NN I-NP B-Chemical
8 897 898 18703024 - HYPH B-NP O
9 898 909 18703024 haloperidol NN I-NP B-Chemical
10 910 917 18703024 binding NN I-NP O
11 918 921 18703024 and CC O O
12 922 931 18703024 decreased VBD B-VP O
13 932 940 18703024 dopamine NN B-NP B-Chemical
14 941 952 18703024 transporter NN I-NP O
15 953 960 18703024 binding NN I-NP O
16 961 963 18703024 in IN B-PP O
17 964 972 18703024 striatum NN B-NP O
18 972 973 18703024 . . O O

1 974 976 18703024 No DT B-NP O
2 977 990 18703024 statistically RB I-NP O
3 991 1002 18703024 significant JJ I-NP O
4 1003 1010 18703024 changes NNS I-NP O
5 1011 1013 18703024 in IN B-PP O
6 1014 1022 18703024 behavior NN B-NP O
7 1023 1025 18703024 or CC I-NP O
8 1026 1034 18703024 receptor NN I-NP O
9 1035 1042 18703024 binding NN I-NP O
10 1043 1047 18703024 were VBD B-VP O
11 1048 1053 18703024 found VBN I-VP O
12 1054 1056 18703024 in IN B-PP O
13 1057 1059 18703024 PD NN B-NP O
14 1060 1065 18703024 males NNS I-NP O
15 1066 1070 18703024 with IN B-PP O
16 1071 1074 18703024 the DT B-NP O
17 1075 1084 18703024 exception NN I-NP O
18 1085 1087 18703024 of IN B-PP O
19 1088 1097 18703024 increased VBN B-NP O
20 1098 1102 18703024 (3)H NN I-NP B-Chemical
21 1102 1103 18703024 - HYPH B-NP O
22 1103 1105 18703024 MK NN I-NP B-Chemical
23 1105 1106 18703024 - HYPH I-NP I-Chemical
24 1106 1109 18703024 801 CD I-NP I-Chemical
25 1110 1117 18703024 binding NN I-NP O
26 1118 1120 18703024 in IN B-PP O
27 1121 1127 18703024 cortex NN B-NP O
28 1127 1128 18703024 . . O O

1 1129 1133 18703024 This DT B-NP O
2 1134 1140 18703024 animal NN I-NP O
3 1141 1146 18703024 model NN I-NP O
4 1147 1150 18703024 may MD B-VP O
5 1151 1153 18703024 be VB I-VP O
6 1154 1160 18703024 useful JJ B-ADJP O
7 1161 1163 18703024 to TO B-VP O
8 1164 1171 18703024 explore VB I-VP O
9 1172 1175 18703024 the DT B-NP O
10 1176 1186 18703024 mechanisms NNS I-NP O
11 1187 1189 18703024 by IN B-PP O
12 1190 1195 18703024 which WDT B-NP O
13 1196 1204 18703024 prenatal JJ B-NP O
14 1205 1216 18703024 nutritional JJ I-NP B-Disease
15 1217 1227 18703024 deficiency NN I-NP I-Disease
16 1228 1236 18703024 enhances VBZ B-VP O
17 1237 1241 18703024 risk NN B-NP O
18 1242 1245 18703024 for IN B-PP O
19 1246 1259 18703024 schizophrenia NN B-NP B-Disease
20 1260 1262 18703024 in IN B-PP O
21 1263 1269 18703024 humans NNS B-NP O
22 1270 1273 18703024 and CC O O
23 1274 1277 18703024 may MD B-VP O
24 1278 1282 18703024 also RB I-VP O
25 1283 1287 18703024 have VB I-VP O
26 1288 1300 18703024 implications NNS B-NP O
27 1301 1304 18703024 for IN B-PP O
28 1305 1318 18703024 developmental JJ B-NP O
29 1319 1328 18703024 processes NNS I-NP O
30 1329 1336 18703024 leading VBG B-VP O
31 1337 1339 18703024 to TO B-PP O
32 1340 1352 18703024 differential JJ B-NP O
33 1353 1364 18703024 sensitivity NN I-NP O
34 1365 1367 18703024 to TO B-PP O
35 1368 1373 18703024 drugs NNS B-NP O
36 1374 1376 18703024 of IN B-PP O
37 1377 1382 18703024 abuse NN B-NP O
38 1382 1383 18703024 . . O O

1 0 0 14659530 -DOCSTART- -X- -X- O

1 0 2 14659530 NO NN B-NP B-Chemical
2 2 3 14659530 - HYPH B-NP O
3 3 10 14659530 induced VBN I-NP O
4 11 19 14659530 migraine NN I-NP B-Disease
5 20 26 14659530 attack NN I-NP O
6 26 27 14659530 : : O O
7 28 34 14659530 strong JJ B-NP O
8 35 43 14659530 increase NN I-NP O
9 44 46 14659530 in IN B-PP O
10 47 53 14659530 plasma NN B-NP O
11 54 64 14659530 calcitonin NN I-NP B-Chemical
12 65 69 14659530 gene NN I-NP I-Chemical
13 69 70 14659530 - HYPH B-VP I-Chemical
14 70 77 14659530 related VBN B-NP I-Chemical
15 78 85 14659530 peptide NN I-NP I-Chemical
16 86 87 14659530 ( ( O O
17 87 91 14659530 CGRP NN B-NP B-Chemical
18 91 92 14659530 ) ) O O
19 93 106 14659530 concentration NN B-NP O
20 107 110 14659530 and CC O O
21 111 119 14659530 negative JJ B-NP O
22 120 131 14659530 correlation NN I-NP O
23 132 136 14659530 with IN B-PP O
24 137 145 14659530 platelet NN B-NP O
25 146 155 14659530 serotonin NN I-NP B-Chemical
26 156 163 14659530 release NN I-NP O
27 163 164 14659530 . . O O
28 165 168 14659530 The DT B-NP O
29 169 172 14659530 aim NN I-NP O
30 173 175 14659530 of IN B-PP O
31 176 179 14659530 the DT B-NP O
32 180 187 14659530 present JJ I-NP O
33 188 193 14659530 study NN I-NP O
34 194 197 14659530 was VBD B-VP O
35 198 200 14659530 to TO B-VP O
36 201 212 14659530 investigate VB I-VP O
37 213 220 14659530 changes NNS B-NP O
38 221 223 14659530 in IN B-PP O
39 224 227 14659530 the DT B-NP O
40 228 234 14659530 plasma NN I-NP O
41 235 245 14659530 calcitonin NN I-NP B-Chemical
42 246 250 14659530 gene NN I-NP I-Chemical
43 250 251 14659530 - HYPH B-VP I-Chemical
44 251 258 14659530 related VBN B-NP I-Chemical
45 259 266 14659530 peptide NN I-NP I-Chemical
46 267 268 14659530 ( ( O O
47 268 272 14659530 CGRP NN B-NP B-Chemical
48 272 273 14659530 ) ) O O
49 274 287 14659530 concentration NN B-NP O
50 288 291 14659530 and CC O O
51 292 300 14659530 platelet NN B-NP O
52 301 310 14659530 serotonin NN I-NP B-Chemical
53 311 312 14659530 ( ( O O
54 312 313 14659530 5 CD B-NP B-Chemical
55 313 314 14659530 - HYPH I-NP I-Chemical
56 314 331 14659530 hydroxytriptamine NN I-NP I-Chemical
57 331 332 14659530 , , O O
58 333 334 14659530 5 CD B-NP B-Chemical
59 334 335 14659530 - HYPH I-NP I-Chemical
60 335 337 14659530 HT NN I-NP I-Chemical
61 337 338 14659530 ) ) O O
62 339 346 14659530 content NN B-NP O
63 347 353 14659530 during IN B-PP O
64 354 357 14659530 the DT B-NP O
65 358 367 14659530 immediate JJ I-NP O
66 368 376 14659530 headache NN I-NP B-Disease
67 377 380 14659530 and CC O O
68 381 384 14659530 the DT B-NP O
69 385 392 14659530 delayed VBN I-NP O
70 393 400 14659530 genuine JJ I-NP O
71 401 409 14659530 migraine NN I-NP B-Disease
72 410 416 14659530 attack NN I-NP O
73 417 425 14659530 provoked VBN B-VP O
74 426 428 14659530 by IN B-PP O
75 429 442 14659530 nitroglycerin NN B-NP B-Chemical
76 442 443 14659530 . . O O

1 444 451 14659530 Fifteen CD B-NP O
2 452 458 14659530 female JJ I-NP O
3 459 470 14659530 migraineurs NNS I-NP B-Disease
4 471 472 14659530 ( ( O I-Disease
5 472 479 14659530 without IN B-PP I-Disease
6 480 484 14659530 aura NN B-NP I-Disease
7 484 485 14659530 ) ) O I-Disease
8 486 489 14659530 and CC O O
9 490 495 14659530 eight CD B-NP O
10 496 504 14659530 controls NNS I-NP O
11 505 517 14659530 participated VBD B-VP O
12 518 520 14659530 in IN B-PP O
13 521 524 14659530 the DT B-NP O
14 525 530 14659530 study NN I-NP O
15 530 531 14659530 . . O O

1 532 542 14659530 Sublingual JJ B-NP O
2 543 556 14659530 nitroglycerin NN I-NP B-Chemical
3 557 558 14659530 ( ( O O
4 558 561 14659530 0.5 CD B-NP O
5 562 564 14659530 mg NN I-NP O
6 564 565 14659530 ) ) O O
7 566 569 14659530 was VBD B-VP O
8 570 582 14659530 administered VBN I-VP O
9 582 583 14659530 . . O O

1 584 589 14659530 Blood NN B-NP O
2 590 593 14659530 was VBD B-VP O
3 594 603 14659530 collected VBN I-VP O
4 604 608 14659530 from IN B-PP O
5 609 612 14659530 the DT B-NP O
6 613 624 14659530 antecubital JJ I-NP O
7 625 629 14659530 vein NN I-NP O
8 630 634 14659530 four CD B-NP O
9 635 640 14659530 times NNS I-NP O
10 640 641 14659530 : : O O
11 642 644 14659530 60 CD B-NP O
12 645 648 14659530 min NN I-NP O
13 649 655 14659530 before IN B-PP O
14 656 659 14659530 and CC I-PP O
15 660 665 14659530 after IN I-PP O
16 666 669 14659530 the DT B-NP O
17 670 683 14659530 nitroglycerin NN I-NP B-Chemical
18 684 695 14659530 application NN I-NP O
19 695 696 14659530 , , O O
20 697 700 14659530 and CC O O
21 701 703 14659530 60 CD B-NP O
22 704 707 14659530 and CC I-NP O
23 708 711 14659530 120 CD I-NP O
24 712 715 14659530 min NN I-NP O
25 716 721 14659530 after IN B-PP O
26 722 725 14659530 the DT B-NP O
27 726 735 14659530 beginning NN I-NP O
28 736 738 14659530 of IN B-PP O
29 739 742 14659530 the DT B-NP O
30 743 751 14659530 migraine NN I-NP B-Disease
31 752 758 14659530 attack NN I-NP O
32 759 760 14659530 ( ( O O
33 760 764 14659530 mean NN B-NP O
34 765 768 14659530 344 CD I-NP O
35 769 772 14659530 and CC I-NP O
36 773 776 14659530 404 CD I-NP O
37 777 780 14659530 min NN I-NP O
38 780 781 14659530 ; : O O
39 782 784 14659530 12 CD B-NP O
40 785 793 14659530 subjects NNS I-NP O
41 793 794 14659530 ) ) O O
42 794 795 14659530 . . O O

1 796 798 14659530 In IN B-PP O
2 799 804 14659530 those DT B-NP O
3 805 813 14659530 subjects NNS I-NP O
4 814 817 14659530 who WP B-NP O
5 818 821 14659530 had VBD B-VP O
6 822 824 14659530 no DT B-NP O
7 825 833 14659530 migraine NN I-NP B-Disease
8 834 840 14659530 attack NN I-NP O
9 841 842 14659530 ( ( O O
10 842 844 14659530 11 CD B-NP O
11 845 853 14659530 subjects NNS I-NP O
12 853 854 14659530 ) ) O O
13 855 856 14659530 a DT B-NP O
14 857 864 14659530 similar JJ I-NP O
15 865 869 14659530 time NN I-NP O
16 870 878 14659530 schedule NN I-NP O
17 879 882 14659530 was VBD B-VP O
18 883 887 14659530 used VBN I-VP O
19 887 888 14659530 . . O O

1 889 895 14659530 Plasma NN B-NP O
2 896 900 14659530 CGRP NN I-NP B-Chemical
3 901 914 14659530 concentration NN I-NP O
4 915 924 14659530 increased VBD B-VP O
5 925 938 14659530 significantly RB B-ADVP O
6 939 940 14659530 ( ( O O
7 940 941 14659530 P NN B-NP O
8 941 942 14659530 < SYM O O
9 942 946 14659530 0.01 CD B-NP O
10 946 947 14659530 ) ) O O
11 948 954 14659530 during IN B-PP O
12 955 958 14659530 the DT B-NP O
13 959 967 14659530 migraine NN I-NP B-Disease
14 968 974 14659530 attack NN I-NP O
15 975 978 14659530 and CC O O
16 979 987 14659530 returned VBD B-VP O
17 988 990 14659530 to TO B-PP O
18 991 999 14659530 baseline NN B-NP O
19 1000 1005 14659530 after IN B-PP O
20 1006 1009 14659530 the DT B-NP O
21 1010 1019 14659530 cessation NN I-NP O
22 1020 1022 14659530 of IN B-PP O
23 1023 1026 14659530 the DT B-NP O
24 1027 1035 14659530 migraine NN I-NP B-Disease
25 1035 1036 14659530 . . O O

1 1037 1039 14659530 In IN B-PP O
2 1040 1048 14659530 addition NN B-NP O
3 1048 1049 14659530 , , O O
4 1050 1054 14659530 both CC O O
5 1055 1061 14659530 change NN B-NP O
6 1062 1065 14659530 and CC I-NP O
7 1066 1070 14659530 peak NN I-NP O
8 1070 1071 14659530 , , O O
9 1072 1078 14659530 showed VBD B-VP O
10 1079 1090 14659530 significant JJ B-NP O
11 1091 1099 14659530 positive JJ I-NP O
12 1100 1112 14659530 correlations NNS I-NP O
13 1113 1117 14659530 with IN B-PP O
14 1118 1126 14659530 migraine NN B-NP B-Disease
15 1127 1135 14659530 headache NN I-NP B-Disease
16 1136 1145 14659530 intensity NN I-NP O
17 1146 1147 14659530 ( ( O O
18 1147 1148 14659530 P NN B-NP O
19 1148 1149 14659530 < SYM O O
20 1149 1154 14659530 0.001 CD B-NP O
21 1154 1155 14659530 ) ) O O
22 1155 1156 14659530 . . O O

1 1157 1164 14659530 However RB B-ADVP O
2 1164 1165 14659530 , , O O
3 1166 1172 14659530 plasma NN B-NP O
4 1173 1177 14659530 CGRP NN I-NP B-Chemical
5 1178 1192 14659530 concentrations NNS I-NP O
6 1193 1199 14659530 failed VBD B-VP O
7 1200 1202 14659530 to TO I-VP O
8 1203 1209 14659530 change VB I-VP O
9 1210 1216 14659530 during IN B-PP O
10 1217 1226 14659530 immediate JJ B-NP O
11 1227 1235 14659530 headache NN I-NP B-Disease
12 1236 1239 14659530 and CC B-PP O
13 1240 1242 14659530 in IN B-PP O
14 1243 1246 14659530 the DT B-NP O
15 1247 1255 14659530 subjects NNS I-NP O
16 1256 1260 14659530 with IN B-PP O
17 1261 1263 14659530 no DT B-NP O
18 1264 1272 14659530 migraine NN I-NP B-Disease
19 1273 1279 14659530 attack NN I-NP O
20 1279 1280 14659530 . . O O

1 1281 1286 14659530 Basal JJ B-NP O
2 1287 1291 14659530 CGRP NN I-NP B-Chemical
3 1292 1305 14659530 concentration NN I-NP O
4 1306 1309 14659530 was VBD B-VP O
5 1310 1323 14659530 significantly RB B-ADJP O
6 1324 1330 14659530 higher JJR I-ADJP O
7 1331 1334 14659530 and CC O O
8 1335 1343 14659530 platelet NN B-NP O
9 1344 1345 14659530 5 CD I-NP B-Chemical
10 1345 1346 14659530 - HYPH I-NP I-Chemical
11 1346 1348 14659530 HT NN I-NP I-Chemical
12 1349 1356 14659530 content NN I-NP O
13 1357 1363 14659530 tended VBD B-VP O
14 1364 1366 14659530 to TO I-VP O
15 1367 1369 14659530 be VB I-VP O
16 1370 1375 14659530 lower JJR B-ADJP O
17 1376 1378 14659530 in IN B-PP O
18 1379 1387 14659530 subjects NNS B-NP O
19 1388 1391 14659530 who WP B-NP O
20 1392 1403 14659530 experienced VBD B-VP O
21 1404 1405 14659530 a DT B-NP O
22 1406 1414 14659530 migraine NN I-NP B-Disease
23 1415 1421 14659530 attack NN I-NP O
24 1421 1422 14659530 . . O O

1 1423 1431 14659530 Platelet NN B-NP O
2 1432 1441 14659530 serotonin NN I-NP B-Chemical
3 1442 1449 14659530 content NN I-NP O
4 1450 1459 14659530 decreased VBD B-VP O
5 1460 1473 14659530 significantly RB B-ADVP O
6 1474 1475 14659530 ( ( O O
7 1475 1476 14659530 P NN B-NP O
8 1476 1477 14659530 < SYM B-NP O
9 1477 1481 14659530 0.01 CD I-NP O
10 1481 1482 14659530 ) ) O O
11 1483 1488 14659530 after IN B-PP O
12 1489 1502 14659530 nitroglycerin NN B-NP B-Chemical
13 1503 1505 14659530 in IN B-PP O
14 1506 1514 14659530 subjects NNS B-NP O
15 1515 1519 14659530 with IN B-PP O
16 1520 1522 14659530 no DT B-NP O
17 1523 1531 14659530 migraine NN I-NP B-Disease
18 1532 1538 14659530 attack NN I-NP O
19 1539 1542 14659530 but CC O O
20 1543 1545 14659530 no DT B-NP O
21 1546 1556 14659530 consistent JJ I-NP O
22 1557 1563 14659530 change NN I-NP O
23 1564 1567 14659530 was VBD B-VP O
24 1568 1576 14659530 observed VBN I-VP O
25 1577 1579 14659530 in IN B-PP O
26 1580 1588 14659530 patients NNS B-NP O
27 1589 1593 14659530 with IN B-PP O
28 1594 1602 14659530 migraine NN B-NP B-Disease
29 1603 1609 14659530 attack NN I-NP O
30 1609 1610 14659530 . . O O

1 1611 1613 14659530 In IN B-PP O
2 1614 1624 14659530 conclusion NN B-NP O
3 1624 1625 14659530 , , O O
4 1626 1629 14659530 the DT B-NP O
5 1630 1634 14659530 fact NN I-NP O
6 1635 1639 14659530 that IN B-SBAR O
7 1640 1646 14659530 plasma NN B-NP O
8 1647 1651 14659530 CGRP NN I-NP B-Chemical
9 1652 1665 14659530 concentration NN I-NP O
10 1666 1676 14659530 correlates VBZ B-VP O
11 1677 1681 14659530 with IN B-PP O
12 1682 1685 14659530 the DT B-NP O
13 1686 1692 14659530 timing NN I-NP O
14 1693 1696 14659530 and CC I-NP O
15 1697 1705 14659530 severity NN I-NP O
16 1706 1708 14659530 of IN B-PP O
17 1709 1710 14659530 a DT B-NP O
18 1711 1719 14659530 migraine NN I-NP B-Disease
19 1720 1728 14659530 headache NN I-NP B-Disease
20 1729 1737 14659530 suggests VBZ B-VP O
21 1738 1739 14659530 a DT B-NP O
22 1740 1746 14659530 direct JJ I-NP O
23 1747 1759 14659530 relationship NN I-NP O
24 1760 1767 14659530 between IN B-PP O
25 1768 1772 14659530 CGRP NN B-NP B-Chemical
26 1773 1776 14659530 and CC I-NP O
27 1777 1785 14659530 migraine NN I-NP B-Disease
28 1785 1786 14659530 . . O O

1 1787 1789 14659530 In IN B-PP O
2 1790 1798 14659530 contrast NN B-NP O
3 1798 1799 14659530 , , O O
4 1800 1809 14659530 serotonin NN B-NP B-Chemical
5 1810 1817 14659530 release NN I-NP O
6 1818 1822 14659530 from IN B-PP O
7 1823 1832 14659530 platelets NNS B-NP O
8 1833 1837 14659530 does VBZ B-VP O
9 1838 1841 14659530 not RB I-VP O
10 1842 1849 14659530 provoke VB I-VP O
11 1850 1858 14659530 migraine NN B-NP B-Disease
12 1858 1859 14659530 , , O O
13 1860 1862 14659530 it PRP B-NP O
14 1863 1866 14659530 may MD B-VP O
15 1867 1871 14659530 even RB I-VP O
16 1872 1882 14659530 counteract VB I-VP O
17 1883 1886 14659530 the DT B-NP O
18 1887 1895 14659530 headache NN I-NP B-Disease
19 1896 1899 14659530 and CC O O
20 1900 1903 14659530 the DT B-NP O
21 1904 1915 14659530 concomitant JJ I-NP O
22 1916 1920 14659530 CGRP NN I-NP B-Chemical
23 1921 1928 14659530 release NN I-NP O
24 1929 1931 14659530 in IN B-PP O
25 1932 1936 14659530 this DT B-NP O
26 1937 1942 14659530 model NN I-NP O
27 1942 1943 14659530 . . O O

1 0 0 18182964 -DOCSTART- -X- -X- O

1 0 9 18182964 Clonidine NN B-NP B-Chemical
2 10 13 18182964 for IN B-PP O
3 14 23 18182964 attention NN B-NP B-Disease
4 23 24 18182964 - HYPH I-NP I-Disease
5 24 31 18182964 deficit NN I-NP I-Disease
6 31 32 18182964 / SYM I-NP I-Disease
7 32 45 18182964 hyperactivity NN I-NP I-Disease
8 46 54 18182964 disorder NN I-NP I-Disease
9 54 55 18182964 : : O O
10 56 58 18182964 II CD B-NP O
11 58 59 18182964 . . O O

1 60 63 18182964 ECG NN B-NP O
2 64 71 18182964 changes NNS I-NP O
3 72 75 18182964 and CC O O
4 76 83 18182964 adverse JJ B-NP O
5 84 90 18182964 events NNS I-NP O
6 91 99 18182964 analysis NN I-NP O
7 99 100 18182964 . . B-NP O
8 101 110 18182964 OBJECTIVE NN I-NP O
9 110 111 18182964 : : O O
10 112 114 18182964 To TO B-VP O
11 115 122 18182964 examine VB I-VP O
12 123 126 18182964 the DT B-NP O
13 127 133 18182964 safety NN I-NP O
14 134 137 18182964 and CC I-NP O
15 138 150 18182964 tolerability NN I-NP O
16 151 153 18182964 of IN B-PP O
17 154 163 18182964 clonidine NN B-NP B-Chemical
18 164 168 18182964 used VBN B-VP O
19 169 174 18182964 alone RB B-ADVP O
20 175 177 18182964 or CC O O
21 178 182 18182964 with IN B-PP O
22 183 198 18182964 methylphenidate NN B-NP B-Chemical
23 199 201 18182964 in IN B-PP O
24 202 210 18182964 children NNS B-NP O
25 211 215 18182964 with IN B-PP O
26 216 225 18182964 attention NN B-NP B-Disease
27 225 226 18182964 - HYPH I-NP I-Disease
28 226 233 18182964 deficit NN I-NP I-Disease
29 233 234 18182964 / SYM O I-Disease
30 234 247 18182964 hyperactivity NN B-NP I-Disease
31 248 256 18182964 disorder NN I-NP I-Disease
32 257 258 18182964 ( ( O O
33 258 262 18182964 ADHD NN B-NP B-Disease
34 262 263 18182964 ) ) O O
35 263 264 18182964 . . O O

1 265 271 18182964 METHOD NN B-NP O
2 271 272 18182964 : : O O
3 273 275 18182964 In IN B-PP O
4 276 277 18182964 a DT B-NP O
5 278 280 18182964 16 CD I-NP O
6 280 281 18182964 - HYPH I-NP O
7 281 285 18182964 week NN I-NP O
8 286 297 18182964 multicenter NN I-NP O
9 297 298 18182964 , , O O
10 299 305 18182964 double JJ B-NP O
11 305 306 18182964 - HYPH I-NP O
12 306 311 18182964 blind JJ I-NP O
13 312 317 18182964 trial NN I-NP O
14 317 318 18182964 , , O O
15 319 322 18182964 122 CD B-NP O
16 323 331 18182964 children NNS I-NP O
17 332 336 18182964 with IN B-PP O
18 337 341 18182964 ADHD NN B-NP B-Disease
19 342 346 18182964 were VBD B-VP O
20 347 355 18182964 randomly RB I-VP O
21 356 364 18182964 assigned VBN I-VP O
22 365 367 18182964 to TO B-PP O
23 368 377 18182964 clonidine NN B-NP B-Chemical
24 378 379 18182964 ( ( O O
25 379 380 18182964 n NN B-NP O
26 381 382 18182964 = SYM B-VP O
27 383 385 18182964 31 CD B-NP O
28 385 386 18182964 ) ) O O
29 386 387 18182964 , , O O
30 388 403 18182964 methylphenidate NN B-NP B-Chemical
31 404 405 18182964 ( ( O O
32 405 406 18182964 n NN B-NP O
33 407 408 18182964 = SYM B-VP O
34 409 411 18182964 29 CD B-NP O
35 411 412 18182964 ) ) O O
36 412 413 18182964 , , O O
37 414 423 18182964 clonidine NN B-NP B-Chemical
38 424 427 18182964 and CC O O
39 428 443 18182964 methylphenidate NN B-NP B-Chemical
40 444 445 18182964 ( ( O O
41 445 446 18182964 n NN B-NP O
42 447 448 18182964 = SYM B-VP O
43 449 451 18182964 32 CD B-NP O
44 451 452 18182964 ) ) O O
45 452 453 18182964 , , O O
46 454 456 18182964 or CC O O
47 457 464 18182964 placebo NN B-NP O
48 465 466 18182964 ( ( O O
49 466 467 18182964 n NN B-NP O
50 468 469 18182964 = SYM B-VP O
51 470 472 18182964 30 CD B-NP O
52 472 473 18182964 ) ) O O
53 473 474 18182964 . . O O

1 475 480 18182964 Doses NNS B-NP O
2 481 485 18182964 were VBD B-VP O
3 486 494 18182964 flexibly RB I-VP O
4 495 503 18182964 titrated VBN I-VP O
5 504 506 18182964 up IN B-NP O
6 507 509 18182964 to TO I-NP O
7 510 513 18182964 0.6 CD I-NP O
8 514 516 18182964 mg NN I-NP O
9 516 517 18182964 / SYM B-NP O
10 517 520 18182964 day NN I-NP O
11 521 524 18182964 for IN B-PP O
12 525 534 18182964 clonidine NN B-NP B-Chemical
13 535 538 18182964 and CC O O
14 539 541 18182964 60 CD B-NP O
15 542 544 18182964 mg NN I-NP O
16 544 545 18182964 / SYM B-NP O
17 545 548 18182964 day NN I-NP O
18 549 552 18182964 for IN B-PP O
19 553 568 18182964 methylphenidate NN B-NP B-Chemical
20 569 570 18182964 ( ( O O
21 570 574 18182964 both DT B-NP O
22 575 579 18182964 with IN B-PP O
23 580 587 18182964 divided VBN B-NP O
24 588 594 18182964 dosing NN I-NP O
25 594 595 18182964 ) ) O O
26 595 596 18182964 . . O O

1 597 603 18182964 Groups NNS B-NP O
2 604 608 18182964 were VBD B-VP O
3 609 617 18182964 compared VBN I-VP O
4 618 627 18182964 regarding VBG B-PP O
5 628 635 18182964 adverse JJ B-NP O
6 636 642 18182964 events NNS I-NP O
7 643 646 18182964 and CC I-NP O
8 647 654 18182964 changes NNS I-NP O
9 655 659 18182964 from IN B-PP O
10 660 668 18182964 baseline NN B-NP O
11 669 671 18182964 to TO B-PP O
12 672 676 18182964 week NN B-NP O
13 677 679 18182964 16 CD I-NP O
14 680 682 18182964 in IN B-PP O
15 683 701 18182964 electrocardiograms NNS B-NP O
16 702 705 18182964 and CC O O
17 706 711 18182964 vital JJ B-NP O
18 712 717 18182964 signs NNS I-NP O
19 717 718 18182964 . . O O

1 719 726 18182964 RESULTS NNS B-NP O
2 726 727 18182964 : : O O
3 728 733 18182964 There EX B-NP O
4 734 738 18182964 were VBD B-VP O
5 739 743 18182964 more JJR B-NP O
6 744 753 18182964 incidents NNS I-NP O
7 754 756 18182964 of IN B-PP O
8 757 768 18182964 bradycardia NN B-NP B-Disease
9 769 771 18182964 in IN B-PP O
10 772 780 18182964 subjects NNS B-NP O
11 781 788 18182964 treated VBN B-VP O
12 789 793 18182964 with IN B-PP O
13 794 803 18182964 clonidine NN B-NP B-Chemical
14 804 812 18182964 compared VBN B-PP O
15 813 817 18182964 with IN B-PP O
16 818 823 18182964 those DT B-NP O
17 824 827 18182964 not RB B-VP O
18 828 835 18182964 treated VBN I-VP O
19 836 840 18182964 with IN B-PP O
20 841 850 18182964 clonidine NN B-NP B-Chemical
21 851 852 18182964 ( ( O O
22 852 857 18182964 17.5% CD B-NP O
23 858 864 18182964 versus CC I-NP O
24 865 869 18182964 3.4% CD I-NP O
25 869 870 18182964 ; : O O
26 871 872 18182964 p NN B-NP O
27 873 874 18182964 = SYM B-VP O
28 874 877 18182964 .02 CD B-NP O
29 877 878 18182964 ) ) O O
30 878 879 18182964 , , O O
31 880 883 18182964 but CC O O
32 884 886 18182964 no DT B-NP O
33 887 892 18182964 other JJ I-NP O
34 893 904 18182964 significant JJ I-NP O
35 905 910 18182964 group NN I-NP O
36 911 922 18182964 differences NNS I-NP O
37 923 932 18182964 regarding VBG B-VP O
38 933 950 18182964 electrocardiogram NN B-NP O
39 951 954 18182964 and CC O O
40 955 960 18182964 other JJ B-NP O
41 961 975 18182964 cardiovascular JJ I-NP O
42 976 984 18182964 outcomes NNS I-NP O
43 984 985 18182964 . . O O

1 986 991 18182964 There EX B-NP O
2 992 996 18182964 were VBD B-VP O
3 997 999 18182964 no DT B-NP O
4 1000 1011 18182964 suggestions NNS I-NP O
5 1012 1014 18182964 of IN B-PP O
6 1015 1027 18182964 interactions NNS B-NP O
7 1028 1035 18182964 between IN B-PP O
8 1036 1045 18182964 clonidine NN B-NP B-Chemical
9 1046 1049 18182964 and CC I-NP O
10 1050 1065 18182964 methylphenidate NN I-NP B-Chemical
11 1066 1075 18182964 regarding VBG B-VP O
12 1076 1090 18182964 cardiovascular JJ B-NP O
13 1091 1099 18182964 outcomes NNS I-NP O
14 1099 1100 18182964 . . O O

1 1101 1109 18182964 Moderate JJ B-NP O
2 1110 1112 18182964 or CC I-NP O
3 1113 1119 18182964 severe JJ I-NP O
4 1120 1127 18182964 adverse JJ I-NP O
5 1128 1134 18182964 events NNS I-NP O
6 1135 1139 18182964 were VBD B-VP O
7 1140 1144 18182964 more RBR B-ADJP O
8 1145 1151 18182964 common JJ I-ADJP O
9 1152 1154 18182964 in IN B-PP O
10 1155 1163 18182964 subjects NNS B-NP O
11 1164 1166 18182964 on IN B-PP O
12 1167 1176 18182964 clonidine NN B-NP B-Chemical
13 1177 1178 18182964 ( ( O O
14 1178 1183 18182964 79.4% CD B-NP O
15 1184 1190 18182964 versus CC I-NP O
16 1191 1196 18182964 49.2% CD I-NP O
17 1196 1197 18182964 ; : O O
18 1198 1199 18182964 p NN B-NP O
19 1200 1201 18182964 = SYM B-VP O
20 1201 1206 18182964 .0006 CD B-NP O
21 1206 1207 18182964 ) ) O O
22 1208 1211 18182964 but CC B-VP O
23 1212 1215 18182964 not RB I-VP O
24 1216 1226 18182964 associated VBN I-VP O
25 1227 1231 18182964 with IN B-PP O
26 1232 1238 18182964 higher JJR B-NP O
27 1239 1244 18182964 rates NNS I-NP O
28 1245 1247 18182964 of IN B-PP O
29 1248 1253 18182964 early JJ B-NP O
30 1254 1259 18182964 study NN I-NP O
31 1260 1270 18182964 withdrawal NN I-NP O
32 1270 1271 18182964 . . O O

1 1272 1282 18182964 Drowsiness NN B-NP B-Disease
2 1283 1286 18182964 was VBD B-VP O
3 1287 1293 18182964 common JJ B-ADJP O
4 1294 1296 18182964 on IN B-PP O
5 1297 1306 18182964 clonidine NN B-NP B-Chemical
6 1306 1307 18182964 , , O O
7 1308 1311 18182964 but CC O O
8 1312 1321 18182964 generally RB B-VP O
9 1322 1330 18182964 resolved VBN I-VP O
10 1331 1333 18182964 by IN B-PP O
11 1334 1335 18182964 6 CD B-NP O
12 1336 1338 18182964 to TO I-NP O
13 1339 1340 18182964 8 CD I-NP O
14 1341 1346 18182964 weeks NNS I-NP O
15 1346 1347 18182964 . . O O

1 1348 1359 18182964 CONCLUSIONS NNS B-NP O
2 1359 1360 18182964 : : O O
3 1361 1370 18182964 Clonidine NN B-NP B-Chemical
4 1370 1371 18182964 , , O O
5 1372 1376 18182964 used VBN B-VP O
6 1377 1382 18182964 alone RB B-ADVP O
7 1383 1385 18182964 or CC O O
8 1386 1390 18182964 with IN B-PP O
9 1391 1406 18182964 methylphenidate NN B-NP B-Chemical
10 1406 1407 18182964 , , O O
11 1408 1415 18182964 appears VBZ B-VP O
12 1416 1420 18182964 safe JJ B-ADJP O
13 1421 1424 18182964 and CC O O
14 1425 1429 18182964 well RB B-ADJP O
15 1430 1439 18182964 tolerated VBN I-ADJP O
16 1440 1442 18182964 in IN B-PP O
17 1443 1452 18182964 childhood NN B-NP O
18 1453 1457 18182964 ADHD NN I-NP B-Disease
19 1457 1458 18182964 . . O O

1 1459 1469 18182964 Physicians NNS B-NP O
2 1470 1481 18182964 prescribing VBG B-VP O
3 1482 1491 18182964 clonidine NN B-NP B-Chemical
4 1492 1498 18182964 should MD B-VP O
5 1499 1506 18182964 monitor VB I-VP O
6 1507 1510 18182964 for IN B-PP O
7 1511 1522 18182964 bradycardia NN B-NP B-Disease
8 1523 1526 18182964 and CC I-NP O
9 1527 1533 18182964 advise NN I-NP O
10 1534 1542 18182964 patients NNS I-NP O
11 1543 1548 18182964 about IN B-PP O
12 1549 1552 18182964 the DT B-NP O
13 1553 1557 18182964 high JJ I-NP O
14 1558 1568 18182964 likelihood NN I-NP O
15 1569 1571 18182964 of IN B-PP O
16 1572 1579 18182964 initial JJ B-NP O
17 1580 1590 18182964 drowsiness NN I-NP B-Disease
18 1590 1591 18182964 . . O O

1 0 0 3409645 -DOCSTART- -X- -X- O

1 0 6 3409645 Sexual JJ B-NP B-Disease
2 7 18 3409645 dysfunction NN I-NP I-Disease
3 19 24 3409645 among IN B-PP O
4 25 33 3409645 patients NNS B-NP O
5 34 38 3409645 with IN B-PP O
6 39 48 3409645 arthritis NN B-NP B-Disease
7 48 49 3409645 . . O O
8 50 53 3409645 The DT B-NP O
9 54 66 3409645 relationship NN I-NP O
10 67 69 3409645 of IN B-PP O
11 70 79 3409645 arthritis NN B-NP B-Disease
12 80 83 3409645 and CC O O
13 84 90 3409645 sexual JJ B-NP B-Disease
14 91 102 3409645 dysfunction NN I-NP I-Disease
15 103 106 3409645 was VBD B-VP O
16 107 119 3409645 investigated VBN I-VP O
17 120 125 3409645 among IN B-PP O
18 126 129 3409645 169 CD B-NP O
19 130 138 3409645 patients NNS I-NP O
20 139 143 3409645 with IN B-PP O
21 144 154 3409645 rheumatoid JJ B-NP B-Disease
22 155 164 3409645 arthritis NN I-NP I-Disease
23 164 165 3409645 , , I-NP O
24 166 180 3409645 osteoarthritis NN I-NP B-Disease
25 181 184 3409645 and CC I-NP O
26 185 204 3409645 spondyloarthropathy NN I-NP B-Disease
27 204 205 3409645 , , O O
28 206 209 3409645 130 CD B-NP O
29 210 212 3409645 of IN B-PP O
30 213 217 3409645 whom WP B-NP O
31 218 222 3409645 were VBD B-VP O
32 223 227 3409645 pair NN I-VP O
33 227 228 3409645 - HYPH O O
34 228 235 3409645 matched VBN B-VP O
35 236 238 3409645 to TO B-PP O
36 239 247 3409645 controls NNS B-NP O
37 247 248 3409645 . . O O

1 249 260 3409645 Assessments NNS B-NP O
2 261 263 3409645 of IN B-PP O
3 264 271 3409645 marital JJ B-NP O
4 272 281 3409645 happiness NN I-NP O
5 282 285 3409645 and CC O O
6 286 295 3409645 depressed JJ B-NP B-Disease
7 296 300 3409645 mood NN I-NP I-Disease
8 301 305 3409645 were VBD B-VP O
9 306 310 3409645 also RB I-VP O
10 311 315 3409645 made VBN I-VP O
11 316 321 3409645 using VBG B-VP O
12 322 325 3409645 the DT B-NP O
13 326 329 3409645 CES NN I-NP O
14 329 330 3409645 - HYPH O O
15 330 331 3409645 D NN B-NP O
16 332 335 3409645 and CC O O
17 336 339 3409645 the DT B-NP O
18 340 345 3409645 Azrin NNP I-NP O
19 346 353 3409645 Marital NNP I-NP O
20 354 363 3409645 Happiness NNP I-NP O
21 364 369 3409645 Scale NNP I-NP O
22 370 371 3409645 ( ( O O
23 371 375 3409645 AMHS NNP B-NP O
24 375 376 3409645 ) ) O O
25 376 377 3409645 . . O O

1 378 384 3409645 Sexual JJ B-NP B-Disease
2 385 397 3409645 dysfunctions NNS I-NP I-Disease
3 398 402 3409645 were VBD B-VP O
4 403 408 3409645 found VBN I-VP O
5 409 411 3409645 to TO I-VP O
6 412 414 3409645 be VB I-VP O
7 415 421 3409645 common JJ B-ADJP O
8 422 427 3409645 among IN B-PP O
9 428 436 3409645 patients NNS B-NP O
10 437 440 3409645 and CC I-NP O
11 441 449 3409645 controls NNS I-NP O
12 449 450 3409645 , , O O
13 451 454 3409645 the DT B-NP O
14 455 463 3409645 majority NN I-NP O
15 464 466 3409645 in IN B-PP O
16 467 471 3409645 both DT B-NP O
17 472 478 3409645 groups NNS I-NP O
18 479 488 3409645 reporting VBG B-VP O
19 489 492 3409645 one CD B-NP O
20 493 495 3409645 or CC I-NP O
21 496 500 3409645 more JJR I-NP O
22 501 513 3409645 dysfunctions NNS I-NP O
23 513 514 3409645 . . O O

1 515 524 3409645 Impotence NN B-NP B-Disease
2 525 528 3409645 was VBD B-VP O
3 529 533 3409645 more RBR B-ADJP O
4 534 540 3409645 common JJ I-ADJP O
5 541 546 3409645 among IN B-PP O
6 547 551 3409645 male JJ B-NP O
7 552 560 3409645 patients NNS I-NP O
8 561 565 3409645 than IN B-PP O
9 566 574 3409645 controls NNS B-NP O
10 575 578 3409645 and CC O O
11 579 582 3409645 was VBD B-VP O
12 583 588 3409645 found VBN I-VP O
13 589 591 3409645 to TO I-VP O
14 592 594 3409645 be VB I-VP O
15 595 605 3409645 associated VBN I-VP O
16 606 610 3409645 with IN B-PP O
17 611 613 3409645 co AFX B-NP O
18 613 614 3409645 - HYPH I-NP O
19 614 623 3409645 morbidity NN I-NP O
20 624 627 3409645 and CC O O
21 628 631 3409645 the DT B-NP O
22 632 638 3409645 taking NN I-NP O
23 639 641 3409645 of IN B-PP O
24 642 654 3409645 methotrexate NN B-NP B-Chemical
25 654 655 3409645 . . O O

1 656 665 3409645 Depressed VBN B-NP B-Disease
2 666 670 3409645 mood NN I-NP I-Disease
3 671 674 3409645 was VBD B-VP O
4 675 679 3409645 more RBR B-ADJP O
5 680 686 3409645 common JJ I-ADJP O
6 687 692 3409645 among IN B-PP O
7 693 701 3409645 patients NNS B-NP O
8 702 705 3409645 and CC O O
9 706 709 3409645 was VBD B-VP O
10 710 720 3409645 associated VBN I-VP O
11 721 725 3409645 with IN B-PP O
12 726 733 3409645 certain JJ B-NP O
13 734 740 3409645 sexual JJ I-NP O
14 741 753 3409645 difficulties NNS I-NP O
15 753 754 3409645 , , B-PP O
16 755 758 3409645 but CC I-PP O
17 759 762 3409645 not RB B-PP O
18 763 767 3409645 with IN I-PP O
19 768 777 3409645 impotence NN B-NP B-Disease
20 777 778 3409645 . . O O

1 779 786 3409645 Marital JJ B-NP O
2 787 798 3409645 unhappiness NN I-NP O
3 798 799 3409645 , , O O
4 800 802 3409645 as IN B-SBAR O
5 803 812 3409645 indicated VBN B-VP O
6 813 815 3409645 by IN B-PP O
7 816 820 3409645 AMHS NN B-NP O
8 821 827 3409645 scores NNS I-NP O
9 827 828 3409645 , , O O
10 829 832 3409645 was VBD B-VP O
11 833 836 3409645 not RB I-VP O
12 837 847 3409645 associated VBN I-VP O
13 848 852 3409645 with IN B-PP O
14 853 862 3409645 arthritis NN B-NP B-Disease
15 863 866 3409645 but CC O O
16 867 870 3409645 was VBD B-VP O
17 871 881 3409645 associated VBN I-VP O
18 882 886 3409645 with IN B-PP O
19 887 893 3409645 sexual JJ B-NP B-Disease
20 894 905 3409645 dysfunction NN I-NP I-Disease
21 905 906 3409645 , , O O
22 907 913 3409645 sexual JJ B-NP O
23 914 929 3409645 dissatisfaction NN I-NP O
24 930 933 3409645 and CC O O
25 934 939 3409645 being VBG B-VP O
26 940 946 3409645 female JJ B-ADJP O
27 946 947 3409645 . . O O

1 0 0 8682684 -DOCSTART- -X- -X- O

1 0 13 8682684 Acetaminophen NN B-NP B-Chemical
2 13 14 8682684 - HYPH B-NP O
3 14 21 8682684 induced VBN I-NP O
4 22 33 8682684 hypotension NN I-NP B-Disease
5 33 34 8682684 . . O O
6 35 42 8682684 Through IN B-PP O
7 43 45 8682684 30 CD B-NP O
8 46 51 8682684 years NNS I-NP O
9 52 54 8682684 of IN B-PP O
10 55 65 8682684 widespread JJ B-NP O
11 66 69 8682684 use NN I-NP O
12 69 70 8682684 , , O O
13 71 84 8682684 acetaminophen NN B-NP B-Chemical
14 85 88 8682684 has VBZ B-VP O
15 89 93 8682684 been VBN I-VP O
16 94 99 8682684 shown VBN I-VP O
17 100 102 8682684 to TO I-VP O
18 103 105 8682684 be VB I-VP O
19 106 107 8682684 a DT B-NP O
20 108 118 8682684 remarkably RB I-NP O
21 119 123 8682684 safe JJ I-NP O
22 124 134 8682684 medication NN I-NP O
23 135 137 8682684 in IN B-PP O
24 138 149 8682684 therapeutic JJ B-NP O
25 150 157 8682684 dosages NNS I-NP O
26 157 158 8682684 . . O O

1 159 162 8682684 The DT B-NP O
2 163 172 8682684 potential NN I-NP O
3 173 176 8682684 for IN B-PP O
4 177 190 8682684 acetaminophen NN B-NP B-Chemical
5 191 193 8682684 to TO B-VP O
6 194 201 8682684 produce VB I-VP O
7 202 216 8682684 cardiovascular JJ B-NP B-Disease
8 217 227 8682684 toxicities NNS I-NP I-Disease
9 228 230 8682684 is VBZ B-VP O
10 231 235 8682684 very RB B-ADJP O
11 236 239 8682684 low JJ I-ADJP O
12 239 240 8682684 . . O O

1 241 248 8682684 However RB B-ADVP O
2 248 249 8682684 , , O O
3 250 263 8682684 acetaminophen NN B-NP B-Chemical
4 264 267 8682684 has VBZ B-VP O
5 268 272 8682684 been VBN I-VP O
6 273 285 8682684 demonstrated VBN I-VP O
7 286 288 8682684 to TO I-VP O
8 289 296 8682684 produce VB I-VP O
9 297 305 8682684 symptoms NNS B-NP O
10 306 308 8682684 of IN B-PP O
11 309 320 8682684 anaphylaxis NN B-NP B-Disease
12 320 321 8682684 , , O O
13 322 331 8682684 including VBG B-PP O
14 332 343 8682684 hypotension NN B-NP B-Disease
15 343 344 8682684 , , O O
16 345 347 8682684 in IN B-PP O
17 348 357 8682684 sensitive JJ B-NP O
18 358 369 8682684 individuals NNS I-NP O
19 369 370 8682684 . . O O

1 371 375 8682684 This DT B-NP O
2 376 383 8682684 article NN I-NP O
3 384 393 8682684 describes VBZ B-VP O
4 394 397 8682684 two CD B-NP O
5 398 408 8682684 critically RB I-NP B-Disease
6 409 412 8682684 ill JJ I-NP I-Disease
7 413 421 8682684 patients NNS I-NP O
8 422 424 8682684 in IN B-PP O
9 425 429 8682684 whom WP B-NP O
10 430 439 8682684 transient JJ B-NP O
11 440 448 8682684 episodes NNS I-NP O
12 449 451 8682684 of IN B-PP O
13 452 463 8682684 hypotension NN B-NP B-Disease
14 464 476 8682684 reproducibly RB B-ADVP O
15 477 486 8682684 developed VBD B-VP O
16 487 492 8682684 after IN B-PP O
17 493 507 8682684 administration NN B-NP O
18 508 510 8682684 of IN B-PP O
19 511 524 8682684 acetaminophen NN B-NP B-Chemical
20 524 525 8682684 . . O O

1 526 531 8682684 Other JJ B-NP O
2 532 540 8682684 symptoms NNS I-NP O
3 541 543 8682684 of IN B-PP O
4 544 552 8682684 allergic JJ B-NP B-Disease
5 553 562 8682684 reactions NNS I-NP I-Disease
6 563 567 8682684 were VBD B-VP O
7 568 571 8682684 not RB O O
8 572 582 8682684 clinically RB B-ADJP O
9 583 593 8682684 detectable JJ I-ADJP O
10 593 594 8682684 . . O O

1 595 598 8682684 The DT B-NP O
2 599 610 8682684 hypotensive JJ I-NP B-Disease
3 611 619 8682684 episodes NNS I-NP O
4 620 624 8682684 were VBD B-VP O
5 625 631 8682684 severe JJ B-ADJP O
6 632 638 8682684 enough RB I-ADJP O
7 639 641 8682684 to TO B-VP O
8 642 649 8682684 require VB I-VP O
9 650 661 8682684 vasopressor NN B-NP O
10 662 676 8682684 administration NN I-NP O
11 676 677 8682684 . . O O

1 678 681 8682684 The DT B-NP O
2 682 689 8682684 reports NNS I-NP O
3 690 700 8682684 illustrate VBP B-VP O
4 701 704 8682684 the DT B-NP O
5 705 709 8682684 need NN I-NP O
6 710 713 8682684 for IN B-SBAR O
7 714 724 8682684 clinicians NNS B-NP O
8 725 727 8682684 to TO B-VP O
9 728 736 8682684 consider VB I-VP O
10 737 750 8682684 acetaminophen NN B-NP B-Chemical
11 751 753 8682684 in IN B-PP O
12 754 762 8682684 patients NNS B-NP O
13 763 767 8682684 with IN B-PP O
14 768 779 8682684 hypotension NN B-NP B-Disease
15 780 782 8682684 of IN B-PP O
16 783 790 8682684 unknown JJ B-NP O
17 791 797 8682684 origin NN I-NP O
18 797 798 8682684 . . O O

1 0 0 11752354 -DOCSTART- -X- -X- O

1 0 4 11752354 Oral JJ B-NP B-Chemical
2 5 19 11752354 contraceptives NNS I-NP I-Chemical
3 20 23 11752354 and CC O O
4 24 27 11752354 the DT B-NP O
5 28 32 11752354 risk NN I-NP O
6 33 35 11752354 of IN B-PP O
7 36 46 11752354 myocardial JJ B-NP B-Disease
8 47 57 11752354 infarction NN I-NP I-Disease
9 57 58 11752354 . . I-NP O
10 59 69 11752354 BACKGROUND NN I-NP O
11 69 70 11752354 : : O O
12 71 73 11752354 An DT B-NP O
13 74 85 11752354 association NN I-NP O
14 86 93 11752354 between IN B-PP O
15 94 97 11752354 the DT B-NP O
16 98 101 11752354 use NN I-NP O
17 102 104 11752354 of IN B-PP O
18 105 109 11752354 oral JJ B-NP B-Chemical
19 110 124 11752354 contraceptives NNS I-NP I-Chemical
20 125 128 11752354 and CC O O
21 129 132 11752354 the DT B-NP O
22 133 137 11752354 risk NN I-NP O
23 138 140 11752354 of IN B-PP O
24 141 151 11752354 myocardial JJ B-NP B-Disease
25 152 162 11752354 infarction NN I-NP I-Disease
26 163 166 11752354 has VBZ B-VP O
27 167 171 11752354 been VBN I-VP O
28 172 177 11752354 found VBN I-VP O
29 178 180 11752354 in IN B-PP O
30 181 185 11752354 some DT B-NP O
31 185 186 11752354 , , O O
32 187 190 11752354 but CC O O
33 191 194 11752354 not RB B-NP O
34 195 198 11752354 all DT I-NP O
35 198 199 11752354 , , O O
36 200 207 11752354 studies NNS B-NP O
37 207 208 11752354 . . O O

1 209 211 11752354 We PRP B-NP O
2 212 224 11752354 investigated VBD B-VP O
3 225 229 11752354 this DT B-NP O
4 230 241 11752354 association NN I-NP O
5 241 242 11752354 , , O O
6 243 252 11752354 according VBG B-PP O
7 253 255 11752354 to TO B-PP O
8 256 259 11752354 the DT B-NP O
9 260 264 11752354 type NN I-NP O
10 265 267 11752354 of IN B-PP O
11 268 279 11752354 progestagen NN B-NP B-Chemical
12 280 288 11752354 included VBN B-VP O
13 289 291 11752354 in IN B-PP O
14 292 297 11752354 third JJ B-NP O
15 297 298 11752354 - HYPH I-NP O
16 298 308 11752354 generation NN I-NP O
17 309 310 11752354 ( ( O O
18 310 314 11752354 i.e. FW B-NP O
19 314 315 11752354 , , O O
20 316 327 11752354 desogestrel NN B-NP B-Chemical
21 328 330 11752354 or CC O O
22 331 340 11752354 gestodene NN B-NP B-Chemical
23 340 341 11752354 ) ) O O
24 342 345 11752354 and CC O O
25 346 352 11752354 second JJ B-NP O
26 352 353 11752354 - HYPH I-NP O
27 353 363 11752354 generation NN I-NP O
28 364 365 11752354 ( ( O O
29 365 369 11752354 i.e. FW B-NP O
30 369 370 11752354 , , O O
31 371 385 11752354 levonorgestrel NN B-NP B-Chemical
32 385 386 11752354 ) ) O O
33 387 391 11752354 oral JJ B-NP B-Chemical
34 392 406 11752354 contraceptives NNS I-NP I-Chemical
35 406 407 11752354 , , O O
36 408 411 11752354 the DT B-NP O
37 412 416 11752354 dose NN I-NP O
38 417 419 11752354 of IN B-PP O
39 420 428 11752354 estrogen NN B-NP B-Chemical
40 428 429 11752354 , , O O
41 430 433 11752354 and CC O O
42 434 437 11752354 the DT B-NP O
43 438 446 11752354 presence NN I-NP O
44 447 449 11752354 or CC I-NP O
45 450 457 11752354 absence NN I-NP O
46 458 460 11752354 of IN B-PP O
47 461 474 11752354 prothrombotic JJ B-NP O
48 475 484 11752354 mutations NNS I-NP O
49 485 492 11752354 METHODS NNS I-NP O
50 492 493 11752354 : : O O
51 494 496 11752354 In IN B-PP O
52 497 498 11752354 a DT B-NP O
53 499 509 11752354 nationwide JJ I-NP O
54 509 510 11752354 , , I-NP O
55 511 521 11752354 population NN I-NP O
56 521 522 11752354 - HYPH I-NP O
57 522 527 11752354 based VBN B-VP O
58 527 528 11752354 , , O O
59 529 533 11752354 case NN B-NP O
60 533 534 11752354 - HYPH I-NP O
61 534 541 11752354 control NN I-NP O
62 542 547 11752354 study NN I-NP O
63 547 548 11752354 , , O O
64 549 551 11752354 we PRP B-NP O
65 552 562 11752354 identified VBD B-VP O
66 563 566 11752354 and CC O O
67 567 575 11752354 enrolled VBD B-VP O
68 576 579 11752354 248 CD B-NP O
69 580 585 11752354 women NNS I-NP O
70 586 588 11752354 18 CD B-NP O
71 589 596 11752354 through IN B-PP O
72 597 599 11752354 49 CD B-NP O
73 600 605 11752354 years NNS I-NP O
74 606 608 11752354 of IN B-PP O
75 609 612 11752354 age NN B-NP O
76 613 616 11752354 who WP B-NP O
77 617 620 11752354 had VBD B-VP O
78 621 624 11752354 had VBN I-VP O
79 625 626 11752354 a DT B-NP O
80 627 632 11752354 first JJ I-NP O
81 633 643 11752354 myocardial JJ I-NP B-Disease
82 644 654 11752354 infarction NN I-NP I-Disease
83 655 662 11752354 between IN B-PP O
84 663 667 11752354 1990 CD B-NP O
85 668 671 11752354 and CC I-NP O
86 672 676 11752354 1995 CD I-NP O
87 677 680 11752354 and CC I-NP O
88 681 684 11752354 925 CD I-NP O
89 685 692 11752354 control NN I-NP O
90 693 698 11752354 women NNS I-NP O
91 699 702 11752354 who WP B-NP O
92 703 706 11752354 had VBD B-VP O
93 707 710 11752354 not RB I-VP O
94 711 714 11752354 had VBN I-VP O
95 715 716 11752354 a DT B-NP O
96 717 727 11752354 myocardial JJ I-NP B-Disease
97 728 738 11752354 infarction NN I-NP I-Disease
98 739 742 11752354 and CC O O
99 743 746 11752354 who WP B-NP O
100 747 751 11752354 were VBD B-VP O
101 752 759 11752354 matched VBN I-VP O
102 760 763 11752354 for IN B-PP O
103 764 767 11752354 age NN B-NP O
104 767 768 11752354 , , O O
105 769 777 11752354 calendar NN B-NP O
106 778 782 11752354 year NN I-NP O
107 783 785 11752354 of IN B-PP O
108 786 789 11752354 the DT B-NP O
109 790 795 11752354 index NN I-NP O
110 796 801 11752354 event NN I-NP O
111 801 802 11752354 , , O O
112 803 806 11752354 and CC O O
113 807 811 11752354 area NN B-NP O
114 812 814 11752354 of IN B-PP O
115 815 824 11752354 residence NN B-NP O
116 824 825 11752354 . . O O

1 826 834 11752354 Subjects NNS B-NP O
2 835 843 11752354 supplied VBD B-VP O
3 844 855 11752354 information NN B-NP O
4 856 858 11752354 on IN B-PP O
5 859 863 11752354 oral JJ B-NP B-Chemical
6 863 864 11752354 - HYPH I-NP I-Chemical
7 864 877 11752354 contraceptive JJ I-NP I-Chemical
8 878 881 11752354 use NN I-NP O
9 882 885 11752354 and CC O O
10 886 891 11752354 major JJ B-NP O
11 892 906 11752354 cardiovascular JJ I-NP O
12 907 911 11752354 risk NN I-NP O
13 912 919 11752354 factors NNS I-NP O
14 919 920 11752354 . . O O

1 921 923 11752354 An DT B-NP O
2 924 932 11752354 analysis NN I-NP O
3 933 936 11752354 for IN B-PP O
4 937 943 11752354 factor NN B-NP O
5 944 945 11752354 V NNP I-NP O
6 946 952 11752354 Leiden NNP I-NP O
7 953 956 11752354 and CC O O
8 957 960 11752354 the DT B-NP O
9 961 968 11752354 G20210A NN I-NP O
10 969 977 11752354 mutation NN I-NP O
11 978 980 11752354 in IN B-PP O
12 981 984 11752354 the DT B-NP O
13 985 996 11752354 prothrombin NN I-NP O
14 997 1001 11752354 gene NN I-NP O
15 1002 1005 11752354 was VBD B-VP O
16 1006 1015 11752354 conducted VBN I-VP O
17 1016 1018 11752354 in IN B-PP O
18 1019 1022 11752354 217 CD B-NP O
19 1023 1031 11752354 patients NNS I-NP O
20 1032 1035 11752354 and CC O O
21 1036 1039 11752354 763 CD B-NP O
22 1040 1048 11752354 controls NNS I-NP O
23 1049 1056 11752354 RESULTS NNS I-NP O
24 1056 1057 11752354 : : O O
25 1058 1061 11752354 The DT B-NP O
26 1062 1066 11752354 odds NNS I-NP O
27 1067 1072 11752354 ratio NN I-NP O
28 1073 1076 11752354 for IN B-PP O
29 1077 1087 11752354 myocardial JJ B-NP B-Disease
30 1088 1098 11752354 infarction NN I-NP I-Disease
31 1099 1104 11752354 among IN B-PP O
32 1105 1110 11752354 women NNS B-NP O
33 1111 1114 11752354 who WP B-NP O
34 1115 1119 11752354 used VBD B-VP O
35 1120 1123 11752354 any DT B-NP O
36 1124 1128 11752354 type NN I-NP O
37 1129 1131 11752354 of IN B-PP O
38 1132 1140 11752354 combined JJ B-NP O
39 1141 1145 11752354 oral JJ I-NP B-Chemical
40 1146 1159 11752354 contraceptive NN I-NP I-Chemical
41 1159 1160 11752354 , , O O
42 1161 1163 11752354 as IN B-SBAR O
43 1164 1172 11752354 compared VBN B-PP O
44 1173 1177 11752354 with IN B-PP O
45 1178 1186 11752354 nonusers NNS B-NP O
46 1186 1187 11752354 , , O O
47 1188 1191 11752354 was VBD B-VP O
48 1192 1195 11752354 2.0 CD B-NP O
49 1196 1197 11752354 ( ( O O
50 1197 1199 11752354 95 CD B-NP O
51 1200 1207 11752354 percent NN I-NP O
52 1208 1218 11752354 confidence NN I-NP O
53 1219 1227 11752354 interval NN I-NP O
54 1227 1228 11752354 , , O O
55 1229 1232 11752354 1.5 CD B-NP O
56 1233 1235 11752354 to TO B-PP O
57 1236 1239 11752354 2.8 CD B-NP O
58 1239 1240 11752354 ) ) O O
59 1240 1241 11752354 . . O O

1 1242 1245 11752354 The DT B-NP O
2 1246 1254 11752354 adjusted VBN I-NP O
3 1255 1259 11752354 odds NNS I-NP O
4 1260 1265 11752354 ratio NN I-NP O
5 1266 1269 11752354 was VBD B-VP O
6 1270 1273 11752354 2.5 CD B-NP O
7 1274 1275 11752354 ( ( O O
8 1275 1277 11752354 95 CD B-NP O
9 1278 1285 11752354 percent NN I-NP O
10 1286 1296 11752354 confidence NN I-NP O
11 1297 1305 11752354 interval NN I-NP O
12 1305 1306 11752354 , , O O
13 1307 1310 11752354 1.5 CD B-NP O
14 1311 1313 11752354 to TO B-PP O
15 1314 1317 11752354 4.1 CD B-NP O
16 1317 1318 11752354 ) ) O O
17 1319 1324 11752354 among IN B-PP O
18 1325 1330 11752354 women NNS B-NP O
19 1331 1334 11752354 who WP B-NP O
20 1335 1339 11752354 used VBD B-VP O
21 1340 1346 11752354 second JJ B-NP O
22 1346 1347 11752354 - HYPH I-NP O
23 1347 1357 11752354 generation NN I-NP O
24 1358 1362 11752354 oral JJ I-NP B-Chemical
25 1363 1377 11752354 contraceptives NNS I-NP I-Chemical
26 1378 1381 11752354 and CC O O
27 1382 1385 11752354 1.3 CD B-NP O
28 1386 1387 11752354 ( ( O O
29 1387 1389 11752354 95 CD B-NP O
30 1390 1397 11752354 percent NN I-NP O
31 1398 1408 11752354 confidence NN I-NP O
32 1409 1417 11752354 interval NN I-NP O
33 1417 1418 11752354 , , O O
34 1419 1422 11752354 0.7 CD B-NP O
35 1423 1425 11752354 to TO B-PP O
36 1426 1429 11752354 2.5 CD B-NP O
37 1429 1430 11752354 ) ) O O
38 1431 1436 11752354 among IN B-PP O
39 1437 1442 11752354 those DT B-NP O
40 1443 1446 11752354 who WP B-NP O
41 1447 1451 11752354 used VBD B-VP O
42 1452 1457 11752354 third JJ B-NP O
43 1457 1458 11752354 - HYPH I-NP O
44 1458 1468 11752354 generation NN I-NP O
45 1469 1473 11752354 oral JJ I-NP B-Chemical
46 1474 1488 11752354 contraceptives NNS I-NP I-Chemical
47 1488 1489 11752354 . . O O

1 1490 1495 11752354 Among IN B-PP O
2 1496 1501 11752354 women NNS B-NP O
3 1502 1505 11752354 who WP B-NP O
4 1506 1510 11752354 used VBD B-VP O
5 1511 1515 11752354 oral JJ B-NP B-Chemical
6 1516 1530 11752354 contraceptives NNS I-NP I-Chemical
7 1530 1531 11752354 , , O O
8 1532 1535 11752354 the DT B-NP O
9 1536 1540 11752354 odds NNS I-NP O
10 1541 1546 11752354 ratio NN I-NP O
11 1547 1550 11752354 was VBD B-VP O
12 1551 1554 11752354 2.1 CD B-NP O
13 1555 1556 11752354 ( ( O O
14 1556 1558 11752354 95 CD B-NP O
15 1559 1566 11752354 percent NN I-NP O
16 1567 1577 11752354 confidence NN I-NP O
17 1578 1586 11752354 interval NN I-NP O
18 1586 1587 11752354 , , O O
19 1588 1591 11752354 1.5 CD B-NP O
20 1592 1594 11752354 to TO B-PP O
21 1595 1598 11752354 3.0 CD B-NP O
22 1598 1599 11752354 ) ) O O
23 1600 1603 11752354 for IN B-PP O
24 1604 1609 11752354 those DT B-NP O
25 1610 1617 11752354 without IN B-PP O
26 1618 1619 11752354 a DT B-NP O
27 1620 1633 11752354 prothrombotic JJ I-NP O
28 1634 1642 11752354 mutation NN I-NP O
29 1643 1646 11752354 and CC O O
30 1647 1650 11752354 1.9 CD B-NP O
31 1651 1652 11752354 ( ( O O
32 1652 1654 11752354 95 CD B-NP O
33 1655 1662 11752354 percent NN I-NP O
34 1663 1673 11752354 confidence NN I-NP O
35 1674 1682 11752354 interval NN I-NP O
36 1682 1683 11752354 , , O O
37 1684 1687 11752354 0.6 CD B-NP O
38 1688 1690 11752354 to TO B-PP O
39 1691 1694 11752354 5.5 CD B-NP O
40 1694 1695 11752354 ) ) O O
41 1696 1699 11752354 for IN B-PP O
42 1700 1705 11752354 those DT B-NP O
43 1706 1710 11752354 with IN B-PP O
44 1711 1712 11752354 a DT B-NP O
45 1713 1721 11752354 mutation NN I-NP O
46 1722 1733 11752354 CONCLUSIONS NNS I-NP O
47 1733 1734 11752354 : : O O
48 1735 1738 11752354 The DT B-NP O
49 1739 1743 11752354 risk NN I-NP O
50 1744 1746 11752354 of IN B-PP O
51 1747 1757 11752354 myocardial JJ B-NP B-Disease
52 1758 1768 11752354 infarction NN I-NP I-Disease
53 1769 1772 11752354 was VBD B-VP O
54 1773 1782 11752354 increased VBN I-VP O
55 1783 1788 11752354 among IN B-PP O
56 1789 1794 11752354 women NNS B-NP O
57 1795 1798 11752354 who WP B-NP O
58 1799 1803 11752354 used VBD B-VP O
59 1804 1810 11752354 second JJ B-NP O
60 1810 1811 11752354 - HYPH I-NP O
61 1811 1821 11752354 generation NN I-NP O
62 1822 1826 11752354 oral JJ I-NP B-Chemical
63 1827 1841 11752354 contraceptives NNS I-NP I-Chemical
64 1841 1842 11752354 . . O O

1 1843 1846 11752354 The DT B-NP O
2 1847 1854 11752354 results NNS I-NP O
3 1855 1859 11752354 with IN B-PP O
4 1860 1867 11752354 respect NN B-NP O
5 1868 1870 11752354 to TO B-PP O
6 1871 1874 11752354 the DT B-NP O
7 1875 1878 11752354 use NN I-NP O
8 1879 1881 11752354 of IN B-PP O
9 1882 1887 11752354 third JJ B-NP O
10 1887 1888 11752354 - HYPH I-NP O
11 1888 1898 11752354 generation NN I-NP O
12 1899 1903 11752354 oral JJ I-NP B-Chemical
13 1904 1918 11752354 contraceptives NNS I-NP I-Chemical
14 1919 1923 11752354 were VBD B-VP O
15 1924 1936 11752354 inconclusive JJ B-ADJP O
16 1937 1940 11752354 but CC O O
17 1941 1950 11752354 suggested VBD B-VP O
18 1951 1955 11752354 that IN B-SBAR O
19 1956 1959 11752354 the DT B-NP O
20 1960 1964 11752354 risk NN I-NP O
21 1965 1968 11752354 was VBD B-VP O
22 1969 1974 11752354 lower JJR B-ADJP O
23 1975 1979 11752354 than IN B-PP O
24 1980 1983 11752354 the DT B-NP O
25 1984 1988 11752354 risk NN I-NP O
26 1989 1999 11752354 associated VBN B-VP O
27 2000 2004 11752354 with IN B-PP O
28 2005 2011 11752354 second JJ B-NP O
29 2011 2012 11752354 - HYPH I-NP O
30 2012 2022 11752354 generation NN I-NP O
31 2023 2027 11752354 oral JJ I-NP B-Chemical
32 2028 2042 11752354 contraceptives NNS I-NP I-Chemical
33 2042 2043 11752354 . . O O

1 2044 2047 11752354 The DT B-NP O
2 2048 2052 11752354 risk NN I-NP O
3 2053 2055 11752354 of IN B-PP O
4 2056 2066 11752354 myocardial JJ B-NP B-Disease
5 2067 2077 11752354 infarction NN I-NP I-Disease
6 2078 2081 11752354 was VBD B-VP O
7 2082 2089 11752354 similar JJ B-ADJP O
8 2090 2095 11752354 among IN B-PP O
9 2096 2101 11752354 women NNS B-NP O
10 2102 2105 11752354 who WP B-NP O
11 2106 2110 11752354 used VBD B-VP O
12 2111 2115 11752354 oral JJ B-NP B-Chemical
13 2116 2130 11752354 contraceptives NNS I-NP I-Chemical
14 2131 2138 11752354 whether IN B-SBAR O
15 2139 2141 11752354 or CC O O
16 2142 2145 11752354 not RB O O
17 2146 2150 11752354 they PRP B-NP O
18 2151 2154 11752354 had VBD B-VP O
19 2155 2156 11752354 a DT B-NP O
20 2157 2170 11752354 prothrombotic JJ I-NP O
21 2171 2179 11752354 mutation NN I-NP O
22 2179 2180 11752354 . . O O

1 0 0 18821488 -DOCSTART- -X- -X- O

1 0 8 18821488 Toxicity NN B-NP B-Disease
2 9 11 18821488 in IN B-PP O
3 12 18 18821488 rhesus NN B-NP O
4 19 26 18821488 monkeys NNS I-NP O
5 27 36 18821488 following VBG B-PP O
6 37 51 18821488 administration NN B-NP O
7 52 54 18821488 of IN B-PP O
8 55 58 18821488 the DT B-NP O
9 59 60 18821488 8 CD I-NP B-Chemical
10 60 61 18821488 - HYPH I-NP I-Chemical
11 61 75 18821488 aminoquinoline NN I-NP I-Chemical
12 76 77 18821488 8 CD I-NP B-Chemical
13 77 78 18821488 - HYPH I-NP I-Chemical
14 78 81 18821488 [(4 CD I-NP I-Chemical
15 81 82 18821488 - HYPH I-NP I-Chemical
16 82 87 18821488 amino JJ I-NP I-Chemical
17 87 88 18821488 - HYPH I-NP I-Chemical
18 88 89 18821488 l NN I-NP I-Chemical
19 89 90 18821488 - HYPH B-NP I-Chemical
20 90 108 18821488 methylbutyl)amino] NN I-NP I-Chemical
21 108 109 18821488 - HYPH B-NP I-Chemical
22 110 111 18821488 5 CD I-NP I-Chemical
23 111 112 18821488 - HYPH I-NP I-Chemical
24 112 114 18821488 (l NN I-NP I-Chemical
25 114 115 18821488 - HYPH B-NP I-Chemical
26 115 124 18821488 hexyloxy) NN I-NP I-Chemical
27 124 125 18821488 - HYPH B-NP I-Chemical
28 125 126 18821488 6 CD I-NP I-Chemical
29 126 127 18821488 - HYPH I-NP I-Chemical
30 127 134 18821488 methoxy NN I-NP I-Chemical
31 134 135 18821488 - HYPH I-NP I-Chemical
32 135 136 18821488 4 CD I-NP I-Chemical
33 136 137 18821488 - HYPH I-NP I-Chemical
34 137 152 18821488 methylquinoline NN I-NP I-Chemical
35 153 154 18821488 ( ( O O
36 154 162 18821488 WR242511 NN B-NP B-Chemical
37 162 163 18821488 ) ) O O
38 163 164 18821488 . . O O
39 165 177 18821488 INTRODUCTION NN B-NP O
40 177 178 18821488 : : O O
41 179 183 18821488 Many JJ B-NP O
42 184 194 18821488 substances NNS I-NP O
43 195 199 18821488 that WDT B-NP O
44 200 204 18821488 form VBP B-VP O
45 205 218 18821488 methemoglobin NN B-NP O
46 219 220 18821488 ( ( O O
47 220 223 18821488 MHb NN B-NP O
48 223 224 18821488 ) ) O O
49 225 236 18821488 effectively RB B-VP O
50 237 244 18821488 counter VBP I-VP O
51 245 252 18821488 cyanide NN B-NP O
52 253 254 18821488 ( ( O O
53 254 256 18821488 CN NN B-NP O
54 256 257 18821488 ) ) O O
55 258 266 18821488 toxicity NN B-NP B-Disease
56 266 267 18821488 . . O O

1 268 276 18821488 Although IN B-SBAR O
2 277 280 18821488 MHb NN B-NP O
3 281 288 18821488 formers NNS I-NP O
4 289 292 18821488 are VBP B-VP O
5 293 302 18821488 generally RB I-VP O
6 303 310 18821488 applied VBN I-VP O
7 311 313 18821488 as IN B-PP O
8 314 324 18821488 treatments NNS B-NP O
9 325 328 18821488 for IN B-PP O
10 329 331 18821488 CN NN B-NP O
11 332 341 18821488 poisoning NN I-NP B-Disease
12 341 342 18821488 , , O O
13 343 345 18821488 it PRP B-NP O
14 346 349 18821488 has VBZ B-VP O
15 350 354 18821488 been VBN I-VP O
16 355 363 18821488 proposed VBN I-VP O
17 364 368 18821488 that IN B-SBAR O
18 369 370 18821488 a DT B-NP O
19 371 377 18821488 stable JJ I-NP O
20 377 378 18821488 , , I-NP O
21 379 383 18821488 long JJ I-NP O
22 383 384 18821488 - HYPH I-NP O
23 384 390 18821488 acting VBG I-NP O
24 391 394 18821488 MHb NN I-NP O
25 395 401 18821488 former JJ B-ADJP O
26 402 407 18821488 could MD B-VP O
27 408 413 18821488 serve VB I-VP O
28 414 416 18821488 as IN B-PP O
29 417 418 18821488 a DT B-NP O
30 419 421 18821488 CN NN I-NP O
31 422 434 18821488 pretreatment NN I-NP O
32 434 435 18821488 . . O O

1 436 441 18821488 Using VBG B-VP O
2 442 446 18821488 this DT B-NP O
3 447 456 18821488 rationale NN I-NP O
4 456 457 18821488 , , O O
5 458 461 18821488 the DT B-NP O
6 462 463 18821488 8 CD I-NP B-Chemical
7 463 464 18821488 - HYPH I-NP I-Chemical
8 464 478 18821488 aminoquinoline NN I-NP I-Chemical
9 479 487 18821488 WR242511 NN I-NP B-Chemical
10 487 488 18821488 , , O O
11 489 490 18821488 a DT B-NP O
12 491 497 18821488 potent JJ I-NP O
13 498 502 18821488 long JJ I-NP O
14 502 503 18821488 - HYPH I-NP O
15 503 510 18821488 lasting VBG B-VP O
16 511 514 18821488 MHb NN B-NP O
17 515 521 18821488 former JJ B-ADJP O
18 522 524 18821488 in IN B-PP O
19 525 532 18821488 rodents NNS B-NP O
20 533 536 18821488 and CC O O
21 537 543 18821488 beagle NN B-NP O
22 544 548 18821488 dogs NNS I-NP O
23 548 549 18821488 , , O O
24 550 553 18821488 was VBD B-VP O
25 554 561 18821488 studied VBN I-VP O
26 562 564 18821488 in IN B-PP O
27 565 568 18821488 the DT B-NP O
28 569 575 18821488 rhesus NN I-NP O
29 576 582 18821488 monkey NN I-NP O
30 583 586 18821488 for IN B-PP O
31 587 595 18821488 advanced VBN B-NP O
32 596 607 18821488 development NN I-NP O
33 608 610 18821488 as IN B-PP O
34 611 612 18821488 a DT B-NP O
35 613 622 18821488 potential JJ I-NP O
36 623 625 18821488 CN NN I-NP O
37 626 638 18821488 pretreatment NN I-NP O
38 638 639 18821488 . . O O

1 640 647 18821488 METHODS NNS B-NP O
2 647 648 18821488 : : O O
3 649 651 18821488 In IN B-PP O
4 652 656 18821488 this DT B-NP O
5 657 662 18821488 study NN I-NP O
6 662 663 18821488 , , O O
7 664 672 18821488 WR242511 NN B-NP B-Chemical
8 673 676 18821488 was VBD B-VP O
9 677 689 18821488 administered VBN I-VP O
10 690 703 18821488 intravenously RB B-NP O
11 704 708 18821488 (IV) NN I-NP O
12 709 711 18821488 in IN B-PP O
13 712 713 18821488 2 CD B-NP O
14 714 720 18821488 female JJ I-NP O
15 721 724 18821488 and CC O O
16 725 726 18821488 4 CD B-NP O
17 727 731 18821488 male JJ I-NP O
18 732 738 18821488 rhesus NN I-NP O
19 739 746 18821488 monkeys NNS I-NP O
20 747 749 18821488 in IN B-PP O
21 750 755 18821488 doses NNS B-NP O
22 756 758 18821488 of IN B-PP O
23 759 762 18821488 3.5 CD B-NP O
24 763 766 18821488 and CC O O
25 766 767 18821488 / SYM B-NP O
26 767 769 18821488 or CC O O
27 770 773 18821488 7.0 CD B-NP O
28 774 776 18821488 mg NN I-NP O
29 776 777 18821488 / SYM B-NP O
30 777 779 18821488 kg NN I-NP O
31 779 780 18821488 ; : O O
32 781 782 18821488 a DT B-NP O
33 783 789 18821488 single JJ I-NP O
34 790 794 18821488 male NN I-NP O
35 795 799 18821488 also RB B-ADVP O
36 800 808 18821488 received VBD B-VP O
37 809 817 18821488 WR242511 NN B-NP B-Chemical
38 818 824 18821488 orally RB B-ADVP O
39 825 826 18821488 ( ( O O
40 826 828 18821488 PO NN B-NP O
41 828 829 18821488 ) ) O O
42 830 832 18821488 at IN B-PP O
43 833 836 18821488 7.0 CD B-NP O
44 837 839 18821488 mg NN I-NP O
45 839 840 18821488 / SYM B-NP O
46 840 842 18821488 kg NN I-NP O
47 842 843 18821488 . . O O

1 844 850 18821488 Health NNP B-NP O
2 851 857 18821488 status NN I-NP O
3 858 861 18821488 and CC I-NP O
4 862 865 18821488 MHb NN I-NP O
5 866 872 18821488 levels NNS I-NP O
6 873 877 18821488 were VBD B-VP O
7 878 887 18821488 monitored VBN I-VP O
8 888 897 18821488 following VBG B-PP O
9 898 906 18821488 exposure NN B-NP O
10 906 907 18821488 . . O O

1 908 915 18821488 RESULTS NNS B-NP O
2 915 916 18821488 : : O O
3 917 920 18821488 The DT B-NP O
4 921 929 18821488 selected VBN I-NP O
5 930 935 18821488 doses NNS I-NP O
6 936 938 18821488 of IN B-PP O
7 939 947 18821488 WR242511 NN B-NP B-Chemical
8 947 948 18821488 , , O O
9 949 954 18821488 which WDT B-NP O
10 955 963 18821488 produced VBD B-VP O
11 964 975 18821488 significant JJ B-NP O
12 976 993 18821488 methemoglobinemia NN I-NP B-Disease
13 994 996 18821488 in IN B-PP O
14 997 1003 18821488 beagle NN B-NP O
15 1004 1008 18821488 dogs NNS I-NP O
16 1009 1011 18821488 in IN B-PP O
17 1012 1019 18821488 earlier JJR B-NP O
18 1020 1027 18821488 studies NNS I-NP O
19 1028 1037 18821488 conducted VBN B-VP O
20 1038 1047 18821488 elsewhere RB B-ADVP O
21 1047 1048 18821488 , , O O
22 1049 1057 18821488 produced VBD B-VP O
23 1058 1062 18821488 very RB B-NP O
24 1063 1069 18821488 little JJ I-NP O
25 1070 1073 18821488 MHb NN I-NP O
26 1074 1075 18821488 ( ( O O
27 1075 1079 18821488 mean NN B-NP O
28 1080 1081 18821488 < SYM O O
29 1082 1086 18821488 2.0% CD B-NP O
30 1086 1087 18821488 ) ) O O
31 1088 1090 18821488 in IN B-PP O
32 1091 1094 18821488 the DT B-NP O
33 1095 1101 18821488 rhesus NN I-NP O
34 1102 1108 18821488 monkey NN I-NP O
35 1108 1109 18821488 . . O O

1 1110 1121 18821488 Furthermore RB B-ADVP O
2 1121 1122 18821488 , , O O
3 1123 1132 18821488 transient JJ B-NP O
4 1133 1147 18821488 hemoglobinuria NN I-NP B-Disease
5 1148 1151 18821488 was VBD B-VP O
6 1152 1157 18821488 noted VBN I-VP O
7 1158 1171 18821488 approximately RB B-NP O
8 1172 1174 18821488 60 CD I-NP O
9 1175 1182 18821488 minutes NNS I-NP O
10 1183 1196 18821488 postinjection NN I-NP O
11 1197 1199 18821488 of IN B-PP O
12 1200 1208 18821488 WR242511 NN B-NP B-Chemical
13 1209 1210 18821488 ( ( O O
14 1210 1213 18821488 3.5 CD B-NP O
15 1214 1216 18821488 or CC I-NP O
16 1217 1220 18821488 7.0 CD I-NP O
17 1221 1223 18821488 mg NN I-NP O
18 1223 1224 18821488 / SYM B-NP O
19 1224 1226 18821488 kg NN I-NP O
20 1226 1227 18821488 ) ) O O
21 1227 1228 18821488 , , O O
22 1229 1232 18821488 and CC O O
23 1233 1234 18821488 2 CD B-NP O
24 1235 1246 18821488 lethalities NNS I-NP O
25 1247 1255 18821488 occurred VBD B-VP O
26 1256 1257 18821488 ( ( O O
27 1257 1260 18821488 one CD B-NP O
28 1261 1263 18821488 IV CD I-NP O
29 1264 1267 18821488 and CC O O
30 1268 1271 18821488 one CD B-NP O
31 1272 1274 18821488 PO NN I-NP O
32 1274 1275 18821488 ) ) O O
33 1276 1285 18821488 following VBG B-PP O
34 1286 1289 18821488 the DT B-NP O
35 1290 1293 18821488 7.0 CD I-NP O
36 1294 1296 18821488 mg NN I-NP O
37 1296 1297 18821488 / SYM B-NP O
38 1297 1299 18821488 kg NN I-NP O
39 1300 1304 18821488 dose NN I-NP O
40 1304 1305 18821488 . . O O

1 1306 1319 18821488 Myoglobinuria NN B-NP B-Disease
2 1320 1323 18821488 was VBD B-VP O
3 1324 1328 18821488 also RB I-VP O
4 1329 1337 18821488 observed VBN I-VP O
5 1338 1347 18821488 following VBG B-PP O
6 1348 1351 18821488 the DT B-NP O
7 1352 1355 18821488 7.0 CD I-NP O
8 1356 1358 18821488 mg NN I-NP O
9 1358 1359 18821488 / SYM B-NP O
10 1359 1361 18821488 kg NN I-NP O
11 1362 1366 18821488 dose NN I-NP O
12 1366 1367 18821488 . . O O

1 1368 1382 18821488 Histopathology NN B-NP O
2 1383 1391 18821488 analyses NNS I-NP O
3 1392 1394 18821488 in IN B-PP O
4 1395 1398 18821488 the DT B-NP O
5 1399 1400 18821488 2 CD I-NP O
6 1401 1408 18821488 animals NNS I-NP O
7 1409 1413 18821488 that WDT B-NP O
8 1414 1418 18821488 died VBD B-VP O
9 1419 1427 18821488 revealed VBN B-NP O
10 1428 1433 18821488 liver NN I-NP B-Disease
11 1434 1437 18821488 and CC I-NP I-Disease
12 1438 1444 18821488 kidney NN I-NP I-Disease
13 1445 1453 18821488 toxicity NN I-NP I-Disease
14 1453 1454 18821488 , , O O
15 1455 1459 18821488 with IN B-PP O
16 1460 1467 18821488 greater JJR B-NP O
17 1468 1476 18821488 severity NN I-NP O
18 1477 1479 18821488 in IN B-PP O
19 1480 1483 18821488 the DT B-NP O
20 1484 1490 18821488 orally RB I-NP O
21 1490 1491 18821488 - HYPH I-NP O
22 1491 1498 18821488 treated VBN I-NP O
23 1499 1505 18821488 animal NN I-NP O
24 1505 1506 18821488 . . O O

1 1507 1518 18821488 CONCLUSIONS NNS B-NP O
2 1518 1519 18821488 : : O O
3 1520 1525 18821488 These DT B-NP O
4 1526 1530 18821488 data NNS I-NP O
5 1531 1542 18821488 demonstrate VBP B-VP O
6 1543 1549 18821488 direct JJ B-ADJP O
7 1550 1553 18821488 and CC O O
8 1553 1554 18821488 / SYM B-NP O
9 1554 1556 18821488 or CC O O
10 1557 1565 18821488 indirect JJ B-NP O
11 1566 1570 18821488 drug NN I-NP O
12 1570 1571 18821488 - HYPH B-NP O
13 1571 1578 18821488 induced VBN I-NP O
14 1579 1587 18821488 toxicity NN I-NP B-Disease
15 1587 1588 18821488 . . O O

1 1589 1591 18821488 It PRP B-NP O
2 1592 1594 18821488 is VBZ B-VP O
3 1595 1604 18821488 concluded VBN I-VP O
4 1605 1609 18821488 that IN B-SBAR O
5 1610 1618 18821488 WR242511 NN B-NP B-Chemical
6 1619 1625 18821488 should MD B-VP O
7 1626 1629 18821488 not RB I-VP O
8 1630 1632 18821488 be VB I-VP O
9 1633 1640 18821488 pursued VBN I-VP O
10 1641 1643 18821488 as IN B-PP O
11 1644 1645 18821488 a DT B-NP O
12 1646 1658 18821488 pretreatment NN I-NP O
13 1659 1662 18821488 for IN B-PP O
14 1663 1665 18821488 CN NN B-NP O
15 1666 1675 18821488 poisoning VBG B-VP B-Disease
16 1676 1682 18821488 unless IN B-SBAR O
17 1683 1686 18821488 the DT B-NP O
18 1687 1691 18821488 anti AFX I-NP O
19 1691 1692 18821488 - HYPH I-NP O
20 1692 1694 18821488 CN NN I-NP O
21 1695 1710 18821488 characteristics NNS I-NP O
22 1711 1713 18821488 of IN B-PP O
23 1714 1718 18821488 this DT B-NP O
24 1719 1727 18821488 compound NN I-NP O
25 1728 1731 18821488 can MD B-VP O
26 1732 1734 18821488 be VB I-VP O
27 1735 1747 18821488 successfully RB I-VP O
28 1748 1759 18821488 dissociated VBN I-VP O
29 1760 1764 18821488 from IN B-PP O
30 1765 1770 18821488 those DT B-NP O
31 1771 1780 18821488 producing VBG B-VP O
32 1781 1792 18821488 undesirable JJ B-NP O
33 1793 1801 18821488 toxicity NN I-NP B-Disease
34 1801 1802 18821488 . . O O

1 0 0 2348231 -DOCSTART- -X- -X- O

1 0 14 2348231 Pentoxifylline NN B-NP B-Chemical
2 15 16 2348231 ( ( O O
3 16 23 2348231 Trental JJ B-ADJP B-Chemical
4 23 24 2348231 ) ) O O
5 25 29 2348231 does VBZ B-VP O
6 30 33 2348231 not RB I-VP O
7 34 41 2348231 inhibit VB I-VP O
8 42 54 2348231 dipyridamole NN B-NP B-Chemical
9 54 55 2348231 - HYPH O O
10 55 62 2348231 induced VBN B-NP O
11 63 71 2348231 coronary JJ I-NP O
12 72 81 2348231 hyperemia NN I-NP B-Disease
13 81 82 2348231 : : O O
14 83 95 2348231 implications NNS B-NP O
15 96 99 2348231 for IN B-PP O
16 100 112 2348231 dipyridamole NN B-NP B-Chemical
17 112 113 2348231 - HYPH B-NP O
18 113 121 2348231 thallium NN I-NP B-Chemical
19 121 122 2348231 - HYPH B-NP O
20 122 125 2348231 201 CD I-NP O
21 126 136 2348231 myocardial JJ I-NP O
22 137 144 2348231 imaging NN I-NP O
23 144 145 2348231 . . I-NP O
24 146 158 2348231 Dipyridamole NN I-NP B-Chemical
25 158 159 2348231 - HYPH B-NP O
26 159 167 2348231 thallium NN I-NP B-Chemical
27 167 168 2348231 - SYM O O
28 168 171 2348231 201 CD B-NP O
29 172 179 2348231 imaging NN I-NP O
30 180 182 2348231 is VBZ B-VP O
31 183 188 2348231 often RB I-VP O
32 189 198 2348231 performed VBN I-VP O
33 199 201 2348231 in IN B-PP O
34 202 210 2348231 patients NNS B-NP O
35 211 217 2348231 unable JJ B-ADJP O
36 218 220 2348231 to TO B-VP O
37 221 229 2348231 exercise VB I-VP O
38 230 237 2348231 because IN B-PP O
39 238 240 2348231 of IN I-PP O
40 241 251 2348231 peripheral JJ B-NP B-Disease
41 252 260 2348231 vascular JJ I-NP I-Disease
42 261 268 2348231 disease NN I-NP I-Disease
43 268 269 2348231 . . O O

1 270 274 2348231 Many JJ B-NP O
2 275 277 2348231 of IN B-PP O
3 278 283 2348231 these DT B-NP O
4 284 292 2348231 patients NNS I-NP O
5 293 296 2348231 are VBP B-VP O
6 297 303 2348231 taking VBG I-VP O
7 304 318 2348231 pentoxifylline NN B-NP B-Chemical
8 319 320 2348231 ( ( O O
9 320 327 2348231 Trental JJ B-ADVP B-Chemical
10 327 328 2348231 ) ) O O
11 328 329 2348231 , , O O
12 330 331 2348231 a DT B-NP O
13 332 346 2348231 methylxanthine NN I-NP B-Chemical
14 347 357 2348231 derivative NN I-NP O
15 358 363 2348231 which WDT B-NP O
16 364 367 2348231 may MD B-VP O
17 368 375 2348231 improve VB I-VP O
18 376 388 2348231 intermittent JJ B-NP B-Disease
19 389 401 2348231 claudication NN I-NP I-Disease
20 401 402 2348231 . . O O

1 403 410 2348231 Whether IN B-SBAR O
2 411 425 2348231 pentoxifylline NN B-NP B-Chemical
3 426 434 2348231 inhibits VBZ B-VP O
4 435 447 2348231 dipyridamole NN B-NP B-Chemical
5 447 448 2348231 - HYPH O O
6 448 455 2348231 induced VBN B-NP O
7 456 464 2348231 coronary JJ I-NP O
8 465 474 2348231 hyperemia NN I-NP B-Disease
9 475 479 2348231 like IN B-PP O
10 480 485 2348231 other JJ B-NP O
11 486 501 2348231 methylxanthines NNS I-NP B-Chemical
12 502 506 2348231 such JJ B-PP O
13 507 509 2348231 as IN I-PP O
14 510 522 2348231 theophylline NN B-NP B-Chemical
15 523 526 2348231 and CC O O
16 527 533 2348231 should MD B-VP O
17 534 536 2348231 be VB I-VP O
18 537 544 2348231 stopped VBN I-VP O
19 545 550 2348231 prior RB B-ADVP O
20 551 553 2348231 to TO B-PP O
21 554 566 2348231 dipyridamole NN B-NP B-Chemical
22 566 567 2348231 - HYPH B-NP O
23 567 575 2348231 thallium NN I-NP B-Chemical
24 575 576 2348231 - SYM I-NP O
25 576 579 2348231 201 CD I-NP O
26 580 587 2348231 imaging NN I-NP O
27 588 590 2348231 is VBZ B-VP O
28 591 598 2348231 unknown JJ B-ADJP O
29 598 599 2348231 . . O O

1 600 609 2348231 Therefore RB B-ADVP O
2 609 610 2348231 , , O O
3 611 613 2348231 we PRP B-NP O
4 614 621 2348231 studied VBD B-VP O
5 622 625 2348231 the DT B-NP O
6 626 635 2348231 hyperemic JJ I-NP O
7 636 644 2348231 response NN I-NP O
8 645 647 2348231 to TO B-PP O
9 648 660 2348231 dipyridamole NN B-NP B-Chemical
10 661 663 2348231 in IN B-PP O
11 664 669 2348231 seven CD B-NP O
12 670 674 2348231 open JJ I-NP O
13 674 675 2348231 - HYPH I-NP O
14 675 680 2348231 chest NN I-NP O
15 681 693 2348231 anesthetized VBN B-VP O
16 694 698 2348231 dogs NNS B-NP O
17 699 704 2348231 after IN B-PP O
18 705 717 2348231 pretreatment NN B-NP O
19 718 722 2348231 with IN B-PP O
20 723 729 2348231 either CC O O
21 730 744 2348231 pentoxifylline NN B-NP B-Chemical
22 745 746 2348231 ( ( O O
23 746 747 2348231 0 CD B-NP O
24 747 748 2348231 , , I-NP O
25 749 752 2348231 7.5 CD I-NP O
26 752 753 2348231 , , O O
27 754 756 2348231 or CC O O
28 757 759 2348231 15 CD B-NP O
29 760 762 2348231 mg NN I-NP O
30 762 763 2348231 / SYM B-NP O
31 763 765 2348231 kg NN I-NP O
32 766 769 2348231 i.v JJ B-ADJP O
33 769 770 2348231 . . O O
34 770 771 2348231 ) ) O O
35 772 774 2348231 or CC O O
36 775 787 2348231 theophylline NN B-NP B-Chemical
37 788 789 2348231 ( ( O O
38 789 790 2348231 3 CD B-NP O
39 791 793 2348231 mg NN I-NP O
40 793 794 2348231 / SYM B-NP O
41 794 796 2348231 kg NN I-NP O
42 797 800 2348231 i.v JJ B-ADJP O
43 800 801 2348231 . . O O
44 801 802 2348231 ) ) O O
45 802 803 2348231 . . O O

1 804 812 2348231 Baseline NNP B-NP O
2 813 823 2348231 circumflex NN I-NP O
3 824 832 2348231 coronary JJ I-NP O
4 833 838 2348231 blood NN I-NP O
5 839 844 2348231 flows NNS I-NP O
6 845 848 2348231 did VBD B-VP O
7 849 852 2348231 not RB I-VP O
8 853 859 2348231 differ VB I-VP O
9 860 873 2348231 significantly RB B-ADVP O
10 874 879 2348231 among IN B-PP O
11 880 889 2348231 treatment NN B-NP O
12 890 896 2348231 groups NNS I-NP O
13 896 897 2348231 . . O O

1 898 910 2348231 Dipyridamole NN B-NP B-Chemical
2 911 924 2348231 significantly RB B-ADVP O
3 925 934 2348231 increased VBD B-VP O
4 935 943 2348231 coronary JJ B-NP O
5 944 949 2348231 blood NN I-NP O
6 950 954 2348231 flow NN I-NP O
7 955 961 2348231 before IN B-PP O
8 962 965 2348231 and CC I-PP O
9 966 971 2348231 after IN I-PP O
10 972 975 2348231 7.5 CD B-NP O
11 976 978 2348231 or CC I-NP O
12 979 981 2348231 15 CD I-NP O
13 982 984 2348231 mm NN I-NP O
14 984 985 2348231 / SYM I-NP O
15 985 987 2348231 kg NN I-NP O
16 988 991 2348231 i.v NN I-NP O
17 991 992 2348231 . . O O

1 993 1007 2348231 pentoxifylline NN B-NP B-Chemical
2 1008 1009 2348231 ( ( O O
3 1009 1010 2348231 p NN B-NP O
4 1011 1015 2348231 less JJR B-ADJP O
5 1016 1020 2348231 than IN B-PP O
6 1021 1026 2348231 0.002 CD B-NP O
7 1026 1027 2348231 ) ) O O
8 1027 1028 2348231 . . O O

1 1029 1036 2348231 Neither CC O O
2 1037 1041 2348231 dose NN B-NP O
3 1042 1044 2348231 of IN B-PP O
4 1045 1059 2348231 pentoxifylline NN B-NP B-Chemical
5 1060 1073 2348231 significantly RB B-ADVP O
6 1074 1083 2348231 decreased VBD B-VP O
7 1084 1087 2348231 the DT B-NP O
8 1088 1100 2348231 dipyridamole NN I-NP B-Chemical
9 1100 1101 2348231 - HYPH B-NP O
10 1101 1108 2348231 induced VBN I-NP O
11 1109 1118 2348231 hyperemia NN I-NP B-Disease
12 1118 1119 2348231 , , O O
13 1120 1125 2348231 while IN B-SBAR O
14 1126 1130 2348231 peak NN B-NP O
15 1131 1139 2348231 coronary JJ I-NP O
16 1140 1145 2348231 blood NN I-NP O
17 1146 1150 2348231 flow NN I-NP O
18 1151 1154 2348231 was VBD B-VP O
19 1155 1168 2348231 significantly RB B-ADJP O
20 1169 1174 2348231 lower JJR I-ADJP O
21 1175 1180 2348231 after IN B-PP O
22 1181 1193 2348231 theophylline NN B-NP B-Chemical
23 1194 1195 2348231 ( ( O O
24 1195 1196 2348231 p NN B-NP O
25 1197 1201 2348231 less JJR B-ADJP O
26 1202 1206 2348231 than IN B-PP O
27 1207 1211 2348231 0.01 CD B-NP O
28 1211 1212 2348231 ) ) O O
29 1212 1213 2348231 . . O O

1 1214 1216 2348231 We PRP B-NP O
2 1217 1225 2348231 conclude VBP B-VP O
3 1226 1230 2348231 that IN B-SBAR O
4 1231 1246 2348231 pentoxyifylline NN B-NP B-Chemical
5 1247 1251 2348231 does VBZ B-VP O
6 1252 1255 2348231 not RB I-VP O
7 1256 1263 2348231 inhibit VB I-VP O
8 1264 1276 2348231 dipyridamole NN B-NP B-Chemical
9 1276 1277 2348231 - HYPH O O
10 1277 1284 2348231 induced VBN B-NP O
11 1285 1293 2348231 coronary JJ I-NP O
12 1294 1303 2348231 hyperemia NN I-NP B-Disease
13 1304 1308 2348231 even RB B-ADVP O
14 1309 1311 2348231 at IN B-PP O
15 1312 1316 2348231 high JJ B-NP O
16 1317 1322 2348231 doses NNS I-NP O
17 1322 1323 2348231 . . O O

1 0 0 8638206 -DOCSTART- -X- -X- O

1 0 10 8638206 Persistent JJ B-NP O
2 11 20 8638206 paralysis NN I-NP B-Disease
3 21 26 8638206 after IN B-PP O
4 27 36 8638206 prolonged JJ B-NP O
5 37 40 8638206 use NN I-NP O
6 41 43 8638206 of IN B-PP O
7 44 54 8638206 atracurium NN B-NP B-Chemical
8 55 57 8638206 in IN B-PP O
9 58 61 8638206 the DT B-NP O
10 62 69 8638206 absence NN I-NP O
11 70 72 8638206 of IN B-PP O
12 73 88 8638206 corticosteroids NNS B-NP O
13 88 89 8638206 . . O O
14 90 103 8638206 Neuromuscular JJ B-NP O
15 104 112 8638206 blocking VBG I-NP O
16 113 119 8638206 agents NNS I-NP O
17 120 121 8638206 ( ( O O
18 121 126 8638206 NMBAs NNS B-NP O
19 126 127 8638206 ) ) O O
20 128 131 8638206 are VBP B-VP O
21 132 137 8638206 often RB I-VP O
22 138 142 8638206 used VBN I-VP O
23 143 146 8638206 for IN B-PP O
24 147 155 8638206 patients NNS B-NP O
25 156 165 8638206 requiring VBG B-VP O
26 166 175 8638206 prolonged JJ B-NP O
27 176 186 8638206 mechanical JJ I-NP O
28 187 198 8638206 ventilation NN I-NP O
29 198 199 8638206 . . O O

1 200 207 8638206 Reports NNS B-NP O
2 208 210 8638206 of IN B-PP O
3 211 221 8638206 persistent JJ B-NP O
4 222 231 8638206 paralysis NN I-NP B-Disease
5 232 237 8638206 after IN B-PP O
6 238 241 8638206 the DT B-NP O
7 242 256 8638206 discontinuance NN I-NP O
8 257 259 8638206 of IN B-PP O
9 260 265 8638206 these DT B-NP O
10 266 271 8638206 drugs NNS I-NP O
11 272 276 8638206 have VBP B-VP O
12 277 281 8638206 most RBS I-VP O
13 282 287 8638206 often RB I-VP O
14 288 296 8638206 involved VBN B-NP O
15 297 309 8638206 aminosteroid NN I-NP O
16 309 310 8638206 - HYPH B-NP O
17 310 315 8638206 based VBN I-NP O
18 316 321 8638206 NMBAs NNS I-NP O
19 322 326 8638206 such JJ B-PP O
20 327 329 8638206 as IN I-PP O
21 330 340 8638206 vecuronium NN B-NP B-Chemical
22 341 348 8638206 bromide NN I-NP I-Chemical
23 348 349 8638206 , , O O
24 350 360 8638206 especially RB B-ADVP O
25 361 365 8638206 when WRB B-ADVP O
26 366 370 8638206 used VBN B-VP O
27 371 373 8638206 in IN B-PP O
28 374 385 8638206 conjunction NN B-NP O
29 386 390 8638206 with IN B-PP O
30 391 406 8638206 corticosteroids NNS B-NP O
31 406 407 8638206 . . O O

1 408 418 8638206 Atracurium NNP B-NP B-Chemical
2 419 427 8638206 besylate NN I-NP I-Chemical
3 427 428 8638206 , , O O
4 429 430 8638206 a DT B-NP O
5 431 436 8638206 short JJ I-NP O
6 436 437 8638206 - HYPH I-NP O
7 437 443 8638206 acting VBG I-NP O
8 444 464 8638206 benzylisoquinolinium NN I-NP B-Chemical
9 465 469 8638206 NMBA NN I-NP O
10 470 474 8638206 that WDT B-NP O
11 475 477 8638206 is VBZ B-VP O
12 478 488 8638206 eliminated VBN I-VP O
13 489 502 8638206 independently RB B-ADVP O
14 503 505 8638206 of IN B-PP O
15 506 511 8638206 renal JJ B-NP O
16 512 514 8638206 or CC I-NP O
17 515 522 8638206 hepatic JJ I-NP O
18 523 531 8638206 function NN I-NP O
19 531 532 8638206 , , O O
20 533 536 8638206 has VBZ B-VP O
21 537 541 8638206 also RB I-VP O
22 542 546 8638206 been VBN I-VP O
23 547 557 8638206 associated VBN I-VP O
24 558 562 8638206 with IN B-PP O
25 563 573 8638206 persistent JJ B-NP O
26 574 583 8638206 paralysis NN I-NP B-Disease
27 583 584 8638206 , , O O
28 585 588 8638206 but CC O O
29 589 593 8638206 only RB O O
30 594 598 8638206 when WRB B-ADVP O
31 599 603 8638206 used VBN B-VP O
32 604 608 8638206 with IN B-PP O
33 609 624 8638206 corticosteroids NNS B-NP O
34 624 625 8638206 . . O O

1 626 628 8638206 We PRP B-NP O
2 629 635 8638206 report VBP B-VP O
3 636 637 8638206 a DT B-NP O
4 638 642 8638206 case NN I-NP O
5 643 645 8638206 of IN B-PP O
6 646 656 8638206 atracurium NN B-NP B-Chemical
7 656 657 8638206 - HYPH B-NP O
8 657 664 8638206 related VBN I-NP O
9 665 674 8638206 paralysis NN I-NP B-Disease
10 675 685 8638206 persisting VBG B-VP O
11 686 689 8638206 for IN B-PP O
12 690 703 8638206 approximately RB B-NP O
13 704 706 8638206 50 CD I-NP O
14 707 712 8638206 hours NNS I-NP O
15 713 715 8638206 in IN B-PP O
16 716 717 8638206 a DT B-NP O
17 718 725 8638206 patient NN I-NP O
18 726 729 8638206 who WP B-NP O
19 730 733 8638206 was VBD B-VP O
20 734 737 8638206 not RB I-VP O
21 738 745 8638206 treated VBN I-VP O
22 746 750 8638206 with IN B-PP O
23 751 766 8638206 corticosteroids NNS B-NP O
24 766 767 8638206 . . O O

1 0 0 16160878 -DOCSTART- -X- -X- O

1 0 10 16160878 Behavioral JJ B-NP O
2 11 18 16160878 effects NNS I-NP O
3 19 21 16160878 of IN B-PP O
4 22 31 16160878 urotensin NN B-NP B-Chemical
5 31 32 16160878 - HYPH B-NP I-Chemical
6 32 34 16160878 II CD I-NP I-Chemical
7 35 44 16160878 centrally RB B-VP O
8 45 57 16160878 administered VBN I-VP O
9 58 60 16160878 in IN B-PP O
10 61 65 16160878 mice NNS B-NP O
11 65 66 16160878 . . O O
12 67 76 16160878 Urotensin NN B-NP B-Chemical
13 76 77 16160878 - HYPH O I-Chemical
14 77 79 16160878 II CD B-NP I-Chemical
15 80 81 16160878 ( ( O O
16 81 82 16160878 U NN B-NP B-Chemical
17 82 83 16160878 - HYPH O I-Chemical
18 83 85 16160878 II CD O I-Chemical
19 85 86 16160878 ) ) O O
20 87 96 16160878 receptors NNS B-NP O
21 97 100 16160878 are VBP B-VP O
22 101 107 16160878 widely RB I-VP O
23 108 119 16160878 distributed VBN I-VP O
24 120 122 16160878 in IN B-PP O
25 123 126 16160878 the DT B-NP O
26 127 134 16160878 central JJ I-NP O
27 135 142 16160878 nervous JJ I-NP O
28 143 149 16160878 system NN I-NP O
29 149 150 16160878 . . O O

1 151 174 16160878 Intracerebroventricular JJ O O
2 175 176 16160878 ( ( O O
3 176 181 16160878 i.c.v JJ O O
4 181 182 16160878 . . O O
5 182 183 16160878 ) ) O O
6 184 193 16160878 injection NN B-NP O
7 194 196 16160878 of IN B-PP O
8 197 198 16160878 U NN B-NP B-Chemical
9 198 199 16160878 - HYPH B-NP I-Chemical
10 199 201 16160878 II CD I-NP I-Chemical
11 202 208 16160878 causes NNS I-NP O
12 209 221 16160878 hypertension NN I-NP B-Disease
13 222 225 16160878 and CC I-NP O
14 226 237 16160878 bradycardia NN I-NP B-Disease
15 238 241 16160878 and CC O O
16 242 252 16160878 stimulates VBZ B-VP O
17 253 262 16160878 prolactin NN B-NP O
18 263 266 16160878 and CC I-NP O
19 267 278 16160878 thyrotropin NN I-NP O
20 279 288 16160878 secretion NN I-NP O
21 288 289 16160878 . . O O

1 290 297 16160878 However RB B-ADVP O
2 297 298 16160878 , , O O
3 299 302 16160878 the DT B-NP O
4 303 313 16160878 behavioral JJ I-NP O
5 314 321 16160878 effects NNS I-NP O
6 322 324 16160878 of IN B-PP O
7 325 334 16160878 centrally RB B-NP O
8 335 347 16160878 administered VBN I-NP O
9 348 349 16160878 U NN I-NP B-Chemical
10 349 350 16160878 - HYPH I-NP I-Chemical
11 350 352 16160878 II CD I-NP I-Chemical
12 353 357 16160878 have VBP B-VP O
13 358 366 16160878 received VBN I-VP O
14 367 373 16160878 little JJ B-NP O
15 374 383 16160878 attention NN I-NP O
16 383 384 16160878 . . O O

1 385 387 16160878 In IN B-PP O
2 388 391 16160878 the DT B-NP O
3 392 399 16160878 present JJ I-NP O
4 400 405 16160878 study NN I-NP O
5 405 406 16160878 , , O O
6 407 409 16160878 we PRP B-NP O
7 410 416 16160878 tested VBD B-VP O
8 417 420 16160878 the DT B-NP O
9 421 428 16160878 effects NNS I-NP O
10 429 431 16160878 of IN B-PP O
11 432 437 16160878 i.c.v NN B-NP O
12 437 438 16160878 . . O O

1 439 449 16160878 injections NNS B-NP O
2 450 452 16160878 of IN B-PP O
3 453 454 16160878 U NN B-NP B-Chemical
4 454 455 16160878 - HYPH B-NP I-Chemical
5 455 457 16160878 II CD I-NP I-Chemical
6 458 460 16160878 on IN B-PP O
7 461 471 16160878 behavioral JJ B-NP O
8 471 472 16160878 , , I-NP O
9 473 482 16160878 metabolic JJ I-NP O
10 482 483 16160878 , , O O
11 484 487 16160878 and CC O O
12 488 497 16160878 endocrine JJ B-NP O
13 498 507 16160878 responses NNS I-NP O
14 508 510 16160878 in IN B-PP O
15 511 515 16160878 mice NNS B-NP O
16 515 516 16160878 . . O O

1 517 531 16160878 Administration NN B-NP O
2 532 534 16160878 of IN B-PP O
3 535 541 16160878 graded VBN B-NP O
4 542 547 16160878 doses NNS I-NP O
5 548 550 16160878 of IN B-PP O
6 551 552 16160878 U NN B-NP B-Chemical
7 552 553 16160878 - HYPH O I-Chemical
8 553 555 16160878 II CD B-NP I-Chemical
9 556 557 16160878 ( ( O O
10 557 558 16160878 1 CD B-NP O
11 558 559 16160878 - HYPH I-NP O
12 559 565 16160878 10,000 CD I-NP O
13 566 568 16160878 ng NN I-NP O
14 568 569 16160878 / SYM B-NP O
15 569 574 16160878 mouse NN I-NP O
16 574 575 16160878 ) ) O O
17 576 584 16160878 provoked VBD B-VP O
18 584 585 16160878 : : O O
19 586 587 16160878 ( ( B-LST O
20 587 588 16160878 1 LS I-LST O
21 588 589 16160878 ) ) O O
22 590 591 16160878 a DT B-NP O
23 592 596 16160878 dose NN I-NP O
24 596 597 16160878 - HYPH B-NP O
25 597 606 16160878 dependent JJ I-NP O
26 607 616 16160878 reduction NN I-NP O
27 617 619 16160878 in IN B-PP O
28 620 623 16160878 the DT B-NP O
29 624 630 16160878 number NN I-NP O
30 631 633 16160878 of IN B-PP O
31 634 638 16160878 head NN B-NP O
32 639 643 16160878 dips NNS I-NP O
33 644 646 16160878 in IN B-PP O
34 647 650 16160878 the DT B-NP O
35 651 655 16160878 hole NN I-NP O
36 655 656 16160878 - HYPH I-NP O
37 656 661 16160878 board NN I-NP O
38 662 666 16160878 test NN I-NP O
39 666 667 16160878 ; : O O
40 668 669 16160878 ( ( B-LST O
41 669 670 16160878 2 LS I-LST O
42 670 671 16160878 ) ) O O
43 672 673 16160878 a DT B-NP O
44 674 678 16160878 dose NN I-NP O
45 678 679 16160878 - HYPH B-NP O
46 679 688 16160878 dependent JJ I-NP O
47 689 698 16160878 reduction NN I-NP O
48 699 701 16160878 in IN B-PP O
49 702 705 16160878 the DT B-NP O
50 706 712 16160878 number NN I-NP O
51 713 715 16160878 of IN B-PP O
52 716 723 16160878 entries NNS B-NP O
53 724 726 16160878 in IN B-PP O
54 727 730 16160878 the DT B-NP O
55 731 736 16160878 white JJ I-NP O
56 737 744 16160878 chamber NN I-NP O
57 745 747 16160878 in IN B-PP O
58 748 751 16160878 the DT B-NP O
59 752 757 16160878 black JJ I-NP O
60 757 758 16160878 - HYPH I-NP O
61 758 761 16160878 and CC I-NP O
62 761 762 16160878 - HYPH I-NP O
63 762 767 16160878 white JJ I-NP O
64 768 779 16160878 compartment NN I-NP O
65 780 784 16160878 test NN I-NP O
66 784 785 16160878 , , O O
67 786 789 16160878 and CC O O
68 790 792 16160878 in IN B-PP O
69 793 796 16160878 the DT B-NP O
70 797 803 16160878 number NN I-NP O
71 804 806 16160878 of IN B-PP O
72 807 814 16160878 entries NNS B-NP O
73 815 817 16160878 in IN B-PP O
74 818 821 16160878 the DT B-NP O
75 822 829 16160878 central JJ I-NP O
76 830 838 16160878 platform NN I-NP O
77 839 842 16160878 and CC O O
78 843 847 16160878 open JJ B-NP O
79 848 852 16160878 arms NNS I-NP O
80 853 855 16160878 in IN B-PP O
81 856 859 16160878 the DT B-NP O
82 860 864 16160878 plus CC I-NP O
83 864 865 16160878 - HYPH I-NP O
84 865 869 16160878 maze NN I-NP O
85 870 874 16160878 test NN I-NP O
86 874 875 16160878 ; : O O
87 876 879 16160878 and CC O O
88 880 881 16160878 ( ( B-LST O
89 881 882 16160878 3 LS I-LST O
90 882 883 16160878 ) ) O O
91 884 885 16160878 a DT B-NP O
92 886 890 16160878 dose NN I-NP O
93 890 891 16160878 - HYPH B-NP O
94 891 900 16160878 dependent JJ I-NP O
95 901 909 16160878 increase NN I-NP O
96 910 912 16160878 in IN B-PP O
97 913 916 16160878 the DT B-NP O
98 917 925 16160878 duration NN I-NP O
99 926 928 16160878 of IN B-PP O
100 929 939 16160878 immobility NN B-NP O
101 940 942 16160878 in IN B-PP O
102 943 946 16160878 the DT B-NP O
103 947 953 16160878 forced VBN I-NP O
104 953 954 16160878 - HYPH I-NP O
105 954 962 16160878 swimming VBG I-NP O
106 963 967 16160878 test NN I-NP O
107 968 971 16160878 and CC I-NP O
108 972 976 16160878 tail NN I-NP O
109 977 987 16160878 suspension NN I-NP O
110 988 992 16160878 test NN I-NP O
111 992 993 16160878 . . O O

1 994 1017 16160878 Intracerebroventricular JJ B-NP O
2 1018 1027 16160878 injection NN I-NP O
3 1028 1030 16160878 of IN B-PP O
4 1031 1032 16160878 U NN B-NP B-Chemical
5 1032 1033 16160878 - HYPH O I-Chemical
6 1033 1035 16160878 II CD B-NP I-Chemical
7 1036 1040 16160878 also RB B-ADVP O
8 1041 1047 16160878 caused VBD B-VP O
9 1048 1050 16160878 an DT B-NP O
10 1051 1059 16160878 increase NN I-NP O
11 1060 1062 16160878 in IN B-PP O
12 1062 1063 16160878 : SYM B-NP O
13 1064 1068 16160878 food NN I-NP O
14 1069 1075 16160878 intake NN I-NP O
15 1076 1078 16160878 at IN B-PP O
16 1079 1084 16160878 doses NNS B-NP O
17 1085 1087 16160878 of IN B-PP O
18 1088 1091 16160878 100 CD B-NP O
19 1092 1095 16160878 and CC I-NP O
20 1096 1101 16160878 1,000 CD I-NP O
21 1102 1104 16160878 ng NN I-NP O
22 1104 1105 16160878 / SYM O O
23 1105 1110 16160878 mouse NN B-NP O
24 1110 1111 16160878 , , O O
25 1112 1117 16160878 water NN B-NP O
26 1118 1124 16160878 intake NN I-NP O
27 1125 1127 16160878 at IN B-PP O
28 1128 1133 16160878 doses NNS B-NP O
29 1134 1136 16160878 of IN B-PP O
30 1137 1140 16160878 100 CD B-NP O
31 1140 1141 16160878 - HYPH I-NP O
32 1141 1147 16160878 10,000 CD I-NP O
33 1148 1150 16160878 ng NN I-NP O
34 1150 1151 16160878 / SYM O O
35 1151 1156 16160878 mouse NN B-NP O
36 1156 1157 16160878 , , O O
37 1158 1161 16160878 and CC O O
38 1162 1172 16160878 horizontal JJ B-NP O
39 1173 1183 16160878 locomotion NN I-NP O
40 1184 1192 16160878 activity NN I-NP O
41 1193 1195 16160878 at IN B-PP O
42 1196 1197 16160878 a DT B-NP O
43 1198 1202 16160878 dose NN I-NP O
44 1203 1205 16160878 of IN B-PP O
45 1206 1212 16160878 10,000 CD B-NP O
46 1213 1215 16160878 ng NN I-NP O
47 1215 1216 16160878 / SYM B-NP O
48 1216 1221 16160878 mouse NN I-NP O
49 1221 1222 16160878 . . O O

1 1223 1231 16160878 Whatever WDT B-NP O
2 1232 1235 16160878 was VBD B-VP O
3 1236 1239 16160878 the DT B-NP O
4 1240 1244 16160878 dose NN I-NP O
5 1244 1245 16160878 , , O O
6 1246 1249 16160878 the DT B-NP O
7 1250 1257 16160878 central JJ I-NP O
8 1258 1272 16160878 administration NN I-NP O
9 1273 1275 16160878 of IN B-PP O
10 1276 1277 16160878 U NN B-NP B-Chemical
11 1277 1278 16160878 - HYPH O I-Chemical
12 1278 1280 16160878 II CD B-NP I-Chemical
13 1281 1284 16160878 had VBD B-VP O
14 1285 1287 16160878 no DT B-NP O
15 1288 1294 16160878 effect NN I-NP O
16 1295 1297 16160878 on IN B-PP O
17 1298 1302 16160878 body NN B-NP O
18 1303 1314 16160878 temperature NN I-NP O
19 1314 1315 16160878 , , O O
20 1316 1327 16160878 nociception NN B-NP O
21 1327 1328 16160878 , , O O
22 1329 1340 16160878 apomorphine NN B-NP B-Chemical
23 1340 1341 16160878 - HYPH O O
24 1341 1348 16160878 induced VBN B-NP O
25 1349 1355 16160878 penile JJ I-NP B-Disease
26 1356 1364 16160878 erection NN I-NP I-Disease
27 1365 1368 16160878 and CC O O
28 1369 1377 16160878 climbing VBG B-VP O
29 1378 1386 16160878 behavior NN B-NP O
30 1386 1387 16160878 , , O O
31 1388 1391 16160878 and CC O O
32 1392 1398 16160878 stress NN B-NP O
33 1398 1399 16160878 - HYPH B-NP O
34 1399 1406 16160878 induced VBN I-NP O
35 1407 1413 16160878 plasma NN I-NP O
36 1414 1428 16160878 corticosterone NN I-NP B-Chemical
37 1429 1434 16160878 level NN I-NP O
38 1434 1435 16160878 . . O O

1 1436 1441 16160878 Taken VBN B-VP O
2 1442 1450 16160878 together RB B-ADVP O
3 1450 1451 16160878 , , O O
4 1452 1455 16160878 the DT B-NP O
5 1456 1463 16160878 present JJ I-NP O
6 1464 1469 16160878 study NN I-NP O
7 1470 1482 16160878 demonstrates VBZ B-VP O
8 1483 1487 16160878 that IN B-SBAR O
9 1488 1491 16160878 the DT B-NP O
10 1492 1499 16160878 central JJ I-NP O
11 1500 1509 16160878 injection NN I-NP O
12 1510 1512 16160878 of IN B-PP O
13 1513 1514 16160878 U NN B-NP B-Chemical
14 1514 1515 16160878 - HYPH B-NP I-Chemical
15 1515 1517 16160878 II CD I-NP I-Chemical
16 1518 1520 16160878 at IN B-PP O
17 1521 1526 16160878 doses NNS B-NP O
18 1527 1529 16160878 of IN B-PP O
19 1530 1531 16160878 1 CD B-NP O
20 1531 1532 16160878 - HYPH I-NP O
21 1532 1538 16160878 10,000 CD I-NP O
22 1539 1541 16160878 ng NN I-NP O
23 1541 1542 16160878 / SYM B-NP O
24 1542 1547 16160878 mouse NN B-NP O
25 1548 1555 16160878 induces VBZ B-VP O
26 1556 1566 16160878 anxiogenic JJ B-NP O
27 1566 1567 16160878 - HYPH I-NP O
28 1568 1571 16160878 and CC I-NP O
29 1572 1582 16160878 depressant NN I-NP O
30 1582 1583 16160878 - HYPH O O
31 1583 1587 16160878 like JJ B-NP O
32 1588 1595 16160878 effects NNS I-NP O
33 1596 1598 16160878 in IN B-PP O
34 1599 1604 16160878 mouse NN B-NP O
35 1604 1605 16160878 . . O O

1 1606 1611 16160878 These DT B-NP O
2 1612 1616 16160878 data NNS I-NP O
3 1617 1624 16160878 suggest VBP B-VP O
4 1625 1629 16160878 that IN B-SBAR O
5 1630 1631 16160878 U NN B-NP B-Chemical
6 1631 1632 16160878 - HYPH B-NP I-Chemical
7 1632 1634 16160878 II NN I-NP I-Chemical
8 1635 1638 16160878 may MD B-VP O
9 1639 1641 16160878 be VB I-VP O
10 1642 1650 16160878 involved VBN I-VP O
11 1651 1653 16160878 in IN B-PP O
12 1654 1658 16160878 some DT B-NP O
13 1659 1666 16160878 aspects NNS I-NP O
14 1667 1669 16160878 of IN B-PP O
15 1670 1681 16160878 psychiatric JJ B-NP B-Disease
16 1682 1691 16160878 disorders NNS I-NP I-Disease
17 1691 1692 16160878 . . O O

1 0 0 8170551 -DOCSTART- -X- -X- O

1 0 13 8170551 Acetazolamide NN B-NP B-Chemical
2 13 14 8170551 - HYPH B-NP O
3 14 21 8170551 induced VBN I-NP O
4 22 37 8170551 nephrolithiasis NN I-NP B-Disease
5 37 38 8170551 : : O O
6 39 51 8170551 implications NNS B-NP O
7 52 55 8170551 for IN B-PP O
8 56 65 8170551 treatment NN B-NP O
9 66 68 8170551 of IN B-PP O
10 69 82 8170551 neuromuscular JJ B-NP B-Disease
11 83 92 8170551 disorders NNS I-NP I-Disease
12 92 93 8170551 . . O O
13 94 102 8170551 Carbonic JJ B-NP O
14 103 112 8170551 anhydrase NN I-NP O
15 113 123 8170551 inhibitors NNS I-NP O
16 124 127 8170551 can MD B-VP O
17 128 133 8170551 cause VB I-VP O
18 134 149 8170551 nephrolithiasis NN B-NP B-Disease
19 149 150 8170551 . . O O

1 151 153 8170551 We PRP B-NP O
2 154 161 8170551 studied VBD B-VP O
3 162 164 8170551 20 CD B-NP O
4 165 173 8170551 patients NNS I-NP O
5 174 183 8170551 receiving VBG B-VP O
6 184 188 8170551 long JJ B-NP O
7 188 189 8170551 - HYPH I-NP O
8 189 193 8170551 term NN I-NP O
9 194 202 8170551 carbonic JJ I-NP O
10 203 212 8170551 anhydrase NN I-NP O
11 213 222 8170551 inhibitor NN I-NP O
12 223 232 8170551 treatment NN I-NP O
13 233 236 8170551 for IN B-PP O
14 237 245 8170551 periodic JJ B-NP O
15 246 255 8170551 paralysis NN I-NP B-Disease
16 256 259 8170551 and CC I-NP O
17 260 268 8170551 myotonia NN I-NP B-Disease
18 268 269 8170551 . . O O

1 270 275 8170551 Three CD B-NP O
2 276 284 8170551 patients NNS I-NP O
3 285 287 8170551 on IN B-PP O
4 288 301 8170551 acetazolamide NN B-NP B-Chemical
5 302 303 8170551 ( ( O O
6 303 306 8170551 15% NN B-NP O
7 306 307 8170551 ) ) O O
8 308 317 8170551 developed VBD B-VP O
9 318 323 8170551 renal JJ B-NP B-Disease
10 324 331 8170551 calculi NNS I-NP I-Disease
11 331 332 8170551 . . O O

1 333 347 8170551 Extracorporeal JJ B-NP O
2 348 359 8170551 lithotripsy NN I-NP O
3 360 372 8170551 successfully RB B-VP O
4 373 380 8170551 removed VBD I-VP O
5 381 382 8170551 a DT B-NP O
6 383 388 8170551 renal JJ I-NP B-Disease
7 389 397 8170551 calculus NN I-NP I-Disease
8 398 400 8170551 in IN B-PP O
9 401 404 8170551 one CD B-NP O
10 405 412 8170551 patient NN I-NP O
11 413 416 8170551 and CC O O
12 417 424 8170551 surgery NN B-NP O
13 425 432 8170551 removed VBD B-VP O
14 433 434 8170551 a DT B-NP O
15 435 443 8170551 staghorn JJ I-NP O
16 444 452 8170551 calculus NN I-NP B-Disease
17 453 455 8170551 in IN B-PP O
18 456 463 8170551 another DT B-NP O
19 463 464 8170551 , , O O
20 465 475 8170551 permitting VBG B-VP O
21 476 485 8170551 continued JJ B-NP O
22 486 495 8170551 treatment NN I-NP O
23 495 496 8170551 . . O O

1 497 502 8170551 Renal JJ B-NP O
2 503 511 8170551 function NN I-NP O
3 512 520 8170551 remained VBD B-VP O
4 521 527 8170551 normal JJ B-ADJP O
5 528 530 8170551 in IN B-PP O
6 531 534 8170551 all DT B-NP O
7 535 543 8170551 patients NNS I-NP O
8 543 544 8170551 . . O O

1 545 560 8170551 Nephrolithiasis NN B-NP B-Disease
2 561 563 8170551 is VBZ B-VP O
3 564 565 8170551 a DT B-NP O
4 566 578 8170551 complication NN I-NP O
5 579 581 8170551 of IN B-PP O
6 582 595 8170551 acetazolamide NN B-NP B-Chemical
7 596 599 8170551 but CC O O
8 600 604 8170551 does VBZ B-VP O
9 605 608 8170551 not RB I-VP O
10 609 617 8170551 preclude VB I-VP O
11 618 621 8170551 its PRP$ B-NP O
12 622 625 8170551 use NN I-NP O
13 625 626 8170551 . . O O

1 0 0 8701950 -DOCSTART- -X- -X- O

1 0 16 8701950 Microangiopathic JJ B-NP B-Disease
2 17 26 8701950 hemolytic JJ I-NP I-Disease
3 27 33 8701950 anemia NN I-NP I-Disease
4 34 46 8701950 complicating VBG B-VP O
5 47 52 8701950 FK506 NN B-NP B-Chemical
6 53 54 8701950 ( ( O O
7 54 64 8701950 tacrolimus NN B-NP B-Chemical
8 64 65 8701950 ) ) O O
9 66 73 8701950 therapy NN B-NP O
10 73 74 8701950 . . O O
11 75 77 8701950 We PRP B-NP O
12 78 86 8701950 describe VBP B-VP O
13 87 88 8701950 3 CD B-NP O
14 89 97 8701950 episodes NNS I-NP O
15 98 100 8701950 of IN B-PP O
16 101 117 8701950 microangiopathic JJ B-NP B-Disease
17 118 127 8701950 hemolytic JJ I-NP I-Disease
18 128 134 8701950 anemia NN I-NP I-Disease
19 135 136 8701950 ( ( O O
20 136 140 8701950 MAHA NN B-NP B-Disease
21 140 141 8701950 ) ) O O
22 142 144 8701950 in IN B-PP O
23 145 146 8701950 2 CD B-NP O
24 147 152 8701950 solid JJ I-NP O
25 153 158 8701950 organ NN I-NP O
26 159 169 8701950 recipients NNS I-NP O
27 170 175 8701950 under IN B-PP O
28 176 181 8701950 FK506 NN B-NP B-Chemical
29 182 183 8701950 ( ( O O
30 183 193 8701950 tacrolimus NN B-NP B-Chemical
31 193 194 8701950 ) ) O O
32 195 202 8701950 therapy NN B-NP O
33 202 203 8701950 . . O O

1 204 206 8701950 In IN B-PP O
2 207 211 8701950 both DT B-NP O
3 212 217 8701950 cases NNS I-NP O
4 217 218 8701950 , , O O
5 219 234 8701950 discontinuation NN B-NP O
6 235 237 8701950 of IN B-PP O
7 238 243 8701950 FK506 NN B-NP B-Chemical
8 244 247 8701950 and CC O O
9 248 257 8701950 treatment NN B-NP O
10 258 262 8701950 with IN B-PP O
11 263 269 8701950 plasma NN B-NP O
12 270 278 8701950 exchange NN I-NP O
13 278 279 8701950 , , O O
14 280 285 8701950 fresh JJ B-NP O
15 286 292 8701950 frozen VBN I-NP O
16 293 299 8701950 plasma NN I-NP O
17 300 311 8701950 replacement NN I-NP O
18 311 312 8701950 , , O O
19 313 328 8701950 corticosteroids NNS B-NP B-Chemical
20 328 329 8701950 , , O O
21 330 337 8701950 aspirin NN B-NP B-Chemical
22 337 338 8701950 , , O O
23 339 342 8701950 and CC O O
24 343 355 8701950 dipyridamole NN B-NP B-Chemical
25 356 359 8701950 led VBD B-VP O
26 360 362 8701950 to TO B-PP O
27 363 373 8701950 resolution NN B-NP O
28 374 376 8701950 of IN B-PP O
29 377 381 8701950 MAHA NN B-NP B-Disease
30 381 382 8701950 . . O O

1 383 385 8701950 In IN B-PP O
2 386 389 8701950 one CD B-NP O
3 390 397 8701950 patient NN I-NP O
4 397 398 8701950 , , O O
5 399 413 8701950 reintroduction NN B-NP O
6 414 416 8701950 of IN B-PP O
7 417 422 8701950 FK506 NN B-NP B-Chemical
8 423 426 8701950 led VBD B-VP O
9 427 429 8701950 to TO B-PP O
10 430 435 8701950 rapid JJ B-NP O
11 436 446 8701950 recurrence NN I-NP O
12 447 449 8701950 of IN B-PP O
13 450 454 8701950 MAHA NN B-NP B-Disease
14 454 455 8701950 . . O O

1 456 461 8701950 FK506 NN B-NP B-Chemical
2 461 462 8701950 - HYPH B-PP O
3 462 472 8701950 associated VBN B-NP O
4 473 477 8701950 MAHA NN I-NP B-Disease
5 478 480 8701950 is VBZ B-VP O
6 481 489 8701950 probably RB B-ADVP O
7 490 494 8701950 rare JJ B-ADJP O
8 495 498 8701950 but CC O O
9 499 509 8701950 physicians NNS B-NP O
10 510 514 8701950 must MD B-VP O
11 515 517 8701950 be VB I-VP O
12 518 523 8701950 aware JJ B-ADJP O
13 524 526 8701950 of IN B-PP O
14 527 531 8701950 this DT B-NP O
15 532 538 8701950 severe JJ I-NP O
16 539 551 8701950 complication NN I-NP O
17 551 552 8701950 . . O O

1 553 555 8701950 In IN B-PP O
2 556 559 8701950 our PRP$ B-NP O
3 560 570 8701950 experience NN I-NP O
4 571 574 8701950 and CC O O
5 575 584 8701950 according VBG B-PP O
6 585 587 8701950 to TO B-PP O
7 588 591 8701950 the DT B-NP O
8 592 602 8701950 literature NN I-NP O
9 602 603 8701950 , , O O
10 604 609 8701950 FK506 NN B-NP B-Chemical
11 610 614 8701950 does VBZ B-VP O
12 615 618 8701950 not RB I-VP O
13 619 623 8701950 seem VB I-VP O
14 624 626 8701950 to TO B-PP O
15 627 632 8701950 cross AFX B-NP O
16 632 633 8701950 - HYPH I-NP O
17 633 638 8701950 react NN I-NP O
18 639 643 8701950 with IN B-PP O
19 644 655 8701950 cyclosporin NN B-NP B-Chemical
20 656 657 8701950 A NN I-NP I-Chemical
21 658 659 8701950 ( ( O O
22 659 662 8701950 CyA NN B-NP B-Chemical
23 662 663 8701950 ) ) O O
24 663 664 8701950 , , O O
25 665 667 8701950 an DT B-NP O
26 668 674 8701950 immuno AFX I-NP O
27 674 675 8701950 - HYPH I-NP O
28 675 686 8701950 suppressive JJ I-NP O
29 687 691 8701950 drug NN I-NP O
30 692 699 8701950 already RB B-VP O
31 700 705 8701950 known VBN I-VP O
32 706 708 8701950 to TO I-VP O
33 709 715 8701950 induce VB I-VP O
34 716 720 8701950 MAHA NN B-NP B-Disease
35 720 721 8701950 . . O O

1 0 0 14976857 -DOCSTART- -X- -X- O

1 0 9 14976857 Transient JJ B-NP O
2 10 19 14976857 platypnea NN I-NP B-Disease
3 19 20 14976857 - HYPH B-NP I-Disease
4 20 31 14976857 orthodeoxia NN I-NP I-Disease
5 31 32 14976857 - HYPH I-NP I-Disease
6 32 36 14976857 like JJ I-NP I-Disease
7 37 45 14976857 syndrome NN I-NP I-Disease
8 46 53 14976857 induced VBN B-VP O
9 54 56 14976857 by IN B-PP O
10 57 68 14976857 propafenone NN B-NP B-Chemical
11 69 77 14976857 overdose NN I-NP B-Disease
12 78 80 14976857 in IN B-PP O
13 81 82 14976857 a DT B-NP O
14 83 88 14976857 young JJ I-NP O
15 89 94 14976857 woman NN I-NP O
16 95 99 14976857 with IN B-PP O
17 100 109 14976857 Ebstein's NNS B-NP B-Disease
18 110 117 14976857 anomaly RB B-ADVP I-Disease
19 117 118 14976857 . . O O
20 119 121 14976857 In IN B-PP O
21 122 126 14976857 this DT B-NP O
22 127 133 14976857 report NN I-NP O
23 134 136 14976857 we PRP B-NP O
24 137 145 14976857 describe VBP B-VP O
25 146 149 14976857 the DT B-NP O
26 150 154 14976857 case NN I-NP O
27 155 157 14976857 of IN B-PP O
28 158 159 14976857 a DT B-NP O
29 160 162 14976857 37 CD I-NP O
30 162 163 14976857 - HYPH I-NP O
31 163 167 14976857 year NN I-NP O
32 167 168 14976857 - HYPH B-NP O
33 168 171 14976857 old JJ I-NP O
34 172 177 14976857 white JJ I-NP O
35 178 183 14976857 woman NN I-NP O
36 184 188 14976857 with IN B-PP O
37 189 198 14976857 Ebstein's NNS B-NP B-Disease
38 199 206 14976857 anomaly RB B-ADVP I-Disease
39 206 207 14976857 , , O O
40 208 211 14976857 who WP B-NP O
41 212 221 14976857 developed VBD B-VP O
42 222 223 14976857 a DT B-NP O
43 224 228 14976857 rare JJ I-NP O
44 229 237 14976857 syndrome NN I-NP O
45 238 244 14976857 called VBN B-VP O
46 245 254 14976857 platypnea NN B-NP B-Disease
47 254 255 14976857 - HYPH B-NP I-Disease
48 255 266 14976857 orthodeoxia NN I-NP I-Disease
49 266 267 14976857 , , O O
50 268 281 14976857 characterized VBN B-VP O
51 282 284 14976857 by IN B-PP O
52 285 292 14976857 massive JJ B-NP O
53 293 298 14976857 right JJ I-NP O
54 298 299 14976857 - HYPH I-NP O
55 299 301 14976857 to TO B-PP O
56 301 302 14976857 - HYPH B-NP O
57 302 306 14976857 left JJ I-NP O
58 307 318 14976857 interatrial JJ I-NP O
59 319 327 14976857 shunting NN I-NP O
60 328 332 14976857 with IN B-PP O
61 333 342 14976857 transient JJ B-NP O
62 343 351 14976857 profound JJ I-NP O
63 352 359 14976857 hypoxia NN I-NP B-Disease
64 360 363 14976857 and CC I-NP O
65 364 372 14976857 cyanosis NN I-NP B-Disease
66 372 373 14976857 . . O O

1 374 378 14976857 This DT B-NP O
2 379 384 14976857 shunt NN I-NP O
3 385 387 14976857 of IN B-PP O
4 388 393 14976857 blood NN B-NP O
5 394 397 14976857 via IN B-PP O
6 398 399 14976857 a DT B-NP O
7 400 406 14976857 patent NN I-NP B-Disease
8 407 414 14976857 foramen NNS I-NP I-Disease
9 415 420 14976857 ovale NN I-NP I-Disease
10 421 429 14976857 occurred VBD B-VP O
11 430 432 14976857 in IN B-PP O
12 433 436 14976857 the DT B-NP O
13 437 445 14976857 presence NN I-NP O
14 446 448 14976857 of IN B-PP O
15 449 450 14976857 a DT B-NP O
16 451 457 14976857 normal JJ I-NP O
17 458 467 14976857 pulmonary JJ I-NP O
18 468 474 14976857 artery NN I-NP O
19 475 483 14976857 pressure NN I-NP O
20 483 484 14976857 , , O O
21 485 488 14976857 and CC O O
22 489 492 14976857 was VBD B-VP O
23 493 501 14976857 probably RB I-VP O
24 502 514 14976857 precipitated VBN I-VP O
25 515 517 14976857 by IN B-PP O
26 518 519 14976857 a DT B-NP O
27 520 531 14976857 propafenone NN I-NP B-Chemical
28 532 540 14976857 overdose NN I-NP B-Disease
29 540 541 14976857 . . O O

1 542 546 14976857 This DT B-NP O
2 547 551 14976857 drug NN I-NP O
3 552 558 14976857 caused VBD B-VP O
4 559 572 14976857 biventricular JJ B-NP B-Disease
5 573 584 14976857 dysfunction NN I-NP I-Disease
6 584 585 14976857 , , O O
7 586 589 14976857 due IN B-PP O
8 590 592 14976857 to TO B-PP O
9 593 596 14976857 its PRP$ B-NP O
10 597 605 14976857 negative JJ I-NP O
11 606 615 14976857 inotropic JJ I-NP O
12 616 622 14976857 effect NN I-NP O
13 622 623 14976857 , , O O
14 624 627 14976857 and CC O O
15 628 639 14976857 hypotension NN B-NP B-Disease
16 639 640 14976857 , , O O
17 641 644 14976857 due IN B-PP O
18 645 647 14976857 to TO B-PP O
19 648 651 14976857 its PRP$ B-NP O
20 652 662 14976857 peripheral JJ I-NP O
21 663 675 14976857 vasodilatory JJ I-NP O
22 676 682 14976857 effect NN I-NP O
23 682 683 14976857 . . O O

1 684 689 14976857 These DT B-NP O
2 690 697 14976857 effects NNS I-NP O
3 698 702 14976857 gave VBD B-VP O
4 703 707 14976857 rise NN B-NP O
5 708 710 14976857 to TO B-PP O
6 711 713 14976857 an DT B-NP O
7 714 722 14976857 increase NN I-NP O
8 723 725 14976857 in IN B-PP O
9 726 729 14976857 the DT B-NP O
10 730 735 14976857 right JJ I-NP O
11 736 742 14976857 atrial JJ I-NP O
12 743 751 14976857 pressure NN I-NP O
13 752 755 14976857 and CC O O
14 756 757 14976857 a DT B-NP O
15 758 766 14976857 decrease NN I-NP O
16 767 769 14976857 in IN B-PP O
17 770 773 14976857 the DT B-NP O
18 774 778 14976857 left JJ I-NP O
19 779 782 14976857 one CD I-NP O
20 783 787 14976857 with IN B-PP O
21 788 789 14976857 a DT B-NP O
22 790 800 14976857 consequent JJ I-NP O
23 801 811 14976857 stretching NN I-NP O
24 812 814 14976857 of IN B-PP O
25 815 818 14976857 the DT B-NP O
26 819 826 14976857 foramen NNS I-NP O
27 827 832 14976857 ovale NN I-NP O
28 833 836 14976857 and CC O O
29 837 840 14976857 the DT B-NP O
30 841 849 14976857 creation NN I-NP O
31 850 852 14976857 of IN B-PP O
32 853 860 14976857 massive JJ B-NP O
33 861 866 14976857 right JJ I-NP O
34 866 867 14976857 - HYPH I-NP O
35 867 869 14976857 to TO B-PP O
36 869 870 14976857 - HYPH B-NP O
37 870 874 14976857 left JJ I-NP O
38 875 883 14976857 shunting NN I-NP O
39 883 884 14976857 . . O O

1 885 887 14976857 In IN B-PP O
2 888 891 14976857 our PRP$ B-NP O
3 892 896 14976857 case NN I-NP O
4 897 901 14976857 this DT B-NP O
5 902 913 14976857 interatrial JJ I-NP O
6 914 919 14976857 shunt NN I-NP O
7 920 923 14976857 was VBD B-VP O
8 924 928 14976857 very RB I-VP O
9 929 939 14976857 accurately RB I-VP O
10 940 948 14976857 detected VBN I-VP O
11 949 951 14976857 at IN B-PP O
12 952 958 14976857 bubble NN B-NP O
13 959 967 14976857 contrast NN I-NP O
14 968 984 14976857 echocardiography NN I-NP O
15 984 985 14976857 . . O O

1 0 0 7862923 -DOCSTART- -X- -X- O

1 0 6 7862923 Effect NN B-NP O
2 7 9 7862923 of IN B-PP O
3 10 19 7862923 switching VBG B-VP O
4 20 33 7862923 carbamazepine NN B-NP B-Chemical
5 34 36 7862923 to TO B-PP O
6 37 50 7862923 oxcarbazepine NN B-NP B-Chemical
7 51 53 7862923 on IN B-PP O
8 54 57 7862923 the DT B-NP O
9 58 64 7862923 plasma NN I-NP O
10 65 71 7862923 levels NNS I-NP O
11 72 74 7862923 of IN B-PP O
12 75 87 7862923 neuroleptics NNS B-NP O
13 87 88 7862923 . . O O

1 89 90 7862923 A DT B-NP O
2 91 95 7862923 case NN I-NP O
3 96 102 7862923 report NN I-NP O
4 102 103 7862923 . . I-NP O
5 104 117 7862923 Carbamazepine NN I-NP B-Chemical
6 118 121 7862923 was VBD B-VP O
7 122 130 7862923 switched VBN I-VP O
8 131 133 7862923 to TO B-PP O
9 134 137 7862923 its PRP$ B-NP O
10 138 140 7862923 10 CD I-NP O
11 140 141 7862923 - HYPH I-NP O
12 141 145 7862923 keto NN I-NP O
13 146 154 7862923 analogue NN I-NP O
14 155 168 7862923 oxcarbazepine NN I-NP B-Chemical
15 169 174 7862923 among IN B-PP O
16 175 178 7862923 six CD B-NP O
17 179 188 7862923 difficult JJ I-NP O
18 188 189 7862923 - HYPH I-NP O
19 189 191 7862923 to TO B-PP O
20 191 192 7862923 - HYPH B-NP O
21 192 197 7862923 treat NN I-NP O
22 198 211 7862923 schizophrenic JJ I-NP B-Disease
23 212 214 7862923 or CC I-NP O
24 215 222 7862923 organic JJ I-NP B-Disease
25 223 232 7862923 psychotic JJ I-NP I-Disease
26 233 241 7862923 patients NNS I-NP O
27 242 247 7862923 using VBG B-VP O
28 248 261 7862923 concomitantly RB B-NP O
29 262 273 7862923 haloperidol NN I-NP B-Chemical
30 273 274 7862923 , , I-NP O
31 275 289 7862923 chlorpromazine NN I-NP B-Chemical
32 290 292 7862923 or CC I-NP O
33 293 302 7862923 clozapine NN I-NP B-Chemical
34 302 303 7862923 . . O O

1 304 308 7862923 This DT B-NP O
2 309 315 7862923 change NN I-NP O
3 316 324 7862923 resulted VBD B-VP O
4 325 331 7862923 within IN B-PP O
5 332 333 7862923 2 CD B-NP O
6 333 334 7862923 - HYPH I-NP O
7 334 335 7862923 4 CD I-NP O
8 336 341 7862923 weeks NNS I-NP O
9 342 344 7862923 in IN B-PP O
10 345 348 7862923 the DT B-NP O
11 349 351 7862923 50 CD I-NP O
12 351 352 7862923 - HYPH I-NP O
13 352 356 7862923 200% CD I-NP O
14 357 365 7862923 increase NN I-NP O
15 366 368 7862923 in IN B-PP O
16 369 372 7862923 the DT B-NP O
17 373 379 7862923 plasma NN I-NP O
18 380 386 7862923 levels NNS I-NP O
19 387 389 7862923 of IN B-PP O
20 390 395 7862923 these DT B-NP O
21 396 408 7862923 neuroleptics NNS I-NP O
22 409 412 7862923 and CC O O
23 413 416 7862923 the DT B-NP O
24 417 427 7862923 appearance NN I-NP O
25 428 430 7862923 of IN B-PP O
26 431 445 7862923 extrapyramidal JJ B-NP B-Disease
27 446 454 7862923 symptoms NNS I-NP I-Disease
28 454 455 7862923 . . O O

1 456 460 7862923 None NN B-NP O
2 461 463 7862923 of IN B-PP O
3 464 467 7862923 the DT B-NP O
4 468 476 7862923 patients NNS I-NP O
5 477 483 7862923 showed VBD B-VP O
6 484 487 7862923 any DT B-NP O
7 488 496 7862923 clinical JJ I-NP O
8 497 510 7862923 deteriotation NN I-NP O
9 511 517 7862923 during IN B-PP O
10 518 521 7862923 the DT B-NP O
11 522 531 7862923 following VBG I-NP O
12 532 533 7862923 3 CD I-NP O
13 533 534 7862923 - HYPH I-NP O
14 534 535 7862923 6 CD I-NP O
15 536 542 7862923 months NNS I-NP O
16 542 543 7862923 . . O O

1 544 547 7862923 The DT B-NP O
2 548 555 7862923 results NNS I-NP O
3 556 558 7862923 of IN B-PP O
4 559 563 7862923 this DT B-NP O
5 564 568 7862923 case NN I-NP O
6 569 575 7862923 report NN I-NP O
7 576 583 7862923 support VBP B-VP O
8 584 587 7862923 the DT B-NP O
9 588 592 7862923 idea NN I-NP O
10 593 597 7862923 that IN B-SBAR O
11 598 600 7862923 in IN B-PP O
12 601 609 7862923 contrast NN B-NP O
13 610 614 7862923 with IN B-PP O
14 615 628 7862923 carbamazepine NN B-NP B-Chemical
15 629 642 7862923 oxcarbazepine NN I-NP B-Chemical
16 643 647 7862923 does VBZ B-VP O
17 648 651 7862923 not RB I-VP O
18 652 658 7862923 induce VB I-VP O
19 659 662 7862923 the DT B-NP O
20 663 670 7862923 hepatic JJ I-NP O
21 671 681 7862923 microsomal JJ I-NP O
22 682 688 7862923 enzyme NN I-NP O
23 689 696 7862923 systems NNS I-NP O
24 697 707 7862923 regulating VBG B-VP O
25 708 711 7862923 the DT B-NP O
26 712 724 7862923 inactivation NN I-NP O
27 725 727 7862923 of IN B-PP O
28 728 741 7862923 antipsychotic JJ B-NP O
29 742 747 7862923 drugs NNS I-NP O
30 747 748 7862923 . . O O

1 0 0 8231633 -DOCSTART- -X- -X- O

1 0 7 8231633 Effects NNS B-NP O
2 8 10 8231633 of IN B-PP O
3 11 18 8231633 calcium NN B-NP B-Chemical
4 19 26 8231633 channel NN I-NP O
5 27 35 8231633 blockers NNS I-NP O
6 36 38 8231633 on IN B-PP O
7 39 50 8231633 bupivacaine NN B-NP B-Chemical
8 50 51 8231633 - HYPH B-NP O
9 51 58 8231633 induced VBN I-NP O
10 59 67 8231633 toxicity NN I-NP B-Disease
11 67 68 8231633 . . O O
12 69 72 8231633 The DT B-NP O
13 73 80 8231633 purpose NN I-NP O
14 81 83 8231633 of IN B-PP O
15 84 88 8231633 this DT B-NP O
16 89 94 8231633 study NN I-NP O
17 95 98 8231633 was VBD B-VP O
18 99 101 8231633 to TO B-VP O
19 102 113 8231633 investigate VB I-VP O
20 114 117 8231633 the DT B-NP O
21 118 127 8231633 influence NN I-NP O
22 128 130 8231633 of IN B-PP O
23 131 138 8231633 calcium NN B-NP B-Chemical
24 139 146 8231633 channel NN I-NP O
25 147 155 8231633 blockers NNS I-NP O
26 156 158 8231633 on IN B-PP O
27 159 170 8231633 bupivacaine NN B-NP B-Chemical
28 170 171 8231633 - HYPH B-NP O
29 171 178 8231633 induced VBN I-NP O
30 179 184 8231633 acute JJ I-NP O
31 185 193 8231633 toxicity NN I-NP B-Disease
32 193 194 8231633 . . O O

1 195 198 8231633 For IN B-PP O
2 199 203 8231633 each DT B-NP O
3 204 206 8231633 of IN B-PP O
4 207 210 8231633 the DT B-NP O
5 211 216 8231633 three CD I-NP O
6 217 223 8231633 tested VBN I-NP O
7 224 231 8231633 calcium NN I-NP B-Chemical
8 232 239 8231633 channel NN I-NP O
9 240 248 8231633 blockers NNS I-NP O
10 249 250 8231633 ( ( O O
11 250 259 8231633 diltiazem NN B-NP B-Chemical
12 259 260 8231633 , , O O
13 261 270 8231633 verapamil NN B-NP B-Chemical
14 271 274 8231633 and CC O O
15 275 283 8231633 bepridil NN B-NP B-Chemical
16 283 284 8231633 ) ) O O
17 285 286 8231633 6 CD B-NP O
18 287 293 8231633 groups NNS I-NP O
19 294 296 8231633 of IN B-PP O
20 297 301 8231633 mice NNS B-NP O
21 302 306 8231633 were VBD B-VP O
22 307 314 8231633 treated VBN I-VP O
23 315 317 8231633 by IN B-PP O
24 318 321 8231633 two CD B-NP O
25 322 331 8231633 different JJ I-NP O
26 332 337 8231633 doses NNS I-NP O
27 337 338 8231633 , , O O
28 339 343 8231633 i.e. FW B-NP O
29 344 345 8231633 2 CD I-NP O
30 346 349 8231633 and CC I-NP O
31 350 352 8231633 10 CD I-NP O
32 353 355 8231633 mg NN I-NP O
33 355 356 8231633 / SYM I-NP O
34 356 358 8231633 kg NN I-NP O
35 358 359 8231633 / SYM B-NP O
36 359 362 8231633 i.p NN I-NP O
37 362 363 8231633 . NN I-NP O
38 363 364 8231633 , , O O
39 365 367 8231633 or CC O O
40 368 370 8231633 an DT B-NP O
41 371 376 8231633 equal JJ I-NP O
42 377 383 8231633 volume NN I-NP O
43 384 386 8231633 of IN B-PP O
44 387 393 8231633 saline NN B-NP O
45 394 397 8231633 for IN B-PP O
46 398 401 8231633 the DT B-NP O
47 402 409 8231633 control NN I-NP O
48 410 415 8231633 group NN I-NP O
49 416 417 8231633 ( ( O O
50 417 418 8231633 n NN B-NP O
51 419 420 8231633 = SYM B-VP O
52 421 423 8231633 20 CD B-NP O
53 423 424 8231633 ) ) O O
54 424 425 8231633 ; : O O
55 426 428 8231633 15 CD B-NP O
56 429 436 8231633 minutes NNS I-NP O
57 437 442 8231633 later RB B-ADVP O
58 442 443 8231633 , , O O
59 444 447 8231633 all PDT B-NP O
60 448 451 8231633 the DT I-NP O
61 452 459 8231633 animals NNS I-NP O
62 460 464 8231633 were VBD B-VP O
63 465 473 8231633 injected VBN I-VP O
64 474 478 8231633 with IN B-PP O
65 479 480 8231633 a DT B-NP O
66 481 487 8231633 single JJ I-NP O
67 488 490 8231633 50 CD I-NP O
68 491 493 8231633 mg NN I-NP O
69 493 494 8231633 / SYM B-NP O
70 494 496 8231633 kg NN I-NP O
71 496 497 8231633 / SYM B-NP O
72 497 500 8231633 i.p NN I-NP O
73 500 501 8231633 . . O O

1 502 506 8231633 dose NN B-NP O
2 507 509 8231633 of IN B-PP O
3 510 521 8231633 bupivacaine NN B-NP B-Chemical
4 521 522 8231633 . . O O

1 523 526 8231633 The DT B-NP O
2 527 537 8231633 convulsant NN I-NP O
3 538 546 8231633 activity NN I-NP O
4 546 547 8231633 , , O O
5 548 551 8231633 the DT B-NP O
6 552 556 8231633 time NN I-NP O
7 557 559 8231633 of IN B-PP O
8 560 567 8231633 latency NN B-NP O
9 568 570 8231633 to TO B-PP O
10 571 579 8231633 convulse NN B-NP O
11 580 583 8231633 and CC O O
12 584 587 8231633 the DT B-NP O
13 588 597 8231633 mortality NN I-NP O
14 598 602 8231633 rate NN I-NP O
15 603 607 8231633 were VBD B-VP O
16 608 616 8231633 assessed VBN I-VP O
17 617 619 8231633 in IN B-PP O
18 620 624 8231633 each DT B-NP O
19 625 630 8231633 group NN I-NP O
20 630 631 8231633 . . O O

1 632 635 8231633 The DT B-NP O
2 636 641 8231633 local JJ I-NP O
3 642 652 8231633 anesthetic NN I-NP O
4 652 653 8231633 - HYPH B-NP O
5 653 660 8231633 induced VBN I-NP O
6 661 670 8231633 mortality NN I-NP O
7 671 674 8231633 was VBD B-VP O
8 675 688 8231633 significantly RB I-VP O
9 689 698 8231633 increased VBN I-VP O
10 699 701 8231633 by IN B-PP O
11 702 705 8231633 the DT B-NP O
12 706 711 8231633 three CD I-NP O
13 712 721 8231633 different JJ I-NP O
14 722 729 8231633 calcium NN I-NP B-Chemical
15 730 737 8231633 channel NN I-NP O
16 738 746 8231633 blockers NNS I-NP O
17 746 747 8231633 . . O O

1 748 751 8231633 The DT B-NP O
2 752 762 8231633 convulsant JJ I-NP O
3 763 771 8231633 activity NN I-NP O
4 772 774 8231633 of IN B-PP O
5 775 786 8231633 bupivacaine NN B-NP B-Chemical
6 787 790 8231633 was VBD B-VP O
7 791 794 8231633 not RB I-VP O
8 795 808 8231633 significantly RB I-VP O
9 809 817 8231633 modified VBN I-VP O
10 818 821 8231633 but CC O O
11 822 829 8231633 calcium NN B-NP B-Chemical
12 830 837 8231633 channel NN I-NP O
13 838 846 8231633 blockers NNS I-NP O
14 847 856 8231633 decreased VBD B-VP O
15 857 860 8231633 the DT B-NP O
16 861 865 8231633 time NN I-NP O
17 866 868 8231633 of IN B-PP O
18 869 876 8231633 latency NN B-NP O
19 877 879 8231633 to TO B-VP O
20 880 886 8231633 obtain VB I-VP O
21 887 898 8231633 bupivacaine NN B-NP B-Chemical
22 898 899 8231633 - HYPH B-NP O
23 899 906 8231633 induced VBN I-NP O
24 907 918 8231633 convulsions NNS I-NP B-Disease
25 918 919 8231633 ; : O O
26 920 924 8231633 this DT B-NP O
27 925 931 8231633 effect NN I-NP O
28 932 935 8231633 was VBD B-VP O
29 936 940 8231633 less RBR B-ADJP O
30 941 951 8231633 pronounced JJ I-ADJP O
31 952 956 8231633 with IN B-PP O
32 957 965 8231633 bepridil NN B-NP B-Chemical
33 965 966 8231633 . . O O

1 0 0 11706060 -DOCSTART- -X- -X- O

1 0 8 11706060 Combined VBN B-NP O
2 9 23 11706060 antiretroviral JJ I-NP O
3 24 31 11706060 therapy NN I-NP O
4 32 38 11706060 causes VBZ B-VP O
5 39 53 11706060 cardiomyopathy NN B-NP B-Disease
6 54 57 11706060 and CC O O
7 58 66 11706060 elevates VBZ B-VP O
8 67 73 11706060 plasma NN B-NP O
9 74 81 11706060 lactate NN I-NP B-Chemical
10 82 84 11706060 in IN B-PP O
11 85 95 11706060 transgenic JJ B-NP O
12 96 100 11706060 AIDS NN I-NP B-Disease
13 101 105 11706060 mice NNS I-NP O
14 105 106 11706060 . . O O
15 107 113 11706060 Highly RB B-NP O
16 114 120 11706060 active JJ I-NP O
17 121 135 11706060 antiretroviral JJ I-NP O
18 136 143 11706060 therapy NN I-NP O
19 144 145 11706060 ( ( O O
20 145 150 11706060 HAART NN B-NP O
21 150 151 11706060 ) ) O O
22 152 154 11706060 is VBZ B-VP O
23 155 165 11706060 implicated VBN I-VP O
24 166 168 11706060 in IN B-PP O
25 169 183 11706060 cardiomyopathy NN B-NP B-Disease
26 184 185 11706060 ( ( O O
27 185 187 11706060 CM NN B-NP B-Disease
28 187 188 11706060 ) ) O O
29 189 192 11706060 and CC O O
30 193 195 11706060 in IN B-PP O
31 196 204 11706060 elevated VBN B-NP O
32 205 211 11706060 plasma NN I-NP O
33 212 219 11706060 lactate NN I-NP B-Chemical
34 220 221 11706060 ( ( O O
35 221 223 11706060 LA NN B-NP B-Chemical
36 223 224 11706060 ) ) O O
37 225 227 11706060 in IN B-PP O
38 228 232 11706060 AIDS NN B-NP B-Disease
39 233 240 11706060 through IN B-PP O
40 241 251 11706060 mechanisms NNS B-NP O
41 252 254 11706060 of IN B-PP O
42 255 268 11706060 mitochondrial JJ B-NP B-Disease
43 269 280 11706060 dysfunction NN I-NP I-Disease
44 280 281 11706060 . . O O

1 282 284 11706060 To TO B-VP O
2 285 294 11706060 determine VB I-VP O
3 295 308 11706060 mitochondrial JJ B-NP O
4 309 315 11706060 events NNS I-NP O
5 316 320 11706060 from IN B-PP O
6 321 326 11706060 HAART NN B-NP O
7 327 329 11706060 in FW B-ADVP O
8 330 334 11706060 vivo FW I-ADVP O
9 334 335 11706060 , , O O
10 336 337 11706060 8 CD B-NP O
11 337 338 11706060 - HYPH I-NP O
12 338 342 11706060 week NN I-NP O
13 342 343 11706060 - HYPH O O
14 343 346 11706060 old JJ B-NP O
15 347 357 11706060 hemizygous JJ I-NP O
16 358 368 11706060 transgenic JJ I-NP O
17 369 373 11706060 AIDS NN I-NP B-Disease
18 374 378 11706060 mice NNS I-NP O
19 379 380 11706060 ( ( O O
20 380 383 11706060 NL4 NN B-NP O
21 383 384 11706060 - HYPH B-NP O
22 384 390 11706060 3Delta SYM I-NP O
23 391 394 11706060 gag NN I-NP O
24 394 395 11706060 / SYM I-NP O
25 395 398 11706060 pol NN I-NP O
26 398 399 11706060 ; : O O
27 400 402 11706060 TG NN B-NP O
28 402 403 11706060 ) ) O O
29 404 407 11706060 and CC O O
30 408 412 11706060 wild JJ B-NP O
31 412 413 11706060 - HYPH I-NP O
32 413 417 11706060 type NN I-NP O
33 418 421 11706060 FVB NN I-NP O
34 421 422 11706060 / SYM B-NP O
35 422 423 11706060 n NN I-NP O
36 424 435 11706060 littermates NNS I-NP O
37 436 440 11706060 were VBD B-VP O
38 441 448 11706060 treated VBN I-VP O
39 449 453 11706060 with IN B-PP O
40 454 457 11706060 the DT B-NP O
41 458 463 11706060 HAART NN I-NP O
42 464 475 11706060 combination NN I-NP O
43 476 478 11706060 of IN B-PP O
44 479 489 11706060 zidovudine NN B-NP B-Chemical
45 489 490 11706060 , , O O
46 491 501 11706060 lamivudine NN B-NP B-Chemical
47 501 502 11706060 , , O O
48 503 506 11706060 and CC O O
49 507 516 11706060 indinavir NN B-NP B-Chemical
50 517 519 11706060 or CC O O
51 520 527 11706060 vehicle NN B-NP O
52 528 535 11706060 control NN I-NP O
53 536 539 11706060 for IN B-PP O
54 540 542 11706060 10 CD B-NP O
55 543 547 11706060 days NNS I-NP O
56 548 550 11706060 or CC O O
57 551 553 11706060 35 CD B-NP O
58 554 558 11706060 days NNS I-NP O
59 558 559 11706060 . . O O

1 560 562 11706060 At IN B-PP O
2 563 574 11706060 termination NN B-NP O
3 575 577 11706060 of IN B-PP O
4 578 581 11706060 the DT B-NP O
5 582 593 11706060 experiments NNS I-NP O
6 593 594 11706060 , , O O
7 595 599 11706060 mice NNS B-NP O
8 600 609 11706060 underwent VBD B-VP O
9 610 626 11706060 echocardiography NN B-NP O
10 626 627 11706060 , , O O
11 628 640 11706060 quantitation NN B-NP O
12 641 643 11706060 of IN B-PP O
13 644 653 11706060 abundance NN B-NP O
14 654 656 11706060 of IN B-PP O
15 657 666 11706060 molecular JJ B-NP O
16 667 674 11706060 markers NNS I-NP O
17 675 677 11706060 of IN B-PP O
18 678 680 11706060 CM NN B-NP B-Disease
19 681 682 11706060 ( ( O O
20 682 693 11706060 ventricular JJ B-NP O
21 694 698 11706060 mRNA NN I-NP O
22 699 707 11706060 encoding VBG B-VP O
23 708 714 11706060 atrial JJ B-NP O
24 715 726 11706060 natriuretic JJ I-NP O
25 727 733 11706060 factor NN I-NP O
26 734 735 11706060 [ ( O O
27 735 738 11706060 ANF NN B-NP O
28 738 739 11706060 ] ) O O
29 740 743 11706060 and CC O O
30 744 756 11706060 sarcoplasmic JJ B-NP O
31 757 764 11706060 calcium NN I-NP B-Chemical
32 765 771 11706060 ATPase NN I-NP O
33 772 773 11706060 [ ( O O
34 773 779 11706060 SERCA2 NN B-NP O
35 779 780 11706060 ] ) O O
36 780 781 11706060 ) ) O O
37 781 782 11706060 , , O O
38 783 786 11706060 and CC O O
39 787 800 11706060 determination NN B-NP O
40 801 803 11706060 of IN B-PP O
41 804 810 11706060 plasma NN B-NP O
42 811 813 11706060 LA NN I-NP B-Chemical
43 813 814 11706060 . . O O

1 815 825 11706060 Myocardial JJ B-NP O
2 826 836 11706060 histologic JJ I-NP O
3 837 845 11706060 features NNS I-NP O
4 846 850 11706060 were VBD B-VP O
5 851 859 11706060 analyzed VBN I-VP O
6 860 878 11706060 semiquantitatively RB B-ADVP O
7 879 882 11706060 and CC O O
8 883 890 11706060 results NNS B-NP O
9 891 895 11706060 were VBD B-VP O
10 896 905 11706060 confirmed VBN I-VP O
11 906 908 11706060 by IN B-PP O
12 909 921 11706060 transmission NN B-NP O
13 922 930 11706060 electron NN I-NP O
14 931 941 11706060 microscopy NN I-NP O
15 941 942 11706060 . . O O

1 943 948 11706060 After IN B-PP O
2 949 951 11706060 35 CD B-NP O
3 952 956 11706060 days NNS I-NP O
4 957 959 11706060 in IN B-PP O
5 960 963 11706060 the DT B-NP O
6 964 966 11706060 TG NN I-NP O
7 967 968 11706060 + SYM B-NP O
8 969 974 11706060 HAART NNP I-NP O
9 975 981 11706060 cohort NN I-NP O
10 981 982 11706060 , , O O
11 983 987 11706060 left VBD B-VP O
12 988 999 11706060 ventricular JJ B-NP O
13 1000 1004 11706060 mass NN I-NP O
14 1005 1014 11706060 increased VBD B-VP O
15 1015 1019 11706060 160% NN B-NP O
16 1020 1022 11706060 by IN B-PP O
17 1023 1039 11706060 echocardiography NN B-NP O
18 1039 1040 11706060 . . O O

1 1041 1052 11706060 Molecularly RB B-ADVP O
2 1052 1053 11706060 , , O O
3 1054 1057 11706060 ANF NN B-NP O
4 1058 1062 11706060 mRNA NN I-NP O
5 1063 1072 11706060 increased VBD B-VP O
6 1073 1077 11706060 250% NN B-NP O
7 1078 1081 11706060 and CC I-NP O
8 1082 1088 11706060 SERCA2 NN I-NP O
9 1089 1093 11706060 mRNA NN I-NP O
10 1094 1103 11706060 decreased VBD B-VP O
11 1104 1107 11706060 57% CD B-NP O
12 1107 1108 11706060 . . O O

1 1109 1122 11706060 Biochemically RB B-ADVP O
2 1122 1123 11706060 , , O O
3 1124 1126 11706060 LA NN B-NP B-Chemical
4 1127 1130 11706060 was VBD B-VP O
5 1131 1139 11706060 elevated VBN I-VP O
6 1140 1141 11706060 ( ( O O
7 1141 1144 11706060 8.5 CD B-NP O
8 1145 1146 11706060 + SYM O O
9 1146 1147 11706060 / SYM O O
10 1147 1148 11706060 - SYM O O
11 1149 1152 11706060 2.0 CD B-NP O
12 1153 1155 11706060 mM NN I-NP O
13 1155 1156 11706060 ) ) O O
14 1156 1157 11706060 . . O O

1 1158 1172 11706060 Pathologically RB B-ADVP O
2 1172 1173 11706060 , , O O
3 1174 1182 11706060 granular JJ B-NP O
4 1183 1194 11706060 cytoplasmic JJ I-NP O
5 1195 1202 11706060 changes NNS I-NP O
6 1203 1207 11706060 were VBD B-VP O
7 1208 1213 11706060 found VBN I-VP O
8 1214 1216 11706060 in IN B-PP O
9 1217 1224 11706060 cardiac JJ B-NP O
10 1225 1233 11706060 myocytes NNS I-NP O
11 1233 1234 11706060 , , O O
12 1235 1245 11706060 indicating VBG B-VP O
13 1246 1254 11706060 enlarged VBN I-VP O
14 1254 1255 11706060 , , O O
15 1256 1263 11706060 damaged VBN B-NP O
16 1264 1276 11706060 mitochondria NNS I-NP O
17 1276 1277 11706060 . . O O

1 1278 1286 11706060 Findings NNS B-NP O
2 1287 1291 11706060 were VBD B-VP O
3 1292 1301 11706060 confirmed VBN I-VP O
4 1302 1319 11706060 ultrastructurally RB B-ADVP O
5 1319 1320 11706060 . . O O

1 1321 1323 11706060 No DT B-NP O
2 1324 1331 11706060 changes NNS I-NP O
3 1332 1336 11706060 were VBD B-VP O
4 1337 1342 11706060 found VBN I-VP O
5 1343 1345 11706060 in IN B-PP O
6 1346 1351 11706060 other JJ B-NP O
7 1352 1359 11706060 cohorts NNS I-NP O
8 1359 1360 11706060 . . O O

1 1361 1366 11706060 After IN B-PP O
2 1367 1369 11706060 10 CD B-NP O
3 1370 1374 11706060 days NNS I-NP O
4 1374 1375 11706060 , , O O
5 1376 1380 11706060 only RB B-NP O
6 1381 1384 11706060 ANF NN I-NP O
7 1385 1388 11706060 was VBD B-VP O
8 1389 1397 11706060 elevated VBN I-VP O
9 1397 1398 11706060 , , O O
10 1399 1402 11706060 and CC O O
11 1403 1407 11706060 only RB B-ADVP O
12 1408 1410 11706060 in IN B-PP O
13 1411 1414 11706060 the DT B-NP O
14 1415 1417 11706060 TG NN I-NP O
15 1418 1419 11706060 + SYM B-NP O
16 1420 1425 11706060 HAART NNP I-NP O
17 1426 1432 11706060 cohort JJ B-ADJP O
18 1432 1433 11706060 . . O O

1 1434 1441 11706060 Results NNS B-NP O
2 1442 1446 11706060 show VBP B-VP O
3 1447 1451 11706060 that IN B-SBAR O
4 1452 1462 11706060 cumulative JJ B-NP O
5 1463 1468 11706060 HAART NN I-NP O
6 1469 1475 11706060 caused VBD B-VP O
7 1476 1489 11706060 mitochondrial JJ B-NP O
8 1490 1492 11706060 CM NN I-NP B-Disease
9 1493 1497 11706060 with IN B-PP O
10 1498 1506 11706060 elevated JJ B-NP O
11 1507 1509 11706060 LA NN I-NP B-Chemical
12 1510 1512 11706060 in IN B-PP O
13 1513 1517 11706060 AIDS NN B-NP B-Disease
14 1518 1528 11706060 transgenic JJ I-NP O
15 1529 1533 11706060 mice NNS I-NP O
16 1533 1534 11706060 . . O O

1 0 0 8953972 -DOCSTART- -X- -X- O

1 0 5 8953972 Fatal JJ B-NP O
2 6 18 8953972 intracranial JJ I-NP B-Disease
3 19 27 8953972 bleeding NN I-NP I-Disease
4 28 38 8953972 associated VBN B-VP O
5 39 43 8953972 with IN B-PP O
6 44 55 8953972 prehospital NN B-NP O
7 56 59 8953972 use NN I-NP O
8 60 62 8953972 of IN B-PP O
9 63 74 8953972 epinephrine NN B-NP B-Chemical
10 74 75 8953972 . . O O
11 76 78 8953972 We PRP B-NP O
12 79 86 8953972 present VBP B-VP O
13 87 88 8953972 a DT B-NP O
14 89 93 8953972 case NN I-NP O
15 94 96 8953972 of IN B-PP O
16 97 106 8953972 paramedic JJ B-NP O
17 107 118 8953972 misjudgment NN I-NP O
18 119 121 8953972 in IN B-PP O
19 122 125 8953972 the DT B-NP O
20 126 135 8953972 execution NN I-NP O
21 136 138 8953972 of IN B-PP O
22 139 140 8953972 a DT B-NP O
23 141 149 8953972 protocol NN I-NP O
24 150 153 8953972 for IN B-PP O
25 154 157 8953972 the DT B-NP O
26 158 167 8953972 treatment NN I-NP O
27 168 170 8953972 of IN B-PP O
28 171 179 8953972 allergic JJ B-NP B-Disease
29 180 188 8953972 reaction NN I-NP I-Disease
30 189 191 8953972 in IN B-PP O
31 192 193 8953972 a DT B-NP O
32 194 198 8953972 case NN I-NP O
33 199 201 8953972 of IN B-PP O
34 202 211 8953972 pulmonary JJ B-NP B-Disease
35 212 217 8953972 edema NN I-NP I-Disease
36 218 222 8953972 with IN B-PP O
37 223 231 8953972 wheezing VBG B-NP B-Disease
38 231 232 8953972 . . O O

1 233 236 8953972 The DT B-NP O
2 237 243 8953972 sudden JJ I-NP O
3 244 249 8953972 onset NN I-NP O
4 250 252 8953972 of IN B-PP O
5 253 264 8953972 respiratory JJ B-NP B-Disease
6 265 273 8953972 distress NN I-NP I-Disease
7 273 274 8953972 , , O O
8 275 279 8953972 rash NN B-NP B-Disease
9 279 280 8953972 , , O O
10 281 284 8953972 and CC O O
11 285 286 8953972 a DT B-NP O
12 287 294 8953972 history NN I-NP O
13 295 297 8953972 of IN B-PP O
14 298 299 8953972 a DT B-NP O
15 300 303 8953972 new JJ I-NP O
16 304 312 8953972 medicine NN I-NP O
17 313 316 8953972 led VBD B-VP O
18 317 320 8953972 the DT B-NP O
19 321 324 8953972 two CD I-NP O
20 325 335 8953972 paramedics NNS I-NP O
21 336 338 8953972 on IN B-PP O
22 339 342 8953972 the DT B-NP O
23 343 348 8953972 scene NN I-NP O
24 349 351 8953972 to TO B-VP O
25 352 362 8953972 administer VB I-VP O
26 363 375 8953972 subcutaneous JJ B-NP O
27 376 387 8953972 epinephrine NN I-NP B-Chemical
28 387 388 8953972 . . O O

1 389 401 8953972 Subsequently RB B-ADVP O
2 401 402 8953972 , , O O
3 403 408 8953972 acute JJ B-NP O
4 409 416 8953972 cardiac JJ I-NP B-Disease
5 417 423 8953972 arrest NN I-NP I-Disease
6 424 427 8953972 and CC O O
7 428 433 8953972 fatal JJ B-NP O
8 434 446 8953972 subarachnoid JJ I-NP B-Disease
9 447 457 8953972 hemorrhage NN I-NP I-Disease
10 458 466 8953972 occurred VBD B-VP O
11 466 467 8953972 . . O O

1 468 479 8953972 Epinephrine NN B-NP B-Chemical
2 480 483 8953972 has VBZ B-VP O
3 484 485 8953972 a DT B-NP O
4 486 492 8953972 proven JJ I-NP O
5 493 497 8953972 role NN I-NP O
6 498 500 8953972 in IN B-PP O
7 501 508 8953972 cardiac JJ B-NP B-Disease
8 509 515 8953972 arrest NN I-NP I-Disease
9 516 518 8953972 in IN B-PP O
10 519 530 8953972 prehospital NN B-NP O
11 531 535 8953972 care NN I-NP O
12 535 536 8953972 ; : O O
13 537 544 8953972 however RB B-ADVP O
14 544 545 8953972 , , O O
15 546 549 8953972 use NN B-NP O
16 550 552 8953972 by IN B-PP O
17 553 563 8953972 paramedics NNS B-NP O
18 564 566 8953972 in IN B-PP O
19 567 575 8953972 patients NNS B-NP O
20 576 580 8953972 with IN B-PP O
21 581 590 8953972 suspected VBN B-NP O
22 591 599 8953972 allergic JJ I-NP B-Disease
23 600 608 8953972 reaction NN I-NP I-Disease
24 609 612 8953972 and CC O O
25 613 619 8953972 severe JJ B-NP O
26 620 632 8953972 hypertension NN I-NP B-Disease
27 633 639 8953972 should MD B-VP O
28 640 642 8953972 be VB I-VP O
29 643 649 8953972 viewed VBN I-VP O
30 650 654 8953972 with IN B-PP O
31 655 662 8953972 caution NN B-NP O
32 662 663 8953972 . . O O

1 0 0 15804801 -DOCSTART- -X- -X- O

1 0 8 15804801 Coronary JJ B-NP B-Disease
2 9 17 15804801 aneurysm NN I-NP I-Disease
3 18 23 15804801 after IN B-PP O
4 24 36 15804801 implantation NN B-NP O
5 37 39 15804801 of IN B-PP O
6 40 41 15804801 a DT B-NP O
7 42 52 15804801 paclitaxel NN I-NP B-Chemical
8 52 53 15804801 - HYPH O O
9 53 60 15804801 eluting VBG B-VP O
10 61 66 15804801 stent NN B-NP O
11 66 67 15804801 . . I-NP O
12 68 77 15804801 Formation NN I-NP O
13 78 80 15804801 of IN B-PP O
14 81 89 15804801 coronary JJ B-NP B-Disease
15 90 98 15804801 aneurysm NN I-NP I-Disease
16 99 101 15804801 is VBZ B-VP O
17 102 103 15804801 a DT B-NP O
18 104 108 15804801 rare JJ I-NP O
19 109 121 15804801 complication NN I-NP O
20 122 124 15804801 of IN B-PP O
21 125 133 15804801 stenting VBG B-VP O
22 134 138 15804801 with IN B-PP O
23 139 143 15804801 bare JJ B-NP O
24 144 149 15804801 metal NN I-NP O
25 150 156 15804801 stents NNS I-NP O
26 156 157 15804801 , , O O
27 158 161 15804801 but CC O O
28 162 167 15804801 based VBN B-PP O
29 168 170 15804801 on IN B-PP O
30 171 183 15804801 experimental JJ B-NP O
31 184 191 15804801 studies NNS I-NP O
32 192 196 15804801 drug NN I-NP O
33 196 197 15804801 - HYPH B-NP O
34 197 204 15804801 eluting VBG I-NP O
35 205 211 15804801 stents NNS I-NP O
36 212 215 15804801 may MD B-VP O
37 216 222 15804801 induce VB I-VP O
38 223 228 15804801 toxic JJ B-NP O
39 229 236 15804801 effects NNS I-NP O
40 237 239 15804801 on IN B-PP O
41 240 243 15804801 the DT B-NP O
42 244 250 15804801 vessel NN I-NP O
43 251 255 15804801 wall NN I-NP O
44 256 260 15804801 with IN B-PP O
45 261 271 15804801 incomplete JJ B-NP O
46 272 277 15804801 stent JJ I-NP O
47 278 288 15804801 apposition NN I-NP O
48 288 289 15804801 , , O O
49 290 298 15804801 aneurysm NN B-NP B-Disease
50 299 308 15804801 formation NN I-NP O
51 309 312 15804801 and CC B-PP O
52 313 317 15804801 with IN B-PP O
53 318 321 15804801 the DT B-NP O
54 322 331 15804801 potential NN I-NP O
55 332 334 15804801 of IN B-PP O
56 335 340 15804801 stent JJ B-NP O
57 341 351 15804801 thrombosis NN I-NP B-Disease
58 352 354 15804801 or CC O O
59 355 361 15804801 vessel NN B-NP B-Disease
60 362 369 15804801 rupture NN I-NP I-Disease
61 369 370 15804801 . . O O

1 371 373 15804801 We PRP B-NP O
2 374 381 15804801 present VBP B-VP O
3 382 383 15804801 a DT B-NP O
4 384 386 15804801 43 CD I-NP O
5 386 387 15804801 - HYPH I-NP O
6 387 391 15804801 year NN I-NP O
7 391 392 15804801 - HYPH B-NP O
8 392 395 15804801 old JJ I-NP O
9 396 399 15804801 man NN I-NP O
10 400 403 15804801 who WP B-NP O
11 404 413 15804801 developed VBD B-VP O
12 414 415 15804801 a DT B-NP O
13 416 424 15804801 coronary JJ I-NP B-Disease
14 425 433 15804801 aneurysm NN I-NP I-Disease
15 434 436 15804801 in IN B-PP O
16 437 440 15804801 the DT B-NP O
17 441 446 15804801 right JJ I-NP O
18 447 455 15804801 coronary JJ I-NP O
19 456 462 15804801 artery NN I-NP O
20 463 464 15804801 6 CD B-NP O
21 465 471 15804801 months NNS I-NP O
22 472 477 15804801 after IN B-PP O
23 478 487 15804801 receiving VBG B-VP O
24 488 489 15804801 a DT B-NP O
25 490 500 15804801 paclitaxel NN I-NP B-Chemical
26 500 501 15804801 - HYPH O O
27 501 508 15804801 eluting VBG B-VP O
28 509 514 15804801 stent NN B-NP O
29 514 515 15804801 . . O O

1 516 519 15804801 The DT B-NP O
2 520 527 15804801 patient NN I-NP O
3 528 531 15804801 was VBD B-VP O
4 532 544 15804801 asymptomatic JJ B-ADJP O
5 545 548 15804801 and CC O O
6 549 552 15804801 the DT B-NP O
7 553 561 15804801 aneurysm NN I-NP B-Disease
8 562 565 15804801 was VBD B-VP O
9 566 574 15804801 detected VBN I-VP O
10 575 577 15804801 in IN B-PP O
11 578 579 15804801 a DT B-NP O
12 580 587 15804801 routine JJ I-NP O
13 588 595 15804801 control NN I-NP O
14 595 596 15804801 . . O O

1 597 608 15804801 Angiography NN B-NP O
2 609 612 15804801 and CC I-NP O
3 613 626 15804801 intracoronary JJ I-NP O
4 627 637 15804801 ultrasound NN I-NP O
5 638 650 15804801 demonstrated VBD B-VP O
6 651 655 15804801 lack NN B-NP O
7 656 658 15804801 of IN B-PP O
8 659 666 15804801 contact NN B-NP O
9 667 674 15804801 between IN B-PP O
10 675 680 15804801 stent NN B-NP O
11 681 684 15804801 and CC I-NP O
12 685 691 15804801 vessel NN I-NP O
13 692 696 15804801 wall NN I-NP O
14 697 699 15804801 in IN B-PP O
15 700 701 15804801 a DT B-NP O
16 702 704 15804801 15 CD I-NP O
17 704 705 15804801 - HYPH I-NP O
18 705 707 15804801 mm NN I-NP O
19 708 712 15804801 long JJ I-NP O
20 713 720 15804801 segment NN I-NP O
21 721 725 15804801 with IN B-PP O
22 726 733 15804801 maximal JJ B-NP O
23 734 742 15804801 aneurysm NN I-NP B-Disease
24 743 751 15804801 diameter NN I-NP O
25 752 754 15804801 of IN B-PP O
26 755 758 15804801 6.0 CD B-NP O
27 759 761 15804801 mm NN I-NP O
28 761 762 15804801 . . O O

1 763 766 15804801 The DT B-NP O
2 767 774 15804801 patient NN I-NP O
3 775 778 15804801 was VBD B-VP O
4 779 791 15804801 successfully RB I-VP O
5 792 799 15804801 treated VBN I-VP O
6 800 804 15804801 with IN B-PP O
7 805 806 15804801 a DT B-NP O
8 807 812 15804801 graft NN I-NP O
9 813 818 15804801 stent NN I-NP O
10 818 819 15804801 . . O O

1 0 0 891050 -DOCSTART- -X- -X- O

1 0 4 891050 Late JJ B-NP O
2 5 13 891050 recovery NN I-NP O
3 14 16 891050 of IN B-PP O
4 17 22 891050 renal JJ B-NP O
5 23 31 891050 function NN I-NP O
6 32 34 891050 in IN B-PP O
7 35 36 891050 a DT B-NP O
8 37 42 891050 woman NN I-NP O
9 43 47 891050 with IN B-PP O
10 48 51 891050 the DT B-NP O
11 52 61 891050 hemolytic JJ I-NP B-Disease
12 62 68 891050 uremic JJ I-NP I-Disease
13 69 77 891050 syndrome NN I-NP I-Disease
14 77 78 891050 . . I-NP O
15 79 80 891050 A NN I-NP O
16 81 85 891050 case NN I-NP O
17 86 88 891050 is VBZ B-VP O
18 89 97 891050 reported VBN I-VP O
19 98 100 891050 of IN B-PP O
20 101 104 891050 the DT B-NP O
21 105 114 891050 hemolytic JJ I-NP B-Disease
22 115 121 891050 uremic JJ I-NP I-Disease
23 122 130 891050 syndrome NN I-NP I-Disease
24 131 132 891050 ( ( O O
25 132 135 891050 HUS NN B-NP B-Disease
26 135 136 891050 ) ) O O
27 137 139 891050 in IN B-PP O
28 140 141 891050 a DT B-NP O
29 142 147 891050 woman NN I-NP O
30 148 154 891050 taking VBG B-VP O
31 155 159 891050 oral JJ B-NP B-Chemical
32 160 174 891050 contraceptives NNS I-NP I-Chemical
33 174 175 891050 . . O O

1 176 179 891050 She PRP B-NP O
2 180 183 891050 was VBD B-VP O
3 184 191 891050 treated VBN I-VP O
4 192 196 891050 with IN B-PP O
5 197 204 891050 heparin NN B-NP B-Chemical
6 204 205 891050 , , I-NP O
7 206 218 891050 dipyridamole NN I-NP B-Chemical
8 219 222 891050 and CC I-NP O
9 223 235 891050 hemodialysis NN I-NP O
10 235 236 891050 ; : O O
11 237 240 891050 and CC O O
12 241 246 891050 after IN B-SBAR O
13 247 251 891050 more JJR B-NP O
14 252 256 891050 than IN I-NP O
15 257 262 891050 three CD I-NP O
16 263 269 891050 months NNS I-NP O
17 269 270 891050 , , O O
18 271 274 891050 her PRP$ B-NP O
19 275 282 891050 urinary JJ I-NP O
20 283 289 891050 output NN I-NP O
21 290 294 891050 rose VBD B-VP O
22 295 300 891050 above IN B-PP O
23 301 304 891050 500 CD B-NP O
24 305 307 891050 ml NN I-NP O
25 307 308 891050 ; : O O
26 309 312 891050 and CC O O
27 313 316 891050 six CD B-NP O
28 317 323 891050 months NNS I-NP O
29 324 329 891050 after IN B-SBAR O
30 330 333 891050 the DT B-NP O
31 334 339 891050 onset NN I-NP O
32 340 342 891050 of IN B-PP O
33 343 349 891050 anuria NN B-NP B-Disease
34 349 350 891050 , , O O
35 351 359 891050 dialysis NN B-NP O
36 360 369 891050 treatment NN I-NP O
37 370 373 891050 was VBD B-VP O
38 374 381 891050 stopped VBN I-VP O
39 381 382 891050 . . O O

1 383 387 891050 This DT B-NP O
2 388 392 891050 case NN I-NP O
3 393 403 891050 emphasizes VBZ B-VP O
4 404 407 891050 the DT B-NP O
5 408 419 891050 possibility NN I-NP O
6 420 424 891050 that IN B-SBAR O
7 425 428 891050 HUS NN B-NP B-Disease
8 429 431 891050 in IN B-PP O
9 432 438 891050 adults NNS B-NP O
10 439 441 891050 is VBZ B-VP O
11 442 445 891050 not RB O O
12 446 456 891050 invariably RB B-ADJP O
13 457 469 891050 irreversible JJ I-ADJP O
14 470 473 891050 and CC O O
15 474 478 891050 that IN B-SBAR O
16 478 479 891050 , , O O
17 480 487 891050 despite IN B-PP O
18 488 497 891050 prolonged JJ B-NP O
19 498 506 891050 oliguria NN I-NP B-Disease
20 506 507 891050 , , O O
21 508 516 891050 recovery NN B-NP O
22 517 519 891050 of IN B-PP O
23 520 525 891050 renal JJ B-NP O
24 526 534 891050 function NN I-NP O
25 535 538 891050 can MD B-VP O
26 539 541 891050 be VB I-VP O
27 542 550 891050 obtained VBN I-VP O
28 550 551 891050 . . O O

1 552 561 891050 Therefore RB B-ADVP O
2 561 562 891050 , , O O
3 563 565 891050 in IN B-PP O
4 566 571 891050 adult JJ B-NP O
5 572 580 891050 patients NNS I-NP O
6 581 589 891050 affected VBN B-VP O
7 590 592 891050 by IN B-PP O
8 593 596 891050 HUS NN B-NP B-Disease
9 596 597 891050 , , O O
10 598 606 891050 dialysis NN B-NP O
11 607 613 891050 should MD B-VP O
12 614 617 891050 not RB I-VP O
13 618 620 891050 be VB I-VP O
14 621 633 891050 discontinued VBN I-VP O
15 634 645 891050 prematurely RB B-ADVP O
16 645 646 891050 ; : O O
17 647 655 891050 moreover RB B-ADVP O
18 655 656 891050 , , O O
19 657 666 891050 bilateral JJ B-NP O
20 667 678 891050 nephrectomy NN I-NP O
21 678 679 891050 , , O O
22 680 683 891050 for IN B-PP O
23 684 693 891050 treatment NN B-NP O
24 694 696 891050 of IN B-PP O
25 697 703 891050 severe JJ B-NP O
26 704 716 891050 hypertension NN I-NP B-Disease
27 717 720 891050 and CC O O
28 721 737 891050 microangiopathic JJ B-NP B-Disease
29 738 747 891050 hemolytic JJ I-NP I-Disease
30 748 754 891050 anemia NN I-NP I-Disease
31 754 755 891050 , , O O
32 756 762 891050 should MD B-VP O
33 763 765 891050 be VB I-VP O
34 766 775 891050 performed VBN I-VP O
35 776 780 891050 with IN B-PP O
36 781 788 891050 caution NN B-NP O
37 788 789 891050 . . O O

1 0 0 10520387 -DOCSTART- -X- -X- O

1 0 3 10520387 The DT B-NP O
2 4 16 10520387 haemodynamic JJ I-NP O
3 17 24 10520387 effects NNS I-NP O
4 25 27 10520387 of IN B-PP O
5 28 36 10520387 propofol NN B-NP B-Chemical
6 37 39 10520387 in IN B-PP O
7 40 51 10520387 combination NN B-NP O
8 52 56 10520387 with IN B-PP O
9 57 66 10520387 ephedrine NN B-NP B-Chemical
10 67 69 10520387 in IN B-PP O
11 70 77 10520387 elderly JJ B-NP O
12 78 86 10520387 patients NNS I-NP O
13 87 88 10520387 ( ( O O
14 88 91 10520387 ASA NN B-NP O
15 92 98 10520387 groups NNS I-NP O
16 99 100 10520387 3 CD B-NP O
17 101 104 10520387 and CC I-NP O
18 105 106 10520387 4 CD I-NP O
19 106 107 10520387 ) ) O O
20 107 108 10520387 . . O O
21 109 112 10520387 The DT B-NP O
22 113 119 10520387 marked JJ I-NP O
23 120 131 10520387 vasodilator NN I-NP O
24 132 135 10520387 and CC O O
25 136 144 10520387 negative JJ B-NP O
26 145 154 10520387 inotropic JJ I-NP O
27 155 162 10520387 effects NNS I-NP O
28 163 165 10520387 of IN B-PP O
29 166 174 10520387 propofol NN B-NP B-Chemical
30 175 178 10520387 are VBP B-VP O
31 179 192 10520387 disadvantages NNS B-NP O
32 193 195 10520387 in IN B-PP O
33 196 201 10520387 frail NN B-NP O
34 202 209 10520387 elderly JJ I-NP O
35 210 218 10520387 patients NNS I-NP O
36 218 219 10520387 . . O O

1 220 222 10520387 We PRP B-NP O
2 223 235 10520387 investigated VBD B-VP O
3 236 239 10520387 the DT B-NP O
4 240 246 10520387 safety NN I-NP O
5 247 250 10520387 and CC I-NP O
6 251 259 10520387 efficacy NN I-NP O
7 260 262 10520387 of IN B-PP O
8 263 269 10520387 adding VBG B-VP O
9 270 279 10520387 different JJ B-NP O
10 280 285 10520387 doses NNS I-NP O
11 286 288 10520387 of IN B-PP O
12 289 298 10520387 ephedrine NN B-NP B-Chemical
13 299 301 10520387 to TO B-PP O
14 302 310 10520387 propofol NN B-NP B-Chemical
15 311 313 10520387 in IN B-SBAR O
16 314 319 10520387 order NN O O
17 320 322 10520387 to TO B-VP O
18 323 329 10520387 obtund VB I-VP O
19 330 333 10520387 the DT B-NP O
20 334 345 10520387 hypotensive JJ I-NP B-Disease
21 346 354 10520387 response NN I-NP O
22 354 355 10520387 . . O O

1 356 359 10520387 The DT B-NP O
2 360 372 10520387 haemodynamic JJ I-NP O
3 373 380 10520387 effects NNS I-NP O
4 381 383 10520387 of IN B-PP O
5 384 390 10520387 adding VBG B-VP O
6 391 393 10520387 15 CD B-NP O
7 393 394 10520387 , , I-NP O
8 395 397 10520387 20 CD I-NP O
9 398 400 10520387 or CC I-NP O
10 401 403 10520387 25 CD I-NP O
11 404 406 10520387 mg NN I-NP O
12 407 409 10520387 of IN B-PP O
13 410 419 10520387 ephedrine NN B-NP B-Chemical
14 420 422 10520387 to TO B-PP O
15 423 426 10520387 200 CD B-NP O
16 427 429 10520387 mg NN I-NP O
17 430 432 10520387 of IN B-PP O
18 433 441 10520387 propofol NN B-NP B-Chemical
19 442 446 10520387 were VBD B-VP O
20 447 455 10520387 compared VBN I-VP O
21 456 458 10520387 to TO I-VP O
22 459 466 10520387 control VB I-VP O
23 467 469 10520387 in IN B-PP O
24 470 472 10520387 40 CD B-NP O
25 473 476 10520387 ASA NN I-NP O
26 477 478 10520387 3 CD B-NP O
27 478 479 10520387 / SYM I-NP O
28 479 480 10520387 4 CD B-NP O
29 481 489 10520387 patients NNS I-NP O
30 490 494 10520387 over IN B-PP O
31 495 497 10520387 60 CD B-NP O
32 498 503 10520387 years NNS I-NP O
33 504 514 10520387 presenting VBG B-VP O
34 515 518 10520387 for IN B-PP O
35 519 525 10520387 genito AFX B-NP O
36 525 526 10520387 - HYPH I-NP O
37 526 533 10520387 urinary JJ I-NP O
38 534 541 10520387 surgery NN I-NP O
39 541 542 10520387 . . O O

1 543 546 10520387 The DT B-NP O
2 547 555 10520387 addition NN I-NP O
3 556 558 10520387 of IN B-PP O
4 559 568 10520387 ephedrine NN B-NP B-Chemical
5 569 571 10520387 to TO B-PP O
6 572 580 10520387 propofol NN B-NP B-Chemical
7 581 588 10520387 appears VBZ B-VP O
8 589 591 10520387 to TO I-VP O
9 592 594 10520387 be VB I-VP O
10 595 597 10520387 an DT B-NP O
11 598 607 10520387 effective JJ I-NP O
12 608 614 10520387 method NN I-NP O
13 615 617 10520387 of IN B-PP O
14 618 627 10520387 obtunding VBG B-VP O
15 628 631 10520387 the DT B-NP O
16 632 643 10520387 hypotensive JJ I-NP B-Disease
17 644 652 10520387 response NN I-NP O
18 653 655 10520387 to TO B-PP O
19 656 664 10520387 propofol NN B-NP B-Chemical
20 665 667 10520387 at IN B-PP O
21 668 671 10520387 all DT B-NP O
22 672 677 10520387 doses NNS I-NP O
23 678 682 10520387 used VBN B-VP O
24 683 685 10520387 in IN B-PP O
25 686 690 10520387 this DT B-NP O
26 691 696 10520387 study NN I-NP O
27 696 697 10520387 . . O O

1 698 705 10520387 However RB B-ADVP O
2 705 706 10520387 , , O O
3 707 713 10520387 marked JJ B-NP O
4 714 725 10520387 tachycardia NN I-NP B-Disease
5 726 736 10520387 associated VBN B-VP O
6 737 741 10520387 with IN B-PP O
7 742 745 10520387 the DT B-NP O
8 746 749 10520387 use NN I-NP O
9 750 752 10520387 of IN B-PP O
10 753 762 10520387 ephedrine NN B-NP B-Chemical
11 763 765 10520387 in IN B-PP O
12 766 777 10520387 combination NN B-NP O
13 778 782 10520387 with IN B-PP O
14 783 791 10520387 propofol NN B-NP B-Chemical
15 792 800 10520387 occurred VBD B-VP O
16 801 803 10520387 in IN B-PP O
17 804 807 10520387 the DT B-NP O
18 808 816 10520387 majority NN I-NP O
19 817 819 10520387 of IN B-PP O
20 820 828 10520387 patients NNS B-NP O
21 828 829 10520387 , , O O
22 830 842 10520387 occasionally RB B-ADVP O
23 843 851 10520387 reaching VBG B-VP O
24 852 856 10520387 high JJ B-NP O
25 857 863 10520387 levels NNS I-NP O
26 864 866 10520387 in IN B-PP O
27 867 877 10520387 individual JJ B-NP O
28 878 886 10520387 patients NNS I-NP O
29 886 887 10520387 . . O O

1 888 891 10520387 Due JJ B-PP O
2 892 894 10520387 to TO I-PP O
3 895 898 10520387 the DT B-NP O
4 899 903 10520387 risk NN I-NP O
5 904 906 10520387 of IN B-PP O
6 907 911 10520387 this DT B-NP O
7 912 923 10520387 tachycardia NN I-NP B-Disease
8 924 932 10520387 inducing VBG B-VP O
9 933 943 10520387 myocardial JJ B-NP B-Disease
10 944 952 10520387 ischemia NN I-NP I-Disease
11 952 953 10520387 , , O O
12 954 956 10520387 we PRP B-NP O
13 957 962 10520387 would MD B-VP O
14 963 966 10520387 not RB I-VP O
15 967 976 10520387 recommend VB I-VP O
16 977 980 10520387 the DT B-NP O
17 981 984 10520387 use NN I-NP O
18 985 987 10520387 in IN B-PP O
19 988 995 10520387 elderly JJ B-NP O
20 996 1004 10520387 patients NNS I-NP O
21 1005 1007 10520387 of IN B-PP O
22 1008 1011 10520387 any DT B-NP O
23 1012 1014 10520387 of IN B-PP O
24 1015 1018 10520387 the DT B-NP O
25 1019 1028 10520387 ephedrine NN I-NP B-Chemical
26 1028 1029 10520387 / SYM B-NP O
27 1029 1037 10520387 propofol NN I-NP B-Chemical
28 1037 1038 10520387 / SYM O O
29 1038 1046 10520387 mixtures NNS B-NP O
30 1047 1054 10520387 studied VBN B-VP O
31 1054 1055 10520387 . . O O

1 0 0 3827439 -DOCSTART- -X- -X- O

1 0 9 3827439 Recurrent JJ B-NP O
2 10 20 3827439 reversible JJ I-NP O
3 21 26 3827439 acute JJ I-NP B-Disease
4 27 32 3827439 renal JJ I-NP I-Disease
5 33 40 3827439 failure NN I-NP I-Disease
6 41 45 3827439 from IN B-PP O
7 46 58 3827439 amphotericin NN B-NP B-Chemical
8 58 59 3827439 . . O O
9 60 61 3827439 A NN B-NP O
10 62 69 3827439 patient NN I-NP O
11 70 74 3827439 with IN B-PP O
12 75 86 3827439 cryptogenic JJ B-NP O
13 87 96 3827439 cirrhosis NN I-NP B-Disease
14 97 100 3827439 and CC O O
15 101 113 3827439 disseminated VBN B-NP O
16 114 128 3827439 sporotrichosis NN I-NP B-Disease
17 129 138 3827439 developed VBD B-VP O
18 139 144 3827439 acute JJ B-NP B-Disease
19 145 150 3827439 renal JJ I-NP I-Disease
20 151 158 3827439 failure NN I-NP I-Disease
21 159 170 3827439 immediately RB B-VP O
22 171 180 3827439 following VBG I-VP O
23 181 184 3827439 the DT B-NP O
24 185 199 3827439 administration NN I-NP O
25 200 202 3827439 of IN B-PP O
26 203 215 3827439 amphotericin NN B-NP B-Chemical
27 216 217 3827439 B NN I-NP I-Chemical
28 218 220 3827439 on IN B-PP O
29 221 225 3827439 four CD B-NP O
30 226 234 3827439 separate JJ I-NP O
31 235 244 3827439 occasions NNS I-NP O
32 244 245 3827439 . . O O

1 246 249 3827439 The DT B-NP O
2 250 260 3827439 abruptness NN I-NP O
3 261 263 3827439 of IN B-PP O
4 264 267 3827439 the DT B-NP O
5 268 273 3827439 renal JJ I-NP B-Disease
6 274 281 3827439 failure NN I-NP I-Disease
7 282 285 3827439 and CC O O
8 286 289 3827439 its PRP$ B-NP O
9 290 303 3827439 reversibility NN I-NP O
10 304 310 3827439 within IN B-PP O
11 311 315 3827439 days NNS B-NP O
12 316 324 3827439 suggests VBZ B-VP O
13 325 329 3827439 that IN B-SBAR O
14 330 335 3827439 there EX B-NP O
15 336 339 3827439 was VBD B-VP O
16 340 341 3827439 a DT B-NP O
17 342 352 3827439 functional JJ I-NP O
18 353 362 3827439 component NN I-NP O
19 363 365 3827439 to TO B-PP O
20 366 369 3827439 the DT B-NP O
21 370 375 3827439 renal JJ I-NP B-Disease
22 376 387 3827439 dysfunction NN I-NP I-Disease
23 387 388 3827439 . . O O

1 389 391 3827439 We PRP B-NP O
2 392 399 3827439 propose VBP B-VP O
3 400 404 3827439 that IN B-SBAR O
4 405 417 3827439 amphotericin NN B-NP B-Chemical
5 417 418 3827439 , , O O
6 419 421 3827439 in IN B-PP O
7 422 425 3827439 the DT B-NP O
8 426 433 3827439 setting NN I-NP O
9 434 436 3827439 of IN B-PP O
10 437 444 3827439 reduced VBN B-NP O
11 445 454 3827439 effective JJ I-NP O
12 455 463 3827439 arterial JJ I-NP O
13 464 470 3827439 volume NN I-NP O
14 470 471 3827439 , , O O
15 472 475 3827439 may MD B-VP O
16 476 484 3827439 activate VB I-VP O
17 485 501 3827439 tubuloglomerular JJ B-NP O
18 502 510 3827439 feedback NN I-NP O
19 510 511 3827439 , , O O
20 512 519 3827439 thereby RB B-VP O
21 520 532 3827439 contributing VBG I-VP O
22 533 535 3827439 to TO B-PP O
23 536 541 3827439 acute JJ B-NP B-Disease
24 542 547 3827439 renal JJ I-NP I-Disease
25 548 555 3827439 failure NN I-NP I-Disease
26 555 556 3827439 . . O O

1 0 0 10193204 -DOCSTART- -X- -X- O

1 0 7 10193204 Effects NNS B-NP O
2 8 10 10193204 of IN B-PP O
3 11 22 10193204 tetrandrine NN B-NP B-Chemical
4 23 26 10193204 and CC I-NP O
5 27 40 10193204 fangchinoline NN I-NP B-Chemical
6 41 43 10193204 on IN B-PP O
7 44 56 10193204 experimental JJ B-NP O
8 57 67 10193204 thrombosis NN I-NP B-Disease
9 68 70 10193204 in IN B-PP O
10 71 75 10193204 mice NNS B-NP O
11 76 79 10193204 and CC O O
12 80 85 10193204 human JJ B-NP O
13 86 94 10193204 platelet NN I-NP B-Disease
14 95 106 10193204 aggregation NN I-NP I-Disease
15 106 107 10193204 . . O O
16 108 119 10193204 Tetrandrine NN B-NP B-Chemical
17 120 121 10193204 ( ( O O
18 121 124 10193204 TET NN B-NP B-Chemical
19 124 125 10193204 ) ) O O
20 126 129 10193204 and CC O O
21 130 143 10193204 fangchinoline NN B-NP B-Chemical
22 144 145 10193204 ( ( O O
23 145 148 10193204 FAN NN B-NP B-Chemical
24 148 149 10193204 ) ) O O
25 150 153 10193204 are VBP B-VP O
26 154 157 10193204 two CD B-NP O
27 158 167 10193204 naturally RB I-NP O
28 168 177 10193204 occurring VBG I-NP O
29 178 187 10193204 analogues NNS B-NP O
30 188 192 10193204 with IN B-PP O
31 193 194 10193204 a DT B-NP O
32 195 216 10193204 bisbenzylisoquinoline NN I-NP B-Chemical
33 217 226 10193204 structure NN I-NP O
34 226 227 10193204 . . O O

1 228 231 10193204 The DT B-NP O
2 232 239 10193204 present JJ I-NP O
3 240 245 10193204 study NN I-NP O
4 246 249 10193204 was VBD B-VP O
5 250 260 10193204 undertaken VBN I-VP O
6 261 263 10193204 to TO I-VP O
7 264 275 10193204 investigate VB I-VP O
8 276 279 10193204 the DT B-NP O
9 280 287 10193204 effects NNS I-NP O
10 288 290 10193204 of IN B-PP O
11 291 294 10193204 TET NN B-NP B-Chemical
12 295 298 10193204 and CC I-NP O
13 299 302 10193204 FAN NN I-NP B-Chemical
14 303 305 10193204 on IN B-PP O
15 306 309 10193204 the DT B-NP O
16 310 322 10193204 experimental JJ I-NP O
17 323 333 10193204 thrombosis NN I-NP B-Disease
18 334 341 10193204 induced VBN B-VP O
19 342 344 10193204 by IN B-PP O
20 345 353 10193204 collagen NN B-NP O
21 354 358 10193204 plus CC O O
22 359 370 10193204 epinephrine NN B-NP B-Chemical
23 371 372 10193204 ( ( O O
24 372 374 10193204 EP NN B-NP B-Chemical
25 374 375 10193204 ) ) O O
26 376 378 10193204 in IN B-PP O
27 379 383 10193204 mice NNS B-NP O
28 383 384 10193204 , , O O
29 385 388 10193204 and CC O O
30 389 397 10193204 platelet NN B-NP B-Disease
31 398 409 10193204 aggregation NN I-NP I-Disease
32 410 413 10193204 and CC O O
33 414 419 10193204 blood NN B-NP B-Disease
34 420 431 10193204 coagulation NN I-NP I-Disease
35 432 434 10193204 in FW B-ADVP O
36 435 440 10193204 vitro FW I-ADVP O
37 440 441 10193204 . . O O

1 442 444 10193204 In IN B-PP O
2 445 448 10193204 the DT B-NP O
3 449 451 10193204 in FW I-NP O
4 452 456 10193204 vivo FW I-NP O
5 457 462 10193204 study NN I-NP O
6 462 463 10193204 , , O O
7 464 467 10193204 the DT B-NP O
8 468 482 10193204 administration NN I-NP O
9 483 484 10193204 ( ( O O
10 484 486 10193204 50 CD B-NP O
11 487 489 10193204 mg NN I-NP O
12 489 490 10193204 / SYM B-NP O
13 490 492 10193204 kg NN I-NP O
14 492 493 10193204 , , O O
15 494 497 10193204 i.p NN B-NP O
16 497 498 10193204 . . O O
17 498 499 10193204 ) ) O O
18 500 502 10193204 of IN B-PP O
19 503 506 10193204 TET NN B-NP B-Chemical
20 507 510 10193204 and CC I-NP O
21 511 514 10193204 FAN NN I-NP B-Chemical
22 515 517 10193204 in IN B-PP O
23 518 522 10193204 mice NNS B-NP O
24 523 529 10193204 showed VBD B-VP O
25 530 533 10193204 the DT B-NP O
26 534 544 10193204 inhibition NN I-NP O
27 545 547 10193204 of IN B-PP O
28 548 558 10193204 thrombosis NN B-NP B-Disease
29 559 561 10193204 by IN B-PP O
30 562 565 10193204 55% CD B-NP O
31 566 569 10193204 and CC I-NP O
32 570 573 10193204 35% CD I-NP O
33 573 574 10193204 , , O O
34 575 587 10193204 respectively RB B-ADVP O
35 587 588 10193204 , , O O
36 589 594 10193204 while IN B-SBAR O
37 595 610 10193204 acetylsalicylic JJ B-NP B-Chemical
38 611 615 10193204 acid NN I-NP I-Chemical
39 616 617 10193204 ( ( O O
40 617 620 10193204 ASA NN B-NP B-Chemical
41 620 621 10193204 , , O O
42 622 624 10193204 50 CD B-NP O
43 625 627 10193204 mg NN I-NP O
44 627 628 10193204 / SYM B-NP O
45 628 630 10193204 kg NN I-NP O
46 630 631 10193204 , , O O
47 632 635 10193204 i.p NN B-NP O
48 635 636 10193204 . . O O
49 636 637 10193204 ) ) O O
50 637 638 10193204 , , O O
51 639 640 10193204 a DT B-NP O
52 641 649 10193204 positive JJ I-NP O
53 650 657 10193204 control NN I-NP O
54 657 658 10193204 , , O O
55 659 665 10193204 showed VBD B-VP O
56 666 670 10193204 only RB B-NP O
57 671 674 10193204 30% CD I-NP O
58 675 685 10193204 inhibition NN I-NP O
59 685 686 10193204 . . O O

1 687 689 10193204 In IN B-PP O
2 690 693 10193204 the DT B-NP O
3 694 699 10193204 vitro FW I-NP O
4 700 705 10193204 human JJ I-NP O
5 706 714 10193204 platelet NN I-NP B-Disease
6 715 727 10193204 aggregations NNS I-NP I-Disease
7 728 735 10193204 induced VBN B-VP O
8 736 738 10193204 by IN B-PP O
9 739 742 10193204 the DT B-NP O
10 743 751 10193204 agonists NNS I-NP O
11 752 756 10193204 used VBN B-VP O
12 757 759 10193204 in IN B-PP O
13 760 765 10193204 tests NNS B-NP O
14 765 766 10193204 , , I-NP O
15 767 770 10193204 TET NN I-NP B-Chemical
16 771 774 10193204 and CC I-NP O
17 775 778 10193204 FAN NN I-NP B-Chemical
18 779 785 10193204 showed VBD B-VP O
19 786 789 10193204 the DT B-NP O
20 790 801 10193204 inhibitions NNS I-NP O
21 802 806 10193204 dose NN I-NP O
22 807 818 10193204 dependently RB B-ADVP O
23 818 819 10193204 . . O O

1 820 822 10193204 In IN B-PP O
2 823 831 10193204 addition NN B-NP O
3 831 832 10193204 , , O O
4 833 840 10193204 neither CC O O
5 841 844 10193204 TET NN B-NP B-Chemical
6 845 848 10193204 nor CC I-NP O
7 849 852 10193204 FAN NN I-NP B-Chemical
8 853 859 10193204 showed VBD B-VP O
9 860 863 10193204 any DT B-NP O
10 864 879 10193204 anticoagulation NN I-NP O
11 880 890 10193204 activities NNS I-NP O
12 891 893 10193204 in IN B-PP O
13 894 897 10193204 the DT B-NP O
14 898 909 10193204 measurement NN I-NP O
15 910 912 10193204 of IN B-PP O
16 913 916 10193204 the DT B-NP O
17 917 926 10193204 activated VBN I-NP O
18 927 934 10193204 partial JJ I-NP O
19 935 949 10193204 thromboplastin NN I-NP O
20 950 954 10193204 time NN I-NP O
21 955 956 10193204 ( ( O O
22 956 960 10193204 APTT NN B-NP O
23 960 961 10193204 ) ) O O
24 961 962 10193204 , , O O
25 963 974 10193204 prothrombin NN B-NP O
26 975 979 10193204 time NN I-NP O
27 980 981 10193204 ( ( O O
28 981 983 10193204 PT NN B-NP O
29 983 984 10193204 ) ) O O
30 985 988 10193204 and CC O O
31 989 997 10193204 thrombin NN B-NP O
32 998 1002 10193204 time NN I-NP O
33 1003 1004 10193204 ( ( O O
34 1004 1006 10193204 TT NN B-NP O
35 1006 1007 10193204 ) ) O O
36 1008 1013 10193204 using VBG B-VP O
37 1014 1019 10193204 human JJ B-NP O
38 1019 1020 10193204 - HYPH I-NP O
39 1020 1028 10193204 citrated VBN I-NP O
40 1029 1035 10193204 plasma NN I-NP O
41 1035 1036 10193204 . . O O

1 1037 1042 10193204 These DT B-NP O
2 1043 1050 10193204 results NNS I-NP O
3 1051 1058 10193204 suggest VBP B-VP O
4 1059 1063 10193204 that IN B-SBAR O
5 1064 1078 10193204 antithrombosis NN B-NP O
6 1079 1081 10193204 of IN B-PP O
7 1082 1085 10193204 TET NN B-NP B-Chemical
8 1086 1089 10193204 and CC I-NP O
9 1090 1093 10193204 FAN NN I-NP B-Chemical
10 1094 1096 10193204 in IN B-PP O
11 1097 1101 10193204 mice NNS B-NP O
12 1102 1105 10193204 may MD B-VP O
13 1106 1108 10193204 be VB I-VP O
14 1109 1115 10193204 mainly RB I-VP O
15 1116 1123 10193204 related VBN I-VP O
16 1124 1126 10193204 to TO B-PP O
17 1127 1130 10193204 the DT B-NP O
18 1131 1143 10193204 antiplatelet JJ I-NP O
19 1144 1155 10193204 aggregation NN I-NP O
20 1156 1166 10193204 activities NNS I-NP O
21 1166 1167 10193204 . . O O

1 0 0 19889778 -DOCSTART- -X- -X- O

1 0 12 19889778 Differential JJ B-NP O
2 13 19 19889778 impact NN I-NP O
3 20 22 19889778 of IN B-PP O
4 23 29 19889778 immune JJ B-NP O
5 30 36 19889778 escape NN I-NP O
6 37 46 19889778 mutations NNS I-NP O
7 47 52 19889778 G145R NN I-NP O
8 53 56 19889778 and CC I-NP O
9 57 62 19889778 P120T NN I-NP O
10 63 65 19889778 on IN B-PP O
11 66 69 19889778 the DT B-NP O
12 70 81 19889778 replication NN I-NP O
13 82 84 19889778 of IN B-PP O
14 85 95 19889778 lamivudine NN B-NP B-Chemical
15 95 96 19889778 - HYPH B-NP O
16 96 105 19889778 resistant JJ I-NP O
17 106 115 19889778 hepatitis NN I-NP B-Chemical
18 116 117 19889778 B NN I-NP I-Chemical
19 118 123 19889778 virus NN I-NP I-Chemical
20 124 125 19889778 e NN I-NP I-Chemical
21 126 133 19889778 antigen NN I-NP I-Chemical
22 133 134 19889778 - HYPH O O
23 134 142 19889778 positive JJ B-NP O
24 143 146 19889778 and CC I-NP O
25 147 148 19889778 - HYPH I-NP O
26 148 156 19889778 negative JJ I-NP O
27 157 164 19889778 strains NNS I-NP O
28 164 165 19889778 . . O O
29 166 172 19889778 Immune JJ B-NP O
30 173 179 19889778 escape NN I-NP O
31 180 188 19889778 variants NNS I-NP O
32 189 191 19889778 of IN B-PP O
33 192 195 19889778 the DT B-NP O
34 196 205 19889778 hepatitis NN I-NP B-Disease
35 206 207 19889778 B NN I-NP I-Disease
36 208 213 19889778 virus NN I-NP O
37 214 215 19889778 ( ( O O
38 215 218 19889778 HBV NN B-NP O
39 218 219 19889778 ) ) O O
40 220 229 19889778 represent VBP B-VP O
41 230 232 19889778 an DT B-NP O
42 233 241 19889778 emerging VBG I-NP O
43 242 250 19889778 clinical JJ I-NP O
44 251 260 19889778 challenge NN I-NP O
45 260 261 19889778 , , O O
46 262 269 19889778 because IN B-SBAR O
47 270 274 19889778 they PRP B-NP O
48 275 278 19889778 can MD B-VP O
49 279 281 19889778 be VB I-VP O
50 282 292 19889778 associated VBN I-VP O
51 293 297 19889778 with IN B-PP O
52 298 305 19889778 vaccine NN B-NP O
53 306 312 19889778 escape NN I-NP O
54 312 313 19889778 , , O O
55 314 317 19889778 HBV NN B-NP O
56 318 330 19889778 reactivation NN I-NP O
57 330 331 19889778 , , O O
58 332 335 19889778 and CC O O
59 336 343 19889778 failure NN B-NP O
60 344 346 19889778 of IN B-PP O
61 347 357 19889778 diagnostic JJ B-NP O
62 358 363 19889778 tests NNS I-NP O
63 363 364 19889778 . . O O

1 365 371 19889778 Recent JJ B-NP O
2 372 376 19889778 data NNS I-NP O
3 377 384 19889778 suggest VBP B-VP O
4 385 386 19889778 a DT B-NP O
5 387 399 19889778 preferential JJ I-NP O
6 400 409 19889778 selection NN I-NP O
7 410 412 19889778 of IN B-PP O
8 413 419 19889778 immune JJ B-NP O
9 420 426 19889778 escape NN I-NP O
10 427 434 19889778 mutants NNS I-NP O
11 435 437 19889778 in IN B-PP O
12 438 446 19889778 distinct JJ B-NP O
13 447 457 19889778 peripheral JJ I-NP O
14 458 463 19889778 blood NN I-NP O
15 464 473 19889778 leukocyte NN I-NP O
16 474 486 19889778 compartments NNS I-NP O
17 487 489 19889778 of IN B-PP O
18 490 498 19889778 infected JJ B-NP O
19 499 510 19889778 individuals NNS I-NP O
20 510 511 19889778 . . O O

1 512 514 19889778 We PRP B-NP O
2 515 524 19889778 therefore RB B-ADVP O
3 525 539 19889778 systematically RB B-ADVP O
4 540 548 19889778 analyzed VBD B-VP O
5 549 552 19889778 the DT B-NP O
6 553 563 19889778 functional JJ I-NP O
7 564 570 19889778 impact NN I-NP O
8 571 573 19889778 of IN B-PP O
9 574 577 19889778 the DT B-NP O
10 578 582 19889778 most RBS I-NP O
11 583 592 19889778 prevalent JJ I-NP O
12 593 599 19889778 immune JJ I-NP O
13 600 606 19889778 escape NN I-NP O
14 607 615 19889778 variants NNS I-NP O
15 615 616 19889778 , , O O
16 617 620 19889778 the DT B-NP O
17 621 627 19889778 sG145R NN I-NP O
18 628 631 19889778 and CC I-NP O
19 632 638 19889778 sP120T NN I-NP O
20 639 646 19889778 mutants NNS I-NP O
21 646 647 19889778 , , O O
22 648 650 19889778 on IN B-PP O
23 651 654 19889778 the DT B-NP O
24 655 660 19889778 viral JJ I-NP O
25 661 672 19889778 replication NN I-NP O
26 673 681 19889778 efficacy NN I-NP O
27 682 685 19889778 and CC O O
28 686 695 19889778 antiviral JJ B-NP O
29 696 700 19889778 drug NN I-NP O
30 701 715 19889778 susceptibility NN I-NP O
31 716 718 19889778 of IN B-PP O
32 719 725 19889778 common JJ B-NP O
33 726 735 19889778 treatment NN I-NP O
34 735 736 19889778 - HYPH B-NP O
35 736 746 19889778 associated VBN I-NP O
36 747 754 19889778 mutants NNS I-NP O
37 755 759 19889778 with IN B-PP O
38 760 770 19889778 resistance NN B-NP O
39 771 773 19889778 to TO B-PP O
40 774 784 19889778 lamivudine NN B-NP B-Chemical
41 785 786 19889778 ( ( O O
42 786 789 19889778 LAM NN B-NP B-Chemical
43 789 790 19889778 ) ) O O
44 791 794 19889778 and CC O O
45 794 795 19889778 / SYM B-NP O
46 795 797 19889778 or CC O O
47 798 803 19889778 HBeAg NN B-NP B-Chemical
48 804 814 19889778 negativity NN I-NP O
49 814 815 19889778 . . O O

1 816 827 19889778 Replication NN B-NP O
2 827 828 19889778 - HYPH I-NP O
3 828 837 19889778 competent JJ I-NP O
4 838 841 19889778 HBV NN I-NP O
5 842 849 19889778 strains NNS I-NP O
6 850 854 19889778 with IN B-PP O
7 855 861 19889778 sG145R NN B-NP O
8 862 864 19889778 or CC O O
9 865 871 19889778 sP120T NN B-NP O
10 872 875 19889778 and CC O O
11 876 879 19889778 LAM NN B-NP B-Chemical
12 880 890 19889778 resistance NN I-NP O
13 891 892 19889778 ( ( O O
14 892 899 19889778 rtM204I NN B-NP O
15 900 902 19889778 or CC O O
16 903 910 19889778 rtL180M NN B-NP O
17 910 911 19889778 / SYM B-NP O
18 911 918 19889778 rtM204V NN I-NP O
19 918 919 19889778 ) ) O O
20 920 924 19889778 were VBD B-VP O
21 925 934 19889778 generated VBN I-VP O
22 935 937 19889778 on IN B-PP O
23 938 940 19889778 an DT B-NP O
24 941 946 19889778 HBeAg NN I-NP B-Chemical
25 946 947 19889778 - HYPH B-VP O
26 947 955 19889778 positive JJ B-ADJP O
27 956 959 19889778 and CC O O
28 960 962 19889778 an DT B-NP O
29 963 968 19889778 HBeAg NN I-NP B-Chemical
30 968 969 19889778 - HYPH B-NP O
31 969 977 19889778 negative JJ I-NP O
32 978 988 19889778 background NN I-NP O
33 989 993 19889778 with IN B-PP O
34 994 1001 19889778 precore NN B-NP O
35 1002 1003 19889778 ( ( O O
36 1003 1005 19889778 PC NN B-NP O
37 1005 1006 19889778 ) ) O O
38 1007 1010 19889778 and CC O O
39 1011 1016 19889778 basal JJ B-NP O
40 1017 1021 19889778 core NN I-NP O
41 1022 1030 19889778 promoter NN I-NP O
42 1031 1032 19889778 ( ( O O
43 1032 1035 19889778 BCP NN B-NP O
44 1035 1036 19889778 ) ) O O
45 1037 1044 19889778 mutants NNS B-NP O
46 1044 1045 19889778 . . O O

1 1046 1049 19889778 The DT B-NP O
2 1050 1056 19889778 sG145R NN I-NP O
3 1057 1065 19889778 mutation NN I-NP O
4 1066 1074 19889778 strongly RB B-ADVP O
5 1075 1082 19889778 reduced VBD B-VP O
6 1083 1088 19889778 HBsAg NN B-NP B-Chemical
7 1089 1095 19889778 levels NNS I-NP O
8 1096 1099 19889778 and CC O O
9 1100 1103 19889778 was VBD B-VP O
10 1104 1108 19889778 able JJ B-ADJP O
11 1109 1111 19889778 to TO B-VP O
12 1112 1117 19889778 fully RB I-VP O
13 1118 1125 19889778 restore VB I-VP O
14 1126 1129 19889778 the DT B-NP O
15 1130 1138 19889778 impaired JJ I-NP O
16 1139 1150 19889778 replication NN I-NP O
17 1151 1153 19889778 of IN B-PP O
18 1154 1157 19889778 LAM NN B-NP B-Chemical
19 1157 1158 19889778 - HYPH B-NP O
20 1158 1167 19889778 resistant JJ I-NP O
21 1168 1171 19889778 HBV NN I-NP O
22 1172 1179 19889778 mutants NNS I-NP O
23 1180 1182 19889778 to TO B-PP O
24 1183 1186 19889778 the DT B-NP O
25 1187 1193 19889778 levels NNS I-NP O
26 1194 1196 19889778 of IN B-PP O
27 1197 1201 19889778 wild JJ B-NP O
28 1201 1202 19889778 - HYPH I-NP O
29 1202 1206 19889778 type NN I-NP O
30 1207 1210 19889778 HBV NN I-NP O
31 1210 1211 19889778 , , O O
32 1212 1215 19889778 and CC O O
33 1216 1218 19889778 PC NN B-NP O
34 1219 1221 19889778 or CC I-NP O
35 1222 1225 19889778 BCP NN I-NP O
36 1226 1235 19889778 mutations NNS I-NP O
37 1236 1243 19889778 further RBR B-ADVP O
38 1244 1252 19889778 enhanced VBD B-VP O
39 1253 1258 19889778 viral JJ B-NP O
40 1259 1270 19889778 replication NN I-NP O
41 1270 1271 19889778 . . O O

1 1272 1280 19889778 Although IN B-SBAR O
2 1281 1284 19889778 the DT B-NP O
3 1285 1291 19889778 sP120T NN I-NP O
4 1292 1304 19889778 substitution NN I-NP O
5 1305 1309 19889778 also RB B-ADVP O
6 1310 1318 19889778 impaired VBD B-VP O
7 1319 1324 19889778 HBsAg NN B-NP B-Chemical
8 1325 1334 19889778 secretion NN I-NP O
9 1334 1335 19889778 , , O O
10 1336 1338 19889778 it PRP B-NP O
11 1339 1342 19889778 did VBD B-VP O
12 1343 1346 19889778 not RB I-VP O
13 1347 1354 19889778 enhance VB I-VP O
14 1355 1358 19889778 the DT B-NP O
15 1359 1370 19889778 replication NN I-NP O
16 1371 1373 19889778 of IN B-PP O
17 1374 1377 19889778 LAM NN B-NP B-Chemical
18 1377 1378 19889778 - HYPH B-NP O
19 1378 1387 19889778 resistant JJ I-NP O
20 1388 1394 19889778 clones NNS I-NP O
21 1394 1395 19889778 . . O O

1 1396 1403 19889778 However RB B-ADVP O
2 1403 1404 19889778 , , O O
3 1405 1408 19889778 the DT B-NP O
4 1409 1420 19889778 concomitant JJ I-NP O
5 1421 1431 19889778 occurrence NN I-NP O
6 1432 1434 19889778 of IN B-PP O
7 1435 1440 19889778 HBeAg NN B-NP B-Chemical
8 1441 1451 19889778 negativity NN I-NP O
9 1452 1453 19889778 ( ( O O
10 1453 1455 19889778 PC NN B-NP O
11 1455 1456 19889778 / SYM O O
12 1456 1459 19889778 BCP NN B-NP O
13 1459 1460 19889778 ) ) O O
14 1460 1461 19889778 , , O O
15 1462 1468 19889778 sP120T NN B-NP O
16 1468 1469 19889778 , , O O
17 1470 1473 19889778 and CC O O
18 1474 1477 19889778 LAM NN B-NP B-Chemical
19 1478 1488 19889778 resistance NN I-NP O
20 1489 1497 19889778 resulted VBD B-VP O
21 1498 1500 19889778 in IN B-PP O
22 1501 1504 19889778 the DT B-NP O
23 1505 1516 19889778 restoration NN I-NP O
24 1517 1519 19889778 of IN B-PP O
25 1520 1531 19889778 replication NN B-NP O
26 1532 1534 19889778 to TO B-PP O
27 1535 1541 19889778 levels NNS B-NP O
28 1542 1544 19889778 of IN B-PP O
29 1545 1549 19889778 wild JJ B-NP O
30 1549 1550 19889778 - HYPH I-NP O
31 1550 1554 19889778 type NN I-NP O
32 1555 1558 19889778 HBV NN I-NP O
33 1558 1559 19889778 . . O O

1 1560 1562 19889778 In IN B-PP O
2 1563 1566 19889778 all DT B-NP O
3 1567 1573 19889778 clones NNS I-NP O
4 1574 1578 19889778 with IN B-PP O
5 1579 1587 19889778 combined JJ B-NP O
6 1588 1594 19889778 immune JJ I-NP O
7 1595 1601 19889778 escape NN I-NP O
8 1602 1605 19889778 and CC I-NP O
9 1606 1609 19889778 LAM NN I-NP B-Chemical
10 1610 1620 19889778 resistance NN I-NP O
11 1621 1630 19889778 mutations NNS I-NP O
12 1630 1631 19889778 , , O O
13 1632 1635 19889778 the DT B-NP O
14 1636 1646 19889778 nucleotide NN I-NP B-Chemical
15 1647 1656 19889778 analogues NNS I-NP O
16 1657 1665 19889778 adefovir NN I-NP B-Chemical
17 1666 1669 19889778 and CC I-NP O
18 1670 1679 19889778 tenofovir NN I-NP B-Chemical
19 1680 1688 19889778 remained VBD B-VP O
20 1689 1698 19889778 effective JJ B-ADJP O
21 1699 1701 19889778 in IN B-PP O
22 1702 1713 19889778 suppressing VBG B-VP O
23 1714 1719 19889778 viral JJ B-NP O
24 1720 1731 19889778 replication NN I-NP O
25 1732 1734 19889778 in FW B-ADVP O
26 1735 1740 19889778 vitro FW I-ADVP O
27 1740 1741 19889778 . . O O

1 1742 1747 19889778 These DT B-NP O
2 1748 1756 19889778 findings NNS I-NP O
3 1757 1763 19889778 reveal VBP B-VP O
4 1764 1767 19889778 the DT B-NP O
5 1768 1780 19889778 differential JJ I-NP O
6 1781 1787 19889778 impact NN I-NP O
7 1788 1790 19889778 of IN B-PP O
8 1791 1797 19889778 immune JJ B-NP O
9 1798 1804 19889778 escape NN I-NP O
10 1805 1813 19889778 variants NNS I-NP O
11 1814 1816 19889778 on IN B-PP O
12 1817 1820 19889778 the DT B-NP O
13 1821 1832 19889778 replication NN I-NP O
14 1833 1836 19889778 and CC I-NP O
15 1837 1841 19889778 drug NN I-NP O
16 1842 1856 19889778 susceptibility NN I-NP O
17 1857 1859 19889778 of IN B-PP O
18 1860 1867 19889778 complex JJ B-NP O
19 1868 1871 19889778 HBV NN I-NP O
20 1872 1879 19889778 mutants NNS I-NP O
21 1879 1880 19889778 , , O O
22 1881 1891 19889778 supporting VBG B-VP O
23 1892 1895 19889778 the DT B-NP O
24 1896 1900 19889778 need NN I-NP O
25 1901 1903 19889778 of IN B-PP O
26 1904 1909 19889778 close JJ B-NP O
27 1910 1922 19889778 surveillance NN I-NP O
28 1923 1926 19889778 and CC I-NP O
29 1927 1936 19889778 treatment NN I-NP O
30 1937 1947 19889778 adjustment NN I-NP O
31 1948 1950 19889778 in IN B-PP O
32 1951 1959 19889778 response NN B-NP O
33 1960 1962 19889778 to TO B-PP O
34 1963 1966 19889778 the DT B-NP O
35 1967 1976 19889778 selection NN I-NP O
36 1977 1979 19889778 of IN B-PP O
37 1980 1988 19889778 distinct JJ B-NP O
38 1989 1999 19889778 mutational JJ I-NP O
39 2000 2008 19889778 patterns NNS I-NP O
40 2008 2009 19889778 . . O O

1 0 0 2476560 -DOCSTART- -X- -X- O

1 0 2 2476560 Is VBZ O O
2 3 6 2476560 the DT B-NP O
3 7 16 2476560 treatment NN I-NP O
4 17 19 2476560 of IN B-PP O
5 20 27 2476560 scabies NNS B-NP B-Disease
6 28 37 2476560 hazardous JJ B-ADJP O
7 37 38 2476560 ? . O O
8 39 48 2476560 Treatment NN B-NP O
9 49 52 2476560 for IN B-PP O
10 53 60 2476560 scabies NNS B-NP B-Disease
11 61 63 2476560 is VBZ B-VP O
12 64 71 2476560 usually RB I-VP O
13 72 81 2476560 initiated VBN I-VP O
14 82 84 2476560 by IN B-PP O
15 85 92 2476560 general JJ B-NP O
16 93 106 2476560 practitioners NNS I-NP O
17 106 107 2476560 ; : O O
18 108 112 2476560 most RBS B-NP O
19 113 121 2476560 consider JJ I-NP O
20 122 129 2476560 lindane NN I-NP B-Chemical
21 130 131 2476560 ( ( O O
22 131 136 2476560 gamma NN B-NP B-Chemical
23 137 144 2476560 benzene NN I-NP I-Chemical
24 145 157 2476560 hexachloride NN I-NP I-Chemical
25 157 158 2476560 ) ) O O
26 159 162 2476560 the DT B-NP O
27 163 172 2476560 treatment NN I-NP O
28 173 175 2476560 of IN B-PP O
29 176 182 2476560 choice NN B-NP O
30 182 183 2476560 . . O O

1 184 191 2476560 Lindane NN B-NP B-Chemical
2 192 194 2476560 is VBZ B-VP O
3 195 199 2476560 also RB B-ADVP O
4 200 206 2476560 widely RB B-VP O
5 207 211 2476560 used VBN I-VP O
6 212 214 2476560 as IN B-PP O
7 215 217 2476560 an DT B-NP O
8 218 230 2476560 agricultural JJ I-NP O
9 231 234 2476560 and CC I-NP O
10 235 245 2476560 industrial JJ I-NP O
11 246 255 2476560 pesticide NN I-NP O
12 255 256 2476560 , , O O
13 257 260 2476560 and CC O O
14 261 263 2476560 as IN B-PP O
15 264 265 2476560 a DT B-NP O
16 266 272 2476560 result NN I-NP O
17 273 276 2476560 the DT B-NP O
18 277 282 2476560 toxic JJ I-NP O
19 283 290 2476560 profile NN I-NP O
20 291 293 2476560 of IN B-PP O
21 294 298 2476560 this DT B-NP O
22 299 310 2476560 insecticide NN I-NP O
23 311 313 2476560 is VBZ B-VP O
24 314 318 2476560 well RB I-VP O
25 319 329 2476560 understood VBN I-VP O
26 329 330 2476560 . . O O

1 331 339 2476560 Evidence NN B-NP O
2 340 342 2476560 is VBZ B-VP O
3 343 355 2476560 accumulating VBG I-VP O
4 356 360 2476560 that DT B-NP O
5 361 368 2476560 lindane NN I-NP B-Chemical
6 369 372 2476560 can MD B-VP O
7 373 375 2476560 be VB I-VP O
8 376 381 2476560 toxic JJ B-ADJP B-Disease
9 382 384 2476560 to TO B-PP I-Disease
10 385 388 2476560 the DT B-NP I-Disease
11 389 396 2476560 central JJ I-NP I-Disease
12 397 404 2476560 nervous JJ I-NP I-Disease
13 405 411 2476560 system NN I-NP I-Disease
14 412 415 2476560 and CC O O
15 416 419 2476560 may MD B-VP O
16 420 422 2476560 be VB I-VP O
17 423 433 2476560 associated VBN I-VP O
18 434 438 2476560 with IN B-PP O
19 439 447 2476560 aplastic JJ B-NP B-Disease
20 448 455 2476560 anaemia NN I-NP I-Disease
21 455 456 2476560 . . O O

1 457 469 2476560 Preparations NNS B-NP O
2 470 480 2476560 containing VBG B-VP O
3 481 488 2476560 lindane NN B-NP B-Chemical
4 489 497 2476560 continue VBP B-VP O
5 498 500 2476560 to TO I-VP O
6 501 503 2476560 be VB I-VP O
7 504 508 2476560 sold VBN I-VP O
8 509 513 2476560 over IN B-PP O
9 514 517 2476560 the DT B-NP O
10 518 525 2476560 counter NN I-NP O
11 526 529 2476560 and CC O O
12 530 533 2476560 may MD B-VP O
13 534 543 2476560 represent VB I-VP O
14 544 545 2476560 a DT B-NP O
15 546 552 2476560 hazard NN I-NP O
16 553 555 2476560 to TO B-PP O
17 556 562 2476560 poorly RB B-NP O
18 563 571 2476560 informed VBN I-NP O
19 572 580 2476560 patients NNS I-NP O
20 580 581 2476560 . . O O

1 582 586 2476560 This DT B-NP O
2 587 597 2476560 literature NN I-NP O
3 598 604 2476560 review NN I-NP O
4 605 613 2476560 suggests VBZ B-VP O
5 614 618 2476560 that IN B-SBAR O
6 619 626 2476560 general JJ B-NP O
7 627 640 2476560 practitioners NNS I-NP O
8 641 647 2476560 should MD B-VP O
9 648 657 2476560 prescribe VB I-VP O
10 658 668 2476560 scabicides NNS B-NP O
11 669 673 2476560 with IN B-PP O
12 674 683 2476560 increased VBN B-NP O
13 684 691 2476560 caution NN I-NP O
14 692 695 2476560 for IN B-PP O
15 696 703 2476560 certain JJ B-NP O
16 704 706 2476560 at IN B-PP O
17 706 707 2476560 - HYPH B-NP O
18 707 711 2476560 risk NN I-NP O
19 712 718 2476560 groups NNS I-NP O
20 718 719 2476560 , , O O
21 720 723 2476560 and CC O O
22 724 728 2476560 give VB B-VP O
23 729 737 2476560 adequate JJ B-NP O
24 738 746 2476560 warnings NNS I-NP O
25 747 756 2476560 regarding VBG B-VP O
26 757 766 2476560 potential JJ B-NP O
27 767 775 2476560 toxicity NN I-NP B-Disease
28 775 776 2476560 . . O O

1 0 0 17242861 -DOCSTART- -X- -X- O

1 0 3 17242861 Use NN B-NP O
2 4 6 17242861 of IN B-PP O
3 7 17 17242861 chromosome NN B-NP O
4 18 30 17242861 substitution NN I-NP O
5 31 38 17242861 strains NNS I-NP O
6 39 41 17242861 to TO B-VP O
7 42 50 17242861 identify VB I-VP O
8 51 58 17242861 seizure NN B-NP B-Disease
9 59 73 17242861 susceptibility NN I-NP O
10 74 78 17242861 loci NNS I-NP O
11 79 81 17242861 in IN B-PP O
12 82 86 17242861 mice NNS B-NP O
13 86 87 17242861 . . O O
14 88 95 17242861 Seizure NN B-NP B-Disease
15 96 110 17242861 susceptibility NN I-NP O
16 111 117 17242861 varies VBZ B-VP O
17 118 123 17242861 among IN B-PP O
18 124 130 17242861 inbred JJ B-NP O
19 131 136 17242861 mouse NN I-NP O
20 137 144 17242861 strains NNS I-NP O
21 144 145 17242861 . . O O

1 146 156 17242861 Chromosome NN B-NP O
2 157 169 17242861 substitution NN I-NP O
3 170 177 17242861 strains NNS I-NP O
4 178 179 17242861 ( ( O O
5 179 182 17242861 CSS NN B-NP O
6 182 183 17242861 ) ) O O
7 183 184 17242861 , , O O
8 185 187 17242861 in IN B-PP O
9 188 193 17242861 which WDT B-NP O
10 194 195 17242861 a DT B-NP O
11 196 202 17242861 single JJ I-NP O
12 203 213 17242861 chromosome NN I-NP O
13 214 218 17242861 from IN B-PP O
14 219 222 17242861 one CD B-NP O
15 223 229 17242861 inbred JJ I-NP O
16 230 236 17242861 strain NN I-NP O
17 237 238 17242861 ( ( O O
18 238 243 17242861 donor NN B-NP O
19 243 244 17242861 ) ) O O
20 245 248 17242861 has VBZ B-VP O
21 249 253 17242861 been VBN I-VP O
22 254 265 17242861 transferred VBN I-VP O
23 266 270 17242861 onto IN B-PP O
24 271 272 17242861 a DT B-NP O
25 273 279 17242861 second JJ I-NP O
26 280 286 17242861 strain NN I-NP O
27 287 288 17242861 ( ( O O
28 288 292 17242861 host NN B-NP O
29 292 293 17242861 ) ) O O
30 294 296 17242861 by IN B-PP O
31 297 305 17242861 repeated VBN B-NP O
32 306 318 17242861 backcrossing NN I-NP O
33 318 319 17242861 , , O O
34 320 323 17242861 may MD B-VP O
35 324 326 17242861 be VB I-VP O
36 327 331 17242861 used VBN I-VP O
37 332 334 17242861 to TO B-VP O
38 335 343 17242861 identify VB I-VP O
39 344 356 17242861 quantitative JJ B-NP O
40 357 362 17242861 trait NN I-NP O
41 363 367 17242861 loci NNS I-NP O
42 368 369 17242861 ( ( O O
43 369 373 17242861 QTLs NNS B-NP O
44 373 374 17242861 ) ) O O
45 375 379 17242861 that WDT B-NP O
46 380 390 17242861 contribute VBP B-VP O
47 391 393 17242861 to TO I-VP O
48 394 401 17242861 seizure VB I-VP B-Disease
49 402 416 17242861 susceptibility NN B-NP O
50 416 417 17242861 . . O O

1 418 422 17242861 QTLs NNS B-NP O
2 423 426 17242861 for IN B-PP O
3 427 441 17242861 susceptibility NN B-NP O
4 442 444 17242861 to TO B-PP O
5 445 456 17242861 pilocarpine NN B-NP B-Chemical
6 456 457 17242861 - HYPH B-NP O
7 457 464 17242861 induced VBN I-NP O
8 465 473 17242861 seizures NNS I-NP B-Disease
9 473 474 17242861 , , O O
10 475 476 17242861 a DT B-NP O
11 477 482 17242861 model NN I-NP O
12 483 485 17242861 of IN B-PP O
13 486 494 17242861 temporal JJ B-NP B-Disease
14 495 499 17242861 lobe NN I-NP I-Disease
15 500 508 17242861 epilepsy NN I-NP I-Disease
16 508 509 17242861 , , O O
17 510 514 17242861 have VBP B-VP O
18 515 518 17242861 not RB I-VP O
19 519 523 17242861 been VBN I-VP O
20 524 532 17242861 reported VBN I-VP O
21 532 533 17242861 , , O O
22 534 537 17242861 and CC O O
23 538 541 17242861 CSS NN B-NP O
24 542 546 17242861 have VBP B-VP O
25 547 550 17242861 not RB I-VP O
26 551 561 17242861 previously RB I-VP O
27 562 566 17242861 been VBN I-VP O
28 567 571 17242861 used VBN I-VP O
29 572 574 17242861 to TO B-VP O
30 575 583 17242861 localize VB I-VP O
31 584 591 17242861 seizure NN B-NP B-Disease
32 592 606 17242861 susceptibility NN I-NP O
33 607 612 17242861 genes NNS I-NP O
34 612 613 17242861 . . O O

1 614 616 17242861 We PRP B-NP O
2 617 623 17242861 report VBP B-VP O
3 624 628 17242861 QTLs NNS B-NP O
4 629 639 17242861 identified VBN B-VP O
5 640 645 17242861 using VBG B-VP O
6 646 647 17242861 a DT B-NP O
7 648 650 17242861 B6 NN I-NP O
8 651 652 17242861 ( ( O O
9 652 656 17242861 host NN B-NP O
10 656 657 17242861 ) ) O O
11 658 659 17242861 x NN B-NP O
12 660 661 17242861 A NN I-NP O
13 661 662 17242861 / SYM O O
14 662 663 17242861 J NN B-NP O
15 664 665 17242861 ( ( O O
16 665 670 17242861 donor NN B-NP O
17 670 671 17242861 ) ) O O
18 672 675 17242861 CSS NN B-NP O
19 676 681 17242861 panel NN I-NP O
20 682 684 17242861 to TO B-VP O
21 685 693 17242861 localize VB I-VP O
22 694 699 17242861 genes NNS B-NP O
23 700 708 17242861 involved VBN B-VP O
24 709 711 17242861 in IN B-PP O
25 712 726 17242861 susceptibility NN B-NP O
26 727 729 17242861 to TO B-PP O
27 730 741 17242861 pilocarpine NN B-NP B-Chemical
28 741 742 17242861 - HYPH B-NP O
29 742 749 17242861 induced VBN I-NP O
30 750 758 17242861 seizures NNS I-NP B-Disease
31 758 759 17242861 . . O O

1 760 765 17242861 Three CD B-NP O
2 766 773 17242861 hundred CD I-NP O
3 774 779 17242861 fifty CD I-NP O
4 779 780 17242861 - HYPH I-NP O
5 780 784 17242861 five CD I-NP O
6 785 790 17242861 adult JJ I-NP O
7 791 795 17242861 male JJ I-NP O
8 796 799 17242861 CSS NN I-NP O
9 800 804 17242861 mice NNS I-NP O
10 804 805 17242861 , , O O
11 806 808 17242861 58 CD B-NP O
12 809 811 17242861 B6 NN I-NP O
13 811 812 17242861 , , O O
14 813 816 17242861 and CC O O
15 817 819 17242861 39 CD B-NP O
16 820 821 17242861 A NN I-NP O
17 821 822 17242861 / SYM B-NP O
18 822 823 17242861 J NN I-NP O
19 824 828 17242861 were VBD B-VP O
20 829 835 17242861 tested VBN I-VP O
21 836 839 17242861 for IN B-PP O
22 840 854 17242861 susceptibility NN B-NP O
23 855 857 17242861 to TO B-PP O
24 858 869 17242861 pilocarpine NN B-NP B-Chemical
25 869 870 17242861 - HYPH B-NP O
26 870 877 17242861 induced VBN I-NP O
27 878 886 17242861 seizures NNS I-NP B-Disease
28 886 887 17242861 . . O O

1 888 895 17242861 Highest JJ B-NP O
2 896 901 17242861 stage NN I-NP O
3 902 909 17242861 reached VBD B-VP O
4 910 913 17242861 and CC O O
5 914 921 17242861 latency NN B-NP O
6 922 924 17242861 to TO B-PP O
7 925 929 17242861 each DT B-NP O
8 930 935 17242861 stage NN I-NP O
9 936 940 17242861 were VBD B-VP O
10 941 949 17242861 recorded VBN I-VP O
11 950 953 17242861 for IN B-PP O
12 954 957 17242861 all DT B-NP O
13 958 962 17242861 mice NNS I-NP O
14 962 963 17242861 . . O O

1 964 966 17242861 B6 NN B-NP O
2 967 971 17242861 mice NNS I-NP O
3 972 976 17242861 were VBD B-VP O
4 977 986 17242861 resistant JJ B-ADJP O
5 987 989 17242861 to TO B-PP O
6 990 998 17242861 seizures NNS B-NP B-Disease
7 999 1002 17242861 and CC O O
8 1003 1009 17242861 slower JJR B-ADJP O
9 1010 1012 17242861 to TO B-VP O
10 1013 1018 17242861 reach VB I-VP O
11 1019 1025 17242861 stages NNS B-NP O
12 1026 1034 17242861 compared VBN B-PP O
13 1035 1037 17242861 to TO B-PP O
14 1038 1039 17242861 A NN B-NP O
15 1039 1040 17242861 / SYM I-NP O
16 1040 1041 17242861 J NN I-NP O
17 1042 1046 17242861 mice NNS I-NP O
18 1046 1047 17242861 . . O O

1 1048 1051 17242861 The DT B-NP O
2 1052 1055 17242861 CSS NN I-NP O
3 1056 1059 17242861 for IN B-PP O
4 1060 1071 17242861 Chromosomes NNS B-NP O
5 1072 1074 17242861 10 CD B-NP O
6 1075 1078 17242861 and CC I-NP O
7 1079 1081 17242861 18 CD I-NP O
8 1082 1092 17242861 progressed VBD B-VP O
9 1093 1095 17242861 to TO B-PP O
10 1096 1099 17242861 the DT B-NP O
11 1100 1104 17242861 most RBS I-NP O
12 1105 1111 17242861 severe JJ I-NP O
13 1112 1118 17242861 stages NNS I-NP O
14 1118 1119 17242861 , , O O
15 1120 1129 17242861 diverging VBG B-VP O
16 1130 1142 17242861 dramatically RB B-ADVP O
17 1143 1147 17242861 from IN B-PP O
18 1148 1151 17242861 the DT B-NP O
19 1152 1154 17242861 B6 NN I-NP O
20 1155 1164 17242861 phenotype NN I-NP O
21 1164 1165 17242861 . . O O

1 1166 1175 17242861 Latencies NNS B-NP O
2 1176 1178 17242861 to TO B-PP O
3 1179 1185 17242861 stages NNS B-NP O
4 1186 1190 17242861 were VBD B-VP O
5 1191 1195 17242861 also RB B-ADVP O
6 1196 1209 17242861 significantly RB B-ADJP O
7 1210 1217 17242861 shorter JJR I-ADJP O
8 1218 1221 17242861 for IN B-PP O
9 1222 1227 17242861 CSS10 NN B-NP O
10 1228 1231 17242861 and CC I-NP O
11 1232 1237 17242861 CSS18 NN I-NP O
12 1238 1242 17242861 mice NNS I-NP O
13 1242 1243 17242861 . . O O

1 1244 1247 17242861 CSS NN B-NP O
2 1248 1255 17242861 mapping NN I-NP O
3 1256 1264 17242861 suggests VBZ B-VP O
4 1265 1272 17242861 seizure NN B-NP B-Disease
5 1273 1287 17242861 susceptibility NN I-NP O
6 1288 1292 17242861 loci NNS I-NP O
7 1293 1295 17242861 on IN B-PP O
8 1296 1301 17242861 mouse NN B-NP O
9 1302 1313 17242861 Chromosomes NNS I-NP O
10 1314 1316 17242861 10 CD B-NP O
11 1317 1320 17242861 and CC I-NP O
12 1321 1323 17242861 18 CD I-NP O
13 1323 1324 17242861 . . O O

1 1325 1329 17242861 This DT B-NP O
2 1330 1338 17242861 approach NN I-NP O
3 1339 1347 17242861 provides VBZ B-VP O
4 1348 1349 17242861 a DT B-NP O
5 1350 1359 17242861 framework NN I-NP O
6 1360 1363 17242861 for IN B-PP O
7 1364 1375 17242861 identifying VBG B-VP O
8 1376 1387 17242861 potentially RB B-NP O
9 1388 1393 17242861 novel JJ I-NP O
10 1394 1404 17242861 homologous JJ I-NP O
11 1405 1414 17242861 candidate NN I-NP O
12 1415 1420 17242861 genes NNS I-NP O
13 1421 1424 17242861 for IN B-PP O
14 1425 1430 17242861 human JJ B-NP O
15 1431 1439 17242861 temporal JJ I-NP B-Disease
16 1440 1444 17242861 lobe NN I-NP I-Disease
17 1445 1453 17242861 epilepsy NN I-NP I-Disease
18 1453 1454 17242861 . . O O

1 0 0 8752018 -DOCSTART- -X- -X- O

1 0 7 8752018 Lithium NN B-NP B-Chemical
2 7 8 8752018 - HYPH B-NP O
3 8 18 8752018 associated VBN I-NP O
4 19 28 8752018 cognitive JJ I-NP B-Disease
5 29 32 8752018 and CC I-NP I-Disease
6 33 43 8752018 functional JJ I-NP I-Disease
7 44 52 8752018 deficits NNS I-NP I-Disease
8 53 60 8752018 reduced VBN B-VP O
9 61 63 8752018 by IN B-PP O
10 64 65 8752018 a DT B-NP O
11 66 72 8752018 switch NN I-NP O
12 73 75 8752018 to TO B-PP O
13 76 86 8752018 divalproex NN B-NP B-Chemical
14 87 93 8752018 sodium NN I-NP I-Chemical
15 93 94 8752018 : : O O
16 95 96 8752018 a DT B-NP O
17 97 101 8752018 case NN I-NP O
18 102 108 8752018 series NN I-NP O
19 108 109 8752018 . . I-NP O
20 110 120 8752018 BACKGROUND NN I-NP O
21 120 121 8752018 : : O O
22 122 129 8752018 Lithium NN B-NP B-Chemical
23 130 137 8752018 remains VBZ B-VP O
24 138 139 8752018 a DT B-NP O
25 140 145 8752018 first JJ I-NP O
26 145 146 8752018 - HYPH I-NP O
27 146 150 8752018 line NN I-NP O
28 151 160 8752018 treatment NN I-NP O
29 161 164 8752018 for IN B-PP O
30 165 168 8752018 the DT B-NP O
31 169 174 8752018 acute JJ I-NP O
32 175 178 8752018 and CC I-NP O
33 179 190 8752018 maintenance NN I-NP O
34 191 200 8752018 treatment NN I-NP O
35 201 203 8752018 of IN B-PP O
36 204 211 8752018 bipolar JJ B-NP B-Disease
37 212 220 8752018 disorder NN I-NP I-Disease
38 220 221 8752018 . . O O

1 222 230 8752018 Although IN B-SBAR O
2 231 235 8752018 much JJ B-NP O
3 236 239 8752018 has VBZ B-VP O
4 240 244 8752018 been VBN I-VP O
5 245 252 8752018 written VBN I-VP O
6 253 258 8752018 about IN B-PP O
7 259 262 8752018 the DT B-NP O
8 263 273 8752018 management NN I-NP O
9 274 276 8752018 of IN B-PP O
10 277 280 8752018 the DT B-NP O
11 281 285 8752018 more RBR I-NP O
12 286 292 8752018 common JJ I-NP O
13 293 300 8752018 adverse JJ I-NP O
14 301 308 8752018 effects NNS I-NP O
15 309 311 8752018 of IN B-PP O
16 312 319 8752018 lithium NN B-NP B-Chemical
17 319 320 8752018 , , O O
18 321 325 8752018 such JJ B-PP O
19 326 328 8752018 as IN I-PP O
20 329 337 8752018 polyuria NN B-NP B-Disease
21 338 341 8752018 and CC I-NP O
22 342 348 8752018 tremor NN I-NP B-Disease
23 348 349 8752018 , , O O
24 350 354 8752018 more RBR B-NP O
25 355 361 8752018 subtle JJ I-NP O
26 362 369 8752018 lithium NN I-NP B-Chemical
27 370 374 8752018 side NN I-NP O
28 375 382 8752018 effects NNS I-NP O
29 383 387 8752018 such JJ B-PP O
30 388 390 8752018 as IN I-PP O
31 391 400 8752018 cognitive JJ B-NP B-Disease
32 401 409 8752018 deficits NNS I-NP I-Disease
33 409 410 8752018 , , O O
34 411 415 8752018 loss NN B-NP B-Disease
35 416 418 8752018 of IN B-PP I-Disease
36 419 429 8752018 creativity NN B-NP I-Disease
37 429 430 8752018 , , O O
38 431 434 8752018 and CC O O
39 435 445 8752018 functional JJ B-NP B-Disease
40 446 457 8752018 impairments NNS I-NP I-Disease
41 458 464 8752018 remain VBP B-VP O
42 465 477 8752018 understudied JJ B-ADJP O
43 477 478 8752018 . . O O

1 479 483 8752018 This DT B-NP O
2 484 490 8752018 report NN I-NP O
3 491 501 8752018 summarizes VBZ B-VP O
4 502 505 8752018 our PRP$ B-NP O
5 506 516 8752018 experience NN I-NP O
6 517 519 8752018 in IN B-PP O
7 520 529 8752018 switching VBG B-VP O
8 530 537 8752018 bipolar JJ B-NP B-Disease
9 538 546 8752018 patients NNS I-NP O
10 547 551 8752018 from IN B-PP O
11 552 559 8752018 lithium NN B-NP B-Chemical
12 560 562 8752018 to TO B-PP O
13 563 573 8752018 divalproex NN B-NP B-Chemical
14 574 580 8752018 sodium NN I-NP I-Chemical
15 581 583 8752018 to TO B-VP O
16 584 593 8752018 alleviate VB I-VP O
17 594 598 8752018 such JJ B-NP O
18 599 608 8752018 cognitive JJ I-NP B-Disease
19 609 612 8752018 and CC I-NP I-Disease
20 613 623 8752018 functional JJ I-NP I-Disease
21 624 635 8752018 impairments NNS I-NP I-Disease
22 635 636 8752018 . . O O

1 637 643 8752018 METHOD NN B-NP O
2 643 644 8752018 : : O O
3 645 649 8752018 Open NN B-NP O
4 649 650 8752018 , , O O
5 651 655 8752018 case NN B-NP O
6 656 662 8752018 series NN I-NP O
7 663 669 8752018 design NN I-NP O
8 669 670 8752018 . . O O

1 671 678 8752018 RESULTS NNS B-NP O
2 678 679 8752018 : : O O
3 680 682 8752018 We PRP B-NP O
4 683 689 8752018 report VBP B-VP O
5 690 695 8752018 seven CD B-NP O
6 696 701 8752018 cases NNS I-NP O
7 702 707 8752018 where WRB B-ADVP O
8 708 720 8752018 substitution NN B-NP O
9 721 723 8752018 of IN B-PP O
10 724 731 8752018 lithium NN B-NP B-Chemical
11 731 732 8752018 , , O O
12 733 739 8752018 either CC O O
13 740 745 8752018 fully RB B-ADVP O
14 746 748 8752018 or CC I-ADVP O
15 749 758 8752018 partially RB I-ADVP O
16 758 759 8752018 , , O O
17 760 764 8752018 with IN B-PP O
18 765 775 8752018 divalproex NN B-NP B-Chemical
19 776 782 8752018 sodium NN I-NP I-Chemical
20 783 786 8752018 was VBD B-VP O
21 787 796 8752018 extremely RB B-ADJP O
22 797 804 8752018 helpful JJ I-ADJP O
23 805 807 8752018 in IN B-PP O
24 808 816 8752018 reducing VBG B-VP O
25 817 820 8752018 the DT B-NP O
26 821 830 8752018 cognitive JJ I-NP B-Disease
27 830 831 8752018 , , I-NP I-Disease
28 832 844 8752018 motivational JJ I-NP I-Disease
29 844 845 8752018 , , I-NP I-Disease
30 846 848 8752018 or CC I-NP I-Disease
31 849 857 8752018 creative JJ I-NP I-Disease
32 858 866 8752018 deficits NNS I-NP I-Disease
33 867 877 8752018 attributed VBN B-VP O
34 878 880 8752018 to TO B-PP O
35 881 888 8752018 lithium NN B-NP B-Chemical
36 889 891 8752018 in IN B-PP O
37 892 895 8752018 our PRP$ B-NP O
38 896 903 8752018 bipolar JJ I-NP B-Disease
39 904 912 8752018 patients NNS I-NP O
40 912 913 8752018 . . O O

1 914 924 8752018 CONCLUSION NN B-NP O
2 924 925 8752018 : : O O
3 926 928 8752018 In IN B-PP O
4 929 933 8752018 this DT B-NP O
5 934 945 8752018 preliminary JJ I-NP O
6 946 952 8752018 report NN I-NP O
7 952 953 8752018 , , O O
8 954 964 8752018 divalproex NN B-NP B-Chemical
9 965 971 8752018 sodium NN I-NP I-Chemical
10 972 975 8752018 was VBD B-VP O
11 976 977 8752018 a DT B-NP O
12 978 986 8752018 superior JJ I-NP O
13 987 998 8752018 alternative NN I-NP O
14 999 1001 8752018 to TO B-PP O
15 1002 1009 8752018 lithium NN B-NP B-Chemical
16 1010 1012 8752018 in IN B-PP O
17 1013 1020 8752018 bipolar JJ B-NP B-Disease
18 1021 1029 8752018 patients NNS I-NP O
19 1030 1042 8752018 experiencing VBG B-VP O
20 1043 1052 8752018 cognitive JJ B-NP B-Disease
21 1053 1061 8752018 deficits NNS I-NP I-Disease
22 1061 1062 8752018 , , O O
23 1063 1067 8752018 loss NN B-NP B-Disease
24 1068 1070 8752018 of IN B-PP I-Disease
25 1071 1081 8752018 creativity NN B-NP I-Disease
26 1081 1082 8752018 , , O O
27 1083 1086 8752018 and CC O O
28 1087 1097 8752018 functional JJ B-NP B-Disease
29 1098 1109 8752018 impairments NNS I-NP I-Disease
30 1109 1110 8752018 . . O O

1 0 0 1732369 -DOCSTART- -X- -X- O

1 0 10 1732369 Dobutamine NN B-NP B-Chemical
2 11 17 1732369 stress NN I-NP O
3 18 34 1732369 echocardiography NN I-NP O
4 34 35 1732369 : : O O
5 36 37 1732369 a DT B-NP O
6 38 47 1732369 sensitive JJ I-NP O
7 48 57 1732369 indicator NN I-NP O
8 58 60 1732369 of IN B-PP O
9 61 71 1732369 diminished VBN B-NP O
10 72 82 1732369 myocardial JJ I-NP O
11 83 91 1732369 function NN I-NP O
12 92 94 1732369 in IN B-PP O
13 95 107 1732369 asymptomatic JJ B-NP O
14 108 119 1732369 doxorubicin NN I-NP B-Chemical
15 119 120 1732369 - HYPH O O
16 120 127 1732369 treated VBN B-NP O
17 128 132 1732369 long JJ I-NP O
18 132 133 1732369 - HYPH I-NP O
19 133 137 1732369 term NN I-NP O
20 138 147 1732369 survivors NNS I-NP O
21 148 150 1732369 of IN B-PP O
22 151 160 1732369 childhood NN B-NP O
23 161 167 1732369 cancer NN I-NP B-Disease
24 167 168 1732369 . . I-NP O
25 169 180 1732369 Doxorubicin NN I-NP B-Chemical
26 181 183 1732369 is VBZ B-VP O
27 184 186 1732369 an DT B-NP O
28 187 196 1732369 effective JJ I-NP O
29 197 207 1732369 anticancer JJ I-NP O
30 208 224 1732369 chemotherapeutic JJ I-NP O
31 225 230 1732369 agent NN I-NP O
32 231 236 1732369 known VBN B-VP O
33 237 239 1732369 to TO B-VP O
34 240 245 1732369 cause VB I-VP O
35 246 251 1732369 acute JJ B-NP O
36 252 255 1732369 and CC I-NP O
37 256 263 1732369 chronic JJ I-NP O
38 264 278 1732369 cardiomyopathy NN I-NP B-Disease
39 278 279 1732369 . . O O

1 280 282 1732369 To TO B-VP O
2 283 290 1732369 develop VB I-VP O
3 291 292 1732369 a DT B-NP O
4 293 297 1732369 more RBR I-NP O
5 298 307 1732369 sensitive JJ I-NP O
6 308 325 1732369 echocardiographic JJ I-NP O
7 326 335 1732369 screening NN I-NP O
8 336 340 1732369 test NN I-NP O
9 341 344 1732369 for IN B-PP O
10 345 352 1732369 cardiac JJ B-NP B-Disease
11 353 359 1732369 damage NN I-NP I-Disease
12 360 363 1732369 due JJ B-ADJP O
13 364 366 1732369 to TO B-PP O
14 367 378 1732369 doxorubicin NN B-NP B-Chemical
15 378 379 1732369 , , O O
16 380 381 1732369 a DT B-NP O
17 382 388 1732369 cohort JJ I-NP O
18 389 394 1732369 study NN I-NP O
19 395 398 1732369 was VBD B-VP O
20 399 408 1732369 performed VBN I-VP O
21 409 414 1732369 using VBG B-VP O
22 415 425 1732369 dobutamine NN B-NP B-Chemical
23 426 434 1732369 infusion NN I-NP O
24 435 437 1732369 to TO B-VP O
25 438 451 1732369 differentiate VB I-VP O
26 452 464 1732369 asymptomatic JJ B-NP O
27 465 469 1732369 long JJ I-NP O
28 469 470 1732369 - HYPH I-NP O
29 470 474 1732369 term NN I-NP O
30 475 484 1732369 survivors NNS I-NP O
31 485 487 1732369 of IN B-PP O
32 488 497 1732369 childhood NN B-NP O
33 498 504 1732369 cancer NN I-NP B-Disease
34 505 512 1732369 treated VBN B-VP O
35 513 517 1732369 with IN B-PP O
36 518 529 1732369 doxorubicin NN B-NP B-Chemical
37 530 534 1732369 from IN B-PP O
38 535 542 1732369 healthy JJ B-NP O
39 543 550 1732369 control NN I-NP O
40 551 559 1732369 subjects NNS I-NP O
41 559 560 1732369 . . O O

1 561 578 1732369 Echocardiographic JJ B-NP O
2 579 583 1732369 data NNS I-NP O
3 584 588 1732369 from IN B-PP O
4 589 592 1732369 the DT B-NP O
5 593 605 1732369 experimental JJ I-NP O
6 606 611 1732369 group NN I-NP O
7 612 614 1732369 of IN B-PP O
8 615 617 1732369 21 CD B-NP O
9 618 626 1732369 patients NNS I-NP O
10 627 628 1732369 ( ( O O
11 628 632 1732369 mean JJ B-NP O
12 633 636 1732369 age NN I-NP O
13 637 639 1732369 16 CD I-NP O
14 640 641 1732369 + SYM O O
15 641 642 1732369 / SYM O O
16 642 643 1732369 - SYM O O
17 644 645 1732369 5 CD B-NP O
18 646 651 1732369 years NNS I-NP O
19 651 652 1732369 ) ) O O
20 653 660 1732369 treated VBN B-VP O
21 661 665 1732369 from IN B-PP O
22 666 669 1732369 1.6 CD B-NP O
23 670 672 1732369 to TO I-NP O
24 673 677 1732369 14.3 CD I-NP O
25 678 683 1732369 years NNS I-NP O
26 684 685 1732369 ( ( O O
27 685 691 1732369 median NN B-NP O
28 692 695 1732369 5.3 CD I-NP O
29 695 696 1732369 ) ) O O
30 697 703 1732369 before IN B-SBAR O
31 704 708 1732369 this DT B-NP O
32 709 714 1732369 study NN I-NP O
33 715 719 1732369 with IN B-PP O
34 720 722 1732369 27 CD B-NP O
35 723 725 1732369 to TO I-NP O
36 726 729 1732369 532 CD I-NP O
37 730 732 1732369 mg NN I-NP O
38 732 733 1732369 / SYM B-NP O
39 733 735 1732369 m2 NN I-NP O
40 736 738 1732369 of IN B-PP O
41 739 750 1732369 doxorubicin NN B-NP B-Chemical
42 751 752 1732369 ( ( O O
43 752 756 1732369 mean NN B-NP O
44 757 760 1732369 196 CD I-NP O
45 760 761 1732369 ) ) O O
46 762 766 1732369 were VBD B-VP O
47 767 775 1732369 compared VBN I-VP O
48 776 780 1732369 with IN B-PP O
49 781 798 1732369 echocardiographic JJ B-NP O
50 799 803 1732369 data NNS I-NP O
51 804 808 1732369 from IN B-PP O
52 809 811 1732369 12 CD B-NP O
53 812 818 1732369 normal JJ I-NP O
54 819 822 1732369 age NN I-NP O
55 822 823 1732369 - HYPH B-VP O
56 823 830 1732369 matched VBN B-NP O
57 831 838 1732369 control NN I-NP O
58 839 847 1732369 subjects NNS I-NP O
59 847 848 1732369 . . O O

1 849 855 1732369 Graded VBN B-NP O
2 856 866 1732369 dobutamine NN I-NP B-Chemical
3 867 876 1732369 infusions NNS I-NP O
4 877 879 1732369 of IN B-PP O
5 880 883 1732369 0.5 CD B-NP O
6 883 884 1732369 , , I-NP O
7 885 888 1732369 2.5 CD I-NP O
8 888 889 1732369 , , I-NP O
9 890 891 1732369 5 CD I-NP O
10 892 895 1732369 and CC I-NP O
11 896 898 1732369 10 CD I-NP O
12 899 909 1732369 micrograms NNS I-NP O
13 909 910 1732369 / SYM I-NP O
14 910 912 1732369 kg NN I-NP O
15 913 916 1732369 per IN B-PP O
16 917 920 1732369 min NN B-NP O
17 921 925 1732369 were VBD B-VP O
18 926 938 1732369 administered VBN I-VP O
19 938 939 1732369 . . O O

1 940 957 1732369 Echocardiographic JJ B-NP O
2 958 965 1732369 Doppler NNP I-NP O
3 966 973 1732369 studies NNS I-NP O
4 974 978 1732369 were VBD B-VP O
5 979 988 1732369 performed VBN I-VP O
6 989 995 1732369 before IN B-PP O
7 996 1004 1732369 infusion NN B-NP O
8 1005 1008 1732369 and CC O O
9 1009 1014 1732369 after IN B-PP O
10 1015 1017 1732369 15 CD B-NP O
11 1018 1021 1732369 min NN I-NP O
12 1022 1024 1732369 of IN B-PP O
13 1025 1033 1732369 infusion NN B-NP O
14 1034 1036 1732369 at IN B-PP O
15 1037 1041 1732369 each DT B-NP O
16 1042 1046 1732369 rate NN I-NP O
17 1046 1047 1732369 . . O O

1 1048 1058 1732369 Dobutamine NN B-NP B-Chemical
2 1059 1067 1732369 infusion NN I-NP O
3 1068 1070 1732369 at IN B-PP O
4 1071 1073 1732369 10 CD B-NP O
5 1074 1084 1732369 micrograms NNS I-NP O
6 1084 1085 1732369 / SYM B-NP O
7 1085 1087 1732369 kg NN I-NP O
8 1088 1091 1732369 per IN B-PP O
9 1092 1095 1732369 min NN B-NP O
10 1096 1099 1732369 was VBD B-VP O
11 1100 1112 1732369 discontinued VBN I-VP O
12 1113 1118 1732369 after IN B-PP O
13 1119 1122 1732369 six CD B-NP O
14 1123 1130 1732369 studies NNS I-NP O
15 1131 1140 1732369 secondary JJ B-ADJP O
16 1141 1143 1732369 to TO B-PP O
17 1144 1145 1732369 a DT B-NP O
18 1146 1149 1732369 50% CD I-NP O
19 1150 1159 1732369 incidence NN I-NP O
20 1160 1164 1732369 rate NN I-NP O
21 1165 1167 1732369 of IN B-PP O
22 1168 1175 1732369 adverse JJ B-NP O
23 1176 1184 1732369 symptoms NNS I-NP O
24 1184 1185 1732369 . . O O

1 1186 1189 1732369 The DT B-NP O
2 1190 1194 1732369 most RBS I-NP O
3 1195 1204 1732369 important JJ I-NP O
4 1205 1213 1732369 findings NNS I-NP O
5 1214 1218 1732369 were VBD B-VP O
6 1219 1223 1732369 that IN B-SBAR O
7 1224 1232 1732369 compared VBN B-PP O
8 1233 1237 1732369 with IN B-PP O
9 1238 1244 1732369 values NNS B-NP O
10 1245 1247 1732369 in IN B-PP O
11 1248 1255 1732369 control JJ B-NP O
12 1256 1264 1732369 subjects NNS I-NP O
13 1264 1265 1732369 , , O O
14 1266 1269 1732369 end NN B-NP O
15 1269 1270 1732369 - HYPH I-NP O
16 1270 1278 1732369 systolic JJ I-NP O
17 1279 1283 1732369 left JJ I-NP O
18 1284 1295 1732369 ventricular JJ I-NP O
19 1296 1305 1732369 posterior JJ I-NP O
20 1306 1310 1732369 wall NN I-NP O
21 1311 1320 1732369 dimension NN I-NP O
22 1321 1324 1732369 and CC I-NP O
23 1325 1332 1732369 percent NN I-NP O
24 1333 1335 1732369 of IN B-PP O
25 1336 1340 1732369 left JJ B-NP O
26 1341 1352 1732369 ventricular JJ I-NP O
27 1353 1362 1732369 posterior JJ I-NP O
28 1363 1367 1732369 wall NN I-NP O
29 1368 1378 1732369 thickening VBG B-VP O
30 1379 1381 1732369 in IN B-PP O
31 1382 1393 1732369 doxorubicin NN B-NP B-Chemical
32 1393 1394 1732369 - HYPH B-NP O
33 1394 1401 1732369 treated VBN I-NP O
34 1402 1410 1732369 patients NNS I-NP O
35 1411 1415 1732369 were VBD B-VP O
36 1416 1425 1732369 decreased VBN I-VP O
37 1426 1428 1732369 at IN B-PP O
38 1429 1437 1732369 baseline NN B-NP O
39 1438 1443 1732369 study NN I-NP O
40 1444 1447 1732369 and CC O O
41 1448 1453 1732369 these DT B-NP O
42 1454 1462 1732369 findings NNS I-NP O
43 1463 1467 1732369 were VBD B-VP O
44 1468 1472 1732369 more RBR I-VP O
45 1473 1480 1732369 clearly RB I-VP O
46 1481 1491 1732369 delineated VBN I-VP O
47 1492 1496 1732369 with IN B-PP O
48 1497 1507 1732369 dobutamine NN B-NP B-Chemical
49 1508 1519 1732369 stimulation NN I-NP O
50 1519 1520 1732369 . . O O

1 1521 1524 1732369 End NN B-NP O
2 1524 1525 1732369 - HYPH I-NP O
3 1525 1533 1732369 systolic JJ I-NP O
4 1534 1538 1732369 left JJ I-NP O
5 1539 1550 1732369 ventricular JJ I-NP O
6 1551 1560 1732369 posterior JJ I-NP O
7 1561 1565 1732369 wall NN I-NP O
8 1566 1575 1732369 dimension NN I-NP O
9 1576 1578 1732369 at IN B-PP O
10 1579 1587 1732369 baseline NN B-NP O
11 1588 1591 1732369 for IN B-PP O
12 1592 1595 1732369 the DT B-NP O
13 1596 1607 1732369 doxorubicin NN I-NP B-Chemical
14 1607 1608 1732369 - HYPH B-NP O
15 1608 1615 1732369 treated VBN I-NP O
16 1616 1621 1732369 group NN I-NP O
17 1622 1625 1732369 was VBD B-VP O
18 1626 1628 1732369 11 CD B-NP O
19 1629 1630 1732369 + SYM O O
20 1630 1631 1732369 / SYM O O
21 1631 1632 1732369 - SYM O O
22 1633 1636 1732369 1.9 CD B-NP O
23 1637 1639 1732369 mm NN I-NP O
24 1640 1646 1732369 versus IN B-PP O
25 1647 1651 1732369 13.1 CD B-NP O
26 1652 1653 1732369 + SYM O O
27 1653 1654 1732369 / SYM O O
28 1654 1655 1732369 - SYM O O
29 1656 1659 1732369 1.5 CD B-NP O
30 1660 1662 1732369 mm NN I-NP O
31 1663 1666 1732369 for IN B-PP O
32 1667 1674 1732369 control JJ B-NP O
33 1675 1683 1732369 subjects NNS I-NP O
34 1684 1685 1732369 ( ( O O
35 1685 1686 1732369 p NN B-NP O
36 1687 1691 1732369 less JJR B-ADJP O
37 1692 1696 1732369 than IN B-PP O
38 1697 1701 1732369 0.01 CD B-NP O
39 1701 1702 1732369 ) ) O O
40 1702 1703 1732369 . . O O

1 1704 1707 1732369 End NN B-NP O
2 1707 1708 1732369 - HYPH I-NP O
3 1708 1716 1732369 systolic JJ I-NP O
4 1717 1721 1732369 left JJ I-NP O
5 1722 1733 1732369 ventricular JJ I-NP O
6 1734 1743 1732369 posterior JJ I-NP O
7 1744 1748 1732369 wall NN I-NP O
8 1749 1758 1732369 dimension NN I-NP O
9 1759 1761 1732369 at IN B-PP O
10 1762 1765 1732369 the DT B-NP O
11 1766 1767 1732369 5 CD I-NP O
12 1767 1768 1732369 - HYPH I-NP O
13 1768 1778 1732369 micrograms NNS I-NP O
14 1778 1779 1732369 / SYM B-NP O
15 1779 1781 1732369 kg NN I-NP O
16 1782 1785 1732369 per IN B-PP O
17 1786 1789 1732369 min NN B-NP O
18 1790 1800 1732369 dobutamine NN I-NP B-Chemical
19 1801 1809 1732369 infusion NN I-NP O
20 1810 1813 1732369 for IN B-PP O
21 1814 1817 1732369 the DT B-NP O
22 1818 1829 1732369 doxorubicin NN I-NP B-Chemical
23 1829 1830 1732369 - HYPH B-NP O
24 1830 1837 1732369 treated VBN I-NP O
25 1838 1843 1732369 group NN I-NP O
26 1844 1847 1732369 was VBD B-VP O
27 1848 1852 1732369 14.1 CD B-NP O
28 1853 1854 1732369 + SYM O O
29 1854 1855 1732369 / SYM O O
30 1855 1856 1732369 - SYM O O
31 1857 1860 1732369 2.4 CD B-NP O
32 1861 1863 1732369 mm NN I-NP O
33 1864 1870 1732369 versus IN B-PP O
34 1871 1875 1732369 19.3 CD B-NP O
35 1876 1877 1732369 + SYM O O
36 1877 1878 1732369 / SYM O O
37 1878 1879 1732369 - SYM O O
38 1880 1883 1732369 2.6 CD B-NP O
39 1884 1886 1732369 mm NN I-NP O
40 1887 1890 1732369 for IN B-PP O
41 1891 1898 1732369 control JJ B-NP O
42 1899 1907 1732369 subjects NNS I-NP O
43 1908 1909 1732369 ( ( O O
44 1909 1910 1732369 p NN B-NP O
45 1911 1915 1732369 less JJR B-ADJP O
46 1916 1920 1732369 than IN B-PP O
47 1921 1936 1732369 0.01).(ABSTRACT NN B-NP O
48 1937 1946 1732369 TRUNCATED VBN B-VP O
49 1947 1949 1732369 AT IN B-PP O
50 1950 1953 1732369 250 CD B-NP O
51 1954 1959 1732369 WORDS NNS I-NP O
52 1959 1960 1732369 ) ) O O

1 0 0 6518066 -DOCSTART- -X- -X- O

1 0 8 6518066 Maternal JJ B-NP O
2 9 16 6518066 lithium NN I-NP B-Chemical
3 17 20 6518066 and CC O O
4 21 29 6518066 neonatal JJ B-NP O
5 30 39 6518066 Ebstein's NNS I-NP B-Disease
6 40 47 6518066 anomaly RB B-ADVP I-Disease
7 47 48 6518066 : : O O
8 49 59 6518066 evaluation NN B-NP O
9 60 64 6518066 with IN B-PP O
10 65 70 6518066 cross AFX B-NP O
11 70 71 6518066 - HYPH I-NP O
12 71 80 6518066 sectional JJ I-NP O
13 81 97 6518066 echocardiography NN I-NP O
14 97 98 6518066 . . I-NP O
15 99 104 6518066 Cross NN I-NP O
16 104 105 6518066 - HYPH B-NP O
17 105 114 6518066 sectional JJ I-NP O
18 115 131 6518066 echocardiography NN I-NP O
19 132 135 6518066 was VBD B-VP O
20 136 140 6518066 used VBN I-VP O
21 141 143 6518066 to TO B-VP O
22 144 152 6518066 evaluate VB I-VP O
23 153 156 6518066 two CD B-NP O
24 157 165 6518066 neonates NNS I-NP O
25 166 171 6518066 whose WP$ B-NP O
26 172 179 6518066 mothers NNS I-NP O
27 180 188 6518066 ingested VBD B-VP O
28 189 196 6518066 lithium NN B-NP B-Chemical
29 197 203 6518066 during IN B-PP O
30 204 213 6518066 pregnancy NN B-NP O
31 213 214 6518066 . . O O

1 215 217 6518066 In IN B-PP O
2 218 221 6518066 one CD B-NP O
3 222 228 6518066 infant NN I-NP O
4 228 229 6518066 , , O O
5 230 239 6518066 Ebstein's NNS B-NP B-Disease
6 240 247 6518066 anomaly RB B-ADVP I-Disease
7 248 250 6518066 of IN B-PP O
8 251 254 6518066 the DT B-NP O
9 255 264 6518066 tricuspid JJ I-NP O
10 265 270 6518066 valve NN I-NP O
11 271 274 6518066 was VBD B-VP O
12 275 285 6518066 identified VBN I-VP O
13 285 286 6518066 . . O O

1 287 289 6518066 In IN B-PP O
2 290 293 6518066 the DT B-NP O
3 294 299 6518066 other JJ I-NP O
4 300 306 6518066 infant NN I-NP O
5 307 312 6518066 cross AFX O O
6 312 313 6518066 - HYPH O O
7 313 322 6518066 sectional JJ B-NP O
8 323 339 6518066 echocardiography NN I-NP O
9 340 348 6518066 provided VBD B-VP O
10 349 360 6518066 reassurance NN B-NP O
11 361 365 6518066 that IN B-SBAR O
12 366 369 6518066 the DT B-NP O
13 370 376 6518066 infant NN I-NP O
14 377 380 6518066 did VBD B-VP O
15 381 384 6518066 not RB I-VP O
16 385 389 6518066 have VB I-VP O
17 390 399 6518066 Ebstein's NNS B-NP B-Disease
18 400 407 6518066 anomaly RB B-ADVP I-Disease
19 407 408 6518066 . . O O

1 409 414 6518066 Cross NN B-NP O
2 414 415 6518066 - HYPH I-NP O
3 415 424 6518066 sectional JJ I-NP O
4 425 442 6518066 echocardiographic JJ I-NP O
5 443 452 6518066 screening NN I-NP O
6 453 455 6518066 of IN B-PP O
7 456 464 6518066 newborns NNS B-NP O
8 465 472 6518066 exposed VBN B-VP O
9 473 475 6518066 to TO B-PP O
10 476 483 6518066 lithium NN B-NP B-Chemical
11 484 490 6518066 during IN B-PP O
12 491 500 6518066 gestation NN B-NP O
13 501 504 6518066 can MD B-VP O
14 505 512 6518066 provide VB I-VP O
15 513 519 6518066 highly RB B-NP O
16 520 528 6518066 accurate JJ I-NP O
17 528 529 6518066 , , I-NP O
18 530 541 6518066 noninvasive JJ I-NP O
19 542 552 6518066 assessment NN I-NP O
20 553 555 6518066 of IN B-PP O
21 556 559 6518066 the DT B-NP O
22 560 568 6518066 presence NN I-NP O
23 569 571 6518066 or CC I-NP O
24 572 579 6518066 absence NN I-NP O
25 580 582 6518066 of IN B-PP O
26 583 590 6518066 lithium NN B-NP B-Chemical
27 590 591 6518066 - HYPH O O
28 591 598 6518066 induced VBN B-NP O
29 599 606 6518066 cardiac JJ I-NP B-Disease
30 607 620 6518066 malformations NNS I-NP I-Disease
31 620 621 6518066 . . O O

1 0 0 11391224 -DOCSTART- -X- -X- O

1 0 11 11391224 Peritubular JJ B-NP O
2 12 21 11391224 capillary JJ I-NP O
3 22 30 11391224 basement NN I-NP O
4 31 39 11391224 membrane NN I-NP O
5 40 53 11391224 reduplication NN I-NP O
6 54 56 11391224 in IN B-PP O
7 57 67 11391224 allografts NNS B-NP O
8 68 71 11391224 and CC O O
9 72 78 11391224 native JJ B-NP O
10 79 85 11391224 kidney NN I-NP B-Disease
11 86 93 11391224 disease NN I-NP I-Disease
12 93 94 11391224 : : O O
13 95 96 11391224 a DT B-NP O
14 97 114 11391224 clinicopathologic JJ I-NP O
15 115 120 11391224 study NN I-NP O
16 121 123 11391224 of IN B-PP O
17 124 127 11391224 278 CD B-NP O
18 128 139 11391224 consecutive JJ I-NP O
19 140 145 11391224 renal JJ I-NP O
20 146 155 11391224 specimens NNS I-NP O
21 155 156 11391224 . . O O
22 157 167 11391224 BACKGROUND NN B-NP O
23 167 168 11391224 : : O O
24 169 171 11391224 An DT B-NP O
25 172 183 11391224 association NN I-NP O
26 184 187 11391224 has VBZ B-VP O
27 188 192 11391224 been VBN I-VP O
28 193 198 11391224 found VBN I-VP O
29 199 206 11391224 between IN B-PP O
30 207 217 11391224 transplant NN B-NP B-Disease
31 218 232 11391224 glomerulopathy NN I-NP I-Disease
32 233 234 11391224 ( ( O O
33 234 236 11391224 TG NN B-NP B-Disease
34 236 237 11391224 ) ) O O
35 238 241 11391224 and CC O O
36 242 255 11391224 reduplication NN B-NP O
37 256 258 11391224 of IN B-PP O
38 259 270 11391224 peritubular JJ B-NP O
39 271 280 11391224 capillary JJ I-NP O
40 281 289 11391224 basement NN I-NP O
41 290 299 11391224 membranes NNS I-NP O
42 300 301 11391224 ( ( O O
43 301 305 11391224 PTCR NN B-NP O
44 305 306 11391224 ) ) O O
45 306 307 11391224 . . O O

1 308 316 11391224 Although IN B-SBAR O
2 317 321 11391224 such JJ B-NP O
3 322 324 11391224 an DT I-NP O
4 325 336 11391224 association NN I-NP O
5 337 339 11391224 is VBZ B-VP O
6 340 342 11391224 of IN B-PP O
7 343 352 11391224 practical JJ B-NP O
8 353 356 11391224 and CC I-NP O
9 357 368 11391224 theoretical JJ I-NP O
10 369 379 11391224 importance NN I-NP O
11 379 380 11391224 , , O O
12 381 385 11391224 only RB B-NP O
13 386 389 11391224 one CD I-NP O
14 390 401 11391224 prospective JJ I-NP O
15 402 407 11391224 study NN I-NP O
16 408 411 11391224 has VBZ B-VP O
17 412 417 11391224 tried VBN I-VP O
18 418 420 11391224 to TO I-VP O
19 421 428 11391224 confirm VB I-VP O
20 429 431 11391224 it PRP B-NP O
21 431 432 11391224 . . O O

1 433 440 11391224 METHODS NNS B-NP O
2 440 441 11391224 : : O O
3 442 444 11391224 We PRP B-NP O
4 445 453 11391224 examined VBD B-VP O
5 454 457 11391224 278 CD B-NP O
6 458 469 11391224 consecutive JJ I-NP O
7 470 475 11391224 renal JJ I-NP O
8 476 485 11391224 specimens NNS I-NP O
9 486 487 11391224 ( ( O O
10 487 491 11391224 from IN B-PP O
11 492 495 11391224 135 CD B-NP O
12 496 507 11391224 transplants NNS I-NP O
13 508 511 11391224 and CC O O
14 512 515 11391224 143 CD B-NP O
15 516 522 11391224 native JJ I-NP O
16 523 530 11391224 kidneys NNS I-NP O
17 530 531 11391224 ) ) O O
18 532 535 11391224 for IN B-PP O
19 536 551 11391224 ultrastructural JJ B-NP O
20 552 560 11391224 evidence NN I-NP O
21 561 563 11391224 of IN B-PP O
22 564 568 11391224 PTCR NN B-NP O
23 568 569 11391224 . . O O

1 570 572 11391224 In IN B-PP O
2 573 581 11391224 addition NN B-NP O
3 582 584 11391224 to TO B-PP O
4 585 590 11391224 renal JJ B-NP O
5 591 601 11391224 allografts NNS I-NP O
6 602 606 11391224 with IN B-PP O
7 607 609 11391224 TG NN B-NP B-Disease
8 609 610 11391224 , , O O
9 611 613 11391224 we PRP B-NP O
10 614 618 11391224 also RB B-ADVP O
11 619 627 11391224 examined VBD B-VP O
12 628 634 11391224 grafts NNS B-NP O
13 635 639 11391224 with IN B-PP O
14 640 645 11391224 acute JJ B-NP O
15 646 655 11391224 rejection NN I-NP O
16 655 656 11391224 , , O O
17 657 666 11391224 recurrent JJ B-NP O
18 667 685 11391224 glomerulonephritis NN I-NP B-Disease
19 685 686 11391224 , , O O
20 687 694 11391224 chronic JJ B-NP B-Disease
21 695 704 11391224 allograft NN I-NP I-Disease
22 705 716 11391224 nephropathy NN I-NP I-Disease
23 717 720 11391224 and CC O O
24 721 727 11391224 stable JJ B-NP O
25 728 734 11391224 grafts NNS I-NP O
26 735 736 11391224 ( ( O O
27 736 737 11391224 " `` O O
28 737 745 11391224 protocol NN B-NP O
29 746 754 11391224 biopsies NNS I-NP O
30 754 755 11391224 " '' O O
31 755 756 11391224 ) ) O O
32 756 757 11391224 . . O O

1 758 764 11391224 Native JJ B-NP O
2 765 771 11391224 kidney NN I-NP O
3 772 781 11391224 specimens NNS I-NP O
4 782 790 11391224 included VBD B-VP O
5 791 792 11391224 a DT B-NP O
6 793 797 11391224 wide JJ I-NP O
7 798 803 11391224 range NN I-NP O
8 804 806 11391224 of IN B-PP O
9 807 823 11391224 glomerulopathies NNS B-NP B-Disease
10 824 826 11391224 as RB B-CONJP O
11 827 831 11391224 well RB I-CONJP O
12 832 834 11391224 as IN I-CONJP O
13 835 840 11391224 cases NNS B-NP O
14 841 843 11391224 of IN B-PP O
15 844 854 11391224 thrombotic JJ B-NP B-Disease
16 855 870 11391224 microangiopathy NN I-NP I-Disease
17 870 871 11391224 , , O O
18 872 881 11391224 malignant JJ B-NP B-Disease
19 882 894 11391224 hypertension NN I-NP I-Disease
20 894 895 11391224 , , O O
21 896 901 11391224 acute JJ B-NP O
22 902 914 11391224 interstitial JJ I-NP B-Disease
23 915 924 11391224 nephritis NN I-NP I-Disease
24 924 925 11391224 , , O O
25 926 929 11391224 and CC O O
26 930 935 11391224 acute JJ B-NP B-Disease
27 936 943 11391224 tubular JJ I-NP I-Disease
28 944 952 11391224 necrosis NN I-NP I-Disease
29 952 953 11391224 . . O O

1 954 961 11391224 RESULTS NNS B-NP O
2 961 962 11391224 : : O O
3 963 965 11391224 We PRP B-NP O
4 966 971 11391224 found VBD B-VP O
5 972 976 11391224 PTCR NN B-NP O
6 977 979 11391224 in IN B-PP O
7 980 982 11391224 14 CD B-NP O
8 983 985 11391224 of IN B-PP O
9 986 988 11391224 15 CD B-NP O
10 989 994 11391224 cases NNS I-NP O
11 995 997 11391224 of IN B-PP O
12 998 1000 11391224 TG NN B-NP B-Disease
13 1000 1001 11391224 , , O O
14 1002 1004 11391224 in IN B-PP O
15 1005 1006 11391224 7 CD B-NP O
16 1007 1017 11391224 transplant NN I-NP O
17 1018 1024 11391224 biopsy NN I-NP O
18 1025 1034 11391224 specimens NNS I-NP O
19 1035 1042 11391224 without IN B-PP O
20 1043 1045 11391224 TG NN B-NP B-Disease
21 1045 1046 11391224 , , O O
22 1047 1050 11391224 and CC O O
23 1051 1053 11391224 in IN B-PP O
24 1054 1056 11391224 13 CD B-NP O
25 1057 1059 11391224 of IN B-PP O
26 1060 1063 11391224 143 CD B-NP O
27 1064 1070 11391224 native JJ I-NP O
28 1071 1077 11391224 kidney NN I-NP O
29 1078 1084 11391224 biopsy NN I-NP O
30 1085 1094 11391224 specimens NNS I-NP O
31 1094 1095 11391224 . . O O

1 1096 1101 11391224 These DT B-NP O
2 1102 1104 11391224 13 CD I-NP O
3 1105 1113 11391224 included VBN I-NP O
4 1114 1119 11391224 cases NNS I-NP O
5 1120 1122 11391224 of IN B-PP O
6 1123 1132 11391224 malignant JJ B-NP B-Disease
7 1133 1145 11391224 hypertension NN I-NP I-Disease
8 1145 1146 11391224 , , O O
9 1147 1157 11391224 thrombotic JJ B-NP B-Disease
10 1158 1173 11391224 microangiopathy NN I-NP I-Disease
11 1173 1174 11391224 , , O O
12 1175 1180 11391224 lupus NN B-NP B-Disease
13 1181 1190 11391224 nephritis NN I-NP I-Disease
14 1190 1191 11391224 , , O O
15 1192 1198 11391224 Henoch NNP B-NP B-Disease
16 1198 1199 11391224 - HYPH I-NP I-Disease
17 1199 1208 11391224 Schonlein NNP I-NP I-Disease
18 1209 1218 11391224 nephritis NN I-NP I-Disease
19 1218 1219 11391224 , , O O
20 1220 1230 11391224 crescentic JJ B-NP O
21 1231 1249 11391224 glomerulonephritis NN I-NP B-Disease
22 1249 1250 11391224 , , O O
23 1251 1254 11391224 and CC O O
24 1255 1262 11391224 cocaine NN B-NP B-Chemical
25 1262 1263 11391224 - HYPH O O
26 1263 1270 11391224 related VBN B-NP O
27 1271 1276 11391224 acute JJ I-NP B-Disease
28 1277 1282 11391224 renal JJ I-NP I-Disease
29 1283 1290 11391224 failure NN I-NP I-Disease
30 1290 1291 11391224 . . O O

1 1292 1296 11391224 Mild JJ B-NP O
2 1297 1301 11391224 PTCR NN I-NP O
3 1302 1304 11391224 in IN B-PP O
4 1305 1315 11391224 allografts NNS B-NP O
5 1316 1323 11391224 without IN B-PP O
6 1324 1326 11391224 TG NN B-NP B-Disease
7 1327 1330 11391224 did VBD B-VP O
8 1331 1334 11391224 not RB I-VP O
9 1335 1342 11391224 predict VB I-VP O
10 1343 1348 11391224 renal JJ B-NP B-Disease
11 1349 1356 11391224 failure NN I-NP I-Disease
12 1357 1359 11391224 or CC O O
13 1360 1371 11391224 significant JJ B-NP O
14 1372 1383 11391224 proteinuria NN I-NP B-Disease
15 1384 1389 11391224 after IN B-SBAR O
16 1390 1396 11391224 follow VB B-VP O
17 1396 1397 11391224 - HYPH O O
18 1397 1399 11391224 up RP B-PRT O
19 1400 1407 11391224 periods NNS B-NP O
20 1408 1410 11391224 of IN B-PP O
21 1411 1418 11391224 between IN B-NP O
22 1419 1420 11391224 3 CD I-NP O
23 1421 1427 11391224 months NNS I-NP O
24 1428 1431 11391224 and CC O O
25 1432 1433 11391224 1 CD B-NP O
26 1434 1438 11391224 year NN I-NP O
27 1438 1439 11391224 . . O O

1 1440 1451 11391224 CONCLUSIONS NNS B-NP O
2 1451 1452 11391224 : : O O
3 1453 1455 11391224 We PRP B-NP O
4 1456 1464 11391224 conclude VBP B-VP O
5 1465 1469 11391224 that IN B-SBAR O
6 1470 1472 11391224 in IN B-PP O
7 1473 1484 11391224 transplants NNS B-NP O
8 1484 1485 11391224 , , O O
9 1486 1491 11391224 there EX B-NP O
10 1492 1494 11391224 is VBZ B-VP O
11 1495 1496 11391224 a DT B-NP O
12 1497 1503 11391224 strong JJ I-NP O
13 1504 1515 11391224 association NN I-NP O
14 1516 1523 11391224 between IN B-PP O
15 1524 1528 11391224 well RB B-NP O
16 1528 1529 11391224 - HYPH I-NP O
17 1529 1538 11391224 developed VBN I-NP O
18 1539 1543 11391224 PTCR NN I-NP O
19 1544 1547 11391224 and CC I-NP O
20 1548 1550 11391224 TG NN I-NP B-Disease
21 1550 1551 11391224 , , O O
22 1552 1557 11391224 while IN B-SBAR O
23 1558 1561 11391224 the DT B-NP O
24 1562 1574 11391224 significance NN I-NP O
25 1575 1577 11391224 of IN B-PP O
26 1578 1582 11391224 mild JJ B-NP O
27 1583 1587 11391224 PTCR NN I-NP O
28 1588 1591 11391224 and CC O O
29 1592 1595 11391224 its PRP$ B-NP O
30 1596 1606 11391224 predictive JJ I-NP O
31 1607 1612 11391224 value NN I-NP O
32 1613 1615 11391224 in IN B-PP O
33 1616 1619 11391224 the DT B-NP O
34 1620 1627 11391224 absence NN I-NP O
35 1628 1630 11391224 of IN B-PP O
36 1631 1633 11391224 TG NN B-NP B-Disease
37 1634 1636 11391224 is VBZ B-VP O
38 1637 1644 11391224 unclear JJ B-ADJP O
39 1644 1645 11391224 . . O O

1 1646 1650 11391224 PTCR NN B-NP O
2 1651 1655 11391224 also RB B-ADVP O
3 1656 1662 11391224 occurs VBZ B-VP O
4 1663 1665 11391224 in IN B-PP O
5 1666 1673 11391224 certain JJ B-NP O
6 1674 1680 11391224 native JJ I-NP O
7 1681 1687 11391224 kidney NN I-NP B-Disease
8 1688 1696 11391224 diseases NNS I-NP I-Disease
9 1696 1697 11391224 , , O O
10 1698 1704 11391224 though IN B-SBAR O
11 1705 1708 11391224 the DT B-NP O
12 1709 1720 11391224 association NN I-NP O
13 1721 1723 11391224 is VBZ B-VP O
14 1724 1727 11391224 not RB O O
15 1728 1730 11391224 as RB B-ADJP O
16 1731 1737 11391224 strong JJ I-ADJP O
17 1738 1740 11391224 as IN B-PP O
18 1741 1745 11391224 that DT B-NP O
19 1746 1749 11391224 for IN B-PP O
20 1750 1752 11391224 TG NN B-NP B-Disease
21 1752 1753 11391224 . . O O

1 1754 1756 11391224 We PRP B-NP O
2 1757 1764 11391224 suggest VBP B-VP O
3 1765 1769 11391224 that IN B-SBAR O
4 1770 1778 11391224 repeated VBN B-NP O
5 1779 1790 11391224 endothelial JJ I-NP B-Disease
6 1791 1797 11391224 injury NN I-NP I-Disease
7 1797 1798 11391224 , , O O
8 1799 1808 11391224 including VBG B-PP O
9 1809 1820 11391224 immunologic JJ B-NP B-Disease
10 1821 1827 11391224 injury NN I-NP I-Disease
11 1827 1828 11391224 , , O O
12 1829 1832 11391224 may MD B-VP O
13 1833 1835 11391224 be VB I-VP O
14 1836 1839 11391224 the DT B-NP O
15 1840 1845 11391224 cause NN I-NP O
16 1846 1848 11391224 of IN B-PP O
17 1849 1853 11391224 this DT B-NP O
18 1854 1860 11391224 lesion NN I-NP O
19 1861 1865 11391224 both CC B-PP O
20 1866 1868 11391224 in IN B-PP O
21 1869 1879 11391224 allografts NNS B-NP O
22 1880 1883 11391224 and CC O O
23 1884 1890 11391224 native JJ B-NP O
24 1891 1898 11391224 kidneys NNS I-NP O
25 1898 1899 11391224 . . O O

1 0 0 18083142 -DOCSTART- -X- -X- O

1 0 14 18083142 Norepinephrine NN B-NP B-Chemical
2 15 24 18083142 signaling NN I-NP O
3 25 32 18083142 through IN B-PP O
4 33 37 18083142 beta SYM B-NP O
5 37 38 18083142 - HYPH B-NP O
6 38 48 18083142 adrenergic JJ I-NP O
7 49 58 18083142 receptors NNS I-NP O
8 59 61 18083142 is VBZ B-VP O
9 62 70 18083142 critical JJ B-ADJP O
10 71 74 18083142 for IN B-PP O
11 75 85 18083142 expression NN B-NP O
12 86 88 18083142 of IN B-PP O
13 89 96 18083142 cocaine NN B-NP B-Chemical
14 96 97 18083142 - HYPH B-NP O
15 97 104 18083142 induced VBN I-NP O
16 105 112 18083142 anxiety NN I-NP B-Disease
17 112 113 18083142 . . I-NP O
18 114 124 18083142 BACKGROUND NN I-NP O
19 124 125 18083142 : : O O
20 126 133 18083142 Cocaine NN B-NP B-Chemical
21 134 136 18083142 is VBZ B-VP O
22 137 138 18083142 a DT B-NP O
23 139 145 18083142 widely RB I-NP O
24 146 152 18083142 abused JJ I-NP O
25 153 168 18083142 psychostimulant NN I-NP O
26 169 173 18083142 that WDT B-NP O
27 174 177 18083142 has VBZ B-VP O
28 178 182 18083142 both CC O O
29 183 192 18083142 rewarding JJ B-NP O
30 193 196 18083142 and CC I-NP O
31 197 205 18083142 aversive JJ I-NP O
32 206 216 18083142 properties NNS I-NP O
33 216 217 18083142 . . O O

1 218 223 18083142 While IN B-SBAR O
2 224 227 18083142 the DT B-NP O
3 228 238 18083142 mechanisms NNS I-NP O
4 239 249 18083142 underlying VBG B-VP O
5 250 259 18083142 cocaine's NNS B-NP B-Chemical
6 260 269 18083142 rewarding JJ B-NP O
7 270 277 18083142 effects NNS I-NP O
8 278 282 18083142 have VBP B-VP O
9 283 287 18083142 been VBN I-VP O
10 288 295 18083142 studied VBN I-VP O
11 296 307 18083142 extensively RB B-ADVP O
12 307 308 18083142 , , O O
13 309 313 18083142 less JJR B-NP O
14 314 323 18083142 attention NN I-NP O
15 324 327 18083142 has VBZ B-VP O
16 328 332 18083142 been VBN I-VP O
17 333 337 18083142 paid VBN I-VP O
18 338 340 18083142 to TO B-PP O
19 341 344 18083142 the DT B-NP O
20 345 355 18083142 unpleasant JJ I-NP O
21 356 366 18083142 behavioral JJ I-NP O
22 367 373 18083142 states NNS I-NP O
23 374 381 18083142 induced VBN B-VP O
24 382 384 18083142 by IN B-PP O
25 385 392 18083142 cocaine NN B-NP B-Chemical
26 392 393 18083142 , , O O
27 394 398 18083142 such JJ B-PP O
28 399 401 18083142 as IN I-PP O
29 402 409 18083142 anxiety NN B-NP B-Disease
30 409 410 18083142 . . O O

1 411 418 18083142 METHODS NNS B-NP O
2 418 419 18083142 : : O O
3 420 422 18083142 In IN B-PP O
4 423 427 18083142 this DT B-NP O
5 428 433 18083142 study NN I-NP O
6 433 434 18083142 , , O O
7 435 437 18083142 we PRP B-NP O
8 438 447 18083142 evaluated VBD B-VP O
9 448 451 18083142 the DT B-NP O
10 452 463 18083142 performance NN I-NP O
11 464 466 18083142 of IN B-PP O
12 467 475 18083142 dopamine NN B-NP B-Chemical
13 476 480 18083142 beta SYM O O
14 480 481 18083142 - HYPH O O
15 481 492 18083142 hydroxylase NN B-NP O
16 493 501 18083142 knockout NN I-NP O
17 502 503 18083142 ( ( O O
18 503 506 18083142 Dbh NN B-NP O
19 507 508 18083142 - HYPH O O
20 508 509 18083142 / SYM O O
21 509 510 18083142 - SYM O O
22 510 511 18083142 ) ) O O
23 512 516 18083142 mice NNS B-NP O
24 516 517 18083142 , , O O
25 518 523 18083142 which WDT B-NP O
26 524 528 18083142 lack VBP B-VP O
27 529 543 18083142 norepinephrine NN B-NP B-Chemical
28 544 545 18083142 ( ( O O
29 545 547 18083142 NE NN B-NP B-Chemical
30 547 548 18083142 ) ) O O
31 548 549 18083142 , , O O
32 550 552 18083142 in IN B-PP O
33 553 556 18083142 the DT B-NP O
34 557 565 18083142 elevated JJ I-NP O
35 566 570 18083142 plus CC O O
36 571 575 18083142 maze NN B-NP O
37 576 577 18083142 ( ( O O
38 577 580 18083142 EPM NN B-NP O
39 580 581 18083142 ) ) O O
40 582 584 18083142 to TO B-VP O
41 585 592 18083142 examine VB I-VP O
42 593 596 18083142 the DT B-NP O
43 597 609 18083142 contribution NN I-NP O
44 610 612 18083142 of IN B-PP O
45 613 626 18083142 noradrenergic JJ B-NP O
46 627 636 18083142 signaling NN I-NP O
47 637 639 18083142 to TO B-PP O
48 640 647 18083142 cocaine NN B-NP B-Chemical
49 647 648 18083142 - HYPH B-NP O
50 648 655 18083142 induced VBN I-NP O
51 656 663 18083142 anxiety NN I-NP B-Disease
52 663 664 18083142 . . O O

1 665 672 18083142 RESULTS NNS B-NP O
2 672 673 18083142 : : O O
3 674 676 18083142 We PRP B-NP O
4 677 682 18083142 found VBD B-VP O
5 683 687 18083142 that IN B-SBAR O
6 688 695 18083142 cocaine NN B-NP B-Chemical
7 696 700 18083142 dose NN I-NP O
8 700 701 18083142 - HYPH B-VP O
9 701 712 18083142 dependently RB I-VP O
10 713 722 18083142 increased VBN B-NP O
11 723 730 18083142 anxiety NN I-NP B-Disease
12 730 731 18083142 - HYPH O O
13 731 735 18083142 like JJ B-NP O
14 736 744 18083142 behavior NN I-NP O
15 745 747 18083142 in IN B-PP O
16 748 755 18083142 control NN B-NP O
17 756 757 18083142 ( ( O O
18 757 760 18083142 Dbh NN B-NP O
19 761 762 18083142 + SYM O O
20 762 763 18083142 / SYM O O
21 763 764 18083142 - SYM O O
22 764 765 18083142 ) ) O O
23 766 770 18083142 mice NNS B-NP O
24 770 771 18083142 , , O O
25 772 774 18083142 as IN B-SBAR O
26 775 783 18083142 measured VBN B-VP O
27 784 786 18083142 by IN B-PP O
28 787 788 18083142 a DT B-NP O
29 789 797 18083142 decrease NN I-NP O
30 798 800 18083142 in IN B-PP O
31 801 805 18083142 open JJ B-NP O
32 806 809 18083142 arm NN I-NP O
33 810 821 18083142 exploration NN I-NP O
34 821 822 18083142 . . O O

1 823 826 18083142 The DT B-NP O
2 827 830 18083142 Dbh NN I-NP O
3 831 832 18083142 - HYPH O O
4 832 833 18083142 / SYM O O
5 833 834 18083142 - HYPH O O
6 835 839 18083142 mice NNS B-NP O
7 840 843 18083142 had VBD B-VP O
8 844 850 18083142 normal JJ B-NP O
9 851 859 18083142 baseline NN I-NP O
10 860 871 18083142 performance NN I-NP O
11 872 874 18083142 in IN B-PP O
12 875 878 18083142 the DT B-NP O
13 879 882 18083142 EPM NN I-NP O
14 883 886 18083142 but CC O O
15 887 891 18083142 were VBD B-VP O
16 892 902 18083142 completely RB B-ADJP O
17 903 912 18083142 resistant JJ I-ADJP O
18 913 915 18083142 to TO B-PP O
19 916 919 18083142 the DT B-NP O
20 920 930 18083142 anxiogenic JJ I-NP O
21 931 938 18083142 effects NNS I-NP O
22 939 941 18083142 of IN B-PP O
23 942 949 18083142 cocaine NN B-NP B-Chemical
24 949 950 18083142 . . O O

1 951 958 18083142 Cocaine NN B-NP B-Chemical
2 958 959 18083142 - HYPH B-NP O
3 959 966 18083142 induced VBN I-NP O
4 967 974 18083142 anxiety NN I-NP B-Disease
5 975 978 18083142 was VBD B-VP O
6 979 983 18083142 also RB I-VP O
7 984 994 18083142 attenuated VBN I-VP O
8 995 997 18083142 in IN B-PP O
9 998 1001 18083142 Dbh NN B-NP O
10 1002 1003 18083142 + SYM O O
11 1003 1004 18083142 / SYM B-NP O
12 1004 1005 18083142 - HYPH B-NP O
13 1006 1010 18083142 mice NNS I-NP O
14 1011 1020 18083142 following VBG B-PP O
15 1021 1035 18083142 administration NN B-NP O
16 1036 1038 18083142 of IN B-PP O
17 1039 1049 18083142 disulfiram NN B-NP B-Chemical
18 1049 1050 18083142 , , O O
19 1051 1052 18083142 a DT B-NP O
20 1053 1061 18083142 dopamine NN I-NP B-Chemical
21 1062 1066 18083142 beta SYM O O
22 1066 1067 18083142 - HYPH O O
23 1067 1078 18083142 hydroxylase NN B-NP O
24 1079 1080 18083142 ( ( O O
25 1080 1083 18083142 DBH NN B-NP O
26 1083 1084 18083142 ) ) O O
27 1085 1094 18083142 inhibitor NN B-NP O
28 1094 1095 18083142 . . O O

1 1096 1098 18083142 In IN B-PP O
2 1099 1110 18083142 experiments NNS B-NP O
3 1111 1116 18083142 using VBG B-VP O
4 1117 1125 18083142 specific JJ B-NP O
5 1126 1136 18083142 adrenergic JJ I-NP O
6 1137 1148 18083142 antagonists NNS I-NP O
7 1148 1149 18083142 , , O O
8 1150 1152 18083142 we PRP B-NP O
9 1153 1158 18083142 found VBD B-VP O
10 1159 1163 18083142 that IN B-SBAR O
11 1164 1176 18083142 pretreatment NN B-NP O
12 1177 1181 18083142 with IN B-PP O
13 1182 1185 18083142 the DT B-NP O
14 1186 1190 18083142 beta SYM I-NP O
15 1190 1191 18083142 - HYPH I-NP O
16 1191 1201 18083142 adrenergic JJ I-NP O
17 1202 1210 18083142 receptor NN I-NP O
18 1211 1221 18083142 antagonist NN I-NP O
19 1222 1233 18083142 propranolol NN I-NP B-Chemical
20 1234 1241 18083142 blocked VBD B-VP O
21 1242 1249 18083142 cocaine NN B-NP B-Chemical
22 1249 1250 18083142 - HYPH O O
23 1250 1257 18083142 induced VBN B-NP O
24 1258 1265 18083142 anxiety NN I-NP B-Disease
25 1265 1266 18083142 - HYPH O O
26 1266 1270 18083142 like JJ B-NP O
27 1271 1279 18083142 behavior NN I-NP O
28 1280 1282 18083142 in IN B-PP O
29 1283 1286 18083142 Dbh NN B-NP O
30 1287 1288 18083142 + SYM B-NP O
31 1288 1289 18083142 / SYM I-NP O
32 1289 1290 18083142 - HYPH I-NP O
33 1291 1294 18083142 and CC I-NP O
34 1295 1299 18083142 wild JJ I-NP O
35 1299 1300 18083142 - HYPH I-NP O
36 1300 1304 18083142 type NN I-NP O
37 1305 1311 18083142 C57BL6 NN I-NP O
38 1311 1312 18083142 / SYM B-NP O
39 1312 1313 18083142 J NN I-NP O
40 1314 1318 18083142 mice NNS I-NP O
41 1318 1319 18083142 , , O O
42 1320 1325 18083142 while IN B-SBAR O
43 1326 1329 18083142 the DT B-NP O
44 1330 1338 18083142 alpha(1) NN I-NP O
45 1339 1349 18083142 antagonist NN I-NP O
46 1350 1358 18083142 prazosin NN I-NP B-Chemical
47 1359 1362 18083142 and CC O O
48 1363 1366 18083142 the DT B-NP O
49 1367 1375 18083142 alpha(2) NN I-NP O
50 1376 1386 18083142 antagonist NN I-NP O
51 1387 1396 18083142 yohimbine NN I-NP B-Chemical
52 1397 1400 18083142 had VBD B-VP O
53 1401 1403 18083142 no DT B-NP O
54 1404 1410 18083142 effect NN I-NP O
55 1410 1411 18083142 . . O O

1 1412 1423 18083142 CONCLUSIONS NNS B-NP O
2 1423 1424 18083142 : : O O
3 1425 1430 18083142 These DT B-NP O
4 1431 1438 18083142 results NNS I-NP O
5 1439 1447 18083142 indicate VBP B-VP O
6 1448 1452 18083142 that IN B-SBAR O
7 1453 1466 18083142 noradrenergic JJ B-NP O
8 1467 1476 18083142 signaling NN I-NP O
9 1477 1480 18083142 via IN B-PP O
10 1481 1485 18083142 beta SYM B-NP O
11 1485 1486 18083142 - HYPH B-NP O
12 1486 1496 18083142 adrenergic JJ I-NP O
13 1497 1506 18083142 receptors NNS I-NP O
14 1507 1509 18083142 is VBZ B-VP O
15 1510 1518 18083142 required VBN I-VP O
16 1519 1522 18083142 for IN B-PP O
17 1523 1530 18083142 cocaine NN B-NP B-Chemical
18 1530 1531 18083142 - HYPH B-NP O
19 1531 1538 18083142 induced VBN I-NP O
20 1539 1546 18083142 anxiety NN I-NP B-Disease
21 1547 1549 18083142 in IN B-PP O
22 1550 1554 18083142 mice NNS B-NP O
23 1554 1555 18083142 . . O O

1 0 0 2024540 -DOCSTART- -X- -X- O

1 0 6 2024540 Design NN B-NP O
2 7 10 2024540 and CC I-NP O
3 11 19 2024540 analysis NN I-NP O
4 20 22 2024540 of IN B-PP O
5 23 26 2024540 the DT B-NP O
6 27 33 2024540 HYPREN NN I-NP O
7 33 34 2024540 - HYPH B-NP O
8 34 39 2024540 trial NN I-NP O
9 39 40 2024540 : : O O
10 41 47 2024540 safety NN B-NP O
11 48 50 2024540 of IN B-PP O
12 51 60 2024540 enalapril NN B-NP B-Chemical
13 61 64 2024540 and CC I-NP O
14 65 73 2024540 prazosin NN I-NP B-Chemical
15 74 76 2024540 in IN B-PP O
16 77 80 2024540 the DT B-NP O
17 81 88 2024540 initial JJ I-NP O
18 89 98 2024540 treatment NN I-NP O
19 99 104 2024540 phase NN I-NP O
20 105 107 2024540 of IN B-PP O
21 108 116 2024540 patients NNS B-NP O
22 117 121 2024540 with IN B-PP O
23 122 132 2024540 congestive JJ B-NP B-Disease
24 133 138 2024540 heart NN I-NP I-Disease
25 139 146 2024540 failure NN I-NP I-Disease
26 146 147 2024540 . . O O
27 148 153 2024540 Since IN B-PP O
28 154 157 2024540 the DT B-NP O
29 158 170 2024540 introduction NN I-NP O
30 171 173 2024540 of IN B-PP O
31 174 185 2024540 angiotensin NN B-NP B-Chemical
32 186 196 2024540 converting VBG B-VP I-Chemical
33 197 203 2024540 enzyme NN B-NP I-Chemical
34 204 205 2024540 ( ( O I-Chemical
35 205 208 2024540 ACE NN B-NP I-Chemical
36 208 209 2024540 ) ) O I-Chemical
37 210 220 2024540 inhibitors NNS B-NP I-Chemical
38 221 225 2024540 into IN B-PP O
39 226 229 2024540 the DT B-NP O
40 230 240 2024540 adjunctive JJ I-NP O
41 241 250 2024540 treatment NN I-NP O
42 251 253 2024540 of IN B-PP O
43 254 262 2024540 patients NNS B-NP O
44 263 267 2024540 with IN B-PP O
45 268 278 2024540 congestive JJ B-NP B-Disease
46 279 284 2024540 heart NN I-NP I-Disease
47 285 292 2024540 failure NN I-NP I-Disease
48 292 293 2024540 , , O O
49 294 299 2024540 cases NNS B-NP O
50 300 302 2024540 of IN B-PP O
51 303 309 2024540 severe JJ B-NP O
52 310 321 2024540 hypotension NN I-NP B-Disease
53 321 322 2024540 , , O O
54 323 333 2024540 especially RB B-ADVP O
55 334 336 2024540 on IN B-PP O
56 337 340 2024540 the DT B-NP O
57 341 346 2024540 first JJ I-NP O
58 347 350 2024540 day NN I-NP O
59 351 353 2024540 of IN B-PP O
60 354 363 2024540 treatment NN B-NP O
61 363 364 2024540 , , O O
62 365 369 2024540 have VBP B-VP O
63 370 382 2024540 occasionally RB I-VP O
64 383 387 2024540 been VBN I-VP O
65 388 396 2024540 reported VBN I-VP O
66 396 397 2024540 . . O O

1 398 400 2024540 To TO B-VP O
2 401 407 2024540 assess VB I-VP O
3 408 411 2024540 the DT B-NP O
4 412 418 2024540 safety NN I-NP O
5 419 421 2024540 of IN B-PP O
6 422 425 2024540 the DT B-NP O
7 426 429 2024540 ACE NN I-NP B-Chemical
8 430 439 2024540 inhibitor NN I-NP I-Chemical
9 440 449 2024540 enalapril VBP B-VP B-Chemical
10 450 451 2024540 a DT B-NP O
11 452 463 2024540 multicenter NN I-NP O
12 463 464 2024540 , , O O
13 465 475 2024540 randomized VBN B-VP O
14 475 476 2024540 , , O O
15 477 485 2024540 prazosin NN B-NP B-Chemical
16 485 486 2024540 - HYPH B-VP O
17 486 496 2024540 controlled VBN B-NP O
18 497 502 2024540 trial NN I-NP O
19 503 506 2024540 was VBD B-VP O
20 507 515 2024540 designed VBN I-VP O
21 516 520 2024540 that WDT B-NP O
22 521 529 2024540 compared VBD B-VP O
23 530 533 2024540 the DT B-NP O
24 534 543 2024540 incidence NN I-NP O
25 544 547 2024540 and CC I-NP O
26 548 556 2024540 severity NN I-NP O
27 557 559 2024540 of IN B-PP O
28 560 571 2024540 symptomatic JJ B-NP O
29 572 583 2024540 hypotension NN I-NP B-Disease
30 584 586 2024540 on IN B-PP O
31 587 590 2024540 the DT B-NP O
32 591 596 2024540 first JJ I-NP O
33 597 600 2024540 day NN I-NP O
34 601 603 2024540 of IN B-PP O
35 604 613 2024540 treatment NN B-NP O
36 613 614 2024540 . . O O

1 615 620 2024540 Trial JJ B-NP O
2 621 631 2024540 medication NN I-NP O
3 632 635 2024540 was VBD B-VP O
4 636 639 2024540 2.5 CD B-NP O
5 640 642 2024540 mg NN I-NP O
6 643 652 2024540 enalapril NN I-NP B-Chemical
7 653 655 2024540 or CC O O
8 656 659 2024540 0.5 CD B-NP O
9 660 668 2024540 prazosin NN I-NP B-Chemical
10 668 669 2024540 . . O O

1 670 678 2024540 Subjects NNS B-NP O
2 679 683 2024540 were VBD B-VP O
3 684 688 2024540 1210 CD B-NP O
4 689 699 2024540 inpatients NNS I-NP O
5 700 704 2024540 with IN B-PP O
6 705 708 2024540 New NNP B-NP O
7 709 713 2024540 York NNP I-NP O
8 714 719 2024540 Heart NNP I-NP O
9 720 731 2024540 Association NNP I-NP O
10 732 733 2024540 ( ( O O
11 733 737 2024540 NYHA NNP B-NP O
12 737 738 2024540 ) ) O O
13 739 749 2024540 functional JJ B-NP O
14 750 755 2024540 class NN I-NP O
15 756 758 2024540 II CD I-NP O
16 759 762 2024540 and CC I-NP O
17 763 766 2024540 III CD I-NP O
18 766 767 2024540 . . O O

1 768 776 2024540 Patients NNS B-NP O
2 777 780 2024540 who WP B-NP O
3 781 789 2024540 received VBD B-VP O
4 790 799 2024540 enalapril NN B-NP B-Chemical
5 800 811 2024540 experienced VBD B-VP O
6 812 822 2024540 clinically RB B-ADVP O
7 823 826 2024540 and CC I-ADVP O
8 827 840 2024540 statistically RB B-NP O
9 841 854 2024540 significantly RB I-NP O
10 855 859 2024540 less RBR I-NP O
11 860 871 2024540 symptomatic JJ I-NP O
12 872 883 2024540 hypotension NN I-NP B-Disease
13 884 885 2024540 ( ( O O
14 885 889 2024540 5.2% NN B-NP O
15 889 890 2024540 ) ) O O
16 891 895 2024540 than IN B-PP O
17 896 899 2024540 the DT B-NP O
18 900 908 2024540 patients NNS I-NP O
19 909 912 2024540 who WP B-NP O
20 913 921 2024540 received VBD B-VP O
21 922 930 2024540 prazosin NN B-NP B-Chemical
22 931 932 2024540 ( ( O O
23 932 937 2024540 12.9% CD B-NP O
24 937 938 2024540 ) ) O O
25 938 939 2024540 . . O O

1 940 943 2024540 All DT B-NP O
2 944 952 2024540 patients NNS I-NP O
3 953 962 2024540 recovered VBD B-VP O
4 962 963 2024540 . . O O

1 964 966 2024540 It PRP B-NP O
2 967 970 2024540 was VBD B-VP O
3 971 980 2024540 concluded VBN I-VP O
4 981 985 2024540 that IN B-SBAR O
5 986 995 2024540 treatment NN B-NP O
6 996 1000 2024540 with IN B-PP O
7 1001 1010 2024540 enalapril NN B-NP B-Chemical
8 1011 1014 2024540 was VBD B-VP O
9 1015 1019 2024540 well RB I-VP O
10 1020 1029 2024540 tolerated VBN I-VP O
11 1030 1033 2024540 and CC O O
12 1034 1036 2024540 it PRP B-NP O
13 1037 1039 2024540 is VBZ B-VP O
14 1039 1040 2024540 , , O O
15 1041 1050 2024540 therefore RB B-ADVP O
16 1050 1051 2024540 , , O O
17 1052 1064 2024540 unreasonable JJ B-ADJP O
18 1065 1067 2024540 to TO B-VP O
19 1068 1076 2024540 restrict VB I-VP O
20 1077 1080 2024540 the DT B-NP O
21 1081 1091 2024540 initiation NN I-NP O
22 1092 1094 2024540 of IN B-PP O
23 1095 1104 2024540 treatment NN B-NP O
24 1105 1109 2024540 with IN B-PP O
25 1110 1119 2024540 enalapril NN B-NP B-Chemical
26 1120 1122 2024540 to TO B-PP O
27 1123 1133 2024540 inpatients NNS B-NP O
28 1133 1134 2024540 . . O O

1 0 0 9293063 -DOCSTART- -X- -X- O

1 0 4 9293063 Bile NN B-NP B-Disease
2 5 9 9293063 duct NN I-NP I-Disease
3 10 19 9293063 hamartoma NN I-NP I-Disease
4 20 29 9293063 occurring VBG B-VP O
5 30 32 9293063 in IN B-PP O
6 33 44 9293063 association NN B-NP O
7 45 49 9293063 with IN B-PP O
8 50 54 9293063 long JJ B-NP O
9 54 55 9293063 - HYPH I-NP O
10 55 59 9293063 term NN I-NP O
11 60 69 9293063 treatment NN I-NP O
12 70 74 9293063 with IN B-PP O
13 75 82 9293063 danazol NN B-NP B-Chemical
14 82 83 9293063 . . O O
15 84 86 9293063 We PRP B-NP O
16 87 93 9293063 report VBP B-VP O
17 94 95 9293063 a DT B-NP O
18 96 100 9293063 case NN I-NP O
19 101 103 9293063 of IN B-PP O
20 104 108 9293063 bile NN B-NP B-Disease
21 109 113 9293063 duct NN I-NP I-Disease
22 114 123 9293063 hamartoma NN I-NP I-Disease
23 124 129 9293063 which WDT B-NP O
24 130 139 9293063 developed VBD B-VP O
25 140 142 9293063 in IN B-PP O
26 143 144 9293063 a DT B-NP O
27 145 152 9293063 patient NN I-NP O
28 153 156 9293063 who WP B-NP O
29 157 160 9293063 had VBD B-VP O
30 161 165 9293063 been VBN I-VP O
31 166 168 9293063 on IN B-PP O
32 169 173 9293063 long JJ B-NP O
33 173 174 9293063 - HYPH I-NP O
34 174 178 9293063 term NN I-NP O
35 179 186 9293063 danazol NN I-NP B-Chemical
36 187 196 9293063 treatment NN I-NP O
37 196 197 9293063 . . O O

1 198 202 9293063 Such JJ B-NP O
2 203 211 9293063 patients NNS I-NP O
3 212 218 9293063 should MD B-VP O
4 219 221 9293063 be VB I-VP O
5 222 227 9293063 under IN B-PP O
6 228 233 9293063 close JJ B-ADJP O
7 234 240 9293063 follow VB B-VP O
8 240 241 9293063 - HYPH O O
9 241 243 9293063 up RP B-PRT O
10 243 244 9293063 , , O O
11 245 255 9293063 preferably RB B-ADVP O
12 256 260 9293063 with IN B-PP O
13 261 269 9293063 periodic JJ B-NP O
14 270 280 9293063 ultrasound NN I-NP O
15 281 292 9293063 examination NN I-NP O
16 293 295 9293063 of IN B-PP O
17 296 299 9293063 the DT B-NP O
18 300 305 9293063 liver NN I-NP O
19 305 306 9293063 . . O O

1 307 309 9293063 If IN B-SBAR O
2 310 313 9293063 the DT B-NP O
3 314 321 9293063 patient NN I-NP O
4 322 330 9293063 develops VBZ B-VP O
5 331 332 9293063 a DT B-NP O
6 333 338 9293063 liver NN I-NP B-Disease
7 339 343 9293063 mass NN I-NP I-Disease
8 343 344 9293063 , , O O
9 345 352 9293063 because IN B-PP O
10 353 355 9293063 of IN I-PP O
11 356 359 9293063 non AFX B-NP O
12 359 360 9293063 - HYPH I-NP O
13 360 368 9293063 specific JJ I-NP O
14 369 377 9293063 clinical JJ I-NP O
15 378 386 9293063 features NNS I-NP O
16 387 390 9293063 and CC O O
17 391 398 9293063 imaging NN B-NP O
18 399 410 9293063 appearances NNS I-NP O
19 410 411 9293063 , , O O
20 412 418 9293063 biopsy NN B-NP O
21 419 422 9293063 may MD B-VP O
22 423 425 9293063 be VB I-VP O
23 426 429 9293063 the DT B-NP O
24 430 434 9293063 only JJ I-NP O
25 435 438 9293063 way NN I-NP O
26 439 441 9293063 to TO B-VP O
27 442 449 9293063 achieve VB I-VP O
28 450 451 9293063 a DT B-NP O
29 452 462 9293063 definitive JJ I-NP O
30 463 472 9293063 diagnosis NN I-NP O
31 472 473 9293063 . . O O

1 0 0 10743446 -DOCSTART- -X- -X- O

1 0 12 10743446 Differential JJ B-NP O
2 13 20 10743446 effects NNS I-NP O
3 21 23 10743446 of IN B-PP O
4 24 36 10743446 systemically RB B-NP O
5 37 49 10743446 administered VBN I-NP O
6 50 58 10743446 ketamine NN I-NP B-Chemical
7 59 62 10743446 and CC I-NP O
8 63 72 10743446 lidocaine NN I-NP B-Chemical
9 73 75 10743446 on IN B-PP O
10 76 83 10743446 dynamic JJ B-NP O
11 84 87 10743446 and CC I-NP O
12 88 94 10743446 static JJ I-NP O
13 95 107 10743446 hyperalgesia NN I-NP B-Disease
14 108 115 10743446 induced VBN B-VP O
15 116 118 10743446 by IN B-PP O
16 119 130 10743446 intradermal JJ B-NP O
17 131 140 10743446 capsaicin NN I-NP B-Chemical
18 141 143 10743446 in IN B-PP O
19 144 150 10743446 humans NNS B-NP O
20 150 151 10743446 . . O O
21 152 154 10743446 We PRP B-NP O
22 155 159 10743446 have VBP B-VP O
23 160 168 10743446 examined VBN I-VP O
24 169 172 10743446 the DT B-NP O
25 173 179 10743446 effect NN I-NP O
26 180 182 10743446 of IN B-PP O
27 183 191 10743446 systemic JJ B-NP O
28 192 206 10743446 administration NN I-NP O
29 207 209 10743446 of IN B-PP O
30 210 218 10743446 ketamine NN B-NP B-Chemical
31 219 222 10743446 and CC I-NP O
32 223 232 10743446 lidocaine NN I-NP B-Chemical
33 233 235 10743446 on IN B-PP O
34 236 241 10743446 brush NN B-NP O
35 241 242 10743446 - HYPH O O
36 242 248 10743446 evoked VBN B-VP O
37 249 250 10743446 ( ( O O
38 250 257 10743446 dynamic JJ O O
39 257 258 10743446 ) ) O O
40 259 263 10743446 pain NN B-NP B-Disease
41 264 267 10743446 and CC I-NP O
42 268 276 10743446 punctate NN I-NP O
43 276 277 10743446 - HYPH O O
44 277 283 10743446 evoked VBN B-VP O
45 284 285 10743446 ( ( O O
46 285 291 10743446 static JJ O O
47 291 292 10743446 ) ) O O
48 293 305 10743446 hyperalgesia NN B-NP B-Disease
49 306 313 10743446 induced VBN B-VP O
50 314 316 10743446 by IN B-PP O
51 317 326 10743446 capsaicin NN B-NP B-Chemical
52 326 327 10743446 . . O O

1 328 330 10743446 In IN B-PP O
2 331 332 10743446 a DT B-NP O
3 333 343 10743446 randomized VBN I-NP O
4 343 344 10743446 , , I-NP O
5 345 351 10743446 double JJ I-NP O
6 351 352 10743446 - HYPH I-NP O
7 352 357 10743446 blind JJ I-NP O
8 357 358 10743446 , , I-NP O
9 359 366 10743446 placebo NN I-NP O
10 366 367 10743446 - HYPH I-NP O
11 367 377 10743446 controlled VBN B-VP O
12 377 378 10743446 , , O O
13 379 388 10743446 crossover NN B-NP O
14 389 394 10743446 study NN I-NP O
15 394 395 10743446 , , O O
16 396 398 10743446 we PRP B-NP O
17 399 406 10743446 studied VBD B-VP O
18 407 409 10743446 12 CD B-NP O
19 410 420 10743446 volunteers NNS I-NP O
20 421 423 10743446 in IN B-PP O
21 424 429 10743446 three CD B-NP O
22 430 441 10743446 experiments NNS I-NP O
23 441 442 10743446 . . O O

1 443 452 10743446 Capsaicin NN B-NP B-Chemical
2 453 456 10743446 100 CD I-NP O
3 457 467 10743446 micrograms NNS I-NP O
4 468 471 10743446 was VBD B-VP O
5 472 480 10743446 injected VBN I-VP O
6 481 494 10743446 intradermally RB B-ADVP O
7 495 497 10743446 on IN B-PP O
8 498 501 10743446 the DT B-NP O
9 502 507 10743446 volar JJ I-NP O
10 508 515 10743446 forearm NN I-NP O
11 516 524 10743446 followed VBN B-VP O
12 525 527 10743446 by IN B-PP O
13 528 530 10743446 an DT B-NP O
14 531 534 10743446 i.v NN I-NP O
15 534 535 10743446 . . O O

1 536 544 10743446 infusion NN B-NP O
2 545 547 10743446 of IN B-PP O
3 548 556 10743446 ketamine NN B-NP B-Chemical
4 557 558 10743446 ( ( O O
5 558 563 10743446 bolus NN B-NP O
6 564 567 10743446 0.1 CD I-NP O
7 568 570 10743446 mg NN I-NP O
8 571 573 10743446 kg NN I-NP O
9 573 574 10743446 - HYPH B-NP O
10 574 575 10743446 1 CD I-NP O
11 576 580 10743446 over IN I-NP O
12 581 583 10743446 10 CD I-NP O
13 584 587 10743446 min NN I-NP O
14 588 596 10743446 followed VBN B-VP O
15 597 599 10743446 by IN B-PP O
16 600 608 10743446 infusion NN B-NP O
17 609 611 10743446 of IN B-PP O
18 612 613 10743446 7 CD B-NP O
19 614 624 10743446 micrograms NNS I-NP O
20 625 627 10743446 kg NN I-NP O
21 627 628 10743446 - HYPH O O
22 628 629 10743446 1 CD B-NP O
23 630 633 10743446 min NN I-NP O
24 633 634 10743446 - HYPH B-NP O
25 634 635 10743446 1 CD I-NP O
26 635 636 10743446 ) ) O O
27 636 637 10743446 , , O O
28 638 647 10743446 lidocaine NN B-NP B-Chemical
29 648 649 10743446 5 CD I-NP O
30 650 652 10743446 mg NN I-NP O
31 653 655 10743446 kg NN I-NP O
32 655 656 10743446 - HYPH B-NP O
33 656 657 10743446 1 CD I-NP O
34 658 660 10743446 or CC O O
35 661 667 10743446 saline NN B-NP O
36 668 671 10743446 for IN B-PP O
37 672 674 10743446 50 CD B-NP O
38 675 678 10743446 min NN I-NP O
39 678 679 10743446 . . O O

1 680 688 10743446 Infusion NN B-NP O
2 689 696 10743446 started VBD B-VP O
3 697 699 10743446 15 CD B-NP O
4 700 703 10743446 min NN I-NP O
5 704 709 10743446 after IN B-PP O
6 710 719 10743446 injection NN B-NP O
7 720 722 10743446 of IN B-PP O
8 723 732 10743446 capsaicin NN B-NP B-Chemical
9 732 733 10743446 . . O O

1 734 737 10743446 The DT B-NP O
2 738 747 10743446 following VBG I-NP O
3 748 752 10743446 were VBD B-VP O
4 753 761 10743446 measured VBN I-VP O
5 761 762 10743446 : : O O
6 763 774 10743446 spontaneous JJ B-NP O
7 775 779 10743446 pain NN I-NP B-Disease
8 779 780 10743446 , , O O
9 781 785 10743446 pain NN B-NP B-Disease
10 786 792 10743446 evoked VBN B-VP O
11 793 795 10743446 by IN B-PP O
12 796 804 10743446 punctate NN B-NP O
13 805 808 10743446 and CC I-NP O
14 809 814 10743446 brush NN I-NP O
15 815 822 10743446 stimuli NNS I-NP O
16 823 824 10743446 ( ( O O
17 824 827 10743446 VAS NNS B-NP O
18 827 828 10743446 ) ) O O
19 828 829 10743446 , , O O
20 830 833 10743446 and CC O O
21 834 839 10743446 areas NNS B-NP O
22 840 842 10743446 of IN B-PP O
23 843 848 10743446 brush NN B-NP O
24 848 849 10743446 - HYPH B-NP O
25 849 855 10743446 evoked VBN B-VP O
26 856 859 10743446 and CC O O
27 860 868 10743446 punctate NN B-NP O
28 868 869 10743446 - HYPH O O
29 869 875 10743446 evoked VBN B-NP O
30 876 888 10743446 hyperalgesia NN I-NP B-Disease
31 888 889 10743446 . . O O

1 890 898 10743446 Ketamine NN B-NP B-Chemical
2 899 906 10743446 reduced VBD B-VP O
3 907 911 10743446 both CC O O
4 912 915 10743446 the DT B-NP O
5 916 920 10743446 area NN I-NP O
6 921 923 10743446 of IN B-PP O
7 924 929 10743446 brush NN B-NP O
8 929 930 10743446 - HYPH B-NP O
9 930 936 10743446 evoked VBN B-VP O
10 937 940 10743446 and CC O O
11 941 949 10743446 punctate NN B-NP O
12 949 950 10743446 - HYPH O O
13 950 956 10743446 evoked VBN B-NP O
14 957 969 10743446 hyperalgesia NN I-NP B-Disease
15 970 983 10743446 significantly RB B-ADVP O
16 984 987 10743446 and CC O O
17 988 990 10743446 it PRP B-NP O
18 991 997 10743446 tended VBD B-VP O
19 998 1000 10743446 to TO I-VP O
20 1001 1007 10743446 reduce VB I-VP O
21 1008 1013 10743446 brush NN B-NP O
22 1013 1014 10743446 - HYPH O O
23 1014 1020 10743446 evoked VBN B-NP O
24 1021 1025 10743446 pain NN I-NP B-Disease
25 1025 1026 10743446 . . O O

1 1027 1036 10743446 Lidocaine NN B-NP B-Chemical
2 1037 1044 10743446 reduced VBD B-VP O
3 1045 1048 10743446 the DT B-NP O
4 1049 1053 10743446 area NN I-NP O
5 1054 1056 10743446 of IN B-PP O
6 1057 1065 10743446 punctate NN B-NP O
7 1065 1066 10743446 - HYPH O O
8 1066 1072 10743446 evoked VBN B-NP O
9 1073 1085 10743446 hyperalgesia NN I-NP B-Disease
10 1086 1099 10743446 significantly RB B-ADVP O
11 1099 1100 10743446 . . O O

1 1101 1103 10743446 It PRP B-NP O
2 1104 1110 10743446 tended VBD B-VP O
3 1111 1113 10743446 to TO I-VP O
4 1114 1120 10743446 reduce VB I-VP O
5 1121 1124 10743446 VAS NNP B-NP O
6 1125 1131 10743446 scores NNS I-NP O
7 1132 1134 10743446 of IN B-PP O
8 1135 1146 10743446 spontaneous JJ B-NP O
9 1147 1151 10743446 pain NN I-NP B-Disease
10 1152 1155 10743446 but CC O O
11 1156 1159 10743446 had VBD B-VP O
12 1160 1162 10743446 no DT B-NP O
13 1163 1169 10743446 effect NN I-NP O
14 1170 1172 10743446 on IN B-PP O
15 1173 1179 10743446 evoked VBN B-NP O
16 1180 1184 10743446 pain NN I-NP B-Disease
17 1184 1185 10743446 . . O O

1 1186 1189 10743446 The DT B-NP O
2 1190 1202 10743446 differential JJ I-NP O
3 1203 1210 10743446 effects NNS I-NP O
4 1211 1213 10743446 of IN B-PP O
5 1214 1222 10743446 ketamine NN B-NP B-Chemical
6 1223 1226 10743446 and CC I-NP O
7 1227 1236 10743446 lidocaine NN I-NP B-Chemical
8 1237 1239 10743446 on IN B-PP O
9 1240 1246 10743446 static JJ B-NP O
10 1247 1250 10743446 and CC I-NP O
11 1251 1258 10743446 dynamic JJ I-NP O
12 1259 1271 10743446 hyperalgesia NN I-NP B-Disease
13 1272 1279 10743446 suggest VBP B-VP O
14 1280 1284 10743446 that IN B-SBAR O
15 1285 1288 10743446 the DT B-NP O
16 1289 1292 10743446 two CD I-NP O
17 1293 1298 10743446 types NNS I-NP O
18 1299 1301 10743446 of IN B-PP O
19 1302 1314 10743446 hyperalgesia NN B-NP B-Disease
20 1315 1318 10743446 are VBP B-VP O
21 1319 1327 10743446 mediated VBN I-VP O
22 1328 1330 10743446 by IN B-PP O
23 1331 1339 10743446 separate JJ B-NP O
24 1340 1350 10743446 mechanisms NNS I-NP O
25 1351 1354 10743446 and CC O O
26 1355 1359 10743446 have VBP B-VP O
27 1360 1361 10743446 a DT B-NP O
28 1362 1370 10743446 distinct JJ I-NP O
29 1371 1383 10743446 pharmacology NN I-NP O
30 1383 1384 10743446 . . O O

1 0 0 12907309 -DOCSTART- -X- -X- O

1 0 15 12907309 Neuroprotective JJ B-NP O
2 16 22 12907309 action NN I-NP O
3 23 25 12907309 of IN B-PP O
4 26 30 12907309 MPEP NN B-NP B-Chemical
5 30 31 12907309 , , O O
6 32 33 12907309 a DT B-NP O
7 34 43 12907309 selective JJ I-NP O
8 44 50 12907309 mGluR5 NN I-NP O
9 51 61 12907309 antagonist NN I-NP O
10 61 62 12907309 , , O O
11 63 65 12907309 in IN B-PP O
12 66 81 12907309 methamphetamine NN B-NP B-Chemical
13 81 82 12907309 - HYPH B-NP O
14 82 89 12907309 induced VBN I-NP O
15 90 102 12907309 dopaminergic JJ I-NP O
16 103 116 12907309 neurotoxicity NN I-NP B-Disease
17 117 119 12907309 is VBZ B-VP O
18 120 130 12907309 associated VBN I-VP O
19 131 135 12907309 with IN B-PP O
20 136 137 12907309 a DT B-NP O
21 138 146 12907309 decrease NN I-NP O
22 147 149 12907309 in IN B-PP O
23 150 158 12907309 dopamine NN B-NP B-Chemical
24 159 166 12907309 outflow NN I-NP O
25 167 170 12907309 and CC I-NP O
26 171 181 12907309 inhibition NN I-NP O
27 182 184 12907309 of IN B-PP O
28 185 197 12907309 hyperthermia NN B-NP B-Disease
29 198 200 12907309 in IN B-PP O
30 201 205 12907309 rats NNS B-NP O
31 205 206 12907309 . . O O
32 207 210 12907309 The DT B-NP O
33 211 214 12907309 aim NN I-NP O
34 215 217 12907309 of IN B-PP O
35 218 222 12907309 this DT B-NP O
36 223 228 12907309 study NN I-NP O
37 229 232 12907309 was VBD B-VP O
38 233 235 12907309 to TO B-VP O
39 236 243 12907309 examine VB I-VP O
40 244 247 12907309 the DT B-NP O
41 248 252 12907309 role NN I-NP O
42 253 255 12907309 of IN B-PP O
43 256 268 12907309 metabotropic JJ B-NP O
44 269 278 12907309 glutamate NN I-NP B-Chemical
45 279 287 12907309 receptor NN I-NP O
46 288 289 12907309 5 CD I-NP O
47 290 291 12907309 ( ( O O
48 291 297 12907309 mGluR5 NN B-NP O
49 297 298 12907309 ) ) O O
50 299 301 12907309 in IN B-PP O
51 302 305 12907309 the DT B-NP O
52 306 311 12907309 toxic JJ I-NP O
53 312 318 12907309 action NN I-NP O
54 319 321 12907309 of IN B-PP O
55 322 337 12907309 methamphetamine NN B-NP B-Chemical
56 338 340 12907309 on IN B-PP O
57 341 353 12907309 dopaminergic JJ B-NP O
58 354 362 12907309 neurones NNS I-NP O
59 363 365 12907309 in IN B-PP O
60 366 370 12907309 rats NNS B-NP O
61 370 371 12907309 . . O O

1 372 387 12907309 Methamphetamine NN B-NP B-Chemical
2 388 389 12907309 ( ( O O
3 389 391 12907309 10 CD B-NP O
4 392 394 12907309 mg NN I-NP O
5 394 395 12907309 / SYM B-NP O
6 395 397 12907309 kg NN I-NP O
7 398 400 12907309 sc NN I-NP O
8 400 401 12907309 ) ) O O
9 401 402 12907309 , , O O
10 403 415 12907309 administered VBN B-VP O
11 416 420 12907309 five CD B-NP O
12 421 426 12907309 times NNS I-NP O
13 426 427 12907309 , , O O
14 428 435 12907309 reduced VBD B-VP O
15 436 439 12907309 the DT B-NP O
16 440 446 12907309 levels NNS I-NP O
17 447 449 12907309 of IN B-PP O
18 450 458 12907309 dopamine NN B-NP B-Chemical
19 459 462 12907309 and CC O O
20 463 466 12907309 its PRP$ B-NP O
21 467 478 12907309 metabolites NNS I-NP O
22 479 481 12907309 in IN B-PP O
23 482 490 12907309 striatal JJ B-NP O
24 491 497 12907309 tissue NN I-NP O
25 498 502 12907309 when WRB B-ADVP O
26 503 511 12907309 measured VBN B-VP O
27 512 514 12907309 72 CD B-NP O
28 515 516 12907309 h NN I-NP O
29 517 522 12907309 after IN B-PP O
30 523 526 12907309 the DT B-NP O
31 527 531 12907309 last JJ I-NP O
32 532 541 12907309 injection NN I-NP O
33 541 542 12907309 . . O O

1 543 544 12907309 A DT B-NP O
2 545 554 12907309 selective JJ I-NP O
3 555 565 12907309 antagonist NN I-NP O
4 566 568 12907309 of IN B-PP O
5 569 575 12907309 mGluR5 NN B-NP O
6 575 576 12907309 , , O O
7 577 578 12907309 2 CD B-NP B-Chemical
8 578 579 12907309 - HYPH I-NP I-Chemical
9 579 585 12907309 methyl NN I-NP I-Chemical
10 585 586 12907309 - HYPH B-NP I-Chemical
11 586 587 12907309 6 CD I-NP I-Chemical
12 587 588 12907309 - HYPH I-NP I-Chemical
13 588 611 12907309 (phenylethynyl)pyridine NN I-NP I-Chemical
14 612 613 12907309 ( ( O O
15 613 617 12907309 MPEP NN B-NP B-Chemical
16 617 618 12907309 ; : O O
17 619 620 12907309 5 CD B-NP O
18 621 623 12907309 mg NN I-NP O
19 623 624 12907309 / SYM B-NP O
20 624 626 12907309 kg NN I-NP O
21 627 629 12907309 ip NN I-NP O
22 629 630 12907309 ) ) O O
23 630 631 12907309 , , O O
24 632 636 12907309 when WRB B-ADVP O
25 637 649 12907309 administered VBN B-VP O
26 650 654 12907309 five CD B-NP O
27 655 660 12907309 times NNS I-NP O
28 661 672 12907309 immediately RB B-ADVP O
29 673 679 12907309 before IN B-SBAR O
30 680 684 12907309 each DT B-NP O
31 685 700 12907309 methamphetamine NN I-NP B-Chemical
32 701 710 12907309 injection NN I-NP O
33 711 719 12907309 reversed VBD B-VP O
34 720 723 12907309 the DT B-NP O
35 724 729 12907309 above RB I-NP O
36 729 730 12907309 - HYPH I-NP O
37 730 739 12907309 mentioned VBN I-NP O
38 740 755 12907309 methamphetamine NN I-NP B-Chemical
39 756 763 12907309 effects NNS I-NP O
40 763 764 12907309 . . O O

1 765 766 12907309 A DT B-NP O
2 767 773 12907309 single JJ I-NP O
3 774 778 12907309 MPEP NN I-NP B-Chemical
4 779 780 12907309 ( ( O O
5 780 781 12907309 5 CD B-NP O
6 782 784 12907309 mg NN I-NP O
7 784 785 12907309 / SYM B-NP O
8 785 787 12907309 kg NN I-NP O
9 788 790 12907309 ip NN I-NP O
10 790 791 12907309 ) ) O O
11 792 801 12907309 injection NN B-NP O
12 802 809 12907309 reduced VBD B-VP O
13 810 813 12907309 the DT B-NP O
14 814 819 12907309 basal JJ I-NP O
15 820 833 12907309 extracellular JJ I-NP O
16 834 842 12907309 dopamine NN I-NP B-Chemical
17 843 848 12907309 level NN I-NP O
18 849 851 12907309 in IN B-PP O
19 852 855 12907309 the DT B-NP O
20 856 864 12907309 striatum NN I-NP O
21 864 865 12907309 , , O O
22 866 868 12907309 as RB B-CONJP O
23 869 873 12907309 well RB I-CONJP O
24 874 876 12907309 as IN I-CONJP O
25 877 885 12907309 dopamine NN B-NP B-Chemical
26 886 893 12907309 release NN I-NP O
27 894 904 12907309 stimulated VBD B-VP O
28 905 911 12907309 either CC O O
29 912 914 12907309 by IN B-PP O
30 915 930 12907309 methamphetamine NN B-NP B-Chemical
31 931 932 12907309 ( ( O O
32 932 934 12907309 10 CD B-NP O
33 935 937 12907309 mg NN I-NP O
34 937 938 12907309 / SYM B-NP O
35 938 940 12907309 kg NN I-NP O
36 941 943 12907309 sc NN I-NP O
37 943 944 12907309 ) ) O O
38 945 947 12907309 or CC O O
39 948 950 12907309 by IN B-PP O
40 951 966 12907309 intrastriatally RB B-NP O
41 967 979 12907309 administered VBN I-NP O
42 980 991 12907309 veratridine NN I-NP B-Chemical
43 992 993 12907309 ( ( O O
44 993 996 12907309 100 CD B-NP O
45 997 1003 12907309 microM NN I-NP O
46 1003 1004 12907309 ) ) O O
47 1004 1005 12907309 . . O O

1 1006 1014 12907309 Moreover RB B-ADVP O
2 1014 1015 12907309 , , O O
3 1016 1018 12907309 it PRP B-NP O
4 1019 1030 12907309 transiently RB B-ADVP O
5 1031 1041 12907309 diminished VBD B-VP O
6 1042 1045 12907309 the DT B-NP O
7 1046 1061 12907309 methamphetamine NN I-NP B-Chemical
8 1062 1063 12907309 ( ( O O
9 1063 1065 12907309 10 CD B-NP O
10 1066 1068 12907309 mg NN I-NP O
11 1068 1069 12907309 / SYM B-NP O
12 1069 1071 12907309 kg NN I-NP O
13 1072 1074 12907309 sc NN I-NP O
14 1074 1075 12907309 ) ) O O
15 1075 1076 12907309 - HYPH O O
16 1076 1083 12907309 induced VBN B-NP O
17 1084 1096 12907309 hyperthermia NN I-NP B-Disease
18 1097 1100 12907309 and CC O O
19 1101 1108 12907309 reduced VBN B-NP O
20 1109 1114 12907309 basal JJ I-NP O
21 1115 1119 12907309 body NN I-NP O
22 1120 1131 12907309 temperature NN I-NP O
23 1131 1132 12907309 . . O O

1 1133 1137 12907309 MPEP NN B-NP B-Chemical
2 1138 1150 12907309 administered VBN B-VP O
3 1151 1155 12907309 into IN B-PP O
4 1156 1159 12907309 the DT B-NP O
5 1160 1168 12907309 striatum NN I-NP O
6 1169 1171 12907309 at IN B-PP O
7 1172 1176 12907309 high JJ B-NP O
8 1177 1191 12907309 concentrations NNS I-NP O
9 1192 1193 12907309 ( ( O O
10 1193 1196 12907309 500 CD B-NP O
11 1197 1203 12907309 microM NN I-NP O
12 1203 1204 12907309 ) ) O O
13 1205 1214 12907309 increased VBD B-VP O
14 1215 1228 12907309 extracellular JJ B-NP O
15 1229 1237 12907309 dopamine NN I-NP B-Chemical
16 1238 1244 12907309 levels NNS I-NP O
17 1244 1245 12907309 , , O O
18 1246 1251 12907309 while IN B-SBAR O
19 1252 1257 12907309 lower JJR B-NP O
20 1258 1272 12907309 concentrations NNS I-NP O
21 1273 1274 12907309 ( ( O O
22 1274 1276 12907309 50 CD B-NP O
23 1276 1277 12907309 - HYPH I-NP O
24 1277 1280 12907309 100 CD I-NP O
25 1281 1287 12907309 microM NN I-NP O
26 1287 1288 12907309 ) ) O O
27 1289 1293 12907309 were VBD B-VP O
28 1294 1300 12907309 devoid JJ B-ADJP O
29 1301 1303 12907309 of IN B-PP O
30 1304 1307 12907309 any DT B-NP O
31 1308 1314 12907309 effect NN I-NP O
32 1314 1315 12907309 . . O O

1 1316 1319 12907309 The DT B-NP O
2 1320 1327 12907309 results NNS I-NP O
3 1328 1330 12907309 of IN B-PP O
4 1331 1335 12907309 this DT B-NP O
5 1336 1341 12907309 study NN I-NP O
6 1342 1349 12907309 suggest VBP B-VP O
7 1350 1354 12907309 that IN B-SBAR O
8 1355 1358 12907309 the DT B-NP O
9 1359 1367 12907309 blockade NN I-NP O
10 1368 1370 12907309 of IN B-PP O
11 1371 1377 12907309 mGluR5 NN B-NP O
12 1378 1380 12907309 by IN B-PP O
13 1381 1385 12907309 MPEP NN B-NP B-Chemical
14 1386 1389 12907309 may MD B-VP O
15 1390 1397 12907309 protect VB I-VP O
16 1398 1410 12907309 dopaminergic JJ B-NP O
17 1411 1419 12907309 neurones NNS I-NP O
18 1420 1427 12907309 against IN B-PP O
19 1428 1443 12907309 methamphetamine NN B-NP B-Chemical
20 1443 1444 12907309 - HYPH B-NP O
21 1444 1451 12907309 induced VBN I-NP O
22 1452 1460 12907309 toxicity NN I-NP B-Disease
23 1460 1461 12907309 . . O O

1 1462 1477 12907309 Neuroprotection NN B-NP O
2 1478 1486 12907309 rendered VBN B-VP O
3 1487 1489 12907309 by IN B-PP O
4 1490 1494 12907309 MPEP NN B-NP B-Chemical
5 1495 1498 12907309 may MD B-VP O
6 1499 1501 12907309 be VB I-VP O
7 1502 1512 12907309 associated VBN I-VP O
8 1513 1517 12907309 with IN B-PP O
9 1518 1521 12907309 the DT B-NP O
10 1522 1531 12907309 reduction NN I-NP O
11 1532 1534 12907309 of IN B-PP O
12 1535 1538 12907309 the DT B-NP O
13 1539 1554 12907309 methamphetamine NN I-NP B-Chemical
14 1554 1555 12907309 - HYPH B-NP O
15 1555 1562 12907309 induced VBN I-NP O
16 1563 1571 12907309 dopamine NN I-NP B-Chemical
17 1572 1578 12907309 efflux NN I-NP O
18 1579 1581 12907309 in IN B-PP O
19 1582 1585 12907309 the DT B-NP O
20 1586 1594 12907309 striatum NN I-NP O
21 1595 1598 12907309 due JJ B-ADJP O
22 1599 1601 12907309 to TO B-PP O
23 1602 1605 12907309 the DT B-NP O
24 1606 1614 12907309 blockade NN I-NP O
25 1615 1617 12907309 of IN B-PP O
26 1618 1631 12907309 extrastriatal JJ B-NP O
27 1632 1638 12907309 mGluR5 NN I-NP O
28 1638 1639 12907309 , , O O
29 1640 1643 12907309 and CC O O
30 1644 1648 12907309 with IN B-PP O
31 1649 1650 12907309 a DT B-NP O
32 1651 1659 12907309 decrease NN I-NP O
33 1660 1662 12907309 in IN B-PP O
34 1663 1675 12907309 hyperthermia NN B-NP B-Disease
35 1675 1676 12907309 . . O O

1 0 0 7088431 -DOCSTART- -X- -X- O

1 0 11 7088431 Development NN B-NP O
2 12 14 7088431 of IN B-PP O
3 15 20 7088431 clear JJ B-NP B-Disease
4 21 25 7088431 cell NN I-NP I-Disease
5 26 40 7088431 adenocarcinoma NN I-NP I-Disease
6 41 43 7088431 in IN B-PP O
7 44 47 7088431 DES NNP B-NP B-Chemical
8 47 48 7088431 - HYPH B-VP O
9 48 55 7088431 exposed VBN B-NP O
10 56 65 7088431 offspring NN I-NP O
11 66 71 7088431 under IN B-PP O
12 72 83 7088431 observation NN B-NP O
13 83 84 7088431 . . O O
14 85 88 7088431 Two CD B-NP O
15 89 94 7088431 cases NNS I-NP O
16 95 97 7088431 of IN B-PP O
17 98 103 7088431 clear JJ B-NP B-Disease
18 104 108 7088431 cell NN I-NP I-Disease
19 109 123 7088431 adenocarcinoma NN I-NP I-Disease
20 124 126 7088431 of IN B-PP I-Disease
21 127 130 7088431 the DT B-NP I-Disease
22 131 137 7088431 vagina NN I-NP I-Disease
23 138 146 7088431 detected VBN B-VP O
24 147 149 7088431 at IN B-PP O
25 150 156 7088431 follow VB B-VP O
26 156 157 7088431 - HYPH O O
27 157 159 7088431 up RP B-PRT O
28 160 162 7088431 in IN B-PP O
29 163 168 7088431 young JJ B-NP O
30 169 174 7088431 women NNS I-NP O
31 175 182 7088431 exposed VBN B-VP O
32 183 185 7088431 in IN B-PP O
33 186 191 7088431 utero NN B-NP O
34 192 194 7088431 to TO B-PP O
35 195 213 7088431 diethylstilbestrol NN B-NP B-Chemical
36 214 217 7088431 are VBP B-VP O
37 218 226 7088431 reported VBN I-VP O
38 226 227 7088431 . . O O

1 228 231 7088431 One CD B-NP O
2 232 239 7088431 patient NN I-NP O
3 239 240 7088431 , , O O
4 241 245 7088431 aged VBN B-VP O
5 246 248 7088431 23 CD B-NP O
6 248 249 7088431 , , O O
7 250 253 7088431 had VBD B-VP O
8 254 258 7088431 been VBN I-VP O
9 259 267 7088431 followed VBN I-VP O
10 268 271 7088431 for IN B-PP O
11 272 273 7088431 2 CD B-NP O
12 274 279 7088431 years NNS I-NP O
13 280 286 7088431 before IN B-SBAR O
14 287 296 7088431 carcinoma NN B-NP B-Disease
15 297 300 7088431 was VBD B-VP O
16 301 310 7088431 diagnosed VBN I-VP O
17 310 311 7088431 ; : O O
18 312 315 7088431 the DT B-NP O
19 316 322 7088431 second JJ I-NP O
20 323 330 7088431 patient NN I-NP O
21 330 331 7088431 , , O O
22 332 336 7088431 aged VBN B-VP O
23 337 339 7088431 22 CD B-NP O
24 339 340 7088431 , , O O
25 341 344 7088431 had VBD B-VP O
26 345 349 7088431 been VBN I-VP O
27 350 354 7088431 seen VBN I-VP O
28 355 357 7088431 on IN B-PP O
29 358 359 7088431 a DT B-NP O
30 360 367 7088431 regular JJ I-NP O
31 368 373 7088431 basis NN I-NP O
32 374 377 7088431 for IN B-PP O
33 378 379 7088431 5 CD B-NP O
34 380 385 7088431 years NNS I-NP O
35 385 386 7088431 , , O O
36 387 388 7088431 8 CD B-NP O
37 389 395 7088431 months NNS I-NP O
38 395 396 7088431 . . O O

1 397 399 7088431 In IN B-PP O
2 400 404 7088431 both DT B-NP O
3 405 414 7088431 instances NNS I-NP O
4 414 415 7088431 , , O O
5 416 425 7088431 suspicion NN B-NP O
6 426 428 7088431 of IN B-PP O
7 429 432 7088431 the DT B-NP O
8 433 441 7088431 presence NN I-NP O
9 442 444 7088431 of IN B-PP O
10 445 454 7088431 carcinoma NN B-NP B-Disease
11 455 458 7088431 was VBD B-VP O
12 459 466 7088431 aroused VBN I-VP O
13 467 469 7088431 by IN B-PP O
14 470 473 7088431 the DT B-NP O
15 474 483 7088431 palpation NN I-NP O
16 484 486 7088431 of IN B-PP O
17 487 488 7088431 a DT B-NP O
18 489 494 7088431 small JJ I-NP O
19 495 501 7088431 nodule NN I-NP O
20 502 504 7088431 in IN B-PP O
21 505 508 7088431 the DT B-NP O
22 509 516 7088431 vaginal JJ I-NP O
23 517 523 7088431 fornix NN I-NP O
24 523 524 7088431 . . O O

1 525 546 7088431 Hysterosalpingography NN B-NP O
2 547 550 7088431 was VBD B-VP O
3 551 560 7088431 performed VBN I-VP O
4 561 563 7088431 on IN B-PP O
5 564 568 7088431 both DT B-NP O
6 569 577 7088431 patients NNS I-NP O
7 578 581 7088431 and CC O O
8 581 582 7088431 , , O O
9 583 585 7088431 in IN B-PP O
10 586 587 7088431 1 CD B-NP O
11 588 596 7088431 instance NN I-NP O
12 596 597 7088431 , , O O
13 598 600 7088431 an DT B-NP O
14 601 609 7088431 abnormal JJ I-NP O
15 610 611 7088431 x NN I-NP O
16 611 612 7088431 - HYPH B-NP O
17 612 615 7088431 ray NN I-NP O
18 616 620 7088431 film NN I-NP O
19 621 624 7088431 was VBD B-VP O
20 625 634 7088431 reflected VBN I-VP O
21 635 637 7088431 by IN B-PP O
22 638 641 7088431 the DT B-NP O
23 642 647 7088431 gross JJ I-NP O
24 648 658 7088431 appearance NN I-NP O
25 659 661 7088431 of IN B-PP O
26 662 665 7088431 the DT B-NP O
27 666 673 7088431 uterine JJ I-NP O
28 674 680 7088431 cavity NN I-NP O
29 681 686 7088431 found VBN B-VP O
30 687 689 7088431 in IN B-PP O
31 690 693 7088431 the DT B-NP O
32 694 702 7088431 surgical JJ I-NP O
33 703 711 7088431 specimen NN I-NP O
34 711 712 7088431 . . O O

1 0 0 12090760 -DOCSTART- -X- -X- O

1 0 10 12090760 Antagonism NN B-NP O
2 11 18 12090760 between IN B-PP O
3 19 30 12090760 interleukin NN B-NP O
4 31 32 12090760 3 CD I-NP O
5 33 36 12090760 and CC O O
6 37 51 12090760 erythropoietin NN B-NP O
7 52 54 12090760 in IN B-PP O
8 55 59 12090760 mice NNS B-NP O
9 60 64 12090760 with IN B-PP O
10 65 79 12090760 azidothymidine NN B-NP B-Chemical
11 79 80 12090760 - HYPH B-NP O
12 80 87 12090760 induced VBN I-NP O
13 88 94 12090760 anemia NN I-NP B-Disease
14 95 98 12090760 and CC B-PP O
15 99 101 12090760 in IN B-PP O
16 102 106 12090760 bone NN B-NP O
17 107 113 12090760 marrow NN I-NP O
18 114 125 12090760 endothelial JJ I-NP O
19 126 131 12090760 cells NNS I-NP O
20 131 132 12090760 . . O O
21 133 147 12090760 Azidothymidine NN B-NP B-Chemical
22 148 149 12090760 ( ( O O
23 149 152 12090760 AZT NN B-NP B-Chemical
24 152 153 12090760 ) ) O O
25 153 154 12090760 - HYPH B-NP O
26 154 161 12090760 induced VBN I-NP O
27 162 168 12090760 anemia NN I-NP B-Disease
28 169 171 12090760 in IN B-PP O
29 172 176 12090760 mice NNS B-NP O
30 177 180 12090760 can MD B-VP O
31 181 183 12090760 be VB I-VP O
32 184 192 12090760 reversed VBN I-VP O
33 193 195 12090760 by IN B-PP O
34 196 199 12090760 the DT B-NP O
35 200 214 12090760 administration NN I-NP O
36 215 217 12090760 of IN B-PP O
37 218 221 12090760 IGF NN B-NP O
38 221 222 12090760 - HYPH B-NP O
39 222 224 12090760 IL NN I-NP O
40 224 225 12090760 - HYPH B-NP O
41 225 226 12090760 3 CD I-NP O
42 227 228 12090760 ( NN I-NP O
43 228 234 12090760 fusion NN I-NP O
44 235 242 12090760 protein NN I-NP O
45 243 245 12090760 of IN B-PP O
46 246 253 12090760 insulin NN B-NP O
47 253 254 12090760 - HYPH B-NP O
48 254 258 12090760 like JJ I-NP O
49 259 265 12090760 growth NN I-NP O
50 266 272 12090760 factor NN I-NP O
51 273 275 12090760 II CD I-NP O
52 276 277 12090760 ( ( O O
53 277 280 12090760 IGF NN B-NP O
54 281 283 12090760 II CD I-NP O
55 283 284 12090760 ) ) O O
56 285 288 12090760 and CC O O
57 289 300 12090760 interleukin NN B-NP O
58 301 302 12090760 3 CD I-NP O
59 302 303 12090760 ) ) O O
60 303 304 12090760 . . O O

1 305 313 12090760 Although IN B-SBAR O
2 314 325 12090760 interleukin NN B-NP O
3 326 327 12090760 3 CD I-NP O
4 328 329 12090760 ( ( O O
5 329 331 12090760 IL NN B-NP O
6 331 332 12090760 - HYPH B-NP O
7 332 333 12090760 3 CD I-NP O
8 333 334 12090760 ) ) O O
9 335 338 12090760 and CC O O
10 339 353 12090760 erythropoietin NN B-NP O
11 354 355 12090760 ( ( O O
12 355 358 12090760 EPO NN B-NP O
13 358 359 12090760 ) ) O O
14 360 363 12090760 are VBP B-VP O
15 364 369 12090760 known VBN I-VP O
16 370 372 12090760 to TO I-VP O
17 373 376 12090760 act VB I-VP O
18 377 392 12090760 synergistically RB B-ADVP O
19 393 395 12090760 on IN B-PP O
20 396 409 12090760 hematopoietic JJ B-NP O
21 410 414 12090760 cell NN I-NP O
22 415 428 12090760 proliferation NN I-NP O
23 429 431 12090760 in FW B-ADVP O
24 432 437 12090760 vitro FW I-ADVP O
25 437 438 12090760 , , O O
26 439 448 12090760 injection NN B-NP O
27 449 451 12090760 of IN B-PP O
28 452 455 12090760 IGF NN B-NP O
29 455 456 12090760 - HYPH B-NP O
30 456 458 12090760 IL NN I-NP O
31 458 459 12090760 - HYPH B-NP O
32 459 460 12090760 3 CD I-NP O
33 461 464 12090760 and CC O O
34 465 468 12090760 EPO NN B-NP O
35 469 471 12090760 in IN B-PP O
36 472 475 12090760 AZT NN B-NP B-Chemical
37 475 476 12090760 - HYPH B-NP O
38 476 483 12090760 treated VBN I-NP O
39 484 488 12090760 mice NNS I-NP O
40 489 497 12090760 resulted VBD B-VP O
41 498 500 12090760 in IN B-PP O
42 501 502 12090760 a DT B-NP O
43 503 512 12090760 reduction NN I-NP O
44 513 515 12090760 of IN B-PP O
45 516 519 12090760 red JJ B-NP O
46 520 525 12090760 cells NNS I-NP O
47 526 529 12090760 and CC O O
48 530 532 12090760 an DT B-NP O
49 533 541 12090760 increase NN I-NP O
50 542 544 12090760 of IN B-PP O
51 545 551 12090760 plasma NN B-NP O
52 552 555 12090760 EPO NN I-NP O
53 556 562 12090760 levels NNS I-NP O
54 563 565 12090760 as IN B-SBAR O
55 566 574 12090760 compared VBN B-VP O
56 575 577 12090760 to TO B-PP O
57 578 585 12090760 animals NNS B-NP O
58 586 593 12090760 treated VBN B-VP O
59 594 598 12090760 with IN B-PP O
60 599 602 12090760 IGF NN B-NP O
61 602 603 12090760 - HYPH B-NP O
62 603 605 12090760 IL NN I-NP O
63 605 606 12090760 - HYPH B-NP O
64 606 607 12090760 3 CD I-NP O
65 608 610 12090760 or CC I-NP O
66 611 614 12090760 EPO NN I-NP O
67 615 620 12090760 alone RB B-ADVP O
68 620 621 12090760 . . O O

1 622 624 12090760 We PRP B-NP O
2 625 631 12090760 tested VBD B-VP O
3 632 635 12090760 the DT B-NP O
4 636 646 12090760 hypothesis NN I-NP O
5 647 651 12090760 that IN B-SBAR O
6 652 655 12090760 the DT B-NP O
7 656 668 12090760 antagonistic JJ I-NP O
8 669 675 12090760 effect NN I-NP O
9 676 678 12090760 of IN B-PP O
10 679 681 12090760 IL NN B-NP O
11 681 682 12090760 - HYPH B-NP O
12 682 683 12090760 3 CD I-NP O
13 684 687 12090760 and CC O O
14 688 691 12090760 EPO NN B-NP O
15 692 694 12090760 on IN B-PP O
16 695 704 12090760 erythroid JJ B-NP O
17 705 710 12090760 cells NNS I-NP O
18 711 714 12090760 may MD B-VP O
19 715 717 12090760 be VB I-VP O
20 718 726 12090760 mediated VBN I-VP O
21 727 729 12090760 by IN B-PP O
22 730 741 12090760 endothelial JJ B-NP O
23 742 747 12090760 cells NNS I-NP O
24 747 748 12090760 . . O O

1 749 755 12090760 Bovine JJ B-NP O
2 756 761 12090760 liver NN I-NP O
3 762 771 12090760 erythroid JJ I-NP O
4 772 777 12090760 cells NNS I-NP O
5 778 782 12090760 were VBD B-VP O
6 783 791 12090760 cultured VBN I-VP O
7 792 794 12090760 on IN B-PP O
8 795 805 12090760 monolayers NNS B-NP O
9 806 808 12090760 of IN B-PP O
10 809 814 12090760 human JJ B-NP O
11 815 819 12090760 bone NN I-NP O
12 820 826 12090760 marrow NN I-NP O
13 827 838 12090760 endothelial JJ I-NP O
14 839 844 12090760 cells NNS I-NP O
15 845 855 12090760 previously RB B-VP O
16 856 863 12090760 treated VBN I-VP O
17 864 868 12090760 with IN B-PP O
18 869 872 12090760 EPO NN B-NP O
19 873 876 12090760 and CC I-NP O
20 877 880 12090760 IGF NN I-NP O
21 880 881 12090760 - HYPH B-NP O
22 881 883 12090760 IL NN I-NP O
23 883 884 12090760 - SYM B-NP O
24 884 885 12090760 3 CD I-NP O
25 885 886 12090760 . . O O

1 887 892 12090760 There EX B-NP O
2 893 896 12090760 was VBD B-VP O
3 897 898 12090760 a DT B-NP O
4 899 910 12090760 significant JJ I-NP O
5 911 920 12090760 reduction NN I-NP O
6 921 923 12090760 of IN B-PP O
7 924 933 12090760 thymidine NN B-NP B-Chemical
8 934 947 12090760 incorporation NN I-NP O
9 948 952 12090760 into IN B-PP O
10 953 957 12090760 both CC O O
11 958 967 12090760 erythroid JJ B-NP O
12 968 971 12090760 and CC I-NP O
13 972 983 12090760 endothelial JJ I-NP O
14 984 989 12090760 cells NNS I-NP O
15 990 992 12090760 in IN B-PP O
16 993 1001 12090760 cultures NNS B-NP O
17 1002 1005 12090760 pre AFX O O
18 1005 1006 12090760 - HYPH O O
19 1006 1013 12090760 treated VBN B-VP O
20 1014 1018 12090760 with IN B-PP O
21 1019 1022 12090760 IGF NN B-NP O
22 1022 1023 12090760 - HYPH B-NP O
23 1023 1025 12090760 IL NN I-NP O
24 1025 1026 12090760 - HYPH B-NP O
25 1026 1027 12090760 3 CD I-NP O
26 1028 1031 12090760 and CC O O
27 1032 1035 12090760 EPO NNP B-NP O
28 1035 1036 12090760 . . O O

1 1037 1048 12090760 Endothelial JJ B-NP O
2 1049 1053 12090760 cell NN I-NP O
3 1054 1061 12090760 culture NN I-NP O
4 1062 1074 12090760 supernatants NNS I-NP O
5 1075 1084 12090760 separated VBN B-VP O
6 1085 1087 12090760 by IN B-PP O
7 1088 1103 12090760 ultrafiltration NN B-NP O
8 1104 1107 12090760 and CC I-NP O
9 1108 1127 12090760 ultracentrifugation NN I-NP O
10 1128 1132 12090760 from IN B-PP O
11 1133 1138 12090760 cells NNS B-NP O
12 1139 1146 12090760 treated VBN B-VP O
13 1147 1151 12090760 with IN B-PP O
14 1152 1155 12090760 EPO NN B-NP O
15 1156 1159 12090760 and CC I-NP O
16 1160 1162 12090760 IL NN I-NP O
17 1162 1163 12090760 - HYPH B-NP O
18 1163 1164 12090760 3 CD I-NP O
19 1165 1178 12090760 significantly RB B-ADVP O
20 1179 1186 12090760 reduced VBD B-VP O
21 1187 1196 12090760 thymidine NN B-NP B-Chemical
22 1197 1210 12090760 incorporation NN I-NP O
23 1211 1215 12090760 into IN B-PP O
24 1216 1225 12090760 erythroid JJ B-NP O
25 1226 1231 12090760 cells NNS I-NP O
26 1232 1234 12090760 as IN B-SBAR O
27 1235 1243 12090760 compared VBN B-VP O
28 1244 1246 12090760 to TO B-PP O
29 1247 1256 12090760 identical JJ B-NP O
30 1257 1266 12090760 fractions NNS I-NP O
31 1267 1275 12090760 obtained VBN B-VP O
32 1276 1280 12090760 from IN B-PP O
33 1281 1284 12090760 the DT B-NP O
34 1285 1290 12090760 media NNS I-NP O
35 1291 1293 12090760 of IN B-PP O
36 1294 1299 12090760 cells NNS B-NP O
37 1300 1308 12090760 cultured VBN B-VP O
38 1309 1313 12090760 with IN B-PP O
39 1314 1317 12090760 EPO NN B-NP O
40 1318 1323 12090760 alone RB B-ADVP O
41 1323 1324 12090760 . . O O

1 1325 1330 12090760 These DT B-NP O
2 1331 1338 12090760 results NNS I-NP O
3 1339 1346 12090760 suggest VBP B-VP O
4 1347 1351 12090760 that IN B-SBAR O
5 1352 1363 12090760 endothelial JJ B-NP O
6 1364 1369 12090760 cells NNS I-NP O
7 1370 1377 12090760 treated VBN B-VP O
8 1378 1392 12090760 simultaneously RB B-ADVP O
9 1393 1397 12090760 with IN B-PP O
10 1398 1401 12090760 EPO NN B-NP O
11 1402 1405 12090760 and CC I-NP O
12 1406 1408 12090760 IL NN I-NP O
13 1408 1409 12090760 - HYPH B-NP O
14 1409 1410 12090760 3 CD I-NP O
15 1411 1415 12090760 have VBP B-VP O
16 1416 1417 12090760 a DT B-NP O
17 1418 1426 12090760 negative JJ I-NP O
18 1427 1433 12090760 effect NN I-NP O
19 1434 1436 12090760 on IN B-PP O
20 1437 1446 12090760 erythroid JJ B-NP O
21 1447 1451 12090760 cell NN I-NP O
22 1452 1462 12090760 production NN I-NP O
23 1462 1463 12090760 . . O O

1 0 0 4812392 -DOCSTART- -X- -X- O

1 0 9 4812392 Treatment NN B-NP O
2 10 12 4812392 of IN B-PP O
3 13 22 4812392 psoriasis NN B-NP B-Disease
4 23 27 4812392 with IN B-PP O
5 28 40 4812392 azathioprine NN B-NP B-Chemical
6 40 41 4812392 . . O O
7 42 54 4812392 Azathioprine NN B-NP B-Chemical
8 55 64 4812392 treatment NN I-NP O
9 65 74 4812392 benefited VBD B-VP O
10 75 77 4812392 19 CD B-NP O
11 78 79 4812392 ( ( O O
12 79 82 4812392 66% CD B-NP O
13 82 83 4812392 ) ) O O
14 84 87 4812392 out IN B-PP O
15 88 90 4812392 of IN B-PP O
16 91 93 4812392 29 CD B-NP O
17 94 102 4812392 patients NNS I-NP O
18 103 112 4812392 suffering VBG B-VP O
19 113 117 4812392 from IN B-PP O
20 118 124 4812392 severe JJ B-NP O
21 125 134 4812392 psoriasis NN I-NP B-Disease
22 134 135 4812392 . . O O

1 136 150 4812392 Haematological JJ B-NP O
2 151 164 4812392 complications NNS I-NP O
3 165 169 4812392 were VBD B-VP O
4 170 173 4812392 not RB O O
5 174 185 4812392 troublesome JJ B-ADJP O
6 186 189 4812392 and CC O O
7 190 197 4812392 results NNS B-NP O
8 198 200 4812392 of IN B-PP O
9 201 212 4812392 biochemical JJ B-NP O
10 213 218 4812392 liver NN I-NP O
11 219 227 4812392 function NN I-NP O
12 228 233 4812392 tests NNS I-NP O
13 234 242 4812392 remained VBD B-VP O
14 243 249 4812392 normal JJ B-ADJP O
15 249 250 4812392 . . O O

1 251 258 4812392 Minimal JJ B-NP O
2 259 270 4812392 cholestasis NN I-NP B-Disease
3 271 274 4812392 was VBD B-VP O
4 275 279 4812392 seen VBN I-VP O
5 280 282 4812392 in IN B-PP O
6 283 286 4812392 two CD B-NP O
7 287 292 4812392 cases NNS I-NP O
8 293 296 4812392 and CC O O
9 297 303 4812392 portal JJ B-NP O
10 304 312 4812392 fibrosis NN I-NP B-Disease
11 313 315 4812392 of IN B-PP O
12 316 317 4812392 a DT B-NP O
13 318 328 4812392 reversible JJ I-NP O
14 329 335 4812392 degree NN I-NP O
15 336 338 4812392 in IN B-PP O
16 339 344 4812392 eight CD B-NP O
17 344 345 4812392 . . O O

1 346 351 4812392 Liver NN B-NP O
2 352 360 4812392 biopsies NNS I-NP O
3 361 367 4812392 should MD B-VP O
4 368 370 4812392 be VB I-VP O
5 371 381 4812392 undertaken VBN I-VP O
6 382 384 4812392 at IN B-PP O
7 385 392 4812392 regular JJ B-NP O
8 393 402 4812392 intervals NNS I-NP O
9 403 405 4812392 if IN B-SBAR O
10 406 418 4812392 azathioprine NN B-NP B-Chemical
11 419 426 4812392 therapy NN I-NP O
12 427 429 4812392 is VBZ B-VP O
13 430 439 4812392 continued VBN I-VP O
14 440 442 4812392 so RB B-SBAR O
15 443 447 4812392 that IN I-SBAR O
16 448 458 4812392 structural JJ B-NP O
17 459 464 4812392 liver NN I-NP B-Disease
18 465 471 4812392 damage NN I-NP I-Disease
19 472 475 4812392 may MD B-VP O
20 476 478 4812392 be VB I-VP O
21 479 487 4812392 detected VBN I-VP O
22 488 490 4812392 at IN B-PP O
23 491 493 4812392 an DT B-NP O
24 494 499 4812392 early JJ I-NP O
25 500 503 4812392 and CC I-NP O
26 504 514 4812392 reversible JJ I-NP O
27 515 520 4812392 stage NN I-NP O
28 520 521 4812392 . . O O

1 0 0 19957053 -DOCSTART- -X- -X- O

1 0 13 19957053 Phenylephrine NN B-NP B-Chemical
2 14 17 19957053 but CC B-NP O
3 18 21 19957053 not RB I-NP O
4 22 31 19957053 ephedrine NN B-NP B-Chemical
5 32 39 19957053 reduces VBZ B-VP B-Disease
6 40 47 19957053 frontal JJ B-NP I-Disease
7 48 52 19957053 lobe NN I-NP I-Disease
8 53 64 19957053 oxygenation NN I-NP I-Disease
9 65 74 19957053 following VBG B-NP O
10 75 85 19957053 anesthesia NN I-NP O
11 85 86 19957053 - HYPH B-NP O
12 86 93 19957053 induced VBN I-NP O
13 94 105 19957053 hypotension NN I-NP B-Disease
14 105 106 19957053 . . I-NP O
15 107 117 19957053 BACKGROUND NN I-NP O
16 117 118 19957053 : : O O
17 119 130 19957053 Vasopressor NN B-NP O
18 131 137 19957053 agents NNS I-NP O
19 138 141 19957053 are VBP B-VP O
20 142 146 19957053 used VBN I-VP O
21 147 149 19957053 to TO B-VP O
22 150 157 19957053 correct VB I-VP O
23 158 168 19957053 anesthesia NN B-NP O
24 168 169 19957053 - HYPH B-NP O
25 169 176 19957053 induced VBN I-NP O
26 177 188 19957053 hypotension NN I-NP B-Disease
27 188 189 19957053 . . O O

1 190 192 19957053 We PRP B-NP O
2 193 201 19957053 describe VBP B-VP O
3 202 205 19957053 the DT B-NP O
4 206 212 19957053 effect NN I-NP O
5 213 215 19957053 of IN B-PP O
6 216 229 19957053 phenylephrine NN B-NP B-Chemical
7 230 233 19957053 and CC I-NP O
8 234 243 19957053 ephedrine NN I-NP B-Chemical
9 244 246 19957053 on IN B-PP O
10 247 254 19957053 frontal JJ B-NP O
11 255 259 19957053 lobe NN I-NP O
12 260 271 19957053 oxygenation NN I-NP O
13 272 273 19957053 ( ( O O
14 273 281 19957053 S(c)O(2) NN B-NP O
15 281 282 19957053 ) ) O O
16 283 292 19957053 following VBG B-PP O
17 293 303 19957053 anesthesia NN B-NP O
18 303 304 19957053 - HYPH B-NP O
19 304 311 19957053 induced VBN I-NP O
20 312 323 19957053 hypotension NN I-NP B-Disease
21 323 324 19957053 . . O O

1 325 332 19957053 METHODS NNS B-NP O
2 332 333 19957053 : : O O
3 334 343 19957053 Following VBG B-VP O
4 344 353 19957053 induction NN B-NP O
5 354 356 19957053 of IN B-PP O
6 357 367 19957053 anesthesia NN B-NP O
7 368 370 19957053 by IN B-PP O
8 371 379 19957053 fentanyl NN B-NP B-Chemical
9 380 381 19957053 ( ( O O
10 381 385 19957053 0.15 CD B-NP O
11 386 388 19957053 mg NN I-NP O
12 389 392 19957053 kg( AFX B-VP O
13 392 393 19957053 - HYPH B-LST O
14 393 395 19957053 1) LS B-LST O
15 395 396 19957053 ) ) O O
16 397 400 19957053 and CC O O
17 401 409 19957053 propofol NN B-NP B-Chemical
18 410 411 19957053 ( ( O O
19 411 414 19957053 2.0 CD B-NP O
20 415 417 19957053 mg NN I-NP O
21 418 421 19957053 kg( AFX B-VP O
22 421 422 19957053 - HYPH B-LST O
23 422 424 19957053 1) LS B-LST O
24 424 425 19957053 ) ) O O
25 425 426 19957053 , , O O
26 427 429 19957053 13 CD B-NP O
27 430 438 19957053 patients NNS I-NP O
28 439 447 19957053 received VBD B-VP O
29 448 461 19957053 phenylephrine NN B-NP B-Chemical
30 462 463 19957053 ( ( O O
31 463 466 19957053 0.1 CD B-NP O
32 467 469 19957053 mg NN I-NP O
33 470 472 19957053 iv NN I-NP O
34 472 473 19957053 ) ) O O
35 474 477 19957053 and CC O O
36 478 480 19957053 12 CD B-NP O
37 481 489 19957053 patients NNS I-NP O
38 490 498 19957053 received VBD B-VP O
39 499 508 19957053 ephedrine NN B-NP B-Chemical
40 509 510 19957053 ( ( O O
41 510 512 19957053 10 CD B-NP O
42 513 515 19957053 mg NN I-NP O
43 516 518 19957053 iv NN I-NP O
44 518 519 19957053 ) ) O O
45 520 522 19957053 to TO B-VP O
46 523 530 19957053 restore VB I-VP O
47 531 535 19957053 mean JJ B-NP O
48 536 544 19957053 arterial JJ I-NP O
49 545 553 19957053 pressure NN I-NP O
50 554 555 19957053 ( ( O O
51 555 558 19957053 MAP NN B-NP O
52 558 559 19957053 ) ) O O
53 559 560 19957053 . . O O

1 561 566 19957053 Heart NN B-NP O
2 567 571 19957053 rate NN I-NP O
3 572 573 19957053 ( ( O O
4 573 575 19957053 HR NN B-NP O
5 575 576 19957053 ) ) O O
6 576 577 19957053 , , O O
7 578 581 19957053 MAP NN B-NP O
8 581 582 19957053 , , O O
9 583 589 19957053 stroke NN B-NP B-Disease
10 590 596 19957053 volume NN I-NP O
11 597 598 19957053 ( ( O O
12 598 600 19957053 SV NN B-NP O
13 600 601 19957053 ) ) O O
14 601 602 19957053 , , O O
15 603 610 19957053 cardiac JJ B-NP O
16 611 617 19957053 output NN I-NP O
17 618 619 19957053 ( ( O O
18 619 621 19957053 CO NN B-NP O
19 621 622 19957053 ) ) O O
20 622 623 19957053 , , O O
21 624 627 19957053 and CC O O
22 628 635 19957053 frontal JJ B-NP O
23 636 640 19957053 lobe NN I-NP O
24 641 652 19957053 oxygenation NN I-NP O
25 653 654 19957053 ( ( O O
26 654 662 19957053 S(c)O(2) NN B-NP O
27 662 663 19957053 ) ) O O
28 664 668 19957053 were VBD B-VP O
29 669 679 19957053 registered VBN I-VP O
30 679 680 19957053 . . O O

1 681 688 19957053 RESULTS NNS B-NP O
2 688 689 19957053 : : O O
3 690 699 19957053 Induction NN B-NP O
4 700 702 19957053 of IN B-PP O
5 703 713 19957053 anesthesia NN B-NP O
6 714 717 19957053 was VBD B-VP O
7 718 726 19957053 followed VBN I-VP O
8 727 729 19957053 by IN B-PP O
9 730 731 19957053 a DT B-NP B-Disease
10 732 740 19957053 decrease NN I-NP I-Disease
11 741 743 19957053 in IN B-PP I-Disease
12 744 747 19957053 MAP NN B-NP I-Disease
13 747 748 19957053 , , O I-Disease
14 749 751 19957053 HR NN B-NP I-Disease
15 751 752 19957053 , , O I-Disease
16 753 755 19957053 SV NN B-NP I-Disease
17 755 756 19957053 , , O I-Disease
18 757 760 19957053 and CC O I-Disease
19 761 763 19957053 CO NN B-NP I-Disease
20 764 775 19957053 concomitant JJ B-ADJP O
21 776 780 19957053 with IN B-PP O
22 781 783 19957053 an DT B-NP O
23 784 793 19957053 elevation NN I-NP O
24 794 796 19957053 in IN B-PP O
25 797 805 19957053 S(c)O(2) NN B-NP O
26 805 806 19957053 . . O O

1 807 812 19957053 After IN B-PP O
2 813 827 19957053 administration NN B-NP O
3 828 830 19957053 of IN B-PP O
4 831 844 19957053 phenylephrine NN B-NP B-Chemical
5 844 845 19957053 , , O O
6 846 849 19957053 MAP NN B-NP O
7 850 859 19957053 increased VBD B-VP O
8 860 861 19957053 ( ( O O
9 861 863 19957053 51 CD B-NP O
10 864 865 19957053 + SYM O O
11 865 866 19957053 / SYM O O
12 866 867 19957053 - SYM O O
13 868 870 19957053 12 CD B-NP O
14 871 873 19957053 to TO B-PP O
15 874 876 19957053 81 CD B-NP O
16 877 878 19957053 + SYM O O
17 878 879 19957053 / SYM O O
18 879 880 19957053 - SYM O O
19 881 883 19957053 13 CD B-NP O
20 884 888 19957053 mmHg NN I-NP O
21 888 889 19957053 ; : O O
22 890 891 19957053 P NN B-NP O
23 892 893 19957053 < SYM B-ADJP O
24 894 899 19957053 0.001 CD B-NP O
25 899 900 19957053 ; : O O
26 901 905 19957053 mean NN B-NP O
27 906 907 19957053 + SYM O O
28 907 908 19957053 / SYM O O
29 908 909 19957053 - HYPH O O
30 910 912 19957053 SD NN B-NP O
31 912 913 19957053 ) ) O O
32 913 914 19957053 . . O O

1 915 922 19957053 However RB B-ADVP O
2 922 923 19957053 , , O O
3 924 925 19957053 a DT B-NP O
4 926 929 19957053 14% NN I-NP O
5 930 931 19957053 ( ( O O
6 931 935 19957053 from IN B-PP O
7 936 938 19957053 70 CD B-NP O
8 939 940 19957053 + SYM B-ADJP O
9 940 941 19957053 / SYM O O
10 941 942 19957053 - SYM B-NP O
11 943 945 19957053 8% CD B-NP O
12 946 948 19957053 to TO I-NP O
13 949 951 19957053 60 CD I-NP O
14 952 953 19957053 + SYM O O
15 953 954 19957053 / SYM O O
16 954 955 19957053 - SYM O O
17 956 958 19957053 7% CD O O
18 958 959 19957053 ) ) O O
19 960 969 19957053 reduction NN B-NP O
20 970 972 19957053 in IN B-PP O
21 973 981 19957053 S(c)O(2) NN B-NP O
22 982 983 19957053 ( ( O O
23 983 984 19957053 P NN B-NP O
24 985 986 19957053 < SYM B-NP O
25 987 991 19957053 0.05 CD I-NP O
26 991 992 19957053 ) ) O O
27 993 1001 19957053 followed VBN B-VP O
28 1002 1006 19957053 with IN B-PP O
29 1007 1009 19957053 no DT B-NP O
30 1010 1016 19957053 change NN I-NP O
31 1017 1019 19957053 in IN B-PP O
32 1020 1022 19957053 CO NN B-NP O
33 1023 1024 19957053 ( ( O O
34 1024 1027 19957053 3.7 CD B-NP O
35 1028 1029 19957053 + SYM O O
36 1029 1030 19957053 / SYM O O
37 1030 1031 19957053 - SYM O O
38 1032 1035 19957053 1.1 CD B-NP O
39 1036 1038 19957053 to TO B-PP O
40 1039 1042 19957053 3.4 CD B-NP O
41 1043 1044 19957053 + SYM O O
42 1044 1045 19957053 / SYM O O
43 1045 1046 19957053 - SYM O O
44 1047 1050 19957053 0.9 CD B-NP O
45 1051 1052 19957053 l NN I-NP O
46 1053 1057 19957053 min( AFX B-VP O
47 1057 1058 19957053 - HYPH B-LST O
48 1058 1060 19957053 1) LS B-LST O
49 1060 1061 19957053 ) ) O O
50 1061 1062 19957053 . . O O

1 1063 1066 19957053 The DT B-NP O
2 1067 1081 19957053 administration NN I-NP O
3 1082 1084 19957053 of IN B-PP O
4 1085 1094 19957053 ephedrine NN B-NP B-Chemical
5 1095 1098 19957053 led VBD B-VP O
6 1099 1101 19957053 to TO B-PP O
7 1102 1103 19957053 a DT B-NP O
8 1104 1111 19957053 similar JJ I-NP O
9 1112 1120 19957053 increase NN I-NP O
10 1121 1123 19957053 in IN B-PP O
11 1124 1127 19957053 MAP NN B-NP O
12 1128 1129 19957053 ( ( O O
13 1129 1131 19957053 53 CD B-NP O
14 1132 1133 19957053 + SYM O O
15 1133 1134 19957053 / SYM O O
16 1134 1135 19957053 - SYM O O
17 1136 1137 19957053 9 CD B-NP O
18 1138 1140 19957053 to TO B-PP O
19 1141 1143 19957053 79 CD B-NP O
20 1144 1145 19957053 + SYM O O
21 1145 1146 19957053 / SYM O O
22 1146 1147 19957053 - SYM O O
23 1148 1149 19957053 8 CD B-NP O
24 1150 1154 19957053 mmHg NN I-NP O
25 1154 1155 19957053 ; : O O
26 1156 1157 19957053 P NN B-NP O
27 1158 1159 19957053 < SYM B-NP O
28 1160 1165 19957053 0.001 CD I-NP O
29 1165 1166 19957053 ) ) O O
30 1166 1167 19957053 , , O O
31 1168 1176 19957053 restored VBD B-VP O
32 1177 1179 19957053 CO NN B-NP O
33 1180 1181 19957053 ( ( O O
34 1181 1184 19957053 3.2 CD B-NP O
35 1185 1186 19957053 + SYM O O
36 1186 1187 19957053 / SYM O O
37 1187 1188 19957053 - SYM O O
38 1189 1192 19957053 1.2 CD B-NP O
39 1193 1195 19957053 to TO B-PP O
40 1196 1199 19957053 5.0 CD B-NP O
41 1200 1201 19957053 + SYM O O
42 1201 1202 19957053 / SYM O O
43 1202 1203 19957053 - SYM O O
44 1204 1207 19957053 1.3 CD B-NP O
45 1208 1209 19957053 l NN I-NP O
46 1210 1214 19957053 min( AFX B-VP O
47 1214 1215 19957053 - HYPH B-LST O
48 1215 1217 19957053 1) LS B-LST O
49 1217 1218 19957053 ) ) O O
50 1218 1219 19957053 , , O O
51 1220 1223 19957053 and CC O O
52 1224 1233 19957053 preserved VBN B-NP O
53 1234 1242 19957053 S(c)O(2) NN I-NP O
54 1242 1243 19957053 . . O O

1 1244 1255 19957053 CONCLUSIONS NNS B-NP O
2 1255 1256 19957053 : : O O
3 1257 1260 19957053 The DT B-NP O
4 1261 1272 19957053 utilization NN I-NP O
5 1273 1275 19957053 of IN B-PP O
6 1276 1289 19957053 phenylephrine NN B-NP B-Chemical
7 1290 1292 19957053 to TO B-VP O
8 1293 1300 19957053 correct VB I-VP O
9 1301 1312 19957053 hypotension NN B-NP B-Disease
10 1313 1320 19957053 induced VBN B-VP O
11 1321 1323 19957053 by IN B-PP O
12 1324 1334 19957053 anesthesia NN B-NP O
13 1335 1338 19957053 has VBZ B-VP O
14 1339 1340 19957053 a DT B-NP O
15 1341 1349 19957053 negative JJ I-NP O
16 1350 1356 19957053 impact NN I-NP O
17 1357 1359 19957053 on IN B-PP O
18 1360 1368 19957053 S(c)O(2) NN B-NP O
19 1369 1374 19957053 while IN B-SBAR O
20 1375 1384 19957053 ephedrine NN B-NP B-Chemical
21 1385 1394 19957053 maintains VBZ B-VP O
22 1395 1402 19957053 frontal JJ B-NP O
23 1403 1407 19957053 lobe NN I-NP O
24 1408 1419 19957053 oxygenation NN I-NP O
25 1420 1431 19957053 potentially RB B-ADJP O
26 1432 1439 19957053 related JJ I-ADJP O
27 1440 1442 19957053 to TO B-PP O
28 1443 1445 19957053 an DT B-NP O
29 1446 1454 19957053 increase NN I-NP O
30 1455 1457 19957053 in IN B-PP O
31 1458 1460 19957053 CO NN B-NP O
32 1460 1461 19957053 . . O O

1 0 0 8372922 -DOCSTART- -X- -X- O

1 0 15 8372922 Neuroplasticity NN B-NP O
2 16 18 8372922 of IN B-PP O
3 19 22 8372922 the DT B-NP O
4 23 28 8372922 adult JJ I-NP O
5 29 36 8372922 primate JJ I-NP O
6 37 45 8372922 auditory JJ I-NP O
7 46 52 8372922 cortex NN I-NP O
8 53 62 8372922 following VBG B-PP O
9 63 71 8372922 cochlear JJ B-NP O
10 72 79 8372922 hearing NN I-NP B-Disease
11 80 84 8372922 loss NN I-NP I-Disease
12 84 85 8372922 . . O O
13 86 95 8372922 Tonotopic JJ B-NP O
14 96 108 8372922 organization NN I-NP O
15 109 111 8372922 is VBZ B-VP O
16 112 114 8372922 an DT B-NP O
17 115 124 8372922 essential JJ I-NP O
18 125 132 8372922 feature NN I-NP O
19 133 135 8372922 of IN B-PP O
20 136 139 8372922 the DT B-NP O
21 140 147 8372922 primary JJ I-NP O
22 148 156 8372922 auditory JJ I-NP O
23 157 161 8372922 area NN I-NP O
24 162 163 8372922 ( ( O O
25 163 165 8372922 A1 NN B-NP O
26 165 166 8372922 ) ) O O
27 167 169 8372922 of IN B-PP O
28 170 177 8372922 primate JJ B-NP O
29 178 184 8372922 cortex NN I-NP O
30 184 185 8372922 . . O O

1 186 188 8372922 In IN B-PP O
2 189 191 8372922 A1 NN B-NP O
3 192 194 8372922 of IN B-PP O
4 195 202 8372922 macaque NN B-NP O
5 203 210 8372922 monkeys NNS I-NP O
6 210 211 8372922 , , O O
7 212 215 8372922 low JJ B-NP O
8 216 227 8372922 frequencies NNS I-NP O
9 228 231 8372922 are VBP B-VP O
10 232 243 8372922 represented VBN I-VP O
11 244 259 8372922 rostrolaterally RB B-ADVP O
12 260 263 8372922 and CC O O
13 264 268 8372922 high JJ B-NP O
14 269 280 8372922 frequencies NNS I-NP O
15 281 284 8372922 are VBP B-VP O
16 285 296 8372922 represented VBN I-VP O
17 297 310 8372922 caudomedially RB B-ADVP O
18 310 311 8372922 . . O O

1 312 315 8372922 The DT B-NP O
2 316 323 8372922 purpose NN I-NP O
3 324 326 8372922 of IN B-PP O
4 327 331 8372922 this DT B-NP O
5 332 337 8372922 study NN I-NP O
6 338 341 8372922 was VBD B-VP O
7 342 344 8372922 to TO B-VP O
8 345 354 8372922 determine VB I-VP O
9 355 357 8372922 if IN B-SBAR O
10 358 365 8372922 changes NNS B-NP O
11 366 371 8372922 occur VBP B-VP O
12 372 374 8372922 in IN B-PP O
13 375 379 8372922 this DT B-NP O
14 380 389 8372922 tonotopic JJ I-NP O
15 390 402 8372922 organization NN I-NP O
16 403 412 8372922 following VBG B-PP O
17 413 421 8372922 cochlear JJ B-NP O
18 422 429 8372922 hearing NN I-NP B-Disease
19 430 434 8372922 loss NN I-NP I-Disease
20 434 435 8372922 . . O O

1 436 441 8372922 Under IN B-PP O
2 442 452 8372922 anesthesia NN B-NP O
3 452 453 8372922 , , O O
4 454 457 8372922 the DT B-NP O
5 458 466 8372922 superior JJ I-NP O
6 467 475 8372922 temporal JJ I-NP O
7 476 481 8372922 gyrus NN I-NP O
8 482 484 8372922 of IN B-PP O
9 485 490 8372922 adult JJ B-NP O
10 491 498 8372922 macaque NN I-NP O
11 499 506 8372922 monkeys NNS I-NP O
12 507 510 8372922 was VBD B-VP O
13 511 518 8372922 exposed VBN I-VP O
14 518 519 8372922 , , O O
15 520 523 8372922 and CC O O
16 524 527 8372922 the DT B-NP O
17 528 537 8372922 tonotopic JJ I-NP O
18 538 550 8372922 organization NN I-NP O
19 551 553 8372922 of IN B-PP O
20 554 556 8372922 A1 NN B-NP O
21 557 560 8372922 was VBD B-VP O
22 561 567 8372922 mapped VBN I-VP O
23 568 573 8372922 using VBG B-VP O
24 574 586 8372922 conventional JJ B-NP O
25 587 601 8372922 microelectrode NN I-NP O
26 602 611 8372922 recording NN I-NP O
27 612 622 8372922 techniques NNS I-NP O
28 622 623 8372922 . . O O

1 624 633 8372922 Following VBG B-PP O
2 634 642 8372922 recovery NN B-NP O
3 642 643 8372922 , , O O
4 644 647 8372922 the DT B-NP O
5 648 655 8372922 monkeys NNS I-NP O
6 656 660 8372922 were VBD B-VP O
7 661 672 8372922 selectively RB I-VP O
8 673 681 8372922 deafened VBN I-VP O
9 682 685 8372922 for IN B-PP O
10 686 690 8372922 high JJ B-NP O
11 691 702 8372922 frequencies NNS I-NP O
12 703 708 8372922 using VBG B-VP O
13 709 718 8372922 kanamycin NN B-NP B-Chemical
14 719 722 8372922 and CC I-NP O
15 723 733 8372922 furosemide NN I-NP B-Chemical
16 733 734 8372922 . . O O

1 735 738 8372922 The DT B-NP O
2 739 745 8372922 actual JJ I-NP O
3 746 757 8372922 frequencies NNS I-NP O
4 758 766 8372922 deafened VBN B-VP O
5 767 771 8372922 were VBD B-VP O
6 772 782 8372922 determined VBN I-VP O
7 783 785 8372922 by IN B-PP O
8 786 789 8372922 the DT B-NP O
9 790 794 8372922 loss NN I-NP O
10 795 797 8372922 of IN B-PP O
11 798 802 8372922 tone NN B-NP O
12 802 803 8372922 - HYPH B-NP O
13 803 808 8372922 burst NN I-NP O
14 809 817 8372922 elicited VBD B-VP O
15 818 826 8372922 auditory JJ B-NP O
16 827 836 8372922 brainstem NN I-NP O
17 837 846 8372922 responses NNS I-NP O
18 846 847 8372922 . . O O

1 848 853 8372922 Three CD B-NP O
2 854 860 8372922 months NNS I-NP O
3 861 866 8372922 after IN B-PP O
4 867 876 8372922 deafening NN B-NP O
5 876 877 8372922 , , O O
6 878 880 8372922 A1 NN B-NP O
7 881 884 8372922 was VBD B-VP O
8 885 893 8372922 remapped VBN I-VP O
9 893 894 8372922 . . O O

1 895 905 8372922 Postmortem JJ B-NP O
2 906 923 8372922 cytoarchitectural JJ I-NP O
3 924 932 8372922 features NNS I-NP O
4 933 944 8372922 identifying VBG B-VP O
5 945 947 8372922 A1 NN B-NP O
6 948 952 8372922 were VBD B-VP O
7 953 963 8372922 correlated VBN I-VP O
8 964 968 8372922 with IN B-PP O
9 969 972 8372922 the DT B-NP O
10 973 991 8372922 electrophysiologic JJ I-NP O
11 992 996 8372922 data NNS I-NP O
12 996 997 8372922 . . O O

1 998 1001 8372922 The DT B-NP O
2 1002 1009 8372922 results NNS I-NP O
3 1010 1018 8372922 indicate VBP B-VP O
4 1019 1023 8372922 that IN B-SBAR O
5 1024 1027 8372922 the DT B-NP O
6 1028 1036 8372922 deprived VBN I-NP O
7 1037 1041 8372922 area NN I-NP O
8 1042 1044 8372922 of IN B-PP O
9 1045 1047 8372922 A1 NN B-NP O
10 1048 1057 8372922 undergoes VBZ B-VP O
11 1058 1067 8372922 extensive JJ B-NP O
12 1068 1082 8372922 reorganization NN I-NP O
13 1083 1086 8372922 and CC O O
14 1087 1094 8372922 becomes VBZ B-VP O
15 1095 1105 8372922 responsive JJ B-ADJP O
16 1106 1108 8372922 to TO B-PP O
17 1109 1115 8372922 intact JJ B-NP O
18 1116 1124 8372922 cochlear JJ I-NP O
19 1125 1136 8372922 frequencies NNS I-NP O
20 1136 1137 8372922 . . O O

1 1138 1141 8372922 The DT B-NP O
2 1142 1148 8372922 region NN I-NP O
3 1149 1151 8372922 of IN B-PP O
4 1152 1158 8372922 cortex NN B-NP O
5 1159 1163 8372922 that WDT B-NP O
6 1164 1174 8372922 represents VBZ B-VP O
7 1175 1178 8372922 the DT B-NP O
8 1179 1182 8372922 low JJ I-NP O
9 1183 1194 8372922 frequencies NNS I-NP O
10 1195 1198 8372922 was VBD B-VP O
11 1199 1202 8372922 not RB I-VP O
12 1203 1212 8372922 obviously RB I-VP O
13 1213 1221 8372922 affected VBN I-VP O
14 1222 1224 8372922 by IN B-PP O
15 1225 1228 8372922 the DT B-NP O
16 1229 1237 8372922 cochlear JJ I-NP O
17 1238 1245 8372922 hearing NN I-NP B-Disease
18 1246 1250 8372922 loss NN I-NP I-Disease
19 1250 1251 8372922 . . O O

1 0 0 11334364 -DOCSTART- -X- -X- O

1 0 2 11334364 In FW B-NP O
2 3 7 11334364 vivo FW I-NP O
3 8 18 11334364 protection NN I-NP O
4 19 21 11334364 of IN B-PP O
5 22 25 11334364 dna NN B-NP O
6 26 32 11334364 damage NN I-NP O
7 33 43 11334364 associated VBN B-VP O
8 44 53 11334364 apoptotic JJ B-NP O
9 54 57 11334364 and CC I-NP O
10 58 66 11334364 necrotic JJ I-NP B-Disease
11 67 71 11334364 cell NN I-NP O
12 72 78 11334364 deaths NNS I-NP O
13 79 85 11334364 during IN B-PP O
14 86 99 11334364 acetaminophen NN B-NP B-Chemical
15 99 100 11334364 - HYPH B-NP O
16 100 107 11334364 induced VBN I-NP O
17 108 122 11334364 nephrotoxicity NN I-NP B-Disease
18 122 123 11334364 , , O O
19 124 134 11334364 amiodarone NN B-NP B-Chemical
20 134 135 11334364 - HYPH B-NP O
21 135 142 11334364 induced VBN I-NP O
22 143 147 11334364 lung NN I-NP B-Disease
23 148 156 11334364 toxicity NN I-NP I-Disease
24 157 160 11334364 and CC I-NP O
25 161 172 11334364 doxorubicin NN I-NP B-Chemical
26 172 173 11334364 - HYPH B-NP O
27 173 180 11334364 induced VBN I-NP O
28 181 195 11334364 cardiotoxicity NN I-NP B-Disease
29 196 198 11334364 by IN B-PP O
30 199 200 11334364 a DT B-NP O
31 201 206 11334364 novel JJ I-NP O
32 207 212 11334364 IH636 NN I-NP B-Chemical
33 213 218 11334364 grape NN I-NP I-Chemical
34 219 223 11334364 seed NN I-NP I-Chemical
35 224 240 11334364 proanthocyanidin NN I-NP I-Chemical
36 241 248 11334364 extract NN I-NP I-Chemical
37 248 249 11334364 . . I-NP O
38 250 255 11334364 Grape NN I-NP B-Chemical
39 256 260 11334364 seed VBD B-VP I-Chemical
40 261 268 11334364 extract NN B-NP I-Chemical
41 268 269 11334364 , , O O
42 270 279 11334364 primarily RB B-ADVP O
43 280 281 11334364 a DT B-NP O
44 282 289 11334364 mixture NN I-NP O
45 290 292 11334364 of IN B-PP O
46 293 310 11334364 proanthocyanidins NNS B-NP B-Chemical
47 310 311 11334364 , , O O
48 312 315 11334364 has VBZ B-VP O
49 316 320 11334364 been VBN I-VP O
50 321 326 11334364 shown VBN I-VP O
51 327 329 11334364 to TO I-VP O
52 330 338 11334364 modulate VB I-VP O
53 339 340 11334364 a DT B-NP O
54 341 345 11334364 wide JJ I-NP O
55 345 346 11334364 - HYPH I-NP O
56 346 351 11334364 range NN I-NP O
57 352 354 11334364 of IN B-PP O
58 355 365 11334364 biological JJ B-NP O
59 365 366 11334364 , , I-NP O
60 367 382 11334364 pharmacological JJ I-NP O
61 383 386 11334364 and CC I-NP O
62 387 400 11334364 toxicological JJ I-NP O
63 401 408 11334364 effects NNS I-NP O
64 409 414 11334364 which WDT B-NP O
65 415 418 11334364 are VBP B-VP O
66 419 425 11334364 mainly RB B-ADJP O
67 426 440 11334364 cytoprotective JJ I-ADJP O
68 440 441 11334364 . . O O

1 442 446 11334364 This DT B-NP O
2 447 452 11334364 study NN I-NP O
3 453 461 11334364 assessed VBD B-VP O
4 462 465 11334364 the DT B-NP O
5 466 473 11334364 ability NN I-NP O
6 474 476 11334364 of IN B-PP O
7 477 482 11334364 IH636 NN B-NP B-Chemical
8 483 488 11334364 grape NN I-NP I-Chemical
9 489 493 11334364 seed NN I-NP I-Chemical
10 494 510 11334364 proanthocyanidin NN I-NP I-Chemical
11 511 518 11334364 extract NN I-NP I-Chemical
12 519 520 11334364 ( ( O O
13 520 524 11334364 GSPE NN B-NP B-Chemical
14 524 525 11334364 ) ) O O
15 526 528 11334364 to TO B-VP O
16 529 536 11334364 prevent VB I-VP O
17 537 550 11334364 acetaminophen NN B-NP B-Chemical
18 551 552 11334364 ( ( O O
19 552 555 11334364 AAP NN B-NP B-Chemical
20 555 556 11334364 ) ) O O
21 556 557 11334364 - HYPH B-NP O
22 557 564 11334364 induced VBN I-NP O
23 565 579 11334364 nephrotoxicity NN I-NP B-Disease
24 579 580 11334364 , , O O
25 581 591 11334364 amiodarone NN B-NP B-Chemical
26 592 593 11334364 ( ( O O
27 593 596 11334364 AMI NN B-NP B-Chemical
28 596 597 11334364 ) ) O O
29 597 598 11334364 - HYPH B-NP O
30 598 605 11334364 induced VBN I-NP O
31 606 610 11334364 lung NN I-NP B-Disease
32 611 619 11334364 toxicity NN I-NP I-Disease
33 619 620 11334364 , , O O
34 621 624 11334364 and CC O O
35 625 636 11334364 doxorubicin NN B-NP B-Chemical
36 637 638 11334364 ( ( O O
37 638 641 11334364 DOX NN B-NP B-Chemical
38 641 642 11334364 ) ) O O
39 642 643 11334364 - HYPH B-NP O
40 643 650 11334364 induced VBN I-NP O
41 651 665 11334364 cardiotoxicity NN I-NP B-Disease
42 666 668 11334364 in IN B-PP O
43 669 673 11334364 mice NNS B-NP O
44 673 674 11334364 . . O O

1 675 687 11334364 Experimental JJ B-NP O
2 688 694 11334364 design NN I-NP O
3 695 704 11334364 consisted VBD B-VP O
4 705 707 11334364 of IN B-PP O
5 708 712 11334364 four CD B-NP O
6 713 719 11334364 groups NNS I-NP O
7 719 720 11334364 : : O O
8 721 728 11334364 control NN B-NP O
9 729 730 11334364 ( ( O O
10 730 737 11334364 vehicle NN B-NP O
11 738 743 11334364 alone RB B-ADVP O
12 743 744 11334364 ) ) O O
13 744 745 11334364 , , O O
14 746 750 11334364 GSPE NN B-NP B-Chemical
15 751 756 11334364 alone RB B-ADVP O
16 756 757 11334364 , , O O
17 758 762 11334364 drug NN B-NP O
18 763 768 11334364 alone RB B-ADVP O
19 769 772 11334364 and CC O O
20 773 777 11334364 GSPE NN B-NP B-Chemical
21 777 778 11334364 + SYM B-NP O
22 778 782 11334364 drug NN I-NP O
23 782 783 11334364 . . O O

1 784 787 11334364 For IN B-PP O
2 788 791 11334364 the DT B-NP O
3 792 806 11334364 cytoprotection NN I-NP O
4 807 812 11334364 study NN I-NP O
5 812 813 11334364 , , O O
6 814 821 11334364 animals NNS B-NP O
7 822 826 11334364 were VBD B-VP O
8 827 833 11334364 orally RB I-VP O
9 834 841 11334364 gavaged VBN I-VP O
10 842 845 11334364 100 CD B-NP O
11 846 848 11334364 mg NN I-NP O
12 848 849 11334364 / SYM B-NP O
13 849 851 11334364 Kg NN I-NP O
14 852 856 11334364 GSPE NN I-NP B-Chemical
15 857 860 11334364 for IN B-PP O
16 861 862 11334364 7 CD B-NP O
17 862 863 11334364 - HYPH I-NP O
18 863 865 11334364 10 CD I-NP O
19 866 870 11334364 days NNS I-NP O
20 871 879 11334364 followed VBN B-VP O
21 880 882 11334364 by IN B-PP O
22 883 886 11334364 i.p NN B-NP O
23 886 887 11334364 . . O O

1 888 898 11334364 injections NNS B-NP O
2 899 901 11334364 of IN B-PP O
3 902 907 11334364 organ NN B-NP O
4 908 916 11334364 specific JJ B-NP O
5 917 922 11334364 three CD I-NP O
6 923 928 11334364 drugs NNS I-NP O
7 929 930 11334364 ( ( O O
8 930 933 11334364 AAP NN B-NP B-Chemical
9 933 934 11334364 : : O O
10 935 938 11334364 500 CD B-NP O
11 939 941 11334364 mg NN I-NP O
12 941 942 11334364 / SYM B-VP O
13 942 944 11334364 Kg NN B-NP O
14 945 948 11334364 for IN B-PP O
15 949 951 11334364 24 CD B-NP O
16 952 953 11334364 h NN I-NP O
17 953 954 11334364 ; : O O
18 955 958 11334364 AMI NN B-NP B-Chemical
19 958 959 11334364 : : O O
20 960 962 11334364 50 CD B-NP O
21 963 965 11334364 mg NN I-NP O
22 965 966 11334364 / SYM B-NP O
23 966 968 11334364 Kg NN I-NP O
24 968 969 11334364 / SYM B-NP O
25 969 972 11334364 day NN I-NP O
26 973 976 11334364 for IN B-PP O
27 977 981 11334364 four CD B-NP O
28 982 986 11334364 days NNS I-NP O
29 986 987 11334364 ; : O O
30 988 991 11334364 DOX NN B-NP B-Chemical
31 991 992 11334364 : : O O
32 993 995 11334364 20 CD B-NP O
33 996 998 11334364 mg NN I-NP O
34 998 999 11334364 / SYM B-NP O
35 999 1001 11334364 Kg NN I-NP O
36 1002 1005 11334364 for IN B-PP O
37 1006 1008 11334364 48 CD B-NP O
38 1009 1010 11334364 h NN I-NP O
39 1010 1011 11334364 ) ) O O
40 1011 1012 11334364 . . O O

1 1013 1023 11334364 Parameters NNS B-NP O
2 1024 1026 11334364 of IN B-PP O
3 1027 1032 11334364 study NN B-NP O
4 1033 1041 11334364 included VBD B-VP O
5 1042 1050 11334364 analysis NN B-NP O
6 1051 1053 11334364 of IN B-PP O
7 1054 1059 11334364 serum NN B-NP O
8 1060 1069 11334364 chemistry NN I-NP O
9 1070 1071 11334364 ( ( O O
10 1071 1074 11334364 ALT NN B-NP O
11 1074 1075 11334364 , , O O
12 1076 1079 11334364 BUN NN B-NP O
13 1080 1083 11334364 and CC O O
14 1084 1087 11334364 CPK NN B-NP O
15 1087 1088 11334364 ) ) O O
16 1088 1089 11334364 , , O O
17 1090 1093 11334364 and CC O O
18 1094 1101 11334364 orderly JJ B-NP O
19 1102 1115 11334364 fragmentation NN I-NP O
20 1116 1118 11334364 of IN B-PP O
21 1119 1126 11334364 genomic JJ B-NP O
22 1127 1130 11334364 DNA NN I-NP O
23 1131 1132 11334364 ( ( O O
24 1132 1136 11334364 both CC O O
25 1137 1149 11334364 endonuclease NN B-NP O
26 1149 1150 11334364 - HYPH B-NP O
27 1150 1159 11334364 dependent JJ I-NP O
28 1160 1163 11334364 and CC I-NP O
29 1164 1175 11334364 independent JJ I-NP O
30 1175 1176 11334364 ) ) O O
31 1177 1179 11334364 in IN B-PP O
32 1180 1188 11334364 addition NN B-NP O
33 1189 1191 11334364 to TO B-PP O
34 1192 1203 11334364 microscopic JJ B-NP O
35 1204 1214 11334364 evaluation NN I-NP O
36 1215 1217 11334364 of IN B-PP O
37 1218 1224 11334364 damage NN B-NP O
38 1225 1228 11334364 and CC O O
39 1228 1229 11334364 / SYM B-NP O
40 1229 1231 11334364 or CC O O
41 1232 1242 11334364 protection NN B-NP O
42 1243 1245 11334364 in IN B-PP O
43 1246 1259 11334364 corresponding VBG B-VP O
44 1260 1263 11334364 PAS NN B-NP O
45 1264 1271 11334364 stained VBD B-VP O
46 1272 1279 11334364 tissues NNS B-NP O
47 1279 1280 11334364 . . O O

1 1281 1288 11334364 Results NNS B-NP O
2 1289 1297 11334364 indicate VBP B-VP O
3 1298 1302 11334364 that IN B-SBAR O
4 1303 1307 11334364 GSPE NN B-NP B-Chemical
5 1308 1319 11334364 preexposure NN I-NP O
6 1320 1325 11334364 prior JJ B-ADJP O
7 1326 1328 11334364 to TO B-PP O
8 1329 1332 11334364 AAP NN B-NP B-Chemical
9 1332 1333 11334364 , , I-NP O
10 1334 1337 11334364 AMI NN I-NP B-Chemical
11 1338 1341 11334364 and CC I-NP O
12 1342 1345 11334364 DOX NN I-NP B-Chemical
13 1345 1346 11334364 , , O O
14 1347 1355 11334364 provided VBN B-PP O
15 1356 1360 11334364 near IN B-PP O
16 1361 1369 11334364 complete JJ B-NP O
17 1370 1380 11334364 protection NN I-NP O
18 1381 1383 11334364 in IN B-PP O
19 1384 1389 11334364 terms NNS B-NP O
20 1390 1392 11334364 of IN B-PP O
21 1393 1398 11334364 serum NN B-NP O
22 1399 1408 11334364 chemistry NN I-NP O
23 1409 1416 11334364 changes NNS I-NP O
24 1417 1418 11334364 ( ( O O
25 1418 1421 11334364 ALT NN B-NP O
26 1421 1422 11334364 , , O O
27 1423 1426 11334364 BUN NN B-NP O
28 1427 1430 11334364 and CC O O
29 1431 1434 11334364 CPK NN B-NP O
30 1434 1435 11334364 ) ) O O
31 1435 1436 11334364 , , O O
32 1437 1440 11334364 and CC O O
33 1441 1454 11334364 significantly RB B-VP O
34 1455 1462 11334364 reduced VBD I-VP O
35 1463 1466 11334364 DNA NN B-NP O
36 1467 1480 11334364 fragmentation NN I-NP O
37 1480 1481 11334364 . . O O

1 1482 1499 11334364 Histopathological JJ B-NP O
2 1500 1511 11334364 examination NN I-NP O
3 1512 1514 11334364 of IN B-PP O
4 1515 1521 11334364 kidney NN B-NP O
5 1521 1522 11334364 , , I-NP O
6 1523 1528 11334364 heart NN I-NP O
7 1529 1532 11334364 and CC I-NP O
8 1533 1537 11334364 lung NN I-NP O
9 1538 1546 11334364 sections NNS I-NP O
10 1547 1555 11334364 revealed VBD B-VP O
11 1556 1564 11334364 moderate JJ B-ADJP O
12 1565 1567 11334364 to TO B-PP O
13 1568 1575 11334364 massive JJ B-NP O
14 1576 1582 11334364 tissue NN I-NP B-Disease
15 1583 1589 11334364 damage NN I-NP I-Disease
16 1590 1594 11334364 with IN B-PP O
17 1595 1596 11334364 a DT B-NP O
18 1597 1604 11334364 variety NN I-NP O
19 1605 1607 11334364 of IN B-PP O
20 1608 1621 11334364 morphological JJ B-NP O
21 1622 1633 11334364 aberrations NNS I-NP O
22 1634 1636 11334364 by IN B-PP O
23 1637 1640 11334364 all PDT B-NP O
24 1641 1644 11334364 the DT I-NP O
25 1645 1650 11334364 three CD I-NP O
26 1651 1656 11334364 drugs NNS I-NP O
27 1657 1659 11334364 in IN B-PP O
28 1660 1663 11334364 the DT B-NP O
29 1664 1671 11334364 absence NN I-NP O
30 1672 1674 11334364 of IN B-PP O
31 1675 1679 11334364 GSPE NN B-NP B-Chemical
32 1680 1691 11334364 preexposure NN I-NP O
33 1692 1696 11334364 than IN B-PP O
34 1697 1699 11334364 in IN B-PP O
35 1700 1703 11334364 its PRP$ B-NP O
36 1704 1712 11334364 presence NN I-NP O
37 1712 1713 11334364 . . O O

1 1714 1718 11334364 GSPE NN B-NP B-Chemical
2 1718 1719 11334364 + SYM I-NP O
3 1719 1723 11334364 drug NN I-NP O
4 1724 1731 11334364 exposed VBN B-VP O
5 1732 1739 11334364 tissues NNS B-NP O
6 1740 1749 11334364 exhibited VBD B-VP O
7 1750 1755 11334364 minor JJ B-NP O
8 1756 1764 11334364 residual JJ I-NP O
9 1765 1771 11334364 damage NN I-NP O
10 1772 1774 11334364 or CC B-PP O
11 1775 1779 11334364 near IN B-PP O
12 1780 1785 11334364 total JJ B-NP O
13 1786 1794 11334364 recovery NN I-NP O
14 1794 1795 11334364 . . O O

1 1796 1808 11334364 Additionally RB B-ADVP O
2 1808 1809 11334364 , , O O
3 1810 1827 11334364 histopathological JJ B-NP O
4 1828 1839 11334364 alterations NNS I-NP O
5 1840 1848 11334364 mirrored VBD B-VP O
6 1849 1853 11334364 both CC O O
7 1854 1859 11334364 serum NN B-NP O
8 1860 1869 11334364 chemistry NN I-NP O
9 1870 1877 11334364 changes NNS I-NP O
10 1878 1881 11334364 and CC O O
11 1882 1885 11334364 the DT B-NP O
12 1886 1893 11334364 pattern NN I-NP O
13 1894 1896 11334364 of IN B-PP O
14 1897 1900 11334364 DNA NN B-NP O
15 1901 1914 11334364 fragmentation NN I-NP O
16 1914 1915 11334364 . . O O

1 1916 1929 11334364 Interestingly RB B-ADVP O
2 1929 1930 11334364 , , O O
3 1931 1934 11334364 all PDT B-NP O
4 1935 1938 11334364 the DT I-NP O
5 1939 1944 11334364 drugs NNS I-NP O
6 1944 1945 11334364 , , O O
7 1946 1950 11334364 such JJ B-PP O
8 1951 1953 11334364 as IN I-PP O
9 1953 1954 11334364 , , O O
10 1955 1958 11334364 AAP NN B-NP B-Chemical
11 1958 1959 11334364 , , O O
12 1960 1963 11334364 AMI NN B-NP B-Chemical
13 1964 1967 11334364 and CC I-NP O
14 1968 1971 11334364 DOX NN I-NP B-Chemical
15 1972 1979 11334364 induced VBD B-VP O
16 1980 1989 11334364 apoptotic JJ B-NP O
17 1990 1995 11334364 death NN I-NP O
18 1996 1998 11334364 in IN B-PP O
19 1999 2007 11334364 addition NN B-NP O
20 2008 2010 11334364 to TO B-PP O
21 2011 2019 11334364 necrosis NN B-NP B-Disease
22 2020 2022 11334364 in IN B-PP O
23 2023 2026 11334364 the DT B-NP O
24 2027 2037 11334364 respective JJ I-NP O
25 2038 2044 11334364 organs NNS I-NP O
26 2045 2050 11334364 which WDT B-NP O
27 2051 2054 11334364 was VBD B-VP O
28 2055 2059 11334364 very RB I-VP O
29 2060 2071 11334364 effectively RB I-VP O
30 2072 2079 11334364 blocked VBN I-VP O
31 2080 2082 11334364 by IN B-PP O
32 2083 2087 11334364 GSPE NN B-NP B-Chemical
33 2087 2088 11334364 . . O O

1 2089 2094 11334364 Since IN B-PP O
2 2095 2098 11334364 AAP NN B-NP B-Chemical
3 2098 2099 11334364 , , O O
4 2100 2103 11334364 AMI NN B-NP B-Chemical
5 2104 2107 11334364 and CC I-NP O
6 2108 2111 11334364 DOX NN I-NP B-Chemical
7 2112 2119 11334364 undergo VBP B-VP O
8 2120 2137 11334364 biotransformation NN B-NP O
9 2138 2141 11334364 and CC O O
10 2142 2145 11334364 are VBP B-VP O
11 2146 2151 11334364 known VBN I-VP O
12 2152 2154 11334364 to TO I-VP O
13 2155 2162 11334364 produce VB I-VP O
14 2163 2171 11334364 damaging JJ B-NP O
15 2172 2180 11334364 radicals NNS I-NP O
16 2181 2183 11334364 in FW B-ADVP O
17 2184 2188 11334364 vivo FW I-ADVP O
18 2188 2189 11334364 , , O O
19 2190 2193 11334364 the DT B-NP O
20 2194 2204 11334364 protection NN I-NP O
21 2205 2207 11334364 by IN B-PP O
22 2208 2212 11334364 GSPE NN B-NP B-Chemical
23 2213 2216 11334364 may MD B-VP O
24 2217 2219 11334364 be VB I-VP O
25 2220 2226 11334364 linked VBN I-VP O
26 2227 2229 11334364 to TO B-PP O
27 2230 2234 11334364 both CC O O
28 2235 2245 11334364 inhibition NN B-NP O
29 2246 2248 11334364 of IN B-PP O
30 2249 2259 11334364 metabolism NN B-NP O
31 2260 2263 11334364 and CC O O
32 2263 2264 11334364 / SYM B-NP O
33 2264 2266 11334364 or CC O O
34 2267 2281 11334364 detoxification NN B-NP O
35 2282 2284 11334364 of IN B-PP O
36 2285 2294 11334364 cytotoxic JJ B-NP O
37 2295 2303 11334364 radicals NNS I-NP O
38 2303 2304 11334364 . . O O

1 2305 2307 11334364 In IN B-PP O
2 2308 2316 11334364 addition NN B-NP O
3 2316 2317 11334364 , , O O
4 2318 2321 11334364 its PRP$ B-NP O
5 2321 2322 11334364 ' `` I-NP O
6 2323 2331 11334364 presumed JJ I-NP O
7 2332 2344 11334364 contribution NN I-NP O
8 2345 2347 11334364 to TO B-PP O
9 2348 2351 11334364 DNA NN B-NP O
10 2352 2358 11334364 repair NN I-NP O
11 2359 2362 11334364 may MD B-VP O
12 2363 2365 11334364 be VB I-VP O
13 2366 2373 11334364 another DT B-NP O
14 2374 2383 11334364 important JJ I-NP O
15 2384 2393 11334364 attribute NN I-NP O
16 2393 2394 11334364 , , O O
17 2395 2400 11334364 which WDT B-NP O
18 2401 2407 11334364 played VBD B-VP O
19 2408 2409 11334364 a DT B-NP O
20 2410 2414 11334364 role NN I-NP O
21 2415 2417 11334364 in IN B-PP O
22 2418 2421 11334364 the DT B-NP O
23 2422 2437 11334364 chemoprevention NN I-NP O
24 2438 2445 11334364 process NN I-NP O
25 2445 2446 11334364 . . O O

1 2447 2459 11334364 Additionally RB B-ADVP O
2 2459 2460 11334364 , , O O
3 2461 2465 11334364 this DT B-NP O
4 2466 2469 11334364 may MD B-VP O
5 2470 2474 11334364 have VB I-VP O
6 2475 2479 11334364 been VBN I-VP O
7 2480 2483 11334364 the DT B-NP O
8 2484 2489 11334364 first JJ I-NP O
9 2490 2496 11334364 report NN I-NP O
10 2497 2499 11334364 on IN B-PP O
11 2500 2503 11334364 AMI NN B-NP B-Chemical
12 2503 2504 11334364 - HYPH B-NP O
13 2504 2511 11334364 induced VBN I-NP O
14 2512 2521 11334364 apoptotic JJ I-NP O
15 2522 2527 11334364 death NN I-NP O
16 2528 2530 11334364 in IN B-PP O
17 2531 2534 11334364 the DT B-NP O
18 2535 2539 11334364 lung NN I-NP O
19 2540 2546 11334364 tissue NN I-NP O
20 2546 2547 11334364 . . O O

1 2548 2553 11334364 Taken VBN B-VP O
2 2554 2562 11334364 together RB B-ADVP O
3 2562 2563 11334364 , , O O
4 2564 2569 11334364 these DT B-NP O
5 2570 2576 11334364 events NNS I-NP O
6 2577 2588 11334364 undoubtedly RB B-ADVP O
7 2589 2598 11334364 establish VBP B-VP O
8 2599 2605 11334364 GSPE's NNS B-NP B-Chemical
9 2606 2614 11334364 abundant JJ B-NP O
10 2615 2630 11334364 bioavailability NN I-NP O
11 2630 2631 11334364 , , O O
12 2632 2635 11334364 and CC O O
13 2636 2639 11334364 the DT B-NP O
14 2640 2645 11334364 power NN I-NP O
15 2646 2648 11334364 to TO B-VP O
16 2649 2655 11334364 defend VB I-VP O
17 2656 2664 11334364 multiple JJ B-NP O
18 2665 2671 11334364 target NN I-NP O
19 2672 2678 11334364 organs NNS I-NP O
20 2679 2683 11334364 from IN B-PP O
21 2684 2689 11334364 toxic JJ B-NP O
22 2690 2698 11334364 assaults NNS I-NP O
23 2699 2706 11334364 induced VBN B-VP O
24 2707 2709 11334364 by IN B-PP O
25 2710 2722 11334364 structurally RB B-NP O
26 2723 2730 11334364 diverse JJ I-NP O
27 2731 2734 11334364 and CC I-NP O
28 2735 2747 11334364 functionally RB I-NP O
29 2748 2757 11334364 different JJ I-NP O
30 2758 2766 11334364 entities NNS I-NP O
31 2767 2769 11334364 in FW B-ADVP O
32 2770 2774 11334364 vivo FW I-ADVP O
33 2774 2775 11334364 . . O O

1 0 0 1835291 -DOCSTART- -X- -X- O

1 0 5 1835291 Acute JJ B-NP O
2 6 21 1835291 bronchodilating JJ I-NP O
3 22 29 1835291 effects NNS I-NP O
4 30 32 1835291 of IN B-PP O
5 33 44 1835291 ipratropium NN B-NP B-Chemical
6 45 52 1835291 bromide NN I-NP I-Chemical
7 53 56 1835291 and CC I-NP O
8 57 69 1835291 theophylline NN I-NP B-Chemical
9 70 72 1835291 in IN B-PP O
10 73 80 1835291 chronic JJ B-NP B-Disease
11 81 92 1835291 obstructive JJ I-NP I-Disease
12 93 102 1835291 pulmonary JJ I-NP I-Disease
13 103 110 1835291 disease NN I-NP I-Disease
14 110 111 1835291 . . O O
15 112 115 1835291 The DT B-NP O
16 116 130 1835291 bronchodilator NN I-NP O
17 131 138 1835291 effects NNS I-NP O
18 139 141 1835291 of IN B-PP O
19 142 143 1835291 a DT B-NP O
20 144 150 1835291 single JJ I-NP O
21 151 155 1835291 dose NN I-NP O
22 156 158 1835291 of IN B-PP O
23 159 170 1835291 ipratropium NN B-NP B-Chemical
24 171 178 1835291 bromide NN I-NP I-Chemical
25 179 186 1835291 aerosol NN I-NP O
26 187 188 1835291 ( ( O O
27 188 190 1835291 36 CD B-NP O
28 191 201 1835291 micrograms NNS I-NP O
29 201 202 1835291 ) ) O O
30 203 206 1835291 and CC O O
31 207 212 1835291 short JJ B-ADJP O
32 212 213 1835291 - HYPH B-NP O
33 213 219 1835291 acting VBG I-NP O
34 220 232 1835291 theophylline NN I-NP B-Chemical
35 233 240 1835291 tablets NNS I-NP O
36 241 242 1835291 ( ( O O
37 242 246 1835291 dose NN B-NP O
38 247 255 1835291 titrated VBN B-VP O
39 256 258 1835291 to TO B-VP O
40 259 266 1835291 produce VB I-VP O
41 267 272 1835291 serum NN B-NP O
42 273 279 1835291 levels NNS I-NP O
43 280 282 1835291 of IN B-PP O
44 283 285 1835291 10 CD B-NP O
45 285 286 1835291 - HYPH I-NP O
46 286 288 1835291 20 CD I-NP O
47 289 299 1835291 micrograms NNS I-NP O
48 299 300 1835291 / SYM B-NP O
49 300 302 1835291 mL NN I-NP O
50 302 303 1835291 ) ) O O
51 304 308 1835291 were VBD B-VP O
52 309 317 1835291 compared VBN I-VP O
53 318 320 1835291 in IN B-PP O
54 321 322 1835291 a DT B-NP O
55 323 329 1835291 double JJ I-NP O
56 329 330 1835291 - HYPH I-NP O
57 330 335 1835291 blind JJ I-NP O
58 335 336 1835291 , , I-NP O
59 337 344 1835291 placebo NN I-NP O
60 344 345 1835291 - HYPH I-NP O
61 345 355 1835291 controlled VBN B-NP O
62 356 365 1835291 crossover NN I-NP O
63 366 371 1835291 study NN I-NP O
64 372 374 1835291 in IN B-PP O
65 375 377 1835291 21 CD B-NP O
66 378 386 1835291 patients NNS I-NP O
67 387 391 1835291 with IN B-PP O
68 392 398 1835291 stable JJ B-NP O
69 398 399 1835291 , , I-NP O
70 400 407 1835291 chronic JJ I-NP B-Disease
71 408 419 1835291 obstructive JJ I-NP I-Disease
72 420 429 1835291 pulmonary JJ I-NP I-Disease
73 430 437 1835291 disease NN I-NP I-Disease
74 437 438 1835291 . . O O

1 439 443 1835291 Mean JJ B-NP O
2 444 448 1835291 peak JJ I-NP O
3 449 455 1835291 forced VBN I-NP O
4 456 466 1835291 expiratory JJ I-NP O
5 467 473 1835291 volume NN I-NP O
6 474 476 1835291 in IN B-PP O
7 477 478 1835291 1 CD B-NP O
8 479 485 1835291 second JJ I-NP O
9 486 487 1835291 ( ( O O
10 487 491 1835291 FEV1 NN B-NP O
11 491 492 1835291 ) ) O O
12 493 502 1835291 increases VBZ B-VP O
13 503 507 1835291 over IN B-PP O
14 508 516 1835291 baseline NN B-NP O
15 517 520 1835291 and CC O O
16 521 524 1835291 the DT B-NP O
17 525 535 1835291 proportion NN I-NP O
18 536 538 1835291 of IN B-PP O
19 539 547 1835291 patients NNS B-NP O
20 548 557 1835291 attaining VBG B-VP O
21 558 560 1835291 at IN B-ADVP O
22 561 566 1835291 least JJS I-ADVP O
23 567 568 1835291 a DT B-NP O
24 569 572 1835291 15% NN I-NP O
25 573 581 1835291 increase NN I-NP O
26 582 584 1835291 in IN B-PP O
27 585 588 1835291 the DT B-NP O
28 589 593 1835291 FEV1 NN I-NP O
29 594 595 1835291 ( ( O O
30 595 605 1835291 responders NNS B-NP O
31 605 606 1835291 ) ) O O
32 607 611 1835291 were VBD B-VP O
33 612 615 1835291 31% CD B-NP O
34 616 619 1835291 and CC I-NP O
35 620 623 1835291 90% CD I-NP O
36 623 624 1835291 , , O O
37 625 637 1835291 respectively RB B-ADVP O
38 637 638 1835291 , , O O
39 639 642 1835291 for IN B-PP O
40 643 654 1835291 ipratropium NN B-NP B-Chemical
41 655 658 1835291 and CC I-NP O
42 659 662 1835291 17% NN I-NP O
43 663 666 1835291 and CC O O
44 667 670 1835291 50% CD B-NP O
45 670 671 1835291 , , O O
46 672 684 1835291 respectively RB B-ADVP O
47 684 685 1835291 , , O O
48 686 689 1835291 for IN B-PP O
49 690 702 1835291 theophylline NN B-NP B-Chemical
50 702 703 1835291 . . O O

1 704 707 1835291 The DT B-NP O
2 708 715 1835291 average JJ I-NP O
3 716 720 1835291 FEV1 NN I-NP O
4 721 730 1835291 increases VBZ B-VP O
5 731 737 1835291 during IN B-PP O
6 738 741 1835291 the DT B-NP O
7 742 743 1835291 6 CD I-NP O
8 743 744 1835291 - HYPH I-NP O
9 744 748 1835291 hour NN I-NP O
10 749 760 1835291 observation NN I-NP O
11 761 767 1835291 period NN I-NP O
12 768 772 1835291 were VBD B-VP O
13 773 776 1835291 18% NN B-NP O
14 777 780 1835291 for IN B-PP O
15 781 792 1835291 ipratropium NN B-NP B-Chemical
16 793 796 1835291 and CC I-NP O
17 797 799 1835291 8% NN I-NP O
18 800 803 1835291 for IN B-PP O
19 804 816 1835291 theophylline NN B-NP B-Chemical
20 816 817 1835291 . . O O

1 818 821 1835291 The DT B-NP O
2 822 826 1835291 mean JJ I-NP O
3 827 835 1835291 duration NN I-NP O
4 836 838 1835291 of IN B-PP O
5 839 845 1835291 action NN B-NP O
6 846 849 1835291 was VBD B-VP O
7 850 853 1835291 3.8 CD B-NP O
8 854 859 1835291 hours NNS I-NP O
9 860 864 1835291 with IN B-PP O
10 865 876 1835291 ipratropium NN B-NP B-Chemical
11 877 880 1835291 and CC O O
12 881 884 1835291 2.4 CD B-NP O
13 885 890 1835291 hours NNS I-NP O
14 891 895 1835291 with IN B-PP O
15 896 908 1835291 theophylline NN B-NP B-Chemical
16 908 909 1835291 . . O O

1 910 915 1835291 While IN B-SBAR O
2 916 920 1835291 side NN B-NP O
3 921 928 1835291 effects NNS I-NP O
4 929 933 1835291 were VBD B-VP O
5 934 938 1835291 rare JJ B-ADJP O
6 938 939 1835291 , , O O
7 940 945 1835291 those DT B-NP O
8 946 957 1835291 experienced VBN B-VP O
9 958 963 1835291 after IN B-PP O
10 964 976 1835291 theophylline NN B-NP B-Chemical
11 977 980 1835291 use NN I-NP O
12 981 984 1835291 did VBD B-VP O
13 985 992 1835291 involve VB I-VP O
14 993 996 1835291 the DT B-NP O
15 997 1011 1835291 cardiovascular JJ I-NP B-Disease
16 1012 1015 1835291 and CC I-NP I-Disease
17 1016 1032 1835291 gastrointestinal JJ I-NP I-Disease
18 1033 1040 1835291 systems NNS I-NP I-Disease
19 1040 1041 1835291 . . O O

1 1042 1047 1835291 These DT B-NP O
2 1048 1055 1835291 results NNS I-NP O
3 1056 1060 1835291 show VBP B-VP O
4 1061 1065 1835291 that IN B-SBAR O
5 1066 1077 1835291 ipratropium NN B-NP B-Chemical
6 1078 1080 1835291 is VBZ B-VP O
7 1081 1082 1835291 a DT B-NP O
8 1083 1087 1835291 more RBR I-NP O
9 1088 1094 1835291 potent JJ I-NP O
10 1095 1109 1835291 bronchodilator NN I-NP O
11 1110 1114 1835291 than IN B-PP O
12 1115 1119 1835291 oral JJ B-NP O
13 1120 1132 1835291 theophylline NN I-NP B-Chemical
14 1133 1135 1835291 in IN B-PP O
15 1136 1144 1835291 patients NNS B-NP O
16 1145 1149 1835291 with IN B-PP O
17 1150 1157 1835291 chronic JJ B-NP B-Disease
18 1158 1165 1835291 airflow NN I-NP I-Disease
19 1166 1177 1835291 obstruction NN I-NP I-Disease
20 1177 1178 1835291 . . O O

1 0 0 1639466 -DOCSTART- -X- -X- O

1 0 7 1639466 Adverse JJ B-NP O
2 8 14 1639466 effect NN I-NP O
3 15 17 1639466 of IN B-PP O
4 18 21 1639466 the DT B-NP O
5 22 29 1639466 calcium NN I-NP B-Chemical
6 30 37 1639466 channel NN I-NP O
7 38 45 1639466 blocker NN I-NP O
8 46 58 1639466 nitrendipine NN I-NP B-Chemical
9 59 61 1639466 on IN B-PP O
10 62 77 1639466 nephrosclerosis NN B-NP B-Disease
11 78 80 1639466 in IN B-PP O
12 81 85 1639466 rats NNS B-NP O
13 86 90 1639466 with IN B-PP O
14 91 103 1639466 renovascular JJ B-NP B-Disease
15 104 116 1639466 hypertension NN I-NP I-Disease
16 116 117 1639466 . . O O
17 118 121 1639466 The DT B-NP O
18 122 128 1639466 effect NN I-NP O
19 129 131 1639466 of IN B-PP O
20 132 133 1639466 a DT B-NP O
21 134 135 1639466 6 CD I-NP O
22 135 136 1639466 - HYPH I-NP O
23 136 140 1639466 week NN I-NP O
24 141 150 1639466 treatment NN I-NP O
25 151 155 1639466 with IN B-PP O
26 156 159 1639466 the DT B-NP O
27 160 167 1639466 calcium NN I-NP B-Chemical
28 168 175 1639466 channel NN I-NP O
29 176 183 1639466 blocker NN I-NP O
30 184 196 1639466 nitrendipine NN I-NP B-Chemical
31 197 199 1639466 or CC O O
32 200 203 1639466 the DT B-NP O
33 204 215 1639466 angiotensin NN I-NP B-Chemical
34 216 226 1639466 converting VBG B-VP O
35 227 233 1639466 enzyme NN B-NP O
36 234 243 1639466 inhibitor NN I-NP O
37 244 253 1639466 enalapril NN I-NP B-Chemical
38 254 256 1639466 on IN B-PP O
39 257 262 1639466 blood NN B-NP O
40 263 271 1639466 pressure NN I-NP O
41 271 272 1639466 , , O O
42 273 284 1639466 albuminuria NN B-NP B-Disease
43 284 285 1639466 , , O O
44 286 291 1639466 renal JJ B-NP O
45 292 304 1639466 hemodynamics NNS I-NP O
46 304 305 1639466 , , O O
47 306 309 1639466 and CC O O
48 310 320 1639466 morphology NN B-NP O
49 321 323 1639466 of IN B-PP O
50 324 327 1639466 the DT B-NP O
51 328 338 1639466 nonclipped JJ I-NP O
52 339 345 1639466 kidney NN I-NP O
53 346 349 1639466 was VBD B-VP O
54 350 357 1639466 studied VBN I-VP O
55 358 360 1639466 in IN B-PP O
56 361 365 1639466 rats NNS B-NP O
57 366 370 1639466 with IN B-PP O
58 371 374 1639466 two CD B-NP O
59 374 375 1639466 - HYPH I-NP O
60 375 381 1639466 kidney NN I-NP O
61 381 382 1639466 , , O O
62 383 386 1639466 one CD B-NP O
63 387 391 1639466 clip NN I-NP O
64 392 404 1639466 renovascular JJ I-NP B-Disease
65 405 417 1639466 hypertension NN I-NP I-Disease
66 417 418 1639466 . . O O

1 419 422 1639466 Six CD B-NP O
2 423 428 1639466 weeks NNS I-NP O
3 429 434 1639466 after IN B-PP O
4 435 443 1639466 clipping VBG B-VP O
5 444 446 1639466 of IN B-PP O
6 447 450 1639466 one CD B-NP O
7 451 456 1639466 renal JJ I-NP O
8 457 463 1639466 artery NN I-NP O
9 463 464 1639466 , , O O
10 465 477 1639466 hypertensive JJ B-NP B-Disease
11 478 482 1639466 rats NNS I-NP O
12 483 484 1639466 ( ( O O
13 484 487 1639466 178 CD B-NP O
14 488 489 1639466 + SYM O O
15 489 490 1639466 / SYM O O
16 490 491 1639466 - SYM O O
17 492 493 1639466 4 CD B-NP O
18 494 496 1639466 mm NN I-NP O
19 497 499 1639466 Hg NN I-NP O
20 499 500 1639466 ) ) O O
21 501 505 1639466 were VBD B-VP O
22 506 514 1639466 randomly RB I-VP O
23 515 523 1639466 assigned VBN I-VP O
24 524 526 1639466 to TO B-PP O
25 527 532 1639466 three CD B-NP O
26 533 539 1639466 groups NNS I-NP O
27 539 540 1639466 : : O O
28 541 550 1639466 untreated JJ B-NP O
29 551 563 1639466 hypertensive JJ I-NP B-Disease
30 564 572 1639466 controls NNS I-NP O
31 573 574 1639466 ( ( O O
32 574 575 1639466 n NN B-NP O
33 576 577 1639466 = SYM B-VP O
34 578 579 1639466 8 CD B-NP O
35 579 580 1639466 ) ) O O
36 580 581 1639466 , , O O
37 582 591 1639466 enalapril NN B-NP B-Chemical
38 591 592 1639466 - HYPH B-VP O
39 592 599 1639466 treated VBN I-VP O
40 600 601 1639466 ( ( O O
41 601 602 1639466 n NN B-NP O
42 603 604 1639466 = SYM B-VP O
43 605 606 1639466 8 CD B-NP O
44 606 607 1639466 ) ) O O
45 607 608 1639466 , , O O
46 609 611 1639466 or CC O O
47 612 624 1639466 nitrendipine NN B-NP B-Chemical
48 624 625 1639466 - HYPH B-VP O
49 625 632 1639466 treated VBN I-VP O
50 633 634 1639466 ( ( O O
51 634 635 1639466 n NN B-NP O
52 636 637 1639466 = SYM B-VP O
53 638 640 1639466 10 CD B-NP O
54 640 641 1639466 ) ) O O
55 641 642 1639466 . . O O

1 643 647 1639466 Sham NN B-NP O
2 647 648 1639466 - HYPH B-NP O
3 648 656 1639466 operated VBN I-NP O
4 657 661 1639466 rats NNS I-NP O
5 662 668 1639466 served VBD B-VP O
6 669 671 1639466 as IN B-PP O
7 672 684 1639466 normotensive JJ B-NP O
8 685 693 1639466 controls NNS I-NP O
9 694 695 1639466 ( ( O O
10 695 698 1639466 128 CD B-NP O
11 699 700 1639466 + SYM O O
12 700 701 1639466 / SYM O O
13 701 702 1639466 - SYM O O
14 703 704 1639466 3 CD B-NP O
15 705 707 1639466 mm NN I-NP O
16 708 710 1639466 Hg NN I-NP O
17 710 711 1639466 , , O O
18 712 713 1639466 n NN B-NP O
19 714 715 1639466 = SYM B-VP O
20 716 717 1639466 8 CD B-NP O
21 717 718 1639466 ) ) O O
22 718 719 1639466 . . O O

1 720 725 1639466 After IN B-PP O
2 726 727 1639466 6 CD B-NP O
3 728 733 1639466 weeks NNS I-NP O
4 734 736 1639466 of IN B-PP O
5 737 746 1639466 treatment NN B-NP O
6 746 747 1639466 , , O O
7 748 753 1639466 renal JJ B-NP O
8 754 766 1639466 hemodynamics NNS I-NP O
9 767 768 1639466 ( ( O O
10 768 778 1639466 glomerular JJ B-NP O
11 779 789 1639466 filtration NN I-NP O
12 790 794 1639466 rate NN I-NP O
13 795 798 1639466 and CC O O
14 799 804 1639466 renal JJ B-NP O
15 805 811 1639466 plasma NN I-NP O
16 812 816 1639466 flow NN I-NP O
17 816 817 1639466 ) ) O O
18 818 822 1639466 were VBD B-VP O
19 823 831 1639466 measured VBN I-VP O
20 832 834 1639466 in IN B-PP O
21 835 838 1639466 the DT B-NP O
22 839 851 1639466 anesthetized VBN I-NP O
23 852 856 1639466 rats NNS I-NP O
24 856 857 1639466 . . O O

1 858 863 1639466 Renal JJ B-NP O
2 864 870 1639466 tissue NN I-NP O
3 871 874 1639466 was VBD B-VP O
4 875 883 1639466 obtained VBN I-VP O
5 884 887 1639466 for IN B-PP O
6 888 901 1639466 determination NN B-NP O
7 902 904 1639466 of IN B-PP O
8 905 915 1639466 glomerular JJ B-NP O
9 916 920 1639466 size NN I-NP O
10 921 924 1639466 and CC I-NP O
11 925 934 1639466 sclerosis NN I-NP O
12 934 935 1639466 . . O O

1 936 945 1639466 Enalapril NNP B-NP B-Chemical
2 946 949 1639466 but CC B-NP O
3 950 953 1639466 not RB I-NP O
4 954 966 1639466 nitrendipine NN B-NP B-Chemical
5 967 974 1639466 reduced VBD B-VP O
6 975 980 1639466 blood NN B-NP O
7 981 989 1639466 pressure NN I-NP O
8 990 1003 1639466 significantly RB B-ADVP O
9 1003 1004 1639466 . . O O

1 1005 1010 1639466 After IN B-PP O
2 1011 1012 1639466 6 CD B-NP O
3 1013 1018 1639466 weeks NNS I-NP O
4 1019 1021 1639466 of IN B-PP O
5 1022 1029 1639466 therapy NN B-NP O
6 1029 1030 1639466 , , O O
7 1031 1041 1639466 glomerular JJ B-NP O
8 1042 1052 1639466 filtration NN I-NP O
9 1053 1057 1639466 rate NN I-NP O
10 1058 1061 1639466 was VBD B-VP O
11 1062 1065 1639466 not RB O O
12 1066 1075 1639466 different JJ B-ADJP O
13 1076 1081 1639466 among IN B-PP O
14 1082 1085 1639466 the DT B-NP O
15 1086 1093 1639466 studied VBN I-NP O
16 1094 1100 1639466 groups NNS I-NP O
17 1100 1101 1639466 . . O O

1 1102 1107 1639466 Renal JJ B-NP O
2 1108 1114 1639466 plasma NN I-NP O
3 1115 1119 1639466 flow NN I-NP O
4 1120 1129 1639466 increased VBD B-VP O
5 1129 1130 1639466 , , O O
6 1131 1134 1639466 but CC O O
7 1135 1142 1639466 albumin NN B-NP O
8 1143 1152 1639466 excretion NN I-NP O
9 1153 1156 1639466 and CC O O
10 1157 1175 1639466 glomerulosclerosis NN B-NP B-Disease
11 1176 1179 1639466 did VBD B-VP O
12 1180 1183 1639466 not RB I-VP O
13 1184 1190 1639466 change VB I-VP O
14 1191 1196 1639466 after IN B-PP O
15 1197 1206 1639466 enalapril NN B-NP B-Chemical
16 1207 1216 1639466 treatment NN I-NP O
17 1216 1217 1639466 . . O O

1 1218 1220 1639466 In IN B-PP O
2 1221 1229 1639466 contrast NN B-NP O
3 1229 1230 1639466 , , O O
4 1231 1233 1639466 in IN B-PP O
5 1234 1237 1639466 the DT B-NP O
6 1238 1250 1639466 nitrendipine NN I-NP B-Chemical
7 1250 1251 1639466 - HYPH B-NP O
8 1251 1258 1639466 treated VBN I-NP O
9 1259 1264 1639466 group NN I-NP O
10 1265 1276 1639466 albuminuria NN I-NP B-Disease
11 1277 1286 1639466 increased VBD B-VP O
12 1287 1291 1639466 from IN B-PP O
13 1292 1296 1639466 12.8 CD B-NP O
14 1297 1298 1639466 + SYM B-ADJP O
15 1298 1299 1639466 / SYM O O
16 1299 1300 1639466 - SYM O O
17 1301 1302 1639466 2 CD B-NP O
18 1303 1316 1639466 progressively RB B-ADVP O
19 1317 1319 1639466 to TO B-PP O
20 1320 1323 1639466 163 CD B-NP O
21 1324 1325 1639466 + SYM O O
22 1325 1326 1639466 / SYM O O
23 1326 1327 1639466 - SYM O O
24 1328 1330 1639466 55 CD B-NP O
25 1331 1339 1639466 compared VBN B-PP O
26 1340 1344 1639466 with IN B-PP O
27 1345 1349 1639466 19.2 CD B-NP O
28 1350 1351 1639466 + SYM O O
29 1351 1352 1639466 / SYM O O
30 1352 1353 1639466 - SYM O O
31 1354 1355 1639466 9 CD B-NP O
32 1356 1358 1639466 mg NN I-NP O
33 1358 1359 1639466 / SYM B-NP O
34 1359 1361 1639466 24 CD B-NP O
35 1362 1364 1639466 hr NN I-NP O
36 1365 1367 1639466 in IN B-PP O
37 1368 1371 1639466 the DT B-NP O
38 1372 1384 1639466 hypertensive JJ I-NP B-Disease
39 1385 1393 1639466 controls NNS I-NP O
40 1393 1394 1639466 . . O O

1 1395 1406 1639466 Furthermore RB B-ADVP O
2 1406 1407 1639466 , , O O
3 1408 1426 1639466 glomerulosclerosis NN B-NP B-Disease
4 1427 1432 1639466 index NN I-NP O
5 1433 1436 1639466 was VBD B-VP O
6 1437 1450 1639466 significantly RB I-VP O
7 1451 1460 1639466 increased VBN I-VP O
8 1461 1463 1639466 in IN B-PP O
9 1464 1467 1639466 the DT B-NP O
10 1468 1480 1639466 nitrendipine NN I-NP B-Chemical
11 1480 1481 1639466 - HYPH B-NP O
12 1481 1488 1639466 treated VBN I-NP O
13 1489 1494 1639466 group NN I-NP O
14 1495 1503 1639466 compared VBN B-PP O
15 1504 1508 1639466 with IN B-PP O
16 1509 1512 1639466 the DT B-NP O
17 1513 1525 1639466 hypertensive JJ I-NP B-Disease
18 1526 1534 1639466 controls NNS I-NP O
19 1535 1536 1639466 ( ( O O
20 1536 1540 1639466 0.38 CD B-NP O
21 1541 1542 1639466 + SYM O O
22 1542 1543 1639466 / SYM O O
23 1543 1544 1639466 - SYM O O
24 1545 1548 1639466 0.1 CD B-NP O
25 1549 1555 1639466 versus IN B-PP O
26 1556 1560 1639466 0.13 CD B-NP O
27 1561 1562 1639466 + SYM O O
28 1562 1563 1639466 / SYM O O
29 1563 1564 1639466 - SYM O O
30 1565 1569 1639466 0.04 CD B-NP O
31 1569 1570 1639466 ) ) O O
32 1570 1571 1639466 . . O O

1 1572 1574 1639466 In IN B-PP O
2 1575 1583 1639466 addition NN B-NP O
3 1583 1584 1639466 , , O O
4 1585 1595 1639466 glomerular JJ B-NP O
5 1596 1600 1639466 size NN I-NP O
6 1601 1604 1639466 was VBD B-VP O
7 1605 1611 1639466 higher JJR B-ADJP O
8 1612 1614 1639466 in IN B-PP O
9 1615 1618 1639466 the DT B-NP O
10 1619 1631 1639466 nitrendipine NN I-NP B-Chemical
11 1631 1632 1639466 - HYPH B-VP O
12 1632 1639 1639466 treated VBN B-NP O
13 1640 1645 1639466 group NN I-NP O
14 1646 1647 1639466 ( ( O O
15 1647 1651 1639466 14.9 CD B-NP O
16 1652 1653 1639466 + SYM O O
17 1653 1654 1639466 / SYM O O
18 1654 1655 1639466 - SYM O O
19 1656 1660 1639466 0.17 CD B-NP O
20 1661 1664 1639466 10( CD I-NP O
21 1664 1665 1639466 - HYPH B-NP O
22 1665 1667 1639466 3) CD I-NP O
23 1668 1671 1639466 mm2 NN I-NP O
24 1671 1672 1639466 ) ) O O
25 1673 1676 1639466 but CC O O
26 1677 1682 1639466 lower JJR B-ADJP O
27 1683 1685 1639466 in IN B-PP O
28 1686 1689 1639466 the DT B-NP O
29 1690 1699 1639466 enalapril NN I-NP B-Chemical
30 1699 1700 1639466 - HYPH B-VP O
31 1700 1707 1639466 treated VBN B-NP O
32 1708 1713 1639466 group NN I-NP O
33 1714 1715 1639466 ( ( O O
34 1715 1719 1639466 11.5 CD B-NP O
35 1720 1721 1639466 + SYM O O
36 1721 1722 1639466 / SYM O O
37 1722 1723 1639466 - SYM O O
38 1724 1728 1639466 0.15 CD B-NP O
39 1729 1732 1639466 10( CD I-NP O
40 1732 1733 1639466 - HYPH B-NP O
41 1733 1735 1639466 3) CD I-NP O
42 1736 1739 1639466 mm2 NN I-NP O
43 1739 1740 1639466 ) ) O O
44 1741 1749 1639466 compared VBN B-PP O
45 1750 1754 1639466 with IN B-PP O
46 1755 1758 1639466 the DT B-NP O
47 1759 1771 1639466 hypertensive JJ I-NP B-Disease
48 1772 1780 1639466 controls NNS I-NP O
49 1781 1782 1639466 ( ( O O
50 1782 1786 1639466 12.1 CD B-NP O
51 1787 1788 1639466 + SYM O O
52 1788 1789 1639466 / SYM O O
53 1789 1790 1639466 - SYM O O
54 1791 1795 1639466 0.17 CD B-NP O
55 1796 1799 1639466 10( CD I-NP O
56 1799 1800 1639466 - HYPH B-NP O
57 1800 1802 1639466 3) CD I-NP O
58 1803 1817 1639466 mm2).(ABSTRACT NN I-NP O
59 1818 1827 1639466 TRUNCATED VBN B-VP O
60 1828 1830 1639466 AT IN B-PP O
61 1831 1834 1639466 250 CD B-NP O
62 1835 1840 1639466 WORDS NNS I-NP O
63 1840 1841 1639466 ) ) O O

1 0 0 220563 -DOCSTART- -X- -X- O

1 0 11 220563 Perhexiline NN B-NP B-Chemical
2 12 19 220563 maleate NN I-NP I-Chemical
3 20 23 220563 and CC O O
4 24 34 220563 peripheral JJ B-NP B-Disease
5 35 45 220563 neuropathy NN I-NP I-Disease
6 45 46 220563 . . O O
7 47 57 220563 Peripheral JJ B-NP B-Disease
8 58 68 220563 neuropathy NN I-NP I-Disease
9 69 72 220563 has VBZ B-VP O
10 73 77 220563 been VBN I-VP O
11 78 83 220563 noted VBN I-VP O
12 84 86 220563 as IN B-PP O
13 87 88 220563 a DT B-NP O
14 89 101 220563 complication NN I-NP O
15 102 104 220563 of IN B-PP O
16 105 112 220563 therapy NN B-NP O
17 113 117 220563 with IN B-PP O
18 118 129 220563 perhexiline NN B-NP B-Chemical
19 130 137 220563 maleate NN I-NP I-Chemical
20 137 138 220563 , , O O
21 139 140 220563 a DT B-NP O
22 141 145 220563 drug NN I-NP O
23 146 152 220563 widely RB B-VP O
24 153 157 220563 used VBN I-VP O
25 158 160 220563 in IN B-PP O
26 161 167 220563 France NNP B-NP O
27 168 169 220563 ( ( O O
28 169 172 220563 and CC O O
29 173 175 220563 in IN B-PP O
30 176 184 220563 clinical JJ B-NP O
31 185 191 220563 trials NNS I-NP O
32 192 194 220563 in IN B-PP O
33 195 198 220563 the DT B-NP O
34 199 205 220563 United NNP I-NP O
35 206 212 220563 States NNPS I-NP O
36 212 213 220563 ) ) O O
37 214 217 220563 for IN B-PP O
38 218 221 220563 the DT B-NP O
39 222 234 220563 prophylactic JJ I-NP O
40 235 244 220563 treatment NN I-NP O
41 245 247 220563 of IN B-PP O
42 248 254 220563 angina NN B-NP B-Disease
43 255 263 220563 pectoris NN I-NP I-Disease
44 263 264 220563 . . O O

1 265 267 220563 In IN B-PP O
2 268 270 220563 24 CD B-NP O
3 271 279 220563 patients NNS I-NP O
4 280 284 220563 with IN B-PP O
5 285 289 220563 this DT B-NP O
6 290 302 220563 complication NN I-NP O
7 302 303 220563 , , O O
8 304 307 220563 the DT B-NP O
9 308 314 220563 marked JJ I-NP O
10 315 322 220563 slowing NN I-NP O
11 323 325 220563 of IN B-PP O
12 326 331 220563 motor NN B-NP O
13 332 337 220563 nerve NN I-NP O
14 338 348 220563 conduction NN I-NP O
15 349 357 220563 velocity NN I-NP O
16 358 361 220563 and CC O O
17 362 365 220563 the DT B-NP O
18 366 383 220563 electromyographic JJ I-NP O
19 384 391 220563 changes NNS I-NP O
20 392 397 220563 imply VBP B-VP O
21 398 404 220563 mainly RB B-ADVP O
22 405 406 220563 a DT B-NP O
23 407 420 220563 demyelinating VBG I-NP B-Disease
24 421 429 220563 disorder NN I-NP I-Disease
25 429 430 220563 . . O O

1 431 442 220563 Improvement NN B-NP O
2 443 446 220563 was VBD B-VP O
3 447 452 220563 noted VBN I-VP O
4 453 457 220563 with IN B-PP O
5 458 467 220563 cessation NN B-NP O
6 468 470 220563 of IN B-PP O
7 471 478 220563 therapy NN B-NP O
8 478 479 220563 . . O O

1 480 482 220563 In IN B-PP O
2 483 484 220563 a DT B-NP O
3 485 488 220563 few JJ I-NP O
4 489 494 220563 cases NNS I-NP O
5 495 498 220563 the DT B-NP O
6 499 507 220563 presence NN I-NP O
7 508 510 220563 of IN B-PP O
8 511 517 220563 active JJ B-NP O
9 518 529 220563 denervation NN I-NP O
10 530 539 220563 signified VBD B-VP O
11 540 541 220563 a DT B-NP O
12 542 546 220563 poor JJ I-NP O
13 547 556 220563 prognosis NN I-NP O
14 556 557 220563 , , O O
15 558 562 220563 with IN B-PP O
16 563 567 220563 only RB B-NP O
17 568 574 220563 slight JJ I-NP O
18 575 586 220563 improvement NN I-NP O
19 586 587 220563 . . O O

1 588 591 220563 The DT B-NP O
2 592 602 220563 underlying VBG I-NP O
3 603 612 220563 mechanism NN I-NP O
4 613 620 220563 causing VBG B-VP O
5 621 624 220563 the DT B-NP O
6 625 635 220563 neuropathy NN I-NP B-Disease
7 636 638 220563 is VBZ B-VP O
8 639 642 220563 not RB O O
9 643 646 220563 yet RB B-VP O
10 647 652 220563 fully RB I-VP O
11 653 658 220563 known VBN I-VP O
12 658 659 220563 , , O O
13 660 668 220563 although IN B-SBAR O
14 669 673 220563 some DT B-NP O
15 674 682 220563 evidence NN I-NP O
16 683 692 220563 indicates VBZ B-VP O
17 693 697 220563 that IN B-SBAR O
18 698 700 220563 it PRP B-NP O
19 701 704 220563 may MD B-VP O
20 705 707 220563 be VB I-VP O
21 708 709 220563 a DT B-NP O
22 710 715 220563 lipid NN I-NP O
23 716 723 220563 storage NN I-NP O
24 724 731 220563 process NN I-NP O
25 731 732 220563 . . O O

1 0 0 9390208 -DOCSTART- -X- -X- O

1 0 9 9390208 Treatment NN B-NP O
2 10 12 9390208 of IN B-PP O
3 13 23 9390208 previously RB B-NP O
4 24 31 9390208 treated VBN I-NP O
5 32 42 9390208 metastatic JJ I-NP O
6 43 49 9390208 breast NN I-NP B-Disease
7 50 56 9390208 cancer NN I-NP I-Disease
8 57 59 9390208 by IN B-PP O
9 60 72 9390208 mitoxantrone NN B-NP B-Chemical
10 73 76 9390208 and CC O O
11 77 79 9390208 48 CD B-NP O
12 79 80 9390208 - HYPH I-NP O
13 80 84 9390208 hour NN I-NP O
14 85 95 9390208 continuous JJ I-NP O
15 96 104 9390208 infusion NN I-NP O
16 105 107 9390208 of IN B-PP O
17 108 112 9390208 high JJ B-NP O
18 112 113 9390208 - HYPH I-NP O
19 113 117 9390208 dose NN B-NP O
20 118 119 9390208 5 CD I-NP B-Chemical
21 119 120 9390208 - HYPH I-NP I-Chemical
22 120 122 9390208 FU NN I-NP I-Chemical
23 123 126 9390208 and CC I-NP O
24 127 137 9390208 leucovorin NN I-NP B-Chemical
25 138 139 9390208 ( ( O O
26 139 142 9390208 MFL NN B-NP B-Chemical
27 142 143 9390208 ) ) O O
28 143 144 9390208 : : O O
29 145 148 9390208 low JJ B-NP O
30 149 159 9390208 palliative JJ I-NP O
31 160 167 9390208 benefit NN I-NP O
32 168 171 9390208 and CC O O
33 172 176 9390208 high JJ B-NP O
34 177 186 9390208 treatment NN I-NP O
35 186 187 9390208 - HYPH B-VP O
36 187 194 9390208 related VBN B-NP O
37 195 203 9390208 toxicity NN I-NP B-Disease
38 203 204 9390208 . . O O
39 205 208 9390208 For IN O O
40 209 219 9390208 previously RB B-NP O
41 220 227 9390208 treated VBN I-NP O
42 228 236 9390208 advanced JJ I-NP O
43 237 243 9390208 breast NN I-NP B-Disease
44 244 250 9390208 cancer NN I-NP I-Disease
45 250 251 9390208 , , O O
46 252 257 9390208 there EX B-NP O
47 258 260 9390208 is VBZ B-VP O
48 261 263 9390208 no DT B-NP O
49 264 272 9390208 standard JJ I-NP O
50 273 279 9390208 second JJ I-NP O
51 279 280 9390208 - HYPH I-NP O
52 280 284 9390208 line NN I-NP O
53 285 292 9390208 therapy NN I-NP O
54 292 293 9390208 . . O O

1 294 305 9390208 Combination NN B-NP O
2 306 318 9390208 chemotherapy NN I-NP O
3 319 323 9390208 with IN B-PP O
4 324 336 9390208 mitoxantrone NN B-NP B-Chemical
5 336 337 9390208 , , O O
6 338 342 9390208 high JJ B-NP O
7 342 343 9390208 - HYPH I-NP O
8 343 347 9390208 dose NN B-NP O
9 348 349 9390208 5 CD I-NP B-Chemical
10 349 350 9390208 - HYPH I-NP I-Chemical
11 350 362 9390208 fluorouracil NN I-NP I-Chemical
12 363 364 9390208 ( ( O O
13 364 365 9390208 5 CD B-NP B-Chemical
14 365 366 9390208 - HYPH I-NP I-Chemical
15 366 368 9390208 FU NN I-NP I-Chemical
16 368 369 9390208 ) ) O O
17 370 373 9390208 and CC O O
18 374 384 9390208 leucovorin NN B-NP B-Chemical
19 385 386 9390208 ( ( O O
20 386 389 9390208 MFL NN B-NP B-Chemical
21 390 397 9390208 regimen NN I-NP I-Chemical
22 397 398 9390208 ) ) O O
23 399 402 9390208 had VBD B-VP O
24 403 407 9390208 been VBN I-VP O
25 408 416 9390208 reported VBN I-VP O
26 417 419 9390208 as IN B-PP O
27 420 422 9390208 an DT B-NP O
28 423 432 9390208 effective JJ I-NP O
29 433 436 9390208 and CC I-NP O
30 437 441 9390208 well RB I-NP O
31 442 451 9390208 tolerated VBN I-NP O
32 452 459 9390208 regimen NN I-NP O
33 459 460 9390208 . . O O

1 461 465 9390208 From IN B-PP O
2 466 473 9390208 October NNP B-NP O
3 474 478 9390208 1993 CD I-NP O
4 479 481 9390208 to TO B-PP O
5 482 490 9390208 November NNP B-NP O
6 491 495 9390208 1995 CD I-NP O
7 495 496 9390208 , , O O
8 497 499 9390208 we PRP B-NP O
9 500 507 9390208 treated VBD B-VP O
10 508 510 9390208 13 CD B-NP O
11 511 519 9390208 patients NNS I-NP O
12 520 524 9390208 with IN B-PP O
13 525 535 9390208 previously RB B-NP O
14 536 548 9390208 chemotherapy NN I-NP O
15 548 549 9390208 - HYPH O O
16 549 556 9390208 treated VBN B-NP O
17 557 567 9390208 metastatic JJ I-NP O
18 568 574 9390208 breast NN I-NP B-Disease
19 575 581 9390208 cancer NN I-NP I-Disease
20 582 584 9390208 by IN B-PP O
21 585 597 9390208 mitoxantrone NN B-NP B-Chemical
22 597 598 9390208 , , O O
23 599 601 9390208 12 CD B-NP O
24 602 604 9390208 mg NN I-NP O
25 604 605 9390208 / SYM O O
26 605 607 9390208 m2 NN B-NP O
27 607 608 9390208 , , O O
28 609 611 9390208 on IN B-PP O
29 612 615 9390208 day NN B-NP O
30 616 617 9390208 1 CD I-NP O
31 618 621 9390208 and CC O O
32 622 632 9390208 continuous JJ B-NP O
33 633 641 9390208 infusion NN I-NP O
34 642 644 9390208 of IN B-PP O
35 645 646 9390208 5 CD B-NP B-Chemical
36 646 647 9390208 - HYPH I-NP I-Chemical
37 647 649 9390208 FU NN I-NP I-Chemical
38 649 650 9390208 , , O O
39 651 655 9390208 3000 CD B-NP O
40 656 658 9390208 mg NN I-NP O
41 658 659 9390208 / SYM O O
42 659 661 9390208 m2 NN B-NP O
43 661 662 9390208 , , O O
44 663 671 9390208 together RB B-ADVP O
45 672 676 9390208 with IN B-PP O
46 677 687 9390208 leucovorin NN B-NP B-Chemical
47 687 688 9390208 , , O O
48 689 692 9390208 300 CD B-NP O
49 693 695 9390208 mg NN I-NP O
50 695 696 9390208 / SYM B-NP O
51 696 698 9390208 m2 NN I-NP O
52 698 699 9390208 , , O O
53 700 703 9390208 for IN B-PP O
54 704 706 9390208 48 CD B-NP O
55 707 708 9390208 h NN I-NP O
56 709 713 9390208 from IN B-PP O
57 714 717 9390208 day NN B-NP O
58 718 719 9390208 1 CD I-NP O
59 720 722 9390208 to TO B-PP O
60 723 724 9390208 2 CD B-NP O
61 724 725 9390208 . . O O

1 726 730 9390208 Each DT B-NP O
2 731 737 9390208 course NN I-NP O
3 738 740 9390208 of IN B-PP O
4 741 753 9390208 chemotherapy NN B-NP O
5 754 757 9390208 was VBD B-VP O
6 758 763 9390208 given VBN I-VP O
7 764 769 9390208 every DT B-NP O
8 770 771 9390208 4 CD I-NP O
9 772 777 9390208 weeks NNS I-NP O
10 777 778 9390208 . . O O

1 779 783 9390208 Most JJS B-NP O
2 784 786 9390208 of IN B-PP O
3 787 792 9390208 these DT B-NP O
4 793 801 9390208 patients NNS I-NP O
5 802 805 9390208 had VBD B-VP O
6 806 810 9390208 more JJR B-NP O
7 811 815 9390208 than IN I-NP O
8 816 819 9390208 two CD I-NP O
9 820 830 9390208 metastatic JJ I-NP O
10 831 836 9390208 sites NNS I-NP O
11 836 837 9390208 , , O O
12 838 842 9390208 with IN B-PP O
13 843 847 9390208 lung NN B-NP O
14 848 858 9390208 metastasis NN I-NP O
15 859 870 9390208 predominant JJ B-ADJP O
16 870 871 9390208 . . O O

1 872 877 9390208 Seven CD B-NP O
2 878 886 9390208 patients NNS I-NP O
3 887 890 9390208 had VBD B-VP O
4 891 895 9390208 been VBN I-VP O
5 896 903 9390208 treated VBN I-VP O
6 904 908 9390208 with IN B-PP O
7 909 922 9390208 anthracycline NN B-NP B-Chemical
8 922 923 9390208 . . O O

1 924 929 9390208 Seven CD B-NP O
2 930 938 9390208 patients NNS I-NP O
3 939 942 9390208 had VBD B-VP O
4 943 953 9390208 previously RB I-VP O
5 954 962 9390208 received VBN I-VP O
6 963 975 9390208 radiotherapy NN B-NP O
7 976 979 9390208 and CC O O
8 980 985 9390208 seven CD B-NP O
9 986 989 9390208 had VBD B-VP O
10 990 998 9390208 received VBN I-VP O
11 999 1006 9390208 hormone NN B-NP O
12 1007 1014 9390208 therapy NN I-NP O
13 1014 1015 9390208 . . O O

1 1016 1022 9390208 Median JJ B-NP O
2 1023 1029 9390208 number NN I-NP O
3 1030 1032 9390208 of IN B-PP O
4 1033 1040 9390208 courses NNS B-NP O
5 1041 1043 9390208 of IN B-PP O
6 1044 1047 9390208 MFL NN B-NP B-Chemical
7 1048 1055 9390208 regimen NN I-NP I-Chemical
8 1056 1061 9390208 given VBN B-VP O
9 1062 1065 9390208 was VBD B-VP O
10 1066 1069 9390208 six CD B-NP O
11 1070 1073 9390208 and CC O O
12 1074 1077 9390208 the DT B-NP O
13 1078 1084 9390208 median JJ I-NP O
14 1085 1095 9390208 cumulative JJ I-NP O
15 1096 1100 9390208 dose NN I-NP O
16 1101 1103 9390208 of IN B-PP O
17 1104 1116 9390208 mitoxantrone NN B-NP B-Chemical
18 1117 1120 9390208 was VBD B-VP O
19 1121 1126 9390208 68.35 CD B-NP O
20 1127 1129 9390208 mg NN I-NP O
21 1129 1130 9390208 / SYM B-NP O
22 1130 1132 9390208 m2 NN I-NP O
23 1132 1133 9390208 . . O O

1 1134 1137 9390208 One CD B-NP O
2 1138 1145 9390208 patient NN I-NP O
3 1146 1149 9390208 had VBD B-VP O
4 1150 1158 9390208 complete JJ B-NP O
5 1159 1167 9390208 response NN I-NP O
6 1167 1168 9390208 , , O O
7 1169 1174 9390208 seven CD B-NP O
8 1175 1178 9390208 had VBD B-VP O
9 1179 1185 9390208 stable JJ B-NP O
10 1186 1193 9390208 disease NN I-NP O
11 1193 1194 9390208 , , O O
12 1195 1199 9390208 none NN B-NP O
13 1200 1203 9390208 had VBD B-VP O
14 1204 1211 9390208 partial JJ B-NP O
15 1212 1220 9390208 response NN I-NP O
16 1221 1224 9390208 and CC O O
17 1225 1229 9390208 five CD B-NP O
18 1230 1233 9390208 had VBD B-VP O
19 1234 1245 9390208 progressive JJ B-NP O
20 1246 1253 9390208 disease NN I-NP O
21 1253 1254 9390208 . . O O

1 1255 1258 9390208 The DT B-NP O
2 1259 1266 9390208 overall JJ I-NP O
3 1267 1276 9390208 objective JJ I-NP O
4 1277 1285 9390208 response NN I-NP O
5 1286 1290 9390208 rate NN I-NP O
6 1291 1294 9390208 was VBD B-VP O
7 1295 1299 9390208 7.6% CD B-NP O
8 1299 1300 9390208 . . O O

1 1301 1304 9390208 The DT B-NP O
2 1305 1311 9390208 median JJ I-NP O
3 1312 1318 9390208 follow VB B-VP O
4 1318 1319 9390208 - HYPH O O
5 1319 1321 9390208 up RP B-PRT O
6 1322 1328 9390208 period NN B-NP O
7 1329 1332 9390208 was VBD B-VP O
8 1333 1335 9390208 14 CD B-NP O
9 1336 1342 9390208 months NNS I-NP O
10 1342 1343 9390208 . . O O

1 1344 1350 9390208 Median JJ B-NP O
2 1351 1359 9390208 survival NN I-NP O
3 1360 1363 9390208 was VBD B-VP O
4 1364 1366 9390208 16 CD B-NP O
5 1367 1373 9390208 months NNS I-NP O
6 1373 1374 9390208 . . O O

1 1375 1381 9390208 Median JJ B-NP O
2 1382 1393 9390208 progression NN I-NP O
3 1393 1394 9390208 - HYPH O O
4 1394 1398 9390208 free JJ B-NP O
5 1399 1407 9390208 survival NN I-NP O
6 1408 1411 9390208 was VBD B-VP O
7 1412 1413 9390208 5 CD B-NP O
8 1414 1420 9390208 months NNS I-NP O
9 1420 1421 9390208 . . O O

1 1422 1423 9390208 A DT B-NP O
2 1424 1432 9390208 complete JJ I-NP O
3 1433 1442 9390208 responder NN I-NP O
4 1443 1446 9390208 had VBD B-VP O
5 1447 1454 9390208 relapse NN B-NP O
6 1454 1455 9390208 - HYPH O O
7 1455 1459 9390208 free JJ B-NP O
8 1460 1468 9390208 survival NN I-NP O
9 1469 1471 9390208 up IN B-NP O
10 1472 1474 9390208 to TO I-NP O
11 1475 1477 9390208 17 CD I-NP O
12 1478 1484 9390208 months NNS I-NP O
13 1484 1485 9390208 . . O O

1 1486 1491 9390208 Major JJ B-NP O
2 1492 1502 9390208 toxicities NNS I-NP B-Disease
3 1503 1507 9390208 were VBD B-VP O
4 1508 1522 9390208 cardiotoxicity NN B-NP B-Disease
5 1523 1526 9390208 and CC I-NP O
6 1527 1537 9390208 leukopenia NN I-NP B-Disease
7 1537 1538 9390208 . . O O

1 1539 1544 9390208 Eight CD B-NP O
2 1545 1553 9390208 patients NNS I-NP O
3 1554 1558 9390208 were VBD B-VP O
4 1559 1563 9390208 dead JJ B-ADJP O
5 1564 1566 9390208 in IN B-PP O
6 1567 1570 9390208 the DT B-NP O
7 1571 1575 9390208 last JJ I-NP O
8 1576 1582 9390208 follow VB I-NP O
9 1582 1583 9390208 - HYPH B-ADJP O
10 1583 1585 9390208 up RP B-PRT O
11 1585 1586 9390208 ; : O O
12 1587 1590 9390208 two CD B-NP O
13 1591 1593 9390208 of IN B-PP O
14 1594 1598 9390208 them PRP B-NP O
15 1599 1603 9390208 died VBD B-VP O
16 1604 1606 9390208 of IN B-PP O
17 1607 1616 9390208 treatment NN B-NP O
18 1616 1617 9390208 - HYPH B-NP O
19 1617 1624 9390208 related VBN I-NP O
20 1625 1633 9390208 toxicity NN I-NP B-Disease
21 1633 1634 9390208 . . O O

1 1635 1638 9390208 The DT B-NP O
2 1639 1642 9390208 MFL NNP I-NP B-Chemical
3 1643 1650 9390208 regimen NN I-NP I-Chemical
4 1651 1659 9390208 achieves VBZ B-VP O
5 1660 1666 9390208 little JJ B-NP O
6 1667 1677 9390208 palliative JJ I-NP O
7 1678 1685 9390208 benefit NN I-NP O
8 1686 1689 9390208 and CC O O
9 1690 1697 9390208 induces VBZ B-VP O
10 1698 1704 9390208 severe JJ B-NP O
11 1705 1713 9390208 toxicity NN I-NP B-Disease
12 1714 1716 9390208 at IN B-PP O
13 1717 1718 9390208 a DT B-NP O
14 1719 1725 9390208 fairly RB I-NP O
15 1726 1730 9390208 high JJ I-NP O
16 1731 1735 9390208 rate NN I-NP O
17 1735 1736 9390208 . . O O

1 1737 1751 9390208 Administration NN B-NP O
2 1752 1754 9390208 of IN B-PP O
3 1755 1759 9390208 this DT B-NP O
4 1760 1767 9390208 regimen NN I-NP O
5 1768 1770 9390208 to TO B-PP O
6 1771 1777 9390208 breast NN B-NP B-Disease
7 1778 1784 9390208 cancer NN I-NP I-Disease
8 1785 1793 9390208 patients NNS I-NP O
9 1794 1797 9390208 who WP B-NP O
10 1798 1802 9390208 have VBP B-VP O
11 1803 1807 9390208 been VBN I-VP O
12 1808 1815 9390208 treated VBN I-VP O
13 1816 1818 9390208 by IN B-PP O
14 1819 1831 9390208 chemotherapy NN B-NP O
15 1832 1835 9390208 and CC O O
16 1836 1841 9390208 those DT B-NP O
17 1842 1846 9390208 with IN B-PP O
18 1847 1855 9390208 impaired JJ B-NP B-Disease
19 1856 1861 9390208 heart NN I-NP I-Disease
20 1862 1870 9390208 function NN I-NP I-Disease
21 1871 1879 9390208 requires VBZ B-VP O
22 1880 1887 9390208 careful JJ B-NP O
23 1888 1897 9390208 attention NN I-NP O
24 1897 1898 9390208 . . O O

1 0 0 8649546 -DOCSTART- -X- -X- O

1 0 11 8649546 Improvement NN B-NP O
2 12 14 8649546 of IN B-PP O
3 15 23 8649546 levodopa NN B-NP B-Chemical
4 23 24 8649546 - HYPH B-NP O
5 24 31 8649546 induced VBN I-NP O
6 32 42 8649546 dyskinesia NN I-NP B-Disease
7 43 45 8649546 by IN B-PP O
8 46 57 8649546 propranolol NN B-NP B-Chemical
9 58 60 8649546 in IN B-PP O
10 61 72 8649546 Parkinson's NNP B-NP B-Disease
11 73 80 8649546 disease NN I-NP I-Disease
12 80 81 8649546 . . O O
13 82 87 8649546 Seven CD B-NP O
14 88 96 8649546 patients NNS I-NP O
15 97 106 8649546 suffering VBG B-VP O
16 107 111 8649546 from IN B-PP O
17 112 123 8649546 Parkinson's NNS B-NP B-Disease
18 124 131 8649546 disease NN I-NP I-Disease
19 132 133 8649546 ( ( O O
20 133 135 8649546 PD NN B-NP B-Disease
21 135 136 8649546 ) ) O O
22 137 141 8649546 with IN B-PP O
23 142 150 8649546 severely RB B-ADVP O
24 151 160 8649546 disabling VBG B-VP O
25 161 171 8649546 dyskinesia NN B-NP B-Disease
26 172 180 8649546 received VBD B-VP O
27 181 184 8649546 low JJ B-NP O
28 184 185 8649546 - HYPH I-NP O
29 185 189 8649546 dose NN I-NP O
30 190 201 8649546 propranolol NN I-NP B-Chemical
31 202 204 8649546 as IN B-PP O
32 205 207 8649546 an DT B-NP O
33 208 215 8649546 adjunct NN I-NP O
34 216 218 8649546 to TO B-PP O
35 219 222 8649546 the DT B-NP O
36 223 232 8649546 currently RB I-NP O
37 233 237 8649546 used VBN I-NP O
38 238 245 8649546 medical JJ I-NP O
39 246 255 8649546 treatment NN I-NP O
40 255 256 8649546 . . O O

1 257 262 8649546 There EX B-NP O
2 263 266 8649546 was VBD B-VP O
3 267 268 8649546 a DT B-NP O
4 269 280 8649546 significant JJ I-NP O
5 281 284 8649546 40% JJ I-NP O
6 285 296 8649546 improvement NN I-NP O
7 297 299 8649546 in IN B-PP O
8 300 303 8649546 the DT B-NP O
9 304 314 8649546 dyskinesia NN I-NP B-Disease
10 315 320 8649546 score NN I-NP O
11 321 328 8649546 without IN B-PP O
12 329 337 8649546 increase NN B-NP O
13 338 340 8649546 of IN B-PP O
14 341 353 8649546 parkinsonian JJ B-NP B-Disease
15 354 359 8649546 motor NN I-NP B-Disease
16 360 370 8649546 disability NN I-NP I-Disease
17 370 371 8649546 . . O O

1 372 381 8649546 Ballistic JJ B-NP O
2 382 385 8649546 and CC I-NP O
3 386 393 8649546 choreic JJ I-NP O
4 394 404 8649546 dyskinesia NN I-NP B-Disease
5 405 409 8649546 were VBD B-VP O
6 410 418 8649546 markedly RB I-VP O
7 419 430 8649546 ameliorated VBN I-VP O
8 430 431 8649546 , , O O
9 432 439 8649546 whereas IN O O
10 440 448 8649546 dystonia NN B-NP B-Disease
11 449 452 8649546 was VBD B-VP O
12 453 456 8649546 not RB O O
13 456 457 8649546 . . O O

1 458 462 8649546 This DT B-NP O
2 463 468 8649546 study NN I-NP O
3 469 477 8649546 suggests VBZ B-VP O
4 478 482 8649546 that IN B-SBAR O
5 483 497 8649546 administration NN B-NP O
6 498 500 8649546 of IN B-PP O
7 501 504 8649546 low JJ B-NP O
8 505 510 8649546 doses NNS I-NP O
9 511 513 8649546 of IN B-PP O
10 514 518 8649546 beta SYM O O
11 518 519 8649546 - HYPH O O
12 519 527 8649546 blockers NNS B-NP O
13 528 531 8649546 may MD B-VP O
14 532 539 8649546 improve VB I-VP O
15 540 548 8649546 levodopa NN B-NP B-Chemical
16 548 549 8649546 - HYPH B-NP O
17 549 556 8649546 induced VBN I-NP O
18 557 566 8649546 ballistic JJ I-NP O
19 567 570 8649546 and CC I-NP O
20 571 578 8649546 choreic JJ I-NP O
21 579 589 8649546 dyskinesia NN I-NP B-Disease
22 590 592 8649546 in IN B-PP O
23 593 595 8649546 PD NN B-NP B-Disease
24 595 596 8649546 . . O O

1 0 0 7977601 -DOCSTART- -X- -X- O

1 0 6 7977601 Survey NN B-NP O
2 7 9 7977601 of IN B-PP O
3 10 23 7977601 complications NNS B-NP O
4 24 26 7977601 of IN B-PP O
5 27 38 7977601 indocyanine NN B-NP B-Chemical
6 39 44 7977601 green JJ I-NP I-Chemical
7 45 56 7977601 angiography NN I-NP O
8 57 59 7977601 in IN B-PP O
9 60 65 7977601 Japan NNP B-NP O
10 65 66 7977601 . . I-NP O
11 67 74 7977601 PURPOSE NNP I-NP O
12 74 75 7977601 : : O O
13 76 78 7977601 We PRP B-NP O
14 79 88 7977601 evaluated VBD B-VP O
15 89 92 7977601 the DT B-NP O
16 93 99 7977601 safety NN I-NP O
17 100 102 7977601 of IN B-PP O
18 103 114 7977601 indocyanine NN B-NP B-Chemical
19 115 120 7977601 green NN I-NP I-Chemical
20 121 124 7977601 for IN B-PP O
21 125 128 7977601 use NN B-NP O
22 129 131 7977601 in IN B-PP O
23 132 138 7977601 fundus NN B-NP O
24 139 150 7977601 angiography NN I-NP O
25 150 151 7977601 . . O O

1 152 159 7977601 METHODS NNS B-NP O
2 159 160 7977601 : : O O
3 161 163 7977601 We PRP B-NP O
4 164 168 7977601 sent VBD B-VP O
5 169 170 7977601 a DT B-NP O
6 171 184 7977601 questionnaire NN I-NP O
7 185 195 7977601 concerning VBG B-VP O
8 196 209 7977601 complications NNS B-NP O
9 210 212 7977601 of IN B-PP O
10 213 224 7977601 indocyanine NN B-NP B-Chemical
11 225 230 7977601 green JJ B-ADJP I-Chemical
12 231 233 7977601 to TO B-PP O
13 234 236 7977601 32 CD B-NP O
14 237 249 7977601 institutions NNS I-NP O
15 250 252 7977601 in IN B-PP O
16 253 258 7977601 Japan NNP B-NP O
17 258 259 7977601 , , O O
18 260 265 7977601 which WDT B-NP O
19 266 270 7977601 were VBD B-VP O
20 271 279 7977601 selected VBN I-VP O
21 280 282 7977601 on IN B-PP O
22 283 286 7977601 the DT B-NP O
23 287 292 7977601 basis NN I-NP O
24 293 295 7977601 of IN B-PP O
25 296 299 7977601 the DT B-NP O
26 300 306 7977601 client NN I-NP O
27 307 311 7977601 list NN I-NP O
28 312 316 7977601 from IN B-PP O
29 317 320 7977601 the DT B-NP O
30 321 327 7977601 Topcon NNP I-NP O
31 328 335 7977601 Company NNP I-NP O
32 335 336 7977601 , , O O
33 337 342 7977601 which WDT B-NP O
34 343 355 7977601 manufactures VBZ B-VP O
35 356 359 7977601 the DT B-NP O
36 360 371 7977601 indocyanine NN I-NP B-Chemical
37 372 377 7977601 green JJ I-NP I-Chemical
38 378 384 7977601 fundus NN I-NP O
39 385 391 7977601 camera NN I-NP O
40 391 392 7977601 . . O O

1 393 400 7977601 RESULTS NNS B-NP O
2 400 401 7977601 : : O O
3 402 418 7977601 Ophthalmologists NNS B-NP O
4 419 421 7977601 at IN B-PP O
5 422 424 7977601 15 CD B-NP O
6 425 437 7977601 institutions NNS I-NP O
7 438 447 7977601 responded VBD B-VP O
8 447 448 7977601 , , O O
9 449 458 7977601 reporting VBG B-VP O
10 459 460 7977601 a DT B-NP O
11 461 466 7977601 total NN I-NP O
12 467 469 7977601 of IN B-PP O
13 470 475 7977601 3,774 CD B-NP O
14 476 487 7977601 indocyanine NN I-NP B-Chemical
15 488 493 7977601 green JJ I-NP I-Chemical
16 494 504 7977601 angiograms NNS I-NP O
17 505 514 7977601 performed VBN B-VP O
18 515 517 7977601 on IN B-PP O
19 518 523 7977601 2,820 CD B-NP O
20 524 532 7977601 patients NNS I-NP O
21 533 540 7977601 between IN B-PP O
22 541 545 7977601 June NNP B-NP O
23 546 550 7977601 1984 CD I-NP O
24 551 554 7977601 and CC O O
25 555 564 7977601 September NNP B-NP O
26 565 569 7977601 1992 CD I-NP O
27 569 570 7977601 . . O O

1 571 577 7977601 Before IN B-PP O
2 578 589 7977601 angiography NN B-NP O
3 589 590 7977601 , , O O
4 591 602 7977601 intradermal JJ B-NP O
5 603 605 7977601 or CC I-NP O
6 606 617 7977601 intravenous JJ I-NP O
7 618 629 7977601 indocyanine NN I-NP B-Chemical
8 630 635 7977601 green JJ I-NP I-Chemical
9 636 643 7977601 testing NN I-NP O
10 643 644 7977601 , , O O
11 645 647 7977601 or CC O O
12 648 652 7977601 both DT B-NP O
13 653 656 7977601 was VBD B-VP O
14 657 666 7977601 performed VBN I-VP O
15 667 669 7977601 at IN B-PP O
16 670 672 7977601 13 CD B-NP O
17 673 675 7977601 of IN B-PP O
18 676 678 7977601 15 CD B-NP O
19 679 691 7977601 institutions NNS I-NP O
20 691 692 7977601 . . O O

1 693 696 7977601 For IN B-PP O
2 697 702 7977601 three CD B-NP O
3 703 711 7977601 patients NNS I-NP O
4 711 712 7977601 , , O O
5 713 716 7977601 the DT B-NP O
6 717 725 7977601 decision NN I-NP O
7 726 729 7977601 was VBD B-VP O
8 730 734 7977601 made VBN I-VP O
9 735 738 7977601 not RB O O
10 739 741 7977601 to TO B-VP O
11 742 749 7977601 proceed VB I-VP O
12 750 754 7977601 with IN B-PP O
13 755 766 7977601 angiography NN B-NP O
14 767 772 7977601 after IN B-PP O
15 773 781 7977601 positive JJ B-NP O
16 782 797 7977601 preangiographic JJ I-NP O
17 798 805 7977601 testing NN I-NP O
18 805 806 7977601 . . O O

1 807 810 7977601 The DT B-NP O
2 811 817 7977601 dosage NN I-NP O
3 818 820 7977601 of IN B-PP O
4 821 832 7977601 indocyanine NN B-NP B-Chemical
5 833 838 7977601 green JJ B-NP I-Chemical
6 839 843 7977601 used VBN B-VP O
7 844 847 7977601 for IN B-PP O
8 848 859 7977601 angiography NN B-NP O
9 860 866 7977601 varied VBD B-VP O
10 867 871 7977601 from IN B-PP O
11 872 874 7977601 25 CD B-NP O
12 875 877 7977601 to TO I-NP O
13 878 880 7977601 75 CD I-NP O
14 881 883 7977601 mg NN I-NP O
15 883 884 7977601 , , O O
16 885 894 7977601 depending VBG B-VP O
17 895 899 7977601 upon IN B-PP O
18 900 903 7977601 the DT B-NP O
19 904 915 7977601 institution NN I-NP O
20 915 916 7977601 . . O O

1 917 922 7977601 There EX B-NP O
2 923 927 7977601 were VBD B-VP O
3 928 930 7977601 13 CD B-NP O
4 931 936 7977601 cases NNS I-NP O
5 937 939 7977601 of IN B-PP O
6 940 947 7977601 adverse JJ B-NP O
7 948 957 7977601 reactions NNS I-NP O
8 958 959 7977601 ( ( O O
9 959 964 7977601 0.34% CD B-NP O
10 964 965 7977601 ) ) O O
11 965 966 7977601 , , O O
12 967 970 7977601 ten CD B-NP O
13 971 973 7977601 of IN B-PP O
14 974 979 7977601 which WDT B-NP O
15 980 984 7977601 were VBD B-VP O
16 985 989 7977601 mild JJ B-NP O
17 990 999 7977601 reactions NNS I-NP O
18 1000 1004 7977601 such JJ B-PP O
19 1005 1007 7977601 as IN I-PP O
20 1008 1014 7977601 nausea NN B-NP B-Disease
21 1014 1015 7977601 , , O O
22 1016 1025 7977601 exanthema NN B-NP B-Disease
23 1025 1026 7977601 , , O O
24 1027 1037 7977601 urtication NN B-NP B-Disease
25 1037 1038 7977601 , , O O
26 1039 1048 7977601 itchiness NN B-NP B-Disease
27 1048 1049 7977601 , , O O
28 1050 1053 7977601 and CC O O
29 1054 1061 7977601 urgency NN B-NP O
30 1062 1064 7977601 to TO B-VP O
31 1065 1073 7977601 defecate VB I-VP O
32 1073 1074 7977601 , , O O
33 1075 1078 7977601 and CC O O
34 1079 1082 7977601 did VBD B-VP O
35 1083 1086 7977601 not RB I-VP O
36 1087 1094 7977601 require VB I-VP O
37 1095 1104 7977601 treatment NN B-NP O
38 1104 1105 7977601 . . O O

1 1106 1110 7977601 Also RB B-VP O
2 1111 1119 7977601 recorded VBN I-VP O
3 1120 1124 7977601 were VBD B-VP O
4 1125 1128 7977601 one CD B-NP O
5 1129 1133 7977601 case NN I-NP O
6 1134 1136 7977601 of IN B-PP O
7 1137 1141 7977601 pain NN B-NP B-Disease
8 1142 1144 7977601 of IN B-PP O
9 1145 1148 7977601 the DT B-NP O
10 1149 1153 7977601 vein NN I-NP O
11 1153 1154 7977601 , , O O
12 1155 1160 7977601 which WDT B-NP O
13 1161 1169 7977601 required VBD B-VP O
14 1170 1179 7977601 treatment NN B-NP O
15 1179 1180 7977601 , , O O
16 1181 1184 7977601 and CC O O
17 1185 1188 7977601 two CD B-NP O
18 1189 1194 7977601 cases NNS I-NP O
19 1195 1197 7977601 of IN B-PP O
20 1198 1209 7977601 hypotension NN B-NP B-Disease
21 1209 1210 7977601 . . O O

1 1211 1214 7977601 The DT B-NP O
2 1215 1218 7977601 two CD I-NP O
3 1219 1230 7977601 hypotensive JJ I-NP B-Disease
4 1231 1239 7977601 patients NNS I-NP O
5 1240 1248 7977601 required VBD B-VP O
6 1249 1258 7977601 treatment NN B-NP O
7 1259 1262 7977601 for IN B-PP O
8 1263 1268 7977601 shock NN B-NP B-Disease
9 1268 1269 7977601 . . O O

1 1270 1281 7977601 CONCLUSIONS NNS B-NP O
2 1281 1282 7977601 : : O O
3 1283 1284 7977601 A DT B-NP O
4 1285 1295 7977601 comparison NN I-NP O
5 1296 1298 7977601 of IN B-PP O
6 1299 1308 7977601 frequency NN B-NP O
7 1309 1311 7977601 of IN B-PP O
8 1312 1319 7977601 adverse JJ B-NP O
9 1320 1329 7977601 reactions NNS I-NP O
10 1330 1332 7977601 to TO B-VP O
11 1333 1344 7977601 indocyanine VB I-VP B-Chemical
12 1345 1350 7977601 green JJ B-ADJP I-Chemical
13 1351 1355 7977601 with IN B-PP O
14 1356 1359 7977601 the DT B-NP O
15 1360 1370 7977601 previously RB I-NP O
16 1371 1379 7977601 reported VBN I-NP O
17 1380 1389 7977601 frequency NN I-NP O
18 1390 1392 7977601 of IN B-PP O
19 1393 1397 7977601 such JJ B-NP O
20 1398 1407 7977601 reactions NNS I-NP O
21 1408 1410 7977601 to TO B-PP O
22 1411 1422 7977601 fluorescein NN B-NP B-Chemical
23 1423 1429 7977601 sodium NN I-NP I-Chemical
24 1430 1439 7977601 indicated VBD B-VP O
25 1440 1444 7977601 that IN B-SBAR O
26 1445 1456 7977601 indocyanine NN B-NP B-Chemical
27 1457 1462 7977601 green NN I-NP I-Chemical
28 1463 1465 7977601 is VBZ B-VP O
29 1466 1467 7977601 a DT B-NP O
30 1468 1472 7977601 safe NN I-NP O
31 1473 1475 7977601 as IN B-PP O
32 1476 1487 7977601 fluorescein NN B-NP B-Chemical
33 1488 1491 7977601 for IN B-PP O
34 1492 1495 7977601 use NN B-NP O
35 1496 1498 7977601 in IN B-PP O
36 1499 1510 7977601 angiography NN B-NP O
37 1510 1511 7977601 . . O O

1 0 0 18217897 -DOCSTART- -X- -X- O

1 0 11 18217897 Thalidomide NN B-NP B-Chemical
2 12 15 18217897 has VBZ B-VP O
3 16 23 18217897 limited VBN I-VP O
4 24 30 18217897 single JJ B-NP O
5 30 31 18217897 - HYPH I-NP O
6 31 36 18217897 agent NN I-NP O
7 37 45 18217897 activity NN I-NP O
8 46 48 18217897 in IN B-PP O
9 49 57 18217897 relapsed JJ B-NP O
10 58 60 18217897 or CC I-NP O
11 61 71 18217897 refractory JJ I-NP O
12 72 80 18217897 indolent JJ I-NP O
13 81 84 18217897 non AFX I-NP B-Disease
14 84 85 18217897 - HYPH I-NP I-Disease
15 85 92 18217897 Hodgkin NN I-NP I-Disease
16 93 102 18217897 lymphomas NNS I-NP I-Disease
17 102 103 18217897 : : O O
18 104 105 18217897 a DT B-NP O
19 106 111 18217897 phase NN I-NP O
20 112 114 18217897 II CD I-NP O
21 115 120 18217897 trial NN I-NP O
22 121 123 18217897 of IN B-PP O
23 124 127 18217897 the DT B-NP O
24 128 134 18217897 Cancer NNP I-NP B-Disease
25 135 138 18217897 and CC I-NP O
26 139 147 18217897 Leukemia NNP I-NP B-Disease
27 148 153 18217897 Group NNP I-NP O
28 154 155 18217897 B NNP I-NP O
29 155 156 18217897 . . I-NP O
30 157 168 18217897 Thalidomide NNP I-NP B-Chemical
31 169 171 18217897 is VBZ B-VP O
32 172 174 18217897 an DT B-NP O
33 175 191 18217897 immunomodulatory JJ I-NP O
34 192 197 18217897 agent NN I-NP O
35 198 202 18217897 with IN B-PP O
36 203 215 18217897 demonstrated VBN B-NP O
37 216 224 18217897 activity NN I-NP O
38 225 227 18217897 in IN B-PP O
39 228 236 18217897 multiple JJ B-NP B-Disease
40 237 244 18217897 myeloma NN I-NP I-Disease
41 244 245 18217897 , , O O
42 246 252 18217897 mantle NN B-NP B-Disease
43 253 257 18217897 cell NN I-NP I-Disease
44 258 266 18217897 lymphoma NN I-NP I-Disease
45 267 270 18217897 and CC O O
46 271 288 18217897 lymphoplasmacytic JJ B-NP B-Disease
47 289 297 18217897 lymphoma NN I-NP I-Disease
48 297 298 18217897 . . O O

1 299 302 18217897 Its PRP$ B-NP O
2 303 311 18217897 activity NN I-NP O
3 312 314 18217897 is VBZ B-VP O
4 315 323 18217897 believed VBN I-VP O
5 324 326 18217897 to TO I-VP O
6 327 329 18217897 be VB I-VP O
7 330 333 18217897 due JJ B-NP O
8 334 344 18217897 modulation NN I-NP O
9 345 347 18217897 of IN B-PP O
10 348 351 18217897 the DT B-NP O
11 352 358 18217897 tumour NN I-NP B-Disease
12 359 365 18217897 milieu NN I-NP O
13 365 366 18217897 , , O O
14 367 376 18217897 including VBG B-PP O
15 377 391 18217897 downregulation NN B-NP O
16 392 394 18217897 of IN B-PP O
17 395 407 18217897 angiogenesis NN B-NP O
18 408 411 18217897 and CC O O
19 412 424 18217897 inflammatory JJ B-NP O
20 425 434 18217897 cytokines NNS I-NP O
21 434 435 18217897 . . O O

1 436 443 18217897 Between IN B-PP O
2 444 448 18217897 July NNP B-NP O
3 449 453 18217897 2001 CD I-NP O
4 454 457 18217897 and CC O O
5 458 463 18217897 April NNP B-NP O
6 464 468 18217897 2004 CD I-NP O
7 468 469 18217897 , , O O
8 470 472 18217897 24 CD B-NP O
9 473 481 18217897 patients NNS I-NP O
10 482 486 18217897 with IN B-PP O
11 487 495 18217897 relapsed VBN B-NP O
12 495 496 18217897 / SYM I-NP O
13 496 506 18217897 refractory JJ I-NP O
14 507 515 18217897 indolent JJ I-NP O
15 516 525 18217897 lymphomas NNS I-NP B-Disease
16 526 534 18217897 received VBD B-VP O
17 535 546 18217897 thalidomide IN B-NP B-Chemical
18 547 550 18217897 200 CD I-NP O
19 551 553 18217897 mg NN I-NP O
20 554 559 18217897 daily RB B-ADVP O
21 560 564 18217897 with IN B-PP O
22 565 575 18217897 escalation NN B-NP O
23 576 578 18217897 by IN B-PP O
24 579 582 18217897 100 CD B-NP O
25 583 585 18217897 mg NN I-NP O
26 586 591 18217897 daily RB B-ADVP O
27 592 597 18217897 every DT B-NP O
28 598 599 18217897 1 CD I-NP O
29 599 600 18217897 - HYPH I-NP O
30 600 601 18217897 2 CD I-NP O
31 602 607 18217897 weeks NNS I-NP O
32 608 610 18217897 as IN B-SBAR O
33 611 620 18217897 tolerated VBN B-VP O
34 620 621 18217897 , , O O
35 622 624 18217897 up IN B-ADVP O
36 625 627 18217897 to TO B-PP O
37 628 629 18217897 a DT B-NP O
38 630 637 18217897 maximum NN I-NP O
39 638 640 18217897 of IN B-PP O
40 641 644 18217897 800 CD B-NP O
41 645 647 18217897 mg NN I-NP O
42 648 653 18217897 daily RB B-ADVP O
43 653 654 18217897 . . O O

1 655 663 18217897 Patients NNS B-NP O
2 664 667 18217897 had VBD B-VP O
3 668 676 18217897 received VBN I-VP O
4 677 678 18217897 a DT B-NP O
5 679 685 18217897 median NN I-NP O
6 686 688 18217897 of IN B-PP O
7 689 690 18217897 2 CD B-NP O
8 691 692 18217897 ( ( O O
9 692 697 18217897 range NN B-NP O
10 697 698 18217897 , , O O
11 699 700 18217897 1 CD B-NP O
12 700 701 18217897 - HYPH I-NP O
13 701 702 18217897 4 CD I-NP O
14 702 703 18217897 ) ) O O
15 704 709 18217897 prior JJ B-NP O
16 710 718 18217897 regimens NNS I-NP O
17 718 719 18217897 . . O O

1 720 722 18217897 Of IN B-PP O
2 723 725 18217897 24 CD B-NP O
3 726 735 18217897 evaluable JJ I-NP O
4 736 744 18217897 patients NNS I-NP O
5 744 745 18217897 , , O O
6 746 749 18217897 two CD B-NP O
7 750 758 18217897 achieved VBD B-VP O
8 759 760 18217897 a DT B-NP O
9 761 769 18217897 complete JJ I-NP O
10 770 779 18217897 remission NN I-NP O
11 780 783 18217897 and CC O O
12 784 787 18217897 one CD B-NP O
13 788 796 18217897 achieved VBD B-VP O
14 797 798 18217897 a DT B-NP O
15 799 806 18217897 partial JJ I-NP O
16 807 816 18217897 remission NN I-NP O
17 817 820 18217897 for IN B-PP O
18 821 823 18217897 an DT B-NP O
19 824 831 18217897 overall JJ I-NP O
20 832 840 18217897 response NN I-NP O
21 841 845 18217897 rate NN I-NP O
22 846 848 18217897 of IN B-PP O
23 849 854 18217897 12.5% NN B-NP O
24 855 856 18217897 ( ( O O
25 856 859 18217897 95% CD B-NP O
26 860 870 18217897 confidence NN I-NP O
27 871 879 18217897 interval NN I-NP O
28 879 880 18217897 : : O O
29 881 884 18217897 2.6 CD B-NP O
30 884 885 18217897 - HYPH I-NP O
31 885 890 18217897 32.4% NN I-NP O
32 890 891 18217897 ) ) O O
33 891 892 18217897 . . O O

1 893 899 18217897 Eleven CD B-NP O
2 900 908 18217897 patients NNS I-NP O
3 909 919 18217897 progressed VBD B-VP O
4 920 926 18217897 during IN B-PP O
5 927 934 18217897 therapy NN B-NP O
6 934 935 18217897 . . O O

1 936 941 18217897 Grade NN B-NP O
2 942 943 18217897 3 CD I-NP O
3 943 944 18217897 - HYPH I-NP O
4 944 945 18217897 4 CD I-NP O
5 946 953 18217897 adverse JJ I-NP O
6 954 961 18217897 effects NNS I-NP O
7 962 970 18217897 included VBD B-VP O
8 971 987 18217897 myelosuppression NN B-NP B-Disease
9 987 988 18217897 , , O O
10 989 996 18217897 fatigue NN B-NP B-Disease
11 996 997 18217897 , , O O
12 998 1008 18217897 somnolence NN B-NP B-Disease
13 1008 1009 18217897 / SYM B-NP O
14 1009 1018 18217897 depressed JJ I-NP B-Disease
15 1019 1023 18217897 mood NN I-NP I-Disease
16 1023 1024 18217897 , , I-NP O
17 1025 1035 18217897 neuropathy NN I-NP B-Disease
18 1036 1039 18217897 and CC I-NP O
19 1040 1047 18217897 dyspnea NN I-NP B-Disease
20 1047 1048 18217897 . . O O

1 1049 1051 18217897 Of IN B-PP O
2 1052 1059 18217897 concern NN B-NP O
3 1060 1063 18217897 was VBD B-VP O
4 1064 1067 18217897 the DT B-NP O
5 1068 1078 18217897 occurrence NN I-NP O
6 1079 1081 18217897 of IN B-PP O
7 1082 1086 18217897 four CD B-NP O
8 1087 1101 18217897 thromboembolic JJ I-NP B-Disease
9 1102 1108 18217897 events NNS I-NP O
10 1108 1109 18217897 . . O O

1 1110 1113 18217897 Our PRP$ B-NP O
2 1114 1121 18217897 results NNS I-NP O
3 1122 1128 18217897 failed VBD B-VP O
4 1129 1131 18217897 to TO I-VP O
5 1132 1143 18217897 demonstrate VB I-VP O
6 1144 1146 18217897 an DT B-NP O
7 1147 1156 18217897 important JJ I-NP O
8 1157 1165 18217897 response NN I-NP O
9 1166 1170 18217897 rate NN I-NP O
10 1171 1173 18217897 to TO B-PP O
11 1174 1180 18217897 single JJ B-NP O
12 1181 1186 18217897 agent NN I-NP O
13 1187 1198 18217897 thalidomide NN I-NP B-Chemical
14 1199 1201 18217897 in IN B-PP O
15 1202 1210 18217897 indolent JJ B-NP O
16 1211 1220 18217897 lymphomas NNS I-NP B-Disease
17 1221 1224 18217897 and CC O O
18 1225 1233 18217897 contrast NN B-NP O
19 1234 1238 18217897 with IN B-PP O
20 1239 1242 18217897 the DT B-NP O
21 1243 1249 18217897 higher JJR I-NP O
22 1250 1258 18217897 activity NN I-NP O
23 1259 1264 18217897 level NN I-NP O
24 1265 1273 18217897 reported VBN B-VP O
25 1274 1278 18217897 with IN B-PP O
26 1279 1282 18217897 the DT B-NP O
27 1283 1289 18217897 second JJ I-NP O
28 1290 1300 18217897 generation NN I-NP O
29 1301 1317 18217897 immunomodulatory JJ I-NP O
30 1318 1323 18217897 agent NN I-NP O
31 1323 1324 18217897 , , O O
32 1325 1337 18217897 lenalidomide NN B-NP B-Chemical
33 1337 1338 18217897 . . O O

1 0 0 16787750 -DOCSTART- -X- -X- O

1 0 8 16787750 Valproic JJ B-NP B-Chemical
2 9 13 16787750 acid NN I-NP I-Chemical
3 14 21 16787750 induced VBN B-NP O
4 22 36 16787750 encephalopathy NN I-NP B-Disease
5 36 37 16787750 - SYM B-NP O
6 37 38 16787750 - SYM B-NP O
7 38 40 16787750 19 CD I-NP O
8 41 44 16787750 new JJ I-NP O
9 45 50 16787750 cases NNS I-NP O
10 51 53 16787750 in IN B-PP O
11 54 61 16787750 Germany NNP B-NP O
12 62 66 16787750 from IN B-PP O
13 67 71 16787750 1994 CD B-NP O
14 72 74 16787750 to TO B-PP O
15 75 79 16787750 2003 CD B-NP O
16 79 80 16787750 - HYPH O O
17 80 81 16787750 - : O O
18 81 82 16787750 a DT B-NP O
19 83 87 16787750 side JJ I-NP O
20 88 94 16787750 effect NN I-NP O
21 95 105 16787750 associated VBN B-VP O
22 106 108 16787750 to TO B-PP O
23 109 112 16787750 VPA NN B-NP B-Chemical
24 112 113 16787750 - HYPH I-NP O
25 113 120 16787750 therapy NN I-NP O
26 121 124 16787750 not RB B-CONJP O
27 125 129 16787750 only RB I-CONJP O
28 130 132 16787750 in IN B-PP O
29 133 138 16787750 young JJ B-NP O
30 139 147 16787750 children NNS I-NP O
31 147 148 16787750 . . O O
32 149 157 16787750 Valproic JJ B-NP B-Chemical
33 158 162 16787750 acid NN I-NP I-Chemical
34 163 164 16787750 ( ( O O
35 164 167 16787750 VPA NN B-NP B-Chemical
36 167 168 16787750 ) ) O O
37 169 171 16787750 is VBZ B-VP O
38 172 173 16787750 a DT B-NP O
39 174 179 16787750 broad JJ I-NP O
40 179 180 16787750 - HYPH I-NP O
41 180 188 16787750 spectrum NN I-NP O
42 189 202 16787750 antiepileptic JJ I-NP O
43 203 207 16787750 drug NN I-NP O
44 208 211 16787750 and CC O O
45 212 214 16787750 is VBZ B-VP O
46 215 222 16787750 usually RB B-ADVP O
47 223 227 16787750 well RB B-ADVP O
48 227 228 16787750 - HYPH B-NP O
49 228 237 16787750 tolerated VBN B-VP O
50 237 238 16787750 . . O O

1 239 243 16787750 Rare NN B-NP O
2 244 251 16787750 serious JJ I-NP O
3 252 265 16787750 complications NNS I-NP O
4 266 269 16787750 may MD B-VP O
5 270 275 16787750 occur VB I-VP O
6 276 278 16787750 in IN B-PP O
7 279 283 16787750 some DT B-NP O
8 284 292 16787750 patients NNS I-NP O
9 292 293 16787750 , , O O
10 294 303 16787750 including VBG B-PP O
11 304 316 16787750 haemorrhagic JJ B-NP O
12 317 329 16787750 pancreatitis NN I-NP B-Disease
13 329 330 16787750 , , O O
14 331 335 16787750 bone NN B-NP B-Disease
15 336 342 16787750 marrow NN I-NP I-Disease
16 343 354 16787750 suppression NN I-NP I-Disease
17 354 355 16787750 , , O O
18 356 359 16787750 VPA NN B-NP B-Chemical
19 359 360 16787750 - HYPH B-NP O
20 360 367 16787750 induced VBN I-NP O
21 368 382 16787750 hepatotoxicity NN I-NP B-Disease
22 383 386 16787750 and CC I-NP O
23 387 390 16787750 VPA NN I-NP B-Chemical
24 390 391 16787750 - HYPH B-NP O
25 391 398 16787750 induced VBN I-NP O
26 399 413 16787750 encephalopathy NN I-NP B-Disease
27 413 414 16787750 . . O O

1 415 418 16787750 The DT B-NP O
2 419 426 16787750 typical JJ I-NP O
3 427 432 16787750 signs NNS I-NP O
4 433 435 16787750 of IN B-PP O
5 436 439 16787750 VPA NN B-NP B-Chemical
6 439 440 16787750 - HYPH B-NP O
7 440 447 16787750 induced VBN I-NP O
8 448 462 16787750 encephalopathy NN I-NP B-Disease
9 463 466 16787750 are VBP B-VP O
10 467 475 16787750 impaired JJ B-NP B-Disease
11 476 489 16787750 consciousness NN I-NP I-Disease
12 489 490 16787750 , , O O
13 491 500 16787750 sometimes RB B-NP O
14 501 507 16787750 marked JJ I-NP O
15 508 511 16787750 EEG NN I-NP O
16 512 522 16787750 background NN I-NP O
17 523 530 16787750 slowing VBG B-VP O
18 530 531 16787750 , , O O
19 532 541 16787750 increased VBN B-NP O
20 542 549 16787750 seizure NN I-NP B-Disease
21 550 559 16787750 frequency NN I-NP O
22 559 560 16787750 , , O O
23 561 565 16787750 with IN B-PP O
24 566 568 16787750 or CC B-PP O
25 569 576 16787750 without IN B-PP O
26 577 591 16787750 hyperammonemia NN B-NP B-Disease
27 591 592 16787750 . . O O

1 593 598 16787750 There EX B-NP O
2 599 601 16787750 is VBZ B-VP O
3 602 607 16787750 still RB B-ADVP O
4 608 610 16787750 no DT B-NP O
5 611 616 16787750 proof NN I-NP O
6 617 619 16787750 of IN B-PP O
7 620 629 16787750 causative JJ B-NP O
8 630 636 16787750 effect NN I-NP O
9 637 639 16787750 of IN B-PP O
10 640 643 16787750 VPA NN B-NP B-Chemical
11 644 646 16787750 in IN B-PP O
12 647 655 16787750 patients NNS B-NP O
13 656 660 16787750 with IN B-PP O
14 661 675 16787750 encephalopathy NN B-NP B-Disease
15 675 676 16787750 , , O O
16 677 680 16787750 but CC O O
17 681 685 16787750 only RB B-ADVP O
18 686 688 16787750 of IN B-PP O
19 689 691 16787750 an DT B-NP O
20 692 703 16787750 association NN I-NP O
21 704 708 16787750 with IN B-PP O
22 709 711 16787750 an DT B-NP O
23 712 719 16787750 assumed VBN I-NP O
24 720 726 16787750 causal JJ I-NP O
25 727 735 16787750 relation NN I-NP O
26 735 736 16787750 . . O O

1 737 739 16787750 We PRP B-NP O
2 740 746 16787750 report VBP B-VP O
3 747 749 16787750 19 CD B-NP O
4 750 758 16787750 patients NNS I-NP O
5 759 763 16787750 with IN B-PP O
6 764 767 16787750 VPA NN B-NP B-Chemical
7 767 768 16787750 - HYPH O O
8 768 778 16787750 associated VBN B-NP O
9 779 793 16787750 encephalopathy NN I-NP B-Disease
10 794 796 16787750 in IN B-PP O
11 797 804 16787750 Germany NNP B-NP O
12 805 809 16787750 from IN B-PP O
13 810 813 16787750 the DT B-NP O
14 814 819 16787750 years NNS I-NP O
15 820 824 16787750 1994 CD B-NP O
16 825 827 16787750 to TO B-PP O
17 828 832 16787750 2003 CD B-NP O
18 832 833 16787750 , , O O
19 834 838 16787750 none NN B-NP O
20 839 841 16787750 of IN B-PP O
21 842 846 16787750 whom WP B-NP O
22 847 850 16787750 had VBD B-VP O
23 851 855 16787750 been VBN I-VP O
24 856 865 16787750 published VBN I-VP O
25 866 876 16787750 previously RB B-ADVP O
26 876 877 16787750 . . O O

1 0 0 17600377 -DOCSTART- -X- -X- O

1 0 1 17600377 A DT B-NP O
2 2 7 17600377 novel JJ I-NP O
3 8 16 17600377 compound NN I-NP O
4 16 17 17600377 , , O O
5 18 26 17600377 maltolyl NN B-NP B-Chemical
6 27 28 17600377 p NN I-NP I-Chemical
7 28 29 17600377 - HYPH B-NP I-Chemical
8 29 38 17600377 coumarate NN I-NP I-Chemical
9 38 39 17600377 , , O O
10 40 50 17600377 attenuates VBZ B-VP O
11 51 60 17600377 cognitive JJ B-NP B-Disease
12 61 69 17600377 deficits NNS I-NP I-Disease
13 70 73 17600377 and CC O O
14 74 79 17600377 shows VBZ B-VP O
15 80 95 17600377 neuroprotective JJ B-NP O
16 96 103 17600377 effects NNS I-NP O
17 104 106 17600377 in FW B-ADVP O
18 107 112 17600377 vitro FW I-ADVP O
19 113 116 17600377 and CC O O
20 117 119 17600377 in FW B-NP O
21 120 124 17600377 vivo FW I-NP O
22 125 133 17600377 dementia NN I-NP B-Disease
23 134 140 17600377 models NNS I-NP O
24 140 141 17600377 . . O O
25 142 144 17600377 To TO B-VP O
26 145 152 17600377 develop VB I-VP O
27 153 154 17600377 a DT B-NP O
28 155 160 17600377 novel JJ I-NP O
29 161 164 17600377 and CC I-NP O
30 165 174 17600377 effective JJ I-NP O
31 175 179 17600377 drug NN I-NP O
32 180 184 17600377 that WDT B-NP O
33 185 190 17600377 could MD B-VP O
34 191 198 17600377 enhance VB I-VP O
35 199 208 17600377 cognitive JJ B-NP O
36 209 217 17600377 function NN I-NP O
37 218 221 17600377 and CC I-NP O
38 222 237 17600377 neuroprotection NN I-NP O
39 237 238 17600377 , , O O
40 239 241 17600377 we PRP B-NP O
41 242 247 17600377 newly RB B-ADVP O
42 248 259 17600377 synthesized VBD B-VP O
43 260 268 17600377 maltolyl NN B-NP B-Chemical
44 269 270 17600377 p NN I-NP I-Chemical
45 270 271 17600377 - HYPH B-NP I-Chemical
46 271 280 17600377 coumarate NN I-NP I-Chemical
47 281 283 17600377 by IN B-PP O
48 284 287 17600377 the DT B-NP O
49 288 302 17600377 esterification NN I-NP O
50 303 305 17600377 of IN B-PP O
51 306 312 17600377 maltol NN B-NP B-Chemical
52 313 316 17600377 and CC I-NP O
53 317 318 17600377 p NN I-NP B-Chemical
54 318 319 17600377 - HYPH B-NP I-Chemical
55 319 327 17600377 coumaric JJ I-NP I-Chemical
56 328 332 17600377 acid NN I-NP I-Chemical
57 332 333 17600377 . . O O

1 334 336 17600377 In IN B-PP O
2 337 340 17600377 the DT B-NP O
3 341 348 17600377 present JJ I-NP O
4 349 354 17600377 study NN I-NP O
5 354 355 17600377 , , O O
6 356 358 17600377 we PRP B-NP O
7 359 371 17600377 investigated VBD B-VP O
8 372 379 17600377 whether IN B-SBAR O
9 380 388 17600377 maltolyl NN B-NP B-Chemical
10 389 390 17600377 p NN I-NP I-Chemical
11 390 391 17600377 - HYPH B-NP I-Chemical
12 391 400 17600377 coumarate NN I-NP I-Chemical
13 401 406 17600377 could MD B-VP O
14 407 414 17600377 improve VB I-VP O
15 415 424 17600377 cognitive JJ B-NP B-Disease
16 425 432 17600377 decline NN I-NP I-Disease
17 433 435 17600377 in IN B-PP O
18 436 447 17600377 scopolamine NN B-NP B-Chemical
19 447 448 17600377 - HYPH B-NP O
20 448 456 17600377 injected VBN I-NP O
21 457 461 17600377 rats NNS I-NP O
22 462 465 17600377 and CC B-PP O
23 466 468 17600377 in IN B-PP O
24 469 476 17600377 amyloid JJ B-NP B-Chemical
25 477 481 17600377 beta SYM I-NP I-Chemical
26 482 491 17600377 peptide(1 NN I-NP I-Chemical
27 491 492 17600377 - HYPH B-NP I-Chemical
28 492 495 17600377 42) NN I-NP I-Chemical
29 495 496 17600377 - HYPH B-NP O
30 496 503 17600377 infused VBN I-NP O
31 504 508 17600377 rats NNS I-NP O
32 508 509 17600377 . . O O

1 510 518 17600377 Maltolyl JJ B-NP B-Chemical
2 519 520 17600377 p NN I-NP I-Chemical
3 520 521 17600377 - HYPH O I-Chemical
4 521 530 17600377 coumarate NN B-NP I-Chemical
5 531 534 17600377 was VBD B-VP O
6 535 540 17600377 found VBN I-VP O
7 541 543 17600377 to TO I-VP O
8 544 553 17600377 attenuate VB I-VP O
9 554 563 17600377 cognitive JJ B-NP B-Disease
10 564 572 17600377 deficits NNS I-NP I-Disease
11 573 575 17600377 in IN B-PP O
12 576 580 17600377 both DT B-NP O
13 581 584 17600377 rat NN I-NP O
14 585 591 17600377 models NNS I-NP O
15 592 597 17600377 using VBG B-VP O
16 598 605 17600377 passive JJ B-NP O
17 606 615 17600377 avoidance NN I-NP O
18 616 620 17600377 test NN I-NP O
19 621 624 17600377 and CC O O
20 625 627 17600377 to TO B-VP O
21 628 634 17600377 reduce VB I-VP O
22 635 644 17600377 apoptotic JJ B-NP O
23 645 649 17600377 cell NN I-NP O
24 650 655 17600377 death NN I-NP O
25 656 664 17600377 observed VBN B-VP O
26 665 667 17600377 in IN B-PP O
27 668 671 17600377 the DT B-NP O
28 672 683 17600377 hippocampus NN I-NP O
29 684 686 17600377 of IN B-PP O
30 687 690 17600377 the DT B-NP O
31 691 698 17600377 amyloid NN I-NP B-Chemical
32 699 703 17600377 beta SYM B-NP I-Chemical
33 704 713 17600377 peptide(1 NN I-NP I-Chemical
34 713 714 17600377 - HYPH B-NP I-Chemical
35 714 717 17600377 42) NN I-NP I-Chemical
36 717 718 17600377 - HYPH B-NP O
37 718 725 17600377 infused VBN I-NP O
38 726 730 17600377 rats NNS I-NP O
39 730 731 17600377 . . O O

1 732 734 17600377 We PRP B-NP O
2 735 739 17600377 also RB B-ADVP O
3 740 748 17600377 examined VBD B-VP O
4 749 752 17600377 the DT B-NP O
5 753 768 17600377 neuroprotective JJ I-NP O
6 769 776 17600377 effects NNS I-NP O
7 777 779 17600377 of IN B-PP O
8 780 788 17600377 maltolyl NN B-NP B-Chemical
9 789 790 17600377 p NN I-NP I-Chemical
10 790 791 17600377 - HYPH B-NP I-Chemical
11 791 800 17600377 coumarate NN I-NP I-Chemical
12 801 803 17600377 in FW B-ADVP O
13 804 809 17600377 vitro FW I-ADVP O
14 810 815 17600377 using VBG B-VP O
15 816 818 17600377 SH NN B-NP O
16 818 819 17600377 - HYPH I-NP O
17 819 823 17600377 SY5Y NN I-NP O
18 824 829 17600377 cells NNS I-NP O
19 829 830 17600377 . . O O

1 831 836 17600377 Cells NNS B-NP O
2 837 841 17600377 were VBD B-VP O
3 842 852 17600377 pretreated VBN I-VP O
4 853 857 17600377 with IN B-PP O
5 858 866 17600377 maltolyl NN B-NP B-Chemical
6 867 868 17600377 p NN I-NP I-Chemical
7 868 869 17600377 - HYPH B-NP I-Chemical
8 869 878 17600377 coumarate NN I-NP I-Chemical
9 878 879 17600377 , , O O
10 880 886 17600377 before IN B-SBAR O
11 887 894 17600377 exposed VBN B-VP O
12 895 897 17600377 to TO B-PP O
13 898 905 17600377 amyloid NN B-NP B-Chemical
14 906 910 17600377 beta SYM B-NP I-Chemical
15 911 920 17600377 peptide(1 NN I-NP I-Chemical
16 920 921 17600377 - HYPH B-NP I-Chemical
17 921 924 17600377 42) NN I-NP I-Chemical
18 924 925 17600377 , , I-NP O
19 926 935 17600377 glutamate NN I-NP B-Chemical
20 936 938 17600377 or CC I-NP O
21 939 943 17600377 H2O2 NN I-NP B-Chemical
22 943 944 17600377 . . O O

1 945 947 17600377 We PRP B-NP O
2 948 953 17600377 found VBD B-VP O
3 954 958 17600377 that IN B-SBAR O
4 959 967 17600377 maltolyl NN B-NP B-Chemical
5 968 969 17600377 p NN I-NP I-Chemical
6 969 970 17600377 - HYPH O I-Chemical
7 970 979 17600377 coumarate NN B-NP I-Chemical
8 980 993 17600377 significantly RB B-ADVP O
9 994 1003 17600377 decreased VBD B-VP O
10 1004 1013 17600377 apoptotic JJ B-NP O
11 1014 1018 17600377 cell NN I-NP O
12 1019 1024 17600377 death NN I-NP O
13 1025 1028 17600377 and CC O O
14 1029 1036 17600377 reduced VBN B-NP O
15 1037 1045 17600377 reactive JJ I-NP O
16 1046 1052 17600377 oxygen NN I-NP O
17 1053 1060 17600377 species NNS I-NP O
18 1060 1061 17600377 , , O O
19 1062 1072 17600377 cytochrome NN B-NP O
20 1073 1074 17600377 c NN I-NP O
21 1075 1082 17600377 release NN I-NP O
22 1082 1083 17600377 , , O O
23 1084 1087 17600377 and CC O O
24 1088 1095 17600377 caspase NN B-NP O
25 1096 1097 17600377 3 CD I-NP O
26 1098 1108 17600377 activation NN I-NP O
27 1108 1109 17600377 . . O O

1 1110 1116 17600377 Taking VBG B-VP O
2 1117 1122 17600377 these DT B-NP O
3 1123 1125 17600377 in FW I-NP O
4 1126 1131 17600377 vitro FW I-NP O
5 1132 1135 17600377 and CC O O
6 1136 1138 17600377 in FW B-NP O
7 1139 1143 17600377 vivo FW I-NP O
8 1144 1151 17600377 results NNS I-NP O
9 1152 1160 17600377 together RB B-ADVP O
10 1160 1161 17600377 , , O O
11 1162 1165 17600377 our PRP$ B-NP O
12 1166 1171 17600377 study NN I-NP O
13 1172 1180 17600377 suggests VBZ B-VP O
14 1181 1185 17600377 that IN B-SBAR O
15 1186 1194 17600377 maltolyl NN B-NP B-Chemical
16 1195 1196 17600377 p NN I-NP I-Chemical
17 1196 1197 17600377 - HYPH B-NP I-Chemical
18 1197 1206 17600377 coumarate NN I-NP I-Chemical
19 1207 1209 17600377 is VBZ B-VP O
20 1210 1211 17600377 a DT B-NP O
21 1212 1223 17600377 potentially RB I-NP O
22 1224 1233 17600377 effective JJ I-NP O
23 1234 1243 17600377 candidate NN I-NP O
24 1244 1251 17600377 against IN B-PP O
25 1252 1263 17600377 Alzheimer's NNP B-NP B-Disease
26 1264 1271 17600377 disease NN I-NP I-Disease
27 1272 1276 17600377 that WDT B-NP O
28 1277 1279 17600377 is VBZ B-VP O
29 1280 1293 17600377 characterized VBN I-VP O
30 1294 1296 17600377 by IN B-PP O
31 1297 1301 17600377 wide JJ B-NP O
32 1302 1308 17600377 spread NN I-NP O
33 1309 1317 17600377 neuronal JJ I-NP B-Disease
34 1318 1323 17600377 death NN I-NP I-Disease
35 1324 1327 17600377 and CC O O
36 1328 1339 17600377 progressive JJ B-NP O
37 1340 1347 17600377 decline NN I-NP B-Disease
38 1348 1350 17600377 of IN B-PP I-Disease
39 1351 1360 17600377 cognitive JJ B-NP I-Disease
40 1361 1369 17600377 function NN I-NP I-Disease
41 1369 1370 17600377 . . O O

1 0 0 603022 -DOCSTART- -X- -X- O

1 0 12 603022 Galanthamine NN B-NP B-Chemical
2 13 25 603022 hydrobromide NN I-NP I-Chemical
3 25 26 603022 , , O O
4 27 28 603022 a DT B-NP O
5 29 35 603022 longer RBR I-NP O
6 36 42 603022 acting VBG I-NP O
7 43 61 603022 anticholinesterase NN I-NP O
8 62 66 603022 drug NN I-NP O
9 66 67 603022 , , O O
10 68 70 603022 in IN B-PP O
11 71 74 603022 the DT B-NP O
12 75 84 603022 treatment NN I-NP O
13 85 87 603022 of IN B-PP O
14 88 91 603022 the DT B-NP O
15 92 99 603022 central JJ I-NP O
16 100 107 603022 effects NNS I-NP O
17 108 110 603022 of IN B-PP O
18 111 122 603022 scopolamine NN B-NP B-Chemical
19 123 124 603022 ( ( O O
20 124 132 603022 Hyoscine NN B-NP B-Chemical
21 132 133 603022 ) ) O O
22 133 134 603022 . . O O
23 135 147 603022 Galanthamine NN B-NP B-Chemical
24 148 160 603022 hydrobromide NN I-NP I-Chemical
25 160 161 603022 , , O O
26 162 164 603022 an DT B-NP O
27 165 183 603022 anticholinesterase NN I-NP O
28 184 188 603022 drug NN I-NP O
29 189 196 603022 capable JJ B-ADJP O
30 197 199 603022 of IN B-PP O
31 200 211 603022 penetrating VBG B-VP O
32 212 215 603022 the DT B-NP O
33 216 221 603022 blood NN I-NP O
34 221 222 603022 - HYPH I-NP O
35 222 227 603022 brain NN I-NP O
36 228 235 603022 barrier NN I-NP O
37 235 236 603022 , , O O
38 237 240 603022 was VBD B-VP O
39 241 245 603022 used VBN I-VP O
40 246 248 603022 in IN B-PP O
41 249 250 603022 a DT B-NP O
42 251 258 603022 patient NN I-NP O
43 259 272 603022 demonstrating VBG B-VP O
44 273 280 603022 central JJ B-NP O
45 281 288 603022 effects NNS I-NP O
46 289 291 603022 of IN B-PP O
47 292 303 603022 scopolamine NN B-NP B-Chemical
48 304 305 603022 ( ( O O
49 305 313 603022 hyoscine NN B-NP B-Chemical
50 313 314 603022 ) ) O O
51 315 325 603022 overdosage NN B-NP B-Disease
52 325 326 603022 . . O O

1 327 329 603022 It PRP B-NP O
2 330 332 603022 is VBZ B-VP O
3 333 339 603022 longer RB I-VP O
4 340 346 603022 acting VBG I-VP O
5 347 351 603022 than IN B-PP O
6 352 365 603022 physostigmine NN B-NP B-Chemical
7 366 369 603022 and CC O O
8 370 372 603022 is VBZ B-VP O
9 373 377 603022 used VBN I-VP O
10 378 380 603022 in IN B-PP O
11 381 392 603022 anaesthesia NN B-NP O
12 393 395 603022 to TO B-VP O
13 396 403 603022 reverse VB I-VP O
14 404 407 603022 the DT B-NP O
15 408 411 603022 non AFX I-NP O
16 411 412 603022 - HYPH I-NP O
17 412 424 603022 depolarizing VBG B-VP O
18 425 438 603022 neuromuscular JJ B-NP O
19 439 444 603022 block NN I-NP O
20 444 445 603022 . . O O

1 446 453 603022 However RB B-ADVP O
2 453 454 603022 , , O O
3 455 462 603022 studies NNS B-NP O
4 463 467 603022 into IN B-PP O
5 468 471 603022 the DT B-NP O
6 472 476 603022 dose NN I-NP O
7 477 486 603022 necessary JJ B-ADJP O
8 487 489 603022 to TO B-PP O
9 490 499 603022 combating VBG B-VP O
10 500 511 603022 scopolamine NN B-NP B-Chemical
11 512 524 603022 intoxication NN I-NP O
12 525 528 603022 are VBP B-VP O
13 529 538 603022 indicated VBN I-VP O
14 538 539 603022 . . O O

1 0 0 16330293 -DOCSTART- -X- -X- O

1 0 6 16330293 Safety NN B-NP O
2 7 14 16330293 profile NN I-NP O
3 15 17 16330293 of IN B-PP O
4 18 19 16330293 a DT B-NP O
5 20 28 16330293 nicotine NN I-NP B-Chemical
6 29 36 16330293 lozenge NN I-NP O
7 37 45 16330293 compared VBN B-VP O
8 46 50 16330293 with IN B-PP O
9 51 55 16330293 that DT B-NP O
10 56 58 16330293 of IN B-PP O
11 59 67 16330293 nicotine NN B-NP B-Chemical
12 68 71 16330293 gum NN I-NP O
13 72 74 16330293 in IN B-PP O
14 75 80 16330293 adult JJ B-NP O
15 81 88 16330293 smokers NNS I-NP O
16 89 93 16330293 with IN B-PP O
17 94 104 16330293 underlying VBG B-VP O
18 105 112 16330293 medical JJ B-NP O
19 113 123 16330293 conditions NNS I-NP O
20 123 124 16330293 : : O O
21 125 126 16330293 a DT B-NP O
22 127 129 16330293 12 CD I-NP O
23 129 130 16330293 - HYPH I-NP O
24 130 134 16330293 week NN I-NP O
25 134 135 16330293 , , O O
26 136 146 16330293 randomized VBN B-NP O
27 146 147 16330293 , , I-NP O
28 148 152 16330293 open JJ I-NP O
29 152 153 16330293 - HYPH I-NP O
30 153 158 16330293 label NN I-NP O
31 159 164 16330293 study NN I-NP O
32 164 165 16330293 . . I-NP O
33 166 176 16330293 BACKGROUND NN I-NP O
34 176 177 16330293 : : O O
35 178 186 16330293 Nicotine NN B-NP B-Chemical
36 187 197 16330293 polacrilex NN I-NP O
37 198 206 16330293 lozenges VBZ B-VP O
38 207 214 16330293 deliver VB I-VP O
39 215 218 16330293 25% CD B-NP O
40 219 221 16330293 to TO I-NP O
41 222 225 16330293 27% CD I-NP O
42 226 230 16330293 more JJR I-NP O
43 231 239 16330293 nicotine NN I-NP B-Chemical
44 240 248 16330293 compared VBN B-PP O
45 249 253 16330293 with IN B-PP O
46 254 264 16330293 equivalent JJ B-NP O
47 265 270 16330293 doses NNS I-NP O
48 271 273 16330293 of IN B-PP O
49 274 282 16330293 nicotine NN B-NP B-Chemical
50 283 293 16330293 polacrilex NN I-NP O
51 294 297 16330293 gum NN I-NP O
52 297 298 16330293 . . O O

1 299 302 16330293 The DT B-NP O
2 303 312 16330293 increased VBN I-NP O
3 313 321 16330293 nicotine NN I-NP B-Chemical
4 322 330 16330293 exposure NN I-NP O
5 331 335 16330293 from IN B-PP O
6 336 339 16330293 the DT B-NP O
7 340 347 16330293 lozenge NN I-NP O
8 348 351 16330293 has VBZ B-VP O
9 352 358 16330293 raised VBN I-VP O
10 359 368 16330293 questions NNS B-NP O
11 369 374 16330293 about IN B-PP O
12 375 378 16330293 the DT B-NP O
13 379 387 16330293 relative JJ I-NP O
14 388 394 16330293 safety NN I-NP O
15 395 397 16330293 of IN B-PP O
16 398 401 16330293 the DT B-NP O
17 402 409 16330293 lozenge NN I-NP O
18 410 413 16330293 and CC I-NP O
19 414 417 16330293 gum NN I-NP O
20 417 418 16330293 . . O O

1 419 428 16330293 OBJECTIVE NN B-NP O
2 428 429 16330293 : : O O
3 430 433 16330293 The DT B-NP O
4 434 443 16330293 objective NN I-NP O
5 444 446 16330293 of IN B-PP O
6 447 451 16330293 this DT B-NP O
7 452 457 16330293 study NN I-NP O
8 458 461 16330293 was VBD B-VP O
9 462 464 16330293 to TO B-VP O
10 465 472 16330293 compare VB I-VP O
11 473 476 16330293 the DT B-NP O
12 477 483 16330293 safety NN I-NP O
13 484 492 16330293 profiles NNS I-NP O
14 493 495 16330293 of IN B-PP O
15 496 499 16330293 the DT B-NP O
16 500 501 16330293 4 CD I-NP O
17 501 502 16330293 - HYPH I-NP O
18 502 504 16330293 mg NN I-NP O
19 505 513 16330293 nicotine NN I-NP B-Chemical
20 514 521 16330293 lozenge NN I-NP O
21 522 525 16330293 and CC O O
22 526 527 16330293 4 CD B-NP O
23 527 528 16330293 - HYPH I-NP O
24 528 530 16330293 mg NN I-NP O
25 531 539 16330293 nicotine NN I-NP B-Chemical
26 540 543 16330293 gum NN I-NP O
27 544 546 16330293 in IN B-PP O
28 547 554 16330293 smokers NNS B-NP O
29 555 559 16330293 with IN B-PP O
30 560 568 16330293 selected VBN B-NP O
31 569 574 16330293 label NN I-NP O
32 574 575 16330293 - HYPH B-NP O
33 575 585 16330293 restricted VBN I-NP O
34 586 594 16330293 diseases NNS I-NP O
35 594 595 16330293 . . O O

1 596 603 16330293 METHODS NNS B-NP O
2 603 604 16330293 : : O O
3 605 609 16330293 This DT B-NP O
4 610 613 16330293 was VBD B-VP O
5 614 615 16330293 a DT B-NP O
6 616 627 16330293 multicenter NN I-NP O
7 627 628 16330293 , , O O
8 629 639 16330293 randomized VBN B-NP O
9 639 640 16330293 , , I-NP O
10 641 645 16330293 open JJ I-NP O
11 645 646 16330293 - HYPH I-NP O
12 646 651 16330293 label NN I-NP O
13 652 657 16330293 study NN I-NP O
14 658 660 16330293 in IN B-PP O
15 661 666 16330293 adult JJ B-NP O
16 667 674 16330293 smokers NNS I-NP O
17 675 679 16330293 with IN B-PP O
18 680 685 16330293 heart NN B-NP B-Disease
19 686 693 16330293 disease NN I-NP I-Disease
20 693 694 16330293 , , O O
21 695 707 16330293 hypertension NN B-NP B-Disease
22 708 711 16330293 not RB B-VP O
23 712 722 16330293 controlled VBN I-VP O
24 723 725 16330293 by IN B-PP O
25 726 736 16330293 medication NN B-NP O
26 736 737 16330293 , , O O
27 738 741 16330293 and CC O O
28 741 742 16330293 / SYM B-NP O
29 742 744 16330293 or CC O O
30 745 753 16330293 diabetes NN B-NP B-Disease
31 754 762 16330293 mellitus NN I-NP I-Disease
32 762 763 16330293 . . O O

1 764 772 16330293 Patients NNS B-NP O
2 773 777 16330293 were VBD B-VP O
3 778 788 16330293 randomized VBN I-VP O
4 789 791 16330293 in IN B-PP O
5 792 793 16330293 a DT B-NP O
6 794 795 16330293 1 CD I-NP O
7 795 796 16330293 : SYM I-NP O
8 796 797 16330293 1 CD I-NP O
9 798 803 16330293 ratio NN I-NP O
10 804 806 16330293 to TO B-VP O
11 807 814 16330293 receive VB I-VP O
12 815 818 16330293 the DT B-NP O
13 819 820 16330293 4 CD I-NP O
14 820 821 16330293 - HYPH I-NP O
15 821 823 16330293 mg NN I-NP O
16 824 832 16330293 nicotine NN I-NP B-Chemical
17 833 840 16330293 lozenge NN I-NP O
18 841 843 16330293 or CC O O
19 844 845 16330293 4 CD B-NP O
20 845 846 16330293 - HYPH I-NP O
21 846 848 16330293 mg NN I-NP O
22 849 857 16330293 nicotine NN I-NP B-Chemical
23 858 861 16330293 gum NN I-NP O
24 861 862 16330293 . . O O

1 863 869 16330293 Safety NN B-NP O
2 870 881 16330293 assessments NNS I-NP O
3 882 886 16330293 were VBD B-VP O
4 887 891 16330293 made VBN I-VP O
5 892 894 16330293 at IN B-PP O
6 895 903 16330293 baseline NN B-NP O
7 904 907 16330293 and CC O O
8 908 910 16330293 at IN B-PP O
9 911 912 16330293 2 CD B-NP O
10 912 913 16330293 , , I-NP O
11 914 915 16330293 4 CD I-NP O
12 915 916 16330293 , , I-NP O
13 917 918 16330293 6 CD I-NP O
14 918 919 16330293 , , O O
15 920 923 16330293 and CC O O
16 924 926 16330293 12 CD B-NP O
17 927 932 16330293 weeks NNS I-NP O
18 933 938 16330293 after IN B-PP O
19 939 942 16330293 the DT B-NP O
20 943 948 16330293 start NN I-NP O
21 949 951 16330293 of IN B-PP O
22 952 959 16330293 product NN B-NP O
23 960 963 16330293 use NN I-NP O
24 963 964 16330293 . . O O

1 965 972 16330293 RESULTS NNS B-NP O
2 972 973 16330293 : : O O
3 974 978 16330293 Nine CD B-NP O
4 979 986 16330293 hundred CD I-NP O
5 987 990 16330293 one CD B-NP O
6 991 999 16330293 patients NNS I-NP O
7 1000 1004 16330293 were VBD B-VP O
8 1005 1015 16330293 randomized VBN I-VP O
9 1016 1018 16330293 to TO B-PP O
10 1019 1028 16330293 treatment NN B-NP O
11 1028 1029 16330293 , , O O
12 1030 1033 16330293 447 CD B-NP O
13 1034 1037 16330293 who WP B-NP O
14 1038 1046 16330293 received VBD B-VP O
15 1047 1050 16330293 the DT B-NP O
16 1051 1058 16330293 lozenge NN I-NP O
17 1059 1062 16330293 and CC O O
18 1063 1066 16330293 454 CD B-NP O
19 1067 1070 16330293 who WP B-NP O
20 1071 1079 16330293 received VBD B-VP O
21 1080 1083 16330293 the DT B-NP O
22 1084 1087 16330293 gum NN I-NP O
23 1088 1089 16330293 ( ( O O
24 1089 1095 16330293 safety NN B-NP O
25 1096 1106 16330293 population NN I-NP O
26 1106 1107 16330293 ) ) O O
27 1107 1108 16330293 . . O O

1 1109 1112 16330293 The DT B-NP O
2 1113 1121 16330293 majority NN I-NP O
3 1122 1126 16330293 were VBD B-VP O
4 1127 1132 16330293 women NNS B-NP O
5 1133 1134 16330293 ( ( O O
6 1134 1139 16330293 52.7% CD B-NP O
7 1139 1140 16330293 ) ) O O
8 1140 1141 16330293 . . O O

1 1142 1151 16330293 Patients' NN B-NP O
2 1152 1156 16330293 mean JJ I-NP O
3 1157 1160 16330293 age NN I-NP O
4 1161 1164 16330293 was VBD B-VP O
5 1165 1169 16330293 53.9 CD B-NP O
6 1170 1175 16330293 years NNS I-NP O
7 1175 1176 16330293 , , O O
8 1177 1182 16330293 their PRP$ B-NP O
9 1183 1187 16330293 mean JJ I-NP O
10 1188 1194 16330293 weight NN I-NP O
11 1195 1198 16330293 was VBD B-VP O
12 1199 1204 16330293 193.9 CD B-NP O
13 1205 1211 16330293 pounds NNS I-NP O
14 1211 1212 16330293 , , O O
15 1213 1216 16330293 and CC O O
16 1217 1221 16330293 they PRP B-NP O
17 1222 1228 16330293 smoked VBD B-VP O
18 1229 1230 16330293 a DT B-NP O
19 1231 1235 16330293 mean NN I-NP O
20 1236 1238 16330293 of IN B-PP O
21 1239 1243 16330293 25.2 CD B-NP O
22 1244 1254 16330293 cigarettes NNS I-NP O
23 1255 1258 16330293 per IN B-PP O
24 1259 1262 16330293 day NN B-NP O
25 1263 1265 16330293 at IN B-PP O
26 1266 1274 16330293 baseline NN B-NP O
27 1274 1275 16330293 . . O O

1 1276 1280 16330293 Five CD B-NP O
2 1281 1288 16330293 hundred CD I-NP O
3 1289 1294 16330293 fifty CD I-NP O
4 1294 1295 16330293 - HYPH O O
5 1295 1300 16330293 three CD B-NP O
6 1301 1309 16330293 patients NNS I-NP O
7 1309 1310 16330293 , , O O
8 1311 1314 16330293 264 CD B-NP O
9 1315 1321 16330293 taking VBG B-VP O
10 1322 1325 16330293 the DT B-NP O
11 1326 1333 16330293 lozenge NN I-NP O
12 1334 1337 16330293 and CC O O
13 1338 1341 16330293 289 CD B-NP O
14 1342 1348 16330293 taking VBG B-VP O
15 1349 1352 16330293 the DT B-NP O
16 1353 1356 16330293 gum NN I-NP O
17 1356 1357 16330293 , , O O
18 1358 1362 16330293 used VBD B-VP O
19 1363 1366 16330293 the DT B-NP O
20 1367 1372 16330293 study NN I-NP O
21 1373 1380 16330293 product NN I-NP O
22 1381 1384 16330293 for IN B-PP O
23 1385 1386 16330293 > SYM B-NP O
24 1387 1389 16330293 or CC O O
25 1390 1391 16330293 = SYM B-VP O
26 1391 1392 16330293 4 CD B-NP O
27 1393 1397 16330293 days NNS I-NP O
28 1398 1401 16330293 per IN B-PP O
29 1402 1406 16330293 week NN B-NP O
30 1407 1413 16330293 during IN B-PP O
31 1414 1417 16330293 the DT B-NP O
32 1418 1423 16330293 first JJ I-NP O
33 1424 1425 16330293 2 CD I-NP O
34 1426 1431 16330293 weeks NNS I-NP O
35 1432 1433 16330293 ( ( O O
36 1433 1442 16330293 evaluable JJ B-NP O
37 1443 1453 16330293 population NN I-NP O
38 1453 1454 16330293 ) ) O O
39 1454 1455 16330293 . . O O

1 1456 1459 16330293 The DT B-NP O
2 1460 1468 16330293 nicotine NN I-NP B-Chemical
3 1469 1476 16330293 lozenge NN I-NP O
4 1477 1480 16330293 and CC O O
5 1481 1489 16330293 nicotine NN B-NP B-Chemical
6 1490 1493 16330293 gum NN I-NP O
7 1494 1498 16330293 were VBD B-VP O
8 1499 1506 16330293 equally RB I-VP O
9 1507 1511 16330293 well RB I-VP O
10 1512 1521 16330293 tolerated VBN I-VP O
11 1521 1522 16330293 , , O O
12 1523 1530 16330293 despite IN B-PP O
13 1531 1540 16330293 increased VBN B-NP O
14 1541 1549 16330293 nicotine NN I-NP B-Chemical
15 1550 1558 16330293 exposure NN I-NP O
16 1559 1563 16330293 from IN B-PP O
17 1564 1567 16330293 the DT B-NP O
18 1568 1575 16330293 lozenge NN I-NP O
19 1575 1576 16330293 . . O O

1 1577 1580 16330293 The DT B-NP O
2 1581 1590 16330293 incidence NN I-NP O
3 1591 1593 16330293 of IN B-PP O
4 1594 1601 16330293 adverse JJ B-NP O
5 1602 1608 16330293 events NNS I-NP O
6 1609 1611 16330293 in IN B-PP O
7 1612 1615 16330293 the DT B-NP O
8 1616 1617 16330293 2 CD I-NP O
9 1618 1624 16330293 groups NNS I-NP O
10 1625 1628 16330293 was VBD B-VP O
11 1629 1636 16330293 similar JJ B-ADJP O
12 1637 1643 16330293 during IN B-PP O
13 1644 1647 16330293 the DT B-NP O
14 1648 1653 16330293 first JJ I-NP O
15 1654 1655 16330293 2 CD I-NP O
16 1656 1661 16330293 weeks NNS I-NP O
17 1662 1664 16330293 of IN B-PP O
18 1665 1672 16330293 product NN B-NP O
19 1673 1676 16330293 use NN I-NP O
20 1677 1678 16330293 ( ( O O
21 1678 1688 16330293 evaluation NN B-NP O
22 1689 1699 16330293 population NN I-NP O
23 1699 1700 16330293 : : O O
24 1701 1706 16330293 55.3% CD B-NP O
25 1707 1714 16330293 lozenge NN I-NP O
26 1714 1715 16330293 , , O O
27 1716 1721 16330293 54.7% NN B-NP O
28 1722 1725 16330293 gum NN I-NP O
29 1725 1726 16330293 ) ) O O
30 1726 1727 16330293 , , O O
31 1728 1730 16330293 as RB B-CONJP O
32 1731 1735 16330293 well RB I-CONJP O
33 1736 1738 16330293 as IN I-CONJP O
34 1739 1745 16330293 during IN B-PP O
35 1746 1749 16330293 the DT B-NP O
36 1750 1756 16330293 entire JJ I-NP O
37 1757 1762 16330293 study NN I-NP O
38 1763 1764 16330293 ( ( O O
39 1764 1770 16330293 safety NN B-NP O
40 1771 1781 16330293 population NN I-NP O
41 1781 1782 16330293 : : O O
42 1783 1788 16330293 63.8% CD B-NP O
43 1789 1792 16330293 and CC I-NP O
44 1793 1798 16330293 58.6% CD I-NP O
45 1798 1799 16330293 , , O O
46 1800 1812 16330293 respectively RB B-ADVP O
47 1812 1813 16330293 ) ) O O
48 1813 1814 16330293 . . O O

1 1815 1829 16330293 Stratification NN B-NP O
2 1830 1832 16330293 of IN B-PP O
3 1833 1841 16330293 patients NNS B-NP O
4 1842 1844 16330293 by IN B-PP O
5 1845 1848 16330293 sex NN B-NP O
6 1848 1849 16330293 , , O O
7 1850 1853 16330293 age NN B-NP O
8 1853 1854 16330293 , , O O
9 1855 1861 16330293 extent NN B-NP O
10 1862 1864 16330293 of IN B-PP O
11 1865 1875 16330293 concurrent JJ B-NP O
12 1876 1883 16330293 smoking NN I-NP O
13 1883 1884 16330293 , , O O
14 1885 1891 16330293 extent NN B-NP O
15 1892 1894 16330293 of IN B-PP O
16 1895 1902 16330293 product NN B-NP O
17 1903 1906 16330293 use NN I-NP O
18 1906 1907 16330293 , , O O
19 1908 1911 16330293 and CC O O
20 1912 1920 16330293 severity NN B-NP O
21 1921 1923 16330293 of IN B-PP O
22 1924 1931 16330293 adverse JJ B-NP O
23 1932 1938 16330293 events NNS I-NP O
24 1939 1947 16330293 revealed VBD B-VP O
25 1948 1950 16330293 no DT B-NP O
26 1951 1961 16330293 clinically RB I-NP O
27 1962 1973 16330293 significant JJ I-NP O
28 1974 1985 16330293 differences NNS I-NP O
29 1986 1993 16330293 between IN B-PP O
30 1994 1997 16330293 the DT B-NP O
31 1998 2005 16330293 lozenge NN I-NP O
32 2006 2009 16330293 and CC I-NP O
33 2010 2013 16330293 gum NN I-NP O
34 2013 2014 16330293 . . O O

1 2015 2018 16330293 The DT B-NP O
2 2019 2023 16330293 most RBS I-NP O
3 2024 2030 16330293 common JJ I-NP O
4 2031 2038 16330293 adverse JJ I-NP O
5 2039 2045 16330293 events NNS I-NP O
6 2046 2050 16330293 were VBD B-VP O
7 2051 2057 16330293 nausea NN B-NP B-Disease
8 2058 2059 16330293 ( ( O O
9 2059 2064 16330293 17.2% CD B-NP O
10 2065 2068 16330293 and CC I-NP O
11 2069 2074 16330293 16.1% CD I-NP O
12 2074 2075 16330293 ; : O O
13 2076 2079 16330293 95% CD B-NP O
14 2080 2082 16330293 CI NN I-NP O
15 2082 2083 16330293 , , O O
16 2084 2085 16330293 - SYM O O
17 2085 2088 16330293 3.7 CD B-NP O
18 2089 2091 16330293 to TO B-PP O
19 2092 2095 16330293 6.0 CD B-NP O
20 2095 2096 16330293 ) ) O O
21 2096 2097 16330293 , , O O
22 2098 2105 16330293 hiccups NNS B-NP B-Disease
23 2106 2107 16330293 ( ( O O
24 2107 2112 16330293 10.7% CD B-NP O
25 2113 2116 16330293 and CC I-NP O
26 2117 2121 16330293 6.6% CD I-NP O
27 2121 2122 16330293 ; : O O
28 2123 2126 16330293 95% CD B-NP O
29 2127 2129 16330293 CI NN I-NP O
30 2129 2130 16330293 , , O O
31 2131 2134 16330293 0.5 CD B-NP O
32 2135 2137 16330293 to TO B-PP O
33 2138 2141 16330293 7.8 CD B-NP O
34 2141 2142 16330293 ) ) O O
35 2142 2143 16330293 , , O O
36 2144 2147 16330293 and CC O O
37 2148 2156 16330293 headache NN B-NP B-Disease
38 2157 2158 16330293 ( ( O O
39 2158 2162 16330293 8.7% CD B-NP O
40 2163 2166 16330293 and CC I-NP O
41 2167 2171 16330293 9.9% CD I-NP O
42 2171 2172 16330293 ; : O O
43 2173 2176 16330293 95% CD B-NP O
44 2177 2179 16330293 Cl NN I-NP O
45 2179 2180 16330293 , , O O
46 2181 2182 16330293 - SYM O O
47 2182 2185 16330293 5.0 CD B-NP O
48 2186 2188 16330293 to TO B-PP O
49 2189 2192 16330293 2.6 CD B-NP O
50 2192 2193 16330293 ) ) O O
51 2193 2194 16330293 . . O O

1 2195 2202 16330293 Serious JJ B-NP O
2 2203 2210 16330293 adverse JJ I-NP O
3 2211 2217 16330293 events NNS I-NP O
4 2218 2222 16330293 were VBD B-VP O
5 2223 2231 16330293 reported VBN I-VP O
6 2232 2234 16330293 in IN B-PP O
7 2235 2237 16330293 11 CD B-NP O
8 2238 2241 16330293 and CC I-NP O
9 2242 2244 16330293 13 CD I-NP O
10 2245 2253 16330293 patients NNS I-NP O
11 2254 2256 16330293 in IN B-PP O
12 2257 2260 16330293 the DT B-NP O
13 2261 2271 16330293 respective JJ I-NP O
14 2272 2278 16330293 groups NNS I-NP O
15 2278 2279 16330293 . . O O

1 2280 2285 16330293 Fewer JJR B-ADJP O
2 2286 2290 16330293 than IN B-PP O
3 2291 2293 16330293 6% CD B-NP O
4 2294 2296 16330293 of IN B-PP O
5 2297 2305 16330293 patients NNS B-NP O
6 2306 2308 16330293 in IN B-PP O
7 2309 2315 16330293 either DT B-NP O
8 2316 2321 16330293 group NN I-NP O
9 2322 2326 16330293 were VBD B-VP O
10 2327 2337 16330293 considered VBN I-VP O
11 2338 2340 16330293 by IN B-PP O
12 2341 2344 16330293 the DT B-NP O
13 2345 2357 16330293 investigator NN I-NP O
14 2358 2360 16330293 to TO B-VP O
15 2361 2365 16330293 have VB I-VP O
16 2366 2367 16330293 a DT B-NP O
17 2368 2377 16330293 worsening NN I-NP O
18 2378 2380 16330293 of IN B-PP O
19 2381 2386 16330293 their PRP$ B-NP O
20 2387 2394 16330293 overall JJ I-NP O
21 2395 2402 16330293 disease NN I-NP O
22 2403 2412 16330293 condition NN I-NP O
23 2413 2419 16330293 during IN B-PP O
24 2420 2423 16330293 the DT B-NP O
25 2424 2429 16330293 study NN I-NP O
26 2429 2430 16330293 . . O O

1 2431 2434 16330293 The DT B-NP O
2 2435 2443 16330293 majority NN I-NP O
3 2444 2446 16330293 of IN B-PP O
4 2447 2455 16330293 patients NNS B-NP O
5 2456 2457 16330293 ( ( O O
6 2457 2458 16330293 > SYM B-NP O
7 2458 2461 16330293 60% CD I-NP O
8 2461 2462 16330293 ) ) O O
9 2463 2474 16330293 experienced VBD B-VP O
10 2475 2477 16330293 no DT B-NP O
11 2478 2484 16330293 change NN I-NP O
12 2485 2487 16330293 in IN B-PP O
13 2488 2493 16330293 their PRP$ B-NP O
14 2494 2501 16330293 disease NN I-NP O
15 2502 2508 16330293 status NN I-NP O
16 2509 2513 16330293 from IN B-PP O
17 2514 2522 16330293 baseline NN B-NP O
18 2522 2523 16330293 . . O O

1 2524 2534 16330293 CONCLUSION NN B-NP O
2 2534 2535 16330293 : : O O
3 2536 2539 16330293 The DT B-NP O
4 2540 2541 16330293 4 CD I-NP O
5 2541 2542 16330293 - HYPH I-NP O
6 2542 2544 16330293 mg NN I-NP O
7 2545 2553 16330293 nicotine NN I-NP B-Chemical
8 2554 2561 16330293 lozenge NN I-NP O
9 2562 2565 16330293 and CC O O
10 2566 2567 16330293 4 CD B-NP O
11 2567 2568 16330293 - HYPH I-NP O
12 2568 2570 16330293 mg NN I-NP O
13 2571 2579 16330293 nicotine NN I-NP B-Chemical
14 2580 2583 16330293 gum NN I-NP O
15 2584 2587 16330293 had VBD B-VP O
16 2588 2598 16330293 comparable JJ B-NP O
17 2599 2605 16330293 safety NN I-NP O
18 2606 2614 16330293 profiles NNS I-NP O
19 2615 2617 16330293 in IN B-PP O
20 2618 2623 16330293 these DT B-NP O
21 2624 2632 16330293 patients NNS I-NP O
22 2633 2637 16330293 with IN B-PP O
23 2638 2643 16330293 label NN B-NP O
24 2643 2644 16330293 - HYPH O O
25 2644 2654 16330293 restricted VBN B-NP O
26 2655 2662 16330293 medical JJ I-NP O
27 2663 2673 16330293 conditions NNS I-NP O
28 2673 2674 16330293 . . O O

1 0 0 88336 -DOCSTART- -X- -X- O

1 0 5 88336 Alpha NN B-NP O
2 6 9 88336 and CC I-NP O
3 10 14 88336 beta NN I-NP O
4 15 19 88336 coma NN I-NP B-Disease
5 20 22 88336 in IN B-PP O
6 23 27 88336 drug NN B-NP O
7 28 40 88336 intoxication NN I-NP O
8 41 54 88336 uncomplicated VBN B-VP O
9 55 57 88336 by IN B-PP O
10 58 66 88336 cerebral JJ B-NP B-Disease
11 67 74 88336 hypoxia NN I-NP I-Disease
12 74 75 88336 . . O O
13 76 80 88336 Four CD B-NP O
14 81 89 88336 patients NNS I-NP O
15 90 93 88336 who WP B-NP O
16 94 98 88336 were VBD B-VP O
17 99 107 88336 rendered VBN I-VP O
18 108 116 88336 comatose NN B-NP B-Disease
19 117 119 88336 or CC O O
20 120 129 88336 stuporous JJ B-ADJP B-Disease
21 130 132 88336 by IN B-PP O
22 133 137 88336 drug NN B-NP O
23 138 150 88336 intoxication NN I-NP O
24 150 151 88336 , , O O
25 152 155 88336 but CC O O
26 156 159 88336 who WP B-NP O
27 160 164 88336 were VBD B-VP O
28 165 168 88336 not RB O O
29 169 176 88336 hypoxic JJ B-ADJP O
30 176 177 88336 , , O O
31 178 181 88336 are VBP B-VP O
32 182 191 88336 described VBN I-VP O
33 191 192 88336 . . O O

1 193 198 88336 Three CD B-NP O
2 199 207 88336 patients NNS I-NP O
3 208 216 88336 received VBD B-VP O
4 217 221 88336 high JJ B-NP O
5 222 227 88336 doses NNS I-NP O
6 228 230 88336 of IN B-PP O
7 231 246 88336 chlormethiazole NN B-NP B-Chemical
8 247 250 88336 for IN B-PP O
9 251 258 88336 alcohol NN B-NP B-Chemical
10 259 269 88336 withdrawal NN I-NP B-Disease
11 270 278 88336 symptoms NNS I-NP I-Disease
12 278 279 88336 , , O O
13 280 283 88336 and CC O O
14 284 287 88336 one CD B-NP O
15 288 292 88336 took VBD B-VP O
16 293 294 88336 a DT B-NP O
17 295 303 88336 suicidal JJ I-NP O
18 304 312 88336 overdose NN I-NP B-Disease
19 313 315 88336 of IN B-PP O
20 316 326 88336 nitrazepam NN B-NP B-Chemical
21 326 327 88336 . . O O

1 328 331 88336 The DT B-NP O
2 332 339 88336 patient NN I-NP O
3 340 344 88336 with IN B-PP O
4 345 355 88336 nitrazepam NN B-NP B-Chemical
5 356 364 88336 overdose NN I-NP B-Disease
6 365 368 88336 and CC O O
7 369 372 88336 two CD B-NP O
8 373 375 88336 of IN B-PP O
9 376 381 88336 those DT B-NP O
10 382 386 88336 with IN B-PP O
11 387 402 88336 chlormethiazole NN B-NP B-Chemical
12 403 415 88336 intoxication NN I-NP O
13 416 425 88336 conformed VBD B-VP O
14 426 428 88336 to TO B-PP O
15 429 432 88336 the DT B-NP O
16 433 441 88336 criteria NNS I-NP O
17 442 444 88336 of IN B-PP O
18 445 446 88336 ' `` O O
19 446 451 88336 alpha NN B-NP O
20 452 456 88336 coma NN I-NP B-Disease
21 456 457 88336 ' '' O O
22 457 458 88336 , , O O
23 459 466 88336 showing VBG B-VP O
24 467 470 88336 non AFX B-NP O
25 470 471 88336 - HYPH I-NP O
26 471 479 88336 reactive JJ I-NP O
27 480 491 88336 generalized VBN B-VP O
28 492 494 88336 or CC O O
29 495 504 88336 frontally RB B-NP O
30 505 516 88336 predominant JJ I-NP O
31 517 522 88336 alpha NN I-NP O
32 523 531 88336 activity NN I-NP O
33 532 534 88336 in IN B-PP O
34 535 538 88336 the DT B-NP O
35 539 542 88336 EEG NN I-NP O
36 542 543 88336 . . O O

1 544 547 88336 The DT B-NP O
2 548 554 88336 fourth JJ I-NP O
3 555 562 88336 patient NN I-NP O
4 563 566 88336 who WP B-NP O
5 567 570 88336 was VBD B-VP O
6 571 582 88336 unconscious JJ B-ADJP O
7 583 588 88336 after IN B-SBAR O
8 589 604 88336 chlormethiazole NN B-NP B-Chemical
9 605 619 88336 administration NN I-NP O
10 620 628 88336 exhibite NN I-NP O
11 629 640 88336 generalized VBN B-VP O
12 641 644 88336 non AFX B-NP O
13 644 645 88336 - HYPH I-NP O
14 645 653 88336 reactive JJ B-NP O
15 654 662 88336 activity NN I-NP O
16 663 665 88336 in IN B-PP O
17 666 669 88336 the DT B-NP O
18 670 674 88336 slow JJ I-NP O
19 675 679 88336 beta NN I-NP O
20 680 685 88336 range NN I-NP O
21 685 686 88336 . . O O

1 687 690 88336 All DT B-NP O
2 691 695 88336 four CD I-NP O
3 696 705 88336 recovered VBD B-VP O
4 706 716 88336 completely RB B-ADVP O
5 717 724 88336 without IN B-PP O
6 725 737 88336 neurological JJ B-NP B-Disease
7 738 746 88336 sequelae NNS I-NP I-Disease
8 747 756 88336 following VBG B-PP O
9 757 760 88336 the DT B-NP O
10 761 771 88336 withdrawal NN I-NP O
11 772 774 88336 of IN B-PP O
12 775 778 88336 the DT B-NP O
13 779 788 88336 offending VBG I-NP O
14 789 795 88336 agents NNS I-NP O
15 795 796 88336 . . O O

1 797 800 88336 The DT B-NP O
2 801 813 88336 similarities NNS I-NP O
3 814 821 88336 between IN B-PP O
4 822 825 88336 the DT B-NP O
5 826 833 88336 effects NNS I-NP O
6 834 836 88336 of IN B-PP O
7 837 847 88336 structural JJ B-NP O
8 848 855 88336 lesions NNS I-NP O
9 856 859 88336 and CC O O
10 860 875 88336 pharmacological JJ B-NP O
11 876 886 88336 depression NN I-NP B-Disease
12 887 889 88336 of IN B-PP O
13 890 893 88336 the DT B-NP O
14 894 899 88336 brain NN I-NP O
15 900 904 88336 stem NN I-NP O
16 905 914 88336 reticular JJ I-NP O
17 915 924 88336 formation NN I-NP O
18 925 928 88336 are VBP B-VP O
19 929 938 88336 discussed VBN I-VP O
20 938 939 88336 . . O O

1 940 942 88336 It PRP B-NP O
2 943 945 88336 is VBZ B-VP O
3 946 955 88336 suggested VBN I-VP O
4 956 960 88336 that IN B-SBAR O
5 961 963 88336 in IN B-PP O
6 964 968 88336 both DT B-NP O
7 969 979 88336 situations NNS I-NP O
8 980 989 88336 disturbed VBD B-VP O
9 990 998 88336 reticulo AFX B-NP O
10 998 999 88336 - HYPH I-NP O
11 999 1007 88336 thalamic JJ B-NP O
12 1008 1020 88336 interactions NNS I-NP O
13 1021 1024 88336 are VBP B-VP O
14 1025 1034 88336 important JJ B-ADJP O
15 1035 1037 88336 in IN B-PP O
16 1038 1041 88336 the DT B-NP O
17 1042 1054 88336 pathogenesis NN I-NP O
18 1055 1057 88336 of IN B-PP O
19 1058 1063 88336 alpha NN B-NP O
20 1064 1068 88336 coma NN I-NP B-Disease
21 1068 1069 88336 . . O O

1 1070 1072 88336 It PRP B-NP O
2 1073 1075 88336 is VBZ B-VP O
3 1076 1085 88336 concluded VBN I-VP O
4 1086 1090 88336 that IN B-SBAR O
5 1091 1095 88336 when WRB B-ADVP O
6 1096 1100 88336 this DT B-NP O
7 1101 1124 88336 electroencephalographic JJ I-NP O
8 1125 1128 88336 and CC I-NP O
9 1129 1140 88336 behavioural JJ I-NP O
10 1141 1148 88336 picture NN I-NP O
11 1149 1151 88336 is VBZ B-VP O
12 1152 1156 88336 seen VBN I-VP O
13 1157 1159 88336 in IN B-PP O
14 1160 1164 88336 drug NN B-NP O
15 1165 1177 88336 intoxication NN I-NP O
16 1177 1178 88336 , , O O
17 1179 1181 88336 in IN B-PP O
18 1182 1185 88336 the DT B-NP O
19 1186 1193 88336 absence NN I-NP O
20 1194 1196 88336 of IN B-PP O
21 1197 1208 88336 significant JJ B-NP O
22 1209 1219 88336 hypoxaemia NN I-NP B-Disease
23 1219 1220 88336 , , O O
24 1221 1222 88336 a DT B-NP O
25 1223 1233 88336 favourable JJ I-NP O
26 1234 1241 88336 outcome NN I-NP O
27 1242 1245 88336 may MD B-VP O
28 1246 1248 88336 be VB I-VP O
29 1249 1260 88336 anticipated VBN I-VP O
30 1260 1261 88336 . . O O

1 0 0 137340 -DOCSTART- -X- -X- O

1 0 6 137340 Effect NN B-NP O
2 7 9 137340 of IN B-PP O
3 10 17 137340 humoral JJ B-NP O
4 18 28 137340 modulators NNS I-NP O
5 29 31 137340 of IN B-PP O
6 32 40 137340 morphine NN B-NP B-Chemical
7 40 41 137340 - HYPH B-NP O
8 41 48 137340 induced VBN I-NP O
9 49 57 137340 increase NN I-NP B-Disease
10 58 60 137340 in IN B-PP I-Disease
11 61 70 137340 locomotor NN B-NP I-Disease
12 71 79 137340 activity NN I-NP I-Disease
13 80 82 137340 of IN B-PP O
14 83 87 137340 mice NNS B-NP O
15 87 88 137340 . . O O
16 89 92 137340 The DT B-NP O
17 93 99 137340 effect NN I-NP O
18 100 102 137340 of IN B-PP O
19 103 110 137340 humoral JJ B-NP O
20 111 121 137340 modulators NNS I-NP O
21 122 124 137340 on IN B-PP O
22 125 128 137340 the DT B-NP O
23 129 137 137340 morphine NN I-NP B-Chemical
24 137 138 137340 - HYPH B-VP O
25 138 145 137340 induced VBN B-NP O
26 146 154 137340 increase NN I-NP B-Disease
27 155 157 137340 in IN B-PP I-Disease
28 158 167 137340 locomotor NN B-NP I-Disease
29 168 176 137340 activity NN I-NP I-Disease
30 177 179 137340 of IN B-PP O
31 180 184 137340 mice NNS B-NP O
32 185 188 137340 was VBD B-VP O
33 189 196 137340 studied VBN I-VP O
34 196 197 137340 . . O O

1 198 201 137340 The DT B-NP O
2 202 214 137340 subcutaneous JJ I-NP O
3 215 229 137340 administration NN I-NP O
4 230 232 137340 of IN B-PP O
5 233 235 137340 10 CD B-NP O
6 236 238 137340 mg NN I-NP O
7 238 239 137340 / SYM B-NP O
8 239 241 137340 kg NN I-NP O
9 242 244 137340 of IN B-PP O
10 245 253 137340 morphine NN B-NP B-Chemical
11 253 254 137340 - HYPH B-NP O
12 254 257 137340 HC1 NN I-NP O
13 258 266 137340 produced VBD B-VP O
14 267 268 137340 a DT B-NP O
15 269 275 137340 marked JJ I-NP O
16 276 284 137340 increase NN I-NP B-Disease
17 285 287 137340 in IN B-PP I-Disease
18 288 297 137340 locomotor NN B-NP I-Disease
19 298 306 137340 activity NN I-NP I-Disease
20 307 309 137340 in IN B-PP O
21 310 314 137340 mice NNS B-NP O
22 314 315 137340 . . O O

1 316 319 137340 The DT B-NP O
2 320 328 137340 morphine NN I-NP B-Chemical
3 328 329 137340 - HYPH B-VP O
4 329 336 137340 induced VBN B-NP O
5 337 350 137340 hyperactivity NN I-NP B-Disease
6 351 354 137340 was VBD B-VP O
7 355 366 137340 potentiated VBN I-VP O
8 367 369 137340 by IN B-PP O
9 370 381 137340 scopolamine NN B-NP B-Chemical
10 382 385 137340 and CC O O
11 386 396 137340 attenuated VBN B-VP O
12 397 399 137340 by IN B-PP O
13 400 413 137340 physostigmine NN B-NP B-Chemical
14 413 414 137340 . . O O

1 415 417 137340 In IN B-PP O
2 418 426 137340 contrast NN B-NP O
3 426 427 137340 , , O O
4 428 432 137340 both CC O O
5 433 448 137340 methscopolamine NN B-NP B-Chemical
6 449 452 137340 and CC I-NP O
7 453 464 137340 neostigmine NN I-NP B-Chemical
8 464 465 137340 , , O O
9 466 471 137340 which WDT B-NP O
10 472 474 137340 do VBP B-VP O
11 475 478 137340 not RB I-VP O
12 479 488 137340 penetrate VB I-VP O
13 489 492 137340 the DT B-NP O
14 493 498 137340 blood NN I-NP O
15 498 499 137340 - HYPH I-NP O
16 499 504 137340 brain NN I-NP O
17 505 512 137340 barrier NN I-NP O
18 512 513 137340 , , O O
19 514 517 137340 had VBD B-VP O
20 518 520 137340 no DT B-NP O
21 521 527 137340 effect NN I-NP O
22 528 530 137340 on IN B-PP O
23 531 534 137340 the DT B-NP O
24 535 548 137340 hyperactivity NN I-NP B-Disease
25 549 557 137340 produced VBN B-VP O
26 558 560 137340 by IN B-PP O
27 561 569 137340 morphine NN B-NP B-Chemical
28 569 570 137340 . . O O

1 571 583 137340 Pretreatment NN B-NP O
2 584 586 137340 of IN B-PP O
3 587 591 137340 mice NNS B-NP O
4 592 596 137340 with IN B-PP O
5 597 602 137340 alpha SYM O B-Chemical
6 602 603 137340 - HYPH O I-Chemical
7 603 617 137340 methyltyrosine NN B-NP I-Chemical
8 618 619 137340 ( ( O O
9 619 621 137340 20 CD B-NP O
10 622 624 137340 mg NN I-NP O
11 624 625 137340 / SYM B-NP O
12 625 627 137340 kg NN I-NP O
13 628 631 137340 i.p NN I-NP O
14 631 632 137340 . NN I-NP O
15 632 633 137340 , , O O
16 634 637 137340 one CD B-NP O
17 638 642 137340 hour NN I-NP O
18 642 643 137340 ) ) O O
19 643 644 137340 , , O O
20 645 647 137340 an DT B-NP O
21 648 657 137340 inhibitor NN I-NP O
22 658 660 137340 of IN B-PP O
23 661 669 137340 tyrosine NN B-NP B-Chemical
24 670 681 137340 hydroxylase NN I-NP O
25 681 682 137340 , , O O
26 683 696 137340 significantly RB B-VP O
27 697 706 137340 decreased VBD I-VP O
28 707 710 137340 the DT B-NP O
29 711 719 137340 activity NN I-NP O
30 719 720 137340 - HYPH O O
31 720 730 137340 increasing VBG B-VP O
32 731 738 137340 effects NNS B-NP O
33 739 741 137340 of IN B-PP O
34 742 750 137340 morphine NN B-NP B-Chemical
35 750 751 137340 . . O O

1 752 754 137340 On IN B-PP O
2 755 758 137340 the DT B-NP O
3 759 764 137340 other JJ I-NP O
4 765 769 137340 hand NN I-NP O
5 769 770 137340 , , O O
6 771 783 137340 pretreatment NN B-NP O
7 784 788 137340 with IN B-PP O
8 789 790 137340 p NN B-NP B-Chemical
9 790 791 137340 - HYPH B-NP I-Chemical
10 791 810 137340 chlorophenylalamine NN I-NP I-Chemical
11 811 812 137340 ( ( O O
12 812 813 137340 3 CD B-NP O
13 814 815 137340 X SYM I-NP O
14 816 819 137340 320 CD I-NP O
15 820 822 137340 mg NN I-NP O
16 822 823 137340 / SYM B-NP O
17 823 825 137340 kg NN I-NP O
18 826 829 137340 i.p NN I-NP O
19 829 830 137340 . NN I-NP O
20 830 831 137340 , , O O
21 832 834 137340 24 CD B-NP O
22 835 837 137340 hr NN I-NP O
23 837 838 137340 ) ) O O
24 838 839 137340 , , O O
25 840 841 137340 a DT B-NP O
26 842 851 137340 serotonin NN I-NP B-Chemical
27 852 860 137340 depletor NN I-NP O
28 860 861 137340 , , O O
29 862 868 137340 caused VBD B-VP O
30 869 871 137340 no DT B-NP O
31 872 883 137340 significant JJ I-NP O
32 884 890 137340 change NN I-NP O
33 891 893 137340 in IN B-PP O
34 894 897 137340 the DT B-NP O
35 898 911 137340 hyperactivity NN I-NP B-Disease
36 911 912 137340 . . O O

1 913 916 137340 The DT B-NP O
2 917 922 137340 study NN I-NP O
3 923 931 137340 suggests VBZ B-VP O
4 932 936 137340 that IN B-SBAR O
5 937 940 137340 the DT B-NP O
6 941 949 137340 activity NN I-NP O
7 949 950 137340 - HYPH O O
8 950 960 137340 increasing VBG B-VP O
9 961 968 137340 effects NNS B-NP O
10 969 971 137340 of IN B-PP O
11 972 980 137340 morphine NN B-NP B-Chemical
12 981 984 137340 are VBP B-VP O
13 985 993 137340 mediated VBN I-VP O
14 994 996 137340 by IN B-PP O
15 997 1000 137340 the DT B-NP O
16 1001 1008 137340 release NN I-NP O
17 1009 1011 137340 of IN B-PP O
18 1012 1026 137340 catecholamines NNS B-NP B-Chemical
19 1027 1031 137340 from IN B-PP O
20 1032 1042 137340 adrenergic JJ B-NP O
21 1043 1050 137340 neurons NNS I-NP O
22 1051 1053 137340 in IN B-PP O
23 1054 1057 137340 the DT B-NP O
24 1058 1063 137340 brain NN I-NP O
25 1063 1064 137340 . . O O

1 1065 1068 137340 And CC O O
2 1069 1072 137340 the DT B-NP O
3 1073 1080 137340 results NNS I-NP O
4 1081 1084 137340 are VBP B-VP O
5 1085 1095 137340 consistent JJ B-ADJP O
6 1096 1100 137340 with IN B-PP O
7 1101 1104 137340 the DT B-NP O
8 1105 1115 137340 hypothesis NN I-NP O
9 1116 1120 137340 that IN B-SBAR O
10 1121 1129 137340 morphine NN B-NP B-Chemical
11 1130 1134 137340 acts VBZ B-VP O
12 1135 1137 137340 by IN B-PP O
13 1138 1147 137340 retarding VBG B-VP O
14 1148 1151 137340 the DT B-NP O
15 1152 1159 137340 release NN I-NP O
16 1160 1162 137340 of IN B-PP O
17 1163 1176 137340 acetylcholine NN B-NP B-Chemical
18 1177 1179 137340 at IN B-PP O
19 1180 1184 137340 some DT B-NP O
20 1185 1192 137340 central JJ I-NP O
21 1193 1204 137340 cholinergic JJ I-NP O
22 1205 1213 137340 synapses NNS I-NP O
23 1213 1214 137340 . . O O

1 1215 1217 137340 It PRP B-NP O
2 1218 1220 137340 is VBZ B-VP O
3 1221 1225 137340 also RB I-VP O
4 1226 1235 137340 suggested VBN I-VP O
5 1236 1240 137340 from IN B-PP O
6 1241 1250 137340 collected VBN B-NP O
7 1251 1259 137340 evidence NN I-NP O
8 1260 1264 137340 that IN B-SBAR O
9 1265 1268 137340 the DT B-NP O
10 1269 1277 137340 activity NN I-NP O
11 1277 1278 137340 - HYPH O O
12 1278 1288 137340 increasing VBG B-VP O
13 1289 1296 137340 effects NNS B-NP O
14 1297 1299 137340 of IN B-PP O
15 1300 1308 137340 morphine NN B-NP B-Chemical
16 1309 1311 137340 in IN B-PP O
17 1312 1316 137340 mice NNS B-NP O
18 1317 1320 137340 are VBP B-VP O
19 1321 1329 137340 mediated VBN I-VP O
20 1330 1332 137340 by IN B-PP O
21 1333 1343 137340 mechanisms NNS B-NP O
22 1344 1353 137340 different JJ B-ADJP O
23 1354 1358 137340 from IN B-PP O
24 1359 1364 137340 those DT B-NP O
25 1365 1370 137340 which WDT B-NP O
26 1371 1378 137340 mediate VBP B-VP O
27 1379 1382 137340 the DT B-NP O
28 1383 1391 137340 activity NN I-NP O
29 1391 1392 137340 - HYPH O O
30 1392 1402 137340 increasing VBG B-VP O
31 1403 1410 137340 effects NNS B-NP O
32 1411 1413 137340 of IN B-PP O
33 1414 1422 137340 morphine NN B-NP B-Chemical
34 1423 1425 137340 in IN B-PP O
35 1426 1430 137340 rats NNS B-NP O
36 1430 1431 137340 . . O O

1 0 0 12523465 -DOCSTART- -X- -X- O

1 0 6 12523465 Visual JJ B-NP B-Disease
2 7 21 12523465 hallucinations NNS I-NP I-Disease
3 22 32 12523465 associated VBN B-VP O
4 33 37 12523465 with IN B-PP O
5 38 48 12523465 zonisamide NN B-NP B-Chemical
6 48 49 12523465 . . O O
7 50 60 12523465 Zonisamide NN B-NP B-Chemical
8 61 63 12523465 is VBZ B-VP O
9 64 65 12523465 a DT B-NP O
10 66 71 12523465 broad JJ I-NP O
11 71 72 12523465 - HYPH I-NP O
12 72 80 12523465 spectrum NN I-NP O
13 81 94 12523465 antiepileptic JJ I-NP O
14 95 99 12523465 drug NN I-NP O
15 100 104 12523465 used VBN B-VP O
16 105 107 12523465 to TO B-VP O
17 108 113 12523465 treat VB I-VP O
18 114 121 12523465 various JJ B-NP O
19 122 127 12523465 types NNS I-NP O
20 128 130 12523465 of IN B-PP O
21 131 139 12523465 seizures NNS B-NP B-Disease
22 139 140 12523465 . . O O

1 141 149 12523465 Although IN B-SBAR O
2 150 156 12523465 visual JJ B-NP B-Disease
3 157 171 12523465 hallucinations NNS I-NP I-Disease
4 172 176 12523465 have VBP B-VP O
5 177 180 12523465 not RB I-VP O
6 181 185 12523465 been VBN I-VP O
7 186 194 12523465 reported VBN I-VP O
8 195 197 12523465 as IN B-PP O
9 198 200 12523465 an DT B-NP O
10 201 208 12523465 adverse JJ I-NP O
11 209 215 12523465 effect NN I-NP O
12 216 218 12523465 of IN B-PP O
13 219 223 12523465 this DT B-NP O
14 224 229 12523465 agent NN I-NP O
15 229 230 12523465 , , O O
16 231 233 12523465 we PRP B-NP O
17 234 242 12523465 describe VBP B-VP O
18 243 248 12523465 three CD B-NP O
19 249 257 12523465 patients NNS I-NP O
20 258 261 12523465 who WP B-NP O
21 262 273 12523465 experienced VBD B-VP O
22 274 281 12523465 complex JJ B-NP O
23 282 288 12523465 visual JJ I-NP B-Disease
24 289 303 12523465 hallucinations NNS I-NP I-Disease
25 304 307 12523465 and CC O O
26 308 315 12523465 altered VBN B-NP O
27 316 322 12523465 mental JJ I-NP O
28 323 329 12523465 status NN I-NP O
29 330 335 12523465 after IN B-PP O
30 336 346 12523465 zonisamide NN B-NP B-Chemical
31 347 356 12523465 treatment NN I-NP O
32 357 360 12523465 was VBD B-VP O
33 361 366 12523465 begun VBN I-VP O
34 367 369 12523465 or CC O O
35 370 373 12523465 its PRP$ B-NP O
36 374 380 12523465 dosage NN I-NP O
37 381 390 12523465 increased VBD B-VP O
38 390 391 12523465 . . O O

1 392 395 12523465 All DT B-NP O
2 396 401 12523465 three CD I-NP O
3 402 405 12523465 had VBD B-VP O
4 406 410 12523465 been VBN I-VP O
5 411 420 12523465 diagnosed VBN I-VP O
6 421 428 12523465 earlier RBR B-ADVP O
7 429 433 12523465 with IN B-PP O
8 434 442 12523465 epilepsy NN B-NP B-Disease
9 442 443 12523465 , , O O
10 444 447 12523465 and CC O O
11 448 453 12523465 their PRP$ B-NP O
12 454 474 12523465 electroencephalogram NN I-NP O
13 475 476 12523465 ( ( O O
14 476 479 12523465 EEG NN B-NP O
15 479 480 12523465 ) ) O O
16 481 489 12523465 findings NNS B-NP O
17 490 494 12523465 were VBD B-VP O
18 495 503 12523465 abnormal JJ B-ADJP O
19 503 504 12523465 . . O O

1 505 511 12523465 During IN B-PP O
2 512 522 12523465 monitoring NN B-NP O
3 522 523 12523465 , , O O
4 524 530 12523465 visual JJ B-NP B-Disease
5 531 545 12523465 hallucinations NNS I-NP I-Disease
6 546 549 12523465 did VBD B-VP O
7 550 553 12523465 not RB I-VP O
8 554 563 12523465 correlate VB I-VP O
9 564 568 12523465 with IN B-PP O
10 569 572 12523465 EEG NN B-NP O
11 573 581 12523465 readings NNS I-NP O
12 581 582 12523465 , , O O
13 583 586 12523465 nor CC O O
14 587 590 12523465 did VBD O O
15 591 596 12523465 video NN B-NP O
16 597 606 12523465 recording VBG B-VP O
17 607 614 12523465 capture NN B-NP O
18 615 618 12523465 any DT B-NP O
19 619 621 12523465 of IN B-PP O
20 622 625 12523465 the DT B-NP O
21 626 635 12523465 described VBN I-NP O
22 636 642 12523465 events NNS I-NP O
23 642 643 12523465 . . O O

1 644 648 12523465 None NN B-NP O
2 649 651 12523465 of IN B-PP O
3 652 655 12523465 the DT B-NP O
4 656 664 12523465 patients NNS I-NP O
5 665 668 12523465 had VBD B-VP O
6 669 680 12523465 experienced VBN I-VP O
7 681 687 12523465 visual JJ B-NP B-Disease
8 688 702 12523465 hallucinations NNS I-NP I-Disease
9 703 709 12523465 before IN B-PP O
10 710 714 12523465 this DT B-NP O
11 715 720 12523465 event NN I-NP O
12 720 721 12523465 . . O O

1 722 725 12523465 The DT B-NP O
2 726 730 12523465 only JJ I-NP O
3 731 737 12523465 recent JJ I-NP O
4 738 744 12523465 change NN I-NP O
5 745 747 12523465 in IN B-PP O
6 748 753 12523465 their PRP$ B-NP O
7 754 763 12523465 treatment NN I-NP O
8 764 767 12523465 was VBD B-VP O
9 768 771 12523465 the DT B-NP O
10 772 784 12523465 introduction NN I-NP O
11 785 787 12523465 or CC O O
12 788 797 12523465 increased VBN B-NP O
13 798 804 12523465 dosage NN I-NP O
14 805 807 12523465 of IN B-PP O
15 808 818 12523465 zonisamide NN B-NP B-Chemical
16 818 819 12523465 . . O O

1 820 824 12523465 With IN B-PP O
2 825 831 12523465 either CC O O
3 832 847 12523465 discontinuation NN B-NP O
4 848 850 12523465 or CC O O
5 851 860 12523465 decreased VBN B-NP O
6 861 867 12523465 dosage NN I-NP O
7 868 870 12523465 of IN B-PP O
8 871 874 12523465 the DT B-NP O
9 875 879 12523465 drug NN I-NP O
10 880 883 12523465 the DT B-NP O
11 884 892 12523465 symptoms NNS I-NP O
12 893 904 12523465 disappeared VBD B-VP O
13 905 908 12523465 and CC O O
14 909 912 12523465 did VBD B-VP O
15 913 916 12523465 not RB I-VP O
16 917 922 12523465 recur VB I-VP O
17 922 923 12523465 . . O O

1 924 931 12523465 Further JJR B-NP O
2 932 944 12523465 observations NNS I-NP O
3 945 948 12523465 and CC I-NP O
4 949 956 12523465 reports NNS I-NP O
5 957 961 12523465 will MD B-VP O
6 962 966 12523465 help VB I-VP O
7 967 974 12523465 clarify VB I-VP O
8 975 979 12523465 this DT B-NP O
9 980 987 12523465 adverse JJ I-NP O
10 988 994 12523465 effect NN I-NP O
11 994 995 12523465 . . O O

1 996 1001 12523465 Until IN B-PP O
2 1002 1006 12523465 then RB B-NP O
3 1006 1007 12523465 , , O O
4 1008 1018 12523465 clinicians NNS B-NP O
5 1019 1023 12523465 need VBP B-VP O
6 1024 1026 12523465 to TO I-VP O
7 1027 1029 12523465 be VB I-VP O
8 1030 1035 12523465 aware JJ B-ADJP O
9 1036 1038 12523465 of IN B-PP O
10 1039 1043 12523465 this DT B-NP O
11 1044 1052 12523465 possible JJ I-NP O
12 1053 1065 12523465 complication NN I-NP O
13 1066 1076 12523465 associated VBN B-VP O
14 1077 1081 12523465 with IN B-PP O
15 1082 1092 12523465 zonisamide NN B-NP B-Chemical
16 1092 1093 12523465 . . O O

1 0 0 2375138 -DOCSTART- -X- -X- O

1 0 8 2375138 Possible JJ B-NP O
2 9 22 2375138 intramuscular JJ I-NP O
3 23 32 2375138 midazolam NN I-NP B-Chemical
4 32 33 2375138 - HYPH O O
5 33 43 2375138 associated VBN B-VP O
6 44 61 2375138 cardiorespiratory JJ B-NP B-Disease
7 62 68 2375138 arrest NN I-NP I-Disease
8 69 72 2375138 and CC I-NP O
9 73 78 2375138 death NN I-NP B-Disease
10 78 79 2375138 . . O O
11 80 89 2375138 Midazolam NN B-NP B-Chemical
12 90 103 2375138 hydrochloride NN I-NP I-Chemical
13 104 106 2375138 is VBZ B-VP O
14 107 115 2375138 commonly RB I-VP O
15 116 120 2375138 used VBN I-VP O
16 121 124 2375138 for IN B-PP O
17 125 131 2375138 dental JJ B-NP O
18 132 134 2375138 or CC I-NP O
19 135 145 2375138 endoscopic JJ I-NP O
20 146 156 2375138 procedures NNS I-NP O
21 156 157 2375138 . . O O

1 158 166 2375138 Although IN B-SBAR O
2 167 176 2375138 generally RB B-ADVP O
3 177 186 2375138 consisted VBN B-VP O
4 187 191 2375138 safe JJ B-ADJP O
5 192 196 2375138 when WRB B-ADVP O
6 197 202 2375138 given VBN B-VP O
7 203 218 2375138 intramuscularly RB B-ADVP O
8 218 219 2375138 , , O O
9 220 231 2375138 intravenous JJ B-NP O
10 232 246 2375138 administration NN I-NP O
11 247 249 2375138 is VBZ B-VP O
12 250 255 2375138 known VBN I-VP O
13 256 258 2375138 to TO I-VP O
14 259 264 2375138 cause VB I-VP O
15 265 276 2375138 respiratory JJ B-NP B-Disease
16 277 280 2375138 and CC I-NP I-Disease
17 281 295 2375138 cardiovascular JJ I-NP I-Disease
18 296 306 2375138 depression NN I-NP I-Disease
19 306 307 2375138 . . O O

1 308 312 2375138 This DT B-NP O
2 313 319 2375138 report NN I-NP O
3 320 329 2375138 describes VBZ B-VP O
4 330 333 2375138 the DT B-NP O
5 334 339 2375138 first JJ I-NP O
6 340 349 2375138 published VBN I-NP O
7 350 354 2375138 case NN I-NP O
8 355 357 2375138 of IN B-PP O
9 358 375 2375138 cardiorespiratory JJ B-NP B-Disease
10 376 382 2375138 arrest NN I-NP I-Disease
11 383 386 2375138 and CC I-NP O
12 387 392 2375138 death NN I-NP B-Disease
13 393 403 2375138 associated VBN B-VP O
14 404 408 2375138 with IN B-PP O
15 409 422 2375138 intramuscular JJ B-NP O
16 423 437 2375138 administration NN I-NP O
17 438 440 2375138 of IN B-PP O
18 441 450 2375138 midazolam NN B-NP B-Chemical
19 450 451 2375138 . . O O

1 452 463 2375138 Information NN B-NP O
2 464 473 2375138 regarding VBG B-VP O
3 474 483 2375138 midazolam NN B-NP B-Chemical
4 484 487 2375138 use NN I-NP O
5 488 490 2375138 is VBZ B-VP O
6 491 499 2375138 reviewed VBN I-VP O
7 500 502 2375138 to TO I-VP O
8 503 510 2375138 provide VB I-VP O
9 511 525 2375138 recommendation NN B-NP O
10 526 529 2375138 for IN B-PP O
11 530 534 2375138 safe JJ B-NP O
12 535 549 2375138 administration NN I-NP O
13 549 550 2375138 . . O O

1 0 0 7248170 -DOCSTART- -X- -X- O

1 0 14 7248170 Phenobarbitone NN B-NP B-Chemical
2 14 15 7248170 - HYPH B-NP O
3 15 22 7248170 induced VBN I-NP O
4 23 34 7248170 enlargement NN I-NP B-Disease
5 35 37 7248170 of IN B-PP I-Disease
6 38 41 7248170 the DT B-NP I-Disease
7 42 47 7248170 liver NN I-NP I-Disease
8 48 50 7248170 in IN B-PP O
9 51 54 7248170 the DT B-NP O
10 55 58 7248170 rat NN I-NP O
11 58 59 7248170 : : O O
12 60 63 7248170 its PRP$ B-NP O
13 64 76 7248170 relationship NN I-NP O
14 77 79 7248170 to TO B-PP O
15 80 86 7248170 carbon NN B-NP B-Chemical
16 87 100 7248170 tetrachloride NN I-NP I-Chemical
17 100 101 7248170 - HYPH B-NP O
18 101 108 7248170 induced VBN I-NP O
19 109 118 7248170 cirrhosis NN I-NP B-Disease
20 118 119 7248170 . . O O
21 120 123 7248170 The DT B-NP O
22 124 129 7248170 yield NN I-NP O
23 130 132 7248170 of IN B-PP O
24 133 139 7248170 severe JJ B-NP O
25 140 149 7248170 cirrhosis NN I-NP B-Disease
26 150 152 7248170 of IN B-PP I-Disease
27 153 156 7248170 the DT B-NP I-Disease
28 157 162 7248170 liver NN I-NP I-Disease
29 163 164 7248170 ( ( O O
30 164 171 7248170 defined VBN B-VP O
31 172 174 7248170 as IN B-PP O
32 175 176 7248170 a DT B-NP O
33 177 185 7248170 shrunken VBN I-NP O
34 186 192 7248170 finely RB I-NP O
35 193 200 7248170 nodular JJ I-NP O
36 201 206 7248170 liver NN I-NP O
37 207 211 7248170 with IN B-PP O
38 212 224 7248170 micronodular JJ B-NP O
39 225 234 7248170 histology NN I-NP O
40 234 235 7248170 , , O O
41 236 243 7248170 ascites VBZ B-VP B-Disease
42 244 251 7248170 greater JJR B-NP O
43 252 256 7248170 than IN I-NP O
44 257 259 7248170 30 CD I-NP O
45 260 262 7248170 ml NN I-NP O
46 262 263 7248170 , , O O
47 264 270 7248170 plasma NN B-NP O
48 271 278 7248170 albumin NN I-NP O
49 279 283 7248170 less JJR B-NP O
50 284 288 7248170 than IN I-NP O
51 289 292 7248170 2.2 CD I-NP O
52 293 294 7248170 g NN I-NP O
53 294 295 7248170 / SYM O O
54 295 297 7248170 dl NN B-NP O
55 297 298 7248170 , , O O
56 299 311 7248170 splenomegaly NN B-NP B-Disease
57 312 313 7248170 2 CD I-NP O
58 313 314 7248170 - HYPH B-NP O
59 314 315 7248170 3 CD I-NP O
60 316 321 7248170 times NNS I-NP O
61 322 328 7248170 normal JJ I-NP O
62 328 329 7248170 , , O O
63 330 333 7248170 and CC O O
64 334 344 7248170 testicular JJ B-NP O
65 345 352 7248170 atrophy NN I-NP B-Disease
66 353 366 7248170 approximately RB B-NP O
67 367 371 7248170 half DT I-NP O
68 372 378 7248170 normal JJ I-NP O
69 379 385 7248170 weight NN I-NP O
70 385 386 7248170 ) ) O O
71 387 392 7248170 after IN B-PP O
72 393 395 7248170 12 CD B-NP O
73 396 401 7248170 doses NNS I-NP O
74 402 404 7248170 of IN B-PP O
75 405 411 7248170 carbon NN B-NP B-Chemical
76 412 425 7248170 tetrachloride NN I-NP I-Chemical
77 426 431 7248170 given VBN B-VP O
78 432 448 7248170 intragastrically RB B-ADVP O
79 449 451 7248170 in IN B-PP O
80 452 455 7248170 the DT B-NP O
81 456 470 7248170 phenobarbitone NN I-NP B-Chemical
82 470 471 7248170 - HYPH B-VP O
83 471 477 7248170 primed VBN B-NP O
84 478 481 7248170 rat NN I-NP O
85 482 485 7248170 was VBD B-VP O
86 486 495 7248170 increased VBN I-VP O
87 496 500 7248170 from IN B-PP O
88 501 504 7248170 25% CD B-NP O
89 505 507 7248170 to TO B-PP O
90 508 511 7248170 56% CD B-NP O
91 512 514 7248170 by IN B-PP O
92 515 521 7248170 giving VBG B-VP O
93 522 525 7248170 the DT B-NP O
94 526 533 7248170 initial JJ I-NP O
95 534 535 7248170 " `` B-VP O
96 535 546 7248170 calibrating VBG I-VP O
97 546 547 7248170 " '' B-NP O
98 548 552 7248170 dose NN I-NP O
99 553 555 7248170 of IN B-PP O
100 556 562 7248170 carbon NN B-NP B-Chemical
101 563 576 7248170 tetrachloride NN I-NP I-Chemical
102 577 579 7248170 at IN B-PP O
103 580 583 7248170 the DT B-NP O
104 584 588 7248170 peak NN I-NP O
105 589 591 7248170 of IN B-PP O
106 592 595 7248170 the DT B-NP O
107 596 610 7248170 phenobarbitone NN I-NP B-Chemical
108 610 611 7248170 - HYPH B-NP O
109 611 618 7248170 induced VBN I-NP O
110 619 630 7248170 enlargement NN I-NP B-Disease
111 631 633 7248170 of IN B-PP I-Disease
112 634 637 7248170 the DT B-NP I-Disease
113 638 643 7248170 liver NN I-NP I-Disease
114 643 644 7248170 . . O O

1 645 647 7248170 At IN B-PP O
2 648 652 7248170 this DT B-NP O
3 653 658 7248170 point NN I-NP O
4 659 661 7248170 it PRP B-NP O
5 662 665 7248170 was VBD B-VP O
6 666 673 7248170 assumed VBN I-VP O
7 674 678 7248170 that IN B-SBAR O
8 679 682 7248170 the DT B-NP O
9 683 693 7248170 cytochrome NN I-NP O
10 694 698 7248170 P450 NN I-NP O
11 698 699 7248170 / SYM B-NP O
12 699 703 7248170 CCl4 NN I-NP B-Chemical
13 704 709 7248170 toxic JJ I-NP O
14 710 715 7248170 state NN I-NP O
15 716 719 7248170 was VBD B-VP O
16 720 724 7248170 both CC O O
17 725 732 7248170 maximal JJ B-ADJP O
18 733 736 7248170 and CC I-ADJP O
19 737 743 7248170 stable JJ I-ADJP O
20 743 744 7248170 . . O O

1 745 748 7248170 The DT B-NP O
2 749 756 7248170 optimal JJ I-NP O
3 757 760 7248170 rat NN I-NP O
4 761 765 7248170 size NN I-NP O
5 766 768 7248170 to TO B-VP O
6 769 774 7248170 begin VB I-VP O
7 775 789 7248170 phenobarbitone NN B-NP B-Chemical
8 790 793 7248170 was VBD B-VP O
9 794 804 7248170 determined VBN I-VP O
10 805 807 7248170 as IN B-PP O
11 808 811 7248170 100 CD B-NP O
12 812 813 7248170 g NN I-NP O
13 813 814 7248170 , , O O
14 815 818 7248170 and CC O O
15 819 823 7248170 this DT B-NP O
16 824 828 7248170 size NN I-NP O
17 829 831 7248170 as IN B-PP O
18 832 833 7248170 a DT B-NP O
19 834 839 7248170 group NN I-NP O
20 840 843 7248170 had VBD B-VP O
21 844 845 7248170 a DT B-NP O
22 846 850 7248170 mean JJ I-NP O
23 851 858 7248170 maximum JJ I-NP O
24 859 867 7248170 relative JJ I-NP O
25 868 873 7248170 liver NN I-NP O
26 874 880 7248170 weight NN I-NP O
27 881 889 7248170 increase VBP B-VP O
28 890 893 7248170 47% CD B-NP O
29 894 901 7248170 greater JJR B-ADJP O
30 902 906 7248170 than IN B-PP O
31 907 913 7248170 normal JJ B-NP O
32 914 918 7248170 rats NNS I-NP O
33 919 921 7248170 of IN B-PP O
34 922 925 7248170 the DT B-NP O
35 926 930 7248170 same JJ I-NP O
36 931 935 7248170 body NN I-NP O
37 936 942 7248170 weight NN I-NP O
38 942 943 7248170 . . O O

1 944 947 7248170 The DT B-NP O
2 948 955 7248170 optimal JJ I-NP O
3 956 960 7248170 time NN I-NP O
4 961 964 7248170 for IN B-PP O
5 965 968 7248170 the DT B-NP O
6 969 976 7248170 initial JJ I-NP O
7 977 981 7248170 dose NN I-NP O
8 982 984 7248170 of IN B-PP O
9 985 991 7248170 carbon NN B-NP B-Chemical
10 992 1005 7248170 tetrachloride NN I-NP I-Chemical
11 1006 1009 7248170 was VBD B-VP O
12 1010 1015 7248170 after IN B-PP O
13 1016 1018 7248170 14 CD B-NP O
14 1019 1023 7248170 days NNS I-NP O
15 1024 1026 7248170 on IN B-PP O
16 1027 1041 7248170 phenobarbitone NN B-NP B-Chemical
17 1041 1042 7248170 . . O O

1 0 0 9625142 -DOCSTART- -X- -X- O

1 0 5 9625142 Acute JJ B-NP O
2 6 15 9625142 hepatitis NN I-NP B-Disease
3 15 16 9625142 , , O O
4 17 27 9625142 autoimmune JJ B-NP B-Disease
5 28 37 9625142 hemolytic JJ I-NP I-Disease
6 38 44 9625142 anemia NN I-NP I-Disease
7 44 45 9625142 , , O O
8 46 49 9625142 and CC O O
9 50 72 9625142 erythroblastocytopenia NN B-NP B-Disease
10 73 80 9625142 induced VBN B-VP O
11 81 83 9625142 by IN B-PP O
12 84 95 9625142 ceftriaxone NN B-NP B-Chemical
13 95 96 9625142 . . O O
14 97 99 9625142 An DT B-NP O
15 100 102 9625142 80 CD I-NP O
16 102 103 9625142 - HYPH I-NP O
17 103 105 9625142 yr NN I-NP O
18 105 106 9625142 - HYPH B-NP O
19 106 109 9625142 old JJ I-NP O
20 110 113 9625142 man NN I-NP O
21 114 123 9625142 developed VBD B-VP O
22 124 129 9625142 acute JJ B-NP O
23 130 139 9625142 hepatitis NN I-NP B-Disease
24 140 147 9625142 shortly RB B-ADVP O
25 148 153 9625142 after IN B-PP O
26 154 163 9625142 ingesting VBG B-VP O
27 164 168 9625142 oral JJ B-NP O
28 169 180 9625142 ceftriaxone NN I-NP B-Chemical
29 180 181 9625142 . . O O

1 182 190 9625142 Although IN B-SBAR O
2 191 194 9625142 the DT B-NP O
3 195 208 9625142 transaminases NNS I-NP O
4 209 218 9625142 gradually RB B-ADVP O
5 219 227 9625142 returned VBD B-VP O
6 228 230 9625142 to TO B-PP O
7 231 239 9625142 baseline NN B-NP O
8 240 245 9625142 after IN B-PP O
9 246 257 9625142 withholding VBG B-VP O
10 258 261 9625142 the DT B-NP O
11 262 266 9625142 beta NN I-NP B-Chemical
12 267 273 9625142 lactam NN I-NP I-Chemical
13 274 284 9625142 antibiotic NN I-NP O
14 284 285 9625142 , , O O
15 286 291 9625142 there EX B-NP O
16 292 295 9625142 was VBD B-VP O
17 296 297 9625142 a DT B-NP O
18 298 305 9625142 gradual JJ I-NP O
19 306 314 9625142 increase NN I-NP O
20 315 317 9625142 in IN B-PP O
21 318 323 9625142 serum NN B-NP O
22 324 333 9625142 bilirubin NN I-NP B-Chemical
23 334 337 9625142 and CC O O
24 338 339 9625142 a DT B-NP O
25 340 348 9625142 decrease NN I-NP O
26 349 351 9625142 in IN B-PP O
27 352 362 9625142 hemoglobin NN B-NP O
28 363 376 9625142 concentration NN I-NP O
29 377 383 9625142 caused VBN B-VP O
30 384 386 9625142 by IN B-PP O
31 387 389 9625142 an DT B-NP O
32 390 400 9625142 autoimmune JJ I-NP B-Disease
33 401 410 9625142 hemolytic JJ I-NP I-Disease
34 411 417 9625142 anemia NN I-NP I-Disease
35 418 421 9625142 and CC I-NP O
36 422 444 9625142 erythroblastocytopenia NN I-NP B-Disease
37 444 445 9625142 . . O O

1 446 451 9625142 These DT B-NP O
2 452 461 9625142 responded VBD B-VP O
3 462 464 9625142 to TO B-PP O
4 465 473 9625142 systemic JJ B-NP O
5 474 482 9625142 steroids NNS I-NP B-Chemical
6 483 486 9625142 and CC I-NP O
7 487 502 9625142 immunoglobulins NNS I-NP O
8 502 503 9625142 . . O O

1 504 511 9625142 Despite IN B-PP O
2 512 515 9625142 the DT B-NP O
3 516 526 9625142 widespread JJ I-NP O
4 527 530 9625142 use NN I-NP O
5 531 533 9625142 of IN B-PP O
6 534 539 9625142 these DT B-NP O
7 540 546 9625142 agents NNS I-NP O
8 547 551 9625142 this DT B-NP O
9 552 557 9625142 triad NN I-NP O
10 558 560 9625142 of IN B-PP O
11 561 565 9625142 side NN B-NP O
12 566 573 9625142 effects NNS I-NP O
13 574 577 9625142 has VBZ B-VP O
14 578 581 9625142 not RB I-VP O
15 582 592 9625142 previously RB I-VP O
16 593 597 9625142 been VBN I-VP O
17 598 606 9625142 reported VBN I-VP O
18 607 609 9625142 in IN B-PP O
19 610 620 9625142 connection NN B-NP O
20 621 625 9625142 with IN B-PP O
21 626 630 9625142 beta SYM B-NP B-Chemical
22 631 637 9625142 lactam NN I-NP I-Chemical
23 638 649 9625142 antibiotics NNS I-NP O
24 649 650 9625142 . . O O

1 0 0 10835440 -DOCSTART- -X- -X- O

1 0 6 10835440 Effect NN B-NP O
2 7 9 10835440 of IN B-PP O
3 10 21 10835440 intravenous JJ B-NP O
4 22 32 10835440 nimodipine NN I-NP B-Chemical
5 33 35 10835440 on IN B-PP O
6 36 41 10835440 blood NN B-NP O
7 42 50 10835440 pressure NN I-NP O
8 51 54 10835440 and CC I-NP O
9 55 62 10835440 outcome NN I-NP O
10 63 68 10835440 after IN B-PP O
11 69 74 10835440 acute JJ B-NP B-Disease
12 75 81 10835440 stroke NN I-NP I-Disease
13 81 82 10835440 . . O O
14 83 93 10835440 BACKGROUND NN B-NP O
15 94 97 10835440 AND CC I-NP O
16 98 105 10835440 PURPOSE NN I-NP O
17 105 106 10835440 : : O O
18 107 110 10835440 The DT B-NP O
19 111 122 10835440 Intravenous JJ I-NP O
20 123 133 10835440 Nimodipine NNP I-NP B-Chemical
21 134 138 10835440 West NNP I-NP O
22 139 147 10835440 European NNP I-NP O
23 148 154 10835440 Stroke NNP I-NP B-Disease
24 155 160 10835440 Trial NNP I-NP O
25 161 162 10835440 ( ( O O
26 162 168 10835440 INWEST NN B-NP O
27 168 169 10835440 ) ) O O
28 170 175 10835440 found VBD B-VP O
29 176 177 10835440 a DT B-NP O
30 178 189 10835440 correlation NN I-NP O
31 190 197 10835440 between IN B-PP O
32 198 208 10835440 nimodipine NN B-NP B-Chemical
33 208 209 10835440 - HYPH B-NP O
34 209 216 10835440 induced VBN I-NP O
35 217 226 10835440 reduction NN I-NP B-Disease
36 227 229 10835440 in IN B-PP I-Disease
37 230 235 10835440 blood NN B-NP I-Disease
38 236 244 10835440 pressure NN I-NP I-Disease
39 245 246 10835440 ( ( O O
40 246 248 10835440 BP NN B-NP O
41 248 249 10835440 ) ) O O
42 250 253 10835440 and CC O O
43 254 256 10835440 an DT B-NP O
44 257 268 10835440 unfavorable JJ I-NP O
45 269 276 10835440 outcome NN I-NP O
46 277 279 10835440 in IN B-PP O
47 280 285 10835440 acute JJ B-NP B-Disease
48 286 292 10835440 stroke NN I-NP I-Disease
49 292 293 10835440 . . O O

1 294 296 10835440 We PRP B-NP O
2 297 303 10835440 sought VBD B-VP O
3 304 306 10835440 to TO I-VP O
4 307 314 10835440 confirm VB I-VP O
5 315 319 10835440 this DT B-NP O
6 320 331 10835440 correlation NN I-NP O
7 332 336 10835440 with IN B-PP O
8 337 340 10835440 and CC B-PP O
9 341 348 10835440 without IN B-PP O
10 349 359 10835440 adjustment NN B-NP O
11 360 363 10835440 for IN B-PP O
12 364 374 10835440 prognostic JJ B-NP O
13 375 384 10835440 variables NNS I-NP O
14 385 388 10835440 and CC O O
15 389 391 10835440 to TO B-VP O
16 392 403 10835440 investigate VB I-VP O
17 404 411 10835440 outcome NN B-NP O
18 412 414 10835440 in IN B-PP O
19 415 424 10835440 subgroups NNS B-NP O
20 425 429 10835440 with IN B-PP O
21 430 440 10835440 increasing VBG B-NP O
22 441 447 10835440 levels NNS I-NP O
23 448 450 10835440 of IN B-PP O
24 451 453 10835440 BP NN B-NP B-Disease
25 454 463 10835440 reduction NN I-NP I-Disease
26 463 464 10835440 . . O O

1 465 472 10835440 METHODS NNS B-NP O
2 472 473 10835440 : : O O
3 474 482 10835440 Patients NNS B-NP O
4 483 487 10835440 with IN B-PP O
5 488 489 10835440 a DT B-NP O
6 490 498 10835440 clinical JJ I-NP O
7 499 508 10835440 diagnosis NN I-NP O
8 509 511 10835440 of IN B-PP O
9 512 520 10835440 ischemic JJ B-NP B-Disease
10 521 527 10835440 stroke NN I-NP I-Disease
11 528 529 10835440 ( ( O O
12 529 535 10835440 within IN B-PP O
13 536 538 10835440 24 CD B-NP O
14 539 544 10835440 hours NNS I-NP O
15 544 545 10835440 ) ) O O
16 546 550 10835440 were VBD B-VP O
17 551 564 10835440 consecutively RB I-VP O
18 565 574 10835440 allocated VBN I-VP O
19 575 577 10835440 to TO I-VP O
20 578 585 10835440 receive VB I-VP O
21 586 593 10835440 placebo NN B-NP O
22 594 595 10835440 ( ( O O
23 595 596 10835440 n NN B-NP O
24 596 597 10835440 = SYM B-VP O
25 597 600 10835440 100 CD B-NP O
26 600 601 10835440 ) ) O O
27 601 602 10835440 , , O O
28 603 604 10835440 1 CD B-NP O
29 605 607 10835440 mg NN I-NP O
30 607 608 10835440 / SYM B-NP O
31 608 609 10835440 h NN I-NP O
32 610 611 10835440 ( ( O O
33 611 614 10835440 low JJ B-NP O
34 614 615 10835440 - HYPH I-NP O
35 615 619 10835440 dose NN I-NP O
36 619 620 10835440 ) ) O O
37 621 631 10835440 nimodipine NN B-NP B-Chemical
38 632 633 10835440 ( ( O O
39 633 634 10835440 n NN B-NP O
40 634 635 10835440 = SYM B-VP O
41 635 638 10835440 101 CD B-NP O
42 638 639 10835440 ) ) O O
43 639 640 10835440 , , O O
44 641 643 10835440 or CC O O
45 644 645 10835440 2 CD B-NP O
46 646 648 10835440 mg NN I-NP O
47 648 649 10835440 / SYM B-NP O
48 649 650 10835440 h NN I-NP O
49 651 652 10835440 ( ( O O
50 652 656 10835440 high JJ B-NP O
51 656 657 10835440 - HYPH I-NP O
52 657 661 10835440 dose NN I-NP O
53 661 662 10835440 ) ) O O
54 663 673 10835440 nimodipine NN B-NP B-Chemical
55 674 675 10835440 ( ( O O
56 675 676 10835440 n NN B-NP O
57 676 677 10835440 = SYM B-VP O
58 677 679 10835440 94 CD B-NP O
59 679 680 10835440 ) ) O O
60 680 681 10835440 . . O O

1 682 685 10835440 The DT B-NP O
2 686 697 10835440 correlation NN I-NP O
3 698 705 10835440 between IN B-PP O
4 706 713 10835440 average JJ B-NP O
5 714 716 10835440 BP NN I-NP O
6 717 723 10835440 change NN I-NP O
7 724 730 10835440 during IN B-PP O
8 731 734 10835440 the DT B-NP O
9 735 740 10835440 first JJ I-NP O
10 741 742 10835440 2 CD I-NP O
11 743 747 10835440 days NNS I-NP O
12 748 751 10835440 and CC O O
13 752 755 10835440 the DT B-NP O
14 756 763 10835440 outcome NN I-NP O
15 764 766 10835440 at IN B-PP O
16 767 770 10835440 day NN B-NP O
17 771 773 10835440 21 CD I-NP O
18 774 777 10835440 was VBD B-VP O
19 778 786 10835440 analyzed VBN I-VP O
20 786 787 10835440 . . O O

1 788 795 10835440 RESULTS NNS B-NP O
2 795 796 10835440 : : O O
3 797 800 10835440 Two CD B-NP O
4 801 808 10835440 hundred CD I-NP O
5 809 814 10835440 sixty CD I-NP O
6 814 815 10835440 - HYPH B-NP O
7 815 819 10835440 five CD I-NP O
8 820 828 10835440 patients NNS I-NP O
9 829 833 10835440 were VBD B-VP O
10 834 842 10835440 included VBN I-VP O
11 843 845 10835440 in IN B-PP O
12 846 850 10835440 this DT B-NP O
13 851 859 10835440 analysis NN I-NP O
14 860 861 10835440 ( ( O O
15 861 862 10835440 n NN B-NP O
16 862 863 10835440 = SYM B-VP O
17 863 865 10835440 92 CD B-NP O
18 865 866 10835440 , , O O
19 867 869 10835440 93 CD B-NP O
20 869 870 10835440 , , O O
21 871 874 10835440 and CC O O
22 875 877 10835440 80 CD B-NP O
23 878 881 10835440 for IN B-PP O
24 882 889 10835440 placebo NN B-NP O
25 889 890 10835440 , , O O
26 891 894 10835440 low JJ B-NP O
27 895 899 10835440 dose NN I-NP O
28 899 900 10835440 , , O O
29 901 904 10835440 and CC O O
30 905 909 10835440 high JJ B-NP O
31 910 914 10835440 dose NN I-NP O
32 914 915 10835440 , , O O
33 916 928 10835440 respectively RB B-ADVP O
34 928 929 10835440 ) ) O O
35 929 930 10835440 . . O O

1 931 941 10835440 Nimodipine NN B-NP B-Chemical
2 942 951 10835440 treatment NN I-NP O
3 952 960 10835440 resulted VBD B-VP O
4 961 963 10835440 in IN B-PP O
5 964 965 10835440 a DT B-NP O
6 966 979 10835440 statistically RB I-NP O
7 980 991 10835440 significant JJ I-NP O
8 992 1001 10835440 reduction NN I-NP B-Disease
9 1002 1004 10835440 in IN B-PP I-Disease
10 1005 1013 10835440 systolic JJ B-NP I-Disease
11 1014 1016 10835440 BP NN I-NP I-Disease
12 1017 1018 10835440 ( ( O O
13 1018 1021 10835440 SBP NN B-NP O
14 1021 1022 10835440 ) ) O O
15 1023 1026 10835440 and CC O O
16 1027 1036 10835440 diastolic JJ B-NP O
17 1037 1039 10835440 BP NN I-NP O
18 1040 1041 10835440 ( ( O O
19 1041 1044 10835440 DBP NN B-NP O
20 1044 1045 10835440 ) ) O O
21 1046 1050 10835440 from IN B-PP O
22 1051 1059 10835440 baseline NN B-NP O
23 1060 1068 10835440 compared VBN B-PP O
24 1069 1073 10835440 with IN B-PP O
25 1074 1081 10835440 placebo NN B-NP O
26 1082 1088 10835440 during IN B-PP O
27 1089 1092 10835440 the DT B-NP O
28 1093 1098 10835440 first JJ I-NP O
29 1099 1102 10835440 few JJ I-NP O
30 1103 1107 10835440 days NNS I-NP O
31 1107 1108 10835440 . . O O

1 1109 1111 10835440 In IN B-PP O
2 1112 1124 10835440 multivariate JJ B-NP O
3 1125 1133 10835440 analysis NN I-NP O
4 1133 1134 10835440 , , O O
5 1135 1136 10835440 a DT B-NP O
6 1137 1148 10835440 significant JJ I-NP O
7 1149 1160 10835440 correlation NN I-NP O
8 1161 1168 10835440 between IN B-PP O
9 1169 1172 10835440 DBP NN B-NP B-Disease
10 1173 1182 10835440 reduction NN I-NP I-Disease
11 1183 1186 10835440 and CC O O
12 1187 1196 10835440 worsening VBG B-VP O
13 1197 1199 10835440 of IN B-PP O
14 1200 1203 10835440 the DT B-NP O
15 1204 1216 10835440 neurological JJ I-NP O
16 1217 1222 10835440 score NN I-NP O
17 1223 1226 10835440 was VBD B-VP O
18 1227 1232 10835440 found VBN I-VP O
19 1233 1236 10835440 for IN B-PP O
20 1237 1240 10835440 the DT B-NP O
21 1241 1245 10835440 high JJ I-NP O
22 1245 1246 10835440 - HYPH I-NP O
23 1246 1250 10835440 dose NN I-NP O
24 1251 1256 10835440 group NN I-NP O
25 1257 1258 10835440 ( ( O O
26 1258 1262 10835440 beta SYM B-NP O
27 1262 1263 10835440 = SYM B-VP O
28 1263 1267 10835440 0.49 CD B-NP O
29 1267 1268 10835440 , , O O
30 1269 1270 10835440 P NN B-NP O
31 1270 1271 10835440 = SYM B-VP O
32 1271 1272 10835440 0 CD B-NP O
33 1272 1273 10835440 . SYM I-NP O
34 1274 1277 10835440 048 CD I-NP O
35 1277 1278 10835440 ) ) O O
36 1278 1279 10835440 . . O O

1 1280 1288 10835440 Patients NNS B-NP O
2 1289 1293 10835440 with IN B-PP O
3 1294 1295 10835440 a DT B-NP O
4 1296 1299 10835440 DBP NN I-NP B-Disease
5 1300 1309 10835440 reduction NN I-NP I-Disease
6 1310 1312 10835440 of IN B-PP O
7 1313 1314 10835440 > SYM B-NP O
8 1315 1317 10835440 or CC O O
9 1318 1319 10835440 = SYM B-VP O
10 1319 1322 10835440 20% CD B-NP O
11 1323 1325 10835440 in IN B-PP O
12 1326 1329 10835440 the DT B-NP O
13 1330 1334 10835440 high JJ I-NP O
14 1334 1335 10835440 - HYPH I-NP O
15 1335 1339 10835440 dose NN I-NP O
16 1340 1345 10835440 group NN I-NP O
17 1346 1349 10835440 had VBD B-VP O
18 1350 1351 10835440 a DT B-NP O
19 1352 1365 10835440 significantly RB I-NP O
20 1366 1375 10835440 increased VBN I-NP O
21 1376 1384 10835440 adjusted VBN I-NP O
22 1385 1387 10835440 OR NN I-NP O
23 1388 1391 10835440 for IN B-PP O
24 1392 1395 10835440 the DT B-NP O
25 1396 1404 10835440 compound NN I-NP O
26 1405 1412 10835440 outcome NN I-NP O
27 1413 1421 10835440 variable JJ I-NP O
28 1422 1427 10835440 death NN I-NP B-Disease
29 1428 1430 10835440 or CC I-NP O
30 1431 1441 10835440 dependency NN I-NP O
31 1442 1443 10835440 ( ( O O
32 1443 1450 10835440 Barthel NNP B-NP O
33 1451 1456 10835440 Index NNP I-NP O
34 1457 1458 10835440 < SYM B-NP O
35 1458 1460 10835440 60 CD I-NP O
36 1460 1461 10835440 ) ) O O
37 1462 1463 10835440 ( ( O O
38 1463 1464 10835440 n NN B-NP O
39 1464 1465 10835440 / SYM O O
40 1465 1466 10835440 N NN B-NP O
41 1466 1467 10835440 = SYM B-VP O
42 1467 1469 10835440 25 CD B-NP O
43 1469 1470 10835440 / SYM O O
44 1470 1472 10835440 26 CD B-NP O
45 1472 1473 10835440 , , O O
46 1474 1476 10835440 OR NN B-NP O
47 1477 1479 10835440 10 CD I-NP O
48 1479 1480 10835440 . . O O

1 1481 1483 10835440 16 CD B-NP O
2 1483 1484 10835440 , , I-NP O
3 1485 1488 10835440 95% CD I-NP O
4 1489 1491 10835440 CI NNP I-NP O
5 1492 1496 10835440 1.02 CD I-NP O
6 1497 1499 10835440 to TO B-PP O
7 1500 1506 10835440 101.74 CD B-NP O
8 1506 1507 10835440 ) ) O O
9 1508 1511 10835440 and CC O O
10 1512 1517 10835440 death NN B-NP B-Disease
11 1518 1523 10835440 alone RB B-ADVP O
12 1524 1525 10835440 ( ( O O
13 1525 1526 10835440 n NN B-NP O
14 1526 1527 10835440 / SYM O O
15 1527 1528 10835440 N NN B-NP O
16 1528 1529 10835440 = SYM B-VP O
17 1529 1530 10835440 9 CD B-NP O
18 1530 1531 10835440 / SYM O O
19 1531 1533 10835440 26 CD B-NP O
20 1533 1534 10835440 , , O O
21 1535 1537 10835440 OR NN B-NP O
22 1538 1543 10835440 4.336 CD I-NP O
23 1543 1544 10835440 , , I-NP O
24 1545 1548 10835440 95% CD I-NP O
25 1549 1551 10835440 CI NNP I-NP O
26 1552 1557 10835440 1.131 CD I-NP O
27 1558 1564 10835440 16.619 CD I-NP O
28 1564 1565 10835440 ) ) O O
29 1566 1574 10835440 compared VBN B-PP O
30 1575 1579 10835440 with IN B-PP O
31 1580 1583 10835440 all DT B-NP O
32 1584 1591 10835440 placebo NN I-NP O
33 1592 1600 10835440 patients NNS I-NP O
34 1601 1602 10835440 ( ( O O
35 1602 1603 10835440 n NN B-NP O
36 1603 1604 10835440 / SYM I-NP O
37 1604 1605 10835440 N NN I-NP O
38 1605 1606 10835440 = SYM B-VP O
39 1606 1608 10835440 62 CD B-NP O
40 1608 1609 10835440 / SYM B-NP O
41 1609 1611 10835440 92 CD I-NP O
42 1612 1615 10835440 and CC I-NP O
43 1616 1618 10835440 14 CD I-NP O
44 1618 1619 10835440 / SYM I-NP O
45 1619 1621 10835440 92 CD I-NP O
46 1621 1622 10835440 , , O O
47 1623 1635 10835440 respectively RB B-ADVP O
48 1635 1636 10835440 ) ) O O
49 1636 1637 10835440 . . O O

1 1638 1643 10835440 There EX B-NP O
2 1644 1647 10835440 was VBD B-VP O
3 1648 1650 10835440 no DT B-NP O
4 1651 1662 10835440 correlation NN I-NP O
5 1663 1670 10835440 between IN B-PP O
6 1671 1674 10835440 SBP NN B-NP O
7 1675 1681 10835440 change NN I-NP O
8 1682 1685 10835440 and CC I-NP O
9 1686 1693 10835440 outcome NN I-NP O
10 1693 1694 10835440 . . O O

1 1695 1706 10835440 CONCLUSIONS NNS B-NP O
2 1706 1707 10835440 : : O O
3 1708 1711 10835440 DBP NN B-NP O
4 1711 1712 10835440 , , O O
5 1713 1716 10835440 but CC O O
6 1717 1720 10835440 not RB O O
7 1721 1724 10835440 SBP NN B-NP O
8 1724 1725 10835440 , , O O
9 1726 1735 10835440 reduction NN B-NP O
10 1736 1739 10835440 was VBD B-VP O
11 1740 1750 10835440 associated VBN I-VP O
12 1751 1755 10835440 with IN B-PP O
13 1756 1768 10835440 neurological JJ B-NP O
14 1769 1778 10835440 worsening VBG I-NP O
15 1779 1784 10835440 after IN B-PP O
16 1785 1788 10835440 the DT B-NP O
17 1789 1800 10835440 intravenous JJ I-NP O
18 1801 1815 10835440 administration NN I-NP O
19 1816 1818 10835440 of IN B-PP O
20 1819 1823 10835440 high JJ B-NP O
21 1823 1824 10835440 - HYPH I-NP O
22 1824 1828 10835440 dose NN I-NP O
23 1829 1839 10835440 nimodipine NN I-NP B-Chemical
24 1840 1845 10835440 after IN B-PP O
25 1846 1851 10835440 acute JJ B-NP B-Disease
26 1852 1858 10835440 stroke NN I-NP I-Disease
27 1858 1859 10835440 . . O O

1 1860 1863 10835440 For IN B-PP O
2 1864 1867 10835440 low JJ B-NP O
3 1867 1868 10835440 - HYPH I-NP O
4 1868 1872 10835440 dose NN I-NP O
5 1873 1883 10835440 nimodipine NN I-NP B-Chemical
6 1883 1884 10835440 , , O O
7 1885 1888 10835440 the DT B-NP O
8 1889 1896 10835440 results NNS I-NP O
9 1897 1901 10835440 were VBD B-VP O
10 1902 1905 10835440 not RB O O
11 1906 1916 10835440 conclusive JJ B-ADJP O
12 1916 1917 10835440 . . O O

1 1918 1923 10835440 These DT B-NP O
2 1924 1931 10835440 results NNS I-NP O
3 1932 1934 10835440 do VBP B-VP O
4 1935 1938 10835440 not RB I-VP O
5 1939 1946 10835440 confirm VB I-VP O
6 1947 1949 10835440 or CC I-VP O
7 1950 1957 10835440 exclude VB I-VP O
8 1958 1959 10835440 a DT B-NP O
9 1960 1975 10835440 neuroprotective JJ I-NP O
10 1976 1984 10835440 property NN I-NP O
11 1985 1987 10835440 of IN B-PP O
12 1988 1998 10835440 nimodipine NN B-NP B-Chemical
13 1998 1999 10835440 . . O O

1 0 0 1728522 -DOCSTART- -X- -X- O

1 0 13 1728522 Granulomatous JJ B-NP B-Disease
2 14 23 1728522 hepatitis NN I-NP I-Disease
3 24 27 1728522 due JJ B-ADJP O
4 28 30 1728522 to TO B-PP O
5 31 42 1728522 combination NN B-NP B-Chemical
6 43 45 1728522 of IN B-PP I-Chemical
7 46 57 1728522 amoxicillin NN B-NP I-Chemical
8 58 61 1728522 and CC O I-Chemical
9 62 72 1728522 clavulanic JJ B-NP I-Chemical
10 73 77 1728522 acid NN I-NP I-Chemical
11 77 78 1728522 . . O O
12 79 81 1728522 We PRP B-NP O
13 82 88 1728522 report VBP B-VP O
14 89 92 1728522 the DT B-NP O
15 93 97 1728522 case NN I-NP O
16 98 100 1728522 of IN B-PP O
17 101 102 1728522 a DT B-NP O
18 103 110 1728522 patient NN I-NP O
19 111 115 1728522 with IN B-PP O
20 116 127 1728522 amoxicillin NN B-NP B-Chemical
21 127 128 1728522 - HYPH O I-Chemical
22 128 138 1728522 clavulanic JJ B-NP I-Chemical
23 139 143 1728522 acid NN I-NP I-Chemical
24 143 144 1728522 - HYPH B-VP O
25 144 151 1728522 induced VBN B-NP O
26 152 161 1728522 hepatitis NN I-NP B-Disease
27 162 166 1728522 with IN B-PP O
28 167 177 1728522 histologic JJ B-NP O
29 178 186 1728522 multiple JJ I-NP O
30 187 197 1728522 granulomas NNS I-NP B-Disease
31 197 198 1728522 . . O O

1 199 203 1728522 This DT B-NP O
2 204 208 1728522 type NN I-NP O
3 209 211 1728522 of IN B-PP O
4 212 218 1728522 lesion NN B-NP O
5 219 227 1728522 broadens VBZ B-VP O
6 228 231 1728522 the DT B-NP O
7 232 240 1728522 spectrum NN I-NP O
8 241 243 1728522 of IN B-PP O
9 244 249 1728522 liver NN B-NP B-Disease
10 250 256 1728522 injury NN I-NP I-Disease
11 257 260 1728522 due JJ B-ADJP O
12 261 263 1728522 to TO B-PP O
13 264 268 1728522 this DT B-NP O
14 269 273 1728522 drug NN I-NP O
15 274 285 1728522 combination NN I-NP O
16 285 286 1728522 , , O O
17 287 293 1728522 mainly RB B-VP O
18 294 305 1728522 represented VBN I-VP O
19 306 308 1728522 by IN B-PP O
20 309 310 1728522 a DT B-NP O
21 311 317 1728522 benign JJ I-NP O
22 318 329 1728522 cholestatic JJ I-NP B-Disease
23 330 338 1728522 syndrome NN I-NP I-Disease
24 338 339 1728522 . . O O

1 340 343 1728522 The DT B-NP O
2 344 355 1728522 association NN I-NP O
3 356 358 1728522 of IN B-PP O
4 359 369 1728522 granulomas NNS B-NP B-Disease
5 370 373 1728522 and CC O O
6 374 386 1728522 eosinophilia NN B-NP B-Disease
7 387 392 1728522 favor VBP B-VP O
8 393 395 1728522 an DT B-NP O
9 396 410 1728522 immunoallergic JJ I-NP O
10 411 420 1728522 mechanism NN I-NP O
11 420 421 1728522 . . O O

1 422 424 1728522 As IN B-SBAR O
2 425 435 1728522 penicillin NN B-NP B-Chemical
3 436 447 1728522 derivatives NNS I-NP O
4 448 451 1728522 and CC O O
5 452 463 1728522 amoxicillin NN B-NP B-Chemical
6 464 469 1728522 alone RB B-ADVP O
7 470 473 1728522 are VBP B-VP O
8 474 479 1728522 known VBN I-VP O
9 480 482 1728522 to TO I-VP O
10 483 489 1728522 induce VB I-VP O
11 490 494 1728522 such JJ B-NP O
12 495 500 1728522 types NNS I-NP O
13 501 503 1728522 of IN B-PP O
14 504 511 1728522 lesions NNS B-NP O
15 511 512 1728522 , , O O
16 513 516 1728522 the DT B-NP O
17 517 528 1728522 amoxicillin NN I-NP B-Chemical
18 529 538 1728522 component NN I-NP O
19 538 539 1728522 , , O O
20 540 544 1728522 with IN B-PP O
21 545 547 1728522 or CC B-PP O
22 548 555 1728522 without IN B-PP O
23 556 557 1728522 a DT B-NP O
24 558 570 1728522 potentiating NN I-NP O
25 571 577 1728522 effect NN I-NP O
26 578 580 1728522 of IN B-PP O
27 581 591 1728522 clavulanic JJ B-NP B-Chemical
28 592 596 1728522 acid NN I-NP I-Chemical
29 596 597 1728522 , , O O
30 598 603 1728522 might MD B-VP O
31 604 608 1728522 have VB I-VP O
32 609 610 1728522 a DT B-NP O
33 611 616 1728522 major JJ I-NP O
34 617 621 1728522 role NN I-NP O
35 621 622 1728522 . . O O

1 0 0 3997294 -DOCSTART- -X- -X- O

1 0 11 3997294 Pneumonitis NN B-NP O
2 12 16 3997294 with IN B-PP O
3 17 24 3997294 pleural JJ B-NP B-Disease
4 25 28 3997294 and CC I-NP I-Disease
5 29 40 3997294 pericardial JJ I-NP I-Disease
6 41 49 3997294 effusion NN I-NP I-Disease
7 50 53 3997294 and CC I-NP O
8 54 64 3997294 neuropathy NN I-NP B-Disease
9 65 71 3997294 during IN B-PP O
10 72 82 3997294 amiodarone NN B-NP B-Chemical
11 83 90 3997294 therapy NN I-NP O
12 90 91 3997294 . . O O
13 92 93 3997294 A NN B-NP O
14 94 101 3997294 patient NN I-NP O
15 102 106 3997294 with IN B-PP O
16 107 117 3997294 sinuatrial JJ B-NP B-Disease
17 118 125 3997294 disease NN I-NP I-Disease
18 126 129 3997294 and CC O O
19 130 139 3997294 implanted VBN B-NP O
20 140 149 3997294 pacemaker NN I-NP O
21 150 153 3997294 was VBD B-VP O
22 154 161 3997294 treated VBN I-VP O
23 162 166 3997294 with IN B-PP O
24 167 177 3997294 amiodarone NN B-NP B-Chemical
25 178 179 3997294 ( ( O O
26 179 186 3997294 maximum JJ B-NP O
27 187 191 3997294 dose NN I-NP O
28 192 196 3997294 1000 CD I-NP O
29 197 199 3997294 mg NN I-NP O
30 199 200 3997294 , , O O
31 201 212 3997294 maintenance NN B-NP O
32 213 217 3997294 dose NN I-NP O
33 218 221 3997294 800 CD I-NP O
34 222 224 3997294 mg NN I-NP O
35 225 230 3997294 daily RB B-ADVP O
36 230 231 3997294 ) ) O O
37 232 235 3997294 for IN B-PP O
38 236 238 3997294 10 CD B-NP O
39 239 245 3997294 months NNS I-NP O
40 245 246 3997294 , , O O
41 247 250 3997294 for IN B-PP O
42 251 258 3997294 control NN B-NP O
43 259 261 3997294 of IN B-PP O
44 262 278 3997294 supraventricular JJ B-NP B-Disease
45 279 295 3997294 tachyarrhythmias NNS I-NP I-Disease
46 295 296 3997294 . . O O

1 297 299 3997294 He PRP B-NP O
2 300 309 3997294 developed VBD B-VP O
3 310 321 3997294 pneumonitis NN B-NP B-Disease
4 321 322 3997294 , , O O
5 323 330 3997294 pleural JJ B-NP B-Disease
6 331 334 3997294 and CC I-NP I-Disease
7 335 346 3997294 pericardial JJ I-NP I-Disease
8 347 356 3997294 effusions NNS I-NP I-Disease
9 356 357 3997294 , , O O
10 358 361 3997294 and CC O O
11 362 363 3997294 a DT B-NP O
12 364 377 3997294 predominantly RB I-NP O
13 378 386 3997294 proximal JJ I-NP B-Disease
14 387 392 3997294 motor NN I-NP I-Disease
15 393 403 3997294 neuropathy NN I-NP I-Disease
16 403 404 3997294 . . O O

1 405 414 3997294 Immediate JJ B-NP O
2 415 418 3997294 but CC I-NP O
3 419 426 3997294 gradual JJ I-NP O
4 427 438 3997294 improvement NN I-NP O
5 439 447 3997294 followed VBD B-VP O
6 448 458 3997294 withdrawal NN B-NP O
7 459 461 3997294 of IN B-PP O
8 462 472 3997294 amiodarone NN B-NP B-Chemical
9 473 476 3997294 and CC I-NP O
10 477 486 3997294 treatment NN I-NP O
11 487 491 3997294 with IN B-PP O
12 492 504 3997294 prednisolone NN B-NP B-Chemical
13 504 505 3997294 . . O O

1 506 512 3997294 Review NN B-NP O
2 513 515 3997294 of IN B-PP O
3 516 520 3997294 this DT B-NP O
4 521 524 3997294 and CC I-NP O
5 525 535 3997294 previously RB I-NP O
6 536 544 3997294 reported VBN I-NP O
7 545 550 3997294 cases NNS I-NP O
8 551 560 3997294 indicates VBZ B-VP O
9 561 564 3997294 the DT B-NP O
10 565 569 3997294 need NN I-NP O
11 570 573 3997294 for IN B-PP O
12 574 579 3997294 early JJ B-NP O
13 580 589 3997294 diagnosis NN I-NP O
14 590 592 3997294 of IN B-PP O
15 593 603 3997294 amiodarone NN B-NP B-Chemical
16 604 615 3997294 pneumonitis NN I-NP B-Disease
17 615 616 3997294 , , O O
18 617 626 3997294 immediate JJ B-NP O
19 627 637 3997294 withdrawal NN I-NP O
20 638 640 3997294 of IN B-PP O
21 641 651 3997294 amiodarone NN B-NP B-Chemical
22 651 652 3997294 , , O O
23 653 656 3997294 and CC O O
24 657 663 3997294 prompt NN B-NP O
25 664 667 3997294 but CC O O
26 668 677 3997294 continued VBD B-VP O
27 678 685 3997294 steroid JJ B-NP B-Chemical
28 686 693 3997294 therapy NN I-NP O
29 694 696 3997294 to TO B-VP O
30 697 703 3997294 ensure VB I-VP O
31 704 708 3997294 full JJ B-NP O
32 709 717 3997294 recovery NN I-NP O
33 717 718 3997294 . . O O

1 0 0 1420741 -DOCSTART- -X- -X- O

1 0 9 1420741 Treatment NN B-NP O
2 10 12 1420741 of IN B-PP O
3 13 20 1420741 Crohn's NNS B-NP B-Disease
4 21 28 1420741 disease NN I-NP I-Disease
5 29 33 1420741 with IN B-PP O
6 34 41 1420741 fusidic JJ B-NP B-Chemical
7 42 46 1420741 acid NN I-NP I-Chemical
8 46 47 1420741 : : O O
9 48 50 1420741 an DT B-NP O
10 51 61 1420741 antibiotic NN I-NP O
11 62 66 1420741 with IN B-PP O
12 67 84 1420741 immunosuppressive JJ B-NP O
13 85 95 1420741 properties NNS I-NP O
14 96 103 1420741 similar JJ B-ADJP O
15 104 106 1420741 to TO B-PP O
16 107 118 1420741 cyclosporin NN B-NP B-Chemical
17 118 119 1420741 . . O O
18 120 127 1420741 Fusidic JJ B-NP O
19 128 132 1420741 acid NN I-NP O
20 133 135 1420741 is VBZ B-VP O
21 136 138 1420741 an DT B-NP O
22 139 149 1420741 antibiotic NN I-NP O
23 150 154 1420741 with IN B-PP O
24 155 156 1420741 T NN B-NP O
25 156 157 1420741 - HYPH I-NP O
26 157 161 1420741 cell NN I-NP O
27 162 170 1420741 specific JJ I-NP O
28 171 188 1420741 immunosuppressive JJ I-NP O
29 189 196 1420741 effects NNS I-NP O
30 197 204 1420741 similar JJ B-ADJP O
31 205 207 1420741 to TO B-PP O
32 208 213 1420741 those DT B-NP O
33 214 216 1420741 of IN B-PP O
34 217 228 1420741 cyclosporin NN B-NP B-Chemical
35 228 229 1420741 . . O O

1 230 237 1420741 Because IN B-PP O
2 238 240 1420741 of IN I-PP O
3 241 244 1420741 the DT B-NP O
4 245 249 1420741 need NN I-NP O
5 250 253 1420741 for IN B-PP O
6 254 257 1420741 the DT B-NP O
7 258 269 1420741 development NN I-NP O
8 270 272 1420741 of IN B-PP O
9 273 276 1420741 new JJ B-NP O
10 277 287 1420741 treatments NNS I-NP O
11 288 291 1420741 for IN B-PP O
12 292 299 1420741 Crohn's NNS B-NP B-Disease
13 300 307 1420741 disease NN I-NP I-Disease
14 307 308 1420741 , , O O
15 309 310 1420741 a DT B-NP O
16 311 316 1420741 pilot NN I-NP O
17 317 322 1420741 study NN I-NP O
18 323 326 1420741 was VBD B-VP O
19 327 337 1420741 undertaken VBN I-VP O
20 338 340 1420741 to TO I-VP O
21 341 349 1420741 estimate VB I-VP O
22 350 353 1420741 the DT B-NP O
23 354 370 1420741 pharmacodynamics NNS I-NP O
24 371 374 1420741 and CC I-NP O
25 375 387 1420741 tolerability NN I-NP O
26 388 390 1420741 of IN B-PP O
27 391 398 1420741 fusidic JJ B-NP B-Chemical
28 399 403 1420741 acid NN I-NP I-Chemical
29 404 413 1420741 treatment NN I-NP O
30 414 416 1420741 in IN B-PP O
31 417 424 1420741 chronic JJ B-NP O
32 425 431 1420741 active JJ I-NP O
33 431 432 1420741 , , I-NP O
34 433 440 1420741 therapy NN I-NP O
35 440 441 1420741 - HYPH I-NP O
36 441 450 1420741 resistant JJ B-NP O
37 451 459 1420741 patients NNS I-NP O
38 459 460 1420741 . . O O

1 461 466 1420741 Eight CD B-NP O
2 467 474 1420741 Crohn's NNS I-NP B-Disease
3 475 482 1420741 disease NN B-NP I-Disease
4 483 491 1420741 patients NNS I-NP O
5 492 496 1420741 were VBD B-VP O
6 497 505 1420741 included VBN I-VP O
7 505 506 1420741 . . O O

1 507 514 1420741 Fusidic JJ B-NP B-Chemical
2 515 519 1420741 acid NN I-NP I-Chemical
3 520 523 1420741 was VBD B-VP O
4 524 536 1420741 administered VBN I-VP O
5 537 543 1420741 orally RB B-ADVP O
6 544 546 1420741 in IN B-PP O
7 547 548 1420741 a DT B-NP O
8 549 553 1420741 dose NN I-NP O
9 554 556 1420741 of IN B-PP O
10 557 560 1420741 500 CD B-NP O
11 561 563 1420741 mg NN I-NP O
12 564 569 1420741 t.d.s NNS I-NP O
13 569 570 1420741 . . O O

1 571 574 1420741 and CC O O
2 575 578 1420741 the DT B-NP O
3 579 588 1420741 treatment NN I-NP O
4 589 592 1420741 was VBD B-VP O
5 593 600 1420741 planned VBN I-VP O
6 601 603 1420741 to TO I-VP O
7 604 608 1420741 last VB I-VP O
8 609 610 1420741 8 CD B-NP O
9 611 616 1420741 weeks NNS I-NP O
10 616 617 1420741 . . O O

1 618 621 1420741 The DT B-NP O
2 622 629 1420741 disease NN I-NP O
3 630 638 1420741 activity NN I-NP O
4 639 642 1420741 was VBD B-VP O
5 643 652 1420741 primarily RB I-VP O
6 653 661 1420741 measured VBN I-VP O
7 662 664 1420741 by IN B-PP O
8 665 666 1420741 a DT B-NP O
9 667 675 1420741 modified VBN I-NP O
10 676 686 1420741 individual JJ I-NP O
11 687 694 1420741 grading NN I-NP O
12 695 700 1420741 score NN I-NP O
13 700 701 1420741 . . O O

1 702 706 1420741 Five CD B-NP O
2 707 709 1420741 of IN B-PP O
3 710 711 1420741 8 CD B-NP O
4 712 720 1420741 patients NNS I-NP O
5 721 722 1420741 ( ( B-LST O
6 722 725 1420741 63% LS I-LST O
7 725 726 1420741 ) ) O O
8 727 735 1420741 improved VBN B-VP O
9 736 742 1420741 during IN B-PP O
10 743 750 1420741 fusidic JJ B-NP B-Chemical
11 751 755 1420741 acid NN I-NP I-Chemical
12 756 765 1420741 treatment NN I-NP O
13 765 766 1420741 : : O O
14 767 768 1420741 3 CD B-NP O
15 769 771 1420741 at IN B-PP O
16 772 775 1420741 two CD B-NP O
17 776 781 1420741 weeks NNS I-NP O
18 782 785 1420741 and CC O O
19 786 787 1420741 2 CD B-NP O
20 788 793 1420741 after IN I-NP O
21 794 798 1420741 four CD B-NP O
22 799 804 1420741 weeks NNS I-NP O
23 804 805 1420741 . . O O

1 806 811 1420741 There EX B-NP O
2 812 816 1420741 were VBD B-VP O
3 817 819 1420741 no DT B-NP O
4 820 827 1420741 serious JJ I-NP O
5 828 836 1420741 clinical JJ I-NP O
6 837 841 1420741 side NN I-NP O
7 842 849 1420741 effects NNS I-NP O
8 849 850 1420741 , , O O
9 851 854 1420741 but CC O O
10 855 859 1420741 dose NN B-NP O
11 860 869 1420741 reduction NN I-NP O
12 870 873 1420741 was VBD B-VP O
13 874 882 1420741 required VBN I-VP O
14 883 885 1420741 in IN B-PP O
15 886 889 1420741 two CD B-NP O
16 890 898 1420741 patients NNS I-NP O
17 899 906 1420741 because IN B-PP O
18 907 909 1420741 of IN I-PP O
19 910 916 1420741 nausea NN B-NP B-Disease
20 916 917 1420741 . . O O

1 918 931 1420741 Biochemically RB B-ADVP O
2 931 932 1420741 , , O O
3 933 935 1420741 an DT B-NP O
4 936 944 1420741 increase NN I-NP O
5 945 947 1420741 in IN B-PP O
6 948 956 1420741 alkaline NN B-NP O
7 957 969 1420741 phosphatases NNS I-NP O
8 970 973 1420741 was VBD B-VP O
9 974 979 1420741 noted VBN I-VP O
10 980 982 1420741 in IN B-PP O
11 983 984 1420741 5 CD B-NP O
12 985 987 1420741 of IN B-PP O
13 988 989 1420741 8 CD B-NP O
14 990 995 1420741 cases NNS I-NP O
15 996 997 1420741 ( ( O O
16 997 1000 1420741 63% NN B-NP O
17 1000 1001 1420741 ) ) O O
18 1001 1002 1420741 , , O O
19 1003 1006 1420741 and CC O O
20 1007 1010 1420741 the DT B-NP O
21 1011 1019 1420741 greatest JJS I-NP O
22 1020 1029 1420741 increases NNS I-NP O
23 1030 1034 1420741 were VBD B-VP O
24 1035 1039 1420741 seen VBN I-VP O
25 1040 1042 1420741 in IN B-PP O
26 1043 1048 1420741 those DT B-NP O
27 1049 1052 1420741 who WP B-NP O
28 1053 1056 1420741 had VBD B-VP O
29 1057 1065 1420741 elevated VBN I-VP O
30 1066 1072 1420741 levels NNS B-NP O
31 1073 1078 1420741 prior RB B-ADVP O
32 1079 1081 1420741 to TO B-PP O
33 1082 1091 1420741 treatment NN B-NP O
34 1091 1092 1420741 . . O O

1 1093 1096 1420741 All DT B-NP O
2 1097 1105 1420741 reversed VBD B-VP O
3 1106 1108 1420741 to TO B-PP O
4 1109 1112 1420741 pre AFX B-NP O
5 1112 1113 1420741 - HYPH I-NP O
6 1113 1122 1420741 treatment NN I-NP O
7 1123 1129 1420741 levels NNS I-NP O
8 1130 1135 1420741 after IN B-PP O
9 1136 1145 1420741 cessation NN B-NP O
10 1146 1148 1420741 of IN B-PP O
11 1149 1158 1420741 treatment NN B-NP O
12 1158 1159 1420741 . . O O

1 1160 1163 1420741 The DT B-NP O
2 1164 1171 1420741 results NNS I-NP O
3 1172 1174 1420741 of IN B-PP O
4 1175 1179 1420741 this DT B-NP O
5 1180 1185 1420741 pilot NN I-NP O
6 1186 1191 1420741 study NN I-NP O
7 1192 1199 1420741 suggest VBP B-VP O
8 1200 1204 1420741 that IN B-SBAR O
9 1205 1212 1420741 fusidic JJ B-NP B-Chemical
10 1213 1217 1420741 acid NN I-NP I-Chemical
11 1218 1221 1420741 may MD B-VP O
12 1222 1224 1420741 be VB I-VP O
13 1225 1227 1420741 of IN B-PP O
14 1228 1235 1420741 benefit NN B-NP O
15 1236 1238 1420741 in IN B-PP O
16 1239 1247 1420741 selected VBN B-NP O
17 1248 1255 1420741 chronic JJ I-NP O
18 1256 1262 1420741 active JJ I-NP O
19 1263 1270 1420741 Crohn's NNS I-NP B-Disease
20 1271 1278 1420741 disease NN B-NP I-Disease
21 1279 1287 1420741 patients NNS I-NP O
22 1288 1290 1420741 in IN B-PP O
23 1291 1295 1420741 whom WP B-NP O
24 1296 1308 1420741 conventional JJ B-NP O
25 1309 1318 1420741 treatment NN I-NP O
26 1319 1321 1420741 is VBZ B-VP O
27 1322 1333 1420741 ineffective JJ B-ADJP O
28 1333 1334 1420741 . . O O

1 1335 1342 1420741 Because IN B-SBAR O
2 1343 1348 1420741 there EX B-NP O
3 1349 1354 1420741 seems VBZ B-VP O
4 1355 1357 1420741 to TO I-VP O
5 1358 1363 1420741 exist VB I-VP O
6 1364 1365 1420741 a DT B-NP O
7 1366 1376 1420741 scientific JJ I-NP O
8 1377 1386 1420741 rationale NN I-NP O
9 1387 1390 1420741 for IN B-PP O
10 1391 1394 1420741 the DT B-NP O
11 1395 1398 1420741 use NN I-NP O
12 1399 1401 1420741 of IN B-PP O
13 1402 1409 1420741 fusidic JJ B-NP B-Chemical
14 1410 1414 1420741 acid NN I-NP I-Chemical
15 1415 1417 1420741 at IN B-PP O
16 1418 1421 1420741 the DT B-NP O
17 1422 1430 1420741 cytokine NN I-NP O
18 1431 1436 1420741 level NN I-NP O
19 1437 1439 1420741 in IN B-PP O
20 1440 1452 1420741 inflammatory JJ B-NP B-Disease
21 1453 1458 1420741 bowel NN I-NP I-Disease
22 1459 1466 1420741 disease NN I-NP I-Disease
23 1466 1467 1420741 , , O O
24 1468 1470 1420741 we PRP B-NP O
25 1471 1478 1420741 suggest VBP B-VP O
26 1479 1483 1420741 that IN B-SBAR O
27 1484 1487 1420741 the DT B-NP O
28 1488 1492 1420741 role NN I-NP O
29 1493 1495 1420741 of IN B-PP O
30 1496 1500 1420741 this DT B-NP O
31 1501 1510 1420741 treatment NN I-NP O
32 1511 1517 1420741 should MD B-VP O
33 1518 1520 1420741 be VB I-VP O
34 1521 1528 1420741 further RBR B-ADJP O
35 1529 1541 1420741 investigated VBN I-ADJP O
36 1541 1542 1420741 . . O O

1 0 0 84204 -DOCSTART- -X- -X- O

1 0 15 84204 Pharmacokinetic JJ B-NP O
2 16 19 84204 and CC I-NP O
3 20 28 84204 clinical JJ I-NP O
4 29 36 84204 studies NNS I-NP O
5 37 39 84204 in IN B-PP O
6 40 48 84204 patients NNS B-NP O
7 49 53 84204 with IN B-PP O
8 54 64 84204 cimetidine NN B-NP B-Chemical
9 64 65 84204 - HYPH O O
10 65 75 84204 associated VBN B-NP O
11 76 82 84204 mental JJ I-NP O
12 83 92 84204 confusion NN I-NP B-Disease
13 92 93 84204 . . O O
14 94 96 84204 15 CD B-NP O
15 97 102 84204 cases NNS I-NP O
16 103 105 84204 of IN B-PP O
17 106 116 84204 cimetidine NN B-NP B-Chemical
18 116 117 84204 - HYPH O O
19 117 127 84204 associated VBN B-NP O
20 128 134 84204 mental JJ I-NP O
21 135 144 84204 confusion NN I-NP B-Disease
22 145 149 84204 have VBP B-VP O
23 150 154 84204 been VBN I-VP O
24 155 163 84204 reported VBN I-VP O
25 163 164 84204 . . O O

1 165 167 84204 In IN B-PP O
2 168 173 84204 order NN B-NP O
3 174 178 84204 that IN B-SBAR O
4 179 183 84204 this DT B-NP O
5 184 192 84204 syndrome NN I-NP O
6 193 198 84204 might MD B-VP O
7 199 201 84204 be VB I-VP O
8 202 214 84204 investigated VBN I-VP O
9 215 222 84204 changes NNS B-NP O
10 223 225 84204 in IN B-PP O
11 226 232 84204 mental JJ B-NP O
12 233 239 84204 status NN I-NP O
13 240 241 84204 ( ( O O
14 241 244 84204 M.S NN B-NP O
15 244 245 84204 . . O O
16 245 246 84204 ) ) O O
17 247 251 84204 were VBD B-VP O
18 252 262 84204 correlated VBN I-VP O
19 263 267 84204 with IN B-PP O
20 268 273 84204 serum NN B-NP O
21 274 288 84204 concentrations NNS I-NP O
22 289 292 84204 and CC O O
23 293 298 84204 renal JJ B-NP O
24 299 302 84204 and CC I-NP O
25 303 310 84204 hepatic JJ I-NP O
26 311 319 84204 function NN I-NP O
27 320 322 84204 in IN B-PP O
28 323 325 84204 36 CD B-NP O
29 326 334 84204 patients NNS I-NP O
30 334 335 84204 , , O O
31 336 338 84204 30 CD B-NP O
32 339 347 84204 patients NNS I-NP O
33 348 351 84204 had VBD B-VP O
34 352 354 84204 no DT B-NP O
35 355 358 84204 M.S NN I-NP O
36 358 359 84204 . . I-NP O
37 360 366 84204 change NN I-NP O
38 367 369 84204 on IN B-PP O
39 370 380 84204 cimetidine NN B-NP B-Chemical
40 381 384 84204 and CC O O
41 385 386 84204 6 CD B-NP O
42 387 390 84204 had VBD B-VP O
43 391 399 84204 moderate JJ B-ADJP O
44 400 402 84204 to TO B-PP O
45 403 409 84204 severe JJ B-NP O
46 410 417 84204 changes NNS I-NP O
47 417 418 84204 . . O O

1 419 424 84204 These DT B-NP O
2 425 426 84204 6 CD I-NP O
3 427 435 84204 patients NNS I-NP O
4 436 439 84204 had VBD B-VP O
5 440 444 84204 both CC B-NP O
6 445 450 84204 renal JJ I-NP B-Disease
7 451 454 84204 and CC O I-Disease
8 455 460 84204 liver NN B-NP I-Disease
9 461 472 84204 dysfunction NN I-NP I-Disease
10 473 474 84204 ( ( O O
11 474 475 84204 P NN B-NP O
12 476 480 84204 less JJR B-ADJP O
13 481 485 84204 than IN B-PP O
14 486 490 84204 0.05 CD B-NP O
15 490 491 84204 ) ) O O
16 491 492 84204 , , O O
17 493 495 84204 as RB B-CONJP O
18 496 500 84204 well RB I-CONJP O
19 501 503 84204 as IN I-CONJP O
20 504 514 84204 cimetidine NN B-NP B-Chemical
21 515 521 84204 trough NN I-NP O
22 521 522 84204 - HYPH O O
23 522 536 84204 concentrations NNS B-NP O
24 537 539 84204 of IN B-PP O
25 540 544 84204 more JJR B-NP O
26 545 549 84204 than IN I-NP O
27 550 554 84204 1.25 CD I-NP O
28 555 564 84204 microgram NN I-NP O
29 564 565 84204 / SYM B-NP O
30 565 567 84204 ml NN B-NP O
31 568 569 84204 ( ( O O
32 569 570 84204 P NN B-NP O
33 571 575 84204 less JJR B-ADJP O
34 576 580 84204 than IN B-PP O
35 581 585 84204 0.05 CD B-NP O
36 585 586 84204 ) ) O O
37 586 587 84204 . . O O

1 588 591 84204 The DT B-NP O
2 592 600 84204 severity NN I-NP O
3 601 603 84204 of IN B-PP O
4 604 607 84204 M.S NN B-NP O
5 607 608 84204 . . O O
6 609 616 84204 changes NNS B-NP O
7 617 626 84204 increased VBD B-VP O
8 627 629 84204 as IN B-PP O
9 630 636 84204 trough NN B-NP O
10 636 637 84204 - HYPH O O
11 637 651 84204 concentrations NNS B-NP O
12 652 656 84204 rose VBD B-VP O
13 656 657 84204 , , O O
14 658 659 84204 5 CD B-NP O
15 660 668 84204 patients NNS I-NP O
16 669 672 84204 had VBD B-VP O
17 673 679 84204 lumbar JJ B-NP O
18 680 688 84204 puncture NN I-NP O
19 688 689 84204 . . O O

1 690 693 84204 The DT B-NP O
2 694 707 84204 cerebrospinal JJ I-NP O
3 708 713 84204 fluid NN I-NP O
4 713 714 84204 : : O O
5 715 720 84204 serum NN B-NP O
6 721 726 84204 ratio NN I-NP O
7 727 729 84204 of IN B-PP O
8 730 740 84204 cimetidine NN B-NP B-Chemical
9 741 755 84204 concentrations NNS I-NP O
10 756 759 84204 was VBD B-VP O
11 760 764 84204 0.24 CD B-NP O
12 764 765 84204 : : O O
13 765 766 84204 1 CD B-NP O
14 767 770 84204 and CC O O
15 771 780 84204 indicates VBZ B-VP O
16 781 785 84204 that IN B-SBAR O
17 786 796 84204 cimetidine NN B-NP B-Chemical
18 797 803 84204 passes VBZ B-VP O
19 804 807 84204 the DT B-NP O
20 808 813 84204 blood NN I-NP O
21 813 814 84204 - HYPH I-NP O
22 814 819 84204 brain NN I-NP O
23 820 827 84204 barrier NN I-NP O
24 827 828 84204 ; : O O
25 829 831 84204 it PRP B-NP O
26 832 836 84204 also RB B-ADVP O
27 837 843 84204 raises VBZ B-VP O
28 844 847 84204 the DT B-NP O
29 848 859 84204 possibility NN I-NP O
30 860 864 84204 that IN B-SBAR O
31 865 868 84204 M.S NN B-NP O
32 868 869 84204 . . I-NP O
33 870 877 84204 changes NNS I-NP O
34 878 881 84204 are VBP B-VP O
35 882 885 84204 due JJ B-ADJP O
36 886 888 84204 to TO B-PP O
37 889 897 84204 blockade NN B-NP O
38 898 900 84204 of IN B-PP O
39 901 910 84204 histamine NN B-NP B-Chemical
40 911 913 84204 H2 NN I-NP O
41 913 914 84204 - HYPH B-NP O
42 914 923 84204 receptors NNS I-NP O
43 924 926 84204 in IN B-PP O
44 927 930 84204 the DT B-NP O
45 931 938 84204 central JJ I-NP O
46 939 946 84204 nervous JJ I-NP O
47 947 953 84204 system NN I-NP O
48 953 954 84204 . . O O

1 955 963 84204 Patients NNS B-NP O
2 964 970 84204 likely JJ B-ADJP O
3 971 973 84204 to TO B-VP O
4 974 978 84204 have VB I-VP O
5 979 983 84204 both CC O O
6 984 990 84204 raised VBN B-NP O
7 991 997 84204 trough NN I-NP O
8 997 998 84204 - HYPH B-NP O
9 998 1012 84204 concentrations NNS I-NP O
10 1013 1016 84204 and CC O O
11 1017 1023 84204 mental JJ B-NP O
12 1024 1033 84204 confusion NN I-NP B-Disease
13 1034 1037 84204 are VBP B-VP O
14 1038 1043 84204 those DT B-NP O
15 1044 1048 84204 with IN B-PP O
16 1049 1053 84204 both CC O O
17 1054 1060 84204 severe JJ B-NP O
18 1061 1066 84204 renal JJ I-NP B-Disease
19 1067 1070 84204 and CC I-NP I-Disease
20 1071 1078 84204 hepatic JJ I-NP I-Disease
21 1079 1090 84204 dysfunction NN I-NP I-Disease
22 1090 1091 84204 . . O O

1 1092 1096 84204 They PRP B-NP O
2 1097 1103 84204 should MD B-VP O
3 1104 1106 84204 be VB I-VP O
4 1107 1114 84204 closely RB I-VP O
5 1115 1123 84204 observed VBN I-VP O
6 1124 1127 84204 and CC O O
7 1128 1134 84204 should MD B-VP O
8 1135 1137 84204 be VB I-VP O
9 1138 1143 84204 given VBN I-VP O
10 1144 1151 84204 reduced VBN B-NP O
11 1152 1157 84204 doses NNS I-NP O
12 1158 1160 84204 of IN B-PP O
13 1161 1171 84204 cimetidine NN B-NP B-Chemical
14 1171 1172 84204 . . O O

1 0 0 9522143 -DOCSTART- -X- -X- O

1 0 3 9522143 The DT B-NP O
2 4 10 9522143 effect NN I-NP O
3 11 13 9522143 of IN B-PP O
4 14 23 9522143 different JJ B-NP O
5 24 35 9522143 anaesthetic JJ I-NP O
6 36 42 9522143 agents NNS I-NP O
7 43 45 9522143 in IN B-PP O
8 46 53 9522143 hearing NN B-NP B-Disease
9 54 58 9522143 loss NN I-NP I-Disease
10 59 68 9522143 following VBG B-PP O
11 69 75 9522143 spinal JJ B-NP O
12 76 87 9522143 anaesthesia NN I-NP O
13 87 88 9522143 . . O O
14 89 92 9522143 The DT B-NP O
15 93 98 9522143 cause NN I-NP O
16 99 101 9522143 of IN B-PP O
17 102 109 9522143 hearing NN B-NP B-Disease
18 110 114 9522143 loss NN I-NP I-Disease
19 115 120 9522143 after IN B-PP O
20 121 127 9522143 spinal JJ B-NP O
21 128 139 9522143 anaesthesia NN I-NP O
22 140 142 9522143 is VBZ B-VP O
23 143 150 9522143 unknown JJ B-ADJP O
24 150 151 9522143 . . O O

1 152 154 9522143 Up IN B-PP O
2 155 160 9522143 until IN B-PP O
3 161 164 9522143 now RB B-NP O
4 164 165 9522143 , , O O
5 166 169 9522143 the DT B-NP O
6 170 174 9522143 only JJ I-NP O
7 175 181 9522143 factor NN I-NP O
8 182 189 9522143 studied VBN B-ADJP O
9 190 193 9522143 has VBZ B-VP O
10 194 198 9522143 been VBN I-VP O
11 199 202 9522143 the DT B-NP O
12 203 209 9522143 effect NN I-NP O
13 210 212 9522143 of IN B-PP O
14 213 216 9522143 the DT B-NP O
15 217 225 9522143 diameter NN I-NP O
16 226 228 9522143 of IN B-PP O
17 229 232 9522143 the DT B-NP O
18 233 239 9522143 spinal JJ I-NP O
19 240 246 9522143 needle NN I-NP O
20 247 249 9522143 on IN B-PP O
21 250 254 9522143 post AFX B-NP O
22 254 255 9522143 - HYPH I-NP O
23 255 264 9522143 operative JJ I-NP O
24 265 278 9522143 sensorineural JJ I-NP B-Disease
25 279 286 9522143 hearing NN I-NP I-Disease
26 287 291 9522143 loss NN I-NP I-Disease
27 291 292 9522143 . . O O

1 293 296 9522143 The DT B-NP O
2 297 300 9522143 aim NN I-NP O
3 301 303 9522143 of IN B-PP O
4 304 308 9522143 this DT B-NP O
5 309 314 9522143 study NN I-NP O
6 315 318 9522143 was VBD B-VP O
7 319 321 9522143 to TO B-VP O
8 322 330 9522143 describe VB I-VP O
9 331 335 9522143 this DT B-NP O
10 336 343 9522143 hearing NN I-NP B-Disease
11 344 348 9522143 loss NN I-NP I-Disease
12 349 352 9522143 and CC O O
13 353 355 9522143 to TO B-VP O
14 356 367 9522143 investigate VB I-VP O
15 368 373 9522143 other JJ B-NP O
16 374 381 9522143 factors NNS I-NP O
17 382 393 9522143 influencing VBG B-VP O
18 394 397 9522143 the DT B-NP O
19 398 404 9522143 degree NN I-NP O
20 405 407 9522143 of IN B-PP O
21 408 415 9522143 hearing NN B-NP B-Disease
22 416 420 9522143 loss NN I-NP I-Disease
23 420 421 9522143 . . O O

1 422 425 9522143 Two CD B-NP O
2 426 432 9522143 groups NNS I-NP O
3 433 435 9522143 of IN B-PP O
4 436 438 9522143 22 CD B-NP O
5 439 446 9522143 similar JJ I-NP O
6 447 455 9522143 patients NNS I-NP O
7 456 460 9522143 were VBD B-VP O
8 461 468 9522143 studied VBN I-VP O
9 468 469 9522143 : : O O
10 470 473 9522143 one CD B-NP O
11 474 479 9522143 group NN I-NP O
12 480 488 9522143 received VBD B-VP O
13 489 490 9522143 6 CD B-NP O
14 491 493 9522143 mL NN I-NP O
15 494 504 9522143 prilocaine NN I-NP B-Chemical
16 505 507 9522143 2% NN I-NP O
17 507 508 9522143 ; : O O
18 509 512 9522143 and CC O O
19 513 516 9522143 the DT B-NP O
20 517 522 9522143 other JJ I-NP O
21 523 531 9522143 received VBD B-VP O
22 532 533 9522143 3 CD B-NP O
23 534 536 9522143 mL NN I-NP O
24 537 548 9522143 bupivacaine NN I-NP B-Chemical
25 549 553 9522143 0.5% CD I-NP O
26 553 554 9522143 . . O O

1 555 563 9522143 Patients NNS B-NP O
2 564 569 9522143 given VBN B-PP O
3 570 580 9522143 prilocaine NN B-NP B-Chemical
4 581 585 9522143 were VBD B-VP O
5 586 590 9522143 more RBR B-ADJP O
6 591 597 9522143 likely JJ I-ADJP O
7 598 600 9522143 to TO B-VP O
8 601 608 9522143 develop VB I-VP O
9 609 616 9522143 hearing NN B-NP B-Disease
10 617 621 9522143 loss NN I-NP I-Disease
11 622 623 9522143 ( ( O O
12 623 625 9522143 10 CD B-NP O
13 626 629 9522143 out IN B-PP O
14 630 632 9522143 of IN B-PP O
15 633 635 9522143 22 CD B-NP O
16 635 636 9522143 ) ) O O
17 637 641 9522143 than IN B-PP O
18 642 647 9522143 those DT B-NP O
19 648 653 9522143 given VBN I-NP O
20 654 665 9522143 bupivacaine NN I-NP B-Chemical
21 666 667 9522143 ( ( O O
22 667 668 9522143 4 CD B-NP O
23 669 672 9522143 out IN B-PP O
24 673 675 9522143 of IN B-PP O
25 676 678 9522143 22 CD B-NP O
26 678 679 9522143 ) ) O O
27 680 681 9522143 ( ( O O
28 681 682 9522143 P NN B-NP O
29 683 684 9522143 < SYM O O
30 685 689 9522143 0.05 CD B-NP O
31 689 690 9522143 ) ) O O
32 690 691 9522143 . . O O

1 692 695 9522143 The DT B-NP O
2 696 703 9522143 average JJ I-NP O
3 704 711 9522143 hearing NN I-NP B-Disease
4 712 716 9522143 loss NN I-NP I-Disease
5 717 720 9522143 for IN B-PP O
6 721 727 9522143 speech NN B-NP O
7 728 739 9522143 frequencies NNS I-NP O
8 740 743 9522143 was VBD B-VP O
9 744 749 9522143 about IN B-NP O
10 750 752 9522143 10 CD I-NP O
11 753 755 9522143 dB NN I-NP O
12 756 761 9522143 after IN B-PP O
13 762 772 9522143 prilocaine NN B-NP B-Chemical
14 773 776 9522143 and CC O O
15 777 779 9522143 15 CD B-NP O
16 780 782 9522143 dB NN I-NP O
17 783 788 9522143 after IN B-PP O
18 789 800 9522143 bupivacaine NN B-NP B-Chemical
19 800 801 9522143 . . O O

1 802 806 9522143 None NN B-NP O
2 807 809 9522143 of IN B-PP O
3 810 813 9522143 the DT B-NP O
4 814 822 9522143 patients NNS I-NP O
5 823 833 9522143 complained VBD B-VP O
6 834 836 9522143 of IN B-PP O
7 837 847 9522143 subjective JJ B-NP O
8 848 855 9522143 hearing NN I-NP B-Disease
9 856 860 9522143 loss NN I-NP I-Disease
10 860 861 9522143 . . O O

1 862 866 9522143 Long JJ B-NP O
2 866 867 9522143 - HYPH I-NP O
3 867 871 9522143 term NN I-NP O
4 872 878 9522143 follow VB B-VP O
5 878 879 9522143 - HYPH O O
6 879 881 9522143 up RP B-PRT O
7 882 884 9522143 of IN B-PP O
8 885 888 9522143 the DT B-NP O
9 889 897 9522143 patients NNS I-NP O
10 898 901 9522143 was VBD B-VP O
11 902 905 9522143 not RB O O
12 906 914 9522143 possible JJ B-ADJP O
13 914 915 9522143 . . O O

1 0 0 11773892 -DOCSTART- -X- -X- O

1 0 3 11773892 End NN B-NP B-Disease
2 3 4 11773892 - HYPH I-NP I-Disease
3 4 9 11773892 stage NN I-NP I-Disease
4 10 15 11773892 renal JJ I-NP I-Disease
5 16 23 11773892 disease NN I-NP I-Disease
6 24 25 11773892 ( ( O O
7 25 29 11773892 ESRD NN B-NP B-Disease
8 29 30 11773892 ) ) O O
9 31 36 11773892 after IN B-PP O
10 37 47 11773892 orthotopic JJ B-NP O
11 48 53 11773892 liver NN I-NP O
12 54 69 11773892 transplantation NN I-NP O
13 70 71 11773892 ( ( O O
14 71 75 11773892 OLTX NN B-NP O
15 75 76 11773892 ) ) O O
16 77 82 11773892 using VBG B-VP O
17 83 94 11773892 calcineurin NN B-NP O
18 94 95 11773892 - HYPH O O
19 95 100 11773892 based VBN B-NP O
20 101 114 11773892 immunotherapy NN I-NP O
21 114 115 11773892 : : O O
22 116 120 11773892 risk NN B-NP O
23 121 123 11773892 of IN B-PP O
24 124 135 11773892 development NN B-NP O
25 136 139 11773892 and CC I-NP O
26 140 149 11773892 treatment NN I-NP O
27 149 150 11773892 . . I-NP O
28 151 161 11773892 BACKGROUND NN I-NP O
29 161 162 11773892 : : O O
30 163 166 11773892 The DT B-NP O
31 167 178 11773892 calcineurin NN I-NP O
32 179 189 11773892 inhibitors NNS I-NP O
33 190 202 11773892 cyclosporine NN I-NP B-Chemical
34 203 206 11773892 and CC I-NP O
35 207 217 11773892 tacrolimus NN I-NP B-Chemical
36 218 221 11773892 are VBP B-VP O
37 222 226 11773892 both DT O O
38 227 232 11773892 known VBN B-VP O
39 233 235 11773892 to TO I-VP O
40 236 238 11773892 be VB I-VP O
41 239 250 11773892 nephrotoxic JJ B-ADJP B-Disease
42 250 251 11773892 . . O O

1 252 257 11773892 Their PRP$ B-NP O
2 258 261 11773892 use NN I-NP O
3 262 264 11773892 in IN B-PP O
4 265 275 11773892 orthotopic JJ B-NP O
5 276 281 11773892 liver NN I-NP O
6 282 297 11773892 transplantation NN I-NP O
7 298 299 11773892 ( ( O O
8 299 303 11773892 OLTX NN B-NP O
9 303 304 11773892 ) ) O O
10 305 308 11773892 has VBZ B-VP O
11 309 321 11773892 dramatically RB I-VP O
12 322 330 11773892 improved VBN B-NP O
13 331 338 11773892 success NN I-NP O
14 339 344 11773892 rates NNS I-NP O
15 344 345 11773892 . . O O

1 346 354 11773892 Recently RB B-ADVP O
2 354 355 11773892 , , O O
3 356 363 11773892 however RB B-ADVP O
4 363 364 11773892 , , O O
5 365 367 11773892 we PRP B-NP O
6 368 372 11773892 have VBP B-VP O
7 373 376 11773892 had VBN I-VP O
8 377 379 11773892 an DT B-NP O
9 380 388 11773892 increase NN I-NP O
10 389 391 11773892 of IN B-PP O
11 392 400 11773892 patients NNS B-NP O
12 401 404 11773892 who WP B-NP O
13 405 408 11773892 are VBP B-VP O
14 409 419 11773892 presenting VBG I-VP O
15 420 425 11773892 after IN B-PP O
16 426 430 11773892 OLTX NN B-NP O
17 431 435 11773892 with IN B-PP O
18 436 439 11773892 end NN B-NP B-Disease
19 439 440 11773892 - HYPH I-NP I-Disease
20 440 445 11773892 stage NN I-NP I-Disease
21 446 451 11773892 renal JJ I-NP I-Disease
22 452 459 11773892 disease NN I-NP I-Disease
23 460 461 11773892 ( ( O O
24 461 465 11773892 ESRD NN B-NP B-Disease
25 465 466 11773892 ) ) O O
26 466 467 11773892 . . O O

1 468 472 11773892 This DT B-NP O
2 473 486 11773892 retrospective JJ I-NP O
3 487 492 11773892 study NN I-NP O
4 493 501 11773892 examines VBZ B-VP O
5 502 505 11773892 the DT B-NP O
6 506 515 11773892 incidence NN I-NP O
7 516 519 11773892 and CC I-NP O
8 520 529 11773892 treatment NN I-NP O
9 530 532 11773892 of IN B-PP O
10 533 537 11773892 ESRD NN B-NP B-Disease
11 538 541 11773892 and CC O O
12 542 549 11773892 chronic JJ B-NP B-Disease
13 550 555 11773892 renal JJ I-NP I-Disease
14 556 563 11773892 failure NN I-NP I-Disease
15 564 565 11773892 ( ( O O
16 565 568 11773892 CRF NN B-NP B-Disease
17 568 569 11773892 ) ) O O
18 570 572 11773892 in IN B-PP O
19 573 577 11773892 OLTX NN B-NP O
20 578 586 11773892 patients NNS I-NP O
21 586 587 11773892 . . O O

1 588 595 11773892 METHODS NNS B-NP O
2 595 596 11773892 : : O O
3 597 605 11773892 Patients NNS B-NP O
4 606 615 11773892 receiving VBG B-VP O
5 616 618 11773892 an DT B-NP O
6 619 623 11773892 OLTX NN I-NP O
7 624 628 11773892 only RB B-ADVP O
8 629 633 11773892 from IN B-PP O
9 634 638 11773892 June NNP B-NP O
10 639 643 11773892 1985 CD I-NP O
11 644 651 11773892 through IN B-PP O
12 652 660 11773892 December NNP B-NP O
13 661 663 11773892 of IN B-PP O
14 664 668 11773892 1994 CD B-NP O
15 669 672 11773892 who WP B-NP O
16 673 681 11773892 survived VBD B-VP O
17 682 683 11773892 6 CD B-NP O
18 684 690 11773892 months NNS I-NP O
19 691 706 11773892 postoperatively RB B-ADVP O
20 707 711 11773892 were VBD B-VP O
21 712 719 11773892 studied VBN I-VP O
22 720 721 11773892 ( ( O O
23 721 722 11773892 n NN B-NP O
24 722 723 11773892 = SYM B-VP O
25 723 726 11773892 834 CD B-NP O
26 726 727 11773892 ) ) O O
27 727 728 11773892 . . O O

1 729 732 11773892 Our PRP$ B-NP O
2 733 746 11773892 prospectively RB I-NP O
3 747 756 11773892 collected VBN I-NP O
4 757 765 11773892 database NN I-NP O
5 766 769 11773892 was VBD B-VP O
6 770 773 11773892 the DT B-NP O
7 774 780 11773892 source NN I-NP O
8 781 783 11773892 of IN B-PP O
9 784 795 11773892 information NN B-NP O
10 795 796 11773892 . . O O

1 797 805 11773892 Patients NNS B-NP O
2 806 810 11773892 were VBD B-VP O
3 811 818 11773892 divided VBN I-VP O
4 819 823 11773892 into IN B-PP O
5 824 829 11773892 three CD B-NP O
6 830 836 11773892 groups NNS I-NP O
7 836 837 11773892 : : O O
8 838 846 11773892 Controls NNS B-NP O
9 846 847 11773892 , , O O
10 848 850 11773892 no DT B-NP O
11 851 854 11773892 CRF NN I-NP B-Disease
12 855 857 11773892 or CC I-NP O
13 858 862 11773892 ESRD NN I-NP B-Disease
14 862 863 11773892 , , O O
15 864 865 11773892 n NN B-NP O
16 865 866 11773892 = SYM B-VP O
17 866 869 11773892 748 CD B-NP O
18 869 870 11773892 ; : O O
19 871 874 11773892 CRF NN B-NP B-Disease
20 874 875 11773892 , , O O
21 876 885 11773892 sustained VBD B-VP O
22 886 891 11773892 serum NN B-NP O
23 892 902 11773892 creatinine NN I-NP B-Chemical
24 903 904 11773892 > SYM O O
25 904 907 11773892 2.5 CD B-NP O
26 908 910 11773892 mg NN I-NP O
27 910 911 11773892 / SYM O O
28 911 913 11773892 dl NN B-NP O
29 913 914 11773892 , , O O
30 915 916 11773892 n NN B-NP O
31 916 917 11773892 = SYM B-VP O
32 917 919 11773892 41 CD B-NP O
33 919 920 11773892 ; : O O
34 921 924 11773892 and CC O O
35 925 929 11773892 ESRD NNP B-NP B-Disease
36 929 930 11773892 , , O O
37 931 932 11773892 n NN B-NP O
38 932 933 11773892 = SYM B-VP O
39 933 935 11773892 45 CD B-NP O
40 935 936 11773892 . . O O

1 937 943 11773892 Groups NNS B-NP O
2 944 948 11773892 were VBD B-VP O
3 949 957 11773892 compared VBN I-VP O
4 958 961 11773892 for IN B-PP O
5 962 974 11773892 preoperative JJ B-NP O
6 975 985 11773892 laboratory NN I-NP O
7 986 995 11773892 variables NNS I-NP O
8 995 996 11773892 , , O O
9 997 1006 11773892 diagnosis NN B-NP O
10 1006 1007 11773892 , , O O
11 1008 1021 11773892 postoperative JJ B-NP O
12 1022 1031 11773892 variables NNS I-NP O
13 1031 1032 11773892 , , O O
14 1033 1041 11773892 survival NN B-NP O
15 1041 1042 11773892 , , O O
16 1043 1047 11773892 type NN B-NP O
17 1048 1050 11773892 of IN B-PP O
18 1051 1055 11773892 ESRD NN B-NP B-Disease
19 1056 1063 11773892 therapy NN I-NP O
20 1063 1064 11773892 , , O O
21 1065 1068 11773892 and CC O O
22 1069 1077 11773892 survival NN B-NP O
23 1078 1082 11773892 from IN B-PP O
24 1083 1088 11773892 onset NN B-NP O
25 1089 1091 11773892 of IN B-PP O
26 1092 1096 11773892 ESRD NNP B-NP B-Disease
27 1096 1097 11773892 . . O O

1 1098 1105 11773892 RESULTS NNS B-NP O
2 1105 1106 11773892 : : O O
3 1107 1109 11773892 At IN B-PP O
4 1110 1112 11773892 13 CD B-NP O
5 1113 1118 11773892 years NNS I-NP O
6 1119 1124 11773892 after IN B-PP O
7 1125 1129 11773892 OLTX NN B-NP O
8 1129 1130 11773892 , , O O
9 1131 1134 11773892 the DT B-NP O
10 1135 1144 11773892 incidence NN I-NP O
11 1145 1147 11773892 of IN B-PP O
12 1148 1154 11773892 severe JJ B-NP O
13 1155 1160 11773892 renal JJ I-NP B-Disease
14 1161 1172 11773892 dysfunction NN I-NP I-Disease
15 1173 1176 11773892 was VBD B-VP O
16 1177 1182 11773892 18.1% CD B-NP O
17 1183 1184 11773892 ( ( O O
18 1184 1187 11773892 CRF NN B-NP B-Disease
19 1188 1192 11773892 8.6% NN I-NP O
20 1193 1196 11773892 and CC O O
21 1197 1201 11773892 ESRD NN B-NP B-Disease
22 1202 1206 11773892 9.5% CD I-NP O
23 1206 1207 11773892 ) ) O O
24 1207 1208 11773892 . . O O

1 1209 1217 11773892 Compared VBN B-PP O
2 1218 1222 11773892 with IN B-PP O
3 1223 1230 11773892 control NN B-NP O
4 1231 1239 11773892 patients NNS I-NP O
5 1239 1240 11773892 , , O O
6 1241 1244 11773892 CRF NN B-NP B-Disease
7 1245 1248 11773892 and CC O O
8 1249 1253 11773892 ESRD NN B-NP B-Disease
9 1254 1262 11773892 patients NNS I-NP O
10 1263 1266 11773892 had VBD B-VP O
11 1267 1273 11773892 higher JJR B-NP O
12 1274 1286 11773892 preoperative JJ I-NP O
13 1287 1292 11773892 serum NN I-NP O
14 1293 1303 11773892 creatinine NN I-NP B-Chemical
15 1304 1310 11773892 levels NNS I-NP O
16 1310 1311 11773892 , , O O
17 1312 1313 11773892 a DT B-NP O
18 1314 1321 11773892 greater JJR I-NP O
19 1322 1332 11773892 percentage NN I-NP O
20 1333 1335 11773892 of IN B-PP O
21 1336 1344 11773892 patients NNS B-NP O
22 1345 1349 11773892 with IN B-PP O
23 1350 1361 11773892 hepatorenal JJ B-NP B-Disease
24 1362 1370 11773892 syndrome NN I-NP I-Disease
25 1370 1371 11773892 , , O O
26 1372 1378 11773892 higher JJR B-NP O
27 1379 1389 11773892 percentage NN I-NP O
28 1390 1401 11773892 requirement NN I-NP O
29 1402 1405 11773892 for IN B-PP O
30 1406 1414 11773892 dialysis NN B-NP O
31 1415 1417 11773892 in IN B-PP O
32 1418 1421 11773892 the DT B-NP O
33 1422 1427 11773892 first JJ I-NP O
34 1428 1429 11773892 3 CD I-NP O
35 1430 1436 11773892 months NNS I-NP O
36 1437 1452 11773892 postoperatively RB B-ADVP O
37 1452 1453 11773892 , , O O
38 1454 1457 11773892 and CC O O
39 1458 1459 11773892 a DT B-NP O
40 1460 1466 11773892 higher JJR I-NP O
41 1467 1468 11773892 1 CD I-NP O
42 1468 1469 11773892 - HYPH I-NP O
43 1469 1473 11773892 year NN I-NP O
44 1474 1479 11773892 serum NN I-NP O
45 1480 1490 11773892 creatinine NN I-NP B-Chemical
46 1490 1491 11773892 . . O O

1 1492 1504 11773892 Multivariate JJ B-NP O
2 1505 1513 11773892 stepwise JJ I-NP O
3 1514 1522 11773892 logistic JJ I-NP O
4 1523 1533 11773892 regression NN I-NP O
5 1534 1542 11773892 analysis NN I-NP O
6 1543 1548 11773892 using VBG B-VP O
7 1549 1561 11773892 preoperative JJ B-NP O
8 1562 1565 11773892 and CC I-NP O
9 1566 1579 11773892 postoperative JJ I-NP O
10 1580 1589 11773892 variables NNS I-NP O
11 1590 1600 11773892 identified VBN B-VP O
12 1601 1605 11773892 that IN B-SBAR O
13 1606 1608 11773892 an DT B-NP O
14 1609 1617 11773892 increase NN I-NP O
15 1618 1620 11773892 of IN B-PP O
16 1621 1626 11773892 serum NN B-NP O
17 1627 1637 11773892 creatinine NN I-NP B-Chemical
18 1638 1646 11773892 compared VBN B-PP O
19 1647 1651 11773892 with IN B-PP O
20 1652 1659 11773892 average NN B-NP O
21 1660 1662 11773892 at IN B-PP O
22 1663 1664 11773892 1 CD B-NP O
23 1665 1669 11773892 year NN I-NP O
24 1669 1670 11773892 , , O O
25 1671 1672 11773892 3 CD B-NP O
26 1673 1679 11773892 months NNS I-NP O
27 1679 1680 11773892 , , O O
28 1681 1684 11773892 and CC O O
29 1685 1686 11773892 4 CD B-NP O
30 1687 1692 11773892 weeks NNS I-NP O
31 1693 1708 11773892 postoperatively RB B-ADVP O
32 1709 1713 11773892 were VBD B-VP O
33 1714 1725 11773892 independent JJ B-NP O
34 1726 1730 11773892 risk NN I-NP O
35 1731 1738 11773892 factors NNS I-NP O
36 1739 1742 11773892 for IN B-PP O
37 1743 1746 11773892 the DT B-NP O
38 1747 1758 11773892 development NN I-NP O
39 1759 1761 11773892 of IN B-PP O
40 1762 1765 11773892 CRF NN B-NP B-Disease
41 1766 1768 11773892 or CC I-NP O
42 1769 1773 11773892 ESRD NN I-NP B-Disease
43 1774 1778 11773892 with IN B-PP O
44 1779 1783 11773892 odds NNS B-NP O
45 1784 1790 11773892 ratios NNS I-NP O
46 1791 1793 11773892 of IN B-PP O
47 1794 1797 11773892 2.6 CD B-NP O
48 1797 1798 11773892 , , I-NP O
49 1799 1802 11773892 2.2 CD I-NP O
50 1802 1803 11773892 , , O O
51 1804 1807 11773892 and CC O O
52 1808 1811 11773892 1.6 CD B-NP O
53 1811 1812 11773892 , , O O
54 1813 1825 11773892 respectively RB B-ADVP O
55 1825 1826 11773892 . . O O

1 1827 1834 11773892 Overall JJ B-NP O
2 1835 1843 11773892 survival NN I-NP O
3 1844 1848 11773892 from IN B-PP O
4 1849 1852 11773892 the DT B-NP O
5 1853 1857 11773892 time NN I-NP O
6 1858 1860 11773892 of IN B-PP O
7 1861 1865 11773892 OLTX NN B-NP O
8 1866 1869 11773892 was VBD B-VP O
9 1870 1873 11773892 not RB O O
10 1874 1887 11773892 significantly RB B-ADJP O
11 1888 1897 11773892 different JJ I-ADJP O
12 1898 1903 11773892 among IN B-PP O
13 1904 1910 11773892 groups NNS B-NP O
14 1910 1911 11773892 , , O O
15 1912 1915 11773892 but CC O O
16 1916 1918 11773892 by IN B-PP O
17 1919 1923 11773892 year NN B-NP O
18 1924 1926 11773892 13 CD I-NP O
19 1926 1927 11773892 , , O O
20 1928 1931 11773892 the DT B-NP O
21 1932 1940 11773892 survival NN I-NP O
22 1941 1943 11773892 of IN B-PP O
23 1944 1947 11773892 the DT B-NP O
24 1948 1956 11773892 patients NNS I-NP O
25 1957 1960 11773892 who WP B-NP O
26 1961 1964 11773892 had VBD B-VP O
27 1965 1969 11773892 ESRD NN B-NP B-Disease
28 1970 1973 11773892 was VBD B-VP O
29 1974 1978 11773892 only RB B-NP O
30 1979 1984 11773892 28.2% CD I-NP O
31 1985 1993 11773892 compared VBN B-PP O
32 1994 1998 11773892 with IN B-PP O
33 1999 2004 11773892 54.6% NN B-NP O
34 2005 2007 11773892 in IN B-PP O
35 2008 2011 11773892 the DT B-NP O
36 2012 2019 11773892 control NN I-NP O
37 2020 2025 11773892 group NN I-NP O
38 2025 2026 11773892 . . O O

1 2027 2035 11773892 Patients NNS B-NP O
2 2036 2046 11773892 developing VBG B-VP O
3 2047 2051 11773892 ESRD NNP B-NP B-Disease
4 2052 2055 11773892 had VBD B-VP O
5 2056 2057 11773892 a DT B-NP O
6 2058 2059 11773892 6 CD I-NP O
7 2059 2060 11773892 - HYPH I-NP O
8 2060 2064 11773892 year NN I-NP O
9 2065 2073 11773892 survival NN I-NP O
10 2074 2079 11773892 after IN B-PP O
11 2080 2085 11773892 onset NN B-NP O
12 2086 2088 11773892 of IN B-PP O
13 2089 2093 11773892 ESRD NN B-NP B-Disease
14 2094 2096 11773892 of IN B-PP O
15 2097 2100 11773892 27% NN B-NP O
16 2101 2104 11773892 for IN B-PP O
17 2105 2108 11773892 the DT B-NP O
18 2109 2117 11773892 patients NNS I-NP O
19 2118 2127 11773892 receiving VBG B-VP O
20 2128 2140 11773892 hemodialysis NN B-NP O
21 2141 2147 11773892 versus IN B-PP O
22 2148 2153 11773892 71.4% NN B-NP O
23 2154 2157 11773892 for IN B-PP O
24 2158 2161 11773892 the DT B-NP O
25 2162 2170 11773892 patients NNS I-NP O
26 2171 2181 11773892 developing VBG B-VP O
27 2182 2186 11773892 ESRD NN B-NP B-Disease
28 2187 2190 11773892 who WP B-NP O
29 2191 2203 11773892 subsequently RB B-VP O
30 2204 2212 11773892 received VBD I-VP O
31 2213 2219 11773892 kidney NN B-NP O
32 2220 2231 11773892 transplants NNS I-NP O
33 2231 2232 11773892 . . O O

1 2233 2244 11773892 CONCLUSIONS NNS B-NP O
2 2244 2245 11773892 : : O O
3 2246 2254 11773892 Patients NNS B-NP O
4 2255 2258 11773892 who WP B-NP O
5 2259 2262 11773892 are VBP B-VP O
6 2263 2267 11773892 more JJR B-NP O
7 2268 2272 11773892 than IN I-NP O
8 2273 2275 11773892 10 CD I-NP O
9 2276 2281 11773892 years NNS I-NP O
10 2282 2286 11773892 post AFX O O
11 2286 2287 11773892 - HYPH O O
12 2287 2291 11773892 OLTX NN B-NP O
13 2292 2296 11773892 have VBP B-VP O
14 2297 2300 11773892 CRF NN B-NP B-Disease
15 2301 2304 11773892 and CC I-NP O
16 2305 2309 11773892 ESRD NN I-NP B-Disease
17 2310 2312 11773892 at IN B-PP O
18 2313 2314 11773892 a DT B-NP O
19 2315 2319 11773892 high JJ I-NP O
20 2320 2324 11773892 rate NN I-NP O
21 2324 2325 11773892 . . O O

1 2326 2329 11773892 The DT B-NP O
2 2330 2341 11773892 development NN I-NP O
3 2342 2344 11773892 of IN B-PP O
4 2345 2349 11773892 ESRD NN B-NP B-Disease
5 2350 2359 11773892 decreases VBZ B-VP O
6 2360 2368 11773892 survival NN B-NP O
7 2368 2369 11773892 , , O O
8 2370 2382 11773892 particularly RB B-ADVP O
9 2383 2385 11773892 in IN B-PP O
10 2386 2391 11773892 those DT B-NP O
11 2392 2400 11773892 patients NNS I-NP O
12 2401 2408 11773892 treated VBN B-VP O
13 2409 2413 11773892 with IN B-PP O
14 2414 2422 11773892 dialysis NN B-NP O
15 2423 2427 11773892 only RB B-ADVP O
16 2427 2428 11773892 . . O O

1 2429 2437 11773892 Patients NNS B-NP O
2 2438 2441 11773892 who WP B-NP O
3 2442 2449 11773892 develop VBP B-VP O
4 2450 2454 11773892 ESRD NNP B-NP B-Disease
5 2455 2459 11773892 have VBP B-VP O
6 2460 2461 11773892 a DT B-NP O
7 2462 2468 11773892 higher JJR I-NP O
8 2469 2481 11773892 preoperative JJ I-NP O
9 2482 2485 11773892 and CC I-NP O
10 2486 2487 11773892 1 CD I-NP O
11 2487 2488 11773892 - HYPH I-NP O
12 2488 2492 11773892 year NN I-NP O
13 2493 2498 11773892 serum NN I-NP O
14 2499 2509 11773892 creatinine NN I-NP B-Chemical
15 2510 2513 11773892 and CC O O
16 2514 2517 11773892 are VBP B-VP O
17 2518 2522 11773892 more RBR B-ADJP O
18 2523 2529 11773892 likely JJ I-ADJP O
19 2530 2532 11773892 to TO B-VP O
20 2533 2537 11773892 have VB I-VP O
21 2538 2549 11773892 hepatorenal JJ B-NP B-Disease
22 2550 2558 11773892 syndrome NN I-NP I-Disease
23 2558 2559 11773892 . . O O

1 2560 2567 11773892 However RB B-ADVP O
2 2567 2568 11773892 , , O O
3 2569 2571 11773892 an DT B-NP O
4 2572 2580 11773892 increase NN I-NP O
5 2581 2583 11773892 of IN B-PP O
6 2584 2589 11773892 serum NN B-NP O
7 2590 2600 11773892 creatinine NN I-NP B-Chemical
8 2601 2603 11773892 at IN B-PP O
9 2604 2611 11773892 various JJ B-NP O
10 2612 2617 11773892 times NNS I-NP O
11 2618 2633 11773892 postoperatively RB B-ADVP O
12 2634 2636 11773892 is VBZ B-VP O
13 2637 2641 11773892 more RBR B-ADJP O
14 2642 2652 11773892 predictive JJ I-ADJP O
15 2653 2655 11773892 of IN B-PP O
16 2656 2659 11773892 the DT B-NP O
17 2660 2671 11773892 development NN I-NP O
18 2672 2674 11773892 of IN B-PP O
19 2675 2678 11773892 CRF NN B-NP B-Disease
20 2679 2681 11773892 or CC I-NP O
21 2682 2686 11773892 ESRD NN I-NP B-Disease
22 2686 2687 11773892 . . O O

1 2688 2691 11773892 New JJ B-NP O
2 2692 2702 11773892 strategies NNS I-NP O
3 2703 2706 11773892 for IN B-PP O
4 2707 2711 11773892 long JJ B-NP O
5 2711 2712 11773892 - HYPH I-NP O
6 2712 2716 11773892 term NN I-NP O
7 2717 2734 11773892 immunosuppression NN I-NP O
8 2735 2738 11773892 may MD B-VP O
9 2739 2741 11773892 be VB I-VP O
10 2742 2748 11773892 needed VBN I-VP O
11 2749 2751 11773892 to TO B-VP O
12 2752 2760 11773892 decrease VB I-VP O
13 2761 2765 11773892 this DT B-NP O
14 2766 2778 11773892 complication NN I-NP O
15 2778 2779 11773892 . . O O

1 0 0 9351491 -DOCSTART- -X- -X- O

1 0 14 9351491 Extrapyramidal JJ B-NP O
2 15 19 9351491 side NN I-NP O
3 20 27 9351491 effects NNS I-NP O
4 28 32 9351491 with IN B-PP O
5 33 44 9351491 risperidone NN B-NP B-Chemical
6 45 48 9351491 and CC I-NP O
7 49 60 9351491 haloperidol NN I-NP B-Chemical
8 61 63 9351491 at IN B-PP O
9 64 74 9351491 comparable JJ B-NP O
10 75 77 9351491 D2 NN I-NP O
11 78 86 9351491 receptor NN I-NP O
12 87 96 9351491 occupancy NN I-NP O
13 97 103 9351491 levels NNS I-NP O
14 103 104 9351491 . . O O
15 105 116 9351491 Risperidone NN B-NP B-Chemical
16 117 119 9351491 is VBZ B-VP O
17 120 122 9351491 an DT B-NP O
18 123 136 9351491 antipsychotic JJ I-NP O
19 137 141 9351491 drug NN I-NP O
20 142 146 9351491 with IN B-PP O
21 147 151 9351491 high JJ B-NP O
22 152 160 9351491 affinity NN I-NP O
23 161 163 9351491 at IN B-PP O
24 164 172 9351491 dopamine NN B-NP B-Chemical
25 173 175 9351491 D2 NN I-NP O
26 176 179 9351491 and CC O O
27 180 189 9351491 serotonin NN B-NP B-Chemical
28 190 191 9351491 5 CD I-NP I-Chemical
29 191 192 9351491 - HYPH I-NP I-Chemical
30 192 195 9351491 HT2 NN I-NP I-Chemical
31 196 205 9351491 receptors NNS I-NP O
32 205 206 9351491 . . O O

1 207 215 9351491 Previous JJ B-NP O
2 216 224 9351491 clinical JJ I-NP O
3 225 232 9351491 studies NNS I-NP O
4 233 237 9351491 have VBP B-VP O
5 238 246 9351491 proposed VBN I-VP O
6 247 251 9351491 that IN B-SBAR O
7 252 265 9351491 risperidone's NNS B-NP B-Chemical
8 266 279 9351491 pharmacologic JJ B-NP O
9 280 287 9351491 profile NN I-NP O
10 288 291 9351491 may MD B-VP O
11 292 299 9351491 produce VB I-VP O
12 300 308 9351491 improved JJ B-NP O
13 309 317 9351491 efficacy NN I-NP O
14 318 321 9351491 for IN B-PP O
15 322 330 9351491 negative JJ B-NP O
16 331 340 9351491 psychotic JJ I-NP B-Disease
17 341 349 9351491 symptoms NNS I-NP I-Disease
18 350 353 9351491 and CC O O
19 354 363 9351491 decreased VBD B-VP O
20 364 374 9351491 propensity NN B-NP O
21 375 378 9351491 for IN B-PP O
22 379 393 9351491 extrapyramidal JJ B-NP O
23 394 398 9351491 side NN I-NP O
24 399 406 9351491 effects NNS I-NP O
25 406 407 9351491 ; : O O
26 408 416 9351491 features NNS B-NP O
27 417 423 9351491 shared VBN B-VP O
28 424 426 9351491 by IN B-PP O
29 427 429 9351491 so RB O O
30 429 430 9351491 - HYPH O O
31 430 436 9351491 called VBN B-VP O
32 437 438 9351491 ' `` B-NP O
33 438 446 9351491 atypical JJ I-NP O
34 446 447 9351491 ' '' I-NP O
35 448 460 9351491 neuroleptics NNS I-NP O
36 460 461 9351491 . . O O

1 462 464 9351491 To TO B-VP O
2 465 474 9351491 determine VB I-VP O
3 475 477 9351491 if IN B-SBAR O
4 478 485 9351491 routine JJ B-NP O
5 486 497 9351491 risperidone NN I-NP B-Chemical
6 498 507 9351491 treatment NN I-NP O
7 508 510 9351491 is VBZ B-VP O
8 511 521 9351491 associated VBN I-VP O
9 522 526 9351491 with IN B-PP O
10 527 528 9351491 a DT B-NP O
11 529 535 9351491 unique JJ I-NP O
12 536 542 9351491 degree NN I-NP O
13 543 545 9351491 of IN B-PP O
14 546 548 9351491 D2 NN B-NP O
15 549 557 9351491 receptor NN I-NP O
16 558 567 9351491 occupancy NN I-NP O
17 568 571 9351491 and CC I-NP O
18 572 579 9351491 pattern NN I-NP O
19 580 582 9351491 of IN B-PP O
20 583 591 9351491 clinical JJ B-NP O
21 592 599 9351491 effects NNS I-NP O
22 599 600 9351491 , , O O
23 601 603 9351491 we PRP B-NP O
24 604 608 9351491 used VBD B-VP O
25 609 619 9351491 [123I]IBZM NN B-NP O
26 620 625 9351491 SPECT NN I-NP O
27 626 628 9351491 to TO B-VP O
28 629 638 9351491 determine VB I-VP O
29 639 641 9351491 D2 NN B-NP O
30 642 651 9351491 occupancy NN I-NP O
31 652 654 9351491 in IN B-PP O
32 655 663 9351491 subjects NNS B-NP O
33 664 671 9351491 treated VBN B-VP O
34 672 676 9351491 with IN B-PP O
35 677 684 9351491 routine JJ B-NP O
36 685 693 9351491 clinical JJ I-NP O
37 694 699 9351491 doses NNS I-NP O
38 700 702 9351491 of IN B-PP O
39 703 714 9351491 risperidone NN B-NP B-Chemical
40 715 716 9351491 ( ( O O
41 716 717 9351491 n NN B-NP O
42 718 719 9351491 = SYM B-VP O
43 720 722 9351491 12 CD B-NP O
44 722 723 9351491 ) ) O O
45 724 726 9351491 or CC O O
46 727 738 9351491 haloperidol NN B-NP B-Chemical
47 739 740 9351491 ( ( O O
48 740 741 9351491 n NN B-NP O
49 742 743 9351491 = SYM B-VP O
50 744 745 9351491 7 CD B-NP O
51 745 746 9351491 ) ) O O
52 746 747 9351491 . . O O

1 748 752 9351491 Both CC O O
2 753 764 9351491 risperidone NN B-NP B-Chemical
3 765 768 9351491 and CC I-NP O
4 769 780 9351491 haloperidol NN I-NP B-Chemical
5 781 789 9351491 produced VBD B-VP O
6 790 792 9351491 D2 NN B-NP O
7 793 802 9351491 occupancy NN I-NP O
8 803 809 9351491 levels NNS I-NP O
9 810 817 9351491 between IN B-PP O
10 818 831 9351491 approximately RB B-NP O
11 832 834 9351491 60 CD I-NP O
12 835 838 9351491 and CC I-NP O
13 839 842 9351491 90% CD I-NP O
14 843 845 9351491 at IN B-PP O
15 846 854 9351491 standard JJ B-NP O
16 855 863 9351491 clinical JJ I-NP O
17 864 869 9351491 doses NNS I-NP O
18 869 870 9351491 . . O O

1 871 876 9351491 There EX B-NP O
2 877 880 9351491 was VBD B-VP O
3 881 883 9351491 no DT B-NP O
4 884 895 9351491 significant JJ I-NP O
5 896 906 9351491 difference NN I-NP O
6 907 914 9351491 between IN B-PP O
7 915 924 9351491 occupancy NN B-NP O
8 925 931 9351491 levels NNS I-NP O
9 932 940 9351491 obtained VBN B-VP O
10 941 945 9351491 with IN B-PP O
11 946 957 9351491 haloperidol NN B-NP B-Chemical
12 958 960 9351491 or CC I-NP O
13 961 972 9351491 risperidone NN I-NP B-Chemical
14 972 973 9351491 . . O O

1 974 978 9351491 Drug NN B-NP B-Disease
2 978 979 9351491 - HYPH B-NP I-Disease
3 979 986 9351491 induced VBN I-NP I-Disease
4 987 999 9351491 parkinsonism NN I-NP I-Disease
5 1000 1003 9351491 was VBD B-VP O
6 1004 1012 9351491 observed VBN I-VP O
7 1013 1015 9351491 in IN B-PP O
8 1016 1024 9351491 subjects NNS B-NP O
9 1025 1032 9351491 treated VBN B-VP O
10 1033 1037 9351491 with IN B-PP O
11 1038 1049 9351491 risperidone NN B-NP B-Chemical
12 1050 1051 9351491 ( ( O O
13 1051 1054 9351491 42% NN B-NP O
14 1054 1055 9351491 ) ) O O
15 1056 1059 9351491 and CC O O
16 1060 1071 9351491 haloperidol NN B-NP B-Chemical
17 1072 1073 9351491 ( ( O O
18 1073 1076 9351491 29% CD B-NP O
19 1076 1077 9351491 ) ) O O
20 1078 1081 9351491 and CC O O
21 1082 1085 9351491 was VBD B-VP O
22 1086 1094 9351491 observed VBN I-VP O
23 1095 1097 9351491 at IN B-PP O
24 1098 1107 9351491 occupancy NN B-NP O
25 1108 1114 9351491 levels NNS I-NP O
26 1115 1120 9351491 above IN B-PP O
27 1121 1124 9351491 60% NN B-NP O
28 1124 1125 9351491 . . O O

1 1126 1131 9351491 Based VBN B-PP O
2 1132 1134 9351491 on IN B-PP O
3 1135 1140 9351491 these DT B-NP O
4 1141 1153 9351491 observations NNS I-NP O
5 1153 1154 9351491 , , O O
6 1155 1157 9351491 it PRP B-NP O
7 1158 1160 9351491 is VBZ B-VP O
8 1161 1170 9351491 concluded VBN I-VP O
9 1171 1175 9351491 that IN B-SBAR O
10 1176 1177 9351491 5 CD B-NP O
11 1177 1178 9351491 - HYPH I-NP O
12 1178 1181 9351491 HT2 NN I-NP O
13 1182 1190 9351491 blockade NN I-NP O
14 1191 1199 9351491 obtained VBN B-VP O
15 1200 1204 9351491 with IN B-PP O
16 1205 1216 9351491 risperidone NN B-NP B-Chemical
17 1217 1219 9351491 at IN B-PP O
18 1220 1222 9351491 D2 NN B-NP O
19 1223 1232 9351491 occupancy NN I-NP O
20 1233 1238 9351491 rates NNS I-NP O
21 1239 1241 9351491 of IN B-PP O
22 1242 1245 9351491 60% NN B-NP O
23 1246 1249 9351491 and CC O O
24 1250 1255 9351491 above IN B-ADVP O
25 1256 1260 9351491 does VBZ B-VP O
26 1261 1264 9351491 not RB I-VP O
27 1265 1271 9351491 appear VB I-VP O
28 1272 1274 9351491 to TO I-VP O
29 1275 1282 9351491 protect VB I-VP O
30 1283 1290 9351491 against IN B-PP O
31 1291 1294 9351491 the DT B-NP O
32 1295 1299 9351491 risk NN I-NP O
33 1300 1303 9351491 for IN B-PP O
34 1304 1318 9351491 extrapyramidal JJ B-NP O
35 1319 1323 9351491 side NN I-NP O
36 1324 1331 9351491 effects NNS I-NP O
37 1331 1332 9351491 . . O O

1 0 0 16337777 -DOCSTART- -X- -X- O

1 0 13 16337777 Investigation NN B-NP O
2 14 16 16337777 of IN B-PP O
3 17 30 16337777 mitochondrial JJ B-NP O
4 31 42 16337777 involvement NN I-NP O
5 43 45 16337777 in IN B-PP O
6 46 49 16337777 the DT B-NP O
7 50 62 16337777 experimental JJ I-NP O
8 63 68 16337777 model NN I-NP O
9 69 71 16337777 of IN B-PP O
10 72 80 16337777 epilepsy NN B-NP B-Disease
11 81 88 16337777 induced VBN B-VP O
12 89 91 16337777 by IN B-PP O
13 92 103 16337777 pilocarpine NN B-NP B-Chemical
14 103 104 16337777 . . O O
15 105 118 16337777 Mitochondrial JJ B-NP B-Disease
16 119 132 16337777 abnormalities NNS I-NP I-Disease
17 133 137 16337777 have VBP B-VP O
18 138 142 16337777 been VBN I-VP O
19 143 153 16337777 associated VBN I-VP O
20 154 158 16337777 with IN B-PP O
21 159 166 16337777 several JJ B-NP O
22 167 174 16337777 aspects NNS I-NP O
23 175 177 16337777 of IN B-PP O
24 178 193 16337777 epileptogenesis NN B-NP O
25 193 194 16337777 , , O O
26 195 199 16337777 such JJ B-PP O
27 200 202 16337777 as IN I-PP O
28 203 209 16337777 energy NN B-NP O
29 210 220 16337777 generation NN I-NP O
30 220 221 16337777 , , O O
31 222 229 16337777 control NN B-NP O
32 230 232 16337777 of IN B-PP O
33 233 237 16337777 cell NN B-NP O
34 238 243 16337777 death NN I-NP B-Disease
35 243 244 16337777 , , O O
36 245 261 16337777 neurotransmitter NN B-NP O
37 262 271 16337777 synthesis NN I-NP O
38 271 272 16337777 , , O O
39 273 276 16337777 and CC O O
40 277 281 16337777 free JJ B-NP O
41 282 289 16337777 radical NN I-NP O
42 290 291 16337777 ( ( O O
43 291 293 16337777 FR NN B-NP O
44 293 294 16337777 ) ) O O
45 295 305 16337777 production NN B-NP O
46 305 306 16337777 . . O O

1 307 316 16337777 Increased VBN B-NP O
2 317 327 16337777 production NN I-NP O
3 328 330 16337777 of IN B-PP O
4 331 334 16337777 FRs NNS B-NP O
5 335 338 16337777 may MD B-VP O
6 339 344 16337777 cause VB I-VP O
7 345 350 16337777 mtDNA NN B-NP O
8 351 357 16337777 damage NN I-NP O
9 358 365 16337777 leading VBG B-VP O
10 366 368 16337777 to TO B-PP O
11 369 378 16337777 decreased VBN B-NP O
12 379 389 16337777 activities NNS I-NP O
13 390 392 16337777 of IN B-PP O
14 393 402 16337777 oxidative JJ B-NP O
15 403 418 16337777 phosphorylation NN I-NP O
16 419 428 16337777 complexes NNS I-NP O
17 429 439 16337777 containing VBG B-VP O
18 440 445 16337777 mtDNA NN B-NP O
19 445 446 16337777 - HYPH B-NP O
20 446 453 16337777 encoded VBN I-NP O
21 454 462 16337777 subunits NNS I-NP O
22 462 463 16337777 . . O O

1 464 466 16337777 In IN B-PP O
2 467 471 16337777 this DT B-NP O
3 472 477 16337777 study NN I-NP O
4 477 478 16337777 , , O O
5 479 481 16337777 we PRP B-NP O
6 482 494 16337777 investigated VBD B-VP O
7 495 502 16337777 whether IN B-SBAR O
8 503 512 16337777 increased VBN B-NP O
9 513 523 16337777 generation NN I-NP O
10 524 526 16337777 of IN B-PP O
11 527 529 16337777 FR NN B-NP O
12 530 536 16337777 during IN B-PP O
13 537 543 16337777 status NN B-NP B-Disease
14 544 555 16337777 epilepticus NN I-NP I-Disease
15 556 561 16337777 would MD B-VP O
16 562 564 16337777 be VB I-VP O
17 565 575 16337777 sufficient JJ B-ADJP O
18 576 578 16337777 to TO B-VP O
19 579 586 16337777 provoke VB I-VP O
20 587 600 16337777 abnormalities NNS B-NP O
21 601 603 16337777 in IN B-PP O
22 604 609 16337777 mtDNA NN B-NP O
23 610 613 16337777 and CC B-PP O
24 614 616 16337777 in IN B-PP O
25 617 620 16337777 the DT B-NP O
26 621 631 16337777 expression NN B-NP O
27 632 635 16337777 and CC O O
28 636 644 16337777 activity NN B-NP O
29 645 647 16337777 of IN B-PP O
30 648 658 16337777 cytochrome NN B-NP O
31 659 660 16337777 c NN I-NP O
32 661 668 16337777 oxidase NN I-NP O
33 669 670 16337777 ( ( O O
34 670 673 16337777 CCO NN B-NP O
35 673 674 16337777 ) ) O O
36 674 675 16337777 , , O O
37 676 683 16337777 complex NN B-NP O
38 684 686 16337777 IV CD I-NP O
39 687 689 16337777 of IN B-PP O
40 690 693 16337777 the DT B-NP O
41 694 705 16337777 respiratory JJ I-NP O
42 706 711 16337777 chain NN I-NP O
43 711 712 16337777 , , O O
44 713 715 16337777 in IN B-PP O
45 716 719 16337777 the DT B-NP O
46 720 727 16337777 chronic JJ I-NP O
47 728 733 16337777 phase NN I-NP O
48 734 736 16337777 of IN B-PP O
49 737 740 16337777 the DT B-NP O
50 741 752 16337777 pilocarpine NN I-NP B-Chemical
51 753 758 16337777 model NN I-NP O
52 759 761 16337777 of IN B-PP O
53 762 770 16337777 temporal JJ B-NP B-Disease
54 771 775 16337777 lobe NN I-NP I-Disease
55 776 784 16337777 epilepsy NN I-NP I-Disease
56 784 785 16337777 . . O O

1 786 789 16337777 DNA NN B-NP O
2 790 798 16337777 analysis NN I-NP O
3 799 807 16337777 revealed VBD B-VP O
4 808 811 16337777 low JJ B-NP O
5 812 819 16337777 amounts NNS I-NP O
6 820 822 16337777 of IN B-PP O
7 823 824 16337777 a DT B-NP O
8 825 828 16337777 4.8 CD I-NP O
9 829 831 16337777 kb NN I-NP O
10 832 837 16337777 mtDNA NN I-NP O
11 838 846 16337777 deletion NN I-NP O
12 847 850 16337777 but CC B-PP O
13 851 855 16337777 with IN B-PP O
14 856 858 16337777 no DT B-NP O
15 859 870 16337777 differences NNS I-NP O
16 871 873 16337777 in IN B-PP O
17 874 883 16337777 frequency NN B-NP O
18 884 886 16337777 or CC I-NP O
19 887 895 16337777 quantity NN I-NP O
20 896 898 16337777 in IN B-PP O
21 899 902 16337777 the DT B-NP O
22 903 910 16337777 control NN I-NP O
23 911 914 16337777 and CC I-NP O
24 915 927 16337777 experimental JJ I-NP O
25 928 934 16337777 groups NNS I-NP O
26 934 935 16337777 . . O O

1 936 938 16337777 We PRP B-NP O
2 939 942 16337777 did VBD B-VP O
3 943 946 16337777 not RB I-VP O
4 947 951 16337777 find VB I-VP O
5 952 965 16337777 abnormalities NNS B-NP O
6 966 968 16337777 in IN B-PP O
7 969 972 16337777 the DT B-NP O
8 973 983 16337777 expression NN B-NP O
9 984 987 16337777 and CC O O
10 988 1000 16337777 distribution NN B-NP O
11 1001 1003 16337777 of IN B-PP O
12 1004 1006 16337777 an DT B-NP O
13 1007 1012 16337777 mtDNA NN I-NP O
14 1012 1013 16337777 - HYPH B-VP O
15 1013 1020 16337777 encoded VBN B-NP O
16 1021 1028 16337777 subunit NN I-NP O
17 1029 1031 16337777 of IN B-PP O
18 1032 1035 16337777 CCO NN B-NP O
19 1036 1037 16337777 ( ( O O
20 1037 1040 16337777 CCO NN B-NP O
21 1040 1041 16337777 - HYPH B-NP O
22 1041 1042 16337777 I NN I-NP O
23 1042 1043 16337777 ) ) O O
24 1044 1046 16337777 or CC O O
25 1047 1048 16337777 a DT B-NP O
26 1049 1057 16337777 relative JJ I-NP O
27 1058 1066 16337777 decrease NN I-NP O
28 1067 1069 16337777 in IN B-PP O
29 1070 1073 16337777 CCO NN B-NP O
30 1073 1074 16337777 - HYPH O O
31 1074 1075 16337777 I PRP B-NP O
32 1076 1080 16337777 when WRB B-ADVP O
33 1081 1089 16337777 compared VBN B-PP O
34 1090 1094 16337777 with IN B-PP O
35 1095 1102 16337777 nuclear JJ B-NP O
36 1102 1103 16337777 - HYPH I-NP O
37 1103 1110 16337777 encoded VBN I-NP O
38 1111 1119 16337777 subunits NNS I-NP O
39 1120 1121 16337777 ( ( O O
40 1121 1124 16337777 CCO NN B-NP O
41 1124 1125 16337777 - HYPH B-NP O
42 1125 1127 16337777 IV CD I-NP O
43 1128 1131 16337777 and CC I-NP O
44 1132 1135 16337777 SDH NN I-NP O
45 1135 1136 16337777 - HYPH B-NP O
46 1136 1138 16337777 fp NN I-NP O
47 1138 1139 16337777 ) ) O O
48 1139 1140 16337777 . . O O

1 1141 1143 16337777 No DT B-NP O
2 1144 1155 16337777 abnormality NN I-NP O
3 1156 1158 16337777 in IN B-PP O
4 1159 1162 16337777 CCO NN B-NP O
5 1163 1171 16337777 activity NN I-NP O
6 1172 1175 16337777 was VBD B-VP O
7 1176 1184 16337777 observed VBN I-VP O
8 1185 1192 16337777 through IN B-PP O
9 1193 1207 16337777 histochemistry NN B-NP O
10 1207 1208 16337777 . . O O

1 1209 1217 16337777 Although IN B-SBAR O
2 1218 1227 16337777 evidences NNS B-NP O
3 1228 1230 16337777 of IN B-PP O
4 1231 1244 16337777 mitochondrial JJ B-NP B-Disease
5 1245 1258 16337777 abnormalities NNS I-NP I-Disease
6 1259 1263 16337777 were VBD B-VP O
7 1264 1269 16337777 found VBN I-VP O
8 1270 1272 16337777 in IN B-PP O
9 1273 1283 16337777 previously RB B-NP O
10 1284 1293 16337777 published VBN I-NP O
11 1294 1301 16337777 studies NNS I-NP O
12 1301 1302 16337777 , , O O
13 1303 1306 16337777 our PRP$ B-NP O
14 1307 1314 16337777 results NNS I-NP O
15 1315 1317 16337777 do VBP B-VP O
16 1318 1321 16337777 not RB I-VP O
17 1322 1329 16337777 suggest VB I-VP O
18 1330 1334 16337777 that IN B-SBAR O
19 1335 1338 16337777 the DT B-NP O
20 1339 1342 16337777 FRs NNS I-NP O
21 1342 1343 16337777 , , O O
22 1344 1353 16337777 generated VBN B-VP O
23 1354 1360 16337777 during IN B-PP O
24 1361 1364 16337777 the DT B-NP O
25 1365 1370 16337777 acute JJ I-NP O
26 1371 1376 16337777 phase NN I-NP O
27 1376 1377 16337777 , , O O
28 1378 1388 16337777 determined VBN B-VP O
29 1389 1398 16337777 important JJ B-NP O
30 1399 1412 16337777 abnormalities NNS I-NP O
31 1413 1415 16337777 in IN B-PP O
32 1416 1421 16337777 mtDNA NN B-NP O
33 1421 1422 16337777 , , O O
34 1423 1425 16337777 in IN B-PP O
35 1426 1436 16337777 expression NN B-NP O
36 1437 1439 16337777 of IN B-PP O
37 1440 1443 16337777 CCO NN B-NP O
38 1443 1444 16337777 - HYPH B-NP O
39 1444 1445 16337777 I NN I-NP O
40 1445 1446 16337777 , , O O
41 1447 1450 16337777 and CC O O
42 1451 1453 16337777 in IN B-PP O
43 1454 1457 16337777 CCO NN B-NP O
44 1458 1466 16337777 activity NN I-NP O
45 1466 1467 16337777 . . O O

1 0 0 11279304 -DOCSTART- -X- -X- O

1 0 5 11279304 Brain NN B-NP O
2 6 17 11279304 natriuretic JJ I-NP O
3 18 25 11279304 peptide NN I-NP O
4 26 28 11279304 is VBZ B-VP O
5 29 30 11279304 a DT B-NP O
6 31 40 11279304 predictor NN I-NP O
7 41 43 11279304 of IN B-PP O
8 44 57 11279304 anthracycline NN B-NP B-Chemical
9 57 58 11279304 - HYPH B-NP O
10 58 65 11279304 induced VBN I-NP O
11 66 80 11279304 cardiotoxicity NN I-NP B-Disease
12 80 81 11279304 . . O O
13 82 96 11279304 Anthracyclines NNS B-NP B-Chemical
14 97 100 11279304 are VBP B-VP O
15 101 110 11279304 effective JJ B-NP O
16 111 125 11279304 antineoplastic JJ I-NP O
17 126 131 11279304 drugs NNS I-NP O
18 131 132 11279304 , , O O
19 133 136 11279304 but CC O O
20 137 141 11279304 they PRP B-NP O
21 142 152 11279304 frequently RB B-ADVP O
22 153 158 11279304 cause VBP B-VP O
23 159 163 11279304 dose NN B-NP O
24 163 164 11279304 - HYPH B-VP O
25 164 171 11279304 related VBN B-NP O
26 172 186 11279304 cardiotoxicity NN I-NP B-Disease
27 186 187 11279304 . . O O

1 188 191 11279304 The DT B-NP O
2 192 206 11279304 cardiotoxicity NN I-NP B-Disease
3 207 209 11279304 of IN B-PP O
4 210 222 11279304 conventional JJ B-NP O
5 223 236 11279304 anthracycline NN I-NP B-Chemical
6 237 244 11279304 therapy NN I-NP O
7 245 255 11279304 highlights VBZ B-VP O
8 256 257 11279304 a DT B-NP O
9 258 262 11279304 need NN I-NP O
10 263 265 11279304 to TO B-VP O
11 266 272 11279304 search VB I-VP O
12 273 276 11279304 for IN B-PP O
13 277 284 11279304 methods NNS B-NP O
14 285 289 11279304 that WDT B-NP O
15 290 293 11279304 are VBP B-VP O
16 294 300 11279304 highly RB B-ADJP O
17 301 310 11279304 sensitive JJ I-ADJP O
18 311 314 11279304 and CC I-ADJP O
19 315 322 11279304 capable JJ I-ADJP O
20 323 325 11279304 of IN B-PP O
21 326 336 11279304 predicting VBG B-VP O
22 337 344 11279304 cardiac JJ B-NP B-Disease
23 345 356 11279304 dysfunction NN I-NP I-Disease
24 356 357 11279304 . . O O

1 358 360 11279304 We PRP B-NP O
2 361 369 11279304 measured VBD B-VP O
3 370 373 11279304 the DT B-NP O
4 374 380 11279304 plasma NN I-NP O
5 381 386 11279304 level NN I-NP O
6 387 389 11279304 of IN B-PP O
7 390 395 11279304 brain NN B-NP O
8 396 407 11279304 natriuretic JJ I-NP O
9 408 415 11279304 peptide NN I-NP O
10 416 417 11279304 ( ( O O
11 417 420 11279304 BNP NN B-NP O
12 420 421 11279304 ) ) O O
13 422 424 11279304 to TO B-VP O
14 425 434 11279304 determine VB I-VP O
15 435 442 11279304 whether IN B-SBAR O
16 443 446 11279304 BNP NN B-NP O
17 447 452 11279304 might MD B-VP O
18 453 458 11279304 serve VB I-VP O
19 459 461 11279304 as IN B-PP O
20 462 463 11279304 a DT B-NP O
21 464 470 11279304 simple JJ I-NP O
22 471 481 11279304 diagnostic JJ I-NP O
23 482 491 11279304 indicator NN I-NP O
24 492 494 11279304 of IN B-PP O
25 495 508 11279304 anthracycline NN B-NP B-Chemical
26 508 509 11279304 - HYPH B-NP O
27 509 516 11279304 induced VBN I-NP O
28 517 531 11279304 cardiotoxicity NN I-NP B-Disease
29 532 534 11279304 in IN B-PP O
30 535 543 11279304 patients NNS B-NP O
31 544 548 11279304 with IN B-PP O
32 549 554 11279304 acute JJ B-NP B-Disease
33 555 563 11279304 leukemia NN I-NP I-Disease
34 564 571 11279304 treated VBN B-VP O
35 572 576 11279304 with IN B-PP O
36 577 578 11279304 a DT B-NP O
37 579 591 11279304 daunorubicin NN I-NP B-Chemical
38 592 593 11279304 ( ( O O
39 593 596 11279304 DNR NN B-NP B-Chemical
40 596 597 11279304 ) ) O O
41 597 598 11279304 - HYPH O O
42 598 608 11279304 containing VBG B-VP O
43 609 616 11279304 regimen NN B-NP O
44 616 617 11279304 . . O O

1 618 626 11279304 Thirteen CD B-NP O
2 627 635 11279304 patients NNS I-NP O
3 636 640 11279304 with IN B-PP O
4 641 646 11279304 acute JJ B-NP B-Disease
5 647 655 11279304 leukemia NN I-NP I-Disease
6 656 660 11279304 were VBD B-VP O
7 661 668 11279304 treated VBN I-VP O
8 669 673 11279304 with IN B-PP O
9 674 675 11279304 a DT B-NP O
10 676 679 11279304 DNR NN I-NP B-Chemical
11 679 680 11279304 - HYPH O O
12 680 690 11279304 containing VBG B-VP O
13 691 698 11279304 regimen NN B-NP O
14 698 699 11279304 . . O O

1 700 707 11279304 Cardiac JJ B-NP O
2 708 717 11279304 functions NNS I-NP O
3 718 722 11279304 were VBD B-VP O
4 723 732 11279304 evaluated VBN I-VP O
5 733 737 11279304 with IN B-PP O
6 738 750 11279304 radionuclide NN B-NP O
7 751 762 11279304 angiography NN I-NP O
8 763 769 11279304 before IN B-PP O
9 770 784 11279304 chemotherapies NNS B-NP O
10 784 785 11279304 . . O O

1 786 789 11279304 The DT B-NP O
2 790 796 11279304 plasma NN I-NP O
3 797 803 11279304 levels NNS I-NP O
4 804 806 11279304 of IN B-PP O
5 807 813 11279304 atrial JJ B-NP O
6 814 825 11279304 natriuretic JJ I-NP O
7 826 833 11279304 peptide NN I-NP O
8 834 835 11279304 ( ( O O
9 835 838 11279304 ANP NN B-NP O
10 838 839 11279304 ) ) O O
11 840 843 11279304 and CC O O
12 844 847 11279304 BNP NN B-NP O
13 848 852 11279304 were VBD B-VP O
14 853 861 11279304 measured VBN I-VP O
15 862 864 11279304 at IN B-PP O
16 865 868 11279304 the DT B-NP O
17 869 873 11279304 time NN I-NP O
18 874 876 11279304 of IN B-PP O
19 877 889 11279304 radionuclide NN B-NP O
20 890 901 11279304 angiography NN I-NP O
21 901 902 11279304 . . O O

1 903 908 11279304 Three CD B-NP O
2 909 917 11279304 patients NNS I-NP O
3 918 927 11279304 developed VBD B-VP O
4 928 938 11279304 congestive JJ B-NP B-Disease
5 939 944 11279304 heart NN I-NP I-Disease
6 945 952 11279304 failure NN I-NP I-Disease
7 953 958 11279304 after IN B-PP O
8 959 962 11279304 the DT B-NP O
9 963 973 11279304 completion NN I-NP O
10 974 976 11279304 of IN B-PP O
11 977 989 11279304 chemotherapy NN B-NP O
12 989 990 11279304 . . O O

1 991 995 11279304 Five CD B-NP O
2 996 1004 11279304 patients NNS I-NP O
3 1005 1009 11279304 were VBD B-VP O
4 1010 1019 11279304 diagnosed VBN I-VP O
5 1020 1022 11279304 as IN B-PP O
6 1023 1029 11279304 having VBG B-VP O
7 1030 1041 11279304 subclinical JJ B-NP O
8 1042 1047 11279304 heart NN I-NP B-Disease
9 1048 1055 11279304 failure NN I-NP I-Disease
10 1056 1061 11279304 after IN B-PP O
11 1062 1065 11279304 the DT B-NP O
12 1066 1076 11279304 completion NN I-NP O
13 1077 1079 11279304 of IN B-PP O
14 1080 1092 11279304 chemotherapy NN B-NP O
15 1092 1093 11279304 . . O O

1 1094 1097 11279304 The DT B-NP O
2 1098 1104 11279304 plasma NN I-NP O
3 1105 1111 11279304 levels NNS I-NP O
4 1112 1114 11279304 of IN B-PP O
5 1115 1118 11279304 BNP NN B-NP O
6 1119 1121 11279304 in IN B-PP O
7 1122 1125 11279304 all PDT B-NP O
8 1126 1129 11279304 the DT I-NP O
9 1130 1138 11279304 patients NNS I-NP O
10 1139 1143 11279304 with IN B-PP O
11 1144 1152 11279304 clinical JJ B-NP O
12 1153 1156 11279304 and CC I-NP O
13 1157 1168 11279304 subclinical JJ I-NP O
14 1169 1174 11279304 heart NN I-NP B-Disease
15 1175 1182 11279304 failure NN I-NP I-Disease
16 1183 1192 11279304 increased VBD B-VP O
17 1193 1198 11279304 above IN B-PP O
18 1199 1202 11279304 the DT B-NP O
19 1203 1209 11279304 normal JJ I-NP O
20 1210 1215 11279304 limit NN I-NP O
21 1216 1217 11279304 ( ( O O
22 1217 1219 11279304 40 CD B-NP O
23 1220 1222 11279304 pg NN I-NP O
24 1222 1223 11279304 / SYM B-NP O
25 1223 1225 11279304 ml NN I-NP O
26 1225 1226 11279304 ) ) O O
27 1227 1233 11279304 before IN B-PP O
28 1234 1237 11279304 the DT B-NP O
29 1238 1247 11279304 detection NN I-NP O
30 1248 1250 11279304 of IN B-PP O
31 1251 1259 11279304 clinical JJ B-NP O
32 1260 1262 11279304 or CC I-NP O
33 1263 1274 11279304 subclinical JJ I-NP O
34 1275 1280 11279304 heart NN I-NP B-Disease
35 1281 1288 11279304 failure NN I-NP I-Disease
36 1289 1291 11279304 by IN B-PP O
37 1292 1304 11279304 radionuclide NN B-NP O
38 1305 1316 11279304 angiography NN I-NP O
39 1316 1317 11279304 . . O O

1 1318 1320 11279304 On IN B-PP O
2 1321 1324 11279304 the DT B-NP O
3 1325 1330 11279304 other JJ I-NP O
4 1331 1335 11279304 hand NN I-NP O
5 1335 1336 11279304 , , O O
6 1337 1340 11279304 BNP NN B-NP O
7 1341 1344 11279304 did VBD B-VP O
8 1345 1348 11279304 not RB I-VP O
9 1349 1357 11279304 increase VB I-VP O
10 1358 1360 11279304 in IN B-PP O
11 1361 1364 11279304 the DT B-NP O
12 1365 1373 11279304 patients NNS I-NP O
13 1374 1381 11279304 without IN B-PP O
14 1382 1387 11279304 heart NN B-NP B-Disease
15 1388 1395 11279304 failure NN I-NP I-Disease
16 1396 1401 11279304 given VBN B-PP O
17 1402 1405 11279304 DNR NN B-NP B-Chemical
18 1405 1406 11279304 , , O O
19 1407 1411 11279304 even RB B-ADVP O
20 1412 1414 11279304 at IN B-PP O
21 1415 1419 11279304 more JJR B-NP O
22 1420 1424 11279304 than IN I-NP O
23 1425 1428 11279304 700 CD I-NP O
24 1429 1431 11279304 mg NN I-NP O
25 1431 1432 11279304 / SYM B-NP O
26 1432 1436 11279304 m(2) NN I-NP O
27 1436 1437 11279304 . . O O

1 1438 1441 11279304 The DT B-NP O
2 1442 1448 11279304 plasma NN I-NP O
3 1449 1454 11279304 level NN I-NP O
4 1455 1457 11279304 of IN B-PP O
5 1458 1461 11279304 ANP NN B-NP O
6 1462 1465 11279304 did VBD B-VP O
7 1466 1469 11279304 not RB I-VP O
8 1470 1476 11279304 always RB I-VP O
9 1477 1485 11279304 increase VB I-VP O
10 1486 1488 11279304 in IN B-PP O
11 1489 1492 11279304 all PDT B-NP O
12 1493 1496 11279304 the DT I-NP O
13 1497 1505 11279304 patients NNS I-NP O
14 1506 1510 11279304 with IN B-PP O
15 1511 1519 11279304 clinical JJ B-NP O
16 1520 1523 11279304 and CC I-NP O
17 1524 1535 11279304 subclinical JJ I-NP O
18 1536 1541 11279304 heart NN I-NP B-Disease
19 1542 1549 11279304 failure NN I-NP I-Disease
20 1549 1550 11279304 . . O O

1 1551 1556 11279304 These DT B-NP O
2 1557 1568 11279304 preliminary JJ I-NP O
3 1569 1576 11279304 results NNS I-NP O
4 1577 1584 11279304 suggest VBP B-VP O
5 1585 1589 11279304 that IN B-SBAR O
6 1590 1593 11279304 BNP NN B-NP O
7 1594 1597 11279304 may MD B-VP O
8 1598 1600 11279304 be VB I-VP O
9 1601 1607 11279304 useful JJ B-ADJP O
10 1608 1610 11279304 as IN B-PP O
11 1611 1613 11279304 an DT B-NP O
12 1614 1619 11279304 early JJ I-NP O
13 1620 1623 11279304 and CC I-NP O
14 1624 1633 11279304 sensitive JJ I-NP O
15 1634 1643 11279304 indicator NN I-NP O
16 1644 1646 11279304 of IN B-PP O
17 1647 1660 11279304 anthracycline NN B-NP B-Chemical
18 1660 1661 11279304 - HYPH B-NP O
19 1661 1668 11279304 induced VBN I-NP O
20 1669 1683 11279304 cardiotoxicity NN I-NP B-Disease
21 1683 1684 11279304 . . O O

1 0 0 7858459 -DOCSTART- -X- -X- O

1 0 5 7858459 Acute JJ B-NP O
2 6 15 7858459 confusion NN I-NP B-Disease
3 16 23 7858459 induced VBN B-VP O
4 24 26 7858459 by IN B-PP O
5 27 28 7858459 a DT B-NP O
6 29 33 7858459 high JJ I-NP O
7 33 34 7858459 - HYPH I-NP O
8 34 38 7858459 dose NN I-NP O
9 39 47 7858459 infusion NN I-NP O
10 48 50 7858459 of IN B-PP O
11 51 52 7858459 5 CD B-NP B-Chemical
12 52 53 7858459 - HYPH I-NP I-Chemical
13 53 65 7858459 fluorouracil NN I-NP I-Chemical
14 66 69 7858459 and CC O O
15 70 77 7858459 folinic JJ B-NP B-Chemical
16 78 82 7858459 acid NN I-NP I-Chemical
17 82 83 7858459 . . O O
18 84 85 7858459 A DT B-NP O
19 86 88 7858459 61 CD I-NP O
20 88 89 7858459 - HYPH I-NP O
21 89 93 7858459 year NN I-NP O
22 93 94 7858459 - HYPH O O
23 94 97 7858459 old JJ B-NP O
24 98 101 7858459 man NN I-NP O
25 102 105 7858459 was VBD B-VP O
26 106 113 7858459 treated VBN I-VP O
27 114 118 7858459 with IN B-PP O
28 119 130 7858459 combination NN B-NP O
29 131 143 7858459 chemotherapy NN I-NP O
30 144 157 7858459 incorporating VBG B-VP O
31 158 169 7858459 cisplatinum NN B-NP B-Chemical
32 169 170 7858459 , , O O
33 171 180 7858459 etoposide NN B-NP B-Chemical
34 180 181 7858459 , , O O
35 182 186 7858459 high JJ B-NP O
36 186 187 7858459 - HYPH I-NP O
37 187 191 7858459 dose NN B-NP O
38 192 193 7858459 5 CD I-NP B-Chemical
39 193 194 7858459 - HYPH I-NP I-Chemical
40 194 206 7858459 fluorouracil NN I-NP I-Chemical
41 207 208 7858459 ( ( O O
42 208 213 7858459 2,250 CD B-NP O
43 214 216 7858459 mg NN I-NP O
44 216 217 7858459 / SYM B-NP O
45 217 219 7858459 m2 NN I-NP O
46 219 220 7858459 / SYM B-NP O
47 220 222 7858459 24 CD B-NP O
48 223 228 7858459 hours NNS I-NP O
49 228 229 7858459 ) ) O O
50 230 233 7858459 and CC O O
51 234 241 7858459 folinic JJ B-NP B-Chemical
52 242 246 7858459 acid NN I-NP I-Chemical
53 247 250 7858459 for IN B-PP O
54 251 253 7858459 an DT B-NP O
55 254 264 7858459 inoperable JJ I-NP O
56 265 272 7858459 gastric JJ I-NP B-Disease
57 273 287 7858459 adenocarcinoma NN I-NP I-Disease
58 287 288 7858459 . . O O

1 289 291 7858459 He PRP B-NP O
2 292 301 7858459 developed VBD B-VP O
3 302 307 7858459 acute JJ B-NP O
4 308 318 7858459 neurologic JJ I-NP O
5 319 327 7858459 symptoms NNS I-NP O
6 328 330 7858459 of IN B-PP O
7 331 337 7858459 mental JJ B-NP O
8 338 347 7858459 confusion NN I-NP B-Disease
9 347 348 7858459 , , I-NP O
10 349 363 7858459 disorientation NN I-NP B-Disease
11 364 367 7858459 and CC I-NP O
12 368 380 7858459 irritability NN I-NP B-Disease
13 380 381 7858459 , , O O
14 382 385 7858459 and CC O O
15 386 390 7858459 then RB B-ADVP O
16 391 397 7858459 lapsed VBD B-VP O
17 398 402 7858459 into IN B-PP O
18 403 404 7858459 a DT B-NP O
19 405 409 7858459 deep JJ I-NP O
20 410 414 7858459 coma NN I-NP B-Disease
21 414 415 7858459 , , O O
22 416 423 7858459 lasting VBG B-VP O
23 424 427 7858459 for IN B-PP O
24 428 441 7858459 approximately RB B-NP O
25 442 444 7858459 40 CD I-NP O
26 445 450 7858459 hours NNS I-NP O
27 451 457 7858459 during IN B-PP O
28 458 461 7858459 the DT B-NP O
29 462 467 7858459 first JJ I-NP O
30 468 472 7858459 dose NN I-NP O
31 473 474 7858459 ( ( O O
32 474 477 7858459 day NN B-NP O
33 478 479 7858459 2 CD I-NP O
34 479 480 7858459 ) ) O O
35 481 483 7858459 of IN B-PP O
36 484 485 7858459 5 CD B-NP B-Chemical
37 485 486 7858459 - HYPH I-NP I-Chemical
38 486 498 7858459 fluorouracil NN I-NP I-Chemical
39 499 502 7858459 and CC O O
40 503 510 7858459 folinic JJ B-NP B-Chemical
41 511 515 7858459 acid NN I-NP I-Chemical
42 516 524 7858459 infusion NN I-NP O
43 524 525 7858459 . . O O

1 526 530 7858459 This DT B-NP O
2 531 543 7858459 complication NN I-NP O
3 544 554 7858459 reappeared VBD B-VP O
4 555 557 7858459 on IN B-PP O
5 558 561 7858459 day NN B-NP O
6 562 564 7858459 25 CD I-NP O
7 565 571 7858459 during IN B-PP O
8 572 575 7858459 the DT B-NP O
9 576 582 7858459 second JJ I-NP O
10 583 587 7858459 dose NN I-NP O
11 588 590 7858459 of IN B-PP O
12 591 592 7858459 5 CD B-NP B-Chemical
13 592 593 7858459 - HYPH I-NP I-Chemical
14 593 605 7858459 fluorouracil NN I-NP I-Chemical
15 606 609 7858459 and CC O O
16 610 617 7858459 folinic JJ B-NP B-Chemical
17 618 622 7858459 acid NN I-NP I-Chemical
18 622 623 7858459 , , O O
19 624 629 7858459 which WDT B-NP O
20 630 634 7858459 were VBD B-VP O
21 635 639 7858459 then RB B-ADVP O
22 640 643 7858459 the DT B-NP O
23 644 648 7858459 only JJ I-NP O
24 649 654 7858459 drugs NNS I-NP O
25 655 660 7858459 given VBN B-VP O
26 660 661 7858459 . . O O

1 662 669 7858459 Because IN B-SBAR O
2 670 677 7858459 folinic JJ B-NP B-Chemical
3 678 682 7858459 acid NN I-NP I-Chemical
4 683 686 7858459 was VBD B-VP O
5 687 695 7858459 unlikely JJ B-ADJP O
6 696 698 7858459 to TO B-VP O
7 699 701 7858459 be VB I-VP O
8 702 712 7858459 associated VBN I-VP O
9 713 717 7858459 with IN B-PP O
10 718 722 7858459 this DT B-NP O
11 723 732 7858459 condition NN I-NP O
12 732 733 7858459 , , O O
13 734 747 7858459 neurotoxicity NN B-NP B-Disease
14 748 751 7858459 due JJ B-ADJP O
15 752 754 7858459 to TO B-PP O
16 755 759 7858459 high JJ B-NP O
17 759 760 7858459 - HYPH I-NP O
18 760 764 7858459 dose NN B-NP O
19 765 766 7858459 5 CD I-NP B-Chemical
20 766 767 7858459 - HYPH I-NP I-Chemical
21 767 779 7858459 fluorouracil NN I-NP I-Chemical
22 780 783 7858459 was VBD B-VP O
23 784 790 7858459 highly RB I-VP O
24 791 800 7858459 suspected VBN I-VP O
25 800 801 7858459 . . O O

1 802 805 7858459 The DT B-NP O
2 806 818 7858459 pathogenesis NN I-NP O
3 819 821 7858459 of IN B-PP O
4 822 823 7858459 5 CD B-NP B-Chemical
5 823 824 7858459 - HYPH I-NP I-Chemical
6 824 836 7858459 fluorouracil NN I-NP I-Chemical
7 837 850 7858459 neurotoxicity NN I-NP B-Disease
8 851 854 7858459 may MD B-VP O
9 855 857 7858459 be VB I-VP O
10 858 861 7858459 due JJ B-ADVP O
11 862 864 7858459 to TO B-PP O
12 865 866 7858459 a DT B-NP O
13 867 872 7858459 Krebs NNP I-NP O
14 873 878 7858459 cycle NN I-NP O
15 879 887 7858459 blockade NN I-NP O
16 888 890 7858459 by IN B-PP O
17 891 904 7858459 fluoroacetate NN B-NP B-Chemical
18 905 908 7858459 and CC I-NP O
19 909 922 7858459 fluorocitrate NN I-NP B-Chemical
20 922 923 7858459 , , O O
21 924 932 7858459 thiamine NN B-NP B-Chemical
22 933 943 7858459 deficiency NN I-NP O
23 943 944 7858459 , , O O
24 945 947 7858459 or CC O O
25 948 961 7858459 dihydrouracil NN B-NP B-Chemical
26 962 975 7858459 dehydrogenase NN I-NP O
27 976 986 7858459 deficiency NN I-NP O
28 986 987 7858459 . . O O

1 988 992 7858459 High JJ B-NP O
2 992 993 7858459 - HYPH I-NP O
3 993 997 7858459 dose NN B-NP O
4 998 999 7858459 5 CD I-NP B-Chemical
5 999 1000 7858459 - HYPH I-NP I-Chemical
6 1000 1012 7858459 fluorouracil NN I-NP I-Chemical
7 1012 1013 7858459 / SYM B-NP O
8 1013 1020 7858459 folinic JJ B-NP B-Chemical
9 1021 1025 7858459 acid NN I-NP I-Chemical
10 1026 1034 7858459 infusion NN I-NP O
11 1035 1042 7858459 therapy NN I-NP O
12 1043 1046 7858459 has VBZ B-VP O
13 1047 1055 7858459 recently RB I-VP O
14 1056 1062 7858459 become VBN I-VP O
15 1063 1064 7858459 a DT B-NP O
16 1065 1072 7858459 popular JJ I-NP O
17 1073 1080 7858459 regimen NN I-NP O
18 1081 1084 7858459 for IN B-PP O
19 1085 1092 7858459 various JJ B-NP O
20 1093 1100 7858459 cancers NNS I-NP B-Disease
21 1100 1101 7858459 . . O O

1 1102 1104 7858459 It PRP B-NP O
2 1105 1107 7858459 is VBZ B-VP O
3 1108 1117 7858459 necessary JJ B-ADJP O
4 1118 1122 7858459 that IN B-SBAR O
5 1123 1127 7858459 both CC O O
6 1128 1139 7858459 oncologists NNS B-NP O
7 1140 1143 7858459 and CC I-NP O
8 1144 1156 7858459 neurologists NNS I-NP O
9 1157 1159 7858459 be VB B-VP O
10 1160 1165 7858459 fully RB B-ADJP O
11 1166 1171 7858459 aware JJ I-ADJP O
12 1172 1174 7858459 of IN B-PP O
13 1175 1179 7858459 this DT B-NP O
14 1180 1187 7858459 unusual JJ I-NP O
15 1188 1200 7858459 complication NN I-NP O
16 1200 1201 7858459 . . O O

1 0 0 8669433 -DOCSTART- -X- -X- O

1 0 8 8669433 Habitual JJ B-NP O
2 9 12 8669433 use NN I-NP O
3 13 15 8669433 of IN B-PP O
4 16 29 8669433 acetaminophen NN B-NP B-Chemical
5 30 32 8669433 as IN B-PP O
6 33 34 8669433 a DT B-NP O
7 35 39 8669433 risk NN I-NP O
8 40 46 8669433 factor NN I-NP O
9 47 50 8669433 for IN B-PP O
10 51 58 8669433 chronic JJ B-NP B-Disease
11 59 64 8669433 renal JJ I-NP I-Disease
12 65 72 8669433 failure NN I-NP I-Disease
13 72 73 8669433 : : O O
14 74 75 8669433 a DT B-NP O
15 76 86 8669433 comparison NN I-NP O
16 87 91 8669433 with IN B-PP O
17 92 102 8669433 phenacetin NN B-NP B-Chemical
18 102 103 8669433 . . O O
19 104 107 8669433 Six CD B-NP O
20 108 121 8669433 epidemiologic JJ I-NP O
21 122 129 8669433 studies NNS I-NP O
22 130 132 8669433 in IN B-PP O
23 133 136 8669433 the DT B-NP O
24 137 143 8669433 United NNP I-NP O
25 144 150 8669433 States NNPS I-NP O
26 151 154 8669433 and CC O O
27 155 161 8669433 Europe NNP B-NP O
28 162 170 8669433 indicate VBP B-VP O
29 171 175 8669433 that IN B-SBAR O
30 176 184 8669433 habitual JJ B-NP O
31 185 188 8669433 use NN I-NP O
32 189 191 8669433 of IN B-PP O
33 192 202 8669433 phenacetin NN B-NP B-Chemical
34 203 205 8669433 is VBZ B-VP O
35 206 216 8669433 associated VBN I-VP O
36 217 221 8669433 with IN B-PP O
37 222 225 8669433 the DT B-NP O
38 226 237 8669433 development NN I-NP O
39 238 240 8669433 of IN B-PP O
40 241 248 8669433 chronic JJ B-NP B-Disease
41 249 254 8669433 renal JJ I-NP I-Disease
42 255 262 8669433 failure NN I-NP I-Disease
43 263 266 8669433 and CC I-NP O
44 267 270 8669433 end NN I-NP B-Disease
45 270 271 8669433 - HYPH B-NP I-Disease
46 271 276 8669433 stage NN I-NP I-Disease
47 277 282 8669433 renal JJ I-NP I-Disease
48 283 290 8669433 disease NN I-NP I-Disease
49 291 292 8669433 ( ( O O
50 292 296 8669433 ESRD NN B-NP B-Disease
51 296 297 8669433 ) ) O O
52 297 298 8669433 , , O O
53 299 303 8669433 with IN B-PP O
54 304 305 8669433 a DT B-NP O
55 306 314 8669433 relative JJ I-NP O
56 315 319 8669433 risk NN I-NP O
57 320 322 8669433 in IN B-PP O
58 323 326 8669433 the DT B-NP O
59 327 332 8669433 range NN I-NP O
60 333 335 8669433 of IN B-PP O
61 336 337 8669433 4 CD B-NP O
62 338 340 8669433 to TO B-PP O
63 341 343 8669433 19 CD B-NP O
64 343 344 8669433 . . O O

1 345 347 8669433 As IN B-PP O
2 348 349 8669433 a DT B-NP O
3 350 356 8669433 result NN I-NP O
4 357 359 8669433 of IN B-PP O
5 360 365 8669433 these DT B-NP O
6 366 369 8669433 and CC I-NP O
7 370 375 8669433 other JJ I-NP O
8 376 383 8669433 studies NNS I-NP O
9 383 384 8669433 , , O O
10 385 395 8669433 phenacetin NN B-NP B-Chemical
11 396 399 8669433 has VBZ B-VP O
12 400 403 8669433 now RB I-VP O
13 404 408 8669433 been VBN I-VP O
14 409 418 8669433 withdrawn VBN I-VP O
15 419 423 8669433 from IN B-PP O
16 424 427 8669433 the DT B-NP O
17 428 434 8669433 market NN I-NP O
18 435 437 8669433 in IN B-PP O
19 438 442 8669433 most JJS B-NP O
20 443 452 8669433 countries NNS I-NP O
21 452 453 8669433 . . O O

1 454 461 8669433 However RB B-ADVP O
2 461 462 8669433 , , O O
3 463 468 8669433 three CD B-NP O
4 469 473 8669433 case NN I-NP O
5 474 481 8669433 control NN I-NP O
6 482 489 8669433 studies NNS I-NP O
7 489 490 8669433 , , O O
8 491 494 8669433 one CD B-NP O
9 495 499 8669433 each DT B-NP O
10 500 502 8669433 in IN B-PP O
11 503 508 8669433 North NNP B-NP O
12 509 517 8669433 Carolina NNP I-NP O
13 517 518 8669433 , , O O
14 519 527 8669433 northern JJ B-NP O
15 528 536 8669433 Maryland NNP I-NP O
16 536 537 8669433 , , O O
17 538 541 8669433 and CC O O
18 542 546 8669433 West NNP B-NP O
19 547 553 8669433 Berlin NNP I-NP O
20 553 554 8669433 , , O O
21 555 562 8669433 Germany NNP B-NP O
22 562 563 8669433 , , O O
23 564 570 8669433 showed VBD B-VP O
24 571 575 8669433 that IN B-SBAR O
25 576 584 8669433 habitual JJ B-NP O
26 585 588 8669433 use NN I-NP O
27 589 591 8669433 of IN B-PP O
28 592 605 8669433 acetaminophen NN B-NP B-Chemical
29 606 608 8669433 is VBZ B-VP O
30 609 613 8669433 also RB I-VP O
31 614 624 8669433 associated VBN I-VP O
32 625 629 8669433 with IN B-PP O
33 630 637 8669433 chronic JJ B-NP B-Disease
34 638 643 8669433 renal JJ I-NP I-Disease
35 644 651 8669433 failure NN I-NP I-Disease
36 652 655 8669433 and CC I-NP O
37 656 660 8669433 ESRD NN I-NP B-Disease
38 660 661 8669433 , , O O
39 662 666 8669433 with IN B-PP O
40 667 668 8669433 a DT B-NP O
41 669 677 8669433 relative JJ I-NP O
42 678 682 8669433 risk NN I-NP O
43 683 685 8669433 in IN B-PP O
44 686 689 8669433 the DT B-NP O
45 690 695 8669433 range NN I-NP O
46 696 698 8669433 of IN B-PP O
47 699 700 8669433 2 CD B-NP O
48 701 703 8669433 to TO B-PP O
49 704 705 8669433 4 CD B-NP O
50 705 706 8669433 . . O O

1 707 712 8669433 These DT B-NP O
2 713 720 8669433 studies NNS I-NP O
3 721 728 8669433 suggest VBP B-VP O
4 729 733 8669433 that IN B-SBAR O
5 734 738 8669433 both CC O O
6 739 749 8669433 phenacetin NN B-NP B-Chemical
7 750 753 8669433 and CC I-NP O
8 754 767 8669433 acetaminophen NN I-NP B-Chemical
9 768 771 8669433 may MD B-VP O
10 772 782 8669433 contribute VB I-VP O
11 783 785 8669433 to TO B-PP O
12 786 789 8669433 the DT B-NP O
13 790 796 8669433 burden NN I-NP O
14 797 799 8669433 of IN B-PP O
15 800 804 8669433 ESRD NNP B-NP B-Disease
16 804 805 8669433 , , O O
17 806 810 8669433 with IN B-PP O
18 811 814 8669433 the DT B-NP O
19 815 819 8669433 risk NN I-NP O
20 820 822 8669433 of IN B-PP O
21 823 826 8669433 the DT B-NP O
22 827 833 8669433 latter JJ I-NP O
23 834 839 8669433 being VBG B-VP O
24 840 848 8669433 somewhat RB B-ADJP O
25 849 853 8669433 less JJR I-ADJP O
26 854 858 8669433 than IN B-PP O
27 859 863 8669433 that DT B-NP O
28 864 866 8669433 of IN B-PP O
29 867 870 8669433 the DT B-NP O
30 871 877 8669433 former JJ I-NP O
31 877 878 8669433 . . O O

1 879 883 8669433 This DT B-NP O
2 884 892 8669433 apparent JJ I-NP O
3 893 903 8669433 difference NN I-NP O
4 904 906 8669433 in IN B-PP O
5 907 911 8669433 risk NN B-NP O
6 912 915 8669433 may MD B-VP O
7 916 919 8669433 not RB I-VP O
8 920 922 8669433 be VB I-VP O
9 923 926 8669433 due JJ B-ADVP O
10 927 929 8669433 to TO B-PP O
11 930 941 8669433 differences NNS B-NP O
12 942 944 8669433 in IN B-PP O
13 945 956 8669433 nephrotoxic JJ B-NP B-Disease
14 957 966 8669433 potential NN I-NP O
15 967 969 8669433 of IN B-PP O
16 970 973 8669433 the DT B-NP O
17 974 979 8669433 drugs NNS I-NP O
18 980 990 8669433 themselves PRP B-NP O
19 990 991 8669433 . . O O

1 992 993 8669433 A DT B-NP O
2 994 999 8669433 lower JJR I-NP O
3 1000 1008 8669433 relative JJ I-NP O
4 1009 1013 8669433 risk NN I-NP O
5 1014 1019 8669433 would MD B-VP O
6 1020 1022 8669433 be VB I-VP O
7 1023 1031 8669433 expected VBN I-VP O
8 1032 1035 8669433 for IN B-PP O
9 1036 1049 8669433 acetaminophen NN B-NP B-Chemical
10 1050 1052 8669433 if IN B-SBAR O
11 1053 1056 8669433 the DT B-NP O
12 1057 1061 8669433 risk NN I-NP O
13 1062 1064 8669433 of IN B-PP O
14 1065 1069 8669433 both DT B-NP O
15 1070 1075 8669433 drugs NNS I-NP O
16 1076 1078 8669433 in IN B-PP O
17 1079 1090 8669433 combination NN B-NP O
18 1091 1095 8669433 with IN B-PP O
19 1096 1101 8669433 other JJ B-NP O
20 1102 1112 8669433 analgesics NNS I-NP O
21 1113 1116 8669433 was VBD B-VP O
22 1117 1123 8669433 higher JJR B-ADJP O
23 1124 1128 8669433 than IN B-PP O
24 1129 1132 8669433 the DT B-NP O
25 1133 1137 8669433 risk NN I-NP O
26 1138 1140 8669433 of IN B-PP O
27 1141 1147 8669433 either DT B-NP O
28 1148 1153 8669433 agent NN I-NP O
29 1154 1159 8669433 alone RB B-ADVP O
30 1159 1160 8669433 . . O O

1 1161 1165 8669433 Thus RB B-ADVP O
2 1165 1166 8669433 , , O O
3 1167 1180 8669433 acetaminophen NN B-NP B-Chemical
4 1181 1184 8669433 has VBZ B-VP O
5 1185 1189 8669433 been VBN I-VP O
6 1190 1194 8669433 used VBN I-VP O
7 1195 1199 8669433 both CC O O
8 1200 1202 8669433 as IN B-PP O
9 1203 1204 8669433 a DT B-NP O
10 1205 1211 8669433 single JJ I-NP O
11 1212 1217 8669433 agent NN I-NP O
12 1218 1221 8669433 and CC B-PP O
13 1222 1224 8669433 in IN B-PP O
14 1225 1236 8669433 combination NN B-NP O
15 1237 1241 8669433 with IN B-PP O
16 1242 1247 8669433 other JJ B-NP O
17 1248 1258 8669433 analgesics NNS I-NP O
18 1258 1259 8669433 , , O O
19 1260 1267 8669433 whereas IN O O
20 1268 1278 8669433 phenacetin NN B-NP B-Chemical
21 1279 1282 8669433 was VBD B-VP O
22 1283 1292 8669433 available JJ B-ADJP O
23 1293 1297 8669433 only RB B-ADVP O
24 1298 1300 8669433 in IN B-PP O
25 1301 1313 8669433 combinations NNS B-NP O
26 1313 1314 8669433 . . O O

1 1315 1318 8669433 The DT B-NP O
2 1319 1330 8669433 possibility NN I-NP O
3 1331 1335 8669433 that IN B-SBAR O
4 1336 1344 8669433 habitual JJ B-NP O
5 1345 1348 8669433 use NN I-NP O
6 1349 1351 8669433 of IN B-PP O
7 1352 1365 8669433 acetaminophen NN B-NP B-Chemical
8 1366 1371 8669433 alone RB B-ADVP O
9 1372 1381 8669433 increases VBZ B-VP O
10 1382 1385 8669433 the DT B-NP O
11 1386 1390 8669433 risk NN I-NP O
12 1391 1393 8669433 of IN B-PP O
13 1394 1398 8669433 ESRD NNP B-NP B-Disease
14 1399 1402 8669433 has VBZ B-VP O
15 1403 1406 8669433 not RB I-VP O
16 1407 1411 8669433 been VBN I-VP O
17 1412 1419 8669433 clearly RB I-VP O
18 1420 1432 8669433 demonstrated VBN I-VP O
19 1432 1433 8669433 , , O O
20 1434 1437 8669433 but CC O O
21 1438 1444 8669433 cannot MD B-VP O
22 1445 1447 8669433 be VB I-VP O
23 1448 1457 8669433 dismissed VBN I-VP O
24 1457 1458 8669433 . . O O

1 0 0 17400887 -DOCSTART- -X- -X- O

1 0 17 17400887 Neuroinflammation NN B-NP B-Disease
2 18 21 17400887 and CC I-NP O
3 22 32 17400887 behavioral JJ I-NP B-Disease
4 33 46 17400887 abnormalities NNS I-NP I-Disease
5 47 52 17400887 after IN B-PP O
6 53 61 17400887 neonatal JJ B-NP O
7 62 73 17400887 terbutaline NN I-NP B-Chemical
8 74 83 17400887 treatment NN I-NP O
9 84 86 17400887 in IN B-PP O
10 87 91 17400887 rats NNS B-NP O
11 91 92 17400887 : : O O
12 93 105 17400887 implications NNS B-NP O
13 106 109 17400887 for IN B-PP O
14 110 116 17400887 autism NN B-NP B-Disease
15 116 117 17400887 . . O O
16 118 124 17400887 Autism NN B-NP B-Disease
17 125 127 17400887 is VBZ B-VP O
18 128 129 17400887 a DT B-NP O
19 130 148 17400887 neurodevelopmental JJ I-NP B-Disease
20 149 157 17400887 disorder NN I-NP I-Disease
21 158 168 17400887 presenting VBG B-VP O
22 169 175 17400887 before IN B-PP O
23 176 177 17400887 3 CD B-NP O
24 178 183 17400887 years NNS I-NP O
25 184 186 17400887 of IN B-PP O
26 187 190 17400887 age NN B-NP O
27 191 195 17400887 with IN B-PP O
28 196 204 17400887 deficits NNS B-NP B-Disease
29 205 207 17400887 in IN B-PP I-Disease
30 208 221 17400887 communication NN B-NP I-Disease
31 222 225 17400887 and CC O I-Disease
32 226 232 17400887 social JJ B-NP I-Disease
33 233 239 17400887 skills NNS I-NP I-Disease
34 240 243 17400887 and CC O O
35 244 254 17400887 repetitive JJ B-NP B-Disease
36 255 264 17400887 behaviors NNS I-NP I-Disease
37 264 265 17400887 . . O O

1 266 268 17400887 In IN B-PP O
2 269 277 17400887 addition NN B-NP O
3 278 280 17400887 to TO B-PP O
4 281 288 17400887 genetic JJ B-NP O
5 289 299 17400887 influences NNS I-NP O
6 299 300 17400887 , , O O
7 301 307 17400887 recent JJ B-NP O
8 308 315 17400887 studies NNS I-NP O
9 316 323 17400887 suggest VBP B-VP O
10 324 328 17400887 that IN B-SBAR O
11 329 337 17400887 prenatal JJ B-NP O
12 338 342 17400887 drug NN I-NP O
13 343 345 17400887 or CC I-NP O
14 346 354 17400887 chemical NN I-NP O
15 355 364 17400887 exposures NNS I-NP O
16 365 368 17400887 are VBP B-VP O
17 369 373 17400887 risk NN B-NP O
18 374 381 17400887 factors NNS I-NP O
19 382 385 17400887 for IN B-PP O
20 386 392 17400887 autism NN B-NP B-Disease
21 392 393 17400887 . . O O

1 394 405 17400887 Terbutaline NN B-NP B-Chemical
2 405 406 17400887 , , O O
3 407 408 17400887 a DT B-NP O
4 409 414 17400887 beta2 NN I-NP O
5 414 415 17400887 - HYPH I-NP O
6 415 427 17400887 adrenoceptor NN I-NP O
7 428 435 17400887 agonist NN I-NP O
8 436 440 17400887 used VBN B-VP O
9 441 443 17400887 to TO B-VP O
10 444 450 17400887 arrest VB I-VP O
11 451 458 17400887 preterm JJ B-NP B-Disease
12 459 464 17400887 labor NN I-NP I-Disease
13 464 465 17400887 , , O O
14 466 469 17400887 has VBZ B-VP O
15 470 474 17400887 been VBN I-VP O
16 475 485 17400887 associated VBN I-VP O
17 486 490 17400887 with IN B-PP O
18 491 500 17400887 increased VBN B-NP O
19 501 512 17400887 concordance NN I-NP O
20 513 516 17400887 for IN B-PP O
21 517 523 17400887 autism NN B-NP B-Disease
22 524 526 17400887 in IN B-PP O
23 527 536 17400887 dizygotic JJ B-NP O
24 537 542 17400887 twins NNS I-NP O
25 542 543 17400887 . . O O

1 544 546 17400887 We PRP B-NP O
2 547 554 17400887 studied VBD B-VP O
3 555 558 17400887 the DT B-NP O
4 559 566 17400887 effects NNS I-NP O
5 567 569 17400887 of IN B-PP O
6 570 581 17400887 terbutaline NN B-NP B-Chemical
7 582 584 17400887 on IN B-PP O
8 585 595 17400887 microglial JJ B-NP O
9 596 606 17400887 activation NN I-NP O
10 607 609 17400887 in IN B-PP O
11 610 619 17400887 different JJ B-NP O
12 620 625 17400887 brain NN I-NP O
13 626 633 17400887 regions NNS I-NP O
14 634 637 17400887 and CC O O
15 638 648 17400887 behavioral JJ B-NP O
16 649 657 17400887 outcomes NNS I-NP O
17 658 660 17400887 in IN B-PP O
18 661 671 17400887 developing VBG B-NP O
19 672 676 17400887 rats NNS I-NP O
20 676 677 17400887 . . O O

1 678 685 17400887 Newborn JJ B-NP O
2 686 690 17400887 rats NNS I-NP O
3 691 695 17400887 were VBD B-VP O
4 696 701 17400887 given VBN I-VP O
5 702 713 17400887 terbutaline NN B-NP B-Chemical
6 714 715 17400887 ( ( O O
7 715 717 17400887 10 CD B-NP O
8 718 720 17400887 mg NN I-NP O
9 720 721 17400887 / SYM B-NP O
10 721 723 17400887 kg NN I-NP O
11 723 724 17400887 ) ) O O
12 725 730 17400887 daily RB B-ADVP O
13 731 733 17400887 on IN B-PP O
14 734 743 17400887 postnatal JJ B-NP O
15 744 748 17400887 days NNS I-NP O
16 749 750 17400887 ( ( O O
17 750 752 17400887 PN NN B-NP O
18 752 753 17400887 ) ) O O
19 754 755 17400887 2 CD B-NP O
20 756 758 17400887 to TO B-PP O
21 759 760 17400887 5 CD B-NP O
22 761 763 17400887 or CC O O
23 764 766 17400887 PN NN B-NP O
24 767 769 17400887 11 CD I-NP O
25 770 772 17400887 to TO I-NP O
26 773 775 17400887 14 CD I-NP O
27 776 779 17400887 and CC O O
28 780 788 17400887 examined VBD B-VP O
29 789 791 17400887 24 CD B-NP O
30 792 793 17400887 h NN I-NP O
31 794 799 17400887 after IN B-PP O
32 800 803 17400887 the DT B-NP O
33 804 808 17400887 last JJ I-NP O
34 809 813 17400887 dose NN I-NP O
35 814 817 17400887 and CC B-PP O
36 818 820 17400887 at IN B-PP O
37 821 823 17400887 PN NN B-NP O
38 824 826 17400887 30 CD I-NP O
39 826 827 17400887 . . O O

1 828 847 17400887 Immunohistochemical JJ B-NP O
2 848 855 17400887 studies NNS I-NP O
3 856 862 17400887 showed VBD B-VP O
4 863 867 17400887 that IN B-SBAR O
5 868 882 17400887 administration NN B-NP O
6 883 885 17400887 of IN B-PP O
7 886 897 17400887 terbutaline NN B-NP B-Chemical
8 898 900 17400887 on IN B-PP O
9 901 903 17400887 PN NN B-NP O
10 904 905 17400887 2 CD I-NP O
11 906 908 17400887 to TO I-NP O
12 909 910 17400887 5 CD I-NP O
13 911 919 17400887 produced VBD B-VP O
14 920 921 17400887 a DT B-NP O
15 922 928 17400887 robust JJ I-NP O
16 929 937 17400887 increase NN I-NP O
17 938 940 17400887 in IN B-PP O
18 941 951 17400887 microglial JJ B-NP O
19 952 962 17400887 activation NN I-NP O
20 963 965 17400887 on IN B-PP O
21 966 968 17400887 PN NN B-NP O
22 969 971 17400887 30 CD I-NP O
23 972 974 17400887 in IN B-PP O
24 975 978 17400887 the DT B-NP O
25 979 987 17400887 cerebral JJ I-NP O
26 988 994 17400887 cortex NN I-NP O
27 994 995 17400887 , , O O
28 996 998 17400887 as RB B-CONJP O
29 999 1003 17400887 well RB I-CONJP O
30 1004 1006 17400887 as IN I-CONJP O
31 1007 1009 17400887 in IN B-PP O
32 1010 1020 17400887 cerebellar JJ B-NP O
33 1021 1024 17400887 and CC I-NP O
34 1025 1040 17400887 cerebrocortical JJ I-NP O
35 1041 1046 17400887 white JJ I-NP O
36 1047 1053 17400887 matter NN I-NP O
37 1053 1054 17400887 . . O O

1 1055 1059 17400887 None NN B-NP O
2 1060 1062 17400887 of IN B-PP O
3 1063 1068 17400887 these DT B-NP O
4 1069 1076 17400887 effects NNS I-NP O
5 1077 1085 17400887 occurred VBD B-VP O
6 1086 1088 17400887 in IN B-PP O
7 1089 1096 17400887 animals NNS B-NP O
8 1097 1102 17400887 given VBN B-VP O
9 1103 1114 17400887 terbutaline NN B-NP B-Chemical
10 1115 1117 17400887 on IN B-PP O
11 1118 1120 17400887 PN NN B-NP O
12 1121 1123 17400887 11 CD I-NP O
13 1124 1126 17400887 to TO B-PP O
14 1127 1129 17400887 14 CD B-NP O
15 1129 1130 17400887 . . O O

1 1131 1133 17400887 In IN B-PP O
2 1134 1144 17400887 behavioral JJ B-NP O
3 1145 1150 17400887 tests NNS I-NP O
4 1150 1151 17400887 , , O O
5 1152 1159 17400887 animals NNS B-NP O
6 1160 1167 17400887 treated VBN B-VP O
7 1168 1172 17400887 with IN B-PP O
8 1173 1184 17400887 terbutaline NN B-NP B-Chemical
9 1185 1187 17400887 on IN B-PP O
10 1188 1190 17400887 PN NN B-NP O
11 1191 1192 17400887 2 CD I-NP O
12 1193 1195 17400887 to TO I-NP O
13 1196 1197 17400887 5 CD I-NP O
14 1198 1204 17400887 showed VBD B-VP O
15 1205 1215 17400887 consistent JJ B-NP O
16 1216 1224 17400887 patterns NNS I-NP O
17 1225 1227 17400887 of IN B-PP O
18 1228 1233 17400887 hyper NN B-NP O
19 1233 1234 17400887 - HYPH B-NP O
20 1234 1244 17400887 reactivity NN I-NP O
21 1245 1247 17400887 to TO B-PP O
22 1248 1255 17400887 novelty NN B-NP O
23 1256 1259 17400887 and CC O O
24 1260 1268 17400887 aversive JJ B-NP O
25 1269 1276 17400887 stimuli NNS I-NP O
26 1277 1281 17400887 when WRB B-ADVP O
27 1282 1290 17400887 assessed VBN B-VP O
28 1291 1293 17400887 in IN B-PP O
29 1294 1295 17400887 a DT B-NP O
30 1296 1301 17400887 novel JJ I-NP O
31 1302 1306 17400887 open JJ I-NP O
32 1307 1312 17400887 field NN I-NP O
33 1312 1313 17400887 , , O O
34 1314 1316 17400887 as RB B-CONJP O
35 1317 1321 17400887 well RB I-CONJP O
36 1322 1324 17400887 as IN I-CONJP O
37 1325 1327 17400887 in IN B-PP O
38 1328 1331 17400887 the DT B-NP O
39 1332 1340 17400887 acoustic JJ I-NP O
40 1341 1348 17400887 startle NN I-NP O
41 1349 1357 17400887 response NN I-NP O
42 1358 1362 17400887 test NN I-NP O
43 1362 1363 17400887 . . O O

1 1364 1367 17400887 Our PRP$ B-NP O
2 1368 1376 17400887 findings NNS I-NP O
3 1377 1385 17400887 indicate VBP B-VP O
4 1386 1390 17400887 that IN B-SBAR O
5 1391 1396 17400887 beta2 NN B-NP O
6 1396 1397 17400887 - HYPH B-NP O
7 1397 1409 17400887 adrenoceptor NN I-NP O
8 1410 1425 17400887 overstimulation NN I-NP O
9 1426 1432 17400887 during IN B-PP O
10 1433 1435 17400887 an DT B-NP O
11 1436 1441 17400887 early JJ I-NP O
12 1442 1450 17400887 critical JJ I-NP O
13 1451 1457 17400887 period NN I-NP O
14 1458 1465 17400887 results VBZ B-VP O
15 1466 1468 17400887 in IN B-PP O
16 1469 1479 17400887 microglial JJ B-NP O
17 1480 1490 17400887 activation NN I-NP O
18 1491 1501 17400887 associated VBN B-VP O
19 1502 1506 17400887 with IN B-PP O
20 1507 1513 17400887 innate JJ B-NP O
21 1514 1531 17400887 neuroinflammatory JJ I-NP O
22 1532 1540 17400887 pathways NNS I-NP O
23 1541 1544 17400887 and CC O O
24 1545 1555 17400887 behavioral JJ B-NP B-Disease
25 1556 1569 17400887 abnormalities NNS I-NP I-Disease
26 1569 1570 17400887 , , O O
27 1571 1578 17400887 similar JJ B-ADJP O
28 1579 1581 17400887 to TO B-PP O
29 1582 1587 17400887 those DT B-NP O
30 1588 1597 17400887 described VBN B-VP O
31 1598 1600 17400887 in IN B-PP O
32 1601 1607 17400887 autism NN B-NP B-Disease
33 1607 1608 17400887 . . O O

1 1609 1613 17400887 This DT B-NP O
2 1614 1619 17400887 study NN I-NP O
3 1620 1628 17400887 provides VBZ B-VP O
4 1629 1630 17400887 a DT B-NP O
5 1631 1637 17400887 useful JJ I-NP O
6 1638 1644 17400887 animal NN I-NP O
7 1645 1650 17400887 model NN I-NP O
8 1651 1654 17400887 for IN B-PP O
9 1655 1668 17400887 understanding VBG B-VP O
10 1669 1672 17400887 the DT B-NP O
11 1673 1690 17400887 neuropathological JJ I-NP O
12 1691 1700 17400887 processes NNS I-NP O
13 1701 1711 17400887 underlying VBG B-VP O
14 1712 1718 17400887 autism NN B-NP B-Disease
15 1719 1727 17400887 spectrum NN I-NP I-Disease
16 1728 1737 17400887 disorders NNS I-NP I-Disease
17 1737 1738 17400887 . . O O

1 0 0 2632720 -DOCSTART- -X- -X- O

1 0 8 2632720 Arterial JJ B-NP O
2 9 21 2632720 hypertension NN I-NP B-Disease
3 22 24 2632720 as IN B-PP O
4 25 26 2632720 a DT B-NP O
5 27 39 2632720 complication NN I-NP O
6 40 42 2632720 of IN B-PP O
7 43 52 2632720 prolonged JJ B-NP O
8 53 65 2632720 ketoconazole NN I-NP B-Chemical
9 66 75 2632720 treatment NN I-NP O
10 75 76 2632720 . . O O
11 77 80 2632720 Two CD B-NP O
12 81 83 2632720 of IN B-PP O
13 84 86 2632720 14 CD B-NP O
14 87 95 2632720 patients NNS I-NP O
15 96 100 2632720 with IN B-PP O
16 101 110 2632720 Cushing's NNS B-NP B-Disease
17 111 119 2632720 syndrome NN I-NP I-Disease
18 120 127 2632720 treated VBN B-VP O
19 128 130 2632720 on IN B-PP O
20 131 132 2632720 a DT B-NP O
21 133 137 2632720 long JJ I-NP O
22 137 138 2632720 - HYPH I-NP O
23 138 142 2632720 term NN I-NP O
24 143 148 2632720 basis NN I-NP O
25 149 153 2632720 with IN B-PP O
26 154 166 2632720 ketoconazole NN B-NP B-Chemical
27 167 176 2632720 developed VBD B-VP O
28 177 186 2632720 sustained JJ B-NP O
29 187 199 2632720 hypertension NN I-NP B-Disease
30 199 200 2632720 . . O O

1 201 203 2632720 In IN B-PP O
2 204 208 2632720 both DT B-NP O
3 209 214 2632720 cases NNS I-NP O
4 215 221 2632720 normal JJ B-NP O
5 222 228 2632720 plasma NN I-NP O
6 229 232 2632720 and CC O O
7 233 240 2632720 urinary JJ B-NP O
8 241 245 2632720 free JJ I-NP O
9 246 254 2632720 cortisol NN I-NP B-Chemical
10 255 261 2632720 levels NNS I-NP O
11 262 265 2632720 had VBD B-VP O
12 266 270 2632720 been VBN I-VP O
13 271 279 2632720 achieved VBN I-VP O
14 280 289 2632720 following VBG B-PP O
15 290 302 2632720 ketoconazole NN B-NP B-Chemical
16 303 310 2632720 therapy NN I-NP O
17 310 311 2632720 , , O O
18 312 315 2632720 yet RB B-NP O
19 316 326 2632720 continuous JJ I-NP O
20 327 332 2632720 blood NN I-NP O
21 333 341 2632720 pressure NN I-NP O
22 342 352 2632720 monitoring NN I-NP O
23 353 365 2632720 demonstrated VBD B-VP O
24 366 378 2632720 hypertension NN B-NP B-Disease
25 379 381 2632720 31 CD I-NP O
26 382 383 2632720 ( ( O O
27 383 390 2632720 patient NN B-NP O
28 391 392 2632720 1 CD I-NP O
29 392 393 2632720 ) ) O O
30 394 397 2632720 and CC O O
31 398 400 2632720 52 CD B-NP O
32 401 406 2632720 weeks NNS I-NP O
33 407 408 2632720 ( ( O O
34 408 415 2632720 patient NN B-NP O
35 416 417 2632720 2 CD I-NP O
36 417 418 2632720 ) ) O O
37 419 424 2632720 after IN B-PP O
38 425 434 2632720 treatment NN B-NP O
39 434 435 2632720 . . O O

1 436 438 2632720 In IN B-PP O
2 439 446 2632720 patient NN B-NP O
3 447 448 2632720 1 CD I-NP O
4 448 449 2632720 , , O O
5 450 456 2632720 plasma NN B-NP O
6 457 463 2632720 levels NNS I-NP O
7 464 466 2632720 of IN B-PP O
8 467 486 2632720 deoxycorticosterone NN B-NP B-Chemical
9 487 490 2632720 and CC O O
10 491 493 2632720 11 CD B-NP B-Chemical
11 493 494 2632720 - HYPH I-NP I-Chemical
12 494 507 2632720 deoxycortisol NN I-NP I-Chemical
13 508 512 2632720 were VBD B-VP O
14 513 521 2632720 elevated VBN I-VP O
15 521 522 2632720 . . O O

1 523 525 2632720 In IN B-PP O
2 526 533 2632720 patient NN B-NP O
3 534 535 2632720 2 CD I-NP O
4 535 536 2632720 , , O O
5 537 539 2632720 in IN B-PP O
6 540 548 2632720 addition NN B-NP O
7 549 551 2632720 to TO B-PP O
8 552 554 2632720 an DT B-NP O
9 555 563 2632720 increase NN I-NP O
10 564 566 2632720 in IN B-PP O
11 567 571 2632720 both CC O O
12 572 591 2632720 deoxycorticosterone NN B-NP B-Chemical
13 592 595 2632720 and CC O O
14 596 598 2632720 11 CD B-NP B-Chemical
15 598 599 2632720 - HYPH I-NP I-Chemical
16 599 612 2632720 deoxycortisol NN I-NP I-Chemical
17 613 619 2632720 levels NNS I-NP O
18 619 620 2632720 , , O O
19 621 627 2632720 plasma NN B-NP O
20 628 639 2632720 aldosterone NN I-NP B-Chemical
21 640 646 2632720 values NNS I-NP O
22 647 651 2632720 were VBD B-VP O
23 652 658 2632720 raised VBN I-VP O
24 658 659 2632720 , , O O
25 660 664 2632720 with IN B-PP O
26 665 666 2632720 a DT B-NP O
27 667 678 2632720 concomitant JJ I-NP O
28 679 690 2632720 suppression NN I-NP O
29 691 693 2632720 of IN B-PP O
30 694 699 2632720 renin NN B-NP O
31 700 706 2632720 levels NNS I-NP O
32 706 707 2632720 . . O O

1 708 711 2632720 Our PRP$ B-NP O
2 712 720 2632720 findings NNS I-NP O
3 721 725 2632720 show VBP B-VP O
4 726 730 2632720 that IN B-SBAR O
5 731 735 2632720 long JJ B-NP O
6 735 736 2632720 - HYPH I-NP O
7 736 740 2632720 term NN I-NP O
8 741 750 2632720 treatment NN I-NP O
9 751 755 2632720 with IN B-PP O
10 756 760 2632720 high JJ B-NP O
11 761 766 2632720 doses NNS I-NP O
12 767 769 2632720 of IN B-PP O
13 770 782 2632720 ketoconazole NN B-NP B-Chemical
14 783 786 2632720 may MD B-VP O
15 787 793 2632720 induce VB I-VP O
16 794 800 2632720 enzyme NN B-NP O
17 801 809 2632720 blockade NN I-NP O
18 810 817 2632720 leading VBG B-VP O
19 818 820 2632720 to TO B-PP O
20 821 838 2632720 mineralocorticoid NN B-NP O
21 838 839 2632720 - HYPH O O
22 839 846 2632720 related VBN B-NP O
23 847 859 2632720 hypertension NN I-NP B-Disease
24 859 860 2632720 . . O O

1 0 0 19581773 -DOCSTART- -X- -X- O

1 0 11 19581773 Development NN B-NP O
2 12 14 19581773 of IN B-PP O
3 15 21 19581773 ocular JJ B-NP B-Disease
4 22 32 19581773 myasthenia NN I-NP I-Disease
5 33 39 19581773 during IN B-PP O
6 40 49 19581773 pegylated VBN B-NP B-Chemical
7 50 60 19581773 interferon NN I-NP I-Chemical
8 61 64 19581773 and CC I-NP O
9 65 74 19581773 ribavirin NN I-NP B-Chemical
10 75 84 19581773 treatment NN I-NP O
11 85 88 19581773 for IN B-PP O
12 89 96 19581773 chronic JJ B-NP B-Disease
13 97 106 19581773 hepatitis NN I-NP I-Disease
14 107 108 19581773 C NN I-NP I-Disease
15 108 109 19581773 . . O O
16 110 111 19581773 A DT B-NP O
17 112 114 19581773 63 CD I-NP O
18 114 115 19581773 - HYPH I-NP O
19 115 119 19581773 year NN I-NP O
20 119 120 19581773 - HYPH O O
21 120 123 19581773 old JJ B-NP O
22 124 128 19581773 male JJ I-NP O
23 129 140 19581773 experienced JJ I-NP O
24 141 147 19581773 sudden JJ I-NP O
25 148 156 19581773 diplopia NN I-NP B-Disease
26 157 162 19581773 after IN B-PP O
27 163 164 19581773 9 CD B-NP O
28 165 170 19581773 weeks NNS I-NP O
29 171 173 19581773 of IN B-PP O
30 174 188 19581773 administration NN B-NP O
31 189 191 19581773 of IN B-PP O
32 192 201 19581773 pegylated VBN B-NP B-Chemical
33 202 212 19581773 interferon NN I-NP I-Chemical
34 213 214 19581773 ( ( O I-Chemical
35 214 217 19581773 IFN NN B-NP I-Chemical
36 217 218 19581773 ) ) O I-Chemical
37 219 224 19581773 alpha SYM B-NP I-Chemical
38 224 225 19581773 - HYPH I-NP I-Chemical
39 225 227 19581773 2b NN I-NP I-Chemical
40 228 231 19581773 and CC I-NP O
41 232 241 19581773 ribavirin NN I-NP B-Chemical
42 242 245 19581773 for IN B-PP O
43 246 253 19581773 chronic JJ B-NP B-Disease
44 254 263 19581773 hepatitis NN I-NP I-Disease
45 264 265 19581773 C NN I-NP I-Disease
46 266 267 19581773 ( ( O O
47 267 270 19581773 CHC NN B-NP B-Disease
48 270 271 19581773 ) ) O O
49 271 272 19581773 . . O O

1 273 287 19581773 Ophthalmologic JJ B-NP O
2 288 300 19581773 examinations NNS I-NP O
3 301 307 19581773 showed VBD B-VP O
4 308 314 19581773 ptosis NN B-NP B-Disease
5 315 317 19581773 on IN B-PP I-Disease
6 318 321 19581773 the DT B-NP I-Disease
7 322 327 19581773 right JJ I-NP I-Disease
8 328 333 19581773 upper JJ I-NP I-Disease
9 334 337 19581773 lid NN I-NP I-Disease
10 338 341 19581773 and CC O O
11 342 352 19581773 restricted JJ B-NP B-Disease
12 353 358 19581773 right JJ I-NP I-Disease
13 359 362 19581773 eye NN I-NP I-Disease
14 363 371 19581773 movement NN I-NP I-Disease
15 372 379 19581773 without IN B-PP O
16 380 383 19581773 any DT B-NP O
17 384 389 19581773 other JJ I-NP O
18 390 402 19581773 neurological JJ I-NP O
19 403 408 19581773 signs NNS I-NP O
20 408 409 19581773 . . O O

1 410 411 19581773 A DT B-NP O
2 412 417 19581773 brain NN I-NP O
3 418 425 19581773 imaging NN I-NP O
4 426 431 19581773 study NN I-NP O
5 432 435 19581773 and CC O O
6 436 446 19581773 repetitive JJ B-NP O
7 447 452 19581773 nerve NN I-NP O
8 453 464 19581773 stimulation NN I-NP O
9 465 469 19581773 test NN I-NP O
10 470 479 19581773 indicated VBD B-VP O
11 480 482 19581773 no DT B-NP O
12 483 494 19581773 abnormality NN I-NP O
13 494 495 19581773 . . O O

1 496 499 19581773 The DT B-NP O
2 500 513 19581773 acetylcholine NN I-NP B-Chemical
3 514 522 19581773 receptor NN I-NP O
4 523 531 19581773 antibody NN I-NP O
5 532 537 19581773 titer NN I-NP O
6 538 541 19581773 and CC O O
7 542 550 19581773 response NN B-NP O
8 551 553 19581773 to TO B-PP O
9 554 574 19581773 acetylcholinesterase NN B-NP O
10 575 585 19581773 inhibitors NNS I-NP O
11 586 590 19581773 were VBD B-VP O
12 591 599 19581773 negative JJ B-ADJP O
13 599 600 19581773 , , O O
14 601 604 19581773 and CC O O
15 605 608 19581773 the DT B-NP O
16 609 616 19581773 results NNS I-NP O
17 617 619 19581773 of IN B-PP O
18 620 627 19581773 thyroid JJ B-NP O
19 628 636 19581773 function NN I-NP O
20 637 642 19581773 tests NNS I-NP O
21 643 647 19581773 were VBD B-VP O
22 648 654 19581773 normal JJ B-ADJP O
23 654 655 19581773 . . O O

1 656 659 19581773 The DT B-NP O
2 660 669 19581773 patient's NNS I-NP O
3 670 686 19581773 ophthalmological JJ B-NP O
4 687 695 19581773 symptoms NNS I-NP O
5 696 704 19581773 improved VBD B-VP O
6 705 712 19581773 rapidly RB B-NP O
7 713 714 19581773 3 CD I-NP O
8 715 720 19581773 weeks NNS I-NP O
9 721 726 19581773 after IN B-PP O
10 727 742 19581773 discontinuation NN B-NP O
11 743 745 19581773 of IN B-PP O
12 746 755 19581773 pegylated VBN B-NP B-Chemical
13 756 759 19581773 IFN NN I-NP I-Chemical
14 760 765 19581773 alpha SYM B-NP I-Chemical
15 765 766 19581773 - HYPH I-NP I-Chemical
16 766 768 19581773 2b NN I-NP I-Chemical
17 769 772 19581773 and CC I-NP O
18 773 782 19581773 ribavirin NN I-NP B-Chemical
19 782 783 19581773 . . O O

1 784 787 19581773 The DT B-NP O
2 788 794 19581773 ocular JJ I-NP B-Disease
3 795 805 19581773 myasthenia NN I-NP I-Disease
4 806 816 19581773 associated VBN B-VP O
5 817 821 19581773 with IN B-PP O
6 822 833 19581773 combination NN B-NP O
7 834 841 19581773 therapy NN I-NP O
8 842 844 19581773 of IN B-PP O
9 845 854 19581773 pegylated VBN B-NP B-Chemical
10 855 858 19581773 IFN NN I-NP I-Chemical
11 859 864 19581773 alpha SYM B-NP I-Chemical
12 864 865 19581773 - HYPH I-NP I-Chemical
13 865 867 19581773 2b NN I-NP I-Chemical
14 868 871 19581773 and CC I-NP O
15 872 881 19581773 ribavirin NN I-NP B-Chemical
16 882 885 19581773 for IN B-PP O
17 886 889 19581773 CHC NN B-NP B-Disease
18 890 892 19581773 is VBZ B-VP O
19 893 897 19581773 very RB B-VP O
20 898 904 19581773 rarely RB I-VP O
21 905 913 19581773 reported VBN I-VP O
22 913 914 19581773 ; : O O
23 915 924 19581773 therefore RB B-ADVP O
24 924 925 19581773 , , O O
25 926 928 19581773 we PRP B-NP O
26 929 936 19581773 present VBP B-VP O
27 937 941 19581773 this DT B-NP O
28 942 946 19581773 case NN I-NP O
29 947 951 19581773 with IN B-PP O
30 952 953 19581773 a DT B-NP O
31 954 960 19581773 review NN I-NP O
32 961 963 19581773 of IN B-PP O
33 964 967 19581773 the DT B-NP O
34 968 975 19581773 various JJ I-NP O
35 976 979 19581773 eye NN I-NP O
36 980 993 19581773 complications NNS I-NP O
37 994 996 19581773 of IN B-PP O
38 997 1000 19581773 IFN NN B-NP B-Chemical
39 1001 1008 19581773 therapy NN I-NP O
40 1008 1009 19581773 . . O O

1 0 0 20520283 -DOCSTART- -X- -X- O

1 0 8 20520283 Efficacy NN B-NP O
2 9 12 20520283 and CC I-NP O
3 13 19 20520283 safety NN I-NP O
4 20 22 20520283 of IN B-PP O
5 23 32 20520283 asenapine NN B-NP B-Chemical
6 33 35 20520283 in IN B-PP O
7 36 37 20520283 a DT B-NP O
8 38 45 20520283 placebo NN I-NP O
9 45 46 20520283 - HYPH B-NP O
10 47 50 20520283 and CC I-NP O
11 51 62 20520283 haloperidol NN I-NP B-Chemical
12 62 63 20520283 - HYPH O O
13 63 73 20520283 controlled VBN B-VP O
14 74 79 20520283 trial NN B-NP O
15 80 82 20520283 in IN B-PP O
16 83 91 20520283 patients NNS B-NP O
17 92 96 20520283 with IN B-PP O
18 97 102 20520283 acute JJ B-NP O
19 103 115 20520283 exacerbation NN I-NP O
20 116 118 20520283 of IN B-PP O
21 119 132 20520283 schizophrenia NN B-NP B-Disease
22 132 133 20520283 . . O O
23 134 143 20520283 Asenapine NN B-NP B-Chemical
24 144 146 20520283 is VBZ B-VP O
25 147 155 20520283 approved VBN I-VP O
26 156 158 20520283 by IN B-PP O
27 159 162 20520283 the DT B-NP O
28 163 167 20520283 Food NNP I-NP O
29 168 171 20520283 and CC I-NP O
30 172 177 20520283 Drugs NNP I-NP O
31 178 192 20520283 Administration NNP I-NP O
32 193 195 20520283 in IN B-PP O
33 196 202 20520283 adults NNS B-NP O
34 203 206 20520283 for IN B-PP O
35 207 212 20520283 acute JJ B-NP O
36 213 222 20520283 treatment NN I-NP O
37 223 225 20520283 of IN B-PP O
38 226 239 20520283 schizophrenia NN B-NP B-Disease
39 240 242 20520283 or CC B-PP O
40 243 245 20520283 of IN B-PP O
41 246 251 20520283 manic JJ B-NP B-Disease
42 252 254 20520283 or CC I-NP O
43 255 260 20520283 mixed JJ I-NP O
44 261 269 20520283 episodes NNS I-NP O
45 270 280 20520283 associated VBN B-VP O
46 281 285 20520283 with IN B-PP O
47 286 293 20520283 bipolar JJ B-NP B-Disease
48 294 295 20520283 I NN I-NP I-Disease
49 296 304 20520283 disorder NN I-NP I-Disease
50 305 309 20520283 with IN B-PP O
51 310 312 20520283 or CC B-PP O
52 313 320 20520283 without IN B-PP O
53 321 330 20520283 psychotic JJ B-NP B-Disease
54 331 339 20520283 features NNS I-NP O
55 339 340 20520283 . . O O

1 341 343 20520283 In IN B-PP O
2 344 345 20520283 a DT B-NP O
3 346 352 20520283 double JJ I-NP O
4 352 353 20520283 - HYPH I-NP O
5 353 358 20520283 blind JJ I-NP O
6 359 360 20520283 6 CD I-NP O
7 360 361 20520283 - HYPH I-NP O
8 361 365 20520283 week NN I-NP O
9 366 371 20520283 trial NN I-NP O
10 371 372 20520283 , , O O
11 373 376 20520283 458 CD B-NP O
12 377 385 20520283 patients NNS I-NP O
13 386 390 20520283 with IN B-PP O
14 391 396 20520283 acute JJ B-NP O
15 397 410 20520283 schizophrenia NN I-NP B-Disease
16 411 415 20520283 were VBD B-VP O
17 416 424 20520283 randomly RB I-VP O
18 425 433 20520283 assigned VBN I-VP O
19 434 436 20520283 to TO B-PP O
20 437 442 20520283 fixed VBN B-NP O
21 442 443 20520283 - HYPH I-NP O
22 443 447 20520283 dose NN I-NP O
23 448 457 20520283 treatment NN I-NP O
24 458 462 20520283 with IN B-PP O
25 463 472 20520283 asenapine NN B-NP B-Chemical
26 473 475 20520283 at IN B-PP O
27 476 477 20520283 5 CD B-NP O
28 478 480 20520283 mg NN I-NP O
29 481 486 20520283 twice RB B-ADVP O
30 487 492 20520283 daily RB O O
31 493 494 20520283 ( ( O O
32 494 497 20520283 BID NN B-NP O
33 497 498 20520283 ) ) O O
34 498 499 20520283 , , O O
35 500 509 20520283 asenapine NN B-NP B-Chemical
36 510 512 20520283 at IN B-PP O
37 513 515 20520283 10 CD B-NP O
38 516 518 20520283 mg NN I-NP O
39 519 522 20520283 BID NN I-NP O
40 522 523 20520283 , , O O
41 524 531 20520283 placebo NN B-NP O
42 531 532 20520283 , , O O
43 533 535 20520283 or CC O O
44 536 547 20520283 haloperidol NN B-NP B-Chemical
45 548 550 20520283 at IN B-PP O
46 551 552 20520283 4 CD B-NP O
47 553 555 20520283 mg NN I-NP O
48 556 559 20520283 BID NN I-NP O
49 560 561 20520283 ( ( O O
50 561 563 20520283 to TO B-VP O
51 564 570 20520283 verify VB I-VP O
52 571 576 20520283 assay NN B-NP O
53 577 588 20520283 sensitivity NN I-NP O
54 588 589 20520283 ) ) O O
55 589 590 20520283 . . O O

1 591 595 20520283 With IN B-PP O
2 596 600 20520283 last JJ B-NP O
3 601 613 20520283 observations NNS I-NP O
4 614 621 20520283 carried VBD B-VP O
5 622 629 20520283 forward JJ B-ADJP O
6 630 631 20520283 ( ( O O
7 631 635 20520283 LOCF NN B-NP O
8 635 636 20520283 ) ) O O
9 636 637 20520283 , , O O
10 638 642 20520283 mean JJ B-NP O
11 643 651 20520283 Positive JJ I-NP O
12 652 655 20520283 and CC I-NP O
13 656 664 20520283 Negative JJ I-NP O
14 665 673 20520283 Syndrome NN I-NP O
15 674 679 20520283 Scale NN I-NP O
16 680 685 20520283 total JJ I-NP O
17 686 691 20520283 score NN I-NP O
18 692 702 20520283 reductions NNS I-NP O
19 703 707 20520283 from IN B-PP O
20 708 716 20520283 baseline NN B-NP O
21 717 719 20520283 to TO B-VP O
22 720 728 20520283 endpoint VB I-VP O
23 729 733 20520283 were VBD B-VP O
24 734 747 20520283 significantly RB B-ADJP O
25 748 755 20520283 greater JJR I-ADJP O
26 756 760 20520283 with IN B-PP O
27 761 770 20520283 asenapine NN B-NP B-Chemical
28 771 773 20520283 at IN B-PP O
29 774 775 20520283 5 CD B-NP O
30 776 778 20520283 mg NN I-NP O
31 779 782 20520283 BID NN I-NP O
32 783 784 20520283 ( ( O O
33 784 785 20520283 - SYM B-NP O
34 785 789 20520283 16.2 CD I-NP O
35 789 790 20520283 ) ) O O
36 791 794 20520283 and CC O O
37 795 806 20520283 haloperidol NN B-NP B-Chemical
38 807 808 20520283 ( ( O O
39 808 809 20520283 - SYM B-NP O
40 809 813 20520283 15.4 CD I-NP O
41 813 814 20520283 ) ) O O
42 815 819 20520283 than IN B-PP O
43 820 827 20520283 placebo NN B-NP O
44 828 829 20520283 ( ( O O
45 829 830 20520283 - SYM B-NP O
46 830 834 20520283 10.7 CD B-NP O
47 834 835 20520283 ; : O O
48 836 840 20520283 both DT B-NP O
49 841 842 20520283 P NN I-NP O
50 843 844 20520283 < JJR I-NP O
51 845 849 20520283 0.05 CD I-NP O
52 849 850 20520283 ) ) O O
53 850 851 20520283 ; : O O
54 852 857 20520283 using VBG B-VP O
55 858 863 20520283 mixed VBN B-NP O
56 864 869 20520283 model NN I-NP O
57 870 873 20520283 for IN B-PP O
58 874 882 20520283 repeated VBN B-NP O
59 883 891 20520283 measures NNS I-NP O
60 892 893 20520283 ( ( O O
61 893 897 20520283 MMRM NN B-NP O
62 897 898 20520283 ) ) O O
63 898 899 20520283 , , O O
64 900 907 20520283 changes NNS B-NP O
65 908 910 20520283 at IN B-PP O
66 911 914 20520283 day NN B-NP O
67 915 917 20520283 42 CD I-NP O
68 918 922 20520283 were VBD B-VP O
69 923 936 20520283 significantly RB B-ADJP O
70 937 944 20520283 greater JJR I-ADJP O
71 945 949 20520283 with IN B-PP O
72 950 959 20520283 asenapine NN B-NP B-Chemical
73 960 962 20520283 at IN B-PP O
74 963 964 20520283 5 CD B-NP O
75 965 968 20520283 and CC I-NP O
76 969 971 20520283 10 CD I-NP O
77 972 974 20520283 mg NN I-NP O
78 975 978 20520283 BID NN I-NP O
79 979 980 20520283 ( ( O O
80 980 981 20520283 - SYM B-NP O
81 981 985 20520283 21.3 CD B-NP O
82 986 989 20520283 and CC O O
83 990 991 20520283 - SYM B-NP O
84 991 995 20520283 19.4 CD B-NP O
85 995 996 20520283 , , O O
86 997 1009 20520283 respectively RB B-ADVP O
87 1009 1010 20520283 ) ) O O
88 1011 1014 20520283 and CC O O
89 1015 1026 20520283 haloperidol NN B-NP B-Chemical
90 1027 1028 20520283 ( ( O O
91 1028 1029 20520283 - SYM B-NP O
92 1029 1033 20520283 20.0 CD I-NP O
93 1033 1034 20520283 ) ) O O
94 1035 1039 20520283 than IN B-PP O
95 1040 1047 20520283 placebo NN B-NP O
96 1048 1049 20520283 ( ( O O
97 1049 1050 20520283 - SYM B-NP O
98 1050 1054 20520283 14.6 CD B-NP O
99 1054 1055 20520283 ; : O O
100 1056 1059 20520283 all DT B-NP O
101 1060 1061 20520283 P NN I-NP O
102 1062 1063 20520283 < JJR B-NP O
103 1064 1068 20520283 0.05 CD I-NP O
104 1068 1069 20520283 ) ) O O
105 1069 1070 20520283 . . O O

1 1071 1073 20520283 On IN B-PP O
2 1074 1077 20520283 the DT B-NP O
3 1078 1086 20520283 Positive JJ I-NP O
4 1087 1090 20520283 and CC I-NP O
5 1091 1099 20520283 Negative JJ I-NP O
6 1100 1108 20520283 Syndrome NN I-NP O
7 1109 1114 20520283 Scale NN I-NP O
8 1115 1123 20520283 positive JJ I-NP O
9 1124 1132 20520283 subscale NN I-NP O
10 1132 1133 20520283 , , O O
11 1134 1137 20520283 all DT B-NP O
12 1138 1148 20520283 treatments NNS I-NP O
13 1149 1153 20520283 were VBD B-VP O
14 1154 1162 20520283 superior JJ B-ADJP O
15 1163 1165 20520283 to TO B-PP O
16 1166 1173 20520283 placebo NN B-NP O
17 1174 1178 20520283 with IN B-PP O
18 1179 1183 20520283 LOCF NN B-NP O
19 1184 1187 20520283 and CC I-NP O
20 1188 1192 20520283 MMRM NN I-NP O
21 1192 1193 20520283 ; : O O
22 1194 1203 20520283 asenapine NN B-NP B-Chemical
23 1204 1206 20520283 at IN B-PP O
24 1207 1208 20520283 5 CD B-NP O
25 1209 1211 20520283 mg NN I-NP O
26 1212 1215 20520283 BID NN I-NP O
27 1216 1219 20520283 was VBD B-VP O
28 1220 1228 20520283 superior JJ B-ADJP O
29 1229 1231 20520283 to TO B-VP O
30 1232 1239 20520283 placebo VB I-VP O
31 1240 1242 20520283 on IN B-PP O
32 1243 1246 20520283 the DT B-NP O
33 1247 1255 20520283 negative JJ I-NP O
34 1256 1264 20520283 subscale NN I-NP O
35 1265 1269 20520283 with IN B-PP O
36 1270 1274 20520283 MMRM NN B-NP O
37 1275 1278 20520283 and CC B-PP O
38 1279 1281 20520283 on IN B-PP O
39 1282 1285 20520283 the DT B-NP O
40 1286 1293 20520283 general JJ I-NP O
41 1294 1309 20520283 psychopathology NN I-NP O
42 1310 1318 20520283 subscale NN I-NP O
43 1319 1323 20520283 with IN B-PP O
44 1324 1328 20520283 LOCF NN B-NP O
45 1329 1332 20520283 and CC I-NP O
46 1333 1337 20520283 MMRM NN I-NP O
47 1337 1338 20520283 . . O O

1 1339 1348 20520283 Treatment NN B-NP O
2 1348 1349 20520283 - HYPH O O
3 1349 1356 20520283 related VBN B-NP O
4 1357 1364 20520283 adverse JJ I-NP O
5 1365 1371 20520283 events NNS I-NP O
6 1372 1373 20520283 ( ( O O
7 1373 1376 20520283 AEs NNS B-NP O
8 1376 1377 20520283 ) ) O O
9 1378 1386 20520283 occurred VBD B-VP O
10 1387 1389 20520283 in IN B-PP O
11 1390 1393 20520283 44% NN B-NP O
12 1394 1397 20520283 and CC I-NP O
13 1398 1401 20520283 52% NN I-NP O
14 1401 1402 20520283 , , O O
15 1403 1406 20520283 57% NN B-NP O
16 1406 1407 20520283 , , O O
17 1408 1411 20520283 and CC O O
18 1412 1415 20520283 41% CD B-NP O
19 1416 1418 20520283 of IN B-PP O
20 1419 1422 20520283 the DT B-NP O
21 1423 1432 20520283 asenapine NN I-NP B-Chemical
22 1433 1435 20520283 at IN B-PP O
23 1436 1437 20520283 5 CD B-NP O
24 1438 1441 20520283 and CC I-NP O
25 1442 1444 20520283 10 CD I-NP O
26 1445 1447 20520283 mg NN I-NP O
27 1448 1451 20520283 BID NN I-NP O
28 1451 1452 20520283 , , O O
29 1453 1464 20520283 haloperidol NN B-NP B-Chemical
30 1464 1465 20520283 , , O O
31 1466 1469 20520283 and CC O O
32 1470 1477 20520283 placebo NN B-NP O
33 1478 1484 20520283 groups NNS I-NP O
34 1484 1485 20520283 , , O O
35 1486 1498 20520283 respectively RB B-ADVP O
36 1498 1499 20520283 . . O O

1 1500 1514 20520283 Extrapyramidal JJ B-NP B-Disease
2 1515 1523 20520283 symptoms NNS I-NP I-Disease
3 1524 1532 20520283 reported VBN B-VP O
4 1533 1535 20520283 as IN B-SBAR O
5 1536 1539 20520283 AEs NNS B-NP O
6 1540 1548 20520283 occurred VBD B-VP O
7 1549 1551 20520283 in IN B-PP O
8 1552 1555 20520283 15% NN B-NP O
9 1556 1559 20520283 and CC I-NP O
10 1560 1563 20520283 18% NN I-NP O
11 1563 1564 20520283 , , O O
12 1565 1568 20520283 34% NN B-NP O
13 1568 1569 20520283 , , O O
14 1570 1573 20520283 and CC O O
15 1574 1577 20520283 10% CD B-NP O
16 1578 1580 20520283 of IN B-PP O
17 1581 1584 20520283 the DT B-NP O
18 1585 1594 20520283 asenapine NN I-NP B-Chemical
19 1595 1597 20520283 at IN B-PP O
20 1598 1599 20520283 5 CD B-NP O
21 1600 1603 20520283 and CC I-NP O
22 1604 1606 20520283 10 CD I-NP O
23 1607 1609 20520283 mg NN I-NP O
24 1610 1613 20520283 BID NN I-NP O
25 1613 1614 20520283 , , O O
26 1615 1626 20520283 haloperidol NN B-NP B-Chemical
27 1626 1627 20520283 , , O O
28 1628 1631 20520283 and CC O O
29 1632 1639 20520283 placebo NN B-NP O
30 1640 1646 20520283 groups NNS I-NP O
31 1646 1647 20520283 , , O O
32 1648 1660 20520283 respectively RB B-ADVP O
33 1660 1661 20520283 . . O O

1 1662 1668 20520283 Across IN B-PP O
2 1669 1672 20520283 all DT B-NP O
3 1673 1679 20520283 groups NNS I-NP O
4 1679 1680 20520283 , , O O
5 1681 1683 20520283 no DT B-NP O
6 1684 1688 20520283 more JJR I-NP O
7 1689 1693 20520283 than IN I-NP O
8 1694 1696 20520283 5% CD I-NP O
9 1697 1699 20520283 of IN B-PP O
10 1700 1708 20520283 patients NNS B-NP O
11 1709 1712 20520283 had VBD B-VP O
12 1713 1723 20520283 clinically RB B-NP O
13 1724 1735 20520283 significant JJ I-NP O
14 1736 1742 20520283 weight NN I-NP O
15 1743 1749 20520283 change NN I-NP O
16 1749 1750 20520283 . . O O

1 1751 1755 20520283 Post JJ B-NP O
2 1756 1759 20520283 hoc NN I-NP O
3 1760 1768 20520283 analyses NNS I-NP O
4 1769 1778 20520283 indicated VBD B-VP O
5 1779 1783 20520283 that IN B-SBAR O
6 1784 1792 20520283 efficacy NN B-NP O
7 1793 1796 20520283 was VBD B-VP O
8 1797 1804 20520283 similar JJ B-ADJP O
9 1805 1809 20520283 with IN B-PP O
10 1810 1819 20520283 asenapine NN B-NP B-Chemical
11 1820 1823 20520283 and CC I-NP O
12 1824 1835 20520283 haloperidol NN I-NP B-Chemical
13 1835 1836 20520283 ; : O O
14 1837 1844 20520283 greater JJR B-NP O
15 1845 1854 20520283 contrasts NNS I-NP O
16 1855 1859 20520283 were VBD B-VP O
17 1860 1864 20520283 seen VBN I-VP O
18 1865 1867 20520283 in IN B-PP O
19 1868 1871 20520283 AEs NNS B-NP O
20 1871 1872 20520283 , , O O
21 1873 1883 20520283 especially RB B-NP O
22 1884 1898 20520283 extrapyramidal JJ I-NP B-Disease
23 1899 1907 20520283 symptoms NNS I-NP I-Disease
24 1907 1908 20520283 . . O O

1 0 0 11166519 -DOCSTART- -X- -X- O

1 0 5 11166519 Acute JJ B-NP O
2 6 13 11166519 cocaine NN I-NP B-Chemical
3 13 14 11166519 - HYPH B-NP O
4 14 21 11166519 induced VBN I-NP O
5 22 30 11166519 seizures NNS I-NP B-Disease
6 30 31 11166519 : : O O
7 32 44 11166519 differential JJ B-NP O
8 45 56 11166519 sensitivity NN I-NP O
9 57 59 11166519 of IN B-PP O
10 60 63 11166519 six CD B-NP O
11 64 70 11166519 inbred JJ I-NP O
12 71 76 11166519 mouse NN I-NP O
13 77 84 11166519 strains NNS I-NP O
14 84 85 11166519 . . O O
15 86 92 11166519 Mature NNP B-NP O
16 93 97 11166519 male JJ I-NP O
17 98 101 11166519 and CC I-NP O
18 102 108 11166519 female JJ I-NP O
19 109 113 11166519 mice NNS I-NP O
20 114 118 11166519 from IN B-PP O
21 119 122 11166519 six CD B-NP O
22 123 129 11166519 inbred JJ I-NP O
23 130 136 11166519 stains NNS I-NP O
24 137 141 11166519 were VBD B-VP O
25 142 148 11166519 tested VBN I-VP O
26 149 152 11166519 for IN B-PP O
27 153 167 11166519 susceptibility NN B-NP O
28 168 170 11166519 to TO B-PP O
29 171 181 11166519 behavioral JJ B-NP O
30 182 190 11166519 seizures NNS I-NP B-Disease
31 191 198 11166519 induced VBN B-VP O
32 199 201 11166519 by IN B-PP O
33 202 203 11166519 a DT B-NP O
34 204 210 11166519 single JJ I-NP O
35 211 220 11166519 injection NN I-NP O
36 221 223 11166519 of IN B-PP O
37 224 231 11166519 cocaine NN B-NP B-Chemical
38 231 232 11166519 . . O O

1 233 240 11166519 Cocaine NN B-NP B-Chemical
2 241 244 11166519 was VBD B-VP O
3 245 253 11166519 injected VBN I-VP O
4 254 256 11166519 ip RB B-ADVP O
5 257 261 11166519 over IN B-PP O
6 262 263 11166519 a DT B-NP O
7 264 269 11166519 range NN I-NP O
8 270 272 11166519 of IN B-PP O
9 273 278 11166519 doses NNS B-NP O
10 279 280 11166519 ( ( O O
11 280 282 11166519 50 CD B-NP O
12 282 283 11166519 - HYPH I-NP O
13 283 286 11166519 100 CD I-NP O
14 287 289 11166519 mg NN I-NP O
15 289 290 11166519 / SYM I-NP O
16 290 292 11166519 kg NN I-NP O
17 292 293 11166519 ) ) O O
18 294 297 11166519 and CC O O
19 298 306 11166519 behavior NN B-NP O
20 307 310 11166519 was VBD B-VP O
21 311 320 11166519 monitored VBN I-VP O
22 321 324 11166519 for IN B-PP O
23 325 327 11166519 20 CD B-NP O
24 328 335 11166519 minutes NNS I-NP O
25 335 336 11166519 . . O O

1 337 344 11166519 Seizure NN B-NP B-Disease
2 345 348 11166519 end NN I-NP O
3 349 355 11166519 points NNS I-NP O
4 356 364 11166519 included VBD B-VP O
5 365 372 11166519 latency NN B-NP O
6 373 375 11166519 to TO B-PP O
7 376 384 11166519 forelimb NN B-NP O
8 385 387 11166519 or CC I-NP O
9 388 396 11166519 hindlimb NN I-NP O
10 397 403 11166519 clonus NN I-NP O
11 403 404 11166519 , , O O
12 405 412 11166519 latency NN B-NP O
13 413 415 11166519 to TO B-PP O
14 416 422 11166519 clonic JJ B-NP O
15 423 430 11166519 running VBG I-NP O
16 431 438 11166519 seizure NN I-NP B-Disease
17 439 442 11166519 and CC I-NP O
18 443 450 11166519 latency NN I-NP O
19 451 453 11166519 to TO B-PP O
20 454 461 11166519 jumping VBG B-VP O
21 462 470 11166519 bouncing VBG B-NP O
22 471 478 11166519 seizure NN I-NP B-Disease
23 478 479 11166519 . . O O

1 480 481 11166519 A DT B-NP O
2 482 487 11166519 range NN I-NP O
3 488 490 11166519 of IN B-PP O
4 491 497 11166519 strain NN B-NP O
5 498 506 11166519 specific JJ I-NP O
6 507 520 11166519 sensitivities NNS I-NP O
7 521 524 11166519 was VBD B-VP O
8 525 535 11166519 documented VBN I-VP O
9 536 540 11166519 with IN B-PP O
10 541 542 11166519 A NN B-NP O
11 542 543 11166519 / SYM I-NP O
12 543 544 11166519 J NN I-NP O
13 545 548 11166519 and CC I-NP O
14 549 552 11166519 SJL NN I-NP O
15 553 557 11166519 mice NNS I-NP O
16 558 563 11166519 being VBG B-VP O
17 564 568 11166519 most RBS B-NP O
18 569 578 11166519 sensitive JJ I-NP O
19 579 582 11166519 and CC I-NP O
20 583 588 11166519 C57BL NN I-NP O
21 588 589 11166519 / SYM I-NP O
22 589 591 11166519 6J NN I-NP O
23 592 596 11166519 most RBS B-ADJP O
24 597 606 11166519 resistant JJ I-ADJP O
25 606 607 11166519 . . O O

1 608 611 11166519 DBA NN B-NP O
2 611 612 11166519 / SYM I-NP O
3 612 614 11166519 2J NN I-NP O
4 614 615 11166519 , , O O
5 616 620 11166519 BALB NN B-NP O
6 620 621 11166519 / SYM B-NP O
7 621 625 11166519 cByJ NN I-NP O
8 626 629 11166519 and CC I-NP O
9 630 633 11166519 NZW NN I-NP O
10 633 634 11166519 / SYM B-NP O
11 634 638 11166519 LacJ NN B-NP O
12 639 646 11166519 strains NNS I-NP O
13 647 656 11166519 exhibited VBD B-VP O
14 657 669 11166519 intermediate JJ B-NP O
15 670 681 11166519 sensitivity NN I-NP O
16 681 682 11166519 . . O O

1 683 686 11166519 EEG NN B-NP O
2 687 697 11166519 recordings NNS I-NP O
3 698 702 11166519 were VBD B-VP O
4 703 707 11166519 made VBN I-VP O
5 708 710 11166519 in IN B-PP O
6 711 714 11166519 SJL NN B-NP O
7 714 715 11166519 , , O O
8 716 717 11166519 A NN B-NP O
9 717 718 11166519 / SYM I-NP O
10 718 719 11166519 J NN I-NP O
11 720 723 11166519 and CC I-NP O
12 724 729 11166519 C57BL NN I-NP O
13 729 730 11166519 / SYM B-NP O
14 730 732 11166519 6J NN B-NP O
15 733 737 11166519 mice NNS I-NP O
16 738 747 11166519 revealing VBG B-VP O
17 748 749 11166519 a DT B-NP O
18 750 755 11166519 close JJ I-NP O
19 756 770 11166519 correspondence NN I-NP O
20 771 778 11166519 between IN B-PP O
21 779 789 11166519 electrical JJ B-NP O
22 790 798 11166519 activity NN I-NP O
23 799 802 11166519 and CC I-NP O
24 803 811 11166519 behavior NN I-NP O
25 811 812 11166519 . . O O

1 813 825 11166519 Additionally RB B-ADVP O
2 825 826 11166519 , , O O
3 827 833 11166519 levels NNS B-NP O
4 834 836 11166519 of IN B-PP O
5 837 844 11166519 cocaine NN B-NP B-Chemical
6 845 855 11166519 determined VBN B-VP O
7 856 858 11166519 in IN B-PP O
8 859 870 11166519 hippocampus NN B-NP O
9 871 874 11166519 and CC I-NP O
10 875 881 11166519 cortex NN I-NP O
11 882 886 11166519 were VBD B-VP O
12 887 890 11166519 not RB B-ADJP O
13 891 900 11166519 different JJ I-ADJP O
14 901 908 11166519 between IN B-PP O
15 909 918 11166519 sensitive JJ B-NP O
16 919 922 11166519 and CC I-NP O
17 923 932 11166519 resistant JJ I-NP O
18 933 940 11166519 strains NNS I-NP O
19 940 941 11166519 . . O O

1 942 952 11166519 Additional JJ B-NP O
2 953 960 11166519 studies NNS I-NP O
3 961 963 11166519 of IN B-PP O
4 964 969 11166519 these DT B-NP O
5 970 976 11166519 murine JJ I-NP O
6 977 984 11166519 strains NNS I-NP O
7 985 988 11166519 may MD B-VP O
8 989 991 11166519 be VB I-VP O
9 992 998 11166519 useful JJ B-ADJP O
10 999 1002 11166519 for IN B-PP O
11 1003 1016 11166519 investigating VBG B-VP O
12 1017 1024 11166519 genetic JJ B-NP O
13 1025 1035 11166519 influences NNS I-NP O
14 1036 1038 11166519 on IN B-PP O
15 1039 1046 11166519 cocaine NN B-NP B-Chemical
16 1046 1047 11166519 - HYPH B-NP O
17 1047 1054 11166519 induced VBN I-NP O
18 1055 1063 11166519 seizures NNS I-NP B-Disease
19 1063 1064 11166519 . . O O

1 0 0 3070035 -DOCSTART- -X- -X- O

1 0 13 3070035 Reversibility NN B-NP O
2 14 16 3070035 of IN B-PP O
3 17 26 3070035 captopril NN B-NP B-Chemical
4 26 27 3070035 - HYPH B-NP O
5 27 34 3070035 induced VBN I-NP O
6 35 40 3070035 renal JJ I-NP B-Disease
7 41 54 3070035 insufficiency NN I-NP I-Disease
8 55 60 3070035 after IN B-PP O
9 61 70 3070035 prolonged JJ B-NP O
10 71 74 3070035 use NN I-NP O
11 75 77 3070035 in IN B-PP O
12 78 80 3070035 an DT B-NP O
13 81 88 3070035 unusual JJ I-NP O
14 89 93 3070035 case NN I-NP O
15 94 96 3070035 of IN B-PP O
16 97 109 3070035 renovascular JJ B-NP B-Disease
17 110 122 3070035 hypertension NN I-NP I-Disease
18 122 123 3070035 . . O O
19 124 126 3070035 We PRP B-NP O
20 127 133 3070035 report VBP B-VP O
21 134 135 3070035 a DT B-NP O
22 136 140 3070035 case NN I-NP O
23 141 143 3070035 of IN B-PP O
24 144 150 3070035 severe JJ B-NP O
25 151 163 3070035 hypertension NN I-NP B-Disease
26 164 168 3070035 with IN B-PP O
27 169 171 3070035 an DT B-NP O
28 172 180 3070035 occluded VBN I-NP O
29 181 186 3070035 renal JJ I-NP O
30 187 193 3070035 artery NN I-NP O
31 194 196 3070035 to TO B-PP O
32 197 198 3070035 a DT B-NP O
33 199 207 3070035 solitary JJ I-NP O
34 208 214 3070035 kidney NN I-NP O
35 214 215 3070035 , , O O
36 216 219 3070035 who WP B-NP O
37 220 229 3070035 developed VBD B-VP O
38 230 236 3070035 sudden JJ B-NP B-Disease
39 237 250 3070035 deterioration NN I-NP I-Disease
40 251 253 3070035 of IN B-PP I-Disease
41 254 259 3070035 renal JJ B-NP I-Disease
42 260 268 3070035 function NN I-NP I-Disease
43 269 278 3070035 following VBG B-PP O
44 279 288 3070035 treatment NN B-NP O
45 289 293 3070035 with IN B-PP O
46 294 303 3070035 captopril NN B-NP B-Chemical
47 303 304 3070035 . . O O

1 305 308 3070035 His PRP$ B-NP O
2 309 314 3070035 renal JJ I-NP O
3 315 323 3070035 function NN I-NP O
4 324 332 3070035 remained VBD B-VP O
5 333 341 3070035 impaired JJ B-ADJP O
6 342 345 3070035 but CC I-ADJP O
7 346 352 3070035 stable JJ I-ADJP O
8 353 359 3070035 during IN B-PP O
9 360 361 3070035 2 CD B-NP O
10 362 367 3070035 years NNS I-NP O
11 367 368 3070035 ' POS B-NP O
12 369 378 3070035 treatment NN I-NP O
13 379 383 3070035 with IN B-PP O
14 384 393 3070035 captopril NN B-NP B-Chemical
15 394 397 3070035 but CC O O
16 398 406 3070035 returned VBD B-VP O
17 407 409 3070035 to TO B-PP O
18 410 413 3070035 pre AFX B-NP O
19 413 414 3070035 - HYPH I-NP O
20 414 423 3070035 treatment NN I-NP O
21 424 430 3070035 levels NNS I-NP O
22 431 435 3070035 soon RB B-ADVP O
23 436 441 3070035 after IN B-PP O
24 442 451 3070035 cessation NN B-NP O
25 452 454 3070035 of IN B-PP O
26 455 458 3070035 the DT B-NP O
27 459 463 3070035 drug NN I-NP O
28 463 464 3070035 . . O O

1 465 469 3070035 This DT B-NP O
2 470 479 3070035 indicates VBZ B-VP O
3 480 493 3070035 reversibility NN B-NP O
4 494 496 3070035 in IN B-PP O
5 497 506 3070035 captopril NN B-NP B-Chemical
6 506 507 3070035 - HYPH B-NP O
7 507 514 3070035 induced VBN I-NP O
8 515 520 3070035 renal JJ I-NP B-Disease
9 521 528 3070035 failure NN I-NP I-Disease
10 529 533 3070035 even RB B-ADVP O
11 534 539 3070035 after IN B-PP O
12 540 543 3070035 its PRP$ B-NP O
13 544 553 3070035 prolonged JJ I-NP O
14 554 557 3070035 use NN I-NP O
15 558 561 3070035 and CC O O
16 562 570 3070035 suggests VBZ B-VP O
17 571 575 3070035 that IN B-SBAR O
18 576 578 3070035 no DT B-NP O
19 579 586 3070035 organic JJ I-NP O
20 587 593 3070035 damage NN I-NP O
21 594 600 3070035 occurs VBZ B-VP O
22 601 603 3070035 to TO B-PP O
23 604 614 3070035 glomerular JJ B-NP O
24 615 625 3070035 arterioles NNS I-NP O
25 626 635 3070035 following VBG B-PP O
26 636 643 3070035 chronic JJ B-NP O
27 644 647 3070035 ACE NN I-NP O
28 648 658 3070035 inhibition NN I-NP O
29 658 659 3070035 . . O O

1 0 0 18208574 -DOCSTART- -X- -X- O

1 0 6 18208574 Higher JJR B-NP O
2 7 14 18208574 optical JJ I-NP O
3 15 22 18208574 density NN I-NP O
4 23 25 18208574 of IN B-PP O
5 26 28 18208574 an DT B-NP O
6 29 36 18208574 antigen NN I-NP O
7 37 42 18208574 assay NN I-NP O
8 43 51 18208574 predicts VBZ B-VP O
9 52 62 18208574 thrombosis NN B-NP B-Disease
10 63 65 18208574 in IN B-PP O
11 66 74 18208574 patients NNS B-NP O
12 75 79 18208574 with IN B-PP O
13 80 87 18208574 heparin NN B-NP B-Chemical
14 87 88 18208574 - HYPH B-NP O
15 88 95 18208574 induced VBN I-NP O
16 96 112 18208574 thrombocytopenia NN I-NP B-Disease
17 112 113 18208574 . . I-NP O
18 114 124 18208574 OBJECTIVES NNS I-NP O
19 124 125 18208574 : : O O
20 126 128 18208574 To TO B-VP O
21 129 138 18208574 correlate VB I-VP O
22 139 146 18208574 optical JJ B-NP O
23 147 154 18208574 density NN I-NP O
24 155 158 18208574 and CC I-NP O
25 159 166 18208574 percent NN I-NP O
26 167 177 18208574 inhibition NN I-NP O
27 178 180 18208574 of IN B-PP O
28 181 182 18208574 a DT B-NP O
29 183 186 18208574 two CD I-NP O
30 186 187 18208574 - HYPH I-NP O
31 187 191 18208574 step NN I-NP O
32 192 199 18208574 heparin NN I-NP B-Chemical
33 199 200 18208574 - HYPH B-VP O
34 200 207 18208574 induced VBN B-NP O
35 208 224 18208574 thrombocytopenia NN I-NP B-Disease
36 225 226 18208574 ( ( O O
37 226 229 18208574 HIT NN B-NP B-Disease
38 229 230 18208574 ) ) O O
39 231 238 18208574 antigen NN B-NP O
40 239 244 18208574 assay NN I-NP O
41 245 249 18208574 with IN B-PP O
42 250 260 18208574 thrombosis NN B-NP B-Disease
43 260 261 18208574 ; : O O
44 262 265 18208574 the DT B-NP O
45 266 271 18208574 assay NN I-NP O
46 272 280 18208574 utilizes VBZ B-VP O
47 281 289 18208574 reaction NN B-NP O
48 290 300 18208574 inhibition NN I-NP O
49 301 316 18208574 characteristics NNS I-NP O
50 317 319 18208574 of IN B-PP O
51 320 321 18208574 a DT B-NP O
52 322 326 18208574 high JJ I-NP O
53 327 334 18208574 heparin NN I-NP B-Chemical
54 335 348 18208574 concentration NN I-NP O
55 348 349 18208574 . . O O

1 350 358 18208574 PATIENTS NNS B-NP O
2 359 362 18208574 AND CC I-NP O
3 363 370 18208574 METHODS NNS I-NP O
4 370 371 18208574 : : O O
5 372 380 18208574 Patients NNS B-NP O
6 381 385 18208574 with IN B-PP O
7 386 390 18208574 more JJR B-NP O
8 391 395 18208574 than IN I-NP O
9 396 399 18208574 50% CD I-NP O
10 400 408 18208574 decrease NN I-NP O
11 409 411 18208574 in IN B-PP O
12 412 420 18208574 platelet NN B-NP O
13 421 426 18208574 count NN I-NP O
14 427 429 18208574 or CC O O
15 430 446 18208574 thrombocytopenia NN B-NP B-Disease
16 447 448 18208574 ( ( O O
17 448 449 18208574 < SYM B-NP O
18 449 452 18208574 150 CD I-NP O
19 453 454 18208574 x SYM I-NP O
20 455 460 18208574 10(9) CD I-NP O
21 460 461 18208574 / SYM I-NP O
22 461 462 18208574 L NN I-NP O
23 462 463 18208574 ) ) O O
24 464 469 18208574 after IN B-PP O
25 470 478 18208574 exposure NN B-NP O
26 479 481 18208574 to TO B-PP O
27 482 489 18208574 heparin NN B-NP B-Chemical
28 489 490 18208574 , , O O
29 491 494 18208574 who WP B-NP O
30 495 498 18208574 had VBD B-VP O
31 499 500 18208574 a DT B-NP O
32 501 509 18208574 positive JJ I-NP O
33 510 513 18208574 two CD I-NP O
34 513 514 18208574 - HYPH I-NP O
35 514 518 18208574 step NN I-NP O
36 519 526 18208574 antigen NN I-NP O
37 527 532 18208574 assay NN I-NP O
38 533 534 18208574 [ ( O O
39 534 541 18208574 optical JJ B-NP O
40 542 549 18208574 density NN I-NP O
41 550 551 18208574 ( ( O O
42 551 553 18208574 OD NN B-NP O
43 553 554 18208574 ) ) O O
44 555 556 18208574 > SYM B-NP O
45 556 559 18208574 0.4 CD I-NP O
46 560 563 18208574 and CC O O
47 564 565 18208574 > SYM B-NP O
48 565 567 18208574 50 CD B-NP O
49 568 578 18208574 inhibition NN I-NP O
50 579 583 18208574 with IN B-PP O
51 584 588 18208574 high JJ B-NP O
52 589 602 18208574 concentration NN I-NP O
53 603 605 18208574 of IN B-PP O
54 606 613 18208574 heparin NN B-NP B-Chemical
55 613 614 18208574 ] ) O O
56 615 619 18208574 were VBD B-VP O
57 620 628 18208574 included VBN I-VP O
58 629 631 18208574 in IN B-PP O
59 632 635 18208574 the DT B-NP O
60 636 641 18208574 study NN I-NP O
61 641 642 18208574 . . O O

1 643 650 18208574 RESULTS NNS B-NP O
2 650 651 18208574 : : O O
3 652 657 18208574 Forty CD B-NP O
4 658 660 18208574 of IN B-PP O
5 661 663 18208574 94 CD B-NP O
6 664 667 18208574 HIT NN I-NP B-Disease
7 668 676 18208574 patients NNS I-NP O
8 677 680 18208574 had VBD B-VP O
9 681 691 18208574 thrombosis NN B-NP B-Disease
10 692 694 18208574 at IN B-PP O
11 695 704 18208574 diagnosis NN B-NP O
12 704 705 18208574 ; : O O
13 706 708 18208574 54 CD B-NP O
14 708 709 18208574 / SYM I-NP O
15 709 711 18208574 94 CD I-NP O
16 712 715 18208574 had VBD B-VP O
17 716 724 18208574 isolated VBN I-VP O
18 724 725 18208574 - HYPH B-NP O
19 725 728 18208574 HIT NN I-NP B-Disease
20 729 736 18208574 without IN B-PP O
21 737 747 18208574 thrombosis NN B-NP B-Disease
22 747 748 18208574 . . O O

1 749 754 18208574 Eight CD B-NP O
2 755 757 18208574 of IN B-PP O
3 758 761 18208574 the DT B-NP O
4 762 770 18208574 isolated VBN I-NP O
5 770 771 18208574 - HYPH I-NP O
6 771 774 18208574 HIT NN I-NP B-Disease
7 775 783 18208574 patients NNS I-NP O
8 784 793 18208574 developed VBD B-VP O
9 794 804 18208574 thrombosis NN B-NP B-Disease
10 805 811 18208574 within IN B-PP O
11 812 815 18208574 the DT B-NP O
12 816 820 18208574 next JJ I-NP O
13 821 823 18208574 30 CD I-NP O
14 824 825 18208574 d NN I-NP O
15 825 826 18208574 ; : O O
16 827 831 18208574 thus RB B-ADVP O
17 831 832 18208574 , , O O
18 833 834 18208574 a DT B-NP O
19 835 840 18208574 total NN I-NP O
20 841 843 18208574 of IN B-PP O
21 844 846 18208574 48 CD B-NP O
22 847 855 18208574 patients NNS I-NP O
23 856 859 18208574 had VBD B-VP O
24 860 870 18208574 thrombosis NN B-NP B-Disease
25 871 873 18208574 at IN B-PP O
26 874 877 18208574 day NN B-NP O
27 878 880 18208574 30 CD I-NP O
28 880 881 18208574 . . O O

1 882 884 18208574 At IN B-PP O
2 885 894 18208574 diagnosis NN B-NP O
3 895 900 18208574 there EX B-NP O
4 901 904 18208574 was VBD B-VP O
5 905 907 18208574 no DT B-NP O
6 908 919 18208574 significant JJ I-NP O
7 920 930 18208574 difference NN I-NP O
8 931 933 18208574 in IN B-PP O
9 934 936 18208574 OD NN B-NP O
10 937 944 18208574 between IN B-PP O
11 945 948 18208574 HIT NN B-NP B-Disease
12 949 957 18208574 patients NNS I-NP O
13 958 962 18208574 with IN B-PP O
14 963 973 18208574 thrombosis NN B-NP B-Disease
15 974 977 18208574 and CC O O
16 978 983 18208574 those DT B-NP O
17 984 988 18208574 with IN B-PP O
18 989 997 18208574 isolated VBN B-NP O
19 997 998 18208574 - HYPH I-NP O
20 998 1001 18208574 HIT NN I-NP B-Disease
21 1001 1002 18208574 . . O O

1 1003 1010 18208574 However RB B-ADVP O
2 1010 1011 18208574 , , O O
3 1012 1014 18208574 OD NN B-NP O
4 1015 1018 18208574 was VBD B-VP O
5 1019 1032 18208574 significantly RB B-ADJP O
6 1033 1039 18208574 higher JJR I-ADJP O
7 1040 1042 18208574 in IN B-PP O
8 1043 1046 18208574 all DT B-NP O
9 1047 1055 18208574 patients NNS I-NP O
10 1056 1060 18208574 with IN B-PP O
11 1061 1071 18208574 thrombosis NN B-NP B-Disease
12 1072 1073 18208574 ( ( O O
13 1073 1074 18208574 n NN B-NP O
14 1075 1076 18208574 = SYM B-VP O
15 1077 1079 18208574 48 CD B-NP O
16 1079 1080 18208574 , , O O
17 1081 1085 18208574 1.34 CD B-NP O
18 1086 1087 18208574 + SYM O O
19 1087 1088 18208574 / SYM O O
20 1088 1089 18208574 - SYM O O
21 1090 1094 18208574 0.89 CD B-NP O
22 1094 1095 18208574 ) ) O O
23 1095 1096 18208574 , , O O
24 1097 1106 18208574 including VBG B-PP O
25 1107 1115 18208574 isolated VBN B-VP O
26 1115 1116 18208574 - HYPH B-NP O
27 1116 1119 18208574 HIT NN I-NP B-Disease
28 1120 1128 18208574 patients NNS I-NP O
29 1129 1132 18208574 who WP B-NP O
30 1133 1138 18208574 later RB B-ADVP O
31 1139 1148 18208574 developed VBD B-VP O
32 1149 1159 18208574 thrombosis NN B-NP B-Disease
33 1160 1166 18208574 within IN B-PP O
34 1167 1169 18208574 30 CD B-NP O
35 1170 1171 18208574 d NN I-NP O
36 1172 1173 18208574 ( ( O O
37 1173 1174 18208574 n NN B-NP O
38 1175 1176 18208574 = SYM B-VP O
39 1177 1178 18208574 8 CD B-NP O
40 1178 1179 18208574 , , O O
41 1180 1184 18208574 1.84 CD B-NP O
42 1185 1186 18208574 + SYM O O
43 1186 1187 18208574 / SYM O O
44 1187 1188 18208574 - SYM O O
45 1189 1193 18208574 0.64 CD B-NP O
46 1193 1194 18208574 ) ) O O
47 1195 1197 18208574 as IN B-SBAR O
48 1198 1206 18208574 compared VBN B-VP O
49 1207 1209 18208574 to TO B-PP O
50 1210 1218 18208574 isolated VBN B-NP O
51 1218 1219 18208574 - HYPH I-NP O
52 1219 1222 18208574 HIT NN B-NP B-Disease
53 1223 1231 18208574 patients NNS I-NP O
54 1232 1235 18208574 who WP B-NP O
55 1236 1239 18208574 did VBD B-VP O
56 1240 1243 18208574 not RB I-VP O
57 1244 1251 18208574 develop VB I-VP O
58 1252 1262 18208574 thrombosis NN B-NP B-Disease
59 1263 1264 18208574 ( ( O O
60 1264 1268 18208574 0.96 CD B-NP O
61 1269 1270 18208574 + SYM O O
62 1270 1271 18208574 / SYM O O
63 1271 1272 18208574 - SYM O O
64 1273 1277 18208574 0.75 CD B-NP O
65 1277 1278 18208574 ; : O O
66 1279 1280 18208574 P NN B-NP O
67 1281 1282 18208574 = SYM B-VP O
68 1283 1288 18208574 0.011 CD B-NP O
69 1289 1292 18208574 and CC O O
70 1293 1294 18208574 P NN B-NP O
71 1295 1296 18208574 = SYM B-VP O
72 1297 1302 18208574 0.008 CD B-NP O
73 1302 1303 18208574 ) ) O O
74 1303 1304 18208574 . . O O

1 1305 1308 18208574 The DT B-NP O
2 1309 1317 18208574 Receiver NNP I-NP O
3 1318 1327 18208574 Operative NNP I-NP O
4 1328 1342 18208574 Characteristic NNP I-NP O
5 1343 1348 18208574 Curve NNP I-NP O
6 1349 1355 18208574 showed VBD B-VP O
7 1356 1360 18208574 that IN B-SBAR O
8 1361 1363 18208574 OD NN B-NP O
9 1364 1365 18208574 > SYM B-VP O
10 1365 1369 18208574 1.27 CD B-NP O
11 1370 1372 18208574 in IN B-PP O
12 1373 1376 18208574 the DT B-NP O
13 1377 1385 18208574 isolated VBN I-NP O
14 1385 1386 18208574 - HYPH I-NP O
15 1386 1389 18208574 HIT NN I-NP B-Disease
16 1390 1395 18208574 group NN I-NP O
17 1396 1399 18208574 had VBD B-VP O
18 1400 1401 18208574 a DT B-NP O
19 1402 1415 18208574 significantly RB I-NP O
20 1416 1422 18208574 higher JJR I-NP O
21 1423 1429 18208574 chance NN I-NP O
22 1430 1432 18208574 of IN B-PP O
23 1433 1443 18208574 developing VBG B-VP O
24 1444 1454 18208574 thrombosis NN B-NP B-Disease
25 1455 1457 18208574 by IN B-PP O
26 1458 1461 18208574 day NN B-NP O
27 1462 1464 18208574 30 CD I-NP O
28 1464 1465 18208574 . . O O

1 1466 1470 18208574 None NN B-NP O
2 1471 1473 18208574 of IN B-PP O
3 1474 1479 18208574 these DT B-NP O
4 1480 1486 18208574 groups NNS I-NP O
5 1487 1493 18208574 showed VBD B-VP O
6 1494 1505 18208574 significant JJ B-NP O
7 1506 1516 18208574 difference NN I-NP O
8 1517 1519 18208574 in IN B-PP O
9 1520 1527 18208574 percent NN B-NP O
10 1528 1538 18208574 inhibition NN I-NP O
11 1538 1539 18208574 . . O O

1 1540 1552 18208574 Multivariate JJ B-NP O
2 1553 1561 18208574 analysis NN I-NP O
3 1562 1568 18208574 showed VBD B-VP O
4 1569 1570 18208574 a DT B-NP O
5 1571 1574 18208574 2.8 CD I-NP O
6 1574 1575 18208574 - HYPH B-NP O
7 1575 1579 18208574 fold RB I-NP O
8 1580 1589 18208574 increased VBN I-NP O
9 1590 1594 18208574 risk NN I-NP O
10 1595 1597 18208574 of IN B-PP O
11 1598 1608 18208574 thrombosis NN B-NP B-Disease
12 1609 1611 18208574 in IN B-PP O
13 1612 1619 18208574 females NNS B-NP O
14 1619 1620 18208574 . . O O

1 1621 1630 18208574 Similarly RB B-ADVP O
2 1630 1631 18208574 , , O O
3 1632 1642 18208574 thrombotic JJ B-NP B-Disease
4 1643 1647 18208574 risk NN I-NP O
5 1648 1657 18208574 increased VBD B-VP O
6 1658 1662 18208574 with IN B-PP O
7 1663 1666 18208574 age NN B-NP O
8 1667 1670 18208574 and CC I-NP O
9 1671 1673 18208574 OD NN I-NP O
10 1674 1680 18208574 values NNS I-NP O
11 1680 1681 18208574 . . O O

1 1682 1692 18208574 CONCLUSION NN B-NP O
2 1692 1693 18208574 : : O O
3 1694 1700 18208574 Higher JJR B-NP O
4 1701 1703 18208574 OD NN I-NP O
5 1704 1706 18208574 is VBZ B-VP O
6 1707 1717 18208574 associated VBN I-VP O
7 1718 1722 18208574 with IN B-PP O
8 1723 1734 18208574 significant JJ B-NP O
9 1735 1739 18208574 risk NN I-NP O
10 1740 1742 18208574 of IN B-PP O
11 1743 1753 18208574 subsequent JJ B-NP O
12 1754 1764 18208574 thrombosis NN I-NP B-Disease
13 1765 1767 18208574 in IN B-PP O
14 1768 1776 18208574 patients NNS B-NP O
15 1777 1781 18208574 with IN B-PP O
16 1782 1790 18208574 isolated VBN B-NP O
17 1790 1791 18208574 - HYPH I-NP O
18 1791 1794 18208574 HIT NN I-NP B-Disease
19 1794 1795 18208574 ; : O O
20 1796 1803 18208574 percent NN B-NP O
21 1804 1814 18208574 inhibition NN I-NP O
22 1814 1815 18208574 , , O O
23 1816 1823 18208574 however RB B-ADVP O
24 1823 1824 18208574 , , O O
25 1825 1828 18208574 was VBD B-VP O
26 1829 1832 18208574 not RB O O
27 1833 1843 18208574 predictive JJ B-ADJP O
28 1843 1844 18208574 . . O O

1 0 0 17854040 -DOCSTART- -X- -X- O

1 0 9 17854040 Mutations NNS B-NP O
2 10 20 17854040 associated VBN B-VP O
3 21 25 17854040 with IN B-PP O
4 26 36 17854040 lamivudine NN B-NP B-Chemical
5 36 37 17854040 - HYPH B-NP O
6 37 47 17854040 resistance NN I-NP O
7 48 50 17854040 in IN B-PP O
8 51 58 17854040 therapy NN B-NP O
9 58 59 17854040 - HYPH B-NP O
10 59 61 17854040 na NN I-NP B-Chemical
11 63 65 17854040 ve NN I-NP O
12 66 75 17854040 hepatitis NN I-NP B-Disease
13 76 77 17854040 B NN I-NP I-Disease
14 78 83 17854040 virus NN I-NP I-Disease
15 84 85 17854040 ( ( O I-Disease
16 85 88 17854040 HBV NN B-NP I-Disease
17 88 89 17854040 ) ) O I-Disease
18 90 98 17854040 infected JJ B-NP I-Disease
19 99 107 17854040 patients NNS I-NP O
20 108 112 17854040 with IN B-PP O
21 113 116 17854040 and CC I-PP O
22 117 124 17854040 without IN I-PP O
23 125 128 17854040 HIV NN B-NP B-Disease
24 129 131 17854040 co AFX O I-Disease
25 131 132 17854040 - HYPH B-NP I-Disease
26 132 141 17854040 infection NN I-NP I-Disease
27 141 142 17854040 : : O O
28 143 155 17854040 implications NNS B-NP O
29 156 159 17854040 for IN B-PP O
30 160 174 17854040 antiretroviral JJ B-NP O
31 175 182 17854040 therapy NN I-NP O
32 183 185 17854040 in IN B-PP O
33 186 189 17854040 HBV NN B-NP B-Disease
34 190 193 17854040 and CC I-NP I-Disease
35 194 197 17854040 HIV NN I-NP I-Disease
36 198 200 17854040 co AFX O I-Disease
37 200 201 17854040 - HYPH O I-Disease
38 201 209 17854040 infected VBN B-VP I-Disease
39 210 215 17854040 South JJ B-NP O
40 216 223 17854040 African JJ I-NP O
41 224 232 17854040 patients NNS I-NP O
42 232 233 17854040 . . O O
43 234 238 17854040 This DT B-NP O
44 239 242 17854040 was VBD B-VP O
45 243 245 17854040 an DT B-NP O
46 246 257 17854040 exploratory JJ I-NP O
47 258 263 17854040 study NN I-NP O
48 264 266 17854040 to TO B-VP O
49 267 278 17854040 investigate VB I-VP O
50 279 289 17854040 lamivudine NN B-NP B-Chemical
51 289 290 17854040 - HYPH B-NP O
52 290 299 17854040 resistant JJ I-NP O
53 300 309 17854040 hepatitis NN I-NP B-Disease
54 310 311 17854040 B NN I-NP I-Disease
55 312 317 17854040 virus NN I-NP O
56 318 319 17854040 ( ( O O
57 319 322 17854040 HBV NN B-NP O
58 322 323 17854040 ) ) O O
59 324 331 17854040 strains NNS B-NP O
60 332 334 17854040 in IN B-PP O
61 335 343 17854040 selected VBN B-NP O
62 344 354 17854040 lamivudine NN I-NP B-Chemical
63 354 355 17854040 - HYPH I-NP O
64 355 357 17854040 na NN I-NP B-Chemical
65 359 361 17854040 ve NN I-NP O
66 362 365 17854040 HBV NN I-NP O
67 366 374 17854040 carriers NNS I-NP O
68 375 379 17854040 with IN B-PP O
69 380 383 17854040 and CC O O
70 384 391 17854040 without IN B-PP O
71 392 397 17854040 human JJ B-NP B-Disease
72 398 414 17854040 immunodeficiency NN I-NP I-Disease
73 415 420 17854040 virus NN I-NP I-Disease
74 421 422 17854040 ( ( O I-Disease
75 422 425 17854040 HIV NN B-NP I-Disease
76 425 426 17854040 ) ) O I-Disease
77 427 429 17854040 co AFX O I-Disease
78 429 430 17854040 - HYPH B-NP I-Disease
79 430 439 17854040 infection NN I-NP I-Disease
80 440 442 17854040 in IN B-PP O
81 443 448 17854040 South JJ B-NP O
82 449 456 17854040 African JJ I-NP O
83 457 465 17854040 patients NNS I-NP O
84 465 466 17854040 . . O O

1 467 473 17854040 Thirty CD B-NP O
2 473 474 17854040 - HYPH I-NP O
3 474 478 17854040 five CD I-NP O
4 479 489 17854040 lamivudine NN I-NP B-Chemical
5 489 490 17854040 - HYPH I-NP O
6 490 492 17854040 na NN I-NP B-Chemical
7 494 496 17854040 ve NN I-NP O
8 497 500 17854040 HBV NN I-NP B-Disease
9 501 509 17854040 infected JJ B-NP I-Disease
10 510 518 17854040 patients NNS I-NP O
11 519 523 17854040 with IN B-PP O
12 524 526 17854040 or CC B-PP O
13 527 534 17854040 without IN B-PP O
14 535 538 17854040 HIV NN B-NP B-Disease
15 539 541 17854040 co AFX O I-Disease
16 541 542 17854040 - HYPH B-NP I-Disease
17 542 551 17854040 infection NN I-NP I-Disease
18 552 556 17854040 were VBD B-VP O
19 557 564 17854040 studied VBN I-VP O
20 564 565 17854040 : : O O
21 566 568 17854040 15 CD B-NP O
22 569 576 17854040 chronic JJ I-NP O
23 577 580 17854040 HBV NN I-NP B-Disease
24 581 585 17854040 mono AFX O I-Disease
25 585 586 17854040 - HYPH B-NP I-Disease
26 586 594 17854040 infected VBN B-NP I-Disease
27 595 603 17854040 patients NNS I-NP O
28 604 607 17854040 and CC O O
29 608 610 17854040 20 CD B-NP O
30 611 614 17854040 HBV NN I-NP B-Disease
31 614 615 17854040 - HYPH B-NP I-Disease
32 615 618 17854040 HIV NN I-NP I-Disease
33 619 621 17854040 co AFX O I-Disease
34 621 622 17854040 - HYPH B-NP I-Disease
35 622 630 17854040 infected VBN B-NP I-Disease
36 631 639 17854040 patients NNS I-NP O
37 639 640 17854040 . . O O

1 641 644 17854040 The DT B-NP O
2 645 651 17854040 latter JJ I-NP O
3 652 657 17854040 group NN I-NP O
4 658 661 17854040 was VBD B-VP O
5 662 669 17854040 further JJ B-ADJP O
6 670 673 17854040 sub AFX O O
7 673 674 17854040 - HYPH O O
8 674 681 17854040 divided VBN B-VP O
9 682 686 17854040 into IN B-PP O
10 687 689 17854040 13 CD B-NP O
11 690 696 17854040 occult JJ I-NP O
12 697 700 17854040 HBV NN I-NP O
13 701 702 17854040 ( ( O O
14 702 707 17854040 HBsAg NN B-NP B-Chemical
15 707 708 17854040 - HYPH O O
16 708 716 17854040 negative JJ B-ADJP O
17 716 717 17854040 ) ) O O
18 718 721 17854040 and CC O O
19 722 723 17854040 7 CD B-NP O
20 724 729 17854040 overt JJ I-NP O
21 730 733 17854040 HBV NN I-NP O
22 734 735 17854040 ( ( O O
23 735 740 17854040 HBsAg NN B-NP B-Chemical
24 740 741 17854040 - HYPH O O
25 742 750 17854040 positive JJ O O
26 750 751 17854040 ) ) O O
27 752 760 17854040 patients NNS B-NP O
28 760 761 17854040 . . O O

1 762 767 17854040 HBsAg NN B-NP B-Chemical
2 767 768 17854040 , , O O
3 769 773 17854040 anti AFX B-NP O
4 773 774 17854040 - HYPH I-NP O
5 774 777 17854040 HBs NNS I-NP O
6 777 778 17854040 , , O O
7 779 783 17854040 anti AFX B-NP O
8 783 784 17854040 - HYPH I-NP O
9 784 787 17854040 HBc NN B-NP O
10 787 788 17854040 , , O O
11 789 792 17854040 and CC O O
12 793 797 17854040 anti AFX O O
13 797 798 17854040 - HYPH O O
14 798 801 17854040 HIV NN B-NP O
15 802 803 17854040 1 CD I-NP O
16 803 804 17854040 / SYM I-NP O
17 804 805 17854040 2 CD I-NP O
18 806 810 17854040 were VBD B-VP O
19 811 821 17854040 determined VBN I-VP O
20 822 824 17854040 as IN B-PP O
21 825 829 17854040 part NN B-NP O
22 830 832 17854040 of IN B-PP O
23 833 840 17854040 routine JJ B-NP O
24 841 850 17854040 diagnosis NN I-NP O
25 851 856 17854040 using VBG B-VP O
26 857 862 17854040 Axsym NN B-NP O
27 863 869 17854040 assays NNS I-NP O
28 870 871 17854040 ( ( O O
29 871 877 17854040 Abbott NNP B-NP O
30 878 890 17854040 Laboratories NNP I-NP O
31 890 891 17854040 , , O O
32 892 897 17854040 North NNP B-NP O
33 898 905 17854040 Chicago NNP I-NP O
34 905 906 17854040 , , O O
35 907 909 17854040 IL NNP B-NP O
36 909 910 17854040 ) ) O O
37 910 911 17854040 . . O O

1 912 917 17854040 Serum NN B-NP O
2 918 925 17854040 samples NNS I-NP O
3 926 930 17854040 were VBD B-VP O
4 931 934 17854040 PCR NN B-NP O
5 935 944 17854040 amplified VBN B-VP O
6 945 949 17854040 with IN B-PP O
7 950 953 17854040 HBV NN B-NP O
8 954 961 17854040 reverse JJ I-NP O
9 962 975 17854040 transcriptase NN I-NP O
10 976 977 17854040 ( ( O O
11 977 979 17854040 RT NN B-NP O
12 979 980 17854040 ) ) O O
13 981 988 17854040 primers NNS B-NP O
14 988 989 17854040 , , O O
15 990 998 17854040 followed VBN B-VP O
16 999 1001 17854040 by IN B-PP O
17 1002 1008 17854040 direct JJ B-NP O
18 1009 1019 17854040 sequencing NN I-NP O
19 1020 1026 17854040 across IN B-PP O
20 1027 1030 17854040 the DT B-NP O
21 1031 1039 17854040 tyrosine NN I-NP B-Chemical
22 1039 1040 17854040 - HYPH B-NP O
23 1040 1050 17854040 methionine NN I-NP B-Chemical
24 1050 1051 17854040 - HYPH B-NP O
25 1051 1060 17854040 aspartate NN I-NP B-Chemical
26 1060 1061 17854040 - HYPH O O
27 1061 1070 17854040 aspartate NN B-NP B-Chemical
28 1071 1072 17854040 ( ( O O
29 1072 1076 17854040 YMDD NN B-NP O
30 1076 1077 17854040 ) ) O O
31 1078 1083 17854040 motif NN B-NP O
32 1084 1086 17854040 of IN B-PP O
33 1087 1090 17854040 the DT B-NP O
34 1091 1096 17854040 major JJ I-NP O
35 1097 1106 17854040 catalytic JJ I-NP O
36 1107 1113 17854040 region NN I-NP O
37 1114 1116 17854040 in IN B-PP O
38 1117 1120 17854040 the DT B-NP O
39 1121 1122 17854040 C NN I-NP O
40 1123 1129 17854040 domain NN I-NP O
41 1130 1132 17854040 of IN B-PP O
42 1133 1136 17854040 the DT B-NP O
43 1137 1140 17854040 HBV NN I-NP O
44 1141 1143 17854040 RT NN I-NP O
45 1144 1150 17854040 enzyme NN I-NP O
46 1150 1151 17854040 . . O O

1 1152 1155 17854040 HBV NN B-NP O
2 1156 1161 17854040 viral JJ I-NP O
3 1162 1166 17854040 load NN I-NP O
4 1167 1170 17854040 was VBD B-VP O
5 1171 1180 17854040 performed VBN I-VP O
6 1181 1185 17854040 with IN B-PP O
7 1186 1194 17854040 Amplicor NNP B-NP O
8 1195 1198 17854040 HBV NNP I-NP O
9 1199 1206 17854040 Monitor NNP I-NP O
10 1207 1211 17854040 test NN I-NP O
11 1212 1216 17854040 v2.0 NN I-NP O
12 1217 1218 17854040 ( ( O O
13 1218 1223 17854040 Roche NNP B-NP O
14 1224 1235 17854040 Diagnostics NNP I-NP O
15 1235 1236 17854040 , , O O
16 1237 1245 17854040 Penzberg NNP B-NP O
17 1245 1246 17854040 , , O O
18 1247 1254 17854040 Germany NNP B-NP O
19 1254 1255 17854040 ) ) O O
20 1255 1256 17854040 . . O O

1 1257 1260 17854040 HBV NN B-NP O
2 1261 1271 17854040 lamivudine NN I-NP B-Chemical
3 1271 1272 17854040 - HYPH O O
4 1272 1281 17854040 resistant JJ B-NP O
5 1282 1289 17854040 strains NNS I-NP O
6 1290 1294 17854040 were VBD B-VP O
7 1295 1303 17854040 detected VBN I-VP O
8 1304 1306 17854040 in IN B-PP O
9 1307 1308 17854040 3 CD B-NP O
10 1309 1311 17854040 of IN B-PP O
11 1312 1314 17854040 15 CD B-NP O
12 1315 1319 17854040 mono AFX I-NP O
13 1319 1320 17854040 - HYPH I-NP O
14 1320 1328 17854040 infected VBN I-NP O
15 1329 1336 17854040 chronic JJ I-NP O
16 1337 1346 17854040 hepatitis NN I-NP B-Disease
17 1347 1348 17854040 B NN I-NP I-Disease
18 1349 1357 17854040 patients NNS I-NP O
19 1358 1361 17854040 and CC O O
20 1362 1364 17854040 10 CD B-NP O
21 1365 1367 17854040 of IN B-PP O
22 1368 1370 17854040 20 CD B-NP O
23 1371 1374 17854040 HBV NN I-NP B-Disease
24 1374 1375 17854040 - HYPH B-NP I-Disease
25 1375 1378 17854040 HIV NN I-NP I-Disease
26 1379 1381 17854040 co AFX O I-Disease
27 1381 1382 17854040 - HYPH B-NP I-Disease
28 1382 1390 17854040 infected VBN B-NP I-Disease
29 1391 1399 17854040 patients NNS I-NP O
30 1399 1400 17854040 . . O O

1 1401 1403 17854040 To TO B-PP O
2 1404 1407 17854040 the DT B-NP O
3 1408 1412 17854040 best JJS I-NP O
4 1413 1415 17854040 of IN B-PP O
5 1416 1419 17854040 our PRP$ B-NP O
6 1420 1429 17854040 knowledge NN I-NP O
7 1429 1430 17854040 , , O O
8 1431 1435 17854040 this DT B-NP O
9 1436 1447 17854040 constitutes VBZ B-VP O
10 1448 1451 17854040 the DT B-NP O
11 1452 1457 17854040 first JJ I-NP O
12 1458 1464 17854040 report NN I-NP O
13 1465 1467 17854040 of IN B-PP O
14 1468 1471 17854040 HBV NN B-NP O
15 1472 1482 17854040 lamivudine NN I-NP B-Chemical
16 1482 1483 17854040 - HYPH O O
17 1483 1492 17854040 resistant JJ B-NP O
18 1493 1500 17854040 strains NNS I-NP O
19 1501 1503 17854040 in IN B-PP O
20 1504 1511 17854040 therapy NN B-NP O
21 1511 1512 17854040 - HYPH B-NP O
22 1512 1514 17854040 na NN I-NP B-Chemical
23 1516 1518 17854040 ve NN I-NP O
24 1519 1522 17854040 HBV NN I-NP B-Disease
25 1522 1523 17854040 - HYPH B-NP I-Disease
26 1523 1526 17854040 HIV NN I-NP I-Disease
27 1527 1529 17854040 co AFX O I-Disease
28 1529 1530 17854040 - HYPH B-NP I-Disease
29 1530 1538 17854040 infected VBN B-NP I-Disease
30 1539 1547 17854040 patients NNS I-NP O
31 1547 1548 17854040 . . O O

1 1549 1552 17854040 The DT B-NP O
2 1553 1556 17854040 HBV NN I-NP O
3 1557 1562 17854040 viral JJ I-NP O
4 1563 1568 17854040 loads NNS I-NP O
5 1569 1572 17854040 for IN B-PP O
6 1573 1577 17854040 mono AFX B-NP O
7 1577 1578 17854040 - HYPH I-NP O
8 1578 1586 17854040 infected VBN B-VP O
9 1587 1590 17854040 and CC O O
10 1591 1593 17854040 co AFX O O
11 1593 1594 17854040 - HYPH B-NP O
12 1594 1602 17854040 infected VBN B-NP O
13 1603 1611 17854040 patients NNS I-NP O
14 1612 1618 17854040 ranged VBD B-VP O
15 1619 1623 17854040 from IN B-PP O
16 1624 1628 17854040 3.32 CD B-NP O
17 1629 1630 17854040 x SYM I-NP O
18 1631 1636 17854040 10(2) CD I-NP O
19 1637 1639 17854040 to TO I-NP O
20 1640 1644 17854040 3.82 CD I-NP O
21 1645 1646 17854040 x CC I-NP O
22 1647 1652 17854040 10(7) CD I-NP O
23 1653 1656 17854040 and CC O O
24 1657 1658 17854040 < SYM B-NP O
25 1658 1661 17854040 200 CD B-NP O
26 1662 1664 17854040 to TO I-NP O
27 1665 1669 17854040 4.40 CD I-NP O
28 1670 1671 17854040 x CC I-NP O
29 1672 1677 17854040 10(3) CD I-NP O
30 1678 1684 17854040 copies NNS I-NP O
31 1684 1685 17854040 / SYM B-NP O
32 1685 1687 17854040 ml NN I-NP O
33 1687 1688 17854040 , , O O
34 1689 1701 17854040 respectively RB B-ADVP O
35 1701 1702 17854040 . . O O

1 1703 1705 17854040 It PRP B-NP O
2 1706 1713 17854040 remains VBZ B-VP O
3 1714 1716 17854040 to TO I-VP O
4 1717 1719 17854040 be VB I-VP O
5 1720 1724 17854040 seen VBN I-VP O
6 1725 1732 17854040 whether IN B-SBAR O
7 1733 1737 17854040 such JJ B-NP O
8 1738 1741 17854040 pre AFX I-NP O
9 1741 1742 17854040 - HYPH B-PP O
10 1742 1750 17854040 existing VBG B-NP O
11 1751 1760 17854040 antiviral JJ I-NP O
12 1761 1770 17854040 mutations NNS I-NP O
13 1771 1776 17854040 could MD B-VP O
14 1777 1783 17854040 result VB I-VP O
15 1784 1786 17854040 in IN B-PP O
16 1787 1797 17854040 widespread JJ B-NP O
17 1798 1807 17854040 emergence NN I-NP O
18 1808 1810 17854040 of IN B-PP O
19 1811 1814 17854040 HBV NN B-NP O
20 1815 1824 17854040 resistant JJ I-NP O
21 1825 1832 17854040 strains NNS I-NP O
22 1833 1837 17854040 when WRB B-ADVP O
23 1838 1848 17854040 lamivudine NN B-NP B-Chemical
24 1848 1849 17854040 - HYPH O O
25 1849 1859 17854040 containing VBG B-VP O
26 1860 1866 17854040 highly RB B-NP O
27 1867 1873 17854040 active JJ I-NP O
28 1874 1888 17854040 antiretroviral JJ I-NP O
29 1889 1890 17854040 ( ( O O
30 1890 1893 17854040 ARV NN B-NP O
31 1893 1894 17854040 ) ) O O
32 1895 1904 17854040 treatment NN B-NP O
33 1905 1906 17854040 ( ( O O
34 1906 1911 17854040 HAART NN B-NP O
35 1911 1912 17854040 ) ) O O
36 1913 1921 17854040 regimens NNS B-NP O
37 1922 1928 17854040 become VBP B-VP O
38 1929 1935 17854040 widely RB I-VP O
39 1936 1943 17854040 applied VBN I-VP O
40 1944 1946 17854040 in IN B-PP O
41 1947 1952 17854040 South NNP B-NP O
42 1953 1959 17854040 Africa NNP I-NP O
43 1959 1960 17854040 , , O O
44 1961 1963 17854040 as IN B-SBAR O
45 1964 1968 17854040 this DT B-NP O
46 1969 1971 17854040 is VBZ B-VP O
47 1972 1978 17854040 likely JJ B-ADJP O
48 1979 1981 17854040 to TO B-VP O
49 1982 1986 17854040 have VB I-VP O
50 1987 1996 17854040 potential JJ B-NP O
51 1997 2009 17854040 implications NNS I-NP O
52 2010 2012 17854040 in IN B-PP O
53 2013 2016 17854040 the DT B-NP O
54 2017 2027 17854040 management NN I-NP O
55 2028 2030 17854040 of IN B-PP O
56 2031 2034 17854040 HBV NN B-NP B-Disease
57 2034 2035 17854040 - HYPH B-NP I-Disease
58 2035 2038 17854040 HIV NN I-NP I-Disease
59 2039 2041 17854040 co AFX O I-Disease
60 2041 2042 17854040 - HYPH B-NP I-Disease
61 2042 2050 17854040 infected VBN B-NP I-Disease
62 2051 2059 17854040 patients NNS I-NP O
63 2059 2060 17854040 . . O O

1 0 0 9522152 -DOCSTART- -X- -X- O

1 0 1 9522152 A DT B-NP O
2 2 11 9522152 transient JJ I-NP O
3 12 24 9522152 neurological JJ I-NP B-Disease
4 25 32 9522152 deficit NN I-NP I-Disease
5 33 42 9522152 following VBG B-PP O
6 43 54 9522152 intrathecal JJ B-NP O
7 55 64 9522152 injection NN I-NP O
8 65 67 9522152 of IN B-PP O
9 68 70 9522152 1% CD B-NP O
10 71 81 9522152 hyperbaric JJ I-NP O
11 82 93 9522152 bupivacaine NN I-NP B-Chemical
12 94 97 9522152 for IN B-PP O
13 98 108 9522152 unilateral JJ B-NP O
14 109 115 9522152 spinal JJ I-NP O
15 116 127 9522152 anaesthesia NN I-NP O
16 127 128 9522152 . . O O
17 129 131 9522152 We PRP B-NP O
18 132 140 9522152 describe VBP B-VP O
19 141 142 9522152 a DT B-NP O
20 143 147 9522152 case NN I-NP O
21 148 150 9522152 of IN B-PP O
22 151 160 9522152 transient JJ B-NP O
23 161 173 9522152 neurological JJ I-NP B-Disease
24 174 181 9522152 deficit NN I-NP I-Disease
25 182 186 9522152 that WDT B-NP O
26 187 195 9522152 occurred VBD B-VP O
27 196 201 9522152 after IN B-PP O
28 202 212 9522152 unilateral JJ B-NP O
29 213 219 9522152 spinal JJ I-NP O
30 220 231 9522152 anaesthesia NN I-NP O
31 232 236 9522152 with IN B-PP O
32 237 238 9522152 8 CD B-NP O
33 239 241 9522152 mg NN I-NP O
34 242 244 9522152 of IN B-PP O
35 245 247 9522152 1% CD B-NP O
36 248 258 9522152 hyperbaric JJ I-NP O
37 259 270 9522152 bupivacaine NN I-NP B-Chemical
38 271 277 9522152 slowly RB B-VP O
39 278 286 9522152 injected VBN I-VP O
40 287 294 9522152 through IN B-PP O
41 295 296 9522152 a DT B-NP O
42 297 299 9522152 25 CD I-NP O
43 299 300 9522152 - HYPH I-NP O
44 300 305 9522152 gauge NN I-NP O
45 306 312 9522152 pencil NN I-NP O
46 312 313 9522152 - HYPH B-NP O
47 313 318 9522152 point NN I-NP O
48 319 325 9522152 spinal JJ I-NP O
49 326 332 9522152 needle NN I-NP O
50 332 333 9522152 . . O O

1 334 337 9522152 The DT B-NP O
2 338 345 9522152 surgery NN I-NP O
3 346 349 9522152 and CC I-NP O
4 350 361 9522152 anaesthesia NN I-NP O
5 362 366 9522152 were VBD B-VP O
6 367 377 9522152 uneventful JJ B-ADJP O
7 377 378 9522152 , , O O
8 379 382 9522152 but CC O O
9 383 384 9522152 3 CD B-NP O
10 385 389 9522152 days NNS I-NP O
11 390 395 9522152 after IN B-PP O
12 396 403 9522152 surgery NN B-NP O
13 403 404 9522152 , , O O
14 405 408 9522152 the DT B-NP O
15 409 416 9522152 patient NN I-NP O
16 417 425 9522152 reported VBD B-VP O
17 426 428 9522152 an DT B-NP O
18 429 433 9522152 area NN I-NP O
19 434 436 9522152 of IN B-PP O
20 437 450 9522152 hypoaesthesia NN B-NP O
21 451 455 9522152 over IN B-PP O
22 456 458 9522152 L3 NN B-NP O
23 458 459 9522152 - HYPH B-NP O
24 459 461 9522152 L4 NN I-NP O
25 462 472 9522152 dermatomes NNS I-NP O
26 473 475 9522152 of IN B-PP O
27 476 479 9522152 the DT B-NP O
28 480 483 9522152 leg NN I-NP O
29 484 489 9522152 which WDT B-NP O
30 490 493 9522152 had VBD B-VP O
31 494 498 9522152 been VBN I-VP O
32 499 507 9522152 operated VBN I-VP O
33 508 510 9522152 on IN B-PP O
34 511 512 9522152 ( ( O O
35 512 516 9522152 loss NN B-NP B-Disease
36 517 519 9522152 of IN B-PP I-Disease
37 520 528 9522152 pinprick NN B-NP I-Disease
38 529 538 9522152 sensation NN I-NP I-Disease
39 538 539 9522152 ) ) O O
40 540 547 9522152 without IN B-PP O
41 548 557 9522152 reduction NN B-NP O
42 558 560 9522152 in IN B-PP O
43 561 569 9522152 muscular JJ B-NP O
44 570 578 9522152 strength NN I-NP O
45 578 579 9522152 . . O O

1 580 589 9522152 Sensation NN B-NP O
2 590 592 9522152 in IN B-PP O
3 593 597 9522152 this DT B-NP O
4 598 602 9522152 area NN I-NP O
5 603 611 9522152 returned VBD B-VP O
6 612 614 9522152 to TO B-PP O
7 615 621 9522152 normal JJ B-ADJP O
8 622 626 9522152 over IN B-PP O
9 627 630 9522152 the DT B-NP O
10 631 640 9522152 following VBG I-NP O
11 641 642 9522152 2 CD I-NP O
12 643 648 9522152 weeks NNS I-NP O
13 648 649 9522152 . . O O

1 650 661 9522152 Prospective JJ B-NP O
2 662 673 9522152 multicentre JJ I-NP O
3 674 681 9522152 studies NNS I-NP O
4 682 686 9522152 with IN B-PP O
5 687 688 9522152 a DT B-NP O
6 689 694 9522152 large JJ I-NP O
7 695 705 9522152 population NN I-NP O
8 706 709 9522152 and CC O O
9 710 711 9522152 a DT B-NP O
10 712 716 9522152 long JJ I-NP O
11 717 723 9522152 follow VB B-VP O
12 723 724 9522152 - HYPH O O
13 724 726 9522152 up RP B-PRT O
14 727 733 9522152 should MD B-VP O
15 734 736 9522152 be VB I-VP O
16 737 746 9522152 performed VBN I-VP O
17 747 749 9522152 in IN B-SBAR O
18 750 755 9522152 order NN O O
19 756 758 9522152 to TO B-VP O
20 759 767 9522152 evaluate VB I-VP O
21 768 771 9522152 the DT B-NP O
22 772 781 9522152 incidence NN I-NP O
23 782 784 9522152 of IN B-PP O
24 785 789 9522152 this DT B-NP O
25 790 797 9522152 unusual JJ I-NP O
26 798 802 9522152 side NN I-NP O
27 803 809 9522152 effect NN I-NP O
28 809 810 9522152 . . O O

1 811 818 9522152 However RB B-ADVP O
2 818 819 9522152 , , O O
3 820 822 9522152 we PRP B-NP O
4 823 830 9522152 suggest VBP B-VP O
5 831 835 9522152 that IN B-SBAR O
6 836 837 9522152 a DT B-NP O
7 838 841 9522152 low JJ I-NP O
8 842 850 9522152 solution NN I-NP O
9 851 864 9522152 concentration NN I-NP O
10 865 871 9522152 should MD B-VP O
11 872 874 9522152 be VB I-VP O
12 875 884 9522152 preferred VBN I-VP O
13 885 888 9522152 for IN B-PP O
14 889 899 9522152 unilateral JJ B-NP O
15 900 906 9522152 spinal JJ I-NP O
16 907 918 9522152 anaesthesia NN I-NP O
17 919 923 9522152 with IN B-PP O
18 924 925 9522152 a DT B-NP O
19 926 936 9522152 hyperbaric JJ I-NP O
20 937 948 9522152 anaesthetic JJ I-NP O
21 949 957 9522152 solution NN I-NP O
22 958 959 9522152 ( ( O O
23 959 961 9522152 if IN B-SBAR O
24 962 968 9522152 pencil NN B-NP O
25 968 969 9522152 - HYPH B-NP O
26 969 974 9522152 point NN I-NP O
27 975 981 9522152 needle NN I-NP O
28 982 985 9522152 and CC O O
29 986 990 9522152 slow JJ B-NP O
30 991 1000 9522152 injection NN I-NP O
31 1001 1005 9522152 rate NN I-NP O
32 1006 1009 9522152 are VBP B-VP O
33 1010 1018 9522152 employed VBN I-VP O
34 1018 1019 9522152 ) ) O O
35 1019 1020 9522152 , , O O
36 1021 1023 9522152 in IN B-SBAR O
37 1024 1029 9522152 order NN O O
38 1030 1032 9522152 to TO B-VP O
39 1033 1041 9522152 minimize VB I-VP O
40 1042 1045 9522152 the DT B-NP O
41 1046 1050 9522152 risk NN I-NP O
42 1051 1053 9522152 of IN B-PP O
43 1054 1055 9522152 a DT B-NP O
44 1056 1065 9522152 localized JJ I-NP O
45 1066 1070 9522152 high JJ I-NP O
46 1071 1075 9522152 peak NN I-NP O
47 1076 1087 9522152 anaesthetic JJ I-NP O
48 1088 1101 9522152 concentration NN I-NP O
49 1101 1102 9522152 , , O O
50 1103 1108 9522152 which WDT B-NP O
51 1109 1114 9522152 might MD B-VP O
52 1115 1119 9522152 lead VB I-VP O
53 1120 1122 9522152 to TO B-PP O
54 1123 1124 9522152 a DT B-NP O
55 1125 1134 9522152 transient JJ I-NP O
56 1135 1147 9522152 neurological JJ I-NP B-Disease
57 1148 1155 9522152 deficit NN I-NP I-Disease
58 1155 1156 9522152 . . O O

1 0 0 20880751 -DOCSTART- -X- -X- O

1 0 8 20880751 Levodopa NN B-NP B-Chemical
2 8 9 20880751 - HYPH B-NP O
3 9 16 20880751 induced VBN I-NP O
4 17 28 20880751 dyskinesias NNS I-NP B-Disease
5 29 31 20880751 in IN B-PP O
6 32 40 20880751 patients NNS B-NP O
7 41 45 20880751 with IN B-PP O
8 46 57 20880751 Parkinson's NNS B-NP B-Disease
9 58 65 20880751 disease NN I-NP I-Disease
10 65 66 20880751 : : O O
11 67 74 20880751 filling VBG B-VP O
12 75 78 20880751 the DT B-NP O
13 79 84 20880751 bench NN I-NP O
14 84 85 20880751 - HYPH B-ADJP O
15 85 87 20880751 to TO B-PP O
16 87 88 20880751 - HYPH B-NP O
17 88 95 20880751 bedside NN I-NP O
18 96 99 20880751 gap NN I-NP O
19 99 100 20880751 . . O O
20 101 109 20880751 Levodopa NNP B-NP B-Chemical
21 110 112 20880751 is VBZ B-VP O
22 113 116 20880751 the DT B-NP O
23 117 121 20880751 most RBS I-NP O
24 122 131 20880751 effective JJ I-NP O
25 132 136 20880751 drug NN I-NP O
26 137 140 20880751 for IN B-PP O
27 141 144 20880751 the DT B-NP O
28 145 154 20880751 treatment NN I-NP O
29 155 157 20880751 of IN B-PP O
30 158 169 20880751 Parkinson's NNP B-NP B-Disease
31 170 177 20880751 disease NN I-NP I-Disease
32 177 178 20880751 . . O O

1 179 186 20880751 However RB B-ADVP O
2 186 187 20880751 , , O O
3 188 191 20880751 the DT B-NP O
4 192 196 20880751 long JJ I-NP O
5 196 197 20880751 - HYPH I-NP O
6 197 201 20880751 term NN I-NP O
7 202 205 20880751 use NN I-NP O
8 206 208 20880751 of IN B-PP O
9 209 213 20880751 this DT B-NP O
10 214 222 20880751 dopamine NN I-NP B-Chemical
11 223 232 20880751 precursor NN I-NP O
12 233 235 20880751 is VBZ B-VP O
13 236 247 20880751 complicated VBN I-VP O
14 248 250 20880751 by IN B-PP O
15 251 257 20880751 highly RB B-VP O
16 258 267 20880751 disabling VBG I-VP O
17 268 280 20880751 fluctuations NNS B-NP O
18 281 284 20880751 and CC I-NP O
19 285 296 20880751 dyskinesias NNS I-NP B-Disease
20 296 297 20880751 . . O O

1 298 306 20880751 Although IN B-SBAR O
2 307 318 20880751 preclinical JJ B-NP O
3 319 322 20880751 and CC I-NP O
4 323 331 20880751 clinical JJ I-NP O
5 332 340 20880751 findings NNS I-NP O
6 341 348 20880751 suggest VBP B-VP O
7 349 358 20880751 pulsatile JJ B-NP O
8 359 370 20880751 stimulation NN I-NP O
9 371 373 20880751 of IN B-PP O
10 374 382 20880751 striatal JJ B-NP O
11 383 395 20880751 postsynaptic JJ I-NP O
12 396 405 20880751 receptors NNS I-NP O
13 406 408 20880751 as IN B-PP O
14 409 410 20880751 a DT B-NP O
15 411 414 20880751 key JJ I-NP O
16 415 424 20880751 mechanism NN I-NP O
17 425 435 20880751 underlying VBG I-NP O
18 436 444 20880751 levodopa NN I-NP B-Chemical
19 444 445 20880751 - HYPH B-NP O
20 445 452 20880751 induced VBN I-NP O
21 453 464 20880751 dyskinesias NNS I-NP B-Disease
22 464 465 20880751 , , O O
23 466 471 20880751 their PRP$ B-NP O
24 472 484 20880751 pathogenesis NN I-NP O
25 485 487 20880751 is VBZ B-VP O
26 488 493 20880751 still RB B-ADVP O
27 494 501 20880751 unclear JJ B-ADJP O
28 501 502 20880751 . . O O

1 503 505 20880751 In IN B-PP O
2 506 512 20880751 recent JJ B-NP O
3 513 518 20880751 years NNS I-NP O
4 518 519 20880751 , , O O
5 520 528 20880751 evidence NN B-NP O
6 529 533 20880751 from IN B-PP O
7 534 540 20880751 animal NN B-NP O
8 541 547 20880751 models NNS I-NP O
9 548 550 20880751 of IN B-PP O
10 551 562 20880751 Parkinson's NNP B-NP B-Disease
11 563 570 20880751 disease NN I-NP I-Disease
12 571 574 20880751 has VBZ B-VP O
13 575 583 20880751 provided VBN I-VP O
14 584 593 20880751 important JJ B-NP O
15 594 605 20880751 information NN I-NP O
16 606 608 20880751 to TO B-VP O
17 609 619 20880751 understand VB I-VP O
18 620 623 20880751 the DT B-NP O
19 624 630 20880751 effect NN I-NP O
20 631 633 20880751 of IN B-PP O
21 634 642 20880751 specific JJ B-NP O
22 643 651 20880751 receptor NN I-NP O
23 652 655 20880751 and CC O O
24 656 660 20880751 post AFX B-NP O
25 660 661 20880751 - HYPH I-NP O
26 661 669 20880751 receptor NN I-NP O
27 670 679 20880751 molecular JJ I-NP O
28 680 690 20880751 mechanisms NNS I-NP O
29 691 701 20880751 underlying VBG B-VP O
30 702 705 20880751 the DT B-NP O
31 706 717 20880751 development NN I-NP O
32 718 720 20880751 of IN B-PP O
33 721 731 20880751 dyskinetic JJ B-NP B-Disease
34 732 741 20880751 movements NNS I-NP I-Disease
35 741 742 20880751 . . O O

1 743 749 20880751 Recent JJ B-NP O
2 750 761 20880751 preclinical JJ I-NP O
3 762 765 20880751 and CC I-NP O
4 766 774 20880751 clinical JJ I-NP O
5 775 779 20880751 data NNS I-NP O
6 780 784 20880751 from IN B-PP O
7 785 794 20880751 promising JJ B-NP O
8 795 800 20880751 lines NNS I-NP O
9 801 803 20880751 of IN B-PP O
10 804 812 20880751 research NN B-NP O
11 813 818 20880751 focus NN I-NP O
12 819 821 20880751 on IN B-PP O
13 822 825 20880751 the DT B-NP O
14 826 838 20880751 differential JJ I-NP O
15 839 843 20880751 role NN I-NP O
16 844 846 20880751 of IN B-PP O
17 847 858 20880751 presynaptic JJ B-NP O
18 859 865 20880751 versus IN B-PP O
19 866 878 20880751 postsynaptic JJ B-NP O
20 879 889 20880751 mechanisms NNS I-NP O
21 889 890 20880751 , , O O
22 891 899 20880751 dopamine NN B-NP B-Chemical
23 900 908 20880751 receptor NN I-NP O
24 909 917 20880751 subtypes NNS I-NP O
25 917 918 20880751 , , O O
26 919 929 20880751 ionotropic JJ B-NP O
27 930 933 20880751 and CC I-NP O
28 934 946 20880751 metabotropic JJ I-NP O
29 947 956 20880751 glutamate NN I-NP B-Chemical
30 957 966 20880751 receptors NNS I-NP O
31 966 967 20880751 , , O O
32 968 971 20880751 and CC O O
33 972 975 20880751 non AFX B-NP O
34 975 976 20880751 - HYPH I-NP O
35 976 988 20880751 dopaminergic JJ I-NP O
36 989 1005 20880751 neurotransmitter NN I-NP O
37 1006 1013 20880751 systems NNS I-NP O
38 1014 1016 20880751 in IN B-PP O
39 1017 1020 20880751 the DT B-NP O
40 1021 1036 20880751 pathophysiology NN I-NP O
41 1037 1039 20880751 of IN B-PP O
42 1040 1048 20880751 levodopa NN B-NP B-Chemical
43 1048 1049 20880751 - HYPH B-NP O
44 1049 1056 20880751 induced VBN I-NP O
45 1057 1068 20880751 dyskinesias NNS I-NP B-Disease
46 1068 1069 20880751 . . O O

1 0 0 8690168 -DOCSTART- -X- -X- O

1 0 9 8690168 Reduction NN B-NP O
2 10 12 8690168 of IN B-PP O
3 13 20 8690168 heparan NN B-NP B-Chemical
4 21 29 8690168 sulphate NN I-NP I-Chemical
5 29 30 8690168 - HYPH O O
6 30 40 8690168 associated VBN B-VP O
7 41 48 8690168 anionic JJ B-NP O
8 49 54 8690168 sites NNS I-NP O
9 55 57 8690168 in IN B-PP O
10 58 61 8690168 the DT B-NP O
11 62 72 8690168 glomerular JJ I-NP O
12 73 81 8690168 basement NN I-NP O
13 82 90 8690168 membrane NN I-NP O
14 91 93 8690168 of IN B-PP O
15 94 98 8690168 rats NNS B-NP O
16 99 103 8690168 with IN B-PP O
17 104 118 8690168 streptozotocin NN B-NP B-Chemical
18 118 119 8690168 - HYPH B-NP O
19 119 126 8690168 induced VBN I-NP O
20 127 135 8690168 diabetic JJ I-NP B-Disease
21 136 147 8690168 nephropathy NN I-NP I-Disease
22 147 148 8690168 . . O O
23 149 156 8690168 Heparan NN B-NP B-Chemical
24 157 165 8690168 sulphate NN I-NP I-Chemical
25 165 166 8690168 - HYPH O O
26 166 176 8690168 associated VBN B-VP O
27 177 184 8690168 anionic JJ B-NP O
28 185 190 8690168 sites NNS I-NP O
29 191 193 8690168 in IN B-PP O
30 194 197 8690168 the DT B-NP O
31 198 208 8690168 glomerular JJ I-NP O
32 209 217 8690168 basement NN I-NP O
33 218 226 8690168 membrane NN I-NP O
34 227 231 8690168 were VBD B-VP O
35 232 239 8690168 studied VBN I-VP O
36 240 242 8690168 in IN B-PP O
37 243 247 8690168 rats NNS B-NP O
38 248 249 8690168 8 CD B-NP O
39 250 256 8690168 months NNS I-NP O
40 257 262 8690168 after IN B-PP O
41 263 272 8690168 induction NN B-NP O
42 273 275 8690168 of IN B-PP O
43 276 284 8690168 diabetes NN B-NP B-Disease
44 285 287 8690168 by IN B-PP O
45 288 302 8690168 streptozotocin NN B-NP B-Chemical
46 303 306 8690168 and CC B-PP O
47 307 309 8690168 in IN B-PP O
48 310 313 8690168 age NN B-NP O
49 313 314 8690168 - HYPH O O
50 315 318 8690168 adn NN B-NP O
51 319 322 8690168 sex NN I-NP O
52 322 323 8690168 - HYPH B-VP O
53 323 330 8690168 matched VBN B-NP O
54 331 338 8690168 control NN I-NP O
55 339 343 8690168 rats NNS I-NP O
56 343 344 8690168 , , O O
57 345 354 8690168 employing VBG B-VP O
58 355 358 8690168 the DT B-NP O
59 359 367 8690168 cationic JJ I-NP O
60 368 371 8690168 dye NN I-NP O
61 372 382 8690168 cuprolinic JJ I-NP B-Chemical
62 383 387 8690168 blue NN I-NP I-Chemical
63 387 388 8690168 . . O O

1 389 401 8690168 Morphometric JJ B-NP O
2 402 410 8690168 analysis NN I-NP O
3 411 413 8690168 at IN B-PP O
4 414 417 8690168 the DT B-NP O
5 418 433 8690168 ultrastructural JJ I-NP O
6 434 439 8690168 level NN I-NP O
7 440 443 8690168 was VBD B-VP O
8 444 453 8690168 performed VBN I-VP O
9 454 459 8690168 using VBG B-VP O
10 460 461 8690168 a DT B-NP O
11 462 474 8690168 computerized JJ I-NP O
12 475 480 8690168 image NN I-NP O
13 481 490 8690168 processor NN I-NP O
14 490 491 8690168 . . O O

1 492 495 8690168 The DT B-NP O
2 496 503 8690168 heparan NN I-NP B-Chemical
3 504 512 8690168 sulphate NN I-NP I-Chemical
4 513 524 8690168 specificity NN I-NP O
5 525 527 8690168 of IN B-PP O
6 528 531 8690168 the DT B-NP O
7 532 542 8690168 cuprolinic JJ I-NP B-Chemical
8 543 547 8690168 blue JJ I-NP I-Chemical
9 548 556 8690168 staining NN I-NP O
10 557 560 8690168 was VBD B-VP O
11 561 573 8690168 demonstrated VBN I-VP O
12 574 576 8690168 by IN B-PP O
13 577 594 8690168 glycosaminoglycan NN B-NP B-Chemical
14 594 595 8690168 - HYPH O O
15 595 604 8690168 degrading VBG B-VP O
16 605 612 8690168 enzymes NNS B-NP O
17 612 613 8690168 , , O O
18 614 621 8690168 showing VBG B-VP O
19 622 626 8690168 that IN B-SBAR O
20 627 639 8690168 pretreatment NN B-NP O
21 640 642 8690168 of IN B-PP O
22 643 646 8690168 the DT B-NP O
23 647 655 8690168 sections NNS I-NP O
24 656 660 8690168 with IN B-PP O
25 661 673 8690168 heparitinase NN B-NP O
26 674 683 8690168 abolished VBD B-VP O
27 684 687 8690168 all DT B-NP O
28 688 696 8690168 staining NN I-NP O
29 696 697 8690168 , , O O
30 698 705 8690168 whereas IN O O
31 706 720 8690168 chondroitinase NN B-NP O
32 721 724 8690168 ABC NNP B-NP O
33 725 728 8690168 had VBD B-VP O
34 729 731 8690168 no DT B-NP O
35 732 738 8690168 effect NN I-NP O
36 738 739 8690168 . . O O

1 740 743 8690168 The DT B-NP O
2 744 752 8690168 majority NN I-NP O
3 753 755 8690168 of IN B-PP O
4 756 763 8690168 anionic JJ B-NP O
5 764 769 8690168 sites NNS I-NP O
6 770 771 8690168 ( ( O O
7 771 774 8690168 74% NN B-NP O
8 775 777 8690168 in IN B-PP O
9 778 786 8690168 diabetic JJ B-NP B-Disease
10 787 790 8690168 and CC I-NP O
11 791 794 8690168 81% NN I-NP O
12 795 797 8690168 in IN B-PP O
13 798 805 8690168 control NN B-NP O
14 806 810 8690168 rats NNS I-NP O
15 810 811 8690168 ) ) O O
16 812 816 8690168 were VBD B-VP O
17 817 822 8690168 found VBN I-VP O
18 823 829 8690168 within IN B-PP O
19 830 833 8690168 the DT B-NP O
20 834 840 8690168 lamina NN I-NP O
21 841 845 8690168 rara NN I-NP O
22 846 853 8690168 externa NN I-NP O
23 854 856 8690168 of IN B-PP O
24 857 860 8690168 the DT B-NP O
25 861 871 8690168 glomerular JJ I-NP O
26 872 880 8690168 basement NN I-NP O
27 881 889 8690168 membrane NN I-NP O
28 889 890 8690168 . . O O

1 891 892 8690168 A DT B-NP O
2 893 901 8690168 minority NN I-NP O
3 902 904 8690168 of IN B-PP O
4 905 912 8690168 anionic JJ B-NP O
5 913 918 8690168 sites NNS I-NP O
6 919 923 8690168 were VBD B-VP O
7 924 933 8690168 scattered VBN I-VP O
8 934 944 8690168 throughout IN B-PP O
9 945 948 8690168 the DT B-NP O
10 949 955 8690168 lamina NN I-NP O
11 956 961 8690168 densa NN I-NP O
12 962 965 8690168 and CC O O
13 966 972 8690168 lamina NN B-NP O
14 973 977 8690168 rara NN I-NP O
15 978 985 8690168 interna NN I-NP O
16 985 986 8690168 , , O O
17 987 990 8690168 and CC O O
18 991 995 8690168 were VBD B-VP O
19 996 1009 8690168 significantly RB B-ADJP O
20 1010 1017 8690168 smaller JJR I-ADJP O
21 1018 1022 8690168 than IN B-PP O
22 1023 1028 8690168 those DT B-NP O
23 1029 1031 8690168 in IN B-PP O
24 1032 1035 8690168 the DT B-NP O
25 1036 1042 8690168 lamina NN I-NP O
26 1043 1047 8690168 rara NN I-NP O
27 1048 1055 8690168 externa NN I-NP O
28 1056 1058 8690168 of IN B-PP O
29 1059 1062 8690168 the DT B-NP O
30 1063 1073 8690168 glomerular JJ I-NP O
31 1074 1082 8690168 basement NN I-NP O
32 1083 1091 8690168 membrane NN I-NP O
33 1092 1093 8690168 ( ( O O
34 1093 1094 8690168 p NN B-NP O
35 1094 1095 8690168 < JJR B-NP O
36 1095 1100 8690168 0.001 CD I-NP O
37 1101 1104 8690168 and CC O O
38 1105 1106 8690168 p NN B-NP O
39 1106 1107 8690168 < SYM O O
40 1107 1111 8690168 0.01 CD B-NP O
41 1112 1115 8690168 for IN B-PP O
42 1116 1124 8690168 diabetic JJ B-NP B-Disease
43 1125 1128 8690168 and CC I-NP O
44 1129 1136 8690168 control NN I-NP O
45 1137 1141 8690168 rats NNS I-NP O
46 1141 1142 8690168 , , O O
47 1143 1155 8690168 respectively RB B-ADVP O
48 1155 1156 8690168 ) ) O O
49 1156 1157 8690168 . . O O

1 1158 1166 8690168 Diabetic JJ B-NP B-Disease
2 1167 1171 8690168 rats NNS I-NP O
3 1172 1185 8690168 progressively RB B-ADVP O
4 1186 1195 8690168 developed VBD B-VP O
5 1196 1207 8690168 albuminuria NN B-NP B-Disease
6 1208 1216 8690168 reaching VBG B-VP O
7 1217 1221 8690168 40.3 CD B-NP O
8 1222 1223 8690168 ( ( O O
9 1223 1227 8690168 32.2 CD B-NP O
10 1227 1228 8690168 - HYPH O O
11 1228 1232 8690168 62.0 CD O O
12 1232 1233 8690168 ) ) O O
13 1234 1236 8690168 mg NN B-NP O
14 1236 1237 8690168 / SYM O O
15 1237 1239 8690168 24 CD B-NP O
16 1240 1241 8690168 h NN I-NP O
17 1242 1247 8690168 after IN B-PP O
18 1248 1249 8690168 8 CD B-NP O
19 1250 1256 8690168 months NNS I-NP O
20 1257 1259 8690168 in IN B-PP O
21 1260 1268 8690168 contrast NN B-NP O
22 1269 1271 8690168 to TO B-PP O
23 1272 1275 8690168 the DT B-NP O
24 1276 1283 8690168 control NN I-NP O
25 1284 1291 8690168 animals NNS I-NP O
26 1292 1293 8690168 ( ( O O
27 1293 1296 8690168 0.8 CD B-NP O
28 1297 1298 8690168 ( ( O O
29 1298 1301 8690168 0.2 CD B-NP O
30 1301 1302 8690168 - HYPH O O
31 1302 1305 8690168 0.9 CD O O
32 1305 1306 8690168 ) ) O O
33 1307 1309 8690168 mg NN B-NP O
34 1309 1310 8690168 / SYM O O
35 1310 1312 8690168 24 CD B-NP O
36 1313 1314 8690168 h NN I-NP O
37 1314 1315 8690168 , , O O
38 1316 1317 8690168 p NN B-NP O
39 1317 1318 8690168 < SYM B-NP O
40 1318 1323 8690168 0.002 CD I-NP O
41 1323 1324 8690168 ) ) O O
42 1324 1325 8690168 . . O O

1 1326 1328 8690168 At IN B-PP O
2 1329 1332 8690168 the DT B-NP O
3 1333 1337 8690168 same JJ I-NP O
4 1338 1342 8690168 time NN I-NP O
5 1342 1343 8690168 , , O O
6 1344 1347 8690168 the DT B-NP O
7 1348 1354 8690168 number NN I-NP O
8 1355 1357 8690168 of IN B-PP O
9 1358 1365 8690168 heparan NN B-NP B-Chemical
10 1366 1374 8690168 sulphate NN I-NP I-Chemical
11 1375 1382 8690168 anionic JJ I-NP O
12 1383 1388 8690168 sites NNS I-NP O
13 1389 1392 8690168 and CC O O
14 1393 1396 8690168 the DT B-NP O
15 1397 1402 8690168 total JJ I-NP O
16 1403 1410 8690168 anionic JJ I-NP O
17 1411 1415 8690168 site NN I-NP O
18 1416 1423 8690168 surface NN I-NP O
19 1424 1425 8690168 ( ( O O
20 1425 1431 8690168 number NN B-NP O
21 1432 1434 8690168 of IN B-PP O
22 1435 1442 8690168 anionic JJ B-NP O
23 1443 1448 8690168 sites NNS I-NP O
24 1449 1450 8690168 x VBP B-VP O
25 1451 1455 8690168 mean JJ B-NP O
26 1456 1463 8690168 anionic JJ I-NP O
27 1464 1468 8690168 site NN I-NP O
28 1469 1476 8690168 surface NN I-NP O
29 1476 1477 8690168 ) ) O O
30 1478 1480 8690168 in IN B-PP O
31 1481 1484 8690168 the DT B-NP O
32 1485 1491 8690168 lamina NN I-NP O
33 1492 1496 8690168 rara NN I-NP O
34 1497 1504 8690168 externa NN I-NP O
35 1505 1507 8690168 of IN B-PP O
36 1508 1511 8690168 the DT B-NP O
37 1512 1522 8690168 glomerular JJ I-NP O
38 1523 1531 8690168 basement NN I-NP O
39 1532 1540 8690168 membrane NN I-NP O
40 1541 1544 8690168 was VBD B-VP O
41 1545 1552 8690168 reduced VBN I-VP O
42 1553 1555 8690168 by IN B-PP O
43 1556 1559 8690168 19% CD B-NP O
44 1560 1561 8690168 ( ( O O
45 1561 1562 8690168 p NN B-NP O
46 1562 1563 8690168 < JJR B-NP O
47 1563 1568 8690168 0.021 CD I-NP O
48 1568 1569 8690168 ) ) O O
49 1570 1573 8690168 and CC O O
50 1574 1576 8690168 by IN B-PP O
51 1577 1580 8690168 26% CD B-NP O
52 1581 1582 8690168 ( ( O O
53 1582 1583 8690168 p NN B-NP O
54 1583 1584 8690168 < JJR B-NP O
55 1584 1588 8690168 0.02 CD I-NP O
56 1588 1589 8690168 ) ) O O
57 1589 1590 8690168 , , O O
58 1591 1603 8690168 respectively RB B-ADVP O
59 1603 1604 8690168 . . O O

1 1605 1611 8690168 Number NN B-NP O
2 1612 1615 8690168 and CC O O
3 1616 1621 8690168 total JJ B-NP O
4 1622 1629 8690168 anionic JJ I-NP O
5 1630 1634 8690168 site NN I-NP O
6 1635 1642 8690168 surface NN I-NP O
7 1643 1645 8690168 in IN B-PP O
8 1646 1649 8690168 the DT B-NP O
9 1650 1659 8690168 remaining VBG I-NP O
10 1660 1664 8690168 part NN I-NP O
11 1665 1667 8690168 of IN B-PP O
12 1668 1671 8690168 the DT B-NP O
13 1672 1682 8690168 glomerular JJ I-NP O
14 1683 1691 8690168 basement NN I-NP O
15 1692 1700 8690168 membrane NN I-NP O
16 1701 1702 8690168 ( ( O O
17 1702 1708 8690168 lamina NN B-NP O
18 1709 1714 8690168 densa NN I-NP O
19 1715 1718 8690168 and CC O O
20 1719 1725 8690168 lamina NN B-NP O
21 1726 1730 8690168 rara NN I-NP O
22 1731 1738 8690168 interna NN I-NP O
23 1738 1739 8690168 ) ) O O
24 1740 1744 8690168 were VBD B-VP O
25 1745 1748 8690168 not RB I-VP O
26 1749 1762 8690168 significantly RB I-VP O
27 1763 1770 8690168 changed VBN I-VP O
28 1770 1771 8690168 . . O O

1 1772 1774 8690168 We PRP B-NP O
2 1775 1783 8690168 conclude VBP B-VP O
3 1784 1788 8690168 that IN B-SBAR O
4 1789 1791 8690168 in IN B-PP O
5 1792 1806 8690168 streptozotocin NN B-NP B-Chemical
6 1806 1807 8690168 - HYPH B-NP O
7 1807 1815 8690168 diabetic JJ I-NP B-Disease
8 1816 1820 8690168 rats NNS I-NP O
9 1821 1825 8690168 with IN B-PP O
10 1826 1828 8690168 an DT B-NP O
11 1829 1838 8690168 increased VBN I-NP O
12 1839 1846 8690168 urinary JJ I-NP O
13 1847 1854 8690168 albumin NN I-NP O
14 1855 1864 8690168 excretion NN I-NP O
15 1864 1865 8690168 , , O O
16 1866 1867 8690168 a DT B-NP O
17 1868 1875 8690168 reduced VBN I-NP O
18 1876 1883 8690168 heparan NN I-NP B-Chemical
19 1884 1892 8690168 sulphate NN I-NP I-Chemical
20 1893 1899 8690168 charge NN I-NP O
21 1900 1907 8690168 barrier NN I-NP O
22 1907 1908 8690168 / SYM B-NP O
23 1908 1915 8690168 density NN I-NP O
24 1916 1918 8690168 is VBZ B-VP O
25 1919 1924 8690168 found VBN I-VP O
26 1925 1927 8690168 at IN B-PP O
27 1928 1931 8690168 the DT B-NP O
28 1932 1938 8690168 lamina NN I-NP O
29 1939 1943 8690168 rara NN I-NP O
30 1944 1951 8690168 externa NN I-NP O
31 1952 1954 8690168 of IN B-PP O
32 1955 1958 8690168 the DT B-NP O
33 1959 1969 8690168 glomerular JJ I-NP O
34 1970 1978 8690168 basement NN I-NP O
35 1979 1987 8690168 membrane NN I-NP O
36 1987 1988 8690168 . . O O

1 0 0 3173179 -DOCSTART- -X- -X- O

1 0 9 3173179 Verapamil NN B-NP B-Chemical
2 10 20 3173179 withdrawal NN I-NP O
3 21 23 3173179 as IN B-PP O
4 24 25 3173179 a DT B-NP O
5 26 34 3173179 possible JJ I-NP O
6 35 40 3173179 cause NN I-NP O
7 41 43 3173179 of IN B-PP O
8 44 54 3173179 myocardial JJ B-NP B-Disease
9 55 65 3173179 infarction NN I-NP I-Disease
10 66 68 3173179 in IN B-PP O
11 69 70 3173179 a DT B-NP O
12 71 83 3173179 hypertensive JJ I-NP B-Disease
13 84 89 3173179 woman NN I-NP O
14 90 94 3173179 with IN B-PP O
15 95 96 3173179 a DT B-NP O
16 97 103 3173179 normal JJ I-NP O
17 104 112 3173179 coronary JJ I-NP O
18 113 122 3173179 angiogram NN I-NP O
19 122 123 3173179 . . I-NP O
20 124 133 3173179 Verapamil NN I-NP B-Chemical
21 134 136 3173179 is VBZ B-VP O
22 137 139 3173179 an DT B-NP O
23 140 149 3173179 effective JJ I-NP O
24 150 153 3173179 and CC O O
25 154 164 3173179 relatively RB B-ADJP O
26 164 165 3173179 - HYPH I-ADJP O
27 165 169 3173179 safe JJ B-NP O
28 170 186 3173179 antihypertensive JJ I-NP O
29 187 191 3173179 drug NN I-NP O
30 191 192 3173179 . . O O

1 193 200 3173179 Serious JJ B-NP O
2 201 208 3173179 adverse JJ I-NP O
3 209 216 3173179 effects NNS I-NP O
4 217 220 3173179 are VBP B-VP O
5 221 229 3173179 uncommon JJ B-ADJP O
6 230 233 3173179 and CC O O
7 234 240 3173179 mainly RB B-VP O
8 241 245 3173179 have VBP I-VP O
9 246 250 3173179 been VBN I-VP O
10 251 258 3173179 related VBN I-VP O
11 259 261 3173179 to TO B-PP O
12 262 265 3173179 the DT B-NP O
13 266 276 3173179 depression NN I-NP B-Disease
14 277 279 3173179 of IN B-PP O
15 280 287 3173179 cardiac JJ B-NP O
16 288 301 3173179 contractility NN I-NP O
17 302 305 3173179 and CC I-NP O
18 306 316 3173179 conduction NN I-NP O
19 316 317 3173179 , , O O
20 318 328 3173179 especially RB B-ADVP O
21 329 333 3173179 when WRB B-ADVP O
22 334 337 3173179 the DT B-NP O
23 338 342 3173179 drug NN I-NP O
24 343 345 3173179 is VBZ B-VP O
25 346 354 3173179 combined VBN I-VP O
26 355 359 3173179 with IN B-PP O
27 360 364 3173179 beta SYM B-NP O
28 364 365 3173179 - HYPH B-PP O
29 365 373 3173179 blocking VBG B-NP O
30 374 380 3173179 agents NNS I-NP O
31 380 381 3173179 . . O O

1 382 384 3173179 We PRP B-NP O
2 385 391 3173179 report VBP B-VP O
3 392 393 3173179 a DT B-NP O
4 394 398 3173179 case NN I-NP O
5 399 401 3173179 in IN B-PP O
6 402 407 3173179 which WDT B-NP O
7 408 418 3173179 myocardial JJ B-NP B-Disease
8 419 429 3173179 infarction NN I-NP I-Disease
9 430 439 3173179 coincided VBD B-VP O
10 440 444 3173179 with IN B-PP O
11 445 448 3173179 the DT B-NP O
12 449 461 3173179 introduction NN I-NP O
13 462 464 3173179 of IN B-PP O
14 465 474 3173179 captopril NN B-NP B-Chemical
15 475 478 3173179 and CC O O
16 479 482 3173179 the DT B-NP O
17 483 493 3173179 withdrawal NN I-NP O
18 494 496 3173179 of IN B-PP O
19 497 506 3173179 verapamil NN B-NP B-Chemical
20 507 509 3173179 in IN B-PP O
21 510 511 3173179 a DT B-NP O
22 512 522 3173179 previously RB I-NP O
23 523 535 3173179 asymptomatic JJ I-NP O
24 536 541 3173179 woman NN I-NP O
25 542 546 3173179 with IN B-PP O
26 547 553 3173179 severe JJ B-NP O
27 554 566 3173179 hypertension NN I-NP B-Disease
28 566 567 3173179 . . O O

1 568 576 3173179 Possible JJ B-NP O
2 577 587 3173179 mechanisms NNS I-NP O
3 588 592 3173179 that WDT B-NP O
4 593 600 3173179 involve VBP B-VP O
5 601 602 3173179 a DT B-NP O
6 603 612 3173179 verapamil NN I-NP B-Chemical
7 612 613 3173179 - HYPH O O
8 613 620 3173179 related VBN B-NP O
9 621 629 3173179 increase NN I-NP O
10 630 632 3173179 in IN B-PP O
11 633 641 3173179 platelet NN B-NP O
12 642 645 3173179 and CC O O
13 645 646 3173179 / SYM B-NP O
14 646 648 3173179 or CC O O
15 649 657 3173179 vascular JJ B-NP O
16 658 663 3173179 alpha NN I-NP O
17 664 665 3173179 2 CD I-NP O
18 665 666 3173179 - HYPH I-NP O
19 666 680 3173179 adrenoreceptor NN I-NP O
20 681 689 3173179 affinity NN I-NP O
21 690 693 3173179 for IN B-PP O
22 694 708 3173179 catecholamines NNS B-NP B-Chemical
23 709 712 3173179 are VBP B-VP O
24 713 722 3173179 discussed VBN I-VP O
25 722 723 3173179 . . O O

1 0 0 3015567 -DOCSTART- -X- -X- O

1 0 10 3015567 Inhibition NN B-NP O
2 11 13 3015567 of IN B-PP O
3 14 28 3015567 immunoreactive JJ B-NP O
4 29 42 3015567 corticotropin NN I-NP O
5 42 43 3015567 - HYPH O O
6 43 52 3015567 releasing VBG B-VP O
7 53 59 3015567 factor NN B-NP O
8 60 69 3015567 secretion NN I-NP O
9 70 74 3015567 into IN B-PP O
10 75 78 3015567 the DT B-NP O
11 79 90 3015567 hypophysial JJ I-NP O
12 90 91 3015567 - HYPH I-NP O
13 91 97 3015567 portal JJ I-NP O
14 98 109 3015567 circulation NN I-NP O
15 110 112 3015567 by IN B-PP O
16 113 120 3015567 delayed VBN B-NP O
17 121 135 3015567 glucocorticoid NN I-NP O
18 136 144 3015567 feedback NN I-NP O
19 144 145 3015567 . . I-NP O
20 146 159 3015567 Nitroprusside NN I-NP B-Chemical
21 159 160 3015567 - HYPH B-NP O
22 160 167 3015567 induced VBN I-NP O
23 168 179 3015567 hypotension NN I-NP B-Disease
24 180 186 3015567 evokes VBZ B-VP O
25 187 191 3015567 ACTH NN B-NP O
26 192 201 3015567 secretion NN I-NP O
27 202 207 3015567 which WDT B-NP O
28 208 210 3015567 is VBZ B-VP O
29 211 220 3015567 primarily RB I-VP O
30 221 229 3015567 mediated VBN I-VP O
31 230 232 3015567 by IN B-PP O
32 233 241 3015567 enhanced VBN B-NP O
33 242 251 3015567 secretion NN I-NP O
34 252 254 3015567 of IN B-PP O
35 255 269 3015567 immunoreactive JJ B-NP O
36 270 283 3015567 corticotropin NN I-NP O
37 283 284 3015567 - HYPH O O
38 284 293 3015567 releasing VBG B-VP O
39 294 300 3015567 factor NN B-NP O
40 301 302 3015567 ( ( O O
41 302 307 3015567 irCRF NN B-NP O
42 307 308 3015567 ) ) O O
43 309 313 3015567 into IN B-PP O
44 314 317 3015567 the DT B-NP O
45 318 329 3015567 hypophysial JJ I-NP O
46 329 330 3015567 - HYPH I-NP O
47 330 336 3015567 portal JJ I-NP O
48 337 348 3015567 circulation NN I-NP O
49 348 349 3015567 . . O O

1 350 356 3015567 Portal JJ B-NP O
2 357 363 3015567 plasma NN I-NP O
3 364 378 3015567 concentrations NNS I-NP O
4 379 381 3015567 of IN B-PP O
5 382 389 3015567 neither CC O O
6 390 398 3015567 arginine NN B-NP B-Chemical
7 399 410 3015567 vasopressin NN I-NP I-Chemical
8 411 414 3015567 nor CC I-NP O
9 415 423 3015567 oxytocin NN I-NP B-Chemical
10 424 427 3015567 are VBP B-VP O
11 428 441 3015567 significantly RB I-VP O
12 442 449 3015567 altered VBN I-VP O
13 450 452 3015567 in IN B-PP O
14 453 457 3015567 this DT B-NP O
15 458 466 3015567 paradigm NN I-NP O
16 466 467 3015567 . . O O

1 468 479 3015567 Application NN B-NP O
2 480 482 3015567 of IN B-PP O
3 483 484 3015567 a DT B-NP O
4 485 492 3015567 delayed VBN I-NP O
5 493 501 3015567 feedback NN I-NP O
6 502 508 3015567 signal NN I-NP O
7 508 509 3015567 , , O O
8 510 512 3015567 in IN B-PP O
9 513 516 3015567 the DT B-NP O
10 517 521 3015567 form NN I-NP O
11 522 524 3015567 of IN B-PP O
12 525 526 3015567 a DT B-NP O
13 527 528 3015567 2 CD I-NP O
14 528 529 3015567 - HYPH I-NP O
15 529 530 3015567 h NN I-NP O
16 531 539 3015567 systemic JJ I-NP O
17 540 554 3015567 corticosterone NN I-NP B-Chemical
18 555 563 3015567 infusion NN I-NP O
19 564 566 3015567 in IN B-PP O
20 567 575 3015567 urethane NN B-NP B-Chemical
21 575 576 3015567 - HYPH B-NP O
22 576 588 3015567 anesthetized VBN I-NP O
23 589 593 3015567 rats NNS I-NP O
24 594 598 3015567 with IN B-PP O
25 599 614 3015567 pharmacological JJ B-NP O
26 615 623 3015567 blockade NN I-NP O
27 624 626 3015567 of IN B-PP O
28 627 641 3015567 glucocorticoid NN B-NP O
29 642 651 3015567 synthesis NN I-NP O
30 651 652 3015567 , , O O
31 653 655 3015567 is VBZ B-VP O
32 656 663 3015567 without IN B-PP O
33 664 670 3015567 effect NN B-NP O
34 671 673 3015567 on IN B-PP O
35 674 677 3015567 the DT B-NP O
36 678 685 3015567 resting VBG I-NP O
37 686 695 3015567 secretion NN I-NP O
38 696 698 3015567 of IN B-PP O
39 699 707 3015567 arginine NN B-NP B-Chemical
40 708 719 3015567 vasopressin NN I-NP I-Chemical
41 720 723 3015567 and CC I-NP O
42 724 732 3015567 oxytocin NN I-NP B-Chemical
43 733 735 3015567 at IN B-PP O
44 736 739 3015567 any DT B-NP O
45 740 754 3015567 corticosterone NN I-NP B-Chemical
46 755 763 3015567 feedback NN I-NP O
47 764 768 3015567 dose NN I-NP O
48 769 775 3015567 tested VBN B-VP O
49 775 776 3015567 . . O O

1 777 784 3015567 Resting VBG B-VP O
2 785 790 3015567 irCRF NN B-NP O
3 791 797 3015567 levels NNS I-NP O
4 798 801 3015567 are VBP B-VP O
5 802 812 3015567 suppressed VBN I-VP O
6 813 817 3015567 only RB B-ADVP O
7 818 820 3015567 at IN B-PP O
8 821 824 3015567 the DT B-NP O
9 825 832 3015567 highest JJS I-NP O
10 833 847 3015567 corticosterone NN I-NP B-Chemical
11 848 856 3015567 infusion NN I-NP O
12 857 861 3015567 rate NN I-NP O
13 861 862 3015567 , , O O
14 863 868 3015567 which WDT B-NP O
15 869 877 3015567 resulted VBD B-VP O
16 878 880 3015567 in IN B-PP O
17 881 889 3015567 systemic JJ B-NP O
18 890 904 3015567 corticosterone NN I-NP B-Chemical
19 905 911 3015567 levels NNS I-NP O
20 912 914 3015567 of IN B-PP O
21 915 917 3015567 40 CD B-NP O
22 918 928 3015567 micrograms NNS I-NP O
23 928 929 3015567 / SYM B-NP O
24 929 931 3015567 dl NN I-NP O
25 931 932 3015567 . . O O

1 933 944 3015567 Suppression NN B-NP O
2 945 947 3015567 of IN B-PP O
3 948 953 3015567 irCRF NN B-NP O
4 954 963 3015567 secretion NN I-NP O
5 964 966 3015567 in IN B-PP O
6 967 975 3015567 response NN I-PP O
7 976 978 3015567 to TO I-PP O
8 979 992 3015567 nitroprusside NN B-NP B-Chemical
9 992 993 3015567 - HYPH B-NP O
10 993 1000 3015567 induced VBN I-NP O
11 1001 1012 3015567 hypotension NN I-NP B-Disease
12 1013 1015 3015567 is VBZ B-VP O
13 1016 1024 3015567 observed VBN I-VP O
14 1025 1028 3015567 and CC O O
15 1029 1035 3015567 occurs VBZ B-VP O
16 1036 1038 3015567 at IN B-PP O
17 1039 1040 3015567 a DT B-NP O
18 1041 1047 3015567 plasma NN I-NP O
19 1048 1062 3015567 corticosterone NN I-NP B-Chemical
20 1063 1068 3015567 level NN I-NP O
21 1069 1076 3015567 between IN B-PP O
22 1077 1078 3015567 8 CD B-NP O
23 1078 1079 3015567 - HYPH I-NP O
24 1079 1081 3015567 12 CD I-NP O
25 1082 1092 3015567 micrograms NNS I-NP O
26 1092 1093 3015567 / SYM B-NP O
27 1093 1095 3015567 dl NN I-NP O
28 1095 1096 3015567 . . O O

1 1097 1102 3015567 These DT B-NP O
2 1103 1110 3015567 studies NNS I-NP O
3 1111 1118 3015567 provide VBP B-VP O
4 1119 1126 3015567 further JJ B-NP O
5 1127 1135 3015567 evidence NN I-NP O
6 1136 1139 3015567 for IN B-PP O
7 1140 1141 3015567 a DT B-NP O
8 1142 1148 3015567 strong JJ I-NP O
9 1149 1156 3015567 central JJ I-NP O
10 1157 1166 3015567 component NN I-NP O
11 1167 1169 3015567 of IN B-PP O
12 1170 1173 3015567 the DT B-NP O
13 1174 1181 3015567 delayed VBN I-NP O
14 1182 1190 3015567 feedback NN I-NP O
15 1191 1198 3015567 process NN I-NP O
16 1199 1204 3015567 which WDT B-NP O
17 1205 1207 3015567 is VBZ B-VP O
18 1208 1216 3015567 mediated VBN I-VP O
19 1217 1219 3015567 by IN B-PP O
20 1220 1230 3015567 modulation NN B-NP O
21 1231 1233 3015567 of IN B-PP O
22 1234 1239 3015567 irCRF NN B-NP O
23 1240 1247 3015567 release NN I-NP O
24 1247 1248 3015567 . . O O

1 0 0 15130900 -DOCSTART- -X- -X- O

1 0 7 15130900 Urinary JJ B-NP B-Disease
2 8 15 15130900 bladder NN I-NP I-Disease
3 16 22 15130900 cancer NN I-NP I-Disease
4 23 25 15130900 in IN B-PP O
5 26 35 15130900 Wegener's NNS B-NP B-Disease
6 36 50 15130900 granulomatosis NN I-NP I-Disease
7 50 51 15130900 : : O O
8 52 57 15130900 risks NNS B-NP O
9 58 61 15130900 and CC O O
10 62 70 15130900 relation NN B-NP O
11 71 73 15130900 to TO B-PP O
12 74 90 15130900 cyclophosphamide NN B-NP B-Chemical
13 90 91 15130900 . . O O
14 92 101 15130900 OBJECTIVE NN B-NP O
15 101 102 15130900 : : O O
16 103 105 15130900 To TO B-VP O
17 106 112 15130900 assess VB I-VP O
18 113 116 15130900 and CC I-VP O
19 117 129 15130900 characterise VB I-VP O
20 130 133 15130900 the DT B-NP O
21 134 138 15130900 risk NN I-NP O
22 139 141 15130900 of IN B-PP O
23 142 149 15130900 bladder NN B-NP B-Disease
24 150 156 15130900 cancer NN I-NP I-Disease
25 156 157 15130900 , , O O
26 158 161 15130900 and CC O O
27 162 165 15130900 its PRP$ B-NP O
28 166 174 15130900 relation NN I-NP O
29 175 177 15130900 to TO B-PP O
30 178 194 15130900 cyclophosphamide NN B-NP B-Chemical
31 194 195 15130900 , , O O
32 196 198 15130900 in IN B-PP O
33 199 207 15130900 patients NNS B-NP O
34 208 212 15130900 with IN B-PP O
35 213 222 15130900 Wegener's NNS B-NP B-Disease
36 223 237 15130900 granulomatosis NN I-NP I-Disease
37 237 238 15130900 . . O O

1 239 246 15130900 METHODS NNS B-NP O
2 246 247 15130900 : : O O
3 248 250 15130900 In IN B-PP O
4 251 254 15130900 the DT B-NP O
5 255 265 15130900 population NN I-NP O
6 266 271 15130900 based VBN B-VP O
7 271 272 15130900 , , O O
8 273 283 15130900 nationwide JJ B-NP O
9 284 291 15130900 Swedish NNP I-NP O
10 292 301 15130900 Inpatient NNP I-NP O
11 302 310 15130900 Register NNP I-NP O
12 311 312 15130900 a DT B-NP O
13 313 319 15130900 cohort NN I-NP O
14 320 322 15130900 of IN B-PP O
15 323 327 15130900 1065 CD B-NP O
16 328 336 15130900 patients NNS I-NP O
17 337 341 15130900 with IN B-PP O
18 342 351 15130900 Wegener's NNS B-NP B-Disease
19 352 366 15130900 granulomatosis NN I-NP I-Disease
20 366 367 15130900 , , O O
21 368 372 15130900 1969 CD B-NP O
22 372 373 15130900 - HYPH I-NP O
23 373 375 15130900 95 CD I-NP O
24 375 376 15130900 , , O O
25 377 380 15130900 was VBD B-VP O
26 381 391 15130900 identified VBN I-VP O
27 391 392 15130900 . . O O

1 393 400 15130900 Through IN B-PP O
2 401 408 15130900 linkage NN B-NP O
3 409 413 15130900 with IN B-PP O
4 414 417 15130900 the DT B-NP O
5 418 425 15130900 Swedish NNP I-NP O
6 426 432 15130900 Cancer NNP I-NP B-Disease
7 433 441 15130900 Register NNP I-NP O
8 441 442 15130900 , , O O
9 443 446 15130900 all DT B-NP O
10 447 455 15130900 subjects NNS I-NP O
11 456 458 15130900 in IN B-PP O
12 459 463 15130900 this DT B-NP O
13 464 470 15130900 cohort NN I-NP O
14 471 480 15130900 diagnosed VBN B-VP O
15 481 485 15130900 with IN B-PP O
16 486 493 15130900 bladder NN B-NP B-Disease
17 494 500 15130900 cancer NN I-NP I-Disease
18 501 505 15130900 were VBD B-VP O
19 506 516 15130900 identified VBN I-VP O
20 516 517 15130900 . . O O

1 518 524 15130900 Nested VBN B-VP O
2 525 531 15130900 within IN B-PP O
3 532 535 15130900 the DT B-NP O
4 536 542 15130900 cohort NN I-NP O
5 542 543 15130900 , , O O
6 544 545 15130900 a DT B-NP O
7 546 553 15130900 matched VBN I-NP O
8 554 558 15130900 case NN I-NP O
9 558 559 15130900 - HYPH B-NP O
10 559 566 15130900 control NN I-NP O
11 567 572 15130900 study NN I-NP O
12 573 576 15130900 was VBD B-VP O
13 577 586 15130900 performed VBN I-VP O
14 587 589 15130900 to TO I-VP O
15 590 598 15130900 estimate VB I-VP O
16 599 602 15130900 the DT B-NP O
17 603 614 15130900 association NN I-NP O
18 615 622 15130900 between IN B-PP O
19 623 639 15130900 cyclophosphamide NN B-NP B-Chemical
20 640 643 15130900 and CC I-NP O
21 644 651 15130900 bladder NN I-NP B-Disease
22 652 658 15130900 cancer NN I-NP I-Disease
23 659 664 15130900 using VBG B-VP O
24 665 669 15130900 odds NNS B-NP O
25 670 676 15130900 ratios NNS I-NP O
26 677 678 15130900 ( ( O O
27 678 681 15130900 ORs NNS B-NP O
28 681 682 15130900 ) ) O O
29 683 685 15130900 as IN B-PP O
30 686 694 15130900 relative JJ B-NP O
31 695 699 15130900 risk NN I-NP O
32 699 700 15130900 . . O O

1 701 703 15130900 In IN B-PP O
2 704 707 15130900 the DT B-NP O
3 708 714 15130900 cohort NN I-NP O
4 715 718 15130900 the DT B-NP O
5 719 729 15130900 cumulative JJ I-NP O
6 730 734 15130900 risk NN I-NP O
7 735 737 15130900 of IN B-PP O
8 738 745 15130900 bladder NN B-NP B-Disease
9 746 752 15130900 cancer NN I-NP I-Disease
10 753 758 15130900 after IN B-PP O
11 759 768 15130900 Wegener's NNS B-NP B-Disease
12 769 783 15130900 granulomatosis NN I-NP I-Disease
13 783 784 15130900 , , O O
14 785 788 15130900 and CC O O
15 789 792 15130900 the DT B-NP O
16 793 801 15130900 relative JJ I-NP O
17 802 812 15130900 prevalence NN I-NP O
18 813 815 15130900 of IN B-PP O
19 816 817 15130900 a DT B-NP O
20 818 825 15130900 history NN I-NP O
21 826 828 15130900 of IN B-PP O
22 829 836 15130900 bladder NN B-NP B-Disease
23 837 843 15130900 cancer NN I-NP I-Disease
24 844 846 15130900 at IN B-PP O
25 847 850 15130900 the DT B-NP O
26 851 855 15130900 time NN I-NP O
27 856 858 15130900 of IN B-PP O
28 859 868 15130900 diagnosis NN B-NP O
29 869 871 15130900 of IN B-PP O
30 872 881 15130900 Wegener's NNS B-NP B-Disease
31 882 896 15130900 granulomatosis NN I-NP I-Disease
32 896 897 15130900 , , O O
33 898 902 15130900 were VBD B-VP O
34 903 907 15130900 also RB I-VP O
35 908 917 15130900 estimated VBN I-VP O
36 917 918 15130900 . . O O

1 919 926 15130900 RESULTS NNS B-NP O
2 926 927 15130900 : : O O
3 928 931 15130900 The DT B-NP O
4 932 938 15130900 median JJ I-NP O
5 939 949 15130900 cumulative JJ I-NP O
6 950 955 15130900 doses NNS I-NP O
7 956 958 15130900 of IN B-PP O
8 959 975 15130900 cyclophosphamide NN B-NP B-Chemical
9 976 981 15130900 among IN B-PP O
10 982 987 15130900 cases NNS B-NP O
11 988 989 15130900 ( ( O O
12 989 990 15130900 n NN B-NP O
13 991 992 15130900 = SYM B-VP O
14 993 995 15130900 11 CD B-NP O
15 995 996 15130900 ) ) O O
16 997 1000 15130900 and CC O O
17 1001 1009 15130900 controls NNS B-NP O
18 1010 1011 15130900 ( ( O O
19 1011 1012 15130900 n NN B-NP O
20 1013 1014 15130900 = SYM B-VP O
21 1015 1017 15130900 25 CD B-NP O
22 1017 1018 15130900 ) ) O O
23 1019 1023 15130900 were VBD B-VP O
24 1024 1027 15130900 113 CD B-NP O
25 1028 1029 15130900 g NN I-NP O
26 1030 1033 15130900 and CC O O
27 1034 1036 15130900 25 CD B-NP O
28 1037 1038 15130900 g NN I-NP O
29 1038 1039 15130900 , , O O
30 1040 1052 15130900 respectively RB B-ADVP O
31 1052 1053 15130900 . . O O

1 1054 1057 15130900 The DT B-NP O
2 1058 1062 15130900 risk NN I-NP O
3 1063 1065 15130900 of IN B-PP O
4 1066 1073 15130900 bladder NN B-NP B-Disease
5 1074 1080 15130900 cancer NN I-NP I-Disease
6 1081 1088 15130900 doubled VBD B-VP O
7 1089 1092 15130900 for IN B-PP O
8 1093 1098 15130900 every DT B-NP O
9 1099 1101 15130900 10 CD I-NP O
10 1102 1103 15130900 g NN I-NP O
11 1104 1113 15130900 increment NN I-NP O
12 1114 1116 15130900 in IN B-PP O
13 1117 1133 15130900 cyclophosphamide NN B-NP B-Chemical
14 1134 1135 15130900 ( ( O O
15 1135 1137 15130900 OR NN B-NP O
16 1138 1139 15130900 = SYM B-VP O
17 1140 1143 15130900 2.0 CD B-NP O
18 1143 1144 15130900 , , O O
19 1145 1148 15130900 95% CD B-NP O
20 1149 1159 15130900 confidence NN I-NP O
21 1160 1168 15130900 interval NN I-NP O
22 1169 1170 15130900 ( ( O O
23 1170 1172 15130900 CI NN B-NP O
24 1172 1173 15130900 ) ) O O
25 1174 1177 15130900 0.8 CD B-NP O
26 1178 1180 15130900 to TO B-PP O
27 1181 1184 15130900 4.9 CD B-NP O
28 1184 1185 15130900 ) ) O O
29 1185 1186 15130900 . . O O

1 1187 1196 15130900 Treatment NN B-NP O
2 1197 1205 15130900 duration NN I-NP O
3 1206 1212 15130900 longer JJR B-ADVP O
4 1213 1217 15130900 than IN B-PP O
5 1218 1219 15130900 1 CD B-NP O
6 1220 1224 15130900 year NN I-NP O
7 1225 1228 15130900 was VBD B-VP O
8 1229 1239 15130900 associated VBN I-VP O
9 1240 1244 15130900 with IN B-PP O
10 1245 1247 15130900 an DT B-NP O
11 1248 1257 15130900 eightfold RB I-NP O
12 1258 1267 15130900 increased VBN I-NP O
13 1268 1272 15130900 risk NN I-NP O
14 1273 1274 15130900 ( ( O O
15 1274 1276 15130900 OR NN B-NP O
16 1277 1278 15130900 = SYM B-VP O
17 1279 1282 15130900 7.7 CD B-NP O
18 1282 1283 15130900 , , O O
19 1284 1287 15130900 95% CD B-NP O
20 1288 1290 15130900 CI NNP I-NP O
21 1291 1294 15130900 0.9 CD I-NP O
22 1295 1297 15130900 to TO B-PP O
23 1298 1300 15130900 69 CD B-NP O
24 1300 1301 15130900 ) ) O O
25 1301 1302 15130900 . . O O

1 1303 1306 15130900 The DT B-NP O
2 1307 1315 15130900 absolute JJ I-NP O
3 1316 1320 15130900 risk NN I-NP O
4 1321 1324 15130900 for IN B-PP O
5 1325 1332 15130900 bladder NN B-NP B-Disease
6 1333 1339 15130900 cancer NN I-NP I-Disease
7 1340 1342 15130900 in IN B-PP O
8 1343 1346 15130900 the DT B-NP O
9 1347 1353 15130900 cohort JJ I-NP O
10 1354 1361 15130900 reached VBN I-NP O
11 1362 1365 15130900 10% CD I-NP O
12 1366 1368 15130900 16 CD I-NP O
13 1369 1374 15130900 years NNS I-NP O
14 1375 1380 15130900 after IN B-PP O
15 1381 1390 15130900 diagnosis NN B-NP O
16 1391 1393 15130900 of IN B-PP O
17 1394 1403 15130900 Wegener's NNS B-NP B-Disease
18 1404 1418 15130900 granulomatosis NN I-NP I-Disease
19 1418 1419 15130900 , , O O
20 1420 1423 15130900 and CC O O
21 1424 1425 15130900 a DT B-NP O
22 1426 1433 15130900 history NN I-NP O
23 1434 1436 15130900 of IN B-PP O
24 1437 1444 15130900 bladder NN B-NP B-Disease
25 1445 1451 15130900 cancer NN I-NP I-Disease
26 1452 1455 15130900 was VBD B-VP O
27 1456 1457 15130900 ( ( O O
28 1457 1460 15130900 non AFX O O
29 1460 1461 15130900 - HYPH O O
30 1461 1474 15130900 significantly RB O O
31 1474 1475 15130900 ) ) O O
32 1476 1481 15130900 twice RB B-ADJP O
33 1482 1484 15130900 as RB I-ADJP O
34 1485 1491 15130900 common JJ I-ADJP O
35 1492 1494 15130900 as IN B-SBAR O
36 1495 1503 15130900 expected VBN B-VP O
37 1504 1506 15130900 at IN B-PP O
38 1507 1510 15130900 the DT B-NP O
39 1511 1515 15130900 time NN I-NP O
40 1516 1518 15130900 of IN B-PP O
41 1519 1528 15130900 diagnosis NN B-NP O
42 1529 1531 15130900 of IN B-PP O
43 1532 1541 15130900 Wegener's NNS B-NP B-Disease
44 1542 1556 15130900 granulomatosis NN I-NP I-Disease
45 1556 1557 15130900 . . O O

1 1558 1568 15130900 CONCLUSION NN B-NP O
2 1568 1569 15130900 : : O O
3 1570 1573 15130900 The DT B-NP O
4 1574 1581 15130900 results NNS I-NP O
5 1582 1590 15130900 indicate VBP B-VP O
6 1591 1592 15130900 a DT B-NP O
7 1593 1597 15130900 dose NN I-NP O
8 1597 1598 15130900 - HYPH B-NP O
9 1598 1606 15130900 response NN I-NP O
10 1607 1619 15130900 relationship NN I-NP O
11 1620 1627 15130900 between IN B-PP O
12 1628 1644 15130900 cyclophosphamide NN B-NP B-Chemical
13 1645 1648 15130900 and CC O O
14 1649 1652 15130900 the DT B-NP O
15 1653 1657 15130900 risk NN I-NP O
16 1658 1660 15130900 of IN B-PP O
17 1661 1668 15130900 bladder NN B-NP B-Disease
18 1669 1675 15130900 cancer NN I-NP I-Disease
19 1675 1676 15130900 , , O O
20 1677 1681 15130900 high JJ B-NP O
21 1682 1692 15130900 cumulative JJ I-NP O
22 1693 1698 15130900 risks NNS I-NP O
23 1699 1701 15130900 in IN B-PP O
24 1702 1705 15130900 the DT B-NP O
25 1706 1712 15130900 entire JJ I-NP O
26 1713 1719 15130900 cohort NN I-NP O
27 1719 1720 15130900 , , O O
28 1721 1724 15130900 and CC O O
29 1725 1729 15130900 also RB B-ADVP O
30 1730 1733 15130900 the DT B-NP O
31 1734 1745 15130900 possibility NN I-NP O
32 1746 1748 15130900 of IN B-PP O
33 1749 1753 15130900 risk NN B-NP O
34 1754 1761 15130900 factors NNS I-NP O
35 1762 1771 15130900 operating VBG B-VP O
36 1772 1776 15130900 even RB B-ADVP O
37 1777 1783 15130900 before IN B-PP O
38 1784 1793 15130900 Wegener's NNS B-NP B-Disease
39 1794 1808 15130900 granulomatosis NN I-NP I-Disease
40 1808 1809 15130900 . . O O

1 0 0 17491223 -DOCSTART- -X- -X- O

1 0 10 17491223 Assessment NN B-NP O
2 11 13 17491223 of IN B-PP O
3 14 15 17491223 a DT B-NP O
4 16 19 17491223 new JJ I-NP O
5 20 23 17491223 non AFX I-NP O
6 23 24 17491223 - HYPH I-NP O
7 24 32 17491223 invasive JJ I-NP O
8 33 38 17491223 index NN I-NP O
9 39 41 17491223 of IN B-PP O
10 42 49 17491223 cardiac JJ B-NP O
11 50 61 17491223 performance NN I-NP O
12 62 65 17491223 for IN B-PP O
13 66 75 17491223 detection NN B-NP O
14 76 78 17491223 of IN B-PP O
15 79 89 17491223 dobutamine NN B-NP B-Chemical
16 89 90 17491223 - HYPH B-NP O
17 90 97 17491223 induced VBN I-NP O
18 98 108 17491223 myocardial JJ I-NP B-Disease
19 109 117 17491223 ischemia NN I-NP I-Disease
20 117 118 17491223 . . I-NP O
21 119 129 17491223 BACKGROUND NN I-NP O
22 129 130 17491223 : : O O
23 131 150 17491223 Electrocardiography NN B-NP O
24 151 154 17491223 has VBZ B-VP O
25 155 156 17491223 a DT B-NP O
26 157 161 17491223 very RB I-NP O
27 162 165 17491223 low JJ I-NP O
28 166 177 17491223 sensitivity NN I-NP O
29 178 180 17491223 in IN B-PP O
30 181 190 17491223 detecting VBG B-VP O
31 191 201 17491223 dobutamine NN B-NP B-Chemical
32 201 202 17491223 - HYPH O O
33 202 209 17491223 induced VBN B-NP O
34 210 220 17491223 myocardial JJ I-NP B-Disease
35 221 229 17491223 ischemia NN I-NP I-Disease
36 229 230 17491223 . . O O

1 231 241 17491223 OBJECTIVES NNS B-NP O
2 241 242 17491223 : : O O
3 243 245 17491223 To TO B-VP O
4 246 252 17491223 assess VB I-VP O
5 253 256 17491223 the DT B-NP O
6 257 262 17491223 added VBN I-NP O
7 263 273 17491223 diagnostic JJ I-NP O
8 274 279 17491223 value NN I-NP O
9 280 282 17491223 of IN B-PP O
10 283 284 17491223 a DT B-NP O
11 285 288 17491223 new JJ I-NP O
12 289 296 17491223 cardiac JJ I-NP O
13 297 308 17491223 performance NN I-NP O
14 309 314 17491223 index NN I-NP O
15 315 316 17491223 ( ( O O
16 316 318 17491223 dP NN B-NP O
17 318 319 17491223 / SYM B-NP O
18 319 324 17491223 dtejc NN I-NP O
19 324 325 17491223 ) ) O O
20 326 337 17491223 measurement NN B-NP O
21 337 338 17491223 , , O O
22 339 344 17491223 based VBN B-PP O
23 345 347 17491223 on IN B-PP O
24 348 356 17491223 brachial JJ B-NP O
25 357 363 17491223 artery NN I-NP O
26 364 368 17491223 flow NN I-NP O
27 369 376 17491223 changes NNS I-NP O
28 376 377 17491223 , , O O
29 378 380 17491223 as IN B-SBAR O
30 381 389 17491223 compared VBN B-VP O
31 390 392 17491223 to TO I-VP O
32 393 401 17491223 standard VB I-VP O
33 402 404 17491223 12 CD B-NP O
34 404 405 17491223 - HYPH I-NP O
35 405 409 17491223 lead NN I-NP O
36 410 413 17491223 ECG NN I-NP O
37 413 414 17491223 , , O O
38 415 418 17491223 for IN B-PP O
39 419 428 17491223 detecting VBG B-VP O
40 429 439 17491223 dobutamine NN B-NP B-Chemical
41 439 440 17491223 - HYPH O O
42 440 447 17491223 induced VBN B-NP O
43 448 458 17491223 myocardial JJ I-NP B-Disease
44 459 467 17491223 ischemia NN I-NP I-Disease
45 467 468 17491223 , , O O
46 469 474 17491223 using VBG B-VP O
47 475 480 17491223 Tc99m NN B-NP B-Chemical
48 480 481 17491223 - HYPH B-NP I-Chemical
49 481 490 17491223 Sestamibi NN I-NP I-Chemical
50 491 497 17491223 single JJ I-NP O
51 497 498 17491223 - HYPH I-NP O
52 498 504 17491223 photon NN I-NP O
53 505 513 17491223 emission NN I-NP O
54 514 522 17491223 computed VBD B-VP O
55 523 533 17491223 tomography NN B-NP O
56 534 536 17491223 as IN B-PP O
57 537 540 17491223 the DT B-NP O
58 541 545 17491223 gold JJ I-NP O
59 546 554 17491223 standard NN I-NP O
60 555 557 17491223 of IN B-PP O
61 558 568 17491223 comparison NN B-NP O
62 569 571 17491223 to TO B-VP O
63 572 578 17491223 assess VB I-VP O
64 579 582 17491223 the DT B-NP O
65 583 591 17491223 presence NN I-NP O
66 592 594 17491223 or CC I-NP O
67 595 602 17491223 absence NN I-NP O
68 603 605 17491223 of IN B-PP O
69 606 614 17491223 ischemia NN B-NP B-Disease
70 614 615 17491223 . . O O

1 616 623 17491223 METHODS NNS B-NP O
2 623 624 17491223 : : O O
3 625 628 17491223 The DT B-NP O
4 629 634 17491223 study NN I-NP O
5 635 640 17491223 group NN I-NP O
6 641 650 17491223 comprised VBD B-VP O
7 651 653 17491223 40 CD B-NP O
8 654 662 17491223 patients NNS I-NP O
9 663 673 17491223 undergoing VBG B-VP O
10 674 683 17491223 Sestamibi NN B-NP B-Chemical
11 683 684 17491223 - HYPH B-NP O
12 684 689 17491223 SPECT NN I-NP O
13 689 690 17491223 / SYM I-NP O
14 690 700 17491223 dobutamine NN I-NP B-Chemical
15 701 707 17491223 stress NN I-NP O
16 708 712 17491223 test NN I-NP O
17 712 713 17491223 . . O O

1 714 726 17491223 Simultaneous JJ B-NP O
2 727 739 17491223 measurements NNS I-NP O
3 740 742 17491223 of IN B-PP O
4 743 746 17491223 ECG NN B-NP O
5 747 750 17491223 and CC O O
6 751 759 17491223 brachial JJ B-NP O
7 760 766 17491223 artery NN I-NP O
8 767 769 17491223 dP NN I-NP O
9 769 770 17491223 / SYM B-NP O
10 770 775 17491223 dtejc NN I-NP O
11 776 780 17491223 were VBD B-VP O
12 781 790 17491223 performed VBN I-VP O
13 791 793 17491223 at IN B-PP O
14 794 798 17491223 each DT B-NP O
15 799 809 17491223 dobutamine NN I-NP B-Chemical
16 810 815 17491223 level NN I-NP O
17 815 816 17491223 . . O O

1 817 819 17491223 In IN B-PP O
2 820 822 17491223 19 CD B-NP O
3 823 825 17491223 of IN B-PP O
4 826 829 17491223 the DT B-NP O
5 830 832 17491223 40 CD I-NP O
6 833 841 17491223 patients NNS I-NP O
7 842 851 17491223 perfusion NN I-NP O
8 852 859 17491223 defects NNS I-NP O
9 860 870 17491223 compatible JJ B-ADJP O
10 871 875 17491223 with IN B-PP O
11 876 884 17491223 ischemia NN B-NP B-Disease
12 885 889 17491223 were VBD B-VP O
13 890 898 17491223 detected VBN I-VP O
14 899 901 17491223 on IN B-PP O
15 902 907 17491223 SPECT NN B-NP O
16 907 908 17491223 . . O O

1 909 912 17491223 The DT B-NP O
2 913 921 17491223 increase NN I-NP O
3 922 924 17491223 in IN B-PP O
4 925 927 17491223 dP NN B-NP O
5 927 928 17491223 / SYM B-NP O
6 928 933 17491223 dtejc NN I-NP O
7 934 940 17491223 during IN B-PP O
8 941 949 17491223 infusion NN B-NP O
9 950 952 17491223 of IN B-PP O
10 953 963 17491223 dobutamine NN B-NP B-Chemical
11 964 966 17491223 in IN B-PP O
12 967 971 17491223 this DT B-NP O
13 972 977 17491223 group NN I-NP O
14 978 981 17491223 was VBD B-VP O
15 982 990 17491223 severely RB B-ADJP O
16 991 999 17491223 impaired JJ I-ADJP O
17 1000 1002 17491223 as IN B-SBAR O
18 1003 1011 17491223 compared VBN B-VP O
19 1012 1014 17491223 to TO B-PP O
20 1015 1018 17491223 the DT B-NP O
21 1019 1022 17491223 non AFX I-NP O
22 1022 1023 17491223 - HYPH I-NP O
23 1023 1031 17491223 ischemic JJ I-NP O
24 1032 1037 17491223 group NN I-NP O
25 1037 1038 17491223 . . O O

1 1039 1041 17491223 dP NN B-NP O
2 1041 1042 17491223 / SYM I-NP O
3 1042 1047 17491223 dtejc NN I-NP O
4 1048 1055 17491223 outcome NN I-NP O
5 1056 1059 17491223 was VBD B-VP O
6 1060 1068 17491223 combined VBN I-VP O
7 1069 1073 17491223 with IN B-PP O
8 1074 1077 17491223 the DT B-NP O
9 1078 1081 17491223 ECG NN I-NP O
10 1082 1089 17491223 results NNS I-NP O
11 1089 1090 17491223 , , O O
12 1091 1097 17491223 giving VBG B-VP O
13 1098 1100 17491223 an DT B-NP O
14 1101 1104 17491223 ECG NN I-NP O
15 1104 1105 17491223 - HYPH B-NP O
16 1105 1113 17491223 enhanced VBN I-NP O
17 1114 1119 17491223 value NN I-NP O
18 1119 1120 17491223 , , O O
19 1121 1124 17491223 and CC O O
20 1125 1133 17491223 compared VBN B-VP O
21 1134 1136 17491223 to TO B-PP O
22 1137 1140 17491223 ECG NN B-NP O
23 1141 1146 17491223 alone RB B-ADVP O
24 1146 1147 17491223 . . O O

1 1148 1155 17491223 RESULTS NNS B-NP O
2 1155 1156 17491223 : : O O
3 1157 1160 17491223 The DT B-NP O
4 1161 1172 17491223 sensitivity NN I-NP O
5 1173 1181 17491223 improved VBD B-VP O
6 1182 1194 17491223 dramatically RB B-ADVP O
7 1195 1199 17491223 from IN B-PP O
8 1200 1203 17491223 16% CD B-NP O
9 1204 1206 17491223 to TO B-PP O
10 1207 1210 17491223 79% CD B-NP O
11 1210 1211 17491223 , , O O
12 1212 1220 17491223 positive JJ B-NP O
13 1221 1231 17491223 predictive JJ I-NP O
14 1232 1237 17491223 value NN I-NP O
15 1238 1247 17491223 increased VBD B-VP O
16 1248 1252 17491223 from IN B-PP O
17 1253 1256 17491223 60% CD B-NP O
18 1257 1259 17491223 to TO B-PP O
19 1260 1263 17491223 68% CD B-NP O
20 1264 1267 17491223 and CC O O
21 1268 1276 17491223 negative JJ B-NP O
22 1277 1287 17491223 predictive JJ I-NP O
23 1288 1293 17491223 value NN I-NP O
24 1294 1298 17491223 from IN B-PP O
25 1299 1302 17491223 54% CD B-NP O
26 1303 1305 17491223 to TO B-PP O
27 1306 1309 17491223 78% CD B-NP O
28 1309 1310 17491223 , , O O
29 1311 1314 17491223 and CC O O
30 1315 1326 17491223 specificity NN B-NP O
31 1327 1336 17491223 decreased VBD B-VP O
32 1337 1341 17491223 from IN B-PP O
33 1342 1345 17491223 90% CD B-NP O
34 1346 1348 17491223 to TO B-PP O
35 1349 1352 17491223 67% CD B-NP O
36 1352 1353 17491223 . . O O

1 1354 1365 17491223 CONCLUSIONS NNS B-NP O
2 1365 1366 17491223 : : O O
3 1367 1369 17491223 If IN B-SBAR O
4 1370 1373 17491223 ECG NN B-NP O
5 1374 1379 17491223 alone RB B-ADVP O
6 1380 1382 17491223 is VBZ B-VP O
7 1383 1387 17491223 used VBN I-VP O
8 1388 1391 17491223 for IN B-PP O
9 1392 1403 17491223 specificity NN B-NP O
10 1403 1404 17491223 , , O O
11 1405 1408 17491223 the DT B-NP O
12 1409 1420 17491223 combination NN I-NP O
13 1421 1425 17491223 with IN B-PP O
14 1426 1428 17491223 dP NN B-NP O
15 1428 1429 17491223 / SYM I-NP O
16 1429 1434 17491223 dtejc NN I-NP O
17 1435 1443 17491223 improved VBD B-VP O
18 1444 1447 17491223 the DT B-NP O
19 1448 1459 17491223 sensitivity NN I-NP O
20 1460 1462 17491223 of IN B-PP O
21 1463 1466 17491223 the DT B-NP O
22 1467 1471 17491223 test NN I-NP O
23 1472 1475 17491223 and CC O O
24 1476 1481 17491223 could MD B-VP O
25 1482 1484 17491223 be VB I-VP O
26 1485 1486 17491223 a DT B-NP O
27 1487 1491 17491223 cost NN I-NP O
28 1491 1492 17491223 - HYPH B-NP O
29 1492 1499 17491223 savings NNS I-NP O
30 1500 1511 17491223 alternative JJ B-ADJP O
31 1512 1514 17491223 to TO B-PP O
32 1515 1522 17491223 cardiac JJ B-NP O
33 1523 1530 17491223 imaging NN I-NP O
34 1531 1533 17491223 or CC I-NP O
35 1534 1543 17491223 perfusion NN I-NP O
36 1544 1551 17491223 studies NNS I-NP O
37 1552 1554 17491223 to TO B-VP O
38 1555 1561 17491223 detect VB I-VP O
39 1562 1572 17491223 myocardial JJ B-NP B-Disease
40 1573 1581 17491223 ischemia NN I-NP I-Disease
41 1581 1582 17491223 , , O O
42 1583 1593 17491223 especially RB B-ADVP O
43 1594 1596 17491223 in IN B-PP O
44 1597 1605 17491223 patients NNS B-NP O
45 1606 1612 17491223 unable JJ B-ADJP O
46 1613 1615 17491223 to TO B-VP O
47 1616 1624 17491223 exercise VB I-VP O
48 1624 1625 17491223 . . O O

1 0 0 18754075 -DOCSTART- -X- -X- O

1 0 7 18754075 Massive JJ B-NP O
2 8 19 18754075 proteinuria NN I-NP B-Disease
3 20 23 18754075 and CC O O
4 24 29 18754075 acute JJ B-NP B-Disease
5 30 35 18754075 renal JJ I-NP I-Disease
6 36 43 18754075 failure NN I-NP I-Disease
7 44 49 18754075 after IN B-PP O
8 50 54 18754075 oral JJ B-NP O
9 55 69 18754075 bisphosphonate NN I-NP B-Chemical
10 70 71 18754075 ( ( O O
11 71 82 18754075 alendronate NN B-NP B-Chemical
12 82 83 18754075 ) ) O O
13 84 98 18754075 administration NN B-NP O
14 99 101 18754075 in IN B-PP O
15 102 103 18754075 a DT B-NP O
16 104 111 18754075 patient NN I-NP O
17 112 116 18754075 with IN B-PP O
18 117 122 18754075 focal JJ B-NP B-Disease
19 123 132 18754075 segmental JJ I-NP I-Disease
20 133 151 18754075 glomerulosclerosis NN I-NP I-Disease
21 151 152 18754075 . . O O
22 153 154 18754075 A DT B-NP O
23 155 157 18754075 61 CD I-NP O
24 157 158 18754075 - HYPH I-NP O
25 158 162 18754075 year NN I-NP O
26 162 163 18754075 - HYPH O O
27 163 166 18754075 old JJ B-NP O
28 167 175 18754075 Japanese JJ I-NP O
29 176 179 18754075 man NN I-NP O
30 180 184 18754075 with IN B-PP O
31 185 194 18754075 nephrotic JJ B-NP B-Disease
32 195 203 18754075 syndrome NN I-NP I-Disease
33 204 207 18754075 due JJ B-PP O
34 208 210 18754075 to TO B-PP O
35 211 216 18754075 focal JJ B-NP B-Disease
36 217 226 18754075 segmental JJ I-NP I-Disease
37 227 245 18754075 glomerulosclerosis NN I-NP I-Disease
38 246 249 18754075 was VBD B-VP O
39 250 259 18754075 initially RB I-VP O
40 260 270 18754075 responding VBG I-VP O
41 271 275 18754075 well RB B-ADVP O
42 276 278 18754075 to TO B-PP O
43 279 286 18754075 steroid NN B-NP B-Chemical
44 287 294 18754075 therapy NN I-NP O
45 294 295 18754075 . . O O

1 296 299 18754075 The DT B-NP O
2 300 306 18754075 amount NN I-NP O
3 307 309 18754075 of IN B-PP O
4 310 315 18754075 daily JJ B-NP O
5 316 323 18754075 urinary JJ I-NP O
6 324 331 18754075 protein NN I-NP O
7 332 341 18754075 decreased VBD B-VP O
8 342 346 18754075 from IN B-PP O
9 347 351 18754075 15.6 CD B-NP O
10 352 354 18754075 to TO I-NP O
11 355 358 18754075 2.8 CD I-NP O
12 359 360 18754075 g NN I-NP O
13 360 361 18754075 . . O O

1 362 368 18754075 Within IN B-PP O
2 369 371 18754075 14 CD B-NP O
3 372 376 18754075 days NNS I-NP O
4 377 379 18754075 of IN B-PP O
5 380 383 18754075 the DT B-NP O
6 384 388 18754075 oral JJ I-NP O
7 389 403 18754075 bisphosphonate NN I-NP B-Chemical
8 404 405 18754075 ( ( O O
9 405 416 18754075 alendronate NN B-NP B-Chemical
10 417 423 18754075 sodium NN I-NP I-Chemical
11 423 424 18754075 ) ) O O
12 425 439 18754075 administration NN B-NP O
13 439 440 18754075 , , O O
14 441 444 18754075 the DT B-NP O
15 445 451 18754075 amount NN I-NP O
16 452 454 18754075 of IN B-PP O
17 455 460 18754075 daily JJ B-NP O
18 461 468 18754075 urinary JJ I-NP O
19 469 476 18754075 protein NN I-NP O
20 477 486 18754075 increased VBD B-VP O
21 487 494 18754075 rapidly RB B-ADVP O
22 495 497 18754075 up IN B-NP O
23 498 500 18754075 to TO I-NP O
24 501 505 18754075 12.8 CD I-NP O
25 506 507 18754075 g NN I-NP O
26 508 512 18754075 with IN B-PP O
27 513 518 18754075 acute JJ B-NP B-Disease
28 519 524 18754075 renal JJ I-NP I-Disease
29 525 532 18754075 failure NN I-NP I-Disease
30 532 533 18754075 . . O O

1 534 539 18754075 After IN B-PP O
2 540 553 18754075 discontinuing VBG B-VP O
3 554 557 18754075 the DT B-NP O
4 558 562 18754075 oral JJ I-NP O
5 563 574 18754075 alendronate NN I-NP B-Chemical
6 574 575 18754075 , , O O
7 576 579 18754075 the DT B-NP O
8 580 587 18754075 patient NN I-NP O
9 588 597 18754075 underwent VBD B-VP O
10 598 601 18754075 six CD B-NP O
11 602 608 18754075 cycles NNS I-NP O
12 609 611 18754075 of IN B-PP O
13 612 624 18754075 hemodialysis NN B-NP O
14 625 628 18754075 and CC O O
15 629 633 18754075 four CD B-NP O
16 634 640 18754075 cycles NNS I-NP O
17 641 643 18754075 of IN B-PP O
18 644 647 18754075 LDL NN B-NP O
19 648 657 18754075 apheresis NN I-NP O
20 657 658 18754075 . . O O

1 659 666 18754075 Urinary JJ B-NP O
2 667 673 18754075 volume NN I-NP O
3 674 677 18754075 and CC I-NP O
4 678 683 18754075 serum NN I-NP O
5 684 694 18754075 creatinine NN I-NP B-Chemical
6 695 701 18754075 levels NNS I-NP O
7 702 711 18754075 recovered VBD B-VP O
8 712 714 18754075 to TO B-PP O
9 715 718 18754075 the DT B-NP O
10 719 725 18754075 normal JJ I-NP O
11 726 731 18754075 range NN I-NP O
12 731 732 18754075 , , O O
13 733 737 18754075 with IN B-PP O
14 738 745 18754075 urinary JJ B-NP O
15 746 753 18754075 protein NN I-NP O
16 754 766 18754075 disappearing VBG B-VP O
17 767 777 18754075 completely RB B-ADVP O
18 778 784 18754075 within IN B-PP O
19 785 787 18754075 40 CD B-NP O
20 788 792 18754075 days NNS I-NP O
21 792 793 18754075 . . O O

1 794 798 18754075 This DT B-NP O
2 799 805 18754075 report NN I-NP O
3 806 818 18754075 demonstrates VBZ B-VP O
4 819 823 18754075 that IN B-SBAR O
5 824 827 18754075 not RB B-CONJP O
6 828 832 18754075 only RB I-CONJP O
7 833 844 18754075 intravenous JJ B-ADJP O
8 844 845 18754075 , , O O
9 846 849 18754075 but CC B-CONJP O
10 850 854 18754075 also RB I-CONJP O
11 855 859 18754075 oral JJ B-NP O
12 860 875 18754075 bisphosphonates NNS I-NP B-Chemical
13 876 879 18754075 can MD B-VP O
14 880 889 18754075 aggravate VB I-VP O
15 890 901 18754075 proteinuria NN B-NP B-Disease
16 902 905 18754075 and CC O O
17 906 911 18754075 acute JJ B-NP B-Disease
18 912 917 18754075 renal JJ I-NP I-Disease
19 918 925 18754075 failure NN I-NP I-Disease
20 925 926 18754075 . . O O

1 0 0 7582165 -DOCSTART- -X- -X- O

1 0 6 7582165 Pseudo AFX B-NP O
2 6 7 7582165 - HYPH I-NP O
3 7 15 7582165 allergic JJ B-NP B-Disease
4 16 25 7582165 reactions NNS I-NP I-Disease
5 26 28 7582165 to TO B-PP O
6 29 44 7582165 corticosteroids NNS B-NP B-Chemical
7 44 45 7582165 : : O O
8 46 55 7582165 diagnosis NN B-NP O
9 56 59 7582165 and CC I-NP O
10 60 72 7582165 alternatives NNS I-NP O
11 72 73 7582165 . . O O
12 74 77 7582165 Two CD B-NP O
13 78 86 7582165 patients NNS I-NP O
14 87 94 7582165 treated VBN B-VP O
15 95 99 7582165 with IN B-PP O
16 100 110 7582165 parenteral JJ B-NP O
17 111 124 7582165 paramethasone NN I-NP B-Chemical
18 125 126 7582165 ( ( O O
19 126 133 7582165 Triniol NN B-NP O
20 133 134 7582165 ) ) O O
21 135 138 7582165 and CC O O
22 139 152 7582165 dexamethasone NN B-NP B-Chemical
23 153 154 7582165 ( ( O O
24 154 163 7582165 Sedionbel NN B-NP O
25 163 164 7582165 ) ) O O
26 165 168 7582165 are VBP B-VP O
27 169 178 7582165 described VBN I-VP O
28 178 179 7582165 . . O O

1 180 181 7582165 A DT B-NP O
2 182 185 7582165 few JJ I-NP O
3 186 193 7582165 minutes NNS I-NP O
4 194 199 7582165 after IN B-PP O
5 200 214 7582165 administration NN B-NP O
6 215 217 7582165 of IN B-PP O
7 218 221 7582165 the DT B-NP O
8 222 227 7582165 drugs NNS I-NP O
9 227 228 7582165 , , O O
10 229 233 7582165 they PRP B-NP O
11 234 243 7582165 presented VBD B-VP O
12 244 253 7582165 urticaria NN B-NP B-Disease
13 254 255 7582165 ( ( O O
14 255 263 7582165 patients NNS B-NP O
15 264 265 7582165 1 CD O O
16 266 269 7582165 and CC O O
17 270 271 7582165 2 CD O O
18 271 272 7582165 ) ) O O
19 273 276 7582165 and CC O O
20 277 291 7582165 conjunctivitis NN B-NP B-Disease
21 292 293 7582165 ( ( O O
22 293 300 7582165 patient NN B-NP O
23 301 302 7582165 1 CD I-NP O
24 302 303 7582165 ) ) O O
25 303 304 7582165 . . O O

1 305 308 7582165 The DT B-NP O
2 309 316 7582165 purpose NN I-NP O
3 317 319 7582165 of IN B-PP O
4 320 323 7582165 our PRP$ B-NP O
5 324 329 7582165 study NN I-NP O
6 330 333 7582165 was VBD B-VP O
7 334 336 7582165 to TO B-VP O
8 337 346 7582165 determine VB I-VP O
9 347 350 7582165 the DT B-NP O
10 351 356 7582165 cause NN I-NP O
11 357 359 7582165 of IN B-PP O
12 360 363 7582165 the DT B-NP O
13 364 372 7582165 patients NNS I-NP O
14 372 373 7582165 ' POS B-NP O
15 374 383 7582165 reactions NNS I-NP O
16 383 384 7582165 , , O O
17 385 388 7582165 the DT B-NP O
18 389 402 7582165 immunological JJ I-NP O
19 403 413 7582165 mechanisms NNS I-NP O
20 414 422 7582165 involved VBN B-VP O
21 423 426 7582165 and CC O O
22 427 434 7582165 whether IN B-SBAR O
23 435 440 7582165 these DT B-NP O
24 441 449 7582165 patients NNS I-NP O
25 450 455 7582165 would MD B-VP O
26 456 458 7582165 be VB I-VP O
27 459 463 7582165 able JJ B-ADJP O
28 464 466 7582165 to TO B-VP O
29 467 475 7582165 tolerate VB I-VP O
30 476 479 7582165 any DT B-NP O
31 480 484 7582165 kind NN I-NP O
32 485 487 7582165 of IN B-PP O
33 488 497 7582165 corticoid NN B-NP O
34 497 498 7582165 . . O O

1 499 507 7582165 Clinical JJ B-NP O
2 508 520 7582165 examinations NNS I-NP O
3 521 524 7582165 and CC I-NP O
4 525 529 7582165 skin NN I-NP O
5 529 530 7582165 , , O O
6 531 535 7582165 oral JJ B-NP O
7 536 539 7582165 and CC I-NP O
8 540 550 7582165 parenteral JJ I-NP O
9 551 561 7582165 challenges NNS I-NP O
10 562 566 7582165 with IN B-PP O
11 567 576 7582165 different JJ B-NP O
12 577 592 7582165 corticosteroids NNS I-NP B-Chemical
13 593 596 7582165 and CC O O
14 597 602 7582165 ELISA NN B-NP O
15 603 608 7582165 tests NNS I-NP O
16 609 613 7582165 were VBD B-VP O
17 614 623 7582165 performed VBN I-VP O
18 623 624 7582165 . . O O

1 625 627 7582165 In IN B-PP O
2 628 631 7582165 the DT B-NP O
3 632 635 7582165 two CD I-NP O
4 636 644 7582165 patients NNS I-NP O
5 644 645 7582165 , , O O
6 646 650 7582165 skin NN B-NP O
7 651 654 7582165 and CC I-NP O
8 655 660 7582165 ELISA NN I-NP O
9 661 666 7582165 tests NNS I-NP O
10 667 671 7582165 with IN B-PP O
11 672 685 7582165 paramethasone NN B-NP B-Chemical
12 686 690 7582165 were VBD B-VP O
13 691 699 7582165 negative JJ B-ADJP O
14 699 700 7582165 , , O O
15 701 703 7582165 as IN B-SBAR O
16 704 707 7582165 was VBD B-VP O
17 708 711 7582165 the DT B-NP O
18 712 717 7582165 prick NN I-NP O
19 718 722 7582165 test NN I-NP O
20 723 727 7582165 with IN B-PP O
21 728 732 7582165 each DT B-NP O
22 733 735 7582165 of IN B-PP O
23 736 739 7582165 its PRP$ B-NP O
24 740 750 7582165 excipients NNS I-NP O
25 750 751 7582165 . . O O

1 752 753 7582165 A DT B-NP O
2 754 760 7582165 single JJ I-NP O
3 760 761 7582165 - HYPH I-NP O
4 761 766 7582165 blind JJ I-NP O
5 767 777 7582165 parenteral JJ I-NP O
6 778 787 7582165 challenge NN I-NP O
7 788 792 7582165 with IN B-PP O
8 793 800 7582165 Triniol NN B-NP O
9 801 804 7582165 was VBD B-VP O
10 805 813 7582165 positive JJ B-ADJP O
11 814 816 7582165 in IN B-PP O
12 817 821 7582165 both DT B-NP O
13 822 830 7582165 patients NNS I-NP O
14 831 836 7582165 after IN B-SBAR O
15 837 840 7582165 the DT B-NP O
16 841 855 7582165 administration NN I-NP O
17 856 858 7582165 of IN B-PP O
18 859 860 7582165 1 CD B-NP O
19 861 863 7582165 ml NN I-NP O
20 864 866 7582165 of IN B-PP O
21 867 870 7582165 the DT B-NP O
22 871 875 7582165 drug NN I-NP O
23 875 876 7582165 , , O O
24 877 880 7582165 and CC O O
25 881 889 7582165 negative JJ B-ADJP O
26 890 894 7582165 with IN B-PP O
27 895 898 7582165 its PRP$ B-NP O
28 899 909 7582165 excipients NNS I-NP O
29 909 910 7582165 . . O O

1 911 913 7582165 We PRP B-NP O
2 914 918 7582165 also RB B-ADVP O
3 919 926 7582165 carried VBD B-VP O
4 927 930 7582165 out RP B-PRT O
5 931 935 7582165 oral JJ B-NP O
6 936 939 7582165 and CC I-NP O
7 940 950 7582165 parenteral JJ I-NP O
8 951 961 7582165 challenges NNS I-NP O
9 962 966 7582165 with IN B-PP O
10 967 972 7582165 other JJ B-NP O
11 973 988 7582165 corticosteroids NNS I-NP B-Chemical
12 989 992 7582165 and CC O O
13 993 998 7582165 found VBN B-VP O
14 999 1010 7582165 intolerance NN B-NP O
15 1011 1013 7582165 to TO B-PP O
16 1014 1018 7582165 some DT B-NP O
17 1019 1021 7582165 of IN B-PP O
18 1022 1026 7582165 them PRP B-NP O
19 1026 1027 7582165 . . O O

1 1028 1033 7582165 These DT B-NP O
2 1034 1041 7582165 results NNS I-NP O
3 1042 1049 7582165 suggest VBP B-VP O
4 1050 1054 7582165 that IN B-SBAR O
5 1055 1068 7582165 paramethasone NN B-NP B-Chemical
6 1069 1075 7582165 caused VBD B-VP O
7 1076 1090 7582165 pseudoallergic JJ B-NP O
8 1091 1100 7582165 reactions NNS I-NP O
9 1101 1103 7582165 in IN B-PP O
10 1104 1107 7582165 our PRP$ B-NP O
11 1108 1116 7582165 patients NNS I-NP O
12 1116 1117 7582165 . . O O

1 1118 1133 7582165 Corticosteroids NNS B-NP O
2 1134 1143 7582165 different JJ B-ADJP O
3 1144 1148 7582165 from IN B-PP O
4 1149 1162 7582165 paramethasone NN B-NP B-Chemical
5 1163 1167 7582165 also RB B-ADVP O
6 1168 1176 7582165 produced VBD B-VP O
7 1177 1193 7582165 hypersensitivity NN B-NP B-Disease
8 1194 1203 7582165 reactions NNS I-NP O
9 1204 1206 7582165 in IN B-PP O
10 1207 1212 7582165 these DT B-NP O
11 1213 1221 7582165 patients NNS I-NP O
12 1221 1222 7582165 ; : O O
13 1223 1230 7582165 however RB B-ADVP O
14 1230 1231 7582165 , , O O
15 1232 1233 7582165 a DT B-NP O
16 1234 1237 7582165 few JJ I-NP O
17 1238 1240 7582165 of IN B-PP O
18 1241 1245 7582165 them PRP B-NP O
19 1246 1250 7582165 were VBD B-VP O
20 1251 1260 7582165 tolerated VBN I-VP O
21 1260 1261 7582165 . . O O

1 1262 1265 7582165 The DT B-NP O
2 1266 1271 7582165 basic JJ I-NP O
3 1272 1282 7582165 mechanisms NNS I-NP O
4 1283 1285 7582165 of IN B-PP O
5 1286 1291 7582165 those DT B-NP O
6 1292 1301 7582165 reactions NNS I-NP O
7 1302 1305 7582165 are VBP B-VP O
8 1306 1309 7582165 not RB O O
9 1310 1313 7582165 yet RB B-ADVP O
10 1314 1319 7582165 fully RB B-ADJP O
11 1320 1330 7582165 understood VBN I-ADJP O
12 1330 1331 7582165 . . O O

1 1332 1334 7582165 To TO B-PP O
2 1335 1338 7582165 our PRP$ B-NP O
3 1339 1348 7582165 knowledge NN I-NP O
4 1348 1349 7582165 , , O O
5 1350 1354 7582165 this DT B-NP O
6 1355 1357 7582165 is VBZ B-VP O
7 1358 1361 7582165 the DT B-NP O
8 1362 1367 7582165 first JJ I-NP O
9 1368 1374 7582165 report NN I-NP O
10 1375 1377 7582165 of IN B-PP O
11 1378 1379 7582165 a DT B-NP O
12 1380 1386 7582165 pseudo AFX I-NP O
13 1386 1387 7582165 - HYPH I-NP O
14 1387 1394 7582165 allergy NN I-NP B-Disease
15 1395 1401 7582165 caused VBN B-VP O
16 1402 1404 7582165 by IN B-PP O
17 1405 1418 7582165 paramethasone NN B-NP B-Chemical
18 1418 1419 7582165 . . O O

1 0 0 20588063 -DOCSTART- -X- -X- O

1 0 12 20588063 Permeability NN B-NP O
2 12 13 20588063 , , O O
3 14 29 20588063 ultrastructural JJ B-NP O
4 30 37 20588063 changes NNS I-NP O
5 37 38 20588063 , , O O
6 39 42 20588063 and CC O O
7 43 55 20588063 distribution NN B-NP O
8 56 58 20588063 of IN B-PP O
9 59 64 20588063 novel JJ B-NP O
10 65 73 20588063 proteins NNS I-NP O
11 74 76 20588063 in IN B-PP O
12 77 80 20588063 the DT B-NP O
13 81 91 20588063 glomerular JJ I-NP O
14 92 99 20588063 barrier NN I-NP O
15 100 102 20588063 in IN B-PP O
16 103 108 20588063 early JJ B-NP O
17 109 118 20588063 puromycin NN I-NP B-Chemical
18 119 134 20588063 aminonucleoside NN I-NP I-Chemical
19 135 144 20588063 nephrosis NN I-NP B-Disease
20 144 145 20588063 . SYM I-NP O
21 146 156 20588063 BACKGROUND NN I-NP O
22 156 157 20588063 / SYM B-NP O
23 157 161 20588063 AIMS NNS I-NP O
24 161 162 20588063 : : O O
25 163 165 20588063 It PRP B-NP O
26 166 168 20588063 is VBZ B-VP O
27 169 174 20588063 still RB B-ADVP O
28 175 182 20588063 unclear JJ B-ADJP O
29 183 187 20588063 what WP B-NP O
30 188 195 20588063 happens VBZ B-VP O
31 196 198 20588063 in IN B-PP O
32 199 202 20588063 the DT B-NP O
33 203 213 20588063 glomerulus NN I-NP O
34 214 218 20588063 when WRB B-ADVP O
35 219 230 20588063 proteinuria NN B-NP B-Disease
36 231 237 20588063 starts VBZ B-VP O
37 237 238 20588063 . . O O

1 239 244 20588063 Using VBG B-VP O
2 245 254 20588063 puromycin NN B-NP B-Chemical
3 255 270 20588063 aminonucleoside NN I-NP I-Chemical
4 271 280 20588063 nephrosis NN I-NP B-Disease
5 281 282 20588063 ( ( O O
6 282 285 20588063 PAN NN B-NP O
7 285 286 20588063 ) ) O O
8 287 291 20588063 rats NNS B-NP O
9 291 292 20588063 , , O O
10 293 295 20588063 we PRP B-NP O
11 296 303 20588063 studied VBD B-VP O
12 304 309 20588063 early RB B-NP O
13 310 325 20588063 ultrastructural JJ I-NP O
14 326 329 20588063 and CC I-NP O
15 330 342 20588063 permeability NN I-NP O
16 343 350 20588063 changes NNS I-NP O
17 351 353 20588063 in IN B-PP O
18 354 362 20588063 relation NN B-NP O
19 363 365 20588063 to TO B-PP O
20 366 369 20588063 the DT B-NP O
21 370 380 20588063 expression NN I-NP O
22 381 383 20588063 of IN B-PP O
23 384 387 20588063 the DT B-NP O
24 388 396 20588063 podocyte NN I-NP O
25 396 397 20588063 - HYPH B-NP O
26 397 407 20588063 associated VBN I-NP O
27 408 417 20588063 molecules NNS I-NP O
28 418 425 20588063 nephrin NN I-NP O
29 425 426 20588063 , , O O
30 427 428 20588063 a DT B-NP O
31 428 429 20588063 - HYPH I-NP O
32 429 436 20588063 actinin NN I-NP O
33 436 437 20588063 , , O O
34 438 445 20588063 dendrin NN B-NP O
35 445 446 20588063 , , O O
36 447 450 20588063 and CC O O
37 451 458 20588063 plekhh2 NN B-NP O
38 458 459 20588063 , , O O
39 460 463 20588063 the DT B-NP O
40 464 468 20588063 last JJ I-NP O
41 469 472 20588063 two CD I-NP O
42 473 475 20588063 of IN B-PP O
43 476 481 20588063 which WDT B-NP O
44 482 486 20588063 were VBD B-VP O
45 487 491 20588063 only RB B-VP O
46 492 500 20588063 recently RB I-VP O
47 501 511 20588063 discovered VBN I-VP O
48 512 514 20588063 in IN B-PP O
49 515 524 20588063 podocytes NNS B-NP O
50 524 525 20588063 . . O O

1 526 533 20588063 METHODS NNS B-NP O
2 533 534 20588063 : : O O
3 535 540 20588063 Using VBG B-VP O
4 541 547 20588063 immune JJ B-NP O
5 548 557 20588063 stainings NNS I-NP O
6 557 558 20588063 , , O O
7 559 575 20588063 semiquantitative JJ B-NP O
8 576 587 20588063 measurement NN I-NP O
9 588 591 20588063 was VBD B-VP O
10 592 601 20588063 performed VBN I-VP O
11 602 607 20588063 under IN B-PP O
12 608 611 20588063 the DT B-NP O
13 612 620 20588063 electron NN I-NP O
14 621 631 20588063 microscope NN I-NP O
15 631 632 20588063 . . O O

1 633 645 20588063 Permeability NN B-NP O
2 646 649 20588063 was VBD B-VP O
3 650 658 20588063 assessed VBN I-VP O
4 659 664 20588063 using VBG B-VP O
5 665 673 20588063 isolated VBN B-NP O
6 674 680 20588063 kidney NN I-NP O
7 681 690 20588063 perfusion NN I-NP O
8 691 695 20588063 with IN B-PP O
9 696 703 20588063 tracers NNS B-NP O
10 703 704 20588063 . . O O

1 705 713 20588063 Possible JJ B-NP O
2 714 721 20588063 effects NNS I-NP O
3 722 724 20588063 of IN B-PP O
4 725 728 20588063 ACE NN B-NP O
5 729 739 20588063 inhibition NN I-NP O
6 740 744 20588063 were VBD B-VP O
7 745 751 20588063 tested VBN I-VP O
8 751 752 20588063 . . O O

1 753 760 20588063 RESULTS NNS B-NP O
2 760 761 20588063 : : O O
3 762 764 20588063 By IN B-PP O
4 765 768 20588063 day NN B-NP O
5 769 770 20588063 2 CD I-NP O
6 770 771 20588063 , , O O
7 772 776 20588063 some DT B-NP O
8 777 783 20588063 patchy JJ I-NP O
9 784 788 20588063 foot NN I-NP O
10 789 796 20588063 process NN I-NP O
11 797 807 20588063 effacement NN I-NP O
12 807 808 20588063 , , O O
13 809 812 20588063 but CC O O
14 813 815 20588063 no DT B-NP O
15 816 827 20588063 proteinuria NN I-NP B-Disease
16 827 828 20588063 , , O O
17 829 837 20588063 appeared VBD B-VP O
18 837 838 20588063 . . O O

1 839 842 20588063 The DT B-NP O
2 843 849 20588063 amount NN I-NP O
3 850 852 20588063 of IN B-PP O
4 853 860 20588063 nephrin NN B-NP O
5 861 864 20588063 was VBD B-VP O
6 865 872 20588063 reduced VBN I-VP O
7 873 875 20588063 in IN B-PP O
8 876 880 20588063 both CC B-NP O
9 881 889 20588063 diseased JJ I-NP O
10 890 893 20588063 and CC I-NP O
11 894 900 20588063 normal JJ I-NP O
12 901 906 20588063 areas NNS I-NP O
13 906 907 20588063 . . O O

1 908 911 20588063 The DT B-NP O
2 912 917 20588063 other JJ I-NP O
3 918 926 20588063 proteins NNS I-NP O
4 927 933 20588063 showed VBD B-VP O
5 934 937 20588063 few JJ B-NP O
6 938 945 20588063 changes NNS I-NP O
7 945 946 20588063 , , O O
8 947 952 20588063 which WDT B-NP O
9 953 957 20588063 were VBD B-VP O
10 958 965 20588063 limited VBN I-VP O
11 966 968 20588063 to TO B-PP O
12 969 977 20588063 diseased JJ B-NP O
13 978 983 20588063 areas NNS I-NP O
14 983 984 20588063 . . O O

1 985 987 20588063 By IN B-PP O
2 988 991 20588063 day NN B-NP O
3 992 993 20588063 4 CD I-NP O
4 993 994 20588063 , , O O
5 995 999 20588063 foot NN B-NP O
6 1000 1007 20588063 process NN I-NP O
7 1008 1018 20588063 effacement NN I-NP O
8 1019 1022 20588063 was VBD B-VP O
9 1023 1031 20588063 complete JJ B-ADJP O
10 1032 1035 20588063 and CC O O
11 1036 1047 20588063 proteinuria NN B-NP B-Disease
12 1048 1056 20588063 appeared VBD B-VP O
13 1057 1059 20588063 in IN B-PP O
14 1060 1068 20588063 parallel NN B-NP O
15 1069 1073 20588063 with IN B-PP O
16 1074 1079 20588063 signs NNS B-NP O
17 1080 1082 20588063 of IN B-PP O
18 1083 1087 20588063 size NN B-NP O
19 1088 1095 20588063 barrier NN I-NP O
20 1096 1102 20588063 damage NN I-NP O
21 1102 1103 20588063 . . O O

1 1104 1111 20588063 Nephrin NN B-NP O
2 1112 1121 20588063 decreased VBD B-VP O
3 1122 1129 20588063 further RBR B-ADVP O
4 1129 1130 20588063 , , O O
5 1131 1136 20588063 while IN B-SBAR O
6 1137 1144 20588063 dendrin NN B-NP O
7 1145 1148 20588063 and CC I-NP O
8 1149 1156 20588063 plekhh2 NN I-NP O
9 1157 1161 20588063 also RB B-ADVP O
10 1162 1171 20588063 decreased VBD B-VP O
11 1172 1175 20588063 but CC O O
12 1176 1177 20588063 a DT O O
13 1177 1178 20588063 - : O O
14 1178 1185 20588063 actinin NN B-NP O
15 1186 1194 20588063 remained VBD B-VP O
16 1195 1204 20588063 unchanged JJ B-ADJP O
17 1204 1205 20588063 . . O O

1 1206 1209 20588063 ACE NN B-NP O
2 1210 1220 20588063 inhibition NN I-NP O
3 1221 1224 20588063 had VBD B-VP O
4 1225 1227 20588063 no DT B-NP O
5 1228 1239 20588063 significant JJ I-NP O
6 1240 1250 20588063 protective JJ I-NP O
7 1251 1257 20588063 effect NN I-NP O
8 1257 1258 20588063 . . O O

1 1259 1270 20588063 CONCLUSIONS NNS B-NP O
2 1270 1271 20588063 : : O O
3 1272 1275 20588063 PAN NN B-NP O
4 1276 1285 20588063 glomeruli NNS I-NP O
5 1286 1293 20588063 already RB B-ADVP O
6 1294 1300 20588063 showed VBD B-VP O
7 1301 1312 20588063 significant JJ B-NP O
8 1313 1322 20588063 pathology NN I-NP O
9 1323 1325 20588063 by IN B-PP O
10 1326 1329 20588063 day NN B-NP O
11 1330 1331 20588063 4 CD I-NP O
12 1331 1332 20588063 , , O O
13 1333 1340 20588063 despite IN B-PP O
14 1341 1351 20588063 relatively RB B-NP O
15 1352 1356 20588063 mild JJ I-NP O
16 1357 1368 20588063 proteinuria NN I-NP B-Disease
17 1368 1369 20588063 . . O O

1 1370 1374 20588063 This DT B-NP O
2 1375 1378 20588063 was VBD B-VP O
3 1379 1387 20588063 preceded VBN I-VP O
4 1388 1390 20588063 by IN B-PP O
5 1391 1398 20588063 altered VBN B-NP O
6 1399 1406 20588063 nephrin NN I-NP O
7 1407 1417 20588063 expression NN I-NP O
8 1417 1418 20588063 , , O O
9 1419 1429 20588063 supporting VBG B-VP O
10 1430 1433 20588063 its PRP$ B-NP O
11 1434 1441 20588063 pivotal JJ I-NP O
12 1442 1446 20588063 role NN I-NP O
13 1447 1449 20588063 in IN B-PP O
14 1450 1458 20588063 podocyte NN B-NP O
15 1459 1469 20588063 morphology NN I-NP O
16 1469 1470 20588063 . . O O

1 1471 1474 20588063 The DT B-NP O
2 1475 1480 20588063 novel JJ I-NP O
3 1481 1489 20588063 proteins NNS I-NP O
4 1490 1497 20588063 dendrin NN I-NP O
5 1498 1501 20588063 and CC I-NP O
6 1502 1509 20588063 plekhh2 NN I-NP O
7 1510 1514 20588063 were VBD B-VP O
8 1515 1519 20588063 both DT O O
9 1520 1527 20588063 reduced VBN B-VP O
10 1527 1528 20588063 , , O O
11 1529 1539 20588063 suggesting VBG B-VP O
12 1540 1545 20588063 roles NNS B-NP O
13 1546 1548 20588063 in IN B-PP O
14 1549 1552 20588063 PAN NN B-NP O
15 1552 1553 20588063 , , O O
16 1554 1561 20588063 whereas IN O O
17 1562 1563 20588063 a DT B-NP O
18 1563 1564 20588063 - HYPH I-NP O
19 1564 1571 20588063 actinin NN I-NP O
20 1572 1575 20588063 was VBD B-VP O
21 1576 1585 20588063 unchanged JJ B-ADJP O
22 1585 1586 20588063 . . O O

1 0 0 15036754 -DOCSTART- -X- -X- O

1 0 15 15036754 Organophosphate NN B-NP B-Chemical
2 15 16 15036754 - HYPH B-NP O
3 16 23 15036754 induced VBN I-NP O
4 24 35 15036754 convulsions NNS I-NP B-Disease
5 36 39 15036754 and CC I-NP O
6 40 50 15036754 prevention NN I-NP O
7 51 53 15036754 of IN B-PP O
8 54 71 15036754 neuropathological JJ B-NP B-Disease
9 72 79 15036754 damages NNS I-NP I-Disease
10 79 80 15036754 . . O O
11 81 85 15036754 Such JJ B-NP O
12 86 102 15036754 organophosphorus NN I-NP B-Chemical
13 103 104 15036754 ( ( O O
14 104 106 15036754 OP NN B-NP B-Chemical
15 106 107 15036754 ) ) O O
16 108 117 15036754 compounds NNS B-NP O
17 118 120 15036754 as IN B-PP O
18 121 147 15036754 diisopropylfluorophosphate NN B-NP B-Chemical
19 148 149 15036754 ( ( O O
20 149 152 15036754 DFP NN B-NP B-Chemical
21 152 153 15036754 ) ) O O
22 153 154 15036754 , , O O
23 155 160 15036754 sarin NN B-NP B-Chemical
24 161 164 15036754 and CC I-NP O
25 165 170 15036754 soman NN I-NP B-Chemical
26 171 174 15036754 are VBP B-VP O
27 175 181 15036754 potent JJ B-NP O
28 182 192 15036754 inhibitors NNS I-NP O
29 193 195 15036754 of IN B-PP O
30 196 217 15036754 acetylcholinesterases NNS B-NP O
31 218 219 15036754 ( ( O O
32 219 224 15036754 AChEs NNS B-NP O
33 224 225 15036754 ) ) O O
34 226 229 15036754 and CC O O
35 230 252 15036754 butyrylcholinesterases NNS B-NP O
36 253 254 15036754 ( ( O O
37 254 259 15036754 BChEs NNS B-NP O
38 259 260 15036754 ) ) O O
39 260 261 15036754 . . O O

1 262 265 15036754 The DT B-NP O
2 266 271 15036754 acute JJ I-NP O
3 272 280 15036754 toxicity NN I-NP B-Disease
4 281 283 15036754 of IN B-PP O
5 284 287 15036754 OPs NNS B-NP B-Chemical
6 288 290 15036754 is VBZ B-VP O
7 291 294 15036754 the DT B-NP O
8 295 301 15036754 result NN I-NP O
9 302 304 15036754 of IN B-PP O
10 305 310 15036754 their PRP$ B-NP O
11 311 323 15036754 irreversible JJ I-NP O
12 324 331 15036754 binding NN I-NP O
13 332 336 15036754 with IN B-PP O
14 337 342 15036754 AChEs NNS B-NP O
15 343 345 15036754 in IN B-PP O
16 346 349 15036754 the DT B-NP O
17 350 357 15036754 central JJ I-NP O
18 358 365 15036754 nervous JJ I-NP O
19 366 372 15036754 system NN I-NP O
20 373 374 15036754 ( ( O O
21 374 377 15036754 CNS NN B-NP O
22 377 378 15036754 ) ) O O
23 378 379 15036754 , , O O
24 380 385 15036754 which WDT B-NP O
25 386 394 15036754 elevates VBZ B-VP O
26 395 408 15036754 acetylcholine NN B-NP B-Chemical
27 409 410 15036754 ( ( O O
28 410 413 15036754 ACh NN B-NP B-Chemical
29 413 414 15036754 ) ) O O
30 415 421 15036754 levels NNS B-NP O
31 421 422 15036754 . . O O

1 423 426 15036754 The DT B-NP O
2 427 437 15036754 protective JJ I-NP O
3 438 444 15036754 action NN I-NP O
4 445 447 15036754 of IN B-PP O
5 448 462 15036754 subcutaneously RB B-NP O
6 463 464 15036754 ( ( O O
7 464 466 15036754 SC NN B-NP O
8 466 467 15036754 ) ) O O
9 468 480 15036754 administered VBN B-NP O
10 481 490 15036754 antidotes NNS I-NP O
11 491 493 15036754 or CC O O
12 494 499 15036754 their PRP$ B-NP O
13 500 512 15036754 combinations NNS I-NP O
14 513 515 15036754 in IN B-PP O
15 516 519 15036754 DFP NN B-NP B-Chemical
16 520 521 15036754 ( ( O O
17 521 524 15036754 2.0 CD B-NP O
18 525 527 15036754 mg NN I-NP O
19 527 528 15036754 / SYM B-NP O
20 528 530 15036754 kg NN I-NP O
21 531 533 15036754 BW NN I-NP O
22 533 534 15036754 ) ) O O
23 535 547 15036754 intoxication NN B-NP O
24 548 551 15036754 was VBD B-VP O
25 552 559 15036754 studied VBN I-VP O
26 560 562 15036754 in IN B-PP O
27 563 564 15036754 9 CD B-NP O
28 564 565 15036754 - HYPH B-NP O
29 565 567 15036754 10 CD I-NP O
30 567 568 15036754 - HYPH I-NP O
31 568 573 15036754 weeks NNS I-NP O
32 573 574 15036754 - HYPH O O
33 574 577 15036754 old JJ B-NP O
34 578 581 15036754 Han NNP I-NP O
35 581 582 15036754 - HYPH B-NP O
36 582 588 15036754 Wistar NNP I-NP O
37 589 593 15036754 male JJ I-NP O
38 594 598 15036754 rats NNS I-NP O
39 598 599 15036754 . . O O

1 600 603 15036754 The DT B-NP O
2 604 608 15036754 rats NNS I-NP O
3 609 617 15036754 received VBD B-VP O
4 618 622 15036754 AChE NN B-NP O
5 623 634 15036754 reactivator NN I-NP O
6 635 646 15036754 pralidoxime NN I-NP B-Chemical
7 646 647 15036754 - HYPH B-NP I-Chemical
8 647 648 15036754 2 CD I-NP I-Chemical
9 648 649 15036754 - HYPH I-NP I-Chemical
10 649 657 15036754 chloride NN I-NP I-Chemical
11 658 659 15036754 ( ( O O
12 659 663 15036754 2PAM NN B-NP B-Chemical
13 663 664 15036754 ) ) O O
14 665 666 15036754 ( ( O O
15 666 670 15036754 30.0 CD B-NP O
16 671 673 15036754 mg NN I-NP O
17 673 674 15036754 / SYM B-NP O
18 674 676 15036754 kg NN I-NP O
19 677 679 15036754 BW NN I-NP O
20 679 680 15036754 ) ) O O
21 680 681 15036754 , , O O
22 682 696 15036754 anticonvulsant JJ B-NP O
23 697 705 15036754 diazepam NN I-NP B-Chemical
24 706 707 15036754 ( ( O O
25 707 710 15036754 2.0 CD B-NP O
26 711 713 15036754 mg NN I-NP O
27 713 714 15036754 / SYM B-NP O
28 714 716 15036754 kg NN I-NP O
29 717 719 15036754 BW NN I-NP O
30 719 720 15036754 ) ) O O
31 720 721 15036754 , , O O
32 722 726 15036754 A(1) NN B-NP O
33 726 727 15036754 - HYPH B-NP O
34 727 736 15036754 adenosine NN I-NP B-Chemical
35 737 745 15036754 receptor NN I-NP O
36 746 753 15036754 agonist NN I-NP O
37 754 758 15036754 N(6) NN I-NP B-Chemical
38 758 759 15036754 - HYPH B-NP I-Chemical
39 759 770 15036754 cyclopentyl NN I-NP I-Chemical
40 771 780 15036754 adenosine NN I-NP I-Chemical
41 781 782 15036754 ( ( O O
42 782 785 15036754 CPA NN B-NP B-Chemical
43 785 786 15036754 ) ) O O
44 787 788 15036754 ( ( O O
45 788 791 15036754 2.0 CD B-NP O
46 792 794 15036754 mg NN I-NP O
47 794 795 15036754 / SYM B-NP O
48 795 797 15036754 kg NN I-NP O
49 798 800 15036754 BW NN I-NP O
50 800 801 15036754 ) ) O O
51 801 802 15036754 , , O O
52 803 807 15036754 NMDA NN B-NP B-Chemical
53 807 808 15036754 - HYPH I-NP O
54 808 816 15036754 receptor NN I-NP O
55 817 827 15036754 antagonist NN I-NP O
56 828 839 15036754 dizocilpine NN I-NP B-Chemical
57 840 847 15036754 maleate NN I-NP I-Chemical
58 848 849 15036754 ( ( O O
59 849 850 15036754 + SYM B-NP O
60 850 851 15036754 - HYPH B-NP O
61 851 856 15036754 MK801 NN I-NP O
62 857 865 15036754 hydrogen NN I-NP O
63 866 873 15036754 maleate NN I-NP O
64 873 874 15036754 ) ) O O
65 875 876 15036754 ( ( O O
66 876 879 15036754 2.0 CD B-NP O
67 880 882 15036754 mg NN I-NP O
68 882 883 15036754 / SYM B-NP O
69 883 885 15036754 kg NN I-NP O
70 886 888 15036754 BW NN I-NP O
71 888 889 15036754 ) ) O O
72 890 892 15036754 or CC O O
73 893 898 15036754 their PRP$ B-NP O
74 899 911 15036754 combinations NNS I-NP O
75 912 916 15036754 with IN B-PP O
76 917 929 15036754 cholinolytic JJ B-NP O
77 930 934 15036754 drug NN I-NP O
78 935 943 15036754 atropine NN I-NP B-Chemical
79 944 951 15036754 sulfate NN I-NP I-Chemical
80 952 953 15036754 ( ( O O
81 953 957 15036754 50.0 CD B-NP O
82 958 960 15036754 mg NN I-NP O
83 960 961 15036754 / SYM B-NP O
84 961 963 15036754 kg NN I-NP O
85 964 966 15036754 BW NN I-NP O
86 966 967 15036754 ) ) O O
87 968 979 15036754 immediately RB B-ADVP O
88 980 982 15036754 or CC O O
89 983 985 15036754 30 CD B-NP O
90 986 989 15036754 min NN I-NP O
91 990 995 15036754 after IN B-PP O
92 996 999 15036754 the DT B-NP O
93 1000 1006 15036754 single JJ I-NP O
94 1007 1009 15036754 SC NN I-NP O
95 1010 1019 15036754 injection NN I-NP O
96 1020 1022 15036754 of IN B-PP O
97 1023 1026 15036754 DFP NN B-NP B-Chemical
98 1026 1027 15036754 . . O O

1 1028 1031 15036754 The DT B-NP O
2 1032 1039 15036754 control NN I-NP O
3 1040 1044 15036754 rats NNS I-NP O
4 1045 1053 15036754 received VBD B-VP O
5 1054 1062 15036754 atropine NN B-NP B-Chemical
6 1063 1070 15036754 sulfate NN I-NP I-Chemical
7 1070 1071 15036754 , , O O
8 1072 1075 15036754 but CC B-CONJP O
9 1076 1080 15036754 also RB I-CONJP O
10 1081 1087 15036754 saline NN B-NP O
11 1088 1091 15036754 and CC I-NP O
12 1092 1097 15036754 olive NN I-NP O
13 1098 1101 15036754 oil NN I-NP O
14 1102 1109 15036754 instead RB B-PP O
15 1110 1112 15036754 of IN I-PP O
16 1113 1118 15036754 other JJ B-NP O
17 1119 1128 15036754 antidotes NNS I-NP O
18 1129 1132 15036754 and CC O O
19 1133 1136 15036754 DFP NN B-NP B-Chemical
20 1136 1137 15036754 , , O O
21 1138 1150 15036754 respectively RB B-ADVP O
22 1150 1151 15036754 . . O O

1 1152 1155 15036754 All DT B-NP O
2 1156 1160 15036754 rats NNS I-NP O
3 1161 1165 15036754 were VBD B-VP O
4 1166 1176 15036754 terminated VBN I-VP O
5 1177 1183 15036754 either CC O O
6 1184 1186 15036754 24 CD B-NP O
7 1187 1188 15036754 h NN I-NP O
8 1189 1191 15036754 or CC O O
9 1192 1193 15036754 3 CD B-NP O
10 1194 1199 15036754 weeks NNS I-NP O
11 1200 1205 15036754 after IN B-PP O
12 1206 1209 15036754 the DT B-NP O
13 1210 1213 15036754 DFP NN I-NP B-Chemical
14 1214 1223 15036754 injection NN I-NP O
15 1223 1224 15036754 . . O O

1 1225 1228 15036754 The DT B-NP O
2 1229 1233 15036754 rats NNS I-NP O
3 1234 1241 15036754 treated VBN B-VP O
4 1242 1246 15036754 with IN B-PP O
5 1247 1250 15036754 DFP NN B-NP B-Chemical
6 1250 1251 15036754 - HYPH O O
7 1251 1259 15036754 atropine NN B-NP B-Chemical
8 1260 1266 15036754 showed VBD B-VP O
9 1267 1273 15036754 severe JJ B-NP O
10 1274 1281 15036754 typical JJ I-NP O
11 1282 1284 15036754 OP NN I-NP B-Chemical
12 1284 1285 15036754 - HYPH B-NP O
13 1285 1292 15036754 induced VBN I-NP O
14 1293 1301 15036754 toxicity NN I-NP B-Disease
15 1302 1307 15036754 signs NNS I-NP O
16 1307 1308 15036754 . . O O

1 1309 1313 15036754 When WRB B-ADVP O
2 1314 1317 15036754 CPA NN B-NP B-Chemical
3 1317 1318 15036754 , , I-NP O
4 1319 1327 15036754 diazepam NN I-NP B-Chemical
5 1328 1330 15036754 or CC I-NP O
6 1331 1335 15036754 2PAM NN I-NP B-Chemical
7 1336 1339 15036754 was VBD B-VP O
8 1340 1345 15036754 given VBN I-VP O
9 1346 1357 15036754 immediately RB B-ADVP O
10 1358 1363 15036754 after IN B-PP O
11 1364 1367 15036754 DFP NN B-NP B-Chemical
12 1367 1368 15036754 - HYPH B-NP O
13 1368 1376 15036754 atropine NN I-NP B-Chemical
14 1376 1377 15036754 , , O O
15 1378 1383 15036754 these DT B-NP O
16 1384 1394 15036754 treatments NNS I-NP O
17 1395 1404 15036754 prevented VBD B-VP O
18 1404 1405 15036754 , , O O
19 1406 1413 15036754 delayed VBD B-VP O
20 1414 1416 15036754 or CC I-VP O
21 1417 1426 15036754 shortened VBD I-VP O
22 1427 1430 15036754 the DT B-NP O
23 1431 1441 15036754 occurrence NN I-NP O
24 1442 1444 15036754 of IN B-PP O
25 1445 1452 15036754 serious JJ B-NP O
26 1453 1458 15036754 signs NNS I-NP O
27 1459 1461 15036754 of IN B-PP O
28 1462 1471 15036754 poisoning NN B-NP B-Disease
29 1471 1472 15036754 . . O O

1 1473 1481 15036754 Atropine NN B-NP B-Chemical
2 1481 1482 15036754 - HYPH O O
3 1482 1487 15036754 MK801 NN B-NP B-Chemical
4 1488 1491 15036754 did VBD B-VP O
5 1492 1495 15036754 not RB I-VP O
6 1496 1501 15036754 offer VB I-VP O
7 1502 1505 15036754 any DT B-NP O
8 1506 1516 15036754 additional JJ I-NP O
9 1517 1527 15036754 protection NN I-NP O
10 1528 1535 15036754 against IN B-PP O
11 1536 1539 15036754 DFP NN B-NP B-Chemical
12 1540 1548 15036754 toxicity NN I-NP B-Disease
13 1548 1549 15036754 . . O O

1 1550 1552 15036754 In IN B-PP O
2 1553 1563 15036754 conclusion NN B-NP O
3 1563 1564 15036754 , , O O
4 1565 1568 15036754 CPA NN B-NP B-Chemical
5 1568 1569 15036754 , , O O
6 1570 1578 15036754 diazepam NN B-NP B-Chemical
7 1579 1582 15036754 and CC I-NP O
8 1583 1587 15036754 2PAM NN I-NP B-Chemical
9 1588 1590 15036754 in IN B-PP O
10 1591 1602 15036754 combination NN B-NP O
11 1603 1607 15036754 with IN B-PP O
12 1608 1616 15036754 atropine NN B-NP B-Chemical
13 1617 1626 15036754 prevented VBD B-VP O
14 1627 1630 15036754 the DT B-NP O
15 1631 1641 15036754 occurrence NN I-NP O
16 1642 1644 15036754 of IN B-PP O
17 1645 1652 15036754 serious JJ B-NP O
18 1653 1658 15036754 signs NNS I-NP O
19 1659 1661 15036754 of IN B-PP O
20 1662 1671 15036754 poisoning NN B-NP B-Disease
21 1672 1675 15036754 and CC O O
22 1676 1680 15036754 thus RB B-VP O
23 1681 1688 15036754 reduced VBD I-VP O
24 1689 1692 15036754 the DT B-NP O
25 1693 1701 15036754 toxicity NN I-NP B-Disease
26 1702 1704 15036754 of IN B-PP O
27 1705 1708 15036754 DFP NN B-NP B-Chemical
28 1709 1711 15036754 in IN B-PP O
29 1712 1715 15036754 rat NN B-NP O
30 1715 1716 15036754 . . O O

1 0 0 6534871 -DOCSTART- -X- -X- O

1 0 7 6534871 Effects NNS B-NP O
2 8 10 6534871 of IN B-PP O
3 11 19 6534871 training NN B-NP O
4 20 22 6534871 on IN B-PP O
5 23 26 6534871 the DT B-NP O
6 27 33 6534871 extent NN I-NP O
7 34 36 6534871 of IN B-PP O
8 37 49 6534871 experimental JJ B-NP O
9 50 60 6534871 myocardial JJ I-NP B-Disease
10 61 71 6534871 infarction NN I-NP I-Disease
11 72 74 6534871 in IN B-PP O
12 75 80 6534871 aging VBG B-NP O
13 81 85 6534871 rats NNS I-NP O
14 85 86 6534871 . . O O
15 87 90 6534871 The DT B-NP O
16 91 98 6534871 effects NNS I-NP O
17 99 101 6534871 of IN B-PP O
18 102 110 6534871 exercise NN B-NP O
19 111 113 6534871 on IN B-PP O
20 114 117 6534871 the DT B-NP O
21 118 126 6534871 severity NN I-NP O
22 127 129 6534871 of IN B-PP O
23 130 143 6534871 isoproterenol NN B-NP B-Chemical
24 143 144 6534871 - HYPH B-NP O
25 144 151 6534871 induced VBN I-NP O
26 152 162 6534871 myocardial JJ I-NP B-Disease
27 163 173 6534871 infarction NN I-NP I-Disease
28 174 178 6534871 were VBD B-VP O
29 179 186 6534871 studied VBN I-VP O
30 187 189 6534871 in IN B-PP O
31 190 196 6534871 female JJ B-NP O
32 197 203 6534871 albino JJ I-NP O
33 204 208 6534871 rats NNS I-NP O
34 209 211 6534871 of IN B-PP O
35 212 220 6534871 20,40,60 CD B-NP O
36 221 224 6534871 and CC I-NP O
37 225 227 6534871 80 CD I-NP O
38 228 233 6534871 weeks NNS I-NP O
39 234 236 6534871 of IN B-PP O
40 237 240 6534871 age NN B-NP O
41 240 241 6534871 . . O O

1 242 245 6534871 The DT B-NP O
2 246 250 6534871 rats NNS I-NP O
3 251 255 6534871 were VBD B-VP O
4 256 263 6534871 trained VBN I-VP O
5 264 266 6534871 to TO I-VP O
6 267 271 6534871 swim VB I-VP O
7 272 275 6534871 for IN B-PP O
8 276 277 6534871 a DT B-NP O
9 278 286 6534871 specific JJ I-NP O
10 287 295 6534871 duration NN I-NP O
11 296 299 6534871 and CC B-PP O
12 300 303 6534871 for IN B-PP O
13 304 305 6534871 a DT B-NP O
14 306 316 6534871 particular JJ I-NP O
15 317 323 6534871 period NN I-NP O
16 323 324 6534871 . . O O

1 325 328 6534871 The DT B-NP O
2 329 339 6534871 occurrence NN I-NP O
3 340 342 6534871 of IN B-PP O
4 343 351 6534871 infarcts NNS B-NP B-Disease
5 352 356 6534871 were VBD B-VP O
6 357 366 6534871 confirmed VBN I-VP O
7 367 369 6534871 by IN B-PP O
8 370 382 6534871 histological JJ B-NP O
9 383 390 6534871 methods NNS I-NP O
10 390 391 6534871 . . O O

1 392 402 6534871 Elevations NNS B-NP O
2 403 405 6534871 in IN B-PP O
3 406 409 6534871 the DT B-NP O
4 410 415 6534871 serum NN I-NP O
5 416 419 6534871 GOT NN I-NP O
6 420 423 6534871 and CC I-NP O
7 424 427 6534871 GPT NN I-NP O
8 428 432 6534871 were VBD B-VP O
9 433 440 6534871 maximum JJ B-ADJP O
10 441 443 6534871 in IN B-PP O
11 444 447 6534871 the DT B-NP O
12 448 457 6534871 sedentary JJ I-NP O
13 457 458 6534871 - HYPH I-NP O
14 458 472 6534871 isoproterenols NNS I-NP B-Chemical
15 473 476 6534871 and CC I-NP O
16 477 484 6534871 minimum NN I-NP O
17 485 487 6534871 in IN B-PP O
18 488 491 6534871 the DT B-NP O
19 492 500 6534871 exercise NN I-NP O
20 500 501 6534871 - HYPH B-VP O
21 501 509 6534871 controls NNS B-NP O
22 509 510 6534871 . . O O

1 511 516 6534871 These DT B-NP O
2 517 524 6534871 changes NNS I-NP O
3 525 527 6534871 in IN B-PP O
4 528 531 6534871 the DT B-NP O
5 532 537 6534871 serum NN I-NP O
6 538 551 6534871 transaminases NNS I-NP O
7 552 556 6534871 were VBD B-VP O
8 557 567 6534871 associated VBN I-VP O
9 568 572 6534871 with IN B-PP O
10 573 586 6534871 corresponding VBG B-VP O
11 587 597 6534871 depletions NNS B-NP O
12 598 600 6534871 in IN B-PP O
13 601 604 6534871 the DT B-NP O
14 605 612 6534871 cardiac JJ I-NP O
15 613 616 6534871 GOT NN I-NP O
16 617 620 6534871 and CC I-NP O
17 621 624 6534871 GPT NN I-NP O
18 624 625 6534871 . . O O

1 626 633 6534871 However RB B-ADVP O
2 633 634 6534871 , , O O
3 635 638 6534871 age NN B-NP O
4 639 642 6534871 was VBD B-VP O
5 643 647 6534871 seen VBN I-VP O
6 648 650 6534871 to TO I-VP O
7 651 660 6534871 interfere VB I-VP O
8 661 665 6534871 with IN B-PP O
9 666 669 6534871 the DT B-NP O
10 670 679 6534871 responses NNS I-NP O
11 680 689 6534871 exhibited VBN B-VP O
12 690 692 6534871 by IN B-PP O
13 693 696 6534871 the DT B-NP O
14 697 702 6534871 young JJ I-NP O
15 703 706 6534871 and CC I-NP O
16 707 710 6534871 old JJ I-NP O
17 711 715 6534871 rats NNS I-NP O
18 715 716 6534871 . . O O

1 717 724 6534871 Studies NNS B-NP O
2 725 732 6534871 dealing VBG B-VP O
3 733 737 6534871 with IN B-PP O
4 738 748 6534871 myocardial JJ B-NP B-Disease
5 749 759 6534871 infarction NN I-NP I-Disease
6 760 763 6534871 are VBP B-VP O
7 764 768 6534871 more RBR B-ADJP O
8 769 780 6534871 informative JJ I-ADJP O
9 781 785 6534871 when WRB B-ADVP O
10 786 791 6534871 dealt NN B-NP O
11 792 796 6534871 with IN B-PP O
12 797 800 6534871 age NN B-NP O
13 800 801 6534871 . . O O

1 0 0 16680561 -DOCSTART- -X- -X- O

1 0 16 16680561 Pharmacokinetics NNS B-NP O
2 17 19 16680561 of IN B-PP O
3 20 31 16680561 desipramine NN B-NP B-Chemical
4 32 35 16680561 HCl NN I-NP I-Chemical
5 36 40 16680561 when WRB B-ADVP O
6 41 53 16680561 administered VBN B-VP O
7 54 58 16680561 with IN B-PP O
8 59 69 16680561 cinacalcet NN B-NP B-Chemical
9 70 73 16680561 HCl NN I-NP I-Chemical
10 73 74 16680561 . . O O
11 75 84 16680561 OBJECTIVE NN B-NP O
12 84 85 16680561 : : O O
13 86 88 16680561 In FW B-NP O
14 89 94 16680561 vitro FW I-NP O
15 95 99 16680561 work NN I-NP O
16 100 103 16680561 has VBZ B-VP O
17 104 116 16680561 demonstrated VBN I-VP O
18 117 121 16680561 that IN B-SBAR O
19 122 132 16680561 cinacalcet NN B-NP B-Chemical
20 133 135 16680561 is VBZ B-VP O
21 136 137 16680561 a DT B-NP O
22 138 144 16680561 strong JJ I-NP O
23 145 154 16680561 inhibitor NN I-NP O
24 155 157 16680561 of IN B-PP O
25 158 168 16680561 cytochrome NN B-NP O
26 169 173 16680561 P450 NN I-NP O
27 174 183 16680561 isoenzyme NN I-NP O
28 184 185 16680561 ( ( O O
29 185 188 16680561 CYP NN B-NP O
30 188 189 16680561 ) ) O O
31 190 193 16680561 2D6 NN B-NP O
32 193 194 16680561 . . O O

1 195 198 16680561 The DT B-NP O
2 199 206 16680561 purpose NN I-NP O
3 207 209 16680561 of IN B-PP O
4 210 214 16680561 this DT B-NP O
5 215 220 16680561 study NN I-NP O
6 221 224 16680561 was VBD B-VP O
7 225 227 16680561 to TO B-VP O
8 228 236 16680561 evaluate VB I-VP O
9 237 240 16680561 the DT B-NP O
10 241 247 16680561 effect NN I-NP O
11 248 250 16680561 of IN B-PP O
12 251 261 16680561 cinacalcet NN B-NP B-Chemical
13 262 264 16680561 on IN B-PP O
14 265 271 16680561 CYP2D6 NN B-NP O
15 272 280 16680561 activity NN I-NP O
16 280 281 16680561 , , O O
17 282 287 16680561 using VBG B-VP O
18 288 299 16680561 desipramine NN B-NP B-Chemical
19 300 302 16680561 as IN B-PP O
20 303 304 16680561 a DT B-NP O
21 305 310 16680561 probe NN I-NP O
22 311 320 16680561 substrate NN I-NP O
23 320 321 16680561 , , O O
24 322 324 16680561 in IN B-PP O
25 325 332 16680561 healthy JJ B-NP O
26 333 341 16680561 subjects NNS I-NP O
27 341 342 16680561 . . O O

1 343 350 16680561 METHODS NNS B-NP O
2 350 351 16680561 : : O O
3 352 361 16680561 Seventeen CD B-NP O
4 362 370 16680561 subjects NNS I-NP O
5 371 374 16680561 who WP B-NP O
6 375 379 16680561 were VBD B-VP O
7 380 389 16680561 genotyped VBN I-VP O
8 390 392 16680561 as IN B-PP O
9 393 399 16680561 CYP2D6 NN B-NP O
10 400 409 16680561 extensive JJ I-NP O
11 410 422 16680561 metabolizers NNS I-NP O
12 423 427 16680561 were VBD B-VP O
13 428 436 16680561 enrolled VBN I-VP O
14 437 439 16680561 in IN B-PP O
15 440 444 16680561 this DT B-NP O
16 445 455 16680561 randomized VBN I-NP O
17 455 456 16680561 , , I-NP O
18 457 461 16680561 open JJ I-NP O
19 461 462 16680561 - HYPH I-NP O
20 462 467 16680561 label NN I-NP O
21 467 468 16680561 , , O O
22 469 478 16680561 crossover NN B-NP O
23 479 484 16680561 study NN I-NP O
24 485 487 16680561 to TO B-VP O
25 488 495 16680561 receive VB I-VP O
26 496 497 16680561 a DT B-NP O
27 498 504 16680561 single JJ I-NP O
28 505 509 16680561 oral JJ I-NP O
29 510 514 16680561 dose NN I-NP O
30 515 517 16680561 of IN B-PP O
31 518 529 16680561 desipramine NN B-NP B-Chemical
32 530 531 16680561 ( ( O O
33 531 533 16680561 50 CD B-NP O
34 534 536 16680561 mg NN I-NP O
35 536 537 16680561 ) ) O O
36 538 540 16680561 on IN B-PP O
37 541 544 16680561 two CD B-NP O
38 545 553 16680561 separate JJ I-NP O
39 554 563 16680561 occasions NNS I-NP O
40 563 564 16680561 , , O O
41 565 569 16680561 once RB B-ADVP O
42 570 575 16680561 alone RB I-ADVP O
43 576 579 16680561 and CC I-ADVP O
44 580 584 16680561 once RB I-ADVP O
45 585 590 16680561 after IN B-SBAR O
46 591 599 16680561 multiple JJ B-NP O
47 600 605 16680561 doses NNS I-NP O
48 606 608 16680561 of IN B-PP O
49 609 619 16680561 cinacalcet NN B-NP B-Chemical
50 620 621 16680561 ( ( O O
51 621 623 16680561 90 CD B-NP O
52 624 626 16680561 mg NN I-NP O
53 627 630 16680561 for IN B-PP O
54 631 632 16680561 7 CD B-NP O
55 633 637 16680561 days NNS I-NP O
56 637 638 16680561 ) ) O O
57 638 639 16680561 . . O O

1 640 645 16680561 Blood NN B-NP O
2 646 653 16680561 samples NNS I-NP O
3 654 658 16680561 were VBD B-VP O
4 659 667 16680561 obtained VBN I-VP O
5 668 675 16680561 predose RB B-ADVP O
6 676 679 16680561 and CC I-ADVP O
7 680 682 16680561 up RB B-NP O
8 683 685 16680561 to TO I-NP O
9 686 688 16680561 72 CD I-NP O
10 689 690 16680561 h NN I-NP O
11 691 699 16680561 postdose NN I-NP O
12 699 700 16680561 . . O O

1 701 708 16680561 RESULTS NNS B-NP O
2 708 709 16680561 : : O O
3 710 718 16680561 Fourteen CD B-NP O
4 719 727 16680561 subjects NNS I-NP O
5 728 737 16680561 completed VBD B-VP O
6 738 742 16680561 both CC O O
7 743 752 16680561 treatment NN B-NP O
8 753 757 16680561 arms NNS I-NP O
9 757 758 16680561 . . O O

1 759 767 16680561 Relative JJ B-ADJP O
2 768 770 16680561 to TO B-PP O
3 771 782 16680561 desipramine NN B-NP B-Chemical
4 783 788 16680561 alone RB B-ADVP O
5 788 789 16680561 , , O O
6 790 794 16680561 mean JJ B-NP O
7 795 798 16680561 AUC NN I-NP O
8 799 802 16680561 and CC I-NP O
9 803 809 16680561 C(max) NN I-NP O
10 810 812 16680561 of IN B-PP O
11 813 824 16680561 desipramine NN B-NP B-Chemical
12 825 834 16680561 increased VBD B-VP O
13 835 838 16680561 3.6 CD B-NP O
14 838 839 16680561 - HYPH O O
15 840 843 16680561 and CC O O
16 844 847 16680561 1.8 CD B-NP O
17 847 848 16680561 - HYPH O O
18 848 852 16680561 fold RB B-ADVP O
19 853 857 16680561 when WRB B-ADVP O
20 858 872 16680561 coadministered VBN B-VP O
21 873 877 16680561 with IN B-PP O
22 878 888 16680561 cinacalcet NN B-NP B-Chemical
23 888 889 16680561 . . O O

1 890 893 16680561 The DT B-NP O
2 894 895 16680561 t NN I-NP O
3 896 897 16680561 ( ( O O
4 897 898 16680561 1 CD B-NP O
5 898 899 16680561 / SYM I-NP O
6 899 902 16680561 2,z NN I-NP O
7 902 903 16680561 ) ) O O
8 904 906 16680561 of IN B-PP O
9 907 918 16680561 desipramine NN B-NP B-Chemical
10 919 922 16680561 was VBD B-VP O
11 923 929 16680561 longer JJR B-ADJP O
12 930 934 16680561 when WRB B-ADVP O
13 935 946 16680561 desipramine NN B-NP B-Chemical
14 947 950 16680561 was VBD B-VP O
15 951 965 16680561 coadministered VBN I-VP O
16 966 970 16680561 with IN B-PP O
17 971 981 16680561 cinacalcet NN B-NP B-Chemical
18 982 983 16680561 ( ( O O
19 983 987 16680561 21.0 CD B-NP O
20 988 994 16680561 versus IN I-NP O
21 995 999 16680561 43.3 CD I-NP O
22 1000 1002 16680561 hs NNS I-NP O
23 1002 1003 16680561 ) ) O O
24 1003 1004 16680561 . . O O

1 1005 1008 16680561 The DT B-NP O
2 1009 1010 16680561 t NN I-NP O
3 1011 1012 16680561 ( ( O O
4 1012 1015 16680561 max NN B-NP O
5 1015 1016 16680561 ) ) O O
6 1017 1020 16680561 was VBD B-VP O
7 1021 1028 16680561 similar JJ B-ADJP O
8 1029 1036 16680561 between IN B-PP O
9 1037 1040 16680561 the DT B-NP O
10 1041 1049 16680561 regimens NNS I-NP O
11 1049 1050 16680561 . . O O

1 1051 1056 16680561 Fewer JJR B-NP O
2 1057 1065 16680561 subjects NNS I-NP O
3 1066 1074 16680561 reported VBD B-VP O
4 1075 1082 16680561 adverse JJ B-NP O
5 1083 1089 16680561 events NNS I-NP O
6 1090 1099 16680561 following VBG B-PP O
7 1100 1109 16680561 treatment NN B-NP O
8 1110 1114 16680561 with IN B-PP O
9 1115 1126 16680561 desipramine NN B-NP B-Chemical
10 1127 1132 16680561 alone RB B-ADVP O
11 1133 1137 16680561 than IN B-PP O
12 1138 1142 16680561 when WRB B-ADVP O
13 1143 1152 16680561 receiving VBG B-VP O
14 1153 1164 16680561 desipramine NN B-NP B-Chemical
15 1165 1169 16680561 with IN B-PP O
16 1170 1180 16680561 cinacalcet NN B-NP B-Chemical
17 1181 1182 16680561 ( ( O O
18 1182 1184 16680561 33 CD B-NP O
19 1185 1191 16680561 versus CC I-NP O
20 1192 1195 16680561 86% CD I-NP O
21 1195 1196 16680561 ) ) O O
22 1196 1197 16680561 , , O O
23 1198 1201 16680561 the DT B-NP O
24 1202 1206 16680561 most RBS I-NP O
25 1207 1215 16680561 frequent JJ I-NP O
26 1216 1218 16680561 of IN B-PP O
27 1219 1224 16680561 which WDT B-NP O
28 1225 1226 16680561 ( ( O O
29 1226 1232 16680561 nausea NN B-NP B-Disease
30 1233 1236 16680561 and CC O O
31 1237 1245 16680561 headache NN B-NP B-Disease
32 1245 1246 16680561 ) ) O O
33 1247 1251 16680561 have VBP B-VP O
34 1252 1256 16680561 been VBN I-VP O
35 1257 1265 16680561 reported VBN I-VP O
36 1266 1269 16680561 for IN B-PP O
37 1270 1278 16680561 patients NNS B-NP O
38 1279 1286 16680561 treated VBN B-VP O
39 1287 1291 16680561 with IN B-PP O
40 1292 1298 16680561 either CC O O
41 1299 1310 16680561 desipramine NN B-NP B-Chemical
42 1311 1313 16680561 or CC I-NP O
43 1314 1324 16680561 cinacalcet NN I-NP B-Chemical
44 1324 1325 16680561 . . O O

1 1326 1336 16680561 CONCLUSION NN B-NP O
2 1336 1337 16680561 : : O O
3 1338 1342 16680561 This DT B-NP O
4 1343 1348 16680561 study NN I-NP O
5 1349 1361 16680561 demonstrates VBZ B-VP O
6 1362 1366 16680561 that IN B-SBAR O
7 1367 1377 16680561 cinacalcet NN B-NP B-Chemical
8 1378 1380 16680561 is VBZ B-VP O
9 1381 1382 16680561 a DT B-NP O
10 1383 1389 16680561 strong JJ I-NP O
11 1390 1399 16680561 inhibitor NN I-NP O
12 1400 1402 16680561 of IN B-PP O
13 1403 1409 16680561 CYP2D6 NN B-NP O
14 1409 1410 16680561 . . O O

1 1411 1416 16680561 These DT B-NP O
2 1417 1421 16680561 data NNS I-NP O
3 1422 1429 16680561 suggest VBP B-VP O
4 1430 1434 16680561 that IN B-SBAR O
5 1435 1441 16680561 during IN B-PP O
6 1442 1453 16680561 concomitant JJ B-NP O
7 1454 1463 16680561 treatment NN I-NP O
8 1464 1468 16680561 with IN B-PP O
9 1469 1479 16680561 cinacalcet NN B-NP B-Chemical
10 1479 1480 16680561 , , O O
11 1481 1485 16680561 dose NN B-NP O
12 1486 1496 16680561 adjustment NN I-NP O
13 1497 1500 16680561 may MD B-VP O
14 1501 1503 16680561 be VB I-VP O
15 1504 1513 16680561 necessary JJ B-ADJP O
16 1514 1517 16680561 for IN B-PP O
17 1518 1523 16680561 drugs NNS B-NP O
18 1524 1528 16680561 that WDT B-NP O
19 1529 1540 16680561 demonstrate VBP B-VP O
20 1541 1542 16680561 a DT B-NP O
21 1543 1549 16680561 narrow JJ I-NP O
22 1550 1561 16680561 therapeutic JJ I-NP O
23 1562 1567 16680561 index NN I-NP O
24 1568 1571 16680561 and CC O O
25 1572 1575 16680561 are VBP B-VP O
26 1576 1587 16680561 metabolized VBN I-VP O
27 1588 1590 16680561 by IN B-PP O
28 1591 1597 16680561 CYP2D6 NN B-NP O
29 1597 1598 16680561 . . O O

1 0 0 17020434 -DOCSTART- -X- -X- O

1 0 10 17020434 Optimising VBG B-VP O
2 11 17 17020434 stroke JJ B-NP B-Disease
3 18 28 17020434 prevention NN I-NP O
4 29 31 17020434 in IN B-PP O
5 32 35 17020434 non AFX B-NP O
6 35 36 17020434 - HYPH I-NP O
7 36 44 17020434 valvular JJ I-NP O
8 45 51 17020434 atrial JJ I-NP B-Disease
9 52 64 17020434 fibrillation NN I-NP I-Disease
10 64 65 17020434 . . O O
11 66 72 17020434 Atrial JJ B-NP B-Disease
12 73 85 17020434 fibrillation NN I-NP I-Disease
13 86 88 17020434 is VBZ B-VP O
14 89 99 17020434 associated VBN I-VP O
15 100 104 17020434 with IN B-PP O
16 105 116 17020434 substantial JJ B-NP O
17 117 126 17020434 morbidity NN I-NP O
18 127 130 17020434 and CC I-NP O
19 131 140 17020434 mortality NN I-NP O
20 140 141 17020434 . . O O

1 142 148 17020434 Pooled VBN B-NP O
2 149 153 17020434 data NNS I-NP O
3 154 158 17020434 from IN B-PP O
4 159 165 17020434 trials NNS B-NP O
5 166 175 17020434 comparing VBG B-VP O
6 176 190 17020434 antithrombotic JJ B-NP O
7 191 200 17020434 treatment NN I-NP O
8 201 205 17020434 with IN B-PP O
9 206 213 17020434 placebo NN B-NP O
10 214 218 17020434 have VBP B-VP O
11 219 224 17020434 shown VBN I-VP O
12 225 229 17020434 that IN B-SBAR O
13 230 238 17020434 warfarin NN B-NP B-Chemical
14 239 246 17020434 reduces VBZ B-VP O
15 247 250 17020434 the DT B-NP O
16 251 255 17020434 risk NN I-NP O
17 256 258 17020434 of IN B-PP O
18 259 265 17020434 stroke NN B-NP B-Disease
19 266 268 17020434 by IN B-PP O
20 269 272 17020434 62% NN B-NP O
21 272 273 17020434 , , O O
22 274 277 17020434 and CC O O
23 278 282 17020434 that IN B-SBAR O
24 283 290 17020434 aspirin NN B-NP B-Chemical
25 291 296 17020434 alone RB B-ADVP O
26 297 304 17020434 reduces VBZ B-VP O
27 305 308 17020434 the DT B-NP O
28 309 313 17020434 risk NN I-NP O
29 314 316 17020434 by IN B-PP O
30 317 320 17020434 22% NN B-NP O
31 320 321 17020434 . . O O

1 322 329 17020434 Overall RB B-ADVP O
2 329 330 17020434 , , O O
3 331 333 17020434 in IN B-PP O
4 334 338 17020434 high JJ B-NP O
5 338 339 17020434 - HYPH I-NP O
6 339 343 17020434 risk NN I-NP O
7 344 352 17020434 patients NNS I-NP O
8 352 353 17020434 , , O O
9 354 362 17020434 warfarin NN B-NP B-Chemical
10 363 365 17020434 is VBZ B-VP O
11 366 374 17020434 superior JJ B-ADJP O
12 375 377 17020434 to TO B-PP O
13 378 385 17020434 aspirin NN B-NP B-Chemical
14 386 388 17020434 in IN B-PP O
15 389 399 17020434 preventing VBG B-VP O
16 400 407 17020434 strokes NNS B-NP B-Disease
17 407 408 17020434 , , O O
18 409 413 17020434 with IN B-PP O
19 414 415 17020434 a DT B-NP O
20 416 424 17020434 relative JJ I-NP O
21 425 429 17020434 risk NN I-NP O
22 430 439 17020434 reduction NN I-NP O
23 440 442 17020434 of IN B-PP O
24 443 446 17020434 36% NN B-NP O
25 446 447 17020434 . . O O

1 448 460 17020434 Ximelagatran NN B-NP B-Chemical
2 460 461 17020434 , , O O
3 462 464 17020434 an DT B-NP O
4 465 469 17020434 oral JJ I-NP O
5 470 476 17020434 direct JJ I-NP O
6 477 485 17020434 thrombin NN I-NP O
7 486 495 17020434 inhibitor NN I-NP O
8 495 496 17020434 , , O O
9 497 500 17020434 was VBD B-VP O
10 501 506 17020434 found VBN I-VP O
11 507 509 17020434 to TO I-VP O
12 510 512 17020434 be VB I-VP O
13 513 515 17020434 as RB B-ADJP O
14 516 525 17020434 efficient JJ I-ADJP O
15 526 528 17020434 as IN B-PP O
16 529 536 17020434 vitamin NN B-NP B-Chemical
17 537 538 17020434 K NN I-NP I-Chemical
18 539 549 17020434 antagonist NN I-NP O
19 550 555 17020434 drugs NNS I-NP O
20 556 558 17020434 in IN B-PP O
21 559 562 17020434 the DT B-NP O
22 563 573 17020434 prevention NN I-NP O
23 574 576 17020434 of IN B-PP O
24 577 584 17020434 embolic JJ B-NP B-Disease
25 585 591 17020434 events NNS I-NP I-Disease
26 591 592 17020434 , , O O
27 593 596 17020434 but CC O O
28 597 600 17020434 has VBZ B-VP O
29 601 605 17020434 been VBN I-VP O
30 606 614 17020434 recently RB I-VP O
31 615 624 17020434 withdrawn VBN I-VP O
32 625 632 17020434 because IN B-PP O
33 633 635 17020434 of IN I-PP O
34 636 644 17020434 abnormal JJ B-NP B-Disease
35 645 650 17020434 liver NN I-NP I-Disease
36 651 659 17020434 function NN I-NP I-Disease
37 660 665 17020434 tests NNS I-NP O
38 665 666 17020434 . . O O

1 667 670 17020434 The DT B-NP O
2 671 677 17020434 ACTIVE NN I-NP O
3 677 678 17020434 - HYPH I-NP O
4 678 679 17020434 W NN I-NP O
5 680 681 17020434 ( ( O O
6 681 687 17020434 Atrial JJ B-NP B-Disease
7 688 700 17020434 Fibrillation NN I-NP I-Disease
8 701 712 17020434 Clopidogrel NN I-NP B-Chemical
9 713 718 17020434 Trial NN I-NP O
10 719 723 17020434 with IN B-PP O
11 724 734 17020434 Irbesartan NN B-NP B-Chemical
12 735 738 17020434 for IN B-PP O
13 739 749 17020434 Prevention NN B-NP O
14 750 752 17020434 of IN B-PP O
15 753 761 17020434 Vascular JJ B-NP O
16 762 768 17020434 Events NNS I-NP O
17 768 769 17020434 ) ) O O
18 770 775 17020434 study NN B-NP O
19 776 779 17020434 has VBZ B-VP O
20 780 792 17020434 demonstrated VBN I-VP O
21 793 797 17020434 that IN B-SBAR O
22 798 806 17020434 warfarin NN B-NP B-Chemical
23 807 809 17020434 is VBZ B-VP O
24 810 818 17020434 superior JJ B-ADJP O
25 819 821 17020434 to TO B-PP O
26 822 830 17020434 platelet NN B-NP O
27 831 838 17020434 therapy NN I-NP O
28 839 840 17020434 ( ( O O
29 840 851 17020434 clopidogrel NN B-NP B-Chemical
30 852 856 17020434 plus CC O O
31 857 864 17020434 aspirin NN B-NP B-Chemical
32 864 865 17020434 ) ) O O
33 866 868 17020434 in IN B-PP O
34 869 872 17020434 the DT B-NP O
35 873 883 17020434 prevention NN I-NP O
36 884 886 17020434 af IN B-PP O
37 887 894 17020434 embolic JJ B-NP B-Disease
38 895 901 17020434 events NNS I-NP I-Disease
39 901 902 17020434 . . O O

1 903 914 17020434 Idraparinux NN B-NP B-Chemical
2 914 915 17020434 , , O O
3 916 917 17020434 a DT B-NP O
4 918 924 17020434 Factor NN I-NP O
5 925 927 17020434 Xa NN I-NP O
6 928 937 17020434 inhibitor NN I-NP O
7 937 938 17020434 , , O O
8 939 941 17020434 is VBZ B-VP O
9 942 947 17020434 being VBG I-VP O
10 948 957 17020434 evaluated VBN I-VP O
11 958 960 17020434 in IN B-PP O
12 961 969 17020434 patients NNS B-NP O
13 970 974 17020434 with IN B-PP O
14 975 981 17020434 atrial JJ B-NP B-Disease
15 982 994 17020434 fibrillation NN I-NP I-Disease
16 994 995 17020434 . . O O

1 996 1007 17020434 Angiotensin NN B-NP B-Chemical
2 1007 1008 17020434 - HYPH O O
3 1008 1018 17020434 converting VBG B-VP O
4 1019 1025 17020434 enzyme NN B-NP O
5 1026 1036 17020434 inhibitors NNS I-NP O
6 1037 1040 17020434 and CC O O
7 1041 1052 17020434 angiotensin NN B-NP B-Chemical
8 1053 1055 17020434 II CD I-NP I-Chemical
9 1056 1064 17020434 receptor NN I-NP O
10 1064 1065 17020434 - HYPH O O
11 1065 1073 17020434 blocking VBG B-VP O
12 1074 1079 17020434 drugs NNS B-NP O
13 1080 1084 17020434 hold VBP B-VP O
14 1085 1092 17020434 promise NN B-NP O
15 1093 1095 17020434 in IN B-PP O
16 1096 1102 17020434 atrial JJ B-NP B-Disease
17 1103 1115 17020434 fibrillation NN I-NP I-Disease
18 1116 1123 17020434 through IN B-PP O
19 1124 1131 17020434 cardiac JJ B-NP B-Disease
20 1132 1143 17020434 remodelling NN I-NP I-Disease
21 1143 1144 17020434 . . O O

1 1145 1156 17020434 Preliminary JJ B-NP O
2 1157 1164 17020434 studies NNS I-NP O
3 1165 1172 17020434 suggest VBP B-VP O
4 1173 1177 17020434 that IN B-SBAR O
5 1178 1185 17020434 statins NNS B-NP B-Chemical
6 1186 1191 17020434 could MD B-VP O
7 1192 1201 17020434 interfere VB I-VP O
8 1202 1206 17020434 with IN B-PP O
9 1207 1210 17020434 the DT B-NP O
10 1211 1215 17020434 risk NN I-NP O
11 1216 1218 17020434 of IN B-PP O
12 1219 1229 17020434 recurrence NN B-NP O
13 1230 1235 17020434 after IN B-PP O
14 1236 1246 17020434 electrical JJ B-NP O
15 1247 1260 17020434 cardioversion NN I-NP O
16 1260 1261 17020434 . . O O

1 1262 1269 17020434 Finally RB B-ADVP O
2 1269 1270 17020434 , , O O
3 1271 1283 17020434 percutaneous JJ B-NP O
4 1284 1291 17020434 methods NNS I-NP O
5 1292 1295 17020434 for IN B-PP O
6 1296 1299 17020434 the DT B-NP O
7 1300 1309 17020434 exclusion NN I-NP O
8 1310 1312 17020434 of IN B-PP O
9 1313 1317 17020434 left JJ B-NP O
10 1318 1324 17020434 atrial JJ I-NP O
11 1325 1334 17020434 appendage NN I-NP O
12 1335 1338 17020434 are VBP B-VP O
13 1339 1344 17020434 under IN B-PP O
14 1345 1358 17020434 investigation NN B-NP O
15 1359 1361 17020434 in IN B-PP O
16 1362 1366 17020434 high JJ B-NP O
17 1366 1367 17020434 - HYPH I-NP O
18 1367 1371 17020434 risk NN B-NP O
19 1372 1380 17020434 patients NNS I-NP O
20 1380 1381 17020434 . . O O

1 0 0 11875660 -DOCSTART- -X- -X- O

1 0 10 11875660 Sequential JJ B-NP O
2 11 23 11875660 observations NNS I-NP O
3 24 26 11875660 of IN B-PP O
4 27 38 11875660 exencephaly RB B-NP B-Disease
5 39 42 11875660 and CC O O
6 43 53 11875660 subsequent JJ B-NP O
7 54 67 11875660 morphological JJ I-NP O
8 68 75 11875660 changes NNS I-NP O
9 76 78 11875660 by IN B-PP O
10 79 84 11875660 mouse NN B-NP O
11 85 88 11875660 exo NN I-NP O
12 89 94 11875660 utero NN I-NP O
13 95 106 11875660 development NN I-NP O
14 107 113 11875660 system NN I-NP O
15 113 114 11875660 : : O O
16 115 123 11875660 analysis NN B-NP O
17 124 126 11875660 of IN B-PP O
18 127 130 11875660 the DT B-NP O
19 131 140 11875660 mechanism NN I-NP O
20 141 143 11875660 of IN B-PP O
21 144 158 11875660 transformation NN B-NP O
22 159 163 11875660 from IN B-PP O
23 164 175 11875660 exencephaly RB B-ADVP B-Disease
24 176 178 11875660 to TO B-PP O
25 179 190 11875660 anencephaly RB B-NP B-Disease
26 190 191 11875660 . . I-NP O
27 192 203 11875660 Anencephaly NNP I-NP B-Disease
28 204 207 11875660 has VBZ B-VP O
29 208 212 11875660 been VBN I-VP O
30 213 222 11875660 suggested VBN I-VP O
31 223 225 11875660 to TO I-VP O
32 226 233 11875660 develop VB I-VP O
33 234 238 11875660 from IN B-PP O
34 239 250 11875660 exencephaly RB B-NP B-Disease
35 250 251 11875660 ; : O O
36 252 259 11875660 however RB B-ADVP O
37 259 260 11875660 , , O O
38 261 266 11875660 there EX B-NP O
39 267 269 11875660 is VBZ B-VP O
40 270 276 11875660 little JJ B-NP O
41 277 283 11875660 direct JJ I-NP O
42 284 296 11875660 experimental JJ I-NP O
43 297 305 11875660 evidence NN I-NP O
44 306 308 11875660 to TO B-VP O
45 309 316 11875660 support VB I-VP O
46 317 321 11875660 this DT B-NP O
47 321 322 11875660 , , O O
48 323 326 11875660 and CC O O
49 327 330 11875660 the DT B-NP O
50 331 340 11875660 mechanism NN I-NP O
51 341 343 11875660 of IN B-PP O
52 344 358 11875660 transformation NN B-NP O
53 359 366 11875660 remains VBZ B-VP O
54 367 374 11875660 unclear JJ B-ADJP O
55 374 375 11875660 . . O O

1 376 378 11875660 We PRP B-NP O
2 379 387 11875660 examined VBD B-VP O
3 388 392 11875660 this DT B-NP O
4 393 399 11875660 theory NN I-NP O
5 400 405 11875660 using VBG B-VP O
6 406 409 11875660 the DT B-NP O
7 410 413 11875660 exo NN I-NP O
8 414 419 11875660 utero NN I-NP O
9 420 431 11875660 development NN I-NP O
10 432 438 11875660 system NN I-NP O
11 439 443 11875660 that WDT B-NP O
12 444 450 11875660 allows VBZ B-VP O
13 451 457 11875660 direct JJ B-NP O
14 458 461 11875660 and CC I-NP O
15 462 472 11875660 sequential JJ I-NP O
16 473 485 11875660 observations NNS I-NP O
17 486 488 11875660 of IN B-PP O
18 489 492 11875660 mid NN B-NP O
19 492 493 11875660 - HYPH B-ADVP O
20 494 496 11875660 to TO B-PP O
21 497 501 11875660 late JJ B-NP O
22 501 502 11875660 - HYPH I-NP O
23 502 511 11875660 gestation NN I-NP O
24 512 517 11875660 mouse NN I-NP O
25 518 525 11875660 embryos NNS I-NP O
26 525 526 11875660 . . O O

1 527 529 11875660 We PRP B-NP O
2 530 538 11875660 observed VBD B-VP O
3 539 542 11875660 the DT B-NP O
4 543 554 11875660 exencephaly RB I-NP B-Disease
5 555 562 11875660 induced VBN I-NP O
6 563 565 11875660 by IN B-PP O
7 566 567 11875660 5 CD B-NP B-Chemical
8 567 568 11875660 - HYPH I-NP I-Chemical
9 568 579 11875660 azacytidine NN I-NP I-Chemical
10 580 582 11875660 at IN B-PP O
11 583 592 11875660 embryonic JJ B-NP O
12 593 596 11875660 day NN I-NP O
13 597 601 11875660 13.5 CD I-NP O
14 602 603 11875660 ( ( O O
15 603 608 11875660 E13.5 NN B-NP O
16 608 609 11875660 ) ) O O
17 609 610 11875660 , , O O
18 611 614 11875660 let VBD B-VP O
19 615 618 11875660 the DT B-NP O
20 619 626 11875660 embryos NNS I-NP O
21 627 634 11875660 develop VBP B-VP O
22 635 638 11875660 exo NN B-NP O
23 639 644 11875660 utero NN I-NP O
24 645 650 11875660 until IN B-PP O
25 651 656 11875660 E18.5 NN B-NP O
26 656 657 11875660 , , O O
27 658 661 11875660 and CC O O
28 662 664 11875660 re NN B-NP O
29 664 665 11875660 - HYPH O O
30 665 673 11875660 observed VBN B-VP O
31 674 677 11875660 the DT B-NP O
32 678 682 11875660 same JJ I-NP O
33 683 690 11875660 embryos NNS I-NP O
34 691 693 11875660 at IN B-PP O
35 694 699 11875660 E18.5 NN B-NP O
36 699 700 11875660 . . O O

1 701 703 11875660 We PRP B-NP O
2 704 713 11875660 confirmed VBD B-VP O
3 714 721 11875660 several JJ B-NP O
4 722 727 11875660 cases NNS I-NP O
5 728 730 11875660 of IN B-PP O
6 731 745 11875660 transformation NN B-NP O
7 746 750 11875660 from IN B-PP O
8 751 762 11875660 exencephaly RB B-ADVP B-Disease
9 763 765 11875660 to TO B-PP O
10 766 777 11875660 anencephaly RB B-NP B-Disease
11 777 778 11875660 . . O O

1 779 786 11875660 However RB B-ADVP O
2 786 787 11875660 , , O O
3 788 790 11875660 in IN B-PP O
4 791 795 11875660 many JJ B-NP O
5 796 801 11875660 cases NNS I-NP O
6 801 802 11875660 , , O O
7 803 806 11875660 the DT B-NP O
8 807 819 11875660 exencephalic JJ I-NP B-Disease
9 820 825 11875660 brain NN I-NP O
10 826 832 11875660 tissue NN I-NP O
11 833 836 11875660 was VBD B-VP O
12 837 846 11875660 preserved VBN I-VP O
13 847 851 11875660 with IN B-PP O
14 852 856 11875660 more JJR B-NP O
15 857 859 11875660 or CC I-NP O
16 860 864 11875660 less JJR I-NP O
17 865 874 11875660 reduction NN I-NP O
18 875 881 11875660 during IN B-PP O
19 882 886 11875660 this DT B-NP O
20 887 893 11875660 period NN I-NP O
21 893 894 11875660 . . O O

1 895 897 11875660 To TO B-VP O
2 898 905 11875660 analyze VB I-VP O
3 906 909 11875660 the DT B-NP O
4 910 924 11875660 transformation NN I-NP O
5 925 933 11875660 patterns NNS I-NP O
6 933 934 11875660 , , O O
7 935 937 11875660 we PRP B-NP O
8 938 948 11875660 classified VBD B-VP O
9 949 952 11875660 the DT B-NP O
10 953 964 11875660 exencephaly NN I-NP B-Disease
11 965 967 11875660 by IN B-PP O
12 968 972 11875660 size NN B-NP O
13 973 976 11875660 and CC I-NP O
14 977 982 11875660 shape NN I-NP O
15 983 985 11875660 of IN B-PP O
16 986 989 11875660 the DT B-NP O
17 990 1002 11875660 exencephalic JJ I-NP B-Disease
18 1003 1009 11875660 tissue NN I-NP O
19 1010 1014 11875660 into IN B-PP O
20 1015 1022 11875660 several JJ B-NP O
21 1023 1028 11875660 types NNS I-NP O
22 1029 1031 11875660 at IN B-PP O
23 1032 1037 11875660 E13.5 NN B-NP O
24 1038 1041 11875660 and CC I-NP O
25 1042 1047 11875660 E18.5 NN I-NP O
26 1047 1048 11875660 . . O O

1 1049 1051 11875660 It PRP B-NP O
2 1052 1055 11875660 was VBD B-VP O
3 1056 1061 11875660 found VBN I-VP O
4 1062 1066 11875660 that IN B-SBAR O
5 1067 1070 11875660 the DT B-NP O
6 1071 1085 11875660 transformation NN I-NP O
7 1086 1088 11875660 of IN B-PP O
8 1089 1101 11875660 exencephalic JJ B-NP B-Disease
9 1102 1108 11875660 tissue NN I-NP O
10 1109 1112 11875660 was VBD B-VP O
11 1113 1116 11875660 not RB O O
12 1117 1123 11875660 simply RB B-ADVP O
13 1124 1128 11875660 size NN B-NP O
14 1128 1129 11875660 - HYPH B-VP O
15 1129 1138 11875660 dependent JJ B-ADJP O
16 1138 1139 11875660 , , O O
17 1140 1143 11875660 and CC O O
18 1144 1147 11875660 all DT B-NP O
19 1148 1153 11875660 cases NNS I-NP O
20 1154 1156 11875660 of IN B-PP O
21 1157 1168 11875660 anencephaly RB B-ADVP B-Disease
22 1169 1171 11875660 at IN B-PP O
23 1172 1177 11875660 E18.5 NN B-NP O
24 1178 1186 11875660 resulted VBD B-VP O
25 1187 1191 11875660 from IN B-PP O
26 1192 1199 11875660 embryos NNS B-NP O
27 1200 1204 11875660 with IN B-PP O
28 1205 1206 11875660 a DT B-NP O
29 1207 1212 11875660 large JJ I-NP O
30 1213 1219 11875660 amount NN I-NP O
31 1220 1222 11875660 of IN B-PP O
32 1223 1235 11875660 exencephalic JJ B-NP B-Disease
33 1236 1242 11875660 tissue NN I-NP O
34 1243 1245 11875660 at IN B-PP O
35 1246 1251 11875660 E13.5 NN B-NP O
36 1251 1252 11875660 . . O O

1 1253 1264 11875660 Microscopic JJ B-NP O
2 1265 1276 11875660 observation NN I-NP O
3 1277 1283 11875660 showed VBD B-VP O
4 1284 1287 11875660 the DT B-NP O
5 1288 1301 11875660 configuration NN I-NP O
6 1302 1304 11875660 of IN B-PP O
7 1305 1316 11875660 exencephaly RB B-ADVP B-Disease
8 1317 1319 11875660 at IN B-PP O
9 1320 1325 11875660 E13.5 NN B-NP O
10 1325 1326 11875660 , , O O
11 1327 1335 11875660 frequent JJ B-NP O
12 1336 1348 11875660 hemorrhaging NN I-NP B-Disease
13 1349 1352 11875660 and CC I-NP O
14 1353 1363 11875660 detachment NN I-NP O
15 1364 1366 11875660 of IN B-PP O
16 1367 1370 11875660 the DT B-NP O
17 1371 1377 11875660 neural JJ I-NP O
18 1378 1383 11875660 plate NN I-NP O
19 1384 1388 11875660 from IN B-PP O
20 1389 1396 11875660 surface NN B-NP O
21 1397 1405 11875660 ectoderm NN I-NP O
22 1406 1408 11875660 in IN B-PP O
23 1409 1412 11875660 the DT B-NP O
24 1413 1425 11875660 exencephalic JJ I-NP B-Disease
25 1426 1430 11875660 head NN I-NP O
26 1431 1433 11875660 at IN B-PP O
27 1434 1439 11875660 E15.5 NN B-NP O
28 1439 1440 11875660 , , O O
29 1441 1444 11875660 and CC O O
30 1445 1453 11875660 multiple JJ B-NP O
31 1454 1459 11875660 modes NNS I-NP O
32 1460 1462 11875660 of IN B-PP O
33 1463 1472 11875660 reduction NN B-NP O
34 1473 1475 11875660 in IN B-PP O
35 1476 1479 11875660 the DT B-NP O
36 1480 1492 11875660 exencephalic JJ I-NP B-Disease
37 1493 1499 11875660 tissue NN I-NP O
38 1500 1502 11875660 at IN B-PP O
39 1503 1508 11875660 E18.5 NN B-NP O
40 1508 1509 11875660 . . O O

1 1510 1514 11875660 From IN B-PP O
2 1515 1527 11875660 observations NNS B-NP O
3 1528 1530 11875660 of IN B-PP O
4 1531 1534 11875660 the DT B-NP O
5 1535 1546 11875660 vasculature NN I-NP O
6 1546 1547 11875660 , , O O
7 1548 1555 11875660 altered JJ B-NP O
8 1556 1568 11875660 distribution NN I-NP O
9 1569 1577 11875660 patterns NNS I-NP O
10 1578 1580 11875660 of IN B-PP O
11 1581 1588 11875660 vessels NNS B-NP O
12 1589 1593 11875660 were VBD B-VP O
13 1594 1604 11875660 identified VBN I-VP O
14 1605 1607 11875660 in IN B-PP O
15 1608 1611 11875660 the DT B-NP O
16 1612 1624 11875660 exencephalic JJ I-NP B-Disease
17 1625 1629 11875660 head NN I-NP O
18 1629 1630 11875660 . . O O

1 1631 1636 11875660 These DT B-NP O
2 1637 1645 11875660 findings NNS I-NP O
3 1646 1653 11875660 suggest VBP B-VP O
4 1654 1658 11875660 that IN B-SBAR O
5 1659 1669 11875660 overgrowth NN B-NP O
6 1670 1672 11875660 of IN B-PP O
7 1673 1676 11875660 the DT B-NP O
8 1677 1689 11875660 exencephalic JJ I-NP B-Disease
9 1690 1696 11875660 neural JJ I-NP O
10 1697 1703 11875660 tissue NN I-NP O
11 1704 1710 11875660 causes VBZ B-VP O
12 1711 1714 11875660 the DT B-NP O
13 1715 1722 11875660 altered VBN I-NP O
14 1723 1735 11875660 distribution NN I-NP O
15 1736 1744 11875660 patterns NNS I-NP O
16 1745 1747 11875660 of IN B-PP O
17 1748 1755 11875660 vessels NNS B-NP O
18 1755 1756 11875660 , , O O
19 1757 1767 11875660 subsequent JJ B-NP O
20 1768 1778 11875660 peripheral JJ I-NP O
21 1779 1790 11875660 circulatory JJ I-NP B-Disease
22 1791 1798 11875660 failure NN I-NP I-Disease
23 1799 1802 11875660 and CC O O
24 1802 1803 11875660 / SYM B-NP O
25 1803 1805 11875660 or CC O O
26 1806 1818 11875660 hemorrhaging NN B-NP B-Disease
27 1819 1821 11875660 in IN B-PP O
28 1822 1829 11875660 various JJ B-NP O
29 1830 1835 11875660 parts NNS I-NP O
30 1836 1838 11875660 of IN B-PP O
31 1839 1842 11875660 the DT B-NP O
32 1843 1855 11875660 exencephalic JJ I-NP B-Disease
33 1856 1860 11875660 head NN I-NP O
34 1860 1861 11875660 , , O O
35 1862 1869 11875660 leading VBG B-VP O
36 1870 1872 11875660 to TO B-PP O
37 1873 1876 11875660 the DT B-NP O
38 1877 1885 11875660 multiple JJ I-NP O
39 1886 1891 11875660 modes NNS I-NP O
40 1892 1894 11875660 of IN B-PP O
41 1895 1901 11875660 tissue NN B-NP O
42 1902 1911 11875660 reduction NN I-NP O
43 1912 1918 11875660 during IN B-PP O
44 1919 1933 11875660 transformation NN B-NP O
45 1934 1938 11875660 from IN B-PP O
46 1939 1950 11875660 exencephaly RB B-ADVP B-Disease
47 1951 1953 11875660 to TO B-PP O
48 1954 1965 11875660 anencephaly RB B-NP B-Disease
49 1965 1966 11875660 . . O O

1 0 0 9931093 -DOCSTART- -X- -X- O

1 0 10 9931093 Mechanisms NNS B-NP O
2 11 13 9931093 of IN B-PP O
3 14 16 9931093 FK NN B-NP B-Chemical
4 17 20 9931093 506 CD I-NP I-Chemical
5 20 21 9931093 - HYPH B-NP O
6 21 28 9931093 induced VBN I-NP O
7 29 41 9931093 hypertension NN I-NP B-Disease
8 42 44 9931093 in IN B-PP O
9 45 48 9931093 the DT B-NP O
10 49 52 9931093 rat NN I-NP O
11 52 53 9931093 . . O O
12 54 55 9931093 - HYPH O O
13 55 65 9931093 Tacrolimus NN B-NP B-Chemical
14 66 67 9931093 ( ( O O
15 67 69 9931093 FK NN B-NP B-Chemical
16 70 73 9931093 506 CD I-NP I-Chemical
17 73 74 9931093 ) ) O O
18 75 77 9931093 is VBZ B-VP O
19 78 79 9931093 a DT B-NP O
20 80 88 9931093 powerful JJ I-NP O
21 88 89 9931093 , , O O
22 90 96 9931093 widely RB B-VP O
23 97 101 9931093 used VBN I-VP O
24 102 119 9931093 immunosuppressant NN B-NP O
25 119 120 9931093 . . O O

1 121 124 9931093 The DT B-NP O
2 125 133 9931093 clinical JJ I-NP O
3 134 141 9931093 utility NN I-NP O
4 142 144 9931093 of IN B-PP O
5 145 147 9931093 FK NN B-NP B-Chemical
6 148 151 9931093 506 CD I-NP I-Chemical
7 152 154 9931093 is VBZ B-VP O
8 155 166 9931093 complicated VBN I-VP O
9 167 169 9931093 by IN B-PP O
10 170 181 9931093 substantial JJ B-NP O
11 182 194 9931093 hypertension NN I-NP B-Disease
12 195 198 9931093 and CC I-NP O
13 199 213 9931093 nephrotoxicity NN I-NP B-Disease
14 213 214 9931093 . . O O

1 215 217 9931093 To TO B-VP O
2 218 225 9931093 clarify VB I-VP O
3 226 229 9931093 the DT B-NP O
4 230 240 9931093 mechanisms NNS I-NP O
5 241 243 9931093 of IN B-PP O
6 244 246 9931093 FK NN B-NP B-Chemical
7 247 250 9931093 506 CD I-NP I-Chemical
8 250 251 9931093 - HYPH B-NP O
9 251 258 9931093 induced VBN I-NP O
10 259 271 9931093 hypertension NN I-NP B-Disease
11 271 272 9931093 , , O O
12 273 275 9931093 we PRP B-NP O
13 276 283 9931093 studied VBD B-VP O
14 284 287 9931093 the DT B-NP O
15 288 295 9931093 chronic JJ I-NP O
16 296 303 9931093 effects NNS I-NP O
17 304 306 9931093 of IN B-PP O
18 307 309 9931093 FK NN B-NP B-Chemical
19 310 313 9931093 506 CD I-NP I-Chemical
20 314 316 9931093 on IN B-PP O
21 317 320 9931093 the DT B-NP O
22 321 330 9931093 synthesis NN I-NP O
23 331 333 9931093 of IN B-PP O
24 334 344 9931093 endothelin NN B-NP O
25 344 345 9931093 - HYPH B-NP O
26 345 346 9931093 1 CD I-NP O
27 347 348 9931093 ( ( O O
28 348 350 9931093 ET NN B-NP O
29 350 351 9931093 - HYPH B-NP O
30 351 352 9931093 1 CD I-NP O
31 352 353 9931093 ) ) O O
32 353 354 9931093 , , O O
33 355 358 9931093 the DT B-NP O
34 359 369 9931093 expression NN I-NP O
35 370 372 9931093 of IN B-PP O
36 373 377 9931093 mRNA NN B-NP O
37 378 380 9931093 of IN B-PP O
38 381 383 9931093 ET NN B-NP O
39 383 384 9931093 - HYPH B-NP O
40 384 385 9931093 1 CD I-NP O
41 386 389 9931093 and CC I-NP O
42 390 400 9931093 endothelin NN I-NP O
43 400 401 9931093 - HYPH O O
44 401 411 9931093 converting VBG B-VP O
45 412 418 9931093 enzyme NN B-NP O
46 418 419 9931093 - HYPH B-NP O
47 419 420 9931093 1 CD I-NP O
48 421 422 9931093 ( ( O O
49 422 425 9931093 ECE NN B-NP O
50 425 426 9931093 - HYPH B-NP O
51 426 427 9931093 1 CD I-NP O
52 427 428 9931093 ) ) O O
53 428 429 9931093 , , O O
54 430 433 9931093 the DT B-NP O
55 434 445 9931093 endothelial JJ I-NP O
56 446 452 9931093 nitric JJ I-NP B-Chemical
57 453 458 9931093 oxide NN I-NP I-Chemical
58 459 467 9931093 synthase NN I-NP O
59 468 469 9931093 ( ( O O
60 469 473 9931093 eNOS NN B-NP O
61 473 474 9931093 ) ) O O
62 475 483 9931093 activity NN B-NP O
63 483 484 9931093 , , O O
64 485 488 9931093 and CC O O
65 489 492 9931093 the DT B-NP O
66 493 503 9931093 expression NN I-NP O
67 504 506 9931093 of IN B-PP O
68 507 511 9931093 mRNA NN B-NP O
69 512 514 9931093 of IN B-PP O
70 515 519 9931093 eNOS NN B-NP O
71 520 523 9931093 and CC I-NP O
72 524 525 9931093 C NN I-NP O
73 525 526 9931093 - HYPH I-NP O
74 526 530 9931093 type NN I-NP O
75 531 542 9931093 natriuretic JJ I-NP O
76 543 550 9931093 peptide NN I-NP O
77 551 552 9931093 ( ( O O
78 552 555 9931093 CNP NN B-NP O
79 555 556 9931093 ) ) O O
80 557 559 9931093 in IN B-PP O
81 560 563 9931093 rat NN B-NP O
82 564 569 9931093 blood NN I-NP O
83 570 577 9931093 vessels NNS I-NP O
84 577 578 9931093 . . O O

1 579 581 9931093 In IN B-PP O
2 582 590 9931093 addition NN B-NP O
3 590 591 9931093 , , O O
4 592 595 9931093 the DT B-NP O
5 596 602 9931093 effect NN I-NP O
6 603 605 9931093 of IN B-PP O
7 606 609 9931093 the DT B-NP O
8 610 618 9931093 specific JJ I-NP O
9 619 629 9931093 endothelin NN I-NP O
10 630 634 9931093 type NN I-NP O
11 635 636 9931093 A NN I-NP O
12 637 645 9931093 receptor NN I-NP O
13 646 656 9931093 antagonist NN I-NP O
14 657 659 9931093 FR NN I-NP B-Chemical
15 660 666 9931093 139317 CD I-NP I-Chemical
16 667 669 9931093 on IN B-PP O
17 670 672 9931093 FK NN B-NP B-Chemical
18 673 676 9931093 506 CD I-NP I-Chemical
19 676 677 9931093 - HYPH B-NP O
20 677 684 9931093 induced VBN I-NP O
21 685 697 9931093 hypertension NN I-NP B-Disease
22 698 700 9931093 in IN B-PP O
23 701 705 9931093 rats NNS B-NP O
24 706 709 9931093 was VBD B-VP O
25 710 717 9931093 studied VBN I-VP O
26 717 718 9931093 . . O O

1 719 721 9931093 FK NN B-NP B-Chemical
2 722 725 9931093 506 CD I-NP I-Chemical
3 725 726 9931093 , , I-NP O
4 727 728 9931093 5 CD I-NP O
5 729 731 9931093 mg NN I-NP O
6 731 732 9931093 . . O O

1 733 735 9931093 kg NN B-NP O
2 735 736 9931093 - HYPH B-NP O
3 736 737 9931093 1 CD I-NP O
4 737 738 9931093 . . O O

1 739 740 9931093 d SYM B-NP O
2 740 741 9931093 - : O O
3 741 742 9931093 1 CD B-NP O
4 743 748 9931093 given VBN B-VP O
5 749 752 9931093 for IN B-PP O
6 753 754 9931093 4 CD B-NP O
7 755 760 9931093 weeks NNS I-NP O
8 760 761 9931093 , , O O
9 762 770 9931093 elevated JJ B-NP O
10 771 776 9931093 blood NN I-NP O
11 777 785 9931093 pressure NN I-NP O
12 786 790 9931093 from IN B-PP O
13 791 795 9931093 102+ SYM B-NP O
14 795 796 9931093 / SYM B-NP O
15 796 797 9931093 - SYM O O
16 797 799 9931093 13 CD B-NP O
17 800 802 9931093 to TO B-PP O
18 803 807 9931093 152+ SYM B-NP O
19 807 808 9931093 / SYM B-VP O
20 808 809 9931093 - SYM B-NP O
21 809 811 9931093 15 CD I-NP O
22 812 814 9931093 mm NN I-NP O
23 815 817 9931093 Hg NN I-NP O
24 818 821 9931093 and CC O O
25 822 831 9931093 increased VBD B-VP O
26 832 835 9931093 the DT B-NP O
27 836 845 9931093 synthesis NN I-NP O
28 846 848 9931093 of IN B-PP O
29 849 851 9931093 ET NN B-NP O
30 851 852 9931093 - HYPH B-NP O
31 852 853 9931093 1 CD I-NP O
32 854 857 9931093 and CC O O
33 858 861 9931093 the DT B-NP O
34 862 868 9931093 levels NNS I-NP O
35 869 871 9931093 of IN B-PP O
36 872 874 9931093 ET NN B-NP O
37 874 875 9931093 - HYPH B-NP O
38 875 876 9931093 1 CD I-NP O
39 877 881 9931093 mRNA NN I-NP O
40 882 884 9931093 in IN B-PP O
41 885 888 9931093 the DT B-NP O
42 889 899 9931093 mesenteric JJ I-NP O
43 900 906 9931093 artery NN I-NP O
44 907 908 9931093 ( ( O O
45 908 912 9931093 240% CD B-NP O
46 913 916 9931093 and CC I-NP O
47 917 921 9931093 230% CD I-NP O
48 921 922 9931093 , , O O
49 923 935 9931093 respectively RB B-ADVP O
50 935 936 9931093 ) ) O O
51 936 937 9931093 . . O O

1 938 944 9931093 Little JJ B-NP O
2 945 951 9931093 change NN I-NP O
3 952 955 9931093 was VBD B-VP O
4 956 964 9931093 observed VBN I-VP O
5 965 967 9931093 in IN B-PP O
6 968 971 9931093 the DT B-NP O
7 972 982 9931093 expression NN I-NP O
8 983 985 9931093 of IN B-PP O
9 986 989 9931093 ECE NN B-NP O
10 989 990 9931093 - HYPH B-NP O
11 990 991 9931093 1 CD I-NP O
12 992 996 9931093 mRNA NN I-NP O
13 997 1000 9931093 and CC I-NP O
14 1001 1004 9931093 CNP NN I-NP O
15 1005 1009 9931093 mRNA NN I-NP O
16 1009 1010 9931093 . . O O

1 1011 1013 9931093 FK NN B-NP B-Chemical
2 1014 1017 9931093 506 CD I-NP I-Chemical
3 1018 1027 9931093 decreased VBD B-VP O
4 1028 1032 9931093 eNOS NN B-NP O
5 1033 1041 9931093 activity NN I-NP O
6 1042 1045 9931093 and CC O O
7 1046 1049 9931093 the DT B-NP O
8 1050 1056 9931093 levels NNS I-NP O
9 1057 1059 9931093 of IN B-PP O
10 1060 1064 9931093 eNOS NN B-NP O
11 1065 1069 9931093 mRNA NN I-NP O
12 1070 1072 9931093 in IN B-PP O
13 1073 1076 9931093 the DT B-NP O
14 1077 1082 9931093 aorta NN I-NP O
15 1083 1084 9931093 ( ( O O
16 1084 1087 9931093 48% CD B-NP O
17 1088 1091 9931093 and CC I-NP O
18 1092 1095 9931093 55% CD I-NP O
19 1095 1096 9931093 , , O O
20 1097 1109 9931093 respectively RB B-ADVP O
21 1109 1110 9931093 ) ) O O
22 1110 1111 9931093 . . O O

1 1112 1115 9931093 The DT B-NP O
2 1116 1130 9931093 administration NN I-NP O
3 1131 1133 9931093 of IN B-PP O
4 1134 1136 9931093 FR NN B-NP B-Chemical
5 1137 1143 9931093 139317 CD I-NP I-Chemical
6 1144 1145 9931093 ( ( O O
7 1145 1147 9931093 10 CD B-NP O
8 1148 1150 9931093 mg NN I-NP O
9 1150 1151 9931093 . . O O

1 1152 1154 9931093 kg NN B-NP O
2 1154 1155 9931093 - HYPH B-NP O
3 1155 1156 9931093 1 CD I-NP O
4 1156 1157 9931093 . . O O

1 1158 1159 9931093 d SYM B-NP O
2 1159 1160 9931093 - : O O
3 1160 1161 9931093 1 CD B-NP O
4 1161 1162 9931093 ) ) O O
5 1163 1172 9931093 prevented VBD B-VP O
6 1173 1175 9931093 FK NN B-NP B-Chemical
7 1176 1179 9931093 506 CD I-NP I-Chemical
8 1179 1180 9931093 - HYPH B-NP O
9 1180 1187 9931093 induced VBN I-NP O
10 1188 1200 9931093 hypertension NN I-NP B-Disease
11 1201 1203 9931093 in IN B-PP O
12 1204 1208 9931093 rats NNS B-NP O
13 1208 1209 9931093 . . O O

1 1210 1215 9931093 These DT B-NP O
2 1216 1223 9931093 results NNS I-NP O
3 1224 1232 9931093 indicate VBP B-VP O
4 1233 1237 9931093 that IN B-SBAR O
5 1238 1240 9931093 FK NN B-NP B-Chemical
6 1241 1244 9931093 506 CD I-NP I-Chemical
7 1245 1248 9931093 may MD B-VP O
8 1249 1257 9931093 increase VB I-VP O
9 1258 1263 9931093 blood NN B-NP O
10 1264 1272 9931093 pressure NN I-NP O
11 1273 1276 9931093 not RB B-CONJP O
12 1277 1281 9931093 only RB I-CONJP O
13 1282 1284 9931093 by IN B-PP O
14 1285 1295 9931093 increasing VBG B-VP O
15 1296 1298 9931093 ET NN B-NP O
16 1298 1299 9931093 - HYPH O O
17 1299 1300 9931093 1 CD B-NP O
18 1301 1311 9931093 production NN I-NP O
19 1312 1315 9931093 but CC B-CONJP O
20 1316 1320 9931093 also RB I-CONJP O
21 1321 1323 9931093 by IN B-PP O
22 1324 1334 9931093 decreasing VBG B-VP O
23 1335 1337 9931093 NO NN B-NP B-Chemical
24 1338 1347 9931093 synthesis NN I-NP O
25 1348 1350 9931093 in IN B-PP O
26 1351 1354 9931093 the DT B-NP O
27 1355 1366 9931093 vasculature NN I-NP O
28 1366 1367 9931093 . . O O

1 0 0 11198499 -DOCSTART- -X- -X- O

1 0 11 11198499 Hypotension NN B-NP B-Disease
2 12 21 11198499 following VBG B-PP O
3 22 25 11198499 the DT B-NP O
4 26 36 11198499 initiation NN I-NP O
5 37 39 11198499 of IN B-PP O
6 40 50 11198499 tizanidine NN B-NP B-Chemical
7 51 53 11198499 in IN B-PP O
8 54 55 11198499 a DT B-NP O
9 56 63 11198499 patient NN I-NP O
10 64 71 11198499 treated VBN B-VP O
11 72 76 11198499 with IN B-PP O
12 77 79 11198499 an DT B-NP O
13 80 91 11198499 angiotensin NN I-NP B-Chemical
14 92 102 11198499 converting VBG B-VP O
15 103 109 11198499 enzyme NN B-NP O
16 110 119 11198499 inhibitor NN I-NP O
17 120 123 11198499 for IN B-PP O
18 124 131 11198499 chronic JJ B-NP O
19 132 144 11198499 hypertension NN I-NP B-Disease
20 144 145 11198499 . . O O
21 146 155 11198499 Centrally NNP B-NP O
22 156 162 11198499 acting VBG B-VP O
23 163 168 11198499 alpha SYM B-NP O
24 168 169 11198499 - HYPH O O
25 169 170 11198499 2 CD B-NP O
26 171 181 11198499 adrenergic JJ I-NP O
27 182 190 11198499 agonists NNS I-NP O
28 191 194 11198499 are VBP B-VP O
29 195 198 11198499 one CD B-NP O
30 199 201 11198499 of IN B-PP O
31 202 209 11198499 several JJ B-NP O
32 210 223 11198499 pharmacologic JJ I-NP O
33 224 230 11198499 agents NNS I-NP O
34 231 235 11198499 used VBN B-VP O
35 236 238 11198499 in IN B-PP O
36 239 242 11198499 the DT B-NP O
37 243 252 11198499 treatment NN I-NP O
38 253 255 11198499 of IN B-PP O
39 256 266 11198499 spasticity NN B-NP B-Disease
40 267 274 11198499 related VBN B-VP O
41 275 277 11198499 to TO B-PP O
42 278 287 11198499 disorders NNS B-NP B-Disease
43 288 290 11198499 of IN B-PP I-Disease
44 291 294 11198499 the DT B-NP I-Disease
45 295 302 11198499 central JJ I-NP I-Disease
46 303 310 11198499 nervous JJ I-NP I-Disease
47 311 317 11198499 system NN I-NP I-Disease
48 317 318 11198499 . . O O

1 319 321 11198499 In IN B-PP O
2 322 330 11198499 addition NN B-NP O
3 331 333 11198499 to TO B-PP O
4 334 339 11198499 their PRP$ B-NP O
5 340 347 11198499 effects NNS I-NP O
6 348 350 11198499 on IN B-PP O
7 351 361 11198499 spasticity NN B-NP B-Disease
8 361 362 11198499 , , O O
9 363 370 11198499 certain JJ B-NP O
10 371 378 11198499 adverse JJ I-NP O
11 379 396 11198499 cardiorespiratory JJ I-NP O
12 397 404 11198499 effects NNS I-NP O
13 405 409 11198499 have VBP B-VP O
14 410 414 11198499 been VBN I-VP O
15 415 423 11198499 reported VBN I-VP O
16 423 424 11198499 . . O O

1 425 431 11198499 Adults NNS B-NP O
2 432 443 11198499 chronically RB B-VP O
3 444 451 11198499 treated VBN I-VP O
4 452 456 11198499 with IN B-PP O
5 457 468 11198499 angiotensin NN B-NP B-Chemical
6 469 479 11198499 converting VBG B-VP O
7 480 486 11198499 enzyme NN B-NP O
8 487 497 11198499 inhibitors NNS I-NP O
9 498 501 11198499 may MD B-VP O
10 502 506 11198499 have VB I-VP O
11 507 508 11198499 a DT B-NP O
12 509 516 11198499 limited VBN I-NP O
13 517 524 11198499 ability NN I-NP O
14 525 527 11198499 to TO B-VP O
15 528 535 11198499 respond VB I-VP O
16 536 538 11198499 to TO B-PP O
17 539 550 11198499 hypotension NN B-NP B-Disease
18 551 555 11198499 when WRB B-ADVP O
19 556 559 11198499 the DT B-NP O
20 560 571 11198499 sympathetic JJ I-NP O
21 572 580 11198499 response NN I-NP O
22 581 583 11198499 is VBZ B-VP O
23 584 598 11198499 simultaneously RB I-VP O
24 599 606 11198499 blocked VBN I-VP O
25 606 607 11198499 . . O O

1 608 611 11198499 The DT B-NP O
2 612 619 11198499 authors NNS I-NP O
3 620 627 11198499 present VBP B-VP O
4 628 629 11198499 a DT B-NP O
5 630 632 11198499 10 CD I-NP O
6 632 633 11198499 - HYPH I-NP O
7 633 637 11198499 year NN I-NP O
8 637 638 11198499 - HYPH O O
9 638 641 11198499 old JJ B-NP O
10 642 645 11198499 boy NN I-NP O
11 646 657 11198499 chronically RB B-VP O
12 658 665 11198499 treated VBN I-VP O
13 666 670 11198499 with IN B-PP O
14 671 681 11198499 lisinopril NN B-NP B-Chemical
15 681 682 11198499 , , O O
16 683 685 11198499 an DT B-NP O
17 686 697 11198499 angiotensin NN I-NP B-Chemical
18 698 708 11198499 converting VBG B-VP O
19 709 715 11198499 enzyme NN B-NP O
20 716 725 11198499 inhibitor NN I-NP O
21 725 726 11198499 , , O O
22 727 729 11198499 to TO B-VP O
23 730 737 11198499 control VB I-VP O
24 738 750 11198499 hypertension NN B-NP B-Disease
25 751 754 11198499 who WP B-NP O
26 755 764 11198499 developed VBD B-VP O
27 765 776 11198499 hypotension NN B-NP B-Disease
28 777 786 11198499 following VBG B-PP O
29 787 790 11198499 the DT B-NP O
30 791 799 11198499 addition NN I-NP O
31 800 802 11198499 of IN B-PP O
32 803 813 11198499 tizanidine NN B-NP B-Chemical
33 813 814 11198499 , , O O
34 815 817 11198499 an DT B-NP O
35 818 823 11198499 alpha SYM I-NP O
36 823 824 11198499 - HYPH I-NP O
37 824 825 11198499 2 CD I-NP O
38 826 833 11198499 agonist NN I-NP O
39 833 834 11198499 , , O O
40 835 838 11198499 for IN B-PP O
41 839 842 11198499 the DT B-NP O
42 843 852 11198499 treatment NN I-NP O
43 853 855 11198499 of IN B-PP O
44 856 866 11198499 spasticity NN B-NP B-Disease
45 866 867 11198499 . . O O

1 868 871 11198499 The DT B-NP O
2 872 880 11198499 possible JJ I-NP O
3 881 892 11198499 interaction NN I-NP O
4 893 895 11198499 of IN B-PP O
5 896 906 11198499 tizanidine NN B-NP B-Chemical
6 907 910 11198499 and CC O O
7 911 916 11198499 other JJ B-NP O
8 917 933 11198499 antihypertensive JJ I-NP O
9 934 940 11198499 agents NNS I-NP O
10 941 947 11198499 should MD B-VP O
11 948 950 11198499 be VB I-VP O
12 951 955 11198499 kept VBN I-VP O
13 956 958 11198499 in IN B-PP O
14 959 963 11198499 mind NN B-NP O
15 964 968 11198499 when WRB B-ADVP O
16 969 980 11198499 prescribing VBG B-VP O
17 981 988 11198499 therapy NN B-NP O
18 989 991 11198499 to TO B-VP O
19 992 997 11198499 treat VB I-VP O
20 998 1004 11198499 either CC O O
21 1005 1017 11198499 hypertension NN B-NP B-Disease
22 1018 1020 11198499 or CC I-NP O
23 1021 1031 11198499 spasticity NN I-NP B-Disease
24 1032 1034 11198499 in IN B-PP O
25 1035 1039 11198499 such JJ B-NP O
26 1040 1048 11198499 patients NNS I-NP O
27 1048 1049 11198499 . . O O

1 0 0 9660111 -DOCSTART- -X- -X- O

1 0 8 9660111 Repeated VBN B-NP O
2 9 21 9660111 trimipramine NN I-NP B-Chemical
3 22 29 9660111 induces VBZ B-VP O
4 30 38 9660111 dopamine NN B-NP B-Chemical
5 39 41 9660111 D2 NN I-NP O
6 41 42 9660111 / SYM B-NP O
7 42 44 9660111 D3 NN I-NP O
8 45 48 9660111 and CC I-NP O
9 49 55 9660111 alpha1 NN I-NP O
10 55 56 9660111 - HYPH O O
11 56 66 9660111 adrenergic JJ B-ADJP O
12 67 69 9660111 up RB B-ADVP O
13 69 70 9660111 - HYPH B-NP O
14 70 80 9660111 regulation NN I-NP O
15 80 81 9660111 . . O O
16 82 94 9660111 Trimipramine NN B-NP B-Chemical
17 95 96 9660111 ( ( O O
18 96 99 9660111 TRI NN B-NP B-Chemical
19 99 100 9660111 ) ) O O
20 100 101 9660111 , , O O
21 102 107 9660111 which WDT B-NP O
22 108 113 9660111 shows VBZ B-VP O
23 114 115 9660111 a DT B-NP O
24 116 124 9660111 clinical JJ I-NP O
25 125 139 9660111 antidepressant NN I-NP B-Chemical
26 140 148 9660111 activity NN I-NP O
27 148 149 9660111 , , O O
28 150 152 9660111 is VBZ B-VP O
29 153 163 9660111 chemically RB B-ADJP O
30 164 171 9660111 related VBN I-ADJP O
31 172 174 9660111 to TO B-PP O
32 175 185 9660111 imipramine NN B-NP B-Chemical
33 186 189 9660111 but CC O O
34 190 194 9660111 does VBZ B-VP O
35 195 198 9660111 not RB I-VP O
36 199 206 9660111 inhibit VB I-VP O
37 207 210 9660111 the DT B-NP O
38 211 219 9660111 reuptake NN I-NP O
39 220 222 9660111 of IN B-PP O
40 223 236 9660111 noradrenaline NN B-NP B-Chemical
41 237 240 9660111 and CC O O
42 241 242 9660111 5 CD B-NP B-Chemical
43 242 243 9660111 - HYPH I-NP I-Chemical
44 243 260 9660111 hydroxytryptamine NN I-NP I-Chemical
45 260 261 9660111 , , O O
46 262 265 9660111 nor CC O O
47 266 270 9660111 does VBZ O O
48 271 273 9660111 it PRP B-NP O
49 274 280 9660111 induce VB B-VP O
50 281 285 9660111 beta SYM B-NP O
51 285 286 9660111 - HYPH O O
52 286 296 9660111 adrenergic JJ B-ADJP O
53 297 301 9660111 down RB B-ADVP O
54 301 302 9660111 - HYPH B-NP O
55 302 312 9660111 regulation NN I-NP O
56 312 313 9660111 . . O O

1 314 317 9660111 The DT B-NP O
2 318 327 9660111 mechanism NN I-NP O
3 328 330 9660111 of IN B-PP O
4 331 334 9660111 its PRP$ B-NP O
5 335 349 9660111 antidepressant NN I-NP B-Chemical
6 350 358 9660111 activity NN I-NP O
7 359 361 9660111 is VBZ B-VP O
8 362 367 9660111 still RB B-ADVP O
9 368 375 9660111 unknown JJ B-ADJP O
10 375 376 9660111 . . O O

1 377 380 9660111 The DT B-NP O
2 381 384 9660111 aim NN I-NP O
3 385 387 9660111 of IN B-PP O
4 388 391 9660111 the DT B-NP O
5 392 399 9660111 present JJ I-NP O
6 400 405 9660111 study NN I-NP O
7 406 409 9660111 was VBD B-VP O
8 410 412 9660111 to TO B-VP O
9 413 417 9660111 find VB I-VP O
10 418 421 9660111 out RP B-PRT O
11 422 429 9660111 whether IN B-SBAR O
12 430 433 9660111 TRI NN B-NP B-Chemical
13 434 439 9660111 given VBN B-VP O
14 440 450 9660111 repeatedly RB B-ADVP O
15 451 454 9660111 was VBD B-VP O
16 455 459 9660111 able JJ B-ADJP O
17 460 462 9660111 to TO B-VP O
18 463 469 9660111 induce VB I-VP O
19 470 478 9660111 adaptive JJ B-NP O
20 479 486 9660111 changes NNS I-NP O
21 487 489 9660111 in IN B-PP O
22 490 493 9660111 the DT B-NP O
23 494 506 9660111 dopaminergic JJ I-NP O
24 507 510 9660111 and CC I-NP O
25 511 517 9660111 alpha1 NN I-NP O
26 517 518 9660111 - HYPH B-NP O
27 518 528 9660111 adrenergic JJ I-NP O
28 529 536 9660111 systems NNS I-NP O
29 536 537 9660111 , , O O
30 538 550 9660111 demonstrated VBN B-VP O
31 551 553 9660111 by IN B-PP O
32 554 556 9660111 us PRP B-NP O
33 557 567 9660111 previously RB B-ADVP O
34 568 571 9660111 for IN B-PP O
35 572 579 9660111 various JJ B-NP O
36 580 595 9660111 antidepressants NNS I-NP B-Chemical
37 595 596 9660111 . . O O

1 597 600 9660111 TRI NN B-NP B-Chemical
2 601 604 9660111 was VBD B-VP O
3 605 610 9660111 given VBN I-VP O
4 611 613 9660111 to TO B-PP O
5 614 618 9660111 male JJ B-NP O
6 619 625 9660111 Wistar NNP I-NP O
7 626 630 9660111 rats NNS I-NP O
8 631 634 9660111 and CC O O
9 635 639 9660111 male JJ B-NP O
10 640 646 9660111 Albino NNP I-NP O
11 647 652 9660111 Swiss JJ I-NP O
12 653 657 9660111 mice NNS I-NP O
13 658 667 9660111 perorally RB B-ADVP O
14 668 673 9660111 twice RB B-ADVP O
15 674 679 9660111 daily RB I-ADVP O
16 680 683 9660111 for IN B-PP O
17 684 686 9660111 14 CD B-NP O
18 687 691 9660111 days NNS I-NP O
19 691 692 9660111 . . O O

1 693 695 9660111 In IN B-PP O
2 696 699 9660111 the DT B-NP O
3 700 705 9660111 acute JJ I-NP O
4 706 716 9660111 experiment NN I-NP O
5 717 720 9660111 TRI NN I-NP B-Chemical
6 721 722 9660111 ( ( O O
7 722 727 9660111 given VBN B-VP O
8 728 731 9660111 i.p NN B-NP O
9 731 732 9660111 . . O O
10 732 733 9660111 ) ) O O
11 734 738 9660111 does VBZ B-VP O
12 739 742 9660111 not RB I-VP O
13 743 753 9660111 antagonize VB I-VP O
14 754 757 9660111 the DT B-NP O
15 758 767 9660111 reserpine NN I-NP B-Chemical
16 768 779 9660111 hypothermia NN I-NP B-Disease
17 780 782 9660111 in IN B-PP O
18 783 787 9660111 mice NNS B-NP O
19 788 791 9660111 and CC O O
20 792 796 9660111 does VBZ B-VP O
21 797 800 9660111 not RB I-VP O
22 801 811 9660111 potentiate VB I-VP O
23 812 815 9660111 the DT B-NP O
24 816 817 9660111 5 CD I-NP B-Chemical
25 817 818 9660111 - HYPH I-NP I-Chemical
26 818 835 9660111 hydroxytryptophan NN I-NP I-Chemical
27 836 840 9660111 head NN I-NP O
28 841 849 9660111 twitches NNS I-NP O
29 850 852 9660111 in IN B-PP O
30 853 857 9660111 rats NNS B-NP O
31 857 858 9660111 . . O O

1 859 862 9660111 TRI NN B-NP B-Chemical
2 863 868 9660111 given VBN B-VP O
3 869 879 9660111 repeatedly RB B-ADVP O
4 880 882 9660111 to TO B-PP O
5 883 887 9660111 rats NNS B-NP O
6 888 897 9660111 increases VBZ B-VP O
7 898 901 9660111 the DT B-NP O
8 902 911 9660111 locomotor JJ I-NP O
9 912 925 9660111 hyperactivity NN I-NP B-Disease
10 926 933 9660111 induced VBN B-VP O
11 934 936 9660111 by IN B-PP O
12 937 938 9660111 d NN B-NP B-Chemical
13 938 939 9660111 - HYPH O I-Chemical
14 939 950 9660111 amphetamine NN B-NP I-Chemical
15 950 951 9660111 , , O O
16 952 962 9660111 quinpirole NN B-NP B-Chemical
17 963 966 9660111 and CC O O
18 967 970 9660111 (+) SYM B-NP O
19 970 971 9660111 - HYPH B-NP O
20 971 972 9660111 7 CD I-NP O
21 972 973 9660111 - HYPH I-NP O
22 973 980 9660111 hydroxy NN I-NP O
23 980 981 9660111 - HYPH O O
24 981 1003 9660111 dipropyloaminotetralin NN B-NP O
25 1004 1005 9660111 ( ( O O
26 1005 1013 9660111 dopamine NN B-NP B-Chemical
27 1014 1016 9660111 D2 NN I-NP O
28 1017 1020 9660111 and CC O O
29 1021 1023 9660111 D3 NN B-NP O
30 1024 1031 9660111 effects NNS I-NP O
31 1031 1032 9660111 ) ) O O
32 1032 1033 9660111 . . O O

1 1034 1037 9660111 The DT B-NP O
2 1038 1050 9660111 stereotypies NNS I-NP O
3 1051 1058 9660111 induced VBN B-VP O
4 1059 1061 9660111 by IN B-PP O
5 1062 1063 9660111 d NN B-NP B-Chemical
6 1063 1064 9660111 - HYPH B-NP I-Chemical
7 1064 1075 9660111 amphetamine NN I-NP I-Chemical
8 1076 1078 9660111 or CC I-NP O
9 1079 1090 9660111 apomorphine NN I-NP B-Chemical
10 1091 1094 9660111 are VBP B-VP O
11 1095 1098 9660111 not RB I-VP O
12 1099 1110 9660111 potentiated VBN I-VP O
13 1111 1113 9660111 by IN B-PP O
14 1114 1117 9660111 TRI NN B-NP B-Chemical
15 1117 1118 9660111 . . O O

1 1119 1121 9660111 It PRP B-NP O
2 1122 1131 9660111 increases VBZ B-VP O
3 1132 1135 9660111 the DT B-NP O
4 1136 1145 9660111 behaviour NN I-NP O
5 1146 1157 9660111 stimulation NN I-NP O
6 1158 1164 9660111 evoked VBN B-VP O
7 1165 1167 9660111 by IN B-PP O
8 1168 1181 9660111 phenylephrine NN B-NP B-Chemical
9 1182 1183 9660111 ( ( O O
10 1183 1188 9660111 given VBN B-VP O
11 1189 1207 9660111 intraventricularly RB B-ADVP O
12 1207 1208 9660111 ) ) O O
13 1209 1211 9660111 in IN B-PP O
14 1212 1216 9660111 rats NNS B-NP O
15 1216 1217 9660111 , , O O
16 1218 1227 9660111 evaluated VBN B-VP O
17 1228 1230 9660111 in IN B-PP O
18 1231 1234 9660111 the DT B-NP O
19 1235 1239 9660111 open JJ I-NP O
20 1240 1245 9660111 field NN I-NP O
21 1246 1250 9660111 test NN I-NP O
22 1251 1253 9660111 as RB B-CONJP O
23 1254 1258 9660111 well RB I-CONJP O
24 1259 1261 9660111 as IN I-CONJP O
25 1262 1265 9660111 the DT B-NP O
26 1266 1280 9660111 aggressiveness NN I-NP B-Disease
27 1281 1287 9660111 evoked VBN B-VP O
28 1288 1290 9660111 by IN B-PP O
29 1291 1300 9660111 clonidine NN B-NP B-Chemical
30 1301 1303 9660111 in IN B-PP O
31 1304 1308 9660111 mice NNS B-NP O
32 1308 1309 9660111 , , O O
33 1310 1314 9660111 both DT B-NP O
34 1315 1320 9660111 these DT B-NP O
35 1321 1328 9660111 effects NNS I-NP O
36 1329 1334 9660111 being VBG B-VP O
37 1335 1343 9660111 mediated VBN I-VP O
38 1344 1346 9660111 by IN B-PP O
39 1347 1349 9660111 an DT B-NP O
40 1350 1356 9660111 alpha1 NN I-NP O
41 1356 1357 9660111 - HYPH B-NP O
42 1357 1367 9660111 adrenergic JJ I-NP O
43 1368 1376 9660111 receptor NN I-NP O
44 1376 1377 9660111 . . O O

1 1378 1380 9660111 It PRP B-NP O
2 1381 1384 9660111 may MD B-VP O
3 1385 1387 9660111 be VB I-VP O
4 1388 1397 9660111 concluded VBN I-VP O
5 1398 1402 9660111 that IN B-SBAR O
6 1402 1403 9660111 , , O O
7 1404 1408 9660111 like IN B-PP O
8 1409 1414 9660111 other JJ B-NP O
9 1415 1424 9660111 tricyclic JJ I-NP O
10 1425 1440 9660111 antidepressants NNS I-NP B-Chemical
11 1441 1448 9660111 studied VBN B-VP O
12 1449 1459 9660111 previously RB B-ADVP O
13 1459 1460 9660111 , , O O
14 1461 1464 9660111 TRI NN B-NP B-Chemical
15 1465 1470 9660111 given VBN B-VP O
16 1471 1481 9660111 repeatedly RB B-ADVP O
17 1482 1491 9660111 increases VBZ B-VP O
18 1492 1495 9660111 the DT B-NP O
19 1496 1510 9660111 responsiveness NN I-NP O
20 1511 1513 9660111 of IN B-PP O
21 1514 1519 9660111 brain NN B-NP O
22 1520 1528 9660111 dopamine NN I-NP B-Chemical
23 1529 1531 9660111 D2 NN I-NP O
24 1532 1535 9660111 and CC O O
25 1536 1538 9660111 D3 NN B-NP O
26 1539 1540 9660111 ( ( O O
27 1540 1549 9660111 locomotor NN B-NP O
28 1550 1558 9660111 activity NN I-NP O
29 1559 1562 9660111 but CC B-CONJP O
30 1563 1566 9660111 not RB I-CONJP O
31 1567 1577 9660111 stereotypy JJ B-ADJP O
32 1577 1578 9660111 ) ) O O
33 1579 1581 9660111 as RB B-CONJP O
34 1582 1586 9660111 well RB I-CONJP O
35 1587 1589 9660111 as IN I-CONJP O
36 1590 1596 9660111 alpha1 NN B-NP O
37 1596 1597 9660111 - HYPH B-NP O
38 1597 1607 9660111 adrenergic JJ I-NP O
39 1608 1617 9660111 receptors NNS I-NP O
40 1618 1620 9660111 to TO B-PP O
41 1621 1626 9660111 their PRP$ B-NP O
42 1627 1635 9660111 agonists NNS I-NP O
43 1635 1636 9660111 . . O O

1 1637 1638 9660111 A DT B-NP O
2 1639 1647 9660111 question NN I-NP O
3 1648 1654 9660111 arises VBZ B-VP O
4 1655 1662 9660111 whether IN B-SBAR O
5 1663 1666 9660111 the DT B-NP O
6 1667 1675 9660111 reuptake NN I-NP O
7 1676 1686 9660111 inhibition NN I-NP O
8 1687 1689 9660111 is VBZ B-VP O
9 1690 1692 9660111 of IN B-PP O
10 1693 1696 9660111 any DT B-NP O
11 1697 1707 9660111 importance NN I-NP O
12 1708 1710 9660111 to TO B-PP O
13 1711 1714 9660111 the DT B-NP O
14 1715 1723 9660111 adaptive JJ I-NP O
15 1724 1731 9660111 changes NNS I-NP O
16 1732 1739 9660111 induced VBN B-VP O
17 1740 1742 9660111 by IN B-PP O
18 1743 1751 9660111 repeated VBN B-NP O
19 1752 1767 9660111 antidepressants NNS I-NP B-Chemical
20 1767 1768 9660111 , , O O
21 1769 1778 9660111 suggested VBD B-VP O
22 1779 1781 9660111 to TO I-VP O
23 1782 1784 9660111 be VB I-VP O
24 1785 1796 9660111 responsible JJ B-ADJP O
25 1797 1800 9660111 for IN B-PP O
26 1801 1804 9660111 the DT B-NP O
27 1805 1819 9660111 antidepressant NN I-NP B-Chemical
28 1820 1828 9660111 activity NN I-NP O
29 1828 1829 9660111 . . O O

1 0 0 12716030 -DOCSTART- -X- -X- O

1 0 6 12716030 Amount NN B-NP O
2 7 9 12716030 of IN B-PP O
3 10 18 12716030 bleeding NN B-NP B-Disease
4 19 22 12716030 and CC I-NP O
5 23 31 12716030 hematoma NN I-NP B-Disease
6 32 36 12716030 size NN I-NP O
7 37 39 12716030 in IN B-PP O
8 40 43 12716030 the DT B-NP O
9 44 55 12716030 collagenase NN I-NP O
10 55 56 12716030 - HYPH O O
11 56 63 12716030 induced VBN B-NP O
12 64 77 12716030 intracerebral JJ I-NP B-Disease
13 78 88 12716030 hemorrhage NN I-NP I-Disease
14 89 92 12716030 rat NN I-NP O
15 93 98 12716030 model NN I-NP O
16 98 99 12716030 . . O O
17 100 103 12716030 The DT B-NP O
18 104 114 12716030 aggravated JJ I-NP O
19 115 119 12716030 risk NN I-NP O
20 120 122 12716030 on IN B-PP O
21 123 136 12716030 intracerebral JJ B-NP B-Disease
22 137 147 12716030 hemorrhage NN I-NP I-Disease
23 148 149 12716030 ( ( O O
24 149 152 12716030 ICH NN B-NP B-Disease
25 152 153 12716030 ) ) O O
26 154 158 12716030 with IN B-PP O
27 159 164 12716030 drugs NNS B-NP O
28 165 169 12716030 used VBN B-VP O
29 170 173 12716030 for IN B-PP O
30 174 180 12716030 stroke NN B-NP B-Disease
31 181 189 12716030 patients NNS I-NP O
32 190 196 12716030 should MD B-VP O
33 197 199 12716030 be VB I-VP O
34 200 209 12716030 estimated VBN I-VP O
35 210 219 12716030 carefully RB B-ADVP O
36 219 220 12716030 . . O O

1 221 223 12716030 We PRP B-NP O
2 224 233 12716030 therefore RB B-ADVP O
3 234 245 12716030 established VBD B-VP O
4 246 255 12716030 sensitive JJ B-NP O
5 256 270 12716030 quantification NN I-NP O
6 271 278 12716030 methods NNS I-NP O
7 279 282 12716030 and CC O O
8 283 291 12716030 provided VBD B-VP O
9 292 293 12716030 a DT B-NP O
10 294 297 12716030 rat NN I-NP O
11 298 301 12716030 ICH NN I-NP B-Disease
12 302 307 12716030 model NN I-NP O
13 308 311 12716030 for IN B-PP O
14 312 321 12716030 detection NN B-NP O
15 322 324 12716030 of IN B-PP O
16 325 328 12716030 ICH NN B-NP B-Disease
17 329 342 12716030 deterioration NN I-NP O
18 342 343 12716030 . . O O

1 344 346 12716030 In IN B-PP O
2 347 350 12716030 ICH NN B-NP B-Disease
3 351 366 12716030 intrastriatally RB B-VP O
4 367 374 12716030 induced VBN I-VP O
5 375 377 12716030 by IN B-PP O
6 378 383 12716030 0.014 CD B-NP O
7 383 384 12716030 - HYPH I-NP O
8 384 388 12716030 unit NN I-NP O
9 388 389 12716030 , , O O
10 390 395 12716030 0.070 CD B-NP O
11 395 396 12716030 - HYPH I-NP O
12 396 400 12716030 unit NN I-NP O
13 400 401 12716030 , , O O
14 402 405 12716030 and CC O O
15 406 411 12716030 0.350 CD B-NP O
16 411 412 12716030 - HYPH I-NP O
17 412 416 12716030 unit NN I-NP O
18 417 428 12716030 collagenase NN I-NP O
19 428 429 12716030 , , O O
20 430 433 12716030 the DT B-NP O
21 434 440 12716030 amount NN I-NP O
22 441 443 12716030 of IN B-PP O
23 444 452 12716030 bleeding NN B-NP B-Disease
24 453 456 12716030 was VBD B-VP O
25 457 465 12716030 measured VBN I-VP O
26 466 471 12716030 using VBG B-VP O
27 472 473 12716030 a DT B-NP O
28 474 484 12716030 hemoglobin NN I-NP O
29 485 490 12716030 assay NN I-NP O
30 491 500 12716030 developed VBN B-VP O
31 501 503 12716030 in IN B-PP O
32 504 507 12716030 the DT B-NP O
33 508 515 12716030 present JJ I-NP O
34 516 521 12716030 study NN I-NP O
35 522 525 12716030 and CC O O
36 526 529 12716030 was VBD B-VP O
37 530 538 12716030 compared VBN I-VP O
38 539 543 12716030 with IN B-PP O
39 544 547 12716030 the DT B-NP O
40 548 563 12716030 morphologically RB I-NP O
41 564 574 12716030 determined VBN I-NP O
42 575 583 12716030 hematoma NN I-NP B-Disease
43 584 590 12716030 volume NN I-NP O
44 590 591 12716030 . . O O

1 592 595 12716030 The DT B-NP O
2 596 601 12716030 blood NN I-NP O
3 602 609 12716030 amounts NNS I-NP O
4 610 613 12716030 and CC O O
5 614 622 12716030 hematoma NN B-NP B-Disease
6 623 630 12716030 volumes NNS I-NP O
7 631 635 12716030 were VBD B-VP O
8 636 649 12716030 significantly RB I-VP O
9 650 660 12716030 correlated VBN I-VP O
10 660 661 12716030 , , O O
11 662 665 12716030 and CC O O
12 666 669 12716030 the DT B-NP O
13 670 678 12716030 hematoma NN I-NP B-Disease
14 679 686 12716030 induced VBN B-VP O
15 687 689 12716030 by IN B-PP O
16 690 695 12716030 0.014 CD B-NP O
17 695 696 12716030 - HYPH I-NP O
18 696 700 12716030 unit NN I-NP O
19 701 712 12716030 collagenase NN I-NP O
20 713 716 12716030 was VBD B-VP O
21 717 725 12716030 adequate JJ B-ADJP O
22 726 728 12716030 to TO B-VP O
23 729 735 12716030 detect VB I-VP O
24 736 739 12716030 ICH NN B-NP B-Disease
25 740 753 12716030 deterioration NN I-NP O
26 753 754 12716030 . . O O

1 755 757 12716030 In IN B-PP O
2 758 761 12716030 ICH NN B-NP B-Disease
3 762 771 12716030 induction NN I-NP O
4 772 777 12716030 using VBG B-VP O
5 778 783 12716030 0.014 CD B-NP O
6 783 784 12716030 - HYPH I-NP O
7 784 788 12716030 unit NN I-NP O
8 789 800 12716030 collagenase NN I-NP O
9 800 801 12716030 , , O O
10 802 809 12716030 heparin NN B-NP B-Chemical
11 810 818 12716030 enhanced VBD B-VP O
12 819 822 12716030 the DT B-NP O
13 823 831 12716030 hematoma NN I-NP B-Disease
14 832 838 12716030 volume NN I-NP O
15 839 842 12716030 3.4 CD I-NP O
16 842 843 12716030 - HYPH B-VP O
17 843 847 12716030 fold RB B-ADVP O
18 848 852 12716030 over IN B-PP O
19 853 857 12716030 that DT B-NP O
20 858 862 12716030 seen VBN B-VP O
21 863 865 12716030 in IN B-PP O
22 866 873 12716030 control NN B-NP O
23 874 877 12716030 ICH NN I-NP B-Disease
24 878 885 12716030 animals NNS I-NP O
25 886 889 12716030 and CC O O
26 890 893 12716030 the DT B-NP O
27 894 902 12716030 bleeding VBG I-NP B-Disease
28 903 906 12716030 7.6 CD I-NP O
29 906 907 12716030 - HYPH B-VP O
30 907 911 12716030 fold RB B-ADVP O
31 911 912 12716030 . . O O

1 913 917 12716030 Data NNS B-NP O
2 918 925 12716030 suggest VBP B-VP O
3 926 930 12716030 that IN B-SBAR O
4 931 935 12716030 this DT B-NP O
5 936 945 12716030 sensitive JJ I-NP O
6 946 956 12716030 hemoglobin NN I-NP O
7 957 962 12716030 assay NN I-NP O
8 963 965 12716030 is VBZ B-VP O
9 966 972 12716030 useful JJ B-ADJP O
10 973 976 12716030 for IN B-PP O
11 977 980 12716030 ICH NN B-NP B-Disease
12 981 990 12716030 detection NN I-NP O
13 990 991 12716030 , , O O
14 992 995 12716030 and CC O O
15 996 1000 12716030 that IN B-SBAR O
16 1001 1002 12716030 a DT B-NP O
17 1003 1008 12716030 model NN I-NP O
18 1009 1013 12716030 with IN B-PP O
19 1014 1015 12716030 a DT B-NP O
20 1016 1021 12716030 small JJ I-NP O
21 1022 1025 12716030 ICH NN I-NP B-Disease
22 1026 1033 12716030 induced VBN B-VP O
23 1034 1038 12716030 with IN B-PP O
24 1039 1040 12716030 a DT B-NP O
25 1041 1044 12716030 low JJ I-NP O
26 1044 1045 12716030 - HYPH I-NP O
27 1045 1049 12716030 dose NN I-NP O
28 1050 1061 12716030 collagenase NN I-NP O
29 1062 1068 12716030 should MD B-VP O
30 1069 1071 12716030 be VB I-VP O
31 1072 1076 12716030 used VBN I-VP O
32 1077 1080 12716030 for IN B-PP O
33 1081 1091 12716030 evaluation NN B-NP O
34 1092 1094 12716030 of IN B-PP O
35 1095 1100 12716030 drugs NNS B-NP O
36 1101 1105 12716030 that WDT B-NP O
37 1106 1109 12716030 may MD B-VP O
38 1110 1116 12716030 affect VB I-VP O
39 1117 1120 12716030 ICH NN B-NP B-Disease
40 1120 1121 12716030 . . O O

1 0 0 18221780 -DOCSTART- -X- -X- O

1 0 3 18221780 Sex NN B-NP O
2 4 15 18221780 differences NNS I-NP O
3 16 18 18221780 in IN B-PP O
4 19 23 18221780 NMDA NN B-NP B-Chemical
5 24 34 18221780 antagonist NN I-NP O
6 35 46 18221780 enhancement NN I-NP O
7 47 49 18221780 of IN B-PP O
8 50 58 18221780 morphine NN B-NP B-Chemical
9 59 75 18221780 antihyperalgesia NN I-NP O
10 76 78 18221780 in IN B-PP O
11 79 80 18221780 a DT B-NP O
12 81 90 18221780 capsaicin NN I-NP B-Chemical
13 91 96 18221780 model NN I-NP O
14 97 99 18221780 of IN B-PP O
15 100 110 18221780 persistent JJ B-NP O
16 111 115 18221780 pain NN I-NP B-Disease
17 115 116 18221780 : : O O
18 117 128 18221780 comparisons NNS B-NP O
19 129 131 18221780 to TO B-PP O
20 132 135 18221780 two CD B-NP O
21 136 142 18221780 models NNS I-NP O
22 143 145 18221780 of IN B-PP O
23 146 151 18221780 acute JJ B-NP B-Disease
24 152 156 18221780 pain NN I-NP I-Disease
25 156 157 18221780 . . O O
26 158 160 18221780 In IN B-PP O
27 161 166 18221780 acute JJ B-NP B-Disease
28 167 171 18221780 pain NN I-NP I-Disease
29 172 178 18221780 models NNS I-NP O
30 178 179 18221780 , , O O
31 180 181 18221780 N NN B-NP B-Chemical
32 181 182 18221780 - HYPH B-NP I-Chemical
33 182 188 18221780 methyl NN I-NP I-Chemical
34 188 189 18221780 - HYPH B-NP I-Chemical
35 189 190 18221780 D NN I-NP I-Chemical
36 190 191 18221780 - HYPH O I-Chemical
37 191 200 18221780 aspartate NN B-NP I-Chemical
38 201 202 18221780 ( ( O O
39 202 206 18221780 NMDA NN B-NP B-Chemical
40 206 207 18221780 ) ) O O
41 208 219 18221780 antagonists NNS B-NP O
42 220 227 18221780 enhance VBP B-VP O
43 228 231 18221780 the DT B-NP O
44 232 247 18221780 antinociceptive JJ I-NP O
45 248 255 18221780 effects NNS I-NP O
46 256 258 18221780 of IN B-PP O
47 259 267 18221780 morphine NN B-NP B-Chemical
48 268 270 18221780 to TO B-PP O
49 271 272 18221780 a DT B-NP O
50 273 280 18221780 greater JJR I-NP O
51 281 287 18221780 extent NN I-NP O
52 288 290 18221780 in IN B-PP O
53 291 296 18221780 males NNS B-NP O
54 297 301 18221780 than IN B-PP O
55 302 309 18221780 females NNS B-NP O
56 309 310 18221780 . . O O

1 311 314 18221780 The DT B-NP O
2 315 322 18221780 purpose NN I-NP O
3 323 325 18221780 of IN B-PP O
4 326 330 18221780 this DT B-NP O
5 331 344 18221780 investigation NN I-NP O
6 345 348 18221780 was VBD B-VP O
7 349 351 18221780 to TO B-VP O
8 352 358 18221780 extend VB I-VP O
9 359 364 18221780 these DT B-NP O
10 365 373 18221780 findings NNS I-NP O
11 374 376 18221780 to TO B-PP O
12 377 378 18221780 a DT B-NP O
13 379 389 18221780 persistent JJ I-NP O
14 390 394 18221780 pain NN I-NP B-Disease
15 395 400 18221780 model NN I-NP O
16 401 406 18221780 which WDT B-NP O
17 407 412 18221780 could MD B-VP O
18 413 415 18221780 be VB I-VP O
19 416 429 18221780 distinguished VBN I-VP O
20 430 434 18221780 from IN B-PP O
21 435 440 18221780 acute JJ B-NP B-Disease
22 441 445 18221780 pain NN I-NP I-Disease
23 446 452 18221780 models NNS I-NP O
24 453 455 18221780 on IN B-PP O
25 456 459 18221780 the DT B-NP O
26 460 465 18221780 basis NN I-NP O
27 466 468 18221780 of IN B-PP O
28 469 472 18221780 the DT B-NP O
29 473 484 18221780 nociceptive JJ I-NP O
30 485 491 18221780 fibers NNS I-NP O
31 492 501 18221780 activated VBN B-VP O
32 501 502 18221780 , , O O
33 503 516 18221780 neurochemical JJ B-NP O
34 517 527 18221780 substrates NNS I-NP O
35 527 528 18221780 , , O O
36 529 532 18221780 and CC O O
37 533 541 18221780 duration NN B-NP O
38 542 544 18221780 of IN B-PP O
39 545 548 18221780 the DT B-NP O
40 549 560 18221780 nociceptive JJ I-NP O
41 561 569 18221780 stimulus NN I-NP O
42 569 570 18221780 . . O O

1 571 573 18221780 To TO B-PP O
2 574 578 18221780 this DT B-NP O
3 579 582 18221780 end NN I-NP O
4 582 583 18221780 , , O O
5 584 594 18221780 persistent JJ B-NP O
6 595 607 18221780 hyperalgesia NN I-NP B-Disease
7 608 611 18221780 was VBD B-VP O
8 612 619 18221780 induced VBN I-VP O
9 620 622 18221780 by IN B-PP O
10 623 637 18221780 administration NN B-NP O
11 638 640 18221780 of IN B-PP O
12 641 650 18221780 capsaicin NN B-NP B-Chemical
13 651 653 18221780 in IN B-PP O
14 654 657 18221780 the DT B-NP O
15 658 662 18221780 tail NN I-NP O
16 663 665 18221780 of IN B-PP O
17 666 675 18221780 gonadally RB B-NP O
18 676 682 18221780 intact JJ I-NP O
19 683 687 18221780 F344 NN I-NP O
20 688 692 18221780 rats NNS I-NP O
21 692 693 18221780 , , O O
22 694 703 18221780 following VBG B-PP O
23 704 709 18221780 which WDT B-NP O
24 710 713 18221780 the DT B-NP O
25 714 718 18221780 tail NN I-NP O
26 719 722 18221780 was VBD B-VP O
27 723 731 18221780 immersed VBN I-VP O
28 732 734 18221780 in IN B-PP O
29 735 736 18221780 a DT B-NP O
30 737 743 18221780 mildly RB I-NP O
31 744 751 18221780 noxious JJ I-NP O
32 752 759 18221780 thermal JJ I-NP O
33 760 768 18221780 stimulus NN I-NP O
34 768 769 18221780 , , O O
35 770 773 18221780 and CC O O
36 774 778 18221780 tail NN B-NP O
37 778 779 18221780 - HYPH B-NP O
38 779 789 18221780 withdrawal NN I-NP O
39 790 799 18221780 latencies NNS I-NP O
40 800 808 18221780 measured VBN B-VP O
41 808 809 18221780 . . O O

1 810 813 18221780 For IN B-PP O
2 814 824 18221780 comparison NN B-NP O
3 824 825 18221780 , , O O
4 826 831 18221780 tests NNS B-NP O
5 832 836 18221780 were VBD B-VP O
6 837 846 18221780 conducted VBN I-VP O
7 847 849 18221780 in IN B-PP O
8 850 853 18221780 two CD B-NP O
9 854 859 18221780 acute JJ I-NP B-Disease
10 860 864 18221780 pain NN I-NP I-Disease
11 865 871 18221780 models NNS I-NP O
12 871 872 18221780 , , O O
13 873 876 18221780 the DT B-NP O
14 877 885 18221780 hotplate NN I-NP O
15 886 889 18221780 and CC I-NP O
16 890 894 18221780 warm JJ I-NP O
17 895 900 18221780 water NN I-NP O
18 901 905 18221780 tail NN I-NP O
19 905 906 18221780 - HYPH B-NP O
20 906 916 18221780 withdrawal NN I-NP O
21 917 927 18221780 procedures NNS I-NP O
22 927 928 18221780 . . O O

1 929 931 18221780 In IN B-PP O
2 932 937 18221780 males NNS B-NP O
3 937 938 18221780 , , O O
4 939 942 18221780 the DT B-NP O
5 943 946 18221780 non AFX I-NP O
6 946 947 18221780 - HYPH I-NP O
7 947 958 18221780 competitive JJ I-NP O
8 959 963 18221780 NMDA NN I-NP B-Chemical
9 964 974 18221780 antagonist NN I-NP O
10 975 991 18221780 dextromethorphan NN I-NP B-Chemical
11 992 1000 18221780 enhanced VBD B-VP O
12 1001 1004 18221780 the DT B-NP O
13 1005 1021 18221780 antihyperalgesic JJ I-NP O
14 1022 1028 18221780 effect NN I-NP O
15 1029 1031 18221780 of IN B-PP O
16 1032 1035 18221780 low JJ B-NP O
17 1036 1038 18221780 to TO B-PP O
18 1039 1047 18221780 moderate JJ B-NP O
19 1048 1053 18221780 doses NNS I-NP O
20 1054 1056 18221780 of IN B-PP O
21 1057 1065 18221780 morphine NN B-NP B-Chemical
22 1066 1068 18221780 in IN B-PP O
23 1069 1070 18221780 a DT B-NP O
24 1071 1075 18221780 dose NN I-NP O
25 1075 1076 18221780 - HYPH O O
26 1076 1079 18221780 and CC O O
27 1080 1084 18221780 time NN B-NP O
28 1084 1085 18221780 - HYPH B-NP O
29 1085 1094 18221780 dependent JJ I-NP O
30 1095 1101 18221780 manner NN I-NP O
31 1101 1102 18221780 . . O O

1 1103 1109 18221780 Across IN B-PP O
2 1110 1113 18221780 the DT B-NP O
3 1114 1119 18221780 doses NNS I-NP O
4 1120 1123 18221780 and CC O O
5 1124 1136 18221780 pretreatment NN B-NP O
6 1137 1142 18221780 times NNS I-NP O
7 1143 1151 18221780 examined VBN B-VP O
8 1151 1152 18221780 , , O O
9 1153 1164 18221780 enhancement NN B-NP O
10 1165 1168 18221780 was VBD B-VP O
11 1169 1172 18221780 not RB I-VP O
12 1173 1181 18221780 observed VBN I-VP O
13 1182 1184 18221780 in IN B-PP O
14 1185 1192 18221780 females NNS B-NP O
15 1192 1193 18221780 . . O O

1 1194 1205 18221780 Enhancement NN B-NP O
2 1206 1208 18221780 of IN B-PP O
3 1209 1217 18221780 morphine NN B-NP B-Chemical
4 1218 1233 18221780 antinociception NN I-NP O
5 1234 1236 18221780 by IN B-PP O
6 1237 1253 18221780 dextromethorphan NN B-NP B-Chemical
7 1254 1257 18221780 was VBD B-VP O
8 1258 1262 18221780 seen VBN I-VP O
9 1263 1265 18221780 in IN B-PP O
10 1266 1270 18221780 both CC B-NP O
11 1271 1276 18221780 males NNS I-NP O
12 1277 1280 18221780 and CC I-NP O
13 1281 1288 18221780 females NNS I-NP O
14 1289 1291 18221780 in IN B-PP O
15 1292 1295 18221780 the DT B-NP O
16 1296 1301 18221780 acute JJ I-NP B-Disease
17 1302 1306 18221780 pain NN I-NP I-Disease
18 1307 1313 18221780 models NNS I-NP O
19 1313 1314 18221780 , , O O
20 1315 1319 18221780 with IN B-PP O
21 1320 1323 18221780 the DT B-NP O
22 1324 1333 18221780 magnitude NN I-NP O
23 1334 1336 18221780 of IN B-PP O
24 1337 1341 18221780 this DT B-NP O
25 1342 1348 18221780 effect NN I-NP O
26 1349 1354 18221780 being VBG B-VP O
27 1355 1362 18221780 greater JJR B-ADJP O
28 1363 1365 18221780 in IN B-PP O
29 1366 1371 18221780 males NNS B-NP O
30 1371 1372 18221780 . . O O

1 1373 1378 18221780 These DT B-NP O
2 1379 1387 18221780 findings NNS I-NP O
3 1388 1399 18221780 demonstrate VBP B-VP O
4 1400 1401 18221780 a DT B-NP O
5 1402 1410 18221780 sexually RB I-NP O
6 1410 1411 18221780 - HYPH I-NP O
7 1411 1420 18221780 dimorphic JJ I-NP O
8 1421 1432 18221780 interaction NN I-NP O
9 1433 1440 18221780 between IN B-PP O
10 1441 1445 18221780 NMDA NN B-NP B-Chemical
11 1446 1457 18221780 antagonists NNS I-NP O
12 1458 1461 18221780 and CC O O
13 1462 1470 18221780 morphine NN B-NP B-Chemical
14 1471 1473 18221780 in IN B-PP O
15 1474 1475 18221780 a DT B-NP O
16 1476 1486 18221780 persistent JJ I-NP O
17 1487 1491 18221780 pain NN I-NP B-Disease
18 1492 1497 18221780 model NN I-NP O
19 1498 1502 18221780 that WDT B-NP O
20 1503 1506 18221780 can MD B-VP O
21 1507 1509 18221780 be VB I-VP O
22 1510 1523 18221780 distinguished VBN I-VP O
23 1524 1528 18221780 from IN B-PP O
24 1529 1534 18221780 those DT B-NP O
25 1535 1543 18221780 observed VBN B-VP O
26 1544 1546 18221780 in IN B-PP O
27 1547 1552 18221780 acute JJ B-NP B-Disease
28 1553 1557 18221780 pain NN I-NP I-Disease
29 1558 1564 18221780 models NNS I-NP O
30 1564 1565 18221780 . . O O

1 0 0 9855119 -DOCSTART- -X- -X- O

1 0 8 9855119 Clinical JJ B-NP O
2 9 12 9855119 and CC I-NP O
3 13 28 9855119 histopathologic JJ I-NP O
4 29 40 9855119 examination NN I-NP O
5 41 43 9855119 of IN B-PP O
6 44 49 9855119 renal JJ B-NP O
7 50 60 9855119 allografts NNS I-NP O
8 61 68 9855119 treated VBN B-VP O
9 69 73 9855119 with IN B-PP O
10 74 84 9855119 tacrolimus NN B-NP B-Chemical
11 85 86 9855119 ( ( O O
12 86 91 9855119 FK506 NN B-NP B-Chemical
13 91 92 9855119 ) ) O O
14 93 96 9855119 for IN B-PP O
15 97 99 9855119 at IN B-NP O
16 100 105 9855119 least JJS I-NP O
17 106 109 9855119 one CD I-NP O
18 110 114 9855119 year NN I-NP O
19 114 115 9855119 . . B-NP O
20 116 126 9855119 BACKGROUND NN I-NP O
21 126 127 9855119 : : O O
22 128 130 9855119 We PRP B-NP O
23 131 141 9855119 clinically RB B-ADVP O
24 142 145 9855119 and CC I-ADVP O
25 146 160 9855119 pathologically RB I-ADVP O
26 161 169 9855119 analyzed VBN B-VP O
27 170 175 9855119 renal JJ B-NP O
28 176 186 9855119 allografts NNS I-NP O
29 187 191 9855119 from IN B-PP O
30 192 193 9855119 1 CD B-NP O
31 194 195 9855119 9 CD I-NP O
32 196 201 9855119 renal JJ I-NP O
33 202 212 9855119 transplant NN I-NP O
34 213 221 9855119 patients NNS I-NP O
35 222 229 9855119 treated VBN B-VP O
36 230 234 9855119 with IN B-PP O
37 235 245 9855119 tacrolimus NN B-NP B-Chemical
38 246 247 9855119 ( ( O O
39 247 252 9855119 FK506 NN B-NP B-Chemical
40 252 253 9855119 ) ) O O
41 254 257 9855119 for IN B-PP O
42 258 262 9855119 more JJR B-NP O
43 263 267 9855119 than IN I-NP O
44 268 269 9855119 1 CD I-NP O
45 270 274 9855119 year NN I-NP O
46 274 275 9855119 . . O O

1 276 283 9855119 METHODS NNS B-NP O
2 283 284 9855119 : : O O
3 285 291 9855119 Twenty CD B-NP O
4 291 292 9855119 - HYPH I-NP O
5 292 295 9855119 six CD I-NP O
6 296 301 9855119 renal JJ I-NP O
7 302 311 9855119 allograft NN I-NP O
8 312 318 9855119 biopsy NN I-NP O
9 319 328 9855119 specimens NNS I-NP O
10 329 333 9855119 from IN B-PP O
11 334 335 9855119 1 CD B-NP O
12 336 337 9855119 9 CD I-NP O
13 338 343 9855119 renal JJ I-NP O
14 344 354 9855119 transplant NN I-NP O
15 355 363 9855119 patients NNS I-NP O
16 364 367 9855119 who WP B-NP O
17 368 377 9855119 underwent VBD B-VP O
18 378 394 9855119 transplantations NNS B-NP O
19 395 402 9855119 between IN B-PP O
20 403 407 9855119 1991 CD B-NP O
21 408 411 9855119 and CC I-NP O
22 412 416 9855119 1993 CD I-NP O
23 417 421 9855119 were VBD B-VP O
24 422 431 9855119 evaluated VBN I-VP O
25 431 432 9855119 . . O O

1 433 441 9855119 Thirteen CD B-NP O
2 442 450 9855119 biopsies NNS I-NP O
3 451 455 9855119 were VBD B-VP O
4 456 465 9855119 performed VBN I-VP O
5 466 470 9855119 from IN B-PP O
6 471 477 9855119 stable JJ B-NP O
7 478 489 9855119 functioning VBG I-NP O
8 490 495 9855119 renal JJ I-NP O
9 496 506 9855119 allografts NNS I-NP O
10 507 511 9855119 with IN B-PP O
11 512 520 9855119 informed VBN B-NP O
12 521 528 9855119 consent NN I-NP O
13 529 530 9855119 ( ( O O
14 530 540 9855119 nonepisode JJ B-NP O
15 541 547 9855119 biopsy NN I-NP O
16 547 548 9855119 ) ) O O
17 549 552 9855119 and CC O O
18 553 556 9855119 the DT B-NP O
19 557 562 9855119 other JJ I-NP O
20 563 565 9855119 13 CD I-NP O
21 566 570 9855119 were VBD B-VP O
22 571 575 9855119 from IN B-PP O
23 576 589 9855119 dysfunctional JJ B-NP O
24 590 595 9855119 renal JJ I-NP O
25 596 606 9855119 allografts NNS I-NP O
26 607 611 9855119 with IN B-PP O
27 612 613 9855119 a DT B-NP O
28 614 622 9855119 clinical JJ I-NP O
29 623 633 9855119 indication NN I-NP O
30 634 637 9855119 for IN B-PP O
31 638 644 9855119 biopsy NN B-NP O
32 645 646 9855119 ( ( O O
33 646 653 9855119 episode NN B-NP O
34 654 660 9855119 biopsy NN I-NP O
35 660 661 9855119 ) ) O O
36 661 662 9855119 . . O O

1 663 670 9855119 RESULTS NNS B-NP O
2 670 671 9855119 : : O O
3 672 675 9855119 The DT B-NP O
4 676 680 9855119 main JJ I-NP O
5 681 691 9855119 pathologic JJ I-NP O
6 692 701 9855119 diagnoses NNS I-NP O
7 702 703 9855119 ( ( O O
8 703 707 9855119 some DT B-NP O
9 708 715 9855119 overlap NN I-NP O
10 715 716 9855119 ) ) O O
11 717 721 9855119 were VBD B-VP O
12 722 727 9855119 acute JJ B-NP O
13 728 737 9855119 rejection NN I-NP O
14 738 739 9855119 ( ( O O
15 739 741 9855119 AR NN B-NP O
16 741 742 9855119 ; : O O
17 743 744 9855119 n NN B-NP O
18 745 746 9855119 = SYM B-VP O
19 747 748 9855119 4 CD B-NP O
20 748 749 9855119 ) ) O O
21 749 750 9855119 , , O O
22 751 758 9855119 chronic JJ B-NP O
23 759 768 9855119 rejection NN I-NP O
24 769 770 9855119 ( ( O O
25 770 772 9855119 CR NN B-NP O
26 772 773 9855119 ; : O O
27 774 775 9855119 n NN B-NP O
28 775 776 9855119 = SYM B-VP O
29 776 777 9855119 5 CD B-NP O
30 777 778 9855119 ) ) O O
31 778 779 9855119 , , O O
32 780 782 9855119 AR NN B-NP O
33 782 783 9855119 + SYM O O
34 783 785 9855119 CR NN B-NP O
35 786 787 9855119 ( ( O O
36 787 788 9855119 n NN B-NP O
37 789 790 9855119 = SYM B-VP O
38 790 791 9855119 4 CD B-NP O
39 791 792 9855119 ) ) O O
40 792 793 9855119 , , O O
41 794 803 9855119 recurrent JJ B-NP O
42 804 807 9855119 IgA NN I-NP B-Disease
43 808 819 9855119 nephropathy NN I-NP I-Disease
44 820 821 9855119 ( ( O O
45 821 822 9855119 n NN B-NP O
46 823 824 9855119 = SYM B-VP O
47 824 825 9855119 5 CD B-NP O
48 825 826 9855119 ) ) O O
49 826 827 9855119 , , O O
50 828 834 9855119 normal JJ B-NP O
51 835 843 9855119 findings NNS I-NP O
52 844 845 9855119 ( ( O O
53 845 846 9855119 n NN B-NP O
54 847 848 9855119 = SYM B-VP O
55 848 849 9855119 2 CD B-NP O
56 849 850 9855119 ) ) O O
57 850 851 9855119 , , O O
58 852 859 9855119 minimal JJ B-NP O
59 859 860 9855119 - HYPH I-NP O
60 860 864 9855119 type NN I-NP O
61 865 872 9855119 chronic JJ I-NP O
62 873 878 9855119 FK506 NN I-NP B-Chemical
63 879 890 9855119 nephropathy NN I-NP B-Disease
64 891 892 9855119 ( ( O O
65 892 893 9855119 n NN B-NP O
66 894 895 9855119 = SYM B-VP O
67 896 897 9855119 9 CD B-NP O
68 897 898 9855119 ) ) O O
69 898 899 9855119 , , O O
70 900 903 9855119 and CC O O
71 904 908 9855119 mild JJ B-NP O
72 908 909 9855119 - HYPH I-NP O
73 909 913 9855119 type NN I-NP O
74 914 919 9855119 FK506 NN I-NP B-Chemical
75 920 931 9855119 nephropathy NN I-NP B-Disease
76 932 933 9855119 ( ( O O
77 933 934 9855119 n NN B-NP O
78 935 936 9855119 = SYM B-VP O
79 937 939 9855119 11 CD B-NP O
80 939 940 9855119 ) ) O O
81 940 941 9855119 . . O O

1 942 944 9855119 Of IN B-PP O
2 945 948 9855119 the DT B-NP O
3 949 959 9855119 nonepisode JJ I-NP O
4 960 968 9855119 biopsies NNS I-NP O
5 968 969 9855119 , , O O
6 970 971 9855119 7 CD B-NP O
7 972 975 9855119 and CC I-NP O
8 976 977 9855119 4 CD I-NP O
9 978 986 9855119 biopsies NNS I-NP O
10 987 993 9855119 showed VBD B-VP O
11 994 1001 9855119 minimal JJ B-NP O
12 1001 1002 9855119 - HYPH I-NP O
13 1002 1006 9855119 type NN I-NP O
14 1007 1010 9855119 and CC I-NP O
15 1011 1015 9855119 mild JJ I-NP O
16 1015 1016 9855119 - HYPH I-NP O
17 1016 1020 9855119 type NN I-NP O
18 1021 1028 9855119 chronic JJ I-NP O
19 1029 1034 9855119 FK506 NN I-NP B-Chemical
20 1035 1046 9855119 nephropathy NN I-NP B-Disease
21 1046 1047 9855119 , , O O
22 1048 1060 9855119 respectively RB B-ADVP O
23 1060 1061 9855119 . . O O

1 1062 1069 9855119 Chronic JJ B-NP O
2 1070 1075 9855119 FK506 NN I-NP B-Chemical
3 1076 1087 9855119 nephropathy NN I-NP B-Disease
4 1088 1097 9855119 consisted VBD B-VP O
5 1098 1100 9855119 of IN B-PP O
6 1101 1106 9855119 rough JJ B-NP O
7 1107 1110 9855119 and CC I-NP O
8 1111 1116 9855119 foamy JJ I-NP O
9 1117 1124 9855119 tubular JJ I-NP O
10 1125 1138 9855119 vacuolization NN I-NP O
11 1139 1140 9855119 ( ( O O
12 1140 1141 9855119 5 CD B-NP O
13 1142 1150 9855119 biopsies NNS I-NP O
14 1150 1151 9855119 ) ) O O
15 1151 1152 9855119 , , O O
16 1153 1167 9855119 arteriolopathy NN B-NP O
17 1168 1169 9855119 ( ( O O
18 1169 1186 9855119 angiodegeneration NN B-NP O
19 1187 1189 9855119 of IN B-PP O
20 1190 1193 9855119 the DT B-NP O
21 1194 1204 9855119 arteriolar JJ I-NP O
22 1205 1209 9855119 wall NN I-NP O
23 1209 1210 9855119 ; : O O
24 1211 1213 9855119 20 CD B-NP O
25 1214 1222 9855119 biopsies NNS I-NP O
26 1222 1223 9855119 ) ) O O
27 1223 1224 9855119 , , O O
28 1225 1230 9855119 focal JJ B-NP B-Disease
29 1231 1240 9855119 segmental JJ I-NP I-Disease
30 1241 1259 9855119 glomerulosclerosis NN I-NP I-Disease
31 1260 1261 9855119 ( ( O O
32 1261 1262 9855119 4 CD B-NP O
33 1263 1271 9855119 biopsies NNS I-NP O
34 1271 1272 9855119 ) ) O O
35 1273 1276 9855119 and CC O O
36 1277 1280 9855119 the DT B-NP O
37 1281 1288 9855119 striped VBN I-NP O
38 1289 1293 9855119 form NN I-NP O
39 1294 1296 9855119 of IN B-PP O
40 1297 1309 9855119 interstitial JJ B-NP B-Disease
41 1310 1318 9855119 fibrosis NN I-NP I-Disease
42 1319 1320 9855119 ( ( O O
43 1320 1322 9855119 11 CD B-NP O
44 1323 1331 9855119 biopsies NNS I-NP O
45 1331 1332 9855119 ) ) O O
46 1332 1333 9855119 . . O O

1 1334 1337 9855119 The DT B-NP O
2 1338 1343 9855119 serum NN I-NP O
3 1344 1354 9855119 creatinine NN I-NP B-Chemical
4 1355 1361 9855119 levels NNS I-NP O
5 1362 1364 9855119 of IN B-PP O
6 1365 1373 9855119 patients NNS B-NP O
7 1374 1376 9855119 in IN B-PP O
8 1377 1380 9855119 the DT B-NP O
9 1381 1385 9855119 mild JJ I-NP O
10 1385 1386 9855119 - HYPH I-NP O
11 1386 1390 9855119 type NN I-NP O
12 1391 1398 9855119 chronic JJ I-NP O
13 1399 1404 9855119 FK506 NN I-NP B-Chemical
14 1405 1416 9855119 nephropathy NN I-NP B-Disease
15 1417 1422 9855119 group NN I-NP O
16 1422 1423 9855119 , , O O
17 1424 1429 9855119 which WDT B-NP O
18 1430 1438 9855119 included VBD B-VP O
19 1439 1440 9855119 7 CD B-NP O
20 1441 1448 9855119 episode NN I-NP O
21 1449 1457 9855119 biopsies NNS I-NP O
22 1457 1458 9855119 , , O O
23 1459 1463 9855119 were VBD B-VP O
24 1464 1477 9855119 statistically RB B-ADJP O
25 1478 1484 9855119 higher JJR I-ADJP O
26 1485 1489 9855119 than IN B-PP O
27 1490 1495 9855119 those DT B-NP O
28 1496 1498 9855119 in IN B-PP O
29 1499 1502 9855119 the DT B-NP O
30 1503 1510 9855119 minimum JJ I-NP O
31 1510 1511 9855119 - HYPH I-NP O
32 1511 1515 9855119 type NN I-NP O
33 1516 1523 9855119 chronic JJ I-NP O
34 1524 1529 9855119 FK506 NN I-NP B-Chemical
35 1529 1530 9855119 - HYPH I-NP O
36 1530 1541 9855119 nephropathy NN I-NP B-Disease
37 1542 1547 9855119 group NN I-NP O
38 1548 1549 9855119 ( ( O O
39 1549 1550 9855119 P NN B-NP O
40 1550 1551 9855119 < SYM O O
41 1552 1557 9855119 0.001 CD B-NP O
42 1557 1558 9855119 ) ) O O
43 1558 1559 9855119 . . O O

1 1560 1571 9855119 CONCLUSIONS NNS B-NP O
2 1571 1572 9855119 : : O O
3 1573 1577 9855119 This DT B-NP O
4 1578 1583 9855119 study NN I-NP O
5 1584 1596 9855119 demonstrates VBZ B-VP O
6 1597 1601 9855119 that IN B-SBAR O
7 1602 1609 9855119 chronic JJ B-NP O
8 1610 1615 9855119 FK506 NN I-NP B-Chemical
9 1616 1627 9855119 nephropathy NN I-NP B-Disease
10 1628 1636 9855119 consists VBZ B-VP O
11 1637 1646 9855119 primarily RB B-ADVP O
12 1647 1649 9855119 of IN B-PP O
13 1650 1664 9855119 arteriolopathy NN B-NP O
14 1665 1676 9855119 manifesting VBG B-VP O
15 1677 1679 9855119 as IN B-SBAR O
16 1680 1690 9855119 insudative JJ B-NP O
17 1691 1701 9855119 hyalinosis NN I-NP O
18 1702 1704 9855119 of IN B-PP O
19 1705 1708 9855119 the DT B-NP O
20 1709 1719 9855119 arteriolar JJ I-NP O
21 1720 1724 9855119 wall NN I-NP O
22 1724 1725 9855119 , , O O
23 1726 1729 9855119 and CC O O
24 1730 1738 9855119 suggests VBZ B-VP O
25 1739 1743 9855119 that IN B-SBAR O
26 1744 1748 9855119 mild JJ B-NP O
27 1748 1749 9855119 - HYPH I-NP O
28 1749 1753 9855119 type NN I-NP O
29 1754 1761 9855119 chronic JJ I-NP O
30 1762 1767 9855119 FK506 NN I-NP B-Chemical
31 1768 1779 9855119 nephropathy NN I-NP B-Disease
32 1780 1782 9855119 is VBZ B-VP O
33 1783 1784 9855119 a DT B-NP O
34 1785 1794 9855119 condition NN I-NP O
35 1795 1800 9855119 which WDT B-NP O
36 1801 1804 9855119 may MD B-VP O
37 1805 1809 9855119 lead VB I-VP O
38 1810 1812 9855119 to TO B-PP O
39 1813 1826 9855119 deterioration NN B-NP O
40 1827 1829 9855119 of IN B-PP O
41 1830 1835 9855119 renal JJ B-NP O
42 1836 1845 9855119 allograft NN I-NP O
43 1846 1854 9855119 function NN I-NP O
44 1854 1855 9855119 . . O O

1 0 0 3560095 -DOCSTART- -X- -X- O

1 0 12 3560095 Flurbiprofen NN B-NP B-Chemical
2 13 15 3560095 in IN B-PP O
3 16 19 3560095 the DT B-NP O
4 20 29 3560095 treatment NN I-NP O
5 30 32 3560095 of IN B-PP O
6 33 41 3560095 juvenile JJ B-NP B-Disease
7 42 52 3560095 rheumatoid JJ I-NP I-Disease
8 53 62 3560095 arthritis NN I-NP I-Disease
9 62 63 3560095 . . O O
10 64 70 3560095 Thirty CD B-NP O
11 70 71 3560095 - HYPH O O
12 71 75 3560095 four CD B-NP O
13 76 84 3560095 patients NNS I-NP O
14 85 89 3560095 with IN B-PP O
15 90 98 3560095 juvenile JJ B-NP B-Disease
16 99 109 3560095 rheumatoid JJ I-NP I-Disease
17 110 119 3560095 arthritis NN I-NP I-Disease
18 119 120 3560095 , , O O
19 121 124 3560095 who WP B-NP O
20 125 129 3560095 were VBD B-VP O
21 130 137 3560095 treated VBN I-VP O
22 138 142 3560095 with IN B-PP O
23 143 155 3560095 flurbiprofen NN B-NP B-Chemical
24 156 158 3560095 at IN B-PP O
25 159 160 3560095 a DT B-NP O
26 161 168 3560095 maximum NN I-NP O
27 169 173 3560095 dose NN I-NP O
28 174 176 3560095 of IN B-PP O
29 177 178 3560095 4 CD B-NP O
30 179 181 3560095 mg NN I-NP O
31 181 182 3560095 / SYM B-NP O
32 182 184 3560095 kg NN I-NP O
33 184 185 3560095 / SYM B-NP O
34 185 188 3560095 day NN I-NP O
35 188 189 3560095 , , O O
36 190 193 3560095 had VBD B-VP O
37 194 207 3560095 statistically RB B-NP O
38 208 219 3560095 significant JJ I-NP O
39 220 229 3560095 decreases NNS I-NP O
40 230 234 3560095 from IN B-PP O
41 235 243 3560095 baseline NN B-NP O
42 244 246 3560095 in IN B-PP O
43 247 248 3560095 6 CD B-NP O
44 249 258 3560095 arthritis NN I-NP B-Disease
45 259 266 3560095 indices NNS I-NP O
46 267 272 3560095 after IN B-PP O
47 273 275 3560095 12 CD B-NP O
48 276 281 3560095 weeks NNS I-NP O
49 282 284 3560095 of IN B-PP O
50 285 294 3560095 treatment NN B-NP O
51 294 295 3560095 . . O O

1 296 308 3560095 Improvements NNS B-NP O
2 309 313 3560095 were VBD B-VP O
3 314 318 3560095 seen VBN I-VP O
4 319 321 3560095 in IN B-PP O
5 322 325 3560095 the DT B-NP O
6 326 332 3560095 number NN I-NP O
7 333 335 3560095 of IN B-PP O
8 336 342 3560095 tender NN B-NP B-Disease
9 343 349 3560095 joints NNS I-NP I-Disease
10 349 350 3560095 , , O O
11 351 354 3560095 the DT B-NP O
12 355 363 3560095 severity NN I-NP O
13 364 366 3560095 of IN B-PP O
14 367 375 3560095 swelling NN B-NP B-Disease
15 376 379 3560095 and CC I-NP O
16 380 390 3560095 tenderness NN I-NP B-Disease
17 390 391 3560095 , , O O
18 392 395 3560095 the DT B-NP O
19 396 400 3560095 time NN I-NP O
20 401 403 3560095 of IN B-PP O
21 404 408 3560095 walk NN B-NP O
22 409 411 3560095 50 CD B-NP O
23 412 416 3560095 feet NNS I-NP O
24 416 417 3560095 , , O O
25 418 421 3560095 the DT B-NP O
26 422 430 3560095 duration NN I-NP O
27 431 433 3560095 of IN B-PP O
28 434 441 3560095 morning NN B-NP B-Disease
29 442 451 3560095 stiffness NN I-NP I-Disease
30 452 455 3560095 and CC O O
31 456 459 3560095 the DT B-NP O
32 460 473 3560095 circumference NN I-NP O
33 474 476 3560095 of IN B-PP O
34 477 480 3560095 the DT B-NP O
35 481 485 3560095 left JJ I-NP O
36 486 490 3560095 knee NN I-NP O
37 490 491 3560095 . . O O

1 492 495 3560095 The DT B-NP O
2 496 500 3560095 most RBS I-NP O
3 501 511 3560095 frequently RB I-NP O
4 512 520 3560095 observed VBN I-NP O
5 521 525 3560095 side NN I-NP O
6 526 532 3560095 effect NN I-NP O
7 533 536 3560095 was VBD B-VP O
8 537 542 3560095 fecal JJ B-NP B-Disease
9 543 549 3560095 occult JJ I-NP I-Disease
10 550 555 3560095 blood NN I-NP I-Disease
11 556 557 3560095 ( ( O O
12 557 560 3560095 25% CD B-NP O
13 561 563 3560095 of IN B-PP O
14 564 572 3560095 patients NNS B-NP O
15 572 573 3560095 ) ) O O
16 573 574 3560095 ; : O O
17 575 582 3560095 however RB B-ADVP O
18 582 583 3560095 , , O O
19 584 589 3560095 there EX B-NP O
20 590 593 3560095 was VBD B-VP O
21 594 596 3560095 no DT B-NP O
22 597 602 3560095 other JJ I-NP O
23 603 611 3560095 evidence NN I-NP O
24 612 614 3560095 of IN B-PP O
25 615 631 3560095 gastrointestinal JJ B-NP B-Disease
26 632 633 3560095 ( ( O I-Disease
27 633 635 3560095 GI NN B-NP I-Disease
28 635 636 3560095 ) ) O I-Disease
29 637 645 3560095 bleeding VBG B-VP I-Disease
30 646 648 3560095 in IN B-PP O
31 649 654 3560095 these DT B-NP O
32 655 663 3560095 patients NNS I-NP O
33 663 664 3560095 . . O O

1 665 668 3560095 One CD B-NP O
2 669 676 3560095 patient NN I-NP O
3 677 680 3560095 was VBD B-VP O
4 681 692 3560095 prematurely RB I-VP O
5 693 705 3560095 discontinued VBN I-VP O
6 706 710 3560095 from IN B-PP O
7 711 714 3560095 the DT B-NP O
8 715 720 3560095 study NN I-NP O
9 721 724 3560095 for IN B-PP O
10 725 731 3560095 severe JJ B-NP O
11 732 740 3560095 headache NN I-NP B-Disease
12 741 744 3560095 and CC O O
13 745 754 3560095 abdominal JJ B-NP B-Disease
14 755 759 3560095 pain NN I-NP I-Disease
15 759 760 3560095 . . O O

1 761 765 3560095 Most JJS B-NP O
2 766 770 3560095 side NN I-NP O
3 771 778 3560095 effects NNS I-NP O
4 779 783 3560095 were VBD B-VP O
5 784 788 3560095 mild JJ B-ADJP O
6 789 792 3560095 and CC O O
7 793 800 3560095 related JJ B-ADJP O
8 801 803 3560095 to TO B-PP O
9 804 807 3560095 the DT B-NP O
10 808 810 3560095 GI NN I-NP O
11 811 816 3560095 tract NN I-NP O
12 816 817 3560095 . . O O

1 0 0 3560096 -DOCSTART- -X- -X- O

1 0 12 3560096 Hyperkalemia NN B-NP B-Disease
2 13 23 3560096 associated VBN B-VP O
3 24 28 3560096 with IN B-PP O
4 29 37 3560096 sulindac NN B-NP B-Chemical
5 38 45 3560096 therapy NN I-NP O
6 45 46 3560096 . . O O
7 47 59 3560096 Hyperkalemia NNP B-NP B-Disease
8 60 63 3560096 has VBZ B-VP O
9 64 72 3560096 recently RB I-VP O
10 73 77 3560096 been VBN I-VP O
11 78 88 3560096 recognized VBN I-VP O
12 89 91 3560096 as IN B-PP O
13 92 93 3560096 a DT B-NP O
14 94 106 3560096 complication NN I-NP O
15 107 109 3560096 of IN B-PP O
16 110 122 3560096 nonsteroidal JJ B-NP O
17 123 139 3560096 antiinflammatory JJ I-NP O
18 140 146 3560096 agents NNS I-NP O
19 147 148 3560096 ( ( O O
20 148 153 3560096 NSAID NN B-NP O
21 153 154 3560096 ) ) O O
22 155 159 3560096 such JJ B-PP O
23 160 162 3560096 as IN I-PP O
24 163 175 3560096 indomethacin NN B-NP B-Chemical
25 175 176 3560096 . . O O

1 177 184 3560096 Several JJ B-NP O
2 185 191 3560096 recent JJ I-NP O
3 192 199 3560096 studies NNS I-NP O
4 200 204 3560096 have VBP B-VP O
5 205 213 3560096 stressed VBN I-VP O
6 214 217 3560096 the DT B-NP O
7 218 223 3560096 renal JJ I-NP O
8 224 231 3560096 sparing VBG I-NP O
9 232 240 3560096 features NNS I-NP O
10 241 243 3560096 of IN B-PP O
11 244 252 3560096 sulindac NN B-NP B-Chemical
12 252 253 3560096 , , O O
13 254 259 3560096 owing VBG B-VP O
14 260 262 3560096 to TO B-PP O
15 263 266 3560096 its PRP$ B-NP O
16 267 271 3560096 lack NN I-NP O
17 272 274 3560096 of IN B-PP O
18 275 287 3560096 interference NN B-NP O
19 288 292 3560096 with IN B-PP O
20 293 298 3560096 renal JJ B-NP O
21 299 311 3560096 prostacyclin NN I-NP B-Chemical
22 312 321 3560096 synthesis NN I-NP O
23 321 322 3560096 . . O O

1 323 325 3560096 We PRP B-NP O
2 326 334 3560096 describe VBP B-VP O
3 335 336 3560096 4 CD B-NP O
4 337 345 3560096 patients NNS I-NP O
5 346 348 3560096 in IN B-PP O
6 349 353 3560096 whom WP B-NP O
7 354 366 3560096 hyperkalemia NN B-NP B-Disease
8 367 374 3560096 ranging VBG B-VP O
9 375 379 3560096 from IN B-PP O
10 380 383 3560096 6.1 CD B-NP O
11 384 386 3560096 to TO I-NP O
12 387 390 3560096 6.9 CD I-NP O
13 391 394 3560096 mEq NN I-NP O
14 394 395 3560096 / SYM B-NP O
15 395 396 3560096 l NN I-NP O
16 397 406 3560096 developed VBN B-VP O
17 407 413 3560096 within IN B-PP O
18 414 415 3560096 3 CD B-NP O
19 416 418 3560096 to TO I-NP O
20 419 420 3560096 8 CD I-NP O
21 421 425 3560096 days NNS I-NP O
22 426 428 3560096 of IN B-PP O
23 429 437 3560096 sulindac NN B-NP B-Chemical
24 438 452 3560096 administration NN I-NP O
25 452 453 3560096 . . O O

1 454 456 3560096 In IN B-PP O
2 457 460 3560096 all DT B-NP O
3 461 463 3560096 of IN B-PP O
4 464 468 3560096 them PRP B-NP O
5 469 475 3560096 normal JJ B-NP O
6 476 481 3560096 serum NN I-NP O
7 482 491 3560096 potassium NN I-NP B-Chemical
8 492 498 3560096 levels NNS I-NP O
9 499 506 3560096 reached VBN B-VP O
10 507 513 3560096 within IN B-PP O
11 514 515 3560096 2 CD B-NP O
12 516 518 3560096 to TO I-NP O
13 519 520 3560096 4 CD I-NP O
14 521 525 3560096 days NNS I-NP O
15 526 528 3560096 of IN B-PP O
16 529 537 3560096 stopping VBG B-VP O
17 538 546 3560096 sulindac NN B-NP B-Chemical
18 546 547 3560096 . . O O

1 548 550 3560096 As IN B-SBAR O
2 551 553 3560096 no DT B-NP O
3 554 559 3560096 other JJ I-NP O
4 560 571 3560096 medications NNS I-NP O
5 572 577 3560096 known VBN B-VP O
6 578 580 3560096 to TO B-VP O
7 581 587 3560096 effect VB I-VP O
8 588 593 3560096 serum NN B-NP O
9 594 603 3560096 potassium NN I-NP B-Chemical
10 604 607 3560096 had VBD B-VP O
11 608 612 3560096 been VBN I-VP O
12 613 618 3560096 given VBN I-VP O
13 619 632 3560096 concomitantly RB B-ADVP O
14 632 633 3560096 , , O O
15 634 638 3560096 this DT B-NP O
16 639 645 3560096 course NN I-NP O
17 646 648 3560096 of IN B-PP O
18 649 655 3560096 events NNS B-NP O
19 656 658 3560096 is VBZ B-VP O
20 659 669 3560096 suggestive JJ B-ADJP O
21 670 672 3560096 of IN B-PP O
22 673 674 3560096 a DT B-NP O
23 675 680 3560096 cause NN I-NP O
24 680 681 3560096 - HYPH B-NP O
25 681 684 3560096 and CC I-NP O
26 684 685 3560096 - HYPH I-NP O
27 685 691 3560096 effect NN I-NP O
28 692 704 3560096 relationship NN I-NP O
29 705 712 3560096 between IN B-PP O
30 713 721 3560096 sulindac NN B-NP B-Chemical
31 722 725 3560096 and CC I-NP O
32 726 738 3560096 hyperkalemia NN I-NP B-Disease
33 738 739 3560096 . . O O

1 740 745 3560096 These DT B-NP O
2 746 758 3560096 observations NNS I-NP O
3 759 767 3560096 indicate VBP B-VP O
4 768 772 3560096 that IN B-SBAR O
5 773 780 3560096 initial JJ B-NP O
6 781 786 3560096 hopes NNS I-NP O
7 787 791 3560096 that IN B-SBAR O
8 792 800 3560096 sulindac NN B-NP B-Chemical
9 801 804 3560096 may MD B-VP O
10 805 808 3560096 not RB I-VP O
11 809 811 3560096 be VB I-VP O
12 812 822 3560096 associated VBN I-VP O
13 823 827 3560096 with IN B-PP O
14 828 831 3560096 the DT B-NP O
15 832 839 3560096 adverse JJ I-NP O
16 840 845 3560096 renal JJ I-NP O
17 846 853 3560096 effects NNS I-NP O
18 854 856 3560096 of IN B-PP O
19 857 862 3560096 other JJ B-NP O
20 863 868 3560096 NSAID NN I-NP O
21 869 872 3560096 are VBP B-VP O
22 873 881 3560096 probably RB B-ADVP O
23 882 885 3560096 not RB O O
24 886 895 3560096 justified JJ B-ADJP O
25 895 896 3560096 . . O O

1 0 0 6640832 -DOCSTART- -X- -X- O

1 0 5 6640832 Early RB B-NP O
2 6 14 6640832 adjuvant JJ I-NP O
3 15 25 6640832 adriamycin NN I-NP B-Chemical
4 26 28 6640832 in IN B-PP O
5 29 40 6640832 superficial JJ B-NP O
6 41 48 6640832 bladder NN I-NP B-Disease
7 49 58 6640832 carcinoma NN I-NP I-Disease
8 58 59 6640832 . . O O
9 60 61 6640832 A DT B-NP O
10 62 73 6640832 multicenter JJ I-NP O
11 74 79 6640832 study NN I-NP O
12 80 83 6640832 was VBD B-VP O
13 84 93 6640832 performed VBN I-VP O
14 94 96 6640832 in IN B-PP O
15 97 100 6640832 110 CD B-NP O
16 101 109 6640832 patients NNS I-NP O
17 110 114 6640832 with IN B-PP O
18 115 126 6640832 superficial JJ B-NP O
19 127 139 6640832 transitional JJ I-NP O
20 140 144 6640832 cell NN I-NP O
21 145 154 6640832 carcinoma NN I-NP B-Disease
22 155 157 6640832 of IN B-PP I-Disease
23 158 161 6640832 the DT B-NP I-Disease
24 162 169 6640832 bladder NN I-NP I-Disease
25 169 170 6640832 . . O O

1 171 181 6640832 Adriamycin NN B-NP B-Chemical
2 182 183 6640832 ( ( O O
3 183 185 6640832 50 CD B-NP O
4 186 188 6640832 mg NN I-NP O
5 188 189 6640832 / SYM B-NP O
6 189 191 6640832 50 CD B-NP O
7 192 194 6640832 ml NN I-NP O
8 194 195 6640832 ) ) O O
9 196 199 6640832 was VBD B-VP O
10 200 212 6640832 administered VBN I-VP O
11 213 227 6640832 intravesically RB B-ADVP O
12 228 234 6640832 within IN B-PP O
13 235 237 6640832 24 CD B-NP O
14 238 239 6640832 h NN I-NP O
15 240 245 6640832 after IN B-PP O
16 246 259 6640832 transurethral JJ B-NP O
17 260 269 6640832 resection NN I-NP O
18 270 272 6640832 of IN B-PP O
19 273 275 6640832 TA NN B-NP O
20 275 276 6640832 - HYPH B-NP O
21 276 278 6640832 T1 NN I-NP O
22 279 280 6640832 ( ( O O
23 280 281 6640832 O NN B-NP O
24 281 282 6640832 - HYPH B-NP O
25 282 283 6640832 A NN I-NP O
26 283 284 6640832 ) ) O O
27 285 292 6640832 bladder NN B-NP B-Disease
28 293 299 6640832 tumors NNS I-NP I-Disease
29 299 300 6640832 . . O O

1 301 313 6640832 Instillation NN B-NP O
2 314 317 6640832 was VBD B-VP O
3 318 326 6640832 repeated VBN I-VP O
4 327 332 6640832 twice RB B-ADVP O
5 333 339 6640832 during IN B-PP O
6 340 343 6640832 the DT B-NP O
7 344 349 6640832 first JJ I-NP O
8 350 354 6640832 week NN I-NP O
9 354 355 6640832 , , O O
10 356 360 6640832 then RB B-ADVP O
11 361 367 6640832 weekly RB I-ADVP O
12 368 374 6640832 during IN B-PP O
13 375 378 6640832 the DT B-NP O
14 379 384 6640832 first JJ I-NP O
15 385 390 6640832 month NN I-NP O
16 391 394 6640832 and CC O O
17 395 405 6640832 afterwards RB B-ADJP O
18 406 413 6640832 monthly JJ I-ADJP O
19 414 417 6640832 for IN B-PP O
20 418 419 6640832 1 CD B-NP O
21 420 424 6640832 year NN I-NP O
22 424 425 6640832 . . O O

1 426 429 6640832 The DT B-NP O
2 430 439 6640832 tolerance NN I-NP O
3 440 443 6640832 was VBD B-VP O
4 444 453 6640832 evaluated VBN I-VP O
5 454 456 6640832 in IN B-PP O
6 457 462 6640832 these DT B-NP O
7 463 466 6640832 110 CD I-NP O
8 467 475 6640832 patients NNS I-NP O
9 475 476 6640832 , , O O
10 477 480 6640832 and CC O O
11 481 483 6640832 29 CD B-NP O
12 484 492 6640832 patients NNS I-NP O
13 493 502 6640832 presented VBD B-VP O
14 503 507 6640832 with IN B-PP O
15 508 513 6640832 local JJ B-NP O
16 514 518 6640832 side NN I-NP O
17 518 519 6640832 - HYPH B-NP O
18 519 526 6640832 effects NNS I-NP O
19 526 527 6640832 . . O O

1 528 530 6640832 In IN B-PP O
2 531 533 6640832 24 CD B-NP O
3 534 536 6640832 of IN B-PP O
4 537 542 6640832 these DT B-NP O
5 543 551 6640832 patients NNS I-NP O
6 552 560 6640832 chemical NN I-NP O
7 561 569 6640832 cystitis NN I-NP B-Disease
8 570 573 6640832 was VBD B-VP O
9 574 580 6640832 severe JJ B-ADJP O
10 581 587 6640832 enough RB I-ADJP O
11 588 591 6640832 for IN B-SBAR O
12 592 596 6640832 them PRP B-NP O
13 597 599 6640832 to TO B-VP O
14 600 604 6640832 drop VB I-VP O
15 605 608 6640832 out IN B-PP O
16 609 611 6640832 of IN B-PP O
17 612 615 6640832 the DT B-NP O
18 616 621 6640832 study NN I-NP O
19 621 622 6640832 . . O O

1 623 625 6640832 No DT B-NP O
2 626 634 6640832 systemic JJ I-NP O
3 635 639 6640832 side NN I-NP O
4 639 640 6640832 - HYPH B-NP O
5 640 647 6640832 effects NNS I-NP O
6 648 652 6640832 were VBD B-VP O
7 653 661 6640832 observed VBN I-VP O
8 661 662 6640832 . . O O

1 663 673 6640832 Recurrence NN B-NP O
2 674 677 6640832 was VBD B-VP O
3 678 685 6640832 studied VBN I-VP O
4 686 688 6640832 in IN B-PP O
5 689 691 6640832 82 CD B-NP O
6 692 701 6640832 evaluable JJ I-NP O
7 702 710 6640832 patients NNS I-NP O
8 711 716 6640832 after IN B-PP O
9 717 718 6640832 1 CD B-NP O
10 719 723 6640832 year NN I-NP O
11 724 726 6640832 of IN B-PP O
12 727 733 6640832 follow VB B-VP O
13 733 734 6640832 - HYPH O O
14 734 736 6640832 up RP B-PRT O
15 737 740 6640832 and CC O O
16 741 743 6640832 in IN B-PP O
17 744 746 6640832 72 CD B-NP O
18 747 755 6640832 patients NNS I-NP O
19 756 764 6640832 followed VBN B-VP O
20 765 768 6640832 for IN B-PP O
21 769 770 6640832 2 CD B-NP O
22 770 771 6640832 - HYPH I-NP O
23 771 772 6640832 3 CD I-NP O
24 773 778 6640832 years NNS I-NP O
25 779 780 6640832 ( ( O O
26 780 784 6640832 mean NN B-NP O
27 785 787 6640832 32 CD B-NP O
28 788 794 6640832 months NNS I-NP O
29 794 795 6640832 ) ) O O
30 795 796 6640832 . . O O

1 797 799 6640832 Of IN B-PP O
2 800 803 6640832 the DT B-NP O
3 804 806 6640832 82 CD I-NP O
4 807 815 6640832 patients NNS I-NP O
5 816 823 6640832 studied VBN B-VP O
6 824 829 6640832 after IN B-PP O
7 830 831 6640832 1 CD B-NP O
8 832 836 6640832 year NN I-NP O
9 836 837 6640832 , , O O
10 838 840 6640832 23 CD B-NP O
11 841 844 6640832 had VBD B-VP O
12 845 852 6640832 primary JJ B-ADJP O
13 853 856 6640832 and CC O O
14 857 859 6640832 59 CD B-NP O
15 860 869 6640832 recurrent JJ I-NP O
16 870 877 6640832 disease NN I-NP O
17 877 878 6640832 . . O O

1 879 881 6640832 Of IN B-PP O
2 882 885 6640832 the DT B-NP O
3 886 888 6640832 82 CD I-NP O
4 889 898 6640832 evaluable JJ I-NP O
5 899 907 6640832 patients NNS I-NP O
6 907 908 6640832 , , O O
7 909 911 6640832 50 CD B-NP O
8 912 915 6640832 did VBD B-VP O
9 916 919 6640832 not RB I-VP O
10 920 924 6640832 show VB I-VP O
11 925 928 6640832 any DT B-NP O
12 929 939 6640832 recurrence NN I-NP O
13 940 945 6640832 after IN B-PP O
14 946 947 6640832 1 CD B-NP O
15 948 952 6640832 year NN I-NP O
16 953 954 6640832 ( ( O O
17 954 957 6640832 61% CD B-NP O
18 957 958 6640832 ) ) O O
19 958 959 6640832 , , O O
20 960 965 6640832 while IN B-SBAR O
21 966 968 6640832 32 CD B-NP O
22 969 978 6640832 presented VBD B-VP O
23 979 983 6640832 with IN B-PP O
24 984 987 6640832 one CD B-NP O
25 988 990 6640832 or CC I-NP O
26 991 995 6640832 more JJR I-NP O
27 996 1007 6640832 recurrences NNS I-NP O
28 1008 1009 6640832 ( ( B-LST O
29 1009 1012 6640832 39% LS I-LST O
30 1012 1013 6640832 ) ) O O
31 1013 1014 6640832 . . O O

1 1015 1017 6640832 Of IN B-PP O
2 1018 1023 6640832 these DT B-NP O
3 1024 1035 6640832 recurrences NNS I-NP O
4 1035 1036 6640832 , , O O
5 1037 1039 6640832 27 CD B-NP O
6 1040 1044 6640832 were VBD B-VP O
7 1045 1047 6640832 T1 NN B-NP O
8 1048 1054 6640832 tumors NNS I-NP B-Disease
9 1055 1060 6640832 while IN B-SBAR O
10 1061 1065 6640832 five CD B-NP O
11 1066 1076 6640832 progressed VBD B-VP O
12 1077 1079 6640832 to TO B-PP O
13 1080 1084 6640832 more RBR B-ADVP O
14 1085 1091 6640832 highly RB I-ADVP O
15 1092 1100 6640832 invasive JJ B-NP O
16 1101 1108 6640832 lesions NNS I-NP O
17 1108 1109 6640832 . . O O

1 1110 1112 6640832 In IN B-PP O
2 1113 1121 6640832 patients NNS B-NP O
3 1122 1126 6640832 that WDT B-NP O
4 1127 1131 6640832 were VBD B-VP O
5 1132 1136 6640832 free JJ B-ADJP O
6 1137 1139 6640832 of IN B-PP O
7 1140 1150 6640832 recurrence NN B-NP O
8 1151 1157 6640832 during IN B-PP O
9 1158 1161 6640832 the DT B-NP O
10 1162 1167 6640832 first JJ I-NP O
11 1168 1172 6640832 year NN I-NP O
12 1172 1173 6640832 , , O O
13 1174 1177 6640832 80% CD B-NP O
14 1178 1186 6640832 remained VBD B-VP O
15 1187 1192 6640832 tumor NN B-NP B-Disease
16 1192 1193 6640832 - HYPH B-ADJP O
17 1193 1197 6640832 free JJ I-ADJP O
18 1198 1204 6640832 during IN B-PP O
19 1205 1208 6640832 the DT B-NP O
20 1209 1210 6640832 2 CD I-NP O
21 1210 1211 6640832 - HYPH B-ADJP O
22 1212 1214 6640832 to TO B-PP O
23 1215 1216 6640832 3 CD B-NP O
24 1216 1217 6640832 - HYPH I-NP O
25 1217 1221 6640832 year NN I-NP O
26 1222 1228 6640832 follow VB B-VP O
27 1228 1229 6640832 - HYPH O O
28 1229 1231 6640832 up RP B-PRT O
29 1232 1238 6640832 period NN B-NP O
30 1238 1239 6640832 . . O O

1 1240 1242 6640832 Of IN B-PP O
2 1243 1246 6640832 the DT B-NP O
3 1247 1255 6640832 patients NNS I-NP O
4 1256 1266 6640832 developing VBG B-VP O
5 1267 1270 6640832 one CD B-NP O
6 1271 1273 6640832 or CC I-NP O
7 1274 1278 6640832 more JJR I-NP O
8 1279 1290 6640832 recurrences NNS I-NP O
9 1291 1297 6640832 during IN B-PP O
10 1298 1301 6640832 the DT B-NP O
11 1302 1307 6640832 first JJ I-NP O
12 1308 1312 6640832 year NN I-NP O
13 1312 1313 6640832 , , O O
14 1314 1318 6640832 only RB B-NP O
15 1319 1322 6640832 50% CD I-NP O
16 1323 1332 6640832 presented VBD B-VP O
17 1333 1337 6640832 with IN B-PP O
18 1338 1345 6640832 further JJ B-NP O
19 1346 1356 6640832 recurrence NN I-NP O
20 1357 1361 6640832 once IN B-SBAR O
21 1362 1365 6640832 the DT B-NP O
22 1366 1379 6640832 instillations NNS I-NP O
23 1380 1384 6640832 were VBD B-VP O
24 1385 1392 6640832 stopped VBN I-VP O
25 1392 1393 6640832 . . O O

1 1394 1397 6640832 The DT B-NP O
2 1398 1408 6640832 beneficial JJ I-NP O
3 1409 1415 6640832 effect NN I-NP O
4 1416 1418 6640832 of IN B-PP O
5 1419 1429 6640832 Adriamycin NN B-NP B-Chemical
6 1430 1437 6640832 appears VBZ B-VP O
7 1438 1445 6640832 obvious JJ B-ADJP O
8 1446 1449 6640832 and CC O O
9 1450 1455 6640832 might MD B-VP O
10 1456 1458 6640832 be VB I-VP O
11 1459 1466 6640832 related JJ B-ADJP O
12 1467 1469 6640832 to TO B-PP O
13 1470 1473 6640832 the DT B-NP O
14 1474 1478 6640832 drug NN I-NP O
15 1479 1485 6640832 itself PRP B-NP O
16 1485 1486 6640832 , , O O
17 1487 1490 6640832 the DT B-NP O
18 1491 1496 6640832 early JJ I-NP O
19 1497 1500 6640832 and CC I-NP O
20 1501 1509 6640832 repeated JJ I-NP O
21 1510 1523 6640832 instillations NNS I-NP O
22 1524 1529 6640832 after IN B-PP O
23 1530 1533 6640832 TUR NN B-NP O
24 1533 1534 6640832 , , O O
25 1535 1537 6640832 or CC O O
26 1538 1542 6640832 both DT B-NP O
27 1542 1543 6640832 . . O O

1 0 0 2894766 -DOCSTART- -X- -X- O

1 0 13 2894766 Sulfasalazine NN B-NP B-Chemical
2 13 14 2894766 - HYPH B-NP O
3 14 21 2894766 induced VBN I-NP O
4 22 27 2894766 lupus NN I-NP B-Disease
5 28 41 2894766 erythematosus NN I-NP I-Disease
6 41 42 2894766 . . I-NP O
7 43 54 2894766 Pneumonitis NN I-NP B-Disease
8 54 55 2894766 , , O O
9 56 65 2894766 bilateral JJ B-NP O
10 66 73 2894766 pleural JJ I-NP B-Disease
11 74 83 2894766 effusions NNS I-NP I-Disease
12 83 84 2894766 , , O O
13 85 102 2894766 echocardiographic JJ B-NP O
14 103 111 2894766 evidence NN I-NP O
15 112 114 2894766 of IN B-PP O
16 115 122 2894766 cardiac JJ B-NP B-Disease
17 123 132 2894766 tamponade NN I-NP I-Disease
18 132 133 2894766 , , O O
19 134 137 2894766 and CC O O
20 138 146 2894766 positive JJ B-NP O
21 147 161 2894766 autoantibodies NNS I-NP O
22 162 171 2894766 developed VBN B-VP O
23 172 174 2894766 in IN B-PP O
24 175 176 2894766 a DT B-NP O
25 177 179 2894766 43 CD I-NP O
26 179 180 2894766 - HYPH I-NP O
27 180 184 2894766 year NN I-NP O
28 184 185 2894766 - HYPH O O
29 185 188 2894766 old JJ B-NP O
30 189 192 2894766 man NN I-NP O
31 192 193 2894766 , , O O
32 194 197 2894766 who WP B-NP O
33 198 201 2894766 was VBD B-VP O
34 202 211 2894766 receiving VBG I-VP O
35 212 216 2894766 long JJ B-NP O
36 216 217 2894766 - HYPH I-NP O
37 217 221 2894766 term NN I-NP O
38 222 235 2894766 sulfasalazine NN I-NP B-Chemical
39 236 243 2894766 therapy NN I-NP O
40 244 247 2894766 for IN B-PP O
41 248 255 2894766 chronic JJ B-NP O
42 256 266 2894766 ulcerative JJ I-NP B-Disease
43 267 274 2894766 colitis NN I-NP I-Disease
44 274 275 2894766 . . O O

1 276 281 2894766 After IN B-PP O
2 282 291 2894766 cessation NN B-NP O
3 292 294 2894766 of IN B-PP O
4 295 298 2894766 the DT B-NP O
5 299 312 2894766 sulfasalazine NN I-NP B-Chemical
6 313 316 2894766 and CC I-NP O
7 317 327 2894766 completion NN I-NP O
8 328 330 2894766 of IN B-PP O
9 331 332 2894766 a DT B-NP O
10 333 336 2894766 six CD I-NP O
11 336 337 2894766 - HYPH I-NP O
12 337 341 2894766 week NN I-NP O
13 342 348 2894766 course NN I-NP O
14 349 351 2894766 of IN B-PP O
15 352 367 2894766 corticosteroids NNS B-NP O
16 367 368 2894766 , , O O
17 369 374 2894766 these DT B-NP O
18 375 383 2894766 problems NNS I-NP O
19 384 392 2894766 resolved VBN B-VP O
20 393 397 2894766 over IN B-PP O
21 398 399 2894766 a DT B-NP O
22 400 406 2894766 period NN I-NP O
23 407 409 2894766 of IN B-PP O
24 410 414 2894766 four CD B-NP O
25 415 417 2894766 to TO I-NP O
26 418 421 2894766 six CD I-NP O
27 422 428 2894766 months NNS I-NP O
28 428 429 2894766 . . O O

1 430 432 2894766 It PRP B-NP O
2 433 435 2894766 is VBZ B-VP O
3 436 445 2894766 suggested VBN I-VP O
4 446 450 2894766 that IN B-SBAR O
5 451 454 2894766 the DT B-NP O
6 455 462 2894766 patient NN I-NP O
7 463 466 2894766 had VBD B-VP O
8 467 480 2894766 sulfasalazine NN B-NP B-Chemical
9 480 481 2894766 - HYPH B-NP O
10 481 488 2894766 induced VBN I-NP O
11 489 494 2894766 lupus NN I-NP B-Disease
12 494 495 2894766 , , O O
13 496 501 2894766 which WDT B-NP O
14 502 512 2894766 manifested VBD B-VP O
15 513 517 2894766 with IN B-PP O
16 518 527 2894766 serositis NN B-NP B-Disease
17 528 531 2894766 and CC O O
18 532 541 2894766 pulmonary JJ B-NP O
19 542 553 2894766 parenchymal JJ I-NP O
20 554 565 2894766 involvement NN I-NP O
21 566 568 2894766 in IN B-PP O
22 569 572 2894766 the DT B-NP O
23 573 580 2894766 absence NN I-NP O
24 581 583 2894766 of IN B-PP O
25 584 589 2894766 joint JJ B-NP O
26 590 598 2894766 symptoms NNS I-NP O
27 598 599 2894766 . . O O

1 600 610 2894766 Physicians NNS B-NP O
2 611 614 2894766 who WP B-NP O
3 615 618 2894766 use VBP B-VP O
4 619 632 2894766 sulfasalazine NN B-NP B-Chemical
5 633 635 2894766 to TO B-VP O
6 636 641 2894766 treat VB I-VP O
7 642 650 2894766 patients NNS B-NP O
8 651 655 2894766 with IN B-PP O
9 656 668 2894766 inflammatory JJ B-NP B-Disease
10 669 674 2894766 bowel NN I-NP I-Disease
11 675 682 2894766 disease NN I-NP I-Disease
12 683 689 2894766 should MD B-VP O
13 690 692 2894766 be VB I-VP O
14 693 698 2894766 aware JJ B-ADJP O
15 699 701 2894766 of IN B-PP O
16 702 705 2894766 the DT B-NP O
17 706 711 2894766 signs NNS I-NP O
18 712 714 2894766 of IN B-PP O
19 715 728 2894766 sulfasalazine NN B-NP B-Chemical
20 728 729 2894766 - HYPH B-NP O
21 729 736 2894766 induced VBN I-NP O
22 737 742 2894766 lupus NN I-NP B-Disease
23 743 751 2894766 syndrome NN I-NP I-Disease
24 751 752 2894766 . . O O

1 0 0 3173180 -DOCSTART- -X- -X- O

1 0 10 3173180 Haemolytic JJ B-NP B-Disease
2 10 11 3173180 - HYPH I-NP I-Disease
3 11 18 3173180 uraemic JJ I-NP I-Disease
4 19 27 3173180 syndrome NN I-NP I-Disease
5 28 33 3173180 after IN B-PP O
6 34 43 3173180 treatment NN B-NP O
7 44 48 3173180 with IN B-PP O
8 49 62 3173180 metronidazole NN B-NP B-Chemical
9 62 63 3173180 . . O O
10 64 68 3173180 This DT B-NP O
11 69 74 3173180 paper NN I-NP O
12 75 84 3173180 describes VBZ B-VP O
13 85 88 3173180 the DT B-NP O
14 89 97 3173180 clinical JJ I-NP O
15 98 106 3173180 features NNS I-NP O
16 107 109 3173180 of IN B-PP O
17 110 113 3173180 six CD B-NP O
18 114 122 3173180 children NNS I-NP O
19 123 126 3173180 who WP B-NP O
20 127 136 3173180 developed VBD B-VP O
21 137 140 3173180 the DT B-NP O
22 141 151 3173180 haemolytic JJ I-NP B-Disease
23 151 152 3173180 - HYPH I-NP I-Disease
24 152 159 3173180 uraemic JJ I-NP I-Disease
25 160 168 3173180 syndrome NN I-NP I-Disease
26 169 174 3173180 after IN B-PP O
27 175 184 3173180 treatment NN B-NP O
28 185 189 3173180 with IN B-PP O
29 190 203 3173180 metronidazole NN B-NP B-Chemical
30 203 204 3173180 . . O O

1 205 210 3173180 These DT B-NP O
2 211 219 3173180 children NNS I-NP O
3 220 224 3173180 were VBD B-VP O
4 225 230 3173180 older JJR B-ADJP O
5 231 234 3173180 and CC O O
6 235 239 3173180 were VBD B-VP O
7 240 244 3173180 more RBR B-ADJP O
8 245 251 3173180 likely JJ I-ADJP O
9 252 254 3173180 to TO B-VP O
10 255 259 3173180 have VB I-VP O
11 260 269 3173180 undergone VBN I-VP O
12 270 276 3173180 recent JJ B-NP O
13 277 282 3173180 bowel NN I-NP O
14 283 290 3173180 surgery NN I-NP O
15 291 295 3173180 than IN B-SBAR O
16 296 299 3173180 are VBP B-VP O
17 300 305 3173180 other JJ B-NP O
18 306 314 3173180 children NNS I-NP O
19 315 319 3173180 with IN B-PP O
20 320 324 3173180 this DT B-NP O
21 325 334 3173180 condition NN I-NP O
22 334 335 3173180 . . O O

1 336 341 3173180 While IN B-SBAR O
2 342 345 3173180 the DT B-NP O
3 346 357 3173180 involvement NN I-NP O
4 358 360 3173180 of IN B-PP O
5 361 374 3173180 metronidazole NN B-NP B-Chemical
6 375 377 3173180 in IN B-PP O
7 378 381 3173180 the DT B-NP O
8 382 391 3173180 aetiology NN I-NP O
9 392 394 3173180 of IN B-PP O
10 395 398 3173180 the DT B-NP O
11 399 409 3173180 haemolytic JJ I-NP B-Disease
12 409 410 3173180 - HYPH I-NP I-Disease
13 410 417 3173180 uraemic JJ I-NP I-Disease
14 418 426 3173180 syndrome NN I-NP I-Disease
15 427 429 3173180 is VBZ B-VP O
16 430 433 3173180 not RB I-VP O
17 434 445 3173180 established VBN I-VP O
18 446 452 3173180 firmly RB B-ADVP O
19 452 453 3173180 , , O O
20 454 457 3173180 the DT B-NP O
21 458 464 3173180 action NN I-NP O
22 465 467 3173180 of IN B-PP O
23 468 472 3173180 this DT B-NP O
24 473 477 3173180 drug NN I-NP O
25 478 480 3173180 in IN B-PP O
26 481 492 3173180 sensitizing VBG B-VP O
27 493 500 3173180 tissues NNS B-NP O
28 501 503 3173180 to TO B-PP O
29 504 513 3173180 oxidation NN B-NP O
30 514 520 3173180 injury NN I-NP O
31 521 524 3173180 and CC O O
32 525 528 3173180 the DT B-NP O
33 529 537 3173180 reported VBN I-NP O
34 538 546 3173180 evidence NN I-NP O
35 547 549 3173180 of IN B-PP O
36 550 559 3173180 oxidation NN B-NP O
37 560 567 3173180 changes NNS I-NP O
38 568 570 3173180 in IN B-PP O
39 571 574 3173180 the DT B-NP O
40 575 585 3173180 haemolytic JJ I-NP B-Disease
41 585 586 3173180 - HYPH I-NP I-Disease
42 586 593 3173180 uraemic JJ I-NP I-Disease
43 594 602 3173180 syndrome NN I-NP I-Disease
44 603 610 3173180 suggest VBP B-VP O
45 611 612 3173180 a DT B-NP O
46 613 621 3173180 possible JJ I-NP O
47 622 626 3173180 link NN I-NP O
48 627 634 3173180 between IN B-PP O
49 635 648 3173180 metronidazole NN B-NP B-Chemical
50 649 658 3173180 treatment NN I-NP O
51 659 662 3173180 and CC O O
52 663 667 3173180 some DT B-NP O
53 668 673 3173180 cases NNS I-NP O
54 674 676 3173180 of IN B-PP O
55 677 680 3173180 the DT B-NP O
56 681 691 3173180 haemolytic JJ I-NP B-Disease
57 691 692 3173180 - HYPH I-NP I-Disease
58 692 699 3173180 uraemic JJ I-NP I-Disease
59 700 708 3173180 syndrome NN I-NP I-Disease
60 708 709 3173180 . . O O

1 0 0 18343374 -DOCSTART- -X- -X- O

1 0 7 18343374 Central JJ B-NP O
2 8 15 18343374 retinal JJ I-NP B-Disease
3 16 20 18343374 vein NN I-NP I-Disease
4 21 30 18343374 occlusion NN I-NP I-Disease
5 31 41 18343374 associated VBN B-VP O
6 42 46 18343374 with IN B-PP O
7 47 57 18343374 clomiphene NN B-NP B-Chemical
8 57 58 18343374 - HYPH B-NP O
9 58 65 18343374 induced VBN I-NP O
10 66 75 18343374 ovulation NN I-NP O
11 75 76 18343374 . . I-NP O
12 77 86 18343374 OBJECTIVE NN I-NP O
13 86 87 18343374 : : O O
14 88 90 18343374 To TO B-VP O
15 91 97 18343374 report VB I-VP O
16 98 99 18343374 a DT B-NP O
17 100 104 18343374 case NN I-NP O
18 105 107 18343374 of IN B-PP O
19 108 115 18343374 central JJ B-NP O
20 116 123 18343374 retinal JJ I-NP B-Disease
21 124 128 18343374 vein NN I-NP I-Disease
22 129 138 18343374 occlusion NN I-NP I-Disease
23 139 149 18343374 associated VBN B-VP O
24 150 154 18343374 with IN B-PP O
25 155 165 18343374 clomiphene NN B-NP B-Chemical
26 166 173 18343374 citrate NN I-NP I-Chemical
27 174 175 18343374 ( ( O O
28 175 177 18343374 CC NN B-NP B-Chemical
29 177 178 18343374 ) ) O O
30 178 179 18343374 . . O O

1 180 186 18343374 DESIGN NN B-NP O
2 186 187 18343374 : : O O
3 188 192 18343374 Case NN B-NP O
4 193 198 18343374 study NN I-NP O
5 198 199 18343374 . . O O

1 200 207 18343374 SETTING NN B-NP O
2 207 208 18343374 : : O O
3 209 222 18343374 Ophthalmology NN B-NP O
4 223 229 18343374 clinic NN I-NP O
5 230 232 18343374 of IN B-PP O
6 233 235 18343374 an DT B-NP O
7 236 244 18343374 academic JJ I-NP O
8 245 253 18343374 hospital NN I-NP O
9 253 254 18343374 . . O O

1 255 265 18343374 PATIENT(S) LS B-LST O
2 265 266 18343374 : : O O
3 267 268 18343374 A DT B-NP O
4 269 271 18343374 36 CD I-NP O
5 271 272 18343374 - HYPH I-NP O
6 272 276 18343374 year NN I-NP O
7 276 277 18343374 - HYPH O O
8 277 280 18343374 old JJ B-NP O
9 281 286 18343374 woman NN I-NP O
10 287 295 18343374 referred VBN B-VP O
11 296 300 18343374 from IN B-PP O
12 301 304 18343374 the DT B-NP O
13 305 316 18343374 infertility NN I-NP B-Disease
14 317 323 18343374 clinic NN I-NP O
15 324 327 18343374 for IN B-PP O
16 328 335 18343374 blurred JJ B-NP B-Disease
17 336 342 18343374 vision NN I-NP I-Disease
18 342 343 18343374 . . O O

1 344 359 18343374 INTERVENTION(S) LS B-LST O
2 359 360 18343374 : : O O
3 361 371 18343374 Ophthalmic JJ B-NP O
4 372 383 18343374 examination NN I-NP O
5 384 389 18343374 after IN B-PP O
6 390 392 18343374 CC NN B-NP B-Chemical
7 393 400 18343374 therapy NN I-NP O
8 400 401 18343374 . . O O

1 402 406 18343374 MAIN NNP B-NP O
2 407 414 18343374 OUTCOME NNP I-NP O
3 415 425 18343374 MEASURE(S) NNP I-NP O
4 425 426 18343374 : : O O
5 427 434 18343374 Central JJ B-NP O
6 435 442 18343374 retinal JJ I-NP B-Disease
7 443 447 18343374 vein NN I-NP I-Disease
8 448 457 18343374 occlusion NN I-NP I-Disease
9 458 463 18343374 after IN B-PP O
10 464 473 18343374 ovulation NN B-NP O
11 474 483 18343374 induction NN I-NP O
12 484 488 18343374 with IN B-PP O
13 489 491 18343374 CC NN B-NP B-Chemical
14 491 492 18343374 . . O O

1 493 502 18343374 RESULT(S) LS B-LST O
2 502 503 18343374 : : O O
3 504 505 18343374 A DT B-NP O
4 506 508 18343374 36 CD I-NP O
5 508 509 18343374 - HYPH I-NP O
6 509 513 18343374 year NN I-NP O
7 513 514 18343374 - HYPH O O
8 514 517 18343374 old JJ B-NP O
9 518 525 18343374 Chinese JJ I-NP O
10 526 531 18343374 woman NN I-NP O
11 532 541 18343374 developed VBD B-VP O
12 542 549 18343374 central JJ B-NP O
13 550 557 18343374 retinal JJ I-NP B-Disease
14 558 562 18343374 vein NN I-NP I-Disease
15 563 572 18343374 occlusion NN I-NP I-Disease
16 573 578 18343374 after IN B-PP O
17 579 584 18343374 eight CD B-NP O
18 585 592 18343374 courses NNS I-NP O
19 593 595 18343374 of IN B-PP O
20 596 598 18343374 CC NN B-NP B-Chemical
21 598 599 18343374 . . O O

1 600 601 18343374 A DT B-NP O
2 602 608 18343374 search NN I-NP O
3 609 611 18343374 of IN B-PP O
4 612 615 18343374 the DT B-NP O
5 616 626 18343374 literature NN I-NP O
6 627 629 18343374 on IN B-PP O
7 630 633 18343374 the DT B-NP O
8 634 648 18343374 thromboembolic JJ I-NP B-Disease
9 649 662 18343374 complications NNS I-NP O
10 663 665 18343374 of IN B-PP O
11 666 668 18343374 CC NN B-NP B-Chemical
12 669 673 18343374 does VBZ B-VP O
13 674 677 18343374 not RB I-VP O
14 678 685 18343374 include VB I-VP O
15 686 690 18343374 this DT B-NP O
16 691 697 18343374 severe JJ I-NP O
17 698 708 18343374 ophthalmic JJ I-NP O
18 709 721 18343374 complication NN I-NP O
19 721 722 18343374 , , O O
20 723 731 18343374 although IN B-SBAR O
21 732 736 18343374 mild JJ B-NP O
22 737 743 18343374 visual JJ I-NP B-Disease
23 744 755 18343374 disturbance NN I-NP I-Disease
24 756 761 18343374 after IN B-PP O
25 762 764 18343374 CC NN B-NP B-Chemical
26 765 771 18343374 intake NN I-NP O
27 772 774 18343374 is VBZ B-VP O
28 775 778 18343374 not RB O O
29 779 787 18343374 uncommon JJ B-ADJP O
30 787 788 18343374 . . O O

1 789 802 18343374 CONCLUSION(S) LS B-LST O
2 802 803 18343374 : : O O
3 804 808 18343374 This DT B-NP O
4 809 811 18343374 is VBZ B-VP O
5 812 815 18343374 the DT B-NP O
6 816 821 18343374 first JJ I-NP O
7 822 830 18343374 reported VBN I-NP O
8 831 835 18343374 case NN I-NP O
9 836 838 18343374 of IN B-PP O
10 839 846 18343374 central JJ B-NP O
11 847 854 18343374 retinal JJ I-NP B-Disease
12 855 859 18343374 vein NN I-NP I-Disease
13 860 869 18343374 occlusion NN I-NP I-Disease
14 870 875 18343374 after IN B-PP O
15 876 885 18343374 treatment NN B-NP O
16 886 890 18343374 with IN B-PP O
17 891 893 18343374 CC NN B-NP B-Chemical
18 893 894 18343374 . . O O

1 895 900 18343374 Extra NNP B-NP O
2 901 908 18343374 caution NN I-NP O
3 909 911 18343374 is VBZ B-VP O
4 912 921 18343374 warranted VBN I-VP O
5 922 924 18343374 in IN B-PP O
6 925 933 18343374 treating VBG B-VP O
7 934 945 18343374 infertility NN B-NP B-Disease
8 946 954 18343374 patients NNS I-NP O
9 955 959 18343374 with IN B-PP O
10 960 962 18343374 CC NN B-NP B-Chemical
11 962 963 18343374 , , O O
12 964 967 18343374 and CC O O
13 968 976 18343374 patients NNS B-NP O
14 977 983 18343374 should MD B-VP O
15 984 986 18343374 be VB I-VP O
16 987 991 18343374 well RB I-VP O
17 992 1000 18343374 informed VBN I-VP O
18 1001 1003 18343374 of IN B-PP O
19 1004 1008 18343374 this DT B-NP O
20 1009 1013 18343374 side NN I-NP O
21 1014 1020 18343374 effect NN I-NP O
22 1021 1027 18343374 before IN B-PP O
23 1028 1040 18343374 commencement NN B-NP O
24 1041 1043 18343374 of IN B-PP O
25 1044 1051 18343374 therapy NN B-NP O
26 1051 1052 18343374 . . O O

1 0 0 3425586 -DOCSTART- -X- -X- O

1 0 7 3425586 Dapsone NN B-NP B-Chemical
2 7 8 3425586 - HYPH B-PP O
3 8 18 3425586 associated VBN B-NP O
4 19 24 3425586 Heinz NN I-NP O
5 25 29 3425586 body NN I-NP O
6 30 39 3425586 hemolytic JJ I-NP B-Disease
7 40 46 3425586 anemia NN I-NP I-Disease
8 47 49 3425586 in IN B-PP O
9 50 51 3425586 a DT B-NP O
10 52 61 3425586 Cambodian JJ I-NP O
11 62 67 3425586 woman NN I-NP O
12 68 72 3425586 with IN B-PP O
13 73 83 3425586 hemoglobin NN B-NP O
14 84 85 3425586 E NN I-NP O
15 86 91 3425586 trait NN I-NP O
16 91 92 3425586 . . O O
17 93 94 3425586 A DT B-NP O
18 95 104 3425586 Cambodian JJ I-NP O
19 105 110 3425586 woman NN I-NP O
20 111 115 3425586 with IN B-PP O
21 116 126 3425586 hemoglobin NN B-NP O
22 127 128 3425586 E NN I-NP O
23 129 134 3425586 trait NN I-NP O
24 135 136 3425586 ( ( O O
25 136 138 3425586 AE NN B-NP O
26 138 139 3425586 ) ) O O
27 140 143 3425586 and CC O O
28 144 151 3425586 leprosy NN B-NP B-Disease
29 152 161 3425586 developed VBD B-VP O
30 162 163 3425586 a DT B-NP O
31 164 169 3425586 Heinz NNP I-NP O
32 170 174 3425586 body NN I-NP O
33 175 184 3425586 hemolytic JJ I-NP B-Disease
34 185 191 3425586 anemia NN I-NP I-Disease
35 192 197 3425586 while IN B-SBAR O
36 198 204 3425586 taking VBG B-VP O
37 205 206 3425586 a DT B-NP O
38 207 211 3425586 dose NN I-NP O
39 212 214 3425586 of IN B-PP O
40 215 222 3425586 dapsone NN B-NP B-Chemical
41 223 224 3425586 ( ( O O
42 224 226 3425586 50 CD B-NP O
43 227 229 3425586 mg NN I-NP O
44 229 230 3425586 / SYM B-NP O
45 230 233 3425586 day NN I-NP O
46 233 234 3425586 ) ) O O
47 235 238 3425586 not RB B-VP O
48 239 246 3425586 usually RB I-VP O
49 247 257 3425586 associated VBN I-VP O
50 258 262 3425586 with IN B-PP O
51 263 271 3425586 clinical JJ B-NP O
52 272 281 3425586 hemolysis NN I-NP B-Disease
53 281 282 3425586 . . O O

1 283 286 3425586 Her PRP$ B-NP O
2 287 290 3425586 red JJ I-NP O
3 291 296 3425586 blood NN I-NP O
4 297 302 3425586 cells NNS I-NP O
5 303 304 3425586 ( ( O O
6 304 308 3425586 RBCs NNS B-NP O
7 308 309 3425586 ) ) O O
8 310 313 3425586 had VBD B-VP O
9 314 323 3425586 increased VBN I-VP O
10 324 333 3425586 incubated VBN B-VP O
11 334 339 3425586 Heinz NNP B-NP O
12 340 344 3425586 body NN I-NP O
13 345 354 3425586 formation NN I-NP O
14 354 355 3425586 , , O O
15 356 365 3425586 decreased VBD B-VP O
16 366 373 3425586 reduced VBN I-VP O
17 374 385 3425586 glutathione NN B-NP B-Chemical
18 386 387 3425586 ( ( O O
19 387 390 3425586 GSH NN B-NP B-Chemical
20 390 391 3425586 ) ) O O
21 391 392 3425586 , , O O
22 393 396 3425586 and CC O O
23 397 406 3425586 decreased VBD B-VP O
24 407 410 3425586 GSH NN B-NP B-Chemical
25 411 420 3425586 stability NN I-NP O
26 420 421 3425586 . . O O

1 422 425 3425586 The DT B-NP O
2 426 433 3425586 pentose NN I-NP B-Chemical
3 434 443 3425586 phosphate NN I-NP I-Chemical
4 444 449 3425586 shunt NN I-NP O
5 450 458 3425586 activity NN I-NP O
6 459 461 3425586 of IN B-PP O
7 462 465 3425586 the DT B-NP O
8 466 473 3425586 dapsone NN I-NP B-Chemical
9 473 474 3425586 - HYPH B-VP O
10 474 481 3425586 exposed VBN B-NP O
11 482 484 3425586 AE NN I-NP O
12 485 489 3425586 RBCs NNS I-NP O
13 490 493 3425586 was VBD B-VP O
14 494 503 3425586 increased VBN I-VP O
15 504 512 3425586 compared VBN B-PP O
16 513 515 3425586 to TO B-PP O
17 516 522 3425586 normal JJ B-NP O
18 523 527 3425586 RBCs NNS I-NP O
19 527 528 3425586 . . O O

1 529 537 3425586 Although IN B-SBAR O
2 538 541 3425586 the DT B-NP O
3 542 544 3425586 AE NN I-NP O
4 545 549 3425586 RBCs NNS I-NP O
5 550 554 3425586 from IN B-PP O
6 555 557 3425586 an DT B-NP O
7 558 568 3425586 individual NN I-NP O
8 569 572 3425586 not RB B-VP O
9 573 579 3425586 taking VBG I-VP O
10 580 587 3425586 dapsone NN B-NP B-Chemical
11 588 591 3425586 had VBD B-VP O
12 592 601 3425586 increased VBN I-VP O
13 602 611 3425586 incubated VBN B-VP O
14 612 617 3425586 Heinz NNP B-NP O
15 618 622 3425586 body NN I-NP O
16 623 632 3425586 formation NN I-NP O
17 632 633 3425586 , , O O
18 634 637 3425586 the DT B-NP O
19 638 641 3425586 GSH NN I-NP B-Chemical
20 642 649 3425586 content NN I-NP O
21 650 653 3425586 and CC O O
22 654 657 3425586 GSH NN B-NP B-Chemical
23 658 667 3425586 stability NN I-NP O
24 668 672 3425586 were VBD B-VP O
25 673 679 3425586 normal JJ B-ADJP O
26 679 680 3425586 . . O O

1 681 684 3425586 The DT B-NP O
2 685 692 3425586 pentose NN I-NP B-Chemical
3 693 702 3425586 phosphate NN I-NP I-Chemical
4 703 708 3425586 shunt NN I-NP O
5 709 717 3425586 activity NN I-NP O
6 718 720 3425586 of IN B-PP O
7 721 724 3425586 the DT B-NP O
8 725 728 3425586 non AFX I-NP O
9 728 729 3425586 - HYPH I-NP O
10 729 736 3425586 dapsone NN I-NP B-Chemical
11 736 737 3425586 - HYPH O O
12 737 744 3425586 exposed VBN B-NP O
13 745 747 3425586 AE NN I-NP O
14 748 752 3425586 RBCs NNS I-NP O
15 753 756 3425586 was VBD B-VP O
16 757 766 3425586 decreased VBN I-VP O
17 767 775 3425586 compared VBN B-PP O
18 776 778 3425586 to TO B-PP O
19 779 785 3425586 normal JJ B-NP O
20 786 790 3425586 RBCs NNS I-NP O
21 790 791 3425586 . . O O

1 792 796 3425586 Thus RB B-ADVP O
2 796 797 3425586 , , O O
3 798 800 3425586 AE NN B-NP O
4 801 805 3425586 RBCs NNS I-NP O
5 806 812 3425586 appear VBP B-VP O
6 813 815 3425586 to TO I-VP O
7 816 820 3425586 have VB I-VP O
8 821 823 3425586 an DT B-NP O
9 824 833 3425586 increased VBN I-NP O
10 834 845 3425586 sensitivity NN I-NP O
11 846 848 3425586 to TO B-PP O
12 849 856 3425586 oxidant JJ B-NP O
13 857 863 3425586 stress NN I-NP O
14 864 868 3425586 both CC O O
15 869 871 3425586 in FW B-ADVP O
16 872 877 3425586 vitro FW I-ADVP O
17 878 881 3425586 and CC O O
18 882 884 3425586 in FW B-ADVP O
19 885 889 3425586 vivo FW I-ADVP O
20 889 890 3425586 , , O O
21 891 896 3425586 since IN B-SBAR O
22 897 904 3425586 dapsone NN B-NP B-Chemical
23 905 909 3425586 does VBZ B-VP O
24 910 913 3425586 not RB I-VP O
25 914 919 3425586 cause VB I-VP O
26 920 929 3425586 hemolytic JJ B-NP B-Disease
27 930 936 3425586 anemia NN I-NP I-Disease
28 937 939 3425586 at IN B-PP O
29 940 944 3425586 this DT B-NP O
30 945 949 3425586 dose NN I-NP O
31 950 952 3425586 in IN B-PP O
32 953 968 3425586 hematologically RB B-NP O
33 969 975 3425586 normal JJ I-NP O
34 976 987 3425586 individuals NNS I-NP O
35 987 988 3425586 . . O O

1 989 994 3425586 Given VBN B-PP O
2 995 998 3425586 the DT B-NP O
3 999 1005 3425586 influx NN I-NP O
4 1006 1008 3425586 of IN B-PP O
5 1009 1018 3425586 Southeast NNP B-NP O
6 1019 1025 3425586 Asians NNPS I-NP O
7 1026 1030 3425586 into IN B-PP O
8 1031 1034 3425586 the DT B-NP O
9 1035 1041 3425586 United NNP I-NP O
10 1042 1048 3425586 States NNPS I-NP O
11 1048 1049 3425586 , , O O
12 1050 1057 3425586 oxidant JJ B-NP O
13 1058 1069 3425586 medications NNS I-NP O
14 1070 1076 3425586 should MD B-VP O
15 1077 1079 3425586 be VB I-VP O
16 1080 1084 3425586 used VBN I-VP O
17 1085 1089 3425586 with IN B-PP O
18 1090 1097 3425586 caution NN B-NP O
19 1097 1098 3425586 , , O O
20 1099 1109 3425586 especially RB B-ADVP O
21 1110 1112 3425586 if IN B-SBAR O
22 1113 1115 3425586 an DT B-NP O
23 1116 1125 3425586 infection NN I-NP B-Disease
24 1126 1128 3425586 is VBZ B-VP O
25 1129 1136 3425586 present JJ B-ADJP O
26 1136 1137 3425586 , , O O
27 1138 1140 3425586 in IN B-PP O
28 1141 1152 3425586 individuals NNS B-NP O
29 1153 1155 3425586 of IN B-PP O
30 1156 1162 3425586 ethnic JJ B-NP O
31 1163 1174 3425586 backgrounds NNS I-NP O
32 1175 1179 3425586 that WDT B-NP O
33 1180 1184 3425586 have VBP B-VP O
34 1185 1187 3425586 an DT B-NP O
35 1188 1197 3425586 increased VBN I-NP O
36 1198 1208 3425586 prevalence NN I-NP O
37 1209 1211 3425586 of IN B-PP O
38 1212 1222 3425586 hemoglobin NN B-NP O
39 1223 1224 3425586 E NN I-NP O
40 1224 1225 3425586 . . O O

1 0 0 18768591 -DOCSTART- -X- -X- O

1 0 5 18768591 Serum NN B-NP O
2 5 6 18768591 - HYPH B-NP O
3 7 10 18768591 and CC I-NP O
4 11 25 18768591 glucocorticoid NN I-NP O
5 25 26 18768591 - HYPH I-NP O
6 26 35 18768591 inducible JJ I-NP O
7 36 42 18768591 kinase NN I-NP O
8 43 44 18768591 1 CD I-NP O
9 45 47 18768591 in IN B-PP O
10 48 59 18768591 doxorubicin NN B-NP B-Chemical
11 59 60 18768591 - HYPH B-NP O
12 60 67 18768591 induced VBN I-NP O
13 68 77 18768591 nephrotic JJ I-NP B-Disease
14 78 86 18768591 syndrome NN I-NP I-Disease
15 86 87 18768591 . . I-NP O
16 88 99 18768591 Doxorubicin NN I-NP B-Chemical
17 99 100 18768591 - HYPH B-NP O
18 100 107 18768591 induced VBN I-NP O
19 108 119 18768591 nephropathy NN I-NP B-Disease
20 120 125 18768591 leads VBZ B-VP O
21 126 128 18768591 to TO B-PP O
22 129 139 18768591 epithelial JJ B-NP O
23 140 146 18768591 sodium NN I-NP B-Chemical
24 147 154 18768591 channel NN I-NP O
25 155 156 18768591 ( ( O O
26 156 160 18768591 ENaC NN B-NP O
27 160 161 18768591 ) ) O O
28 161 162 18768591 - HYPH B-NP O
29 162 171 18768591 dependent JJ I-NP O
30 172 178 18768591 volume NN I-NP B-Disease
31 179 188 18768591 retention NN I-NP I-Disease
32 189 192 18768591 and CC O O
33 193 198 18768591 renal JJ B-NP O
34 199 207 18768591 fibrosis NN I-NP B-Disease
35 207 208 18768591 . . O O

1 209 212 18768591 The DT B-NP O
2 213 224 18768591 aldosterone NN I-NP B-Chemical
3 224 225 18768591 - HYPH O O
4 225 234 18768591 sensitive JJ B-NP O
5 235 240 18768591 serum NN I-NP O
6 240 241 18768591 - HYPH B-NP O
7 242 245 18768591 and CC I-NP O
8 246 260 18768591 glucocorticoid NN I-NP O
9 260 261 18768591 - HYPH I-NP O
10 261 270 18768591 inducible JJ I-NP O
11 271 277 18768591 kinase NN I-NP O
12 278 282 18768591 SGK1 NN I-NP O
13 283 286 18768591 has VBZ B-VP O
14 287 291 18768591 been VBN I-VP O
15 292 297 18768591 shown VBN I-VP O
16 298 300 18768591 to TO I-VP O
17 301 312 18768591 participate VB I-VP O
18 313 315 18768591 in IN B-PP O
19 316 319 18768591 the DT B-NP O
20 320 331 18768591 stimulation NN I-NP O
21 332 334 18768591 of IN B-PP O
22 335 339 18768591 ENaC NN B-NP O
23 340 343 18768591 and CC O O
24 344 346 18768591 to TO B-VP O
25 347 354 18768591 mediate VB I-VP O
26 355 360 18768591 renal JJ B-NP O
27 361 369 18768591 fibrosis NN I-NP B-Disease
28 370 379 18768591 following VBG B-PP O
29 380 397 18768591 mineralocorticoid NN B-NP O
30 398 401 18768591 and CC I-NP O
31 402 406 18768591 salt NN I-NP O
32 407 413 18768591 excess NN I-NP O
33 413 414 18768591 . . O O

1 415 418 18768591 The DT B-NP O
2 419 426 18768591 present JJ I-NP O
3 427 432 18768591 study NN I-NP O
4 433 436 18768591 was VBD B-VP O
5 437 446 18768591 performed VBN I-VP O
6 447 449 18768591 to TO I-VP O
7 450 459 18768591 elucidate VB I-VP O
8 460 463 18768591 the DT B-NP O
9 464 468 18768591 role NN I-NP O
10 469 471 18768591 of IN B-PP O
11 472 476 18768591 SGK1 NN B-NP O
12 477 479 18768591 in IN B-PP O
13 480 483 18768591 the DT B-NP O
14 484 490 18768591 volume NN I-NP B-Disease
15 491 500 18768591 retention NN I-NP I-Disease
16 501 504 18768591 and CC I-NP O
17 505 513 18768591 fibrosis NN I-NP B-Disease
18 514 520 18768591 during IN B-PP O
19 521 530 18768591 nephrotic JJ B-NP B-Disease
20 531 539 18768591 syndrome NN I-NP I-Disease
21 539 540 18768591 . . O O

1 541 543 18768591 To TO B-PP O
2 544 548 18768591 this DT B-NP O
3 549 552 18768591 end NN I-NP O
4 552 553 18768591 , , O O
5 554 565 18768591 doxorubicin NN B-NP B-Chemical
6 566 567 18768591 ( ( O O
7 567 569 18768591 15 CD B-NP O
8 570 573 18768591 mug NN I-NP O
9 573 574 18768591 / SYM B-NP O
10 574 575 18768591 g NN I-NP O
11 576 580 18768591 body NN I-NP O
12 581 583 18768591 wt NN I-NP O
13 583 584 18768591 ) ) O O
14 585 588 18768591 was VBD B-VP O
15 589 597 18768591 injected VBN I-VP O
16 598 611 18768591 intravenously RB B-ADVP O
17 612 616 18768591 into IN B-PP O
18 617 621 18768591 gene NN B-NP O
19 621 622 18768591 - HYPH B-NP O
20 622 630 18768591 targeted VBN I-NP O
21 631 635 18768591 mice NNS I-NP O
22 636 643 18768591 lacking VBG B-VP O
23 644 648 18768591 SGK1 NN B-NP O
24 649 650 18768591 ( ( O O
25 650 655 18768591 sgk1( NN B-NP O
26 655 656 18768591 - HYPH O O
27 656 657 18768591 / SYM O O
28 657 658 18768591 - SYM O O
29 658 659 18768591 ) ) O O
30 659 660 18768591 ) ) O O
31 661 664 18768591 and CC O O
32 665 670 18768591 their PRP$ B-NP O
33 671 675 18768591 wild JJ I-NP O
34 675 676 18768591 - HYPH I-NP O
35 676 680 18768591 type NN I-NP O
36 681 692 18768591 littermates NNS I-NP O
37 693 694 18768591 ( ( O O
38 694 700 18768591 sgk1(+ NN B-NP O
39 700 701 18768591 / SYM O O
40 701 702 18768591 + SYM O O
41 702 703 18768591 ) ) O O
42 703 704 18768591 ) ) O O
43 704 705 18768591 . . O O

1 706 717 18768591 Doxorubicin NN B-NP B-Chemical
2 718 727 18768591 treatment NN I-NP O
3 728 736 18768591 resulted VBD B-VP O
4 737 739 18768591 in IN B-PP O
5 740 745 18768591 heavy JJ B-NP O
6 746 757 18768591 proteinuria NN I-NP B-Disease
7 758 759 18768591 ( ( O O
8 759 760 18768591 > SYM B-NP O
9 760 763 18768591 100 CD I-NP O
10 764 766 18768591 mg NN I-NP O
11 767 774 18768591 protein NN I-NP O
12 774 775 18768591 / SYM B-NP O
13 775 777 18768591 mg NN I-NP O
14 778 782 18768591 crea NN I-NP O
15 782 783 18768591 ) ) O O
16 784 786 18768591 in IN B-PP O
17 787 789 18768591 15 CD B-NP O
18 789 790 18768591 / SYM I-NP O
19 790 792 18768591 44 CD I-NP O
20 793 795 18768591 of IN B-PP O
21 796 802 18768591 sgk1(+ NN B-NP O
22 802 803 18768591 / SYM B-NP O
23 803 804 18768591 + SYM B-NP O
24 804 805 18768591 ) ) O O
25 806 809 18768591 and CC O O
26 810 812 18768591 15 CD B-NP O
27 812 813 18768591 / SYM I-NP O
28 813 815 18768591 44 CD I-NP O
29 816 818 18768591 of IN B-PP O
30 819 824 18768591 sgk1( NN B-NP O
31 824 825 18768591 - HYPH O O
32 825 826 18768591 / SYM O O
33 826 827 18768591 - SYM O O
34 827 828 18768591 ) ) O O
35 829 833 18768591 mice NNS B-NP O
36 834 841 18768591 leading VBG B-VP O
37 842 844 18768591 to TO B-PP O
38 845 851 18768591 severe JJ B-NP O
39 852 861 18768591 nephrotic JJ I-NP B-Disease
40 862 870 18768591 syndrome NN I-NP I-Disease
41 871 875 18768591 with IN B-PP O
42 876 883 18768591 ascites NNS B-NP B-Disease
43 883 884 18768591 , , O O
44 885 894 18768591 lipidemia NN B-NP B-Disease
45 894 895 18768591 , , O O
46 896 899 18768591 and CC O O
47 900 915 18768591 hypoalbuminemia NN B-NP B-Disease
48 916 918 18768591 in IN B-PP O
49 919 923 18768591 both DT B-NP O
50 924 933 18768591 genotypes NNS I-NP O
51 933 934 18768591 . . O O

1 935 941 18768591 Plasma NN B-NP O
2 942 953 18768591 aldosterone NN I-NP B-Chemical
3 954 960 18768591 levels NNS I-NP O
4 961 970 18768591 increased VBD B-VP O
5 971 973 18768591 in IN B-PP O
6 974 983 18768591 nephrotic JJ B-NP B-Disease
7 984 988 18768591 mice NNS I-NP O
8 989 991 18768591 of IN B-PP O
9 992 996 18768591 both CC O O
10 997 1006 18768591 genotypes NNS B-NP O
11 1007 1010 18768591 and CC O O
12 1011 1014 18768591 was VBD B-VP O
13 1015 1023 18768591 followed VBN I-VP O
14 1024 1026 18768591 by IN B-PP O
15 1027 1036 18768591 increased VBN B-NP O
16 1037 1041 18768591 SGK1 NN I-NP O
17 1042 1049 18768591 protein NN I-NP O
18 1050 1060 18768591 expression NN I-NP O
19 1061 1063 18768591 in IN B-PP O
20 1064 1070 18768591 sgk1(+ NN B-NP O
21 1070 1071 18768591 / SYM O O
22 1071 1072 18768591 + SYM O O
23 1072 1073 18768591 ) ) O O
24 1074 1078 18768591 mice NNS B-NP O
25 1078 1079 18768591 . . O O

1 1080 1087 18768591 Urinary JJ B-NP O
2 1088 1094 18768591 sodium NN I-NP B-Chemical
3 1095 1104 18768591 excretion NN I-NP O
4 1105 1112 18768591 reached VBD B-VP O
5 1113 1125 18768591 signficantly RB B-NP O
6 1126 1131 18768591 lower JJR I-NP O
7 1132 1138 18768591 values NNS I-NP O
8 1139 1141 18768591 in IN B-PP O
9 1142 1148 18768591 sgk1(+ NN B-NP O
10 1148 1149 18768591 / SYM O O
11 1149 1150 18768591 + SYM O O
12 1150 1151 18768591 ) ) O O
13 1152 1156 18768591 mice NNS B-NP O
14 1157 1158 18768591 ( ( O O
15 1158 1160 18768591 15 CD B-NP O
16 1161 1162 18768591 + SYM O O
17 1162 1163 18768591 / SYM O O
18 1163 1164 18768591 - SYM O O
19 1165 1166 18768591 5 CD B-NP O
20 1167 1172 18768591 mumol NN I-NP O
21 1172 1173 18768591 / SYM B-NP O
22 1173 1175 18768591 mg NN I-NP O
23 1176 1180 18768591 crea NN I-NP O
24 1180 1181 18768591 ) ) O O
25 1182 1186 18768591 than IN B-PP O
26 1187 1189 18768591 in IN B-PP O
27 1190 1195 18768591 sgk1( NN B-NP O
28 1195 1196 18768591 - HYPH O O
29 1196 1197 18768591 / SYM O O
30 1197 1198 18768591 - SYM O O
31 1198 1199 18768591 ) ) O O
32 1200 1204 18768591 mice NNS B-NP O
33 1205 1206 18768591 ( ( O O
34 1206 1208 18768591 35 CD B-NP O
35 1209 1210 18768591 + SYM O O
36 1210 1211 18768591 / SYM O O
37 1211 1212 18768591 - SYM O O
38 1213 1214 18768591 5 CD B-NP O
39 1215 1220 18768591 mumol NN I-NP O
40 1220 1221 18768591 / SYM B-NP O
41 1221 1223 18768591 mg NN I-NP O
42 1224 1228 18768591 crea NN I-NP O
43 1228 1229 18768591 ) ) O O
44 1230 1233 18768591 and CC O O
45 1234 1237 18768591 was VBD B-VP O
46 1238 1248 18768591 associated VBN I-VP O
47 1249 1253 18768591 with IN B-PP O
48 1254 1255 18768591 a DT B-NP O
49 1256 1269 18768591 significantly RB I-NP O
50 1270 1276 18768591 higher JJR I-NP O
51 1277 1281 18768591 body NN I-NP O
52 1282 1288 18768591 weight NN I-NP B-Disease
53 1289 1293 18768591 gain NN I-NP I-Disease
54 1294 1296 18768591 in IN B-PP O
55 1297 1303 18768591 sgk1(+ NN B-NP O
56 1303 1304 18768591 / SYM O O
57 1304 1305 18768591 + SYM O O
58 1305 1306 18768591 ) ) O O
59 1307 1315 18768591 compared VBN B-PP O
60 1316 1320 18768591 with IN B-PP O
61 1321 1326 18768591 sgk1( NN B-NP O
62 1326 1327 18768591 - HYPH O O
63 1327 1328 18768591 / SYM O O
64 1328 1329 18768591 - SYM O O
65 1329 1330 18768591 ) ) O O
66 1331 1335 18768591 mice NNS B-NP O
67 1336 1337 18768591 ( ( O O
68 1337 1338 18768591 + SYM B-NP O
69 1338 1341 18768591 6.6 CD I-NP O
70 1342 1343 18768591 + SYM B-NP O
71 1343 1344 18768591 / SYM B-NP O
72 1344 1345 18768591 - SYM B-VP O
73 1346 1349 18768591 0.7 CD B-NP O
74 1350 1352 18768591 vs NNS I-NP O
75 1352 1353 18768591 . . O O
76 1354 1355 18768591 + SYM B-NP O
77 1355 1358 18768591 4.1 CD I-NP O
78 1359 1360 18768591 + SYM O O
79 1360 1361 18768591 / SYM O O
80 1361 1362 18768591 - SYM O O
81 1363 1366 18768591 0.8 CD B-NP O
82 1367 1368 18768591 g NN I-NP O
83 1368 1369 18768591 ) ) O O
84 1369 1370 18768591 . . O O

1 1371 1377 18768591 During IN B-PP O
2 1378 1381 18768591 the DT B-NP O
3 1382 1388 18768591 course NN I-NP O
4 1389 1391 18768591 of IN B-PP O
5 1392 1401 18768591 nephrotic JJ B-NP B-Disease
6 1402 1410 18768591 syndrome NN I-NP I-Disease
7 1410 1411 18768591 , , O O
8 1412 1417 18768591 serum NN B-NP O
9 1418 1422 18768591 urea NN I-NP B-Chemical
10 1423 1437 18768591 concentrations NNS I-NP O
11 1438 1447 18768591 increased VBD B-VP O
12 1448 1461 18768591 significantly RB B-ADJP O
13 1462 1468 18768591 faster JJR I-ADJP O
14 1469 1471 18768591 in IN B-PP O
15 1472 1477 18768591 sgk1( NN B-NP O
16 1477 1478 18768591 - HYPH O O
17 1478 1479 18768591 / SYM O O
18 1479 1480 18768591 - SYM O O
19 1480 1481 18768591 ) ) O O
20 1482 1486 18768591 mice NNS B-NP O
21 1487 1491 18768591 than IN B-PP O
22 1492 1494 18768591 in IN B-PP O
23 1495 1501 18768591 sgk1(+ NN B-NP O
24 1501 1502 18768591 / SYM O O
25 1502 1503 18768591 + SYM O O
26 1503 1504 18768591 ) ) O O
27 1505 1509 18768591 mice NNS B-NP O
28 1510 1517 18768591 leading VBG B-VP O
29 1518 1520 18768591 to TO B-PP O
30 1521 1527 18768591 uremia NN B-NP B-Disease
31 1528 1531 18768591 and CC O O
32 1532 1533 18768591 a DT B-NP O
33 1534 1541 18768591 reduced VBN I-NP O
34 1542 1548 18768591 median NN I-NP O
35 1549 1557 18768591 survival NN I-NP O
36 1558 1560 18768591 in IN B-PP O
37 1561 1566 18768591 sgk1( NN B-NP O
38 1566 1567 18768591 - HYPH O O
39 1567 1568 18768591 / SYM O O
40 1568 1569 18768591 - SYM O O
41 1569 1570 18768591 ) ) O O
42 1571 1575 18768591 mice NNS B-NP O
43 1576 1577 18768591 ( ( O O
44 1577 1579 18768591 29 CD B-NP O
45 1580 1582 18768591 vs NNS I-NP O
46 1582 1583 18768591 . . O O
47 1584 1586 18768591 40 CD B-NP O
48 1587 1591 18768591 days NNS I-NP O
49 1592 1594 18768591 in IN B-PP O
50 1595 1601 18768591 sgk1(+ NN B-NP O
51 1601 1602 18768591 / SYM O O
52 1602 1603 18768591 + SYM O O
53 1603 1604 18768591 ) ) O O
54 1605 1609 18768591 mice NNS B-NP O
55 1609 1610 18768591 ) ) O O
56 1610 1611 18768591 . . O O

1 1612 1614 18768591 In IN B-PP O
2 1615 1625 18768591 conclusion NN B-NP O
3 1625 1626 18768591 , , O O
4 1627 1631 18768591 gene NN B-NP O
5 1631 1632 18768591 - HYPH O O
6 1632 1640 18768591 targeted VBN B-NP O
7 1641 1645 18768591 mice NNS I-NP O
8 1646 1653 18768591 lacking VBG B-VP O
9 1654 1658 18768591 SGK1 NN B-NP O
10 1659 1665 18768591 showed VBD B-VP O
11 1666 1673 18768591 blunted JJ B-NP O
12 1674 1680 18768591 volume NN I-NP B-Disease
13 1681 1690 18768591 retention NN I-NP I-Disease
14 1690 1691 18768591 , , O O
15 1692 1695 18768591 yet RB O O
16 1696 1700 18768591 were VBD B-VP O
17 1701 1704 18768591 not RB I-VP O
18 1705 1714 18768591 protected VBN I-VP O
19 1715 1722 18768591 against IN B-PP O
20 1723 1728 18768591 renal JJ B-NP O
21 1729 1737 18768591 fibrosis NN I-NP B-Disease
22 1738 1744 18768591 during IN B-PP O
23 1745 1757 18768591 experimental JJ B-NP O
24 1758 1767 18768591 nephrotic JJ I-NP B-Disease
25 1768 1776 18768591 syndrome NN I-NP I-Disease
26 1776 1777 18768591 . . O O

1 0 0 17615423 -DOCSTART- -X- -X- O

1 0 6 17615423 Severe JJ B-NP O
2 7 21 17615423 rhabdomyolysis NN I-NP B-Disease
3 22 25 17615423 and CC O O
4 26 31 17615423 acute JJ B-NP B-Disease
5 32 37 17615423 renal JJ I-NP I-Disease
6 38 45 17615423 failure NN I-NP I-Disease
7 46 55 17615423 secondary JJ B-ADJP O
8 56 58 17615423 to TO B-PP O
9 59 70 17615423 concomitant JJ B-NP O
10 71 74 17615423 use NN I-NP O
11 75 77 17615423 of IN B-PP O
12 78 89 17615423 simvastatin NN B-NP B-Chemical
13 89 90 17615423 , , O O
14 91 101 17615423 amiodarone NN B-NP B-Chemical
15 101 102 17615423 , , O O
16 103 106 17615423 and CC O O
17 107 117 17615423 atazanavir NN B-NP B-Chemical
18 117 118 17615423 . . I-NP O
19 119 128 17615423 OBJECTIVE NN I-NP O
20 128 129 17615423 : : O O
21 130 132 17615423 To TO B-VP O
22 133 139 17615423 report VB I-VP O
23 140 141 17615423 a DT B-NP O
24 142 146 17615423 case NN I-NP O
25 147 149 17615423 of IN B-PP O
26 150 151 17615423 a DT B-NP O
27 152 158 17615423 severe JJ I-NP O
28 159 170 17615423 interaction NN I-NP O
29 171 178 17615423 between IN B-PP O
30 179 190 17615423 simvastatin NN B-NP B-Chemical
31 190 191 17615423 , , O O
32 192 202 17615423 amiodarone NN B-NP B-Chemical
33 202 203 17615423 , , O O
34 204 207 17615423 and CC O O
35 208 218 17615423 atazanavir NN B-NP B-Chemical
36 219 228 17615423 resulting VBG B-VP O
37 229 231 17615423 in IN B-PP O
38 232 246 17615423 rhabdomyolysis NN B-NP B-Disease
39 247 250 17615423 and CC O O
40 251 256 17615423 acute JJ B-NP B-Disease
41 257 262 17615423 renal JJ I-NP I-Disease
42 263 270 17615423 failure NN I-NP I-Disease
43 270 271 17615423 . . O O

1 272 282 17615423 BACKGROUND NN B-NP O
2 282 283 17615423 : : O O
3 284 285 17615423 A DT B-NP O
4 286 288 17615423 72 CD I-NP O
5 288 289 17615423 - HYPH I-NP O
6 289 293 17615423 year NN I-NP O
7 293 294 17615423 - HYPH B-NP O
8 294 297 17615423 old JJ I-NP O
9 298 303 17615423 white JJ I-NP O
10 304 307 17615423 man NN I-NP O
11 308 312 17615423 with IN B-PP O
12 313 323 17615423 underlying VBG B-VP O
13 324 329 17615423 human JJ B-NP B-Disease
14 330 346 17615423 immunodeficiency NN I-NP I-Disease
15 347 352 17615423 virus NN I-NP I-Disease
16 352 353 17615423 , , O O
17 354 360 17615423 atrial JJ B-NP B-Disease
18 361 373 17615423 fibrillation NN I-NP I-Disease
19 373 374 17615423 , , O O
20 375 383 17615423 coronary JJ B-NP B-Disease
21 384 390 17615423 artery NN I-NP I-Disease
22 391 398 17615423 disease NN I-NP I-Disease
23 398 399 17615423 , , O O
24 400 403 17615423 and CC O O
25 404 418 17615423 hyperlipidemia NN B-NP B-Disease
26 419 428 17615423 presented VBD B-VP O
27 429 433 17615423 with IN B-PP O
28 434 445 17615423 generalized VBN B-NP O
29 446 450 17615423 pain NN I-NP B-Disease
30 450 451 17615423 , , O O
31 452 459 17615423 fatigue NN B-NP B-Disease
32 459 460 17615423 , , O O
33 461 464 17615423 and CC O O
34 465 469 17615423 dark JJ B-NP O
35 470 476 17615423 orange JJ I-NP O
36 477 482 17615423 urine NN I-NP O
37 483 486 17615423 for IN B-PP O
38 487 488 17615423 3 CD B-NP O
39 489 493 17615423 days NNS I-NP O
40 493 494 17615423 . . O O

1 495 498 17615423 The DT B-NP O
2 499 506 17615423 patient NN I-NP O
3 507 510 17615423 was VBD B-VP O
4 511 517 17615423 taking VBG I-VP O
5 518 520 17615423 80 CD B-NP O
6 521 523 17615423 mg NN I-NP O
7 524 535 17615423 simvastatin NN I-NP B-Chemical
8 536 538 17615423 at IN B-PP O
9 539 546 17615423 bedtime NN B-NP O
10 547 548 17615423 ( ( O O
11 548 557 17615423 initiated VBN B-VP O
12 558 560 17615423 27 CD B-NP O
13 561 565 17615423 days NNS I-NP O
14 566 573 17615423 earlier RBR B-ADVP O
15 573 574 17615423 ) ) O O
16 574 575 17615423 ; : O O
17 576 586 17615423 amiodarone NN B-NP B-Chemical
18 587 589 17615423 at IN B-PP O
19 590 591 17615423 a DT B-NP O
20 592 596 17615423 dose NN I-NP O
21 597 599 17615423 of IN B-PP O
22 600 603 17615423 400 CD B-NP O
23 604 606 17615423 mg NN I-NP O
24 607 612 17615423 daily RB B-ADVP O
25 613 616 17615423 for IN B-PP O
26 617 618 17615423 7 CD B-NP O
27 619 623 17615423 days NNS I-NP O
28 623 624 17615423 , , O O
29 625 629 17615423 then RB B-ADVP O
30 630 633 17615423 200 CD B-NP O
31 634 636 17615423 mg NN I-NP O
32 637 642 17615423 daily JJ I-NP O
33 643 644 17615423 ( ( O O
34 644 653 17615423 initiated VBN B-VP O
35 654 656 17615423 19 CD B-NP O
36 657 661 17615423 days NNS I-NP O
37 662 669 17615423 earlier RBR B-ADVP O
38 669 670 17615423 ) ) O O
39 670 671 17615423 ; : O O
40 672 675 17615423 and CC O O
41 676 679 17615423 400 CD B-NP O
42 680 682 17615423 mg NN I-NP O
43 683 693 17615423 atazanavir NN I-NP B-Chemical
44 694 699 17615423 daily JJ I-NP O
45 700 701 17615423 ( ( O O
46 701 710 17615423 initiated VBN B-VP O
47 711 713 17615423 at IN B-NP O
48 714 719 17615423 least JJS I-NP O
49 720 721 17615423 2 CD I-NP O
50 722 727 17615423 years NNS I-NP O
51 728 738 17615423 previously RB B-ADVP O
52 738 739 17615423 ) ) O O
53 739 740 17615423 . . O O

1 741 751 17615423 Laboratory NN B-NP O
2 752 762 17615423 evaluation NN I-NP O
3 763 771 17615423 revealed VBD B-VP O
4 772 778 17615423 66,680 CD B-NP O
5 779 780 17615423 U NN I-NP O
6 780 781 17615423 / SYM B-NP O
7 781 782 17615423 L NN I-NP O
8 783 791 17615423 creatine NN I-NP B-Chemical
9 792 798 17615423 kinase NN I-NP O
10 798 799 17615423 , , O O
11 800 802 17615423 93 CD B-NP O
12 803 805 17615423 mg NN I-NP O
13 805 806 17615423 / SYM B-NP O
14 806 808 17615423 dL NN I-NP O
15 809 814 17615423 blood NN I-NP B-Chemical
16 815 819 17615423 urea NN I-NP I-Chemical
17 820 828 17615423 nitrogen NN I-NP I-Chemical
18 828 829 17615423 , , O O
19 830 833 17615423 4.6 CD B-NP O
20 834 836 17615423 mg NN I-NP O
21 836 837 17615423 / SYM B-NP O
22 837 839 17615423 dL NN I-NP O
23 840 850 17615423 creatinine NN I-NP B-Chemical
24 850 851 17615423 , , O O
25 852 856 17615423 1579 CD B-NP O
26 857 858 17615423 U NN I-NP O
27 858 859 17615423 / SYM B-NP O
28 859 860 17615423 L NN I-NP O
29 861 870 17615423 aspartate NN I-NP B-Chemical
30 871 887 17615423 aminotransferase NN I-NP O
31 887 888 17615423 , , O O
32 889 892 17615423 and CC O O
33 893 896 17615423 738 CD B-NP O
34 897 898 17615423 U NN I-NP O
35 898 899 17615423 / SYM B-NP O
36 899 900 17615423 L NN I-NP O
37 901 908 17615423 alanine NN I-NP B-Chemical
38 909 925 17615423 aminotransferase NN I-NP O
39 925 926 17615423 . . O O

1 927 938 17615423 Simvastatin NN B-NP B-Chemical
2 938 939 17615423 , , O O
3 940 950 17615423 amiodarone NN B-NP B-Chemical
4 950 951 17615423 , , O O
5 952 955 17615423 and CC O O
6 956 959 17615423 the DT B-NP O
7 960 969 17615423 patient's NNS I-NP O
8 970 975 17615423 human JJ B-NP B-Disease
9 976 992 17615423 immunodeficiency NN I-NP I-Disease
10 993 998 17615423 virus NN I-NP I-Disease
11 999 1010 17615423 medications NNS I-NP O
12 1011 1015 17615423 were VBD B-VP O
13 1016 1019 17615423 all DT B-NP O
14 1020 1031 17615423 temporarily RB I-NP O
15 1032 1044 17615423 discontinued VBN I-NP O
16 1045 1048 17615423 and CC O O
17 1049 1052 17615423 the DT B-NP O
18 1053 1060 17615423 patient NN I-NP O
19 1061 1064 17615423 was VBD B-VP O
20 1065 1070 17615423 given VBN I-VP O
21 1071 1077 17615423 forced VBN B-NP O
22 1078 1086 17615423 alkaline NN I-NP O
23 1087 1095 17615423 diuresis NN I-NP O
24 1096 1099 17615423 and CC O O
25 1100 1107 17615423 started VBN B-VP O
26 1108 1110 17615423 on IN B-PP O
27 1111 1119 17615423 dialysis NN B-NP O
28 1119 1120 17615423 . . O O

1 1121 1125 17615423 Nine CD B-NP O
2 1126 1130 17615423 days NNS I-NP O
3 1131 1136 17615423 later RB B-ADVP O
4 1137 1140 17615423 the DT B-NP O
5 1141 1150 17615423 patient's NNS I-NP O
6 1151 1159 17615423 creatine NN I-NP B-Chemical
7 1160 1166 17615423 kinase NN I-NP O
8 1167 1170 17615423 had VBD B-VP O
9 1171 1178 17615423 dropped VBN I-VP O
10 1179 1181 17615423 to TO B-PP O
11 1182 1186 17615423 1695 CD B-NP O
12 1187 1188 17615423 U NN I-NP O
13 1188 1189 17615423 / SYM B-NP O
14 1189 1190 17615423 L NN B-NP O
15 1191 1194 17615423 and CC I-NP O
16 1195 1205 17615423 creatinine NN I-NP B-Chemical
17 1206 1209 17615423 was VBD B-VP O
18 1210 1213 17615423 3.3 CD B-NP O
19 1214 1216 17615423 mg NN I-NP O
20 1216 1217 17615423 / SYM B-NP O
21 1217 1219 17615423 dL NN I-NP O
22 1219 1220 17615423 . . O O

1 1221 1224 17615423 The DT B-NP O
2 1225 1232 17615423 patient NN I-NP O
3 1233 1236 17615423 was VBD B-VP O
4 1237 1247 17615423 discharged VBN I-VP O
5 1248 1251 17615423 and CC O O
6 1252 1261 17615423 continued VBN B-NP O
7 1262 1272 17615423 outpatient NN I-NP O
8 1273 1281 17615423 dialysis NN I-NP O
9 1282 1285 17615423 for IN B-PP O
10 1286 1287 17615423 1 CD B-NP O
11 1288 1293 17615423 month NN I-NP O
12 1294 1299 17615423 until IN B-PP O
13 1300 1303 17615423 his PRP$ B-NP O
14 1304 1309 17615423 renal JJ I-NP O
15 1310 1318 17615423 function NN I-NP O
16 1319 1328 17615423 recovered VBD B-VP O
17 1328 1329 17615423 . . O O

1 1330 1340 17615423 DISCUSSION NN B-NP O
2 1340 1341 17615423 : : O O
3 1342 1345 17615423 The DT B-NP O
4 1346 1350 17615423 risk NN I-NP O
5 1351 1353 17615423 of IN B-PP O
6 1354 1368 17615423 rhabdomyolysis NN B-NP B-Disease
7 1369 1371 17615423 is VBZ B-VP O
8 1372 1381 17615423 increased VBN I-VP O
9 1382 1384 17615423 in IN B-PP O
10 1385 1388 17615423 the DT B-NP O
11 1389 1397 17615423 presence NN I-NP O
12 1398 1400 17615423 of IN B-PP O
13 1401 1412 17615423 concomitant JJ B-NP O
14 1413 1418 17615423 drugs NNS I-NP O
15 1419 1423 17615423 that WDT B-NP O
16 1424 1431 17615423 inhibit VBP B-VP O
17 1432 1443 17615423 simvastatin NN B-NP B-Chemical
18 1444 1454 17615423 metabolism NN I-NP O
19 1454 1455 17615423 . . O O

1 1456 1467 17615423 Simvastatin NN B-NP B-Chemical
2 1468 1470 17615423 is VBZ B-VP O
3 1471 1482 17615423 metabolized VBN I-VP O
4 1483 1485 17615423 by IN B-PP O
5 1486 1492 17615423 CYP3A4 NN B-NP O
6 1492 1493 17615423 . . O O

1 1494 1504 17615423 Amiodarone NN B-NP B-Chemical
2 1505 1508 17615423 and CC I-NP O
3 1509 1519 17615423 atazanavir NN I-NP B-Chemical
4 1520 1523 17615423 are VBP B-VP O
5 1524 1534 17615423 recognized VBN I-VP O
6 1535 1541 17615423 CYP3A4 NN B-NP O
7 1542 1552 17615423 inhibitors NNS I-NP O
8 1552 1553 17615423 . . O O

1 1554 1565 17615423 CONCLUSIONS NNS B-NP O
2 1565 1566 17615423 : : O O
3 1567 1582 17615423 Pharmacokinetic JJ B-NP O
4 1583 1594 17615423 differences NNS I-NP O
5 1595 1597 17615423 in IN B-PP O
6 1598 1605 17615423 statins NNS B-NP B-Chemical
7 1606 1609 17615423 are VBP B-VP O
8 1610 1612 17615423 an DT B-NP O
9 1613 1622 17615423 important JJ I-NP O
10 1623 1636 17615423 consideration NN I-NP O
11 1637 1640 17615423 for IN B-PP O
12 1641 1650 17615423 assessing VBG B-VP O
13 1651 1654 17615423 the DT B-NP O
14 1655 1659 17615423 risk NN I-NP O
15 1660 1662 17615423 of IN B-PP O
16 1663 1672 17615423 potential JJ B-NP O
17 1673 1677 17615423 drug NN I-NP O
18 1678 1690 17615423 interactions NNS I-NP O
19 1690 1691 17615423 . . O O

1 1692 1694 17615423 In IN B-PP O
2 1695 1703 17615423 patients NNS B-NP O
3 1704 1713 17615423 requiring VBG B-VP O
4 1714 1717 17615423 the DT B-NP O
5 1718 1728 17615423 concurrent JJ I-NP O
6 1729 1732 17615423 use NN I-NP O
7 1733 1735 17615423 of IN B-PP O
8 1736 1743 17615423 statins NNS B-NP B-Chemical
9 1744 1747 17615423 and CC O O
10 1748 1754 17615423 CYP3A4 NN B-NP O
11 1755 1765 17615423 inhibitors NNS I-NP O
12 1765 1766 17615423 , , O O
13 1767 1778 17615423 pravastatin NN B-NP B-Chemical
14 1778 1779 17615423 , , O O
15 1780 1791 17615423 fluvastatin NN B-NP B-Chemical
16 1791 1792 17615423 , , O O
17 1793 1796 17615423 and CC O O
18 1797 1809 17615423 rosuvastatin NN B-NP B-Chemical
19 1810 1815 17615423 carry VBP B-VP O
20 1816 1819 17615423 the DT B-NP O
21 1820 1826 17615423 lowest JJS I-NP O
22 1827 1831 17615423 risk NN I-NP O
23 1832 1834 17615423 of IN B-PP O
24 1835 1839 17615423 drug NN B-NP O
25 1840 1852 17615423 interactions NNS I-NP O
26 1852 1853 17615423 ; : O O
27 1854 1866 17615423 atorvastatin NN B-NP B-Chemical
28 1867 1874 17615423 carries VBZ B-VP O
29 1875 1883 17615423 moderate JJ B-NP O
30 1884 1888 17615423 risk NN I-NP O
31 1888 1889 17615423 , , O O
32 1890 1897 17615423 whereas IN O O
33 1898 1909 17615423 simvastatin NN B-NP B-Chemical
34 1910 1913 17615423 and CC I-NP O
35 1914 1924 17615423 lovastatin NN I-NP B-Chemical
36 1925 1929 17615423 have VBP B-VP O
37 1930 1933 17615423 the DT B-NP O
38 1934 1941 17615423 highest JJS I-NP O
39 1942 1946 17615423 risk NN I-NP O
40 1947 1950 17615423 and CC O O
41 1951 1957 17615423 should MD B-VP O
42 1958 1960 17615423 be VB I-VP O
43 1961 1968 17615423 avoided VBN I-VP O
44 1969 1971 17615423 in IN B-PP O
45 1972 1980 17615423 patients NNS B-NP O
46 1981 1987 17615423 taking VBG B-VP O
47 1988 1999 17615423 concomitant JJ B-NP O
48 2000 2006 17615423 CYP3A4 NN I-NP O
49 2007 2017 17615423 inhibitors NNS I-NP O
50 2017 2018 17615423 . . O O

1 0 0 6133211 -DOCSTART- -X- -X- O

1 0 8 6133211 Possible JJ B-NP O
2 9 23 6133211 teratogenicity NN I-NP O
3 24 26 6133211 of IN B-PP O
4 27 41 6133211 sulphasalazine NN B-NP B-Chemical
5 41 42 6133211 . . O O
6 43 48 6133211 Three CD B-NP O
7 49 56 6133211 infants NNS I-NP O
8 56 57 6133211 , , O O
9 58 62 6133211 born VBN B-VP O
10 63 65 6133211 of IN B-PP O
11 66 69 6133211 two CD B-NP O
12 70 77 6133211 mothers NNS I-NP O
13 78 82 6133211 with IN B-PP O
14 83 95 6133211 inflammatory JJ B-NP B-Disease
15 96 101 6133211 bowel NN I-NP I-Disease
16 102 109 6133211 disease NN I-NP I-Disease
17 110 113 6133211 who WP B-NP O
18 114 122 6133211 received VBD B-VP O
19 123 132 6133211 treatment NN B-NP O
20 133 137 6133211 with IN B-PP O
21 138 152 6133211 sulphasalazine NN B-NP B-Chemical
22 153 163 6133211 throughout IN B-PP O
23 164 173 6133211 pregnancy NN B-NP O
24 173 174 6133211 , , O O
25 175 179 6133211 were VBD B-VP O
26 180 185 6133211 found VBN I-VP O
27 186 188 6133211 to TO I-VP O
28 189 193 6133211 have VB I-VP O
29 194 199 6133211 major JJ B-NP O
30 200 210 6133211 congenital JJ I-NP B-Disease
31 211 220 6133211 anomalies NNS I-NP I-Disease
32 220 221 6133211 . . O O

1 222 224 6133211 In IN B-PP O
2 225 228 6133211 the DT B-NP O
3 229 238 6133211 singleton JJ I-NP O
4 239 248 6133211 pregnancy NN I-NP O
5 248 249 6133211 , , O O
6 250 253 6133211 the DT B-NP O
7 254 260 6133211 mother NN I-NP O
8 261 264 6133211 had VBD B-VP O
9 265 275 6133211 ulcerative JJ B-NP B-Disease
10 276 283 6133211 colitis NN I-NP I-Disease
11 283 284 6133211 , , O O
12 285 288 6133211 and CC O O
13 289 292 6133211 the DT B-NP O
14 293 299 6133211 infant NN I-NP O
15 299 300 6133211 , , O O
16 301 302 6133211 a DT B-NP O
17 303 307 6133211 male NN I-NP O
18 307 308 6133211 , , O O
19 309 312 6133211 had VBD B-VP O
20 313 324 6133211 coarctation NN B-NP B-Disease
21 325 327 6133211 of IN B-PP I-Disease
22 328 331 6133211 the DT B-NP I-Disease
23 332 337 6133211 aorta NN I-NP I-Disease
24 338 341 6133211 and CC O O
25 342 343 6133211 a DT B-NP O
26 344 355 6133211 ventricular JJ I-NP B-Disease
27 356 362 6133211 septal JJ I-NP I-Disease
28 363 369 6133211 defect NN I-NP I-Disease
29 369 370 6133211 . . O O

1 371 373 6133211 In IN B-PP O
2 374 377 6133211 the DT B-NP O
3 378 382 6133211 twin NN I-NP O
4 383 392 6133211 pregnancy NN I-NP O
5 392 393 6133211 , , O O
6 394 397 6133211 the DT B-NP O
7 398 404 6133211 mother NN I-NP O
8 405 408 6133211 had VBD B-VP O
9 409 416 6133211 Crohn's NNS B-NP B-Disease
10 417 424 6133211 disease NN I-NP I-Disease
11 424 425 6133211 . . O O

1 426 429 6133211 The DT B-NP O
2 430 435 6133211 first JJ I-NP O
3 436 440 6133211 twin NN I-NP O
4 440 441 6133211 , , O O
5 442 443 6133211 a DT B-NP O
6 444 450 6133211 female NN I-NP O
7 450 451 6133211 , , O O
8 452 455 6133211 had VBD B-VP O
9 456 457 6133211 a DT B-NP O
10 458 462 6133211 left JJ I-NP O
11 463 469 6133211 Potter NN I-NP B-Disease
12 469 470 6133211 - HYPH I-NP I-Disease
13 470 474 6133211 type NN I-NP I-Disease
14 475 478 6133211 IIa NN I-NP I-Disease
15 479 489 6133211 polycystic JJ I-NP I-Disease
16 490 496 6133211 kidney NN I-NP I-Disease
17 497 500 6133211 and CC O O
18 501 502 6133211 a DT B-NP O
19 503 514 6133211 rudimentary JJ I-NP B-Disease
20 515 519 6133211 left JJ I-NP I-Disease
21 520 527 6133211 uterine JJ I-NP I-Disease
22 528 533 6133211 cornu NN I-NP I-Disease
23 533 534 6133211 . . O O

1 535 538 6133211 The DT B-NP O
2 539 545 6133211 second JJ I-NP O
3 546 550 6133211 twin NN I-NP O
4 550 551 6133211 , , O O
5 552 553 6133211 a DT B-NP O
6 554 558 6133211 male NN I-NP O
7 558 559 6133211 , , O O
8 560 563 6133211 had VBD B-VP O
9 564 568 6133211 some DT B-NP O
10 569 577 6133211 features NNS I-NP O
11 578 580 6133211 of IN B-PP O
12 581 589 6133211 Potter's NNS B-NP B-Disease
13 590 596 6133211 facies NNS I-NP I-Disease
14 596 597 6133211 , , O O
15 598 609 6133211 hypoplastic JJ B-NP B-Disease
16 610 615 6133211 lungs NNS I-NP I-Disease
17 615 616 6133211 , , O O
18 617 623 6133211 absent JJ B-NP B-Disease
19 624 631 6133211 kidneys NNS I-NP I-Disease
20 632 635 6133211 and CC I-NP I-Disease
21 636 643 6133211 ureters NNS I-NP I-Disease
22 643 644 6133211 , , O O
23 645 648 6133211 and CC O O
24 649 656 6133211 talipes NNS B-NP B-Disease
25 657 668 6133211 equinovarus NN I-NP I-Disease
26 668 669 6133211 . . O O

1 670 677 6133211 Despite IN B-PP O
2 678 685 6133211 reports NNS B-NP O
3 686 688 6133211 to TO B-PP O
4 689 692 6133211 the DT B-NP O
5 693 701 6133211 contrary NN I-NP O
6 701 702 6133211 , , O O
7 703 705 6133211 it PRP B-NP O
8 706 708 6133211 is VBZ B-VP O
9 709 718 6133211 suggested VBN I-VP O
10 719 723 6133211 that IN B-SBAR O
11 724 738 6133211 sulphasalazine NN B-NP B-Chemical
12 739 742 6133211 may MD B-VP O
13 743 745 6133211 be VB I-VP O
14 746 757 6133211 teratogenic JJ B-ADJP O
15 757 758 6133211 . . O O

1 0 0 347884 -DOCSTART- -X- -X- O

1 0 8 347884 Clinical JJ B-NP O
2 9 20 347884 experiences NNS I-NP O
3 21 23 347884 in IN B-PP O
4 24 26 347884 an DT B-NP O
5 27 31 347884 open JJ I-NP O
6 32 35 347884 and CC O O
7 36 37 347884 a DT B-NP O
8 38 44 347884 double JJ I-NP O
9 44 45 347884 - HYPH I-NP O
10 45 50 347884 blind JJ I-NP O
11 51 56 347884 trial NN I-NP O
12 56 57 347884 . . I-NP O
13 58 59 347884 A NN I-NP O
14 60 65 347884 total NN I-NP O
15 66 68 347884 of IN B-PP O
16 69 74 347884 sixty JJ B-NP O
17 75 83 347884 patients NNS I-NP O
18 84 88 347884 were VBD B-VP O
19 89 95 347884 trated VBN I-VP O
20 96 100 347884 with IN B-PP O
21 101 112 347884 bromperidol NN B-NP B-Chemical
22 113 118 347884 first RB B-ADVP O
23 119 121 347884 in IN B-PP O
24 122 126 347884 open JJ B-NP O
25 127 137 347884 conditions NNS I-NP O
26 138 139 347884 ( ( O O
27 139 141 347884 20 CD B-NP O
28 142 150 347884 patients NNS I-NP O
29 150 151 347884 ) ) O O
30 151 152 347884 , , O O
31 153 157 347884 then RB B-ADVP O
32 158 160 347884 on IN B-PP O
33 161 162 347884 a DT B-NP O
34 163 169 347884 double JJ I-NP O
35 170 175 347884 blind JJ I-NP O
36 176 181 347884 basis NN I-NP O
37 182 183 347884 ( ( O O
38 183 185 347884 40 CD B-NP O
39 186 194 347884 patients NNS I-NP O
40 194 195 347884 ) ) O O
41 196 200 347884 with IN B-PP O
42 201 212 347884 haloperidol NN B-NP B-Chemical
43 213 215 347884 as IN B-PP O
44 216 219 347884 the DT B-NP O
45 220 229 347884 reference NN I-NP O
46 230 239 347884 substance NN I-NP O
47 239 240 347884 . . O O

1 241 244 347884 The DT B-NP O
2 245 249 347884 open JJ I-NP O
3 250 255 347884 study NN I-NP O
4 256 262 347884 lasted VBD B-VP O
5 263 266 347884 for IN B-PP O
6 267 271 347884 four CD B-NP O
7 272 277 347884 weeks NNS I-NP O
8 277 278 347884 ; : O O
9 279 282 347884 the DT B-NP O
10 283 287 347884 drug NN I-NP O
11 288 291 347884 was VBD B-VP O
12 292 305 347884 administrated VBN I-VP O
13 306 308 347884 in IN B-PP O
14 309 312 347884 the DT B-NP O
15 313 317 347884 form NN I-NP O
16 318 320 347884 of IN B-PP O
17 321 322 347884 1 CD B-NP O
18 323 325 347884 mg NN I-NP O
19 326 333 347884 tablets NNS I-NP O
20 333 334 347884 . . O O

1 335 338 347884 The DT B-NP O
2 339 344 347884 daily JJ I-NP O
3 345 349 347884 dose NN I-NP O
4 350 351 347884 ( ( O O
5 351 358 347884 initial JJ B-NP O
6 359 363 347884 dose NN I-NP O
7 363 364 347884 : : O O
8 365 366 347884 1 CD B-NP O
9 367 369 347884 mg NN I-NP O
10 369 370 347884 ; : O O
11 371 375 347884 mean JJ B-NP O
12 376 380 347884 dose NN I-NP O
13 381 383 347884 at IN B-PP O
14 384 387 347884 the DT B-NP O
15 388 391 347884 end NN I-NP O
16 392 394 347884 of IN B-PP O
17 395 398 347884 the DT B-NP O
18 399 404 347884 trial NN I-NP O
19 404 405 347884 : : O O
20 406 410 347884 4.47 CD B-NP O
21 411 413 347884 mg NN I-NP O
22 413 414 347884 ) ) O O
23 415 418 347884 was VBD B-VP O
24 419 425 347884 always RB I-VP O
25 426 438 347884 administered VBN I-VP O
26 439 441 347884 in IN B-PP O
27 442 445 347884 one CD B-NP O
28 446 452 347884 single JJ I-NP O
29 453 457 347884 dose NN I-NP O
30 457 458 347884 . . O O

1 459 467 347884 Nineteen CD B-NP O
2 468 476 347884 patients NNS I-NP O
3 477 485 347884 finished VBD B-VP O
4 486 489 347884 the DT B-NP O
5 490 495 347884 trial NN I-NP O
6 495 496 347884 , , O O
7 497 500 347884 and CC O O
8 501 503 347884 in IN B-PP O
9 504 506 347884 18 CD B-NP O
10 507 512 347884 cases NNS I-NP O
11 513 516 347884 the DT B-NP O
12 517 528 347884 therapeutic JJ I-NP O
13 529 535 347884 result NN I-NP O
14 536 539 347884 was VBD B-VP O
15 540 550 347884 considered VBN I-VP O
16 551 555 347884 very RB B-ADJP O
17 556 560 347884 good JJ I-ADJP O
18 561 563 347884 to TO B-PP O
19 564 568 347884 good JJ B-ADJP O
20 568 569 347884 . . O O

1 570 575 347884 These DT B-NP O
2 576 583 347884 results NNS I-NP O
3 584 588 347884 were VBD B-VP O
4 589 598 347884 confirmed VBN I-VP O
5 599 601 347884 by IN B-PP O
6 602 613 347884 statistical JJ B-NP O
7 614 622 347884 analysis NN I-NP O
8 622 623 347884 . . O O

1 624 628 347884 Nine CD B-NP O
2 629 637 347884 patients NNS I-NP O
3 638 647 347884 exhibited VBD B-VP O
4 648 652 347884 mild JJ B-ADJP O
5 653 655 347884 to TO B-VP O
6 656 664 347884 moderate VB I-VP O
7 665 679 347884 extrapyramidal JJ B-NP B-Disease
8 680 691 347884 concomitant JJ I-NP I-Disease
9 692 700 347884 symptoms NNS I-NP I-Disease
10 700 701 347884 ; : O O
11 702 704 347884 no DT B-NP O
12 705 710 347884 other JJ I-NP O
13 711 715 347884 side NN I-NP O
14 716 723 347884 effects NNS I-NP O
15 724 728 347884 were VBD B-VP O
16 729 737 347884 observed VBN I-VP O
17 737 738 347884 . . O O

1 739 742 347884 The DT B-NP O
2 743 750 347884 results NNS I-NP O
3 751 753 347884 of IN B-PP O
4 754 762 347884 detailed JJ B-NP O
5 763 773 347884 laboratory NN I-NP O
6 774 779 347884 tests NNS I-NP O
7 780 783 347884 and CC I-NP O
8 784 795 347884 evaluations NNS I-NP O
9 796 798 347884 of IN B-PP O
10 799 806 347884 various JJ B-NP O
11 807 819 347884 quantitative JJ I-NP O
12 820 823 347884 and CC I-NP O
13 824 835 347884 qualitative JJ I-NP O
14 836 848 347884 tolerability NN I-NP O
15 849 859 347884 parameters NNS I-NP O
16 860 864 347884 were VBD B-VP O
17 865 868 347884 not RB O O
18 869 879 347884 indicative JJ B-ADJP O
19 880 882 347884 of IN B-PP O
20 883 888 347884 toxic JJ B-NP O
21 889 896 347884 effects NNS I-NP O
22 896 897 347884 . . O O

1 898 900 347884 In IN B-PP O
2 901 904 347884 the DT B-NP O
3 905 911 347884 double JJ I-NP O
4 912 917 347884 blind JJ I-NP O
5 918 923 347884 study NN I-NP O
6 924 928 347884 with IN B-PP O
7 929 940 347884 haloperidol NN B-NP B-Chemical
8 940 941 347884 , , O O
9 942 946 347884 both DT B-NP O
10 947 957 347884 substances NNS I-NP O
11 958 962 347884 were VBD B-VP O
12 963 968 347884 found VBN I-VP O
13 969 971 347884 to TO I-VP O
14 972 974 347884 be VB I-VP O
15 975 981 347884 highly RB B-ADJP O
16 982 991 347884 effective JJ I-ADJP O
17 992 994 347884 in IN B-PP O
18 995 998 347884 the DT B-NP O
19 999 1008 347884 treatment NN I-NP O
20 1009 1011 347884 of IN B-PP O
21 1012 1021 347884 psychotic JJ B-NP B-Disease
22 1022 1031 347884 syndromes NNS I-NP I-Disease
23 1032 1041 347884 belonging VBG B-VP I-Disease
24 1042 1055 347884 predominantly RB B-ADVP I-Disease
25 1056 1058 347884 to TO B-PP I-Disease
26 1059 1062 347884 the DT B-NP I-Disease
27 1063 1076 347884 schizophrenia NN I-NP I-Disease
28 1077 1082 347884 group NN I-NP I-Disease
29 1082 1083 347884 . . O O

1 1084 1091 347884 Certain JJ B-NP O
2 1092 1097 347884 clues NNS I-NP O
3 1097 1098 347884 , , O O
4 1099 1108 347884 including VBG B-PP O
5 1109 1112 347884 the DT B-NP O
6 1113 1118 347884 onset NN I-NP O
7 1119 1121 347884 of IN B-PP O
8 1122 1128 347884 action NN B-NP O
9 1128 1129 347884 , , O O
10 1130 1134 347884 seem VBP B-VP O
11 1135 1137 347884 to TO I-VP O
12 1138 1140 347884 be VB I-VP O
13 1141 1151 347884 indicative JJ B-ADJP O
14 1152 1154 347884 of IN B-PP O
15 1155 1158 347884 the DT B-NP O
16 1159 1170 347884 superiority NN I-NP O
17 1171 1173 347884 of IN B-PP O
18 1174 1185 347884 bromperidol NN B-NP B-Chemical
19 1185 1186 347884 . . O O

1 1187 1189 347884 No DT B-NP O
2 1190 1201 347884 differences NNS I-NP O
3 1202 1206 347884 were VBD B-VP O
4 1207 1215 347884 observed VBN I-VP O
5 1216 1220 347884 with IN B-PP O
6 1221 1228 347884 respect NN B-NP O
7 1229 1231 347884 to TO B-PP O
8 1232 1236 347884 side NN B-NP O
9 1237 1244 347884 effects NNS I-NP O
10 1245 1248 347884 and CC O O
11 1249 1256 347884 general JJ B-NP O
12 1257 1269 347884 tolerability NN I-NP O
13 1269 1270 347884 . . O O

1 0 0 17147461 -DOCSTART- -X- -X- O

1 0 9 17147461 Sirolimus NN B-NP B-Chemical
2 9 10 17147461 - HYPH B-NP O
3 10 20 17147461 associated VBN I-NP O
4 21 32 17147461 proteinuria NN I-NP B-Disease
5 33 36 17147461 and CC I-NP O
6 37 42 17147461 renal JJ I-NP B-Disease
7 43 54 17147461 dysfunction NN I-NP I-Disease
8 54 55 17147461 . . I-NP O
9 56 65 17147461 Sirolimus NN I-NP B-Chemical
10 66 68 17147461 is VBZ B-VP O
11 69 70 17147461 a DT B-NP O
12 71 76 17147461 novel JJ I-NP O
13 77 94 17147461 immunosuppressant NN I-NP O
14 95 99 17147461 with IN B-PP O
15 100 106 17147461 potent JJ B-NP O
16 107 124 17147461 antiproliferative JJ I-NP O
17 125 132 17147461 actions NNS I-NP O
18 133 140 17147461 through IN B-PP O
19 141 144 17147461 its PRP$ B-NP O
20 145 152 17147461 ability NN I-NP O
21 153 155 17147461 to TO B-VP O
22 156 163 17147461 inhibit VB I-VP O
23 164 167 17147461 the DT B-NP O
24 168 174 17147461 raptor NN I-NP O
25 174 175 17147461 - HYPH O O
26 175 185 17147461 containing VBG B-VP O
27 186 195 17147461 mammalian JJ B-NP O
28 196 202 17147461 target NN I-NP O
29 203 205 17147461 of IN B-PP O
30 206 215 17147461 rapamycin NN B-NP B-Chemical
31 216 223 17147461 protein NN I-NP O
32 224 230 17147461 kinase NN I-NP O
33 230 231 17147461 . . O O

1 232 241 17147461 Sirolimus NNP B-NP B-Chemical
2 242 252 17147461 represents VBZ B-VP O
3 253 254 17147461 a DT B-NP O
4 255 260 17147461 major JJ I-NP O
5 261 272 17147461 therapeutic JJ I-NP O
6 273 280 17147461 advance NN I-NP O
7 281 283 17147461 in IN B-PP O
8 284 287 17147461 the DT B-NP O
9 288 298 17147461 prevention NN I-NP O
10 299 301 17147461 of IN B-PP O
11 302 307 17147461 acute JJ B-NP O
12 308 313 17147461 renal JJ I-NP O
13 314 323 17147461 allograft NN I-NP O
14 324 333 17147461 rejection NN I-NP O
15 334 337 17147461 and CC O O
16 338 345 17147461 chronic JJ B-NP O
17 346 355 17147461 allograft NN I-NP O
18 356 367 17147461 nephropathy NN I-NP B-Disease
19 367 368 17147461 . . O O

1 369 372 17147461 Its PRP$ B-NP O
2 373 377 17147461 role NN I-NP O
3 378 380 17147461 in IN B-PP O
4 381 384 17147461 the DT B-NP O
5 385 392 17147461 therapy NN I-NP O
6 393 395 17147461 of IN B-PP O
7 396 414 17147461 glomerulonephritis NN B-NP B-Disease
8 414 415 17147461 , , O O
9 416 428 17147461 autoimmunity NN B-NP B-Disease
10 428 429 17147461 , , O O
11 430 436 17147461 cystic JJ B-NP B-Disease
12 437 442 17147461 renal JJ I-NP I-Disease
13 443 451 17147461 diseases NNS I-NP I-Disease
14 452 455 17147461 and CC O O
15 456 461 17147461 renal JJ B-NP B-Disease
16 462 468 17147461 cancer NN I-NP I-Disease
17 469 471 17147461 is VBZ B-VP O
18 472 477 17147461 under IN B-PP O
19 478 491 17147461 investigation NN B-NP O
20 491 492 17147461 . . O O

1 493 500 17147461 Because IN B-SBAR O
2 501 510 17147461 sirolimus NN B-NP B-Chemical
3 511 515 17147461 does VBZ B-VP O
4 516 519 17147461 not RB I-VP O
5 520 525 17147461 share VB I-VP O
6 526 529 17147461 the DT B-NP O
7 530 539 17147461 vasomotor NN I-NP O
8 540 545 17147461 renal JJ I-NP O
9 546 553 17147461 adverse JJ I-NP O
10 554 561 17147461 effects NNS I-NP O
11 562 571 17147461 exhibited VBN B-VP O
12 572 574 17147461 by IN B-PP O
13 575 586 17147461 calcineurin NN B-NP O
14 587 597 17147461 inhibitors NNS I-NP O
15 597 598 17147461 , , O O
16 599 601 17147461 it PRP B-NP O
17 602 605 17147461 has VBZ B-VP O
18 606 610 17147461 been VBN I-VP O
19 611 621 17147461 designated VBN I-VP O
20 622 623 17147461 a DT B-NP O
21 624 625 17147461 ' `` I-NP O
22 625 628 17147461 non AFX I-NP O
23 628 629 17147461 - HYPH I-NP O
24 629 640 17147461 nephrotoxic JJ I-NP B-Disease
25 641 645 17147461 drug NN I-NP O
26 645 646 17147461 ' '' O O
27 646 647 17147461 . . O O

1 648 655 17147461 However RB B-ADVP O
2 655 656 17147461 , , O O
3 657 665 17147461 clinical JJ B-NP O
4 666 673 17147461 reports NNS I-NP O
5 674 681 17147461 suggest VBP B-VP O
6 682 686 17147461 that IN B-SBAR O
7 686 687 17147461 , , O O
8 688 693 17147461 under IN B-PP O
9 694 698 17147461 some DT B-NP O
10 699 712 17147461 circumstances NNS I-NP O
11 712 713 17147461 , , O O
12 714 723 17147461 sirolimus NN B-NP B-Chemical
13 724 726 17147461 is VBZ B-VP O
14 727 737 17147461 associated VBN I-VP O
15 738 742 17147461 with IN B-PP O
16 743 754 17147461 proteinuria NN B-NP B-Disease
17 755 758 17147461 and CC O O
18 759 764 17147461 acute JJ B-NP B-Disease
19 765 770 17147461 renal JJ I-NP I-Disease
20 771 782 17147461 dysfunction NN I-NP I-Disease
21 782 783 17147461 . . O O

1 784 785 17147461 A DT B-NP O
2 786 792 17147461 common JJ I-NP O
3 793 797 17147461 risk NN I-NP O
4 798 804 17147461 factor NN I-NP O
5 805 812 17147461 appears VBZ B-VP O
6 813 815 17147461 to TO I-VP O
7 816 818 17147461 be VB I-VP O
8 819 827 17147461 presence NN B-NP O
9 828 830 17147461 of IN B-PP O
10 831 834 17147461 pre AFX B-NP O
11 834 835 17147461 - HYPH B-VP O
12 835 843 17147461 existing VBG B-NP O
13 844 851 17147461 chronic JJ I-NP B-Disease
14 852 857 17147461 renal JJ I-NP I-Disease
15 858 864 17147461 damage NN I-NP I-Disease
16 864 865 17147461 . . O O

1 866 869 17147461 The DT B-NP O
2 870 880 17147461 mechanisms NNS I-NP O
3 881 883 17147461 of IN B-PP O
4 884 893 17147461 sirolimus NN B-NP B-Chemical
5 893 894 17147461 - HYPH B-NP O
6 894 904 17147461 associated VBN I-NP O
7 905 916 17147461 proteinuria NN I-NP B-Disease
8 917 920 17147461 are VBP B-VP O
9 921 935 17147461 multifactorial JJ B-ADJP O
10 936 939 17147461 and CC O O
11 940 943 17147461 may MD B-VP O
12 944 946 17147461 be VB I-VP O
13 947 950 17147461 due JJ B-ADVP O
14 951 953 17147461 to TO B-PP O
15 954 956 17147461 an DT B-NP O
16 957 965 17147461 increase NN I-NP O
17 966 968 17147461 in IN B-PP O
18 969 979 17147461 glomerular JJ B-NP O
19 980 989 17147461 capillary JJ I-NP O
20 990 998 17147461 pressure NN I-NP O
21 999 1008 17147461 following VBG B-PP O
22 1009 1020 17147461 calcineurin NN B-NP O
23 1021 1030 17147461 inhibitor NN I-NP O
24 1031 1041 17147461 withdrawal NN I-NP O
25 1041 1042 17147461 . . O O

1 1043 1045 17147461 It PRP B-NP O
2 1046 1049 17147461 has VBZ B-VP O
3 1050 1054 17147461 also RB I-VP O
4 1055 1059 17147461 been VBN I-VP O
5 1060 1069 17147461 suggested VBN I-VP O
6 1070 1074 17147461 that IN B-SBAR O
7 1075 1084 17147461 sirolimus NN B-NP B-Chemical
8 1085 1093 17147461 directly RB B-ADVP O
9 1094 1100 17147461 causes VBZ B-VP O
10 1101 1110 17147461 increased VBN I-VP O
11 1111 1121 17147461 glomerular JJ B-NP O
12 1122 1134 17147461 permeability NN I-NP O
13 1134 1135 17147461 / SYM B-NP O
14 1135 1141 17147461 injury NN I-NP O
15 1141 1142 17147461 , , O O
16 1143 1146 17147461 but CC O O
17 1147 1155 17147461 evidence NN B-NP O
18 1156 1159 17147461 for IN B-PP O
19 1160 1164 17147461 this DT B-NP O
20 1165 1174 17147461 mechanism NN I-NP O
21 1175 1177 17147461 is VBZ B-VP O
22 1178 1187 17147461 currently RB B-ADJP O
23 1188 1200 17147461 inconclusive JJ I-ADJP O
24 1200 1201 17147461 . . O O

1 1202 1205 17147461 The DT B-NP O
2 1206 1211 17147461 acute JJ I-NP B-Disease
3 1212 1217 17147461 renal JJ I-NP I-Disease
4 1218 1229 17147461 dysfunction NN I-NP I-Disease
5 1230 1240 17147461 associated VBN B-VP O
6 1241 1245 17147461 with IN B-PP O
7 1246 1255 17147461 sirolimus NN B-NP B-Chemical
8 1256 1257 17147461 ( ( O O
9 1257 1261 17147461 such JJ B-PP O
10 1262 1264 17147461 as IN I-PP O
11 1265 1267 17147461 in IN B-PP O
12 1268 1275 17147461 delayed VBN B-NP O
13 1276 1281 17147461 graft NN I-NP O
14 1282 1290 17147461 function NN I-NP O
15 1290 1291 17147461 ) ) O O
16 1292 1295 17147461 may MD B-VP O
17 1296 1298 17147461 be VB I-VP O
18 1299 1302 17147461 due JJ B-ADJP O
19 1303 1305 17147461 to TO B-PP O
20 1306 1317 17147461 suppression NN B-NP O
21 1318 1320 17147461 of IN B-PP O
22 1321 1333 17147461 compensatory JJ B-NP O
23 1334 1339 17147461 renal JJ I-NP O
24 1340 1344 17147461 cell NN I-NP O
25 1345 1358 17147461 proliferation NN I-NP O
26 1359 1362 17147461 and CC I-NP O
27 1363 1371 17147461 survival NN I-NP O
28 1371 1372 17147461 / SYM I-NP O
29 1372 1378 17147461 repair NN I-NP O
30 1379 1388 17147461 processes NNS I-NP O
31 1388 1389 17147461 . . O O

1 1390 1398 17147461 Although IN B-SBAR O
2 1399 1404 17147461 these DT B-NP O
3 1405 1412 17147461 adverse JJ I-NP O
4 1413 1420 17147461 effects NNS I-NP O
5 1421 1426 17147461 occur VBP B-VP O
6 1427 1429 17147461 in IN B-PP O
7 1430 1434 17147461 some DT B-NP O
8 1435 1443 17147461 patients NNS I-NP O
9 1443 1444 17147461 , , O O
10 1445 1450 17147461 their PRP$ B-NP O
11 1451 1461 17147461 occurrence NN I-NP O
12 1462 1467 17147461 could MD B-VP O
13 1468 1470 17147461 be VB I-VP O
14 1471 1480 17147461 minimised VBN I-VP O
15 1481 1483 17147461 by IN B-PP O
16 1484 1493 17147461 knowledge NN B-NP O
17 1494 1496 17147461 of IN B-PP O
18 1497 1500 17147461 the DT B-NP O
19 1501 1510 17147461 molecular JJ I-NP O
20 1511 1518 17147461 effects NNS I-NP O
21 1519 1521 17147461 of IN B-PP O
22 1522 1531 17147461 sirolimus NN B-NP B-Chemical
23 1532 1534 17147461 on IN B-PP O
24 1535 1538 17147461 the DT B-NP O
25 1539 1545 17147461 kidney NN I-NP O
26 1545 1546 17147461 , , O O
27 1547 1550 17147461 the DT B-NP O
28 1551 1554 17147461 use NN I-NP O
29 1555 1557 17147461 of IN B-PP O
30 1558 1567 17147461 sirolimus NN B-NP B-Chemical
31 1568 1570 17147461 in IN B-PP O
32 1571 1582 17147461 appropriate JJ B-NP O
33 1583 1590 17147461 patient NN I-NP O
34 1591 1602 17147461 populations NNS I-NP O
35 1602 1603 17147461 , , O O
36 1604 1609 17147461 close JJ B-NP O
37 1610 1620 17147461 monitoring NN I-NP O
38 1621 1623 17147461 of IN B-PP O
39 1624 1635 17147461 proteinuria NN B-NP B-Disease
40 1636 1639 17147461 and CC O O
41 1640 1645 17147461 renal JJ B-NP O
42 1646 1654 17147461 function NN I-NP O
43 1654 1655 17147461 , , O O
44 1656 1659 17147461 use NN B-NP O
45 1660 1662 17147461 of IN B-PP O
46 1663 1674 17147461 angiotensin NN B-NP B-Chemical
47 1674 1675 17147461 - HYPH O O
48 1675 1685 17147461 converting VBG B-VP O
49 1686 1692 17147461 enzyme NN B-NP O
50 1693 1703 17147461 inhibitors NNS I-NP O
51 1704 1706 17147461 or CC O O
52 1707 1718 17147461 angiotensin NN B-NP B-Chemical
53 1719 1721 17147461 II CD I-NP I-Chemical
54 1722 1730 17147461 receptor NN I-NP O
55 1731 1739 17147461 blockers NNS I-NP O
56 1740 1742 17147461 if IN B-SBAR O
57 1743 1754 17147461 proteinuria NN B-NP B-Disease
58 1755 1761 17147461 occurs VBZ B-VP O
59 1762 1765 17147461 and CC O O
60 1766 1776 17147461 withdrawal NN B-NP O
61 1777 1779 17147461 if IN B-SBAR O
62 1780 1786 17147461 needed VBN B-VP O
63 1786 1787 17147461 . . O O

1 1788 1795 17147461 Further RB B-NP O
2 1796 1800 17147461 long JJ I-NP O
3 1800 1801 17147461 - HYPH I-NP O
4 1801 1805 17147461 term NN I-NP O
5 1806 1814 17147461 analysis NN I-NP O
6 1815 1817 17147461 of IN B-PP O
7 1818 1823 17147461 renal JJ B-NP O
8 1824 1833 17147461 allograft NN I-NP O
9 1834 1841 17147461 studies NNS I-NP O
10 1842 1847 17147461 using VBG B-VP O
11 1848 1857 17147461 sirolimus NN B-NP B-Chemical
12 1858 1860 17147461 as IN B-PP O
13 1861 1863 17147461 de FW B-NP O
14 1864 1868 17147461 novo FW I-NP O
15 1869 1886 17147461 immunosuppression NN I-NP O
16 1887 1892 17147461 along IN B-PP O
17 1893 1897 17147461 with IN B-PP O
18 1898 1906 17147461 clinical JJ B-NP O
19 1907 1910 17147461 and CC I-NP O
20 1911 1921 17147461 laboratory JJ I-NP O
21 1922 1929 17147461 studies NNS I-NP O
22 1930 1934 17147461 will MD B-VP O
23 1935 1941 17147461 refine VB I-VP O
24 1942 1947 17147461 these DT B-NP O
25 1948 1954 17147461 issues NNS I-NP O
26 1955 1957 17147461 in IN B-PP O
27 1958 1961 17147461 the DT B-NP O
28 1962 1968 17147461 future NN I-NP O
29 1968 1969 17147461 . . O O

1 0 0 20619828 -DOCSTART- -X- -X- O

1 0 1 20619828 A DT B-NP O
2 2 7 20619828 novel JJ I-NP O
3 7 8 20619828 , , I-NP O
4 9 17 20619828 multiple JJ I-NP O
5 18 25 20619828 symptom NN I-NP O
6 26 31 20619828 model NN I-NP O
7 32 34 20619828 of IN B-PP O
8 35 44 20619828 obsessive JJ B-NP B-Disease
9 44 45 20619828 - HYPH I-NP I-Disease
10 45 55 20619828 compulsive JJ I-NP I-Disease
11 55 56 20619828 - HYPH I-NP I-Disease
12 56 60 20619828 like JJ I-NP I-Disease
13 61 70 20619828 behaviors NNS I-NP I-Disease
14 71 73 20619828 in IN B-PP O
15 74 81 20619828 animals NNS B-NP O
16 81 82 20619828 . . O O
17 83 93 20619828 BACKGROUND NN B-NP O
18 93 94 20619828 : : O O
19 95 102 20619828 Current JJ B-NP O
20 103 109 20619828 animal NN I-NP O
21 110 116 20619828 models NNS I-NP O
22 117 119 20619828 of IN B-PP O
23 120 129 20619828 obsessive JJ B-NP B-Disease
24 129 130 20619828 - HYPH I-NP I-Disease
25 130 140 20619828 compulsive JJ I-NP I-Disease
26 141 149 20619828 disorder NN I-NP I-Disease
27 150 151 20619828 ( ( O O
28 151 154 20619828 OCD NN B-NP B-Disease
29 154 155 20619828 ) ) O O
30 156 165 20619828 typically RB B-ADVP O
31 166 173 20619828 involve VBP B-VP O
32 174 179 20619828 acute JJ B-NP O
33 179 180 20619828 , , I-NP O
34 181 185 20619828 drug NN I-NP O
35 185 186 20619828 - HYPH B-NP O
36 186 193 20619828 induced VBN I-NP O
37 194 201 20619828 symptom NN I-NP O
38 202 213 20619828 provocation NN I-NP O
39 214 216 20619828 or CC O O
40 217 218 20619828 a DT B-NP O
41 219 226 20619828 genetic JJ I-NP O
42 227 238 20619828 association NN I-NP O
43 239 243 20619828 with IN B-PP O
44 244 256 20619828 stereotypies NNS B-NP O
45 257 259 20619828 or CC O O
46 260 267 20619828 anxiety NN B-NP B-Disease
47 267 268 20619828 . . O O

1 269 273 20619828 None NN B-NP O
2 274 276 20619828 of IN B-PP O
3 277 282 20619828 these DT B-NP O
4 283 290 20619828 current JJ I-NP O
5 291 297 20619828 models NNS I-NP O
6 298 309 20619828 demonstrate VBP B-VP O
7 310 318 20619828 multiple JJ B-NP O
8 319 322 20619828 OCD NNP I-NP B-Disease
9 322 323 20619828 - HYPH B-NP O
10 323 327 20619828 like JJ I-NP O
11 328 337 20619828 behaviors NNS I-NP O
12 337 338 20619828 . . O O

1 339 346 20619828 METHODS NNS B-NP O
2 346 347 20619828 : : O O
3 348 356 20619828 Neonatal JJ B-NP O
4 357 361 20619828 rats NNS I-NP O
5 362 366 20619828 were VBD B-VP O
6 367 374 20619828 treated VBN I-VP O
7 375 379 20619828 with IN B-PP O
8 380 383 20619828 the DT B-NP O
9 384 393 20619828 tricyclic JJ I-NP O
10 394 408 20619828 antidepressant NN I-NP B-Chemical
11 409 421 20619828 clomipramine NN I-NP B-Chemical
12 422 424 20619828 or CC I-NP O
13 425 432 20619828 vehicle NN I-NP O
14 433 440 20619828 between IN B-PP O
15 441 445 20619828 days NNS B-NP O
16 446 447 20619828 9 CD B-NP O
17 448 451 20619828 and CC I-NP O
18 452 454 20619828 16 CD I-NP O
19 455 460 20619828 twice RB I-NP O
20 461 466 20619828 daily RB I-NP O
21 467 470 20619828 and CC O O
22 471 483 20619828 behaviorally RB B-VP O
23 484 490 20619828 tested VBN I-VP O
24 491 493 20619828 in IN B-PP O
25 494 503 20619828 adulthood NN B-NP O
26 503 504 20619828 . . O O

1 505 512 20619828 RESULTS NNS B-NP O
2 512 513 20619828 : : O O
3 514 526 20619828 Clomipramine NN B-NP B-Chemical
4 527 535 20619828 exposure NN I-NP O
5 536 538 20619828 in IN B-PP O
6 539 547 20619828 immature JJ B-NP O
7 548 552 20619828 rats NNS I-NP O
8 553 561 20619828 produced VBD B-VP O
9 562 573 20619828 significant JJ B-NP O
10 574 584 20619828 behavioral JJ I-NP O
11 585 588 20619828 and CC I-NP O
12 589 600 20619828 biochemical JJ I-NP O
13 601 608 20619828 changes NNS I-NP O
14 609 613 20619828 that WDT B-NP O
15 614 621 20619828 include VBP B-VP O
16 622 630 20619828 enhanced VBN I-VP O
17 631 638 20619828 anxiety NN B-NP B-Disease
18 639 640 20619828 ( ( O O
19 640 648 20619828 elevated VBN B-VP O
20 649 653 20619828 plus CC O O
21 654 658 20619828 maze NN B-NP O
22 659 662 20619828 and CC I-NP O
23 663 669 20619828 marble NN I-NP O
24 670 677 20619828 burying NN I-NP O
25 677 678 20619828 ) ) O O
26 678 679 20619828 , , O O
27 680 690 20619828 behavioral JJ B-NP B-Disease
28 691 704 20619828 inflexibility NN I-NP I-Disease
29 705 706 20619828 ( ( O O
30 706 719 20619828 perseveration NN B-NP O
31 720 722 20619828 in IN B-PP O
32 723 726 20619828 the DT B-NP O
33 727 738 20619828 spontaneous JJ I-NP O
34 739 750 20619828 alternation NN I-NP O
35 751 755 20619828 task NN I-NP O
36 756 759 20619828 and CC O O
37 760 768 20619828 impaired JJ B-NP O
38 769 777 20619828 reversal NN I-NP O
39 778 786 20619828 learning NN I-NP O
40 786 787 20619828 ) ) O O
41 787 788 20619828 , , O O
42 789 796 20619828 working VBG B-VP O
43 797 803 20619828 memory NN B-NP B-Disease
44 804 814 20619828 impairment NN I-NP I-Disease
45 815 816 20619828 ( ( O O
46 816 820 20619828 e.g. FW B-NP O
47 820 821 20619828 , , O O
48 822 825 20619828 win NN B-NP O
49 825 826 20619828 - HYPH I-NP O
50 826 831 20619828 shift NN I-NP O
51 832 840 20619828 paradigm NN I-NP O
52 840 841 20619828 ) ) O O
53 841 842 20619828 , , O O
54 843 851 20619828 hoarding VBG B-VP B-Disease
55 851 852 20619828 , , O O
56 853 856 20619828 and CC O O
57 857 872 20619828 corticostriatal JJ B-NP B-Disease
58 873 884 20619828 dysfunction NN I-NP I-Disease
59 884 885 20619828 . . O O

1 886 894 20619828 Dopamine NN B-NP B-Chemical
2 895 897 20619828 D2 NN I-NP O
3 898 907 20619828 receptors NNS I-NP O
4 908 912 20619828 were VBD B-VP O
5 913 921 20619828 elevated VBN I-VP O
6 922 924 20619828 in IN B-PP O
7 925 928 20619828 the DT B-NP O
8 929 937 20619828 striatum NN I-NP O
9 937 938 20619828 , , O O
10 939 946 20619828 whereas IN O O
11 947 956 20619828 serotonin NN B-NP B-Chemical
12 957 959 20619828 2C NN I-NP O
13 959 960 20619828 , , O O
14 961 964 20619828 but CC O O
15 965 968 20619828 not RB O O
16 969 978 20619828 serotonin NN B-NP B-Chemical
17 979 981 20619828 1A NN I-NP O
18 981 982 20619828 , , O O
19 983 992 20619828 receptors NNS B-NP O
20 993 997 20619828 were VBD B-VP O
21 998 1006 20619828 elevated VBN I-VP O
22 1007 1009 20619828 in IN B-PP O
23 1010 1013 20619828 the DT B-NP O
24 1014 1021 20619828 orbital JJ I-NP O
25 1022 1029 20619828 frontal JJ I-NP O
26 1030 1036 20619828 cortex NN I-NP O
27 1036 1037 20619828 . . O O

1 1038 1049 20619828 CONCLUSIONS NNS B-NP O
2 1049 1050 20619828 : : O O
3 1051 1055 20619828 This DT B-NP O
4 1056 1058 20619828 is VBZ B-VP O
5 1059 1062 20619828 the DT B-NP O
6 1063 1068 20619828 first JJ I-NP O
7 1069 1082 20619828 demonstration NN I-NP O
8 1083 1085 20619828 of IN B-PP O
9 1086 1094 20619828 multiple JJ B-NP O
10 1095 1103 20619828 symptoms NNS I-NP O
11 1104 1114 20619828 consistent JJ B-ADJP O
12 1115 1119 20619828 with IN B-PP O
13 1120 1122 20619828 an DT B-NP O
14 1123 1126 20619828 OCD NN I-NP B-Disease
15 1126 1127 20619828 - HYPH B-NP O
16 1127 1131 20619828 like JJ I-NP O
17 1132 1139 20619828 profile NN I-NP O
18 1140 1142 20619828 in IN B-PP O
19 1143 1150 20619828 animals NNS B-NP O
20 1150 1151 20619828 . . O O

1 1152 1160 20619828 Moreover RB B-ADVP O
2 1160 1161 20619828 , , O O
3 1162 1167 20619828 these DT B-NP O
4 1168 1177 20619828 behaviors NNS I-NP O
5 1178 1181 20619828 are VBP B-VP O
6 1182 1193 20619828 accompanied VBN I-VP O
7 1194 1196 20619828 by IN B-PP O
8 1197 1208 20619828 biochemical JJ B-NP O
9 1209 1216 20619828 changes NNS I-NP O
10 1217 1219 20619828 in IN B-PP O
11 1220 1225 20619828 brain NN B-NP O
12 1226 1233 20619828 regions NNS I-NP O
13 1234 1244 20619828 previously RB B-VP O
14 1245 1255 20619828 identified VBN I-VP O
15 1256 1258 20619828 as IN B-PP O
16 1259 1267 20619828 relevant JJ B-ADJP O
17 1268 1270 20619828 to TO B-PP O
18 1271 1274 20619828 OCD NNP B-NP B-Disease
19 1274 1275 20619828 . . O O

1 1276 1280 20619828 This DT B-NP O
2 1281 1286 20619828 novel JJ I-NP O
3 1287 1292 20619828 model NN I-NP O
4 1293 1295 20619828 of IN B-PP O
5 1296 1299 20619828 OCD NN B-NP B-Disease
6 1300 1312 20619828 demonstrates VBZ B-VP O
7 1313 1317 20619828 that IN B-SBAR O
8 1318 1322 20619828 drug NN B-NP O
9 1323 1331 20619828 exposure NN I-NP O
10 1332 1338 20619828 during IN B-PP O
11 1339 1340 20619828 a DT B-NP O
12 1341 1350 20619828 sensitive JJ I-NP O
13 1351 1357 20619828 period NN I-NP O
14 1358 1361 20619828 can MD B-VP O
15 1362 1369 20619828 program VB I-VP O
16 1370 1377 20619828 disease NN B-NP O
17 1377 1378 20619828 - HYPH B-NP O
18 1378 1382 20619828 like JJ I-NP O
19 1383 1390 20619828 systems NNS I-NP O
20 1391 1402 20619828 permanently RB B-ADVP O
21 1402 1403 20619828 , , O O
22 1404 1409 20619828 which WDT B-NP O
23 1410 1415 20619828 could MD B-VP O
24 1416 1420 20619828 have VB I-VP O
25 1421 1433 20619828 implications NNS B-NP O
26 1434 1437 20619828 for IN B-PP O
27 1438 1445 20619828 current JJ B-NP O
28 1446 1449 20619828 and CC I-NP O
29 1450 1456 20619828 future JJ I-NP O
30 1457 1468 20619828 therapeutic JJ I-NP O
31 1469 1479 20619828 strategies NNS I-NP O
32 1480 1483 20619828 for IN B-PP O
33 1484 1488 20619828 this DT B-NP O
34 1489 1492 20619828 and CC O O
35 1493 1498 20619828 other JJ B-NP O
36 1499 1510 20619828 psychiatric JJ I-NP B-Disease
37 1511 1520 20619828 disorders NNS I-NP I-Disease
38 1520 1521 20619828 . . O O

1 0 0 8073369 -DOCSTART- -X- -X- O

1 0 6 8073369 Effect NN B-NP O
2 7 9 8073369 of IN B-PP O
3 10 17 8073369 coniine NN B-NP B-Chemical
4 18 20 8073369 on IN B-PP O
5 21 24 8073369 the DT B-NP O
6 25 35 8073369 developing VBG I-NP O
7 36 41 8073369 chick NN I-NP O
8 42 48 8073369 embryo NN I-NP O
9 48 49 8073369 . . O O
10 50 57 8073369 Coniine NNP B-NP B-Chemical
11 57 58 8073369 , , O O
12 59 61 8073369 an DT B-NP O
13 62 70 8073369 alkaloid NN I-NP O
14 71 75 8073369 from IN B-PP O
15 76 82 8073369 Conium NN B-NP O
16 83 92 8073369 maculatum NN I-NP O
17 93 94 8073369 ( ( O O
18 94 100 8073369 poison NN B-NP O
19 101 108 8073369 hemlock NN I-NP O
20 108 109 8073369 ) ) O O
21 109 110 8073369 , , O O
22 111 114 8073369 has VBZ B-VP O
23 115 119 8073369 been VBN I-VP O
24 120 125 8073369 shown VBN I-VP O
25 126 128 8073369 to TO I-VP O
26 129 131 8073369 be VB I-VP O
27 132 143 8073369 teratogenic JJ B-ADJP O
28 144 146 8073369 in IN B-PP O
29 147 156 8073369 livestock NN B-NP O
30 156 157 8073369 . . O O

1 158 161 8073369 The DT B-NP O
2 162 167 8073369 major JJ I-NP O
3 168 179 8073369 teratogenic JJ I-NP O
4 180 187 8073369 outcome NN I-NP O
5 188 190 8073369 is VBZ B-VP O
6 191 205 8073369 arthrogryposis NN B-NP B-Disease
7 205 206 8073369 , , O O
8 207 217 8073369 presumably RB B-ADJP O
9 218 221 8073369 due JJ I-ADJP O
10 222 224 8073369 to TO B-PP O
11 225 234 8073369 nicotinic JJ B-NP O
12 235 243 8073369 receptor NN I-NP O
13 244 252 8073369 blockade NN I-NP O
14 252 253 8073369 . . O O

1 254 261 8073369 However RB B-ADVP O
2 261 262 8073369 , , O O
3 263 270 8073369 coniine NN B-NP B-Chemical
4 271 274 8073369 has VBZ B-VP O
5 275 281 8073369 failed VBN I-VP O
6 282 284 8073369 to TO I-VP O
7 285 292 8073369 produce VB I-VP O
8 293 307 8073369 arthrogryposis NN B-NP B-Disease
9 308 310 8073369 in IN B-PP O
10 311 315 8073369 rats NNS B-NP O
11 316 318 8073369 or CC I-NP O
12 319 323 8073369 mice NNS I-NP O
13 324 327 8073369 and CC O O
14 328 330 8073369 is VBZ B-VP O
15 331 335 8073369 only RB B-ADJP O
16 336 342 8073369 weakly RB I-ADJP O
17 343 354 8073369 teratogenic JJ I-ADJP O
18 355 357 8073369 in IN B-PP O
19 358 365 8073369 rabbits NNS B-NP O
20 365 366 8073369 . . O O

1 367 370 8073369 The DT B-NP O
2 371 378 8073369 purpose NN I-NP O
3 379 381 8073369 of IN B-PP O
4 382 386 8073369 this DT B-NP O
5 387 392 8073369 study NN I-NP O
6 393 396 8073369 was VBD B-VP O
7 397 399 8073369 to TO B-VP O
8 400 408 8073369 evaluate VB I-VP O
9 409 412 8073369 and CC I-VP O
10 413 420 8073369 compare VB I-VP O
11 421 424 8073369 the DT B-NP O
12 425 432 8073369 effects NNS I-NP O
13 433 435 8073369 of IN B-PP O
14 436 443 8073369 coniine NN B-NP B-Chemical
15 444 447 8073369 and CC I-NP O
16 448 456 8073369 nicotine NN I-NP B-Chemical
17 457 459 8073369 in IN B-PP O
18 460 463 8073369 the DT B-NP O
19 464 474 8073369 developing VBG I-NP O
20 475 480 8073369 chick NN I-NP O
21 480 481 8073369 . . O O

1 482 496 8073369 Concentrations NNS B-NP O
2 497 499 8073369 of IN B-PP O
3 500 507 8073369 coniine NN B-NP B-Chemical
4 508 511 8073369 and CC I-NP O
5 512 520 8073369 nicotine NN I-NP B-Chemical
6 521 528 8073369 sulfate NN I-NP O
7 529 533 8073369 were VBD B-VP O
8 534 540 8073369 0.015% CD B-NP O
9 540 541 8073369 , , I-NP O
10 542 547 8073369 0.03% CD I-NP O
11 547 548 8073369 , , I-NP O
12 549 555 8073369 0.075% CD I-NP O
13 555 556 8073369 , , I-NP O
14 557 562 8073369 0.15% CD I-NP O
15 562 563 8073369 , , I-NP O
16 564 569 8073369 0.75% CD I-NP O
17 569 570 8073369 , , I-NP O
18 571 575 8073369 1.5% CD I-NP O
19 575 576 8073369 , , I-NP O
20 577 579 8073369 3% CD I-NP O
21 579 580 8073369 , , O O
22 581 584 8073369 and CC O O
23 585 587 8073369 6% NN B-NP O
24 588 591 8073369 and CC I-NP O
25 592 594 8073369 1% NN I-NP O
26 594 595 8073369 , , O O
27 596 598 8073369 5% NN B-NP O
28 598 599 8073369 , , O O
29 600 603 8073369 and CC O O
30 604 607 8073369 10% CD B-NP O
31 607 608 8073369 , , O O
32 609 621 8073369 respectively RB B-ADVP O
33 621 622 8073369 . . O O

1 623 627 8073369 Both DT B-NP O
2 628 637 8073369 compounds NNS I-NP O
3 638 644 8073369 caused VBD B-VP O
4 645 657 8073369 deformations NNS B-NP B-Disease
5 658 661 8073369 and CC O O
6 662 671 8073369 lethality NN B-NP O
7 672 674 8073369 in IN B-PP O
8 675 676 8073369 a DT B-NP O
9 677 681 8073369 dose NN I-NP O
10 681 682 8073369 - HYPH B-NP O
11 682 691 8073369 dependent JJ I-NP O
12 692 698 8073369 manner NN I-NP O
13 698 699 8073369 . . O O

1 700 703 8073369 All DT B-NP O
2 704 718 8073369 concentrations NNS I-NP O
3 719 721 8073369 of IN B-PP O
4 722 730 8073369 nicotine NN B-NP B-Chemical
5 731 738 8073369 sulfate NN I-NP O
6 739 745 8073369 caused VBD B-VP O
7 746 750 8073369 some DT B-NP O
8 751 760 8073369 lethality NN I-NP O
9 761 764 8073369 but CC O O
10 765 766 8073369 a DT B-NP O
11 767 769 8073369 no DT I-NP O
12 770 776 8073369 effect NN I-NP O
13 777 782 8073369 level NN I-NP O
14 783 786 8073369 for IN B-PP O
15 787 794 8073369 coniine NN B-NP B-Chemical
16 795 804 8073369 lethality NN I-NP O
17 805 808 8073369 was VBD B-VP O
18 809 814 8073369 0.75% CD B-NP O
19 814 815 8073369 . . O O

1 816 819 8073369 The DT B-NP O
2 820 832 8073369 deformations NNS I-NP B-Disease
3 833 839 8073369 caused VBN B-VP O
4 840 842 8073369 by IN B-PP O
5 843 847 8073369 both CC O O
6 848 855 8073369 coniine NN B-NP B-Chemical
7 856 859 8073369 and CC O O
8 860 868 8073369 nicotine NN B-NP B-Chemical
9 869 876 8073369 sulfate NN I-NP O
10 877 881 8073369 were VBD B-VP O
11 882 891 8073369 excessive JJ B-NP B-Disease
12 892 899 8073369 flexion NN I-NP I-Disease
13 900 902 8073369 or CC I-NP I-Disease
14 903 912 8073369 extension NN I-NP I-Disease
15 913 915 8073369 of IN B-PP I-Disease
16 916 919 8073369 one CD B-NP I-Disease
17 920 922 8073369 or CC I-NP I-Disease
18 923 927 8073369 more JJR I-NP I-Disease
19 928 932 8073369 toes NNS I-NP I-Disease
20 932 933 8073369 . . O O

1 934 936 8073369 No DT B-NP O
2 937 954 8073369 histopathological JJ I-NP O
3 955 966 8073369 alterations NNS I-NP O
4 967 969 8073369 or CC I-NP O
5 970 981 8073369 differences NNS I-NP O
6 982 984 8073369 in IN B-PP O
7 985 989 8073369 bone NN B-NP O
8 990 999 8073369 formation NN I-NP O
9 1000 1004 8073369 were VBD B-VP O
10 1005 1009 8073369 seen VBN I-VP O
11 1010 1012 8073369 in IN B-PP O
12 1013 1016 8073369 the DT B-NP O
13 1017 1022 8073369 limbs NNS I-NP O
14 1023 1025 8073369 or CC I-NP O
15 1026 1030 8073369 toes NNS I-NP O
16 1031 1033 8073369 of IN B-PP O
17 1034 1037 8073369 any DT B-NP O
18 1038 1044 8073369 chicks NNS I-NP O
19 1045 1049 8073369 from IN B-PP O
20 1050 1053 8073369 any DT B-NP O
21 1054 1059 8073369 group NN I-NP O
22 1059 1060 8073369 ; : O O
23 1061 1068 8073369 however RB B-ADVP O
24 1068 1069 8073369 , , O O
25 1070 1079 8073369 extensive JJ B-NP O
26 1080 1087 8073369 cranial JJ I-NP B-Disease
27 1088 1098 8073369 hemorrhage NN I-NP I-Disease
28 1099 1107 8073369 occurred VBD B-VP O
29 1108 1110 8073369 in IN B-PP O
30 1111 1114 8073369 all DT B-NP O
31 1115 1123 8073369 nicotine NN I-NP B-Chemical
32 1124 1131 8073369 sulfate NN I-NP O
33 1131 1132 8073369 - HYPH B-NP O
34 1132 1139 8073369 treated VBN I-NP O
35 1140 1146 8073369 chicks NNS I-NP O
36 1146 1147 8073369 . . O O

1 1148 1153 8073369 There EX B-NP O
2 1154 1157 8073369 was VBD B-VP O
3 1158 1159 8073369 a DT B-NP O
4 1160 1173 8073369 statistically RB I-NP O
5 1174 1185 8073369 significant JJ I-NP O
6 1186 1187 8073369 ( ( O O
7 1187 1188 8073369 P NN B-NP O
8 1189 1190 8073369 < SYM B-VP O
9 1191 1193 8073369 or CC O O
10 1194 1195 8073369 = SYM B-VP O
11 1196 1200 8073369 0.01 CD B-NP O
12 1200 1201 8073369 ) ) O O
13 1202 1210 8073369 decrease NN B-NP O
14 1211 1213 8073369 in IN B-PP O
15 1214 1222 8073369 movement NN B-NP O
16 1223 1225 8073369 in IN B-PP O
17 1226 1233 8073369 coniine NN B-NP B-Chemical
18 1234 1237 8073369 and CC I-NP O
19 1238 1246 8073369 nicotine NN I-NP B-Chemical
20 1247 1254 8073369 sulfate NN I-NP O
21 1255 1262 8073369 treated VBN B-VP O
22 1263 1269 8073369 chicks NNS B-NP O
23 1270 1272 8073369 as IN B-SBAR O
24 1273 1283 8073369 determined VBN B-VP O
25 1284 1286 8073369 by IN B-PP O
26 1287 1297 8073369 ultrasound NN B-NP O
27 1297 1298 8073369 . . O O

1 1299 1306 8073369 Control NN B-NP O
2 1307 1313 8073369 chicks NNS I-NP O
3 1314 1318 8073369 were VBD B-VP O
4 1319 1321 8073369 in IN B-PP O
5 1322 1328 8073369 motion NN B-NP O
6 1329 1331 8073369 an DT B-NP O
7 1332 1339 8073369 average NN I-NP O
8 1340 1342 8073369 of IN B-PP O
9 1343 1349 8073369 33.67% NN B-NP O
10 1350 1352 8073369 of IN B-PP O
11 1353 1356 8073369 the DT B-NP O
12 1357 1361 8073369 time NN I-NP O
13 1361 1362 8073369 , , O O
14 1363 1368 8073369 while IN B-SBAR O
15 1369 1376 8073369 coniine NN B-NP B-Chemical
16 1376 1377 8073369 - HYPH B-NP O
17 1377 1384 8073369 treated VBN I-NP O
18 1385 1391 8073369 chicks NNS I-NP O
19 1392 1396 8073369 were VBD B-VP O
20 1397 1401 8073369 only RB I-VP O
21 1402 1408 8073369 moving VBG I-VP O
22 1409 1414 8073369 8.95% CD B-NP O
23 1415 1417 8073369 of IN B-PP O
24 1418 1419 8073369 a DT B-NP O
25 1420 1421 8073369 5 CD I-NP O
26 1421 1422 8073369 - HYPH I-NP O
27 1422 1425 8073369 min NN I-NP O
28 1426 1434 8073369 interval NN I-NP O
29 1434 1435 8073369 , , O O
30 1436 1439 8073369 and CC O O
31 1440 1442 8073369 no DT B-NP O
32 1443 1451 8073369 movement NN I-NP O
33 1452 1455 8073369 was VBD B-VP O
34 1456 1464 8073369 observed VBN I-VP O
35 1465 1468 8073369 for IN B-PP O
36 1469 1477 8073369 nicotine NN B-NP B-Chemical
37 1478 1485 8073369 sulfate NN I-NP O
38 1486 1493 8073369 treated VBN B-NP O
39 1494 1500 8073369 chicks NNS I-NP O
40 1500 1501 8073369 . . O O

1 1502 1504 8073369 In IN B-PP O
2 1505 1512 8073369 summary NN B-NP O
3 1512 1513 8073369 , , O O
4 1514 1517 8073369 the DT B-NP O
5 1518 1523 8073369 chick NN I-NP O
6 1524 1530 8073369 embryo NN I-NP O
7 1531 1539 8073369 provides VBZ B-VP O
8 1540 1541 8073369 a DT B-NP O
9 1542 1550 8073369 reliable JJ I-NP O
10 1551 1554 8073369 and CC I-NP O
11 1555 1561 8073369 simple JJ I-NP O
12 1562 1574 8073369 experimental JJ I-NP O
13 1575 1581 8073369 animal NN I-NP O
14 1582 1587 8073369 model NN I-NP O
15 1588 1590 8073369 of IN B-PP O
16 1591 1598 8073369 coniine NN B-NP B-Chemical
17 1598 1599 8073369 - HYPH B-NP O
18 1599 1606 8073369 induced VBN I-NP O
19 1607 1621 8073369 arthrogryposis NN I-NP B-Disease
20 1621 1622 8073369 . . O O

1 1623 1627 8073369 Data NNS B-NP O
2 1628 1632 8073369 from IN B-PP O
3 1633 1637 8073369 this DT B-NP O
4 1638 1643 8073369 model NN I-NP O
5 1644 1651 8073369 support VBP B-VP O
6 1652 1653 8073369 a DT B-NP O
7 1654 1663 8073369 mechanism NN I-NP O
8 1664 1673 8073369 involving VBG B-VP O
9 1674 1683 8073369 nicotinic JJ B-NP O
10 1684 1692 8073369 receptor NN I-NP O
11 1693 1701 8073369 blockade NN I-NP O
12 1702 1706 8073369 with IN B-PP O
13 1707 1717 8073369 subsequent JJ B-NP O
14 1718 1727 8073369 decreased VBN I-NP O
15 1728 1733 8073369 fetal JJ I-NP O
16 1734 1742 8073369 movement NN I-NP O
17 1742 1743 8073369 . . O O

1 0 0 2951327 -DOCSTART- -X- -X- O

1 0 10 2951327 Inhibition NN B-NP O
2 11 13 2951327 of IN B-PP O
3 14 29 2951327 sympathoadrenal JJ B-NP O
4 30 38 2951327 activity NN I-NP O
5 39 41 2951327 by IN B-PP O
6 42 48 2951327 atrial JJ B-NP O
7 49 60 2951327 natriuretic JJ I-NP O
8 61 67 2951327 factor NN I-NP O
9 68 70 2951327 in IN B-PP O
10 71 75 2951327 dogs NNS B-NP O
11 75 76 2951327 . . O O
12 77 79 2951327 In IN B-PP O
13 80 83 2951327 six CD B-NP O
14 84 93 2951327 conscious JJ I-NP O
15 93 94 2951327 , , I-NP O
16 95 102 2951327 trained JJ I-NP O
17 103 107 2951327 dogs NNS I-NP O
18 107 108 2951327 , , O O
19 109 119 2951327 maintained VBN B-VP O
20 120 122 2951327 on IN B-PP O
21 123 124 2951327 a DT B-NP O
22 125 131 2951327 normal JJ I-NP O
23 132 138 2951327 sodium NN I-NP B-Chemical
24 139 145 2951327 intake NN I-NP O
25 146 148 2951327 of IN B-PP O
26 149 150 2951327 2 CD B-NP O
27 151 153 2951327 to TO I-NP O
28 154 155 2951327 4 CD I-NP O
29 156 159 2951327 mEq NN I-NP O
30 159 160 2951327 / SYM B-NP O
31 160 162 2951327 kg NN I-NP O
32 162 163 2951327 / SYM B-NP O
33 163 166 2951327 day NN I-NP O
34 166 167 2951327 , , O O
35 168 179 2951327 sympathetic JJ B-NP O
36 180 188 2951327 activity NN I-NP O
37 189 192 2951327 was VBD B-VP O
38 193 201 2951327 assessed VBN I-VP O
39 202 204 2951327 as IN B-PP O
40 205 208 2951327 the DT B-NP O
41 209 216 2951327 release NN I-NP O
42 217 221 2951327 rate NN I-NP O
43 222 224 2951327 of IN B-PP O
44 225 239 2951327 norepinephrine NN B-NP B-Chemical
45 240 243 2951327 and CC I-NP O
46 244 255 2951327 epinephrine NN I-NP B-Chemical
47 256 262 2951327 during IN B-PP O
48 263 265 2951327 15 CD B-NP O
49 265 266 2951327 - HYPH I-NP O
50 266 272 2951327 minute NN I-NP O
51 273 276 2951327 i.v NN I-NP O
52 276 277 2951327 . . O O

1 278 287 2951327 infusions NNS B-NP O
2 288 290 2951327 of IN B-PP O
3 291 296 2951327 human JJ B-NP O
4 297 302 2951327 alpha SYM I-NP O
5 302 303 2951327 - HYPH I-NP O
6 303 309 2951327 atrial JJ I-NP O
7 310 321 2951327 natriuretic JJ I-NP O
8 322 328 2951327 factor NN I-NP O
9 328 329 2951327 . . O O

1 330 334 2951327 Mean JJ B-NP O
2 335 343 2951327 arterial JJ I-NP O
3 344 352 2951327 pressure NN I-NP O
4 353 354 2951327 ( ( O O
5 354 356 2951327 as IN B-PP O
6 357 358 2951327 a DT B-NP O
7 359 369 2951327 percentage NN I-NP O
8 370 372 2951327 of IN B-PP O
9 373 380 2951327 control NN B-NP O
10 381 382 2951327 + SYM B-NP O
11 382 383 2951327 / SYM B-VP O
12 383 384 2951327 - HYPH B-NP O
13 385 388 2951327 SEM NN I-NP O
14 388 389 2951327 ) ) O O
15 390 396 2951327 during IN B-PP O
16 397 407 2951327 randomized VBN B-NP O
17 408 417 2951327 infusions NNS I-NP O
18 418 420 2951327 of IN B-PP O
19 421 425 2951327 0.03 CD B-NP O
20 425 426 2951327 , , I-NP O
21 427 430 2951327 0.1 CD I-NP O
22 430 431 2951327 , , I-NP O
23 432 435 2951327 0.3 CD I-NP O
24 435 436 2951327 , , O O
25 437 439 2951327 or CC O O
26 440 443 2951327 1.0 CD B-NP O
27 444 453 2951327 microgram NN I-NP O
28 453 454 2951327 / SYM B-NP O
29 454 456 2951327 kg NN I-NP O
30 456 457 2951327 / SYM B-NP O
31 457 460 2951327 min NN I-NP O
32 461 464 2951327 was VBD B-VP O
33 465 467 2951327 99 CD B-NP O
34 468 469 2951327 + SYM B-VP O
35 469 470 2951327 / SYM B-NP O
36 470 471 2951327 - SYM B-NP O
37 472 473 2951327 1 CD I-NP O
38 473 474 2951327 , , I-NP O
39 475 477 2951327 95 CD I-NP O
40 478 479 2951327 + SYM O O
41 479 480 2951327 / SYM B-NP O
42 480 481 2951327 - SYM B-NP O
43 482 483 2951327 1 CD I-NP O
44 484 485 2951327 ( ( O O
45 485 486 2951327 p NN B-NP O
46 487 491 2951327 less JJR B-ADJP O
47 492 496 2951327 than IN B-PP O
48 497 501 2951327 0.05 CD B-NP O
49 501 502 2951327 ) ) O O
50 502 503 2951327 , , O O
51 504 506 2951327 93 CD B-NP O
52 507 508 2951327 + SYM O O
53 508 509 2951327 / SYM B-NP O
54 509 510 2951327 - SYM B-NP O
55 511 512 2951327 1 CD I-NP O
56 513 514 2951327 ( ( O O
57 514 515 2951327 p NN B-NP O
58 516 520 2951327 less JJR B-ADJP O
59 521 525 2951327 than IN B-PP O
60 526 530 2951327 0.01 CD B-NP O
61 530 531 2951327 ) ) O O
62 531 532 2951327 , , O O
63 533 535 2951327 or CC O O
64 536 538 2951327 79 CD B-NP O
65 539 540 2951327 + SYM O O
66 540 541 2951327 / SYM O O
67 541 542 2951327 - SYM O O
68 543 545 2951327 6% CD B-NP O
69 546 547 2951327 ( ( O O
70 547 548 2951327 p NN B-NP O
71 549 553 2951327 less JJR B-ADJP O
72 554 558 2951327 than IN B-PP O
73 559 564 2951327 0.001 CD B-NP O
74 564 565 2951327 ) ) O O
75 565 566 2951327 , , O O
76 567 579 2951327 respectively RB B-ADVP O
77 579 580 2951327 , , O O
78 581 584 2951327 but CC O O
79 585 587 2951327 no DT B-NP O
80 588 599 2951327 tachycardia NN I-NP B-Disease
81 600 603 2951327 and CC O O
82 604 606 2951327 no DT B-NP O
83 607 619 2951327 augmentation NN I-NP O
84 620 622 2951327 of IN B-PP O
85 623 626 2951327 the DT B-NP O
86 627 641 2951327 norepinephrine NN I-NP B-Chemical
87 642 649 2951327 release NN I-NP O
88 650 654 2951327 rate NN I-NP O
89 655 656 2951327 ( ( O O
90 656 658 2951327 up RB B-NP O
91 659 661 2951327 to TO I-NP O
92 662 665 2951327 0.3 CD I-NP O
93 666 675 2951327 microgram NN I-NP O
94 675 676 2951327 / SYM B-NP O
95 676 678 2951327 kg NN I-NP O
96 678 679 2951327 / SYM B-NP O
97 679 682 2951327 min NN I-NP O
98 682 683 2951327 ) ) O O
99 684 688 2951327 were VBD B-VP O
100 689 697 2951327 observed VBN I-VP O
101 697 698 2951327 , , O O
102 699 704 2951327 which WDT B-NP O
103 705 707 2951327 is VBZ B-VP O
104 708 710 2951327 in IN B-PP O
105 711 719 2951327 contrast NN B-NP O
106 720 722 2951327 to TO B-PP O
107 723 733 2951327 comparable JJ B-NP O
108 734 745 2951327 hypotension NN I-NP B-Disease
109 746 753 2951327 induced VBN B-VP O
110 754 756 2951327 by IN B-PP O
111 757 768 2951327 hydralazine NN B-NP B-Chemical
112 769 771 2951327 or CC I-NP O
113 772 785 2951327 nitroglycerin NN I-NP B-Chemical
114 785 786 2951327 . . O O

1 787 790 2951327 The DT B-NP O
2 791 798 2951327 release NN I-NP O
3 799 803 2951327 rate NN I-NP O
4 804 806 2951327 of IN B-PP O
5 807 818 2951327 epinephrine NN B-NP B-Chemical
6 819 820 2951327 ( ( O O
7 820 827 2951327 control NN B-NP O
8 827 828 2951327 , , O O
9 829 832 2951327 6.7 CD B-NP O
10 833 834 2951327 + SYM O O
11 834 835 2951327 / SYM O O
12 835 836 2951327 - SYM O O
13 837 840 2951327 0.6 CD B-NP O
14 841 843 2951327 ng NN I-NP O
15 843 844 2951327 / SYM B-NP O
16 844 846 2951327 kg NN I-NP O
17 846 847 2951327 / SYM B-NP O
18 847 850 2951327 min NN I-NP O
19 850 851 2951327 ) ) O O
20 852 860 2951327 declined VBD B-VP O
21 861 872 2951327 immediately RB B-ADVP O
22 873 879 2951327 during IN B-PP O
23 880 889 2951327 infusions NNS B-NP O
24 890 892 2951327 of IN B-PP O
25 893 899 2951327 atrial JJ B-NP O
26 900 911 2951327 natriuretic JJ I-NP O
27 912 918 2951327 factor NN I-NP O
28 919 921 2951327 to TO B-PP O
29 922 923 2951327 a DT B-NP O
30 924 931 2951327 minimum NN I-NP O
31 932 934 2951327 of IN B-PP O
32 935 937 2951327 49 CD B-NP O
33 938 939 2951327 + SYM O O
34 939 940 2951327 / SYM O O
35 940 941 2951327 - SYM O O
36 942 944 2951327 5% NN B-NP O
37 945 947 2951327 of IN B-PP O
38 948 955 2951327 control NN B-NP O
39 956 957 2951327 ( ( O O
40 957 958 2951327 p NN B-NP O
41 959 963 2951327 less JJR B-ADJP O
42 964 968 2951327 than IN B-PP O
43 969 974 2951327 0.001 CD B-NP O
44 974 975 2951327 ) ) O O
45 976 982 2951327 during IN B-PP O
46 983 986 2951327 0.1 CD B-NP O
47 987 996 2951327 microgram NN I-NP O
48 996 997 2951327 / SYM B-NP O
49 997 999 2951327 kg NN I-NP O
50 999 1000 2951327 / SYM B-NP O
51 1000 1003 2951327 min NN B-NP O
52 1004 1007 2951327 and CC B-PP O
53 1008 1010 2951327 to TO B-PP O
54 1011 1013 2951327 63 CD B-NP O
55 1014 1015 2951327 + SYM O O
56 1015 1016 2951327 / SYM O O
57 1016 1017 2951327 - SYM O O
58 1018 1020 2951327 5% CD B-NP O
59 1021 1022 2951327 ( ( O O
60 1022 1025 2951327 0.1 CD B-NP O
61 1026 1033 2951327 greater JJR B-ADJP O
62 1034 1038 2951327 than IN B-PP O
63 1039 1040 2951327 p NN B-NP O
64 1041 1048 2951327 greater JJR B-ADJP O
65 1049 1053 2951327 than IN B-PP O
66 1054 1058 2951327 0.05 CD B-NP O
67 1058 1059 2951327 ) ) O O
68 1060 1062 2951327 or CC O O
69 1063 1065 2951327 95 CD B-NP O
70 1066 1067 2951327 + SYM O O
71 1067 1068 2951327 / SYM O O
72 1068 1069 2951327 - SYM O O
73 1070 1073 2951327 13% NN B-NP O
74 1074 1075 2951327 ( ( O O
75 1075 1078 2951327 not RB O O
76 1079 1090 2951327 significant JJ B-ADJP O
77 1090 1091 2951327 ) ) O O
78 1092 1098 2951327 during IN B-PP O
79 1099 1102 2951327 0.3 CD B-NP O
80 1103 1105 2951327 or CC I-NP O
81 1106 1109 2951327 1.0 CD I-NP O
82 1110 1119 2951327 microgram NN I-NP O
83 1119 1120 2951327 / SYM B-NP O
84 1120 1122 2951327 kg NN I-NP O
85 1122 1123 2951327 / SYM I-NP O
86 1123 1126 2951327 min NN I-NP O
87 1126 1127 2951327 . . O O

1 1128 1134 2951327 Steady JJ B-NP O
2 1135 1140 2951327 state NN I-NP O
3 1141 1149 2951327 arterial JJ I-NP O
4 1150 1156 2951327 plasma NN I-NP O
5 1157 1171 2951327 concentrations NNS I-NP O
6 1172 1174 2951327 of IN B-PP O
7 1175 1181 2951327 atrial JJ B-NP O
8 1182 1193 2951327 natriuretic JJ I-NP O
9 1194 1200 2951327 factor NN I-NP O
10 1201 1205 2951327 were VBD B-VP O
11 1206 1208 2951327 39 CD B-NP O
12 1209 1210 2951327 + SYM O O
13 1210 1211 2951327 / SYM O O
14 1211 1212 2951327 - SYM B-NP O
15 1213 1215 2951327 10 CD B-NP O
16 1216 1218 2951327 pg NN I-NP O
17 1218 1219 2951327 / SYM B-NP O
18 1219 1221 2951327 ml NN B-NP O
19 1222 1223 2951327 ( ( O O
20 1223 1224 2951327 n NN B-NP O
21 1225 1226 2951327 = SYM B-VP O
22 1227 1228 2951327 6 CD B-NP O
23 1228 1229 2951327 ) ) O O
24 1230 1236 2951327 during IN B-PP O
25 1237 1246 2951327 infusions NNS B-NP O
26 1247 1249 2951327 of IN B-PP O
27 1250 1256 2951327 saline NN B-NP O
28 1257 1260 2951327 and CC O O
29 1261 1264 2951327 284 CD B-NP O
30 1265 1266 2951327 + SYM O O
31 1266 1267 2951327 / SYM O O
32 1267 1268 2951327 - SYM O O
33 1269 1271 2951327 24 CD B-NP O
34 1272 1274 2951327 pg NN I-NP O
35 1274 1275 2951327 / SYM B-NP O
36 1275 1277 2951327 ml NN B-NP O
37 1278 1279 2951327 ( ( O O
38 1279 1280 2951327 n NN B-NP O
39 1281 1282 2951327 = SYM B-VP O
40 1283 1284 2951327 6 CD B-NP O
41 1284 1285 2951327 ) ) O O
42 1286 1289 2951327 and CC O O
43 1290 1294 2951327 1520 CD B-NP O
44 1295 1296 2951327 + SYM O O
45 1296 1297 2951327 / SYM O O
46 1297 1298 2951327 - SYM O O
47 1299 1302 2951327 300 CD B-NP O
48 1303 1305 2951327 pg NN I-NP O
49 1305 1306 2951327 / SYM B-NP O
50 1306 1308 2951327 ml NN B-NP O
51 1309 1310 2951327 ( ( O O
52 1310 1311 2951327 n NN B-NP O
53 1312 1313 2951327 = SYM B-VP O
54 1314 1315 2951327 9 CD B-NP O
55 1315 1316 2951327 ) ) O O
56 1317 1323 2951327 during IN B-PP O
57 1324 1328 2951327 0.03 CD B-NP O
58 1329 1332 2951327 and CC I-NP O
59 1333 1336 2951327 0.1 CD I-NP O
60 1337 1346 2951327 microgram NN I-NP O
61 1346 1347 2951327 / SYM B-NP O
62 1347 1349 2951327 kg NN I-NP O
63 1349 1350 2951327 / SYM B-NP O
64 1350 1353 2951327 min NN B-NP O
65 1354 1363 2951327 infusions NNS I-NP O
66 1364 1366 2951327 of IN B-PP O
67 1367 1370 2951327 the DT B-NP O
68 1371 1387 2951327 factor.(ABSTRACT NN I-NP O
69 1388 1397 2951327 TRUNCATED VBN B-VP O
70 1398 1400 2951327 AT IN B-PP O
71 1401 1404 2951327 250 CD B-NP O
72 1405 1410 2951327 WORDS NNS I-NP O
73 1410 1411 2951327 ) ) O O

1 0 0 3107448 -DOCSTART- -X- -X- O

1 0 9 3107448 Glyburide NN B-NP B-Chemical
2 9 10 3107448 - HYPH B-PP O
3 10 17 3107448 induced VBN B-NP O
4 18 27 3107448 hepatitis NN I-NP B-Disease
5 27 28 3107448 . . I-NP O
6 29 33 3107448 Drug NN I-NP O
7 33 34 3107448 - HYPH B-NP O
8 34 41 3107448 induced VBN I-NP O
9 42 56 3107448 hepatotoxicity NN I-NP B-Disease
10 56 57 3107448 , , O O
11 58 66 3107448 although IN B-SBAR O
12 67 73 3107448 common JJ B-ADJP O
13 73 74 3107448 , , O O
14 75 78 3107448 has VBZ B-VP O
15 79 83 3107448 been VBN I-VP O
16 84 92 3107448 reported VBN I-VP O
17 93 97 3107448 only RB B-ADVP O
18 98 110 3107448 infrequently RB I-ADVP O
19 111 115 3107448 with IN B-PP O
20 116 129 3107448 sulfonylureas NNS B-NP B-Chemical
21 129 130 3107448 . . O O

1 131 134 3107448 For IN B-PP O
2 135 144 3107448 glyburide NN B-NP B-Chemical
3 144 145 3107448 , , O O
4 146 147 3107448 a DT B-NP O
5 148 154 3107448 second JJ I-NP O
6 154 155 3107448 - HYPH I-NP O
7 155 165 3107448 generation NN I-NP O
8 166 178 3107448 sulfonylurea NN I-NP B-Chemical
9 178 179 3107448 , , O O
10 180 184 3107448 only RB B-NP O
11 185 188 3107448 two CD I-NP O
12 189 194 3107448 brief JJ I-NP O
13 195 202 3107448 reports NNS I-NP O
14 203 205 3107448 of IN B-PP O
15 206 220 3107448 hepatotoxicity NN B-NP B-Disease
16 221 226 3107448 exist NN I-NP O
17 226 227 3107448 . . O O

1 228 231 3107448 Two CD B-NP O
2 232 240 3107448 patients NNS I-NP O
3 241 245 3107448 with IN B-PP O
4 246 250 3107448 type NN B-NP B-Disease
5 251 253 3107448 II CD I-NP I-Disease
6 254 262 3107448 diabetes NNS I-NP I-Disease
7 263 271 3107448 mellitus NN I-NP I-Disease
8 272 281 3107448 developed VBD B-VP O
9 282 284 3107448 an DT B-NP O
10 285 290 3107448 acute JJ I-NP B-Disease
11 291 300 3107448 hepatitis NN I-NP I-Disease
12 300 301 3107448 - HYPH B-NP I-Disease
13 301 305 3107448 like JJ I-NP I-Disease
14 306 314 3107448 syndrome NN I-NP I-Disease
15 315 319 3107448 soon RB B-ADVP O
16 320 325 3107448 after IN B-PP O
17 326 336 3107448 initiation NN B-NP O
18 337 339 3107448 of IN B-PP O
19 340 349 3107448 glyburide NN B-NP B-Chemical
20 350 357 3107448 therapy NN I-NP O
21 357 358 3107448 . . O O

1 359 364 3107448 There EX B-NP O
2 365 368 3107448 was VBD B-VP O
3 369 371 3107448 no DT B-NP O
4 372 381 3107448 serologic JJ I-NP O
5 382 390 3107448 evidence NN I-NP O
6 391 393 3107448 of IN B-PP O
7 394 399 3107448 viral JJ B-NP B-Disease
8 400 409 3107448 infection NN I-NP I-Disease
9 409 410 3107448 , , O O
10 411 414 3107448 and CC O O
11 415 416 3107448 a DT B-NP O
12 417 422 3107448 liver NN I-NP O
13 423 429 3107448 biopsy NN I-NP O
14 430 436 3107448 sample NN I-NP O
15 437 443 3107448 showed VBD B-VP O
16 444 445 3107448 a DT B-NP O
17 446 456 3107448 histologic JJ I-NP O
18 457 464 3107448 pattern NN I-NP O
19 465 475 3107448 consistent JJ B-ADJP O
20 476 480 3107448 with IN B-PP O
21 481 485 3107448 drug NN B-NP B-Disease
22 485 486 3107448 - HYPH B-NP I-Disease
23 486 493 3107448 induced VBN I-NP I-Disease
24 494 503 3107448 hepatitis NN I-NP I-Disease
25 503 504 3107448 . . O O

1 505 509 3107448 Both DT B-NP O
2 510 518 3107448 patients NNS I-NP O
3 519 528 3107448 recovered VBD B-VP O
4 529 536 3107448 quickly RB B-ADVP O
5 537 542 3107448 after IN B-PP O
6 543 551 3107448 stopping VBG B-VP O
7 552 561 3107448 glyburide NN B-NP B-Chemical
8 562 569 3107448 therapy NN I-NP O
9 570 573 3107448 and CC O O
10 574 578 3107448 have VBP B-VP O
11 579 587 3107448 remained VBN I-VP O
12 588 592 3107448 well RB B-ADVP O
13 593 596 3107448 for IN B-PP O
14 597 598 3107448 a DT B-NP O
15 599 605 3107448 follow VB I-NP O
16 605 606 3107448 - HYPH O O
17 606 608 3107448 up RP B-PRT O
18 609 615 3107448 period NN B-NP O
19 616 618 3107448 of IN B-PP O
20 619 620 3107448 1 CD B-NP O
21 621 625 3107448 year NN I-NP O
22 625 626 3107448 . . O O

1 627 636 3107448 Glyburide NN B-NP B-Chemical
2 637 640 3107448 can MD B-VP O
3 641 648 3107448 produce VB I-VP O
4 649 651 3107448 an DT B-NP O
5 652 657 3107448 acute JJ I-NP B-Disease
6 658 667 3107448 hepatitis NN I-NP I-Disease
7 667 668 3107448 - HYPH B-NP I-Disease
8 668 672 3107448 like JJ I-NP I-Disease
9 673 680 3107448 illness NN I-NP I-Disease
10 681 683 3107448 in IN B-PP O
11 684 688 3107448 some DT B-NP O
12 689 696 3107448 persons NNS I-NP O
13 696 697 3107448 . . O O

1 0 0 2802551 -DOCSTART- -X- -X- O

1 0 6 2802551 Sodium NN B-NP B-Chemical
2 7 13 2802551 status NN I-NP O
3 14 24 2802551 influences VBZ B-VP O
4 25 32 2802551 chronic JJ B-NP O
5 33 45 2802551 amphotericin NN I-NP B-Chemical
6 46 47 2802551 B NN I-NP I-Chemical
7 48 62 2802551 nephrotoxicity NN I-NP B-Disease
8 63 65 2802551 in IN B-PP O
9 66 70 2802551 rats NNS B-NP O
10 70 71 2802551 . . O O
11 72 75 2802551 The DT B-NP O
12 76 87 2802551 nephrotoxic JJ I-NP B-Disease
13 88 97 2802551 potential NN I-NP O
14 98 100 2802551 of IN B-PP O
15 101 113 2802551 amphotericin NN B-NP B-Chemical
16 114 115 2802551 B NN I-NP I-Chemical
17 116 117 2802551 ( ( O O
18 117 118 2802551 5 CD B-NP O
19 119 121 2802551 mg NN I-NP O
20 121 122 2802551 / SYM B-NP O
21 122 124 2802551 kg NN I-NP O
22 125 128 2802551 per IN B-PP O
23 129 132 2802551 day NN B-NP O
24 133 150 2802551 intraperitoneally RB B-ADVP O
25 151 154 2802551 for IN B-PP O
26 155 156 2802551 3 CD B-NP O
27 157 162 2802551 weeks NNS I-NP O
28 162 163 2802551 ) ) O O
29 164 167 2802551 has VBZ B-VP O
30 168 172 2802551 been VBN I-VP O
31 173 185 2802551 investigated VBN I-VP O
32 186 188 2802551 in IN B-PP O
33 189 193 2802551 salt NN B-NP O
34 193 194 2802551 - HYPH B-NP O
35 194 202 2802551 depleted VBN I-NP O
36 202 203 2802551 , , I-NP O
37 204 210 2802551 normal JJ I-NP O
38 210 211 2802551 - HYPH I-NP O
39 211 215 2802551 salt NN I-NP O
40 215 216 2802551 , , O O
41 217 220 2802551 and CC O O
42 221 225 2802551 salt NN B-NP O
43 225 226 2802551 - HYPH B-NP O
44 226 232 2802551 loaded VBN I-NP O
45 233 237 2802551 rats NNS I-NP O
46 237 238 2802551 . . O O

1 239 241 2802551 In IN B-PP O
2 242 246 2802551 salt NN B-NP O
3 246 247 2802551 - HYPH B-NP O
4 247 255 2802551 depleted VBN I-NP O
5 256 260 2802551 rats NNS I-NP O
6 260 261 2802551 , , O O
7 262 274 2802551 amphotericin NN B-NP B-Chemical
8 275 276 2802551 B NN I-NP I-Chemical
9 277 286 2802551 decreased VBD B-VP O
10 287 297 2802551 creatinine NN B-NP B-Chemical
11 298 307 2802551 clearance NN I-NP O
12 308 316 2802551 linearly RB B-ADVP O
13 317 321 2802551 with IN B-PP O
14 322 326 2802551 time NN B-NP O
15 326 327 2802551 , , O O
16 328 332 2802551 with IN B-PP O
17 333 335 2802551 an DT B-NP O
18 336 339 2802551 85% NN I-NP O
19 340 349 2802551 reduction NN I-NP O
20 350 352 2802551 by IN B-PP O
21 353 357 2802551 week NN B-NP O
22 358 359 2802551 3 CD I-NP O
23 359 360 2802551 . . O O

1 361 363 2802551 In IN B-PP O
2 364 372 2802551 contrast NN B-NP O
3 372 373 2802551 , , O O
4 374 376 2802551 in IN B-PP O
5 377 383 2802551 normal JJ B-NP O
6 383 384 2802551 - HYPH I-NP O
7 384 388 2802551 salt NN I-NP O
8 389 393 2802551 rats NNS I-NP O
9 394 404 2802551 creatinine NN I-NP B-Chemical
10 405 414 2802551 clearance NN I-NP O
11 415 418 2802551 was VBD B-VP O
12 419 428 2802551 decreased VBN I-VP O
13 429 432 2802551 but CC B-PP O
14 433 435 2802551 to TO B-PP O
15 436 437 2802551 a DT B-NP O
16 438 444 2802551 lesser JJR I-NP O
17 445 451 2802551 extent NN I-NP O
18 452 454 2802551 at IN B-PP O
19 455 459 2802551 week NN B-NP O
20 460 461 2802551 2 CD I-NP O
21 462 465 2802551 and CC I-NP O
22 466 467 2802551 3 CD I-NP O
23 467 468 2802551 , , O O
24 469 472 2802551 and CC O O
25 473 475 2802551 in IN B-PP O
26 476 480 2802551 salt NN B-NP O
27 480 481 2802551 - HYPH B-NP O
28 481 487 2802551 loaded VBN I-NP O
29 488 492 2802551 rats NNS I-NP O
30 493 503 2802551 creatinine NN I-NP B-Chemical
31 504 513 2802551 clearance NN I-NP O
32 514 517 2802551 did VBD B-VP O
33 518 521 2802551 not RB I-VP O
34 522 528 2802551 change VB I-VP O
35 529 532 2802551 for IN B-PP O
36 533 534 2802551 2 CD B-NP O
37 535 540 2802551 weeks NNS I-NP O
38 541 544 2802551 and CC O O
39 545 548 2802551 was VBD B-VP O
40 549 558 2802551 decreased VBN I-VP O
41 559 561 2802551 by IN B-PP O
42 562 565 2802551 43% NN B-NP O
43 566 568 2802551 at IN B-PP O
44 569 573 2802551 week NN B-NP O
45 574 575 2802551 3 CD I-NP O
46 575 576 2802551 . . O O

1 577 580 2802551 All DT B-NP O
2 581 585 2802551 rats NNS I-NP O
3 586 588 2802551 in IN B-PP O
4 589 592 2802551 the DT B-NP O
5 593 599 2802551 sodium NN I-NP B-Chemical
6 599 600 2802551 - HYPH B-VP O
7 600 608 2802551 depleted VBN B-NP O
8 609 614 2802551 group NN I-NP O
9 615 618 2802551 had VBD B-VP O
10 619 636 2802551 histopathological JJ B-NP O
11 637 645 2802551 evidence NN I-NP O
12 646 648 2802551 of IN B-PP O
13 649 655 2802551 patchy JJ B-NP O
14 656 663 2802551 tubular JJ I-NP O
15 664 675 2802551 cytoplasmic JJ I-NP O
16 676 688 2802551 degeneration NN I-NP O
17 689 691 2802551 in IN B-PP O
18 692 699 2802551 tubules NNS B-NP O
19 700 704 2802551 that WDT B-NP O
20 705 708 2802551 was VBD B-VP O
21 709 712 2802551 not RB I-VP O
22 713 721 2802551 observed VBN I-VP O
23 722 724 2802551 in IN B-PP O
24 725 728 2802551 any DT B-NP O
25 729 735 2802551 normal JJ I-NP O
26 735 736 2802551 - HYPH I-NP O
27 736 740 2802551 salt NN I-NP O
28 741 743 2802551 or CC I-NP O
29 744 748 2802551 salt NN I-NP O
30 748 749 2802551 - HYPH O O
31 749 755 2802551 loaded VBN B-NP O
32 756 759 2802551 rat NN I-NP O
33 759 760 2802551 . . O O

1 761 775 2802551 Concentrations NNS B-NP O
2 776 778 2802551 of IN B-PP O
3 779 791 2802551 amphotericin NN B-NP B-Chemical
4 792 793 2802551 B NN I-NP I-Chemical
5 794 796 2802551 in IN B-PP O
6 797 803 2802551 plasma NN B-NP O
7 804 808 2802551 were VBD B-VP O
8 809 812 2802551 not RB B-ADJP O
9 813 826 2802551 significantly RB I-ADJP O
10 827 836 2802551 different JJ I-ADJP O
11 837 842 2802551 among IN B-PP O
12 843 846 2802551 the DT B-NP O
13 847 852 2802551 three CD I-NP O
14 853 859 2802551 groups NNS I-NP O
15 860 862 2802551 at IN B-PP O
16 863 866 2802551 any DT B-NP O
17 867 871 2802551 time NN I-NP O
18 872 878 2802551 during IN B-PP O
19 879 882 2802551 the DT B-NP O
20 883 888 2802551 study NN I-NP O
21 888 889 2802551 . . O O

1 890 897 2802551 However RB B-ADVP O
2 897 898 2802551 , , O O
3 899 901 2802551 at IN B-PP O
4 902 905 2802551 the DT B-NP O
5 906 909 2802551 end NN I-NP O
6 910 912 2802551 of IN B-PP O
7 913 914 2802551 3 CD B-NP O
8 915 920 2802551 weeks NNS I-NP O
9 920 921 2802551 , , O O
10 922 934 2802551 amphotericin NN B-NP B-Chemical
11 935 936 2802551 B NN I-NP I-Chemical
12 937 943 2802551 levels NNS I-NP O
13 944 946 2802551 in IN B-PP O
14 947 950 2802551 the DT B-NP O
15 951 958 2802551 kidneys NNS I-NP O
16 959 962 2802551 and CC I-NP O
17 963 968 2802551 liver NN I-NP O
18 969 973 2802551 were VBD B-VP O
19 974 987 2802551 significantly RB B-ADJP O
20 988 994 2802551 higher JJR I-ADJP O
21 995 997 2802551 in IN B-PP O
22 998 1002 2802551 salt NN B-NP O
23 1002 1003 2802551 - HYPH O O
24 1003 1011 2802551 depleted VBN B-NP O
25 1012 1015 2802551 and CC I-NP O
26 1016 1022 2802551 normal JJ I-NP O
27 1022 1023 2802551 - HYPH I-NP O
28 1023 1027 2802551 salt NN I-NP O
29 1028 1032 2802551 rats NNS I-NP O
30 1033 1037 2802551 than IN B-PP O
31 1038 1043 2802551 those DT B-NP O
32 1044 1046 2802551 in IN B-PP O
33 1047 1051 2802551 salt NN B-NP O
34 1051 1052 2802551 - HYPH B-NP O
35 1052 1058 2802551 loaded VBN I-NP O
36 1059 1063 2802551 rats NNS I-NP O
37 1063 1064 2802551 , , O O
38 1065 1069 2802551 with IN B-PP O
39 1070 1076 2802551 plasma NN B-NP O
40 1076 1077 2802551 / SYM B-VP O
41 1077 1083 2802551 kidney NN B-NP O
42 1084 1090 2802551 ratios NNS I-NP O
43 1091 1093 2802551 of IN B-PP O
44 1094 1096 2802551 21 CD B-NP O
45 1096 1097 2802551 , , I-NP O
46 1098 1100 2802551 14 CD I-NP O
47 1100 1101 2802551 , , O O
48 1102 1105 2802551 and CC O O
49 1106 1107 2802551 8 CD B-NP O
50 1108 1110 2802551 in IN B-PP O
51 1111 1115 2802551 salt NN B-NP O
52 1115 1116 2802551 - HYPH B-NP O
53 1116 1124 2802551 depleted VBN I-NP O
54 1124 1125 2802551 , , I-NP O
55 1126 1132 2802551 normal JJ I-NP O
56 1132 1133 2802551 - HYPH I-NP O
57 1133 1137 2802551 salt NN I-NP O
58 1137 1138 2802551 , , O O
59 1139 1142 2802551 and CC O O
60 1143 1147 2802551 salt NN B-NP O
61 1147 1148 2802551 - HYPH B-NP O
62 1148 1154 2802551 loaded VBN I-NP O
63 1155 1159 2802551 rats NNS I-NP O
64 1159 1160 2802551 , , O O
65 1161 1173 2802551 respectively RB B-ADVP O
66 1173 1174 2802551 . . O O

1 1175 1177 2802551 In IN B-PP O
2 1178 1188 2802551 conclusion NN B-NP O
3 1188 1189 2802551 , , O O
4 1190 1200 2802551 reductions NNS B-NP O
5 1201 1203 2802551 in IN B-PP O
6 1204 1214 2802551 creatinine NN B-NP B-Chemical
7 1215 1224 2802551 clearance NN I-NP O
8 1225 1228 2802551 and CC O O
9 1229 1234 2802551 renal JJ B-NP O
10 1235 1247 2802551 amphotericin NN I-NP B-Chemical
11 1248 1249 2802551 B NN I-NP I-Chemical
12 1250 1262 2802551 accumulation NN I-NP O
13 1263 1268 2802551 after IN B-PP O
14 1269 1276 2802551 chronic JJ B-NP O
15 1277 1289 2802551 amphotericin NN I-NP B-Chemical
16 1290 1291 2802551 B NN I-NP I-Chemical
17 1292 1306 2802551 administration NN I-NP O
18 1307 1311 2802551 were VBD B-VP O
19 1312 1320 2802551 enhanced VBN I-VP O
20 1321 1323 2802551 by IN B-PP O
21 1324 1328 2802551 salt NN B-NP O
22 1329 1338 2802551 depletion NN I-NP O
23 1339 1342 2802551 and CC O O
24 1343 1353 2802551 attenuated VBN B-VP O
25 1354 1356 2802551 by IN B-PP O
26 1357 1363 2802551 sodium NN B-NP B-Chemical
27 1364 1371 2802551 loading NN I-NP O
28 1372 1374 2802551 in IN B-PP O
29 1375 1379 2802551 rats NNS B-NP O
30 1379 1380 2802551 . . O O

1 0 0 6692345 -DOCSTART- -X- -X- O

1 0 6 6692345 Effect NN B-NP O
2 7 9 6692345 of IN B-PP O
3 10 17 6692345 aspirin NN B-NP B-Chemical
4 18 20 6692345 on IN B-PP O
5 21 22 6692345 N NN B-NP B-Chemical
6 22 23 6692345 - HYPH B-NP I-Chemical
7 23 25 6692345 [4 CD I-NP I-Chemical
8 25 26 6692345 - HYPH I-NP I-Chemical
9 26 28 6692345 (5 CD I-NP I-Chemical
10 28 29 6692345 - HYPH I-NP I-Chemical
11 29 34 6692345 nitro NN I-NP I-Chemical
12 34 35 6692345 - HYPH B-NP I-Chemical
13 35 36 6692345 2 CD I-NP I-Chemical
14 36 37 6692345 - HYPH I-NP I-Chemical
15 37 43 6692345 furyl) NN I-NP I-Chemical
16 43 44 6692345 - HYPH B-NP I-Chemical
17 44 45 6692345 2 CD I-NP I-Chemical
18 45 46 6692345 - HYPH I-NP I-Chemical
19 46 56 6692345 thiazolyl] NN I-NP I-Chemical
20 56 57 6692345 - HYPH B-NP I-Chemical
21 57 66 6692345 formamide NN I-NP I-Chemical
22 66 67 6692345 - HYPH O O
23 67 74 6692345 induced VBN B-NP O
24 75 85 6692345 epithelial JJ I-NP O
25 86 99 6692345 proliferation NN I-NP O
26 100 102 6692345 in IN B-PP O
27 103 106 6692345 the DT B-NP O
28 107 114 6692345 urinary JJ I-NP O
29 115 122 6692345 bladder NN I-NP O
30 123 126 6692345 and CC I-NP O
31 127 138 6692345 forestomach NN I-NP O
32 139 141 6692345 of IN B-PP O
33 142 145 6692345 the DT B-NP O
34 146 149 6692345 rat NN I-NP O
35 149 150 6692345 . . O O
36 151 154 6692345 The DT B-NP O
37 155 157 6692345 co AFX I-NP O
38 157 158 6692345 - HYPH I-NP O
39 158 172 6692345 administration NN I-NP O
40 173 175 6692345 of IN B-PP O
41 176 183 6692345 aspirin NN B-NP B-Chemical
42 184 188 6692345 with IN B-PP O
43 189 190 6692345 N NN B-NP B-Chemical
44 190 191 6692345 - HYPH B-NP I-Chemical
45 191 193 6692345 [4 CD I-NP I-Chemical
46 193 194 6692345 - HYPH I-NP I-Chemical
47 194 196 6692345 (5 CD I-NP I-Chemical
48 196 197 6692345 - HYPH I-NP I-Chemical
49 197 202 6692345 nitro NN I-NP I-Chemical
50 202 203 6692345 - HYPH B-NP I-Chemical
51 203 204 6692345 2 CD I-NP I-Chemical
52 204 205 6692345 - HYPH I-NP I-Chemical
53 205 211 6692345 furyl) NN I-NP I-Chemical
54 211 212 6692345 - HYPH B-NP I-Chemical
55 212 213 6692345 2 CD I-NP I-Chemical
56 213 214 6692345 - HYPH I-NP I-Chemical
57 214 224 6692345 thiazolyl] NN I-NP I-Chemical
58 224 225 6692345 - HYPH O I-Chemical
59 225 234 6692345 formamide NN B-NP I-Chemical
60 235 236 6692345 ( ( O O
61 236 241 6692345 FANFT NN B-NP B-Chemical
62 241 242 6692345 ) ) O O
63 243 245 6692345 to TO B-PP O
64 246 250 6692345 rats NNS B-NP O
65 251 259 6692345 resulted VBD B-VP O
66 260 262 6692345 in IN B-PP O
67 263 264 6692345 a DT B-NP O
68 265 272 6692345 reduced VBN I-NP O
69 273 282 6692345 incidence NN I-NP O
70 283 285 6692345 of IN B-PP O
71 286 291 6692345 FANFT NN B-NP B-Chemical
72 291 292 6692345 - HYPH B-NP O
73 292 299 6692345 induced VBN I-NP O
74 300 307 6692345 bladder NN I-NP B-Disease
75 308 318 6692345 carcinomas NNS I-NP I-Disease
76 319 322 6692345 but CC O O
77 323 324 6692345 a DT B-NP O
78 325 336 6692345 concomitant JJ I-NP O
79 337 346 6692345 induction NN I-NP O
80 347 349 6692345 of IN B-PP O
81 350 361 6692345 forestomach NN B-NP B-Disease
82 362 368 6692345 tumors NNS I-NP I-Disease
83 368 369 6692345 . . O O

1 370 372 6692345 An DT B-NP O
2 373 389 6692345 autoradiographic JJ I-NP O
3 390 395 6692345 study NN I-NP O
4 396 399 6692345 was VBD B-VP O
5 400 409 6692345 performed VBN I-VP O
6 410 412 6692345 on IN B-PP O
7 413 417 6692345 male JJ B-NP O
8 418 419 6692345 F NN I-NP O
9 419 420 6692345 - HYPH O O
10 420 423 6692345 344 CD B-NP O
11 424 428 6692345 rats NNS I-NP O
12 429 432 6692345 fed VBN B-VP O
13 433 437 6692345 diet NN B-NP O
14 438 448 6692345 containing VBG B-VP O
15 449 454 6692345 FANFT NN B-NP B-Chemical
16 455 457 6692345 at IN B-PP O
17 458 459 6692345 a DT B-NP O
18 460 465 6692345 level NN I-NP O
19 466 468 6692345 of IN B-PP O
20 469 473 6692345 0.2% CD B-NP O
21 474 477 6692345 and CC O O
22 477 478 6692345 / SYM B-NP O
23 478 480 6692345 or CC O O
24 481 488 6692345 aspirin NN B-NP B-Chemical
25 489 491 6692345 at IN B-PP O
26 492 493 6692345 a DT B-NP O
27 494 499 6692345 level NN I-NP O
28 500 502 6692345 of IN B-PP O
29 503 507 6692345 0.5% CD B-NP O
30 508 510 6692345 to TO B-VP O
31 511 519 6692345 evaluate VB I-VP O
32 520 523 6692345 the DT B-NP O
33 524 530 6692345 effect NN I-NP O
34 531 533 6692345 of IN B-PP O
35 534 541 6692345 aspirin NN B-NP B-Chemical
36 542 544 6692345 on IN B-PP O
37 545 548 6692345 the DT B-NP O
38 549 558 6692345 increased VBN I-NP O
39 559 563 6692345 cell NN I-NP O
40 564 577 6692345 proliferation NN I-NP O
41 578 585 6692345 induced VBN B-VP O
42 586 588 6692345 by IN B-PP O
43 589 594 6692345 FANFT NN B-NP B-Chemical
44 595 597 6692345 in IN B-PP O
45 598 601 6692345 the DT B-NP O
46 602 613 6692345 forestomach NN I-NP O
47 614 617 6692345 and CC I-NP O
48 618 625 6692345 bladder NN I-NP O
49 625 626 6692345 . . O O

1 627 632 6692345 FANFT NN B-NP B-Chemical
2 632 633 6692345 - HYPH B-NP O
3 633 640 6692345 induced VBN I-NP O
4 641 645 6692345 cell NN I-NP O
5 646 659 6692345 proliferation NN I-NP O
6 660 662 6692345 in IN B-PP O
7 663 666 6692345 the DT B-NP O
8 667 674 6692345 bladder NN I-NP O
9 675 678 6692345 was VBD B-VP O
10 679 692 6692345 significantly RB I-VP O
11 693 703 6692345 suppressed VBN I-VP O
12 704 706 6692345 by IN B-PP O
13 707 714 6692345 aspirin NN B-NP B-Chemical
14 715 717 6692345 co AFX O O
15 717 718 6692345 - HYPH O O
16 718 732 6692345 administration NN B-NP O
17 733 738 6692345 after IN B-PP O
18 739 740 6692345 4 CD B-NP O
19 741 746 6692345 weeks NNS I-NP O
20 747 750 6692345 but CC B-PP O
21 751 754 6692345 not RB B-PP O
22 755 760 6692345 after IN I-PP O
23 761 763 6692345 12 CD B-NP O
24 764 769 6692345 weeks NNS I-NP O
25 769 770 6692345 . . O O

1 771 773 6692345 In IN B-PP O
2 774 777 6692345 the DT B-NP O
3 778 789 6692345 forestomach NN I-NP O
4 789 790 6692345 , , O O
5 791 794 6692345 and CC O O
6 795 799 6692345 also RB B-ADVP O
7 800 802 6692345 in IN B-PP O
8 803 806 6692345 the DT B-NP O
9 807 812 6692345 liver NN I-NP O
10 812 813 6692345 , , O O
11 814 821 6692345 aspirin NN B-NP B-Chemical
12 822 825 6692345 did VBD B-VP O
13 826 829 6692345 not RB I-VP O
14 830 836 6692345 affect VB I-VP O
15 837 840 6692345 the DT B-NP O
16 841 846 6692345 FANFT NN I-NP B-Chemical
17 846 847 6692345 - HYPH B-VP O
18 847 854 6692345 induced VBN B-NP O
19 855 863 6692345 increase NN I-NP O
20 864 866 6692345 in IN B-PP O
21 867 875 6692345 labeling VBG B-VP O
22 876 881 6692345 index NN B-NP O
23 881 882 6692345 . . O O

1 883 886 6692345 The DT B-NP O
2 887 894 6692345 present JJ I-NP O
3 895 902 6692345 results NNS I-NP O
4 903 906 6692345 are VBP B-VP O
5 907 917 6692345 consistent JJ B-ADJP O
6 918 922 6692345 with IN B-PP O
7 923 926 6692345 the DT B-NP O
8 927 942 6692345 carcinogenicity NN I-NP O
9 943 953 6692345 experiment NN I-NP O
10 954 964 6692345 suggesting VBG B-VP O
11 965 969 6692345 that IN B-SBAR O
12 970 979 6692345 different JJ B-NP O
13 980 990 6692345 mechanisms NNS I-NP O
14 991 994 6692345 are VBP B-VP O
15 995 1003 6692345 involved VBN I-VP O
16 1004 1006 6692345 in IN B-PP O
17 1007 1012 6692345 FANFT NN B-NP B-Chemical
18 1013 1027 6692345 carcinogenesis NN I-NP B-Disease
19 1028 1030 6692345 in IN B-PP O
20 1031 1034 6692345 the DT B-NP O
21 1035 1042 6692345 bladder NN I-NP O
22 1043 1046 6692345 and CC I-NP O
23 1047 1058 6692345 forestomach NN I-NP O
24 1058 1059 6692345 , , O O
25 1060 1063 6692345 and CC O O
26 1064 1068 6692345 that IN B-SBAR O
27 1069 1078 6692345 aspirin's NNS B-NP B-Chemical
28 1079 1085 6692345 effect NN I-NP O
29 1086 1088 6692345 on IN B-PP O
30 1089 1094 6692345 FANFT NN B-NP B-Chemical
31 1095 1097 6692345 in IN B-PP O
32 1098 1101 6692345 the DT B-NP O
33 1102 1113 6692345 forestomach NN I-NP O
34 1114 1116 6692345 is VBZ B-VP O
35 1117 1120 6692345 not RB O O
36 1121 1124 6692345 due JJ B-ADJP O
37 1125 1127 6692345 to TO B-PP O
38 1128 1130 6692345 an DT B-NP O
39 1131 1139 6692345 irritant JJ I-NP O
40 1140 1146 6692345 effect NN I-NP O
41 1147 1157 6692345 associated VBN B-VP O
42 1158 1162 6692345 with IN B-PP O
43 1163 1172 6692345 increased VBN B-NP O
44 1173 1177 6692345 cell NN I-NP O
45 1178 1191 6692345 proliferation NN I-NP O
46 1191 1192 6692345 . . O O

1 1193 1197 6692345 Also RB B-ADVP O
2 1197 1198 6692345 , , O O
3 1199 1204 6692345 there EX B-NP O
4 1205 1212 6692345 appears VBZ B-VP O
5 1213 1215 6692345 to TO I-VP O
6 1216 1218 6692345 be VB I-VP O
7 1219 1221 6692345 an DT B-NP O
8 1222 1232 6692345 adaptation NN I-NP O
9 1233 1235 6692345 by IN B-PP O
10 1236 1239 6692345 the DT B-NP O
11 1240 1244 6692345 rats NNS I-NP O
12 1245 1247 6692345 to TO B-PP O
13 1248 1251 6692345 the DT B-NP O
14 1252 1259 6692345 chronic JJ I-NP O
15 1260 1269 6692345 ingestion NN I-NP O
16 1270 1272 6692345 of IN B-PP O
17 1273 1280 6692345 aspirin NN B-NP B-Chemical
18 1280 1281 6692345 . . O O

1 0 0 19729346 -DOCSTART- -X- -X- O

1 0 11 19729346 Comparative JJ B-NP O
2 12 21 19729346 cognitive JJ I-NP O
3 22 25 19729346 and CC I-NP O
4 26 36 19729346 subjective JJ I-NP O
5 37 41 19729346 side NN I-NP O
6 42 49 19729346 effects NNS I-NP O
7 50 52 19729346 of IN B-PP O
8 53 62 19729346 immediate JJ B-NP O
9 62 63 19729346 - HYPH I-NP O
10 63 70 19729346 release NN I-NP O
11 71 80 19729346 oxycodone NN I-NP B-Chemical
12 81 83 19729346 in IN B-PP O
13 84 91 19729346 healthy JJ B-NP O
14 92 98 19729346 middle JJ I-NP O
15 98 99 19729346 - HYPH I-NP O
16 99 103 19729346 aged JJ I-NP O
17 104 107 19729346 and CC I-NP O
18 108 113 19729346 older JJR I-NP O
19 114 120 19729346 adults NNS I-NP O
20 120 121 19729346 . . O O
21 122 126 19729346 This DT B-NP O
22 127 132 19729346 study NN I-NP O
23 133 141 19729346 measured VBD B-VP O
24 142 145 19729346 the DT B-NP O
25 146 155 19729346 objective JJ I-NP O
26 156 159 19729346 and CC I-NP O
27 160 170 19729346 subjective JJ I-NP O
28 171 185 19729346 neurocognitive JJ I-NP O
29 186 193 19729346 effects NNS I-NP O
30 194 196 19729346 of IN B-PP O
31 197 198 19729346 a DT B-NP O
32 199 205 19729346 single JJ I-NP O
33 206 208 19729346 10 CD I-NP O
34 208 209 19729346 - HYPH I-NP O
35 209 211 19729346 mg NN I-NP O
36 212 216 19729346 dose NN I-NP O
37 217 219 19729346 of IN B-PP O
38 220 229 19729346 immediate JJ B-NP O
39 229 230 19729346 - HYPH I-NP O
40 230 237 19729346 release NN I-NP O
41 238 247 19729346 oxycodone NN I-NP B-Chemical
42 248 250 19729346 in IN B-PP O
43 251 258 19729346 healthy JJ B-NP O
44 258 259 19729346 , , O O
45 260 265 19729346 older JJR B-ADJP O
46 266 267 19729346 ( ( O O
47 267 268 19729346 > JJR B-NP O
48 269 271 19729346 65 CD I-NP O
49 272 277 19729346 years NNS I-NP O
50 277 278 19729346 ) ) O O
51 278 279 19729346 , , O O
52 280 283 19729346 and CC O O
53 284 290 19729346 middle JJ B-ADJP O
54 290 291 19729346 - HYPH O O
55 291 295 19729346 aged JJ B-ADJP O
56 296 297 19729346 ( ( O O
57 297 299 19729346 35 CD B-NP O
58 300 302 19729346 to TO O O
59 303 305 19729346 55 CD B-NP O
60 306 311 19729346 years NNS I-NP O
61 311 312 19729346 ) ) O O
62 313 319 19729346 adults NNS B-NP O
63 320 323 19729346 who WP B-NP O
64 324 328 19729346 were VBD B-VP O
65 329 332 19729346 not RB I-VP O
66 333 342 19729346 suffering VBG I-VP O
67 343 347 19729346 from IN B-PP O
68 348 355 19729346 chronic JJ B-NP O
69 356 358 19729346 or CC I-NP O
70 359 370 19729346 significant JJ I-NP O
71 371 376 19729346 daily JJ I-NP O
72 377 381 19729346 pain NN I-NP B-Disease
73 381 382 19729346 . . O O

1 383 390 19729346 Seventy CD B-NP O
2 390 391 19729346 - HYPH I-NP O
3 391 394 19729346 one CD I-NP O
4 395 407 19729346 participants NNS I-NP O
5 408 417 19729346 completed VBD B-VP O
6 418 419 19729346 2 CD B-NP O
7 420 428 19729346 separate JJ I-NP O
8 429 434 19729346 study NN I-NP O
9 435 439 19729346 days NNS I-NP O
10 440 443 19729346 and CC O O
11 444 448 19729346 were VBD B-VP O
12 449 454 19729346 blind JJ B-ADJP O
13 455 457 19729346 to TO B-PP O
14 458 468 19729346 medication NN B-NP O
15 469 478 19729346 condition NN I-NP O
16 479 480 19729346 ( ( O O
17 480 487 19729346 placebo NN B-NP O
18 487 488 19729346 , , O O
19 489 491 19729346 10 CD B-NP O
20 491 492 19729346 - HYPH I-NP O
21 492 494 19729346 mg NN I-NP O
22 495 504 19729346 oxycodone NN I-NP B-Chemical
23 504 505 19729346 ) ) O O
24 505 506 19729346 . . O O

1 507 513 19729346 Plasma NN B-NP O
2 514 523 19729346 oxycodone NN I-NP B-Chemical
3 524 537 19729346 concentration NN I-NP O
4 538 544 19729346 peaked VBD B-VP O
5 545 552 19729346 between IN B-PP O
6 553 555 19729346 60 CD B-NP O
7 556 559 19729346 and CC I-NP O
8 560 562 19729346 90 CD I-NP O
9 563 570 19729346 minutes NNS I-NP O
10 571 579 19729346 postdose NN I-NP O
11 580 581 19729346 ( ( O O
12 581 582 19729346 P NN B-NP O
13 583 584 19729346 < JJR B-NP O
14 585 588 19729346 .01 CD I-NP O
15 588 589 19729346 ) ) O O
16 590 593 19729346 and CC O O
17 594 599 19729346 pupil NN B-NP O
18 600 604 19729346 size NN I-NP O
19 604 605 19729346 , , O O
20 606 608 19729346 an DT B-NP O
21 609 619 19729346 indication NN I-NP O
22 620 622 19729346 of IN B-PP O
23 623 636 19729346 physiological JJ B-NP O
24 637 644 19729346 effects NNS I-NP O
25 645 647 19729346 of IN B-PP O
26 648 651 19729346 the DT B-NP O
27 652 662 19729346 medication NN I-NP O
28 662 663 19729346 , , O O
29 664 670 19729346 peaked VBD B-VP O
30 671 673 19729346 at IN B-PP O
31 674 687 19729346 approximately RB B-NP O
32 688 690 19729346 90 CD I-NP O
33 691 693 19729346 to TO I-NP O
34 694 697 19729346 120 CD I-NP O
35 698 705 19729346 minutes NNS I-NP O
36 706 714 19729346 postdose NN I-NP O
37 715 716 19729346 ( ( O O
38 716 717 19729346 P NN B-NP O
39 718 719 19729346 < JJR B-NP O
40 720 723 19729346 .01 CD I-NP O
41 723 724 19729346 ) ) O O
42 724 725 19729346 . . O O

1 726 737 19729346 Significant JJ B-NP O
2 738 746 19729346 declines NNS I-NP B-Disease
3 747 749 19729346 in IN B-PP I-Disease
4 750 756 19729346 simple JJ B-NP I-Disease
5 757 760 19729346 and CC I-NP I-Disease
6 761 770 19729346 sustained JJ I-NP I-Disease
7 771 780 19729346 attention NN I-NP I-Disease
8 780 781 19729346 , , O I-Disease
9 782 789 19729346 working VBG B-VP I-Disease
10 790 796 19729346 memory NN B-NP I-Disease
11 796 797 19729346 , , O I-Disease
12 798 801 19729346 and CC O I-Disease
13 802 808 19729346 verbal JJ B-NP I-Disease
14 809 815 19729346 memory NN I-NP I-Disease
15 816 820 19729346 were VBD B-VP O
16 821 829 19729346 observed VBN I-VP O
17 830 832 19729346 at IN B-PP O
18 833 834 19729346 1 CD B-NP O
19 835 839 19729346 hour NN I-NP O
20 840 848 19729346 postdose NN I-NP O
21 849 857 19729346 compared VBN B-VP O
22 858 860 19729346 to TO B-PP O
23 861 869 19729346 baseline NN B-NP O
24 870 873 19729346 for IN B-PP O
25 874 878 19729346 both DT B-NP O
26 879 882 19729346 age NN I-NP O
27 883 889 19729346 groups NNS I-NP O
28 890 894 19729346 with IN B-PP O
29 895 896 19729346 a DT B-NP O
30 897 902 19729346 trend NN I-NP O
31 903 909 19729346 toward IN B-PP O
32 910 916 19729346 return NN B-NP O
33 917 919 19729346 to TO B-PP O
34 920 928 19729346 baseline NN B-NP O
35 929 931 19729346 by IN B-PP O
36 932 933 19729346 5 CD B-NP O
37 934 939 19729346 hours NNS I-NP O
38 940 948 19729346 postdose VBP B-VP O
39 948 949 19729346 . . O O

1 950 953 19729346 For IN B-PP O
2 954 960 19729346 almost RB B-NP O
3 961 964 19729346 all DT I-NP O
4 965 974 19729346 cognitive JJ I-NP O
5 975 983 19729346 measures NNS I-NP O
6 983 984 19729346 , , O O
7 985 990 19729346 there EX B-NP O
8 991 995 19729346 were VBD B-VP O
9 996 998 19729346 no DT B-NP O
10 999 1009 19729346 medication NN I-NP O
11 1010 1012 19729346 by IN B-PP O
12 1013 1016 19729346 age NN B-NP O
13 1016 1017 19729346 - HYPH I-NP O
14 1017 1028 19729346 interaction NN I-NP O
15 1029 1036 19729346 effects NNS I-NP O
16 1036 1037 19729346 , , O O
17 1038 1043 19729346 which WDT B-NP O
18 1044 1053 19729346 indicates VBZ B-VP O
19 1054 1058 19729346 that IN B-SBAR O
20 1059 1062 19729346 the DT B-NP O
21 1063 1064 19729346 2 CD I-NP O
22 1065 1068 19729346 age NN I-NP O
23 1069 1075 19729346 groups NNS I-NP O
24 1076 1085 19729346 exhibited VBD B-VP O
25 1086 1093 19729346 similar JJ B-NP O
26 1094 1103 19729346 responses NNS I-NP O
27 1104 1106 19729346 to TO B-PP O
28 1107 1110 19729346 the DT B-NP O
29 1111 1121 19729346 medication NN I-NP O
30 1122 1131 19729346 challenge NN I-NP O
31 1131 1132 19729346 . . O O

1 1133 1137 19729346 This DT B-NP O
2 1138 1143 19729346 study NN I-NP O
3 1144 1152 19729346 suggests VBZ B-VP O
4 1153 1157 19729346 that IN B-SBAR O
5 1158 1161 19729346 for IN B-PP O
6 1162 1169 19729346 healthy JJ B-NP O
7 1170 1175 19729346 older JJR I-NP O
8 1176 1182 19729346 adults NNS I-NP O
9 1183 1186 19729346 who WP B-NP O
10 1187 1190 19729346 are VBP B-VP O
11 1191 1194 19729346 not RB I-VP O
12 1195 1204 19729346 suffering VBG I-VP O
13 1205 1209 19729346 from IN B-PP O
14 1210 1217 19729346 chronic JJ B-NP B-Disease
15 1218 1222 19729346 pain NN I-NP I-Disease
16 1222 1223 19729346 , , O O
17 1224 1238 19729346 neurocognitive JJ B-NP O
18 1239 1242 19729346 and CC I-NP O
19 1243 1258 19729346 pharmacodynamic JJ I-NP O
20 1259 1266 19729346 changes NNS I-NP O
21 1267 1269 19729346 in IN B-PP O
22 1270 1278 19729346 response NN B-NP O
23 1279 1281 19729346 to TO B-PP O
24 1282 1283 19729346 a DT B-NP O
25 1284 1286 19729346 10 CD I-NP O
26 1286 1287 19729346 - HYPH I-NP O
27 1287 1289 19729346 mg NN I-NP O
28 1290 1294 19729346 dose NN I-NP O
29 1295 1297 19729346 of IN B-PP O
30 1298 1307 19729346 immediate JJ B-NP O
31 1307 1308 19729346 - HYPH I-NP O
32 1308 1315 19729346 release NN I-NP O
33 1316 1325 19729346 oxycodone NN I-NP B-Chemical
34 1326 1329 19729346 are VBP B-VP O
35 1330 1337 19729346 similar JJ B-ADJP O
36 1338 1340 19729346 to TO B-PP O
37 1341 1346 19729346 those DT B-NP O
38 1347 1355 19729346 observed VBN B-VP O
39 1356 1359 19729346 for IN B-PP O
40 1360 1366 19729346 middle JJ B-NP O
41 1366 1367 19729346 - HYPH I-NP O
42 1367 1371 19729346 aged JJ I-NP O
43 1372 1378 19729346 adults NNS I-NP O
44 1378 1379 19729346 . . O O

1 1380 1391 19729346 PERSPECTIVE NN B-NP O
2 1391 1392 19729346 : : O O
3 1393 1398 19729346 Study NN B-NP O
4 1399 1407 19729346 findings NNS I-NP O
5 1408 1416 19729346 indicate VBP B-VP O
6 1417 1421 19729346 that IN B-SBAR O
7 1422 1425 19729346 the DT B-NP O
8 1426 1436 19729346 metabolism NN I-NP O
9 1436 1437 19729346 , , O O
10 1438 1452 19729346 neurocognitive JJ B-NP O
11 1453 1460 19729346 effects NNS I-NP O
12 1460 1461 19729346 , , O O
13 1462 1465 19729346 and CC O O
14 1466 1474 19729346 physical JJ B-NP O
15 1475 1479 19729346 side NN I-NP O
16 1480 1487 19729346 effects NNS I-NP O
17 1488 1490 19729346 of IN B-PP O
18 1491 1495 19729346 oral JJ B-NP O
19 1496 1505 19729346 oxycodone NN I-NP B-Chemical
20 1506 1509 19729346 are VBP B-VP O
21 1510 1517 19729346 similar JJ B-ADJP O
22 1518 1521 19729346 for IN B-PP O
23 1522 1529 19729346 healthy JJ B-NP O
24 1530 1536 19729346 middle JJ I-NP O
25 1536 1537 19729346 - HYPH I-NP O
26 1537 1541 19729346 aged JJ I-NP O
27 1542 1545 19729346 and CC I-NP O
28 1546 1551 19729346 older JJR I-NP O
29 1552 1558 19729346 adults NNS I-NP O
30 1558 1559 19729346 . . O O

1 1560 1569 19729346 Therefore RB B-ADVP O
2 1569 1570 19729346 , , O O
3 1571 1581 19729346 clinicians NNS B-NP O
4 1582 1588 19729346 should MD B-VP O
5 1589 1592 19729346 not RB I-VP O
6 1593 1598 19729346 avoid VB I-VP O
7 1599 1610 19729346 prescribing VBG I-VP O
8 1611 1615 19729346 oral JJ B-NP O
9 1616 1623 19729346 opioids NNS I-NP O
10 1624 1626 19729346 to TO B-PP O
11 1627 1632 19729346 older JJR B-NP O
12 1633 1639 19729346 adults NNS I-NP O
13 1640 1645 19729346 based VBN B-PP O
14 1646 1648 19729346 on IN B-PP O
15 1649 1652 19729346 the DT B-NP O
16 1653 1659 19729346 belief NN I-NP O
17 1660 1664 19729346 that IN B-SBAR O
18 1665 1670 19729346 older JJR B-NP O
19 1671 1677 19729346 adults NNS I-NP O
20 1678 1681 19729346 are VBP B-VP O
21 1682 1684 19729346 at IN B-PP O
22 1685 1691 19729346 higher JJR B-NP O
23 1692 1696 19729346 risk NN I-NP O
24 1697 1700 19729346 for IN B-PP O
25 1701 1705 19729346 side NN B-NP O
26 1706 1713 19729346 effects NNS I-NP O
27 1714 1718 19729346 than IN B-PP O
28 1719 1726 19729346 younger JJR B-NP O
29 1727 1733 19729346 adults NNS I-NP O
30 1733 1734 19729346 . . O O

1 0 0 8741744 -DOCSTART- -X- -X- O

1 0 3 8741744 The DT B-NP O
2 4 19 8741744 interpeduncular JJ I-NP O
3 20 27 8741744 nucleus NN I-NP O
4 28 37 8741744 regulates VBZ B-VP O
5 38 48 8741744 nicotine's NNS B-NP B-Chemical
6 49 56 8741744 effects NNS I-NP O
7 57 59 8741744 on IN B-PP O
8 60 64 8741744 free JJ B-NP O
9 64 65 8741744 - HYPH I-NP O
10 65 70 8741744 field NN I-NP O
11 71 79 8741744 activity NN I-NP O
12 79 80 8741744 . . O O
13 81 88 8741744 Partial JJ B-NP O
14 89 96 8741744 lesions NNS I-NP O
15 97 101 8741744 were VBD B-VP O
16 102 106 8741744 made VBN I-VP O
17 107 111 8741744 with IN B-PP O
18 112 118 8741744 kainic JJ B-NP B-Chemical
19 119 123 8741744 acid NN I-NP I-Chemical
20 124 126 8741744 in IN B-PP O
21 127 130 8741744 the DT B-NP O
22 131 146 8741744 interpeduncular JJ I-NP O
23 147 154 8741744 nucleus NN I-NP O
24 155 157 8741744 of IN B-PP O
25 158 161 8741744 the DT B-NP O
26 162 169 8741744 ventral JJ I-NP O
27 170 178 8741744 midbrain NN I-NP O
28 179 181 8741744 of IN B-PP O
29 182 185 8741744 the DT B-NP O
30 186 189 8741744 rat NN I-NP O
31 189 190 8741744 . . O O

1 191 199 8741744 Compared VBN B-PP O
2 200 204 8741744 with IN B-PP O
3 205 209 8741744 sham NN B-NP O
4 209 210 8741744 - HYPH B-NP O
5 210 218 8741744 operated VBN I-NP O
6 219 227 8741744 controls NNS I-NP O
7 227 228 8741744 , , O O
8 229 236 8741744 lesions NNS B-NP O
9 237 250 8741744 significantly RB B-ADVP O
10 251 252 8741744 ( ( O O
11 252 253 8741744 p NN B-NP O
12 254 255 8741744 < JJR B-NP O
13 256 260 8741744 0.25 CD I-NP O
14 260 261 8741744 ) ) O O
15 262 269 8741744 blunted VBD B-VP O
16 270 273 8741744 the DT B-NP O
17 274 279 8741744 early JJ I-NP O
18 280 281 8741744 ( ( O O
19 281 282 8741744 < SYM O O
20 282 284 8741744 60 CD B-NP O
21 285 288 8741744 min NN I-NP O
22 288 289 8741744 ) ) O O
23 290 294 8741744 free JJ B-NP O
24 294 295 8741744 - HYPH I-NP O
25 295 300 8741744 field NN I-NP O
26 301 310 8741744 locomotor NN I-NP B-Disease
27 311 323 8741744 hypoactivity NN I-NP I-Disease
28 324 330 8741744 caused VBN B-VP O
29 331 333 8741744 by IN B-PP O
30 334 342 8741744 nicotine NN B-NP B-Chemical
31 343 344 8741744 ( ( O O
32 344 347 8741744 0.5 CD B-NP O
33 348 350 8741744 mg NN I-NP O
34 351 354 8741744 kg( AFX B-VP O
35 354 355 8741744 - HYPH B-ADJP O
36 355 357 8741744 1) LS B-LST O
37 357 358 8741744 , , O O
38 359 362 8741744 i.m RB B-ADVP O
39 362 363 8741744 . . O O
40 363 364 8741744 ) ) O O
41 364 365 8741744 , , O O
42 366 374 8741744 enhanced VBD B-VP O
43 375 378 8741744 the DT B-NP O
44 379 384 8741744 later JJ I-NP O
45 385 386 8741744 ( ( O O
46 386 388 8741744 60 CD B-NP O
47 388 389 8741744 - HYPH I-NP O
48 389 392 8741744 120 CD I-NP O
49 393 396 8741744 min NN I-NP O
50 396 397 8741744 ) ) O O
51 398 406 8741744 nicotine NN B-NP B-Chemical
52 406 407 8741744 - HYPH B-NP O
53 407 414 8741744 induced VBN I-NP O
54 415 428 8741744 hyperactivity NN I-NP B-Disease
55 428 429 8741744 , , O O
56 430 433 8741744 and CC O O
57 434 440 8741744 raised VBD B-VP O
58 441 452 8741744 spontaneous JJ B-NP O
59 453 462 8741744 nocturnal JJ I-NP O
60 463 471 8741744 activity NN I-NP O
61 471 472 8741744 . . O O

1 473 480 8741744 Lesions NNS B-NP O
2 481 488 8741744 reduced VBD B-VP O
3 489 492 8741744 the DT B-NP O
4 493 499 8741744 extent NN I-NP O
5 500 502 8741744 of IN B-PP O
6 503 521 8741744 immunohistological JJ B-NP O
7 522 530 8741744 staining NN I-NP O
8 531 534 8741744 for IN B-PP O
9 535 542 8741744 choline NN B-NP B-Chemical
10 543 560 8741744 acetyltransferase NN I-NP O
11 561 563 8741744 in IN B-PP O
12 564 567 8741744 the DT B-NP O
13 568 583 8741744 interpeduncular JJ I-NP O
14 584 591 8741744 nucleus NN I-NP O
15 592 593 8741744 ( ( O O
16 593 594 8741744 p NN B-NP O
17 595 596 8741744 < JJR B-NP O
18 596 601 8741744 0.025 CD I-NP O
19 601 602 8741744 ) ) O O
20 602 603 8741744 , , O O
21 604 607 8741744 but CC O O
22 608 611 8741744 not RB O O
23 612 615 8741744 for IN B-PP O
24 616 624 8741744 tyrosine NN B-NP B-Chemical
25 625 636 8741744 hydroxylase NN I-NP O
26 637 639 8741744 in IN B-PP O
27 640 643 8741744 the DT B-NP O
28 644 655 8741744 surrounding VBG I-NP O
29 656 673 8741744 catecholaminergic JJ I-NP O
30 674 677 8741744 A10 NN I-NP O
31 678 684 8741744 region NN I-NP O
32 684 685 8741744 . . O O

1 686 688 8741744 We PRP B-NP O
2 689 697 8741744 conclude VBP B-VP O
3 698 702 8741744 that IN B-SBAR O
4 703 706 8741744 the DT B-NP O
5 707 722 8741744 interpeduncular JJ I-NP O
6 723 730 8741744 nucleus NN I-NP O
7 731 739 8741744 mediates VBZ B-VP O
8 740 749 8741744 nicotinic JJ B-NP O
9 750 760 8741744 depression NN I-NP B-Disease
10 761 763 8741744 of IN B-PP O
11 764 773 8741744 locomotor NN B-NP O
12 774 782 8741744 activity NN I-NP O
13 783 786 8741744 and CC O O
14 787 794 8741744 dampens VBZ B-VP O
15 795 804 8741744 nicotinic JJ B-NP O
16 805 812 8741744 arousal JJ I-NP O
17 813 823 8741744 mechanisms NNS I-NP O
18 824 831 8741744 located VBN B-VP O
19 832 841 8741744 elsewhere RB B-ADVP O
20 842 844 8741744 in IN B-PP O
21 845 848 8741744 the DT B-NP O
22 849 854 8741744 brain NN I-NP O
23 854 855 8741744 . . O O

1 0 0 12063090 -DOCSTART- -X- -X- O

1 0 9 12063090 Metamizol NN B-NP B-Chemical
2 10 21 12063090 potentiates VBZ B-VP O
3 22 30 12063090 morphine NN B-NP B-Chemical
4 31 46 12063090 antinociception NN I-NP O
5 47 50 12063090 but CC B-NP O
6 51 54 12063090 not RB I-NP O
7 55 67 12063090 constipation NN B-NP B-Disease
8 68 73 12063090 after IN B-PP O
9 74 81 12063090 chronic JJ B-NP O
10 82 91 12063090 treatment NN I-NP O
11 91 92 12063090 . . O O
12 93 97 12063090 This DT B-NP O
13 98 102 12063090 work NN I-NP O
14 103 112 12063090 evaluates VBZ B-VP O
15 113 116 12063090 the DT B-NP O
16 117 132 12063090 antinociceptive JJ I-NP O
17 133 136 12063090 and CC I-NP O
18 137 149 12063090 constipating JJ I-NP B-Disease
19 150 157 12063090 effects NNS I-NP O
20 158 160 12063090 of IN B-PP O
21 161 164 12063090 the DT B-NP O
22 165 176 12063090 combination NN I-NP O
23 177 179 12063090 of IN B-PP O
24 180 183 12063090 3.2 CD B-NP O
25 184 186 12063090 mg NN I-NP O
26 186 187 12063090 / SYM B-NP O
27 187 189 12063090 kg NN I-NP O
28 190 193 12063090 s.c NN I-NP O
29 193 194 12063090 . . O O

1 195 203 12063090 morphine NN B-NP B-Chemical
2 204 208 12063090 with IN B-PP O
3 209 214 12063090 177.8 CD B-NP O
4 215 217 12063090 mg NN I-NP O
5 217 218 12063090 / SYM B-NP O
6 218 220 12063090 kg NN I-NP O
7 221 224 12063090 s.c NN I-NP O
8 224 225 12063090 . . O O

1 226 235 12063090 metamizol NN B-NP B-Chemical
2 236 238 12063090 in IN B-PP O
3 239 246 12063090 acutely RB B-ADVP O
4 247 250 12063090 and CC I-ADVP O
5 251 262 12063090 chronically RB I-ADVP O
6 263 270 12063090 treated VBN B-VP O
7 271 272 12063090 ( ( O O
8 272 276 12063090 once RB O O
9 277 278 12063090 a DT B-NP O
10 279 282 12063090 day NN I-NP O
11 283 286 12063090 for IN B-PP O
12 287 289 12063090 12 CD B-NP O
13 290 294 12063090 days NNS I-NP O
14 294 295 12063090 ) ) O O
15 296 300 12063090 rats NNS B-NP O
16 300 301 12063090 . . O O

1 302 304 12063090 On IN B-PP O
2 305 308 12063090 the DT B-NP O
3 309 313 12063090 13th JJ I-NP O
4 314 317 12063090 day NN I-NP O
5 317 318 12063090 , , O O
6 319 334 12063090 antinociceptive JJ B-NP O
7 335 342 12063090 effects NNS I-NP O
8 343 347 12063090 were VBD B-VP O
9 348 356 12063090 assessed VBN I-VP O
10 357 362 12063090 using VBG B-VP O
11 363 364 12063090 a DT B-NP O
12 365 370 12063090 model NN I-NP O
13 371 373 12063090 of IN B-PP O
14 374 386 12063090 inflammatory JJ B-NP O
15 387 398 12063090 nociception NN I-NP O
16 398 399 12063090 , , O O
17 400 404 12063090 pain NN B-NP B-Disease
18 404 405 12063090 - HYPH O O
19 405 412 12063090 induced VBN B-NP O
20 413 423 12063090 functional JJ I-NP O
21 424 434 12063090 impairment NN I-NP O
22 435 440 12063090 model NN I-NP O
23 440 441 12063090 , , O O
24 442 445 12063090 and CC O O
25 446 449 12063090 the DT B-NP O
26 450 458 12063090 charcoal NN I-NP B-Chemical
27 459 463 12063090 meal JJ I-NP O
28 464 468 12063090 test NN I-NP O
29 469 472 12063090 was VBD B-VP O
30 473 477 12063090 used VBN I-VP O
31 478 480 12063090 to TO B-VP O
32 481 489 12063090 evaluate VB I-VP O
33 490 493 12063090 the DT B-NP O
34 494 504 12063090 intestinal JJ I-NP O
35 505 512 12063090 transit NN I-NP O
36 512 513 12063090 . . O O

1 514 526 12063090 Simultaneous JJ B-NP O
2 527 541 12063090 administration NN I-NP O
3 542 544 12063090 of IN B-PP O
4 545 553 12063090 morphine NN B-NP B-Chemical
5 554 558 12063090 with IN B-PP O
6 559 568 12063090 metamizol NN B-NP B-Chemical
7 569 577 12063090 resulted VBD B-VP O
8 578 580 12063090 in IN B-PP O
9 581 582 12063090 a DT B-NP O
10 583 591 12063090 markedly RB I-NP O
11 592 607 12063090 antinociceptive JJ I-NP O
12 608 620 12063090 potentiation NN I-NP O
13 621 624 12063090 and CC O O
14 625 627 12063090 an DT B-NP O
15 628 638 12063090 increasing NN I-NP O
16 639 641 12063090 of IN B-PP O
17 642 645 12063090 the DT B-NP O
18 646 654 12063090 duration NN I-NP O
19 655 657 12063090 of IN B-PP O
20 658 664 12063090 action NN B-NP O
21 665 670 12063090 after IN B-PP O
22 671 672 12063090 a DT B-NP O
23 673 679 12063090 single JJ I-NP O
24 680 681 12063090 ( ( O O
25 681 685 12063090 298+ JJ B-ADJP O
26 685 686 12063090 / SYM O O
27 686 687 12063090 - SYM O O
28 687 688 12063090 7 CD B-NP O
29 689 691 12063090 vs NNS I-NP O
30 691 692 12063090 . . O O
31 693 697 12063090 139+ CD B-NP O
32 697 698 12063090 / SYM O O
33 698 699 12063090 - HYPH O O
34 699 701 12063090 36 CD B-NP O
35 702 707 12063090 units NNS I-NP O
36 708 712 12063090 area NN B-NP O
37 713 714 12063090 ( ( O O
38 714 716 12063090 ua NN B-NP O
39 716 717 12063090 ) ) O O
40 717 718 12063090 ; : O O
41 719 720 12063090 P NN B-NP O
42 720 721 12063090 < SYM B-NP O
43 721 726 12063090 0.001 CD I-NP O
44 726 727 12063090 ) ) O O
45 728 731 12063090 and CC O O
46 732 740 12063090 repeated VBN B-NP O
47 741 755 12063090 administration NN I-NP O
48 756 757 12063090 ( ( O O
49 757 761 12063090 280+ SYM B-NP O
50 761 762 12063090 / SYM B-NP O
51 762 763 12063090 - SYM B-VP O
52 763 765 12063090 17 CD B-NP O
53 766 768 12063090 vs NNS I-NP O
54 768 769 12063090 . . O O
55 770 774 12063090 131+ SYM O O
56 774 775 12063090 / SYM O O
57 775 776 12063090 - SYM O O
58 776 778 12063090 22 CD B-NP O
59 779 781 12063090 ua NN I-NP O
60 781 782 12063090 ; : O O
61 783 784 12063090 P NN B-NP O
62 784 785 12063090 < SYM B-NP O
63 785 790 12063090 0.001 CD I-NP O
64 790 791 12063090 ) ) O O
65 791 792 12063090 . . O O

1 793 808 12063090 Antinociceptive JJ B-NP O
2 809 815 12063090 effect NN I-NP O
3 816 818 12063090 of IN B-PP O
4 819 827 12063090 morphine NN B-NP B-Chemical
5 828 831 12063090 was VBD B-VP O
6 832 839 12063090 reduced VBN I-VP O
7 840 842 12063090 in IN B-PP O
8 843 854 12063090 chronically RB B-NP O
9 855 862 12063090 treated VBN I-NP O
10 863 867 12063090 rats NNS I-NP O
11 868 869 12063090 ( ( O O
12 869 872 12063090 39+ SYM B-NP O
13 872 873 12063090 / SYM O O
14 873 874 12063090 - SYM B-NP O
15 874 876 12063090 10 CD B-NP O
16 877 879 12063090 vs NNS I-NP O
17 879 880 12063090 . . O O
18 881 884 12063090 18+ JJ B-NP O
19 884 885 12063090 / SYM I-NP O
20 885 886 12063090 - SYM I-NP O
21 886 887 12063090 5 CD B-NP O
22 888 890 12063090 au SYM B-NP O
23 890 891 12063090 ) ) O O
24 892 897 12063090 while IN B-SBAR O
25 898 901 12063090 the DT B-NP O
26 902 913 12063090 combination NN I-NP O
27 913 914 12063090 - HYPH B-NP O
28 914 921 12063090 induced VBN I-NP O
29 922 937 12063090 antinociception NN I-NP O
30 938 941 12063090 was VBD B-VP O
31 942 950 12063090 remained VBN I-VP O
32 951 958 12063090 similar JJ B-ADJP O
33 959 961 12063090 as IN B-PP O
34 962 964 12063090 an DT B-NP O
35 965 970 12063090 acute JJ I-NP O
36 971 980 12063090 treatment NN I-NP O
37 981 982 12063090 ( ( O O
38 982 986 12063090 298+ SYM B-NP O
39 986 987 12063090 / SYM B-NP O
40 987 988 12063090 - SYM B-VP O
41 988 989 12063090 7 CD B-NP O
42 990 992 12063090 vs NNS I-NP O
43 992 993 12063090 . . O O
44 994 998 12063090 280+ JJ B-NP O
45 998 999 12063090 / SYM I-NP O
46 999 1000 12063090 - SYM I-NP O
47 1000 1002 12063090 17 CD I-NP O
48 1003 1005 12063090 au SYM B-NP O
49 1005 1006 12063090 ) ) O O
50 1006 1007 12063090 . . O O

1 1008 1013 12063090 Acute JJ B-NP O
2 1014 1029 12063090 antinociceptive JJ I-NP O
3 1030 1037 12063090 effects NNS I-NP O
4 1038 1040 12063090 of IN B-PP O
5 1041 1044 12063090 the DT B-NP O
6 1045 1056 12063090 combination NN I-NP O
7 1057 1061 12063090 were VBD B-VP O
8 1062 1071 12063090 partially RB I-VP O
9 1072 1081 12063090 prevented VBN I-VP O
10 1082 1084 12063090 by IN B-PP O
11 1085 1088 12063090 3.2 CD B-NP O
12 1089 1091 12063090 mg NN I-NP O
13 1091 1092 12063090 / SYM B-NP O
14 1092 1094 12063090 kg NN I-NP O
15 1095 1103 12063090 naloxone NN I-NP B-Chemical
16 1104 1107 12063090 s.c NN I-NP O
17 1107 1108 12063090 . . O O

1 1109 1110 12063090 ( ( O O
2 1110 1111 12063090 P NN B-NP O
3 1111 1112 12063090 < SYM O O
4 1112 1116 12063090 0.05 CD B-NP O
5 1116 1117 12063090 ) ) O O
6 1117 1118 12063090 , , O O
7 1119 1129 12063090 suggesting VBG B-VP O
8 1130 1133 12063090 the DT B-NP O
9 1134 1141 12063090 partial JJ I-NP O
10 1142 1153 12063090 involvement NN I-NP O
11 1154 1156 12063090 of IN B-PP O
12 1157 1160 12063090 the DT B-NP O
13 1161 1172 12063090 opioidergic JJ I-NP O
14 1173 1179 12063090 system NN I-NP O
15 1180 1182 12063090 in IN B-PP O
16 1183 1186 12063090 the DT B-NP O
17 1187 1196 12063090 synergism NN I-NP O
18 1197 1205 12063090 observed VBN B-VP O
19 1205 1206 12063090 . . O O

1 1207 1209 12063090 In IN B-PP O
2 1210 1221 12063090 independent JJ B-NP O
3 1222 1228 12063090 groups NNS I-NP O
4 1228 1229 12063090 , , O O
5 1230 1238 12063090 morphine NN B-NP B-Chemical
6 1239 1248 12063090 inhibited VBD B-VP O
7 1249 1252 12063090 the DT B-NP O
8 1253 1263 12063090 intestinal JJ I-NP O
9 1264 1271 12063090 transit NN I-NP O
10 1272 1274 12063090 in IN B-PP O
11 1275 1278 12063090 48+ JJ B-NP O
12 1278 1279 12063090 / SYM I-NP O
13 1279 1280 12063090 - SYM I-NP O
14 1280 1282 12063090 4% CD B-NP O
15 1283 1286 12063090 and CC O O
16 1287 1290 12063090 38+ JJ B-NP O
17 1290 1291 12063090 / SYM I-NP O
18 1291 1292 12063090 - HYPH I-NP O
19 1292 1294 12063090 4% NN I-NP O
20 1295 1300 12063090 after IN B-PP O
21 1301 1306 12063090 acute JJ B-NP O
22 1307 1310 12063090 and CC I-NP O
23 1311 1318 12063090 chronic JJ I-NP O
24 1319 1328 12063090 treatment NN I-NP O
25 1328 1329 12063090 , , O O
26 1330 1342 12063090 respectively RB B-ADVP O
27 1342 1343 12063090 , , O O
28 1344 1354 12063090 suggesting VBG B-VP O
29 1355 1359 12063090 that IN B-SBAR O
30 1360 1369 12063090 tolerance NN B-NP O
31 1370 1373 12063090 did VBD B-VP O
32 1374 1377 12063090 not RB I-VP O
33 1378 1385 12063090 develop VB I-VP O
34 1386 1388 12063090 to TO B-PP O
35 1389 1392 12063090 the DT B-NP O
36 1393 1405 12063090 constipating VBG I-NP B-Disease
37 1406 1413 12063090 effects NNS I-NP O
38 1413 1414 12063090 . . O O

1 1415 1418 12063090 The DT B-NP O
2 1419 1430 12063090 combination NN I-NP O
3 1431 1440 12063090 inhibited VBD B-VP O
4 1441 1451 12063090 intestinal JJ B-NP O
5 1452 1459 12063090 transit NN I-NP O
6 1460 1467 12063090 similar JJ B-ADJP O
7 1468 1470 12063090 to TO B-PP O
8 1471 1475 12063090 that DT B-NP O
9 1476 1484 12063090 produced VBN B-VP O
10 1485 1487 12063090 by IN B-PP O
11 1488 1496 12063090 morphine NN B-NP B-Chemical
12 1497 1507 12063090 regardless RB B-ADVP O
13 1508 1510 12063090 of IN B-PP O
14 1511 1514 12063090 the DT B-NP O
15 1515 1519 12063090 time NN I-NP O
16 1520 1522 12063090 of IN B-PP O
17 1523 1532 12063090 treatment NN B-NP O
18 1532 1533 12063090 , , O O
19 1534 1544 12063090 suggesting VBG B-VP O
20 1545 1549 12063090 that IN B-SBAR O
21 1550 1559 12063090 metamizol NN B-NP B-Chemical
22 1560 1563 12063090 did VBD B-VP O
23 1564 1567 12063090 not RB I-VP O
24 1568 1578 12063090 potentiate VB I-VP O
25 1579 1587 12063090 morphine NN B-NP B-Chemical
26 1587 1588 12063090 - HYPH B-NP O
27 1588 1595 12063090 induced VBN I-NP O
28 1596 1608 12063090 constipation NN I-NP B-Disease
29 1608 1609 12063090 . . O O

1 1610 1615 12063090 These DT B-NP O
2 1616 1624 12063090 findings NNS I-NP O
3 1625 1629 12063090 show VBP B-VP O
4 1630 1631 12063090 a DT B-NP O
5 1632 1643 12063090 significant JJ I-NP O
6 1644 1655 12063090 interaction NN I-NP O
7 1656 1663 12063090 between IN B-PP O
8 1664 1672 12063090 morphine NN B-NP B-Chemical
9 1673 1676 12063090 and CC I-NP O
10 1677 1686 12063090 metamizol NN I-NP B-Chemical
11 1687 1689 12063090 in IN B-PP O
12 1690 1701 12063090 chronically RB B-NP O
13 1702 1709 12063090 treated VBN I-NP O
14 1710 1714 12063090 rats NNS I-NP O
15 1714 1715 12063090 , , O O
16 1716 1726 12063090 suggesting VBG B-VP O
17 1727 1731 12063090 that IN B-SBAR O
18 1732 1736 12063090 this DT B-NP O
19 1737 1748 12063090 combination NN I-NP O
20 1749 1754 12063090 could MD B-VP O
21 1755 1757 12063090 be VB I-VP O
22 1758 1764 12063090 useful JJ B-ADJP O
23 1765 1768 12063090 for IN B-PP O
24 1769 1772 12063090 the DT B-NP O
25 1773 1782 12063090 treatment NN I-NP O
26 1783 1785 12063090 of IN B-PP O
27 1786 1793 12063090 chronic JJ B-NP B-Disease
28 1794 1798 12063090 pain NN I-NP I-Disease
29 1798 1799 12063090 . . O O

1 0 0 15572383 -DOCSTART- -X- -X- O

1 0 10 15572383 Individual JJ B-NP O
2 11 22 15572383 differences NNS I-NP O
3 23 25 15572383 in IN B-PP O
4 26 31 15572383 renal JJ B-NP O
5 32 35 15572383 ACE NN I-NP O
6 36 44 15572383 activity NN I-NP O
7 45 47 15572383 in IN B-PP O
8 48 55 15572383 healthy JJ B-NP O
9 56 60 15572383 rats NNS I-NP O
10 61 68 15572383 predict VBP B-VP O
11 69 83 15572383 susceptibility NN B-NP O
12 84 86 15572383 to TO B-PP O
13 87 97 15572383 adriamycin NN B-NP B-Chemical
14 97 98 15572383 - HYPH O O
15 98 105 15572383 induced VBN B-NP O
16 106 111 15572383 renal JJ I-NP B-Disease
17 112 118 15572383 damage NN I-NP I-Disease
18 118 119 15572383 . . I-NP O
19 120 130 15572383 BACKGROUND NN I-NP O
20 130 131 15572383 : : O O
21 132 134 15572383 In IN B-PP O
22 135 138 15572383 man NN B-NP O
23 138 139 15572383 , , O O
24 140 151 15572383 differences NNS B-NP O
25 152 154 15572383 in IN B-PP O
26 155 166 15572383 angiotensin NN B-NP B-Chemical
27 166 167 15572383 - HYPH O O
28 167 177 15572383 converting VBG B-VP O
29 178 184 15572383 enzyme NN B-NP O
30 185 186 15572383 ( ( O O
31 186 189 15572383 ACE NN B-NP O
32 189 190 15572383 ) ) O O
33 191 197 15572383 levels NNS B-NP O
34 197 198 15572383 , , O O
35 199 206 15572383 related VBN B-VP O
36 207 209 15572383 to TO B-PP O
37 210 213 15572383 ACE NN B-NP O
38 214 215 15572383 ( ( O O
39 215 216 15572383 I NN B-NP O
40 216 217 15572383 / SYM B-NP O
41 217 218 15572383 D NN I-NP O
42 218 219 15572383 ) ) O O
43 220 228 15572383 genotype NN B-NP O
44 228 229 15572383 , , O O
45 230 233 15572383 are VBP B-VP O
46 234 244 15572383 associated VBN I-VP O
47 245 249 15572383 with IN B-PP O
48 250 255 15572383 renal JJ B-NP O
49 256 265 15572383 prognosis NN I-NP O
50 265 266 15572383 . . O O

1 267 271 15572383 This DT B-NP O
2 272 278 15572383 raises VBZ B-VP O
3 279 282 15572383 the DT B-NP O
4 283 293 15572383 hypothesis NN I-NP O
5 294 298 15572383 that IN B-SBAR O
6 299 309 15572383 individual JJ B-NP O
7 310 321 15572383 differences NNS I-NP O
8 322 324 15572383 in IN B-PP O
9 325 330 15572383 renal JJ B-NP O
10 331 334 15572383 ACE NN I-NP O
11 335 343 15572383 activity NN I-NP O
12 344 347 15572383 are VBP B-VP O
13 348 356 15572383 involved VBN I-VP O
14 357 359 15572383 in IN B-PP O
15 360 365 15572383 renal JJ B-NP O
16 366 380 15572383 susceptibility NN I-NP O
17 381 383 15572383 to TO B-PP O
18 384 393 15572383 inflicted VBN B-NP O
19 394 400 15572383 damage NN I-NP O
20 400 401 15572383 . . O O

1 402 411 15572383 Therefore RB B-ADVP O
2 411 412 15572383 , , O O
3 413 415 15572383 we PRP B-NP O
4 416 423 15572383 studied VBD B-VP O
5 424 427 15572383 the DT B-NP O
6 428 438 15572383 predictive JJ I-NP O
7 439 445 15572383 effect NN I-NP O
8 446 448 15572383 of IN B-PP O
9 449 454 15572383 renal JJ B-NP O
10 455 458 15572383 ACE NN I-NP O
11 459 467 15572383 activity NN I-NP O
12 468 471 15572383 for IN B-PP O
13 472 475 15572383 the DT B-NP O
14 476 484 15572383 severity NN I-NP O
15 485 487 15572383 of IN B-PP O
16 488 493 15572383 renal JJ B-NP B-Disease
17 494 500 15572383 damage NN I-NP I-Disease
18 501 508 15572383 induced VBN B-VP O
19 509 511 15572383 by IN B-PP O
20 512 513 15572383 a DT B-NP O
21 514 520 15572383 single JJ I-NP O
22 521 530 15572383 injection NN I-NP O
23 531 533 15572383 of IN B-PP O
24 534 544 15572383 adriamycin NN B-NP B-Chemical
25 545 547 15572383 in IN B-PP O
26 548 552 15572383 rats NNS B-NP O
27 552 553 15572383 . . O O

1 554 561 15572383 METHODS NNS B-NP O
2 561 562 15572383 : : O O
3 563 568 15572383 Renal JJ B-NP O
4 569 572 15572383 ACE NN I-NP O
5 573 581 15572383 activity NN I-NP O
6 582 583 15572383 ( ( O O
7 583 586 15572383 Hip NN B-NP B-Chemical
8 586 587 15572383 - HYPH B-NP I-Chemical
9 587 590 15572383 His NN I-NP I-Chemical
10 590 591 15572383 - HYPH B-NP I-Chemical
11 591 594 15572383 Leu NN I-NP I-Chemical
12 595 603 15572383 cleavage NN I-NP O
13 604 606 15572383 by IN B-PP O
14 607 615 15572383 cortical JJ B-NP O
15 616 627 15572383 homogenates NNS I-NP O
16 627 628 15572383 ) ) O O
17 629 632 15572383 was VBD B-VP O
18 633 643 15572383 determined VBN I-VP O
19 644 646 15572383 by IN B-PP O
20 647 652 15572383 renal JJ B-NP O
21 653 659 15572383 biopsy NN I-NP O
22 660 662 15572383 in IN B-PP O
23 663 665 15572383 27 CD B-NP O
24 666 671 15572383 adult JJ I-NP O
25 672 676 15572383 male JJ I-NP O
26 677 683 15572383 Wistar NNP I-NP O
27 684 688 15572383 rats NNS I-NP O
28 688 689 15572383 . . O O

1 690 695 15572383 After IN B-PP O
2 696 697 15572383 1 CD B-NP O
3 698 702 15572383 week NN I-NP O
4 703 705 15572383 of IN B-PP O
5 706 714 15572383 recovery NN B-NP O
6 714 715 15572383 , , O O
7 716 727 15572383 proteinuria NN B-NP B-Disease
8 728 731 15572383 was VBD B-VP O
9 732 739 15572383 induced VBN I-VP O
10 740 742 15572383 by IN B-PP O
11 743 753 15572383 adriamycin NN B-NP B-Chemical
12 754 755 15572383 [ ( O O
13 755 758 15572383 1.5 CD B-NP O
14 759 761 15572383 mg NN I-NP O
15 761 762 15572383 / SYM O O
16 762 764 15572383 kg NN B-NP O
17 765 778 15572383 intravenously RB B-ADVP O
18 779 780 15572383 ( ( O O
19 780 783 15572383 i.v JJ O O
20 783 784 15572383 . . O O
21 784 785 15572383 ) ) O O
22 786 787 15572383 n NN B-NP O
23 788 789 15572383 = SYM B-VP O
24 790 792 15572383 18 CD B-NP O
25 792 793 15572383 ; : O O
26 794 802 15572383 controls NNS B-NP O
27 802 803 15572383 , , O O
28 804 810 15572383 saline NN B-NP O
29 811 814 15572383 i.v NN I-NP O
30 814 815 15572383 . . O O

1 816 817 15572383 n NN B-NP O
2 818 819 15572383 = SYM B-VP O
3 820 821 15572383 9 CD B-NP O
4 821 822 15572383 ] ) O O
5 822 823 15572383 . . O O

1 824 835 15572383 Proteinuria NNP B-NP B-Disease
2 836 839 15572383 was VBD B-VP O
3 840 848 15572383 measured VBN I-VP O
4 849 854 15572383 every DT B-NP O
5 855 856 15572383 2 CD I-NP O
6 857 862 15572383 weeks NNS I-NP O
7 862 863 15572383 . . O O

1 864 869 15572383 After IN B-PP O
2 870 872 15572383 12 CD B-NP O
3 873 878 15572383 weeks NNS I-NP O
4 878 879 15572383 , , O O
5 880 884 15572383 rats NNS B-NP O
6 885 889 15572383 were VBD B-VP O
7 890 900 15572383 sacrificed VBN I-VP O
8 901 904 15572383 and CC O O
9 905 910 15572383 their PRP$ B-NP O
10 911 918 15572383 kidneys NNS I-NP O
11 919 928 15572383 harvested VBN B-VP O
12 928 929 15572383 . . O O

1 930 937 15572383 RESULTS NNS B-NP O
2 937 938 15572383 : : O O
3 939 941 15572383 As IN B-SBAR O
4 942 953 15572383 anticipated VBN B-VP O
5 953 954 15572383 , , O O
6 955 965 15572383 adriamycin NN B-NP B-Chemical
7 966 974 15572383 elicited VBD B-VP O
8 975 984 15572383 nephrotic JJ B-NP B-Disease
9 985 990 15572383 range NN I-NP O
10 991 1002 15572383 proteinuria NN I-NP B-Disease
11 1002 1003 15572383 , , O O
12 1004 1009 15572383 renal JJ B-NP B-Disease
13 1010 1022 15572383 interstitial JJ I-NP I-Disease
14 1023 1029 15572383 damage NN I-NP I-Disease
15 1030 1033 15572383 and CC O O
16 1034 1038 15572383 mild JJ B-NP O
17 1039 1044 15572383 focal JJ I-NP B-Disease
18 1045 1063 15572383 glomerulosclerosis NN I-NP I-Disease
19 1063 1064 15572383 . . O O

1 1065 1073 15572383 Baseline NN B-NP O
2 1074 1079 15572383 renal JJ I-NP O
3 1080 1083 15572383 ACE NN I-NP O
4 1084 1094 15572383 positively RB B-ADVP O
5 1095 1105 15572383 correlated VBD B-VP O
6 1106 1110 15572383 with IN B-PP O
7 1111 1114 15572383 the DT B-NP O
8 1115 1123 15572383 relative JJ I-NP O
9 1124 1128 15572383 rise NN I-NP O
10 1129 1131 15572383 in IN B-PP O
11 1132 1143 15572383 proteinuria NN B-NP B-Disease
12 1144 1149 15572383 after IN B-PP O
13 1150 1160 15572383 adriamycin NN B-NP B-Chemical
14 1161 1162 15572383 ( ( O O
15 1162 1163 15572383 r NN B-NP O
16 1164 1165 15572383 = SYM B-VP O
17 1166 1170 15572383 0.62 CD B-NP O
18 1170 1171 15572383 , , O O
19 1172 1173 15572383 P NN B-NP O
20 1173 1174 15572383 < SYM B-NP O
21 1174 1178 15572383 0.01 CD I-NP O
22 1178 1179 15572383 ) ) O O
23 1179 1180 15572383 , , O O
24 1181 1186 15572383 renal JJ B-NP O
25 1187 1199 15572383 interstitial JJ I-NP O
26 1200 1205 15572383 alpha SYM B-NP O
27 1205 1206 15572383 - HYPH I-NP O
28 1206 1212 15572383 smooth JJ I-NP O
29 1213 1219 15572383 muscle NN I-NP O
30 1220 1225 15572383 actin NN I-NP O
31 1226 1227 15572383 ( ( O O
32 1227 1228 15572383 r NN B-NP O
33 1229 1230 15572383 = SYM B-VP O
34 1231 1235 15572383 0.49 CD B-NP O
35 1235 1236 15572383 , , O O
36 1237 1238 15572383 P NN B-NP O
37 1238 1239 15572383 < SYM B-NP O
38 1239 1243 15572383 0.05 CD I-NP O
39 1243 1244 15572383 ) ) O O
40 1244 1245 15572383 , , O O
41 1246 1258 15572383 interstitial JJ B-NP O
42 1259 1269 15572383 macrophage NN I-NP O
43 1270 1276 15572383 influx NN I-NP O
44 1277 1278 15572383 ( ( O O
45 1278 1279 15572383 r NN B-NP O
46 1280 1281 15572383 = SYM B-VP O
47 1282 1286 15572383 0.56 CD B-NP O
48 1286 1287 15572383 , , O O
49 1288 1289 15572383 P NN B-NP O
50 1289 1290 15572383 < SYM B-NP O
51 1290 1294 15572383 0.05 CD I-NP O
52 1294 1295 15572383 ) ) O O
53 1295 1296 15572383 , , O O
54 1297 1309 15572383 interstitial JJ B-NP O
55 1310 1318 15572383 collagen NN I-NP O
56 1319 1322 15572383 III CD I-NP O
57 1323 1324 15572383 ( ( O O
58 1324 1325 15572383 r NN B-NP O
59 1326 1327 15572383 = SYM B-VP O
60 1328 1332 15572383 0.53 CD B-NP O
61 1332 1333 15572383 , , O O
62 1334 1335 15572383 P NN B-NP O
63 1335 1336 15572383 < SYM B-NP O
64 1336 1340 15572383 0.05 CD I-NP O
65 1340 1341 15572383 ) ) O O
66 1341 1342 15572383 , , O O
67 1343 1353 15572383 glomerular JJ B-ADJP O
68 1354 1359 15572383 alpha SYM B-NP O
69 1359 1360 15572383 - HYPH I-NP O
70 1360 1366 15572383 smooth JJ I-NP O
71 1367 1373 15572383 muscle NN I-NP O
72 1374 1379 15572383 actin NN I-NP O
73 1380 1381 15572383 ( ( O O
74 1381 1382 15572383 r NN B-NP O
75 1383 1384 15572383 = SYM B-VP O
76 1385 1389 15572383 0.74 CD B-NP O
77 1389 1390 15572383 , , O O
78 1391 1392 15572383 P NN B-NP O
79 1392 1393 15572383 < SYM B-NP O
80 1393 1397 15572383 0.01 CD I-NP O
81 1397 1398 15572383 ) ) O O
82 1399 1402 15572383 and CC O O
83 1403 1413 15572383 glomerular JJ B-NP O
84 1414 1420 15572383 desmin NN I-NP O
85 1421 1422 15572383 ( ( O O
86 1422 1423 15572383 r NN B-NP O
87 1424 1425 15572383 = SYM B-VP O
88 1426 1430 15572383 0.48 CD B-NP O
89 1430 1431 15572383 , , O O
90 1432 1433 15572383 P NN B-NP O
91 1433 1434 15572383 < SYM B-NP O
92 1434 1438 15572383 0.05 CD I-NP O
93 1438 1439 15572383 ) ) O O
94 1439 1440 15572383 . . O O

1 1441 1449 15572383 Baseline NN B-NP O
2 1450 1455 15572383 renal JJ I-NP O
3 1456 1459 15572383 ACE NN I-NP O
4 1460 1463 15572383 did VBD B-VP O
5 1464 1467 15572383 not RB I-VP O
6 1468 1477 15572383 correlate VB I-VP O
7 1478 1482 15572383 with IN B-PP O
8 1483 1488 15572383 focal JJ B-NP B-Disease
9 1489 1507 15572383 glomerulosclerosis NN I-NP I-Disease
10 1508 1509 15572383 ( ( O O
11 1509 1510 15572383 r NN B-NP O
12 1511 1512 15572383 = SYM B-VP O
13 1513 1517 15572383 0.22 CD B-NP O
14 1517 1518 15572383 , , O O
15 1519 1521 15572383 NS NN B-NP O
16 1521 1522 15572383 ) ) O O
17 1522 1523 15572383 . . O O

1 1524 1526 15572383 In IN B-PP O
2 1527 1535 15572383 controls NNS B-NP O
3 1535 1536 15572383 , , O O
4 1537 1539 15572383 no DT B-NP O
5 1540 1550 15572383 predictive JJ I-NP O
6 1551 1557 15572383 values NNS I-NP O
7 1558 1561 15572383 for IN B-PP O
8 1562 1567 15572383 renal JJ B-NP O
9 1568 1578 15572383 parameters NNS I-NP O
10 1579 1583 15572383 were VBD B-VP O
11 1584 1592 15572383 observed VBN I-VP O
12 1592 1593 15572383 . . O O

1 1594 1604 15572383 CONCLUSION NN B-NP O
2 1604 1605 15572383 : : O O
3 1606 1616 15572383 Individual JJ B-NP O
4 1617 1628 15572383 differences NNS I-NP O
5 1629 1631 15572383 in IN B-PP O
6 1632 1637 15572383 renal JJ B-NP O
7 1638 1641 15572383 ACE NN I-NP O
8 1642 1650 15572383 activity NN I-NP O
9 1651 1658 15572383 predict VBP B-VP O
10 1659 1662 15572383 the DT B-NP O
11 1663 1671 15572383 severity NN I-NP O
12 1672 1674 15572383 of IN B-PP O
13 1675 1685 15572383 adriamycin NN B-NP B-Chemical
14 1685 1686 15572383 - HYPH O O
15 1686 1693 15572383 induced VBN B-NP O
16 1694 1699 15572383 renal JJ I-NP B-Disease
17 1700 1706 15572383 damage NN I-NP I-Disease
18 1707 1709 15572383 in IN B-PP O
19 1710 1714 15572383 this DT B-NP O
20 1715 1722 15572383 outbred JJ I-NP O
21 1723 1726 15572383 rat NN I-NP O
22 1727 1733 15572383 strain NN I-NP O
23 1733 1734 15572383 . . O O

1 1735 1739 15572383 This DT B-NP O
2 1740 1748 15572383 supports VBZ B-VP O
3 1749 1752 15572383 the DT B-NP O
4 1753 1763 15572383 assumption NN I-NP O
5 1764 1768 15572383 that IN B-SBAR O
6 1769 1780 15572383 differences NNS B-NP O
7 1781 1783 15572383 in IN B-PP O
8 1784 1789 15572383 renal JJ B-NP O
9 1790 1793 15572383 ACE NN I-NP O
10 1794 1802 15572383 activity NN I-NP O
11 1803 1813 15572383 predispose VBP B-VP O
12 1814 1816 15572383 to TO B-PP O
13 1817 1818 15572383 a DT B-NP O
14 1819 1823 15572383 less RBR I-NP O
15 1824 1834 15572383 favourable JJ I-NP O
16 1835 1841 15572383 course NN I-NP O
17 1842 1844 15572383 of IN B-PP O
18 1845 1850 15572383 renal JJ B-NP B-Disease
19 1851 1857 15572383 damage NN I-NP I-Disease
20 1857 1858 15572383 . . O O

1 0 0 7504976 -DOCSTART- -X- -X- O

1 0 5 7504976 Toxic JJ B-NP B-Disease
2 6 15 7504976 hepatitis NN I-NP I-Disease
3 16 23 7504976 induced VBN B-VP O
4 24 26 7504976 by IN B-PP O
5 27 38 7504976 antithyroid JJ B-NP O
6 39 44 7504976 drugs NNS I-NP O
7 44 45 7504976 : : O O
8 46 50 7504976 four CD B-NP O
9 51 56 7504976 cases NNS I-NP O
10 57 66 7504976 including VBG B-PP O
11 67 70 7504976 one CD B-NP O
12 71 75 7504976 with IN B-PP O
13 76 81 7504976 cross AFX B-NP O
14 81 82 7504976 - HYPH I-NP O
15 82 92 7504976 reactivity NN I-NP O
16 93 100 7504976 between IN B-PP O
17 101 112 7504976 carbimazole NN B-NP B-Chemical
18 113 116 7504976 and CC I-NP O
19 117 133 7504976 benzylthiouracil NN I-NP B-Chemical
20 133 134 7504976 . . I-NP O
21 135 144 7504976 OBJECTIVE NN I-NP O
22 144 145 7504976 : : O O
23 146 150 7504976 This DT B-NP O
24 151 156 7504976 study NN I-NP O
25 157 160 7504976 was VBD B-VP O
26 161 170 7504976 conducted VBN I-VP O
27 171 173 7504976 to TO I-VP O
28 174 180 7504976 assess VB I-VP O
29 181 184 7504976 the DT B-NP O
30 185 195 7504976 occurrence NN I-NP O
31 196 198 7504976 of IN B-PP O
32 199 206 7504976 hepatic JJ B-NP B-Disease
33 207 214 7504976 adverse JJ I-NP I-Disease
34 215 222 7504976 effects NNS I-NP I-Disease
35 223 234 7504976 encountered VBN B-VP O
36 235 239 7504976 with IN B-PP O
37 240 251 7504976 antithyroid JJ B-NP O
38 252 257 7504976 drugs NNS I-NP O
39 257 258 7504976 . . O O

1 259 266 7504976 METHODS NNS B-NP O
2 266 267 7504976 : : O O
3 268 281 7504976 Retrospective JJ B-NP O
4 282 288 7504976 review NN I-NP O
5 289 291 7504976 of IN B-PP O
6 292 299 7504976 medical JJ B-NP O
7 300 307 7504976 records NNS I-NP O
8 308 310 7504976 of IN B-PP O
9 311 314 7504976 236 CD B-NP O
10 315 323 7504976 patients NNS I-NP O
11 324 328 7504976 with IN B-PP O
12 329 344 7504976 hyperthyroidism NN B-NP B-Disease
13 345 353 7504976 admitted VBN B-VP O
14 354 356 7504976 in IN B-PP O
15 357 360 7504976 our PRP$ B-NP O
16 361 371 7504976 department NN I-NP O
17 372 373 7504976 ( ( O O
18 373 375 7504976 in IN B-PP O
19 375 376 7504976 - HYPH B-NP O
20 377 379 7504976 or CC O O
21 380 383 7504976 out RP B-PRT O
22 383 384 7504976 - HYPH B-NP O
23 384 392 7504976 patients NNS I-NP O
24 392 393 7504976 ) ) O O
25 394 398 7504976 from IN B-PP O
26 399 403 7504976 1986 CD B-NP O
27 404 406 7504976 to TO B-PP O
28 407 411 7504976 1992 CD B-NP O
29 411 412 7504976 . . O O

1 413 420 7504976 RESULTS NNS B-NP O
2 420 421 7504976 : : O O
3 422 426 7504976 Four CD B-NP O
4 427 435 7504976 patients NNS I-NP O
5 436 437 7504976 ( ( O O
6 437 441 7504976 1.7% CD B-NP O
7 441 442 7504976 ) ) O O
8 443 447 7504976 were VBD B-VP O
9 448 458 7504976 identified VBN I-VP O
10 459 463 7504976 with IN B-PP O
11 464 469 7504976 toxic JJ B-NP B-Disease
12 470 479 7504976 hepatitis NN I-NP I-Disease
13 480 485 7504976 which WDT B-NP O
14 486 491 7504976 could MD B-VP O
15 492 502 7504976 reasonably RB I-VP O
16 503 505 7504976 be VB I-VP O
17 506 516 7504976 attributed VBN I-VP O
18 517 519 7504976 to TO B-PP O
19 520 523 7504976 the DT B-NP O
20 524 527 7504976 use NN I-NP O
21 528 530 7504976 of IN B-PP O
22 531 542 7504976 antithyroid JJ B-NP O
23 543 548 7504976 agent NN I-NP O
24 548 549 7504976 . . O O

1 550 553 7504976 Two CD B-NP O
2 554 562 7504976 patients NNS I-NP O
3 563 566 7504976 had VBD B-VP O
4 567 568 7504976 a DT B-NP O
5 569 580 7504976 cholestatic JJ I-NP B-Disease
6 581 590 7504976 hepatitis NN I-NP I-Disease
7 591 598 7504976 induced VBN B-VP O
8 599 601 7504976 by IN B-PP O
9 602 613 7504976 carbimazole NN B-NP B-Chemical
10 614 615 7504976 ( ( O O
11 615 616 7504976 N NN B-NP B-Chemical
12 618 628 7504976 omercazole NN I-NP I-Chemical
13 628 629 7504976 ) ) O O
14 629 630 7504976 . . O O

1 631 634 7504976 Two CD B-NP O
2 635 641 7504976 others NNS I-NP O
3 642 645 7504976 had VBD B-VP O
4 646 647 7504976 a DT O O
5 648 653 7504976 mixed JJ O O
6 654 655 7504976 ( ( O O
7 655 666 7504976 cholestatic JJ B-NP B-Disease
8 667 670 7504976 and CC I-NP O
9 671 680 7504976 cytolytic JJ I-NP O
10 680 681 7504976 ) ) I-NP O
11 682 691 7504976 hepatitis NN I-NP B-Disease
12 692 701 7504976 following VBG B-PP O
13 702 713 7504976 carbimazole NN B-NP B-Chemical
14 713 714 7504976 . . O O

1 715 718 7504976 One CD B-NP O
2 719 721 7504976 of IN B-PP O
3 722 725 7504976 the DT B-NP O
4 726 732 7504976 latter JJ I-NP O
5 733 736 7504976 two CD I-NP O
6 737 745 7504976 patients NNS I-NP O
7 746 753 7504976 further RBR B-ADVP O
8 754 765 7504976 experienced VBD B-VP O
9 766 767 7504976 a DT B-NP O
10 768 777 7504976 cytolytic JJ I-NP O
11 778 787 7504976 hepatitis NN I-NP B-Disease
12 788 793 7504976 which WDT B-NP O
13 794 802 7504976 appeared VBD B-VP O
14 803 808 7504976 after IN B-PP O
15 809 825 7504976 Benzylthiouracil NN B-NP B-Chemical
16 826 827 7504976 ( ( O O
17 827 831 7504976 Basd NN B-NP B-Chemical
18 833 835 7504976 ne NN I-NP I-Chemical
19 835 836 7504976 ) ) O O
20 837 840 7504976 had VBD B-VP O
21 841 849 7504976 replaced VBN I-VP O
22 850 861 7504976 carbimazole NN B-NP B-Chemical
23 861 862 7504976 . . O O

1 863 873 7504976 Biological JJ B-NP O
2 874 882 7504976 features NNS I-NP O
3 883 885 7504976 of IN B-PP O
4 886 895 7504976 hepatitis NN B-NP B-Disease
5 896 907 7504976 disappeared VBD B-VP O
6 908 910 7504976 in IN B-PP O
7 911 914 7504976 all DT B-NP O
8 915 920 7504976 cases NNS I-NP O
9 921 926 7504976 after IN B-PP O
10 927 936 7504976 cessation NN B-NP O
11 937 939 7504976 of IN B-PP O
12 940 943 7504976 the DT B-NP O
13 944 956 7504976 incriminated VBN I-NP O
14 957 961 7504976 drug NN I-NP O
15 961 962 7504976 , , O O
16 963 968 7504976 while IN B-SBAR O
17 969 976 7504976 biliary JJ B-NP O
18 976 977 7504976 , , I-NP O
19 978 983 7504976 viral JJ I-NP O
20 984 987 7504976 and CC I-NP O
21 988 1001 7504976 immunological JJ I-NP O
22 1002 1010 7504976 searches NNS I-NP O
23 1011 1015 7504976 were VBD B-VP O
24 1016 1024 7504976 negative JJ B-ADJP O
25 1024 1025 7504976 . . O O

1 1026 1030 7504976 Only RB B-NP O
2 1031 1032 7504976 2 CD I-NP O
3 1033 1041 7504976 patients NNS I-NP O
4 1042 1044 7504976 of IN B-PP O
5 1045 1048 7504976 our PRP$ B-NP O
6 1049 1062 7504976 retrospective JJ I-NP O
7 1063 1068 7504976 study NN I-NP O
8 1069 1080 7504976 experienced VBD B-VP O
9 1081 1082 7504976 a DT B-NP O
10 1083 1087 7504976 mild JJ I-NP O
11 1088 1090 7504976 or CC I-NP O
12 1091 1097 7504976 severe JJ I-NP O
13 1098 1109 7504976 neutropenia NN I-NP B-Disease
14 1109 1110 7504976 . . O O

1 1111 1121 7504976 CONCLUSION NN B-NP O
2 1121 1122 7504976 : : O O
3 1123 1128 7504976 Toxic JJ B-NP B-Disease
4 1129 1138 7504976 hepatitis NN I-NP I-Disease
5 1139 1141 7504976 is VBZ B-VP O
6 1142 1143 7504976 a DT B-NP O
7 1144 1153 7504976 potential JJ I-NP O
8 1154 1161 7504976 adverse JJ I-NP O
9 1162 1168 7504976 effect NN I-NP O
10 1169 1171 7504976 of IN B-PP O
11 1172 1183 7504976 antithyroid JJ B-NP O
12 1184 1189 7504976 drugs NNS I-NP O
13 1190 1195 7504976 which WDT B-NP O
14 1196 1204 7504976 warrants NNS B-NP O
15 1204 1205 7504976 , , O O
16 1206 1208 7504976 as IN B-PP O
17 1209 1212 7504976 for IN B-PP O
18 1213 1227 7504976 haematological JJ B-NP O
19 1228 1240 7504976 disturbances NNS I-NP O
20 1240 1241 7504976 , , O O
21 1242 1243 7504976 a DT B-NP O
22 1244 1247 7504976 pre AFX I-NP O
23 1247 1248 7504976 - HYPH I-NP O
24 1248 1259 7504976 therapeutic JJ I-NP O
25 1260 1273 7504976 determination NN I-NP O
26 1274 1277 7504976 and CC O O
27 1278 1279 7504976 a DT B-NP O
28 1280 1287 7504976 careful JJ I-NP O
29 1288 1294 7504976 follow VB B-VP O
30 1294 1295 7504976 - HYPH O O
31 1295 1297 7504976 up RP B-PRT O
32 1298 1300 7504976 of IN B-PP O
33 1301 1309 7504976 relevant JJ B-NP O
34 1310 1320 7504976 biological JJ I-NP O
35 1321 1328 7504976 markers NNS I-NP O
36 1328 1329 7504976 . . O O

1 1330 1338 7504976 Moreover RB B-ADVP O
2 1338 1339 7504976 , , O O
3 1340 1354 7504976 hepatotoxicity NN B-NP B-Disease
4 1355 1358 7504976 may MD B-VP O
5 1359 1362 7504976 not RB I-VP O
6 1363 1365 7504976 be VB I-VP O
7 1366 1376 7504976 restricted VBN I-VP O
8 1377 1379 7504976 to TO B-PP O
9 1380 1383 7504976 one CD B-NP O
10 1384 1389 7504976 class NN I-NP O
11 1390 1392 7504976 of IN B-PP O
12 1393 1404 7504976 antithyroid JJ B-NP O
13 1405 1411 7504976 agents NNS I-NP O
14 1411 1412 7504976 . . O O

1 0 0 7802851 -DOCSTART- -X- -X- O

1 0 6 7802851 Safety NN B-NP O
2 7 10 7802851 and CC I-NP O
3 11 15 7802851 side NN I-NP O
4 15 16 7802851 - HYPH O O
5 16 23 7802851 effects NNS B-NP O
6 24 26 7802851 of IN B-PP O
7 27 37 7802851 alprazolam NN B-NP B-Chemical
8 37 38 7802851 . . O O

1 39 49 7802851 Controlled VBN B-NP O
2 50 55 7802851 study NN I-NP O
3 56 58 7802851 in IN B-PP O
4 59 70 7802851 agoraphobia NN B-NP B-Disease
5 71 75 7802851 with IN B-PP O
6 76 81 7802851 panic NN B-NP B-Disease
7 82 90 7802851 disorder NN I-NP I-Disease
8 90 91 7802851 . . I-NP O
9 92 102 7802851 BACKGROUND NN I-NP O
10 102 103 7802851 : : O O
11 104 107 7802851 The DT B-NP O
12 108 118 7802851 widespread JJ I-NP O
13 119 122 7802851 use NN I-NP O
14 123 125 7802851 of IN B-PP O
15 126 141 7802851 benzodiazepines NNS B-NP B-Chemical
16 142 145 7802851 has VBZ B-VP O
17 146 149 7802851 led VBN I-VP O
18 150 152 7802851 to TO B-PP O
19 153 163 7802851 increasing VBG B-NP O
20 164 175 7802851 recognition NN I-NP O
21 176 178 7802851 of IN B-PP O
22 179 184 7802851 their PRP$ B-NP O
23 185 193 7802851 unwanted JJ I-NP O
24 194 201 7802851 effects NNS I-NP O
25 201 202 7802851 . . O O

1 203 206 7802851 The DT B-NP O
2 207 215 7802851 efficacy NN I-NP O
3 216 218 7802851 of IN B-PP O
4 219 229 7802851 alprazolam NN B-NP B-Chemical
5 230 233 7802851 and CC I-NP O
6 234 241 7802851 placebo NN I-NP O
7 242 244 7802851 in IN B-PP O
8 245 250 7802851 panic NN B-NP B-Disease
9 251 259 7802851 disorder NN I-NP I-Disease
10 260 264 7802851 with IN B-PP O
11 265 276 7802851 agoraphobia NN B-NP B-Disease
12 276 277 7802851 , , O O
13 278 281 7802851 and CC O O
14 282 285 7802851 the DT B-NP O
15 286 290 7802851 side NN I-NP O
16 290 291 7802851 - HYPH O O
17 291 297 7802851 effect NN B-NP O
18 298 301 7802851 and CC O O
19 302 309 7802851 adverse JJ B-NP O
20 310 316 7802851 effect NN I-NP O
21 317 325 7802851 profiles NNS I-NP O
22 326 328 7802851 of IN B-PP O
23 329 333 7802851 both DT B-NP O
24 334 338 7802851 drug NN I-NP O
25 339 345 7802851 groups NNS I-NP O
26 346 350 7802851 were VBD B-VP O
27 351 359 7802851 measured VBN I-VP O
28 359 360 7802851 . . O O

1 361 367 7802851 METHOD NN B-NP O
2 367 368 7802851 : : O O
3 369 371 7802851 In IN B-PP O
4 372 378 7802851 London NNP B-NP O
5 379 382 7802851 and CC O O
6 383 390 7802851 Toronto NNP B-NP O
7 391 394 7802851 154 CD B-NP O
8 395 403 7802851 patients NNS I-NP O
9 404 407 7802851 who WP B-NP O
10 408 411 7802851 met VBD B-VP O
11 412 415 7802851 DSM NN B-NP O
12 415 416 7802851 - HYPH O O
13 416 419 7802851 III CD B-NP O
14 420 428 7802851 criteria NNS I-NP O
15 429 432 7802851 for IN B-PP O
16 433 438 7802851 panic NN B-NP B-Disease
17 439 447 7802851 disorder NN I-NP I-Disease
18 448 452 7802851 with IN B-PP O
19 453 464 7802851 agoraphobia NN B-NP B-Disease
20 465 469 7802851 were VBD B-VP O
21 470 480 7802851 randomised VBN I-VP O
22 481 483 7802851 to TO B-PP O
23 484 494 7802851 alprazolam NN B-NP B-Chemical
24 495 497 7802851 or CC I-NP O
25 498 505 7802851 placebo NN I-NP O
26 505 506 7802851 . . O O

1 507 515 7802851 Subjects NNS B-NP O
2 516 518 7802851 in IN B-PP O
3 519 523 7802851 each DT B-NP O
4 524 528 7802851 drug NN I-NP O
5 529 534 7802851 group NN I-NP O
6 535 539 7802851 also RB B-ADVP O
7 540 548 7802851 received VBD B-VP O
8 549 555 7802851 either CC O O
9 556 564 7802851 exposure NN B-NP O
10 565 567 7802851 or CC I-NP O
11 568 578 7802851 relaxation NN I-NP O
12 578 579 7802851 . . O O

1 580 589 7802851 Treatment NN B-NP O
2 590 593 7802851 was VBD B-VP O
3 594 598 7802851 from IN B-PP O
4 599 604 7802851 weeks NNS B-NP O
5 605 606 7802851 0 CD B-NP O
6 607 609 7802851 to TO O O
7 610 611 7802851 8 CD B-NP O
8 612 615 7802851 and CC O O
9 616 619 7802851 was VBD B-VP O
10 620 624 7802851 then RB I-VP O
11 625 632 7802851 tapered VBN I-VP O
12 633 637 7802851 from IN B-PP O
13 638 643 7802851 weeks NNS B-NP O
14 644 645 7802851 8 CD B-NP O
15 646 648 7802851 to TO B-PP O
16 649 651 7802851 16 CD B-NP O
17 651 652 7802851 . . O O

1 653 660 7802851 RESULTS NNS B-NP O
2 660 661 7802851 : : O O
3 662 666 7802851 Mean JJ B-NP O
4 667 677 7802851 alprazolam NN I-NP B-Chemical
5 678 682 7802851 dose NN I-NP O
6 683 686 7802851 was VBD B-VP O
7 687 688 7802851 5 CD B-NP O
8 689 691 7802851 mg NN I-NP O
9 692 697 7802851 daily RB B-ADVP O
10 697 698 7802851 . . O O

1 699 707 7802851 Compared VBN B-PP O
2 708 712 7802851 with IN B-PP O
3 713 720 7802851 placebo NN B-NP O
4 721 729 7802851 subjects NNS I-NP O
5 729 730 7802851 , , O O
6 731 741 7802851 alprazolam NN B-NP B-Chemical
7 742 750 7802851 patients NNS I-NP O
8 751 760 7802851 developed VBD B-VP O
9 761 765 7802851 more RBR B-NP O
10 766 773 7802851 adverse JJ I-NP O
11 774 783 7802851 reactions NNS I-NP O
12 784 785 7802851 ( ( O O
13 785 788 7802851 21% CD B-NP O
14 789 790 7802851 v NN I-NP O
15 790 791 7802851 . . O O

1 792 794 7802851 0% LS B-LST O
2 794 795 7802851 ) ) O O
3 796 798 7802851 of IN B-PP O
4 799 809 7802851 depression NN B-NP B-Disease
5 809 810 7802851 , , I-NP O
6 811 819 7802851 enuresis NN I-NP B-Disease
7 819 820 7802851 , , I-NP O
8 821 834 7802851 disinhibition NN I-NP O
9 835 838 7802851 and CC I-NP O
10 839 849 7802851 aggression NN I-NP B-Disease
11 849 850 7802851 ; : O O
12 851 854 7802851 and CC O O
13 855 859 7802851 more JJR B-NP O
14 860 864 7802851 side NN I-NP O
15 864 865 7802851 - HYPH B-NP O
16 865 872 7802851 effects NNS I-NP O
17 872 873 7802851 , , O O
18 874 886 7802851 particularly RB B-ADVP O
19 887 895 7802851 sedation NN B-NP O
20 895 896 7802851 , , O O
21 897 909 7802851 irritability NN B-NP B-Disease
22 909 910 7802851 , , O O
23 911 919 7802851 impaired JJ B-NP B-Disease
24 920 926 7802851 memory NN I-NP I-Disease
25 926 927 7802851 , , O O
26 928 934 7802851 weight NN B-NP B-Disease
27 935 939 7802851 loss NN I-NP I-Disease
28 940 943 7802851 and CC I-NP O
29 944 950 7802851 ataxia NN I-NP B-Disease
30 950 951 7802851 . . O O

1 952 956 7802851 Side NN B-NP O
2 956 957 7802851 - HYPH I-NP O
3 957 964 7802851 effects NNS I-NP O
4 965 971 7802851 tended VBD B-VP O
5 972 974 7802851 to TO I-VP O
6 975 983 7802851 diminish VB I-VP O
7 984 990 7802851 during IN B-PP O
8 991 1000 7802851 treatment NN B-NP O
9 1001 1004 7802851 but CC O O
10 1005 1013 7802851 remained VBD B-VP O
11 1014 1025 7802851 significant JJ B-ADJP O
12 1026 1028 7802851 at IN B-PP O
13 1029 1033 7802851 week NN B-NP O
14 1034 1035 7802851 8 CD I-NP O
15 1035 1036 7802851 . . O O

1 1037 1044 7802851 Despite IN B-PP O
2 1045 1049 7802851 this DT B-NP O
3 1049 1050 7802851 , , O O
4 1051 1054 7802851 the DT B-NP O
5 1055 1059 7802851 drop VB I-NP O
6 1059 1060 7802851 - HYPH B-VP O
7 1060 1063 7802851 out RP B-PRT O
8 1064 1068 7802851 rate NN B-NP O
9 1069 1072 7802851 was VBD B-VP O
10 1073 1076 7802851 low JJ B-ADJP O
11 1076 1077 7802851 . . O O

1 1078 1089 7802851 CONCLUSIONS NNS B-NP O
2 1089 1090 7802851 : : O O
3 1091 1101 7802851 Alprazolam NN B-NP B-Chemical
4 1102 1108 7802851 caused VBD B-VP O
5 1109 1113 7802851 side NN B-NP O
6 1113 1114 7802851 - HYPH B-NP O
7 1114 1121 7802851 effects NNS I-NP O
8 1122 1125 7802851 and CC O O
9 1126 1133 7802851 adverse JJ B-NP O
10 1134 1141 7802851 effects NNS I-NP O
11 1142 1148 7802851 during IN B-PP O
12 1149 1158 7802851 treatment NN B-NP O
13 1159 1162 7802851 but CC O O
14 1163 1167 7802851 many JJ B-NP O
15 1168 1176 7802851 patients NNS I-NP O
16 1177 1181 7802851 were VBD B-VP O
17 1182 1189 7802851 willing JJ B-ADJP O
18 1190 1192 7802851 to TO B-VP O
19 1193 1199 7802851 accept VB I-VP O
20 1200 1205 7802851 these DT B-NP O
21 1205 1206 7802851 . . O O

1 0 0 9698967 -DOCSTART- -X- -X- O

1 0 2 9698967 An DT B-NP O
2 3 10 9698967 unusual JJ I-NP O
3 11 16 9698967 toxic JJ I-NP O
4 17 25 9698967 reaction NN I-NP O
5 26 28 9698967 to TO B-PP O
6 29 37 9698967 axillary JJ B-NP O
7 38 43 9698967 block NN I-NP O
8 44 46 9698967 by IN B-PP O
9 47 58 9698967 mepivacaine NN B-NP B-Chemical
10 59 63 9698967 with IN B-PP O
11 64 74 9698967 adrenaline NN B-NP B-Chemical
12 74 75 9698967 . . O O
13 76 78 9698967 An DT B-NP O
14 79 87 9698967 increase NN I-NP B-Disease
15 88 90 9698967 in IN B-PP I-Disease
16 91 96 9698967 blood NN B-NP I-Disease
17 97 105 9698967 pressure NN I-NP I-Disease
18 105 106 9698967 , , O O
19 107 118 9698967 accompanied VBN B-VP O
20 119 121 9698967 by IN B-PP O
21 122 128 9698967 atrial JJ B-NP B-Disease
22 129 141 9698967 fibrillation NN I-NP I-Disease
23 141 142 9698967 , , O O
24 143 152 9698967 agitation NN B-NP B-Disease
25 152 153 9698967 , , O O
26 154 170 9698967 incomprehensible JJ B-NP B-Disease
27 171 177 9698967 shouts NNS I-NP I-Disease
28 178 181 9698967 and CC O O
29 182 186 9698967 loss NN B-NP B-Disease
30 187 189 9698967 of IN B-PP I-Disease
31 190 203 9698967 consciousness NN B-NP I-Disease
32 203 204 9698967 , , O O
33 205 208 9698967 was VBD B-VP O
34 209 217 9698967 observed VBN I-VP O
35 218 220 9698967 in IN B-PP O
36 221 223 9698967 an DT B-NP O
37 224 231 9698967 elderly JJ I-NP O
38 231 232 9698967 , , I-NP O
39 233 236 9698967 ASA NN I-NP O
40 237 251 9698967 classification NN I-NP O
41 252 257 9698967 group NN I-NP O
42 258 260 9698967 II CD I-NP O
43 260 261 9698967 , , O O
44 262 278 9698967 cardiovascularly RB B-NP O
45 279 288 9698967 medicated VBN I-NP O
46 289 293 9698967 male NN I-NP O
47 293 294 9698967 , , O O
48 295 297 9698967 12 CD B-NP O
49 298 301 9698967 min NN I-NP O
50 302 307 9698967 after IN B-PP O
51 308 319 9698967 performance NN B-NP O
52 320 322 9698967 of IN B-PP O
53 323 331 9698967 axillary JJ B-NP O
54 332 337 9698967 block NN I-NP O
55 338 342 9698967 with IN B-PP O
56 343 354 9698967 mepivacaine NN B-NP B-Chemical
57 355 358 9698967 850 CD I-NP O
58 359 361 9698967 mg NN I-NP O
59 362 372 9698967 containing VBG B-VP O
60 373 383 9698967 adrenaline NN B-NP B-Chemical
61 384 389 9698967 0.225 CD I-NP O
62 390 392 9698967 mg NN I-NP O
63 392 393 9698967 , , O O
64 394 397 9698967 for IN B-PP O
65 398 408 9698967 correction NN B-NP O
66 409 411 9698967 of IN B-PP O
67 412 423 9698967 Dupuytren's NNS B-NP B-Disease
68 424 435 9698967 contracture NN I-NP I-Disease
69 435 436 9698967 . . O O

1 437 442 9698967 After IN B-PP O
2 443 454 9698967 intravenous JJ B-NP O
3 455 469 9698967 administration NN I-NP O
4 470 472 9698967 of IN B-PP O
5 473 482 9698967 labetalol NN B-NP B-Chemical
6 482 483 9698967 , , O O
7 484 494 9698967 metoprolol NN B-NP B-Chemical
8 495 498 9698967 and CC O O
9 499 508 9698967 midazolam NN B-NP B-Chemical
10 509 512 9698967 the DT B-NP O
11 513 522 9698967 patient's NNS I-NP O
12 523 532 9698967 condition NN I-NP O
13 533 541 9698967 improved VBD B-VP O
14 541 542 9698967 , , O O
15 543 546 9698967 and CC O O
16 547 549 9698967 15 CD B-NP O
17 550 553 9698967 min NN I-NP O
18 554 559 9698967 later RB B-ADVP O
19 560 562 9698967 he PRP B-NP O
20 563 567 9698967 woke VBD B-VP O
21 568 570 9698967 up RP B-PRT O
22 570 571 9698967 . . O O

1 572 575 9698967 The DT B-NP O
2 576 581 9698967 block NN I-NP O
3 582 585 9698967 was VBD B-VP O
4 586 596 9698967 successful JJ B-ADJP O
5 597 600 9698967 and CC O O
6 601 608 9698967 surgery NN B-NP O
7 609 612 9698967 was VBD B-VP O
8 613 622 9698967 conducted VBN I-VP O
9 623 625 9698967 as IN B-SBAR O
10 626 635 9698967 scheduled VBN B-VP O
11 636 643 9698967 despite IN B-PP O
12 644 654 9698967 persisting VBG B-VP O
13 655 661 9698967 atrial JJ B-NP B-Disease
14 662 674 9698967 fibrillation NN I-NP I-Disease
15 674 675 9698967 . . O O

1 676 691 9698967 Postoperatively RB B-ADVP O
2 691 692 9698967 , , O O
3 693 696 9698967 the DT B-NP O
4 697 704 9698967 patient NN I-NP O
5 705 712 9698967 refused VBD B-VP O
6 713 715 9698967 DC NN B-NP O
7 716 729 9698967 cardioversion NN I-NP O
8 730 733 9698967 and CC O O
9 734 737 9698967 was VBD B-VP O
10 738 745 9698967 treated VBN I-VP O
11 746 755 9698967 medically RB B-ADVP O
12 755 756 9698967 . . O O

1 757 761 9698967 Both CC O O
2 762 765 9698967 the DT B-NP O
3 766 774 9698967 temporal JJ I-NP O
4 775 787 9698967 relationship NN I-NP O
5 788 790 9698967 of IN B-PP O
6 791 797 9698967 events NNS B-NP O
7 798 801 9698967 and CC O O
8 802 805 9698967 the DT B-NP O
9 806 814 9698967 response NN I-NP O
10 815 817 9698967 to TO B-PP O
11 818 827 9698967 treatment NN B-NP O
12 828 835 9698967 suggest VBP B-VP O
13 836 840 9698967 that IN B-SBAR O
14 841 842 9698967 a DT B-NP O
15 843 848 9698967 rapid JJ I-NP O
16 849 857 9698967 systemic JJ I-NP O
17 858 868 9698967 absorption NN I-NP O
18 869 871 9698967 of IN B-PP O
19 872 883 9698967 mepivacaine NN B-NP B-Chemical
20 884 888 9698967 with IN B-PP O
21 889 899 9698967 adrenaline NN B-NP B-Chemical
22 900 903 9698967 and CC O O
23 903 904 9698967 / SYM B-NP O
24 904 906 9698967 or CC O O
25 907 918 9698967 interaction NN B-NP O
26 919 921 9698967 of IN B-PP O
27 922 927 9698967 these DT B-NP O
28 928 933 9698967 drugs NNS I-NP O
29 934 938 9698967 with IN B-PP O
30 939 942 9698967 the DT B-NP O
31 943 952 9698967 patient's NNS I-NP O
32 953 967 9698967 cardiovascular JJ B-NP O
33 968 979 9698967 medications NNS I-NP O
34 980 984 9698967 were VBD B-VP O
35 985 996 9698967 responsible JJ B-ADJP O
36 997 1000 9698967 for IN B-PP O
37 1001 1004 9698967 the DT B-NP O
38 1005 1018 9698967 perioperative JJ I-NP O
39 1019 1032 9698967 complications NNS I-NP O
40 1032 1033 9698967 . . O O

1 0 0 983936 -DOCSTART- -X- -X- O

1 0 7 983936 Effects NNS B-NP O
2 8 10 983936 of IN B-PP O
3 11 26 983936 acetylsalicylic JJ B-NP B-Chemical
4 27 31 983936 acid NN I-NP I-Chemical
5 31 32 983936 , , O O
6 33 45 983936 dipyridamole NN B-NP B-Chemical
7 45 46 983936 , , O O
8 47 50 983936 and CC O O
9 51 65 983936 hydrocortisone NN B-NP B-Chemical
10 66 68 983936 on IN B-PP O
11 69 80 983936 epinephrine NN B-NP B-Chemical
12 80 81 983936 - HYPH B-NP O
13 81 88 983936 induced VBN I-NP O
14 89 99 983936 myocardial JJ I-NP B-Disease
15 100 106 983936 injury NN I-NP I-Disease
16 107 109 983936 in IN B-PP O
17 110 114 983936 dogs NNS B-NP O
18 114 115 983936 . . O O
19 116 117 983936 A DT B-NP O
20 118 130 983936 reproducible JJ I-NP O
21 131 136 983936 model NN I-NP O
22 137 140 983936 for IN B-PP O
23 141 150 983936 producing VBG B-VP O
24 151 158 983936 diffuse JJ B-NP O
25 159 169 983936 myocardial JJ I-NP B-Disease
26 170 176 983936 injury NN I-NP I-Disease
27 177 178 983936 ( ( O O
28 178 189 983936 epinephrine NN B-NP B-Chemical
29 190 198 983936 infusion NN I-NP O
30 198 199 983936 ) ) O O
31 200 203 983936 has VBZ B-VP O
32 204 208 983936 been VBN I-VP O
33 209 218 983936 developed VBN I-VP O
34 219 221 983936 to TO I-VP O
35 222 227 983936 study VB I-VP O
36 228 231 983936 the DT B-NP O
37 232 248 983936 cardioprotective JJ I-NP O
38 249 256 983936 effects NNS I-NP O
39 257 259 983936 of IN B-PP O
40 260 266 983936 agents NNS B-NP O
41 267 269 983936 or CC I-NP O
42 270 279 983936 maneuvers NNS I-NP O
43 280 285 983936 which WDT B-NP O
44 286 291 983936 might MD B-VP O
45 292 297 983936 alter VB I-VP O
46 298 301 983936 the DT B-NP O
47 302 311 983936 evolution NN I-NP O
48 312 314 983936 of IN B-PP O
49 315 320 983936 acute JJ B-NP O
50 321 331 983936 myocardial JJ I-NP B-Disease
51 332 342 983936 infarction NN I-NP I-Disease
52 342 343 983936 . . O O

1 344 353 983936 Infusions NNS B-NP O
2 354 356 983936 of IN B-PP O
3 357 368 983936 epinephrine NN B-NP B-Chemical
4 369 370 983936 ( ( O O
5 370 371 983936 4 CD B-NP O
6 372 375 983936 mug NN I-NP O
7 376 379 983936 per IN B-PP O
8 380 388 983936 kilogram NN B-NP O
9 389 392 983936 per IN B-PP O
10 393 399 983936 minute NN B-NP O
11 400 403 983936 for IN B-PP O
12 404 405 983936 6 CD B-NP O
13 406 411 983936 hours NNS I-NP O
14 411 412 983936 ) ) O O
15 413 422 983936 increased VBN B-NP O
16 423 435 983936 radiocalcium NN I-NP B-Chemical
17 436 443 983936 uptakes VBZ B-VP O
18 444 448 983936 into IN B-PP O
19 449 455 983936 intact JJ B-NP O
20 456 466 983936 myocardium NN I-NP O
21 467 470 983936 and CC O O
22 471 475 983936 each DT B-NP O
23 476 478 983936 of IN B-PP O
24 479 482 983936 its PRP$ B-NP O
25 483 494 983936 subcellular JJ I-NP O
26 495 505 983936 components NNS I-NP O
27 506 510 983936 with IN B-PP O
28 511 514 983936 the DT B-NP O
29 515 528 983936 mitochondrial JJ I-NP O
30 529 537 983936 fraction NN I-NP O
31 538 545 983936 showing VBG B-VP O
32 546 549 983936 the DT B-NP O
33 550 554 983936 most RBS I-NP O
34 555 565 983936 consistent JJ I-NP O
35 566 573 983936 changes NNS I-NP O
36 574 578 983936 when WRB B-ADVP O
37 579 587 983936 compared VBN B-VP O
38 588 590 983936 to TO B-PP O
39 591 597 983936 saline NN B-NP O
40 597 598 983936 - HYPH O O
41 598 605 983936 infused VBN B-NP O
42 606 613 983936 control NN I-NP O
43 614 621 983936 animals NNS I-NP O
44 622 623 983936 ( ( O O
45 623 628 983936 4,957 CD B-NP O
46 629 631 983936 vs NNS I-NP O
47 631 632 983936 . . O O
48 633 636 983936 827 CD B-NP O
49 637 643 983936 counts NNS I-NP O
50 644 647 983936 per IN B-PP O
51 648 654 983936 minute NN B-NP O
52 655 658 983936 per IN B-PP O
53 659 663 983936 gram NN B-NP O
54 664 666 983936 of IN B-PP O
55 667 672 983936 dried VBN B-NP O
56 673 679 983936 tissue NN I-NP O
57 680 682 983936 or CC I-NP O
58 683 691 983936 fraction NN I-NP O
59 691 692 983936 ) ) O O
60 692 693 983936 . . O O

1 694 704 983936 Myocardial JJ B-NP O
2 705 719 983936 concentrations NNS I-NP O
3 720 722 983936 of IN B-PP O
4 723 730 983936 calcium NN B-NP B-Chemical
5 731 735 983936 also RB B-ADVP O
6 736 745 983936 increased VBD B-VP O
7 746 759 983936 significantly RB B-ADVP O
8 760 761 983936 ( ( O O
9 761 765 983936 12.0 CD B-NP O
10 766 768 983936 vs NNS I-NP O
11 768 769 983936 . . O O
12 770 773 983936 5.0 CD B-NP O
13 774 780 983936 mg.per NN I-NP O
14 781 784 983936 100 CD B-NP O
15 785 787 983936 Gm NN I-NP O
16 787 788 983936 . . O O
17 789 791 983936 of IN B-PP O
18 792 795 983936 fat JJ B-NP O
19 795 796 983936 - HYPH I-NP O
20 796 800 983936 free JJ I-NP O
21 801 804 983936 dry JJ I-NP O
22 805 811 983936 weight NN I-NP O
23 811 812 983936 ) ) O O
24 812 813 983936 . . O O

1 814 823 983936 Infusions NNS B-NP O
2 824 826 983936 of IN B-PP O
3 827 834 983936 calcium NN B-NP B-Chemical
4 835 843 983936 chloride NN I-NP I-Chemical
5 844 854 983936 sufficient JJ B-ADJP O
6 855 857 983936 to TO B-VP O
7 858 863 983936 raise VB I-VP O
8 864 869 983936 serum NN B-NP O
9 870 877 983936 calcium NN I-NP B-Chemical
10 878 892 983936 concentrations NNS I-NP O
11 893 894 983936 2 CD B-NP O
12 895 898 983936 mEq NN I-NP O
13 898 899 983936 . . O O
14 900 903 983936 per IN B-PP O
15 904 909 983936 liter NN B-NP O
16 910 916 983936 failed VBD B-VP O
17 917 919 983936 to TO I-VP O
18 920 928 983936 increase VB I-VP O
19 929 936 983936 calcium NN B-NP B-Chemical
20 937 943 983936 influx NN I-NP O
21 944 948 983936 into IN B-PP O
22 949 952 983936 the DT B-NP O
23 953 963 983936 myocardial JJ I-NP O
24 964 968 983936 cell NN I-NP O
25 968 969 983936 . . O O

1 970 983 983936 Mitochondrial JJ B-NP O
2 984 996 983936 radiocalcium NN I-NP B-Chemical
3 997 1004 983936 uptakes NNS I-NP O
4 1005 1009 983936 were VBD B-VP O
5 1010 1023 983936 significantly RB I-VP O
6 1024 1033 983936 decreased VBN I-VP O
7 1034 1036 983936 in IN B-PP O
8 1037 1044 983936 animals NNS B-NP O
9 1045 1055 983936 pretreated VBN B-VP O
10 1056 1060 983936 with IN B-PP O
11 1061 1076 983936 acetylsalicylic JJ B-NP B-Chemical
12 1077 1081 983936 acid NN I-NP I-Chemical
13 1082 1084 983936 or CC O O
14 1085 1097 983936 dipyridamole NN B-NP B-Chemical
15 1098 1100 983936 or CC O O
16 1101 1105 983936 when WRB B-ADVP O
17 1106 1120 983936 hydrocortisone NN B-NP B-Chemical
18 1121 1124 983936 was VBD B-VP O
19 1125 1130 983936 added VBN I-VP O
20 1131 1133 983936 to TO B-PP O
21 1134 1137 983936 the DT B-NP O
22 1138 1149 983936 epinephrine NN I-NP B-Chemical
23 1150 1158 983936 infusion NN I-NP O
24 1159 1160 983936 ( ( O O
25 1160 1171 983936 2,682,2,803 CD B-NP O
26 1171 1172 983936 , , O O
27 1173 1176 983936 and CC O O
28 1177 1182 983936 3,424 CD B-NP O
29 1183 1189 983936 counts NNS I-NP O
30 1190 1193 983936 per IN B-PP O
31 1194 1200 983936 minute NN B-NP O
32 1201 1204 983936 per IN B-PP O
33 1205 1209 983936 gram NN B-NP O
34 1210 1212 983936 of IN B-PP O
35 1213 1218 983936 dried VBN B-NP O
36 1219 1227 983936 fraction NN I-NP O
37 1227 1228 983936 , , O O
38 1229 1241 983936 respectively RB B-ADVP O
39 1241 1242 983936 ) ) O O
40 1242 1243 983936 . . O O

1 1244 1254 983936 Myocardial JJ B-NP O
2 1255 1262 983936 calcium NN I-NP B-Chemical
3 1263 1277 983936 concentrations NNS I-NP O
4 1278 1282 983936 also RB B-ADVP O
5 1283 1287 983936 were VBD B-VP O
6 1288 1297 983936 decreased VBN I-VP O
7 1298 1299 983936 ( ( O O
8 1299 1303 983936 11.2 CD B-NP O
9 1303 1304 983936 , , I-NP O
10 1305 1308 983936 8.3 CD I-NP O
11 1308 1309 983936 , , O O
12 1310 1313 983936 and CC O O
13 1314 1317 983936 8.9 CD B-NP O
14 1318 1320 983936 mg NN I-NP O
15 1320 1321 983936 . . O O

1 1322 1325 983936 per IN B-PP O
2 1326 1329 983936 100 CD B-NP O
3 1330 1332 983936 Gm NN I-NP O
4 1332 1333 983936 . . O O
5 1334 1336 983936 of IN B-PP O
6 1337 1340 983936 fat JJ B-NP O
7 1340 1341 983936 - HYPH I-NP O
8 1341 1345 983936 free JJ I-NP O
9 1346 1349 983936 dry JJ I-NP O
10 1350 1356 983936 weight NN I-NP O
11 1356 1357 983936 , , O O
12 1358 1370 983936 respectively RB B-ADVP O
13 1370 1371 983936 ) ) O O
14 1372 1374 983936 in IN B-PP O
15 1375 1378 983936 the DT B-NP O
16 1379 1384 983936 three CD I-NP O
17 1385 1394 983936 treatment NN I-NP O
18 1395 1401 983936 groups NNS I-NP O
19 1401 1402 983936 , , O O
20 1403 1408 983936 being VBG B-VP O
21 1409 1422 983936 significantly RB I-VP O
22 1423 1432 983936 decreased VBN I-VP O
23 1433 1437 983936 only RB B-ADVP O
24 1438 1440 983936 in IN B-PP O
25 1441 1444 983936 the DT B-NP O
26 1445 1449 983936 last JJ I-NP O
27 1450 1453 983936 two CD I-NP O
28 1453 1454 983936 . . O O

1 1455 1463 983936 Evidence NN B-NP O
2 1464 1466 983936 of IN B-PP O
3 1467 1478 983936 microscopic JJ B-NP O
4 1479 1485 983936 damage NN I-NP O
5 1486 1489 983936 was VBD B-VP O
6 1490 1496 983936 graded VBN I-VP O
7 1497 1499 983936 as IN B-PP O
8 1500 1504 983936 less RBR B-ADJP O
9 1505 1511 983936 severe JJ I-ADJP O
10 1512 1514 983936 in IN B-PP O
11 1515 1518 983936 the DT B-NP O
12 1519 1524 983936 three CD I-NP O
13 1525 1534 983936 treatment NN I-NP O
14 1535 1541 983936 groups NNS I-NP O
15 1541 1542 983936 . . O O

1 1543 1558 983936 Acetylsalicylic JJ B-NP B-Chemical
2 1559 1563 983936 acid NN I-NP I-Chemical
3 1563 1564 983936 , , O O
4 1565 1577 983936 dipyridamole NN B-NP B-Chemical
5 1577 1578 983936 , , O O
6 1579 1582 983936 and CC O O
7 1583 1597 983936 hydrocortisone NN B-NP B-Chemical
8 1598 1601 983936 all DT O O
9 1602 1608 983936 appear VBP B-VP O
10 1609 1611 983936 to TO I-VP O
11 1612 1616 983936 have VB I-VP O
12 1617 1633 983936 cardioprotective JJ B-NP O
13 1634 1641 983936 effects NNS I-NP O
14 1642 1646 983936 when WRB B-ADVP O
15 1647 1653 983936 tested VBN B-VP O
16 1654 1656 983936 in IN B-PP O
17 1657 1661 983936 this DT B-NP O
18 1662 1667 983936 model NN I-NP O
19 1667 1668 983936 . . O O

1 0 0 9195768 -DOCSTART- -X- -X- O

1 0 3 9195768 The DT B-NP O
2 4 8 9195768 site NN I-NP O
3 9 11 9195768 of IN B-PP O
4 12 18 9195768 common JJ B-NP O
5 19 23 9195768 side NN I-NP O
6 24 31 9195768 effects NNS I-NP O
7 32 34 9195768 of IN B-PP O
8 35 46 9195768 sumatriptan NN B-NP B-Chemical
9 46 47 9195768 . . O O
10 48 56 9195768 Atypical JJ B-NP B-Disease
11 57 67 9195768 sensations NNS I-NP I-Disease
12 68 77 9195768 following VBG B-PP O
13 78 81 9195768 the DT B-NP O
14 82 85 9195768 use NN I-NP O
15 86 88 9195768 of IN B-PP O
16 89 101 9195768 subcutaneous JJ B-NP O
17 102 113 9195768 sumatriptan NN I-NP B-Chemical
18 114 117 9195768 are VBP B-VP O
19 118 124 9195768 common JJ B-ADJP O
20 124 125 9195768 , , O O
21 126 129 9195768 but CC O O
22 130 132 9195768 of IN B-PP O
23 133 142 9195768 uncertain JJ B-NP O
24 143 149 9195768 origin NN I-NP O
25 149 150 9195768 . . O O

1 151 155 9195768 They PRP B-NP O
2 156 159 9195768 are VBP B-VP O
3 160 166 9195768 almost RB B-ADJP O
4 167 173 9195768 always RB I-ADJP O
5 174 180 9195768 benign JJ I-ADJP O
6 180 181 9195768 , , O O
7 182 185 9195768 but CC O O
8 186 189 9195768 can MD B-VP O
9 190 192 9195768 be VB I-VP O
10 193 201 9195768 mistaken VBN I-VP O
11 202 205 9195768 for IN B-PP O
12 206 207 9195768 a DT B-NP O
13 208 215 9195768 serious JJ I-NP O
14 216 223 9195768 adverse JJ I-NP O
15 224 229 9195768 event NN I-NP O
16 230 232 9195768 by IN B-PP O
17 233 236 9195768 the DT B-NP O
18 237 244 9195768 patient NN I-NP O
19 244 245 9195768 . . O O

1 246 249 9195768 Two CD B-NP O
2 250 258 9195768 patients NNS I-NP O
3 259 262 9195768 are VBP B-VP O
4 263 272 9195768 presented VBN I-VP O
5 273 277 9195768 with IN B-PP O
6 278 286 9195768 tingling VBG B-VP B-Disease
7 287 289 9195768 or CC I-VP I-Disease
8 290 297 9195768 burning VBG I-VP I-Disease
9 298 308 9195768 sensations NNS B-NP I-Disease
10 309 316 9195768 limited VBN B-VP O
11 317 319 9195768 to TO B-PP O
12 320 325 9195768 areas NNS B-NP O
13 326 328 9195768 of IN B-PP O
14 329 333 9195768 heat NN B-NP O
15 334 342 9195768 exposure NN I-NP O
16 343 345 9195768 or CC I-NP O
17 346 353 9195768 sunburn NN I-NP B-Disease
18 353 354 9195768 . . O O

1 355 357 9195768 In IN B-PP O
2 358 363 9195768 these DT B-NP O
3 364 375 9195768 individuals NNS I-NP O
4 375 376 9195768 , , O O
5 377 381 9195768 side NN B-NP O
6 382 389 9195768 effects NNS I-NP O
7 390 393 9195768 are VBP B-VP O
8 394 398 9195768 most RBS I-VP O
9 399 405 9195768 likely RB I-VP O
10 406 415 9195768 generated VBN I-VP O
11 416 429 9195768 superficially RB B-ADVP O
12 430 432 9195768 in IN B-PP O
13 433 436 9195768 the DT B-NP O
14 437 441 9195768 skin NN I-NP O
15 441 442 9195768 . . O O

1 0 0 17261653 -DOCSTART- -X- -X- O

1 0 6 17261653 Direct JJ B-NP O
2 7 17 17261653 inhibition NN I-NP O
3 18 20 17261653 of IN B-PP O
4 21 28 17261653 cardiac JJ B-NP O
5 29 46 17261653 hyperpolarization NN I-NP O
6 46 47 17261653 - HYPH O O
7 47 56 17261653 activated VBN B-VP O
8 57 63 17261653 cyclic JJ B-NP B-Chemical
9 64 74 17261653 nucleotide NN I-NP I-Chemical
10 74 75 17261653 - HYPH B-VP O
11 75 80 17261653 gated VBN B-NP O
12 81 90 17261653 pacemaker NN I-NP O
13 91 99 17261653 channels NNS I-NP O
14 100 102 17261653 by IN B-PP O
15 103 112 17261653 clonidine NN B-NP B-Chemical
16 112 113 17261653 . . O O
17 114 124 17261653 BACKGROUND NN B-NP O
18 124 125 17261653 : : O O
19 126 136 17261653 Inhibition NN B-NP O
20 137 139 17261653 of IN B-PP O
21 140 147 17261653 cardiac JJ B-NP O
22 148 159 17261653 sympathetic JJ I-NP O
23 160 164 17261653 tone NN I-NP O
24 165 175 17261653 represents VBZ B-VP O
25 176 178 17261653 an DT B-NP O
26 179 188 17261653 important JJ I-NP O
27 189 197 17261653 strategy NN I-NP O
28 198 201 17261653 for IN B-PP O
29 202 211 17261653 treatment NN B-NP O
30 212 214 17261653 of IN B-PP O
31 215 229 17261653 cardiovascular JJ B-NP B-Disease
32 230 237 17261653 disease NN I-NP I-Disease
33 237 238 17261653 , , O O
34 239 248 17261653 including VBG B-PP O
35 249 259 17261653 arrhythmia NN B-NP B-Disease
36 259 260 17261653 , , O O
37 261 269 17261653 coronary JJ B-NP B-Disease
38 270 275 17261653 heart NN I-NP I-Disease
39 276 283 17261653 disease NN I-NP I-Disease
40 283 284 17261653 , , O O
41 285 288 17261653 and CC O O
42 289 296 17261653 chronic JJ B-NP O
43 297 302 17261653 heart NN I-NP B-Disease
44 303 310 17261653 failure NN I-NP I-Disease
45 310 311 17261653 . . O O

1 312 322 17261653 Activation NN B-NP O
2 323 325 17261653 of IN B-PP O
3 326 337 17261653 presynaptic JJ B-NP O
4 338 344 17261653 alpha2 NN I-NP O
5 344 345 17261653 - HYPH B-NP O
6 345 358 17261653 adrenoceptors NNS I-NP O
7 359 361 17261653 is VBZ B-VP O
8 362 365 17261653 the DT B-NP O
9 366 370 17261653 most RBS I-NP O
10 371 377 17261653 widely RB I-NP O
11 378 386 17261653 accepted VBN I-NP O
12 387 396 17261653 mechanism NN I-NP O
13 397 399 17261653 of IN B-PP O
14 400 406 17261653 action NN B-NP O
15 407 409 17261653 of IN B-PP O
16 410 413 17261653 the DT B-NP O
17 414 429 17261653 antisympathetic JJ I-NP O
18 430 434 17261653 drug NN I-NP O
19 435 444 17261653 clonidine NN I-NP B-Chemical
20 444 445 17261653 ; : O O
21 446 453 17261653 however RB B-ADVP O
22 453 454 17261653 , , O O
23 455 460 17261653 other JJ B-NP O
24 461 467 17261653 target NN I-NP O
25 468 476 17261653 proteins NNS I-NP O
26 477 481 17261653 have VBP B-VP O
27 482 486 17261653 been VBN I-VP O
28 487 497 17261653 postulated VBN I-VP O
29 498 500 17261653 to TO I-VP O
30 501 511 17261653 contribute VB I-VP O
31 512 514 17261653 to TO B-PP O
32 515 518 17261653 the DT B-NP O
33 519 521 17261653 in FW I-NP O
34 522 526 17261653 vivo FW I-NP O
35 527 534 17261653 actions NNS I-NP O
36 535 537 17261653 of IN B-PP O
37 538 547 17261653 clonidine NN B-NP B-Chemical
38 547 548 17261653 . . O O

1 549 556 17261653 METHODS NNS B-NP O
2 557 560 17261653 AND CC I-NP O
3 561 568 17261653 RESULTS NNS I-NP O
4 568 569 17261653 : : O O
5 570 572 17261653 To TO B-VP O
6 573 577 17261653 test VB I-VP O
7 578 585 17261653 whether IN B-SBAR O
8 586 595 17261653 clonidine NN B-NP B-Chemical
9 596 603 17261653 elicits VBZ B-VP O
10 604 619 17261653 pharmacological JJ B-NP O
11 620 627 17261653 effects NNS I-NP O
12 628 639 17261653 independent JJ B-ADJP O
13 640 642 17261653 of IN B-PP O
14 643 649 17261653 alpha2 NN B-NP O
15 649 650 17261653 - HYPH B-NP O
16 650 663 17261653 adrenoceptors NNS I-NP O
17 663 664 17261653 , , O O
18 665 667 17261653 we PRP B-NP O
19 668 672 17261653 have VBP B-VP O
20 673 682 17261653 generated VBN I-VP O
21 683 687 17261653 mice NNS B-NP O
22 688 692 17261653 with IN B-PP O
23 693 694 17261653 a DT B-NP O
24 695 703 17261653 targeted VBN I-NP O
25 704 712 17261653 deletion NN I-NP O
26 713 715 17261653 of IN B-PP O
27 716 719 17261653 all DT B-NP O
28 720 721 17261653 3 CD I-NP O
29 722 728 17261653 alpha2 NN I-NP O
30 728 729 17261653 - HYPH O O
31 729 741 17261653 adrenoceptor NN B-NP O
32 742 750 17261653 subtypes NNS I-NP O
33 751 752 17261653 ( ( O O
34 752 761 17261653 alpha2ABC NN B-NP O
35 761 762 17261653 - HYPH O O
36 762 763 17261653 / SYM B-NP O
37 763 764 17261653 - SYM B-NP O
38 764 765 17261653 ) ) O O
39 765 766 17261653 . . O O

1 767 776 17261653 Alpha2ABC NN B-NP O
2 776 777 17261653 - HYPH O O
3 777 778 17261653 / SYM O O
4 778 779 17261653 - HYPH O O
5 780 784 17261653 mice NNS B-NP O
6 785 789 17261653 were VBD B-VP O
7 790 800 17261653 completely RB B-ADJP O
8 801 813 17261653 unresponsive JJ I-ADJP O
9 814 816 17261653 to TO B-PP O
10 817 820 17261653 the DT B-NP O
11 821 830 17261653 analgesic JJ I-NP O
12 831 834 17261653 and CC I-NP O
13 835 843 17261653 hypnotic JJ I-NP O
14 844 851 17261653 effects NNS I-NP O
15 852 854 17261653 of IN B-PP O
16 855 864 17261653 clonidine NN B-NP B-Chemical
17 864 865 17261653 ; : O O
18 866 873 17261653 however RB B-ADVP O
19 873 874 17261653 , , O O
20 875 884 17261653 clonidine NN B-NP B-Chemical
21 885 898 17261653 significantly RB B-ADVP O
22 899 906 17261653 lowered VBD B-VP O
23 907 912 17261653 heart NN B-NP O
24 913 917 17261653 rate NN I-NP O
25 918 920 17261653 in IN B-PP O
26 921 930 17261653 alpha2ABC NN B-NP O
27 930 931 17261653 - HYPH O O
28 931 932 17261653 / SYM O O
29 932 933 17261653 - HYPH O O
30 934 938 17261653 mice NNS B-NP O
31 939 941 17261653 by IN B-PP O
32 942 944 17261653 up RB B-NP O
33 945 947 17261653 to TO I-NP O
34 948 951 17261653 150 CD I-NP O
35 952 955 17261653 bpm NN I-NP O
36 955 956 17261653 . . O O

1 957 966 17261653 Clonidine NN B-NP B-Chemical
2 966 967 17261653 - HYPH B-PP O
3 967 974 17261653 induced VBN B-NP O
4 975 986 17261653 bradycardia NN I-NP B-Disease
5 987 989 17261653 in IN B-PP O
6 990 999 17261653 conscious JJ B-NP O
7 1000 1009 17261653 alpha2ABC NN I-NP O
8 1009 1010 17261653 - HYPH O O
9 1010 1011 17261653 / SYM O O
10 1011 1012 17261653 - HYPH O O
11 1013 1017 17261653 mice NNS B-NP O
12 1018 1021 17261653 was VBD B-VP O
13 1022 1027 17261653 32.3% CD B-NP O
14 1028 1029 17261653 ( ( O O
15 1029 1031 17261653 10 CD B-NP O
16 1032 1038 17261653 microg NN I-NP O
17 1038 1039 17261653 / SYM B-NP O
18 1039 1041 17261653 kg NN I-NP O
19 1041 1042 17261653 ) ) O O
20 1043 1046 17261653 and CC O O
21 1047 1052 17261653 26.6% CD B-NP O
22 1053 1054 17261653 ( ( O O
23 1054 1057 17261653 100 CD B-NP O
24 1058 1064 17261653 microg NN I-NP O
25 1064 1065 17261653 / SYM B-NP O
26 1065 1067 17261653 kg NN I-NP O
27 1067 1068 17261653 ) ) O O
28 1069 1071 17261653 of IN B-PP O
29 1072 1075 17261653 the DT B-NP O
30 1076 1082 17261653 effect NN I-NP O
31 1083 1085 17261653 in IN B-PP O
32 1086 1090 17261653 wild JJ B-NP O
33 1090 1091 17261653 - HYPH I-NP O
34 1091 1095 17261653 type NN I-NP O
35 1096 1100 17261653 mice NNS I-NP O
36 1100 1101 17261653 . . O O

1 1102 1103 17261653 A DT B-NP O
2 1104 1111 17261653 similar JJ I-NP O
3 1112 1123 17261653 bradycardic JJ I-NP O
4 1124 1130 17261653 effect NN I-NP O
5 1131 1133 17261653 of IN B-PP O
6 1134 1143 17261653 clonidine NN B-NP B-Chemical
7 1144 1147 17261653 was VBD B-VP O
8 1148 1156 17261653 observed VBN I-VP O
9 1157 1159 17261653 in IN B-PP O
10 1160 1168 17261653 isolated VBN B-VP O
11 1169 1182 17261653 spontaneously RB B-VP O
12 1183 1190 17261653 beating VBG I-VP O
13 1191 1196 17261653 right JJ B-NP O
14 1197 1202 17261653 atria NN I-NP O
15 1203 1207 17261653 from IN B-PP O
16 1208 1217 17261653 alpha2ABC NN B-NP O
17 1217 1218 17261653 - HYPH B-NP O
18 1218 1226 17261653 knockout NN I-NP O
19 1227 1230 17261653 and CC O O
20 1231 1235 17261653 wild JJ B-NP O
21 1235 1236 17261653 - HYPH I-NP O
22 1236 1240 17261653 type NN I-NP O
23 1241 1245 17261653 mice NNS I-NP O
24 1245 1246 17261653 . . O O

1 1247 1256 17261653 Clonidine NN B-NP B-Chemical
2 1257 1266 17261653 inhibited VBD B-VP O
3 1267 1270 17261653 the DT B-NP O
4 1271 1277 17261653 native JJ I-NP O
5 1278 1287 17261653 pacemaker NN I-NP O
6 1288 1295 17261653 current NN I-NP O
7 1296 1297 17261653 ( ( O O
8 1297 1301 17261653 I(f) NN B-NP O
9 1301 1302 17261653 ) ) O O
10 1303 1305 17261653 in IN B-PP O
11 1306 1314 17261653 isolated VBN B-NP O
12 1315 1325 17261653 sinoatrial JJ I-NP O
13 1326 1330 17261653 node NN I-NP O
14 1331 1340 17261653 pacemaker NN I-NP O
15 1341 1346 17261653 cells NNS I-NP O
16 1347 1350 17261653 and CC O O
17 1351 1354 17261653 the DT B-NP O
18 1355 1359 17261653 I(f) NN I-NP O
19 1359 1360 17261653 - HYPH O O
20 1360 1370 17261653 generating VBG B-VP O
21 1371 1388 17261653 hyperpolarization NN B-NP O
22 1388 1389 17261653 - HYPH O O
23 1389 1398 17261653 activated VBN B-VP O
24 1399 1405 17261653 cyclic JJ B-NP B-Chemical
25 1406 1416 17261653 nucleotide NN I-NP I-Chemical
26 1416 1417 17261653 - HYPH B-VP O
27 1417 1422 17261653 gated VBN I-VP O
28 1423 1424 17261653 ( ( O O
29 1424 1427 17261653 HCN NN B-NP O
30 1427 1428 17261653 ) ) O O
31 1429 1430 17261653 2 CD B-NP O
32 1431 1434 17261653 and CC O O
33 1435 1439 17261653 HCN4 NN B-NP O
34 1440 1448 17261653 channels NNS I-NP O
35 1449 1451 17261653 in IN B-PP O
36 1452 1463 17261653 transfected VBN B-NP O
37 1464 1470 17261653 HEK293 NN I-NP O
38 1471 1476 17261653 cells NNS I-NP O
39 1476 1477 17261653 . . O O

1 1478 1480 17261653 As IN B-PP O
2 1481 1482 17261653 a DT B-NP O
3 1483 1494 17261653 consequence NN I-NP O
4 1495 1497 17261653 of IN B-PP O
5 1498 1506 17261653 blocking VBG B-VP O
6 1507 1511 17261653 I(f) NN B-NP O
7 1511 1512 17261653 , , O O
8 1513 1522 17261653 clonidine NN B-NP B-Chemical
9 1523 1530 17261653 reduced VBD B-VP O
10 1531 1534 17261653 the DT B-NP O
11 1535 1540 17261653 slope NN I-NP O
12 1541 1543 17261653 of IN B-PP O
13 1544 1547 17261653 the DT B-NP O
14 1548 1557 17261653 diastolic JJ I-NP O
15 1558 1572 17261653 depolarization NN I-NP O
16 1573 1576 17261653 and CC O O
17 1577 1580 17261653 the DT B-NP O
18 1581 1590 17261653 frequency NN I-NP O
19 1591 1593 17261653 of IN B-PP O
20 1594 1603 17261653 pacemaker NN B-NP O
21 1604 1614 17261653 potentials NNS I-NP O
22 1615 1617 17261653 in IN B-PP O
23 1618 1628 17261653 sinoatrial JJ B-NP O
24 1629 1633 17261653 node NN I-NP O
25 1634 1639 17261653 cells NNS I-NP O
26 1640 1644 17261653 from IN B-PP O
27 1645 1649 17261653 wild JJ B-NP O
28 1649 1650 17261653 - HYPH I-NP O
29 1650 1654 17261653 type NN I-NP O
30 1655 1658 17261653 and CC I-NP O
31 1659 1668 17261653 alpha2ABC NN I-NP O
32 1668 1669 17261653 - HYPH B-NP O
33 1669 1677 17261653 knockout NN I-NP O
34 1678 1682 17261653 mice NNS I-NP O
35 1682 1683 17261653 . . O O

1 1684 1695 17261653 CONCLUSIONS NNS B-NP O
2 1695 1696 17261653 : : O O
3 1697 1703 17261653 Direct JJ B-NP O
4 1704 1714 17261653 inhibition NN I-NP O
5 1715 1717 17261653 of IN B-PP O
6 1718 1725 17261653 cardiac JJ B-NP O
7 1726 1729 17261653 HCN NN I-NP O
8 1730 1739 17261653 pacemaker NN I-NP O
9 1740 1748 17261653 channels NNS I-NP O
10 1749 1760 17261653 contributes VBZ B-VP O
11 1761 1763 17261653 to TO B-PP O
12 1764 1767 17261653 the DT B-NP O
13 1768 1779 17261653 bradycardic JJ I-NP O
14 1780 1787 17261653 effects NNS I-NP O
15 1788 1790 17261653 of IN B-PP O
16 1791 1800 17261653 clonidine NN B-NP B-Chemical
17 1801 1805 17261653 gene NN I-NP O
18 1805 1806 17261653 - HYPH B-NP O
19 1806 1814 17261653 targeted VBN I-NP O
20 1815 1819 17261653 mice NNS I-NP O
21 1820 1822 17261653 in FW B-ADVP O
22 1823 1827 17261653 vivo FW I-ADVP O
23 1827 1828 17261653 , , O O
24 1829 1832 17261653 and CC O O
25 1833 1837 17261653 thus RB O O
26 1837 1838 17261653 , , O O
27 1839 1848 17261653 clonidine NN B-NP B-Chemical
28 1848 1849 17261653 - HYPH B-NP O
29 1849 1853 17261653 like JJ I-NP O
30 1854 1859 17261653 drugs NNS I-NP O
31 1860 1869 17261653 represent VBP B-VP O
32 1870 1875 17261653 novel JJ B-NP O
33 1876 1886 17261653 structures NNS I-NP O
34 1887 1890 17261653 for IN B-PP O
35 1891 1897 17261653 future JJ B-NP O
36 1898 1901 17261653 HCN NN I-NP O
37 1902 1909 17261653 channel NN I-NP O
38 1910 1920 17261653 inhibitors NNS I-NP O
39 1920 1921 17261653 . . O O

1 0 0 9284778 -DOCSTART- -X- -X- O

1 0 8 9284778 Epidemic JJ B-NP O
2 9 11 9284778 of IN B-PP O
3 12 17 9284778 liver NN B-NP B-Disease
4 18 25 9284778 disease NN I-NP I-Disease
5 26 32 9284778 caused VBN B-VP O
6 33 35 9284778 by IN B-PP O
7 36 60 9284778 hydrochlorofluorocarbons NNS B-NP B-Chemical
8 61 65 9284778 used VBN B-VP O
9 66 68 9284778 as IN B-PP O
10 69 74 9284778 ozone NN B-NP B-Chemical
11 74 75 9284778 - HYPH O O
12 75 82 9284778 sparing VBG B-VP O
13 83 94 9284778 substitutes NNS B-NP O
14 95 97 9284778 of IN B-PP O
15 98 117 9284778 chlorofluorocarbons NNS B-NP B-Chemical
16 117 118 9284778 . . B-NP O
17 119 129 9284778 BACKGROUND NN I-NP O
18 129 130 9284778 : : O O
19 131 155 9284778 Hydrochlorofluorocarbons NNS B-NP B-Chemical
20 156 157 9284778 ( ( O O
21 157 162 9284778 HCFCs NNS B-NP B-Chemical
22 162 163 9284778 ) ) O O
23 164 167 9284778 are VBP B-VP O
24 168 172 9284778 used VBN I-VP O
25 173 185 9284778 increasingly RB B-ADVP O
26 186 188 9284778 in IN B-PP O
27 189 197 9284778 industry NN B-NP O
28 198 200 9284778 as IN B-PP O
29 201 212 9284778 substitutes NNS B-NP O
30 213 216 9284778 for IN B-PP O
31 217 222 9284778 ozone NN B-NP B-Chemical
32 222 223 9284778 - HYPH O O
33 223 232 9284778 depleting VBG B-VP O
34 233 252 9284778 chlorofluorocarbons NNS B-NP B-Chemical
35 253 254 9284778 ( ( O O
36 254 258 9284778 CFCs NNS B-NP B-Chemical
37 258 259 9284778 ) ) O O
38 259 260 9284778 . . O O

1 261 268 9284778 Limited JJ B-NP O
2 269 276 9284778 studies NNS I-NP O
3 277 279 9284778 in IN B-PP O
4 280 287 9284778 animals NNS B-NP O
5 288 296 9284778 indicate VBP B-VP O
6 297 306 9284778 potential JJ B-NP O
7 307 321 9284778 hepatotoxicity NN I-NP B-Disease
8 322 324 9284778 of IN B-PP O
9 325 329 9284778 some DT B-NP O
10 330 332 9284778 of IN B-PP O
11 333 338 9284778 these DT B-NP O
12 339 348 9284778 compounds NNS I-NP O
13 348 349 9284778 . . O O

1 350 352 9284778 We PRP B-NP O
2 353 365 9284778 investigated VBD B-VP O
3 366 368 9284778 an DT B-NP O
4 369 377 9284778 epidemic NN I-NP O
5 378 380 9284778 of IN B-PP O
6 381 386 9284778 liver NN B-NP B-Disease
7 387 394 9284778 disease NN I-NP I-Disease
8 395 397 9284778 in IN B-PP O
9 398 402 9284778 nine CD B-NP O
10 403 413 9284778 industrial JJ I-NP O
11 414 421 9284778 workers NNS I-NP O
12 422 425 9284778 who WP B-NP O
13 426 429 9284778 had VBD B-VP O
14 430 433 9284778 had VBN I-VP O
15 434 442 9284778 repeated VBN I-VP O
16 443 453 9284778 accidental JJ B-NP O
17 454 462 9284778 exposure NN I-NP O
18 463 465 9284778 to TO B-PP O
19 466 467 9284778 a DT B-NP O
20 468 475 9284778 mixture NN I-NP O
21 476 478 9284778 of IN B-PP O
22 479 482 9284778 1,1 CD B-NP B-Chemical
23 482 483 9284778 - HYPH O I-Chemical
24 483 491 9284778 dichloro AFX O I-Chemical
25 491 492 9284778 - HYPH B-NP I-Chemical
26 492 497 9284778 2,2,2 CD I-NP I-Chemical
27 497 498 9284778 - HYPH I-NP I-Chemical
28 498 513 9284778 trifluoroethane NN I-NP I-Chemical
29 514 515 9284778 ( ( O O
30 515 519 9284778 HCFC NN B-NP B-Chemical
31 520 523 9284778 123 CD I-NP I-Chemical
32 523 524 9284778 ) ) O O
33 525 528 9284778 and CC O O
34 529 530 9284778 1 CD B-NP B-Chemical
35 530 531 9284778 - HYPH I-NP I-Chemical
36 531 537 9284778 chloro NN I-NP I-Chemical
37 537 538 9284778 - HYPH B-NP I-Chemical
38 538 545 9284778 1,2,2,2 CD I-NP I-Chemical
39 545 546 9284778 - HYPH I-NP I-Chemical
40 546 563 9284778 tetrafluoroethane NN I-NP I-Chemical
41 564 565 9284778 ( ( O O
42 565 569 9284778 HCFC NN B-NP B-Chemical
43 570 573 9284778 124 CD I-NP I-Chemical
44 573 574 9284778 ) ) O O
45 574 575 9284778 . . O O

1 576 579 9284778 All DT B-NP O
2 580 584 9284778 nine CD I-NP O
3 585 592 9284778 exposed VBN I-NP O
4 593 600 9284778 workers NNS I-NP O
5 601 605 9284778 were VBD B-VP O
6 606 614 9284778 affected VBN I-VP O
7 615 617 9284778 to TO B-PP O
8 618 625 9284778 various JJ B-NP O
9 626 633 9284778 degrees NNS I-NP O
10 633 634 9284778 . . O O

1 635 639 9284778 Both DT B-NP O
2 640 649 9284778 compounds NNS I-NP O
3 650 653 9284778 are VBP B-VP O
4 654 665 9284778 metabolised VBN I-VP O
5 666 668 9284778 in IN B-PP O
6 669 672 9284778 the DT B-NP O
7 673 677 9284778 same JJ I-NP O
8 678 681 9284778 way NN I-NP O
9 682 684 9284778 as IN B-PP O
10 685 686 9284778 1 CD B-NP B-Chemical
11 686 687 9284778 - HYPH O I-Chemical
12 687 692 9284778 bromo AFX O I-Chemical
13 692 693 9284778 - HYPH B-NP I-Chemical
14 693 694 9284778 1 CD I-NP I-Chemical
15 694 695 9284778 - HYPH I-NP I-Chemical
16 695 701 9284778 chloro NN I-NP I-Chemical
17 701 702 9284778 - HYPH B-NP I-Chemical
18 702 707 9284778 2,2,2 CD I-NP I-Chemical
19 707 708 9284778 - HYPH I-NP I-Chemical
20 708 723 9284778 trifluoroethane NN I-NP I-Chemical
21 724 725 9284778 ( ( O O
22 725 734 9284778 halothane NN B-NP B-Chemical
23 734 735 9284778 ) ) O O
24 736 738 9284778 to TO B-VP O
25 739 743 9284778 form VB I-VP O
26 744 752 9284778 reactive JJ B-NP O
27 753 768 9284778 trifluoroacetyl NN I-NP B-Chemical
28 769 775 9284778 halide NN I-NP O
29 776 789 9284778 intermediates NNS I-NP O
30 789 790 9284778 , , O O
31 791 796 9284778 which WDT B-NP O
32 797 801 9284778 have VBP B-VP O
33 802 806 9284778 been VBN I-VP O
34 807 817 9284778 implicated VBN I-VP O
35 818 820 9284778 in IN B-PP O
36 821 824 9284778 the DT B-NP O
37 825 839 9284778 hepatotoxicity NN I-NP B-Disease
38 840 842 9284778 of IN B-PP O
39 843 852 9284778 halothane NN B-NP B-Chemical
40 852 853 9284778 . . O O

1 854 856 9284778 We PRP B-NP O
2 857 862 9284778 aimed VBD B-VP O
3 863 865 9284778 to TO I-VP O
4 866 870 9284778 test VB I-VP O
5 871 878 9284778 whether IN B-SBAR O
6 879 884 9284778 HCFCs NNS B-NP B-Chemical
7 885 888 9284778 123 CD B-NP I-Chemical
8 889 892 9284778 and CC I-NP I-Chemical
9 893 896 9284778 124 CD I-NP I-Chemical
10 897 900 9284778 can MD B-VP O
11 901 907 9284778 result VB I-VP O
12 908 910 9284778 in IN B-PP O
13 911 918 9284778 serious JJ B-NP O
14 919 924 9284778 liver NN I-NP B-Disease
15 925 932 9284778 disease NN I-NP I-Disease
16 932 933 9284778 . . O O

1 934 941 9284778 METHODS NNS B-NP O
2 941 942 9284778 : : O O
3 943 946 9284778 For IN O O
4 947 950 9284778 one CD B-NP O
5 951 959 9284778 severely RB B-VP O
6 960 968 9284778 affected VBD I-VP O
7 969 975 9284778 worker NN B-NP O
8 976 981 9284778 liver NN I-NP O
9 982 988 9284778 biopsy NN I-NP O
10 989 992 9284778 and CC O O
11 993 1012 9284778 immunohistochemical JJ B-NP O
12 1013 1022 9284778 stainings NNS I-NP O
13 1023 1026 9284778 for IN B-PP O
14 1027 1030 9284778 the DT B-NP O
15 1031 1039 9284778 presence NN I-NP O
16 1040 1042 9284778 of IN B-PP O
17 1043 1058 9284778 trifluoroacetyl NN B-NP B-Chemical
18 1059 1066 9284778 protein NN I-NP O
19 1067 1074 9284778 adducts NNS I-NP O
20 1075 1079 9284778 were VBD B-VP O
21 1080 1084 9284778 done VBN I-VP O
22 1084 1085 9284778 . . O O

1 1086 1089 9284778 The DT B-NP O
2 1090 1095 9284778 serum NN I-NP O
3 1096 1098 9284778 of IN B-PP O
4 1099 1102 9284778 six CD B-NP O
5 1103 1111 9284778 affected VBN I-NP O
6 1112 1119 9284778 workers NNS I-NP O
7 1120 1123 9284778 and CC O O
8 1124 1128 9284778 five CD B-NP O
9 1129 1137 9284778 controls NNS I-NP O
10 1138 1141 9284778 was VBD B-VP O
11 1142 1148 9284778 tested VBN I-VP O
12 1149 1152 9284778 for IN B-PP O
13 1153 1167 9284778 autoantibodies NNS B-NP O
14 1168 1172 9284778 that WDT B-NP O
15 1173 1178 9284778 react VBP B-VP O
16 1179 1183 9284778 with IN B-PP O
17 1184 1189 9284778 human JJ B-NP O
18 1190 1195 9284778 liver NN I-NP O
19 1196 1206 9284778 cytochrome NN I-NP O
20 1206 1207 9284778 - HYPH B-NP O
21 1207 1211 9284778 P450 NN I-NP O
22 1212 1215 9284778 2E1 NN I-NP O
23 1216 1217 9284778 ( ( O O
24 1217 1221 9284778 P450 NN B-NP O
25 1222 1225 9284778 2E1 NN I-NP O
26 1225 1226 9284778 ) ) O O
27 1227 1230 9284778 and CC O O
28 1231 1234 9284778 P58 NN B-NP O
29 1235 1242 9284778 protein NN I-NP O
30 1243 1253 9284778 disulphide NN I-NP O
31 1254 1263 9284778 isomerase NN I-NP O
32 1264 1271 9284778 isoform NN I-NP O
33 1272 1273 9284778 ( ( O O
34 1273 1276 9284778 P58 NN B-NP O
35 1276 1277 9284778 ) ) O O
36 1277 1278 9284778 . . O O

1 1279 1287 9284778 FINDINGS NNS B-NP O
2 1287 1288 9284778 : : O O
3 1289 1292 9284778 The DT B-NP O
4 1293 1298 9284778 liver NN I-NP O
5 1299 1305 9284778 biopsy NN I-NP O
6 1306 1312 9284778 sample NN I-NP O
7 1313 1319 9284778 showed VBD B-VP O
8 1320 1334 9284778 hepatocellular JJ B-NP O
9 1335 1343 9284778 necrosis NN I-NP B-Disease
10 1344 1349 9284778 which WDT B-NP O
11 1350 1353 9284778 was VBD B-VP O
12 1354 1363 9284778 prominent JJ B-ADJP O
13 1364 1366 9284778 in IN B-PP O
14 1367 1378 9284778 perivenular JJ B-NP O
15 1379 1383 9284778 zone NN I-NP O
16 1384 1389 9284778 three CD I-NP O
17 1390 1393 9284778 and CC O O
18 1394 1402 9284778 extended VBD B-VP O
19 1403 1410 9284778 focally RB B-ADVP O
20 1411 1415 9284778 from IN B-PP O
21 1416 1422 9284778 portal JJ B-NP O
22 1423 1429 9284778 tracts NNS I-NP O
23 1430 1432 9284778 to TO B-PP O
24 1433 1439 9284778 portal JJ B-NP O
25 1440 1446 9284778 tracts NNS I-NP O
26 1447 1450 9284778 and CC O O
27 1451 1464 9284778 centrilobular JJ B-NP O
28 1465 1470 9284778 areas NNS I-NP O
29 1471 1472 9284778 ( ( O O
30 1472 1480 9284778 bridging VBG B-VP O
31 1481 1489 9284778 necrosis NN B-NP B-Disease
32 1489 1490 9284778 ) ) O O
33 1490 1491 9284778 . . O O

1 1492 1507 9284778 Trifluoroacetyl NN B-NP B-Chemical
2 1507 1508 9284778 - HYPH B-NP O
3 1508 1516 9284778 adducted VBN I-NP O
4 1517 1525 9284778 proteins NNS I-NP O
5 1526 1530 9284778 were VBD B-VP O
6 1531 1539 9284778 detected VBN I-VP O
7 1540 1542 9284778 in IN B-PP O
8 1543 1552 9284778 surviving VBG B-VP O
9 1553 1564 9284778 hepatocytes NNS B-NP O
10 1564 1565 9284778 . . O O

1 1566 1580 9284778 Autoantibodies NNS B-NP O
2 1581 1588 9284778 against IN B-PP O
3 1589 1593 9284778 P450 NN B-NP O
4 1594 1597 9284778 2E1 NN I-NP O
5 1598 1600 9284778 or CC I-NP O
6 1601 1604 9284778 P58 NN I-NP O
7 1604 1605 9284778 , , O O
8 1606 1616 9284778 previously RB B-VP O
9 1617 1627 9284778 associated VBN I-VP O
10 1628 1632 9284778 with IN B-PP O
11 1633 1642 9284778 halothane NN B-NP B-Disease
12 1643 1652 9284778 hepatitis NN I-NP I-Disease
13 1652 1653 9284778 , , O O
14 1654 1658 9284778 were VBD B-VP O
15 1659 1667 9284778 detected VBN I-VP O
16 1668 1670 9284778 in IN B-PP O
17 1671 1674 9284778 the DT B-NP O
18 1675 1680 9284778 serum NN I-NP O
19 1681 1683 9284778 of IN B-PP O
20 1684 1688 9284778 five CD B-NP O
21 1689 1697 9284778 affected VBN I-NP O
22 1698 1705 9284778 workers NNS I-NP O
23 1705 1706 9284778 . . O O

1 1707 1721 9284778 INTERPRETATION NN B-NP O
2 1721 1722 9284778 : : O O
3 1723 1731 9284778 Repeated VBN B-NP O
4 1732 1740 9284778 exposure NN I-NP O
5 1741 1743 9284778 of IN B-PP O
6 1744 1749 9284778 human JJ B-NP O
7 1750 1756 9284778 beings NNS I-NP O
8 1757 1759 9284778 to TO B-PP O
9 1760 1765 9284778 HCFCs NNS B-NP B-Chemical
10 1766 1769 9284778 123 CD B-NP I-Chemical
11 1770 1773 9284778 and CC I-NP I-Chemical
12 1774 1777 9284778 124 CD I-NP I-Chemical
13 1778 1781 9284778 can MD B-VP O
14 1782 1788 9284778 result VB I-VP O
15 1789 1791 9284778 in IN B-PP O
16 1792 1799 9284778 serious JJ B-NP O
17 1800 1805 9284778 liver NN I-NP B-Disease
18 1806 1812 9284778 injury NN I-NP I-Disease
19 1813 1815 9284778 in IN B-PP O
20 1816 1817 9284778 a DT B-NP O
21 1818 1823 9284778 large JJ I-NP O
22 1824 1834 9284778 proportion NN I-NP O
23 1835 1837 9284778 of IN B-PP O
24 1838 1841 9284778 the DT B-NP O
25 1842 1849 9284778 exposed VBN I-NP O
26 1850 1860 9284778 population NN I-NP O
27 1860 1861 9284778 . . O O

1 1862 1870 9284778 Although IN B-SBAR O
2 1871 1874 9284778 the DT B-NP O
3 1875 1880 9284778 exact JJ I-NP O
4 1881 1890 9284778 mechanism NN I-NP O
5 1891 1893 9284778 of IN B-PP O
6 1894 1908 9284778 hepatotoxicity NN B-NP B-Disease
7 1909 1911 9284778 of IN B-PP O
8 1912 1917 9284778 these DT B-NP O
9 1918 1924 9284778 agents NNS I-NP O
10 1925 1927 9284778 is VBZ B-VP O
11 1928 1931 9284778 not RB I-VP O
12 1932 1937 9284778 known VBN I-VP O
13 1937 1938 9284778 , , O O
14 1939 1942 9284778 the DT B-NP O
15 1943 1950 9284778 results NNS I-NP O
16 1951 1958 9284778 suggest VBP B-VP O
17 1959 1963 9284778 that IN B-SBAR O
18 1964 1979 9284778 trifluoroacetyl NN B-NP B-Chemical
19 1979 1980 9284778 - HYPH B-VP O
20 1980 1987 9284778 altered VBN B-NP O
21 1988 1993 9284778 liver NN I-NP O
22 1994 2002 9284778 proteins NNS I-NP O
23 2003 2006 9284778 are VBP B-VP O
24 2007 2015 9284778 involved VBN I-VP O
25 2015 2016 9284778 . . O O

1 2017 2019 9284778 In IN B-PP O
2 2020 2024 9284778 view NN B-NP O
3 2025 2027 9284778 of IN B-PP O
4 2028 2031 9284778 the DT B-NP O
5 2032 2043 9284778 potentially RB I-NP O
6 2044 2054 9284778 widespread JJ I-NP O
7 2055 2058 9284778 use NN I-NP O
8 2059 2061 9284778 of IN B-PP O
9 2062 2067 9284778 these DT B-NP O
10 2068 2077 9284778 compounds NNS I-NP O
11 2077 2078 9284778 , , O O
12 2079 2084 9284778 there EX B-NP O
13 2085 2087 9284778 is VBZ B-VP O
14 2088 2090 9284778 an DT B-NP O
15 2091 2097 9284778 urgent JJ I-NP O
16 2098 2102 9284778 need NN I-NP O
17 2103 2105 9284778 to TO B-VP O
18 2106 2113 9284778 develop VB I-VP O
19 2114 2119 9284778 safer JJR B-NP O
20 2120 2132 9284778 alternatives NNS I-NP O
21 2132 2133 9284778 . . O O

1 0 0 2265898 -DOCSTART- -X- -X- O

1 0 6 2265898 Serial JJ B-NP O
2 7 15 2265898 epilepsy NN I-NP B-Disease
3 16 22 2265898 caused VBN B-VP O
4 23 25 2265898 by IN B-PP O
5 26 34 2265898 levodopa NN B-NP B-Chemical
6 34 35 2265898 / SYM O I-Chemical
7 35 44 2265898 carbidopa NN B-NP I-Chemical
8 45 59 2265898 administration NN I-NP O
9 60 62 2265898 in IN B-PP O
10 63 66 2265898 two CD B-NP O
11 67 75 2265898 patients NNS I-NP O
12 76 78 2265898 on IN B-PP O
13 79 91 2265898 hemodialysis NN B-NP O
14 91 92 2265898 . . O O
15 93 96 2265898 Two CD B-NP O
16 97 105 2265898 patients NNS I-NP O
17 106 110 2265898 with IN B-PP O
18 111 118 2265898 similar JJ B-NP O
19 119 127 2265898 clinical JJ I-NP O
20 128 136 2265898 features NNS I-NP O
21 137 140 2265898 are VBP B-VP O
22 141 150 2265898 presented VBN I-VP O
23 150 151 2265898 : : O O
24 152 156 2265898 both DT B-NP O
25 157 165 2265898 patients NNS I-NP O
26 166 169 2265898 had VBD B-VP O
27 170 177 2265898 chronic JJ B-NP B-Disease
28 178 183 2265898 renal JJ I-NP I-Disease
29 184 191 2265898 failure NN I-NP I-Disease
30 191 192 2265898 , , O O
31 193 195 2265898 on IN B-PP O
32 196 208 2265898 hemodialysis NN B-NP O
33 209 212 2265898 for IN B-PP O
34 213 217 2265898 many JJ B-NP O
35 218 223 2265898 years NNS I-NP O
36 224 227 2265898 but CC O O
37 228 236 2265898 recently RB B-VP O
38 237 242 2265898 begun VBN I-VP O
39 243 245 2265898 on IN B-PP O
40 246 247 2265898 a DT B-NP O
41 248 252 2265898 high JJ I-NP O
42 252 253 2265898 - HYPH I-NP O
43 253 257 2265898 flux NN I-NP O
44 258 266 2265898 dialyzer NN I-NP O
45 266 267 2265898 ; : O O
46 268 272 2265898 both DT B-NP O
47 273 276 2265898 had VBD B-VP O
48 277 281 2265898 been VBN I-VP O
49 282 291 2265898 receiving VBG I-VP O
50 292 293 2265898 a DT B-NP O
51 294 303 2265898 carbidopa NN I-NP B-Chemical
52 303 304 2265898 / SYM B-NP I-Chemical
53 304 312 2265898 levodopa NN I-NP I-Chemical
54 313 324 2265898 preparation NN I-NP O
55 324 325 2265898 ; : O O
56 326 329 2265898 and CC O O
57 330 334 2265898 both DT B-NP O
58 335 338 2265898 had VBD B-VP O
59 339 342 2265898 the DT B-NP O
60 343 348 2265898 onset NN I-NP O
61 349 351 2265898 of IN B-PP O
62 352 364 2265898 hallucinosis NN B-NP B-Disease
63 365 368 2265898 and CC O O
64 369 378 2265898 recurrent JJ B-NP O
65 379 387 2265898 seizures NNS I-NP B-Disease
66 387 388 2265898 , , O O
67 389 394 2265898 which WDT B-NP O
68 395 399 2265898 were VBD B-VP O
69 400 410 2265898 refractory JJ B-ADJP O
70 411 413 2265898 to TO B-PP O
71 414 429 2265898 anticonvulsants NNS B-NP O
72 429 430 2265898 . . O O

1 431 434 2265898 The DT B-NP O
2 435 440 2265898 first JJ I-NP O
3 441 448 2265898 patient NN I-NP O
4 449 453 2265898 died VBD B-VP O
5 454 461 2265898 without IN B-PP O
6 462 463 2265898 a DT B-NP O
7 464 473 2265898 diagnosis NN I-NP O
8 473 474 2265898 ; : O O
9 475 478 2265898 the DT B-NP O
10 479 485 2265898 second JJ I-NP O
11 486 493 2265898 patient NN I-NP O
12 494 497 2265898 had VBD B-VP O
13 498 499 2265898 a DT B-NP O
14 500 508 2265898 dramatic JJ I-NP O
15 509 517 2265898 recovery NN I-NP O
16 518 527 2265898 following VBG B-PP O
17 528 531 2265898 the DT B-NP O
18 532 546 2265898 administration NN I-NP O
19 547 549 2265898 of IN B-PP O
20 550 557 2265898 vitamin NN B-NP B-Chemical
21 558 560 2265898 B6 NN I-NP I-Chemical
22 560 561 2265898 . . O O

1 562 569 2265898 Neither DT B-NP O
2 570 577 2265898 patient NN I-NP O
3 578 581 2265898 was VBD B-VP O
4 582 592 2265898 considered VBN I-VP O
5 593 595 2265898 to TO I-VP O
6 596 600 2265898 have VB I-VP O
7 601 602 2265898 a DT B-NP O
8 603 608 2265898 renal JJ I-NP O
9 609 614 2265898 state NN I-NP O
10 615 627 2265898 sufficiently RB B-ADJP O
11 628 634 2265898 severe JJ I-ADJP O
12 635 641 2265898 enough RB B-ADVP O
13 642 644 2265898 to TO B-VP O
14 645 652 2265898 explain VB I-VP O
15 653 658 2265898 their PRP$ B-NP O
16 659 671 2265898 presentation NN I-NP O
17 671 672 2265898 . . O O

1 0 0 11256525 -DOCSTART- -X- -X- O

1 0 8 11256525 Repeated VBN B-NP O
2 9 18 11256525 transient JJ I-NP O
3 19 25 11256525 anuria NN I-NP B-Disease
4 26 35 11256525 following VBG B-PP O
5 36 44 11256525 losartan NN B-NP B-Chemical
6 45 59 11256525 administration NN I-NP O
7 60 62 11256525 in IN B-PP O
8 63 64 11256525 a DT B-NP O
9 65 72 11256525 patient NN I-NP O
10 73 77 11256525 with IN B-PP O
11 78 79 11256525 a DT B-NP O
12 80 88 11256525 solitary JJ I-NP O
13 89 95 11256525 kidney NN I-NP O
14 95 96 11256525 . . O O
15 97 99 11256525 We PRP B-NP O
16 100 106 11256525 report VBP B-VP O
17 107 110 11256525 the DT B-NP O
18 111 115 11256525 case NN I-NP O
19 116 118 11256525 of IN B-PP O
20 119 120 11256525 a DT B-NP O
21 121 123 11256525 70 CD I-NP O
22 123 124 11256525 - HYPH I-NP O
23 124 128 11256525 year NN I-NP O
24 128 129 11256525 - HYPH O O
25 129 132 11256525 old JJ B-NP O
26 133 145 11256525 hypertensive JJ I-NP B-Disease
27 146 149 11256525 man NN I-NP O
28 150 154 11256525 with IN B-PP O
29 155 156 11256525 a DT B-NP O
30 157 165 11256525 solitary JJ I-NP O
31 166 172 11256525 kidney NN I-NP O
32 173 176 11256525 and CC O O
33 177 184 11256525 chronic JJ B-NP B-Disease
34 185 190 11256525 renal JJ I-NP I-Disease
35 191 204 11256525 insufficiency NN I-NP I-Disease
36 205 208 11256525 who WP B-NP O
37 209 218 11256525 developed VBD B-VP O
38 219 222 11256525 two CD B-NP O
39 223 231 11256525 episodes NNS I-NP O
40 232 234 11256525 of IN B-PP O
41 235 244 11256525 transient JJ B-NP O
42 245 251 11256525 anuria NN I-NP B-Disease
43 252 257 11256525 after IN B-PP O
44 258 266 11256525 losartan NN B-NP B-Chemical
45 267 281 11256525 administration NN I-NP O
46 281 282 11256525 . . O O

1 283 285 11256525 He PRP B-NP O
2 286 289 11256525 was VBD B-VP O
3 290 302 11256525 hospitalized VBN I-VP O
4 303 306 11256525 for IN B-PP O
5 307 308 11256525 a DT B-NP O
6 309 319 11256525 myocardial JJ I-NP B-Disease
7 320 330 11256525 infarction NN I-NP I-Disease
8 331 335 11256525 with IN B-PP O
9 336 345 11256525 pulmonary JJ B-NP B-Disease
10 346 351 11256525 edema NN I-NP I-Disease
11 351 352 11256525 , , O O
12 353 360 11256525 treated VBN B-VP O
13 361 365 11256525 with IN B-PP O
14 366 370 11256525 high JJ B-NP O
15 370 371 11256525 - HYPH I-NP O
16 371 375 11256525 dose NN I-NP O
17 376 385 11256525 diuretics NNS I-NP O
18 385 386 11256525 . . O O

1 387 390 11256525 Due JJ B-PP O
2 391 393 11256525 to TO B-PP O
3 394 400 11256525 severe JJ B-NP O
4 401 409 11256525 systolic JJ I-NP B-Disease
5 410 421 11256525 dysfunction NN I-NP I-Disease
6 422 430 11256525 losartan NN I-NP B-Chemical
7 431 434 11256525 was VBD B-VP O
8 435 445 11256525 prescribed VBN I-VP O
9 445 446 11256525 . . O O

1 447 459 11256525 Surprisingly RB B-ADVP O
2 459 460 11256525 , , O O
3 461 464 11256525 the DT B-NP O
4 465 470 11256525 first JJ I-NP O
5 471 475 11256525 dose NN I-NP O
6 476 478 11256525 of IN B-PP O
7 479 481 11256525 50 CD B-NP O
8 482 484 11256525 mg NN I-NP O
9 485 487 11256525 of IN B-PP O
10 488 496 11256525 losartan NN B-NP B-Chemical
11 497 505 11256525 resulted VBD B-VP O
12 506 508 11256525 in IN B-PP O
13 509 510 11256525 a DT B-NP O
14 511 517 11256525 sudden JJ I-NP O
15 518 524 11256525 anuria NN I-NP B-Disease
16 524 525 11256525 , , O O
17 526 531 11256525 which WDT B-NP O
18 532 538 11256525 lasted VBD B-VP O
19 539 544 11256525 eight CD B-NP O
20 545 550 11256525 hours NNS I-NP O
21 551 558 11256525 despite IN B-PP O
22 559 563 11256525 high JJ B-NP O
23 563 564 11256525 - HYPH I-NP O
24 564 568 11256525 dose NN I-NP O
25 569 579 11256525 furosemide NN I-NP B-Chemical
26 580 583 11256525 and CC O O
27 584 589 11256525 amine NN B-NP B-Chemical
28 590 598 11256525 infusion NN I-NP O
29 598 599 11256525 . . O O

1 600 603 11256525 One CD B-NP O
2 604 608 11256525 week NN I-NP O
3 609 614 11256525 later RB B-ADVP O
4 614 615 11256525 , , O O
5 616 618 11256525 by IN B-PP O
6 619 626 11256525 mistake NN B-NP O
7 626 627 11256525 , , O O
8 628 636 11256525 losartan NN B-NP B-Chemical
9 637 640 11256525 was VBD B-VP O
10 641 651 11256525 prescribed VBN I-VP O
11 652 657 11256525 again RB B-ADVP O
12 658 661 11256525 and CC O O
13 662 667 11256525 after IN B-PP O
14 668 671 11256525 the DT B-NP O
15 672 678 11256525 second JJ I-NP O
16 679 683 11256525 dose NN I-NP O
17 684 686 11256525 of IN B-PP O
18 687 689 11256525 50 CD B-NP O
19 690 692 11256525 mg NN I-NP O
20 692 693 11256525 , , O O
21 694 697 11256525 the DT B-NP O
22 698 705 11256525 patient NN I-NP O
23 706 715 11256525 developed VBD B-VP O
24 716 717 11256525 a DT B-NP O
25 718 724 11256525 second JJ I-NP O
26 725 732 11256525 episode NN I-NP O
27 733 735 11256525 of IN B-PP O
28 736 745 11256525 transient JJ B-NP O
29 746 752 11256525 anuria NN I-NP B-Disease
30 753 760 11256525 lasting VBG B-VP O
31 761 763 11256525 10 CD B-NP O
32 764 769 11256525 hours NNS I-NP O
33 769 770 11256525 . . O O

1 771 777 11256525 During IN B-PP O
2 778 783 11256525 these DT B-NP O
3 784 787 11256525 two CD I-NP O
4 788 796 11256525 episodes NNS I-NP O
5 796 797 11256525 , , O O
6 798 801 11256525 his PRP$ B-NP O
7 802 807 11256525 blood NN I-NP O
8 808 816 11256525 pressure NN I-NP O
9 817 827 11256525 diminished VBD B-VP O
10 828 831 11256525 but CC O O
11 832 834 11256525 no DT B-NP O
12 835 841 11256525 severe JJ I-NP O
13 842 853 11256525 hypotension NN I-NP B-Disease
14 854 857 11256525 was VBD B-VP O
15 858 863 11256525 noted VBN I-VP O
16 863 864 11256525 . . O O

1 865 875 11256525 Ultimately RB B-ADVP O
2 875 876 11256525 , , O O
3 877 879 11256525 an DT B-NP O
4 880 893 11256525 arteriography NN I-NP O
5 894 900 11256525 showed VBD B-VP O
6 901 902 11256525 a DT B-NP O
7 903 905 11256525 70 CD I-NP O
8 905 906 11256525 - HYPH I-NP O
9 906 909 11256525 80% CD I-NP O
10 910 915 11256525 renal JJ I-NP B-Disease
11 916 922 11256525 artery NN I-NP I-Disease
12 923 931 11256525 stenosis NN I-NP I-Disease
13 931 932 11256525 . . O O

1 933 935 11256525 In IN B-PP O
2 936 940 11256525 this DT B-NP O
3 941 948 11256525 patient NN I-NP O
4 948 949 11256525 , , O O
5 950 955 11256525 renal JJ B-NP B-Disease
6 956 962 11256525 artery NN I-NP I-Disease
7 963 971 11256525 stenosis NN I-NP I-Disease
8 972 980 11256525 combined VBN B-VP O
9 981 985 11256525 with IN B-PP O
10 986 991 11256525 heart NN B-NP B-Disease
11 992 999 11256525 failure NN I-NP I-Disease
12 1000 1003 11256525 and CC O O
13 1004 1012 11256525 diuretic JJ B-NP O
14 1013 1020 11256525 therapy NN I-NP O
15 1021 1030 11256525 certainly RB B-ADVP O
16 1031 1039 11256525 resulted VBD B-VP O
17 1040 1042 11256525 in IN B-PP O
18 1043 1044 11256525 a DT B-NP O
19 1045 1051 11256525 strong JJ I-NP O
20 1052 1062 11256525 activation NN I-NP O
21 1063 1065 11256525 of IN B-PP O
22 1066 1069 11256525 the DT B-NP O
23 1070 1075 11256525 renin NN I-NP O
24 1075 1076 11256525 - HYPH I-NP O
25 1076 1087 11256525 angiotensin NN I-NP B-Chemical
26 1088 1094 11256525 system NN I-NP O
27 1095 1096 11256525 ( ( O O
28 1096 1099 11256525 RAS NN B-NP O
29 1099 1100 11256525 ) ) O O
30 1100 1101 11256525 . . O O

1 1102 1107 11256525 Under IN B-PP O
2 1108 1112 11256525 such JJ B-NP O
3 1113 1123 11256525 conditions NNS I-NP O
4 1123 1124 11256525 , , O O
5 1125 1136 11256525 angiotensin NN B-NP B-Chemical
6 1137 1139 11256525 II CD I-NP I-Chemical
7 1140 1148 11256525 receptor NN I-NP O
8 1149 1157 11256525 blockade NN I-NP O
9 1158 1160 11256525 by IN B-PP O
10 1161 1169 11256525 losartan NN B-NP B-Chemical
11 1170 1178 11256525 probably RB B-ADVP O
12 1179 1186 11256525 induced VBD B-VP O
13 1187 1188 11256525 a DT B-NP O
14 1189 1197 11256525 critical JJ I-NP O
15 1198 1202 11256525 fall NN I-NP O
16 1203 1205 11256525 in IN B-PP O
17 1206 1216 11256525 glomerular JJ B-NP O
18 1217 1227 11256525 filtration NN I-NP O
19 1228 1236 11256525 pressure NN I-NP O
20 1236 1237 11256525 . . O O

1 1238 1242 11256525 This DT B-NP O
2 1243 1247 11256525 case NN I-NP O
3 1248 1254 11256525 report NN I-NP O
4 1255 1265 11256525 highlights VBZ B-VP O
5 1266 1269 11256525 the DT B-NP O
6 1270 1274 11256525 fact NN I-NP O
7 1275 1279 11256525 that IN B-SBAR O
8 1280 1283 11256525 the DT B-NP O
9 1284 1295 11256525 angiotensin NN I-NP B-Chemical
10 1296 1298 11256525 II CD I-NP I-Chemical
11 1299 1307 11256525 receptor NN I-NP O
12 1308 1318 11256525 antagonist NN I-NP O
13 1319 1327 11256525 losartan NN I-NP B-Chemical
14 1328 1331 11256525 can MD B-VP O
15 1332 1337 11256525 cause VB I-VP O
16 1338 1345 11256525 serious JJ B-NP O
17 1346 1356 11256525 unexpected JJ I-NP O
18 1357 1370 11256525 complications NNS I-NP O
19 1371 1373 11256525 in IN B-PP O
20 1374 1382 11256525 patients NNS B-NP O
21 1383 1387 11256525 with IN B-PP O
22 1388 1400 11256525 renovascular JJ B-NP B-Disease
23 1401 1408 11256525 disease NN I-NP I-Disease
24 1409 1412 11256525 and CC O O
25 1413 1419 11256525 should MD B-VP O
26 1420 1422 11256525 be VB I-VP O
27 1423 1427 11256525 used VBN I-VP O
28 1428 1432 11256525 with IN B-PP O
29 1433 1440 11256525 extreme JJ B-NP O
30 1441 1448 11256525 caution NN I-NP O
31 1449 1451 11256525 in IN B-PP O
32 1452 1456 11256525 this DT B-NP O
33 1457 1464 11256525 setting NN I-NP O
34 1464 1465 11256525 . . O O

1 0 0 17111419 -DOCSTART- -X- -X- O

1 0 6 17111419 Severe JJ B-NP O
2 7 14 17111419 citrate NN I-NP B-Chemical
3 15 23 17111419 toxicity NN I-NP B-Disease
4 24 36 17111419 complicating VBG B-VP O
5 37 46 17111419 volunteer NN B-NP O
6 47 56 17111419 apheresis NN I-NP O
7 57 65 17111419 platelet NN I-NP O
8 66 74 17111419 donation NN I-NP O
9 74 75 17111419 . . O O
10 76 78 17111419 We PRP B-NP O
11 79 85 17111419 report VBP B-VP O
12 86 87 17111419 a DT B-NP O
13 88 92 17111419 case NN I-NP O
14 93 95 17111419 of IN B-PP O
15 96 102 17111419 severe JJ B-NP O
16 103 110 17111419 citrate NN I-NP B-Chemical
17 111 119 17111419 toxicity NN I-NP B-Disease
18 120 126 17111419 during IN B-PP O
19 127 136 17111419 volunteer NN B-NP O
20 137 142 17111419 donor NN I-NP O
21 143 152 17111419 apheresis NN I-NP O
22 153 161 17111419 platelet NN I-NP O
23 162 172 17111419 collection NN I-NP O
24 172 173 17111419 . . O O

1 174 177 17111419 The DT B-NP O
2 178 183 17111419 donor NN I-NP O
3 184 187 17111419 was VBD B-VP O
4 188 189 17111419 a DT B-NP O
5 190 192 17111419 40 CD I-NP O
6 192 193 17111419 - HYPH I-NP O
7 193 197 17111419 year NN I-NP O
8 197 198 17111419 - HYPH O O
9 198 201 17111419 old JJ B-NP O
10 202 208 17111419 female JJ I-NP O
11 208 209 17111419 , , I-NP O
12 210 215 17111419 first JJ I-NP O
13 215 216 17111419 - HYPH I-NP O
14 216 220 17111419 time NN I-NP O
15 221 230 17111419 apheresis NN I-NP O
16 231 239 17111419 platelet NN I-NP O
17 240 245 17111419 donor NN I-NP O
18 245 246 17111419 . . O O

1 247 251 17111419 Past JJ B-NP O
2 252 259 17111419 medical JJ I-NP O
3 260 267 17111419 history NN I-NP O
4 268 271 17111419 was VBD B-VP O
5 272 282 17111419 remarkable JJ B-ADJP O
6 283 286 17111419 for IN B-PP O
7 287 299 17111419 hypertension NN B-NP B-Disease
8 299 300 17111419 , , O O
9 301 315 17111419 hyperlipidemia NN B-NP B-Disease
10 315 316 17111419 , , O O
11 317 320 17111419 and CC O O
12 321 331 17111419 depression NN B-NP B-Disease
13 331 332 17111419 . . O O

1 333 341 17111419 Reported VBN B-NP O
2 342 353 17111419 medications NNS I-NP O
3 354 362 17111419 included VBD B-VP O
4 363 373 17111419 bumetanide NN B-NP B-Chemical
5 373 374 17111419 , , O O
6 375 386 17111419 pravastatin NN B-NP B-Chemical
7 386 387 17111419 , , O O
8 388 391 17111419 and CC O O
9 392 402 17111419 paroxetine NN B-NP B-Chemical
10 402 403 17111419 . . O O

1 404 410 17111419 Thirty CD B-NP O
2 411 418 17111419 minutes NNS I-NP O
3 419 423 17111419 from IN B-PP O
4 424 427 17111419 the DT B-NP O
5 428 433 17111419 start NN I-NP O
6 434 436 17111419 of IN B-PP O
7 437 440 17111419 the DT B-NP O
8 441 450 17111419 procedure NN I-NP O
9 450 451 17111419 , , O O
10 452 455 17111419 the DT B-NP O
11 456 461 17111419 donor NN I-NP O
12 462 467 17111419 noted VBD B-VP O
13 468 476 17111419 tingling VBG I-VP O
14 477 483 17111419 around IN B-PP O
15 484 487 17111419 the DT B-NP O
16 488 493 17111419 mouth NN I-NP O
17 493 494 17111419 , , O O
18 495 500 17111419 hands NNS B-NP O
19 500 501 17111419 , , O O
20 502 505 17111419 and CC O O
21 506 510 17111419 feet NNS B-NP O
22 510 511 17111419 . . O O

1 512 515 17111419 She PRP B-NP O
2 516 520 17111419 then RB B-ADVP O
3 521 525 17111419 very RB B-ADVP O
4 526 533 17111419 rapidly RB I-ADVP O
5 534 543 17111419 developed VBD B-VP O
6 544 549 17111419 acute JJ B-NP O
7 550 555 17111419 onset NN I-NP O
8 556 558 17111419 of IN B-PP O
9 559 565 17111419 severe JJ B-NP O
10 566 572 17111419 facial JJ I-NP O
11 573 576 17111419 and CC I-NP O
12 577 586 17111419 extremity NN I-NP O
13 587 593 17111419 tetany NN I-NP B-Disease
14 593 594 17111419 . . O O

1 595 604 17111419 Empirical JJ B-NP O
2 605 614 17111419 treatment NN I-NP O
3 615 619 17111419 with IN B-PP O
4 620 631 17111419 intravenous JJ B-NP O
5 632 639 17111419 calcium NN I-NP B-Chemical
6 640 649 17111419 gluconate NN I-NP I-Chemical
7 650 653 17111419 was VBD B-VP O
8 654 663 17111419 initiated VBN I-VP O
9 663 664 17111419 , , O O
10 665 668 17111419 and CC O O
11 669 675 17111419 muscle NN B-NP B-Disease
12 676 688 17111419 contractions NNS I-NP I-Disease
13 689 695 17111419 slowly RB B-ADVP O
14 696 704 17111419 subsided VBD B-VP O
15 705 709 17111419 over IN B-PP O
16 710 723 17111419 approximately RB B-NP O
17 724 726 17111419 10 CD I-NP O
18 727 729 17111419 to TO I-NP O
19 730 732 17111419 15 CD I-NP O
20 733 740 17111419 minutes NNS I-NP O
21 740 741 17111419 . . O O

1 742 745 17111419 The DT B-NP O
2 746 752 17111419 events NNS I-NP O
3 753 756 17111419 are VBP B-VP O
4 757 767 17111419 consistent JJ B-ADJP O
5 768 772 17111419 with IN B-PP O
6 773 774 17111419 a DT B-NP O
7 775 781 17111419 severe JJ I-NP O
8 782 790 17111419 reaction NN I-NP O
9 791 793 17111419 to TO B-PP O
10 794 801 17111419 calcium NN B-NP B-Chemical
11 802 811 17111419 chelation NN I-NP O
12 812 814 17111419 by IN B-PP O
13 815 821 17111419 sodium NN B-NP B-Chemical
14 822 829 17111419 citrate NN I-NP I-Chemical
15 830 843 17111419 anticoagulant NN I-NP O
16 844 853 17111419 resulting VBG B-VP O
17 854 856 17111419 in IN B-PP O
18 857 868 17111419 symptomatic JJ B-NP O
19 869 877 17111419 systemic JJ I-NP O
20 878 890 17111419 hypocalcemia NN I-NP B-Disease
21 890 891 17111419 . . O O

1 892 896 17111419 Upon IN B-PP O
2 897 907 17111419 additional JJ B-NP O
3 908 921 17111419 retrospective JJ I-NP O
4 922 930 17111419 analysis NN I-NP O
5 930 931 17111419 , , O O
6 932 934 17111419 it PRP B-NP O
7 935 938 17111419 was VBD B-VP O
8 939 944 17111419 noted VBN I-VP O
9 945 949 17111419 that IN B-SBAR O
10 950 960 17111419 bumetanide NN B-NP B-Chemical
11 961 963 17111419 is VBZ B-VP O
12 964 965 17111419 a DT B-NP O
13 966 970 17111419 loop NN I-NP B-Chemical
14 971 979 17111419 diuretic JJ I-NP I-Chemical
15 980 984 17111419 that WDT B-NP O
16 985 988 17111419 may MD B-VP O
17 989 994 17111419 cause VB I-VP O
18 995 1006 17111419 significant JJ B-NP O
19 1007 1019 17111419 hypocalcemia NN I-NP B-Disease
20 1019 1020 17111419 . . O O

1 1021 1023 17111419 We PRP B-NP O
2 1024 1032 17111419 conclude VBP B-VP O
3 1033 1037 17111419 that IN B-SBAR O
4 1038 1045 17111419 careful JJ B-NP O
5 1046 1055 17111419 screening NN I-NP O
6 1056 1059 17111419 for IN B-PP O
7 1060 1071 17111419 medications NNS B-NP O
8 1072 1075 17111419 and CC O O
9 1076 1086 17111419 underlying VBG B-VP O
10 1087 1097 17111419 conditions NNS B-NP O
11 1098 1110 17111419 predisposing VBG B-VP O
12 1111 1113 17111419 to TO B-PP O
13 1114 1126 17111419 hypocalcemia NN B-NP B-Disease
14 1127 1129 17111419 is VBZ B-VP O
15 1130 1141 17111419 recommended VBN I-VP O
16 1142 1144 17111419 to TO I-VP O
17 1145 1149 17111419 help VB I-VP O
18 1150 1157 17111419 prevent VB I-VP O
19 1158 1164 17111419 severe JJ B-NP O
20 1165 1174 17111419 reactions NNS I-NP O
21 1175 1178 17111419 due JJ B-ADJP O
22 1179 1181 17111419 to TO B-VP O
23 1182 1189 17111419 citrate VB I-VP B-Chemical
24 1190 1198 17111419 toxicity NN B-NP B-Disease
25 1198 1199 17111419 . . O O

1 1200 1210 17111419 Laboratory NN B-NP O
2 1211 1222 17111419 measurement NN I-NP O
3 1223 1225 17111419 of IN B-PP O
4 1226 1229 17111419 pre AFX B-NP O
5 1229 1230 17111419 - HYPH I-NP O
6 1230 1239 17111419 procedure NN I-NP O
7 1240 1245 17111419 serum NN I-NP O
8 1246 1253 17111419 calcium NN I-NP B-Chemical
9 1254 1260 17111419 levels NNS I-NP O
10 1261 1263 17111419 in IN B-PP O
11 1264 1272 17111419 selected VBN B-NP O
12 1273 1279 17111419 donors NNS I-NP O
13 1280 1283 17111419 may MD B-VP O
14 1284 1292 17111419 identify VB I-VP O
15 1293 1298 17111419 cases NNS B-NP O
16 1299 1308 17111419 requiring VBG B-VP O
17 1309 1319 17111419 heightened VBN B-NP O
18 1320 1329 17111419 vigilance NN I-NP O
19 1329 1330 17111419 . . O O

1 1331 1334 17111419 The DT B-NP O
2 1335 1339 17111419 case NN I-NP O
3 1340 1344 17111419 also RB B-ADVP O
4 1345 1356 17111419 illustrates VBZ B-VP O
5 1357 1360 17111419 the DT B-NP O
6 1361 1371 17111419 importance NN I-NP O
7 1372 1374 17111419 of IN B-PP O
8 1375 1386 17111419 maintaining VBG B-VP O
9 1387 1399 17111419 preparedness NN B-NP O
10 1400 1403 17111419 for IN B-PP O
11 1404 1412 17111419 managing VBG B-VP O
12 1413 1417 17111419 rare JJ B-NP O
13 1418 1421 17111419 but CC I-NP O
14 1422 1429 17111419 serious JJ I-NP O
15 1430 1439 17111419 reactions NNS I-NP O
16 1440 1442 17111419 in IN B-PP O
17 1443 1452 17111419 volunteer NN B-NP O
18 1453 1462 17111419 apheresis NN I-NP O
19 1463 1468 17111419 blood NN I-NP O
20 1469 1475 17111419 donors NNS I-NP O
21 1475 1476 17111419 . . O O

1 0 0 1992636 -DOCSTART- -X- -X- O

1 0 9 1992636 Hemolytic JJ B-NP B-Disease
2 10 16 1992636 anemia NN I-NP I-Disease
3 17 27 1992636 associated VBN B-VP O
4 28 32 1992636 with IN B-PP O
5 33 36 1992636 the DT B-NP O
6 37 40 1992636 use NN I-NP O
7 41 43 1992636 of IN B-PP O
8 44 54 1992636 omeprazole NN B-NP B-Chemical
9 54 55 1992636 . . O O
10 56 66 1992636 Omeprazole NN B-NP B-Chemical
11 67 69 1992636 is VBZ B-VP O
12 70 73 1992636 the DT B-NP O
13 74 79 1992636 first JJ I-NP O
14 80 84 1992636 drug NN I-NP O
15 85 93 1992636 designed VBN B-VP O
16 94 96 1992636 to TO I-VP O
17 97 102 1992636 block VB I-VP O
18 103 106 1992636 the DT B-NP O
19 107 112 1992636 final JJ I-NP O
20 113 117 1992636 step NN I-NP O
21 118 120 1992636 in IN B-PP O
22 121 124 1992636 the DT B-NP O
23 125 129 1992636 acid NN I-NP O
24 130 139 1992636 secretory JJ I-NP O
25 140 147 1992636 process NN I-NP O
26 148 154 1992636 within IN B-PP O
27 155 158 1992636 the DT B-NP O
28 159 167 1992636 parietal JJ I-NP O
29 168 172 1992636 cell NN I-NP O
30 172 173 1992636 . . O O

1 174 176 1992636 It PRP B-NP O
2 177 180 1992636 has VBZ B-VP O
3 181 185 1992636 been VBN I-VP O
4 186 191 1992636 shown VBN I-VP O
5 192 194 1992636 to TO I-VP O
6 195 197 1992636 be VB I-VP O
7 198 207 1992636 extremely RB B-ADJP O
8 208 217 1992636 effective JJ I-ADJP O
9 218 220 1992636 in IN B-PP O
10 221 224 1992636 the DT B-NP O
11 225 234 1992636 treatment NN I-NP O
12 235 237 1992636 of IN B-PP O
13 238 244 1992636 peptic JJ B-NP B-Disease
14 245 250 1992636 ulcer NN I-NP I-Disease
15 251 258 1992636 disease NN I-NP I-Disease
16 258 259 1992636 , , O O
17 260 266 1992636 reflux NN B-NP B-Disease
18 267 278 1992636 esophagitis NN I-NP I-Disease
19 278 279 1992636 , , O O
20 280 283 1992636 and CC O O
21 284 287 1992636 the DT B-NP O
22 288 297 1992636 Zollinger NN I-NP B-Disease
23 297 298 1992636 - HYPH I-NP I-Disease
24 298 305 1992636 Ellison NN I-NP I-Disease
25 306 314 1992636 syndrome NN I-NP I-Disease
26 314 315 1992636 . . O O

1 316 324 1992636 Although IN B-SBAR O
2 325 333 1992636 clinical JJ B-NP O
3 334 344 1992636 experience NN I-NP O
4 345 349 1992636 with IN B-PP O
5 350 360 1992636 omeprazole NN B-NP B-Chemical
6 361 363 1992636 is VBZ B-VP O
7 364 369 1992636 still RB B-ADVP O
8 370 377 1992636 limited JJ B-ADJP O
9 377 378 1992636 , , O O
10 379 383 1992636 many JJ B-NP O
11 384 394 1992636 controlled JJ I-NP O
12 395 402 1992636 studies NNS I-NP O
13 403 407 1992636 have VBP B-VP O
14 408 419 1992636 established VBN I-VP O
15 420 423 1992636 the DT B-NP O
16 424 429 1992636 short JJ I-NP O
17 429 430 1992636 - HYPH I-NP O
18 430 434 1992636 term NN I-NP O
19 435 441 1992636 safety NN I-NP O
20 442 444 1992636 of IN B-PP O
21 445 449 1992636 this DT B-NP O
22 450 454 1992636 drug NN I-NP O
23 454 455 1992636 . . O O

1 456 458 1992636 We PRP B-NP O
2 459 465 1992636 report VBP B-VP O
3 466 469 1992636 the DT B-NP O
4 470 475 1992636 first JJ I-NP O
5 476 480 1992636 case NN I-NP O
6 481 483 1992636 of IN B-PP O
7 484 485 1992636 a DT B-NP O
8 486 493 1992636 serious JJ I-NP O
9 494 499 1992636 short JJ I-NP O
10 499 500 1992636 - HYPH I-NP O
11 500 504 1992636 term NN I-NP O
12 505 512 1992636 adverse JJ I-NP O
13 513 521 1992636 reaction NN I-NP O
14 522 526 1992636 with IN B-PP O
15 527 530 1992636 the DT B-NP O
16 531 534 1992636 use NN I-NP O
17 535 537 1992636 of IN B-PP O
18 538 548 1992636 omeprazole NN B-NP B-Chemical
19 548 549 1992636 : : O O
20 550 559 1992636 hemolytic JJ B-NP B-Disease
21 560 566 1992636 anemia NN I-NP I-Disease
22 566 567 1992636 . . O O

1 568 571 1992636 The DT B-NP O
2 572 579 1992636 patient NN I-NP O
3 580 589 1992636 developed VBD B-VP O
4 590 598 1992636 weakness NN B-NP O
5 598 599 1992636 , , O O
6 600 608 1992636 lethargy NN B-NP B-Disease
7 608 609 1992636 , , O O
8 610 613 1992636 and CC O O
9 614 623 1992636 shortness NN B-NP B-Disease
10 624 626 1992636 of IN B-PP I-Disease
11 627 633 1992636 breath NN B-NP I-Disease
12 634 635 1992636 2 CD B-NP O
13 636 640 1992636 days NNS I-NP O
14 641 646 1992636 after IN B-PP O
15 647 655 1992636 starting VBG B-VP O
16 656 663 1992636 therapy NN B-NP O
17 664 668 1992636 with IN B-PP O
18 669 679 1992636 omeprazole NN B-NP B-Chemical
19 679 680 1992636 . . O O

1 681 684 1992636 Two CD B-NP O
2 685 690 1992636 weeks NNS I-NP O
3 691 696 1992636 after IN B-PP O
4 697 700 1992636 the DT B-NP O
5 701 711 1992636 initiation NN I-NP O
6 712 714 1992636 of IN B-PP O
7 715 722 1992636 therapy NN B-NP O
8 722 723 1992636 , , O O
9 724 727 1992636 her PRP$ B-NP O
10 728 738 1992636 hematocrit NN I-NP O
11 739 742 1992636 had VBD B-VP O
12 743 752 1992636 decreased VBN I-VP O
13 753 757 1992636 from IN B-PP O
14 758 763 1992636 44.1% CD B-NP O
15 764 766 1992636 to TO B-PP O
16 767 772 1992636 20.4% CD B-NP O
17 772 773 1992636 , , O O
18 774 777 1992636 and CC O O
19 778 781 1992636 she PRP B-NP O
20 782 785 1992636 had VBD B-VP O
21 786 787 1992636 a DT B-NP O
22 788 796 1992636 positive JJ I-NP O
23 797 803 1992636 direct JJ I-NP O
24 804 810 1992636 Coombs NNS I-NP O
25 811 823 1992636 antiglobulin NN I-NP O
26 824 828 1992636 test NN I-NP O
27 829 832 1992636 and CC O O
28 833 835 1992636 an DT B-NP O
29 836 844 1992636 elevated VBN I-NP O
30 845 853 1992636 indirect JJ I-NP O
31 854 863 1992636 bilirubin NN I-NP B-Chemical
32 863 864 1992636 . . O O

1 865 870 1992636 After IN B-SBAR O
2 871 874 1992636 she PRP B-NP O
3 875 887 1992636 discontinued VBD B-VP O
4 888 891 1992636 the DT B-NP O
5 892 902 1992636 omeprazole NN I-NP B-Chemical
6 902 903 1992636 , , O O
7 904 907 1992636 her PRP$ B-NP O
8 908 918 1992636 hemoglobin NN I-NP O
9 919 922 1992636 and CC I-NP O
10 923 933 1992636 hematocrit NN I-NP O
11 934 943 1992636 gradually RB B-ADVP O
12 944 952 1992636 returned VBD B-VP O
13 953 955 1992636 to TO B-PP O
14 956 962 1992636 normal JJ B-NP O
15 962 963 1992636 . . O O

1 964 967 1992636 The DT B-NP O
2 968 977 1992636 mechanism NN I-NP O
3 978 980 1992636 by IN B-PP O
4 981 986 1992636 which WDT B-NP O
5 987 997 1992636 omeprazole NN B-NP B-Chemical
6 998 1004 1992636 caused VBD B-VP O
7 1005 1008 1992636 the DT B-NP O
8 1009 1018 1992636 patient's NNS I-NP O
9 1019 1028 1992636 hemolytic JJ B-NP B-Disease
10 1029 1035 1992636 anemia NN I-NP I-Disease
11 1036 1038 1992636 is VBZ B-VP O
12 1039 1048 1992636 uncertain JJ B-ADJP O
13 1048 1049 1992636 , , O O
14 1050 1053 1992636 but CC O O
15 1054 1064 1992636 physicians NNS B-NP O
16 1065 1071 1992636 should MD B-VP O
17 1072 1074 1992636 be VB I-VP O
18 1075 1082 1992636 alerted VBN I-VP O
19 1083 1085 1992636 to TO B-PP O
20 1086 1090 1992636 this DT B-NP O
21 1091 1099 1992636 possible JJ I-NP O
22 1100 1107 1992636 adverse JJ I-NP O
23 1108 1114 1992636 effect NN I-NP O
24 1114 1115 1992636 . . O O

1 0 0 11206082 -DOCSTART- -X- -X- O

1 0 3 11206082 Two CD B-NP O
2 4 9 11206082 mouse NN I-NP O
3 10 15 11206082 lines NNS I-NP O
4 16 24 11206082 selected VBN B-VP O
5 25 28 11206082 for IN B-PP O
6 29 41 11206082 differential JJ B-NP O
7 42 55 11206082 sensitivities NNS I-NP O
8 56 58 11206082 to TO B-PP O
9 59 63 11206082 beta SYM B-NP B-Chemical
10 63 64 11206082 - HYPH B-NP I-Chemical
11 64 73 11206082 carboline NN I-NP I-Chemical
12 73 74 11206082 - HYPH B-NP O
13 74 81 11206082 induced VBN I-NP O
14 82 90 11206082 seizures NNS I-NP B-Disease
15 91 94 11206082 are VBP B-VP O
16 95 99 11206082 also RB B-ADVP O
17 100 114 11206082 differentially RB B-ADJP O
18 115 124 11206082 sensitive JJ I-ADJP O
19 125 127 11206082 to TO B-PP O
20 128 135 11206082 various JJ B-NP O
21 136 151 11206082 pharmacological JJ I-NP O
22 152 159 11206082 effects NNS I-NP O
23 160 162 11206082 of IN B-PP O
24 163 168 11206082 other JJ B-NP O
25 169 176 11206082 GABA(A) NN I-NP B-Chemical
26 177 185 11206082 receptor NN I-NP O
27 186 193 11206082 ligands NNS I-NP O
28 193 194 11206082 . . O O
29 195 198 11206082 Two CD B-NP O
30 199 204 11206082 mouse NN I-NP O
31 205 210 11206082 lines NNS I-NP O
32 211 215 11206082 were VBD B-VP O
33 216 227 11206082 selectively RB I-VP O
34 228 232 11206082 bred VBN I-VP O
35 233 242 11206082 according VBG B-PP O
36 243 245 11206082 to TO B-PP O
37 246 251 11206082 their PRP$ B-NP O
38 252 263 11206082 sensitivity NN I-NP O
39 264 265 11206082 ( ( O O
40 265 267 11206082 BS NN B-NP O
41 268 272 11206082 line NN I-NP O
42 272 273 11206082 ) ) O O
43 274 276 11206082 or CC O O
44 277 287 11206082 resistance NN B-NP O
45 288 289 11206082 ( ( O O
46 289 291 11206082 BR NN B-NP O
47 292 296 11206082 line NN I-NP O
48 296 297 11206082 ) ) O O
49 298 300 11206082 to TO B-PP O
50 301 309 11206082 seizures NNS B-NP B-Disease
51 310 317 11206082 induced VBN B-VP O
52 318 320 11206082 by IN B-PP O
53 321 322 11206082 a DT B-NP O
54 323 329 11206082 single JJ I-NP O
55 330 333 11206082 i.p NN I-NP O
56 333 334 11206082 . . O O

1 335 344 11206082 injection NN B-NP O
2 345 347 11206082 of IN B-PP O
3 348 354 11206082 methyl NN B-NP B-Chemical
4 355 359 11206082 beta SYM B-NP I-Chemical
5 359 360 11206082 - HYPH B-NP I-Chemical
6 360 369 11206082 carboline NN I-NP I-Chemical
7 369 370 11206082 - HYPH B-NP I-Chemical
8 370 371 11206082 3 CD I-NP I-Chemical
9 371 372 11206082 - HYPH I-NP I-Chemical
10 372 383 11206082 carboxylate NN I-NP I-Chemical
11 384 385 11206082 ( ( O O
12 385 389 11206082 beta SYM O B-Chemical
13 389 390 11206082 - HYPH O I-Chemical
14 390 393 11206082 CCM NN B-NP I-Chemical
15 393 394 11206082 ) ) O O
16 394 395 11206082 , , O O
17 396 398 11206082 an DT B-NP O
18 399 406 11206082 inverse JJ I-NP O
19 407 414 11206082 agonist NN I-NP O
20 415 417 11206082 of IN B-PP O
21 418 421 11206082 the DT B-NP O
22 422 429 11206082 GABA(A) NN I-NP B-Chemical
23 430 438 11206082 receptor NN I-NP O
24 439 453 11206082 benzodiazepine NN I-NP B-Chemical
25 454 458 11206082 site NN I-NP O
26 458 459 11206082 . . O O

1 460 463 11206082 Our PRP$ B-NP O
2 464 467 11206082 aim NN I-NP O
3 468 471 11206082 was VBD B-VP O
4 472 474 11206082 to TO B-VP O
5 475 487 11206082 characterize VB I-VP O
6 488 492 11206082 both DT B-NP O
7 493 498 11206082 lines NNS I-NP O
8 498 499 11206082 ' POS B-NP O
9 500 513 11206082 sensitivities NNS I-NP O
10 514 516 11206082 to TO B-PP O
11 517 524 11206082 various JJ B-NP O
12 525 538 11206082 physiological JJ I-NP O
13 539 546 11206082 effects NNS I-NP O
14 547 549 11206082 of IN B-PP O
15 550 555 11206082 other JJ B-NP O
16 556 563 11206082 ligands NNS I-NP O
17 564 566 11206082 of IN B-PP O
18 567 570 11206082 the DT B-NP O
19 571 578 11206082 GABA(A) NN I-NP B-Chemical
20 579 587 11206082 receptor NN I-NP O
21 587 588 11206082 . . O O

1 589 591 11206082 We PRP B-NP O
2 592 600 11206082 measured VBD B-VP O
3 601 609 11206082 diazepam NN B-NP B-Chemical
4 609 610 11206082 - HYPH O O
5 610 617 11206082 induced VBN B-NP O
6 618 628 11206082 anxiolysis NN I-NP O
7 629 633 11206082 with IN B-PP O
8 634 637 11206082 the DT B-NP O
9 638 646 11206082 elevated VBN I-NP O
10 647 651 11206082 plus CC I-NP O
11 651 652 11206082 - HYPH I-NP O
12 652 656 11206082 maze NN I-NP O
13 657 661 11206082 test NN I-NP O
14 661 662 11206082 , , O O
15 663 671 11206082 diazepam NN B-NP B-Chemical
16 671 672 11206082 - HYPH B-VP O
17 672 679 11206082 induced VBN B-NP O
18 680 688 11206082 sedation NN I-NP O
19 689 691 11206082 by IN B-PP O
20 692 701 11206082 recording VBG B-VP O
21 702 705 11206082 the DT B-NP O
22 706 715 11206082 vigilance NN I-NP O
23 716 722 11206082 states NNS I-NP O
24 722 723 11206082 , , O O
25 724 727 11206082 and CC O O
26 728 738 11206082 picrotoxin NN B-NP B-Chemical
27 738 739 11206082 - HYPH O O
28 740 743 11206082 and CC O O
29 744 761 11206082 pentylenetetrazol NN B-NP B-Chemical
30 761 762 11206082 - HYPH B-NP O
31 762 769 11206082 induced VBN I-NP O
32 770 778 11206082 seizures NNS I-NP B-Disease
33 779 784 11206082 after IN B-PP O
34 785 788 11206082 i.p NN B-NP O
35 788 789 11206082 . . O O

1 790 800 11206082 injections NNS B-NP O
2 800 801 11206082 . . O O

1 802 809 11206082 Results NNS B-NP O
2 810 819 11206082 presented VBN B-VP O
3 820 824 11206082 here RB B-ADVP O
4 825 829 11206082 show VBP B-VP O
5 830 834 11206082 that IN B-SBAR O
6 835 838 11206082 the DT B-NP O
7 839 851 11206082 differential JJ I-NP O
8 852 865 11206082 sensitivities NNS I-NP O
9 866 868 11206082 of IN B-PP O
10 869 871 11206082 BS NN B-NP O
11 872 875 11206082 and CC I-NP O
12 876 878 11206082 BR NN I-NP O
13 879 884 11206082 lines NNS I-NP O
14 885 887 11206082 to TO B-PP O
15 888 892 11206082 beta SYM O B-Chemical
16 892 893 11206082 - HYPH O I-Chemical
17 893 896 11206082 CCM NN B-NP I-Chemical
18 897 900 11206082 can MD B-VP O
19 901 903 11206082 be VB I-VP O
20 904 912 11206082 extended VBN I-VP O
21 913 915 11206082 to TO B-PP O
22 916 924 11206082 diazepam NN B-NP B-Chemical
23 924 925 11206082 , , O O
24 926 936 11206082 picrotoxin NN B-NP B-Chemical
25 936 937 11206082 , , O O
26 938 941 11206082 and CC O O
27 942 959 11206082 pentylenetetrazol NN B-NP B-Chemical
28 959 960 11206082 , , O O
29 961 971 11206082 suggesting VBG B-VP O
30 972 973 11206082 a DT B-NP O
31 974 981 11206082 genetic JJ I-NP O
32 982 991 11206082 selection NN I-NP O
33 992 994 11206082 of IN B-PP O
34 995 996 11206082 a DT B-NP O
35 997 1004 11206082 general JJ I-NP O
36 1005 1016 11206082 sensitivity NN I-NP O
37 1017 1020 11206082 and CC I-NP O
38 1021 1031 11206082 resistance NN I-NP O
39 1032 1034 11206082 to TO B-PP O
40 1035 1042 11206082 several JJ B-NP O
41 1043 1050 11206082 ligands NNS I-NP O
42 1051 1053 11206082 of IN B-PP O
43 1054 1057 11206082 the DT B-NP O
44 1058 1065 11206082 GABA(A) NN I-NP B-Chemical
45 1066 1074 11206082 receptor NN I-NP O
46 1074 1075 11206082 . . O O

1 0 0 7199841 -DOCSTART- -X- -X- O

1 0 10 7199841 Neurologic JJ B-NP O
2 11 18 7199841 effects NNS I-NP O
3 19 21 7199841 of IN B-PP O
4 22 34 7199841 subarachnoid JJ B-NP O
5 35 49 7199841 administration NN I-NP O
6 50 52 7199841 of IN B-PP O
7 53 54 7199841 2 CD B-NP B-Chemical
8 54 55 7199841 - HYPH I-NP I-Chemical
9 55 69 7199841 chloroprocaine NN I-NP I-Chemical
10 69 70 7199841 - HYPH O I-Chemical
11 70 72 7199841 CE NN B-NP I-Chemical
12 72 73 7199841 , , O O
13 74 85 7199841 bupivacaine NN B-NP B-Chemical
14 85 86 7199841 , , O O
15 87 90 7199841 and CC O O
16 91 94 7199841 low JJ B-NP O
17 95 97 7199841 pH NN I-NP O
18 98 104 7199841 normal JJ I-NP O
19 105 111 7199841 saline NN I-NP O
20 112 114 7199841 in IN B-PP O
21 115 119 7199841 dogs NNS B-NP O
22 119 120 7199841 . . O O
23 121 124 7199841 The DT B-NP O
24 125 132 7199841 purpose NN I-NP O
25 133 135 7199841 of IN B-PP O
26 136 140 7199841 this DT B-NP O
27 141 146 7199841 study NN I-NP O
28 147 150 7199841 was VBD B-VP O
29 151 153 7199841 to TO B-VP O
30 154 162 7199841 evaluate VB I-VP O
31 163 166 7199841 the DT B-NP O
32 167 177 7199841 neurologic JJ I-NP O
33 178 190 7199841 consequences NNS I-NP O
34 191 193 7199841 of IN B-PP O
35 194 204 7199841 deliberate JJ B-NP O
36 205 217 7199841 subarachnoid JJ I-NP O
37 218 227 7199841 injection NN I-NP O
38 228 230 7199841 of IN B-PP O
39 231 236 7199841 large JJ B-NP O
40 237 244 7199841 volumes NNS I-NP O
41 245 247 7199841 of IN B-PP O
42 248 249 7199841 2 CD B-NP B-Chemical
43 249 250 7199841 - HYPH I-NP I-Chemical
44 250 264 7199841 chloroprocaine NN I-NP I-Chemical
45 264 265 7199841 - HYPH I-NP I-Chemical
46 265 267 7199841 CE NN I-NP I-Chemical
47 268 270 7199841 in IN B-PP O
48 271 283 7199841 experimental JJ B-NP O
49 284 291 7199841 animals NNS I-NP O
50 291 292 7199841 . . O O

1 293 296 7199841 The DT B-NP O
2 297 305 7199841 possible JJ I-NP O
3 306 310 7199841 role NN I-NP O
4 311 313 7199841 of IN B-PP O
5 314 317 7199841 low JJ B-NP O
6 318 320 7199841 pH NN I-NP O
7 321 323 7199841 as RB B-CONJP O
8 324 328 7199841 well RB I-CONJP O
9 329 331 7199841 as IN I-CONJP O
10 332 337 7199841 total JJ B-NP O
11 338 344 7199841 volume NN I-NP O
12 345 347 7199841 as IN B-PP O
13 348 357 7199841 potential JJ B-NP O
14 358 365 7199841 factors NNS I-NP O
15 366 368 7199841 in IN B-PP O
16 369 376 7199841 causing VBG B-VP O
17 377 390 7199841 neurotoxicity NN B-NP B-Disease
18 391 394 7199841 was VBD B-VP O
19 395 404 7199841 evaluated VBN I-VP O
20 404 405 7199841 . . O O

1 406 409 7199841 The DT B-NP O
2 410 412 7199841 65 CD I-NP O
3 413 417 7199841 dogs NNS I-NP O
4 418 420 7199841 in IN B-PP O
5 421 424 7199841 the DT B-NP O
6 425 430 7199841 study NN I-NP O
7 431 439 7199841 received VBD B-VP O
8 440 450 7199841 injections NNS B-NP O
9 451 453 7199841 in IN B-PP O
10 454 457 7199841 the DT B-NP O
11 458 470 7199841 subarachnoid JJ I-NP O
12 471 476 7199841 space NN I-NP O
13 477 479 7199841 as IN B-SBAR O
14 480 487 7199841 follows VBZ B-VP O
15 487 488 7199841 : : O O
16 489 490 7199841 6 CD B-NP O
17 491 493 7199841 to TO I-NP O
18 494 495 7199841 8 CD I-NP O
19 496 498 7199841 ml NN I-NP O
20 499 501 7199841 of IN B-PP O
21 502 513 7199841 bupivacaine NN B-NP B-Chemical
22 514 515 7199841 ( ( O O
23 515 516 7199841 N NN B-NP O
24 517 518 7199841 = SYM B-VP O
25 519 521 7199841 15 CD B-NP O
26 521 522 7199841 ) ) O O
27 522 523 7199841 , , O O
28 524 525 7199841 2 CD B-NP B-Chemical
29 525 526 7199841 - HYPH I-NP I-Chemical
30 526 540 7199841 chloroprocaine NN I-NP I-Chemical
31 540 541 7199841 - HYPH O I-Chemical
32 541 543 7199841 CE NN B-NP I-Chemical
33 544 545 7199841 ( ( O O
34 545 546 7199841 N NN B-NP O
35 547 548 7199841 = SYM B-VP O
36 549 551 7199841 20 CD B-NP O
37 551 552 7199841 ) ) O O
38 552 553 7199841 , , O O
39 554 557 7199841 low JJ B-NP O
40 558 560 7199841 pH NN I-NP O
41 561 567 7199841 normal JJ I-NP O
42 568 574 7199841 saline NN I-NP O
43 575 576 7199841 ( ( O O
44 576 578 7199841 pH NN B-NP O
45 579 582 7199841 3.0 CD I-NP O
46 582 583 7199841 ) ) O O
47 584 585 7199841 ( ( O O
48 585 586 7199841 N NN B-NP O
49 587 588 7199841 = SYM B-VP O
50 589 591 7199841 20 CD B-NP O
51 591 592 7199841 ) ) O O
52 592 593 7199841 , , O O
53 594 596 7199841 or CC O O
54 597 603 7199841 normal JJ B-NP O
55 604 610 7199841 saline NN I-NP O
56 611 612 7199841 ( ( O O
57 612 613 7199841 N NN B-NP O
58 614 615 7199841 = SYM B-VP O
59 616 618 7199841 10 CD B-NP O
60 618 619 7199841 ) ) O O
61 619 620 7199841 . . O O

1 621 623 7199841 Of IN B-PP O
2 624 627 7199841 the DT B-NP O
3 628 630 7199841 20 CD I-NP O
4 631 638 7199841 animals NNS I-NP O
5 639 643 7199841 that WDT B-NP O
6 644 652 7199841 received VBD B-VP O
7 653 665 7199841 subarachnoid JJ B-NP O
8 666 675 7199841 injection NN I-NP O
9 676 678 7199841 of IN B-PP O
10 679 680 7199841 2 CD B-NP B-Chemical
11 680 681 7199841 - HYPH I-NP I-Chemical
12 681 695 7199841 chloroprocaine NN I-NP I-Chemical
13 695 696 7199841 - HYPH O I-Chemical
14 696 698 7199841 CE NN B-NP I-Chemical
15 699 704 7199841 seven CD I-NP O
16 705 706 7199841 ( ( O O
17 706 709 7199841 35% NN B-NP O
18 709 710 7199841 ) ) O O
19 711 720 7199841 developed VBD B-VP O
20 721 725 7199841 hind NN B-NP O
21 725 726 7199841 - HYPH B-NP O
22 726 730 7199841 limb NN I-NP O
23 731 740 7199841 paralysis NN I-NP B-Disease
24 740 741 7199841 . . O O

1 742 746 7199841 None NN B-NP O
2 747 749 7199841 of IN B-PP O
3 750 753 7199841 the DT B-NP O
4 754 761 7199841 animals NNS I-NP O
5 762 766 7199841 that WDT B-NP O
6 767 775 7199841 received VBD B-VP O
7 776 787 7199841 bupivacaine NN B-NP B-Chemical
8 787 788 7199841 , , O O
9 789 795 7199841 normal JJ B-NP O
10 796 802 7199841 saline NN I-NP O
11 802 803 7199841 , , O O
12 804 806 7199841 or CC O O
13 807 813 7199841 normal JJ B-NP O
14 814 820 7199841 saline NN I-NP O
15 821 829 7199841 titrated VBN B-VP O
16 830 832 7199841 to TO B-PP O
17 833 834 7199841 a DT B-NP O
18 835 837 7199841 pH NN I-NP O
19 838 841 7199841 3.0 CD I-NP O
20 842 851 7199841 developed VBD B-VP O
21 852 856 7199841 hind NN B-NP O
22 856 857 7199841 - HYPH B-NP O
23 857 861 7199841 limb NN I-NP O
24 862 871 7199841 paralysis NN I-NP B-Disease
25 871 872 7199841 . . O O

1 873 875 7199841 Of IN B-PP O
2 876 879 7199841 the DT B-NP O
3 880 882 7199841 15 CD I-NP O
4 883 889 7199841 spinal JJ I-NP O
5 890 895 7199841 cords NNS I-NP O
6 896 898 7199841 of IN B-PP O
7 899 902 7199841 the DT B-NP O
8 903 910 7199841 animals NNS I-NP O
9 911 915 7199841 that WDT B-NP O
10 916 924 7199841 received VBD B-VP O
11 925 926 7199841 2 CD B-NP B-Chemical
12 926 927 7199841 - HYPH I-NP I-Chemical
13 927 941 7199841 chloroprocaine NN I-NP I-Chemical
14 941 942 7199841 - HYPH I-NP I-Chemical
15 942 944 7199841 CE NN I-NP I-Chemical
16 944 945 7199841 , , O O
17 946 948 7199841 13 CD B-NP O
18 949 955 7199841 showed VBD B-VP O
19 956 963 7199841 subpial JJ B-NP B-Disease
20 964 972 7199841 necrosis NN I-NP I-Disease
21 972 973 7199841 ; : O O
22 974 977 7199841 the DT B-NP O
23 978 983 7199841 nerve NN I-NP O
24 984 989 7199841 roots NNS I-NP O
25 990 993 7199841 and CC O O
26 994 1006 7199841 subarachnoid JJ B-NP O
27 1007 1014 7199841 vessels NNS I-NP O
28 1015 1019 7199841 were VBD B-VP O
29 1020 1026 7199841 normal JJ B-ADJP O
30 1026 1027 7199841 . . O O

1 1028 1031 7199841 The DT B-NP O
2 1032 1038 7199841 spinal JJ I-NP O
3 1039 1044 7199841 cords NNS I-NP O
4 1045 1047 7199841 of IN B-PP O
5 1048 1051 7199841 the DT B-NP O
6 1052 1059 7199841 animals NNS I-NP O
7 1060 1064 7199841 that WDT B-NP O
8 1065 1073 7199841 received VBD B-VP O
9 1074 1085 7199841 bupivacaine NN B-NP B-Chemical
10 1085 1086 7199841 , , O O
11 1087 1090 7199841 low JJ B-NP O
12 1091 1093 7199841 pH NN I-NP O
13 1094 1100 7199841 normal JJ I-NP O
14 1101 1107 7199841 saline NN I-NP O
15 1108 1109 7199841 ( ( O O
16 1109 1111 7199841 pH NN B-NP O
17 1112 1115 7199841 3.0 CD I-NP O
18 1115 1116 7199841 ) ) O O
19 1116 1117 7199841 , , O O
20 1118 1120 7199841 or CC O O
21 1121 1127 7199841 normal JJ B-NP O
22 1128 1134 7199841 saline NN I-NP O
23 1135 1138 7199841 did VBD B-VP O
24 1139 1142 7199841 not RB I-VP O
25 1143 1147 7199841 show VB I-VP O
26 1148 1156 7199841 abnormal JJ B-NP O
27 1157 1165 7199841 findings NNS I-NP O
28 1165 1166 7199841 . . O O

1 0 0 19820426 -DOCSTART- -X- -X- O

1 0 4 19820426 Twin CD B-NP O
2 5 12 19820426 preterm JJ I-NP O
3 13 21 19820426 neonates NNS I-NP O
4 22 26 19820426 with IN B-PP O
5 27 34 19820426 cardiac JJ B-NP B-Disease
6 35 43 19820426 toxicity NN I-NP I-Disease
7 44 51 19820426 related VBN B-VP O
8 52 54 19820426 to TO B-PP O
9 55 64 19820426 lopinavir NN B-NP B-Chemical
10 64 65 19820426 / SYM O I-Chemical
11 65 74 19820426 ritonavir NN B-NP I-Chemical
12 75 82 19820426 therapy NN I-NP O
13 82 83 19820426 . . O O
14 84 86 19820426 We PRP B-NP O
15 87 93 19820426 report VBP B-VP O
16 94 98 19820426 twin JJ B-NP O
17 99 107 19820426 neonates NNS I-NP O
18 108 111 19820426 who WP B-NP O
19 112 116 19820426 were VBD B-VP O
20 117 121 19820426 born VBN I-VP O
21 122 133 19820426 prematurely RB B-ADVP O
22 134 136 19820426 at IN B-PP O
23 137 139 19820426 32 CD B-NP O
24 140 145 19820426 weeks NNS I-NP O
25 146 148 19820426 of IN B-PP O
26 149 158 19820426 gestation NN B-NP O
27 159 161 19820426 to TO B-PP O
28 162 163 19820426 a DT B-NP O
29 164 170 19820426 mother NN I-NP O
30 171 175 19820426 with IN B-PP O
31 176 181 19820426 human JJ B-NP B-Disease
32 182 198 19820426 immunodeficiency NN I-NP I-Disease
33 199 204 19820426 virus NN I-NP I-Disease
34 205 214 19820426 infection NN I-NP I-Disease
35 214 215 19820426 . . O O

1 216 219 19820426 One CD B-NP O
2 220 222 19820426 of IN B-PP O
3 223 226 19820426 the DT B-NP O
4 227 232 19820426 twins NNS I-NP O
5 233 242 19820426 developed VBD B-VP O
6 243 251 19820426 complete JJ B-NP O
7 252 257 19820426 heart NN I-NP B-Disease
8 258 263 19820426 block NN I-NP I-Disease
9 264 267 19820426 and CC O O
10 268 275 19820426 dilated JJ B-NP B-Disease
11 276 290 19820426 cardiomyopathy NN I-NP I-Disease
12 291 298 19820426 related VBN B-VP O
13 299 301 19820426 to TO B-PP O
14 302 311 19820426 lopinavir NN B-NP B-Chemical
15 311 312 19820426 / SYM B-NP I-Chemical
16 312 321 19820426 ritonavir NN I-NP I-Chemical
17 322 329 19820426 therapy NN I-NP O
18 329 330 19820426 , , O O
19 331 332 19820426 a DT B-NP O
20 333 340 19820426 boosted VBN I-NP O
21 341 349 19820426 protease NN I-NP O
22 349 350 19820426 - HYPH I-NP O
23 350 359 19820426 inhibitor NN I-NP O
24 360 365 19820426 agent NN I-NP O
25 365 366 19820426 , , O O
26 367 372 19820426 while IN B-SBAR O
27 373 376 19820426 the DT B-NP O
28 377 382 19820426 other JJ I-NP O
29 383 387 19820426 twin NN I-NP O
30 388 397 19820426 developed VBD B-VP O
31 398 402 19820426 mild JJ B-NP O
32 403 414 19820426 bradycardia NN I-NP B-Disease
33 414 415 19820426 . . O O

1 416 418 19820426 We PRP B-NP O
2 419 428 19820426 recommend VBP B-VP O
3 429 436 19820426 caution NN B-NP O
4 437 439 19820426 in IN B-PP O
5 440 443 19820426 the DT B-NP O
6 444 447 19820426 use NN I-NP O
7 448 450 19820426 of IN B-PP O
8 451 460 19820426 lopinavir NN B-NP B-Chemical
9 460 461 19820426 / SYM B-NP I-Chemical
10 461 470 19820426 ritonavir NN I-NP I-Chemical
11 471 473 19820426 in IN B-PP O
12 474 477 19820426 the DT B-NP O
13 478 487 19820426 immediate JJ I-NP O
14 488 496 19820426 neonatal JJ I-NP O
15 497 503 19820426 period NN I-NP O
16 503 504 19820426 . . O O

1 0 0 20003049 -DOCSTART- -X- -X- O

1 0 9 20003049 Prolonged JJ B-NP O
2 10 19 20003049 elevation NN I-NP O
3 20 22 20003049 of IN B-PP O
4 23 29 20003049 plasma NN B-NP O
5 30 40 20003049 argatroban NN I-NP B-Chemical
6 41 43 20003049 in IN B-PP O
7 44 45 20003049 a DT B-NP O
8 46 53 20003049 cardiac JJ I-NP O
9 54 64 20003049 transplant NN I-NP O
10 65 72 20003049 patient NN I-NP O
11 73 77 20003049 with IN B-PP O
12 78 79 20003049 a DT B-NP O
13 80 89 20003049 suspected VBN I-NP O
14 90 97 20003049 history NN I-NP O
15 98 100 20003049 of IN B-PP O
16 101 108 20003049 heparin NN B-NP B-Chemical
17 108 109 20003049 - HYPH B-NP O
18 109 116 20003049 induced VBN I-NP O
19 117 133 20003049 thrombocytopenia NN I-NP B-Disease
20 134 138 20003049 with IN B-PP O
21 139 149 20003049 thrombosis NN B-NP B-Disease
22 149 150 20003049 . . O O
23 151 161 20003049 BACKGROUND NN B-NP O
24 161 162 20003049 : : O O
25 163 169 20003049 Direct JJ B-NP O
26 170 178 20003049 thrombin NN I-NP O
27 179 189 20003049 inhibitors NNS I-NP O
28 190 191 20003049 ( ( O O
29 191 195 20003049 DTIs NNS B-NP O
30 195 196 20003049 ) ) O O
31 197 204 20003049 provide VBP B-VP O
32 205 207 20003049 an DT B-NP O
33 208 219 20003049 alternative JJ I-NP O
34 220 226 20003049 method NN I-NP O
35 227 229 20003049 of IN B-PP O
36 230 245 20003049 anticoagulation NN B-NP O
37 246 249 20003049 for IN B-PP O
38 250 258 20003049 patients NNS B-NP O
39 259 263 20003049 with IN B-PP O
40 264 265 20003049 a DT B-NP O
41 266 273 20003049 history NN I-NP O
42 274 276 20003049 of IN B-PP O
43 277 284 20003049 heparin NN B-NP B-Chemical
44 284 285 20003049 - HYPH B-NP O
45 285 292 20003049 induced VBN I-NP O
46 293 309 20003049 thrombocytopenia NN I-NP B-Disease
47 310 311 20003049 ( ( O O
48 311 314 20003049 HIT NN B-NP B-Disease
49 314 315 20003049 ) ) O O
50 316 318 20003049 or CC O O
51 319 322 20003049 HIT NN B-NP B-Disease
52 323 327 20003049 with IN B-PP O
53 328 338 20003049 thrombosis NN B-NP B-Disease
54 339 340 20003049 ( ( O O
55 340 344 20003049 HITT NN B-NP B-Disease
56 344 345 20003049 ) ) O O
57 346 356 20003049 undergoing VBG B-VP O
58 357 372 20003049 cardiopulmonary JJ B-NP O
59 373 379 20003049 bypass NN I-NP O
60 380 381 20003049 ( ( O O
61 381 384 20003049 CPB NN B-NP O
62 384 385 20003049 ) ) O O
63 385 386 20003049 . . O O

1 387 389 20003049 In IN B-PP O
2 390 393 20003049 the DT B-NP O
3 394 403 20003049 following VBG I-NP O
4 404 410 20003049 report NN I-NP O
5 410 411 20003049 , , O O
6 412 413 20003049 a DT B-NP O
7 414 416 20003049 65 CD I-NP O
8 416 417 20003049 - HYPH I-NP O
9 417 421 20003049 year NN I-NP O
10 421 422 20003049 - HYPH O O
11 422 425 20003049 old JJ B-NP O
12 426 436 20003049 critically RB I-NP B-Disease
13 437 440 20003049 ill JJ I-NP I-Disease
14 441 448 20003049 patient NN I-NP O
15 449 453 20003049 with IN B-PP O
16 454 455 20003049 a DT B-NP O
17 456 465 20003049 suspected VBN I-NP O
18 466 473 20003049 history NN I-NP O
19 474 476 20003049 of IN B-PP O
20 477 481 20003049 HITT NN B-NP B-Disease
21 482 485 20003049 was VBD B-VP O
22 486 498 20003049 administered VBN I-VP O
23 499 509 20003049 argatroban NN B-NP B-Chemical
24 510 513 20003049 for IN B-PP O
25 514 529 20003049 anticoagulation NN B-NP O
26 530 532 20003049 on IN B-PP O
27 533 539 20003049 bypass NN B-NP O
28 540 546 20003049 during IN B-PP O
29 547 552 20003049 heart NN B-NP O
30 553 568 20003049 transplantation NN I-NP O
31 568 569 20003049 . . O O

1 570 573 20003049 The DT B-NP O
2 574 581 20003049 patient NN I-NP O
3 582 590 20003049 required VBD B-VP O
4 591 598 20003049 massive JJ B-NP O
5 599 610 20003049 transfusion NN I-NP O
6 611 618 20003049 support NN I-NP O
7 619 620 20003049 ( ( O O
8 620 622 20003049 55 CD B-NP O
9 623 628 20003049 units NNS I-NP O
10 629 631 20003049 of IN B-PP O
11 632 635 20003049 red JJ B-NP O
12 636 641 20003049 blood NN I-NP O
13 642 647 20003049 cells NNS I-NP O
14 647 648 20003049 , , O O
15 649 651 20003049 42 CD B-NP O
16 652 657 20003049 units NNS I-NP O
17 658 660 20003049 of IN B-PP O
18 661 666 20003049 fresh JJ B-NP O
19 666 667 20003049 - HYPH I-NP O
20 667 673 20003049 frozen JJ I-NP O
21 674 680 20003049 plasma NN I-NP O
22 680 681 20003049 , , O O
23 682 684 20003049 40 CD B-NP O
24 685 690 20003049 units NNS I-NP O
25 691 693 20003049 of IN B-PP O
26 694 709 20003049 cryoprecipitate NN B-NP O
27 709 710 20003049 , , O O
28 711 713 20003049 40 CD B-NP O
29 714 719 20003049 units NNS I-NP O
30 720 722 20003049 of IN B-PP O
31 723 732 20003049 platelets NNS B-NP O
32 732 733 20003049 , , O O
33 734 737 20003049 and CC O O
34 738 743 20003049 three CD B-NP O
35 744 749 20003049 doses NNS I-NP O
36 750 752 20003049 of IN B-PP O
37 753 764 20003049 recombinant JJ B-NP O
38 765 771 20003049 Factor NN I-NP O
39 772 776 20003049 VIIa NN I-NP O
40 776 777 20003049 ) ) O O
41 778 781 20003049 for IN B-PP O
42 782 788 20003049 severe JJ B-NP O
43 789 803 20003049 intraoperative JJ I-NP B-Disease
44 804 807 20003049 and CC I-NP I-Disease
45 808 821 20003049 postoperative JJ I-NP I-Disease
46 822 830 20003049 bleeding NN I-NP I-Disease
47 830 831 20003049 . . O O

1 832 837 20003049 STUDY NN B-NP O
2 838 844 20003049 DESIGN NN I-NP O
3 845 848 20003049 AND CC I-NP O
4 849 856 20003049 METHODS NNS I-NP O
5 856 857 20003049 : : O O
6 858 864 20003049 Plasma NN B-NP O
7 865 872 20003049 samples NNS I-NP O
8 873 877 20003049 from IN B-PP O
9 878 884 20003049 before IN B-PP O
10 885 888 20003049 and CC I-PP O
11 889 894 20003049 after IN I-PP O
12 895 898 20003049 CPB NN B-NP O
13 899 903 20003049 were VBD B-VP O
14 904 912 20003049 analyzed VBN I-VP O
15 913 928 20003049 postoperatively RB B-ADVP O
16 929 932 20003049 for IN B-PP O
17 933 943 20003049 argatroban JJ B-NP B-Chemical
18 944 957 20003049 concentration NN I-NP O
19 958 963 20003049 using VBG B-VP O
20 964 965 20003049 a DT B-NP O
21 966 974 20003049 modified VBN I-NP O
22 975 981 20003049 ecarin NN I-NP O
23 982 990 20003049 clotting NN I-NP O
24 991 995 20003049 time NN I-NP O
25 996 997 20003049 ( ( O O
26 997 1000 20003049 ECT NN B-NP O
27 1000 1001 20003049 ) ) O O
28 1002 1007 20003049 assay NN B-NP O
29 1007 1008 20003049 . . O O

1 1009 1016 20003049 RESULTS NNS B-NP O
2 1016 1017 20003049 : : O O
3 1018 1030 20003049 Unexpectedly RB B-NP O
4 1031 1035 20003049 high JJ I-NP O
5 1036 1050 20003049 concentrations NNS I-NP O
6 1051 1053 20003049 of IN B-PP O
7 1054 1064 20003049 argatroban NN B-NP B-Chemical
8 1065 1069 20003049 were VBD B-VP O
9 1070 1078 20003049 measured VBN I-VP O
10 1079 1081 20003049 in IN B-PP O
11 1082 1087 20003049 these DT B-NP O
12 1088 1095 20003049 samples NNS I-NP O
13 1096 1097 20003049 ( ( O O
14 1097 1102 20003049 range NN B-NP O
15 1102 1103 20003049 , , O O
16 1104 1105 20003049 0 CD B-NP O
17 1105 1106 20003049 - HYPH I-NP O
18 1106 1108 20003049 32 CD I-NP O
19 1109 1115 20003049 microg NN I-NP O
20 1115 1116 20003049 / SYM B-NP O
21 1116 1118 20003049 mL NN I-NP O
22 1118 1119 20003049 ) ) O O
23 1119 1120 20003049 , , O O
24 1121 1124 20003049 and CC O O
25 1125 1126 20003049 a DT B-NP O
26 1127 1136 20003049 prolonged VBN I-NP O
27 1137 1143 20003049 plasma NN I-NP O
28 1144 1154 20003049 argatroban NN I-NP B-Chemical
29 1155 1159 20003049 half NN I-NP O
30 1160 1164 20003049 life NN I-NP O
31 1165 1166 20003049 ( ( O O
32 1166 1169 20003049 t(1 NN B-NP O
33 1169 1170 20003049 / SYM O O
34 1170 1171 20003049 2 CD B-NP O
35 1171 1172 20003049 ) ) O O
36 1172 1173 20003049 ) ) O O
37 1174 1176 20003049 of IN B-PP O
38 1177 1180 20003049 514 CD B-NP O
39 1181 1188 20003049 minutes NNS I-NP O
40 1189 1192 20003049 was VBD B-VP O
41 1193 1201 20003049 observed VBN I-VP O
42 1202 1203 20003049 ( ( O O
43 1203 1212 20003049 published VBN B-NP O
44 1213 1224 20003049 elimination NN I-NP O
45 1225 1228 20003049 t(1 NN I-NP O
46 1228 1229 20003049 / SYM B-NP O
47 1229 1230 20003049 2 CD I-NP O
48 1230 1231 20003049 ) ) O O
49 1232 1234 20003049 is VBZ B-VP O
50 1235 1237 20003049 39 CD B-NP O
51 1237 1238 20003049 - HYPH I-NP O
52 1238 1240 20003049 51 CD I-NP O
53 1241 1248 20003049 minutes NNS I-NP O
54 1249 1250 20003049 [ ( O O
55 1250 1251 20003049 < SYM B-NP O
56 1252 1254 20003049 or CC O O
57 1255 1256 20003049 = SYM B-VP O
58 1257 1260 20003049 181 CD B-NP O
59 1261 1268 20003049 minutes NNS I-NP O
60 1269 1273 20003049 with IN B-PP O
61 1274 1281 20003049 hepatic JJ B-NP B-Disease
62 1282 1292 20003049 impairment NN I-NP I-Disease
63 1292 1293 20003049 ] ) O O
64 1293 1294 20003049 ) ) O O
65 1294 1295 20003049 . . O O

1 1296 1307 20003049 CONCLUSIONS NNS B-NP O
2 1307 1308 20003049 : : O O
3 1309 1320 20003049 Correlation NN B-NP O
4 1321 1323 20003049 of IN B-PP O
5 1324 1330 20003049 plasma NN B-NP O
6 1331 1341 20003049 argatroban NN I-NP B-Chemical
7 1342 1355 20003049 concentration NN I-NP O
8 1356 1362 20003049 versus IN B-PP O
9 1363 1366 20003049 the DT B-NP O
10 1367 1376 20003049 patient's NNS I-NP O
11 1377 1388 20003049 coagulation NN I-NP O
12 1389 1398 20003049 variables NNS I-NP O
13 1399 1402 20003049 and CC O O
14 1403 1411 20003049 clinical JJ B-NP O
15 1412 1418 20003049 course NN I-NP O
16 1419 1426 20003049 suggest VBP B-VP O
17 1427 1431 20003049 that IN B-SBAR O
18 1432 1441 20003049 prolonged JJ B-NP O
19 1442 1450 20003049 elevated JJ I-NP O
20 1451 1457 20003049 levels NNS I-NP O
21 1458 1460 20003049 of IN B-PP O
22 1461 1467 20003049 plasma NN B-NP O
23 1468 1478 20003049 argatroban NN I-NP B-Chemical
24 1479 1482 20003049 may MD B-VP O
25 1483 1487 20003049 have VB I-VP O
26 1488 1499 20003049 contributed VBN I-VP O
27 1500 1502 20003049 to TO B-PP O
28 1503 1506 20003049 the DT B-NP O
29 1507 1516 20003049 patient's NNS I-NP O
30 1517 1525 20003049 extended VBD B-VP O
31 1526 1538 20003049 coagulopathy NN B-NP B-Disease
32 1538 1539 20003049 . . O O

1 1540 1547 20003049 Because IN B-SBAR O
2 1548 1552 20003049 DTIs NNS B-NP O
3 1553 1555 20003049 do VBP B-VP O
4 1556 1559 20003049 not RB I-VP O
5 1560 1564 20003049 have VB I-VP O
6 1565 1573 20003049 reversal JJ B-NP O
7 1574 1580 20003049 agents NNS I-NP O
8 1580 1581 20003049 , , O O
9 1582 1590 20003049 surgical JJ B-NP O
10 1591 1596 20003049 teams NNS I-NP O
11 1597 1600 20003049 and CC O O
12 1601 1612 20003049 transfusion NN B-NP O
13 1613 1621 20003049 services NNS I-NP O
14 1622 1628 20003049 should MD B-VP O
15 1629 1635 20003049 remain VB I-VP O
16 1636 1641 20003049 aware JJ B-ADJP O
17 1642 1644 20003049 of IN B-PP O
18 1645 1648 20003049 the DT B-NP O
19 1649 1660 20003049 possibility NN I-NP O
20 1661 1663 20003049 of IN B-PP O
21 1664 1671 20003049 massive JJ B-NP O
22 1672 1683 20003049 transfusion NN I-NP O
23 1684 1690 20003049 events NNS I-NP O
24 1691 1697 20003049 during IN B-PP O
25 1698 1713 20003049 anticoagulation NN B-NP O
26 1714 1718 20003049 with IN B-PP O
27 1719 1724 20003049 these DT B-NP O
28 1725 1731 20003049 agents NNS I-NP O
29 1731 1732 20003049 . . O O

1 1733 1737 20003049 This DT B-NP O
2 1738 1740 20003049 is VBZ B-VP O
3 1741 1744 20003049 the DT B-NP O
4 1745 1750 20003049 first JJ I-NP O
5 1751 1757 20003049 report NN I-NP O
6 1758 1760 20003049 to TO B-VP O
7 1761 1768 20003049 measure VB I-VP O
8 1769 1775 20003049 plasma NN B-NP O
9 1776 1786 20003049 argatroban JJ I-NP B-Chemical
10 1787 1800 20003049 concentration NN I-NP O
11 1801 1803 20003049 in IN B-PP O
12 1804 1807 20003049 the DT B-NP O
13 1808 1815 20003049 context NN I-NP O
14 1816 1818 20003049 of IN B-PP O
15 1819 1822 20003049 CPB NN B-NP O
16 1823 1826 20003049 and CC O O
17 1827 1835 20003049 extended JJ B-NP O
18 1836 1848 20003049 coagulopathy NN I-NP B-Disease
19 1848 1849 20003049 . . O O

1 0 0 10706004 -DOCSTART- -X- -X- O

1 0 7 10706004 Changes NNS B-NP O
2 8 10 10706004 of IN B-PP O
3 11 17 10706004 sodium NN B-NP B-Chemical
4 18 21 10706004 and CC I-NP O
5 22 25 10706004 ATP NN I-NP B-Chemical
6 26 36 10706004 affinities NNS I-NP O
7 37 39 10706004 of IN B-PP O
8 40 43 10706004 the DT B-NP O
9 44 51 10706004 cardiac JJ I-NP O
10 52 58 10706004 (Na,K) NN I-NP B-Chemical
11 58 59 10706004 - HYPH B-NP O
12 59 65 10706004 ATPase NN I-NP O
13 66 72 10706004 during IN B-PP O
14 73 76 10706004 and CC I-PP O
15 77 82 10706004 after IN I-PP O
16 83 89 10706004 nitric JJ B-NP B-Chemical
17 90 95 10706004 oxide NN I-NP I-Chemical
18 96 105 10706004 deficient JJ I-NP O
19 106 118 10706004 hypertension NN I-NP B-Disease
20 118 119 10706004 . . O O
21 120 122 10706004 In IN B-PP O
22 123 126 10706004 the DT B-NP O
23 127 141 10706004 cardiovascular JJ I-NP O
24 142 148 10706004 system NN I-NP O
25 148 149 10706004 , , O O
26 150 152 10706004 NO NN B-NP B-Chemical
27 153 155 10706004 is VBZ B-VP O
28 156 164 10706004 involved VBN I-VP O
29 165 167 10706004 in IN B-PP O
30 168 171 10706004 the DT B-NP O
31 172 182 10706004 regulation NN I-NP O
32 183 185 10706004 of IN B-PP O
33 186 187 10706004 a DT B-NP O
34 188 195 10706004 variety NN I-NP O
35 196 198 10706004 of IN B-PP O
36 199 208 10706004 functions NNS B-NP O
37 208 209 10706004 . . O O

1 210 220 10706004 Inhibition NN B-NP O
2 221 223 10706004 of IN B-PP O
3 224 226 10706004 NO NN B-NP B-Chemical
4 227 236 10706004 synthesis NN I-NP O
5 237 244 10706004 induces VBZ B-VP O
6 245 254 10706004 sustained JJ B-NP O
7 255 267 10706004 hypertension NN I-NP B-Disease
8 267 268 10706004 . . O O

1 269 271 10706004 In IN B-PP O
2 272 279 10706004 several JJ B-NP O
3 280 286 10706004 models NNS I-NP O
4 287 289 10706004 of IN B-PP O
5 290 302 10706004 hypertension NN B-NP B-Disease
6 302 303 10706004 , , O O
7 304 313 10706004 elevation NN B-NP O
8 314 316 10706004 of IN B-PP O
9 317 330 10706004 intracellular JJ B-NP O
10 331 337 10706004 sodium NN I-NP B-Chemical
11 338 343 10706004 level NN I-NP O
12 344 347 10706004 was VBD B-VP O
13 348 358 10706004 documented VBN I-VP O
14 359 361 10706004 in IN B-PP O
15 362 369 10706004 cardiac JJ B-NP O
16 370 376 10706004 tissue NN I-NP O
17 376 377 10706004 . . O O

1 378 380 10706004 To TO B-VP O
2 381 387 10706004 assess VB I-VP O
3 388 391 10706004 the DT B-NP O
4 392 401 10706004 molecular JJ I-NP O
5 402 407 10706004 basis NN I-NP O
6 408 410 10706004 of IN B-PP O
7 411 423 10706004 disturbances NNS B-NP O
8 424 426 10706004 in IN B-PP O
9 427 443 10706004 transmembraneous JJ B-NP O
10 444 453 10706004 transport NN I-NP O
11 454 456 10706004 of IN B-PP O
12 457 460 10706004 Na+ NN B-NP B-Chemical
13 460 461 10706004 , , O O
14 462 464 10706004 we PRP B-NP O
15 465 472 10706004 studied VBD B-VP O
16 473 476 10706004 the DT B-NP O
17 477 485 10706004 response NN I-NP O
18 486 488 10706004 of IN B-PP O
19 489 496 10706004 cardiac JJ B-NP O
20 497 503 10706004 (Na,K) NN I-NP B-Chemical
21 503 504 10706004 - HYPH B-NP O
22 504 510 10706004 ATPase NN I-NP O
23 511 513 10706004 to TO B-PP O
24 514 516 10706004 NO NN B-NP B-Chemical
25 516 517 10706004 - HYPH B-NP O
26 517 526 10706004 deficient JJ I-NP O
27 527 539 10706004 hypertension NN I-NP B-Disease
28 540 547 10706004 induced VBN B-VP O
29 548 550 10706004 in IN B-PP O
30 551 555 10706004 rats NNS B-NP O
31 556 558 10706004 by IN B-PP O
32 559 561 10706004 NO NN B-NP B-Chemical
33 561 562 10706004 - HYPH I-NP O
34 562 570 10706004 synthase NN I-NP O
35 571 581 10706004 inhibition NN I-NP O
36 582 586 10706004 with IN B-PP O
37 587 589 10706004 40 CD B-NP O
38 590 592 10706004 mg NN I-NP O
39 592 593 10706004 / SYM B-NP O
40 593 595 10706004 kg NN I-NP O
41 595 596 10706004 / SYM O O
42 596 599 10706004 day NN B-NP O
43 600 604 10706004 N(G) NN I-NP B-Chemical
44 604 605 10706004 - HYPH B-NP I-Chemical
45 605 610 10706004 nitro NN I-NP I-Chemical
46 610 611 10706004 - HYPH B-NP I-Chemical
47 611 612 10706004 L NN I-NP I-Chemical
48 612 613 10706004 - HYPH B-NP I-Chemical
49 613 621 10706004 arginine NN I-NP I-Chemical
50 622 628 10706004 methyl NN I-NP I-Chemical
51 629 634 10706004 ester NN I-NP I-Chemical
52 635 636 10706004 ( ( O O
53 636 637 10706004 L NN B-NP B-Chemical
54 637 638 10706004 - HYPH O I-Chemical
55 638 642 10706004 NAME NN B-NP I-Chemical
56 642 643 10706004 ) ) O O
57 644 647 10706004 for IN B-PP O
58 648 649 10706004 4 CD B-NP O
59 650 654 10706004 four CD I-NP O
60 655 660 10706004 weeks NNS I-NP O
61 660 661 10706004 . . O O

1 662 667 10706004 After IN B-PP O
2 668 669 10706004 4 CD B-NP O
3 669 670 10706004 - HYPH B-NP O
4 670 674 10706004 week NN I-NP O
5 675 689 10706004 administration NN I-NP O
6 690 692 10706004 of IN B-PP O
7 693 694 10706004 L NN B-NP B-Chemical
8 694 695 10706004 - HYPH O I-Chemical
9 695 699 10706004 NAME NN B-NP I-Chemical
10 699 700 10706004 , , O O
11 701 704 10706004 the DT B-NP O
12 705 713 10706004 systolic JJ I-NP O
13 714 719 10706004 blood NN I-NP O
14 720 728 10706004 pressure NN I-NP O
15 729 730 10706004 ( ( O O
16 730 733 10706004 SBP NN B-NP O
17 733 734 10706004 ) ) O O
18 735 744 10706004 increased VBN B-VP O
19 745 747 10706004 by IN B-PP O
20 748 751 10706004 36% NN B-NP O
21 751 752 10706004 . . O O

1 753 756 10706004 Two CD B-NP O
2 757 762 10706004 weeks NNS I-NP O
3 763 768 10706004 after IN B-PP O
4 769 780 10706004 terminating VBG B-VP O
5 781 784 10706004 the DT B-NP O
6 785 794 10706004 treatment NN I-NP O
7 794 795 10706004 , , O O
8 796 799 10706004 the DT B-NP O
9 800 803 10706004 SBP NN I-NP O
10 804 813 10706004 recovered VBD B-VP O
11 814 816 10706004 to TO B-VP O
12 817 824 10706004 control VB I-VP O
13 825 830 10706004 value NN B-NP O
14 830 831 10706004 . . O O

1 832 836 10706004 When WRB B-ADVP O
2 837 847 10706004 activating VBG B-VP O
3 848 851 10706004 the DT B-NP O
4 852 858 10706004 (Na,K) NN I-NP B-Chemical
5 858 859 10706004 - HYPH B-NP O
6 859 865 10706004 ATPase NN I-NP O
7 866 870 10706004 with IN B-PP O
8 871 874 10706004 its PRP$ B-NP O
9 875 884 10706004 substrate NN I-NP O
10 885 888 10706004 ATP NN I-NP B-Chemical
11 888 889 10706004 , , O O
12 890 892 10706004 no DT B-NP O
13 893 900 10706004 changes NNS I-NP O
14 901 903 10706004 in IN B-PP O
15 904 906 10706004 Km NN B-NP O
16 907 910 10706004 and CC I-NP O
17 911 915 10706004 Vmax NN I-NP O
18 916 922 10706004 values NNS I-NP O
19 923 927 10706004 were VBD B-VP O
20 928 936 10706004 observed VBN I-VP O
21 937 939 10706004 in IN B-PP O
22 940 942 10706004 NO NN B-NP B-Chemical
23 942 943 10706004 - HYPH B-NP O
24 943 952 10706004 deficient JJ I-NP O
25 953 957 10706004 rats NNS I-NP O
26 957 958 10706004 . . O O

1 959 965 10706004 During IN B-PP O
2 966 976 10706004 activation NN B-NP O
3 977 981 10706004 with IN B-PP O
4 982 985 10706004 Na+ NN B-NP B-Chemical
5 985 986 10706004 , , O O
6 987 990 10706004 the DT B-NP O
7 991 995 10706004 Vmax NN I-NP O
8 996 1004 10706004 remained VBD B-VP O
9 1005 1014 10706004 unchanged JJ B-ADJP O
10 1014 1015 10706004 , , O O
11 1016 1023 10706004 however RB B-ADVP O
12 1024 1027 10706004 the DT B-NP O
13 1028 1033 10706004 K(Na) NN I-NP B-Chemical
14 1034 1043 10706004 increased VBD B-VP O
15 1044 1046 10706004 by IN B-PP O
16 1047 1050 10706004 50% CD B-NP O
17 1050 1051 10706004 , , O O
18 1052 1062 10706004 indicating VBG B-VP O
19 1063 1064 10706004 a DT B-NP O
20 1065 1073 10706004 profound JJ I-NP O
21 1074 1082 10706004 decrease NN I-NP O
22 1083 1085 10706004 in IN B-PP O
23 1086 1089 10706004 the DT B-NP O
24 1090 1098 10706004 affinity NN I-NP O
25 1099 1101 10706004 of IN B-PP O
26 1102 1105 10706004 the DT B-NP O
27 1106 1109 10706004 Na+ NN I-NP B-Chemical
28 1109 1110 10706004 - HYPH O O
29 1110 1117 10706004 binding VBG B-VP O
30 1118 1122 10706004 site NN B-NP O
31 1123 1125 10706004 in IN B-PP O
32 1126 1128 10706004 NO NN B-NP B-Chemical
33 1128 1129 10706004 - HYPH B-NP O
34 1129 1138 10706004 deficient JJ I-NP O
35 1139 1143 10706004 rats NNS I-NP O
36 1143 1144 10706004 . . O O

1 1145 1150 10706004 After IN B-PP O
2 1151 1159 10706004 recovery NN B-NP O
3 1160 1164 10706004 from IN B-PP O
4 1165 1177 10706004 hypertension NN B-NP B-Disease
5 1177 1178 10706004 , , O O
6 1179 1182 10706004 the DT B-NP O
7 1183 1191 10706004 activity NN I-NP O
8 1192 1194 10706004 of IN B-PP O
9 1195 1201 10706004 (Na,K) NN B-NP B-Chemical
10 1201 1202 10706004 - HYPH B-NP O
11 1202 1208 10706004 ATPase NN I-NP O
12 1209 1218 10706004 increased VBD B-VP O
13 1218 1219 10706004 , , O O
14 1220 1223 10706004 due JJ B-ADJP O
15 1224 1226 10706004 to TO B-PP O
16 1227 1233 10706004 higher JJR B-NP O
17 1234 1242 10706004 affinity NN I-NP O
18 1243 1245 10706004 of IN B-PP O
19 1246 1249 10706004 the DT B-NP O
20 1250 1253 10706004 ATP NN I-NP B-Chemical
21 1253 1254 10706004 - HYPH B-PP O
22 1254 1261 10706004 binding VBG B-NP O
23 1262 1266 10706004 site NN I-NP O
24 1266 1267 10706004 , , O O
25 1268 1270 10706004 as IN B-SBAR O
26 1271 1279 10706004 revealed VBN B-VP O
27 1280 1284 10706004 from IN B-PP O
28 1285 1288 10706004 the DT B-NP O
29 1289 1296 10706004 lowered JJ I-NP O
30 1297 1299 10706004 Km NN I-NP O
31 1300 1305 10706004 value NN I-NP O
32 1306 1309 10706004 for IN B-PP O
33 1310 1313 10706004 ATP NN B-NP B-Chemical
34 1313 1314 10706004 . . O O

1 1315 1318 10706004 The DT B-NP O
2 1319 1324 10706004 K(Na) NN I-NP B-Chemical
3 1325 1330 10706004 value NN I-NP O
4 1331 1334 10706004 for IN B-PP O
5 1335 1338 10706004 Na+ NN B-NP B-Chemical
6 1339 1347 10706004 returned VBD B-VP O
7 1348 1350 10706004 to TO I-VP O
8 1351 1358 10706004 control VB I-VP O
9 1359 1364 10706004 value NN B-NP O
10 1364 1365 10706004 . . O O

1 1366 1376 10706004 Inhibition NN B-NP O
2 1377 1379 10706004 of IN B-PP O
3 1380 1382 10706004 NO NN B-NP B-Chemical
4 1382 1383 10706004 - HYPH B-NP O
5 1383 1391 10706004 synthase NN I-NP O
6 1392 1399 10706004 induced VBD B-VP O
7 1400 1401 10706004 a DT B-NP O
8 1402 1412 10706004 reversible JJ I-NP O
9 1413 1425 10706004 hypertension NN I-NP B-Disease
10 1426 1437 10706004 accompanied VBN B-VP O
11 1438 1440 10706004 by IN B-PP O
12 1441 1450 10706004 depressed JJ B-NP B-Disease
13 1451 1454 10706004 Na+ NN I-NP B-Chemical
14 1454 1455 10706004 - HYPH B-NP O
15 1455 1464 10706004 extrusion NN I-NP O
16 1465 1469 10706004 from IN B-PP O
17 1470 1477 10706004 cardiac JJ B-NP O
18 1478 1483 10706004 cells NNS I-NP O
19 1484 1486 10706004 as IN B-PP O
20 1487 1488 10706004 a DT B-NP O
21 1489 1500 10706004 consequence NN I-NP O
22 1501 1503 10706004 of IN B-PP O
23 1504 1516 10706004 deteriorated VBN B-NP O
24 1517 1520 10706004 Na+ NN I-NP B-Chemical
25 1520 1521 10706004 - HYPH O O
26 1521 1528 10706004 binding VBG B-NP O
27 1529 1539 10706004 properties NNS I-NP O
28 1540 1542 10706004 of IN B-PP O
29 1543 1546 10706004 the DT B-NP O
30 1547 1553 10706004 (Na,K) NN I-NP B-Chemical
31 1553 1554 10706004 - HYPH B-NP O
32 1554 1560 10706004 ATPase NN I-NP O
33 1560 1561 10706004 . . O O

1 1562 1567 10706004 After IN B-PP O
2 1568 1576 10706004 recovery NN B-NP O
3 1577 1579 10706004 of IN B-PP O
4 1580 1585 10706004 blood NN B-NP O
5 1586 1594 10706004 pressure NN I-NP O
6 1595 1597 10706004 to TO B-PP O
7 1598 1605 10706004 control NN B-NP O
8 1606 1612 10706004 values NNS I-NP O
9 1612 1613 10706004 , , O O
10 1614 1617 10706004 the DT B-NP O
11 1618 1627 10706004 extrusion NN I-NP O
12 1628 1630 10706004 of IN B-PP O
13 1631 1634 10706004 Na+ NN B-NP B-Chemical
14 1635 1639 10706004 from IN B-PP O
15 1640 1647 10706004 cardiac JJ B-NP O
16 1648 1653 10706004 cells NNS I-NP O
17 1654 1657 10706004 was VBD B-VP O
18 1658 1668 10706004 normalized VBN I-VP O
19 1668 1669 10706004 , , O O
20 1670 1672 10706004 as IN B-SBAR O
21 1673 1681 10706004 revealed VBN B-VP O
22 1682 1684 10706004 by IN B-PP O
23 1685 1696 10706004 restoration NN B-NP O
24 1697 1699 10706004 of IN B-PP O
25 1700 1703 10706004 the DT B-NP O
26 1704 1710 10706004 (Na,K) NN I-NP B-Chemical
27 1710 1711 10706004 - HYPH B-NP O
28 1711 1717 10706004 ATPase NN I-NP O
29 1718 1726 10706004 activity NN I-NP O
30 1726 1727 10706004 . . O O

1 0 0 7083920 -DOCSTART- -X- -X- O

1 0 7 7083920 Further JJ B-NP O
2 8 20 7083920 observations NNS I-NP O
3 21 23 7083920 on IN B-PP O
4 24 27 7083920 the DT B-NP O
5 28 46 7083920 electrophysiologic JJ I-NP O
6 47 54 7083920 effects NNS I-NP O
7 55 57 7083920 of IN B-PP O
8 58 62 7083920 oral JJ B-NP O
9 63 73 7083920 amiodarone NN I-NP B-Chemical
10 74 81 7083920 therapy NN I-NP O
11 81 82 7083920 . . O O
12 83 84 7083920 A NN B-NP O
13 85 89 7083920 case NN I-NP O
14 90 92 7083920 is VBZ B-VP O
15 93 102 7083920 presented VBN I-VP O
16 103 105 7083920 of IN B-PP O
17 106 107 7083920 a DT B-NP O
18 108 118 7083920 reversible JJ I-NP O
19 119 124 7083920 intra AFX I-NP B-Disease
20 124 125 7083920 - HYPH I-NP I-Disease
21 125 131 7083920 Hisian JJ I-NP I-Disease
22 132 137 7083920 block NN I-NP I-Disease
23 138 147 7083920 occurring VBG B-VP O
24 148 153 7083920 under IN B-PP O
25 154 164 7083920 amiodarone NN B-NP B-Chemical
26 165 174 7083920 treatment NN I-NP O
27 175 178 7083920 for IN B-PP O
28 179 185 7083920 atrial JJ B-NP B-Disease
29 186 197 7083920 tachycardia NN I-NP I-Disease
30 198 200 7083920 in IN B-PP O
31 201 202 7083920 a DT B-NP O
32 203 210 7083920 patient NN I-NP O
33 211 218 7083920 without IN B-PP O
34 219 224 7083920 clear JJ B-NP O
35 225 241 7083920 intraventricular JJ I-NP B-Disease
36 242 252 7083920 conduction NN I-NP I-Disease
37 253 266 7083920 abnormalities NNS I-NP I-Disease
38 266 267 7083920 . . O O

1 268 271 7083920 His PRP$ B-NP O
2 272 278 7083920 bundle NN I-NP O
3 279 289 7083920 recordings NNS I-NP O
4 290 296 7083920 showed VBD B-VP O
5 297 299 7083920 an DT B-NP O
6 300 306 7083920 atrial JJ I-NP B-Disease
7 307 318 7083920 tachycardia NN I-NP I-Disease
8 319 323 7083920 with IN B-PP O
9 324 336 7083920 intermittent JJ B-NP O
10 337 341 7083920 exit NN I-NP O
11 342 347 7083920 block NN I-NP O
12 348 351 7083920 and CC O O
13 352 359 7083920 greatly RB B-VP O
14 360 369 7083920 prolonged VBD I-VP O
15 370 372 7083920 BH NN B-NP O
16 373 376 7083920 and CC I-NP O
17 377 379 7083920 HV NN I-NP O
18 380 389 7083920 intervals NNS I-NP O
19 390 391 7083920 ( ( O O
20 391 393 7083920 40 CD B-NP O
21 394 397 7083920 and CC I-NP O
22 398 401 7083920 100 CD I-NP O
23 402 406 7083920 msec NN I-NP O
24 406 407 7083920 , , O O
25 408 420 7083920 respectively RB B-ADVP O
26 420 421 7083920 ) ) O O
27 421 422 7083920 . . O O

1 423 429 7083920 Thirty CD B-NP O
2 430 434 7083920 days NNS I-NP O
3 435 440 7083920 after IN B-PP O
4 441 451 7083920 amiodarone NN B-NP B-Chemical
5 452 467 7083920 discontinuation NN I-NP O
6 467 468 7083920 , , O O
7 469 472 7083920 His PRP$ B-NP O
8 473 479 7083920 bundle NN I-NP O
9 480 492 7083920 electrograms NNS I-NP O
10 493 499 7083920 showed VBD B-VP O
11 500 506 7083920 atrial JJ B-NP B-Disease
12 507 514 7083920 flutter NN I-NP I-Disease
13 515 522 7083920 without IN B-PP O
14 523 528 7083920 intra AFX B-NP O
15 528 529 7083920 - HYPH I-NP O
16 529 535 7083920 Hisian JJ I-NP O
17 536 538 7083920 or CC I-NP O
18 539 544 7083920 infra AFX I-NP O
19 544 545 7083920 - HYPH I-NP O
20 545 551 7083920 Hisian JJ I-NP O
21 552 557 7083920 delay NN I-NP O
22 557 558 7083920 . . O O

1 559 569 7083920 Amiodarone NN B-NP B-Chemical
2 570 576 7083920 should MD B-VP O
3 577 579 7083920 be VB I-VP O
4 580 584 7083920 used VBN I-VP O
5 585 589 7083920 with IN B-PP O
6 590 597 7083920 caution NN B-NP O
7 598 604 7083920 during IN B-PP O
8 605 609 7083920 long JJ B-NP O
9 609 610 7083920 - HYPH I-NP O
10 610 614 7083920 term NN I-NP O
11 615 619 7083920 oral JJ I-NP O
12 620 627 7083920 therapy NN I-NP O
13 628 630 7083920 in IN B-PP O
14 631 639 7083920 patients NNS B-NP O
15 640 644 7083920 with IN B-PP O
16 645 647 7083920 or CC B-PP O
17 648 655 7083920 without IN B-PP O
18 656 661 7083920 clear JJ B-NP O
19 662 678 7083920 intraventricular JJ I-NP O
20 679 689 7083920 conduction NN I-NP O
21 690 697 7083920 defects NNS I-NP O
22 697 698 7083920 . . O O

1 0 0 20080983 -DOCSTART- -X- -X- O

1 0 11 20080983 Normalizing VBG B-VP O
2 12 19 20080983 effects NNS B-NP O
3 20 22 20080983 of IN B-PP O
4 23 32 20080983 modafinil NN B-NP B-Chemical
5 33 35 20080983 on IN B-PP O
6 36 41 20080983 sleep NN B-NP O
7 42 44 20080983 in IN B-PP O
8 45 52 20080983 chronic JJ B-NP O
9 53 60 20080983 cocaine NN I-NP B-Chemical
10 61 66 20080983 users NNS I-NP O
11 66 67 20080983 . . O O
12 68 77 20080983 OBJECTIVE NN B-NP O
13 77 78 20080983 : : O O
14 79 82 20080983 The DT B-NP O
15 83 90 20080983 purpose NN I-NP O
16 91 93 20080983 of IN B-PP O
17 94 97 20080983 the DT B-NP O
18 98 105 20080983 present JJ I-NP O
19 106 111 20080983 study NN I-NP O
20 112 115 20080983 was VBD B-VP O
21 116 118 20080983 to TO B-VP O
22 119 128 20080983 determine VB I-VP O
23 129 132 20080983 the DT B-NP O
24 133 139 20080983 effect NN I-NP O
25 140 142 20080983 of IN B-PP O
26 143 150 20080983 morning NN B-NP O
27 150 151 20080983 - HYPH O O
28 151 156 20080983 dosed VBN B-NP O
29 157 166 20080983 modafinil NN I-NP B-Chemical
30 167 169 20080983 on IN B-PP O
31 170 175 20080983 sleep NN B-NP O
32 176 179 20080983 and CC I-NP O
33 180 187 20080983 daytime NN I-NP B-Disease
34 188 198 20080983 sleepiness NN I-NP I-Disease
35 199 201 20080983 in IN B-PP O
36 202 209 20080983 chronic JJ B-NP O
37 210 217 20080983 cocaine NN I-NP B-Chemical
38 218 223 20080983 users NNS I-NP O
39 223 224 20080983 . . O O

1 225 231 20080983 METHOD NN B-NP O
2 231 232 20080983 : : O O
3 233 239 20080983 Twenty CD B-NP O
4 240 247 20080983 cocaine NN I-NP B-Chemical
5 247 248 20080983 - HYPH B-NP O
6 248 257 20080983 dependent JJ I-NP O
7 258 270 20080983 participants NNS I-NP O
8 271 275 20080983 were VBD B-VP O
9 276 284 20080983 randomly RB I-VP O
10 285 293 20080983 assigned VBN I-VP O
11 294 296 20080983 to TO I-VP O
12 297 304 20080983 receive VB I-VP O
13 305 314 20080983 modafinil NN B-NP B-Chemical
14 314 315 20080983 , , O O
15 316 319 20080983 400 CD B-NP O
16 320 322 20080983 mg NN I-NP O
17 323 324 20080983 ( ( O O
18 324 325 20080983 N NN B-NP O
19 325 326 20080983 = SYM B-VP O
20 326 328 20080983 10 CD B-NP O
21 328 329 20080983 ) ) O O
22 329 330 20080983 , , O O
23 331 333 20080983 or CC O O
24 334 341 20080983 placebo NN B-NP O
25 342 343 20080983 ( ( O O
26 343 344 20080983 N NN B-NP O
27 344 345 20080983 = SYM B-VP O
28 345 347 20080983 10 CD B-NP O
29 347 348 20080983 ) ) O O
30 349 354 20080983 every DT B-NP O
31 355 362 20080983 morning NN I-NP O
32 363 365 20080983 at IN B-PP O
33 366 367 20080983 7 CD B-NP O
34 367 368 20080983 : : O O
35 368 370 20080983 30 CD B-NP O
36 371 374 20080983 a.m RB I-NP O
37 374 375 20080983 . . O O

1 376 379 20080983 for IN B-PP O
2 380 382 20080983 16 CD B-NP O
3 383 387 20080983 days NNS I-NP O
4 388 390 20080983 in IN B-PP O
5 391 393 20080983 an DT B-NP O
6 394 403 20080983 inpatient NN I-NP O
7 403 404 20080983 , , O O
8 405 411 20080983 double JJ B-NP O
9 411 412 20080983 - HYPH I-NP O
10 412 417 20080983 blind JJ I-NP O
11 418 428 20080983 randomized VBN I-NP O
12 429 434 20080983 trial NN I-NP O
13 434 435 20080983 . . O O

1 436 448 20080983 Participants NNS B-NP O
2 449 458 20080983 underwent VBD B-VP O
3 459 475 20080983 polysomnographic JJ B-NP O
4 476 481 20080983 sleep NN I-NP O
5 482 492 20080983 recordings NNS I-NP O
6 493 495 20080983 on IN B-PP O
7 496 500 20080983 days NNS B-NP O
8 501 502 20080983 1 CD B-NP O
9 503 505 20080983 to TO B-PP O
10 506 507 20080983 3 CD B-NP O
11 507 508 20080983 , , O O
12 509 510 20080983 7 CD B-NP O
13 511 513 20080983 to TO B-PP O
14 514 515 20080983 9 CD B-NP O
15 515 516 20080983 , , O O
16 517 520 20080983 and CC O O
17 521 523 20080983 14 CD B-NP O
18 524 526 20080983 to TO I-NP O
19 527 529 20080983 16 CD I-NP O
20 530 531 20080983 ( ( O O
21 531 536 20080983 first JJ B-ADVP O
22 536 537 20080983 , , O O
23 538 544 20080983 second JJ B-ADJP O
24 544 545 20080983 , , O O
25 546 549 20080983 and CC O O
26 550 555 20080983 third JJ B-NP O
27 556 561 20080983 weeks NNS I-NP O
28 562 564 20080983 of IN B-PP O
29 565 575 20080983 abstinence NN B-NP O
30 575 576 20080983 ) ) O O
31 576 577 20080983 . . O O

1 578 581 20080983 The DT B-NP O
2 582 590 20080983 Multiple JJ I-NP O
3 591 596 20080983 Sleep NN I-NP O
4 597 604 20080983 Latency NN I-NP O
5 605 609 20080983 Test NN I-NP O
6 610 613 20080983 was VBD B-VP O
7 614 623 20080983 performed VBN I-VP O
8 624 626 20080983 at IN B-PP O
9 627 629 20080983 11 CD B-NP O
10 629 630 20080983 : : O O
11 630 632 20080983 30 CD B-NP O
12 633 636 20080983 a.m RB I-NP O
13 636 637 20080983 . . O O
14 637 638 20080983 , , O O
15 639 640 20080983 2 CD B-NP O
16 640 641 20080983 : : O O
17 641 643 20080983 00 CD B-NP O
18 644 647 20080983 p.m NN I-NP O
19 647 648 20080983 . NN I-NP O
20 648 649 20080983 , , O O
21 650 653 20080983 and CC O O
22 654 655 20080983 4 CD B-NP O
23 655 656 20080983 : : O O
24 656 658 20080983 30 CD B-NP O
25 659 662 20080983 p.m RB I-NP O
26 662 663 20080983 . . O O

1 664 666 20080983 on IN B-PP O
2 667 671 20080983 days NNS B-NP O
3 672 673 20080983 2 CD I-NP O
4 673 674 20080983 , , I-NP O
5 675 676 20080983 8 CD I-NP O
6 676 677 20080983 , , O O
7 678 681 20080983 and CC O O
8 682 684 20080983 15 CD B-NP O
9 684 685 20080983 . . O O

1 686 689 20080983 For IN B-PP O
2 690 700 20080983 comparison NN B-NP O
3 701 703 20080983 of IN B-PP O
4 704 709 20080983 sleep JJ B-NP O
5 710 722 20080983 architecture NN I-NP O
6 723 732 20080983 variables NNS I-NP O
7 732 733 20080983 , , O O
8 734 736 20080983 12 CD B-NP O
9 737 744 20080983 healthy JJ I-NP O
10 745 755 20080983 comparison NN I-NP O
11 756 768 20080983 participants NNS I-NP O
12 769 778 20080983 underwent VBD B-VP O
13 779 780 20080983 a DT B-NP O
14 781 787 20080983 single JJ I-NP O
15 788 793 20080983 night NN I-NP O
16 794 796 20080983 of IN B-PP O
17 797 809 20080983 experimental JJ B-NP O
18 810 825 20080983 polysomnography NN I-NP O
19 826 830 20080983 that WDT B-NP O
20 831 839 20080983 followed VBD B-VP O
21 840 841 20080983 1 CD B-NP O
22 842 847 20080983 night NN I-NP O
23 848 850 20080983 of IN B-PP O
24 851 864 20080983 accommodation NN B-NP O
25 865 880 20080983 polysomnography NN I-NP O
26 880 881 20080983 . . O O

1 882 889 20080983 RESULTS NNS B-NP O
2 889 890 20080983 : : O O
3 891 902 20080983 Progressive JJ B-NP O
4 903 913 20080983 abstinence NN I-NP O
5 914 918 20080983 from IN B-PP O
6 919 926 20080983 cocaine NN B-NP B-Chemical
7 927 930 20080983 was VBD B-VP O
8 931 941 20080983 associated VBN I-VP O
9 942 946 20080983 with IN B-PP O
10 947 956 20080983 worsening VBG B-NP O
11 957 959 20080983 of IN B-PP O
12 960 963 20080983 all DT B-NP O
13 964 972 20080983 measured VBN I-NP O
14 973 989 20080983 polysomnographic JJ I-NP O
15 990 995 20080983 sleep NN I-NP O
16 996 1004 20080983 outcomes NNS I-NP O
17 1004 1005 20080983 . . O O

1 1006 1014 20080983 Compared VBN B-PP O
2 1015 1019 20080983 with IN B-PP O
3 1020 1027 20080983 placebo NN B-NP O
4 1027 1028 20080983 , , O O
5 1029 1038 20080983 modafinil NN B-NP B-Chemical
6 1039 1048 20080983 decreased VBD B-VP O
7 1049 1058 20080983 nighttime RB I-VP O
8 1059 1064 20080983 sleep VB I-VP O
9 1065 1072 20080983 latency NN B-NP O
10 1073 1076 20080983 and CC O O
11 1077 1086 20080983 increased VBD B-VP O
12 1087 1091 20080983 slow JJ B-NP O
13 1091 1092 20080983 - HYPH I-NP O
14 1092 1096 20080983 wave NN I-NP O
15 1097 1102 20080983 sleep NN I-NP O
16 1103 1107 20080983 time NN I-NP O
17 1108 1110 20080983 in IN B-PP O
18 1111 1118 20080983 cocaine NN B-NP B-Chemical
19 1118 1119 20080983 - HYPH B-NP O
20 1119 1128 20080983 dependent JJ I-NP O
21 1129 1141 20080983 participants NNS I-NP O
22 1141 1142 20080983 . . O O

1 1143 1146 20080983 The DT B-NP O
2 1147 1153 20080983 effect NN I-NP O
3 1154 1156 20080983 of IN B-PP O
4 1157 1166 20080983 modafinil NN B-NP B-Chemical
5 1167 1177 20080983 interacted VBD B-VP O
6 1178 1182 20080983 with IN B-PP O
7 1183 1186 20080983 the DT B-NP O
8 1187 1197 20080983 abstinence NN I-NP O
9 1198 1202 20080983 week NN I-NP O
10 1203 1206 20080983 and CC O O
11 1207 1210 20080983 was VBD B-VP O
12 1211 1221 20080983 associated VBN I-VP O
13 1222 1226 20080983 with IN B-PP O
14 1227 1233 20080983 longer JJR B-NP O
15 1234 1239 20080983 total JJ I-NP O
16 1240 1245 20080983 sleep NN I-NP O
17 1246 1250 20080983 time NN I-NP O
18 1251 1254 20080983 and CC O O
19 1255 1262 20080983 shorter JJR B-NP O
20 1263 1266 20080983 REM NN I-NP O
21 1267 1272 20080983 sleep NN I-NP O
22 1273 1280 20080983 latency NN I-NP O
23 1281 1283 20080983 in IN B-PP O
24 1284 1287 20080983 the DT B-NP O
25 1288 1293 20080983 third JJ I-NP O
26 1294 1298 20080983 week NN I-NP O
27 1299 1301 20080983 of IN B-PP O
28 1302 1312 20080983 abstinence NN B-NP O
29 1312 1313 20080983 . . O O

1 1314 1324 20080983 Comparison NN B-NP O
2 1325 1327 20080983 of IN B-PP O
3 1328 1332 20080983 slow JJ B-NP O
4 1332 1333 20080983 - HYPH I-NP O
5 1333 1337 20080983 wave NN I-NP O
6 1338 1343 20080983 sleep NN I-NP O
7 1344 1348 20080983 time NN I-NP O
8 1348 1349 20080983 , , O O
9 1350 1355 20080983 total JJ B-NP O
10 1356 1361 20080983 sleep NN I-NP O
11 1362 1366 20080983 time NN I-NP O
12 1366 1367 20080983 , , O O
13 1368 1371 20080983 and CC O O
14 1372 1377 20080983 sleep VB B-VP O
15 1378 1385 20080983 latency NN B-NP O
16 1386 1388 20080983 in IN B-PP O
17 1389 1396 20080983 cocaine NN B-NP B-Chemical
18 1396 1397 20080983 - HYPH B-NP O
19 1397 1406 20080983 dependent JJ I-NP O
20 1407 1410 20080983 and CC I-NP O
21 1411 1418 20080983 healthy JJ I-NP O
22 1419 1431 20080983 participants NNS I-NP O
23 1432 1440 20080983 revealed VBD B-VP O
24 1441 1442 20080983 a DT B-NP O
25 1443 1454 20080983 normalizing VBG I-NP O
26 1455 1461 20080983 effect NN I-NP O
27 1462 1464 20080983 of IN B-PP O
28 1465 1474 20080983 modafinil NN B-NP B-Chemical
29 1475 1477 20080983 in IN B-PP O
30 1478 1485 20080983 cocaine NN B-NP B-Chemical
31 1485 1486 20080983 - HYPH B-NP O
32 1486 1495 20080983 dependent JJ I-NP O
33 1496 1508 20080983 participants NNS I-NP O
34 1508 1509 20080983 . . O O

1 1510 1519 20080983 Modafinil NN B-NP B-Chemical
2 1520 1523 20080983 was VBD B-VP O
3 1524 1534 20080983 associated VBN I-VP O
4 1535 1539 20080983 with IN B-PP O
5 1540 1549 20080983 increased VBN B-NP O
6 1550 1557 20080983 daytime NN I-NP O
7 1558 1563 20080983 sleep NN I-NP O
8 1564 1571 20080983 latency NN I-NP O
9 1571 1572 20080983 , , O O
10 1573 1575 20080983 as IN B-SBAR O
11 1576 1584 20080983 measured VBN B-VP O
12 1585 1587 20080983 by IN B-PP O
13 1588 1591 20080983 the DT B-NP O
14 1592 1600 20080983 Multiple NNP I-NP O
15 1601 1606 20080983 Sleep NNP I-NP O
16 1607 1614 20080983 Latency NNP I-NP O
17 1615 1619 20080983 Test NNP I-NP O
18 1619 1620 20080983 , , O O
19 1621 1624 20080983 and CC O O
20 1625 1626 20080983 a DT B-NP O
21 1627 1633 20080983 nearly RB I-NP O
22 1634 1645 20080983 significant JJ I-NP O
23 1646 1654 20080983 decrease NN I-NP O
24 1655 1657 20080983 in IN B-PP O
25 1658 1668 20080983 subjective JJ B-NP O
26 1669 1676 20080983 daytime NN I-NP B-Disease
27 1677 1687 20080983 sleepiness NN I-NP I-Disease
28 1687 1688 20080983 . . O O

1 1689 1700 20080983 CONCLUSIONS NNS B-NP O
2 1700 1701 20080983 : : O O
3 1702 1709 20080983 Morning NN B-NP O
4 1709 1710 20080983 - HYPH O O
5 1710 1715 20080983 dosed VBN B-NP O
6 1716 1725 20080983 modafinil NN I-NP B-Chemical
7 1726 1734 20080983 promotes VBZ B-VP O
8 1735 1744 20080983 nocturnal JJ B-NP O
9 1745 1750 20080983 sleep NN I-NP O
10 1750 1751 20080983 , , O O
11 1752 1762 20080983 normalizes VBZ B-VP O
12 1763 1768 20080983 sleep NN B-NP O
13 1769 1781 20080983 architecture NN I-NP O
14 1781 1782 20080983 , , O O
15 1783 1786 20080983 and CC O O
16 1787 1796 20080983 decreases VBZ B-VP O
17 1797 1804 20080983 daytime NN B-NP B-Disease
18 1805 1815 20080983 sleepiness NN I-NP I-Disease
19 1816 1818 20080983 in IN B-PP O
20 1819 1828 20080983 abstinent JJ B-NP O
21 1829 1836 20080983 cocaine NN I-NP B-Chemical
22 1837 1842 20080983 users NNS I-NP O
23 1842 1843 20080983 . . O O

1 1844 1849 20080983 These DT B-NP O
2 1850 1857 20080983 effects NNS I-NP O
3 1858 1861 20080983 may MD B-VP O
4 1862 1864 20080983 be VB I-VP O
5 1865 1873 20080983 relevant JJ B-ADJP O
6 1874 1876 20080983 in IN B-PP O
7 1877 1880 20080983 the DT B-NP O
8 1881 1890 20080983 treatment NN I-NP O
9 1891 1893 20080983 of IN B-PP O
10 1894 1901 20080983 cocaine NN B-NP B-Chemical
11 1902 1912 20080983 dependence NN I-NP O
12 1912 1913 20080983 . . O O

1 0 0 2673163 -DOCSTART- -X- -X- O

1 0 6 2673163 Stroke NN B-NP B-Disease
2 7 17 2673163 associated VBN B-VP O
3 18 22 2673163 with IN B-PP O
4 23 30 2673163 cocaine NN B-NP B-Chemical
5 31 34 2673163 use NN I-NP O
6 34 35 2673163 . . O O
7 36 38 2673163 We PRP B-NP O
8 39 47 2673163 describe VBP B-VP O
9 48 53 2673163 eight CD B-NP O
10 54 62 2673163 patients NNS I-NP O
11 63 65 2673163 in IN B-PP O
12 66 70 2673163 whom WP B-NP O
13 71 78 2673163 cocaine NN B-NP B-Chemical
14 79 82 2673163 use NN I-NP O
15 83 86 2673163 was VBD B-VP O
16 87 94 2673163 related VBN I-VP O
17 95 97 2673163 to TO I-VP O
18 98 104 2673163 stroke VB I-VP B-Disease
19 105 108 2673163 and CC I-VP O
20 109 115 2673163 review VB I-VP O
21 116 118 2673163 39 CD B-NP O
22 119 124 2673163 cases NNS I-NP O
23 125 129 2673163 from IN B-PP O
24 130 133 2673163 the DT B-NP O
25 134 144 2673163 literature NN I-NP O
26 144 145 2673163 . . O O

1 146 151 2673163 Among IN B-PP O
2 152 157 2673163 these DT B-NP O
3 158 160 2673163 47 CD I-NP O
4 161 169 2673163 patients NNS I-NP O
5 170 173 2673163 the DT B-NP O
6 174 178 2673163 mean JJ I-NP O
7 179 180 2673163 ( ( O O
8 180 181 2673163 + SYM O O
9 181 182 2673163 / SYM O O
10 182 183 2673163 - HYPH B-NP O
11 184 186 2673163 SD NN I-NP O
12 186 187 2673163 ) ) O O
13 188 191 2673163 age NN B-NP O
14 192 195 2673163 was VBD B-VP O
15 196 200 2673163 32.5 CD B-NP O
16 201 202 2673163 + SYM O O
17 202 203 2673163 / SYM O O
18 203 204 2673163 - SYM O O
19 205 209 2673163 12.1 CD B-NP O
20 210 215 2673163 years NNS I-NP O
21 215 216 2673163 ; : O O
22 217 220 2673163 76% CD B-NP O
23 221 222 2673163 ( ( O O
24 222 224 2673163 34 CD B-NP O
25 224 225 2673163 / SYM B-NP O
26 225 227 2673163 45 CD I-NP O
27 227 228 2673163 ) ) O O
28 229 233 2673163 were VBD B-VP O
29 234 237 2673163 men NNS B-NP O
30 237 238 2673163 . . O O

1 239 245 2673163 Stroke NNP B-NP B-Disease
2 246 254 2673163 followed VBD B-VP O
3 255 262 2673163 cocaine NN B-NP B-Chemical
4 263 266 2673163 use NN I-NP O
5 267 269 2673163 by IN B-PP O
6 270 280 2673163 inhalation NN B-NP O
7 280 281 2673163 , , O O
8 282 292 2673163 intranasal JJ B-NP O
9 292 293 2673163 , , I-NP O
10 294 305 2673163 intravenous JJ I-NP O
11 305 306 2673163 , , O O
12 307 310 2673163 and CC O O
13 311 324 2673163 intramuscular JJ B-NP O
14 325 331 2673163 routes NNS I-NP O
15 331 332 2673163 . . O O

1 333 345 2673163 Intracranial JJ B-NP B-Disease
2 346 355 2673163 aneurysms NNS I-NP I-Disease
3 356 358 2673163 or CC O O
4 359 372 2673163 arteriovenous JJ B-NP B-Disease
5 373 386 2673163 malformations NNS I-NP I-Disease
6 387 391 2673163 were VBD B-VP O
7 392 399 2673163 present JJ B-ADJP O
8 400 402 2673163 in IN B-PP O
9 403 405 2673163 17 CD B-NP O
10 406 408 2673163 of IN B-PP O
11 409 411 2673163 32 CD B-NP O
12 412 420 2673163 patients NNS I-NP O
13 421 428 2673163 studied VBN B-VP O
14 429 445 2673163 angiographically RB B-ADVP O
15 446 448 2673163 or CC O O
16 449 451 2673163 at IN B-PP O
17 452 459 2673163 autopsy NN B-NP O
18 459 460 2673163 ; : O O
19 461 469 2673163 cerebral JJ B-NP B-Disease
20 470 480 2673163 vasculitis NN I-NP I-Disease
21 481 484 2673163 was VBD B-VP O
22 485 492 2673163 present JJ B-ADJP O
23 493 495 2673163 in IN B-PP O
24 496 499 2673163 two CD B-NP O
25 500 508 2673163 patients NNS I-NP O
26 508 509 2673163 . . O O

1 510 518 2673163 Cerebral JJ B-NP B-Disease
2 519 529 2673163 infarction NN I-NP I-Disease
3 530 538 2673163 occurred VBD B-VP O
4 539 541 2673163 in IN B-PP O
5 542 544 2673163 10 CD B-NP O
6 545 553 2673163 patients NNS I-NP O
7 554 555 2673163 ( ( O O
8 555 558 2673163 22% NN B-NP O
9 558 559 2673163 ) ) O O
10 559 560 2673163 , , O O
11 561 574 2673163 intracerebral JJ B-NP B-Disease
12 575 585 2673163 hemorrhage NN I-NP I-Disease
13 586 588 2673163 in IN B-PP O
14 589 591 2673163 22 CD B-NP O
15 592 593 2673163 ( ( O O
16 593 596 2673163 49% NN B-NP O
17 596 597 2673163 ) ) O O
18 597 598 2673163 , , O O
19 599 602 2673163 and CC O O
20 603 615 2673163 subarachnoid JJ B-NP B-Disease
21 616 626 2673163 hemorrhage NN I-NP I-Disease
22 627 629 2673163 in IN B-PP O
23 630 632 2673163 13 CD B-NP O
24 633 634 2673163 ( ( O O
25 634 637 2673163 29% CD B-NP O
26 637 638 2673163 ) ) O O
27 638 639 2673163 . . O O

1 640 645 2673163 These DT B-NP O
2 646 650 2673163 data NNS I-NP O
3 651 659 2673163 indicate VBP B-VP O
4 660 664 2673163 that IN B-SBAR O
5 665 666 2673163 ( ( B-LST O
6 666 667 2673163 1 LS I-LST O
7 667 668 2673163 ) ) O O
8 669 672 2673163 the DT B-NP O
9 673 681 2673163 apparent JJ I-NP O
10 682 691 2673163 incidence NN I-NP O
11 692 694 2673163 of IN B-PP O
12 695 701 2673163 stroke NN B-NP B-Disease
13 702 709 2673163 related VBN B-VP O
14 710 712 2673163 to TO B-PP O
15 713 720 2673163 cocaine NN B-NP B-Chemical
16 721 724 2673163 use NN I-NP O
17 725 727 2673163 is VBZ B-VP O
18 728 738 2673163 increasing VBG I-VP O
19 738 739 2673163 ; : O O
20 740 741 2673163 ( ( B-LST O
21 741 742 2673163 2 LS I-LST O
22 742 743 2673163 ) ) O O
23 744 751 2673163 cocaine NN B-NP B-Chemical
24 751 752 2673163 - HYPH O O
25 752 762 2673163 associated VBN B-NP O
26 763 769 2673163 stroke NN I-NP B-Disease
27 770 776 2673163 occurs VBZ B-VP O
28 777 786 2673163 primarily RB B-ADVP O
29 787 789 2673163 in IN B-PP O
30 790 795 2673163 young JJ B-NP O
31 796 802 2673163 adults NNS I-NP O
32 802 803 2673163 ; : O O
33 804 805 2673163 ( ( B-LST O
34 805 806 2673163 3 LS I-LST O
35 806 807 2673163 ) ) O O
36 808 814 2673163 stroke NN B-NP B-Disease
37 815 818 2673163 may MD B-VP O
38 819 825 2673163 follow VB I-VP O
39 826 829 2673163 any DT B-NP O
40 830 835 2673163 route NN I-NP O
41 836 838 2673163 of IN B-PP O
42 839 846 2673163 cocaine NN B-NP B-Chemical
43 847 861 2673163 administration NN I-NP O
44 861 862 2673163 ; : O O
45 863 864 2673163 ( ( B-LST O
46 864 865 2673163 4 LS I-LST O
47 865 866 2673163 ) ) O O
48 867 873 2673163 stroke VB B-VP B-Disease
49 874 879 2673163 after IN B-PP O
50 880 887 2673163 cocaine NN B-NP B-Chemical
51 888 891 2673163 use NN I-NP O
52 892 894 2673163 is VBZ B-VP O
53 895 905 2673163 frequently RB I-VP O
54 906 916 2673163 associated VBN I-VP O
55 917 921 2673163 with IN B-PP O
56 922 934 2673163 intracranial JJ B-NP B-Disease
57 935 944 2673163 aneurysms NNS I-NP I-Disease
58 945 948 2673163 and CC O O
59 949 962 2673163 arteriovenous JJ B-NP B-Disease
60 963 976 2673163 malformations NNS I-NP I-Disease
61 976 977 2673163 ; : O O
62 978 981 2673163 and CC O O
63 982 983 2673163 ( ( B-LST O
64 983 984 2673163 5 LS I-LST O
65 984 985 2673163 ) ) O O
66 986 988 2673163 in IN B-PP O
67 989 996 2673163 cocaine NN B-NP B-Chemical
68 996 997 2673163 - HYPH B-NP O
69 997 1007 2673163 associated VBN I-NP O
70 1008 1014 2673163 stroke NN I-NP B-Disease
71 1014 1015 2673163 , , O O
72 1016 1019 2673163 the DT B-NP O
73 1020 1029 2673163 frequency NN I-NP O
74 1030 1032 2673163 of IN B-PP O
75 1033 1045 2673163 intracranial JJ B-NP B-Disease
76 1046 1056 2673163 hemorrhage NN I-NP I-Disease
77 1057 1064 2673163 exceeds VBZ B-VP O
78 1065 1069 2673163 that DT B-NP O
79 1070 1072 2673163 of IN B-PP O
80 1073 1081 2673163 cerebral JJ B-NP B-Disease
81 1082 1092 2673163 infarction NN I-NP I-Disease
82 1092 1093 2673163 . . O O

1 0 0 11897407 -DOCSTART- -X- -X- O

1 0 5 11897407 99mTc NN B-NP B-Chemical
2 5 6 11897407 - HYPH I-NP I-Chemical
3 6 15 11897407 glucarate NN I-NP I-Chemical
4 16 19 11897407 for IN B-PP O
5 20 29 11897407 detection NN B-NP O
6 30 32 11897407 of IN B-PP O
7 33 46 11897407 isoproterenol NN B-NP B-Chemical
8 46 47 11897407 - HYPH B-NP O
9 47 54 11897407 induced VBN I-NP O
10 55 65 11897407 myocardial JJ I-NP B-Disease
11 66 76 11897407 infarction NN I-NP I-Disease
12 77 79 11897407 in IN B-PP O
13 80 84 11897407 rats NNS B-NP O
14 84 85 11897407 . . O O
15 86 93 11897407 Infarct NN B-NP B-Disease
16 93 94 11897407 - HYPH B-NP O
17 94 98 11897407 avid JJ I-NP O
18 99 119 11897407 radiopharmaceuticals NNS I-NP O
19 120 123 11897407 are VBP B-VP O
20 124 133 11897407 necessary JJ B-ADJP O
21 134 137 11897407 for IN B-PP O
22 138 143 11897407 rapid JJ B-NP O
23 144 147 11897407 and CC I-NP O
24 148 154 11897407 timely JJ I-NP O
25 155 164 11897407 diagnosis NN I-NP O
26 165 167 11897407 of IN B-PP O
27 168 173 11897407 acute JJ B-NP O
28 174 184 11897407 myocardial JJ I-NP B-Disease
29 185 195 11897407 infarction NN I-NP I-Disease
30 195 196 11897407 . . O O

1 197 200 11897407 The DT B-NP O
2 201 207 11897407 animal NN I-NP O
3 208 213 11897407 model NN I-NP O
4 214 218 11897407 used VBN B-VP O
5 219 221 11897407 to TO B-VP O
6 222 229 11897407 produce VB I-VP O
7 230 240 11897407 infarction NN B-NP B-Disease
8 241 248 11897407 implies VBZ B-VP O
9 249 255 11897407 artery NN B-NP O
10 256 264 11897407 ligation NN I-NP O
11 265 268 11897407 but CC O O
12 269 277 11897407 chemical JJ B-NP O
13 278 287 11897407 induction NN I-NP O
14 288 291 11897407 can MD B-VP O
15 292 294 11897407 be VB I-VP O
16 295 301 11897407 easily RB I-VP O
17 302 310 11897407 obtained VBN I-VP O
18 311 315 11897407 with IN B-PP O
19 316 329 11897407 isoproterenol NN B-NP B-Chemical
20 329 330 11897407 . . O O

1 331 332 11897407 A DT B-NP O
2 333 336 11897407 new JJ I-NP O
3 337 344 11897407 infarct NN I-NP B-Disease
4 344 345 11897407 - HYPH I-NP O
5 345 349 11897407 avid NN I-NP O
6 350 369 11897407 radiopharmaceutical NN I-NP O
7 370 375 11897407 based VBN B-VP O
8 376 378 11897407 on IN B-PP O
9 379 387 11897407 glucaric JJ B-NP B-Chemical
10 388 392 11897407 acid NN I-NP I-Chemical
11 393 396 11897407 was VBD B-VP O
12 397 405 11897407 prepared VBN I-VP O
13 406 408 11897407 in IN B-PP O
14 409 412 11897407 the DT B-NP O
15 413 421 11897407 hospital NN I-NP O
16 422 435 11897407 radiopharmacy NN I-NP O
17 436 438 11897407 of IN B-PP O
18 439 442 11897407 the DT B-NP O
19 443 450 11897407 INCMNSZ NN I-NP O
20 450 451 11897407 . . I-NP O
21 452 457 11897407 99mTc NN I-NP B-Chemical
22 457 458 11897407 - HYPH O I-Chemical
23 458 467 11897407 glucarate NN B-NP I-Chemical
24 468 471 11897407 was VBD B-VP O
25 472 476 11897407 easy JJ B-ADJP O
26 477 479 11897407 to TO B-VP O
27 480 487 11897407 prepare VB I-VP O
28 487 488 11897407 , , O O
29 489 495 11897407 stable JJ B-ADJP O
30 496 499 11897407 for IN B-PP O
31 500 502 11897407 96 CD B-NP O
32 503 504 11897407 h NN I-NP O
33 505 508 11897407 and CC O O
34 509 512 11897407 was VBD B-VP O
35 513 517 11897407 used VBN I-VP O
36 518 520 11897407 to TO B-VP O
37 521 526 11897407 study VB I-VP O
38 527 530 11897407 its PRP$ B-NP O
39 531 546 11897407 biodistribution NN I-NP O
40 547 549 11897407 in IN B-PP O
41 550 554 11897407 rats NNS B-NP O
42 555 559 11897407 with IN B-PP O
43 560 573 11897407 isoproterenol NN B-NP B-Chemical
44 573 574 11897407 - HYPH B-NP O
45 574 581 11897407 induced VBN I-NP O
46 582 587 11897407 acute JJ I-NP O
47 588 598 11897407 myocardial JJ I-NP B-Disease
48 599 609 11897407 infarction NN I-NP I-Disease
49 609 610 11897407 . . O O

1 611 623 11897407 Histological JJ B-NP O
2 624 631 11897407 studies NNS I-NP O
3 632 644 11897407 demonstrated VBD B-VP O
4 645 649 11897407 that IN B-SBAR O
5 650 653 11897407 the DT B-NP O
6 654 658 11897407 rats NNS I-NP O
7 659 668 11897407 developed VBD B-VP O
8 669 671 11897407 an DT B-NP O
9 672 679 11897407 infarct NN I-NP B-Disease
10 680 682 11897407 18 CD I-NP O
11 683 684 11897407 h NN I-NP O
12 685 690 11897407 after IN B-PP O
13 691 704 11897407 isoproterenol NN B-NP B-Chemical
14 705 719 11897407 administration NN I-NP O
15 719 720 11897407 . . O O

1 721 724 11897407 The DT B-NP O
2 725 728 11897407 rat NN I-NP O
3 729 744 11897407 biodistribution NN I-NP O
4 745 752 11897407 studies NNS I-NP O
5 753 759 11897407 showed VBD B-VP O
6 760 761 11897407 a DT B-NP O
7 762 767 11897407 rapid JJ I-NP O
8 768 773 11897407 blood NN I-NP O
9 774 783 11897407 clearance NN I-NP O
10 784 787 11897407 via IN B-PP O
11 788 791 11897407 the DT B-NP O
12 792 799 11897407 kidneys NNS I-NP O
13 799 800 11897407 . . O O

1 801 807 11897407 Thirty CD B-NP O
2 808 815 11897407 minutes NNS I-NP O
3 816 821 11897407 after IN B-PP O
4 822 827 11897407 99mTc NN B-NP B-Chemical
5 827 828 11897407 - HYPH B-NP I-Chemical
6 828 837 11897407 glucarate NN I-NP I-Chemical
7 838 852 11897407 administration NN I-NP O
8 853 856 11897407 the DT B-NP O
9 857 869 11897407 standardised JJ I-NP O
10 870 875 11897407 heart NN I-NP O
11 876 882 11897407 uptake NN I-NP O
12 883 888 11897407 value NN I-NP O
13 889 895 11897407 S(h)UV NN I-NP O
14 896 899 11897407 was VBD B-VP O
15 900 903 11897407 4.7 CD B-NP O
16 904 906 11897407 in IN B-PP O
17 907 916 11897407 infarcted VBN B-NP O
18 917 920 11897407 rat NN I-NP O
19 921 926 11897407 heart NN I-NP O
20 927 932 11897407 which WDT B-NP O
21 933 935 11897407 is VBZ B-VP O
22 936 939 11897407 six CD B-ADJP O
23 940 945 11897407 times NNS I-ADJP O
24 946 950 11897407 more JJR I-ADJP O
25 951 955 11897407 than IN B-PP O
26 956 958 11897407 in IN B-PP O
27 959 965 11897407 normal JJ B-NP O
28 966 970 11897407 rats NNS I-NP O
29 970 971 11897407 . . O O

1 972 976 11897407 ROIs NNS B-NP O
2 977 982 11897407 drawn VBN B-VP O
3 983 987 11897407 over IN B-PP O
4 988 991 11897407 the DT B-NP O
5 992 997 11897407 gamma NN I-NP O
6 998 1004 11897407 camera NN I-NP O
7 1005 1011 11897407 images NNS I-NP O
8 1012 1018 11897407 showed VBD B-VP O
9 1019 1020 11897407 a DT B-NP O
10 1021 1026 11897407 ratio NN I-NP O
11 1027 1029 11897407 of IN B-PP O
12 1030 1033 11897407 4.4 CD B-NP O
13 1033 1034 11897407 . . O O

1 1035 1038 11897407 The DT B-NP O
2 1039 1043 11897407 high JJ I-NP O
3 1044 1049 11897407 image NN I-NP O
4 1050 1057 11897407 quality NN I-NP O
5 1058 1066 11897407 suggests VBZ B-VP O
6 1067 1071 11897407 that IN B-SBAR O
7 1072 1076 11897407 high JJ B-NP O
8 1077 1085 11897407 contrast NN I-NP O
9 1086 1092 11897407 images NNS I-NP O
10 1093 1096 11897407 can MD B-VP O
11 1097 1099 11897407 be VB I-VP O
12 1100 1108 11897407 obtained VBN I-VP O
13 1109 1111 11897407 in IN B-PP O
14 1112 1118 11897407 humans NNS B-NP O
15 1119 1122 11897407 and CC O O
16 1123 1126 11897407 the DT B-NP O
17 1127 1129 11897407 96 CD I-NP O
18 1130 1131 11897407 h NN I-NP O
19 1132 1141 11897407 stability NN I-NP O
20 1142 1147 11897407 makes VBZ B-VP O
21 1148 1150 11897407 it PRP B-NP O
22 1151 1153 11897407 an DT B-NP O
23 1154 1159 11897407 ideal JJ I-NP O
24 1160 1165 11897407 agent NN I-NP O
25 1166 1168 11897407 to TO B-VP O
26 1169 1175 11897407 detect VB I-VP O
27 1175 1176 11897407 , , O O
28 1177 1179 11897407 in IN B-PP O
29 1180 1188 11897407 patients NNS B-NP O
30 1188 1189 11897407 , , O O
31 1190 1195 11897407 early JJ B-NP O
32 1196 1203 11897407 cardiac JJ I-NP B-Disease
33 1204 1214 11897407 infarction NN I-NP I-Disease
34 1214 1215 11897407 . . O O

1 0 0 2887062 -DOCSTART- -X- -X- O

1 0 19 2887062 Immunohistochemical JJ B-NP O
2 19 20 2887062 , , I-NP O
3 21 29 2887062 electron NN I-NP O
4 30 41 2887062 microscopic JJ I-NP O
5 42 45 2887062 and CC I-NP O
6 46 58 2887062 morphometric JJ I-NP O
7 59 66 2887062 studies NNS I-NP O
8 67 69 2887062 of IN B-PP O
9 70 78 2887062 estrogen NN B-NP B-Chemical
10 78 79 2887062 - HYPH B-NP O
11 79 86 2887062 induced VBN I-NP O
12 87 90 2887062 rat NN I-NP O
13 91 104 2887062 prolactinomas NNS I-NP B-Disease
14 105 110 2887062 after IN B-PP O
15 111 124 2887062 bromocriptine NN B-NP B-Chemical
16 125 134 2887062 treatment NN I-NP O
17 134 135 2887062 . . O O
18 136 138 2887062 To TO B-VP O
19 139 146 2887062 clarify VB I-VP O
20 147 150 2887062 the DT B-NP O
21 151 158 2887062 effects NNS I-NP O
22 159 161 2887062 of IN B-PP O
23 162 175 2887062 bromocriptine NN B-NP B-Chemical
24 176 178 2887062 on IN B-PP O
25 179 191 2887062 prolactinoma NN B-NP B-Disease
26 192 197 2887062 cells NNS I-NP O
27 198 200 2887062 in FW B-ADVP O
28 201 205 2887062 vivo FW I-ADVP O
29 205 206 2887062 , , O O
30 207 226 2887062 immunohistochemical JJ B-NP O
31 226 227 2887062 , , I-NP O
32 228 243 2887062 ultrastructural JJ I-NP O
33 244 247 2887062 and CC I-NP O
34 248 262 2887062 morphometrical JJ I-NP O
35 263 271 2887062 analyses NNS I-NP O
36 272 276 2887062 were VBD B-VP O
37 277 284 2887062 applied VBN I-VP O
38 285 287 2887062 to TO B-PP O
39 288 296 2887062 estrogen NN B-NP B-Chemical
40 296 297 2887062 - HYPH B-NP O
41 297 304 2887062 induced VBN I-NP O
42 305 308 2887062 rat NN I-NP O
43 309 321 2887062 prolactinoma NN I-NP B-Disease
44 322 327 2887062 cells NNS I-NP O
45 328 329 2887062 1 CD B-NP O
46 330 331 2887062 h NN I-NP O
47 332 335 2887062 and CC I-NP O
48 336 337 2887062 6 CD I-NP O
49 338 339 2887062 h NN I-NP O
50 340 345 2887062 after IN B-PP O
51 346 355 2887062 injection NN B-NP O
52 356 358 2887062 of IN B-PP O
53 359 372 2887062 bromocriptine NN B-NP B-Chemical
54 373 374 2887062 ( ( O O
55 374 375 2887062 3 CD B-NP O
56 376 378 2887062 mg NN I-NP O
57 378 379 2887062 / SYM B-NP O
58 379 381 2887062 kg NN I-NP O
59 382 384 2887062 of IN B-PP O
60 385 389 2887062 body NN B-NP O
61 390 396 2887062 weight NN I-NP O
62 396 397 2887062 ) ) O O
63 397 398 2887062 . . O O

1 399 402 2887062 One CD B-NP O
2 403 404 2887062 h NN I-NP O
3 405 410 2887062 after IN B-PP O
4 411 420 2887062 treatment NN B-NP O
5 420 421 2887062 , , O O
6 422 427 2887062 serum NN B-NP O
7 428 437 2887062 prolactin NN I-NP O
8 438 444 2887062 levels NNS I-NP O
9 445 454 2887062 decreased VBD B-VP O
10 455 463 2887062 markedly RB B-ADVP O
11 463 464 2887062 . . O O

1 465 473 2887062 Electron NN B-NP O
2 474 484 2887062 microscopy NN I-NP O
3 485 494 2887062 disclosed VBD B-VP O
4 495 499 2887062 many JJ B-NP O
5 500 509 2887062 secretory JJ I-NP O
6 510 518 2887062 granules NNS I-NP O
7 518 519 2887062 , , O O
8 520 528 2887062 slightly RB B-NP O
9 529 538 2887062 distorted JJ I-NP O
10 539 544 2887062 rough JJ I-NP O
11 545 556 2887062 endoplasmic JJ I-NP O
12 557 566 2887062 reticulum NN I-NP O
13 566 567 2887062 , , O O
14 568 571 2887062 and CC O O
15 572 581 2887062 partially RB B-NP O
16 582 589 2887062 dilated JJ I-NP O
17 590 595 2887062 Golgi NNP I-NP O
18 596 605 2887062 cisternae NNS I-NP O
19 606 608 2887062 in IN B-PP O
20 609 612 2887062 the DT B-NP O
21 613 625 2887062 prolactinoma NN I-NP B-Disease
22 626 631 2887062 cells NNS I-NP O
23 631 632 2887062 . . O O

1 633 645 2887062 Morphometric JJ B-NP O
2 646 654 2887062 analysis NN I-NP O
3 655 663 2887062 revealed VBD B-VP O
4 664 668 2887062 that IN B-SBAR O
5 669 672 2887062 the DT B-NP O
6 673 679 2887062 volume NN I-NP O
7 680 687 2887062 density NN I-NP O
8 688 690 2887062 of IN B-PP O
9 691 700 2887062 secretory JJ B-NP O
10 701 709 2887062 granules NNS I-NP O
11 710 719 2887062 increased VBD B-VP O
12 719 720 2887062 , , O O
13 721 726 2887062 while IN B-SBAR O
14 727 730 2887062 the DT B-NP O
15 731 737 2887062 volume NN I-NP O
16 738 745 2887062 density NN I-NP O
17 746 748 2887062 of IN B-PP O
18 749 760 2887062 cytoplasmic JJ B-NP O
19 761 773 2887062 microtubules NNS I-NP O
20 774 783 2887062 decreased VBD B-VP O
21 783 784 2887062 . . O O

1 785 790 2887062 These DT B-NP O
2 791 799 2887062 findings NNS I-NP O
3 800 807 2887062 suggest VBP B-VP O
4 808 812 2887062 that IN B-SBAR O
5 813 820 2887062 lowered VBN B-NP O
6 821 826 2887062 serum NN I-NP O
7 827 836 2887062 prolactin NN I-NP O
8 837 843 2887062 levels NNS I-NP O
9 844 846 2887062 in IN B-PP O
10 847 850 2887062 the DT B-NP O
11 851 856 2887062 early JJ I-NP O
12 857 862 2887062 phase NN I-NP O
13 863 865 2887062 of IN B-PP O
14 866 879 2887062 bromocriptine NN B-NP B-Chemical
15 880 889 2887062 treatment NN I-NP O
16 890 893 2887062 may MD B-VP O
17 894 900 2887062 result VB I-VP O
18 901 905 2887062 from IN B-PP O
19 906 908 2887062 an DT B-NP O
20 909 917 2887062 impaired JJ I-NP O
21 918 927 2887062 secretion NN I-NP O
22 928 930 2887062 of IN B-PP O
23 931 940 2887062 prolactin NN B-NP O
24 941 944 2887062 due JJ B-ADJP O
25 945 947 2887062 to TO B-PP O
26 948 958 2887062 decreasing VBG B-NP O
27 959 966 2887062 numbers NNS I-NP O
28 967 969 2887062 of IN B-PP O
29 970 981 2887062 cytoplasmic JJ B-NP O
30 982 994 2887062 microtubules NNS I-NP O
31 994 995 2887062 . . O O

1 996 998 2887062 At IN B-PP O
2 999 1000 2887062 6 CD B-NP O
3 1001 1002 2887062 h NN I-NP O
4 1003 1008 2887062 after IN B-PP O
5 1009 1018 2887062 injection NN B-NP O
6 1018 1019 2887062 , , O O
7 1020 1025 2887062 serum NN B-NP O
8 1026 1035 2887062 prolactin NN I-NP O
9 1036 1042 2887062 levels NNS I-NP O
10 1043 1047 2887062 were VBD B-VP O
11 1048 1053 2887062 still RB B-ADVP O
12 1054 1066 2887062 considerably RB B-ADJP O
13 1067 1072 2887062 lower JJR I-ADJP O
14 1073 1077 2887062 than IN B-PP O
15 1078 1080 2887062 in IN B-PP O
16 1081 1089 2887062 controls NNS B-NP O
17 1089 1090 2887062 . . O O

1 1091 1094 2887062 The DT B-NP O
2 1095 1107 2887062 prolactinoma NN I-NP B-Disease
3 1108 1113 2887062 cells NNS I-NP O
4 1114 1116 2887062 at IN B-PP O
5 1117 1121 2887062 this DT B-NP O
6 1122 1126 2887062 time NN I-NP O
7 1127 1131 2887062 were VBD B-VP O
8 1132 1136 2887062 well RB I-VP O
9 1137 1147 2887062 granulated VBN I-VP O
10 1147 1148 2887062 , , O O
11 1149 1153 2887062 with IN B-PP O
12 1154 1165 2887062 vesiculated VBN B-NP O
13 1166 1171 2887062 rough JJ I-NP O
14 1172 1183 2887062 endoplasmic JJ I-NP O
15 1184 1193 2887062 reticulum NN I-NP O
16 1194 1197 2887062 and CC O O
17 1198 1206 2887062 markedly RB B-VP O
18 1207 1214 2887062 dilated VBD I-VP O
19 1215 1220 2887062 Golgi NNP B-NP O
20 1221 1230 2887062 cisternae NNS I-NP O
21 1230 1231 2887062 . . O O

1 1232 1240 2887062 Electron NN B-NP O
2 1241 1254 2887062 microscopical JJ I-NP O
3 1255 1275 2887062 immunohistochemistry NN I-NP O
4 1276 1284 2887062 revealed VBD B-VP O
5 1285 1293 2887062 positive JJ B-NP O
6 1294 1302 2887062 reaction NN I-NP O
7 1303 1311 2887062 products NNS I-NP O
8 1312 1317 2887062 noted VBN B-VP O
9 1318 1320 2887062 on IN B-PP O
10 1321 1324 2887062 the DT B-NP O
11 1325 1334 2887062 secretory JJ I-NP O
12 1335 1343 2887062 granules NNS I-NP O
13 1343 1344 2887062 , , O O
14 1345 1350 2887062 Golgi NNP B-NP O
15 1351 1360 2887062 cisternae NNS I-NP O
16 1360 1361 2887062 , , O O
17 1362 1365 2887062 and CC O O
18 1366 1377 2887062 endoplasmic JJ B-NP O
19 1378 1387 2887062 reticulum NN I-NP O
20 1388 1390 2887062 of IN B-PP O
21 1391 1394 2887062 the DT B-NP O
22 1395 1404 2887062 untreated JJ I-NP O
23 1405 1408 2887062 rat NN I-NP O
24 1409 1421 2887062 prolactinoma NN I-NP B-Disease
25 1422 1427 2887062 cells NNS I-NP O
26 1427 1428 2887062 . . O O

1 1429 1436 2887062 However RB B-ADVP O
2 1436 1437 2887062 , , O O
3 1438 1442 2887062 only RB B-NP O
4 1443 1452 2887062 secretory JJ I-NP O
5 1453 1461 2887062 granules NNS I-NP O
6 1462 1468 2887062 showed VBD B-VP O
7 1469 1472 2887062 the DT B-NP O
8 1473 1481 2887062 positive JJ I-NP O
9 1482 1490 2887062 reaction NN I-NP O
10 1491 1499 2887062 products NNS I-NP O
11 1500 1503 2887062 for IN B-PP O
12 1504 1513 2887062 prolactin NN B-NP O
13 1514 1515 2887062 6 CD I-NP O
14 1516 1517 2887062 h NN I-NP O
15 1518 1523 2887062 after IN B-PP O
16 1524 1537 2887062 bromocriptine NN B-NP B-Chemical
17 1538 1547 2887062 treatment NN I-NP O
18 1548 1550 2887062 of IN B-PP O
19 1551 1554 2887062 the DT B-NP O
20 1555 1562 2887062 adenoma NN I-NP B-Disease
21 1563 1568 2887062 cells NNS I-NP O
22 1568 1569 2887062 . . O O

1 1570 1572 2887062 An DT B-NP O
2 1573 1581 2887062 increase NN I-NP O
3 1582 1584 2887062 in IN B-PP O
4 1585 1588 2887062 the DT B-NP O
5 1589 1595 2887062 volume NN I-NP O
6 1596 1603 2887062 density NN I-NP O
7 1604 1606 2887062 of IN B-PP O
8 1607 1616 2887062 secretory JJ B-NP O
9 1617 1625 2887062 granules NNS I-NP O
10 1626 1629 2887062 and CC O O
11 1630 1631 2887062 a DT B-NP O
12 1632 1640 2887062 decrease NN I-NP O
13 1641 1643 2887062 in IN B-PP O
14 1644 1647 2887062 the DT B-NP O
15 1648 1654 2887062 volume NN I-NP O
16 1655 1664 2887062 densities NNS I-NP O
17 1665 1667 2887062 of IN B-PP O
18 1668 1673 2887062 rough JJ B-NP O
19 1674 1685 2887062 endoplasmic JJ I-NP O
20 1686 1695 2887062 reticulum NN I-NP O
21 1696 1699 2887062 and CC I-NP O
22 1700 1712 2887062 microtubules NNS I-NP O
23 1713 1716 2887062 was VBD B-VP O
24 1717 1727 2887062 determined VBN I-VP O
25 1728 1730 2887062 by IN B-PP O
26 1731 1743 2887062 morphometric JJ B-NP O
27 1744 1752 2887062 analysis NN I-NP O
28 1752 1753 2887062 , , O O
29 1754 1764 2887062 suggesting VBG B-VP O
30 1765 1769 2887062 that IN B-SBAR O
31 1770 1783 2887062 bromocriptine NN B-NP B-Chemical
32 1784 1792 2887062 inhibits VBZ B-VP O
33 1793 1800 2887062 protein NN B-NP O
34 1801 1810 2887062 synthesis NN I-NP O
35 1811 1813 2887062 as RB B-CONJP O
36 1814 1818 2887062 well RB I-CONJP O
37 1819 1821 2887062 as IN I-CONJP O
38 1822 1830 2887062 bringing VBG B-VP O
39 1831 1836 2887062 about IN B-PP O
40 1837 1838 2887062 a DT B-NP O
41 1839 1850 2887062 disturbance NN I-NP O
42 1851 1853 2887062 of IN B-PP O
43 1854 1857 2887062 the DT B-NP O
44 1858 1867 2887062 prolactin NN I-NP O
45 1868 1877 2887062 secretion NN I-NP O
46 1877 1878 2887062 . . O O

1 0 0 9034419 -DOCSTART- -X- -X- O

1 0 7 9034419 Seizure NN B-NP B-Disease
2 8 17 9034419 resulting VBG B-VP O
3 18 22 9034419 from IN B-PP O
4 23 24 9034419 a DT B-NP O
5 25 36 9034419 venlafaxine NN I-NP B-Chemical
6 37 45 9034419 overdose NN I-NP B-Disease
7 45 46 9034419 . . I-NP O
8 47 56 9034419 OBJECTIVE NN I-NP O
9 56 57 9034419 : : O O
10 58 60 9034419 To TO B-VP O
11 61 67 9034419 report VB I-VP O
12 68 69 9034419 a DT B-NP O
13 70 74 9034419 case NN I-NP O
14 75 77 9034419 of IN B-PP O
15 78 89 9034419 venlafaxine NN B-NP B-Chemical
16 90 98 9034419 overdose NN I-NP B-Disease
17 98 99 9034419 . . O O

1 100 104 9034419 CASE NN B-NP O
2 105 112 9034419 SUMMARY NN I-NP O
3 112 113 9034419 : : O O
4 114 115 9034419 A DT B-NP O
5 116 118 9034419 40 CD I-NP O
6 118 119 9034419 - HYPH I-NP O
7 119 123 9034419 year NN I-NP O
8 123 124 9034419 - HYPH O O
9 124 127 9034419 old JJ B-NP O
10 128 133 9034419 woman NN I-NP O
11 134 138 9034419 with IN B-PP O
12 139 144 9034419 major JJ B-NP B-Disease
13 145 155 9034419 depression NN I-NP I-Disease
14 156 160 9034419 took VBD B-VP O
15 161 163 9034419 an DT B-NP O
16 164 172 9034419 overdose NN I-NP B-Disease
17 173 175 9034419 of IN B-PP O
18 176 187 9034419 venlafaxine NN B-NP B-Chemical
19 188 190 9034419 in IN B-PP O
20 191 193 9034419 an DT B-NP O
21 194 202 9034419 apparent JJ I-NP O
22 203 210 9034419 suicide NN I-NP O
23 211 218 9034419 attempt NN I-NP O
24 218 219 9034419 . . O O

1 220 225 9034419 After IN B-PP O
2 226 229 9034419 the DT B-NP O
3 230 239 9034419 ingestion NN I-NP O
4 240 242 9034419 of IN B-PP O
5 243 245 9034419 26 CD B-NP O
6 246 257 9034419 venlafaxine NN I-NP B-Chemical
7 258 260 9034419 50 CD B-NP O
8 260 261 9034419 - HYPH I-NP O
9 261 263 9034419 mg NN I-NP O
10 264 271 9034419 tablets NNS I-NP O
11 271 272 9034419 , , O O
12 273 276 9034419 the DT B-NP O
13 277 284 9034419 patient NN I-NP O
14 285 296 9034419 experienced VBD B-VP O
15 297 298 9034419 a DT B-NP O
16 299 308 9034419 witnessed VBN I-NP O
17 309 320 9034419 generalized VBN I-NP O
18 321 328 9034419 seizure NN I-NP B-Disease
19 328 329 9034419 . . O O

1 330 333 9034419 She PRP B-NP O
2 334 337 9034419 was VBD B-VP O
3 338 346 9034419 admitted VBN I-VP O
4 347 349 9034419 to TO B-PP O
5 350 353 9034419 the DT B-NP O
6 354 361 9034419 medical JJ I-NP O
7 362 371 9034419 intensive JJ I-NP O
8 372 376 9034419 care NN I-NP O
9 377 381 9034419 unit NN I-NP O
10 381 382 9034419 , , O O
11 383 394 9034419 venlafaxine NN B-NP B-Chemical
12 395 398 9034419 was VBD B-VP O
13 399 411 9034419 discontinued VBN I-VP O
14 411 412 9034419 , , O O
15 413 416 9034419 and CC O O
16 417 419 9034419 no DT B-NP O
17 420 427 9034419 further JJ I-NP O
18 428 436 9034419 sequelae NNS I-NP O
19 437 441 9034419 were VBD B-VP O
20 442 446 9034419 seen VBN I-VP O
21 446 447 9034419 . . O O

1 448 458 9034419 DISCUSSION NN B-NP O
2 458 459 9034419 : : O O
3 460 462 9034419 To TO B-PP O
4 463 466 9034419 our PRP$ B-NP O
5 467 476 9034419 knowledge NN I-NP O
6 476 477 9034419 , , O O
7 478 482 9034419 this DT B-NP O
8 483 485 9034419 is VBZ B-VP O
9 486 489 9034419 the DT B-NP O
10 490 495 9034419 first JJ I-NP O
11 496 504 9034419 reported VBN I-NP O
12 505 509 9034419 case NN I-NP O
13 510 512 9034419 of IN B-PP O
14 513 524 9034419 venlafaxine NN B-NP B-Chemical
15 525 533 9034419 overdose NN I-NP B-Disease
16 534 538 9034419 that WDT B-NP O
17 539 547 9034419 resulted VBD B-VP O
18 548 550 9034419 in IN B-PP O
19 551 552 9034419 a DT B-NP O
20 553 564 9034419 generalized VBN I-NP O
21 565 572 9034419 seizure NN I-NP B-Disease
22 572 573 9034419 . . O O

1 574 579 9034419 Based VBN B-PP O
2 580 582 9034419 on IN B-PP O
3 583 594 9034419 nonoverdose JJ B-NP O
4 595 611 9034419 pharmacokinetics NNS I-NP O
5 612 615 9034419 and CC I-NP O
6 616 632 9034419 pharmacodynamics NNS I-NP O
7 633 635 9034419 of IN B-PP O
8 636 647 9034419 venlafaxine NN B-NP B-Chemical
9 648 651 9034419 and CC O O
10 652 655 9034419 the DT B-NP O
11 656 665 9034419 potential JJ I-NP O
12 666 671 9034419 risks NNS I-NP O
13 672 674 9034419 of IN B-PP O
14 675 684 9034419 available JJ B-NP O
15 685 698 9034419 interventions NNS I-NP O
16 698 699 9034419 , , O O
17 700 702 9034419 no DT B-NP O
18 703 711 9034419 emergent JJ I-NP O
19 712 719 9034419 therapy NN I-NP O
20 720 723 9034419 was VBD B-VP O
21 724 734 9034419 instituted VBN I-VP O
22 734 735 9034419 . . O O

1 736 747 9034419 CONCLUSIONS NNS B-NP O
2 747 748 9034419 : : O O
3 749 752 9034419 The DT B-NP O
4 753 764 9034419 venlafaxine NN I-NP B-Chemical
5 765 773 9034419 overdose NN I-NP B-Disease
6 774 776 9034419 in IN B-PP O
7 777 780 9034419 our PRP$ B-NP O
8 781 788 9034419 patient NN I-NP O
9 789 797 9034419 resulted VBD B-VP O
10 798 800 9034419 in IN B-PP O
11 801 802 9034419 a DT B-NP O
12 803 809 9034419 single JJ I-NP O
13 810 817 9034419 episode NN I-NP O
14 818 820 9034419 of IN B-PP O
15 821 832 9034419 generalized VBN B-NP O
16 833 840 9034419 seizure NN I-NP B-Disease
17 841 844 9034419 but CC O O
18 845 853 9034419 elicited VBD B-VP O
19 854 856 9034419 no DT B-NP O
20 857 864 9034419 further JJ I-NP O
21 865 873 9034419 sequelae NNS I-NP O
22 873 874 9034419 . . O O

1 0 0 2425813 -DOCSTART- -X- -X- O

1 0 2 2425813 On IN B-PP O
2 3 6 2425813 two CD B-NP O
3 7 18 2425813 paradoxical JJ I-NP O
4 19 23 2425813 side NN I-NP O
5 23 24 2425813 - HYPH O O
6 24 31 2425813 effects NNS B-NP O
7 32 34 2425813 of IN B-PP O
8 35 47 2425813 prednisolone NN B-NP B-Chemical
9 48 50 2425813 in IN B-PP O
10 51 55 2425813 rats NNS B-NP O
11 55 56 2425813 , , O O
12 57 66 2425813 ribosomal JJ B-NP O
13 67 70 2425813 RNA NN I-NP O
14 71 83 2425813 biosyntheses NNS I-NP O
15 83 84 2425813 , , O O
16 85 88 2425813 and CC O O
17 89 90 2425813 a DT B-NP O
18 91 100 2425813 mechanism NN I-NP O
19 101 103 2425813 of IN B-PP O
20 104 110 2425813 action NN B-NP O
21 110 111 2425813 . . O O
22 112 117 2425813 Liver NN B-NP B-Disease
23 118 129 2425813 enlargement NN I-NP I-Disease
24 130 133 2425813 and CC O O
25 134 140 2425813 muscle NN B-NP B-Disease
26 141 148 2425813 wastage NN I-NP I-Disease
27 149 157 2425813 occurred VBD B-VP O
28 158 160 2425813 in IN B-PP O
29 161 167 2425813 Wistar NNP B-NP O
30 168 172 2425813 rats NNS I-NP O
31 173 182 2425813 following VBG B-PP O
32 183 186 2425813 the DT B-NP O
33 187 199 2425813 subcutaneous JJ I-NP O
34 200 214 2425813 administration NN I-NP O
35 215 217 2425813 of IN B-PP O
36 218 230 2425813 prednisolone NN B-NP B-Chemical
37 230 231 2425813 . . O O

1 232 234 2425813 In IN B-PP O
2 235 238 2425813 the DT B-NP O
3 239 244 2425813 liver NN I-NP O
4 245 249 2425813 both CC O O
5 250 253 2425813 the DT B-NP O
6 254 261 2425813 content NN I-NP O
7 262 264 2425813 of IN B-PP O
8 265 268 2425813 RNA NN B-NP O
9 269 272 2425813 and CC O O
10 273 276 2425813 the DT B-NP O
11 277 289 2425813 biosynthesis NN I-NP O
12 290 292 2425813 of IN B-PP O
13 293 302 2425813 ribosomal JJ B-NP O
14 303 306 2425813 RNA NN I-NP O
15 307 316 2425813 increased VBD B-VP O
16 317 322 2425813 while IN B-SBAR O
17 323 327 2425813 both CC O O
18 328 331 2425813 the DT B-NP O
19 332 335 2425813 RNA NN I-NP O
20 336 343 2425813 content NN I-NP O
21 344 347 2425813 and CC O O
22 348 357 2425813 ribosomal JJ B-NP O
23 358 361 2425813 RNA NN I-NP O
24 362 374 2425813 biosynthesis NN I-NP O
25 375 379 2425813 were VBD B-VP O
26 380 387 2425813 reduced VBN I-VP O
27 388 390 2425813 in IN B-PP O
28 391 394 2425813 the DT B-NP O
29 395 408 2425813 gastrocnemius NN I-NP O
30 409 415 2425813 muscle NN I-NP O
31 415 416 2425813 . . O O

1 417 419 2425813 It PRP B-NP O
2 420 422 2425813 is VBZ B-VP O
3 423 432 2425813 suggested VBN I-VP O
4 433 437 2425813 that IN B-SBAR O
5 438 441 2425813 the DT B-NP O
6 442 446 2425813 drug NN I-NP O
7 447 452 2425813 acted VBD B-VP O
8 453 455 2425813 in IN B-PP O
9 456 457 2425813 a DT B-NP O
10 458 467 2425813 selective JJ I-NP O
11 468 471 2425813 and CC I-NP O
12 472 478 2425813 tissue NN I-NP O
13 478 479 2425813 - HYPH B-NP O
14 479 487 2425813 specific JJ I-NP O
15 488 494 2425813 manner NN I-NP O
16 495 497 2425813 to TO B-VP O
17 498 505 2425813 enhance VB I-VP O
18 506 515 2425813 ribosomal JJ B-NP O
19 516 519 2425813 RNA NN I-NP O
20 520 529 2425813 synthesis NN I-NP O
21 530 532 2425813 in IN B-PP O
22 533 536 2425813 the DT B-NP O
23 537 542 2425813 liver NN I-NP O
24 543 546 2425813 and CC O O
25 547 554 2425813 depress VBP B-VP O
26 555 559 2425813 such JJ B-NP O
27 560 569 2425813 synthesis NN I-NP O
28 570 572 2425813 in IN B-PP O
29 573 576 2425813 the DT B-NP O
30 577 583 2425813 muscle NN I-NP O
31 583 584 2425813 . . O O

1 585 589 2425813 This DT B-NP O
2 590 594 2425813 view NN I-NP O
3 595 603 2425813 supports VBZ B-VP O
4 604 607 2425813 the DT B-NP O
5 608 618 2425813 contention NN I-NP O
6 619 623 2425813 that IN B-SBAR O
7 624 627 2425813 the DT B-NP O
8 628 633 2425813 liver NN I-NP O
9 634 637 2425813 and CC I-NP O
10 638 644 2425813 muscle NN I-NP O
11 645 648 2425813 are VBP B-VP O
12 649 660 2425813 independent JJ B-NP O
13 661 666 2425813 sites NNS I-NP O
14 667 669 2425813 of IN B-PP O
15 670 682 2425813 prednisolone JJ B-NP B-Chemical
16 683 689 2425813 action NN I-NP O
17 689 690 2425813 . . O O

1 0 0 12617329 -DOCSTART- -X- -X- O

1 0 3 12617329 The DT B-NP O
2 4 10 12617329 effect NN I-NP O
3 11 13 12617329 of IN B-PP O
4 14 23 12617329 treatment NN B-NP O
5 24 28 12617329 with IN B-PP O
6 29 32 12617329 gum NN B-NP B-Chemical
7 33 39 12617329 Arabic JJ B-ADJP I-Chemical
8 40 42 12617329 on IN B-PP O
9 43 53 12617329 gentamicin NN B-NP B-Chemical
10 54 68 12617329 nephrotoxicity NN I-NP B-Disease
11 69 71 12617329 in IN B-PP O
12 72 76 12617329 rats NNS B-NP O
13 76 77 12617329 : : O O
14 78 79 12617329 a DT B-NP O
15 80 91 12617329 preliminary JJ I-NP O
16 92 97 12617329 study NN I-NP O
17 97 98 12617329 . . O O
18 99 101 12617329 In IN B-PP O
19 102 105 12617329 the DT B-NP O
20 106 113 12617329 present JJ I-NP O
21 114 118 12617329 work NN I-NP O
22 119 121 12617329 we PRP B-NP O
23 122 130 12617329 assessed VBD B-VP O
24 131 134 12617329 the DT B-NP O
25 135 141 12617329 effect NN I-NP O
26 142 144 12617329 of IN B-PP O
27 145 154 12617329 treatment NN B-NP O
28 155 157 12617329 of IN B-PP O
29 158 162 12617329 rats NNS B-NP O
30 163 167 12617329 with IN B-PP O
31 168 171 12617329 gum NN B-NP B-Chemical
32 172 178 12617329 Arabic JJ B-ADJP I-Chemical
33 179 181 12617329 on IN B-PP O
34 182 187 12617329 acute JJ B-NP B-Disease
35 188 193 12617329 renal JJ I-NP I-Disease
36 194 201 12617329 failure NN I-NP I-Disease
37 202 209 12617329 induced VBN B-VP O
38 210 212 12617329 by IN B-PP O
39 213 223 12617329 gentamicin NN B-NP B-Chemical
40 224 225 12617329 ( ( O O
41 225 227 12617329 GM NN B-NP B-Chemical
42 227 228 12617329 ) ) O O
43 229 243 12617329 nephrotoxicity NN B-NP B-Disease
44 243 244 12617329 . . O O

1 245 249 12617329 Rats NNS B-NP O
2 250 254 12617329 were VBD B-VP O
3 255 262 12617329 treated VBN I-VP O
4 263 267 12617329 with IN B-PP O
5 268 271 12617329 the DT B-NP O
6 272 279 12617329 vehicle NN I-NP O
7 280 281 12617329 ( ( O O
8 281 282 12617329 2 CD B-NP O
9 283 285 12617329 mL NN I-NP O
10 285 286 12617329 / SYM B-NP O
11 286 288 12617329 kg NN I-NP O
12 289 291 12617329 of IN B-PP O
13 292 301 12617329 distilled JJ B-NP O
14 302 307 12617329 water NN I-NP O
15 308 311 12617329 and CC O O
16 312 314 12617329 5% CD B-NP O
17 315 316 12617329 w NN I-NP O
18 316 317 12617329 / SYM B-NP O
19 317 318 12617329 v NN I-NP O
20 319 328 12617329 cellulose NN I-NP O
21 328 329 12617329 , , O O
22 330 332 12617329 10 CD B-NP O
23 333 337 12617329 days NNS I-NP O
24 337 338 12617329 ) ) O O
25 338 339 12617329 , , O O
26 340 343 12617329 gum NN B-NP B-Chemical
27 344 350 12617329 Arabic JJ B-ADJP I-Chemical
28 351 352 12617329 ( ( O O
29 352 353 12617329 2 CD B-NP O
30 354 356 12617329 mL NN I-NP O
31 356 357 12617329 / SYM B-NP O
32 357 359 12617329 kg NN I-NP O
33 360 362 12617329 of IN B-PP O
34 363 364 12617329 a DT B-NP O
35 365 368 12617329 10% CD I-NP O
36 369 370 12617329 w NN I-NP O
37 370 371 12617329 / SYM B-NP O
38 371 372 12617329 v NN I-NP O
39 373 380 12617329 aqueous JJ I-NP O
40 381 391 12617329 suspension NN I-NP O
41 392 394 12617329 of IN B-PP O
42 395 398 12617329 gum NN B-NP B-Chemical
43 399 405 12617329 Arabic JJ I-NP I-Chemical
44 406 412 12617329 powder NN I-NP O
45 412 413 12617329 , , O O
46 414 420 12617329 orally RB B-ADVP O
47 421 424 12617329 for IN B-PP O
48 425 427 12617329 10 CD B-NP O
49 428 432 12617329 days NNS I-NP O
50 432 433 12617329 ) ) O O
51 433 434 12617329 , , O O
52 435 437 12617329 or CC O O
53 438 441 12617329 gum NN B-NP B-Chemical
54 442 448 12617329 Arabic NNP I-NP I-Chemical
55 449 462 12617329 concomitantly RB B-ADVP O
56 463 467 12617329 with IN B-PP O
57 468 470 12617329 GM NNP B-NP B-Chemical
58 471 472 12617329 ( ( O O
59 472 476 12617329 80mg NN B-NP O
60 476 477 12617329 / SYM B-NP O
61 477 479 12617329 kg NN I-NP O
62 479 480 12617329 / SYM I-NP O
63 480 483 12617329 day NN I-NP O
64 484 499 12617329 intramuscularly RB B-ADVP O
65 499 500 12617329 , , O O
66 501 507 12617329 during IN B-PP O
67 508 511 12617329 the DT B-NP O
68 512 516 12617329 last JJ I-NP O
69 517 520 12617329 six CD I-NP O
70 521 525 12617329 days NNS I-NP O
71 526 528 12617329 of IN B-PP O
72 529 532 12617329 the DT B-NP O
73 533 542 12617329 treatment NN I-NP O
74 543 549 12617329 period NN I-NP O
75 549 550 12617329 ) ) O O
76 550 551 12617329 . . O O

1 552 566 12617329 Nephrotoxicity NN B-NP B-Disease
2 567 570 12617329 was VBD B-VP O
3 571 579 12617329 assessed VBN I-VP O
4 580 582 12617329 by IN B-PP O
5 583 592 12617329 measuring VBG B-VP O
6 593 596 12617329 the DT B-NP O
7 597 611 12617329 concentrations NNS I-NP O
8 612 614 12617329 of IN B-PP O
9 615 625 12617329 creatinine NN B-NP B-Chemical
10 626 629 12617329 and CC I-NP O
11 630 634 12617329 urea NN I-NP B-Chemical
12 635 637 12617329 in IN B-PP O
13 638 641 12617329 the DT B-NP O
14 642 648 12617329 plasma NN I-NP O
15 649 652 12617329 and CC O O
16 653 660 12617329 reduced VBN B-NP O
17 661 672 12617329 glutathione NN I-NP B-Chemical
18 673 674 12617329 ( ( O O
19 674 677 12617329 GSH NN B-NP B-Chemical
20 677 678 12617329 ) ) O O
21 679 681 12617329 in IN B-PP O
22 682 685 12617329 the DT B-NP O
23 686 692 12617329 kidney NN I-NP O
24 693 699 12617329 cortex NN I-NP O
25 699 700 12617329 , , O O
26 701 704 12617329 and CC O O
27 705 707 12617329 by IN B-PP O
28 708 713 12617329 light NN B-NP O
29 714 725 12617329 microscopic JJ I-NP O
30 726 737 12617329 examination NN I-NP O
31 738 740 12617329 of IN B-PP O
32 741 747 12617329 kidney NN B-NP O
33 748 756 12617329 sections NNS I-NP O
34 756 757 12617329 . . O O

1 758 761 12617329 The DT B-NP O
2 762 769 12617329 results NNS I-NP O
3 770 779 12617329 indicated VBD B-VP O
4 780 784 12617329 that IN B-SBAR O
5 785 796 12617329 concomitant JJ B-NP O
6 797 806 12617329 treatment NN I-NP O
7 807 811 12617329 with IN B-PP O
8 812 815 12617329 gum NN B-NP B-Chemical
9 816 822 12617329 Arabic NNP I-NP I-Chemical
10 823 826 12617329 and CC I-NP O
11 827 829 12617329 GM NNP I-NP B-Chemical
12 830 843 12617329 significantly RB B-ADVP O
13 844 853 12617329 increased VBD B-VP O
14 854 864 12617329 creatinine NN B-NP B-Chemical
15 865 868 12617329 and CC I-NP O
16 869 873 12617329 urea NN I-NP B-Chemical
17 874 876 12617329 by IN B-PP O
18 877 882 12617329 about RB B-NP O
19 883 886 12617329 183 CD I-NP O
20 887 890 12617329 and CC I-NP O
21 891 895 12617329 239% CD I-NP O
22 895 896 12617329 , , O O
23 897 909 12617329 respectively RB B-ADVP O
24 910 911 12617329 ( ( O O
25 911 919 12617329 compared VBN B-VP O
26 920 922 12617329 to TO B-PP O
27 923 926 12617329 432 CD B-NP O
28 927 930 12617329 and CC I-NP O
29 931 935 12617329 346% CD I-NP O
30 935 936 12617329 , , O O
31 937 949 12617329 respectively RB B-ADVP O
32 949 950 12617329 , , O O
33 951 953 12617329 in IN B-PP O
34 954 958 12617329 rats NNS B-NP O
35 959 966 12617329 treated VBN B-VP O
36 967 971 12617329 with IN B-PP O
37 972 981 12617329 cellulose NN B-NP O
38 982 985 12617329 and CC O O
39 986 988 12617329 GM NN B-NP B-Chemical
40 988 989 12617329 ) ) O O
41 989 990 12617329 , , O O
42 991 994 12617329 and CC O O
43 995 1004 12617329 decreased VBD B-VP O
44 1005 1009 12617329 that IN B-SBAR O
45 1010 1012 12617329 of IN B-PP O
46 1013 1021 12617329 cortical JJ B-NP O
47 1022 1025 12617329 GSH NN I-NP B-Chemical
48 1026 1028 12617329 by IN B-PP O
49 1029 1032 12617329 21% CD B-NP O
50 1033 1034 12617329 ( ( O O
51 1034 1042 12617329 compared VBN B-VP O
52 1043 1045 12617329 to TO I-VP O
53 1046 1049 12617329 27% VB I-VP O
54 1050 1052 12617329 in IN B-PP O
55 1053 1056 12617329 the DT B-NP O
56 1057 1066 12617329 cellulose NN I-NP O
57 1067 1071 12617329 plus CC O O
58 1072 1074 12617329 GM NNP B-NP B-Chemical
59 1075 1080 12617329 group NN I-NP O
60 1080 1081 12617329 ) ) O O
61 1082 1085 12617329 The DT B-NP O
62 1086 1088 12617329 GM NNP I-NP B-Chemical
63 1088 1089 12617329 - HYPH B-VP O
64 1089 1096 12617329 induced VBN B-NP O
65 1097 1105 12617329 proximal JJ I-NP O
66 1106 1113 12617329 tubular JJ I-NP B-Disease
67 1114 1122 12617329 necrosis NN I-NP I-Disease
68 1123 1131 12617329 appeared VBD B-VP O
69 1132 1134 12617329 to TO I-VP O
70 1135 1137 12617329 be VB I-VP O
71 1138 1146 12617329 slightly RB B-ADJP O
72 1147 1151 12617329 less RBR I-ADJP O
73 1152 1158 12617329 severe JJ I-ADJP O
74 1159 1161 12617329 in IN B-PP O
75 1162 1166 12617329 rats NNS B-NP O
76 1167 1172 12617329 given VBN B-VP O
77 1173 1175 12617329 GM NNP B-NP B-Chemical
78 1176 1184 12617329 together RB B-ADVP O
79 1185 1189 12617329 with IN B-PP O
80 1190 1193 12617329 gum NN B-NP B-Chemical
81 1194 1200 12617329 Arabic JJ B-ADJP I-Chemical
82 1201 1205 12617329 than IN B-PP O
83 1206 1208 12617329 in IN B-PP O
84 1209 1214 12617329 those DT B-NP O
85 1215 1220 12617329 given VBN B-PP O
86 1221 1223 12617329 GM NNP B-NP B-Chemical
87 1224 1227 12617329 and CC O O
88 1228 1237 12617329 cellulose NN B-NP O
89 1237 1238 12617329 . . O O

1 1239 1241 12617329 It PRP B-NP O
2 1242 1247 12617329 could MD B-VP O
3 1248 1250 12617329 be VB I-VP O
4 1251 1259 12617329 inferred VBN I-VP O
5 1260 1264 12617329 that IN B-SBAR O
6 1265 1268 12617329 gum NN B-NP B-Chemical
7 1269 1275 12617329 Arabic JJ I-NP I-Chemical
8 1276 1285 12617329 treatment NN I-NP O
9 1286 1289 12617329 has VBZ B-VP O
10 1290 1297 12617329 induced VBN I-VP O
11 1298 1299 12617329 a DT B-NP O
12 1300 1306 12617329 modest JJ I-NP O
13 1307 1319 12617329 amelioration NN I-NP O
14 1320 1322 12617329 of IN B-PP O
15 1323 1327 12617329 some DT B-NP O
16 1328 1330 12617329 of IN B-PP O
17 1331 1334 12617329 the DT B-NP O
18 1335 1347 12617329 histological JJ I-NP O
19 1348 1351 12617329 and CC I-NP O
20 1352 1363 12617329 biochemical JJ I-NP O
21 1364 1371 12617329 indices NNS I-NP O
22 1372 1374 12617329 of IN B-PP O
23 1375 1377 12617329 GM NNP B-NP B-Chemical
24 1378 1392 12617329 nephrotoxicity NN I-NP B-Disease
25 1392 1393 12617329 . . O O

1 1394 1401 12617329 Further JJ B-NP O
2 1402 1406 12617329 work NN I-NP O
3 1407 1409 12617329 is VBZ B-VP O
4 1410 1419 12617329 warranted VBN I-VP O
5 1420 1422 12617329 on IN B-PP O
6 1423 1426 12617329 the DT B-NP O
7 1427 1433 12617329 effect NN I-NP O
8 1434 1436 12617329 of IN B-PP O
9 1437 1440 12617329 the DT B-NP O
10 1441 1451 12617329 treatments NNS I-NP O
11 1452 1454 12617329 on IN B-PP O
12 1455 1460 12617329 renal JJ B-NP O
13 1461 1471 12617329 functional JJ I-NP O
14 1472 1479 12617329 aspects NNS I-NP O
15 1480 1482 12617329 in IN B-PP O
16 1483 1489 12617329 models NNS B-NP O
17 1490 1492 12617329 of IN B-PP O
18 1493 1500 12617329 chronic JJ B-NP B-Disease
19 1501 1506 12617329 renal JJ I-NP I-Disease
20 1507 1514 12617329 failure NN I-NP I-Disease
21 1514 1515 12617329 , , B-PP O
22 1516 1519 12617329 and CC I-PP O
23 1520 1522 12617329 on IN B-PP O
24 1523 1526 12617329 the DT B-NP O
25 1527 1536 12617329 mechanism NN I-NP O
26 1536 1537 12617329 ( ( I-NP O
27 1537 1538 12617329 s NNS I-NP O
28 1538 1539 12617329 ) ) O O
29 1540 1548 12617329 involved VBN B-VP O
30 1548 1549 12617329 . . O O

1 0 0 14513889 -DOCSTART- -X- -X- O

1 0 12 14513889 Ketoconazole NN B-NP B-Chemical
2 12 13 14513889 - HYPH O O
3 13 20 14513889 induced VBN B-NP O
4 21 31 14513889 neurologic JJ I-NP B-Disease
5 32 40 14513889 sequelae NNS I-NP I-Disease
6 40 41 14513889 . . O O
7 42 43 14513889 A DT B-NP O
8 44 46 14513889 77 CD I-NP O
9 46 47 14513889 - HYPH I-NP O
10 47 48 14513889 y NN I-NP O
11 48 49 14513889 - HYPH I-NP O
12 49 52 14513889 old JJ I-NP O
13 53 60 14513889 patient NN I-NP O
14 61 70 14513889 developed VBD B-VP O
15 71 79 14513889 weakness NN B-NP B-Disease
16 80 82 14513889 of IN B-PP I-Disease
17 83 94 14513889 extremities NNS B-NP I-Disease
18 94 95 14513889 , , O O
19 96 100 14513889 legs NNS B-NP B-Disease
20 101 110 14513889 paralysis NN I-NP I-Disease
21 110 111 14513889 , , O O
22 112 122 14513889 dysarthria NN B-NP B-Disease
23 123 126 14513889 and CC O O
24 127 133 14513889 tremor NN B-NP B-Disease
25 134 135 14513889 1 CD I-NP O
26 136 137 14513889 h NN I-NP O
27 138 143 14513889 after IN B-PP O
28 144 153 14513889 ingestion NN B-NP O
29 154 156 14513889 of IN B-PP O
30 157 160 14513889 200 CD B-NP O
31 161 163 14513889 mg NN I-NP O
32 164 176 14513889 ketoconazole NN I-NP B-Chemical
33 177 180 14513889 for IN B-PP O
34 181 184 14513889 the DT B-NP O
35 185 190 14513889 first JJ I-NP O
36 191 195 14513889 time NN I-NP O
37 196 198 14513889 in IN B-PP O
38 199 202 14513889 his PRP$ B-NP O
39 203 207 14513889 life NN I-NP O
40 207 208 14513889 . . O O

1 209 212 14513889 All DT B-NP O
2 213 223 14513889 complaints NNS I-NP O
3 224 229 14513889 faded VBD B-VP O
4 230 234 14513889 away RB B-ADVP O
5 235 241 14513889 within IN B-PP O
6 242 244 14513889 24 CD B-NP O
7 245 246 14513889 h NN I-NP O
8 246 247 14513889 . . O O

1 248 251 14513889 Few JJ B-NP O
2 252 256 14513889 days NNS I-NP O
3 257 262 14513889 later RB B-ADVP O
4 262 263 14513889 , , O O
5 264 267 14513889 the DT B-NP O
6 268 275 14513889 patient NN I-NP O
7 276 280 14513889 used VBD B-VP O
8 281 288 14513889 another DT B-NP O
9 289 292 14513889 200 CD I-NP O
10 293 295 14513889 mg NN I-NP O
11 296 308 14513889 ketoconazole NN I-NP B-Chemical
12 309 315 14513889 tablet NN I-NP O
13 315 316 14513889 , , O O
14 317 320 14513889 and CC O O
15 321 327 14513889 within IN B-PP O
16 328 330 14513889 an DT B-NP O
17 331 335 14513889 hour NN I-NP O
18 336 347 14513889 experienced VBD B-VP O
19 348 349 14513889 a DT B-NP O
20 350 357 14513889 similar JJ I-NP O
21 358 366 14513889 clinical JJ I-NP O
22 367 374 14513889 picture NN I-NP O
23 374 375 14513889 , , O O
24 376 381 14513889 which WDT B-NP O
25 382 390 14513889 resolved VBD B-VP O
26 391 396 14513889 again RB B-ADVP O
27 397 410 14513889 spontaneously RB B-ADVP O
28 411 417 14513889 within IN B-PP O
29 418 423 14513889 hours NNS B-NP O
30 423 424 14513889 . . O O

1 425 435 14513889 Laboratory NN B-NP O
2 436 447 14513889 evaluations NNS I-NP O
3 447 448 14513889 , , O O
4 449 458 14513889 including VBG B-PP O
5 459 463 14513889 head NN B-NP O
6 464 466 14513889 CT NN I-NP O
7 467 471 14513889 scan NN I-NP O
8 471 472 14513889 , , O O
9 473 477 14513889 were VBD B-VP O
10 478 484 14513889 normal JJ B-ADJP O
11 484 485 14513889 . . O O

1 486 490 14513889 This DT B-NP O
2 491 495 14513889 case NN I-NP O
3 496 507 14513889 illustrates VBZ B-VP O
4 508 511 14513889 the DT B-NP O
5 512 516 14513889 need NN I-NP O
6 517 520 14513889 for IN B-PP O
7 521 526 14513889 close JJ B-NP O
8 527 536 14513889 vigilance NN I-NP O
9 537 539 14513889 in IN B-PP O
10 540 547 14513889 adverse JJ B-NP B-Disease
11 548 552 14513889 drug NN I-NP I-Disease
12 553 562 14513889 reactions NNS I-NP I-Disease
13 562 563 14513889 , , O O
14 564 576 14513889 particularly RB B-ADVP O
15 577 579 14513889 in IN B-PP O
16 580 583 14513889 the DT B-NP O
17 584 591 14513889 elderly JJ I-NP O
18 591 592 14513889 . . O O

1 0 0 18503483 -DOCSTART- -X- -X- O

1 0 8 18503483 Recovery NN B-NP O
2 9 11 18503483 of IN B-PP O
3 12 22 18503483 tacrolimus NN B-NP B-Chemical
4 22 23 18503483 - HYPH O O
5 23 33 18503483 associated VBN B-NP O
6 34 42 18503483 brachial JJ I-NP B-Disease
7 43 51 18503483 neuritis NN I-NP I-Disease
8 52 57 18503483 after IN B-PP O
9 58 68 18503483 conversion NN B-NP O
10 69 71 18503483 to TO B-PP O
11 72 82 18503483 everolimus NN B-NP B-Chemical
12 83 85 18503483 in IN B-PP O
13 86 87 18503483 a DT B-NP O
14 88 97 18503483 pediatric JJ I-NP O
15 98 103 18503483 renal JJ I-NP O
16 104 114 18503483 transplant NN I-NP O
17 115 124 18503483 recipient NN I-NP O
18 124 125 18503483 - HYPH O O
19 125 126 18503483 - HYPH B-NP O
20 126 130 18503483 case NN I-NP O
21 131 137 18503483 report NN I-NP O
22 138 141 18503483 and CC O O
23 142 148 18503483 review NN B-NP O
24 149 151 18503483 of IN B-PP O
25 152 155 18503483 the DT B-NP O
26 156 166 18503483 literature NN I-NP O
27 166 167 18503483 . . I-NP O
28 168 171 18503483 TAC NN I-NP B-Chemical
29 172 175 18503483 has VBZ B-VP O
30 176 180 18503483 been VBN I-VP O
31 181 186 18503483 shown VBN I-VP O
32 187 189 18503483 to TO I-VP O
33 190 192 18503483 be VB I-VP O
34 193 194 18503483 a DT B-NP O
35 195 201 18503483 potent JJ I-NP O
36 202 219 18503483 immunosuppressive JJ I-NP O
37 220 225 18503483 agent NN I-NP O
38 226 229 18503483 for IN B-PP O
39 230 235 18503483 solid JJ B-NP O
40 236 241 18503483 organ NN I-NP O
41 242 257 18503483 transplantation NN I-NP O
42 258 260 18503483 in IN B-PP O
43 261 271 18503483 pediatrics NNS B-NP O
44 271 272 18503483 . . O O

1 273 286 18503483 Neurotoxicity NN B-NP B-Disease
2 287 289 18503483 is VBZ B-VP O
3 290 291 18503483 a DT B-NP O
4 292 303 18503483 potentially RB I-NP O
5 304 311 18503483 serious JJ I-NP O
6 312 317 18503483 toxic JJ I-NP O
7 318 324 18503483 effect NN I-NP O
8 324 325 18503483 . . O O

1 326 328 18503483 It PRP B-NP O
2 329 331 18503483 is VBZ B-VP O
3 332 345 18503483 characterized VBN I-VP O
4 346 348 18503483 by IN B-PP O
5 349 363 18503483 encephalopathy NN B-NP B-Disease
6 363 364 18503483 , , O O
7 365 374 18503483 headaches NNS B-NP B-Disease
8 374 375 18503483 , , O O
9 376 384 18503483 seizures NNS B-NP B-Disease
10 384 385 18503483 , , O O
11 386 388 18503483 or CC O O
12 389 401 18503483 neurological JJ B-NP B-Disease
13 402 410 18503483 deficits NNS I-NP I-Disease
14 410 411 18503483 . . O O

1 412 416 18503483 Here RB B-ADVP O
2 416 417 18503483 , , O O
3 418 420 18503483 we PRP B-NP O
4 421 429 18503483 describe VBP B-VP O
5 430 432 18503483 an DT B-NP O
6 433 438 18503483 eight CD I-NP O
7 438 439 18503483 - HYPH I-NP O
8 439 442 18503483 and CC I-NP O
9 442 443 18503483 - HYPH I-NP O
10 443 444 18503483 a SYM B-NP O
11 444 445 18503483 - HYPH I-NP O
12 445 449 18503483 half JJ I-NP O
13 449 450 18503483 - HYPH I-NP O
14 450 452 18503483 yr NN I-NP O
15 452 453 18503483 - HYPH I-NP O
16 453 456 18503483 old JJ I-NP O
17 457 461 18503483 male JJ I-NP O
18 462 467 18503483 renal JJ I-NP O
19 468 478 18503483 transplant NN I-NP O
20 479 488 18503483 recipient NN I-NP O
21 489 493 18503483 with IN B-PP O
22 494 499 18503483 right JJ B-NP O
23 500 502 18503483 BN NN I-NP O
24 502 503 18503483 . . O O

1 504 507 18503483 MRI NN B-NP O
2 508 520 18503483 demonstrated VBD B-VP O
3 521 533 18503483 hyperintense JJ B-NP O
4 534 536 18503483 T2 NN I-NP O
5 537 544 18503483 signals NNS I-NP O
6 545 547 18503483 in IN B-PP O
7 548 551 18503483 the DT B-NP O
8 552 560 18503483 cervical JJ I-NP O
9 561 565 18503483 cord NN I-NP O
10 566 569 18503483 and CC O O
11 570 575 18503483 right JJ B-NP O
12 576 584 18503483 brachial JJ I-NP O
13 585 591 18503483 plexus NN I-NP O
14 592 597 18503483 roots NNS I-NP O
15 598 608 18503483 indicative JJ B-ADJP O
16 609 611 18503483 of IN B-PP O
17 612 616 18503483 both CC O O
18 617 625 18503483 myelitis NN B-NP B-Disease
19 626 629 18503483 and CC O O
20 630 635 18503483 right JJ B-NP O
21 636 644 18503483 brachial JJ I-NP B-Disease
22 645 653 18503483 plexitis NN I-NP I-Disease
23 653 654 18503483 . . O O

1 655 663 18503483 Symptoms NNS B-NP O
2 664 673 18503483 persisted VBD B-VP O
3 674 677 18503483 for IN B-PP O
4 678 683 18503483 three CD B-NP O
5 684 690 18503483 months NNS I-NP O
6 691 698 18503483 despite IN B-PP O
7 699 702 18503483 TAC NN B-NP B-Chemical
8 703 707 18503483 dose NN I-NP O
9 708 717 18503483 reduction NN I-NP O
10 717 718 18503483 , , O O
11 719 733 18503483 administration NN B-NP O
12 734 736 18503483 of IN B-PP O
13 737 741 18503483 IVIG NN B-NP O
14 742 745 18503483 and CC O O
15 746 750 18503483 four CD B-NP O
16 751 756 18503483 doses NNS I-NP O
17 757 759 18503483 of IN B-PP O
18 760 778 18503483 methylprednisolone NN B-NP B-Chemical
19 779 784 18503483 pulse NN I-NP O
20 785 792 18503483 therapy NN I-NP O
21 792 793 18503483 . . O O

1 794 805 18503483 Improvement NN B-NP O
2 806 809 18503483 and CC O O
3 810 820 18503483 eventually RB B-ADVP O
4 821 825 18503483 full JJ B-NP O
5 826 834 18503483 recovery NN I-NP O
6 835 839 18503483 only RB B-ADVP O
7 840 848 18503483 occurred VBD B-VP O
8 849 854 18503483 after IN B-SBAR O
9 855 858 18503483 TAC NN B-NP B-Chemical
10 859 862 18503483 was VBD B-VP O
11 863 873 18503483 completely RB I-VP O
12 874 886 18503483 discontinued VBN I-VP O
13 887 890 18503483 and CC O O
14 891 903 18503483 successfully RB B-VP O
15 904 912 18503483 replaced VBN I-VP O
16 913 915 18503483 by IN B-PP O
17 916 926 18503483 everolimus NN B-NP B-Chemical
18 926 927 18503483 . . O O

1 0 0 234669 -DOCSTART- -X- -X- O

1 0 7 234669 Effects NNS B-NP O
2 8 10 234669 of IN B-PP O
3 11 24 234669 aminophylline NN B-NP B-Chemical
4 25 27 234669 on IN B-PP O
5 28 31 234669 the DT B-NP O
6 32 41 234669 threshold NN I-NP O
7 42 45 234669 for IN B-PP O
8 46 56 234669 initiating VBG B-VP O
9 57 68 234669 ventricular JJ B-NP B-Disease
10 69 81 234669 fibrillation NN I-NP I-Disease
11 82 88 234669 during IN B-PP O
12 89 100 234669 respiratory JJ B-NP B-Disease
13 101 108 234669 failure NN I-NP I-Disease
14 108 109 234669 . . O O
15 110 117 234669 Cardiac JJ B-NP B-Disease
16 118 129 234669 arrhythmias NNS I-NP I-Disease
17 130 134 234669 have VBP B-VP O
18 135 145 234669 frequently RB I-VP O
19 146 150 234669 been VBN I-VP O
20 151 159 234669 reported VBN I-VP O
21 160 162 234669 in IN B-PP O
22 163 174 234669 association NN B-NP O
23 175 179 234669 with IN B-PP O
24 180 191 234669 respiratory JJ B-NP B-Disease
25 192 199 234669 failure NN I-NP I-Disease
26 199 200 234669 . . O O

1 201 204 234669 The DT B-NP O
2 205 213 234669 possible JJ I-NP O
3 214 222 234669 additive JJ I-NP O
4 223 227 234669 role NN I-NP O
5 228 230 234669 of IN B-PP O
6 231 244 234669 pharmacologic JJ B-NP O
7 245 251 234669 agents NNS I-NP O
8 252 254 234669 in IN B-PP O
9 255 268 234669 precipitating VBG B-VP O
10 269 276 234669 cardiac JJ B-NP B-Disease
11 277 289 234669 disturbances NNS I-NP I-Disease
12 290 292 234669 in IN B-PP O
13 293 301 234669 patients NNS B-NP O
14 302 306 234669 with IN B-PP O
15 307 318 234669 respiratory JJ B-NP B-Disease
16 319 326 234669 failure NN I-NP I-Disease
17 327 330 234669 has VBZ B-VP O
18 331 335 234669 only RB I-VP O
19 336 344 234669 recently RB I-VP O
20 345 349 234669 been VBN I-VP O
21 350 360 234669 emphasized VBN I-VP O
22 360 361 234669 . . O O

1 362 365 234669 The DT B-NP O
2 366 373 234669 effects NNS I-NP O
3 374 376 234669 of IN B-PP O
4 377 390 234669 aminophylline NN B-NP B-Chemical
5 391 393 234669 on IN B-PP O
6 394 397 234669 the DT B-NP O
7 398 409 234669 ventricular JJ I-NP B-Disease
8 410 422 234669 fibrillation NN I-NP I-Disease
9 423 432 234669 threshold NN I-NP O
10 433 439 234669 during IN B-PP O
11 440 446 234669 normal JJ B-NP O
12 447 451 234669 acid NN I-NP O
13 451 452 234669 - HYPH B-NP O
14 452 456 234669 base NN I-NP O
15 457 467 234669 conditions NNS I-NP O
16 468 471 234669 and CC B-PP O
17 472 478 234669 during IN B-PP O
18 479 490 234669 respiratory JJ B-NP B-Disease
19 491 498 234669 failure NN I-NP I-Disease
20 499 503 234669 were VBD B-VP O
21 504 511 234669 studied VBN I-VP O
22 512 514 234669 in IN B-PP O
23 515 527 234669 anesthetized VBN B-NP O
24 528 532 234669 open JJ I-NP O
25 533 538 234669 chest NN I-NP O
26 539 543 234669 dogs NNS I-NP O
27 543 544 234669 . . O O

1 545 548 234669 The DT B-NP O
2 549 560 234669 ventricular JJ I-NP B-Disease
3 561 573 234669 fibrillation NN I-NP I-Disease
4 574 583 234669 threshold NN I-NP O
5 584 587 234669 was VBD B-VP O
6 588 596 234669 measured VBN I-VP O
7 597 599 234669 by IN B-PP O
8 600 607 234669 passing VBG B-VP O
9 608 609 234669 a DT B-NP O
10 610 615 234669 gated VBN I-NP O
11 616 621 234669 train NN I-NP O
12 622 624 234669 of IN B-PP O
13 625 627 234669 12 CD B-NP O
14 628 636 234669 constant JJ I-NP O
15 637 644 234669 current JJ I-NP O
16 645 651 234669 pulses NNS I-NP O
17 652 659 234669 through IN B-PP O
18 660 663 234669 the DT B-NP O
19 664 675 234669 ventricular JJ I-NP O
20 676 686 234669 myocardium NN I-NP O
21 687 693 234669 during IN B-PP O
22 694 697 234669 the DT B-NP O
23 698 708 234669 vulnerable JJ I-NP O
24 709 715 234669 period NN I-NP O
25 716 718 234669 of IN B-PP O
26 719 722 234669 the DT B-NP O
27 723 730 234669 cardiac JJ I-NP O
28 731 736 234669 cycle NN I-NP O
29 736 737 234669 . . O O

1 738 744 234669 During IN B-PP O
2 745 748 234669 the DT B-NP O
3 749 757 234669 infusion NN I-NP O
4 758 760 234669 of IN B-PP O
5 761 774 234669 aminophylline NN B-NP B-Chemical
6 774 775 234669 , , O O
7 776 779 234669 the DT B-NP O
8 780 791 234669 ventricular JJ I-NP B-Disease
9 792 804 234669 fibrillation NN I-NP I-Disease
10 805 814 234669 threshold NN I-NP O
11 815 818 234669 was VBD B-VP O
12 819 826 234669 reduced VBN I-VP O
13 827 829 234669 by IN B-PP O
14 830 832 234669 30 CD B-NP O
15 833 835 234669 to TO I-NP O
16 836 838 234669 40 CD I-NP O
17 839 846 234669 percent NN I-NP O
18 847 849 234669 of IN B-PP O
19 850 853 234669 the DT B-NP O
20 854 861 234669 control NN I-NP O
21 862 866 234669 when WRB B-ADVP O
22 867 869 234669 pH NN B-NP O
23 870 873 234669 and CC I-NP O
24 874 881 234669 partial JJ I-NP O
25 882 891 234669 pressures NNS I-NP O
26 892 894 234669 of IN B-PP O
27 895 901 234669 oxygen NN B-NP B-Chemical
28 902 903 234669 ( ( O O
29 903 906 234669 PO2 NN B-NP B-Chemical
30 906 907 234669 ) ) O O
31 908 911 234669 and CC O O
32 912 918 234669 carbon NN B-NP B-Chemical
33 919 926 234669 dioxide NN I-NP I-Chemical
34 927 928 234669 ( ( O O
35 928 931 234669 CO2 NN B-NP B-Chemical
36 931 932 234669 ) ) O O
37 933 937 234669 were VBD B-VP O
38 938 942 234669 kept VBN I-VP O
39 943 949 234669 within IN B-PP O
40 950 956 234669 normal JJ B-NP O
41 957 963 234669 limits NNS I-NP O
42 963 964 234669 . . O O

1 965 969 234669 When WRB B-ADVP O
2 970 981 234669 respiratory JJ B-NP B-Disease
3 982 989 234669 failure NN I-NP I-Disease
4 990 993 234669 was VBD B-VP O
5 994 1002 234669 produced VBN I-VP O
6 1003 1005 234669 by IN B-PP O
7 1006 1021 234669 hypoventilation NN B-NP B-Disease
8 1022 1023 234669 ( ( O O
9 1023 1025 234669 pH NN B-NP O
10 1026 1030 234669 7.05 CD I-NP O
11 1031 1033 234669 to TO B-PP O
12 1034 1038 234669 7.25 CD B-NP O
13 1038 1039 234669 ; : O O
14 1040 1044 234669 PC02 NN B-NP O
15 1045 1047 234669 70 CD B-NP O
16 1048 1050 234669 to TO I-NP O
17 1051 1054 234669 100 CD I-NP O
18 1055 1057 234669 mm NN I-NP O
19 1058 1060 234669 Hg NN I-NP O
20 1060 1061 234669 : : O O
21 1062 1065 234669 P02 NN B-NP O
22 1066 1068 234669 20 CD B-NP O
23 1069 1071 234669 to TO I-NP O
24 1072 1074 234669 40 CD I-NP O
25 1075 1077 234669 mm NN I-NP O
26 1078 1080 234669 Hg NN I-NP O
27 1080 1081 234669 ) ) O O
28 1081 1082 234669 , , O O
29 1083 1091 234669 infusion NN B-NP O
30 1092 1094 234669 of IN B-PP O
31 1095 1108 234669 aminophylline NN B-NP B-Chemical
32 1109 1117 234669 resulted VBD B-VP O
33 1118 1120 234669 in IN B-PP O
34 1121 1123 234669 an DT B-NP O
35 1124 1128 234669 even RB I-NP O
36 1129 1136 234669 greater JJR I-NP O
37 1137 1145 234669 decrease NN I-NP O
38 1146 1148 234669 in IN B-PP O
39 1149 1160 234669 ventricular JJ B-NP B-Disease
40 1161 1173 234669 fibrillation NN I-NP I-Disease
41 1174 1183 234669 threshold NN I-NP O
42 1184 1186 234669 to TO B-PP O
43 1187 1189 234669 60 CD B-NP O
44 1190 1197 234669 percent NN I-NP O
45 1198 1200 234669 of IN B-PP O
46 1201 1204 234669 the DT B-NP O
47 1205 1212 234669 control NN I-NP O
48 1213 1218 234669 level NN I-NP O
49 1218 1219 234669 . . O O

1 1220 1225 234669 These DT B-NP O
2 1226 1237 234669 experiments NNS I-NP O
3 1238 1245 234669 suggest VBP B-VP O
4 1246 1250 234669 that IN B-SBAR O
5 1251 1259 234669 although IN B-SBAR O
6 1260 1264 234669 many JJ B-NP O
7 1265 1272 234669 factors NNS I-NP O
8 1273 1276 234669 may MD B-VP O
9 1277 1287 234669 contribute VB I-VP O
10 1288 1290 234669 to TO B-PP O
11 1291 1294 234669 the DT B-NP O
12 1295 1304 234669 increased VBN I-NP O
13 1305 1314 234669 incidence NN I-NP O
14 1315 1317 234669 of IN B-PP O
15 1318 1329 234669 ventricular JJ B-NP B-Disease
16 1330 1341 234669 arrhythmias NNS I-NP I-Disease
17 1342 1344 234669 in IN B-PP O
18 1345 1356 234669 respiratory JJ B-NP B-Disease
19 1357 1364 234669 failure NN I-NP I-Disease
20 1364 1365 234669 , , O O
21 1366 1379 234669 pharmacologic JJ B-NP O
22 1380 1386 234669 agents NNS I-NP O
23 1386 1387 234669 , , O O
24 1388 1400 234669 particularly RB B-ADVP O
25 1401 1414 234669 aminophylline NN B-NP B-Chemical
26 1414 1415 234669 , , O O
27 1416 1419 234669 may MD B-VP O
28 1420 1424 234669 play VB I-VP O
29 1425 1426 234669 a DT B-NP O
30 1427 1438 234669 significant JJ I-NP O
31 1439 1443 234669 role NN I-NP O
32 1443 1444 234669 . . O O

1 0 0 17639754 -DOCSTART- -X- -X- O

1 0 11 17639754 Interaction NN B-NP O
2 12 19 17639754 between IN B-PP O
3 20 28 17639754 warfarin NN B-NP B-Chemical
4 29 32 17639754 and CC I-NP O
5 33 45 17639754 levofloxacin NN I-NP B-Chemical
6 45 46 17639754 : : O O
7 47 51 17639754 case NN B-NP O
8 52 58 17639754 series NN I-NP O
9 58 59 17639754 . . O O
10 60 68 17639754 Warfarin NNP B-NP B-Chemical
11 69 71 17639754 is VBZ B-VP O
12 72 75 17639754 the DT B-NP O
13 76 80 17639754 most RBS I-NP O
14 81 87 17639754 widely RB I-NP O
15 88 92 17639754 used VBN I-NP O
16 93 97 17639754 oral JJ I-NP O
17 98 111 17639754 anticoagulant NN I-NP O
18 112 115 17639754 and CC O O
19 116 118 17639754 is VBZ B-VP O
20 119 128 17639754 indicated VBN I-VP O
21 129 132 17639754 for IN B-PP O
22 133 137 17639754 many JJ B-NP O
23 138 146 17639754 clinical JJ I-NP O
24 147 157 17639754 conditions NNS I-NP O
25 157 158 17639754 . . O O

1 159 171 17639754 Levofloxacin NN B-NP B-Chemical
2 171 172 17639754 , , O O
3 173 174 17639754 a DT B-NP O
4 175 190 17639754 fluoroquinolone NN I-NP B-Chemical
5 190 191 17639754 , , O O
6 192 194 17639754 is VBZ B-VP O
7 195 198 17639754 one CD B-NP O
8 199 201 17639754 of IN B-PP O
9 202 205 17639754 the DT B-NP O
10 206 210 17639754 most RBS I-NP O
11 211 219 17639754 commonly RB I-NP O
12 220 230 17639754 prescribed VBN I-NP O
13 231 242 17639754 antibiotics NNS I-NP O
14 243 245 17639754 in IN B-PP O
15 246 254 17639754 clinical JJ B-NP O
16 255 263 17639754 practice NN I-NP O
17 264 267 17639754 and CC O O
18 268 270 17639754 is VBZ B-VP O
19 271 280 17639754 effective JJ B-ADJP O
20 281 288 17639754 against IN B-PP O
21 289 293 17639754 Gram NN B-NP O
22 293 294 17639754 - HYPH B-NP O
23 294 302 17639754 positive JJ I-NP O
24 302 303 17639754 , , I-NP O
25 304 308 17639754 Gram NN I-NP O
26 308 309 17639754 - HYPH I-NP O
27 309 317 17639754 negative JJ B-ADJP O
28 317 318 17639754 , , O O
29 319 322 17639754 and CC O O
30 323 331 17639754 atypical JJ B-NP O
31 332 340 17639754 bacteria NNS I-NP O
32 340 341 17639754 . . O O

1 342 347 17639754 While IN B-SBAR O
2 348 353 17639754 small JJ B-NP O
3 354 365 17639754 prospective JJ I-NP O
4 366 373 17639754 studies NNS I-NP O
5 374 378 17639754 have VBP B-VP O
6 379 382 17639754 not RB I-VP O
7 383 391 17639754 revealed VBN I-VP O
8 392 395 17639754 any DT B-NP O
9 396 407 17639754 significant JJ I-NP O
10 408 412 17639754 drug NN I-NP O
11 412 413 17639754 - HYPH B-NP O
12 413 417 17639754 drug NN I-NP O
13 418 429 17639754 interaction NN I-NP O
14 430 437 17639754 between IN B-PP O
15 438 446 17639754 warfarin NN B-NP B-Chemical
16 447 450 17639754 and CC I-NP O
17 451 463 17639754 levofloxacin NN I-NP B-Chemical
18 463 464 17639754 , , O O
19 465 472 17639754 several JJ B-NP O
20 473 477 17639754 case NN I-NP O
21 478 485 17639754 reports NNS I-NP O
22 486 490 17639754 have VBP B-VP O
23 491 500 17639754 indicated VBN I-VP O
24 501 505 17639754 that IN B-SBAR O
25 506 518 17639754 levofloxacin NN B-NP B-Chemical
26 519 522 17639754 may MD B-VP O
27 523 536 17639754 significantly RB I-VP O
28 537 547 17639754 potentiate VB I-VP O
29 548 551 17639754 the DT B-NP O
30 552 567 17639754 anticoagulation NN I-NP O
31 568 574 17639754 effect NN I-NP O
32 575 577 17639754 of IN B-PP O
33 578 586 17639754 warfarin NN B-NP B-Chemical
34 586 587 17639754 . . O O

1 588 590 17639754 We PRP B-NP O
2 591 597 17639754 report VBP B-VP O
3 598 599 17639754 3 CD B-NP O
4 600 605 17639754 cases NNS I-NP O
5 606 608 17639754 of IN B-PP O
6 609 616 17639754 serious JJ B-NP O
7 617 625 17639754 bleeding VBG I-NP B-Disease
8 626 639 17639754 complications NNS I-NP O
9 640 644 17639754 that WDT B-NP O
10 645 651 17639754 appear VBP B-VP O
11 652 654 17639754 to TO I-VP O
12 655 657 17639754 be VB I-VP O
13 658 661 17639754 the DT B-NP O
14 662 668 17639754 result NN I-NP O
15 669 671 17639754 of IN B-PP O
16 672 675 17639754 the DT B-NP O
17 676 687 17639754 interaction NN I-NP O
18 688 695 17639754 between IN B-PP O
19 696 704 17639754 warfarin NN B-NP B-Chemical
20 705 708 17639754 and CC I-NP O
21 709 721 17639754 levofloxacin NN I-NP B-Chemical
22 721 722 17639754 . . O O

1 723 733 17639754 Physicians NNS B-NP O
2 734 740 17639754 should MD B-VP O
3 741 743 17639754 be VB I-VP O
4 744 749 17639754 aware JJ B-ADJP O
5 750 752 17639754 of IN B-PP O
6 753 757 17639754 this DT B-NP O
7 758 767 17639754 potential JJ I-NP O
8 768 779 17639754 interaction NN I-NP O
9 780 783 17639754 and CC I-NP O
10 784 787 17639754 use NN I-NP O
11 788 795 17639754 caution NN I-NP O
12 796 800 17639754 when WRB B-ADVP O
13 801 812 17639754 prescribing VBG B-VP O
14 813 825 17639754 levofloxacin NN B-NP B-Chemical
15 826 828 17639754 to TO B-PP O
16 829 837 17639754 patients NNS B-NP O
17 838 844 17639754 taking VBG B-VP O
18 845 853 17639754 warfarin NN B-NP B-Chemical
19 853 854 17639754 . . O O

1 0 0 11807648 -DOCSTART- -X- -X- O

1 0 9 11807648 Epileptic JJ B-NP B-Disease
2 10 18 11807648 seizures NNS I-NP I-Disease
3 19 28 11807648 following VBG B-PP O
4 29 37 11807648 cortical JJ B-NP O
5 38 49 11807648 application NN I-NP O
6 50 52 11807648 of IN B-PP O
7 53 59 11807648 fibrin NN B-NP O
8 60 68 11807648 sealants NNS I-NP O
9 69 79 11807648 containing VBG B-VP O
10 80 90 11807648 tranexamic JJ B-NP B-Chemical
11 91 95 11807648 acid NN I-NP I-Chemical
12 96 98 11807648 in IN B-PP O
13 99 103 11807648 rats NNS B-NP O
14 103 104 11807648 . . O O
15 105 115 11807648 BACKGROUND NN B-NP O
16 115 116 11807648 : : O O
17 117 123 11807648 Fibrin NN B-NP O
18 124 132 11807648 sealants NNS I-NP O
19 133 134 11807648 ( ( O O
20 134 136 11807648 FS NNS B-NP O
21 136 137 11807648 ) ) O O
22 138 145 11807648 derived VBN B-VP O
23 146 150 11807648 from IN B-PP O
24 151 156 11807648 human JJ B-NP O
25 157 163 11807648 plasma NN I-NP O
26 164 167 11807648 are VBP B-VP O
27 168 178 11807648 frequently RB I-VP O
28 179 183 11807648 used VBN I-VP O
29 184 186 11807648 in IN B-PP O
30 187 199 11807648 neurosurgery NN B-NP O
31 199 200 11807648 . . O O

1 201 203 11807648 In IN B-SBAR O
2 204 209 11807648 order NN O O
3 210 212 11807648 to TO B-VP O
4 213 221 11807648 increase VB I-VP O
5 222 226 11807648 clot NN B-NP O
6 227 236 11807648 stability NN I-NP O
7 236 237 11807648 , , O O
8 238 240 11807648 FS NN B-NP O
9 241 250 11807648 typically RB B-ADVP O
10 251 258 11807648 contain VBP B-VP O
11 259 268 11807648 aprotinin NN B-NP O
12 268 269 11807648 , , O O
13 270 271 11807648 a DT B-NP O
14 272 279 11807648 natural JJ I-NP O
15 280 292 11807648 fibrinolysis NN I-NP O
16 293 302 11807648 inhibitor NN I-NP O
17 302 303 11807648 . . O O

1 304 312 11807648 Recently RB B-ADVP O
2 312 313 11807648 , , O O
3 314 323 11807648 synthetic JJ B-NP O
4 324 336 11807648 fibrinolysis NN I-NP O
5 337 347 11807648 inhibitors NNS I-NP O
6 348 352 11807648 such JJ B-PP O
7 353 355 11807648 as IN I-PP O
8 356 366 11807648 tranexamic JJ B-NP B-Chemical
9 367 371 11807648 acid NN I-NP I-Chemical
10 372 373 11807648 ( ( O O
11 373 378 11807648 tAMCA NN B-NP B-Chemical
12 378 379 11807648 ) ) O O
13 380 384 11807648 have VBP B-VP O
14 385 389 11807648 been VBN I-VP O
15 390 400 11807648 considered VBN I-VP O
16 401 403 11807648 as IN B-PP O
17 404 415 11807648 substitutes NNS B-NP O
18 416 419 11807648 for IN B-PP O
19 420 429 11807648 aprotinin NN B-NP O
20 429 430 11807648 . . O O

1 431 438 11807648 However RB B-ADVP O
2 438 439 11807648 , , O O
3 440 445 11807648 tAMCA NN B-NP B-Chemical
4 446 449 11807648 has VBZ B-VP O
5 450 454 11807648 been VBN I-VP O
6 455 460 11807648 shown VBN I-VP O
7 461 463 11807648 to TO I-VP O
8 464 469 11807648 cause VB I-VP O
9 470 479 11807648 epileptic JJ B-NP B-Disease
10 480 488 11807648 seizures NNS I-NP I-Disease
11 488 489 11807648 . . O O

1 490 492 11807648 We PRP B-NP O
2 493 499 11807648 wanted VBD B-VP O
3 500 502 11807648 to TO I-VP O
4 503 508 11807648 study VB I-VP O
5 509 516 11807648 whether IN B-SBAR O
6 517 522 11807648 tAMCA NN B-NP B-Chemical
7 523 530 11807648 retains VBZ B-VP O
8 531 534 11807648 its PRP$ B-NP O
9 535 545 11807648 convulsive JJ I-NP B-Disease
10 546 552 11807648 action NN I-NP O
11 553 555 11807648 if IN B-SBAR O
12 556 568 11807648 incorporated VBN B-VP O
13 569 573 11807648 into IN B-PP O
14 574 575 11807648 a DT B-NP O
15 576 578 11807648 FS NN I-NP O
16 578 579 11807648 . . O O

1 580 586 11807648 METHOD NN B-NP O
2 586 587 11807648 : : O O
3 588 590 11807648 FS NN B-NP O
4 591 601 11807648 containing VBG B-VP O
5 602 611 11807648 aprotinin NN B-NP O
6 612 614 11807648 or CC O O
7 615 624 11807648 different JJ B-NP O
8 625 639 11807648 concentrations NNS I-NP O
9 640 642 11807648 of IN B-PP O
10 643 648 11807648 tAMCA NN B-NP B-Chemical
11 649 650 11807648 ( ( O O
12 650 653 11807648 0.5 CD B-NP O
13 653 654 11807648 - HYPH I-NP O
14 654 658 11807648 47.5 CD I-NP O
15 659 661 11807648 mg NN I-NP O
16 661 662 11807648 / SYM B-NP O
17 662 664 11807648 ml NN I-NP O
18 664 665 11807648 ) ) O O
19 666 670 11807648 were VBD B-VP O
20 671 678 11807648 applied VBN I-VP O
21 679 681 11807648 to TO B-PP O
22 682 685 11807648 the DT B-NP O
23 686 690 11807648 pial JJ I-NP O
24 691 698 11807648 surface NN I-NP O
25 699 701 11807648 of IN B-PP O
26 702 705 11807648 the DT B-NP O
27 706 712 11807648 cortex NN I-NP O
28 713 715 11807648 of IN B-PP O
29 716 729 11807648 anaesthetized VBN B-NP O
30 730 734 11807648 rats NNS I-NP O
31 734 735 11807648 . . O O

1 736 739 11807648 The DT B-NP O
2 740 748 11807648 response NN I-NP O
3 749 751 11807648 of IN B-PP O
4 752 755 11807648 the DT B-NP O
5 756 763 11807648 animals NNS I-NP O
6 764 767 11807648 was VBD B-VP O
7 768 777 11807648 evaluated VBN I-VP O
8 778 783 11807648 using VBG B-VP O
9 784 806 11807648 electroencephalography NN B-NP O
10 807 810 11807648 and CC B-PP O
11 811 813 11807648 by IN B-PP O
12 814 824 11807648 monitoring VBG B-VP O
13 825 828 11807648 the DT B-NP O
14 829 837 11807648 clinical JJ I-NP O
15 838 847 11807648 behaviour NN I-NP O
16 848 854 11807648 during IN B-PP O
17 855 858 11807648 and CC I-PP O
18 859 864 11807648 after IN I-PP O
19 865 873 11807648 recovery NN B-NP O
20 874 878 11807648 from IN B-PP O
21 879 890 11807648 anaesthesia NN B-NP O
22 890 891 11807648 . . O O

1 892 900 11807648 FINDINGS NNS B-NP O
2 900 901 11807648 : : O O
3 902 904 11807648 FS NN B-NP O
4 905 915 11807648 containing VBG B-VP O
5 916 921 11807648 tAMCA NN B-NP B-Chemical
6 922 928 11807648 caused VBD B-VP O
7 929 939 11807648 paroxysmal JJ B-NP O
8 940 945 11807648 brain NN I-NP O
9 946 954 11807648 activity NN I-NP O
10 955 960 11807648 which WDT B-NP O
11 961 964 11807648 was VBD B-VP O
12 965 975 11807648 associated VBN I-VP O
13 976 980 11807648 with IN B-PP O
14 981 989 11807648 distinct JJ B-NP O
15 990 1000 11807648 convulsive JJ I-NP B-Disease
16 1001 1011 11807648 behaviours NNS I-NP O
17 1011 1012 11807648 . . O O

1 1013 1016 11807648 The DT B-NP O
2 1017 1023 11807648 degree NN I-NP O
3 1024 1026 11807648 of IN B-PP O
4 1027 1032 11807648 these DT B-NP O
5 1033 1041 11807648 seizures NNS I-NP B-Disease
6 1042 1051 11807648 increased VBD B-VP O
7 1052 1056 11807648 with IN B-PP O
8 1057 1067 11807648 increasing VBG B-NP O
9 1068 1081 11807648 concentration NN I-NP O
10 1082 1084 11807648 of IN B-PP O
11 1085 1090 11807648 tAMCA NN B-NP B-Chemical
12 1090 1091 11807648 . . O O

1 1092 1096 11807648 Thus RB B-ADVP O
2 1096 1097 11807648 , , O O
3 1098 1100 11807648 FS NN B-NP O
4 1101 1111 11807648 containing VBG B-VP O
5 1112 1116 11807648 47.5 CD B-NP O
6 1117 1119 11807648 mg NN I-NP O
7 1119 1120 11807648 / SYM B-NP O
8 1120 1122 11807648 ml NN I-NP O
9 1123 1128 11807648 tAMCA NN I-NP B-Chemical
10 1129 1135 11807648 evoked VBD B-VP O
11 1136 1147 11807648 generalized VBN B-NP B-Disease
12 1148 1156 11807648 seizures NNS I-NP I-Disease
13 1157 1159 11807648 in IN B-PP O
14 1160 1163 11807648 all DT B-NP O
15 1164 1170 11807648 tested VBN I-NP O
16 1171 1175 11807648 rats NNS I-NP O
17 1176 1177 11807648 ( ( O O
18 1177 1178 11807648 n NN B-NP O
19 1178 1179 11807648 = SYM B-VP O
20 1179 1180 11807648 6 CD B-NP O
21 1180 1181 11807648 ) ) O O
22 1182 1187 11807648 while IN B-SBAR O
23 1188 1191 11807648 the DT B-NP O
24 1192 1198 11807648 lowest JJS I-NP O
25 1199 1212 11807648 concentration NN I-NP O
26 1213 1215 11807648 of IN B-PP O
27 1216 1221 11807648 tAMCA NN B-NP B-Chemical
28 1222 1223 11807648 ( ( O O
29 1223 1226 11807648 0.5 CD B-NP O
30 1227 1229 11807648 mg NN I-NP O
31 1229 1230 11807648 / SYM B-NP O
32 1230 1232 11807648 ml NN I-NP O
33 1232 1233 11807648 ) ) O O
34 1234 1238 11807648 only RB B-ADVP O
35 1239 1245 11807648 evoked VBD B-VP O
36 1246 1251 11807648 brief JJ B-NP O
37 1252 1260 11807648 episodes NNS I-NP O
38 1261 1263 11807648 of IN B-PP O
39 1264 1268 11807648 jerk NN B-NP O
40 1268 1269 11807648 - HYPH O O
41 1269 1279 11807648 correlated VBN B-NP O
42 1280 1290 11807648 convulsive JJ I-NP B-Disease
43 1291 1301 11807648 potentials NNS I-NP O
44 1302 1304 11807648 in IN B-PP O
45 1305 1306 11807648 1 CD B-NP O
46 1307 1309 11807648 of IN B-PP O
47 1310 1311 11807648 6 CD B-NP O
48 1312 1316 11807648 rats NNS I-NP O
49 1316 1317 11807648 . . O O

1 1318 1320 11807648 In IN B-PP O
2 1321 1329 11807648 contrast NN B-NP O
3 1329 1330 11807648 , , O O
4 1331 1333 11807648 FS NN B-NP O
5 1334 1344 11807648 containing VBG B-VP O
6 1345 1354 11807648 aprotinin NN B-NP O
7 1355 1358 11807648 did VBD B-VP O
8 1359 1362 11807648 not RB I-VP O
9 1363 1368 11807648 evoke VB I-VP O
10 1369 1372 11807648 any DT B-NP O
11 1373 1383 11807648 paroxysmal JJ I-NP O
12 1384 1392 11807648 activity NN I-NP O
13 1392 1393 11807648 . . O O

1 1394 1408 11807648 INTERPRETATION NN B-NP O
2 1408 1409 11807648 : : O O
3 1410 1420 11807648 Tranexamic JJ B-NP B-Chemical
4 1421 1425 11807648 acid NN I-NP I-Chemical
5 1426 1433 11807648 retains VBZ B-VP O
6 1434 1437 11807648 its PRP$ B-NP O
7 1438 1448 11807648 convulsive JJ I-NP B-Disease
8 1449 1455 11807648 action NN I-NP O
9 1456 1462 11807648 within IN B-PP O
10 1463 1465 11807648 FS NN B-NP O
11 1465 1466 11807648 . . O O

1 1467 1471 11807648 Thus RB B-ADVP O
2 1471 1472 11807648 , , O O
3 1473 1476 11807648 use NN B-NP O
4 1477 1479 11807648 of IN B-PP O
5 1480 1482 11807648 FS NN B-NP O
6 1483 1493 11807648 containing VBG B-VP O
7 1494 1499 11807648 tAMCA NN B-NP B-Chemical
8 1500 1503 11807648 for IN B-PP O
9 1504 1511 11807648 surgery NN B-NP O
10 1512 1518 11807648 within IN B-PP O
11 1519 1521 11807648 or CC O O
12 1522 1527 11807648 close RB B-ADVP O
13 1528 1530 11807648 to TO B-PP O
14 1531 1534 11807648 the DT B-NP O
15 1535 1538 11807648 CNS NN I-NP O
16 1539 1542 11807648 may MD B-VP O
17 1543 1547 11807648 pose VB I-VP O
18 1548 1549 11807648 a DT B-NP O
19 1550 1561 11807648 substantial JJ I-NP O
20 1562 1566 11807648 risk NN I-NP O
21 1567 1569 11807648 to TO B-PP O
22 1570 1573 11807648 the DT B-NP O
23 1574 1581 11807648 patient NN I-NP O
24 1581 1582 11807648 . . O O

1 0 0 8421099 -DOCSTART- -X- -X- O

1 0 11 8421099 Prospective JJ B-NP O
2 12 17 8421099 study NN I-NP O
3 18 20 8421099 of IN B-PP O
4 21 24 8421099 the DT B-NP O
5 25 29 8421099 long JJ I-NP O
6 29 30 8421099 - HYPH I-NP O
7 30 34 8421099 term NN I-NP O
8 35 42 8421099 effects NNS I-NP O
9 43 45 8421099 of IN B-PP O
10 46 58 8421099 somatostatin NN B-NP O
11 59 65 8421099 analog NN I-NP O
12 66 67 8421099 ( ( O O
13 67 77 8421099 octreotide NN B-NP B-Chemical
14 77 78 8421099 ) ) O O
15 79 81 8421099 on IN B-PP O
16 82 93 8421099 gallbladder NN B-NP O
17 94 102 8421099 function NN I-NP O
18 103 106 8421099 and CC O O
19 107 116 8421099 gallstone NN B-NP B-Disease
20 117 126 8421099 formation NN I-NP O
21 127 129 8421099 in IN B-PP O
22 130 137 8421099 Chinese JJ B-NP O
23 138 149 8421099 acromegalic JJ I-NP B-Disease
24 150 158 8421099 patients NNS I-NP O
25 158 159 8421099 . . O O
26 160 164 8421099 This DT B-NP O
27 165 172 8421099 article NN I-NP O
28 173 180 8421099 reports VBZ B-VP O
29 181 184 8421099 the DT B-NP O
30 185 192 8421099 changes NNS I-NP O
31 193 195 8421099 in IN B-PP O
32 196 207 8421099 gallbladder NN B-NP O
33 208 216 8421099 function NN I-NP O
34 217 225 8421099 examined VBN B-VP O
35 226 228 8421099 by IN B-PP O
36 229 244 8421099 ultrasonography NN B-NP O
37 245 247 8421099 in IN B-PP O
38 248 250 8421099 20 CD B-NP O
39 251 258 8421099 Chinese JJ I-NP O
40 259 267 8421099 patients NNS I-NP O
41 268 272 8421099 with IN B-PP O
42 273 279 8421099 active JJ B-NP O
43 280 290 8421099 acromegaly RB B-VP B-Disease
44 291 298 8421099 treated VBN I-VP O
45 299 303 8421099 with IN B-PP O
46 304 306 8421099 sc NN B-NP O
47 307 316 8421099 injection NN I-NP O
48 317 319 8421099 of IN B-PP O
49 320 323 8421099 the DT B-NP O
50 324 336 8421099 somatostatin NN I-NP O
51 337 343 8421099 analog NN I-NP O
52 344 354 8421099 octreotide NN I-NP B-Chemical
53 355 357 8421099 in IN B-PP O
54 358 365 8421099 dosages NNS B-NP O
55 366 368 8421099 of IN B-PP O
56 369 372 8421099 300 CD B-NP O
57 372 373 8421099 - HYPH I-NP O
58 373 377 8421099 1500 CD I-NP O
59 378 388 8421099 micrograms NNS I-NP O
60 388 389 8421099 / SYM B-NP O
61 389 392 8421099 day NN I-NP O
62 393 396 8421099 for IN B-PP O
63 397 398 8421099 a DT B-NP O
64 399 403 8421099 mean NN I-NP O
65 404 406 8421099 of IN B-PP O
66 407 411 8421099 24.2 CD B-NP O
67 412 413 8421099 + SYM O O
68 413 414 8421099 / SYM O O
69 414 415 8421099 - SYM B-NP O
70 416 420 8421099 13.9 CD B-NP O
71 421 427 8421099 months NNS I-NP O
72 427 428 8421099 . . O O

1 429 435 8421099 During IN B-PP O
2 436 445 8421099 treatment NN B-NP O
3 446 450 8421099 with IN B-PP O
4 451 461 8421099 octreotide NN B-NP B-Chemical
5 461 462 8421099 , , O O
6 463 465 8421099 17 CD B-NP O
7 466 474 8421099 patients NNS I-NP O
8 475 484 8421099 developed VBD B-VP O
9 485 491 8421099 sludge NN B-NP O
10 491 492 8421099 , , O O
11 493 495 8421099 10 CD B-NP O
12 496 499 8421099 had VBD B-VP O
13 500 510 8421099 gallstones NNS B-NP B-Disease
14 510 511 8421099 , , O O
15 512 515 8421099 and CC O O
16 516 517 8421099 1 CD B-NP O
17 518 527 8421099 developed VBD B-VP O
18 528 533 8421099 acute JJ B-NP B-Disease
19 534 547 8421099 cholecystitis NN I-NP I-Disease
20 548 557 8421099 requiring VBG B-VP O
21 558 565 8421099 surgery NN B-NP O
22 565 566 8421099 . . O O

1 567 569 8421099 In IN B-PP O
2 570 573 8421099 all DT B-NP O
3 574 576 8421099 of IN B-PP O
4 577 578 8421099 7 CD B-NP O
5 579 587 8421099 patients NNS I-NP O
6 588 596 8421099 examined VBN B-VP O
7 597 604 8421099 acutely RB B-ADVP O
8 604 605 8421099 , , O O
9 606 617 8421099 gallbladder NN B-NP O
10 618 631 8421099 contractility NN I-NP O
11 632 635 8421099 was VBD B-VP O
12 636 645 8421099 inhibited VBN I-VP O
13 646 651 8421099 after IN B-PP O
14 652 653 8421099 a DT B-NP O
15 654 660 8421099 single JJ I-NP O
16 661 664 8421099 100 CD I-NP O
17 664 665 8421099 - HYPH I-NP O
18 665 675 8421099 micrograms NNS I-NP O
19 676 685 8421099 injection NN I-NP O
20 685 686 8421099 . . O O

1 687 689 8421099 In IN B-PP O
2 690 691 8421099 8 CD B-NP O
3 692 700 8421099 patients NNS I-NP O
4 701 709 8421099 followed VBN B-VP O
5 710 713 8421099 for IN B-PP O
6 714 716 8421099 24 CD B-NP O
7 717 722 8421099 weeks NNS I-NP O
8 722 723 8421099 , , O O
9 724 735 8421099 gallbladder NN B-NP O
10 736 749 8421099 contractility NN I-NP O
11 750 758 8421099 remained VBD B-VP O
12 759 768 8421099 depressed JJ B-ADJP B-Disease
13 769 779 8421099 throughout IN B-PP O
14 780 787 8421099 therapy NN B-NP O
15 787 788 8421099 . . O O

1 789 794 8421099 After IN B-PP O
2 795 805 8421099 withdrawal NN B-NP O
3 806 808 8421099 of IN B-PP O
4 809 819 8421099 octreotide NN B-NP B-Chemical
5 820 822 8421099 in IN B-PP O
6 823 825 8421099 10 CD B-NP O
7 826 834 8421099 patients NNS I-NP O
8 835 842 8421099 without IN B-PP O
9 843 853 8421099 gallstones NNS B-NP B-Disease
10 853 854 8421099 , , O O
11 855 856 8421099 8 CD B-NP O
12 857 865 8421099 patients NNS I-NP O
13 866 874 8421099 assessed VBN B-VP O
14 875 878 8421099 had VBD B-VP O
15 879 885 8421099 return NN B-NP O
16 886 888 8421099 of IN B-PP O
17 889 895 8421099 normal JJ B-NP O
18 896 907 8421099 gallbladder NN I-NP O
19 908 921 8421099 contractility NN I-NP O
20 922 928 8421099 within IN B-PP O
21 929 930 8421099 1 CD B-NP O
22 931 936 8421099 month NN I-NP O
23 936 937 8421099 . . O O

1 938 940 8421099 In IN B-PP O
2 941 942 8421099 8 CD B-NP O
3 943 945 8421099 of IN B-PP O
4 946 949 8421099 the DT B-NP O
5 950 959 8421099 remaining VBG I-NP O
6 960 962 8421099 10 CD I-NP O
7 963 971 8421099 patients NNS I-NP O
8 972 975 8421099 who WP B-NP O
9 976 985 8421099 developed VBD B-VP O
10 986 996 8421099 gallstones NNS B-NP B-Disease
11 997 1003 8421099 during IN B-PP O
12 1004 1013 8421099 treatment NN B-NP O
13 1013 1014 8421099 , , O O
14 1015 1026 8421099 gallbladder NN B-NP O
15 1027 1040 8421099 contractility NN I-NP O
16 1041 1051 8421099 normalized VBD B-VP O
17 1052 1054 8421099 in IN B-PP O
18 1055 1056 8421099 5 CD B-NP O
19 1057 1065 8421099 patients NNS I-NP O
20 1066 1067 8421099 ( ( O O
21 1067 1068 8421099 3 CD B-NP O
22 1069 1071 8421099 of IN B-PP O
23 1072 1076 8421099 whom WP B-NP O
24 1077 1080 8421099 has VBZ B-VP O
25 1081 1094 8421099 disappearance NN B-NP O
26 1095 1097 8421099 of IN B-PP O
27 1098 1103 8421099 their PRP$ B-NP O
28 1104 1110 8421099 stones NNS I-NP O
29 1111 1117 8421099 within IN B-PP O
30 1118 1119 8421099 3 CD B-NP O
31 1120 1125 8421099 weeks NNS I-NP O
32 1125 1126 8421099 ) ) O O
33 1126 1127 8421099 , , O O
34 1128 1131 8421099 and CC O O
35 1132 1140 8421099 remained VBD B-VP O
36 1141 1150 8421099 depressed VBN I-VP B-Disease
37 1151 1153 8421099 in IN B-PP O
38 1154 1155 8421099 3 CD B-NP O
39 1156 1157 8421099 ( ( O O
40 1157 1158 8421099 2 CD B-NP O
41 1159 1161 8421099 of IN B-PP O
42 1162 1166 8421099 whom WP B-NP O
43 1167 1170 8421099 had VBD B-VP O
44 1171 1177 8421099 stones NNS B-NP O
45 1178 1185 8421099 present JJ B-ADJP O
46 1186 1188 8421099 at IN B-PP O
47 1189 1190 8421099 6 CD B-NP O
48 1191 1197 8421099 months NNS I-NP O
49 1197 1198 8421099 ) ) O O
50 1198 1199 8421099 . . O O

1 1200 1203 8421099 Our PRP$ B-NP O
2 1204 1211 8421099 results NNS I-NP O
3 1212 1219 8421099 suggest VBP B-VP O
4 1220 1224 8421099 that IN B-SBAR O
5 1225 1228 8421099 the DT B-NP O
6 1229 1240 8421099 suppression NN I-NP O
7 1241 1243 8421099 of IN B-PP O
8 1244 1255 8421099 gallbladder NN B-NP O
9 1256 1269 8421099 contractility NN I-NP O
10 1270 1272 8421099 is VBZ B-VP O
11 1273 1276 8421099 the DT B-NP O
12 1277 1282 8421099 cause NN I-NP O
13 1283 1285 8421099 of IN B-PP O
14 1286 1289 8421099 the DT B-NP O
15 1290 1300 8421099 successive JJ I-NP O
16 1301 1310 8421099 formation NN I-NP O
17 1311 1313 8421099 of IN B-PP O
18 1314 1318 8421099 bile NN B-NP O
19 1319 1325 8421099 sludge NN I-NP O
20 1325 1326 8421099 , , O O
21 1327 1337 8421099 gallstones NNS B-NP B-Disease
22 1337 1338 8421099 , , O O
23 1339 1342 8421099 and CC O O
24 1343 1356 8421099 cholecystitis NN B-NP B-Disease
25 1357 1363 8421099 during IN B-PP O
26 1364 1374 8421099 octreotide NN B-NP B-Chemical
27 1375 1382 8421099 therapy NN I-NP O
28 1383 1385 8421099 in IN B-PP O
29 1386 1393 8421099 Chinese JJ B-NP O
30 1394 1405 8421099 acromegalic JJ I-NP B-Disease
31 1406 1414 8421099 patients NNS I-NP O
32 1414 1415 8421099 . . O O

1 1416 1418 8421099 It PRP B-NP O
2 1419 1421 8421099 is VBZ B-VP O
3 1422 1431 8421099 therefore RB B-ADVP O
4 1432 1436 8421099 very RB B-ADJP O
5 1437 1446 8421099 important JJ I-ADJP O
6 1447 1449 8421099 to TO B-VP O
7 1450 1456 8421099 follow VB I-VP O
8 1457 1460 8421099 the DT B-NP O
9 1461 1468 8421099 changes NNS I-NP O
10 1469 1471 8421099 of IN B-PP O
11 1472 1483 8421099 gallbladder NN B-NP O
12 1484 1492 8421099 function NN I-NP O
13 1493 1499 8421099 during IN B-PP O
14 1500 1504 8421099 long JJ B-NP O
15 1504 1505 8421099 - HYPH I-NP O
16 1505 1509 8421099 term NN I-NP O
17 1510 1520 8421099 octreotide NN I-NP B-Chemical
18 1521 1528 8421099 therapy NN I-NP O
19 1529 1531 8421099 of IN B-PP O
20 1532 1543 8421099 acromegalic JJ B-NP B-Disease
21 1544 1552 8421099 patients NNS I-NP O
22 1552 1553 8421099 . . O O

1 0 0 1428568 -DOCSTART- -X- -X- O

1 0 7 1428568 Changes NNS B-NP O
2 8 10 1428568 in IN B-PP O
3 11 21 1428568 depressive JJ B-NP B-Disease
4 22 28 1428568 status NN I-NP O
5 29 39 1428568 associated VBN B-VP O
6 40 44 1428568 with IN B-PP O
7 45 52 1428568 topical JJ B-NP O
8 53 57 1428568 beta SYM I-NP O
9 57 58 1428568 - HYPH I-NP O
10 58 66 1428568 blockers NNS B-NP O
11 66 67 1428568 . . O O
12 68 78 1428568 Depression NN B-NP B-Disease
13 79 82 1428568 and CC O O
14 83 89 1428568 sexual JJ B-NP B-Disease
15 90 101 1428568 dysfunction NN I-NP I-Disease
16 102 106 1428568 have VBP B-VP O
17 107 111 1428568 been VBN I-VP O
18 112 119 1428568 related VBN I-VP O
19 120 122 1428568 to TO B-PP O
20 123 127 1428568 side JJ B-NP O
21 128 135 1428568 effects NNS I-NP O
22 136 138 1428568 of IN B-PP O
23 139 146 1428568 topical JJ B-NP O
24 147 151 1428568 beta SYM I-NP O
25 151 152 1428568 - HYPH I-NP O
26 152 160 1428568 blockers NNS I-NP O
27 160 161 1428568 . . O O

1 162 164 1428568 We PRP B-NP O
2 165 174 1428568 performed VBD B-VP O
3 175 176 1428568 a DT B-NP O
4 177 188 1428568 preliminary JJ I-NP O
5 189 194 1428568 study NN I-NP O
6 195 197 1428568 in IN B-SBAR O
7 198 203 1428568 order NN O O
8 204 206 1428568 to TO B-VP O
9 207 216 1428568 determine VB I-VP O
10 217 220 1428568 any DT B-NP O
11 221 231 1428568 difference NN I-NP O
12 232 239 1428568 between IN B-PP O
13 240 241 1428568 a DT B-NP O
14 242 245 1428568 non JJ I-NP O
15 246 255 1428568 selective JJ I-NP O
16 256 260 1428568 beta SYM O O
17 260 261 1428568 - HYPH O O
18 261 268 1428568 blocker NN B-NP O
19 269 270 1428568 ( ( O O
20 270 277 1428568 timolol NN B-NP B-Chemical
21 277 278 1428568 ) ) O O
22 279 282 1428568 and CC O O
23 283 284 1428568 a DT B-NP O
24 285 294 1428568 selective JJ I-NP O
25 295 299 1428568 beta SYM I-NP O
26 299 300 1428568 - HYPH I-NP O
27 300 307 1428568 blocker NN B-NP O
28 308 309 1428568 ( ( O O
29 309 318 1428568 betaxolol NN B-NP B-Chemical
30 318 319 1428568 ) ) O O
31 320 329 1428568 regarding VBG B-VP O
32 330 333 1428568 CNS NN B-NP O
33 334 338 1428568 side NN I-NP O
34 339 346 1428568 effects NNS I-NP O
35 346 347 1428568 . . O O

1 348 353 1428568 Eight CD B-NP O
2 354 366 1428568 glaucomatous JJ I-NP B-Disease
3 367 375 1428568 patients NNS I-NP O
4 376 387 1428568 chronically RB B-VP O
5 388 395 1428568 treated VBN I-VP O
6 396 400 1428568 with IN B-PP O
7 401 408 1428568 timolol NN B-NP B-Chemical
8 409 413 1428568 0.5% CD I-NP O
9 413 414 1428568 / SYM I-NP O
10 414 417 1428568 12h NN I-NP O
11 417 418 1428568 , , O O
12 419 428 1428568 suffering VBG B-VP O
13 429 433 1428568 from IN B-PP O
14 434 444 1428568 depression NN B-NP B-Disease
15 445 454 1428568 diagnosed VBN B-VP O
16 455 462 1428568 through IN B-PP O
17 463 466 1428568 DMS NN B-NP O
18 466 467 1428568 - HYPH B-NP O
19 467 470 1428568 III CD I-NP O
20 470 471 1428568 - HYPH I-NP O
21 471 472 1428568 R NN I-NP O
22 473 481 1428568 criteria NNS I-NP O
23 481 482 1428568 , , O O
24 483 487 1428568 were VBD B-VP O
25 488 496 1428568 included VBN I-VP O
26 497 499 1428568 in IN B-PP O
27 500 503 1428568 the DT B-NP O
28 504 509 1428568 study NN I-NP O
29 509 510 1428568 . . O O

1 511 517 1428568 During IN B-PP O
2 518 521 1428568 the DT B-NP O
3 522 525 1428568 six CD I-NP O
4 525 526 1428568 - HYPH I-NP O
5 526 531 1428568 month NN I-NP O
6 532 538 1428568 follow VB B-VP O
7 539 541 1428568 up RP B-PRT O
8 541 542 1428568 , , O O
9 543 553 1428568 depression NN B-NP B-Disease
10 554 557 1428568 was VBD B-VP O
11 558 568 1428568 quantified VBN I-VP O
12 569 576 1428568 through IN B-PP O
13 577 580 1428568 the DT B-NP O
14 581 585 1428568 Beck NNP I-NP O
15 586 589 1428568 and CC I-NP O
16 590 594 1428568 Zung NNP I-NP O
17 594 595 1428568 - HYPH O O
18 595 600 1428568 Conde NNP B-NP O
19 601 607 1428568 scales VBZ B-VP O
20 608 613 1428568 every DT B-NP O
21 614 617 1428568 two CD I-NP O
22 618 624 1428568 months NNS I-NP O
23 624 625 1428568 . . O O

1 626 628 1428568 In IN B-PP O
2 629 630 1428568 a DT B-NP O
3 631 637 1428568 double JJ I-NP O
4 638 643 1428568 blind JJ I-NP O
5 644 649 1428568 cross AFX O O
6 649 650 1428568 - HYPH O O
7 650 654 1428568 over IN B-PP O
8 655 660 1428568 study NN B-NP O
9 661 665 1428568 with IN B-PP O
10 666 673 1428568 control NN B-NP O
11 674 679 1428568 group NN I-NP O
12 679 680 1428568 , , O O
13 681 684 1428568 the DT B-NP O
14 685 693 1428568 patients NNS I-NP O
15 694 699 1428568 under IN B-PP O
16 700 707 1428568 timolol NN B-NP B-Chemical
17 708 717 1428568 treatment NN I-NP O
18 718 727 1428568 presented VBD B-VP O
19 728 734 1428568 higher JJR B-NP O
20 735 745 1428568 depression NN I-NP B-Disease
21 746 752 1428568 values NNS I-NP O
22 753 761 1428568 measured VBN B-VP O
23 762 769 1428568 through IN B-PP O
24 770 773 1428568 the DT B-NP O
25 774 778 1428568 Beck NNP I-NP O
26 779 782 1428568 and CC O O
27 783 786 1428568 the DT B-NP O
28 787 791 1428568 Zung NN I-NP O
29 791 792 1428568 - HYPH B-NP O
30 792 797 1428568 Conde NN I-NP O
31 798 804 1428568 scales NNS I-NP O
32 805 806 1428568 ( ( O O
33 806 807 1428568 p NN B-NP O
34 808 809 1428568 < JJR B-NP O
35 810 815 1428568 0.001 CD I-NP O
36 816 818 1428568 vs CC O O
37 819 826 1428568 control NN B-NP O
38 826 827 1428568 ) ) O O
39 827 828 1428568 . . O O

1 829 834 1428568 These DT B-NP O
2 835 842 1428568 results NNS I-NP O
3 843 850 1428568 suggest VBP B-VP O
4 851 855 1428568 that IN B-SBAR O
5 856 865 1428568 betaxolol NN B-NP B-Chemical
6 866 871 1428568 could MD B-VP O
7 872 874 1428568 be VB I-VP O
8 875 879 1428568 less JJR B-NP O
9 880 882 1428568 of IN B-PP O
10 883 884 1428568 a DT B-NP O
11 885 895 1428568 depression NN I-NP B-Disease
12 895 896 1428568 - HYPH O O
13 896 903 1428568 inducer NN B-NP O
14 904 908 1428568 than IN B-PP O
15 909 916 1428568 timolol NN B-NP B-Chemical
16 917 919 1428568 in IN B-PP O
17 920 931 1428568 predisposed VBN B-NP O
18 932 940 1428568 patients NNS I-NP O
19 940 941 1428568 . . O O

1 0 0 3693336 -DOCSTART- -X- -X- O

1 0 9 3693336 Triazolam NN B-NP B-Chemical
2 9 10 3693336 - HYPH O O
3 10 17 3693336 induced VBN B-NP O
4 18 23 3693336 brief JJ I-NP O
5 24 32 3693336 episodes NNS I-NP O
6 33 35 3693336 of IN B-PP O
7 36 45 3693336 secondary JJ B-NP O
8 46 51 3693336 mania NN I-NP B-Disease
9 52 54 3693336 in IN B-PP O
10 55 56 3693336 a DT B-NP O
11 57 66 3693336 depressed JJ I-NP B-Disease
12 67 74 3693336 patient NN I-NP O
13 74 75 3693336 . . O O
14 76 81 3693336 Large JJ B-NP O
15 82 87 3693336 doses NNS I-NP O
16 88 90 3693336 of IN B-PP O
17 91 100 3693336 triazolam NN B-NP B-Chemical
18 101 111 3693336 repeatedly RB B-ADVP O
19 112 119 3693336 induced VBD B-VP O
20 120 125 3693336 brief JJ B-NP O
21 126 134 3693336 episodes NNS I-NP O
22 135 137 3693336 of IN B-PP O
23 138 143 3693336 mania NN B-NP B-Disease
24 144 146 3693336 in IN B-PP O
25 147 148 3693336 a DT B-NP O
26 149 158 3693336 depressed JJ I-NP B-Disease
27 159 166 3693336 elderly JJ I-NP O
28 167 172 3693336 woman NN I-NP O
29 172 173 3693336 . . O O

1 174 182 3693336 Features NNS B-NP O
2 183 185 3693336 of IN B-PP O
3 186 193 3693336 organic JJ B-NP B-Disease
4 194 200 3693336 mental JJ I-NP I-Disease
5 201 209 3693336 disorder NN I-NP I-Disease
6 210 211 3693336 ( ( O O
7 211 219 3693336 delirium NN B-NP B-Disease
8 219 220 3693336 ) ) O O
9 221 225 3693336 were VBD B-VP O
10 226 229 3693336 not RB O O
11 230 237 3693336 present JJ B-ADJP O
12 237 238 3693336 . . O O

1 239 244 3693336 Manic JJ B-NP B-Disease
2 245 255 3693336 excitement NN I-NP O
3 256 259 3693336 was VBD B-VP O
4 260 270 3693336 coincident JJ B-ADJP O
5 271 275 3693336 with IN B-PP O
6 276 279 3693336 the DT B-NP O
7 280 288 3693336 duration NN I-NP O
8 289 291 3693336 of IN B-PP O
9 292 298 3693336 action NN B-NP O
10 299 301 3693336 of IN B-PP O
11 302 311 3693336 triazolam NN B-NP B-Chemical
12 311 312 3693336 . . O O

1 313 316 3693336 The DT B-NP O
2 317 325 3693336 possible JJ I-NP O
3 326 338 3693336 contribution NN I-NP O
4 339 341 3693336 of IN B-PP O
5 342 345 3693336 the DT B-NP O
6 346 354 3693336 triazolo NN I-NP B-Chemical
7 355 360 3693336 group NN I-NP O
8 361 363 3693336 to TO B-PP O
9 364 371 3693336 changes NNS B-NP O
10 372 374 3693336 in IN B-PP O
11 375 384 3693336 affective JJ B-NP O
12 385 391 3693336 status NN I-NP O
13 392 394 3693336 is VBZ B-VP O
14 395 404 3693336 discussed VBN I-VP O
15 404 405 3693336 . . O O

1 0 0 20080419 -DOCSTART- -X- -X- O

1 0 10 20080419 Prevention NN B-NP O
2 11 13 20080419 of IN B-PP O
3 14 22 20080419 seizures NNS B-NP B-Disease
4 23 26 20080419 and CC O O
5 27 41 20080419 reorganization NN B-NP O
6 42 44 20080419 of IN B-PP O
7 45 56 20080419 hippocampal JJ B-NP O
8 57 66 20080419 functions NNS I-NP O
9 67 69 20080419 by IN B-PP O
10 70 85 20080419 transplantation NN B-NP O
11 86 88 20080419 of IN B-PP O
12 89 93 20080419 bone NN B-NP O
13 94 100 20080419 marrow NN I-NP O
14 101 106 20080419 cells NNS I-NP O
15 107 109 20080419 in IN B-PP O
16 110 113 20080419 the DT B-NP O
17 114 119 20080419 acute JJ I-NP O
18 120 125 20080419 phase NN I-NP O
19 126 128 20080419 of IN B-PP O
20 129 141 20080419 experimental JJ B-NP O
21 142 150 20080419 epilepsy NN I-NP B-Disease
22 150 151 20080419 . . O O
23 152 154 20080419 In IN B-PP O
24 155 159 20080419 this DT B-NP O
25 160 165 20080419 study NN I-NP O
26 165 166 20080419 , , O O
27 167 169 20080419 we PRP B-NP O
28 170 182 20080419 investigated VBD B-VP O
29 183 186 20080419 the DT B-NP O
30 187 198 20080419 therapeutic JJ I-NP O
31 199 208 20080419 potential NN I-NP O
32 209 211 20080419 of IN B-PP O
33 212 216 20080419 bone NN B-NP O
34 217 223 20080419 marrow NN I-NP O
35 224 235 20080419 mononuclear JJ I-NP O
36 236 241 20080419 cells NNS I-NP O
37 242 243 20080419 ( ( O O
38 243 247 20080419 BMCs NNS B-NP O
39 247 248 20080419 ) ) O O
40 249 251 20080419 in IN B-PP O
41 252 253 20080419 a DT B-NP O
42 254 259 20080419 model NN I-NP O
43 260 262 20080419 of IN B-PP O
44 263 271 20080419 epilepsy NN B-NP B-Disease
45 272 279 20080419 induced VBN B-VP O
46 280 282 20080419 by IN B-PP O
47 283 294 20080419 pilocarpine NN B-NP B-Chemical
48 295 297 20080419 in IN B-PP O
49 298 302 20080419 rats NNS B-NP O
50 302 303 20080419 . . O O

1 304 308 20080419 BMCs NNS B-NP O
2 309 317 20080419 obtained VBN B-VP O
3 318 322 20080419 from IN B-PP O
4 323 328 20080419 green JJ B-NP O
5 329 340 20080419 fluorescent JJ I-NP O
6 341 348 20080419 protein NN I-NP O
7 349 350 20080419 ( ( O O
8 350 353 20080419 GFP NN B-NP O
9 353 354 20080419 ) ) O O
10 355 365 20080419 transgenic JJ B-NP O
11 366 370 20080419 mice NNS I-NP O
12 371 373 20080419 or CC I-NP O
13 374 378 20080419 rats NNS I-NP O
14 379 383 20080419 were VBD B-VP O
15 384 396 20080419 transplanted VBN I-VP O
16 397 410 20080419 intravenously RB B-ADVP O
17 411 416 20080419 after IN B-PP O
18 417 426 20080419 induction NN B-NP O
19 427 429 20080419 of IN B-PP O
20 430 436 20080419 status NN B-NP B-Disease
21 437 448 20080419 epilepticus NN I-NP I-Disease
22 449 450 20080419 ( ( O O
23 450 452 20080419 SE NN B-NP B-Disease
24 452 453 20080419 ) ) O O
25 453 454 20080419 . . O O

1 455 466 20080419 Spontaneous JJ B-NP B-Disease
2 467 476 20080419 recurrent JJ I-NP I-Disease
3 477 485 20080419 seizures NNS I-NP I-Disease
4 486 487 20080419 ( ( O O
5 487 490 20080419 SRS NNS B-NP B-Disease
6 490 491 20080419 ) ) O O
7 492 496 20080419 were VBD B-VP O
8 497 506 20080419 monitored VBN I-VP O
9 507 512 20080419 using VBG B-VP O
10 513 521 20080419 Racine's NNS B-NP O
11 522 529 20080419 seizure NN I-NP B-Disease
12 530 538 20080419 severity NN I-NP O
13 539 544 20080419 scale NN I-NP O
14 544 545 20080419 . . O O

1 546 549 20080419 All DT B-NP O
2 550 552 20080419 of IN B-PP O
3 553 556 20080419 the DT B-NP O
4 557 561 20080419 rats NNS I-NP O
5 562 564 20080419 in IN B-PP O
6 565 568 20080419 the DT B-NP O
7 569 575 20080419 saline NN I-NP O
8 575 576 20080419 - HYPH O O
9 576 583 20080419 treated VBN B-VP O
10 584 593 20080419 epileptic JJ B-NP B-Disease
11 594 601 20080419 control NN I-NP O
12 602 607 20080419 group NN I-NP O
13 608 617 20080419 developed VBD B-VP O
14 618 621 20080419 SRS NN B-NP B-Disease
15 621 622 20080419 , , O O
16 623 630 20080419 whereas IN O O
17 631 635 20080419 none NN B-NP O
18 636 638 20080419 of IN B-PP O
19 639 642 20080419 the DT B-NP O
20 643 646 20080419 BMC NN I-NP O
21 646 647 20080419 - HYPH O O
22 647 654 20080419 treated VBN B-VP O
23 655 664 20080419 epileptic JJ B-NP B-Disease
24 665 672 20080419 animals NNS I-NP O
25 673 676 20080419 had VBD B-VP O
26 677 685 20080419 seizures NNS B-NP B-Disease
27 686 688 20080419 in IN B-PP O
28 689 692 20080419 the DT B-NP O
29 693 698 20080419 short JJ I-NP O
30 699 703 20080419 term NN I-NP O
31 704 705 20080419 ( ( O O
32 705 707 20080419 15 CD B-NP O
33 708 712 20080419 days NNS I-NP O
34 713 718 20080419 after IN B-PP O
35 719 734 20080419 transplantation NN B-NP O
36 734 735 20080419 ) ) O O
37 735 736 20080419 , , O O
38 737 747 20080419 regardless RB B-ADVP O
39 748 750 20080419 of IN B-PP O
40 751 754 20080419 the DT B-NP O
41 755 758 20080419 BMC NN I-NP O
42 759 765 20080419 source NN I-NP O
43 765 766 20080419 . . O O

1 767 771 20080419 Over IN B-PP O
2 772 775 20080419 the DT B-NP O
3 776 780 20080419 long JJ I-NP O
4 780 781 20080419 - HYPH I-NP O
5 781 785 20080419 term NN I-NP O
6 786 793 20080419 chronic JJ I-NP O
7 794 799 20080419 phase NN I-NP O
8 800 801 20080419 ( ( O O
9 801 804 20080419 120 CD B-NP O
10 805 809 20080419 days NNS I-NP O
11 810 815 20080419 after IN B-PP O
12 816 831 20080419 transplantation NN B-NP O
13 831 832 20080419 ) ) O O
14 832 833 20080419 , , O O
15 834 838 20080419 only RB B-NP O
16 839 842 20080419 25% CD I-NP O
17 843 845 20080419 of IN B-PP O
18 846 849 20080419 BMC NN B-NP O
19 849 850 20080419 - HYPH O O
20 850 857 20080419 treated VBN B-VP O
21 858 867 20080419 epileptic JJ B-NP B-Disease
22 868 875 20080419 animals NNS I-NP O
23 876 879 20080419 had VBD B-VP O
24 880 888 20080419 seizures NNS B-NP B-Disease
25 888 889 20080419 , , O O
26 890 893 20080419 but CC O O
27 894 898 20080419 with IN B-PP O
28 899 900 20080419 a DT B-NP O
29 901 906 20080419 lower JJR I-NP O
30 907 916 20080419 frequency NN I-NP O
31 917 920 20080419 and CC I-NP O
32 921 929 20080419 duration NN I-NP O
33 930 938 20080419 compared VBN B-PP O
34 939 941 20080419 to TO B-PP O
35 942 945 20080419 the DT B-NP O
36 946 955 20080419 epileptic JJ I-NP B-Disease
37 956 963 20080419 control NN I-NP O
38 964 969 20080419 group NN I-NP O
39 969 970 20080419 . . O O

1 971 974 20080419 The DT B-NP O
2 975 982 20080419 density NN I-NP O
3 983 985 20080419 of IN B-PP O
4 986 997 20080419 hippocampal JJ B-NP O
5 998 1005 20080419 neurons NNS I-NP O
6 1006 1008 20080419 in IN B-PP O
7 1009 1012 20080419 the DT B-NP O
8 1013 1019 20080419 brains NNS I-NP O
9 1020 1022 20080419 of IN B-PP O
10 1023 1030 20080419 animals NNS B-NP O
11 1031 1038 20080419 treated VBN B-VP O
12 1039 1043 20080419 with IN B-PP O
13 1044 1048 20080419 BMCs NNS B-NP O
14 1049 1052 20080419 was VBD B-VP O
15 1053 1061 20080419 markedly RB I-VP O
16 1062 1071 20080419 preserved VBN I-VP O
17 1071 1072 20080419 . . O O

1 1073 1075 20080419 At IN B-PP O
2 1076 1087 20080419 hippocampal JJ B-NP O
3 1088 1097 20080419 Schaeffer NNP I-NP O
4 1098 1108 20080419 collateral NN I-NP O
5 1108 1109 20080419 - HYPH B-NP O
6 1109 1112 20080419 CA1 NN I-NP O
7 1113 1121 20080419 synapses NNS I-NP O
8 1121 1122 20080419 , , O O
9 1123 1127 20080419 long JJ B-NP O
10 1127 1128 20080419 - HYPH I-NP O
11 1128 1132 20080419 term NN I-NP O
12 1133 1145 20080419 potentiation NN I-NP O
13 1146 1149 20080419 was VBD B-VP O
14 1150 1159 20080419 preserved VBN I-VP O
15 1160 1162 20080419 in IN B-PP O
16 1163 1166 20080419 BMC NN B-NP O
17 1166 1167 20080419 - HYPH B-NP O
18 1167 1179 20080419 transplanted VBN I-NP O
19 1180 1184 20080419 rats NNS I-NP O
20 1185 1193 20080419 compared VBN B-VP O
21 1194 1196 20080419 to TO B-PP O
22 1197 1206 20080419 epileptic JJ B-NP B-Disease
23 1207 1215 20080419 controls NNS I-NP O
24 1215 1216 20080419 . . O O

1 1217 1220 20080419 The DT B-NP O
2 1221 1226 20080419 donor NN I-NP O
3 1226 1227 20080419 - HYPH B-VP O
4 1227 1234 20080419 derived VBN B-NP O
5 1235 1241 20080419 GFP(+) NN I-NP O
6 1242 1247 20080419 cells NNS I-NP O
7 1248 1252 20080419 were VBD B-VP O
8 1253 1259 20080419 rarely RB I-VP O
9 1260 1265 20080419 found VBN I-VP O
10 1266 1268 20080419 in IN B-PP O
11 1269 1272 20080419 the DT B-NP O
12 1273 1279 20080419 brains NNS I-NP O
13 1280 1282 20080419 of IN B-PP O
14 1283 1295 20080419 transplanted VBN B-NP O
15 1296 1305 20080419 epileptic JJ I-NP B-Disease
16 1306 1310 20080419 rats NNS I-NP O
17 1310 1311 20080419 . . O O

1 1312 1314 20080419 In IN B-PP O
2 1315 1325 20080419 conclusion NN B-NP O
3 1325 1326 20080419 , , O O
4 1327 1336 20080419 treatment NN B-NP O
5 1337 1341 20080419 with IN B-PP O
6 1342 1346 20080419 BMCs NNS B-NP O
7 1347 1350 20080419 can MD B-VP O
8 1351 1358 20080419 prevent VB I-VP O
9 1359 1362 20080419 the DT B-NP O
10 1363 1374 20080419 development NN I-NP O
11 1375 1377 20080419 of IN B-PP O
12 1378 1385 20080419 chronic JJ B-NP O
13 1386 1394 20080419 seizures NNS I-NP B-Disease
14 1394 1395 20080419 , , O O
15 1396 1402 20080419 reduce VB B-VP O
16 1403 1411 20080419 neuronal JJ B-NP B-Disease
17 1412 1416 20080419 loss NN I-NP I-Disease
18 1416 1417 20080419 , , O O
19 1418 1421 20080419 and CC O O
20 1422 1431 20080419 influence VB B-VP O
21 1432 1435 20080419 the DT B-NP O
22 1436 1450 20080419 reorganization NN I-NP O
23 1451 1453 20080419 of IN B-PP O
24 1454 1457 20080419 the DT B-NP O
25 1458 1469 20080419 hippocampal JJ I-NP O
26 1470 1478 20080419 neuronal JJ I-NP O
27 1479 1486 20080419 network NN I-NP O
28 1486 1487 20080419 . . O O

1 0 0 6466532 -DOCSTART- -X- -X- O

1 0 10 6466532 Comparison NN B-NP O
2 11 13 6466532 of IN B-PP O
3 14 17 6466532 i.v NN B-NP O
4 17 18 6466532 . . O O

1 19 33 6466532 glycopyrrolate NN B-NP B-Chemical
2 34 37 6466532 and CC I-NP O
3 38 46 6466532 atropine NN I-NP B-Chemical
4 47 49 6466532 in IN B-PP O
5 50 53 6466532 the DT B-NP O
6 54 64 6466532 prevention NN I-NP O
7 65 67 6466532 of IN B-PP O
8 68 79 6466532 bradycardia NN B-NP B-Disease
9 80 83 6466532 and CC I-NP O
10 84 95 6466532 arrhythmias NNS I-NP B-Disease
11 96 105 6466532 following VBG B-PP O
12 106 114 6466532 repeated VBN B-NP O
13 115 120 6466532 doses NNS I-NP O
14 121 123 6466532 of IN B-PP O
15 124 137 6466532 suxamethonium NN B-NP B-Chemical
16 138 140 6466532 in IN B-PP O
17 141 149 6466532 children NNS B-NP O
18 149 150 6466532 . . O O
19 151 154 6466532 The DT B-NP O
20 155 168 6466532 effectiveness NN I-NP O
21 169 171 6466532 of IN B-PP O
22 172 186 6466532 administration NN B-NP O
23 187 189 6466532 of IN B-PP O
24 190 204 6466532 glycopyrrolate NN B-NP B-Chemical
25 205 206 6466532 5 CD I-NP O
26 207 210 6466532 and CC I-NP O
27 211 213 6466532 10 CD I-NP O
28 214 224 6466532 micrograms NNS I-NP O
29 225 227 6466532 kg NN I-NP O
30 227 228 6466532 - HYPH B-NP O
31 228 229 6466532 1 CD I-NP O
32 230 233 6466532 and CC O O
33 234 242 6466532 atropine NN B-NP B-Chemical
34 243 245 6466532 10 CD I-NP O
35 246 249 6466532 and CC I-NP O
36 250 252 6466532 20 CD I-NP O
37 253 263 6466532 micrograms NNS I-NP O
38 264 266 6466532 kg NN I-NP O
39 266 267 6466532 - HYPH B-NP O
40 267 268 6466532 1 CD I-NP O
41 269 272 6466532 i.v NN I-NP O
42 272 273 6466532 . . O O

1 274 285 6466532 immediately RB B-ADVP O
2 286 292 6466532 before IN B-PP O
3 293 296 6466532 the DT B-NP O
4 297 306 6466532 induction NN I-NP O
5 307 309 6466532 of IN B-PP O
6 310 321 6466532 anaesthesia NN B-NP O
7 321 322 6466532 , , O O
8 323 325 6466532 to TO B-VP O
9 326 333 6466532 prevent VB I-VP O
10 334 344 6466532 arrhythmia NN B-NP B-Disease
11 345 348 6466532 and CC I-NP O
12 349 360 6466532 bradycardia NN I-NP B-Disease
13 361 370 6466532 following VBG B-PP O
14 371 379 6466532 repeated JJ B-NP O
15 380 385 6466532 doses NNS I-NP O
16 386 388 6466532 of IN B-PP O
17 389 402 6466532 suxamethonium NN B-NP B-Chemical
18 403 405 6466532 in IN B-PP O
19 406 414 6466532 children NNS B-NP O
20 414 415 6466532 , , O O
21 416 419 6466532 was VBD B-VP O
22 420 427 6466532 studied VBN I-VP O
23 427 428 6466532 . . O O

1 429 430 6466532 A DT B-NP O
2 431 438 6466532 control NN I-NP O
3 439 444 6466532 group NN I-NP O
4 445 448 6466532 was VBD B-VP O
5 449 457 6466532 included VBN I-VP O
6 458 461 6466532 for IN B-PP O
7 462 472 6466532 comparison NN B-NP O
8 473 477 6466532 with IN B-PP O
9 478 481 6466532 the DT B-NP O
10 482 487 6466532 lower JJR I-NP O
11 488 492 6466532 dose NN I-NP O
12 493 498 6466532 range NN I-NP O
13 499 501 6466532 of IN B-PP O
14 502 516 6466532 glycopyrrolate NN B-NP B-Chemical
15 517 520 6466532 and CC I-NP O
16 521 529 6466532 atropine NN I-NP B-Chemical
17 529 530 6466532 . . O O

1 531 532 6466532 A DT B-NP O
2 533 542 6466532 frequency NN I-NP O
3 543 545 6466532 of IN B-PP O
4 546 557 6466532 bradycardia NN B-NP B-Disease
5 558 560 6466532 of IN B-PP O
6 561 564 6466532 50% CD B-NP O
7 565 568 6466532 was VBD B-VP O
8 569 574 6466532 noted VBN I-VP O
9 575 577 6466532 in IN B-PP O
10 578 581 6466532 the DT B-NP O
11 582 589 6466532 control NN I-NP O
12 590 595 6466532 group NN I-NP O
13 595 596 6466532 , , O O
14 597 600 6466532 but CC O O
15 601 605 6466532 this DT B-NP O
16 606 609 6466532 was VBD B-VP O
17 610 613 6466532 not RB O O
18 614 627 6466532 significantly RB B-ADJP O
19 628 637 6466532 different JJ I-ADJP O
20 638 642 6466532 from IN B-PP O
21 643 646 6466532 the DT B-NP O
22 647 656 6466532 frequency NN I-NP O
23 657 661 6466532 with IN B-PP O
24 662 665 6466532 the DT B-NP O
25 666 672 6466532 active JJ I-NP O
26 673 678 6466532 drugs NNS I-NP O
27 678 679 6466532 . . O O

1 680 691 6466532 Bradycardia NNP B-NP B-Disease
2 692 693 6466532 ( ( O O
3 693 700 6466532 defined VBN B-VP O
4 701 703 6466532 as IN B-PP O
5 704 705 6466532 a DT B-NP O
6 706 714 6466532 decrease NN I-NP O
7 715 717 6466532 in IN B-PP O
8 718 723 6466532 heart NN B-NP O
9 724 728 6466532 rate NN I-NP O
10 729 731 6466532 to TO B-PP O
11 732 736 6466532 less JJR B-NP O
12 737 741 6466532 than IN I-NP O
13 742 744 6466532 50 CD I-NP O
14 745 749 6466532 beat NN I-NP O
15 750 753 6466532 min NN I-NP O
16 753 754 6466532 - HYPH B-NP O
17 754 755 6466532 1 CD I-NP O
18 755 756 6466532 ) ) O O
19 757 760 6466532 was VBD B-VP O
20 761 770 6466532 prevented VBN I-VP O
21 771 775 6466532 when WRB B-ADVP O
22 776 779 6466532 the DT B-NP O
23 780 786 6466532 larger JJR I-NP O
24 787 791 6466532 dose NN I-NP O
25 792 794 6466532 of IN B-PP O
26 795 801 6466532 either CC B-NP O
27 802 808 6466532 active JJ I-NP O
28 809 813 6466532 drug NN I-NP O
29 814 817 6466532 was VBD B-VP O
30 818 822 6466532 used VBN I-VP O
31 822 823 6466532 . . O O

1 824 826 6466532 It PRP B-NP O
2 827 829 6466532 is VBZ B-VP O
3 830 841 6466532 recommended VBN I-VP O
4 842 846 6466532 that IN B-SBAR O
5 847 853 6466532 either CC O O
6 854 868 6466532 glycopyrrolate NN B-NP B-Chemical
7 869 871 6466532 10 CD B-NP O
8 872 882 6466532 micrograms NNS I-NP O
9 883 885 6466532 kg NN I-NP O
10 885 886 6466532 - HYPH B-NP O
11 886 887 6466532 1 CD I-NP O
12 888 890 6466532 or CC O O
13 891 899 6466532 atropine NN B-NP B-Chemical
14 900 902 6466532 20 CD I-NP O
15 903 913 6466532 micrograms NNS I-NP O
16 914 916 6466532 kg NN I-NP O
17 916 917 6466532 - HYPH B-NP O
18 917 918 6466532 1 CD I-NP O
19 919 922 6466532 i.v NN I-NP O
20 922 923 6466532 . . O O

1 924 930 6466532 should MD B-VP O
2 931 942 6466532 immediately RB I-VP O
3 943 950 6466532 precede VB I-VP O
4 951 960 6466532 induction NN B-NP O
5 961 963 6466532 of IN B-PP O
6 964 975 6466532 anaesthesia NN B-NP O
7 975 976 6466532 , , O O
8 977 979 6466532 in IN B-PP O
9 980 988 6466532 children NNS B-NP O
10 988 989 6466532 , , O O
11 990 992 6466532 if IN B-SBAR O
12 993 996 6466532 the DT B-NP O
13 997 1005 6466532 repeated VBN I-NP O
14 1006 1020 6466532 administration NN I-NP O
15 1021 1023 6466532 of IN B-PP O
16 1024 1037 6466532 suxamethonium NN B-NP B-Chemical
17 1038 1040 6466532 is VBZ B-VP O
18 1041 1052 6466532 anticipated VBN I-VP O
19 1052 1053 6466532 . . O O

1 0 0 14698717 -DOCSTART- -X- -X- O

1 0 5 14698717 Acute JJ B-NP B-Disease
2 6 15 14698717 psychosis NN I-NP I-Disease
3 16 19 14698717 due JJ B-ADJP O
4 20 22 14698717 to TO B-PP O
5 23 32 14698717 treatment NN B-NP O
6 33 37 14698717 with IN B-PP O
7 38 47 14698717 phenytoin NN B-NP B-Chemical
8 48 50 14698717 in IN B-PP O
9 51 52 14698717 a DT B-NP O
10 53 65 14698717 nonepileptic JJ I-NP O
11 66 73 14698717 patient NN I-NP O
12 73 74 14698717 . . O O
13 75 78 14698717 The DT B-NP O
14 79 90 14698717 development NN I-NP O
15 91 93 14698717 of IN B-PP O
16 94 103 14698717 psychosis NN B-NP B-Disease
17 104 111 14698717 related VBN B-VP O
18 112 114 14698717 to TO B-PP O
19 115 128 14698717 antiepileptic JJ B-NP O
20 129 133 14698717 drug NN I-NP O
21 134 143 14698717 treatment NN I-NP O
22 144 146 14698717 is VBZ B-VP O
23 147 154 14698717 usually RB I-VP O
24 155 165 14698717 attributed VBN I-VP O
25 166 168 14698717 to TO B-PP O
26 169 172 14698717 the DT B-NP O
27 173 184 14698717 interaction NN I-NP O
28 185 192 14698717 between IN B-PP O
29 193 196 14698717 the DT B-NP O
30 197 206 14698717 epileptic JJ I-NP B-Disease
31 207 212 14698717 brain NN I-NP O
32 213 223 14698717 substratum NN I-NP O
33 224 227 14698717 and CC O O
34 228 231 14698717 the DT B-NP O
35 232 245 14698717 antiepileptic JJ I-NP O
36 246 251 14698717 drugs NNS I-NP O
37 251 252 14698717 . . O O

1 253 256 14698717 The DT B-NP O
2 257 261 14698717 case NN I-NP O
3 262 264 14698717 of IN B-PP O
4 265 266 14698717 a DT B-NP O
5 267 279 14698717 nonepileptic JJ I-NP O
6 280 287 14698717 patient NN I-NP O
7 288 291 14698717 who WP B-NP O
8 292 301 14698717 developed VBD B-VP O
9 302 311 14698717 psychosis NN B-NP B-Disease
10 312 321 14698717 following VBG B-PP O
11 322 331 14698717 phenytoin NN B-NP B-Chemical
12 332 341 14698717 treatment NN I-NP O
13 342 345 14698717 for IN B-PP O
14 346 356 14698717 trigeminal JJ B-NP B-Disease
15 357 366 14698717 neuralgia NN I-NP I-Disease
16 367 369 14698717 is VBZ B-VP O
17 370 379 14698717 described VBN I-VP O
18 379 380 14698717 . . O O

1 381 385 14698717 This DT B-NP O
2 386 390 14698717 case NN I-NP O
3 391 399 14698717 suggests VBZ B-VP O
4 400 404 14698717 that IN B-SBAR O
5 405 408 14698717 the DT B-NP O
6 409 418 14698717 psychotic JJ I-NP B-Disease
7 419 427 14698717 symptoms NNS I-NP I-Disease
8 428 432 14698717 that WDT B-NP O
9 433 438 14698717 occur VBP B-VP O
10 439 448 14698717 following VBG B-PP O
11 449 458 14698717 phenytoin NN B-NP B-Chemical
12 459 468 14698717 treatment NN I-NP O
13 469 471 14698717 in IN B-PP O
14 472 476 14698717 some DT B-NP O
15 477 486 14698717 epileptic JJ I-NP B-Disease
16 487 495 14698717 patients NNS I-NP O
17 496 499 14698717 may MD B-VP O
18 500 502 14698717 be VB I-VP O
19 503 506 14698717 the DT B-NP O
20 507 513 14698717 direct JJ I-NP O
21 514 520 14698717 result NN I-NP O
22 521 523 14698717 of IN B-PP O
23 524 534 14698717 medication NN B-NP O
24 534 535 14698717 , , O O
25 536 545 14698717 unrelated JJ B-ADJP O
26 546 548 14698717 to TO B-PP O
27 549 557 14698717 seizures NNS B-NP B-Disease
28 557 558 14698717 . . O O

1 0 0 2505783 -DOCSTART- -X- -X- O

1 0 18 2505783 Chloroacetaldehyde NN B-NP B-Chemical
2 19 22 2505783 and CC O O
3 23 26 2505783 its PRP$ B-NP O
4 27 39 2505783 contribution NN I-NP O
5 40 42 2505783 to TO B-PP O
6 43 54 2505783 urotoxicity NN B-NP O
7 55 61 2505783 during IN B-PP O
8 62 71 2505783 treatment NN B-NP O
9 72 76 2505783 with IN B-PP O
10 77 93 2505783 cyclophosphamide NN B-NP B-Chemical
11 94 96 2505783 or CC I-NP O
12 97 107 2505783 ifosfamide NN I-NP B-Chemical
13 107 108 2505783 . . O O

1 109 111 2505783 An DT B-NP O
2 112 124 2505783 experimental JJ I-NP O
3 125 130 2505783 study NN I-NP O
4 130 131 2505783 / SYM B-NP O
5 131 136 2505783 short JJ I-NP O
6 137 150 2505783 communication NN I-NP O
7 150 151 2505783 . . O O
8 152 157 2505783 Based VBN B-VP O
9 158 160 2505783 on IN B-PP O
10 161 169 2505783 clinical JJ B-NP O
11 170 174 2505783 data NNS I-NP O
12 174 175 2505783 , , O O
13 176 186 2505783 indicating VBG B-VP O
14 187 191 2505783 that IN B-SBAR O
15 192 210 2505783 chloroacetaldehyde NN B-NP B-Chemical
16 211 212 2505783 ( ( O O
17 212 215 2505783 CAA NN B-NP B-Chemical
18 215 216 2505783 ) ) O O
19 217 219 2505783 is VBZ B-VP O
20 220 222 2505783 an DT B-NP O
21 223 232 2505783 important JJ I-NP O
22 233 243 2505783 metabolite NN I-NP O
23 244 246 2505783 of IN B-PP O
24 247 263 2505783 oxazaphosphorine NN B-NP O
25 264 275 2505783 cytostatics NNS I-NP O
26 275 276 2505783 , , O O
27 277 279 2505783 an DT B-NP O
28 280 292 2505783 experimental JJ I-NP O
29 293 298 2505783 study NN I-NP O
30 299 302 2505783 was VBD B-VP O
31 303 310 2505783 carried VBN I-VP O
32 311 314 2505783 out RP B-PRT O
33 315 317 2505783 in IN B-SBAR O
34 318 323 2505783 order NN O O
35 324 326 2505783 to TO B-VP O
36 327 336 2505783 elucidate VB I-VP O
37 337 340 2505783 the DT B-NP O
38 341 345 2505783 role NN I-NP O
39 346 348 2505783 of IN B-PP O
40 349 352 2505783 CAA NN B-NP B-Chemical
41 353 355 2505783 in IN B-PP O
42 356 359 2505783 the DT B-NP O
43 360 371 2505783 development NN I-NP O
44 372 374 2505783 of IN B-PP O
45 375 386 2505783 hemorrhagic JJ B-NP B-Disease
46 387 395 2505783 cystitis NN I-NP I-Disease
47 395 396 2505783 . . O O

1 397 400 2505783 The DT B-NP O
2 401 405 2505783 data NNS I-NP O
3 406 417 2505783 demonstrate VBP B-VP O
4 418 422 2505783 that IN B-SBAR O
5 423 426 2505783 CAA NN B-NP B-Chemical
6 427 432 2505783 after IN B-PP O
7 433 436 2505783 i.v NN B-NP O
8 436 437 2505783 . . O O

1 438 452 2505783 administration NN B-NP O
2 453 457 2505783 does VBZ B-VP O
3 458 461 2505783 not RB I-VP O
4 462 472 2505783 contribute VB I-VP O
5 473 475 2505783 to TO B-PP O
6 476 483 2505783 bladder NN B-NP B-Disease
7 484 490 2505783 damage NN I-NP I-Disease
8 490 491 2505783 . . O O

1 492 496 2505783 When WRB B-ADVP O
2 497 506 2505783 instilled VBN B-VP O
3 507 515 2505783 directly RB B-ADVP O
4 516 520 2505783 into IN B-PP O
5 521 524 2505783 the DT B-NP O
6 525 532 2505783 bladder NN I-NP O
7 532 533 2505783 , , O O
8 534 537 2505783 CAA NN B-NP B-Chemical
9 538 544 2505783 exerts VBZ B-VP O
10 545 553 2505783 urotoxic JJ B-NP O
11 554 561 2505783 effects NNS I-NP O
12 561 562 2505783 , , O O
13 563 565 2505783 it PRP B-NP O
14 566 568 2505783 is VBZ B-VP O
15 568 569 2505783 , , O O
16 570 577 2505783 however RB B-ADVP O
17 577 578 2505783 , , O O
18 579 590 2505783 susceptible JJ B-ADJP O
19 591 593 2505783 to TO B-PP O
20 594 608 2505783 detoxification NN B-NP O
21 609 613 2505783 with IN B-PP O
22 614 619 2505783 mesna NN B-NP B-Chemical
23 619 620 2505783 . . O O

1 0 0 1967484 -DOCSTART- -X- -X- O

1 0 9 1967484 Sulpiride NN B-NP B-Chemical
2 9 10 1967484 - HYPH B-NP O
3 10 17 1967484 induced VBN I-NP O
4 18 25 1967484 tardive NN I-NP B-Disease
5 26 34 1967484 dystonia NN I-NP I-Disease
6 34 35 1967484 . . I-NP O
7 36 45 1967484 Sulpiride NN I-NP B-Chemical
8 46 48 1967484 is VBZ B-VP O
9 49 50 1967484 a DT B-NP O
10 51 60 1967484 selective JJ I-NP O
11 61 63 1967484 D2 NN I-NP O
12 63 64 1967484 - HYPH B-NP O
13 64 72 1967484 receptor NN I-NP O
14 73 83 1967484 antagonist NN I-NP O
15 84 88 1967484 with IN B-PP O
16 89 102 1967484 antipsychotic JJ B-NP O
17 103 106 1967484 and CC I-NP O
18 107 121 1967484 antidepressant JJ I-NP B-Chemical
19 122 132 1967484 properties NNS I-NP O
20 132 133 1967484 . . O O

1 134 142 1967484 Although IN B-SBAR O
2 143 152 1967484 initially RB B-VP O
3 153 160 1967484 thought VBN I-VP O
4 161 163 1967484 to TO I-VP O
5 164 166 1967484 be VB I-VP O
6 167 171 1967484 free JJ B-ADJP O
7 172 174 1967484 of IN B-PP O
8 175 189 1967484 extrapyramidal JJ B-NP O
9 190 194 1967484 side NN I-NP O
10 195 202 1967484 effects NNS I-NP O
11 202 203 1967484 , , O O
12 204 213 1967484 sulpiride NN B-NP B-Chemical
13 213 214 1967484 - HYPH B-NP O
14 214 221 1967484 induced VBN I-NP O
15 222 229 1967484 tardive NN I-NP B-Disease
16 230 240 1967484 dyskinesia NN I-NP I-Disease
17 241 244 1967484 and CC I-NP O
18 245 257 1967484 parkinsonism NN I-NP B-Disease
19 258 262 1967484 have VBP B-VP O
20 263 267 1967484 been VBN I-VP O
21 268 276 1967484 reported VBN I-VP O
22 277 289 1967484 occasionally RB B-ADVP O
23 289 290 1967484 . . O O

1 291 293 1967484 We PRP B-NP O
2 294 301 1967484 studied VBD B-VP O
3 302 303 1967484 a DT B-NP O
4 304 306 1967484 37 CD I-NP O
5 306 307 1967484 - HYPH I-NP O
6 307 311 1967484 year NN I-NP O
7 311 312 1967484 - HYPH B-NP O
8 312 315 1967484 old JJ I-NP O
9 316 319 1967484 man NN I-NP O
10 320 323 1967484 who WP B-NP O
11 324 333 1967484 developed VBD B-VP O
12 334 344 1967484 persistent JJ B-NP O
13 345 354 1967484 segmental JJ I-NP O
14 355 363 1967484 dystonia NN I-NP B-Disease
15 364 370 1967484 within IN B-PP O
16 371 372 1967484 2 CD B-NP O
17 373 379 1967484 months NNS I-NP O
18 380 385 1967484 after IN B-PP O
19 386 394 1967484 starting VBG B-VP O
20 395 404 1967484 sulpiride NN B-NP B-Chemical
21 405 412 1967484 therapy NN I-NP O
22 412 413 1967484 . . O O

1 414 416 1967484 We PRP B-NP O
2 417 422 1967484 could MD B-VP O
3 423 426 1967484 not RB I-VP O
4 427 431 1967484 find VB I-VP O
5 432 435 1967484 any DT B-NP O
6 436 444 1967484 previous JJ I-NP O
7 445 452 1967484 reports NNS I-NP O
8 453 455 1967484 of IN B-PP O
9 456 465 1967484 sulpiride NN B-NP B-Chemical
10 465 466 1967484 - HYPH B-NP O
11 466 473 1967484 induced VBN I-NP O
12 474 481 1967484 tardive NN I-NP B-Disease
13 482 490 1967484 dystonia NN I-NP I-Disease
14 490 491 1967484 . . O O

1 0 0 8739323 -DOCSTART- -X- -X- O

1 0 6 8739323 Effect NN B-NP O
2 7 9 8739323 of IN B-PP O
3 10 14 8739323 some DT B-NP O
4 15 25 8739323 anticancer JJ I-NP O
5 26 31 8739323 drugs NNS I-NP O
6 32 35 8739323 and CC O O
7 36 44 8739323 combined JJ B-NP O
8 45 57 8739323 chemotherapy NN I-NP O
9 58 60 8739323 on IN B-PP O
10 61 66 8739323 renal JJ B-NP B-Disease
11 67 75 8739323 toxicity NN I-NP I-Disease
12 75 76 8739323 . . O O
13 77 80 8739323 The DT B-NP O
14 81 92 8739323 nephrotoxic JJ I-NP B-Disease
15 93 99 8739323 action NN I-NP O
16 100 102 8739323 of IN B-PP O
17 103 113 8739323 anticancer JJ B-NP O
18 114 119 8739323 drugs NNS I-NP O
19 120 124 8739323 such JJ B-PP O
20 125 127 8739323 as IN I-PP O
21 128 143 8739323 nitrogranulogen NN B-NP B-Chemical
22 144 145 8739323 ( ( O O
23 145 147 8739323 NG NN B-NP B-Chemical
24 147 148 8739323 ) ) O O
25 148 149 8739323 , , O O
26 150 162 8739323 methotrexate NN B-NP B-Chemical
27 163 164 8739323 ( ( O O
28 164 167 8739323 MTX NN B-NP B-Chemical
29 167 168 8739323 ) ) O O
30 168 169 8739323 , , O O
31 170 171 8739323 5 CD B-NP B-Chemical
32 171 172 8739323 - HYPH I-NP I-Chemical
33 172 184 8739323 fluorouracil NN I-NP I-Chemical
34 185 186 8739323 ( ( O O
35 186 187 8739323 5 CD B-NP B-Chemical
36 187 188 8739323 - HYPH I-NP I-Chemical
37 188 190 8739323 FU NN I-NP I-Chemical
38 190 191 8739323 ) ) O O
39 192 195 8739323 and CC O O
40 196 212 8739323 cyclophosphamide NN B-NP B-Chemical
41 213 214 8739323 ( ( O O
42 214 216 8739323 CY NN B-NP B-Chemical
43 216 217 8739323 ) ) O O
44 218 230 8739323 administered VBN B-VP O
45 231 236 8739323 alone RB B-ADVP O
46 237 239 8739323 or CC O O
47 240 242 8739323 in IN B-PP O
48 243 254 8739323 combination NN B-NP O
49 255 256 8739323 [ ( O O
50 256 259 8739323 MTX NN B-NP B-Chemical
51 260 261 8739323 + SYM O O
52 262 263 8739323 5 CD B-NP B-Chemical
53 263 264 8739323 - HYPH I-NP I-Chemical
54 264 266 8739323 FU NN I-NP I-Chemical
55 267 268 8739323 + SYM O O
56 269 271 8739323 CY NN B-NP B-Chemical
57 272 273 8739323 ( ( O O
58 273 276 8739323 CMF NN B-NP O
59 276 277 8739323 ) ) O O
60 277 278 8739323 ] ) O O
61 279 282 8739323 was VBD B-VP O
62 283 292 8739323 evaluated VBN I-VP O
63 293 295 8739323 in IN B-PP O
64 296 307 8739323 experiments NNS B-NP O
65 308 310 8739323 on IN B-PP O
66 311 317 8739323 Wistar NNP B-NP O
67 318 322 8739323 rats NNS I-NP O
68 322 323 8739323 . . O O

1 324 329 8739323 After IN B-PP O
2 330 334 8739323 drug NN B-NP O
3 335 349 8739323 administration NN I-NP O
4 349 350 8739323 , , O O
5 351 361 8739323 creatinine NN B-NP B-Chemical
6 362 376 8739323 concentrations NNS I-NP O
7 377 379 8739323 in IN B-PP O
8 380 383 8739323 the DT B-NP O
9 384 390 8739323 plasma NN I-NP O
10 391 394 8739323 and CC B-PP O
11 395 397 8739323 in IN B-PP O
12 398 401 8739323 the DT B-NP O
13 402 407 8739323 urine NN I-NP O
14 408 410 8739323 of IN B-PP O
15 411 414 8739323 the DT B-NP O
16 415 419 8739323 rats NNS I-NP O
17 420 424 8739323 were VBD B-VP O
18 425 435 8739323 determined VBN I-VP O
19 435 436 8739323 , , O O
20 437 439 8739323 as RB B-CONJP O
21 440 444 8739323 well RB I-CONJP O
22 445 447 8739323 as IN I-CONJP O
23 448 458 8739323 creatinine NN B-NP B-Chemical
24 459 468 8739323 clearance NN I-NP O
25 468 469 8739323 . . O O

1 470 485 8739323 Histopathologic JJ B-NP O
2 486 496 8739323 evaluation NN I-NP O
3 497 499 8739323 of IN B-PP O
4 500 503 8739323 the DT B-NP O
5 504 511 8739323 kidneys NNS I-NP O
6 512 515 8739323 was VBD B-VP O
7 516 520 8739323 also RB I-VP O
8 521 530 8739323 performed VBN I-VP O
9 530 531 8739323 . . O O

1 532 537 8739323 After IN B-PP O
2 538 541 8739323 MTX NN B-NP B-Chemical
3 542 556 8739323 administration NN I-NP O
4 557 558 8739323 a DT B-NP O
5 559 570 8739323 significant JJ I-NP O
6 571 579 8739323 increase NN I-NP O
7 580 581 8739323 ( ( O O
8 581 582 8739323 p NN B-NP O
9 583 584 8739323 = SYM B-VP O
10 585 591 8739323 0.0228 CD B-NP O
11 591 592 8739323 ) ) O O
12 593 595 8739323 in IN B-PP O
13 596 599 8739323 the DT B-NP O
14 600 606 8739323 plasma NN I-NP O
15 607 617 8739323 creatinine NN I-NP B-Chemical
16 618 631 8739323 concentration NN I-NP O
17 632 635 8739323 and CC O O
18 636 637 8739323 a DT B-NP O
19 638 649 8739323 significant JJ I-NP O
20 650 651 8739323 ( ( O O
21 651 652 8739323 p NN B-NP O
22 653 654 8739323 = SYM B-VP O
23 655 661 8739323 0.0001 CD B-NP O
24 661 662 8739323 ) ) O O
25 663 671 8739323 decrease NN B-NP O
26 672 674 8739323 in IN B-PP O
27 675 685 8739323 creatinine NN B-NP B-Chemical
28 686 695 8739323 clearance NN I-NP O
29 696 699 8739323 was VBD B-VP O
30 700 705 8739323 noted VBN I-VP O
31 706 714 8739323 compared VBN B-PP O
32 715 717 8739323 to TO B-PP O
33 718 726 8739323 controls NNS B-NP O
34 726 727 8739323 . . O O

1 728 733 8739323 After IN B-SBAR O
2 734 737 8739323 the DT B-NP O
3 738 752 8739323 administration NN I-NP O
4 753 755 8739323 of IN B-PP O
5 756 758 8739323 NG NN B-NP B-Chemical
6 758 759 8739323 , , O O
7 760 761 8739323 5 CD B-NP B-Chemical
8 761 762 8739323 - HYPH I-NP I-Chemical
9 762 764 8739323 FU NN I-NP I-Chemical
10 765 768 8739323 and CC I-NP O
11 769 771 8739323 CY NN I-NP B-Chemical
12 772 779 8739323 neither CC O O
13 780 781 8739323 a DT B-NP O
14 782 795 8739323 statistically RB I-NP O
15 796 807 8739323 significant JJ I-NP O
16 808 816 8739323 increase NN I-NP O
17 817 819 8739323 in IN B-PP O
18 820 830 8739323 creatinine NN B-NP B-Chemical
19 831 844 8739323 concentration NN I-NP O
20 845 848 8739323 nor CC O O
21 849 851 8739323 an DT B-NP O
22 852 860 8739323 increase NN I-NP O
23 861 863 8739323 in IN B-PP O
24 864 874 8739323 creatinine NN B-NP B-Chemical
25 875 884 8739323 clearance NN I-NP O
26 885 888 8739323 was VBD B-VP O
27 889 897 8739323 observed VBN I-VP O
28 898 906 8739323 compared VBN B-PP O
29 907 909 8739323 to TO B-PP O
30 910 913 8739323 the DT B-NP O
31 914 919 8739323 group NN I-NP O
32 920 929 8739323 receiving VBG B-VP O
33 930 932 8739323 no DT B-NP O
34 933 944 8739323 cytostatics NNS I-NP O
35 944 945 8739323 . . O O

1 946 955 8739323 Following VBG B-PP O
2 956 967 8739323 polytherapy NN B-NP O
3 968 977 8739323 according VBG B-PP O
4 978 980 8739323 to TO B-PP O
5 981 984 8739323 the DT B-NP O
6 985 988 8739323 CMF NN I-NP O
7 989 996 8739323 regimen NN I-NP O
8 996 997 8739323 , , O O
9 998 999 8739323 a DT B-NP O
10 1000 1013 8739323 statistically RB I-NP O
11 1014 1025 8739323 significant JJ I-NP O
12 1026 1034 8739323 decrease NN I-NP O
13 1035 1036 8739323 ( ( O O
14 1036 1037 8739323 p NN B-NP O
15 1038 1039 8739323 = SYM B-VP O
16 1040 1046 8739323 0.0343 CD B-NP O
17 1046 1047 8739323 ) ) O O
18 1048 1050 8739323 in IN B-PP O
19 1051 1061 8739323 creatinine NN B-NP B-Chemical
20 1062 1071 8739323 clearance NN I-NP O
21 1072 1075 8739323 was VBD B-VP O
22 1076 1081 8739323 found VBN I-VP O
23 1081 1082 8739323 , , O O
24 1083 1086 8739323 but CC O O
25 1087 1097 8739323 creatinine NN B-NP B-Chemical
26 1098 1111 8739323 concentration NN I-NP O
27 1112 1115 8739323 did VBD B-VP O
28 1116 1119 8739323 not RB I-VP O
29 1120 1128 8739323 increase VB I-VP O
30 1129 1142 8739323 significantly RB B-VP O
31 1143 1151 8739323 compared VBN I-VP O
32 1152 1154 8739323 to TO B-PP O
33 1155 1163 8739323 controls NNS B-NP O
34 1163 1164 8739323 . . O O

1 1165 1167 8739323 CY NN B-NP B-Chemical
2 1168 1174 8739323 caused VBD B-VP O
3 1175 1186 8739323 hemorrhagic JJ B-NP B-Disease
4 1187 1195 8739323 cystitis NN I-NP I-Disease
5 1196 1198 8739323 in IN B-PP O
6 1199 1202 8739323 40% CD B-NP O
7 1203 1205 8739323 of IN B-PP O
8 1206 1210 8739323 rats NNS B-NP O
9 1210 1211 8739323 , , O O
10 1212 1215 8739323 but CC O O
11 1216 1218 8739323 it PRP B-NP O
12 1219 1222 8739323 did VBD B-VP O
13 1223 1226 8739323 not RB I-VP O
14 1227 1232 8739323 cause VB I-VP O
15 1233 1237 8739323 this DT B-NP O
16 1238 1250 8739323 complication NN I-NP O
17 1251 1255 8739323 when WRB B-ADVP O
18 1256 1264 8739323 combined VBN B-VP O
19 1265 1269 8739323 with IN B-PP O
20 1270 1271 8739323 5 CD B-NP B-Chemical
21 1271 1272 8739323 - HYPH I-NP I-Chemical
22 1272 1274 8739323 FU NN I-NP I-Chemical
23 1275 1278 8739323 and CC I-NP O
24 1279 1282 8739323 MTX NN I-NP B-Chemical
25 1282 1283 8739323 . . O O

1 1284 1294 8739323 Histologic JJ B-NP O
2 1295 1302 8739323 changes NNS I-NP O
3 1303 1307 8739323 were VBD B-VP O
4 1308 1313 8739323 found VBN I-VP O
5 1314 1316 8739323 in IN B-PP O
6 1317 1320 8739323 rat NN B-NP O
7 1321 1328 8739323 kidneys NNS I-NP O
8 1329 1334 8739323 after IN B-PP O
9 1335 1349 8739323 administration NN B-NP O
10 1350 1352 8739323 of IN B-PP O
11 1353 1356 8739323 MTX NN B-NP B-Chemical
12 1356 1357 8739323 , , I-NP O
13 1358 1360 8739323 CY NN I-NP B-Chemical
14 1361 1364 8739323 and CC I-NP O
15 1365 1367 8739323 NG NN I-NP B-Chemical
16 1367 1368 8739323 , , O O
17 1369 1374 8739323 while IN B-SBAR O
18 1375 1377 8739323 no DT B-NP O
19 1378 1382 8739323 such JJ I-NP O
20 1383 1389 8739323 change NN I-NP O
21 1390 1393 8739323 was VBD B-VP O
22 1394 1402 8739323 observed VBN I-VP O
23 1403 1408 8739323 after IN B-PP O
24 1409 1410 8739323 5 CD B-NP B-Chemical
25 1410 1411 8739323 - HYPH I-NP I-Chemical
26 1411 1413 8739323 FU NN I-NP I-Chemical
27 1414 1417 8739323 and CC O O
28 1418 1423 8739323 joint JJ B-NP O
29 1424 1438 8739323 administration NN I-NP O
30 1439 1441 8739323 of IN B-PP O
31 1442 1445 8739323 MTX NN B-NP B-Chemical
32 1446 1447 8739323 + SYM B-NP O
33 1448 1449 8739323 5 CD I-NP B-Chemical
34 1449 1450 8739323 - HYPH I-NP I-Chemical
35 1450 1452 8739323 FU NN I-NP I-Chemical
36 1453 1454 8739323 + SYM B-NP O
37 1455 1457 8739323 CY NN I-NP B-Chemical
38 1458 1466 8739323 compared VBN B-VP O
39 1467 1469 8739323 to TO B-PP O
40 1470 1478 8739323 controls NNS B-NP O
41 1478 1479 8739323 . . O O

1 1480 1483 8739323 Our PRP$ B-NP O
2 1484 1491 8739323 studies NNS I-NP O
3 1492 1500 8739323 indicate VBP B-VP O
4 1501 1505 8739323 that IN B-SBAR O
5 1506 1520 8739323 nephrotoxicity NN B-NP B-Disease
6 1521 1523 8739323 of IN B-PP O
7 1524 1527 8739323 MTX NN B-NP B-Chemical
8 1528 1529 8739323 + SYM B-NP O
9 1530 1531 8739323 5 CD I-NP B-Chemical
10 1531 1532 8739323 - HYPH I-NP I-Chemical
11 1532 1534 8739323 FU NN I-NP I-Chemical
12 1535 1536 8739323 + SYM B-NP O
13 1537 1539 8739323 CY NN I-NP B-Chemical
14 1540 1552 8739323 administered VBN B-VP O
15 1553 1560 8739323 jointly RB B-ADVP O
16 1561 1563 8739323 is VBZ B-VP O
17 1564 1569 8739323 lower JJR B-ADJP O
18 1570 1574 8739323 than IN B-PP O
19 1575 1577 8739323 in IN B-PP O
20 1578 1589 8739323 monotherapy NN B-NP O
21 1589 1590 8739323 . . O O

1 0 0 14657095 -DOCSTART- -X- -X- O

1 0 10 14657095 Reversible JJ B-NP O
2 11 18 14657095 dilated JJ I-NP B-Disease
3 19 33 14657095 cardiomyopathy NN I-NP I-Disease
4 34 41 14657095 related VBN B-VP O
5 42 44 14657095 to TO B-PP O
6 45 57 14657095 amphotericin NN B-NP B-Chemical
7 58 59 14657095 B NN I-NP I-Chemical
8 60 67 14657095 therapy NN I-NP O
9 67 68 14657095 . . O O
10 69 71 14657095 We PRP B-NP O
11 72 80 14657095 describe VBP B-VP O
12 81 82 14657095 a DT B-NP O
13 83 90 14657095 patient NN I-NP O
14 91 94 14657095 who WP B-NP O
15 95 104 14657095 developed VBD B-VP O
16 105 112 14657095 dilated VBN I-VP B-Disease
17 113 127 14657095 cardiomyopathy NN B-NP I-Disease
18 128 131 14657095 and CC O O
19 132 140 14657095 clinical JJ B-NP O
20 141 151 14657095 congestive JJ I-NP O
21 152 157 14657095 heart NN I-NP B-Disease
22 158 165 14657095 failure NN I-NP I-Disease
23 166 171 14657095 after IN B-PP O
24 172 173 14657095 2 CD B-NP O
25 174 180 14657095 months NNS I-NP O
26 181 183 14657095 of IN B-PP O
27 184 191 14657095 therapy NN B-NP O
28 192 196 14657095 with IN B-PP O
29 197 209 14657095 amphotericin NN B-NP B-Chemical
30 210 211 14657095 B NN I-NP I-Chemical
31 212 213 14657095 ( ( O O
32 213 216 14657095 AmB NN B-NP B-Chemical
33 216 217 14657095 ) ) O O
34 218 221 14657095 for IN B-PP O
35 222 234 14657095 disseminated VBN B-NP O
36 235 253 14657095 coccidioidomycosis NN I-NP B-Disease
37 253 254 14657095 . . O O

1 255 258 14657095 His PRP$ B-NP O
2 259 276 14657095 echocardiographic JJ I-NP O
3 277 290 14657095 abnormalities NNS I-NP O
4 291 294 14657095 and CC O O
5 295 300 14657095 heart NN B-NP B-Disease
6 301 308 14657095 failure NN I-NP I-Disease
7 309 317 14657095 resolved VBN B-VP O
8 318 323 14657095 after IN B-PP O
9 324 336 14657095 posaconazole NN B-NP B-Chemical
10 337 340 14657095 was VBD B-VP O
11 341 352 14657095 substituted VBN I-VP O
12 353 356 14657095 for IN B-PP O
13 357 360 14657095 AmB NN B-NP B-Chemical
14 360 361 14657095 . . O O

1 362 364 14657095 It PRP B-NP O
2 365 367 14657095 is VBZ B-VP O
3 368 377 14657095 important JJ B-ADJP O
4 378 380 14657095 to TO B-VP O
5 381 390 14657095 recognize VB I-VP O
6 391 394 14657095 the DT B-NP O
7 395 399 14657095 rare JJ I-NP O
8 400 403 14657095 and CC I-NP O
9 404 415 14657095 potentially RB I-NP O
10 416 426 14657095 reversible JJ I-NP O
11 427 435 14657095 toxicity NN I-NP B-Disease
12 436 438 14657095 of IN B-PP O
13 439 442 14657095 AmB NN B-NP B-Chemical
14 442 443 14657095 . . O O

1 0 0 1749407 -DOCSTART- -X- -X- O

1 0 7 1749407 Cocaine NN B-NP B-Chemical
2 7 8 1749407 - HYPH O O
3 8 15 1749407 induced VBN B-NP O
4 16 26 1749407 myocardial JJ I-NP B-Disease
5 27 37 1749407 infarction NN I-NP I-Disease
6 37 38 1749407 : : O O
7 39 47 1749407 clinical JJ B-NP O
8 48 60 1749407 observations NNS I-NP O
9 61 64 1749407 and CC O O
10 65 77 1749407 pathogenetic JJ B-NP O
11 78 92 1749407 considerations NNS I-NP O
12 92 93 1749407 . . O O
13 94 102 1749407 Clinical JJ B-NP O
14 103 106 1749407 and CC I-NP O
15 107 119 1749407 experimental JJ I-NP O
16 120 124 1749407 data NNS I-NP O
17 125 134 1749407 published VBN B-VP O
18 135 137 1749407 to TO B-PP O
19 138 142 1749407 date NN B-NP O
20 143 150 1749407 suggest VBP B-VP O
21 151 158 1749407 several JJ B-NP O
22 159 167 1749407 possible JJ I-NP O
23 168 178 1749407 mechanisms NNS I-NP O
24 179 181 1749407 by IN B-PP O
25 182 187 1749407 which WDT B-NP O
26 188 195 1749407 cocaine NN B-NP B-Chemical
27 196 199 1749407 may MD B-VP O
28 200 206 1749407 result VB I-VP O
29 207 209 1749407 in IN B-PP O
30 210 215 1749407 acute JJ B-NP B-Disease
31 216 226 1749407 myocardial JJ I-NP I-Disease
32 227 237 1749407 infarction NN I-NP I-Disease
33 237 238 1749407 . . O O

1 239 241 1749407 In IN B-PP O
2 242 253 1749407 individuals NNS B-NP O
3 254 258 1749407 with IN B-PP O
4 259 270 1749407 preexisting JJ B-NP O
5 270 271 1749407 , , I-NP O
6 272 276 1749407 high JJ I-NP O
7 276 277 1749407 - HYPH I-NP O
8 277 282 1749407 grade NN I-NP O
9 283 291 1749407 coronary JJ I-NP O
10 292 300 1749407 arterial JJ I-NP O
11 301 310 1749407 narrowing NN I-NP O
12 310 311 1749407 , , O O
13 312 317 1749407 acute JJ B-NP B-Disease
14 318 328 1749407 myocardial JJ I-NP I-Disease
15 329 339 1749407 infarction NN I-NP I-Disease
16 340 343 1749407 may MD B-VP O
17 344 350 1749407 result VB I-VP O
18 351 355 1749407 from IN B-PP O
19 356 358 1749407 an DT B-NP O
20 359 367 1749407 increase NN I-NP O
21 368 370 1749407 in IN B-PP O
22 371 381 1749407 myocardial JJ B-NP O
23 382 388 1749407 oxygen NN I-NP B-Chemical
24 389 395 1749407 demand NN I-NP O
25 396 406 1749407 associated VBN B-VP O
26 407 411 1749407 with IN B-PP O
27 412 419 1749407 cocaine NN B-NP B-Chemical
28 419 420 1749407 - HYPH B-NP O
29 420 427 1749407 induced VBN I-NP O
30 428 436 1749407 increase NN I-NP O
31 437 439 1749407 in IN B-PP O
32 440 444 1749407 rate NN B-NP O
33 444 445 1749407 - HYPH B-NP O
34 445 453 1749407 pressure NN I-NP O
35 454 461 1749407 product NN I-NP O
36 461 462 1749407 . . O O

1 463 465 1749407 In IN B-PP O
2 466 471 1749407 other JJ B-NP O
3 472 483 1749407 individuals NNS I-NP O
4 484 488 1749407 with IN B-PP O
5 489 491 1749407 no DT B-NP O
6 492 502 1749407 underlying VBG I-NP O
7 503 518 1749407 atherosclerotic JJ I-NP B-Disease
8 519 530 1749407 obstruction NN I-NP I-Disease
9 530 531 1749407 , , O O
10 532 540 1749407 coronary JJ B-NP B-Disease
11 541 550 1749407 occlusion NN I-NP I-Disease
12 551 554 1749407 may MD B-VP O
13 555 557 1749407 be VB I-VP O
14 558 561 1749407 due JJ B-ADJP O
15 562 564 1749407 to TO B-PP O
16 565 570 1749407 spasm NN B-NP B-Disease
17 570 571 1749407 , , O O
18 572 580 1749407 thrombus NN B-NP B-Disease
19 580 581 1749407 , , O O
20 582 584 1749407 or CC O O
21 585 589 1749407 both DT B-NP O
22 589 590 1749407 . . O O

1 591 595 1749407 With IN B-PP O
2 596 602 1749407 regard NN B-NP O
3 603 605 1749407 to TO B-PP O
4 606 611 1749407 spasm NN B-NP B-Disease
5 611 612 1749407 , , O O
6 613 616 1749407 the DT B-NP O
7 617 625 1749407 clinical JJ I-NP O
8 626 634 1749407 findings NNS I-NP O
9 635 638 1749407 are VBP B-VP O
10 639 646 1749407 largely RB B-ADJP O
11 647 661 1749407 circumstantial JJ I-ADJP O
12 661 662 1749407 , , O O
13 663 666 1749407 and CC O O
14 667 670 1749407 the DT B-NP O
15 671 676 1749407 locus NN I-NP O
16 677 679 1749407 of IN B-PP O
17 680 687 1749407 cocaine NN B-NP B-Chemical
18 687 688 1749407 - HYPH B-NP O
19 688 695 1749407 induced VBN I-NP O
20 696 712 1749407 vasoconstriction NN I-NP O
21 713 720 1749407 remains VBZ B-VP O
22 721 732 1749407 speculative JJ B-ADJP O
23 732 733 1749407 . . O O

1 734 742 1749407 Although IN B-SBAR O
2 743 750 1749407 certain JJ B-NP O
3 751 759 1749407 clinical JJ I-NP O
4 760 763 1749407 and CC I-NP O
5 764 776 1749407 experimental JJ I-NP O
6 777 785 1749407 findings NNS I-NP O
7 786 793 1749407 support VBP B-VP O
8 794 797 1749407 the DT B-NP O
9 798 808 1749407 hypothesis NN I-NP O
10 809 813 1749407 that IN B-SBAR O
11 814 819 1749407 spasm NN B-NP B-Disease
12 820 828 1749407 involves VBZ B-VP O
13 829 832 1749407 the DT B-NP O
14 833 843 1749407 epicardial JJ I-NP O
15 843 844 1749407 , , I-NP O
16 845 851 1749407 medium JJ I-NP O
17 851 852 1749407 - HYPH I-NP O
18 852 856 1749407 size NN I-NP O
19 857 864 1749407 vessels NNS I-NP O
20 864 865 1749407 , , O O
21 866 871 1749407 other JJ B-NP O
22 872 876 1749407 data NNS I-NP O
23 877 884 1749407 suggest VBP B-VP O
24 885 895 1749407 intramural JJ B-NP O
25 896 912 1749407 vasoconstriction NN I-NP O
26 912 913 1749407 . . O O

1 914 921 1749407 Diffuse NN B-NP O
2 922 932 1749407 intramural JJ I-NP O
3 933 949 1749407 vasoconstriction NN I-NP O
4 950 952 1749407 is VBZ B-VP O
5 953 956 1749407 not RB O O
6 957 967 1749407 consistent JJ B-ADJP O
7 968 972 1749407 with IN B-PP O
8 973 980 1749407 reports NNS B-NP O
9 981 983 1749407 of IN B-PP O
10 984 993 1749407 segmental JJ B-NP O
11 993 994 1749407 , , I-NP O
12 995 1003 1749407 discrete JJ I-NP O
13 1004 1014 1749407 infarction NN I-NP B-Disease
14 1014 1015 1749407 . . O O

1 1016 1023 1749407 Whereas IN B-PP O
2 1024 1031 1749407 certain JJ B-NP O
3 1032 1034 1749407 in FW I-NP O
4 1035 1039 1749407 vivo FW I-NP O
5 1040 1044 1749407 data NNS I-NP O
6 1045 1052 1749407 suggest VBP B-VP O
7 1053 1057 1749407 that IN B-SBAR O
8 1058 1063 1749407 these DT B-NP O
9 1064 1071 1749407 effects NNS I-NP O
10 1072 1075 1749407 are VBP B-VP O
11 1076 1081 1749407 alpha SYM B-NP O
12 1081 1082 1749407 - HYPH O O
13 1082 1090 1749407 mediated VBN B-VP O
14 1090 1091 1749407 , , O O
15 1092 1097 1749407 other JJ B-NP O
16 1098 1100 1749407 in FW I-NP O
17 1101 1106 1749407 vitro FW I-NP O
18 1107 1111 1749407 data NNS I-NP O
19 1112 1119 1749407 suggest VBP B-VP O
20 1120 1123 1749407 the DT B-NP O
21 1124 1132 1749407 opposite NN I-NP O
22 1132 1133 1749407 . . O O

1 1134 1137 1749407 The DT B-NP O
2 1138 1145 1749407 finding NN I-NP O
3 1146 1148 1749407 of IN B-PP O
4 1149 1156 1749407 cocaine NN B-NP B-Chemical
5 1156 1157 1749407 - HYPH B-NP O
6 1157 1164 1749407 induced VBN I-NP O
7 1165 1181 1749407 vasoconstriction NN I-NP O
8 1182 1184 1749407 in IN B-PP O
9 1185 1193 1749407 segments NNS B-NP O
10 1194 1196 1749407 of IN B-PP O
11 1197 1198 1749407 ( ( O O
12 1198 1211 1749407 noninnervated JJ B-ADJP O
13 1211 1212 1749407 ) ) O O
14 1213 1218 1749407 human JJ B-NP O
15 1219 1228 1749407 umbilical JJ I-NP O
16 1229 1235 1749407 artery NN I-NP O
17 1236 1244 1749407 suggests VBZ B-VP O
18 1245 1249 1749407 that IN B-SBAR O
19 1250 1253 1749407 the DT B-NP O
20 1254 1262 1749407 presence NN I-NP O
21 1263 1265 1749407 or CC I-NP O
22 1266 1273 1749407 absence NN I-NP O
23 1274 1276 1749407 of IN B-PP O
24 1277 1283 1749407 intact JJ B-NP O
25 1284 1295 1749407 innervation NN I-NP O
26 1296 1298 1749407 is VBZ B-VP O
27 1299 1302 1749407 not RB O O
28 1303 1313 1749407 sufficient JJ B-ADJP O
29 1314 1316 1749407 to TO B-VP O
30 1317 1324 1749407 explain VB I-VP O
31 1325 1328 1749407 the DT B-NP O
32 1329 1339 1749407 discrepant JJ I-NP O
33 1340 1344 1749407 data NNS I-NP O
34 1345 1354 1749407 involving VBG B-VP O
35 1355 1358 1749407 the DT B-NP O
36 1359 1370 1749407 possibility NN I-NP O
37 1371 1373 1749407 of IN B-PP O
38 1374 1379 1749407 alpha SYM B-NP O
39 1379 1380 1749407 - HYPH B-NP O
40 1380 1388 1749407 mediated VBN I-NP O
41 1389 1396 1749407 effects NNS I-NP O
42 1396 1397 1749407 . . O O

1 1398 1405 1749407 Finally RB B-ADVP O
2 1405 1406 1749407 , , O O
3 1407 1410 1749407 the DT B-NP O
4 1411 1423 1749407 contribution NN I-NP O
5 1424 1426 1749407 of IN B-PP O
6 1427 1428 1749407 a DT B-NP O
7 1429 1436 1749407 primary JJ I-NP O
8 1436 1437 1749407 , , I-NP O
9 1438 1448 1749407 thrombotic JJ I-NP B-Disease
10 1449 1455 1749407 effect NN I-NP O
11 1456 1458 1749407 of IN B-PP O
12 1459 1466 1749407 cocaine NN B-NP B-Chemical
13 1467 1470 1749407 has VBZ B-VP O
14 1471 1474 1749407 not RB I-VP O
15 1475 1479 1749407 been VBN I-VP O
16 1480 1488 1749407 excluded VBN I-VP O
17 1488 1489 1749407 . . O O

1 0 0 3371379 -DOCSTART- -X- -X- O

1 0 9 3371379 Verapamil NN B-NP B-Chemical
2 9 10 3371379 - HYPH B-NP O
3 10 17 3371379 induced VBN I-NP O
4 18 31 3371379 carbamazepine NN I-NP B-Chemical
5 32 45 3371379 neurotoxicity NN I-NP B-Disease
6 45 46 3371379 . . O O

1 47 48 3371379 A DT B-NP O
2 49 55 3371379 report NN I-NP O
3 56 58 3371379 of IN B-PP O
4 59 62 3371379 two CD B-NP O
5 63 68 3371379 cases NNS I-NP O
6 68 69 3371379 . . O O
7 70 73 3371379 Two CD B-NP O
8 74 82 3371379 patients NNS I-NP O
9 83 87 3371379 with IN B-PP O
10 88 93 3371379 signs NNS B-NP O
11 94 96 3371379 of IN B-PP O
12 97 110 3371379 carbamazepine NN B-NP B-Chemical
13 111 124 3371379 neurotoxicity NN I-NP B-Disease
14 125 130 3371379 after IN B-PP O
15 131 139 3371379 combined JJ B-NP O
16 140 149 3371379 treatment NN I-NP O
17 150 154 3371379 with IN B-PP O
18 155 164 3371379 verapamil NN B-NP B-Chemical
19 165 171 3371379 showed VBD B-VP O
20 172 180 3371379 complete JJ B-NP O
21 181 189 3371379 recovery NN I-NP O
22 190 195 3371379 after IN B-PP O
23 196 211 3371379 discontinuation NN B-NP O
24 212 214 3371379 of IN B-PP O
25 215 218 3371379 the DT B-NP O
26 219 226 3371379 calcium NN I-NP B-Chemical
27 227 232 3371379 entry NN I-NP O
28 233 240 3371379 blocker NN I-NP O
29 240 241 3371379 . . O O

1 242 245 3371379 Use NN B-NP O
2 246 248 3371379 of IN B-PP O
3 249 258 3371379 verapamil NN B-NP B-Chemical
4 259 261 3371379 in IN B-PP O
5 262 273 3371379 combination NN B-NP O
6 274 278 3371379 with IN B-PP O
7 279 292 3371379 carbamazepine NN B-NP B-Chemical
8 293 299 3371379 should MD B-VP O
9 300 306 3371379 either RB I-VP O
10 307 309 3371379 be VB I-VP O
11 310 317 3371379 avoided VBN I-VP O
12 318 320 3371379 or CC I-VP O
13 321 331 3371379 prescribed VBN I-VP O
14 332 336 3371379 only RB B-ADVP O
15 337 341 3371379 with IN B-PP O
16 342 353 3371379 appropriate JJ B-NP O
17 354 364 3371379 adjustment NN I-NP O
18 365 367 3371379 of IN B-PP O
19 368 371 3371379 the DT B-NP O
20 372 385 3371379 carbamazepine NN I-NP B-Chemical
21 386 390 3371379 dose NN I-NP O
22 391 392 3371379 ( ( O O
23 392 399 3371379 usually RB B-ADVP O
24 400 409 3371379 reduction NN B-NP O
25 410 412 3371379 of IN B-PP O
26 413 416 3371379 the DT B-NP O
27 417 430 3371379 carbamazepine NN I-NP B-Chemical
28 431 435 3371379 dose NN I-NP O
29 436 438 3371379 by IN B-PP O
30 439 442 3371379 one CD B-NP O
31 443 447 3371379 half NN I-NP O
32 447 448 3371379 ) ) O O
33 448 449 3371379 . . O O

1 0 0 16428221 -DOCSTART- -X- -X- O

1 0 8 16428221 Cerebral JJ B-NP B-Disease
2 9 19 16428221 vasculitis NN I-NP I-Disease
3 20 29 16428221 following VBG B-PP O
4 30 34 16428221 oral JJ B-NP O
5 35 50 16428221 methylphenidate NN I-NP B-Chemical
6 51 57 16428221 intake NN I-NP O
7 58 60 16428221 in IN B-PP O
8 61 63 16428221 an DT B-NP O
9 64 69 16428221 adult NN I-NP O
10 69 70 16428221 : : O O
11 71 72 16428221 a DT B-NP O
12 73 77 16428221 case NN I-NP O
13 78 84 16428221 report NN I-NP O
14 84 85 16428221 . . I-NP O
15 86 101 16428221 Methylphenidate NN I-NP B-Chemical
16 102 104 16428221 is VBZ B-VP O
17 105 117 16428221 structurally RB B-ADJP O
18 118 121 16428221 and CC I-ADJP O
19 122 134 16428221 functionally RB I-ADJP O
20 135 142 16428221 similar JJ I-ADJP O
21 143 145 16428221 to TO B-PP O
22 146 157 16428221 amphetamine NN B-NP B-Chemical
23 157 158 16428221 . . O O

1 159 167 16428221 Cerebral JJ B-NP B-Disease
2 168 178 16428221 vasculitis NN I-NP I-Disease
3 179 189 16428221 associated VBN B-VP O
4 190 194 16428221 with IN B-PP O
5 195 206 16428221 amphetamine NN B-NP B-Disease
6 207 212 16428221 abuse NN I-NP I-Disease
7 213 215 16428221 is VBZ B-VP O
8 216 220 16428221 well RB I-VP O
9 221 231 16428221 documented VBN I-VP O
10 231 232 16428221 , , O O
11 233 236 16428221 and CC O O
12 237 239 16428221 in IN B-PP O
13 240 244 16428221 rare JJ B-NP O
14 245 250 16428221 cases NNS I-NP O
15 251 260 16428221 ischaemic JJ B-NP B-Disease
16 261 267 16428221 stroke NN I-NP I-Disease
17 268 271 16428221 has VBZ B-VP O
18 272 276 16428221 been VBN I-VP O
19 277 285 16428221 reported VBN I-VP O
20 286 291 16428221 after IN B-PP O
21 292 307 16428221 methylphenidate NN B-NP B-Chemical
22 308 314 16428221 intake NN I-NP O
23 315 317 16428221 in IN B-PP O
24 318 326 16428221 children NNS B-NP O
25 326 327 16428221 . . O O

1 328 330 16428221 We PRP B-NP O
2 331 337 16428221 report VBP B-VP O
3 338 341 16428221 the DT B-NP O
4 342 346 16428221 case NN I-NP O
5 347 349 16428221 of IN B-PP O
6 350 351 16428221 a DT B-NP O
7 352 354 16428221 63 CD I-NP O
8 354 355 16428221 - HYPH I-NP O
9 355 359 16428221 year NN I-NP O
10 359 360 16428221 - HYPH B-NP O
11 360 363 16428221 old JJ I-NP O
12 364 370 16428221 female NN I-NP O
13 371 374 16428221 who WP B-NP O
14 375 378 16428221 was VBD B-VP O
15 379 386 16428221 treated VBN I-VP O
16 387 391 16428221 with IN B-PP O
17 392 407 16428221 methylphenidate NN B-NP B-Chemical
18 408 411 16428221 due JJ B-ADJP O
19 412 414 16428221 to TO B-PP O
20 415 428 16428221 hyperactivity NN B-NP B-Disease
21 429 432 16428221 and CC O O
22 433 441 16428221 suffered VBD B-VP O
23 442 446 16428221 from IN B-PP O
24 447 455 16428221 multiple JJ B-NP O
25 456 465 16428221 ischaemic JJ I-NP B-Disease
26 466 473 16428221 strokes NNS I-NP I-Disease
27 473 474 16428221 . . O O

1 475 477 16428221 We PRP B-NP O
2 478 486 16428221 consider VBP B-VP O
3 487 491 16428221 drug NN B-NP O
4 491 492 16428221 - HYPH O O
5 492 499 16428221 induced VBN B-NP O
6 500 508 16428221 cerebral JJ I-NP B-Disease
7 509 519 16428221 vasculitis NN I-NP I-Disease
8 520 522 16428221 as IN B-PP O
9 523 526 16428221 the DT B-NP O
10 527 531 16428221 most RBS I-NP O
11 532 538 16428221 likely JJ I-NP O
12 539 544 16428221 cause NN I-NP O
13 545 547 16428221 of IN B-PP O
14 548 557 16428221 recurrent JJ B-NP O
15 558 567 16428221 ischaemic JJ I-NP B-Disease
16 568 575 16428221 strokes NNS I-NP I-Disease
17 576 578 16428221 in IN B-PP O
18 579 582 16428221 the DT B-NP O
19 583 590 16428221 absence NN I-NP O
20 591 593 16428221 of IN B-PP O
21 594 597 16428221 any DT B-NP O
22 598 610 16428221 pathological JJ I-NP O
23 611 619 16428221 findings NNS I-NP O
24 620 626 16428221 during IN B-PP O
25 627 630 16428221 the DT B-NP O
26 631 641 16428221 diagnostic JJ I-NP O
27 642 646 16428221 work NN I-NP O
28 646 647 16428221 - HYPH B-VP O
29 647 649 16428221 up RP B-PRT O
30 649 650 16428221 . . O O

1 651 653 16428221 We PRP B-NP O
2 654 662 16428221 conclude VBP B-VP O
3 663 667 16428221 that IN B-SBAR O
4 668 683 16428221 methylphenidate NN B-NP B-Chemical
5 684 692 16428221 mediated VBN I-NP O
6 693 703 16428221 vasculitis NN I-NP B-Disease
7 704 710 16428221 should MD B-VP O
8 711 713 16428221 be VB I-VP O
9 714 724 16428221 considered VBN I-VP O
10 725 727 16428221 in IN B-PP O
11 728 736 16428221 patients NNS B-NP O
12 737 741 16428221 with IN B-PP O
13 742 754 16428221 neurological JJ B-NP O
14 755 763 16428221 symptoms NNS I-NP O
15 764 767 16428221 and CC O O
16 768 769 16428221 a DT B-NP O
17 770 777 16428221 history NN I-NP O
18 778 780 16428221 of IN B-PP O
19 781 796 16428221 methylphenidate NN B-NP B-Chemical
20 797 804 16428221 therapy NN I-NP O
21 804 805 16428221 . . O O

1 806 810 16428221 This DT B-NP O
2 811 820 16428221 potential JJ I-NP O
3 821 825 16428221 side NN I-NP O
4 825 826 16428221 - HYPH B-NP O
5 826 832 16428221 effect NN I-NP O
6 832 833 16428221 , , O O
7 834 840 16428221 though IN B-SBAR O
8 841 845 16428221 very RB B-ADJP O
9 846 850 16428221 rare JJ I-ADJP O
10 850 851 16428221 , , O O
11 852 862 16428221 represents VBZ B-VP O
12 863 866 16428221 one CD B-NP O
13 867 871 16428221 more JJR I-NP O
14 872 878 16428221 reason NN I-NP O
15 879 881 16428221 to TO B-VP O
16 882 884 16428221 be VB I-VP O
17 885 889 16428221 very RB B-ADJP O
18 890 901 16428221 restrictive JJ I-ADJP O
19 902 904 16428221 in IN B-PP O
20 905 908 16428221 the DT B-NP O
21 909 912 16428221 use NN I-NP O
22 913 915 16428221 of IN B-PP O
23 916 931 16428221 methylphenidate NN B-NP B-Chemical
24 931 932 16428221 . . O O

1 0 0 19308880 -DOCSTART- -X- -X- O

1 0 9 19308880 Confusion NN B-NP B-Disease
2 9 10 19308880 , , O O
3 11 12 19308880 a DT B-NP O
4 13 19 19308880 rather RB I-NP O
5 20 27 19308880 serious JJ I-NP O
6 28 35 19308880 adverse JJ I-NP O
7 36 40 19308880 drug NN I-NP O
8 41 49 19308880 reaction NN I-NP O
9 50 54 19308880 with IN B-PP O
10 55 63 19308880 valproic JJ B-NP B-Chemical
11 64 68 19308880 acid NN I-NP I-Chemical
12 68 69 19308880 : : O O
13 70 71 19308880 a DT B-NP O
14 72 78 19308880 review NN I-NP O
15 79 81 19308880 of IN B-PP O
16 82 85 19308880 the DT B-NP O
17 86 92 19308880 French JJ I-NP O
18 93 110 19308880 Pharmacovigilance NN I-NP O
19 111 119 19308880 database NN I-NP O
20 119 120 19308880 . . I-NP O
21 121 133 19308880 INTRODUCTION NN I-NP O
22 133 134 19308880 : : O O
23 135 144 19308880 Confusion NN B-NP B-Disease
24 145 147 19308880 is VBZ B-VP O
25 148 150 19308880 an DT B-NP O
26 151 158 19308880 adverse JJ I-NP O
27 159 163 19308880 drug NN I-NP O
28 164 172 19308880 reaction NN I-NP O
29 173 183 19308880 frequently RB B-VP O
30 184 192 19308880 observed VBN I-VP O
31 193 197 19308880 with IN B-PP O
32 198 206 19308880 valproic JJ B-NP B-Chemical
33 207 211 19308880 acid NN I-NP I-Chemical
34 211 212 19308880 . . O O

1 213 217 19308880 Some DT B-NP O
2 218 222 19308880 case NN I-NP O
3 223 230 19308880 reports NNS I-NP O
4 231 234 19308880 are VBP B-VP O
5 235 244 19308880 published VBN I-VP O
6 245 247 19308880 in IN B-PP O
7 248 251 19308880 the DT B-NP O
8 252 262 19308880 literature NN I-NP O
9 263 266 19308880 but CC O O
10 267 269 19308880 no DT B-NP O
11 270 280 19308880 systematic JJ I-NP O
12 281 286 19308880 study NN I-NP O
13 287 291 19308880 from IN B-PP O
14 292 293 19308880 a DT B-NP O
15 294 300 19308880 sample NN I-NP O
16 301 303 19308880 of IN B-PP O
17 304 312 19308880 patients NNS B-NP O
18 313 316 19308880 has VBZ B-VP O
19 317 321 19308880 been VBN I-VP O
20 322 331 19308880 published VBN I-VP O
21 331 332 19308880 . . O O

1 333 335 19308880 We PRP B-NP O
2 336 345 19308880 performed VBD B-VP O
3 346 350 19308880 this DT B-NP O
4 351 356 19308880 study NN I-NP O
5 357 359 19308880 in IN B-SBAR O
6 360 365 19308880 order NN O O
7 366 368 19308880 to TO B-VP O
8 369 377 19308880 describe VB I-VP O
9 378 381 19308880 the DT B-NP O
10 382 386 19308880 main JJ I-NP O
11 387 402 19308880 characteristics NNS I-NP O
12 403 405 19308880 of IN B-PP O
13 406 410 19308880 this DT B-NP O
14 411 418 19308880 adverse JJ I-NP O
15 419 423 19308880 drug NN I-NP O
16 424 432 19308880 reaction NN I-NP O
17 432 433 19308880 . . O O

1 434 441 19308880 METHODS NNS B-NP O
2 441 442 19308880 : : O O
3 443 448 19308880 Using VBG B-VP O
4 449 452 19308880 the DT B-NP O
5 453 459 19308880 French JJ I-NP O
6 460 477 19308880 Pharmacovigilance NN I-NP O
7 478 486 19308880 database NN I-NP O
8 486 487 19308880 , , O O
9 488 490 19308880 we PRP B-NP O
10 491 499 19308880 selected VBD B-VP O
11 500 503 19308880 the DT B-NP O
12 504 509 19308880 cases NNS I-NP O
13 510 512 19308880 of IN B-PP O
14 513 522 19308880 confusion NN B-NP B-Disease
15 523 531 19308880 reported VBD B-VP O
16 532 537 19308880 since IN B-PP O
17 538 542 19308880 1985 CD B-NP O
18 543 547 19308880 with IN B-PP O
19 548 556 19308880 valproic JJ B-NP B-Chemical
20 557 561 19308880 acid NN I-NP I-Chemical
21 561 562 19308880 . . O O

1 563 570 19308880 RESULTS NNS B-NP O
2 570 571 19308880 : : O O
3 572 575 19308880 272 CD B-NP O
4 576 581 19308880 cases NNS I-NP O
5 582 584 19308880 of IN B-PP O
6 585 594 19308880 confusion NN B-NP B-Disease
7 595 599 19308880 were VBD B-VP O
8 600 608 19308880 reported VBN I-VP O
9 609 613 19308880 with IN B-PP O
10 614 622 19308880 valproic JJ B-NP B-Chemical
11 623 627 19308880 acid NN I-NP I-Chemical
12 627 628 19308880 : : O O
13 629 632 19308880 153 CD B-NP O
14 633 638 19308880 women NNS I-NP O
15 639 642 19308880 and CC O O
16 643 646 19308880 119 CD B-NP O
17 647 650 19308880 men NNS I-NP O
18 650 651 19308880 . . O O

1 652 661 19308880 Confusion NN B-NP B-Disease
2 662 668 19308880 mostly RB B-ADVP O
3 669 677 19308880 occurred VBD B-VP O
4 678 684 19308880 during IN B-PP O
5 685 688 19308880 the DT B-NP O
6 689 692 19308880 two CD I-NP O
7 693 698 19308880 first JJ I-NP O
8 699 704 19308880 weeks NNS I-NP O
9 705 714 19308880 following VBG B-PP O
10 715 723 19308880 valproic JJ B-NP B-Chemical
11 724 728 19308880 acid NN I-NP I-Chemical
12 729 737 19308880 exposure NN I-NP O
13 738 739 19308880 ( ( O O
14 739 744 19308880 39.7% NN B-NP O
15 744 745 19308880 ) ) O O
16 745 746 19308880 . . O O

1 747 749 19308880 It PRP B-NP O
2 750 753 19308880 was VBD B-VP O
3 754 755 19308880 " `` B-ADJP O
4 755 762 19308880 serious JJ I-ADJP O
5 762 763 19308880 " '' O O
6 764 767 19308880 for IN B-PP O
7 768 774 19308880 almost RB B-NP O
8 775 776 19308880 2 CD I-NP O
9 776 777 19308880 / SYM I-NP O
10 777 778 19308880 3 CD I-NP O
11 779 781 19308880 of IN B-PP O
12 782 785 19308880 the DT B-NP O
13 786 794 19308880 patients NNS I-NP O
14 795 796 19308880 ( ( O O
15 796 801 19308880 62.5% CD B-NP O
16 801 802 19308880 ) ) O O
17 803 806 19308880 and CC O O
18 807 810 19308880 its PRP$ B-NP O
19 811 818 19308880 outcome NN I-NP O
20 819 829 19308880 favourable JJ B-ADJP O
21 830 832 19308880 in IN B-PP O
22 833 837 19308880 most JJS B-NP O
23 838 840 19308880 of IN B-PP O
24 841 844 19308880 the DT B-NP O
25 845 850 19308880 cases NNS I-NP O
26 851 852 19308880 ( ( O O
27 852 855 19308880 82% CD B-NP O
28 855 856 19308880 ) ) O O
29 856 857 19308880 . . O O

1 858 861 19308880 The DT B-NP O
2 862 872 19308880 occurrence NN I-NP O
3 873 875 19308880 of IN B-PP O
4 876 880 19308880 this DT B-NP O
5 881 884 19308880 ADR NN I-NP O
6 885 888 19308880 was VBD B-VP O
7 889 893 19308880 more RBR B-ADJP O
8 894 902 19308880 frequent JJ I-ADJP O
9 903 905 19308880 in IN B-PP O
10 906 914 19308880 patients NNS B-NP O
11 915 919 19308880 aged JJ B-ADJP O
12 920 927 19308880 between IN B-PP O
13 928 930 19308880 61 CD B-NP O
14 931 934 19308880 and CC I-NP O
15 935 937 19308880 80 CD I-NP O
16 938 943 19308880 years NNS I-NP O
17 943 944 19308880 . . O O

1 945 955 19308880 CONCLUSION NN B-NP O
2 955 956 19308880 : : O O
3 957 961 19308880 This DT B-NP O
4 962 966 19308880 work NN I-NP O
5 967 972 19308880 shows VBZ B-VP O
6 973 977 19308880 that IN B-SBAR O
7 978 987 19308880 confusion NN B-NP B-Disease
8 988 992 19308880 with IN B-PP O
9 993 1001 19308880 valproic JJ B-NP B-Chemical
10 1002 1006 19308880 acid NN I-NP I-Chemical
11 1007 1009 19308880 is VBZ B-VP O
12 1010 1011 19308880 a DT B-NP O
13 1012 1019 19308880 serious JJ I-NP O
14 1019 1020 19308880 , , I-NP O
15 1021 1027 19308880 rather RB I-NP O
16 1028 1036 19308880 frequent JJ I-NP O
17 1037 1040 19308880 but CC I-NP O
18 1041 1051 19308880 reversible JJ I-NP O
19 1052 1059 19308880 adverse JJ I-NP O
20 1060 1064 19308880 drug NN I-NP O
21 1065 1073 19308880 reaction NN I-NP O
22 1073 1074 19308880 . . O O

1 1075 1077 19308880 It PRP B-NP O
2 1078 1084 19308880 occurs VBZ B-VP O
3 1085 1095 19308880 especially RB B-ADVP O
4 1096 1098 19308880 in IN B-PP O
5 1099 1104 19308880 older JJR B-NP O
6 1105 1113 19308880 patients NNS I-NP O
7 1114 1117 19308880 and CC B-PP O
8 1118 1124 19308880 during IN B-PP O
9 1125 1128 19308880 the DT B-NP O
10 1129 1134 19308880 first JJ I-NP O
11 1135 1138 19308880 two CD I-NP O
12 1139 1144 19308880 weeks NNS I-NP O
13 1145 1147 19308880 of IN B-PP O
14 1148 1157 19308880 treatment NN B-NP O
15 1157 1158 19308880 . . O O

1 0 0 12041669 -DOCSTART- -X- -X- O

1 0 13 12041669 Antithymocyte NN B-NP B-Chemical
2 14 22 12041669 globulin NN I-NP I-Chemical
3 23 25 12041669 in IN B-PP O
4 26 29 12041669 the DT B-NP O
5 30 39 12041669 treatment NN I-NP O
6 40 42 12041669 of IN B-PP O
7 43 44 12041669 D NN B-NP B-Chemical
8 44 45 12041669 - HYPH B-NP I-Chemical
9 45 58 12041669 penicillamine NN I-NP I-Chemical
10 58 59 12041669 - HYPH O O
11 59 66 12041669 induced VBN B-NP O
12 67 75 12041669 aplastic JJ I-NP B-Disease
13 76 82 12041669 anemia NN I-NP I-Disease
14 82 83 12041669 . . O O
15 84 85 12041669 A DT B-NP O
16 86 93 12041669 patient NN I-NP O
17 94 97 12041669 who WP B-NP O
18 98 106 12041669 received VBD B-VP O
19 107 120 12041669 antithymocyte JJ B-NP B-Chemical
20 121 129 12041669 globulin NN I-NP I-Chemical
21 130 137 12041669 therapy NN I-NP O
22 138 141 12041669 for IN B-PP O
23 142 150 12041669 aplastic JJ B-NP B-Disease
24 151 157 12041669 anemia NN I-NP I-Disease
25 158 161 12041669 due JJ B-ADJP O
26 162 164 12041669 to TO B-PP O
27 165 166 12041669 D NN B-NP B-Chemical
28 166 167 12041669 - HYPH I-NP I-Chemical
29 167 180 12041669 penicillamine NN I-NP I-Chemical
30 181 188 12041669 therapy NN I-NP O
31 189 191 12041669 is VBZ B-VP O
32 192 201 12041669 described VBN I-VP O
33 201 202 12041669 . . O O

1 203 207 12041669 Bone NN B-NP O
2 208 214 12041669 marrow NN I-NP O
3 215 223 12041669 recovery NN I-NP O
4 224 227 12041669 and CC O O
5 228 238 12041669 peripheral JJ B-NP O
6 239 244 12041669 blood NN I-NP O
7 245 253 12041669 recovery NN I-NP O
8 254 258 12041669 were VBD B-VP O
9 259 267 12041669 complete JJ B-NP O
10 268 269 12041669 1 CD I-NP O
11 270 275 12041669 month NN I-NP O
12 276 279 12041669 and CC O O
13 280 281 12041669 3 CD B-NP O
14 282 288 12041669 months NNS I-NP O
15 288 289 12041669 , , O O
16 290 302 12041669 respectively RB B-ADVP O
17 302 303 12041669 , , O O
18 304 309 12041669 after IN B-PP O
19 310 319 12041669 treatment NN B-NP O
20 319 320 12041669 , , O O
21 321 324 12041669 and CC O O
22 325 330 12041669 blood NN B-NP O
23 331 342 12041669 transfusion NN I-NP O
24 343 345 12041669 or CC O O
25 346 351 12041669 other JJ B-NP O
26 352 361 12041669 therapies NNS I-NP O
27 362 366 12041669 were VBD B-VP O
28 367 370 12041669 not RB O O
29 371 380 12041669 necessary JJ B-ADJP O
30 381 383 12041669 in IN B-PP O
31 384 385 12041669 a DT B-NP O
32 386 392 12041669 follow VB I-NP O
33 392 393 12041669 - HYPH I-NP O
34 393 395 12041669 up RP B-PRT O
35 396 402 12041669 period NN B-NP O
36 403 405 12041669 of IN B-PP O
37 406 410 12041669 more JJR B-NP O
38 411 415 12041669 than IN I-NP O
39 416 417 12041669 2 CD I-NP O
40 418 423 12041669 years NNS I-NP O
41 423 424 12041669 . . O O

1 425 428 12041669 Use NN B-NP O
2 429 431 12041669 of IN B-PP O
3 432 445 12041669 antithymocyte JJ B-NP B-Chemical
4 446 454 12041669 globulin NN I-NP I-Chemical
5 455 458 12041669 may MD B-VP O
6 459 461 12041669 be VB I-VP O
7 462 465 12041669 the DT B-NP O
8 466 473 12041669 optimal JJ I-NP O
9 474 483 12041669 treatment NN I-NP O
10 484 486 12041669 of IN B-PP O
11 487 488 12041669 D NN B-NP B-Chemical
12 488 489 12041669 - HYPH B-NP I-Chemical
13 489 502 12041669 penicillamine NN I-NP I-Chemical
14 502 503 12041669 - HYPH O O
15 503 510 12041669 induced VBN B-NP O
16 511 519 12041669 aplastic JJ I-NP B-Disease
17 520 526 12041669 anemia NN I-NP I-Disease
18 526 527 12041669 . . O O

1 0 0 2559236 -DOCSTART- -X- -X- O

1 0 6 2559236 Effect NN B-NP O
2 7 9 2559236 of IN B-PP O
3 10 20 2559236 converting VBG B-VP O
4 21 27 2559236 enzyme NN B-NP O
5 28 38 2559236 inhibition NN I-NP O
6 39 41 2559236 on IN B-PP O
7 42 45 2559236 the DT B-NP O
8 46 52 2559236 course NN I-NP O
9 53 55 2559236 of IN B-PP O
10 56 66 2559236 adriamycin NN B-NP B-Chemical
11 66 67 2559236 - HYPH B-NP O
12 67 74 2559236 induced VBN I-NP O
13 75 86 2559236 nephropathy NN I-NP B-Disease
14 86 87 2559236 . . O O
15 88 91 2559236 The DT B-NP O
16 92 98 2559236 effect NN I-NP O
17 99 101 2559236 of IN B-PP O
18 102 105 2559236 the DT B-NP O
19 106 116 2559236 converting VBG I-NP O
20 117 123 2559236 enzyme NN I-NP O
21 124 133 2559236 inhibitor NN I-NP O
22 134 135 2559236 ( ( O O
23 135 138 2559236 CEI NN B-NP O
24 138 139 2559236 ) ) O O
25 140 149 2559236 enalapril NN B-NP B-Chemical
26 150 153 2559236 was VBD B-VP O
27 154 162 2559236 assessed VBN I-VP O
28 163 165 2559236 in IN B-PP O
29 166 172 2559236 Munich NNP B-NP O
30 172 173 2559236 - HYPH I-NP O
31 173 179 2559236 Wistar NNP I-NP O
32 180 184 2559236 rats NNS I-NP O
33 185 189 2559236 with IN B-PP O
34 190 201 2559236 established VBN B-NP O
35 202 212 2559236 adriamycin NN I-NP B-Chemical
36 213 222 2559236 nephrosis NN I-NP B-Disease
37 222 223 2559236 . . O O

1 224 228 2559236 Rats NNS B-NP O
2 229 233 2559236 were VBD B-VP O
3 234 239 2559236 given VBN I-VP O
4 240 241 2559236 a DT B-NP O
5 242 248 2559236 single JJ I-NP O
6 249 253 2559236 dose NN I-NP O
7 254 256 2559236 of IN B-PP O
8 257 267 2559236 adriamycin NN B-NP B-Chemical
9 268 271 2559236 and CC O O
10 272 275 2559236 one CD B-NP O
11 276 281 2559236 month NN I-NP O
12 282 287 2559236 later RB B-VP O
13 288 295 2559236 divided VBN I-VP O
14 296 300 2559236 into IN B-PP O
15 301 305 2559236 four CD B-NP O
16 306 312 2559236 groups NNS I-NP O
17 313 320 2559236 matched VBN B-VP O
18 321 324 2559236 for IN B-PP O
19 325 336 2559236 albuminuria NN B-NP B-Disease
20 336 337 2559236 , , O O
21 338 343 2559236 blood NN B-NP O
22 344 352 2559236 pressure NN I-NP O
23 352 353 2559236 , , O O
24 354 357 2559236 and CC O O
25 358 364 2559236 plasma NN B-NP O
26 365 372 2559236 albumin NN I-NP O
27 373 386 2559236 concentration NN I-NP O
28 386 387 2559236 . . O O

1 388 394 2559236 Groups NNS B-NP O
2 395 396 2559236 1 CD I-NP O
3 397 400 2559236 and CC I-NP O
4 401 402 2559236 3 CD I-NP O
5 403 411 2559236 remained VBD B-VP O
6 412 421 2559236 untreated JJ B-ADJP O
7 422 427 2559236 while IN B-SBAR O
8 428 434 2559236 groups NNS B-NP O
9 435 436 2559236 2 CD B-NP O
10 437 440 2559236 and CC I-NP O
11 441 442 2559236 4 CD I-NP O
12 443 451 2559236 received VBD B-VP O
13 452 461 2559236 enalapril NN B-NP B-Chemical
14 461 462 2559236 . . O O

1 463 469 2559236 Groups NNS B-NP O
2 470 471 2559236 1 CD I-NP O
3 472 475 2559236 and CC I-NP O
4 476 477 2559236 2 CD I-NP O
5 478 487 2559236 underwent VBD B-VP O
6 488 501 2559236 micropuncture NN B-NP O
7 502 509 2559236 studies NNS I-NP O
8 510 515 2559236 after IN B-PP O
9 516 518 2559236 10 CD B-NP O
10 519 523 2559236 days NNS I-NP O
11 523 524 2559236 . . O O

1 525 530 2559236 These DT B-NP O
2 531 536 2559236 short JJ I-NP O
3 536 537 2559236 - HYPH I-NP O
4 537 541 2559236 term NN I-NP O
5 542 549 2559236 studies NNS I-NP O
6 550 556 2559236 showed VBD B-VP O
7 557 561 2559236 that IN B-SBAR O
8 562 571 2559236 enalapril NN B-NP B-Chemical
9 572 579 2559236 reduced VBD B-VP O
10 580 588 2559236 arterial JJ B-NP O
11 589 594 2559236 blood NN I-NP O
12 595 603 2559236 pressure NN I-NP O
13 604 605 2559236 ( ( O O
14 605 608 2559236 101 CD B-NP O
15 609 610 2559236 + SYM O O
16 610 611 2559236 / SYM O O
17 611 612 2559236 - SYM O O
18 613 614 2559236 2 CD B-NP O
19 615 617 2559236 vs NNS I-NP O
20 617 618 2559236 . . O O
21 619 622 2559236 124 CD B-NP O
22 623 624 2559236 + SYM O O
23 624 625 2559236 / SYM O O
24 625 626 2559236 - SYM O O
25 627 628 2559236 3 CD B-NP O
26 629 631 2559236 mm NN I-NP O
27 632 634 2559236 Hg NN I-NP O
28 634 635 2559236 , , O O
29 636 641 2559236 group NN B-NP O
30 642 643 2559236 2 CD B-NP O
31 644 646 2559236 vs NNS I-NP O
32 646 647 2559236 . . O O
33 648 649 2559236 1 CD B-NP O
34 649 650 2559236 , , O O
35 651 652 2559236 P NN B-NP O
36 653 657 2559236 less JJR B-ADJP O
37 658 662 2559236 than IN B-PP O
38 663 667 2559236 0.05 CD B-NP O
39 667 668 2559236 ) ) O O
40 669 672 2559236 and CC O O
41 673 683 2559236 glomerular JJ B-NP O
42 684 693 2559236 capillary JJ I-NP O
43 694 702 2559236 pressure NN I-NP O
44 703 704 2559236 ( ( O O
45 704 706 2559236 54 CD B-NP O
46 707 708 2559236 + SYM O O
47 708 709 2559236 / SYM O O
48 709 710 2559236 - SYM O O
49 711 712 2559236 1 CD B-NP O
50 713 715 2559236 vs NNS I-NP O
51 715 716 2559236 . . O O
52 717 719 2559236 61 CD B-NP O
53 720 721 2559236 + SYM O O
54 721 722 2559236 / SYM O O
55 722 723 2559236 - SYM B-NP O
56 724 725 2559236 2 CD I-NP O
57 726 728 2559236 mm NN I-NP O
58 729 731 2559236 Hg NN I-NP O
59 731 732 2559236 , , O O
60 733 734 2559236 P NN B-NP O
61 735 739 2559236 less JJR B-ADJP O
62 740 744 2559236 than IN B-PP O
63 745 749 2559236 0.05 CD B-NP O
64 749 750 2559236 ) ) O O
65 751 758 2559236 without IN B-PP O
66 759 767 2559236 reducing VBG B-VP O
67 768 779 2559236 albuminuria NN B-NP B-Disease
68 780 781 2559236 ( ( O O
69 781 784 2559236 617 CD B-NP O
70 785 786 2559236 + SYM O O
71 786 787 2559236 / SYM O O
72 787 788 2559236 - SYM O O
73 789 791 2559236 50 CD B-NP O
74 792 794 2559236 vs NNS I-NP O
75 794 795 2559236 . . O O
76 796 799 2559236 570 CD B-NP O
77 800 801 2559236 + SYM O O
78 801 802 2559236 / SYM O O
79 802 803 2559236 - SYM O O
80 804 806 2559236 47 CD B-NP O
81 807 809 2559236 mg NN I-NP O
82 809 810 2559236 / SYM B-NP O
83 810 813 2559236 day NN I-NP O
84 813 814 2559236 ) ) O O
85 815 817 2559236 or CC O O
86 818 821 2559236 GFR NN B-NP O
87 822 823 2559236 ( ( O O
88 823 827 2559236 1.03 CD B-NP O
89 828 829 2559236 + SYM O O
90 829 830 2559236 / SYM O O
91 830 831 2559236 - SYM O O
92 832 836 2559236 0.04 CD B-NP O
93 837 839 2559236 vs NNS I-NP O
94 839 840 2559236 . . O O
95 841 845 2559236 1.04 CD B-NP O
96 846 847 2559236 + SYM O O
97 847 848 2559236 / SYM O O
98 848 849 2559236 - SYM O O
99 850 854 2559236 0.11 CD B-NP O
100 855 857 2559236 ml NN I-NP O
101 857 858 2559236 / SYM B-NP O
102 858 861 2559236 min NN I-NP O
103 861 862 2559236 ) ) O O
104 862 863 2559236 . . O O

1 864 870 2559236 Groups NNS B-NP O
2 871 872 2559236 3 CD I-NP O
3 873 876 2559236 and CC I-NP O
4 877 878 2559236 4 CD I-NP O
5 879 883 2559236 were VBD B-VP O
6 884 891 2559236 studied VBN I-VP O
7 892 894 2559236 at IN B-PP O
8 895 899 2559236 four CD B-NP O
9 900 903 2559236 and CC O O
10 904 906 2559236 at IN B-PP O
11 907 910 2559236 six CD B-NP O
12 911 917 2559236 months NNS I-NP O
13 918 920 2559236 to TO B-VP O
14 921 927 2559236 assess VB I-VP O
15 928 931 2559236 the DT B-NP O
16 932 938 2559236 effect NN I-NP O
17 939 941 2559236 of IN B-PP O
18 942 951 2559236 enalapril NN B-NP B-Chemical
19 952 954 2559236 on IN B-PP O
20 955 966 2559236 progression NN B-NP O
21 967 969 2559236 of IN B-PP O
22 970 975 2559236 renal JJ B-NP B-Disease
23 976 982 2559236 injury NN I-NP I-Disease
24 983 985 2559236 in IN B-PP O
25 986 996 2559236 adriamycin NN B-NP B-Chemical
26 997 1006 2559236 nephrosis NN I-NP B-Disease
27 1006 1007 2559236 . . O O

1 1008 1015 2559236 Chronic JJ B-NP O
2 1016 1025 2559236 enalapril NN I-NP B-Chemical
3 1026 1035 2559236 treatment NN I-NP O
4 1036 1043 2559236 reduced VBD B-VP O
5 1044 1049 2559236 blood NN B-NP O
6 1050 1058 2559236 pressure NN I-NP O
7 1059 1066 2559236 without IN B-PP O
8 1067 1075 2559236 reducing VBG B-VP O
9 1076 1087 2559236 albuminuria NN B-NP B-Disease
10 1088 1090 2559236 in IN B-PP O
11 1091 1096 2559236 group NN B-NP O
12 1097 1098 2559236 4 CD I-NP O
13 1098 1099 2559236 . . O O

1 1100 1109 2559236 Untreated JJ B-NP O
2 1110 1115 2559236 group NN I-NP O
3 1116 1117 2559236 3 CD B-NP O
4 1118 1122 2559236 rats NNS I-NP O
5 1123 1132 2559236 exhibited VBD B-VP O
6 1133 1134 2559236 a DT B-NP O
7 1135 1146 2559236 progressive JJ I-NP O
8 1147 1156 2559236 reduction NN I-NP O
9 1157 1159 2559236 in IN B-PP O
10 1160 1163 2559236 GFR NN B-NP O
11 1164 1165 2559236 ( ( O O
12 1165 1169 2559236 0.35 CD B-NP O
13 1170 1171 2559236 + SYM O O
14 1171 1172 2559236 / SYM O O
15 1172 1173 2559236 - SYM O O
16 1174 1178 2559236 0.08 CD B-NP O
17 1179 1181 2559236 ml NN I-NP O
18 1181 1182 2559236 / SYM B-NP O
19 1182 1185 2559236 min NN I-NP O
20 1186 1188 2559236 at IN B-PP O
21 1189 1190 2559236 4 CD B-NP O
22 1191 1197 2559236 months NNS I-NP O
23 1197 1198 2559236 , , O O
24 1199 1203 2559236 0.27 CD B-NP O
25 1204 1205 2559236 + SYM O O
26 1205 1206 2559236 / SYM O O
27 1206 1207 2559236 - SYM O O
28 1208 1212 2559236 0.07 CD B-NP O
29 1213 1215 2559236 ml NN I-NP O
30 1215 1216 2559236 / SYM B-NP O
31 1216 1219 2559236 min NN I-NP O
32 1220 1222 2559236 at IN B-PP O
33 1223 1224 2559236 6 CD B-NP O
34 1225 1231 2559236 months NNS I-NP O
35 1231 1232 2559236 ) ) O O
36 1232 1233 2559236 . . O O

1 1234 1243 2559236 Enalapril NNP B-NP B-Chemical
2 1244 1253 2559236 treatment NN I-NP O
3 1254 1261 2559236 blunted VBD B-VP O
4 1262 1265 2559236 but CC O O
5 1266 1269 2559236 did VBD B-VP O
6 1270 1273 2559236 not RB I-VP O
7 1274 1281 2559236 prevent VB I-VP O
8 1282 1291 2559236 reduction NN B-NP O
9 1292 1294 2559236 in IN B-PP O
10 1295 1298 2559236 GFR NN B-NP O
11 1299 1301 2559236 in IN B-PP O
12 1302 1307 2559236 group NN B-NP O
13 1308 1309 2559236 4 CD I-NP O
14 1310 1311 2559236 ( ( O O
15 1311 1315 2559236 0.86 CD B-NP O
16 1316 1317 2559236 + SYM O O
17 1317 1318 2559236 / SYM O O
18 1318 1319 2559236 - SYM O O
19 1320 1324 2559236 0.15 CD B-NP O
20 1325 1327 2559236 ml NN I-NP O
21 1327 1328 2559236 / SYM B-NP O
22 1328 1331 2559236 min NN I-NP O
23 1332 1334 2559236 at IN B-PP O
24 1335 1336 2559236 4 CD B-NP O
25 1337 1343 2559236 months NNS I-NP O
26 1343 1344 2559236 , , O O
27 1345 1349 2559236 0.69 CD B-NP O
28 1350 1351 2559236 + SYM O O
29 1351 1352 2559236 / SYM O O
30 1352 1353 2559236 - SYM O O
31 1354 1358 2559236 0.13 CD B-NP O
32 1359 1361 2559236 ml NN I-NP O
33 1361 1362 2559236 / SYM B-NP O
34 1362 1365 2559236 min NN I-NP O
35 1366 1368 2559236 at IN B-PP O
36 1369 1370 2559236 6 CD B-NP O
37 1371 1377 2559236 months NNS I-NP O
38 1377 1378 2559236 , , O O
39 1379 1383 2559236 both DT B-NP O
40 1384 1385 2559236 P NN I-NP O
41 1386 1390 2559236 less JJR B-NP O
42 1391 1395 2559236 than IN I-NP O
43 1396 1400 2559236 0.05 CD I-NP O
44 1401 1403 2559236 vs NNS I-NP O
45 1403 1404 2559236 . . O O
46 1405 1410 2559236 group NN B-NP O
47 1411 1412 2559236 3 CD I-NP O
48 1412 1413 2559236 ) ) O O
49 1413 1414 2559236 . . O O

1 1415 1424 2559236 Reduction NN B-NP O
2 1425 1427 2559236 in IN B-PP O
3 1428 1431 2559236 GFR NN B-NP O
4 1432 1435 2559236 was VBD B-VP O
5 1436 1446 2559236 associated VBN I-VP O
6 1447 1451 2559236 with IN B-PP O
7 1452 1455 2559236 the DT B-NP O
8 1456 1467 2559236 development NN I-NP O
9 1468 1470 2559236 of IN B-PP O
10 1471 1481 2559236 glomerular JJ B-NP B-Disease
11 1482 1491 2559236 sclerosis NN I-NP I-Disease
12 1492 1494 2559236 in IN B-PP O
13 1495 1499 2559236 both CC B-NP O
14 1500 1507 2559236 treated VBN I-NP O
15 1508 1511 2559236 and CC I-NP O
16 1512 1521 2559236 untreated JJ I-NP O
17 1522 1536 2559236 rats.(ABSTRACT NN I-NP O
18 1537 1546 2559236 TRUNCATED VBN B-VP O
19 1547 1549 2559236 AT IN B-PP O
20 1550 1553 2559236 250 CD B-NP O
21 1554 1559 2559236 WORDS NNS I-NP O
22 1559 1560 2559236 ) ) O O

1 0 0 11672959 -DOCSTART- -X- -X- O

1 0 3 11672959 The DT B-NP O
2 4 5 11672959 3 CD I-NP O
3 5 6 11672959 - HYPH I-NP O
4 6 10 11672959 week NN I-NP O
5 11 25 11672959 sulphasalazine NN I-NP B-Chemical
6 26 34 11672959 syndrome NN I-NP O
7 35 42 11672959 strikes VBZ B-VP O
8 43 48 11672959 again RB B-ADVP O
9 48 49 11672959 . . O O
10 50 51 11672959 A DT B-NP O
11 52 54 11672959 34 CD I-NP O
12 54 55 11672959 - HYPH I-NP O
13 55 59 11672959 year NN I-NP O
14 59 60 11672959 - HYPH O O
15 60 63 11672959 old JJ B-NP O
16 64 68 11672959 lady NN I-NP O
17 69 78 11672959 developed VBD B-VP O
18 79 80 11672959 a DT B-NP O
19 81 94 11672959 constellation NN I-NP O
20 95 97 11672959 of IN B-PP O
21 98 108 11672959 dermatitis NN B-NP B-Disease
22 108 109 11672959 , , I-NP O
23 110 115 11672959 fever NN I-NP B-Disease
24 115 116 11672959 , , I-NP O
25 117 132 11672959 lymphadenopathy NN I-NP B-Disease
26 133 136 11672959 and CC I-NP O
27 137 146 11672959 hepatitis NN I-NP B-Disease
28 146 147 11672959 , , O O
29 148 157 11672959 beginning VBG B-VP O
30 158 160 11672959 on IN B-PP O
31 161 164 11672959 the DT B-NP O
32 165 169 11672959 17th JJ I-NP O
33 170 173 11672959 day NN I-NP O
34 174 176 11672959 of IN B-PP O
35 177 178 11672959 a DT B-NP O
36 179 185 11672959 course NN I-NP O
37 186 188 11672959 of IN B-PP O
38 189 193 11672959 oral JJ B-NP O
39 194 208 11672959 sulphasalazine NN I-NP B-Chemical
40 209 212 11672959 for IN B-PP O
41 213 217 11672959 sero AFX B-NP O
42 217 218 11672959 - HYPH I-NP O
43 218 226 11672959 negative JJ I-NP O
44 227 237 11672959 rheumatoid JJ I-NP B-Disease
45 238 247 11672959 arthritis NN I-NP I-Disease
46 247 248 11672959 . . O O

1 249 257 11672959 Cervical JJ B-NP O
2 258 261 11672959 and CC I-NP O
3 262 270 11672959 inguinal JJ I-NP O
4 271 276 11672959 lymph NN I-NP O
5 277 281 11672959 node NN I-NP O
6 282 290 11672959 biopsies NNS I-NP O
7 291 297 11672959 showed VBD B-VP O
8 298 301 11672959 the DT B-NP O
9 302 310 11672959 features NNS I-NP O
10 311 313 11672959 of IN B-PP O
11 314 320 11672959 severe JJ B-NP O
12 321 332 11672959 necrotising NN I-NP O
13 333 346 11672959 lymphadenitis NN I-NP B-Disease
14 346 347 11672959 , , O O
15 348 358 11672959 associated VBN B-VP O
16 359 363 11672959 with IN B-PP O
17 364 383 11672959 erythrophagocytosis NN B-NP O
18 384 387 11672959 and CC O O
19 388 397 11672959 prominent JJ B-NP O
20 398 410 11672959 eosinophilic JJ I-NP O
21 411 422 11672959 infiltrates NNS I-NP O
22 422 423 11672959 , , O O
23 424 431 11672959 without IN B-PP O
24 432 437 11672959 viral JJ B-NP O
25 438 447 11672959 inclusion NN I-NP O
26 448 454 11672959 bodies NNS I-NP O
27 454 455 11672959 , , O O
28 456 466 11672959 suggestive JJ B-ADJP O
29 467 469 11672959 of IN B-PP O
30 470 472 11672959 an DT B-NP O
31 473 480 11672959 adverse JJ I-NP B-Disease
32 481 485 11672959 drug NN I-NP I-Disease
33 486 496 11672959 reaction.A NN I-NP I-Disease
34 497 501 11672959 week NN I-NP O
35 502 507 11672959 later RB B-ADVP O
36 507 508 11672959 , , O O
37 509 518 11672959 fulminant JJ B-NP O
38 519 523 11672959 drug NN I-NP B-Disease
39 523 524 11672959 - HYPH B-NP I-Disease
40 524 531 11672959 induced VBN I-NP I-Disease
41 532 541 11672959 hepatitis NN I-NP I-Disease
42 541 542 11672959 , , O O
43 543 553 11672959 associated VBN B-VP O
44 554 558 11672959 with IN B-PP O
45 559 562 11672959 the DT B-NP O
46 563 571 11672959 presence NN I-NP O
47 572 574 11672959 of IN B-PP O
48 575 579 11672959 anti AFX B-NP O
49 579 580 11672959 - HYPH I-NP O
50 580 587 11672959 nuclear JJ I-NP O
51 588 602 11672959 autoantibodies NNS I-NP O
52 603 604 11672959 ( ( O O
53 604 607 11672959 but CC B-PP O
54 608 611 11672959 not RB B-PP O
55 612 616 11672959 with IN I-PP O
56 617 622 11672959 other JJ B-NP O
57 623 630 11672959 markers NNS I-NP O
58 631 633 11672959 of IN B-PP O
59 634 646 11672959 autoimmunity NN B-NP B-Disease
60 646 647 11672959 ) ) O O
61 647 648 11672959 , , O O
62 649 652 11672959 and CC O O
63 653 664 11672959 accompanied VBN B-VP O
64 665 667 11672959 by IN B-PP O
65 668 673 11672959 multi AFX B-NP B-Disease
66 673 674 11672959 - HYPH I-NP I-Disease
67 674 679 11672959 organ NN I-NP I-Disease
68 680 687 11672959 failure NN I-NP I-Disease
69 688 691 11672959 and CC I-NP O
70 692 698 11672959 sepsis NN I-NP B-Disease
71 698 699 11672959 , , O O
72 700 710 11672959 supervened VBD B-VP O
73 710 711 11672959 . . O O

1 712 715 11672959 She PRP B-NP O
2 716 728 11672959 subsequently RB B-ADVP O
3 729 733 11672959 died VBD B-VP O
4 734 738 11672959 some DT B-NP O
5 739 740 11672959 5 CD I-NP O
6 741 746 11672959 weeks NNS I-NP O
7 747 752 11672959 after IN B-PP O
8 753 756 11672959 the DT B-NP O
9 757 769 11672959 commencement NN I-NP O
10 770 772 11672959 of IN B-PP O
11 773 776 11672959 her PRP$ B-NP O
12 777 781 11672959 drug NN I-NP O
13 782 794 11672959 therapy.Post NN I-NP O
14 794 795 11672959 - HYPH B-NP O
15 795 801 11672959 mortem NN I-NP O
16 802 813 11672959 examination NN I-NP O
17 814 820 11672959 showed VBD B-VP O
18 821 829 11672959 evidence NN B-NP O
19 830 832 11672959 of IN B-PP O
20 833 840 11672959 massive JJ B-NP B-Disease
21 841 855 11672959 hepatocellular JJ I-NP I-Disease
22 856 864 11672959 necrosis NN I-NP I-Disease
23 864 865 11672959 , , O O
24 866 871 11672959 acute JJ B-NP O
25 872 888 11672959 hypersensitivity NN I-NP O
26 889 900 11672959 myocarditis NN I-NP B-Disease
27 900 901 11672959 , , O O
28 902 907 11672959 focal JJ B-NP O
29 908 913 11672959 acute JJ I-NP O
30 914 920 11672959 tubulo AFX B-NP O
31 920 921 11672959 - HYPH I-NP O
32 921 933 11672959 interstitial JJ I-NP O
33 934 943 11672959 nephritis NN I-NP B-Disease
34 944 947 11672959 and CC O O
35 948 957 11672959 extensive JJ B-NP O
36 958 962 11672959 bone NN I-NP B-Disease
37 963 969 11672959 marrow NN I-NP I-Disease
38 970 978 11672959 necrosis NN I-NP I-Disease
39 978 979 11672959 , , O O
40 980 984 11672959 with IN B-PP O
41 985 987 11672959 no DT B-NP O
42 988 996 11672959 evidence NN I-NP O
43 997 999 11672959 of IN B-PP O
44 1000 1010 11672959 malignancy NN B-NP B-Disease
45 1010 1011 11672959 . . O O

1 1012 1014 11672959 It PRP B-NP O
2 1015 1017 11672959 is VBZ B-VP O
3 1018 1025 11672959 thought VBN I-VP O
4 1026 1030 11672959 that IN B-SBAR O
5 1031 1034 11672959 the DT B-NP O
6 1035 1042 11672959 clinico AFX I-NP O
7 1042 1043 11672959 - HYPH I-NP O
8 1043 1055 11672959 pathological JJ I-NP O
9 1056 1064 11672959 features NNS I-NP O
10 1065 1068 11672959 and CC O O
11 1069 1079 11672959 chronology NN B-NP O
12 1080 1082 11672959 of IN B-PP O
13 1083 1087 11672959 this DT B-NP O
14 1088 1092 11672959 case NN I-NP O
15 1093 1097 11672959 bore VBD B-VP O
16 1098 1101 11672959 the DT B-NP O
17 1102 1111 11672959 hallmarks NNS I-NP O
18 1112 1114 11672959 of IN B-PP O
19 1115 1118 11672959 the DT B-NP O
20 1119 1121 11672959 so RB I-NP O
21 1121 1122 11672959 - HYPH I-NP O
22 1122 1128 11672959 called VBN B-VP O
23 1129 1130 11672959 " `` B-NP O
24 1130 1131 11672959 3 CD I-NP O
25 1131 1132 11672959 - HYPH I-NP O
26 1132 1136 11672959 week NN I-NP O
27 1137 1151 11672959 sulphasalazine NN I-NP B-Chemical
28 1152 1160 11672959 syndrome NN I-NP O
29 1160 1161 11672959 " '' O O
30 1161 1162 11672959 , , O O
31 1163 1164 11672959 a DT B-NP O
32 1165 1169 11672959 rare JJ I-NP O
33 1169 1170 11672959 , , O O
34 1171 1174 11672959 but CC O O
35 1175 1180 11672959 often RB B-NP O
36 1181 1186 11672959 fatal JJ I-NP O
37 1186 1187 11672959 , , I-NP O
38 1188 1202 11672959 immunoallergic JJ I-NP O
39 1203 1211 11672959 reaction NN I-NP O
40 1212 1214 11672959 to TO B-PP O
41 1215 1229 11672959 sulphasalazine NN B-NP B-Chemical
42 1229 1230 11672959 . . O O

1 0 0 14568327 -DOCSTART- -X- -X- O

1 0 11 14568327 Development NN B-NP O
2 12 14 14568327 of IN B-PP O
3 15 23 14568327 levodopa NN B-NP B-Chemical
4 23 24 14568327 - HYPH B-NP O
5 24 31 14568327 induced VBN I-NP O
6 32 43 14568327 dyskinesias NNS I-NP B-Disease
7 44 46 14568327 in IN B-PP O
8 47 59 14568327 parkinsonian JJ B-NP B-Disease
9 60 67 14568327 monkeys NNS I-NP O
10 68 71 14568327 may MD B-VP O
11 72 78 14568327 depend VB I-VP O
12 79 83 14568327 upon IN B-PP O
13 84 88 14568327 rate NN B-NP O
14 89 91 14568327 of IN B-PP O
15 92 99 14568327 symptom NN B-NP O
16 100 105 14568327 onset NN I-NP O
17 106 109 14568327 and CC O O
18 109 110 14568327 / SYM B-NP O
19 110 112 14568327 or CC O O
20 113 121 14568327 duration NN B-NP O
21 122 124 14568327 of IN B-PP O
22 125 133 14568327 symptoms NNS B-NP O
23 133 134 14568327 . . O O
24 135 143 14568327 Levodopa NN B-NP B-Chemical
25 143 144 14568327 - HYPH B-NP O
26 144 151 14568327 induced VBN I-NP O
27 152 163 14568327 dyskinesias NNS I-NP B-Disease
28 164 165 14568327 ( ( O O
29 165 169 14568327 LIDs NNS B-NP B-Disease
30 169 170 14568327 ) ) O O
31 171 178 14568327 present VBP B-VP O
32 179 180 14568327 a DT B-NP O
33 181 186 14568327 major JJ I-NP O
34 187 194 14568327 problem NN I-NP O
35 195 198 14568327 for IN B-PP O
36 199 202 14568327 the DT B-NP O
37 203 207 14568327 long JJ I-NP O
38 207 208 14568327 - HYPH I-NP O
39 208 212 14568327 term NN I-NP O
40 213 223 14568327 management NN I-NP O
41 224 226 14568327 of IN B-PP O
42 227 238 14568327 Parkinson's NNS B-NP B-Disease
43 239 246 14568327 disease NN B-NP I-Disease
44 247 248 14568327 ( ( O O
45 248 250 14568327 PD NN B-NP B-Disease
46 250 251 14568327 ) ) O O
47 252 260 14568327 patients NNS B-NP O
48 260 261 14568327 . . O O

1 262 265 14568327 Due JJ B-PP O
2 266 268 14568327 to TO I-PP O
3 269 272 14568327 the DT B-NP O
4 273 288 14568327 interdependence NN I-NP O
5 289 291 14568327 of IN B-PP O
6 292 296 14568327 risk NN B-NP O
7 297 304 14568327 factors NNS I-NP O
8 305 307 14568327 in IN B-PP O
9 308 316 14568327 clinical JJ B-NP O
10 317 328 14568327 populations NNS I-NP O
11 328 329 14568327 , , O O
12 330 332 14568327 it PRP B-NP O
13 333 335 14568327 is VBZ B-VP O
14 336 345 14568327 difficult JJ B-ADJP O
15 346 348 14568327 to TO B-VP O
16 349 362 14568327 independently RB I-VP O
17 363 370 14568327 examine VB I-VP O
18 371 378 14568327 factors NNS B-NP O
19 379 383 14568327 that WDT B-NP O
20 384 387 14568327 may MD B-VP O
21 388 397 14568327 influence VB I-VP O
22 398 401 14568327 the DT B-NP O
23 402 413 14568327 development NN I-NP O
24 414 416 14568327 of IN B-PP O
25 417 421 14568327 LIDs NNS B-NP B-Disease
26 421 422 14568327 . . O O

1 423 428 14568327 Using VBG B-VP O
2 429 436 14568327 macaque JJ B-NP O
3 437 444 14568327 monkeys NNS I-NP O
4 445 449 14568327 with IN B-PP O
5 450 459 14568327 different JJ B-NP O
6 460 465 14568327 types NNS I-NP O
7 466 468 14568327 of IN B-PP O
8 469 473 14568327 MPTP NN B-NP B-Chemical
9 473 474 14568327 - HYPH B-NP O
10 474 481 14568327 induced VBN I-NP O
11 482 494 14568327 parkinsonism NN I-NP B-Disease
12 494 495 14568327 , , O O
13 496 499 14568327 the DT B-NP O
14 500 507 14568327 current JJ I-NP O
15 508 513 14568327 study NN I-NP O
16 514 523 14568327 evaluated VBD B-VP O
17 524 527 14568327 the DT B-NP O
18 528 534 14568327 degree NN I-NP O
19 535 537 14568327 to TO B-PP O
20 538 543 14568327 which WDT B-NP O
21 544 548 14568327 rate NN B-NP O
22 549 551 14568327 of IN B-PP O
23 552 559 14568327 symptom NN B-NP O
24 560 571 14568327 progression NN I-NP O
25 571 572 14568327 , , O O
26 573 580 14568327 symptom NN B-NP O
27 581 589 14568327 severity NN I-NP O
28 589 590 14568327 , , O O
29 591 594 14568327 and CC O O
30 595 603 14568327 response NN B-NP O
31 604 606 14568327 to TO B-PP O
32 607 610 14568327 and CC O O
33 611 619 14568327 duration NN B-NP O
34 620 622 14568327 of IN B-PP O
35 623 631 14568327 levodopa NN B-NP B-Chemical
36 632 639 14568327 therapy NN I-NP O
37 640 643 14568327 may MD B-VP O
38 644 646 14568327 be VB I-VP O
39 647 655 14568327 involved VBN I-VP O
40 656 658 14568327 in IN B-PP O
41 659 662 14568327 the DT B-NP O
42 663 674 14568327 development NN I-NP O
43 675 677 14568327 of IN B-PP O
44 678 682 14568327 LIDs NNS B-NP B-Disease
45 682 683 14568327 . . O O

1 684 691 14568327 Monkeys NNS B-NP O
2 692 696 14568327 with IN B-PP O
3 697 702 14568327 acute JJ O O
4 703 704 14568327 ( ( O O
5 704 709 14568327 short JJ B-NP O
6 709 710 14568327 - HYPH I-NP O
7 710 714 14568327 term NN I-NP O
8 714 715 14568327 ) ) O O
9 716 720 14568327 MPTP NN B-NP B-Chemical
10 721 729 14568327 exposure NN I-NP O
11 729 730 14568327 , , O O
12 731 736 14568327 rapid JJ B-NP O
13 737 744 14568327 symptom NN I-NP O
14 745 750 14568327 onset NN I-NP O
15 751 754 14568327 and CC O O
16 755 760 14568327 short JJ B-NP O
17 761 768 14568327 symptom NN I-NP O
18 769 777 14568327 duration NN I-NP O
19 778 783 14568327 prior JJ B-ADJP O
20 784 786 14568327 to TO B-PP O
21 787 797 14568327 initiation NN B-NP O
22 798 800 14568327 of IN B-PP O
23 801 809 14568327 levodopa NN B-NP B-Chemical
24 810 817 14568327 therapy NN I-NP O
25 818 827 14568327 developed VBD B-VP O
26 828 838 14568327 dyskinesia NN B-NP B-Disease
27 839 846 14568327 between IN B-PP O
28 847 849 14568327 11 CD B-NP O
29 850 853 14568327 and CC I-NP O
30 854 856 14568327 24 CD I-NP O
31 857 861 14568327 days NNS I-NP O
32 862 864 14568327 of IN B-PP O
33 865 870 14568327 daily JJ B-NP O
34 871 879 14568327 levodopa NN I-NP B-Chemical
35 880 894 14568327 administration NN I-NP O
36 894 895 14568327 . . O O

1 896 898 14568327 In IN B-PP O
2 899 907 14568327 contrast NN B-NP O
3 907 908 14568327 , , O O
4 909 916 14568327 monkeys NNS B-NP O
5 917 921 14568327 with IN B-PP O
6 922 926 14568327 long JJ B-NP O
7 926 927 14568327 - HYPH I-NP O
8 927 931 14568327 term NN I-NP O
9 932 936 14568327 MPTP NN I-NP B-Chemical
10 937 945 14568327 exposure NN I-NP O
11 945 946 14568327 , , O O
12 947 951 14568327 slow JJ B-NP O
13 952 959 14568327 symptom NN I-NP O
14 960 971 14568327 progression NN I-NP O
15 972 975 14568327 and CC O O
16 975 976 14568327 / SYM B-NP O
17 976 978 14568327 or CC O O
18 979 983 14568327 long JJ B-NP O
19 984 991 14568327 symptom NN I-NP O
20 992 1000 14568327 duration NN I-NP O
21 1001 1006 14568327 prior JJ B-ADJP O
22 1007 1009 14568327 to TO B-PP O
23 1010 1020 14568327 initiation NN B-NP O
24 1021 1023 14568327 of IN B-PP O
25 1024 1032 14568327 levodopa NN B-NP B-Chemical
26 1033 1040 14568327 therapy NN I-NP O
27 1041 1045 14568327 were VBD B-VP O
28 1046 1050 14568327 more RBR B-ADJP O
29 1051 1060 14568327 resistant JJ I-ADJP O
30 1061 1063 14568327 to TO B-PP O
31 1064 1074 14568327 developing VBG B-NP O
32 1075 1079 14568327 LIDs NNS I-NP B-Disease
33 1080 1081 14568327 ( ( O O
34 1081 1085 14568327 e.g. FW B-NP O
35 1085 1086 14568327 , , O O
36 1087 1097 14568327 dyskinesia NN B-NP B-Disease
37 1098 1107 14568327 developed VBD B-VP O
38 1108 1110 14568327 no DT B-NP O
39 1111 1117 14568327 sooner RBR I-NP O
40 1118 1122 14568327 than IN I-NP O
41 1123 1126 14568327 146 CD I-NP O
42 1127 1131 14568327 days NNS I-NP O
43 1132 1134 14568327 of IN B-PP O
44 1135 1142 14568327 chronic JJ B-NP O
45 1143 1151 14568327 levodopa NN I-NP B-Chemical
46 1152 1166 14568327 administration NN I-NP O
47 1166 1167 14568327 ) ) O O
48 1167 1168 14568327 . . O O

1 1169 1172 14568327 All DT B-NP O
2 1173 1180 14568327 animals NNS I-NP O
3 1181 1185 14568327 were VBD B-VP O
4 1186 1195 14568327 similarly RB B-ADJP O
5 1196 1207 14568327 symptomatic JJ I-ADJP O
6 1208 1210 14568327 at IN B-PP O
7 1211 1214 14568327 the DT B-NP O
8 1215 1220 14568327 start NN I-NP O
9 1221 1223 14568327 of IN B-PP O
10 1224 1232 14568327 levodopa NN B-NP B-Chemical
11 1233 1242 14568327 treatment NN I-NP O
12 1243 1246 14568327 and CC O O
13 1247 1250 14568327 had VBD B-VP O
14 1251 1258 14568327 similar JJ B-NP O
15 1259 1270 14568327 therapeutic JJ I-NP O
16 1271 1280 14568327 responses NNS I-NP O
17 1281 1283 14568327 to TO B-PP O
18 1284 1287 14568327 the DT B-NP O
19 1288 1292 14568327 drug NN I-NP O
20 1292 1293 14568327 . . O O

1 1294 1299 14568327 These DT B-NP O
2 1300 1304 14568327 data NNS I-NP O
3 1305 1312 14568327 suggest VBP B-VP O
4 1313 1321 14568327 distinct JJ B-NP O
5 1322 1333 14568327 differences NNS I-NP O
6 1334 1336 14568327 in IN B-PP O
7 1337 1340 14568327 the DT B-NP O
8 1341 1351 14568327 propensity NN I-NP O
9 1352 1354 14568327 to TO B-VP O
10 1355 1362 14568327 develop VB I-VP O
11 1363 1367 14568327 LIDs NNS B-NP B-Disease
12 1368 1370 14568327 in IN B-PP O
13 1371 1378 14568327 monkeys NNS B-NP O
14 1379 1383 14568327 with IN B-PP O
15 1384 1393 14568327 different JJ B-NP O
16 1394 1399 14568327 rates NNS I-NP O
17 1400 1402 14568327 of IN B-PP O
18 1403 1410 14568327 symptom NN B-NP O
19 1411 1422 14568327 progression NN I-NP O
20 1423 1425 14568327 or CC I-NP O
21 1426 1433 14568327 symptom NN I-NP O
22 1434 1443 14568327 durations NNS I-NP O
23 1444 1449 14568327 prior RB B-ADVP O
24 1450 1452 14568327 to TO B-PP O
25 1453 1461 14568327 levodopa NN B-NP B-Chemical
26 1462 1465 14568327 and CC O O
27 1466 1477 14568327 demonstrate VBP B-VP O
28 1478 1481 14568327 the DT B-NP O
29 1482 1487 14568327 value NN I-NP O
30 1488 1490 14568327 of IN B-PP O
31 1491 1496 14568327 these DT B-NP O
32 1497 1503 14568327 models NNS I-NP O
33 1504 1507 14568327 for IN B-PP O
34 1508 1515 14568327 further RB B-ADVP O
35 1516 1524 14568327 studying VBG B-VP O
36 1525 1528 14568327 the DT B-NP O
37 1529 1544 14568327 pathophysiology NN I-NP O
38 1545 1547 14568327 of IN B-PP O
39 1548 1552 14568327 LIDs NNS B-NP B-Disease
40 1552 1553 14568327 . . O O

1 0 0 7516729 -DOCSTART- -X- -X- O

1 0 11 7516729 Interactive JJ B-NP O
2 12 19 7516729 effects NNS I-NP O
3 20 22 7516729 of IN B-PP O
4 23 33 7516729 variations NNS B-NP O
5 34 36 7516729 in IN B-PP O
6 37 42 7516729 [Na]o NN B-NP B-Chemical
7 43 46 7516729 and CC I-NP O
8 47 52 7516729 [Ca]o NN I-NP B-Chemical
9 53 55 7516729 on IN B-PP O
10 56 59 7516729 rat NN B-NP O
11 60 66 7516729 atrial JJ I-NP O
12 67 78 7516729 spontaneous JJ I-NP O
13 79 88 7516729 frequency NN I-NP O
14 88 89 7516729 . . O O
15 90 93 7516729 The DT B-NP O
16 94 101 7516729 effects NNS I-NP O
17 102 104 7516729 of IN B-PP O
18 105 112 7516729 varying VBG B-VP O
19 113 116 7516729 the DT B-NP O
20 117 130 7516729 extracellular JJ I-NP O
21 131 145 7516729 concentrations NNS I-NP O
22 146 148 7516729 of IN B-PP O
23 149 151 7516729 Na NN B-NP B-Chemical
24 152 155 7516729 and CC O O
25 156 158 7516729 Ca NN B-NP B-Chemical
26 159 160 7516729 ( ( O O
27 160 165 7516729 [Na]o NN B-NP B-Chemical
28 166 169 7516729 and CC O O
29 170 175 7516729 [Ca]o NN B-NP B-Chemical
30 175 176 7516729 ) ) O O
31 177 179 7516729 on IN B-PP O
32 180 184 7516729 both CC O O
33 184 185 7516729 , , O O
34 186 189 7516729 the DT B-NP O
35 190 201 7516729 spontaneous JJ I-NP O
36 202 209 7516729 beating NN I-NP O
37 210 213 7516729 and CC O O
38 214 217 7516729 the DT B-NP O
39 218 226 7516729 negative JJ I-NP O
40 227 239 7516729 chronotropic JJ I-NP O
41 240 246 7516729 action NN I-NP O
42 247 249 7516729 of IN B-PP O
43 250 259 7516729 verapamil NN B-NP B-Chemical
44 259 260 7516729 , , O O
45 261 265 7516729 were VBD B-VP O
46 266 273 7516729 studied VBN I-VP O
47 274 276 7516729 in IN B-PP O
48 277 280 7516729 the DT B-NP O
49 281 289 7516729 isolated VBN I-NP O
50 290 293 7516729 rat NN I-NP O
51 294 299 7516729 atria NN I-NP O
52 299 300 7516729 . . O O

1 301 306 7516729 Basal JJ B-NP O
2 307 316 7516729 frequency NN I-NP O
3 317 318 7516729 ( ( O O
4 318 320 7516729 BF NN B-NP O
5 320 321 7516729 ) ) O O
6 322 331 7516729 evaluated VBN B-VP O
7 332 334 7516729 by IN B-PP O
8 335 342 7516729 surface NN B-NP O
9 343 354 7516729 electrogram NN I-NP O
10 355 358 7516729 was VBD B-VP O
11 359 362 7516729 223 CD B-NP O
12 363 364 7516729 + SYM O O
13 364 365 7516729 / SYM O O
14 365 366 7516729 - SYM B-NP O
15 367 368 7516729 4 CD B-NP O
16 369 374 7516729 beats NNS I-NP O
17 374 375 7516729 / SYM B-NP O
18 375 378 7516729 min NN I-NP O
19 378 379 7516729 . . O O

1 380 382 7516729 in IN B-PP O
2 383 390 7516729 control NN B-NP O
3 391 396 7516729 Krebs NNS I-NP O
4 396 397 7516729 - HYPH B-NP O
5 397 403 7516729 Ringer NN I-NP O
6 404 414 7516729 containing VBG B-VP O
7 415 418 7516729 137 CD B-NP O
8 419 421 7516729 mM NN I-NP O
9 422 424 7516729 Na NN I-NP B-Chemical
10 425 428 7516729 and CC O O
11 429 433 7516729 1.35 CD B-NP O
12 434 436 7516729 mM NN I-NP O
13 437 439 7516729 Ca NN I-NP B-Chemical
14 440 441 7516729 ( ( O O
15 441 442 7516729 N NN B-NP O
16 442 443 7516729 ) ) O O
17 443 444 7516729 . . O O

1 445 447 7516729 It PRP B-NP O
2 448 457 7516729 decreased VBD B-VP O
3 458 460 7516729 by IN B-PP O
4 461 463 7516729 16 CD B-NP O
5 464 465 7516729 + SYM O O
6 465 466 7516729 / SYM O O
7 466 467 7516729 - SYM O O
8 468 470 7516729 3% NN B-NP O
9 471 473 7516729 by IN B-PP O
10 474 482 7516729 lowering VBG B-VP O
11 483 488 7516729 [Na]o NNP B-NP B-Chemical
12 489 491 7516729 to TO B-PP O
13 492 494 7516729 78 CD B-NP O
14 495 497 7516729 mM NN I-NP O
15 498 499 7516729 ( ( O O
16 499 502 7516729 LNa NN B-NP O
17 502 503 7516729 ) ) O O
18 503 504 7516729 , , O O
19 505 507 7516729 23 CD B-NP O
20 508 509 7516729 + SYM O O
21 509 510 7516729 / SYM O O
22 510 511 7516729 - SYM O O
23 512 514 7516729 2% NN B-NP O
24 515 517 7516729 by IN B-PP O
25 518 526 7516729 lowering VBG B-VP O
26 527 541 7516729 simultaneously RB B-ADVP O
27 542 547 7516729 [Na]o NNP B-NP B-Chemical
28 548 550 7516729 to TO B-PP O
29 551 553 7516729 78 CD B-NP O
30 554 556 7516729 mM NN I-NP O
31 557 560 7516729 and CC I-NP O
32 561 566 7516729 [Ca]o NN I-NP B-Chemical
33 567 569 7516729 to TO B-PP O
34 570 575 7516729 0.675 CD B-NP O
35 576 578 7516729 mM NN I-NP O
36 579 580 7516729 ( ( O O
37 580 583 7516729 LNa NN B-NP O
38 583 584 7516729 + SYM B-NP O
39 584 587 7516729 LCa NN I-NP O
40 587 588 7516729 ) ) O O
41 589 592 7516729 and CC O O
42 593 595 7516729 31 CD B-NP O
43 596 597 7516729 + SYM O O
44 597 598 7516729 / SYM O O
45 598 599 7516729 - SYM O O
46 600 602 7516729 5% CD B-NP O
47 603 605 7516729 by IN B-PP O
48 606 614 7516729 lowering VBG B-VP O
49 615 620 7516729 [Na]o NNP B-NP B-Chemical
50 621 623 7516729 to TO B-PP O
51 624 626 7516729 78 CD B-NP O
52 627 629 7516729 mM NN I-NP O
53 630 634 7516729 plus CC O O
54 635 645 7516729 increasing VBG B-NP O
55 646 651 7516729 [Ca]o NN I-NP B-Chemical
56 652 654 7516729 to TO B-PP O
57 655 658 7516729 3.6 CD B-NP O
58 659 661 7516729 mM NN I-NP O
59 662 663 7516729 ( ( O O
60 663 666 7516729 LNa NN B-NP O
61 666 667 7516729 + SYM O O
62 667 670 7516729 HCa NN B-NP O
63 670 671 7516729 ) ) O O
64 671 672 7516729 . . O O

1 673 675 7516729 At IN B-PP O
2 676 682 7516729 normal JJ B-NP O
3 683 688 7516729 [Na]o NN I-NP B-Chemical
4 688 689 7516729 , , O O
5 690 698 7516729 decrease NN B-NP O
6 699 700 7516729 ( ( O O
7 700 705 7516729 0.675 CD B-NP O
8 706 708 7516729 mM NN I-NP O
9 708 709 7516729 ) ) O O
10 710 712 7516729 or CC O O
11 713 721 7516729 increase NN B-NP O
12 722 723 7516729 ( ( O O
13 723 726 7516729 3.6 CD B-NP O
14 727 729 7516729 mM NN I-NP O
15 729 730 7516729 ) ) O O
16 731 733 7516729 of IN B-PP O
17 734 739 7516729 [Ca]o NN B-NP B-Chemical
18 740 743 7516729 did VBD B-VP O
19 744 747 7516729 not RB I-VP O
20 748 754 7516729 modify VB I-VP O
21 755 757 7516729 BF NN B-NP O
22 757 758 7516729 ; : O O
23 759 760 7516729 a DT B-NP O
24 761 770 7516729 reduction NN I-NP O
25 771 773 7516729 of IN B-PP O
26 774 777 7516729 ten CD B-NP O
27 778 783 7516729 times NNS I-NP O
28 784 785 7516729 ( ( O O
29 785 790 7516729 0.135 CD B-NP O
30 791 793 7516729 mM NN I-NP O
31 794 796 7516729 of IN B-PP O
32 797 803 7516729 normal JJ B-NP O
33 804 809 7516729 [Ca]o NN I-NP B-Chemical
34 810 813 7516729 was VBD B-VP O
35 814 823 7516729 effective JJ B-ADJP O
36 824 826 7516729 to TO B-VP O
37 827 833 7516729 reduce VB I-VP O
38 834 836 7516729 BF NN B-NP O
39 837 839 7516729 by IN B-PP O
40 840 842 7516729 40 CD B-NP O
41 843 844 7516729 + SYM B-NP O
42 844 845 7516729 / SYM I-NP O
43 845 846 7516729 - SYM I-NP O
44 847 850 7516729 13% NN B-NP O
45 850 851 7516729 . . O O

1 852 855 7516729 All DT B-NP O
2 856 864 7516729 negative JJ I-NP O
3 865 877 7516729 chronotropic JJ I-NP O
4 878 885 7516729 effects NNS I-NP O
5 886 890 7516729 were VBD B-VP O
6 891 893 7516729 BF NN B-NP O
7 893 894 7516729 - HYPH B-VP O
8 894 903 7516729 dependent JJ B-ADJP O
9 903 904 7516729 . . O O

1 905 909 7516729 Dose NN B-NP O
2 909 910 7516729 - HYPH I-NP O
3 910 919 7516729 dependent JJ I-NP O
4 920 931 7516729 bradycardia NN I-NP B-Disease
5 932 939 7516729 induced VBN B-VP O
6 940 942 7516729 by IN B-PP O
7 943 952 7516729 verapamil NN B-NP B-Chemical
8 953 956 7516729 was VBD B-VP O
9 957 968 7516729 potentiated VBN I-VP O
10 969 971 7516729 by IN B-PP O
11 972 975 7516729 LNa NN B-NP O
12 975 976 7516729 , , O O
13 977 980 7516729 LCa NN B-NP O
14 980 981 7516729 , , O O
15 982 985 7516729 and CC O O
16 986 989 7516729 HCa NN B-NP O
17 989 990 7516729 . . O O

1 991 1002 7516729 Independent JJ B-ADJP O
2 1003 1006 7516729 but CC I-ADJP O
3 1007 1010 7516729 not RB I-ADJP O
4 1011 1019 7516729 additive JJ B-NP O
5 1020 1027 7516729 effects NNS I-NP O
6 1028 1030 7516729 of IN B-PP O
7 1031 1033 7516729 Na NN B-NP B-Chemical
8 1034 1037 7516729 and CC I-NP O
9 1038 1040 7516729 Ca NN I-NP B-Chemical
10 1041 1044 7516729 are VBP B-VP O
11 1045 1050 7516729 shown VBN I-VP O
12 1051 1053 7516729 by IN B-PP O
13 1054 1063 7516729 decreases NNS B-NP O
14 1064 1066 7516729 in IN B-PP O
15 1067 1070 7516729 the DT B-NP O
16 1071 1077 7516729 values NNS I-NP O
17 1078 1080 7516729 of IN B-PP O
18 1081 1093 7516729 [verapamil]o NN B-NP B-Chemical
19 1094 1100 7516729 needed VBN B-VP O
20 1101 1103 7516729 to TO B-VP O
21 1104 1110 7516729 reduce VB I-VP O
22 1111 1113 7516729 BF NN B-NP O
23 1114 1116 7516729 by IN B-PP O
24 1117 1120 7516729 30% CD B-NP O
25 1121 1122 7516729 ( ( O O
26 1122 1126 7516729 IC30 NN B-NP O
27 1126 1127 7516729 ) ) O O
28 1128 1132 7516729 with IN B-PP O
29 1133 1136 7516729 the DT B-NP O
30 1137 1146 7516729 following VBG I-NP O
31 1147 1152 7516729 order NN I-NP O
32 1153 1155 7516729 of IN B-PP O
33 1156 1166 7516729 inhibitory JJ B-NP O
34 1167 1174 7516729 potency NN I-NP O
35 1174 1175 7516729 : : O O
36 1176 1179 7516729 LNa NN B-NP O
37 1180 1181 7516729 > SYM B-NP O
38 1182 1185 7516729 LCa NN I-NP O
39 1186 1187 7516729 > SYM I-NP O
40 1188 1191 7516729 HCa NN I-NP O
41 1192 1193 7516729 > SYM I-NP O
42 1194 1195 7516729 N NN I-NP O
43 1195 1196 7516729 , , O O
44 1197 1206 7516729 resulting VBG B-VP O
45 1207 1210 7516729 LNa NN B-NP O
46 1210 1211 7516729 + SYM B-NP O
47 1211 1214 7516729 HCa NN I-NP O
48 1215 1222 7516729 similar JJ B-ADJP O
49 1223 1225 7516729 to TO B-PP O
50 1226 1229 7516729 LNa NN B-NP O
51 1229 1230 7516729 . . O O

1 1231 1234 7516729 The DT B-NP O
2 1235 1247 7516729 [verapamil]o NN I-NP B-Chemical
3 1248 1252 7516729 that WDT B-NP O
4 1253 1261 7516729 arrested VBD B-VP O
5 1262 1268 7516729 atrial JJ B-NP O
6 1269 1276 7516729 beating NN I-NP O
7 1277 1278 7516729 ( ( O O
8 1278 1280 7516729 AC NN B-NP O
9 1280 1281 7516729 ) ) O O
10 1282 1285 7516729 was VBD B-VP O
11 1286 1290 7516729 also RB I-VP O
12 1291 1302 7516729 potentiated VBN I-VP O
13 1303 1307 7516729 with IN B-PP O
14 1308 1311 7516729 the DT B-NP O
15 1312 1317 7516729 order NN I-NP O
16 1318 1321 7516729 LNa NN I-NP O
17 1322 1323 7516729 = SYM B-VP O
18 1324 1327 7516729 LNa NN B-NP O
19 1327 1328 7516729 + SYM B-NP O
20 1328 1331 7516729 LCa NN I-NP O
21 1332 1333 7516729 = SYM B-VP O
22 1334 1337 7516729 LNa NN B-NP O
23 1337 1338 7516729 + SYM B-NP O
24 1338 1341 7516729 HCa NN I-NP O
25 1342 1343 7516729 = SYM B-VP O
26 1344 1347 7516729 LCa NN B-NP O
27 1348 1349 7516729 > SYM B-NP O
28 1350 1353 7516729 HCa NN I-NP O
29 1354 1355 7516729 = SYM B-VP O
30 1356 1357 7516729 N NN B-NP O
31 1357 1358 7516729 . . O O

1 1359 1362 7516729 The DT B-NP O
2 1363 1370 7516729 results NNS I-NP O
3 1371 1379 7516729 indicate VBP B-VP O
4 1380 1384 7516729 that IN B-SBAR O
5 1385 1388 7516729 rat NN B-NP O
6 1389 1395 7516729 atrial JJ I-NP O
7 1396 1407 7516729 spontaneous JJ I-NP O
8 1408 1415 7516729 beating NN I-NP O
9 1416 1418 7516729 is VBZ B-VP O
10 1419 1423 7516729 more RBR B-ADJP O
11 1424 1433 7516729 dependent JJ I-ADJP O
12 1434 1436 7516729 on IN B-PP O
13 1437 1442 7516729 [Na]o NNP B-NP B-Chemical
14 1443 1447 7516729 than IN B-PP O
15 1448 1450 7516729 on IN B-PP O
16 1451 1456 7516729 [Ca]o NNP B-NP B-Chemical
17 1457 1459 7516729 in IN B-PP O
18 1460 1461 7516729 a DT B-NP O
19 1462 1467 7516729 range NN I-NP O
20 1468 1470 7516729 of IN B-PP O
21 1471 1472 7516729 + SYM B-NP O
22 1472 1473 7516729 / SYM B-NP O
23 1473 1474 7516729 - SYM B-VP O
24 1475 1478 7516729 50% CD B-NP O
25 1479 1481 7516729 of IN B-PP O
26 1482 1487 7516729 their PRP$ B-NP O
27 1488 1494 7516729 normal JJ I-NP O
28 1495 1508 7516729 concentration NN I-NP O
29 1508 1509 7516729 . . O O

1 1510 1514 7516729 Also RB B-ADVP O
2 1515 1518 7516729 the DT B-NP O
3 1519 1530 7516729 enhancement NN I-NP O
4 1531 1533 7516729 of IN B-PP O
5 1534 1543 7516729 verapamil NN B-NP B-Chemical
6 1544 1551 7516729 effects NNS I-NP O
7 1552 1554 7516729 on IN B-PP O
8 1555 1561 7516729 atrial JJ B-NP O
9 1562 1569 7516729 beating NN I-NP O
10 1570 1573 7516729 was VBD B-VP O
11 1574 1578 7516729 more RBR B-ADJP O
12 1579 1589 7516729 pronounced JJ I-ADJP O
13 1590 1592 7516729 at IN B-PP O
14 1593 1596 7516729 LNa NN B-NP O
15 1597 1601 7516729 than IN B-PP O
16 1602 1604 7516729 at IN B-PP O
17 1605 1618 7516729 LCa.(ABSTRACT NN B-NP O
18 1619 1628 7516729 TRUNCATED VBN B-VP O
19 1629 1631 7516729 AT IN B-PP O
20 1632 1635 7516729 250 CD B-NP O
21 1636 1641 7516729 WORDS NNS I-NP O
22 1641 1642 7516729 ) ) O O

1 0 0 2950248 -DOCSTART- -X- -X- O

1 0 12 2950248 Dipyridamole NN B-NP B-Chemical
2 12 13 2950248 - HYPH O O
3 13 20 2950248 induced VBN B-NP O
4 21 31 2950248 myocardial JJ I-NP B-Disease
5 32 40 2950248 ischemia NN I-NP I-Disease
6 40 41 2950248 . . O O
7 42 48 2950248 Angina NNP B-NP B-Disease
8 49 52 2950248 and CC O O
9 53 61 2950248 ischemic JJ B-NP O
10 62 82 2950248 electrocardiographic JJ I-NP O
11 83 90 2950248 changes NNS I-NP O
12 91 99 2950248 occurred VBD B-VP O
13 100 105 2950248 after IN B-PP O
14 106 120 2950248 administration NN B-NP O
15 121 123 2950248 of IN B-PP O
16 124 128 2950248 oral JJ B-NP O
17 129 141 2950248 dipyridamole NN I-NP B-Chemical
18 142 144 2950248 in IN B-PP O
19 145 149 2950248 four CD B-NP O
20 150 158 2950248 patients NNS I-NP O
21 159 167 2950248 awaiting VBG B-VP O
22 168 174 2950248 urgent JJ B-NP O
23 175 185 2950248 myocardial JJ I-NP O
24 186 203 2950248 revascularization NN I-NP O
25 204 214 2950248 procedures NNS I-NP O
26 214 215 2950248 . . O O

1 216 218 2950248 To TO B-PP O
2 219 222 2950248 our PRP$ B-NP O
3 223 232 2950248 knowledge NN I-NP O
4 232 233 2950248 , , O O
5 234 238 2950248 this DT B-NP O
6 239 242 2950248 has VBZ B-VP O
7 243 246 2950248 not RB I-VP O
8 247 257 2950248 previously RB I-VP O
9 258 262 2950248 been VBN I-VP O
10 263 271 2950248 reported VBN I-VP O
11 272 274 2950248 as IN B-PP O
12 275 276 2950248 a DT B-NP O
13 277 281 2950248 side NN I-NP O
14 282 288 2950248 effect NN I-NP O
15 289 291 2950248 of IN B-PP O
16 292 304 2950248 preoperative JJ B-NP O
17 305 317 2950248 dipyridamole NN I-NP B-Chemical
18 318 325 2950248 therapy NN I-NP O
19 325 326 2950248 , , O O
20 327 335 2950248 although IN B-SBAR O
21 336 348 2950248 dipyridamole NN B-NP B-Chemical
22 348 349 2950248 - HYPH B-NP O
23 349 356 2950248 induced VBN I-NP O
24 357 367 2950248 myocardial JJ I-NP B-Disease
25 368 376 2950248 ischemia NN I-NP I-Disease
26 377 380 2950248 has VBZ B-VP O
27 381 385 2950248 been VBN I-VP O
28 386 398 2950248 demonstrated VBN I-VP O
29 399 401 2950248 to TO I-VP O
30 402 407 2950248 occur VB I-VP O
31 408 410 2950248 in IN B-PP O
32 411 418 2950248 animals NNS B-NP O
33 419 422 2950248 and CC I-NP O
34 423 429 2950248 humans NNS I-NP O
35 430 434 2950248 with IN B-PP O
36 435 443 2950248 coronary JJ B-NP B-Disease
37 444 450 2950248 artery NN I-NP I-Disease
38 451 458 2950248 disease NN I-NP I-Disease
39 458 459 2950248 . . O O

1 460 470 2950248 Epicardial JJ B-NP O
2 471 479 2950248 coronary JJ I-NP O
3 480 490 2950248 collateral NN I-NP O
4 491 498 2950248 vessels NNS I-NP O
5 499 503 2950248 were VBD B-VP O
6 504 516 2950248 demonstrated VBN I-VP O
7 517 519 2950248 in IN B-PP O
8 520 523 2950248 all DT B-NP O
9 524 528 2950248 four CD I-NP O
10 529 537 2950248 patients NNS I-NP O
11 537 538 2950248 ; : O O
12 539 540 2950248 a DT B-NP O
13 541 549 2950248 coronary JJ I-NP O
14 550 551 2950248 " `` I-NP O
15 551 556 2950248 steal JJ I-NP O
16 556 557 2950248 " '' I-NP O
17 558 568 2950248 phenomenon NN I-NP O
18 569 572 2950248 may MD B-VP O
19 573 575 2950248 be VB I-VP O
20 576 579 2950248 the DT B-NP O
21 580 589 2950248 mechanism NN I-NP O
22 590 592 2950248 of IN B-PP O
23 593 596 2950248 the DT B-NP O
24 597 609 2950248 dipyridamole NN I-NP B-Chemical
25 609 610 2950248 - HYPH B-NP O
26 610 617 2950248 induced VBN I-NP O
27 618 626 2950248 ischemia NN I-NP B-Disease
28 627 635 2950248 observed VBN B-VP O
29 635 636 2950248 . . O O

1 0 0 2355241 -DOCSTART- -X- -X- O

1 0 5 2355241 Cause NN B-NP O
2 6 8 2355241 of IN B-PP O
3 9 14 2355241 death NN B-NP B-Disease
4 15 20 2355241 among IN B-PP O
5 21 29 2355241 patients NNS B-NP O
6 30 34 2355241 with IN B-PP O
7 35 46 2355241 Parkinson's NNS B-NP B-Disease
8 47 54 2355241 disease NN I-NP I-Disease
9 54 55 2355241 : : O O
10 56 57 2355241 a DT B-NP O
11 58 62 2355241 rare JJ I-NP O
12 63 72 2355241 mortality NN I-NP O
13 73 76 2355241 due JJ B-PP O
14 77 79 2355241 to TO B-PP O
15 80 88 2355241 cerebral JJ B-NP B-Disease
16 89 100 2355241 haemorrhage NN I-NP I-Disease
17 100 101 2355241 . . I-NP O
18 102 108 2355241 Causes NNS I-NP O
19 109 111 2355241 of IN B-PP O
20 112 117 2355241 death NN B-NP B-Disease
21 117 118 2355241 , , O O
22 119 123 2355241 with IN B-PP O
23 124 131 2355241 special JJ B-NP O
24 132 141 2355241 reference NN I-NP O
25 142 144 2355241 to TO B-PP O
26 145 153 2355241 cerebral JJ B-NP B-Disease
27 154 165 2355241 haemorrhage NN I-NP I-Disease
28 165 166 2355241 , , O O
29 167 172 2355241 among IN B-PP O
30 173 176 2355241 240 CD B-NP O
31 177 185 2355241 patients NNS I-NP O
32 186 190 2355241 with IN B-PP O
33 191 205 2355241 pathologically RB B-NP O
34 206 214 2355241 verified VBN I-NP O
35 215 226 2355241 Parkinson's NNS I-NP B-Disease
36 227 234 2355241 disease NN I-NP I-Disease
37 235 239 2355241 were VBD B-VP O
38 240 252 2355241 investigated VBN I-VP O
39 253 258 2355241 using VBG B-VP O
40 259 262 2355241 the DT B-NP O
41 263 270 2355241 Annuals NNS I-NP O
42 271 273 2355241 of IN B-PP O
43 274 277 2355241 the DT B-NP O
44 278 290 2355241 Pathological JJ I-NP O
45 291 298 2355241 Autopsy NN I-NP O
46 299 304 2355241 Cases NNS I-NP O
47 305 307 2355241 in IN B-PP O
48 308 313 2355241 Japan NNP B-NP O
49 314 318 2355241 from IN B-PP O
50 319 323 2355241 1981 CD B-NP O
51 324 326 2355241 to TO B-PP O
52 327 331 2355241 1985 CD B-NP O
53 331 332 2355241 . . O O

1 333 336 2355241 The DT B-NP O
2 337 344 2355241 leading VBG I-NP O
3 345 351 2355241 causes NNS I-NP O
4 352 354 2355241 of IN B-PP O
5 355 360 2355241 death NN B-NP B-Disease
6 361 365 2355241 were VBD B-VP O
7 366 375 2355241 pneumonia NN B-NP B-Disease
8 376 379 2355241 and CC O O
9 380 390 2355241 bronchitis NN B-NP B-Disease
10 391 392 2355241 ( ( O O
11 392 397 2355241 44.1% NN B-NP O
12 397 398 2355241 ) ) O O
13 398 399 2355241 , , O O
14 400 409 2355241 malignant JJ B-NP O
15 410 419 2355241 neoplasms NNS I-NP B-Disease
16 420 421 2355241 ( ( O O
17 421 426 2355241 11.6% NN B-NP O
18 426 427 2355241 ) ) O O
19 427 428 2355241 , , O O
20 429 434 2355241 heart NN B-NP B-Disease
21 435 443 2355241 diseases NNS I-NP I-Disease
22 444 445 2355241 ( ( O O
23 445 449 2355241 4.1% NN B-NP O
24 449 450 2355241 ) ) O O
25 450 451 2355241 , , O O
26 452 460 2355241 cerebral JJ B-NP B-Disease
27 461 471 2355241 infarction NN I-NP I-Disease
28 472 473 2355241 ( ( O O
29 473 477 2355241 3.7% NN B-NP O
30 477 478 2355241 ) ) O O
31 479 482 2355241 and CC O O
32 483 494 2355241 septicaemia NN B-NP B-Disease
33 495 496 2355241 ( ( O O
34 496 500 2355241 3.3% CD B-NP O
35 500 501 2355241 ) ) O O
36 501 502 2355241 . . O O

1 503 511 2355241 Cerebral JJ B-NP B-Disease
2 512 523 2355241 haemorrhage NN I-NP I-Disease
3 524 527 2355241 was VBD B-VP O
4 528 531 2355241 the DT B-NP O
5 532 536 2355241 11th JJ I-NP O
6 537 541 2355241 most RBS I-NP O
7 542 550 2355241 frequent JJ I-NP O
8 551 556 2355241 cause NN I-NP O
9 557 559 2355241 of IN B-PP O
10 560 565 2355241 death NN B-NP B-Disease
11 565 566 2355241 , , O O
12 567 577 2355241 accounting VBG B-VP O
13 578 581 2355241 for IN B-PP O
14 582 586 2355241 only RB B-NP O
15 587 591 2355241 0.8% CD I-NP O
16 592 594 2355241 of IN B-PP O
17 595 601 2355241 deaths NNS B-NP B-Disease
18 602 607 2355241 among IN B-PP O
19 608 611 2355241 the DT B-NP O
20 612 620 2355241 patients NNS I-NP O
21 620 621 2355241 , , O O
22 622 629 2355241 whereas IN O O
23 630 632 2355241 it PRP B-NP O
24 633 636 2355241 was VBD B-VP O
25 637 640 2355241 the DT B-NP O
26 641 644 2355241 5th JJ I-NP O
27 645 649 2355241 most RBS I-NP O
28 650 656 2355241 common JJ I-NP O
29 657 662 2355241 cause NN I-NP O
30 663 665 2355241 of IN B-PP O
31 666 671 2355241 death NN B-NP B-Disease
32 672 677 2355241 among IN B-PP O
33 678 681 2355241 the DT B-NP O
34 682 690 2355241 Japanese JJ I-NP O
35 691 698 2355241 general JJ I-NP O
36 699 709 2355241 population NN I-NP O
37 710 712 2355241 in IN B-PP O
38 713 717 2355241 1985 CD B-NP O
39 717 718 2355241 . . O O

1 719 722 2355241 The DT B-NP O
2 723 726 2355241 low JJ I-NP O
3 727 736 2355241 incidence NN I-NP O
4 737 739 2355241 of IN B-PP O
5 740 748 2355241 cerebral JJ B-NP B-Disease
6 749 760 2355241 haemorrhage NN I-NP I-Disease
7 761 763 2355241 as IN B-PP O
8 764 765 2355241 a DT B-NP O
9 766 771 2355241 cause NN I-NP O
10 772 774 2355241 of IN B-PP O
11 775 780 2355241 death NN B-NP B-Disease
12 781 783 2355241 in IN B-PP O
13 784 792 2355241 patients NNS B-NP O
14 793 797 2355241 with IN B-PP O
15 798 809 2355241 Parkinson's NNS B-NP B-Disease
16 810 817 2355241 disease NN I-NP I-Disease
17 818 821 2355241 may MD B-VP O
18 822 829 2355241 reflect VB I-VP O
19 830 833 2355241 the DT B-NP O
20 834 845 2355241 hypotensive JJ I-NP B-Disease
21 846 852 2355241 effect NN I-NP O
22 853 855 2355241 of IN B-PP O
23 856 864 2355241 levodopa NN B-NP B-Chemical
24 865 868 2355241 and CC O O
25 869 870 2355241 a DT B-NP O
26 871 882 2355241 hypotensive JJ I-NP B-Disease
27 883 892 2355241 mechanism NN I-NP O
28 893 896 2355241 due JJ B-PP O
29 897 899 2355241 to TO B-PP O
30 900 907 2355241 reduced VBN B-NP O
31 908 921 2355241 noradrenaline NN I-NP B-Chemical
32 922 928 2355241 levels NNS I-NP O
33 929 931 2355241 in IN B-PP O
34 932 935 2355241 the DT B-NP O
35 936 948 2355241 parkinsonian JJ I-NP B-Disease
36 949 954 2355241 brain NN I-NP O
37 954 955 2355241 . . O O

1 0 0 2054792 -DOCSTART- -X- -X- O

1 0 6 2054792 Effect NN B-NP O
2 7 9 2054792 of IN B-PP O
3 10 20 2054792 adriamycin NN B-NP B-Chemical
4 21 29 2054792 combined VBN B-VP O
5 30 34 2054792 with IN B-PP O
6 35 40 2054792 whole JJ B-NP O
7 41 45 2054792 body NN I-NP O
8 46 58 2054792 hyperthermia NN I-NP B-Disease
9 59 61 2054792 on IN B-PP O
10 62 67 2054792 tumor NN B-NP B-Disease
11 68 71 2054792 and CC O O
12 72 78 2054792 normal JJ B-NP O
13 79 86 2054792 tissues NNS I-NP O
14 86 87 2054792 . . O O
15 88 95 2054792 Thermal JJ B-NP O
16 96 107 2054792 enhancement NN I-NP O
17 108 110 2054792 of IN B-PP O
18 111 121 2054792 Adriamycin NN B-NP B-Chemical
19 121 122 2054792 - HYPH O O
20 122 130 2054792 mediated VBN B-VP O
21 131 140 2054792 antitumor JJ B-NP O
22 141 149 2054792 activity NN I-NP O
23 150 153 2054792 and CC O O
24 154 160 2054792 normal JJ B-NP O
25 161 167 2054792 tissue NN I-NP O
26 168 178 2054792 toxicities NNS I-NP B-Disease
27 179 181 2054792 by IN B-PP O
28 182 187 2054792 whole JJ B-NP O
29 188 192 2054792 body NN I-NP O
30 193 205 2054792 hyperthermia NN I-NP B-Disease
31 206 210 2054792 were VBD B-VP O
32 211 219 2054792 compared VBN I-VP O
33 220 225 2054792 using VBG B-VP O
34 226 227 2054792 a DT B-NP O
35 228 232 2054792 F344 NN I-NP O
36 233 236 2054792 rat NN I-NP O
37 237 242 2054792 model NN I-NP O
38 242 243 2054792 . . O O

1 244 253 2054792 Antitumor NN B-NP O
2 254 262 2054792 activity NN I-NP O
3 263 266 2054792 was VBD B-VP O
4 267 274 2054792 studied VBN I-VP O
5 275 280 2054792 using VBG B-VP O
6 281 282 2054792 a DT B-NP O
7 283 288 2054792 tumor NN I-NP B-Disease
8 289 295 2054792 growth NN I-NP O
9 296 301 2054792 delay NN I-NP O
10 302 307 2054792 assay NN I-NP O
11 307 308 2054792 . . O O

1 309 314 2054792 Acute JJ B-NP O
2 315 321 2054792 normal JJ I-NP O
3 322 328 2054792 tissue NN I-NP O
4 329 339 2054792 toxicities NNS I-NP B-Disease
5 340 341 2054792 ( ( O O
6 341 345 2054792 i.e. FW B-NP O
7 345 346 2054792 , , O O
8 347 357 2054792 leukopenia NN B-NP B-Disease
9 358 361 2054792 and CC O O
10 362 378 2054792 thrombocytopenia NN B-NP B-Disease
11 378 379 2054792 ) ) O O
12 380 383 2054792 and CC O O
13 384 388 2054792 late JJ B-NP O
14 389 395 2054792 normal JJ I-NP O
15 396 402 2054792 tissue NN I-NP O
16 403 413 2054792 toxicities NNS I-NP B-Disease
17 414 415 2054792 ( ( O O
18 415 419 2054792 i.e. FW B-NP O
19 419 420 2054792 , , O O
20 421 431 2054792 myocardial JJ B-NP B-Disease
21 432 435 2054792 and CC I-NP I-Disease
22 436 442 2054792 kidney NN I-NP I-Disease
23 443 449 2054792 injury NN I-NP I-Disease
24 449 450 2054792 ) ) O O
25 451 455 2054792 were VBD B-VP O
26 456 465 2054792 evaluated VBN I-VP O
27 466 468 2054792 by IN B-PP O
28 469 479 2054792 functional JJ B-NP O
29 479 480 2054792 / SYM I-NP O
30 480 493 2054792 physiological JJ I-NP O
31 494 500 2054792 assays NNS I-NP O
32 501 504 2054792 and CC B-PP O
33 505 507 2054792 by IN B-PP O
34 508 521 2054792 morphological JJ B-NP O
35 522 532 2054792 techniques NNS I-NP O
36 532 533 2054792 . . O O

1 534 539 2054792 Whole JJ B-NP O
2 540 544 2054792 body NN I-NP O
3 545 557 2054792 hyperthermia NN I-NP B-Disease
4 558 559 2054792 ( ( O O
5 559 562 2054792 120 CD B-NP O
6 563 566 2054792 min NN I-NP O
7 567 569 2054792 at IN B-PP O
8 570 574 2054792 41.5 CD B-NP O
9 575 582 2054792 degrees NNS I-NP O
10 583 584 2054792 C NN I-NP O
11 584 585 2054792 ) ) O O
12 586 594 2054792 enhanced VBD B-VP O
13 595 599 2054792 both CC O O
14 600 610 2054792 Adriamycin NN B-NP B-Chemical
15 610 611 2054792 - HYPH O O
16 611 619 2054792 mediated VBN B-VP O
17 620 629 2054792 antitumor JJ B-NP O
18 630 638 2054792 activity NN I-NP O
19 639 642 2054792 and CC O O
20 643 648 2054792 toxic JJ B-NP O
21 649 653 2054792 side NN I-NP O
22 654 661 2054792 effects NNS I-NP O
23 661 662 2054792 . . O O

1 663 666 2054792 The DT B-NP O
2 667 674 2054792 thermal JJ I-NP O
3 675 686 2054792 enhancement NN I-NP O
4 687 692 2054792 ratio NN I-NP O
5 693 703 2054792 calculated VBN B-VP O
6 704 707 2054792 for IN B-PP O
7 708 717 2054792 antitumor JJ B-NP O
8 718 726 2054792 activity NN I-NP O
9 727 730 2054792 was VBD B-VP O
10 731 734 2054792 1.6 CD B-NP O
11 734 735 2054792 . . O O

1 736 743 2054792 Thermal JJ B-NP O
2 744 755 2054792 enhancement NN I-NP O
3 756 762 2054792 ratios NNS I-NP O
4 763 772 2054792 estimated VBN B-VP O
5 773 776 2054792 for IN B-PP O
6 777 778 2054792 " `` B-NP O
7 778 783 2054792 acute JJ I-NP O
8 783 784 2054792 " '' I-NP O
9 785 798 2054792 hematological JJ I-NP O
10 799 806 2054792 changes NNS I-NP O
11 807 811 2054792 were VBD B-VP O
12 812 815 2054792 1.3 CD B-NP O
13 815 816 2054792 , , O O
14 817 824 2054792 whereas IN O O
15 825 830 2054792 those DT B-NP O
16 831 840 2054792 estimated VBN B-VP O
17 841 844 2054792 for IN B-PP O
18 845 846 2054792 " `` O O
19 846 850 2054792 late JJ B-NP O
20 850 851 2054792 " '' I-NP O
21 852 858 2054792 damage NN I-NP O
22 859 860 2054792 ( ( O O
23 860 865 2054792 based VBN B-PP O
24 866 868 2054792 on IN B-PP O
25 869 882 2054792 morphological JJ B-NP O
26 883 890 2054792 cardiac JJ I-NP B-Disease
27 891 894 2054792 and CC I-NP I-Disease
28 895 900 2054792 renal JJ I-NP I-Disease
29 901 908 2054792 lesions NNS I-NP I-Disease
30 908 909 2054792 ) ) O O
31 910 916 2054792 varied VBD B-VP O
32 917 924 2054792 between IN B-PP O
33 925 928 2054792 2.4 CD B-NP O
34 929 932 2054792 and CC I-NP O
35 933 936 2054792 4.3 CD I-NP O
36 936 937 2054792 . . O O

1 938 942 2054792 Thus RB B-ADVP O
2 942 943 2054792 , , O O
3 944 949 2054792 while IN B-SBAR O
4 950 955 2054792 whole JJ B-NP O
5 956 960 2054792 body NN I-NP O
6 961 973 2054792 hyperthermia NN I-NP B-Disease
7 974 982 2054792 enhances VBZ B-VP O
8 983 993 2054792 Adriamycin NN B-NP B-Chemical
9 993 994 2054792 - HYPH O O
10 994 1002 2054792 mediated VBN B-NP O
11 1003 1012 2054792 antitumor NN I-NP O
12 1013 1019 2054792 effect NN I-NP O
13 1019 1020 2054792 , , O O
14 1021 1027 2054792 normal JJ B-NP O
15 1028 1034 2054792 tissue NN I-NP O
16 1035 1043 2054792 toxicity NN I-NP B-Disease
17 1044 1046 2054792 is VBZ B-VP O
18 1047 1051 2054792 also RB I-VP O
19 1052 1061 2054792 increased VBN I-VP O
20 1061 1062 2054792 , , O O
21 1063 1066 2054792 and CC O O
22 1067 1070 2054792 the DT B-NP O
23 1071 1080 2054792 potential JJ I-NP O
24 1081 1092 2054792 therapeutic JJ I-NP O
25 1093 1097 2054792 gain NN I-NP O
26 1098 1100 2054792 of IN B-PP O
27 1101 1104 2054792 the DT B-NP O
28 1105 1113 2054792 combined JJ I-NP O
29 1114 1122 2054792 modality NN I-NP O
30 1123 1132 2054792 treatment NN I-NP O
31 1133 1135 2054792 is VBZ B-VP O
32 1136 1142 2054792 eroded VBN I-VP O
33 1142 1143 2054792 . . O O

1 0 0 6287825 -DOCSTART- -X- -X- O

1 0 8 6287825 Diseases NNS B-NP B-Disease
2 9 11 6287825 of IN B-PP I-Disease
3 12 22 6287825 peripheral JJ B-NP I-Disease
4 23 29 6287825 nerves NNS I-NP I-Disease
5 30 32 6287825 as IN B-SBAR O
6 33 37 6287825 seen VBN B-VP O
7 38 40 6287825 in IN B-PP O
8 41 44 6287825 the DT B-NP O
9 45 53 6287825 Nigerian JJ I-NP O
10 54 61 6287825 African NNP I-NP O
11 61 62 6287825 . . O O
12 63 66 6287825 The DT B-NP O
13 67 77 6287825 anatomical JJ I-NP O
14 78 81 6287825 and CC I-NP O
15 82 94 6287825 aetiological JJ I-NP O
16 95 104 6287825 diagnoses NNS I-NP O
17 105 107 6287825 of IN B-PP O
18 108 118 6287825 peripheral JJ B-NP B-Disease
19 119 124 6287825 nerve NN I-NP I-Disease
20 125 132 6287825 disease NN I-NP I-Disease
21 133 142 6287825 excluding VBG B-PP O
22 143 146 6287825 its PRP$ B-NP O
23 147 154 6287825 primary JJ I-NP O
24 155 161 6287825 benign JJ I-NP O
25 162 165 6287825 and CC I-NP O
26 166 175 6287825 malignant JJ I-NP O
27 176 185 6287825 disorders NNS I-NP O
28 185 186 6287825 , , O O
29 187 189 6287825 as IN B-SBAR O
30 190 194 6287825 seen VBN B-VP O
31 195 197 6287825 in IN B-PP O
32 198 201 6287825 358 CD B-NP O
33 202 211 6287825 Nigerians NNPS I-NP O
34 212 215 6287825 are VBP B-VP O
35 216 225 6287825 presented VBN I-VP O
36 225 226 6287825 . . O O

1 227 232 6287825 There EX B-NP O
2 233 235 6287825 is VBZ B-VP O
3 236 237 6287825 a DT B-NP O
4 238 242 6287825 male JJ I-NP O
5 243 256 6287825 preponderance NN I-NP O
6 257 260 6287825 and CC O O
7 261 264 6287825 the DT B-NP O
8 265 269 6287825 peak JJ I-NP O
9 270 279 6287825 incidence NN I-NP O
10 280 282 6287825 is VBZ B-VP O
11 283 285 6287825 in IN B-PP O
12 286 289 6287825 the DT B-NP O
13 290 296 6287825 fourth JJ I-NP O
14 297 303 6287825 decade NN I-NP O
15 303 304 6287825 . . O O

1 305 312 6287825 Sensori AFX B-NP B-Disease
2 312 313 6287825 - HYPH I-NP I-Disease
3 313 318 6287825 motor NN I-NP I-Disease
4 319 329 6287825 neuropathy NN I-NP I-Disease
5 330 333 6287825 was VBD B-VP O
6 334 337 6287825 the DT B-NP O
7 338 347 6287825 commonest JJS I-NP O
8 348 360 6287825 presentation NN I-NP O
9 361 362 6287825 ( ( O O
10 362 365 6287825 50% CD B-NP O
11 365 366 6287825 ) ) O O
12 366 367 6287825 . . O O

1 368 376 6287825 Guillain NNP B-NP B-Disease
2 376 377 6287825 - HYPH I-NP I-Disease
3 377 381 6287825 Barr NNP I-NP I-Disease
4 384 392 6287825 syndrome NN I-NP I-Disease
5 393 396 6287825 was VBD B-VP O
6 397 400 6287825 the DT B-NP O
7 401 410 6287825 commonest JJS I-NP O
8 411 423 6287825 identifiable JJ I-NP O
9 424 429 6287825 cause NN I-NP O
10 430 431 6287825 ( ( O O
11 431 436 6287825 15.6% NN B-NP O
12 436 437 6287825 ) ) O O
13 437 438 6287825 , , O O
14 439 449 6287825 accounting VBG B-VP O
15 450 453 6287825 for IN B-PP O
16 454 458 6287825 half NN B-NP O
17 459 461 6287825 of IN B-PP O
18 462 465 6287825 the DT B-NP O
19 466 471 6287825 cases NNS I-NP O
20 472 476 6287825 with IN B-PP O
21 477 482 6287825 motor NN B-NP B-Disease
22 483 493 6287825 neuropathy NN I-NP I-Disease
23 493 494 6287825 . . O O

1 495 505 6287825 Peripheral JJ B-NP B-Disease
2 506 516 6287825 neuropathy NN I-NP I-Disease
3 517 520 6287825 due JJ B-PP O
4 521 523 6287825 to TO B-PP O
5 524 535 6287825 nutritional JJ B-NP B-Disease
6 536 546 6287825 deficiency NN I-NP I-Disease
7 547 549 6287825 of IN B-PP O
8 550 558 6287825 thiamine NN B-NP B-Chemical
9 559 562 6287825 and CC I-NP O
10 563 573 6287825 riboflavin NN I-NP B-Chemical
11 574 577 6287825 was VBD B-VP O
12 578 584 6287825 common JJ B-ADJP O
13 585 586 6287825 ( ( O O
14 586 591 6287825 10.1% JJ B-ADJP O
15 591 592 6287825 ) ) O O
16 593 596 6287825 and CC O O
17 597 606 6287825 presented VBN B-VP O
18 607 613 6287825 mainly RB B-ADVP O
19 614 616 6287825 as IN B-PP O
20 617 624 6287825 sensory JJ B-ADJP O
21 625 628 6287825 and CC O O
22 629 636 6287825 sensori AFX B-NP B-Disease
23 636 637 6287825 - HYPH I-NP I-Disease
24 637 642 6287825 motor NN I-NP I-Disease
25 643 653 6287825 neuropathy NN I-NP I-Disease
26 653 654 6287825 . . O O

1 655 663 6287825 Diabetes NN B-NP B-Disease
2 664 672 6287825 mellitus NN I-NP I-Disease
3 673 676 6287825 was VBD B-VP O
4 677 680 6287825 the DT B-NP O
5 681 686 6287825 major JJ I-NP O
6 687 692 6287825 cause NN I-NP O
7 693 695 6287825 of IN B-PP O
8 696 705 6287825 autonomic JJ B-NP B-Disease
9 706 716 6287825 neuropathy NN I-NP I-Disease
10 716 717 6287825 . . O O

1 718 727 6287825 Isoniazid NN B-NP B-Chemical
2 728 731 6287825 was VBD B-VP O
3 732 735 6287825 the DT B-NP O
4 736 740 6287825 most RBS I-NP O
5 741 749 6287825 frequent JJ I-NP O
6 750 755 6287825 agent NN I-NP O
7 756 758 6287825 in IN B-PP O
8 759 763 6287825 drug NN B-NP O
9 763 764 6287825 - HYPH B-NP O
10 764 771 6287825 induced VBN I-NP O
11 772 782 6287825 neuropathy NN I-NP B-Disease
12 782 783 6287825 . . O O

1 784 792 6287825 Migraine NN B-NP B-Disease
2 793 794 6287825 ( ( O O
3 794 797 6287825 20% NN B-NP O
4 797 798 6287825 ) ) O O
5 799 802 6287825 was VBD B-VP O
6 803 806 6287825 not RB O O
7 807 809 6287825 an DT B-NP O
8 810 818 6287825 uncommon JJ I-NP O
9 819 824 6287825 cause NN I-NP O
10 825 827 6287825 of IN B-PP O
11 828 835 6287825 cranial JJ B-NP B-Disease
12 836 846 6287825 neuropathy NN I-NP I-Disease
13 847 855 6287825 although IN B-SBAR O
14 856 868 6287825 malignancies NNS B-NP B-Disease
15 869 876 6287825 arising VBG B-VP O
16 877 881 6287825 from IN B-PP O
17 882 885 6287825 the DT B-NP O
18 886 905 6287825 reticuloendothelial JJ I-NP O
19 906 912 6287825 system NN I-NP O
20 913 915 6287825 or CC O O
21 916 923 6287825 related VBN B-NP O
22 924 934 6287825 structures NNS I-NP O
23 935 937 6287825 of IN B-PP O
24 938 941 6287825 the DT B-NP O
25 942 946 6287825 head NN I-NP O
26 947 950 6287825 and CC I-NP O
27 951 955 6287825 neck NN I-NP O
28 956 960 6287825 were VBD B-VP O
29 961 965 6287825 more RBR B-ADJP O
30 966 974 6287825 frequent JJ I-ADJP O
31 975 976 6287825 ( ( O O
32 976 979 6287825 26% CD B-NP O
33 979 980 6287825 ) ) O O
34 980 981 6287825 . . O O

1 982 984 6287825 In IN B-PP O
2 985 990 6287825 26.5% CD B-NP O
3 991 993 6287825 of IN B-PP O
4 994 997 6287825 all PDT B-NP O
5 998 1001 6287825 the DT I-NP O
6 1002 1007 6287825 cases NNS I-NP O
7 1007 1008 6287825 , , O O
8 1009 1012 6287825 the DT B-NP O
9 1013 1022 6287825 aetiology NN I-NP O
10 1023 1025 6287825 of IN B-PP O
11 1026 1029 6287825 the DT B-NP O
12 1030 1040 6287825 neuropathy NN I-NP B-Disease
13 1041 1044 6287825 was VBD B-VP O
14 1045 1057 6287825 undetermined JJ B-ADJP O
15 1057 1058 6287825 . . O O

1 1059 1073 6287825 Heredofamilial JJ B-NP O
2 1074 1077 6287825 and CC I-NP O
3 1078 1088 6287825 connective JJ I-NP B-Disease
4 1089 1095 6287825 tissue NN I-NP I-Disease
5 1096 1105 6287825 disorders NNS I-NP I-Disease
6 1106 1110 6287825 were VBD B-VP O
7 1111 1115 6287825 rare JJ B-ADJP O
8 1115 1116 6287825 . . O O

1 1117 1121 6287825 Some DT B-NP O
2 1122 1124 6287825 of IN B-PP O
3 1125 1128 6287825 the DT B-NP O
4 1129 1136 6287825 factors NNS I-NP O
5 1137 1144 6287825 related JJ B-ADJP O
6 1145 1147 6287825 to TO B-PP O
7 1148 1151 6287825 the DT B-NP O
8 1152 1160 6287825 clinical JJ I-NP O
9 1161 1173 6287825 presentation NN I-NP O
10 1174 1177 6287825 and CC I-NP O
11 1178 1190 6287825 pathogenesis NN I-NP O
12 1191 1193 6287825 of IN B-PP O
13 1194 1197 6287825 the DT B-NP O
14 1198 1210 6287825 neuropathies NNS I-NP B-Disease
15 1211 1214 6287825 are VBP B-VP O
16 1215 1222 6287825 briefly RB I-VP O
17 1223 1232 6287825 discussed VBN I-VP O
18 1232 1233 6287825 . . O O

1 0 0 7423039 -DOCSTART- -X- -X- O

1 0 9 7423039 Metabolic JJ B-NP O
2 10 21 7423039 involvement NN I-NP O
3 22 24 7423039 in IN B-PP O
4 25 35 7423039 adriamycin NN B-NP B-Chemical
5 36 50 7423039 cardiotoxicity NN I-NP B-Disease
6 50 51 7423039 . . O O
7 52 55 7423039 The DT B-NP O
8 56 67 7423039 cardiotoxic JJ I-NP B-Disease
9 68 75 7423039 effects NNS I-NP O
10 76 78 7423039 of IN B-PP O
11 79 89 7423039 adriamycin NN B-NP B-Chemical
12 90 94 7423039 were VBD B-VP O
13 95 102 7423039 studied VBN I-VP O
14 103 105 7423039 in IN B-PP O
15 106 115 7423039 mammalian JJ B-NP O
16 116 126 7423039 myocardial JJ I-NP O
17 127 132 7423039 cells NNS I-NP O
18 133 135 7423039 in IN B-PP O
19 136 143 7423039 culture NN B-NP O
20 144 146 7423039 as IN B-PP O
21 147 148 7423039 a DT B-NP O
22 149 154 7423039 model NN I-NP O
23 155 161 7423039 system NN I-NP O
24 161 162 7423039 . . O O

1 163 173 7423039 Adriamycin NN B-NP B-Chemical
2 174 183 7423039 inhibited VBD B-VP O
3 184 188 7423039 cell NN B-NP O
4 189 195 7423039 growth NN I-NP O
5 196 199 7423039 and CC O O
6 200 203 7423039 the DT B-NP O
7 204 212 7423039 rhythmic JJ I-NP O
8 213 225 7423039 contractions NNS I-NP O
9 226 240 7423039 characteristic JJ B-ADJP O
10 241 243 7423039 of IN B-PP O
11 244 254 7423039 myocardial JJ B-NP O
12 255 260 7423039 cells NNS I-NP O
13 261 263 7423039 in IN B-PP O
14 264 271 7423039 culture NN B-NP O
15 271 272 7423039 . . O O

1 273 274 7423039 A DT B-NP O
2 275 283 7423039 possible JJ I-NP O
3 284 295 7423039 involvement NN I-NP O
4 296 298 7423039 of IN B-PP O
5 299 305 7423039 energy NN B-NP O
6 306 316 7423039 metabolism NN I-NP O
7 317 320 7423039 was VBD B-VP O
8 321 330 7423039 suggested VBN I-VP O
9 331 341 7423039 previously RB B-ADVP O
10 341 342 7423039 , , O O
11 343 346 7423039 and CC O O
12 347 349 7423039 in IN B-PP O
13 350 354 7423039 this DT B-NP O
14 355 360 7423039 study NN I-NP O
15 361 364 7423039 the DT B-NP O
16 365 374 7423039 adenylate NN I-NP O
17 375 381 7423039 energy NN I-NP O
18 382 388 7423039 charge NN I-NP O
19 389 392 7423039 and CC I-NP O
20 393 411 7423039 phosphorylcreatine NN I-NP B-Chemical
21 412 416 7423039 mole NN I-NP O
22 417 425 7423039 fraction NN I-NP O
23 426 430 7423039 were VBD B-VP O
24 431 441 7423039 determined VBN I-VP O
25 442 444 7423039 in IN B-PP O
26 445 448 7423039 the DT B-NP O
27 449 459 7423039 adriamycin NN I-NP B-Chemical
28 459 460 7423039 - HYPH B-NP O
29 460 467 7423039 treated VBN I-NP O
30 468 473 7423039 cells NNS I-NP O
31 473 474 7423039 . . O O

1 475 478 7423039 The DT B-NP O
2 479 488 7423039 adenylate NN I-NP O
3 489 495 7423039 energy NN I-NP O
4 496 502 7423039 charge NN I-NP O
5 503 506 7423039 was VBD B-VP O
6 507 512 7423039 found VBN I-VP O
7 513 515 7423039 to TO I-VP O
8 516 518 7423039 be VB I-VP O
9 519 532 7423039 significantly RB I-VP O
10 533 542 7423039 decreased VBN I-VP O
11 542 543 7423039 , , O O
12 544 549 7423039 while IN B-SBAR O
13 550 553 7423039 the DT B-NP O
14 554 571 7423039 phophorylcreatine NN I-NP B-Chemical
15 572 576 7423039 mole NN I-NP O
16 577 585 7423039 fraction NN I-NP O
17 586 589 7423039 was VBD B-VP O
18 590 599 7423039 unchanged JJ B-ADJP O
19 599 600 7423039 . . O O

1 601 605 7423039 Such JJ B-NP O
2 606 615 7423039 disparity NN I-NP O
3 616 624 7423039 suggests VBZ B-VP O
4 625 627 7423039 an DT B-NP O
5 628 638 7423039 inhibition NN I-NP O
6 639 641 7423039 of IN B-PP O
7 642 650 7423039 creatine NN B-NP B-Chemical
8 651 664 7423039 phosphokinase NN I-NP O
9 664 665 7423039 . . O O

1 666 669 7423039 The DT B-NP O
2 670 678 7423039 addition NN I-NP O
3 679 681 7423039 of IN B-PP O
4 682 683 7423039 1 CD B-NP O
5 684 686 7423039 mM NN I-NP O
6 687 696 7423039 adenosine NN I-NP B-Chemical
7 697 699 7423039 to TO B-PP O
8 700 703 7423039 the DT B-NP O
9 704 714 7423039 myocardial JJ I-NP O
10 715 719 7423039 cell NN I-NP O
11 720 728 7423039 cultures NNS I-NP O
12 729 737 7423039 markedly RB B-ADVP O
13 738 747 7423039 increases VBZ B-VP O
14 748 751 7423039 the DT B-NP O
15 752 755 7423039 ATP NN I-NP B-Chemical
16 756 769 7423039 concentration NN I-NP O
17 770 777 7423039 through IN B-PP O
18 778 779 7423039 a DT B-NP O
19 780 787 7423039 pathway NN I-NP O
20 788 798 7423039 reportedly RB B-VP O
21 799 806 7423039 leading VBG I-VP O
22 807 809 7423039 to TO B-PP O
23 810 811 7423039 a DT B-NP O
24 812 829 7423039 compartmentalized VBN I-NP O
25 830 833 7423039 ATP NN I-NP B-Chemical
26 834 838 7423039 pool NN I-NP O
27 838 839 7423039 . . O O

1 840 842 7423039 In IN B-PP O
2 843 846 7423039 the DT B-NP O
3 847 857 7423039 adriamycin NN I-NP B-Chemical
4 857 858 7423039 - HYPH B-NP O
5 858 865 7423039 treated VBN I-NP O
6 866 871 7423039 cells NNS I-NP O
7 871 872 7423039 , , O O
8 873 876 7423039 the DT B-NP O
9 877 885 7423039 addition NN I-NP O
10 886 888 7423039 of IN B-PP O
11 889 898 7423039 adenosine NN B-NP B-Chemical
12 899 908 7423039 increased VBD B-VP O
13 909 912 7423039 the DT B-NP O
14 913 922 7423039 adenylate NN I-NP O
15 923 929 7423039 charge NN I-NP O
16 930 933 7423039 and CC O O
17 933 934 7423039 , , O O
18 935 946 7423039 concomitant JJ B-ADJP O
19 947 951 7423039 with IN B-PP O
20 952 956 7423039 this DT B-NP O
21 957 965 7423039 inrcease NN I-NP O
22 965 966 7423039 , , O O
23 967 970 7423039 the DT B-NP O
24 971 976 7423039 cells NNS I-NP O
25 976 977 7423039 ' POS B-NP O
26 978 988 7423039 functional JJ I-NP O
27 989 998 7423039 integrity NN I-NP O
28 998 999 7423039 , , O O
29 1000 1002 7423039 in IN B-PP O
30 1003 1008 7423039 terms NNS B-NP O
31 1009 1011 7423039 of IN B-PP O
32 1012 1022 7423039 percentage NN B-NP O
33 1023 1025 7423039 of IN B-PP O
34 1026 1033 7423039 beating VBG B-VP O
35 1034 1039 7423039 cells NNS B-NP O
36 1040 1043 7423039 and CC O O
37 1044 1048 7423039 rate NN B-NP O
38 1049 1051 7423039 of IN B-PP O
39 1052 1064 7423039 contractions NNS B-NP O
40 1064 1065 7423039 , , O O
41 1066 1069 7423039 was VBD B-VP O
42 1070 1080 7423039 maintained VBN I-VP O
43 1080 1081 7423039 . . O O

1 0 0 6286738 -DOCSTART- -X- -X- O

1 0 7 6286738 Vitamin NN B-NP B-Chemical
2 8 10 6286738 D3 NN I-NP I-Chemical
3 11 19 6286738 toxicity NN I-NP B-Disease
4 20 22 6286738 in IN B-PP O
5 23 28 6286738 dairy NN B-NP O
6 29 33 6286738 cows NNS I-NP O
7 33 34 6286738 . . O O
8 35 40 6286738 Large JJ B-NP O
9 41 51 6286738 parenteral JJ I-NP O
10 52 57 6286738 doses NNS I-NP O
11 58 60 6286738 of IN B-PP O
12 61 68 6286738 vitamin NN B-NP B-Chemical
13 69 71 6286738 D3 NN I-NP I-Chemical
14 72 73 6286738 ( ( O O
15 73 75 6286738 15 CD B-NP O
16 76 78 6286738 to TO I-NP O
17 79 83 6286738 17.5 CD I-NP O
18 84 85 6286738 x SYM I-NP O
19 86 91 6286738 10(6) CD I-NP O
20 92 94 6286738 IU NN I-NP O
21 95 102 6286738 vitamin NN I-NP B-Chemical
22 103 105 6286738 D3 NN I-NP I-Chemical
23 105 106 6286738 ) ) O O
24 107 111 6286738 were VBD B-VP O
25 112 122 6286738 associated VBN I-VP O
26 123 127 6286738 with IN B-PP O
27 128 137 6286738 prolonged JJ B-NP O
28 138 151 6286738 hypercalcemia NN I-NP B-Disease
29 151 152 6286738 , , O O
30 153 170 6286738 hyperphosphatemia NN B-NP B-Disease
31 170 171 6286738 , , O O
32 172 175 6286738 and CC O O
33 176 181 6286738 large JJ B-NP O
34 182 191 6286738 increases NNS I-NP O
35 192 194 6286738 of IN B-PP O
36 195 202 6286738 vitamin NN B-NP B-Chemical
37 203 205 6286738 D3 NN I-NP I-Chemical
38 206 209 6286738 and CC O O
39 210 213 6286738 its PRP$ B-NP O
40 214 225 6286738 metabolites NNS I-NP O
41 226 228 6286738 in IN B-PP O
42 229 232 6286738 the DT B-NP O
43 233 238 6286738 blood NN I-NP O
44 239 245 6286738 plasma NN I-NP O
45 246 248 6286738 of IN B-PP O
46 249 261 6286738 nonlactating JJ B-NP O
47 262 273 6286738 nonpregnant JJ I-NP O
48 274 277 6286738 and CC I-NP O
49 278 286 6286738 pregnant JJ I-NP O
50 287 293 6286738 Jersey NNP I-NP O
51 294 298 6286738 cows NNS I-NP O
52 298 299 6286738 . . O O

1 300 307 6286738 Calcium NN B-NP B-Chemical
2 308 322 6286738 concentrations NNS I-NP O
3 323 324 6286738 1 CD I-NP O
4 325 328 6286738 day NN I-NP O
5 329 339 6286738 postpartum NN I-NP O
6 340 344 6286738 were VBD B-VP O
7 345 351 6286738 higher JJR B-ADJP O
8 352 354 6286738 in IN B-PP O
9 355 359 6286738 cows NNS B-NP O
10 360 367 6286738 treated VBN B-VP O
11 368 372 6286738 with IN B-PP O
12 373 380 6286738 vitamin NN B-NP B-Chemical
13 381 383 6286738 D3 NN I-NP I-Chemical
14 384 389 6286738 about IN B-NP O
15 390 392 6286738 32 CD I-NP O
16 393 397 6286738 days NNS I-NP O
17 398 407 6286738 prepartum NN I-NP O
18 408 409 6286738 ( ( O O
19 409 412 6286738 8.8 CD B-NP O
20 413 415 6286738 mg NN I-NP O
21 415 416 6286738 / SYM B-NP O
22 416 419 6286738 100 CD B-NP O
23 420 422 6286738 ml NN I-NP O
24 422 423 6286738 ) ) O O
25 424 428 6286738 than IN B-PP O
26 429 431 6286738 in IN B-PP O
27 432 439 6286738 control NN B-NP O
28 440 444 6286738 cows NNS I-NP O
29 445 446 6286738 ( ( O O
30 446 449 6286738 5.5 CD B-NP O
31 450 452 6286738 mg NN I-NP O
32 452 453 6286738 / SYM B-NP O
33 453 456 6286738 100 CD B-NP O
34 457 459 6286738 ml NN I-NP O
35 459 460 6286738 ) ) O O
36 460 461 6286738 . . O O

1 462 466 6286738 None NN B-NP O
2 467 469 6286738 of IN B-PP O
3 470 473 6286738 the DT B-NP O
4 474 478 6286738 cows NNS I-NP O
5 479 486 6286738 treated VBN B-VP O
6 487 491 6286738 with IN B-PP O
7 492 499 6286738 vitamin NN B-NP B-Chemical
8 500 502 6286738 D3 NN I-NP I-Chemical
9 503 509 6286738 showed VBD B-VP O
10 510 515 6286738 signs NNS B-NP O
11 516 518 6286738 of IN B-PP O
12 519 523 6286738 milk NN B-NP B-Disease
13 524 529 6286738 fever NN I-NP I-Disease
14 530 536 6286738 during IN B-PP O
15 537 540 6286738 the DT B-NP O
16 541 551 6286738 peripartal JJ I-NP O
17 552 558 6286738 period NN I-NP O
18 558 559 6286738 ; : O O
19 560 567 6286738 however RB B-ADVP O
20 567 568 6286738 , , O O
21 569 572 6286738 22% CD B-NP O
22 573 575 6286738 of IN B-PP O
23 576 579 6286738 the DT B-NP O
24 580 587 6286738 control NN I-NP O
25 588 592 6286738 cows NNS I-NP O
26 593 602 6286738 developed VBD B-VP O
27 603 611 6286738 clinical JJ B-NP O
28 612 617 6286738 signs NNS I-NP O
29 618 620 6286738 of IN B-PP O
30 621 625 6286738 milk NN B-NP B-Disease
31 626 631 6286738 fever NN I-NP I-Disease
32 632 638 6286738 during IN B-PP O
33 639 643 6286738 this DT B-NP O
34 644 650 6286738 period NN I-NP O
35 650 651 6286738 . . O O

1 652 657 6286738 Signs NNS B-NP O
2 658 660 6286738 of IN B-PP O
3 661 668 6286738 vitamin NN B-NP B-Chemical
4 669 671 6286738 D3 NN I-NP I-Chemical
5 672 680 6286738 toxicity NN I-NP B-Disease
6 681 685 6286738 were VBD B-VP O
7 686 689 6286738 not RB I-VP O
8 690 698 6286738 observed VBN I-VP O
9 699 701 6286738 in IN B-PP O
10 702 714 6286738 nonlactating JJ B-NP O
11 715 726 6286738 nonpregnant JJ I-NP O
12 727 731 6286738 cows NNS I-NP O
13 731 732 6286738 ; : O O
14 733 740 6286738 however RB B-ADVP O
15 740 741 6286738 , , O O
16 742 750 6286738 pregnant JJ B-NP O
17 751 755 6286738 cows NNS I-NP O
18 756 764 6286738 commonly RB B-ADVP O
19 765 774 6286738 developed VBD B-VP O
20 775 781 6286738 severe JJ B-NP O
21 782 787 6286738 signs NNS I-NP O
22 788 790 6286738 of IN B-PP O
23 791 798 6286738 vitamin NN B-NP B-Chemical
24 799 801 6286738 D3 NN I-NP I-Chemical
25 802 810 6286738 toxicity NN I-NP B-Disease
26 811 814 6286738 and CC O O
27 815 817 6286738 10 CD B-NP O
28 818 820 6286738 of IN B-PP O
29 821 823 6286738 17 CD B-NP O
30 824 828 6286738 cows NNS I-NP O
31 829 833 6286738 died VBD B-VP O
32 833 834 6286738 . . O O

1 835 840 6286738 There EX B-NP O
2 841 844 6286738 was VBD B-VP O
3 845 855 6286738 widespread JJ B-NP O
4 856 866 6286738 metastatic JJ I-NP O
5 867 880 6286738 calcification NN I-NP O
6 881 883 6286738 in IN B-PP O
7 884 887 6286738 the DT B-NP O
8 888 892 6286738 cows NNS I-NP O
9 893 897 6286738 that WDT B-NP O
10 898 902 6286738 died VBD B-VP O
11 902 903 6286738 . . O O

1 904 911 6286738 Because IN B-PP O
2 912 914 6286738 of IN I-PP O
3 915 918 6286738 the DT B-NP O
4 919 926 6286738 extreme JJ I-NP O
5 927 935 6286738 toxicity NN I-NP B-Disease
6 936 938 6286738 of IN B-PP O
7 939 946 6286738 vitamin NN B-NP B-Chemical
8 947 949 6286738 D3 NN I-NP I-Chemical
9 950 952 6286738 in IN B-PP O
10 953 961 6286738 pregnant JJ B-NP O
11 962 968 6286738 Jersey NNP I-NP O
12 969 973 6286738 cows NNS I-NP O
13 974 977 6286738 and CC O O
14 978 981 6286738 the DT B-NP O
15 982 985 6286738 low JJ I-NP O
16 986 992 6286738 margin NN I-NP O
17 993 995 6286738 of IN B-PP O
18 996 1002 6286738 safety NN B-NP O
19 1003 1010 6286738 between IN B-PP O
20 1011 1016 6286738 doses NNS B-NP O
21 1017 1019 6286738 of IN B-PP O
22 1020 1027 6286738 vitamin NN B-NP B-Chemical
23 1028 1030 6286738 D3 NN I-NP I-Chemical
24 1031 1035 6286738 that WDT B-NP O
25 1036 1043 6286738 prevent VBP B-VP O
26 1044 1048 6286738 milk NN B-NP B-Disease
27 1049 1054 6286738 fever NN I-NP I-Disease
28 1055 1058 6286738 and CC I-NP O
29 1059 1064 6286738 doses NNS I-NP O
30 1065 1069 6286738 that WDT B-NP O
31 1070 1076 6286738 induce VBP B-VP O
32 1077 1081 6286738 milk NN B-NP B-Disease
33 1082 1087 6286738 fever NN I-NP I-Disease
34 1087 1088 6286738 , , O O
35 1089 1091 6286738 we PRP B-NP O
36 1092 1101 6286738 concluded VBD B-VP O
37 1102 1106 6286738 that IN B-SBAR O
38 1107 1114 6286738 vitamin NN B-NP B-Chemical
39 1115 1117 6286738 D3 NN I-NP I-Chemical
40 1118 1124 6286738 cannot MD B-VP O
41 1125 1127 6286738 be VB I-VP O
42 1128 1132 6286738 used VBN I-VP O
43 1133 1144 6286738 practically RB B-ADVP O
44 1145 1147 6286738 to TO B-VP O
45 1148 1155 6286738 prevent VB I-VP O
46 1156 1160 6286738 milk NN B-NP B-Disease
47 1161 1166 6286738 fever NN I-NP I-Disease
48 1167 1171 6286738 when WRB B-ADVP O
49 1172 1180 6286738 injected VBN B-VP O
50 1181 1188 6286738 several JJ B-NP O
51 1189 1194 6286738 weeks NNS I-NP O
52 1195 1204 6286738 prepartum NN I-NP O
53 1204 1205 6286738 . . O O

1 0 0 9653867 -DOCSTART- -X- -X- O

1 0 9 9653867 Thyroxine NN B-NP B-Chemical
2 10 15 9653867 abuse NN I-NP O
3 15 16 9653867 : : O O
4 17 19 9653867 an DT B-NP O
5 20 27 9653867 unusual JJ I-NP O
6 28 32 9653867 case NN I-NP O
7 33 35 9653867 of IN B-PP O
8 36 50 9653867 thyrotoxicosis NN B-NP B-Disease
9 51 53 9653867 in IN B-PP O
10 54 63 9653867 pregnancy NN B-NP O
11 63 64 9653867 . . O O
12 65 71 9653867 Eating VBG B-VP B-Disease
13 72 81 9653867 disorders NNS B-NP I-Disease
14 82 85 9653867 and CC O O
15 86 89 9653867 the DT B-NP O
16 90 100 9653867 associated VBN I-NP O
17 101 112 9653867 behavioural JJ I-NP O
18 113 121 9653867 problems NNS I-NP O
19 122 125 9653867 and CC I-NP O
20 126 130 9653867 drug NN I-NP B-Disease
21 131 136 9653867 abuse NN I-NP I-Disease
22 137 140 9653867 are VBP B-VP O
23 141 149 9653867 uncommon JJ B-ADJP O
24 150 152 9653867 in IN B-PP O
25 153 162 9653867 pregnancy NN B-NP O
26 162 163 9653867 . . O O

1 164 168 9653867 When WRB B-ADVP O
2 169 173 9653867 they PRP B-NP O
3 174 176 9653867 do VBP B-VP O
4 177 182 9653867 occur VB I-VP O
5 183 187 9653867 they PRP B-NP O
6 188 191 9653867 are VBP B-VP O
7 192 197 9653867 often RB B-ADVP O
8 198 210 9653867 unrecognized JJ B-ADJP O
9 211 218 9653867 because IN B-PP O
10 219 221 9653867 of IN I-PP O
11 222 228 9653867 denial NN B-NP O
12 229 232 9653867 but CC O O
13 233 237 9653867 when WRB B-ADVP O
14 238 249 9653867 significant JJ B-NP O
15 250 253 9653867 may MD B-VP O
16 254 258 9653867 pose VB I-VP O
17 259 260 9653867 a DT B-NP O
18 261 265 9653867 risk NN I-NP O
19 266 268 9653867 to TO B-PP O
20 269 273 9653867 both CC O O
21 274 277 9653867 the DT B-NP O
22 278 284 9653867 mother NN I-NP O
23 285 288 9653867 and CC O O
24 289 292 9653867 her PRP$ B-NP O
25 293 298 9653867 fetus NN I-NP O
26 298 299 9653867 . . O O

1 300 304 9653867 This DT B-NP O
2 305 309 9653867 case NN I-NP O
3 310 321 9653867 illustrates VBZ B-VP O
4 322 323 9653867 a DT B-NP O
5 324 330 9653867 number NN I-NP O
6 331 333 9653867 of IN B-PP O
7 334 342 9653867 problems NNS B-NP O
8 343 347 9653867 that WDT B-NP O
9 348 351 9653867 may MD B-VP O
10 352 354 9653867 be VB I-VP O
11 355 366 9653867 encountered VBN I-VP O
12 367 369 9653867 in IN B-PP O
13 370 375 9653867 women NNS B-NP O
14 376 380 9653867 with IN B-PP O
15 381 387 9653867 eating VBG B-VP B-Disease
16 388 397 9653867 disorders NNS B-NP I-Disease
17 398 400 9653867 in IN B-PP O
18 401 410 9653867 pregnancy NN B-NP O
19 410 411 9653867 , , O O
20 412 421 9653867 including VBG B-PP O
21 422 431 9653867 prolonged JJ B-NP O
22 432 435 9653867 and CC I-NP O
23 436 445 9653867 recurrent JJ I-NP O
24 446 455 9653867 metabolic JJ I-NP O
25 456 468 9653867 disturbances NNS I-NP O
26 469 472 9653867 and CC O O
27 473 481 9653867 diuretic JJ B-NP O
28 482 487 9653867 abuse NN I-NP O
29 487 488 9653867 . . O O

1 489 491 9653867 In IN B-PP O
2 492 502 9653867 particular JJ B-NP O
3 503 505 9653867 it PRP B-NP O
4 506 517 9653867 illustrates VBZ B-VP O
5 518 521 9653867 the DT B-NP O
6 522 534 9653867 derangements NNS I-NP O
7 535 537 9653867 of IN B-PP O
8 538 545 9653867 thyroid NN B-NP O
9 546 554 9653867 function NN I-NP O
10 555 559 9653867 seen VBN B-VP O
11 560 562 9653867 in IN B-PP O
12 563 571 9653867 pregnant JJ B-NP O
13 572 577 9653867 women NNS I-NP O
14 578 582 9653867 with IN B-PP O
15 583 589 9653867 eating VBG B-NP B-Disease
16 590 599 9653867 disorders NNS I-NP I-Disease
17 600 603 9653867 and CC O O
18 604 611 9653867 reminds VBZ B-VP O
19 612 614 9653867 us PRP B-NP O
20 615 619 9653867 that IN B-SBAR O
21 620 624 9653867 when WRB B-ADVP O
22 625 626 9653867 a DT B-NP O
23 627 632 9653867 cause NN I-NP O
24 633 636 9653867 for IN B-PP O
25 637 651 9653867 thyrotoxicosis NN B-NP B-Disease
26 652 659 9653867 remains VBZ B-VP O
27 660 667 9653867 obscure JJ B-ADJP O
28 667 668 9653867 , , O O
29 669 678 9653867 thyroxine NN B-NP B-Chemical
30 679 684 9653867 abuse NN I-NP O
31 685 691 9653867 should MD B-VP O
32 692 694 9653867 be VB I-VP O
33 695 705 9653867 considered VBN I-VP O
34 706 709 9653867 and CC I-VP O
35 710 718 9653867 explored VBN I-VP O
36 718 719 9653867 . . O O

1 0 0 15009014 -DOCSTART- -X- -X- O

1 0 7 15009014 Noxious JJ B-NP O
2 8 16 15009014 chemical NN I-NP O
3 17 28 15009014 stimulation NN I-NP O
4 29 31 15009014 of IN B-PP O
5 32 35 15009014 rat NN B-NP O
6 36 42 15009014 facial JJ I-NP O
7 43 49 15009014 mucosa NN I-NP O
8 50 59 15009014 increases VBZ B-VP O
9 60 72 15009014 intracranial JJ B-NP O
10 73 78 15009014 blood NN I-NP O
11 79 83 15009014 flow NN I-NP O
12 84 91 15009014 through IN B-PP O
13 92 93 15009014 a DT B-NP O
14 94 103 15009014 trigemino AFX I-NP O
15 103 104 15009014 - HYPH I-NP O
16 104 119 15009014 parasympathetic JJ I-NP O
17 120 126 15009014 reflex NN I-NP O
18 126 127 15009014 - HYPH B-VP O
19 127 128 15009014 - HYPH B-NP O
20 128 130 15009014 an DT B-NP O
21 131 143 15009014 experimental JJ I-NP O
22 144 149 15009014 model NN I-NP O
23 150 153 15009014 for IN B-PP O
24 154 162 15009014 vascular JJ B-NP B-Disease
25 163 175 15009014 dysfunctions NNS I-NP I-Disease
26 176 178 15009014 in IN B-PP O
27 179 186 15009014 cluster NN B-NP B-Disease
28 187 195 15009014 headache NN I-NP I-Disease
29 195 196 15009014 . . O O
30 197 204 15009014 Cluster NNP B-NP B-Disease
31 205 213 15009014 headache PRP B-NP I-Disease
32 214 216 15009014 is VBZ B-VP O
33 217 230 15009014 characterized VBN I-VP O
34 231 233 15009014 by IN B-PP O
35 234 241 15009014 typical JJ B-NP O
36 242 251 15009014 autonomic JJ I-NP O
37 252 264 15009014 dysfunctions NNS I-NP O
38 265 274 15009014 including VBG B-PP O
39 275 281 15009014 facial JJ B-NP O
40 282 285 15009014 and CC I-NP O
41 286 298 15009014 intracranial JJ I-NP B-Disease
42 299 307 15009014 vascular JJ I-NP I-Disease
43 308 320 15009014 disturbances NNS I-NP I-Disease
44 320 321 15009014 . . O O

1 322 326 15009014 Both CC O O
2 327 330 15009014 the DT B-NP O
3 331 341 15009014 trigeminal JJ I-NP O
4 342 345 15009014 and CC O O
5 346 349 15009014 the DT B-NP O
6 350 357 15009014 cranial JJ I-NP O
7 358 373 15009014 parasympathetic JJ I-NP O
8 374 381 15009014 systems NNS I-NP O
9 382 385 15009014 may MD B-VP O
10 386 388 15009014 be VB I-VP O
11 389 397 15009014 involved VBN I-VP O
12 398 400 15009014 in IN B-PP O
13 401 410 15009014 mediating VBG B-VP O
14 411 416 15009014 these DT B-NP O
15 417 429 15009014 dysfunctions NNS I-NP O
16 429 430 15009014 . . O O

1 431 433 15009014 An DT B-NP O
2 434 446 15009014 experimental JJ I-NP O
3 447 452 15009014 model NN I-NP O
4 453 456 15009014 was VBD B-VP O
5 457 466 15009014 developed VBN I-VP O
6 467 469 15009014 in IN B-PP O
7 470 473 15009014 the DT B-NP O
8 474 477 15009014 rat NN I-NP O
9 478 480 15009014 to TO B-VP O
10 481 488 15009014 measure VB I-VP O
11 489 496 15009014 changes NNS B-NP O
12 497 499 15009014 in IN B-PP O
13 500 511 15009014 lacrimation NN B-NP O
14 512 515 15009014 and CC O O
15 516 528 15009014 intracranial JJ B-NP O
16 529 534 15009014 blood NN I-NP O
17 535 539 15009014 flow NN I-NP O
18 540 549 15009014 following VBG B-PP O
19 550 557 15009014 noxious JJ B-NP O
20 558 566 15009014 chemical NN I-NP O
21 567 578 15009014 stimulation NN I-NP O
22 579 581 15009014 of IN B-PP O
23 582 588 15009014 facial JJ B-NP O
24 589 595 15009014 mucosa NN I-NP O
25 595 596 15009014 . . O O

1 597 602 15009014 Blood NN B-NP O
2 603 607 15009014 flow NN I-NP O
3 608 611 15009014 was VBD B-VP O
4 612 621 15009014 monitored VBN I-VP O
5 622 624 15009014 in IN B-PP O
6 625 633 15009014 arteries NNS B-NP O
7 634 636 15009014 of IN B-PP O
8 637 640 15009014 the DT B-NP O
9 641 648 15009014 exposed VBN I-NP O
10 649 656 15009014 cranial JJ I-NP O
11 657 661 15009014 dura NN I-NP O
12 662 667 15009014 mater NN I-NP O
13 668 671 15009014 and CC O O
14 672 675 15009014 the DT B-NP O
15 676 684 15009014 parietal JJ I-NP O
16 685 691 15009014 cortex NN I-NP O
17 692 697 15009014 using VBG B-VP O
18 698 703 15009014 laser NN B-NP O
19 704 711 15009014 Doppler NNP I-NP O
20 712 721 15009014 flowmetry NN I-NP O
21 721 722 15009014 . . O O

1 723 732 15009014 Capsaicin NN B-NP B-Chemical
2 733 734 15009014 ( ( O O
3 734 738 15009014 0.01 CD B-NP O
4 738 739 15009014 - HYPH O O
5 739 740 15009014 1 CD B-NP O
6 741 743 15009014 mm NN I-NP O
7 743 744 15009014 ) ) O O
8 745 752 15009014 applied VBD B-VP O
9 753 755 15009014 to TO B-PP O
10 756 760 15009014 oral JJ B-NP O
11 761 763 15009014 or CC I-NP O
12 764 769 15009014 nasal JJ I-NP O
13 770 776 15009014 mucosa NN I-NP O
14 777 784 15009014 induced VBD B-VP O
15 785 794 15009014 increases NNS B-NP B-Disease
16 795 797 15009014 in IN B-PP I-Disease
17 798 803 15009014 dural JJ B-NP I-Disease
18 804 807 15009014 and CC I-NP I-Disease
19 808 816 15009014 cortical JJ I-NP I-Disease
20 817 822 15009014 blood NN I-NP I-Disease
21 823 827 15009014 flow NN I-NP I-Disease
22 828 831 15009014 and CC O O
23 832 840 15009014 provoked JJ B-NP O
24 841 852 15009014 lacrimation NN I-NP O
25 852 853 15009014 . . O O

1 854 859 15009014 These DT B-NP O
2 860 869 15009014 responses NNS I-NP O
3 870 874 15009014 were VBD B-VP O
4 875 882 15009014 blocked VBN I-VP O
5 883 885 15009014 by IN B-PP O
6 886 894 15009014 systemic JJ B-NP O
7 895 898 15009014 pre AFX I-NP O
8 898 899 15009014 - HYPH I-NP O
9 899 913 15009014 administration NN B-NP O
10 914 916 15009014 of IN B-PP O
11 917 930 15009014 hexamethonium NN B-NP B-Chemical
12 931 939 15009014 chloride NN I-NP I-Chemical
13 940 941 15009014 ( ( O O
14 941 943 15009014 20 CD B-NP O
15 944 946 15009014 mg NN I-NP O
16 946 947 15009014 / SYM B-NP O
17 947 949 15009014 kg NN I-NP O
18 949 950 15009014 ) ) O O
19 950 951 15009014 . . O O

1 952 955 15009014 The DT B-NP O
2 956 962 15009014 evoked VBN I-NP O
3 963 972 15009014 increases NNS I-NP B-Disease
4 973 975 15009014 in IN B-PP I-Disease
5 976 981 15009014 dural JJ B-NP I-Disease
6 982 987 15009014 blood NN I-NP I-Disease
7 988 992 15009014 flow NN I-NP I-Disease
8 993 997 15009014 were VBD B-VP O
9 998 1002 15009014 also RB I-VP O
10 1003 1012 15009014 abolished VBN I-VP O
11 1013 1015 15009014 by IN B-PP O
12 1016 1023 15009014 topical JJ B-NP O
13 1024 1027 15009014 pre AFX I-NP O
14 1027 1028 15009014 - HYPH I-NP O
15 1028 1042 15009014 administration NN B-NP O
16 1043 1045 15009014 of IN B-PP O
17 1046 1054 15009014 atropine NN B-NP B-Chemical
18 1055 1056 15009014 ( ( O O
19 1056 1057 15009014 1 CD B-NP O
20 1058 1060 15009014 mm NN I-NP O
21 1060 1061 15009014 ) ) O O
22 1062 1065 15009014 and CC O O
23 1066 1067 15009014 [ ( O O
24 1067 1071 15009014 Lys1 NN B-NP O
25 1071 1072 15009014 , , O O
26 1073 1079 15009014 Pro2,5 NN B-NP O
27 1079 1080 15009014 , , O O
28 1081 1087 15009014 Arg3,4 NN B-NP O
29 1087 1088 15009014 , , O O
30 1089 1094 15009014 Tyr6] NN B-NP O
31 1094 1095 15009014 - HYPH O O
32 1095 1098 15009014 VIP NN B-NP O
33 1099 1100 15009014 ( ( O O
34 1100 1103 15009014 0.1 CD B-NP O
35 1104 1106 15009014 mm NN I-NP O
36 1106 1107 15009014 ) ) O O
37 1107 1108 15009014 , , O O
38 1109 1110 15009014 a DT B-NP O
39 1111 1121 15009014 vasoactive JJ I-NP O
40 1122 1132 15009014 intestinal JJ I-NP O
41 1133 1144 15009014 polypeptide NN I-NP O
42 1145 1146 15009014 ( ( O O
43 1146 1149 15009014 VIP NN B-NP O
44 1149 1150 15009014 ) ) O O
45 1151 1161 15009014 antagonist NN B-NP O
46 1161 1162 15009014 , , O O
47 1163 1167 15009014 onto IN B-PP O
48 1168 1171 15009014 the DT B-NP O
49 1172 1179 15009014 exposed VBN I-NP O
50 1180 1184 15009014 dura NN I-NP O
51 1185 1190 15009014 mater NN I-NP O
52 1190 1191 15009014 . . O O

1 1192 1194 15009014 We PRP B-NP O
2 1195 1203 15009014 conclude VBP B-VP O
3 1204 1208 15009014 that IN B-SBAR O
4 1209 1216 15009014 noxious JJ B-NP O
5 1217 1228 15009014 stimulation NN I-NP O
6 1229 1231 15009014 of IN B-PP O
7 1232 1238 15009014 facial JJ B-NP O
8 1239 1245 15009014 mucosa NN I-NP O
9 1246 1255 15009014 increases VBZ B-VP O
10 1256 1268 15009014 intracranial JJ B-NP O
11 1269 1274 15009014 blood NN I-NP O
12 1275 1279 15009014 flow NN I-NP O
13 1280 1283 15009014 and CC I-NP O
14 1284 1295 15009014 lacrimation NN I-NP O
15 1296 1299 15009014 via IN B-PP O
16 1300 1301 15009014 a DT B-NP O
17 1302 1311 15009014 trigemino AFX I-NP O
18 1311 1312 15009014 - HYPH I-NP O
19 1312 1327 15009014 parasympathetic JJ I-NP O
20 1328 1334 15009014 reflex NN I-NP O
21 1334 1335 15009014 . . O O

1 1336 1339 15009014 The DT B-NP O
2 1340 1345 15009014 blood NN I-NP O
3 1346 1350 15009014 flow NN I-NP O
4 1351 1360 15009014 responses NNS I-NP O
5 1361 1365 15009014 seem VBP B-VP O
6 1366 1368 15009014 to TO I-VP O
7 1369 1371 15009014 be VB I-VP O
8 1372 1380 15009014 mediated VBN I-VP O
9 1381 1383 15009014 by IN B-PP O
10 1384 1387 15009014 the DT B-NP O
11 1388 1395 15009014 release NN I-NP O
12 1396 1398 15009014 of IN B-PP O
13 1399 1412 15009014 acetylcholine NN B-NP B-Chemical
14 1413 1416 15009014 and CC I-NP O
15 1417 1420 15009014 VIP NN I-NP O
16 1421 1427 15009014 within IN B-PP O
17 1428 1431 15009014 the DT B-NP O
18 1432 1440 15009014 meninges NNS I-NP O
19 1440 1441 15009014 . . O O

1 1442 1449 15009014 Similar JJ B-NP O
2 1450 1460 15009014 mechanisms NNS I-NP O
3 1461 1464 15009014 may MD B-VP O
4 1465 1467 15009014 be VB I-VP O
5 1468 1476 15009014 involved VBN I-VP O
6 1477 1479 15009014 in IN B-PP O
7 1480 1483 15009014 the DT B-NP O
8 1484 1496 15009014 pathogenesis NN I-NP O
9 1497 1499 15009014 of IN B-PP O
10 1500 1507 15009014 cluster NN B-NP B-Disease
11 1508 1516 15009014 headache NN I-NP I-Disease
12 1516 1517 15009014 . . O O

1 0 0 3101906 -DOCSTART- -X- -X- O

1 0 7 3101906 Hepatic JJ B-NP O
2 8 17 3101906 reactions NNS I-NP O
3 18 28 3101906 associated VBN B-VP O
4 29 33 3101906 with IN B-PP O
5 34 46 3101906 ketoconazole NN B-NP B-Chemical
6 47 49 3101906 in IN B-PP O
7 50 53 3101906 the DT B-NP O
8 54 60 3101906 United NNP I-NP O
9 61 68 3101906 Kingdom NNP I-NP O
10 68 69 3101906 . . I-NP O
11 70 82 3101906 Ketoconazole NNP I-NP B-Chemical
12 83 86 3101906 was VBD B-VP O
13 87 97 3101906 introduced VBN I-VP O
14 98 100 3101906 in IN B-PP O
15 101 104 3101906 the DT B-NP O
16 105 111 3101906 United NNP I-NP O
17 112 119 3101906 Kingdom NNP I-NP O
18 120 122 3101906 in IN B-PP O
19 123 127 3101906 1981 CD B-NP O
20 127 128 3101906 . . O O

1 129 131 3101906 By IN B-PP O
2 132 140 3101906 November NNP B-NP O
3 141 145 3101906 1984 CD I-NP O
4 146 149 3101906 the DT B-NP O
5 150 159 3101906 Committee NNP I-NP O
6 160 162 3101906 on IN B-PP O
7 163 169 3101906 Safety NNP B-NP O
8 170 172 3101906 of IN B-PP O
9 173 182 3101906 Medicines NNP B-NP O
10 183 186 3101906 had VBD B-VP O
11 187 195 3101906 received VBN I-VP O
12 196 198 3101906 82 CD B-NP O
13 199 206 3101906 reports NNS I-NP O
14 207 209 3101906 of IN B-PP O
15 210 218 3101906 possible JJ B-NP O
16 219 233 3101906 hepatotoxicity NN I-NP B-Disease
17 234 244 3101906 associated VBN B-VP O
18 245 249 3101906 with IN B-PP O
19 250 253 3101906 the DT B-NP O
20 254 258 3101906 drug NN I-NP O
21 258 259 3101906 , , O O
22 260 269 3101906 including VBG B-PP O
23 270 274 3101906 five CD B-NP O
24 275 281 3101906 deaths NNS I-NP B-Disease
25 281 282 3101906 . . O O

1 283 285 3101906 An DT B-NP O
2 286 294 3101906 analysis NN I-NP O
3 295 297 3101906 of IN B-PP O
4 298 301 3101906 the DT B-NP O
5 302 304 3101906 75 CD I-NP O
6 305 310 3101906 cases NNS I-NP O
7 311 315 3101906 that WDT B-NP O
8 316 319 3101906 had VBD B-VP O
9 320 324 3101906 been VBN I-VP O
10 325 335 3101906 adequately RB I-VP O
11 336 344 3101906 followed VBN I-VP O
12 345 347 3101906 up RP B-PRT O
13 348 357 3101906 suggested VBD B-VP O
14 358 362 3101906 that IN B-SBAR O
15 363 365 3101906 16 CD B-NP O
16 365 366 3101906 , , O O
17 367 376 3101906 including VBG B-PP O
18 377 382 3101906 three CD B-NP O
19 383 389 3101906 deaths NNS I-NP B-Disease
20 389 390 3101906 , , O O
21 391 395 3101906 were VBD B-VP O
22 396 404 3101906 probably RB I-VP O
23 405 412 3101906 related VBN I-VP O
24 413 415 3101906 to TO B-PP O
25 416 425 3101906 treatment NN B-NP O
26 426 430 3101906 with IN B-PP O
27 431 434 3101906 the DT B-NP O
28 435 439 3101906 drug NN I-NP O
29 439 440 3101906 . . O O

1 441 443 3101906 Of IN B-PP O
2 444 447 3101906 the DT B-NP O
3 448 457 3101906 remainder NN I-NP O
4 457 458 3101906 , , O O
5 459 461 3101906 48 CD B-NP O
6 462 466 3101906 were VBD B-VP O
7 467 475 3101906 possibly RB I-VP O
8 476 483 3101906 related VBN I-VP O
9 484 486 3101906 to TO B-PP O
10 487 496 3101906 treatment NN B-NP O
11 496 497 3101906 , , O O
12 498 502 3101906 five CD B-NP O
13 503 507 3101906 were VBD B-VP O
14 508 516 3101906 unlikely JJ B-ADJP O
15 517 519 3101906 to TO B-VP O
16 520 522 3101906 be VB I-VP O
17 523 525 3101906 so RB B-ADVP O
18 525 526 3101906 , , O O
19 527 530 3101906 and CC O O
20 531 534 3101906 six CD B-NP O
21 535 539 3101906 were VBD B-VP O
22 540 554 3101906 unclassifiable JJ B-ADJP O
23 554 555 3101906 . . O O

1 556 559 3101906 The DT B-NP O
2 560 564 3101906 mean JJ I-NP O
3 565 568 3101906 age NN I-NP O
4 569 571 3101906 of IN B-PP O
5 572 580 3101906 patients NNS B-NP O
6 581 583 3101906 in IN B-PP O
7 584 587 3101906 the DT B-NP O
8 588 590 3101906 16 CD I-NP O
9 591 599 3101906 probable JJ I-NP O
10 600 605 3101906 cases NNS I-NP O
11 606 609 3101906 was VBD B-VP O
12 610 614 3101906 57.9 CD B-NP O
13 614 615 3101906 , , O O
14 616 620 3101906 with IN B-PP O
15 621 635 3101906 hepatotoxicity NN B-NP B-Disease
16 636 641 3101906 being VBG B-VP O
17 642 646 3101906 more RBR B-ADJP O
18 647 653 3101906 common JJ I-ADJP O
19 654 656 3101906 in IN B-PP O
20 657 662 3101906 women NNS B-NP O
21 662 663 3101906 . . O O

1 664 667 3101906 The DT B-NP O
2 668 675 3101906 average JJ I-NP O
3 676 684 3101906 duration NN I-NP O
4 685 687 3101906 of IN B-PP O
5 688 697 3101906 treatment NN B-NP O
6 698 704 3101906 before IN B-PP O
7 705 708 3101906 the DT B-NP O
8 709 714 3101906 onset NN I-NP O
9 715 717 3101906 of IN B-PP O
10 718 726 3101906 jaundice NN B-NP B-Disease
11 727 730 3101906 was VBD B-VP O
12 731 733 3101906 61 CD B-NP O
13 734 738 3101906 days NNS I-NP O
14 738 739 3101906 . . O O

1 740 744 3101906 None NN B-NP O
2 745 747 3101906 of IN B-PP O
3 748 753 3101906 these DT B-NP O
4 754 758 3101906 well RB I-NP O
5 759 768 3101906 validated VBN I-NP O
6 769 774 3101906 cases NNS I-NP O
7 775 783 3101906 occurred VBD B-VP O
8 784 790 3101906 within IN B-PP O
9 791 794 3101906 the DT B-NP O
10 795 800 3101906 first JJ I-NP O
11 801 803 3101906 10 CD I-NP O
12 804 808 3101906 days NNS I-NP O
13 809 814 3101906 after IN B-PP O
14 815 824 3101906 treatment NN B-NP O
15 824 825 3101906 . . O O

1 826 829 3101906 The DT B-NP O
2 830 837 3101906 results NNS I-NP O
3 838 840 3101906 of IN B-PP O
4 841 846 3101906 serum NN B-NP O
5 847 852 3101906 liver NN I-NP O
6 853 861 3101906 function NN I-NP O
7 862 867 3101906 tests NNS I-NP O
8 868 877 3101906 suggested VBD B-VP O
9 878 892 3101906 hepatocellular JJ B-NP B-Disease
10 893 899 3101906 injury NN I-NP I-Disease
11 900 902 3101906 in IN B-PP O
12 903 905 3101906 10 CD B-NP O
13 906 907 3101906 ( ( O O
14 907 910 3101906 63% NN B-NP O
15 910 911 3101906 ) ) O O
16 911 912 3101906 ; : O O
17 913 916 3101906 the DT B-NP O
18 917 921 3101906 rest NN I-NP O
19 922 928 3101906 showed VBD B-VP O
20 929 930 3101906 a DT B-NP O
21 931 936 3101906 mixed VBN I-NP O
22 937 944 3101906 pattern NN I-NP O
23 944 945 3101906 . . O O

1 946 948 3101906 In IN B-PP O
2 949 957 3101906 contrast NN B-NP O
3 957 958 3101906 , , O O
4 959 962 3101906 the DT B-NP O
5 963 970 3101906 results NNS I-NP O
6 971 973 3101906 of IN B-PP O
7 974 986 3101906 histological JJ B-NP O
8 987 998 3101906 examination NN I-NP O
9 999 1001 3101906 of IN B-PP O
10 1002 1005 3101906 the DT B-NP O
11 1006 1011 3101906 liver NN I-NP O
12 1012 1017 3101906 often RB B-ADVP O
13 1018 1024 3101906 showed VBD B-VP O
14 1025 1033 3101906 evidence NN B-NP O
15 1034 1036 3101906 of IN B-PP O
16 1037 1048 3101906 cholestasis NN B-NP B-Disease
17 1048 1049 3101906 . . O O

1 1050 1053 3101906 The DT B-NP O
2 1054 1069 3101906 characteristics NNS I-NP O
3 1070 1072 3101906 of IN B-PP O
4 1073 1076 3101906 the DT B-NP O
5 1077 1079 3101906 48 CD I-NP O
6 1080 1088 3101906 patients NNS I-NP O
7 1089 1091 3101906 in IN B-PP O
8 1092 1095 3101906 the DT B-NP O
9 1096 1104 3101906 possible JJ I-NP O
10 1105 1110 3101906 cases NNS I-NP O
11 1111 1115 3101906 were VBD B-VP O
12 1116 1123 3101906 similar JJ B-ADJP O
13 1123 1124 3101906 . . O O

1 1125 1133 3101906 Allergic JJ B-NP O
2 1134 1148 3101906 manifestations NNS I-NP O
3 1149 1153 3101906 such JJ B-PP O
4 1154 1156 3101906 as IN I-PP O
5 1157 1161 3101906 rash NN B-NP B-Disease
6 1162 1165 3101906 and CC I-NP O
7 1166 1178 3101906 eosinophilia NN I-NP B-Disease
8 1179 1183 3101906 were VBD B-VP O
9 1184 1188 3101906 rare JJ B-ADJP O
10 1188 1189 3101906 . . O O

1 1190 1199 3101906 Hepatitis NN B-NP B-Disease
2 1200 1203 3101906 was VBD B-VP O
3 1204 1211 3101906 usually RB B-ADVP O
4 1212 1222 3101906 reversible JJ B-ADJP O
5 1223 1227 3101906 when WRB B-ADVP O
6 1228 1237 3101906 treatment NN B-NP O
7 1238 1241 3101906 was VBD B-VP O
8 1242 1249 3101906 stopped VBN I-VP O
9 1249 1250 3101906 , , O O
10 1251 1255 3101906 with IN B-PP O
11 1256 1259 3101906 the DT B-NP O
12 1260 1267 3101906 results NNS I-NP O
13 1268 1270 3101906 of IN B-PP O
14 1271 1276 3101906 liver NN B-NP O
15 1277 1285 3101906 function NN I-NP O
16 1286 1291 3101906 tests NNS I-NP O
17 1292 1301 3101906 returning VBG B-VP O
18 1302 1304 3101906 to TO B-PP O
19 1305 1311 3101906 normal JJ B-ADJP O
20 1312 1317 3101906 after IN B-PP O
21 1318 1320 3101906 an DT B-NP O
22 1321 1328 3101906 average NN I-NP O
23 1329 1331 3101906 of IN B-PP O
24 1332 1335 3101906 3.1 CD B-NP O
25 1336 1342 3101906 months NNS I-NP O
26 1342 1343 3101906 . . O O

1 1344 1346 3101906 In IN B-PP O
2 1347 1350 3101906 two CD B-NP O
3 1351 1353 3101906 of IN B-PP O
4 1354 1357 3101906 the DT B-NP O
5 1358 1363 3101906 three CD I-NP O
6 1364 1370 3101906 deaths NNS I-NP B-Disease
7 1371 1379 3101906 probably RB B-ADVP O
8 1380 1390 3101906 associated VBN B-VP O
9 1391 1395 3101906 with IN B-PP O
10 1396 1408 3101906 ketoconazole NN B-NP B-Chemical
11 1409 1418 3101906 treatment NN I-NP O
12 1419 1422 3101906 the DT B-NP O
13 1423 1427 3101906 drug NN I-NP O
14 1428 1431 3101906 had VBD B-VP O
15 1432 1436 3101906 been VBN I-VP O
16 1437 1446 3101906 continued VBN I-VP O
17 1447 1452 3101906 after IN B-PP O
18 1453 1456 3101906 the DT B-NP O
19 1457 1462 3101906 onset NN I-NP O
20 1463 1465 3101906 of IN B-PP O
21 1466 1474 3101906 jaundice NN B-NP B-Disease
22 1475 1478 3101906 and CC O O
23 1479 1484 3101906 other JJ B-NP O
24 1485 1493 3101906 symptoms NNS I-NP O
25 1494 1496 3101906 of IN B-PP O
26 1497 1506 3101906 hepatitis NN B-NP B-Disease
27 1506 1507 3101906 . . O O

1 1508 1516 3101906 Clinical JJ B-NP O
2 1517 1520 3101906 and CC I-NP O
3 1521 1532 3101906 biochemical JJ I-NP O
4 1533 1543 3101906 monitoring NN I-NP O
5 1544 1546 3101906 at IN B-PP O
6 1547 1554 3101906 regular JJ B-NP O
7 1555 1564 3101906 intervals NNS I-NP O
8 1565 1568 3101906 for IN B-PP O
9 1569 1577 3101906 evidence NN B-NP O
10 1578 1580 3101906 of IN B-PP O
11 1581 1590 3101906 hepatitis NN B-NP B-Disease
12 1591 1593 3101906 is VBZ B-VP O
13 1594 1601 3101906 advised VBN I-VP O
14 1602 1608 3101906 during IN B-PP O
15 1609 1613 3101906 long JJ B-NP O
16 1614 1618 3101906 term NN I-NP O
17 1619 1628 3101906 treatment NN I-NP O
18 1629 1633 3101906 with IN B-PP O
19 1634 1646 3101906 ketoconazole NN B-NP B-Chemical
20 1647 1649 3101906 to TO B-VP O
21 1650 1657 3101906 prevent VB I-VP O
22 1658 1666 3101906 possible JJ B-NP O
23 1667 1674 3101906 serious JJ I-NP O
24 1675 1682 3101906 hepatic JJ I-NP B-Disease
25 1683 1689 3101906 injury NN I-NP I-Disease
26 1689 1690 3101906 . . O O

1 0 0 8955532 -DOCSTART- -X- -X- O

1 0 4 8955532 Role NN B-NP O
2 5 7 8955532 of IN B-PP O
3 8 18 8955532 activation NN B-NP O
4 19 21 8955532 of IN B-PP O
5 22 32 8955532 bradykinin NN B-NP B-Chemical
6 33 35 8955532 B2 NN I-NP O
7 36 45 8955532 receptors NNS I-NP O
8 46 48 8955532 in IN B-PP O
9 49 59 8955532 disruption NN B-NP O
10 60 62 8955532 of IN B-PP O
11 63 66 8955532 the DT B-NP O
12 67 72 8955532 blood NN I-NP O
13 72 73 8955532 - HYPH I-NP O
14 73 78 8955532 brain NN I-NP O
15 79 86 8955532 barrier NN I-NP O
16 87 93 8955532 during IN B-PP O
17 94 99 8955532 acute JJ B-NP O
18 100 112 8955532 hypertension NN I-NP B-Disease
19 112 113 8955532 . . O O
20 114 122 8955532 Cellular JJ B-NP O
21 123 133 8955532 mechanisms NNS I-NP O
22 134 139 8955532 which WDT B-NP O
23 140 147 8955532 account VBP B-VP O
24 148 151 8955532 for IN B-PP O
25 152 162 8955532 disruption NN B-NP O
26 163 166 8955532 the DT B-NP O
27 167 172 8955532 blood NN I-NP O
28 172 173 8955532 - HYPH I-NP O
29 173 178 8955532 brain NN I-NP O
30 179 186 8955532 barrier NN I-NP O
31 187 193 8955532 during IN B-PP O
32 194 199 8955532 acute JJ B-NP O
33 200 212 8955532 hypertension NN I-NP B-Disease
34 213 216 8955532 are VBP B-VP O
35 217 220 8955532 not RB O O
36 221 226 8955532 clear JJ B-ADJP O
37 226 227 8955532 . . O O

1 228 231 8955532 The DT B-NP O
2 232 236 8955532 goal NN I-NP O
3 237 239 8955532 of IN B-PP O
4 240 244 8955532 this DT B-NP O
5 245 250 8955532 study NN I-NP O
6 251 254 8955532 was VBD B-VP O
7 255 257 8955532 to TO B-VP O
8 258 267 8955532 determine VB I-VP O
9 268 271 8955532 the DT B-NP O
10 272 276 8955532 role NN I-NP O
11 277 279 8955532 of IN B-PP O
12 280 289 8955532 synthesis NN B-NP O
13 289 290 8955532 / SYM B-NP O
14 290 297 8955532 release NN I-NP O
15 298 300 8955532 of IN B-PP O
16 301 311 8955532 bradykinin NN B-NP B-Chemical
17 312 314 8955532 to TO B-VP O
18 315 323 8955532 activate VB I-VP O
19 324 326 8955532 B2 NN B-NP O
20 327 336 8955532 receptors NNS I-NP O
21 337 339 8955532 in IN B-PP O
22 340 350 8955532 disruption NN B-NP O
23 351 353 8955532 of IN B-PP O
24 354 357 8955532 the DT B-NP O
25 358 363 8955532 blood NN I-NP O
26 363 364 8955532 - HYPH I-NP O
27 364 369 8955532 brain NN I-NP O
28 370 377 8955532 barrier NN I-NP O
29 378 384 8955532 during IN B-PP O
30 385 390 8955532 acute JJ B-NP O
31 391 403 8955532 hypertension NN I-NP B-Disease
32 403 404 8955532 . . O O

1 405 417 8955532 Permeability NN B-NP O
2 418 420 8955532 of IN B-PP O
3 421 424 8955532 the DT B-NP O
4 425 430 8955532 blood NN I-NP O
5 430 431 8955532 - HYPH I-NP O
6 431 436 8955532 brain NN I-NP O
7 437 444 8955532 barrier NN I-NP O
8 445 448 8955532 was VBD B-VP O
9 449 460 8955532 quantitated VBN I-VP O
10 461 463 8955532 by IN B-PP O
11 464 473 8955532 clearance NN B-NP O
12 474 476 8955532 of IN B-PP O
13 477 488 8955532 fluorescent NN B-NP O
14 488 489 8955532 - HYPH O O
15 489 496 8955532 labeled VBN B-VP O
16 497 504 8955532 dextran NN B-NP B-Chemical
17 505 511 8955532 before IN B-PP O
18 512 515 8955532 and CC I-PP O
19 516 522 8955532 during IN I-PP O
20 523 536 8955532 phenylephrine NN B-NP B-Chemical
21 536 537 8955532 - HYPH B-NP O
22 537 544 8955532 induced VBN I-NP O
23 545 550 8955532 acute JJ I-NP O
24 551 563 8955532 hypertension NN I-NP B-Disease
25 564 566 8955532 in IN B-PP O
26 567 571 8955532 rats NNS B-NP O
27 572 579 8955532 treated VBN B-VP O
28 580 584 8955532 with IN B-PP O
29 585 592 8955532 vehicle NN B-NP O
30 593 596 8955532 and CC I-NP O
31 597 600 8955532 Hoe NN I-NP B-Chemical
32 600 601 8955532 - HYPH O I-Chemical
33 601 604 8955532 140 CD B-NP I-Chemical
34 605 606 8955532 ( ( O O
35 606 609 8955532 0.1 CD B-NP O
36 610 616 8955532 microM NN I-NP O
37 616 617 8955532 ) ) O O
38 617 618 8955532 . . O O

1 619 632 8955532 Phenylephrine NN B-NP B-Chemical
2 633 641 8955532 infusion NN I-NP O
3 642 651 8955532 increased VBD B-VP O
4 652 660 8955532 arterial JJ B-NP O
5 661 669 8955532 pressure NN I-NP O
6 669 670 8955532 , , O O
7 671 681 8955532 arteriolar JJ B-NP O
8 682 690 8955532 diameter NN I-NP O
9 691 694 8955532 and CC I-NP O
10 695 704 8955532 clearance NN I-NP O
11 705 707 8955532 of IN B-PP O
12 708 719 8955532 fluorescent JJ B-NP O
13 720 727 8955532 dextran NN I-NP B-Chemical
14 728 730 8955532 by IN B-PP O
15 731 732 8955532 a DT B-NP O
16 733 740 8955532 similar JJ I-NP O
17 741 750 8955532 magnitude NN I-NP O
18 751 753 8955532 in IN B-PP O
19 754 758 8955532 both DT B-NP O
20 759 765 8955532 groups NNS I-NP O
21 765 766 8955532 . . O O

1 767 772 8955532 These DT B-NP O
2 773 781 8955532 findings NNS I-NP O
3 782 789 8955532 suggest VBP B-VP O
4 790 794 8955532 that IN B-SBAR O
5 795 805 8955532 disruption NN B-NP O
6 806 808 8955532 of IN B-PP O
7 809 812 8955532 the DT B-NP O
8 813 818 8955532 blood NN I-NP O
9 818 819 8955532 - HYPH I-NP O
10 819 824 8955532 brain NN I-NP O
11 825 832 8955532 barrier NN I-NP O
12 833 839 8955532 during IN B-PP O
13 840 845 8955532 acute JJ B-NP O
14 846 858 8955532 hypertension NN I-NP B-Disease
15 859 861 8955532 is VBZ B-VP O
16 862 865 8955532 not RB O O
17 866 873 8955532 related JJ B-ADJP O
18 874 876 8955532 to TO B-PP O
19 877 880 8955532 the DT B-NP O
20 881 890 8955532 synthesis NN I-NP O
21 890 891 8955532 / SYM B-NP O
22 891 898 8955532 release NN I-NP O
23 899 901 8955532 of IN B-PP O
24 902 912 8955532 bradykinin NN B-NP B-Chemical
25 913 915 8955532 to TO B-VP O
26 916 924 8955532 activate VB I-VP O
27 925 927 8955532 B2 NN B-NP O
28 928 937 8955532 receptors NNS I-NP O
29 937 938 8955532 . . O O

1 0 0 16403073 -DOCSTART- -X- -X- O

1 0 12 16403073 Ketoconazole NN B-NP B-Chemical
2 13 20 16403073 induced VBD B-VP O
3 21 29 16403073 torsades NNS B-NP B-Disease
4 30 32 16403073 de IN B-PP I-Disease
5 33 40 16403073 pointes NNS B-NP I-Disease
6 41 48 16403073 without IN B-PP O
7 49 60 16403073 concomitant JJ B-NP O
8 61 64 16403073 use NN I-NP O
9 65 67 16403073 of IN B-PP O
10 68 70 16403073 QT NN B-NP O
11 71 79 16403073 interval NN I-NP O
12 79 80 16403073 - HYPH O O
13 80 90 16403073 prolonging VBG B-VP O
14 91 95 16403073 drug NN B-NP O
15 95 96 16403073 . . O O
16 97 109 16403073 Ketoconazole NN B-NP B-Chemical
17 110 112 16403073 is VBZ B-VP O
18 113 116 16403073 not RB I-VP O
19 117 122 16403073 known VBN I-VP O
20 123 125 16403073 to TO I-VP O
21 126 128 16403073 be VB I-VP O
22 129 142 16403073 proarrhythmic JJ B-ADJP O
23 143 150 16403073 without IN B-PP O
24 151 162 16403073 concomitant JJ B-NP O
25 163 166 16403073 use NN I-NP O
26 167 169 16403073 of IN B-PP O
27 170 172 16403073 QT NN B-NP O
28 173 181 16403073 interval NN I-NP O
29 181 182 16403073 - HYPH O O
30 182 192 16403073 prolonging VBG B-VP O
31 193 198 16403073 drugs NNS B-NP O
32 198 199 16403073 . . O O

1 200 202 16403073 We PRP B-NP O
2 203 209 16403073 report VBP B-VP O
3 210 211 16403073 a DT B-NP O
4 212 217 16403073 woman NN I-NP O
5 218 222 16403073 with IN B-PP O
6 223 231 16403073 coronary JJ B-NP B-Disease
7 232 238 16403073 artery NN I-NP I-Disease
8 239 246 16403073 disease NN I-NP I-Disease
9 247 250 16403073 who WP B-NP O
10 251 260 16403073 developed VBD B-VP O
11 261 262 16403073 a DT B-NP O
12 263 271 16403073 markedly RB I-NP O
13 272 281 16403073 prolonged VBN I-NP B-Disease
14 282 284 16403073 QT NN I-NP I-Disease
15 285 293 16403073 interval NN I-NP I-Disease
16 294 297 16403073 and CC O O
17 298 306 16403073 torsades NNS B-NP B-Disease
18 307 309 16403073 de FW I-NP I-Disease
19 310 317 16403073 pointes FW I-NP I-Disease
20 318 319 16403073 ( ( O O
21 319 322 16403073 TdP NN B-NP B-Disease
22 322 323 16403073 ) ) O O
23 324 329 16403073 after IN B-PP O
24 330 336 16403073 taking VBG B-VP O
25 337 349 16403073 ketoconazole NN B-NP B-Chemical
26 350 353 16403073 for IN B-PP O
27 354 363 16403073 treatment NN B-NP O
28 364 366 16403073 of IN B-PP O
29 367 373 16403073 fungal JJ B-NP B-Disease
30 374 383 16403073 infection NN I-NP I-Disease
31 383 384 16403073 . . O O

1 385 388 16403073 Her PRP$ B-NP O
2 389 391 16403073 QT NN I-NP O
3 392 400 16403073 interval NN I-NP O
4 401 409 16403073 returned VBD B-VP O
5 410 412 16403073 to TO B-PP O
6 413 419 16403073 normal JJ B-NP O
7 420 424 16403073 upon IN B-PP O
8 425 435 16403073 withdrawal NN B-NP O
9 436 438 16403073 of IN B-PP O
10 439 451 16403073 ketoconazole NN B-NP B-Chemical
11 451 452 16403073 . . O O

1 453 460 16403073 Genetic JJ B-NP O
2 461 466 16403073 study NN I-NP O
3 467 470 16403073 did VBD B-VP O
4 471 474 16403073 not RB I-VP O
5 475 479 16403073 find VB I-VP O
6 480 483 16403073 any DT B-NP O
7 484 492 16403073 mutation NN I-NP O
8 493 495 16403073 in IN B-PP O
9 496 499 16403073 her PRP$ B-NP O
10 500 505 16403073 genes NNS I-NP O
11 506 510 16403073 that WDT B-NP O
12 511 517 16403073 encode VBP B-VP O
13 518 525 16403073 cardiac JJ B-NP O
14 526 529 16403073 IKr NN I-NP O
15 530 537 16403073 channel NN I-NP O
16 538 546 16403073 proteins NNS I-NP O
17 546 547 16403073 . . O O

1 548 550 16403073 We PRP B-NP O
2 551 560 16403073 postulate VBP B-VP O
3 561 565 16403073 that IN B-SBAR O
4 566 568 16403073 by IN B-PP O
5 569 575 16403073 virtue NN B-NP O
6 576 578 16403073 of IN B-PP O
7 579 582 16403073 its PRP$ B-NP O
8 583 589 16403073 direct JJ I-NP O
9 590 598 16403073 blocking VBG I-NP O
10 599 605 16403073 action NN I-NP O
11 606 608 16403073 on IN B-PP O
12 609 612 16403073 IKr NN B-NP O
13 612 613 16403073 , , O O
14 614 626 16403073 ketoconazole NN B-NP B-Chemical
15 627 632 16403073 alone RB B-ADVP O
16 633 636 16403073 may MD B-VP O
17 637 644 16403073 prolong VB I-VP O
18 645 647 16403073 QT NN B-NP O
19 648 656 16403073 interval NN I-NP O
20 657 660 16403073 and CC O O
21 661 667 16403073 induce VB B-VP O
22 668 671 16403073 TdP NN B-NP B-Disease
23 671 672 16403073 . . O O

1 673 677 16403073 This DT B-NP O
2 678 683 16403073 calls VBZ B-VP O
3 684 687 16403073 for IN B-PP O
4 688 697 16403073 attention NN B-NP O
5 698 702 16403073 when WRB B-ADVP O
6 703 715 16403073 ketoconazole NN B-NP B-Chemical
7 716 718 16403073 is VBZ B-VP O
8 719 731 16403073 administered VBN I-VP O
9 732 734 16403073 to TO B-PP O
10 735 743 16403073 patients NNS B-NP O
11 744 748 16403073 with IN B-PP O
12 749 753 16403073 risk NN B-NP O
13 754 761 16403073 factors NNS I-NP O
14 762 765 16403073 for IN B-PP O
15 766 774 16403073 acquired VBN B-NP O
16 775 779 16403073 long JJ I-NP B-Disease
17 780 782 16403073 QT NN I-NP I-Disease
18 783 791 16403073 syndrome NN I-NP I-Disease
19 791 792 16403073 . . O O

1 0 0 809711 -DOCSTART- -X- -X- O

1 0 8 809711 Reversal NN B-NP O
2 9 11 809711 by IN B-PP O
3 12 25 809711 phenylephrine NN B-NP B-Chemical
4 26 28 809711 of IN B-PP O
5 29 32 809711 the DT B-NP O
6 33 43 809711 beneficial JJ I-NP O
7 44 51 809711 effects NNS I-NP O
8 52 54 809711 of IN B-PP O
9 55 66 809711 intravenous JJ B-NP O
10 67 80 809711 nitroglycerin NN I-NP B-Chemical
11 81 83 809711 in IN B-PP O
12 84 92 809711 patients NNS B-NP O
13 93 97 809711 with IN B-PP O
14 98 103 809711 acute JJ B-NP B-Disease
15 104 114 809711 myocardial JJ I-NP I-Disease
16 115 125 809711 infarction NN I-NP I-Disease
17 125 126 809711 . . I-NP O
18 127 140 809711 Nitroglycerin NN I-NP B-Chemical
19 141 144 809711 has VBZ B-VP O
20 145 149 809711 been VBN I-VP O
21 150 155 809711 shown VBN I-VP O
22 156 158 809711 to TO I-VP O
23 159 165 809711 reduce VB I-VP O
24 166 168 809711 ST NN B-NP O
25 168 169 809711 - HYPH I-NP O
26 169 176 809711 segment NN I-NP O
27 177 186 809711 elevation NN I-NP O
28 187 193 809711 during IN B-PP O
29 194 199 809711 acute JJ B-NP B-Disease
30 200 210 809711 myocardial JJ I-NP I-Disease
31 211 221 809711 infarction NN I-NP I-Disease
32 221 222 809711 , , O O
33 223 225 809711 an DT B-NP O
34 226 232 809711 effect NN I-NP O
35 233 244 809711 potentiated VBD B-VP O
36 245 247 809711 in IN B-PP O
37 248 251 809711 the DT B-NP O
38 252 255 809711 dog NN I-NP O
39 256 258 809711 by IN B-PP O
40 259 265 809711 agents NNS B-NP O
41 266 270 809711 that WDT B-NP O
42 271 278 809711 reverse VBP B-VP O
43 279 292 809711 nitroglycerin NN B-NP B-Chemical
44 292 293 809711 - HYPH B-NP O
45 293 300 809711 induced VBN I-NP O
46 301 312 809711 hypotension NN I-NP B-Disease
47 312 313 809711 . . O O

1 314 317 809711 Our PRP$ B-NP O
2 318 323 809711 study NN I-NP O
3 324 327 809711 was VBD B-VP O
4 328 336 809711 designed VBN I-VP O
5 337 339 809711 to TO B-VP O
6 340 349 809711 determine VB I-VP O
7 350 353 809711 the DT B-NP O
8 354 361 809711 effects NNS I-NP O
9 362 364 809711 of IN B-PP O
10 365 373 809711 combined VBN B-NP O
11 374 387 809711 nitroglycerin NN I-NP B-Chemical
12 388 391 809711 and CC I-NP O
13 392 405 809711 phenylephrine NN I-NP B-Chemical
14 406 413 809711 therapy NN I-NP O
15 413 414 809711 . . O O

1 415 418 809711 Ten CD B-NP O
2 419 427 809711 patients NNS I-NP O
3 428 432 809711 with IN B-PP O
4 433 438 809711 acute JJ B-NP O
5 439 449 809711 transmural JJ I-NP O
6 450 460 809711 myocardial JJ I-NP B-Disease
7 461 472 809711 infarctions NNS I-NP I-Disease
8 473 481 809711 received VBD B-VP O
9 482 493 809711 intravenous JJ B-NP O
10 494 507 809711 nitroglycerin NN I-NP B-Chemical
11 507 508 809711 , , O O
12 509 519 809711 sufficient JJ B-ADJP O
13 520 522 809711 to TO B-VP O
14 523 529 809711 reduce VB I-VP O
15 530 534 809711 mean JJ B-NP O
16 535 543 809711 arterial JJ I-NP O
17 544 552 809711 pressure NN I-NP O
18 553 557 809711 from IN B-PP O
19 558 561 809711 107 CD B-NP O
20 562 563 809711 + SYM B-ADJP O
21 563 564 809711 / SYM O O
22 564 565 809711 - SYM B-NP O
23 566 567 809711 6 CD B-NP O
24 568 570 809711 to TO I-NP O
25 571 573 809711 85 CD I-NP O
26 574 575 809711 + SYM I-NP O
27 575 576 809711 / SYM I-NP O
28 576 577 809711 - SYM I-NP O
29 578 579 809711 6 CD I-NP O
30 580 582 809711 mm NN I-NP O
31 583 585 809711 Hg NN I-NP O
32 586 587 809711 ( ( O O
33 587 588 809711 P NN B-NP O
34 589 593 809711 less JJR B-ADJP O
35 594 598 809711 than IN B-PP O
36 599 604 809711 0.001 CD B-NP O
37 604 605 809711 ) ) O O
38 605 606 809711 , , O O
39 607 610 809711 for IN B-PP O
40 611 613 809711 60 CD B-NP O
41 614 621 809711 minutes NNS I-NP O
42 621 622 809711 . . O O

1 623 627 809711 Left VBN B-NP O
2 628 639 809711 ventricular JJ I-NP O
3 640 647 809711 filling NN I-NP O
4 648 656 809711 pressure NN I-NP O
5 657 666 809711 decreased VBD B-VP O
6 667 671 809711 from IN B-PP O
7 672 674 809711 19 CD B-NP O
8 675 676 809711 + SYM B-ADJP O
9 676 677 809711 / SYM O O
10 677 678 809711 - SYM O O
11 679 680 809711 2 CD B-NP O
12 681 683 809711 to TO B-PP O
13 684 686 809711 11 CD B-NP O
14 687 688 809711 + SYM O O
15 688 689 809711 / SYM O O
16 689 690 809711 - SYM B-NP O
17 691 692 809711 2 CD I-NP O
18 693 695 809711 mm NN I-NP O
19 696 698 809711 Hg NN I-NP O
20 699 700 809711 ( ( O O
21 700 701 809711 P NN B-NP O
22 702 706 809711 less JJR B-ADJP O
23 707 711 809711 than IN B-PP O
24 712 717 809711 0.001 CD B-NP O
25 717 718 809711 ) ) O O
26 718 719 809711 . . O O

1 720 727 809711 SigmaST NN B-NP O
2 727 728 809711 , , O O
3 729 732 809711 the DT B-NP O
4 733 736 809711 sum NN I-NP O
5 737 739 809711 of IN B-PP O
6 740 742 809711 ST NN B-NP O
7 742 743 809711 - HYPH I-NP O
8 743 750 809711 segment NN I-NP O
9 751 761 809711 elevations NNS I-NP O
10 762 764 809711 in IN B-PP O
11 765 767 809711 16 CD B-NP O
12 768 778 809711 precordial JJ I-NP O
13 779 784 809711 leads NNS I-NP O
14 784 785 809711 , , O O
15 786 795 809711 decreased VBD B-VP O
16 796 797 809711 ( ( O O
17 797 798 809711 P NN B-NP O
18 799 803 809711 less JJR B-ADJP O
19 804 808 809711 than IN B-PP O
20 809 813 809711 0.02 CD B-NP O
21 813 814 809711 ) ) O O
22 815 819 809711 with IN B-PP O
23 820 831 809711 intravenous JJ B-NP O
24 832 845 809711 nitroglycerin NN I-NP B-Chemical
25 845 846 809711 . . O O

1 847 857 809711 Subsequent JJ B-NP O
2 858 866 809711 addition NN I-NP O
3 867 869 809711 of IN B-PP O
4 870 883 809711 phenylephrine NN B-NP B-Chemical
5 884 892 809711 infusion NN I-NP O
6 892 893 809711 , , O O
7 894 904 809711 sufficient JJ B-ADJP O
8 905 907 809711 to TO B-VP O
9 908 910 809711 re VB I-VP O
10 910 911 809711 - HYPH O O
11 911 918 809711 elevate VB B-VP O
12 919 923 809711 mean JJ B-NP O
13 924 932 809711 arterial JJ I-NP O
14 933 941 809711 pressure NN I-NP O
15 942 944 809711 to TO B-PP O
16 945 948 809711 106 CD B-NP O
17 949 950 809711 + SYM B-NP O
18 950 951 809711 / SYM I-NP O
19 951 952 809711 - SYM I-NP O
20 953 954 809711 4 CD I-NP O
21 955 957 809711 mm NN I-NP O
22 958 960 809711 Hg NN I-NP O
23 961 962 809711 ( ( O O
24 962 963 809711 P NN B-NP O
25 964 968 809711 less JJR B-ADJP O
26 969 973 809711 than IN B-PP O
27 974 979 809711 0.001 CD B-NP O
28 979 980 809711 ) ) O O
29 981 984 809711 for IN B-PP O
30 985 987 809711 30 CD B-NP O
31 988 995 809711 minutes NNS I-NP O
32 995 996 809711 , , O O
33 997 1006 809711 increased VBN B-VP O
34 1007 1011 809711 left VBD B-VP O
35 1012 1023 809711 ventricular JJ B-NP O
36 1024 1031 809711 filling NN I-NP O
37 1032 1040 809711 pressure NN I-NP O
38 1041 1043 809711 to TO B-PP O
39 1044 1046 809711 17 CD B-NP O
40 1047 1048 809711 + SYM O O
41 1048 1049 809711 / SYM O O
42 1049 1050 809711 - SYM B-NP O
43 1051 1052 809711 2 CD I-NP O
44 1053 1055 809711 mm NN I-NP O
45 1056 1058 809711 Hg NN I-NP O
46 1059 1060 809711 ( ( O O
47 1060 1061 809711 P NN B-NP O
48 1062 1066 809711 less JJR B-ADJP O
49 1067 1071 809711 than IN B-PP O
50 1072 1076 809711 0.05 CD B-NP O
51 1076 1077 809711 ) ) O O
52 1078 1081 809711 and CC O O
53 1082 1086 809711 also RB B-ADVP O
54 1087 1100 809711 significantly RB B-ADVP O
55 1101 1110 809711 increased VBN B-NP O
56 1111 1118 809711 sigmaST NN I-NP O
57 1119 1120 809711 ( ( O O
58 1120 1121 809711 P NN B-NP O
59 1122 1126 809711 less JJR B-ADJP O
60 1127 1131 809711 than IN B-PP O
61 1132 1136 809711 0.05 CD B-NP O
62 1136 1137 809711 ) ) O O
63 1137 1138 809711 . . O O

1 1139 1142 809711 Our PRP$ B-NP O
2 1143 1150 809711 results NNS I-NP O
3 1151 1158 809711 suggest VBP B-VP O
4 1159 1163 809711 that IN B-SBAR O
5 1164 1172 809711 addition NN B-NP O
6 1173 1175 809711 of IN B-PP O
7 1176 1189 809711 phenylephrine NN B-NP B-Chemical
8 1190 1192 809711 to TO B-PP O
9 1193 1206 809711 nitroglycerin NN B-NP B-Chemical
10 1207 1209 809711 is VBZ B-VP O
11 1210 1213 809711 not RB O O
12 1214 1224 809711 beneficial JJ B-ADJP O
13 1225 1227 809711 in IN B-PP O
14 1228 1231 809711 the DT B-NP O
15 1232 1241 809711 treatment NN I-NP O
16 1242 1244 809711 of IN B-PP O
17 1245 1253 809711 patients NNS B-NP O
18 1254 1258 809711 with IN B-PP O
19 1259 1264 809711 acute JJ B-NP B-Disease
20 1265 1275 809711 myocardial JJ I-NP I-Disease
21 1276 1286 809711 infarction NN I-NP I-Disease
22 1286 1287 809711 . . O O

1 0 0 7628595 -DOCSTART- -X- -X- O

1 0 5 7628595 Study NN B-NP O
2 6 8 7628595 of IN B-PP O
3 9 12 7628595 the DT B-NP O
4 13 17 7628595 role NN I-NP O
5 18 20 7628595 of IN B-PP O
6 21 28 7628595 vitamin NN B-NP B-Chemical
7 29 32 7628595 B12 NN I-NP I-Chemical
8 33 36 7628595 and CC O O
9 37 44 7628595 folinic JJ B-NP B-Chemical
10 45 49 7628595 acid NN I-NP I-Chemical
11 50 65 7628595 supplementation NN I-NP O
12 66 68 7628595 in IN B-PP O
13 69 79 7628595 preventing VBG B-VP O
14 80 91 7628595 hematologic JJ B-NP O
15 92 100 7628595 toxicity NN I-NP B-Disease
16 101 103 7628595 of IN B-PP O
17 104 114 7628595 zidovudine NN B-NP B-Chemical
18 114 115 7628595 . . O O
19 116 117 7628595 A DT B-NP O
20 118 129 7628595 prospective JJ I-NP O
21 129 130 7628595 , , I-NP O
22 131 141 7628595 randomized VBN I-NP O
23 142 147 7628595 study NN I-NP O
24 148 151 7628595 was VBD B-VP O
25 152 161 7628595 conducted VBN I-VP O
26 162 164 7628595 to TO I-VP O
27 165 173 7628595 evaluate VB I-VP O
28 174 177 7628595 the DT B-NP O
29 178 182 7628595 role NN I-NP O
30 183 185 7628595 of IN B-PP O
31 186 193 7628595 vitamin NN B-NP B-Chemical
32 194 197 7628595 B12 NN I-NP I-Chemical
33 198 201 7628595 and CC O O
34 202 209 7628595 folinic JJ B-NP B-Chemical
35 210 214 7628595 acid NN I-NP I-Chemical
36 215 230 7628595 supplementation NN I-NP O
37 231 233 7628595 in IN B-PP O
38 234 244 7628595 preventing VBG B-VP O
39 245 255 7628595 zidovudine NN B-NP B-Chemical
40 256 257 7628595 ( ( O O
41 257 260 7628595 ZDV NN B-NP B-Chemical
42 260 261 7628595 ) ) O O
43 261 262 7628595 - HYPH B-NP O
44 262 269 7628595 induced VBN I-NP O
45 270 274 7628595 bone NN I-NP B-Disease
46 275 281 7628595 marrow NN I-NP I-Disease
47 282 293 7628595 suppression NN I-NP I-Disease
48 293 294 7628595 . . O O

1 295 302 7628595 Seventy CD B-NP O
2 302 303 7628595 - HYPH I-NP O
3 303 307 7628595 five CD I-NP O
4 308 313 7628595 human JJ I-NP B-Disease
5 314 330 7628595 immunodeficiency NN I-NP I-Disease
6 331 336 7628595 virus NN I-NP I-Disease
7 337 342 7628595 (HIV) NN I-NP I-Disease
8 342 343 7628595 - HYPH O I-Disease
9 343 351 7628595 infected VBN B-VP I-Disease
10 352 360 7628595 patients NNS B-NP O
11 361 365 7628595 with IN B-PP O
12 366 370 7628595 CD4+ JJ B-NP O
13 371 375 7628595 cell NN I-NP O
14 376 382 7628595 counts NNS I-NP O
15 383 384 7628595 < SYM O O
16 385 388 7628595 500 CD B-NP O
17 388 389 7628595 / SYM I-NP O
18 389 392 7628595 mm3 NN I-NP O
19 393 397 7628595 were VBD B-VP O
20 398 408 7628595 randomized VBN I-VP O
21 409 411 7628595 to TO B-VP O
22 412 419 7628595 receive VB I-VP O
23 420 426 7628595 either CC O O
24 427 430 7628595 ZDV NN B-NP B-Chemical
25 431 432 7628595 ( ( O O
26 432 435 7628595 500 CD B-NP O
27 436 438 7628595 mg NN I-NP O
28 439 444 7628595 daily JJ I-NP O
29 444 445 7628595 ) ) O O
30 446 451 7628595 alone RB B-ADVP O
31 452 453 7628595 ( ( O O
32 453 458 7628595 group NN B-NP O
33 459 460 7628595 I NN I-NP O
34 460 461 7628595 , , O O
35 462 463 7628595 n NN B-NP O
36 464 465 7628595 = SYM B-VP O
37 466 468 7628595 38 CD B-NP O
38 468 469 7628595 ) ) O O
39 470 472 7628595 or CC O O
40 473 475 7628595 in IN B-PP O
41 476 487 7628595 combination NN B-NP O
42 488 492 7628595 with IN B-PP O
43 493 500 7628595 folinic JJ B-NP B-Chemical
44 501 505 7628595 acid NN I-NP I-Chemical
45 506 507 7628595 ( ( O O
46 507 509 7628595 15 CD B-NP O
47 510 512 7628595 mg NN I-NP O
48 513 518 7628595 daily JJ I-NP O
49 518 519 7628595 ) ) O O
50 520 523 7628595 and CC O O
51 524 537 7628595 intramascular JJ B-NP O
52 538 545 7628595 vitamin NN I-NP B-Chemical
53 546 549 7628595 B12 NN I-NP I-Chemical
54 550 551 7628595 ( ( O O
55 551 555 7628595 1000 CD B-NP O
56 556 566 7628595 micrograms NNS I-NP O
57 567 574 7628595 monthly JJ B-ADJP O
58 574 575 7628595 ) ) O O
59 576 577 7628595 ( ( O O
60 577 582 7628595 group NN B-NP O
61 583 585 7628595 II CD I-NP O
62 585 586 7628595 , , O O
63 587 588 7628595 n NN B-NP O
64 589 590 7628595 = SYM B-VP O
65 591 593 7628595 37 CD B-NP O
66 593 594 7628595 ) ) O O
67 594 595 7628595 . . O O

1 596 603 7628595 Finally RB B-ADVP O
2 603 604 7628595 , , O O
3 605 607 7628595 15 CD B-NP O
4 608 616 7628595 patients NNS I-NP O
5 617 621 7628595 were VBD B-VP O
6 622 630 7628595 excluded VBN I-VP O
7 631 635 7628595 from IN B-PP O
8 636 639 7628595 the DT B-NP O
9 640 645 7628595 study NN I-NP O
10 646 647 7628595 ( ( O O
11 647 660 7628595 noncompliance NN B-NP O
12 661 663 7628595 14 CD I-NP O
13 663 664 7628595 , , O O
14 665 670 7628595 death NN B-NP B-Disease
15 671 672 7628595 1 CD I-NP O
16 672 673 7628595 ) ) O O
17 673 674 7628595 ; : O O
18 675 679 7628595 thus RB B-ADVP O
19 679 680 7628595 , , O O
20 681 683 7628595 60 CD B-NP O
21 684 692 7628595 patients NNS I-NP O
22 693 694 7628595 ( ( O O
23 694 696 7628595 31 CD B-NP O
24 697 699 7628595 in IN B-PP O
25 700 705 7628595 group NN B-NP O
26 706 707 7628595 I CD I-NP O
27 708 711 7628595 and CC I-NP O
28 712 714 7628595 29 CD I-NP O
29 715 717 7628595 in IN B-PP O
30 718 723 7628595 group NN B-NP O
31 724 726 7628595 II CD I-NP O
32 726 727 7628595 ) ) O O
33 728 732 7628595 were VBD B-VP O
34 733 741 7628595 eligible JJ B-ADJP O
35 742 745 7628595 for IN B-PP O
36 746 754 7628595 analysis NN B-NP O
37 754 755 7628595 . . O O

1 756 758 7628595 No DT B-NP O
2 759 770 7628595 significant JJ I-NP O
3 771 782 7628595 differences NNS I-NP O
4 783 790 7628595 between IN B-PP O
5 791 797 7628595 groups NNS B-NP O
6 798 802 7628595 were VBD B-VP O
7 803 808 7628595 found VBN I-VP O
8 809 811 7628595 at IN B-PP O
9 812 822 7628595 enrollment NN B-NP O
10 822 823 7628595 . . O O

1 824 830 7628595 During IN B-PP O
2 831 834 7628595 the DT B-NP O
3 835 840 7628595 study NN I-NP O
4 840 841 7628595 , , O O
5 842 849 7628595 vitamin NN B-NP B-Chemical
6 850 853 7628595 B12 NN I-NP I-Chemical
7 854 857 7628595 and CC I-NP O
8 858 864 7628595 folate NN I-NP B-Chemical
9 865 871 7628595 levels NNS I-NP O
10 872 876 7628595 were VBD B-VP O
11 877 890 7628595 significantly RB B-ADJP O
12 891 897 7628595 higher JJR I-ADJP O
13 898 900 7628595 in IN B-PP O
14 901 906 7628595 group NN B-NP O
15 907 909 7628595 II CD B-NP O
16 910 918 7628595 patients NNS I-NP O
17 918 919 7628595 ; : O O
18 920 927 7628595 however RB B-ADVP O
19 927 928 7628595 , , O O
20 929 931 7628595 no DT B-NP O
21 932 943 7628595 differences NNS I-NP O
22 944 946 7628595 in IN B-PP O
23 947 957 7628595 hemoglobin NN B-NP O
24 957 958 7628595 , , O O
25 959 969 7628595 hematocrit NN B-NP O
26 969 970 7628595 , , O O
27 971 975 7628595 mean JJ B-NP O
28 976 987 7628595 corpuscular JJ I-NP O
29 988 994 7628595 volume NN I-NP O
30 994 995 7628595 , , O O
31 996 999 7628595 and CC O O
32 1000 1005 7628595 white JJ B-NP O
33 1005 1006 7628595 - HYPH I-NP O
34 1006 1010 7628595 cell NN I-NP O
35 1010 1011 7628595 , , I-NP O
36 1012 1022 7628595 neutrophil NN I-NP O
37 1023 1026 7628595 and CC I-NP O
38 1027 1035 7628595 platelet NN I-NP O
39 1036 1042 7628595 counts NNS I-NP O
40 1043 1047 7628595 were VBD B-VP O
41 1048 1056 7628595 observed VBN I-VP O
42 1057 1064 7628595 between IN B-PP O
43 1065 1071 7628595 groups NNS B-NP O
44 1072 1074 7628595 at IN B-PP O
45 1075 1076 7628595 3 CD B-NP O
46 1076 1077 7628595 , , I-NP O
47 1078 1079 7628595 6 CD I-NP O
48 1079 1080 7628595 , , I-NP O
49 1081 1082 7628595 9 CD I-NP O
50 1083 1086 7628595 and CC I-NP O
51 1087 1089 7628595 12 CD I-NP O
52 1090 1096 7628595 months NNS I-NP O
53 1096 1097 7628595 . . O O

1 1098 1104 7628595 Severe JJ B-NP O
2 1105 1116 7628595 hematologic JJ I-NP O
3 1117 1125 7628595 toxicity NN I-NP B-Disease
4 1126 1127 7628595 ( ( O O
5 1127 1137 7628595 neutrophil NN B-NP O
6 1138 1143 7628595 count NN I-NP O
7 1144 1145 7628595 < SYM B-NP O
8 1146 1150 7628595 1000 CD B-NP O
9 1150 1151 7628595 / SYM I-NP O
10 1151 1154 7628595 mm3 NN I-NP O
11 1155 1158 7628595 and CC O O
12 1158 1159 7628595 / SYM B-NP O
13 1159 1161 7628595 or CC O O
14 1162 1172 7628595 hemoglobin NN B-NP O
15 1173 1174 7628595 < SYM O O
16 1175 1176 7628595 8 CD B-NP O
17 1177 1178 7628595 g NN I-NP O
18 1178 1179 7628595 / SYM B-NP O
19 1179 1181 7628595 dl NN I-NP O
20 1181 1182 7628595 ) ) O O
21 1183 1191 7628595 occurred VBD B-VP O
22 1192 1194 7628595 in IN B-PP O
23 1195 1196 7628595 4 CD B-NP O
24 1197 1205 7628595 patients NNS I-NP O
25 1206 1214 7628595 assigned VBN B-VP O
26 1215 1217 7628595 to TO B-PP O
27 1218 1223 7628595 group NN B-NP O
28 1224 1225 7628595 I CD I-NP O
29 1226 1229 7628595 and CC I-NP O
30 1230 1231 7628595 7 CD I-NP O
31 1232 1240 7628595 assigned VBN B-VP O
32 1241 1243 7628595 to TO B-PP O
33 1244 1249 7628595 group NN B-NP O
34 1250 1252 7628595 II CD I-NP O
35 1252 1253 7628595 . . O O

1 1254 1259 7628595 There EX B-NP O
2 1260 1263 7628595 was VBD B-VP O
3 1264 1266 7628595 no DT B-NP O
4 1267 1278 7628595 correlation NN I-NP O
5 1279 1286 7628595 between IN B-PP O
6 1287 1294 7628595 vitamin NN B-NP B-Chemical
7 1295 1298 7628595 B12 NN I-NP I-Chemical
8 1299 1301 7628595 or CC O O
9 1302 1308 7628595 folate JJ B-NP B-Chemical
10 1309 1315 7628595 levels NNS I-NP O
11 1316 1319 7628595 and CC O O
12 1320 1331 7628595 development NN B-NP O
13 1332 1334 7628595 of IN B-PP O
14 1335 1351 7628595 myelosuppression NN B-NP B-Disease
15 1351 1352 7628595 . . O O

1 1353 1360 7628595 Vitamin NN B-NP B-Chemical
2 1361 1364 7628595 B12 NN I-NP I-Chemical
3 1365 1368 7628595 and CC O O
4 1369 1376 7628595 folinic JJ B-NP B-Chemical
5 1377 1381 7628595 acid NN I-NP I-Chemical
6 1382 1397 7628595 supplementation NN I-NP O
7 1398 1400 7628595 of IN B-PP O
8 1401 1404 7628595 ZDV NN B-NP B-Chemical
9 1405 1412 7628595 therapy NN I-NP O
10 1413 1417 7628595 does VBZ B-VP O
11 1418 1421 7628595 not RB I-VP O
12 1422 1426 7628595 seem VB I-VP O
13 1427 1433 7628595 useful JJ B-ADJP O
14 1434 1436 7628595 in IN B-PP O
15 1437 1447 7628595 preventing VBG B-VP O
16 1448 1450 7628595 or CC I-VP O
17 1451 1459 7628595 reducing VBG I-VP O
18 1460 1463 7628595 ZDV NN B-NP B-Chemical
19 1463 1464 7628595 - HYPH O O
20 1464 1471 7628595 induced VBN B-NP O
21 1472 1485 7628595 myelotoxicity NN I-NP B-Disease
22 1486 1488 7628595 in IN B-PP O
23 1489 1492 7628595 the DT B-NP O
24 1493 1500 7628595 overall JJ I-NP O
25 1501 1508 7628595 treated VBN I-NP O
26 1509 1519 7628595 population NN I-NP O
27 1519 1520 7628595 , , O O
28 1521 1529 7628595 although IN B-SBAR O
29 1530 1531 7628595 a DT B-NP O
30 1532 1542 7628595 beneficial JJ I-NP O
31 1543 1549 7628595 effect NN I-NP O
32 1550 1552 7628595 in IN B-PP O
33 1553 1560 7628595 certain JJ B-NP O
34 1561 1570 7628595 subgroups NNS I-NP O
35 1571 1573 7628595 of IN B-PP O
36 1574 1582 7628595 patients NNS B-NP O
37 1583 1589 7628595 cannot MD B-VP O
38 1590 1592 7628595 be VB I-VP O
39 1593 1601 7628595 excluded VBN I-VP O
40 1601 1602 7628595 . . O O

1 0 0 19387625 -DOCSTART- -X- -X- O

1 0 11 19387625 Attentional JJ B-NP O
2 12 22 19387625 modulation NN I-NP O
3 23 25 19387625 of IN B-PP O
4 26 35 19387625 perceived VBN B-NP O
5 36 40 19387625 pain NN I-NP B-Disease
6 41 50 19387625 intensity NN I-NP O
7 51 53 19387625 in IN B-PP O
8 54 63 19387625 capsaicin NN B-NP B-Chemical
9 63 64 19387625 - HYPH B-NP O
10 64 71 19387625 induced VBN I-NP O
11 72 81 19387625 secondary JJ I-NP O
12 82 94 19387625 hyperalgesia NN I-NP B-Disease
13 94 95 19387625 . . O O
14 96 105 19387625 Perceived VBN B-VP O
15 106 110 19387625 pain JJ B-NP B-Disease
16 111 120 19387625 intensity NN I-NP O
17 121 123 19387625 is VBZ B-VP O
18 124 133 19387625 modulated VBN I-VP O
19 134 136 19387625 by IN B-PP O
20 137 146 19387625 attention NN B-NP O
21 146 147 19387625 . . O O

1 148 155 19387625 However RB B-ADVP O
2 155 156 19387625 , , O O
3 157 159 19387625 it PRP B-NP O
4 160 162 19387625 is VBZ B-VP O
5 163 166 19387625 not RB I-VP O
6 167 172 19387625 known VBN I-VP O
7 173 177 19387625 that IN B-SBAR O
8 178 181 19387625 how WRB B-ADVP O
9 182 186 19387625 pain JJ B-NP B-Disease
10 187 196 19387625 intensity NN I-NP O
11 197 204 19387625 ratings NNS I-NP O
12 205 208 19387625 are VBP B-VP O
13 209 217 19387625 affected VBN I-VP O
14 218 220 19387625 by IN B-PP O
15 221 230 19387625 attention NN B-NP O
16 231 233 19387625 in IN B-PP O
17 234 243 19387625 capsaicin NN B-NP B-Chemical
18 243 244 19387625 - HYPH B-NP O
19 244 251 19387625 induced VBN I-NP O
20 252 261 19387625 secondary JJ I-NP O
21 262 274 19387625 hyperalgesia NN I-NP B-Disease
22 274 275 19387625 . . O O

1 276 280 19387625 Here RB B-ADVP O
2 281 283 19387625 we PRP B-NP O
3 284 288 19387625 show VBP B-VP O
4 289 293 19387625 that IN B-SBAR O
5 294 303 19387625 perceived VBN B-NP O
6 304 308 19387625 pain NN I-NP B-Disease
7 309 318 19387625 intensity NN I-NP O
8 319 321 19387625 in IN B-PP O
9 322 331 19387625 secondary JJ B-NP O
10 332 344 19387625 hyperalgesia NN I-NP B-Disease
11 345 347 19387625 is VBZ B-VP O
12 348 357 19387625 decreased VBN I-VP O
13 358 362 19387625 when WRB B-ADVP O
14 363 372 19387625 attention NN B-NP O
15 373 375 19387625 is VBZ B-VP O
16 376 386 19387625 distracted VBN I-VP O
17 387 391 19387625 away RB B-ADVP O
18 392 396 19387625 from IN B-PP O
19 397 400 19387625 the DT B-NP O
20 401 408 19387625 painful JJ I-NP O
21 409 417 19387625 pinprick NN I-NP O
22 418 426 19387625 stimulus NN I-NP O
23 427 431 19387625 with IN B-PP O
24 432 433 19387625 a DT B-NP O
25 434 440 19387625 visual JJ I-NP O
26 441 445 19387625 task NN I-NP O
27 445 446 19387625 . . O O

1 447 458 19387625 Furthermore RB B-ADVP O
2 458 459 19387625 , , O O
3 460 462 19387625 it PRP B-NP O
4 463 466 19387625 was VBD B-VP O
5 467 472 19387625 found VBN I-VP O
6 473 477 19387625 that IN B-SBAR O
7 478 481 19387625 the DT B-NP O
8 482 491 19387625 magnitude NN I-NP O
9 492 494 19387625 of IN B-PP O
10 495 506 19387625 attentional JJ B-NP O
11 507 517 19387625 modulation NN I-NP O
12 518 520 19387625 in IN B-PP O
13 521 530 19387625 secondary JJ B-NP O
14 531 543 19387625 hyperalgesia NN I-NP B-Disease
15 544 546 19387625 is VBZ B-VP O
16 547 551 19387625 very RB B-ADJP O
17 552 559 19387625 similar JJ I-ADJP O
18 560 562 19387625 to TO B-PP O
19 563 567 19387625 that DT B-NP O
20 568 570 19387625 of IN B-PP O
21 571 580 19387625 capsaicin NN B-NP B-Chemical
22 580 581 19387625 - HYPH B-NP O
23 581 590 19387625 untreated JJ I-NP O
24 590 591 19387625 , , I-NP O
25 592 599 19387625 control JJ I-NP O
26 600 609 19387625 condition NN I-NP O
27 609 610 19387625 . . O O

1 611 614 19387625 Our PRP$ B-NP O
2 615 623 19387625 findings NNS I-NP O
3 623 624 19387625 , , O O
4 625 632 19387625 showing VBG B-VP O
5 633 635 19387625 no DT B-NP O
6 636 647 19387625 interaction NN I-NP O
7 648 655 19387625 between IN B-PP O
8 656 665 19387625 capsaicin NN B-NP B-Chemical
9 666 675 19387625 treatment NN I-NP O
10 676 679 19387625 and CC O O
11 680 691 19387625 attentional JJ B-NP O
12 692 702 19387625 modulation NN I-NP O
13 703 710 19387625 suggest VBP B-VP O
14 711 715 19387625 that IN B-SBAR O
15 716 725 19387625 capsaicin NN B-NP B-Chemical
16 725 726 19387625 - HYPH B-NP O
17 726 733 19387625 induced VBN I-NP O
18 734 743 19387625 secondary JJ I-NP O
19 744 756 19387625 hyperalgesia NN I-NP B-Disease
20 757 760 19387625 and CC I-NP O
21 761 770 19387625 attention NN I-NP O
22 771 776 19387625 might MD B-VP O
23 777 783 19387625 affect VB I-VP O
24 784 794 19387625 mechanical JJ B-NP O
25 795 799 19387625 pain NN I-NP B-Disease
26 800 807 19387625 through IN B-PP O
27 808 819 19387625 independent JJ B-NP O
28 820 830 19387625 mechanisms NNS I-NP O
29 830 831 19387625 . . O O

1 0 0 8864707 -DOCSTART- -X- -X- O

1 0 8 8864707 Magnetic JJ B-NP O
2 9 18 8864707 resonance NN I-NP O
3 19 28 8864707 volumetry NN I-NP O
4 29 31 8864707 of IN B-PP O
5 32 35 8864707 the DT B-NP O
6 36 46 8864707 cerebellum NN I-NP O
7 47 49 8864707 in IN B-PP O
8 50 59 8864707 epileptic JJ B-NP B-Disease
9 60 68 8864707 patients NNS I-NP O
10 69 74 8864707 after IN B-PP O
11 75 84 8864707 phenytoin NN B-NP B-Chemical
12 85 96 8864707 overdosages NNS I-NP B-Disease
13 96 97 8864707 . . O O
14 98 101 8864707 The DT B-NP O
15 102 105 8864707 aim NN I-NP O
16 106 108 8864707 of IN B-PP O
17 109 113 8864707 this DT B-NP O
18 114 119 8864707 study NN I-NP O
19 120 123 8864707 was VBD B-VP O
20 124 126 8864707 to TO B-VP O
21 127 135 8864707 evaluate VB I-VP O
22 136 139 8864707 the DT B-NP O
23 140 152 8864707 relationship NN I-NP O
24 153 160 8864707 between IN B-PP O
25 161 170 8864707 phenytoin NN B-NP B-Chemical
26 171 181 8864707 medication NN I-NP O
27 182 185 8864707 and CC O O
28 186 196 8864707 cerebellar JJ B-NP B-Disease
29 197 204 8864707 atrophy NN I-NP I-Disease
30 205 207 8864707 in IN B-PP O
31 208 216 8864707 patients NNS B-NP O
32 217 220 8864707 who WP B-NP O
33 221 224 8864707 had VBD B-VP O
34 225 236 8864707 experienced VBN I-VP O
35 237 245 8864707 clinical JJ B-NP O
36 246 258 8864707 intoxication NN I-NP O
37 258 259 8864707 . . O O

1 260 264 8864707 Five CD B-NP O
2 265 272 8864707 females NNS I-NP O
3 273 276 8864707 and CC O O
4 277 278 8864707 6 CD B-NP O
5 279 284 8864707 males NNS I-NP O
6 284 285 8864707 , , O O
7 286 288 8864707 21 CD B-NP O
8 288 289 8864707 - HYPH I-NP O
9 289 291 8864707 59 CD I-NP O
10 292 297 8864707 years NNS I-NP O
11 298 300 8864707 of IN B-PP O
12 301 304 8864707 age NN B-NP O
13 304 305 8864707 , , O O
14 306 310 8864707 were VBD B-VP O
15 311 319 8864707 examined VBN I-VP O
16 320 324 8864707 with IN B-PP O
17 325 326 8864707 a DT B-NP O
18 327 330 8864707 1.5 CD I-NP O
19 330 331 8864707 - HYPH I-NP O
20 331 332 8864707 T NN I-NP O
21 333 338 8864707 whole JJ I-NP O
22 338 339 8864707 - HYPH I-NP O
23 339 343 8864707 body NN I-NP O
24 344 350 8864707 system NN I-NP O
25 351 356 8864707 using VBG B-VP O
26 357 358 8864707 a DT B-NP O
27 359 367 8864707 circular JJ I-NP O
28 368 377 8864707 polarized VBN I-NP O
29 378 382 8864707 head NN I-NP O
30 383 387 8864707 coil NN I-NP O
31 387 388 8864707 . . O O

1 389 401 8864707 Conventional JJ B-NP O
2 402 406 8864707 spin NN I-NP O
3 407 411 8864707 echo NN I-NP O
4 412 418 8864707 images NNS I-NP O
5 419 423 8864707 were VBD B-VP O
6 424 432 8864707 acquired VBN I-VP O
7 433 435 8864707 in IN B-PP O
8 436 439 8864707 the DT B-NP O
9 440 448 8864707 sagittal JJ I-NP O
10 449 452 8864707 and CC I-NP O
11 453 463 8864707 transverse JJ I-NP O
12 464 475 8864707 orientation NN I-NP O
13 475 476 8864707 . . O O

1 477 479 8864707 In IN B-PP O
2 480 488 8864707 addition NN B-NP O
3 488 489 8864707 , , O O
4 490 492 8864707 we PRP B-NP O
5 493 502 8864707 performed VBD B-VP O
6 503 504 8864707 a DT B-NP O
7 505 509 8864707 high JJ I-NP O
8 509 510 8864707 - HYPH I-NP O
9 510 520 8864707 resolution NN I-NP O
10 521 523 8864707 3D NN I-NP O
11 524 532 8864707 gradient NN I-NP O
12 533 537 8864707 echo NN I-NP O
13 537 538 8864707 , , O O
14 539 541 8864707 T1 NN B-NP O
15 541 542 8864707 - HYPH O O
16 542 550 8864707 weighted VBN B-VP O
17 551 560 8864707 sequences NNS B-NP O
18 561 563 8864707 at IN B-PP O
19 564 565 8864707 a DT B-NP O
20 566 567 8864707 1 CD I-NP O
21 567 568 8864707 - HYPH I-NP O
22 568 570 8864707 mm NN I-NP O
23 571 576 8864707 slice NN I-NP O
24 577 586 8864707 thickness NN I-NP O
25 586 587 8864707 . . O O

1 588 591 8864707 The DT B-NP O
2 592 598 8864707 images NNS I-NP O
3 599 603 8864707 were VBD B-VP O
4 604 616 8864707 subsequently RB I-VP O
5 617 626 8864707 processed VBN I-VP O
6 627 629 8864707 to TO B-VP O
7 630 636 8864707 obtain VB I-VP O
8 637 647 8864707 volumetric JJ B-NP O
9 648 652 8864707 data NNS I-NP O
10 653 656 8864707 for IN B-PP O
11 657 660 8864707 the DT B-NP O
12 661 671 8864707 cerebellum NN I-NP O
13 671 672 8864707 . . O O

1 673 683 8864707 Cerebellar JJ B-NP O
2 684 690 8864707 volume NN I-NP O
3 691 694 8864707 for IN B-PP O
4 695 698 8864707 the DT B-NP O
5 699 706 8864707 patient NN I-NP O
6 707 712 8864707 group NN I-NP O
7 713 719 8864707 ranged VBD B-VP O
8 720 727 8864707 between IN B-PP O
9 728 733 8864707 67.66 CD B-NP O
10 734 737 8864707 and CC I-NP O
11 738 744 8864707 131.08 CD I-NP O
12 745 747 8864707 ml NN I-NP O
13 748 749 8864707 ( ( O O
14 749 753 8864707 mean NN B-NP O
15 754 759 8864707 108.9 CD I-NP O
16 760 762 8864707 ml NN I-NP O
17 762 763 8864707 ) ) O O
18 763 764 8864707 . . O O

1 765 767 8864707 In IN B-PP O
2 768 776 8864707 addition NN B-NP O
3 777 779 8864707 3D NN I-NP O
4 780 788 8864707 gradient NN I-NP O
5 789 793 8864707 echo JJ I-NP O
6 794 798 8864707 data NNS I-NP O
7 799 803 8864707 sets NNS I-NP O
8 804 808 8864707 from IN B-PP O
9 809 811 8864707 10 CD B-NP O
10 812 819 8864707 healthy JJ I-NP O
11 820 824 8864707 male JJ I-NP O
12 825 828 8864707 and CC I-NP O
13 829 831 8864707 10 CD I-NP O
14 832 839 8864707 healthy JJ I-NP O
15 840 846 8864707 female JJ I-NP O
16 847 850 8864707 age NN I-NP O
17 850 851 8864707 - HYPH B-NP O
18 851 858 8864707 matched VBN I-NP O
19 859 869 8864707 volunteers NNS I-NP O
20 870 874 8864707 were VBD B-VP O
21 875 879 8864707 used VBN I-VP O
22 880 882 8864707 to TO B-VP O
23 883 890 8864707 compare VB I-VP O
24 891 901 8864707 cerebellar JJ B-NP O
25 902 909 8864707 volumes NNS I-NP O
26 909 910 8864707 . . O O

1 911 916 8864707 Using VBG B-VP O
2 917 923 8864707 linear JJ B-NP O
3 924 934 8864707 regression NN I-NP O
4 935 937 8864707 we PRP B-NP O
5 938 943 8864707 found VBD B-VP O
6 944 948 8864707 that IN B-SBAR O
7 949 951 8864707 no DT B-NP O
8 952 963 8864707 correlation NN I-NP O
9 964 970 8864707 exists VBZ B-VP O
10 971 978 8864707 between IN B-PP O
11 979 986 8864707 seizure NN B-NP B-Disease
12 987 995 8864707 duration NN I-NP O
13 995 996 8864707 , , O O
14 997 1006 8864707 elevation NN B-NP O
15 1007 1009 8864707 of IN B-PP O
16 1010 1019 8864707 phenytoin NN B-NP B-Chemical
17 1020 1025 8864707 serum NN I-NP O
18 1026 1032 8864707 levels NNS I-NP O
19 1033 1036 8864707 and CC O O
20 1037 1047 8864707 cerebellar JJ B-NP O
21 1048 1054 8864707 volume NN I-NP O
22 1054 1055 8864707 . . O O

1 1056 1063 8864707 However RB B-ADVP O
2 1063 1064 8864707 , , O O
3 1065 1073 8864707 multiple JJ B-NP O
4 1074 1084 8864707 regression NN I-NP O
5 1085 1088 8864707 for IN B-PP O
6 1089 1092 8864707 the DT B-NP O
7 1093 1098 8864707 daily JJ I-NP O
8 1099 1105 8864707 dosage NN I-NP O
9 1105 1106 8864707 , , O O
10 1107 1115 8864707 duration NN B-NP O
11 1116 1118 8864707 of IN B-PP O
12 1119 1128 8864707 phenytoin NN B-NP B-Chemical
13 1129 1138 8864707 treatment NN I-NP O
14 1139 1142 8864707 and CC O O
15 1143 1153 8864707 cerebellar JJ B-NP O
16 1154 1160 8864707 volume NN I-NP O
17 1161 1169 8864707 revealed VBD B-VP O
18 1170 1171 8864707 a DT B-NP O
19 1172 1183 8864707 correlation NN I-NP O
20 1184 1186 8864707 of IN B-PP O
21 1187 1192 8864707 these DT B-NP O
22 1193 1203 8864707 parameters NNS I-NP O
23 1203 1204 8864707 . . O O

1 1205 1207 8864707 We PRP B-NP O
2 1208 1216 8864707 conclude VBP B-VP O
3 1217 1221 8864707 that IN B-SBAR O
4 1222 1231 8864707 phenytoin NN B-NP B-Chemical
5 1232 1242 8864707 overdosage NN I-NP B-Disease
6 1243 1247 8864707 does VBZ B-VP O
7 1248 1251 8864707 not RB I-VP O
8 1252 1263 8864707 necessarily RB I-VP O
9 1264 1270 8864707 result VB I-VP O
10 1271 1273 8864707 in IN B-PP O
11 1274 1284 8864707 cerebellar JJ B-NP B-Disease
12 1285 1292 8864707 atrophy NN I-NP I-Disease
13 1293 1296 8864707 and CC O O
14 1297 1299 8864707 it PRP B-NP O
15 1300 1302 8864707 is VBZ B-VP O
16 1303 1311 8864707 unlikely JJ B-ADJP O
17 1312 1316 8864707 that IN B-SBAR O
18 1317 1326 8864707 phenytoin NN B-NP B-Chemical
19 1327 1337 8864707 medication NN I-NP O
20 1338 1341 8864707 was VBD B-VP O
21 1342 1345 8864707 the DT B-NP O
22 1346 1350 8864707 only JJ I-NP O
23 1351 1356 8864707 cause NN I-NP O
24 1357 1359 8864707 of IN B-PP O
25 1360 1370 8864707 cerebellar JJ B-NP B-Disease
26 1371 1378 8864707 atrophy NN I-NP I-Disease
27 1379 1381 8864707 in IN B-PP O
28 1382 1385 8864707 the DT B-NP O
29 1386 1395 8864707 remaining VBG I-NP O
30 1396 1404 8864707 patients NNS I-NP O
31 1404 1405 8864707 . . O O

1 1406 1418 8864707 Quantitative JJ B-NP O
2 1419 1431 8864707 morphometric JJ I-NP O
3 1432 1439 8864707 studies NNS I-NP O
4 1440 1442 8864707 of IN B-PP O
5 1443 1446 8864707 the DT B-NP O
6 1447 1457 8864707 cerebellum NN I-NP O
7 1458 1465 8864707 provide VBP B-VP O
8 1466 1474 8864707 valuable JJ B-NP O
9 1475 1483 8864707 insights NNS I-NP O
10 1484 1488 8864707 into IN B-PP O
11 1489 1492 8864707 the DT B-NP O
12 1493 1505 8864707 pathogenesis NN I-NP O
13 1506 1508 8864707 of IN B-PP O
14 1509 1519 8864707 cerebellar JJ B-NP B-Disease
15 1520 1529 8864707 disorders NNS I-NP I-Disease
16 1529 1530 8864707 . . O O

1 0 0 18261172 -DOCSTART- -X- -X- O

1 0 11 18261172 Development NN B-NP O
2 12 14 18261172 of IN B-PP O
3 15 26 18261172 proteinuria NN B-NP B-Disease
4 27 32 18261172 after IN B-PP O
5 33 39 18261172 switch NN B-NP O
6 40 42 18261172 to TO B-PP O
7 43 52 18261172 sirolimus NN B-NP B-Chemical
8 52 53 18261172 - HYPH O O
9 53 58 18261172 based VBN B-NP O
10 59 76 18261172 immunosuppression NN I-NP O
11 77 79 18261172 in IN B-PP O
12 80 84 18261172 long JJ B-NP O
13 84 85 18261172 - HYPH I-NP O
14 85 89 18261172 term NN I-NP O
15 90 97 18261172 cardiac JJ I-NP O
16 98 108 18261172 transplant NN I-NP O
17 109 117 18261172 patients NNS I-NP O
18 117 118 18261172 . . O O
19 119 130 18261172 Calcineurin NN B-NP O
20 130 131 18261172 - HYPH I-NP O
21 131 140 18261172 inhibitor NN I-NP O
22 141 148 18261172 therapy NN I-NP O
23 149 152 18261172 can MD B-VP O
24 153 157 18261172 lead VB I-VP O
25 158 160 18261172 to TO B-PP O
26 161 166 18261172 renal JJ B-NP B-Disease
27 167 178 18261172 dysfunction NN I-NP I-Disease
28 179 181 18261172 in IN B-PP O
29 182 187 18261172 heart NN B-NP O
30 188 203 18261172 transplantation NN I-NP O
31 204 212 18261172 patients NNS I-NP O
32 212 213 18261172 . . O O

1 214 217 18261172 The DT B-NP O
2 218 223 18261172 novel JJ I-NP O
3 224 241 18261172 immunosuppressive JJ I-NP O
4 242 243 18261172 ( ( O O
5 243 245 18261172 IS NN B-NP O
6 245 246 18261172 ) ) O O
7 247 251 18261172 drug NN B-NP O
8 252 260 18261172 sirolmus NN I-NP B-Chemical
9 261 262 18261172 ( ( O O
10 262 265 18261172 Srl NN B-NP B-Chemical
11 265 266 18261172 ) ) O O
12 267 272 18261172 lacks VBZ B-VP O
13 273 284 18261172 nephrotoxic JJ B-NP B-Disease
14 285 292 18261172 effects NNS I-NP O
15 292 293 18261172 ; : O O
16 294 301 18261172 however RB B-ADVP O
17 301 302 18261172 , , O O
18 303 314 18261172 proteinuria NN B-NP B-Disease
19 315 325 18261172 associated VBN B-VP O
20 326 330 18261172 with IN B-PP O
21 331 334 18261172 Srl NN B-NP B-Chemical
22 335 338 18261172 has VBZ B-VP O
23 339 343 18261172 been VBN I-VP O
24 344 352 18261172 reported VBN I-VP O
25 353 362 18261172 following VBG B-PP O
26 363 368 18261172 renal JJ B-NP O
27 369 384 18261172 transplantation NN I-NP O
28 384 385 18261172 . . O O

1 386 388 18261172 In IN B-PP O
2 389 396 18261172 cardiac JJ B-NP O
3 397 412 18261172 transplantation NN I-NP O
4 412 413 18261172 , , O O
5 414 417 18261172 the DT B-NP O
6 418 427 18261172 incidence NN I-NP O
7 428 430 18261172 of IN B-PP O
8 431 442 18261172 proteinuria NN B-NP B-Disease
9 443 453 18261172 associated VBN B-VP O
10 454 458 18261172 with IN B-PP O
11 459 462 18261172 Srl NN B-NP B-Chemical
12 463 465 18261172 is VBZ B-VP O
13 466 473 18261172 unknown JJ B-ADJP O
14 473 474 18261172 . . O O

1 475 477 18261172 In IN B-PP O
2 478 482 18261172 this DT B-NP O
3 483 488 18261172 study NN I-NP O
4 488 489 18261172 , , O O
5 490 494 18261172 long JJ B-NP O
6 494 495 18261172 - HYPH I-NP O
7 495 499 18261172 term NN I-NP O
8 500 507 18261172 cardiac JJ I-NP O
9 508 518 18261172 transplant NN I-NP O
10 519 527 18261172 patients NNS I-NP O
11 528 532 18261172 were VBD B-VP O
12 533 541 18261172 switched VBN I-VP O
13 542 546 18261172 from IN B-PP O
14 547 559 18261172 cyclosporine NN B-NP B-Chemical
15 560 562 18261172 to TO B-PP O
16 563 566 18261172 Srl NN B-NP B-Chemical
17 566 567 18261172 - HYPH O O
18 567 572 18261172 based VBN B-NP O
19 573 575 18261172 IS NN I-NP O
20 575 576 18261172 . . O O

1 577 588 18261172 Concomitant JJ B-NP O
2 589 591 18261172 IS NN I-NP O
3 592 601 18261172 consisted VBD B-VP O
4 602 604 18261172 of IN B-PP O
5 605 618 18261172 mycophenolate NN B-NP B-Chemical
6 619 626 18261172 mofetil NN I-NP I-Chemical
7 627 628 18261172 + SYM B-NP O
8 628 629 18261172 / SYM B-VP O
9 629 630 18261172 - HYPH B-ADVP O
10 631 639 18261172 steroids NNS B-NP B-Chemical
11 639 640 18261172 . . O O

1 641 652 18261172 Proteinuria NNP B-NP O
2 653 662 18261172 increased VBD B-VP O
3 663 676 18261172 significantly RB B-ADVP O
4 677 681 18261172 from IN B-PP O
5 682 683 18261172 a DT B-NP O
6 684 690 18261172 median NN I-NP O
7 691 693 18261172 of IN B-PP O
8 694 698 18261172 0.13 CD B-NP O
9 699 700 18261172 g NN I-NP O
10 700 701 18261172 / SYM B-NP O
11 701 704 18261172 day NN I-NP O
12 705 706 18261172 ( ( O O
13 706 711 18261172 range NN B-NP O
14 712 713 18261172 0 CD I-NP O
15 713 714 18261172 - HYPH B-NP O
16 714 717 18261172 5.7 CD I-NP O
17 717 718 18261172 ) ) O O
18 719 728 18261172 preswitch NN B-NP O
19 729 731 18261172 to TO B-PP O
20 732 736 18261172 0.23 CD B-NP O
21 737 738 18261172 g NN I-NP O
22 738 739 18261172 / SYM B-NP O
23 739 742 18261172 day NN I-NP O
24 743 744 18261172 ( ( O O
25 744 745 18261172 0 CD B-NP O
26 745 746 18261172 - HYPH O O
27 746 750 18261172 9.88 CD B-NP O
28 750 751 18261172 ) ) O O
29 752 754 18261172 at IN B-PP O
30 755 757 18261172 24 CD B-NP O
31 758 764 18261172 months NNS I-NP O
32 765 775 18261172 postswitch NN B-NP O
33 776 777 18261172 ( ( O O
34 777 778 18261172 p NN B-NP O
35 779 780 18261172 = SYM B-VP O
36 781 787 18261172 0.0024 CD B-NP O
37 787 788 18261172 ) ) O O
38 788 789 18261172 . . O O

1 790 796 18261172 Before IN B-PP O
2 797 800 18261172 the DT B-NP O
3 801 807 18261172 switch NN I-NP O
4 807 808 18261172 , , O O
5 809 814 18261172 11.5% CD B-NP O
6 815 817 18261172 of IN B-PP O
7 818 826 18261172 patients NNS B-NP O
8 827 830 18261172 had VBD B-VP O
9 831 835 18261172 high JJ B-NP O
10 835 836 18261172 - HYPH I-NP O
11 836 841 18261172 grade NN I-NP O
12 842 853 18261172 proteinuria NN I-NP B-Disease
13 854 855 18261172 ( ( O O
14 855 856 18261172 > SYM B-NP O
15 856 859 18261172 1.0 CD B-NP O
16 860 861 18261172 g NN I-NP O
17 861 862 18261172 / SYM B-NP O
18 862 865 18261172 day NN I-NP O
19 865 866 18261172 ) ) O O
20 866 867 18261172 ; : O O
21 868 872 18261172 this DT B-NP O
22 873 882 18261172 increased VBD B-VP O
23 883 885 18261172 to TO B-PP O
24 886 891 18261172 22.9% CD B-NP O
25 892 902 18261172 postswitch NN I-NP O
26 903 904 18261172 ( ( O O
27 904 905 18261172 p NN B-NP O
28 906 907 18261172 = SYM B-VP O
29 908 913 18261172 0.006 CD B-NP O
30 913 914 18261172 ) ) O O
31 914 915 18261172 . . O O

1 916 919 18261172 ACE NN B-NP B-Chemical
2 920 929 18261172 inhibitor NN I-NP I-Chemical
3 930 933 18261172 and CC I-NP O
4 934 945 18261172 angiotensin NN I-NP B-Chemical
5 945 946 18261172 - HYPH O I-Chemical
6 946 955 18261172 releasing VBG B-VP I-Chemical
7 956 963 18261172 blocker NN B-NP I-Chemical
8 964 965 18261172 ( ( O O
9 965 968 18261172 ARB NN B-NP B-Chemical
10 968 969 18261172 ) ) O O
11 970 977 18261172 therapy NN B-NP O
12 978 985 18261172 reduced VBD B-VP O
13 986 997 18261172 proteinuria NN B-NP B-Disease
14 998 1009 18261172 development NN I-NP O
15 1009 1010 18261172 . . O O

1 1011 1019 18261172 Patients NNS B-NP O
2 1020 1027 18261172 without IN B-PP O
3 1028 1039 18261172 proteinuria NN B-NP B-Disease
4 1040 1043 18261172 had VBD B-VP O
5 1044 1053 18261172 increased VBN I-VP O
6 1054 1059 18261172 renal JJ B-NP O
7 1060 1068 18261172 function NN I-NP O
8 1069 1070 18261172 ( ( O O
9 1070 1076 18261172 median NN B-NP O
10 1077 1081 18261172 42.5 CD B-NP O
11 1082 1084 18261172 vs NNS I-NP O
12 1084 1085 18261172 . . O O
13 1086 1090 18261172 64.1 CD B-NP O
14 1090 1091 18261172 , , O O
15 1092 1093 18261172 p NN B-NP O
16 1094 1095 18261172 = SYM B-VP O
17 1096 1100 18261172 0.25 CD B-NP O
18 1100 1101 18261172 ) ) O O
19 1101 1102 18261172 , , O O
20 1103 1110 18261172 whereas IN O O
21 1111 1119 18261172 patients NNS B-NP O
22 1120 1123 18261172 who WP B-NP O
23 1124 1133 18261172 developed VBD B-VP O
24 1134 1138 18261172 high JJ B-NP O
25 1138 1139 18261172 - HYPH I-NP O
26 1139 1144 18261172 grade NN I-NP O
27 1145 1156 18261172 proteinuria NN I-NP B-Disease
28 1157 1163 18261172 showed VBD B-VP O
29 1164 1173 18261172 decreased VBN I-VP O
30 1174 1179 18261172 renal JJ B-NP O
31 1180 1188 18261172 function NN I-NP O
32 1189 1191 18261172 at IN B-PP O
33 1192 1195 18261172 the DT B-NP O
34 1196 1199 18261172 end NN I-NP O
35 1200 1202 18261172 of IN B-PP O
36 1203 1209 18261172 follow VB B-VP O
37 1209 1210 18261172 - HYPH O O
38 1210 1212 18261172 up RP B-PRT O
39 1213 1214 18261172 ( ( O O
40 1214 1220 18261172 median JJ B-NP O
41 1221 1225 18261172 39.6 CD I-NP O
42 1226 1228 18261172 vs NNS I-NP O
43 1228 1229 18261172 . . O O
44 1230 1234 18261172 29.2 CD B-NP O
45 1234 1235 18261172 , , O O
46 1236 1237 18261172 p NN B-NP O
47 1238 1239 18261172 = SYM B-VP O
48 1240 1245 18261172 0.125 CD B-NP O
49 1245 1246 18261172 ) ) O O
50 1246 1247 18261172 . . O O

1 1248 1252 18261172 Thus RB B-ADVP O
2 1252 1253 18261172 , , O O
3 1254 1265 18261172 proteinuria NN B-NP B-Disease
4 1266 1269 18261172 may MD B-VP O
5 1270 1277 18261172 develop VB I-VP O
6 1278 1280 18261172 in IN B-PP O
7 1281 1288 18261172 cardiac JJ B-NP O
8 1289 1299 18261172 transplant NN I-NP O
9 1300 1308 18261172 patients NNS I-NP O
10 1309 1314 18261172 after IN B-PP O
11 1315 1321 18261172 switch NN B-NP O
12 1322 1324 18261172 to TO B-PP O
13 1325 1328 18261172 Srl NN B-NP B-Chemical
14 1328 1329 18261172 , , O O
15 1330 1335 18261172 which WDT B-NP O
16 1336 1339 18261172 may MD B-VP O
17 1340 1344 18261172 have VB I-VP O
18 1345 1347 18261172 an DT B-NP O
19 1348 1355 18261172 adverse JJ I-NP O
20 1356 1362 18261172 effect NN I-NP O
21 1363 1365 18261172 on IN B-PP O
22 1366 1371 18261172 renal JJ B-NP O
23 1372 1380 18261172 function NN I-NP O
24 1381 1383 18261172 in IN B-PP O
25 1384 1389 18261172 these DT B-NP O
26 1390 1398 18261172 patients NNS I-NP O
27 1398 1399 18261172 . . O O

1 1400 1403 18261172 Srl NN B-NP B-Chemical
2 1404 1410 18261172 should MD B-VP O
3 1411 1413 18261172 be VB I-VP O
4 1414 1418 18261172 used VBN I-VP O
5 1419 1423 18261172 with IN B-PP O
6 1424 1428 18261172 ACEi NN B-NP B-Chemical
7 1428 1429 18261172 / SYM I-NP O
8 1429 1432 18261172 ARB NN I-NP B-Chemical
9 1433 1440 18261172 therapy NN I-NP O
10 1441 1444 18261172 and CC O O
11 1445 1453 18261172 patients NNS B-NP O
12 1454 1463 18261172 monitored VBN B-VP O
13 1464 1467 18261172 for IN B-PP O
14 1468 1479 18261172 proteinuria NN B-NP B-Disease
15 1480 1483 18261172 and CC O O
16 1484 1493 18261172 increased VBD B-VP O
17 1494 1499 18261172 renal JJ B-NP B-Disease
18 1500 1511 18261172 dysfunction NN I-NP I-Disease
19 1511 1512 18261172 . . O O

1 0 0 9495837 -DOCSTART- -X- -X- O

1 0 15 9495837 Antinociceptive JJ B-NP O
2 16 19 9495837 and CC I-NP O
3 20 31 9495837 antiamnesic JJ I-NP O
4 32 42 9495837 properties NNS I-NP O
5 43 45 9495837 of IN B-PP O
6 46 49 9495837 the DT B-NP O
7 50 61 9495837 presynaptic JJ I-NP O
8 62 73 9495837 cholinergic JJ I-NP O
9 74 83 9495837 amplifier NN I-NP O
10 84 86 9495837 PG NN I-NP B-Chemical
11 86 87 9495837 - HYPH B-NP I-Chemical
12 87 88 9495837 9 CD I-NP I-Chemical
13 88 89 9495837 . . O O
14 90 93 9495837 The DT B-NP O
15 94 109 9495837 antinociceptive JJ I-NP O
16 110 116 9495837 effect NN I-NP O
17 117 119 9495837 of IN B-PP O
18 120 121 9495837 3 CD B-NP B-Chemical
19 122 127 9495837 alpha SYM I-NP I-Chemical
20 127 128 9495837 - HYPH I-NP I-Chemical
21 128 134 9495837 tropyl NN B-NP I-Chemical
22 135 136 9495837 2 CD I-NP I-Chemical
23 136 137 9495837 - HYPH I-NP I-Chemical
24 137 139 9495837 (p NN I-NP I-Chemical
25 139 140 9495837 - HYPH I-NP I-Chemical
26 140 162 9495837 bromophenyl)propionate NN I-NP I-Chemical
27 163 164 9495837 [ ( O O
28 164 165 9495837 ( ( O O
29 165 166 9495837 + SYM O O
30 166 167 9495837 / SYM O O
31 167 168 9495837 - SYM O O
32 168 169 9495837 ) ) O O
33 169 170 9495837 - HYPH B-NP O
34 170 172 9495837 PG NN I-NP B-Chemical
35 172 173 9495837 - HYPH B-NP I-Chemical
36 173 174 9495837 9 CD I-NP I-Chemical
37 174 175 9495837 ] ) O O
38 176 177 9495837 ( ( O O
39 177 179 9495837 10 CD B-NP O
40 179 180 9495837 - HYPH I-NP O
41 180 182 9495837 40 CD I-NP O
42 183 185 9495837 mg NN I-NP O
43 186 188 9495837 kg NN I-NP O
44 188 189 9495837 - HYPH B-NP O
45 189 190 9495837 1 CD I-NP O
46 191 194 9495837 s.c NN I-NP O
47 194 195 9495837 . . O O
48 195 196 9495837 ; : O O
49 197 199 9495837 30 CD B-NP O
50 199 200 9495837 - HYPH I-NP O
51 200 202 9495837 60 CD I-NP O
52 203 205 9495837 mg NN I-NP O
53 206 208 9495837 kg NN I-NP O
54 208 209 9495837 - HYPH B-NP O
55 209 210 9495837 1 CD I-NP O
56 211 214 9495837 p.o NN I-NP O
57 214 215 9495837 . . O O
58 215 216 9495837 ; : O O
59 217 219 9495837 10 CD B-NP O
60 219 220 9495837 - HYPH I-NP O
61 220 222 9495837 30 CD I-NP O
62 223 225 9495837 mg NN I-NP O
63 226 228 9495837 kg NN I-NP O
64 228 229 9495837 - HYPH B-NP O
65 229 230 9495837 1 CD I-NP O
66 231 234 9495837 i.v NN I-NP O
67 234 235 9495837 . . O O
68 235 236 9495837 ; : O O
69 237 239 9495837 10 CD B-NP O
70 239 240 9495837 - HYPH I-NP O
71 240 242 9495837 30 CD I-NP O
72 243 253 9495837 micrograms NNS I-NP O
73 253 254 9495837 / SYM B-NP O
74 254 259 9495837 mouse NN I-NP O
75 260 265 9495837 i.c.v NN I-NP O
76 265 266 9495837 . . O O
77 266 267 9495837 ) ) O O
78 268 271 9495837 was VBD B-VP O
79 272 280 9495837 examined VBN I-VP O
80 281 283 9495837 in IN B-PP O
81 284 288 9495837 mice NNS B-NP O
82 288 289 9495837 , , O O
83 290 294 9495837 rats NNS B-NP O
84 295 298 9495837 and CC O O
85 299 305 9495837 guinea NN B-NP O
86 306 310 9495837 pigs NNS I-NP O
87 311 313 9495837 by IN B-PP O
88 314 317 9495837 use NN B-NP O
89 318 320 9495837 of IN B-PP O
90 321 324 9495837 the DT B-NP O
91 325 328 9495837 hot JJ I-NP O
92 328 329 9495837 - HYPH I-NP O
93 329 334 9495837 plate NN I-NP O
94 334 335 9495837 , , O O
95 336 345 9495837 abdominal JJ B-NP O
96 345 346 9495837 - HYPH I-NP O
97 346 358 9495837 constriction NN I-NP O
98 358 359 9495837 , , O O
99 360 364 9495837 tail NN B-NP O
100 364 365 9495837 - HYPH I-NP O
101 365 370 9495837 flick NN I-NP O
102 371 374 9495837 and CC I-NP O
103 375 378 9495837 paw NN I-NP O
104 378 379 9495837 - HYPH B-NP O
105 379 387 9495837 pressure NN I-NP O
106 388 393 9495837 tests NNS I-NP O
107 393 394 9495837 . . O O

1 395 396 9495837 ( ( O O
2 396 397 9495837 + SYM B-NP O
3 397 398 9495837 / SYM O O
4 398 399 9495837 - SYM O O
5 399 400 9495837 ) ) O O
6 400 401 9495837 - HYPH B-NP O
7 401 403 9495837 PG NN I-NP B-Chemical
8 403 404 9495837 - HYPH B-NP I-Chemical
9 404 405 9495837 9 CD I-NP I-Chemical
10 406 421 9495837 antinociception NN I-NP O
11 422 428 9495837 peaked VBD B-VP O
12 429 431 9495837 15 CD B-NP O
13 432 435 9495837 min NN I-NP O
14 436 441 9495837 after IN B-PP O
15 442 451 9495837 injection NN B-NP O
16 452 455 9495837 and CC O O
17 456 460 9495837 then RB B-VP O
18 461 467 9495837 slowly RB I-VP O
19 468 478 9495837 diminished VBN I-VP O
20 478 479 9495837 . . O O

1 480 483 9495837 The DT B-NP O
2 484 499 9495837 antinociception NN I-NP O
3 500 508 9495837 produced VBN B-VP O
4 509 511 9495837 by IN B-PP O
5 512 513 9495837 ( ( O O
6 513 514 9495837 + SYM B-NP O
7 514 515 9495837 / SYM O O
8 515 516 9495837 - SYM O O
9 516 517 9495837 ) ) O O
10 517 518 9495837 - HYPH B-NP O
11 518 520 9495837 PG NN I-NP B-Chemical
12 520 521 9495837 - HYPH B-NP I-Chemical
13 521 522 9495837 9 CD I-NP I-Chemical
14 523 526 9495837 was VBD B-VP O
15 527 536 9495837 prevented VBN I-VP O
16 537 539 9495837 by IN B-PP O
17 540 543 9495837 the DT B-NP O
18 544 555 9495837 unselective JJ I-NP O
19 556 566 9495837 muscarinic JJ I-NP O
20 567 577 9495837 antagonist NN I-NP O
21 578 586 9495837 atropine NN I-NP B-Chemical
22 586 587 9495837 , , O O
23 588 591 9495837 the DT B-NP O
24 592 594 9495837 M1 NN I-NP O
25 594 595 9495837 - HYPH B-NP O
26 595 604 9495837 selective JJ I-NP O
27 605 616 9495837 antagonists NNS I-NP O
28 617 628 9495837 pirenzepine NN I-NP B-Chemical
29 629 632 9495837 and CC I-NP O
30 633 644 9495837 dicyclomine NN I-NP B-Chemical
31 645 648 9495837 and CC O O
32 649 652 9495837 the DT B-NP O
33 653 666 9495837 acetylcholine NN I-NP B-Chemical
34 667 675 9495837 depletor NN I-NP O
35 676 689 9495837 hemicholinium NN I-NP B-Chemical
36 689 690 9495837 - HYPH B-NP I-Chemical
37 690 691 9495837 3 CD I-NP I-Chemical
38 691 692 9495837 , , O O
39 693 696 9495837 but CC B-PP O
40 697 700 9495837 not RB I-PP O
41 701 703 9495837 by IN B-PP O
42 704 707 9495837 the DT B-NP O
43 708 714 9495837 opioid JJ I-NP O
44 715 725 9495837 antagonist NN I-NP O
45 726 734 9495837 naloxone NN I-NP B-Chemical
46 734 735 9495837 , , O O
47 736 739 9495837 the DT B-NP O
48 740 745 9495837 gamma SYM I-NP B-Chemical
49 745 746 9495837 - HYPH I-NP I-Chemical
50 746 758 9495837 aminobutyric JJ I-NP I-Chemical
51 759 764 9495837 acidB NN I-NP I-Chemical
52 765 775 9495837 antagonist NN I-NP O
53 776 777 9495837 3 CD I-NP B-Chemical
54 777 778 9495837 - HYPH I-NP I-Chemical
55 778 789 9495837 aminopropyl NN I-NP I-Chemical
56 789 790 9495837 - HYPH B-NP I-Chemical
57 790 798 9495837 diethoxy NN I-NP I-Chemical
58 798 799 9495837 - HYPH B-NP I-Chemical
59 799 805 9495837 methyl NN I-NP I-Chemical
60 805 806 9495837 - HYPH O I-Chemical
61 806 816 9495837 phosphinic JJ B-NP I-Chemical
62 817 821 9495837 acid NN I-NP I-Chemical
63 821 822 9495837 , , O O
64 823 826 9495837 the DT B-NP O
65 827 829 9495837 H3 NN I-NP O
66 830 837 9495837 agonist NN I-NP O
67 838 839 9495837 R NN I-NP B-Chemical
68 839 840 9495837 - HYPH O I-Chemical
69 840 847 9495837 (alpha) SYM O I-Chemical
70 847 848 9495837 - HYPH O I-Chemical
71 848 863 9495837 methylhistamine NN B-NP I-Chemical
72 863 864 9495837 , , O O
73 865 868 9495837 the DT B-NP O
74 869 871 9495837 D2 NN I-NP O
75 872 882 9495837 antagonist NN I-NP O
76 883 893 9495837 quinpirole NN I-NP B-Chemical
77 893 894 9495837 , , O O
78 895 898 9495837 the DT B-NP O
79 899 900 9495837 5 CD I-NP B-Chemical
80 900 901 9495837 - HYPH I-NP I-Chemical
81 901 919 9495837 hydroxytryptamine4 NN I-NP I-Chemical
82 920 930 9495837 antagonist NN I-NP O
83 931 932 9495837 2 CD I-NP B-Chemical
84 932 933 9495837 - HYPH I-NP I-Chemical
85 933 940 9495837 methoxy NN I-NP I-Chemical
86 940 941 9495837 - HYPH B-NP I-Chemical
87 941 942 9495837 4 CD I-NP I-Chemical
88 942 943 9495837 - HYPH I-NP I-Chemical
89 943 948 9495837 amino JJ I-NP I-Chemical
90 948 949 9495837 - HYPH I-NP I-Chemical
91 949 950 9495837 5 CD I-NP I-Chemical
92 950 951 9495837 - HYPH I-NP I-Chemical
93 951 964 9495837 chlorobenzoic JJ I-NP I-Chemical
94 965 969 9495837 acid NN I-NP I-Chemical
95 970 971 9495837 2 CD I-NP I-Chemical
96 971 972 9495837 - HYPH I-NP I-Chemical
97 972 991 9495837 (diethylamino)ethyl NN I-NP I-Chemical
98 992 997 9495837 ester NN I-NP I-Chemical
99 998 1011 9495837 hydrochloride NN I-NP O
100 1011 1012 9495837 , , O O
101 1013 1016 9495837 the DT B-NP O
102 1017 1018 9495837 5 CD I-NP B-Chemical
103 1018 1019 9495837 - HYPH I-NP I-Chemical
104 1019 1037 9495837 hydroxytryptamin1A NN I-NP I-Chemical
105 1038 1048 9495837 antagonist NN I-NP O
106 1049 1050 9495837 1 CD I-NP B-Chemical
107 1050 1051 9495837 - HYPH I-NP I-Chemical
108 1051 1053 9495837 (2 CD I-NP I-Chemical
109 1053 1054 9495837 - HYPH I-NP I-Chemical
110 1054 1068 9495837 methoxyphenyl) NN I-NP I-Chemical
111 1068 1069 9495837 - HYPH B-NP I-Chemical
112 1069 1070 9495837 4 CD I-NP I-Chemical
113 1070 1071 9495837 - HYPH I-NP I-Chemical
114 1071 1073 9495837 [4 CD I-NP I-Chemical
115 1073 1074 9495837 - HYPH I-NP I-Chemical
116 1074 1076 9495837 (2 CD I-NP I-Chemical
117 1076 1077 9495837 - HYPH I-NP I-Chemical
118 1077 1105 9495837 phthalimido)butyl]piperazine NN I-NP I-Chemical
119 1106 1118 9495837 hydrobromide NN I-NP O
120 1119 1122 9495837 and CC O O
121 1123 1126 9495837 the DT B-NP O
122 1127 1137 9495837 polyamines NNS I-NP O
123 1138 1146 9495837 depletor NN I-NP O
124 1147 1156 9495837 reserpine NN I-NP B-Chemical
125 1156 1157 9495837 . . O O

1 1158 1163 9495837 Based VBN B-PP O
2 1164 1166 9495837 on IN B-PP O
3 1167 1172 9495837 these DT B-NP O
4 1173 1177 9495837 data NNS I-NP O
5 1177 1178 9495837 , , O O
6 1179 1181 9495837 it PRP B-NP O
7 1182 1185 9495837 can MD B-VP O
8 1186 1188 9495837 be VB I-VP O
9 1189 1199 9495837 postulated VBN I-VP O
10 1200 1204 9495837 that IN B-SBAR O
11 1205 1206 9495837 ( ( O O
12 1206 1207 9495837 + SYM B-NP O
13 1207 1208 9495837 / SYM O O
14 1208 1209 9495837 - SYM O O
15 1209 1210 9495837 ) ) O O
16 1210 1211 9495837 - HYPH B-NP O
17 1211 1213 9495837 PG NN I-NP B-Chemical
18 1213 1214 9495837 - HYPH O I-Chemical
19 1214 1215 9495837 9 CD B-NP I-Chemical
20 1216 1223 9495837 exerted VBD B-VP O
21 1224 1226 9495837 an DT B-NP O
22 1227 1242 9495837 antinociceptive JJ I-NP O
23 1243 1249 9495837 effect NN I-NP O
24 1250 1258 9495837 mediated VBN B-VP O
25 1259 1261 9495837 by IN B-PP O
26 1262 1263 9495837 a DT B-NP O
27 1264 1271 9495837 central JJ I-NP O
28 1272 1284 9495837 potentiation NN I-NP O
29 1285 1287 9495837 of IN B-PP O
30 1288 1299 9495837 cholinergic JJ B-NP O
31 1300 1312 9495837 transmission NN I-NP O
32 1312 1313 9495837 . . O O

1 1314 1315 9495837 ( ( O O
2 1315 1316 9495837 + SYM B-NP O
3 1316 1317 9495837 / SYM O O
4 1317 1318 9495837 - SYM O O
5 1318 1319 9495837 ) ) O O
6 1319 1320 9495837 - HYPH B-NP O
7 1320 1322 9495837 PG NN I-NP B-Chemical
8 1322 1323 9495837 - HYPH O I-Chemical
9 1323 1324 9495837 9 CD B-NP I-Chemical
10 1325 1326 9495837 ( NN I-NP O
11 1326 1328 9495837 10 CD B-NP O
12 1328 1329 9495837 - HYPH I-NP O
13 1329 1331 9495837 40 CD I-NP O
14 1332 1334 9495837 mg NN I-NP O
15 1335 1337 9495837 kg NN I-NP O
16 1337 1338 9495837 - HYPH B-NP O
17 1338 1339 9495837 1 CD I-NP O
18 1340 1343 9495837 i.p NN I-NP O
19 1343 1344 9495837 . . O O
20 1344 1345 9495837 ) ) O O
21 1346 1349 9495837 was VBD B-VP O
22 1350 1354 9495837 able JJ B-ADJP O
23 1355 1357 9495837 to TO B-VP O
24 1358 1365 9495837 prevent VB I-VP O
25 1366 1373 9495837 amnesia NN B-NP B-Disease
26 1374 1381 9495837 induced VBN B-VP O
27 1382 1384 9495837 by IN B-PP O
28 1385 1396 9495837 scopolamine NN B-NP B-Chemical
29 1397 1398 9495837 ( ( O O
30 1398 1399 9495837 1 CD B-NP O
31 1400 1402 9495837 mg NN I-NP O
32 1403 1405 9495837 kg NN I-NP O
33 1405 1406 9495837 - HYPH B-NP O
34 1406 1407 9495837 1 CD I-NP O
35 1408 1411 9495837 i.p NN I-NP O
36 1411 1412 9495837 . . O O
37 1412 1413 9495837 ) ) O O
38 1414 1417 9495837 and CC O O
39 1418 1429 9495837 dicyclomine NN B-NP B-Chemical
40 1430 1431 9495837 ( ( O O
41 1431 1432 9495837 2 CD B-NP O
42 1433 1435 9495837 mg NN I-NP O
43 1436 1438 9495837 kg NN I-NP O
44 1438 1439 9495837 - HYPH B-NP O
45 1439 1440 9495837 1 CD I-NP O
46 1441 1444 9495837 i.p NN I-NP O
47 1444 1445 9495837 . . O O
48 1445 1446 9495837 ) ) O O
49 1447 1449 9495837 in IN B-PP O
50 1450 1453 9495837 the DT B-NP O
51 1454 1459 9495837 mouse NN I-NP O
52 1460 1467 9495837 passive JJ I-NP O
53 1467 1468 9495837 - HYPH I-NP O
54 1468 1477 9495837 avoidance NN I-NP O
55 1478 1482 9495837 test NN I-NP O
56 1482 1483 9495837 . . O O

1 1484 1492 9495837 Affinity NN B-NP O
2 1493 1501 9495837 profiles NNS I-NP O
3 1502 1504 9495837 of IN B-PP O
4 1505 1506 9495837 ( ( O O
5 1506 1507 9495837 + SYM B-NP O
6 1507 1508 9495837 / SYM O O
7 1508 1509 9495837 - SYM O O
8 1509 1510 9495837 ) ) O O
9 1510 1511 9495837 - HYPH B-NP O
10 1511 1513 9495837 PG NN I-NP B-Chemical
11 1513 1514 9495837 - HYPH B-NP I-Chemical
12 1514 1515 9495837 9 CD I-NP I-Chemical
13 1516 1519 9495837 for IN B-PP O
14 1520 1530 9495837 muscarinic JJ B-NP O
15 1531 1539 9495837 receptor NN I-NP O
16 1540 1548 9495837 subtypes NNS I-NP O
17 1548 1549 9495837 , , O O
18 1550 1560 9495837 determined VBN B-VP O
19 1561 1563 9495837 by IN B-PP O
20 1564 1574 9495837 functional JJ B-NP O
21 1575 1582 9495837 studies NNS I-NP O
22 1583 1584 9495837 ( ( O O
23 1584 1590 9495837 rabbit NN B-NP O
24 1591 1594 9495837 vas NN I-NP O
25 1595 1603 9495837 deferens NNS I-NP O
26 1604 1607 9495837 for IN B-PP O
27 1608 1610 9495837 M1 NN B-NP O
28 1610 1611 9495837 , , O O
29 1612 1618 9495837 guinea NN B-NP O
30 1619 1622 9495837 pig NN I-NP O
31 1623 1629 9495837 atrium NN I-NP O
32 1630 1633 9495837 for IN B-PP O
33 1634 1636 9495837 M2 NN B-NP O
34 1636 1637 9495837 , , O O
35 1638 1644 9495837 guinea NN B-NP O
36 1645 1648 9495837 pig NN I-NP O
37 1649 1654 9495837 ileum NN I-NP O
38 1655 1658 9495837 for IN B-PP O
39 1659 1661 9495837 M3 NN B-NP O
40 1662 1665 9495837 and CC O O
41 1666 1674 9495837 immature JJ B-NP O
42 1675 1681 9495837 guinea NN I-NP O
43 1682 1685 9495837 pig NN I-NP O
44 1686 1692 9495837 uterus NN I-NP O
45 1693 1696 9495837 for IN B-PP O
46 1697 1705 9495837 putative JJ B-NP O
47 1706 1708 9495837 M4 NN I-NP O
48 1708 1709 9495837 ) ) O O
49 1709 1710 9495837 , , O O
50 1711 1715 9495837 have VBP B-VP O
51 1716 1721 9495837 shown VBN I-VP O
52 1722 1724 9495837 an DT B-NP O
53 1725 1727 9495837 M4 NN I-NP O
54 1727 1728 9495837 / SYM B-VP O
55 1728 1730 9495837 M1 NN B-NP O
56 1731 1742 9495837 selectivity NN I-NP O
57 1743 1748 9495837 ratio NN I-NP O
58 1749 1751 9495837 of IN B-PP O
59 1752 1756 9495837 10.2 CD B-NP O
60 1757 1761 9495837 that WDT B-NP O
61 1762 1767 9495837 might MD B-VP O
62 1768 1770 9495837 be VB I-VP O
63 1771 1782 9495837 responsible JJ B-ADJP O
64 1783 1786 9495837 for IN B-PP O
65 1787 1790 9495837 the DT B-NP O
66 1791 1806 9495837 antinociception NN I-NP O
67 1807 1810 9495837 and CC O O
68 1811 1814 9495837 the DT B-NP O
69 1815 1819 9495837 anti AFX I-NP O
70 1819 1820 9495837 - HYPH I-NP O
71 1820 1827 9495837 amnesic JJ I-NP B-Disease
72 1828 1834 9495837 effect NN I-NP O
73 1835 1842 9495837 induced VBN B-VP O
74 1843 1845 9495837 by IN B-PP O
75 1846 1847 9495837 ( ( O O
76 1847 1848 9495837 + SYM B-NP O
77 1848 1849 9495837 / SYM O O
78 1849 1850 9495837 - SYM O O
79 1850 1851 9495837 ) ) O O
80 1851 1852 9495837 - HYPH B-NP O
81 1852 1854 9495837 PG NN I-NP B-Chemical
82 1854 1855 9495837 - HYPH O I-Chemical
83 1855 1856 9495837 9 CD B-NP I-Chemical
84 1857 1864 9495837 through IN B-PP O
85 1865 1867 9495837 an DT B-NP O
86 1868 1876 9495837 increase NN I-NP O
87 1877 1879 9495837 in IN B-PP O
88 1880 1893 9495837 acetylcholine NN B-NP B-Chemical
89 1894 1907 9495837 extracellular JJ I-NP O
90 1908 1914 9495837 levels NNS I-NP O
91 1914 1915 9495837 . . O O

1 1916 1918 9495837 In IN B-PP O
2 1919 1922 9495837 the DT B-NP O
3 1923 1938 9495837 antinociceptive JJ I-NP O
4 1939 1942 9495837 and CC I-NP O
5 1943 1954 9495837 antiamnesic JJ I-NP O
6 1955 1959 9495837 dose NN I-NP O
7 1960 1965 9495837 range NN I-NP O
8 1965 1966 9495837 , , O O
9 1967 1968 9495837 ( ( O O
10 1968 1969 9495837 + SYM B-NP O
11 1969 1970 9495837 / SYM O O
12 1970 1971 9495837 - SYM O O
13 1971 1972 9495837 ) ) O O
14 1972 1973 9495837 - HYPH B-NP O
15 1973 1975 9495837 PG NN I-NP B-Chemical
16 1975 1976 9495837 - HYPH O I-Chemical
17 1976 1977 9495837 9 CD B-NP I-Chemical
18 1978 1981 9495837 did VBD B-VP O
19 1982 1985 9495837 not RB I-VP O
20 1986 1992 9495837 impair VB I-VP O
21 1993 1998 9495837 mouse NN B-NP O
22 1999 2010 9495837 performance NN I-NP O
23 2011 2020 9495837 evaluated VBN B-VP O
24 2021 2023 9495837 by IN B-PP O
25 2024 2027 9495837 the DT B-NP O
26 2028 2032 9495837 rota NN I-NP O
27 2032 2033 9495837 - HYPH B-NP O
28 2033 2036 9495837 rod NN I-NP O
29 2037 2041 9495837 test NN I-NP O
30 2042 2045 9495837 and CC O O
31 2046 2052 9495837 Animex NNP B-NP O
32 2053 2062 9495837 apparatus NN I-NP O
33 2062 2063 9495837 . . O O

1 0 0 435349 -DOCSTART- -X- -X- O

1 0 13 435349 Suxamethonium NN B-NP B-Chemical
2 14 22 435349 infusion NN I-NP O
3 23 27 435349 rate NN I-NP O
4 28 31 435349 and CC O O
5 32 40 435349 observed VBN B-NP O
6 41 55 435349 fasciculations NNS I-NP B-Disease
7 55 56 435349 . . O O

1 57 58 435349 A DT B-NP O
2 59 63 435349 dose NN I-NP O
3 63 64 435349 - HYPH O O
4 64 72 435349 response NN B-NP O
5 73 78 435349 study NN I-NP O
6 78 79 435349 . . O O
7 80 93 435349 Suxamethonium NN B-NP B-Chemical
8 94 102 435349 chloride NN I-NP I-Chemical
9 103 104 435349 ( ( O O
10 104 107 435349 Sch NN B-NP B-Chemical
11 107 108 435349 ) ) O O
12 109 112 435349 was VBD B-VP O
13 113 125 435349 administered VBN I-VP O
14 126 129 435349 i.v JJ B-ADJP O
15 129 130 435349 . . O O

1 131 133 435349 to TO B-PP O
2 134 136 435349 36 CD B-NP O
3 137 142 435349 adult JJ I-NP O
4 143 148 435349 males NNS I-NP O
5 149 151 435349 at IN B-PP O
6 152 155 435349 six CD B-NP O
7 156 161 435349 rates NNS I-NP O
8 161 162 435349 : : O O
9 163 167 435349 0.25 CD B-NP O
10 168 170 435349 mg NN I-NP O
11 171 172 435349 s SYM B-NP O
12 172 173 435349 - SYM B-ADJP O
13 173 174 435349 1 CD B-NP O
14 175 177 435349 to TO I-NP O
15 178 180 435349 20 CD I-NP O
16 181 183 435349 mg NN I-NP O
17 184 185 435349 s AFX O O
18 185 186 435349 - HYPH B-NP O
19 186 187 435349 1 CD I-NP O
20 187 188 435349 . . O O

1 189 192 435349 The DT B-NP O
2 193 201 435349 infusion NN I-NP O
3 202 205 435349 was VBD B-VP O
4 206 218 435349 discontinued VBN I-VP O
5 219 225 435349 either CC O O
6 226 230 435349 when WRB B-ADVP O
7 231 236 435349 there EX B-NP O
8 237 240 435349 was VBD B-VP O
9 241 243 435349 no DT B-NP O
10 244 252 435349 muscular JJ I-NP O
11 253 261 435349 response NN I-NP O
12 262 264 435349 to TO B-PP O
13 265 272 435349 tetanic JJ B-NP B-Disease
14 273 284 435349 stimulation NN I-NP O
15 285 287 435349 of IN B-PP O
16 288 291 435349 the DT B-NP O
17 292 297 435349 ulnar JJ I-NP O
18 298 303 435349 nerve NN I-NP O
19 304 306 435349 or CC O O
20 307 311 435349 when WRB B-ADVP O
21 312 315 435349 Sch NNP B-NP B-Chemical
22 316 319 435349 120 CD I-NP O
23 320 322 435349 mg NN I-NP O
24 323 326 435349 was VBD B-VP O
25 327 335 435349 exceeded VBN I-VP O
26 335 336 435349 . . O O

1 337 340 435349 Six CD B-NP O
2 341 351 435349 additional JJ I-NP O
3 352 360 435349 patients NNS I-NP O
4 361 369 435349 received VBD B-VP O
5 370 371 435349 a DT B-NP O
6 372 374 435349 30 CD I-NP O
7 374 375 435349 - HYPH I-NP O
8 375 377 435349 mg NN I-NP O
9 378 381 435349 i.v NN I-NP O
10 381 382 435349 . . O O

1 383 388 435349 bolus NN B-NP O
2 389 393 435349 dose NN I-NP O
3 393 394 435349 . . O O

1 395 409 435349 Fasciculations NNS B-NP B-Disease
2 410 412 435349 in IN B-PP O
3 413 416 435349 six CD B-NP O
4 417 422 435349 areas NNS I-NP O
5 423 425 435349 of IN B-PP O
6 426 429 435349 the DT B-NP O
7 430 434 435349 body NN I-NP O
8 435 439 435349 were VBD B-VP O
9 440 446 435349 scored VBN I-VP O
10 447 451 435349 from IN B-PP O
11 452 453 435349 0 CD B-NP O
12 454 456 435349 to TO B-PP O
13 457 458 435349 3 CD B-NP O
14 459 462 435349 and CC O O
15 463 471 435349 summated VBN B-VP O
16 472 474 435349 as IN B-PP O
17 475 476 435349 a DT B-NP O
18 477 482 435349 total JJ I-NP O
19 483 496 435349 fasciculation NN I-NP B-Disease
20 497 502 435349 score NN I-NP O
21 502 503 435349 . . O O

1 504 507 435349 The DT B-NP O
2 508 513 435349 times NNS I-NP O
3 514 516 435349 to TO B-PP O
4 517 522 435349 first JJ B-NP O
5 523 536 435349 fasciculation NN I-NP B-Disease
6 536 537 435349 , , O O
7 538 544 435349 twitch NN B-NP B-Disease
8 545 556 435349 suppression NN I-NP O
9 557 560 435349 and CC O O
10 561 568 435349 tetanus NN B-NP B-Disease
11 569 580 435349 suppression NN I-NP O
12 581 585 435349 were VBD B-VP O
13 586 595 435349 inversely RB I-VP O
14 596 603 435349 related VBN I-VP O
15 604 606 435349 to TO B-PP O
16 607 610 435349 the DT B-NP O
17 611 619 435349 infusion NN I-NP O
18 620 625 435349 rates NNS I-NP O
19 625 626 435349 . . O O

1 627 641 435349 Fasciculations NNS B-NP B-Disease
2 642 644 435349 in IN B-PP O
3 645 648 435349 the DT B-NP O
4 649 652 435349 six CD I-NP O
5 653 658 435349 areas NNS I-NP O
6 659 662 435349 and CC O O
7 663 666 435349 the DT B-NP O
8 667 672 435349 total JJ I-NP O
9 673 686 435349 fasciculation NN I-NP B-Disease
10 687 692 435349 score NN I-NP O
11 693 697 435349 were VBD B-VP O
12 698 705 435349 related VBN I-VP O
13 706 714 435349 directly RB B-ADVP O
14 715 717 435349 to TO B-PP O
15 718 721 435349 the DT B-NP O
16 722 726 435349 rate NN I-NP O
17 727 729 435349 of IN B-PP O
18 730 738 435349 infusion NN B-NP O
19 738 739 435349 . . O O

1 740 745 435349 Total JJ B-NP O
2 746 759 435349 fasciculation NN I-NP B-Disease
3 760 766 435349 scores NNS I-NP O
4 767 769 435349 in IN B-PP O
5 770 773 435349 the DT B-NP O
6 774 776 435349 30 CD I-NP O
7 776 777 435349 - HYPH I-NP O
8 777 779 435349 mg NN I-NP O
9 780 785 435349 bolus NN I-NP O
10 786 791 435349 group NN I-NP O
11 792 795 435349 and CC O O
12 796 799 435349 the DT B-NP O
13 800 801 435349 5 CD I-NP O
14 801 802 435349 - HYPH I-NP O
15 802 804 435349 mg NN I-NP O
16 805 806 435349 s AFX O O
17 806 807 435349 - HYPH B-NP O
18 807 808 435349 1 CD I-NP O
19 809 812 435349 and CC I-NP O
20 813 815 435349 20 CD I-NP O
21 815 816 435349 - HYPH I-NP O
22 816 818 435349 mg NN I-NP O
23 819 820 435349 s AFX O O
24 820 821 435349 - HYPH B-NP O
25 821 822 435349 1 CD I-NP O
26 823 831 435349 infusion NN I-NP O
27 832 838 435349 groups NNS I-NP O
28 839 843 435349 were VBD B-VP O
29 844 847 435349 not RB B-ADJP O
30 848 861 435349 significantly RB I-ADJP O
31 862 871 435349 different JJ I-ADJP O
32 871 872 435349 . . O O

1 0 0 19299179 -DOCSTART- -X- -X- O

1 0 6 19299179 Severe JJ B-NP O
2 7 10 19299179 and CC I-NP O
3 11 15 19299179 long JJ I-NP O
4 16 23 19299179 lasting JJ I-NP O
5 24 35 19299179 cholestasis NN I-NP B-Disease
6 36 41 19299179 after IN B-PP O
7 42 46 19299179 high JJ B-NP O
8 46 47 19299179 - HYPH I-NP O
9 47 51 19299179 dose NN I-NP O
10 52 54 19299179 co AFX O B-Chemical
11 54 55 19299179 - HYPH B-NP I-Chemical
12 55 66 19299179 trimoxazole NN I-NP I-Chemical
13 67 76 19299179 treatment NN I-NP O
14 77 80 19299179 for IN B-PP O
15 81 93 19299179 Pneumocystis NN B-NP B-Disease
16 94 103 19299179 pneumonia NN I-NP I-Disease
17 104 106 19299179 in IN B-PP O
18 107 110 19299179 HIV NN B-NP B-Disease
19 110 111 19299179 - HYPH O I-Disease
20 111 119 19299179 infected VBN B-NP I-Disease
21 120 128 19299179 patients NNS I-NP O
22 128 129 19299179 - SYM O O
23 129 130 19299179 - HYPH O O
24 130 131 19299179 a DT B-NP O
25 132 138 19299179 report NN I-NP O
26 139 141 19299179 of IN B-PP O
27 142 145 19299179 two CD B-NP O
28 146 151 19299179 cases NNS I-NP O
29 151 152 19299179 . . O O
30 153 165 19299179 Pneumocystis NN B-NP B-Disease
31 166 175 19299179 pneumonia NN I-NP I-Disease
32 176 177 19299179 ( ( O O
33 177 180 19299179 PCP NN B-NP B-Disease
34 180 181 19299179 ) ) O O
35 181 182 19299179 , , O O
36 183 184 19299179 a DT B-NP O
37 185 191 19299179 common JJ I-NP O
38 192 205 19299179 opportunistic JJ I-NP B-Disease
39 206 215 19299179 infection NN I-NP I-Disease
40 216 218 19299179 in IN B-PP O
41 219 222 19299179 HIV NN B-NP B-Disease
42 222 223 19299179 - HYPH B-NP I-Disease
43 223 231 19299179 infected VBN I-NP I-Disease
44 232 243 19299179 individuals NNS I-NP O
45 243 244 19299179 , , O O
46 245 247 19299179 is VBZ B-VP O
47 248 257 19299179 generally RB I-VP O
48 258 265 19299179 treated VBN I-VP O
49 266 270 19299179 with IN B-PP O
50 271 275 19299179 high JJ B-NP O
51 276 281 19299179 doses NNS I-NP O
52 282 284 19299179 of IN B-PP O
53 285 287 19299179 co AFX B-NP B-Chemical
54 287 288 19299179 - HYPH I-NP I-Chemical
55 288 299 19299179 trimoxazole NN I-NP I-Chemical
56 299 300 19299179 . . O O

1 301 308 19299179 However RB B-ADVP O
2 308 309 19299179 , , O O
3 310 319 19299179 treatment NN B-NP O
4 320 322 19299179 is VBZ B-VP O
5 323 328 19299179 often RB I-VP O
6 329 336 19299179 limited VBN I-VP O
7 337 339 19299179 by IN B-PP O
8 340 347 19299179 adverse JJ B-NP O
9 348 355 19299179 effects NNS I-NP O
10 355 356 19299179 . . O O

1 357 361 19299179 Here RB B-ADVP O
2 361 362 19299179 , , O O
3 363 365 19299179 we PRP B-NP O
4 366 372 19299179 report VBP B-VP O
5 373 376 19299179 two CD B-NP O
6 377 382 19299179 cases NNS I-NP O
7 383 385 19299179 of IN B-PP O
8 386 394 19299179 severely RB B-NP O
9 395 412 19299179 immunocompromised VBN I-NP O
10 413 416 19299179 HIV NN I-NP B-Disease
11 416 417 19299179 - HYPH B-NP I-Disease
12 417 425 19299179 infected VBN I-NP I-Disease
13 426 434 19299179 patients NNS I-NP O
14 435 438 19299179 who WP B-NP O
15 439 448 19299179 developed VBD B-VP O
16 449 455 19299179 severe JJ B-NP O
17 456 468 19299179 intrahepatic JJ I-NP B-Disease
18 469 480 19299179 cholestasis NN I-NP I-Disease
19 480 481 19299179 , , O O
20 482 485 19299179 and CC O O
21 486 488 19299179 in IN B-PP O
22 489 492 19299179 one CD B-NP O
23 493 500 19299179 patient NN I-NP O
24 501 508 19299179 lesions NNS I-NP O
25 509 518 19299179 mimicking VBG B-VP O
26 519 524 19299179 liver NN B-NP B-Disease
27 525 532 19299179 abscess NN I-NP I-Disease
28 533 542 19299179 formation NN I-NP O
29 543 545 19299179 on IN B-PP O
30 546 556 19299179 radiologic JJ B-NP O
31 557 562 19299179 exams NNS I-NP O
32 562 563 19299179 , , O O
33 564 570 19299179 during IN B-PP O
34 571 573 19299179 co AFX B-NP B-Chemical
35 573 574 19299179 - HYPH I-NP I-Chemical
36 574 585 19299179 trimoxazole NN I-NP I-Chemical
37 586 595 19299179 treatment NN I-NP O
38 596 599 19299179 for IN B-PP O
39 600 603 19299179 PCP NN B-NP B-Disease
40 603 604 19299179 . . O O

1 605 612 19299179 Whereas IN B-SBAR O
2 613 620 19299179 patient NN B-NP O
3 621 622 19299179 1 CD I-NP O
4 623 629 19299179 showed VBD B-VP O
5 630 637 19299179 lesions NNS B-NP O
6 638 640 19299179 of IN B-PP O
7 641 643 19299179 up IN B-NP O
8 644 646 19299179 to TO I-NP O
9 647 648 19299179 1 CD I-NP O
10 649 651 19299179 cm NN I-NP O
11 652 659 19299179 readily RB B-ADJP O
12 660 670 19299179 detectable JJ I-ADJP O
13 671 673 19299179 on IN B-PP O
14 674 682 19299179 magnetic JJ B-NP O
15 683 692 19299179 resonance NN I-NP O
16 693 700 19299179 imaging NN I-NP O
17 701 706 19299179 under IN B-PP O
18 707 716 19299179 prolonged JJ B-NP O
19 717 719 19299179 co AFX I-NP B-Chemical
20 719 720 19299179 - HYPH I-NP I-Chemical
21 720 731 19299179 trimoxazole NN I-NP I-Chemical
22 732 741 19299179 treatment NN I-NP O
23 741 742 19299179 , , O O
24 743 750 19299179 therapy NN B-NP O
25 751 753 19299179 of IN B-PP O
26 754 761 19299179 patient NN B-NP O
27 762 763 19299179 2 CD I-NP O
28 764 767 19299179 was VBD B-VP O
29 768 776 19299179 switched VBN I-VP O
30 777 782 19299179 early RB B-ADVP O
31 782 783 19299179 . . O O

1 0 0 8590259 -DOCSTART- -X- -X- O

1 0 10 8590259 Evaluation NN B-NP O
2 11 13 8590259 of IN B-PP O
3 14 21 8590259 adverse JJ B-NP O
4 22 31 8590259 reactions NNS I-NP O
5 32 34 8590259 of IN B-PP O
6 35 44 8590259 aponidine NN B-NP B-Chemical
7 45 58 8590259 hydrochloride NN I-NP I-Chemical
8 59 69 8590259 ophthalmic JJ I-NP O
9 70 78 8590259 solution NN I-NP O
10 78 79 8590259 . . O O
11 80 82 8590259 We PRP B-NP O
12 83 96 8590259 prospectively RB B-ADVP O
13 97 106 8590259 evaluated VBD B-VP O
14 107 110 8590259 the DT B-NP O
15 111 118 8590259 adverse JJ I-NP O
16 119 128 8590259 reactions NNS I-NP O
17 129 131 8590259 of IN B-PP O
18 132 145 8590259 apraclonidine NN B-NP B-Chemical
19 146 148 8590259 in IN B-PP O
20 149 151 8590259 20 CD B-NP O
21 152 158 8590259 normal JJ I-NP O
22 159 169 8590259 volunteers NNS I-NP O
23 170 172 8590259 by IN B-PP O
24 173 183 8590259 instilling VBG B-VP O
25 184 185 8590259 a DT B-NP O
26 186 192 8590259 single JJ I-NP O
27 193 197 8590259 drop NN I-NP O
28 198 200 8590259 of IN B-PP O
29 201 203 8590259 1% NN B-NP O
30 204 217 8590259 apraclonidine NN I-NP B-Chemical
31 218 220 8590259 in IN B-PP O
32 221 226 8590259 their PRP$ B-NP O
33 227 232 8590259 right JJ I-NP O
34 233 237 8590259 eyes NNS I-NP O
35 237 238 8590259 . . O O

1 239 251 8590259 Examinations NNS B-NP O
2 251 252 8590259 , , O O
3 253 262 8590259 including VBG B-PP O
4 263 268 8590259 blood NN B-NP O
5 269 277 8590259 pressure NN I-NP O
6 277 278 8590259 , , O O
7 279 284 8590259 pulse NN B-NP O
8 285 289 8590259 rate NN I-NP O
9 289 290 8590259 , , O O
10 291 302 8590259 conjunctiva NN B-NP O
11 303 306 8590259 and CC I-NP O
12 307 313 8590259 cornea NN I-NP O
13 313 314 8590259 , , O O
14 315 326 8590259 intraocular JJ B-NP O
15 327 335 8590259 pressure NN I-NP O
16 336 337 8590259 ( ( O O
17 337 340 8590259 IOP NN B-NP O
18 340 341 8590259 ) ) O O
19 341 342 8590259 , , O O
20 343 348 8590259 pupil NN B-NP O
21 349 357 8590259 diameter NN I-NP O
22 357 358 8590259 , , O O
23 359 364 8590259 basal JJ B-NP O
24 365 369 8590259 tear NN I-NP O
25 370 379 8590259 secretion NN I-NP O
26 380 383 8590259 and CC O O
27 384 390 8590259 margin NN B-NP O
28 391 397 8590259 reflex NN I-NP O
29 398 406 8590259 distance NN I-NP O
30 407 409 8590259 of IN B-PP O
31 410 414 8590259 both CC B-NP O
32 415 420 8590259 upper JJ I-NP O
33 421 424 8590259 and CC I-NP O
34 425 430 8590259 lower JJR I-NP O
35 431 438 8590259 eyelids NNS I-NP O
36 438 439 8590259 , , O O
37 440 444 8590259 were VBD B-VP O
38 445 454 8590259 performed VBN I-VP O
39 455 460 8590259 prior RB B-ADVP O
40 461 463 8590259 to TO B-PP O
41 464 469 8590259 entry NN B-NP O
42 470 473 8590259 and CC O O
43 474 476 8590259 at IN B-PP O
44 477 478 8590259 1 CD B-NP O
45 478 479 8590259 , , I-NP O
46 480 481 8590259 3 CD I-NP O
47 481 482 8590259 , , I-NP O
48 483 484 8590259 5 CD I-NP O
49 485 488 8590259 and CC I-NP O
50 489 490 8590259 7 CD I-NP O
51 491 496 8590259 hours NNS I-NP O
52 497 502 8590259 after IN B-PP O
53 503 515 8590259 instillation NN B-NP O
54 515 516 8590259 . . O O

1 517 520 8590259 The DT B-NP O
2 521 527 8590259 ocular JJ I-NP B-Disease
3 528 539 8590259 hypotensive JJ I-NP I-Disease
4 540 547 8590259 effects NNS I-NP O
5 548 552 8590259 were VBD B-VP O
6 553 566 8590259 statistically RB B-ADJP O
7 567 578 8590259 significant JJ I-ADJP O
8 579 582 8590259 for IN B-PP O
9 583 596 8590259 apraclonidine NN B-NP B-Chemical
10 596 597 8590259 - HYPH B-NP O
11 597 604 8590259 treated VBN I-NP O
12 605 609 8590259 eyes NNS I-NP O
13 610 620 8590259 throughout IN B-PP O
14 621 624 8590259 the DT B-NP O
15 625 630 8590259 study NN I-NP O
16 631 634 8590259 and CC O O
17 635 639 8590259 also RB B-ADVP O
18 640 653 8590259 statistically RB B-ADJP O
19 654 665 8590259 significant JJ I-ADJP O
20 666 669 8590259 for IN B-PP O
21 670 683 8590259 contralateral JJ B-NP O
22 684 688 8590259 eyes NNS I-NP O
23 689 693 8590259 from IN B-PP O
24 694 699 8590259 three CD B-NP O
25 700 705 8590259 hours NNS I-NP O
26 706 711 8590259 after IN B-PP O
27 712 719 8590259 topical JJ B-NP O
28 720 734 8590259 administration NN I-NP O
29 735 737 8590259 of IN B-PP O
30 738 740 8590259 1% NN B-NP O
31 741 754 8590259 apraclonidine NN I-NP B-Chemical
32 754 755 8590259 . . O O

1 756 765 8590259 Decreases NNS B-NP B-Disease
2 766 768 8590259 in IN B-PP I-Disease
3 769 777 8590259 systolic JJ B-NP I-Disease
4 778 783 8590259 blood NN I-NP I-Disease
5 784 792 8590259 pressure NN I-NP I-Disease
6 793 797 8590259 were VBD B-VP O
7 798 811 8590259 statistically RB B-ADVP O
8 811 812 8590259 , , O O
9 813 816 8590259 but CC O O
10 817 820 8590259 not RB O O
11 821 831 8590259 clinically RB B-ADVP O
12 831 832 8590259 , , O O
13 833 844 8590259 significant JJ B-ADJP O
14 844 845 8590259 . . O O

1 846 848 8590259 No DT B-NP O
2 849 860 8590259 significant JJ I-NP O
3 861 868 8590259 changes NNS I-NP O
4 869 871 8590259 in IN B-PP O
5 872 881 8590259 diastolic JJ B-NP O
6 882 887 8590259 blood NN I-NP O
7 888 896 8590259 pressure NN I-NP O
8 896 897 8590259 , , O O
9 898 903 8590259 pulse NN B-NP O
10 904 908 8590259 rate NN I-NP O
11 909 912 8590259 and CC O O
12 913 918 8590259 basal JJ B-NP O
13 919 923 8590259 tear NN I-NP O
14 924 933 8590259 secretion NN I-NP O
15 934 938 8590259 were VBD B-VP O
16 939 944 8590259 noted VBN I-VP O
17 944 945 8590259 . . O O

1 946 958 8590259 Conjunctival JJ B-NP B-Disease
2 959 968 8590259 blanching NN I-NP I-Disease
3 969 972 8590259 and CC I-NP O
4 973 982 8590259 mydriasis NN I-NP B-Disease
5 983 987 8590259 were VBD B-VP O
6 988 996 8590259 commonly RB I-VP O
7 997 1002 8590259 found VBN I-VP O
8 1002 1003 8590259 . . O O

1 1004 1009 8590259 Upper IN B-PP O
2 1010 1013 8590259 lid JJ B-NP O
3 1014 1024 8590259 retraction NN I-NP O
4 1025 1028 8590259 was VBD B-VP O
5 1029 1039 8590259 frequently RB I-VP O
6 1040 1045 8590259 noted VBN I-VP O
7 1045 1046 8590259 . . O O

1 1047 1052 8590259 While IN B-SBAR O
2 1053 1056 8590259 the DT B-NP O
3 1057 1067 8590259 elevations NNS I-NP O
4 1068 1070 8590259 of IN B-PP O
5 1071 1074 8590259 the DT B-NP O
6 1075 1080 8590259 upper JJ I-NP O
7 1081 1084 8590259 lid JJ I-NP O
8 1085 1091 8590259 margin NN I-NP O
9 1092 1094 8590259 in IN B-PP O
10 1095 1099 8590259 most JJS B-NP O
11 1100 1108 8590259 subjects NNS I-NP O
12 1109 1113 8590259 were VBD B-VP O
13 1114 1117 8590259 not RB O O
14 1118 1122 8590259 more JJR B-NP O
15 1123 1127 8590259 than IN I-NP O
16 1128 1129 8590259 2 CD I-NP O
17 1130 1132 8590259 mm NN I-NP O
18 1133 1136 8590259 and CC O O
19 1137 1140 8590259 did VBD B-VP O
20 1141 1144 8590259 not RB I-VP O
21 1145 1150 8590259 cause VB I-VP O
22 1151 1161 8590259 noticeable JJ B-NP O
23 1162 1168 8590259 change NN I-NP O
24 1169 1171 8590259 in IN B-PP O
25 1172 1182 8590259 appearance NN B-NP O
26 1182 1183 8590259 , , O O
27 1184 1187 8590259 one CD B-NP O
28 1188 1195 8590259 subject NN I-NP O
29 1196 1204 8590259 suffered VBD B-VP O
30 1205 1209 8590259 from IN B-PP O
31 1210 1220 8590259 mechanical JJ B-NP O
32 1221 1230 8590259 entropion NN I-NP B-Disease
33 1231 1234 8590259 and CC O O
34 1235 1241 8590259 marked JJ B-NP O
35 1242 1249 8590259 corneal JJ I-NP B-Disease
36 1250 1258 8590259 abrasion NN I-NP I-Disease
37 1259 1260 8590259 3 CD B-NP O
38 1261 1266 8590259 hours NNS I-NP O
39 1267 1272 8590259 after IN B-PP O
40 1273 1285 8590259 instillation NN B-NP O
41 1286 1288 8590259 of IN B-PP O
42 1289 1292 8590259 the DT B-NP O
43 1293 1303 8590259 medication NN I-NP O
44 1303 1304 8590259 . . O O

1 1305 1309 8590259 This DT B-NP O
2 1310 1313 8590259 may MD B-VP O
3 1314 1318 8590259 well RB I-VP O
4 1319 1321 8590259 be VB I-VP O
5 1322 1323 8590259 a DT B-NP O
6 1324 1336 8590259 particularly RB I-NP O
7 1337 1344 8590259 notable JJ I-NP O
8 1345 1352 8590259 finding NN I-NP O
9 1353 1355 8590259 in IN B-PP O
10 1356 1361 8590259 Asian JJ B-NP O
11 1362 1368 8590259 people NNS I-NP O
12 1368 1369 8590259 . . O O

1 0 0 12653683 -DOCSTART- -X- -X- O

1 0 10 12653683 Epithelial JJ B-NP O
2 11 17 12653683 sodium NN I-NP B-Chemical
3 18 25 12653683 channel NN I-NP O
4 26 27 12653683 ( ( O O
5 27 31 12653683 ENaC NN B-NP O
6 31 32 12653683 ) ) O O
7 33 40 12653683 subunit NN B-NP O
8 41 45 12653683 mRNA NN I-NP O
9 46 49 12653683 and CC O O
10 50 57 12653683 protein NN B-NP O
11 58 68 12653683 expression NN I-NP O
12 69 71 12653683 in IN B-PP O
13 72 76 12653683 rats NNS B-NP O
14 77 81 12653683 with IN B-PP O
15 82 91 12653683 puromycin NN B-NP B-Chemical
16 92 107 12653683 aminonucleoside NN I-NP I-Chemical
17 107 108 12653683 - HYPH O O
18 108 115 12653683 induced VBN B-NP O
19 116 125 12653683 nephrotic JJ I-NP B-Disease
20 126 134 12653683 syndrome NN I-NP I-Disease
21 134 135 12653683 . . O O
22 136 138 12653683 In IN B-PP O
23 139 151 12653683 experimental JJ B-NP O
24 152 161 12653683 nephrotic JJ I-NP B-Disease
25 162 170 12653683 syndrome NN I-NP I-Disease
26 170 171 12653683 , , O O
27 172 179 12653683 urinary JJ B-NP O
28 180 186 12653683 sodium NN I-NP B-Chemical
29 187 196 12653683 excretion NN I-NP O
30 197 199 12653683 is VBZ B-VP O
31 200 209 12653683 decreased VBN I-VP O
32 210 216 12653683 during IN B-PP O
33 217 220 12653683 the DT B-NP O
34 221 226 12653683 early JJ I-NP O
35 227 232 12653683 phase NN I-NP O
36 233 235 12653683 of IN B-PP O
37 236 239 12653683 the DT B-NP O
38 240 247 12653683 disease NN I-NP O
39 247 248 12653683 . . O O

1 249 252 12653683 The DT B-NP O
2 253 262 12653683 molecular JJ I-NP O
3 263 272 12653683 mechanism NN I-NP O
4 272 273 12653683 ( ( I-NP O
5 273 274 12653683 s NNS I-NP O
6 274 275 12653683 ) ) O O
7 276 283 12653683 leading VBG B-VP O
8 284 286 12653683 to TO B-PP O
9 287 291 12653683 salt NN B-NP O
10 292 301 12653683 retention NN I-NP O
11 302 305 12653683 has VBZ B-VP O
12 306 309 12653683 not RB I-VP O
13 310 314 12653683 been VBN I-VP O
14 315 325 12653683 completely RB B-ADJP O
15 326 336 12653683 elucidated VBN I-ADJP O
16 336 337 12653683 . . O O

1 338 341 12653683 The DT B-NP O
2 342 346 12653683 rate NN I-NP O
3 346 347 12653683 - HYPH O O
4 347 355 12653683 limiting VBG B-VP O
5 356 367 12653683 constituent NN B-NP O
6 368 370 12653683 of IN B-PP O
7 371 381 12653683 collecting VBG B-VP O
8 382 386 12653683 duct NN B-NP O
9 387 393 12653683 sodium NN I-NP B-Chemical
10 394 403 12653683 transport NN I-NP O
11 404 406 12653683 is VBZ B-VP O
12 407 410 12653683 the DT B-NP O
13 411 421 12653683 epithelial JJ I-NP O
14 422 428 12653683 sodium NN I-NP B-Chemical
15 429 436 12653683 channel NN I-NP O
16 437 438 12653683 ( ( O O
17 438 442 12653683 ENaC NN B-NP O
18 442 443 12653683 ) ) O O
19 443 444 12653683 . . O O

1 445 447 12653683 We PRP B-NP O
2 448 456 12653683 examined VBD B-VP O
3 457 460 12653683 the DT B-NP O
4 461 470 12653683 abundance NN I-NP O
5 471 473 12653683 of IN B-PP O
6 474 478 12653683 ENaC NN B-NP O
7 479 486 12653683 subunit NN I-NP O
8 487 492 12653683 mRNAs NNS I-NP O
9 493 496 12653683 and CC I-NP O
10 497 505 12653683 proteins NNS I-NP O
11 506 508 12653683 in IN B-PP O
12 509 518 12653683 puromycin NN B-NP B-Chemical
13 519 534 12653683 aminonucleoside NN I-NP I-Chemical
14 535 536 12653683 ( ( O O
15 536 539 12653683 PAN NN B-NP B-Chemical
16 539 540 12653683 ) ) O O
17 540 541 12653683 - HYPH O O
18 541 548 12653683 induced VBN B-NP O
19 549 558 12653683 nephrotic JJ I-NP B-Disease
20 559 567 12653683 syndrome NN I-NP I-Disease
21 567 568 12653683 . . O O

1 569 572 12653683 The DT B-NP O
2 573 577 12653683 time NN I-NP O
3 578 585 12653683 courses NNS I-NP O
4 586 588 12653683 of IN B-PP O
5 589 596 12653683 urinary JJ B-NP O
6 597 603 12653683 sodium NN I-NP B-Chemical
7 604 613 12653683 excretion NN I-NP O
8 613 614 12653683 , , O O
9 615 621 12653683 plasma NN B-NP O
10 622 633 12653683 aldosterone NN I-NP B-Chemical
11 634 647 12653683 concentration NN I-NP O
12 648 651 12653683 and CC I-NP O
13 652 663 12653683 proteinuria NN I-NP B-Disease
14 664 668 12653683 were VBD B-VP O
15 669 676 12653683 studied VBN I-VP O
16 677 679 12653683 in IN B-PP O
17 680 684 12653683 male JJ B-NP O
18 685 692 12653683 Sprague NNP I-NP O
19 692 693 12653683 - HYPH I-NP O
20 693 699 12653683 Dawley NNP I-NP O
21 700 704 12653683 rats NNS I-NP O
22 705 712 12653683 treated VBN B-VP O
23 713 717 12653683 with IN B-PP O
24 718 719 12653683 a DT B-NP O
25 720 726 12653683 single JJ I-NP O
26 727 731 12653683 dose NN I-NP O
27 732 734 12653683 of IN B-PP O
28 735 741 12653683 either CC O O
29 742 745 12653683 PAN NN B-NP B-Chemical
30 746 748 12653683 or CC I-NP O
31 749 756 12653683 vehicle NN I-NP O
32 756 757 12653683 . . O O

1 758 761 12653683 The DT B-NP O
2 762 770 12653683 relative JJ I-NP O
3 771 778 12653683 amounts NNS I-NP O
4 779 781 12653683 of IN B-PP O
5 782 791 12653683 alphaENaC NN B-NP O
6 791 792 12653683 , , I-NP O
7 793 801 12653683 betaENaC NN I-NP O
8 802 805 12653683 and CC I-NP O
9 806 815 12653683 gammaENaC NN I-NP O
10 816 821 12653683 mRNAs NNS I-NP O
11 822 826 12653683 were VBD B-VP O
12 827 837 12653683 determined VBN I-VP O
13 838 840 12653683 in IN B-PP O
14 841 848 12653683 kidneys NNS B-NP O
15 849 853 12653683 from IN B-PP O
16 854 859 12653683 these DT B-NP O
17 860 864 12653683 rats NNS I-NP O
18 865 867 12653683 by IN B-PP O
19 868 872 12653683 real JJ B-NP O
20 872 873 12653683 - HYPH I-NP O
21 873 877 12653683 time NN I-NP O
22 878 890 12653683 quantitative JJ B-NP O
23 891 897 12653683 TaqMan NNP I-NP O
24 898 901 12653683 PCR NN I-NP O
25 901 902 12653683 , , O O
26 903 906 12653683 and CC O O
27 907 910 12653683 the DT B-NP O
28 911 918 12653683 amounts NNS I-NP O
29 919 921 12653683 of IN B-PP O
30 922 930 12653683 proteins NNS B-NP O
31 931 933 12653683 by IN B-PP O
32 934 941 12653683 Western JJ B-NP O
33 942 946 12653683 blot NN I-NP O
34 946 947 12653683 . . O O

1 948 951 12653683 The DT B-NP O
2 952 960 12653683 kinetics NNS I-NP O
3 961 963 12653683 of IN B-PP O
4 964 971 12653683 urinary JJ B-NP O
5 972 978 12653683 sodium NN I-NP B-Chemical
6 979 988 12653683 excretion NN I-NP O
7 989 992 12653683 and CC O O
8 993 996 12653683 the DT B-NP O
9 997 1007 12653683 appearance NN I-NP O
10 1008 1010 12653683 of IN B-PP O
11 1011 1022 12653683 proteinuria NN B-NP B-Disease
12 1023 1027 12653683 were VBD B-VP O
13 1028 1038 12653683 comparable JJ B-ADJP O
14 1039 1043 12653683 with IN B-PP O
15 1044 1049 12653683 those DT B-NP O
16 1050 1058 12653683 reported VBN B-VP O
17 1059 1069 12653683 previously RB B-ADVP O
18 1069 1070 12653683 . . O O

1 1071 1077 12653683 Sodium NN B-NP B-Chemical
2 1078 1087 12653683 retention NN I-NP O
3 1088 1096 12653683 occurred VBD B-VP O
4 1097 1099 12653683 on IN B-PP O
5 1100 1104 12653683 days NNS B-NP O
6 1105 1106 12653683 2 CD I-NP O
7 1106 1107 12653683 , , I-NP O
8 1108 1109 12653683 3 CD I-NP O
9 1110 1113 12653683 and CC I-NP O
10 1114 1115 12653683 6 CD I-NP O
11 1116 1121 12653683 after IN B-SBAR O
12 1122 1125 12653683 PAN NN B-NP B-Chemical
13 1126 1135 12653683 injection NN I-NP O
14 1135 1136 12653683 . . O O

1 1137 1138 12653683 A DT B-NP O
2 1139 1150 12653683 significant JJ I-NP O
3 1151 1153 12653683 up RB I-NP O
4 1153 1154 12653683 - HYPH I-NP O
5 1154 1164 12653683 regulation NN B-NP O
6 1165 1167 12653683 of IN B-PP O
7 1168 1177 12653683 alphaENaC NN B-NP O
8 1178 1181 12653683 and CC I-NP O
9 1182 1190 12653683 betaENaC NN I-NP O
10 1191 1195 12653683 mRNA NN I-NP O
11 1196 1205 12653683 abundance NN I-NP O
12 1206 1208 12653683 on IN B-PP O
13 1209 1213 12653683 days NNS B-NP O
14 1214 1215 12653683 1 CD I-NP O
15 1216 1219 12653683 and CC I-NP O
16 1220 1221 12653683 2 CD I-NP O
17 1222 1230 12653683 preceded JJ I-NP O
18 1231 1237 12653683 sodium NN I-NP B-Chemical
19 1238 1247 12653683 retention NN I-NP O
20 1248 1250 12653683 on IN B-PP O
21 1251 1255 12653683 days NNS B-NP O
22 1256 1257 12653683 2 CD I-NP O
23 1258 1261 12653683 and CC I-NP O
24 1262 1263 12653683 3 CD I-NP O
25 1263 1264 12653683 . . O O

1 1265 1275 12653683 Conversely RB B-ADVP O
2 1275 1276 12653683 , , O O
3 1277 1281 12653683 down RB B-ADVP O
4 1281 1282 12653683 - HYPH B-NP O
5 1282 1292 12653683 regulation NN I-NP O
6 1293 1295 12653683 of IN B-PP O
7 1296 1305 12653683 alphaENaC NN B-NP O
8 1305 1306 12653683 , , O O
9 1307 1315 12653683 betaENaC NN B-NP O
10 1316 1319 12653683 and CC O O
11 1320 1329 12653683 gammaENaC NN B-NP O
12 1330 1334 12653683 mRNA NN I-NP O
13 1335 1345 12653683 expression NN I-NP O
14 1346 1348 12653683 on IN B-PP O
15 1349 1352 12653683 day NN B-NP O
16 1353 1354 12653683 3 CD I-NP O
17 1355 1363 12653683 occurred VBD B-VP O
18 1364 1366 12653683 in IN B-PP O
19 1367 1370 12653683 the DT B-NP O
20 1371 1379 12653683 presence NN I-NP O
21 1380 1382 12653683 of IN B-PP O
22 1383 1387 12653683 high JJ B-NP O
23 1388 1399 12653683 aldosterone NN I-NP B-Chemical
24 1400 1414 12653683 concentrations NNS I-NP O
25 1414 1415 12653683 , , O O
26 1416 1419 12653683 and CC O O
27 1420 1423 12653683 was VBD B-VP O
28 1424 1432 12653683 followed VBN I-VP O
29 1433 1435 12653683 by IN B-PP O
30 1436 1437 12653683 a DT B-NP O
31 1438 1444 12653683 return NN I-NP O
32 1445 1447 12653683 of IN B-PP O
33 1448 1454 12653683 sodium NN B-NP B-Chemical
34 1455 1464 12653683 excretion NN I-NP O
35 1465 1467 12653683 to TO B-PP O
36 1468 1475 12653683 control NN B-NP O
37 1476 1482 12653683 values NNS I-NP O
38 1482 1483 12653683 . . O O

1 1484 1487 12653683 The DT B-NP O
2 1488 1495 12653683 amounts NNS I-NP O
3 1496 1498 12653683 of IN B-PP O
4 1499 1508 12653683 alphaENaC NN B-NP O
5 1508 1509 12653683 , , I-NP O
6 1510 1518 12653683 betaENaC NN I-NP O
7 1519 1522 12653683 and CC I-NP O
8 1523 1532 12653683 gammaENaC NN I-NP O
9 1533 1541 12653683 proteins NNS I-NP O
10 1542 1546 12653683 were VBD B-VP O
11 1547 1550 12653683 not RB I-VP O
12 1551 1560 12653683 increased VBN I-VP O
13 1561 1567 12653683 during IN B-PP O
14 1568 1571 12653683 PAN NN B-NP B-Chemical
15 1571 1572 12653683 - HYPH B-NP O
16 1572 1579 12653683 induced VBN I-NP O
17 1580 1586 12653683 sodium NN I-NP B-Chemical
18 1587 1596 12653683 retention NN I-NP O
19 1596 1597 12653683 . . O O

1 1598 1600 12653683 In IN B-PP O
2 1601 1611 12653683 conclusion NN B-NP O
3 1611 1612 12653683 , , O O
4 1613 1617 12653683 ENaC NN B-NP O
5 1618 1622 12653683 mRNA NN I-NP O
6 1623 1633 12653683 expression NN I-NP O
7 1633 1634 12653683 , , O O
8 1635 1645 12653683 especially RB B-NP O
9 1646 1655 12653683 alphaENaC NN I-NP O
10 1655 1656 12653683 , , O O
11 1657 1659 12653683 is VBZ B-VP O
12 1660 1669 12653683 increased VBN I-VP O
13 1670 1672 12653683 in IN B-PP O
14 1673 1676 12653683 the DT B-NP O
15 1677 1681 12653683 very RB I-NP O
16 1682 1687 12653683 early JJ I-NP O
17 1688 1693 12653683 phase NN I-NP O
18 1694 1696 12653683 of IN B-PP O
19 1697 1700 12653683 the DT B-NP O
20 1701 1713 12653683 experimental JJ I-NP O
21 1714 1719 12653683 model NN I-NP O
22 1720 1722 12653683 of IN B-PP O
23 1723 1726 12653683 PAN NN B-NP B-Chemical
24 1726 1727 12653683 - HYPH B-NP O
25 1727 1734 12653683 induced VBN I-NP O
26 1735 1744 12653683 nephrotic JJ I-NP B-Disease
27 1745 1753 12653683 syndrome NN I-NP I-Disease
28 1754 1756 12653683 in IN B-PP O
29 1757 1761 12653683 rats NNS B-NP O
30 1761 1762 12653683 , , O O
31 1763 1766 12653683 but CC O O
32 1767 1774 12653683 appears VBZ B-VP O
33 1775 1777 12653683 to TO I-VP O
34 1778 1784 12653683 escape VB I-VP O
35 1785 1789 12653683 from IN B-PP O
36 1790 1793 12653683 the DT B-NP O
37 1794 1804 12653683 regulation NN I-NP O
38 1805 1807 12653683 by IN B-PP O
39 1808 1819 12653683 aldosterone NN B-NP B-Chemical
40 1820 1825 12653683 after IN B-PP O
41 1826 1829 12653683 day NN B-NP O
42 1830 1831 12653683 3 CD I-NP O
43 1831 1832 12653683 . . O O

1 0 0 19356053 -DOCSTART- -X- -X- O

1 0 10 19356053 Clinically RB B-NP O
2 11 22 19356053 significant JJ I-NP O
3 23 34 19356053 proteinuria NN I-NP B-Disease
4 35 44 19356053 following VBG B-PP O
5 45 48 19356053 the DT B-NP O
6 49 63 19356053 administration NN I-NP O
7 64 66 19356053 of IN B-PP O
8 67 76 19356053 sirolimus NN B-NP B-Chemical
9 77 79 19356053 to TO B-PP O
10 80 85 19356053 renal JJ B-NP O
11 86 96 19356053 transplant NN I-NP O
12 97 107 19356053 recipients NNS I-NP O
13 107 108 19356053 . . O O
14 109 119 19356053 BACKGROUND NN B-NP O
15 119 120 19356053 : : O O
16 121 130 19356053 Sirolimus NNP B-NP B-Chemical
17 131 133 19356053 is VBZ B-VP O
18 134 137 19356053 the DT B-NP O
19 138 144 19356053 latest JJS I-NP O
20 145 162 19356053 immunosuppressive JJ I-NP O
21 163 168 19356053 agent NN I-NP O
22 169 173 19356053 used VBN B-VP O
23 174 176 19356053 to TO B-VP O
24 177 184 19356053 prevent VB I-VP O
25 185 194 19356053 rejection NN B-NP O
26 194 195 19356053 , , O O
27 196 199 19356053 and CC O O
28 200 203 19356053 may MD B-VP O
29 204 208 19356053 have VB I-VP O
30 209 213 19356053 less JJR B-NP O
31 214 228 19356053 nephrotoxicity NN I-NP B-Disease
32 229 233 19356053 than IN B-PP O
33 234 245 19356053 calcineurin NN B-NP O
34 246 255 19356053 inhibitor NN I-NP O
35 256 257 19356053 ( ( O O
36 257 260 19356053 CNI NN B-NP O
37 260 261 19356053 ) ) O O
38 261 262 19356053 - HYPH B-NP O
39 262 267 19356053 based VBN I-NP O
40 268 276 19356053 regimens NNS I-NP O
41 276 277 19356053 . . O O

1 278 280 19356053 To TO B-PP O
2 281 285 19356053 date NN B-NP O
3 286 291 19356053 there EX B-NP O
4 292 295 19356053 has VBZ B-VP O
5 296 300 19356053 been VBN I-VP O
6 301 307 19356053 little JJ B-NP O
7 308 321 19356053 documentation NN I-NP O
8 322 324 19356053 of IN B-PP O
9 325 335 19356053 clinically RB B-NP O
10 336 347 19356053 significant JJ I-NP O
11 348 359 19356053 proteinuria NN I-NP B-Disease
12 360 366 19356053 linked VBN B-VP O
13 367 371 19356053 with IN B-PP O
14 372 375 19356053 the DT B-NP O
15 376 379 19356053 use NN I-NP O
16 380 382 19356053 of IN B-PP O
17 383 392 19356053 sirolimus NN B-NP B-Chemical
18 392 393 19356053 . . O O

1 394 396 19356053 We PRP B-NP O
2 397 401 19356053 have VBP B-VP O
3 402 413 19356053 encountered VBN I-VP O
4 414 421 19356053 several JJ B-NP O
5 422 430 19356053 patients NNS I-NP O
6 431 434 19356053 who WP B-NP O
7 435 444 19356053 developed VBD B-VP O
8 445 456 19356053 substantial JJ B-NP O
9 457 468 19356053 proteinuria NN I-NP B-Disease
10 469 479 19356053 associated VBN B-VP O
11 480 484 19356053 with IN B-PP O
12 485 494 19356053 sirolimus NN B-NP B-Chemical
13 495 498 19356053 use NN I-NP O
14 498 499 19356053 . . O O

1 500 502 19356053 In IN B-PP O
2 503 507 19356053 each DT B-NP O
3 508 515 19356053 patient NN I-NP O
4 515 516 19356053 , , O O
5 517 520 19356053 the DT B-NP O
6 521 526 19356053 close JJ I-NP O
7 527 535 19356053 temporal JJ I-NP O
8 536 547 19356053 association NN I-NP O
9 548 555 19356053 between IN B-PP O
10 556 559 19356053 the DT B-NP O
11 560 572 19356053 commencement NN I-NP O
12 573 575 19356053 of IN B-PP O
13 576 585 19356053 sirolimus NN B-NP B-Chemical
14 586 593 19356053 therapy NN I-NP O
15 594 597 19356053 and CC I-NP O
16 598 609 19356053 proteinuria NN I-NP B-Disease
17 610 620 19356053 implicated VBD B-VP O
18 621 630 19356053 sirolimus NN B-NP B-Chemical
19 631 633 19356053 as IN B-PP O
20 634 637 19356053 the DT B-NP O
21 638 642 19356053 most RBS I-NP O
22 643 649 19356053 likely JJ I-NP O
23 650 658 19356053 etiology NN I-NP O
24 659 661 19356053 of IN B-PP O
25 662 665 19356053 the DT B-NP O
26 666 677 19356053 proteinuria NN I-NP B-Disease
27 677 678 19356053 . . O O

1 679 686 19356053 METHODS NNS B-NP O
2 686 687 19356053 : : O O
3 688 690 19356053 We PRP B-NP O
4 691 699 19356053 analyzed VBD B-VP O
5 700 703 19356053 the DT B-NP O
6 704 712 19356053 clinical JJ I-NP O
7 713 716 19356053 and CC I-NP O
8 717 727 19356053 laboratory JJ I-NP O
9 728 739 19356053 information NN I-NP O
10 740 749 19356053 available JJ B-ADJP O
11 750 753 19356053 for IN B-PP O
12 754 757 19356053 all DT B-NP O
13 758 761 19356053 119 CD I-NP O
14 762 770 19356053 patients NNS I-NP O
15 771 783 19356053 transplanted VBN B-VP O
16 784 786 19356053 at IN B-PP O
17 787 790 19356053 the DT B-NP O
18 791 801 19356053 Washington NNP I-NP O
19 802 810 19356053 Hospital NNP I-NP O
20 811 817 19356053 Center NNP I-NP O
21 818 825 19356053 between IN B-PP O
22 826 830 19356053 1999 CD B-NP O
23 830 831 19356053 - HYPH I-NP O
24 831 835 19356053 2003 CD I-NP O
25 836 839 19356053 for IN B-PP O
26 840 844 19356053 whom WP B-NP O
27 845 854 19356053 sirolimus NN I-NP B-Chemical
28 855 858 19356053 was VBD B-VP O
29 859 860 19356053 a DT B-NP O
30 861 870 19356053 component NN I-NP O
31 871 873 19356053 of IN B-PP O
32 874 879 19356053 their PRP$ B-NP O
33 880 897 19356053 immunosuppressant JJ I-NP O
34 898 905 19356053 regimen NN I-NP O
35 905 906 19356053 . . O O

1 907 909 19356053 In IN B-PP O
2 910 915 19356053 these DT B-NP O
3 916 924 19356053 patients NNS I-NP O
4 924 925 19356053 , , O O
5 926 929 19356053 the DT B-NP O
6 930 939 19356053 magnitude NN I-NP O
7 940 942 19356053 of IN B-PP O
8 943 954 19356053 proteinuria NN B-NP B-Disease
9 955 958 19356053 was VBD B-VP O
10 959 967 19356053 assessed VBN I-VP O
11 968 970 19356053 on IN B-PP O
12 971 978 19356053 morning NN B-NP O
13 979 984 19356053 urine NN I-NP O
14 985 992 19356053 samples NNS I-NP O
15 993 995 19356053 by IN B-PP O
16 996 1009 19356053 turbidometric JJ B-NP O
17 1010 1021 19356053 measurement NN I-NP O
18 1022 1024 19356053 or CC O O
19 1025 1031 19356053 random JJ B-NP O
20 1032 1037 19356053 urine NN I-NP O
21 1038 1045 19356053 protein NN I-NP O
22 1045 1046 19356053 : : O O
23 1046 1056 19356053 creatinine NN B-NP B-Chemical
24 1057 1063 19356053 ratios NNS I-NP O
25 1063 1064 19356053 , , O O
26 1065 1067 19356053 an DT B-NP O
27 1068 1076 19356053 estimate NN I-NP O
28 1077 1079 19356053 of IN B-PP O
29 1080 1085 19356053 grams NNS B-NP O
30 1086 1088 19356053 of IN B-PP O
31 1089 1100 19356053 proteinuria NN B-NP B-Disease
32 1100 1101 19356053 / SYM B-NP O
33 1101 1104 19356053 day NN I-NP O
34 1104 1105 19356053 . . O O

1 1106 1116 19356053 Laboratory NN B-NP O
2 1117 1124 19356053 results NNS I-NP O
3 1125 1129 19356053 were VBD B-VP O
4 1130 1138 19356053 compared VBN I-VP O
5 1139 1146 19356053 between IN B-PP O
6 1147 1152 19356053 prior JJ B-NP O
7 1152 1153 19356053 , , O O
8 1154 1160 19356053 during IN B-PP O
9 1161 1164 19356053 and CC O O
10 1165 1174 19356053 following VBG B-PP O
11 1175 1184 19356053 sirolimus NN B-NP B-Chemical
12 1185 1188 19356053 use NN I-NP O
13 1188 1189 19356053 . . O O

1 1190 1197 19356053 RESULTS NNS B-NP O
2 1197 1198 19356053 : : O O
3 1199 1205 19356053 Twenty CD B-NP O
4 1205 1206 19356053 - HYPH O O
5 1206 1211 19356053 eight CD B-NP O
6 1212 1220 19356053 patients NNS I-NP O
7 1221 1222 19356053 ( ( O O
8 1222 1225 19356053 24% NN B-NP O
9 1225 1226 19356053 ) ) O O
10 1227 1236 19356053 developed VBD B-VP O
11 1237 1246 19356053 increased VBN B-NP O
12 1247 1258 19356053 proteinuria NN I-NP B-Disease
13 1259 1263 19356053 from IN B-PP O
14 1264 1272 19356053 baseline NN B-NP O
15 1273 1279 19356053 during IN B-PP O
16 1280 1285 19356053 their PRP$ B-NP O
17 1286 1290 19356053 post AFX I-NP O
18 1290 1291 19356053 - HYPH I-NP O
19 1291 1306 19356053 transplantation NN I-NP O
20 1307 1313 19356053 course NN I-NP O
21 1313 1314 19356053 . . O O

1 1315 1317 19356053 In IN B-PP O
2 1318 1320 19356053 21 CD B-NP O
3 1321 1329 19356053 patients NNS I-NP O
4 1330 1332 19356053 an DT B-NP O
5 1333 1344 19356053 alternative JJ I-NP O
6 1345 1350 19356053 cause NN I-NP O
7 1351 1353 19356053 of IN B-PP O
8 1354 1365 19356053 proteinuria NN B-NP B-Disease
9 1366 1369 19356053 was VBD B-VP O
10 1370 1376 19356053 either CC O O
11 1377 1384 19356053 obvious JJ B-NP O
12 1385 1387 19356053 or CC I-NP O
13 1388 1400 19356053 insufficient JJ I-NP O
14 1401 1405 19356053 data NNS I-NP O
15 1406 1409 19356053 was VBD B-VP O
16 1410 1419 19356053 available JJ B-ADJP O
17 1420 1422 19356053 to TO B-VP O
18 1423 1425 19356053 be VB I-VP O
19 1426 1436 19356053 conclusive JJ B-ADJP O
20 1436 1437 19356053 . . O O

1 1438 1440 19356053 In IN B-PP O
2 1441 1442 19356053 7 CD B-NP O
3 1443 1445 19356053 of IN B-PP O
4 1446 1449 19356053 the DT B-NP O
5 1450 1452 19356053 28 CD I-NP O
6 1453 1461 19356053 patients NNS I-NP O
7 1462 1467 19356053 there EX B-NP O
8 1468 1471 19356053 was VBD B-VP O
9 1472 1473 19356053 a DT B-NP O
10 1474 1482 19356053 striking JJ I-NP O
11 1483 1491 19356053 temporal JJ I-NP O
12 1492 1503 19356053 association NN I-NP O
13 1504 1511 19356053 between IN B-PP O
14 1512 1515 19356053 the DT B-NP O
15 1516 1526 19356053 initiation NN I-NP O
16 1527 1529 19356053 of IN B-PP O
17 1530 1539 19356053 sirolimus NN B-NP B-Chemical
18 1540 1543 19356053 and CC O O
19 1544 1547 19356053 the DT B-NP O
20 1548 1559 19356053 development NN I-NP O
21 1560 1562 19356053 of IN B-PP O
22 1563 1572 19356053 nephrotic JJ B-NP B-Disease
23 1572 1573 19356053 - HYPH I-NP O
24 1573 1578 19356053 range NN I-NP O
25 1579 1590 19356053 proteinuria NN I-NP B-Disease
26 1590 1591 19356053 . . O O

1 1592 1603 19356053 Proteinuria NNP B-NP B-Disease
2 1604 1614 19356053 correlated VBD B-VP O
3 1615 1619 19356053 most RBS B-ADVP O
4 1620 1628 19356053 strongly RB I-ADVP O
5 1629 1633 19356053 with IN B-PP O
6 1634 1643 19356053 sirolimus NN B-NP B-Chemical
7 1644 1651 19356053 therapy NN I-NP O
8 1652 1656 19356053 when WRB B-ADVP O
9 1657 1665 19356053 compared VBN B-VP O
10 1666 1668 19356053 to TO B-PP O
11 1669 1674 19356053 other JJ B-NP O
12 1675 1686 19356053 demographic JJ I-NP O
13 1687 1690 19356053 and CC I-NP O
14 1691 1699 19356053 clinical JJ I-NP O
15 1700 1709 19356053 variables NNS I-NP O
16 1709 1710 19356053 . . O O

1 1711 1713 19356053 In IN B-PP O
2 1714 1718 19356053 most JJS B-NP O
3 1719 1727 19356053 patients NNS I-NP O
4 1727 1728 19356053 , , O O
5 1729 1744 19356053 discontinuation NN B-NP O
6 1745 1747 19356053 of IN B-PP O
7 1748 1757 19356053 sirolimus NN B-NP B-Chemical
8 1758 1766 19356053 resulted VBD B-VP O
9 1767 1769 19356053 in IN B-PP O
10 1770 1771 19356053 a DT B-NP O
11 1772 1780 19356053 decrease NN I-NP O
12 1780 1781 19356053 , , O O
13 1782 1785 19356053 but CC O O
14 1786 1789 19356053 not RB O O
15 1790 1800 19356053 resolution NN B-NP O
16 1800 1801 19356053 , , O O
17 1802 1804 19356053 of IN B-PP O
18 1805 1816 19356053 proteinuria NN B-NP B-Disease
19 1816 1817 19356053 . . O O

1 1818 1829 19356053 CONCLUSIONS NNS B-NP O
2 1829 1830 19356053 : : O O
3 1831 1840 19356053 Sirolimus NN B-NP B-Chemical
4 1841 1848 19356053 induces VBZ B-VP O
5 1849 1851 19356053 or CC I-VP O
6 1852 1862 19356053 aggravates VBZ I-VP O
7 1863 1866 19356053 pre AFX B-NP O
8 1866 1867 19356053 - HYPH B-PP O
9 1867 1875 19356053 existing VBG B-NP O
10 1876 1887 19356053 proteinuria NN I-NP B-Disease
11 1888 1890 19356053 in IN B-PP O
12 1891 1893 19356053 an DT B-NP O
13 1894 1907 19356053 unpredictable JJ I-NP O
14 1908 1914 19356053 subset NN I-NP O
15 1915 1917 19356053 of IN B-PP O
16 1918 1923 19356053 renal JJ B-NP O
17 1924 1933 19356053 allograft NN I-NP O
18 1934 1944 19356053 recipients NNS I-NP O
19 1944 1945 19356053 . . O O

1 1946 1957 19356053 Proteinuria NNP B-NP B-Disease
2 1958 1961 19356053 may MD B-VP O
3 1962 1969 19356053 improve VB I-VP O
4 1969 1970 19356053 , , O O
5 1971 1974 19356053 but CC O O
6 1975 1979 19356053 does VBZ B-VP O
7 1980 1983 19356053 not RB I-VP O
8 1984 1991 19356053 resolve VB I-VP O
9 1991 1992 19356053 , , O O
10 1993 1997 19356053 when WRB B-ADVP O
11 1998 2007 19356053 sirolimus NN B-NP B-Chemical
12 2008 2010 19356053 is VBZ B-VP O
13 2011 2020 19356053 withdrawn VBN I-VP O
14 2020 2021 19356053 . . O O

1 0 0 8829025 -DOCSTART- -X- -X- O

1 0 6 8829025 Effect NN B-NP O
2 7 9 8829025 of IN B-PP O
3 10 20 8829025 nifedipine NN B-NP B-Chemical
4 21 23 8829025 on IN B-PP O
5 24 29 8829025 renal JJ B-NP O
6 30 38 8829025 function NN I-NP O
7 39 41 8829025 in IN B-PP O
8 42 47 8829025 liver NN B-NP O
9 48 58 8829025 transplant NN I-NP O
10 59 69 8829025 recipients NNS I-NP O
11 70 79 8829025 receiving VBG B-VP O
12 80 90 8829025 tacrolimus NN B-NP B-Chemical
13 90 91 8829025 . . O O
14 92 95 8829025 The DT B-NP O
15 96 102 8829025 effect NN I-NP O
16 103 105 8829025 of IN B-PP O
17 106 116 8829025 nifedipine NN B-NP B-Chemical
18 117 119 8829025 on IN B-PP O
19 120 125 8829025 renal JJ B-NP O
20 126 134 8829025 function NN I-NP O
21 135 137 8829025 in IN B-PP O
22 138 143 8829025 liver NN B-NP O
23 144 154 8829025 transplant NN I-NP O
24 155 165 8829025 recipients NNS I-NP O
25 166 169 8829025 who WP B-NP O
26 170 174 8829025 were VBD B-VP O
27 175 184 8829025 receiving VBG I-VP O
28 185 195 8829025 tacrolimus NN B-NP B-Chemical
29 196 199 8829025 was VBD B-VP O
30 200 209 8829025 evaluated VBN I-VP O
31 210 217 8829025 between IN B-PP O
32 218 225 8829025 January NNP B-NP O
33 226 230 8829025 1992 CD I-NP O
34 231 234 8829025 and CC O O
35 235 242 8829025 January NNP B-NP O
36 243 247 8829025 1996 CD I-NP O
37 247 248 8829025 . . O O

1 249 252 8829025 Two CD B-NP O
2 253 259 8829025 groups NNS I-NP O
3 260 262 8829025 of IN B-PP O
4 263 271 8829025 patients NNS B-NP O
5 272 281 8829025 receiving VBG B-VP O
6 282 292 8829025 tacrolimus NN B-NP B-Chemical
7 293 297 8829025 were VBD B-VP O
8 298 306 8829025 compared VBN I-VP O
9 307 311 8829025 over IN B-PP O
10 312 313 8829025 a DT B-NP O
11 314 320 8829025 period NN I-NP O
12 321 323 8829025 of IN B-PP O
13 324 325 8829025 1 CD B-NP O
14 326 330 8829025 year NN I-NP O
15 330 331 8829025 , , O O
16 332 335 8829025 one CD B-NP O
17 336 341 8829025 group NN I-NP O
18 342 352 8829025 comprising VBG B-VP O
19 353 365 8829025 hypertensive JJ B-NP B-Disease
20 366 374 8829025 patients NNS I-NP O
21 375 378 8829025 who WP B-NP O
22 379 383 8829025 were VBD B-VP O
23 384 393 8829025 receiving VBG I-VP O
24 394 404 8829025 nifedipine NN B-NP B-Chemical
25 404 405 8829025 , , O O
26 406 409 8829025 and CC O O
27 410 413 8829025 the DT B-NP O
28 414 419 8829025 other JJ I-NP O
29 420 430 8829025 comprising JJ I-NP O
30 431 446 8829025 nonhypertensive JJ I-NP O
31 447 455 8829025 patients NNS I-NP O
32 456 459 8829025 not RB B-VP O
33 460 469 8829025 receiving VBG I-VP O
34 470 480 8829025 nifedipine NN B-NP B-Chemical
35 480 481 8829025 . . O O

1 482 485 8829025 The DT B-NP O
2 486 490 8829025 time NN I-NP O
3 491 495 8829025 from IN B-PP O
4 496 506 8829025 transplant NN B-NP O
5 507 509 8829025 to TO B-PP O
6 510 518 8829025 baseline NN B-NP O
7 519 522 8829025 was VBD B-VP O
8 523 530 8829025 similar JJ B-ADJP O
9 531 533 8829025 in IN B-PP O
10 534 537 8829025 all DT B-NP O
11 538 546 8829025 patients NNS I-NP O
12 546 547 8829025 . . O O

1 548 558 8829025 Nifedipine NN B-NP B-Chemical
2 559 572 8829025 significantly RB B-ADVP O
3 573 581 8829025 improved VBD B-VP O
4 582 588 8829025 kidney NN B-NP O
5 589 597 8829025 function NN I-NP O
6 598 600 8829025 as IN B-SBAR O
7 601 610 8829025 indicated VBN B-VP O
8 611 613 8829025 by IN B-PP O
9 614 615 8829025 a DT B-NP O
10 616 627 8829025 significant JJ I-NP O
11 628 636 8829025 lowering NN I-NP O
12 637 639 8829025 of IN B-PP O
13 640 645 8829025 serum NN B-NP O
14 646 656 8829025 creatinine NN I-NP B-Chemical
15 657 663 8829025 levels NNS I-NP O
16 664 666 8829025 at IN B-PP O
17 667 668 8829025 6 CD B-NP O
18 669 672 8829025 and CC I-NP O
19 673 675 8829025 12 CD I-NP O
20 676 682 8829025 months NNS I-NP O
21 682 683 8829025 . . O O

1 684 687 8829025 The DT B-NP O
2 688 696 8829025 observed VBN I-NP O
3 697 705 8829025 positive JJ I-NP O
4 706 712 8829025 impact NN I-NP O
5 713 715 8829025 of IN B-PP O
6 716 726 8829025 nifedipine NN B-NP B-Chemical
7 727 729 8829025 on IN B-PP O
8 730 738 8829025 reducing VBG B-VP O
9 739 742 8829025 the DT B-NP O
10 743 757 8829025 nephrotoxicity NN I-NP B-Disease
11 758 768 8829025 associated VBN B-VP O
12 769 773 8829025 with IN B-PP O
13 774 784 8829025 tacrolimus NN B-NP B-Chemical
14 785 787 8829025 in IN B-PP O
15 788 793 8829025 liver NN B-NP O
16 794 804 8829025 transplant NN I-NP O
17 805 815 8829025 recipients NNS I-NP O
18 816 822 8829025 should MD B-VP O
19 823 825 8829025 be VB I-VP O
20 826 828 8829025 an DT B-NP O
21 829 838 8829025 important JJ I-NP O
22 839 845 8829025 factor NN I-NP O
23 846 848 8829025 in IN B-PP O
24 849 858 8829025 selecting VBG B-VP O
25 859 861 8829025 an DT B-NP O
26 862 867 8829025 agent NN I-NP O
27 868 870 8829025 to TO B-VP O
28 871 876 8829025 treat VB I-VP O
29 877 889 8829025 hypertension NN B-NP B-Disease
30 890 892 8829025 in IN B-PP O
31 893 897 8829025 this DT B-NP O
32 898 908 8829025 population NN I-NP O
33 908 909 8829025 . . O O

1 0 0 2549018 -DOCSTART- -X- -X- O

1 0 10 2549018 Fluoxetine NN B-NP B-Chemical
2 10 11 2549018 - HYPH B-NP O
3 11 18 2549018 induced VBN I-NP O
4 19 28 2549018 akathisia NN I-NP B-Disease
5 28 29 2549018 : : O O
6 30 38 2549018 clinical JJ B-NP O
7 39 42 2549018 and CC I-NP O
8 43 54 2549018 theoretical JJ I-NP O
9 55 67 2549018 implications NNS I-NP O
10 67 68 2549018 . . O O
11 69 73 2549018 Five CD B-NP O
12 74 82 2549018 patients NNS I-NP O
13 83 92 2549018 receiving VBG B-VP O
14 93 103 2549018 fluoxetine NN B-NP B-Chemical
15 104 107 2549018 for IN B-PP O
16 108 111 2549018 the DT B-NP O
17 112 121 2549018 treatment NN I-NP O
18 122 124 2549018 of IN B-PP O
19 125 134 2549018 obsessive JJ B-NP B-Disease
20 135 145 2549018 compulsive JJ I-NP I-Disease
21 146 154 2549018 disorder NN I-NP I-Disease
22 155 157 2549018 or CC O O
23 158 163 2549018 major JJ B-NP B-Disease
24 164 174 2549018 depression NN I-NP I-Disease
25 175 184 2549018 developed VBD B-VP O
26 185 194 2549018 akathisia NN B-NP B-Disease
27 194 195 2549018 . . O O

1 196 199 2549018 The DT B-NP O
2 200 207 2549018 typical JJ I-NP O
3 208 218 2549018 fluoxetine NN I-NP B-Chemical
4 218 219 2549018 - HYPH B-NP O
5 219 226 2549018 induced VBN I-NP O
6 227 235 2549018 symptoms NNS I-NP O
7 236 238 2549018 of IN B-PP O
8 239 251 2549018 restlessness NN B-NP O
9 251 252 2549018 , , O O
10 253 261 2549018 constant JJ B-NP O
11 262 268 2549018 pacing NN I-NP O
12 268 269 2549018 , , O O
13 270 281 2549018 purposeless JJ B-NP O
14 282 291 2549018 movements NNS I-NP O
15 292 294 2549018 of IN B-PP O
16 295 298 2549018 the DT B-NP O
17 299 303 2549018 feet NNS I-NP O
18 304 307 2549018 and CC I-NP O
19 308 312 2549018 legs NNS I-NP O
20 312 313 2549018 , , O O
21 314 317 2549018 and CC O O
22 318 324 2549018 marked JJ B-NP O
23 325 332 2549018 anxiety NN I-NP B-Disease
24 333 337 2549018 were VBD B-VP O
25 338 355 2549018 indistinguishable JJ B-ADJP O
26 356 360 2549018 from IN B-PP O
27 361 366 2549018 those DT B-NP O
28 367 369 2549018 of IN B-PP O
29 370 381 2549018 neuroleptic JJ B-NP O
30 381 382 2549018 - HYPH I-NP O
31 382 389 2549018 induced VBN I-NP O
32 390 399 2549018 akathisia NN I-NP B-Disease
33 399 400 2549018 . . O O

1 401 406 2549018 Three CD B-NP O
2 407 415 2549018 patients NNS I-NP O
3 416 419 2549018 who WP B-NP O
4 420 423 2549018 had VBD B-VP O
5 424 435 2549018 experienced VBN I-VP O
6 436 447 2549018 neuroleptic JJ B-NP O
7 447 448 2549018 - HYPH I-NP O
8 448 455 2549018 induced VBN I-NP O
9 456 465 2549018 akathisia NN I-NP B-Disease
10 466 468 2549018 in IN B-PP O
11 469 472 2549018 the DT B-NP O
12 473 477 2549018 past NN I-NP O
13 478 486 2549018 reported VBD B-VP O
14 487 491 2549018 that IN B-SBAR O
15 492 495 2549018 the DT B-NP O
16 496 504 2549018 symptoms NNS I-NP O
17 505 507 2549018 of IN B-PP O
18 508 518 2549018 fluoxetine NN B-NP B-Chemical
19 518 519 2549018 - HYPH B-NP O
20 519 526 2549018 induced VBN I-NP O
21 527 536 2549018 akathisia NN I-NP B-Disease
22 537 541 2549018 were VBD B-VP O
23 542 551 2549018 identical JJ B-ADJP O
24 551 552 2549018 , , O O
25 553 561 2549018 although IN B-SBAR O
26 562 570 2549018 somewhat RB B-ADJP O
27 571 577 2549018 milder JJR I-ADJP O
28 577 578 2549018 . . O O

1 579 588 2549018 Akathisia NNP B-NP B-Disease
2 589 597 2549018 appeared VBD B-VP O
3 598 600 2549018 to TO I-VP O
4 601 603 2549018 be VB I-VP O
5 604 605 2549018 a DT B-NP O
6 606 612 2549018 common JJ I-NP O
7 613 617 2549018 side NN I-NP O
8 618 624 2549018 effect NN I-NP O
9 625 627 2549018 of IN B-PP O
10 628 638 2549018 fluoxetine NN B-NP B-Chemical
11 639 642 2549018 and CC O O
12 643 652 2549018 generally RB B-VP O
13 653 662 2549018 responded VBD I-VP O
14 663 667 2549018 well RB I-VP O
15 668 670 2549018 to TO I-VP O
16 671 680 2549018 treatment NN B-NP O
17 681 685 2549018 with IN B-PP O
18 686 689 2549018 the DT B-NP O
19 690 694 2549018 beta SYM I-NP O
20 694 695 2549018 - HYPH I-NP O
21 695 705 2549018 adrenergic JJ I-NP O
22 706 716 2549018 antagonist NN I-NP O
23 717 728 2549018 propranolol NN I-NP B-Chemical
24 728 729 2549018 , , O O
25 730 734 2549018 dose NN B-NP O
26 735 744 2549018 reduction NN I-NP O
27 744 745 2549018 , , O O
28 746 748 2549018 or CC O O
29 749 753 2549018 both DT B-NP O
30 753 754 2549018 . . O O

1 755 758 2549018 The DT B-NP O
2 759 766 2549018 authors NNS I-NP O
3 767 774 2549018 suggest VBP B-VP O
4 775 779 2549018 that IN B-SBAR O
5 780 790 2549018 fluoxetine NN B-NP B-Chemical
6 790 791 2549018 - HYPH B-NP O
7 791 798 2549018 induced VBN I-NP O
8 799 808 2549018 akathisia NN I-NP B-Disease
9 809 812 2549018 may MD B-VP O
10 813 815 2549018 be VB I-VP O
11 816 822 2549018 caused VBN I-VP O
12 823 825 2549018 by IN B-PP O
13 826 842 2549018 serotonergically RB B-NP O
14 843 851 2549018 mediated VBN I-NP O
15 852 862 2549018 inhibition NN I-NP O
16 863 865 2549018 of IN B-PP O
17 866 878 2549018 dopaminergic JJ B-NP O
18 879 896 2549018 neurotransmission NN I-NP O
19 897 900 2549018 and CC O O
20 901 905 2549018 that IN B-SBAR O
21 906 909 2549018 the DT B-NP O
22 910 925 2549018 pathophysiology NN I-NP O
23 926 928 2549018 of IN B-PP O
24 929 939 2549018 fluoxetine NN B-NP B-Chemical
25 939 940 2549018 - HYPH B-NP O
26 940 947 2549018 induced VBN I-NP O
27 948 957 2549018 akathisia NN I-NP B-Disease
28 958 961 2549018 and CC O O
29 962 971 2549018 tricyclic JJ B-NP O
30 972 986 2549018 antidepressant NN I-NP B-Chemical
31 986 987 2549018 - HYPH B-VP O
32 987 994 2549018 induced VBN B-NP O
33 995 996 2549018 " `` I-NP O
34 996 1007 2549018 jitteriness NN I-NP O
35 1007 1008 2549018 " '' O O
36 1009 1012 2549018 may MD B-VP O
37 1013 1015 2549018 be VB I-VP O
38 1016 1025 2549018 identical JJ B-ADJP O
39 1025 1026 2549018 . . O O

1 0 0 9249847 -DOCSTART- -X- -X- O

1 0 14 9249847 Iatrogenically RB B-NP O
2 15 22 9249847 induced VBN I-NP O
3 23 34 9249847 intractable JJ I-NP O
4 35 51 9249847 atrioventricular JJ I-NP B-Disease
5 52 61 9249847 reentrant JJ I-NP I-Disease
6 62 73 9249847 tachycardia NN I-NP I-Disease
7 74 79 9249847 after IN B-PP O
8 80 89 9249847 verapamil NN B-NP B-Chemical
9 90 93 9249847 and CC I-NP O
10 94 102 9249847 catheter NN I-NP O
11 103 111 9249847 ablation NN I-NP O
12 112 114 9249847 in IN B-PP O
13 115 116 9249847 a DT B-NP O
14 117 124 9249847 patient NN I-NP O
15 125 129 9249847 with IN B-PP O
16 130 135 9249847 Wolff NNP B-NP B-Disease
17 135 136 9249847 - HYPH B-NP I-Disease
18 136 145 9249847 Parkinson NNP I-NP I-Disease
19 145 146 9249847 - HYPH I-NP I-Disease
20 146 151 9249847 White NNP I-NP I-Disease
21 152 160 9249847 syndrome NN I-NP I-Disease
22 161 164 9249847 and CC I-NP O
23 165 175 9249847 idiopathic JJ I-NP B-Disease
24 176 183 9249847 dilated JJ I-NP I-Disease
25 184 198 9249847 cardiomyopathy NN I-NP I-Disease
26 198 199 9249847 . . O O
27 200 202 9249847 In IN B-PP O
28 203 204 9249847 a DT B-NP O
29 205 212 9249847 patient NN I-NP O
30 213 217 9249847 with IN B-PP O
31 218 221 9249847 WPW NN B-NP B-Disease
32 222 230 9249847 syndrome NN I-NP I-Disease
33 231 234 9249847 and CC O O
34 235 245 9249847 idiopathic JJ B-NP B-Disease
35 246 253 9249847 dilated JJ I-NP I-Disease
36 254 268 9249847 cardiomyopathy NN I-NP I-Disease
37 268 269 9249847 , , O O
38 270 281 9249847 intractable JJ B-NP O
39 282 298 9249847 atrioventricular JJ I-NP B-Disease
40 299 308 9249847 reentrant NN I-NP I-Disease
41 309 320 9249847 tachycardia NN I-NP I-Disease
42 321 322 9249847 ( ( O O
43 322 326 9249847 AVRT NN B-NP B-Disease
44 326 327 9249847 ) ) O O
45 328 331 9249847 was VBD B-VP O
46 332 346 9249847 iatrogenically RB I-VP O
47 347 354 9249847 induced VBN I-VP O
48 354 355 9249847 . . O O

1 356 359 9249847 QRS NNS B-NP O
2 360 367 9249847 without IN B-PP O
3 368 381 9249847 preexcitation NN B-NP O
4 381 382 9249847 , , O O
5 383 389 9249847 caused VBN B-VP O
6 390 392 9249847 by IN B-PP O
7 393 403 9249847 junctional JJ B-NP O
8 404 410 9249847 escape NN I-NP O
9 411 416 9249847 beats NNS I-NP O
10 417 422 9249847 after IN B-PP O
11 423 432 9249847 verapamil NN B-NP B-Chemical
12 433 435 9249847 or CC O O
13 436 450 9249847 unidirectional JJ B-NP O
14 451 460 9249847 antegrade NN I-NP O
15 461 466 9249847 block NN I-NP O
16 467 469 9249847 of IN B-PP O
17 470 479 9249847 accessory JJ B-NP O
18 480 487 9249847 pathway NN I-NP O
19 488 493 9249847 after IN B-PP O
20 494 502 9249847 catheter NN B-NP O
21 503 511 9249847 ablation NN I-NP O
22 511 512 9249847 , , O O
23 513 524 9249847 established VBN B-VP O
24 525 533 9249847 frequent JJ B-NP O
25 534 538 9249847 AVRT NN I-NP B-Disease
26 539 545 9249847 attack NN I-NP O
27 545 546 9249847 . . O O

1 0 0 8386779 -DOCSTART- -X- -X- O

1 0 6 8386779 Sodium NN B-NP B-Chemical
2 7 18 8386779 bicarbonate NN I-NP I-Chemical
3 19 29 8386779 alleviates VBZ B-VP O
4 30 36 8386779 penile JJ B-NP B-Disease
5 37 41 8386779 pain NN I-NP I-Disease
6 42 49 8386779 induced VBN B-VP O
7 50 52 8386779 by IN B-PP O
8 53 67 8386779 intracavernous JJ B-NP O
9 68 78 8386779 injections NNS I-NP O
10 79 82 8386779 for IN B-PP O
11 83 91 8386779 erectile JJ B-NP B-Disease
12 92 103 8386779 dysfunction NN I-NP I-Disease
13 103 104 8386779 . . O O
14 105 107 8386779 In IN B-PP O
15 108 110 8386779 an DT B-NP O
16 111 118 8386779 attempt NN I-NP O
17 119 121 8386779 to TO B-VP O
18 122 131 8386779 determine VB I-VP O
19 132 139 8386779 whether IN B-SBAR O
20 140 146 8386779 penile JJ B-NP B-Disease
21 147 151 8386779 pain NN I-NP I-Disease
22 152 162 8386779 associated VBN B-VP O
23 163 167 8386779 with IN B-PP O
24 168 182 8386779 intracorporeal JJ B-NP O
25 183 193 8386779 injections NNS I-NP O
26 194 199 8386779 could MD B-VP O
27 200 202 8386779 be VB I-VP O
28 203 206 8386779 due JJ B-ADVP O
29 207 209 8386779 to TO B-PP O
30 210 213 8386779 the DT B-NP O
31 214 221 8386779 acidity NN I-NP O
32 222 224 8386779 of IN B-PP O
33 225 228 8386779 the DT B-NP O
34 229 239 8386779 medication NN I-NP O
35 239 240 8386779 , , O O
36 241 243 8386779 we PRP B-NP O
37 244 253 8386779 performed VBD B-VP O
38 254 255 8386779 a DT B-NP O
39 256 266 8386779 randomized VBN I-NP O
40 267 272 8386779 study NN I-NP O
41 273 282 8386779 comparing VBG B-VP O
42 283 286 8386779 the DT B-NP O
43 287 296 8386779 incidence NN I-NP O
44 297 299 8386779 of IN B-PP O
45 300 306 8386779 penile JJ B-NP B-Disease
46 307 311 8386779 pain NN I-NP I-Disease
47 312 321 8386779 following VBG B-PP O
48 322 336 8386779 intracorporeal JJ B-NP O
49 337 347 8386779 injections NNS I-NP O
50 348 352 8386779 with IN B-PP O
51 353 355 8386779 or CC B-PP O
52 356 363 8386779 without IN B-PP O
53 364 367 8386779 the DT B-NP O
54 368 376 8386779 addition NN I-NP O
55 377 379 8386779 of IN B-PP O
56 380 386 8386779 sodium NN B-NP B-Chemical
57 387 398 8386779 bicarbonate NN I-NP I-Chemical
58 399 401 8386779 to TO B-PP O
59 402 405 8386779 the DT B-NP O
60 406 420 8386779 intracorporeal JJ I-NP O
61 421 432 8386779 medications NNS I-NP O
62 432 433 8386779 . . O O

1 434 435 8386779 A DT B-NP O
2 436 441 8386779 total NN I-NP O
3 442 444 8386779 of IN B-PP O
4 445 447 8386779 38 CD B-NP O
5 448 459 8386779 consecutive JJ I-NP O
6 460 468 8386779 patients NNS I-NP O
7 469 472 8386779 who WP B-NP O
8 473 482 8386779 presented VBD B-VP O
9 483 485 8386779 to TO B-PP O
10 486 489 8386779 our PRP$ B-NP O
11 490 496 8386779 clinic NN I-NP O
12 497 501 8386779 with IN B-PP O
13 502 511 8386779 impotence NN B-NP B-Disease
14 512 520 8386779 received VBD B-VP O
15 521 524 8386779 0.2 CD B-NP O
16 525 527 8386779 ml NN I-NP O
17 527 528 8386779 . . O O

1 529 531 8386779 of IN B-PP O
2 532 533 8386779 a DT B-NP O
3 534 545 8386779 combination NN I-NP O
4 546 548 8386779 of IN B-PP O
5 549 550 8386779 3 CD B-NP O
6 551 556 8386779 drugs NNS I-NP O
7 556 557 8386779 : : O O
8 558 559 8386779 6 CD B-NP O
9 560 562 8386779 mg NN I-NP O
10 562 563 8386779 . . O O

1 564 574 8386779 papaverine NN B-NP B-Chemical
2 574 575 8386779 , , O O
3 576 579 8386779 100 CD B-NP O
4 580 590 8386779 micrograms NNS I-NP O
5 590 591 8386779 . . O O

1 592 604 8386779 phentolamine NN B-NP B-Chemical
2 605 608 8386779 and CC O O
3 609 611 8386779 10 CD B-NP O
4 612 622 8386779 micrograms NNS I-NP O
5 622 623 8386779 . . O O

1 624 637 8386779 prostaglandin NN B-NP B-Chemical
2 638 640 8386779 E1 NN I-NP I-Chemical
3 641 645 8386779 with IN B-PP O
4 646 647 8386779 ( ( O O
5 647 649 8386779 pH NN B-NP O
6 650 654 8386779 7.05 CD I-NP O
7 654 655 8386779 ) ) O O
8 656 658 8386779 or CC O O
9 659 666 8386779 without IN B-PP O
10 667 668 8386779 ( ( O O
11 668 670 8386779 pH NN B-NP O
12 671 675 8386779 4.17 CD I-NP O
13 675 676 8386779 ) ) O O
14 677 680 8386779 the DT B-NP O
15 681 689 8386779 addition NN I-NP O
16 690 692 8386779 of IN B-PP O
17 693 699 8386779 sodium NN B-NP B-Chemical
18 700 711 8386779 bicarbonate NN I-NP I-Chemical
19 712 713 8386779 ( ( O O
20 713 717 8386779 0.03 CD B-NP O
21 718 721 8386779 mEq NN I-NP O
22 721 722 8386779 . . O O
23 722 723 8386779 ) ) O O
24 723 724 8386779 . . O O

1 725 727 8386779 Of IN B-PP O
2 728 731 8386779 the DT B-NP O
3 732 734 8386779 19 CD I-NP O
4 735 743 8386779 patients NNS I-NP O
5 744 751 8386779 without IN B-PP O
6 752 758 8386779 sodium NN B-NP B-Chemical
7 759 770 8386779 bicarbonate NN I-NP I-Chemical
8 771 776 8386779 added VBN B-VP O
9 777 779 8386779 to TO B-PP O
10 780 783 8386779 the DT B-NP O
11 784 794 8386779 medication NN I-NP O
12 795 797 8386779 11 CD I-NP O
13 798 799 8386779 ( ( O O
14 799 802 8386779 58% NN B-NP O
15 802 803 8386779 ) ) O O
16 804 814 8386779 complained VBD B-VP O
17 815 817 8386779 of IN B-PP O
18 818 824 8386779 penile JJ B-NP B-Disease
19 825 829 8386779 pain NN I-NP I-Disease
20 830 833 8386779 due JJ B-PP O
21 834 836 8386779 to TO B-PP O
22 837 840 8386779 the DT B-NP O
23 841 851 8386779 medication NN I-NP O
24 851 852 8386779 , , O O
25 853 858 8386779 while IN B-SBAR O
26 859 863 8386779 only RB B-NP O
27 864 865 8386779 1 CD I-NP O
28 866 868 8386779 of IN B-PP O
29 869 872 8386779 the DT B-NP O
30 873 875 8386779 19 CD I-NP O
31 876 879 8386779 men NNS I-NP O
32 880 881 8386779 ( ( O O
33 881 883 8386779 5% LS O O
34 883 884 8386779 ) ) O O
35 885 888 8386779 who WP B-NP O
36 889 897 8386779 received VBD B-VP O
37 898 904 8386779 sodium NN B-NP B-Chemical
38 905 916 8386779 bicarbonate NN I-NP I-Chemical
39 917 927 8386779 complained VBN B-VP O
40 928 930 8386779 of IN B-PP O
41 931 937 8386779 penile JJ B-NP B-Disease
42 938 942 8386779 pain NN I-NP I-Disease
43 942 943 8386779 . . O O

1 944 948 8386779 From IN B-PP O
2 949 954 8386779 these DT B-NP O
3 955 959 8386779 data NNS I-NP O
4 960 962 8386779 we PRP B-NP O
5 963 971 8386779 conclude VBP B-VP O
6 972 976 8386779 that IN B-SBAR O
7 977 980 8386779 the DT B-NP O
8 981 987 8386779 penile JJ I-NP B-Disease
9 988 992 8386779 pain NN I-NP I-Disease
10 993 1002 8386779 following VBG B-PP O
11 1003 1017 8386779 intracorporeal JJ B-NP O
12 1018 1028 8386779 injections NNS I-NP O
13 1029 1031 8386779 is VBZ B-VP O
14 1032 1036 8386779 most RBS B-ADVP O
15 1037 1043 8386779 likely RB I-ADVP O
16 1044 1047 8386779 due IN B-PP O
17 1048 1050 8386779 to TO B-PP O
18 1051 1054 8386779 the DT B-NP O
19 1055 1062 8386779 acidity NN I-NP O
20 1063 1065 8386779 of IN B-PP O
21 1066 1069 8386779 the DT B-NP O
22 1070 1080 8386779 medication NN I-NP O
23 1080 1081 8386779 , , O O
24 1082 1087 8386779 which WDT B-NP O
25 1088 1091 8386779 can MD B-VP O
26 1092 1094 8386779 be VB I-VP O
27 1095 1103 8386779 overcome VBN I-VP O
28 1104 1106 8386779 by IN B-PP O
29 1107 1116 8386779 elevating VBG B-VP O
30 1117 1120 8386779 the DT B-NP O
31 1121 1123 8386779 pH NN I-NP O
32 1124 1126 8386779 to TO B-PP O
33 1127 1128 8386779 a DT B-NP O
34 1129 1136 8386779 neutral JJ I-NP O
35 1137 1142 8386779 level NN I-NP O
36 1142 1143 8386779 . . O O

1 0 0 11679859 -DOCSTART- -X- -X- O

1 0 11 11679859 Intravenous JJ B-NP O
2 12 26 11679859 administration NN I-NP O
3 27 29 11679859 of IN B-PP O
4 30 46 11679859 prochlorperazine NN B-NP B-Chemical
5 47 49 11679859 by IN B-PP O
6 50 52 11679859 15 CD B-NP O
7 52 53 11679859 - HYPH I-NP O
8 53 59 11679859 minute NN I-NP O
9 60 68 11679859 infusion NN I-NP O
10 69 75 11679859 versus IN B-PP O
11 76 77 11679859 2 CD B-NP O
12 77 78 11679859 - HYPH I-NP O
13 78 84 11679859 minute NN I-NP O
14 85 90 11679859 bolus NN I-NP O
15 91 95 11679859 does VBZ B-VP O
16 96 99 11679859 not RB I-VP O
17 100 106 11679859 affect VB I-VP O
18 107 110 11679859 the DT B-NP O
19 111 120 11679859 incidence NN I-NP O
20 121 123 11679859 of IN B-PP O
21 124 133 11679859 akathisia NN B-NP B-Disease
22 133 134 11679859 : : O O
23 135 136 11679859 a DT B-NP O
24 137 148 11679859 prospective JJ I-NP O
25 148 149 11679859 , , I-NP O
26 150 160 11679859 randomized VBN I-NP O
27 160 161 11679859 , , I-NP O
28 162 172 11679859 controlled VBN I-NP O
29 173 178 11679859 trial NN I-NP O
30 178 179 11679859 . . I-NP O
31 180 185 11679859 STUDY NN I-NP O
32 186 195 11679859 OBJECTIVE NN I-NP O
33 195 196 11679859 : : O O
34 197 199 11679859 We PRP B-NP O
35 200 206 11679859 sought VBD B-VP O
36 207 209 11679859 to TO I-VP O
37 210 217 11679859 compare VB I-VP O
38 218 221 11679859 the DT B-NP O
39 222 226 11679859 rate NN I-NP O
40 227 229 11679859 of IN B-PP O
41 230 239 11679859 akathisia NN B-NP B-Disease
42 240 245 11679859 after IN B-PP O
43 246 260 11679859 administration NN B-NP O
44 261 263 11679859 of IN B-PP O
45 264 275 11679859 intravenous JJ B-NP O
46 276 292 11679859 prochlorperazine NN I-NP B-Chemical
47 293 295 11679859 as IN B-PP O
48 296 297 11679859 a DT B-NP O
49 298 299 11679859 2 CD I-NP O
50 299 300 11679859 - HYPH I-NP O
51 300 306 11679859 minute NN I-NP O
52 307 312 11679859 bolus NN I-NP O
53 313 315 11679859 or CC O O
54 316 318 11679859 15 CD B-NP O
55 318 319 11679859 - HYPH I-NP O
56 319 325 11679859 minute NN I-NP O
57 326 334 11679859 infusion NN I-NP O
58 334 335 11679859 . . O O

1 336 343 11679859 METHODS NNS B-NP O
2 343 344 11679859 : : O O
3 345 347 11679859 We PRP B-NP O
4 348 357 11679859 conducted VBD B-VP O
5 358 359 11679859 a DT B-NP O
6 360 371 11679859 prospective JJ I-NP O
7 371 372 11679859 , , I-NP O
8 373 383 11679859 randomized VBN I-NP O
9 383 384 11679859 , , I-NP O
10 385 391 11679859 double JJ I-NP O
11 391 392 11679859 - HYPH I-NP O
12 392 397 11679859 blind JJ I-NP O
13 398 403 11679859 study NN I-NP O
14 404 406 11679859 in IN B-PP O
15 407 410 11679859 the DT B-NP O
16 411 420 11679859 emergency NN I-NP O
17 421 431 11679859 department NN I-NP O
18 432 434 11679859 of IN B-PP O
19 435 436 11679859 a DT B-NP O
20 437 444 11679859 central JJ I-NP O
21 444 445 11679859 - HYPH I-NP O
22 445 449 11679859 city NN I-NP O
23 450 458 11679859 teaching NN I-NP O
24 459 467 11679859 hospital NN I-NP O
25 467 468 11679859 . . O O

1 469 477 11679859 Patients NNS B-NP O
2 478 482 11679859 aged VBN B-ADJP O
3 483 485 11679859 18 CD B-NP O
4 486 491 11679859 years NNS I-NP O
5 492 494 11679859 or CC O O
6 495 500 11679859 older JJR B-NP O
7 501 508 11679859 treated VBN B-VP O
8 509 513 11679859 with IN B-PP O
9 514 530 11679859 prochlorperazine NN B-NP B-Chemical
10 531 534 11679859 for IN B-PP O
11 535 543 11679859 headache NN B-NP B-Disease
12 543 544 11679859 , , O O
13 545 551 11679859 nausea NN B-NP B-Disease
14 551 552 11679859 , , O O
15 553 555 11679859 or CC O O
16 556 564 11679859 vomiting NN B-NP B-Disease
17 565 569 11679859 were VBD B-VP O
18 570 578 11679859 eligible JJ B-ADJP O
19 579 582 11679859 for IN B-PP O
20 583 592 11679859 inclusion NN B-NP O
21 592 593 11679859 . . O O

1 594 599 11679859 Study NN B-NP O
2 600 612 11679859 participants NNS I-NP O
3 613 617 11679859 were VBD B-VP O
4 618 628 11679859 randomized VBN I-VP O
5 629 631 11679859 to TO I-VP O
6 632 639 11679859 receive VB I-VP O
7 640 642 11679859 10 CD B-NP O
8 643 645 11679859 mg NN I-NP O
9 646 648 11679859 of IN B-PP O
10 649 665 11679859 prochlorperazine NN B-NP B-Chemical
11 666 678 11679859 administered VBN B-VP O
12 679 692 11679859 intravenously RB B-ADVP O
13 693 695 11679859 by IN B-PP O
14 696 701 11679859 means NNS B-NP O
15 702 704 11679859 of IN B-PP O
16 705 706 11679859 2 CD B-NP O
17 706 707 11679859 - HYPH I-NP O
18 707 713 11679859 minute NN I-NP O
19 714 718 11679859 push NN I-NP O
20 719 720 11679859 ( ( O O
21 720 725 11679859 bolus NN B-NP O
22 726 731 11679859 group NN I-NP O
23 731 732 11679859 ) ) O O
24 733 735 11679859 or CC O O
25 736 738 11679859 10 CD B-NP O
26 739 741 11679859 mg NN I-NP O
27 742 749 11679859 diluted VBN B-VP O
28 750 752 11679859 in IN B-PP O
29 753 755 11679859 50 CD B-NP O
30 756 758 11679859 mL NN I-NP O
31 759 761 11679859 of IN B-PP O
32 762 768 11679859 normal JJ B-NP O
33 769 775 11679859 saline NN I-NP O
34 776 784 11679859 solution NN I-NP O
35 785 797 11679859 administered VBN B-VP O
36 798 800 11679859 by IN B-PP O
37 801 806 11679859 means NNS B-NP O
38 807 809 11679859 of IN B-PP O
39 810 821 11679859 intravenous JJ B-NP O
40 822 830 11679859 infusion NN I-NP O
41 831 837 11679859 during IN B-PP O
42 838 839 11679859 a DT B-NP O
43 840 842 11679859 15 CD I-NP O
44 842 843 11679859 - HYPH I-NP O
45 843 849 11679859 minute NN I-NP O
46 850 856 11679859 period NN I-NP O
47 857 858 11679859 ( ( O O
48 858 866 11679859 infusion NN B-NP O
49 867 872 11679859 group NN I-NP O
50 872 873 11679859 ) ) O O
51 873 874 11679859 . . O O

1 875 878 11679859 The DT B-NP O
2 879 883 11679859 main JJ I-NP O
3 884 891 11679859 outcome NN I-NP O
4 892 895 11679859 was VBD B-VP O
5 896 899 11679859 the DT B-NP O
6 900 906 11679859 number NN I-NP O
7 907 909 11679859 of IN B-PP O
8 910 915 11679859 study NN B-NP O
9 916 928 11679859 participants NNS I-NP O
10 929 941 11679859 experiencing VBG B-VP O
11 942 951 11679859 akathisia NN B-NP B-Disease
12 952 958 11679859 within IN B-PP O
13 959 961 11679859 60 CD B-NP O
14 962 969 11679859 minutes NNS I-NP O
15 970 972 11679859 of IN B-PP O
16 973 987 11679859 administration NN B-NP O
17 987 988 11679859 . . O O

1 989 998 11679859 Akathisia NN B-NP O
2 999 1002 11679859 was VBD B-VP O
3 1003 1010 11679859 defined VBN I-VP O
4 1011 1013 11679859 as IN B-PP O
5 1014 1020 11679859 either CC O O
6 1021 1022 11679859 a DT B-NP O
7 1023 1034 11679859 spontaneous JJ I-NP O
8 1035 1041 11679859 report NN I-NP O
9 1042 1044 11679859 of IN B-PP O
10 1045 1057 11679859 restlessness NN B-NP O
11 1058 1060 11679859 or CC I-NP O
12 1061 1070 11679859 agitation NN I-NP B-Disease
13 1071 1073 11679859 or CC O O
14 1074 1075 11679859 a DT B-NP O
15 1076 1082 11679859 change NN I-NP O
16 1083 1085 11679859 of IN B-PP O
17 1086 1087 11679859 2 CD B-NP O
18 1088 1090 11679859 or CC I-NP O
19 1091 1095 11679859 more JJR I-NP O
20 1096 1098 11679859 in IN B-PP O
21 1099 1102 11679859 the DT B-NP O
22 1103 1110 11679859 patient NN I-NP O
23 1110 1111 11679859 - HYPH B-VP O
24 1111 1119 11679859 reported VBN B-NP O
25 1120 1129 11679859 akathisia NN I-NP B-Disease
26 1130 1136 11679859 rating NN I-NP O
27 1137 1142 11679859 scale NN I-NP O
28 1143 1146 11679859 and CC O O
29 1147 1148 11679859 a DT B-NP O
30 1149 1155 11679859 change NN I-NP O
31 1156 1158 11679859 of IN B-PP O
32 1159 1161 11679859 at IN B-NP O
33 1162 1167 11679859 least JJS I-NP O
34 1168 1169 11679859 1 CD I-NP O
35 1170 1172 11679859 in IN B-PP O
36 1173 1176 11679859 the DT B-NP O
37 1177 1189 11679859 investigator NN I-NP O
38 1189 1190 11679859 - HYPH B-VP O
39 1190 1198 11679859 observed VBN B-NP O
40 1199 1208 11679859 akathisia NN I-NP B-Disease
41 1209 1215 11679859 rating NN I-NP O
42 1216 1221 11679859 scale NN I-NP O
43 1221 1222 11679859 . . O O

1 1223 1226 11679859 The DT B-NP O
2 1227 1236 11679859 intensity NN I-NP O
3 1237 1239 11679859 of IN B-PP O
4 1240 1248 11679859 headache NN B-NP B-Disease
5 1249 1252 11679859 and CC I-NP O
6 1253 1259 11679859 nausea NN I-NP B-Disease
7 1260 1263 11679859 was VBD B-VP O
8 1264 1272 11679859 measured VBN I-VP O
9 1273 1277 11679859 with IN B-PP O
10 1278 1279 11679859 a DT B-NP O
11 1280 1283 11679859 100 CD I-NP O
12 1283 1284 11679859 - HYPH I-NP O
13 1284 1286 11679859 mm NN I-NP O
14 1287 1293 11679859 visual JJ I-NP O
15 1294 1300 11679859 analog NN I-NP O
16 1301 1306 11679859 scale NN I-NP O
17 1306 1307 11679859 . . O O

1 1308 1315 11679859 RESULTS NNS B-NP O
2 1315 1316 11679859 : : O O
3 1317 1320 11679859 One CD B-NP O
4 1321 1328 11679859 hundred CD I-NP O
5 1329 1337 11679859 patients NNS I-NP O
6 1338 1342 11679859 were VBD B-VP O
7 1343 1351 11679859 enrolled VBN I-VP O
8 1351 1352 11679859 . . O O

1 1353 1356 11679859 One CD B-NP O
2 1357 1362 11679859 study NN I-NP O
3 1363 1374 11679859 participant NN I-NP O
4 1375 1378 11679859 was VBD B-VP O
5 1379 1387 11679859 excluded VBN I-VP O
6 1388 1393 11679859 after IN B-PP O
7 1394 1402 11679859 protocol NN B-NP O
8 1403 1412 11679859 violation NN I-NP O
9 1412 1413 11679859 . . O O

1 1414 1421 11679859 Seventy CD B-NP O
2 1421 1422 11679859 - HYPH I-NP O
3 1422 1427 11679859 three CD I-NP O
4 1428 1435 11679859 percent NN I-NP O
5 1436 1437 11679859 ( ( O O
6 1437 1439 11679859 73 CD B-NP O
7 1439 1440 11679859 / SYM O O
8 1440 1442 11679859 99 CD B-NP O
9 1442 1443 11679859 ) ) O O
10 1444 1446 11679859 of IN B-PP O
11 1447 1450 11679859 the DT B-NP O
12 1451 1456 11679859 study NN I-NP O
13 1457 1469 11679859 participants NNS I-NP O
14 1470 1474 11679859 were VBD B-VP O
15 1475 1482 11679859 treated VBN I-VP O
16 1483 1486 11679859 for IN B-PP O
17 1487 1495 11679859 headache NN B-NP B-Disease
18 1496 1499 11679859 and CC I-NP O
19 1500 1503 11679859 70% NN I-NP O
20 1504 1505 11679859 ( ( O O
21 1505 1507 11679859 70 CD B-NP O
22 1507 1508 11679859 / SYM I-NP O
23 1508 1510 11679859 99 CD I-NP O
24 1510 1511 11679859 ) ) O O
25 1512 1515 11679859 for IN B-PP O
26 1516 1522 11679859 nausea NN B-NP B-Disease
27 1522 1523 11679859 . . O O

1 1524 1526 11679859 In IN B-PP O
2 1527 1530 11679859 the DT B-NP O
3 1531 1536 11679859 bolus NN I-NP O
4 1537 1542 11679859 group NN I-NP O
5 1542 1543 11679859 , , O O
6 1544 1549 11679859 26.0% CD B-NP O
7 1550 1551 11679859 ( ( O O
8 1551 1553 11679859 13 CD B-NP O
9 1553 1554 11679859 / SYM B-NP O
10 1554 1556 11679859 50 CD I-NP O
11 1556 1557 11679859 ) ) O O
12 1558 1561 11679859 had VBD B-VP O
13 1562 1571 11679859 akathisia NN B-NP B-Disease
14 1572 1580 11679859 compared VBN B-PP O
15 1581 1585 11679859 with IN B-PP O
16 1586 1591 11679859 32.7% NN B-NP O
17 1592 1593 11679859 ( ( O O
18 1593 1595 11679859 16 CD B-NP O
19 1595 1596 11679859 / SYM I-NP O
20 1596 1598 11679859 49 CD I-NP O
21 1598 1599 11679859 ) ) O O
22 1600 1602 11679859 in IN B-PP O
23 1603 1606 11679859 the DT B-NP O
24 1607 1615 11679859 infusion NN I-NP O
25 1616 1621 11679859 group NN I-NP O
26 1622 1623 11679859 ( ( O O
27 1623 1628 11679859 Delta NN B-NP O
28 1628 1629 11679859 = SYM B-VP O
29 1629 1630 11679859 - SYM B-NP O
30 1630 1634 11679859 6.7% CD I-NP O
31 1634 1635 11679859 ; : O O
32 1636 1639 11679859 95% CD B-NP O
33 1640 1650 11679859 confidence NN I-NP O
34 1651 1659 11679859 interval NN I-NP O
35 1660 1661 11679859 [ ( O O
36 1661 1663 11679859 CI NN B-NP O
37 1663 1664 11679859 ] ) O O
38 1665 1666 11679859 - SYM O O
39 1666 1671 11679859 24.6% CD B-NP O
40 1672 1674 11679859 to TO B-PP O
41 1675 1680 11679859 11.2% CD B-NP O
42 1680 1681 11679859 ) ) O O
43 1681 1682 11679859 . . O O

1 1683 1686 11679859 The DT B-NP O
2 1687 1697 11679859 difference NN I-NP O
3 1698 1705 11679859 between IN B-PP O
4 1706 1709 11679859 the DT B-NP O
5 1710 1715 11679859 bolus NN I-NP O
6 1716 1719 11679859 and CC I-NP O
7 1720 1728 11679859 infusion NN I-NP O
8 1729 1735 11679859 groups NNS I-NP O
9 1736 1738 11679859 in IN B-PP O
10 1739 1742 11679859 the DT B-NP O
11 1743 1753 11679859 percentage NN I-NP O
12 1754 1756 11679859 of IN B-PP O
13 1757 1769 11679859 participants NNS B-NP O
14 1770 1773 11679859 who WP B-NP O
15 1774 1777 11679859 saw VBD B-VP O
16 1778 1779 11679859 a DT B-NP O
17 1780 1783 11679859 50% JJ I-NP O
18 1784 1793 11679859 reduction NN I-NP O
19 1794 1796 11679859 in IN B-PP O
20 1797 1802 11679859 their PRP$ B-NP O
21 1803 1811 11679859 headache NN I-NP B-Disease
22 1812 1821 11679859 intensity NN I-NP O
23 1822 1828 11679859 within IN B-PP O
24 1829 1831 11679859 30 CD B-NP O
25 1832 1839 11679859 minutes NNS I-NP O
26 1840 1843 11679859 was VBD B-VP O
27 1844 1849 11679859 11.8% CD B-NP O
28 1850 1851 11679859 ( ( O O
29 1851 1854 11679859 95% CD B-NP O
30 1855 1857 11679859 CI NN I-NP O
31 1858 1859 11679859 - SYM B-NP O
32 1859 1863 11679859 9.6% CD B-NP O
33 1864 1866 11679859 to TO B-PP O
34 1867 1872 11679859 33.3% CD B-NP O
35 1872 1873 11679859 ) ) O O
36 1873 1874 11679859 . . O O

1 1875 1878 11679859 The DT B-NP O
2 1879 1889 11679859 difference NN I-NP O
3 1890 1892 11679859 in IN B-PP O
4 1893 1896 11679859 the DT B-NP O
5 1897 1907 11679859 percentage NN I-NP O
6 1908 1910 11679859 of IN B-PP O
7 1911 1919 11679859 patients NNS B-NP O
8 1920 1924 11679859 with IN B-PP O
9 1925 1926 11679859 a DT B-NP O
10 1927 1930 11679859 50% CD I-NP O
11 1931 1940 11679859 reduction NN I-NP O
12 1941 1943 11679859 in IN B-PP O
13 1944 1949 11679859 their PRP$ B-NP O
14 1950 1956 11679859 nausea NN I-NP B-Disease
15 1957 1960 11679859 was VBD B-VP O
16 1961 1966 11679859 12.6% CD B-NP O
17 1967 1968 11679859 ( ( O O
18 1968 1971 11679859 95% CD B-NP O
19 1972 1974 11679859 CI NN I-NP O
20 1975 1976 11679859 - HYPH O O
21 1976 1980 11679859 4.6% CD B-NP O
22 1981 1983 11679859 to TO B-PP O
23 1984 1989 11679859 29.8% CD B-NP O
24 1989 1990 11679859 ) ) O O
25 1990 1991 11679859 . . O O

1 1992 2002 11679859 CONCLUSION NN B-NP O
2 2002 2003 11679859 : : O O
3 2004 2005 11679859 A DT B-NP O
4 2006 2009 11679859 50% CD I-NP O
5 2010 2019 11679859 reduction NN I-NP O
6 2020 2022 11679859 in IN B-PP O
7 2023 2026 11679859 the DT B-NP O
8 2027 2036 11679859 incidence NN I-NP O
9 2037 2039 11679859 of IN B-PP O
10 2040 2049 11679859 akathisia NN B-NP B-Disease
11 2050 2054 11679859 when WRB B-ADVP O
12 2055 2071 11679859 prochlorperazine NN B-NP B-Chemical
13 2072 2075 11679859 was VBD B-VP O
14 2076 2088 11679859 administered VBN I-VP O
15 2089 2091 11679859 by IN B-PP O
16 2092 2097 11679859 means NNS B-NP O
17 2098 2100 11679859 of IN B-PP O
18 2101 2103 11679859 15 CD B-NP O
19 2103 2104 11679859 - HYPH I-NP O
20 2104 2110 11679859 minute JJ I-NP O
21 2111 2122 11679859 intravenous JJ I-NP O
22 2123 2131 11679859 infusion NN I-NP O
23 2132 2138 11679859 versus IN B-PP O
24 2139 2140 11679859 a DT B-NP O
25 2141 2142 11679859 2 CD I-NP O
26 2142 2143 11679859 - HYPH I-NP O
27 2143 2149 11679859 minute JJ I-NP O
28 2150 2161 11679859 intravenous JJ I-NP O
29 2162 2166 11679859 push NN I-NP O
30 2167 2170 11679859 was VBD B-VP O
31 2171 2174 11679859 not RB I-VP O
32 2175 2183 11679859 detected VBN I-VP O
33 2183 2184 11679859 . . O O

1 2185 2188 11679859 The DT B-NP O
2 2189 2197 11679859 efficacy NN I-NP O
3 2198 2200 11679859 of IN B-PP O
4 2201 2217 11679859 prochlorperazine NN B-NP B-Chemical
5 2218 2220 11679859 in IN B-PP O
6 2221 2224 11679859 the DT B-NP O
7 2225 2234 11679859 treatment NN I-NP O
8 2235 2237 11679859 of IN B-PP O
9 2238 2246 11679859 headache NN B-NP B-Disease
10 2247 2250 11679859 and CC I-NP O
11 2251 2257 11679859 nausea NN I-NP B-Disease
12 2258 2266 11679859 likewise RB B-ADVP O
13 2267 2270 11679859 did VBD B-VP O
14 2271 2274 11679859 not RB I-VP O
15 2275 2281 11679859 appear VB I-VP O
16 2282 2284 11679859 to TO I-VP O
17 2285 2287 11679859 be VB I-VP O
18 2288 2296 11679859 affected VBN I-VP O
19 2297 2299 11679859 by IN B-PP O
20 2300 2303 11679859 the DT B-NP O
21 2304 2308 11679859 rate NN I-NP O
22 2309 2311 11679859 of IN B-PP O
23 2312 2326 11679859 administration NN B-NP O
24 2326 2327 11679859 , , O O
25 2328 2336 11679859 although IN B-SBAR O
26 2337 2339 11679859 no DT B-NP O
27 2340 2346 11679859 formal JJ I-NP O
28 2347 2358 11679859 statistical JJ I-NP O
29 2359 2370 11679859 comparisons NNS I-NP O
30 2371 2375 11679859 were VBD B-VP O
31 2376 2380 11679859 made VBN I-VP O
32 2380 2381 11679859 . . O O

1 0 0 15737522 -DOCSTART- -X- -X- O

1 0 11 15737522 Ceftriaxone NN B-NP B-Chemical
2 11 12 15737522 - HYPH O O
3 12 22 15737522 associated VBN B-VP O
4 23 30 15737522 biliary JJ B-NP B-Disease
5 31 46 15737522 pseudolithiasis NN I-NP I-Disease
6 47 49 15737522 in IN B-PP O
7 50 60 15737522 paediatric JJ B-NP O
8 61 69 15737522 surgical JJ I-NP O
9 70 78 15737522 patients NNS I-NP O
10 78 79 15737522 . . O O
11 80 82 15737522 It PRP B-NP O
12 83 85 15737522 is VBZ B-VP O
13 86 90 15737522 well RB I-VP O
14 91 96 15737522 known VBN I-VP O
15 97 101 15737522 that IN B-SBAR O
16 102 113 15737522 ceftriaxone NN B-NP B-Chemical
17 114 119 15737522 leads VBZ B-VP O
18 120 122 15737522 to TO B-PP O
19 123 138 15737522 pseudolithiasis NN B-NP B-Disease
20 139 141 15737522 in IN B-PP O
21 142 146 15737522 some DT B-NP O
22 147 155 15737522 patients NNS I-NP O
23 155 156 15737522 . . O O

1 157 165 15737522 Clinical JJ B-NP O
2 166 169 15737522 and CC I-NP O
3 170 182 15737522 experimental JJ I-NP O
4 183 190 15737522 studies NNS I-NP O
5 191 195 15737522 also RB B-ADVP O
6 196 203 15737522 suggest VBP B-VP O
7 204 208 15737522 that IN B-SBAR O
8 209 219 15737522 situations NNS B-NP O
9 220 227 15737522 causing VBG B-VP O
10 228 239 15737522 gallbladder NN B-NP B-Disease
11 240 251 15737522 dysfunction NN I-NP I-Disease
12 251 252 15737522 , , O O
13 253 257 15737522 such JJ B-PP O
14 258 260 15737522 as IN I-PP O
15 261 268 15737522 fasting VBG B-VP O
16 268 269 15737522 , , O O
17 270 273 15737522 may MD B-VP O
18 274 278 15737522 have VB I-VP O
19 279 280 15737522 a DT B-NP O
20 281 285 15737522 role NN I-NP O
21 286 289 15737522 for IN B-PP O
22 290 293 15737522 the DT B-NP O
23 294 305 15737522 development NN I-NP O
24 306 308 15737522 of IN B-PP O
25 309 324 15737522 pseudolithiasis NN B-NP B-Disease
26 324 325 15737522 . . O O

1 326 328 15737522 In IN B-PP O
2 329 333 15737522 this DT B-NP O
3 334 339 15737522 study NN I-NP O
4 339 340 15737522 , , O O
5 341 343 15737522 we PRP B-NP O
6 344 357 15737522 prospectively RB B-ADVP O
7 358 367 15737522 evaluated VBD B-VP O
8 368 371 15737522 the DT B-NP O
9 372 381 15737522 incidence NN I-NP O
10 382 385 15737522 and CC O O
11 386 394 15737522 clinical JJ B-NP O
12 395 405 15737522 importance NN I-NP O
13 406 408 15737522 of IN B-PP O
14 409 424 15737522 pseudolithiasis NN B-NP B-Disease
15 425 427 15737522 in IN B-PP O
16 428 438 15737522 paediatric JJ B-NP O
17 439 447 15737522 surgical JJ I-NP O
18 448 456 15737522 patients NNS I-NP O
19 457 466 15737522 receiving VBG B-VP O
20 467 478 15737522 ceftriaxone NN B-NP B-Chemical
21 479 488 15737522 treatment NN I-NP O
22 488 489 15737522 , , O O
23 490 493 15737522 who WP B-NP O
24 494 499 15737522 often RB B-ADVP O
25 500 503 15737522 had VBD B-VP O
26 504 506 15737522 to TO I-VP O
27 507 511 15737522 fast VB I-VP O
28 512 514 15737522 in IN B-PP O
29 515 518 15737522 the DT B-NP O
30 519 523 15737522 post AFX I-NP O
31 523 524 15737522 - HYPH I-NP O
32 524 533 15737522 operative JJ I-NP O
33 534 540 15737522 period NN I-NP O
34 540 541 15737522 . . O O

1 542 547 15737522 Fifty CD B-NP O
2 548 556 15737522 children NNS I-NP O
3 557 560 15737522 who WP B-NP O
4 561 565 15737522 were VBD B-VP O
5 566 571 15737522 given VBN I-VP O
6 572 583 15737522 ceftriaxone NN B-NP B-Chemical
7 584 588 15737522 were VBD B-VP O
8 589 598 15737522 evaluated VBN I-VP O
9 599 601 15737522 by IN B-PP O
10 602 608 15737522 serial JJ B-NP O
11 609 618 15737522 abdominal JJ I-NP O
12 619 628 15737522 sonograms NNS I-NP O
13 628 629 15737522 . . O O

1 630 632 15737522 Of IN B-PP O
2 633 638 15737522 those DT B-NP O
3 638 639 15737522 , , O O
4 640 642 15737522 13 CD B-NP O
5 643 644 15737522 ( ( O O
6 644 647 15737522 26% NN B-NP O
7 647 648 15737522 ) ) O O
8 649 658 15737522 developed VBD B-VP O
9 659 666 15737522 biliary JJ B-NP O
10 667 676 15737522 pathology NN I-NP O
11 676 677 15737522 . . O O

1 678 688 15737522 Comparison NN B-NP O
2 689 691 15737522 of IN B-PP O
3 692 695 15737522 the DT B-NP O
4 696 704 15737522 patients NNS I-NP O
5 705 709 15737522 with IN B-PP O
6 710 712 15737522 or CC B-PP O
7 713 720 15737522 without IN B-PP O
8 721 736 15737522 pseudolithiasis NN B-NP B-Disease
9 737 745 15737522 revealed VBD B-VP O
10 746 748 15737522 no DT B-NP O
11 749 760 15737522 significant JJ I-NP O
12 761 771 15737522 difference NN I-NP O
13 772 776 15737522 with IN B-PP O
14 777 784 15737522 respect NN B-NP O
15 785 787 15737522 to TO B-PP O
16 788 791 15737522 age NN B-NP O
17 791 792 15737522 , , O O
18 793 796 15737522 sex NN B-NP O
19 796 797 15737522 , , O O
20 798 806 15737522 duration NN B-NP O
21 807 809 15737522 of IN B-PP O
22 810 813 15737522 the DT B-NP O
23 814 823 15737522 treatment NN I-NP O
24 824 827 15737522 and CC I-NP O
25 828 838 15737522 starvation NN I-NP O
26 839 848 15737522 variables NNS I-NP O
27 848 849 15737522 . . O O

1 850 855 15737522 After IN B-PP O
2 856 865 15737522 cessation NN B-NP O
3 866 868 15737522 of IN B-PP O
4 869 872 15737522 the DT B-NP O
5 873 882 15737522 treatment NN I-NP O
6 882 883 15737522 , , O O
7 884 899 15737522 pseudolithiasis NN B-NP B-Disease
8 900 908 15737522 resolved VBD B-VP O
9 909 922 15737522 spontaneously RB B-ADVP O
10 923 929 15737522 within IN B-PP O
11 930 931 15737522 a DT B-NP O
12 932 937 15737522 short JJ I-NP O
13 938 944 15737522 period NN I-NP O
14 944 945 15737522 . . O O

1 946 949 15737522 The DT B-NP O
2 950 959 15737522 incidence NN I-NP O
3 960 962 15737522 of IN B-PP O
4 963 978 15737522 pseudolithiasis NN B-NP B-Disease
5 979 981 15737522 is VBZ B-VP O
6 982 985 15737522 not RB I-VP O
7 986 994 15737522 affected VBN I-VP O
8 995 997 15737522 by IN B-PP O
9 998 1005 15737522 fasting VBG B-VP O
10 1005 1006 15737522 . . O O

1 0 0 10526274 -DOCSTART- -X- -X- O

1 0 11 10526274 Gemcitabine NN B-NP B-Chemical
2 12 16 10526274 plus CC I-NP O
3 17 28 10526274 vinorelbine NN I-NP B-Chemical
4 29 31 10526274 in IN B-PP O
5 32 40 10526274 nonsmall JJ B-NP B-Disease
6 41 45 10526274 cell NN I-NP I-Disease
7 46 50 10526274 lung NN I-NP I-Disease
8 51 60 10526274 carcinoma NN I-NP I-Disease
9 61 69 10526274 patients NNS I-NP O
10 70 73 10526274 age NN I-NP O
11 74 76 10526274 70 CD B-NP O
12 77 82 10526274 years NNS I-NP O
13 83 85 10526274 or CC O O
14 86 91 10526274 older JJR B-ADJP O
15 92 94 10526274 or CC O O
16 95 103 10526274 patients NNS B-NP O
17 104 107 10526274 who WP B-NP O
18 108 114 10526274 cannot MD B-VP O
19 115 122 10526274 receive VB I-VP O
20 123 132 10526274 cisplatin NN B-NP B-Chemical
21 132 133 10526274 . . O O

1 134 141 10526274 Oncopaz NNP B-NP O
2 142 153 10526274 Cooperative NNP I-NP O
3 154 159 10526274 Group NNP I-NP O
4 159 160 10526274 . . I-NP O
5 161 171 10526274 BACKGROUND NN I-NP O
6 171 172 10526274 : : O O
7 173 181 10526274 Although IN B-SBAR O
8 182 185 10526274 the DT B-NP O
9 186 196 10526274 prevalence NN I-NP O
10 197 199 10526274 of IN B-PP O
11 200 208 10526274 nonsmall JJ B-NP B-Disease
12 209 213 10526274 cell NN I-NP I-Disease
13 214 218 10526274 lung NN I-NP I-Disease
14 219 228 10526274 carcinoma NN I-NP I-Disease
15 229 230 10526274 ( ( O O
16 230 235 10526274 NSCLC NN B-NP B-Disease
17 235 236 10526274 ) ) O O
18 237 239 10526274 is VBZ B-VP O
19 240 244 10526274 high JJ B-ADJP O
20 245 250 10526274 among IN B-PP O
21 251 258 10526274 elderly JJ B-NP O
22 259 267 10526274 patients NNS I-NP O
23 267 268 10526274 , , O O
24 269 272 10526274 few JJ B-NP O
25 273 277 10526274 data NNS I-NP O
26 278 281 10526274 are VBP B-VP O
27 282 291 10526274 available JJ B-ADJP O
28 292 301 10526274 regarding VBG B-VP O
29 302 305 10526274 the DT B-NP O
30 306 314 10526274 efficacy NN I-NP O
31 315 318 10526274 and CC I-NP O
32 319 327 10526274 toxicity NN I-NP B-Disease
33 328 330 10526274 of IN B-PP O
34 331 343 10526274 chemotherapy NN B-NP O
35 344 346 10526274 in IN B-PP O
36 347 351 10526274 this DT B-NP O
37 352 357 10526274 group NN I-NP O
38 358 360 10526274 of IN B-PP O
39 361 369 10526274 patients NNS B-NP O
40 369 370 10526274 . . O O

1 371 377 10526274 Recent JJ B-NP O
2 378 385 10526274 reports NNS I-NP O
3 386 394 10526274 indicate VBP B-VP O
4 395 399 10526274 that IN B-SBAR O
5 400 406 10526274 single JJ B-NP O
6 407 412 10526274 agent NN I-NP O
7 413 420 10526274 therapy NN I-NP O
8 421 425 10526274 with IN B-PP O
9 426 437 10526274 vinorelbine NN B-NP B-Chemical
10 438 439 10526274 ( ( O O
11 439 442 10526274 VNB NN B-NP B-Chemical
12 442 443 10526274 ) ) O O
13 444 446 10526274 or CC O O
14 447 458 10526274 gemcitabine NN B-NP B-Chemical
15 459 460 10526274 ( ( O O
16 460 463 10526274 GEM NN B-NP B-Chemical
17 463 464 10526274 ) ) O O
18 465 468 10526274 may MD B-VP O
19 469 475 10526274 obtain VB I-VP O
20 476 477 10526274 a DT B-NP O
21 478 486 10526274 response NN I-NP O
22 487 491 10526274 rate NN I-NP O
23 492 494 10526274 of IN B-PP O
24 495 497 10526274 20 CD B-NP O
25 497 498 10526274 - HYPH I-NP O
26 498 501 10526274 30% CD I-NP O
27 502 504 10526274 in IN B-PP O
28 505 512 10526274 elderly JJ B-NP O
29 513 521 10526274 patients NNS I-NP O
30 521 522 10526274 , , O O
31 523 527 10526274 with IN B-PP O
32 528 538 10526274 acceptable JJ B-NP O
33 539 547 10526274 toxicity NN I-NP B-Disease
34 548 551 10526274 and CC I-NP O
35 552 563 10526274 improvement NN I-NP O
36 564 566 10526274 in IN B-PP O
37 567 575 10526274 symptoms NNS B-NP O
38 576 579 10526274 and CC O O
39 580 587 10526274 quality NN B-NP O
40 588 590 10526274 of IN B-PP O
41 591 595 10526274 life NN B-NP O
42 595 596 10526274 . . O O

1 597 599 10526274 In IN B-PP O
2 600 603 10526274 the DT B-NP O
3 604 611 10526274 current JJ I-NP O
4 612 617 10526274 study NN I-NP O
5 618 621 10526274 the DT B-NP O
6 622 630 10526274 efficacy NN I-NP O
7 631 634 10526274 and CC I-NP O
8 635 643 10526274 toxicity NN I-NP B-Disease
9 644 646 10526274 of IN B-PP O
10 647 650 10526274 the DT B-NP O
11 651 662 10526274 combination NN I-NP O
12 663 665 10526274 of IN B-PP O
13 666 669 10526274 GEM NN B-NP B-Chemical
14 670 673 10526274 and CC I-NP O
15 674 677 10526274 VNB NN I-NP B-Chemical
16 678 680 10526274 in IN B-PP O
17 681 688 10526274 elderly JJ B-NP O
18 689 697 10526274 patients NNS I-NP O
19 698 702 10526274 with IN B-PP O
20 703 711 10526274 advanced VBN B-NP O
21 712 717 10526274 NSCLC NN I-NP B-Disease
22 718 720 10526274 or CC O O
23 721 726 10526274 those DT B-NP O
24 727 731 10526274 with IN B-PP O
25 732 736 10526274 some DT B-NP O
26 737 753 10526274 contraindication NN I-NP O
27 754 756 10526274 to TO B-PP O
28 757 766 10526274 receiving VBG B-VP O
29 767 776 10526274 cisplatin NN B-NP B-Chemical
30 777 781 10526274 were VBD B-VP O
31 782 790 10526274 assessed VBN I-VP O
32 790 791 10526274 . . O O

1 792 799 10526274 METHODS NNS B-NP O
2 799 800 10526274 : : O O
3 801 806 10526274 Forty CD B-NP O
4 806 807 10526274 - HYPH O O
5 807 811 10526274 nine CD B-NP O
6 812 820 10526274 patients NNS I-NP O
7 821 825 10526274 with IN B-PP O
8 826 834 10526274 advanced VBN B-NP O
9 835 840 10526274 NSCLC NN I-NP B-Disease
10 841 845 10526274 were VBD B-VP O
11 846 854 10526274 included VBN I-VP O
12 854 855 10526274 , , O O
13 856 858 10526274 38 CD B-NP O
14 859 861 10526274 of IN B-PP O
15 862 866 10526274 whom WP B-NP O
16 867 871 10526274 were VBD B-VP O
17 872 875 10526274 age NN I-VP O
18 876 877 10526274 > SYM O O
19 877 878 10526274 / SYM B-NP O
20 878 879 10526274 = SYM B-VP O
21 880 882 10526274 70 CD B-NP O
22 883 888 10526274 years NNS I-NP O
23 889 892 10526274 and CC O O
24 893 895 10526274 11 CD B-NP O
25 896 900 10526274 were VBD B-VP O
26 901 904 10526274 age NN B-NP O
27 905 906 10526274 < SYM O O
28 907 909 10526274 70 CD B-NP O
29 910 915 10526274 years NNS I-NP O
30 916 919 10526274 but CC O O
31 920 923 10526274 who WP B-NP O
32 924 927 10526274 had VBD B-VP O
33 928 932 10526274 some DT B-NP O
34 933 949 10526274 contraindication NN I-NP O
35 950 952 10526274 to TO B-PP O
36 953 962 10526274 receiving VBG B-VP O
37 963 972 10526274 cisplatin NN B-NP B-Chemical
38 972 973 10526274 . . O O

1 974 977 10526274 All DT B-NP O
2 978 986 10526274 patients NNS I-NP O
3 987 991 10526274 were VBD B-VP O
4 992 1001 10526274 evaluable JJ B-ADJP O
5 1002 1005 10526274 for IN B-PP O
6 1006 1014 10526274 response NN B-NP O
7 1015 1018 10526274 and CC I-NP O
8 1019 1027 10526274 toxicity NN I-NP B-Disease
9 1027 1028 10526274 . . O O

1 1029 1038 10526274 Treatment NN B-NP O
2 1039 1042 10526274 was VBD B-VP O
3 1043 1052 10526274 comprised VBN I-VP O
4 1053 1055 10526274 of IN B-PP O
5 1056 1059 10526274 VNB NN B-NP B-Chemical
6 1059 1060 10526274 , , O O
7 1061 1063 10526274 25 CD B-NP O
8 1064 1066 10526274 mg NN I-NP O
9 1066 1067 10526274 / SYM B-NP O
10 1067 1071 10526274 m(2) NN I-NP O
11 1071 1072 10526274 , , O O
12 1073 1077 10526274 plus CC B-PP O
13 1078 1081 10526274 GEM NN B-NP B-Chemical
14 1081 1082 10526274 , , O O
15 1083 1087 10526274 1000 CD B-NP O
16 1088 1090 10526274 mg NN I-NP O
17 1090 1091 10526274 / SYM B-NP O
18 1091 1095 10526274 m(2) NN I-NP O
19 1095 1096 10526274 , , O O
20 1097 1101 10526274 both DT O O
21 1102 1104 10526274 on IN B-PP O
22 1105 1109 10526274 Days NNS B-NP O
23 1110 1111 10526274 1 CD I-NP O
24 1111 1112 10526274 , , I-NP O
25 1113 1114 10526274 8 CD I-NP O
26 1114 1115 10526274 , , O O
27 1116 1119 10526274 and CC O O
28 1120 1122 10526274 15 CD B-NP O
29 1123 1128 10526274 every DT B-NP O
30 1129 1131 10526274 28 CD I-NP O
31 1132 1136 10526274 days NNS I-NP O
32 1136 1137 10526274 . . O O

1 1138 1146 10526274 Patients NNS B-NP O
2 1147 1155 10526274 received VBD B-VP O
3 1156 1157 10526274 a DT B-NP O
4 1158 1165 10526274 minimum NN I-NP O
5 1166 1168 10526274 of IN B-PP O
6 1169 1174 10526274 three CD B-NP O
7 1175 1182 10526274 courses NNS I-NP O
8 1183 1189 10526274 unless IN B-SBAR O
9 1190 1201 10526274 progressive JJ B-NP O
10 1202 1209 10526274 disease NN I-NP O
11 1210 1213 10526274 was VBD B-VP O
12 1214 1222 10526274 detected VBN I-VP O
13 1222 1223 10526274 . . O O

1 1224 1231 10526274 RESULTS NNS B-NP O
2 1231 1232 10526274 : : O O
3 1233 1236 10526274 One CD B-NP O
4 1237 1244 10526274 hundred CD I-NP O
5 1245 1250 10526274 sixty CD I-NP O
6 1250 1251 10526274 - HYPH I-NP O
7 1251 1255 10526274 five CD I-NP O
8 1256 1263 10526274 courses NNS I-NP O
9 1264 1268 10526274 were VBD B-VP O
10 1269 1281 10526274 administered VBN I-VP O
11 1281 1282 10526274 , , O O
12 1283 1287 10526274 with IN B-PP O
13 1288 1289 10526274 a DT B-NP O
14 1290 1296 10526274 median NN I-NP O
15 1297 1299 10526274 of IN B-PP O
16 1300 1301 10526274 3 CD B-NP O
17 1301 1302 10526274 . . O O
18 1303 1304 10526274 6 CD B-NP O
19 1305 1312 10526274 courses NNS I-NP O
20 1313 1316 10526274 per IN B-PP O
21 1317 1324 10526274 patient NN B-NP O
22 1324 1325 10526274 . . O O

1 1326 1329 10526274 The DT B-NP O
2 1330 1337 10526274 overall JJ I-NP O
3 1338 1346 10526274 response NN I-NP O
4 1347 1351 10526274 rate NN I-NP O
5 1352 1355 10526274 was VBD B-VP O
6 1356 1359 10526274 26% CD B-NP O
7 1360 1361 10526274 ( ( O O
8 1361 1364 10526274 95% CD B-NP O
9 1365 1375 10526274 confidence NN I-NP O
10 1376 1384 10526274 interval NN I-NP O
11 1384 1385 10526274 , , O O
12 1386 1388 10526274 15 CD B-NP O
13 1388 1389 10526274 - HYPH I-NP O
14 1389 1392 10526274 41% CD I-NP O
15 1392 1393 10526274 ) ) O O
16 1393 1394 10526274 . . O O

1 1395 1398 10526274 Two CD B-NP O
2 1399 1407 10526274 patients NNS I-NP O
3 1408 1416 10526274 attained VBD B-VP O
4 1417 1418 10526274 a DT B-NP O
5 1419 1427 10526274 complete JJ I-NP O
6 1428 1436 10526274 response NN I-NP O
7 1437 1438 10526274 ( ( O O
8 1438 1440 10526274 4% NN B-NP O
9 1440 1441 10526274 ) ) O O
10 1442 1445 10526274 and CC O O
11 1446 1448 10526274 11 CD B-NP O
12 1449 1457 10526274 patients NNS I-NP O
13 1458 1459 10526274 ( ( O O
14 1459 1462 10526274 22% NN B-NP O
15 1462 1463 10526274 ) ) O O
16 1464 1472 10526274 achieved VBD B-VP O
17 1473 1474 10526274 a DT B-NP O
18 1475 1482 10526274 partial JJ I-NP O
19 1483 1491 10526274 response NN I-NP O
20 1491 1492 10526274 . . O O

1 1493 1500 10526274 Eastern NNP B-NP O
2 1501 1512 10526274 Cooperative NNP I-NP O
3 1513 1521 10526274 Oncology NNP I-NP O
4 1522 1527 10526274 Group NNP I-NP O
5 1528 1539 10526274 performance NN I-NP O
6 1540 1546 10526274 status NN I-NP O
7 1547 1555 10526274 improved VBN B-VP O
8 1556 1558 10526274 in IN B-PP O
9 1559 1562 10526274 35% CD B-NP O
10 1563 1565 10526274 of IN B-PP O
11 1566 1571 10526274 those DT B-NP O
12 1572 1580 10526274 patients NNS I-NP O
13 1581 1585 10526274 with IN B-PP O
14 1586 1588 10526274 an DT B-NP O
15 1589 1596 10526274 initial JJ I-NP O
16 1597 1602 10526274 value NN I-NP O
17 1603 1604 10526274 > SYM O O
18 1605 1606 10526274 0 CD B-NP O
19 1606 1607 10526274 , , O O
20 1608 1615 10526274 whereas IN O O
21 1616 1622 10526274 relief NN B-NP O
22 1623 1625 10526274 of IN B-PP O
23 1626 1628 10526274 at IN B-NP O
24 1629 1634 10526274 least JJS I-NP O
25 1635 1636 10526274 1 CD I-NP O
26 1637 1644 10526274 symptom NN I-NP O
27 1645 1652 10526274 without IN B-PP O
28 1653 1662 10526274 worsening VBG B-VP O
29 1663 1665 10526274 of IN B-PP O
30 1666 1671 10526274 other JJ B-NP O
31 1672 1680 10526274 symptoms NNS I-NP O
32 1681 1684 10526274 was VBD B-VP O
33 1685 1690 10526274 noted VBN I-VP O
34 1691 1693 10526274 in IN B-PP O
35 1694 1696 10526274 27 CD B-NP O
36 1697 1705 10526274 patients NNS I-NP O
37 1706 1707 10526274 ( ( O O
38 1707 1710 10526274 55% CD B-NP O
39 1710 1711 10526274 ) ) O O
40 1711 1712 10526274 . . O O

1 1713 1716 10526274 The DT B-NP O
2 1717 1723 10526274 median JJ I-NP O
3 1724 1728 10526274 time NN I-NP O
4 1729 1731 10526274 to TO B-PP O
5 1732 1743 10526274 progression NN B-NP O
6 1744 1747 10526274 was VBD B-VP O
7 1748 1750 10526274 16 CD B-NP O
8 1751 1756 10526274 weeks NNS I-NP O
9 1757 1760 10526274 and CC O O
10 1761 1764 10526274 the DT B-NP O
11 1765 1766 10526274 1 CD I-NP O
12 1766 1767 10526274 - HYPH I-NP O
13 1767 1771 10526274 year NN I-NP O
14 1772 1780 10526274 survival NN I-NP O
15 1781 1785 10526274 rate NN I-NP O
16 1786 1789 10526274 was VBD B-VP O
17 1790 1793 10526274 33% CD B-NP O
18 1793 1794 10526274 . . O O

1 1795 1803 10526274 Toxicity NN B-NP B-Disease
2 1804 1807 10526274 was VBD B-VP O
3 1808 1812 10526274 mild JJ B-ADJP O
4 1812 1813 10526274 . . O O

1 1814 1817 10526274 Six CD B-NP O
2 1818 1826 10526274 patients NNS I-NP O
3 1827 1828 10526274 ( ( O O
4 1828 1831 10526274 12% NN B-NP O
5 1831 1832 10526274 ) ) O O
6 1833 1836 10526274 had VBD B-VP O
7 1837 1842 10526274 World NNP B-NP O
8 1843 1849 10526274 Health NNP I-NP O
9 1850 1862 10526274 Organization NNP I-NP O
10 1863 1868 10526274 Grade NNP I-NP O
11 1869 1870 10526274 3 CD I-NP O
12 1870 1871 10526274 - HYPH I-NP O
13 1871 1872 10526274 4 CD I-NP O
14 1873 1884 10526274 neutropenia NN I-NP B-Disease
15 1884 1885 10526274 , , O O
16 1886 1887 10526274 2 CD B-NP O
17 1888 1896 10526274 patients NNS I-NP O
18 1897 1898 10526274 ( ( O O
19 1898 1900 10526274 4% NN B-NP O
20 1900 1901 10526274 ) ) O O
21 1902 1905 10526274 had VBD B-VP O
22 1906 1911 10526274 Grade NN B-NP O
23 1912 1913 10526274 3 CD I-NP O
24 1913 1914 10526274 - HYPH I-NP O
25 1914 1915 10526274 4 CD I-NP O
26 1916 1932 10526274 thrombocytopenia NN I-NP B-Disease
27 1932 1933 10526274 , , O O
28 1934 1937 10526274 and CC O O
29 1938 1939 10526274 2 CD B-NP O
30 1940 1948 10526274 patients NNS I-NP O
31 1949 1950 10526274 ( ( O O
32 1950 1952 10526274 4% NN B-NP O
33 1952 1953 10526274 ) ) O O
34 1954 1957 10526274 had VBD B-VP O
35 1958 1963 10526274 Grade NN B-NP O
36 1964 1965 10526274 3 CD I-NP O
37 1966 1979 10526274 neurotoxicity NN I-NP B-Disease
38 1979 1980 10526274 . . O O

1 1981 1986 10526274 Three CD B-NP O
2 1987 1995 10526274 patients NNS I-NP O
3 1996 2000 10526274 with IN B-PP O
4 2001 2007 10526274 severe JJ B-NP O
5 2008 2019 10526274 neutropenia NN I-NP B-Disease
6 2020 2021 10526274 ( ( O O
7 2021 2023 10526274 6% NN B-NP O
8 2023 2024 10526274 ) ) O O
9 2025 2029 10526274 died VBD B-VP O
10 2030 2032 10526274 of IN B-PP O
11 2033 2039 10526274 sepsis NN B-NP B-Disease
12 2039 2040 10526274 . . O O

1 2041 2044 10526274 The DT B-NP O
2 2045 2051 10526274 median JJ I-NP O
3 2052 2055 10526274 age NN I-NP O
4 2056 2058 10526274 of IN B-PP O
5 2059 2064 10526274 those DT B-NP O
6 2065 2073 10526274 patients NNS I-NP O
7 2074 2084 10526274 developing VBG B-VP O
8 2085 2090 10526274 Grade NN B-NP O
9 2091 2092 10526274 3 CD I-NP O
10 2092 2093 10526274 - HYPH I-NP O
11 2093 2094 10526274 4 CD I-NP O
12 2095 2106 10526274 neutropenia NN I-NP B-Disease
13 2107 2110 10526274 was VBD B-VP O
14 2111 2124 10526274 significantly RB B-ADJP O
15 2125 2131 10526274 higher JJR I-ADJP O
16 2132 2136 10526274 than IN B-PP O
17 2137 2141 10526274 that DT B-NP O
18 2142 2144 10526274 of IN B-PP O
19 2145 2148 10526274 the DT B-NP O
20 2149 2158 10526274 remaining VBG I-NP O
21 2159 2167 10526274 patients NNS I-NP O
22 2168 2169 10526274 ( ( O O
23 2169 2171 10526274 75 CD B-NP O
24 2172 2177 10526274 years NNS I-NP O
25 2178 2180 10526274 vs IN B-ADVP O
26 2180 2181 10526274 . . O O
27 2182 2184 10526274 72 CD B-NP O
28 2185 2190 10526274 years NNS I-NP O
29 2190 2191 10526274 ; : O O
30 2192 2193 10526274 P NN B-NP O
31 2194 2195 10526274 = SYM B-VP O
32 2196 2201 10526274 0.047 CD B-NP O
33 2201 2202 10526274 ) ) O O
34 2202 2203 10526274 . . O O

1 2204 2215 10526274 CONCLUSIONS NNS B-NP O
2 2215 2216 10526274 : : O O
3 2217 2220 10526274 The DT B-NP O
4 2221 2232 10526274 combination NN I-NP O
5 2233 2235 10526274 of IN B-PP O
6 2236 2239 10526274 GEM NN B-NP B-Chemical
7 2240 2243 10526274 and CC I-NP O
8 2244 2247 10526274 VNB NN I-NP B-Chemical
9 2248 2250 10526274 is VBZ B-VP O
10 2251 2261 10526274 moderately RB B-ADJP O
11 2262 2268 10526274 active JJ I-ADJP O
12 2269 2272 10526274 and CC O O
13 2273 2277 10526274 well RB B-VP O
14 2278 2287 10526274 tolerated VBN I-VP O
15 2288 2294 10526274 except IN B-PP O
16 2295 2297 10526274 in IN B-PP O
17 2298 2306 10526274 patients NNS B-NP O
18 2307 2310 10526274 age NN I-NP O
19 2311 2312 10526274 > SYM O O
20 2312 2313 10526274 / SYM B-NP O
21 2313 2314 10526274 = SYM B-VP O
22 2315 2317 10526274 75 CD B-NP O
23 2318 2323 10526274 years NNS I-NP O
24 2323 2324 10526274 . . O O

1 2325 2329 10526274 This DT B-NP O
2 2330 2333 10526274 age NN I-NP O
3 2334 2339 10526274 group NN I-NP O
4 2340 2343 10526274 had VBD B-VP O
5 2344 2346 10526274 an DT B-NP O
6 2347 2356 10526274 increased VBN I-NP O
7 2357 2361 10526274 risk NN I-NP O
8 2362 2364 10526274 of IN B-PP O
9 2365 2381 10526274 myelosuppression NN B-NP B-Disease
10 2381 2382 10526274 . . O O

1 2383 2392 10526274 Therefore RB B-ADVP O
2 2393 2396 10526274 the DT B-NP O
3 2397 2409 10526274 prophylactic JJ I-NP O
4 2410 2413 10526274 use NN I-NP O
5 2414 2416 10526274 of IN B-PP O
6 2417 2428 10526274 granulocyte NN B-NP O
7 2428 2429 10526274 - HYPH B-NP O
8 2429 2435 10526274 colony NN I-NP O
9 2436 2447 10526274 stimulating NN I-NP O
10 2448 2454 10526274 factor NN I-NP O
11 2455 2461 10526274 should MD B-VP O
12 2462 2464 10526274 be VB I-VP O
13 2465 2475 10526274 considered VBN I-VP O
14 2476 2480 10526274 with IN B-PP O
15 2481 2485 10526274 this DT B-NP O
16 2486 2495 10526274 treatment NN I-NP O
17 2495 2496 10526274 . . O O

1 2497 2500 10526274 New JJ B-NP O
2 2501 2513 10526274 chemotherapy NN I-NP O
3 2514 2526 10526274 combinations NNS I-NP O
4 2527 2531 10526274 with IN B-PP O
5 2532 2538 10526274 higher JJR B-NP O
6 2539 2547 10526274 activity NN I-NP O
7 2548 2551 10526274 and CC O O
8 2552 2557 10526274 lower JJR B-NP O
9 2558 2566 10526274 toxicity NN I-NP B-Disease
10 2567 2570 10526274 are VBP B-VP O
11 2571 2577 10526274 needed VBN I-VP O
12 2578 2581 10526274 for IN B-PP O
13 2582 2589 10526274 elderly JJ B-NP O
14 2590 2598 10526274 patients NNS I-NP O
15 2599 2603 10526274 with IN B-PP O
16 2604 2612 10526274 advanced JJ B-NP O
17 2613 2618 10526274 NSCLC NN I-NP B-Disease
18 2618 2619 10526274 . . O O

1 0 0 10737864 -DOCSTART- -X- -X- O

1 0 1 10737864 A DT B-NP O
2 2 15 10737864 developmental JJ I-NP O
3 16 24 10737864 analysis NN I-NP O
4 25 27 10737864 of IN B-PP O
5 28 39 10737864 clonidine's NNS B-NP B-Chemical
6 40 47 10737864 effects NNS I-NP O
7 48 50 10737864 on IN B-PP O
8 51 58 10737864 cardiac JJ B-NP O
9 59 63 10737864 rate NN I-NP O
10 64 67 10737864 and CC I-NP O
11 68 78 10737864 ultrasound NN I-NP O
12 79 89 10737864 production NN I-NP O
13 90 92 10737864 in IN B-PP O
14 93 99 10737864 infant JJ B-NP O
15 100 104 10737864 rats NNS I-NP O
16 104 105 10737864 . . O O
17 106 111 10737864 Under IN B-PP O
18 112 122 10737864 controlled JJ B-NP O
19 123 133 10737864 conditions NNS I-NP O
20 133 134 10737864 , , O O
21 135 141 10737864 infant JJ B-NP O
22 142 146 10737864 rats NNS I-NP O
23 147 151 10737864 emit VBP B-VP O
24 152 162 10737864 ultrasonic JJ B-NP O
25 163 176 10737864 vocalizations NNS I-NP O
26 177 183 10737864 during IN B-PP O
27 184 191 10737864 extreme JJ B-NP O
28 192 196 10737864 cold JJ I-NP O
29 197 205 10737864 exposure NN I-NP O
30 206 209 10737864 and CC B-PP O
31 210 215 10737864 after IN B-PP O
32 216 230 10737864 administration NN B-NP O
33 231 233 10737864 of IN B-PP O
34 234 237 10737864 the DT B-NP O
35 238 246 10737864 alpha(2) NN I-NP O
36 247 259 10737864 adrenoceptor NN I-NP O
37 260 267 10737864 agonist NN I-NP O
38 267 268 10737864 , , O O
39 269 278 10737864 clonidine NN B-NP B-Chemical
40 278 279 10737864 . . O O

1 280 288 10737864 Previous JJ B-NP O
2 289 303 10737864 investigations NNS I-NP O
3 304 308 10737864 have VBP B-VP O
4 309 319 10737864 determined VBN I-VP O
5 320 324 10737864 that IN B-SBAR O
6 324 325 10737864 , , O O
7 326 328 10737864 in IN B-PP O
8 329 337 10737864 response NN I-PP O
9 338 340 10737864 to TO I-PP O
10 341 350 10737864 clonidine NN B-NP B-Chemical
11 350 351 10737864 , , O O
12 352 362 10737864 ultrasound NN B-NP O
13 363 373 10737864 production NN I-NP O
14 374 383 10737864 increases VBZ B-VP O
15 384 391 10737864 through IN B-PP O
16 392 395 10737864 the DT B-NP O
17 396 399 10737864 2nd NN I-NP O
18 399 400 10737864 - HYPH B-NP O
19 400 404 10737864 week NN I-NP O
20 405 415 10737864 postpartum NN I-NP O
21 416 419 10737864 and CC O O
22 420 429 10737864 decreases VBZ B-VP O
23 430 440 10737864 thereafter RB B-ADVP O
24 440 441 10737864 . . O O

1 442 447 10737864 Given VBN B-VP O
2 448 452 10737864 that IN B-SBAR O
3 453 464 10737864 sympathetic JJ B-NP O
4 465 471 10737864 neural JJ I-NP O
5 472 481 10737864 dominance NN I-NP O
6 482 490 10737864 exhibits VBZ B-VP O
7 491 492 10737864 a DT B-NP O
8 493 500 10737864 similar JJ I-NP O
9 501 514 10737864 developmental JJ I-NP O
10 515 522 10737864 pattern NN I-NP O
11 522 523 10737864 , , O O
12 524 527 10737864 and CC O O
13 528 533 10737864 given VBN B-VP O
14 534 538 10737864 that IN B-SBAR O
15 539 548 10737864 clonidine NN B-NP B-Chemical
16 549 556 10737864 induces VBZ B-VP O
17 557 568 10737864 sympathetic JJ B-NP O
18 569 579 10737864 withdrawal NN I-NP O
19 580 583 10737864 and CC I-NP O
20 584 595 10737864 bradycardia NN I-NP B-Disease
21 595 596 10737864 , , O O
22 597 599 10737864 we PRP B-NP O
23 600 612 10737864 hypothesized VBD B-VP O
24 613 617 10737864 that IN B-SBAR O
25 618 629 10737864 clonidine's NNS B-NP B-Chemical
26 630 643 10737864 developmental JJ B-NP O
27 644 651 10737864 effects NNS I-NP O
28 652 654 10737864 on IN B-PP O
29 655 662 10737864 cardiac JJ B-NP O
30 663 667 10737864 rate NN I-NP O
31 668 671 10737864 and CC I-NP O
32 672 682 10737864 ultrasound NN I-NP O
33 683 693 10737864 production NN I-NP O
34 694 699 10737864 would MD B-VP O
35 700 706 10737864 mirror VB I-VP O
36 707 711 10737864 each DT B-NP O
37 712 717 10737864 other JJ I-NP O
38 717 718 10737864 . . O O

1 719 728 10737864 Therefore RB B-ADVP O
2 728 729 10737864 , , O O
3 730 732 10737864 in IN B-PP O
4 733 736 10737864 the DT B-NP O
5 737 744 10737864 present JJ I-NP O
6 745 755 10737864 experiment NN I-NP O
7 755 756 10737864 , , O O
8 757 760 10737864 the DT B-NP O
9 761 768 10737864 effects NNS I-NP O
10 769 771 10737864 of IN B-PP O
11 772 781 10737864 clonidine NN B-NP B-Chemical
12 782 796 10737864 administration NN I-NP O
13 797 798 10737864 ( ( O O
14 798 801 10737864 0.5 CD B-NP O
15 802 804 10737864 mg NN I-NP O
16 804 805 10737864 / SYM B-NP O
17 805 807 10737864 kg NN I-NP O
18 807 808 10737864 ) ) O O
19 809 811 10737864 on IN B-PP O
20 812 819 10737864 cardiac JJ B-NP O
21 820 824 10737864 rate NN I-NP O
22 825 828 10737864 and CC I-NP O
23 829 839 10737864 ultrasound NN I-NP O
24 840 850 10737864 production NN I-NP O
25 851 855 10737864 were VBD B-VP O
26 856 864 10737864 examined VBN I-VP O
27 865 867 10737864 in IN B-PP O
28 868 869 10737864 2 CD B-NP O
29 869 870 10737864 - HYPH B-ADJP O
30 870 871 10737864 , , O O
31 872 873 10737864 8 CD B-NP O
32 873 874 10737864 - HYPH I-NP O
33 874 875 10737864 , , O O
34 876 878 10737864 15 CD B-NP O
35 878 879 10737864 - HYPH I-NP O
36 879 880 10737864 , , O O
37 881 884 10737864 and CC O O
38 885 887 10737864 20 CD B-NP O
39 887 888 10737864 - HYPH I-NP O
40 888 891 10737864 day NN I-NP O
41 891 892 10737864 - HYPH O O
42 892 895 10737864 old JJ B-NP O
43 896 900 10737864 rats NNS I-NP O
44 900 901 10737864 . . O O

1 902 905 10737864 Age NN B-NP O
2 905 906 10737864 - HYPH B-NP O
3 906 913 10737864 related VBN I-NP O
4 914 921 10737864 changes NNS I-NP O
5 922 924 10737864 in IN B-PP O
6 925 935 10737864 ultrasound JJ B-NP O
7 936 946 10737864 production NN I-NP O
8 947 959 10737864 corresponded VBD B-VP O
9 960 964 10737864 with IN B-PP O
10 965 972 10737864 changes NNS B-NP O
11 973 975 10737864 in IN B-PP O
12 976 990 10737864 cardiovascular JJ B-NP O
13 991 1000 10737864 variables NNS I-NP O
14 1000 1001 10737864 , , O O
15 1002 1011 10737864 including VBG B-PP O
16 1012 1020 10737864 baseline NN B-NP O
17 1021 1028 10737864 cardiac JJ I-NP O
18 1029 1033 10737864 rate NN I-NP O
19 1034 1037 10737864 and CC I-NP O
20 1038 1047 10737864 clonidine NN I-NP B-Chemical
21 1047 1048 10737864 - HYPH B-NP O
22 1048 1055 10737864 induced VBN I-NP O
23 1056 1067 10737864 bradycardia NN I-NP B-Disease
24 1067 1068 10737864 . . O O

1 1069 1073 10737864 This DT B-NP O
2 1074 1084 10737864 experiment NN I-NP O
3 1085 1087 10737864 is VBZ B-VP O
4 1088 1097 10737864 discussed VBN I-VP O
5 1098 1102 10737864 with IN B-PP O
6 1103 1109 10737864 regard NN B-NP O
7 1110 1112 10737864 to TO B-PP O
8 1113 1116 10737864 the DT B-NP O
9 1117 1127 10737864 hypothesis NN I-NP O
10 1128 1132 10737864 that IN B-SBAR O
11 1133 1143 10737864 ultrasound JJ B-NP O
12 1144 1154 10737864 production NN I-NP O
13 1155 1157 10737864 is VBZ B-VP O
14 1158 1161 10737864 the DT B-NP O
15 1162 1170 10737864 acoustic NN I-NP O
16 1171 1173 10737864 by IN B-PP O
17 1173 1174 10737864 - HYPH B-NP O
18 1174 1181 10737864 product NN I-NP O
19 1182 1184 10737864 of IN B-PP O
20 1185 1186 10737864 a DT B-NP O
21 1187 1200 10737864 physiological JJ I-NP O
22 1201 1209 10737864 maneuver NN I-NP O
23 1210 1214 10737864 that WDT B-NP O
24 1215 1226 10737864 compensates VBZ B-VP O
25 1227 1230 10737864 for IN B-PP O
26 1231 1242 10737864 clonidine's NNS B-NP B-Chemical
27 1243 1254 10737864 detrimental JJ B-NP O
28 1255 1262 10737864 effects NNS I-NP O
29 1263 1265 10737864 on IN B-PP O
30 1266 1280 10737864 cardiovascular JJ B-NP O
31 1281 1289 10737864 function NN I-NP O
32 1289 1290 10737864 . . O O

1 0 0 322550 -DOCSTART- -X- -X- O

1 0 9 322550 Pulmonary JJ B-NP O
2 10 15 322550 shunt NN I-NP O
3 16 19 322550 and CC O O
4 20 34 322550 cardiovascular JJ B-NP O
5 35 44 322550 responses NNS I-NP O
6 45 47 322550 to TO B-PP O
7 48 52 322550 CPAP NN B-NP O
8 53 59 322550 during IN B-PP O
9 60 73 322550 nitroprusside NN B-NP B-Chemical
10 73 74 322550 - HYPH B-NP O
11 74 81 322550 induced VBN I-NP O
12 82 93 322550 hypotension NN I-NP B-Disease
13 93 94 322550 . . O O
14 95 98 322550 The DT B-NP O
15 99 106 322550 effects NNS I-NP O
16 107 109 322550 of IN B-PP O
17 110 120 322550 continuous JJ B-NP O
18 121 129 322550 positive JJ I-NP O
19 130 136 322550 airway NN I-NP O
20 137 145 322550 pressure NN I-NP O
21 146 147 322550 ( ( O O
22 147 151 322550 CPAP NN B-NP O
23 151 152 322550 ) ) O O
24 153 155 322550 on IN B-PP O
25 156 170 322550 cardiovascular JJ B-NP O
26 171 179 322550 dynamics NNS I-NP O
27 180 183 322550 and CC O O
28 184 193 322550 pulmonary JJ B-NP O
29 194 199 322550 shunt NN I-NP O
30 200 201 322550 ( ( O O
31 201 203 322550 QS NN B-NP O
32 203 204 322550 / SYM B-NP O
33 204 206 322550 QT NN I-NP O
34 206 207 322550 ) ) O O
35 208 212 322550 were VBD B-VP O
36 213 225 322550 investigated VBN I-VP O
37 226 228 322550 in IN B-PP O
38 229 231 322550 12 CD B-NP O
39 232 236 322550 dogs NNS I-NP O
40 237 243 322550 before IN B-PP O
41 244 247 322550 and CC I-PP O
42 248 254 322550 during IN I-PP O
43 255 261 322550 sodium NN B-NP B-Chemical
44 262 275 322550 nitroprusside NN I-NP I-Chemical
45 276 284 322550 infusion NN I-NP O
46 285 289 322550 that WDT B-NP O
47 290 299 322550 decreased VBD B-VP O
48 300 304 322550 mean JJ B-NP O
49 305 313 322550 arterial JJ I-NP O
50 314 319 322550 blood NN I-NP O
51 320 328 322550 pressure NN I-NP O
52 329 331 322550 40 CD I-NP O
53 331 332 322550 - HYPH I-NP O
54 332 334 322550 50 CD I-NP O
55 335 338 322550 per IN B-PP O
56 339 343 322550 cent NN B-NP O
57 343 344 322550 . . O O

1 345 351 322550 Before IN B-PP O
2 352 365 322550 nitroprusside NN B-NP B-Chemical
3 366 374 322550 infusion NN I-NP O
4 374 375 322550 , , O O
5 376 377 322550 5 CD B-NP O
6 378 380 322550 cm NN I-NP O
7 381 384 322550 H2O NN I-NP B-Chemical
8 385 389 322550 CPAP NN I-NP O
9 390 403 322550 significantly RB B-ADVP O
10 403 404 322550 , , O O
11 405 406 322550 P NN B-NP O
12 407 411 322550 less JJR B-ADJP O
13 412 416 322550 than IN B-PP O
14 417 420 322550 .05 CD B-NP O
15 420 421 322550 , , O O
16 422 431 322550 decreased VBD B-VP O
17 432 440 322550 arterial JJ B-NP O
18 441 446 322550 blood NN I-NP O
19 447 455 322550 pressure NN I-NP O
20 455 456 322550 , , O O
21 457 460 322550 but CC O O
22 461 464 322550 did VBD B-VP O
23 465 468 322550 not RB I-VP O
24 469 482 322550 significantly RB I-VP O
25 483 488 322550 alter VB I-VP O
26 489 494 322550 heart NN B-NP O
27 495 499 322550 rate NN I-NP O
28 499 500 322550 , , O O
29 501 508 322550 cardiac JJ B-NP O
30 509 515 322550 output NN I-NP O
31 515 516 322550 , , O O
32 517 525 322550 systemic JJ B-NP O
33 526 534 322550 vascular JJ I-NP O
34 535 545 322550 resistance NN I-NP O
35 545 546 322550 , , O O
36 547 549 322550 or CC O O
37 550 552 322550 QS NN B-NP O
38 552 553 322550 / SYM B-NP O
39 553 555 322550 QT NN I-NP O
40 555 556 322550 . . O O

1 557 560 322550 Ten CD B-NP O
2 561 563 322550 cm NN I-NP O
3 564 567 322550 H2O NN I-NP B-Chemical
4 568 572 322550 CPAP NN I-NP O
5 573 579 322550 before IN B-PP O
6 580 593 322550 nitroprusside NN B-NP B-Chemical
7 594 602 322550 infusion NN I-NP O
8 603 611 322550 produced VBD B-VP O
9 612 613 322550 a DT B-NP O
10 614 621 322550 further JJ I-NP O
11 622 630 322550 decrease NN I-NP B-Disease
12 631 633 322550 in IN B-PP I-Disease
13 634 642 322550 arterial JJ B-NP I-Disease
14 643 648 322550 blood NN I-NP I-Disease
15 649 657 322550 pressure NN I-NP I-Disease
16 658 661 322550 and CC O O
17 662 675 322550 significantly RB B-VP O
18 676 685 322550 increased VBD I-VP O
19 686 691 322550 heart NN B-NP O
20 692 696 322550 rate NN I-NP O
21 697 700 322550 and CC O O
22 701 710 322550 decreased VBD B-VP B-Disease
23 711 718 322550 cardiac JJ B-NP I-Disease
24 719 725 322550 output NN I-NP I-Disease
25 726 729 322550 and CC I-NP O
26 730 732 322550 QS NN I-NP O
27 732 733 322550 / SYM B-NP O
28 733 735 322550 QT NN I-NP O
29 735 736 322550 . . O O

1 737 750 322550 Nitroprusside NNP B-NP B-Chemical
2 751 757 322550 caused VBD B-VP O
3 758 769 322550 significant JJ B-NP O
4 770 779 322550 decreases NNS I-NP B-Disease
5 780 782 322550 in IN B-PP I-Disease
6 783 791 322550 arterial JJ B-NP I-Disease
7 792 797 322550 blood NN I-NP I-Disease
8 798 806 322550 pressure NN I-NP I-Disease
9 807 810 322550 and CC O O
10 811 819 322550 systemic JJ B-NP O
11 820 828 322550 vascular JJ I-NP O
12 829 839 322550 resistance NN I-NP O
13 840 843 322550 and CC I-NP O
14 844 853 322550 increases NNS I-NP O
15 854 856 322550 in IN B-PP O
16 857 862 322550 heart NN B-NP O
17 863 867 322550 rate NN I-NP O
18 867 868 322550 , , O O
19 869 872 322550 but CC O O
20 873 876 322550 did VBD B-VP O
21 877 880 322550 not RB I-VP O
22 881 887 322550 change VB I-VP O
23 888 895 322550 cardiac JJ B-NP O
24 896 902 322550 output NN I-NP O
25 903 905 322550 or CC I-NP O
26 906 908 322550 QS NN I-NP O
27 908 909 322550 / SYM B-NP O
28 909 911 322550 QT NN I-NP O
29 911 912 322550 . . O O

1 913 917 322550 Five CD B-NP O
2 918 920 322550 cm NN I-NP O
3 921 924 322550 H2O NN I-NP B-Chemical
4 925 929 322550 CPAP NN I-NP O
5 930 936 322550 during IN B-PP O
6 937 950 322550 nitroprusside NN B-NP B-Chemical
7 951 954 322550 did VBD B-VP O
8 955 958 322550 not RB I-VP O
9 959 966 322550 further RBR I-VP O
10 967 972 322550 alter VB I-VP O
11 973 976 322550 any DT B-NP O
12 977 979 322550 of IN B-PP O
13 980 983 322550 the DT B-NP O
14 984 989 322550 above RB I-NP O
15 989 990 322550 - HYPH I-NP O
16 990 999 322550 mentioned VBN I-NP O
17 1000 1009 322550 variables NNS I-NP O
18 1009 1010 322550 . . O O

1 1011 1018 322550 However RB B-ADVP O
2 1018 1019 322550 , , O O
3 1020 1022 322550 10 CD B-NP O
4 1023 1025 322550 cm NN I-NP O
5 1026 1029 322550 H2O NN I-NP B-Chemical
6 1030 1034 322550 CPAP NN I-NP O
7 1035 1044 322550 decreased VBD B-VP O
8 1045 1053 322550 arterial JJ B-NP O
9 1054 1059 322550 blood NN I-NP O
10 1060 1068 322550 pressure NN I-NP O
11 1068 1069 322550 , , O O
12 1070 1077 322550 cardiac JJ B-NP O
13 1078 1084 322550 output NN I-NP O
14 1084 1085 322550 , , O O
15 1086 1089 322550 and CC O O
16 1090 1092 322550 QS NN B-NP O
17 1092 1093 322550 / SYM B-NP O
18 1093 1095 322550 QT NN I-NP O
19 1095 1096 322550 . . O O

1 1097 1102 322550 These DT B-NP O
2 1103 1107 322550 data NNS I-NP O
3 1108 1116 322550 indicate VBP B-VP O
4 1117 1121 322550 that IN B-SBAR O
5 1122 1135 322550 nitroprusside NN B-NP B-Chemical
6 1136 1144 322550 infusion NN I-NP O
7 1145 1150 322550 rates NNS I-NP O
8 1151 1155 322550 that WDT B-NP O
9 1156 1164 322550 decrease VBP B-VP O
10 1165 1169 322550 mean JJ B-NP O
11 1170 1178 322550 arterial JJ I-NP O
12 1179 1184 322550 blood NN I-NP O
13 1185 1193 322550 pressure NN I-NP O
14 1194 1196 322550 by IN B-PP O
15 1197 1199 322550 40 CD B-NP O
16 1199 1200 322550 - HYPH I-NP O
17 1200 1202 322550 50 CD I-NP O
18 1203 1206 322550 per IN B-PP O
19 1207 1211 322550 cent NN B-NP O
20 1212 1214 322550 do VBP B-VP O
21 1215 1218 322550 not RB I-VP O
22 1219 1225 322550 change VB I-VP O
23 1226 1233 322550 cardiac JJ B-NP O
24 1234 1240 322550 output NN I-NP O
25 1241 1243 322550 or CC I-NP O
26 1244 1246 322550 QS NN I-NP O
27 1246 1247 322550 / SYM B-NP O
28 1247 1249 322550 QT NN I-NP O
29 1249 1250 322550 . . O O

1 1251 1257 322550 During IN B-PP O
2 1258 1271 322550 nitroprusside NN B-NP B-Chemical
3 1272 1280 322550 infusion NN I-NP O
4 1281 1284 322550 low JJ I-NP O
5 1285 1291 322550 levels NNS I-NP O
6 1292 1294 322550 of IN B-PP O
7 1295 1299 322550 CPAP NN B-NP O
8 1300 1302 322550 do VBP B-VP O
9 1303 1306 322550 not RB I-VP O
10 1307 1315 322550 markedly RB I-VP O
11 1316 1321 322550 alter VB I-VP O
12 1322 1336 322550 cardiovascular JJ B-NP O
13 1337 1345 322550 dynamics NNS I-NP O
14 1345 1346 322550 , , O O
15 1347 1350 322550 but CC O O
16 1351 1355 322550 high JJ B-NP O
17 1356 1362 322550 levels NNS I-NP O
18 1363 1365 322550 of IN B-PP O
19 1366 1370 322550 CPAP NN B-NP O
20 1371 1372 322550 ( ( O O
21 1372 1374 322550 10 CD B-NP O
22 1375 1377 322550 cm NN I-NP O
23 1378 1381 322550 H2O NN I-NP B-Chemical
24 1381 1382 322550 ) ) O O
25 1382 1383 322550 , , O O
26 1384 1389 322550 while IN B-SBAR O
27 1390 1400 322550 decreasing VBG B-VP O
28 1401 1403 322550 QS NN B-NP O
29 1403 1404 322550 / SYM B-NP O
30 1404 1406 322550 QT NN I-NP O
31 1406 1407 322550 , , O O
32 1408 1415 322550 produce VBP B-VP O
33 1416 1422 322550 marked JJ B-NP O
34 1423 1432 322550 decreases NNS I-NP B-Disease
35 1433 1435 322550 in IN B-PP I-Disease
36 1436 1444 322550 arterial JJ B-NP I-Disease
37 1445 1450 322550 blood NN I-NP I-Disease
38 1451 1459 322550 pressure NN I-NP I-Disease
39 1460 1463 322550 and CC O I-Disease
40 1464 1471 322550 cardiac JJ B-NP I-Disease
41 1472 1478 322550 output NN I-NP I-Disease
42 1478 1479 322550 . . O O

1 0 0 20067456 -DOCSTART- -X- -X- O

1 0 3 20067456 The DT B-NP O
2 4 11 20067456 effects NNS I-NP O
3 12 14 20067456 of IN B-PP O
4 15 18 20067456 the DT B-NP O
5 19 29 20067456 adjunctive JJ I-NP O
6 30 39 20067456 bupropion NN I-NP B-Chemical
7 40 42 20067456 on IN B-PP O
8 43 47 20067456 male JJ B-NP O
9 48 54 20067456 sexual JJ I-NP B-Disease
10 55 66 20067456 dysfunction NN I-NP I-Disease
11 67 74 20067456 induced VBN B-VP O
12 75 77 20067456 by IN B-PP O
13 78 79 20067456 a DT B-NP O
14 80 89 20067456 selective JJ I-NP B-Chemical
15 90 99 20067456 serotonin NN I-NP I-Chemical
16 100 108 20067456 reuptake NN I-NP I-Chemical
17 109 118 20067456 inhibitor NN I-NP I-Chemical
18 118 119 20067456 : : O O
19 120 121 20067456 a DT B-NP O
20 122 128 20067456 double JJ I-NP O
21 128 129 20067456 - HYPH I-NP O
22 129 134 20067456 blind JJ I-NP O
23 135 142 20067456 placebo NN I-NP O
24 142 143 20067456 - HYPH B-NP O
25 143 153 20067456 controlled VBN I-NP O
26 154 157 20067456 and CC I-NP O
27 158 168 20067456 randomized VBN I-NP O
28 169 174 20067456 study NN I-NP O
29 174 175 20067456 . . I-NP O
30 176 185 20067456 OBJECTIVE NN I-NP O
31 185 186 20067456 : : O O
32 187 189 20067456 To TO B-VP O
33 190 199 20067456 determine VB I-VP O
34 200 203 20067456 the DT B-NP O
35 204 210 20067456 safety NN I-NP O
36 211 214 20067456 and CC I-NP O
37 215 223 20067456 efficacy NN I-NP O
38 224 226 20067456 of IN B-PP O
39 227 237 20067456 adjunctive JJ B-NP O
40 238 247 20067456 bupropion NN I-NP B-Chemical
41 248 257 20067456 sustained VBN B-VP O
42 257 258 20067456 - HYPH B-NP O
43 258 265 20067456 release NN I-NP O
44 266 267 20067456 ( ( O O
45 267 269 20067456 SR NN B-NP O
46 269 270 20067456 ) ) O O
47 271 273 20067456 on IN B-PP O
48 274 278 20067456 male JJ B-NP O
49 279 285 20067456 sexual JJ I-NP B-Disease
50 286 297 20067456 dysfunction NN I-NP I-Disease
51 298 299 20067456 ( ( O O
52 299 301 20067456 SD NN B-NP B-Disease
53 301 302 20067456 ) ) O O
54 303 310 20067456 induced VBN B-VP O
55 311 313 20067456 by IN B-PP O
56 314 315 20067456 a DT B-NP O
57 316 325 20067456 selective JJ I-NP B-Chemical
58 326 335 20067456 serotonin NN I-NP I-Chemical
59 336 344 20067456 reuptake NN I-NP I-Chemical
60 345 354 20067456 inhibitor NN I-NP I-Chemical
61 355 356 20067456 ( ( O O
62 356 360 20067456 SSRI NN B-NP B-Chemical
63 360 361 20067456 ) ) O O
64 361 362 20067456 , , O O
65 363 365 20067456 as IN B-SBAR O
66 366 368 20067456 SD NN B-NP B-Disease
67 369 371 20067456 is VBZ B-VP O
68 372 373 20067456 a DT B-NP O
69 374 380 20067456 common JJ I-NP O
70 381 385 20067456 side NN I-NP O
71 385 386 20067456 - HYPH B-NP O
72 386 392 20067456 effect NN I-NP O
73 393 395 20067456 of IN B-PP O
74 396 401 20067456 SSRIs NNS B-NP B-Chemical
75 402 405 20067456 and CC O O
76 406 409 20067456 the DT B-NP O
77 410 414 20067456 most RBS I-NP O
78 415 424 20067456 effective JJ I-NP O
79 425 435 20067456 treatments NNS I-NP O
80 436 440 20067456 have VBP B-VP O
81 441 444 20067456 yet RB I-VP O
82 445 447 20067456 to TO I-VP O
83 448 450 20067456 be VB I-VP O
84 451 461 20067456 determined VBN I-VP O
85 461 462 20067456 . . O O

1 463 471 20067456 PATIENTS NNS B-NP O
2 472 475 20067456 AND CC I-NP O
3 476 483 20067456 METHODS NNS I-NP O
4 483 484 20067456 : : O O
5 485 488 20067456 The DT B-NP O
6 489 499 20067456 randomized VBN I-NP O
7 500 506 20067456 sample NN I-NP O
8 507 516 20067456 consisted VBD B-VP O
9 517 519 20067456 of IN B-PP O
10 520 523 20067456 234 CD B-NP O
11 524 532 20067456 euthymic JJ I-NP O
12 533 536 20067456 men NNS I-NP O
13 537 540 20067456 who WP B-NP O
14 541 545 20067456 were VBD B-VP O
15 546 555 20067456 receiving VBG I-VP O
16 556 560 20067456 some DT B-NP O
17 561 565 20067456 type NN I-NP O
18 566 568 20067456 of IN B-PP O
19 569 573 20067456 SSRI NN B-NP B-Chemical
20 573 574 20067456 . . O O

1 575 578 20067456 The DT B-NP O
2 579 582 20067456 men NNS I-NP O
3 583 587 20067456 were VBD B-VP O
4 588 596 20067456 randomly RB I-VP O
5 597 605 20067456 assigned VBN I-VP O
6 606 608 20067456 to TO B-PP O
7 609 618 20067456 bupropion NN B-NP B-Chemical
8 619 621 20067456 SR NN I-NP O
9 622 623 20067456 ( ( O O
10 623 626 20067456 150 CD B-NP O
11 627 629 20067456 mg NN I-NP O
12 630 635 20067456 twice RB B-ADVP O
13 636 641 20067456 daily RB I-ADVP O
14 641 642 20067456 , , O O
15 643 646 20067456 117 CD B-NP O
16 646 647 20067456 ) ) O O
17 648 650 20067456 or CC O O
18 651 658 20067456 placebo NN B-NP O
19 659 660 20067456 ( ( O O
20 660 665 20067456 twice RB B-ADVP O
21 666 671 20067456 daily RB B-ADVP O
22 671 672 20067456 , , O O
23 673 676 20067456 117 CD B-NP O
24 676 677 20067456 ) ) O O
25 678 681 20067456 for IN B-PP O
26 682 684 20067456 12 CD B-NP O
27 685 690 20067456 weeks NNS I-NP O
28 690 691 20067456 . . O O

1 692 700 20067456 Efficacy NN B-NP O
2 701 704 20067456 was VBD B-VP O
3 705 714 20067456 evaluated VBN I-VP O
4 715 720 20067456 using VBG B-VP O
5 721 724 20067456 the DT B-NP O
6 725 733 20067456 Clinical JJ I-NP O
7 734 740 20067456 Global NNP I-NP O
8 741 751 20067456 Impression NN I-NP O
9 751 752 20067456 - HYPH B-NP O
10 752 758 20067456 Sexual JJ I-NP O
11 759 767 20067456 Function NN I-NP O
12 768 769 20067456 ( ( O O
13 769 772 20067456 CGI NN B-NP O
14 772 773 20067456 - HYPH B-NP O
15 773 775 20067456 SF NN I-NP O
16 775 776 20067456 ; : O O
17 777 780 20067456 the DT B-NP O
18 781 788 20067456 primary JJ I-NP O
19 789 796 20067456 outcome NN I-NP O
20 797 804 20067456 measure NN I-NP O
21 804 805 20067456 ) ) O O
22 805 806 20067456 , , O O
23 807 810 20067456 the DT B-NP O
24 811 824 20067456 International NNP I-NP O
25 825 830 20067456 Index NNP I-NP O
26 831 833 20067456 of IN B-PP O
27 834 842 20067456 Erectile NNP B-NP O
28 843 851 20067456 Function NNP I-NP O
29 852 853 20067456 ( ( O O
30 853 857 20067456 IIEF NN B-NP O
31 857 858 20067456 ) ) O O
32 858 859 20067456 , , O O
33 860 867 20067456 Arizona NNP B-NP O
34 868 874 20067456 Sexual NNP I-NP O
35 875 885 20067456 Experience NNP I-NP O
36 886 891 20067456 Scale NNP I-NP O
37 892 893 20067456 ( ( O O
38 893 897 20067456 ASEX NNP B-NP O
39 897 898 20067456 ) ) O O
40 898 899 20067456 , , O O
41 900 903 20067456 and CC O O
42 904 912 20067456 Erectile JJ B-NP B-Disease
43 913 924 20067456 Dysfunction NN I-NP I-Disease
44 925 934 20067456 Inventory NN I-NP O
45 935 937 20067456 of IN B-PP O
46 938 947 20067456 Treatment NN B-NP O
47 948 960 20067456 Satisfaction NN I-NP O
48 961 962 20067456 ( ( O O
49 962 967 20067456 EDITS NN B-NP O
50 967 968 20067456 ) ) O O
51 969 970 20067456 ( ( O O
52 970 979 20067456 secondary JJ B-NP O
53 980 987 20067456 outcome NN I-NP O
54 988 996 20067456 measures NNS I-NP O
55 996 997 20067456 ) ) O O
56 997 998 20067456 . . O O

1 999 1011 20067456 Participants NNS B-NP O
2 1012 1016 20067456 were VBD B-VP O
3 1017 1025 20067456 followed VBN I-VP O
4 1026 1034 20067456 biweekly RB B-ADVP O
5 1035 1041 20067456 during IN B-PP O
6 1042 1047 20067456 study NN B-NP O
7 1048 1054 20067456 period NN I-NP O
8 1054 1055 20067456 . . O O

1 1056 1063 20067456 RESULTS NNS B-NP O
2 1063 1064 20067456 : : O O
3 1065 1070 20067456 After IN B-NP O
4 1071 1073 20067456 12 CD I-NP O
5 1074 1079 20067456 weeks NNS I-NP O
6 1080 1082 20067456 of IN B-PP O
7 1083 1092 20067456 treatment NN B-NP O
8 1092 1093 20067456 , , O O
9 1094 1097 20067456 the DT B-NP O
10 1098 1102 20067456 mean JJ I-NP O
11 1103 1104 20067456 ( ( O O
12 1104 1106 20067456 sd JJ B-ADJP O
13 1106 1107 20067456 ) ) O O
14 1108 1114 20067456 scores NNS B-NP O
15 1115 1118 20067456 for IN B-PP O
16 1119 1122 20067456 CGI NN B-NP O
17 1122 1123 20067456 - HYPH B-NP O
18 1123 1125 20067456 SF NN I-NP O
19 1126 1130 20067456 were VBD B-VP O
20 1131 1144 20067456 significantly RB B-ADJP O
21 1145 1150 20067456 lower JJR I-ADJP O
22 1150 1151 20067456 , , O O
23 1152 1156 20067456 i.e. FW B-ADVP O
24 1157 1163 20067456 better RBR I-ADVP O
25 1163 1164 20067456 , , O O
26 1165 1167 20067456 in IN B-PP O
27 1168 1176 20067456 patients NNS B-NP O
28 1177 1179 20067456 on IN B-PP O
29 1180 1189 20067456 bupropion NN B-NP B-Chemical
30 1190 1192 20067456 SR NN I-NP O
31 1192 1193 20067456 , , O O
32 1194 1196 20067456 at IN B-PP O
33 1197 1200 20067456 2.4 CD B-NP O
34 1201 1202 20067456 ( ( O O
35 1202 1205 20067456 1.2 CD B-NP O
36 1205 1206 20067456 ) ) O O
37 1206 1207 20067456 , , O O
38 1208 1212 20067456 than IN B-PP O
39 1213 1215 20067456 in IN B-PP O
40 1216 1219 20067456 the DT B-NP O
41 1220 1227 20067456 placebo NN I-NP O
42 1228 1233 20067456 group NN I-NP O
43 1233 1234 20067456 , , O O
44 1235 1237 20067456 at IN B-PP O
45 1238 1241 20067456 3.9 CD B-NP O
46 1242 1243 20067456 ( ( O O
47 1243 1246 20067456 1.1 CD B-NP O
48 1246 1247 20067456 ) ) O O
49 1248 1249 20067456 ( ( O O
50 1249 1250 20067456 P NN B-NP O
51 1250 1251 20067456 = SYM B-VP O
52 1252 1256 20067456 0.01 CD B-NP O
53 1256 1257 20067456 ) ) O O
54 1257 1258 20067456 . . O O

1 1259 1262 20067456 Men NN B-NP O
2 1263 1266 20067456 who WP B-NP O
3 1267 1275 20067456 received VBD B-VP O
4 1276 1285 20067456 bupropion NN B-NP B-Chemical
5 1286 1289 20067456 had VBD B-VP O
6 1290 1291 20067456 a DT B-NP O
7 1292 1303 20067456 significant JJ I-NP O
8 1304 1312 20067456 increase NN I-NP O
9 1313 1315 20067456 in IN B-PP O
10 1316 1319 20067456 the DT B-NP O
11 1320 1325 20067456 total JJ I-NP O
12 1326 1330 20067456 IIEF NN I-NP O
13 1331 1336 20067456 score NN I-NP O
14 1337 1338 20067456 ( ( O O
15 1338 1343 20067456 54.4% CD B-NP O
16 1344 1346 20067456 vs CC I-NP O
17 1347 1351 20067456 1.2% CD I-NP O
18 1351 1352 20067456 ; : O O
19 1353 1354 20067456 P NN B-NP O
20 1354 1355 20067456 = SYM B-VP O
21 1356 1361 20067456 0.003 CD B-NP O
22 1361 1362 20067456 ) ) O O
23 1362 1363 20067456 , , O O
24 1364 1367 20067456 and CC O O
25 1368 1370 20067456 in IN B-PP O
26 1371 1374 20067456 the DT B-NP O
27 1375 1379 20067456 five CD I-NP O
28 1380 1389 20067456 different JJ I-NP O
29 1390 1397 20067456 domains NNS I-NP O
30 1398 1400 20067456 of IN B-PP O
31 1401 1404 20067456 the DT B-NP O
32 1405 1409 20067456 IIEF NN I-NP O
33 1409 1410 20067456 . . O O

1 1411 1416 20067456 Total JJ B-NP O
2 1417 1421 20067456 ASEX NN I-NP O
3 1422 1428 20067456 scores NNS I-NP O
4 1429 1433 20067456 were VBD B-VP O
5 1434 1447 20067456 significantly RB B-ADJP O
6 1448 1453 20067456 lower JJR I-ADJP O
7 1453 1454 20067456 , , O O
8 1455 1459 20067456 i.e. FW B-ADVP O
9 1460 1466 20067456 better RBR I-ADVP O
10 1466 1467 20067456 , , O O
11 1468 1473 20067456 among IN B-PP O
12 1474 1477 20067456 men NNS B-NP O
13 1478 1481 20067456 who WP B-NP O
14 1482 1490 20067456 received VBD B-VP O
15 1491 1500 20067456 bupropion NN B-NP B-Chemical
16 1501 1505 20067456 than IN B-PP O
17 1506 1513 20067456 placebo NN B-NP O
18 1513 1514 20067456 , , O O
19 1515 1517 20067456 at IN B-PP O
20 1518 1522 20067456 15.5 CD B-NP O
21 1523 1524 20067456 ( ( O O
22 1524 1527 20067456 4.3 CD B-NP O
23 1527 1528 20067456 ) ) O O
24 1529 1531 20067456 vs IN B-PP O
25 1532 1536 20067456 21.5 CD B-NP O
26 1537 1538 20067456 ( ( O O
27 1538 1541 20067456 4.7 CD B-NP O
28 1541 1542 20067456 ) ) O O
29 1543 1544 20067456 ( ( O O
30 1544 1545 20067456 P NN B-NP O
31 1545 1546 20067456 = SYM B-VP O
32 1547 1552 20067456 0.002 CD B-NP O
33 1552 1553 20067456 ) ) O O
34 1553 1554 20067456 . . O O

1 1555 1558 20067456 The DT B-NP O
2 1559 1564 20067456 EDITS NNS I-NP O
3 1565 1571 20067456 scores NNS I-NP O
4 1572 1576 20067456 were VBD B-VP O
5 1577 1581 20067456 67.4 CD B-NP O
6 1582 1583 20067456 ( ( O O
7 1583 1587 20067456 10.2 CD B-NP O
8 1587 1588 20067456 ) ) O O
9 1589 1592 20067456 for IN B-PP O
10 1593 1596 20067456 the DT B-NP O
11 1597 1606 20067456 bupropion NN I-NP B-Chemical
12 1607 1610 20067456 and CC O O
13 1611 1615 20067456 36.3 CD B-NP O
14 1616 1617 20067456 ( ( O O
15 1617 1621 20067456 11.7 CD B-NP O
16 1621 1622 20067456 ) ) O O
17 1623 1626 20067456 for IN B-PP O
18 1627 1630 20067456 the DT B-NP O
19 1631 1638 20067456 placebo NN I-NP O
20 1639 1644 20067456 group NN I-NP O
21 1645 1646 20067456 ( ( O O
22 1646 1647 20067456 P NN B-NP O
23 1647 1648 20067456 = SYM B-VP O
24 1649 1654 20067456 0.001 CD B-NP O
25 1654 1655 20067456 ) ) O O
26 1655 1656 20067456 . . O O

1 1657 1660 20067456 The DT B-NP O
2 1661 1665 20067456 ASEX NN I-NP O
3 1666 1671 20067456 score NN I-NP O
4 1672 1675 20067456 and CC I-NP O
5 1676 1679 20067456 CGI NN I-NP O
6 1679 1680 20067456 - HYPH B-NP O
7 1680 1682 20067456 SF NN I-NP O
8 1683 1688 20067456 score NN I-NP O
9 1689 1693 20067456 were VBD B-VP O
10 1694 1704 20067456 correlated VBN I-VP O
11 1705 1706 20067456 ( ( O O
12 1706 1707 20067456 P NN B-NP O
13 1707 1708 20067456 = SYM B-VP O
14 1709 1714 20067456 0.003 CD B-NP O
15 1714 1715 20067456 ) ) O O
16 1715 1716 20067456 . . O O

1 1717 1719 20067456 In IN B-PP O
2 1720 1726 20067456 linear JJ B-NP O
3 1727 1737 20067456 regression NN I-NP O
4 1738 1746 20067456 analyses NNS I-NP O
5 1747 1750 20067456 the DT B-NP O
6 1751 1754 20067456 CGI NN I-NP O
7 1754 1755 20067456 - HYPH B-NP O
8 1755 1757 20067456 SF NN I-NP O
9 1758 1763 20067456 score NN I-NP O
10 1764 1767 20067456 was VBD B-VP O
11 1768 1771 20067456 not RB I-VP O
12 1772 1780 20067456 affected VBN I-VP O
13 1781 1794 20067456 significantly RB B-ADVP O
14 1795 1797 20067456 by IN B-PP O
15 1798 1801 20067456 the DT B-NP O
16 1802 1810 20067456 duration NN I-NP O
17 1811 1813 20067456 of IN B-PP O
18 1814 1816 20067456 SD NN B-NP B-Disease
19 1816 1817 20067456 , , O O
20 1818 1822 20067456 type NN B-NP O
21 1823 1825 20067456 of IN B-PP O
22 1826 1830 20067456 SSRI NN B-NP B-Chemical
23 1831 1835 20067456 used VBN B-VP O
24 1836 1839 20067456 and CC O O
25 1840 1843 20067456 age NN B-NP O
26 1843 1844 20067456 . . O O

1 1845 1856 20067456 CONCLUSIONS NNS B-NP O
2 1856 1857 20067456 : : O O
3 1858 1867 20067456 Bupropion NN B-NP B-Chemical
4 1868 1870 20067456 is VBZ B-VP O
5 1871 1873 20067456 an DT B-NP O
6 1874 1883 20067456 effective JJ I-NP O
7 1884 1893 20067456 treatment NN I-NP O
8 1894 1897 20067456 for IN B-PP O
9 1898 1902 20067456 male JJ B-NP O
10 1903 1905 20067456 SD NN I-NP B-Disease
11 1906 1913 20067456 induced VBN B-VP O
12 1914 1916 20067456 by IN B-PP O
13 1917 1922 20067456 SSRIs NNS B-NP B-Chemical
14 1922 1923 20067456 . . O O

1 1924 1929 20067456 These DT B-NP O
2 1930 1937 20067456 results NNS I-NP O
3 1938 1945 20067456 provide VBP B-VP O
4 1946 1955 20067456 empirical JJ B-NP O
5 1956 1963 20067456 support NN I-NP O
6 1964 1967 20067456 for IN B-PP O
7 1968 1978 20067456 conducting VBG B-VP O
8 1979 1980 20067456 a DT B-NP O
9 1981 1988 20067456 further JJ I-NP O
10 1989 1994 20067456 study NN I-NP O
11 1995 1997 20067456 of IN B-PP O
12 1998 2007 20067456 bupropion NN B-NP B-Chemical
13 2007 2008 20067456 . . O O

1 0 0 2445283 -DOCSTART- -X- -X- O

1 0 9 2445283 Tolerance NN B-NP O
2 10 13 2445283 and CC I-NP O
3 14 23 2445283 antiviral JJ I-NP O
4 24 30 2445283 effect NN I-NP O
5 31 33 2445283 of IN B-PP O
6 34 43 2445283 ribavirin NN B-NP B-Chemical
7 44 46 2445283 in IN B-PP O
8 47 55 2445283 patients NNS B-NP O
9 56 60 2445283 with IN B-PP O
10 61 70 2445283 Argentine JJ B-NP B-Disease
11 71 82 2445283 hemorrhagic JJ I-NP I-Disease
12 83 88 2445283 fever NN I-NP I-Disease
13 88 89 2445283 . . O O
14 90 99 2445283 Tolerance NN B-NP O
15 100 103 2445283 and CC O O
16 104 113 2445283 antiviral JJ B-NP O
17 114 120 2445283 effect NN I-NP O
18 121 123 2445283 of IN B-PP O
19 124 133 2445283 ribavirin NN B-NP B-Chemical
20 134 137 2445283 was VBD B-VP O
21 138 145 2445283 studied VBN I-VP O
22 146 148 2445283 in IN B-PP O
23 149 150 2445283 6 CD B-NP O
24 151 159 2445283 patients NNS I-NP O
25 160 164 2445283 with IN B-PP O
26 165 174 2445283 Argentine JJ B-NP B-Disease
27 175 186 2445283 hemorrhagic JJ I-NP I-Disease
28 187 192 2445283 fever NN I-NP I-Disease
29 193 194 2445283 ( ( O O
30 194 197 2445283 AHF NN B-NP B-Disease
31 197 198 2445283 ) ) O O
32 199 201 2445283 of IN B-PP O
33 202 206 2445283 more JJR B-NP O
34 207 211 2445283 than IN I-NP O
35 212 213 2445283 8 CD I-NP O
36 214 218 2445283 days NNS I-NP O
37 219 221 2445283 of IN B-PP O
38 222 231 2445283 evolution NN B-NP O
39 231 232 2445283 . . O O

1 233 247 2445283 Administration NN B-NP O
2 248 250 2445283 of IN B-PP O
3 251 260 2445283 ribavirin NN B-NP B-Chemical
4 261 269 2445283 resulted VBD B-VP O
5 270 272 2445283 in IN B-PP O
6 273 274 2445283 a DT B-NP O
7 275 289 2445283 neutralization NN I-NP O
8 290 292 2445283 of IN B-PP O
9 293 300 2445283 viremia NN B-NP B-Disease
10 301 304 2445283 and CC O O
11 305 306 2445283 a DT B-NP O
12 307 311 2445283 drop NN I-NP O
13 312 314 2445283 of IN B-PP O
14 315 325 2445283 endogenous JJ B-NP O
15 326 336 2445283 interferon NN I-NP O
16 337 343 2445283 titers NNS I-NP O
17 343 344 2445283 . . O O

1 345 348 2445283 The DT B-NP O
2 349 356 2445283 average JJ I-NP O
3 357 361 2445283 time NN I-NP O
4 362 364 2445283 of IN B-PP O
5 365 370 2445283 death NN B-NP B-Disease
6 371 374 2445283 was VBD B-VP O
7 375 382 2445283 delayed VBN I-VP O
8 382 383 2445283 . . O O

1 384 385 2445283 A DT B-NP O
2 386 396 2445283 reversible JJ I-NP O
3 397 403 2445283 anemia NN I-NP B-Disease
4 404 407 2445283 was VBD B-VP O
5 408 411 2445283 the DT B-NP O
6 412 416 2445283 only RB I-NP O
7 417 424 2445283 adverse JJ I-NP O
8 425 431 2445283 effect NN I-NP O
9 432 440 2445283 observed VBN B-VP O
10 440 441 2445283 . . O O

1 442 446 2445283 From IN B-PP O
2 447 452 2445283 these DT B-NP O
3 453 460 2445283 results NNS I-NP O
4 460 461 2445283 , , O O
5 462 464 2445283 we PRP B-NP O
6 465 473 2445283 conclude VBP B-VP O
7 474 478 2445283 that IN B-SBAR O
8 479 488 2445283 ribavirin NN B-NP B-Chemical
9 489 492 2445283 has VBZ B-VP O
10 493 495 2445283 an DT B-NP O
11 496 505 2445283 antiviral JJ I-NP O
12 506 512 2445283 effect NN I-NP O
13 513 515 2445283 in IN B-PP O
14 516 524 2445283 advanced VBN B-NP O
15 525 530 2445283 cases NNS I-NP O
16 531 533 2445283 of IN B-PP O
17 534 537 2445283 AHF NN B-NP B-Disease
18 537 538 2445283 , , O O
19 539 542 2445283 and CC O O
20 543 547 2445283 that IN B-SBAR O
21 548 554 2445283 anemia NN B-NP B-Disease
22 554 555 2445283 , , O O
23 556 559 2445283 the DT B-NP O
24 560 564 2445283 only RB I-NP O
25 565 574 2445283 secondary JJ I-NP O
26 575 583 2445283 reaction NN I-NP O
27 584 592 2445283 observed VBN B-VP O
28 592 593 2445283 , , O O
29 594 597 2445283 can MD B-VP O
30 598 600 2445283 be VB I-VP O
31 601 607 2445283 easily RB I-VP O
32 608 615 2445283 managed VBN I-VP O
33 615 616 2445283 . . O O

1 617 620 2445283 The DT B-NP O
2 621 629 2445283 possible JJ I-NP O
3 630 640 2445283 beneficial JJ I-NP O
4 641 647 2445283 effect NN I-NP O
5 648 650 2445283 of IN B-PP O
6 651 660 2445283 ribavirin NN B-NP B-Chemical
7 661 667 2445283 during IN B-PP O
8 668 671 2445283 the DT B-NP O
9 672 679 2445283 initial JJ I-NP O
10 680 684 2445283 days NNS I-NP O
11 685 687 2445283 of IN B-PP O
12 688 691 2445283 AHF NN B-NP B-Disease
13 692 694 2445283 is VBZ B-VP O
14 695 704 2445283 discussed VBN I-VP O
15 704 705 2445283 . . O O

1 0 0 12198388 -DOCSTART- -X- -X- O

1 0 3 12198388 The DT B-NP O
2 4 16 12198388 relationship NN I-NP O
3 17 24 12198388 between IN B-PP O
4 25 36 12198388 hippocampal JJ B-NP O
5 37 50 12198388 acetylcholine NN I-NP B-Chemical
6 51 58 12198388 release NN I-NP O
7 59 62 12198388 and CC O O
8 63 74 12198388 cholinergic JJ B-NP O
9 75 85 12198388 convulsant JJ I-NP O
10 86 97 12198388 sensitivity NN I-NP O
11 98 100 12198388 in IN B-PP O
12 101 111 12198388 withdrawal NN B-NP O
13 112 119 12198388 seizure NN I-NP B-Disease
14 119 120 12198388 - HYPH B-NP O
15 120 125 12198388 prone NN I-NP O
16 126 129 12198388 and CC I-NP O
17 130 140 12198388 withdrawal NN I-NP O
18 141 148 12198388 seizure NN I-NP B-Disease
19 148 149 12198388 - HYPH B-ADJP O
20 149 158 12198388 resistant JJ B-NP O
21 159 167 12198388 selected VBN I-NP O
22 168 173 12198388 mouse NN I-NP O
23 174 179 12198388 lines NNS I-NP O
24 179 180 12198388 . . O O
25 181 191 12198388 BACKGROUND NN B-NP O
26 191 192 12198388 : : O O
27 193 196 12198388 The DT B-NP O
28 197 202 12198388 septo AFX I-NP O
29 202 203 12198388 - HYPH I-NP O
30 203 214 12198388 hippocampal JJ I-NP O
31 215 226 12198388 cholinergic JJ I-NP O
32 227 234 12198388 pathway NN I-NP O
33 235 238 12198388 has VBZ B-VP O
34 239 243 12198388 been VBN I-VP O
35 244 254 12198388 implicated VBN I-VP O
36 255 257 12198388 in IN B-PP O
37 258 273 12198388 epileptogenesis NN B-NP O
38 273 274 12198388 , , O O
39 275 278 12198388 and CC O O
40 279 286 12198388 genetic JJ B-NP O
41 287 294 12198388 factors NNS I-NP O
42 295 304 12198388 influence VBP B-VP O
43 305 308 12198388 the DT B-NP O
44 309 317 12198388 response NN I-NP O
45 318 320 12198388 to TO B-PP O
46 321 332 12198388 cholinergic JJ B-NP O
47 333 339 12198388 agents NNS I-NP O
48 339 340 12198388 , , O O
49 341 344 12198388 but CC O O
50 345 352 12198388 limited JJ B-NP O
51 353 357 12198388 data NNS I-NP O
52 358 361 12198388 are VBP B-VP O
53 362 371 12198388 available JJ B-ADJP O
54 372 374 12198388 on IN B-PP O
55 375 386 12198388 cholinergic JJ B-NP O
56 387 398 12198388 involvement NN I-NP O
57 399 401 12198388 in IN B-PP O
58 402 409 12198388 alcohol NN B-NP B-Chemical
59 410 420 12198388 withdrawal NN I-NP O
60 421 429 12198388 severity NN I-NP O
61 429 430 12198388 . . O O

1 431 435 12198388 Thus RB B-ADVP O
2 435 436 12198388 , , O O
3 437 440 12198388 the DT B-NP O
4 441 453 12198388 relationship NN I-NP O
5 454 461 12198388 between IN B-PP O
6 462 473 12198388 cholinergic JJ B-NP O
7 474 482 12198388 activity NN I-NP O
8 483 486 12198388 and CC O O
9 487 501 12198388 responsiveness NN B-NP O
10 502 505 12198388 and CC I-NP O
11 506 513 12198388 alcohol NN I-NP B-Chemical
12 514 524 12198388 withdrawal NN I-NP O
13 525 528 12198388 was VBD B-VP O
14 529 541 12198388 investigated VBN I-VP O
15 542 544 12198388 in IN B-PP O
16 545 546 12198388 a DT B-NP O
17 547 554 12198388 genetic JJ I-NP O
18 555 561 12198388 animal NN I-NP O
19 562 567 12198388 model NN I-NP O
20 568 570 12198388 of IN B-PP O
21 571 578 12198388 ethanol NN B-NP B-Chemical
22 579 589 12198388 withdrawal NN I-NP O
23 590 598 12198388 severity NN I-NP O
24 598 599 12198388 . . O O

1 600 607 12198388 METHODS NNS B-NP O
2 607 608 12198388 : : O O
3 609 620 12198388 Cholinergic JJ B-NP O
4 621 631 12198388 convulsant JJ I-NP O
5 632 643 12198388 sensitivity NN I-NP O
6 644 647 12198388 was VBD B-VP O
7 648 656 12198388 examined VBN I-VP O
8 657 659 12198388 in IN B-PP O
9 660 667 12198388 alcohol NN B-NP B-Chemical
10 667 668 12198388 - HYPH B-NP O
11 668 670 12198388 na NN I-NP O
12 672 674 12198388 ve NN I-NP O
13 675 685 12198388 Withdrawal NN I-NP O
14 686 693 12198388 Seizure NN I-NP B-Disease
15 693 694 12198388 - HYPH O O
16 694 699 12198388 Prone NN B-NP O
17 700 701 12198388 ( ( O O
18 701 704 12198388 WSP NN B-NP O
19 704 705 12198388 ) ) O O
20 706 709 12198388 and CC O O
21 709 710 12198388 - HYPH O O
22 710 719 12198388 Resistant JJ O O
23 720 721 12198388 ( ( O O
24 721 724 12198388 WSR JJ B-ADJP O
25 724 725 12198388 ) ) O O
26 726 730 12198388 mice NNS B-NP O
27 730 731 12198388 . . O O

1 732 739 12198388 Animals NNS B-NP O
2 740 744 12198388 were VBD B-VP O
3 745 757 12198388 administered VBN I-VP O
4 758 766 12198388 nicotine NN B-NP B-Chemical
5 766 767 12198388 , , O O
6 768 777 12198388 carbachol NN B-NP B-Chemical
7 777 778 12198388 , , O O
8 779 781 12198388 or CC O O
9 782 793 12198388 neostigmine NN B-NP B-Chemical
10 794 797 12198388 via IN B-PP O
11 798 803 12198388 timed VBN B-NP O
12 804 808 12198388 tail NN I-NP O
13 809 813 12198388 vein NN I-NP O
14 814 822 12198388 infusion NN I-NP O
15 822 823 12198388 , , O O
16 824 827 12198388 and CC O O
17 828 831 12198388 the DT B-NP O
18 832 841 12198388 latencies NNS I-NP O
19 842 844 12198388 to TO B-PP O
20 845 850 12198388 onset NN B-NP O
21 851 853 12198388 of IN B-PP O
22 854 860 12198388 tremor NN B-NP B-Disease
23 861 864 12198388 and CC I-NP O
24 865 871 12198388 clonus NN I-NP O
25 872 876 12198388 were VBD B-VP O
26 877 885 12198388 recorded VBN I-VP O
27 886 889 12198388 and CC O O
28 890 899 12198388 converted VBN B-VP O
29 900 902 12198388 to TO B-VP O
30 903 912 12198388 threshold VB I-VP O
31 913 917 12198388 dose NN B-NP O
32 917 918 12198388 . . O O

1 919 921 12198388 We PRP B-NP O
2 922 926 12198388 also RB B-ADVP O
3 927 931 12198388 used VBD B-VP O
4 932 945 12198388 microdialysis NN B-NP O
5 946 948 12198388 to TO B-VP O
6 949 956 12198388 measure VB I-VP O
7 957 962 12198388 basal JJ B-NP O
8 963 966 12198388 and CC I-NP O
9 967 976 12198388 potassium NN I-NP B-Chemical
10 976 977 12198388 - HYPH O O
11 977 987 12198388 stimulated VBN B-VP O
12 988 1001 12198388 acetylcholine NN B-NP B-Chemical
13 1002 1003 12198388 ( ( O O
14 1003 1006 12198388 ACh NN B-NP B-Chemical
15 1006 1007 12198388 ) ) O O
16 1008 1015 12198388 release NN B-NP O
17 1016 1018 12198388 in IN B-PP O
18 1019 1022 12198388 the DT B-NP O
19 1023 1026 12198388 CA1 NN I-NP O
20 1027 1033 12198388 region NN I-NP O
21 1034 1036 12198388 of IN B-PP O
22 1037 1040 12198388 the DT B-NP O
23 1041 1052 12198388 hippocampus NN I-NP O
24 1052 1053 12198388 . . O O

1 1054 1063 12198388 Potassium NN B-NP B-Chemical
2 1064 1067 12198388 was VBD B-VP O
3 1068 1075 12198388 applied VBN I-VP O
4 1076 1078 12198388 by IN B-PP O
5 1079 1086 12198388 reverse JJ B-NP O
6 1087 1095 12198388 dialysis NN I-NP O
7 1096 1101 12198388 twice RB B-ADVP O
8 1101 1102 12198388 , , O O
9 1103 1112 12198388 separated VBN B-VP O
10 1113 1115 12198388 by IN B-PP O
11 1116 1118 12198388 75 CD B-NP O
12 1119 1122 12198388 min NN I-NP O
13 1122 1123 12198388 . . O O

1 1124 1135 12198388 Hippocampal JJ B-NP O
2 1136 1139 12198388 ACh NN I-NP B-Chemical
3 1140 1144 12198388 also RB B-ADVP O
4 1145 1148 12198388 was VBD B-VP O
5 1149 1157 12198388 measured VBN I-VP O
6 1158 1164 12198388 during IN B-PP O
7 1165 1172 12198388 testing NN B-NP O
8 1173 1176 12198388 for IN B-PP O
9 1177 1185 12198388 handling NN B-NP O
10 1185 1186 12198388 - HYPH B-NP O
11 1186 1193 12198388 induced VBN I-NP O
12 1194 1205 12198388 convulsions NNS I-NP B-Disease
13 1205 1206 12198388 . . O O

1 1207 1214 12198388 RESULTS NNS B-NP O
2 1214 1215 12198388 : : O O
3 1216 1227 12198388 Sensitivity NN B-NP O
4 1228 1230 12198388 to TO B-PP O
5 1231 1238 12198388 several JJ B-NP O
6 1239 1249 12198388 convulsion NN I-NP B-Disease
7 1250 1259 12198388 endpoints NNS I-NP O
8 1260 1267 12198388 induced VBN B-VP O
9 1268 1270 12198388 by IN B-PP O
10 1271 1279 12198388 nicotine NN B-NP B-Chemical
11 1279 1280 12198388 , , O O
12 1281 1290 12198388 carbachol NN B-NP B-Chemical
13 1290 1291 12198388 , , O O
14 1292 1295 12198388 and CC O O
15 1296 1307 12198388 neostigmine NN B-NP B-Chemical
16 1308 1312 12198388 were VBD B-VP O
17 1313 1326 12198388 significantly RB B-ADJP O
18 1327 1334 12198388 greater JJR I-ADJP O
19 1335 1337 12198388 in IN B-PP O
20 1338 1341 12198388 WSR NN B-NP O
21 1342 1348 12198388 versus IN B-PP O
22 1349 1352 12198388 WSP NN B-NP O
23 1353 1357 12198388 mice NNS I-NP O
24 1357 1358 12198388 . . O O

1 1359 1361 12198388 In IN B-PP O
2 1362 1375 12198388 microdialysis NN B-NP O
3 1376 1387 12198388 experiments NNS I-NP O
4 1387 1388 12198388 , , O O
5 1389 1392 12198388 the DT B-NP O
6 1393 1398 12198388 lines NNS I-NP O
7 1399 1402 12198388 did VBD B-VP O
8 1403 1406 12198388 not RB I-VP O
9 1407 1413 12198388 differ VB I-VP O
10 1414 1416 12198388 in IN B-PP O
11 1417 1422 12198388 basal JJ B-NP O
12 1423 1430 12198388 release NN I-NP O
13 1431 1433 12198388 of IN B-PP O
14 1434 1437 12198388 ACh NN B-NP B-Chemical
15 1437 1438 12198388 , , O O
16 1439 1442 12198388 and CC O O
17 1443 1445 12198388 50 CD B-NP O
18 1446 1448 12198388 mM NN I-NP O
19 1449 1452 12198388 KCl NN I-NP B-Chemical
20 1453 1462 12198388 increased VBD B-VP O
21 1463 1466 12198388 ACh NN B-NP B-Chemical
22 1467 1473 12198388 output NN I-NP O
23 1474 1476 12198388 in IN B-PP O
24 1477 1481 12198388 both DT B-NP O
25 1482 1487 12198388 lines NNS I-NP O
26 1488 1490 12198388 of IN B-PP O
27 1491 1495 12198388 mice NNS B-NP O
28 1495 1496 12198388 . . O O

1 1497 1504 12198388 However RB B-ADVP O
2 1504 1505 12198388 , , O O
3 1506 1509 12198388 the DT B-NP O
4 1510 1518 12198388 increase NN I-NP O
5 1519 1521 12198388 in IN B-PP O
6 1522 1529 12198388 release NN B-NP O
7 1530 1532 12198388 of IN B-PP O
8 1533 1536 12198388 ACh NN B-NP B-Chemical
9 1537 1545 12198388 produced VBN B-VP O
10 1546 1548 12198388 by IN B-PP O
11 1549 1552 12198388 the DT B-NP O
12 1553 1558 12198388 first JJ I-NP O
13 1559 1570 12198388 application NN I-NP O
14 1571 1573 12198388 of IN B-PP O
15 1574 1577 12198388 KCl NN B-NP B-Chemical
16 1578 1581 12198388 was VBD B-VP O
17 1582 1583 12198388 2 CD B-NP O
18 1583 1584 12198388 - HYPH B-ADJP O
19 1584 1588 12198388 fold RB I-ADJP O
20 1589 1595 12198388 higher JJR I-ADJP O
21 1596 1598 12198388 in IN B-PP O
22 1599 1602 12198388 WSP NN B-NP O
23 1603 1609 12198388 versus IN B-PP O
24 1610 1613 12198388 WSR NN B-NP O
25 1614 1618 12198388 mice NNS I-NP O
26 1618 1619 12198388 . . O O

1 1620 1624 12198388 When WRB B-ADVP O
2 1625 1636 12198388 hippocampal JJ B-NP O
3 1637 1640 12198388 ACh NN I-NP B-Chemical
4 1641 1644 12198388 was VBD B-VP O
5 1645 1653 12198388 measured VBN I-VP O
6 1654 1660 12198388 during IN B-PP O
7 1661 1668 12198388 testing NN B-NP O
8 1669 1672 12198388 for IN B-PP O
9 1673 1681 12198388 handling NN B-NP O
10 1681 1682 12198388 - HYPH B-NP O
11 1682 1689 12198388 induced VBN I-NP O
12 1690 1701 12198388 convulsions NNS I-NP B-Disease
13 1701 1702 12198388 , , O O
14 1703 1716 12198388 extracellular JJ B-NP O
15 1717 1720 12198388 ACh NN I-NP B-Chemical
16 1721 1724 12198388 was VBD B-VP O
17 1725 1738 12198388 significantly RB B-ADJP O
18 1739 1747 12198388 elevated JJ I-ADJP O
19 1748 1749 12198388 ( ( O O
20 1749 1753 12198388 192% CD B-NP O
21 1753 1754 12198388 ) ) O O
22 1755 1757 12198388 in IN B-PP O
23 1758 1761 12198388 WSP NN B-NP O
24 1762 1766 12198388 mice NNS I-NP O
25 1766 1767 12198388 , , O O
26 1768 1771 12198388 but CC O O
27 1772 1775 12198388 was VBD B-VP O
28 1776 1792 12198388 nonsignificantly RB B-ADJP O
29 1793 1801 12198388 elevated JJ I-ADJP O
30 1802 1803 12198388 ( ( B-LST O
31 1803 1806 12198388 59% LS I-LST O
32 1806 1807 12198388 ) ) O O
33 1808 1810 12198388 in IN B-PP O
34 1811 1814 12198388 WSR JJ B-NP O
35 1815 1819 12198388 mice NNS I-NP O
36 1819 1820 12198388 . . O O

1 1821 1832 12198388 CONCLUSIONS NNS B-NP O
2 1832 1833 12198388 : : O O
3 1834 1839 12198388 These DT B-NP O
4 1840 1847 12198388 results NNS I-NP O
5 1848 1855 12198388 suggest VBP B-VP O
6 1856 1860 12198388 that IN B-SBAR O
7 1861 1872 12198388 differences NNS B-NP O
8 1873 1875 12198388 in IN B-PP O
9 1876 1887 12198388 cholinergic JJ B-NP O
10 1888 1896 12198388 activity NN I-NP O
11 1897 1900 12198388 and CC O O
12 1901 1913 12198388 postsynaptic JJ B-NP O
13 1914 1925 12198388 sensitivity NN I-NP O
14 1926 1928 12198388 to TO B-PP O
15 1929 1940 12198388 cholinergic JJ B-NP O
16 1941 1952 12198388 convulsants NNS I-NP B-Disease
17 1953 1956 12198388 may MD B-VP O
18 1957 1959 12198388 be VB I-VP O
19 1960 1970 12198388 associated VBN I-VP O
20 1971 1975 12198388 with IN B-PP O
21 1976 1983 12198388 ethanol NN B-NP B-Chemical
22 1984 1994 12198388 withdrawal NN I-NP O
23 1995 2003 12198388 severity NN I-NP O
24 2004 2007 12198388 and CC O O
25 2008 2017 12198388 implicate VBP B-VP O
26 2018 2029 12198388 cholinergic JJ B-NP O
27 2030 2040 12198388 mechanisms NNS I-NP O
28 2041 2043 12198388 in IN B-PP O
29 2044 2051 12198388 alcohol NN B-NP B-Chemical
30 2052 2062 12198388 withdrawal NN I-NP O
31 2062 2063 12198388 . . O O

1 2064 2076 12198388 Specifically RB B-ADVP O
2 2076 2077 12198388 , , O O
3 2078 2081 12198388 WSP NN B-NP O
4 2082 2086 12198388 mice NNS I-NP O
5 2087 2090 12198388 may MD B-VP O
6 2091 2095 12198388 have VB I-VP O
7 2096 2101 12198388 lower JJR B-NP O
8 2102 2113 12198388 sensitivity NN I-NP O
9 2114 2116 12198388 to TO B-PP O
10 2117 2128 12198388 cholinergic JJ B-NP O
11 2129 2140 12198388 convulsants NNS I-NP B-Disease
12 2141 2149 12198388 compared VBN B-PP O
13 2150 2154 12198388 with IN B-PP O
14 2155 2158 12198388 WSR NN B-NP O
15 2159 2166 12198388 because IN B-PP O
16 2167 2169 12198388 of IN I-PP O
17 2170 2182 12198388 postsynaptic JJ B-NP O
18 2183 2191 12198388 receptor NN I-NP O
19 2192 2207 12198388 desensitization NN I-NP O
20 2208 2215 12198388 brought VBD B-VP O
21 2216 2218 12198388 on RP B-PRT O
22 2219 2221 12198388 by IN B-PP O
23 2222 2228 12198388 higher JJR B-NP O
24 2229 2237 12198388 activity NN I-NP O
25 2238 2240 12198388 of IN B-PP O
26 2241 2252 12198388 cholinergic JJ B-NP O
27 2253 2260 12198388 neurons NNS I-NP O
28 2260 2261 12198388 . . O O

1 0 0 6103707 -DOCSTART- -X- -X- O

1 0 10 6103707 Comparison NN B-NP O
2 11 13 6103707 of IN B-PP O
3 14 17 6103707 the DT B-NP O
4 18 28 6103707 subjective JJ I-NP O
5 29 36 6103707 effects NNS I-NP O
6 37 40 6103707 and CC O O
7 41 47 6103707 plasma NN B-NP O
8 48 62 6103707 concentrations NNS I-NP O
9 63 72 6103707 following VBG B-PP O
10 73 77 6103707 oral JJ B-ADJP O
11 78 81 6103707 and CC I-ADJP O
12 82 85 6103707 i.m JJ I-ADJP O
13 85 86 6103707 . . O O

1 87 101 6103707 administration NN B-NP O
2 102 104 6103707 of IN B-PP O
3 105 118 6103707 flunitrazepam NN B-NP B-Chemical
4 119 121 6103707 in IN B-PP O
5 122 132 6103707 volunteers NNS B-NP O
6 132 133 6103707 . . O O
7 134 147 6103707 Flunitrazepam NNP B-NP B-Chemical
8 148 151 6103707 0.5 CD I-NP O
9 151 152 6103707 , , I-NP O
10 153 156 6103707 1.0 CD I-NP O
11 157 159 6103707 or CC I-NP O
12 160 163 6103707 2.0 CD I-NP O
13 164 166 6103707 mg NN I-NP O
14 167 170 6103707 was VBD B-VP O
15 171 176 6103707 given VBN I-VP O
16 177 179 6103707 by IN B-PP O
17 180 183 6103707 the DT B-NP O
18 184 188 6103707 oral JJ I-NP O
19 189 191 6103707 or CC I-NP O
20 192 195 6103707 i.m JJ I-NP O
21 195 196 6103707 . . O O

1 197 203 6103707 routes NNS B-NP O
2 204 206 6103707 to TO B-PP O
3 207 213 6103707 groups NNS B-NP O
4 214 216 6103707 of IN B-PP O
5 217 227 6103707 volunteers NNS B-NP O
6 228 231 6103707 and CC O O
7 232 235 6103707 its PRP$ B-NP O
8 236 243 6103707 effects NNS I-NP O
9 244 252 6103707 compared VBN B-VP O
10 252 253 6103707 . . O O

1 254 260 6103707 Plasma NN B-NP O
2 261 275 6103707 concentrations NNS I-NP O
3 276 278 6103707 of IN B-PP O
4 279 282 6103707 the DT B-NP O
5 283 287 6103707 drug NN I-NP O
6 288 292 6103707 were VBD B-VP O
7 293 302 6103707 estimated VBN I-VP O
8 303 305 6103707 by IN B-PP O
9 306 309 6103707 gas NN B-NP O
10 309 310 6103707 - HYPH I-NP O
11 310 316 6103707 liquid NN I-NP O
12 317 331 6103707 chromatography NN I-NP O
13 331 332 6103707 , , O O
14 333 335 6103707 in IN B-PP O
15 336 337 6103707 a DT B-NP O
16 338 345 6103707 smaller JJR I-NP O
17 346 352 6103707 number NN I-NP O
18 353 355 6103707 of IN B-PP O
19 356 359 6103707 the DT B-NP O
20 360 368 6103707 subjects NNS I-NP O
21 368 369 6103707 . . O O

1 370 373 6103707 The DT B-NP O
2 374 378 6103707 most RBS I-NP O
3 379 387 6103707 striking JJ I-NP O
4 388 394 6103707 effect NN I-NP O
5 395 398 6103707 was VBD B-VP O
6 399 407 6103707 sedation NN B-NP O
7 408 413 6103707 which WDT B-NP O
8 414 423 6103707 increased VBD B-VP O
9 424 428 6103707 with IN B-PP O
10 429 432 6103707 the DT B-NP O
11 433 437 6103707 dose NN I-NP O
12 437 438 6103707 , , O O
13 439 440 6103707 2 CD B-NP O
14 441 443 6103707 mg NN I-NP O
15 444 453 6103707 producing VBG B-VP O
16 454 458 6103707 deep JJ B-NP O
17 459 464 6103707 sleep NN I-NP O
18 465 473 6103707 although IN B-SBAR O
19 474 477 6103707 the DT B-NP O
20 478 486 6103707 subjects NNS I-NP O
21 487 492 6103707 could MD B-VP O
22 493 498 6103707 still RB I-VP O
23 499 501 6103707 be VB I-VP O
24 502 509 6103707 aroused VBN I-VP O
25 509 510 6103707 . . O O

1 511 514 6103707 The DT B-NP O
2 515 522 6103707 effects NNS I-NP O
3 523 525 6103707 of IN B-PP O
4 526 529 6103707 i.m RB B-NP O
5 529 530 6103707 . . O O

1 531 545 6103707 administration NN B-NP O
2 546 550 6103707 were VBD B-VP O
3 551 559 6103707 apparent JJ B-ADJP O
4 560 567 6103707 earlier RBR B-ADVP O
5 568 571 6103707 and CC O O
6 572 581 6103707 sometimes RB B-VP O
7 582 588 6103707 lasted VBN I-VP O
8 589 595 6103707 longer JJR B-ADJP O
9 596 600 6103707 than IN B-PP O
10 601 606 6103707 those DT B-NP O
11 607 616 6103707 following VBG B-PP O
12 617 621 6103707 oral JJ B-NP O
13 622 636 6103707 administration NN I-NP O
14 636 637 6103707 . . O O

1 638 647 6103707 Dizziness NN B-NP B-Disease
2 648 651 6103707 was VBD B-VP O
3 652 656 6103707 less RBR B-ADJP O
4 657 663 6103707 marked JJ I-ADJP O
5 664 668 6103707 than IN B-PP O
6 669 677 6103707 sedation NN B-NP O
7 677 678 6103707 , , O O
8 679 682 6103707 but CC O O
9 683 692 6103707 increased VBD B-VP O
10 693 697 6103707 with IN B-PP O
11 698 701 6103707 the DT B-NP O
12 702 706 6103707 dose NN I-NP O
13 706 707 6103707 . . O O

1 708 713 6103707 There EX B-NP O
2 714 717 6103707 was VBD B-VP O
3 718 722 6103707 pain NN B-NP B-Disease
4 723 725 6103707 on IN B-PP O
5 726 729 6103707 i.m NN B-NP O
6 729 730 6103707 . . O O

1 731 740 6103707 injection NN B-NP O
2 741 743 6103707 of IN B-PP O
3 744 757 6103707 flunitrazepam NN B-NP B-Chemical
4 758 771 6103707 significantly RB B-ADVP O
5 772 776 6103707 more RBR I-ADVP O
6 777 782 6103707 often RB I-ADVP O
7 783 787 6103707 than IN B-PP O
8 788 792 6103707 with IN B-PP O
9 793 801 6103707 isotonic JJ B-NP O
10 802 808 6103707 saline NN I-NP O
11 808 809 6103707 . . O O

1 810 816 6103707 Plasma NN B-NP O
2 817 831 6103707 concentrations NNS I-NP O
3 832 838 6103707 varied VBD B-VP O
4 839 843 6103707 with IN B-PP O
5 844 848 6103707 dose NN B-NP O
6 849 852 6103707 and CC I-NP O
7 853 858 6103707 route NN I-NP O
8 859 862 6103707 and CC O O
9 863 875 6103707 corresponded VBD B-VP O
10 876 889 6103707 qualitatively RB B-ADVP O
11 890 894 6103707 with IN B-PP O
12 895 898 6103707 the DT B-NP O
13 899 909 6103707 subjective JJ I-NP O
14 910 917 6103707 effects NNS I-NP O
15 917 918 6103707 . . O O

1 919 922 6103707 The DT B-NP O
2 923 927 6103707 drug NN I-NP O
3 928 931 6103707 was VBD B-VP O
4 932 937 6103707 still RB B-ADVP O
5 938 945 6103707 present JJ B-ADJP O
6 946 948 6103707 in IN B-PP O
7 949 959 6103707 measurable JJ B-NP O
8 960 970 6103707 quantities NNS I-NP O
9 971 976 6103707 after IN B-PP O
10 977 979 6103707 24 CD B-NP O
11 980 981 6103707 h NN I-NP O
12 982 986 6103707 even RB B-ADVP O
13 987 991 6103707 with IN B-PP O
14 992 995 6103707 the DT B-NP O
15 996 1004 6103707 smallest JJS I-NP O
16 1005 1009 6103707 dose NN I-NP O
17 1009 1010 6103707 . . O O

1 0 0 6203452 -DOCSTART- -X- -X- O

1 0 10 6203452 Thrombotic JJ B-NP B-Disease
2 11 26 6203452 microangiopathy NN I-NP I-Disease
3 27 30 6203452 and CC O O
4 31 36 6203452 renal JJ B-NP B-Disease
5 37 44 6203452 failure NN I-NP I-Disease
6 45 55 6203452 associated VBN B-VP O
7 56 60 6203452 with IN B-PP O
8 61 75 6203452 antineoplastic JJ B-NP O
9 76 88 6203452 chemotherapy NN I-NP O
10 88 89 6203452 . . O O
11 90 94 6203452 Five CD B-NP O
12 95 103 6203452 patients NNS I-NP O
13 104 108 6203452 with IN B-PP O
14 109 118 6203452 carcinoma NN B-NP B-Disease
15 119 128 6203452 developed VBD B-VP O
16 129 139 6203452 thrombotic JJ B-NP B-Disease
17 140 155 6203452 microangiopathy NN I-NP I-Disease
18 156 157 6203452 ( ( O O
19 157 170 6203452 characterized VBN B-VP O
20 171 173 6203452 by IN B-PP O
21 174 179 6203452 renal JJ B-NP B-Disease
22 180 193 6203452 insufficiency NN I-NP I-Disease
23 193 194 6203452 , , O O
24 195 211 6203452 microangiopathic JJ B-NP B-Disease
25 212 221 6203452 hemolytic JJ I-NP I-Disease
26 222 228 6203452 anemia NN I-NP I-Disease
27 228 229 6203452 , , O O
28 230 233 6203452 and CC O O
29 234 241 6203452 usually RB B-ADVP O
30 242 258 6203452 thrombocytopenia NN B-NP B-Disease
31 258 259 6203452 ) ) O O
32 260 265 6203452 after IN B-PP O
33 266 275 6203452 treatment NN B-NP O
34 276 280 6203452 with IN B-PP O
35 281 290 6203452 cisplatin NN B-NP B-Chemical
36 290 291 6203452 , , O O
37 292 301 6203452 bleomycin NN B-NP B-Chemical
38 301 302 6203452 , , O O
39 303 306 6203452 and CC O O
40 307 308 6203452 a DT B-NP O
41 309 314 6203452 vinca NN I-NP B-Chemical
42 315 323 6203452 alkaloid NN I-NP I-Chemical
43 323 324 6203452 . . O O

1 325 328 6203452 One CD B-NP O
2 329 336 6203452 patient NN I-NP O
3 337 340 6203452 had VBD B-VP O
4 341 351 6203452 thrombotic JJ B-NP B-Disease
5 352 368 6203452 thrombocytopenic JJ I-NP I-Disease
6 369 376 6203452 purpura NN I-NP I-Disease
7 376 377 6203452 , , O O
8 378 383 6203452 three CD B-NP O
9 384 387 6203452 the DT B-NP O
10 388 397 6203452 hemolytic JJ I-NP B-Disease
11 397 398 6203452 - HYPH I-NP I-Disease
12 398 404 6203452 uremic JJ I-NP I-Disease
13 405 413 6203452 syndrome NN I-NP I-Disease
14 413 414 6203452 , , O O
15 415 418 6203452 and CC O O
16 419 422 6203452 one CD B-NP O
17 423 425 6203452 an DT B-NP O
18 426 434 6203452 apparent JJ I-NP O
19 435 440 6203452 forme NN I-NP O
20 441 447 6203452 fruste NN I-NP O
21 448 450 6203452 of IN B-PP O
22 451 454 6203452 one CD B-NP O
23 455 457 6203452 of IN B-PP O
24 458 463 6203452 these DT B-NP O
25 464 473 6203452 disorders NNS I-NP O
26 473 474 6203452 . . O O

1 475 485 6203452 Histologic JJ B-NP O
2 486 497 6203452 examination NN I-NP O
3 498 500 6203452 of IN B-PP O
4 501 504 6203452 the DT B-NP O
5 505 510 6203452 renal JJ I-NP O
6 511 517 6203452 tissue NN I-NP O
7 518 524 6203452 showed VBD B-VP O
8 525 533 6203452 evidence NN B-NP O
9 534 536 6203452 of IN B-PP O
10 537 550 6203452 intravascular JJ B-NP B-Disease
11 551 562 6203452 coagulation NN I-NP I-Disease
12 562 563 6203452 , , O O
13 564 573 6203452 primarily RB B-ADVP O
14 574 583 6203452 affecting VBG B-VP O
15 584 587 6203452 the DT B-NP O
16 588 593 6203452 small JJ I-NP O
17 594 602 6203452 arteries NNS I-NP O
18 602 603 6203452 , , O O
19 604 614 6203452 arterioles NNS B-NP O
20 614 615 6203452 , , O O
21 616 619 6203452 and CC O O
22 620 629 6203452 glomeruli NNS B-NP O
23 629 630 6203452 . . O O

1 631 638 6203452 Because IN B-SBAR O
2 639 643 6203452 each DT B-NP O
3 644 651 6203452 patient NN I-NP O
4 652 655 6203452 was VBD B-VP O
5 656 661 6203452 tumor NN B-NP B-Disease
6 661 662 6203452 - HYPH B-PP O
7 662 666 6203452 free JJ B-ADJP O
8 667 669 6203452 or CC O O
9 670 673 6203452 had VBD B-VP O
10 674 678 6203452 only RB B-NP O
11 679 680 6203452 a DT I-NP O
12 681 686 6203452 small JJ I-NP O
13 687 692 6203452 tumor NN I-NP B-Disease
14 693 695 6203452 at IN B-PP O
15 696 699 6203452 the DT B-NP O
16 700 705 6203452 onset NN I-NP O
17 706 708 6203452 of IN B-PP O
18 709 713 6203452 this DT B-NP O
19 714 722 6203452 syndrome NN I-NP O
20 722 723 6203452 , , O O
21 724 727 6203452 the DT B-NP O
22 728 738 6203452 thrombotic JJ I-NP B-Disease
23 739 754 6203452 microangiopathy NN I-NP I-Disease
24 755 758 6203452 may MD B-VP O
25 759 763 6203452 have VB I-VP O
26 764 768 6203452 been VBN I-VP O
27 769 776 6203452 induced VBN I-VP O
28 777 779 6203452 by IN B-PP O
29 780 792 6203452 chemotherapy NN B-NP O
30 792 793 6203452 . . O O

1 794 803 6203452 Diagnosis NN B-NP O
2 804 806 6203452 of IN B-PP O
3 807 811 6203452 this DT B-NP O
4 812 823 6203452 potentially RB I-NP O
5 824 829 6203452 fatal JJ I-NP O
6 830 842 6203452 complication NN I-NP O
7 843 846 6203452 may MD B-VP O
8 847 849 6203452 be VB I-VP O
9 850 857 6203452 delayed VBN I-VP O
10 858 860 6203452 or CC I-VP O
11 861 867 6203452 missed VBN I-VP O
12 868 870 6203452 if IN B-SBAR O
13 871 876 6203452 renal JJ B-NP O
14 877 883 6203452 tissue NN I-NP O
15 884 886 6203452 or CC O O
16 887 890 6203452 the DT B-NP O
17 891 901 6203452 peripheral JJ I-NP O
18 902 907 6203452 blood NN I-NP O
19 908 913 6203452 smear NN I-NP O
20 914 916 6203452 is VBZ B-VP O
21 917 920 6203452 not RB I-VP O
22 921 929 6203452 examined VBN I-VP O
23 929 930 6203452 , , O O
24 931 938 6203452 because IN B-SBAR O
25 939 944 6203452 renal JJ B-NP B-Disease
26 945 952 6203452 failure NN I-NP I-Disease
27 953 956 6203452 may MD B-VP O
28 957 959 6203452 be VB I-VP O
29 960 968 6203452 ascribed VBN I-VP O
30 969 971 6203452 to TO B-PP O
31 972 981 6203452 cisplatin NN B-NP B-Chemical
32 982 996 6203452 nephrotoxicity NN I-NP B-Disease
33 997 1000 6203452 and CC O O
34 1001 1004 6203452 the DT B-NP O
35 1005 1011 6203452 anemia NN I-NP B-Disease
36 1012 1015 6203452 and CC I-NP O
37 1016 1032 6203452 thrombocytopenia NN I-NP B-Disease
38 1033 1035 6203452 to TO B-PP O
39 1036 1040 6203452 drug NN B-NP O
40 1040 1041 6203452 - HYPH B-NP O
41 1041 1048 6203452 induced VBN I-NP O
42 1049 1053 6203452 bone NN I-NP B-Disease
43 1054 1060 6203452 marrow NN I-NP I-Disease
44 1061 1072 6203452 suppression NN I-NP I-Disease
45 1072 1073 6203452 . . O O

1 0 0 8410052 -DOCSTART- -X- -X- O

1 0 19 8410052 Immunohistochemical JJ B-NP O
2 20 27 8410052 studies NNS I-NP O
3 28 32 8410052 with IN B-PP O
4 33 43 8410052 antibodies NNS B-NP O
5 44 46 8410052 to TO B-PP O
6 47 60 8410052 neurofilament NN B-NP O
7 61 69 8410052 proteins NNS I-NP O
8 70 72 8410052 on IN B-PP O
9 73 79 8410052 axonal JJ B-NP B-Disease
10 80 86 8410052 damage NN I-NP I-Disease
11 87 89 8410052 in IN B-PP O
12 90 102 8410052 experimental JJ B-NP O
13 103 108 8410052 focal JJ I-NP O
14 109 116 8410052 lesions NNS I-NP O
15 117 119 8410052 in IN B-PP O
16 120 123 8410052 rat NN B-NP O
17 123 124 8410052 . . O O
18 125 145 8410052 Immunohistochemistry NN B-NP O
19 146 150 8410052 with IN B-PP O
20 151 161 8410052 monoclonal JJ B-NP O
21 162 172 8410052 antibodies NNS I-NP O
22 173 180 8410052 against IN B-PP O
23 181 194 8410052 neurofilament NN B-NP O
24 195 196 8410052 ( ( O O
25 196 198 8410052 NF NN B-NP O
26 198 199 8410052 ) ) O O
27 200 208 8410052 proteins NNS B-NP O
28 209 211 8410052 of IN B-PP O
29 212 218 8410052 middle JJ B-NP O
30 219 222 8410052 and CC I-NP O
31 223 227 8410052 high JJ I-NP O
32 228 237 8410052 molecular JJ I-NP O
33 238 244 8410052 weight NN I-NP O
34 245 250 8410052 class NN I-NP O
35 250 251 8410052 , , O O
36 252 254 8410052 NF NN B-NP O
37 254 255 8410052 - HYPH B-NP O
38 255 256 8410052 M NN I-NP O
39 257 260 8410052 and CC I-NP O
40 261 263 8410052 NF NN I-NP O
41 263 264 8410052 - HYPH B-NP O
42 264 265 8410052 H NN I-NP O
43 265 266 8410052 , , O O
44 267 270 8410052 was VBD B-VP O
45 271 275 8410052 used VBN I-VP O
46 276 278 8410052 to TO B-VP O
47 279 284 8410052 study VB I-VP O
48 285 291 8410052 axonal JJ B-NP B-Disease
49 292 298 8410052 injury NN I-NP I-Disease
50 299 301 8410052 in IN B-PP O
51 302 305 8410052 the DT B-NP O
52 306 316 8410052 borderzone NN I-NP O
53 317 319 8410052 of IN B-PP O
54 320 325 8410052 focal JJ B-NP O
55 326 333 8410052 lesions NNS I-NP O
56 334 336 8410052 in IN B-PP O
57 337 341 8410052 rats NNS B-NP O
58 341 342 8410052 . . O O

1 343 348 8410052 Focal JJ B-NP O
2 349 355 8410052 injury NN I-NP B-Disease
3 356 358 8410052 in IN B-PP I-Disease
4 359 362 8410052 the DT B-NP I-Disease
5 363 369 8410052 cortex NN I-NP I-Disease
6 370 373 8410052 was VBD B-VP O
7 374 382 8410052 produced VBN I-VP O
8 383 385 8410052 by IN B-PP O
9 386 394 8410052 infusion NN B-NP O
10 395 397 8410052 of IN B-PP O
11 398 405 8410052 lactate NN B-NP B-Chemical
12 406 408 8410052 at IN B-PP O
13 409 413 8410052 acid NN B-NP O
14 414 416 8410052 pH NN I-NP O
15 417 419 8410052 or CC B-PP O
16 420 422 8410052 by IN B-PP O
17 423 427 8410052 stab NN B-NP O
18 428 434 8410052 caused VBN B-VP O
19 435 437 8410052 by IN B-PP O
20 438 444 8410052 needle NN B-NP O
21 445 454 8410052 insertion NN I-NP O
22 454 455 8410052 . . O O

1 456 464 8410052 Infarcts NNS B-NP B-Disease
2 465 467 8410052 in IN B-PP I-Disease
3 468 478 8410052 substantia NN B-NP I-Disease
4 479 484 8410052 nigra NN I-NP I-Disease
5 485 489 8410052 pars NNS I-NP I-Disease
6 490 500 8410052 reticulata NNS I-NP I-Disease
7 501 505 8410052 were VBD B-VP O
8 506 512 8410052 evoked VBN I-VP O
9 513 515 8410052 by IN B-PP O
10 516 525 8410052 prolonged VBN B-NP O
11 526 537 8410052 pilocarpine NN I-NP B-Chemical
12 537 538 8410052 - HYPH O O
13 538 545 8410052 induced VBN B-NP O
14 546 552 8410052 status NN I-NP B-Disease
15 553 564 8410052 epilepticus NN I-NP I-Disease
16 564 565 8410052 . . O O

1 566 585 8410052 Immunohistochemical JJ B-NP O
2 586 594 8410052 staining NN I-NP O
3 595 598 8410052 for IN B-PP O
4 599 602 8410052 NFs NNS B-NP O
5 603 609 8410052 showed VBD B-VP O
6 610 624 8410052 characteristic JJ B-NP O
7 625 633 8410052 terminal JJ I-NP O
8 634 639 8410052 clubs NNS I-NP O
9 640 642 8410052 of IN B-PP O
10 643 648 8410052 axons NNS B-NP O
11 649 651 8410052 in IN B-PP O
12 652 655 8410052 the DT B-NP O
13 656 666 8410052 borderzone NN I-NP O
14 667 669 8410052 of IN B-PP O
15 670 677 8410052 lesions NNS B-NP O
16 677 678 8410052 . . O O

1 679 690 8410052 Differences NNS B-NP O
2 691 693 8410052 in IN B-PP O
3 694 697 8410052 the DT B-NP O
4 698 707 8410052 labelling NN I-NP O
5 708 715 8410052 pattern NN I-NP O
6 716 724 8410052 occurred VBD B-VP O
7 725 729 8410052 with IN B-PP O
8 730 739 8410052 different JJ B-NP O
9 740 750 8410052 antibodies NNS I-NP O
10 751 756 8410052 which WDT B-NP O
11 757 767 8410052 apparently RB B-ADVP O
12 768 776 8410052 depended VBD B-VP O
13 777 779 8410052 on IN B-PP O
14 780 789 8410052 molecular JJ B-NP O
15 790 796 8410052 weight NN I-NP O
16 797 802 8410052 class NN I-NP O
17 803 805 8410052 of IN B-PP O
18 806 809 8410052 NFs NNS B-NP O
19 810 813 8410052 and CC O O
20 814 829 8410052 phosphorylation NN B-NP O
21 830 835 8410052 state NN I-NP O
22 835 836 8410052 . . O O

1 837 842 8410052 These DT B-NP O
2 843 862 8410052 immunohistochemical JJ I-NP O
3 863 870 8410052 changes NNS I-NP O
4 871 873 8410052 of IN B-PP O
5 874 877 8410052 NFs NNS B-NP O
6 878 881 8410052 can MD B-VP O
7 882 887 8410052 serve VB I-VP O
8 888 890 8410052 as IN B-PP O
9 891 892 8410052 a DT B-NP O
10 893 899 8410052 marker NN I-NP O
11 900 903 8410052 for IN B-PP O
12 904 910 8410052 axonal JJ B-NP B-Disease
13 911 917 8410052 damage NN I-NP I-Disease
14 918 920 8410052 in IN B-PP O
15 921 928 8410052 various JJ B-NP O
16 929 941 8410052 experimental JJ I-NP O
17 942 951 8410052 traumatic JJ I-NP B-Disease
18 952 954 8410052 or CC I-NP O
19 955 963 8410052 ischemic JJ I-NP O
20 964 971 8410052 lesions NNS I-NP O
21 971 972 8410052 . . O O

1 0 0 15899738 -DOCSTART- -X- -X- O

1 0 4 15899738 Lone NN B-NP O
2 5 11 15899738 atrial JJ I-NP B-Disease
3 12 24 15899738 fibrillation NN I-NP I-Disease
4 25 35 15899738 associated VBN B-VP O
5 36 40 15899738 with IN B-PP O
6 41 49 15899738 creatine NN B-NP B-Chemical
7 50 61 15899738 monohydrate NN I-NP O
8 62 77 15899738 supplementation NN I-NP O
9 77 78 15899738 . . O O
10 79 85 15899738 Atrial JJ B-NP B-Disease
11 86 98 15899738 fibrillation NN I-NP I-Disease
12 99 101 15899738 in IN B-PP O
13 102 107 15899738 young JJ B-NP O
14 108 116 15899738 patients NNS I-NP O
15 117 124 15899738 without IN B-PP O
16 125 135 15899738 structural JJ B-NP O
17 136 141 15899738 heart NN I-NP B-Disease
18 142 149 15899738 disease NN I-NP I-Disease
19 150 152 15899738 is VBZ B-VP O
20 153 157 15899738 rare JJ B-ADJP O
21 157 158 15899738 . . O O

1 159 168 15899738 Therefore RB B-ADVP O
2 168 169 15899738 , , O O
3 170 174 15899738 when WRB B-ADVP O
4 175 178 15899738 the DT B-NP O
5 179 189 15899738 arrhythmia NN I-NP B-Disease
6 190 192 15899738 is VBZ B-VP O
7 193 200 15899738 present JJ B-ADJP O
8 201 203 15899738 in IN B-PP O
9 204 208 15899738 this DT B-NP O
10 209 219 15899738 population NN I-NP O
11 219 220 15899738 , , O O
12 221 231 15899738 reversible JJ B-NP O
13 232 238 15899738 causes NNS I-NP O
14 239 243 15899738 must MD B-VP O
15 244 246 15899738 be VB I-VP O
16 247 257 15899738 identified VBN I-VP O
17 258 261 15899738 and CC O O
18 262 270 15899738 resolved VBN B-VP O
19 270 271 15899738 . . O O

1 272 279 15899738 Thyroid JJ B-NP B-Disease
2 280 289 15899738 disorders NNS I-NP I-Disease
3 289 290 15899738 , , O O
4 291 298 15899738 illicit JJ B-NP O
5 299 303 15899738 drug NN I-NP O
6 304 306 15899738 or CC I-NP O
7 307 316 15899738 stimulant NN I-NP O
8 317 320 15899738 use NN I-NP O
9 320 321 15899738 , , O O
10 322 325 15899738 and CC O O
11 326 331 15899738 acute JJ B-NP B-Disease
12 332 339 15899738 alcohol NN I-NP I-Disease
13 340 352 15899738 intoxication NN I-NP I-Disease
14 353 356 15899738 are VBP B-VP O
15 357 362 15899738 among IN B-PP O
16 363 368 15899738 these DT B-NP O
17 369 375 15899738 causes NNS I-NP O
18 375 376 15899738 . . O O

1 377 379 15899738 We PRP B-NP O
2 380 386 15899738 report VBP B-VP O
3 387 390 15899738 the DT B-NP O
4 391 395 15899738 case NN I-NP O
5 396 398 15899738 of IN B-PP O
6 399 400 15899738 a DT B-NP O
7 401 403 15899738 30 CD I-NP O
8 403 404 15899738 - HYPH I-NP O
9 404 408 15899738 year NN I-NP O
10 408 409 15899738 - HYPH O O
11 409 412 15899738 old JJ B-NP O
12 413 422 15899738 Caucasian JJ I-NP O
13 423 426 15899738 man NN I-NP O
14 427 430 15899738 who WP B-NP O
15 431 435 15899738 came VBD B-VP O
16 436 438 15899738 to TO B-PP O
17 439 442 15899738 the DT B-NP O
18 443 452 15899738 emergency NN I-NP O
19 453 463 15899738 department NN I-NP O
20 464 466 15899738 in IN B-PP O
21 467 473 15899738 atrial JJ B-NP B-Disease
22 474 486 15899738 fibrillation NN I-NP I-Disease
23 487 491 15899738 with IN B-PP O
24 492 497 15899738 rapid JJ B-NP O
25 498 509 15899738 ventricular JJ I-NP O
26 510 518 15899738 response NN I-NP O
27 518 519 15899738 . . O O

1 520 523 15899738 His PRP$ B-NP O
2 524 531 15899738 medical JJ I-NP O
3 532 539 15899738 history NN I-NP O
4 540 543 15899738 was VBD B-VP O
5 544 556 15899738 unremarkable JJ B-ADJP O
6 556 557 15899738 , , O O
7 558 564 15899738 except IN B-PP O
8 565 568 15899738 for IN B-PP O
9 569 574 15899738 minor JJ B-NP O
10 575 584 15899738 fractures NNS I-NP B-Disease
11 585 587 15899738 of IN B-PP O
12 588 591 15899738 the DT B-NP O
13 592 599 15899738 fingers NNS I-NP O
14 600 603 15899738 and CC I-NP O
15 604 608 15899738 foot NN I-NP O
16 608 609 15899738 . . O O

1 610 617 15899738 Thyroid NN B-NP O
2 617 618 15899738 - HYPH O O
3 618 629 15899738 stimulating VBG B-VP O
4 630 637 15899738 hormone NN B-NP O
5 637 638 15899738 , , O O
6 639 648 15899738 magnesium NN B-NP B-Chemical
7 648 649 15899738 , , O O
8 650 653 15899738 and CC O O
9 654 663 15899738 potassium NN B-NP B-Chemical
10 664 670 15899738 levels NNS I-NP O
11 671 675 15899738 were VBD B-VP O
12 676 682 15899738 within IN B-PP O
13 683 689 15899738 normal JJ B-NP O
14 690 696 15899738 limits NNS I-NP O
15 696 697 15899738 , , O O
16 698 703 15899738 urine NN B-NP O
17 704 708 15899738 drug NN I-NP O
18 709 715 15899738 screen NN I-NP O
19 716 719 15899738 was VBD B-VP O
20 720 728 15899738 negative JJ B-ADJP O
21 728 729 15899738 , , O O
22 730 733 15899738 and CC O O
23 734 741 15899738 alcohol NN B-NP B-Chemical
24 742 745 15899738 use NN I-NP O
25 746 749 15899738 was VBD B-VP O
26 750 756 15899738 denied VBN I-VP O
27 756 757 15899738 . . O O

1 758 765 15899738 However RB B-ADVP O
2 765 766 15899738 , , O O
3 767 771 15899738 when WRB B-ADVP O
4 772 775 15899738 the DT B-NP O
5 776 783 15899738 patient NN I-NP O
6 784 787 15899738 was VBD B-VP O
7 788 798 15899738 questioned VBN I-VP O
8 799 804 15899738 about IN B-PP O
9 805 808 15899738 use NN B-NP O
10 809 811 15899738 of IN B-PP O
11 812 818 15899738 herbal JJ B-NP O
12 819 827 15899738 products NNS I-NP O
13 828 831 15899738 and CC I-NP O
14 832 843 15899738 supplements NNS I-NP O
15 843 844 15899738 , , O O
16 845 848 15899738 the DT B-NP O
17 849 852 15899738 use NN I-NP O
18 853 855 15899738 of IN B-PP O
19 856 864 15899738 creatine NN B-NP B-Chemical
20 865 876 15899738 monohydrate NN I-NP O
21 877 880 15899738 was VBD B-VP O
22 881 889 15899738 revealed VBN I-VP O
23 889 890 15899738 . . O O

1 891 894 15899738 The DT B-NP O
2 895 902 15899738 patient NN I-NP O
3 903 906 15899738 was VBD B-VP O
4 907 915 15899738 admitted VBN I-VP O
5 916 918 15899738 to TO B-PP O
6 919 922 15899738 the DT B-NP O
7 923 931 15899738 hospital NN I-NP O
8 931 932 15899738 , , O O
9 933 947 15899738 anticoagulated VBN B-VP O
10 948 952 15899738 with IN B-PP O
11 953 967 15899738 unfractionated JJ B-NP O
12 968 975 15899738 heparin NN I-NP B-Chemical
13 975 976 15899738 , , O O
14 977 980 15899738 and CC O O
15 981 986 15899738 given VBN B-VP O
16 987 998 15899738 intravenous JJ B-NP O
17 999 1008 15899738 diltiazem NN I-NP B-Chemical
18 1009 1012 15899738 for IN B-PP O
19 1013 1017 15899738 rate NN B-NP O
20 1018 1025 15899738 control NN I-NP O
21 1026 1029 15899738 and CC O O
22 1030 1041 15899738 intravenous JJ B-NP O
23 1042 1052 15899738 amiodarone NN I-NP B-Chemical
24 1053 1056 15899738 for IN B-PP O
25 1057 1061 15899738 rate NN B-NP O
26 1062 1065 15899738 and CC I-NP O
27 1066 1072 15899738 rhythm NN I-NP O
28 1073 1080 15899738 control NN I-NP O
29 1080 1081 15899738 . . O O

1 1082 1086 15899738 When WRB B-ADVP O
2 1087 1097 15899738 discharged VBN B-VP O
3 1098 1102 15899738 less JJR B-NP O
4 1103 1107 15899738 than IN I-NP O
5 1108 1110 15899738 24 CD I-NP O
6 1111 1116 15899738 hours NNS I-NP O
7 1117 1122 15899738 later RB B-ADVP O
8 1122 1123 15899738 , , O O
9 1124 1126 15899738 he PRP B-NP O
10 1127 1130 15899738 was VBD B-VP O
11 1131 1140 15899738 receiving VBG I-VP O
12 1141 1151 15899738 metoprolol NN B-NP B-Chemical
13 1152 1155 15899738 and CC I-NP O
14 1156 1163 15899738 aspirin NN I-NP B-Chemical
15 1163 1164 15899738 , , O O
16 1165 1169 15899738 with IN B-PP O
17 1170 1176 15899738 follow VB B-VP O
18 1176 1177 15899738 - HYPH O O
19 1177 1179 15899738 up RP B-PRT O
20 1180 1185 15899738 plans NNS B-NP O
21 1186 1189 15899738 for IN B-PP O
22 1190 1206 15899738 echocardiography NN B-NP O
23 1207 1210 15899738 and CC O O
24 1211 1218 15899738 nuclear JJ B-NP O
25 1219 1226 15899738 imaging NN I-NP O
26 1227 1229 15899738 to TO B-VP O
27 1230 1236 15899738 assess VB I-VP O
28 1237 1246 15899738 perfusion NN B-NP O
29 1246 1247 15899738 . . O O

1 1248 1257 15899738 Exogenous JJ B-NP O
2 1258 1266 15899738 creatine NN I-NP B-Chemical
3 1267 1269 15899738 is VBZ B-VP O
4 1270 1274 15899738 used VBN I-VP O
5 1275 1277 15899738 by IN B-PP O
6 1278 1286 15899738 athletes NNS B-NP O
7 1287 1289 15899738 to TO B-VP O
8 1290 1303 15899738 theoretically RB I-VP O
9 1304 1311 15899738 improve VB I-VP O
10 1312 1320 15899738 exercise NN B-NP O
11 1321 1332 15899738 performance NN I-NP O
12 1332 1333 15899738 . . O O

1 1334 1345 15899738 Vegetarians NNS B-NP O
2 1346 1349 15899738 may MD B-VP O
3 1350 1354 15899738 also RB I-VP O
4 1355 1359 15899738 take VB I-VP O
5 1360 1368 15899738 creatine NN B-NP B-Chemical
6 1369 1371 15899738 to TO B-VP O
7 1372 1379 15899738 replace VB I-VP O
8 1380 1384 15899738 what WP B-NP O
9 1385 1389 15899738 they PRP B-NP O
10 1390 1393 15899738 are VBP B-VP O
11 1394 1397 15899738 not RB I-VP O
12 1398 1407 15899738 consuming VBG I-VP O
13 1408 1412 15899738 from IN B-PP O
14 1413 1417 15899738 meat NN B-NP O
15 1417 1418 15899738 , , O O
16 1419 1423 15899738 fish NN B-NP O
17 1423 1424 15899738 , , O O
18 1425 1428 15899738 and CC O O
19 1429 1434 15899738 other JJ B-NP O
20 1435 1441 15899738 animal NN I-NP O
21 1442 1450 15899738 products NNS I-NP O
22 1450 1451 15899738 . . O O

1 1452 1460 15899738 Previous JJ B-NP O
2 1461 1470 15899738 anecdotal JJ I-NP O
3 1471 1478 15899738 reports NNS I-NP O
4 1479 1483 15899738 have VBP B-VP O
5 1484 1490 15899738 linked VBN I-VP O
6 1491 1499 15899738 creatine NN B-NP B-Chemical
7 1500 1502 15899738 to TO B-PP O
8 1503 1506 15899738 the DT B-NP O
9 1507 1518 15899738 development NN I-NP O
10 1519 1521 15899738 of IN B-PP O
11 1522 1532 15899738 arrhythmia NN B-NP B-Disease
12 1532 1533 15899738 . . O O

1 1534 1544 15899738 Clinicians NNS B-NP O
2 1545 1549 15899738 must MD B-VP O
3 1550 1552 15899738 be VB I-VP O
4 1553 1561 15899738 diligent JJ B-ADJP O
5 1562 1566 15899738 when WRB B-ADVP O
6 1567 1579 15899738 interviewing VBG B-VP O
7 1580 1588 15899738 patients NNS B-NP O
8 1589 1594 15899738 about IN B-PP O
9 1595 1600 15899738 their PRP$ B-NP O
10 1601 1605 15899738 drug NN I-NP O
11 1606 1613 15899738 therapy NN I-NP O
12 1614 1623 15899738 histories NNS I-NP O
13 1624 1627 15899738 and CC O O
14 1628 1635 15899738 include VBP B-VP O
15 1636 1645 15899738 questions NNS B-NP O
16 1646 1651 15899738 about IN B-PP O
17 1652 1657 15899738 their PRP$ B-NP O
18 1658 1661 15899738 use NN I-NP O
19 1662 1664 15899738 of IN B-PP O
20 1665 1671 15899738 herbal JJ B-NP O
21 1672 1680 15899738 products NNS I-NP O
22 1681 1684 15899738 and CC O O
23 1685 1692 15899738 dietary JJ B-NP O
24 1693 1704 15899738 supplements NNS I-NP O
25 1704 1705 15899738 . . O O

1 1706 1708 15899738 In IN B-PP O
2 1709 1717 15899738 addition NN B-NP O
3 1717 1718 15899738 , , O O
4 1719 1721 15899738 it PRP B-NP O
5 1722 1724 15899738 is VBZ B-VP O
6 1725 1734 15899738 important JJ B-ADJP O
7 1735 1737 15899738 to TO B-VP O
8 1738 1744 15899738 report VB I-VP O
9 1745 1752 15899738 adverse JJ B-NP O
10 1753 1760 15899738 effects NNS I-NP O
11 1761 1771 15899738 associated VBN B-VP O
12 1772 1776 15899738 with IN B-PP O
13 1777 1787 15899738 frequently RB B-NP O
14 1788 1796 15899738 consumed VBN I-NP O
15 1797 1808 15899738 supplements NNS I-NP O
16 1809 1812 15899738 and CC O O
17 1813 1819 15899738 herbal JJ B-NP O
18 1820 1828 15899738 products NNS I-NP O
19 1829 1831 15899738 to TO B-PP O
20 1832 1835 15899738 the DT B-NP O
21 1836 1840 15899738 Food NNP I-NP O
22 1841 1844 15899738 and CC I-NP O
23 1845 1849 15899738 Drug NNP I-NP O
24 1850 1864 15899738 Administration NNP I-NP O
25 1865 1868 15899738 and CC B-PP O
26 1869 1871 15899738 in IN B-PP O
27 1872 1875 15899738 the DT B-NP O
28 1876 1886 15899738 literature NN I-NP O
29 1886 1887 15899738 . . O O

1 0 0 19473225 -DOCSTART- -X- -X- O

1 0 4 19473225 Long JJ B-NP O
2 4 5 19473225 - HYPH I-NP O
3 5 9 19473225 term NN I-NP O
4 10 19 19473225 glutamate NN I-NP B-Chemical
5 20 35 19473225 supplementation NN I-NP O
6 36 42 19473225 failed VBD B-VP O
7 43 45 19473225 to TO I-VP O
8 46 53 19473225 protect VB I-VP O
9 54 61 19473225 against IN B-PP O
10 62 72 19473225 peripheral JJ B-NP B-Disease
11 73 86 19473225 neurotoxicity NN I-NP I-Disease
12 87 89 19473225 of IN B-PP O
13 90 100 19473225 paclitaxel NN B-NP B-Chemical
14 100 101 19473225 . . O O
15 102 107 19473225 Toxic JJ B-NP O
16 108 118 19473225 peripheral JJ I-NP B-Disease
17 119 129 19473225 neuropathy NN I-NP I-Disease
18 130 132 19473225 is VBZ B-VP O
19 133 138 19473225 still RB B-ADVP O
20 139 140 19473225 a DT B-NP O
21 141 152 19473225 significant JJ I-NP O
22 153 161 19473225 limiting VBG I-NP O
23 162 168 19473225 factor NN I-NP O
24 169 172 19473225 for IN B-PP O
25 173 185 19473225 chemotherapy NN B-NP O
26 186 190 19473225 with IN B-PP O
27 191 201 19473225 paclitaxel NN B-NP B-Chemical
28 202 203 19473225 ( ( O O
29 203 206 19473225 PAC NN B-NP B-Chemical
30 206 207 19473225 ) ) O O
31 207 208 19473225 , , O O
32 209 217 19473225 although IN B-SBAR O
33 218 227 19473225 glutamate NN B-NP B-Chemical
34 228 231 19473225 and CC O O
35 232 235 19473225 its PRP$ B-NP O
36 236 243 19473225 closely RB I-NP O
37 244 251 19473225 related JJ I-NP O
38 252 257 19473225 amino JJ I-NP B-Chemical
39 258 262 19473225 acid NN I-NP I-Chemical
40 263 272 19473225 glutamine NN I-NP B-Chemical
41 273 277 19473225 were VBD B-VP O
42 278 285 19473225 claimed VBN I-VP O
43 286 288 19473225 to TO B-VP O
44 289 299 19473225 ameliorate VB I-VP O
45 300 303 19473225 PAC NN B-NP B-Chemical
46 304 317 19473225 neurotoxicity NN I-NP B-Disease
47 317 318 19473225 . . O O

1 319 323 19473225 This DT B-NP O
2 324 329 19473225 pilot NN I-NP O
3 330 335 19473225 trial NN I-NP O
4 336 341 19473225 aimed VBN B-VP O
5 342 344 19473225 to TO I-VP O
6 345 353 19473225 evaluate VB I-VP O
7 354 357 19473225 the DT B-NP O
8 358 362 19473225 role NN I-NP O
9 363 365 19473225 of IN B-PP O
10 366 375 19473225 glutamate NN B-NP B-Chemical
11 376 391 19473225 supplementation NN I-NP O
12 392 395 19473225 for IN B-PP O
13 396 406 19473225 preventing VBG B-VP O
14 407 410 19473225 PAC NN B-NP B-Chemical
15 410 411 19473225 - HYPH O O
16 411 418 19473225 induced VBN B-NP O
17 419 429 19473225 peripheral JJ I-NP B-Disease
18 430 440 19473225 neuropathy NN I-NP I-Disease
19 441 443 19473225 in IN B-PP O
20 444 445 19473225 a DT B-NP O
21 446 456 19473225 randomized VBN I-NP O
22 456 457 19473225 , , I-NP O
23 458 465 19473225 placebo NN I-NP O
24 465 466 19473225 - HYPH I-NP O
25 466 476 19473225 controlled VBN B-VP O
26 476 477 19473225 , , O O
27 478 484 19473225 double JJ B-NP O
28 484 485 19473225 - HYPH I-NP O
29 485 492 19473225 blinded VBN B-VP O
30 493 501 19473225 clinical JJ B-ADJP O
31 502 505 19473225 and CC O O
32 506 513 19473225 electro AFX B-NP O
33 513 514 19473225 - HYPH I-NP O
34 514 524 19473225 diagnostic JJ I-NP O
35 525 530 19473225 study NN I-NP O
36 530 531 19473225 . . O O

1 532 537 19473225 Forty CD B-NP O
2 537 538 19473225 - HYPH I-NP O
3 538 543 19473225 three CD I-NP O
4 544 551 19473225 ovarian JJ I-NP B-Disease
5 552 558 19473225 cancer NN I-NP I-Disease
6 559 567 19473225 patients NNS I-NP O
7 568 572 19473225 were VBD B-VP O
8 573 582 19473225 available JJ B-ADJP O
9 583 586 19473225 for IN B-PP O
10 587 595 19473225 analysis NN B-NP O
11 596 605 19473225 following VBG B-PP O
12 606 609 19473225 six CD B-NP O
13 610 616 19473225 cycles NNS I-NP O
14 617 619 19473225 of IN B-PP O
15 620 623 19473225 the DT B-NP O
16 624 628 19473225 same JJ I-NP O
17 629 632 19473225 PAC NN I-NP B-Chemical
18 632 633 19473225 - HYPH O O
19 633 643 19473225 containing VBG B-VP O
20 644 651 19473225 regimen NN B-NP O
21 651 652 19473225 : : O O
22 653 655 19473225 23 CD B-NP O
23 656 659 19473225 had VBD B-VP O
24 660 664 19473225 been VBN I-VP O
25 665 677 19473225 supplemented VBN I-VP O
26 678 680 19473225 by IN B-PP O
27 681 690 19473225 glutamate NN B-NP B-Chemical
28 691 694 19473225 all DT O O
29 695 700 19473225 along IN B-PP O
30 701 704 19473225 the DT B-NP O
31 705 714 19473225 treatment NN I-NP O
32 715 721 19473225 period NN I-NP O
33 721 722 19473225 , , O O
34 723 725 19473225 at IN B-PP O
35 726 727 19473225 a DT B-NP O
36 728 733 19473225 daily JJ I-NP O
37 734 738 19473225 dose NN I-NP O
38 739 741 19473225 of IN B-PP O
39 742 747 19473225 three CD B-NP O
40 748 753 19473225 times NNS I-NP O
41 754 757 19473225 500 CD I-NP O
42 758 760 19473225 mg NN I-NP O
43 761 762 19473225 ( ( O O
44 762 767 19473225 group NN B-NP O
45 768 769 19473225 G NN I-NP O
46 769 770 19473225 ) ) O O
47 770 771 19473225 , , O O
48 772 775 19473225 and CC O O
49 776 778 19473225 20 CD B-NP O
50 779 782 19473225 had VBD B-VP O
51 783 791 19473225 received VBN I-VP O
52 792 793 19473225 a DT B-NP O
53 794 801 19473225 placebo NN I-NP O
54 802 803 19473225 ( ( O O
55 803 808 19473225 group NN B-NP O
56 809 810 19473225 P NN I-NP O
57 810 811 19473225 ) ) O O
58 811 812 19473225 . . O O

1 813 821 19473225 Patients NNS B-NP O
2 822 826 19473225 were VBD B-VP O
3 827 836 19473225 evaluated VBN I-VP O
4 837 839 19473225 by IN B-PP O
5 840 852 19473225 neurological JJ B-NP O
6 853 865 19473225 examinations NNS I-NP O
7 865 866 19473225 , , O O
8 867 881 19473225 questionnaires NNS B-NP O
9 882 885 19473225 and CC O O
10 886 893 19473225 sensory JJ B-NP O
11 893 894 19473225 - HYPH I-NP O
12 894 899 19473225 motor NN I-NP O
13 900 905 19473225 nerve NN I-NP O
14 906 916 19473225 conduction NN I-NP O
15 917 924 19473225 studies NNS I-NP O
16 924 925 19473225 . . O O

1 926 931 19473225 There EX B-NP O
2 932 935 19473225 was VBD B-VP O
3 936 938 19473225 no DT B-NP O
4 939 950 19473225 significant JJ I-NP O
5 951 961 19473225 difference NN I-NP O
6 962 964 19473225 in IN B-PP O
7 965 968 19473225 the DT B-NP O
8 969 978 19473225 frequency NN I-NP O
9 979 981 19473225 of IN B-PP O
10 982 987 19473225 signs NNS B-NP O
11 988 990 19473225 or CC I-NP O
12 991 999 19473225 symptoms NNS I-NP O
13 1000 1007 19473225 between IN B-PP O
14 1008 1011 19473225 the DT B-NP O
15 1012 1015 19473225 two CD I-NP O
16 1016 1022 19473225 groups NNS I-NP O
17 1023 1031 19473225 although IN B-SBAR O
18 1032 1045 19473225 neurotoxicity NN B-NP B-Disease
19 1046 1054 19473225 symptoms NNS I-NP O
20 1055 1064 19473225 presented VBN B-VP O
21 1065 1071 19473225 mostly RB B-ADVP O
22 1072 1076 19473225 with IN B-PP O
23 1077 1082 19473225 lower JJR B-NP O
24 1083 1089 19473225 scores NNS I-NP O
25 1090 1092 19473225 of IN B-PP O
26 1093 1101 19473225 severity NN B-NP O
27 1102 1104 19473225 in IN B-PP O
28 1105 1110 19473225 group NN B-NP O
29 1111 1112 19473225 G NN I-NP O
30 1112 1113 19473225 . . O O

1 1114 1121 19473225 However RB B-ADVP O
2 1121 1122 19473225 , , O O
3 1123 1127 19473225 this DT B-NP O
4 1128 1138 19473225 difference NN I-NP O
5 1139 1146 19473225 reached VBD B-VP O
6 1147 1158 19473225 statistical JJ B-NP O
7 1159 1171 19473225 significance NN I-NP O
8 1172 1176 19473225 only RB B-ADVP O
9 1177 1181 19473225 with IN B-PP O
10 1182 1188 19473225 regard NN B-NP O
11 1189 1191 19473225 to TO B-PP O
12 1192 1200 19473225 reported VBN B-NP O
13 1201 1205 19473225 pain NN I-NP B-Disease
14 1206 1215 19473225 sensation NN I-NP O
15 1216 1217 19473225 ( ( O O
16 1217 1218 19473225 P NN B-NP O
17 1219 1220 19473225 = SYM B-VP O
18 1221 1226 19473225 0.011 CD B-NP O
19 1226 1227 19473225 ) ) O O
20 1227 1228 19473225 . . O O

1 1229 1233 19473225 Also RB B-ADVP O
2 1234 1237 19473225 the DT B-NP O
3 1238 1247 19473225 frequency NN I-NP O
4 1248 1250 19473225 of IN B-PP O
5 1251 1259 19473225 abnormal JJ B-NP O
6 1260 1267 19473225 electro AFX I-NP O
7 1267 1268 19473225 - HYPH I-NP O
8 1268 1278 19473225 diagnostic JJ I-NP O
9 1279 1287 19473225 findings NNS I-NP O
10 1288 1294 19473225 showed VBD B-VP O
11 1295 1305 19473225 similarity NN B-NP O
12 1306 1313 19473225 between IN B-PP O
13 1314 1317 19473225 the DT B-NP O
14 1318 1321 19473225 two CD I-NP O
15 1322 1328 19473225 groups NNS I-NP O
16 1329 1330 19473225 ( ( O O
17 1330 1331 19473225 G NN B-NP O
18 1331 1332 19473225 : : O O
19 1333 1334 19473225 7 CD B-NP O
20 1334 1335 19473225 / SYM I-NP O
21 1335 1337 19473225 23 CD I-NP O
22 1338 1339 19473225 = SYM B-VP O
23 1340 1345 19473225 30.4% CD B-NP O
24 1345 1346 19473225 ; : O O
25 1347 1348 19473225 P NN B-NP O
26 1348 1349 19473225 : : O O
27 1350 1351 19473225 6 CD B-NP O
28 1351 1352 19473225 / SYM I-NP O
29 1352 1354 19473225 20 CD I-NP O
30 1355 1356 19473225 = SYM I-NP O
31 1357 1360 19473225 30% CD B-NP O
32 1360 1361 19473225 ) ) O O
33 1361 1362 19473225 . . O O

1 1363 1367 19473225 This DT B-NP O
2 1368 1373 19473225 pilot NN I-NP O
3 1374 1379 19473225 study NN I-NP O
4 1380 1385 19473225 leads VBZ B-VP O
5 1386 1388 19473225 to TO B-PP O
6 1389 1392 19473225 the DT B-NP O
7 1393 1403 19473225 conclusion NN I-NP O
8 1404 1408 19473225 that IN B-SBAR O
9 1409 1418 19473225 glutamate NN B-NP B-Chemical
10 1419 1434 19473225 supplementation NN I-NP O
11 1435 1437 19473225 at IN B-PP O
12 1438 1441 19473225 the DT B-NP O
13 1442 1448 19473225 chosen VBN I-NP O
14 1449 1456 19473225 regimen NN I-NP O
15 1457 1462 19473225 fails VBZ B-VP O
16 1463 1465 19473225 to TO I-VP O
17 1466 1473 19473225 protect VB I-VP O
18 1474 1481 19473225 against IN B-PP O
19 1482 1492 19473225 peripheral JJ B-NP B-Disease
20 1493 1506 19473225 neurotoxicity NN I-NP I-Disease
21 1507 1509 19473225 of IN B-PP O
22 1510 1513 19473225 PAC NN B-NP B-Chemical
23 1513 1514 19473225 . . O O

1 0 0 17343925 -DOCSTART- -X- -X- O

1 0 9 17343925 Influence NN B-NP O
2 10 12 17343925 of IN B-PP O
3 13 20 17343925 smoking NN B-NP B-Chemical
4 21 23 17343925 on IN B-PP O
5 24 34 17343925 developing VBG B-VP O
6 35 42 17343925 cochlea NN B-NP O
7 42 43 17343925 . . O O

1 44 48 17343925 Does VBZ O O
2 49 56 17343925 smoking NN B-NP B-Chemical
3 57 63 17343925 during IN B-PP O
4 64 73 17343925 pregnancy NN B-NP O
5 74 80 17343925 affect VBP B-VP O
6 81 84 17343925 the DT B-NP O
7 85 95 17343925 amplitudes NNS I-NP O
8 96 98 17343925 of IN B-PP O
9 99 108 17343925 transient JJ B-NP O
10 109 115 17343925 evoked VBN I-NP O
11 116 127 17343925 otoacoustic JJ I-NP O
12 128 137 17343925 emissions NNS I-NP O
13 138 140 17343925 in IN B-PP O
14 141 149 17343925 newborns NNS B-NP O
15 149 150 17343925 ? . O O
16 151 160 17343925 OBJECTIVE NN B-NP O
17 160 161 17343925 : : O O
18 162 170 17343925 Maternal JJ B-NP O
19 171 178 17343925 tobacco NN I-NP O
20 179 186 17343925 smoking NN I-NP B-Chemical
21 187 190 17343925 has VBZ B-VP O
22 191 199 17343925 negative JJ B-NP O
23 200 207 17343925 effects NNS I-NP O
24 208 210 17343925 on IN B-PP O
25 211 216 17343925 fetal JJ B-NP O
26 217 223 17343925 growth NN I-NP O
27 223 224 17343925 . . O O

1 225 228 17343925 The DT B-NP O
2 229 238 17343925 influence NN I-NP O
3 239 241 17343925 of IN B-PP O
4 242 249 17343925 smoking NN B-NP B-Chemical
5 250 256 17343925 during IN B-PP O
6 257 266 17343925 pregnancy NN B-NP O
7 267 269 17343925 on IN B-PP O
8 270 273 17343925 the DT B-NP O
9 274 284 17343925 developing VBG I-NP O
10 285 292 17343925 cochlea NN I-NP O
11 293 296 17343925 has VBZ B-VP O
12 297 300 17343925 not RB I-VP O
13 301 305 17343925 been VBN I-VP O
14 306 315 17343925 estimated VBN I-VP O
15 315 316 17343925 , , O O
16 317 325 17343925 although IN B-SBAR O
17 326 333 17343925 smoking NN B-NP B-Chemical
18 334 337 17343925 has VBZ B-VP O
19 338 342 17343925 been VBN I-VP O
20 343 353 17343925 positively RB I-VP O
21 354 364 17343925 associated VBN I-VP O
22 365 369 17343925 with IN B-PP O
23 370 377 17343925 hearing NN B-NP B-Disease
24 378 382 17343925 loss NN I-NP I-Disease
25 383 385 17343925 in IN B-PP O
26 386 392 17343925 adults NNS B-NP O
27 392 393 17343925 . . O O

1 394 397 17343925 The DT B-NP O
2 398 407 17343925 objective NN I-NP O
3 408 410 17343925 of IN B-PP O
4 411 415 17343925 this DT B-NP O
5 416 421 17343925 study NN I-NP O
6 422 425 17343925 was VBD B-VP O
7 426 428 17343925 to TO B-VP O
8 429 438 17343925 determine VB I-VP O
9 439 442 17343925 the DT B-NP O
10 443 450 17343925 effects NNS I-NP O
11 451 453 17343925 of IN B-PP O
12 454 462 17343925 maternal JJ B-NP O
13 463 470 17343925 smoking NN I-NP B-Chemical
14 471 473 17343925 on IN B-PP O
15 474 483 17343925 transient JJ B-NP O
16 484 490 17343925 evoked VBN I-NP O
17 491 502 17343925 otoacoustic JJ I-NP O
18 503 512 17343925 emissions NNS I-NP O
19 513 514 17343925 ( ( O O
20 514 520 17343925 TEOAEs NNS B-NP O
21 520 521 17343925 ) ) O O
22 522 524 17343925 of IN B-PP O
23 525 532 17343925 healthy JJ B-NP O
24 533 541 17343925 neonates NNS I-NP O
25 541 542 17343925 . . O O

1 543 550 17343925 METHODS NNS B-NP O
2 550 551 17343925 : : O O
3 552 556 17343925 This DT B-NP O
4 557 562 17343925 study NN I-NP O
5 563 566 17343925 was VBD B-VP O
6 567 577 17343925 undertaken VBN I-VP O
7 578 580 17343925 as IN B-PP O
8 581 585 17343925 part NN B-NP O
9 586 588 17343925 of IN B-PP O
10 589 597 17343925 neonatal JJ B-NP O
11 598 607 17343925 screening NN I-NP O
12 608 611 17343925 for IN B-PP O
13 612 619 17343925 hearing VBG B-VP B-Disease
14 620 630 17343925 impairment NN B-NP I-Disease
15 631 634 17343925 and CC O O
16 635 643 17343925 involved VBD B-VP O
17 644 648 17343925 both DT B-NP O
18 649 653 17343925 ears NNS I-NP O
19 654 656 17343925 of IN B-PP O
20 657 660 17343925 200 CD B-NP O
21 661 669 17343925 newborns NNS I-NP O
22 669 670 17343925 . . O O

1 671 679 17343925 Newborns NNS B-NP O
2 680 685 17343925 whose WP$ B-NP O
3 686 693 17343925 mothers NNS I-NP O
4 694 702 17343925 reported VBD B-VP O
5 703 710 17343925 smoking NN B-NP B-Chemical
6 711 717 17343925 during IN B-PP O
7 718 727 17343925 pregnancy NN B-NP O
8 728 729 17343925 ( ( O O
9 729 730 17343925 n NN B-NP O
10 730 731 17343925 = SYM B-VP O
11 731 734 17343925 200 CD B-NP O
12 735 739 17343925 ears NNS I-NP O
13 739 740 17343925 ) ) O O
14 741 745 17343925 were VBD B-VP O
15 746 754 17343925 compared VBN I-VP O
16 755 757 17343925 to TO B-PP O
17 758 759 17343925 a DT B-NP O
18 760 767 17343925 control NN I-NP O
19 768 773 17343925 group NN I-NP O
20 774 776 17343925 of IN B-PP O
21 777 785 17343925 newborns NNS B-NP O
22 786 787 17343925 ( ( O O
23 787 788 17343925 n NN B-NP O
24 788 789 17343925 = SYM B-VP O
25 789 792 17343925 200 CD B-NP O
26 793 797 17343925 ears NNS I-NP O
27 797 798 17343925 ) ) O O
28 798 799 17343925 , , O O
29 800 805 17343925 whose WP$ B-NP O
30 806 813 17343925 mothers NNS I-NP O
31 814 818 17343925 were VBD B-VP O
32 819 822 17343925 non AFX B-ADJP O
33 822 823 17343925 - HYPH B-NP O
34 823 830 17343925 smokers NNS I-NP O
35 830 831 17343925 . . O O

1 832 840 17343925 Exposure NN B-NP O
2 841 843 17343925 to TO B-PP O
3 844 851 17343925 tobacco NN B-NP O
4 852 855 17343925 was VBD B-VP O
5 856 869 17343925 characterized VBN I-VP O
6 870 872 17343925 as IN B-PP O
7 873 876 17343925 low JJ B-ADJP O
8 877 878 17343925 ( ( O O
9 878 879 17343925 < SYM O O
10 879 880 17343925 5 CD B-NP O
11 881 891 17343925 cigarettes NNS I-NP O
12 892 895 17343925 per IN B-PP O
13 896 899 17343925 day NN B-NP O
14 899 900 17343925 , , O O
15 901 902 17343925 n NN B-NP O
16 902 903 17343925 = SYM B-VP O
17 903 905 17343925 88 CD B-NP O
18 906 910 17343925 ears NNS I-NP O
19 910 911 17343925 ) ) O O
20 911 912 17343925 , , O O
21 913 921 17343925 moderate JJ B-ADJP O
22 922 923 17343925 ( ( O O
23 923 924 17343925 5 CD B-NP O
24 924 925 17343925 < SYM O O
25 926 928 17343925 or CC O O
26 929 930 17343925 = SYM B-VP O
27 930 940 17343925 cigarettes NNS B-NP O
28 941 944 17343925 per IN B-PP O
29 945 948 17343925 day NN B-NP O
30 948 949 17343925 < SYM O O
31 949 951 17343925 10 CD B-NP O
32 951 952 17343925 , , O O
33 953 954 17343925 n NN B-NP O
34 954 955 17343925 = SYM B-VP O
35 955 957 17343925 76 CD B-NP O
36 957 958 17343925 ) ) O O
37 959 961 17343925 or CC O O
38 962 966 17343925 high JJ B-ADJP O
39 967 968 17343925 ( ( O O
40 968 969 17343925 > SYM B-NP O
41 970 972 17343925 or CC O O
42 973 974 17343925 = SYM B-NP O
43 974 976 17343925 10 CD B-NP O
44 977 987 17343925 cigarettes NNS I-NP O
45 988 991 17343925 per IN B-PP O
46 992 995 17343925 day NN B-NP O
47 995 996 17343925 , , O O
48 997 998 17343925 n NN B-NP O
49 998 999 17343925 = JJ B-VP O
50 999 1001 17343925 36 CD B-NP O
51 1001 1002 17343925 ) ) O O
52 1002 1003 17343925 . . O O

1 1004 1011 17343925 RESULTS NNS B-NP O
2 1011 1012 17343925 : : O O
3 1013 1015 17343925 In IN B-PP O
4 1016 1023 17343925 exposed VBN B-NP O
5 1024 1032 17343925 neonates NNS I-NP O
6 1032 1033 17343925 , , O O
7 1034 1040 17343925 TEOAEs NNS B-NP O
8 1041 1045 17343925 mean VBP B-VP O
9 1046 1054 17343925 response NN B-NP O
10 1055 1056 17343925 ( ( O O
11 1056 1062 17343925 across IN B-PP O
12 1063 1072 17343925 frequency NN B-NP O
13 1072 1073 17343925 ) ) O O
14 1074 1077 17343925 and CC O O
15 1078 1082 17343925 mean JJ B-NP O
16 1083 1092 17343925 amplitude NN I-NP O
17 1093 1095 17343925 at IN B-PP O
18 1096 1102 17343925 4000Hz NN B-NP O
19 1103 1106 17343925 was VBD B-VP O
20 1107 1120 17343925 significantly RB B-ADJP O
21 1121 1126 17343925 lower JJR I-ADJP O
22 1127 1131 17343925 than IN B-PP O
23 1132 1134 17343925 in IN B-PP O
24 1135 1138 17343925 non AFX B-NP O
25 1138 1139 17343925 - HYPH I-NP O
26 1139 1146 17343925 exposed VBN B-NP O
27 1147 1155 17343925 neonates NNS I-NP O
28 1155 1156 17343925 . . O O

1 1157 1168 17343925 Comparisons NNS B-NP O
2 1169 1176 17343925 between IN B-PP O
3 1177 1184 17343925 exposed VBN B-NP O
4 1185 1193 17343925 newborns NNS I-NP O
5 1193 1194 17343925 ' POS B-NP O
6 1195 1204 17343925 subgroups NNS I-NP O
7 1205 1213 17343925 revealed VBD B-VP O
8 1214 1216 17343925 no DT B-NP O
9 1217 1228 17343925 significant JJ I-NP O
10 1229 1240 17343925 differences NNS I-NP O
11 1240 1241 17343925 . . O O

1 1242 1249 17343925 However RB B-ADVP O
2 1249 1250 17343925 , , O O
3 1251 1253 17343925 by IN B-PP O
4 1254 1263 17343925 comparing VBG B-VP O
5 1264 1268 17343925 each DT B-NP O
6 1269 1277 17343925 subgroup NN I-NP O
7 1278 1280 17343925 to TO B-PP O
8 1281 1288 17343925 control NN B-NP O
9 1289 1294 17343925 group NN I-NP O
10 1294 1295 17343925 , , O O
11 1296 1298 17343925 we PRP B-NP O
12 1299 1304 17343925 found VBD B-VP O
13 1305 1318 17343925 statistically RB B-NP O
14 1319 1330 17343925 significant JJ I-NP O
15 1331 1340 17343925 decreases NNS I-NP B-Disease
16 1341 1343 17343925 of IN B-PP I-Disease
17 1344 1350 17343925 TEOAEs NNS B-NP I-Disease
18 1351 1361 17343925 amplitudes NNS I-NP I-Disease
19 1362 1364 17343925 at IN B-PP O
20 1365 1371 17343925 4000Hz NNP B-NP O
21 1372 1375 17343925 for IN B-PP O
22 1376 1379 17343925 all DT B-NP O
23 1380 1385 17343925 three CD I-NP O
24 1386 1392 17343925 groups NNS I-NP O
25 1392 1393 17343925 . . O O

1 1394 1398 17343925 Mean JJ B-NP O
2 1399 1405 17343925 TEOAEs NNS I-NP O
3 1406 1415 17343925 responses NNS I-NP O
4 1416 1418 17343925 of IN B-PP O
5 1419 1425 17343925 highly RB B-NP O
6 1426 1433 17343925 exposed VBN I-NP O
7 1434 1442 17343925 newborns NNS I-NP O
8 1443 1447 17343925 were VBD B-VP O
9 1448 1452 17343925 also RB B-ADVP O
10 1453 1466 17343925 significantly RB B-ADJP O
11 1467 1472 17343925 lower JJR I-ADJP O
12 1473 1475 17343925 in IN B-PP O
13 1476 1486 17343925 comparison NN B-NP O
14 1487 1489 17343925 to TO B-PP O
15 1490 1493 17343925 our PRP$ B-NP O
16 1494 1501 17343925 control NN I-NP O
17 1502 1507 17343925 group NN I-NP O
18 1507 1508 17343925 . . O O

1 1509 1519 17343925 CONCLUSION NN B-NP O
2 1519 1520 17343925 : : O O
3 1521 1523 17343925 In IN B-PP O
4 1524 1529 17343925 utero NN B-NP O
5 1529 1530 17343925 , , O O
6 1531 1539 17343925 exposure NN B-NP O
7 1540 1542 17343925 to TO B-PP O
8 1543 1550 17343925 tobacco NN B-NP O
9 1551 1558 17343925 smoking NN I-NP B-Chemical
10 1559 1564 17343925 seems VBZ B-VP O
11 1565 1567 17343925 to TO I-VP O
12 1568 1572 17343925 have VB I-VP O
13 1573 1574 17343925 a DT B-NP O
14 1575 1580 17343925 small JJ I-NP O
15 1581 1587 17343925 impact NN I-NP O
16 1588 1590 17343925 on IN B-PP O
17 1591 1596 17343925 outer JJ B-NP O
18 1597 1601 17343925 hair NN I-NP O
19 1602 1607 17343925 cells NNS I-NP O
20 1607 1608 17343925 . . O O

1 1609 1614 17343925 These DT B-NP O
2 1615 1622 17343925 effects NNS I-NP O
3 1623 1627 17343925 seem VBP B-VP O
4 1628 1630 17343925 to TO I-VP O
5 1631 1633 17343925 be VB I-VP O
6 1634 1641 17343925 equally RB B-ADJP O
7 1642 1646 17343925 true JJ I-ADJP O
8 1647 1650 17343925 for IN B-PP O
9 1651 1654 17343925 all DT B-NP O
10 1655 1662 17343925 exposed VBN I-NP O
11 1663 1671 17343925 newborns NNS I-NP O
12 1671 1672 17343925 , , O O
13 1673 1683 17343925 regardless RB B-ADVP O
14 1684 1686 17343925 of IN B-PP O
15 1687 1690 17343925 the DT B-NP O
16 1691 1697 17343925 degree NN I-NP O
17 1698 1700 17343925 of IN B-PP O
18 1701 1709 17343925 exposure NN B-NP O
19 1709 1710 17343925 . . O O

1 1711 1718 17343925 Further JJ B-NP O
2 1719 1726 17343925 studies NNS I-NP O
3 1727 1730 17343925 are VBP B-VP O
4 1731 1737 17343925 needed VBN I-VP O
5 1738 1740 17343925 in IN B-SBAR O
6 1741 1746 17343925 order NN O O
7 1747 1749 17343925 to TO B-VP O
8 1750 1759 17343925 establish VB I-VP O
9 1760 1761 17343925 a DT B-NP O
10 1762 1771 17343925 potential JJ I-NP O
11 1772 1780 17343925 negative JJ I-NP O
12 1781 1787 17343925 effect NN I-NP O
13 1788 1790 17343925 of IN B-PP O
14 1791 1799 17343925 maternal JJ B-NP O
15 1800 1807 17343925 smoking NN I-NP B-Chemical
16 1808 1810 17343925 on IN B-PP O
17 1811 1814 17343925 the DT B-NP O
18 1815 1824 17343925 neonate's NNS I-NP O
19 1825 1832 17343925 hearing VBG B-VP O
20 1833 1839 17343925 acuity NN B-NP O
21 1839 1840 17343925 . . O O

1 0 0 9587734 -DOCSTART- -X- -X- O

1 0 13 9587734 Suxamethonium NN B-NP B-Chemical
2 13 14 9587734 - HYPH O O
3 14 21 9587734 induced VBN B-NP O
4 22 29 9587734 cardiac JJ I-NP B-Disease
5 30 36 9587734 arrest NN I-NP I-Disease
6 37 40 9587734 and CC I-NP O
7 41 46 9587734 death NN I-NP B-Disease
8 47 56 9587734 following VBG B-PP O
9 57 58 9587734 5 CD B-NP O
10 59 63 9587734 days NNS I-NP O
11 64 66 9587734 of IN B-PP O
12 67 81 9587734 immobilization NN B-NP O
13 81 82 9587734 . . O O
14 83 86 9587734 The DT B-NP O
15 87 94 9587734 present JJ I-NP O
16 95 101 9587734 report NN I-NP O
17 102 111 9587734 describes VBZ B-VP O
18 112 113 9587734 a DT B-NP O
19 114 118 9587734 case NN I-NP O
20 119 121 9587734 of IN B-PP O
21 122 129 9587734 cardiac JJ B-NP B-Disease
22 130 136 9587734 arrest NN I-NP I-Disease
23 137 140 9587734 and CC O O
24 141 151 9587734 subsequent JJ B-NP O
25 152 157 9587734 death NN I-NP B-Disease
26 158 160 9587734 as IN B-PP O
27 161 162 9587734 a DT B-NP O
28 163 169 9587734 result NN I-NP O
29 170 172 9587734 of IN B-PP O
30 173 186 9587734 hyperkalaemia NN B-NP B-Disease
31 187 196 9587734 following VBG B-PP O
32 197 200 9587734 the DT B-NP O
33 201 204 9587734 use NN I-NP O
34 205 207 9587734 of IN B-PP O
35 208 221 9587734 suxamethonium NN B-NP B-Chemical
36 222 224 9587734 in IN B-PP O
37 225 226 9587734 a DT B-NP O
38 227 229 9587734 23 CD I-NP O
39 229 230 9587734 - HYPH I-NP O
40 230 234 9587734 year NN I-NP O
41 234 235 9587734 - HYPH O O
42 235 238 9587734 old JJ B-NP O
43 239 247 9587734 Malawian JJ I-NP O
44 248 253 9587734 woman NN I-NP O
45 253 254 9587734 . . O O

1 255 259 9587734 Five CD B-NP O
2 260 264 9587734 days NNS I-NP O
3 265 270 9587734 after IN B-PP O
4 271 274 9587734 the DT B-NP O
5 275 280 9587734 onset NN I-NP O
6 281 283 9587734 of IN B-PP O
7 284 287 9587734 the DT B-NP O
8 288 296 9587734 symptoms NNS I-NP O
9 297 299 9587734 of IN B-PP O
10 300 310 9587734 meningitis NN B-NP B-Disease
11 310 311 9587734 , , O O
12 312 315 9587734 the DT B-NP O
13 316 323 9587734 patient NN I-NP O
14 324 333 9587734 aspirated VBD B-VP O
15 334 341 9587734 stomach NN B-NP O
16 342 350 9587734 contents NNS I-NP O
17 351 354 9587734 and CC O O
18 355 361 9587734 needed VBN B-NP O
19 362 374 9587734 endotracheal JJ I-NP O
20 375 385 9587734 intubation NN I-NP O
21 385 386 9587734 . . O O

1 387 392 9587734 Forty CD B-NP O
2 393 400 9587734 seconds NNS I-NP O
3 401 406 9587734 after IN B-PP O
4 407 416 9587734 injection NN B-NP O
5 417 419 9587734 of IN B-PP O
6 420 433 9587734 suxamethonium NN B-NP B-Chemical
7 433 434 9587734 , , O O
8 435 446 9587734 bradycardia NN B-NP B-Disease
9 447 450 9587734 and CC O O
10 451 458 9587734 cardiac JJ B-NP B-Disease
11 459 465 9587734 arrest NN I-NP I-Disease
12 466 474 9587734 occurred VBD B-VP O
13 474 475 9587734 . . O O

1 476 484 9587734 Attempts NNS B-NP O
2 485 487 9587734 to TO B-VP O
3 488 499 9587734 resuscitate VB I-VP O
4 500 503 9587734 the DT B-NP O
5 504 511 9587734 patient NN I-NP O
6 512 516 9587734 were VBD B-VP O
7 517 520 9587734 not RB O O
8 521 531 9587734 successful JJ B-ADJP O
9 531 532 9587734 . . O O

1 533 536 9587734 The DT B-NP O
2 537 542 9587734 serum NN I-NP O
3 543 548 9587734 level NN I-NP O
4 549 551 9587734 of IN B-PP O
5 552 561 9587734 potassium NN B-NP B-Chemical
6 562 565 9587734 was VBD B-VP O
7 566 574 9587734 observed VBN I-VP O
8 575 577 9587734 to TO I-VP O
9 578 580 9587734 be VB I-VP O
10 581 584 9587734 8.4 CD B-NP O
11 585 591 9587734 mequiv NN I-NP O
12 592 593 9587734 L NN I-NP O
13 593 594 9587734 - HYPH B-NP O
14 594 595 9587734 1 CD I-NP O
15 595 596 9587734 . . O O

1 597 602 9587734 Apart RB B-ADVP O
2 603 607 9587734 from IN B-PP O
3 608 611 9587734 the DT B-NP O
4 612 621 9587734 reduction NN I-NP O
5 622 624 9587734 in IN B-PP O
6 625 628 9587734 the DT B-NP O
7 629 638 9587734 patient's NNS I-NP O
8 639 644 9587734 level NN I-NP O
9 645 647 9587734 of IN B-PP O
10 648 661 9587734 consciousness NN B-NP O
11 661 662 9587734 , , O O
12 663 668 9587734 there EX B-NP O
13 669 673 9587734 were VBD B-VP O
14 674 676 9587734 no DT B-NP O
15 677 682 9587734 signs NNS I-NP O
16 683 685 9587734 of IN B-PP O
17 686 691 9587734 motor NN B-NP O
18 692 699 9587734 neurone NN I-NP O
19 700 706 9587734 damage NN I-NP O
20 707 709 9587734 or CC B-PP O
21 710 712 9587734 of IN B-PP O
22 713 716 9587734 any DT B-NP O
23 717 719 9587734 of IN B-PP O
24 720 723 9587734 the DT B-NP O
25 724 729 9587734 other JJ I-NP O
26 730 735 9587734 known VBN I-NP O
27 736 748 9587734 predisposing VBG I-NP O
28 749 759 9587734 conditions NNS I-NP O
29 760 763 9587734 for IN B-PP O
30 764 777 9587734 hyperkalaemia NN B-NP B-Disease
31 778 787 9587734 following VBG B-PP O
32 788 791 9587734 the DT B-NP O
33 792 806 9587734 administration NN I-NP O
34 807 809 9587734 of IN B-PP O
35 810 823 9587734 suxamethonium NN B-NP B-Chemical
36 823 824 9587734 . . O O

1 825 827 9587734 It PRP B-NP O
2 828 830 9587734 is VBZ B-VP O
3 831 841 9587734 postulated VBN I-VP O
4 842 846 9587734 that IN B-SBAR O
5 847 850 9587734 her PRP$ B-NP O
6 851 856 9587734 death NN I-NP B-Disease
7 857 860 9587734 was VBD B-VP O
8 861 867 9587734 caused VBN I-VP O
9 868 870 9587734 by IN B-PP O
10 871 887 9587734 hypersensitivity NN B-NP B-Disease
11 888 890 9587734 to TO B-PP O
12 891 904 9587734 suxamethonium NN B-NP B-Chemical
13 904 905 9587734 , , O O
14 906 916 9587734 associated VBN B-VP O
15 917 921 9587734 with IN B-PP O
16 922 925 9587734 her PRP B-NP O
17 926 927 9587734 5 CD I-NP O
18 927 928 9587734 - HYPH I-NP O
19 928 931 9587734 day NN I-NP O
20 932 946 9587734 immobilization NN I-NP O
21 946 947 9587734 . . O O

1 0 0 10721819 -DOCSTART- -X- -X- O

1 0 7 10721819 Effects NNS B-NP O
2 8 10 10721819 of IN B-PP O
3 11 15 10721819 long JJ B-NP O
4 15 16 10721819 - HYPH I-NP O
5 16 20 10721819 term NN I-NP O
6 21 33 10721819 pretreatment NN I-NP O
7 34 38 10721819 with IN B-PP O
8 39 52 10721819 isoproterenol NN B-NP B-Chemical
9 53 55 10721819 on IN B-PP O
10 56 69 10721819 bromocriptine NN B-NP B-Chemical
11 69 70 10721819 - HYPH B-NP O
12 70 77 10721819 induced VBN I-NP O
13 78 89 10721819 tachycardia NN I-NP B-Disease
14 90 92 10721819 in IN B-PP O
15 93 102 10721819 conscious JJ B-NP O
16 103 107 10721819 rats NNS I-NP O
17 107 108 10721819 . . O O
18 109 111 10721819 It PRP B-NP O
19 112 115 10721819 has VBZ B-VP O
20 116 120 10721819 been VBN I-VP O
21 121 126 10721819 shown VBN I-VP O
22 127 131 10721819 that IN B-SBAR O
23 132 145 10721819 bromocriptine NN B-NP B-Chemical
24 145 146 10721819 - HYPH B-NP O
25 146 153 10721819 induced VBN I-NP O
26 154 165 10721819 tachycardia NN I-NP B-Disease
27 165 166 10721819 , , O O
28 167 172 10721819 which WDT B-NP O
29 173 182 10721819 persisted VBD B-VP O
30 183 188 10721819 after IN B-PP O
31 189 202 10721819 adrenalectomy NN B-NP O
32 202 203 10721819 , , O O
33 204 206 10721819 is VBZ B-VP O
34 207 210 10721819 (i) LS O O
35 211 219 10721819 mediated VBN B-VP O
36 220 222 10721819 by IN B-PP O
37 223 230 10721819 central JJ B-NP O
38 231 239 10721819 dopamine NN I-NP B-Chemical
39 240 242 10721819 D2 NN I-NP O
40 243 251 10721819 receptor NN I-NP O
41 252 262 10721819 activation NN I-NP O
42 263 266 10721819 and CC O O
43 267 271 10721819 (ii) LS B-NP O
44 272 279 10721819 reduced VBN B-VP O
45 280 282 10721819 by IN B-PP O
46 283 284 10721819 5 CD B-NP O
47 284 285 10721819 - HYPH I-NP O
48 285 288 10721819 day NN I-NP O
49 289 302 10721819 isoproterenol NN I-NP B-Chemical
50 303 315 10721819 pretreatment NN I-NP O
51 315 316 10721819 , , O O
52 317 327 10721819 supporting VBG B-VP O
53 328 337 10721819 therefore RB B-ADVP O
54 338 341 10721819 the DT B-NP O
55 342 352 10721819 hypothesis NN I-NP O
56 353 357 10721819 that IN B-SBAR O
57 358 362 10721819 this DT B-NP O
58 363 369 10721819 effect NN I-NP O
59 370 372 10721819 is VBZ B-VP O
60 373 382 10721819 dependent JJ B-ADJP O
61 383 385 10721819 on IN B-PP O
62 386 397 10721819 sympathetic JJ B-NP O
63 398 405 10721819 outflow NN I-NP O
64 406 408 10721819 to TO B-PP O
65 409 412 10721819 the DT B-NP O
66 413 418 10721819 heart NN I-NP O
67 418 419 10721819 . . O O

1 420 424 10721819 This DT B-NP O
2 425 430 10721819 study NN I-NP O
3 431 434 10721819 was VBD B-VP O
4 435 444 10721819 conducted VBN I-VP O
5 445 447 10721819 to TO I-VP O
6 448 455 10721819 examine VB I-VP O
7 456 463 10721819 whether IN B-SBAR O
8 464 473 10721819 prolonged VBN B-NP O
9 474 486 10721819 pretreatment NN I-NP O
10 487 491 10721819 with IN B-PP O
11 492 505 10721819 isoproterenol NN B-NP B-Chemical
12 506 511 10721819 could MD B-VP O
13 512 519 10721819 abolish VB I-VP O
14 520 533 10721819 bromocriptine NN B-NP B-Chemical
15 533 534 10721819 - HYPH B-NP O
16 534 541 10721819 induced VBN I-NP O
17 542 553 10721819 tachycardia NN I-NP B-Disease
18 554 556 10721819 in IN B-PP O
19 557 566 10721819 conscious JJ B-NP O
20 567 571 10721819 rats NNS I-NP O
21 571 572 10721819 . . O O

1 573 586 10721819 Isoproterenol NN B-NP B-Chemical
2 587 599 10721819 pretreatment NN I-NP O
3 600 603 10721819 for IN B-PP O
4 604 606 10721819 15 CD B-NP O
5 607 611 10721819 days NNS I-NP O
6 612 618 10721819 caused VBD B-VP O
7 619 626 10721819 cardiac JJ B-NP B-Disease
8 627 638 10721819 hypertrophy NN I-NP I-Disease
9 639 646 10721819 without IN B-PP O
10 647 656 10721819 affecting VBG B-VP O
11 657 665 10721819 baseline NN B-NP O
12 666 671 10721819 blood NN I-NP O
13 672 680 10721819 pressure NN I-NP O
14 681 684 10721819 and CC I-NP O
15 685 690 10721819 heart NN I-NP O
16 691 695 10721819 rate NN I-NP O
17 695 696 10721819 . . O O

1 697 699 10721819 In IN B-PP O
2 700 707 10721819 control NN B-NP O
3 708 712 10721819 rats NNS I-NP O
4 712 713 10721819 , , O O
5 714 725 10721819 intravenous JJ B-NP O
6 726 739 10721819 bromocriptine NN I-NP B-Chemical
7 740 741 10721819 ( ( O O
8 741 744 10721819 150 CD B-NP O
9 745 751 10721819 microg NN I-NP O
10 751 752 10721819 / SYM B-NP O
11 752 754 10721819 kg NN I-NP O
12 754 755 10721819 ) ) O O
13 756 763 10721819 induced VBD B-VP O
14 764 775 10721819 significant JJ B-NP O
15 776 787 10721819 hypotension NN I-NP B-Disease
16 788 791 10721819 and CC I-NP O
17 792 803 10721819 tachycardia NN I-NP B-Disease
18 803 804 10721819 . . O O

1 805 818 10721819 Bromocriptine NN B-NP B-Chemical
2 818 819 10721819 - HYPH B-NP O
3 819 826 10721819 induced VBN I-NP O
4 827 838 10721819 hypotension NN I-NP B-Disease
5 839 842 10721819 was VBD B-VP O
6 843 853 10721819 unaffected JJ B-ADJP O
7 854 856 10721819 by IN B-PP O
8 857 870 10721819 isoproterenol NN B-NP B-Chemical
9 871 883 10721819 pretreatment NN I-NP O
10 883 884 10721819 , , O O
11 885 890 10721819 while IN B-SBAR O
12 891 902 10721819 tachycardia NN B-NP B-Disease
13 903 906 10721819 was VBD B-VP O
14 907 915 10721819 reversed VBN I-VP O
15 916 918 10721819 to TO B-PP O
16 919 930 10721819 significant JJ B-NP O
17 931 942 10721819 bradycardia NN I-NP B-Disease
18 942 943 10721819 , , O O
19 944 946 10721819 an DT B-NP O
20 947 953 10721819 effect NN I-NP O
21 954 958 10721819 that WDT B-NP O
22 959 962 10721819 was VBD B-VP O
23 963 969 10721819 partly RB I-VP O
24 970 977 10721819 reduced VBN I-VP O
25 978 980 10721819 by IN B-PP O
26 981 984 10721819 i.v NN B-NP O
27 984 985 10721819 . . O O

1 986 997 10721819 domperidone NN B-NP B-Chemical
2 998 999 10721819 ( ( O O
3 999 1002 10721819 0.5 CD B-NP O
4 1003 1005 10721819 mg NN I-NP O
5 1005 1006 10721819 / SYM B-NP O
6 1006 1008 10721819 kg NN I-NP O
7 1008 1009 10721819 ) ) O O
8 1009 1010 10721819 . . O O

1 1011 1018 10721819 Neither CC O O
2 1019 1026 10721819 cardiac JJ B-NP O
3 1027 1032 10721819 vagal JJ I-NP O
4 1033 1036 10721819 nor CC I-NP O
5 1037 1048 10721819 sympathetic JJ I-NP O
6 1049 1053 10721819 tone NN I-NP O
7 1054 1057 10721819 was VBD B-VP O
8 1058 1065 10721819 altered VBN I-VP O
9 1066 1068 10721819 by IN B-PP O
10 1069 1082 10721819 isoproterenol NN B-NP B-Chemical
11 1083 1095 10721819 pretreatment NN I-NP O
12 1095 1096 10721819 . . O O

1 1097 1099 10721819 In IN B-PP O
2 1100 1108 10721819 isolated VBN B-NP O
3 1109 1117 10721819 perfused VBN I-NP O
4 1118 1123 10721819 heart NN B-NP O
5 1124 1136 10721819 preparations NNS I-NP O
6 1137 1141 10721819 from IN B-PP O
7 1142 1155 10721819 isoproterenol NN B-NP B-Chemical
8 1155 1156 10721819 - HYPH B-NP O
9 1156 1166 10721819 pretreated VBN I-NP O
10 1167 1171 10721819 rats NNS I-NP O
11 1171 1172 10721819 , , O O
12 1173 1176 10721819 the DT B-NP O
13 1177 1190 10721819 isoproterenol NN I-NP B-Chemical
14 1190 1191 10721819 - HYPH O O
15 1191 1198 10721819 induced VBN B-NP O
16 1199 1206 10721819 maximal JJ I-NP O
17 1207 1215 10721819 increase NN I-NP O
18 1216 1218 10721819 in IN B-PP O
19 1219 1223 10721819 left JJ B-NP O
20 1224 1235 10721819 ventricular JJ I-NP O
21 1236 1244 10721819 systolic JJ I-NP O
22 1245 1253 10721819 pressure NN I-NP O
23 1254 1257 10721819 was VBD B-VP O
24 1258 1271 10721819 significantly RB I-VP O
25 1272 1279 10721819 reduced VBN I-VP O
26 1279 1280 10721819 , , O O
27 1281 1289 10721819 compared VBN B-PP O
28 1290 1294 10721819 with IN B-PP O
29 1295 1301 10721819 saline NN B-NP O
30 1301 1302 10721819 - HYPH B-NP O
31 1302 1312 10721819 pretreated VBN I-NP O
32 1313 1317 10721819 rats NNS I-NP O
33 1318 1319 10721819 ( ( O O
34 1319 1322 10721819 the DT B-NP O
35 1323 1327 10721819 EC50 NN I-NP O
36 1328 1330 10721819 of IN B-PP O
37 1331 1334 10721819 the DT B-NP O
38 1335 1348 10721819 isoproterenol NN I-NP B-Chemical
39 1348 1349 10721819 - HYPH B-VP O
40 1349 1356 10721819 induced VBN B-NP O
41 1357 1365 10721819 increase NN I-NP O
42 1366 1368 10721819 in IN B-PP O
43 1369 1373 10721819 left JJ B-NP O
44 1374 1385 10721819 ventricular JJ I-NP O
45 1386 1394 10721819 systolic JJ I-NP O
46 1395 1403 10721819 pressure NN I-NP O
47 1404 1407 10721819 was VBD B-VP O
48 1408 1416 10721819 enhanced VBN I-VP O
49 1417 1430 10721819 approximately RB B-NP O
50 1431 1433 10721819 22 CD I-NP O
51 1433 1434 10721819 - HYPH O O
52 1434 1438 10721819 fold RB B-ADVP O
53 1438 1439 10721819 ) ) O O
54 1439 1440 10721819 . . O O

1 1441 1446 10721819 These DT B-NP O
2 1447 1454 10721819 results NNS I-NP O
3 1455 1459 10721819 show VBP B-VP O
4 1460 1464 10721819 that IN B-SBAR O
5 1465 1467 10721819 15 CD B-NP O
6 1467 1468 10721819 - HYPH I-NP O
7 1468 1471 10721819 day NN I-NP O
8 1472 1485 10721819 isoproterenol NN I-NP B-Chemical
9 1486 1498 10721819 pretreatment NN I-NP O
10 1499 1502 10721819 not RB B-CONJP O
11 1503 1507 10721819 only RB I-CONJP O
12 1508 1517 10721819 abolished VBD B-VP O
13 1518 1521 10721819 but CC I-VP O
14 1522 1530 10721819 reversed VBD I-VP O
15 1531 1544 10721819 bromocriptine NN B-NP B-Chemical
16 1544 1545 10721819 - HYPH B-NP O
17 1545 1552 10721819 induced VBN I-NP O
18 1553 1564 10721819 tachycardia NN I-NP B-Disease
19 1565 1567 10721819 to TO B-PP O
20 1568 1579 10721819 bradycardia NN B-NP B-Disease
21 1579 1580 10721819 , , O O
22 1581 1583 10721819 an DT B-NP O
23 1584 1590 10721819 effect NN I-NP O
24 1591 1595 10721819 that WDT B-NP O
25 1596 1598 10721819 is VBZ B-VP O
26 1599 1605 10721819 mainly RB I-VP O
27 1606 1613 10721819 related VBN I-VP O
28 1614 1616 10721819 to TO I-VP O
29 1617 1624 10721819 further VB I-VP O
30 1625 1632 10721819 cardiac JJ B-NP O
31 1633 1637 10721819 beta SYM I-NP O
32 1637 1638 10721819 - HYPH I-NP O
33 1638 1650 10721819 adrenoceptor NN I-NP O
34 1651 1666 10721819 desensitization NN I-NP O
35 1667 1673 10721819 rather RB B-CONJP O
36 1674 1678 10721819 than IN I-CONJP O
37 1679 1681 10721819 to TO B-PP O
38 1682 1692 10721819 impairment NN B-NP O
39 1693 1695 10721819 of IN B-PP O
40 1696 1705 10721819 autonomic JJ B-NP O
41 1706 1716 10721819 regulation NN I-NP O
42 1717 1719 10721819 of IN B-PP O
43 1720 1723 10721819 the DT B-NP O
44 1724 1729 10721819 heart NN I-NP O
45 1729 1730 10721819 . . O O

1 1731 1735 10721819 They PRP B-NP O
2 1736 1743 10721819 suggest VBP B-VP O
3 1744 1748 10721819 that IN B-SBAR O
4 1748 1749 10721819 , , O O
5 1750 1752 10721819 in IN B-PP O
6 1753 1759 10721819 normal JJ B-NP O
7 1760 1769 10721819 conscious JJ I-NP O
8 1770 1774 10721819 rats NNS I-NP O
9 1774 1775 10721819 , , O O
10 1776 1779 10721819 the DT B-NP O
11 1780 1787 10721819 central JJ I-NP O
12 1788 1799 10721819 tachycardia NN I-NP B-Disease
13 1800 1802 10721819 of IN B-PP O
14 1803 1816 10721819 bromocriptine NN B-NP B-Chemical
15 1817 1824 10721819 appears VBZ B-VP O
16 1825 1827 10721819 to TO I-VP O
17 1828 1839 10721819 predominate VB I-VP O
18 1840 1843 10721819 and CC O O
19 1844 1846 10721819 to TO B-VP O
20 1847 1851 10721819 mask VB I-VP O
21 1852 1855 10721819 the DT B-NP O
22 1856 1867 10721819 bradycardia NN I-NP B-Disease
23 1868 1870 10721819 of IN B-PP O
24 1871 1875 10721819 this DT B-NP O
25 1876 1883 10721819 agonist NN I-NP O
26 1884 1886 10721819 at IN B-PP O
27 1887 1897 10721819 peripheral JJ B-NP O
28 1898 1906 10721819 dopamine NN I-NP B-Chemical
29 1907 1909 10721819 D2 NN I-NP O
30 1910 1919 10721819 receptors NNS I-NP O
31 1919 1920 10721819 . . O O

1 0 0 20621845 -DOCSTART- -X- -X- O

1 0 9 20621845 Elevation NN B-NP O
2 10 12 20621845 of IN B-PP O
3 13 19 20621845 ADAM10 NN B-NP O
4 19 20 20621845 , , O O
5 21 27 20621845 ADAM17 NN B-NP O
6 27 28 20621845 , , O O
7 29 32 20621845 MMP NN B-NP O
8 32 33 20621845 - HYPH B-NP O
9 33 34 20621845 2 CD I-NP O
10 35 38 20621845 and CC I-NP O
11 39 42 20621845 MMP NN I-NP O
12 42 43 20621845 - HYPH O O
13 43 44 20621845 9 CD B-NP O
14 45 55 20621845 expression NN I-NP O
15 56 60 20621845 with IN B-PP O
16 61 66 20621845 media NNS B-NP O
17 67 79 20621845 degeneration NN I-NP O
18 80 88 20621845 features VBZ B-VP O
19 89 94 20621845 CaCl2 NN B-NP B-Chemical
20 94 95 20621845 - HYPH O O
21 95 102 20621845 induced VBN B-NP O
22 103 111 20621845 thoracic JJ I-NP B-Disease
23 112 118 20621845 aortic JJ I-NP I-Disease
24 119 127 20621845 aneurysm NN I-NP I-Disease
25 128 130 20621845 in IN B-PP O
26 131 132 20621845 a DT B-NP O
27 133 136 20621845 rat NN I-NP O
28 137 142 20621845 model NN I-NP O
29 142 143 20621845 . . I-NP O
30 144 151 20621845 PURPOSE NN I-NP O
31 151 152 20621845 : : O O
32 153 157 20621845 This DT B-NP O
33 158 163 20621845 study NN I-NP O
34 164 167 20621845 was VBD B-VP O
35 168 176 20621845 designed VBN I-VP O
36 177 179 20621845 to TO B-VP O
37 180 189 20621845 establish VB I-VP O
38 190 191 20621845 a DT B-NP O
39 192 195 20621845 rat NN I-NP O
40 196 201 20621845 model NN I-NP O
41 202 204 20621845 of IN B-PP O
42 205 213 20621845 thoracic JJ B-NP B-Disease
43 214 220 20621845 aortic JJ I-NP I-Disease
44 221 229 20621845 aneurysm NN I-NP I-Disease
45 230 231 20621845 ( ( O O
46 231 234 20621845 TAA NN B-NP B-Disease
47 234 235 20621845 ) ) O O
48 236 238 20621845 by IN B-PP O
49 239 246 20621845 calcium NN B-NP B-Chemical
50 247 255 20621845 chloride NN I-NP I-Chemical
51 256 257 20621845 ( ( O O
52 257 264 20621845 CaCl(2) NN B-NP B-Chemical
53 264 265 20621845 ) ) O O
54 265 266 20621845 - HYPH O O
55 266 273 20621845 induced VBN B-NP O
56 274 282 20621845 arterial JJ I-NP B-Disease
57 283 289 20621845 injury NN I-NP I-Disease
58 290 293 20621845 and CC O O
59 294 296 20621845 to TO B-VP O
60 297 304 20621845 explore VB I-VP O
61 305 308 20621845 the DT B-NP O
62 309 318 20621845 potential JJ I-NP O
63 319 323 20621845 role NN I-NP O
64 324 326 20621845 of IN B-PP O
65 327 328 20621845 a DT B-NP O
66 329 340 20621845 disintegrin NN I-NP O
67 341 344 20621845 and CC I-NP O
68 345 362 20621845 metalloproteinase NN I-NP O
69 363 364 20621845 ( ( O O
70 364 368 20621845 ADAM NN B-NP O
71 368 369 20621845 ) ) O O
72 369 370 20621845 , , O O
73 371 377 20621845 matrix NN B-NP O
74 378 396 20621845 metalloproteinases NNS I-NP O
75 397 398 20621845 ( ( O O
76 398 402 20621845 MMPs NNS B-NP O
77 402 403 20621845 ) ) O O
78 404 407 20621845 and CC O O
79 408 413 20621845 their PRP$ B-NP O
80 414 424 20621845 endogenous JJ I-NP O
81 425 435 20621845 inhibitors NNS I-NP O
82 436 437 20621845 ( ( O O
83 437 442 20621845 TIMPs NNS B-NP O
84 442 443 20621845 ) ) O O
85 444 446 20621845 in IN B-PP O
86 447 450 20621845 TAA NN B-NP B-Disease
87 451 460 20621845 formation NN I-NP O
88 460 461 20621845 . . O O

1 462 469 20621845 METHODS NNS B-NP O
2 469 470 20621845 : : O O
3 471 479 20621845 Thoracic JJ B-NP O
4 480 485 20621845 aorta NN I-NP O
5 486 488 20621845 of IN B-PP O
6 489 493 20621845 male JJ B-NP O
7 494 501 20621845 Sprague NNP I-NP O
8 501 502 20621845 - HYPH I-NP O
9 502 508 20621845 Dawley NNP I-NP O
10 509 513 20621845 rats NNS I-NP O
11 514 517 20621845 was VBD B-VP O
12 518 525 20621845 exposed VBN I-VP O
13 526 528 20621845 to TO B-PP O
14 529 533 20621845 0.5M NN B-NP O
15 534 541 20621845 CaCl(2) NN I-NP B-Chemical
16 542 544 20621845 or CC O O
17 545 551 20621845 normal JJ B-NP O
18 552 558 20621845 saline NN I-NP O
19 559 560 20621845 ( ( O O
20 560 564 20621845 NaCl NN B-NP B-Chemical
21 564 565 20621845 ) ) O O
22 565 566 20621845 . . O O

1 567 572 20621845 After IN B-PP O
2 573 580 20621845 12weeks NNS B-NP O
3 580 581 20621845 , , O O
4 582 589 20621845 animals NNS B-NP O
5 590 594 20621845 were VBD B-VP O
6 595 605 20621845 euthanized VBN I-VP O
7 605 606 20621845 , , O O
8 607 610 20621845 and CC O O
9 611 618 20621845 CaCl(2) NN B-NP B-Chemical
10 618 619 20621845 - HYPH O O
11 619 626 20621845 treated VBN B-VP O
12 626 627 20621845 , , O O
13 628 635 20621845 CaCl(2) NN B-NP B-Chemical
14 635 636 20621845 - HYPH B-ADJP O
15 636 645 20621845 untreated JJ I-ADJP O
16 646 647 20621845 ( ( O O
17 647 648 20621845 n NN B-NP O
18 648 649 20621845 = SYM B-VP O
19 649 651 20621845 12 CD B-NP O
20 651 652 20621845 ) ) O O
21 653 656 20621845 and CC O O
22 657 661 20621845 NaCl NN B-NP B-Chemical
23 661 662 20621845 - HYPH B-VP O
24 662 669 20621845 treated VBN B-NP O
25 670 676 20621845 aortic JJ I-NP O
26 677 685 20621845 segments NNS I-NP O
27 686 687 20621845 ( ( O O
28 687 688 20621845 n NN B-NP O
29 688 689 20621845 = SYM B-VP O
30 689 691 20621845 12 CD B-NP O
31 691 692 20621845 ) ) O O
32 693 697 20621845 were VBD B-VP O
33 698 707 20621845 collected VBN I-VP O
34 708 711 20621845 for IN B-PP O
35 712 724 20621845 histological JJ B-NP O
36 725 728 20621845 and CC I-NP O
37 729 738 20621845 molecular JJ I-NP O
38 739 750 20621845 assessments NNS I-NP O
39 750 751 20621845 . . O O

1 752 755 20621845 MMP NN B-NP O
2 755 756 20621845 - HYPH I-NP O
3 756 760 20621845 TIMP NN I-NP O
4 761 764 20621845 and CC I-NP O
5 765 769 20621845 ADAM NN I-NP O
6 770 775 20621845 mRNAs NNS I-NP O
7 776 780 20621845 were VBD B-VP O
8 781 785 20621845 semi AFX O O
9 785 786 20621845 - HYPH O O
10 786 800 20621845 quantitatively RB B-VP O
11 801 809 20621845 analyzed VBN I-VP O
12 810 813 20621845 and CC O O
13 814 821 20621845 protein NN B-NP O
14 822 833 20621845 expressions NNS I-NP O
15 834 838 20621845 were VBD B-VP O
16 839 849 20621845 determined VBN I-VP O
17 850 852 20621845 by IN B-PP O
18 853 873 20621845 immunohistochemistry NN B-NP O
19 873 874 20621845 . . O O

1 875 882 20621845 RESULTS NNS B-NP O
2 882 883 20621845 : : O O
3 884 891 20621845 Despite IN B-PP O
4 892 899 20621845 similar JJ B-NP O
5 900 908 20621845 external JJ I-NP O
6 909 918 20621845 diameters NNS I-NP O
7 919 924 20621845 among IN B-PP O
8 925 932 20621845 CaCl(2) NN B-NP B-Chemical
9 932 933 20621845 - HYPH O O
10 933 940 20621845 treated VBN B-VP O
11 940 941 20621845 , , O O
12 942 945 20621845 non AFX O O
13 945 946 20621845 - HYPH B-NP O
14 946 953 20621845 CaCl(2) NN I-NP B-Chemical
15 953 954 20621845 - HYPH B-VP O
16 954 961 20621845 treated VBN I-VP O
17 962 965 20621845 and CC O O
18 966 970 20621845 NaCl NN B-NP B-Chemical
19 970 971 20621845 - HYPH B-NP O
20 971 978 20621845 treated VBN I-NP O
21 979 987 20621845 segments NNS I-NP O
22 987 988 20621845 , , O O
23 989 998 20621845 aneurymal JJ B-NP O
24 999 1009 20621845 alteration NN I-NP O
25 1010 1011 20621845 ( ( O O
26 1011 1012 20621845 n NN B-NP O
27 1012 1013 20621845 = SYM B-VP O
28 1013 1014 20621845 6 CD B-NP O
29 1014 1015 20621845 , , O O
30 1016 1019 20621845 50% CD B-NP O
31 1019 1020 20621845 ) ) O O
32 1020 1021 20621845 , , O O
33 1022 1027 20621845 media NNS B-NP O
34 1028 1040 20621845 degeneration NN I-NP O
35 1041 1045 20621845 with IN B-PP O
36 1046 1054 20621845 regional JJ B-NP O
37 1055 1065 20621845 disruption NN I-NP O
38 1065 1066 20621845 , , O O
39 1067 1080 20621845 fragmentation NN B-NP O
40 1081 1083 20621845 of IN B-PP O
41 1084 1091 20621845 elastic JJ B-NP O
42 1092 1097 20621845 fiber NN I-NP O
43 1097 1098 20621845 , , O O
44 1099 1102 20621845 and CC O O
45 1103 1112 20621845 increased VBD B-VP O
46 1113 1121 20621845 collagen NN B-NP O
47 1122 1132 20621845 deposition NN I-NP O
48 1133 1134 20621845 ( ( O O
49 1134 1135 20621845 n NN B-NP O
50 1135 1136 20621845 = SYM B-VP O
51 1136 1138 20621845 12 CD B-NP O
52 1138 1139 20621845 , , O O
53 1140 1144 20621845 100% CD B-NP O
54 1144 1145 20621845 ) ) O O
55 1146 1150 20621845 were VBD B-VP O
56 1151 1163 20621845 demonstrated VBN I-VP O
57 1164 1166 20621845 in IN B-PP O
58 1167 1174 20621845 CaCl(2) NN B-NP B-Chemical
59 1174 1175 20621845 - HYPH B-NP O
60 1175 1182 20621845 treated VBN I-NP O
61 1183 1191 20621845 segments NNS I-NP O
62 1191 1192 20621845 . . O O

1 1193 1196 20621845 MMP NN B-NP O
2 1196 1197 20621845 - HYPH O O
3 1197 1198 20621845 2 CD B-NP O
4 1198 1199 20621845 , , O O
5 1200 1203 20621845 MMP NN B-NP O
6 1203 1204 20621845 - HYPH O O
7 1204 1205 20621845 9 CD B-NP O
8 1205 1206 20621845 , , O O
9 1207 1211 20621845 ADAM NN B-NP O
10 1211 1212 20621845 - HYPH B-NP O
11 1212 1214 20621845 10 CD I-NP O
12 1215 1218 20621845 and CC I-NP O
13 1219 1223 20621845 ADAM NN I-NP O
14 1223 1224 20621845 - HYPH O O
15 1224 1226 20621845 17 CD B-NP O
16 1227 1231 20621845 mRNA NN I-NP O
17 1232 1238 20621845 levels NNS I-NP O
18 1239 1243 20621845 were VBD B-VP O
19 1244 1253 20621845 increased VBN I-VP O
20 1254 1256 20621845 in IN B-PP O
21 1257 1264 20621845 CaCl(2) NN B-NP B-Chemical
22 1264 1265 20621845 - HYPH B-NP O
23 1265 1272 20621845 treated VBN I-NP O
24 1273 1281 20621845 segments NNS I-NP O
25 1282 1283 20621845 ( ( O O
26 1283 1286 20621845 all DT B-NP O
27 1287 1288 20621845 p NN I-NP O
28 1288 1289 20621845 < JJR B-NP O
29 1289 1293 20621845 0.01 CD I-NP O
30 1293 1294 20621845 ) ) O O
31 1294 1295 20621845 , , O O
32 1296 1300 20621845 with IN B-PP O
33 1301 1307 20621845 trends NNS B-NP O
34 1308 1310 20621845 of IN B-PP O
35 1311 1320 20621845 elevation NN B-NP O
36 1321 1323 20621845 in IN B-PP O
37 1324 1331 20621845 CaCl(2) NN B-NP B-Chemical
38 1331 1332 20621845 - HYPH B-NP O
39 1332 1341 20621845 untreated JJ I-NP O
40 1342 1350 20621845 segments NNS I-NP O
41 1350 1351 20621845 , , O O
42 1352 1354 20621845 as IN B-SBAR O
43 1355 1363 20621845 compared VBN B-PP O
44 1364 1368 20621845 with IN B-PP O
45 1369 1373 20621845 NaCl NN B-NP B-Chemical
46 1373 1374 20621845 - HYPH B-NP O
47 1374 1381 20621845 treated VBN I-NP O
48 1382 1390 20621845 segments NNS I-NP O
49 1390 1391 20621845 . . O O

1 1392 1412 20621845 Immunohistochemistry NN B-NP O
2 1413 1422 20621845 displayed VBD B-VP O
3 1423 1436 20621845 significantly RB B-NP O
4 1437 1446 20621845 increased VBN I-NP O
5 1447 1458 20621845 expressions NNS I-NP O
6 1459 1461 20621845 of IN B-PP O
7 1462 1465 20621845 MMP NN B-NP O
8 1465 1466 20621845 - HYPH B-NP O
9 1466 1467 20621845 2 CD I-NP O
10 1467 1468 20621845 , , O O
11 1469 1472 20621845 MMP NN B-NP O
12 1472 1473 20621845 - HYPH O O
13 1473 1474 20621845 9 CD B-NP O
14 1474 1475 20621845 , , O O
15 1476 1480 20621845 ADAM NN B-NP O
16 1480 1481 20621845 - HYPH B-NP O
17 1481 1483 20621845 10 CD I-NP O
18 1484 1487 20621845 and CC I-NP O
19 1488 1492 20621845 ADAM NN I-NP O
20 1492 1493 20621845 - HYPH B-NP O
21 1493 1495 20621845 17 CD I-NP O
22 1496 1497 20621845 ( ( O O
23 1497 1500 20621845 all DT B-NP O
24 1501 1502 20621845 p NN I-NP O
25 1502 1503 20621845 < JJR B-NP O
26 1503 1507 20621845 0.01 CD I-NP O
27 1507 1508 20621845 ) ) O O
28 1509 1511 20621845 in IN B-PP O
29 1512 1518 20621845 intima NNS B-NP O
30 1519 1522 20621845 and CC I-NP O
31 1523 1528 20621845 media NNS I-NP O
32 1529 1532 20621845 for IN B-PP O
33 1533 1540 20621845 CaCl(2) NN B-NP B-Chemical
34 1540 1541 20621845 - HYPH B-NP O
35 1541 1548 20621845 treated VBN I-NP O
36 1549 1557 20621845 segments NNS I-NP O
37 1557 1558 20621845 . . O O

1 1559 1563 20621845 TIMP NN B-NP O
2 1564 1568 20621845 mRNA NN I-NP O
3 1569 1572 20621845 and CC I-NP O
4 1573 1579 20621845 tissue NN I-NP O
5 1580 1586 20621845 levels NNS I-NP O
6 1587 1590 20621845 did VBD B-VP O
7 1591 1594 20621845 not RB I-VP O
8 1595 1601 20621845 differ VB I-VP O
9 1602 1611 20621845 obviously RB B-ADVP O
10 1612 1617 20621845 among IN B-PP O
11 1618 1621 20621845 the DT B-NP O
12 1622 1627 20621845 three CD I-NP O
13 1628 1634 20621845 aortic JJ I-NP O
14 1635 1643 20621845 segments NNS I-NP O
15 1643 1644 20621845 . . O O

1 1645 1655 20621845 CONCLUSION NN B-NP O
2 1655 1656 20621845 : : O O
3 1657 1661 20621845 This DT B-NP O
4 1662 1667 20621845 study NN I-NP O
5 1668 1679 20621845 establishes VBZ B-VP O
6 1680 1681 20621845 a DT B-NP O
7 1682 1685 20621845 TAA NN I-NP B-Disease
8 1686 1691 20621845 model NN I-NP O
9 1692 1694 20621845 by IN B-PP O
10 1695 1707 20621845 periarterial JJ B-NP O
11 1708 1715 20621845 CaCl(2) NN I-NP B-Chemical
12 1716 1724 20621845 exposure NN I-NP O
13 1725 1727 20621845 in IN B-PP O
14 1728 1732 20621845 rats NNS B-NP O
15 1732 1733 20621845 , , O O
16 1734 1737 20621845 and CC O O
17 1738 1750 20621845 demonstrates VBZ B-VP O
18 1751 1752 20621845 a DT B-NP O
19 1753 1764 20621845 significant JJ I-NP O
20 1765 1774 20621845 elevation NN I-NP O
21 1775 1777 20621845 of IN B-PP O
22 1778 1788 20621845 expression NN B-NP O
23 1789 1791 20621845 of IN B-PP O
24 1792 1795 20621845 MMP NN B-NP O
25 1795 1796 20621845 - HYPH B-NP O
26 1796 1797 20621845 2 CD I-NP O
27 1797 1798 20621845 , , O O
28 1799 1802 20621845 MMP NN B-NP O
29 1802 1803 20621845 - HYPH O O
30 1803 1804 20621845 9 CD B-NP O
31 1804 1805 20621845 , , O O
32 1806 1812 20621845 ADAM10 NN B-NP O
33 1813 1816 20621845 and CC I-NP O
34 1817 1823 20621845 ADAM17 NN I-NP O
35 1824 1826 20621845 in IN B-PP O
36 1827 1830 20621845 the DT B-NP O
37 1831 1843 20621845 pathogenesis NN I-NP O
38 1844 1846 20621845 of IN B-PP O
39 1847 1855 20621845 vascular JJ B-NP O
40 1856 1866 20621845 remodeling NN I-NP O
41 1866 1867 20621845 . . O O

1 0 0 20698227 -DOCSTART- -X- -X- O

1 0 3 20698227 Can MD O O
2 4 16 20698227 angiogenesis NN B-NP O
3 17 19 20698227 be VB B-VP O
4 20 21 20698227 a DT B-NP O
5 22 28 20698227 target NN I-NP O
6 29 31 20698227 of IN B-PP O
7 32 41 20698227 treatment NN B-NP O
8 42 45 20698227 for IN B-PP O
9 46 55 20698227 ribavirin NN B-NP B-Chemical
10 56 66 20698227 associated JJ I-NP O
11 67 76 20698227 hemolytic JJ I-NP B-Disease
12 77 83 20698227 anemia NN I-NP I-Disease
13 83 84 20698227 ? . O O
14 85 95 20698227 BACKGROUND NN B-NP O
15 95 96 20698227 / SYM B-NP O
16 96 100 20698227 AIMS NNS I-NP O
17 100 101 20698227 : : O O
18 102 110 20698227 Recently RB B-NP O
19 111 120 20698227 ribavirin NN I-NP B-Chemical
20 121 124 20698227 has VBZ B-VP O
21 125 129 20698227 been VBN I-VP O
22 130 135 20698227 found VBN I-VP O
23 136 138 20698227 to TO I-VP O
24 139 146 20698227 inhibit VB I-VP O
25 147 159 20698227 angiogenesis NN B-NP O
26 160 163 20698227 and CC O O
27 164 165 20698227 a DT B-NP O
28 166 172 20698227 number NN I-NP O
29 173 175 20698227 of IN B-PP O
30 176 188 20698227 angiogenesis NN B-NP O
31 189 199 20698227 inhibitors NNS I-NP O
32 200 204 20698227 such JJ B-PP O
33 205 207 20698227 as IN I-PP O
34 208 217 20698227 sunitinib NN B-NP B-Chemical
35 218 221 20698227 and CC I-NP O
36 222 231 20698227 sorafenib NN I-NP B-Chemical
37 232 236 20698227 have VBP B-VP O
38 237 241 20698227 been VBN I-VP O
39 242 247 20698227 found VBN I-VP O
40 248 250 20698227 to TO I-VP O
41 251 256 20698227 cause VB I-VP O
42 257 262 20698227 acute JJ B-NP O
43 263 272 20698227 hemolysis NN I-NP B-Disease
44 272 273 20698227 . . O O

1 274 276 20698227 We PRP B-NP O
2 277 282 20698227 aimed VBD B-VP O
3 283 285 20698227 to TO I-VP O
4 286 297 20698227 investigate VB I-VP O
5 298 305 20698227 whether IN B-SBAR O
6 306 311 20698227 there EX B-NP O
7 312 314 20698227 is VBZ B-VP O
8 315 316 20698227 a DT B-NP O
9 317 325 20698227 relation NN I-NP O
10 326 333 20698227 between IN B-PP O
11 334 344 20698227 hemoglobin NN B-NP O
12 344 345 20698227 , , O O
13 346 357 20698227 haptoglobin NN B-NP O
14 358 361 20698227 and CC O O
15 362 374 20698227 angiogenesis NN B-NP O
16 375 382 20698227 soluble JJ I-NP O
17 383 390 20698227 markers NNS I-NP O
18 391 396 20698227 which WDT B-NP O
19 397 400 20698227 are VBP B-VP O
20 401 411 20698227 modifiable JJ B-ADJP O
21 412 415 20698227 and CC O O
22 416 419 20698227 can MD B-VP O
23 420 424 20698227 help VB I-VP O
24 425 427 20698227 in IN B-PP O
25 428 438 20698227 developing VBG B-VP O
26 439 449 20698227 strategies NNS B-NP O
27 450 457 20698227 against IN B-PP O
28 458 464 20698227 anemia NN B-NP B-Disease
29 464 465 20698227 . . O O

1 466 473 20698227 METHODS NNS B-NP O
2 473 474 20698227 : : O O
3 475 483 20698227 Fourteen CD B-NP O
4 484 492 20698227 patients NNS I-NP O
5 493 504 20698227 chronically RB B-VP B-Disease
6 505 513 20698227 infected VBN I-VP I-Disease
7 514 518 20698227 with IN B-PP I-Disease
8 519 528 20698227 hepatitis NN B-NP I-Disease
9 529 530 20698227 C NN I-NP I-Disease
10 531 536 20698227 virus NN I-NP I-Disease
11 537 541 20698227 were VBD B-VP O
12 542 549 20698227 treated VBN I-VP O
13 550 552 20698227 by IN B-PP O
14 553 562 20698227 pegylated VBN B-NP B-Chemical
15 563 573 20698227 interferon NN I-NP I-Chemical
16 574 579 20698227 alpha NN I-NP I-Chemical
17 580 582 20698227 2a NN I-NP I-Chemical
18 583 586 20698227 and CC I-NP O
19 587 596 20698227 ribavirin NN I-NP B-Chemical
20 596 597 20698227 . . O O

1 598 603 20698227 Serum NN B-NP O
2 604 614 20698227 hemoglobin NN I-NP O
3 614 615 20698227 , , O O
4 616 627 20698227 haptoglobin NN B-NP O
5 628 631 20698227 and CC I-NP O
6 632 644 20698227 angiogenesis NN I-NP O
7 645 652 20698227 markers NNS I-NP O
8 653 655 20698227 of IN B-PP O
9 656 664 20698227 vascular JJ B-NP O
10 665 676 20698227 endothelial JJ I-NP O
11 677 683 20698227 growth NN I-NP O
12 684 690 20698227 factor NN I-NP O
13 691 694 20698227 and CC I-NP O
14 695 706 20698227 angiopoetin NN I-NP O
15 706 707 20698227 - HYPH B-NP O
16 707 708 20698227 2 CD I-NP O
17 709 713 20698227 were VBD B-VP O
18 714 726 20698227 investigated VBN I-VP O
19 727 733 20698227 before IN B-PP O
20 734 737 20698227 and CC I-PP O
21 738 743 20698227 after IN I-PP O
22 744 751 20698227 therapy NN B-NP O
23 751 752 20698227 . . O O

1 753 760 20698227 RESULTS NNS B-NP O
2 760 761 20698227 : : O O
3 762 764 20698227 We PRP B-NP O
4 765 773 20698227 observed VBD B-VP O
5 774 775 20698227 a DT B-NP O
6 776 787 20698227 significant JJ I-NP O
7 788 796 20698227 decrease NN I-NP O
8 797 799 20698227 in IN B-PP O
9 800 811 20698227 haptoglobin NN B-NP O
10 812 818 20698227 levels NNS I-NP O
11 819 821 20698227 at IN B-PP O
12 822 825 20698227 the DT B-NP O
13 826 829 20698227 end NN I-NP O
14 830 832 20698227 of IN B-PP O
15 833 836 20698227 the DT B-NP O
16 837 846 20698227 treatment NN I-NP O
17 847 853 20698227 period NN I-NP O
18 853 854 20698227 . . O O

1 855 865 20698227 Hemoglobin NN B-NP O
2 866 872 20698227 levels NNS I-NP O
3 873 877 20698227 also RB B-ADVP O
4 878 887 20698227 decreased VBD B-VP O
5 888 891 20698227 but CC O O
6 892 907 20698227 insignificantly RB B-ADVP O
7 908 910 20698227 by IN B-PP O
8 911 920 20698227 treatment NN B-NP O
9 920 921 20698227 . . O O

1 922 924 20698227 In IN B-PP O
2 925 933 20698227 contrast NN B-NP O
3 934 938 20698227 with IN B-PP O
4 939 942 20698227 the DT B-NP O
5 943 953 20698227 literature NN I-NP O
6 953 954 20698227 , , O O
7 955 960 20698227 serum NN B-NP O
8 961 967 20698227 levels NNS I-NP O
9 968 970 20698227 of IN B-PP O
10 971 983 20698227 angiogenesis NN B-NP O
11 984 991 20698227 factors NNS I-NP O
12 992 995 20698227 did VBD B-VP O
13 996 999 20698227 not RB I-VP O
14 1000 1006 20698227 change VB I-VP O
15 1007 1020 20698227 significantly RB B-ADVP O
16 1021 1023 20698227 by IN B-PP O
17 1024 1033 20698227 pegylated VBN B-NP B-Chemical
18 1034 1044 20698227 interferon NN I-NP I-Chemical
19 1045 1048 20698227 and CC I-NP O
20 1049 1058 20698227 ribavirin NN I-NP B-Chemical
21 1059 1066 20698227 therapy NN I-NP O
22 1066 1067 20698227 . . O O

1 1068 1070 20698227 We PRP B-NP O
2 1071 1076 20698227 found VBD B-VP O
3 1077 1079 20698227 no DT B-NP O
4 1080 1091 20698227 correlation NN I-NP O
5 1092 1094 20698227 of IN B-PP O
6 1095 1107 20698227 angiogenesis NN B-NP O
7 1108 1115 20698227 soluble JJ I-NP O
8 1116 1123 20698227 markers NNS I-NP O
9 1124 1128 20698227 with IN B-PP O
10 1129 1135 20698227 either CC O O
11 1136 1146 20698227 hemoglobin NN B-NP O
12 1147 1149 20698227 or CC I-NP O
13 1150 1161 20698227 haptoglobin NN I-NP O
14 1161 1162 20698227 . . O O

1 1163 1173 20698227 CONCLUSION NN B-NP O
2 1173 1174 20698227 : : O O
3 1175 1179 20698227 This DT B-NP O
4 1180 1182 20698227 is VBZ B-VP O
5 1183 1186 20698227 the DT B-NP O
6 1187 1192 20698227 first JJ I-NP O
7 1193 1198 20698227 study NN I-NP O
8 1199 1201 20698227 in IN B-PP O
9 1202 1205 20698227 the DT B-NP O
10 1206 1216 20698227 literature NN I-NP O
11 1217 1230 20698227 investigating VBG B-VP O
12 1231 1232 20698227 a DT B-NP O
13 1233 1237 20698227 link NN I-NP O
14 1238 1245 20698227 between IN B-PP O
15 1246 1258 20698227 angiogenesis NN B-NP O
16 1259 1266 20698227 soluble JJ I-NP O
17 1267 1274 20698227 markers NNS I-NP O
18 1275 1278 20698227 and CC I-NP O
19 1279 1288 20698227 ribavirin NN I-NP B-Chemical
20 1289 1296 20698227 induced VBD B-VP O
21 1297 1303 20698227 anemia NN B-NP B-Disease
22 1304 1306 20698227 in IN B-PP O
23 1307 1315 20698227 patients NNS B-NP O
24 1316 1320 20698227 with IN B-PP O
25 1321 1330 20698227 hepatitis NN B-NP B-Disease
26 1331 1332 20698227 C NN I-NP I-Disease
27 1333 1336 20698227 and CC O O
28 1337 1339 20698227 we PRP B-NP O
29 1340 1345 20698227 could MD B-VP O
30 1346 1349 20698227 not RB I-VP O
31 1350 1354 20698227 find VB I-VP O
32 1355 1358 20698227 any DT B-NP O
33 1359 1367 20698227 relation NN I-NP O
34 1367 1368 20698227 . . O O

1 1369 1375 20698227 Future JJ B-NP O
2 1376 1384 20698227 research NN I-NP O
3 1385 1389 20698227 with IN B-PP O
4 1390 1396 20698227 larger JJR B-NP O
5 1397 1403 20698227 number NN I-NP O
6 1404 1406 20698227 of IN B-PP O
7 1407 1415 20698227 patients NNS B-NP O
8 1416 1418 20698227 is VBZ B-VP O
9 1419 1425 20698227 needed VBN I-VP O
10 1426 1428 20698227 to TO I-VP O
11 1429 1433 20698227 find VB I-VP O
12 1434 1437 20698227 out RP B-PRT O
13 1438 1448 20698227 modifiable JJ B-NP O
14 1449 1456 20698227 factors NNS I-NP O
15 1457 1461 20698227 that WDT B-NP O
16 1462 1466 20698227 will MD B-VP O
17 1467 1474 20698227 improve VB I-VP O
18 1475 1478 20698227 the DT B-NP O
19 1479 1485 20698227 safety NN I-NP O
20 1486 1488 20698227 of IN B-PP O
21 1489 1498 20698227 ribavirin NN B-NP B-Chemical
22 1499 1506 20698227 therapy NN I-NP O
23 1506 1507 20698227 . . O O

1 0 0 6747681 -DOCSTART- -X- -X- O

1 0 5 6747681 Intra AFX B-NP O
2 5 6 6747681 - HYPH I-NP O
3 6 14 6747681 arterial JJ I-NP O
4 15 19 6747681 BCNU NN I-NP B-Chemical
5 20 32 6747681 chemotherapy NN I-NP O
6 33 36 6747681 for IN B-PP O
7 37 46 6747681 treatment NN B-NP O
8 47 49 6747681 of IN B-PP O
9 50 59 6747681 malignant JJ B-NP B-Disease
10 60 67 6747681 gliomas NNS I-NP I-Disease
11 68 70 6747681 of IN B-PP O
12 71 74 6747681 the DT B-NP O
13 75 82 6747681 central JJ I-NP O
14 83 90 6747681 nervous JJ I-NP O
15 91 97 6747681 system NN I-NP O
16 97 98 6747681 . . O O
17 99 106 6747681 Because IN B-PP O
18 107 109 6747681 of IN I-PP O
19 110 113 6747681 the DT B-NP O
20 114 119 6747681 rapid JJ I-NP O
21 120 128 6747681 systemic JJ I-NP O
22 129 138 6747681 clearance NN I-NP O
23 139 141 6747681 of IN B-PP O
24 142 146 6747681 BCNU NN B-NP B-Chemical
25 147 148 6747681 ( ( O O
26 148 151 6747681 1,3 CD B-NP B-Chemical
27 151 152 6747681 - HYPH I-NP I-Chemical
28 152 155 6747681 bis NN I-NP I-Chemical
29 155 156 6747681 - HYPH B-NP I-Chemical
30 156 158 6747681 (2 CD I-NP I-Chemical
31 158 159 6747681 - HYPH I-NP I-Chemical
32 159 171 6747681 chloroethyl) NN I-NP I-Chemical
33 171 172 6747681 - HYPH B-NP I-Chemical
34 172 173 6747681 1 CD I-NP I-Chemical
35 173 174 6747681 - HYPH I-NP I-Chemical
36 174 185 6747681 nitrosourea NN I-NP I-Chemical
37 185 186 6747681 ) ) O O
38 186 187 6747681 , , O O
39 188 193 6747681 intra AFX O O
40 193 194 6747681 - HYPH O O
41 194 202 6747681 arterial JJ B-NP O
42 203 217 6747681 administration NN I-NP O
43 218 224 6747681 should MD B-VP O
44 225 232 6747681 provide VB I-VP O
45 233 234 6747681 a DT B-NP O
46 235 246 6747681 substantial JJ I-NP O
47 247 256 6747681 advantage NN I-NP O
48 257 261 6747681 over IN B-PP O
49 262 273 6747681 intravenous JJ B-NP O
50 274 288 6747681 administration NN I-NP O
51 289 292 6747681 for IN B-PP O
52 293 296 6747681 the DT B-NP O
53 297 306 6747681 treatment NN I-NP O
54 307 309 6747681 of IN B-PP O
55 310 319 6747681 malignant JJ B-NP B-Disease
56 320 327 6747681 gliomas NNS I-NP I-Disease
57 327 328 6747681 . . O O

1 329 335 6747681 Thirty CD B-NP O
2 335 336 6747681 - HYPH I-NP O
3 336 339 6747681 six CD I-NP O
4 340 348 6747681 patients NNS I-NP O
5 349 353 6747681 were VBD B-VP O
6 354 361 6747681 treated VBN I-VP O
7 362 366 6747681 with IN B-PP O
8 367 371 6747681 BCNU NN B-NP B-Chemical
9 372 377 6747681 every DT B-NP O
10 378 379 6747681 6 CD I-NP O
11 380 382 6747681 to TO I-NP O
12 383 384 6747681 8 CD I-NP O
13 385 390 6747681 weeks NNS I-NP O
14 390 391 6747681 , , O O
15 392 398 6747681 either CC O O
16 399 401 6747681 by IN B-PP O
17 402 414 6747681 transfemoral JJ B-NP O
18 415 430 6747681 catheterization NN I-NP O
19 431 433 6747681 of IN B-PP O
20 434 437 6747681 the DT B-NP O
21 438 446 6747681 internal JJ I-NP O
22 447 454 6747681 carotid NN I-NP O
23 455 457 6747681 or CC O O
24 458 467 6747681 vertebral JJ B-NP O
25 468 474 6747681 artery NN I-NP O
26 475 477 6747681 or CC B-PP O
27 478 485 6747681 through IN B-PP O
28 486 487 6747681 a DT B-NP O
29 488 493 6747681 fully RB I-NP O
30 494 505 6747681 implantable JJ I-NP O
31 506 518 6747681 intracarotid JJ I-NP O
32 519 523 6747681 drug NN I-NP O
33 524 532 6747681 delivery NN I-NP O
34 533 539 6747681 system NN I-NP O
35 539 540 6747681 , , O O
36 541 550 6747681 beginning VBG B-VP O
37 551 555 6747681 with IN B-PP O
38 556 557 6747681 a DT B-NP O
39 558 562 6747681 dose NN I-NP O
40 563 565 6747681 of IN B-PP O
41 566 569 6747681 200 CD B-NP O
42 570 572 6747681 mg NN I-NP O
43 572 573 6747681 / SYM B-NP O
44 573 575 6747681 sq NN I-NP O
45 576 577 6747681 m NN I-NP O
46 578 582 6747681 body NN I-NP O
47 583 590 6747681 surface NN I-NP O
48 591 595 6747681 area NN I-NP O
49 595 596 6747681 . . O O

1 597 603 6747681 Twelve CD B-NP O
2 604 612 6747681 patients NNS I-NP O
3 613 617 6747681 with IN B-PP O
4 618 623 6747681 Grade NN B-NP O
5 624 627 6747681 III CD I-NP O
6 628 630 6747681 or CC I-NP O
7 631 633 6747681 IV CD I-NP O
8 634 646 6747681 astrocytomas NNS I-NP B-Disease
9 647 651 6747681 were VBD B-VP O
10 652 659 6747681 treated VBN I-VP O
11 660 665 6747681 after IN B-PP O
12 666 673 6747681 partial JJ B-NP O
13 674 683 6747681 resection NN I-NP O
14 684 686 6747681 of IN B-PP O
15 687 690 6747681 the DT B-NP O
16 691 696 6747681 tumor NN I-NP B-Disease
17 697 704 6747681 without IN B-PP O
18 705 710 6747681 prior JJ B-NP O
19 711 720 6747681 radiation NN I-NP O
20 721 728 6747681 therapy NN I-NP O
21 728 729 6747681 . . O O

1 730 735 6747681 After IN B-PP O
2 736 739 6747681 two CD B-NP O
3 740 742 6747681 to TO I-NP O
4 743 748 6747681 seven CD I-NP O
5 749 755 6747681 cycles NNS I-NP O
6 756 758 6747681 of IN B-PP O
7 759 771 6747681 chemotherapy NN B-NP O
8 771 772 6747681 , , O O
9 773 777 6747681 nine CD B-NP O
10 778 786 6747681 patients NNS I-NP O
11 787 793 6747681 showed VBD B-VP O
12 794 795 6747681 a DT B-NP O
13 796 804 6747681 decrease NN I-NP O
14 805 807 6747681 in IN B-PP O
15 808 813 6747681 tumor NN B-NP B-Disease
16 814 818 6747681 size NN I-NP O
17 819 822 6747681 and CC O O
18 823 834 6747681 surrounding VBG B-VP O
19 835 840 6747681 edema NN B-NP B-Disease
20 841 843 6747681 on IN B-PP O
21 844 852 6747681 contrast NN B-NP O
22 852 853 6747681 - HYPH O O
23 853 861 6747681 enhanced VBN B-VP O
24 862 874 6747681 computerized VBN B-NP O
25 875 885 6747681 tomography NN I-NP O
26 886 891 6747681 scans NNS I-NP O
27 891 892 6747681 . . O O

1 893 895 6747681 In IN B-PP O
2 896 899 6747681 the DT B-NP O
3 900 904 6747681 nine CD I-NP O
4 905 915 6747681 responders NNS I-NP O
5 915 916 6747681 , , O O
6 917 923 6747681 median JJ B-NP O
7 924 932 6747681 duration NN I-NP O
8 933 935 6747681 of IN B-PP O
9 936 948 6747681 chemotherapy NN B-NP O
10 949 957 6747681 response NN I-NP O
11 958 962 6747681 from IN B-PP O
12 963 966 6747681 the DT B-NP O
13 967 971 6747681 time NN I-NP O
14 972 974 6747681 of IN B-PP O
15 975 984 6747681 operation NN B-NP O
16 985 988 6747681 was VBD B-VP O
17 989 991 6747681 25 CD B-NP O
18 992 997 6747681 weeks NNS I-NP O
19 998 999 6747681 ( ( O O
20 999 1004 6747681 range NN B-NP O
21 1005 1007 6747681 12 CD I-NP O
22 1008 1010 6747681 to TO B-PP O
23 1011 1015 6747681 more JJR B-NP O
24 1016 1020 6747681 than IN I-NP O
25 1021 1023 6747681 91 CD I-NP O
26 1024 1029 6747681 weeks NNS I-NP O
27 1029 1030 6747681 ) ) O O
28 1030 1031 6747681 . . O O

1 1032 1035 6747681 The DT B-NP O
2 1036 1042 6747681 median JJ I-NP O
3 1043 1051 6747681 duration NN I-NP O
4 1052 1054 6747681 of IN B-PP O
5 1055 1063 6747681 survival NN B-NP O
6 1064 1066 6747681 in IN B-PP O
7 1067 1070 6747681 the DT B-NP O
8 1071 1073 6747681 12 CD I-NP O
9 1074 1082 6747681 patients NNS I-NP O
10 1083 1086 6747681 was VBD B-VP O
11 1087 1089 6747681 54 CD B-NP O
12 1090 1095 6747681 weeks NNS I-NP O
13 1096 1097 6747681 ( ( O O
14 1097 1102 6747681 range NN B-NP O
15 1103 1105 6747681 21 CD I-NP O
16 1106 1108 6747681 to TO B-PP O
17 1109 1113 6747681 more JJR B-NP O
18 1114 1118 6747681 than IN I-NP O
19 1119 1122 6747681 156 CD I-NP O
20 1123 1128 6747681 weeks NNS I-NP O
21 1128 1129 6747681 ) ) O O
22 1129 1130 6747681 , , O O
23 1131 1135 6747681 with IN B-PP O
24 1136 1138 6747681 an DT B-NP O
25 1139 1141 6747681 18 CD I-NP O
26 1141 1142 6747681 - HYPH I-NP O
27 1142 1147 6747681 month NN I-NP O
28 1148 1156 6747681 survival NN I-NP O
29 1157 1161 6747681 rate NN I-NP O
30 1162 1164 6747681 of IN B-PP O
31 1165 1168 6747681 42% NN B-NP O
32 1168 1169 6747681 . . O O

1 1170 1176 6747681 Twenty CD B-NP O
2 1176 1177 6747681 - HYPH I-NP O
3 1177 1181 6747681 four CD B-NP O
4 1182 1190 6747681 patients NNS I-NP O
5 1191 1195 6747681 with IN B-PP O
6 1196 1205 6747681 recurrent JJ B-NP O
7 1206 1211 6747681 Grade NN I-NP O
8 1212 1213 6747681 I CD I-NP O
9 1214 1216 6747681 to TO I-NP O
10 1217 1219 6747681 IV CD I-NP O
11 1220 1232 6747681 astrocytomas NNS I-NP B-Disease
12 1232 1233 6747681 , , O O
13 1234 1239 6747681 whose WP$ B-NP O
14 1240 1249 6747681 resection NN I-NP O
15 1250 1253 6747681 and CC I-NP O
16 1254 1265 6747681 irradiation NN I-NP O
17 1266 1273 6747681 therapy NN I-NP O
18 1274 1277 6747681 had VBD B-VP O
19 1278 1284 6747681 failed VBN I-VP O
20 1284 1285 6747681 , , O O
21 1286 1294 6747681 received VBD B-VP O
22 1295 1298 6747681 two CD B-NP O
23 1299 1301 6747681 to TO I-NP O
24 1302 1307 6747681 eight CD I-NP O
25 1308 1315 6747681 courses NNS I-NP O
26 1316 1318 6747681 of IN B-PP O
27 1319 1324 6747681 intra AFX B-NP O
28 1324 1325 6747681 - HYPH I-NP O
29 1325 1333 6747681 arterial JJ I-NP O
30 1334 1338 6747681 BCNU NN I-NP B-Chemical
31 1339 1346 6747681 therapy NN I-NP O
32 1346 1347 6747681 . . O O

1 1348 1357 6747681 Seventeen CD B-NP O
2 1358 1360 6747681 of IN B-PP O
3 1361 1366 6747681 these DT B-NP O
4 1367 1370 6747681 had VBD B-VP O
5 1371 1372 6747681 a DT B-NP O
6 1373 1381 6747681 response NN I-NP O
7 1382 1384 6747681 or CC O O
8 1385 1389 6747681 were VBD B-VP O
9 1390 1396 6747681 stable JJ B-ADJP O
10 1397 1400 6747681 for IN B-PP O
11 1401 1402 6747681 a DT B-NP O
12 1403 1409 6747681 median NN I-NP O
13 1410 1412 6747681 of IN B-PP O
14 1413 1415 6747681 20 CD B-NP O
15 1416 1421 6747681 weeks NNS I-NP O
16 1422 1423 6747681 ( ( O O
17 1423 1428 6747681 range NN B-NP O
18 1429 1430 6747681 6 CD I-NP O
19 1431 1433 6747681 to TO B-PP O
20 1434 1438 6747681 more JJR B-NP O
21 1439 1443 6747681 than IN I-NP O
22 1444 1446 6747681 66 CD I-NP O
23 1447 1452 6747681 weeks NNS I-NP O
24 1452 1453 6747681 ) ) O O
25 1453 1454 6747681 . . O O

1 1455 1458 6747681 The DT B-NP O
2 1459 1474 6747681 catheterization NN I-NP O
3 1475 1484 6747681 procedure NN I-NP O
4 1485 1487 6747681 is VBZ B-VP O
5 1488 1492 6747681 safe JJ B-ADJP O
6 1492 1493 6747681 , , O O
7 1494 1498 6747681 with IN B-PP O
8 1499 1501 6747681 no DT B-NP O
9 1502 1511 6747681 immediate JJ I-NP O
10 1512 1524 6747681 complication NN I-NP O
11 1525 1527 6747681 in IN B-PP O
12 1528 1531 6747681 111 CD B-NP O
13 1532 1541 6747681 infusions NNS I-NP O
14 1542 1544 6747681 of IN B-PP O
15 1545 1549 6747681 BCNU NN B-NP B-Chemical
16 1549 1550 6747681 . . O O

1 1551 1552 6747681 A DT B-NP O
2 1553 1560 6747681 delayed VBN I-NP O
3 1561 1573 6747681 complication NN I-NP O
4 1574 1576 6747681 in IN B-PP O
5 1577 1581 6747681 nine CD B-NP O
6 1582 1590 6747681 patients NNS I-NP O
7 1591 1594 6747681 has VBZ B-VP O
8 1595 1599 6747681 been VBN I-VP O
9 1600 1610 6747681 unilateral JJ B-NP O
10 1611 1615 6747681 loss NN I-NP B-Disease
11 1616 1618 6747681 of IN B-PP I-Disease
12 1619 1625 6747681 vision NN B-NP I-Disease
13 1626 1635 6747681 secondary JJ B-ADJP O
14 1636 1638 6747681 to TO B-PP O
15 1639 1640 6747681 a DT B-NP O
16 1641 1648 6747681 retinal JJ I-NP B-Disease
17 1649 1659 6747681 vasculitis NN I-NP I-Disease
18 1659 1660 6747681 . . O O

1 1661 1664 6747681 The DT B-NP O
2 1665 1674 6747681 frequency NN I-NP O
3 1675 1677 6747681 of IN B-PP O
4 1678 1684 6747681 visual JJ B-NP B-Disease
5 1685 1689 6747681 loss NN I-NP I-Disease
6 1690 1699 6747681 decreased VBD B-VP O
7 1700 1705 6747681 after IN B-SBAR O
8 1706 1709 6747681 the DT B-NP O
9 1710 1723 6747681 concentration NN I-NP O
10 1724 1726 6747681 of IN B-PP O
11 1727 1730 6747681 the DT B-NP O
12 1731 1738 6747681 ethanol NN I-NP B-Chemical
13 1739 1746 6747681 diluent NN I-NP O
14 1747 1750 6747681 was VBD B-VP O
15 1751 1758 6747681 lowered VBN I-VP O
16 1758 1759 6747681 . . O O

1 0 0 6229975 -DOCSTART- -X- -X- O

1 0 7 6229975 Changes NNS B-NP O
2 8 10 6229975 in IN B-PP O
3 11 16 6229975 heart NN B-NP O
4 17 21 6229975 size NN I-NP O
5 22 28 6229975 during IN B-PP O
6 29 33 6229975 long JJ B-NP O
7 33 34 6229975 - HYPH I-NP O
8 34 38 6229975 term NN I-NP O
9 39 46 6229975 timolol NN I-NP B-Chemical
10 47 56 6229975 treatment NN I-NP O
11 57 62 6229975 after IN B-PP O
12 63 73 6229975 myocardial JJ B-NP B-Disease
13 74 84 6229975 infarction NN I-NP I-Disease
14 84 85 6229975 . . O O
15 86 89 6229975 The DT B-NP O
16 90 96 6229975 effect NN I-NP O
17 97 99 6229975 of IN B-PP O
18 100 104 6229975 long JJ B-NP O
19 104 105 6229975 - HYPH I-NP O
20 105 109 6229975 term NN I-NP O
21 110 117 6229975 timolol NN I-NP B-Chemical
22 118 127 6229975 treatment NN I-NP O
23 128 130 6229975 on IN B-PP O
24 131 136 6229975 heart NN B-NP O
25 137 141 6229975 size NN I-NP O
26 142 147 6229975 after IN B-PP O
27 148 158 6229975 myocardial JJ B-NP B-Disease
28 159 169 6229975 infarction NN I-NP I-Disease
29 170 173 6229975 was VBD B-VP O
30 174 183 6229975 evaluated VBN I-VP O
31 184 186 6229975 by IN B-PP O
32 187 188 6229975 X NN B-NP O
33 188 189 6229975 - HYPH B-NP O
34 189 192 6229975 ray NN I-NP O
35 193 195 6229975 in IN B-PP O
36 196 197 6229975 a DT B-NP O
37 198 204 6229975 double JJ I-NP O
38 204 205 6229975 - HYPH I-NP O
39 205 210 6229975 blind JJ I-NP O
40 211 216 6229975 study NN I-NP O
41 217 226 6229975 including VBG B-PP O
42 227 230 6229975 241 CD B-NP O
43 231 239 6229975 patients NNS I-NP O
44 240 241 6229975 ( ( O O
45 241 248 6229975 placebo NN B-NP O
46 249 252 6229975 126 CD I-NP O
47 252 253 6229975 , , O O
48 254 261 6229975 timolol NN B-NP B-Chemical
49 262 265 6229975 115 CD I-NP O
50 265 266 6229975 ) ) O O
51 266 267 6229975 . . O O

1 268 271 6229975 The DT B-NP O
2 272 278 6229975 follow VB I-NP O
3 278 279 6229975 - HYPH B-VP O
4 279 281 6229975 up RP B-PRT O
5 282 288 6229975 period NN B-NP O
6 289 292 6229975 was VBD B-VP O
7 293 295 6229975 12 CD B-NP O
8 296 302 6229975 months NNS I-NP O
9 302 303 6229975 . . O O

1 304 307 6229975 The DT B-NP O
2 308 315 6229975 timolol NN I-NP B-Chemical
3 315 316 6229975 - HYPH O O
4 316 323 6229975 treated VBN B-NP O
5 324 332 6229975 patients NNS I-NP O
6 333 339 6229975 showed VBD B-VP O
7 340 341 6229975 a DT B-NP O
8 342 347 6229975 small JJ I-NP O
9 348 351 6229975 but CC I-NP O
10 352 363 6229975 significant JJ I-NP O
11 364 372 6229975 increase NN I-NP O
12 373 375 6229975 in IN B-PP O
13 376 381 6229975 heart NN B-NP O
14 382 386 6229975 size NN I-NP O
15 387 391 6229975 from IN B-PP O
16 392 400 6229975 baseline NN B-NP O
17 401 403 6229975 in IN B-PP O
18 404 412 6229975 contrast NN B-NP O
19 413 415 6229975 to TO B-PP O
20 416 417 6229975 a DT B-NP O
21 418 426 6229975 decrease NN I-NP O
22 427 429 6229975 in IN B-PP O
23 430 433 6229975 the DT B-NP O
24 434 441 6229975 placebo NN I-NP O
25 442 447 6229975 group NN I-NP O
26 447 448 6229975 . . O O

1 449 454 6229975 These DT B-NP O
2 455 466 6229975 differences NNS I-NP O
3 467 470 6229975 may MD B-VP O
4 471 473 6229975 be VB I-VP O
5 474 480 6229975 caused VBN I-VP O
6 481 483 6229975 by IN B-PP O
7 484 491 6229975 timolol NN B-NP B-Chemical
8 491 492 6229975 - HYPH O O
9 492 499 6229975 induced VBN B-NP O
10 500 511 6229975 bradycardia NN I-NP B-Disease
11 512 515 6229975 and CC O O
12 516 517 6229975 a DT B-NP O
13 518 530 6229975 compensatory JJ I-NP O
14 531 539 6229975 increase NN I-NP O
15 540 542 6229975 in IN B-PP O
16 543 546 6229975 end NN B-NP O
17 546 547 6229975 - HYPH B-NP O
18 547 556 6229975 diastolic JJ I-NP O
19 557 563 6229975 volume NN I-NP O
20 563 564 6229975 . . O O

1 565 568 6229975 The DT B-NP O
2 569 576 6229975 timolol NN I-NP B-Chemical
3 576 577 6229975 - HYPH B-VP O
4 577 584 6229975 related VBN B-NP O
5 585 593 6229975 increase NN I-NP O
6 594 596 6229975 in IN B-PP O
7 597 602 6229975 heart NN B-NP O
8 603 607 6229975 size NN I-NP O
9 608 611 6229975 was VBD B-VP O
10 612 620 6229975 observed VBN I-VP O
11 621 625 6229975 only RB B-ADVP O
12 626 628 6229975 in IN B-PP O
13 629 637 6229975 patients NNS B-NP O
14 638 642 6229975 with IN B-PP O
15 643 649 6229975 normal JJ B-NP O
16 650 653 6229975 and CC I-NP O
17 654 664 6229975 borderline JJ I-NP O
18 665 670 6229975 heart NN I-NP O
19 671 675 6229975 size NN I-NP O
20 675 676 6229975 . . O O

1 677 679 6229975 In IN B-PP O
2 680 688 6229975 patients NNS B-NP O
3 689 693 6229975 with IN B-PP O
4 694 706 6229975 cardiomegaly NN B-NP B-Disease
5 706 707 6229975 , , O O
6 708 711 6229975 the DT B-NP O
7 712 720 6229975 increase NN I-NP O
8 721 723 6229975 in IN B-PP O
9 724 729 6229975 heart NN B-NP O
10 730 734 6229975 size NN I-NP O
11 735 738 6229975 was VBD B-VP O
12 739 746 6229975 similar JJ B-ADJP O
13 747 749 6229975 in IN B-PP O
14 750 754 6229975 both DT B-NP O
15 755 761 6229975 groups NNS I-NP O
16 761 762 6229975 . . O O

1 763 768 6229975 After IN B-PP O
2 769 771 6229975 re AFX B-NP O
3 771 772 6229975 - HYPH I-NP O
4 772 782 6229975 infarction NN I-NP B-Disease
5 782 783 6229975 , , O O
6 784 789 6229975 heart NN B-NP O
7 790 794 6229975 size NN I-NP O
8 795 804 6229975 increased VBD B-VP O
9 805 807 6229975 in IN B-PP O
10 808 811 6229975 the DT B-NP O
11 812 819 6229975 placebo NN I-NP O
12 820 825 6229975 group NN I-NP O
13 826 829 6229975 and CC O O
14 830 838 6229975 remained VBD B-VP O
15 839 848 6229975 unchanged JJ B-ADJP O
16 849 851 6229975 in IN B-PP O
17 852 855 6229975 the DT B-NP O
18 856 863 6229975 timolol NN I-NP B-Chemical
19 864 869 6229975 group NN I-NP O
20 869 870 6229975 . . O O

1 0 0 19269743 -DOCSTART- -X- -X- O

1 0 8 19269743 Explicit JJ B-NP O
2 9 17 19269743 episodic JJ I-NP O
3 18 24 19269743 memory NN I-NP O
4 25 28 19269743 for IN B-PP O
5 29 36 19269743 sensory NN B-NP O
6 36 37 19269743 - HYPH B-NP O
7 37 51 19269743 discriminative JJ I-NP O
8 52 62 19269743 components NNS I-NP O
9 63 65 19269743 of IN B-PP O
10 66 75 19269743 capsaicin NN B-NP B-Chemical
11 75 76 19269743 - HYPH B-NP O
12 76 83 19269743 induced VBN I-NP O
13 84 88 19269743 pain NN I-NP B-Disease
14 88 89 19269743 : : O O
15 90 99 19269743 immediate JJ B-NP O
16 100 103 19269743 and CC I-NP O
17 104 111 19269743 delayed VBN I-NP O
18 112 119 19269743 ratings NNS I-NP O
19 119 120 19269743 . . O O
20 121 125 19269743 Pain NNP B-NP B-Disease
21 126 132 19269743 memory NN I-NP O
22 133 135 19269743 is VBZ B-VP O
23 136 143 19269743 thought VBN I-VP O
24 144 146 19269743 to TO I-VP O
25 147 153 19269743 affect VB I-VP O
26 154 160 19269743 future JJ B-NP O
27 161 165 19269743 pain NN I-NP B-Disease
28 166 177 19269743 sensitivity NN I-NP O
29 178 181 19269743 and CC O O
30 182 186 19269743 thus RB B-ADVP O
31 187 197 19269743 contribute VBP B-VP O
32 198 200 19269743 to TO B-PP O
33 201 209 19269743 clinical JJ B-NP O
34 210 214 19269743 pain NN I-NP B-Disease
35 215 225 19269743 conditions NNS I-NP O
36 225 226 19269743 . . O O

1 227 237 19269743 Systematic JJ B-NP O
2 238 252 19269743 investigations NNS I-NP O
3 253 255 19269743 of IN B-PP O
4 256 259 19269743 the DT B-NP O
5 260 265 19269743 human JJ I-NP O
6 266 274 19269743 capacity NN I-NP O
7 275 277 19269743 to TO B-VP O
8 278 286 19269743 remember VB I-VP O
9 287 294 19269743 sensory JJ B-NP O
10 295 303 19269743 features NNS I-NP O
11 304 306 19269743 of IN B-PP O
12 307 319 19269743 experimental JJ B-NP O
13 320 324 19269743 pain NN I-NP B-Disease
14 325 328 19269743 are VBP B-VP O
15 329 335 19269743 sparse JJ B-ADJP O
16 335 336 19269743 . . O O

1 337 339 19269743 In IN B-SBAR O
2 340 345 19269743 order NN O O
3 346 348 19269743 to TO B-VP O
4 349 356 19269743 address VB I-VP O
5 357 361 19269743 long JJ B-NP O
6 361 362 19269743 - HYPH I-NP O
7 362 366 19269743 term NN I-NP O
8 367 371 19269743 pain NN I-NP B-Disease
9 372 378 19269743 memory NN I-NP O
10 378 379 19269743 , , O O
11 380 384 19269743 nine CD B-NP O
12 385 392 19269743 healthy JJ I-NP O
13 393 397 19269743 male JJ I-NP O
14 398 408 19269743 volunteers NNS I-NP O
15 409 417 19269743 received VBD B-VP O
16 418 429 19269743 intradermal JJ B-NP O
17 430 440 19269743 injections NNS I-NP O
18 441 443 19269743 of IN B-PP O
19 444 449 19269743 three CD B-NP O
20 450 455 19269743 doses NNS I-NP O
21 456 458 19269743 of IN B-PP O
22 459 468 19269743 capsaicin NN B-NP B-Chemical
23 469 470 19269743 ( ( O O
24 470 474 19269743 0.05 CD B-NP O
25 474 475 19269743 , , I-NP O
26 476 477 19269743 1 CD I-NP O
27 478 481 19269743 and CC I-NP O
28 482 484 19269743 20 CD I-NP O
29 485 491 19269743 microg NN I-NP O
30 491 492 19269743 , , O O
31 493 502 19269743 separated VBN B-VP O
32 503 505 19269743 by IN B-PP O
33 506 508 19269743 15 CD B-NP O
34 509 512 19269743 min NN I-NP O
35 513 519 19269743 breaks NNS I-NP O
36 519 520 19269743 ) ) O O
37 520 521 19269743 , , O O
38 522 526 19269743 each DT B-NP O
39 527 532 19269743 given VBN B-VP O
40 533 538 19269743 three CD B-NP O
41 539 544 19269743 times NNS I-NP O
42 545 547 19269743 in IN B-PP O
43 548 549 19269743 a DT B-NP O
44 550 558 19269743 balanced JJ I-NP O
45 559 565 19269743 design NN I-NP O
46 566 572 19269743 across IN B-PP O
47 573 578 19269743 three CD B-NP O
48 579 587 19269743 sessions NNS I-NP O
49 588 590 19269743 at IN B-PP O
50 591 594 19269743 one CD B-NP O
51 595 599 19269743 week NN I-NP O
52 600 609 19269743 intervals NNS I-NP O
53 609 610 19269743 . . O O

1 611 615 19269743 Pain NN B-NP B-Disease
2 616 622 19269743 rating NN I-NP O
3 623 626 19269743 was VBD B-VP O
4 627 636 19269743 performed VBN I-VP O
5 637 642 19269743 using VBG B-VP O
6 643 644 19269743 a DT B-NP O
7 645 657 19269743 computerized JJ I-NP O
8 658 664 19269743 visual JJ I-NP O
9 665 673 19269743 analogue NN I-NP O
10 674 679 19269743 scale NN I-NP O
11 680 681 19269743 ( ( O O
12 681 682 19269743 0 CD B-NP O
13 682 683 19269743 - HYPH I-NP O
14 683 686 19269743 100 CD I-NP O
15 686 687 19269743 ) ) O O
16 688 697 19269743 digitized VBN B-VP O
17 698 700 19269743 at IN B-PP O
18 701 702 19269743 1 CD B-NP O
19 702 703 19269743 / SYM I-NP O
20 703 704 19269743 s NN I-NP O
21 704 705 19269743 , , O O
22 706 712 19269743 either CC O O
23 713 724 19269743 immediately RB B-ADVP O
24 725 731 19269743 online NN B-NP O
25 732 734 19269743 or CC O O
26 735 738 19269743 one CD B-NP O
27 739 743 19269743 hour NN I-NP O
28 744 746 19269743 or CC O O
29 747 750 19269743 one CD B-NP O
30 751 754 19269743 day NN I-NP O
31 755 760 19269743 after IN B-PP O
32 761 770 19269743 injection NN B-NP O
33 770 771 19269743 . . O O

1 772 780 19269743 Subjects NNS B-NP O
2 781 785 19269743 also RB B-ADVP O
3 786 794 19269743 recalled VBD B-VP O
4 795 800 19269743 their PRP$ B-NP O
5 801 806 19269743 pains NNS I-NP B-Disease
6 807 810 19269743 one CD B-NP O
7 811 815 19269743 week NN I-NP O
8 816 821 19269743 later RB B-ADVP O
9 821 822 19269743 . . O O

1 823 832 19269743 Capsaicin NN B-NP B-Chemical
2 833 842 19269743 injection NN I-NP O
3 843 851 19269743 reliably RB B-ADVP O
4 852 859 19269743 induced VBD B-VP O
5 860 861 19269743 a DT B-NP O
6 862 866 19269743 dose NN I-NP O
7 866 867 19269743 - HYPH B-NP O
8 867 876 19269743 dependent JJ I-NP O
9 877 882 19269743 flare NN I-NP O
10 883 884 19269743 ( ( O O
11 884 885 19269743 p NN B-NP O
12 885 886 19269743 < SYM O O
13 886 891 19269743 0.001 CD B-NP O
14 891 892 19269743 ) ) O O
15 893 900 19269743 without IN B-PP O
16 901 904 19269743 any DT B-NP O
17 905 915 19269743 difference NN I-NP O
18 916 922 19269743 within IN B-PP O
19 923 925 19269743 or CC I-PP O
20 926 932 19269743 across IN I-PP O
21 933 941 19269743 sessions NNS B-NP O
22 941 942 19269743 . . O O

1 943 946 19269743 The DT B-NP O
2 947 953 19269743 strong JJ I-NP O
3 954 961 19269743 burning VBG I-NP O
4 962 966 19269743 pain NN I-NP B-Disease
5 967 974 19269743 decayed VBD B-VP O
6 975 988 19269743 exponentially RB B-ADVP O
7 989 995 19269743 within IN B-PP O
8 996 997 19269743 a DT B-NP O
9 998 1001 19269743 few JJ I-NP O
10 1002 1009 19269743 minutes NNS I-NP O
11 1009 1010 19269743 . . O O

1 1011 1019 19269743 Subjects NNS B-NP O
2 1020 1024 19269743 were VBD B-VP O
3 1025 1029 19269743 able JJ B-ADJP O
4 1030 1032 19269743 to TO B-VP O
5 1033 1041 19269743 reliably RB I-VP O
6 1042 1054 19269743 discriminate VB I-VP O
7 1055 1059 19269743 pain NN B-NP B-Disease
8 1060 1069 19269743 magnitude NN I-NP O
9 1070 1073 19269743 and CC I-NP O
10 1074 1082 19269743 duration NN I-NP O
11 1083 1089 19269743 across IN B-PP O
12 1090 1099 19269743 capsaicin NN B-NP B-Chemical
13 1100 1105 19269743 doses NNS I-NP O
14 1106 1107 19269743 ( ( O O
15 1107 1111 19269743 both CC O O
16 1112 1113 19269743 p NN B-NP O
17 1113 1114 19269743 < SYM O O
18 1114 1119 19269743 0.001 CD B-NP O
19 1119 1120 19269743 ) ) O O
20 1120 1121 19269743 , , O O
21 1122 1132 19269743 regardless RB B-ADVP O
22 1133 1135 19269743 of IN B-PP O
23 1136 1143 19269743 whether IN B-SBAR O
24 1144 1149 19269743 first JJ B-NP O
25 1149 1150 19269743 - HYPH I-NP O
26 1150 1154 19269743 time NN I-NP O
27 1155 1162 19269743 ratings NNS I-NP O
28 1163 1167 19269743 were VBD B-VP O
29 1168 1177 19269743 requested VBN I-VP O
30 1178 1189 19269743 immediately RB B-ADVP O
31 1189 1190 19269743 , , O O
32 1191 1196 19269743 after IN B-SBAR O
33 1197 1200 19269743 one CD B-NP O
34 1201 1205 19269743 hour NN I-NP O
35 1206 1208 19269743 or CC O O
36 1209 1214 19269743 after IN B-PP O
37 1215 1218 19269743 one CD B-NP O
38 1219 1222 19269743 day NN I-NP O
39 1222 1223 19269743 . . O O

1 1224 1228 19269743 Pain NNP B-NP B-Disease
2 1229 1235 19269743 recall VBP B-VP O
3 1236 1241 19269743 after IN B-PP O
4 1242 1245 19269743 one CD B-NP O
5 1246 1250 19269743 week NN I-NP O
6 1251 1254 19269743 was VBD B-VP O
7 1255 1264 19269743 similarly RB B-ADJP O
8 1265 1272 19269743 precise JJ I-ADJP O
9 1273 1274 19269743 ( ( O O
10 1274 1283 19269743 magnitude NN B-NP O
11 1283 1284 19269743 : : O O
12 1285 1286 19269743 p NN B-NP O
13 1286 1287 19269743 < SYM O O
14 1287 1291 19269743 0.01 CD B-NP O
15 1291 1292 19269743 , , O O
16 1293 1301 19269743 duration NN B-NP O
17 1301 1302 19269743 : SYM B-NP O
18 1303 1304 19269743 p NN I-NP O
19 1304 1305 19269743 < SYM B-NP O
20 1305 1309 19269743 0.05 CD I-NP O
21 1309 1310 19269743 ) ) O O
22 1310 1311 19269743 . . O O

1 1312 1323 19269743 Correlation NN B-NP O
2 1324 1328 19269743 with IN B-PP O
3 1329 1335 19269743 rating NN B-NP O
4 1336 1342 19269743 recall NN I-NP O
5 1343 1348 19269743 after IN B-PP O
6 1349 1352 19269743 one CD B-NP O
7 1353 1357 19269743 week NN I-NP O
8 1358 1361 19269743 was VBD B-VP O
9 1362 1366 19269743 best RBS B-ADVP O
10 1367 1371 19269743 when WRB B-ADVP O
11 1372 1377 19269743 first JJ B-NP O
12 1377 1378 19269743 - HYPH I-NP O
13 1378 1382 19269743 time NN I-NP O
14 1383 1390 19269743 ratings NNS I-NP O
15 1391 1395 19269743 were VBD B-VP O
16 1396 1405 19269743 requested VBN I-VP O
17 1406 1408 19269743 as IN B-PP O
18 1409 1413 19269743 late RB B-NP O
19 1414 1416 19269743 as IN I-NP O
20 1417 1420 19269743 one CD B-NP O
21 1421 1424 19269743 day NN I-NP O
22 1425 1430 19269743 after IN B-PP O
23 1431 1440 19269743 injection NN B-NP O
24 1441 1442 19269743 ( ( O O
25 1442 1446 19269743 R(2) NN B-NP O
26 1446 1447 19269743 = SYM B-VP O
27 1447 1451 19269743 0.79 CD B-NP O
28 1451 1452 19269743 ) ) O O
29 1453 1463 19269743 indicating VBG B-VP O
30 1464 1468 19269743 that IN B-SBAR O
31 1469 1473 19269743 both CC O O
32 1474 1480 19269743 rating NN B-NP O
33 1481 1491 19269743 retrievals NNS I-NP O
34 1492 1500 19269743 utilized VBD B-VP O
35 1501 1508 19269743 similar JJ B-NP O
36 1509 1515 19269743 memory NN I-NP O
37 1516 1522 19269743 traces NNS I-NP O
38 1522 1523 19269743 . . O O

1 1524 1529 19269743 These DT B-NP O
2 1530 1537 19269743 results NNS I-NP O
3 1538 1546 19269743 indicate VBP B-VP O
4 1547 1548 19269743 a DT B-NP O
5 1549 1557 19269743 reliable JJ I-NP O
6 1558 1564 19269743 memory NN I-NP O
7 1565 1568 19269743 for IN B-PP O
8 1569 1578 19269743 magnitude NN B-NP O
9 1579 1582 19269743 and CC I-NP O
10 1583 1591 19269743 duration NN I-NP O
11 1592 1594 19269743 of IN B-PP O
12 1595 1609 19269743 experimentally RB B-NP O
13 1610 1617 19269743 induced VBN I-NP O
14 1618 1622 19269743 pain NN I-NP B-Disease
15 1622 1623 19269743 . . O O

1 1624 1627 19269743 The DT B-NP O
2 1628 1632 19269743 data NNS I-NP O
3 1633 1640 19269743 further RB B-ADVP O
4 1641 1648 19269743 suggest VBP B-VP O
5 1649 1653 19269743 that IN B-SBAR O
6 1654 1657 19269743 the DT B-NP O
7 1658 1671 19269743 consolidation NN I-NP O
8 1672 1674 19269743 of IN B-PP O
9 1675 1679 19269743 this DT B-NP O
10 1680 1686 19269743 memory NN I-NP O
11 1687 1689 19269743 is VBZ B-VP O
12 1690 1692 19269743 an DT B-NP O
13 1693 1702 19269743 important JJ I-NP O
14 1703 1710 19269743 interim JJ I-NP O
15 1711 1716 19269743 stage NN I-NP O
16 1716 1717 19269743 , , O O
17 1718 1721 19269743 and CC O O
18 1722 1725 19269743 may MD B-VP O
19 1726 1730 19269743 take VB I-VP O
20 1731 1733 19269743 up RB B-NP O
21 1734 1736 19269743 to TO I-NP O
22 1737 1740 19269743 one CD I-NP O
23 1741 1744 19269743 day NN I-NP O
24 1744 1745 19269743 . . O O

1 0 0 3750012 -DOCSTART- -X- -X- O

1 0 10 3750012 Myasthenia NN B-NP B-Disease
2 11 17 3750012 gravis NN I-NP I-Disease
3 18 24 3750012 caused VBN B-VP O
4 25 27 3750012 by IN B-PP O
5 28 41 3750012 penicillamine NN B-NP B-Chemical
6 42 45 3750012 and CC I-NP O
7 46 57 3750012 chloroquine NN I-NP B-Chemical
8 58 65 3750012 therapy NN I-NP O
9 66 69 3750012 for IN B-PP O
10 70 80 3750012 rheumatoid JJ B-NP B-Disease
11 81 90 3750012 arthritis NN I-NP I-Disease
12 90 91 3750012 . . O O
13 92 94 3750012 We PRP B-NP O
14 95 99 3750012 have VBP B-VP O
15 100 109 3750012 described VBN I-VP O
16 110 111 3750012 a DT B-NP O
17 112 118 3750012 unique JJ I-NP O
18 119 126 3750012 patient NN I-NP O
19 127 130 3750012 who WP B-NP O
20 131 134 3750012 had VBD B-VP O
21 135 145 3750012 reversible JJ B-NP O
22 146 149 3750012 and CC I-NP O
23 150 154 3750012 dose NN I-NP O
24 154 155 3750012 - HYPH B-NP O
25 155 162 3750012 related VBN I-NP O
26 163 173 3750012 myasthenia NN I-NP B-Disease
27 174 180 3750012 gravis NN I-NP I-Disease
28 181 186 3750012 after IN B-PP O
29 187 200 3750012 penicillamine NN B-NP B-Chemical
30 201 204 3750012 and CC I-NP O
31 205 216 3750012 chloroquine NN I-NP B-Chemical
32 217 224 3750012 therapy NN I-NP O
33 225 228 3750012 for IN B-PP O
34 229 239 3750012 rheumatoid JJ B-NP B-Disease
35 240 249 3750012 arthritis NN I-NP I-Disease
36 249 250 3750012 . . O O

1 251 259 3750012 Although IN B-SBAR O
2 260 273 3750012 acetylcholine NN B-NP B-Chemical
3 274 282 3750012 receptor NN I-NP O
4 283 293 3750012 antibodies NNS I-NP O
5 294 298 3750012 were VBD B-VP O
6 299 302 3750012 not RB O O
7 303 313 3750012 detectable JJ B-ADJP O
8 313 314 3750012 , , O O
9 315 318 3750012 the DT B-NP O
10 319 323 3750012 time NN I-NP O
11 324 330 3750012 course NN I-NP O
12 331 334 3750012 was VBD B-VP O
13 335 345 3750012 consistent JJ B-ADJP O
14 346 350 3750012 with IN B-PP O
15 351 353 3750012 an DT B-NP O
16 354 364 3750012 autoimmune JJ I-NP O
17 365 372 3750012 process NN I-NP O
18 372 373 3750012 . . O O

1 0 0 3031535 -DOCSTART- -X- -X- O

1 0 13 3031535 Noradrenergic JJ B-NP O
2 14 25 3031535 involvement NN I-NP O
3 26 28 3031535 in IN B-PP O
4 29 38 3031535 catalepsy NN B-NP B-Disease
5 39 46 3031535 induced VBN B-VP O
6 47 49 3031535 by IN B-PP O
7 50 55 3031535 delta SYM B-NP B-Chemical
8 56 57 3031535 9 CD I-NP I-Chemical
9 57 58 3031535 - HYPH I-NP I-Chemical
10 58 78 3031535 tetrahydrocannabinol NN I-NP I-Chemical
11 78 79 3031535 . . O O
12 80 82 3031535 In IN B-SBAR O
13 83 88 3031535 order NN O O
14 89 91 3031535 to TO B-VP O
15 92 101 3031535 elucidate VB I-VP O
16 102 105 3031535 the DT B-NP O
17 106 110 3031535 role NN I-NP O
18 111 113 3031535 of IN B-PP O
19 114 117 3031535 the DT B-NP O
20 118 135 3031535 catecholaminergic JJ I-NP O
21 136 142 3031535 system NN I-NP O
22 143 145 3031535 in IN B-PP O
23 146 149 3031535 the DT B-NP O
24 150 164 3031535 cataleptogenic JJ I-NP O
25 165 171 3031535 effect NN I-NP O
26 172 174 3031535 of IN B-PP O
27 175 180 3031535 delta SYM B-NP B-Chemical
28 181 182 3031535 9 CD I-NP I-Chemical
29 182 183 3031535 - HYPH O I-Chemical
30 183 203 3031535 tetrahydrocannabinol NN B-NP I-Chemical
31 204 205 3031535 ( ( O O
32 205 208 3031535 THC NN B-NP B-Chemical
33 208 209 3031535 ) ) O O
34 209 210 3031535 , , O O
35 211 214 3031535 the DT B-NP O
36 215 221 3031535 effect NN I-NP O
37 222 224 3031535 of IN B-PP O
38 225 237 3031535 pretreatment NN B-NP O
39 238 242 3031535 with IN B-PP O
40 243 244 3031535 6 CD B-NP B-Chemical
41 244 245 3031535 - HYPH I-NP I-Chemical
42 245 260 3031535 hydroxydopamine NN I-NP I-Chemical
43 261 262 3031535 ( ( O O
44 262 263 3031535 6 CD B-NP B-Chemical
45 263 264 3031535 - HYPH I-NP I-Chemical
46 264 268 3031535 OHDA NN I-NP I-Chemical
47 268 269 3031535 ) ) O O
48 270 272 3031535 or CC O O
49 273 277 3031535 with IN B-PP O
50 278 289 3031535 desipramine NN B-NP B-Chemical
51 290 293 3031535 and CC O O
52 294 295 3031535 6 CD B-NP B-Chemical
53 295 296 3031535 - HYPH I-NP I-Chemical
54 296 300 3031535 OHDA NN I-NP I-Chemical
55 301 304 3031535 and CC I-NP O
56 305 312 3031535 lesions NNS I-NP O
57 313 315 3031535 of IN B-PP O
58 316 319 3031535 the DT B-NP O
59 320 325 3031535 locus NN I-NP O
60 326 335 3031535 coeruleus NN I-NP O
61 336 340 3031535 were VBD B-VP O
62 341 353 3031535 investigated VBN I-VP O
63 354 356 3031535 in IN B-PP O
64 357 361 3031535 rats NNS B-NP O
65 361 362 3031535 . . O O

1 363 366 3031535 The DT B-NP O
2 367 381 3031535 cataleptogenic JJ I-NP O
3 382 388 3031535 effect NN I-NP O
4 389 391 3031535 of IN B-PP O
5 392 395 3031535 THC NN B-NP B-Chemical
6 396 399 3031535 was VBD B-VP O
7 400 413 3031535 significantly RB I-VP O
8 414 421 3031535 reduced VBN I-VP O
9 422 424 3031535 in IN B-PP O
10 425 429 3031535 rats NNS B-NP O
11 430 437 3031535 treated VBN B-VP O
12 438 442 3031535 with IN B-PP O
13 443 444 3031535 6 CD B-NP B-Chemical
14 444 445 3031535 - HYPH I-NP I-Chemical
15 445 449 3031535 OHDA NN I-NP I-Chemical
16 450 453 3031535 and CC B-PP O
17 454 456 3031535 in IN B-PP O
18 457 461 3031535 rats NNS B-NP O
19 462 466 3031535 with IN B-PP O
20 467 474 3031535 lesions NNS B-NP O
21 475 477 3031535 of IN B-PP O
22 478 481 3031535 the DT B-NP O
23 482 487 3031535 locus NN I-NP O
24 488 497 3031535 coeruleus NN I-NP O
25 498 501 3031535 but CC B-PP O
26 502 505 3031535 not RB B-PP O
27 506 508 3031535 in IN I-PP O
28 509 513 3031535 rats NNS B-NP O
29 514 521 3031535 treated VBN B-VP O
30 522 526 3031535 with IN B-PP O
31 527 538 3031535 desipramine NN B-NP B-Chemical
32 539 542 3031535 and CC O O
33 543 544 3031535 6 CD B-NP B-Chemical
34 544 545 3031535 - HYPH I-NP I-Chemical
35 545 549 3031535 OHDA NN I-NP I-Chemical
36 549 550 3031535 , , O O
37 551 553 3031535 as IN B-SBAR O
38 554 562 3031535 compared VBN B-PP O
39 563 567 3031535 with IN B-PP O
40 568 575 3031535 control NN B-NP O
41 576 580 3031535 rats NNS I-NP O
42 580 581 3031535 . . O O

1 582 584 3031535 On IN B-PP O
2 585 588 3031535 the DT B-NP O
3 589 597 3031535 contrary NN I-NP O
4 597 598 3031535 , , O O
5 599 602 3031535 the DT B-NP O
6 603 617 3031535 cataleptogenic JJ I-NP O
7 618 624 3031535 effect NN I-NP O
8 625 627 3031535 of IN B-PP O
9 628 639 3031535 haloperidol NN B-NP B-Chemical
10 640 643 3031535 was VBD B-VP O
11 644 657 3031535 significantly RB I-VP O
12 658 665 3031535 reduced VBN I-VP O
13 666 668 3031535 in IN B-PP O
14 669 673 3031535 rats NNS B-NP O
15 674 681 3031535 treated VBN B-VP O
16 682 686 3031535 with IN B-PP O
17 687 698 3031535 desipramine NN B-NP B-Chemical
18 699 702 3031535 and CC O O
19 703 704 3031535 6 CD B-NP B-Chemical
20 704 705 3031535 - HYPH I-NP I-Chemical
21 705 709 3031535 OHDA NN I-NP I-Chemical
22 710 713 3031535 but CC B-PP O
23 714 717 3031535 not RB B-PP O
24 718 720 3031535 in IN I-PP O
25 721 725 3031535 rats NNS B-NP O
26 726 733 3031535 treated VBN B-VP O
27 734 738 3031535 with IN B-PP O
28 739 740 3031535 6 CD B-NP B-Chemical
29 740 741 3031535 - HYPH I-NP I-Chemical
30 741 745 3031535 OHDA NN I-NP I-Chemical
31 746 748 3031535 or CC B-PP O
32 749 751 3031535 in IN B-PP O
33 752 756 3031535 rats NNS B-NP O
34 757 761 3031535 with IN B-PP O
35 762 769 3031535 lesions NNS B-NP O
36 770 772 3031535 of IN B-PP O
37 773 776 3031535 the DT B-NP O
38 777 782 3031535 locus NN I-NP O
39 783 792 3031535 coeruleus NN I-NP O
40 792 793 3031535 . . O O

1 794 799 3031535 These DT B-NP O
2 800 807 3031535 results NNS I-NP O
3 808 816 3031535 indicate VBP B-VP O
4 817 821 3031535 that IN B-SBAR O
5 822 835 3031535 noradrenergic JJ B-NP O
6 836 843 3031535 neurons NNS I-NP O
7 844 848 3031535 have VBP B-VP O
8 849 851 3031535 an DT B-NP O
9 852 861 3031535 important JJ I-NP O
10 862 866 3031535 role NN I-NP O
11 867 869 3031535 in IN B-PP O
12 870 873 3031535 the DT B-NP O
13 874 887 3031535 manifestation NN I-NP O
14 888 890 3031535 of IN B-PP O
15 891 900 3031535 catalepsy NN B-NP B-Disease
16 901 908 3031535 induced VBN B-VP O
17 909 911 3031535 by IN B-PP O
18 912 915 3031535 THC NN B-NP B-Chemical
19 915 916 3031535 , , O O
20 917 924 3031535 whereas IN O O
21 925 937 3031535 dopaminergic JJ B-NP O
22 938 945 3031535 neurons NNS I-NP O
23 946 949 3031535 are VBP B-VP O
24 950 959 3031535 important JJ B-ADJP O
25 960 962 3031535 in IN B-PP O
26 963 972 3031535 catalepsy NN B-NP B-Disease
27 973 980 3031535 induced VBN B-VP O
28 981 983 3031535 by IN B-PP O
29 984 995 3031535 haloperidol NN B-NP B-Chemical
30 995 996 3031535 . . O O

1 0 0 1987816 -DOCSTART- -X- -X- O

1 0 4 1987816 Less RBR B-NP O
2 5 13 1987816 frequent JJ I-NP O
3 14 21 1987816 lithium NN I-NP B-Chemical
4 22 36 1987816 administration NN I-NP O
5 37 40 1987816 and CC O O
6 41 46 1987816 lower JJR B-NP O
7 47 52 1987816 urine NN I-NP O
8 53 59 1987816 volume NN I-NP O
9 59 60 1987816 . . I-NP O
10 61 70 1987816 OBJECTIVE NN I-NP O
11 70 71 1987816 : : O O
12 72 76 1987816 This DT B-NP O
13 77 82 1987816 study NN I-NP O
14 83 86 1987816 was VBD B-VP O
15 87 95 1987816 designed VBN I-VP O
16 96 98 1987816 to TO B-VP O
17 99 108 1987816 determine VB I-VP O
18 109 116 1987816 whether IN B-SBAR O
19 117 125 1987816 patients NNS B-NP O
20 126 136 1987816 maintained VBN B-VP O
21 137 139 1987816 on IN B-PP O
22 140 141 1987816 a DT B-NP O
23 142 149 1987816 regimen NN I-NP O
24 150 152 1987816 of IN B-PP O
25 153 160 1987816 lithium NN B-NP B-Chemical
26 161 163 1987816 on IN B-PP O
27 164 165 1987816 a DT B-NP O
28 166 170 1987816 once RB I-NP O
29 170 171 1987816 - HYPH I-NP O
30 171 174 1987816 per AFX I-NP O
31 174 175 1987816 - HYPH I-NP O
32 175 178 1987816 day NN B-NP O
33 179 187 1987816 schedule NN I-NP O
34 188 192 1987816 have VBP B-VP O
35 193 198 1987816 lower JJR B-NP O
36 199 204 1987816 urine NN I-NP O
37 205 212 1987816 volumes NNS I-NP O
38 213 217 1987816 than IN B-SBAR O
39 218 220 1987816 do VBP O O
40 221 229 1987816 patients NNS B-NP O
41 230 239 1987816 receiving VBG B-VP O
42 240 248 1987816 multiple JJ B-NP O
43 249 254 1987816 doses NNS I-NP O
44 255 258 1987816 per IN B-PP O
45 259 262 1987816 day NN B-NP O
46 262 263 1987816 . . O O

1 264 270 1987816 METHOD NN B-NP O
2 270 271 1987816 : : O O
3 272 276 1987816 This DT B-NP O
4 277 280 1987816 was VBD B-VP O
5 281 282 1987816 a DT B-NP O
6 283 288 1987816 cross AFX I-NP O
7 288 289 1987816 - HYPH I-NP O
8 289 298 1987816 sectional JJ I-NP O
9 299 304 1987816 study NN I-NP O
10 305 307 1987816 of IN B-PP O
11 308 310 1987816 85 CD B-NP O
12 311 319 1987816 patients NNS I-NP O
13 320 324 1987816 from IN B-PP O
14 325 326 1987816 a DT B-NP O
15 327 334 1987816 lithium NN I-NP B-Chemical
16 335 341 1987816 clinic NN I-NP O
17 342 345 1987816 who WP B-NP O
18 346 354 1987816 received VBD B-VP O
19 355 364 1987816 different JJ B-NP O
20 365 369 1987816 dose NN I-NP O
21 370 379 1987816 schedules NNS I-NP O
22 379 380 1987816 . . O O

1 381 389 1987816 Patients NNS B-NP O
2 390 394 1987816 were VBD B-VP O
3 395 403 1987816 admitted VBN I-VP O
4 404 406 1987816 to TO B-PP O
5 407 410 1987816 the DT B-NP O
6 411 419 1987816 hospital NN I-NP O
7 420 423 1987816 for IN B-PP O
8 424 435 1987816 measurement NN B-NP O
9 436 438 1987816 of IN B-PP O
10 439 446 1987816 lithium NN B-NP B-Chemical
11 447 452 1987816 level NN I-NP O
12 452 453 1987816 , , O O
13 454 464 1987816 creatinine NN B-NP B-Chemical
14 465 474 1987816 clearance NN I-NP O
15 474 475 1987816 , , O O
16 476 481 1987816 urine NN B-NP O
17 482 488 1987816 volume NN I-NP O
18 488 489 1987816 , , O O
19 490 493 1987816 and CC O O
20 494 501 1987816 maximum JJ B-NP O
21 502 512 1987816 osmolality NN I-NP O
22 512 513 1987816 . . O O

1 514 521 1987816 RESULTS NNS B-NP O
2 521 522 1987816 : : O O
3 523 531 1987816 Multiple JJ B-NP O
4 532 537 1987816 daily JJ I-NP O
5 538 543 1987816 doses NNS I-NP O
6 544 546 1987816 of IN B-PP O
7 547 554 1987816 lithium NN B-NP B-Chemical
8 555 559 1987816 were VBD B-VP O
9 560 570 1987816 associated VBN I-VP O
10 571 575 1987816 with IN B-PP O
11 576 582 1987816 higher JJR B-NP O
12 583 588 1987816 urine NN I-NP O
13 589 596 1987816 volumes NNS I-NP O
14 596 597 1987816 . . O O

1 598 601 1987816 The DT B-NP O
2 602 608 1987816 dosing NN I-NP O
3 609 617 1987816 schedule NN I-NP O
4 617 618 1987816 , , O O
5 619 627 1987816 duration NN B-NP O
6 628 630 1987816 of IN B-PP O
7 631 638 1987816 lithium NN B-NP B-Chemical
8 639 648 1987816 treatment NN I-NP O
9 648 649 1987816 , , O O
10 650 653 1987816 and CC O O
11 654 659 1987816 daily JJ B-NP O
12 660 664 1987816 dose NN I-NP O
13 665 667 1987816 of IN B-PP O
14 668 675 1987816 lithium NN B-NP B-Chemical
15 676 679 1987816 did VBD B-VP O
16 680 683 1987816 not RB I-VP O
17 684 690 1987816 affect VB I-VP O
18 691 698 1987816 maximum JJ B-NP O
19 699 709 1987816 osmolality NN I-NP O
20 710 712 1987816 or CC I-NP O
21 713 723 1987816 creatinine NN I-NP B-Chemical
22 724 733 1987816 clearance NN I-NP O
23 733 734 1987816 . . O O

1 735 746 1987816 CONCLUSIONS NNS B-NP O
2 746 747 1987816 : : O O
3 748 753 1987816 Urine NN B-NP O
4 754 760 1987816 volume NN I-NP O
5 761 764 1987816 can MD B-VP O
6 765 767 1987816 be VB I-VP O
7 768 775 1987816 reduced VBN I-VP O
8 776 778 1987816 by IN B-PP O
9 779 785 1987816 giving VBG B-VP O
10 786 793 1987816 lithium NN B-NP B-Chemical
11 794 798 1987816 once RB B-ADVP O
12 799 804 1987816 daily RB I-ADVP O
13 805 808 1987816 and CC O O
14 808 809 1987816 / SYM B-NP O
15 809 811 1987816 or CC O O
16 812 814 1987816 by IN B-PP O
17 815 823 1987816 lowering VBG B-VP O
18 824 827 1987816 the DT B-NP O
19 828 833 1987816 total JJ I-NP O
20 834 839 1987816 daily JJ I-NP O
21 840 844 1987816 dose NN I-NP O
22 844 845 1987816 . . O O

1 846 853 1987816 Lithium NN B-NP B-Chemical
2 853 854 1987816 - HYPH B-NP O
3 854 861 1987816 induced VBN I-NP O
4 862 870 1987816 polyuria NN I-NP B-Disease
5 871 876 1987816 seems VBZ B-VP O
6 877 879 1987816 to TO I-VP O
7 880 882 1987816 be VB I-VP O
8 883 890 1987816 related JJ B-ADJP O
9 891 893 1987816 to TO B-PP O
10 894 904 1987816 extrarenal JJ O O
11 905 907 1987816 as RB B-CONJP O
12 908 912 1987816 well RB I-CONJP O
13 913 915 1987816 as IN I-CONJP O
14 916 918 1987816 to TO B-PP O
15 919 924 1987816 renal JJ B-NP O
16 925 932 1987816 effects NNS I-NP O
17 932 933 1987816 . . O O

1 0 0 1867351 -DOCSTART- -X- -X- O

1 0 16 1867351 Neuropsychiatric JJ B-NP O
2 17 21 1867351 side NN I-NP O
3 22 29 1867351 effects NNS I-NP O
4 30 35 1867351 after IN B-PP O
5 36 39 1867351 the DT B-NP O
6 40 43 1867351 use NN I-NP O
7 44 46 1867351 of IN B-PP O
8 47 57 1867351 mefloquine NN B-NP B-Chemical
9 57 58 1867351 . . O O
10 59 63 1867351 This DT B-NP O
11 64 69 1867351 study NN I-NP O
12 70 79 1867351 describes VBZ B-VP O
13 80 96 1867351 neuropsychiatric JJ B-NP O
14 97 101 1867351 side JJ I-NP O
15 102 109 1867351 effects NNS I-NP O
16 110 112 1867351 in IN B-PP O
17 113 121 1867351 patients NNS B-NP O
18 122 127 1867351 after IN B-PP O
19 128 137 1867351 treatment NN B-NP O
20 138 142 1867351 with IN B-PP O
21 143 153 1867351 mefloquine NN B-NP B-Chemical
22 153 154 1867351 . . O O

1 155 164 1867351 Reactions NNS B-NP O
2 165 174 1867351 consisted VBD B-VP O
3 175 181 1867351 mainly RB B-ADVP O
4 182 184 1867351 of IN B-PP O
5 185 193 1867351 seizures NNS B-NP B-Disease
6 193 194 1867351 , , O O
7 195 200 1867351 acute JJ B-NP O
8 201 210 1867351 psychoses NNS I-NP B-Disease
9 210 211 1867351 , , O O
10 212 219 1867351 anxiety NN B-NP B-Disease
11 220 228 1867351 neurosis NN I-NP I-Disease
12 228 229 1867351 , , O O
13 230 233 1867351 and CC O O
14 234 239 1867351 major JJ B-NP O
15 240 252 1867351 disturbances NNS I-NP B-Disease
16 253 255 1867351 of IN B-PP I-Disease
17 256 261 1867351 sleep NN B-NP I-Disease
18 261 262 1867351 - HYPH B-NP I-Disease
19 262 266 1867351 wake NN I-NP I-Disease
20 267 273 1867351 rhythm NN I-NP I-Disease
21 273 274 1867351 . . O O

1 275 279 1867351 Side NN B-NP O
2 280 287 1867351 effects NNS I-NP O
3 288 296 1867351 occurred VBD B-VP O
4 297 302 1867351 after IN B-PP O
5 303 307 1867351 both CC B-NP O
6 308 319 1867351 therapeutic JJ I-NP O
7 320 323 1867351 and CC I-NP O
8 324 336 1867351 prophylactic JJ I-NP O
9 337 343 1867351 intake NN I-NP O
10 344 347 1867351 and CC O O
11 348 352 1867351 were VBD B-VP O
12 353 359 1867351 graded VBN I-VP O
13 360 364 1867351 from IN B-PP O
14 365 373 1867351 moderate JJ B-ADJP O
15 374 376 1867351 to TO B-PP O
16 377 383 1867351 severe JJ B-ADJP O
17 383 384 1867351 . . O O

1 385 387 1867351 In IN B-PP O
2 388 389 1867351 a DT B-NP O
3 390 394 1867351 risk NN I-NP O
4 395 403 1867351 analysis NN I-NP O
5 404 406 1867351 of IN B-PP O
6 407 423 1867351 neuropsychiatric JJ B-NP O
7 424 428 1867351 side NN I-NP O
8 429 436 1867351 effects NNS I-NP O
9 437 439 1867351 in IN B-PP O
10 440 447 1867351 Germany NNP B-NP O
11 447 448 1867351 , , O O
12 449 451 1867351 it PRP B-NP O
13 452 454 1867351 is VBZ B-VP O
14 455 464 1867351 estimated VBN I-VP O
15 465 469 1867351 that IN B-SBAR O
16 470 473 1867351 one CD B-NP O
17 474 476 1867351 of IN B-PP O
18 477 482 1867351 8,000 CD B-NP O
19 483 493 1867351 mefloquine NN I-NP B-Chemical
20 494 499 1867351 users NNS I-NP O
21 500 507 1867351 suffers VBZ B-VP O
22 508 512 1867351 from IN B-PP O
23 513 517 1867351 such JJ B-NP O
24 518 527 1867351 reactions NNS I-NP O
25 527 528 1867351 . . O O

1 529 532 1867351 The DT B-NP O
2 533 542 1867351 incidence NN I-NP O
3 543 554 1867351 calculation NN I-NP O
4 555 563 1867351 revealed VBD B-VP O
5 564 568 1867351 that IN B-SBAR O
6 569 572 1867351 one CD B-NP O
7 573 575 1867351 of IN B-PP O
8 576 579 1867351 215 CD B-NP O
9 580 591 1867351 therapeutic JJ I-NP O
10 592 597 1867351 users NNS I-NP O
11 598 601 1867351 had VBD B-VP O
12 602 611 1867351 reactions NNS B-NP O
13 611 612 1867351 , , O O
14 613 621 1867351 compared VBN B-PP O
15 622 626 1867351 with IN B-PP O
16 627 630 1867351 one CD B-NP O
17 631 633 1867351 of IN B-PP O
18 634 640 1867351 13,000 CD B-NP O
19 641 643 1867351 in IN B-PP O
20 644 647 1867351 the DT B-NP O
21 648 659 1867351 prophylaxis NN I-NP O
22 660 665 1867351 group NN I-NP O
23 665 666 1867351 , , O O
24 667 673 1867351 making VBG B-VP O
25 674 677 1867351 the DT B-NP O
26 678 682 1867351 risk NN I-NP O
27 683 685 1867351 of IN B-PP O
28 686 702 1867351 neuropsychiatric JJ B-NP O
29 703 712 1867351 reactions NNS I-NP O
30 713 718 1867351 after IN B-PP O
31 719 729 1867351 mefloquine NN B-NP B-Chemical
32 730 739 1867351 treatment NN I-NP O
33 740 742 1867351 60 CD B-ADJP O
34 743 748 1867351 times NNS I-ADJP O
35 749 755 1867351 higher JJR I-ADJP O
36 756 760 1867351 than IN B-PP O
37 761 766 1867351 after IN B-PP O
38 767 778 1867351 prophylaxis NN B-NP O
39 778 779 1867351 . . O O

1 780 789 1867351 Therefore RB B-ADVP O
2 789 790 1867351 , , O O
3 791 798 1867351 certain JJ B-NP O
4 799 810 1867351 limitations NNS I-NP O
5 811 814 1867351 for IN B-PP O
6 815 822 1867351 malaria NN B-NP B-Disease
7 823 834 1867351 prophylaxis NN I-NP O
8 835 838 1867351 and CC O O
9 839 848 1867351 treatment NN B-NP O
10 849 853 1867351 with IN B-PP O
11 854 864 1867351 mefloquine NN B-NP B-Chemical
12 865 868 1867351 are VBP B-VP O
13 869 880 1867351 recommended VBN I-VP O
14 880 881 1867351 . . O O

1 0 0 12639165 -DOCSTART- -X- -X- O

1 0 11 12639165 Ticlopidine NN B-NP B-Chemical
2 11 12 12639165 - HYPH O O
3 12 19 12639165 induced VBN B-NP O
4 20 31 12639165 cholestatic JJ I-NP B-Disease
5 32 41 12639165 hepatitis NN I-NP I-Disease
6 41 42 12639165 . . I-NP O
7 43 52 12639165 OBJECTIVE NN I-NP O
8 52 53 12639165 : : O O
9 54 56 12639165 To TO B-VP O
10 57 63 12639165 report VB I-VP O
11 64 65 12639165 2 CD B-NP O
12 66 71 12639165 cases NNS I-NP O
13 72 74 12639165 of IN B-PP O
14 75 86 12639165 ticlopidine NN B-NP B-Chemical
15 86 87 12639165 - HYPH B-NP O
16 87 94 12639165 induced VBN I-NP O
17 95 106 12639165 cholestatic JJ I-NP B-Disease
18 107 116 12639165 hepatitis NN I-NP I-Disease
19 116 117 12639165 , , O O
20 118 129 12639165 investigate VB B-VP O
21 130 133 12639165 its PRP$ B-NP O
22 134 143 12639165 mechanism NN I-NP O
23 143 144 12639165 , , O O
24 145 148 12639165 and CC O O
25 149 156 12639165 compare VBP B-VP O
26 157 160 12639165 the DT B-NP O
27 161 169 12639165 observed VBN I-NP O
28 170 174 12639165 main JJ I-NP O
29 175 190 12639165 characteristics NNS I-NP O
30 191 195 12639165 with IN B-PP O
31 196 201 12639165 those DT B-NP O
32 202 204 12639165 of IN B-PP O
33 205 208 12639165 the DT B-NP O
34 209 218 12639165 published VBN I-NP O
35 219 224 12639165 cases NNS I-NP O
36 224 225 12639165 . . O O

1 226 230 12639165 CASE NN B-NP O
2 231 240 12639165 SUMMARIES NNS I-NP O
3 240 241 12639165 : : O O
4 242 245 12639165 Two CD B-NP O
5 246 254 12639165 patients NNS I-NP O
6 255 264 12639165 developed VBD B-VP O
7 265 274 12639165 prolonged JJ B-NP O
8 275 286 12639165 cholestatic JJ I-NP B-Disease
9 287 296 12639165 hepatitis NN I-NP I-Disease
10 297 302 12639165 after IN B-PP O
11 303 312 12639165 receiving VBG B-VP O
12 313 324 12639165 ticlopidine NN B-NP B-Chemical
13 325 334 12639165 following VBG B-PP O
14 335 347 12639165 percutaneous JJ B-NP O
15 348 356 12639165 coronary JJ I-NP O
16 357 368 12639165 angioplasty NN I-NP O
17 368 369 12639165 , , O O
18 370 374 12639165 with IN B-PP O
19 375 383 12639165 complete JJ B-NP O
20 384 393 12639165 remission NN I-NP O
21 394 400 12639165 during IN B-PP O
22 401 404 12639165 the DT B-NP O
23 405 411 12639165 follow VB I-NP O
24 411 412 12639165 - HYPH B-VP O
25 412 414 12639165 up RP B-PRT O
26 415 421 12639165 period NN B-NP O
27 421 422 12639165 . . O O

1 423 424 12639165 T NN B-NP O
2 424 425 12639165 - HYPH I-NP O
3 425 429 12639165 cell NN I-NP O
4 430 441 12639165 stimulation NN I-NP O
5 442 444 12639165 by IN B-PP O
6 445 456 12639165 therapeutic JJ B-NP O
7 457 470 12639165 concentration NN I-NP O
8 471 473 12639165 of IN B-PP O
9 474 485 12639165 ticlopidine NN B-NP B-Chemical
10 486 489 12639165 was VBD B-VP O
11 490 502 12639165 demonstrated VBN I-VP O
12 503 505 12639165 in FW B-ADVP O
13 506 511 12639165 vitro FW I-ADVP O
14 512 514 12639165 in IN B-PP O
15 515 518 12639165 the DT B-NP O
16 519 527 12639165 patients NNS I-NP O
17 527 528 12639165 , , O O
18 529 532 12639165 but CC O O
19 533 536 12639165 not RB B-PP O
20 537 539 12639165 in IN I-PP O
21 540 547 12639165 healthy JJ B-NP O
22 548 556 12639165 controls NNS I-NP O
23 556 557 12639165 . . O O

1 558 568 12639165 DISCUSSION NN B-NP O
2 568 569 12639165 : : O O
3 570 581 12639165 Cholestatic JJ B-NP B-Disease
4 582 591 12639165 hepatitis NN I-NP I-Disease
5 592 594 12639165 is VBZ B-VP O
6 595 596 12639165 a DT B-NP O
7 597 601 12639165 rare JJ I-NP O
8 602 614 12639165 complication NN I-NP O
9 615 617 12639165 of IN B-PP O
10 618 621 12639165 the DT B-NP O
11 622 634 12639165 antiplatelet JJ I-NP O
12 635 640 12639165 agent NN I-NP O
13 641 652 12639165 ticlopidine NN I-NP B-Chemical
14 652 653 12639165 ; : O O
15 654 661 12639165 several JJ B-NP O
16 662 667 12639165 cases NNS I-NP O
17 668 672 12639165 have VBP B-VP O
18 673 677 12639165 been VBN I-VP O
19 678 686 12639165 reported VBN I-VP O
20 687 690 12639165 but CC O O
21 691 694 12639165 few JJ B-ADJP O
22 695 697 12639165 in IN B-PP O
23 698 701 12639165 the DT B-NP O
24 702 709 12639165 English JJ I-NP O
25 710 720 12639165 literature NN I-NP O
26 720 721 12639165 . . O O

1 722 725 12639165 Our PRP$ B-NP O
2 726 734 12639165 patients NNS I-NP O
3 735 744 12639165 developed VBD B-VP O
4 745 753 12639165 jaundice NN B-NP B-Disease
5 754 763 12639165 following VBG B-PP O
6 764 773 12639165 treatment NN B-NP O
7 774 778 12639165 with IN B-PP O
8 779 790 12639165 ticlopidine NN B-NP B-Chemical
9 791 794 12639165 and CC O O
10 795 801 12639165 showed VBD B-VP O
11 802 805 12639165 the DT B-NP O
12 806 814 12639165 clinical JJ I-NP O
13 815 818 12639165 and CC I-NP O
14 819 829 12639165 laboratory JJ I-NP O
15 830 845 12639165 characteristics NNS I-NP O
16 846 848 12639165 of IN B-PP O
17 849 860 12639165 cholestatic JJ B-NP B-Disease
18 861 870 12639165 hepatitis NN I-NP I-Disease
19 870 871 12639165 , , O O
20 872 877 12639165 which WDT B-NP O
21 878 886 12639165 resolved VBD B-VP O
22 887 892 12639165 after IN B-PP O
23 893 908 12639165 discontinuation NN B-NP O
24 909 911 12639165 of IN B-PP O
25 912 915 12639165 the DT B-NP O
26 916 920 12639165 drug NN I-NP O
27 920 921 12639165 . . O O

1 922 931 12639165 Hepatitis NN B-NP B-Disease
2 932 935 12639165 may MD B-VP O
3 936 943 12639165 develop VB I-VP O
4 944 949 12639165 weeks NNS B-NP O
5 950 955 12639165 after IN B-PP O
6 956 971 12639165 discontinuation NN B-NP O
7 972 974 12639165 of IN B-PP O
8 975 978 12639165 the DT B-NP O
9 979 983 12639165 drug NN I-NP O
10 984 987 12639165 and CC O O
11 988 991 12639165 may MD B-VP O
12 992 995 12639165 run VB I-VP O
13 996 997 12639165 a DT B-NP O
14 998 1007 12639165 prolonged VBN I-NP O
15 1008 1014 12639165 course NN I-NP O
16 1014 1015 12639165 , , O O
17 1016 1019 12639165 but CC O O
18 1020 1028 12639165 complete JJ B-NP O
19 1029 1038 12639165 remission NN I-NP O
20 1039 1042 12639165 was VBD B-VP O
21 1043 1051 12639165 observed VBN I-VP O
22 1052 1054 12639165 in IN B-PP O
23 1055 1058 12639165 all DT B-NP O
24 1059 1067 12639165 reported VBN I-NP O
25 1068 1073 12639165 cases NNS I-NP O
26 1073 1074 12639165 . . O O

1 1075 1077 12639165 An DT B-NP O
2 1078 1087 12639165 objective JJ I-NP O
3 1088 1097 12639165 causality NN I-NP O
4 1098 1108 12639165 assessment NN I-NP O
5 1109 1117 12639165 revealed VBD B-VP O
6 1118 1122 12639165 that IN B-SBAR O
7 1123 1126 12639165 the DT B-NP O
8 1127 1134 12639165 adverse JJ I-NP O
9 1135 1139 12639165 drug NN I-NP O
10 1140 1145 12639165 event NN I-NP O
11 1146 1149 12639165 was VBD B-VP O
12 1150 1158 12639165 probably RB I-VP O
13 1159 1166 12639165 related VBN I-VP O
14 1167 1169 12639165 to TO B-PP O
15 1170 1173 12639165 the DT B-NP O
16 1174 1177 12639165 use NN I-NP O
17 1178 1180 12639165 of IN B-PP O
18 1181 1192 12639165 ticlopidine NN B-NP B-Chemical
19 1192 1193 12639165 . . O O

1 1194 1197 12639165 The DT B-NP O
2 1198 1208 12639165 mechanisms NNS I-NP O
3 1209 1211 12639165 of IN B-PP O
4 1212 1216 12639165 this DT B-NP O
5 1217 1228 12639165 ticlopidine NN I-NP B-Chemical
6 1228 1229 12639165 - HYPH B-VP O
7 1229 1236 12639165 induced VBN B-NP O
8 1237 1248 12639165 cholestasis NN I-NP B-Disease
9 1249 1252 12639165 are VBP B-VP O
10 1253 1260 12639165 unclear JJ B-ADJP O
11 1260 1261 12639165 . . O O

1 1262 1268 12639165 Immune JJ B-NP O
2 1269 1279 12639165 mechanisms NNS I-NP O
3 1280 1283 12639165 may MD B-VP O
4 1284 1286 12639165 be VB I-VP O
5 1287 1295 12639165 involved VBN I-VP O
6 1296 1298 12639165 in IN B-PP O
7 1299 1302 12639165 the DT B-NP O
8 1303 1309 12639165 drug's NNS I-NP O
9 1310 1324 12639165 hepatotoxicity NN I-NP B-Disease
10 1324 1325 12639165 , , O O
11 1326 1328 12639165 as IN B-SBAR O
12 1329 1338 12639165 suggested VBN B-VP O
13 1339 1341 12639165 by IN B-PP O
14 1342 1345 12639165 the DT B-NP O
15 1346 1347 12639165 T NN I-NP O
16 1347 1348 12639165 - HYPH B-NP O
17 1348 1352 12639165 cell NN I-NP O
18 1353 1364 12639165 stimulation NN I-NP O
19 1365 1370 12639165 study NN I-NP O
20 1371 1379 12639165 reported VBD B-VP O
21 1380 1384 12639165 here RB B-ADVP O
22 1384 1385 12639165 . . O O

1 1386 1397 12639165 CONCLUSIONS NNS B-NP O
2 1397 1398 12639165 : : O O
3 1399 1410 12639165 Cholestatic JJ B-NP B-Disease
4 1411 1420 12639165 hepatitis NN I-NP I-Disease
5 1421 1423 12639165 is VBZ B-VP O
6 1424 1425 12639165 a DT B-NP O
7 1426 1430 12639165 rare JJ I-NP O
8 1431 1438 12639165 adverse JJ I-NP O
9 1439 1445 12639165 effect NN I-NP O
10 1446 1448 12639165 of IN B-PP O
11 1449 1460 12639165 ticlopidine NN B-NP B-Chemical
12 1461 1465 12639165 that WDT B-NP O
13 1466 1469 12639165 may MD B-VP O
14 1470 1472 12639165 be VB I-VP O
15 1473 1479 12639165 immune JJ B-ADJP O
16 1480 1488 12639165 mediated VBN B-VP O
17 1488 1489 12639165 . . O O

1 1490 1498 12639165 Patients NNS B-NP O
2 1499 1508 12639165 receiving VBG B-VP O
3 1509 1512 12639165 the DT B-NP O
4 1513 1517 12639165 drug NN I-NP O
5 1518 1524 12639165 should MD B-VP O
6 1525 1527 12639165 be VB I-VP O
7 1528 1537 12639165 monitored VBN I-VP O
8 1538 1542 12639165 with IN B-PP O
9 1543 1548 12639165 liver NN B-NP O
10 1549 1557 12639165 function NN I-NP O
11 1558 1563 12639165 tests NNS I-NP O
12 1564 1569 12639165 along IN B-PP O
13 1570 1574 12639165 with IN B-PP O
14 1575 1583 12639165 complete JJ B-NP O
15 1584 1589 12639165 blood NN I-NP O
16 1590 1594 12639165 cell NN I-NP O
17 1595 1601 12639165 counts NNS I-NP O
18 1601 1602 12639165 . . O O

1 1603 1607 12639165 This DT B-NP O
2 1608 1620 12639165 complication NN I-NP O
3 1621 1625 12639165 will MD B-VP O
4 1626 1628 12639165 be VB I-VP O
5 1629 1637 12639165 observed VBN I-VP O
6 1638 1642 12639165 even RB B-ADVP O
7 1643 1647 12639165 less RBR I-ADVP O
8 1648 1653 12639165 often RB I-ADVP O
9 1654 1656 12639165 in IN B-PP O
10 1657 1660 12639165 the DT B-NP O
11 1661 1667 12639165 future NN I-NP O
12 1668 1670 12639165 as IN B-SBAR O
13 1671 1682 12639165 ticlopidine NN B-NP B-Chemical
14 1683 1685 12639165 is VBZ B-VP O
15 1686 1691 12639165 being VBG I-VP O
16 1692 1700 12639165 replaced VBN I-VP O
17 1701 1703 12639165 by IN B-PP O
18 1704 1707 12639165 the DT B-NP O
19 1708 1713 12639165 newer JJR I-NP O
20 1714 1726 12639165 antiplatelet JJ I-NP O
21 1727 1732 12639165 agent NN I-NP O
22 1733 1744 12639165 clopidogrel NN I-NP B-Chemical
23 1744 1745 12639165 . . O O

1 0 0 10739826 -DOCSTART- -X- -X- O

1 0 9 10739826 Recurrent JJ B-NP O
2 10 13 10739826 use NN I-NP O
3 14 16 10739826 of IN B-PP O
4 17 22 10739826 newer JJR B-NP O
5 23 27 10739826 oral JJ I-NP B-Chemical
6 28 42 10739826 contraceptives NNS I-NP I-Chemical
7 43 46 10739826 and CC O O
8 47 50 10739826 the DT B-NP O
9 51 55 10739826 risk NN I-NP O
10 56 58 10739826 of IN B-PP O
11 59 65 10739826 venous JJ B-NP B-Disease
12 66 81 10739826 thromboembolism NN I-NP I-Disease
13 81 82 10739826 . . O O
14 83 86 10739826 The DT B-NP O
15 87 102 10739826 epidemiological JJ I-NP O
16 103 110 10739826 studies NNS I-NP O
17 111 115 10739826 that WDT B-NP O
18 116 124 10739826 assessed VBD B-VP O
19 125 128 10739826 the DT B-NP O
20 129 133 10739826 risk NN I-NP O
21 134 136 10739826 of IN B-PP O
22 137 143 10739826 venous JJ B-NP B-Disease
23 144 159 10739826 thromboembolism NN I-NP I-Disease
24 160 161 10739826 ( ( O O
25 161 164 10739826 VTE NN B-NP B-Disease
26 164 165 10739826 ) ) O O
27 166 176 10739826 associated VBN B-VP O
28 177 181 10739826 with IN B-PP O
29 182 187 10739826 newer JJR B-NP O
30 188 192 10739826 oral JJ I-NP B-Chemical
31 193 207 10739826 contraceptives NNS I-NP I-Chemical
32 208 209 10739826 ( ( O O
33 209 211 10739826 OC NN B-NP B-Chemical
34 211 212 10739826 ) ) O O
35 213 216 10739826 did VBD B-VP O
36 217 220 10739826 not RB I-VP O
37 221 232 10739826 distinguish VB I-VP O
38 233 240 10739826 between IN B-PP O
39 241 249 10739826 patterns NNS B-NP O
40 250 252 10739826 of IN B-PP O
41 253 255 10739826 OC NN B-NP B-Chemical
42 256 259 10739826 use NN I-NP O
43 259 260 10739826 , , O O
44 261 267 10739826 namely RB B-NP O
45 268 273 10739826 first JJ I-NP O
46 273 274 10739826 - HYPH I-NP O
47 274 278 10739826 time NN I-NP O
48 279 284 10739826 users NNS I-NP O
49 284 285 10739826 , , O O
50 286 295 10739826 repeaters NNS B-NP O
51 296 299 10739826 and CC I-NP O
52 300 309 10739826 switchers NNS I-NP O
53 309 310 10739826 . . O O

1 311 315 10739826 Data NNS B-NP O
2 316 320 10739826 from IN B-PP O
3 321 322 10739826 a DT B-NP O
4 323 336 10739826 Transnational JJ I-NP O
5 337 341 10739826 case NN I-NP O
6 341 342 10739826 - HYPH B-NP O
7 342 349 10739826 control NN I-NP O
8 350 355 10739826 study NN I-NP O
9 356 360 10739826 were VBD B-VP O
10 361 365 10739826 used VBN I-VP O
11 366 368 10739826 to TO B-VP O
12 369 375 10739826 assess VB I-VP O
13 376 379 10739826 the DT B-NP O
14 380 384 10739826 risk NN I-NP O
15 385 387 10739826 of IN B-PP O
16 388 391 10739826 VTE NN B-NP B-Disease
17 392 395 10739826 for IN B-PP O
18 396 399 10739826 the DT B-NP O
19 400 406 10739826 latter JJ I-NP O
20 407 415 10739826 patterns NNS I-NP O
21 416 418 10739826 of IN B-PP O
22 419 422 10739826 use NN B-NP O
23 422 423 10739826 , , O O
24 424 429 10739826 while IN B-SBAR O
25 430 440 10739826 accounting VBG B-VP O
26 441 444 10739826 for IN B-PP O
27 445 453 10739826 duration NN B-NP O
28 454 456 10739826 of IN B-PP O
29 457 460 10739826 use NN B-NP O
30 460 461 10739826 . . O O

1 462 466 10739826 Over IN B-PP O
2 467 470 10739826 the DT B-NP O
3 471 477 10739826 period NN I-NP O
4 478 482 10739826 1993 CD I-NP O
5 482 483 10739826 - HYPH I-NP O
6 483 487 10739826 1996 CD I-NP O
7 487 488 10739826 , , O O
8 489 492 10739826 551 CD B-NP O
9 493 498 10739826 cases NNS I-NP O
10 499 501 10739826 of IN B-PP O
11 502 505 10739826 VTE NN B-NP B-Disease
12 506 510 10739826 were VBD B-VP O
13 511 521 10739826 identified VBN I-VP O
14 522 524 10739826 in IN B-PP O
15 525 532 10739826 Germany NNP B-NP O
16 533 536 10739826 and CC O O
17 537 540 10739826 the DT B-NP O
18 541 543 10739826 UK NNP I-NP O
19 544 549 10739826 along IN B-PP O
20 550 554 10739826 with IN B-PP O
21 555 559 10739826 2066 CD B-NP O
22 560 568 10739826 controls NNS I-NP O
23 568 569 10739826 . . O O

1 570 576 10739826 Totals NNS B-NP O
2 577 579 10739826 of IN B-PP O
3 580 583 10739826 128 CD B-NP O
4 584 589 10739826 cases NNS I-NP O
5 590 593 10739826 and CC O O
6 594 597 10739826 650 CD B-NP O
7 598 606 10739826 controls NNS I-NP O
8 607 611 10739826 were VBD B-VP O
9 612 620 10739826 analysed VBN I-VP O
10 621 624 10739826 for IN B-PP O
11 625 631 10739826 repeat NN B-NP O
12 632 635 10739826 use NN I-NP O
13 636 639 10739826 and CC O O
14 640 643 10739826 135 CD B-NP O
15 644 649 10739826 cases NNS I-NP O
16 650 653 10739826 and CC O O
17 654 657 10739826 622 CD B-NP O
18 658 666 10739826 controls NNS I-NP O
19 667 670 10739826 for IN B-PP O
20 671 680 10739826 switching VBG B-VP O
21 681 689 10739826 patterns NNS B-NP O
22 689 690 10739826 . . O O

1 691 694 10739826 The DT B-NP O
2 695 703 10739826 adjusted VBN I-NP O
3 704 708 10739826 rate NN I-NP O
4 709 714 10739826 ratio NN I-NP O
5 715 717 10739826 of IN B-PP O
6 718 721 10739826 VTE NN B-NP B-Disease
7 722 725 10739826 for IN B-PP O
8 726 732 10739826 repeat NN B-NP O
9 733 738 10739826 users NNS I-NP O
10 739 741 10739826 of IN B-PP O
11 742 747 10739826 third JJ B-NP O
12 748 758 10739826 generation NN I-NP O
13 759 761 10739826 OC NN I-NP B-Chemical
14 762 765 10739826 was VBD B-VP O
15 766 769 10739826 0.6 CD B-NP O
16 770 771 10739826 ( ( O O
17 771 774 10739826 95% CD B-NP O
18 775 777 10739826 CI NNP I-NP O
19 777 778 10739826 : : O O
20 778 781 10739826 0.3 CD B-NP O
21 781 782 10739826 - HYPH I-NP O
22 782 785 10739826 1.2 CD I-NP O
23 785 786 10739826 ) ) O O
24 787 795 10739826 relative JJ B-ADJP O
25 796 798 10739826 to TO B-VP O
26 799 805 10739826 repeat VB I-VP O
27 806 811 10739826 users NNS B-NP O
28 812 814 10739826 of IN B-PP O
29 815 821 10739826 second JJ B-NP O
30 822 832 10739826 generation NN I-NP O
31 833 838 10739826 pills NNS I-NP O
32 838 839 10739826 , , O O
33 840 847 10739826 whereas IN O O
34 848 850 10739826 it PRP B-NP O
35 851 854 10739826 was VBD B-VP O
36 855 858 10739826 1.3 CD B-NP O
37 859 860 10739826 ( ( O O
38 860 863 10739826 95% CD B-NP O
39 864 866 10739826 CI NNP I-NP O
40 866 867 10739826 : : O O
41 867 870 10739826 0.7 CD B-NP O
42 870 871 10739826 - HYPH I-NP O
43 871 874 10739826 2.4 CD I-NP O
44 874 875 10739826 ) ) O O
45 876 879 10739826 for IN B-PP O
46 880 889 10739826 switchers NNS B-NP O
47 890 894 10739826 from IN B-PP O
48 895 901 10739826 second JJ B-NP O
49 902 904 10739826 to TO B-PP O
50 905 910 10739826 third JJ B-NP O
51 911 921 10739826 generation NN I-NP O
52 922 927 10739826 pills NNS I-NP O
53 928 936 10739826 relative JJ B-ADVP O
54 937 939 10739826 to TO B-PP O
55 940 949 10739826 switchers NNS B-NP O
56 950 954 10739826 from IN B-PP O
57 955 960 10739826 third JJ B-ADJP O
58 961 963 10739826 to TO B-PP O
59 964 970 10739826 second JJ B-NP O
60 971 981 10739826 generation NN I-NP O
61 982 987 10739826 pills NNS I-NP O
62 987 988 10739826 . . O O

1 989 991 10739826 We PRP B-NP O
2 992 1000 10739826 conclude VBP B-VP O
3 1001 1005 10739826 that IN B-SBAR O
4 1006 1012 10739826 second JJ B-NP O
5 1013 1016 10739826 and CC I-NP O
6 1017 1022 10739826 third JJ I-NP O
7 1023 1033 10739826 generation NN I-NP O
8 1034 1040 10739826 agents NNS I-NP O
9 1041 1044 10739826 are VBP B-VP O
10 1045 1055 10739826 associated VBN I-VP O
11 1056 1060 10739826 with IN B-PP O
12 1061 1071 10739826 equivalent JJ B-NP O
13 1072 1077 10739826 risks NNS I-NP O
14 1078 1080 10739826 of IN B-PP O
15 1081 1084 10739826 VTE NN B-NP B-Disease
16 1085 1089 10739826 when WRB B-ADVP O
17 1090 1093 10739826 the DT B-NP O
18 1094 1098 10739826 same JJ I-NP O
19 1099 1104 10739826 agent NN I-NP O
20 1105 1107 10739826 is VBZ B-VP O
21 1108 1112 10739826 used VBN I-VP O
22 1113 1123 10739826 repeatedly RB B-ADVP O
23 1124 1129 10739826 after IN B-PP O
24 1130 1142 10739826 interruption NN B-NP O
25 1143 1150 10739826 periods NNS I-NP O
26 1151 1153 10739826 or CC O O
27 1154 1158 10739826 when WRB B-ADVP O
28 1159 1164 10739826 users NNS B-NP O
29 1165 1168 10739826 are VBP B-VP O
30 1169 1177 10739826 switched VBN I-VP O
31 1178 1185 10739826 between IN B-PP O
32 1186 1189 10739826 the DT B-NP O
33 1190 1193 10739826 two CD I-NP O
34 1194 1205 10739826 generations NNS I-NP O
35 1206 1208 10739826 of IN B-PP O
36 1209 1214 10739826 pills NNS B-NP O
37 1214 1215 10739826 . . O O

1 1216 1221 10739826 These DT B-NP O
2 1222 1230 10739826 analyses NNS I-NP O
3 1231 1238 10739826 suggest VBP B-VP O
4 1239 1243 10739826 that IN B-SBAR O
5 1244 1247 10739826 the DT B-NP O
6 1248 1254 10739826 higher JJR I-NP O
7 1255 1259 10739826 risk NN I-NP O
8 1260 1268 10739826 observed VBN B-VP O
9 1269 1272 10739826 for IN B-PP O
10 1273 1276 10739826 the DT B-NP O
11 1277 1282 10739826 newer JJR I-NP O
12 1283 1285 10739826 OC NN I-NP B-Chemical
13 1286 1288 10739826 in IN B-PP O
14 1289 1294 10739826 other JJ B-NP O
15 1295 1302 10739826 studies NNS I-NP O
16 1303 1306 10739826 may MD B-VP O
17 1307 1309 10739826 be VB I-VP O
18 1310 1313 10739826 the DT B-NP O
19 1314 1320 10739826 result NN I-NP O
20 1321 1323 10739826 of IN B-PP O
21 1324 1334 10739826 inadequate JJ B-NP O
22 1335 1346 10739826 comparisons NNS I-NP O
23 1347 1349 10739826 of IN B-PP O
24 1350 1354 10739826 pill NN B-NP O
25 1355 1360 10739826 users NNS I-NP O
26 1361 1365 10739826 with IN B-PP O
27 1366 1375 10739826 different JJ B-NP O
28 1376 1384 10739826 patterns NNS I-NP O
29 1385 1387 10739826 of IN B-PP O
30 1388 1392 10739826 pill NN B-NP O
31 1393 1396 10739826 use NN I-NP O
32 1396 1397 10739826 . . O O

1 0 0 17466854 -DOCSTART- -X- -X- O

1 0 4 17466854 Side NN B-NP O
2 5 12 17466854 effects NNS I-NP O
3 13 15 17466854 of IN B-PP O
4 16 29 17466854 postoperative JJ B-NP O
5 30 44 17466854 administration NN I-NP O
6 45 47 17466854 of IN B-PP O
7 48 66 17466854 methylprednisolone NN B-NP B-Chemical
8 67 70 17466854 and CC I-NP O
9 71 81 17466854 gentamicin NN I-NP B-Chemical
10 82 86 17466854 into IN B-PP O
11 87 90 17466854 the DT B-NP O
12 91 100 17466854 posterior JJ I-NP O
13 101 104 17466854 sub AFX I-NP O
14 104 105 17466854 - HYPH I-NP O
15 105 112 17466854 Tenon's NNP I-NP O
16 113 118 17466854 space NN I-NP O
17 118 119 17466854 . . I-NP O
18 120 127 17466854 PURPOSE NN I-NP O
19 127 128 17466854 : : O O
20 129 131 17466854 To TO B-VP O
21 132 138 17466854 assess VB I-VP O
22 139 142 17466854 the DT B-NP O
23 143 152 17466854 incidence NN I-NP O
24 153 155 17466854 of IN B-PP O
25 156 169 17466854 postoperative JJ B-NP O
26 170 176 17466854 emetic JJ I-NP O
27 177 181 17466854 side NN I-NP O
28 182 189 17466854 effects NNS I-NP O
29 190 195 17466854 after IN B-SBAR O
30 196 199 17466854 the DT B-NP O
31 200 214 17466854 administration NN I-NP O
32 215 217 17466854 of IN B-PP O
33 218 236 17466854 methylprednisolone NN B-NP B-Chemical
34 237 240 17466854 and CC I-NP O
35 241 251 17466854 gentamicin NN I-NP B-Chemical
36 252 256 17466854 into IN B-PP O
37 257 260 17466854 the DT B-NP O
38 261 270 17466854 posterior JJ I-NP O
39 271 274 17466854 sub AFX I-NP O
40 274 275 17466854 - HYPH I-NP O
41 275 282 17466854 Tenon's NNP I-NP O
42 283 288 17466854 space NN I-NP O
43 289 291 17466854 at IN B-PP O
44 292 295 17466854 the DT B-NP O
45 296 299 17466854 end NN I-NP O
46 300 302 17466854 of IN B-PP O
47 303 310 17466854 routine JJ B-NP O
48 311 319 17466854 cataract NN I-NP B-Disease
49 320 327 17466854 surgery NN I-NP O
50 327 328 17466854 . . O O

1 329 336 17466854 SETTING NN B-NP O
2 336 337 17466854 : : O O
3 338 340 17466854 St NN B-NP O
4 340 341 17466854 . . O O

1 342 348 17466854 Luke's NNP B-NP O
2 349 357 17466854 Hospital NNP I-NP O
3 357 358 17466854 , , O O
4 359 371 17466854 Gwardamangia NNP B-NP O
5 371 372 17466854 , , O O
6 373 378 17466854 Malta NNP B-NP O
7 378 379 17466854 . . O O

1 380 387 17466854 METHODS NNS B-NP O
2 387 388 17466854 : : O O
3 389 390 17466854 A DT B-NP O
4 391 397 17466854 double JJ I-NP O
5 397 398 17466854 - HYPH I-NP O
6 398 403 17466854 blind JJ I-NP O
7 404 410 17466854 double JJ I-NP O
8 410 411 17466854 - HYPH I-NP O
9 411 416 17466854 armed JJ I-NP O
10 417 428 17466854 prospective JJ I-NP O
11 429 434 17466854 study NN I-NP O
12 435 444 17466854 comprised VBD B-VP O
13 445 447 17466854 40 CD B-NP O
14 448 456 17466854 patients NNS I-NP O
15 457 460 17466854 who WP B-NP O
16 461 464 17466854 had VBD B-VP O
17 465 475 17466854 uneventful JJ B-NP O
18 476 486 17466854 sutureless JJ I-NP O
19 487 506 17466854 phacoemulsification NN I-NP O
20 507 512 17466854 under IN B-PP O
21 513 516 17466854 sub AFX B-NP O
22 516 517 17466854 - HYPH I-NP O
23 517 524 17466854 Tenon's NNPS I-NP O
24 525 530 17466854 local JJ I-NP O
25 531 543 17466854 infiltration NN I-NP O
26 544 546 17466854 of IN B-PP O
27 547 548 17466854 3 CD B-NP O
28 549 551 17466854 mL NN I-NP O
29 552 554 17466854 of IN B-PP O
30 555 560 17466854 plain JJ B-NP O
31 561 571 17466854 lignocaine NN I-NP B-Chemical
32 571 572 17466854 . . O O

1 573 575 17466854 At IN B-PP O
2 576 579 17466854 the DT B-NP O
3 580 583 17466854 end NN I-NP O
4 584 586 17466854 of IN B-PP O
5 587 590 17466854 the DT B-NP O
6 591 600 17466854 procedure NN I-NP O
7 600 601 17466854 , , O O
8 602 607 17466854 Group NN B-NP O
9 608 609 17466854 A NN I-NP O
10 610 611 17466854 ( ( O O
11 611 612 17466854 n NN B-NP O
12 613 614 17466854 = SYM B-VP O
13 615 617 17466854 20 CD B-NP O
14 617 618 17466854 ) ) O O
15 619 622 17466854 had VBD B-VP O
16 623 625 17466854 20 CD B-NP O
17 626 628 17466854 mg NN I-NP O
18 628 629 17466854 / SYM B-NP O
19 629 632 17466854 0.5 CD B-NP O
20 633 635 17466854 mL NN I-NP O
21 636 638 17466854 of IN B-PP O
22 639 657 17466854 methylprednisolone NN B-NP B-Chemical
23 658 661 17466854 and CC O O
24 662 664 17466854 10 CD B-NP O
25 665 667 17466854 mg NN I-NP O
26 667 668 17466854 / SYM I-NP O
27 668 671 17466854 0.5 CD I-NP O
28 672 674 17466854 mL NN I-NP O
29 675 677 17466854 of IN B-PP O
30 678 688 17466854 gentamicin NN B-NP B-Chemical
31 689 697 17466854 injected VBN B-VP O
32 698 702 17466854 into IN B-PP O
33 703 706 17466854 the DT B-NP O
34 707 716 17466854 posterior JJ I-NP O
35 717 720 17466854 sub AFX I-NP O
36 720 721 17466854 - HYPH I-NP O
37 721 728 17466854 Tenon's NNS I-NP O
38 729 734 17466854 space NN I-NP O
39 735 738 17466854 and CC I-NP O
40 739 744 17466854 Group NN I-NP O
41 745 746 17466854 B NN I-NP O
42 747 748 17466854 ( ( O O
43 748 749 17466854 n NN B-NP O
44 750 751 17466854 = SYM B-VP O
45 752 754 17466854 20 CD B-NP O
46 754 755 17466854 ) ) O O
47 756 759 17466854 had VBD B-VP O
48 760 763 17466854 the DT B-NP O
49 764 768 17466854 same JJ I-NP O
50 769 780 17466854 combination NN I-NP O
51 781 789 17466854 injected VBN B-VP O
52 790 794 17466854 into IN B-PP O
53 795 798 17466854 the DT B-NP O
54 799 807 17466854 anterior JJ I-NP O
55 808 811 17466854 sub AFX I-NP O
56 811 812 17466854 - HYPH I-NP O
57 812 819 17466854 Tenon's NNP I-NP O
58 820 825 17466854 space NN I-NP O
59 825 826 17466854 . . O O

1 827 842 17466854 Postoperatively RB B-ADVP O
2 842 843 17466854 , , O O
3 844 847 17466854 all DT B-NP O
4 848 856 17466854 patients NNS I-NP O
5 857 861 17466854 were VBD B-VP O
6 862 870 17466854 assessed VBN I-VP O
7 871 874 17466854 for IN B-PP O
8 875 883 17466854 symptoms NNS B-NP O
9 884 886 17466854 of IN B-PP O
10 887 893 17466854 nausea NN B-NP B-Disease
11 893 894 17466854 , , O I-Disease
12 895 903 17466854 vomiting NN B-NP I-Disease
13 903 904 17466854 , , O O
14 905 908 17466854 and CC O O
15 909 917 17466854 headache NN B-NP B-Disease
16 917 918 17466854 . . O O

1 919 920 17466854 A DT B-NP O
2 921 924 17466854 chi AFX I-NP O
3 924 925 17466854 - HYPH I-NP O
4 925 931 17466854 square NN I-NP O
5 932 936 17466854 test NN I-NP O
6 937 940 17466854 was VBD B-VP O
7 941 945 17466854 used VBN I-VP O
8 946 948 17466854 to TO B-VP O
9 949 955 17466854 assess VB I-VP O
10 956 959 17466854 the DT B-NP O
11 960 971 17466854 statistical JJ I-NP O
12 972 984 17466854 significance NN I-NP O
13 985 987 17466854 of IN B-PP O
14 988 995 17466854 results NNS B-NP O
15 995 996 17466854 . . O O

1 997 1004 17466854 RESULTS NNS B-NP O
2 1004 1005 17466854 : : O O
3 1006 1011 17466854 Sixty CD B-NP O
4 1012 1019 17466854 percent NN I-NP O
5 1020 1022 17466854 in IN B-PP O
6 1023 1028 17466854 Group NN B-NP O
7 1029 1030 17466854 A NN I-NP O
8 1031 1040 17466854 developed VBD B-VP O
9 1041 1054 17466854 postoperative JJ B-NP B-Disease
10 1055 1061 17466854 emetic JJ I-NP I-Disease
11 1062 1070 17466854 symptoms NNS I-NP I-Disease
12 1070 1071 17466854 , , O O
13 1072 1080 17466854 headache NN B-NP B-Disease
14 1080 1081 17466854 , , O O
15 1082 1084 17466854 or CC O O
16 1085 1089 17466854 both DT B-NP O
17 1089 1090 17466854 ; : O O
18 1091 1092 17466854 1 CD B-NP O
19 1093 1100 17466854 patient NN I-NP O
20 1101 1103 17466854 in IN B-PP O
21 1104 1109 17466854 Group NN B-NP O
22 1110 1111 17466854 B NN I-NP O
23 1112 1121 17466854 developed VBD B-VP O
24 1122 1130 17466854 symptoms NNS B-NP O
25 1130 1131 17466854 . . O O

1 1132 1143 17466854 CONCLUSIONS NNS B-NP O
2 1143 1144 17466854 : : O O
3 1145 1148 17466854 The DT B-NP O
4 1149 1163 17466854 administration NN I-NP O
5 1164 1166 17466854 of IN B-PP O
6 1167 1185 17466854 methylprednisolone NN B-NP B-Chemical
7 1186 1189 17466854 and CC I-NP O
8 1190 1200 17466854 gentamicin NN I-NP B-Chemical
9 1201 1203 17466854 in IN B-PP O
10 1204 1207 17466854 the DT B-NP O
11 1208 1217 17466854 posterior JJ I-NP O
12 1218 1221 17466854 sub AFX I-NP O
13 1221 1222 17466854 - HYPH I-NP O
14 1222 1229 17466854 Tenon's NNP I-NP O
15 1230 1235 17466854 space NN I-NP O
16 1236 1239 17466854 was VBD B-VP O
17 1240 1247 17466854 related VBN I-VP O
18 1248 1250 17466854 to TO B-PP O
19 1251 1252 17466854 a DT B-NP O
20 1253 1257 17466854 high JJ I-NP O
21 1258 1267 17466854 incidence NN I-NP O
22 1268 1270 17466854 of IN B-PP O
23 1271 1275 17466854 side NN B-NP O
24 1276 1283 17466854 effects NNS I-NP O
25 1284 1293 17466854 including VBG B-PP O
26 1294 1300 17466854 nausea NN B-NP B-Disease
27 1300 1301 17466854 , , O I-Disease
28 1302 1310 17466854 vomiting NN B-NP I-Disease
29 1310 1311 17466854 , , O O
30 1312 1315 17466854 and CC O O
31 1316 1324 17466854 headache NN B-NP B-Disease
32 1324 1325 17466854 . . O O

1 1326 1329 17466854 All DT B-NP O
2 1330 1337 17466854 adverse JJ I-NP O
3 1338 1345 17466854 effects NNS I-NP O
4 1346 1350 17466854 were VBD B-VP O
5 1351 1355 17466854 self AFX B-ADJP O
6 1355 1356 17466854 - HYPH O O
7 1356 1364 17466854 limiting VBG B-VP O
8 1364 1365 17466854 . . O O

1 0 0 10901305 -DOCSTART- -X- -X- O

1 0 8 10901305 Ketamine NN B-NP B-Chemical
2 9 17 10901305 sedation NN I-NP O
3 18 21 10901305 for IN B-PP O
4 22 25 10901305 the DT B-NP O
5 26 35 10901305 reduction NN I-NP O
6 36 38 10901305 of IN B-PP O
7 39 49 10901305 children's NNS B-NP O
8 50 59 10901305 fractures NNS I-NP B-Disease
9 60 62 10901305 in IN B-PP O
10 63 66 10901305 the DT B-NP O
11 67 76 10901305 emergency NN I-NP O
12 77 87 10901305 department NN I-NP O
13 87 88 10901305 . . I-NP O
14 89 99 10901305 BACKGROUND NN I-NP O
15 99 100 10901305 : : O O
16 101 106 10901305 There EX B-NP O
17 107 115 10901305 recently RB B-ADVP O
18 116 119 10901305 has VBZ B-VP O
19 120 124 10901305 been VBN I-VP O
20 125 126 10901305 a DT B-NP O
21 127 137 10901305 resurgence NN I-NP O
22 138 140 10901305 in IN B-PP O
23 141 144 10901305 the DT B-NP O
24 145 156 10901305 utilization NN I-NP O
25 157 159 10901305 of IN B-PP O
26 160 168 10901305 ketamine NN B-NP B-Chemical
27 168 169 10901305 , , O O
28 170 171 10901305 a DT B-NP O
29 172 178 10901305 unique JJ I-NP O
30 179 189 10901305 anesthetic NN I-NP O
31 189 190 10901305 , , O O
32 191 194 10901305 for IN B-PP O
33 195 204 10901305 emergency NN B-NP O
34 204 205 10901305 - HYPH I-NP O
35 205 215 10901305 department NN I-NP O
36 216 226 10901305 procedures NNS I-NP O
37 227 236 10901305 requiring VBG B-VP O
38 237 245 10901305 sedation NN B-NP O
39 245 246 10901305 . . O O

1 247 250 10901305 The DT B-NP O
2 251 258 10901305 purpose NN I-NP O
3 259 261 10901305 of IN B-PP O
4 262 265 10901305 the DT B-NP O
5 266 273 10901305 present JJ I-NP O
6 274 279 10901305 study NN I-NP O
7 280 283 10901305 was VBD B-VP O
8 284 286 10901305 to TO B-VP O
9 287 294 10901305 examine VB I-VP O
10 295 298 10901305 the DT B-NP O
11 299 305 10901305 safety NN I-NP O
12 306 309 10901305 and CC I-NP O
13 310 318 10901305 efficacy NN I-NP O
14 319 321 10901305 of IN B-PP O
15 322 330 10901305 ketamine NN B-NP B-Chemical
16 331 334 10901305 for IN B-PP O
17 335 343 10901305 sedation NN B-NP O
18 344 346 10901305 in IN B-PP O
19 347 350 10901305 the DT B-NP O
20 351 360 10901305 treatment NN I-NP O
21 361 363 10901305 of IN B-PP O
22 364 374 10901305 children's NNS B-NP O
23 375 384 10901305 fractures NNS I-NP B-Disease
24 385 387 10901305 in IN B-PP O
25 388 391 10901305 the DT B-NP O
26 392 401 10901305 emergency NN I-NP O
27 402 412 10901305 department NN I-NP O
28 412 413 10901305 . . O O

1 414 421 10901305 METHODS NNS B-NP O
2 421 422 10901305 : : O O
3 423 426 10901305 One CD B-NP O
4 427 434 10901305 hundred CD I-NP O
5 435 438 10901305 and CC I-NP O
6 439 447 10901305 fourteen CD I-NP O
7 448 456 10901305 children NNS I-NP O
8 457 458 10901305 ( ( O O
9 458 465 10901305 average JJ B-NP O
10 466 469 10901305 age NN I-NP O
11 469 470 10901305 , , O O
12 471 474 10901305 5.3 CD B-NP O
13 475 480 10901305 years NNS I-NP O
14 480 481 10901305 ; : O O
15 482 487 10901305 range NN B-NP O
16 487 488 10901305 , , O O
17 489 495 10901305 twelve CD B-NP O
18 496 502 10901305 months NNS I-NP O
19 503 505 10901305 to TO B-PP O
20 506 509 10901305 ten CD B-NP O
21 510 515 10901305 years NNS I-NP O
22 516 519 10901305 and CC O O
23 520 523 10901305 ten CD B-NP O
24 524 530 10901305 months NNS I-NP O
25 530 531 10901305 ) ) O O
26 532 535 10901305 who WP B-NP O
27 536 545 10901305 underwent VBD B-VP O
28 546 552 10901305 closed VBN B-VP O
29 553 562 10901305 reduction NN B-NP O
30 563 565 10901305 of IN B-PP O
31 566 568 10901305 an DT B-NP O
32 569 577 10901305 isolated VBN I-NP O
33 578 586 10901305 fracture NN I-NP B-Disease
34 587 589 10901305 or CC I-NP O
35 590 601 10901305 dislocation NN I-NP B-Disease
36 602 604 10901305 in IN B-PP O
37 605 608 10901305 the DT B-NP O
38 609 618 10901305 emergency NN I-NP O
39 619 629 10901305 department NN I-NP O
40 630 632 10901305 at IN B-PP O
41 633 634 10901305 a DT B-NP O
42 635 640 10901305 level NN I-NP O
43 640 641 10901305 - HYPH B-NP O
44 641 642 10901305 I NN I-NP O
45 643 649 10901305 trauma NN I-NP B-Disease
46 650 656 10901305 center NN I-NP O
47 657 661 10901305 were VBD B-VP O
48 662 675 10901305 prospectively RB I-VP O
49 676 685 10901305 evaluated VBN I-VP O
50 685 686 10901305 . . O O

1 687 695 10901305 Ketamine NN B-NP B-Chemical
2 696 709 10901305 hydrochloride NN I-NP I-Chemical
3 710 713 10901305 was VBD B-VP O
4 714 726 10901305 administered VBN I-VP O
5 727 740 10901305 intravenously RB B-ADVP O
6 741 742 10901305 ( ( O O
7 742 744 10901305 at IN B-PP O
8 745 746 10901305 a DT B-NP O
9 747 751 10901305 dose NN I-NP O
10 752 754 10901305 of IN B-PP O
11 755 758 10901305 two CD B-NP O
12 759 769 10901305 milligrams NNS I-NP O
13 770 773 10901305 per IN B-PP O
14 774 782 10901305 kilogram NN B-NP O
15 783 785 10901305 of IN B-PP O
16 786 790 10901305 body NN B-NP O
17 791 797 10901305 weight NN I-NP O
18 797 798 10901305 ) ) O O
19 799 801 10901305 in IN B-PP O
20 802 808 10901305 ninety CD B-NP O
21 808 809 10901305 - HYPH I-NP O
22 809 813 10901305 nine CD I-NP O
23 814 816 10901305 of IN B-PP O
24 817 820 10901305 the DT B-NP O
25 821 829 10901305 patients NNS I-NP O
26 830 833 10901305 and CC O O
27 834 849 10901305 intramuscularly RB B-ADVP O
28 850 851 10901305 ( ( O O
29 851 853 10901305 at IN B-PP O
30 854 855 10901305 a DT B-NP O
31 856 860 10901305 dose NN I-NP O
32 861 863 10901305 of IN B-PP O
33 864 868 10901305 four CD B-NP O
34 869 879 10901305 milligrams NNS I-NP O
35 880 883 10901305 per IN B-PP O
36 884 892 10901305 kilogram NN B-NP O
37 893 895 10901305 of IN B-PP O
38 896 900 10901305 body NN B-NP O
39 901 907 10901305 weight NN I-NP O
40 907 908 10901305 ) ) O O
41 909 911 10901305 in IN B-PP O
42 912 915 10901305 the DT B-NP O
43 916 921 10901305 other JJ I-NP O
44 922 929 10901305 fifteen CD I-NP O
45 929 930 10901305 . . O O

1 931 932 10901305 A DT B-NP O
2 933 938 10901305 board NN I-NP O
3 938 939 10901305 - HYPH B-VP O
4 939 948 10901305 certified VBN B-NP O
5 949 958 10901305 emergency NN I-NP O
6 959 968 10901305 physician NN I-NP O
7 969 976 10901305 skilled VBN B-VP O
8 977 979 10901305 in IN B-PP O
9 980 986 10901305 airway NN B-NP O
10 987 997 10901305 management NN I-NP O
11 998 1008 10901305 supervised VBD B-VP O
12 1009 1023 10901305 administration NN B-NP O
13 1024 1026 10901305 of IN B-PP O
14 1027 1030 10901305 the DT B-NP O
15 1031 1041 10901305 anesthetic JJ I-NP O
16 1041 1042 10901305 , , O O
17 1043 1046 10901305 and CC O O
18 1047 1050 10901305 the DT B-NP O
19 1051 1059 10901305 patients NNS I-NP O
20 1060 1064 10901305 were VBD B-VP O
21 1065 1074 10901305 monitored VBN I-VP O
22 1075 1077 10901305 by IN B-PP O
23 1078 1079 10901305 a DT B-NP O
24 1080 1090 10901305 registered VBN I-NP O
25 1091 1096 10901305 nurse NN I-NP O
26 1096 1097 10901305 . . O O

1 1098 1101 10901305 Any DT B-NP O
2 1102 1106 10901305 pain NN I-NP B-Disease
3 1107 1113 10901305 during IN B-PP O
4 1114 1117 10901305 the DT B-NP O
5 1118 1127 10901305 reduction NN I-NP O
6 1128 1131 10901305 was VBD B-VP O
7 1132 1137 10901305 rated VBN I-VP O
8 1138 1140 10901305 by IN B-PP O
9 1141 1144 10901305 the DT B-NP O
10 1145 1156 10901305 orthopaedic JJ I-NP O
11 1157 1164 10901305 surgeon NN I-NP O
12 1165 1173 10901305 treating VBG B-VP O
13 1174 1177 10901305 the DT B-NP O
14 1178 1185 10901305 patient NN I-NP O
15 1186 1195 10901305 according VBG B-PP O
16 1196 1198 10901305 to TO B-PP O
17 1199 1202 10901305 the DT B-NP O
18 1203 1213 10901305 Children's NNP I-NP O
19 1214 1222 10901305 Hospital NNP I-NP O
20 1223 1225 10901305 of IN B-PP O
21 1226 1233 10901305 Eastern NNP B-NP O
22 1234 1241 10901305 Ontario NNP I-NP O
23 1242 1246 10901305 Pain NNP I-NP B-Disease
24 1247 1252 10901305 Scale NNP I-NP O
25 1253 1254 10901305 ( ( O O
26 1254 1260 10901305 CHEOPS NNP B-NP O
27 1260 1261 10901305 ) ) O O
28 1261 1262 10901305 . . O O

1 1263 1270 10901305 RESULTS NNS B-NP O
2 1270 1271 10901305 : : O O
3 1272 1275 10901305 The DT B-NP O
4 1276 1283 10901305 average JJ I-NP O
5 1284 1288 10901305 time NN I-NP O
6 1289 1293 10901305 from IN B-PP O
7 1294 1305 10901305 intravenous JJ B-NP O
8 1306 1320 10901305 administration NN I-NP O
9 1321 1323 10901305 of IN B-PP O
10 1324 1332 10901305 ketamine NN B-NP B-Chemical
11 1333 1335 10901305 to TO B-PP O
12 1336 1348 10901305 manipulation NN B-NP O
13 1349 1351 10901305 of IN B-PP O
14 1352 1355 10901305 the DT B-NP O
15 1356 1364 10901305 fracture NN I-NP B-Disease
16 1365 1367 10901305 or CC I-NP O
17 1368 1379 10901305 dislocation NN I-NP B-Disease
18 1380 1383 10901305 was VBD B-VP O
19 1384 1387 10901305 one CD B-NP O
20 1388 1394 10901305 minute NN I-NP O
21 1395 1398 10901305 and CC O O
22 1399 1405 10901305 thirty CD B-NP O
23 1405 1406 10901305 - HYPH I-NP O
24 1406 1409 10901305 six CD I-NP O
25 1410 1417 10901305 seconds NNS I-NP O
26 1418 1419 10901305 ( ( O O
27 1419 1424 10901305 range NN B-NP O
28 1424 1425 10901305 , , O O
29 1426 1432 10901305 twenty CD B-NP O
30 1433 1440 10901305 seconds NNS I-NP O
31 1441 1443 10901305 to TO B-PP O
32 1444 1448 10901305 five CD B-NP O
33 1449 1456 10901305 minutes NNS I-NP O
34 1456 1457 10901305 ) ) O O
35 1457 1458 10901305 , , O O
36 1459 1462 10901305 and CC O O
37 1463 1466 10901305 the DT B-NP O
38 1467 1474 10901305 average JJ I-NP O
39 1475 1479 10901305 time NN I-NP O
40 1480 1484 10901305 from IN B-PP O
41 1485 1498 10901305 intramuscular JJ B-NP O
42 1499 1513 10901305 administration NN I-NP O
43 1514 1516 10901305 to TO B-PP O
44 1517 1529 10901305 manipulation NN B-NP O
45 1530 1533 10901305 was VBD B-VP O
46 1534 1538 10901305 four CD B-NP O
47 1539 1546 10901305 minutes NNS I-NP O
48 1547 1550 10901305 and CC I-NP O
49 1551 1556 10901305 forty NN I-NP O
50 1556 1557 10901305 - HYPH O O
51 1557 1560 10901305 two CD B-NP O
52 1561 1568 10901305 seconds NNS I-NP O
53 1569 1570 10901305 ( ( O O
54 1570 1575 10901305 range NN B-NP O
55 1575 1576 10901305 , , O O
56 1577 1582 10901305 sixty JJ B-NP O
57 1583 1590 10901305 seconds NNS I-NP O
58 1591 1593 10901305 to TO B-PP O
59 1594 1601 10901305 fifteen CD B-NP O
60 1602 1609 10901305 minutes NNS I-NP O
61 1609 1610 10901305 ) ) O O
62 1610 1611 10901305 . . O O

1 1612 1615 10901305 The DT B-NP O
2 1616 1623 10901305 average JJ I-NP O
3 1624 1629 10901305 score NN I-NP O
4 1630 1639 10901305 according VBG B-PP O
5 1640 1642 10901305 to TO B-PP O
6 1643 1646 10901305 the DT B-NP O
7 1647 1657 10901305 Children's NNP I-NP O
8 1658 1666 10901305 Hospital NNP I-NP O
9 1667 1669 10901305 of IN B-PP O
10 1670 1677 10901305 Eastern NNP B-NP O
11 1678 1685 10901305 Ontario NNP I-NP O
12 1686 1690 10901305 Pain NNP I-NP B-Disease
13 1691 1696 10901305 Scale NNP I-NP O
14 1697 1700 10901305 was VBD B-VP O
15 1701 1704 10901305 6.4 CD B-NP O
16 1705 1711 10901305 points NNS I-NP O
17 1712 1713 10901305 ( ( O O
18 1713 1718 10901305 range NN B-NP O
19 1718 1719 10901305 , , O O
20 1720 1721 10901305 5 CD B-NP O
21 1722 1724 10901305 to TO I-NP O
22 1725 1727 10901305 10 CD I-NP O
23 1728 1734 10901305 points NNS I-NP O
24 1734 1735 10901305 ) ) O O
25 1735 1736 10901305 , , O O
26 1737 1747 10901305 reflecting VBG B-VP O
27 1748 1755 10901305 minimal JJ B-NP O
28 1756 1758 10901305 or CC I-NP O
29 1759 1761 10901305 no DT I-NP O
30 1762 1766 10901305 pain NN I-NP B-Disease
31 1767 1773 10901305 during IN B-PP O
32 1774 1782 10901305 fracture NN B-NP B-Disease
33 1783 1792 10901305 reduction NN I-NP O
34 1792 1793 10901305 . . O O

1 1794 1802 10901305 Adequate JJ B-NP O
2 1803 1811 10901305 fracture NN I-NP B-Disease
3 1812 1821 10901305 reduction NN I-NP O
4 1822 1825 10901305 was VBD B-VP O
5 1826 1834 10901305 obtained VBN I-VP O
6 1835 1837 10901305 in IN B-PP O
7 1838 1841 10901305 111 CD B-NP O
8 1842 1844 10901305 of IN B-PP O
9 1845 1848 10901305 the DT B-NP O
10 1849 1857 10901305 children NNS I-NP O
11 1857 1858 10901305 . . O O

1 1859 1865 10901305 Ninety CD B-NP O
2 1865 1866 10901305 - HYPH I-NP O
3 1866 1870 10901305 nine CD I-NP O
4 1871 1878 10901305 percent NN I-NP O
5 1879 1880 10901305 ( ( O O
6 1880 1885 10901305 sixty CD B-NP O
7 1885 1886 10901305 - HYPH I-NP O
8 1886 1891 10901305 eight CD I-NP O
9 1891 1892 10901305 ) ) O O
10 1893 1895 10901305 of IN B-PP O
11 1896 1899 10901305 the DT B-NP O
12 1900 1905 10901305 sixty CD I-NP O
13 1905 1906 10901305 - HYPH I-NP O
14 1906 1910 10901305 nine CD I-NP O
15 1911 1918 10901305 parents NNS I-NP O
16 1919 1926 10901305 present JJ B-ADJP O
17 1927 1933 10901305 during IN B-PP O
18 1934 1937 10901305 the DT B-NP O
19 1938 1947 10901305 reduction NN I-NP O
20 1948 1952 10901305 were VBD B-VP O
21 1953 1960 10901305 pleased VBN I-VP O
22 1961 1965 10901305 with IN B-PP O
23 1966 1969 10901305 the DT B-NP O
24 1970 1978 10901305 sedation NN I-NP O
25 1979 1982 10901305 and CC O O
26 1983 1988 10901305 would MD B-VP O
27 1989 1994 10901305 allow VB I-VP O
28 1995 1997 10901305 it PRP B-NP O
29 1998 2000 10901305 to TO B-VP O
30 2001 2003 10901305 be VB I-VP O
31 2004 2008 10901305 used VBN I-VP O
32 2009 2014 10901305 again RB B-ADVP O
33 2015 2017 10901305 in IN B-PP O
34 2018 2019 10901305 a DT B-NP O
35 2020 2027 10901305 similar JJ I-NP O
36 2028 2037 10901305 situation NN I-NP O
37 2037 2038 10901305 . . O O

1 2039 2046 10901305 Patency NN B-NP O
2 2047 2049 10901305 of IN B-PP O
3 2050 2053 10901305 the DT B-NP O
4 2054 2060 10901305 airway NN I-NP O
5 2061 2064 10901305 and CC O O
6 2065 2076 10901305 independent JJ B-NP O
7 2077 2088 10901305 respiration NN I-NP O
8 2089 2093 10901305 were VBD B-VP O
9 2094 2104 10901305 maintained VBN I-VP O
10 2105 2107 10901305 in IN B-PP O
11 2108 2111 10901305 all DT B-NP O
12 2112 2114 10901305 of IN B-PP O
13 2115 2118 10901305 the DT B-NP O
14 2119 2127 10901305 patients NNS I-NP O
15 2127 2128 10901305 . . O O

1 2129 2134 10901305 Blood NN B-NP O
2 2135 2143 10901305 pressure NN I-NP O
3 2144 2147 10901305 and CC I-NP O
4 2148 2153 10901305 heart NN I-NP O
5 2154 2158 10901305 rate NN I-NP O
6 2159 2167 10901305 remained VBD B-VP O
7 2168 2174 10901305 stable JJ B-ADJP O
8 2174 2175 10901305 . . O O

1 2176 2181 10901305 Minor JJ B-NP O
2 2182 2186 10901305 side NN I-NP O
3 2187 2194 10901305 effects NNS I-NP O
4 2195 2203 10901305 included VBD B-VP O
5 2204 2210 10901305 nausea NN B-NP B-Disease
6 2211 2212 10901305 ( ( O O
7 2212 2220 10901305 thirteen CD B-NP O
8 2221 2229 10901305 patients NNS I-NP O
9 2229 2230 10901305 ) ) O O
10 2230 2231 10901305 , , O O
11 2232 2238 10901305 emesis NN B-NP B-Disease
12 2239 2240 10901305 ( ( O O
13 2240 2245 10901305 eight CD B-NP O
14 2246 2248 10901305 of IN B-PP O
15 2249 2252 10901305 the DT B-NP O
16 2253 2261 10901305 thirteen CD I-NP O
17 2262 2270 10901305 patients NNS I-NP O
18 2271 2275 10901305 with IN B-PP O
19 2276 2282 10901305 nausea NN B-NP B-Disease
20 2282 2283 10901305 ) ) O O
21 2283 2284 10901305 , , O O
22 2285 2295 10901305 clumsiness NN B-NP B-Disease
23 2296 2297 10901305 ( ( O O
24 2297 2304 10901305 evident JJ B-ADJP O
25 2305 2307 10901305 as IN B-PP O
26 2308 2314 10901305 ataxic JJ B-NP B-Disease
27 2315 2324 10901305 movements NNS I-NP I-Disease
28 2325 2327 10901305 in IN B-PP O
29 2328 2331 10901305 ten CD B-NP O
30 2332 2340 10901305 patients NNS I-NP O
31 2340 2341 10901305 ) ) O O
32 2341 2342 10901305 , , O O
33 2343 2346 10901305 and CC O O
34 2347 2356 10901305 dysphoric JJ B-NP B-Disease
35 2357 2365 10901305 reaction NN I-NP I-Disease
36 2366 2367 10901305 ( ( O O
37 2367 2370 10901305 one CD B-NP O
38 2371 2378 10901305 patient NN I-NP O
39 2378 2379 10901305 ) ) O O
40 2379 2380 10901305 . . O O

1 2381 2383 10901305 No DT B-NP O
2 2384 2388 10901305 long JJ I-NP O
3 2388 2389 10901305 - HYPH I-NP O
4 2389 2393 10901305 term NN I-NP O
5 2394 2402 10901305 sequelae NNS I-NP O
6 2403 2407 10901305 were VBD B-VP O
7 2408 2413 10901305 noted VBN I-VP O
8 2413 2414 10901305 , , O O
9 2415 2418 10901305 and CC O O
10 2419 2421 10901305 no DT B-NP O
11 2422 2430 10901305 patients NNS I-NP O
12 2431 2434 10901305 had VBD B-VP O
13 2435 2449 10901305 hallucinations NNS B-NP B-Disease
14 2450 2452 10901305 or CC I-NP O
15 2453 2463 10901305 nightmares NNS I-NP O
16 2463 2464 10901305 . . O O

1 2465 2476 10901305 CONCLUSIONS NNS B-NP O
2 2476 2477 10901305 : : O O
3 2478 2486 10901305 Ketamine NN B-NP B-Chemical
4 2487 2495 10901305 reliably RB B-ADVP O
5 2495 2496 10901305 , , O O
6 2497 2503 10901305 safely RB B-ADVP O
7 2503 2504 10901305 , , O O
8 2505 2508 10901305 and CC O O
9 2509 2516 10901305 quickly RB B-VP O
10 2517 2525 10901305 provided VBD I-VP O
11 2526 2534 10901305 adequate JJ B-NP O
12 2535 2543 10901305 sedation NN I-NP O
13 2544 2546 10901305 to TO B-VP O
14 2547 2558 10901305 effectively RB I-VP O
15 2559 2569 10901305 facilitate VB I-VP O
16 2570 2573 10901305 the DT B-NP O
17 2574 2583 10901305 reduction NN I-NP O
18 2584 2586 10901305 of IN B-PP O
19 2587 2597 10901305 children's NNS B-NP O
20 2598 2607 10901305 fractures NNS I-NP B-Disease
21 2608 2610 10901305 in IN B-PP O
22 2611 2614 10901305 the DT B-NP O
23 2615 2624 10901305 emergency NN I-NP O
24 2625 2635 10901305 department NN I-NP O
25 2636 2638 10901305 at IN B-PP O
26 2639 2642 10901305 our PRP$ B-NP O
27 2643 2654 10901305 institution NN I-NP O
28 2654 2655 10901305 . . O O

1 2656 2664 10901305 Ketamine NN B-NP B-Chemical
2 2665 2671 10901305 should MD B-VP O
3 2672 2676 10901305 only RB I-VP O
4 2677 2679 10901305 be VB I-VP O
5 2680 2684 10901305 used VBN I-VP O
6 2685 2687 10901305 in IN B-PP O
7 2688 2690 10901305 an DT B-NP O
8 2691 2702 10901305 environment NN I-NP O
9 2703 2707 10901305 such JJ B-PP O
10 2708 2710 10901305 as IN I-PP O
11 2711 2714 10901305 the DT B-NP O
12 2715 2724 10901305 emergency NN I-NP O
13 2725 2735 10901305 department NN I-NP O
14 2735 2736 10901305 , , O O
15 2737 2742 10901305 where WRB B-ADVP O
16 2743 2749 10901305 proper JJ B-NP O
17 2750 2753 10901305 one CD I-NP O
18 2753 2754 10901305 - HYPH B-ADVP O
19 2754 2756 10901305 on IN B-PP O
20 2756 2757 10901305 - HYPH B-NP O
21 2757 2760 10901305 one CD I-NP O
22 2761 2771 10901305 monitoring NN I-NP O
23 2772 2774 10901305 is VBZ B-VP O
24 2775 2779 10901305 used VBN I-VP O
25 2780 2783 10901305 and CC O O
26 2784 2789 10901305 board NN B-NP O
27 2789 2790 10901305 - HYPH B-NP O
28 2790 2799 10901305 certified VBN I-NP O
29 2800 2810 10901305 physicians NNS I-NP O
30 2811 2818 10901305 skilled VBD B-VP O
31 2819 2821 10901305 in IN B-PP O
32 2822 2828 10901305 airway NN B-NP O
33 2829 2839 10901305 management NN I-NP O
34 2840 2843 10901305 are VBP B-VP O
35 2844 2852 10901305 directly RB I-VP O
36 2853 2861 10901305 involved VBN I-VP O
37 2862 2864 10901305 in IN B-PP O
38 2865 2868 10901305 the DT B-NP O
39 2869 2873 10901305 care NN I-NP O
40 2874 2876 10901305 of IN B-PP O
41 2877 2880 10901305 the DT B-NP O
42 2881 2888 10901305 patient NN I-NP O
43 2888 2889 10901305 . . O O

1 0 0 16330766 -DOCSTART- -X- -X- O

1 0 15 16330766 Pharmacological JJ B-NP O
2 16 26 16330766 modulation NN I-NP O
3 27 29 16330766 of IN B-PP O
4 30 34 16330766 pain NN B-NP B-Disease
5 34 35 16330766 - HYPH B-NP O
6 35 42 16330766 related VBN I-NP O
7 43 48 16330766 brain NN I-NP O
8 49 57 16330766 activity NN I-NP O
9 58 64 16330766 during IN B-PP O
10 65 71 16330766 normal JJ B-NP O
11 72 75 16330766 and CC I-NP O
12 76 83 16330766 central JJ I-NP O
13 84 97 16330766 sensitization NN I-NP O
14 98 104 16330766 states NNS I-NP O
15 105 107 16330766 in IN B-PP O
16 108 114 16330766 humans NNS B-NP O
17 114 115 16330766 . . O O
18 116 124 16330766 Abnormal JJ B-NP O
19 125 135 16330766 processing NN I-NP O
20 136 138 16330766 of IN B-PP O
21 139 152 16330766 somatosensory JJ B-NP O
22 153 159 16330766 inputs NNS I-NP O
23 160 162 16330766 in IN B-PP O
24 163 166 16330766 the DT B-NP O
25 167 174 16330766 central JJ I-NP O
26 175 182 16330766 nervous JJ I-NP O
27 183 189 16330766 system NN I-NP O
28 190 191 16330766 ( ( O O
29 191 198 16330766 central JJ B-NP O
30 199 212 16330766 sensitization NN I-NP O
31 212 213 16330766 ) ) O O
32 214 216 16330766 is VBZ B-VP O
33 217 220 16330766 the DT B-NP O
34 221 230 16330766 mechanism NN I-NP O
35 231 241 16330766 accounting VBG B-VP O
36 242 245 16330766 for IN B-PP O
37 246 249 16330766 the DT B-NP O
38 250 258 16330766 enhanced VBN I-NP O
39 259 263 16330766 pain NN I-NP B-Disease
40 264 275 16330766 sensitivity NN I-NP O
41 276 278 16330766 in IN B-PP O
42 279 282 16330766 the DT B-NP O
43 283 287 16330766 skin NN I-NP O
44 288 299 16330766 surrounding VBG B-VP O
45 300 306 16330766 tissue NN B-NP B-Disease
46 307 313 16330766 injury NN I-NP I-Disease
47 314 315 16330766 ( ( O O
48 315 324 16330766 secondary JJ B-NP B-Disease
49 325 337 16330766 hyperalgesia NN I-NP I-Disease
50 337 338 16330766 ) ) O O
51 338 339 16330766 . . O O

1 340 349 16330766 Secondary JJ B-NP B-Disease
2 350 362 16330766 hyperalgesia NN I-NP I-Disease
3 363 369 16330766 shares VBZ B-VP O
4 370 378 16330766 clinical JJ B-NP O
5 379 394 16330766 characteristics NNS I-NP O
6 395 399 16330766 with IN B-PP O
7 400 410 16330766 neurogenic JJ B-NP B-Disease
8 411 423 16330766 hyperalgesia NN I-NP I-Disease
9 424 426 16330766 in IN B-PP O
10 427 435 16330766 patients NNS B-NP O
11 436 440 16330766 with IN B-PP O
12 441 452 16330766 neuropathic JJ B-NP B-Disease
13 453 457 16330766 pain NN I-NP I-Disease
14 457 458 16330766 . . O O

1 459 467 16330766 Abnormal JJ B-NP O
2 468 473 16330766 brain NN I-NP O
3 474 483 16330766 responses NNS I-NP O
4 484 486 16330766 to TO B-PP O
5 487 500 16330766 somatosensory JJ B-NP O
6 501 508 16330766 stimuli NNS I-NP O
7 509 513 16330766 have VBP B-VP O
8 514 518 16330766 been VBN I-VP O
9 519 524 16330766 found VBN I-VP O
10 525 527 16330766 in IN B-PP O
11 528 536 16330766 patients NNS B-NP O
12 537 541 16330766 with IN B-PP O
13 542 554 16330766 hyperalgesia NN B-NP B-Disease
14 555 557 16330766 as RB B-CONJP O
15 558 562 16330766 well RB I-CONJP O
16 563 565 16330766 as IN I-CONJP O
17 566 568 16330766 in IN B-PP O
18 569 575 16330766 normal JJ B-NP O
19 576 584 16330766 subjects NNS I-NP O
20 585 591 16330766 during IN B-PP O
21 592 604 16330766 experimental JJ B-NP O
22 605 612 16330766 central JJ I-NP O
23 613 626 16330766 sensitization NN I-NP O
24 626 627 16330766 . . O O

1 628 631 16330766 The DT B-NP O
2 632 635 16330766 aim NN I-NP O
3 636 638 16330766 of IN B-PP O
4 639 643 16330766 this DT B-NP O
5 644 649 16330766 study NN I-NP O
6 650 653 16330766 was VBD B-VP O
7 654 656 16330766 to TO B-VP O
8 657 663 16330766 assess VB I-VP O
9 664 667 16330766 the DT B-NP O
10 668 675 16330766 effects NNS I-NP O
11 676 678 16330766 of IN B-PP O
12 679 689 16330766 gabapentin NN B-NP B-Chemical
13 689 690 16330766 , , O O
14 691 692 16330766 a DT B-NP O
15 693 697 16330766 drug NN I-NP O
16 698 707 16330766 effective JJ B-ADJP O
17 708 710 16330766 in IN B-PP O
18 711 722 16330766 neuropathic JJ B-NP B-Disease
19 723 727 16330766 pain NN I-NP I-Disease
20 728 736 16330766 patients NNS I-NP O
21 736 737 16330766 , , O O
22 738 740 16330766 on IN B-PP O
23 741 746 16330766 brain NN B-NP O
24 747 757 16330766 processing NN I-NP O
25 758 760 16330766 of IN B-PP O
26 761 772 16330766 nociceptive JJ B-NP O
27 773 784 16330766 information NN I-NP O
28 785 787 16330766 in IN B-PP O
29 788 794 16330766 normal JJ B-NP O
30 795 798 16330766 and CC I-NP O
31 799 806 16330766 central JJ I-NP O
32 807 820 16330766 sensitization NN I-NP O
33 821 827 16330766 states NNS I-NP O
34 827 828 16330766 . . O O

1 829 834 16330766 Using VBG B-VP O
2 835 845 16330766 functional JJ B-NP O
3 846 854 16330766 magnetic JJ I-NP O
4 855 864 16330766 resonance NN I-NP O
5 865 872 16330766 imaging NN I-NP O
6 873 874 16330766 ( ( O O
7 874 878 16330766 fMRI NN B-NP O
8 878 879 16330766 ) ) O O
9 880 882 16330766 in IN B-PP O
10 883 889 16330766 normal JJ B-NP O
11 890 900 16330766 volunteers NNS I-NP O
12 900 901 16330766 , , O O
13 902 904 16330766 we PRP B-NP O
14 905 912 16330766 studied VBD B-VP O
15 913 916 16330766 the DT B-NP O
16 917 927 16330766 gabapentin NN I-NP B-Chemical
17 927 928 16330766 - HYPH B-NP O
18 928 935 16330766 induced VBN I-NP O
19 936 946 16330766 modulation NN I-NP O
20 947 949 16330766 of IN B-PP O
21 950 955 16330766 brain NN B-NP O
22 956 964 16330766 activity NN I-NP O
23 965 967 16330766 in IN B-PP O
24 968 976 16330766 response NN B-NP O
25 977 979 16330766 to TO B-PP O
26 980 991 16330766 nociceptive JJ B-NP O
27 992 1002 16330766 mechanical JJ I-NP O
28 1003 1014 16330766 stimulation NN I-NP O
29 1015 1017 16330766 of IN B-PP O
30 1018 1024 16330766 normal JJ B-NP O
31 1025 1029 16330766 skin NN I-NP O
32 1030 1033 16330766 and CC I-NP O
33 1034 1043 16330766 capsaicin NN I-NP B-Chemical
34 1043 1044 16330766 - HYPH O O
35 1044 1051 16330766 induced VBN B-NP O
36 1052 1061 16330766 secondary JJ I-NP B-Disease
37 1062 1074 16330766 hyperalgesia NN I-NP I-Disease
38 1074 1075 16330766 . . O O

1 1076 1079 16330766 The DT B-NP O
2 1080 1084 16330766 dose NN I-NP O
3 1085 1087 16330766 of IN B-PP O
4 1088 1098 16330766 gabapentin NN B-NP B-Chemical
5 1099 1102 16330766 was VBD B-VP O
6 1103 1108 16330766 1,800 CD B-NP O
7 1109 1111 16330766 mg NN I-NP O
8 1112 1115 16330766 per IN B-PP O
9 1116 1118 16330766 os NNS B-NP O
10 1118 1119 16330766 , , O O
11 1120 1122 16330766 in IN B-PP O
12 1123 1124 16330766 a DT B-NP O
13 1125 1131 16330766 single JJ I-NP O
14 1132 1146 16330766 administration NN I-NP O
15 1146 1147 16330766 . . O O

1 1148 1150 16330766 We PRP B-NP O
2 1151 1156 16330766 found VBD B-VP O
3 1157 1161 16330766 that IN B-SBAR O
4 1162 1165 16330766 (i) LS B-NP O
5 1166 1176 16330766 gabapentin NN I-NP B-Chemical
6 1177 1184 16330766 reduced VBD B-VP O
7 1185 1188 16330766 the DT B-NP O
8 1189 1200 16330766 activations NNS I-NP O
9 1201 1203 16330766 in IN B-PP O
10 1204 1207 16330766 the DT B-NP O
11 1208 1217 16330766 bilateral JJ I-NP O
12 1218 1233 16330766 operculoinsular JJ I-NP O
13 1234 1240 16330766 cortex NN I-NP O
14 1240 1241 16330766 , , O O
15 1242 1255 16330766 independently RB B-ADVP O
16 1256 1258 16330766 of IN B-PP O
17 1259 1262 16330766 the DT B-NP O
18 1263 1271 16330766 presence NN I-NP O
19 1272 1274 16330766 of IN B-PP O
20 1275 1282 16330766 central JJ B-NP O
21 1283 1296 16330766 sensitization NN I-NP O
22 1296 1297 16330766 ; : O O
23 1298 1302 16330766 (ii) LS B-NP O
24 1303 1313 16330766 gabapentin NN I-NP B-Chemical
25 1314 1321 16330766 reduced VBD B-VP O
26 1322 1325 16330766 the DT B-NP O
27 1326 1336 16330766 activation NN I-NP O
28 1337 1339 16330766 in IN B-PP O
29 1340 1343 16330766 the DT B-NP O
30 1344 1353 16330766 brainstem NN I-NP O
31 1353 1354 16330766 , , O O
32 1355 1359 16330766 only RB B-ADVP O
33 1360 1366 16330766 during IN B-PP O
34 1367 1374 16330766 central JJ B-NP O
35 1375 1388 16330766 sensitization NN I-NP O
36 1388 1389 16330766 ; : O O
37 1390 1395 16330766 (iii) LS B-NP O
38 1396 1406 16330766 gabapentin NN I-NP B-Chemical
39 1407 1417 16330766 suppressed VBD B-VP O
40 1418 1426 16330766 stimulus NN B-NP O
41 1426 1427 16330766 - HYPH B-NP O
42 1427 1434 16330766 induced VBN I-NP O
43 1435 1448 16330766 deactivations NNS I-NP O
44 1448 1449 16330766 , , O O
45 1450 1454 16330766 only RB B-ADVP O
46 1455 1461 16330766 during IN B-PP O
47 1462 1469 16330766 central JJ B-NP O
48 1470 1483 16330766 sensitization NN I-NP O
49 1483 1484 16330766 ; : O O
50 1485 1489 16330766 this DT B-NP O
51 1490 1496 16330766 effect NN I-NP O
52 1497 1500 16330766 was VBD B-VP O
53 1501 1505 16330766 more RBR B-ADJP O
54 1506 1512 16330766 robust JJ I-ADJP O
55 1513 1517 16330766 than IN B-PP O
56 1518 1521 16330766 the DT B-NP O
57 1522 1528 16330766 effect NN I-NP O
58 1529 1531 16330766 on IN B-PP O
59 1532 1537 16330766 brain NN B-NP O
60 1538 1548 16330766 activation NN I-NP O
61 1548 1549 16330766 . . O O

1 1550 1553 16330766 The DT B-NP O
2 1554 1562 16330766 observed VBN I-NP O
3 1563 1567 16330766 drug NN I-NP O
4 1567 1568 16330766 - HYPH B-NP O
5 1568 1575 16330766 induced VBN I-NP O
6 1576 1583 16330766 effects NNS I-NP O
7 1584 1588 16330766 were VBD B-VP O
8 1589 1592 16330766 not RB O O
9 1593 1596 16330766 due JJ B-ADJP O
10 1597 1599 16330766 to TO B-PP O
11 1600 1607 16330766 changes NNS B-NP O
12 1608 1610 16330766 in IN B-PP O
13 1611 1614 16330766 the DT B-NP O
14 1615 1623 16330766 baseline NN I-NP O
15 1624 1628 16330766 fMRI NN I-NP O
16 1629 1635 16330766 signal NN I-NP O
17 1635 1636 16330766 . . O O

1 1637 1642 16330766 These DT B-NP O
2 1643 1651 16330766 findings NNS I-NP O
3 1652 1660 16330766 indicate VBP B-VP O
4 1661 1665 16330766 that IN B-SBAR O
5 1666 1676 16330766 gabapentin NN B-NP B-Chemical
6 1677 1680 16330766 has VBZ B-VP O
7 1681 1682 16330766 a DT B-NP O
8 1683 1693 16330766 measurable JJ I-NP O
9 1694 1709 16330766 antinociceptive JJ I-NP O
10 1710 1716 16330766 effect NN I-NP O
11 1717 1720 16330766 and CC O O
12 1721 1722 16330766 a DT B-NP O
13 1723 1731 16330766 stronger JJR I-NP O
14 1732 1748 16330766 antihyperalgesic JJ I-NP O
15 1749 1755 16330766 effect NN I-NP O
16 1756 1760 16330766 most RBS B-ADJP O
17 1761 1768 16330766 evident JJ I-ADJP O
18 1769 1771 16330766 in IN B-PP O
19 1772 1775 16330766 the DT B-NP O
20 1776 1781 16330766 brain NN I-NP O
21 1782 1787 16330766 areas NNS I-NP O
22 1788 1798 16330766 undergoing VBG B-VP O
23 1799 1811 16330766 deactivation NN B-NP O
24 1811 1812 16330766 , , O O
25 1813 1817 16330766 thus RB B-ADVP O
26 1818 1828 16330766 supporting VBG B-VP O
27 1829 1832 16330766 the DT B-NP O
28 1833 1840 16330766 concept NN I-NP O
29 1841 1845 16330766 that IN B-SBAR O
30 1846 1856 16330766 gabapentin NN B-NP B-Chemical
31 1857 1859 16330766 is VBZ B-VP O
32 1860 1864 16330766 more RBR B-ADJP O
33 1865 1874 16330766 effective JJ I-ADJP O
34 1875 1877 16330766 in IN B-PP O
35 1878 1888 16330766 modulating VBG B-VP O
36 1889 1900 16330766 nociceptive JJ B-NP O
37 1901 1913 16330766 transmission NN I-NP O
38 1914 1918 16330766 when WRB B-ADVP O
39 1919 1926 16330766 central JJ B-NP O
40 1927 1940 16330766 sensitization NN I-NP O
41 1941 1943 16330766 is VBZ B-VP O
42 1944 1951 16330766 present JJ B-ADJP O
43 1951 1952 16330766 . . O O

1 0 0 1436384 -DOCSTART- -X- -X- O

1 0 10 1436384 Protection NN B-NP O
2 11 18 1436384 against IN B-PP O
3 19 30 1436384 amphetamine NN B-NP B-Chemical
4 30 31 1436384 - HYPH B-NP O
5 31 38 1436384 induced VBN I-NP O
6 39 52 1436384 neurotoxicity NN I-NP B-Disease
7 53 59 1436384 toward IN B-PP O
8 60 68 1436384 striatal JJ B-NP O
9 69 77 1436384 dopamine NN I-NP B-Chemical
10 78 85 1436384 neurons NNS I-NP O
11 86 88 1436384 in IN B-PP O
12 89 96 1436384 rodents NNS B-NP O
13 97 99 1436384 by IN B-PP O
14 100 108 1436384 LY274614 NN B-NP B-Chemical
15 108 109 1436384 , , O O
16 110 112 1436384 an DT B-NP O
17 113 123 1436384 excitatory JJ I-NP O
18 124 129 1436384 amino NN I-NP B-Chemical
19 130 134 1436384 acid NN I-NP I-Chemical
20 135 145 1436384 antagonist NN I-NP O
21 145 146 1436384 . . O O
22 147 155 1436384 LY274614 NN B-NP B-Chemical
23 155 156 1436384 , , O O
24 157 174 1436384 3SR,4aRS,6SR,8aRS NN B-NP B-Chemical
25 174 175 1436384 - HYPH B-NP I-Chemical
26 175 176 1436384 6 CD I-NP I-Chemical
27 176 177 1436384 - HYPH I-NP I-Chemical
28 177 202 1436384 [phosphonomethyl]decahydr NN I-NP I-Chemical
29 203 216 1436384 oisoquinoline NN I-NP I-Chemical
30 216 217 1436384 - HYPH B-NP I-Chemical
31 217 218 1436384 3 CD I-NP I-Chemical
32 218 219 1436384 - HYPH I-NP I-Chemical
33 220 230 1436384 carboxylic JJ I-NP I-Chemical
34 231 235 1436384 acid NN I-NP I-Chemical
35 235 236 1436384 , , O O
36 237 240 1436384 has VBZ B-VP O
37 241 245 1436384 been VBN I-VP O
38 246 255 1436384 described VBN I-VP O
39 256 258 1436384 as IN B-PP O
40 259 260 1436384 a DT B-NP O
41 261 267 1436384 potent JJ I-NP O
42 268 278 1436384 antagonist NN I-NP O
43 279 281 1436384 of IN B-PP O
44 282 285 1436384 the DT B-NP O
45 286 287 1436384 N NN I-NP B-Chemical
46 287 288 1436384 - HYPH B-NP I-Chemical
47 288 294 1436384 methyl NN I-NP I-Chemical
48 294 295 1436384 - HYPH B-NP I-Chemical
49 295 296 1436384 D NN I-NP I-Chemical
50 296 297 1436384 - HYPH O I-Chemical
51 297 306 1436384 aspartate NN B-NP I-Chemical
52 307 308 1436384 ( ( O O
53 308 312 1436384 NMDA NN B-NP B-Chemical
54 312 313 1436384 ) ) O O
55 314 321 1436384 subtype NN B-NP O
56 322 324 1436384 of IN B-PP O
57 325 334 1436384 glutamate NN B-NP B-Chemical
58 335 343 1436384 receptor NN I-NP O
59 343 344 1436384 . . O O

1 345 349 1436384 Here RB B-ADVP O
2 350 353 1436384 its PRP$ B-NP O
3 354 361 1436384 ability NN I-NP O
4 362 364 1436384 to TO B-VP O
5 365 375 1436384 antagonize VB I-VP O
6 376 379 1436384 the DT B-NP O
7 380 389 1436384 prolonged VBN I-NP O
8 390 399 1436384 depletion NN I-NP O
9 400 402 1436384 of IN B-PP O
10 403 411 1436384 dopamine NN B-NP B-Chemical
11 412 414 1436384 in IN B-PP O
12 415 418 1436384 the DT B-NP O
13 419 427 1436384 striatum NN I-NP O
14 428 430 1436384 by IN B-PP O
15 431 442 1436384 amphetamine NN B-NP B-Chemical
16 443 445 1436384 in IN B-PP O
17 446 455 1436384 iprindole NN B-NP B-Chemical
18 455 456 1436384 - HYPH B-NP O
19 456 463 1436384 treated VBN I-NP O
20 464 468 1436384 rats NNS I-NP O
21 469 471 1436384 is VBZ B-VP O
22 472 480 1436384 reported VBN I-VP O
23 480 481 1436384 . . O O

1 482 483 1436384 A DT B-NP O
2 484 490 1436384 single JJ I-NP O
3 491 495 1436384 18.4 CD I-NP O
4 496 498 1436384 mg NN I-NP O
5 498 499 1436384 / SYM B-NP O
6 499 501 1436384 kg NN I-NP O
7 502 503 1436384 ( ( O O
8 503 506 1436384 i.p JJ O O
9 506 507 1436384 . . O O
10 507 508 1436384 ) ) O O
11 509 513 1436384 dose NN B-NP O
12 514 516 1436384 of IN B-PP O
13 517 518 1436384 ( ( O O
14 518 519 1436384 + SYM B-NP O
15 519 520 1436384 / SYM O O
16 520 521 1436384 - SYM O O
17 521 522 1436384 ) ) O O
18 522 523 1436384 - HYPH B-NP O
19 523 534 1436384 amphetamine NN I-NP B-Chemical
20 535 546 1436384 hemisulfate NN I-NP O
21 546 547 1436384 , , O O
22 548 553 1436384 given VBN B-PP O
23 554 556 1436384 to TO B-PP O
24 557 561 1436384 rats NNS B-NP O
25 562 572 1436384 pretreated VBN B-VP O
26 573 577 1436384 with IN B-PP O
27 578 587 1436384 iprindole NN B-NP B-Chemical
28 587 588 1436384 , , O O
29 589 597 1436384 resulted VBD B-VP O
30 598 600 1436384 in IN B-PP O
31 601 611 1436384 persistent JJ B-NP O
32 612 621 1436384 depletion NN I-NP O
33 622 624 1436384 of IN B-PP O
34 625 633 1436384 dopamine NN B-NP B-Chemical
35 634 636 1436384 in IN B-PP O
36 637 640 1436384 the DT B-NP O
37 641 649 1436384 striatum NN I-NP O
38 650 651 1436384 1 CD I-NP O
39 652 656 1436384 week NN I-NP O
40 657 662 1436384 later RB B-ADVP O
41 662 663 1436384 . . O O

1 664 668 1436384 This DT B-NP O
2 669 678 1436384 prolonged JJ I-NP O
3 679 688 1436384 depletion NN I-NP O
4 689 691 1436384 of IN B-PP O
5 692 700 1436384 dopamine NN B-NP B-Chemical
6 701 703 1436384 in IN B-PP O
7 704 707 1436384 the DT B-NP O
8 708 716 1436384 striatum NN I-NP O
9 717 720 1436384 was VBD B-VP O
10 721 732 1436384 antagonized VBN I-VP O
11 733 735 1436384 by IN B-PP O
12 736 747 1436384 dizocilpine NN B-NP B-Chemical
13 748 749 1436384 ( ( O O
14 749 751 1436384 MK NN B-NP B-Chemical
15 751 752 1436384 - HYPH O I-Chemical
16 752 755 1436384 801 CD B-NP I-Chemical
17 755 756 1436384 , , O O
18 757 758 1436384 a DT B-NP O
19 759 762 1436384 non AFX I-NP O
20 762 763 1436384 - HYPH I-NP O
21 763 774 1436384 competitive JJ I-NP O
22 775 785 1436384 antagonist NN I-NP O
23 786 788 1436384 of IN B-PP O
24 789 793 1436384 NMDA NN B-NP B-Chemical
25 794 803 1436384 receptors NNS I-NP O
26 803 804 1436384 ) ) O O
27 805 807 1436384 or CC O O
28 808 810 1436384 by IN B-PP O
29 811 819 1436384 LY274614 NN B-NP B-Chemical
30 820 821 1436384 ( ( O O
31 821 822 1436384 a DT B-NP O
32 823 834 1436384 competitive JJ I-NP O
33 835 845 1436384 antagonist NN I-NP O
34 846 848 1436384 of IN B-PP O
35 849 853 1436384 NMDA NN B-NP B-Chemical
36 854 863 1436384 receptors NNS I-NP O
37 863 864 1436384 ) ) O O
38 864 865 1436384 . . O O

1 866 869 1436384 The DT B-NP O
2 870 880 1436384 protective JJ I-NP O
3 881 887 1436384 effect NN I-NP O
4 888 890 1436384 of IN B-PP O
5 891 899 1436384 LY274614 NN B-NP B-Chemical
6 900 903 1436384 was VBD B-VP O
7 904 908 1436384 dose NN B-NP O
8 908 909 1436384 - HYPH B-PP O
9 909 918 1436384 dependent JJ B-ADJP O
10 918 919 1436384 , , O O
11 920 925 1436384 being VBG B-VP O
12 926 933 1436384 maximum NN B-NP O
13 934 936 1436384 at IN B-PP O
14 937 939 1436384 10 CD B-NP O
15 939 940 1436384 - HYPH I-NP O
16 940 942 1436384 40 CD I-NP O
17 943 947 1436384 mgkg NN I-NP O
18 948 949 1436384 ( ( O O
19 949 952 1436384 i.p JJ O O
20 952 953 1436384 . . O O
21 953 954 1436384 ) ) O O
22 954 955 1436384 . . O O

1 956 957 1436384 A DT B-NP O
2 958 960 1436384 10 CD I-NP O
3 961 963 1436384 mg NN I-NP O
4 963 964 1436384 / SYM I-NP O
5 964 966 1436384 kg NN I-NP O
6 967 971 1436384 dose NN I-NP O
7 972 974 1436384 of IN B-PP O
8 975 983 1436384 LY274614 NN B-NP B-Chemical
9 984 987 1436384 was VBD B-VP O
10 988 997 1436384 effective JJ B-ADJP O
11 998 1000 1436384 in IN B-PP O
12 1001 1013 1436384 antagonizing VBG B-VP O
13 1014 1017 1436384 the DT B-NP O
14 1018 1027 1436384 depletion NN I-NP O
15 1028 1030 1436384 of IN B-PP O
16 1031 1039 1436384 dopamine NN B-NP B-Chemical
17 1040 1042 1436384 in IN B-PP O
18 1043 1046 1436384 the DT B-NP O
19 1047 1055 1436384 striatum NN I-NP O
20 1055 1056 1436384 , , O O
21 1057 1061 1436384 when WRB B-ADVP O
22 1062 1067 1436384 given VBN B-VP O
23 1068 1070 1436384 as RB B-ADVP O
24 1071 1075 1436384 long RB I-ADVP O
25 1076 1078 1436384 as IN B-SBAR O
26 1079 1080 1436384 8 CD B-NP O
27 1081 1083 1436384 hr NN I-NP O
28 1084 1089 1436384 prior JJ B-ADJP O
29 1090 1092 1436384 to TO B-PP O
30 1093 1104 1436384 amphetamine NN B-NP B-Chemical
31 1105 1108 1436384 but CC O O
32 1109 1112 1436384 not RB O O
33 1113 1117 1436384 when WRB B-ADVP O
34 1118 1123 1436384 given VBN B-VP O
35 1124 1126 1436384 24 CD B-NP O
36 1127 1129 1436384 hr NN I-NP O
37 1130 1135 1436384 prior JJ B-ADJP O
38 1136 1138 1436384 to TO B-PP O
39 1139 1150 1436384 amphetamine NN B-NP B-Chemical
40 1150 1151 1436384 . . O O

1 1152 1161 1436384 Depletion NN B-NP O
2 1162 1164 1436384 of IN B-PP O
3 1165 1173 1436384 dopamine NN B-NP B-Chemical
4 1174 1176 1436384 in IN B-PP O
5 1177 1180 1436384 the DT B-NP O
6 1181 1189 1436384 striatum NN I-NP O
7 1190 1193 1436384 was VBD B-VP O
8 1194 1198 1436384 also RB I-VP O
9 1199 1210 1436384 antagonized VBN I-VP O
10 1211 1215 1436384 when WRB B-ADVP O
11 1216 1224 1436384 LY274614 NN B-NP B-Chemical
12 1225 1228 1436384 was VBD B-VP O
13 1229 1234 1436384 given VBN I-VP O
14 1235 1240 1436384 after IN B-PP O
15 1241 1244 1436384 the DT B-NP O
16 1245 1254 1436384 injection NN I-NP O
17 1255 1257 1436384 of IN B-PP O
18 1258 1269 1436384 amphetamine NN B-NP B-Chemical
19 1269 1270 1436384 ; : O O
20 1271 1279 1436384 LY274614 NN B-NP B-Chemical
21 1280 1289 1436384 protected VBD B-VP O
22 1290 1294 1436384 when WRB B-ADVP O
23 1295 1300 1436384 given VBN B-PP O
24 1301 1303 1436384 up IN B-NP O
25 1304 1306 1436384 to TO I-NP O
26 1307 1308 1436384 4 CD I-NP O
27 1309 1311 1436384 hr NN I-NP O
28 1312 1317 1436384 after IN B-PP O
29 1318 1321 1436384 but CC O O
30 1322 1325 1436384 not RB O O
31 1326 1330 1436384 when WRB B-ADVP O
32 1331 1336 1436384 given VBN B-VP O
33 1337 1338 1436384 8 CD B-NP O
34 1339 1341 1436384 or CC I-NP O
35 1342 1344 1436384 24 CD I-NP O
36 1345 1347 1436384 hr NN I-NP O
37 1348 1353 1436384 after IN B-PP O
38 1354 1365 1436384 amphetamine NN B-NP B-Chemical
39 1365 1366 1436384 . . O O

1 1367 1370 1436384 The DT B-NP O
2 1371 1380 1436384 prolonged VBN I-NP O
3 1381 1390 1436384 depletion NN I-NP O
4 1391 1393 1436384 of IN B-PP O
5 1394 1402 1436384 dopamine NN B-NP B-Chemical
6 1403 1405 1436384 in IN B-PP O
7 1406 1409 1436384 the DT B-NP O
8 1410 1418 1436384 striatum NN I-NP O
9 1419 1421 1436384 in IN B-PP O
10 1422 1426 1436384 mice NNS B-NP O
11 1426 1427 1436384 , , O O
12 1428 1433 1436384 given VBN B-PP O
13 1434 1442 1436384 multiple JJ B-NP O
14 1443 1453 1436384 injections NNS I-NP O
15 1454 1456 1436384 of IN B-PP O
16 1457 1472 1436384 methamphetamine NN B-NP B-Chemical
17 1472 1473 1436384 , , O O
18 1474 1477 1436384 was VBD B-VP O
19 1478 1482 1436384 also RB I-VP O
20 1483 1494 1436384 antagonized VBN I-VP O
21 1495 1499 1436384 dose NN B-NP O
22 1499 1500 1436384 - HYPH O O
23 1500 1511 1436384 dependently RB B-ADVP O
24 1512 1515 1436384 and CC I-ADVP O
25 1516 1526 1436384 completely RB I-ADVP O
26 1527 1529 1436384 by IN B-PP O
27 1530 1538 1436384 LY274614 NN B-NP B-Chemical
28 1538 1539 1436384 . . O O

1 1540 1543 1436384 The DT B-NP O
2 1544 1548 1436384 data NNS I-NP O
3 1549 1559 1436384 strengthen VBP B-VP O
4 1560 1563 1436384 the DT B-NP O
5 1564 1572 1436384 evidence NN I-NP O
6 1573 1577 1436384 that IN B-SBAR O
7 1578 1581 1436384 the DT B-NP O
8 1582 1592 1436384 neurotoxic JJ I-NP B-Disease
9 1593 1599 1436384 effect NN I-NP O
10 1600 1602 1436384 of IN B-PP O
11 1603 1614 1436384 amphetamine NN B-NP B-Chemical
12 1615 1618 1436384 and CC I-NP O
13 1619 1626 1436384 related VBN I-NP O
14 1627 1636 1436384 compounds NNS I-NP O
15 1637 1643 1436384 toward IN B-PP O
16 1644 1657 1436384 nigrostriatal JJ B-NP O
17 1658 1666 1436384 dopamine NN I-NP B-Chemical
18 1667 1674 1436384 neurons NNS I-NP O
19 1675 1683 1436384 involves VBZ B-VP O
20 1684 1688 1436384 NMDA NN B-NP B-Chemical
21 1689 1698 1436384 receptors NNS I-NP O
22 1699 1702 1436384 and CC O O
23 1703 1707 1436384 that IN B-SBAR O
24 1708 1716 1436384 LY274614 NN B-NP B-Chemical
25 1717 1719 1436384 is VBZ B-VP O
26 1720 1722 1436384 an DT B-NP O
27 1723 1727 1436384 NMDA NN I-NP B-Chemical
28 1728 1736 1436384 receptor NN I-NP O
29 1737 1747 1436384 antagonist NN I-NP O
30 1748 1752 1436384 with IN B-PP O
31 1753 1757 1436384 long RB B-ADVP O
32 1757 1758 1436384 - HYPH B-NP O
33 1758 1765 1436384 lasting VBG B-VP O
34 1766 1768 1436384 in FW B-NP O
35 1769 1773 1436384 vivo FW I-NP O
36 1774 1781 1436384 effects NNS I-NP O
37 1782 1784 1436384 in IN B-PP O
38 1785 1789 1436384 rats NNS B-NP O
39 1789 1790 1436384 . . O O

1 0 0 17244258 -DOCSTART- -X- -X- O

1 0 2 17244258 In FW B-NP O
2 3 8 17244258 vitro FW I-NP O
3 9 25 17244258 characterization NN I-NP O
4 26 28 17244258 of IN B-PP O
5 29 44 17244258 parasympathetic JJ B-NP O
6 45 48 17244258 and CC I-NP O
7 49 60 17244258 sympathetic JJ I-NP O
8 61 70 17244258 responses NNS I-NP O
9 71 73 17244258 in IN B-PP O
10 74 90 17244258 cyclophosphamide NN B-NP B-Chemical
11 90 91 17244258 - HYPH B-NP O
12 91 98 17244258 induced VBN I-NP O
13 99 107 17244258 cystitis NN I-NP B-Disease
14 108 110 17244258 in IN B-PP O
15 111 114 17244258 the DT B-NP O
16 115 118 17244258 rat NN I-NP O
17 118 119 17244258 . . O O
18 120 122 17244258 In IN B-PP O
19 123 139 17244258 cyclophosphamide NN B-NP B-Chemical
20 139 140 17244258 - HYPH B-NP O
21 140 147 17244258 induced VBN I-NP O
22 148 156 17244258 cystitis NN I-NP B-Disease
23 157 159 17244258 in IN B-PP O
24 160 163 17244258 the DT B-NP O
25 164 167 17244258 rat NN I-NP O
26 167 168 17244258 , , O O
27 169 177 17244258 detrusor NN B-NP O
28 178 186 17244258 function NN I-NP O
29 187 189 17244258 is VBZ B-VP O
30 190 198 17244258 impaired JJ B-ADJP O
31 199 202 17244258 and CC O O
32 203 206 17244258 the DT B-NP O
33 207 217 17244258 expression NN B-NP O
34 218 221 17244258 and CC O O
35 222 229 17244258 effects NNS B-NP O
36 230 232 17244258 of IN B-PP O
37 233 243 17244258 muscarinic JJ B-NP O
38 244 253 17244258 receptors NNS I-NP O
39 254 261 17244258 altered VBN B-VP O
40 261 262 17244258 . . O O

1 263 270 17244258 Whether RB B-ADVP O
2 271 273 17244258 or CC O O
3 274 277 17244258 not RB O O
4 278 281 17244258 the DT B-NP O
5 282 290 17244258 neuronal JJ I-NP O
6 291 303 17244258 transmission NN I-NP O
7 304 307 17244258 may MD B-VP O
8 308 310 17244258 be VB I-VP O
9 311 319 17244258 affected VBN I-VP O
10 320 322 17244258 by IN B-PP O
11 323 331 17244258 cystitis NN B-NP B-Disease
12 332 335 17244258 was VBD B-VP O
13 336 345 17244258 presently RB I-VP O
14 346 358 17244258 investigated VBN I-VP O
15 358 359 17244258 . . O O

1 360 369 17244258 Responses NNS B-NP O
2 370 372 17244258 of IN B-PP O
3 373 380 17244258 urinary JJ B-NP O
4 381 386 17244258 strip NN I-NP O
5 387 399 17244258 preparations NNS I-NP O
6 400 404 17244258 from IN B-PP O
7 405 412 17244258 control NN B-NP O
8 413 416 17244258 and CC I-NP O
9 417 433 17244258 cyclophosphamide NN I-NP B-Chemical
10 433 434 17244258 - HYPH B-NP O
11 434 444 17244258 pretreated VBN I-NP O
12 445 449 17244258 rats NNS I-NP O
13 450 452 17244258 to TO B-PP O
14 453 463 17244258 electrical JJ B-NP O
15 464 469 17244258 field NN I-NP O
16 470 481 17244258 stimulation NN I-NP O
17 482 485 17244258 and CC B-PP O
18 486 488 17244258 to TO B-PP O
19 489 497 17244258 agonists NNS B-NP O
20 498 502 17244258 were VBD B-VP O
21 503 511 17244258 assessed VBN I-VP O
22 512 514 17244258 in IN B-PP O
23 515 518 17244258 the DT B-NP O
24 519 526 17244258 absence NN I-NP O
25 527 530 17244258 and CC I-NP O
26 531 539 17244258 presence NN I-NP O
27 540 542 17244258 of IN B-PP O
28 543 553 17244258 muscarinic JJ B-NP O
29 553 554 17244258 , , I-NP O
30 555 565 17244258 adrenergic JJ I-NP O
31 566 569 17244258 and CC I-NP O
32 570 580 17244258 purinergic JJ I-NP O
33 581 589 17244258 receptor NN I-NP O
34 590 601 17244258 antagonists NNS I-NP O
35 601 602 17244258 . . O O

1 603 612 17244258 Generally RB B-ADVP O
2 612 613 17244258 , , O O
3 614 622 17244258 atropine NN B-NP B-Chemical
4 623 630 17244258 reduced VBD B-VP O
5 631 643 17244258 contractions NNS B-NP O
6 643 644 17244258 , , O O
7 645 648 17244258 but CC O O
8 649 651 17244258 in IN B-PP O
9 652 660 17244258 contrast NN B-NP O
10 661 663 17244258 to TO B-PP O
11 664 672 17244258 controls NNS B-NP O
12 672 673 17244258 , , O O
13 674 676 17244258 it PRP B-NP O
14 677 681 17244258 also RB B-ADVP O
15 682 689 17244258 reduced VBD B-VP O
16 690 699 17244258 responses NNS B-NP O
17 700 702 17244258 to TO B-PP O
18 703 706 17244258 low JJ B-NP O
19 707 717 17244258 electrical JJ I-NP O
20 718 723 17244258 field NN I-NP O
21 724 735 17244258 stimulation NN I-NP O
22 736 745 17244258 intensity NN I-NP O
23 746 747 17244258 ( ( O O
24 747 748 17244258 1 CD B-NP O
25 748 749 17244258 - HYPH I-NP O
26 749 750 17244258 5 CD I-NP O
27 751 753 17244258 Hz NN I-NP O
28 753 754 17244258 ) ) O O
29 755 757 17244258 in IN B-PP O
30 758 766 17244258 inflamed JJ B-NP O
31 767 779 17244258 preparations NNS I-NP O
32 779 780 17244258 . . O O

1 781 783 17244258 In IN B-PP O
2 784 788 17244258 both DT B-NP O
3 789 794 17244258 types NNS I-NP O
4 794 795 17244258 , , O O
5 796 808 17244258 purinoceptor NN B-NP O
6 809 824 17244258 desensitization NN I-NP O
7 825 829 17244258 with IN B-PP O
8 830 840 17244258 alpha,beta NN B-NP B-Chemical
9 840 841 17244258 - HYPH O I-Chemical
10 841 850 17244258 methylene NN B-NP I-Chemical
11 851 860 17244258 adenosine NN I-NP I-Chemical
12 860 861 17244258 - HYPH B-NP I-Chemical
13 861 863 17244258 5' JJ I-NP I-Chemical
14 863 864 17244258 - HYPH I-NP I-Chemical
15 864 876 17244258 triphosphate NN I-NP I-Chemical
16 877 878 17244258 ( ( O O
17 878 888 17244258 alpha,beta NN B-NP B-Chemical
18 888 889 17244258 - HYPH B-NP I-Chemical
19 889 894 17244258 meATP NN I-NP I-Chemical
20 894 895 17244258 ) ) O O
21 896 902 17244258 caused VBD B-VP O
22 903 910 17244258 further JJ B-NP O
23 911 921 17244258 reductions NNS I-NP O
24 922 924 17244258 at IN B-PP O
25 925 928 17244258 low JJ B-NP O
26 929 940 17244258 frequencies NNS I-NP O
27 941 942 17244258 ( ( O O
28 942 943 17244258 < SYM B-NP O
29 943 945 17244258 10 CD I-NP O
30 946 948 17244258 Hz NN I-NP O
31 948 949 17244258 ) ) O O
32 949 950 17244258 . . O O

1 951 954 17244258 The DT B-NP O
2 955 965 17244258 muscarinic JJ I-NP O
3 966 974 17244258 receptor NN I-NP O
4 975 986 17244258 antagonists NNS I-NP O
5 987 995 17244258 atropine NN I-NP B-Chemical
6 995 996 17244258 , , O O
7 997 998 17244258 4 CD B-NP B-Chemical
8 998 999 17244258 - HYPH I-NP I-Chemical
9 999 1014 17244258 diphenylacetoxy NN I-NP I-Chemical
10 1014 1015 17244258 - HYPH B-NP I-Chemical
11 1015 1016 17244258 N NN I-NP I-Chemical
12 1016 1017 17244258 - HYPH O I-Chemical
13 1017 1033 17244258 methylpiperidine NN B-NP I-Chemical
14 1034 1035 17244258 ( ( O O
15 1035 1036 17244258 4 CD B-NP B-Chemical
16 1036 1037 17244258 - HYPH I-NP I-Chemical
17 1037 1041 17244258 DAMP NN I-NP I-Chemical
18 1041 1042 17244258 ) ) O O
19 1043 1044 17244258 ( ( O O
20 1044 1045 17244258 ' SYM B-NP O
21 1045 1049 17244258 M(1) NN I-NP O
22 1049 1050 17244258 / SYM I-NP O
23 1050 1054 17244258 M(3) NN I-NP O
24 1054 1055 17244258 / SYM B-NP O
25 1055 1059 17244258 M(5) NN I-NP O
26 1059 1060 17244258 - HYPH I-NP O
27 1060 1069 17244258 selective JJ I-NP O
28 1069 1070 17244258 ' '' O O
29 1070 1071 17244258 ) ) O O
30 1071 1072 17244258 , , O O
31 1073 1086 17244258 methoctramine NN B-NP B-Chemical
32 1087 1088 17244258 ( ( O O
33 1088 1089 17244258 ' `` O O
34 1089 1093 17244258 M(2) NN B-NP O
35 1093 1094 17244258 - HYPH I-NP O
36 1094 1103 17244258 selective JJ I-NP O
37 1103 1104 17244258 ' '' O O
38 1104 1105 17244258 ) ) O O
39 1106 1109 17244258 and CC O O
40 1110 1121 17244258 pirenzepine NN B-NP B-Chemical
41 1122 1123 17244258 ( ( O O
42 1123 1124 17244258 ' `` O O
43 1124 1128 17244258 M(1) NN B-NP O
44 1128 1129 17244258 - HYPH I-NP O
45 1129 1138 17244258 selective JJ I-NP O
46 1138 1139 17244258 ' '' O O
47 1139 1140 17244258 ) ) O O
48 1141 1152 17244258 antagonized VBD B-VP O
49 1153 1156 17244258 the DT B-NP O
50 1157 1162 17244258 tonic JJ I-NP O
51 1163 1172 17244258 component NN I-NP O
52 1173 1175 17244258 of IN B-PP O
53 1176 1179 17244258 the DT B-NP O
54 1180 1190 17244258 electrical JJ I-NP O
55 1191 1196 17244258 field NN I-NP O
56 1197 1208 17244258 stimulation NN I-NP O
57 1208 1209 17244258 - HYPH O O
58 1209 1215 17244258 evoked VBN B-VP O
59 1216 1227 17244258 contractile JJ B-NP O
60 1228 1236 17244258 response NN I-NP O
61 1237 1241 17244258 more RBR B-ADVP O
62 1242 1250 17244258 potently RB I-ADVP O
63 1251 1255 17244258 than IN B-PP O
64 1256 1259 17244258 the DT B-NP O
65 1260 1266 17244258 phasic JJ I-NP O
66 1267 1276 17244258 component NN I-NP O
67 1276 1277 17244258 . . O O

1 1278 1279 17244258 4 CD B-NP B-Chemical
2 1279 1280 17244258 - HYPH I-NP I-Chemical
3 1280 1284 17244258 DAMP NN I-NP I-Chemical
4 1285 1294 17244258 inhibited VBD B-VP O
5 1295 1298 17244258 the DT B-NP O
6 1299 1304 17244258 tonic JJ I-NP O
7 1305 1317 17244258 contractions NNS I-NP O
8 1318 1320 17244258 in IN B-PP O
9 1321 1329 17244258 controls NNS B-NP O
10 1330 1334 17244258 more RBR B-ADVP O
11 1335 1343 17244258 potently RB I-ADVP O
12 1344 1348 17244258 than IN B-PP O
13 1349 1362 17244258 methoctramine NN B-NP B-Chemical
14 1363 1366 17244258 and CC I-NP O
15 1367 1378 17244258 pirenzepine NN I-NP B-Chemical
16 1378 1379 17244258 . . O O

1 1380 1382 17244258 In IN B-PP O
2 1383 1391 17244258 inflamed JJ B-NP O
3 1392 1404 17244258 preparations NNS I-NP O
4 1404 1405 17244258 , , O O
5 1406 1409 17244258 the DT B-NP O
6 1410 1420 17244258 muscarinic JJ I-NP O
7 1421 1429 17244258 receptor NN I-NP O
8 1430 1440 17244258 antagonism NN I-NP O
9 1441 1443 17244258 on IN B-PP O
10 1444 1447 17244258 the DT B-NP O
11 1448 1454 17244258 phasic JJ I-NP O
12 1455 1464 17244258 component NN I-NP O
13 1465 1467 17244258 of IN B-PP O
14 1468 1471 17244258 the DT B-NP O
15 1472 1482 17244258 electrical JJ I-NP O
16 1483 1488 17244258 field NN I-NP O
17 1489 1500 17244258 stimulation NN I-NP O
18 1500 1501 17244258 - HYPH B-VP O
19 1501 1507 17244258 evoked VBN B-NP O
20 1508 1519 17244258 contraction NN I-NP O
21 1520 1523 17244258 was VBD B-VP O
22 1524 1533 17244258 decreased VBN I-VP O
23 1534 1537 17244258 and CC O O
24 1538 1541 17244258 the DT B-NP O
25 1542 1553 17244258 pirenzepine NN I-NP B-Chemical
26 1554 1557 17244258 and CC I-NP O
27 1558 1559 17244258 4 CD I-NP B-Chemical
28 1559 1560 17244258 - HYPH I-NP I-Chemical
29 1560 1564 17244258 DAMP NN I-NP I-Chemical
30 1565 1575 17244258 antagonism NN I-NP O
31 1576 1578 17244258 on IN B-PP O
32 1579 1582 17244258 the DT B-NP O
33 1583 1588 17244258 tonic JJ I-NP O
34 1589 1598 17244258 component NN I-NP O
35 1599 1602 17244258 was VBD B-VP O
36 1603 1607 17244258 much RB B-ADJP O
37 1608 1612 17244258 less RBR I-ADJP O
38 1613 1622 17244258 efficient JJ I-ADJP O
39 1623 1627 17244258 than IN B-PP O
40 1628 1630 17244258 in IN B-PP O
41 1631 1639 17244258 controls NNS B-NP O
42 1639 1640 17244258 . . O O

1 1641 1643 17244258 In IN B-PP O
2 1644 1652 17244258 contrast NN B-NP O
3 1653 1655 17244258 to TO B-PP O
4 1656 1664 17244258 controls NNS B-NP O
5 1664 1665 17244258 , , O O
6 1666 1679 17244258 methoctramine NN B-NP B-Chemical
7 1680 1689 17244258 increased VBD B-VP O
8 1690 1691 17244258 - SYM B-NP O
9 1691 1692 17244258 - HYPH B-NP O
10 1693 1700 17244258 instead RB B-PP O
11 1701 1703 17244258 of IN I-PP O
12 1704 1713 17244258 decreased VBN B-NP O
13 1714 1715 17244258 - SYM I-NP O
14 1715 1716 17244258 - HYPH O O
15 1717 1720 17244258 the DT B-NP O
16 1721 1726 17244258 tonic JJ I-NP O
17 1727 1736 17244258 responses NNS I-NP O
18 1737 1739 17244258 at IN B-PP O
19 1740 1744 17244258 high JJ B-NP O
20 1745 1756 17244258 frequencies NNS I-NP O
21 1756 1757 17244258 . . O O

1 1758 1763 17244258 While IN B-SBAR O
2 1764 1776 17244258 contractions NNS B-NP O
3 1777 1779 17244258 to TO B-PP O
4 1780 1789 17244258 carbachol NN B-NP B-Chemical
5 1790 1793 17244258 and CC I-NP O
6 1794 1797 17244258 ATP NN I-NP B-Chemical
7 1798 1802 17244258 were VBD B-VP O
8 1803 1806 17244258 the DT B-NP O
9 1807 1811 17244258 same JJ I-NP O
10 1812 1814 17244258 in IN B-PP O
11 1815 1823 17244258 inflamed JJ B-ADJP O
12 1824 1827 17244258 and CC O O
13 1828 1830 17244258 in IN B-PP O
14 1831 1838 17244258 control NN B-NP O
15 1839 1845 17244258 strips NNS I-NP O
16 1846 1850 17244258 when WRB B-ADVP O
17 1851 1858 17244258 related VBN B-VP O
18 1859 1861 17244258 to TO B-PP O
19 1862 1863 17244258 a DT B-NP O
20 1864 1873 17244258 reference NN I-NP O
21 1874 1883 17244258 potassium NN I-NP B-Chemical
22 1884 1892 17244258 response NN I-NP O
23 1892 1893 17244258 , , O O
24 1894 1906 17244258 isoprenaline NN B-NP B-Chemical
25 1906 1907 17244258 - HYPH B-NP O
26 1907 1914 17244258 induced VBN I-NP O
27 1915 1926 17244258 relaxations NNS I-NP O
28 1927 1931 17244258 were VBD B-VP O
29 1932 1939 17244258 smaller JJR B-ADJP O
30 1940 1942 17244258 in IN B-PP O
31 1943 1951 17244258 inflamed JJ B-NP O
32 1952 1958 17244258 strips NNS I-NP O
33 1958 1959 17244258 . . O O

1 1960 1964 17244258 Thus RB B-ADVP O
2 1964 1965 17244258 , , O O
3 1966 1968 17244258 in IN B-PP O
4 1969 1977 17244258 cystitis NN B-NP B-Disease
5 1978 1989 17244258 substantial JJ I-NP O
6 1990 1997 17244258 changes NNS I-NP O
7 1998 2000 17244258 of IN B-PP O
8 2001 2004 17244258 the DT B-NP O
9 2005 2013 17244258 efferent JJ I-NP O
10 2014 2024 17244258 functional JJ I-NP O
11 2025 2034 17244258 responses NNS I-NP O
12 2035 2040 17244258 occur VBP B-VP O
13 2040 2041 17244258 . . O O

1 2042 2047 17244258 While IN B-SBAR O
2 2048 2062 17244258 postjunctional JJ B-ADJP O
3 2063 2067 17244258 beta SYM O O
4 2067 2068 17244258 - HYPH B-NP O
5 2068 2080 17244258 adrenoceptor NN I-NP O
6 2080 2081 17244258 - HYPH B-NP O
7 2081 2089 17244258 mediated VBN I-NP O
8 2090 2101 17244258 relaxations NNS I-NP O
9 2102 2105 17244258 are VBP B-VP O
10 2106 2113 17244258 reduced VBN I-VP O
11 2113 2114 17244258 , , O O
12 2115 2122 17244258 effects NNS B-NP O
13 2123 2125 17244258 by IN B-PP O
14 2126 2139 17244258 prejunctional JJ B-NP O
15 2140 2150 17244258 inhibitory JJ I-NP O
16 2151 2161 17244258 muscarinic JJ I-NP O
17 2162 2171 17244258 receptors NNS I-NP O
18 2172 2175 17244258 may MD B-VP O
19 2176 2178 17244258 be VB I-VP O
20 2179 2188 17244258 increased VBN I-VP O
21 2188 2189 17244258 . . O O

1 0 0 12202650 -DOCSTART- -X- -X- O

1 0 9 12202650 Capsaicin NN B-NP B-Chemical
2 9 10 12202650 - HYPH B-NP O
3 10 17 12202650 induced VBN I-NP O
4 18 24 12202650 muscle NN I-NP B-Disease
5 25 29 12202650 pain NN I-NP I-Disease
6 30 36 12202650 alters VBZ B-VP O
7 37 40 12202650 the DT B-NP O
8 41 53 12202650 excitability NN I-NP O
9 54 56 12202650 of IN B-PP O
10 57 60 12202650 the DT B-NP O
11 61 66 12202650 human JJ I-NP O
12 67 70 12202650 jaw NN I-NP O
13 70 71 12202650 - HYPH I-NP O
14 71 78 12202650 stretch NN I-NP O
15 79 85 12202650 reflex NN I-NP O
16 85 86 12202650 . . O O
17 87 90 12202650 The DT B-NP O
18 91 106 12202650 pathophysiology NN I-NP O
19 107 109 12202650 of IN B-PP O
20 110 117 12202650 painful JJ B-NP O
21 118 135 12202650 temporomandibular JJ I-NP B-Disease
22 136 145 12202650 disorders NNS I-NP I-Disease
23 146 148 12202650 is VBZ B-VP O
24 149 152 12202650 not RB I-VP O
25 153 158 12202650 fully RB I-VP O
26 159 169 12202650 understood VBN I-VP O
27 169 170 12202650 , , O O
28 171 174 12202650 but CC O O
29 175 183 12202650 evidence NN B-NP O
30 184 192 12202650 suggests VBZ B-VP O
31 193 197 12202650 that IN B-SBAR O
32 198 204 12202650 muscle NN B-NP B-Disease
33 205 209 12202650 pain NN I-NP I-Disease
34 210 219 12202650 modulates VBZ B-VP O
35 220 225 12202650 motor NN B-NP O
36 226 234 12202650 function NN I-NP O
37 235 237 12202650 in IN B-PP O
38 238 252 12202650 characteristic JJ B-NP O
39 253 257 12202650 ways NNS I-NP O
40 257 258 12202650 . . O O

1 259 263 12202650 This DT B-NP O
2 264 269 12202650 study NN I-NP O
3 270 276 12202650 tested VBD B-VP O
4 277 280 12202650 the DT B-NP O
5 281 291 12202650 hypothesis NN I-NP O
6 292 296 12202650 that IN B-SBAR O
7 297 307 12202650 activation NN B-NP O
8 308 310 12202650 of IN B-PP O
9 311 322 12202650 nociceptive JJ B-NP B-Disease
10 323 329 12202650 muscle NN I-NP I-Disease
11 330 338 12202650 afferent JJ I-NP O
12 339 345 12202650 fibers NNS I-NP O
13 346 351 12202650 would MD B-VP O
14 352 354 12202650 be VB I-VP O
15 355 361 12202650 linked VBN I-VP O
16 362 364 12202650 to TO B-PP O
17 365 367 12202650 an DT B-NP O
18 368 377 12202650 increased VBN I-NP O
19 378 390 12202650 excitability NN I-NP O
20 391 393 12202650 of IN B-PP O
21 394 397 12202650 the DT B-NP O
22 398 403 12202650 human JJ I-NP O
23 404 407 12202650 jaw NN I-NP O
24 407 408 12202650 - HYPH I-NP O
25 408 415 12202650 stretch NN I-NP O
26 416 422 12202650 reflex NN I-NP O
27 423 426 12202650 and CC O O
28 427 434 12202650 whether IN B-SBAR O
29 435 439 12202650 this DT B-NP O
30 440 447 12202650 process NN I-NP O
31 448 453 12202650 would MD B-VP O
32 454 456 12202650 be VB I-VP O
33 457 466 12202650 sensitive JJ B-ADJP O
34 467 469 12202650 to TO B-PP O
35 470 476 12202650 length NN B-NP O
36 477 480 12202650 and CC I-NP O
37 481 489 12202650 velocity NN I-NP O
38 490 492 12202650 of IN B-PP O
39 493 496 12202650 the DT B-NP O
40 497 504 12202650 stretch NN I-NP O
41 504 505 12202650 . . O O

1 506 515 12202650 Capsaicin NN B-NP B-Chemical
2 516 517 12202650 ( ( O O
3 517 519 12202650 10 CD B-NP O
4 520 525 12202650 micro NN I-NP O
5 526 527 12202650 g NN I-NP O
6 527 528 12202650 ) ) O O
7 529 532 12202650 was VBD B-VP O
8 533 541 12202650 injected VBN I-VP O
9 542 546 12202650 into IN B-PP O
10 547 550 12202650 the DT B-NP O
11 551 559 12202650 masseter NN I-NP O
12 560 566 12202650 muscle NN I-NP O
13 567 569 12202650 to TO B-VP O
14 570 576 12202650 induce VB I-VP O
15 577 581 12202650 pain NN B-NP B-Disease
16 582 584 12202650 in IN B-PP O
17 585 587 12202650 11 CD B-NP O
18 588 595 12202650 healthy JJ I-NP O
19 596 606 12202650 volunteers NNS I-NP O
20 606 607 12202650 . . O O

1 608 613 12202650 Short JJ B-NP O
2 613 614 12202650 - HYPH I-NP O
3 614 621 12202650 latency NN I-NP O
4 622 628 12202650 reflex NN I-NP O
5 629 638 12202650 responses NNS I-NP O
6 639 643 12202650 were VBD B-VP O
7 644 650 12202650 evoked VBN I-VP O
8 651 653 12202650 in IN B-PP O
9 654 657 12202650 the DT B-NP O
10 658 666 12202650 masseter NN I-NP O
11 667 670 12202650 and CC I-NP O
12 671 681 12202650 temporalis NN I-NP O
13 682 689 12202650 muscles NNS I-NP O
14 690 692 12202650 by IN B-PP O
15 693 694 12202650 a DT B-NP O
16 695 702 12202650 stretch NN I-NP O
17 703 709 12202650 device NN I-NP O
18 710 714 12202650 with IN B-PP O
19 715 724 12202650 different JJ B-NP O
20 725 735 12202650 velocities NNS I-NP O
21 736 739 12202650 and CC I-NP O
22 740 753 12202650 displacements NNS I-NP O
23 754 760 12202650 before RB B-ADVP O
24 760 761 12202650 , , O O
25 762 768 12202650 during IN B-ADVP O
26 768 769 12202650 , , O O
27 770 773 12202650 and CC O O
28 774 779 12202650 after IN B-PP O
29 780 783 12202650 the DT B-NP O
30 784 788 12202650 pain NN I-NP B-Disease
31 788 789 12202650 . . O O

1 790 793 12202650 The DT B-NP O
2 794 804 12202650 normalized JJ I-NP O
3 805 811 12202650 reflex NN I-NP O
4 812 821 12202650 amplitude NN I-NP O
5 822 831 12202650 increased VBD B-VP O
6 832 836 12202650 with IN B-PP O
7 837 839 12202650 an DT B-NP O
8 840 848 12202650 increase NN I-NP O
9 849 851 12202650 in IN B-PP O
10 852 860 12202650 velocity NN B-NP O
11 861 863 12202650 at IN B-PP O
12 864 865 12202650 a DT B-NP O
13 866 871 12202650 given VBN I-NP O
14 872 884 12202650 displacement NN I-NP O
15 884 885 12202650 , , O O
16 886 889 12202650 but CC O O
17 890 898 12202650 remained VBD B-VP O
18 899 907 12202650 constant JJ B-ADJP O
19 908 912 12202650 with IN B-PP O
20 913 922 12202650 different JJ B-NP O
21 923 936 12202650 displacements NNS I-NP O
22 937 939 12202650 at IN B-PP O
23 940 941 12202650 a DT B-NP O
24 942 947 12202650 given VBN I-NP O
25 948 956 12202650 velocity NN I-NP O
26 956 957 12202650 . . O O

1 958 961 12202650 The DT B-NP O
2 962 972 12202650 normalized JJ I-NP O
3 973 979 12202650 reflex NN I-NP O
4 980 989 12202650 amplitude NN I-NP O
5 990 993 12202650 was VBD B-VP O
6 994 1007 12202650 significantly RB B-ADJP O
7 1008 1014 12202650 higher JJR I-ADJP O
8 1015 1021 12202650 during IN B-PP O
9 1022 1026 12202650 pain NN B-NP B-Disease
10 1026 1027 12202650 , , O O
11 1028 1031 12202650 but CC O O
12 1032 1036 12202650 only RB B-ADVP O
13 1037 1039 12202650 at IN B-PP O
14 1040 1046 12202650 faster JJR B-NP O
15 1047 1056 12202650 stretches NNS I-NP O
16 1057 1059 12202650 in IN B-PP O
17 1060 1063 12202650 the DT B-NP O
18 1064 1071 12202650 painful JJ I-NP B-Disease
19 1072 1078 12202650 muscle NN I-NP I-Disease
20 1078 1079 12202650 . . O O

1 1080 1089 12202650 Increased VBN B-NP O
2 1090 1101 12202650 sensitivity NN I-NP O
3 1102 1104 12202650 of IN B-PP O
4 1105 1108 12202650 the DT B-NP O
5 1109 1118 12202650 fusimotor NN I-NP O
6 1119 1125 12202650 system NN I-NP O
7 1126 1132 12202650 during IN B-PP O
8 1133 1138 12202650 acute JJ B-NP O
9 1139 1145 12202650 muscle NN I-NP B-Disease
10 1146 1150 12202650 pain NN I-NP I-Disease
11 1151 1156 12202650 could MD B-VP O
12 1157 1159 12202650 be VB I-VP O
13 1160 1163 12202650 one CD B-NP O
14 1164 1170 12202650 likely JJ I-NP O
15 1171 1180 12202650 mechanism NN I-NP O
16 1181 1183 12202650 to TO B-VP O
17 1184 1191 12202650 explain VB I-VP O
18 1192 1195 12202650 the DT B-NP O
19 1196 1204 12202650 findings NNS I-NP O
20 1204 1205 12202650 . . O O

1 0 0 1378968 -DOCSTART- -X- -X- O

1 0 7 1378968 Effects NNS B-NP O
2 8 10 1378968 of IN B-PP O
3 11 25 1378968 uninephrectomy JJ B-NP O
4 26 29 1378968 and CC I-NP O
5 30 34 1378968 high JJ I-NP O
6 35 42 1378968 protein NN I-NP O
7 43 50 1378968 feeding NN I-NP O
8 51 53 1378968 on IN B-PP O
9 54 61 1378968 lithium NN B-NP B-Chemical
10 61 62 1378968 - HYPH B-NP O
11 62 69 1378968 induced VBN I-NP O
12 70 77 1378968 chronic JJ I-NP B-Disease
13 78 83 1378968 renal JJ I-NP I-Disease
14 84 91 1378968 failure NN I-NP I-Disease
15 92 94 1378968 in IN B-PP O
16 95 99 1378968 rats NNS B-NP O
17 99 100 1378968 . . O O
18 101 105 1378968 Rats NNS B-NP O
19 106 110 1378968 with IN B-PP O
20 111 118 1378968 lithium NN B-NP B-Chemical
21 118 119 1378968 - HYPH B-NP O
22 119 126 1378968 induced VBN I-NP O
23 127 138 1378968 nephropathy NN I-NP B-Disease
24 139 143 1378968 were VBD B-VP O
25 144 153 1378968 subjected VBN I-VP O
26 154 156 1378968 to TO B-PP O
27 157 161 1378968 high JJ B-NP O
28 162 169 1378968 protein NN I-NP O
29 170 171 1378968 ( ( O O
30 171 173 1378968 HP NN B-NP O
31 173 174 1378968 ) ) O O
32 175 182 1378968 feeding NN B-NP O
33 182 183 1378968 , , O O
34 184 198 1378968 uninephrectomy NN B-NP O
35 199 200 1378968 ( ( O O
36 200 202 1378968 NX NN B-NP O
37 202 203 1378968 ) ) O O
38 204 206 1378968 or CC O O
39 207 208 1378968 a DT B-NP O
40 209 220 1378968 combination NN I-NP O
41 221 223 1378968 of IN B-PP O
42 224 229 1378968 these DT B-NP O
43 229 230 1378968 , , O O
44 231 233 1378968 in IN B-PP O
45 234 236 1378968 an DT B-NP O
46 237 244 1378968 attempt NN I-NP O
47 245 247 1378968 to TO B-VP O
48 248 254 1378968 induce VB I-VP O
49 255 265 1378968 glomerular JJ B-NP O
50 266 281 1378968 hyperfiltration NN I-NP O
51 282 285 1378968 and CC O O
52 286 293 1378968 further JJ B-NP O
53 294 305 1378968 progression NN I-NP O
54 306 308 1378968 of IN B-PP O
55 309 314 1378968 renal JJ B-NP B-Disease
56 315 322 1378968 failure NN I-NP I-Disease
57 322 323 1378968 . . O O

1 324 331 1378968 Newborn JJ B-NP O
2 332 338 1378968 female JJ I-NP O
3 339 345 1378968 Wistar NNP I-NP O
4 346 350 1378968 rats NNS I-NP O
5 351 355 1378968 were VBD B-VP O
6 356 359 1378968 fed VBN I-VP O
7 360 361 1378968 a DT B-NP O
8 362 369 1378968 lithium NN I-NP B-Chemical
9 369 370 1378968 - HYPH O O
10 370 380 1378968 containing VBG B-VP O
11 381 385 1378968 diet NN B-NP O
12 386 387 1378968 ( ( O O
13 387 389 1378968 50 CD B-NP O
14 390 394 1378968 mmol NN I-NP O
15 394 395 1378968 / SYM B-NP O
16 395 397 1378968 kg NN I-NP O
17 397 398 1378968 ) ) O O
18 399 402 1378968 for IN B-PP O
19 403 404 1378968 8 CD B-NP O
20 405 410 1378968 weeks NNS I-NP O
21 411 414 1378968 and CC O O
22 415 419 1378968 then RB B-ADVP O
23 420 430 1378968 randomized VBD B-VP O
24 431 433 1378968 to TO B-PP O
25 434 440 1378968 normal JJ B-NP O
26 441 445 1378968 diet NN I-NP O
27 445 446 1378968 , , O O
28 447 449 1378968 HP NN B-NP O
29 450 454 1378968 diet NN I-NP O
30 455 456 1378968 ( ( O O
31 456 458 1378968 40 CD B-NP O
32 459 461 1378968 vs NNS I-NP O
33 461 462 1378968 . . O O
34 463 466 1378968 19% CD B-NP O
35 466 467 1378968 ) ) O O
36 467 468 1378968 , , O O
37 469 471 1378968 NX NN B-NP O
38 472 474 1378968 or CC I-NP O
39 475 477 1378968 HP NN I-NP O
40 477 478 1378968 + SYM B-NP O
41 478 480 1378968 NX NN I-NP O
42 481 484 1378968 for IN B-PP O
43 485 492 1378968 another DT B-NP O
44 493 494 1378968 8 CD I-NP O
45 495 500 1378968 weeks NNS I-NP O
46 500 501 1378968 . . O O

1 502 515 1378968 Corresponding VBG B-VP O
2 516 519 1378968 non AFX B-NP O
3 519 520 1378968 - HYPH I-NP O
4 520 527 1378968 lithium NN I-NP B-Chemical
5 528 538 1378968 pretreated VBN I-NP O
6 539 545 1378968 groups NNS I-NP O
7 546 550 1378968 were VBD B-VP O
8 551 560 1378968 generated VBN I-VP O
9 560 561 1378968 . . O O

1 562 566 1378968 When WRB B-ADVP O
2 567 576 1378968 comparing VBG B-VP O
3 577 580 1378968 all DT B-NP O
4 581 588 1378968 lithium NN I-NP B-Chemical
5 589 596 1378968 treated VBN B-VP O
6 597 603 1378968 versus IN B-PP O
7 604 607 1378968 non AFX B-NP O
8 607 608 1378968 - HYPH I-NP O
9 608 615 1378968 lithium NN I-NP B-Chemical
10 615 616 1378968 - HYPH B-NP O
11 616 623 1378968 treated VBN I-NP O
12 624 630 1378968 groups NNS I-NP O
13 630 631 1378968 , , O O
14 632 639 1378968 lithium NN B-NP B-Chemical
15 640 646 1378968 caused VBD B-VP O
16 647 648 1378968 a DT B-NP O
17 649 658 1378968 reduction NN I-NP O
18 659 661 1378968 in IN B-PP O
19 662 672 1378968 glomerular JJ B-NP O
20 673 683 1378968 filtration NN I-NP O
21 684 688 1378968 rate NN I-NP O
22 689 690 1378968 ( ( O O
23 690 693 1378968 GFR NN B-NP O
24 693 694 1378968 ) ) O O
25 695 702 1378968 without IN B-PP O
26 703 714 1378968 significant JJ B-NP O
27 715 722 1378968 changes NNS I-NP O
28 723 725 1378968 in IN B-PP O
29 726 735 1378968 effective JJ B-NP O
30 736 741 1378968 renal JJ I-NP O
31 742 748 1378968 plasma NN I-NP O
32 749 753 1378968 flow NN I-NP O
33 754 755 1378968 ( ( O O
34 755 757 1378968 as IN B-SBAR O
35 758 768 1378968 determined VBN B-VP O
36 769 771 1378968 by IN B-PP O
37 772 773 1378968 a DT B-NP O
38 774 780 1378968 marker NN I-NP O
39 781 789 1378968 secreted VBN B-VP O
40 790 794 1378968 into IN B-PP O
41 795 798 1378968 the DT B-NP O
42 799 807 1378968 proximal JJ I-NP O
43 808 815 1378968 tubules NNS I-NP O
44 815 816 1378968 ) ) O O
45 817 819 1378968 or CC O O
46 820 827 1378968 lithium NN B-NP B-Chemical
47 828 837 1378968 clearance NN I-NP O
48 837 838 1378968 . . O O

1 839 851 1378968 Consequently RB B-ADVP O
2 851 852 1378968 , , O O
3 853 860 1378968 lithium NN B-NP B-Chemical
4 861 873 1378968 pretreatment NN I-NP O
5 874 880 1378968 caused VBD B-VP O
6 881 882 1378968 a DT B-NP O
7 883 887 1378968 fall NN I-NP O
8 888 890 1378968 in IN B-PP O
9 891 901 1378968 filtration NN B-NP O
10 902 910 1378968 fraction NN I-NP O
11 911 914 1378968 and CC O O
12 915 917 1378968 an DT B-NP O
13 918 926 1378968 increase NN I-NP O
14 927 929 1378968 in IN B-PP O
15 930 940 1378968 fractional JJ B-NP O
16 941 943 1378968 Li NNP I-NP B-Chemical
17 944 953 1378968 excretion NN I-NP O
18 953 954 1378968 . . O O

1 955 962 1378968 Lithium NN B-NP B-Chemical
2 963 967 1378968 also RB B-ADVP O
3 968 974 1378968 caused VBD B-VP O
4 975 986 1378968 proteinuria NN B-NP B-Disease
5 987 990 1378968 and CC O O
6 991 999 1378968 systolic JJ B-NP O
7 1000 1012 1378968 hypertension NN I-NP B-Disease
8 1013 1015 1378968 in IN B-PP O
9 1016 1023 1378968 absence NN B-NP O
10 1024 1026 1378968 of IN B-PP O
11 1027 1045 1378968 glomerulosclerosis NN B-NP B-Disease
12 1045 1046 1378968 . . O O

1 1047 1049 1378968 HP NN B-NP O
2 1050 1056 1378968 failed VBD B-VP O
3 1057 1059 1378968 to TO I-VP O
4 1060 1071 1378968 accentuante VB I-VP O
5 1072 1083 1378968 progression NN B-NP O
6 1084 1086 1378968 of IN B-PP O
7 1087 1092 1378968 renal JJ B-NP B-Disease
8 1093 1100 1378968 failure NN I-NP I-Disease
9 1101 1104 1378968 and CC B-PP O
10 1105 1107 1378968 in IN B-PP O
11 1108 1112 1378968 fact NN B-NP O
12 1113 1119 1378968 tended VBD B-VP O
13 1120 1122 1378968 to TO I-VP O
14 1123 1131 1378968 increase VB I-VP O
15 1132 1135 1378968 GFR NN B-NP O
16 1136 1139 1378968 and CC O O
17 1140 1148 1378968 decrease VB B-VP O
18 1149 1155 1378968 plasma NN B-NP O
19 1156 1166 1378968 creatinine NN I-NP B-Chemical
20 1167 1173 1378968 levels NNS I-NP O
21 1174 1176 1378968 in IN B-PP O
22 1177 1184 1378968 lithium NN B-NP B-Chemical
23 1185 1195 1378968 pretreated VBN B-NP O
24 1196 1200 1378968 rats NNS I-NP O
25 1200 1201 1378968 . . O O

1 1202 1204 1378968 NX NN B-NP O
2 1205 1211 1378968 caused VBD B-VP O
3 1212 1214 1378968 an DT B-NP O
4 1215 1223 1378968 additive JJ I-NP O
5 1224 1237 1378968 deterioration NN I-NP O
6 1238 1240 1378968 in IN B-PP O
7 1241 1244 1378968 GFR NN B-NP O
8 1245 1250 1378968 which WDT B-NP O
9 1250 1251 1378968 , , O O
10 1252 1259 1378968 however RB B-ADVP O
11 1259 1260 1378968 , , O O
12 1261 1264 1378968 was VBD B-VP O
13 1265 1276 1378968 ameliorated VBN I-VP O
14 1277 1279 1378968 by IN B-PP O
15 1280 1282 1378968 HP NN B-NP O
16 1282 1283 1378968 . . O O

1 1284 1286 1378968 NX NN B-NP O
2 1286 1287 1378968 + SYM I-NP O
3 1287 1289 1378968 HP NN I-NP O
4 1290 1296 1378968 caused VBD B-VP O
5 1297 1298 1378968 a DT B-NP O
6 1299 1306 1378968 further JJ I-NP O
7 1307 1311 1378968 rise NN I-NP O
8 1312 1314 1378968 in IN B-PP O
9 1315 1320 1378968 blood NN B-NP O
10 1321 1329 1378968 pressure NN I-NP O
11 1330 1332 1378968 in IN B-PP O
12 1333 1335 1378968 Li NN B-NP B-Chemical
13 1335 1336 1378968 - HYPH B-NP O
14 1336 1346 1378968 pretreated VBN I-NP O
15 1347 1351 1378968 rats NNS I-NP O
16 1351 1352 1378968 . . O O

1 1353 1356 1378968 The DT B-NP O
2 1357 1364 1378968 results NNS I-NP O
3 1365 1373 1378968 indicate VBP B-VP O
4 1374 1378 1378968 that IN B-SBAR O
5 1379 1381 1378968 Li NN B-NP B-Chemical
6 1381 1382 1378968 - HYPH B-NP O
7 1382 1389 1378968 induced VBN I-NP O
8 1390 1401 1378968 nephropathy NN I-NP B-Disease
9 1401 1402 1378968 , , O O
10 1403 1407 1378968 even RB B-ADVP O
11 1408 1412 1378968 when WRB I-ADVP O
12 1413 1416 1378968 the DT B-NP O
13 1417 1420 1378968 GFR NN I-NP O
14 1421 1423 1378968 is VBZ B-VP O
15 1424 1428 1378968 only RB I-VP O
16 1429 1437 1378968 modestly RB I-VP O
17 1438 1445 1378968 reduced VBN I-VP O
18 1445 1446 1378968 , , O O
19 1447 1449 1378968 is VBZ B-VP O
20 1450 1460 1378968 associated VBN I-VP O
21 1461 1465 1378968 with IN B-PP O
22 1466 1477 1378968 proteinuria NN B-NP B-Disease
23 1478 1481 1378968 and CC O O
24 1482 1490 1378968 arterial JJ B-NP O
25 1491 1499 1378968 systolic JJ I-NP O
26 1500 1512 1378968 hypertension NN I-NP B-Disease
27 1512 1513 1378968 . . O O

1 1514 1516 1378968 In IN B-PP O
2 1517 1521 1378968 this DT B-NP O
3 1522 1527 1378968 model NN I-NP O
4 1528 1530 1378968 of IN B-PP O
5 1531 1538 1378968 chronic JJ B-NP B-Disease
6 1539 1544 1378968 renal JJ I-NP I-Disease
7 1545 1552 1378968 failure NN I-NP I-Disease
8 1553 1556 1378968 the DT B-NP O
9 1557 1564 1378968 decline NN I-NP O
10 1565 1567 1378968 in IN B-PP O
11 1568 1571 1378968 GFR NN B-NP O
12 1572 1574 1378968 is VBZ B-VP O
13 1575 1578 1378968 not RB I-VP O
14 1579 1590 1378968 accompanied VBN I-VP O
15 1591 1593 1378968 by IN B-PP O
16 1594 1595 1378968 a DT B-NP O
17 1596 1609 1378968 corresponding JJ I-NP O
18 1610 1614 1378968 fall NN I-NP O
19 1615 1617 1378968 in IN B-PP O
20 1618 1627 1378968 effective JJ B-NP O
21 1628 1633 1378968 renal JJ I-NP O
22 1634 1640 1378968 plasma NN I-NP O
23 1641 1645 1378968 flow NN I-NP O
24 1645 1646 1378968 , , O O
25 1647 1652 1378968 which WDT B-NP O
26 1653 1656 1378968 may MD B-VP O
27 1657 1659 1378968 be VB I-VP O
28 1660 1663 1378968 the DT B-NP O
29 1664 1674 1378968 functional JJ I-NP O
30 1675 1685 1378968 expression NN I-NP O
31 1686 1688 1378968 of IN B-PP O
32 1689 1692 1378968 the DT B-NP O
33 1693 1702 1378968 formation NN I-NP O
34 1703 1705 1378968 of IN B-PP O
35 1706 1719 1378968 nonfiltrating JJ B-NP O
36 1720 1728 1378968 atubular JJ I-NP O
37 1729 1738 1378968 glomeruli NNS I-NP O
38 1738 1739 1378968 . . O O

1 1740 1743 1378968 The DT B-NP O
2 1744 1754 1378968 fractional JJ I-NP O
3 1755 1767 1378968 reabsorption NN I-NP O
4 1768 1770 1378968 of IN B-PP O
5 1771 1778 1378968 tubular JJ B-NP O
6 1779 1784 1378968 fluid NN I-NP O
7 1785 1787 1378968 by IN B-PP O
8 1788 1791 1378968 the DT B-NP O
9 1792 1800 1378968 proximal JJ I-NP O
10 1801 1808 1378968 tubules NNS I-NP O
11 1809 1811 1378968 is VBZ B-VP O
12 1812 1819 1378968 reduced VBN I-VP O
13 1819 1820 1378968 , , O O
14 1821 1828 1378968 leaving VBG B-VP O
15 1829 1832 1378968 the DT B-NP O
16 1833 1839 1378968 distal JJ I-NP O
17 1840 1848 1378968 delivery NN I-NP O
18 1849 1868 1378968 unchanged.(ABSTRACT NN I-NP O
19 1869 1878 1378968 TRUNCATED VBN B-VP O
20 1879 1881 1378968 AT IN B-PP O
21 1882 1885 1378968 250 CD B-NP O
22 1886 1891 1378968 WORDS NNS I-NP O
23 1891 1892 1378968 ) ) O O

1 0 0 3828020 -DOCSTART- -X- -X- O

1 0 8 3828020 Cerebral JJ B-NP B-Disease
2 9 19 3828020 infarction NN I-NP I-Disease
3 20 24 3828020 with IN B-PP O
4 25 26 3828020 a DT B-NP O
5 27 33 3828020 single JJ I-NP O
6 34 38 3828020 oral JJ I-NP O
7 39 43 3828020 dose NN I-NP O
8 44 46 3828020 of IN B-PP O
9 47 66 3828020 phenylpropanolamine NN B-NP B-Chemical
10 66 67 3828020 . . O O
11 68 87 3828020 Phenylpropanolamine NN B-NP B-Chemical
12 88 89 3828020 ( ( O O
13 89 92 3828020 PPA NN B-NP B-Chemical
14 92 93 3828020 ) ) O O
15 93 94 3828020 , , O O
16 95 96 3828020 a DT B-NP O
17 97 106 3828020 synthetic JJ I-NP O
18 107 122 3828020 sympathomimetic NN I-NP O
19 123 127 3828020 that WDT B-NP O
20 128 130 3828020 is VBZ B-VP O
21 131 143 3828020 structurally RB B-ADJP O
22 144 151 3828020 similar JJ I-ADJP O
23 152 154 3828020 to TO B-PP O
24 155 166 3828020 amphetamine NN B-NP B-Chemical
25 166 167 3828020 , , O O
26 168 170 3828020 is VBZ B-VP O
27 171 180 3828020 available JJ B-ADJP O
28 181 185 3828020 over IN B-PP O
29 186 189 3828020 the DT B-NP O
30 190 197 3828020 counter NN I-NP O
31 198 200 3828020 in IN B-PP O
32 201 211 3828020 anorectics NNS B-NP O
33 211 212 3828020 , , O O
34 213 218 3828020 nasal JJ B-NP O
35 219 230 3828020 congestants NNS I-NP O
36 230 231 3828020 , , O O
37 232 235 3828020 and CC O O
38 236 240 3828020 cold JJ B-NP O
39 241 253 3828020 preparations NNS I-NP O
40 253 254 3828020 . . O O

1 255 258 3828020 Its PRP$ B-NP O
2 259 268 3828020 prolonged JJ I-NP O
3 269 272 3828020 use NN I-NP O
4 273 275 3828020 or CC I-NP O
5 276 283 3828020 overuse NN I-NP O
6 284 287 3828020 has VBZ B-VP O
7 288 292 3828020 been VBN I-VP O
8 293 303 3828020 associated VBN I-VP O
9 304 308 3828020 with IN B-PP O
10 309 317 3828020 seizures NNS B-NP B-Disease
11 317 318 3828020 , , O O
12 319 332 3828020 intracerebral JJ B-NP B-Disease
13 333 343 3828020 hemorrhage NN I-NP I-Disease
14 343 344 3828020 , , O O
15 345 361 3828020 neuropsychiatric JJ B-NP B-Disease
16 362 370 3828020 symptoms NNS I-NP I-Disease
17 370 371 3828020 , , O O
18 372 375 3828020 and CC O O
19 376 390 3828020 nonhemorrhagic JJ B-NP O
20 391 399 3828020 cerebral JJ I-NP B-Disease
21 400 410 3828020 infarction NN I-NP I-Disease
22 410 411 3828020 . . O O

1 412 414 3828020 We PRP B-NP O
2 415 421 3828020 report VBP B-VP O
3 422 425 3828020 the DT B-NP O
4 426 430 3828020 case NN I-NP O
5 431 433 3828020 of IN B-PP O
6 434 435 3828020 a DT B-NP O
7 436 441 3828020 young JJ I-NP O
8 442 447 3828020 woman NN I-NP O
9 448 451 3828020 who WP B-NP O
10 452 460 3828020 suffered VBD B-VP O
11 461 462 3828020 a DT B-NP O
12 463 471 3828020 cerebral JJ I-NP B-Disease
13 472 482 3828020 infarction NN I-NP I-Disease
14 483 488 3828020 after IN B-PP O
15 489 495 3828020 taking VBG B-VP O
16 496 497 3828020 a DT B-NP O
17 498 504 3828020 single JJ I-NP O
18 505 509 3828020 oral JJ I-NP O
19 510 514 3828020 dose NN I-NP O
20 515 517 3828020 of IN B-PP O
21 518 521 3828020 PPA NN B-NP B-Chemical
22 521 522 3828020 . . O O

1 0 0 9727773 -DOCSTART- -X- -X- O

1 0 4 9727773 High JJ B-NP O
2 5 14 9727773 incidence NN I-NP O
3 15 17 9727773 of IN B-PP O
4 18 25 9727773 primary JJ B-NP B-Disease
5 26 35 9727773 pulmonary JJ I-NP I-Disease
6 36 48 9727773 hypertension NN I-NP I-Disease
7 49 59 9727773 associated VBN B-VP O
8 60 64 9727773 with IN B-PP O
9 65 73 9727773 appetite JJ B-NP B-Chemical
10 74 86 9727773 suppressants NNS I-NP I-Chemical
11 87 89 9727773 in IN B-PP O
12 90 97 9727773 Belgium NNP B-NP O
13 97 98 9727773 . . I-NP O
14 99 106 9727773 Primary JJ I-NP B-Disease
15 107 116 9727773 pulmonary JJ I-NP I-Disease
16 117 129 9727773 hypertension NN I-NP I-Disease
17 130 132 9727773 is VBZ B-VP O
18 133 134 9727773 a DT B-NP O
19 135 139 9727773 rare JJ I-NP O
20 139 140 9727773 , , I-NP O
21 141 152 9727773 progressive JJ I-NP O
22 153 156 9727773 and CC I-NP O
23 157 166 9727773 incurable JJ I-NP O
24 167 174 9727773 disease NN I-NP O
25 174 175 9727773 , , O O
26 176 181 9727773 which WDT B-NP O
27 182 185 9727773 has VBZ B-VP O
28 186 190 9727773 been VBN I-VP O
29 191 201 9727773 associated VBN I-VP O
30 202 206 9727773 with IN B-PP O
31 207 210 9727773 the DT B-NP O
32 211 217 9727773 intake NN I-NP O
33 218 220 9727773 of IN B-PP O
34 221 229 9727773 appetite JJ B-NP B-Chemical
35 230 241 9727773 suppressant NN I-NP I-Chemical
36 242 247 9727773 drugs NNS I-NP O
37 247 248 9727773 . . O O

1 249 252 9727773 The DT B-NP O
2 253 263 9727773 importance NN I-NP O
3 264 266 9727773 of IN B-PP O
4 267 271 9727773 this DT B-NP O
5 272 283 9727773 association NN I-NP O
6 284 287 9727773 was VBD B-VP O
7 288 297 9727773 evaluated VBN I-VP O
8 298 300 9727773 in IN B-PP O
9 301 308 9727773 Belgium NNP B-NP O
10 309 314 9727773 while IN B-SBAR O
11 315 319 9727773 this DT B-NP O
12 320 327 9727773 country NN I-NP O
13 328 333 9727773 still RB B-ADVP O
14 334 337 9727773 had VBD B-VP O
15 338 340 9727773 no DT B-NP O
16 341 352 9727773 restriction NN I-NP O
17 353 355 9727773 on IN B-PP O
18 356 359 9727773 the DT B-NP O
19 360 372 9727773 prescription NN I-NP O
20 373 375 9727773 of IN B-PP O
21 376 384 9727773 appetite JJ B-NP B-Chemical
22 385 397 9727773 suppressants NNS I-NP I-Chemical
23 397 398 9727773 . . O O

1 399 405 9727773 Thirty CD B-NP O
2 405 406 9727773 - HYPH I-NP O
3 406 410 9727773 five CD B-NP O
4 411 419 9727773 patients NNS I-NP O
5 420 424 9727773 with IN B-PP O
6 425 432 9727773 primary JJ B-NP B-Disease
7 433 442 9727773 pulmonary JJ I-NP I-Disease
8 443 455 9727773 hypertension NN I-NP I-Disease
9 456 459 9727773 and CC O O
10 460 462 9727773 85 CD B-NP O
11 463 470 9727773 matched VBN I-NP O
12 471 479 9727773 controls NNS I-NP O
13 480 484 9727773 were VBD B-VP O
14 485 494 9727773 recruited VBN I-VP O
15 495 499 9727773 over IN B-PP O
16 500 502 9727773 32 CD B-NP O
17 503 509 9727773 months NNS I-NP O
18 510 511 9727773 ( ( O O
19 511 515 9727773 1992 CD B-NP O
20 515 516 9727773 - HYPH I-NP O
21 516 520 9727773 1994 CD I-NP O
22 520 521 9727773 ) ) O O
23 522 524 9727773 in IN B-PP O
24 525 532 9727773 Belgium NNP B-NP O
25 532 533 9727773 . . O O

1 534 542 9727773 Exposure NN B-NP O
2 543 545 9727773 to TO B-VP O
3 546 554 9727773 appetite VB I-VP B-Chemical
4 554 555 9727773 - HYPH B-NP I-Chemical
5 555 567 9727773 suppressants NNS I-NP I-Chemical
6 568 571 9727773 was VBD B-VP O
7 572 580 9727773 assessed VBN I-VP O
8 581 583 9727773 on IN B-PP O
9 584 587 9727773 the DT B-NP O
10 588 593 9727773 basis NN I-NP O
11 594 596 9727773 of IN B-PP O
12 597 605 9727773 hospital NN B-NP O
13 606 613 9727773 records NNS I-NP O
14 614 617 9727773 and CC O O
15 618 630 9727773 standardized JJ B-NP O
16 631 640 9727773 interview NN I-NP O
17 640 641 9727773 . . O O

1 642 648 9727773 Twenty CD B-NP O
2 648 649 9727773 - HYPH I-NP O
3 649 654 9727773 three CD I-NP O
4 655 657 9727773 of IN B-PP O
5 658 661 9727773 the DT B-NP O
6 662 670 9727773 patients NNS I-NP O
7 671 674 9727773 had VBD B-VP O
8 675 685 9727773 previously RB I-VP O
9 686 691 9727773 taken VBN I-VP O
10 692 700 9727773 appetite NN B-NP B-Chemical
11 701 713 9727773 suppressants NNS I-NP I-Chemical
12 713 714 9727773 , , O O
13 715 721 9727773 mainly RB B-NP O
14 722 735 9727773 fenfluramines NNS I-NP B-Chemical
15 735 736 9727773 , , O O
16 737 739 9727773 as IN B-SBAR O
17 740 748 9727773 compared VBN B-PP O
18 749 753 9727773 with IN B-PP O
19 754 758 9727773 only RB B-NP O
20 759 760 9727773 5 CD I-NP O
21 761 763 9727773 of IN B-PP O
22 764 767 9727773 the DT B-NP O
23 768 776 9727773 controls NNS I-NP O
24 777 778 9727773 ( ( O O
25 778 780 9727773 66 CD B-NP O
26 781 787 9727773 versus IN B-PP O
27 788 790 9727773 6% NN B-NP O
28 790 791 9727773 , , O O
29 792 793 9727773 p NN B-NP O
30 793 794 9727773 < SYM B-NP O
31 794 800 9727773 0.0001 CD I-NP O
32 800 801 9727773 ) ) O O
33 801 802 9727773 . . O O

1 803 807 9727773 Five CD B-NP O
2 808 816 9727773 patients NNS I-NP O
3 817 821 9727773 died VBD B-VP O
4 822 828 9727773 before IN B-PP O
5 829 832 9727773 the DT B-NP O
6 833 842 9727773 interview NN I-NP O
7 842 843 9727773 , , O O
8 844 847 9727773 all DT B-NP O
9 848 850 9727773 of IN B-PP O
10 851 855 9727773 them PRP B-NP O
11 856 859 9727773 had VBD B-VP O
12 860 865 9727773 taken VBN I-VP O
13 866 874 9727773 appetite JJ B-NP B-Chemical
14 875 887 9727773 suppressants NNS I-NP I-Chemical
15 887 888 9727773 . . O O

1 889 891 9727773 In IN B-PP O
2 892 893 9727773 8 CD B-NP O
3 894 902 9727773 patients NNS I-NP O
4 903 906 9727773 the DT B-NP O
5 907 916 9727773 diagnosis NN I-NP O
6 917 919 9727773 of IN B-PP O
7 920 927 9727773 primary JJ B-NP B-Disease
8 928 937 9727773 pulmonary JJ I-NP I-Disease
9 938 950 9727773 hypertension NN I-NP I-Disease
10 951 954 9727773 was VBD B-VP O
11 955 964 9727773 uncertain JJ B-ADJP O
12 964 965 9727773 , , O O
13 966 967 9727773 5 CD B-NP O
14 968 970 9727773 of IN B-PP O
15 971 975 9727773 them PRP B-NP O
16 976 979 9727773 had VBD B-VP O
17 980 985 9727773 taken VBN I-VP O
18 986 994 9727773 appetite JJ B-NP B-Chemical
19 995 1007 9727773 suppressants NNS I-NP I-Chemical
20 1007 1008 9727773 . . O O

1 1009 1012 9727773 The DT B-NP O
2 1013 1021 9727773 patients NNS I-NP O
3 1022 1025 9727773 who WP B-NP O
4 1026 1029 9727773 had VBD B-VP O
5 1030 1034 9727773 been VBN I-VP O
6 1035 1042 9727773 exposed VBN I-VP O
7 1043 1045 9727773 to TO I-VP O
8 1046 1054 9727773 appetite VB I-VP B-Chemical
9 1055 1067 9727773 suppressants NNS B-NP I-Chemical
10 1068 1074 9727773 tended VBD B-VP O
11 1075 1077 9727773 to TO I-VP O
12 1078 1080 9727773 be VB I-VP O
13 1081 1083 9727773 on IN B-PP O
14 1084 1091 9727773 average NN B-NP O
15 1092 1096 9727773 more RBR B-ADJP O
16 1097 1105 9727773 severely RB I-ADJP O
17 1106 1109 9727773 ill JJ I-ADJP O
18 1109 1110 9727773 , , O O
19 1111 1114 9727773 and CC O O
20 1115 1117 9727773 to TO B-VP O
21 1118 1122 9727773 have VB I-VP O
22 1123 1124 9727773 a DT B-NP O
23 1125 1132 9727773 shorter JJR I-NP O
24 1133 1139 9727773 median JJ I-NP O
25 1140 1145 9727773 delay NN I-NP O
26 1146 1153 9727773 between IN B-PP O
27 1154 1159 9727773 onset NN B-NP O
28 1160 1162 9727773 of IN B-PP O
29 1163 1171 9727773 symptoms NNS B-NP O
30 1172 1175 9727773 and CC I-NP O
31 1176 1185 9727773 diagnosis NN I-NP O
32 1185 1186 9727773 . . O O

1 1187 1188 9727773 A DT B-NP O
2 1189 1195 9727773 policy NN I-NP O
3 1196 1198 9727773 of IN B-PP O
4 1199 1211 9727773 unrestricted JJ B-NP O
5 1212 1224 9727773 prescription NN I-NP O
6 1225 1227 9727773 of IN B-PP O
7 1228 1236 9727773 appetite JJ B-NP B-Chemical
8 1237 1249 9727773 suppressants NNS I-NP I-Chemical
9 1250 1253 9727773 may MD B-VP O
10 1254 1258 9727773 lead VB I-VP O
11 1259 1261 9727773 to TO B-PP O
12 1262 1263 9727773 a DT B-NP O
13 1264 1268 9727773 high JJ I-NP O
14 1269 1278 9727773 incidence NN I-NP O
15 1279 1281 9727773 of IN B-PP O
16 1282 1292 9727773 associated VBN B-NP O
17 1293 1300 9727773 primary JJ I-NP B-Disease
18 1301 1310 9727773 pulmonary JJ I-NP I-Disease
19 1311 1323 9727773 hypertension NN I-NP I-Disease
20 1323 1324 9727773 . . O O

1 1325 1331 9727773 Intake NN B-NP O
2 1332 1334 9727773 of IN B-PP O
3 1335 1343 9727773 appetite JJ B-NP B-Chemical
4 1344 1356 9727773 suppressants NNS I-NP I-Chemical
5 1357 1360 9727773 may MD B-VP O
6 1361 1371 9727773 accelerate VB I-VP O
7 1372 1375 9727773 the DT B-NP O
8 1376 1387 9727773 progression NN I-NP O
9 1388 1390 9727773 of IN B-PP O
10 1391 1394 9727773 the DT B-NP O
11 1395 1402 9727773 disease NN I-NP O
12 1402 1403 9727773 . . O O

1 0 0 7269015 -DOCSTART- -X- -X- O

1 0 8 7269015 Busulfan NN B-NP B-Chemical
2 8 9 7269015 - HYPH O O
3 9 16 7269015 induced VBN B-NP O
4 17 28 7269015 hemorrhagic JJ I-NP B-Disease
5 29 37 7269015 cystitis NN I-NP I-Disease
6 37 38 7269015 . . O O
7 39 40 7269015 A DT B-NP O
8 41 45 7269015 case NN I-NP O
9 46 48 7269015 of IN B-PP O
10 49 50 7269015 a DT B-NP O
11 51 59 7269015 busulfan NN I-NP B-Chemical
12 59 60 7269015 - HYPH B-NP O
13 60 67 7269015 induced VBN I-NP O
14 68 78 7269015 hemorrhage NN I-NP B-Disease
15 79 87 7269015 cystitis NN I-NP I-Disease
16 88 90 7269015 is VBZ B-VP O
17 91 99 7269015 reported VBN I-VP O
18 99 100 7269015 . . O O

1 101 112 7269015 Spontaneous JJ B-NP O
2 113 123 7269015 resolution NN I-NP O
3 124 132 7269015 occurred VBD B-VP O
4 133 142 7269015 following VBG I-VP O
5 143 152 7269015 cessation NN B-NP O
6 153 155 7269015 of IN B-PP O
7 156 159 7269015 the DT B-NP O
8 160 164 7269015 drug NN I-NP O
9 164 165 7269015 . . O O

1 166 169 7269015 The DT B-NP O
2 170 180 7269015 similarity NN I-NP O
3 181 188 7269015 between IN B-PP O
4 189 192 7269015 the DT B-NP O
5 193 203 7269015 histologic JJ I-NP O
6 204 215 7269015 appearances NNS I-NP O
7 216 218 7269015 of IN B-PP O
8 219 227 7269015 busulfan NN B-NP B-Chemical
9 228 236 7269015 cystitis NN I-NP B-Disease
10 237 240 7269015 and CC O O
11 241 245 7269015 both CC O O
12 246 255 7269015 radiation NN B-NP O
13 256 259 7269015 and CC I-NP O
14 260 276 7269015 cyclophosphamide NN I-NP B-Chemical
15 276 277 7269015 - HYPH B-NP O
16 277 284 7269015 induced VBN I-NP O
17 285 293 7269015 cystitis NN I-NP B-Disease
18 294 296 7269015 is VBZ B-VP O
19 297 306 7269015 discussed VBN I-VP O
20 307 310 7269015 and CC O O
21 311 314 7269015 the DT B-NP O
22 315 320 7269015 world NN I-NP O
23 321 331 7269015 literature NN I-NP O
24 332 340 7269015 reviewed VBN B-VP O
25 340 341 7269015 . . O O

1 342 344 7269015 In IN B-PP O
2 345 349 7269015 view NN B-NP O
3 350 352 7269015 of IN B-PP O
4 353 356 7269015 the DT B-NP O
5 357 362 7269015 known JJ I-NP O
6 363 371 7269015 tendency NN I-NP O
7 372 374 7269015 of IN B-PP O
8 375 383 7269015 busulfan NN B-NP B-Chemical
9 384 386 7269015 to TO B-VP O
10 387 393 7269015 induce VB I-VP O
11 394 402 7269015 cellular JJ B-NP O
12 403 409 7269015 atypia NN I-NP O
13 410 413 7269015 and CC I-NP O
14 414 423 7269015 carcinoma NN I-NP B-Disease
15 424 426 7269015 in IN B-PP O
16 427 432 7269015 other JJ B-NP O
17 433 438 7269015 sites NNS I-NP O
18 438 439 7269015 , , O O
19 440 448 7269015 periodic JJ B-NP O
20 449 456 7269015 urinary JJ I-NP O
21 457 465 7269015 cytology NN I-NP O
22 466 468 7269015 is VBZ B-VP O
23 469 478 7269015 suggested VBN I-VP O
24 479 481 7269015 in IN B-PP O
25 482 490 7269015 patients NNS B-NP O
26 491 493 7269015 on IN B-PP O
27 494 498 7269015 long JJ B-NP O
28 498 499 7269015 - HYPH I-NP O
29 499 503 7269015 term NN I-NP O
30 504 511 7269015 therapy NN I-NP O
31 511 512 7269015 . . O O

1 0 0 8919272 -DOCSTART- -X- -X- O

1 0 13 8919272 Morphological JJ B-NP O
2 14 22 8919272 features NNS I-NP O
3 23 25 8919272 of IN B-PP O
4 26 40 8919272 encephalopathy NN B-NP B-Disease
5 41 46 8919272 after IN B-SBAR O
6 47 54 8919272 chronic JJ B-NP O
7 55 69 8919272 administration NN I-NP O
8 70 72 8919272 of IN B-PP O
9 73 76 8919272 the DT B-NP O
10 77 90 8919272 antiepileptic JJ I-NP O
11 91 95 8919272 drug NN I-NP O
12 96 105 8919272 valproate NN I-NP B-Chemical
13 106 108 8919272 to TO B-PP O
14 109 113 8919272 rats NNS B-NP O
15 113 114 8919272 . . O O

1 115 116 8919272 A DT B-NP O
2 117 129 8919272 transmission NN I-NP O
3 130 138 8919272 electron NN I-NP O
4 139 150 8919272 microscopic JJ I-NP O
5 151 156 8919272 study NN I-NP O
6 157 159 8919272 of IN B-PP O
7 160 171 8919272 capillaries NNS B-NP O
8 172 174 8919272 in IN B-PP O
9 175 178 8919272 the DT B-NP O
10 179 189 8919272 cerebellar JJ I-NP O
11 190 196 8919272 cortex NN I-NP O
12 196 197 8919272 . . O O
13 198 202 8919272 Long JJ B-NP O
14 202 203 8919272 - HYPH I-NP O
15 203 207 8919272 term NN I-NP O
16 208 220 8919272 intragastric JJ I-NP O
17 221 232 8919272 application NN I-NP O
18 233 235 8919272 of IN B-PP O
19 236 239 8919272 the DT B-NP O
20 240 253 8919272 antiepileptic JJ I-NP O
21 254 258 8919272 drug NN I-NP O
22 259 265 8919272 sodium NN I-NP B-Chemical
23 266 275 8919272 valproate NN I-NP I-Chemical
24 276 277 8919272 ( ( O O
25 277 283 8919272 Vupral JJ B-NP O
26 284 285 8919272 " `` I-NP O
27 285 290 8919272 Polfa NNP I-NP O
28 290 291 8919272 " '' O O
29 291 292 8919272 ) ) O O
30 293 295 8919272 at IN B-PP O
31 296 299 8919272 the DT B-NP O
32 300 309 8919272 effective JJ I-NP O
33 310 314 8919272 dose NN I-NP O
34 315 317 8919272 of IN B-PP O
35 318 321 8919272 200 CD B-NP O
36 322 324 8919272 mg NN I-NP O
37 324 325 8919272 / SYM B-NP O
38 325 327 8919272 kg NN I-NP O
39 328 329 8919272 b NN I-NP O
40 329 330 8919272 . . O O

1 331 332 8919272 w LS B-LST O
2 332 333 8919272 . . O O

1 334 338 8919272 once RB B-ADVP O
2 339 344 8919272 daily RB I-ADVP O
3 345 347 8919272 to TO B-PP O
4 348 352 8919272 rats NNS B-NP O
5 353 356 8919272 for IN B-PP O
6 357 358 8919272 1 CD B-NP O
7 358 359 8919272 , , I-NP O
8 360 361 8919272 3 CD I-NP O
9 361 362 8919272 , , I-NP O
10 363 364 8919272 6 CD I-NP O
11 364 365 8919272 , , I-NP O
12 366 367 8919272 9 CD I-NP O
13 368 371 8919272 and CC I-NP O
14 372 374 8919272 12 CD I-NP O
15 375 381 8919272 months NNS I-NP O
16 382 390 8919272 revealed VBD B-VP O
17 391 403 8919272 neurological JJ B-NP B-Disease
18 404 413 8919272 disorders NNS I-NP I-Disease
19 414 424 8919272 indicating VBG B-VP O
20 425 435 8919272 cerebellum NN B-NP B-Disease
21 436 442 8919272 damage NN I-NP I-Disease
22 443 444 8919272 ( ( O O
23 444 445 8919272 " `` O O
24 445 454 8919272 valproate NN B-NP B-Chemical
25 455 469 8919272 encephalopathy NN I-NP B-Disease
26 469 470 8919272 " '' O O
27 470 471 8919272 ) ) O O
28 471 472 8919272 . . O O

1 473 476 8919272 The DT B-NP O
2 477 482 8919272 first JJ I-NP O
3 483 498 8919272 ultrastructural JJ I-NP O
4 499 506 8919272 changes NNS I-NP O
5 507 509 8919272 in IN B-PP O
6 510 520 8919272 structural JJ B-NP O
7 521 529 8919272 elements NNS I-NP O
8 530 532 8919272 of IN B-PP O
9 533 536 8919272 the DT B-NP O
10 537 542 8919272 blood NN I-NP O
11 542 543 8919272 - HYPH B-NP O
12 543 548 8919272 brain NN I-NP O
13 548 549 8919272 - HYPH O O
14 549 556 8919272 barrier NN B-NP O
15 557 558 8919272 ( ( O O
16 558 561 8919272 BBB NN B-NP O
17 561 562 8919272 ) ) O O
18 563 565 8919272 in IN B-PP O
19 566 569 8919272 the DT B-NP O
20 570 580 8919272 cerebellar JJ I-NP O
21 581 587 8919272 cortex NN I-NP O
22 588 592 8919272 were VBD B-VP O
23 593 603 8919272 detectable JJ B-ADJP O
24 604 609 8919272 after IN B-PP O
25 610 611 8919272 3 CD B-NP O
26 612 618 8919272 months NNS I-NP O
27 619 621 8919272 of IN B-PP O
28 622 625 8919272 the DT B-NP O
29 626 636 8919272 experiment NN I-NP O
30 636 637 8919272 . . O O

1 638 642 8919272 They PRP B-NP O
2 643 649 8919272 became VBD B-VP O
3 650 654 8919272 more RBR B-ADJP O
4 655 661 8919272 severe JJ I-ADJP O
5 662 664 8919272 in IN B-PP O
6 665 668 8919272 the DT B-NP O
7 669 674 8919272 later JJ I-NP O
8 675 681 8919272 months NNS I-NP O
9 682 684 8919272 of IN B-PP O
10 685 688 8919272 the DT B-NP O
11 689 699 8919272 experiment NN I-NP O
12 699 700 8919272 , , O O
13 701 704 8919272 and CC O O
14 705 709 8919272 were VBD B-VP O
15 710 714 8919272 most RBS B-ADJP O
16 715 721 8919272 severe JJ I-ADJP O
17 722 727 8919272 after IN B-PP O
18 728 730 8919272 12 CD B-NP O
19 731 737 8919272 months NNS I-NP O
20 737 738 8919272 , , O O
21 739 746 8919272 located JJ B-ADJP O
22 747 753 8919272 mainly RB B-ADVP O
23 754 756 8919272 in IN B-PP O
24 757 760 8919272 the DT B-NP O
25 761 770 8919272 molecular JJ I-NP O
26 771 776 8919272 layer NN I-NP O
27 777 779 8919272 of IN B-PP O
28 780 783 8919272 the DT B-NP O
29 784 794 8919272 cerebellar JJ I-NP O
30 795 801 8919272 cortex NN I-NP O
31 801 802 8919272 . . O O

1 803 810 8919272 Lesions NNS B-NP O
2 811 813 8919272 of IN B-PP O
3 814 817 8919272 the DT B-NP O
4 818 827 8919272 capillary NN I-NP O
5 828 836 8919272 included VBD B-VP O
6 837 845 8919272 necrosis NN B-NP B-Disease
7 846 848 8919272 of IN B-PP O
8 849 860 8919272 endothelial JJ B-NP O
9 861 866 8919272 cells NNS I-NP O
10 866 867 8919272 . . O O

1 868 878 8919272 Organelles NNS B-NP O
2 879 881 8919272 of IN B-PP O
3 882 887 8919272 these DT B-NP O
4 888 893 8919272 cells NNS I-NP O
5 893 894 8919272 , , O O
6 895 897 8919272 in IN B-PP O
7 898 908 8919272 particular JJ B-ADJP O
8 909 912 8919272 the DT B-NP O
9 913 925 8919272 mitochondria NNS I-NP O
10 926 927 8919272 ( ( O O
11 927 936 8919272 increased VBN B-NP O
12 937 943 8919272 number NN I-NP O
13 944 947 8919272 and CC I-NP O
14 948 952 8919272 size NN I-NP O
15 952 953 8919272 , , O O
16 954 962 8919272 distinct JJ B-NP O
17 963 975 8919272 degeneration NN I-NP O
18 976 978 8919272 of IN B-PP O
19 979 984 8919272 their PRP$ B-NP O
20 985 991 8919272 matrix NN I-NP O
21 992 995 8919272 and CC I-NP O
22 996 1003 8919272 cristae NN I-NP O
23 1003 1004 8919272 ) ) O O
24 1005 1008 8919272 and CC O O
25 1009 1014 8919272 Golgi NNP B-NP O
26 1015 1024 8919272 apparatus NN I-NP O
27 1025 1029 8919272 were VBD B-VP O
28 1030 1037 8919272 altered VBN I-VP O
29 1037 1038 8919272 . . O O

1 1039 1046 8919272 Reduced VBN B-NP O
2 1047 1051 8919272 size NN I-NP O
3 1052 1054 8919272 of IN B-PP O
4 1055 1064 8919272 capillary JJ B-NP O
5 1065 1070 8919272 lumen NN I-NP O
6 1071 1074 8919272 and CC I-NP O
7 1075 1084 8919272 occlusion NN I-NP O
8 1085 1089 8919272 were VBD B-VP O
9 1090 1096 8919272 caused VBN I-VP O
10 1097 1099 8919272 by IN B-PP O
11 1100 1107 8919272 swollen VBN B-NP O
12 1108 1119 8919272 endothelial JJ I-NP O
13 1120 1125 8919272 cells NNS I-NP O
14 1126 1131 8919272 which WDT B-NP O
15 1132 1135 8919272 had VBD B-VP O
16 1136 1143 8919272 luminal JJ B-NP B-Chemical
17 1144 1155 8919272 protrusions NNS I-NP O
18 1156 1159 8919272 and CC O O
19 1160 1167 8919272 swollen JJ B-NP O
20 1168 1178 8919272 microvilli NNS I-NP O
21 1178 1179 8919272 . . O O

1 1180 1188 8919272 Pressure NN B-NP O
2 1189 1191 8919272 on IN B-PP O
3 1192 1195 8919272 the DT B-NP O
4 1196 1202 8919272 vessel NN I-NP O
5 1203 1207 8919272 wall NN I-NP O
6 1208 1211 8919272 was VBD B-VP O
7 1212 1220 8919272 produced VBN I-VP O
8 1221 1223 8919272 by IN B-PP O
9 1224 1232 8919272 enlarged JJ B-NP O
10 1233 1245 8919272 perivascular JJ I-NP O
11 1246 1256 8919272 astrocytic JJ I-NP O
12 1257 1266 8919272 processes NNS I-NP O
13 1266 1267 8919272 . . O O

1 1268 1277 8919272 Fragments NNS B-NP O
2 1278 1280 8919272 of IN B-PP O
3 1281 1289 8919272 necrotic JJ B-NP B-Disease
4 1290 1301 8919272 endothelial JJ I-NP O
5 1302 1307 8919272 cells NNS I-NP O
6 1308 1312 8919272 were VBD B-VP O
7 1313 1315 8919272 in IN B-PP O
8 1316 1319 8919272 the DT B-NP O
9 1320 1328 8919272 vascular JJ I-NP O
10 1329 1335 8919272 lumens NNS I-NP O
11 1336 1339 8919272 and CC B-PP O
12 1340 1342 8919272 in IN B-PP O
13 1343 1348 8919272 these DT B-NP O
14 1349 1354 8919272 there EX B-NP O
15 1355 1358 8919272 was VBD B-VP O
16 1359 1368 8919272 loosening VBG I-VP O
17 1369 1372 8919272 and CC O O
18 1373 1381 8919272 breaking NN B-NP O
19 1382 1384 8919272 of IN B-PP O
20 1385 1390 8919272 tight JJ B-NP O
21 1391 1399 8919272 cellular JJ I-NP O
22 1400 1409 8919272 junctions NNS I-NP O
23 1409 1410 8919272 . . O O

1 1411 1417 8919272 Damage NN B-NP O
2 1418 1420 8919272 to TO B-PP O
3 1421 1424 8919272 the DT B-NP O
4 1425 1433 8919272 vascular JJ I-NP O
5 1434 1442 8919272 basement NN I-NP O
6 1443 1449 8919272 lamina NN I-NP O
7 1450 1453 8919272 was VBD B-VP O
8 1454 1458 8919272 also RB I-VP O
9 1459 1467 8919272 observed VBN I-VP O
10 1467 1468 8919272 . . O O

1 1469 1475 8919272 Damage NN B-NP O
2 1476 1478 8919272 to TO B-PP O
3 1479 1482 8919272 the DT B-NP O
4 1483 1492 8919272 capillary NN I-NP O
5 1493 1496 8919272 was VBD B-VP O
6 1497 1508 8919272 accompanied VBN I-VP O
7 1509 1511 8919272 by IN B-PP O
8 1512 1518 8919272 marked JJ B-NP O
9 1519 1525 8919272 damage NN I-NP O
10 1526 1528 8919272 to TO B-PP O
11 1529 1539 8919272 neuroglial JJ B-NP O
12 1540 1545 8919272 cells NNS I-NP O
13 1545 1546 8919272 , , O O
14 1547 1553 8919272 mainly RB B-ADVP O
15 1554 1556 8919272 to TO B-PP O
16 1557 1569 8919272 perivascular JJ B-NP O
17 1570 1579 8919272 processes NNS I-NP O
18 1580 1582 8919272 of IN B-PP O
19 1583 1593 8919272 astrocytes NNS B-NP O
20 1593 1594 8919272 . . O O

1 1595 1598 8919272 The DT B-NP O
2 1599 1612 8919272 proliferation NN I-NP O
3 1613 1615 8919272 of IN B-PP O
4 1616 1626 8919272 astrocytes NNS B-NP O
5 1627 1628 8919272 ( ( O O
6 1628 1638 8919272 Bergmann's NNS B-NP O
7 1639 1641 8919272 in IN B-PP O
8 1642 1652 8919272 particular JJ B-ADJP O
9 1652 1653 8919272 ) ) O O
10 1654 1657 8919272 and CC O O
11 1658 1670 8919272 occasionally RB B-ADVP O
12 1671 1673 8919272 of IN B-PP O
13 1674 1690 8919272 oligodendrocytes NNS B-NP O
14 1691 1694 8919272 was VBD B-VP O
15 1695 1700 8919272 found VBN I-VP O
16 1700 1701 8919272 . . O O

1 1702 1713 8919272 Alterations NNS B-NP O
2 1714 1716 8919272 in IN B-PP O
3 1717 1720 8919272 the DT B-NP O
4 1721 1731 8919272 structural JJ I-NP O
5 1732 1740 8919272 elements NNS I-NP O
6 1741 1743 8919272 of IN B-PP O
7 1744 1747 8919272 the DT B-NP O
8 1748 1751 8919272 BBB NNP I-NP O
9 1752 1761 8919272 coexisted VBD B-VP O
10 1762 1766 8919272 with IN B-PP O
11 1767 1773 8919272 marked JJ B-NP O
12 1774 1781 8919272 lesions NNS I-NP O
13 1782 1784 8919272 of IN B-PP O
14 1785 1792 8919272 neurons NNS B-NP O
15 1793 1795 8919272 of IN B-PP O
16 1796 1799 8919272 the DT B-NP O
17 1800 1810 8919272 cerebellum NN I-NP O
18 1811 1812 8919272 ( ( O O
19 1812 1820 8919272 Purkinje NN B-NP O
20 1821 1826 8919272 cells NNS I-NP O
21 1827 1830 8919272 are VBP B-VP O
22 1831 1839 8919272 earliest JJS B-ADJP O
23 1839 1840 8919272 ) ) O O
24 1840 1841 8919272 . . O O

1 1842 1844 8919272 In IN B-PP O
2 1845 1853 8919272 electron NN B-NP O
3 1854 1865 8919272 micrographs NNS I-NP O
4 1866 1870 8919272 both CC O O
5 1871 1878 8919272 luminal JJ B-NP B-Chemical
6 1879 1882 8919272 and CC I-NP O
7 1883 1894 8919272 antiluminal JJ I-NP O
8 1895 1900 8919272 sides NNS I-NP O
9 1901 1903 8919272 of IN B-PP O
10 1904 1907 8919272 the DT B-NP O
11 1908 1911 8919272 BBB NN I-NP O
12 1912 1914 8919272 of IN B-PP O
13 1915 1918 8919272 the DT B-NP O
14 1919 1929 8919272 cerebellar JJ I-NP O
15 1930 1936 8919272 cortex NN I-NP O
16 1937 1940 8919272 had VBD B-VP O
17 1941 1948 8919272 similar JJ B-NP O
18 1949 1956 8919272 lesions NNS I-NP O
19 1956 1957 8919272 . . O O

1 1958 1961 8919272 The DT B-NP O
2 1962 1970 8919272 possible JJ I-NP O
3 1971 1980 8919272 influence NN I-NP O
4 1981 1983 8919272 of IN B-PP O
5 1984 1987 8919272 the DT B-NP O
6 1988 1995 8919272 hepatic JJ I-NP B-Disease
7 1996 2002 8919272 damage NN I-NP I-Disease
8 2002 2003 8919272 , , O O
9 2004 2010 8919272 mainly RB B-NP O
10 2011 2025 8919272 hyperammonemia NN I-NP B-Disease
11 2025 2026 8919272 , , O O
12 2027 2031 8919272 upon IN B-PP O
13 2032 2035 8919272 the DT B-NP O
14 2036 2047 8919272 development NN I-NP O
15 2048 2050 8919272 of IN B-PP O
16 2051 2060 8919272 valproate NN B-NP B-Chemical
17 2061 2075 8919272 encephalopathy NN I-NP B-Disease
18 2076 2078 8919272 is VBZ B-VP O
19 2079 2088 8919272 discussed VBN I-VP O
20 2088 2089 8919272 . . O O

1 0 0 11587867 -DOCSTART- -X- -X- O

1 0 5 11587867 Fatal JJ B-NP O
2 6 25 11587867 myeloencephalopathy NN I-NP B-Disease
3 26 29 11587867 due JJ B-PP O
4 30 32 11587867 to TO B-PP O
5 33 43 11587867 accidental JJ B-NP O
6 44 55 11587867 intrathecal JJ I-NP O
7 56 66 11587867 vincristin NN I-NP B-Chemical
8 67 81 11587867 administration NN I-NP O
9 81 82 11587867 : : O O
10 83 84 11587867 a DT B-NP O
11 85 91 11587867 report NN I-NP O
12 92 94 11587867 of IN B-PP O
13 95 98 11587867 two CD B-NP O
14 99 104 11587867 cases NNS I-NP O
15 104 105 11587867 . . O O
16 106 108 11587867 We PRP B-NP O
17 109 115 11587867 report VBP B-VP O
18 116 118 11587867 on IN B-PP O
19 119 122 11587867 two CD B-NP O
20 123 128 11587867 fatal JJ I-NP O
21 129 134 11587867 cases NNS I-NP O
22 135 137 11587867 of IN B-PP O
23 138 148 11587867 accidental JJ B-NP O
24 149 160 11587867 intrathecal JJ I-NP O
25 161 172 11587867 vincristine NN I-NP B-Chemical
26 173 185 11587867 instillation NN I-NP O
27 186 188 11587867 in IN B-PP O
28 189 190 11587867 a DT B-NP O
29 191 192 11587867 5 CD I-NP O
30 192 193 11587867 - HYPH I-NP O
31 193 197 11587867 year NN I-NP O
32 198 201 11587867 old JJ I-NP O
33 202 206 11587867 girl NN I-NP O
34 207 211 11587867 with IN B-PP O
35 212 221 11587867 recurrent JJ B-NP O
36 222 227 11587867 acute JJ I-NP B-Disease
37 228 241 11587867 lymphoblastic JJ I-NP I-Disease
38 242 250 11587867 leucemia NN I-NP I-Disease
39 251 254 11587867 and CC O O
40 255 256 11587867 a DT B-NP O
41 257 259 11587867 57 CD I-NP O
42 259 260 11587867 - HYPH I-NP O
43 260 264 11587867 year NN I-NP O
44 265 268 11587867 old JJ I-NP O
45 269 272 11587867 man NN I-NP O
46 273 277 11587867 with IN B-PP O
47 278 291 11587867 lymphoblastic JJ B-NP B-Disease
48 292 300 11587867 lymphoma NN I-NP I-Disease
49 300 301 11587867 . . O O

1 302 305 11587867 The DT B-NP O
2 306 310 11587867 girl NN I-NP O
3 311 315 11587867 died VBD B-VP O
4 316 321 11587867 seven CD B-NP O
5 322 326 11587867 days NNS I-NP O
6 326 327 11587867 , , O O
7 328 331 11587867 the DT B-NP O
8 332 335 11587867 man NN I-NP O
9 336 340 11587867 four CD B-NP O
10 341 346 11587867 weeks NNS I-NP O
11 347 352 11587867 after IN B-PP O
12 353 364 11587867 intrathecal JJ B-NP O
13 365 374 11587867 injection NN I-NP O
14 375 377 11587867 of IN B-PP O
15 378 389 11587867 vincristine NN B-NP B-Chemical
16 389 390 11587867 . . O O

1 391 401 11587867 Clinically RB B-ADVP O
2 401 402 11587867 , , O O
3 403 406 11587867 the DT B-NP O
4 407 412 11587867 onset NN I-NP O
5 413 416 11587867 was VBD B-VP O
6 417 430 11587867 characterized VBN I-VP O
7 431 433 11587867 by IN B-PP O
8 434 437 11587867 the DT B-NP O
9 438 443 11587867 signs NNS I-NP O
10 444 446 11587867 of IN B-PP O
11 447 459 11587867 opistothonus NN B-NP B-Disease
12 459 460 11587867 , , O I-Disease
13 461 468 11587867 sensory NN B-NP I-Disease
14 469 472 11587867 and CC O I-Disease
15 473 478 11587867 motor NN B-NP I-Disease
16 479 490 11587867 dysfunction NN I-NP I-Disease
17 491 494 11587867 and CC O O
18 495 504 11587867 ascending VBG B-VP O
19 505 514 11587867 paralysis NN B-NP B-Disease
20 514 515 11587867 . . O O

1 516 528 11587867 Histological JJ B-NP O
2 529 532 11587867 and CC I-NP O
3 533 552 11587867 immunohistochemical JJ I-NP O
4 553 567 11587867 investigations NNS I-NP O
5 568 569 11587867 ( ( O O
6 569 571 11587867 HE NN B-NP O
7 571 572 11587867 - HYPH O O
8 572 575 11587867 LFB NN B-NP O
9 575 576 11587867 , , O O
10 577 579 11587867 CD NN B-NP O
11 579 580 11587867 - HYPH I-NP O
12 580 582 11587867 68 CD I-NP O
13 582 583 11587867 , , I-NP O
14 584 597 11587867 Neurofilament NN I-NP O
15 597 598 11587867 ) ) O O
16 599 607 11587867 revealed VBD B-VP O
17 608 620 11587867 degeneration NN B-NP B-Disease
18 621 623 11587867 of IN B-PP I-Disease
19 624 630 11587867 myelin NN B-NP I-Disease
20 631 634 11587867 and CC I-NP I-Disease
21 635 640 11587867 axons NNS I-NP I-Disease
22 641 643 11587867 as RB B-CONJP O
23 644 648 11587867 well RB I-CONJP O
24 649 651 11587867 as IN I-CONJP O
25 652 664 11587867 pseudocystic JJ B-NP B-Disease
26 665 679 11587867 transformation NN I-NP I-Disease
27 680 682 11587867 in IN B-PP O
28 683 688 11587867 areas NNS B-NP O
29 689 696 11587867 exposed VBN B-VP O
30 697 699 11587867 to TO B-PP O
31 700 711 11587867 vincristine NN B-NP B-Chemical
32 711 712 11587867 , , O O
33 713 724 11587867 accompanied VBN B-VP O
34 725 727 11587867 by IN B-PP O
35 728 737 11587867 secondary JJ B-NP O
36 738 745 11587867 changes NNS I-NP O
37 746 750 11587867 with IN B-PP O
38 751 759 11587867 numerous JJ B-NP O
39 760 769 11587867 prominent JJ I-NP O
40 770 781 11587867 macrophages NNS I-NP O
41 781 782 11587867 . . O O

1 783 786 11587867 The DT B-NP O
2 787 795 11587867 clinical JJ I-NP O
3 796 802 11587867 course NN I-NP O
4 803 806 11587867 and CC O O
5 807 824 11587867 histopathological JJ B-NP O
6 825 832 11587867 results NNS I-NP O
7 833 835 11587867 of IN B-PP O
8 836 839 11587867 the DT B-NP O
9 840 843 11587867 two CD I-NP O
10 844 849 11587867 cases NNS I-NP O
11 850 853 11587867 are VBP B-VP O
12 854 863 11587867 presented VBN I-VP O
13 863 864 11587867 . . O O

1 865 866 11587867 A DT B-NP O
2 867 873 11587867 review NN I-NP O
3 874 876 11587867 of IN B-PP O
4 877 880 11587867 all DT B-NP O
5 881 889 11587867 reported VBN I-NP O
6 890 895 11587867 cases NNS I-NP O
7 896 898 11587867 in IN B-PP O
8 899 902 11587867 the DT B-NP O
9 903 913 11587867 literature NN I-NP O
10 914 916 11587867 is VBZ B-VP O
11 917 922 11587867 given VBN I-VP O
12 922 923 11587867 . . O O

1 924 925 11587867 A DT B-NP O
2 926 932 11587867 better JJR I-NP O
3 933 943 11587867 controlled VBN I-NP O
4 944 951 11587867 regimen NN I-NP O
5 952 955 11587867 for IN B-PP O
6 956 969 11587867 administering VBG B-VP O
7 970 981 11587867 vincristine NN B-NP B-Chemical
8 982 985 11587867 and CC O O
9 986 997 11587867 intrathecal JJ B-NP O
10 998 1010 11587867 chemotherapy NN I-NP O
11 1011 1013 11587867 is VBZ B-VP O
12 1014 1025 11587867 recommended VBN I-VP O
13 1025 1026 11587867 . . O O

1 0 0 18162529 -DOCSTART- -X- -X- O

1 0 12 18162529 Hypothalamic JJ B-NP O
2 13 22 18162529 prolactin NN I-NP O
3 23 31 18162529 receptor NN I-NP O
4 32 41 18162529 messenger NN I-NP O
5 42 53 18162529 ribonucleic JJ I-NP B-Chemical
6 54 58 18162529 acid NN I-NP I-Chemical
7 59 65 18162529 levels NNS I-NP O
8 65 66 18162529 , , O O
9 67 76 18162529 prolactin NN B-NP O
10 77 86 18162529 signaling NN I-NP O
11 86 87 18162529 , , O O
12 88 91 18162529 and CC O O
13 92 110 18162529 hyperprolactinemic JJ B-NP B-Disease
14 111 121 18162529 inhibition NN I-NP O
15 122 124 18162529 of IN B-PP O
16 125 134 18162529 pulsatile JJ B-NP O
17 135 146 18162529 luteinizing NN I-NP O
18 147 154 18162529 hormone NN I-NP O
19 155 164 18162529 secretion NN I-NP O
20 165 168 18162529 are VBP B-VP O
21 169 178 18162529 dependent JJ B-ADJP O
22 179 181 18162529 on IN B-PP O
23 182 191 18162529 estradiol NN B-NP B-Chemical
24 191 192 18162529 . . O O
25 193 211 18162529 Hyperprolactinemia NN B-NP B-Disease
26 212 215 18162529 can MD B-VP O
27 216 222 18162529 reduce VB I-VP O
28 223 232 18162529 fertility NN B-NP O
29 233 236 18162529 and CC I-NP O
30 237 243 18162529 libido NN I-NP O
31 243 244 18162529 . . O O

1 245 253 18162529 Although IN B-SBAR O
2 254 261 18162529 central JJ B-NP O
3 262 271 18162529 prolactin NN I-NP O
4 272 279 18162529 actions NNS I-NP O
5 280 283 18162529 are VBP B-VP O
6 284 291 18162529 thought VBN I-VP O
7 292 294 18162529 to TO I-VP O
8 295 305 18162529 contribute VB I-VP O
9 306 308 18162529 to TO B-PP O
10 309 313 18162529 this DT B-NP O
11 313 314 18162529 , , O O
12 315 318 18162529 the DT B-NP O
13 319 329 18162529 mechanisms NNS I-NP O
14 330 333 18162529 are VBP B-VP O
15 334 340 18162529 poorly RB I-VP O
16 341 351 18162529 understood VBN I-VP O
17 351 352 18162529 . . O O

1 353 355 18162529 We PRP B-NP O
2 356 361 18162529 first RB B-ADVP O
3 362 368 18162529 tested VBD B-VP O
4 369 376 18162529 whether IN B-SBAR O
5 377 384 18162529 chronic JJ B-NP O
6 385 403 18162529 hyperprolactinemia NN I-NP B-Disease
7 404 413 18162529 inhibited VBD B-VP O
8 414 417 18162529 two CD B-NP O
9 418 432 18162529 neuroendocrine JJ I-NP O
10 433 443 18162529 parameters NNS I-NP O
11 444 453 18162529 necessary JJ B-ADJP O
12 454 457 18162529 for IN B-PP O
13 458 464 18162529 female JJ B-NP O
14 465 474 18162529 fertility NN I-NP O
15 474 475 18162529 : : O O
16 476 485 18162529 pulsatile JJ B-NP O
17 486 488 18162529 LH NN I-NP O
18 489 498 18162529 secretion NN I-NP O
19 499 502 18162529 and CC O O
20 503 506 18162529 the DT B-NP O
21 507 515 18162529 estrogen NN I-NP B-Chemical
22 515 516 18162529 - HYPH B-NP O
23 516 523 18162529 induced VBN I-NP O
24 524 526 18162529 LH NN I-NP O
25 527 532 18162529 surge NN I-NP O
26 532 533 18162529 . . O O

1 534 541 18162529 Chronic JJ B-NP O
2 542 560 18162529 hyperprolactinemia NN I-NP B-Disease
3 561 568 18162529 induced VBN B-VP O
4 569 571 18162529 by IN B-PP O
5 572 575 18162529 the DT B-NP O
6 576 584 18162529 dopamine NN I-NP B-Chemical
7 585 595 18162529 antagonist NN I-NP O
8 596 605 18162529 sulpiride NN I-NP B-Chemical
9 606 612 18162529 caused VBD B-VP O
10 613 614 18162529 a DT B-NP O
11 615 618 18162529 40% JJ I-NP O
12 619 628 18162529 reduction NN I-NP O
13 629 631 18162529 LH NN I-NP O
14 632 637 18162529 pulse NN I-NP O
15 638 647 18162529 frequency NN I-NP O
16 648 650 18162529 in IN B-PP O
17 651 665 18162529 ovariectomized VBN B-NP O
18 666 670 18162529 rats NNS I-NP O
19 670 671 18162529 , , O O
20 672 675 18162529 but CC O O
21 676 680 18162529 only RB B-ADVP O
22 681 683 18162529 in IN B-PP O
23 684 687 18162529 the DT B-NP O
24 688 696 18162529 presence NN I-NP O
25 697 699 18162529 of IN B-PP O
26 700 707 18162529 chronic JJ B-NP O
27 708 711 18162529 low JJ I-NP O
28 712 718 18162529 levels NNS I-NP O
29 719 721 18162529 of IN B-PP O
30 722 731 18162529 estradiol NN B-NP B-Chemical
31 731 732 18162529 . . O O

1 733 742 18162529 Sulpiride NN B-NP B-Chemical
2 743 746 18162529 did VBD B-VP O
3 747 750 18162529 not RB I-VP O
4 751 757 18162529 affect VB I-VP O
5 758 761 18162529 the DT B-NP O
6 762 771 18162529 magnitude NN I-NP O
7 772 774 18162529 of IN B-PP O
8 775 776 18162529 a DT B-NP O
9 777 784 18162529 steroid NN I-NP B-Chemical
10 784 785 18162529 - HYPH B-NP O
11 785 792 18162529 induced VBN I-NP O
12 793 795 18162529 LH NN I-NP O
13 796 801 18162529 surge NN I-NP O
14 802 804 18162529 or CC O O
15 805 808 18162529 the DT B-NP O
16 809 819 18162529 percentage NN I-NP O
17 820 822 18162529 of IN B-PP O
18 823 827 18162529 GnRH NN B-NP O
19 828 835 18162529 neurons NNS I-NP O
20 836 845 18162529 activated VBN B-VP O
21 846 852 18162529 during IN B-PP O
22 853 856 18162529 the DT B-NP O
23 857 862 18162529 surge NN I-NP O
24 862 863 18162529 . . O O

1 864 873 18162529 Estradiol NN B-NP B-Chemical
2 874 876 18162529 is VBZ B-VP O
3 877 882 18162529 known VBN I-VP O
4 883 885 18162529 to TO I-VP O
5 886 895 18162529 influence VB I-VP O
6 896 906 18162529 expression NN B-NP O
7 907 909 18162529 of IN B-PP O
8 910 913 18162529 the DT B-NP O
9 914 918 18162529 long JJ I-NP O
10 919 923 18162529 form NN I-NP O
11 924 926 18162529 of IN B-PP O
12 927 936 18162529 prolactin NN B-NP O
13 937 946 18162529 receptors NNS I-NP O
14 947 948 18162529 ( ( O O
15 948 951 18162529 PRL NN B-NP O
16 951 952 18162529 - HYPH B-NP O
17 952 953 18162529 R NN I-NP O
18 953 954 18162529 ) ) O O
19 955 958 18162529 and CC O O
20 959 969 18162529 components NNS B-NP O
21 970 972 18162529 of IN B-PP O
22 973 984 18162529 prolactin's NNS B-NP O
23 985 994 18162529 signaling VBG B-VP O
24 995 1002 18162529 pathway NN B-NP O
25 1002 1003 18162529 . . O O

1 1004 1006 18162529 To TO B-VP O
2 1007 1011 18162529 test VB I-VP O
3 1012 1015 18162529 the DT B-NP O
4 1016 1026 18162529 hypothesis NN I-NP O
5 1027 1031 18162529 that IN B-SBAR O
6 1032 1040 18162529 estrogen NN B-NP B-Chemical
7 1041 1050 18162529 increases VBZ B-VP O
8 1051 1054 18162529 PRL NN B-NP O
9 1054 1055 18162529 - HYPH I-NP O
10 1055 1056 18162529 R NN I-NP O
11 1057 1067 18162529 expression NN I-NP O
12 1068 1071 18162529 and CC O O
13 1072 1083 18162529 sensitivity NN B-NP O
14 1084 1086 18162529 to TO B-PP O
15 1087 1096 18162529 prolactin NN B-NP O
16 1096 1097 18162529 , , O O
17 1098 1100 18162529 we PRP B-NP O
18 1101 1105 18162529 next RB B-ADVP O
19 1106 1118 18162529 demonstrated VBD B-VP O
20 1119 1123 18162529 that IN B-SBAR O
21 1124 1133 18162529 estradiol NN B-NP B-Chemical
22 1134 1141 18162529 greatly RB B-ADVP O
23 1142 1150 18162529 augments VBZ B-VP O
24 1151 1160 18162529 prolactin NN B-NP O
25 1160 1161 18162529 - HYPH O O
26 1161 1168 18162529 induced VBN B-NP O
27 1169 1174 18162529 STAT5 NN I-NP O
28 1175 1185 18162529 activation NN I-NP O
29 1185 1186 18162529 . . O O

1 1187 1193 18162529 Lastly RB B-ADVP O
2 1193 1194 18162529 , , O O
3 1195 1197 18162529 we PRP B-NP O
4 1198 1206 18162529 measured VBD B-VP O
5 1207 1210 18162529 PRL NN B-NP O
6 1210 1211 18162529 - HYPH B-NP O
7 1211 1212 18162529 R NN I-NP O
8 1213 1216 18162529 and CC I-NP O
9 1217 1227 18162529 suppressor NN I-NP O
10 1228 1230 18162529 of IN B-PP O
11 1231 1239 18162529 cytokine NN B-NP O
12 1240 1249 18162529 signaling NN I-NP O
13 1250 1251 18162529 ( ( O O
14 1251 1255 18162529 SOCS NN B-NP O
15 1255 1256 18162529 - HYPH B-NP O
16 1256 1257 18162529 1 CD I-NP O
17 1258 1261 18162529 and CC O O
18 1262 1263 18162529 - SYM B-NP O
19 1263 1264 18162529 3 CD I-NP O
20 1265 1268 18162529 and CC O O
21 1269 1272 18162529 CIS NN B-NP O
22 1272 1273 18162529 , , O O
23 1274 1279 18162529 which WDT B-NP O
24 1280 1287 18162529 reflect VBP B-VP O
25 1288 1291 18162529 the DT B-NP O
26 1292 1297 18162529 level NN I-NP O
27 1298 1300 18162529 of IN B-PP O
28 1301 1310 18162529 prolactin NN B-NP O
29 1311 1320 18162529 signaling NN I-NP O
30 1320 1321 18162529 ) ) O O
31 1322 1327 18162529 mRNAs NNS B-NP O
32 1328 1330 18162529 in IN B-PP O
33 1331 1339 18162529 response NN B-NP O
34 1340 1342 18162529 to TO B-PP O
35 1343 1352 18162529 sulpiride NN B-NP B-Chemical
36 1353 1356 18162529 and CC I-NP O
37 1357 1366 18162529 estradiol NN I-NP B-Chemical
38 1366 1367 18162529 . . O O

1 1368 1377 18162529 Sulpiride NN B-NP B-Chemical
2 1378 1385 18162529 induced VBD B-VP O
3 1386 1390 18162529 only RB B-NP O
4 1391 1395 18162529 SOCS NN I-NP O
5 1395 1396 18162529 - HYPH B-NP O
6 1396 1397 18162529 1 CD I-NP O
7 1398 1400 18162529 in IN B-PP O
8 1401 1404 18162529 the DT B-NP O
9 1405 1411 18162529 medial JJ I-NP O
10 1412 1420 18162529 preoptic JJ I-NP O
11 1421 1425 18162529 area NN I-NP O
12 1425 1426 18162529 , , O O
13 1427 1432 18162529 where WRB B-ADVP O
14 1433 1437 18162529 GnRH NN B-NP O
15 1438 1445 18162529 neurons NNS I-NP O
16 1446 1449 18162529 are VBP B-VP O
17 1450 1459 18162529 regulated VBN I-VP O
18 1459 1460 18162529 , , O O
19 1461 1464 18162529 but CC O O
20 1465 1467 18162529 in IN B-PP O
21 1468 1471 18162529 the DT B-NP O
22 1472 1479 18162529 arcuate JJ I-NP O
23 1480 1487 18162529 nucleus NN I-NP O
24 1488 1491 18162529 and CC O O
25 1492 1499 18162529 choroid JJ B-NP O
26 1500 1506 18162529 plexus NN I-NP O
27 1506 1507 18162529 , , O O
28 1508 1511 18162529 PRL NN B-NP O
29 1511 1512 18162529 - HYPH B-NP O
30 1512 1513 18162529 R NN I-NP O
31 1513 1514 18162529 , , O O
32 1515 1519 18162529 SOCS NN B-NP O
33 1519 1520 18162529 - HYPH B-NP O
34 1520 1521 18162529 3 CD I-NP O
35 1521 1522 18162529 , , O O
36 1523 1526 18162529 and CC O O
37 1527 1530 18162529 CIS NN B-NP O
38 1531 1535 18162529 mRNA NN I-NP O
39 1536 1542 18162529 levels NNS I-NP O
40 1543 1547 18162529 were VBD B-VP O
41 1548 1552 18162529 also RB I-VP O
42 1553 1560 18162529 induced VBN I-VP O
43 1560 1561 18162529 . . O O

1 1562 1571 18162529 Estradiol NN B-NP B-Chemical
2 1572 1580 18162529 enhanced VBD B-VP O
3 1581 1586 18162529 these DT B-NP O
4 1587 1594 18162529 effects NNS I-NP O
5 1595 1597 18162529 on IN B-PP O
6 1598 1602 18162529 SOCS NN B-NP O
7 1602 1603 18162529 - HYPH B-NP O
8 1603 1604 18162529 3 CD I-NP O
9 1605 1608 18162529 and CC I-NP O
10 1609 1612 18162529 CIS NN I-NP O
11 1612 1613 18162529 . . O O

1 1614 1627 18162529 Interestingly RB B-ADVP O
2 1627 1628 18162529 , , O O
3 1629 1638 18162529 estradiol NN B-NP B-Chemical
4 1639 1643 18162529 also RB B-ADVP O
5 1644 1651 18162529 induced VBD B-VP O
6 1652 1655 18162529 PRL NN B-NP O
7 1655 1656 18162529 - HYPH B-NP O
8 1656 1657 18162529 R NN I-NP O
9 1657 1658 18162529 , , O O
10 1659 1663 18162529 SOCS NN B-NP O
11 1663 1664 18162529 - HYPH B-NP O
12 1664 1665 18162529 3 CD I-NP O
13 1665 1666 18162529 , , O O
14 1667 1670 18162529 and CC O O
15 1671 1674 18162529 CIS NN B-NP O
16 1675 1679 18162529 mRNA NN I-NP O
17 1680 1686 18162529 levels NNS I-NP O
18 1687 1700 18162529 independently RB B-ADVP O
19 1700 1701 18162529 . . O O

1 1702 1707 18162529 These DT B-NP O
2 1708 1712 18162529 data NNS I-NP O
3 1713 1717 18162529 show VBP B-VP O
4 1718 1722 18162529 that IN B-SBAR O
5 1723 1727 18162529 GnRH NN B-NP O
6 1728 1733 18162529 pulse NN I-NP O
7 1734 1743 18162529 frequency NN I-NP O
8 1744 1746 18162529 is VBZ B-VP O
9 1747 1756 18162529 inhibited VBN I-VP O
10 1757 1759 18162529 by IN B-PP O
11 1760 1767 18162529 chronic JJ B-NP O
12 1768 1786 18162529 hyperprolactinemia NN I-NP B-Disease
13 1787 1789 18162529 in IN B-PP O
14 1790 1791 18162529 a DT B-NP O
15 1792 1799 18162529 steroid NN I-NP B-Chemical
16 1799 1800 18162529 - HYPH B-NP O
17 1800 1809 18162529 dependent JJ I-NP O
18 1810 1816 18162529 manner NN I-NP O
19 1816 1817 18162529 . . O O

1 1818 1822 18162529 They PRP B-NP O
2 1823 1827 18162529 also RB B-ADVP O
3 1828 1835 18162529 provide VBP B-VP O
4 1836 1844 18162529 evidence NN B-NP O
5 1845 1848 18162529 for IN B-PP O
6 1849 1858 18162529 estradiol NN B-NP B-Chemical
7 1858 1859 18162529 - HYPH B-NP O
8 1859 1868 18162529 dependent JJ I-NP O
9 1869 1872 18162529 and CC I-NP O
10 1873 1878 18162529 brain NN I-NP O
11 1879 1885 18162529 region NN I-NP O
12 1885 1886 18162529 - HYPH B-NP O
13 1886 1894 18162529 specific JJ I-NP O
14 1895 1905 18162529 regulation NN I-NP O
15 1906 1908 18162529 of IN B-PP O
16 1909 1912 18162529 PRL NN B-NP O
17 1912 1913 18162529 - HYPH B-NP O
18 1913 1914 18162529 R NN I-NP O
19 1915 1925 18162529 expression NN I-NP O
20 1926 1929 18162529 and CC O O
21 1930 1939 18162529 signaling NN B-NP O
22 1940 1949 18162529 responses NNS I-NP O
23 1950 1952 18162529 by IN B-PP O
24 1953 1962 18162529 prolactin NN B-NP O
25 1962 1963 18162529 . . O O

1 0 0 3782049 -DOCSTART- -X- -X- O

1 0 1 3782049 A DT B-NP O
2 2 6 3782049 case NN I-NP O
3 7 9 3782049 of IN B-PP O
4 10 17 3782049 massive JJ B-NP O
5 18 32 3782049 rhabdomyolysis NN I-NP B-Disease
6 33 42 3782049 following VBG B-PP O
7 43 52 3782049 molindone NN B-NP B-Chemical
8 53 67 3782049 administration NN I-NP O
9 67 68 3782049 . . B-NP O
10 69 83 3782049 Rhabdomyolysis NN I-NP B-Disease
11 84 86 3782049 is VBZ B-VP O
12 87 88 3782049 a DT B-NP O
13 89 100 3782049 potentially RB I-NP O
14 101 107 3782049 lethal JJ I-NP O
15 108 116 3782049 syndrome NN I-NP O
16 117 121 3782049 that IN B-NP O
17 122 133 3782049 psychiatric JJ B-NP B-Disease
18 134 142 3782049 patients NNS I-NP O
19 143 147 3782049 seem VBP B-VP O
20 148 159 3782049 predisposed VBN I-VP O
21 160 162 3782049 to TO I-VP O
22 163 170 3782049 develop VB I-VP O
23 170 171 3782049 . . O O

1 172 175 3782049 The DT B-NP O
2 176 184 3782049 clinical JJ I-NP O
3 185 190 3782049 signs NNS I-NP O
4 191 194 3782049 and CC I-NP O
5 195 203 3782049 symptoms NNS I-NP O
6 203 204 3782049 , , O O
7 205 212 3782049 typical JJ B-NP O
8 213 223 3782049 laboratory NN I-NP O
9 224 232 3782049 features NNS I-NP O
10 232 233 3782049 , , O O
11 234 237 3782049 and CC O O
12 238 251 3782049 complications NNS B-NP O
13 252 254 3782049 of IN B-PP O
14 255 269 3782049 rhabdomyolysis NN B-NP B-Disease
15 270 273 3782049 are VBP B-VP O
16 274 283 3782049 presented VBN I-VP O
17 283 284 3782049 . . O O

1 285 288 3782049 The DT B-NP O
2 289 293 3782049 case NN I-NP O
3 294 296 3782049 of IN B-PP O
4 297 298 3782049 a DT B-NP O
5 299 312 3782049 schizophrenic JJ I-NP B-Disease
6 313 320 3782049 patient NN I-NP O
7 321 323 3782049 is VBZ B-VP O
8 324 332 3782049 reported VBN I-VP O
9 333 335 3782049 to TO I-VP O
10 336 346 3782049 illustrate VB I-VP O
11 347 354 3782049 massive JJ B-NP O
12 355 369 3782049 rhabdomyolysis NN I-NP B-Disease
13 370 373 3782049 and CC O O
14 374 384 3782049 subsequent JJ B-NP O
15 385 390 3782049 acute JJ I-NP B-Disease
16 391 396 3782049 renal JJ I-NP I-Disease
17 397 404 3782049 failure NN I-NP I-Disease
18 405 414 3782049 following VBG B-PP O
19 415 424 3782049 molindone NN B-NP B-Chemical
20 425 439 3782049 administration NN I-NP O
21 439 440 3782049 . . O O

1 441 451 3782049 Physicians NNS B-NP O
2 452 455 3782049 who WP B-NP O
3 456 465 3782049 prescribe VBP B-VP O
4 466 475 3782049 molindone NN B-NP B-Chemical
5 476 482 3782049 should MD B-VP O
6 483 485 3782049 be VB I-VP O
7 486 491 3782049 aware JJ B-ADJP O
8 492 494 3782049 of IN B-PP O
9 495 499 3782049 this DT B-NP O
10 500 508 3782049 reaction NN I-NP O
11 508 509 3782049 . . O O

1 0 0 15188772 -DOCSTART- -X- -X- O

1 0 6 15188772 Severe JJ B-NP O
2 7 17 15188772 reversible JJ I-NP O
3 18 22 15188772 left JJ I-NP B-Disease
4 23 34 15188772 ventricular JJ I-NP I-Disease
5 35 43 15188772 systolic JJ I-NP I-Disease
6 44 47 15188772 and CC I-NP I-Disease
7 48 57 15188772 diastolic JJ I-NP I-Disease
8 58 69 15188772 dysfunction NN I-NP I-Disease
9 70 73 15188772 due JJ B-PP O
10 74 76 15188772 to TO B-PP O
11 77 87 15188772 accidental JJ B-NP O
12 88 98 15188772 iatrogenic JJ I-NP O
13 99 110 15188772 epinephrine NN I-NP B-Chemical
14 111 119 15188772 overdose NN I-NP B-Disease
15 119 120 15188772 . . B-NP O
16 121 134 15188772 Catecholamine NN I-NP B-Chemical
17 134 135 15188772 - HYPH B-NP O
18 135 142 15188772 induced VBN I-NP O
19 143 157 15188772 cardiomyopathy NN I-NP B-Disease
20 158 161 15188772 due IN B-PP O
21 162 164 15188772 to TO B-PP O
22 165 172 15188772 chronic JJ B-NP O
23 173 179 15188772 excess NN I-NP O
24 180 182 15188772 of IN B-PP O
25 183 193 15188772 endogenous JJ B-NP O
26 194 208 15188772 catecholamines NNS I-NP B-Chemical
27 209 212 15188772 has VBZ B-VP O
28 213 217 15188772 been VBN I-VP O
29 218 228 15188772 recognized VBN I-VP O
30 229 232 15188772 for IN B-PP O
31 233 240 15188772 decades NNS B-NP O
32 241 243 15188772 as IN B-PP O
33 244 245 15188772 a DT B-NP O
34 246 254 15188772 clinical JJ I-NP O
35 255 265 15188772 phenomenon NN I-NP O
36 265 266 15188772 . . O O

1 267 269 15188772 In IN B-PP O
2 270 278 15188772 contrast NN B-NP O
3 278 279 15188772 , , O O
4 280 287 15188772 reports NNS B-NP O
5 288 290 15188772 of IN B-PP O
6 291 301 15188772 myocardial JJ B-NP B-Disease
7 302 313 15188772 dysfunction NN I-NP I-Disease
8 314 317 15188772 due JJ B-PP O
9 318 320 15188772 to TO B-PP O
10 321 326 15188772 acute JJ B-NP O
11 327 337 15188772 iatrogenic JJ I-NP O
12 338 346 15188772 overdose NN I-NP B-Disease
13 347 350 15188772 are VBP B-VP O
14 351 355 15188772 rare JJ B-ADJP O
15 355 356 15188772 . . O O

1 357 358 15188772 A DT B-NP O
2 359 361 15188772 35 CD I-NP O
3 361 362 15188772 - HYPH I-NP O
4 362 366 15188772 year NN I-NP O
5 366 367 15188772 - HYPH O O
6 367 370 15188772 old JJ B-NP O
7 371 376 15188772 woman NN I-NP O
8 377 382 15188772 whose WP$ B-NP O
9 383 389 15188772 cervix NN I-NP O
10 390 395 15188772 uteri NNS I-NP O
11 396 399 15188772 was VBD B-VP O
12 400 413 15188772 inadvertently RB I-VP O
13 414 422 15188772 injected VBN I-VP O
14 423 427 15188772 with IN B-PP O
15 428 429 15188772 8 CD B-NP O
16 430 432 15188772 mg NN I-NP O
17 433 435 15188772 of IN B-PP O
18 436 447 15188772 epinephrine NN B-NP B-Chemical
19 448 457 15188772 developed VBD B-VP O
20 458 468 15188772 myocardial JJ B-NP B-Disease
21 469 477 15188772 stunning NN I-NP I-Disease
22 478 482 15188772 that WDT B-NP O
23 483 486 15188772 was VBD B-VP O
24 487 500 15188772 characterized VBN I-VP O
25 501 503 15188772 by IN B-PP O
26 504 510 15188772 severe JJ B-NP O
27 511 522 15188772 hemodynamic JJ I-NP O
28 523 533 15188772 compromise NN I-NP O
29 533 534 15188772 , , O O
30 535 543 15188772 profound NN B-NP O
31 543 544 15188772 , , O O
32 545 551 15188772 albeit IN B-PP O
33 552 561 15188772 transient JJ B-ADJP O
34 561 562 15188772 , , O O
35 563 567 15188772 left VBD B-VP B-Disease
36 568 579 15188772 ventricular JJ B-NP I-Disease
37 580 588 15188772 systolic JJ I-NP I-Disease
38 589 592 15188772 and CC I-NP I-Disease
39 593 602 15188772 diastolic JJ I-NP I-Disease
40 603 614 15188772 dysfunction NN I-NP I-Disease
41 614 615 15188772 , , O O
42 616 619 15188772 and CC O O
43 620 624 15188772 only RB B-NP O
44 625 633 15188772 modestly RB I-NP O
45 634 642 15188772 elevated JJ I-NP O
46 643 654 15188772 biochemical JJ I-NP O
47 655 662 15188772 markers NNS I-NP O
48 663 665 15188772 of IN B-PP O
49 666 676 15188772 myocardial JJ B-NP B-Disease
50 677 685 15188772 necrosis NN I-NP I-Disease
51 685 686 15188772 . . O O

1 687 690 15188772 Our PRP$ B-NP O
2 691 695 15188772 case NN I-NP O
3 696 707 15188772 illustrates VBZ B-VP O
4 708 711 15188772 the DT B-NP O
5 712 719 15188772 serious JJ I-NP O
6 720 732 15188772 consequences NNS I-NP O
7 733 735 15188772 of IN B-PP O
8 736 743 15188772 medical JJ B-NP O
9 744 750 15188772 errors NNS I-NP O
10 751 755 15188772 that WDT B-NP O
11 756 759 15188772 can MD B-VP O
12 760 762 15188772 be VB I-VP O
13 763 770 15188772 avoided VBN I-VP O
14 771 778 15188772 through IN B-PP O
15 779 787 15188772 improved VBN B-NP O
16 788 798 15188772 medication NN I-NP O
17 799 807 15188772 labeling NN I-NP O
18 808 811 15188772 and CC I-NP O
19 812 817 15188772 staff NN I-NP O
20 818 829 15188772 supervision NN I-NP O
21 829 830 15188772 . . O O

1 0 0 15278670 -DOCSTART- -X- -X- O

1 0 3 15278670 The DT B-NP O
2 4 11 15278670 effects NNS I-NP O
3 12 14 15278670 of IN B-PP O
4 15 26 15278670 sevoflurane NN B-NP B-Chemical
5 27 29 15278670 on IN B-PP O
6 30 39 15278670 lidocaine NN B-NP B-Chemical
7 39 40 15278670 - HYPH B-NP O
8 40 47 15278670 induced VBN I-NP O
9 48 59 15278670 convulsions NNS I-NP B-Disease
10 59 60 15278670 . . O O
11 61 64 15278670 The DT B-NP O
12 65 74 15278670 influence NN I-NP O
13 75 77 15278670 of IN B-PP O
14 78 89 15278670 sevoflurane NN B-NP B-Chemical
15 90 92 15278670 on IN B-PP O
16 93 102 15278670 lidocaine NN B-NP B-Chemical
17 102 103 15278670 - HYPH B-NP O
18 103 110 15278670 induced VBN I-NP O
19 111 122 15278670 convulsions NNS I-NP B-Disease
20 123 126 15278670 was VBD B-VP O
21 127 134 15278670 studied VBN I-VP O
22 135 137 15278670 in IN B-PP O
23 138 142 15278670 cats NNS B-NP O
24 142 143 15278670 . . O O

1 144 147 15278670 The DT B-NP O
2 148 158 15278670 convulsive JJ I-NP B-Disease
3 159 168 15278670 threshold NN I-NP O
4 169 170 15278670 ( ( O O
5 170 174 15278670 mean NN B-NP O
6 175 176 15278670 + SYM O O
7 176 177 15278670 / SYM B-NP O
8 177 178 15278670 - HYPH B-NP O
9 179 181 15278670 SD NN I-NP O
10 181 182 15278670 ) ) O O
11 183 186 15278670 was VBD B-VP O
12 187 191 15278670 41.4 CD B-NP O
13 192 193 15278670 + SYM O O
14 193 194 15278670 / SYM O O
15 194 195 15278670 - SYM O O
16 196 199 15278670 6.5 CD B-NP O
17 200 202 15278670 mg NN I-NP O
18 202 203 15278670 . . O O

1 204 206 15278670 l( AFX B-NP O
2 206 207 15278670 - HYPH I-NP O
3 207 209 15278670 1) LS B-LST O
4 210 214 15278670 with IN B-PP O
5 215 224 15278670 lidocaine NN B-NP B-Chemical
6 225 233 15278670 infusion NN I-NP O
7 234 235 15278670 ( ( O O
8 235 236 15278670 6 CD B-NP O
9 237 243 15278670 mg.kg( NN I-NP O
10 243 244 15278670 - HYPH B-NP O
11 244 251 15278670 1).min( CD I-NP O
12 251 252 15278670 - HYPH I-NP O
13 252 254 15278670 1) NN I-NP O
14 254 255 15278670 ) ) O O
15 255 256 15278670 , , O O
16 257 267 15278670 increasing VBG B-VP O
17 268 281 15278670 significantly RB B-ADVP O
18 282 284 15278670 to TO B-PP O
19 285 289 15278670 66.6 CD B-NP O
20 290 291 15278670 + SYM O O
21 291 292 15278670 / SYM O O
22 292 293 15278670 - SYM O O
23 294 298 15278670 10.9 CD B-NP O
24 299 301 15278670 mg NN I-NP O
25 301 302 15278670 . . O O

1 303 305 15278670 l( AFX B-NP O
2 305 306 15278670 - HYPH I-NP O
3 306 308 15278670 1) LS B-LST O
4 309 313 15278670 when WRB B-ADVP O
5 314 317 15278670 the DT B-NP O
6 318 321 15278670 end NN I-NP O
7 321 322 15278670 - HYPH B-NP O
8 322 327 15278670 tidal JJ I-NP O
9 328 341 15278670 concentration NN I-NP O
10 342 344 15278670 of IN B-PP O
11 345 356 15278670 sevoflurane NN B-NP B-Chemical
12 357 360 15278670 was VBD B-VP O
13 361 365 15278670 0.8% CD B-NP O
14 365 366 15278670 . . O O

1 367 374 15278670 However RB B-ADVP O
2 374 375 15278670 , , O O
3 376 379 15278670 the DT B-NP O
4 380 389 15278670 threshold NN I-NP O
5 390 391 15278670 ( ( O O
6 391 395 15278670 61.6 CD B-NP O
7 396 397 15278670 + SYM O O
8 397 398 15278670 / SYM O O
9 398 399 15278670 - SYM O O
10 400 403 15278670 8.7 CD B-NP O
11 404 406 15278670 mg NN I-NP O
12 406 407 15278670 . . O O

1 408 410 15278670 l( AFX B-NP O
2 410 411 15278670 - HYPH I-NP O
3 411 413 15278670 1) LS B-LST O
4 413 414 15278670 ) ) O O
5 415 421 15278670 during IN B-PP O
6 422 426 15278670 1.6% CD B-NP O
7 427 438 15278670 sevoflurane NN I-NP B-Chemical
8 439 442 15278670 was VBD B-VP O
9 443 446 15278670 not RB O O
10 447 458 15278670 significant JJ B-ADJP O
11 459 463 15278670 from IN B-PP O
12 464 468 15278670 that DT B-NP O
13 469 475 15278670 during IN B-PP O
14 476 480 15278670 0.8% CD B-NP O
15 481 492 15278670 sevoflurane NN I-NP B-Chemical
16 492 493 15278670 , , O O
17 494 504 15278670 indicating VBG B-VP O
18 505 506 15278670 a DT B-NP O
19 507 514 15278670 celling NN I-NP O
20 515 521 15278670 effect NN I-NP O
21 521 522 15278670 . . O O

1 523 528 15278670 There EX B-NP O
2 529 532 15278670 was VBD B-VP O
3 533 535 15278670 no DT B-NP O
4 536 547 15278670 significant JJ I-NP O
5 548 558 15278670 difference NN I-NP O
6 559 561 15278670 in IN B-PP O
7 562 565 15278670 the DT B-NP O
8 566 576 15278670 convulsive JJ I-NP B-Disease
9 577 586 15278670 threshold NN I-NP O
10 587 594 15278670 between IN B-PP O
11 595 606 15278670 sevoflurane NN B-NP B-Chemical
12 607 610 15278670 and CC I-NP O
13 611 620 15278670 enflurane NN I-NP B-Chemical
14 620 621 15278670 . . O O

1 622 625 15278670 The DT B-NP O
2 626 630 15278670 rise NN I-NP O
3 631 633 15278670 in IN B-PP O
4 634 639 15278670 blood NN B-NP O
5 640 648 15278670 pressure NN I-NP O
6 649 655 15278670 became VBD B-VP O
7 656 660 15278670 less RBR B-ADJP O
8 661 667 15278670 marked JJ I-ADJP O
9 668 672 15278670 when WRB B-ADVP O
10 673 679 15278670 higher JJR B-NP O
11 680 694 15278670 concentrations NNS I-NP O
12 695 697 15278670 of IN B-PP O
13 698 709 15278670 sevoflurane NN B-NP B-Chemical
14 710 712 15278670 or CC I-NP O
15 713 722 15278670 enflurane NN I-NP B-Chemical
16 723 727 15278670 were VBD B-VP O
17 728 740 15278670 administered VBN I-VP O
18 741 744 15278670 and CC O O
19 745 748 15278670 the DT B-NP O
20 749 754 15278670 blood NN I-NP O
21 755 763 15278670 pressure NN I-NP O
22 764 766 15278670 at IN B-PP O
23 767 778 15278670 convulsions NNS B-NP B-Disease
24 779 788 15278670 decreased VBD B-VP O
25 789 802 15278670 significantly RB B-ADVP O
26 803 805 15278670 in IN B-PP O
27 806 810 15278670 1.6% CD B-NP O
28 811 822 15278670 sevoflurane NN I-NP B-Chemical
29 822 823 15278670 , , O O
30 824 827 15278670 and CC O O
31 828 830 15278670 in IN B-PP O
32 831 835 15278670 0.8% CD B-NP O
33 836 839 15278670 and CC I-NP O
34 840 844 15278670 1.6% CD I-NP O
35 845 854 15278670 enflurane NN I-NP B-Chemical
36 854 855 15278670 . . O O

1 856 863 15278670 However RB B-ADVP O
2 863 864 15278670 , , O O
3 865 870 15278670 there EX B-NP O
4 871 874 15278670 was VBD B-VP O
5 875 877 15278670 no DT B-NP O
6 878 889 15278670 significant JJ I-NP O
7 890 900 15278670 difference NN I-NP O
8 901 903 15278670 in IN B-PP O
9 904 907 15278670 the DT B-NP O
10 908 917 15278670 lidocaine NN I-NP B-Chemical
11 918 932 15278670 concentrations NNS I-NP O
12 933 941 15278670 measured VBN B-VP O
13 942 946 15278670 when WRB B-ADVP O
14 947 950 15278670 the DT B-NP O
15 951 959 15278670 systolic JJ I-NP O
16 960 965 15278670 blood NN I-NP O
17 966 974 15278670 pressure NN I-NP O
18 975 981 15278670 became VBD B-VP O
19 982 984 15278670 70 CD B-NP O
20 985 989 15278670 mmHg NN I-NP O
21 989 990 15278670 . . O O

1 991 997 15278670 Apamin NN B-NP B-Chemical
2 997 998 15278670 , , O O
3 999 1000 15278670 a DT B-NP O
4 1001 1010 15278670 selective JJ I-NP O
5 1011 1018 15278670 blocker NN I-NP O
6 1019 1021 15278670 of IN B-PP O
7 1022 1029 15278670 calcium NN B-NP B-Chemical
8 1029 1030 15278670 - HYPH B-NP O
9 1030 1039 15278670 dependent JJ I-NP O
10 1040 1049 15278670 potassium NN I-NP B-Chemical
11 1050 1058 15278670 channels NNS I-NP O
12 1058 1059 15278670 , , O O
13 1060 1063 15278670 was VBD B-VP O
14 1064 1076 15278670 administered VBN I-VP O
15 1077 1102 15278670 intracerebroventricularly RB B-ADVP O
16 1103 1105 15278670 in IN B-PP O
17 1106 1110 15278670 rats NNS B-NP O
18 1111 1123 15278670 anesthetized VBN B-VP O
19 1124 1128 15278670 with IN B-PP O
20 1129 1133 15278670 0.8% CD B-NP O
21 1134 1145 15278670 sevoflurane NN I-NP B-Chemical
22 1146 1148 15278670 to TO B-VP O
23 1149 1160 15278670 investigate VB I-VP O
24 1161 1164 15278670 the DT B-NP O
25 1165 1174 15278670 mechanism NN I-NP O
26 1175 1177 15278670 of IN B-PP O
27 1178 1181 15278670 the DT B-NP O
28 1182 1196 15278670 anticonvulsive JJ I-NP O
29 1197 1204 15278670 effects NNS I-NP O
30 1204 1205 15278670 . . O O

1 1206 1212 15278670 Apamin NN B-NP B-Chemical
2 1213 1214 15278670 ( ( O O
3 1214 1216 15278670 10 CD B-NP O
4 1217 1219 15278670 ng NN I-NP O
5 1219 1220 15278670 ) ) O O
6 1221 1224 15278670 had VBD B-VP O
7 1225 1226 15278670 a DT B-NP O
8 1227 1235 15278670 tendency NN I-NP O
9 1236 1238 15278670 to TO B-VP O
10 1239 1247 15278670 decrease VB I-VP O
11 1248 1251 15278670 the DT B-NP O
12 1252 1262 15278670 convulsive JJ I-NP B-Disease
13 1263 1272 15278670 threshold NN I-NP O
14 1273 1274 15278670 ( ( O O
15 1274 1278 15278670 21.6 CD B-NP O
16 1279 1280 15278670 + SYM O O
17 1280 1281 15278670 / SYM O O
18 1281 1282 15278670 - SYM O O
19 1283 1286 15278670 2.2 CD B-NP O
20 1287 1289 15278670 to TO B-PP O
21 1290 1294 15278670 19.9 CD B-NP O
22 1295 1296 15278670 + SYM O O
23 1296 1297 15278670 / SYM O O
24 1297 1298 15278670 - SYM O O
25 1299 1302 15278670 2.5 CD B-NP O
26 1303 1305 15278670 mg NN I-NP O
27 1305 1306 15278670 . . O O

1 1307 1309 15278670 l( AFX B-NP O
2 1309 1310 15278670 - HYPH I-NP O
3 1310 1312 15278670 1) LS B-LST O
4 1312 1313 15278670 ) ) O O
5 1314 1317 15278670 but CC O O
6 1318 1322 15278670 this DT B-NP O
7 1323 1326 15278670 was VBD B-VP O
8 1327 1330 15278670 not RB O O
9 1331 1344 15278670 statistically RB B-ADJP O
10 1345 1356 15278670 significant JJ I-ADJP O
11 1356 1357 15278670 . . O O

1 1358 1360 15278670 It PRP B-NP O
2 1361 1363 15278670 is VBZ B-VP O
3 1364 1373 15278670 suggested VBN I-VP O
4 1374 1378 15278670 that IN B-SBAR O
5 1379 1390 15278670 sevoflurane NN B-NP B-Chemical
6 1391 1398 15278670 reduces VBZ B-VP O
7 1399 1402 15278670 the DT B-NP O
8 1403 1413 15278670 convulsive JJ I-NP B-Disease
9 1414 1420 15278670 effect NN I-NP O
10 1421 1423 15278670 of IN B-PP O
11 1424 1433 15278670 lidocaine NN B-NP B-Chemical
12 1434 1442 15278670 toxicity NN I-NP B-Disease
13 1443 1446 15278670 but CC O O
14 1447 1454 15278670 carries VBZ B-VP O
15 1455 1459 15278670 some DT B-NP O
16 1460 1464 15278670 risk NN I-NP O
17 1465 1468 15278670 due JJ B-ADJP O
18 1469 1471 15278670 to TO B-PP O
19 1472 1483 15278670 circulatory JJ B-NP O
20 1484 1494 15278670 depression NN I-NP B-Disease
21 1494 1495 15278670 . . O O

1 0 0 8558192 -DOCSTART- -X- -X- O

1 0 5 8558192 Phase NN B-NP O
2 6 8 8558192 II CD I-NP O
3 9 14 8558192 trial NN I-NP O
4 15 17 8558192 of IN B-PP O
5 18 29 8558192 vinorelbine NN B-NP B-Chemical
6 30 32 8558192 in IN B-PP O
7 33 43 8558192 metastatic JJ B-NP O
8 44 52 8558192 squamous JJ I-NP B-Disease
9 53 57 8558192 cell NN I-NP I-Disease
10 58 68 8558192 esophageal JJ I-NP I-Disease
11 69 78 8558192 carcinoma NN I-NP I-Disease
12 78 79 8558192 . . O O

1 80 88 8558192 European NNP B-NP O
2 89 101 8558192 Organization NNP I-NP O
3 102 105 8558192 for IN B-PP O
4 106 114 8558192 Research NNP B-NP O
5 115 118 8558192 and CC I-NP O
6 119 128 8558192 Treatment NNP I-NP O
7 129 131 8558192 of IN B-PP O
8 132 138 8558192 Cancer NNP B-NP B-Disease
9 139 155 8558192 Gastrointestinal NNP I-NP O
10 156 161 8558192 Treat NNP I-NP O
11 162 168 8558192 Cancer NNP I-NP B-Disease
12 169 180 8558192 Cooperative NNP I-NP O
13 181 186 8558192 Group NNP I-NP O
14 186 187 8558192 . . I-NP O
15 188 195 8558192 PURPOSE NNP I-NP O
16 195 196 8558192 : : O O
17 197 199 8558192 To TO B-VP O
18 200 208 8558192 evaluate VB I-VP O
19 209 212 8558192 the DT B-NP O
20 213 221 8558192 response NN I-NP O
21 222 226 8558192 rate NN I-NP O
22 227 230 8558192 and CC O O
23 231 236 8558192 toxic JJ B-NP O
24 237 244 8558192 effects NNS I-NP O
25 245 247 8558192 of IN B-PP O
26 248 259 8558192 vinorelbine NN B-NP B-Chemical
27 260 261 8558192 ( ( O O
28 261 264 8558192 VNB NN B-NP B-Chemical
29 264 265 8558192 ) ) O O
30 266 278 8558192 administered VBN B-VP O
31 279 281 8558192 as IN B-PP O
32 282 283 8558192 a DT B-NP O
33 284 290 8558192 single JJ I-NP O
34 291 296 8558192 agent NN I-NP O
35 297 299 8558192 in IN B-PP O
36 300 310 8558192 metastatic JJ B-NP O
37 311 319 8558192 squamous JJ I-NP B-Disease
38 320 324 8558192 cell NN I-NP I-Disease
39 325 335 8558192 esophageal JJ I-NP I-Disease
40 336 345 8558192 carcinoma NN I-NP I-Disease
41 345 346 8558192 . . O O

1 347 355 8558192 PATIENTS NNS B-NP O
2 356 359 8558192 AND CC I-NP O
3 360 367 8558192 METHODS NNS I-NP O
4 367 368 8558192 : : O O
5 369 374 8558192 Forty CD B-NP O
6 374 375 8558192 - HYPH I-NP O
7 375 378 8558192 six CD I-NP O
8 379 387 8558192 eligible JJ I-NP O
9 388 396 8558192 patients NNS I-NP O
10 397 401 8558192 with IN B-PP O
11 402 412 8558192 measurable JJ B-NP O
12 413 420 8558192 lesions NNS I-NP O
13 421 425 8558192 were VBD B-VP O
14 426 434 8558192 included VBN I-VP O
15 435 438 8558192 and CC O O
16 439 443 8558192 were VBD B-VP O
17 444 454 8558192 stratified VBN I-VP O
18 455 464 8558192 according VBG B-PP O
19 465 467 8558192 to TO B-PP O
20 468 476 8558192 previous JJ B-NP O
21 477 489 8558192 chemotherapy NN I-NP O
22 489 490 8558192 . . O O

1 491 497 8558192 Thirty CD B-NP O
2 498 506 8558192 patients NNS I-NP O
3 507 514 8558192 without IN B-PP O
4 515 520 8558192 prior JJ B-NP O
5 521 533 8558192 chemotherapy NN I-NP O
6 534 537 8558192 and CC O O
7 538 540 8558192 16 CD B-NP O
8 541 551 8558192 pretreated VBN B-VP O
9 552 556 8558192 with IN B-PP O
10 557 566 8558192 cisplatin NN B-NP B-Chemical
11 566 567 8558192 - HYPH B-NP O
12 567 572 8558192 based VBN I-NP O
13 573 585 8558192 chemotherapy NN I-NP O
14 586 590 8558192 were VBD B-VP O
15 591 601 8558192 assessable JJ B-ADJP O
16 602 605 8558192 for IN B-PP O
17 606 614 8558192 toxicity NN B-NP B-Disease
18 615 618 8558192 and CC I-NP O
19 619 627 8558192 response NN I-NP O
20 627 628 8558192 . . O O

1 629 632 8558192 VNB NN B-NP B-Chemical
2 633 636 8558192 was VBD B-VP O
3 637 649 8558192 administered VBN I-VP O
4 650 656 8558192 weekly RB B-ADVP O
5 657 659 8558192 as IN B-PP O
6 660 661 8558192 a DT B-NP O
7 662 664 8558192 25 CD I-NP O
8 664 665 8558192 - HYPH I-NP O
9 665 667 8558192 mg NN I-NP O
10 667 668 8558192 / SYM B-NP O
11 668 670 8558192 m2 NN I-NP O
12 671 676 8558192 short JJ B-NP O
13 677 688 8558192 intravenous JJ I-NP O
14 689 690 8558192 ( ( O O
15 690 693 8558192 i.v JJ O O
16 693 694 8558192 . . O O
17 694 695 8558192 ) ) O O
18 696 704 8558192 infusion NN B-NP O
19 704 705 8558192 . . O O

1 706 713 8558192 RESULTS NNS B-NP O
2 713 714 8558192 : : O O
3 715 718 8558192 Six CD B-NP O
4 719 721 8558192 of IN B-PP O
5 722 724 8558192 30 CD B-NP O
6 725 733 8558192 patients NNS I-NP O
7 734 735 8558192 ( ( B-LST O
8 735 738 8558192 20% LS I-LST O
9 738 739 8558192 ) ) O O
10 740 747 8558192 without IN B-PP O
11 748 753 8558192 prior JJ B-NP O
12 754 766 8558192 chemotherapy NN I-NP O
13 767 775 8558192 achieved VBD B-VP O
14 776 777 8558192 a DT B-NP O
15 778 785 8558192 partial JJ I-NP O
16 786 794 8558192 response NN I-NP O
17 795 796 8558192 ( ( O O
18 796 798 8558192 PR NN B-NP O
19 798 799 8558192 ) ) O O
20 800 801 8558192 ( ( O O
21 801 804 8558192 95% CD B-NP O
22 805 815 8558192 confidence NN I-NP O
23 816 824 8558192 interval NN I-NP O
24 825 826 8558192 [ ( O O
25 826 828 8558192 CI NN B-NP O
26 828 829 8558192 ] ) O O
27 829 830 8558192 , , O O
28 831 833 8558192 8% CD B-NP O
29 834 836 8558192 to TO B-PP O
30 837 840 8558192 39% CD B-NP O
31 840 841 8558192 ) ) O O
32 841 842 8558192 . . O O

1 843 846 8558192 The DT B-NP O
2 847 853 8558192 median JJ I-NP O
3 854 862 8558192 duration NN I-NP O
4 863 865 8558192 of IN B-PP O
5 866 874 8558192 response NN B-NP O
6 875 878 8558192 was VBD B-VP O
7 879 881 8558192 21 CD B-NP O
8 882 887 8558192 weeks NNS I-NP O
9 888 889 8558192 ( ( O O
10 889 894 8558192 range NN B-NP O
11 894 895 8558192 , , O O
12 896 898 8558192 17 CD B-NP O
13 899 901 8558192 to TO B-PP O
14 902 904 8558192 28 CD B-NP O
15 904 905 8558192 ) ) O O
16 905 906 8558192 . . O O

1 907 910 8558192 One CD B-NP O
2 911 913 8558192 of IN B-PP O
3 914 916 8558192 16 CD B-NP O
4 917 925 8558192 patients NNS I-NP O
5 926 927 8558192 ( ( B-LST O
6 927 929 8558192 6% LS I-LST O
7 929 930 8558192 ) ) O O
8 931 935 8558192 with IN B-PP O
9 936 941 8558192 prior JJ B-NP O
10 942 954 8558192 chemotherapy NN I-NP O
11 955 958 8558192 had VBD B-VP O
12 959 960 8558192 a DT B-NP O
13 961 969 8558192 complete JJ I-NP O
14 970 978 8558192 response NN I-NP O
15 979 980 8558192 ( ( O O
16 980 982 8558192 CR NN B-NP O
17 982 983 8558192 ) ) O O
18 984 986 8558192 of IN B-PP O
19 987 989 8558192 31 CD B-NP O
20 990 995 8558192 weeks NNS I-NP O
21 995 996 8558192 ' POS B-NP O
22 997 1005 8558192 duration NN I-NP O
23 1006 1007 8558192 ( ( O O
24 1007 1010 8558192 95% CD B-NP O
25 1011 1013 8558192 CI NN I-NP O
26 1013 1014 8558192 , , O O
27 1015 1017 8558192 0% CD B-NP O
28 1018 1020 8558192 to TO B-PP O
29 1021 1024 8558192 30% CD B-NP O
30 1024 1025 8558192 ) ) O O
31 1025 1026 8558192 . . O O

1 1027 1030 8558192 The DT B-NP O
2 1031 1038 8558192 overall JJ I-NP O
3 1039 1047 8558192 response NN I-NP O
4 1048 1052 8558192 rate NN I-NP O
5 1053 1054 8558192 ( ( O O
6 1054 1059 8558192 World NNP B-NP O
7 1060 1066 8558192 Health NNP I-NP O
8 1067 1079 8558192 Organization NNP I-NP O
9 1080 1081 8558192 [ ( O O
10 1081 1084 8558192 WHO WP B-NP O
11 1084 1085 8558192 ] ) O O
12 1086 1094 8558192 criteria NNS B-NP O
13 1094 1095 8558192 ) ) O O
14 1096 1099 8558192 was VBD B-VP O
15 1100 1103 8558192 15% NN B-NP O
16 1104 1105 8558192 ( ( O O
17 1105 1107 8558192 CR NN B-NP O
18 1107 1108 8558192 , , O O
19 1109 1111 8558192 2% NN B-NP O
20 1111 1112 8558192 ; : O O
21 1113 1115 8558192 PR NN B-NP O
22 1116 1119 8558192 13% CD I-NP O
23 1119 1120 8558192 ; : O O
24 1121 1124 8558192 95% CD B-NP O
25 1125 1127 8558192 CI NN I-NP O
26 1127 1128 8558192 , , O O
27 1129 1131 8558192 6% CD B-NP O
28 1132 1134 8558192 to TO B-PP O
29 1135 1138 8558192 29% CD B-NP O
30 1138 1139 8558192 ) ) O O
31 1139 1140 8558192 . . O O

1 1141 1144 8558192 The DT B-NP O
2 1145 1151 8558192 median JJ I-NP O
3 1152 1156 8558192 dose NN I-NP O
4 1156 1157 8558192 - HYPH O O
5 1157 1166 8558192 intensity NN B-NP O
6 1167 1168 8558192 ( ( O O
7 1168 1170 8558192 DI NN B-NP O
8 1170 1171 8558192 ) ) O O
9 1172 1175 8558192 was VBD B-VP O
10 1176 1178 8558192 20 CD B-NP O
11 1179 1181 8558192 mg NN I-NP O
12 1181 1182 8558192 / SYM B-NP O
13 1182 1184 8558192 m2 NN I-NP O
14 1184 1185 8558192 / SYM I-NP O
15 1185 1187 8558192 wk NN I-NP O
16 1187 1188 8558192 . . O O

1 1189 1192 8558192 VNB NN B-NP B-Chemical
2 1193 1196 8558192 was VBD B-VP O
3 1197 1201 8558192 well RB I-VP O
4 1202 1211 8558192 tolerated VBN I-VP O
5 1212 1215 8558192 and CC O O
6 1216 1220 8558192 zero CD B-NP O
7 1221 1230 8558192 instances NNS I-NP O
8 1231 1233 8558192 of IN B-PP O
9 1234 1237 8558192 WHO NN B-NP O
10 1238 1243 8558192 grade NN I-NP O
11 1244 1245 8558192 4 CD I-NP O
12 1246 1260 8558192 nonhematologic JJ I-NP O
13 1261 1269 8558192 toxicity NN I-NP B-Disease
14 1270 1278 8558192 occurred VBD B-VP O
15 1278 1279 8558192 . . O O

1 1280 1282 8558192 At IN B-NP O
2 1283 1288 8558192 least JJS I-NP O
3 1289 1292 8558192 one CD I-NP O
4 1293 1300 8558192 episode NN I-NP O
5 1301 1303 8558192 of IN B-PP O
6 1304 1309 8558192 grade NN B-NP O
7 1310 1311 8558192 3 CD I-NP O
8 1312 1314 8558192 or CC I-NP O
9 1315 1316 8558192 4 CD I-NP O
10 1317 1333 8558192 granulocytopenia NN I-NP B-Disease
11 1334 1337 8558192 was VBD B-VP O
12 1338 1342 8558192 seen VBN I-VP O
13 1343 1345 8558192 in IN B-PP O
14 1346 1349 8558192 59% NN B-NP O
15 1350 1352 8558192 of IN B-PP O
16 1353 1361 8558192 patients NNS B-NP O
17 1361 1362 8558192 . . O O

1 1363 1364 8558192 A DT B-NP O
2 1365 1370 8558192 grade NN I-NP O
3 1371 1372 8558192 2 CD I-NP O
4 1373 1375 8558192 or CC I-NP O
5 1376 1377 8558192 3 CD I-NP O
6 1378 1387 8558192 infection NN I-NP B-Disease
7 1388 1396 8558192 occurred VBD B-VP O
8 1397 1399 8558192 in IN B-PP O
9 1400 1403 8558192 16% NN B-NP O
10 1404 1406 8558192 of IN B-PP O
11 1407 1415 8558192 patients NNS B-NP O
12 1415 1416 8558192 , , O O
13 1417 1420 8558192 but CC O O
14 1421 1423 8558192 no DT B-NP O
15 1424 1429 8558192 toxic JJ I-NP O
16 1430 1436 8558192 deaths NNS I-NP B-Disease
17 1437 1445 8558192 occurred VBD B-VP O
18 1445 1446 8558192 . . O O

1 1447 1452 8558192 Other JJ B-NP O
2 1453 1457 8558192 side NN I-NP O
3 1458 1465 8558192 effects NNS I-NP O
4 1466 1470 8558192 were VBD B-VP O
5 1471 1475 8558192 rare JJ B-ADJP O
6 1475 1476 8558192 , , O O
7 1477 1480 8558192 and CC O O
8 1481 1491 8558192 peripheral JJ B-NP B-Disease
9 1492 1505 8558192 neurotoxicity NN I-NP I-Disease
10 1506 1509 8558192 has VBZ B-VP O
11 1510 1514 8558192 been VBN I-VP O
12 1515 1520 8558192 minor JJ B-ADJP O
13 1521 1522 8558192 ( ( O O
14 1522 1525 8558192 26% CD B-NP O
15 1526 1531 8558192 grade NN I-NP O
16 1532 1533 8558192 1 CD I-NP O
17 1533 1534 8558192 ) ) O O
18 1534 1535 8558192 . . O O

1 1536 1546 8558192 CONCLUSION NN B-NP O
2 1546 1547 8558192 : : O O
3 1548 1553 8558192 These DT B-NP O
4 1554 1558 8558192 data NNS I-NP O
5 1559 1567 8558192 indicate VBP B-VP O
6 1568 1572 8558192 that IN B-SBAR O
7 1573 1576 8558192 VNB NN B-NP B-Chemical
8 1577 1579 8558192 is VBZ B-VP O
9 1580 1582 8558192 an DT B-NP O
10 1583 1589 8558192 active JJ I-NP O
11 1590 1595 8558192 agent NN I-NP O
12 1596 1598 8558192 in IN B-PP O
13 1599 1609 8558192 metastatic JJ B-NP O
14 1610 1620 8558192 esophageal JJ I-NP B-Disease
15 1621 1629 8558192 squamous JJ I-NP I-Disease
16 1630 1634 8558192 cell NN I-NP I-Disease
17 1635 1644 8558192 carcinoma NN I-NP I-Disease
18 1644 1645 8558192 . . O O

1 1646 1651 8558192 Given VBN B-VP O
2 1652 1655 8558192 its PRP$ B-NP O
3 1656 1665 8558192 excellent JJ I-NP O
4 1666 1675 8558192 tolerance NN I-NP O
5 1676 1683 8558192 profile NN I-NP O
6 1684 1687 8558192 and CC O O
7 1688 1691 8558192 low JJ B-NP O
8 1692 1700 8558192 toxicity NN I-NP B-Disease
9 1700 1701 8558192 , , O O
10 1702 1709 8558192 further JJ B-NP O
11 1710 1720 8558192 evaluation NN I-NP O
12 1721 1723 8558192 of IN B-PP O
13 1724 1727 8558192 VNB NN B-NP B-Chemical
14 1728 1730 8558192 in IN B-PP O
15 1731 1742 8558192 combination NN B-NP O
16 1743 1750 8558192 therapy NN I-NP O
17 1751 1753 8558192 is VBZ B-VP O
18 1754 1763 8558192 warranted VBN I-VP O
19 1763 1764 8558192 . . O O

1 0 0 10457883 -DOCSTART- -X- -X- O

1 0 14 10457883 Recurarization NN B-NP O
2 15 17 10457883 in IN B-PP O
3 18 21 10457883 the DT B-NP O
4 22 30 10457883 recovery NN I-NP O
5 31 35 10457883 room NN I-NP O
6 35 36 10457883 . . O O
7 37 38 10457883 A DT B-NP O
8 39 43 10457883 case NN I-NP O
9 44 46 10457883 of IN B-PP O
10 47 61 10457883 recurarization NN B-NP O
11 62 64 10457883 in IN B-PP O
12 65 68 10457883 the DT B-NP O
13 69 77 10457883 recovery NN I-NP O
14 78 82 10457883 room NN I-NP O
15 83 85 10457883 is VBZ B-VP O
16 86 94 10457883 reported VBN I-VP O
17 94 95 10457883 . . O O

1 96 108 10457883 Accumulation NN B-NP O
2 109 111 10457883 of IN B-PP O
3 112 122 10457883 atracurium NN B-NP B-Chemical
4 123 125 10457883 in IN B-PP O
5 126 129 10457883 the DT B-NP O
6 130 141 10457883 intravenous JJ I-NP O
7 142 146 10457883 line NN I-NP O
8 147 150 10457883 led VBD B-VP O
9 151 153 10457883 to TO B-PP O
10 154 168 10457883 recurarization NN B-NP O
11 169 174 10457883 after IN B-PP O
12 175 183 10457883 flushing VBG B-VP O
13 184 187 10457883 the DT B-NP O
14 188 192 10457883 line NN I-NP O
15 193 195 10457883 in IN B-PP O
16 196 199 10457883 the DT B-NP O
17 200 208 10457883 recovery NN I-NP O
18 209 213 10457883 room NN I-NP O
19 213 214 10457883 . . O O

1 215 216 10457883 A DT B-NP O
2 217 228 10457883 respiratory JJ I-NP B-Disease
3 229 235 10457883 arrest NN I-NP I-Disease
4 236 240 10457883 with IN B-PP O
5 241 247 10457883 severe JJ B-NP O
6 248 260 10457883 desaturation NN I-NP B-Disease
7 261 264 10457883 and CC I-NP O
8 265 276 10457883 bradycardia NN I-NP B-Disease
9 277 285 10457883 occurred VBD B-VP O
10 285 286 10457883 . . O O

1 287 300 10457883 Circumstances NNS B-NP O
2 301 308 10457883 leading VBG B-VP O
3 309 311 10457883 to TO B-PP O
4 312 316 10457883 this DT B-NP O
5 317 322 10457883 event NN I-NP O
6 323 326 10457883 and CC O O
7 327 330 10457883 the DT B-NP O
8 331 341 10457883 mechanisms NNS I-NP O
9 342 350 10457883 enabling VBG B-VP O
10 351 352 10457883 a DT B-NP O
11 353 366 10457883 neuromuscular JJ I-NP B-Disease
12 367 375 10457883 blockade NN I-NP I-Disease
13 376 378 10457883 to TO B-VP O
14 379 384 10457883 occur VB I-VP O
15 384 385 10457883 , , O O
16 386 395 10457883 following VBG B-PP O
17 396 399 10457883 the DT B-NP O
18 400 414 10457883 administration NN I-NP O
19 415 417 10457883 of IN B-PP O
20 418 419 10457883 a DT B-NP O
21 420 425 10457883 small JJ I-NP O
22 426 430 10457883 dose NN I-NP O
23 431 433 10457883 of IN B-PP O
24 434 442 10457883 relaxant NN B-NP O
25 442 443 10457883 , , O O
26 444 447 10457883 are VBP B-VP O
27 448 457 10457883 discussed VBN I-VP O
28 457 458 10457883 . . O O

1 0 0 2515254 -DOCSTART- -X- -X- O

1 0 6 2515254 Source NN B-NP O
2 7 9 2515254 of IN B-PP O
3 10 14 2515254 pain NN B-NP B-Disease
4 15 18 2515254 and CC O O
5 19 28 2515254 primitive JJ B-NP O
6 29 40 2515254 dysfunction NN I-NP O
7 41 43 2515254 in IN B-PP O
8 44 52 2515254 migraine NN B-NP B-Disease
9 52 53 2515254 : : O O
10 54 56 2515254 an DT B-NP O
11 57 66 2515254 identical JJ I-NP O
12 67 71 2515254 site NN I-NP O
13 71 72 2515254 ? . O O
14 73 79 2515254 Twenty CD B-NP O
15 80 86 2515254 common JJ I-NP O
16 87 95 2515254 migraine NN I-NP B-Disease
17 96 104 2515254 patients NNS I-NP O
18 105 113 2515254 received VBD B-VP O
19 114 115 2515254 a DT B-NP O
20 116 119 2515254 one CD I-NP O
21 120 125 2515254 sided JJ I-NP O
22 126 140 2515254 frontotemporal JJ I-NP O
23 141 152 2515254 application NN I-NP O
24 153 155 2515254 of IN B-PP O
25 156 169 2515254 nitroglycerin NN B-NP B-Chemical
26 170 171 2515254 ( ( O O
27 171 173 2515254 10 CD B-NP O
28 174 182 2515254 patients NNS I-NP O
29 182 183 2515254 ) ) O O
30 184 186 2515254 or CC O O
31 187 194 2515254 placebo NN B-NP O
32 195 203 2515254 ointment NN I-NP O
33 204 205 2515254 ( ( O O
34 205 207 2515254 10 CD B-NP O
35 208 216 2515254 patients NNS I-NP O
36 216 217 2515254 ) ) O O
37 218 220 2515254 in IN B-PP O
38 221 222 2515254 a DT B-NP O
39 223 229 2515254 double JJ I-NP O
40 230 235 2515254 blind JJ I-NP O
41 236 241 2515254 study NN I-NP O
42 241 242 2515254 . . O O

1 243 248 2515254 Early JJ B-NP O
2 249 254 2515254 onset NN I-NP O
3 255 263 2515254 migraine NN I-NP B-Disease
4 264 271 2515254 attacks NNS I-NP O
5 272 276 2515254 were VBD B-VP O
6 277 284 2515254 induced VBN I-VP O
7 285 287 2515254 by IN B-PP O
8 288 301 2515254 nitroglycerin NN B-NP B-Chemical
9 302 304 2515254 in IN B-PP O
10 305 310 2515254 seven CD B-NP O
11 311 314 2515254 out IN I-NP O
12 315 317 2515254 of IN I-NP O
13 318 320 2515254 10 CD I-NP O
14 321 329 2515254 patients NNS I-NP O
15 330 336 2515254 versus IN B-PP O
16 337 339 2515254 no DT B-NP O
17 340 347 2515254 patient NN I-NP O
18 348 350 2515254 in IN B-PP O
19 351 354 2515254 the DT B-NP O
20 355 362 2515254 placebo NN I-NP O
21 363 368 2515254 group NN I-NP O
22 368 369 2515254 . . O O

1 370 382 2515254 Subsequently RB B-NP O
2 383 385 2515254 20 CD I-NP O
3 386 394 2515254 migraine NN I-NP B-Disease
4 395 403 2515254 patients NNS I-NP O
5 403 404 2515254 , , O O
6 405 408 2515254 who WP B-NP O
7 409 418 2515254 developed VBD B-VP O
8 419 421 2515254 an DT B-NP O
9 422 427 2515254 early JJ I-NP O
10 428 433 2515254 onset NN I-NP O
11 434 440 2515254 attack NN I-NP O
12 441 445 2515254 with IN B-PP O
13 446 460 2515254 frontotemporal JJ B-NP O
14 461 474 2515254 nitroglycerin NN I-NP B-Chemical
15 474 475 2515254 , , O O
16 476 484 2515254 received VBD B-VP O
17 485 488 2515254 the DT B-NP O
18 489 493 2515254 drug NN I-NP O
19 494 496 2515254 in IN B-PP O
20 497 498 2515254 a DT B-NP O
21 499 505 2515254 second JJ I-NP O
22 506 515 2515254 induction NN I-NP O
23 516 520 2515254 test NN I-NP O
24 521 523 2515254 at IN B-PP O
25 524 529 2515254 other JJ B-NP O
26 530 534 2515254 body NN I-NP O
27 535 540 2515254 areas NNS I-NP O
28 540 541 2515254 . . O O

1 542 544 2515254 No DT B-NP O
2 545 550 2515254 early JJ I-NP O
3 551 556 2515254 onset NN I-NP O
4 557 565 2515254 migraine NN I-NP B-Disease
5 566 569 2515254 was VBD B-VP O
6 570 578 2515254 observed VBN I-VP O
7 578 579 2515254 . . O O

1 580 584 2515254 Thus RB B-ADVP O
2 585 588 2515254 the DT B-NP O
3 589 597 2515254 migraine NN I-NP B-Disease
4 597 598 2515254 - HYPH O O
5 598 606 2515254 inducing VBG B-VP O
6 607 613 2515254 effect NN B-NP O
7 614 616 2515254 of IN B-PP O
8 617 630 2515254 nitroglycerin NN B-NP B-Chemical
9 631 636 2515254 seems VBZ B-VP O
10 637 639 2515254 to TO I-VP O
11 640 646 2515254 depend VB I-VP O
12 647 649 2515254 on IN B-PP O
13 650 656 2515254 direct JJ B-NP O
14 657 668 2515254 stimulation NN I-NP O
15 669 671 2515254 of IN B-PP O
16 672 675 2515254 the DT B-NP O
17 676 684 2515254 habitual JJ I-NP O
18 685 689 2515254 site NN I-NP O
19 690 692 2515254 of IN B-PP O
20 693 697 2515254 pain NN B-NP B-Disease
21 697 698 2515254 , , O O
22 699 709 2515254 suggesting VBG B-VP O
23 710 714 2515254 that IN B-SBAR O
24 715 718 2515254 the DT B-NP O
25 719 733 2515254 frontotemporal JJ I-NP O
26 734 740 2515254 region NN I-NP O
27 741 743 2515254 is VBZ B-VP O
28 744 746 2515254 of IN B-PP O
29 747 754 2515254 crucial JJ B-NP O
30 755 765 2515254 importance NN I-NP O
31 766 768 2515254 in IN B-PP O
32 769 772 2515254 the DT B-NP O
33 773 784 2515254 development NN I-NP O
34 785 787 2515254 of IN B-PP O
35 788 789 2515254 a DT B-NP O
36 790 798 2515254 migraine NN I-NP B-Disease
37 799 805 2515254 crisis NN I-NP O
38 805 806 2515254 . . O O

1 807 811 2515254 This DT B-NP O
2 812 814 2515254 is VBZ B-VP O
3 815 818 2515254 not RB O O
4 819 829 2515254 consistent JJ B-ADJP O
5 830 834 2515254 with IN B-PP O
6 835 836 2515254 a DT B-NP O
7 837 840 2515254 CNS NN I-NP O
8 841 847 2515254 origin NN I-NP O
9 848 850 2515254 of IN B-PP O
10 851 859 2515254 migraine NN B-NP B-Disease
11 860 866 2515254 attack NN I-NP O
12 866 867 2515254 . . O O

1 0 0 11426838 -DOCSTART- -X- -X- O

1 0 16 11426838 Conformationally RB B-NP O
2 17 27 11426838 restricted VBN I-NP O
3 28 35 11426838 analogs NNS I-NP O
4 36 38 11426838 of IN B-PP O
5 39 45 11426838 BD1008 NN B-NP B-Chemical
6 46 49 11426838 and CC O O
7 50 52 11426838 an DT B-NP O
8 53 62 11426838 antisense JJ I-NP O
9 63 83 11426838 oligodeoxynucleotide NN I-NP B-Chemical
10 84 93 11426838 targeting VBG B-VP O
11 94 100 11426838 sigma1 NN B-NP O
12 101 110 11426838 receptors NNS I-NP O
13 111 118 11426838 produce VBP B-VP O
14 119 123 11426838 anti AFX B-NP O
15 123 124 11426838 - HYPH I-NP O
16 124 131 11426838 cocaine NN I-NP B-Chemical
17 132 139 11426838 effects NNS I-NP O
18 140 142 11426838 in IN B-PP O
19 143 147 11426838 mice NNS B-NP O
20 147 148 11426838 . . O O
21 149 158 11426838 Cocaine's NNS B-NP B-Chemical
22 159 166 11426838 ability NN I-NP O
23 167 169 11426838 to TO B-VP O
24 170 178 11426838 interact VB I-VP O
25 179 183 11426838 with IN B-PP O
26 184 189 11426838 sigma SYM B-NP O
27 190 199 11426838 receptors NNS I-NP O
28 200 208 11426838 suggests VBZ B-VP O
29 209 213 11426838 that IN B-SBAR O
30 214 219 11426838 these DT B-NP O
31 220 228 11426838 proteins NNS I-NP O
32 229 236 11426838 mediate VBP B-VP O
33 237 241 11426838 some DT B-NP O
34 242 244 11426838 of IN B-PP O
35 245 248 11426838 its PRP$ B-NP O
36 249 259 11426838 behavioral JJ I-NP O
37 260 267 11426838 effects NNS I-NP O
38 267 268 11426838 . . O O

1 269 278 11426838 Therefore RB B-ADVP O
2 278 279 11426838 , , O O
3 280 285 11426838 three CD B-NP O
4 286 291 11426838 novel JJ I-NP O
5 292 297 11426838 sigma NN I-NP O
6 298 306 11426838 receptor NN I-NP O
7 307 314 11426838 ligands NNS I-NP O
8 315 319 11426838 with IN B-PP O
9 320 330 11426838 antagonist NN B-NP O
10 331 339 11426838 activity NN I-NP O
11 340 344 11426838 were VBD B-VP O
12 345 354 11426838 evaluated VBN I-VP O
13 355 357 11426838 in IN B-PP O
14 358 363 11426838 Swiss NNP B-NP O
15 364 371 11426838 Webster NNP I-NP O
16 372 376 11426838 mice NNS I-NP O
17 376 377 11426838 : : O O
18 378 384 11426838 BD1018 NN B-NP B-Chemical
19 385 386 11426838 ( ( O O
20 386 388 11426838 3S NN B-NP B-Chemical
21 388 389 11426838 - HYPH B-NP I-Chemical
22 389 390 11426838 1 CD I-NP I-Chemical
23 390 391 11426838 - HYPH I-NP I-Chemical
24 391 393 11426838 [2 CD I-NP I-Chemical
25 393 394 11426838 - HYPH I-NP I-Chemical
26 394 398 11426838 (3,4 CD I-NP I-Chemical
27 398 399 11426838 - HYPH I-NP I-Chemical
28 399 420 11426838 dichlorophenyl)ethyl] NN I-NP I-Chemical
29 420 421 11426838 - HYPH B-NP I-Chemical
30 421 424 11426838 1,4 CD I-NP I-Chemical
31 424 425 11426838 - HYPH I-NP I-Chemical
32 425 450 11426838 diazabicyclo[4.3.0]nonane NN I-NP I-Chemical
33 450 451 11426838 ) ) O O
34 451 452 11426838 , , O O
35 453 459 11426838 BD1063 NN B-NP B-Chemical
36 460 461 11426838 ( ( O O
37 461 462 11426838 1 CD B-NP B-Chemical
38 462 463 11426838 - HYPH O I-Chemical
39 463 465 11426838 [2 CD B-NP I-Chemical
40 465 466 11426838 - HYPH I-NP I-Chemical
41 466 470 11426838 (3,4 CD I-NP I-Chemical
42 470 471 11426838 - HYPH I-NP I-Chemical
43 471 492 11426838 dichlorophenyl)ethyl] NN I-NP I-Chemical
44 492 493 11426838 - HYPH B-NP I-Chemical
45 493 494 11426838 4 CD I-NP I-Chemical
46 494 495 11426838 - HYPH I-NP I-Chemical
47 495 511 11426838 methylpiperazine NN I-NP I-Chemical
48 511 512 11426838 ) ) O O
49 512 513 11426838 , , O O
50 514 517 11426838 and CC O O
51 518 523 11426838 LR132 NN B-NP B-Chemical
52 524 525 11426838 ( ( O O
53 525 530 11426838 1R,2S NN B-NP O
54 530 531 11426838 - HYPH O O
55 531 534 11426838 (+) SYM B-NP O
56 534 535 11426838 - HYPH B-NP O
57 535 538 11426838 cis NN I-NP O
58 538 539 11426838 - HYPH B-NP O
59 539 540 11426838 N NN I-NP O
60 540 541 11426838 - HYPH B-NP O
61 541 543 11426838 [2 CD I-NP O
62 543 544 11426838 - HYPH I-NP O
63 544 548 11426838 (3,4 CD I-NP O
64 548 549 11426838 - HYPH I-NP O
65 549 570 11426838 dichlorophenyl)ethyl] NN I-NP O
66 570 571 11426838 - HYPH B-NP O
67 571 572 11426838 2 CD I-NP O
68 572 573 11426838 - HYPH I-NP O
69 573 575 11426838 (1 CD I-NP O
70 575 576 11426838 - HYPH I-NP O
71 576 604 11426838 pyrrolidinyl)cyclohexylamine NN I-NP O
72 604 605 11426838 ) ) O O
73 605 606 11426838 . . O O

1 607 618 11426838 Competition NN B-NP O
2 619 626 11426838 binding NN I-NP O
3 627 633 11426838 assays NNS I-NP O
4 634 646 11426838 demonstrated VBD B-VP O
5 647 651 11426838 that IN B-SBAR O
6 652 655 11426838 all DT B-NP O
7 656 661 11426838 three CD I-NP O
8 662 671 11426838 compounds NNS I-NP O
9 672 676 11426838 have VBP B-VP O
10 677 681 11426838 high JJ B-NP O
11 682 692 11426838 affinities NNS I-NP O
12 693 696 11426838 for IN B-PP O
13 697 703 11426838 sigma1 NN B-NP O
14 704 713 11426838 receptors NNS I-NP O
15 713 714 11426838 . . O O

1 715 718 11426838 The DT B-NP O
2 719 724 11426838 three CD I-NP O
3 725 734 11426838 compounds NNS I-NP O
4 735 739 11426838 vary VBP B-VP O
5 740 742 11426838 in IN B-PP O
6 743 748 11426838 their PRP$ B-NP O
7 749 759 11426838 affinities NNS I-NP O
8 760 763 11426838 for IN B-PP O
9 764 770 11426838 sigma2 NN B-NP O
10 771 780 11426838 receptors NNS I-NP O
11 781 784 11426838 and CC O O
12 785 792 11426838 exhibit VBP B-VP O
13 793 803 11426838 negligible JJ B-NP O
14 804 814 11426838 affinities NNS I-NP O
15 815 818 11426838 for IN B-PP O
16 819 827 11426838 dopamine NN B-NP B-Chemical
17 827 828 11426838 , , I-NP O
18 829 835 11426838 opioid NN I-NP O
19 835 836 11426838 , , I-NP O
20 837 844 11426838 GABA(A) NN I-NP B-Chemical
21 845 848 11426838 and CC I-NP O
22 849 853 11426838 NMDA NN I-NP B-Chemical
23 854 863 11426838 receptors NNS I-NP O
24 863 864 11426838 . . O O

1 865 867 11426838 In IN B-PP O
2 868 878 11426838 behavioral JJ B-NP O
3 879 886 11426838 studies NNS I-NP O
4 886 887 11426838 , , O O
5 888 891 11426838 pre AFX B-NP O
6 891 892 11426838 - HYPH I-NP O
7 892 901 11426838 treatment NN I-NP O
8 902 904 11426838 of IN B-PP O
9 905 909 11426838 mice NNS B-NP O
10 910 914 11426838 with IN B-PP O
11 915 921 11426838 BD1018 NN B-NP B-Chemical
12 921 922 11426838 , , O O
13 923 929 11426838 BD1063 NN B-NP B-Chemical
14 929 930 11426838 , , O O
15 931 933 11426838 or CC O O
16 934 939 11426838 LR132 NN B-NP B-Chemical
17 940 953 11426838 significantly RB B-ADVP O
18 954 964 11426838 attenuated VBD B-VP O
19 965 972 11426838 cocaine NN B-NP B-Chemical
20 972 973 11426838 - HYPH B-NP O
21 973 980 11426838 induced VBN I-NP O
22 981 992 11426838 convulsions NNS I-NP B-Disease
23 993 996 11426838 and CC I-NP O
24 997 1006 11426838 lethality NN I-NP O
25 1006 1007 11426838 . . O O

1 1008 1016 11426838 Moreover RB B-ADVP O
2 1016 1017 11426838 , , O O
3 1018 1022 11426838 post AFX B-NP O
4 1022 1023 11426838 - HYPH I-NP O
5 1023 1032 11426838 treatment NN B-NP O
6 1033 1037 11426838 with IN B-PP O
7 1038 1043 11426838 LR132 NN B-NP B-Chemical
8 1044 1053 11426838 prevented VBD B-VP O
9 1054 1061 11426838 cocaine NN B-NP B-Chemical
10 1061 1062 11426838 - HYPH O O
11 1062 1069 11426838 induced VBN B-NP O
12 1070 1079 11426838 lethality NN I-NP O
13 1080 1082 11426838 in IN B-PP O
14 1083 1084 11426838 a DT B-NP O
15 1085 1096 11426838 significant JJ I-NP O
16 1097 1107 11426838 proportion NN I-NP O
17 1108 1110 11426838 of IN B-PP O
18 1111 1118 11426838 animals NNS B-NP O
19 1118 1119 11426838 . . O O

1 1120 1122 11426838 In IN B-PP O
2 1123 1131 11426838 contrast NN B-NP O
3 1132 1134 11426838 to TO B-PP O
4 1135 1138 11426838 the DT B-NP O
5 1139 1149 11426838 protection NN I-NP O
6 1150 1158 11426838 provided VBN B-VP O
7 1159 1161 11426838 by IN B-PP O
8 1162 1165 11426838 the DT B-NP O
9 1166 1174 11426838 putative JJ I-NP O
10 1175 1186 11426838 antagonists NNS I-NP O
11 1186 1187 11426838 , , O O
12 1188 1191 11426838 the DT B-NP O
13 1192 1196 11426838 well RB I-NP O
14 1196 1197 11426838 - HYPH I-NP O
15 1197 1210 11426838 characterized VBN I-NP O
16 1211 1216 11426838 sigma NN I-NP O
17 1217 1225 11426838 receptor NN I-NP O
18 1226 1233 11426838 agonist NN I-NP O
19 1234 1236 11426838 di AFX O B-Chemical
20 1236 1237 11426838 - HYPH O I-Chemical
21 1237 1238 11426838 o AFX O I-Chemical
22 1238 1239 11426838 - HYPH O I-Chemical
23 1239 1253 11426838 tolylguanidine NN B-NP I-Chemical
24 1254 1255 11426838 ( ( O O
25 1255 1258 11426838 DTG NN B-NP B-Chemical
26 1258 1259 11426838 ) ) O O
27 1260 1263 11426838 and CC O O
28 1264 1267 11426838 the DT B-NP O
29 1268 1273 11426838 novel JJ I-NP O
30 1274 1279 11426838 sigma NN I-NP O
31 1280 1288 11426838 receptor NN I-NP O
32 1289 1296 11426838 agonist NN I-NP O
33 1297 1303 11426838 BD1031 NN I-NP B-Chemical
34 1304 1305 11426838 ( ( O O
35 1305 1307 11426838 3R NN B-NP B-Chemical
36 1307 1308 11426838 - HYPH B-NP I-Chemical
37 1308 1309 11426838 1 CD I-NP I-Chemical
38 1309 1310 11426838 - HYPH I-NP I-Chemical
39 1310 1312 11426838 [2 CD I-NP I-Chemical
40 1312 1313 11426838 - HYPH I-NP I-Chemical
41 1313 1317 11426838 (3,4 CD I-NP I-Chemical
42 1317 1318 11426838 - HYPH I-NP I-Chemical
43 1318 1339 11426838 dichlorophenyl)ethyl] NN I-NP I-Chemical
44 1339 1340 11426838 - HYPH B-NP I-Chemical
45 1340 1343 11426838 1,4 CD I-NP I-Chemical
46 1343 1344 11426838 - HYPH I-NP I-Chemical
47 1344 1369 11426838 diazabicyclo[4.3.0]nonane NN I-NP I-Chemical
48 1369 1370 11426838 ) ) O O
49 1371 1375 11426838 each DT B-NP O
50 1376 1384 11426838 worsened VBD B-VP O
51 1385 1388 11426838 the DT B-NP O
52 1389 1399 11426838 behavioral JJ I-NP O
53 1400 1408 11426838 toxicity NN I-NP B-Disease
54 1409 1411 11426838 of IN B-PP O
55 1412 1419 11426838 cocaine NN B-NP B-Chemical
56 1419 1420 11426838 . . O O

1 1421 1423 11426838 At IN B-PP O
2 1424 1429 11426838 doses NNS B-NP O
3 1430 1435 11426838 where WRB B-ADVP O
4 1436 1441 11426838 alone RB I-ADVP O
5 1441 1442 11426838 , , O O
6 1443 1447 11426838 they PRP B-NP O
7 1448 1456 11426838 produced VBD B-VP O
8 1457 1459 11426838 no DT B-NP O
9 1460 1471 11426838 significant JJ I-NP O
10 1472 1479 11426838 effects NNS I-NP O
11 1480 1482 11426838 on IN B-PP O
12 1483 1493 11426838 locomotion NN B-NP O
13 1493 1494 11426838 , , O O
14 1495 1501 11426838 BD1018 NN B-NP B-Chemical
15 1501 1502 11426838 , , O O
16 1503 1509 11426838 BD1063 NN B-NP B-Chemical
17 1510 1513 11426838 and CC O O
18 1514 1519 11426838 LR132 NN B-NP B-Chemical
19 1520 1533 11426838 significantly RB B-ADVP O
20 1534 1544 11426838 attenuated VBD B-VP O
21 1545 1548 11426838 the DT B-NP O
22 1549 1558 11426838 locomotor JJ I-NP O
23 1559 1570 11426838 stimulatory JJ I-NP O
24 1571 1578 11426838 effects NNS I-NP O
25 1579 1581 11426838 of IN B-PP O
26 1582 1589 11426838 cocaine NN B-NP B-Chemical
27 1589 1590 11426838 . . O O

1 1591 1593 11426838 To TO B-VP O
2 1594 1601 11426838 further RB I-VP O
3 1602 1610 11426838 validate VB I-VP O
4 1611 1614 11426838 the DT B-NP O
5 1615 1625 11426838 hypothesis NN I-NP O
6 1626 1630 11426838 that IN B-SBAR O
7 1631 1634 11426838 the DT B-NP O
8 1635 1639 11426838 anti AFX I-NP O
9 1639 1640 11426838 - HYPH I-NP O
10 1640 1647 11426838 cocaine NN I-NP B-Chemical
11 1648 1655 11426838 effects NNS I-NP O
12 1656 1658 11426838 of IN B-PP O
13 1659 1662 11426838 the DT B-NP O
14 1663 1668 11426838 novel JJ I-NP O
15 1669 1676 11426838 ligands NNS I-NP O
16 1677 1685 11426838 involved VBD B-VP O
17 1686 1696 11426838 antagonism NN B-NP O
18 1697 1699 11426838 of IN B-PP O
19 1700 1705 11426838 sigma NN B-NP O
20 1706 1715 11426838 receptors NNS I-NP O
21 1715 1716 11426838 , , O O
22 1717 1719 11426838 an DT B-NP O
23 1720 1729 11426838 antisense JJ I-NP O
24 1730 1750 11426838 oligodeoxynucleotide NN I-NP B-Chemical
25 1751 1758 11426838 against IN B-PP O
26 1759 1765 11426838 sigma1 NN B-NP O
27 1766 1775 11426838 receptors NNS I-NP O
28 1776 1779 11426838 was VBD B-VP O
29 1780 1784 11426838 also RB I-VP O
30 1785 1790 11426838 shown VBN I-VP O
31 1791 1793 11426838 to TO I-VP O
32 1794 1807 11426838 significantly RB I-VP O
33 1808 1817 11426838 attenuate VB I-VP O
34 1818 1821 11426838 the DT B-NP O
35 1822 1832 11426838 convulsive JJ I-NP B-Disease
36 1833 1836 11426838 and CC I-NP O
37 1837 1846 11426838 locomotor JJ I-NP O
38 1847 1858 11426838 stimulatory JJ I-NP O
39 1859 1866 11426838 effects NNS I-NP O
40 1867 1869 11426838 of IN B-PP O
41 1870 1877 11426838 cocaine NN B-NP B-Chemical
42 1877 1878 11426838 . . O O

1 1879 1887 11426838 Together RB B-ADVP O
2 1887 1888 11426838 , , O O
3 1889 1892 11426838 the DT B-NP O
4 1893 1897 11426838 data NNS I-NP O
5 1898 1906 11426838 suggests VBZ B-VP O
6 1907 1911 11426838 that IN B-SBAR O
7 1912 1922 11426838 functional JJ B-NP O
8 1923 1933 11426838 antagonism NN I-NP O
9 1934 1936 11426838 of IN B-PP O
10 1937 1942 11426838 sigma NN B-NP O
11 1943 1952 11426838 receptors NNS I-NP O
12 1953 1955 11426838 is VBZ B-VP O
13 1956 1963 11426838 capable JJ B-ADJP O
14 1964 1966 11426838 of IN B-PP O
15 1967 1978 11426838 attenuating VBG B-VP O
16 1979 1980 11426838 a DT B-NP O
17 1981 1987 11426838 number NN I-NP O
18 1988 1990 11426838 of IN B-PP O
19 1991 1998 11426838 cocaine NN B-NP B-Chemical
20 1998 1999 11426838 - HYPH B-NP O
21 1999 2006 11426838 induced VBN I-NP O
22 2007 2016 11426838 behaviors NNS I-NP O
23 2016 2017 11426838 . . O O

1 0 0 19445921 -DOCSTART- -X- -X- O

1 0 16 19445921 Cardioprotective JJ B-NP O
2 17 23 19445921 effect NN I-NP O
3 24 26 19445921 of IN B-PP O
4 27 38 19445921 salvianolic JJ B-NP B-Chemical
5 39 43 19445921 acid NN I-NP I-Chemical
6 44 45 19445921 A NN I-NP I-Chemical
7 46 48 19445921 on IN B-PP O
8 49 62 19445921 isoproterenol NN B-NP B-Chemical
9 62 63 19445921 - HYPH B-NP O
10 63 70 19445921 induced VBN I-NP O
11 71 81 19445921 myocardial JJ I-NP B-Disease
12 82 92 19445921 infarction NN I-NP I-Disease
13 93 95 19445921 in IN B-PP O
14 96 100 19445921 rats NNS B-NP O
15 100 101 19445921 . . O O
16 102 105 19445921 The DT B-NP O
17 106 113 19445921 present JJ I-NP O
18 114 119 19445921 study NN I-NP O
19 120 123 19445921 was VBD B-VP O
20 124 132 19445921 designed VBN I-VP O
21 133 135 19445921 to TO B-VP O
22 136 144 19445921 evaluate VB I-VP O
23 145 148 19445921 the DT B-NP O
24 149 165 19445921 cardioprotective JJ I-NP O
25 166 175 19445921 potential NN I-NP O
26 176 178 19445921 of IN B-PP O
27 179 190 19445921 salvianolic JJ B-NP B-Chemical
28 191 195 19445921 acid NN I-NP I-Chemical
29 196 197 19445921 A NN I-NP I-Chemical
30 198 200 19445921 on IN B-PP O
31 201 214 19445921 isoproterenol NN B-NP B-Chemical
32 214 215 19445921 - HYPH B-NP O
33 215 222 19445921 induced VBN I-NP O
34 223 233 19445921 myocardial JJ I-NP B-Disease
35 234 244 19445921 infarction NN I-NP I-Disease
36 245 247 19445921 in IN B-PP O
37 248 252 19445921 rats NNS B-NP O
38 252 253 19445921 . . O O

1 254 265 19445921 Hemodynamic JJ B-NP O
2 266 276 19445921 parameters NNS I-NP O
3 277 280 19445921 and CC O O
4 281 285 19445921 lead VBP B-VP O
5 286 288 19445921 II CD B-NP O
6 289 307 19445921 electrocardiograph NN I-NP O
7 308 312 19445921 were VBD B-VP O
8 313 322 19445921 monitored VBN I-VP O
9 323 326 19445921 and CC O O
10 327 335 19445921 recorded VBN B-VP O
11 336 348 19445921 continuously RB B-ADVP O
12 348 349 19445921 . . O O

1 350 357 19445921 Cardiac JJ B-NP O
2 358 364 19445921 marker NN I-NP O
3 365 372 19445921 enzymes NNS I-NP O
4 373 376 19445921 and CC O O
5 377 390 19445921 antioxidative JJ B-NP O
6 391 401 19445921 parameters NNS I-NP O
7 402 404 19445921 in IN B-PP O
8 405 410 19445921 serum NN B-NP O
9 411 414 19445921 and CC I-NP O
10 415 420 19445921 heart NN I-NP O
11 421 428 19445921 tissues NNS I-NP O
12 429 433 19445921 were VBD B-VP O
13 434 442 19445921 measured VBN I-VP O
14 442 443 19445921 . . O O

1 444 449 19445921 Assay NN B-NP O
2 450 453 19445921 for IN B-PP O
3 454 467 19445921 mitochondrial JJ B-NP O
4 468 479 19445921 respiratory JJ I-NP O
5 480 488 19445921 function NN I-NP O
6 489 492 19445921 and CC O O
7 493 510 19445921 histopathological JJ B-NP O
8 511 522 19445921 examination NN I-NP O
9 523 525 19445921 of IN B-PP O
10 526 531 19445921 heart NN B-NP O
11 532 539 19445921 tissues NNS I-NP O
12 540 544 19445921 were VBD B-VP O
13 545 554 19445921 performed VBN I-VP O
14 554 555 19445921 . . O O

1 556 569 19445921 Isoproterenol NN B-NP B-Chemical
2 569 570 19445921 - HYPH B-NP O
3 570 577 19445921 treated VBN I-NP O
4 578 582 19445921 rats NNS I-NP O
5 583 589 19445921 showed VBD B-VP O
6 590 601 19445921 significant JJ B-NP O
7 602 611 19445921 increases NNS I-NP O
8 612 614 19445921 in IN B-PP O
9 615 618 19445921 the DT B-NP O
10 619 625 19445921 levels NNS I-NP O
11 626 628 19445921 of IN B-PP O
12 629 636 19445921 lactate NN B-NP B-Chemical
13 637 650 19445921 dehydrogenase NN I-NP O
14 650 651 19445921 , , O O
15 652 661 19445921 aspartate NN B-NP B-Chemical
16 662 674 19445921 transaminase NN I-NP O
17 674 675 19445921 , , O O
18 676 684 19445921 creatine NN B-NP B-Chemical
19 685 691 19445921 kinase NN I-NP O
20 692 695 19445921 and CC I-NP O
21 696 711 19445921 malondialdehyde NN I-NP B-Chemical
22 712 715 19445921 and CC O O
23 716 727 19445921 significant JJ B-NP O
24 728 737 19445921 decreases NNS I-NP O
25 738 740 19445921 in IN B-PP O
26 741 744 19445921 the DT B-NP O
27 745 755 19445921 activities NNS I-NP O
28 756 758 19445921 of IN B-PP O
29 759 769 19445921 superoxide NN B-NP B-Chemical
30 770 779 19445921 dismutase NN I-NP O
31 779 780 19445921 , , O O
32 781 789 19445921 catalase NN B-NP O
33 790 793 19445921 and CC O O
34 794 805 19445921 glutathione NN B-NP B-Chemical
35 806 816 19445921 peroxidase NN I-NP O
36 817 819 19445921 in IN B-PP O
37 820 825 19445921 serum NN B-NP O
38 826 829 19445921 and CC I-NP O
39 830 835 19445921 heart NN I-NP O
40 835 836 19445921 . . O O

1 837 842 19445921 These DT B-NP O
2 843 847 19445921 rats NNS I-NP O
3 848 852 19445921 also RB B-ADVP O
4 853 859 19445921 showed VBD B-VP O
5 860 868 19445921 declines NNS B-NP O
6 869 871 19445921 in IN B-PP O
7 872 876 19445921 left JJ B-NP O
8 877 888 19445921 ventricular JJ I-NP O
9 889 897 19445921 systolic JJ I-NP O
10 898 906 19445921 pressure NN I-NP O
11 906 907 19445921 , , O O
12 908 915 19445921 maximum NN B-NP O
13 916 919 19445921 and CC I-NP O
14 920 927 19445921 minimum NN I-NP O
15 928 932 19445921 rate NN I-NP O
16 933 935 19445921 of IN B-PP O
17 936 945 19445921 developed VBN B-NP O
18 946 950 19445921 left JJ I-NP O
19 951 962 19445921 ventricular JJ I-NP O
20 963 971 19445921 pressure NN I-NP O
21 971 972 19445921 , , O O
22 973 976 19445921 and CC O O
23 977 986 19445921 elevation NN B-NP O
24 987 989 19445921 of IN B-PP O
25 990 994 19445921 left JJ B-NP O
26 995 1006 19445921 ventricular JJ I-NP O
27 1007 1010 19445921 end NN I-NP O
28 1010 1011 19445921 - HYPH B-NP O
29 1011 1020 19445921 diastolic JJ I-NP O
30 1021 1029 19445921 pressure NN I-NP O
31 1030 1033 19445921 and CC I-NP O
32 1034 1036 19445921 ST NN I-NP O
33 1036 1037 19445921 - HYPH I-NP O
34 1037 1044 19445921 segment NN I-NP O
35 1044 1045 19445921 . . O O

1 1046 1048 19445921 In IN B-PP O
2 1049 1057 19445921 addition NN B-NP O
3 1057 1058 19445921 , , O O
4 1059 1072 19445921 mitochondrial JJ B-NP O
5 1073 1084 19445921 respiratory JJ I-NP B-Disease
6 1085 1096 19445921 dysfunction NN I-NP I-Disease
7 1097 1110 19445921 characterized VBN B-VP O
8 1111 1113 19445921 by IN B-PP O
9 1114 1123 19445921 decreased VBN B-NP O
10 1124 1135 19445921 respiratory JJ I-NP O
11 1136 1143 19445921 control NN I-NP O
12 1144 1149 19445921 ratio NN I-NP O
13 1150 1153 19445921 and CC I-NP O
14 1154 1157 19445921 ADP NN I-NP B-Chemical
15 1157 1158 19445921 / SYM B-NP O
16 1158 1159 19445921 O NN I-NP O
17 1160 1163 19445921 was VBD B-VP O
18 1164 1172 19445921 observed VBN I-VP O
19 1173 1175 19445921 in IN B-PP O
20 1176 1189 19445921 isoproterenol NN B-NP B-Chemical
21 1189 1190 19445921 - HYPH B-NP O
22 1190 1197 19445921 treated VBN I-NP O
23 1198 1202 19445921 rats NNS I-NP O
24 1202 1203 19445921 . . O O

1 1204 1218 19445921 Administration NN B-NP O
2 1219 1221 19445921 of IN B-PP O
3 1222 1233 19445921 salvianolic JJ B-NP B-Chemical
4 1234 1238 19445921 acid NN I-NP I-Chemical
5 1239 1240 19445921 A NN I-NP I-Chemical
6 1241 1244 19445921 for IN B-PP O
7 1245 1246 19445921 a DT B-NP O
8 1247 1253 19445921 period NN I-NP O
9 1254 1256 19445921 of IN B-PP O
10 1257 1258 19445921 8 CD B-NP O
11 1259 1263 19445921 days NNS I-NP O
12 1264 1277 19445921 significantly RB B-ADVP O
13 1278 1288 19445921 attenuated VBD B-VP O
14 1289 1302 19445921 isoproterenol NN B-NP B-Chemical
15 1302 1303 19445921 - HYPH O O
16 1303 1310 19445921 induced VBN B-NP O
17 1311 1318 19445921 cardiac JJ I-NP B-Disease
18 1319 1330 19445921 dysfunction NN I-NP I-Disease
19 1331 1334 19445921 and CC O O
20 1335 1345 19445921 myocardial JJ B-NP B-Disease
21 1346 1352 19445921 injury NN I-NP I-Disease
22 1353 1356 19445921 and CC O O
23 1357 1365 19445921 improved VBN B-NP O
24 1366 1379 19445921 mitochondrial JJ I-NP O
25 1380 1391 19445921 respiratory JJ I-NP O
26 1392 1400 19445921 function NN I-NP O
27 1400 1401 19445921 . . O O

1 1402 1405 19445921 The DT B-NP O
2 1406 1416 19445921 protective JJ I-NP O
3 1417 1421 19445921 role NN I-NP O
4 1422 1424 19445921 of IN B-PP O
5 1425 1436 19445921 salvianolic JJ B-NP B-Chemical
6 1437 1441 19445921 acid NN I-NP I-Chemical
7 1442 1443 19445921 A NN I-NP I-Chemical
8 1444 1451 19445921 against IN B-PP O
9 1452 1465 19445921 isoproterenol NN B-NP B-Chemical
10 1465 1466 19445921 - HYPH O O
11 1466 1473 19445921 induced VBN B-NP O
12 1474 1484 19445921 myocardial JJ I-NP B-Disease
13 1485 1491 19445921 damage NN I-NP I-Disease
14 1492 1495 19445921 was VBD B-VP O
15 1496 1503 19445921 further RBR I-VP O
16 1504 1513 19445921 confirmed VBN I-VP O
17 1514 1516 19445921 by IN B-PP O
18 1517 1534 19445921 histopathological JJ B-NP O
19 1535 1546 19445921 examination NN I-NP O
20 1546 1547 19445921 . . O O

1 1548 1551 19445921 The DT B-NP O
2 1552 1559 19445921 results NNS I-NP O
3 1560 1562 19445921 of IN B-PP O
4 1563 1566 19445921 our PRP$ B-NP O
5 1567 1572 19445921 study NN I-NP O
6 1573 1580 19445921 suggest VBP B-VP O
7 1581 1585 19445921 that IN B-SBAR O
8 1586 1597 19445921 salvianolic JJ B-NP B-Chemical
9 1598 1602 19445921 acid NN I-NP I-Chemical
10 1603 1604 19445921 A NN I-NP I-Chemical
11 1605 1615 19445921 possessing VBG B-VP O
12 1616 1627 19445921 antioxidant JJ B-NP O
13 1628 1636 19445921 activity NN I-NP O
14 1637 1640 19445921 has VBZ B-VP O
15 1641 1642 19445921 a DT B-NP O
16 1643 1654 19445921 significant JJ I-NP O
17 1655 1665 19445921 protective JJ I-NP O
18 1666 1672 19445921 effect NN I-NP O
19 1673 1680 19445921 against IN B-PP O
20 1681 1694 19445921 isoproterenol NN B-NP B-Chemical
21 1694 1695 19445921 - HYPH B-NP O
22 1695 1702 19445921 induced VBN I-NP O
23 1703 1713 19445921 myocardial JJ I-NP B-Disease
24 1714 1724 19445921 infarction NN I-NP I-Disease
25 1724 1725 19445921 . . O O

1 0 0 6387529 -DOCSTART- -X- -X- O

1 0 10 6387529 Behavioral JJ B-NP O
2 11 18 6387529 effects NNS I-NP O
3 19 21 6387529 of IN B-PP O
4 22 30 6387529 diazepam NN B-NP B-Chemical
5 31 34 6387529 and CC I-NP O
6 35 46 6387529 propranolol NN I-NP B-Chemical
7 47 49 6387529 in IN B-PP O
8 50 58 6387529 patients NNS B-NP O
9 59 63 6387529 with IN B-PP O
10 64 69 6387529 panic NN B-NP B-Disease
11 70 78 6387529 disorder NN I-NP I-Disease
12 79 82 6387529 and CC I-NP O
13 83 94 6387529 agoraphobia NN I-NP B-Disease
14 94 95 6387529 . . O O
15 96 99 6387529 The DT B-NP O
16 100 107 6387529 effects NNS I-NP O
17 108 110 6387529 of IN B-PP O
18 111 115 6387529 oral JJ B-NP O
19 116 121 6387529 doses NNS I-NP O
20 122 124 6387529 of IN B-PP O
21 125 133 6387529 diazepam NN B-NP B-Chemical
22 134 135 6387529 ( ( O O
23 135 141 6387529 single JJ B-NP O
24 142 146 6387529 dose NN I-NP O
25 147 149 6387529 of IN B-PP O
26 150 152 6387529 10 CD B-NP O
27 153 155 6387529 mg NN I-NP O
28 156 159 6387529 and CC O O
29 160 161 6387529 a DT B-NP O
30 162 168 6387529 median JJ I-NP O
31 169 173 6387529 dose NN I-NP O
32 174 176 6387529 of IN B-PP O
33 177 179 6387529 30 CD B-NP O
34 180 182 6387529 mg NN I-NP O
35 182 183 6387529 / SYM B-NP O
36 183 186 6387529 day NN I-NP O
37 187 190 6387529 for IN B-PP O
38 191 192 6387529 2 CD B-NP O
39 193 198 6387529 weeks NNS I-NP O
40 198 199 6387529 ) ) O O
41 200 203 6387529 and CC O O
42 204 215 6387529 propranolol NN B-NP B-Chemical
43 216 217 6387529 ( ( O O
44 217 223 6387529 single JJ B-NP O
45 224 228 6387529 dose NN I-NP O
46 229 231 6387529 of IN B-PP O
47 232 234 6387529 80 CD B-NP O
48 235 237 6387529 mg NN I-NP O
49 238 241 6387529 and CC O O
50 242 243 6387529 a DT B-NP O
51 244 250 6387529 median JJ I-NP O
52 251 255 6387529 dose NN I-NP O
53 256 258 6387529 of IN B-PP O
54 259 262 6387529 240 CD B-NP O
55 263 265 6387529 mg NN I-NP O
56 265 266 6387529 / SYM B-NP O
57 266 269 6387529 day NN I-NP O
58 270 273 6387529 for IN B-PP O
59 274 275 6387529 2 CD B-NP O
60 276 281 6387529 weeks NNS I-NP O
61 281 282 6387529 ) ) O O
62 283 285 6387529 on IN B-PP O
63 286 299 6387529 psychological JJ B-NP O
64 300 311 6387529 performance NN I-NP O
65 312 314 6387529 of IN B-PP O
66 315 323 6387529 patients NNS B-NP O
67 324 328 6387529 with IN B-PP O
68 329 334 6387529 panic NN B-NP B-Disease
69 335 344 6387529 disorders NNS I-NP I-Disease
70 345 348 6387529 and CC O O
71 349 360 6387529 agoraphobia NN B-NP B-Disease
72 361 365 6387529 were VBD B-VP O
73 366 378 6387529 investigated VBN I-VP O
74 379 381 6387529 in IN B-PP O
75 382 383 6387529 a DT B-NP O
76 384 390 6387529 double JJ I-NP O
77 390 391 6387529 - HYPH I-NP O
78 391 396 6387529 blind JJ I-NP O
79 396 397 6387529 , , O O
80 398 408 6387529 randomized VBN B-VP O
81 409 412 6387529 and CC O O
82 413 422 6387529 crossover NN B-NP O
83 423 429 6387529 design NN I-NP O
84 429 430 6387529 . . O O

1 431 435 6387529 Both DT B-NP O
2 436 441 6387529 drugs NNS I-NP O
3 442 450 6387529 impaired VBD B-VP B-Disease
4 451 460 6387529 immediate JJ B-NP I-Disease
5 461 465 6387529 free JJ I-NP I-Disease
6 466 472 6387529 recall NN I-NP I-Disease
7 473 476 6387529 but CC O O
8 477 480 6387529 the DT B-NP O
9 481 489 6387529 decrease NN I-NP O
10 490 493 6387529 was VBD B-VP O
11 494 501 6387529 greater JJR B-ADJP O
12 502 505 6387529 for IN B-PP O
13 506 514 6387529 diazepam NN B-NP B-Chemical
14 515 519 6387529 than IN B-PP O
15 520 531 6387529 propranolol NN B-NP B-Chemical
16 531 532 6387529 . . O O

1 533 540 6387529 Delayed VBN B-NP B-Disease
2 541 545 6387529 free JJ I-NP I-Disease
3 546 552 6387529 recall NN I-NP I-Disease
4 553 556 6387529 was VBD B-VP I-Disease
5 557 561 6387529 also RB B-ADVP I-Disease
6 562 570 6387529 impaired JJ B-ADJP I-Disease
7 571 574 6387529 but CC O O
8 575 578 6387529 the DT B-NP O
9 579 582 6387529 two CD I-NP O
10 583 588 6387529 drugs NNS I-NP O
11 589 592 6387529 did VBD B-VP O
12 593 596 6387529 not RB I-VP O
13 597 603 6387529 differ VB I-VP O
14 603 604 6387529 . . O O

1 605 613 6387529 Patients NNS B-NP O
2 614 620 6387529 tapped VBD B-VP O
3 621 627 6387529 faster RBR B-ADVP O
4 628 633 6387529 after IN B-PP O
5 634 645 6387529 propranolol NN B-NP B-Chemical
6 646 650 6387529 than IN B-PP O
7 651 659 6387529 diazepam NN B-NP B-Chemical
8 660 663 6387529 and CC O O
9 664 668 6387529 they PRP B-NP O
10 669 673 6387529 were VBD B-VP O
11 674 678 6387529 more RBR I-VP O
12 679 686 6387529 sedated VBN I-VP O
13 687 692 6387529 after IN B-PP O
14 693 701 6387529 diazepam NN B-NP B-Chemical
15 702 706 6387529 than IN B-PP O
16 707 718 6387529 propranolol NN B-NP B-Chemical
17 718 719 6387529 . . O O

1 720 725 6387529 After IN B-PP O
2 726 727 6387529 2 CD B-NP O
3 728 733 6387529 weeks NNS I-NP O
4 734 736 6387529 of IN B-PP O
5 737 746 6387529 treatment NN B-NP O
6 746 747 6387529 , , O O
7 748 756 6387529 patients NNS B-NP O
8 757 763 6387529 tested VBN B-VP O
9 764 765 6387529 5 CD B-NP O
10 765 766 6387529 - HYPH I-NP O
11 766 767 6387529 8 CD I-NP O
12 768 769 6387529 h NN I-NP O
13 770 775 6387529 after IN B-PP O
14 776 779 6387529 the DT B-NP O
15 780 784 6387529 last JJ I-NP O
16 785 789 6387529 dose NN I-NP O
17 790 792 6387529 of IN B-PP O
18 793 803 6387529 medication NN B-NP O
19 804 807 6387529 did VBD B-VP O
20 808 811 6387529 not RB I-VP O
21 812 816 6387529 show VB I-VP O
22 817 820 6387529 any DT B-NP O
23 821 830 6387529 decrement NN I-NP O
24 831 833 6387529 of IN B-PP O
25 834 845 6387529 performance NN B-NP O
26 845 846 6387529 . . O O

1 847 852 6387529 These DT B-NP O
2 853 860 6387529 results NNS I-NP O
3 861 864 6387529 are VBP B-VP O
4 865 872 6387529 similar JJ B-ADJP O
5 873 875 6387529 to TO B-PP O
6 876 881 6387529 those DT B-NP O
7 882 892 6387529 previously RB B-VP O
8 893 898 6387529 found VBN I-VP O
9 899 901 6387529 in IN B-PP O
10 902 909 6387529 healthy JJ B-NP O
11 910 918 6387529 subjects NNS I-NP O
12 918 919 6387529 . . O O

1 920 932 6387529 Accumulation NN B-NP O
2 933 935 6387529 of IN B-PP O
3 936 941 6387529 drugs NNS B-NP O
4 942 945 6387529 was VBD B-VP O
5 946 949 6387529 not RB I-VP O
6 950 959 6387529 reflected VBN I-VP O
7 960 962 6387529 in IN B-PP O
8 963 972 6387529 prolonged JJ B-NP O
9 973 983 6387529 behavioral JJ I-NP B-Disease
10 984 994 6387529 impairment NN I-NP I-Disease
11 994 995 6387529 . . O O

1 0 0 12820454 -DOCSTART- -X- -X- O

1 0 8 12820454 Combined VBN B-NP O
2 9 17 12820454 androgen NN I-NP O
3 18 26 12820454 blockade NN I-NP O
4 26 27 12820454 - HYPH B-NP O
5 27 34 12820454 induced VBN I-NP O
6 35 41 12820454 anemia NN I-NP B-Disease
7 42 44 12820454 in IN B-PP O
8 45 53 12820454 prostate NN B-NP B-Disease
9 54 60 12820454 cancer NN I-NP I-Disease
10 61 69 12820454 patients NNS I-NP O
11 70 77 12820454 without IN B-PP O
12 78 82 12820454 bone NN B-NP O
13 83 94 12820454 involvement NN I-NP O
14 94 95 12820454 . . I-NP O
15 96 106 12820454 BACKGROUND NN I-NP O
16 106 107 12820454 : : O O
17 108 110 12820454 To TO B-VP O
18 111 120 12820454 determine VB I-VP O
19 121 124 12820454 the DT B-NP O
20 125 130 12820454 onset NN I-NP O
21 131 134 12820454 and CC I-NP O
22 135 141 12820454 extent NN I-NP O
23 142 144 12820454 of IN B-PP O
24 145 153 12820454 combined VBN B-NP O
25 154 162 12820454 androgen NN I-NP O
26 163 171 12820454 blockade NN I-NP O
27 172 173 12820454 ( ( O O
28 173 176 12820454 CAB NN B-NP O
29 176 177 12820454 ) ) O O
30 177 178 12820454 - HYPH B-NP O
31 178 185 12820454 induced VBN I-NP O
32 186 192 12820454 anemia NN I-NP B-Disease
33 193 195 12820454 in IN B-PP O
34 196 204 12820454 prostate NN B-NP B-Disease
35 205 211 12820454 cancer NN I-NP I-Disease
36 212 220 12820454 patients NNS I-NP O
37 221 228 12820454 without IN B-PP O
38 229 233 12820454 bone NN B-NP O
39 234 245 12820454 involvement NN I-NP O
40 245 246 12820454 . . O O

1 247 255 12820454 PATIENTS NNS B-NP O
2 256 259 12820454 AND CC I-NP O
3 260 267 12820454 METHODS NNS I-NP O
4 267 268 12820454 : : O O
5 269 274 12820454 Forty CD B-NP O
6 274 275 12820454 - HYPH O O
7 275 278 12820454 two CD B-NP O
8 279 287 12820454 patients NNS I-NP O
9 288 292 12820454 with IN B-PP O
10 293 299 12820454 biopsy NN B-NP O
11 299 300 12820454 - HYPH O O
12 300 306 12820454 proven VBN B-VP O
13 307 316 12820454 prostatic JJ B-NP B-Disease
14 317 331 12820454 adenocarcinoma NN I-NP I-Disease
15 332 333 12820454 [ ( O O
16 333 335 12820454 26 CD B-NP O
17 336 340 12820454 with IN B-PP O
18 341 346 12820454 stage NN B-NP O
19 347 348 12820454 C NN I-NP O
20 349 350 12820454 ( ( O O
21 350 356 12820454 T3N0M0 NN B-NP O
22 356 357 12820454 ) ) O O
23 358 361 12820454 and CC O O
24 362 364 12820454 16 CD B-NP O
25 365 369 12820454 with IN B-PP O
26 370 375 12820454 stage NN B-NP O
27 376 378 12820454 D1 NN I-NP O
28 379 380 12820454 ( ( O O
29 380 386 12820454 T3N1M0 NN B-NP O
30 386 387 12820454 ) ) O O
31 387 388 12820454 ] ) O O
32 389 393 12820454 were VBD B-VP O
33 394 402 12820454 included VBN I-VP O
34 403 405 12820454 in IN B-PP O
35 406 410 12820454 this DT B-NP O
36 411 416 12820454 study NN I-NP O
37 416 417 12820454 . . O O

1 418 421 12820454 All DT B-NP O
2 422 430 12820454 patients NNS I-NP O
3 431 439 12820454 received VBD B-VP O
4 440 443 12820454 CAB NN B-NP O
5 444 445 12820454 [ ( O O
6 445 455 12820454 leuprolide NN B-NP B-Chemical
7 456 463 12820454 acetate NN I-NP I-Chemical
8 464 465 12820454 ( ( O O
9 465 469 12820454 LHRH NN B-NP B-Chemical
10 469 470 12820454 - HYPH B-NP I-Chemical
11 470 471 12820454 A NN I-NP I-Chemical
12 471 472 12820454 ) ) O O
13 473 477 12820454 3.75 CD B-NP O
14 478 480 12820454 mg NN I-NP O
15 480 481 12820454 , , O O
16 482 497 12820454 intramuscularly RB B-ADVP O
17 497 498 12820454 , , O O
18 499 504 12820454 every DT B-NP O
19 505 507 12820454 28 CD I-NP O
20 508 512 12820454 days NNS I-NP O
21 513 517 12820454 plus CC O O
22 518 521 12820454 250 CD B-NP O
23 522 524 12820454 mg NN I-NP O
24 525 534 12820454 flutamide NN I-NP B-Chemical
25 534 535 12820454 , , O O
26 536 539 12820454 tid NN B-NP O
27 539 540 12820454 , , O O
28 541 544 12820454 per IN B-PP O
29 545 547 12820454 Os NNS B-NP O
30 547 548 12820454 ] ) O O
31 549 552 12820454 and CC O O
32 553 557 12820454 were VBD B-VP O
33 558 567 12820454 evaluated VBN I-VP O
34 568 571 12820454 for IN B-PP O
35 572 578 12820454 anemia NN B-NP B-Disease
36 579 581 12820454 by IN B-PP O
37 582 590 12820454 physical JJ B-NP O
38 591 602 12820454 examination NN I-NP O
39 603 606 12820454 and CC I-NP O
40 607 617 12820454 laboratory NN I-NP O
41 618 623 12820454 tests NNS I-NP O
42 624 626 12820454 at IN B-PP O
43 627 635 12820454 baseline NN B-NP O
44 636 639 12820454 and CC O O
45 640 641 12820454 4 CD B-NP O
46 642 652 12820454 subsequent JJ I-NP O
47 653 662 12820454 intervals NNS I-NP O
48 663 664 12820454 ( ( O O
49 664 665 12820454 1 CD B-NP O
50 665 666 12820454 , , I-NP O
51 667 668 12820454 2 CD I-NP O
52 668 669 12820454 , , I-NP O
53 670 671 12820454 3 CD I-NP O
54 672 675 12820454 and CC I-NP O
55 676 677 12820454 6 CD I-NP O
56 678 684 12820454 months NNS I-NP O
57 685 689 12820454 post AFX O O
58 689 690 12820454 - HYPH O O
59 690 693 12820454 CAB NN B-NP O
60 693 694 12820454 ) ) O O
61 694 695 12820454 . . O O

1 696 698 12820454 Hb NN B-NP O
2 698 699 12820454 , , I-NP O
3 700 703 12820454 PSA NN I-NP O
4 704 707 12820454 and CC I-NP O
5 708 720 12820454 Testosterone NN I-NP B-Chemical
6 721 733 12820454 measurements NNS I-NP O
7 734 738 12820454 were VBD B-VP O
8 739 747 12820454 recorded VBN I-VP O
9 747 748 12820454 . . O O

1 749 757 12820454 Patients NNS B-NP O
2 758 762 12820454 with IN B-PP O
3 763 768 12820454 stage NN B-NP O
4 769 771 12820454 D2 NN I-NP O
5 771 772 12820454 - HYPH B-NP O
6 772 773 12820454 3 CD I-NP O
7 774 781 12820454 disease NN I-NP O
8 781 782 12820454 , , O O
9 783 791 12820454 abnormal JJ B-NP O
10 792 802 12820454 hemoglobin NN I-NP O
11 803 808 12820454 level NN I-NP O
12 809 811 12820454 or CC O O
13 812 817 12820454 renal JJ B-ADJP O
14 818 821 12820454 and CC O O
15 822 827 12820454 liver NN B-NP O
16 828 836 12820454 function NN I-NP O
17 837 842 12820454 tests NNS I-NP O
18 843 847 12820454 that WDT B-NP O
19 848 852 12820454 were VBD B-VP O
20 853 859 12820454 higher JJR B-ADJP O
21 860 864 12820454 than IN B-PP O
22 865 868 12820454 the DT B-NP O
23 869 874 12820454 upper JJ I-NP O
24 875 881 12820454 limits NNS I-NP O
25 882 886 12820454 were VBD B-VP O
26 887 895 12820454 excluded VBN I-VP O
27 896 900 12820454 from IN B-PP O
28 901 904 12820454 the DT B-NP O
29 905 910 12820454 study NN I-NP O
30 910 911 12820454 . . O O

1 912 915 12820454 The DT B-NP O
2 916 924 12820454 duration NN I-NP O
3 925 927 12820454 of IN B-PP O
4 928 931 12820454 the DT B-NP O
5 932 937 12820454 study NN I-NP O
6 938 941 12820454 was VBD B-VP O
7 942 945 12820454 six CD B-NP O
8 946 952 12820454 months NNS I-NP O
9 952 953 12820454 . . O O

1 954 961 12820454 RESULTS NNS B-NP O
2 961 962 12820454 : : O O
3 963 966 12820454 The DT B-NP O
4 967 971 12820454 mean JJ I-NP O
5 972 982 12820454 hemoglobin NN I-NP O
6 983 984 12820454 ( ( O O
7 984 986 12820454 Hb NN B-NP O
8 986 987 12820454 ) ) O O
9 988 994 12820454 levels NNS B-NP O
10 995 999 12820454 were VBD B-VP O
11 1000 1013 12820454 significantly RB I-VP O
12 1014 1022 12820454 declined VBN I-VP O
13 1023 1025 12820454 in IN B-PP O
14 1026 1029 12820454 all DT B-NP O
15 1030 1038 12820454 patients NNS I-NP O
16 1039 1043 12820454 from IN B-PP O
17 1044 1052 12820454 baseline NN B-NP O
18 1053 1055 12820454 of IN B-PP O
19 1056 1060 12820454 14.2 CD B-NP O
20 1061 1062 12820454 g NN I-NP O
21 1062 1063 12820454 / SYM B-NP O
22 1063 1065 12820454 dl NN I-NP O
23 1066 1068 12820454 to TO B-PP O
24 1069 1073 12820454 14.0 CD B-NP O
25 1074 1075 12820454 g NN I-NP O
26 1075 1076 12820454 / SYM B-NP O
27 1076 1078 12820454 dl NN I-NP O
28 1078 1079 12820454 , , O O
29 1080 1084 12820454 13.5 CD B-NP O
30 1085 1086 12820454 g NN I-NP O
31 1086 1087 12820454 / SYM B-NP O
32 1087 1089 12820454 dl NN I-NP O
33 1089 1090 12820454 , , O O
34 1091 1095 12820454 13.2 CD B-NP O
35 1096 1097 12820454 g NN I-NP O
36 1097 1098 12820454 / SYM B-NP O
37 1098 1100 12820454 dl NN I-NP O
38 1101 1104 12820454 and CC O O
39 1105 1109 12820454 12.7 CD B-NP O
40 1110 1111 12820454 g NN I-NP O
41 1111 1112 12820454 / SYM B-NP O
42 1112 1114 12820454 dl NN I-NP O
43 1115 1117 12820454 at IN B-PP O
44 1118 1119 12820454 1 CD B-NP O
45 1119 1120 12820454 , , I-NP O
46 1121 1122 12820454 2 CD I-NP O
47 1122 1123 12820454 , , I-NP O
48 1124 1125 12820454 3 CD I-NP O
49 1126 1129 12820454 and CC I-NP O
50 1130 1131 12820454 6 CD I-NP O
51 1132 1138 12820454 months NNS I-NP O
52 1139 1143 12820454 post AFX B-NP O
53 1143 1144 12820454 - HYPH I-NP O
54 1144 1147 12820454 CAB NN B-NP O
55 1147 1148 12820454 , , O O
56 1149 1161 12820454 respectively RB B-ADVP O
57 1161 1162 12820454 . . O O

1 1163 1169 12820454 Severe JJ B-NP O
2 1170 1173 12820454 and CC I-NP O
3 1174 1184 12820454 clinically RB I-NP O
4 1185 1192 12820454 evident JJ I-NP O
5 1193 1199 12820454 anemia NN I-NP B-Disease
6 1200 1202 12820454 of IN B-PP O
7 1203 1205 12820454 Hb NN B-NP O
8 1206 1207 12820454 < SYM O O
9 1208 1210 12820454 11 CD B-NP O
10 1211 1212 12820454 g NN I-NP O
11 1212 1213 12820454 / SYM B-NP O
12 1213 1215 12820454 dl NN I-NP O
13 1216 1220 12820454 with IN B-PP O
14 1221 1229 12820454 clinical JJ B-NP O
15 1230 1238 12820454 symptoms NNS I-NP O
16 1239 1242 12820454 was VBD B-VP O
17 1243 1251 12820454 detected VBN I-VP O
18 1252 1254 12820454 in IN B-PP O
19 1255 1256 12820454 6 CD B-NP O
20 1257 1265 12820454 patients NNS I-NP O
21 1266 1267 12820454 ( ( O O
22 1267 1272 12820454 14.3% NN B-NP O
23 1272 1273 12820454 ) ) O O
24 1273 1274 12820454 . . O O

1 1275 1279 12820454 This DT B-NP O
2 1280 1283 12820454 CAB NN I-NP O
3 1283 1284 12820454 - HYPH B-NP O
4 1284 1291 12820454 induced VBN I-NP O
5 1292 1298 12820454 anemia NN I-NP B-Disease
6 1299 1302 12820454 was VBD B-VP O
7 1303 1315 12820454 normochromic JJ B-ADJP O
8 1316 1319 12820454 and CC I-ADJP O
9 1320 1330 12820454 normocytic JJ I-ADJP O
10 1330 1331 12820454 . . O O

1 1332 1334 12820454 At IN B-PP O
2 1335 1338 12820454 six CD B-NP O
3 1339 1345 12820454 months NNS I-NP O
4 1346 1350 12820454 post AFX B-NP O
5 1350 1351 12820454 - HYPH I-NP O
6 1351 1354 12820454 CAB NN B-NP O
7 1354 1355 12820454 , , O O
8 1356 1364 12820454 patients NNS B-NP O
9 1365 1369 12820454 with IN B-PP O
10 1370 1376 12820454 severe JJ B-NP O
11 1377 1383 12820454 anemia NN I-NP B-Disease
12 1384 1387 12820454 had VBD B-VP O
13 1388 1389 12820454 a DT B-NP O
14 1390 1392 12820454 Hb NN I-NP O
15 1393 1397 12820454 mean NN I-NP O
16 1398 1403 12820454 value NN I-NP O
17 1404 1406 12820454 of IN B-PP O
18 1407 1411 12820454 10.2 CD B-NP O
19 1412 1413 12820454 + SYM O O
20 1413 1414 12820454 / SYM O O
21 1414 1415 12820454 - SYM O O
22 1416 1419 12820454 0.1 CD B-NP O
23 1420 1421 12820454 g NN I-NP O
24 1421 1422 12820454 / SYM B-NP O
25 1422 1424 12820454 dl NN B-NP O
26 1425 1426 12820454 ( ( O O
27 1426 1427 12820454 X NN B-NP O
28 1428 1429 12820454 + SYM O O
29 1429 1430 12820454 / SYM O O
30 1430 1431 12820454 - HYPH O O
31 1432 1434 12820454 SE NN B-NP O
32 1434 1435 12820454 ) ) O O
33 1435 1436 12820454 , , O O
34 1437 1444 12820454 whereas IN O O
35 1445 1448 12820454 the DT B-NP O
36 1449 1454 12820454 other JJ I-NP O
37 1455 1463 12820454 patients NNS I-NP O
38 1464 1467 12820454 had VBD B-VP O
39 1468 1472 12820454 mild JJ B-NP O
40 1473 1479 12820454 anemia NN I-NP B-Disease
41 1480 1484 12820454 with IN B-PP O
42 1485 1487 12820454 Hb NN B-NP O
43 1488 1492 12820454 mean NN I-NP O
44 1493 1498 12820454 value NN I-NP O
45 1499 1501 12820454 of IN B-PP O
46 1502 1506 12820454 13.2 CD B-NP O
47 1507 1508 12820454 + SYM O O
48 1508 1509 12820454 / SYM O O
49 1509 1510 12820454 - SYM O O
50 1511 1515 12820454 0.17 CD B-NP O
51 1516 1517 12820454 ( ( O O
52 1517 1518 12820454 X NN B-NP O
53 1519 1520 12820454 + SYM O O
54 1520 1521 12820454 / SYM O O
55 1521 1522 12820454 - HYPH O O
56 1523 1525 12820454 SE NN B-NP O
57 1525 1526 12820454 ) ) O O
58 1526 1527 12820454 . . O O

1 1528 1531 12820454 The DT B-NP O
2 1532 1543 12820454 development NN I-NP O
3 1544 1546 12820454 of IN B-PP O
4 1547 1553 12820454 severe JJ B-NP O
5 1554 1560 12820454 anemia NN I-NP B-Disease
6 1561 1563 12820454 at IN B-PP O
7 1564 1565 12820454 6 CD B-NP O
8 1566 1572 12820454 months NNS I-NP O
9 1573 1577 12820454 post AFX O O
10 1577 1578 12820454 - HYPH O O
11 1578 1581 12820454 CAB NN B-NP O
12 1582 1585 12820454 was VBD B-VP O
13 1586 1597 12820454 predictable JJ B-ADJP O
14 1598 1600 12820454 by IN B-PP O
15 1601 1604 12820454 the DT B-NP O
16 1605 1614 12820454 reduction NN I-NP O
17 1615 1617 12820454 of IN B-PP O
18 1618 1620 12820454 Hb NN B-NP O
19 1621 1629 12820454 baseline NN I-NP O
20 1630 1635 12820454 value NN I-NP O
21 1636 1638 12820454 of IN B-PP O
22 1639 1643 12820454 more JJR B-NP O
23 1644 1648 12820454 than IN I-NP O
24 1649 1652 12820454 2.5 CD I-NP O
25 1653 1654 12820454 g NN I-NP O
26 1654 1655 12820454 / SYM B-NP O
27 1655 1657 12820454 dl NN I-NP O
28 1658 1663 12820454 after IN B-PP O
29 1664 1665 12820454 3 CD B-NP O
30 1666 1672 12820454 months NNS I-NP O
31 1673 1675 12820454 of IN B-PP O
32 1676 1679 12820454 CAB NN B-NP O
33 1680 1681 12820454 ( ( O O
34 1681 1682 12820454 p NN B-NP O
35 1683 1684 12820454 = SYM B-VP O
36 1685 1689 12820454 0.01 CD B-NP O
37 1689 1690 12820454 ) ) O O
38 1690 1691 12820454 . . O O

1 1692 1695 12820454 The DT B-NP O
2 1696 1707 12820454 development NN I-NP O
3 1708 1710 12820454 of IN B-PP O
4 1711 1717 12820454 severe JJ B-NP O
5 1718 1721 12820454 CAB NN I-NP O
6 1721 1722 12820454 - HYPH B-VP O
7 1722 1729 12820454 induced VBN B-NP O
8 1730 1736 12820454 anemia NN I-NP B-Disease
9 1737 1739 12820454 in IN B-PP O
10 1740 1748 12820454 prostate NN B-NP B-Disease
11 1749 1755 12820454 cancer NN I-NP I-Disease
12 1756 1764 12820454 patients NNS I-NP O
13 1765 1768 12820454 did VBD B-VP O
14 1769 1772 12820454 not RB I-VP O
15 1773 1782 12820454 correlate VB I-VP O
16 1783 1787 12820454 with IN B-PP O
17 1788 1789 12820454 T NN B-NP O
18 1790 1798 12820454 baseline NN I-NP O
19 1799 1805 12820454 values NNS I-NP O
20 1806 1807 12820454 ( ( O O
21 1807 1808 12820454 T NN B-NP O
22 1809 1810 12820454 < SYM B-NP O
23 1811 1812 12820454 3 CD I-NP O
24 1813 1815 12820454 ng NN I-NP O
25 1815 1816 12820454 / SYM B-NP O
26 1816 1818 12820454 ml NN I-NP O
27 1819 1825 12820454 versus IN B-PP O
28 1826 1827 12820454 T NN B-NP O
29 1828 1829 12820454 > SYM B-NP O
30 1830 1832 12820454 or CC O O
31 1833 1834 12820454 = SYM B-VP O
32 1835 1836 12820454 3 CD B-NP O
33 1837 1839 12820454 ng NN I-NP O
34 1839 1840 12820454 / SYM B-NP O
35 1840 1842 12820454 ml NN I-NP O
36 1842 1843 12820454 ) ) O O
37 1843 1844 12820454 , , O O
38 1845 1849 12820454 with IN B-PP O
39 1850 1853 12820454 age NN B-NP O
40 1854 1855 12820454 ( ( O O
41 1855 1856 12820454 < SYM B-NP O
42 1857 1859 12820454 76 CD B-NP O
43 1860 1863 12820454 yrs NNS I-NP O
44 1864 1870 12820454 versus CC O O
45 1871 1872 12820454 > SYM B-NP O
46 1873 1875 12820454 or CC O O
47 1876 1877 12820454 = SYM B-VP O
48 1878 1880 12820454 76 CD B-NP O
49 1881 1884 12820454 yrs NNS I-NP O
50 1884 1885 12820454 ) ) O O
51 1885 1886 12820454 , , O O
52 1887 1890 12820454 and CC O O
53 1891 1899 12820454 clinical JJ B-NP O
54 1900 1905 12820454 stage NN I-NP O
55 1906 1907 12820454 ( ( O O
56 1907 1912 12820454 stage NN B-NP O
57 1913 1914 12820454 C NN I-NP O
58 1915 1921 12820454 versus IN B-PP O
59 1922 1927 12820454 stage NN B-NP O
60 1928 1930 12820454 D1 NN I-NP O
61 1930 1931 12820454 ) ) O O
62 1931 1932 12820454 . . O O

1 1933 1939 12820454 Severe JJ B-NP O
2 1940 1943 12820454 and CC I-NP O
3 1944 1954 12820454 clinically RB I-NP O
4 1955 1962 12820454 evident JJ I-NP O
5 1963 1969 12820454 anemia NN I-NP B-Disease
6 1970 1973 12820454 was VBD B-VP O
7 1974 1980 12820454 easily RB I-VP O
8 1981 1990 12820454 corrected VBN I-VP O
9 1991 1993 12820454 by IN B-PP O
10 1994 2006 12820454 subcutaneous JJ B-NP O
11 2007 2017 12820454 injections NNS I-NP O
12 2018 2019 12820454 ( ( O O
13 2019 2020 12820454 3 CD B-NP O
14 2021 2026 12820454 times NNS I-NP O
15 2026 2027 12820454 / SYM B-NP O
16 2027 2031 12820454 week NN I-NP O
17 2032 2035 12820454 for IN B-PP O
18 2036 2037 12820454 1 CD B-NP O
19 2038 2043 12820454 month NN I-NP O
20 2043 2044 12820454 ) ) O O
21 2045 2047 12820454 of IN B-PP O
22 2048 2059 12820454 recombinant JJ B-NP O
23 2060 2074 12820454 erythropoietin NN I-NP O
24 2075 2076 12820454 ( ( O O
25 2076 2082 12820454 rHuEPO NN B-NP O
26 2082 2083 12820454 - HYPH O O
27 2083 2087 12820454 beta SYM B-NP O
28 2087 2088 12820454 ) ) O O
29 2088 2089 12820454 . . O O

1 2090 2100 12820454 CONCLUSION NN B-NP O
2 2100 2101 12820454 : : O O
3 2102 2105 12820454 Our PRP$ B-NP O
4 2106 2110 12820454 data NNS I-NP O
5 2111 2118 12820454 suggest VBP B-VP O
6 2119 2123 12820454 that IN B-SBAR O
7 2124 2130 12820454 rHuEPO NN B-NP O
8 2130 2131 12820454 - HYPH B-NP O
9 2131 2135 12820454 beta NN I-NP O
10 2136 2147 12820454 correctable JJ I-NP O
11 2148 2151 12820454 CAB NN I-NP O
12 2151 2152 12820454 - HYPH B-NP O
13 2152 2159 12820454 induced VBN I-NP O
14 2160 2166 12820454 anemia NN I-NP B-Disease
15 2167 2173 12820454 occurs VBZ B-VP O
16 2174 2176 12820454 in IN B-PP O
17 2177 2182 12820454 14.3% NN B-NP O
18 2183 2185 12820454 of IN B-PP O
19 2186 2194 12820454 prostate NN B-NP B-Disease
20 2195 2201 12820454 cancer NN I-NP I-Disease
21 2202 2210 12820454 patients NNS I-NP O
22 2211 2216 12820454 after IN B-PP O
23 2217 2218 12820454 6 CD B-NP O
24 2219 2225 12820454 months NNS I-NP O
25 2226 2228 12820454 of IN B-PP O
26 2229 2236 12820454 therapy NN B-NP O
27 2236 2237 12820454 . . O O

1 0 0 227508 -DOCSTART- -X- -X- O

1 0 8 227508 Naloxone NN B-NP B-Chemical
2 9 17 227508 reverses VBZ B-VP O
3 18 21 227508 the DT B-NP O
4 22 38 227508 antihypertensive JJ I-NP O
5 39 45 227508 effect NN I-NP O
6 46 48 227508 of IN B-PP O
7 49 58 227508 clonidine NN B-NP B-Chemical
8 58 59 227508 . . O O
9 60 62 227508 In IN B-PP O
10 63 77 227508 unanesthetized JJ B-NP O
11 77 78 227508 , , I-NP O
12 79 92 227508 spontaneously RB I-NP O
13 93 105 227508 hypertensive JJ I-NP B-Disease
14 106 110 227508 rats NNS I-NP O
15 111 114 227508 the DT B-NP O
16 115 123 227508 decrease NN I-NP O
17 124 126 227508 in IN B-PP O
18 127 132 227508 blood NN B-NP O
19 133 141 227508 pressure NN I-NP O
20 142 145 227508 and CC I-NP O
21 146 151 227508 heart NN I-NP O
22 152 156 227508 rate NN I-NP O
23 157 165 227508 produced VBN B-VP O
24 166 168 227508 by IN B-PP O
25 169 180 227508 intravenous JJ B-NP O
26 181 190 227508 clonidine NN I-NP B-Chemical
27 190 191 227508 , , O O
28 192 193 227508 5 CD B-NP O
29 194 196 227508 to TO I-NP O
30 197 199 227508 20 CD I-NP O
31 200 210 227508 micrograms NNS I-NP O
32 210 211 227508 / SYM B-NP O
33 211 213 227508 kg NN I-NP O
34 213 214 227508 , , O O
35 215 218 227508 was VBD B-VP O
36 219 228 227508 inhibited VBN I-VP O
37 229 231 227508 or CC I-VP O
38 232 240 227508 reversed VBN I-VP O
39 241 243 227508 by IN B-PP O
40 244 252 227508 nalozone NN B-NP B-Chemical
41 252 253 227508 , , O O
42 254 257 227508 0.2 CD B-NP O
43 258 260 227508 to TO I-NP O
44 261 262 227508 2 CD I-NP O
45 263 265 227508 mg NN I-NP O
46 265 266 227508 / SYM B-NP O
47 266 268 227508 kg NN I-NP O
48 268 269 227508 . . O O

1 270 273 227508 The DT B-NP O
2 274 285 227508 hypotensive JJ I-NP B-Disease
3 286 292 227508 effect NN I-NP O
4 293 295 227508 of IN B-PP O
5 296 299 227508 100 CD B-NP O
6 300 302 227508 mg NN I-NP O
7 302 303 227508 / SYM B-NP O
8 303 305 227508 kg NN I-NP O
9 306 311 227508 alpha SYM O B-Chemical
10 311 312 227508 - HYPH O I-Chemical
11 312 322 227508 methyldopa NN B-NP I-Chemical
12 323 326 227508 was VBD B-VP O
13 327 331 227508 also RB I-VP O
14 332 341 227508 partially RB I-VP O
15 342 350 227508 reversed VBN I-VP O
16 351 353 227508 by IN B-PP O
17 354 362 227508 naloxone NN B-NP B-Chemical
18 362 363 227508 . . O O

1 364 372 227508 Naloxone NN B-NP B-Chemical
2 373 378 227508 alone RB B-ADVP O
3 379 382 227508 did VBD B-VP O
4 383 386 227508 not RB I-VP O
5 387 393 227508 affect VB I-VP O
6 394 400 227508 either CC O O
7 401 406 227508 blood NN B-NP O
8 407 415 227508 pressure NN I-NP O
9 416 418 227508 or CC O O
10 419 424 227508 heart NN B-NP O
11 425 429 227508 rate NN I-NP O
12 429 430 227508 . . O O

1 431 433 227508 In IN B-PP O
2 434 439 227508 brain NN B-NP O
3 440 449 227508 membranes NNS I-NP O
4 450 454 227508 from IN B-PP O
5 455 468 227508 spontaneously RB B-NP O
6 469 481 227508 hypertensive JJ I-NP B-Disease
7 482 486 227508 rats NNS I-NP O
8 487 496 227508 clonidine NN I-NP B-Chemical
9 496 497 227508 , , O O
10 498 501 227508 10( CD B-NP O
11 501 502 227508 - HYPH I-NP O
12 502 504 227508 8) CD I-NP O
13 505 507 227508 to TO I-NP O
14 508 511 227508 10( CD I-NP O
15 511 512 227508 - HYPH I-NP O
16 512 514 227508 5) CD I-NP O
17 515 516 227508 M NN I-NP O
18 516 517 227508 , , O O
19 518 521 227508 did VBD B-VP O
20 522 525 227508 not RB I-VP O
21 526 535 227508 influence VB I-VP O
22 536 551 227508 stereoselective JJ B-NP O
23 552 559 227508 binding NN I-NP O
24 560 562 227508 of IN B-PP O
25 563 567 227508 [3H] NN B-NP B-Chemical
26 567 568 227508 - HYPH B-NP I-Chemical
27 568 576 227508 naloxone NN I-NP I-Chemical
28 577 578 227508 ( ( O O
29 578 579 227508 8 CD B-NP O
30 580 582 227508 nM NN I-NP O
31 582 583 227508 ) ) O O
32 583 584 227508 , , O O
33 585 588 227508 and CC O O
34 589 597 227508 naloxone NN B-NP B-Chemical
35 597 598 227508 , , O O
36 599 602 227508 10( CD B-NP O
37 602 603 227508 - HYPH I-NP O
38 603 605 227508 8) CD I-NP O
39 606 608 227508 to TO I-NP O
40 609 612 227508 10( CD I-NP O
41 612 613 227508 - HYPH I-NP O
42 613 615 227508 4) CD I-NP O
43 616 617 227508 M NN I-NP O
44 617 618 227508 , , O O
45 619 622 227508 did VBD B-VP O
46 623 626 227508 not RB I-VP O
47 627 636 227508 influence VB I-VP O
48 637 646 227508 clonidine NN B-NP B-Chemical
49 646 647 227508 - HYPH B-NP O
50 647 659 227508 suppressible JJ I-NP O
51 660 667 227508 binding NN I-NP O
52 668 670 227508 of IN B-PP O
53 671 675 227508 [3H] NN B-NP B-Chemical
54 675 676 227508 - HYPH B-NP I-Chemical
55 676 695 227508 dihydroergocryptine NN I-NP I-Chemical
56 696 697 227508 ( ( O O
57 697 698 227508 1 CD B-NP O
58 699 701 227508 nM NN I-NP O
59 701 702 227508 ) ) O O
60 702 703 227508 . . O O

1 704 709 227508 These DT B-NP O
2 710 718 227508 findings NNS I-NP O
3 719 727 227508 indicate VBP B-VP O
4 728 732 227508 that IN B-SBAR O
5 733 735 227508 in IN B-PP O
6 736 749 227508 spontaneously RB B-NP O
7 750 762 227508 hypertensive JJ I-NP B-Disease
8 763 767 227508 rats NNS I-NP O
9 768 771 227508 the DT B-NP O
10 772 779 227508 effects NNS I-NP O
11 780 782 227508 of IN B-PP O
12 783 790 227508 central JJ B-NP O
13 791 796 227508 alpha SYM I-NP O
14 796 797 227508 - HYPH I-NP O
15 797 809 227508 adrenoceptor NN I-NP O
16 810 821 227508 stimulation NN I-NP O
17 822 829 227508 involve VBP B-VP O
18 830 840 227508 activation NN B-NP O
19 841 843 227508 of IN B-PP O
20 844 850 227508 opiate JJ B-NP O
21 851 860 227508 receptors NNS I-NP O
22 860 861 227508 . . O O

1 862 864 227508 As IN B-SBAR O
2 865 873 227508 naloxone NN B-NP B-Chemical
3 874 877 227508 and CC I-NP O
4 878 887 227508 clonidine NN I-NP B-Chemical
5 888 890 227508 do VBP B-VP O
6 891 894 227508 not RB I-VP O
7 895 901 227508 appear VB I-VP O
8 902 904 227508 to TO I-VP O
9 905 913 227508 interact VB I-VP O
10 914 918 227508 with IN B-PP O
11 919 922 227508 the DT B-NP O
12 923 927 227508 same JJ I-NP O
13 928 936 227508 receptor NN I-NP O
14 937 941 227508 site NN I-NP O
15 941 942 227508 , , O O
16 943 946 227508 the DT B-NP O
17 947 955 227508 observed VBN I-NP O
18 956 966 227508 functional JJ I-NP O
19 967 977 227508 antagonism NN I-NP O
20 978 986 227508 suggests VBZ B-VP O
21 987 990 227508 the DT B-NP O
22 991 998 227508 release NN I-NP O
23 999 1001 227508 of IN B-PP O
24 1002 1004 227508 an DT B-NP O
25 1005 1015 227508 endogenous JJ I-NP O
26 1016 1022 227508 opiate NN I-NP O
27 1023 1025 227508 by IN B-PP O
28 1026 1035 227508 clonidine NN B-NP B-Chemical
29 1036 1038 227508 or CC O O
30 1039 1044 227508 alpha SYM O B-Chemical
31 1044 1045 227508 - HYPH O I-Chemical
32 1045 1055 227508 methyldopa NN B-NP I-Chemical
33 1056 1059 227508 and CC O O
34 1060 1063 227508 the DT B-NP O
35 1064 1072 227508 possible JJ I-NP O
36 1073 1077 227508 role NN I-NP O
37 1078 1080 227508 of IN B-PP O
38 1081 1084 227508 the DT B-NP O
39 1085 1091 227508 opiate NN I-NP O
40 1092 1094 227508 in IN B-PP O
41 1095 1098 227508 the DT B-NP O
42 1099 1106 227508 central JJ I-NP O
43 1107 1114 227508 control NN I-NP O
44 1115 1117 227508 of IN B-PP O
45 1118 1129 227508 sympathetic JJ B-NP O
46 1130 1134 227508 tone NN I-NP O
47 1134 1135 227508 . . O O

1 0 0 18464113 -DOCSTART- -X- -X- O

1 0 10 18464113 Lamivudine NN B-NP B-Chemical
2 11 14 18464113 for IN B-PP O
3 15 18 18464113 the DT B-NP O
4 19 29 18464113 prevention NN I-NP O
5 30 32 18464113 of IN B-PP O
6 33 42 18464113 hepatitis NN B-NP B-Disease
7 43 44 18464113 B NN I-NP I-Disease
8 45 50 18464113 virus NN I-NP O
9 51 63 18464113 reactivation NN I-NP O
10 64 66 18464113 in IN B-PP O
11 67 76 18464113 hepatitis NN B-NP B-Chemical
12 76 77 18464113 - HYPH B-NP I-Chemical
13 77 78 18464113 B NN I-NP I-Chemical
14 79 86 18464113 surface NN I-NP I-Chemical
15 87 94 18464113 antigen NN I-NP I-Chemical
16 95 96 18464113 ( ( O O
17 96 101 18464113 HBSAG NN B-NP B-Chemical
18 101 102 18464113 ) ) O O
19 103 115 18464113 seropositive JJ B-NP O
20 116 122 18464113 cancer NN I-NP B-Disease
21 123 131 18464113 patients NNS I-NP O
22 132 142 18464113 undergoing VBG B-VP O
23 143 152 18464113 cytotoxic JJ B-NP O
24 153 165 18464113 chemotherapy NN I-NP O
25 165 166 18464113 . . O O
26 167 176 18464113 Hepatitis NN B-NP B-Disease
27 177 178 18464113 B NN I-NP I-Disease
28 179 184 18464113 virus NN I-NP O
29 185 186 18464113 ( ( O O
30 186 189 18464113 HBV NN B-NP O
31 189 190 18464113 ) ) O O
32 191 193 18464113 is VBZ B-VP O
33 194 197 18464113 one CD B-NP O
34 198 200 18464113 of IN B-PP O
35 201 204 18464113 the DT B-NP O
36 205 210 18464113 major JJ I-NP O
37 211 217 18464113 causes NNS I-NP O
38 218 220 18464113 of IN B-PP O
39 221 228 18464113 chronic JJ B-NP O
40 229 234 18464113 liver NN I-NP B-Disease
41 235 242 18464113 disease NN I-NP I-Disease
42 243 252 18464113 worldwide RB B-ADVP O
43 252 253 18464113 . . O O

1 254 260 18464113 Cancer NN B-NP B-Disease
2 261 269 18464113 patients NNS I-NP O
3 270 273 18464113 who WP B-NP O
4 274 277 18464113 are VBP B-VP O
5 278 285 18464113 chronic JJ B-NP O
6 286 294 18464113 carriers NNS I-NP O
7 295 297 18464113 of IN B-PP O
8 298 301 18464113 HBV NN B-NP O
9 302 306 18464113 have VBP B-VP O
10 307 308 18464113 a DT B-NP O
11 309 315 18464113 higher JJR I-NP O
12 316 323 18464113 hepatic JJ I-NP B-Disease
13 324 336 18464113 complication NN I-NP I-Disease
14 337 341 18464113 rate NN I-NP O
15 342 347 18464113 while IN B-SBAR O
16 348 357 18464113 receiving VBG B-VP O
17 358 367 18464113 cytotoxic JJ B-NP O
18 368 380 18464113 chemotherapy NN I-NP O
19 381 382 18464113 ( ( O O
20 382 384 18464113 CT NN B-NP O
21 384 385 18464113 ) ) O O
22 386 389 18464113 and CC O O
23 390 394 18464113 this DT B-NP O
24 395 398 18464113 has VBZ B-VP O
25 399 405 18464113 mainly RB I-VP O
26 406 410 18464113 been VBN I-VP O
27 411 421 18464113 attributed VBN I-VP O
28 422 424 18464113 to TO B-PP O
29 425 428 18464113 HBV NN B-NP O
30 429 441 18464113 reactivation NN I-NP O
31 441 442 18464113 . . O O

1 443 445 18464113 In IN B-PP O
2 446 450 18464113 this DT B-NP O
3 451 456 18464113 study NN I-NP O
4 456 457 18464113 , , O O
5 458 464 18464113 cancer NN B-NP B-Disease
6 465 473 18464113 patients NNS I-NP O
7 474 477 18464113 who WP B-NP O
8 478 482 18464113 have VBP B-VP O
9 483 488 18464113 solid JJ B-NP O
10 489 492 18464113 and CC I-NP O
11 493 506 18464113 hematological JJ I-NP B-Disease
12 507 519 18464113 malignancies NNS I-NP I-Disease
13 520 524 18464113 with IN B-PP O
14 525 532 18464113 chronic JJ B-NP O
15 533 536 18464113 HBV NN I-NP B-Disease
16 537 546 18464113 infection NN I-NP I-Disease
17 547 555 18464113 received VBD B-VP O
18 556 559 18464113 the DT B-NP O
19 560 569 18464113 antiviral JJ I-NP O
20 570 575 18464113 agent NN I-NP O
21 576 586 18464113 lamivudine NN I-NP B-Chemical
22 587 592 18464113 prior RB B-ADVP O
23 593 596 18464113 and CC O O
24 597 603 18464113 during IN B-PP O
25 604 606 18464113 CT NN B-NP O
26 607 615 18464113 compared VBN B-PP O
27 616 620 18464113 with IN B-PP O
28 621 631 18464113 historical JJ B-NP O
29 632 639 18464113 control NN I-NP O
30 640 645 18464113 group NN I-NP O
31 646 649 18464113 who WP B-NP O
32 650 653 18464113 did VBD B-VP O
33 654 657 18464113 not RB I-VP O
34 658 665 18464113 receive VB I-VP O
35 666 676 18464113 lamivudine NN B-NP B-Chemical
36 676 677 18464113 . . O O

1 678 681 18464113 The DT B-NP O
2 682 692 18464113 objectives NNS I-NP O
3 693 697 18464113 were VBD B-VP O
4 698 700 18464113 to TO I-VP O
5 701 707 18464113 assess VB I-VP O
6 708 711 18464113 the DT B-NP O
7 712 720 18464113 efficacy NN I-NP O
8 721 723 18464113 of IN B-PP O
9 724 734 18464113 lamivudine NN B-NP B-Chemical
10 735 737 18464113 in IN B-PP O
11 738 746 18464113 reducing VBG B-VP O
12 747 750 18464113 the DT B-NP O
13 751 760 18464113 incidence NN I-NP O
14 761 763 18464113 of IN B-PP O
15 764 767 18464113 HBV NN B-NP O
16 768 780 18464113 reactivation NN I-NP O
17 780 781 18464113 , , O O
18 782 785 18464113 and CC O O
19 786 797 18464113 diminishing VBG B-VP O
20 798 807 18464113 morbidity NN B-NP O
21 808 811 18464113 and CC I-NP O
22 812 821 18464113 mortality NN I-NP O
23 822 828 18464113 during IN B-PP O
24 829 831 18464113 CT NN B-NP O
25 831 832 18464113 . . O O

1 833 836 18464113 Two CD B-NP O
2 837 843 18464113 groups NNS I-NP O
3 844 848 18464113 were VBD B-VP O
4 849 857 18464113 compared VBN I-VP O
5 858 860 18464113 in IN B-PP O
6 861 865 18464113 this DT B-NP O
7 866 871 18464113 study NN I-NP O
8 871 872 18464113 . . O O

1 873 876 18464113 The DT B-NP O
2 877 889 18464113 prophylactic JJ I-NP O
3 890 899 18464113 lamivudin NN I-NP B-Chemical
4 900 905 18464113 group NN I-NP O
5 906 915 18464113 consisted VBD B-VP O
6 916 918 18464113 of IN B-PP O
7 919 921 18464113 37 CD B-NP O
8 922 930 18464113 patients NNS I-NP O
9 931 934 18464113 who WP B-NP O
10 935 943 18464113 received VBD B-VP O
11 944 956 18464113 prophylactic JJ B-NP O
12 957 967 18464113 lamivudine NN I-NP B-Chemical
13 968 977 18464113 treatment NN I-NP O
14 977 978 18464113 . . O O

1 979 982 18464113 The DT B-NP O
2 983 993 18464113 historical JJ I-NP O
3 994 1002 18464113 controls NNS I-NP O
4 1003 1012 18464113 consisted VBD B-VP O
5 1013 1015 18464113 of IN B-PP O
6 1016 1018 18464113 50 CD B-NP O
7 1019 1030 18464113 consecutive JJ I-NP O
8 1031 1039 18464113 patients NNS I-NP O
9 1040 1043 18464113 who WP B-NP O
10 1044 1053 18464113 underwent VBD B-VP O
11 1054 1056 18464113 CT NN B-NP O
12 1057 1064 18464113 without IN B-PP O
13 1065 1077 18464113 prophylactic JJ B-NP O
14 1078 1088 18464113 lamivudine NN I-NP B-Chemical
15 1088 1089 18464113 . . O O

1 1090 1094 18464113 They PRP B-NP O
2 1095 1099 18464113 were VBD B-VP O
3 1100 1108 18464113 followed VBN I-VP O
4 1109 1111 18464113 up RP B-PRT O
5 1112 1118 18464113 during IN B-PP O
6 1119 1122 18464113 and CC I-PP O
7 1123 1126 18464113 for IN I-PP O
8 1127 1128 18464113 8 CD B-NP O
9 1129 1134 18464113 weeks NNS I-NP O
10 1135 1140 18464113 after IN B-PP O
11 1141 1143 18464113 CT NN B-NP O
12 1143 1144 18464113 . . O O

1 1145 1148 18464113 The DT B-NP O
2 1149 1157 18464113 outcomes NNS I-NP O
3 1158 1162 18464113 were VBD B-VP O
4 1163 1171 18464113 compared VBN I-VP O
5 1172 1175 18464113 for IN B-PP O
6 1176 1180 18464113 both DT B-NP O
7 1181 1187 18464113 groups NNS I-NP O
8 1187 1188 18464113 . . O O

1 1189 1191 18464113 Of IN B-PP O
2 1192 1195 18464113 our PRP$ B-NP O
3 1196 1203 18464113 control NN I-NP O
4 1204 1209 18464113 group NN I-NP O
5 1210 1211 18464113 ( ( O O
6 1211 1212 18464113 n NN B-NP O
7 1212 1213 18464113 = SYM B-VP O
8 1214 1216 18464113 50 CD B-NP O
9 1216 1217 18464113 ) ) O O
10 1217 1218 18464113 , , O O
11 1219 1221 18464113 21 CD B-NP O
12 1222 1230 18464113 patients NNS I-NP O
13 1231 1232 18464113 ( ( O O
14 1232 1235 18464113 42% NN B-NP O
15 1235 1236 18464113 ) ) O O
16 1237 1241 18464113 were VBD B-VP O
17 1242 1253 18464113 established VBN I-VP O
18 1254 1263 18464113 hepatitis NN B-NP B-Disease
19 1263 1264 18464113 . . O O

1 1265 1271 18464113 Twelve CD B-NP O
2 1272 1273 18464113 ( ( O O
3 1273 1276 18464113 24% NN B-NP O
4 1276 1277 18464113 ) ) O O
5 1278 1280 18464113 of IN B-PP O
6 1281 1285 18464113 them PRP B-NP O
7 1286 1290 18464113 were VBD B-VP O
8 1291 1300 18464113 evaluated VBN I-VP O
9 1301 1303 18464113 as IN B-PP O
10 1304 1310 18464113 severe JJ B-NP O
11 1311 1320 18464113 hepatitis NN I-NP B-Disease
12 1320 1321 18464113 . . O O

1 1322 1324 18464113 In IN B-PP O
2 1325 1328 18464113 the DT B-NP O
3 1329 1341 18464113 prophylactic JJ I-NP O
4 1342 1352 18464113 lamivudine NN I-NP B-Chemical
5 1353 1358 18464113 group NN I-NP O
6 1359 1365 18464113 severe JJ I-NP O
7 1366 1375 18464113 hepatitis NN I-NP B-Disease
8 1376 1380 18464113 were VBD B-VP O
9 1381 1389 18464113 observed VBN I-VP O
10 1390 1394 18464113 only RB B-ADVP O
11 1395 1397 18464113 in IN B-PP O
12 1398 1399 18464113 1 CD B-NP O
13 1400 1407 18464113 patient NN I-NP O
14 1408 1409 18464113 ( ( O O
15 1409 1413 18464113 2.7% CD B-NP O
16 1413 1414 18464113 ) ) O O
17 1415 1417 18464113 of IN B-PP O
18 1418 1420 18464113 37 CD B-NP O
19 1421 1429 18464113 patients NNS I-NP O
20 1430 1431 18464113 ( ( O O
21 1431 1432 18464113 p NN B-NP O
22 1433 1434 18464113 < JJR B-NP O
23 1435 1440 18464113 0.006 CD I-NP O
24 1440 1441 18464113 ) ) O O
25 1441 1442 18464113 . . O O

1 1443 1453 18464113 Comparison NN B-NP O
2 1454 1456 18464113 of IN B-PP O
3 1457 1460 18464113 the DT B-NP O
4 1461 1465 18464113 mean JJ I-NP O
5 1466 1469 18464113 ALT NN I-NP O
6 1470 1476 18464113 values NNS I-NP O
7 1477 1485 18464113 revealed VBD B-VP O
8 1486 1499 18464113 significantly RB B-NP O
9 1500 1506 18464113 higher JJR I-NP O
10 1507 1511 18464113 mean JJ I-NP O
11 1512 1519 18464113 alanine NN I-NP B-Chemical
12 1520 1536 18464113 aminotransferase NN I-NP O
13 1537 1538 18464113 ( ( O O
14 1538 1541 18464113 ALT NN B-NP O
15 1541 1542 18464113 ) ) O O
16 1543 1549 18464113 values NNS B-NP O
17 1550 1552 18464113 in IN B-PP O
18 1553 1556 18464113 the DT B-NP O
19 1557 1564 18464113 control NN I-NP O
20 1565 1570 18464113 group NN I-NP O
21 1571 1575 18464113 than IN B-PP O
22 1576 1579 18464113 the DT B-NP O
23 1580 1592 18464113 prophylactic JJ I-NP O
24 1593 1603 18464113 lamivudine NN I-NP B-Chemical
25 1604 1609 18464113 group NN I-NP O
26 1609 1610 18464113 ; : O O
27 1611 1614 18464113 154 CD B-NP O
28 1614 1615 18464113 : : O O
29 1615 1617 18464113 64 CD B-NP O
30 1618 1619 18464113 ( ( O O
31 1619 1620 18464113 p NN B-NP O
32 1621 1622 18464113 < JJR B-NP O
33 1623 1627 18464113 0.32 CD I-NP O
34 1627 1628 18464113 ) ) O O
35 1628 1629 18464113 . . O O

1 1630 1633 18464113 Our PRP$ B-NP O
2 1634 1639 18464113 study NN I-NP O
3 1640 1648 18464113 suggests VBZ B-VP O
4 1649 1653 18464113 that IN B-SBAR O
5 1654 1666 18464113 prophylactic JJ B-NP O
6 1667 1677 18464113 lamivudine NN I-NP B-Chemical
7 1678 1691 18464113 significantly RB B-ADVP O
8 1692 1701 18464113 decreases VBZ B-VP O
9 1702 1705 18464113 the DT B-NP O
10 1706 1715 18464113 incidence NN I-NP O
11 1716 1718 18464113 of IN B-PP O
12 1719 1722 18464113 HBV NN B-NP O
13 1723 1735 18464113 reactivation NN I-NP O
14 1736 1739 18464113 and CC O O
15 1740 1747 18464113 overall JJ B-NP O
16 1748 1757 18464113 morbidity NN I-NP O
17 1758 1760 18464113 in IN B-PP O
18 1761 1767 18464113 cancer NN B-NP B-Disease
19 1768 1776 18464113 patients NNS I-NP O
20 1777 1783 18464113 during IN B-PP O
21 1784 1787 18464113 and CC I-PP O
22 1788 1793 18464113 after IN I-PP O
23 1794 1811 18464113 immunosuppressive JJ B-NP O
24 1812 1819 18464113 therapy NN I-NP O
25 1819 1820 18464113 . . O O

1 1821 1828 18464113 Further JJ B-NP O
2 1829 1836 18464113 studies NNS I-NP O
3 1837 1840 18464113 are VBP B-VP O
4 1841 1847 18464113 needed VBN I-VP O
5 1848 1850 18464113 to TO B-VP O
6 1851 1860 18464113 determine VB I-VP O
7 1861 1864 18464113 the DT B-NP O
8 1865 1869 18464113 most RBS I-NP O
9 1870 1881 18464113 appropriate JJ I-NP O
10 1882 1892 18464113 nucleoside NN I-NP B-Chemical
11 1893 1895 18464113 or CC I-NP O
12 1896 1906 18464113 nucleotide NN I-NP B-Chemical
13 1907 1915 18464113 analogue NN I-NP O
14 1916 1919 18464113 for IN B-PP O
15 1920 1929 18464113 antiviral JJ B-NP O
16 1930 1941 18464113 prophylaxis NN I-NP O
17 1942 1948 18464113 during IN B-PP O
18 1949 1951 18464113 CT NN B-NP O
19 1952 1955 18464113 and CC O O
20 1956 1959 18464113 the DT B-NP O
21 1960 1967 18464113 optimal JJ I-NP O
22 1968 1976 18464113 duration NN I-NP O
23 1977 1979 18464113 of IN B-PP O
24 1980 1994 18464113 administration NN B-NP O
25 1995 2000 18464113 after IN B-PP O
26 2001 2011 18464113 completion NN B-NP O
27 2012 2014 18464113 of IN B-PP O
28 2015 2017 18464113 CT NN B-NP O
29 2017 2018 18464113 . . O O

1 0 0 2008831 -DOCSTART- -X- -X- O

1 0 6 2008831 Effect NN B-NP O
2 7 9 2008831 of IN B-PP O
3 10 16 2008831 direct JJ B-NP O
4 17 30 2008831 intracoronary JJ I-NP O
5 31 45 2008831 administration NN I-NP O
6 46 48 2008831 of IN B-PP O
7 49 65 2008831 methylergonovine NN B-NP B-Chemical
8 66 68 2008831 in IN B-PP O
9 69 77 2008831 patients NNS B-NP O
10 78 82 2008831 with IN B-PP O
11 83 86 2008831 and CC O O
12 87 94 2008831 without IN B-PP O
13 95 102 2008831 variant JJ B-NP B-Disease
14 103 109 2008831 angina NN I-NP I-Disease
15 109 110 2008831 . . O O
16 111 114 2008831 The DT B-NP O
17 115 122 2008831 effects NNS I-NP O
18 123 125 2008831 of IN B-PP O
19 126 139 2008831 intracoronary JJ B-NP O
20 140 154 2008831 administration NN I-NP O
21 155 157 2008831 of IN B-PP O
22 158 174 2008831 methylergonovine NN B-NP B-Chemical
23 175 179 2008831 were VBD B-VP O
24 180 187 2008831 studied VBN I-VP O
25 188 190 2008831 in IN B-PP O
26 191 193 2008831 21 CD B-NP O
27 194 202 2008831 patients NNS I-NP O
28 203 207 2008831 with IN B-PP O
29 208 215 2008831 variant JJ B-NP B-Disease
30 216 222 2008831 angina NN I-NP I-Disease
31 223 226 2008831 and CC O O
32 227 229 2008831 22 CD B-NP O
33 230 238 2008831 patients NNS I-NP O
34 239 243 2008831 with IN B-PP O
35 244 252 2008831 atypical JJ B-NP O
36 253 258 2008831 chest NN I-NP B-Disease
37 259 263 2008831 pain NN I-NP I-Disease
38 264 267 2008831 and CC B-PP O
39 268 270 2008831 in IN B-PP O
40 271 277 2008831 others NNS B-NP O
41 278 285 2008831 without IN B-PP O
42 286 292 2008831 angina NN B-NP B-Disease
43 293 301 2008831 pectoris NN I-NP I-Disease
44 302 303 2008831 ( ( O O
45 303 310 2008831 control NN B-NP O
46 311 316 2008831 group NN I-NP O
47 316 317 2008831 ) ) O O
48 317 318 2008831 . . O O

1 319 335 2008831 Methylergonovine NN B-NP B-Chemical
2 336 339 2008831 was VBD B-VP O
3 340 352 2008831 administered VBN I-VP O
4 353 365 2008831 continuously RB B-ADVP O
5 366 368 2008831 at IN B-PP O
6 369 370 2008831 a DT B-NP O
7 371 375 2008831 rate NN I-NP O
8 376 378 2008831 of IN B-PP O
9 379 381 2008831 10 CD B-NP O
10 382 392 2008831 micrograms NNS I-NP O
11 392 393 2008831 / SYM O O
12 393 396 2008831 min NN B-NP O
13 397 399 2008831 up RB B-NP O
14 400 402 2008831 to TO I-NP O
15 403 405 2008831 50 CD I-NP O
16 406 416 2008831 micrograms NNS I-NP O
17 416 417 2008831 . . O O

1 418 420 2008831 In IN B-PP O
2 421 424 2008831 all DT B-NP O
3 425 433 2008831 patients NNS I-NP O
4 434 438 2008831 with IN B-PP O
5 439 446 2008831 variant JJ B-NP B-Disease
6 447 453 2008831 angina NN I-NP I-Disease
7 453 454 2008831 , , O O
8 455 463 2008831 coronary JJ B-NP B-Disease
9 464 469 2008831 spasm NN I-NP I-Disease
10 470 473 2008831 was VBD B-VP O
11 474 482 2008831 provoked VBN I-VP O
12 483 485 2008831 at IN B-PP O
13 486 487 2008831 a DT B-NP O
14 488 492 2008831 mean JJ I-NP O
15 493 497 2008831 dose NN I-NP O
16 498 500 2008831 of IN B-PP O
17 501 503 2008831 28 CD B-NP O
18 504 505 2008831 + SYM O O
19 505 506 2008831 / SYM O O
20 506 507 2008831 - SYM B-NP O
21 508 510 2008831 13 CD B-NP O
22 511 521 2008831 micrograms NNS I-NP O
23 522 523 2008831 ( ( O O
24 523 527 2008831 mean NN B-NP O
25 528 529 2008831 + SYM O O
26 529 530 2008831 / SYM O O
27 530 531 2008831 - HYPH O O
28 532 534 2008831 SD NN B-NP O
29 534 535 2008831 ) ) O O
30 535 536 2008831 . . O O

1 537 539 2008831 In IN B-PP O
2 540 543 2008831 the DT B-NP O
3 544 551 2008831 control NN I-NP O
4 552 557 2008831 group NN I-NP O
5 558 565 2008831 neither CC O O
6 566 574 2008831 ischemic JJ B-NP O
7 575 577 2008831 ST NN I-NP O
8 578 584 2008831 change NN I-NP O
9 585 588 2008831 nor CC O O
10 589 598 2008831 localized JJ B-NP O
11 599 604 2008831 spasm NN I-NP B-Disease
12 605 613 2008831 occurred VBD B-VP O
13 613 614 2008831 . . O O

1 615 618 2008831 The DT B-NP O
2 619 624 2008831 basal JJ I-NP O
3 625 629 2008831 tone NN I-NP O
4 630 632 2008831 of IN B-PP O
5 633 636 2008831 the DT B-NP O
6 637 642 2008831 right JJ I-NP O
7 643 651 2008831 coronary JJ I-NP O
8 652 658 2008831 artery NN I-NP O
9 659 662 2008831 was VBD B-VP O
10 663 676 2008831 significantly RB B-ADJP O
11 677 682 2008831 lower JJR I-ADJP O
12 683 687 2008831 than IN B-PP O
13 688 692 2008831 that DT B-NP O
14 693 695 2008831 of IN B-PP O
15 696 699 2008831 the DT B-NP O
16 700 704 2008831 left JJ I-NP O
17 705 713 2008831 coronary JJ I-NP O
18 714 720 2008831 artery NN I-NP O
19 720 721 2008831 . . O O

1 722 725 2008831 The DT B-NP O
2 726 736 2008831 percentage NN I-NP O
3 737 739 2008831 of IN B-PP O
4 740 756 2008831 vasoconstriction NN B-NP O
5 757 759 2008831 of IN B-PP O
6 760 763 2008831 the DT B-NP O
7 764 769 2008831 right JJ I-NP O
8 770 778 2008831 coronary JJ I-NP O
9 779 785 2008831 artery NN I-NP O
10 786 789 2008831 was VBD B-VP O
11 790 803 2008831 significantly RB B-ADJP O
12 804 810 2008831 higher JJR I-ADJP O
13 811 815 2008831 than IN B-PP O
14 816 820 2008831 that DT B-NP O
15 821 823 2008831 of IN B-PP O
16 824 827 2008831 the DT B-NP O
17 828 832 2008831 left JJ I-NP O
18 833 841 2008831 coronary JJ I-NP O
19 842 848 2008831 artery NN I-NP O
20 848 849 2008831 . . O O

1 850 855 2008831 These DT B-NP O
2 856 863 2008831 results NNS I-NP O
3 864 871 2008831 suggest VBP B-VP O
4 872 876 2008831 that IN B-SBAR O
5 877 882 2008831 spasm NN B-NP B-Disease
6 883 894 2008831 provocation NN I-NP O
7 895 900 2008831 tests NNS I-NP O
8 900 901 2008831 , , O O
9 902 907 2008831 which WDT B-NP O
10 908 911 2008831 use VBP B-VP O
11 912 914 2008831 an DT B-NP O
12 915 928 2008831 intracoronary JJ I-NP O
13 929 938 2008831 injection NN I-NP O
14 939 941 2008831 of IN B-PP O
15 942 943 2008831 a DT B-NP O
16 944 954 2008831 relatively RB I-NP O
17 955 958 2008831 low JJ I-NP O
18 959 963 2008831 dose NN I-NP O
19 964 966 2008831 of IN B-PP O
20 967 983 2008831 methylergonovine NN B-NP B-Chemical
21 983 984 2008831 , , O O
22 985 989 2008831 have VBP B-VP O
23 990 991 2008831 a DT B-NP O
24 992 996 2008831 high JJ I-NP O
25 997 1008 2008831 sensitivity NN I-NP O
26 1009 1011 2008831 in IN B-PP O
27 1012 1019 2008831 variant JJ B-NP B-Disease
28 1020 1026 2008831 angina NN I-NP I-Disease
29 1027 1030 2008831 and CC O O
30 1031 1034 2008831 the DT B-NP O
31 1035 1049 2008831 vasoreactivity NN I-NP O
32 1050 1052 2008831 of IN B-PP O
33 1053 1056 2008831 the DT B-NP O
34 1057 1062 2008831 right JJ I-NP O
35 1063 1071 2008831 coronary JJ I-NP O
36 1072 1078 2008831 artery NN I-NP O
37 1079 1082 2008831 may MD B-VP O
38 1083 1085 2008831 be VB I-VP O
39 1086 1093 2008831 greater JJR B-ADJP O
40 1094 1098 2008831 than IN B-PP O
41 1099 1103 2008831 that DT B-NP O
42 1104 1106 2008831 of IN B-PP O
43 1107 1110 2008831 the DT B-NP O
44 1111 1116 2008831 other JJ I-NP O
45 1117 1125 2008831 coronary JJ I-NP O
46 1126 1134 2008831 arteries NNS I-NP O
47 1134 1135 2008831 . . O O

1 0 0 3865016 -DOCSTART- -X- -X- O

1 0 11 3865016 Interaction NN B-NP O
2 12 14 3865016 of IN B-PP O
3 15 26 3865016 cyclosporin NN B-NP B-Chemical
4 27 28 3865016 A NN I-NP I-Chemical
5 29 33 3865016 with IN B-PP O
6 34 48 3865016 antineoplastic JJ B-NP O
7 49 55 3865016 agents NNS I-NP O
8 55 56 3865016 . . O O
9 57 58 3865016 A DT B-NP O
10 59 70 3865016 synergistic JJ I-NP O
11 71 77 3865016 effect NN I-NP O
12 78 80 3865016 of IN B-PP O
13 81 90 3865016 etoposide NN B-NP B-Chemical
14 91 94 3865016 and CC O O
15 95 106 3865016 cyclosporin NN B-NP B-Chemical
16 107 108 3865016 A NN I-NP I-Chemical
17 109 112 3865016 was VBD B-VP O
18 113 121 3865016 observed VBN I-VP O
19 122 124 3865016 in IN B-PP O
20 125 126 3865016 a DT B-NP O
21 127 134 3865016 patient NN I-NP O
22 135 139 3865016 with IN B-PP O
23 140 145 3865016 acute JJ B-NP B-Disease
24 146 147 3865016 T NN I-NP I-Disease
25 147 148 3865016 - HYPH B-NP I-Disease
26 148 159 3865016 lymphocytic JJ I-NP I-Disease
27 160 168 3865016 leukemia NN I-NP I-Disease
28 169 171 3865016 in IN B-PP O
29 172 179 3865016 relapse NN B-NP O
30 179 180 3865016 . . O O

1 181 184 3865016 The DT B-NP O
2 185 196 3865016 concomitant JJ I-NP O
3 197 211 3865016 administration NN I-NP O
4 212 214 3865016 of IN B-PP O
5 215 224 3865016 etoposide NN B-NP B-Chemical
6 225 228 3865016 and CC O O
7 229 240 3865016 cyclosporin NN B-NP B-Chemical
8 241 242 3865016 A NN I-NP I-Chemical
9 243 251 3865016 resulted VBD B-VP O
10 252 254 3865016 in IN B-PP O
11 255 266 3865016 eradication NN B-NP O
12 267 269 3865016 of IN B-PP O
13 270 278 3865016 hitherto NN B-NP O
14 279 289 3865016 refractory JJ I-NP O
15 290 298 3865016 leukemic JJ I-NP B-Disease
16 299 311 3865016 infiltration NN I-NP I-Disease
17 312 314 3865016 of IN B-PP O
18 315 319 3865016 bone NN B-NP O
19 320 326 3865016 marrow NN I-NP O
20 326 327 3865016 . . O O

1 328 334 3865016 Severe JJ B-NP O
2 335 339 3865016 side NN I-NP O
3 340 347 3865016 effects NNS I-NP O
4 348 350 3865016 in IN B-PP O
5 351 356 3865016 terms NNS B-NP O
6 357 359 3865016 of IN B-PP O
7 360 366 3865016 mental JJ B-NP O
8 367 376 3865016 confusion NN I-NP B-Disease
9 377 380 3865016 and CC O O
10 381 392 3865016 progressive JJ B-NP O
11 393 411 3865016 hyperbilirubinemia NN I-NP B-Disease
12 411 412 3865016 , , O O
13 413 420 3865016 however RB B-ADVP O
14 420 421 3865016 , , O O
15 422 427 3865016 point NN B-NP O
16 428 430 3865016 to TO B-PP O
17 431 433 3865016 an DT B-NP O
18 434 445 3865016 enhancement NN I-NP O
19 446 449 3865016 not RB B-CONJP O
20 450 454 3865016 only RB I-CONJP O
21 455 457 3865016 of IN B-PP O
22 458 472 3865016 antineoplastic JJ B-NP O
23 473 480 3865016 effects NNS I-NP O
24 481 484 3865016 but CC O O
25 485 489 3865016 also RB B-ADVP O
26 490 492 3865016 of IN B-PP O
27 493 501 3865016 toxicity NN B-NP B-Disease
28 502 504 3865016 in IN B-PP O
29 505 511 3865016 normal JJ B-NP O
30 512 519 3865016 tissues NNS I-NP O
31 519 520 3865016 . . O O

1 521 525 3865016 This DT B-NP O
2 526 532 3865016 report NN I-NP O
3 533 545 3865016 demonstrates VBZ B-VP O
4 546 549 3865016 for IN B-PP O
5 550 553 3865016 the DT B-NP O
6 554 559 3865016 first JJ I-NP O
7 560 564 3865016 time NN I-NP O
8 565 569 3865016 that IN B-ADVP O
9 570 573 3865016 the DT B-NP O
10 574 589 3865016 pharmacodynamic JJ I-NP O
11 590 600 3865016 properties NNS I-NP O
12 601 603 3865016 of IN B-PP O
13 604 615 3865016 cyclosporin NN B-NP B-Chemical
14 616 617 3865016 A NN I-NP I-Chemical
15 618 621 3865016 may MD B-VP O
16 622 625 3865016 not RB I-VP O
17 626 628 3865016 be VB I-VP O
18 629 637 3865016 confined VBN I-VP O
19 638 646 3865016 strictly RB B-ADVP O
20 647 649 3865016 to TO B-PP O
21 650 661 3865016 suppression NN B-NP O
22 662 664 3865016 of IN B-PP O
23 665 671 3865016 normal JJ B-NP O
24 672 673 3865016 T NN I-NP O
25 673 674 3865016 - HYPH B-NP O
26 674 678 3865016 cell NN I-NP O
27 679 688 3865016 functions NNS I-NP O
28 688 689 3865016 . . O O

1 0 0 11431197 -DOCSTART- -X- -X- O

1 0 10 11431197 Ranitidine NN B-NP B-Chemical
2 10 11 11431197 - HYPH O O
3 11 18 11431197 induced VBN B-NP O
4 19 24 11431197 acute JJ I-NP O
5 25 37 11431197 interstitial JJ I-NP B-Disease
6 38 47 11431197 nephritis NN I-NP I-Disease
7 48 50 11431197 in IN B-PP O
8 51 52 11431197 a DT B-NP O
9 53 62 11431197 cadaveric JJ I-NP O
10 63 68 11431197 renal JJ I-NP O
11 69 78 11431197 allograft NN I-NP O
12 78 79 11431197 . . I-NP O
13 80 90 11431197 Ranitidine NN I-NP B-Chemical
14 91 101 11431197 frequently RB B-ADVP O
15 102 104 11431197 is VBZ B-VP O
16 105 109 11431197 used VBN I-VP O
17 110 113 11431197 for IN B-PP O
18 114 124 11431197 preventing VBG B-VP O
19 125 131 11431197 peptic JJ B-NP O
20 132 142 11431197 ulceration NN I-NP O
21 143 148 11431197 after IN B-PP O
22 149 154 11431197 renal JJ B-NP O
23 155 170 11431197 transplantation NN I-NP O
24 170 171 11431197 . . O O

1 172 176 11431197 This DT B-NP O
2 177 181 11431197 drug NN I-NP O
3 182 194 11431197 occasionally RB B-ADVP O
4 195 198 11431197 has VBZ B-VP O
5 199 203 11431197 been VBN I-VP O
6 204 214 11431197 associated VBN I-VP O
7 215 219 11431197 with IN B-PP O
8 220 225 11431197 acute JJ B-NP O
9 226 238 11431197 interstitial JJ I-NP B-Disease
10 239 248 11431197 nephritis NN I-NP I-Disease
11 249 251 11431197 in IN B-PP O
12 252 258 11431197 native JJ B-NP O
13 259 266 11431197 kidneys NNS I-NP O
14 266 267 11431197 . . O O

1 268 273 11431197 There EX B-NP O
2 274 277 11431197 are VBP B-VP O
3 278 280 11431197 no DT B-NP O
4 281 288 11431197 similar JJ I-NP O
5 289 296 11431197 reports NNS I-NP O
6 297 301 11431197 with IN B-PP O
7 302 307 11431197 renal JJ B-NP O
8 308 323 11431197 transplantation NN I-NP O
9 323 324 11431197 . . O O

1 325 327 11431197 We PRP B-NP O
2 328 334 11431197 report VBP B-VP O
3 335 336 11431197 a DT B-NP O
4 337 341 11431197 case NN I-NP O
5 342 344 11431197 of IN B-PP O
6 345 355 11431197 ranitidine NN B-NP B-Chemical
7 355 356 11431197 - HYPH B-NP O
8 356 363 11431197 induced VBN I-NP O
9 364 369 11431197 acute JJ I-NP O
10 370 382 11431197 interstitial JJ I-NP B-Disease
11 383 392 11431197 nephritis NN I-NP I-Disease
12 393 395 11431197 in IN B-PP O
13 396 397 11431197 a DT B-NP O
14 398 407 11431197 recipient NN I-NP O
15 408 410 11431197 of IN B-PP O
16 411 412 11431197 a DT B-NP O
17 413 422 11431197 cadaveric JJ I-NP O
18 423 428 11431197 renal JJ I-NP O
19 429 438 11431197 allograft NN I-NP O
20 439 449 11431197 presenting VBG B-VP O
21 450 454 11431197 with IN B-PP O
22 455 460 11431197 acute JJ B-NP O
23 461 470 11431197 allograft NN I-NP O
24 471 482 11431197 dysfunction NN I-NP O
25 483 489 11431197 within IN B-PP O
26 490 492 11431197 48 CD B-NP O
27 493 498 11431197 hours NNS I-NP O
28 499 501 11431197 of IN B-PP O
29 502 510 11431197 exposure NN B-NP O
30 511 513 11431197 to TO B-PP O
31 514 517 11431197 the DT B-NP O
32 518 522 11431197 drug NN I-NP O
33 522 523 11431197 . . O O

1 524 527 11431197 The DT B-NP O
2 528 534 11431197 biopsy NN I-NP O
3 535 543 11431197 specimen NN I-NP O
4 544 550 11431197 showed VBD B-VP O
5 551 564 11431197 pathognomonic JJ B-NP O
6 565 573 11431197 features NNS I-NP O
7 573 574 11431197 , , O O
8 575 584 11431197 including VBG B-PP O
9 585 597 11431197 eosinophilic JJ B-NP O
10 598 610 11431197 infiltration NN I-NP O
11 611 613 11431197 of IN B-PP O
12 614 617 11431197 the DT B-NP O
13 618 630 11431197 interstitial JJ I-NP O
14 631 642 11431197 compartment NN I-NP O
15 642 643 11431197 . . O O

1 644 653 11431197 Allograft NN B-NP O
2 654 662 11431197 function NN I-NP O
3 663 671 11431197 improved VBD B-VP O
4 672 679 11431197 rapidly RB B-ADVP O
5 680 683 11431197 and CC O O
6 684 692 11431197 returned VBD B-VP O
7 693 695 11431197 to TO B-PP O
8 696 704 11431197 baseline NN B-NP O
9 705 710 11431197 after IN B-PP O
10 711 719 11431197 stopping VBG B-VP O
11 720 723 11431197 the DT B-NP O
12 724 728 11431197 drug NN I-NP O
13 728 729 11431197 . . O O

1 0 0 3437726 -DOCSTART- -X- -X- O

1 0 6 3437726 Severe JJ B-NP O
2 7 20 3437726 complications NNS I-NP O
3 21 23 3437726 of IN B-PP O
4 24 35 3437726 antianginal JJ B-NP O
5 36 40 3437726 drug NN I-NP O
6 41 48 3437726 therapy NN I-NP O
7 49 51 3437726 in IN B-PP O
8 52 53 3437726 a DT B-NP O
9 54 61 3437726 patient NN I-NP O
10 62 72 3437726 identified VBN B-VP O
11 73 75 3437726 as IN B-PP O
12 76 77 3437726 a DT B-NP O
13 78 82 3437726 poor JJ I-NP O
14 83 94 3437726 metabolizer NN I-NP O
15 95 97 3437726 of IN B-PP O
16 98 108 3437726 metoprolol NN B-NP B-Chemical
17 108 109 3437726 , , O O
18 110 121 3437726 propafenone NN B-NP B-Chemical
19 121 122 3437726 , , O O
20 123 132 3437726 diltiazem NN B-NP B-Chemical
21 132 133 3437726 , , O O
22 134 137 3437726 and CC O O
23 138 147 3437726 sparteine NN B-NP B-Chemical
24 147 148 3437726 . . O O
25 149 150 3437726 A DT B-NP O
26 151 153 3437726 47 CD I-NP O
27 153 154 3437726 - HYPH I-NP O
28 154 158 3437726 year NN I-NP O
29 158 159 3437726 - HYPH O O
30 159 162 3437726 old JJ B-NP O
31 163 170 3437726 patient NN I-NP O
32 171 180 3437726 suffering VBG B-VP O
33 181 185 3437726 from IN B-PP O
34 186 194 3437726 coronary JJ B-NP B-Disease
35 195 201 3437726 artery NN I-NP I-Disease
36 202 209 3437726 disease NN I-NP I-Disease
37 210 213 3437726 was VBD B-VP O
38 214 222 3437726 admitted VBN I-VP O
39 223 225 3437726 to TO B-PP O
40 226 229 3437726 the DT B-NP O
41 230 233 3437726 CCU NN I-NP O
42 234 236 3437726 in IN B-PP O
43 237 242 3437726 shock NN B-NP B-Disease
44 243 247 3437726 with IN B-PP O
45 248 251 3437726 III CD B-NP O
46 251 252 3437726 . . O O

1 253 255 3437726 AV NN B-NP B-Disease
2 256 261 3437726 block NN I-NP I-Disease
3 261 262 3437726 , , O O
4 263 269 3437726 severe JJ B-NP O
5 270 281 3437726 hypotension NN I-NP B-Disease
6 281 282 3437726 , , O O
7 283 286 3437726 and CC O O
8 287 297 3437726 impairment NN B-NP B-Disease
9 298 300 3437726 of IN B-PP I-Disease
10 301 312 3437726 ventricular JJ B-NP I-Disease
11 313 321 3437726 function NN I-NP I-Disease
12 321 322 3437726 . . O O

1 323 326 3437726 One CD B-NP O
2 327 331 3437726 week NN I-NP O
3 332 337 3437726 prior JJ B-ADJP O
4 338 340 3437726 to TO B-VP O
5 341 350 3437726 admission NN I-VP O
6 351 352 3437726 a DT B-NP O
7 353 360 3437726 therapy NN I-NP O
8 361 365 3437726 with IN B-PP O
9 366 374 3437726 standard JJ B-NP O
10 375 380 3437726 doses NNS I-NP O
11 381 383 3437726 of IN B-PP O
12 384 394 3437726 metoprolol NN B-NP B-Chemical
13 395 396 3437726 ( ( O O
14 396 399 3437726 100 CD B-NP O
15 400 402 3437726 mg NN I-NP O
16 403 408 3437726 t.i.d NN I-NP O
17 408 409 3437726 . . O O

1 410 413 3437726 and CC O O
2 414 418 3437726 then RB O O
3 419 422 3437726 100 CD B-NP O
4 423 425 3437726 mg NN I-NP O
5 426 431 3437726 b.i.d NN I-NP O
6 431 432 3437726 . . O O
7 432 433 3437726 ) ) O O
8 434 437 3437726 had VBD B-VP O
9 438 442 3437726 been VBN I-VP O
10 443 452 3437726 initiated VBN I-VP O
11 452 453 3437726 . . O O

1 454 457 3437726 Two CD B-NP O
2 458 462 3437726 days NNS I-NP O
3 463 469 3437726 before IN B-PP O
4 470 479 3437726 admission NN B-NP O
5 480 489 3437726 diltiazem NN I-NP B-Chemical
6 490 491 3437726 ( ( O O
7 491 493 3437726 60 CD B-NP O
8 494 496 3437726 mg NN I-NP O
9 497 502 3437726 b.i.d NN I-NP O
10 502 503 3437726 . . O O
11 503 504 3437726 ) ) O O
12 505 508 3437726 was VBD B-VP O
13 509 519 3437726 prescribed VBN I-VP O
14 520 522 3437726 in IN B-PP O
15 523 531 3437726 addition NN B-NP O
16 531 532 3437726 . . O O

1 533 541 3437726 Analyses NNS B-NP O
2 542 544 3437726 of IN B-PP O
3 545 546 3437726 a DT B-NP O
4 547 552 3437726 blood NN I-NP O
5 553 559 3437726 sample NN I-NP O
6 560 568 3437726 revealed VBD B-VP O
7 569 578 3437726 unusually RB B-NP O
8 579 583 3437726 high JJ I-NP O
9 584 590 3437726 plasma NN I-NP O
10 591 605 3437726 concentrations NNS I-NP O
11 606 608 3437726 of IN B-PP O
12 609 619 3437726 metoprolol NN B-NP B-Chemical
13 620 621 3437726 ( ( O O
14 621 628 3437726 greater JJR B-NP O
15 629 633 3437726 than IN I-NP O
16 634 638 3437726 3000 CD I-NP O
17 639 641 3437726 ng NN I-NP O
18 641 642 3437726 / SYM B-NP O
19 642 644 3437726 ml NN I-NP O
20 644 645 3437726 ) ) O O
21 646 649 3437726 and CC O O
22 650 659 3437726 diltiazem NN B-NP B-Chemical
23 660 661 3437726 ( ( O O
24 661 664 3437726 526 CD B-NP O
25 665 667 3437726 ng NN I-NP O
26 667 668 3437726 / SYM B-NP O
27 668 670 3437726 ml NN I-NP O
28 670 671 3437726 ) ) O O
29 671 672 3437726 . . O O

1 673 676 3437726 The DT B-NP O
2 677 684 3437726 patient NN I-NP O
3 685 694 3437726 recovered VBD B-VP O
4 695 701 3437726 within IN B-PP O
5 702 703 3437726 1 CD B-NP O
6 704 708 3437726 week NN I-NP O
7 709 718 3437726 following VBG B-PP O
8 719 734 3437726 discontinuation NN B-NP O
9 735 737 3437726 of IN B-PP O
10 738 749 3437726 antianginal JJ B-NP O
11 750 757 3437726 therapy NN I-NP O
12 757 758 3437726 . . O O

1 759 764 3437726 Three CD B-NP O
2 765 771 3437726 months NNS I-NP O
3 772 777 3437726 later RB B-ADVP O
4 778 781 3437726 the DT B-NP O
5 782 789 3437726 patient NN I-NP O
6 790 793 3437726 was VBD B-VP O
7 794 801 3437726 exposed VBN I-VP O
8 802 804 3437726 to TO B-PP O
9 805 806 3437726 a DT B-NP O
10 807 813 3437726 single JJ I-NP O
11 814 818 3437726 dose NN I-NP O
12 819 821 3437726 of IN B-PP O
13 822 832 3437726 metoprolol NN B-NP B-Chemical
14 832 833 3437726 , , O O
15 834 843 3437726 diltiazem NN B-NP B-Chemical
16 843 844 3437726 , , O O
17 845 856 3437726 propafenone NN B-NP B-Chemical
18 857 858 3437726 ( ( O O
19 858 863 3437726 since IN B-SBAR O
20 864 866 3437726 he PRP B-NP O
21 867 870 3437726 had VBD B-VP O
22 871 879 3437726 received VBN I-VP O
23 880 884 3437726 this DT B-NP O
24 885 889 3437726 drug NN I-NP O
25 890 892 3437726 in IN B-PP O
26 893 896 3437726 the DT B-NP O
27 897 901 3437726 past NN I-NP O
28 901 902 3437726 ) ) O O
29 902 903 3437726 , , O O
30 904 907 3437726 and CC O O
31 908 917 3437726 sparteine NN B-NP B-Chemical
32 918 919 3437726 ( ( O O
33 919 921 3437726 as IN B-PP O
34 922 923 3437726 a DT B-NP O
35 924 929 3437726 probe NN I-NP O
36 930 933 3437726 for IN B-PP O
37 934 937 3437726 the DT B-NP O
38 938 950 3437726 debrisoquine NN I-NP B-Chemical
39 950 951 3437726 / SYM B-NP O
40 951 960 3437726 sparteine NN I-NP B-Chemical
41 961 965 3437726 type NN I-NP O
42 966 978 3437726 polymorphism NN I-NP O
43 979 981 3437726 of IN B-PP O
44 982 991 3437726 oxidative JJ B-NP O
45 992 996 3437726 drug NN I-NP O
46 997 1007 3437726 metabolism NN I-NP O
47 1007 1008 3437726 ) ) O O
48 1008 1009 3437726 . . O O

1 1010 1012 3437726 It PRP B-NP O
2 1013 1016 3437726 was VBD B-VP O
3 1017 1022 3437726 found VBN I-VP O
4 1023 1027 3437726 that IN B-SBAR O
5 1028 1030 3437726 he PRP B-NP O
6 1031 1034 3437726 was VBD B-VP O
7 1035 1036 3437726 a DT B-NP O
8 1037 1041 3437726 poor JJ I-NP O
9 1042 1053 3437726 metabolizer NN I-NP O
10 1054 1056 3437726 of IN B-PP O
11 1057 1060 3437726 all DT B-NP O
12 1061 1065 3437726 four CD I-NP O
13 1066 1071 3437726 drugs NNS I-NP O
14 1071 1072 3437726 , , O O
15 1073 1083 3437726 indicating VBG B-VP O
16 1084 1088 3437726 that IN B-SBAR O
17 1089 1094 3437726 their PRP$ B-NP O
18 1095 1105 3437726 metabolism NN I-NP O
19 1106 1108 3437726 is VBZ B-VP O
20 1109 1114 3437726 under IN B-PP O
21 1115 1118 3437726 the DT B-NP O
22 1119 1123 3437726 same JJ I-NP O
23 1124 1131 3437726 genetic JJ I-NP O
24 1132 1139 3437726 control NN I-NP O
25 1139 1140 3437726 . . O O

1 1141 1150 3437726 Therefore RB B-ADVP O
2 1150 1151 3437726 , , O O
3 1152 1160 3437726 patients NNS B-NP O
4 1161 1170 3437726 belonging VBG B-VP O
5 1171 1173 3437726 to TO B-PP O
6 1174 1177 3437726 the DT B-NP O
7 1178 1182 3437726 poor JJ I-NP O
8 1182 1183 3437726 - HYPH I-NP O
9 1183 1194 3437726 metabolizer NN I-NP O
10 1195 1204 3437726 phenotype NN I-NP O
11 1205 1207 3437726 of IN B-PP O
12 1208 1217 3437726 sparteine NN B-NP B-Chemical
13 1217 1218 3437726 / SYM B-NP O
14 1218 1230 3437726 debrisoquine NN I-NP B-Chemical
15 1231 1243 3437726 polymorphism NN I-NP O
16 1244 1246 3437726 in IN B-PP O
17 1247 1251 3437726 drug NN B-NP O
18 1252 1262 3437726 metabolism NN I-NP O
19 1262 1263 3437726 , , O O
20 1264 1269 3437726 which WDT B-NP O
21 1270 1281 3437726 constitutes VBZ B-VP O
22 1282 1286 3437726 6.4% CD B-NP O
23 1287 1289 3437726 of IN B-PP O
24 1290 1293 3437726 the DT B-NP O
25 1294 1300 3437726 German JJ I-NP O
26 1301 1311 3437726 population NN I-NP O
27 1311 1312 3437726 , , O O
28 1313 1316 3437726 may MD B-VP O
29 1317 1327 3437726 experience VB I-VP O
30 1328 1335 3437726 adverse JJ B-NP B-Disease
31 1336 1340 3437726 drug NN I-NP I-Disease
32 1341 1350 3437726 reactions NNS I-NP I-Disease
33 1351 1355 3437726 when WRB B-ADVP O
34 1356 1363 3437726 treated VBN B-VP O
35 1364 1368 3437726 with IN B-PP O
36 1369 1377 3437726 standard JJ B-NP O
37 1378 1383 3437726 doses NNS I-NP O
38 1384 1386 3437726 of IN B-PP O
39 1387 1390 3437726 one CD B-NP O
40 1391 1393 3437726 of IN B-PP O
41 1394 1399 3437726 these DT B-NP O
42 1400 1405 3437726 drugs NNS I-NP O
43 1406 1411 3437726 alone RB B-ADVP O
44 1411 1412 3437726 . . O O

1 1413 1421 3437726 Moreover RB B-ADVP O
2 1421 1422 3437726 , , O O
3 1423 1426 3437726 the DT B-NP O
4 1427 1443 3437726 coadministration NN I-NP O
5 1444 1446 3437726 of IN B-PP O
6 1447 1452 3437726 these DT B-NP O
7 1453 1463 3437726 frequently RB I-NP O
8 1464 1468 3437726 used VBN I-NP O
9 1469 1474 3437726 drugs NNS I-NP O
10 1475 1477 3437726 is VBZ B-VP O
11 1478 1486 3437726 expected VBN I-VP O
12 1487 1489 3437726 to TO I-VP O
13 1490 1492 3437726 be VB I-VP O
14 1493 1503 3437726 especially RB B-ADJP O
15 1504 1511 3437726 harmful JJ I-ADJP O
16 1512 1514 3437726 in IN B-PP O
17 1515 1519 3437726 this DT B-NP O
18 1520 1528 3437726 subgroup NN I-NP O
19 1529 1531 3437726 of IN B-PP O
20 1532 1540 3437726 patients NNS B-NP O
21 1540 1541 3437726 . . O O

1 0 0 11250767 -DOCSTART- -X- -X- O

1 0 16 11250767 Propylthiouracil NN B-NP B-Chemical
2 16 17 11250767 - HYPH O O
3 17 24 11250767 induced VBN B-NP O
4 25 36 11250767 perinuclear JJ I-NP O
5 36 37 11250767 - HYPH I-NP O
6 37 45 11250767 staining NN I-NP O
7 46 60 11250767 antineutrophil NN I-NP O
8 61 72 11250767 cytoplasmic JJ I-NP O
9 73 85 11250767 autoantibody NN I-NP O
10 85 86 11250767 - HYPH B-NP O
11 86 94 11250767 positive JJ I-NP O
12 95 105 11250767 vasculitis NN I-NP B-Disease
13 106 108 11250767 in IN B-PP O
14 109 120 11250767 conjunction NN B-NP O
15 121 125 11250767 with IN B-PP O
16 126 138 11250767 pericarditis NN B-NP B-Disease
17 138 139 11250767 . . O O
18 140 149 11250767 OBJECTIVE NN B-NP O
19 149 150 11250767 : : O O
20 151 153 11250767 To TO B-VP O
21 154 162 11250767 describe VB I-VP O
22 163 164 11250767 a DT B-NP O
23 165 169 11250767 case NN I-NP O
24 170 172 11250767 of IN B-PP O
25 173 189 11250767 propylthiouracil NN B-NP B-Chemical
26 189 190 11250767 - HYPH B-NP O
27 190 197 11250767 induced VBN I-NP O
28 198 208 11250767 vasculitis NN I-NP B-Disease
29 209 220 11250767 manifesting VBG B-VP O
30 221 225 11250767 with IN B-PP O
31 226 238 11250767 pericarditis NN B-NP B-Disease
32 238 239 11250767 . . O O

1 240 247 11250767 METHODS NNS B-NP O
2 247 248 11250767 : : O O
3 249 251 11250767 We PRP B-NP O
4 252 259 11250767 present VBP B-VP O
5 260 263 11250767 the DT B-NP O
6 264 269 11250767 first JJ I-NP O
7 270 274 11250767 case NN I-NP O
8 275 281 11250767 report NN I-NP O
9 282 284 11250767 of IN B-PP O
10 285 286 11250767 a DT B-NP O
11 287 292 11250767 woman NN I-NP O
12 293 297 11250767 with IN B-PP O
13 298 313 11250767 hyperthyroidism NN B-NP B-Disease
14 314 321 11250767 treated VBN B-VP O
15 322 326 11250767 with IN B-PP O
16 327 343 11250767 propylthiouracil NN B-NP B-Chemical
17 344 346 11250767 in IN B-PP O
18 347 351 11250767 whom WP B-NP O
19 352 353 11250767 a DT B-NP O
20 354 362 11250767 syndrome NN I-NP O
21 363 365 11250767 of IN B-PP O
22 366 378 11250767 pericarditis NN B-NP B-Disease
23 378 379 11250767 , , O O
24 380 385 11250767 fever NN B-NP B-Disease
25 385 386 11250767 , , O O
26 387 390 11250767 and CC O O
27 391 409 11250767 glomerulonephritis NN B-NP B-Disease
28 410 419 11250767 developed VBD B-VP O
29 419 420 11250767 . . O O

1 421 430 11250767 Serologic JJ B-NP O
2 431 438 11250767 testing NN I-NP O
3 439 442 11250767 and CC O O
4 443 454 11250767 immunologic JJ B-NP O
5 455 462 11250767 studies NNS I-NP O
6 463 467 11250767 were VBD B-VP O
7 468 472 11250767 done VBN I-VP O
8 472 473 11250767 , , O O
9 474 477 11250767 and CC O O
10 478 479 11250767 a DT B-NP O
11 480 491 11250767 pericardial JJ I-NP O
12 492 498 11250767 biopsy NN I-NP O
13 499 502 11250767 was VBD B-VP O
14 503 512 11250767 performed VBN I-VP O
15 512 513 11250767 . . O O

1 514 521 11250767 RESULTS NNS B-NP O
2 521 522 11250767 : : O O
3 523 524 11250767 A DT B-NP O
4 525 527 11250767 25 CD I-NP O
5 527 528 11250767 - HYPH I-NP O
6 528 532 11250767 year NN I-NP O
7 532 533 11250767 - HYPH O O
8 533 536 11250767 old JJ B-NP O
9 537 542 11250767 woman NN I-NP O
10 543 547 11250767 with IN B-PP O
11 548 555 11250767 Graves' NN B-NP B-Disease
12 556 563 11250767 disease NN I-NP I-Disease
13 564 567 11250767 had VBD B-VP O
14 568 569 11250767 a DT B-NP O
15 570 577 11250767 febrile JJ I-NP B-Disease
16 578 585 11250767 illness NN I-NP I-Disease
17 586 589 11250767 and CC I-NP O
18 590 598 11250767 evidence NN I-NP O
19 599 601 11250767 of IN B-PP O
20 602 614 11250767 pericarditis NN B-NP B-Disease
21 614 615 11250767 , , O O
22 616 621 11250767 which WDT B-NP O
23 622 625 11250767 was VBD B-VP O
24 626 635 11250767 confirmed VBN I-VP O
25 636 638 11250767 by IN B-PP O
26 639 645 11250767 biopsy NN B-NP O
27 645 646 11250767 . . O O

1 647 656 11250767 Serologic JJ B-NP O
2 657 667 11250767 evaluation NN I-NP O
3 668 676 11250767 revealed VBD B-VP O
4 677 680 11250767 the DT B-NP O
5 681 689 11250767 presence NN I-NP O
6 690 692 11250767 of IN B-PP O
7 693 704 11250767 perinuclear JJ B-NP O
8 704 705 11250767 - HYPH I-NP O
9 705 713 11250767 staining NN I-NP O
10 714 728 11250767 antineutrophil NN I-NP O
11 729 740 11250767 cytoplasmic JJ I-NP O
12 741 755 11250767 autoantibodies NNS I-NP O
13 756 757 11250767 ( ( O O
14 757 762 11250767 pANCA NN B-NP O
15 762 763 11250767 ) ) O O
16 764 771 11250767 against IN B-PP O
17 772 787 11250767 myeloperoxidase NN B-NP O
18 788 789 11250767 ( ( O O
19 789 792 11250767 MPO NN B-NP O
20 792 793 11250767 ) ) O O
21 793 794 11250767 . . O O

1 795 811 11250767 Propylthiouracil NN B-NP B-Chemical
2 812 819 11250767 therapy NN I-NP O
3 820 823 11250767 was VBD B-VP O
4 824 833 11250767 withdrawn VBN I-VP O
5 833 834 11250767 , , O O
6 835 838 11250767 and CC O O
7 839 842 11250767 she PRP B-NP O
8 843 846 11250767 was VBD B-VP O
9 847 854 11250767 treated VBN I-VP O
10 855 859 11250767 with IN B-PP O
11 860 861 11250767 a DT B-NP O
12 862 863 11250767 1 CD I-NP O
13 863 864 11250767 - HYPH I-NP O
14 864 869 11250767 month NN I-NP O
15 870 876 11250767 course NN I-NP O
16 877 879 11250767 of IN B-PP O
17 880 890 11250767 prednisone NN B-NP B-Chemical
18 890 891 11250767 , , O O
19 892 897 11250767 which WDT B-NP O
20 898 908 11250767 alleviated VBD B-VP O
21 909 912 11250767 her PRP$ B-NP O
22 913 921 11250767 symptoms NNS I-NP O
23 921 922 11250767 . . O O

1 923 924 11250767 A DT B-NP O
2 925 935 11250767 literature NN I-NP O
3 936 942 11250767 review NN I-NP O
4 943 951 11250767 revealed VBD B-VP O
5 952 954 11250767 no DT B-NP O
6 955 960 11250767 prior JJ I-NP O
7 961 968 11250767 reports NNS I-NP O
8 969 971 11250767 of IN B-PP O
9 972 984 11250767 pericarditis NN B-NP B-Disease
10 985 987 11250767 in IN B-PP O
11 988 992 11250767 anti AFX B-NP O
12 992 993 11250767 - HYPH I-NP O
13 993 996 11250767 MPO NN I-NP O
14 997 1002 11250767 pANCA NN I-NP O
15 1002 1003 11250767 - HYPH B-NP O
16 1003 1011 11250767 positive JJ I-NP O
17 1012 1022 11250767 vasculitis NN I-NP B-Disease
18 1023 1033 11250767 associated VBN B-VP O
19 1034 1038 11250767 with IN B-PP O
20 1039 1049 11250767 propylthio AFX B-NP B-Chemical
21 1049 1050 11250767 - HYPH I-NP I-Chemical
22 1051 1057 11250767 uracil NN I-NP I-Chemical
23 1058 1065 11250767 therapy NN I-NP O
24 1065 1066 11250767 . . O O

1 1067 1077 11250767 CONCLUSION NN B-NP O
2 1077 1078 11250767 : : O O
3 1079 1091 11250767 Pericarditis NN B-NP B-Disease
4 1092 1095 11250767 may MD B-VP O
5 1096 1098 11250767 be VB I-VP O
6 1099 1102 11250767 the DT B-NP O
7 1103 1110 11250767 initial JJ I-NP O
8 1111 1124 11250767 manifestation NN I-NP O
9 1125 1127 11250767 of IN B-PP O
10 1128 1132 11250767 drug NN B-NP O
11 1132 1133 11250767 - HYPH B-NP O
12 1133 1140 11250767 induced VBN I-NP O
13 1141 1151 11250767 vasculitis NN I-NP B-Disease
14 1152 1164 11250767 attributable JJ B-ADJP O
15 1165 1167 11250767 to TO B-PP O
16 1168 1178 11250767 propylthio AFX B-NP B-Chemical
17 1178 1179 11250767 - HYPH I-NP I-Chemical
18 1180 1186 11250767 uracil NN I-NP I-Chemical
19 1187 1194 11250767 therapy NN I-NP O
20 1194 1195 11250767 . . O O

1 0 0 18619688 -DOCSTART- -X- -X- O

1 0 10 18619688 Adriamycin NN B-NP B-Chemical
2 10 11 18619688 - HYPH O O
3 11 18 18619688 induced VBN B-NP O
4 19 29 18619688 autophagic JJ I-NP O
5 30 43 18619688 cardiomyocyte NN I-NP O
6 44 49 18619688 death NN I-NP B-Disease
7 50 55 18619688 plays VBZ B-VP O
8 56 57 18619688 a DT B-NP O
9 58 68 18619688 pathogenic JJ I-NP O
10 69 73 18619688 role NN I-NP O
11 74 76 18619688 in IN B-PP O
12 77 78 18619688 a DT B-NP O
13 79 82 18619688 rat NN I-NP O
14 83 88 18619688 model NN I-NP O
15 89 91 18619688 of IN B-PP O
16 92 97 18619688 heart NN B-NP B-Disease
17 98 105 18619688 failure NN I-NP I-Disease
18 105 106 18619688 . . I-NP O
19 107 117 18619688 BACKGROUND NN I-NP O
20 117 118 18619688 : : O O
21 119 122 18619688 The DT B-NP O
22 123 133 18619688 mechanisms NNS I-NP O
23 134 144 18619688 underlying VBG B-VP O
24 145 150 18619688 heart NN B-NP B-Disease
25 151 158 18619688 failure NN I-NP I-Disease
26 159 166 18619688 induced VBN B-VP O
27 167 169 18619688 by IN B-PP O
28 170 180 18619688 adriamycin NN B-NP B-Chemical
29 181 184 18619688 are VBP B-VP O
30 185 189 18619688 very RB B-ADJP O
31 190 201 18619688 complicated VBN I-ADJP O
32 202 205 18619688 and CC O O
33 206 211 18619688 still RB B-ADJP O
34 212 219 18619688 unclear JJ I-ADJP O
35 219 220 18619688 . . O O

1 221 224 18619688 The DT B-NP O
2 225 228 18619688 aim NN I-NP O
3 229 231 18619688 of IN B-PP O
4 232 236 18619688 this DT B-NP O
5 237 242 18619688 study NN I-NP O
6 243 246 18619688 was VBD B-VP O
7 247 249 18619688 to TO B-VP O
8 250 261 18619688 investigate VB I-VP O
9 262 269 18619688 whether IN B-SBAR O
10 270 279 18619688 autophagy NN B-NP O
11 280 283 18619688 was VBD B-VP O
12 284 292 18619688 involved VBN I-VP O
13 293 295 18619688 in IN B-PP O
14 296 299 18619688 the DT B-NP O
15 300 311 18619688 progression NN I-NP O
16 312 314 18619688 of IN B-PP O
17 315 320 18619688 heart NN B-NP B-Disease
18 321 328 18619688 failure NN I-NP I-Disease
19 329 336 18619688 induced VBN B-VP O
20 337 339 18619688 by IN B-PP O
21 340 350 18619688 adriamycin NN B-NP B-Chemical
22 350 351 18619688 , , O O
23 352 354 18619688 so IN B-SBAR O
24 355 359 18619688 that IN I-SBAR O
25 360 362 18619688 we PRP B-NP O
26 363 366 18619688 can MD B-VP O
27 367 374 18619688 develop VB I-VP O
28 375 376 18619688 a DT B-NP O
29 377 382 18619688 novel JJ I-NP O
30 383 392 18619688 treatment NN I-NP O
31 393 401 18619688 strategy NN I-NP O
32 402 405 18619688 for IN B-PP O
33 406 411 18619688 heart NN B-NP B-Disease
34 412 419 18619688 failure NN I-NP I-Disease
35 419 420 18619688 . . O O

1 421 428 18619688 METHODS NNS B-NP O
2 428 429 18619688 : : O O
3 430 431 18619688 3 CD B-NP B-Chemical
4 431 432 18619688 - HYPH I-NP I-Chemical
5 432 445 18619688 methyladenine NN I-NP I-Chemical
6 446 447 18619688 ( ( O O
7 447 450 18619688 3MA NN B-NP B-Chemical
8 450 451 18619688 ) ) O O
9 451 452 18619688 , , O O
10 453 454 18619688 a DT B-NP O
11 455 463 18619688 specific JJ I-NP O
12 464 473 18619688 inhibitor NN I-NP O
13 474 476 18619688 on IN B-PP O
14 477 486 18619688 autophagy NN B-NP O
15 487 490 18619688 was VBD B-VP O
16 491 495 18619688 used VBN I-VP O
17 496 498 18619688 in IN B-PP O
18 499 500 18619688 a DT B-NP O
19 501 506 18619688 heart NN I-NP B-Disease
20 507 514 18619688 failure NN I-NP I-Disease
21 515 520 18619688 model NN I-NP O
22 521 523 18619688 of IN B-PP O
23 524 528 18619688 rats NNS B-NP O
24 529 536 18619688 induced VBN B-VP O
25 537 539 18619688 by IN B-PP O
26 540 550 18619688 adriamycin NN B-NP B-Chemical
27 550 551 18619688 . . O O

1 552 560 18619688 Neonatal JJ B-NP O
2 561 575 18619688 cardiomyocytes NNS I-NP O
3 576 580 18619688 were VBD B-VP O
4 581 589 18619688 isolated VBN I-VP O
5 590 594 18619688 from IN B-PP O
6 595 602 18619688 Sprague NNP B-NP O
7 602 603 18619688 - HYPH I-NP O
8 603 609 18619688 Dawley NNP I-NP O
9 610 613 18619688 rat NN I-NP O
10 614 620 18619688 hearts NNS I-NP O
11 621 624 18619688 and CC O O
12 625 633 18619688 randomly RB B-VP O
13 634 641 18619688 divided VBN I-VP O
14 642 646 18619688 into IN B-PP O
15 647 655 18619688 controls NNS B-NP O
16 655 656 18619688 , , O O
17 657 659 18619688 an DT B-NP O
18 660 670 18619688 adriamycin NN I-NP B-Chemical
19 670 671 18619688 - HYPH B-NP O
20 671 678 18619688 treated VBN I-NP O
21 679 684 18619688 group NN I-NP O
22 684 685 18619688 , , O O
23 686 689 18619688 and CC O O
24 690 691 18619688 a DT B-NP O
25 692 695 18619688 3MA NN I-NP B-Chemical
26 696 700 18619688 plus CC I-NP O
27 701 711 18619688 adriamycin NN I-NP B-Chemical
28 711 712 18619688 - HYPH B-NP O
29 712 719 18619688 treated VBN I-NP O
30 720 725 18619688 group NN I-NP O
31 725 726 18619688 . . O O

1 727 729 18619688 We PRP B-NP O
2 730 734 18619688 then RB B-ADVP O
3 735 743 18619688 examined VBD B-VP O
4 744 747 18619688 the DT B-NP O
5 748 758 18619688 morphology NN I-NP O
6 758 759 18619688 , , O O
7 760 770 18619688 expression NN B-NP O
8 771 773 18619688 of IN B-PP O
9 774 780 18619688 beclin NN B-NP O
10 781 782 18619688 1 CD I-NP O
11 783 787 18619688 gene NN I-NP O
12 787 788 18619688 , , O O
13 789 802 18619688 mitochondrial JJ B-NP O
14 803 815 18619688 permeability NN I-NP O
15 816 826 18619688 transition NN I-NP O
16 827 828 18619688 ( ( O O
17 828 831 18619688 MPT NN B-NP O
18 831 832 18619688 ) ) O O
19 832 833 18619688 , , O O
20 834 837 18619688 and CC O O
21 838 841 18619688 Na+ NN B-NP O
22 841 842 18619688 - HYPH O O
23 842 844 18619688 K+ SYM O B-Chemical
24 845 851 18619688 ATPase NN B-NP O
25 852 860 18619688 activity NN I-NP O
26 861 863 18619688 in FW B-ADVP O
27 864 868 18619688 vivo FW I-ADVP O
28 868 869 18619688 . . O O

1 870 872 18619688 We PRP B-NP O
2 873 877 18619688 also RB B-ADVP O
3 878 886 18619688 assessed VBD B-VP O
4 887 891 18619688 cell NN B-NP O
5 892 901 18619688 viability NN I-NP O
6 901 902 18619688 , , O O
7 903 916 18619688 mitochondrial JJ B-NP O
8 917 925 18619688 membrane NN I-NP O
9 926 935 18619688 potential NN I-NP O
10 936 943 18619688 changes NNS I-NP O
11 944 947 18619688 and CC O O
12 948 955 18619688 counted VBD B-VP O
13 956 966 18619688 autophagic JJ B-NP O
14 967 975 18619688 vacuoles NNS I-NP O
15 976 978 18619688 in IN B-PP O
16 979 987 18619688 cultured VBN B-NP O
17 988 1002 18619688 cardiomyocytes NNS I-NP O
18 1002 1003 18619688 . . O O

1 1004 1006 18619688 In IN B-PP O
2 1007 1015 18619688 addition NN B-NP O
3 1015 1016 18619688 , , O O
4 1017 1019 18619688 we PRP B-NP O
5 1020 1028 18619688 analyzed VBD B-VP O
6 1029 1032 18619688 the DT B-NP O
7 1033 1043 18619688 expression NN I-NP O
8 1044 1046 18619688 of IN B-PP O
9 1047 1056 18619688 autophagy NN B-NP O
10 1057 1067 18619688 associated JJ I-NP O
11 1068 1072 18619688 gene NN I-NP O
12 1072 1073 18619688 , , O O
13 1074 1080 18619688 beclin NN B-NP O
14 1081 1082 18619688 1 CD I-NP O
15 1083 1088 18619688 using VBG B-VP O
16 1089 1091 18619688 RT NN B-NP O
17 1091 1092 18619688 - HYPH I-NP O
18 1092 1095 18619688 PCR NN I-NP O
19 1096 1099 18619688 and CC I-NP O
20 1100 1107 18619688 Western NN I-NP O
21 1108 1116 18619688 blotting NN I-NP O
22 1117 1119 18619688 in IN B-PP O
23 1120 1122 18619688 an DT B-NP O
24 1123 1129 18619688 animal NN I-NP O
25 1130 1135 18619688 model NN I-NP O
26 1135 1136 18619688 . . O O

1 1137 1144 18619688 RESULTS NNS B-NP O
2 1144 1145 18619688 : : O O
3 1146 1149 18619688 3MA NN B-NP B-Chemical
4 1150 1163 18619688 significantly RB B-ADVP O
5 1164 1172 18619688 improved VBD B-VP O
6 1173 1180 18619688 cardiac JJ B-NP O
7 1181 1189 18619688 function NN I-NP O
8 1190 1193 18619688 and CC O O
9 1194 1201 18619688 reduced VBN B-NP O
10 1202 1215 18619688 mitochondrial JJ I-NP O
11 1216 1222 18619688 injury NN I-NP O
12 1222 1223 18619688 . . O O

1 1224 1235 18619688 Furthermore RB B-ADVP O
2 1235 1236 18619688 , , O O
3 1237 1247 18619688 adriamycin NN B-NP B-Chemical
4 1248 1255 18619688 induced VBD B-VP O
5 1256 1259 18619688 the DT B-NP O
6 1260 1269 18619688 formation NN I-NP O
7 1270 1272 18619688 of IN B-PP O
8 1273 1283 18619688 autophagic JJ B-NP O
9 1284 1292 18619688 vacuoles NNS I-NP O
10 1292 1293 18619688 , , O O
11 1294 1297 18619688 and CC O O
12 1298 1301 18619688 3MA NN B-NP B-Chemical
13 1302 1310 18619688 strongly RB B-ADVP O
14 1311 1324 18619688 downregulated VBD B-VP O
15 1325 1328 18619688 the DT B-NP O
16 1329 1339 18619688 expression NN I-NP O
17 1340 1342 18619688 of IN B-PP O
18 1343 1349 18619688 beclin NN B-NP O
19 1350 1351 18619688 1 CD I-NP O
20 1352 1354 18619688 in IN B-PP O
21 1355 1365 18619688 adriamycin NN B-NP B-Chemical
22 1365 1366 18619688 - HYPH B-VP O
23 1366 1373 18619688 induced VBN I-VP O
24 1374 1381 18619688 failing VBG B-VP O
25 1382 1387 18619688 heart NN B-NP O
26 1388 1391 18619688 and CC O O
27 1392 1401 18619688 inhibited VBD B-VP O
28 1402 1405 18619688 the DT B-NP O
29 1406 1415 18619688 formation NN I-NP O
30 1416 1418 18619688 of IN B-PP O
31 1419 1429 18619688 autophagic JJ B-NP O
32 1430 1438 18619688 vacuoles NNS I-NP O
33 1438 1439 18619688 . . O O

1 1440 1450 18619688 CONCLUSION NN B-NP O
2 1450 1451 18619688 : : O O
3 1452 1462 18619688 Autophagic JJ B-NP O
4 1463 1476 18619688 cardiomyocyte NN I-NP O
5 1477 1482 18619688 death NN I-NP B-Disease
6 1483 1488 18619688 plays VBZ B-VP O
7 1489 1491 18619688 an DT B-NP O
8 1492 1501 18619688 important JJ I-NP O
9 1502 1506 18619688 role NN I-NP O
10 1507 1509 18619688 in IN B-PP O
11 1510 1513 18619688 the DT B-NP O
12 1514 1526 18619688 pathogenesis NN I-NP O
13 1527 1529 18619688 of IN B-PP O
14 1530 1535 18619688 heart NN B-NP B-Disease
15 1536 1543 18619688 failure NN I-NP I-Disease
16 1544 1546 18619688 in IN B-PP O
17 1547 1551 18619688 rats NNS B-NP O
18 1552 1559 18619688 induced VBN B-VP O
19 1560 1562 18619688 by IN B-PP O
20 1563 1573 18619688 adriamycin NN B-NP B-Chemical
21 1573 1574 18619688 . . O O

1 1575 1588 18619688 Mitochondrial JJ B-NP O
2 1589 1595 18619688 injury NN I-NP O
3 1596 1599 18619688 may MD B-VP O
4 1600 1602 18619688 be VB I-VP O
5 1603 1611 18619688 involved VBN I-VP O
6 1612 1614 18619688 in IN B-PP O
7 1615 1618 18619688 the DT B-NP O
8 1619 1630 18619688 progression NN I-NP O
9 1631 1633 18619688 of IN B-PP O
10 1634 1639 18619688 heart NN B-NP B-Disease
11 1640 1647 18619688 failure NN I-NP I-Disease
12 1648 1654 18619688 caused VBN B-VP O
13 1655 1657 18619688 by IN B-PP O
14 1658 1668 18619688 adriamycin NN B-NP B-Chemical
15 1669 1672 18619688 via IN B-PP O
16 1673 1676 18619688 the DT B-NP O
17 1677 1686 18619688 autophagy NN I-NP O
18 1687 1694 18619688 pathway NN I-NP O
19 1694 1695 18619688 . . O O

1 0 0 6888657 -DOCSTART- -X- -X- O

1 0 16 6888657 Characterization NN B-NP O
2 17 19 6888657 of IN B-PP O
3 20 28 6888657 estrogen NN B-NP B-Chemical
4 28 29 6888657 - HYPH B-NP O
5 29 36 6888657 induced VBN I-NP O
6 37 53 6888657 adenohypophyseal JJ I-NP B-Disease
7 54 60 6888657 tumors NNS I-NP I-Disease
8 61 63 6888657 in IN B-PP O
9 64 67 6888657 the DT B-NP O
10 68 75 6888657 Fischer NNP I-NP O
11 76 79 6888657 344 CD I-NP O
12 80 83 6888657 rat NN I-NP O
13 83 84 6888657 . . O O
14 85 94 6888657 Pituitary JJ B-NP B-Disease
15 95 101 6888657 tumors NNS I-NP I-Disease
16 102 106 6888657 were VBD B-VP O
17 107 114 6888657 induced VBN I-VP O
18 115 117 6888657 in IN B-PP O
19 118 122 6888657 F344 NN B-NP O
20 123 129 6888657 female JJ I-NP O
21 130 134 6888657 rats NNS I-NP O
22 135 137 6888657 by IN B-PP O
23 138 145 6888657 chronic JJ B-NP O
24 146 155 6888657 treatment NN I-NP O
25 156 160 6888657 with IN B-PP O
26 161 179 6888657 diethylstilbestrol NN B-NP B-Chemical
27 180 181 6888657 ( ( O O
28 181 184 6888657 DES NNP B-NP B-Chemical
29 184 185 6888657 , , O O
30 186 187 6888657 8 CD B-NP O
31 187 188 6888657 - HYPH I-NP O
32 188 190 6888657 10 CD I-NP O
33 191 193 6888657 mg NN I-NP O
34 193 194 6888657 ) ) O O
35 195 204 6888657 implanted VBN B-VP O
36 205 219 6888657 subcutaneously RB B-ADVP O
37 220 222 6888657 in IN B-PP O
38 223 231 6888657 silastic JJ B-NP O
39 232 240 6888657 capsules NNS I-NP O
40 240 241 6888657 . . O O

1 242 246 6888657 Over IN B-PP O
2 247 248 6888657 a DT B-NP O
3 249 254 6888657 range NN I-NP O
4 255 257 6888657 of IN B-PP O
5 258 259 6888657 1 CD B-NP O
6 259 260 6888657 - HYPH I-NP O
7 260 263 6888657 150 CD I-NP O
8 264 268 6888657 days NNS I-NP O
9 269 271 6888657 of IN B-PP O
10 272 275 6888657 DES NNP B-NP B-Chemical
11 276 285 6888657 treatment NN I-NP O
12 285 286 6888657 , , O O
13 287 292 6888657 pairs NNS B-NP O
14 293 295 6888657 of IN B-PP O
15 296 303 6888657 control NN B-NP O
16 304 307 6888657 and CC I-NP O
17 308 311 6888657 DES NN I-NP B-Chemical
18 311 312 6888657 - HYPH B-NP O
19 312 319 6888657 treated VBN I-NP O
20 320 324 6888657 rats NNS I-NP O
21 325 329 6888657 were VBD B-VP O
22 330 340 6888657 sacrificed VBN I-VP O
23 340 341 6888657 , , O O
24 342 345 6888657 and CC O O
25 346 351 6888657 their PRP$ B-NP O
26 352 363 6888657 pituitaries NNS I-NP O
27 364 375 6888657 dissociated VBN B-VP O
28 376 389 6888657 enzymatically RB B-ADVP O
29 390 394 6888657 into IN B-PP O
30 395 401 6888657 single JJ B-NP O
31 401 402 6888657 - HYPH I-NP O
32 402 406 6888657 cell NN I-NP O
33 407 419 6888657 preparations NNS I-NP O
34 419 420 6888657 . . O O

1 421 424 6888657 The DT B-NP O
2 425 429 6888657 cell NN I-NP O
3 430 441 6888657 populations NNS I-NP O
4 442 446 6888657 were VBD B-VP O
5 447 455 6888657 examined VBN I-VP O
6 456 465 6888657 regarding VBG B-PP O
7 466 471 6888657 total JJ B-NP O
8 472 476 6888657 cell NN I-NP O
9 477 485 6888657 recovery NN I-NP O
10 486 496 6888657 correlated VBD B-VP O
11 497 501 6888657 with IN B-PP O
12 502 507 6888657 gland NN B-NP O
13 508 514 6888657 weight NN I-NP O
14 514 515 6888657 , , O O
15 516 529 6888657 intracellular JJ B-NP O
16 530 539 6888657 prolactin NN I-NP O
17 540 541 6888657 ( ( O O
18 541 544 6888657 PRL NN B-NP O
19 544 545 6888657 ) ) O O
20 546 553 6888657 content NN B-NP O
21 554 557 6888657 and CC O O
22 558 568 6888657 subsequent JJ B-NP O
23 569 576 6888657 release NN I-NP O
24 577 579 6888657 in IN B-PP O
25 580 587 6888657 primary JJ B-NP O
26 588 595 6888657 culture NN I-NP O
27 595 596 6888657 , , O O
28 597 615 6888657 immunocytochemical JJ B-NP O
29 616 619 6888657 PRL NN I-NP O
30 620 628 6888657 staining NN I-NP O
31 628 629 6888657 , , O O
32 630 637 6888657 density NN B-NP O
33 638 641 6888657 and CC O O
34 641 642 6888657 / SYM B-NP O
35 642 644 6888657 or CC O O
36 645 649 6888657 size NN B-NP O
37 650 661 6888657 alterations NNS I-NP O
38 662 665 6888657 via IN B-PP O
39 666 676 6888657 separation NN B-NP O
40 677 679 6888657 on IN B-PP O
41 680 686 6888657 Ficoll NN B-NP O
42 686 687 6888657 - HYPH I-NP O
43 687 694 6888657 Hypaque NN I-NP O
44 695 698 6888657 and CC B-PP O
45 699 701 6888657 by IN B-PP O
46 702 706 6888657 unit NN B-NP O
47 707 714 6888657 gravity NN I-NP O
48 715 728 6888657 sedimentation NN I-NP O
49 728 729 6888657 , , O O
50 730 733 6888657 and CC O O
51 734 738 6888657 cell NN B-NP O
52 739 744 6888657 cycle NN I-NP O
53 745 753 6888657 analysis NN I-NP O
54 753 754 6888657 , , O O
55 755 760 6888657 after IN B-PP O
56 761 772 6888657 acriflavine NN B-NP B-Chemical
57 773 776 6888657 DNA NN I-NP O
58 777 785 6888657 staining NN I-NP O
59 785 786 6888657 , , O O
60 787 789 6888657 by IN B-PP O
61 790 795 6888657 laser NN B-NP O
62 796 800 6888657 flow NN I-NP O
63 801 810 6888657 cytometry NN I-NP O
64 810 811 6888657 . . O O

1 812 817 6888657 Total JJ B-NP O
2 818 822 6888657 cell NN I-NP O
3 823 829 6888657 yields NNS I-NP O
4 830 834 6888657 from IN B-PP O
5 835 838 6888657 DES NNP B-NP B-Chemical
6 838 839 6888657 - HYPH B-NP O
7 839 846 6888657 treated VBN I-NP O
8 847 858 6888657 pituitaries NNS I-NP O
9 859 868 6888657 increased VBD B-VP O
10 869 873 6888657 from IN B-PP O
11 874 877 6888657 1.3 CD B-NP O
12 878 883 6888657 times NNS I-NP O
13 884 891 6888657 control VBP B-VP O
14 892 898 6888657 yields NNS B-NP O
15 899 901 6888657 at IN B-PP O
16 902 903 6888657 8 CD B-NP O
17 904 908 6888657 days NNS I-NP O
18 909 911 6888657 of IN B-PP O
19 912 921 6888657 treatment NN B-NP O
20 922 924 6888657 to TO B-PP O
21 925 929 6888657 58.9 CD B-NP O
22 930 935 6888657 times NNS I-NP O
23 936 943 6888657 control VBP B-VP O
24 944 950 6888657 values NNS B-NP O
25 951 953 6888657 by IN B-PP O
26 954 957 6888657 day NN B-NP O
27 958 961 6888657 150 CD I-NP O
28 961 962 6888657 . . O O

1 963 976 6888657 Intracellular JJ B-NP O
2 977 980 6888657 PRL NN I-NP O
3 981 988 6888657 content NN I-NP O
4 989 995 6888657 ranged VBD B-VP O
5 996 1000 6888657 from IN B-PP O
6 1001 1004 6888657 1.9 CD B-NP O
7 1005 1007 6888657 to TO I-NP O
8 1008 1011 6888657 9.4 CD I-NP O
9 1012 1017 6888657 times NNS I-NP O
10 1018 1025 6888657 control NN I-NP O
11 1026 1032 6888657 levels NNS I-NP O
12 1032 1033 6888657 , , O O
13 1034 1037 6888657 and CC O O
14 1038 1041 6888657 PRL NN B-NP O
15 1042 1049 6888657 release NN I-NP O
16 1050 1052 6888657 in FW B-ADVP O
17 1053 1058 6888657 vitro FW I-ADVP O
18 1059 1062 6888657 was VBD B-VP O
19 1063 1076 6888657 significantly RB B-ADVP O
20 1077 1080 6888657 and CC I-ADVP O
21 1081 1093 6888657 consistently RB B-ADJP O
22 1094 1100 6888657 higher JJR I-ADJP O
23 1101 1105 6888657 than IN B-PP O
24 1106 1114 6888657 controls NNS B-NP O
25 1114 1115 6888657 , , O O
26 1116 1121 6888657 after IN B-PP O
27 1122 1124 6888657 at IN B-NP O
28 1125 1130 6888657 least JJS I-NP O
29 1131 1132 6888657 8 CD I-NP O
30 1133 1137 6888657 days NNS I-NP O
31 1138 1140 6888657 of IN B-PP O
32 1141 1144 6888657 DES NNP B-NP B-Chemical
33 1145 1153 6888657 exposure NN I-NP O
34 1153 1154 6888657 . . O O

1 1155 1161 6888657 Beyond IN B-PP O
2 1162 1163 6888657 8 CD B-NP O
3 1164 1168 6888657 days NNS I-NP O
4 1169 1171 6888657 of IN B-PP O
5 1172 1175 6888657 DES NNP B-NP B-Chemical
6 1176 1184 6888657 exposure NN I-NP O
7 1184 1185 6888657 , , O O
8 1186 1189 6888657 the DT B-NP O
9 1190 1206 6888657 immunochemically RB I-NP O
10 1207 1210 6888657 PRL NN I-NP O
11 1210 1211 6888657 - HYPH I-NP O
12 1211 1219 6888657 positive JJ I-NP O
13 1220 1230 6888657 proportion NN I-NP O
14 1231 1233 6888657 of IN B-PP O
15 1234 1239 6888657 cells NNS B-NP O
16 1240 1249 6888657 increased VBN B-VP O
17 1250 1252 6888657 to TO B-PP O
18 1253 1257 6888657 over IN B-NP O
19 1258 1261 6888657 50% CD I-NP O
20 1262 1264 6888657 of IN B-PP O
21 1265 1268 6888657 the DT B-NP O
22 1269 1274 6888657 total JJ I-NP O
23 1275 1285 6888657 population NN I-NP O
24 1285 1286 6888657 . . O O

1 1287 1296 6888657 Increased VBN B-NP O
2 1297 1304 6888657 density NN I-NP O
3 1305 1308 6888657 and CC O O
4 1308 1309 6888657 / SYM B-NP O
5 1309 1311 6888657 or CC O O
6 1312 1316 6888657 size NN B-NP O
7 1317 1320 6888657 and CC I-NP O
8 1321 1324 6888657 PRL NN I-NP O
9 1325 1332 6888657 content NN I-NP O
10 1333 1337 6888657 were VBD B-VP O
11 1338 1347 6888657 indicated VBN I-VP O
12 1348 1351 6888657 for IN B-PP O
13 1352 1355 6888657 the DT B-NP O
14 1356 1364 6888657 majority NN I-NP O
15 1365 1367 6888657 of IN B-PP O
16 1368 1371 6888657 the DT B-NP O
17 1372 1375 6888657 PRL NN I-NP O
18 1376 1380 6888657 cell NN I-NP O
19 1381 1391 6888657 population NN I-NP O
20 1392 1394 6888657 in IN B-PP O
21 1395 1399 6888657 both DT B-NP O
22 1400 1405 6888657 types NNS I-NP O
23 1406 1408 6888657 of IN B-PP O
24 1409 1419 6888657 separation NN B-NP O
25 1420 1429 6888657 protocols NNS I-NP O
26 1429 1430 6888657 . . O O

1 1431 1434 6888657 All PDT B-NP O
2 1435 1440 6888657 these DT I-NP O
3 1441 1448 6888657 effects NNS I-NP O
4 1449 1451 6888657 of IN B-PP O
5 1452 1455 6888657 DES NNS B-NP B-Chemical
6 1456 1460 6888657 were VBD B-VP O
7 1461 1465 6888657 more RBR B-ADJP O
8 1466 1476 6888657 pronounced JJ I-ADJP O
9 1477 1482 6888657 among IN B-PP O
10 1483 1493 6888657 previously RB B-NP O
11 1494 1508 6888657 ovariectomized VBN I-NP O
12 1509 1516 6888657 animals NNS I-NP O
13 1516 1517 6888657 . . O O

1 1518 1521 6888657 The DT B-NP O
2 1522 1526 6888657 data NNS I-NP O
3 1527 1533 6888657 extend VBP B-VP O
4 1534 1537 6888657 the DT B-NP O
5 1538 1546 6888657 findings NNS I-NP O
6 1547 1549 6888657 of IN B-PP O
7 1550 1555 6888657 other JJ B-NP O
8 1556 1569 6888657 investigators NNS I-NP O
9 1569 1570 6888657 , , O O
10 1571 1578 6888657 further RB B-ADVP O
11 1579 1591 6888657 establishing VBG B-VP O
12 1592 1595 6888657 the DT B-NP O
13 1596 1599 6888657 DES NNP I-NP B-Chemical
14 1599 1600 6888657 - HYPH B-NP O
15 1600 1607 6888657 induced VBN I-NP O
16 1608 1613 6888657 tumor NN I-NP B-Disease
17 1614 1616 6888657 as IN B-PP O
18 1617 1618 6888657 a DT B-NP O
19 1619 1624 6888657 model NN I-NP O
20 1625 1628 6888657 for IN B-PP O
21 1629 1634 6888657 study NN B-NP O
22 1635 1637 6888657 of IN B-PP O
23 1638 1641 6888657 PRL NN B-NP O
24 1642 1650 6888657 cellular JJ I-NP O
25 1651 1658 6888657 control NN I-NP O
26 1659 1669 6888657 mechanisms NNS I-NP O
27 1669 1670 6888657 . . O O

1 0 0 6538499 -DOCSTART- -X- -X- O

1 0 6 6538499 Effect NN B-NP O
2 7 9 6538499 of IN B-PP O
3 10 22 6538499 polyethylene NN B-NP B-Chemical
4 23 29 6538499 glycol NN I-NP I-Chemical
5 30 33 6538499 400 CD I-NP I-Chemical
6 34 36 6538499 on IN B-PP O
7 37 47 6538499 adriamycin NN B-NP B-Chemical
8 48 56 6538499 toxicity NN I-NP B-Disease
9 57 59 6538499 in IN B-PP O
10 60 64 6538499 mice NNS B-NP O
11 64 65 6538499 . . O O
12 66 69 6538499 The DT B-NP O
13 70 76 6538499 effect NN I-NP O
14 77 79 6538499 of IN B-PP O
15 80 81 6538499 a DT B-NP O
16 82 88 6538499 widely RB I-NP O
17 89 93 6538499 used VBN I-NP O
18 94 101 6538499 organic JJ I-NP O
19 102 109 6538499 solvent NN I-NP O
20 109 110 6538499 , , O O
21 111 123 6538499 polyethylene NN B-NP B-Chemical
22 124 130 6538499 glycol NN I-NP I-Chemical
23 131 134 6538499 400 CD I-NP I-Chemical
24 135 136 6538499 ( ( O O
25 136 139 6538499 PEG NN B-NP B-Chemical
26 140 143 6538499 400 CD I-NP I-Chemical
27 143 144 6538499 ) ) O O
28 144 145 6538499 , , O O
29 146 148 6538499 on IN B-PP O
30 149 152 6538499 the DT B-NP O
31 153 158 6538499 toxic JJ I-NP O
32 159 165 6538499 action NN I-NP O
33 166 168 6538499 of IN B-PP O
34 169 171 6538499 an DT B-NP O
35 172 177 6538499 acute JJ I-NP O
36 178 180 6538499 or CC I-NP O
37 181 188 6538499 chronic JJ I-NP O
38 189 198 6538499 treatment NN I-NP O
39 199 203 6538499 with IN B-PP O
40 204 214 6538499 adriamycin NN B-NP B-Chemical
41 215 216 6538499 ( ( O O
42 216 219 6538499 ADR NN B-NP B-Chemical
43 219 220 6538499 ) ) O O
44 221 224 6538499 was VBD B-VP O
45 225 234 6538499 evaluated VBN I-VP O
46 235 237 6538499 in IN B-PP O
47 238 242 6538499 mice NNS B-NP O
48 242 243 6538499 . . O O

1 244 247 6538499 PEG NN B-NP B-Chemical
2 248 251 6538499 400 CD I-NP I-Chemical
3 252 264 6538499 impressively RB B-ADVP O
4 265 274 6538499 decreased VBD B-VP O
5 275 279 6538499 both CC O O
6 280 285 6538499 acute JJ B-NP O
7 286 290 6538499 high JJ I-NP O
8 290 291 6538499 - HYPH I-NP O
9 291 295 6538499 dose NN I-NP O
10 296 299 6538499 and CC O O
11 300 307 6538499 chronic JJ B-NP O
12 308 311 6538499 low JJ I-NP O
13 311 312 6538499 - HYPH I-NP O
14 312 316 6538499 dose NN I-NP O
15 316 317 6538499 - HYPH B-NP O
16 317 320 6538499 ADR NN I-NP B-Chemical
17 320 321 6538499 - HYPH O O
18 321 331 6538499 associated VBN B-NP O
19 332 341 6538499 lethality NN I-NP O
20 341 342 6538499 . . O O

1 343 348 6538499 Light NN B-NP O
2 349 360 6538499 microscopic JJ I-NP O
3 361 369 6538499 analysis NN I-NP O
4 370 376 6538499 showed VBD B-VP O
5 377 378 6538499 a DT B-NP O
6 379 390 6538499 significant JJ I-NP O
7 391 401 6538499 protection NN I-NP O
8 402 409 6538499 against IN B-PP O
9 410 413 6538499 ADR NN B-NP B-Chemical
10 413 414 6538499 - HYPH B-NP O
11 414 421 6538499 induced VBN I-NP O
12 422 429 6538499 cardiac JJ I-NP B-Disease
13 430 443 6538499 morphological JJ I-NP I-Disease
14 444 455 6538499 alterations NNS I-NP I-Disease
15 455 456 6538499 . . O O

1 457 461 6538499 Such JJ B-NP O
2 462 471 6538499 treatment NN I-NP O
3 472 475 6538499 did VBD B-VP O
4 476 479 6538499 not RB I-VP O
5 480 488 6538499 diminish VB I-VP O
6 489 492 6538499 the DT B-NP O
7 493 496 6538499 ADR NN I-NP B-Chemical
8 497 506 6538499 antitumor NN I-NP O
9 507 515 6538499 activity NN I-NP O
10 516 518 6538499 in IN B-PP O
11 519 524 6538499 L1210 NN B-NP B-Disease
12 525 533 6538499 leukemia NN I-NP I-Disease
13 534 537 6538499 and CC B-PP O
14 538 540 6538499 in IN B-PP O
15 541 548 6538499 Ehrlich NNP B-NP B-Disease
16 549 556 6538499 ascites NNS I-NP I-Disease
17 557 562 6538499 tumor NN I-NP I-Disease
18 562 563 6538499 . . O O

1 0 0 19211690 -DOCSTART- -X- -X- O

1 0 12 19211690 Testosterone NN B-NP B-Chemical
2 12 13 19211690 - HYPH I-NP O
3 13 22 19211690 dependent JJ I-NP O
4 23 35 19211690 hypertension NN I-NP B-Disease
5 36 39 19211690 and CC I-NP O
6 40 52 19211690 upregulation NN I-NP O
7 53 55 19211690 of IN B-PP O
8 56 66 19211690 intrarenal JJ B-NP O
9 67 82 19211690 angiotensinogen NN I-NP O
10 83 85 19211690 in IN B-PP O
11 86 90 19211690 Dahl NN B-NP O
12 91 95 19211690 salt NN I-NP B-Chemical
13 95 96 19211690 - HYPH B-NP O
14 96 105 19211690 sensitive JJ I-NP O
15 106 110 19211690 rats NNS I-NP O
16 110 111 19211690 . . O O
17 112 117 19211690 Blood NN B-NP O
18 118 126 19211690 pressure NN I-NP O
19 127 128 19211690 ( ( O O
20 128 130 19211690 BP NN B-NP O
21 130 131 19211690 ) ) O O
22 132 134 19211690 is VBZ B-VP O
23 135 139 19211690 more JJR B-NP O
24 140 144 19211690 salt NN I-NP B-Chemical
25 145 154 19211690 sensitive JJ B-ADJP O
26 155 157 19211690 in IN B-PP O
27 158 161 19211690 men NNS B-NP O
28 162 166 19211690 than IN B-PP O
29 167 169 19211690 in IN B-PP O
30 170 183 19211690 premenopausal JJ B-NP O
31 184 189 19211690 women NNS I-NP O
32 189 190 19211690 . . O O

1 191 193 19211690 In IN B-PP O
2 194 198 19211690 Dahl NN B-NP O
3 199 203 19211690 salt NN I-NP B-Chemical
4 203 204 19211690 - HYPH B-NP O
5 204 213 19211690 sensitive JJ I-NP O
6 214 218 19211690 rats NNS I-NP O
7 219 220 19211690 ( ( O O
8 220 222 19211690 DS NN B-NP O
9 222 223 19211690 ) ) O O
10 223 224 19211690 , , O O
11 225 229 19211690 high JJ B-ADJP O
12 229 230 19211690 - HYPH O O
13 230 234 19211690 salt NN B-NP B-Chemical
14 235 236 19211690 ( ( O O
15 236 238 19211690 HS NN B-NP O
16 238 239 19211690 ) ) O O
17 240 244 19211690 diet NN B-NP O
18 245 254 19211690 increases VBZ B-VP O
19 255 257 19211690 BP NN B-NP O
20 258 262 19211690 more JJR I-NP O
21 263 265 19211690 in IN B-PP O
22 266 271 19211690 males NNS B-NP O
23 272 276 19211690 than IN B-PP O
24 277 284 19211690 females NNS B-NP O
25 284 285 19211690 . . O O

1 286 288 19211690 In IN B-PP O
2 289 297 19211690 contrast NN B-NP O
3 298 300 19211690 to TO B-PP O
4 301 304 19211690 the DT B-NP O
5 305 313 19211690 systemic JJ I-NP O
6 314 319 19211690 renin NN I-NP O
7 319 320 19211690 - HYPH I-NP O
8 320 331 19211690 angiotensin NN I-NP B-Chemical
9 332 338 19211690 system NN I-NP O
10 338 339 19211690 , , O O
11 340 345 19211690 which WDT B-NP O
12 346 348 19211690 is VBZ B-VP O
13 349 359 19211690 suppressed VBN I-VP O
14 360 362 19211690 in IN B-PP O
15 363 371 19211690 response NN B-NP O
16 372 374 19211690 to TO B-PP O
17 375 377 19211690 HS NN B-NP O
18 378 380 19211690 in IN B-PP O
19 381 385 19211690 male JJ B-NP O
20 386 388 19211690 DS NN I-NP O
21 388 389 19211690 , , O O
22 390 400 19211690 intrarenal JJ B-NP O
23 401 416 19211690 angiotensinogen NN I-NP O
24 417 427 19211690 expression NN I-NP O
25 428 430 19211690 is VBZ B-VP O
26 431 440 19211690 increased VBN I-VP O
27 440 441 19211690 , , O O
28 442 445 19211690 and CC O O
29 446 456 19211690 intrarenal JJ B-NP O
30 457 463 19211690 levels NNS I-NP O
31 464 466 19211690 of IN B-PP O
32 467 470 19211690 ANG NN B-NP O
33 471 473 19211690 II CD I-NP O
34 474 477 19211690 are VBP B-VP O
35 478 481 19211690 not RB I-VP O
36 482 492 19211690 suppressed VBN I-VP O
37 492 493 19211690 . . O O

1 494 496 19211690 In IN B-PP O
2 497 501 19211690 this DT B-NP O
3 502 507 19211690 study NN I-NP O
4 507 508 19211690 , , O O
5 509 512 19211690 the DT B-NP O
6 513 523 19211690 hypothesis NN I-NP O
7 524 527 19211690 was VBD B-VP O
8 528 534 19211690 tested VBN I-VP O
9 535 539 19211690 that IN B-SBAR O
10 540 545 19211690 there EX B-NP O
11 546 548 19211690 is VBZ B-VP O
12 549 550 19211690 a DT B-NP O
13 551 557 19211690 sexual JJ I-NP O
14 558 568 19211690 dimorphism NN I-NP O
15 569 571 19211690 in IN B-PP O
16 572 574 19211690 HS NN B-NP O
17 574 575 19211690 - HYPH B-NP O
18 575 582 19211690 induced VBN I-NP O
19 583 595 19211690 upregulation NN I-NP O
20 596 598 19211690 of IN B-PP O
21 599 609 19211690 intrarenal JJ B-NP O
22 610 625 19211690 angiotensinogen NN I-NP O
23 626 634 19211690 mediated VBN B-VP O
24 635 637 19211690 by IN B-PP O
25 638 650 19211690 testosterone NN B-NP B-Chemical
26 651 655 19211690 that WDT B-NP O
27 656 660 19211690 also RB B-ADVP O
28 661 667 19211690 causes VBZ B-VP O
29 668 677 19211690 increases NNS B-NP O
30 678 680 19211690 in IN B-PP O
31 681 683 19211690 BP NN B-NP O
32 684 687 19211690 and CC O O
33 688 693 19211690 renal JJ B-NP B-Disease
34 694 700 19211690 injury NN I-NP I-Disease
35 700 701 19211690 . . O O

1 702 704 19211690 On IN B-PP O
2 705 706 19211690 a DT B-NP O
3 707 710 19211690 low JJ I-NP O
4 710 711 19211690 - HYPH I-NP O
5 711 715 19211690 salt NN I-NP B-Chemical
6 716 717 19211690 ( ( O O
7 717 719 19211690 LS NN B-NP O
8 719 720 19211690 ) ) O O
9 721 725 19211690 diet NN B-NP O
10 725 726 19211690 , , O O
11 727 731 19211690 male JJ B-NP O
12 732 734 19211690 DS NN I-NP O
13 735 738 19211690 had VBD B-VP O
14 739 745 19211690 higher JJR B-NP O
15 746 752 19211690 levels NNS I-NP O
16 753 755 19211690 of IN B-PP O
17 756 766 19211690 intrarenal JJ B-NP O
18 767 782 19211690 angiotensinogen NN I-NP O
19 783 787 19211690 mRNA NN I-NP O
20 788 792 19211690 than IN B-PP O
21 793 800 19211690 females NNS B-NP O
22 800 801 19211690 . . O O

1 802 804 19211690 HS NN B-NP O
2 805 809 19211690 diet NN I-NP O
3 810 813 19211690 for IN B-PP O
4 814 815 19211690 4 CD B-NP O
5 816 818 19211690 wk NN I-NP O
6 819 828 19211690 increased VBD B-VP O
7 829 834 19211690 renal JJ B-NP O
8 835 843 19211690 cortical JJ I-NP O
9 844 859 19211690 angiotensinogen NN I-NP O
10 860 864 19211690 mRNA NN I-NP O
11 865 868 19211690 and CC I-NP O
12 869 876 19211690 protein NN I-NP O
13 877 881 19211690 only RB B-PP O
14 882 884 19211690 in IN I-PP O
15 885 889 19211690 male JJ B-NP O
16 890 892 19211690 DS NN I-NP O
17 892 893 19211690 , , O O
18 894 899 19211690 which WDT B-NP O
19 900 903 19211690 was VBD B-VP O
20 904 913 19211690 prevented VBN I-VP O
21 914 916 19211690 by IN B-PP O
22 917 927 19211690 castration NN B-NP O
23 927 928 19211690 . . O O

1 929 940 19211690 Ovariectomy NN B-NP O
2 941 943 19211690 of IN B-PP O
3 944 950 19211690 female JJ B-NP O
4 951 953 19211690 DS NN I-NP O
5 954 957 19211690 had VBD B-VP O
6 958 960 19211690 no DT B-NP O
7 961 967 19211690 effect NN I-NP O
8 968 970 19211690 on IN B-PP O
9 971 981 19211690 intrarenal JJ B-NP O
10 982 997 19211690 angiotensinogen NN I-NP O
11 998 1008 19211690 expression NN I-NP O
12 1009 1011 19211690 on IN B-PP O
13 1012 1018 19211690 either DT B-NP O
14 1019 1023 19211690 diet NN I-NP O
15 1023 1024 19211690 . . O O

1 1025 1040 19211690 Radiotelemetric JJ B-NP O
2 1041 1043 19211690 BP NN I-NP O
3 1044 1047 19211690 was VBD B-VP O
4 1048 1055 19211690 similar JJ B-ADJP O
5 1056 1063 19211690 between IN B-PP O
6 1064 1069 19211690 males NNS B-NP O
7 1070 1073 19211690 and CC O O
8 1074 1083 19211690 castrated VBN B-VP O
9 1084 1088 19211690 rats NNS B-NP O
10 1089 1091 19211690 on IN B-PP O
11 1092 1094 19211690 LS NN B-NP O
12 1095 1099 19211690 diet NN I-NP O
13 1099 1100 19211690 . . O O

1 1101 1103 19211690 HS NN B-NP O
2 1104 1108 19211690 diet NN I-NP O
3 1109 1112 19211690 for IN B-PP O
4 1113 1114 19211690 4 CD B-NP O
5 1115 1117 19211690 wk NN I-NP O
6 1118 1124 19211690 caused VBD B-VP O
7 1125 1126 19211690 a DT B-NP O
8 1127 1138 19211690 progressive JJ I-NP O
9 1139 1147 19211690 increase NN I-NP O
10 1148 1150 19211690 in IN B-PP O
11 1151 1153 19211690 BP NN B-NP O
12 1153 1154 19211690 , , O O
13 1155 1162 19211690 protein NN B-NP O
14 1163 1166 19211690 and CC O O
15 1167 1174 19211690 albumin NN B-NP O
16 1175 1184 19211690 excretion NN I-NP O
17 1184 1185 19211690 , , O O
18 1186 1189 19211690 and CC O O
19 1190 1200 19211690 glomerular JJ B-NP B-Disease
20 1201 1210 19211690 sclerosis NN I-NP I-Disease
21 1211 1213 19211690 in IN B-PP O
22 1214 1218 19211690 male JJ B-NP O
23 1219 1221 19211690 DS NN I-NP O
24 1222 1226 19211690 rats NNS I-NP O
25 1226 1227 19211690 , , O O
26 1228 1233 19211690 which WDT B-NP O
27 1234 1238 19211690 were VBD B-VP O
28 1239 1249 19211690 attenuated VBN I-VP O
29 1250 1252 19211690 by IN B-PP O
30 1253 1263 19211690 castration NN B-NP O
31 1263 1264 19211690 . . O O

1 1265 1277 19211690 Testosterone NN B-NP B-Chemical
2 1278 1289 19211690 replacement NN I-NP O
3 1290 1292 19211690 in IN B-PP O
4 1293 1302 19211690 castrated VBN B-NP O
5 1303 1305 19211690 DS NN I-NP O
6 1306 1310 19211690 rats NNS I-NP O
7 1311 1320 19211690 increased VBD B-VP O
8 1321 1323 19211690 BP NN B-NP O
9 1323 1324 19211690 , , O O
10 1325 1330 19211690 renal JJ B-NP B-Disease
11 1331 1337 19211690 injury NN I-NP I-Disease
12 1337 1338 19211690 , , O O
13 1339 1342 19211690 and CC O O
14 1343 1355 19211690 upregulation NN B-NP O
15 1356 1358 19211690 of IN B-PP O
16 1359 1364 19211690 renal JJ B-NP O
17 1365 1380 19211690 angiotensinogen NN I-NP O
18 1381 1391 19211690 associated VBN B-VP O
19 1392 1396 19211690 with IN B-PP O
20 1397 1399 19211690 HS NN B-NP O
21 1400 1404 19211690 diet NN I-NP O
22 1404 1405 19211690 . . O O

1 1406 1418 19211690 Testosterone NN B-NP B-Chemical
2 1419 1430 19211690 contributes VBZ B-VP O
3 1431 1433 19211690 to TO B-PP O
4 1434 1437 19211690 the DT B-NP O
5 1438 1449 19211690 development NN I-NP O
6 1450 1452 19211690 of IN B-PP O
7 1453 1465 19211690 hypertension NN B-NP B-Disease
8 1466 1469 19211690 and CC O O
9 1470 1475 19211690 renal JJ B-NP B-Disease
10 1476 1482 19211690 injury NN I-NP I-Disease
11 1483 1485 19211690 in IN B-PP O
12 1486 1490 19211690 male JJ B-NP O
13 1491 1493 19211690 DS NN I-NP O
14 1494 1498 19211690 rats NNS I-NP O
15 1499 1501 19211690 on IN B-PP O
16 1502 1504 19211690 HS NN B-NP O
17 1505 1509 19211690 diet NN I-NP O
18 1510 1518 19211690 possibly RB B-ADVP O
19 1519 1526 19211690 through IN B-PP O
20 1527 1539 19211690 upregulation NN B-NP O
21 1540 1542 19211690 of IN B-PP O
22 1543 1546 19211690 the DT B-NP O
23 1547 1557 19211690 intrarenal JJ I-NP O
24 1558 1563 19211690 renin NN I-NP O
25 1563 1564 19211690 - HYPH I-NP O
26 1564 1575 19211690 angiotensin NN I-NP B-Chemical
27 1576 1582 19211690 system NN I-NP O
28 1582 1583 19211690 . . O O

1 0 0 12443032 -DOCSTART- -X- -X- O

1 0 7 12443032 Cocaine NN B-NP B-Chemical
2 8 15 12443032 related JJ I-NP O
3 16 21 12443032 chest NN I-NP B-Disease
4 22 26 12443032 pain NN I-NP I-Disease
5 26 27 12443032 : : O O
6 28 31 12443032 are VBP B-VP O
7 32 34 12443032 we PRP B-NP O
8 35 41 12443032 seeing VBG B-VP O
9 42 45 12443032 the DT B-NP O
10 46 49 12443032 tip NN I-NP O
11 50 52 12443032 of IN B-PP O
12 53 55 12443032 an DT B-NP O
13 56 63 12443032 iceberg NN I-NP O
14 63 64 12443032 ? . O O
15 65 68 12443032 The DT B-NP O
16 69 81 12443032 recreational JJ I-NP O
17 82 85 12443032 use NN I-NP O
18 86 88 12443032 of IN B-PP O
19 89 96 12443032 cocaine NN B-NP B-Chemical
20 97 99 12443032 is VBZ B-VP O
21 100 102 12443032 on IN B-PP O
22 103 106 12443032 the DT B-NP O
23 107 115 12443032 increase NN I-NP O
24 115 116 12443032 . . O O

1 117 120 12443032 The DT B-NP O
2 121 130 12443032 emergency NN I-NP O
3 131 136 12443032 nurse NN I-NP O
4 137 142 12443032 ought MD B-VP O
5 143 145 12443032 to TO I-VP O
6 146 148 12443032 be VB I-VP O
7 149 157 12443032 familiar JJ B-ADJP O
8 158 162 12443032 with IN B-PP O
9 163 167 12443032 some DT B-NP O
10 168 170 12443032 of IN B-PP O
11 171 174 12443032 the DT B-NP O
12 175 189 12443032 cardiovascular JJ I-NP O
13 190 202 12443032 consequences NNS I-NP O
14 203 205 12443032 of IN B-PP O
15 206 213 12443032 cocaine NN B-NP B-Chemical
16 214 217 12443032 use NN I-NP O
17 217 218 12443032 . . O O

1 219 221 12443032 In IN B-PP O
2 222 232 12443032 particular JJ B-NP O
3 232 233 12443032 , , O O
4 234 237 12443032 the DT B-NP O
5 238 246 12443032 tendency NN I-NP O
6 247 249 12443032 of IN B-PP O
7 250 257 12443032 cocaine NN B-NP B-Chemical
8 258 260 12443032 to TO B-VP O
9 261 268 12443032 produce VB I-VP O
10 269 274 12443032 chest NN B-NP B-Disease
11 275 279 12443032 pain NN I-NP I-Disease
12 280 285 12443032 ought MD B-VP O
13 286 288 12443032 to TO I-VP O
14 289 291 12443032 be VB I-VP O
15 292 294 12443032 in IN B-PP O
16 295 298 12443032 the DT B-NP O
17 299 303 12443032 mind NN I-NP O
18 304 306 12443032 of IN B-PP O
19 307 310 12443032 the DT B-NP O
20 311 320 12443032 emergency NN I-NP O
21 321 326 12443032 nurse NN I-NP O
22 327 331 12443032 when WRB B-ADVP O
23 332 337 12443032 faced VBN B-VP O
24 338 342 12443032 with IN B-PP O
25 343 344 12443032 a DT B-NP O
26 345 350 12443032 young JJ I-NP O
27 351 357 12443032 victim NN I-NP O
28 358 360 12443032 of IN B-PP O
29 361 366 12443032 chest NN B-NP B-Disease
30 367 371 12443032 pain NN I-NP I-Disease
31 372 375 12443032 who WP B-NP O
32 376 378 12443032 is VBZ B-VP O
33 379 388 12443032 otherwise RB B-ADVP O
34 389 391 12443032 at IN B-PP O
35 392 395 12443032 low JJ B-NP O
36 396 400 12443032 risk NN I-NP O
37 400 401 12443032 . . O O

1 402 405 12443032 The DT B-NP O
2 406 415 12443032 mechanism NN I-NP O
3 416 418 12443032 of IN B-PP O
4 419 424 12443032 chest NN B-NP B-Disease
5 425 429 12443032 pain NN I-NP I-Disease
6 430 437 12443032 related VBN B-VP O
7 438 440 12443032 to TO B-PP O
8 441 448 12443032 cocaine NN B-NP B-Chemical
9 449 452 12443032 use NN I-NP O
10 453 455 12443032 is VBZ B-VP O
11 456 465 12443032 discussed VBN I-VP O
12 466 469 12443032 and CC O O
13 470 479 12443032 treatment NN B-NP O
14 480 488 12443032 dilemmas NNS I-NP O
15 489 492 12443032 are VBP B-VP O
16 493 502 12443032 discussed VBN I-VP O
17 502 503 12443032 . . O O

1 504 511 12443032 Finally RB B-ADVP O
2 511 512 12443032 , , O O
3 513 518 12443032 moral JJ B-NP O
4 519 525 12443032 issues NNS I-NP O
5 526 534 12443032 relating VBG B-VP O
6 535 537 12443032 to TO B-PP O
7 538 541 12443032 the DT B-NP O
8 542 549 12443032 testing NN I-NP O
9 550 552 12443032 of IN B-PP O
10 553 562 12443032 potential JJ B-NP O
11 563 570 12443032 cocaine NN I-NP B-Chemical
12 571 576 12443032 users NNS I-NP O
13 577 581 12443032 will MD B-VP O
14 582 584 12443032 be VB I-VP O
15 585 594 12443032 addressed VBN I-VP O
16 594 595 12443032 . . O O

1 0 0 3403780 -DOCSTART- -X- -X- O

1 0 11 3403780 Paracetamol NN B-NP B-Chemical
2 11 12 3403780 - HYPH B-PP O
3 12 22 3403780 associated VBN B-NP O
4 23 27 3403780 coma NN I-NP B-Disease
5 27 28 3403780 , , O O
6 29 38 3403780 metabolic JJ B-NP B-Disease
7 39 47 3403780 acidosis NN I-NP I-Disease
8 47 48 3403780 , , O O
9 49 54 3403780 renal JJ B-NP B-Disease
10 55 58 3403780 and CC I-NP I-Disease
11 59 66 3403780 hepatic JJ I-NP I-Disease
12 67 74 3403780 failure NN I-NP I-Disease
13 74 75 3403780 . . O O
14 76 77 3403780 A DT B-NP O
15 78 82 3403780 case NN I-NP O
16 83 85 3403780 of IN B-PP O
17 86 95 3403780 metabolic JJ B-NP B-Disease
18 96 104 3403780 acidosis NN I-NP I-Disease
19 104 105 3403780 , , O O
20 106 111 3403780 acute JJ B-NP B-Disease
21 112 117 3403780 renal JJ I-NP I-Disease
22 118 125 3403780 failure NN I-NP I-Disease
23 126 129 3403780 and CC O I-Disease
24 130 137 3403780 hepatic JJ B-NP I-Disease
25 138 145 3403780 failure NN I-NP I-Disease
26 146 155 3403780 following VBG B-PP O
27 156 167 3403780 paracetamol NN B-NP B-Chemical
28 168 177 3403780 ingestion NN I-NP O
29 178 180 3403780 is VBZ B-VP O
30 181 190 3403780 presented VBN I-VP O
31 190 191 3403780 . . O O

1 192 195 3403780 The DT B-NP O
2 196 206 3403780 diagnostic JJ I-NP O
3 207 217 3403780 difficulty NN I-NP O
4 218 220 3403780 at IN B-PP O
5 221 233 3403780 presentation NN B-NP O
6 234 236 3403780 is VBZ B-VP O
7 237 248 3403780 highlighted VBN I-VP O
8 248 249 3403780 . . O O

1 250 260 3403780 Continuous JJ B-NP O
2 261 274 3403780 arteriovenous JJ I-NP O
3 275 290 3403780 haemofiltration NN I-NP O
4 291 297 3403780 proved VBD B-VP O
5 298 299 3403780 a DT B-NP O
6 300 308 3403780 valuable JJ I-NP O
7 309 314 3403780 means NNS I-NP O
8 315 317 3403780 of IN B-PP O
9 318 329 3403780 maintaining VBG B-VP O
10 330 335 3403780 fluid NN B-NP O
11 336 339 3403780 and CC I-NP O
12 340 351 3403780 electrolyte NN I-NP O
13 352 359 3403780 balance NN I-NP O
14 359 360 3403780 . . O O

1 361 364 3403780 The DT B-NP O
2 365 372 3403780 patient NN I-NP O
3 373 382 3403780 recovered VBD B-VP O
4 382 383 3403780 . . O O

1 0 0 3800626 -DOCSTART- -X- -X- O

1 0 11 3800626 Compression NN B-NP B-Disease
2 12 22 3800626 neuropathy NN I-NP I-Disease
3 23 25 3800626 of IN B-PP I-Disease
4 26 29 3800626 the DT B-NP I-Disease
5 30 36 3800626 radial JJ I-NP I-Disease
6 37 42 3800626 nerve NN I-NP I-Disease
7 43 46 3800626 due JJ B-ADJP O
8 47 49 3800626 to TO B-PP O
9 50 61 3800626 pentazocine NN B-NP B-Chemical
10 61 62 3800626 - HYPH B-NP O
11 62 69 3800626 induced VBN I-NP O
12 70 77 3800626 fibrous JJ I-NP B-Disease
13 78 86 3800626 myopathy NN I-NP I-Disease
14 86 87 3800626 . . I-NP O
15 88 95 3800626 Fibrous JJ I-NP B-Disease
16 96 104 3800626 myopathy NN I-NP I-Disease
17 105 107 3800626 is VBZ B-VP O
18 108 109 3800626 a DT B-NP O
19 110 116 3800626 common JJ I-NP O
20 116 117 3800626 , , O O
21 118 122 3800626 well RB B-ADVP O
22 122 123 3800626 - HYPH B-NP O
23 123 128 3800626 known VBN I-NP O
24 129 133 3800626 side NN I-NP O
25 134 140 3800626 effect NN I-NP O
26 141 143 3800626 of IN B-PP O
27 144 152 3800626 repeated VBN B-NP O
28 153 164 3800626 pentazocine NN I-NP B-Chemical
29 165 174 3800626 injection NN I-NP O
30 174 175 3800626 . . O O

1 176 183 3800626 However RB B-ADVP O
2 183 184 3800626 , , O O
3 185 196 3800626 compression NN B-NP B-Disease
4 197 207 3800626 neuropathy NN I-NP I-Disease
5 208 211 3800626 due JJ B-ADJP O
6 212 214 3800626 to TO B-PP O
7 215 223 3800626 fibrotic JJ B-NP O
8 224 230 3800626 muscle NN I-NP O
9 231 239 3800626 affected VBN B-VP O
10 240 242 3800626 by IN B-PP O
11 243 254 3800626 pentazocine NN B-NP B-Chemical
12 254 255 3800626 - HYPH B-NP O
13 255 262 3800626 induced VBN I-NP O
14 263 271 3800626 myopathy NN I-NP B-Disease
15 272 275 3800626 has VBZ B-VP O
16 276 279 3800626 not RB I-VP O
17 280 290 3800626 previously RB I-VP O
18 291 295 3800626 been VBN I-VP O
19 296 304 3800626 reported VBN I-VP O
20 304 305 3800626 . . O O

1 306 308 3800626 In IN B-PP O
2 309 310 3800626 a DT B-NP O
3 311 313 3800626 37 CD I-NP O
4 313 314 3800626 - HYPH I-NP O
5 314 318 3800626 year NN I-NP O
6 318 319 3800626 - HYPH O O
7 319 322 3800626 old JJ B-NP O
8 323 328 3800626 woman NN I-NP O
9 329 333 3800626 with IN B-PP O
10 334 344 3800626 documented VBN B-NP O
11 345 356 3800626 pentazocine NN I-NP B-Chemical
12 356 357 3800626 - HYPH B-VP O
13 357 364 3800626 induced VBN B-NP O
14 365 372 3800626 fibrous JJ I-NP B-Disease
15 373 381 3800626 myopathy NN I-NP I-Disease
16 382 384 3800626 of IN B-PP O
17 385 392 3800626 triceps NNS B-NP O
18 393 396 3800626 and CC O O
19 397 404 3800626 deltoid JJ B-NP O
20 405 412 3800626 muscles NNS I-NP O
21 413 424 3800626 bilaterally RB B-ADVP O
22 425 428 3800626 and CC O O
23 429 430 3800626 a DT B-NP O
24 431 436 3800626 three CD I-NP O
25 436 437 3800626 - HYPH I-NP O
26 437 441 3800626 week NN I-NP O
27 442 449 3800626 history NN I-NP O
28 450 452 3800626 of IN B-PP O
29 453 458 3800626 right JJ B-NP O
30 459 464 3800626 wrist NN I-NP O
31 465 469 3800626 drop NN I-NP O
32 469 470 3800626 , , O O
33 471 488 3800626 electrodiagnostic JJ B-NP O
34 489 500 3800626 examination NN I-NP O
35 501 507 3800626 showed VBD B-VP O
36 508 509 3800626 a DT B-NP O
37 510 516 3800626 severe JJ I-NP O
38 517 520 3800626 but CC I-NP O
39 521 528 3800626 partial JJ I-NP O
40 529 535 3800626 lesion NN I-NP O
41 536 538 3800626 of IN B-PP O
42 539 542 3800626 the DT B-NP O
43 543 548 3800626 right JJ I-NP O
44 549 555 3800626 radial JJ I-NP O
45 556 561 3800626 nerve NN I-NP O
46 562 568 3800626 distal JJ B-ADJP O
47 569 571 3800626 to TO B-PP O
48 572 575 3800626 the DT B-NP O
49 576 584 3800626 branches NNS I-NP O
50 585 587 3800626 to TO B-PP O
51 588 591 3800626 the DT B-NP O
52 592 599 3800626 triceps NNS I-NP O
53 599 600 3800626 , , O O
54 601 603 3800626 in IN B-PP O
55 604 612 3800626 addition NN B-NP O
56 613 615 3800626 to TO B-PP O
57 616 619 3800626 the DT B-NP O
58 620 627 3800626 fibrous JJ I-NP B-Disease
59 628 636 3800626 myopathy NN I-NP I-Disease
60 636 637 3800626 . . O O

1 638 645 3800626 Surgery NNP B-NP O
2 646 654 3800626 revealed VBD B-VP O
3 655 658 3800626 the DT B-NP O
4 659 664 3800626 right JJ I-NP O
5 665 671 3800626 radial JJ I-NP O
6 672 677 3800626 nerve NN I-NP O
7 678 680 3800626 to TO B-VP O
8 681 683 3800626 be VB I-VP O
9 684 692 3800626 severely RB I-VP O
10 693 703 3800626 compressed VBN I-VP O
11 704 706 3800626 by IN B-PP O
12 707 710 3800626 the DT B-NP O
13 711 718 3800626 densely RB I-NP O
14 719 727 3800626 fibrotic JJ I-NP O
15 728 735 3800626 lateral JJ I-NP O
16 736 740 3800626 head NN I-NP O
17 741 743 3800626 of IN B-PP O
18 744 747 3800626 the DT B-NP O
19 748 755 3800626 triceps NNS I-NP O
20 755 756 3800626 . . O O

1 757 770 3800626 Decompression NN B-NP O
2 771 774 3800626 and CC I-NP O
3 775 785 3800626 neurolysis NN I-NP O
4 786 790 3800626 were VBD B-VP O
5 791 800 3800626 performed VBN I-VP O
6 801 805 3800626 with IN B-PP O
7 806 810 3800626 good JJ B-NP O
8 811 821 3800626 subsequent JJ I-NP O
9 822 830 3800626 recovery NN I-NP O
10 831 833 3800626 of IN B-PP O
11 834 842 3800626 function NN B-NP O
12 842 843 3800626 . . O O

1 0 0 6666578 -DOCSTART- -X- -X- O

1 0 1 6666578 D NN B-NP B-Chemical
2 1 2 6666578 - HYPH B-NP I-Chemical
3 2 15 6666578 penicillamine NN I-NP I-Chemical
4 15 16 6666578 - HYPH O O
5 16 23 6666578 induced VBN B-NP O
6 24 34 6666578 angiopathy NN I-NP B-Disease
7 35 37 6666578 in IN B-PP O
8 38 42 6666578 rats NNS B-NP O
9 42 43 6666578 . . O O

1 44 47 6666578 The DT B-NP O
2 48 54 6666578 effect NN I-NP O
3 55 57 6666578 of IN B-PP O
4 58 62 6666578 high JJ B-NP O
5 63 67 6666578 dose NN I-NP O
6 68 69 6666578 D NN I-NP B-Chemical
7 69 70 6666578 - HYPH B-NP I-Chemical
8 70 83 6666578 penicillamine NN I-NP I-Chemical
9 84 93 6666578 treatment NN I-NP O
10 94 96 6666578 on IN B-PP O
11 97 103 6666578 aortic JJ B-NP O
12 104 116 6666578 permeability NN I-NP O
13 117 119 6666578 to TO B-PP O
14 120 127 6666578 albumin NN B-NP O
15 128 131 6666578 and CC B-PP O
16 132 134 6666578 on IN B-PP O
17 135 138 6666578 the DT B-NP O
18 139 153 6666578 ultrastructure NN I-NP O
19 154 156 6666578 of IN B-PP O
20 157 160 6666578 the DT B-NP O
21 161 167 6666578 vessel NN I-NP O
22 167 168 6666578 . . O O
23 169 173 6666578 Male NNP B-NP O
24 174 181 6666578 Sprague NNP I-NP O
25 181 182 6666578 - HYPH B-NP O
26 182 188 6666578 Dawley NNP I-NP O
27 189 193 6666578 rats NNS I-NP O
28 194 198 6666578 were VBD B-VP O
29 199 206 6666578 treated VBN I-VP O
30 207 211 6666578 with IN B-PP O
31 212 213 6666578 D NN B-NP B-Chemical
32 213 214 6666578 - HYPH O I-Chemical
33 214 227 6666578 penicillamine NN B-NP I-Chemical
34 228 229 6666578 ( ( O O
35 229 230 6666578 D NN B-NP B-Chemical
36 230 231 6666578 - HYPH B-NP I-Chemical
37 231 234 6666578 pen NN I-NP I-Chemical
38 234 235 6666578 ) ) O O
39 236 239 6666578 500 CD B-NP O
40 240 242 6666578 mg NN I-NP O
41 242 243 6666578 / SYM B-NP O
42 243 245 6666578 kg NN I-NP O
43 245 246 6666578 / SYM B-NP O
44 246 249 6666578 day NN I-NP O
45 250 253 6666578 for IN B-PP O
46 254 256 6666578 10 CD B-NP O
47 257 259 6666578 or CC I-NP O
48 260 262 6666578 42 CD I-NP O
49 263 267 6666578 days NNS I-NP O
50 267 268 6666578 . . O O

1 269 273 6666578 Pair NN B-NP O
2 274 277 6666578 fed VBN I-NP O
3 278 282 6666578 rats NNS I-NP O
4 283 289 6666578 served VBD B-VP O
5 290 292 6666578 as IN B-PP O
6 293 301 6666578 controls NNS B-NP O
7 301 302 6666578 . . O O

1 303 310 6666578 Changes NNS B-NP O
2 311 313 6666578 in IN B-PP O
3 314 320 6666578 aortic JJ B-NP O
4 321 331 6666578 morphology NN I-NP O
5 332 336 6666578 were VBD B-VP O
6 337 345 6666578 examined VBN I-VP O
7 346 348 6666578 by IN B-PP O
8 349 354 6666578 light NN B-NP O
9 354 355 6666578 - HYPH O O
10 356 359 6666578 and CC O O
11 360 372 6666578 transmission NN B-NP O
12 372 373 6666578 - HYPH O O
13 373 381 6666578 electron NN B-NP O
14 382 392 6666578 microscopy NN I-NP O
15 393 394 6666578 ( ( O O
16 394 397 6666578 TEM NN B-NP O
17 397 398 6666578 ) ) O O
18 398 399 6666578 . . O O

1 400 402 6666578 In IN B-PP O
2 403 411 6666578 addition NN B-NP O
3 411 412 6666578 , , O O
4 413 416 6666578 the DT B-NP O
5 417 428 6666578 endothelial JJ I-NP O
6 429 441 6666578 permeability NN I-NP O
7 442 445 6666578 and CC O O
8 446 449 6666578 the DT B-NP O
9 450 461 6666578 penetration NN I-NP O
10 462 469 6666578 through IN B-PP O
11 470 473 6666578 the DT B-NP O
12 474 480 6666578 aortic JJ I-NP O
13 481 485 6666578 wall NN I-NP O
14 486 488 6666578 of IN B-PP O
15 489 496 6666578 albumin NN B-NP O
16 497 501 6666578 were VBD B-VP O
17 502 509 6666578 studied VBN I-VP O
18 510 512 6666578 10 CD B-NP O
19 513 520 6666578 minutes NNS I-NP O
20 520 521 6666578 , , O O
21 522 524 6666578 24 CD B-NP O
22 525 528 6666578 and CC I-NP O
23 529 531 6666578 48 CD I-NP O
24 532 537 6666578 hours NNS I-NP O
25 538 543 6666578 after IN B-PP O
26 544 545 6666578 i NN B-NP O
27 545 546 6666578 . . O O

1 547 548 6666578 v NN B-NP O
2 548 549 6666578 . . O O

1 550 559 6666578 injection NN B-NP O
2 560 562 6666578 of IN B-PP O
3 563 568 6666578 human JJ B-NP O
4 569 574 6666578 serum NN I-NP O
5 575 579 6666578 131I NN I-NP O
6 579 580 6666578 - HYPH B-NP O
7 580 587 6666578 albumin NN I-NP O
8 588 589 6666578 ( ( O O
9 589 593 6666578 131I NN B-NP O
10 593 594 6666578 - HYPH B-NP O
11 594 597 6666578 HSA NN I-NP O
12 597 598 6666578 ) ) O O
13 598 599 6666578 . . O O

1 600 603 6666578 TEM NN B-NP O
2 604 612 6666578 revealed VBD B-VP O
3 613 622 6666578 extensive JJ B-NP O
4 623 634 6666578 elastolysis NN I-NP O
5 635 637 6666578 in IN B-PP O
6 638 641 6666578 the DT B-NP O
7 642 650 6666578 arterial JJ I-NP O
8 651 655 6666578 wall NN I-NP O
9 656 658 6666578 of IN B-PP O
10 659 660 6666578 D NN B-NP B-Chemical
11 660 661 6666578 - HYPH B-NP I-Chemical
12 661 664 6666578 pen NN I-NP I-Chemical
13 664 665 6666578 - HYPH B-NP O
14 665 672 6666578 treated VBN I-NP O
15 673 677 6666578 rats NNS I-NP O
16 677 678 6666578 , , O O
17 679 689 6666578 consistent JJ B-ADJP O
18 690 694 6666578 with IN B-PP O
19 695 697 6666578 an DT B-NP O
20 698 708 6666578 inhibitory JJ I-NP O
21 709 715 6666578 effect NN I-NP O
22 716 718 6666578 on IN B-PP O
23 719 728 6666578 crosslink NN B-NP O
24 729 738 6666578 formation NN I-NP O
25 738 739 6666578 . . O O

1 740 742 6666578 In IN B-PP O
2 743 755 6666578 experimental JJ B-NP O
3 756 763 6666578 animals NNS I-NP O
4 764 770 6666578 excess JJ B-NP O
5 771 781 6666578 deposition NN I-NP O
6 782 784 6666578 of IN B-PP O
7 785 793 6666578 collagen NN B-NP O
8 794 797 6666578 and CC I-NP O
9 798 815 6666578 glycoaminoglycans NNS I-NP O
10 816 819 6666578 was VBD B-VP O
11 820 828 6666578 observed VBN I-VP O
12 829 831 6666578 in IN B-PP O
13 832 835 6666578 the DT B-NP O
14 836 850 6666578 subendothelial JJ I-NP O
15 851 854 6666578 and CC I-NP O
16 855 861 6666578 medial JJ I-NP O
17 862 867 6666578 layer NN I-NP O
18 868 870 6666578 of IN B-PP O
19 871 874 6666578 the DT B-NP O
20 875 881 6666578 aortic JJ I-NP O
21 882 886 6666578 wall NN I-NP O
22 886 887 6666578 , , O O
23 888 896 6666578 together RB B-ADVP O
24 897 901 6666578 with IN B-PP O
25 902 911 6666578 prominent JJ B-NP O
26 912 917 6666578 basal JJ I-NP O
27 918 926 6666578 membrane NN I-NP O
28 927 936 6666578 substance NN I-NP O
29 937 943 6666578 around IN B-PP O
30 944 950 6666578 aortic JJ B-NP O
31 951 957 6666578 smooth JJ I-NP O
32 958 964 6666578 muscle NN I-NP O
33 965 970 6666578 cells NNS I-NP O
34 970 971 6666578 . . O O

1 972 975 6666578 The DT B-NP O
2 976 981 6666578 aorta NN I-NP O
3 981 982 6666578 / SYM B-NP O
4 982 987 6666578 serum NN I-NP O
5 987 988 6666578 - HYPH B-NP O
6 988 993 6666578 ratio NN I-NP O
7 994 997 6666578 and CC O O
8 998 1001 6666578 the DT B-NP O
9 1002 1013 6666578 radioactive JJ I-NP O
10 1014 1019 6666578 build VB B-VP O
11 1019 1020 6666578 - HYPH B-ADJP O
12 1020 1022 6666578 up RP B-PRT O
13 1023 1025 6666578 24 CD B-NP O
14 1026 1029 6666578 and CC I-NP O
15 1030 1032 6666578 48 CD I-NP O
16 1033 1038 6666578 hours NNS I-NP O
17 1039 1044 6666578 after IN B-PP O
18 1045 1054 6666578 injection NN B-NP O
19 1055 1057 6666578 of IN B-PP O
20 1058 1062 6666578 131I NN B-NP O
21 1062 1063 6666578 - HYPH B-NP O
22 1063 1066 6666578 HSA NN I-NP O
23 1067 1070 6666578 was VBD B-VP O
24 1071 1078 6666578 reduced VBN I-VP O
25 1079 1081 6666578 in IN B-PP O
26 1082 1089 6666578 animals NNS B-NP O
27 1090 1097 6666578 treated VBN B-VP O
28 1098 1102 6666578 with IN B-PP O
29 1103 1104 6666578 D NN B-NP B-Chemical
30 1104 1105 6666578 - HYPH B-NP I-Chemical
31 1105 1108 6666578 pen NN I-NP I-Chemical
32 1109 1112 6666578 for IN B-PP O
33 1113 1115 6666578 42 CD B-NP O
34 1116 1120 6666578 days NNS I-NP O
35 1120 1121 6666578 , , O O
36 1122 1132 6666578 indicating VBG B-VP O
37 1133 1135 6666578 an DT B-NP O
38 1136 1143 6666578 impeded JJ I-NP O
39 1144 1154 6666578 transmural JJ I-NP O
40 1155 1164 6666578 transport NN I-NP O
41 1165 1167 6666578 of IN B-PP O
42 1168 1174 6666578 tracer NN B-NP O
43 1175 1180 6666578 which WDT B-NP O
44 1181 1184 6666578 may MD B-VP O
45 1185 1187 6666578 be VB I-VP O
46 1188 1194 6666578 caused VBN I-VP O
47 1195 1197 6666578 by IN B-PP O
48 1198 1199 6666578 a DT B-NP O
49 1200 1206 6666578 steric JJ I-NP O
50 1207 1216 6666578 exclusion NN I-NP O
51 1217 1223 6666578 effect NN I-NP O
52 1224 1226 6666578 of IN B-PP O
53 1227 1235 6666578 abundant JJ B-NP O
54 1236 1247 6666578 hyaluronate NN I-NP B-Chemical
55 1247 1248 6666578 . . O O

1 1249 1252 6666578 The DT B-NP O
2 1253 1264 6666578 endothelial JJ I-NP O
3 1265 1279 6666578 ultrastructure NN I-NP O
4 1280 1283 6666578 was VBD B-VP O
5 1284 1294 6666578 unaffected JJ B-ADJP O
6 1295 1297 6666578 by IN B-PP O
7 1298 1299 6666578 D NN B-NP B-Chemical
8 1299 1300 6666578 - HYPH I-NP I-Chemical
9 1300 1303 6666578 pen NN I-NP I-Chemical
10 1303 1304 6666578 , , O O
11 1305 1308 6666578 and CC O O
12 1309 1311 6666578 no DT B-NP O
13 1312 1323 6666578 differences NNS I-NP O
14 1324 1326 6666578 in IN B-PP O
15 1327 1333 6666578 aortic JJ B-NP O
16 1334 1338 6666578 131I NN I-NP O
17 1338 1339 6666578 - HYPH B-NP O
18 1339 1342 6666578 HSA NN I-NP O
19 1343 1356 6666578 radioactivity NN I-NP O
20 1357 1359 6666578 or CC I-NP O
21 1360 1365 6666578 aorta NN I-NP O
22 1365 1366 6666578 / SYM B-NP O
23 1366 1371 6666578 serum NN I-NP O
24 1371 1372 6666578 - HYPH B-NP O
25 1372 1377 6666578 ratio NN I-NP O
26 1378 1382 6666578 were VBD B-VP O
27 1383 1391 6666578 recorded VBN I-VP O
28 1392 1399 6666578 between IN B-PP O
29 1400 1412 6666578 experimental JJ B-NP O
30 1413 1416 6666578 and CC I-NP O
31 1417 1424 6666578 control NN I-NP O
32 1425 1431 6666578 groups NNS I-NP O
33 1432 1434 6666578 10 CD B-NP O
34 1435 1442 6666578 minutes NNS I-NP O
35 1443 1448 6666578 after IN B-PP O
36 1449 1455 6666578 tracer NN B-NP O
37 1456 1465 6666578 injection NN I-NP O
38 1465 1466 6666578 , , O O
39 1467 1477 6666578 indicating VBG B-VP O
40 1478 1482 6666578 that IN B-SBAR O
41 1483 1486 6666578 the DT B-NP O
42 1487 1499 6666578 permeability NN I-NP O
43 1500 1502 6666578 of IN B-PP O
44 1503 1506 6666578 the DT B-NP O
45 1507 1518 6666578 endothelial JJ I-NP O
46 1519 1526 6666578 barrier NN I-NP O
47 1527 1529 6666578 to TO B-PP O
48 1530 1537 6666578 albumin NN B-NP O
49 1538 1546 6666578 remained VBD B-VP O
50 1547 1557 6666578 unaffected JJ B-ADJP O
51 1558 1560 6666578 by IN B-PP O
52 1561 1562 6666578 D NN B-NP B-Chemical
53 1562 1563 6666578 - HYPH B-NP I-Chemical
54 1563 1566 6666578 pen NN I-NP I-Chemical
55 1567 1576 6666578 treatment NN I-NP O
56 1576 1577 6666578 . . O O

1 1578 1583 6666578 These DT B-NP O
2 1584 1596 6666578 observations NNS I-NP O
3 1597 1604 6666578 support VBP B-VP O
4 1605 1608 6666578 the DT B-NP O
5 1609 1619 6666578 hypothesis NN I-NP O
6 1620 1624 6666578 that IN B-SBAR O
7 1625 1634 6666578 treatment NN B-NP O
8 1635 1639 6666578 with IN B-PP O
9 1640 1644 6666578 high JJ B-NP O
10 1645 1650 6666578 doses NNS I-NP O
11 1651 1653 6666578 of IN B-PP O
12 1654 1655 6666578 D NN B-NP B-Chemical
13 1655 1656 6666578 - HYPH B-NP I-Chemical
14 1656 1659 6666578 pen NN I-NP I-Chemical
15 1660 1663 6666578 may MD B-VP O
16 1664 1670 6666578 induce VB I-VP O
17 1671 1672 6666578 a DT B-NP O
18 1673 1691 6666578 fibroproliferative JJ I-NP O
19 1692 1700 6666578 response NN I-NP O
20 1701 1703 6666578 in IN B-PP O
21 1704 1707 6666578 rat NN B-NP O
22 1708 1713 6666578 aorta NN I-NP O
23 1713 1714 6666578 , , O O
24 1715 1723 6666578 possibly RB B-ADVP O
25 1724 1726 6666578 by IN B-PP O
26 1727 1729 6666578 an DT B-NP O
27 1730 1740 6666578 inhibitory JJ I-NP O
28 1741 1747 6666578 effect NN I-NP O
29 1748 1750 6666578 on IN B-PP O
30 1751 1754 6666578 the DT B-NP O
31 1755 1760 6666578 cross AFX I-NP O
32 1760 1761 6666578 - HYPH I-NP O
33 1761 1768 6666578 linking VBG I-NP O
34 1769 1771 6666578 of IN B-PP O
35 1772 1780 6666578 collagen NN B-NP O
36 1781 1784 6666578 and CC I-NP O
37 1785 1792 6666578 elastin NN I-NP O
38 1792 1793 6666578 . . O O

1 0 0 18560792 -DOCSTART- -X- -X- O

1 0 8 18560792 Valvular JJ B-NP B-Disease
2 9 14 18560792 heart NN I-NP I-Disease
3 15 22 18560792 disease NN I-NP I-Disease
4 23 25 18560792 in IN B-PP O
5 26 34 18560792 patients NNS B-NP O
6 35 39 18560792 with IN B-PP O
7 40 51 18560792 Parkinson's NNS B-NP B-Disease
8 52 59 18560792 disease NN I-NP I-Disease
9 60 67 18560792 treated VBN B-VP O
10 68 72 18560792 with IN B-PP O
11 73 82 18560792 pergolide NN B-NP B-Chemical
12 82 83 18560792 . . O O

1 84 90 18560792 Course NN B-NP O
2 91 100 18560792 following VBG B-PP O
3 101 110 18560792 treatment NN B-NP O
4 111 124 18560792 modifications NNS I-NP O
5 124 125 18560792 . . O O
6 126 134 18560792 Valvular JJ B-NP B-Disease
7 135 140 18560792 heart NN I-NP I-Disease
8 141 154 18560792 abnormalities NNS I-NP I-Disease
9 155 159 18560792 have VBP B-VP O
10 160 164 18560792 been VBN I-VP O
11 165 173 18560792 reported VBN I-VP O
12 174 176 18560792 in IN B-PP O
13 177 185 18560792 patients NNS B-NP O
14 186 190 18560792 with IN B-PP O
15 191 202 18560792 Parkinson's NNS B-NP B-Disease
16 203 210 18560792 disease NN B-NP I-Disease
17 211 212 18560792 ( ( O O
18 212 214 18560792 PD NN B-NP B-Disease
19 214 215 18560792 ) ) O O
20 216 223 18560792 treated VBN B-VP O
21 224 228 18560792 with IN B-PP O
22 229 238 18560792 pergolide NN B-NP B-Chemical
23 238 239 18560792 . . O O

1 240 247 18560792 However RB B-ADVP O
2 247 248 18560792 , , O O
3 249 252 18560792 the DT B-NP O
4 253 262 18560792 incidence NN I-NP O
5 263 266 18560792 and CC I-NP O
6 267 275 18560792 severity NN I-NP O
7 276 278 18560792 of IN B-PP O
8 279 284 18560792 these DT B-NP O
9 285 298 18560792 abnormalities NNS I-NP O
10 299 303 18560792 vary VBP B-VP O
11 304 308 18560792 from IN B-PP O
12 309 314 18560792 study NN B-NP O
13 315 317 18560792 to TO B-VP O
14 318 323 18560792 study VB I-VP O
15 324 327 18560792 and CC O O
16 328 333 18560792 their PRP$ B-NP O
17 334 340 18560792 course NN I-NP O
18 341 346 18560792 after IN B-PP O
19 347 351 18560792 drug NN B-NP O
20 352 362 18560792 withdrawal NN I-NP O
21 363 366 18560792 has VBZ B-VP O
22 367 370 18560792 not RB I-VP O
23 371 375 18560792 been VBN I-VP O
24 376 390 18560792 systematically RB I-VP O
25 391 399 18560792 assessed VBN I-VP O
26 399 400 18560792 . . O O

1 401 411 18560792 OBJECTIVES NNS B-NP O
2 411 412 18560792 : : O O
3 413 415 18560792 To TO B-VP O
4 416 424 18560792 estimate VB I-VP O
5 425 428 18560792 the DT B-NP O
6 429 438 18560792 frequency NN I-NP O
7 439 442 18560792 and CC I-NP O
8 443 451 18560792 severity NN I-NP O
9 452 454 18560792 of IN B-PP O
10 455 463 18560792 valvular JJ B-NP B-Disease
11 464 469 18560792 heart NN I-NP I-Disease
12 470 481 18560792 abnormality NN I-NP I-Disease
13 482 485 18560792 and CC O O
14 486 489 18560792 its PRP$ B-NP O
15 490 498 18560792 possible JJ I-NP O
16 499 512 18560792 reversibility NN I-NP O
17 513 518 18560792 after IN B-PP O
18 519 523 18560792 drug NN B-NP O
19 524 534 18560792 withdrawal NN I-NP O
20 535 537 18560792 in IN B-PP O
21 538 539 18560792 a DT B-NP O
22 540 544 18560792 case NN I-NP O
23 544 545 18560792 - HYPH B-NP O
24 545 552 18560792 control NN I-NP O
25 553 558 18560792 study NN I-NP O
26 558 559 18560792 . . O O

1 560 567 18560792 METHODS NNS B-NP O
2 567 568 18560792 : : O O
3 569 572 18560792 All DT B-NP O
4 573 575 18560792 PD NN I-NP B-Disease
5 576 584 18560792 patients NNS I-NP O
6 585 587 18560792 in IN B-PP O
7 588 591 18560792 the DT B-NP O
8 592 598 18560792 Amiens NNP I-NP O
9 599 603 18560792 area NN I-NP O
10 604 611 18560792 treated VBN B-VP O
11 612 616 18560792 with IN B-PP O
12 617 626 18560792 pergolide NN B-NP B-Chemical
13 627 631 18560792 were VBD B-VP O
14 632 639 18560792 invited VBN I-VP O
15 640 642 18560792 to TO B-VP O
16 643 649 18560792 attend VB I-VP O
17 650 651 18560792 a DT B-NP O
18 652 663 18560792 cardiologic JJ I-NP O
19 664 674 18560792 assessment NN I-NP O
20 675 684 18560792 including VBG B-PP O
21 685 698 18560792 transthoracic JJ B-NP O
22 699 715 18560792 echocardiography NN I-NP O
23 715 716 18560792 . . O O

1 717 723 18560792 Thirty CD B-NP O
2 724 726 18560792 PD NN I-NP B-Disease
3 727 735 18560792 patients NNS I-NP O
4 736 748 18560792 participated VBD B-VP O
5 749 751 18560792 in IN B-PP O
6 752 755 18560792 the DT B-NP O
7 756 761 18560792 study NN I-NP O
8 761 762 18560792 . . O O

1 763 764 18560792 A DT B-NP O
2 765 771 18560792 second JJ I-NP O
3 772 788 18560792 echocardiography NN I-NP O
4 789 792 18560792 was VBD B-VP O
5 793 802 18560792 performed VBN I-VP O
6 803 804 18560792 ( ( O O
7 804 810 18560792 median JJ B-NP O
8 811 819 18560792 interval NN I-NP O
9 819 820 18560792 : : O O
10 821 823 18560792 13 CD B-NP O
11 824 830 18560792 months NNS I-NP O
12 830 831 18560792 ) ) O O
13 832 837 18560792 after IN B-PP O
14 838 847 18560792 pergolide NN B-NP B-Chemical
15 848 858 18560792 withdrawal NN I-NP O
16 859 860 18560792 ( ( O O
17 860 861 18560792 n NN B-NP O
18 861 862 18560792 = SYM B-VP O
19 862 864 18560792 10 CD B-NP O
20 865 873 18560792 patients NNS I-NP O
21 873 874 18560792 ) ) O O
22 874 875 18560792 . . O O

1 876 884 18560792 Controls NNS B-NP O
2 885 889 18560792 were VBD B-VP O
3 890 893 18560792 age NN B-NP O
4 893 894 18560792 - HYPH B-ADJP O
5 895 898 18560792 and CC O O
6 899 902 18560792 sex NN B-NP O
7 902 903 18560792 - HYPH O O
8 903 910 18560792 matched VBN B-VP O
9 911 914 18560792 non AFX B-NP O
10 914 915 18560792 - HYPH I-NP O
11 915 917 18560792 PD NN B-NP B-Disease
12 918 926 18560792 patients NNS I-NP O
13 927 935 18560792 referred VBD B-VP O
14 936 938 18560792 to TO B-PP O
15 939 942 18560792 the DT B-NP O
16 943 953 18560792 cardiology NN I-NP O
17 954 964 18560792 department NN I-NP O
18 964 965 18560792 . . O O

1 966 973 18560792 RESULTS NNS B-NP O
2 973 974 18560792 : : O O
3 975 983 18560792 Compared VBN B-VP O
4 984 986 18560792 to TO B-PP O
5 987 995 18560792 controls NNS B-NP O
6 995 996 18560792 , , O O
7 997 1003 18560792 aortic JJ B-NP B-Disease
8 1004 1017 18560792 regurgitation NN I-NP I-Disease
9 1018 1019 18560792 ( ( O O
10 1019 1021 18560792 OR NN B-NP O
11 1021 1022 18560792 : : O O
12 1023 1026 18560792 3.1 CD B-NP O
13 1026 1027 18560792 ; : O O
14 1028 1031 18560792 95% CD B-NP O
15 1032 1034 18560792 IC NN I-NP O
16 1034 1035 18560792 : : O O
17 1036 1039 18560792 1.1 CD B-NP O
18 1039 1040 18560792 - HYPH I-NP O
19 1040 1043 18560792 8.8 CD I-NP O
20 1043 1044 18560792 ) ) O O
21 1045 1048 18560792 and CC O O
22 1049 1055 18560792 mitral JJ B-NP B-Disease
23 1056 1069 18560792 regurgitation NN I-NP I-Disease
24 1070 1071 18560792 ( ( O O
25 1071 1073 18560792 OR NN B-NP O
26 1073 1074 18560792 : : O O
27 1075 1079 18560792 10.7 CD B-NP O
28 1079 1080 18560792 ; : O O
29 1081 1084 18560792 95% CD B-NP O
30 1085 1087 18560792 IC NN I-NP O
31 1087 1088 18560792 : : O O
32 1089 1092 18560792 2.1 CD B-NP O
33 1092 1093 18560792 - HYPH I-NP O
34 1093 1095 18560792 53 CD I-NP O
35 1095 1096 18560792 ) ) O O
36 1097 1101 18560792 were VBD B-VP O
37 1102 1106 18560792 more RBR B-ADJP O
38 1107 1115 18560792 frequent JJ I-ADJP O
39 1116 1118 18560792 in IN B-PP O
40 1119 1121 18560792 PD NN B-NP B-Disease
41 1122 1130 18560792 patients NNS I-NP O
42 1131 1132 18560792 ( ( O O
43 1132 1141 18560792 tricuspid NN B-NP O
44 1141 1142 18560792 : : O O
45 1143 1145 18560792 NS NN B-NP O
46 1145 1146 18560792 ) ) O O
47 1146 1147 18560792 . . O O

1 1148 1151 18560792 The DT B-NP O
2 1152 1158 18560792 number NN I-NP O
3 1159 1161 18560792 of IN B-PP O
4 1162 1170 18560792 affected VBN B-NP O
5 1171 1177 18560792 valves NNS I-NP O
6 1178 1179 18560792 ( ( O O
7 1179 1180 18560792 n NN B-NP O
8 1180 1181 18560792 = SYM B-VP O
9 1181 1185 18560792 2.4+ SYM B-NP O
10 1185 1186 18560792 / SYM O O
11 1186 1187 18560792 - SYM O O
12 1187 1190 18560792 0.7 CD B-NP O
13 1190 1191 18560792 ) ) O O
14 1192 1195 18560792 and CC O O
15 1196 1199 18560792 the DT B-NP O
16 1200 1203 18560792 sum NN I-NP O
17 1204 1206 18560792 of IN B-PP O
18 1207 1220 18560792 regurgitation NN B-NP O
19 1221 1227 18560792 grades NNS I-NP O
20 1228 1229 18560792 ( ( O O
21 1229 1230 18560792 n NN B-NP O
22 1230 1231 18560792 = SYM B-VP O
23 1231 1235 18560792 2.8+ SYM B-NP O
24 1235 1236 18560792 / SYM B-VP O
25 1236 1237 18560792 - SYM B-NP O
26 1237 1241 18560792 1.09 CD I-NP O
27 1241 1242 18560792 ) ) O O
28 1243 1247 18560792 were VBD B-VP O
29 1248 1254 18560792 higher JJR B-ADJP O
30 1255 1256 18560792 ( ( O O
31 1256 1257 18560792 p NN B-NP O
32 1257 1258 18560792 = SYM B-VP O
33 1258 1263 18560792 0.008 CD B-NP O
34 1264 1267 18560792 and CC O O
35 1268 1269 18560792 p NN B-NP O
36 1269 1270 18560792 = SYM B-VP O
37 1270 1275 18560792 0.006 CD B-NP O
38 1275 1276 18560792 , , O O
39 1277 1289 18560792 respectively RB B-ADVP O
40 1289 1290 18560792 ) ) O O
41 1291 1293 18560792 in IN B-PP O
42 1294 1297 18560792 the DT B-NP O
43 1298 1307 18560792 pergolide NN I-NP B-Chemical
44 1308 1313 18560792 group NN I-NP O
45 1313 1314 18560792 . . O O

1 1315 1323 18560792 Severity NN B-NP O
2 1324 1326 18560792 of IN B-PP O
3 1327 1340 18560792 regurgitation NN B-NP O
4 1341 1344 18560792 was VBD B-VP O
5 1345 1348 18560792 not RB I-VP O
6 1349 1359 18560792 correlated VBN I-VP O
7 1360 1364 18560792 with IN B-PP O
8 1365 1374 18560792 pergolide NN B-NP B-Chemical
9 1375 1385 18560792 cumulative JJ I-NP O
10 1386 1390 18560792 dose NN I-NP O
11 1390 1391 18560792 . . O O

1 1392 1393 18560792 A DT B-NP O
2 1394 1405 18560792 restrictive JJ I-NP O
3 1406 1413 18560792 pattern NN I-NP O
4 1414 1416 18560792 of IN B-PP O
5 1417 1425 18560792 valvular JJ B-NP B-Disease
6 1426 1439 18560792 regurgitation NN I-NP I-Disease
7 1439 1440 18560792 , , O O
8 1441 1451 18560792 suggestive JJ B-ADJP O
9 1452 1454 18560792 of IN B-PP O
10 1455 1458 18560792 the DT B-NP O
11 1459 1463 18560792 role NN I-NP O
12 1464 1466 18560792 of IN B-PP O
13 1467 1476 18560792 pergolide NN B-NP B-Chemical
14 1476 1477 18560792 , , O O
15 1478 1481 18560792 was VBD B-VP O
16 1482 1490 18560792 observed VBN I-VP O
17 1491 1493 18560792 in IN B-PP O
18 1494 1496 18560792 12 CD B-NP O
19 1496 1497 18560792 / SYM O O
20 1497 1499 18560792 30 CD B-NP O
21 1500 1501 18560792 ( ( O O
22 1501 1504 18560792 40% CD B-NP O
23 1504 1505 18560792 ) ) O O
24 1506 1514 18560792 patients NNS B-NP O
25 1515 1524 18560792 including VBG B-PP O
26 1525 1528 18560792 two CD B-NP O
27 1529 1533 18560792 with IN B-PP O
28 1534 1539 18560792 heart NN B-NP B-Disease
29 1540 1547 18560792 failure NN I-NP I-Disease
30 1547 1548 18560792 . . O O

1 1549 1558 18560792 Pergolide NN B-NP B-Chemical
2 1559 1562 18560792 was VBD B-VP O
3 1563 1575 18560792 discontinued VBN I-VP O
4 1576 1578 18560792 in IN B-PP O
5 1579 1581 18560792 10 CD B-NP O
6 1582 1590 18560792 patients NNS I-NP O
7 1591 1595 18560792 with IN B-PP O
8 1596 1604 18560792 valvular JJ B-NP B-Disease
9 1605 1610 18560792 heart NN I-NP I-Disease
10 1611 1618 18560792 disease NN I-NP I-Disease
11 1618 1619 18560792 , , O O
12 1620 1629 18560792 resulting VBG B-VP O
13 1630 1632 18560792 in IN B-PP O
14 1633 1634 18560792 a DT B-NP O
15 1635 1640 18560792 lower JJR I-NP O
16 1641 1654 18560792 regurgitation NN I-NP O
17 1655 1660 18560792 grade NN I-NP O
18 1661 1662 18560792 ( ( O O
19 1662 1663 18560792 p NN B-NP O
20 1663 1664 18560792 = SYM B-VP O
21 1664 1668 18560792 0.01 CD B-NP O
22 1668 1669 18560792 ) ) O O
23 1670 1672 18560792 at IN B-PP O
24 1673 1676 18560792 the DT B-NP O
25 1677 1683 18560792 second JJ I-NP O
26 1684 1697 18560792 transthoracic JJ I-NP O
27 1698 1714 18560792 echocardiography NN I-NP O
28 1715 1718 18560792 and CC O O
29 1719 1722 18560792 the DT B-NP O
30 1723 1726 18560792 two CD I-NP O
31 1727 1735 18560792 patients NNS I-NP O
32 1736 1740 18560792 with IN B-PP O
33 1741 1746 18560792 heart NN B-NP B-Disease
34 1747 1754 18560792 failure NN I-NP I-Disease
35 1755 1763 18560792 returned VBD B-VP O
36 1764 1766 18560792 to TO B-PP O
37 1767 1773 18560792 nearly RB B-NP O
38 1774 1780 18560792 normal JJ I-NP O
39 1781 1789 18560792 clinical JJ I-NP O
40 1790 1801 18560792 examination NN I-NP O
41 1801 1802 18560792 . . O O

1 1803 1807 18560792 This DT B-NP O
2 1808 1813 18560792 study NN I-NP O
3 1814 1822 18560792 supports VBZ B-VP O
4 1823 1826 18560792 the DT B-NP O
5 1827 1831 18560792 high JJ I-NP O
6 1832 1841 18560792 frequency NN I-NP O
7 1842 1844 18560792 of IN B-PP O
8 1845 1856 18560792 restrictive JJ B-NP O
9 1857 1862 18560792 valve NN I-NP B-Disease
10 1863 1876 18560792 regurgitation NN I-NP I-Disease
11 1877 1879 18560792 in IN B-PP O
12 1880 1882 18560792 PD NN B-NP B-Disease
13 1883 1891 18560792 patients NNS I-NP O
14 1892 1899 18560792 treated VBN B-VP O
15 1900 1904 18560792 with IN B-PP O
16 1905 1914 18560792 pergolide NN B-NP B-Chemical
17 1915 1918 18560792 and CC O O
18 1919 1926 18560792 reveals VBZ B-VP O
19 1927 1931 18560792 that IN B-SBAR O
20 1932 1933 18560792 a DT B-NP O
21 1934 1945 18560792 significant JJ I-NP O
22 1946 1957 18560792 improvement NN I-NP O
23 1958 1960 18560792 is VBZ B-VP O
24 1961 1966 18560792 usual JJ B-ADJP O
25 1967 1971 18560792 when WRB B-ADVP O
26 1972 1975 18560792 the DT B-NP O
27 1976 1985 18560792 treatment NN I-NP O
28 1986 1988 18560792 is VBZ B-VP O
29 1989 1998 18560792 converted VBN I-VP O
30 1999 2001 18560792 to TO B-PP O
31 2002 2005 18560792 non AFX B-NP O
32 2005 2006 18560792 - HYPH I-NP O
33 2006 2011 18560792 ergot NN I-NP O
34 2012 2020 18560792 dopamine NN I-NP B-Chemical
35 2021 2029 18560792 agonists NNS I-NP O
36 2029 2030 18560792 . . O O

1 0 0 19843802 -DOCSTART- -X- -X- O

1 0 4 19843802 When WRB B-ADVP O
2 5 10 19843802 drugs NNS B-NP O
3 11 20 19843802 disappear VBP B-VP O
4 21 25 19843802 from IN B-PP O
5 26 29 19843802 the DT B-NP O
6 30 37 19843802 patient NN I-NP O
7 37 38 19843802 : : O O
8 39 50 19843802 elimination NN B-NP O
9 51 53 19843802 of IN B-PP O
10 54 65 19843802 intravenous JJ B-NP O
11 66 76 19843802 medication NN I-NP O
12 77 79 19843802 by IN B-PP O
13 80 97 19843802 hemodiafiltration NN B-NP O
14 97 98 19843802 . . O O
15 99 105 19843802 Twenty CD B-NP O
16 105 106 19843802 - HYPH I-NP O
17 106 111 19843802 three CD I-NP O
18 112 117 19843802 hours NNS I-NP O
19 118 123 19843802 after IN B-PP O
20 124 129 19843802 heart NN B-NP O
21 130 145 19843802 transplantation NN I-NP O
22 145 146 19843802 , , O O
23 147 151 19843802 life NN B-NP O
24 151 152 19843802 - HYPH O O
25 152 163 19843802 threatening VBG B-VP O
26 164 169 19843802 acute JJ B-NP O
27 170 175 19843802 right JJ I-NP B-Disease
28 176 181 19843802 heart NN I-NP I-Disease
29 182 189 19843802 failure NN I-NP I-Disease
30 190 193 19843802 was VBD B-VP O
31 194 203 19843802 diagnosed VBN I-VP O
32 204 206 19843802 in IN B-PP O
33 207 208 19843802 a DT B-NP O
34 209 216 19843802 patient NN I-NP O
35 217 226 19843802 requiring VBG B-VP O
36 227 237 19843802 continuous JJ B-NP O
37 238 248 19843802 venovenous JJ I-NP O
38 249 266 19843802 hemodiafiltration NN I-NP O
39 267 268 19843802 ( ( O O
40 268 274 19843802 CVVHDF NN B-NP O
41 274 275 19843802 ) ) O O
42 275 276 19843802 . . O O

1 277 287 19843802 Increasing VBG B-VP O
2 288 293 19843802 doses NNS B-NP O
3 294 296 19843802 of IN B-PP O
4 297 311 19843802 catecholamines NNS B-NP B-Chemical
5 311 312 19843802 , , O O
6 313 322 19843802 sedatives NNS B-NP O
7 322 323 19843802 , , O O
8 324 327 19843802 and CC O O
9 328 334 19843802 muscle NN B-NP O
10 335 344 19843802 relaxants NNS I-NP O
11 345 357 19843802 administered VBN B-VP O
12 358 365 19843802 through IN B-PP O
13 366 367 19843802 a DT B-NP O
14 368 375 19843802 central JJ I-NP O
15 376 382 19843802 venous JJ I-NP O
16 383 391 19843802 catheter NN I-NP O
17 392 396 19843802 were VBD B-VP O
18 397 408 19843802 ineffective JJ B-ADJP O
19 408 409 19843802 . . O O

1 410 417 19843802 However RB B-ADVP O
2 417 418 19843802 , , O O
3 419 420 19843802 a DT B-NP O
4 421 426 19843802 bolus NN I-NP O
5 427 429 19843802 of IN B-PP O
6 430 441 19843802 epinephrine NN B-NP B-Chemical
7 442 450 19843802 injected VBN B-VP O
8 451 458 19843802 through IN B-PP O
9 459 461 19843802 an DT B-NP O
10 462 473 19843802 alternative JJ I-NP O
11 474 482 19843802 catheter NN I-NP O
12 483 491 19843802 provoked VBD B-VP O
13 492 493 19843802 a DT B-NP O
14 494 506 19843802 hypertensive JJ I-NP B-Disease
15 507 513 19843802 crisis NN I-NP O
16 513 514 19843802 . . O O

1 515 519 19843802 Thus RB B-ADVP O
2 519 520 19843802 , , O O
3 521 533 19843802 interference NN B-NP O
4 534 538 19843802 with IN B-PP O
5 539 542 19843802 the DT B-NP O
6 543 550 19843802 central JJ I-NP O
7 551 557 19843802 venous JJ I-NP O
8 558 566 19843802 infusion NN I-NP O
9 567 569 19843802 by IN B-PP O
10 570 573 19843802 the DT B-NP O
11 574 582 19843802 dialysis NN I-NP O
12 583 591 19843802 catheter NN I-NP O
13 592 595 19843802 was VBD B-VP O
14 596 605 19843802 suspected VBN I-VP O
15 605 606 19843802 . . O O

1 607 610 19843802 The DT B-NP O
2 611 620 19843802 catheters NNS I-NP O
3 621 625 19843802 were VBD B-VP O
4 626 633 19843802 changed VBN I-VP O
5 633 634 19843802 , , O O
6 635 638 19843802 and CC O O
7 639 651 19843802 hemodynamics NNS B-NP O
8 652 662 19843802 stabilized VBD B-VP O
9 663 665 19843802 at IN B-PP O
10 666 671 19843802 lower JJR B-NP O
11 672 685 19843802 catecholamine NN I-NP B-Chemical
12 686 691 19843802 doses NNS I-NP O
13 691 692 19843802 . . O O

1 693 697 19843802 When WRB B-ADVP O
2 698 701 19843802 the DT B-NP O
3 702 709 19843802 effects NNS I-NP O
4 710 712 19843802 of IN B-PP O
5 713 715 19843802 IV CD B-NP O
6 716 721 19843802 drugs NNS I-NP O
7 722 725 19843802 are VBP B-VP O
8 726 736 19843802 inadequate JJ B-ADJP O
9 737 739 19843802 in IN B-PP O
10 740 748 19843802 patients NNS B-NP O
11 749 758 19843802 receiving VBG B-VP O
12 759 765 19843802 CVVHDF NN B-NP O
13 765 766 19843802 , , O O
14 767 779 19843802 interference NN B-NP O
15 780 784 19843802 with IN B-PP O
16 785 793 19843802 adjacent JJ B-NP O
17 794 803 19843802 catheters NNS I-NP O
18 804 813 19843802 resulting VBG B-VP O
19 814 816 19843802 in IN B-PP O
20 817 828 19843802 elimination NN B-NP O
21 829 831 19843802 of IN B-PP O
22 832 835 19843802 the DT B-NP O
23 836 840 19843802 drug NN I-NP O
24 841 843 19843802 by IN B-PP O
25 844 850 19843802 CVVHDF NN B-NP O
26 851 857 19843802 should MD B-VP O
27 858 860 19843802 be VB I-VP O
28 861 870 19843802 suspected VBN I-VP O
29 870 871 19843802 . . O O

1 0 0 18186898 -DOCSTART- -X- -X- O

1 0 5 18186898 Renal JJ B-NP B-Disease
2 6 13 18186898 Fanconi NNP I-NP I-Disease
3 14 22 18186898 syndrome NN I-NP I-Disease
4 23 26 18186898 and CC I-NP O
5 27 35 18186898 myopathy NN I-NP B-Disease
6 36 41 18186898 after IN B-PP O
7 42 47 18186898 liver NN B-NP O
8 48 63 18186898 transplantation NN I-NP O
9 63 64 18186898 : : O O
10 65 69 18186898 drug NN B-NP O
11 69 70 18186898 - HYPH O O
12 70 77 18186898 related VBN B-NP O
13 78 91 18186898 mitochondrial JJ I-NP B-Disease
14 92 101 18186898 cytopathy NN I-NP I-Disease
15 101 102 18186898 ? . O O
16 103 111 18186898 Advances NNS B-NP O
17 112 114 18186898 in IN B-PP O
18 115 118 18186898 the DT B-NP O
19 119 124 18186898 field NN I-NP O
20 125 127 18186898 of IN B-PP O
21 128 143 18186898 transplantation NN B-NP O
22 144 151 18186898 provide VBP B-VP O
23 152 153 18186898 a DT B-NP O
24 154 160 18186898 better JJR I-NP O
25 161 168 18186898 quality NN I-NP O
26 169 171 18186898 of IN B-PP O
27 172 176 18186898 life NN B-NP O
28 177 180 18186898 and CC O O
29 181 186 18186898 allow VB B-VP O
30 187 191 18186898 more RBR B-NP O
31 192 201 18186898 favorable JJ I-NP O
32 202 212 18186898 conditions NNS I-NP O
33 213 216 18186898 for IN B-PP O
34 217 223 18186898 growth NN B-NP O
35 224 227 18186898 and CC I-NP O
36 228 239 18186898 development NN I-NP O
37 240 242 18186898 in IN B-PP O
38 243 251 18186898 children NNS B-NP O
39 251 252 18186898 . . O O

1 253 260 18186898 However RB B-ADVP O
2 260 261 18186898 , , O O
3 262 274 18186898 combinations NNS B-NP O
4 275 277 18186898 of IN B-PP O
5 278 287 18186898 different JJ B-NP O
6 288 299 18186898 therapeutic JJ I-NP O
7 300 308 18186898 regimens NNS I-NP O
8 309 316 18186898 require VBP B-VP O
9 317 330 18186898 consideration NN B-NP O
10 331 333 18186898 of IN B-PP O
11 334 343 18186898 potential JJ B-NP O
12 344 351 18186898 adverse JJ I-NP O
13 352 361 18186898 reactions NNS I-NP O
14 361 362 18186898 . . O O

1 363 365 18186898 We PRP B-NP O
2 366 374 18186898 describe VBP B-VP O
3 375 376 18186898 a DT B-NP O
4 377 379 18186898 15 CD I-NP O
5 379 380 18186898 - HYPH I-NP O
6 380 382 18186898 yr NN I-NP O
7 382 383 18186898 - HYPH I-NP O
8 383 386 18186898 old JJ I-NP O
9 387 391 18186898 girl NN I-NP O
10 392 395 18186898 who WP B-NP O
11 396 399 18186898 had VBD B-VP O
12 400 410 18186898 orthotopic JJ B-NP O
13 411 416 18186898 liver NN I-NP O
14 417 432 18186898 transplantation NN I-NP O
15 433 440 18186898 because IN B-PP O
16 441 443 18186898 of IN I-PP O
17 444 452 18186898 Wilson's NNS B-NP B-Disease
18 453 460 18186898 disease NN I-NP I-Disease
19 460 461 18186898 . . O O

1 462 472 18186898 Tacrolimus NN B-NP B-Chemical
2 472 473 18186898 , , O O
3 474 477 18186898 MMF NN B-NP B-Chemical
4 477 478 18186898 , , O O
5 479 482 18186898 and CC O O
6 483 491 18186898 steroids NNS B-NP B-Chemical
7 492 496 18186898 were VBD B-VP O
8 497 502 18186898 given VBN I-VP O
9 503 505 18186898 as IN B-PP O
10 506 523 18186898 immunosuppressant NN B-NP O
11 523 524 18186898 . . O O

1 525 535 18186898 Lamivudine NN B-NP B-Chemical
2 536 539 18186898 was VBD B-VP O
3 540 545 18186898 added VBN I-VP O
4 546 553 18186898 because IN B-PP O
5 554 556 18186898 of IN I-PP O
6 557 559 18186898 de FW B-NP O
7 560 564 18186898 nova FW I-NP O
8 565 574 18186898 hepatitis NN I-NP B-Disease
9 575 576 18186898 B NN I-NP I-Disease
10 577 586 18186898 infection NN I-NP I-Disease
11 587 593 18186898 during IN B-PP O
12 594 597 18186898 her PRP B-NP O
13 598 604 18186898 follow VB B-VP O
14 604 605 18186898 - HYPH B-ADJP O
15 605 607 18186898 up RP B-PRT O
16 607 608 18186898 . . O O

1 609 614 18186898 Three CD B-NP O
2 615 617 18186898 yr NN I-NP O
3 618 623 18186898 after IN B-PP O
4 624 639 18186898 transplantation NN B-NP O
5 640 643 18186898 she PRP B-NP O
6 644 653 18186898 developed VBD B-VP O
7 654 659 18186898 renal JJ B-NP B-Disease
8 660 667 18186898 Fanconi NNP I-NP I-Disease
9 668 676 18186898 syndrome NN I-NP I-Disease
10 677 681 18186898 with IN B-PP O
11 682 688 18186898 severe JJ B-NP O
12 689 698 18186898 metabolic JJ I-NP B-Disease
13 699 707 18186898 acidosis NN I-NP I-Disease
14 707 708 18186898 , , O O
15 709 725 18186898 hypophosphatemia NN B-NP B-Disease
16 725 726 18186898 , , O O
17 727 737 18186898 glycosuria NN B-NP B-Disease
18 737 738 18186898 , , O O
19 739 742 18186898 and CC O O
20 743 756 18186898 aminoaciduria NN B-NP B-Disease
21 756 757 18186898 . . O O

1 758 766 18186898 Although IN B-SBAR O
2 767 777 18186898 tacrolimus NN B-NP B-Chemical
3 778 781 18186898 was VBD B-VP O
4 782 791 18186898 suspected VBN I-VP O
5 792 794 18186898 to TO I-VP O
6 795 797 18186898 be VB I-VP O
7 798 801 18186898 the DT B-NP O
8 802 807 18186898 cause NN I-NP O
9 808 810 18186898 of IN B-PP O
10 811 815 18186898 late JJ B-NP O
11 816 820 18186898 post AFX I-NP O
12 820 821 18186898 - HYPH I-NP O
13 821 831 18186898 transplant NN I-NP O
14 832 837 18186898 renal JJ I-NP O
15 838 846 18186898 acidosis NN I-NP B-Disease
16 847 850 18186898 and CC O O
17 851 854 18186898 was VBD B-VP O
18 855 863 18186898 replaced VBN I-VP O
19 864 866 18186898 by IN B-PP O
20 867 876 18186898 sirolimus NN B-NP B-Chemical
21 876 877 18186898 , , O O
22 878 886 18186898 acidosis NN B-NP B-Disease
23 886 887 18186898 , , O O
24 888 891 18186898 and CC O O
25 892 903 18186898 electrolyte NN B-NP O
26 904 913 18186898 imbalance NN I-NP O
27 914 917 18186898 got VBD B-VP O
28 918 923 18186898 worse JJR B-ADJP O
29 923 924 18186898 . . O O

1 925 933 18186898 Proximal JJ B-NP O
2 934 940 18186898 muscle NN I-NP B-Disease
3 941 949 18186898 weakness NN I-NP I-Disease
4 950 953 18186898 has VBZ B-VP O
5 954 963 18186898 developed VBN I-VP O
6 964 970 18186898 during IN B-PP O
7 971 974 18186898 her PRP B-NP O
8 975 981 18186898 follow VB B-VP O
9 981 982 18186898 - HYPH B-ADJP O
10 982 984 18186898 up RP B-PRT O
11 984 985 18186898 . . O O

1 986 993 18186898 Fanconi NNP B-NP B-Disease
2 994 1002 18186898 syndrome NN I-NP I-Disease
3 1002 1003 18186898 , , O O
4 1004 1006 18186898 as RB B-CONJP O
5 1007 1011 18186898 well RB I-CONJP O
6 1012 1014 18186898 as IN I-CONJP O
7 1015 1023 18186898 myopathy NN B-NP B-Disease
8 1023 1024 18186898 , , O O
9 1025 1027 18186898 is VBZ B-VP O
10 1028 1032 18186898 well RB I-VP O
11 1033 1043 18186898 recognized VBN I-VP O
12 1044 1046 18186898 in IN B-PP O
13 1047 1055 18186898 patients NNS B-NP O
14 1056 1060 18186898 with IN B-PP O
15 1061 1074 18186898 mitochondrial JJ B-NP B-Disease
16 1075 1084 18186898 disorders NNS I-NP I-Disease
17 1085 1088 18186898 and CC O O
18 1089 1095 18186898 caused VBN B-VP O
19 1096 1098 18186898 by IN B-PP O
20 1099 1108 18186898 depletion NN B-NP O
21 1109 1111 18186898 of IN B-PP O
22 1112 1117 18186898 mtDNA NN B-NP O
23 1117 1118 18186898 . . O O

1 1119 1121 18186898 We PRP B-NP O
2 1122 1129 18186898 suggest VBP B-VP O
3 1130 1134 18186898 that IN B-SBAR O
4 1135 1138 18186898 our PRP$ B-NP O
5 1139 1148 18186898 patient's NNS I-NP O
6 1149 1156 18186898 tubular JJ I-NP B-Disease
7 1157 1168 18186898 dysfunction NN I-NP I-Disease
8 1169 1172 18186898 and CC I-NP O
9 1173 1181 18186898 myopathy NN I-NP B-Disease
10 1182 1185 18186898 may MD B-VP O
11 1186 1190 18186898 have VB I-VP O
12 1191 1199 18186898 resulted VBN I-VP O
13 1200 1204 18186898 from IN B-PP O
14 1205 1218 18186898 mitochondrial JJ B-NP B-Disease
15 1219 1230 18186898 dysfunction NN I-NP I-Disease
16 1231 1236 18186898 which WDT B-NP O
17 1237 1239 18186898 is VBZ B-VP O
18 1240 1249 18186898 triggered VBN I-VP O
19 1250 1252 18186898 by IN B-PP O
20 1253 1263 18186898 tacrolimus NN B-NP B-Chemical
21 1264 1267 18186898 and CC O O
22 1268 1277 18186898 augmented VBN B-VP O
23 1278 1280 18186898 by IN B-PP O
24 1281 1291 18186898 lamivudine NN B-NP B-Chemical
25 1291 1292 18186898 . . O O

1 0 0 16755009 -DOCSTART- -X- -X- O

1 0 15 16755009 Pharmacological JJ B-NP O
2 16 24 16755009 evidence NN I-NP O
3 25 28 16755009 for IN B-PP O
4 29 32 16755009 the DT B-NP O
5 33 42 16755009 potential NN I-NP O
6 43 45 16755009 of IN B-PP O
7 46 52 16755009 Daucus NN B-NP O
8 53 59 16755009 carota NN I-NP O
9 60 62 16755009 in IN B-PP O
10 63 66 16755009 the DT B-NP O
11 67 77 16755009 management NN I-NP O
12 78 80 16755009 of IN B-PP O
13 81 90 16755009 cognitive JJ B-NP B-Disease
14 91 103 16755009 dysfunctions NNS I-NP I-Disease
15 103 104 16755009 . . O O
16 105 108 16755009 The DT B-NP O
17 109 116 16755009 present JJ I-NP O
18 117 122 16755009 study NN I-NP O
19 123 126 16755009 was VBD B-VP O
20 127 132 16755009 aimed VBN I-VP O
21 133 135 16755009 at IN B-PP O
22 136 149 16755009 investigating VBG B-VP O
23 150 153 16755009 the DT B-NP O
24 154 161 16755009 effects NNS I-NP O
25 162 164 16755009 of IN B-PP O
26 165 171 16755009 Daucus NN B-NP O
27 172 178 16755009 carota NN I-NP O
28 179 184 16755009 seeds NNS I-NP O
29 185 187 16755009 on IN B-PP O
30 188 197 16755009 cognitive JJ B-NP O
31 198 207 16755009 functions NNS I-NP O
32 207 208 16755009 , , O O
33 209 214 16755009 total JJ B-NP O
34 215 220 16755009 serum NN I-NP O
35 221 232 16755009 cholesterol NN I-NP B-Chemical
36 233 239 16755009 levels NNS I-NP O
37 240 243 16755009 and CC O O
38 244 249 16755009 brain NN B-NP O
39 250 264 16755009 cholinesterase NN I-NP O
40 265 273 16755009 activity NN I-NP O
41 274 276 16755009 in IN B-PP O
42 277 281 16755009 mice NNS B-NP O
43 281 282 16755009 . . O O

1 283 286 16755009 The DT B-NP O
2 287 296 16755009 ethanolic JJ I-NP O
3 297 304 16755009 extract NN I-NP B-Chemical
4 305 307 16755009 of IN B-PP I-Chemical
5 308 314 16755009 Daucus NN B-NP I-Chemical
6 315 321 16755009 carota NN I-NP I-Chemical
7 322 327 16755009 seeds NNS I-NP I-Chemical
8 328 329 16755009 ( ( O O
9 329 332 16755009 DCE NN B-NP B-Chemical
10 332 333 16755009 ) ) O O
11 334 337 16755009 was VBD B-VP O
12 338 350 16755009 administered VBN I-VP O
13 351 357 16755009 orally RB B-ADVP O
14 358 360 16755009 in IN B-PP O
15 361 366 16755009 three CD B-NP O
16 367 372 16755009 doses NNS I-NP O
17 373 374 16755009 ( ( O O
18 374 377 16755009 100 CD B-NP O
19 377 378 16755009 , , I-NP O
20 379 382 16755009 200 CD I-NP O
21 382 383 16755009 , , I-NP O
22 384 387 16755009 400 CD I-NP O
23 388 390 16755009 mg NN I-NP O
24 390 391 16755009 / SYM B-NP O
25 391 393 16755009 kg NN I-NP O
26 393 394 16755009 ) ) O O
27 395 398 16755009 for IN B-PP O
28 399 404 16755009 seven CD B-NP O
29 405 415 16755009 successive JJ I-NP O
30 416 420 16755009 days NNS I-NP O
31 421 423 16755009 to TO B-PP O
32 424 433 16755009 different JJ B-NP O
33 434 440 16755009 groups NNS I-NP O
34 441 443 16755009 of IN B-PP O
35 444 449 16755009 young JJ B-NP O
36 450 453 16755009 and CC I-NP O
37 454 458 16755009 aged JJ I-NP O
38 459 463 16755009 mice NNS I-NP O
39 463 464 16755009 . . O O

1 465 473 16755009 Elevated VBN B-VP O
2 474 478 16755009 plus CC O O
3 479 483 16755009 maze NN B-NP O
4 484 487 16755009 and CC O O
5 488 495 16755009 passive JJ B-NP O
6 496 505 16755009 avoidance NN I-NP O
7 506 515 16755009 apparatus NN I-NP O
8 516 522 16755009 served VBD B-VP O
9 523 525 16755009 as IN B-PP O
10 526 529 16755009 the DT B-NP O
11 530 543 16755009 exteroceptive JJ I-NP O
12 544 554 16755009 behavioral JJ I-NP O
13 555 561 16755009 models NNS I-NP O
14 562 565 16755009 for IN B-PP O
15 566 573 16755009 testing NN B-NP O
16 574 580 16755009 memory NN I-NP O
17 580 581 16755009 . . O O

1 582 590 16755009 Diazepam NN B-NP B-Chemical
2 590 591 16755009 - HYPH B-ADJP O
3 591 592 16755009 , , O O
4 593 604 16755009 scopolamine NN B-NP B-Chemical
5 604 605 16755009 - HYPH B-NP O
6 606 609 16755009 and CC I-NP O
7 610 616 16755009 ageing NN I-NP O
8 616 617 16755009 - HYPH O O
9 617 624 16755009 induced VBN B-NP O
10 625 632 16755009 amnesia NN I-NP B-Disease
11 633 639 16755009 served VBD B-VP O
12 640 642 16755009 as IN B-PP O
13 643 646 16755009 the DT B-NP O
14 647 660 16755009 interoceptive JJ I-NP O
15 661 671 16755009 behavioral JJ I-NP O
16 672 678 16755009 models NNS I-NP O
17 678 679 16755009 . . O O

1 680 683 16755009 DCE NN B-NP B-Chemical
2 684 685 16755009 ( ( O O
3 685 688 16755009 200 CD B-NP O
4 688 689 16755009 , , O O
5 690 693 16755009 400 CD B-NP O
6 694 696 16755009 mg NN I-NP O
7 696 697 16755009 / SYM B-NP O
8 697 699 16755009 kg NN B-NP O
9 699 700 16755009 , , O O
10 701 704 16755009 p.o FW B-NP O
11 704 705 16755009 . . O O
12 705 706 16755009 ) ) O O
13 707 713 16755009 showed VBD B-VP O
14 714 725 16755009 significant JJ B-NP O
15 726 737 16755009 improvement NN I-NP O
16 738 740 16755009 in IN B-PP O
17 741 747 16755009 memory NN B-NP O
18 748 754 16755009 scores NNS I-NP O
19 755 757 16755009 of IN B-PP O
20 758 763 16755009 young JJ B-NP O
21 764 767 16755009 and CC I-NP O
22 768 772 16755009 aged JJ I-NP O
23 773 777 16755009 mice NNS I-NP O
24 777 778 16755009 . . O O

1 779 782 16755009 The DT B-NP O
2 783 789 16755009 extent NN I-NP O
3 790 792 16755009 of IN B-PP O
4 793 799 16755009 memory NN B-NP O
5 800 811 16755009 improvement NN I-NP O
6 812 818 16755009 evoked VBN B-VP O
7 819 821 16755009 by IN B-PP O
8 822 825 16755009 DCE NN B-NP B-Chemical
9 826 829 16755009 was VBD B-VP O
10 830 833 16755009 23% CD B-NP O
11 834 836 16755009 at IN B-PP O
12 837 840 16755009 the DT B-NP O
13 841 845 16755009 dose NN I-NP O
14 846 848 16755009 of IN B-PP O
15 849 852 16755009 200 CD B-NP O
16 853 855 16755009 mg NN I-NP O
17 855 856 16755009 / SYM B-NP O
18 856 858 16755009 kg NN I-NP O
19 859 862 16755009 and CC I-NP O
20 863 866 16755009 35% NN I-NP O
21 867 869 16755009 at IN B-PP O
22 870 873 16755009 the DT B-NP O
23 874 878 16755009 dose NN I-NP O
24 879 881 16755009 of IN B-PP O
25 882 885 16755009 400 CD B-NP O
26 886 888 16755009 mg NN I-NP O
27 888 889 16755009 / SYM B-NP O
28 889 891 16755009 kg NN I-NP O
29 892 894 16755009 in IN B-PP O
30 895 900 16755009 young JJ B-NP O
31 901 905 16755009 mice NNS I-NP O
32 906 911 16755009 using VBG B-VP O
33 912 920 16755009 elevated VBN B-VP O
34 921 925 16755009 plus CC O O
35 926 930 16755009 maze NN B-NP O
36 930 931 16755009 . . O O

1 932 941 16755009 Similarly RB B-ADVP O
2 941 942 16755009 , , O O
3 943 954 16755009 significant JJ B-NP O
4 955 967 16755009 improvements NNS I-NP O
5 968 970 16755009 in IN B-PP O
6 971 977 16755009 memory NN B-NP O
7 978 984 16755009 scores NNS I-NP O
8 985 989 16755009 were VBD B-VP O
9 990 998 16755009 observed VBN I-VP O
10 999 1004 16755009 using VBG B-VP O
11 1005 1012 16755009 passive JJ B-NP O
12 1013 1022 16755009 avoidance NN I-NP O
13 1023 1032 16755009 apparatus NN I-NP O
14 1033 1036 16755009 and CC O O
15 1037 1041 16755009 aged JJ B-NP O
16 1042 1046 16755009 mice NNS I-NP O
17 1046 1047 16755009 . . O O

1 1048 1059 16755009 Furthermore RB B-ADVP O
2 1059 1060 16755009 , , O O
3 1061 1064 16755009 DCE NN B-NP B-Chemical
4 1065 1073 16755009 reversed VBD B-VP O
5 1074 1077 16755009 the DT B-NP O
6 1078 1085 16755009 amnesia NN I-NP B-Disease
7 1086 1093 16755009 induced VBN B-VP O
8 1094 1096 16755009 by IN B-PP O
9 1097 1108 16755009 scopolamine NN B-NP B-Chemical
10 1109 1110 16755009 ( ( O O
11 1110 1113 16755009 0.4 CD B-NP O
12 1114 1116 16755009 mg NN I-NP O
13 1116 1117 16755009 / SYM B-NP O
14 1117 1119 16755009 kg NN I-NP O
15 1119 1120 16755009 , , O O
16 1121 1124 16755009 i.p NN B-NP O
17 1124 1125 16755009 . . O O
18 1125 1126 16755009 ) ) O O
19 1127 1130 16755009 and CC O O
20 1131 1139 16755009 diazepam NN B-NP B-Chemical
21 1140 1141 16755009 ( ( O O
22 1141 1142 16755009 1 CD B-NP O
23 1143 1145 16755009 mg NN I-NP O
24 1145 1146 16755009 / SYM B-NP O
25 1146 1148 16755009 kg NN I-NP O
26 1148 1149 16755009 , , O O
27 1150 1153 16755009 i.p NN B-NP O
28 1153 1154 16755009 . . O O
29 1154 1155 16755009 ) ) O O
30 1155 1156 16755009 . . O O

1 1157 1163 16755009 Daucus NN B-NP B-Chemical
2 1164 1170 16755009 carota NN I-NP I-Chemical
3 1171 1178 16755009 extract NN I-NP I-Chemical
4 1179 1180 16755009 ( ( O O
5 1180 1183 16755009 200 CD B-NP O
6 1183 1184 16755009 , , O O
7 1185 1188 16755009 400 CD B-NP O
8 1189 1191 16755009 mg NN I-NP O
9 1191 1192 16755009 / SYM B-NP O
10 1192 1194 16755009 kg NN B-NP O
11 1194 1195 16755009 , , O O
12 1196 1199 16755009 p.o FW B-NP O
13 1199 1200 16755009 . . O O
14 1200 1201 16755009 ) ) O O
15 1202 1209 16755009 reduced VBD B-VP O
16 1210 1223 16755009 significantly RB B-ADVP O
17 1224 1227 16755009 the DT B-NP O
18 1228 1233 16755009 brain NN I-NP O
19 1234 1254 16755009 acetylcholinesterase NN I-NP O
20 1255 1263 16755009 activity NN I-NP O
21 1264 1267 16755009 and CC O O
22 1268 1279 16755009 cholesterol NN B-NP B-Chemical
23 1280 1286 16755009 levels NNS I-NP O
24 1287 1289 16755009 in IN B-PP O
25 1290 1295 16755009 young JJ B-NP O
26 1296 1299 16755009 and CC I-NP O
27 1300 1304 16755009 aged JJ I-NP O
28 1305 1309 16755009 mice NNS I-NP O
29 1309 1310 16755009 . . O O

1 1311 1314 16755009 The DT B-NP O
2 1315 1321 16755009 extent NN I-NP O
3 1322 1324 16755009 of IN B-PP O
4 1325 1335 16755009 inhibition NN B-NP O
5 1336 1338 16755009 of IN B-PP O
6 1339 1344 16755009 brain NN B-NP O
7 1345 1359 16755009 cholinesterase NN I-NP O
8 1360 1368 16755009 activity NN I-NP O
9 1369 1375 16755009 evoked VBN B-VP O
10 1376 1378 16755009 by IN B-PP O
11 1379 1382 16755009 DCE NN B-NP B-Chemical
12 1383 1385 16755009 at IN B-PP O
13 1386 1389 16755009 the DT B-NP O
14 1390 1394 16755009 dose NN I-NP O
15 1395 1397 16755009 of IN B-PP O
16 1398 1401 16755009 400 CD B-NP O
17 1402 1404 16755009 mg NN I-NP O
18 1404 1405 16755009 / SYM B-NP O
19 1405 1407 16755009 kg NN I-NP O
20 1408 1411 16755009 was VBD B-VP O
21 1412 1415 16755009 22% CD B-NP O
22 1416 1418 16755009 in IN B-PP O
23 1419 1424 16755009 young JJ B-NP O
24 1425 1428 16755009 and CC I-NP O
25 1429 1432 16755009 19% CD I-NP O
26 1433 1435 16755009 in IN B-PP O
27 1436 1440 16755009 aged JJ B-NP O
28 1441 1445 16755009 mice NNS I-NP O
29 1445 1446 16755009 . . O O

1 1447 1452 16755009 There EX B-NP O
2 1453 1456 16755009 was VBD B-VP O
3 1457 1458 16755009 a DT B-NP O
4 1459 1469 16755009 remarkable JJ I-NP O
5 1470 1479 16755009 reduction NN I-NP O
6 1480 1482 16755009 in IN B-PP O
7 1483 1488 16755009 total JJ B-NP O
8 1489 1500 16755009 cholesterol NN I-NP B-Chemical
9 1501 1506 16755009 level NN I-NP O
10 1507 1509 16755009 as RB B-ADVP O
11 1510 1514 16755009 well RB I-ADVP O
12 1514 1515 16755009 , , O O
13 1516 1518 16755009 to TO B-PP O
14 1519 1522 16755009 the DT B-NP O
15 1523 1529 16755009 extent NN I-NP O
16 1530 1532 16755009 of IN B-PP O
17 1533 1536 16755009 23% NN B-NP O
18 1537 1539 16755009 in IN B-PP O
19 1540 1545 16755009 young JJ B-NP O
20 1546 1549 16755009 and CC I-NP O
21 1550 1553 16755009 21% JJ I-NP O
22 1554 1556 16755009 in IN B-PP O
23 1557 1561 16755009 aged JJ B-NP O
24 1562 1569 16755009 animals NNS I-NP O
25 1570 1574 16755009 with IN B-PP O
26 1575 1579 16755009 this DT B-NP O
27 1580 1584 16755009 dose NN I-NP O
28 1585 1587 16755009 of IN B-PP O
29 1588 1591 16755009 DCE NN B-NP B-Chemical
30 1591 1592 16755009 . . O O

1 1593 1602 16755009 Therefore RB B-ADVP O
2 1602 1603 16755009 , , O O
3 1604 1607 16755009 DCE NN B-NP B-Chemical
4 1608 1611 16755009 may MD B-VP O
5 1612 1617 16755009 prove VB I-VP O
6 1618 1620 16755009 to TO I-VP O
7 1621 1623 16755009 be VB I-VP O
8 1624 1625 16755009 a DT B-NP O
9 1626 1632 16755009 useful JJ I-NP O
10 1633 1639 16755009 remedy NN I-NP O
11 1640 1643 16755009 for IN B-PP O
12 1644 1647 16755009 the DT B-NP O
13 1648 1658 16755009 management NN I-NP O
14 1659 1661 16755009 of IN B-PP O
15 1662 1671 16755009 cognitive JJ B-NP B-Disease
16 1672 1684 16755009 dysfunctions NNS I-NP I-Disease
17 1685 1687 16755009 on IN B-PP O
18 1688 1695 16755009 account NN B-NP O
19 1696 1698 16755009 of IN B-PP O
20 1699 1702 16755009 its PRP$ B-NP O
21 1703 1715 16755009 multifarious JJ I-NP O
22 1716 1726 16755009 beneficial JJ I-NP O
23 1727 1734 16755009 effects NNS I-NP O
24 1735 1739 16755009 such JJ B-PP O
25 1740 1742 16755009 as IN I-PP O
26 1742 1743 16755009 , , O O
27 1744 1750 16755009 memory NN B-NP O
28 1751 1760 16755009 improving VBG B-VP O
29 1761 1769 16755009 property NN B-NP O
30 1769 1770 16755009 , , O O
31 1771 1782 16755009 cholesterol NN B-NP B-Chemical
32 1783 1791 16755009 lowering VBG B-VP O
33 1792 1800 16755009 property NN B-NP O
34 1801 1804 16755009 and CC I-NP O
35 1805 1823 16755009 anticholinesterase NN I-NP O
36 1824 1832 16755009 activity NN I-NP O
37 1832 1833 16755009 . . O O

1 0 0 4071154 -DOCSTART- -X- -X- O

1 0 12 4071154 Indomethacin NN B-NP B-Chemical
2 12 13 4071154 - HYPH O O
3 13 20 4071154 induced VBN B-NP O
4 21 26 4071154 renal JJ I-NP B-Disease
5 27 40 4071154 insufficiency NN I-NP I-Disease
6 40 41 4071154 : : O O
7 42 52 4071154 recurrence NN B-NP O
8 53 55 4071154 on IN B-PP O
9 56 67 4071154 rechallenge NN B-NP O
10 67 68 4071154 . . O O
11 69 71 4071154 We PRP B-NP O
12 72 76 4071154 have VBP B-VP O
13 77 85 4071154 reported VBN I-VP O
14 86 87 4071154 a DT B-NP O
15 88 92 4071154 case NN I-NP O
16 93 95 4071154 of IN B-PP O
17 96 101 4071154 acute JJ B-NP O
18 102 110 4071154 oliguric JJ I-NP O
19 111 116 4071154 renal JJ I-NP B-Disease
20 117 124 4071154 failure NN I-NP I-Disease
21 125 129 4071154 with IN B-PP O
22 130 142 4071154 hyperkalemia NN B-NP B-Disease
23 143 145 4071154 in IN B-PP O
24 146 147 4071154 a DT B-NP O
25 148 155 4071154 patient NN I-NP O
26 156 160 4071154 with IN B-PP O
27 161 170 4071154 cirrhosis NN B-NP B-Disease
28 170 171 4071154 , , O O
29 172 179 4071154 ascites NNS B-NP B-Disease
30 179 180 4071154 , , O O
31 181 184 4071154 and CC O O
32 185 188 4071154 cor NN B-NP B-Disease
33 189 198 4071154 pulmonale NN I-NP I-Disease
34 199 204 4071154 after IN B-PP O
35 205 217 4071154 indomethacin NN B-NP B-Chemical
36 218 225 4071154 therapy NN I-NP O
37 225 226 4071154 . . O O

1 227 233 4071154 Prompt JJ B-NP O
2 234 245 4071154 restoration NN I-NP O
3 246 248 4071154 of IN B-PP O
4 249 254 4071154 renal JJ B-NP O
5 255 263 4071154 function NN I-NP O
6 264 272 4071154 followed VBD B-VP O
7 273 277 4071154 drug NN B-NP O
8 278 288 4071154 withdrawal NN I-NP O
9 288 289 4071154 , , O O
10 290 295 4071154 while IN B-SBAR O
11 296 298 4071154 re AFX B-NP O
12 298 299 4071154 - HYPH I-NP O
13 299 307 4071154 exposure NN I-NP O
14 308 310 4071154 to TO B-PP O
15 311 312 4071154 a DT B-NP O
16 313 319 4071154 single JJ I-NP O
17 320 324 4071154 dose NN I-NP O
18 325 327 4071154 of IN B-PP O
19 328 340 4071154 indomethacin NN B-NP B-Chemical
20 341 347 4071154 caused VBD B-VP O
21 348 358 4071154 recurrence NN B-NP O
22 359 361 4071154 of IN B-PP O
23 362 367 4071154 acute JJ B-NP O
24 368 378 4071154 reversible JJ I-NP O
25 379 387 4071154 oliguria NN I-NP B-Disease
26 387 388 4071154 . . O O

1 389 392 4071154 Our PRP$ B-NP O
2 393 397 4071154 case NN I-NP O
3 398 406 4071154 supports VBZ B-VP O
4 407 410 4071154 the DT B-NP O
5 411 421 4071154 hypothesis NN I-NP O
6 422 426 4071154 that IN B-SBAR O
7 427 437 4071154 endogenous JJ B-NP O
8 438 443 4071154 renal JJ I-NP O
9 444 458 4071154 prostaglandins NNS I-NP B-Chemical
10 459 463 4071154 play VBP B-VP O
11 464 465 4071154 a DT B-NP O
12 466 470 4071154 role NN I-NP O
13 471 473 4071154 in IN B-PP O
14 474 477 4071154 the DT B-NP O
15 478 489 4071154 maintenance NN I-NP O
16 490 492 4071154 of IN B-PP O
17 493 498 4071154 renal JJ B-NP O
18 499 504 4071154 blood NN I-NP O
19 505 509 4071154 flow NN I-NP O
20 510 514 4071154 when WRB B-ADVP O
21 515 526 4071154 circulating VBG B-VP O
22 527 533 4071154 plasma NN B-NP O
23 534 540 4071154 volume NN I-NP O
24 541 543 4071154 is VBZ B-VP O
25 544 554 4071154 diminished VBN I-VP O
26 554 555 4071154 . . O O

1 556 561 4071154 Since IN B-SBAR O
2 562 574 4071154 nonsteroidal JJ B-NP O
3 575 579 4071154 anti AFX I-NP O
4 579 580 4071154 - HYPH I-NP O
5 580 592 4071154 inflammatory JJ B-NP O
6 593 599 4071154 agents NNS I-NP O
7 600 609 4071154 interfere VBP B-VP O
8 610 614 4071154 with IN B-PP O
9 615 619 4071154 this DT B-NP O
10 620 632 4071154 compensatory JJ I-NP O
11 633 642 4071154 mechanism NN I-NP O
12 643 646 4071154 and CC O O
13 647 650 4071154 may MD B-VP O
14 651 656 4071154 cause VB I-VP O
15 657 662 4071154 acute JJ B-NP B-Disease
16 663 668 4071154 renal JJ I-NP I-Disease
17 669 676 4071154 failure NN I-NP I-Disease
18 676 677 4071154 , , O O
19 678 682 4071154 they PRP B-NP O
20 683 689 4071154 should MD B-VP O
21 690 692 4071154 be VB I-VP O
22 693 697 4071154 used VBN I-VP O
23 698 702 4071154 with IN B-PP O
24 703 710 4071154 caution NN B-NP O
25 711 713 4071154 in IN B-PP O
26 714 718 4071154 such JJ B-NP O
27 719 727 4071154 patients NNS I-NP O
28 727 728 4071154 . . O O

1 0 0 15120741 -DOCSTART- -X- -X- O

1 0 9 15120741 Recurrent JJ B-NP O
2 10 20 15120741 excitation NN I-NP O
3 21 23 15120741 in IN B-PP O
4 24 27 15120741 the DT B-NP O
5 28 35 15120741 dentate NN I-NP O
6 36 41 15120741 gyrus NN I-NP O
7 42 44 15120741 of IN B-PP O
8 45 46 15120741 a DT B-NP O
9 47 53 15120741 murine JJ I-NP O
10 54 59 15120741 model NN I-NP O
11 60 62 15120741 of IN B-PP O
12 63 71 15120741 temporal JJ B-NP B-Disease
13 72 76 15120741 lobe NN I-NP I-Disease
14 77 85 15120741 epilepsy NN I-NP I-Disease
15 85 86 15120741 . . O O
16 87 94 15120741 Similar JJ B-ADJP O
17 95 97 15120741 to TO B-PP O
18 98 102 15120741 rats NNS B-NP O
19 102 103 15120741 , , O O
20 104 112 15120741 systemic JJ B-NP O
21 113 124 15120741 pilocarpine NN I-NP B-Chemical
22 125 134 15120741 injection NN I-NP O
23 135 141 15120741 causes VBZ B-VP O
24 142 148 15120741 status NN B-NP B-Disease
25 149 160 15120741 epilepticus NN I-NP I-Disease
26 161 162 15120741 ( ( O O
27 162 164 15120741 SE NN B-NP B-Disease
28 164 165 15120741 ) ) O O
29 166 169 15120741 and CC O O
30 170 173 15120741 the DT B-NP O
31 174 182 15120741 eventual JJ I-NP O
32 183 194 15120741 development NN I-NP O
33 195 197 15120741 of IN B-PP O
34 198 209 15120741 spontaneous JJ B-NP O
35 210 218 15120741 seizures NNS I-NP B-Disease
36 219 222 15120741 and CC O O
37 223 228 15120741 mossy NN B-NP O
38 229 234 15120741 fiber NN I-NP O
39 235 244 15120741 sprouting VBG B-VP O
40 245 247 15120741 in IN B-PP O
41 248 253 15120741 C57BL NN B-NP O
42 253 254 15120741 / SYM B-NP O
43 254 255 15120741 6 CD I-NP O
44 256 259 15120741 and CC I-NP O
45 260 263 15120741 CD1 NN I-NP O
46 264 268 15120741 mice NNS I-NP O
47 268 269 15120741 , , O O
48 270 273 15120741 but CC O O
49 274 277 15120741 the DT B-NP O
50 278 291 15120741 physiological JJ I-NP O
51 292 302 15120741 correlates NNS I-NP O
52 303 305 15120741 of IN B-PP O
53 306 311 15120741 these DT B-NP O
54 312 318 15120741 events NNS I-NP O
55 319 323 15120741 have VBP B-VP O
56 324 327 15120741 not RB I-VP O
57 328 332 15120741 been VBN I-VP O
58 333 343 15120741 identified VBN I-VP O
59 344 346 15120741 in IN B-PP O
60 347 351 15120741 mice NNS B-NP O
61 351 352 15120741 . . O O

1 353 363 15120741 Population NN B-NP O
2 364 373 15120741 responses NNS I-NP O
3 374 376 15120741 in IN B-PP O
4 377 384 15120741 granule NN B-NP O
5 385 390 15120741 cells NNS I-NP O
6 391 393 15120741 of IN B-PP O
7 394 397 15120741 the DT B-NP O
8 398 405 15120741 dentate NN I-NP O
9 406 411 15120741 gyrus NN I-NP O
10 412 416 15120741 were VBD B-VP O
11 417 425 15120741 examined VBN I-VP O
12 426 428 15120741 in IN B-PP O
13 429 439 15120741 transverse JJ B-NP O
14 440 446 15120741 slices NNS I-NP O
15 447 449 15120741 of IN B-PP O
16 450 453 15120741 the DT B-NP O
17 454 461 15120741 ventral JJ I-NP O
18 462 473 15120741 hippocampus NN I-NP O
19 474 478 15120741 from IN B-PP O
20 479 490 15120741 pilocarpine NN B-NP B-Chemical
21 490 491 15120741 - HYPH B-ADVP O
22 491 498 15120741 treated VBN B-NP O
23 499 502 15120741 and CC I-NP O
24 503 512 15120741 untreated JJ I-NP O
25 513 517 15120741 mice NNS I-NP O
26 517 518 15120741 . . O O

1 519 521 15120741 In IN B-PP O
2 522 528 15120741 Mg(2+) NN B-NP B-Chemical
3 528 529 15120741 - HYPH O O
4 529 533 15120741 free JJ B-NP O
5 534 541 15120741 bathing NN I-NP O
6 542 548 15120741 medium NN I-NP O
7 549 559 15120741 containing VBG B-VP O
8 560 571 15120741 bicuculline NN B-NP B-Chemical
9 571 572 15120741 , , O O
10 573 583 15120741 conditions NNS B-NP O
11 584 592 15120741 designed VBN B-VP O
12 593 595 15120741 to TO I-VP O
13 596 604 15120741 increase VB I-VP O
14 605 617 15120741 excitability NN B-NP O
15 618 620 15120741 in IN B-PP O
16 621 624 15120741 the DT B-NP O
17 625 631 15120741 slices NNS I-NP O
18 631 632 15120741 , , O O
19 633 643 15120741 electrical JJ B-NP O
20 644 655 15120741 stimulation NN I-NP O
21 656 658 15120741 of IN B-PP O
22 659 662 15120741 the DT B-NP O
23 663 668 15120741 hilus NN I-NP O
24 669 677 15120741 resulted VBD B-VP O
25 678 680 15120741 in IN B-PP O
26 681 682 15120741 a DT B-NP O
27 683 689 15120741 single JJ I-NP O
28 690 700 15120741 population NN I-NP O
29 701 706 15120741 spike NN I-NP O
30 707 709 15120741 in IN B-PP O
31 710 717 15120741 granule NN B-NP O
32 718 723 15120741 cells NNS I-NP O
33 724 728 15120741 from IN B-PP O
34 729 736 15120741 control NN B-NP O
35 737 741 15120741 mice NNS I-NP O
36 742 745 15120741 and CC I-NP O
37 746 757 15120741 pilocarpine NN I-NP B-Chemical
38 757 758 15120741 - HYPH B-NP O
39 758 765 15120741 treated VBN I-NP O
40 766 770 15120741 mice NNS I-NP O
41 771 775 15120741 that WDT B-NP O
42 776 779 15120741 did VBD B-VP O
43 780 783 15120741 not RB I-VP O
44 784 794 15120741 experience VB I-VP O
45 795 797 15120741 SE NN B-NP B-Disease
46 797 798 15120741 . . O O

1 799 801 15120741 In IN B-PP O
2 802 804 15120741 SE NN B-NP B-Disease
3 805 814 15120741 survivors NNS I-NP O
4 814 815 15120741 , , O O
5 816 823 15120741 similar JJ B-NP O
6 824 835 15120741 stimulation NN I-NP O
7 836 844 15120741 resulted VBD B-VP O
8 845 847 15120741 in IN B-PP O
9 848 849 15120741 a DT B-NP O
10 850 860 15120741 population NN I-NP O
11 861 866 15120741 spike NN I-NP O
12 867 875 15120741 followed VBD B-VP O
13 875 876 15120741 , , O O
14 877 879 15120741 at IN B-PP O
15 880 881 15120741 a DT B-NP O
16 882 890 15120741 variable JJ I-NP O
17 891 898 15120741 latency NN I-NP O
18 898 899 15120741 , , O O
19 900 902 15120741 by IN B-PP O
20 903 911 15120741 negative JJ B-NP O
21 912 914 15120741 DC NN I-NP O
22 915 921 15120741 shifts NNS I-NP O
23 922 925 15120741 and CC O O
24 926 936 15120741 repetitive JJ B-NP O
25 937 952 15120741 afterdischarges NNS I-NP O
26 953 955 15120741 of IN B-PP O
27 956 957 15120741 3 CD B-NP O
28 957 958 15120741 - HYPH I-NP O
29 958 960 15120741 60 CD I-NP O
30 961 962 15120741 s NN I-NP O
31 963 971 15120741 duration NN I-NP O
32 971 972 15120741 , , O O
33 973 978 15120741 which WDT B-NP O
34 979 983 15120741 were VBD B-VP O
35 984 991 15120741 blocked VBN I-VP O
36 992 994 15120741 by IN B-PP O
37 995 1005 15120741 ionotropic JJ B-NP O
38 1006 1015 15120741 glutamate NN I-NP B-Chemical
39 1016 1024 15120741 receptor NN I-NP O
40 1025 1036 15120741 antagonists NNS I-NP O
41 1036 1037 15120741 . . O O

1 1038 1043 15120741 Focal JJ B-NP O
2 1044 1053 15120741 glutamate NN I-NP B-Chemical
3 1054 1070 15120741 photostimulation NN I-NP O
4 1071 1073 15120741 of IN B-PP O
5 1074 1077 15120741 the DT B-NP O
6 1078 1085 15120741 granule NN I-NP O
7 1086 1090 15120741 cell NN I-NP O
8 1091 1096 15120741 layer NN I-NP O
9 1097 1099 15120741 at IN B-PP O
10 1100 1105 15120741 sites NNS B-NP O
11 1106 1113 15120741 distant JJ B-ADJP O
12 1114 1118 15120741 from IN B-PP O
13 1119 1122 15120741 the DT B-NP O
14 1123 1132 15120741 recording VBG I-NP O
15 1133 1140 15120741 pipette NN I-NP O
16 1141 1149 15120741 resulted VBD B-VP O
17 1150 1152 15120741 in IN B-PP O
18 1153 1163 15120741 population NN B-NP O
19 1164 1173 15120741 responses NNS I-NP O
20 1174 1176 15120741 of IN B-PP O
21 1177 1178 15120741 1 CD B-NP O
22 1178 1179 15120741 - HYPH I-NP O
23 1179 1181 15120741 30 CD I-NP O
24 1182 1183 15120741 s NN I-NP O
25 1184 1192 15120741 duration NN I-NP O
26 1193 1195 15120741 in IN B-PP O
27 1196 1202 15120741 slices NNS B-NP O
28 1203 1207 15120741 from IN B-PP O
29 1208 1210 15120741 SE NN B-NP B-Disease
30 1211 1220 15120741 survivors NNS I-NP O
31 1221 1224 15120741 but CC O O
32 1225 1228 15120741 not RB O O
33 1229 1234 15120741 other JJ B-NP O
34 1235 1241 15120741 groups NNS I-NP O
35 1241 1242 15120741 . . O O

1 1243 1248 15120741 These DT B-NP O
2 1249 1253 15120741 data NNS I-NP O
3 1254 1261 15120741 support VBP B-VP O
4 1262 1265 15120741 the DT B-NP O
5 1266 1276 15120741 hypothesis NN I-NP O
6 1277 1281 15120741 that IN B-SBAR O
7 1282 1284 15120741 SE NN B-NP B-Disease
8 1284 1285 15120741 - HYPH B-NP O
9 1285 1292 15120741 induced VBN I-NP O
10 1293 1298 15120741 mossy NN I-NP O
11 1299 1304 15120741 fiber NN I-NP O
12 1305 1314 15120741 sprouting VBG B-VP O
13 1315 1318 15120741 and CC O O
14 1319 1327 15120741 synaptic JJ B-NP O
15 1328 1342 15120741 reorganization NN I-NP O
16 1343 1346 15120741 are VBP B-VP O
17 1347 1355 15120741 relevant JJ B-NP O
18 1356 1371 15120741 characteristics NNS I-NP O
19 1372 1374 15120741 of IN B-PP O
20 1375 1382 15120741 seizure NN B-NP B-Disease
21 1383 1394 15120741 development NN I-NP O
22 1395 1397 15120741 in IN B-PP O
23 1398 1403 15120741 these DT B-NP O
24 1404 1410 15120741 murine JJ I-NP O
25 1411 1418 15120741 strains NNS I-NP O
26 1418 1419 15120741 , , O O
27 1420 1430 15120741 resembling VBG B-VP O
28 1431 1434 15120741 rat NN B-NP O
29 1435 1441 15120741 models NNS I-NP O
30 1442 1444 15120741 of IN B-PP O
31 1445 1450 15120741 human JJ B-NP O
32 1451 1459 15120741 temporal JJ I-NP B-Disease
33 1460 1464 15120741 lobe NN I-NP I-Disease
34 1465 1473 15120741 epilepsy NN I-NP I-Disease
35 1473 1474 15120741 . . O O

1 0 0 1549199 -DOCSTART- -X- -X- O

1 0 12 1549199 Optimization NN B-NP O
2 13 15 1549199 of IN B-PP O
3 16 24 1549199 levodopa NN B-NP B-Chemical
4 25 32 1549199 therapy NN I-NP O
5 32 33 1549199 . . O O
6 34 39 1549199 While IN B-SBAR O
7 40 45 1549199 there EX B-NP O
8 46 48 1549199 is VBZ B-VP O
9 49 51 1549199 no DT B-NP O
10 52 58 1549199 single JJ I-NP O
11 59 66 1549199 correct JJ I-NP O
12 67 75 1549199 starting NN I-NP O
13 76 80 1549199 dose NN I-NP O
14 81 84 1549199 for IN B-PP O
15 85 93 1549199 levodopa NN B-NP B-Chemical
16 94 101 1549199 therapy NN I-NP O
17 101 102 1549199 , , O O
18 103 107 1549199 many JJ B-NP O
19 108 119 1549199 individuals NNS I-NP O
20 120 123 1549199 can MD B-VP O
21 124 126 1549199 be VB I-VP O
22 127 134 1549199 started VBN I-VP O
23 135 137 1549199 on IN B-PP O
24 138 144 1549199 either CC O O
25 145 148 1549199 the DT B-NP O
26 149 151 1549199 25 CD I-NP O
27 151 152 1549199 / SYM I-NP O
28 152 155 1549199 100 CD I-NP O
29 156 158 1549199 or CC O O
30 159 169 1549199 controlled VBN B-VP O
31 169 170 1549199 - HYPH B-NP O
32 170 177 1549199 release NN I-NP O
33 178 185 1549199 formula NN I-NP O
34 185 186 1549199 , , O O
35 187 196 1549199 following VBG B-PP O
36 197 200 1549199 the DT B-NP O
37 201 208 1549199 general JJ I-NP O
38 209 213 1549199 rule NN I-NP O
39 214 217 1549199 not RB O O
40 218 220 1549199 to TO B-VP O
41 221 228 1549199 attempt VB I-VP O
42 229 231 1549199 to TO I-VP O
43 232 239 1549199 titrate VB I-VP O
44 240 249 1549199 carbidopa NN B-NP B-Chemical
45 249 250 1549199 - HYPH O O
46 250 258 1549199 levodopa NN B-NP B-Chemical
47 259 261 1549199 to TO B-PP O
48 262 265 1549199 the DT B-NP O
49 266 271 1549199 point NN I-NP O
50 272 274 1549199 of IN B-PP O
51 275 276 1549199 " `` O O
52 276 285 1549199 normality NN B-NP O
53 285 286 1549199 , , O O
54 286 287 1549199 " '' O O
55 288 293 1549199 which WDT B-NP O
56 294 297 1549199 can MD B-VP O
57 298 302 1549199 lead VB I-VP O
58 303 305 1549199 to TO B-PP O
59 306 314 1549199 toxicity NN B-NP B-Disease
60 314 315 1549199 . . O O

1 316 319 1549199 The DT B-NP O
2 320 329 1549199 physician NN I-NP O
3 330 336 1549199 should MD B-VP O
4 337 341 1549199 also RB I-VP O
5 342 351 1549199 determine VB I-VP O
6 352 355 1549199 the DT B-NP O
7 356 362 1549199 proper JJ I-NP O
8 363 366 1549199 use NN I-NP O
9 367 369 1549199 of IN B-PP O
10 370 373 1549199 any DT B-NP O
11 374 384 1549199 adjunctive JJ I-NP O
12 385 396 1549199 medications NNS I-NP O
13 396 397 1549199 ; : O O
14 398 402 1549199 such JJ B-NP O
15 403 411 1549199 combined JJ I-NP O
16 412 419 1549199 therapy NN I-NP O
17 420 423 1549199 has VBZ B-VP O
18 424 430 1549199 become VBN I-VP O
19 431 434 1549199 the DT B-NP O
20 435 443 1549199 standard JJ I-NP O
21 444 452 1549199 approach NN I-NP O
22 453 455 1549199 to TO B-PP O
23 456 465 1549199 treatment NN B-NP O
24 465 466 1549199 . . O O

1 467 476 1549199 Following VBG B-PP O
2 477 480 1549199 the DT B-NP O
3 481 488 1549199 initial JJ I-NP O
4 489 495 1549199 period NN I-NP O
5 496 498 1549199 of IN B-PP O
6 499 506 1549199 therapy NN B-NP O
7 506 507 1549199 , , O O
8 508 516 1549199 emerging VBG B-VP O
9 517 529 1549199 difficulties NNS B-NP O
10 530 537 1549199 require VBP B-VP O
11 538 539 1549199 a DT B-NP O
12 540 552 1549199 reassessment NN I-NP O
13 553 555 1549199 of IN B-PP O
14 556 567 1549199 therapeutic JJ B-NP O
15 568 578 1549199 approaches NNS I-NP O
16 578 579 1549199 , , O O
17 580 584 1549199 such JJ B-PP O
18 585 587 1549199 as IN I-PP O
19 588 594 1549199 dosage NN B-NP O
20 595 605 1549199 adjustment NN I-NP O
21 606 608 1549199 or CC I-NP O
22 609 621 1549199 introduction NN I-NP O
23 622 624 1549199 of IN B-PP O
24 625 626 1549199 a DT B-NP O
25 627 635 1549199 dopamine NN I-NP B-Chemical
26 636 643 1549199 agonist NN I-NP O
27 643 644 1549199 . . O O

1 645 650 1549199 Other JJ B-NP O
2 651 659 1549199 possible JJ I-NP O
3 660 667 1549199 adverse JJ I-NP O
4 668 675 1549199 effects NNS I-NP O
5 675 676 1549199 - HYPH O O
6 676 677 1549199 - HYPH O O
7 677 681 1549199 such JJ B-PP O
8 682 684 1549199 as IN I-PP O
9 685 701 1549199 gastrointestinal JJ B-NP B-Disease
10 702 711 1549199 disorders NNS I-NP I-Disease
11 711 712 1549199 , , O O
12 713 724 1549199 orthostatic JJ B-NP B-Disease
13 725 736 1549199 hypotension NN I-NP I-Disease
14 736 737 1549199 , , O O
15 738 746 1549199 levodopa NN B-NP B-Chemical
16 746 747 1549199 - HYPH B-NP O
17 747 754 1549199 induced VBN I-NP O
18 755 764 1549199 psychosis NN I-NP B-Disease
19 764 765 1549199 , , O O
20 766 771 1549199 sleep NN B-NP B-Disease
21 772 784 1549199 disturbances NNS I-NP I-Disease
22 785 787 1549199 or CC I-NP O
23 788 799 1549199 parasomnias NNS I-NP B-Disease
24 799 800 1549199 , , O O
25 801 803 1549199 or CC O O
26 804 808 1549199 drug NN B-NP O
27 809 821 1549199 interactions NNS I-NP O
28 821 822 1549199 - : O O
29 822 823 1549199 - HYPH B-NP O
30 823 827 1549199 also RB B-ADVP O
31 828 835 1549199 require VBP B-VP O
32 836 845 1549199 carefully RB I-VP O
33 846 855 1549199 monitored VBN I-VP O
34 856 866 1549199 individual JJ B-NP O
35 867 876 1549199 treatment NN I-NP O
36 876 877 1549199 . . O O

1 878 894 1549199 Nonpharmacologic JJ B-NP O
2 895 903 1549199 concerns NNS I-NP O
3 904 907 1549199 can MD B-VP O
4 908 912 1549199 help VB I-VP O
5 913 916 1549199 the DT B-NP O
6 917 928 1549199 Parkinson's NNP I-NP B-Disease
7 929 936 1549199 disease NN I-NP I-Disease
8 937 944 1549199 patient NN I-NP O
9 945 952 1549199 achieve NN I-NP O
10 953 956 1549199 and CC O O
11 957 965 1549199 maintain VBP B-VP O
12 966 973 1549199 optimal JJ B-NP O
13 974 985 1549199 functioning NN I-NP O
14 985 986 1549199 , , O O
15 987 996 1549199 including VBG B-PP O
16 997 1002 1549199 daily JJ B-NP O
17 1003 1011 1549199 exercise NN I-NP O
18 1011 1012 1549199 , , O O
19 1013 1021 1549199 physical JJ B-NP O
20 1022 1029 1549199 therapy NN I-NP O
21 1029 1030 1549199 , , O O
22 1031 1034 1549199 and CC O O
23 1035 1046 1549199 involvement NN B-NP O
24 1047 1051 1549199 with IN B-PP O
25 1052 1059 1549199 support NN B-NP O
26 1060 1066 1549199 groups NNS I-NP O
27 1066 1067 1549199 . . O O

1 0 0 6773726 -DOCSTART- -X- -X- O

1 0 11 6773726 Provocation NN B-NP O
2 12 14 6773726 of IN B-PP O
3 15 23 6773726 postural JJ B-NP O
4 24 35 6773726 hypotension NN I-NP B-Disease
5 36 38 6773726 by IN B-PP O
6 39 52 6773726 nitroglycerin NN B-NP B-Chemical
7 53 55 6773726 in IN B-PP O
8 56 64 6773726 diabetic JJ B-NP B-Disease
9 65 74 6773726 autonomic JJ I-NP I-Disease
10 75 85 6773726 neuropathy NN I-NP I-Disease
11 85 86 6773726 ? . O O
12 87 90 6773726 The DT B-NP O
13 91 97 6773726 effect NN I-NP O
14 98 100 6773726 of IN B-PP O
15 101 114 6773726 nitroglycerin NN B-NP B-Chemical
16 115 117 6773726 on IN B-PP O
17 118 123 6773726 heart NN B-NP O
18 124 128 6773726 rate NN I-NP O
19 129 132 6773726 and CC O O
20 133 141 6773726 systolic JJ B-NP O
21 142 147 6773726 blood NN I-NP O
22 148 156 6773726 pressure NN I-NP O
23 157 160 6773726 was VBD B-VP O
24 161 169 6773726 compared VBN I-VP O
25 170 172 6773726 in IN B-PP O
26 173 174 6773726 5 CD B-NP O
27 175 181 6773726 normal JJ I-NP O
28 182 190 6773726 subjects NNS I-NP O
29 190 191 6773726 , , O O
30 192 194 6773726 12 CD B-NP O
31 195 203 6773726 diabetic JJ I-NP B-Disease
32 204 212 6773726 subjects NNS I-NP O
33 213 220 6773726 without IN B-PP O
34 221 230 6773726 autonomic JJ B-NP B-Disease
35 231 241 6773726 neuropathy NN I-NP I-Disease
36 241 242 6773726 , , O O
37 243 246 6773726 and CC O O
38 247 248 6773726 5 CD B-NP O
39 249 257 6773726 diabetic JJ I-NP B-Disease
40 258 266 6773726 subjects NNS I-NP O
41 267 271 6773726 with IN B-PP O
42 272 281 6773726 autonomic JJ B-NP B-Disease
43 282 292 6773726 neuropathy NN I-NP I-Disease
44 292 293 6773726 . . O O

1 294 297 6773726 The DT B-NP O
2 298 307 6773726 magnitude NN I-NP O
3 308 311 6773726 and CC I-NP O
4 312 316 6773726 time NN I-NP O
5 317 323 6773726 course NN I-NP O
6 324 326 6773726 of IN B-PP O
7 327 330 6773726 the DT B-NP O
8 331 339 6773726 increase NN I-NP O
9 340 342 6773726 in IN B-PP O
10 343 348 6773726 heart NN B-NP O
11 349 353 6773726 rate NN I-NP O
12 354 357 6773726 and CC O O
13 358 361 6773726 the DT B-NP O
14 362 370 6773726 decrease NN I-NP O
15 371 373 6773726 in IN B-PP O
16 374 382 6773726 systolic JJ B-NP O
17 383 388 6773726 blood NN I-NP O
18 389 397 6773726 pressure NN I-NP O
19 398 403 6773726 after IN B-PP O
20 404 417 6773726 nitroglycerin NN B-NP B-Chemical
21 418 422 6773726 were VBD B-VP O
22 423 430 6773726 similar JJ B-ADJP O
23 431 433 6773726 in IN B-PP O
24 434 437 6773726 the DT B-NP O
25 438 444 6773726 normal JJ I-NP O
26 445 448 6773726 and CC I-NP O
27 449 457 6773726 diabetic JJ I-NP B-Disease
28 458 466 6773726 subjects NNS I-NP O
29 467 474 6773726 without IN B-PP O
30 475 484 6773726 autonomic JJ B-NP B-Disease
31 485 495 6773726 neuropathy NN I-NP I-Disease
32 495 496 6773726 , , O O
33 497 504 6773726 whereas IN O O
34 505 506 6773726 a DT B-NP O
35 507 513 6773726 lesser JJR I-NP O
36 514 522 6773726 increase NN I-NP O
37 523 525 6773726 in IN B-PP O
38 526 531 6773726 heart NN B-NP O
39 532 536 6773726 rate NN I-NP O
40 537 540 6773726 and CC O O
41 541 542 6773726 a DT B-NP O
42 543 550 6773726 greater JJR I-NP O
43 551 559 6773726 decrease NN I-NP O
44 560 562 6773726 in IN B-PP O
45 563 571 6773726 systolic JJ B-NP O
46 572 577 6773726 blood NN I-NP O
47 578 586 6773726 pressure NN I-NP O
48 587 595 6773726 occurred VBD B-VP O
49 596 598 6773726 in IN B-PP O
50 599 602 6773726 the DT B-NP O
51 603 611 6773726 diabetic JJ I-NP B-Disease
52 612 620 6773726 subjects NNS I-NP O
53 621 625 6773726 with IN B-PP O
54 626 635 6773726 autonomic JJ B-NP B-Disease
55 636 646 6773726 neuropathy NN I-NP I-Disease
56 646 647 6773726 . . O O

1 648 650 6773726 It PRP B-NP O
2 651 653 6773726 is VBZ B-VP O
3 654 663 6773726 therefore RB I-VP O
4 664 673 6773726 suggested VBN I-VP O
5 674 678 6773726 that IN B-SBAR O
6 679 686 6773726 caution NN B-NP O
7 687 693 6773726 should MD B-VP O
8 694 696 6773726 be VB I-VP O
9 697 706 6773726 exercised VBN I-VP O
10 707 711 6773726 when WRB B-ADVP O
11 712 723 6773726 prescribing VBG B-VP O
12 724 735 6773726 vasodilator NN B-NP O
13 736 741 6773726 drugs NNS I-NP O
14 742 744 6773726 in IN B-PP O
15 745 753 6773726 diabetic JJ B-NP B-Disease
16 754 762 6773726 patients NNS I-NP O
17 762 763 6773726 , , O O
18 764 776 6773726 particularly RB B-ADVP O
19 777 782 6773726 those DT B-NP O
20 783 787 6773726 with IN B-PP O
21 788 797 6773726 autonomic JJ B-NP B-Disease
22 798 808 6773726 neuropathy NN I-NP I-Disease
23 808 809 6773726 . . O O

1 0 0 2385256 -DOCSTART- -X- -X- O

1 0 10 2385256 Myasthenia NNP B-NP B-Disease
2 11 17 2385256 gravis VBZ B-VP I-Disease
3 18 28 2385256 presenting VBG I-VP O
4 29 31 2385256 as IN B-PP O
5 32 40 2385256 weakness NN B-NP O
6 41 46 2385256 after IN B-PP O
7 47 56 2385256 magnesium NN B-NP B-Chemical
8 57 71 2385256 administration NN I-NP O
9 71 72 2385256 . . O O
10 73 75 2385256 We PRP B-NP O
11 76 83 2385256 studied VBD B-VP O
12 84 85 2385256 a DT B-NP O
13 86 93 2385256 patient NN I-NP O
14 94 98 2385256 with IN B-PP O
15 99 101 2385256 no DT B-NP O
16 102 107 2385256 prior JJ I-NP O
17 108 115 2385256 history NN I-NP O
18 116 118 2385256 of IN B-PP O
19 119 132 2385256 neuromuscular JJ B-NP B-Disease
20 133 140 2385256 disease NN I-NP I-Disease
21 141 144 2385256 who WP B-NP O
22 145 151 2385256 became VBD B-VP O
23 152 161 2385256 virtually RB B-ADJP O
24 162 174 2385256 quadriplegic JJ I-ADJP B-Disease
25 175 180 2385256 after IN B-PP O
26 181 191 2385256 parenteral JJ B-NP O
27 192 201 2385256 magnesium NN I-NP B-Chemical
28 202 216 2385256 administration NN I-NP O
29 217 220 2385256 for IN B-PP O
30 221 233 2385256 preeclampsia NN B-NP B-Disease
31 233 234 2385256 . . O O

1 235 238 2385256 The DT B-NP O
2 239 244 2385256 serum NN I-NP O
3 245 254 2385256 magnesium NN I-NP B-Chemical
4 255 268 2385256 concentration NN I-NP O
5 269 272 2385256 was VBD B-VP O
6 273 276 2385256 3.0 CD B-NP O
7 277 280 2385256 mEq NN I-NP O
8 280 281 2385256 / SYM B-NP O
9 281 282 2385256 L NN I-NP O
10 282 283 2385256 , , O O
11 284 289 2385256 which WDT B-NP O
12 290 292 2385256 is VBZ B-VP O
13 293 300 2385256 usually RB B-ADVP O
14 301 305 2385256 well RB B-ADJP O
15 306 315 2385256 tolerated VBN I-ADJP O
16 315 316 2385256 . . O O

1 317 320 2385256 The DT B-NP O
2 321 330 2385256 magnesium NN I-NP B-Chemical
3 331 334 2385256 was VBD B-VP O
4 335 342 2385256 stopped VBN I-VP O
5 343 346 2385256 and CC O O
6 347 350 2385256 she PRP B-NP O
7 351 360 2385256 recovered VBD B-VP O
8 361 365 2385256 over IN B-PP O
9 366 367 2385256 a DT B-NP O
10 368 371 2385256 few JJ I-NP O
11 372 376 2385256 days NNS I-NP O
12 376 377 2385256 . . O O

1 378 383 2385256 While IN B-SBAR O
2 384 387 2385256 she PRP B-NP O
3 388 391 2385256 was VBD B-VP O
4 392 396 2385256 weak JJ B-ADJP O
5 396 397 2385256 , , O O
6 398 399 2385256 2 CD B-NP O
7 399 400 2385256 - HYPH I-NP O
8 400 402 2385256 Hz NN I-NP O
9 403 413 2385256 repetitive JJ I-NP O
10 414 425 2385256 stimulation NN I-NP O
11 426 434 2385256 revealed VBD B-VP O
12 435 436 2385256 a DT B-NP O
13 437 446 2385256 decrement NN I-NP O
14 447 454 2385256 without IN B-PP O
15 455 466 2385256 significant JJ B-NP O
16 467 479 2385256 facilitation NN I-NP O
17 480 482 2385256 at IN B-PP O
18 483 488 2385256 rapid JJ B-NP O
19 489 494 2385256 rates NNS I-NP O
20 495 497 2385256 or CC B-PP O
21 498 503 2385256 after IN B-PP O
22 504 512 2385256 exercise NN B-NP O
23 512 513 2385256 , , O O
24 514 524 2385256 suggesting VBG B-VP O
25 525 537 2385256 postsynaptic JJ B-NP B-Disease
26 538 551 2385256 neuromuscular JJ I-NP I-Disease
27 552 560 2385256 blockade NN I-NP I-Disease
28 560 561 2385256 . . O O

1 562 567 2385256 After IN B-PP O
2 568 571 2385256 her PRP$ B-NP O
3 572 580 2385256 strength NN I-NP O
4 581 589 2385256 returned VBD B-VP O
5 589 590 2385256 , , O O
6 591 601 2385256 repetitive JJ B-NP O
7 602 613 2385256 stimulation NN I-NP O
8 614 617 2385256 was VBD B-VP O
9 618 624 2385256 normal JJ B-ADJP O
10 624 625 2385256 , , O O
11 626 629 2385256 but CC O O
12 630 636 2385256 single JJ B-NP O
13 637 642 2385256 fiber NN I-NP O
14 643 646 2385256 EMG NN I-NP O
15 647 655 2385256 revealed VBD B-VP O
16 656 665 2385256 increased VBN B-NP O
17 666 672 2385256 jitter NN I-NP O
18 673 676 2385256 and CC I-NP O
19 677 685 2385256 blocking NN I-NP O
20 685 686 2385256 . . O O

1 687 690 2385256 Her PRP$ B-NP O
2 691 704 2385256 acetylcholine NN I-NP B-Chemical
3 705 713 2385256 receptor NN I-NP O
4 714 722 2385256 antibody NN I-NP O
5 723 728 2385256 level NN I-NP O
6 729 732 2385256 was VBD B-VP O
7 733 741 2385256 markedly RB B-ADJP O
8 742 750 2385256 elevated JJ I-ADJP O
9 750 751 2385256 . . O O

1 752 760 2385256 Although IN B-SBAR O
2 761 770 2385256 paralysis NN B-NP B-Disease
3 771 776 2385256 after IN B-PP O
4 777 786 2385256 magnesium NN B-NP B-Chemical
5 787 801 2385256 administration NN I-NP O
6 802 805 2385256 has VBZ B-VP O
7 806 810 2385256 been VBN I-VP O
8 811 820 2385256 described VBN I-VP O
9 821 823 2385256 in IN B-PP O
10 824 832 2385256 patients NNS B-NP O
11 833 837 2385256 with IN B-PP O
12 838 843 2385256 known VBN B-NP O
13 844 854 2385256 myasthenia NN I-NP B-Disease
14 855 861 2385256 gravis NN I-NP I-Disease
15 861 862 2385256 , , O O
16 863 865 2385256 it PRP B-NP O
17 866 869 2385256 has VBZ B-VP O
18 870 873 2385256 not RB I-VP O
19 874 884 2385256 previously RB I-VP O
20 885 889 2385256 been VBN I-VP O
21 890 898 2385256 reported VBN I-VP O
22 899 901 2385256 to TO I-VP O
23 902 904 2385256 be VB I-VP O
24 905 908 2385256 the DT B-NP O
25 909 916 2385256 initial JJ I-NP O
26 917 919 2385256 or CC I-NP O
27 920 924 2385256 only JJ I-NP O
28 925 938 2385256 manifestation NN I-NP O
29 939 941 2385256 of IN B-PP O
30 942 945 2385256 the DT B-NP O
31 946 953 2385256 disease NN I-NP O
32 953 954 2385256 . . O O

1 955 963 2385256 Patients NNS B-NP O
2 964 967 2385256 who WP B-NP O
3 968 971 2385256 are VBP B-VP O
4 972 981 2385256 unusually RB B-ADJP O
5 982 991 2385256 sensitive JJ I-ADJP O
6 992 994 2385256 to TO B-PP O
7 995 998 2385256 the DT B-NP O
8 999 1012 2385256 neuromuscular JJ I-NP O
9 1013 1020 2385256 effects NNS I-NP O
10 1021 1023 2385256 of IN B-PP O
11 1024 1033 2385256 magnesium NN B-NP B-Chemical
12 1034 1040 2385256 should MD B-VP O
13 1041 1043 2385256 be VB I-VP O
14 1044 1053 2385256 suspected VBN I-VP O
15 1054 1056 2385256 of IN B-PP O
16 1057 1063 2385256 having VBG B-VP O
17 1064 1066 2385256 an DT B-NP O
18 1067 1077 2385256 underlying VBG I-NP O
19 1078 1086 2385256 disorder NN I-NP B-Disease
20 1087 1089 2385256 of IN B-PP I-Disease
21 1090 1103 2385256 neuromuscular JJ B-NP I-Disease
22 1104 1116 2385256 transmission NN I-NP I-Disease
23 1116 1117 2385256 . . O O

1 0 0 18023325 -DOCSTART- -X- -X- O

1 0 5 18023325 Acute JJ B-NP O
2 6 11 18023325 vocal JJ I-NP B-Disease
3 12 16 18023325 fold JJ I-NP I-Disease
4 17 22 18023325 palsy NN I-NP I-Disease
5 23 28 18023325 after IN B-PP O
6 29 34 18023325 acute JJ B-NP O
7 35 45 18023325 disulfiram NN I-NP B-Chemical
8 46 58 18023325 intoxication NN I-NP O
9 58 59 18023325 . . O O
10 60 65 18023325 Acute JJ B-NP O
11 66 76 18023325 peripheral JJ I-NP B-Disease
12 77 87 18023325 neuropathy NN I-NP I-Disease
13 88 94 18023325 caused VBN B-VP O
14 95 97 18023325 by IN B-PP O
15 98 99 18023325 a DT B-NP O
16 100 110 18023325 disulfiram NN I-NP B-Chemical
17 111 119 18023325 overdose NN I-NP B-Disease
18 120 122 18023325 is VBZ B-VP O
19 123 127 18023325 very RB B-ADJP O
20 128 132 18023325 rare JJ I-ADJP O
21 133 136 18023325 and CC O O
22 137 142 18023325 there EX B-NP O
23 143 145 18023325 is VBZ B-VP O
24 146 148 18023325 no DT B-NP O
25 149 155 18023325 report NN I-NP O
26 156 158 18023325 of IN B-PP O
27 159 161 18023325 it PRP B-NP O
28 162 169 18023325 leading VBG B-VP O
29 170 172 18023325 to TO B-PP O
30 173 178 18023325 vocal JJ B-NP B-Disease
31 179 183 18023325 fold JJ I-NP I-Disease
32 184 189 18023325 palsy NN I-NP I-Disease
33 189 190 18023325 . . O O

1 191 192 18023325 A DT B-NP O
2 193 195 18023325 49 CD I-NP O
3 195 196 18023325 - HYPH I-NP O
4 196 200 18023325 year NN I-NP O
5 200 201 18023325 - HYPH O O
6 201 204 18023325 old JJ B-NP O
7 205 210 18023325 woman NN I-NP O
8 211 214 18023325 was VBD B-VP O
9 215 226 18023325 transferred VBN I-VP O
10 227 229 18023325 to TO B-PP O
11 230 233 18023325 our PRP$ B-NP O
12 234 244 18023325 department NN I-NP O
13 245 252 18023325 because IN B-PP O
14 253 255 18023325 of IN I-PP O
15 256 269 18023325 quadriparesis NN B-NP B-Disease
16 269 270 18023325 , , O O
17 271 282 18023325 lancinating VBG B-VP O
18 283 287 18023325 pain NN B-NP B-Disease
19 287 288 18023325 , , O O
20 289 296 18023325 sensory JJ B-NP B-Disease
21 297 301 18023325 loss NN I-NP I-Disease
22 301 302 18023325 , , O O
23 303 306 18023325 and CC O O
24 307 318 18023325 paresthesia NN B-NP B-Disease
25 319 321 18023325 of IN B-PP O
26 322 325 18023325 the DT B-NP O
27 326 332 18023325 distal JJ I-NP O
28 333 338 18023325 limbs NNS I-NP O
29 338 339 18023325 . . O O

1 340 343 18023325 One CD B-NP O
2 344 349 18023325 month NN I-NP O
3 350 360 18023325 previously RB B-ADVP O
4 360 361 18023325 , , O O
5 362 365 18023325 she PRP B-NP O
6 366 369 18023325 had VBD B-VP O
7 370 375 18023325 taken VBN I-VP O
8 376 377 18023325 a DT B-NP O
9 378 384 18023325 single JJ I-NP O
10 385 389 18023325 high JJ I-NP O
11 390 394 18023325 dose NN I-NP O
12 395 397 18023325 of IN B-PP O
13 398 408 18023325 disulfiram NN B-NP B-Chemical
14 409 410 18023325 ( ( O O
15 410 413 18023325 130 CD B-NP O
16 414 421 18023325 tablets NNS I-NP O
17 422 424 18023325 of IN B-PP O
18 425 432 18023325 ALCOHOL NNP B-NP B-Chemical
19 433 437 18023325 STOP NNP I-NP O
20 438 441 18023325 TAB NNP I-NP O
21 441 442 18023325 , , O O
22 443 447 18023325 Shin NNP B-NP O
23 447 448 18023325 - HYPH B-NP O
24 448 453 18023325 Poong NNP I-NP O
25 454 459 18023325 Pharm NNP I-NP O
26 459 460 18023325 . . O O

1 461 463 18023325 Co NNP B-NP O
2 463 464 18023325 . NN I-NP O
3 464 465 18023325 , , O O
4 466 471 18023325 Ansan NNP B-NP O
5 471 472 18023325 , , O O
6 473 478 18023325 Korea NNP B-NP O
7 478 479 18023325 ) ) O O
8 480 482 18023325 in IN B-PP O
9 483 484 18023325 a DT B-NP O
10 485 492 18023325 suicide NN I-NP O
11 493 500 18023325 attempt NN I-NP O
12 500 501 18023325 . . O O

1 502 505 18023325 She PRP B-NP O
2 506 509 18023325 was VBD B-VP O
3 510 513 18023325 not RB O O
4 514 516 18023325 an DT B-NP O
5 517 526 18023325 alcoholic JJ I-NP O
6 526 527 18023325 . . O O

1 528 531 18023325 For IN B-PP O
2 532 535 18023325 the DT B-NP O
3 536 541 18023325 first JJ I-NP O
4 542 545 18023325 few JJ I-NP O
5 546 550 18023325 days NNS I-NP O
6 551 556 18023325 after IN B-PP O
7 557 566 18023325 ingestion NN B-NP O
8 566 567 18023325 , , O O
9 568 571 18023325 she PRP B-NP O
10 572 575 18023325 was VBD B-VP O
11 576 578 18023325 in IN B-PP O
12 579 580 18023325 a DT B-NP O
13 581 589 18023325 confused JJ I-NP O
14 590 595 18023325 state NN I-NP O
15 596 599 18023325 and CC O O
16 600 603 18023325 had VBD B-VP O
17 604 608 18023325 mild JJ B-ADJP O
18 609 611 18023325 to TO B-PP O
19 612 620 18023325 moderate JJ B-NP O
20 621 627 18023325 ataxia NN I-NP B-Disease
21 628 631 18023325 and CC I-NP O
22 632 641 18023325 giddiness NN I-NP B-Disease
23 641 642 18023325 . . O O

1 643 646 18023325 She PRP B-NP O
2 647 654 18023325 noticed VBD B-VP O
3 655 665 18023325 hoarseness NN B-NP B-Disease
4 666 669 18023325 and CC O O
5 670 678 18023325 distally RB B-VP O
6 679 690 18023325 accentuated VBN I-VP O
7 691 696 18023325 motor NN B-NP O
8 697 700 18023325 and CC O O
9 701 708 18023325 sensory JJ B-NP O
10 709 720 18023325 dysfunction NN I-NP O
11 721 726 18023325 after IN B-SBAR O
12 727 730 18023325 she PRP B-NP O
13 731 734 18023325 had VBD B-VP O
14 735 744 18023325 recovered VBN I-VP O
15 745 749 18023325 from IN B-PP O
16 750 754 18023325 this DT B-NP O
17 755 760 18023325 state NN I-NP O
18 760 761 18023325 . . O O

1 762 763 18023325 A DT B-NP O
2 764 769 18023325 nerve NN I-NP O
3 770 780 18023325 conduction NN I-NP O
4 781 786 18023325 study NN I-NP O
5 787 790 18023325 was VBD B-VP O
6 791 801 18023325 consistent JJ B-ADJP O
7 802 806 18023325 with IN B-PP O
8 807 813 18023325 severe JJ B-NP O
9 814 826 18023325 sensorimotor NN I-NP O
10 827 833 18023325 axonal JJ I-NP O
11 834 848 18023325 polyneuropathy NN I-NP B-Disease
12 848 849 18023325 . . O O

1 850 859 18023325 Laryngeal JJ B-NP O
2 860 876 18023325 electromyography NN I-NP O
3 877 878 18023325 ( ( O O
4 878 892 18023325 thyroarytenoid NN B-NP O
5 893 899 18023325 muscle NN I-NP O
6 899 900 18023325 ) ) O O
7 901 907 18023325 showed VBD B-VP O
8 908 913 18023325 ample JJ B-NP O
9 914 925 18023325 denervation NN I-NP O
10 926 936 18023325 potentials NNS I-NP O
11 936 937 18023325 . . O O

1 938 950 18023325 Laryngoscopy NNP B-NP O
2 951 959 18023325 revealed VBD B-VP O
3 960 970 18023325 asymmetric JJ B-NP O
4 971 976 18023325 vocal JJ I-NP O
5 977 981 18023325 fold JJ I-NP O
6 982 991 18023325 movements NNS I-NP O
7 992 998 18023325 during IN B-PP O
8 999 1008 18023325 phonation NN B-NP O
9 1008 1009 18023325 . . O O

1 1010 1013 18023325 Her PRP$ B-NP O
2 1014 1019 18023325 vocal JJ I-NP O
3 1020 1026 18023325 change NN I-NP O
4 1027 1030 18023325 and CC I-NP O
5 1031 1039 18023325 weakness NN I-NP O
6 1040 1045 18023325 began VBD B-VP O
7 1046 1048 18023325 to TO I-VP O
8 1049 1056 18023325 improve VB I-VP O
9 1057 1070 18023325 spontaneously RB B-ADVP O
10 1071 1076 18023325 about IN B-NP O
11 1077 1078 18023325 3 CD I-NP O
12 1079 1084 18023325 weeks NNS I-NP O
13 1085 1090 18023325 after IN B-PP O
14 1091 1099 18023325 transfer NN B-NP O
15 1099 1100 18023325 . . O O

1 1101 1105 18023325 This DT B-NP O
2 1106 1109 18023325 was VBD B-VP O
3 1110 1111 18023325 a DT B-NP O
4 1112 1116 18023325 case NN I-NP O
5 1117 1119 18023325 of IN B-PP O
6 1120 1125 18023325 acute JJ B-NP O
7 1126 1131 18023325 palsy NN I-NP B-Disease
8 1132 1134 18023325 of IN B-PP O
9 1135 1138 18023325 the DT B-NP O
10 1139 1148 18023325 recurrent JJ I-NP O
11 1149 1158 18023325 laryngeal JJ I-NP O
12 1159 1164 18023325 nerve NN I-NP O
13 1165 1168 18023325 and CC O O
14 1169 1181 18023325 superimposed VBN B-VP O
15 1182 1188 18023325 severe JJ B-NP O
16 1189 1194 18023325 acute JJ I-NP O
17 1195 1207 18023325 sensorimotor NN I-NP O
18 1208 1214 18023325 axonal JJ I-NP O
19 1215 1229 18023325 polyneuropathy NN I-NP B-Disease
20 1230 1236 18023325 caused VBN B-VP O
21 1237 1239 18023325 by IN B-PP O
22 1240 1244 18023325 high JJ B-NP O
23 1244 1245 18023325 - HYPH I-NP O
24 1245 1249 18023325 dose NN I-NP O
25 1250 1260 18023325 disulfiram NN I-NP B-Chemical
26 1261 1273 18023325 intoxication NN I-NP O
27 1273 1274 18023325 . . O O

1 0 0 10669626 -DOCSTART- -X- -X- O

1 0 8 10669626 Warfarin NN B-NP B-Chemical
2 8 9 10669626 - HYPH B-NP O
3 9 16 10669626 induced VBN I-NP O
4 17 23 10669626 artery NN I-NP B-Disease
5 24 37 10669626 calcification NN I-NP I-Disease
6 38 40 10669626 is VBZ B-VP O
7 41 52 10669626 accelerated VBN I-VP O
8 53 55 10669626 by IN B-PP O
9 56 62 10669626 growth NN B-NP O
10 63 66 10669626 and CC I-NP O
11 67 74 10669626 vitamin NN I-NP B-Chemical
12 75 76 10669626 D NN I-NP I-Chemical
13 76 77 10669626 . . O O
14 78 81 10669626 The DT B-NP O
15 82 89 10669626 present JJ I-NP O
16 90 97 10669626 studies NNS I-NP O
17 98 109 10669626 demonstrate VBP B-VP O
18 110 114 10669626 that IN B-SBAR O
19 115 121 10669626 growth NN B-NP O
20 122 125 10669626 and CC I-NP O
21 126 133 10669626 vitamin NN I-NP B-Chemical
22 134 135 10669626 D NN I-NP I-Chemical
23 136 145 10669626 treatment NN I-NP O
24 146 153 10669626 enhance VBP B-VP O
25 154 157 10669626 the DT B-NP O
26 158 164 10669626 extent NN I-NP O
27 165 167 10669626 of IN B-PP O
28 168 174 10669626 artery NN B-NP B-Disease
29 175 188 10669626 calcification NN I-NP I-Disease
30 189 191 10669626 in IN B-PP O
31 192 196 10669626 rats NNS B-NP O
32 197 202 10669626 given VBN B-VP O
33 203 213 10669626 sufficient JJ B-NP O
34 214 219 10669626 doses NNS I-NP O
35 220 222 10669626 of IN B-PP O
36 223 231 10669626 Warfarin NNP B-NP B-Chemical
37 232 234 10669626 to TO B-VP O
38 235 242 10669626 inhibit VB I-VP O
39 243 248 10669626 gamma NN B-NP O
40 248 249 10669626 - HYPH O O
41 249 262 10669626 carboxylation NN B-NP O
42 263 265 10669626 of IN B-PP O
43 266 272 10669626 matrix NN B-NP O
44 273 276 10669626 Gla NN I-NP O
45 277 284 10669626 protein NN I-NP O
46 284 285 10669626 , , O O
47 286 287 10669626 a DT B-NP O
48 288 301 10669626 calcification NN I-NP B-Disease
49 302 311 10669626 inhibitor NN I-NP O
50 312 317 10669626 known VBN B-VP O
51 318 320 10669626 to TO I-VP O
52 321 323 10669626 be VB I-VP O
53 324 333 10669626 expressed VBN I-VP O
54 334 336 10669626 by IN B-PP O
55 337 343 10669626 smooth JJ B-NP O
56 344 350 10669626 muscle NN I-NP O
57 351 356 10669626 cells NNS I-NP O
58 357 360 10669626 and CC O O
59 361 372 10669626 macrophages NNS B-NP O
60 373 375 10669626 in IN B-PP O
61 376 379 10669626 the DT B-NP O
62 380 386 10669626 artery NN I-NP O
63 387 391 10669626 wall NN I-NP O
64 391 392 10669626 . . O O

1 393 396 10669626 The DT B-NP O
2 397 402 10669626 first JJ I-NP O
3 403 409 10669626 series NN I-NP O
4 410 412 10669626 of IN B-PP O
5 413 424 10669626 experiments NNS B-NP O
6 425 433 10669626 examined VBN B-VP O
7 434 437 10669626 the DT B-NP O
8 438 447 10669626 influence NN I-NP O
9 448 450 10669626 of IN B-PP O
10 451 454 10669626 age NN B-NP O
11 455 458 10669626 and CC I-NP O
12 459 465 10669626 growth NN I-NP O
13 466 472 10669626 status NN I-NP O
14 473 475 10669626 on IN B-PP O
15 476 482 10669626 artery NN B-NP B-Disease
16 483 496 10669626 calcification NN I-NP I-Disease
17 497 499 10669626 in IN B-PP O
18 500 508 10669626 Warfarin NN B-NP B-Chemical
19 508 509 10669626 - HYPH B-NP O
20 509 516 10669626 treated VBN I-NP O
21 517 521 10669626 rats NNS I-NP O
22 521 522 10669626 . . O O

1 523 532 10669626 Treatment NN B-NP O
2 533 536 10669626 for IN B-PP O
3 537 538 10669626 2 CD B-NP O
4 539 544 10669626 weeks NNS I-NP O
5 545 549 10669626 with IN B-PP O
6 550 558 10669626 Warfarin NN B-NP B-Chemical
7 559 565 10669626 caused VBD B-VP O
8 566 573 10669626 massive JJ B-NP O
9 574 579 10669626 focal JJ I-NP O
10 580 593 10669626 calcification NN I-NP B-Disease
11 594 596 10669626 of IN B-PP I-Disease
12 597 600 10669626 the DT B-NP I-Disease
13 601 607 10669626 artery NN I-NP I-Disease
14 608 613 10669626 media NNS I-NP O
15 614 616 10669626 in IN B-PP O
16 617 619 10669626 20 CD B-NP O
17 619 620 10669626 - HYPH I-NP O
18 620 623 10669626 day NN I-NP O
19 623 624 10669626 - HYPH O O
20 624 627 10669626 old JJ B-NP O
21 628 632 10669626 rats NNS I-NP O
22 633 636 10669626 and CC O O
23 637 641 10669626 less RBR B-NP O
24 642 651 10669626 extensive JJ I-NP O
25 652 657 10669626 focal JJ I-NP O
26 658 671 10669626 calcification NN I-NP B-Disease
27 672 674 10669626 in IN B-PP O
28 675 677 10669626 42 CD B-NP O
29 677 678 10669626 - HYPH I-NP O
30 678 681 10669626 day NN I-NP O
31 681 682 10669626 - HYPH O O
32 682 685 10669626 old JJ B-NP O
33 686 690 10669626 rats NNS I-NP O
34 690 691 10669626 . . O O

1 692 694 10669626 In IN B-PP O
2 695 703 10669626 contrast NN B-NP O
3 703 704 10669626 , , O O
4 705 707 10669626 no DT B-NP O
5 708 714 10669626 artery NN I-NP B-Disease
6 715 728 10669626 calcification NN I-NP I-Disease
7 729 734 10669626 could MD B-VP O
8 735 737 10669626 be VB I-VP O
9 738 746 10669626 detected VBN I-VP O
10 747 749 10669626 in IN B-PP O
11 750 752 10669626 10 CD B-NP O
12 752 753 10669626 - HYPH I-NP O
13 753 758 10669626 month NN I-NP O
14 758 759 10669626 - HYPH O O
15 759 762 10669626 old JJ B-NP O
16 763 768 10669626 adult JJ I-NP O
17 769 773 10669626 rats NNS I-NP O
18 774 778 10669626 even RB B-ADVP O
19 779 784 10669626 after IN B-PP O
20 785 786 10669626 4 CD B-NP O
21 787 792 10669626 weeks NNS I-NP O
22 793 795 10669626 of IN B-PP O
23 796 804 10669626 Warfarin NN B-NP B-Chemical
24 805 814 10669626 treatment NN I-NP O
25 814 815 10669626 . . O O

1 816 818 10669626 To TO B-VP O
2 819 827 10669626 directly RB I-VP O
3 828 835 10669626 examine VB I-VP O
4 836 839 10669626 the DT B-NP O
5 840 850 10669626 importance NN I-NP O
6 851 853 10669626 of IN B-PP O
7 854 860 10669626 growth NN B-NP O
8 861 863 10669626 to TO B-PP O
9 864 872 10669626 Warfarin NN B-NP B-Chemical
10 872 873 10669626 - HYPH B-NP O
11 873 880 10669626 induced VBN I-NP O
12 881 887 10669626 artery NN I-NP B-Disease
13 888 901 10669626 calcification NN I-NP I-Disease
14 902 904 10669626 in IN B-PP O
15 905 912 10669626 animals NNS B-NP O
16 913 915 10669626 of IN B-PP O
17 916 919 10669626 the DT B-NP O
18 920 924 10669626 same JJ I-NP O
19 925 928 10669626 age NN I-NP O
20 928 929 10669626 , , O O
21 930 932 10669626 20 CD B-NP O
22 932 933 10669626 - HYPH I-NP O
23 933 936 10669626 day NN I-NP O
24 936 937 10669626 - HYPH O O
25 937 940 10669626 old JJ B-NP O
26 941 945 10669626 rats NNS I-NP O
27 946 950 10669626 were VBD B-VP O
28 951 954 10669626 fed VBN I-VP O
29 955 958 10669626 for IN B-PP O
30 959 960 10669626 2 CD B-NP O
31 961 966 10669626 weeks NNS I-NP O
32 967 973 10669626 either CC O O
33 974 976 10669626 an DT B-NP O
34 977 979 10669626 ad NN I-NP O
35 980 987 10669626 libitum NN I-NP O
36 988 992 10669626 diet NN I-NP O
37 993 995 10669626 or CC O O
38 996 997 10669626 a DT B-NP O
39 998 999 10669626 6 CD I-NP O
40 999 1000 10669626 - HYPH I-NP O
41 1000 1001 10669626 g NN I-NP O
42 1001 1002 10669626 / SYM I-NP O
43 1002 1003 10669626 d NN I-NP O
44 1004 1014 10669626 restricted JJ I-NP O
45 1015 1019 10669626 diet NN I-NP O
46 1020 1024 10669626 that WDT B-NP O
47 1025 1034 10669626 maintains VBZ B-VP O
48 1035 1041 10669626 weight NN B-NP O
49 1042 1045 10669626 but CC O O
50 1046 1054 10669626 prevents VBZ B-VP O
51 1055 1061 10669626 growth NN B-NP O
52 1061 1062 10669626 . . O O

1 1063 1073 10669626 Concurrent JJ B-NP O
2 1074 1083 10669626 treatment NN I-NP O
3 1084 1086 10669626 of IN B-PP O
4 1087 1091 10669626 both DT B-NP O
5 1092 1099 10669626 dietary JJ I-NP O
6 1100 1106 10669626 groups NNS I-NP O
7 1107 1111 10669626 with IN B-PP O
8 1112 1120 10669626 Warfarin NN B-NP B-Chemical
9 1121 1129 10669626 produced VBD B-VP O
10 1130 1137 10669626 massive JJ B-NP O
11 1138 1143 10669626 focal JJ I-NP O
12 1144 1157 10669626 calcification NN I-NP B-Disease
13 1158 1160 10669626 of IN B-PP I-Disease
14 1161 1164 10669626 the DT B-NP I-Disease
15 1165 1171 10669626 artery NN I-NP I-Disease
16 1172 1177 10669626 media NNS I-NP O
17 1178 1180 10669626 in IN B-PP O
18 1181 1184 10669626 the DT B-NP O
19 1185 1187 10669626 ad NN I-NP O
20 1188 1195 10669626 libitum NN I-NP O
21 1195 1196 10669626 - HYPH B-NP O
22 1196 1199 10669626 fed VBN I-NP O
23 1200 1204 10669626 rats NNS I-NP O
24 1205 1208 10669626 but CC O O
25 1209 1211 10669626 no DT B-NP O
26 1212 1222 10669626 detectable JJ I-NP O
27 1223 1229 10669626 artery NN I-NP B-Disease
28 1230 1243 10669626 calcification NN I-NP I-Disease
29 1244 1246 10669626 in IN B-PP O
30 1247 1250 10669626 the DT B-NP O
31 1251 1261 10669626 restricted JJ I-NP O
32 1261 1262 10669626 - HYPH I-NP O
33 1262 1266 10669626 diet NN I-NP O
34 1266 1267 10669626 , , O O
35 1268 1274 10669626 growth NN B-NP O
36 1274 1275 10669626 - HYPH B-VP O
37 1275 1284 10669626 inhibited VBN B-NP O
38 1285 1290 10669626 group NN I-NP O
39 1290 1291 10669626 . . O O

1 1292 1300 10669626 Although IN B-SBAR O
2 1301 1304 10669626 the DT B-NP O
3 1305 1316 10669626 explanation NN I-NP O
4 1317 1320 10669626 for IN B-PP O
5 1321 1324 10669626 the DT B-NP O
6 1325 1336 10669626 association NN I-NP O
7 1337 1344 10669626 between IN B-PP O
8 1345 1351 10669626 artery NN B-NP B-Disease
9 1352 1365 10669626 calcification NN I-NP I-Disease
10 1366 1369 10669626 and CC O O
11 1370 1376 10669626 growth NN B-NP O
12 1377 1383 10669626 status NN I-NP O
13 1384 1390 10669626 cannot MD B-VP O
14 1391 1393 10669626 be VB I-VP O
15 1394 1404 10669626 determined VBN I-VP O
16 1405 1409 10669626 from IN B-PP O
17 1410 1413 10669626 the DT B-NP O
18 1414 1421 10669626 present JJ I-NP O
19 1422 1427 10669626 study NN I-NP O
20 1427 1428 10669626 , , O O
21 1429 1434 10669626 there EX B-NP O
22 1435 1438 10669626 was VBD B-VP O
23 1439 1440 10669626 a DT B-NP O
24 1441 1453 10669626 relationship NN I-NP O
25 1454 1461 10669626 between IN B-PP O
26 1462 1468 10669626 higher JJR B-NP O
27 1469 1474 10669626 serum NN I-NP O
28 1475 1484 10669626 phosphate NN I-NP B-Chemical
29 1485 1488 10669626 and CC O O
30 1489 1503 10669626 susceptibility NN B-NP O
31 1504 1506 10669626 to TO B-PP O
32 1507 1513 10669626 artery NN B-NP B-Disease
33 1514 1527 10669626 calcification NN I-NP I-Disease
34 1527 1528 10669626 , , O O
35 1529 1533 10669626 with IN B-PP O
36 1534 1537 10669626 30% CD B-NP O
37 1538 1544 10669626 higher JJR I-NP O
38 1545 1551 10669626 levels NNS I-NP O
39 1552 1554 10669626 of IN B-PP O
40 1555 1560 10669626 serum NN B-NP O
41 1561 1570 10669626 phosphate NN I-NP B-Chemical
42 1571 1573 10669626 in IN B-PP O
43 1574 1579 10669626 young JJ B-NP O
44 1579 1580 10669626 , , O O
45 1581 1583 10669626 ad NN B-NP O
46 1584 1591 10669626 libitum NN I-NP O
47 1591 1592 10669626 - HYPH B-NP O
48 1592 1595 10669626 fed VBN I-NP O
49 1596 1600 10669626 rats NNS I-NP O
50 1601 1609 10669626 compared VBN B-PP O
51 1610 1614 10669626 with IN B-PP O
52 1615 1621 10669626 either DT B-NP O
53 1622 1624 10669626 of IN B-PP O
54 1625 1628 10669626 the DT B-NP O
55 1629 1635 10669626 groups NNS I-NP O
56 1636 1640 10669626 that WDT B-NP O
57 1641 1644 10669626 was VBD B-VP O
58 1645 1654 10669626 resistant JJ B-ADJP O
59 1655 1657 10669626 to TO B-PP O
60 1658 1666 10669626 Warfarin NN B-NP B-Chemical
61 1666 1667 10669626 - HYPH B-NP O
62 1667 1674 10669626 induced VBN I-NP O
63 1675 1681 10669626 artery NN I-NP B-Disease
64 1682 1695 10669626 calcification NN I-NP I-Disease
65 1695 1696 10669626 , , O O
66 1697 1699 10669626 ie FW B-NP O
67 1699 1700 10669626 , , O O
68 1701 1704 10669626 the DT B-NP O
69 1705 1707 10669626 10 CD I-NP O
70 1707 1708 10669626 - HYPH I-NP O
71 1708 1713 10669626 month NN I-NP O
72 1713 1714 10669626 - HYPH O O
73 1714 1717 10669626 old JJ B-NP O
74 1718 1722 10669626 rats NNS I-NP O
75 1723 1726 10669626 and CC O O
76 1727 1730 10669626 the DT B-NP O
77 1731 1741 10669626 restricted JJ I-NP O
78 1741 1742 10669626 - HYPH I-NP O
79 1742 1746 10669626 diet NN I-NP O
80 1746 1747 10669626 , , O O
81 1748 1754 10669626 growth NN B-NP O
82 1754 1755 10669626 - HYPH O O
83 1755 1764 10669626 inhibited VBN B-NP O
84 1765 1770 10669626 young JJ I-NP O
85 1771 1775 10669626 rats NNS I-NP O
86 1775 1776 10669626 . . O O

1 1777 1781 10669626 This DT B-NP O
2 1782 1793 10669626 observation NN I-NP O
3 1794 1802 10669626 suggests VBZ B-VP O
4 1803 1807 10669626 that IN B-SBAR O
5 1808 1817 10669626 increased VBN B-NP O
6 1818 1832 10669626 susceptibility NN I-NP O
7 1833 1835 10669626 to TO B-PP O
8 1836 1844 10669626 Warfarin NN B-NP B-Chemical
9 1844 1845 10669626 - HYPH B-NP O
10 1845 1852 10669626 induced VBN I-NP O
11 1853 1859 10669626 artery NN I-NP B-Disease
12 1860 1873 10669626 calcification NN I-NP I-Disease
13 1874 1879 10669626 could MD B-VP O
14 1880 1882 10669626 be VB I-VP O
15 1883 1890 10669626 related VBN I-VP O
16 1891 1893 10669626 to TO B-PP O
17 1894 1900 10669626 higher JJR B-NP O
18 1901 1906 10669626 serum NN I-NP O
19 1907 1916 10669626 phosphate NN I-NP B-Chemical
20 1917 1923 10669626 levels NNS I-NP O
21 1923 1924 10669626 . . O O

1 1925 1928 10669626 The DT B-NP O
2 1929 1935 10669626 second JJ I-NP O
3 1936 1939 10669626 set NN I-NP O
4 1940 1942 10669626 of IN B-PP O
5 1943 1954 10669626 experiments NNS B-NP O
6 1955 1963 10669626 examined VBD B-VP O
7 1964 1967 10669626 the DT B-NP O
8 1968 1976 10669626 possible JJ I-NP O
9 1977 1984 10669626 synergy NN I-NP O
10 1985 1992 10669626 between IN B-PP O
11 1993 2000 10669626 vitamin NN B-NP B-Chemical
12 2001 2002 10669626 D NN I-NP I-Chemical
13 2003 2006 10669626 and CC I-NP O
14 2007 2015 10669626 Warfarin NN I-NP B-Chemical
15 2016 2018 10669626 in IN B-PP O
16 2019 2025 10669626 artery NN B-NP B-Disease
17 2026 2039 10669626 calcification NN I-NP I-Disease
18 2039 2040 10669626 . . O O

1 2041 2045 10669626 High JJ B-NP O
2 2046 2051 10669626 doses NNS I-NP O
3 2052 2054 10669626 of IN B-PP O
4 2055 2062 10669626 vitamin NN B-NP B-Chemical
5 2063 2064 10669626 D NN I-NP I-Chemical
6 2065 2068 10669626 are VBP B-VP O
7 2069 2074 10669626 known VBN I-VP O
8 2075 2077 10669626 to TO I-VP O
9 2078 2083 10669626 cause VB I-VP O
10 2084 2097 10669626 calcification NN B-NP B-Disease
11 2098 2100 10669626 of IN B-PP I-Disease
12 2101 2104 10669626 the DT B-NP I-Disease
13 2105 2111 10669626 artery NN I-NP I-Disease
14 2112 2117 10669626 media NNS I-NP O
15 2118 2120 10669626 in IN B-PP O
16 2121 2123 10669626 as RB B-NP O
17 2124 2130 10669626 little JJ I-NP O
18 2131 2133 10669626 as IN I-NP O
19 2134 2135 10669626 3 CD I-NP O
20 2136 2138 10669626 to TO I-NP O
21 2139 2140 10669626 4 CD I-NP O
22 2141 2145 10669626 days NNS I-NP O
23 2145 2146 10669626 . . O O

1 2147 2151 10669626 High JJ B-NP O
2 2152 2157 10669626 doses NNS I-NP O
3 2158 2160 10669626 of IN B-PP O
4 2161 2164 10669626 the DT B-NP O
5 2165 2172 10669626 vitamin NN I-NP B-Chemical
6 2173 2174 10669626 K NN I-NP I-Chemical
7 2175 2185 10669626 antagonist NN I-NP O
8 2186 2194 10669626 Warfarin NN I-NP B-Chemical
9 2195 2198 10669626 are VBP B-VP O
10 2199 2203 10669626 also RB I-VP O
11 2204 2209 10669626 known VBN I-VP O
12 2210 2212 10669626 to TO I-VP O
13 2213 2218 10669626 cause VB I-VP O
14 2219 2232 10669626 calcification NN B-NP B-Disease
15 2233 2235 10669626 of IN B-PP I-Disease
16 2236 2239 10669626 the DT B-NP I-Disease
17 2240 2246 10669626 artery NN I-NP I-Disease
18 2247 2252 10669626 media NNS I-NP O
19 2252 2253 10669626 , , O O
20 2254 2257 10669626 but CC O O
21 2258 2260 10669626 at IN B-PP O
22 2261 2270 10669626 treatment NN B-NP O
23 2271 2276 10669626 times NNS I-NP O
24 2277 2279 10669626 of IN B-PP O
25 2280 2281 10669626 2 CD B-NP O
26 2282 2287 10669626 weeks NNS I-NP O
27 2288 2290 10669626 or CC O O
28 2291 2297 10669626 longer JJR B-ADJP O
29 2298 2301 10669626 yet CC O O
30 2302 2305 10669626 not RB O O
31 2306 2308 10669626 at IN B-PP O
32 2309 2310 10669626 1 CD B-NP O
33 2311 2315 10669626 week NN I-NP O
34 2315 2316 10669626 . . O O

1 2317 2319 10669626 In IN B-PP O
2 2320 2323 10669626 the DT B-NP O
3 2324 2331 10669626 current JJ I-NP O
4 2332 2337 10669626 study NN I-NP O
5 2337 2338 10669626 , , O O
6 2339 2341 10669626 we PRP B-NP O
7 2342 2354 10669626 investigated VBD B-VP O
8 2355 2358 10669626 the DT B-NP O
9 2359 2366 10669626 synergy NN I-NP O
10 2367 2374 10669626 between IN B-PP O
11 2375 2380 10669626 these DT B-NP O
12 2381 2382 10669626 2 CD I-NP O
13 2383 2393 10669626 treatments NNS I-NP O
14 2394 2397 10669626 and CC O O
15 2398 2403 10669626 found VBD B-VP O
16 2404 2408 10669626 that IN B-SBAR O
17 2409 2419 10669626 concurrent JJ B-NP O
18 2420 2428 10669626 Warfarin NNP I-NP B-Chemical
19 2429 2443 10669626 administration NN I-NP O
20 2444 2456 10669626 dramatically RB B-ADVP O
21 2457 2466 10669626 increased VBD B-VP O
22 2467 2470 10669626 the DT B-NP O
23 2471 2477 10669626 extent NN I-NP O
24 2478 2480 10669626 of IN B-PP O
25 2481 2494 10669626 calcification NN B-NP B-Disease
26 2495 2497 10669626 in IN B-PP O
27 2498 2501 10669626 the DT B-NP O
28 2502 2507 10669626 media NNS I-NP O
29 2508 2510 10669626 of IN B-PP O
30 2511 2518 10669626 vitamin NN B-NP B-Chemical
31 2519 2520 10669626 D NN I-NP I-Chemical
32 2520 2521 10669626 - HYPH B-NP O
33 2521 2528 10669626 treated VBN I-NP O
34 2529 2533 10669626 rats NNS I-NP O
35 2534 2536 10669626 at IN B-PP O
36 2537 2538 10669626 3 CD B-NP O
37 2539 2542 10669626 and CC I-NP O
38 2543 2544 10669626 4 CD I-NP O
39 2545 2549 10669626 days NNS I-NP O
40 2549 2550 10669626 . . O O

1 2551 2556 10669626 There EX B-NP O
2 2557 2560 10669626 was VBD B-VP O
3 2561 2562 10669626 a DT B-NP O
4 2563 2568 10669626 close JJ I-NP O
5 2569 2577 10669626 parallel NN I-NP O
6 2578 2585 10669626 between IN B-PP O
7 2586 2589 10669626 the DT B-NP O
8 2590 2596 10669626 effect NN I-NP O
9 2597 2599 10669626 of IN B-PP O
10 2600 2607 10669626 vitamin NN B-NP B-Chemical
11 2608 2609 10669626 D NN I-NP I-Chemical
12 2610 2614 10669626 dose NN I-NP O
13 2615 2617 10669626 on IN B-PP O
14 2618 2624 10669626 artery NN B-NP B-Disease
15 2625 2638 10669626 calcification NN I-NP I-Disease
16 2639 2642 10669626 and CC O O
17 2643 2646 10669626 the DT B-NP O
18 2647 2653 10669626 effect NN I-NP O
19 2654 2656 10669626 of IN B-PP O
20 2657 2664 10669626 vitamin NN B-NP B-Chemical
21 2665 2666 10669626 D NN I-NP I-Chemical
22 2667 2671 10669626 dose NN I-NP O
23 2672 2674 10669626 on IN B-PP O
24 2675 2678 10669626 the DT B-NP O
25 2679 2688 10669626 elevation NN I-NP O
26 2689 2691 10669626 of IN B-PP O
27 2692 2697 10669626 serum NN B-NP O
28 2698 2705 10669626 calcium NN I-NP B-Chemical
29 2705 2706 10669626 , , O O
30 2707 2712 10669626 which WDT B-NP O
31 2713 2721 10669626 suggests VBZ B-VP O
32 2722 2726 10669626 that IN B-SBAR O
33 2727 2734 10669626 vitamin NN B-NP B-Chemical
34 2735 2736 10669626 D NN I-NP I-Chemical
35 2737 2740 10669626 may MD B-VP O
36 2741 2747 10669626 induce VB I-VP O
37 2748 2754 10669626 artery NN B-NP B-Disease
38 2755 2768 10669626 calcification NN I-NP I-Disease
39 2769 2776 10669626 through IN B-PP O
40 2777 2780 10669626 its PRP$ B-NP O
41 2781 2787 10669626 effect NN I-NP O
42 2788 2790 10669626 on IN B-PP O
43 2791 2796 10669626 serum NN B-NP O
44 2797 2804 10669626 calcium NN I-NP B-Chemical
45 2804 2805 10669626 . . O O

1 2806 2813 10669626 Because IN B-SBAR O
2 2814 2822 10669626 Warfarin NN B-NP B-Chemical
3 2823 2832 10669626 treatment NN I-NP O
4 2833 2836 10669626 had VBD B-VP O
5 2837 2839 10669626 no DT B-NP O
6 2840 2846 10669626 effect NN I-NP O
7 2847 2849 10669626 on IN B-PP O
8 2850 2853 10669626 the DT B-NP O
9 2854 2863 10669626 elevation NN I-NP O
10 2864 2866 10669626 in IN B-PP O
11 2867 2872 10669626 serum NN B-NP O
12 2873 2880 10669626 calcium NN I-NP B-Chemical
13 2881 2889 10669626 produced VBN B-VP O
14 2890 2892 10669626 by IN B-PP O
15 2893 2900 10669626 vitamin NN B-NP B-Chemical
16 2901 2902 10669626 D NN I-NP I-Chemical
17 2902 2903 10669626 , , O O
18 2904 2907 10669626 the DT B-NP O
19 2908 2915 10669626 synergy NN I-NP O
20 2916 2923 10669626 between IN B-PP O
21 2924 2932 10669626 Warfarin NN B-NP B-Chemical
22 2933 2936 10669626 and CC I-NP O
23 2937 2944 10669626 vitamin NN I-NP B-Chemical
24 2945 2946 10669626 D NN I-NP I-Chemical
25 2947 2949 10669626 is VBZ B-VP O
26 2950 2958 10669626 probably RB I-VP O
27 2959 2963 10669626 best RBS I-VP O
28 2964 2973 10669626 explained VBN I-VP O
29 2974 2976 10669626 by IN B-PP O
30 2977 2980 10669626 the DT B-NP O
31 2981 2991 10669626 hypothesis NN I-NP O
32 2992 2996 10669626 that IN B-SBAR O
33 2997 3005 10669626 Warfarin NN B-NP B-Chemical
34 3006 3014 10669626 inhibits VBZ B-VP O
35 3015 3018 10669626 the DT B-NP O
36 3019 3027 10669626 activity NN I-NP O
37 3028 3030 10669626 of IN B-PP O
38 3031 3037 10669626 matrix NN B-NP O
39 3038 3041 10669626 Gla NN I-NP O
40 3042 3049 10669626 protein NN I-NP O
41 3050 3052 10669626 as IN B-PP O
42 3053 3054 10669626 a DT B-NP O
43 3055 3068 10669626 calcification NN I-NP B-Disease
44 3069 3078 10669626 inhibitor NN I-NP O
45 3078 3079 10669626 . . O O

1 3080 3084 10669626 High JJ B-NP O
2 3085 3091 10669626 levels NNS I-NP O
3 3092 3094 10669626 of IN B-PP O
4 3095 3101 10669626 matrix NN B-NP O
5 3102 3105 10669626 Gla NN I-NP O
6 3106 3113 10669626 protein NN I-NP O
7 3114 3117 10669626 are VBP B-VP O
8 3118 3123 10669626 found VBN I-VP O
9 3124 3126 10669626 at IN B-PP O
10 3127 3132 10669626 sites NNS B-NP O
11 3133 3135 10669626 of IN B-PP O
12 3136 3142 10669626 artery NN B-NP B-Disease
13 3143 3156 10669626 calcification NN I-NP I-Disease
14 3157 3159 10669626 in IN B-PP O
15 3160 3164 10669626 rats NNS B-NP O
16 3165 3172 10669626 treated VBN B-VP O
17 3173 3177 10669626 with IN B-PP O
18 3178 3185 10669626 vitamin NN B-NP B-Chemical
19 3186 3187 10669626 D NN I-NP I-Chemical
20 3188 3192 10669626 plus CC O O
21 3193 3201 10669626 Warfarin NN B-NP B-Chemical
22 3201 3202 10669626 , , O O
23 3203 3206 10669626 and CC O O
24 3207 3215 10669626 chemical NN B-NP O
25 3216 3224 10669626 analysis NN I-NP O
26 3225 3231 10669626 showed VBD B-VP O
27 3232 3236 10669626 that IN B-SBAR O
28 3237 3240 10669626 the DT B-NP O
29 3241 3248 10669626 protein NN I-NP O
30 3249 3253 10669626 that WDT B-NP O
31 3254 3265 10669626 accumulated VBD B-VP O
32 3266 3269 10669626 was VBD B-VP O
33 3270 3276 10669626 indeed RB B-ADVP O
34 3277 3280 10669626 not RB B-NP O
35 3281 3286 10669626 gamma NN I-NP B-Chemical
36 3286 3287 10669626 - HYPH B-NP I-Chemical
37 3287 3299 10669626 carboxylated VBN B-VP I-Chemical
38 3299 3300 10669626 . . O O

1 3301 3306 10669626 These DT B-NP O
2 3307 3319 10669626 observations NNS I-NP O
3 3320 3328 10669626 indicate VBP B-VP O
4 3329 3333 10669626 that IN B-SBAR O
5 3334 3342 10669626 although IN B-SBAR O
6 3343 3346 10669626 the DT B-NP O
7 3347 3352 10669626 gamma SYM I-NP B-Chemical
8 3352 3353 10669626 - HYPH I-NP I-Chemical
9 3353 3369 10669626 carboxyglutamate NN I-NP I-Chemical
10 3370 3378 10669626 residues NNS I-NP O
11 3379 3381 10669626 of IN B-PP O
12 3382 3388 10669626 matrix NN B-NP O
13 3389 3392 10669626 Gla NN I-NP O
14 3393 3400 10669626 protein NN I-NP O
15 3401 3404 10669626 are VBP B-VP O
16 3405 3415 10669626 apparently RB I-VP O
17 3416 3424 10669626 required VBN I-VP O
18 3425 3428 10669626 for IN B-PP O
19 3429 3432 10669626 its PRP$ B-NP O
20 3433 3441 10669626 function NN I-NP O
21 3442 3444 10669626 as IN B-PP O
22 3445 3446 10669626 a DT B-NP O
23 3447 3460 10669626 calcification NN I-NP B-Disease
24 3461 3470 10669626 inhibitor NN I-NP O
25 3470 3471 10669626 , , O O
26 3472 3476 10669626 they PRP B-NP O
27 3477 3480 10669626 are VBP B-VP O
28 3481 3484 10669626 not RB I-VP O
29 3485 3493 10669626 required VBN I-VP O
30 3494 3497 10669626 for IN B-PP O
31 3498 3501 10669626 its PRP$ B-NP O
32 3502 3514 10669626 accumulation NN I-NP O
33 3515 3517 10669626 at IN B-PP O
34 3518 3531 10669626 calcification NN B-NP B-Disease
35 3532 3537 10669626 sites NNS I-NP O
36 3537 3538 10669626 . . O O

1 0 0 17175308 -DOCSTART- -X- -X- O

1 0 11 17175308 Proteinuria NN B-NP B-Disease
2 12 17 17175308 after IN B-PP O
3 18 28 17175308 conversion NN B-NP O
4 29 31 17175308 to TO B-PP O
5 32 41 17175308 sirolimus NN B-NP B-Chemical
6 42 44 17175308 in IN B-PP O
7 45 50 17175308 renal JJ B-NP O
8 51 61 17175308 transplant NN I-NP O
9 62 72 17175308 recipients NNS I-NP O
10 72 73 17175308 . . O O
11 74 83 17175308 Sirolimus NN B-NP B-Chemical
12 84 85 17175308 ( ( O O
13 85 88 17175308 SRL NN B-NP B-Chemical
14 88 89 17175308 ) ) O O
15 90 92 17175308 is VBZ B-VP O
16 93 94 17175308 a DT B-NP O
17 95 98 17175308 new JJ I-NP O
18 98 99 17175308 , , I-NP O
19 100 106 17175308 potent JJ I-NP O
20 107 124 17175308 immunosuppressive JJ I-NP O
21 125 130 17175308 agent NN I-NP O
22 130 131 17175308 . . O O

1 132 136 17175308 More RBR B-ADVP O
2 137 145 17175308 recently RB I-ADVP O
3 145 146 17175308 , , O O
4 147 158 17175308 proteinuria NN B-NP B-Disease
5 159 162 17175308 has VBZ B-VP O
6 163 167 17175308 been VBN I-VP O
7 168 176 17175308 reported VBN I-VP O
8 177 179 17175308 as IN B-PP O
9 180 181 17175308 a DT B-NP O
10 182 193 17175308 consequence NN I-NP O
11 194 196 17175308 of IN B-PP O
12 197 206 17175308 sirolimus NN B-NP B-Chemical
13 207 214 17175308 therapy NN I-NP O
14 214 215 17175308 , , O O
15 216 224 17175308 although IN B-SBAR O
16 225 228 17175308 the DT B-NP O
17 229 238 17175308 mechanism NN I-NP O
18 239 242 17175308 has VBZ B-VP O
19 243 251 17175308 remained VBN I-VP O
20 252 259 17175308 unclear JJ B-ADJP O
21 259 260 17175308 . . O O

1 261 263 17175308 We PRP B-NP O
2 264 279 17175308 retrospectively RB B-ADVP O
3 280 288 17175308 examined VBD B-VP O
4 289 292 17175308 the DT B-NP O
5 293 300 17175308 records NNS I-NP O
6 301 303 17175308 of IN B-PP O
7 304 306 17175308 25 CD B-NP O
8 307 312 17175308 renal JJ I-NP O
9 313 323 17175308 transplant NN I-NP O
10 324 332 17175308 patients NNS I-NP O
11 332 333 17175308 , , O O
12 334 337 17175308 who WP B-NP O
13 338 347 17175308 developed VBD B-VP O
14 348 350 17175308 or CC I-VP O
15 351 360 17175308 displayed VBD I-VP O
16 361 370 17175308 increased VBN B-NP O
17 371 382 17175308 proteinuria NN I-NP B-Disease
18 383 388 17175308 after IN B-PP O
19 389 392 17175308 SRL NN B-NP B-Chemical
20 393 403 17175308 conversion NN I-NP O
21 403 404 17175308 . . O O

1 405 408 17175308 The DT B-NP O
2 409 416 17175308 patient NN I-NP O
3 417 423 17175308 cohort NN I-NP O
4 424 425 17175308 ( ( O O
5 425 427 17175308 14 CD B-NP O
6 428 431 17175308 men NNS I-NP O
7 431 432 17175308 , , O O
8 433 435 17175308 11 CD B-NP O
9 436 441 17175308 women NNS I-NP O
10 441 442 17175308 ) ) O O
11 443 446 17175308 was VBD B-VP O
12 447 454 17175308 treated VBN I-VP O
13 455 459 17175308 with IN B-PP O
14 460 463 17175308 SRL NN B-NP B-Chemical
15 464 466 17175308 as IN B-PP O
16 467 477 17175308 conversion NN B-NP O
17 478 485 17175308 therapy NN I-NP O
18 485 486 17175308 , , O O
19 487 490 17175308 due JJ B-PP O
20 491 493 17175308 to TO B-PP O
21 494 501 17175308 chronic JJ B-NP B-Disease
22 502 511 17175308 allograft NN I-NP I-Disease
23 512 523 17175308 nephropathy NN I-NP I-Disease
24 524 525 17175308 ( ( O O
25 525 528 17175308 CAN NN B-NP B-Disease
26 528 529 17175308 ) ) O O
27 530 531 17175308 ( ( O O
28 531 532 17175308 n NN B-NP O
29 533 534 17175308 = SYM B-VP O
30 535 537 17175308 15 CD B-NP O
31 537 538 17175308 ) ) O O
32 539 548 17175308 neoplasia NN B-NP B-Disease
33 549 550 17175308 ( ( O O
34 550 551 17175308 n NN B-NP O
35 552 553 17175308 = SYM B-VP O
36 554 555 17175308 8 CD B-NP O
37 555 556 17175308 ) ) O O
38 556 557 17175308 ; : O O
39 558 566 17175308 Kaposi's NNP B-NP B-Disease
40 567 574 17175308 sarcoma NN I-NP I-Disease
41 574 575 17175308 , , O O
42 576 580 17175308 Four CD B-NP O
43 581 585 17175308 skin NN I-NP B-Disease
44 586 593 17175308 cancers NNS I-NP I-Disease
45 593 594 17175308 , , O O
46 595 598 17175308 One CD B-NP O
47 599 609 17175308 intestinal JJ I-NP B-Disease
48 610 616 17175308 tumors NNS I-NP I-Disease
49 616 617 17175308 , , O O
50 618 621 17175308 One CD B-NP O
51 622 627 17175308 renal JJ I-NP B-Disease
52 628 632 17175308 cell NN I-NP I-Disease
53 633 641 17175308 carsinom NN I-NP I-Disease
54 641 642 17175308 ) ) O O
55 643 645 17175308 or CC O O
56 646 648 17175308 BK NN B-NP O
57 649 654 17175308 virus NN I-NP O
58 655 666 17175308 nephropathy NN I-NP B-Disease
59 667 668 17175308 ( ( O O
60 668 669 17175308 n NN B-NP O
61 670 671 17175308 = SYM B-VP O
62 672 673 17175308 2 CD B-NP O
63 673 674 17175308 ) ) O O
64 674 675 17175308 . . O O

1 676 679 17175308 SRL NN B-NP B-Chemical
2 680 683 17175308 was VBD B-VP O
3 684 691 17175308 started VBN I-VP O
4 692 694 17175308 at IN B-PP O
5 695 696 17175308 a DT B-NP O
6 697 701 17175308 mean NN I-NP O
7 702 704 17175308 of IN B-PP O
8 705 707 17175308 78 CD B-NP O
9 708 709 17175308 + SYM O O
10 709 710 17175308 / SYM O O
11 710 711 17175308 - SYM O O
12 712 714 17175308 42 CD B-NP O
13 715 716 17175308 ( ( O O
14 716 718 17175308 15 CD B-NP O
15 719 721 17175308 to TO O O
16 722 725 17175308 163 CD O O
17 725 726 17175308 ) ) O O
18 727 733 17175308 months NNS B-NP O
19 734 739 17175308 after IN B-PP O
20 740 755 17175308 transplantation NN B-NP O
21 755 756 17175308 . . O O

1 757 761 17175308 Mean JJ B-NP O
2 762 768 17175308 follow VB B-VP O
3 768 769 17175308 - HYPH O O
4 769 771 17175308 up RP B-PRT O
5 772 774 17175308 on IN B-PP O
6 775 778 17175308 SRL NN B-NP B-Chemical
7 779 786 17175308 therapy NN I-NP O
8 787 790 17175308 was VBD B-VP O
9 791 793 17175308 20 CD B-NP O
10 794 795 17175308 + SYM O O
11 795 796 17175308 / SYM O O
12 796 797 17175308 - SYM O O
13 798 800 17175308 12 CD B-NP O
14 801 802 17175308 ( ( O O
15 802 803 17175308 6 CD B-NP O
16 804 806 17175308 to TO O O
17 807 809 17175308 43 CD O O
18 809 810 17175308 ) ) O O
19 811 817 17175308 months NNS B-NP O
20 817 818 17175308 . . O O

1 819 830 17175308 Proteinuria NNP B-NP B-Disease
2 831 840 17175308 increased VBD B-VP O
3 841 845 17175308 from IN B-PP O
4 846 851 17175308 0.445 CD B-NP O
5 852 853 17175308 ( ( O O
6 853 854 17175308 0 CD B-NP O
7 855 857 17175308 to TO O O
8 858 861 17175308 1.5 CD O O
9 861 862 17175308 ) ) O O
10 863 864 17175308 g NN B-NP O
11 864 865 17175308 / SYM B-NP O
12 865 866 17175308 d NN I-NP O
13 867 873 17175308 before IN B-PP O
14 874 884 17175308 conversion NN B-NP O
15 885 887 17175308 to TO B-PP O
16 888 891 17175308 3.2 CD B-NP O
17 892 893 17175308 g NN I-NP O
18 893 894 17175308 / SYM B-NP O
19 894 896 17175308 dL NN B-NP O
20 897 898 17175308 ( ( O O
21 898 901 17175308 0.2 CD B-NP O
22 902 904 17175308 to TO O O
23 905 907 17175308 12 CD B-NP O
24 907 908 17175308 ) ) O O
25 909 914 17175308 after IN B-PP O
26 915 925 17175308 conversion NN B-NP O
27 926 927 17175308 ( ( O O
28 927 928 17175308 P NN B-NP O
29 929 930 17175308 = SYM B-VP O
30 931 936 17175308 0.001 CD B-NP O
31 936 937 17175308 ) ) O O
32 937 938 17175308 . . O O

1 939 945 17175308 Before IN B-PP O
2 946 956 17175308 conversion NN B-NP O
3 957 958 17175308 8 CD I-NP O
4 959 960 17175308 ( ( O O
5 960 963 17175308 32% CD B-NP O
6 963 964 17175308 ) ) O O
7 965 973 17175308 patients NNS B-NP O
8 974 977 17175308 had VBD B-VP O
9 978 980 17175308 no DT B-NP O
10 981 992 17175308 proteinuria NN I-NP B-Disease
11 992 993 17175308 , , O O
12 994 1001 17175308 whereas IN O O
13 1002 1012 17175308 afterwards RB O O
14 1013 1016 17175308 all DT B-NP O
15 1017 1025 17175308 patients NNS I-NP O
16 1026 1029 17175308 had VBD B-VP O
17 1030 1041 17175308 proteinuria NN B-NP B-Disease
18 1041 1042 17175308 . . O O

1 1043 1045 17175308 In IN B-PP O
2 1046 1049 17175308 28% CD B-NP O
3 1050 1052 17175308 of IN B-PP O
4 1053 1061 17175308 patients NNS B-NP O
5 1062 1073 17175308 proteinuria NNS I-NP B-Disease
6 1074 1082 17175308 remained VBD B-VP O
7 1083 1092 17175308 unchanged JJ B-ADJP O
8 1092 1093 17175308 , , O O
9 1094 1101 17175308 whereas IN O O
10 1102 1104 17175308 it PRP B-NP O
11 1105 1114 17175308 increased VBD B-VP O
12 1115 1117 17175308 in IN B-PP O
13 1118 1121 17175308 68% CD B-NP O
14 1122 1124 17175308 of IN B-PP O
15 1125 1133 17175308 patients NNS B-NP O
16 1133 1134 17175308 . . O O

1 1135 1137 17175308 In IN B-PP O
2 1138 1141 17175308 40% CD B-NP O
3 1142 1144 17175308 it PRP B-NP O
4 1145 1154 17175308 increased VBD B-VP O
5 1155 1157 17175308 by IN B-PP O
6 1158 1162 17175308 more JJR B-NP O
7 1163 1167 17175308 than IN I-NP O
8 1168 1172 17175308 100% CD I-NP O
9 1172 1173 17175308 . . O O

1 1174 1180 17175308 Twenty CD B-NP O
2 1180 1181 17175308 - HYPH I-NP O
3 1181 1186 17175308 eight CD I-NP O
4 1187 1194 17175308 percent NN I-NP O
5 1195 1197 17175308 of IN B-PP O
6 1198 1206 17175308 patients NNS B-NP O
7 1207 1213 17175308 showed VBD B-VP O
8 1214 1223 17175308 increased VBN B-NP O
9 1224 1235 17175308 proteinuria NN I-NP B-Disease
10 1236 1238 17175308 to TO B-PP O
11 1239 1242 17175308 the DT B-NP O
12 1243 1252 17175308 nephrotic JJ I-NP B-Disease
13 1253 1258 17175308 range NN I-NP O
14 1258 1259 17175308 . . O O

1 1260 1268 17175308 Biopsies NNS B-NP O
2 1269 1278 17175308 performed VBN B-VP O
3 1279 1281 17175308 in IN B-PP O
4 1282 1286 17175308 five CD B-NP O
5 1287 1295 17175308 patients NNS I-NP O
6 1296 1304 17175308 revealed VBD B-VP O
7 1305 1308 17175308 new JJ B-NP O
8 1309 1321 17175308 pathological JJ I-NP O
9 1322 1329 17175308 changes NNS I-NP O
10 1329 1330 17175308 : : O O
11 1331 1334 17175308 One CD B-NP O
12 1335 1356 17175308 membranoproliferative JJ I-NP B-Disease
13 1357 1371 17175308 glomerulopathy NN I-NP I-Disease
14 1372 1375 17175308 and CC O O
15 1376 1388 17175308 interstitial JJ B-NP B-Disease
16 1389 1398 17175308 nephritis NN I-NP I-Disease
17 1398 1399 17175308 . . O O

1 1400 1405 17175308 These DT B-NP O
2 1406 1414 17175308 patients NNS I-NP O
3 1415 1421 17175308 showed VBD B-VP O
4 1422 1434 17175308 persistently RB B-NP O
5 1435 1439 17175308 good JJ I-NP O
6 1440 1445 17175308 graft NN I-NP O
7 1446 1454 17175308 function NN I-NP O
8 1454 1455 17175308 . . O O

1 1456 1461 17175308 Serum NN B-NP O
2 1462 1472 17175308 creatinine NN I-NP B-Chemical
3 1473 1479 17175308 values NNS I-NP O
4 1480 1483 17175308 did VBD B-VP O
5 1484 1487 17175308 not RB I-VP O
6 1488 1494 17175308 change VB I-VP O
7 1495 1508 17175308 significantly RB B-ADVP O
8 1508 1509 17175308 : : O O
9 1510 1514 17175308 1.98 CD B-NP O
10 1515 1516 17175308 + SYM O O
11 1516 1517 17175308 / SYM O O
12 1517 1518 17175308 - SYM O O
13 1519 1522 17175308 0.8 CD B-NP O
14 1523 1525 17175308 mg NN I-NP O
15 1525 1526 17175308 / SYM B-NP O
16 1526 1528 17175308 dL NN I-NP O
17 1529 1535 17175308 before IN B-PP O
18 1536 1539 17175308 SRL NN B-NP B-Chemical
19 1540 1547 17175308 therapy NN I-NP O
20 1548 1551 17175308 and CC O O
21 1552 1556 17175308 2.53 CD B-NP O
22 1557 1558 17175308 + SYM O O
23 1558 1559 17175308 / SYM O O
24 1559 1560 17175308 - SYM O O
25 1561 1564 17175308 1.9 CD B-NP O
26 1565 1567 17175308 mg NN I-NP O
27 1567 1568 17175308 / SYM B-NP O
28 1568 1570 17175308 dL NN I-NP O
29 1571 1573 17175308 at IN B-PP O
30 1574 1578 17175308 last JJ B-NP O
31 1579 1585 17175308 follow VB I-NP O
32 1585 1586 17175308 - HYPH O O
33 1586 1588 17175308 up RP B-PRT O
34 1589 1590 17175308 ( ( O O
35 1590 1591 17175308 P NN B-NP O
36 1592 1593 17175308 = SYM B-VP O
37 1594 1597 17175308 .14 CD B-NP O
38 1597 1598 17175308 ) ) O O
39 1598 1599 17175308 . . O O

1 1600 1604 17175308 Five CD B-NP O
2 1605 1611 17175308 grafts NNS I-NP O
3 1612 1616 17175308 were VBD B-VP O
4 1617 1621 17175308 lost VBN I-VP O
5 1622 1625 17175308 and CC O O
6 1626 1629 17175308 the DT B-NP O
7 1630 1638 17175308 patients NNS I-NP O
8 1639 1647 17175308 returned VBD B-VP O
9 1648 1650 17175308 to TO B-PP O
10 1651 1659 17175308 dialysis NN B-NP O
11 1659 1660 17175308 . . O O

1 1661 1665 17175308 Five CD B-NP O
2 1666 1674 17175308 patients NNS I-NP O
3 1675 1684 17175308 displayed VBD B-VP O
4 1685 1688 17175308 CAN NN B-NP B-Disease
5 1689 1692 17175308 and CC O O
6 1693 1701 17175308 Kaposi's NNP B-NP B-Disease
7 1702 1709 17175308 sarcoma NN I-NP I-Disease
8 1709 1710 17175308 . . O O

1 1711 1715 17175308 Mean JJ B-NP O
2 1716 1723 17175308 urinary JJ I-NP O
3 1724 1731 17175308 protein NN I-NP O
4 1732 1734 17175308 of IN B-PP O
5 1735 1743 17175308 patients NNS B-NP O
6 1744 1747 17175308 who WP B-NP O
7 1748 1756 17175308 returned VBD B-VP O
8 1757 1759 17175308 to TO B-PP O
9 1760 1768 17175308 dialysis NN B-NP O
10 1769 1772 17175308 was VBD B-VP O
11 1773 1777 17175308 1.26 CD B-NP O
12 1778 1779 17175308 ( ( O O
13 1779 1782 17175308 0.5 CD B-NP O
14 1783 1785 17175308 to TO O O
15 1786 1789 17175308 3.5 CD O O
16 1789 1790 17175308 ) ) O O
17 1791 1792 17175308 g NN B-NP O
18 1792 1793 17175308 / SYM B-VP O
19 1793 1794 17175308 d NN B-NP O
20 1795 1801 17175308 before IN B-PP O
21 1802 1805 17175308 and CC O O
22 1806 1809 17175308 4.7 CD B-NP O
23 1810 1811 17175308 ( ( O O
24 1811 1812 17175308 3 CD B-NP O
25 1813 1815 17175308 to TO O O
26 1816 1818 17175308 12 CD O O
27 1818 1819 17175308 ) ) O O
28 1820 1821 17175308 g NN B-NP O
29 1821 1822 17175308 / SYM B-NP O
30 1822 1823 17175308 d NN I-NP O
31 1824 1829 17175308 after IN B-PP O
32 1830 1840 17175308 conversion NN B-NP O
33 1841 1842 17175308 ( ( O O
34 1842 1843 17175308 P NN B-NP O
35 1844 1845 17175308 = SYM B-VP O
36 1846 1849 17175308 .01 CD B-NP O
37 1849 1850 17175308 ) ) O O
38 1850 1851 17175308 . . O O

1 1852 1856 17175308 Mean JJ B-NP O
2 1857 1862 17175308 serum NN I-NP O
3 1863 1873 17175308 creatinine NN I-NP B-Chemical
4 1874 1879 17175308 level NN I-NP O
5 1880 1886 17175308 before IN B-PP O
6 1887 1897 17175308 conversion NN B-NP O
7 1898 1901 17175308 was VBD B-VP O
8 1902 1906 17175308 2.21 CD B-NP O
9 1907 1909 17175308 mg NN I-NP O
10 1909 1910 17175308 / SYM B-NP O
11 1910 1912 17175308 dL NN I-NP O
12 1913 1916 17175308 and CC O O
13 1917 1927 17175308 thereafter RB B-ADVP O
14 1927 1928 17175308 , , O O
15 1929 1933 17175308 4.93 CD B-NP O
16 1934 1936 17175308 mg NN I-NP O
17 1936 1937 17175308 / SYM B-NP O
18 1937 1939 17175308 dL NN B-NP O
19 1940 1941 17175308 ( ( O O
20 1941 1942 17175308 P NN B-NP O
21 1943 1944 17175308 = SYM B-VP O
22 1945 1948 17175308 .02 CD B-NP O
23 1948 1949 17175308 ) ) O O
24 1949 1950 17175308 . . O O

1 1951 1956 17175308 Heavy JJ B-NP O
2 1957 1968 17175308 proteinuria NN I-NP B-Disease
3 1969 1972 17175308 was VBD B-VP O
4 1973 1979 17175308 common JJ B-ADJP O
5 1980 1985 17175308 after IN B-SBAR O
6 1986 1989 17175308 the DT B-NP O
7 1990 1993 17175308 use NN I-NP O
8 1994 1996 17175308 of IN B-PP O
9 1997 2000 17175308 SRL NN B-NP B-Chemical
10 2001 2003 17175308 as IN B-PP O
11 2004 2010 17175308 rescue NN B-NP O
12 2011 2018 17175308 therapy NN I-NP O
13 2019 2022 17175308 for IN B-PP O
14 2023 2028 17175308 renal JJ B-NP O
15 2029 2044 17175308 transplantation NN I-NP O
16 2044 2045 17175308 . . O O

1 2046 2055 17175308 Therefore RB B-ADVP O
2 2055 2056 17175308 , , O O
3 2057 2067 17175308 conversion NN B-NP O
4 2068 2074 17175308 should MD B-VP O
5 2075 2077 17175308 be VB I-VP O
6 2078 2088 17175308 considered VBN I-VP O
7 2089 2092 17175308 for IN B-PP O
8 2093 2101 17175308 patients NNS B-NP O
9 2102 2105 17175308 who WP B-NP O
10 2106 2110 17175308 have VBP B-VP O
11 2111 2114 17175308 not RB I-VP O
12 2115 2124 17175308 developed VBN I-VP O
13 2125 2133 17175308 advanced JJ B-NP O
14 2134 2137 17175308 CAN NN I-NP B-Disease
15 2138 2141 17175308 and CC I-NP O
16 2142 2153 17175308 proteinuria NN I-NP B-Disease
17 2153 2154 17175308 . . O O

1 2155 2158 17175308 The DT B-NP O
2 2159 2170 17175308 possibility NN I-NP O
3 2171 2173 17175308 of IN B-PP O
4 2174 2176 17175308 de FW B-NP O
5 2177 2181 17175308 novo FW I-NP O
6 2182 2192 17175308 glomerular JJ I-NP O
7 2193 2202 17175308 pathology NN I-NP O
8 2203 2208 17175308 under IN B-PP O
9 2209 2212 17175308 SRL NN B-NP B-Chemical
10 2213 2222 17175308 treatment NN I-NP O
11 2223 2231 17175308 requires VBZ B-VP O
12 2232 2239 17175308 further JJR B-NP O
13 2240 2253 17175308 investigation NN I-NP O
14 2254 2256 17175308 by IN B-PP O
15 2257 2262 17175308 renal JJ B-NP O
16 2263 2269 17175308 biopsy NN I-NP O
17 2269 2270 17175308 . . O O

1 0 0 15515654 -DOCSTART- -X- -X- O

1 0 4 15515654 Long JJ B-NP O
2 5 9 15515654 term NN I-NP O
3 10 22 15515654 audiological JJ I-NP O
4 23 33 15515654 evaluation NN I-NP O
5 34 36 15515654 of IN B-PP O
6 37 41 15515654 beta SYM B-NP B-Disease
7 41 42 15515654 - HYPH O I-Disease
8 42 53 15515654 thalassemic JJ B-NP I-Disease
9 54 62 15515654 patients NNS I-NP O
10 62 63 15515654 . . O O
11 64 73 15515654 OBJECTIVE NN B-NP O
12 73 74 15515654 : : O O
13 75 78 15515654 The DT B-NP O
14 79 88 15515654 objective NN I-NP O
15 89 91 15515654 of IN B-PP O
16 92 96 15515654 this DT B-NP O
17 97 102 15515654 study NN I-NP O
18 103 106 15515654 was VBD B-VP O
19 107 109 15515654 to TO B-VP O
20 110 118 15515654 identify VB I-VP O
21 119 122 15515654 the DT B-NP O
22 123 132 15515654 incidence NN I-NP O
23 133 136 15515654 and CC O O
24 137 139 15515654 to TO B-VP O
25 140 147 15515654 monitor VB I-VP O
26 148 151 15515654 the DT B-NP O
27 152 163 15515654 progression NN I-NP O
28 164 166 15515654 of IN B-PP O
29 167 174 15515654 hearing NN B-NP B-Disease
30 175 179 15515654 loss NN I-NP I-Disease
31 180 182 15515654 in IN B-PP O
32 183 191 15515654 children NNS B-NP O
33 192 195 15515654 and CC O O
34 196 201 15515654 young JJ B-NP O
35 202 208 15515654 adults NNS I-NP O
36 209 213 15515654 with IN B-PP O
37 214 218 15515654 beta SYM B-NP B-Disease
38 218 219 15515654 - HYPH I-NP I-Disease
39 219 230 15515654 thalassemia NN I-NP I-Disease
40 231 236 15515654 major NN I-NP O
41 236 237 15515654 . . O O

1 238 245 15515654 METHODS NNS B-NP O
2 245 246 15515654 : : O O
3 247 250 15515654 One CD B-NP O
4 251 258 15515654 hundred CD I-NP O
5 259 262 15515654 and CC I-NP O
6 263 267 15515654 four CD I-NP O
7 268 269 15515654 ( ( O O
8 269 272 15515654 104 CD B-NP O
9 272 273 15515654 ) ) O O
10 274 282 15515654 patients NNS B-NP O
11 283 287 15515654 aged VBN B-ADJP O
12 288 289 15515654 6 CD B-NP O
13 289 290 15515654 - HYPH I-NP O
14 290 292 15515654 35 CD I-NP O
15 293 298 15515654 years NNS I-NP O
16 299 300 15515654 ( ( O O
17 300 304 15515654 mean NN B-NP O
18 305 309 15515654 17,2 CD B-NP O
19 310 315 15515654 years NNS I-NP O
20 315 316 15515654 ) ) O O
21 317 329 15515654 participated VBN B-VP O
22 330 332 15515654 in IN B-PP O
23 333 336 15515654 the DT B-NP O
24 337 342 15515654 study NN I-NP O
25 342 343 15515654 . . O O

1 344 347 15515654 All DT B-NP O
2 348 356 15515654 patients NNS I-NP O
3 357 361 15515654 were VBD B-VP O
4 362 364 15515654 on IN B-PP O
5 365 366 15515654 a DT B-NP O
6 367 374 15515654 regular JJ I-NP O
7 375 386 15515654 transfusion NN I-NP O
8 386 387 15515654 - HYPH B-NP O
9 387 396 15515654 chelation NN I-NP O
10 397 404 15515654 program NN I-NP O
11 405 416 15515654 maintaining VBG B-VP O
12 417 418 15515654 a DT B-NP O
13 419 423 15515654 mean JJ I-NP O
14 424 434 15515654 hemoglobin NN I-NP O
15 435 440 15515654 level NN I-NP O
16 441 443 15515654 of IN B-PP O
17 444 447 15515654 9.5 CD B-NP O
18 448 450 15515654 gr NN I-NP O
19 450 451 15515654 / SYM B-NP O
20 451 453 15515654 dl NN I-NP O
21 453 454 15515654 . . O O

1 455 463 15515654 Subjects NNS B-NP O
2 464 468 15515654 were VBD B-VP O
3 469 478 15515654 receiving VBG I-VP O
4 479 494 15515654 desferrioxamine NN B-NP B-Chemical
5 495 496 15515654 ( ( O O
6 496 499 15515654 DFO NN B-NP B-Chemical
7 499 500 15515654 ) ) O O
8 501 510 15515654 chelation NN B-NP O
9 511 520 15515654 treatment NN I-NP O
10 521 525 15515654 with IN B-PP O
11 526 527 15515654 a DT B-NP O
12 528 532 15515654 mean JJ I-NP O
13 533 538 15515654 daily JJ I-NP O
14 539 543 15515654 dose NN I-NP O
15 544 546 15515654 of IN B-PP O
16 547 549 15515654 50 CD B-NP O
17 549 550 15515654 - HYPH I-NP O
18 550 552 15515654 60 CD I-NP O
19 553 555 15515654 mg NN I-NP O
20 555 556 15515654 / SYM B-NP O
21 556 558 15515654 kg NN I-NP O
22 558 559 15515654 , , O O
23 560 561 15515654 5 CD B-NP O
24 561 562 15515654 - HYPH I-NP O
25 562 563 15515654 6 CD I-NP O
26 564 568 15515654 days NNS I-NP O
27 569 570 15515654 a DT B-NP O
28 571 575 15515654 week NN I-NP O
29 576 582 15515654 during IN B-PP O
30 583 586 15515654 the DT B-NP O
31 587 592 15515654 first JJ I-NP O
32 593 596 15515654 six CD I-NP O
33 597 602 15515654 years NNS I-NP O
34 603 605 15515654 of IN B-PP O
35 606 609 15515654 the DT B-NP O
36 610 615 15515654 study NN I-NP O
37 615 616 15515654 , , O O
38 617 622 15515654 which WDT B-NP O
39 623 626 15515654 was VBD B-VP O
40 627 631 15515654 then RB I-VP O
41 632 639 15515654 reduced VBN I-VP O
42 640 642 15515654 to TO B-PP O
43 643 645 15515654 40 CD B-NP O
44 645 646 15515654 - HYPH I-NP O
45 646 648 15515654 50 CD I-NP O
46 649 651 15515654 mg NN I-NP O
47 651 652 15515654 / SYM B-NP O
48 652 654 15515654 kg NN I-NP O
49 655 658 15515654 for IN B-PP O
50 659 662 15515654 the DT B-NP O
51 663 672 15515654 following VBG I-NP O
52 673 678 15515654 eight CD I-NP O
53 679 684 15515654 years NNS I-NP O
54 684 685 15515654 . . O O

1 686 694 15515654 Patients NNS B-NP O
2 695 699 15515654 were VBD B-VP O
3 700 708 15515654 followed VBN I-VP O
4 709 712 15515654 for IN B-PP O
5 713 714 15515654 8 CD B-NP O
6 714 715 15515654 - HYPH I-NP O
7 715 717 15515654 14 CD I-NP O
8 718 723 15515654 years NNS I-NP O
9 723 724 15515654 . . O O

1 725 732 15515654 RESULTS NNS B-NP O
2 732 733 15515654 : : O O
3 734 741 15515654 Overall JJ B-ADVP O
4 741 742 15515654 , , O O
5 743 745 15515654 21 CD B-NP O
6 746 749 15515654 out IN B-PP O
7 750 752 15515654 of IN B-PP O
8 753 756 15515654 104 CD B-NP O
9 757 765 15515654 patients NNS I-NP O
10 766 767 15515654 ( ( O O
11 767 772 15515654 20.2% NN B-NP O
12 772 773 15515654 ) ) O O
13 774 783 15515654 presented VBD B-VP O
14 784 788 15515654 with IN B-PP O
15 789 793 15515654 high JJ B-NP O
16 794 803 15515654 frequency NN I-NP O
17 804 817 15515654 sensorineural JJ I-NP B-Disease
18 818 825 15515654 hearing NN I-NP I-Disease
19 826 830 15515654 loss NN I-NP I-Disease
20 831 832 15515654 ( ( O O
21 832 836 15515654 SNHL NN B-NP B-Disease
22 836 837 15515654 ) ) O O
23 837 838 15515654 , , O O
24 839 845 15515654 either CC O O
25 846 856 15515654 unilateral JJ B-ADJP O
26 857 859 15515654 or CC I-ADJP O
27 860 869 15515654 bilateral JJ I-ADJP O
28 869 870 15515654 . . O O

1 871 873 15515654 No DT B-NP O
2 874 882 15515654 ototoxic JJ I-NP B-Disease
3 883 889 15515654 factor NN I-NP O
4 889 890 15515654 , , O O
5 891 896 15515654 other JJ B-ADJP O
6 897 901 15515654 than IN B-PP O
7 902 905 15515654 DFO NNP B-NP B-Chemical
8 905 906 15515654 , , O O
9 907 910 15515654 was VBD B-VP O
10 911 918 15515654 present JJ B-ADJP O
11 919 921 15515654 in IN B-PP O
12 922 925 15515654 any DT B-NP O
13 926 928 15515654 of IN B-PP O
14 929 932 15515654 the DT B-NP O
15 933 941 15515654 patients NNS I-NP O
16 941 942 15515654 . . O O

1 943 951 15515654 Patients NNS B-NP O
2 952 956 15515654 with IN B-PP O
3 957 961 15515654 SNHL NN B-NP B-Disease
4 962 971 15515654 presented VBD B-VP O
5 972 976 15515654 with IN B-PP O
6 977 987 15515654 relatively RB B-NP O
7 988 993 15515654 lower JJR I-NP O
8 994 999 15515654 serum NN I-NP O
9 1000 1008 15515654 ferritin NN I-NP O
10 1009 1015 15515654 levels NNS I-NP O
11 1016 1020 15515654 than IN B-PP O
12 1021 1026 15515654 those DT B-NP O
13 1027 1031 15515654 with IN B-PP O
14 1032 1038 15515654 normal JJ B-NP O
15 1039 1046 15515654 hearing NN I-NP O
16 1046 1047 15515654 , , O O
17 1048 1055 15515654 however RB B-ADVP O
18 1055 1056 15515654 , , O O
19 1057 1059 15515654 no DT B-NP O
20 1060 1073 15515654 statistically RB I-NP O
21 1074 1085 15515654 significant JJ I-NP O
22 1086 1096 15515654 difference NN I-NP O
23 1097 1100 15515654 was VBD B-VP O
24 1101 1109 15515654 observed VBN I-VP O
25 1109 1110 15515654 . . O O

1 1111 1119 15515654 Subjects NNS B-NP O
2 1120 1124 15515654 with IN B-PP O
3 1125 1129 15515654 SNHL NN B-NP B-Disease
4 1130 1134 15515654 were VBD B-VP O
5 1135 1144 15515654 submitted VBN I-VP O
6 1145 1147 15515654 to TO B-PP O
7 1148 1151 15515654 DFO NN B-NP B-Chemical
8 1152 1161 15515654 reduction NN I-NP O
9 1162 1164 15515654 or CC O O
10 1165 1174 15515654 temporary JJ B-NP O
11 1175 1185 15515654 withdrawal NN I-NP O
12 1185 1186 15515654 . . O O

1 1187 1196 15515654 Following VBG B-PP O
2 1197 1209 15515654 intervention NN B-NP O
3 1209 1210 15515654 , , O O
4 1211 1212 15515654 7 CD B-NP O
5 1213 1216 15515654 out IN B-PP O
6 1217 1219 15515654 of IN B-PP O
7 1220 1222 15515654 21 CD B-NP O
8 1223 1231 15515654 affected JJ I-NP O
9 1232 1240 15515654 patients NNS I-NP O
10 1241 1250 15515654 recovered VBD B-VP O
11 1250 1251 15515654 , , O O
12 1252 1254 15515654 10 CD B-NP O
13 1255 1263 15515654 remained VBD B-VP O
14 1264 1270 15515654 stable JJ B-ADJP O
15 1271 1274 15515654 and CC O O
16 1275 1276 15515654 4 CD B-NP O
17 1277 1289 15515654 demonstrated VBD B-VP O
18 1290 1301 15515654 aggravation NN B-NP O
19 1301 1302 15515654 . . O O

1 1303 1313 15515654 CONCLUSION NN B-NP O
2 1313 1314 15515654 : : O O
3 1315 1318 15515654 The DT B-NP O
4 1319 1327 15515654 findings NNS I-NP O
5 1328 1331 15515654 are VBP B-VP O
6 1332 1342 15515654 indicative JJ B-ADJP O
7 1343 1345 15515654 of IN B-PP O
8 1346 1351 15515654 DFO's NNS B-NP B-Chemical
9 1352 1364 15515654 contributing VBG B-VP O
10 1365 1369 15515654 role NN B-NP O
11 1370 1372 15515654 in IN B-PP O
12 1373 1376 15515654 the DT B-NP O
13 1377 1388 15515654 development NN I-NP O
14 1389 1391 15515654 of IN B-PP O
15 1392 1399 15515654 hearing VBG B-VP B-Disease
16 1400 1410 15515654 impairment NN B-NP I-Disease
17 1410 1411 15515654 . . O O

1 1412 1419 15515654 Regular JJ B-NP O
2 1420 1430 15515654 audiologic JJ I-NP O
3 1431 1441 15515654 evaluation NN I-NP O
4 1442 1444 15515654 is VBZ B-VP O
5 1445 1455 15515654 imperative JJ B-ADJP O
6 1456 1458 15515654 in IN B-PP O
7 1459 1462 15515654 all DT B-NP O
8 1463 1474 15515654 thalassemic JJ I-NP B-Disease
9 1475 1483 15515654 patients NNS I-NP O
10 1484 1486 15515654 so IN B-SBAR O
11 1487 1491 15515654 that IN I-SBAR O
12 1492 1497 15515654 early JJ B-NP O
13 1498 1505 15515654 changes NNS I-NP O
14 1506 1509 15515654 may MD B-VP O
15 1510 1512 15515654 be VB I-VP O
16 1513 1523 15515654 recognized VBN I-VP O
17 1524 1527 15515654 and CC O O
18 1528 1537 15515654 treatment NN B-NP O
19 1538 1541 15515654 may MD B-VP O
20 1542 1544 15515654 be VB I-VP O
21 1545 1556 15515654 judiciously RB I-VP O
22 1557 1565 15515654 adjusted VBN I-VP O
23 1566 1568 15515654 in IN B-SBAR O
24 1569 1574 15515654 order NN O O
25 1575 1577 15515654 to TO B-VP O
26 1578 1585 15515654 prevent VB I-VP O
27 1586 1588 15515654 or CC I-VP O
28 1589 1596 15515654 reverse VB I-VP O
29 1597 1604 15515654 hearing VBG B-NP B-Disease
30 1605 1615 15515654 impairment NN I-NP I-Disease
31 1615 1616 15515654 . . O O

1 0 0 14596845 -DOCSTART- -X- -X- O

1 0 1 14596845 A DT B-NP O
2 2 6 14596845 diet NN I-NP O
3 7 16 14596845 promoting VBG B-VP O
4 17 22 14596845 sugar NN B-NP B-Disease
5 23 33 14596845 dependency NN I-NP I-Disease
6 34 40 14596845 causes VBZ B-VP O
7 41 51 14596845 behavioral JJ B-NP B-Disease
8 52 57 14596845 cross AFX I-NP I-Disease
9 57 58 14596845 - HYPH I-NP I-Disease
10 58 71 14596845 sensitization NN I-NP I-Disease
11 72 74 14596845 to TO B-PP O
12 75 76 14596845 a DT B-NP O
13 77 80 14596845 low JJ I-NP O
14 81 85 14596845 dose NN I-NP O
15 86 88 14596845 of IN B-PP O
16 89 100 14596845 amphetamine NN B-NP B-Chemical
17 100 101 14596845 . . O O
18 102 110 14596845 Previous JJ B-NP O
19 111 119 14596845 research NN I-NP O
20 120 122 14596845 in IN B-PP O
21 123 127 14596845 this DT B-NP O
22 128 138 14596845 laboratory NN I-NP O
23 139 142 14596845 has VBZ B-VP O
24 143 148 14596845 shown VBN I-VP O
25 149 153 14596845 that IN B-SBAR O
26 154 155 14596845 a DT B-NP O
27 156 160 14596845 diet NN I-NP O
28 161 163 14596845 of IN B-PP O
29 164 176 14596845 intermittent JJ B-NP O
30 177 186 14596845 excessive JJ I-NP O
31 187 192 14596845 sugar NN I-NP O
32 193 204 14596845 consumption NN I-NP O
33 205 213 14596845 produces VBZ B-VP O
34 214 215 14596845 a DT B-NP O
35 216 221 14596845 state NN I-NP O
36 222 226 14596845 with IN B-PP O
37 227 240 14596845 neurochemical JJ B-NP O
38 241 244 14596845 and CC I-NP O
39 245 255 14596845 behavioral JJ I-NP O
40 256 268 14596845 similarities NNS I-NP O
41 269 271 14596845 to TO B-PP O
42 272 276 14596845 drug NN B-NP B-Disease
43 277 287 14596845 dependency NN I-NP I-Disease
44 287 288 14596845 . . O O

1 289 292 14596845 The DT B-NP O
2 293 300 14596845 present JJ I-NP O
3 301 306 14596845 study NN I-NP O
4 307 315 14596845 examined VBD B-VP O
5 316 323 14596845 whether IN B-SBAR O
6 324 330 14596845 female JJ B-NP O
7 331 335 14596845 rats NNS I-NP O
8 336 338 14596845 on IN B-PP O
9 339 346 14596845 various JJ B-NP O
10 347 355 14596845 regimens NNS I-NP O
11 356 358 14596845 of IN B-PP O
12 359 364 14596845 sugar NN B-NP O
13 365 371 14596845 access NN I-NP O
14 372 377 14596845 would MD B-VP O
15 378 382 14596845 show VB I-VP O
16 383 393 14596845 behavioral JJ B-ADJP B-Disease
17 394 399 14596845 cross AFX B-NP I-Disease
18 399 400 14596845 - HYPH I-NP I-Disease
19 400 413 14596845 sensitization NN I-NP I-Disease
20 414 416 14596845 to TO B-PP O
21 417 418 14596845 a DT B-NP O
22 419 422 14596845 low JJ I-NP O
23 423 427 14596845 dose NN I-NP O
24 428 430 14596845 of IN B-PP O
25 431 442 14596845 amphetamine NN B-NP B-Chemical
26 442 443 14596845 . . O O

1 444 449 14596845 After IN B-PP O
2 450 451 14596845 a DT B-NP O
3 452 454 14596845 30 CD I-NP O
4 454 455 14596845 - HYPH I-NP O
5 455 458 14596845 min NN I-NP O
6 459 467 14596845 baseline NN I-NP O
7 468 475 14596845 measure NN I-NP O
8 476 478 14596845 of IN B-PP O
9 479 488 14596845 locomotor NN B-NP O
10 489 497 14596845 activity NN I-NP O
11 498 499 14596845 ( ( O O
12 499 502 14596845 day NN B-NP O
13 503 504 14596845 0 CD I-NP O
14 504 505 14596845 ) ) O O
15 505 506 14596845 , , O O
16 507 514 14596845 animals NNS B-NP O
17 515 519 14596845 were VBD B-VP O
18 520 530 14596845 maintained VBN I-VP O
19 531 533 14596845 on IN B-PP O
20 534 535 14596845 a DT B-NP O
21 536 542 14596845 cyclic JJ I-NP O
22 543 547 14596845 diet NN I-NP O
23 548 550 14596845 of IN B-PP O
24 551 553 14596845 12 CD B-NP O
25 553 554 14596845 - HYPH I-NP O
26 554 555 14596845 h NN I-NP O
27 556 567 14596845 deprivation NN I-NP O
28 568 576 14596845 followed VBN B-VP O
29 577 579 14596845 by IN B-PP O
30 580 582 14596845 12 CD B-NP O
31 582 583 14596845 - HYPH I-NP O
32 583 584 14596845 h NN I-NP O
33 585 591 14596845 access NN I-NP O
34 592 594 14596845 to TO B-PP O
35 595 598 14596845 10% CD B-NP O
36 599 606 14596845 sucrose NN I-NP B-Chemical
37 607 615 14596845 solution NN I-NP O
38 616 619 14596845 and CC I-NP O
39 620 624 14596845 chow NN I-NP O
40 625 632 14596845 pellets NNS I-NP O
41 633 634 14596845 ( ( O O
42 634 636 14596845 12 CD B-NP O
43 637 638 14596845 h NN I-NP O
44 639 645 14596845 access NN I-NP O
45 646 654 14596845 starting VBG B-VP O
46 655 656 14596845 4 CD B-NP O
47 657 658 14596845 h NN I-NP O
48 659 664 14596845 after IN B-PP O
49 665 670 14596845 onset NN B-NP O
50 671 673 14596845 of IN B-PP O
51 674 677 14596845 the DT B-NP O
52 678 682 14596845 dark JJ I-NP O
53 683 689 14596845 period NN I-NP O
54 689 690 14596845 ) ) O O
55 691 694 14596845 for IN B-PP O
56 695 697 14596845 21 CD B-NP O
57 698 702 14596845 days NNS I-NP O
58 702 703 14596845 . . O O

1 704 713 14596845 Locomotor NN B-NP O
2 714 722 14596845 activity NN I-NP O
3 723 726 14596845 was VBD B-VP O
4 727 735 14596845 measured VBN I-VP O
5 736 741 14596845 again RB B-ADVP O
6 742 745 14596845 for IN B-PP O
7 746 748 14596845 30 CD B-NP O
8 749 752 14596845 min NN I-NP O
9 753 755 14596845 at IN B-PP O
10 756 759 14596845 the DT B-NP O
11 760 769 14596845 beginning NN I-NP O
12 770 772 14596845 of IN B-PP O
13 773 777 14596845 days NNS B-NP O
14 778 779 14596845 1 CD I-NP O
15 780 783 14596845 and CC I-NP O
16 784 786 14596845 21 CD I-NP O
17 787 789 14596845 of IN B-PP O
18 790 795 14596845 sugar NN B-NP O
19 796 802 14596845 access NN I-NP O
20 802 803 14596845 . . O O

1 804 813 14596845 Beginning VBG B-VP O
2 814 816 14596845 on IN B-PP O
3 817 820 14596845 day NN B-NP O
4 821 823 14596845 22 CD I-NP O
5 823 824 14596845 , , O O
6 825 828 14596845 all DT B-NP O
7 829 833 14596845 rats NNS I-NP O
8 834 838 14596845 were VBD B-VP O
9 839 849 14596845 maintained VBN I-VP O
10 850 852 14596845 on IN B-PP O
11 853 855 14596845 ad NN B-NP O
12 856 863 14596845 libitum NN I-NP O
13 864 868 14596845 chow NN I-NP O
14 868 869 14596845 . . O O

1 870 874 14596845 Nine CD B-NP O
2 875 879 14596845 days NNS I-NP O
3 880 885 14596845 later RB B-NP O
4 886 895 14596845 locomotor NN I-NP O
5 896 904 14596845 activity NN I-NP O
6 905 908 14596845 was VBD B-VP O
7 909 917 14596845 measured VBN I-VP O
8 918 920 14596845 in IN B-PP O
9 921 929 14596845 response NN B-NP O
10 930 932 14596845 to TO B-PP O
11 933 934 14596845 a DT B-NP O
12 935 941 14596845 single JJ I-NP O
13 942 945 14596845 low JJ I-NP O
14 946 950 14596845 dose NN I-NP O
15 951 953 14596845 of IN B-PP O
16 954 965 14596845 amphetamine NN B-NP B-Chemical
17 966 967 14596845 ( ( O O
18 967 970 14596845 0.5 CD B-NP O
19 971 973 14596845 mg NN I-NP O
20 973 974 14596845 / SYM B-NP O
21 974 976 14596845 kg NN I-NP O
22 976 977 14596845 ) ) O O
23 977 978 14596845 . . O O

1 979 982 14596845 The DT B-NP O
2 983 990 14596845 animals NNS I-NP O
3 991 995 14596845 that WDT B-NP O
4 996 999 14596845 had VBD B-VP O
5 1000 1011 14596845 experienced VBN I-VP O
6 1012 1018 14596845 cyclic JJ B-NP O
7 1019 1026 14596845 sucrose NN I-NP B-Chemical
8 1027 1030 14596845 and CC I-NP O
9 1031 1035 14596845 chow NN I-NP O
10 1036 1040 14596845 were VBD B-VP O
11 1041 1052 14596845 hyperactive JJ B-ADJP B-Disease
12 1053 1055 14596845 in IN B-PP O
13 1056 1064 14596845 response NN B-NP O
14 1065 1067 14596845 to TO B-PP O
15 1068 1079 14596845 amphetamine NN B-NP B-Chemical
16 1080 1088 14596845 compared VBN B-PP O
17 1089 1093 14596845 with IN B-PP O
18 1094 1098 14596845 four CD B-NP O
19 1099 1106 14596845 control NN I-NP O
20 1107 1113 14596845 groups NNS I-NP O
21 1114 1115 14596845 ( ( O O
22 1115 1117 14596845 ad NN B-NP O
23 1118 1125 14596845 libitum NN I-NP O
24 1126 1129 14596845 10% CD B-NP O
25 1130 1137 14596845 sucrose NN I-NP B-Chemical
26 1138 1141 14596845 and CC I-NP O
27 1142 1146 14596845 chow NN I-NP O
28 1147 1155 14596845 followed VBN B-VP O
29 1156 1158 14596845 by IN B-PP O
30 1159 1170 14596845 amphetamine NN B-NP B-Chemical
31 1171 1180 14596845 injection NN I-NP O
32 1180 1181 14596845 , , O O
33 1182 1188 14596845 cyclic JJ B-NP O
34 1189 1193 14596845 chow NN I-NP O
35 1194 1202 14596845 followed VBN B-VP O
36 1203 1205 14596845 by IN B-PP O
37 1206 1217 14596845 amphetamine NN B-NP B-Chemical
38 1218 1227 14596845 injection NN I-NP O
39 1227 1228 14596845 , , O O
40 1229 1231 14596845 ad NN B-NP O
41 1232 1239 14596845 libitum NN I-NP O
42 1240 1244 14596845 chow NN I-NP O
43 1245 1249 14596845 with IN B-PP O
44 1250 1261 14596845 amphetamine NN B-NP B-Chemical
45 1261 1262 14596845 , , O O
46 1263 1265 14596845 or CC O O
47 1266 1272 14596845 cyclic JJ B-NP O
48 1273 1276 14596845 10% CD I-NP O
49 1277 1284 14596845 sucrose NN I-NP B-Chemical
50 1285 1288 14596845 and CC I-NP O
51 1289 1293 14596845 chow NN I-NP O
52 1294 1298 14596845 with IN B-PP O
53 1299 1300 14596845 a DT B-NP O
54 1301 1307 14596845 saline NN I-NP O
55 1308 1317 14596845 injection NN I-NP O
56 1317 1318 14596845 ) ) O O
57 1318 1319 14596845 . . O O

1 1320 1325 14596845 These DT B-NP O
2 1326 1333 14596845 results NNS I-NP O
3 1334 1341 14596845 suggest VBP B-VP O
4 1342 1346 14596845 that IN B-SBAR O
5 1347 1348 14596845 a DT B-NP O
6 1349 1353 14596845 diet NN I-NP O
7 1354 1363 14596845 comprised VBN B-VP O
8 1364 1366 14596845 of IN B-PP O
9 1367 1378 14596845 alternating VBG B-VP O
10 1379 1390 14596845 deprivation NN B-NP O
11 1391 1394 14596845 and CC I-NP O
12 1395 1401 14596845 access NN I-NP O
13 1402 1404 14596845 to TO B-PP O
14 1405 1406 14596845 a DT B-NP O
15 1407 1412 14596845 sugar NN I-NP O
16 1413 1421 14596845 solution NN I-NP O
17 1422 1425 14596845 and CC I-NP O
18 1426 1430 14596845 chow NN I-NP O
19 1431 1439 14596845 produces VBZ B-VP O
20 1440 1448 14596845 bingeing VBG I-VP O
21 1449 1451 14596845 on IN B-PP O
22 1452 1457 14596845 sugar NN B-NP O
23 1458 1462 14596845 that WDT B-NP O
24 1463 1468 14596845 leads VBZ B-VP O
25 1469 1471 14596845 to TO B-PP O
26 1472 1473 14596845 a DT B-NP O
27 1474 1478 14596845 long JJ I-NP O
28 1479 1486 14596845 lasting JJ I-NP O
29 1487 1492 14596845 state NN I-NP O
30 1493 1495 14596845 of IN B-PP O
31 1496 1505 14596845 increased VBN B-NP O
32 1506 1517 14596845 sensitivity NN I-NP O
33 1518 1520 14596845 to TO B-PP O
34 1521 1532 14596845 amphetamine NN B-NP B-Chemical
35 1532 1533 14596845 , , O O
36 1534 1542 14596845 possibly RB B-ADVP O
37 1543 1546 14596845 due JJ B-PP O
38 1547 1549 14596845 to TO B-PP O
39 1550 1551 14596845 a DT B-NP O
40 1552 1559 14596845 lasting JJ I-NP O
41 1560 1570 14596845 alteration NN I-NP O
42 1571 1573 14596845 in IN B-PP O
43 1574 1577 14596845 the DT B-NP O
44 1578 1586 14596845 dopamine NN I-NP B-Chemical
45 1587 1593 14596845 system NN I-NP O
46 1593 1594 14596845 . . O O

1 0 0 20528871 -DOCSTART- -X- -X- O

1 0 7 20528871 Salvage NN B-NP O
2 8 15 20528871 therapy NN I-NP O
3 16 20 20528871 with IN B-PP O
4 21 31 20528871 nelarabine NN B-NP B-Chemical
5 31 32 20528871 , , O O
6 33 42 20528871 etoposide NN B-NP B-Chemical
7 42 43 20528871 , , O O
8 44 47 20528871 and CC O O
9 48 64 20528871 cyclophosphamide NN B-NP B-Chemical
10 65 67 20528871 in IN B-PP O
11 68 76 20528871 relapsed VBN B-NP O
12 76 77 20528871 / SYM I-NP O
13 77 87 20528871 refractory JJ I-NP O
14 88 98 20528871 paediatric JJ I-NP O
15 99 100 20528871 T NN I-NP B-Disease
16 100 101 20528871 - HYPH I-NP I-Disease
17 101 105 20528871 cell NN I-NP I-Disease
18 106 119 20528871 lymphoblastic JJ I-NP I-Disease
19 120 129 20528871 leukaemia NN I-NP I-Disease
20 130 133 20528871 and CC I-NP I-Disease
21 134 142 20528871 lymphoma NN I-NP I-Disease
22 142 143 20528871 . . I-NP O
23 144 145 20528871 A NN I-NP O
24 146 157 20528871 combination NN I-NP O
25 158 160 20528871 of IN B-PP O
26 161 162 20528871 5 CD B-NP O
27 163 164 20528871 d NN I-NP O
28 165 167 20528871 of IN B-PP O
29 168 178 20528871 nelarabine NN B-NP B-Chemical
30 179 180 20528871 ( ( O O
31 180 184 20528871 AraG NN B-NP B-Chemical
32 184 185 20528871 ) ) O O
33 186 190 20528871 with IN B-PP O
34 191 192 20528871 5 CD B-NP O
35 193 194 20528871 d NN I-NP O
36 195 197 20528871 of IN B-PP O
37 198 207 20528871 etoposide NN B-NP B-Chemical
38 208 209 20528871 ( ( O O
39 209 211 20528871 VP NN B-NP B-Chemical
40 211 212 20528871 ) ) O O
41 213 216 20528871 and CC O O
42 217 233 20528871 cyclophosphamide NN B-NP B-Chemical
43 234 235 20528871 ( ( O O
44 235 238 20528871 CPM NN B-NP B-Chemical
45 238 239 20528871 ) ) O O
46 240 243 20528871 and CC O O
47 244 256 20528871 prophylactic JJ B-NP O
48 257 268 20528871 intrathecal JJ I-NP O
49 269 281 20528871 chemotherapy NN I-NP O
50 282 285 20528871 was VBD B-VP O
51 286 290 20528871 used VBN I-VP O
52 291 293 20528871 as IN B-PP O
53 294 301 20528871 salvage NN B-NP O
54 302 309 20528871 therapy NN I-NP O
55 310 312 20528871 in IN B-PP O
56 313 318 20528871 seven CD B-NP O
57 319 327 20528871 children NNS I-NP O
58 328 332 20528871 with IN B-PP O
59 333 343 20528871 refractory JJ B-NP O
60 344 346 20528871 or CC I-NP O
61 347 355 20528871 relapsed VBN I-NP O
62 356 357 20528871 T NN I-NP B-Disease
63 357 358 20528871 - HYPH I-NP I-Disease
64 358 362 20528871 cell NN I-NP I-Disease
65 363 372 20528871 leukaemia NN I-NP I-Disease
66 373 375 20528871 or CC I-NP I-Disease
67 376 384 20528871 lymphoma NN I-NP I-Disease
68 384 385 20528871 . . O O

1 386 389 20528871 The DT B-NP O
2 390 394 20528871 most RBS I-NP O
3 395 401 20528871 common JJ I-NP O
4 402 406 20528871 side NN I-NP O
5 407 414 20528871 effects NNS I-NP O
6 415 427 20528871 attributable JJ B-ADJP O
7 428 430 20528871 to TO B-PP O
8 431 434 20528871 the DT B-NP O
9 435 439 20528871 AraG NN I-NP B-Chemical
10 440 448 20528871 included VBD B-VP O
11 449 454 20528871 Grade NN B-NP O
12 455 456 20528871 2 CD I-NP O
13 457 460 20528871 and CC I-NP O
14 461 462 20528871 3 CD I-NP O
15 463 470 20528871 sensory JJ I-NP O
16 471 474 20528871 and CC I-NP O
17 475 480 20528871 motor NN I-NP O
18 481 491 20528871 neuropathy NN I-NP B-Disease
19 492 495 20528871 and CC O O
20 496 511 20528871 musculoskeletal JJ B-NP B-Disease
21 512 516 20528871 pain NN I-NP I-Disease
22 516 517 20528871 . . O O

1 518 532 20528871 Haematological JJ B-NP B-Disease
2 533 541 20528871 toxicity NN I-NP I-Disease
3 542 545 20528871 was VBD B-VP O
4 546 553 20528871 greater JJR B-ADJP O
5 554 557 20528871 for IN B-PP O
6 558 561 20528871 the DT B-NP O
7 562 573 20528871 combination NN I-NP O
8 574 578 20528871 than IN B-PP O
9 579 583 20528871 AraG NN B-NP B-Chemical
10 584 589 20528871 alone RB B-ADVP O
11 589 590 20528871 , , O O
12 591 599 20528871 although IN B-SBAR O
13 600 606 20528871 median JJ B-NP O
14 607 611 20528871 time NN I-NP O
15 612 614 20528871 to TO B-PP O
16 615 625 20528871 neutrophil NN B-NP O
17 626 629 20528871 and CC I-NP O
18 630 638 20528871 platelet NN I-NP O
19 639 647 20528871 recovery NN I-NP O
20 648 651 20528871 was VBD B-VP O
21 652 662 20528871 consistent JJ B-ADJP O
22 663 667 20528871 with IN B-PP O
23 668 673 20528871 other JJ B-NP O
24 674 681 20528871 salvage NN I-NP O
25 682 691 20528871 therapies NNS I-NP O
26 691 692 20528871 . . O O

1 693 696 20528871 All DT B-NP O
2 697 705 20528871 patients NNS I-NP O
3 706 709 20528871 had VBD B-VP O
4 710 714 20528871 some DT B-NP O
5 715 723 20528871 response NN I-NP O
6 724 726 20528871 to TO B-PP O
7 727 730 20528871 the DT B-NP O
8 731 739 20528871 combined JJ I-NP O
9 740 747 20528871 therapy NN I-NP O
10 748 751 20528871 and CC O O
11 752 756 20528871 five CD B-NP O
12 757 759 20528871 of IN B-PP O
13 760 763 20528871 the DT B-NP O
14 764 769 20528871 seven CD I-NP O
15 770 774 20528871 went VBD B-VP O
16 775 779 20528871 into IN B-PP O
17 780 788 20528871 complete JJ B-NP O
18 789 798 20528871 remission NN I-NP O
19 799 804 20528871 after IN B-PP O
20 805 808 20528871 one CD B-NP O
21 809 811 20528871 or CC I-NP O
22 812 815 20528871 two CD I-NP O
23 816 823 20528871 courses NNS I-NP O
24 824 826 20528871 of IN B-PP O
25 827 831 20528871 AraG NN B-NP B-Chemical
26 831 832 20528871 / SYM B-NP O
27 832 834 20528871 VP NN I-NP B-Chemical
28 834 835 20528871 / SYM B-NP O
29 835 838 20528871 CPM NN I-NP B-Chemical
30 838 839 20528871 . . O O

1 840 843 20528871 Our PRP$ B-NP O
2 844 854 20528871 experience NN I-NP O
3 855 863 20528871 supports VBZ B-VP O
4 864 867 20528871 the DT B-NP O
5 868 874 20528871 safety NN I-NP O
6 875 877 20528871 of IN B-PP O
7 878 884 20528871 giving VBG B-VP O
8 885 889 20528871 AraG NN B-NP B-Chemical
9 890 892 20528871 as IN B-PP O
10 893 900 20528871 salvage NN B-NP O
11 901 908 20528871 therapy NN I-NP O
12 909 911 20528871 in IN B-PP O
13 912 921 20528871 synchrony NN B-NP O
14 922 926 20528871 with IN B-PP O
15 927 936 20528871 etoposide NN B-NP B-Chemical
16 937 940 20528871 and CC I-NP O
17 941 957 20528871 cyclophosphamide NN I-NP B-Chemical
18 957 958 20528871 , , O O
19 959 967 20528871 although IN B-SBAR O
20 968 980 20528871 neurological JJ B-NP B-Disease
21 981 989 20528871 toxicity NN I-NP I-Disease
22 990 994 20528871 must MD B-VP O
23 995 997 20528871 be VB I-VP O
24 998 1005 20528871 closely RB I-VP O
25 1006 1015 20528871 monitored VBN I-VP O
26 1015 1016 20528871 . . O O

1 0 0 10807237 -DOCSTART- -X- -X- O

1 0 12 10807237 Intracranial JJ B-NP B-Disease
2 13 22 10807237 aneurysms NNS I-NP I-Disease
3 23 26 10807237 and CC O O
4 27 34 10807237 cocaine NN B-NP B-Disease
5 35 40 10807237 abuse NN I-NP I-Disease
6 40 41 10807237 : : O O
7 42 50 10807237 analysis NN B-NP O
8 51 53 10807237 of IN B-PP O
9 54 64 10807237 prognostic JJ B-NP O
10 65 75 10807237 indicators NNS I-NP O
11 75 76 10807237 . . O O
12 77 86 10807237 OBJECTIVE NN B-NP O
13 86 87 10807237 : : O O
14 88 91 10807237 The DT B-NP O
15 92 99 10807237 outcome NN I-NP O
16 100 102 10807237 of IN B-PP O
17 103 115 10807237 subarachnoid JJ B-NP B-Disease
18 116 126 10807237 hemorrhage NN I-NP I-Disease
19 127 137 10807237 associated VBN B-VP O
20 138 142 10807237 with IN B-PP O
21 143 150 10807237 cocaine NN B-NP B-Disease
22 151 156 10807237 abuse NN I-NP I-Disease
23 157 159 10807237 is VBZ B-VP O
24 160 170 10807237 reportedly RB B-ADJP O
25 171 175 10807237 poor JJ I-ADJP O
26 175 176 10807237 . . O O

1 177 184 10807237 However RB B-ADVP O
2 184 185 10807237 , , O O
3 186 188 10807237 no DT B-NP O
4 189 194 10807237 study NN I-NP O
5 195 197 10807237 in IN B-PP O
6 198 201 10807237 the DT B-NP O
7 202 212 10807237 literature NN I-NP O
8 213 216 10807237 has VBZ B-VP O
9 217 225 10807237 reported VBN I-VP O
10 226 229 10807237 the DT B-NP O
11 230 233 10807237 use NN I-NP O
12 234 236 10807237 of IN B-PP O
13 237 238 10807237 a DT B-NP O
14 239 250 10807237 statistical JJ I-NP O
15 251 256 10807237 model NN I-NP O
16 257 259 10807237 to TO B-VP O
17 260 267 10807237 analyze VB I-VP O
18 268 271 10807237 the DT B-NP O
19 272 281 10807237 variables NNS I-NP O
20 282 286 10807237 that WDT B-NP O
21 287 296 10807237 influence VBP B-VP O
22 297 304 10807237 outcome NN B-NP O
23 304 305 10807237 . . O O

1 306 313 10807237 METHODS NNS B-NP O
2 313 314 10807237 : : O O
3 315 316 10807237 A DT B-NP O
4 317 323 10807237 review NN I-NP O
5 324 326 10807237 of IN B-PP O
6 327 337 10807237 admissions NNS B-NP O
7 338 344 10807237 during IN B-PP O
8 345 346 10807237 a DT B-NP O
9 347 348 10807237 6 CD I-NP O
10 348 349 10807237 - HYPH I-NP O
11 349 353 10807237 year NN I-NP O
12 354 360 10807237 period NN I-NP O
13 361 369 10807237 revealed VBD B-VP O
14 370 372 10807237 14 CD B-NP O
15 373 381 10807237 patients NNS I-NP O
16 382 386 10807237 with IN B-PP O
17 387 394 10807237 cocaine NN B-NP B-Chemical
18 394 395 10807237 - HYPH B-NP O
19 395 402 10807237 related VBN I-NP O
20 403 412 10807237 aneurysms NNS I-NP B-Disease
21 412 413 10807237 . . O O

1 414 418 10807237 This DT B-NP O
2 419 424 10807237 group NN I-NP O
3 425 428 10807237 was VBD B-VP O
4 429 437 10807237 compared VBN I-VP O
5 438 442 10807237 with IN B-PP O
6 443 444 10807237 a DT B-NP O
7 445 452 10807237 control NN I-NP O
8 453 458 10807237 group NN I-NP O
9 459 461 10807237 of IN B-PP O
10 462 465 10807237 135 CD B-NP O
11 466 474 10807237 patients NNS I-NP O
12 475 479 10807237 with IN B-PP O
13 480 488 10807237 ruptured JJ B-NP B-Disease
14 489 498 10807237 aneurysms NNS I-NP I-Disease
15 499 502 10807237 and CC O O
16 503 505 10807237 no DT B-NP O
17 506 513 10807237 history NN I-NP O
18 514 516 10807237 of IN B-PP O
19 517 524 10807237 cocaine NN B-NP B-Disease
20 525 530 10807237 abuse NN I-NP I-Disease
21 530 531 10807237 . . O O

1 532 535 10807237 Age NN B-NP O
2 536 538 10807237 at IN B-PP O
3 539 551 10807237 presentation NN B-NP O
4 551 552 10807237 , , O O
5 553 557 10807237 time NN B-NP O
6 558 560 10807237 of IN B-PP O
7 561 566 10807237 ictus NN B-NP O
8 567 572 10807237 after IN B-PP O
9 573 585 10807237 intoxication NN B-NP O
10 585 586 10807237 , , O O
11 587 591 10807237 Hunt NNP B-NP O
12 592 595 10807237 and CC I-NP O
13 596 600 10807237 Hess NNP I-NP O
14 601 606 10807237 grade NN I-NP O
15 607 609 10807237 of IN B-PP O
16 610 622 10807237 subarachnoid JJ B-NP B-Disease
17 623 633 10807237 hemorrhage NN I-NP I-Disease
18 633 634 10807237 , , O O
19 635 639 10807237 size NN B-NP O
20 640 642 10807237 of IN B-PP O
21 643 646 10807237 the DT B-NP O
22 647 655 10807237 aneurysm NN I-NP B-Disease
23 655 656 10807237 , , O O
24 657 665 10807237 location NN B-NP O
25 666 668 10807237 of IN B-PP O
26 669 672 10807237 the DT B-NP O
27 673 681 10807237 aneurysm NN I-NP B-Disease
28 681 682 10807237 , , O O
29 683 686 10807237 and CC O O
30 687 690 10807237 the DT B-NP O
31 691 698 10807237 Glasgow NNP I-NP O
32 699 706 10807237 Outcome NNP I-NP O
33 707 712 10807237 Scale NNP I-NP O
34 713 718 10807237 score NN I-NP O
35 719 723 10807237 were VBD B-VP O
36 724 732 10807237 assessed VBN I-VP O
37 733 736 10807237 and CC O O
38 737 745 10807237 compared VBN B-VP O
39 745 746 10807237 . . O O

1 747 754 10807237 RESULTS NNS B-NP O
2 754 755 10807237 : : O O
3 756 759 10807237 The DT B-NP O
4 760 768 10807237 patients NNS I-NP O
5 769 771 10807237 in IN B-PP O
6 772 775 10807237 the DT B-NP O
7 776 781 10807237 study NN I-NP O
8 782 787 10807237 group NN I-NP O
9 788 792 10807237 were VBD B-VP O
10 793 806 10807237 significantly RB B-ADJP O
11 807 814 10807237 younger JJR I-ADJP O
12 815 819 10807237 than IN B-PP O
13 820 823 10807237 the DT B-NP O
14 824 832 10807237 patients NNS I-NP O
15 833 835 10807237 in IN B-PP O
16 836 839 10807237 the DT B-NP O
17 840 847 10807237 control NN I-NP O
18 848 853 10807237 group NN I-NP O
19 854 855 10807237 ( ( O O
20 855 856 10807237 P NN B-NP O
21 857 858 10807237 < JJR B-NP O
22 859 864 10807237 0.002 CD I-NP O
23 864 865 10807237 ) ) O O
24 865 866 10807237 . . O O

1 867 869 10807237 In IN B-PP O
2 870 878 10807237 patients NNS B-NP O
3 879 881 10807237 in IN B-PP O
4 882 885 10807237 the DT B-NP O
5 886 891 10807237 study NN I-NP O
6 892 897 10807237 group NN I-NP O
7 897 898 10807237 , , O O
8 899 902 10807237 all DT B-NP O
9 903 912 10807237 aneurysms NNS I-NP B-Disease
10 913 917 10807237 were VBD B-VP O
11 918 925 10807237 located VBN I-VP O
12 926 928 10807237 in IN B-PP O
13 929 932 10807237 the DT B-NP O
14 933 941 10807237 anterior JJ I-NP O
15 942 953 10807237 circulation NN I-NP O
16 953 954 10807237 . . O O

1 955 958 10807237 The DT B-NP O
2 959 967 10807237 majority NN I-NP O
3 968 970 10807237 of IN B-PP O
4 971 976 10807237 these DT B-NP O
5 977 986 10807237 aneurysms NNS I-NP B-Disease
6 987 991 10807237 were VBD B-VP O
7 992 999 10807237 smaller JJR B-ADJP O
8 1000 1004 10807237 than IN B-PP O
9 1005 1010 10807237 those DT B-NP O
10 1011 1013 10807237 of IN B-PP O
11 1014 1017 10807237 the DT B-NP O
12 1018 1025 10807237 control NN I-NP O
13 1026 1031 10807237 group NN I-NP O
14 1032 1033 10807237 ( ( O O
15 1033 1034 10807237 8 CD B-NP O
16 1035 1036 10807237 + SYM O O
17 1036 1037 10807237 / SYM O O
18 1037 1038 10807237 - SYM O O
19 1039 1043 10807237 6.08 CD B-NP O
20 1044 1046 10807237 mm NN I-NP O
21 1047 1053 10807237 versus IN B-PP O
22 1054 1056 10807237 11 CD B-NP O
23 1057 1058 10807237 + SYM O O
24 1058 1059 10807237 / SYM O O
25 1059 1060 10807237 - SYM O O
26 1061 1064 10807237 5.4 CD B-NP O
27 1065 1067 10807237 mm NN I-NP O
28 1067 1068 10807237 ; : O O
29 1069 1070 10807237 P NN B-NP O
30 1071 1072 10807237 = SYM B-VP O
31 1073 1077 10807237 0.05 CD B-NP O
32 1077 1078 10807237 ) ) O O
33 1078 1079 10807237 . . O O

1 1080 1083 10807237 The DT B-NP O
2 1084 1095 10807237 differences NNS I-NP O
3 1096 1098 10807237 in IN B-PP O
4 1099 1108 10807237 mortality NN B-NP O
5 1109 1112 10807237 and CC I-NP O
6 1113 1122 10807237 morbidity NN I-NP O
7 1123 1130 10807237 between IN B-PP O
8 1131 1134 10807237 the DT B-NP O
9 1135 1138 10807237 two CD I-NP O
10 1139 1145 10807237 groups NNS I-NP O
11 1146 1150 10807237 were VBD B-VP O
12 1151 1154 10807237 not RB O O
13 1155 1166 10807237 significant JJ B-ADJP O
14 1166 1167 10807237 . . O O

1 1168 1172 10807237 Hunt NNP B-NP O
2 1173 1176 10807237 and CC I-NP O
3 1177 1181 10807237 Hess NNP I-NP O
4 1182 1187 10807237 grade NN I-NP O
5 1188 1189 10807237 ( ( O O
6 1189 1190 10807237 P NN B-NP O
7 1191 1192 10807237 < SYM O O
8 1193 1198 10807237 0.005 CD B-NP O
9 1198 1199 10807237 ) ) O O
10 1200 1203 10807237 and CC O O
11 1204 1207 10807237 age NN B-NP O
12 1208 1209 10807237 ( ( O O
13 1209 1210 10807237 P NN B-NP O
14 1211 1212 10807237 < JJR B-NP O
15 1213 1218 10807237 0.007 CD I-NP O
16 1218 1219 10807237 ) ) O O
17 1220 1224 10807237 were VBD B-VP O
18 1225 1236 10807237 significant JJ B-NP O
19 1237 1247 10807237 predictors NNS I-NP O
20 1248 1250 10807237 of IN B-PP O
21 1251 1258 10807237 outcome NN B-NP O
22 1259 1262 10807237 for IN B-PP O
23 1263 1266 10807237 the DT B-NP O
24 1267 1275 10807237 patients NNS I-NP O
25 1276 1280 10807237 with IN B-PP O
26 1281 1288 10807237 cocaine NN B-NP B-Chemical
27 1288 1289 10807237 - HYPH B-NP O
28 1289 1296 10807237 related VBN I-NP O
29 1297 1306 10807237 aneurysms NNS I-NP B-Disease
30 1306 1307 10807237 . . O O

1 1308 1318 10807237 CONCLUSION NN B-NP O
2 1318 1319 10807237 : : O O
3 1320 1327 10807237 Cocaine NN B-NP B-Chemical
4 1328 1331 10807237 use NN I-NP O
5 1332 1343 10807237 predisposed VBD B-VP O
6 1344 1354 10807237 aneurysmal JJ B-NP B-Disease
7 1355 1362 10807237 rupture NN I-NP I-Disease
8 1363 1365 10807237 at IN B-PP O
9 1366 1367 10807237 a DT B-NP O
10 1368 1381 10807237 significantly RB I-NP O
11 1382 1389 10807237 earlier JJR I-NP O
12 1390 1393 10807237 age NN I-NP O
13 1394 1397 10807237 and CC B-PP O
14 1398 1400 10807237 in IN B-PP O
15 1401 1405 10807237 much RB B-NP O
16 1406 1413 10807237 smaller JJR I-NP O
17 1414 1423 10807237 aneurysms NNS I-NP B-Disease
18 1423 1424 10807237 . . O O

1 1425 1433 10807237 Contrary JJ B-ADVP O
2 1434 1436 10807237 to TO B-PP O
3 1437 1440 10807237 the DT B-NP O
4 1441 1450 10807237 published VBN I-NP O
5 1451 1461 10807237 literature NN I-NP O
6 1461 1462 10807237 , , O O
7 1463 1467 10807237 this DT B-NP O
8 1468 1473 10807237 group NN I-NP O
9 1474 1477 10807237 did VBD B-VP O
10 1478 1488 10807237 reasonably RB B-ADVP O
11 1489 1493 10807237 well RB I-ADVP O
12 1494 1498 10807237 with IN B-PP O
13 1499 1509 10807237 aggressive JJ B-NP O
14 1510 1520 10807237 management NN I-NP O
15 1520 1521 10807237 . . O O

1 0 0 15145918 -DOCSTART- -X- -X- O

1 0 12 15145918 Differential JJ B-NP O
2 13 23 15145918 modulation NN I-NP O
3 24 26 15145918 by IN B-PP O
4 27 35 15145918 estrogen NN B-NP B-Chemical
5 36 38 15145918 of IN B-PP O
6 39 45 15145918 alpha2 NN B-NP O
7 45 46 15145918 - HYPH B-NP O
8 46 56 15145918 adrenergic JJ I-NP O
9 57 60 15145918 and CC I-NP O
10 61 63 15145918 I1 NN I-NP O
11 63 64 15145918 - HYPH O O
12 64 75 15145918 imidazoline NN B-NP B-Chemical
13 76 84 15145918 receptor NN I-NP O
14 84 85 15145918 - HYPH B-VP O
15 85 93 15145918 mediated VBN B-NP O
16 94 105 15145918 hypotension NN I-NP B-Disease
17 106 108 15145918 in IN B-PP O
18 109 115 15145918 female JJ B-NP O
19 116 120 15145918 rats NNS I-NP O
20 120 121 15145918 . . O O
21 122 124 15145918 We PRP B-NP O
22 125 129 15145918 have VBP B-VP O
23 130 138 15145918 recently RB I-VP O
24 139 144 15145918 shown VBN I-VP O
25 145 149 15145918 that IN B-SBAR O
26 150 158 15145918 estrogen NN B-NP B-Chemical
27 159 169 15145918 negatively RB B-ADVP O
28 170 179 15145918 modulates VBZ B-VP O
29 180 183 15145918 the DT B-NP O
30 184 195 15145918 hypotensive JJ I-NP B-Disease
31 196 202 15145918 effect NN I-NP O
32 203 205 15145918 of IN B-PP O
33 206 215 15145918 clonidine NN B-NP B-Chemical
34 216 217 15145918 ( ( O O
35 217 222 15145918 mixed VBN B-NP O
36 223 229 15145918 alpha2 NN I-NP O
37 229 230 15145918 - HYPH O O
38 230 231 15145918 / SYM B-NP O
39 231 233 15145918 I1 NN I-NP O
40 233 234 15145918 - HYPH B-NP O
41 234 242 15145918 receptor NN I-NP O
42 243 250 15145918 agonist NN I-NP O
43 250 251 15145918 ) ) O O
44 252 254 15145918 in IN B-PP O
45 255 261 15145918 female JJ B-NP O
46 262 266 15145918 rats NNS I-NP O
47 267 270 15145918 and CC O O
48 271 281 15145918 implicates VBZ B-VP O
49 282 285 15145918 the DT B-NP O
50 286 300 15145918 cardiovascular JJ I-NP O
51 301 310 15145918 autonomic JJ I-NP O
52 311 318 15145918 control NN I-NP O
53 319 321 15145918 in IN B-PP O
54 322 326 15145918 this DT B-NP O
55 327 338 15145918 interaction NN I-NP O
56 338 339 15145918 . . O O

1 340 343 15145918 The DT B-NP O
2 344 351 15145918 present JJ I-NP O
3 352 357 15145918 study NN I-NP O
4 358 370 15145918 investigated VBD B-VP O
5 371 378 15145918 whether IN B-SBAR O
6 379 383 15145918 this DT B-NP O
7 384 390 15145918 effect NN I-NP O
8 391 393 15145918 of IN B-PP O
9 394 402 15145918 estrogen NN B-NP B-Chemical
10 403 411 15145918 involves VBZ B-VP O
11 412 423 15145918 interaction NN B-NP O
12 424 428 15145918 with IN B-PP O
13 429 435 15145918 alpha2 NN B-NP O
14 435 436 15145918 - HYPH O O
15 437 440 15145918 and CC O O
16 440 441 15145918 / SYM B-NP O
17 441 443 15145918 or CC O O
18 444 446 15145918 I1 NN B-NP O
19 446 447 15145918 - HYPH B-NP O
20 447 456 15145918 receptors NNS I-NP O
21 456 457 15145918 . . O O

1 458 465 15145918 Changes NNS B-NP O
2 466 472 15145918 evoked VBN B-VP O
3 473 475 15145918 by IN B-PP O
4 476 477 15145918 a DT B-NP O
5 478 484 15145918 single JJ I-NP O
6 485 500 15145918 intraperitoneal JJ I-NP O
7 501 510 15145918 injection NN I-NP O
8 511 513 15145918 of IN B-PP O
9 514 525 15145918 rilmenidine NN B-NP B-Chemical
10 526 527 15145918 ( ( O O
11 527 530 15145918 600 CD B-NP O
12 531 537 15145918 microg NN I-NP O
13 537 538 15145918 / SYM B-NP O
14 538 540 15145918 kg NN I-NP O
15 540 541 15145918 ) ) O O
16 542 544 15145918 or CC O O
17 545 550 15145918 alpha SYM O B-Chemical
18 550 551 15145918 - HYPH O I-Chemical
19 551 561 15145918 methyldopa NN B-NP I-Chemical
20 562 563 15145918 ( ( O O
21 563 566 15145918 100 CD B-NP O
22 567 569 15145918 mg NN I-NP O
23 569 570 15145918 / SYM B-NP O
24 570 572 15145918 kg NN I-NP O
25 572 573 15145918 ) ) O O
26 573 574 15145918 , , O O
27 575 584 15145918 selective JJ B-NP O
28 585 587 15145918 I1 NN I-NP O
29 587 588 15145918 - HYPH B-NP O
30 589 592 15145918 and CC I-NP O
31 593 599 15145918 alpha2 NN I-NP O
32 599 600 15145918 - HYPH I-NP O
33 600 608 15145918 receptor NN I-NP O
34 609 617 15145918 agonists NNS I-NP O
35 617 618 15145918 , , O O
36 619 631 15145918 respectively RB B-ADVP O
37 631 632 15145918 , , O O
38 633 635 15145918 in IN B-PP O
39 636 641 15145918 blood NN B-NP O
40 642 650 15145918 pressure NN I-NP O
41 650 651 15145918 , , O O
42 652 663 15145918 hemodynamic JJ B-NP O
43 664 675 15145918 variability NN I-NP O
44 675 676 15145918 , , O O
45 677 680 15145918 and CC O O
46 681 690 15145918 locomotor NN B-NP O
47 691 699 15145918 activity NN I-NP O
48 700 704 15145918 were VBD B-VP O
49 705 713 15145918 assessed VBN I-VP O
50 714 716 15145918 in IN B-PP O
51 717 733 15145918 radiotelemetered VBN B-NP O
52 734 738 15145918 sham NN I-NP O
53 738 739 15145918 - HYPH B-VP O
54 739 747 15145918 operated VBN I-VP O
55 748 751 15145918 and CC I-VP O
56 752 766 15145918 ovariectomized VBN I-VP O
57 767 768 15145918 ( ( O O
58 768 771 15145918 Ovx NN B-NP O
59 771 772 15145918 ) ) O O
60 773 780 15145918 Sprague NNP B-NP O
61 780 781 15145918 - HYPH B-NP O
62 781 787 15145918 Dawley NNP I-NP O
63 788 794 15145918 female JJ I-NP O
64 795 799 15145918 rats NNS I-NP O
65 800 804 15145918 with IN B-PP O
66 805 807 15145918 or CC B-PP O
67 808 815 15145918 without IN B-PP O
68 816 818 15145918 12 CD B-NP O
69 818 819 15145918 - HYPH I-NP O
70 819 821 15145918 wk NN I-NP O
71 822 830 15145918 estrogen NN I-NP B-Chemical
72 831 842 15145918 replacement NN I-NP O
73 842 843 15145918 . . O O

1 844 849 15145918 Three CD B-NP O
2 850 854 15145918 time NN I-NP O
3 855 861 15145918 domain NN B-NP O
4 862 869 15145918 indexes NNS I-NP O
5 870 872 15145918 of IN B-PP O
6 873 884 15145918 hemodynamic JJ B-NP O
7 885 896 15145918 variability NN I-NP O
8 897 901 15145918 were VBD B-VP O
9 902 910 15145918 employed VBN I-VP O
10 910 911 15145918 : : O O
11 912 915 15145918 the DT B-NP O
12 916 924 15145918 standard JJ I-NP O
13 925 934 15145918 deviation NN I-NP O
14 935 937 15145918 of IN B-PP O
15 938 942 15145918 mean JJ B-NP O
16 943 951 15145918 arterial JJ I-NP O
17 952 960 15145918 pressure NN I-NP O
18 961 963 15145918 as IN B-PP O
19 964 965 15145918 a DT B-NP O
20 966 973 15145918 measure NN I-NP O
21 974 976 15145918 of IN B-PP O
22 977 982 15145918 blood NN B-NP O
23 983 991 15145918 pressure NN I-NP O
24 992 1003 15145918 variability NN I-NP O
25 1004 1007 15145918 and CC O O
26 1008 1011 15145918 the DT B-NP O
27 1012 1020 15145918 standard JJ I-NP O
28 1021 1030 15145918 deviation NN I-NP O
29 1031 1033 15145918 of IN B-PP O
30 1034 1038 15145918 beat NN B-NP O
31 1038 1039 15145918 - HYPH B-ADVP O
32 1039 1041 15145918 to TO B-PP O
33 1041 1042 15145918 - HYPH B-NP O
34 1042 1046 15145918 beat JJ I-NP O
35 1047 1056 15145918 intervals NNS I-NP O
36 1057 1058 15145918 ( ( O O
37 1058 1062 15145918 SDRR NN B-NP O
38 1062 1063 15145918 ) ) O O
39 1064 1067 15145918 and CC O O
40 1068 1071 15145918 the DT B-NP O
41 1072 1076 15145918 root NN I-NP O
42 1077 1081 15145918 mean JJ I-NP O
43 1082 1088 15145918 square NN I-NP O
44 1089 1091 15145918 of IN B-PP O
45 1092 1102 15145918 successive JJ B-NP O
46 1103 1114 15145918 differences NNS I-NP O
47 1115 1117 15145918 in IN B-PP O
48 1118 1119 15145918 R NN B-NP O
49 1119 1120 15145918 - HYPH B-NP O
50 1120 1124 15145918 wave NN I-NP O
51 1124 1125 15145918 - HYPH B-ADJP O
52 1125 1127 15145918 to TO B-PP O
53 1127 1128 15145918 - HYPH B-NP O
54 1128 1129 15145918 R NN I-NP O
55 1129 1130 15145918 - HYPH B-NP O
56 1130 1134 15145918 wave NN I-NP O
57 1135 1144 15145918 intervals NNS I-NP O
58 1145 1147 15145918 as IN B-PP O
59 1148 1156 15145918 measures NNS B-NP O
60 1157 1159 15145918 of IN B-PP O
61 1160 1165 15145918 heart NN B-NP O
62 1166 1170 15145918 rate NN I-NP O
63 1171 1182 15145918 variability NN I-NP O
64 1182 1183 15145918 . . O O

1 1184 1186 15145918 In IN B-PP O
2 1187 1191 15145918 sham NN B-NP O
3 1191 1192 15145918 - HYPH B-NP O
4 1192 1200 15145918 operated VBN I-NP O
5 1201 1205 15145918 rats NNS I-NP O
6 1205 1206 15145918 , , O O
7 1207 1218 15145918 rilmenidine NN B-NP B-Chemical
8 1219 1221 15145918 or CC O O
9 1222 1227 15145918 alpha SYM O B-Chemical
10 1227 1228 15145918 - HYPH O I-Chemical
11 1228 1238 15145918 methyldopa NN B-NP I-Chemical
12 1239 1247 15145918 elicited VBD B-VP O
13 1248 1255 15145918 similar JJ B-NP O
14 1256 1267 15145918 hypotension NN I-NP B-Disease
15 1268 1272 15145918 that WDT B-NP O
16 1273 1279 15145918 lasted VBD B-VP O
17 1280 1282 15145918 at IN B-NP O
18 1283 1288 15145918 least JJS I-NP O
19 1289 1290 15145918 5 CD I-NP O
20 1291 1292 15145918 h NN I-NP O
21 1293 1296 15145918 and CC O O
22 1297 1300 15145918 was VBD B-VP O
23 1301 1311 15145918 associated VBN I-VP O
24 1312 1316 15145918 with IN B-PP O
25 1317 1327 15145918 reductions NNS B-NP O
26 1328 1330 15145918 in IN B-PP O
27 1331 1339 15145918 standard JJ B-NP O
28 1340 1349 15145918 deviation NN I-NP O
29 1350 1352 15145918 of IN B-PP O
30 1353 1357 15145918 mean JJ B-NP O
31 1358 1366 15145918 arterial JJ I-NP O
32 1367 1375 15145918 pressure NN I-NP O
33 1375 1376 15145918 . . O O

1 1377 1381 15145918 SDRR NN B-NP O
2 1382 1385 15145918 was VBD B-VP O
3 1386 1393 15145918 reduced VBN I-VP O
4 1394 1398 15145918 only RB B-ADVP O
5 1399 1401 15145918 by IN B-PP O
6 1402 1407 15145918 alpha SYM B-NP B-Chemical
7 1407 1408 15145918 - HYPH B-VP I-Chemical
8 1408 1418 15145918 methyldopa NN B-NP I-Chemical
9 1418 1419 15145918 . . O O

1 1420 1423 15145918 Ovx NN B-NP O
2 1424 1437 15145918 significantly RB B-ADVP O
3 1438 1446 15145918 enhanced VBD B-VP O
4 1447 1450 15145918 the DT B-NP O
5 1451 1462 15145918 hypotensive JJ I-NP B-Disease
6 1463 1471 15145918 response NN I-NP O
7 1472 1474 15145918 to TO B-PP O
8 1475 1480 15145918 alpha SYM O B-Chemical
9 1480 1481 15145918 - HYPH O I-Chemical
10 1481 1491 15145918 methyldopa NN B-NP I-Chemical
11 1491 1492 15145918 , , O O
12 1493 1495 15145918 in IN B-PP O
13 1496 1504 15145918 contrast NN B-NP O
14 1505 1507 15145918 to TO B-PP O
15 1508 1510 15145918 no DT B-NP O
16 1511 1517 15145918 effect NN I-NP O
17 1518 1520 15145918 on IN B-PP O
18 1521 1532 15145918 rilmenidine NN B-NP B-Chemical
19 1533 1544 15145918 hypotension NN I-NP B-Disease
20 1544 1545 15145918 . . O O

1 1546 1549 15145918 The DT B-NP O
2 1550 1558 15145918 enhanced VBN I-NP O
3 1559 1564 15145918 alpha SYM I-NP B-Chemical
4 1564 1565 15145918 - HYPH I-NP I-Chemical
5 1565 1575 15145918 methyldopa NN I-NP I-Chemical
6 1576 1587 15145918 hypotension NN I-NP B-Disease
7 1588 1590 15145918 in IN B-PP O
8 1591 1594 15145918 Ovx NN B-NP O
9 1595 1599 15145918 rats NNS I-NP O
10 1600 1603 15145918 was VBD B-VP O
11 1604 1614 15145918 paralleled VBN I-VP O
12 1615 1619 15145918 with IN B-PP O
13 1620 1627 15145918 further JJ B-NP O
14 1628 1637 15145918 reduction NN I-NP O
15 1638 1640 15145918 in IN B-PP O
16 1641 1645 15145918 SDRR NN B-NP O
17 1646 1649 15145918 and CC O O
18 1650 1651 15145918 a DT B-NP B-Disease
19 1652 1659 15145918 reduced VBN I-NP I-Disease
20 1660 1669 15145918 locomotor NN I-NP I-Disease
21 1670 1678 15145918 activity NN I-NP I-Disease
22 1678 1679 15145918 . . O O

1 1680 1688 15145918 Estrogen NN B-NP O
2 1689 1700 15145918 replacement NN I-NP O
3 1701 1702 15145918 ( ( O O
4 1702 1708 15145918 17beta NN B-NP B-Chemical
5 1708 1709 15145918 - HYPH B-NP I-Chemical
6 1709 1718 15145918 estradiol NN I-NP I-Chemical
7 1719 1731 15145918 subcutaneous JJ I-NP O
8 1732 1738 15145918 pellet NN I-NP O
9 1738 1739 15145918 , , O O
10 1740 1744 15145918 14.2 CD B-NP O
11 1745 1751 15145918 microg NN I-NP O
12 1751 1752 15145918 / SYM B-NP O
13 1752 1755 15145918 day NN I-NP O
14 1755 1756 15145918 , , O O
15 1757 1759 15145918 12 CD B-NP O
16 1760 1762 15145918 wk NN I-NP O
17 1762 1763 15145918 ) ) O O
18 1764 1766 15145918 of IN B-PP O
19 1767 1770 15145918 Ovx NN B-NP O
20 1771 1775 15145918 rats NNS I-NP O
21 1776 1784 15145918 restored VBD B-VP O
22 1785 1788 15145918 the DT B-NP O
23 1789 1800 15145918 hemodynamic JJ I-NP O
24 1801 1804 15145918 and CC I-NP O
25 1805 1814 15145918 locomotor JJ I-NP O
26 1815 1822 15145918 effects NNS I-NP O
27 1823 1825 15145918 of IN B-PP O
28 1826 1831 15145918 alpha SYM B-NP B-Chemical
29 1831 1832 15145918 - HYPH O I-Chemical
30 1832 1842 15145918 methyldopa NN B-NP I-Chemical
31 1843 1845 15145918 to TO B-PP O
32 1846 1850 15145918 sham NN B-NP O
33 1850 1851 15145918 - HYPH B-NP O
34 1851 1859 15145918 operated VBN I-NP O
35 1860 1866 15145918 levels NNS I-NP O
36 1866 1867 15145918 . . O O

1 1868 1873 15145918 These DT B-NP O
2 1874 1882 15145918 findings NNS I-NP O
3 1883 1890 15145918 suggest VBP B-VP O
4 1891 1895 15145918 that IN B-SBAR O
5 1896 1904 15145918 estrogen NN B-NP B-Chemical
6 1905 1918 15145918 downregulates VBZ B-VP O
7 1919 1925 15145918 alpha2 NN B-NP O
8 1925 1926 15145918 - HYPH B-ADJP O
9 1927 1930 15145918 but CC B-NP O
10 1931 1934 15145918 not RB I-NP O
11 1935 1937 15145918 I1 NN B-NP O
12 1937 1938 15145918 - HYPH B-NP O
13 1938 1946 15145918 receptor NN I-NP O
14 1946 1947 15145918 - HYPH O O
15 1947 1955 15145918 mediated VBN B-NP O
16 1956 1967 15145918 hypotension NN I-NP B-Disease
17 1968 1971 15145918 and CC O O
18 1972 1981 15145918 highlight VBP B-VP O
19 1982 1983 15145918 a DT B-NP O
20 1984 1988 15145918 role NN I-NP O
21 1989 1992 15145918 for IN B-PP O
22 1993 1996 15145918 the DT B-NP O
23 1997 2004 15145918 cardiac JJ I-NP O
24 2005 2014 15145918 autonomic JJ I-NP O
25 2015 2022 15145918 control NN I-NP O
26 2023 2025 15145918 in IN B-PP O
27 2026 2031 15145918 alpha SYM B-NP B-Chemical
28 2031 2032 15145918 - HYPH B-NP I-Chemical
29 2032 2042 15145918 methyldopa NN I-NP I-Chemical
30 2042 2043 15145918 - HYPH I-NP O
31 2043 2051 15145918 estrogen NN I-NP B-Chemical
32 2052 2063 15145918 interaction NN I-NP O
33 2063 2064 15145918 . . O O

1 0 0 18631865 -DOCSTART- -X- -X- O

1 0 4 18631865 mToR NN B-NP O
2 5 15 18631865 inhibitors NNS I-NP O
3 15 16 18631865 - HYPH B-NP O
4 16 23 18631865 induced VBN I-NP O
5 24 35 18631865 proteinuria NN I-NP B-Disease
6 35 36 18631865 : : O O
7 37 47 18631865 mechanisms NNS B-NP O
8 47 48 18631865 , , O O
9 49 61 18631865 significance NN B-NP O
10 61 62 18631865 , , O O
11 63 66 18631865 and CC O O
12 67 77 18631865 management NN B-NP O
13 77 78 18631865 . . O O
14 79 86 18631865 Massive JJ B-NP O
15 87 94 18631865 urinary JJ I-NP O
16 95 102 18631865 protein NN I-NP O
17 103 112 18631865 excretion NN I-NP O
18 113 116 18631865 has VBZ B-VP O
19 117 121 18631865 been VBN I-VP O
20 122 130 18631865 observed VBN I-VP O
21 131 136 18631865 after IN B-PP O
22 137 147 18631865 conversion NN B-NP O
23 148 152 18631865 from IN B-PP O
24 153 164 18631865 calcineurin NN B-NP O
25 165 175 18631865 inhibitors NNS I-NP O
26 176 178 18631865 to TO B-PP O
27 179 188 18631865 mammalian JJ B-NP O
28 189 195 18631865 target NN I-NP O
29 196 198 18631865 of IN B-PP O
30 199 208 18631865 rapamycin NN B-NP B-Chemical
31 209 210 18631865 ( ( O O
32 210 214 18631865 mToR NN B-NP O
33 214 215 18631865 ) ) O O
34 216 226 18631865 inhibitors NNS B-NP O
35 226 227 18631865 , , O O
36 228 238 18631865 especially RB B-NP O
37 239 248 18631865 sirolimus NN I-NP B-Chemical
38 248 249 18631865 , , O O
39 250 252 18631865 in IN B-PP O
40 253 258 18631865 renal JJ B-NP O
41 259 269 18631865 transplant NN I-NP O
42 270 280 18631865 recipients NNS I-NP O
43 281 285 18631865 with IN B-PP O
44 286 293 18631865 chronic JJ B-NP B-Disease
45 294 303 18631865 allograft NN I-NP I-Disease
46 304 315 18631865 nephropathy NN I-NP I-Disease
47 315 316 18631865 . . O O

1 317 324 18631865 Because IN B-SBAR O
2 325 336 18631865 proteinuria NN B-NP B-Disease
3 337 339 18631865 is VBZ B-VP O
4 340 341 18631865 a DT B-NP O
5 342 347 18631865 major JJ I-NP O
6 348 358 18631865 predictive JJ I-NP O
7 359 365 18631865 factor NN I-NP O
8 366 368 18631865 of IN B-PP O
9 369 373 18631865 poor JJ B-NP O
10 374 389 18631865 transplantation NN I-NP O
11 390 397 18631865 outcome NN I-NP O
12 397 398 18631865 , , O O
13 399 403 18631865 many JJ B-NP O
14 404 411 18631865 studies NNS I-NP O
15 412 419 18631865 focused VBN B-VP O
16 420 422 18631865 on IN B-PP O
17 423 427 18631865 this DT B-NP O
18 428 435 18631865 adverse JJ I-NP O
19 436 441 18631865 event NN I-NP O
20 442 448 18631865 during IN B-PP O
21 449 452 18631865 the DT B-NP O
22 453 457 18631865 past JJ I-NP O
23 458 463 18631865 years NNS I-NP O
24 463 464 18631865 . . O O

1 465 472 18631865 Whether IN B-SBAR O
2 473 484 18631865 proteinuria NN B-NP B-Disease
3 485 488 18631865 was VBD B-VP O
4 489 492 18631865 due IN B-PP O
5 493 495 18631865 to TO B-PP O
6 496 505 18631865 sirolimus NN B-NP B-Chemical
7 506 508 18631865 or CC O O
8 509 513 18631865 only RB B-NP O
9 514 515 18631865 a DT I-NP O
10 516 527 18631865 consequence NN I-NP O
11 528 530 18631865 of IN B-PP O
12 531 542 18631865 calcineurin NN B-NP O
13 543 553 18631865 inhibitors NNS I-NP O
14 554 564 18631865 withdrawal NN I-NP O
15 565 573 18631865 remained VBD B-VP O
16 574 582 18631865 unsolved JJ B-ADJP O
17 583 588 18631865 until IN B-SBAR O
18 589 593 18631865 high JJ B-NP O
19 594 599 18631865 range NN I-NP O
20 600 611 18631865 proteinuria NN I-NP B-Disease
21 612 615 18631865 has VBZ B-VP O
22 616 620 18631865 been VBN I-VP O
23 621 629 18631865 observed VBN I-VP O
24 630 636 18631865 during IN B-PP O
25 637 646 18631865 sirolimus NN B-NP B-Chemical
26 647 654 18631865 therapy NN I-NP O
27 655 657 18631865 in IN B-PP O
28 658 663 18631865 islet NN B-NP O
29 664 679 18631865 transplantation NN I-NP O
30 680 683 18631865 and CC B-PP O
31 684 686 18631865 in IN B-PP O
32 687 695 18631865 patients NNS B-NP O
33 696 699 18631865 who WP B-NP O
34 700 708 18631865 received VBD B-VP O
35 709 718 18631865 sirolimus FW B-NP B-Chemical
36 719 721 18631865 de FW I-NP O
37 722 726 18631865 novo FW I-NP O
38 726 727 18631865 . . O O

1 728 736 18631865 Podocyte NN B-NP O
2 737 743 18631865 injury NN I-NP O
3 744 747 18631865 and CC O O
4 748 753 18631865 focal JJ B-NP O
5 754 763 18631865 segmental JJ I-NP O
6 764 782 18631865 glomerulosclerosis NN I-NP B-Disease
7 783 787 18631865 have VBP B-VP O
8 788 792 18631865 been VBN I-VP O
9 793 800 18631865 related VBN I-VP O
10 801 803 18631865 to TO B-PP O
11 804 808 18631865 mToR NN B-NP O
12 809 819 18631865 inhibition NN I-NP O
13 820 822 18631865 in IN B-PP O
14 823 827 18631865 some DT B-NP O
15 828 836 18631865 patients NNS I-NP O
16 836 837 18631865 , , O O
17 838 841 18631865 but CC O O
18 842 845 18631865 the DT B-NP O
19 846 854 18631865 pathways NNS I-NP O
20 855 865 18631865 underlying VBG B-VP O
21 866 871 18631865 these DT B-NP O
22 872 879 18631865 lesions NNS I-NP O
23 880 886 18631865 remain VBP B-VP O
24 887 897 18631865 hypothetic JJ B-ADJP O
25 897 898 18631865 . . O O

1 899 901 18631865 We PRP B-NP O
2 902 909 18631865 discuss VBP B-VP O
3 910 916 18631865 herein RB B-ADVP O
4 917 920 18631865 the DT B-NP O
5 921 929 18631865 possible JJ I-NP O
6 930 940 18631865 mechanisms NNS I-NP O
7 941 944 18631865 and CC O O
8 945 948 18631865 the DT B-NP O
9 949 961 18631865 significance NN I-NP O
10 962 964 18631865 of IN B-PP O
11 965 969 18631865 mToR NN B-NP O
12 970 978 18631865 blockade NN I-NP O
13 978 979 18631865 - HYPH B-NP O
14 979 986 18631865 induced VBN I-NP O
15 987 998 18631865 proteinuria NN I-NP B-Disease
16 998 999 18631865 . . O O

1 0 0 3714122 -DOCSTART- -X- -X- O

1 0 3 3714122 The DT B-NP O
2 4 15 3714122 correlation NN I-NP O
3 16 23 3714122 between IN B-PP O
4 24 34 3714122 neurotoxic JJ B-NP B-Disease
5 35 43 3714122 esterase NN I-NP O
6 44 54 3714122 inhibition NN I-NP O
7 55 58 3714122 and CC I-NP O
8 59 66 3714122 mipafox NN I-NP B-Chemical
9 66 67 3714122 - HYPH O O
10 67 74 3714122 induced VBN B-NP O
11 75 86 3714122 neuropathic JJ I-NP B-Disease
12 87 93 3714122 damage NN I-NP I-Disease
13 94 96 3714122 in IN B-PP O
14 97 101 3714122 rats NNS B-NP O
15 101 102 3714122 . . O O
16 103 106 3714122 The DT B-NP O
17 107 118 3714122 correlation NN I-NP O
18 119 126 3714122 between IN B-PP O
19 127 138 3714122 neuropathic JJ B-NP B-Disease
20 139 145 3714122 damage NN I-NP I-Disease
21 146 149 3714122 and CC I-NP O
22 150 160 3714122 inhibition NN I-NP O
23 161 163 3714122 of IN B-PP O
24 164 174 3714122 neurotoxic JJ B-NP B-Disease
25 175 183 3714122 esterase NN I-NP O
26 184 186 3714122 or CC I-NP O
27 187 197 3714122 neuropathy NN I-NP B-Disease
28 198 204 3714122 target NN I-NP O
29 205 211 3714122 enzyme NN I-NP O
30 212 213 3714122 ( ( O O
31 213 216 3714122 NTE NN B-NP O
32 216 217 3714122 ) ) O O
33 218 221 3714122 was VBD B-VP O
34 222 230 3714122 examined VBN I-VP O
35 231 233 3714122 in IN B-PP O
36 234 238 3714122 rats NNS B-NP O
37 239 246 3714122 acutely RB B-VP O
38 247 254 3714122 exposed VBN I-VP O
39 255 257 3714122 to TO B-PP O
40 258 265 3714122 Mipafox NNP B-NP B-Chemical
41 266 267 3714122 ( ( O O
42 267 268 3714122 N NN B-NP B-Chemical
43 268 269 3714122 , , O I-Chemical
44 270 272 3714122 N' NN B-NP I-Chemical
45 272 273 3714122 - HYPH B-NP I-Chemical
46 273 310 3714122 diisopropylphosphorodiamidofluoridate NN I-NP I-Chemical
47 310 311 3714122 ) ) O O
48 311 312 3714122 , , O O
49 313 314 3714122 a DT B-NP O
50 315 325 3714122 neurotoxic JJ I-NP B-Disease
51 326 341 3714122 organophosphate NN I-NP B-Chemical
52 341 342 3714122 . . O O

1 343 348 3714122 Brain NN B-NP O
2 349 352 3714122 and CC I-NP O
3 353 359 3714122 spinal JJ I-NP O
4 360 364 3714122 cord NN I-NP O
5 365 368 3714122 NTE NN I-NP O
6 369 379 3714122 activities NNS I-NP O
7 380 384 3714122 were VBD B-VP O
8 385 393 3714122 measured VBN I-VP O
9 394 396 3714122 in IN B-PP O
10 397 401 3714122 Long NNP B-NP O
11 401 402 3714122 - HYPH I-NP O
12 402 407 3714122 Evans NNP I-NP O
13 408 412 3714122 male JJ I-NP O
14 413 417 3714122 rats NNS I-NP O
15 418 419 3714122 1 CD I-NP O
16 420 422 3714122 hr NN I-NP O
17 423 427 3714122 post AFX O O
18 427 428 3714122 - HYPH O O
19 428 436 3714122 exposure NN B-NP O
20 437 439 3714122 to TO B-PP O
21 440 447 3714122 various JJ B-NP O
22 448 455 3714122 dosages NNS I-NP O
23 456 458 3714122 of IN B-PP O
24 459 466 3714122 Mipafox NNP B-NP B-Chemical
25 467 468 3714122 ( ( O O
26 468 470 3714122 ip RB B-ADVP O
27 470 471 3714122 , , O O
28 472 473 3714122 1 CD B-NP O
29 473 474 3714122 - HYPH I-NP O
30 474 476 3714122 15 CD I-NP O
31 477 479 3714122 mg NN I-NP O
32 479 480 3714122 / SYM I-NP O
33 480 482 3714122 kg NN I-NP O
34 482 483 3714122 ) ) O O
35 483 484 3714122 . . O O

1 485 490 3714122 These DT B-NP O
2 491 495 3714122 data NNS I-NP O
3 496 500 3714122 were VBD B-VP O
4 501 511 3714122 correlated VBN I-VP O
5 512 516 3714122 with IN B-PP O
6 517 531 3714122 histologically RB B-NP O
7 532 538 3714122 scored VBN I-NP O
8 539 547 3714122 cervical JJ I-NP O
9 548 552 3714122 cord NN I-NP B-Disease
10 553 559 3714122 damage NN I-NP I-Disease
11 560 562 3714122 in IN B-PP O
12 563 564 3714122 a DT B-NP O
13 565 573 3714122 separate JJ I-NP O
14 574 579 3714122 group NN I-NP O
15 580 582 3714122 of IN B-PP O
16 583 592 3714122 similarly RB B-NP O
17 593 598 3714122 dosed VBN I-NP O
18 599 603 3714122 rats NNS I-NP O
19 604 611 3714122 sampled VBD B-VP O
20 612 614 3714122 14 CD B-NP O
21 614 615 3714122 - HYPH I-NP O
22 615 617 3714122 21 CD I-NP O
23 618 622 3714122 days NNS I-NP O
24 623 627 3714122 post AFX B-NP O
25 627 628 3714122 - HYPH I-NP O
26 628 636 3714122 exposure NN I-NP O
27 636 637 3714122 . . O O

1 638 643 3714122 Those DT B-NP O
2 644 651 3714122 dosages NNS I-NP O
3 652 653 3714122 ( ( O O
4 653 660 3714122 greater JJR B-ADJP O
5 661 665 3714122 than IN B-PP O
6 666 668 3714122 or CC O O
7 669 674 3714122 equal JJ B-ADJP O
8 675 677 3714122 to TO B-PP O
9 678 680 3714122 10 CD B-NP O
10 681 683 3714122 mg NN I-NP O
11 683 684 3714122 / SYM B-NP O
12 684 686 3714122 kg NN I-NP O
13 686 687 3714122 ) ) O O
14 688 692 3714122 that WDT B-NP O
15 693 702 3714122 inhibited VBD B-VP O
16 703 707 3714122 mean JJ B-NP O
17 708 711 3714122 NTE NN I-NP O
18 712 720 3714122 activity NN I-NP O
19 721 723 3714122 in IN B-PP O
20 724 727 3714122 the DT B-NP O
21 728 734 3714122 spinal JJ I-NP O
22 735 739 3714122 cord NN I-NP O
23 740 747 3714122 greater JJR B-ADJP O
24 748 752 3714122 than IN B-PP O
25 753 755 3714122 or CC O O
26 756 761 3714122 equal JJ B-ADJP O
27 762 764 3714122 to TO B-PP O
28 765 768 3714122 73% NN B-NP O
29 769 772 3714122 and CC I-NP O
30 773 778 3714122 brain NN I-NP O
31 779 786 3714122 greater JJR B-ADJP O
32 787 791 3714122 than IN B-PP O
33 792 794 3714122 or CC O O
34 795 800 3714122 equal JJ B-ADJP O
35 801 803 3714122 to TO B-PP O
36 804 807 3714122 67% CD B-NP O
37 808 810 3714122 of IN B-PP O
38 811 818 3714122 control NN B-NP O
39 819 825 3714122 values NNS I-NP O
40 826 834 3714122 produced VBD B-VP O
41 835 841 3714122 severe JJ B-ADJP O
42 842 843 3714122 ( ( O O
43 843 850 3714122 greater JJR B-ADJP O
44 851 855 3714122 than IN B-PP O
45 856 858 3714122 or CC O O
46 859 864 3714122 equal JJ B-ADJP O
47 865 867 3714122 to TO B-PP O
48 868 869 3714122 3 CD B-NP O
49 869 870 3714122 ) ) O O
50 871 879 3714122 cervical JJ B-NP O
51 880 884 3714122 cord NN I-NP O
52 885 894 3714122 pathology NN I-NP O
53 895 897 3714122 in IN B-PP O
54 898 901 3714122 85% NN B-NP O
55 902 904 3714122 of IN B-PP O
56 905 908 3714122 the DT B-NP O
57 909 913 3714122 rats NNS I-NP O
58 913 914 3714122 . . O O

1 915 917 3714122 In IN B-PP O
2 918 926 3714122 contrast NN B-NP O
3 926 927 3714122 , , O O
4 928 935 3714122 dosages NNS B-NP O
5 936 938 3714122 of IN B-PP O
6 939 946 3714122 Mipafox NNP B-NP B-Chemical
7 947 948 3714122 ( ( O O
8 948 952 3714122 less JJR B-ADJP O
9 953 957 3714122 than IN B-PP O
10 958 960 3714122 or CC O O
11 961 966 3714122 equal JJ B-ADJP O
12 967 969 3714122 to TO B-PP O
13 970 971 3714122 5 CD B-NP O
14 972 974 3714122 mg NN I-NP O
15 974 975 3714122 / SYM B-NP O
16 975 977 3714122 kg NN I-NP O
17 977 978 3714122 ) ) O O
18 979 984 3714122 which WDT B-NP O
19 985 994 3714122 inhibited VBD B-VP O
20 995 999 3714122 mean JJ B-NP O
21 1000 1003 3714122 NTE NN I-NP O
22 1004 1012 3714122 activity NN I-NP O
23 1013 1015 3714122 in IN B-PP O
24 1016 1022 3714122 spinal JJ B-NP O
25 1023 1027 3714122 cord NN I-NP O
26 1028 1032 3714122 less JJR B-ADJP O
27 1033 1037 3714122 than IN B-PP O
28 1038 1040 3714122 or CC O O
29 1041 1046 3714122 equal JJ B-ADJP O
30 1047 1049 3714122 to TO B-PP O
31 1050 1053 3714122 61% NN B-NP O
32 1054 1057 3714122 and CC I-NP O
33 1058 1063 3714122 brain NN I-NP O
34 1064 1068 3714122 less JJR B-ADJP O
35 1069 1073 3714122 than IN B-PP O
36 1074 1076 3714122 or CC O O
37 1077 1082 3714122 equal JJ B-ADJP O
38 1083 1085 3714122 to TO B-PP O
39 1086 1089 3714122 60% NN B-NP O
40 1090 1098 3714122 produced VBD B-VP O
41 1099 1103 3714122 this DT B-NP O
42 1104 1110 3714122 degree NN I-NP O
43 1111 1113 3714122 of IN B-PP O
44 1114 1118 3714122 cord NN B-NP B-Disease
45 1119 1125 3714122 damage NN I-NP I-Disease
46 1126 1128 3714122 in IN B-PP O
47 1129 1133 3714122 only RB B-NP O
48 1134 1136 3714122 9% CD I-NP O
49 1137 1139 3714122 of IN B-PP O
50 1140 1143 3714122 the DT B-NP O
51 1144 1151 3714122 animals NNS I-NP O
52 1151 1152 3714122 . . O O

1 1153 1158 3714122 These DT B-NP O
2 1159 1163 3714122 data NNS I-NP O
3 1164 1172 3714122 indicate VBP B-VP O
4 1173 1177 3714122 that IN B-SBAR O
5 1178 1179 3714122 a DT B-NP O
6 1180 1188 3714122 critical JJ I-NP O
7 1189 1199 3714122 percentage NN I-NP O
8 1200 1202 3714122 of IN B-PP O
9 1203 1206 3714122 NTE NN B-NP O
10 1207 1217 3714122 inhibition NN I-NP O
11 1218 1220 3714122 in IN B-PP O
12 1221 1226 3714122 brain NN B-NP O
13 1227 1230 3714122 and CC O O
14 1231 1237 3714122 spinal JJ B-NP O
15 1238 1242 3714122 cord NN I-NP O
16 1243 1250 3714122 sampled VBN B-VP O
17 1251 1258 3714122 shortly RB B-ADVP O
18 1259 1264 3714122 after IN B-PP O
19 1265 1272 3714122 Mipafox NNP B-NP B-Chemical
20 1273 1281 3714122 exposure NN I-NP O
21 1282 1285 3714122 can MD B-VP O
22 1286 1293 3714122 predict VB I-VP O
23 1294 1305 3714122 neuropathic JJ B-NP B-Disease
24 1306 1312 3714122 damage NN I-NP I-Disease
25 1313 1315 3714122 in IN B-PP O
26 1316 1320 3714122 rats NNS B-NP O
27 1321 1328 3714122 several JJ B-NP O
28 1329 1334 3714122 weeks NNS I-NP O
29 1335 1340 3714122 later RB B-ADVP O
30 1340 1341 3714122 . . O O

1 0 0 1833784 -DOCSTART- -X- -X- O

1 0 8 1833784 Evidence NN B-NP O
2 9 12 1833784 for IN B-PP O
3 13 15 1833784 an DT B-NP O
4 16 27 1833784 involvement NN I-NP O
5 28 30 1833784 of IN B-PP O
6 31 33 1833784 D1 NN B-NP O
7 34 37 1833784 and CC I-NP O
8 38 40 1833784 D2 NN I-NP O
9 41 49 1833784 dopamine NN I-NP B-Chemical
10 50 59 1833784 receptors NNS I-NP O
11 60 62 1833784 in IN B-PP O
12 63 72 1833784 mediating VBG B-VP O
13 73 81 1833784 nicotine NN B-NP B-Chemical
14 81 82 1833784 - HYPH O O
15 82 89 1833784 induced VBN B-NP O
16 90 103 1833784 hyperactivity NN I-NP B-Disease
17 104 106 1833784 in IN B-PP O
18 107 111 1833784 rats NNS B-NP O
19 111 112 1833784 . . O O
20 113 121 1833784 Previous JJ B-NP O
21 122 129 1833784 studies NNS I-NP O
22 130 134 1833784 have VBP B-VP O
23 135 144 1833784 suggested VBN I-VP O
24 145 149 1833784 that IN B-SBAR O
25 150 158 1833784 repeated VBN B-NP O
26 159 167 1833784 exposure NN I-NP O
27 168 170 1833784 of IN B-PP O
28 171 175 1833784 rats NNS B-NP O
29 176 178 1833784 to TO B-PP O
30 179 182 1833784 the DT B-NP O
31 183 187 1833784 drug NN I-NP O
32 188 190 1833784 or CC B-PP O
33 191 193 1833784 to TO B-PP O
34 194 197 1833784 the DT B-NP O
35 198 210 1833784 experimental JJ I-NP O
36 211 222 1833784 environment NN I-NP O
37 223 225 1833784 is VBZ B-VP O
38 226 235 1833784 necessary JJ B-ADJP O
39 236 238 1833784 to TO B-VP O
40 239 246 1833784 observe VB I-VP O
41 247 255 1833784 nicotine NN B-NP B-Chemical
42 255 256 1833784 - HYPH B-NP O
43 256 263 1833784 induced VBN I-NP O
44 264 273 1833784 locomotor NN I-NP O
45 274 285 1833784 stimulation NN I-NP O
46 285 286 1833784 . . O O

1 287 289 1833784 In IN B-PP O
2 290 293 1833784 the DT B-NP O
3 294 301 1833784 present JJ I-NP O
4 302 307 1833784 study NN I-NP O
5 308 311 1833784 the DT B-NP O
6 312 316 1833784 role NN I-NP O
7 317 319 1833784 of IN B-PP O
8 320 331 1833784 habituation NN B-NP O
9 332 334 1833784 to TO B-PP O
10 335 338 1833784 the DT B-NP O
11 339 351 1833784 experimental JJ I-NP O
12 352 363 1833784 environment NN I-NP O
13 364 366 1833784 on IN B-PP O
14 367 370 1833784 the DT B-NP O
15 371 380 1833784 stimulant JJ I-NP O
16 381 387 1833784 effect NN I-NP O
17 388 390 1833784 of IN B-PP O
18 391 399 1833784 nicotine NN B-NP B-Chemical
19 400 402 1833784 in IN B-PP O
20 403 407 1833784 rats NNS B-NP O
21 408 411 1833784 was VBD B-VP O
22 412 420 1833784 examined VBN I-VP O
23 420 421 1833784 . . O O

1 422 424 1833784 In IN B-PP O
2 425 433 1833784 addition NN B-NP O
3 433 434 1833784 , , O O
4 435 438 1833784 the DT B-NP O
5 439 443 1833784 role NN I-NP O
6 444 446 1833784 of IN B-PP O
7 447 455 1833784 dopamine NN B-NP B-Chemical
8 456 465 1833784 receptors NNS I-NP O
9 466 468 1833784 in IN B-PP O
10 469 478 1833784 mediating VBG B-VP O
11 479 487 1833784 nicotine NN B-NP B-Chemical
12 487 488 1833784 - HYPH B-NP O
13 488 495 1833784 induced VBN I-NP O
14 496 505 1833784 locomotor NN I-NP O
15 506 517 1833784 stimulation NN I-NP O
16 518 521 1833784 was VBD B-VP O
17 522 534 1833784 investigated VBN I-VP O
18 535 537 1833784 by IN B-PP O
19 538 547 1833784 examining VBG B-VP O
20 548 551 1833784 the DT B-NP O
21 552 559 1833784 effects NNS I-NP O
22 560 562 1833784 of IN B-PP O
23 563 572 1833784 selective JJ B-NP O
24 573 575 1833784 D1 NN I-NP O
25 576 579 1833784 and CC I-NP O
26 580 582 1833784 D2 NN I-NP O
27 583 591 1833784 dopamine NN I-NP B-Chemical
28 592 600 1833784 receptor NN I-NP O
29 601 612 1833784 antagonists NNS I-NP O
30 613 615 1833784 on IN B-PP O
31 616 624 1833784 activity NN B-NP O
32 625 632 1833784 induced VBN B-VP O
33 633 635 1833784 by IN B-PP O
34 636 644 1833784 nicotine NN B-NP B-Chemical
35 644 645 1833784 . . O O

1 646 655 1833784 Locomotor NN B-NP O
2 656 664 1833784 activity NN I-NP O
3 665 668 1833784 was VBD B-VP O
4 669 677 1833784 assessed VBN I-VP O
5 678 680 1833784 in IN B-PP O
6 681 685 1833784 male JJ B-NP O
7 686 693 1833784 Sprague NNP I-NP O
8 693 694 1833784 - HYPH I-NP O
9 694 700 1833784 Dawley NNP I-NP O
10 701 705 1833784 rats NNS I-NP O
11 706 712 1833784 tested VBN B-VP O
12 713 715 1833784 in IN B-PP O
13 716 725 1833784 photocell NN B-NP O
14 726 731 1833784 cages NNS I-NP O
15 731 732 1833784 . . O O

1 733 741 1833784 Nicotine NN B-NP B-Chemical
2 742 743 1833784 ( ( O O
3 743 746 1833784 1.0 CD B-NP O
4 747 749 1833784 mg NN I-NP O
5 749 750 1833784 / SYM B-NP O
6 750 752 1833784 kg NN I-NP O
7 752 753 1833784 ) ) O O
8 754 760 1833784 caused VBD B-VP O
9 761 762 1833784 a DT B-NP O
10 763 774 1833784 significant JJ I-NP O
11 775 783 1833784 increase NN I-NP B-Disease
12 784 786 1833784 in IN B-PP I-Disease
13 787 796 1833784 locomotor NN B-NP I-Disease
14 797 805 1833784 activity NN I-NP I-Disease
15 806 808 1833784 in IN B-PP O
16 809 813 1833784 rats NNS B-NP O
17 814 818 1833784 that WDT B-NP O
18 819 823 1833784 were VBD B-VP O
19 824 834 1833784 habituated VBN I-VP O
20 835 837 1833784 to TO B-PP O
21 838 841 1833784 the DT B-NP O
22 842 846 1833784 test NN I-NP O
23 847 858 1833784 environment NN I-NP O
24 858 859 1833784 , , O O
25 860 863 1833784 but CC O O
26 864 867 1833784 had VBD B-VP O
27 868 872 1833784 only RB B-NP O
28 873 874 1833784 a DT I-NP O
29 875 879 1833784 weak JJ I-NP O
30 880 883 1833784 and CC I-NP O
31 884 891 1833784 delayed VBN I-NP O
32 892 901 1833784 stimulant NN I-NP O
33 902 908 1833784 action NN I-NP O
34 909 911 1833784 in IN B-PP O
35 912 916 1833784 rats NNS B-NP O
36 917 921 1833784 that WDT B-NP O
37 922 926 1833784 were VBD B-VP O
38 927 937 1833784 unfamiliar JJ B-ADJP O
39 938 942 1833784 with IN B-PP O
40 943 946 1833784 the DT B-NP O
41 947 951 1833784 test NN I-NP O
42 952 963 1833784 environment NN I-NP O
43 963 964 1833784 . . O O

1 965 968 1833784 The DT B-NP O
2 969 978 1833784 stimulant JJ I-NP O
3 979 985 1833784 action NN I-NP O
4 986 988 1833784 of IN B-PP O
5 989 997 1833784 nicotine NN B-NP B-Chemical
6 998 1001 1833784 was VBD B-VP O
7 1002 1009 1833784 blocked VBN I-VP O
8 1010 1012 1833784 by IN B-PP O
9 1013 1016 1833784 the DT B-NP O
10 1017 1024 1833784 central JJ I-NP O
11 1025 1034 1833784 nicotinic JJ I-NP O
12 1035 1045 1833784 antagonist NN I-NP O
13 1046 1058 1833784 mecamylamine NN I-NP B-Chemical
14 1059 1062 1833784 but CC B-PP O
15 1063 1066 1833784 not RB B-PP O
16 1067 1069 1833784 by IN I-PP O
17 1070 1073 1833784 the DT B-NP O
18 1074 1084 1833784 peripheral JJ I-NP O
19 1085 1094 1833784 nicotinic JJ I-NP O
20 1095 1102 1833784 blocker NN I-NP O
21 1103 1116 1833784 hexamethonium NN I-NP B-Chemical
22 1116 1117 1833784 , , O O
23 1118 1128 1833784 indicating VBG B-VP O
24 1129 1133 1833784 that IN B-SBAR O
25 1134 1137 1833784 the DT B-NP O
26 1138 1146 1833784 response NN I-NP O
27 1147 1149 1833784 is VBZ B-VP O
28 1150 1158 1833784 probably RB I-VP O
29 1159 1167 1833784 mediated VBN I-VP O
30 1168 1170 1833784 by IN B-PP O
31 1171 1178 1833784 central JJ B-NP O
32 1179 1188 1833784 nicotinic JJ I-NP O
33 1189 1198 1833784 receptors NNS I-NP O
34 1198 1199 1833784 . . O O

1 1200 1208 1833784 Nicotine NN B-NP B-Chemical
2 1208 1209 1833784 - HYPH B-NP O
3 1209 1216 1833784 induced VBN I-NP O
4 1217 1230 1833784 hyperactivity NN I-NP B-Disease
5 1231 1234 1833784 was VBD B-VP O
6 1235 1242 1833784 blocked VBN I-VP O
7 1243 1245 1833784 by IN B-PP O
8 1246 1249 1833784 the DT B-NP O
9 1250 1259 1833784 selective JJ I-NP O
10 1260 1262 1833784 D1 NN I-NP O
11 1263 1273 1833784 antagonist NN I-NP O
12 1274 1277 1833784 SCH NN I-NP B-Chemical
13 1278 1283 1833784 23390 CD I-NP I-Chemical
14 1283 1284 1833784 , , O O
15 1285 1288 1833784 the DT B-NP O
16 1289 1298 1833784 selective JJ I-NP O
17 1299 1301 1833784 D2 NN I-NP O
18 1302 1312 1833784 antagonist NN I-NP O
19 1313 1323 1833784 raclopride NN I-NP B-Chemical
20 1324 1327 1833784 and CC O O
21 1328 1331 1833784 the DT B-NP O
22 1332 1334 1833784 D1 NN I-NP O
23 1334 1335 1833784 / SYM B-NP O
24 1335 1337 1833784 D2 NN I-NP O
25 1338 1348 1833784 antagonist NN I-NP O
26 1349 1361 1833784 fluphenazine NN I-NP B-Chemical
27 1361 1362 1833784 . . O O

1 1363 1375 1833784 Pretreatment NN B-NP O
2 1376 1380 1833784 with IN B-PP O
3 1381 1384 1833784 the DT B-NP O
4 1385 1387 1833784 D2 NN I-NP O
5 1388 1395 1833784 agonist NN I-NP O
6 1396 1400 1833784 PHNO NN I-NP B-Chemical
7 1401 1409 1833784 enhanced VBD B-VP O
8 1410 1418 1833784 nicotine NN B-NP B-Chemical
9 1418 1419 1833784 - HYPH B-NP O
10 1419 1426 1833784 induced VBN I-NP O
11 1427 1440 1833784 hyperactivity NN I-NP B-Disease
12 1440 1441 1833784 , , O O
13 1442 1449 1833784 whereas IN O O
14 1450 1453 1833784 the DT B-NP O
15 1454 1456 1833784 D1 NN I-NP O
16 1457 1464 1833784 agonist NN I-NP O
17 1465 1468 1833784 SKF NN I-NP B-Chemical
18 1469 1474 1833784 38393 CD I-NP I-Chemical
19 1475 1478 1833784 had VBD B-VP O
20 1479 1481 1833784 no DT B-NP O
21 1482 1488 1833784 effect NN I-NP O
22 1488 1489 1833784 . . O O

1 1490 1493 1833784 The DT B-NP O
2 1494 1501 1833784 results NNS I-NP O
3 1502 1510 1833784 indicate VBP B-VP O
4 1511 1515 1833784 that IN B-SBAR O
5 1516 1521 1833784 acute JJ B-NP O
6 1522 1530 1833784 nicotine NN I-NP B-Chemical
7 1531 1540 1833784 injection NN I-NP O
8 1541 1548 1833784 induces VBZ B-VP O
9 1549 1550 1833784 a DT B-NP O
10 1551 1561 1833784 pronounced JJ I-NP O
11 1562 1575 1833784 hyperactivity NN I-NP B-Disease
12 1576 1578 1833784 in IN B-PP O
13 1579 1583 1833784 rats NNS B-NP O
14 1584 1594 1833784 habituated VBN B-VP O
15 1595 1597 1833784 to TO B-PP O
16 1598 1601 1833784 the DT B-NP O
17 1602 1606 1833784 test NN I-NP O
18 1607 1618 1833784 environment NN I-NP O
19 1618 1619 1833784 . . O O

1 1620 1623 1833784 The DT B-NP O
2 1624 1630 1833784 effect NN I-NP O
3 1631 1638 1833784 appears VBZ B-VP O
4 1639 1641 1833784 to TO I-VP O
5 1642 1644 1833784 be VB I-VP O
6 1645 1653 1833784 mediated VBN I-VP O
7 1654 1656 1833784 by IN B-PP O
8 1657 1664 1833784 central JJ B-NP O
9 1665 1673 1833784 nicotine NN I-NP B-Chemical
10 1674 1683 1833784 receptors NNS I-NP O
11 1683 1684 1833784 , , O O
12 1685 1693 1833784 possibly RB B-VP O
13 1694 1701 1833784 located VBN I-VP O
14 1702 1704 1833784 on IN B-PP O
15 1705 1717 1833784 dopaminergic JJ B-NP O
16 1718 1725 1833784 neurons NNS I-NP O
17 1725 1726 1833784 , , O O
18 1727 1730 1833784 and CC O O
19 1731 1735 1833784 also RB B-VP O
20 1736 1744 1833784 requires VBZ I-VP O
21 1745 1748 1833784 the DT B-NP O
22 1749 1759 1833784 activation NN I-NP O
23 1760 1762 1833784 of IN B-PP O
24 1763 1767 1833784 both CC O O
25 1768 1770 1833784 D1 NN B-NP O
26 1771 1774 1833784 and CC O O
27 1775 1777 1833784 D2 NN B-NP O
28 1778 1786 1833784 dopamine NN I-NP B-Chemical
29 1787 1796 1833784 receptors NNS I-NP O
30 1796 1797 1833784 . . O O

1 0 0 16167916 -DOCSTART- -X- -X- O

1 0 3 16167916 The DT B-NP O
2 4 11 16167916 effects NNS I-NP O
3 12 14 16167916 of IN B-PP O
4 15 20 16167916 short JJ B-NP O
5 20 21 16167916 - HYPH I-NP O
6 21 25 16167916 term NN I-NP O
7 26 36 16167916 raloxifene NN I-NP B-Chemical
8 37 44 16167916 therapy NN I-NP O
9 45 47 16167916 on IN B-PP O
10 48 60 16167916 fibrinolysis NN B-NP O
11 61 68 16167916 markers NNS I-NP O
12 68 69 16167916 : : O O
13 70 74 16167916 TAFI NN B-NP O
14 74 75 16167916 , , O O
15 76 79 16167916 tPA NN B-NP O
16 79 80 16167916 , , O O
17 81 84 16167916 and CC O O
18 85 88 16167916 PAI NN B-NP O
19 88 89 16167916 - HYPH B-NP O
20 89 90 16167916 1 CD I-NP O
21 90 91 16167916 . . I-NP O
22 92 102 16167916 BACKGROUND NN I-NP O
23 102 103 16167916 : : O O
24 104 111 16167916 Markers NNS B-NP O
25 112 114 16167916 of IN B-PP O
26 115 127 16167916 fibrinolysis NN B-NP O
27 127 128 16167916 , , O O
28 129 137 16167916 thrombin NN B-NP O
29 137 138 16167916 - HYPH B-NP O
30 138 149 16167916 activatable JJ I-NP O
31 150 162 16167916 fibrinolysis NN I-NP O
32 163 172 16167916 inhibitor NN I-NP O
33 173 174 16167916 ( ( O O
34 174 178 16167916 TAFI NN B-NP O
35 178 179 16167916 ) ) O O
36 179 180 16167916 , , O O
37 181 187 16167916 tissue NN B-NP O
38 187 188 16167916 - HYPH I-NP O
39 188 192 16167916 type NN I-NP O
40 193 204 16167916 plasminogen NN I-NP O
41 205 214 16167916 activator NN I-NP O
42 215 216 16167916 ( ( O O
43 216 219 16167916 tPA NN B-NP O
44 219 220 16167916 ) ) O O
45 220 221 16167916 , , O O
46 222 225 16167916 and CC O O
47 226 237 16167916 plasminogen NN B-NP O
48 238 247 16167916 activator NN I-NP O
49 248 257 16167916 inhibitor NN I-NP O
50 257 258 16167916 - HYPH B-NP O
51 258 259 16167916 1 CD I-NP O
52 260 261 16167916 ( ( O O
53 261 264 16167916 PAI NN B-NP O
54 264 265 16167916 - HYPH B-NP O
55 265 266 16167916 1 CD I-NP O
56 266 267 16167916 ) ) O O
57 268 274 16167916 levels NNS B-NP O
58 275 279 16167916 were VBD B-VP O
59 280 287 16167916 studied VBN I-VP O
60 288 291 16167916 for IN B-PP O
61 292 295 16167916 the DT B-NP O
62 296 306 16167916 evaluation NN I-NP O
63 307 309 16167916 of IN B-PP O
64 310 315 16167916 short JJ B-NP O
65 315 316 16167916 - HYPH I-NP O
66 316 320 16167916 term NN I-NP O
67 321 328 16167916 effects NNS I-NP O
68 329 331 16167916 of IN B-PP O
69 332 342 16167916 raloxifene NN B-NP B-Chemical
70 343 357 16167916 administration NN I-NP O
71 358 360 16167916 in IN B-PP O
72 361 375 16167916 postmenopausal JJ B-NP O
73 376 381 16167916 women NNS I-NP O
74 381 382 16167916 . . O O

1 383 390 16167916 METHODS NNS B-NP O
2 390 391 16167916 : : O O
3 392 398 16167916 Thirty CD B-NP O
4 398 399 16167916 - HYPH I-NP O
5 399 403 16167916 nine CD I-NP O
6 404 418 16167916 postmenopausal JJ I-NP O
7 419 424 16167916 women NNS I-NP O
8 425 429 16167916 with IN B-PP O
9 430 440 16167916 osteopenia NN B-NP B-Disease
10 441 443 16167916 or CC I-NP O
11 444 456 16167916 osteoporosis NN I-NP B-Disease
12 457 461 16167916 were VBD B-VP O
13 462 470 16167916 included VBN I-VP O
14 471 473 16167916 in IN B-PP O
15 474 478 16167916 this DT B-NP O
16 479 490 16167916 prospective JJ I-NP O
17 490 491 16167916 , , I-NP O
18 492 502 16167916 controlled JJ I-NP O
19 503 511 16167916 clinical JJ I-NP O
20 512 517 16167916 study NN I-NP O
21 517 518 16167916 . . O O

1 519 525 16167916 Twenty CD B-NP O
2 525 526 16167916 - HYPH I-NP O
3 526 530 16167916 five CD I-NP O
4 531 536 16167916 women NNS I-NP O
5 537 541 16167916 were VBD B-VP O
6 542 547 16167916 given VBN I-VP O
7 548 558 16167916 raloxifene NN B-NP B-Chemical
8 559 572 16167916 hydrochloride NN I-NP I-Chemical
9 573 574 16167916 ( ( O O
10 574 576 16167916 60 CD B-NP O
11 577 579 16167916 mg NN I-NP O
12 579 580 16167916 / SYM B-NP O
13 580 583 16167916 day NN I-NP O
14 583 584 16167916 ) ) O O
15 585 589 16167916 plus CC O O
16 590 597 16167916 calcium NN B-NP B-Chemical
17 598 599 16167916 ( ( O O
18 599 602 16167916 500 CD B-NP O
19 603 605 16167916 mg NN I-NP O
20 605 606 16167916 / SYM B-NP O
21 606 609 16167916 day NN I-NP O
22 609 610 16167916 ) ) O O
23 610 611 16167916 . . O O

1 612 615 16167916 Age NN B-NP O
2 615 616 16167916 - HYPH B-NP O
3 616 623 16167916 matched VBN I-NP O
4 624 632 16167916 controls NNS I-NP O
5 633 634 16167916 ( ( O O
6 634 635 16167916 n NN B-NP O
7 636 637 16167916 = SYM B-VP O
8 638 640 16167916 14 CD B-NP O
9 640 641 16167916 ) ) O O
10 642 646 16167916 were VBD B-VP O
11 647 652 16167916 given VBN I-VP O
12 653 657 16167916 only RB B-NP O
13 658 665 16167916 calcium NN I-NP B-Chemical
14 665 666 16167916 . . O O

1 667 673 16167916 Plasma NN B-NP O
2 674 678 16167916 TAFI NN I-NP O
3 678 679 16167916 , , O O
4 680 683 16167916 tPA NN B-NP O
5 683 684 16167916 , , O O
6 685 688 16167916 and CC O O
7 689 692 16167916 PAI NN B-NP O
8 692 693 16167916 - HYPH B-NP O
9 693 694 16167916 1 CD I-NP O
10 695 702 16167916 antigen NN I-NP O
11 703 709 16167916 levels NNS I-NP O
12 710 714 16167916 were VBD B-VP O
13 715 723 16167916 measured VBN I-VP O
14 724 726 16167916 at IN B-PP O
15 727 735 16167916 baseline NN B-NP O
16 736 739 16167916 and CC O O
17 740 745 16167916 after IN B-PP O
18 746 747 16167916 3 CD B-NP O
19 748 754 16167916 months NNS I-NP O
20 755 757 16167916 of IN B-PP O
21 758 767 16167916 treatment NN B-NP O
22 768 770 16167916 by IN B-PP O
23 771 783 16167916 commercially RB B-NP O
24 784 793 16167916 available JJ I-NP O
25 794 799 16167916 ELISA NN I-NP O
26 800 804 16167916 kits NNS I-NP O
27 804 805 16167916 . . O O

1 806 816 16167916 Variations NNS B-NP O
2 817 819 16167916 of IN B-PP O
3 820 831 16167916 individuals NNS B-NP O
4 832 836 16167916 were VBD B-VP O
5 837 845 16167916 assessed VBN I-VP O
6 846 848 16167916 by IN B-PP O
7 849 859 16167916 Wilcoxon's NNP B-NP O
8 860 864 16167916 test NN I-NP O
9 864 865 16167916 . . O O

1 866 878 16167916 Relationship NN B-NP O
2 879 886 16167916 between IN B-PP O
3 887 892 16167916 those DT B-NP O
4 893 900 16167916 markers NNS I-NP O
5 901 904 16167916 and CC O O
6 905 916 16167916 demographic JJ B-NP O
7 917 932 16167916 characteristics NNS I-NP O
8 933 937 16167916 were VBD B-VP O
9 938 950 16167916 investigated VBN I-VP O
10 950 951 16167916 . . O O

1 952 959 16167916 RESULTS NNS B-NP O
2 959 960 16167916 : : O O
3 961 966 16167916 Three CD B-NP O
4 967 973 16167916 months NNS I-NP O
5 974 976 16167916 of IN B-PP O
6 977 987 16167916 raloxifene NN B-NP B-Chemical
7 988 997 16167916 treatment NN I-NP O
8 998 1001 16167916 was VBD B-VP O
9 1002 1012 16167916 associated VBN I-VP O
10 1013 1017 16167916 with IN B-PP O
11 1018 1019 16167916 a DT B-NP O
12 1020 1031 16167916 significant JJ I-NP O
13 1032 1040 16167916 decrease NN I-NP O
14 1041 1043 16167916 in IN B-PP O
15 1044 1047 16167916 the DT B-NP O
16 1048 1054 16167916 plasma NN I-NP O
17 1055 1059 16167916 TAFI NN I-NP O
18 1060 1067 16167916 antigen NN I-NP O
19 1068 1082 16167916 concentrations NNS I-NP O
20 1083 1084 16167916 ( ( O O
21 1084 1087 16167916 16% NN B-NP O
22 1088 1094 16167916 change NN I-NP O
23 1094 1095 16167916 , , O O
24 1096 1097 16167916 P NN B-NP O
25 1098 1099 16167916 < SYM B-NP O
26 1100 1104 16167916 0.01 CD I-NP O
27 1104 1105 16167916 ) ) O O
28 1105 1106 16167916 , , O O
29 1107 1110 16167916 and CC O O
30 1111 1112 16167916 a DT B-NP O
31 1113 1124 16167916 significant JJ I-NP O
32 1125 1133 16167916 increase NN I-NP O
33 1134 1136 16167916 in IN B-PP O
34 1137 1140 16167916 tPA NN B-NP O
35 1141 1148 16167916 antigen NN I-NP O
36 1149 1163 16167916 concentrations NNS I-NP O
37 1164 1165 16167916 ( ( O O
38 1165 1168 16167916 25% CD B-NP O
39 1169 1175 16167916 change NN I-NP O
40 1175 1176 16167916 , , O O
41 1177 1178 16167916 P NN B-NP O
42 1179 1180 16167916 < SYM B-NP O
43 1181 1185 16167916 0.05 CD I-NP O
44 1185 1186 16167916 ) ) O O
45 1186 1187 16167916 . . O O

1 1188 1189 16167916 A DT B-NP O
2 1190 1201 16167916 significant JJ I-NP O
3 1202 1213 16167916 correlation NN I-NP O
4 1214 1217 16167916 was VBD B-VP O
5 1218 1223 16167916 found VBN I-VP O
6 1224 1231 16167916 between IN B-PP O
7 1232 1240 16167916 baseline NN B-NP O
8 1241 1245 16167916 TAFI NN I-NP O
9 1246 1253 16167916 antigen NN I-NP O
10 1254 1268 16167916 concentrations NNS I-NP O
11 1269 1272 16167916 and CC O O
12 1273 1276 16167916 the DT B-NP O
13 1277 1285 16167916 duration NN I-NP O
14 1286 1288 16167916 of IN B-PP O
15 1289 1299 16167916 amenorrhea NN B-NP B-Disease
16 1300 1301 16167916 ( ( O O
17 1301 1302 16167916 P NN B-NP O
18 1303 1304 16167916 < SYM O O
19 1305 1309 16167916 0.05 CD B-NP O
20 1309 1310 16167916 ; : O O
21 1311 1312 16167916 r NN B-NP O
22 1313 1314 16167916 = SYM B-VP O
23 1315 1319 16167916 0.33 CD B-NP O
24 1319 1320 16167916 ) ) O O
25 1320 1321 16167916 . . O O

1 1322 1332 16167916 CONCLUSION NN B-NP O
2 1332 1333 16167916 : : O O
3 1334 1336 16167916 We PRP B-NP O
4 1337 1344 16167916 suggest VBP B-VP O
5 1345 1349 16167916 that IN B-SBAR O
6 1350 1353 16167916 the DT B-NP O
7 1354 1363 16167916 increased VBN I-NP O
8 1364 1368 16167916 risk NN I-NP O
9 1369 1371 16167916 of IN B-PP O
10 1372 1378 16167916 venous JJ B-NP B-Disease
11 1379 1394 16167916 thromboembolism NN I-NP I-Disease
12 1395 1398 16167916 due JJ B-ADJP O
13 1399 1401 16167916 to TO B-PP O
14 1402 1412 16167916 raloxifene NN B-NP B-Chemical
15 1413 1422 16167916 treatment NN I-NP O
16 1423 1426 16167916 may MD B-VP O
17 1427 1429 16167916 be VB I-VP O
18 1430 1437 16167916 related VBN I-VP O
19 1438 1440 16167916 to TO B-PP O
20 1441 1450 16167916 increased VBN B-NP O
21 1451 1454 16167916 tPA NN I-NP O
22 1455 1461 16167916 levels NNS I-NP O
23 1461 1462 16167916 , , O O
24 1463 1466 16167916 but CC O O
25 1467 1470 16167916 not RB O O
26 1471 1475 16167916 TAFI NN B-NP O
27 1476 1482 16167916 levels NNS I-NP O
28 1482 1483 16167916 . . O O

1 0 0 20633755 -DOCSTART- -X- -X- O

1 0 13 20633755 Suxamethonium NN B-NP B-Chemical
2 14 21 20633755 induced VBD B-VP O
3 22 31 20633755 prolonged JJ B-NP O
4 32 37 20633755 apnea NN I-NP B-Disease
5 38 40 20633755 in IN B-PP O
6 41 42 20633755 a DT B-NP O
7 43 50 20633755 patient NN I-NP O
8 51 60 20633755 receiving VBG B-VP O
9 61 78 20633755 electroconvulsive JJ B-NP O
10 79 86 20633755 therapy NN I-NP O
11 86 87 20633755 . . I-NP O
12 88 101 20633755 Suxamethonium NN I-NP B-Chemical
13 102 108 20633755 causes VBZ B-VP O
14 109 118 20633755 prolonged JJ B-NP O
15 119 124 20633755 apnea NN I-NP B-Disease
16 125 127 20633755 in IN B-PP O
17 128 136 20633755 patients NNS B-NP O
18 137 139 20633755 in IN B-PP O
19 140 144 20633755 whom WP B-NP O
20 145 165 20633755 pseudocholinesterase NN B-NP O
21 166 172 20633755 enzyme NN I-NP O
22 173 177 20633755 gets VBZ B-VP O
23 178 189 20633755 deactivated VBN I-VP O
24 190 192 20633755 by IN B-PP O
25 193 209 20633755 organophosphorus NN B-NP B-Chemical
26 210 211 20633755 ( ( O I-Chemical
27 211 213 20633755 OP NN B-NP I-Chemical
28 213 214 20633755 ) ) O I-Chemical
29 215 222 20633755 poisons NNS B-NP I-Chemical
30 222 223 20633755 . . O O

1 224 228 20633755 Here RB B-ADVP O
2 228 229 20633755 , , O O
3 230 232 20633755 we PRP B-NP O
4 233 240 20633755 present VBP B-VP O
5 241 242 20633755 a DT B-NP O
6 243 250 20633755 similar JJ I-NP O
7 251 259 20633755 incident NN I-NP O
8 260 262 20633755 in IN B-PP O
9 263 264 20633755 a DT B-NP O
10 265 273 20633755 severely RB I-NP O
11 274 283 20633755 depressed JJ I-NP B-Disease
12 284 291 20633755 patient NN I-NP O
13 292 295 20633755 who WP B-NP O
14 296 304 20633755 received VBD B-VP O
15 305 322 20633755 electroconvulsive JJ B-NP O
16 323 330 20633755 therapy NN I-NP O
17 331 332 20633755 ( ( O O
18 332 335 20633755 ECT NN B-NP O
19 335 336 20633755 ) ) O O
20 336 337 20633755 . . O O

1 338 347 20633755 Prolonged JJ B-NP O
2 348 353 20633755 apnea NN I-NP B-Disease
3 354 356 20633755 in IN B-PP O
4 357 360 20633755 our PRP$ B-NP O
5 361 365 20633755 case NN I-NP O
6 366 372 20633755 ensued VBD B-VP O
7 373 380 20633755 because IN B-SBAR O
8 381 384 20633755 the DT B-NP O
9 385 396 20633755 information NN I-NP O
10 397 402 20633755 about IN B-PP O
11 403 411 20633755 suicidal JJ B-NP O
12 412 419 20633755 attempt NN I-NP O
13 420 422 20633755 by IN B-PP O
14 423 425 20633755 OP NN B-NP B-Chemical
15 426 434 20633755 compound NN I-NP I-Chemical
16 435 438 20633755 was VBD B-VP O
17 439 448 20633755 concealed VBN I-VP O
18 449 453 20633755 from IN B-PP O
19 454 457 20633755 the DT B-NP O
20 458 466 20633755 treating VBG I-NP O
21 467 471 20633755 team NN I-NP O
22 471 472 20633755 . . O O

1 0 0 3676049 -DOCSTART- -X- -X- O

1 0 8 3676049 Cerebral JJ B-NP O
2 9 14 3676049 blood NN I-NP O
3 15 19 3676049 flow NN I-NP O
4 20 23 3676049 and CC I-NP O
5 24 34 3676049 metabolism NN I-NP O
6 35 41 3676049 during IN B-PP O
7 42 52 3676049 isoflurane NN B-NP B-Chemical
8 52 53 3676049 - HYPH B-NP O
9 53 60 3676049 induced VBN I-NP O
10 61 72 3676049 hypotension NN I-NP B-Disease
11 73 75 3676049 in IN B-PP O
12 76 84 3676049 patients NNS B-NP O
13 85 94 3676049 subjected VBN B-VP O
14 95 97 3676049 to TO B-PP O
15 98 105 3676049 surgery NN B-NP O
16 106 109 3676049 for IN B-PP O
17 110 118 3676049 cerebral JJ B-NP B-Disease
18 119 128 3676049 aneurysms NNS I-NP I-Disease
19 128 129 3676049 . . O O
20 130 138 3676049 Cerebral JJ B-NP O
21 139 144 3676049 blood NN I-NP O
22 145 149 3676049 flow NN I-NP O
23 150 153 3676049 and CC O O
24 154 162 3676049 cerebral JJ B-NP O
25 163 172 3676049 metabolic JJ I-NP O
26 173 177 3676049 rate NN I-NP O
27 178 181 3676049 for IN B-PP O
28 182 188 3676049 oxygen NN B-NP B-Chemical
29 189 193 3676049 were VBD B-VP O
30 194 202 3676049 measured VBN I-VP O
31 203 209 3676049 during IN B-PP O
32 210 220 3676049 isoflurane NN B-NP B-Chemical
33 220 221 3676049 - HYPH B-NP O
34 221 228 3676049 induced VBN I-NP O
35 229 240 3676049 hypotension NN I-NP B-Disease
36 241 243 3676049 in IN B-PP O
37 244 246 3676049 10 CD B-NP O
38 247 255 3676049 patients NNS I-NP O
39 256 265 3676049 subjected VBN B-VP O
40 266 268 3676049 to TO B-PP O
41 269 279 3676049 craniotomy NN B-NP O
42 280 283 3676049 for IN B-PP O
43 284 292 3676049 clipping NN B-NP O
44 293 295 3676049 of IN B-PP O
45 296 297 3676049 a DT B-NP O
46 298 306 3676049 cerebral JJ I-NP B-Disease
47 307 315 3676049 aneurysm NN I-NP I-Disease
48 315 316 3676049 . . O O

1 317 321 3676049 Flow NN B-NP O
2 322 325 3676049 and CC I-NP O
3 326 336 3676049 metabolism NN I-NP O
4 337 341 3676049 were VBD B-VP O
5 342 350 3676049 measured VBN I-VP O
6 351 352 3676049 5 CD B-NP O
7 352 353 3676049 - HYPH I-NP O
8 353 355 3676049 13 CD I-NP O
9 356 360 3676049 days NNS I-NP O
10 361 366 3676049 after IN B-PP O
11 367 370 3676049 the DT B-NP O
12 371 383 3676049 subarachnoid JJ I-NP B-Disease
13 384 395 3676049 haemorrhage NN I-NP I-Disease
14 396 398 3676049 by IN B-PP O
15 399 400 3676049 a DT B-NP O
16 401 413 3676049 modification NN I-NP O
17 414 416 3676049 of IN B-PP O
18 417 420 3676049 the DT B-NP O
19 421 430 3676049 classical JJ I-NP O
20 431 435 3676049 Kety NNP I-NP O
21 435 436 3676049 - HYPH I-NP O
22 436 443 3676049 Schmidt NNP I-NP O
23 444 453 3676049 technique NN I-NP O
24 454 459 3676049 using VBG B-VP O
25 460 465 3676049 xenon NN B-NP B-Chemical
26 465 466 3676049 - HYPH I-NP O
27 466 469 3676049 133 CD I-NP O
28 470 473 3676049 i.v NN I-NP O
29 473 474 3676049 . . O O

1 475 486 3676049 Anaesthesia NN B-NP O
2 487 490 3676049 was VBD B-VP O
3 491 501 3676049 maintained VBN I-VP O
4 502 506 3676049 with IN B-PP O
5 507 509 3676049 an DT B-NP O
6 510 518 3676049 inspired JJ I-NP O
7 519 529 3676049 isoflurane NN I-NP B-Chemical
8 530 543 3676049 concentration NN I-NP O
9 544 546 3676049 of IN B-PP O
10 547 552 3676049 0.75% CD B-NP O
11 553 554 3676049 ( ( O O
12 554 558 3676049 plus CC O O
13 559 562 3676049 67% CD B-NP O
14 563 570 3676049 nitrous JJ I-NP B-Chemical
15 571 576 3676049 oxide NN I-NP I-Chemical
16 577 579 3676049 in IN B-PP O
17 580 586 3676049 oxygen NN B-NP B-Chemical
18 586 587 3676049 ) ) O O
19 587 588 3676049 , , O O
20 589 595 3676049 during IN B-PP O
21 596 601 3676049 which WDT B-NP O
22 602 605 3676049 CBF NN B-NP O
23 606 609 3676049 and CC I-NP O
24 610 615 3676049 CMRO2 NN I-NP O
25 616 620 3676049 were VBD B-VP O
26 621 625 3676049 34.3 CD B-NP O
27 626 627 3676049 + SYM O O
28 627 628 3676049 / SYM O O
29 628 629 3676049 - SYM O O
30 630 633 3676049 2.1 CD B-NP O
31 634 636 3676049 ml NN I-NP O
32 636 637 3676049 / SYM B-NP O
33 637 640 3676049 100 CD B-NP O
34 641 642 3676049 g NN I-NP O
35 643 646 3676049 min NN I-NP O
36 646 647 3676049 - HYPH B-NP O
37 647 648 3676049 1 CD I-NP O
38 649 652 3676049 and CC I-NP O
39 653 657 3676049 2.32 CD I-NP O
40 658 659 3676049 + SYM O O
41 659 660 3676049 / SYM O O
42 660 661 3676049 - SYM O O
43 662 666 3676049 0.16 CD B-NP O
44 667 669 3676049 ml NN I-NP O
45 669 670 3676049 / SYM B-NP O
46 670 673 3676049 100 CD B-NP O
47 674 675 3676049 g NN I-NP O
48 676 679 3676049 min NN I-NP O
49 679 680 3676049 - HYPH B-NP O
50 680 681 3676049 1 CD I-NP O
51 682 684 3676049 at IN B-PP O
52 685 690 3676049 PaCO2 NN B-NP O
53 691 694 3676049 4.1 CD I-NP O
54 695 696 3676049 + SYM O O
55 696 697 3676049 / SYM O O
56 697 698 3676049 - SYM O O
57 699 702 3676049 0.1 CD B-NP O
58 703 706 3676049 kPa NN I-NP O
59 707 708 3676049 ( ( O O
60 708 712 3676049 mean NN B-NP O
61 713 714 3676049 + SYM O O
62 714 715 3676049 / SYM O O
63 715 716 3676049 - HYPH O O
64 717 720 3676049 SEM NN B-NP O
65 720 721 3676049 ) ) O O
66 721 722 3676049 . . O O

1 723 733 3676049 Controlled JJ B-NP O
2 734 745 3676049 hypotension NN I-NP B-Disease
3 746 748 3676049 to TO B-PP O
4 749 751 3676049 an DT B-NP O
5 752 759 3676049 average JJ I-NP O
6 760 763 3676049 MAP NN I-NP O
7 764 766 3676049 of IN B-PP O
8 767 769 3676049 50 CD B-NP O
9 769 770 3676049 - HYPH I-NP O
10 770 772 3676049 55 CD I-NP O
11 773 775 3676049 mm NN I-NP O
12 776 778 3676049 Hg NN I-NP B-Chemical
13 779 782 3676049 was VBD B-VP O
14 783 790 3676049 induced VBN I-VP O
15 791 793 3676049 by IN B-PP O
16 794 804 3676049 increasing VBG B-VP O
17 805 808 3676049 the DT B-NP O
18 809 813 3676049 dose NN I-NP O
19 814 816 3676049 of IN B-PP O
20 817 827 3676049 isoflurane NN B-NP B-Chemical
21 827 828 3676049 , , O O
22 829 832 3676049 and CC O O
23 833 843 3676049 maintained VBD B-VP O
24 844 846 3676049 at IN B-PP O
25 847 849 3676049 an DT B-NP O
26 850 858 3676049 inspired JJ I-NP O
27 859 872 3676049 concentration NN I-NP O
28 873 875 3676049 of IN B-PP O
29 876 879 3676049 2.2 CD B-NP O
30 880 881 3676049 + SYM B-NP O
31 881 882 3676049 / SYM B-NP O
32 882 883 3676049 - SYM B-VP O
33 884 888 3676049 0.2% CD B-NP O
34 888 889 3676049 . . O O

1 890 894 3676049 This DT B-NP O
2 895 903 3676049 resulted VBD B-VP O
3 904 906 3676049 in IN B-PP O
4 907 908 3676049 a DT B-NP O
5 909 920 3676049 significant JJ I-NP O
6 921 929 3676049 decrease NN I-NP O
7 930 932 3676049 in IN B-PP O
8 933 938 3676049 CMRO2 NN B-NP O
9 939 940 3676049 ( ( O O
10 940 942 3676049 to TO B-PP O
11 943 947 3676049 1.73 CD B-NP O
12 948 949 3676049 + SYM O O
13 949 950 3676049 / SYM O O
14 950 951 3676049 - SYM O O
15 952 956 3676049 0.16 CD B-NP O
16 957 959 3676049 ml NN I-NP O
17 959 960 3676049 / SYM B-NP O
18 960 963 3676049 100 CD B-NP O
19 964 965 3676049 g NN I-NP O
20 966 969 3676049 min NN I-NP O
21 969 970 3676049 - HYPH B-NP O
22 970 971 3676049 1 CD I-NP O
23 971 972 3676049 ) ) O O
24 972 973 3676049 , , O O
25 974 979 3676049 while IN B-SBAR O
26 980 983 3676049 CBF NN B-NP O
27 984 987 3676049 was VBD B-VP O
28 988 997 3676049 unchanged JJ B-ADJP O
29 997 998 3676049 . . O O

1 999 1004 3676049 After IN B-PP O
2 1005 1008 3676049 the DT B-NP O
3 1009 1017 3676049 clipping NN I-NP O
4 1018 1020 3676049 of IN B-PP O
5 1021 1024 3676049 the DT B-NP O
6 1025 1033 3676049 aneurysm NN I-NP B-Disease
7 1034 1037 3676049 the DT B-NP O
8 1038 1048 3676049 isoflurane NN I-NP B-Chemical
9 1049 1062 3676049 concentration NN I-NP O
10 1063 1066 3676049 was VBD B-VP O
11 1067 1074 3676049 reduced VBN I-VP O
12 1075 1077 3676049 to TO B-PP O
13 1078 1083 3676049 0.75% CD B-NP O
14 1083 1084 3676049 . . O O

1 1085 1090 3676049 There EX B-NP O
2 1091 1094 3676049 was VBD B-VP O
3 1095 1096 3676049 a DT B-NP O
4 1097 1108 3676049 significant JJ I-NP O
5 1109 1117 3676049 increase NN I-NP O
6 1118 1120 3676049 in IN B-PP O
7 1121 1124 3676049 CBF NN B-NP O
8 1124 1125 3676049 , , O O
9 1126 1134 3676049 although IN B-SBAR O
10 1135 1140 3676049 CMRO2 NN B-NP O
11 1141 1144 3676049 was VBD B-VP O
12 1145 1154 3676049 unchanged JJ B-ADJP O
13 1154 1155 3676049 , , O O
14 1156 1164 3676049 compared VBN B-PP O
15 1165 1169 3676049 with IN B-PP O
16 1170 1173 3676049 pre AFX B-NP O
17 1173 1174 3676049 - HYPH I-NP O
18 1174 1185 3676049 hypotensive JJ I-NP B-Disease
19 1186 1192 3676049 values NNS I-NP O
20 1192 1193 3676049 . . O O

1 1194 1199 3676049 These DT B-NP O
2 1200 1207 3676049 changes NNS I-NP O
3 1208 1213 3676049 might MD B-VP O
4 1214 1219 3676049 offer VB I-VP O
5 1220 1230 3676049 protection NN B-NP O
6 1231 1233 3676049 to TO B-PP O
7 1234 1239 3676049 brain NN B-NP O
8 1240 1246 3676049 tissue NN I-NP O
9 1247 1253 3676049 during IN B-PP O
10 1254 1261 3676049 periods NNS B-NP O
11 1262 1264 3676049 of IN B-PP O
12 1265 1272 3676049 induced VBN B-NP O
13 1273 1284 3676049 hypotension NN I-NP B-Disease
14 1284 1285 3676049 . . O O

1 0 0 15632880 -DOCSTART- -X- -X- O

1 0 14 15632880 Spironolactone NN B-NP B-Chemical
2 14 15 15632880 - HYPH O O
3 15 22 15632880 induced VBN B-NP O
4 23 28 15632880 renal JJ I-NP B-Disease
5 29 42 15632880 insufficiency NN I-NP I-Disease
6 43 46 15632880 and CC I-NP O
7 47 59 15632880 hyperkalemia NN I-NP B-Disease
8 60 62 15632880 in IN B-PP O
9 63 71 15632880 patients NNS B-NP O
10 72 76 15632880 with IN B-PP O
11 77 82 15632880 heart NN B-NP B-Disease
12 83 90 15632880 failure NN I-NP I-Disease
13 90 91 15632880 . . I-NP O
14 92 102 15632880 BACKGROUND NN I-NP O
15 102 103 15632880 : : O O
16 104 105 15632880 A DT B-NP O
17 106 114 15632880 previous JJ I-NP O
18 115 125 15632880 randomized VBN I-NP O
19 126 136 15632880 controlled VBN I-NP O
20 137 142 15632880 trial NN I-NP O
21 143 153 15632880 evaluating VBG B-VP O
22 154 157 15632880 the DT B-NP O
23 158 161 15632880 use NN I-NP O
24 162 164 15632880 of IN B-PP O
25 165 179 15632880 spironolactone NN B-NP B-Chemical
26 180 182 15632880 in IN B-PP O
27 183 188 15632880 heart NN B-NP B-Disease
28 189 196 15632880 failure NN I-NP I-Disease
29 197 205 15632880 patients NNS I-NP O
30 206 214 15632880 reported VBD B-VP O
31 215 216 15632880 a DT B-NP O
32 217 220 15632880 low JJ I-NP O
33 221 225 15632880 risk NN I-NP O
34 226 228 15632880 of IN B-PP O
35 229 241 15632880 hyperkalemia NN B-NP B-Disease
36 242 243 15632880 ( ( O O
37 243 245 15632880 2% NN B-NP O
38 245 246 15632880 ) ) O O
39 247 250 15632880 and CC O O
40 251 256 15632880 renal JJ B-NP B-Disease
41 257 270 15632880 insufficiency NN I-NP I-Disease
42 271 272 15632880 ( ( O O
43 272 274 15632880 0% CD B-NP O
44 274 275 15632880 ) ) O O
45 275 276 15632880 . . O O

1 277 284 15632880 Because IN B-SBAR O
2 285 295 15632880 treatments NNS B-NP O
3 296 299 15632880 for IN B-PP O
4 300 305 15632880 heart NN B-NP B-Disease
5 306 313 15632880 failure NN I-NP I-Disease
6 314 318 15632880 have VBP B-VP O
7 319 326 15632880 changed VBN I-VP O
8 327 332 15632880 since IN B-PP O
9 333 336 15632880 the DT B-NP O
10 337 345 15632880 benefits NNS I-NP O
11 346 348 15632880 of IN B-PP O
12 349 363 15632880 spironolactone NN B-NP B-Chemical
13 364 368 15632880 were VBD B-VP O
14 369 377 15632880 reported VBN I-VP O
15 377 378 15632880 , , O O
16 379 382 15632880 the DT B-NP O
17 383 393 15632880 prevalence NN I-NP O
18 394 396 15632880 of IN B-PP O
19 397 402 15632880 these DT B-NP O
20 403 416 15632880 complications NNS I-NP O
21 417 420 15632880 may MD B-VP O
22 421 427 15632880 differ VB I-VP O
23 428 430 15632880 in IN B-PP O
24 431 438 15632880 current JJ B-NP O
25 439 447 15632880 clinical JJ I-NP O
26 448 456 15632880 practice NN I-NP O
27 456 457 15632880 . . O O

1 458 460 15632880 We PRP B-NP O
2 461 470 15632880 therefore RB B-ADVP O
3 471 477 15632880 sought VBD B-VP O
4 478 480 15632880 to TO I-VP O
5 481 490 15632880 determine VB I-VP O
6 491 494 15632880 the DT B-NP O
7 495 505 15632880 prevalence NN I-NP O
8 506 509 15632880 and CC O O
9 510 518 15632880 clinical JJ B-NP O
10 519 531 15632880 associations NNS I-NP O
11 532 534 15632880 of IN B-PP O
12 535 547 15632880 hyperkalemia NN B-NP B-Disease
13 548 551 15632880 and CC O O
14 552 557 15632880 renal JJ B-NP B-Disease
15 558 571 15632880 insufficiency NN I-NP I-Disease
16 572 574 15632880 in IN B-PP O
17 575 580 15632880 heart NN B-NP B-Disease
18 581 588 15632880 failure NN I-NP I-Disease
19 589 597 15632880 patients NNS I-NP O
20 598 605 15632880 treated VBN B-VP O
21 606 610 15632880 with IN B-PP O
22 611 625 15632880 spironolactone NN B-NP B-Chemical
23 625 626 15632880 . . O O

1 627 634 15632880 METHODS NNS B-NP O
2 634 635 15632880 : : O O
3 636 638 15632880 We PRP B-NP O
4 639 648 15632880 performed VBD B-VP O
5 649 650 15632880 a DT B-NP O
6 651 655 15632880 case NN I-NP O
7 656 663 15632880 control NN I-NP O
8 664 669 15632880 study NN I-NP O
9 670 672 15632880 of IN B-PP O
10 673 678 15632880 heart NN B-NP B-Disease
11 679 686 15632880 failure NN I-NP I-Disease
12 687 695 15632880 patients NNS I-NP O
13 696 703 15632880 treated VBN B-VP O
14 704 708 15632880 with IN B-PP O
15 709 723 15632880 spironolactone NN B-NP B-Chemical
16 724 726 15632880 in IN B-PP O
17 727 730 15632880 our PRP$ B-NP O
18 731 739 15632880 clinical JJ I-NP O
19 740 748 15632880 practice NN I-NP O
20 748 749 15632880 . . O O

1 750 755 15632880 Cases NNS B-NP O
2 756 760 15632880 were VBD B-VP O
3 761 769 15632880 patients NNS B-NP O
4 770 773 15632880 who WP B-NP O
5 774 783 15632880 developed VBD B-VP O
6 784 796 15632880 hyperkalemia NN B-NP B-Disease
7 797 798 15632880 ( ( O O
8 798 802 15632880 K(+) NN B-NP B-Chemical
9 803 804 15632880 > SYM O O
10 804 807 15632880 5.0 CD B-NP O
11 808 811 15632880 mEq NN I-NP O
12 811 812 15632880 / SYM B-NP O
13 812 813 15632880 L NN I-NP O
14 813 814 15632880 ) ) O O
15 815 817 15632880 or CC O O
16 818 823 15632880 renal JJ B-NP B-Disease
17 824 837 15632880 insufficiency NN I-NP I-Disease
18 838 839 15632880 ( ( O O
19 839 841 15632880 Cr NN B-NP B-Chemical
20 842 843 15632880 > SYM B-VP O
21 843 845 15632880 or CC O O
22 845 846 15632880 = SYM B-VP O
23 846 849 15632880 2.5 CD B-NP O
24 850 852 15632880 mg NN I-NP O
25 852 853 15632880 / SYM B-NP O
26 853 855 15632880 dL NN I-NP O
27 855 856 15632880 ) ) O O
28 856 857 15632880 , , O O
29 858 861 15632880 and CC O O
30 862 866 15632880 they PRP B-NP O
31 867 871 15632880 were VBD B-VP O
32 872 880 15632880 compared VBN I-VP O
33 881 883 15632880 to TO B-PP O
34 884 885 15632880 2 CD B-NP O
35 886 894 15632880 randomly RB I-NP O
36 895 903 15632880 selected VBN I-NP O
37 904 912 15632880 controls NNS I-NP O
38 913 916 15632880 per IN B-PP O
39 917 921 15632880 case NN B-NP O
40 921 922 15632880 . . O O

1 923 931 15632880 Clinical JJ B-NP O
2 932 947 15632880 characteristics NNS I-NP O
3 947 948 15632880 , , O O
4 949 960 15632880 medications NNS B-NP O
5 960 961 15632880 , , O O
6 962 965 15632880 and CC O O
7 966 971 15632880 serum NN B-NP O
8 972 983 15632880 chemistries NNS I-NP O
9 984 986 15632880 at IN B-PP O
10 987 995 15632880 baseline NN B-NP O
11 996 999 15632880 and CC O O
12 1000 1006 15632880 follow VB B-VP O
13 1006 1007 15632880 - HYPH O O
14 1007 1009 15632880 up RP B-PRT O
15 1010 1014 15632880 time NN B-NP O
16 1015 1022 15632880 periods NNS I-NP O
17 1023 1027 15632880 were VBD B-VP O
18 1028 1036 15632880 compared VBN I-VP O
19 1036 1037 15632880 . . O O

1 1038 1045 15632880 RESULTS NNS B-NP O
2 1045 1046 15632880 : : O O
3 1047 1052 15632880 Sixty CD B-NP O
4 1052 1053 15632880 - HYPH I-NP O
5 1053 1058 15632880 seven CD I-NP O
6 1059 1061 15632880 of IN B-PP O
7 1062 1065 15632880 926 CD B-NP O
8 1066 1074 15632880 patients NNS I-NP O
9 1075 1076 15632880 ( ( O O
10 1076 1080 15632880 7.2% NN B-NP O
11 1080 1081 15632880 ) ) O O
12 1082 1090 15632880 required VBD B-VP O
13 1091 1106 15632880 discontinuation NN B-NP O
14 1107 1109 15632880 of IN B-PP O
15 1110 1124 15632880 spironolactone NN B-NP B-Chemical
16 1125 1128 15632880 due JJ B-ADJP O
17 1129 1131 15632880 to TO B-PP O
18 1132 1144 15632880 hyperkalemia NN B-NP B-Disease
19 1145 1146 15632880 ( ( O O
20 1146 1147 15632880 n NN B-NP O
21 1148 1149 15632880 = SYM B-VP O
22 1150 1152 15632880 33 CD B-NP O
23 1152 1153 15632880 ) ) O O
24 1154 1156 15632880 or CC O O
25 1157 1162 15632880 renal JJ B-NP B-Disease
26 1163 1170 15632880 failure NN I-NP I-Disease
27 1171 1172 15632880 ( ( O O
28 1172 1173 15632880 n NN B-NP O
29 1174 1175 15632880 = SYM B-VP O
30 1176 1178 15632880 34 CD B-NP O
31 1178 1179 15632880 ) ) O O
32 1179 1180 15632880 . . O O

1 1181 1189 15632880 Patients NNS B-NP O
2 1190 1193 15632880 who WP B-NP O
3 1194 1203 15632880 developed VBD B-VP O
4 1204 1216 15632880 hyperkalemia NN B-NP B-Disease
5 1217 1221 15632880 were VBD B-VP O
6 1222 1227 15632880 older JJR B-ADJP O
7 1228 1231 15632880 and CC O O
8 1232 1236 15632880 more RBR B-ADJP O
9 1237 1243 15632880 likely JJ I-ADJP O
10 1244 1246 15632880 to TO B-VP O
11 1247 1251 15632880 have VB I-VP O
12 1252 1260 15632880 diabetes NNS B-NP B-Disease
13 1260 1261 15632880 , , O O
14 1262 1265 15632880 had VBD B-VP O
15 1266 1272 15632880 higher JJR B-NP O
16 1273 1281 15632880 baseline NN I-NP O
17 1282 1287 15632880 serum NN I-NP O
18 1288 1297 15632880 potassium NN I-NP B-Chemical
19 1298 1304 15632880 levels NNS I-NP O
20 1305 1308 15632880 and CC O O
21 1309 1314 15632880 lower JJR B-NP O
22 1315 1323 15632880 baseline NN I-NP O
23 1324 1333 15632880 potassium NN I-NP B-Chemical
24 1334 1344 15632880 supplement NN I-NP O
25 1345 1350 15632880 doses NNS I-NP O
26 1350 1351 15632880 , , O O
27 1352 1355 15632880 and CC O O
28 1356 1360 15632880 were VBD B-VP O
29 1361 1365 15632880 more RBR B-ADJP O
30 1366 1372 15632880 likely JJ I-ADJP O
31 1373 1375 15632880 to TO B-VP O
32 1376 1378 15632880 be VB I-VP O
33 1379 1386 15632880 treated VBN I-VP O
34 1387 1391 15632880 with IN B-PP O
35 1392 1396 15632880 beta SYM B-NP O
36 1396 1397 15632880 - HYPH B-VP O
37 1397 1405 15632880 blockers NNS B-NP O
38 1406 1410 15632880 than IN B-PP O
39 1411 1419 15632880 controls NNS B-NP O
40 1420 1421 15632880 ( ( O O
41 1421 1422 15632880 n NN B-NP O
42 1423 1424 15632880 = SYM B-VP O
43 1425 1428 15632880 134 CD B-NP O
44 1428 1429 15632880 ) ) O O
45 1429 1430 15632880 . . O O

1 1431 1439 15632880 Patients NNS B-NP O
2 1440 1443 15632880 who WP B-NP O
3 1444 1453 15632880 developed VBD B-VP O
4 1454 1459 15632880 renal JJ B-NP B-Disease
5 1460 1473 15632880 insufficiency NN I-NP I-Disease
6 1474 1477 15632880 had VBD B-VP O
7 1478 1483 15632880 lower JJR B-NP O
8 1484 1492 15632880 baseline NN I-NP O
9 1493 1497 15632880 body NN I-NP O
10 1498 1504 15632880 weight NN I-NP O
11 1505 1508 15632880 and CC O O
12 1509 1515 15632880 higher JJR B-NP O
13 1516 1524 15632880 baseline NN I-NP O
14 1525 1530 15632880 serum NN I-NP O
15 1531 1541 15632880 creatinine NN I-NP B-Chemical
16 1541 1542 15632880 , , O O
17 1543 1551 15632880 required VBD B-VP O
18 1552 1558 15632880 higher JJR B-NP O
19 1559 1564 15632880 doses NNS I-NP O
20 1565 1567 15632880 of IN B-PP O
21 1568 1572 15632880 loop NN B-NP O
22 1573 1582 15632880 diuretics NNS I-NP O
23 1582 1583 15632880 , , O O
24 1584 1587 15632880 and CC O O
25 1588 1592 15632880 were VBD B-VP O
26 1593 1597 15632880 more RBR B-ADJP O
27 1598 1604 15632880 likely JJ I-ADJP O
28 1605 1607 15632880 to TO B-VP O
29 1608 1610 15632880 be VB I-VP O
30 1611 1618 15632880 treated VBN I-VP O
31 1619 1623 15632880 with IN B-PP O
32 1624 1632 15632880 thiazide NN B-NP B-Chemical
33 1633 1642 15632880 diuretics NNS I-NP O
34 1643 1647 15632880 than IN B-PP O
35 1648 1656 15632880 controls NNS B-NP O
36 1656 1657 15632880 . . O O

1 1658 1669 15632880 CONCLUSIONS NNS B-NP O
2 1669 1670 15632880 : : O O
3 1671 1685 15632880 Spironolactone NN B-NP B-Chemical
4 1685 1686 15632880 - HYPH B-NP O
5 1686 1693 15632880 induced VBN I-NP O
6 1694 1706 15632880 hyperkalemia NN I-NP B-Disease
7 1707 1710 15632880 and CC I-NP O
8 1711 1716 15632880 renal JJ I-NP B-Disease
9 1717 1730 15632880 insufficiency NN I-NP I-Disease
10 1731 1734 15632880 are VBP B-VP O
11 1735 1739 15632880 more RBR B-ADJP O
12 1740 1746 15632880 common JJ I-ADJP O
13 1747 1749 15632880 in IN B-PP O
14 1750 1753 15632880 our PRP$ B-NP O
15 1754 1762 15632880 clinical JJ I-NP O
16 1763 1773 15632880 experience NN I-NP O
17 1774 1778 15632880 than IN B-SBAR O
18 1779 1787 15632880 reported VBN B-VP O
19 1788 1798 15632880 previously RB B-ADVP O
20 1798 1799 15632880 . . O O

1 1800 1804 15632880 This DT B-NP O
2 1805 1815 15632880 difference NN I-NP O
3 1816 1818 15632880 is VBZ B-VP O
4 1819 1828 15632880 explained VBN I-VP O
5 1829 1831 15632880 by IN B-PP O
6 1832 1839 15632880 patient NN B-NP O
7 1840 1853 15632880 comorbidities NNS I-NP O
8 1854 1857 15632880 and CC O O
9 1858 1862 15632880 more RBR B-NP O
10 1863 1871 15632880 frequent JJ I-NP O
11 1872 1875 15632880 use NN I-NP O
12 1876 1878 15632880 of IN B-PP O
13 1879 1883 15632880 beta SYM B-NP O
14 1883 1884 15632880 - HYPH B-VP O
15 1884 1892 15632880 blockers NNS B-NP O
16 1892 1893 15632880 . . O O

1 0 0 16574712 -DOCSTART- -X- -X- O

1 0 4 16574712 MDMA NN B-NP B-Chemical
2 5 13 16574712 polydrug NN I-NP O
3 14 19 16574712 users NNS I-NP O
4 20 24 16574712 show VBP B-VP O
5 25 32 16574712 process NN B-NP O
6 32 33 16574712 - HYPH O O
7 33 41 16574712 specific JJ B-NP O
8 42 49 16574712 central JJ I-NP O
9 50 59 16574712 executive NN I-NP O
10 60 71 16574712 impairments NNS I-NP O
11 72 79 16574712 coupled VBN B-VP O
12 80 84 16574712 with IN B-PP O
13 85 93 16574712 impaired VBN B-NP B-Disease
14 94 100 16574712 social JJ I-NP I-Disease
15 101 104 16574712 and CC I-NP I-Disease
16 105 114 16574712 emotional JJ I-NP I-Disease
17 115 124 16574712 judgement NN I-NP I-Disease
18 125 134 16574712 processes NNS I-NP I-Disease
19 134 135 16574712 . . O O
20 136 138 16574712 In IN B-PP O
21 139 145 16574712 recent JJ B-NP O
22 146 151 16574712 years NNS I-NP O
23 152 159 16574712 working VBG B-VP O
24 160 166 16574712 memory NN B-NP B-Disease
25 167 175 16574712 deficits NNS I-NP I-Disease
26 176 180 16574712 have VBP B-VP O
27 181 185 16574712 been VBN I-VP O
28 186 194 16574712 reported VBN I-VP O
29 195 197 16574712 in IN B-PP O
30 198 203 16574712 users NNS B-NP O
31 204 206 16574712 of IN B-PP O
32 207 211 16574712 MDMA NN B-NP B-Chemical
33 212 213 16574712 ( ( O O
34 213 216 16574712 3,4 CD B-NP B-Chemical
35 216 217 16574712 - HYPH I-NP I-Chemical
36 217 246 16574712 methylenedioxymethamphetamine NN I-NP I-Chemical
37 246 247 16574712 , , O O
38 248 255 16574712 ecstasy JJ B-ADJP B-Chemical
39 255 256 16574712 ) ) O O
40 256 257 16574712 . . O O

1 258 261 16574712 The DT B-NP O
2 262 269 16574712 current JJ I-NP O
3 270 275 16574712 study NN I-NP O
4 276 281 16574712 aimed VBD B-VP O
5 282 284 16574712 to TO I-VP O
6 285 291 16574712 assess VB I-VP O
7 292 295 16574712 the DT B-NP O
8 296 302 16574712 impact NN I-NP O
9 303 305 16574712 of IN B-PP O
10 306 310 16574712 MDMA NN B-NP B-Chemical
11 311 314 16574712 use NN I-NP O
12 315 317 16574712 on IN B-PP O
13 318 323 16574712 three CD B-NP O
14 324 332 16574712 separate JJ I-NP O
15 333 340 16574712 central JJ I-NP O
16 341 350 16574712 executive NN I-NP O
17 351 360 16574712 processes NNS I-NP O
18 361 362 16574712 ( ( O O
19 362 365 16574712 set VBN B-VP O
20 366 374 16574712 shifting NN B-NP O
21 374 375 16574712 , , I-NP O
22 376 386 16574712 inhibition NN I-NP O
23 387 390 16574712 and CC I-NP O
24 391 397 16574712 memory NN I-NP O
25 398 406 16574712 updating VBG B-VP O
26 406 407 16574712 ) ) O O
27 408 411 16574712 and CC O O
28 412 416 16574712 also RB B-ADVP O
29 417 419 16574712 on IN B-PP O
30 420 421 16574712 " `` B-NP O
31 421 431 16574712 prefrontal JJ I-NP O
32 431 432 16574712 " '' I-NP O
33 433 441 16574712 mediated VBN I-NP O
34 442 448 16574712 social JJ I-NP O
35 449 452 16574712 and CC I-NP O
36 453 462 16574712 emotional JJ I-NP O
37 463 472 16574712 judgement NN I-NP O
38 473 482 16574712 processes NNS I-NP O
39 482 483 16574712 . . O O

1 484 491 16574712 Fifteen CD B-NP O
2 492 500 16574712 polydrug NN I-NP O
3 501 508 16574712 ecstasy JJ I-NP B-Chemical
4 509 514 16574712 users NNS I-NP O
5 515 518 16574712 and CC O O
6 519 521 16574712 15 CD B-NP O
7 522 530 16574712 polydrug NN I-NP O
8 531 534 16574712 non AFX O O
9 534 535 16574712 - HYPH O O
10 535 542 16574712 ecstasy JJ B-NP B-Chemical
11 543 547 16574712 user NN I-NP O
12 548 556 16574712 controls NNS I-NP O
13 557 566 16574712 completed VBD B-VP O
14 567 568 16574712 a DT B-NP O
15 569 576 16574712 general JJ I-NP O
16 577 581 16574712 drug NN I-NP O
17 582 585 16574712 use NN I-NP O
18 586 599 16574712 questionnaire NN I-NP O
19 599 600 16574712 , , O O
20 601 604 16574712 the DT B-NP O
21 605 612 16574712 Brixton NNP I-NP O
22 613 620 16574712 Spatial NNP I-NP O
23 621 633 16574712 Anticipation NNP I-NP O
24 634 638 16574712 task NN I-NP O
25 639 640 16574712 ( ( O O
26 640 643 16574712 set NN B-NP O
27 644 652 16574712 shifting NN I-NP O
28 652 653 16574712 ) ) O O
29 653 654 16574712 , , O O
30 655 663 16574712 Backward NNP B-NP O
31 664 669 16574712 Digit NNP I-NP O
32 670 674 16574712 Span NNP I-NP O
33 675 684 16574712 procedure NN I-NP O
34 685 686 16574712 ( ( O O
35 686 692 16574712 memory NN B-NP O
36 693 701 16574712 updating VBG B-VP O
37 701 702 16574712 ) ) O O
38 702 703 16574712 , , O O
39 704 714 16574712 Inhibition NN B-NP O
40 715 717 16574712 of IN B-PP O
41 718 724 16574712 Return NN B-NP O
42 725 726 16574712 ( ( O O
43 726 736 16574712 inhibition NN B-NP O
44 736 737 16574712 ) ) O O
45 737 738 16574712 , , O O
46 739 741 16574712 an DT B-NP O
47 742 751 16574712 emotional JJ I-NP O
48 752 764 16574712 intelligence NN I-NP O
49 765 770 16574712 scale NN I-NP O
50 770 771 16574712 , , O O
51 772 775 16574712 the DT B-NP O
52 776 782 16574712 Tromso NNP I-NP O
53 783 789 16574712 Social NNP I-NP O
54 790 802 16574712 Intelligence NNP I-NP O
55 803 808 16574712 Scale NNP I-NP O
56 809 812 16574712 and CC O O
57 813 816 16574712 the DT B-NP O
58 817 829 16574712 Dysexecutive NN I-NP O
59 830 843 16574712 Questionnaire NN I-NP O
60 844 845 16574712 ( ( O O
61 845 848 16574712 DEX NN B-NP O
62 848 849 16574712 ) ) O O
63 849 850 16574712 . . O O

1 851 859 16574712 Compared VBN B-PP O
2 860 864 16574712 with IN B-PP O
3 865 869 16574712 MDMA NN B-NP B-Chemical
4 869 870 16574712 - HYPH B-NP O
5 870 874 16574712 free JJ I-NP O
6 875 883 16574712 polydrug NN I-NP O
7 884 892 16574712 controls NNS I-NP O
8 892 893 16574712 , , O O
9 894 898 16574712 MDMA NN B-NP B-Chemical
10 899 907 16574712 polydrug NN I-NP O
11 908 913 16574712 users NNS I-NP O
12 914 920 16574712 showed VBD B-VP O
13 921 932 16574712 impairments NNS B-NP O
14 933 935 16574712 in IN B-PP O
15 936 939 16574712 set NN B-NP O
16 940 948 16574712 shifting NN I-NP O
17 949 952 16574712 and CC I-NP O
18 953 959 16574712 memory NN I-NP O
19 960 968 16574712 updating VBG B-ADJP O
20 968 969 16574712 , , O O
21 970 973 16574712 and CC O O
22 974 978 16574712 also RB B-ADVP O
23 979 981 16574712 in IN B-PP O
24 982 988 16574712 social JJ B-NP O
25 989 992 16574712 and CC I-NP O
26 993 1002 16574712 emotional JJ I-NP O
27 1003 1012 16574712 judgement NN I-NP O
28 1013 1022 16574712 processes NNS I-NP O
29 1022 1023 16574712 . . O O

1 1024 1027 16574712 The DT B-NP O
2 1028 1034 16574712 latter JJ I-NP O
3 1035 1038 16574712 two CD I-NP O
4 1039 1047 16574712 deficits NNS I-NP O
5 1048 1056 16574712 remained VBD B-VP O
6 1057 1068 16574712 significant JJ B-ADJP O
7 1069 1074 16574712 after IN B-PP O
8 1075 1086 16574712 controlling VBG B-VP O
9 1087 1090 16574712 for IN B-PP O
10 1091 1096 16574712 other JJ B-NP O
11 1097 1101 16574712 drug NN I-NP O
12 1102 1105 16574712 use NN I-NP O
13 1105 1106 16574712 . . O O

1 1107 1112 16574712 These DT B-NP O
2 1113 1117 16574712 data NNS I-NP O
3 1118 1122 16574712 lend VBP B-VP O
4 1123 1130 16574712 further JJ B-NP O
5 1131 1138 16574712 support NN I-NP O
6 1139 1141 16574712 to TO B-PP O
7 1142 1145 16574712 the DT B-NP O
8 1146 1154 16574712 proposal NN I-NP O
9 1155 1159 16574712 that IN B-SBAR O
10 1160 1169 16574712 cognitive JJ B-NP O
11 1170 1179 16574712 processes NNS I-NP O
12 1180 1188 16574712 mediated VBN B-VP O
13 1189 1191 16574712 by IN B-PP O
14 1192 1195 16574712 the DT B-NP O
15 1196 1206 16574712 prefrontal JJ I-NP O
16 1207 1213 16574712 cortex NN I-NP O
17 1214 1217 16574712 may MD B-VP O
18 1218 1220 16574712 be VB I-VP O
19 1221 1229 16574712 impaired VBN I-VP O
20 1230 1232 16574712 by IN B-PP O
21 1233 1245 16574712 recreational JJ B-NP O
22 1246 1253 16574712 ecstasy JJ I-NP B-Chemical
23 1254 1257 16574712 use NN I-NP O
24 1257 1258 16574712 . . O O

1 0 0 2611118 -DOCSTART- -X- -X- O

1 0 7 2611118 Chronic JJ B-NP B-Disease
2 8 14 2611118 active JJ I-NP I-Disease
3 15 24 2611118 hepatitis NN I-NP I-Disease
4 25 35 2611118 associated VBN B-VP O
5 36 40 2611118 with IN B-PP O
6 41 51 2611118 diclofenac NN B-NP B-Chemical
7 52 58 2611118 sodium NN I-NP I-Chemical
8 59 66 2611118 therapy NN I-NP O
9 66 67 2611118 . . O O
10 68 78 2611118 Diclofenac NN B-NP B-Chemical
11 79 85 2611118 sodium NN I-NP I-Chemical
12 86 87 2611118 ( ( O O
13 87 95 2611118 Voltarol NNP B-NP B-Chemical
14 95 96 2611118 , , O O
15 97 102 2611118 Geigy NNP B-NP O
16 103 118 2611118 Pharmaceuticals NNP I-NP O
17 118 119 2611118 ) ) O O
18 120 122 2611118 is VBZ B-VP O
19 123 124 2611118 a DT B-NP O
20 125 128 2611118 non AFX I-NP O
21 128 129 2611118 - HYPH I-NP O
22 129 138 2611118 steroidal JJ I-NP O
23 139 143 2611118 anti AFX I-NP O
24 143 144 2611118 - HYPH I-NP O
25 144 156 2611118 inflammatory JJ I-NP O
26 157 167 2611118 derivative NN I-NP O
27 168 170 2611118 of IN B-PP O
28 171 183 2611118 phenylacetic JJ B-NP B-Chemical
29 184 188 2611118 acid NN I-NP I-Chemical
30 188 189 2611118 . . O O

1 190 198 2611118 Although IN B-SBAR O
2 199 208 2611118 generally RB B-VP O
3 209 213 2611118 well RB I-VP O
4 213 214 2611118 - HYPH I-VP O
5 214 223 2611118 tolerated VBN I-VP O
6 223 224 2611118 , , O O
7 225 237 2611118 asymptomatic JJ B-NP O
8 238 251 2611118 abnormalities NNS I-NP B-Disease
9 252 254 2611118 of IN B-PP I-Disease
10 255 260 2611118 liver NN B-NP I-Disease
11 261 269 2611118 function NN I-NP I-Disease
12 270 274 2611118 have VBP B-VP O
13 275 279 2611118 been VBN I-VP O
14 280 288 2611118 recorded VBN I-VP O
15 289 292 2611118 and CC O O
16 292 293 2611118 , , O O
17 294 298 2611118 less RBR B-ADVP O
18 299 307 2611118 commonly RB I-ADVP O
19 307 308 2611118 , , O O
20 309 315 2611118 severe JJ B-NP O
21 316 325 2611118 hepatitis NN I-NP B-Disease
22 326 333 2611118 induced VBN B-VP O
23 334 336 2611118 by IN B-PP O
24 337 347 2611118 diclofenac NN B-NP B-Chemical
25 347 348 2611118 . . O O

1 349 352 2611118 The DT B-NP O
2 353 360 2611118 patient NN I-NP O
3 361 370 2611118 described VBN B-VP O
4 371 380 2611118 developed VBD B-VP O
5 381 388 2611118 chronic JJ B-NP B-Disease
6 389 395 2611118 active JJ I-NP I-Disease
7 396 405 2611118 hepatitis NN I-NP I-Disease
8 406 411 2611118 after IN B-PP O
9 412 415 2611118 six CD B-NP O
10 416 422 2611118 months NNS I-NP O
11 423 430 2611118 therapy NN B-NP O
12 431 435 2611118 with IN B-PP O
13 436 446 2611118 diclofenac NN B-NP B-Chemical
14 447 453 2611118 sodium NN I-NP I-Chemical
15 454 459 2611118 which WDT B-NP O
16 460 470 2611118 progressed VBD B-VP O
17 471 478 2611118 despite IN B-PP O
18 479 482 2611118 the DT B-NP O
19 483 493 2611118 withdrawal NN I-NP O
20 494 496 2611118 of IN B-PP O
21 497 500 2611118 the DT B-NP O
22 501 505 2611118 drug NN I-NP O
23 505 506 2611118 , , O O
24 507 508 2611118 a DT B-NP O
25 509 516 2611118 finding NN I-NP O
26 517 520 2611118 not RB O O
27 521 531 2611118 previously RB B-VP O
28 532 540 2611118 reported VBN I-VP O
29 540 541 2611118 . . O O

1 0 0 20882060 -DOCSTART- -X- -X- O

1 0 7 20882060 Effects NNS B-NP O
2 8 10 20882060 of IN B-PP O
3 11 19 20882060 pallidal JJ B-NP O
4 20 31 20882060 neurotensin NN I-NP B-Chemical
5 32 34 20882060 on IN B-PP O
6 35 46 20882060 haloperidol NN B-NP B-Chemical
7 46 47 20882060 - HYPH B-NP O
8 47 54 20882060 induced VBN I-NP O
9 55 67 20882060 parkinsonian JJ I-NP B-Disease
10 68 77 20882060 catalepsy NN I-NP I-Disease
11 77 78 20882060 : : O O
12 79 89 20882060 behavioral JJ B-NP O
13 90 93 20882060 and CC I-NP O
14 94 114 20882060 electrophysiological JJ I-NP O
15 115 122 20882060 studies NNS I-NP O
16 122 123 20882060 . . I-NP O
17 124 133 20882060 OBJECTIVE NN I-NP O
18 133 134 20882060 : : O O
19 135 138 20882060 The DT B-NP O
20 139 145 20882060 globus NN I-NP O
21 146 154 20882060 pallidus NN I-NP O
22 155 160 20882060 plays VBZ B-VP O
23 161 162 20882060 a DT B-NP O
24 163 171 20882060 critical JJ I-NP O
25 172 176 20882060 role NN I-NP O
26 177 179 20882060 in IN B-PP O
27 180 188 20882060 movement NN B-NP O
28 189 199 20882060 regulation NN I-NP O
29 199 200 20882060 . . O O

1 201 209 20882060 Previous JJ B-NP O
2 210 217 20882060 studies NNS I-NP O
3 218 222 20882060 have VBP B-VP O
4 223 232 20882060 indicated VBN I-VP O
5 233 237 20882060 that IN B-SBAR O
6 238 241 20882060 the DT B-NP O
7 242 248 20882060 globus NN I-NP O
8 249 257 20882060 pallidus NN I-NP O
9 258 266 20882060 receives VBZ B-VP O
10 267 283 20882060 neurotensinergic JJ B-NP O
11 284 295 20882060 innervation NN I-NP O
12 296 300 20882060 from IN B-PP O
13 301 304 20882060 the DT B-NP O
14 305 313 20882060 striatum NN I-NP O
15 313 314 20882060 , , O O
16 315 318 20882060 and CC O O
17 319 327 20882060 systemic JJ B-NP O
18 328 342 20882060 administration NN I-NP O
19 343 345 20882060 of IN B-PP O
20 346 347 20882060 a DT B-NP O
21 348 359 20882060 neurotensin NN I-NP B-Chemical
22 360 366 20882060 analog NN I-NP O
23 367 372 20882060 could MD B-VP O
24 373 380 20882060 produce VB I-VP O
25 381 397 20882060 antiparkinsonian JJ B-NP O
26 398 405 20882060 effects NNS I-NP O
27 405 406 20882060 . . O O

1 407 410 20882060 The DT B-NP O
2 411 418 20882060 present JJ I-NP O
3 419 424 20882060 study NN I-NP O
4 425 430 20882060 aimed VBD B-VP O
5 431 433 20882060 to TO I-VP O
6 434 445 20882060 investigate VB I-VP O
7 446 449 20882060 the DT B-NP O
8 450 457 20882060 effects NNS I-NP O
9 458 460 20882060 of IN B-PP O
10 461 469 20882060 pallidal JJ B-NP O
11 470 481 20882060 neurotensin NN I-NP B-Chemical
12 482 484 20882060 on IN B-PP O
13 485 496 20882060 haloperidol NN B-NP B-Chemical
14 496 497 20882060 - HYPH O O
15 497 504 20882060 induced VBN B-NP O
16 505 517 20882060 parkinsonian JJ I-NP B-Disease
17 518 526 20882060 symptoms NNS I-NP I-Disease
18 526 527 20882060 . . O O

1 528 535 20882060 METHODS NNS B-NP O
2 535 536 20882060 : : O O
3 537 547 20882060 Behavioral JJ B-NP O
4 548 559 20882060 experiments NNS I-NP O
5 560 563 20882060 and CC O O
6 564 584 20882060 electrophysiological JJ B-NP O
7 585 595 20882060 recordings NNS I-NP O
8 596 600 20882060 were VBD B-VP O
9 601 610 20882060 performed VBN I-VP O
10 611 613 20882060 in IN B-PP O
11 614 617 20882060 the DT B-NP O
12 618 625 20882060 present JJ I-NP O
13 626 631 20882060 study NN I-NP O
14 631 632 20882060 . . O O

1 633 640 20882060 RESULTS NNS B-NP O
2 640 641 20882060 : : O O
3 642 651 20882060 Bilateral JJ B-NP O
4 652 661 20882060 infusions NNS I-NP O
5 662 664 20882060 of IN B-PP O
6 665 676 20882060 neurotensin NN B-NP B-Chemical
7 677 681 20882060 into IN B-PP O
8 682 685 20882060 the DT B-NP O
9 686 692 20882060 globus NN I-NP O
10 693 701 20882060 pallidus NN I-NP O
11 702 710 20882060 reversed VBD B-VP O
12 711 722 20882060 haloperidol NN B-NP B-Chemical
13 722 723 20882060 - HYPH O O
14 723 730 20882060 induced VBN B-NP O
15 731 743 20882060 parkinsonian JJ I-NP B-Disease
16 744 753 20882060 catalepsy NN I-NP I-Disease
17 754 756 20882060 in IN B-PP O
18 757 761 20882060 rats NNS B-NP O
19 761 762 20882060 . . O O

1 763 783 20882060 Electrophysiological JJ B-NP O
2 784 794 20882060 recordings NNS I-NP O
3 795 801 20882060 showed VBD B-VP O
4 802 806 20882060 that IN B-SBAR O
5 807 821 20882060 microinjection NN B-NP O
6 822 824 20882060 of IN B-PP O
7 825 836 20882060 neurotensin NN B-NP B-Chemical
8 837 844 20882060 induced VBD B-VP O
9 845 855 20882060 excitation NN B-NP O
10 856 858 20882060 of IN B-PP O
11 859 867 20882060 pallidal JJ B-NP O
12 868 875 20882060 neurons NNS I-NP O
13 876 878 20882060 in IN B-PP O
14 879 882 20882060 the DT B-NP O
15 883 891 20882060 presence NN I-NP O
16 892 894 20882060 of IN B-PP O
17 895 903 20882060 systemic JJ B-NP O
18 904 915 20882060 haloperidol NN I-NP B-Chemical
19 916 930 20882060 administration NN I-NP O
20 930 931 20882060 . . O O

1 932 935 20882060 The DT B-NP O
2 936 947 20882060 neurotensin NN I-NP B-Chemical
3 948 952 20882060 type NN I-NP I-Chemical
4 952 953 20882060 - HYPH I-NP I-Chemical
5 953 954 20882060 1 CD I-NP I-Chemical
6 955 963 20882060 receptor NN I-NP I-Chemical
7 964 974 20882060 antagonist NN I-NP I-Chemical
8 975 982 20882060 SR48692 NN I-NP B-Chemical
9 983 990 20882060 blocked VBD B-VP O
10 991 995 20882060 both CC O O
11 996 999 20882060 the DT B-NP O
12 1000 1010 20882060 behavioral NN I-NP O
13 1011 1014 20882060 and CC O O
14 1015 1018 20882060 the DT B-NP O
15 1019 1039 20882060 electrophysiological JJ I-NP O
16 1040 1047 20882060 effects NNS I-NP O
17 1048 1055 20882060 induced VBN B-VP O
18 1056 1058 20882060 by IN B-PP O
19 1059 1070 20882060 neurotensin NN B-NP B-Chemical
20 1070 1071 20882060 . . O O

1 1072 1082 20882060 CONCLUSION NN B-NP O
2 1082 1083 20882060 : : O O
3 1084 1094 20882060 Activation NN B-NP O
4 1095 1097 20882060 of IN B-PP O
5 1098 1106 20882060 pallidal JJ B-NP O
6 1107 1118 20882060 neurotensin NN I-NP B-Chemical
7 1119 1128 20882060 receptors NNS I-NP O
8 1129 1132 20882060 may MD B-VP O
9 1133 1135 20882060 be VB I-VP O
10 1136 1144 20882060 involved VBN I-VP O
11 1145 1147 20882060 in IN B-PP O
12 1148 1159 20882060 neurotensin NN B-NP B-Chemical
13 1159 1160 20882060 - HYPH B-NP O
14 1160 1167 20882060 induced VBN I-NP O
15 1168 1184 20882060 antiparkinsonian JJ I-NP O
16 1185 1192 20882060 effects NNS I-NP O
17 1192 1193 20882060 . . O O

1 0 0 11642480 -DOCSTART- -X- -X- O

1 0 9 11642480 Palpebral JJ B-NP B-Disease
2 10 19 11642480 twitching NN I-NP I-Disease
3 20 22 11642480 in IN B-PP O
4 23 24 11642480 a DT B-NP O
5 25 34 11642480 depressed JJ I-NP B-Disease
6 35 45 11642480 adolescent NN I-NP O
7 46 48 11642480 on IN B-PP O
8 49 59 11642480 citalopram NN B-NP B-Chemical
9 59 60 11642480 . . O O
10 61 68 11642480 Current JJ B-NP O
11 69 78 11642480 estimates NNS I-NP O
12 79 86 11642480 suggest VBP B-VP O
13 87 91 11642480 that IN B-SBAR O
14 92 99 11642480 between IN B-NP O
15 100 104 11642480 0.4% CD I-NP O
16 105 108 11642480 and CC I-NP O
17 109 113 11642480 8.3% CD I-NP O
18 114 116 11642480 of IN B-PP O
19 117 125 11642480 children NNS B-NP O
20 126 129 11642480 and CC I-NP O
21 130 141 11642480 adolescents NNS I-NP O
22 142 145 11642480 are VBP B-VP O
23 146 154 11642480 affected VBN I-VP O
24 155 157 11642480 by IN B-PP O
25 158 163 11642480 major JJ B-NP B-Disease
26 164 174 11642480 depression NN I-NP I-Disease
27 174 175 11642480 . . O O

1 176 178 11642480 We PRP B-NP O
2 179 185 11642480 report VBP B-VP O
3 186 187 11642480 a DT B-NP O
4 188 197 11642480 favorable JJ I-NP O
5 198 206 11642480 response NN I-NP O
6 207 209 11642480 to TO B-PP O
7 210 219 11642480 treatment NN B-NP O
8 220 224 11642480 with IN B-PP O
9 225 235 11642480 citalopram NN B-NP B-Chemical
10 236 238 11642480 by IN B-PP O
11 239 240 11642480 a DT B-NP O
12 241 243 11642480 15 CD I-NP O
13 243 244 11642480 - HYPH I-NP O
14 244 248 11642480 year NN I-NP O
15 248 249 11642480 - HYPH O O
16 249 252 11642480 old JJ B-NP O
17 253 256 11642480 boy NN I-NP O
18 257 261 11642480 with IN B-PP O
19 262 267 11642480 major JJ B-NP B-Disease
20 268 278 11642480 depression NN I-NP I-Disease
21 279 282 11642480 who WP B-NP O
22 283 292 11642480 exhibited VBD B-VP O
23 293 302 11642480 palpebral JJ B-NP B-Disease
24 303 312 11642480 twitching NN I-NP I-Disease
25 313 319 11642480 during IN B-PP O
26 320 323 11642480 his PRP$ B-NP O
27 324 329 11642480 first JJ I-NP O
28 330 331 11642480 2 CD I-NP O
29 332 337 11642480 weeks NNS I-NP O
30 338 340 11642480 of IN B-PP O
31 341 350 11642480 treatment NN B-NP O
32 350 351 11642480 . . O O

1 352 356 11642480 This DT B-NP O
2 357 360 11642480 may MD B-VP O
3 361 365 11642480 have VB I-VP O
4 366 370 11642480 been VBN I-VP O
5 371 372 11642480 a DT B-NP O
6 373 377 11642480 side JJ I-NP O
7 378 384 11642480 effect NN I-NP O
8 385 387 11642480 of IN B-PP O
9 388 398 11642480 citalopram NN B-NP B-Chemical
10 399 401 11642480 as IN B-SBAR O
11 402 404 11642480 it PRP B-NP O
12 405 413 11642480 remitted VBD B-VP O
13 414 418 11642480 with IN B-PP O
14 419 433 11642480 redistribution NN B-NP O
15 434 436 11642480 of IN B-PP O
16 437 442 11642480 doses NNS B-NP O
17 442 443 11642480 . . O O

1 0 0 2273650 -DOCSTART- -X- -X- O

1 0 12 2273650 Facilitation NN B-NP O
2 13 15 2273650 of IN B-PP O
3 16 22 2273650 memory NN B-NP O
4 23 32 2273650 retrieval NN I-NP O
5 33 35 2273650 by IN B-PP O
6 36 39 2273650 pre AFX B-NP O
7 39 40 2273650 - HYPH I-NP O
8 40 44 2273650 test NN I-NP O
9 45 53 2273650 morphine NN I-NP B-Chemical
10 54 57 2273650 and CC O O
11 58 61 2273650 its PRP$ B-NP O
12 62 67 2273650 state NN I-NP O
13 68 78 2273650 dependency NN I-NP O
14 79 81 2273650 in IN B-PP O
15 82 85 2273650 the DT B-NP O
16 86 90 2273650 step NN I-NP O
17 90 91 2273650 - HYPH B-VP O
18 91 98 2273650 through IN B-PP O
19 99 103 2273650 type NN B-NP O
20 104 111 2273650 passive JJ I-NP O
21 112 121 2273650 avoidance NN I-NP O
22 122 130 2273650 learning VBG B-VP O
23 131 135 2273650 test NN B-NP O
24 136 138 2273650 in IN B-PP O
25 139 143 2273650 mice NNS B-NP O
26 143 144 2273650 . . O O
27 145 152 2273650 Amnesia NNP B-NP B-Disease
28 153 161 2273650 produced VBN B-VP O
29 162 164 2273650 by IN B-PP O
30 165 176 2273650 scopolamine NN B-NP B-Chemical
31 177 180 2273650 and CC I-NP O
32 181 194 2273650 cycloheximide NN I-NP B-Chemical
33 195 199 2273650 were VBD B-VP O
34 200 208 2273650 reversed VBN I-VP O
35 209 211 2273650 by IN B-PP O
36 212 220 2273650 morphine NN B-NP B-Chemical
37 221 226 2273650 given VBN B-VP O
38 227 229 2273650 30 CD B-NP O
39 230 233 2273650 min NN I-NP O
40 234 240 2273650 before IN B-PP O
41 241 244 2273650 the DT B-NP O
42 245 249 2273650 test NN I-NP O
43 250 255 2273650 trial NN I-NP O
44 256 257 2273650 ( ( O O
45 257 260 2273650 pre AFX O O
46 260 261 2273650 - HYPH O O
47 261 265 2273650 test NN B-NP O
48 265 266 2273650 ) ) O O
49 266 267 2273650 , , O O
50 268 271 2273650 and CC O O
51 272 275 2273650 pre AFX B-NP O
52 275 276 2273650 - HYPH I-NP O
53 276 280 2273650 test NN I-NP O
54 281 289 2273650 morphine NN I-NP B-Chemical
55 290 294 2273650 also RB B-ADVP O
56 295 306 2273650 facilitated VBD B-VP O
57 307 310 2273650 the DT B-NP O
58 311 317 2273650 memory NN I-NP O
59 318 327 2273650 retrieval NN I-NP O
60 328 330 2273650 in IN B-PP O
61 331 334 2273650 the DT B-NP O
62 335 342 2273650 animals NNS I-NP O
63 343 355 2273650 administered VBN B-VP O
64 356 364 2273650 naloxone NN B-NP B-Chemical
65 365 371 2273650 during IN B-PP O
66 372 375 2273650 the DT B-NP O
67 376 384 2273650 training NN I-NP O
68 385 390 2273650 trial NN I-NP O
69 390 391 2273650 . . O O

1 392 401 2273650 Similarly RB B-ADVP O
2 401 402 2273650 , , O O
3 403 406 2273650 pre AFX B-NP O
4 406 407 2273650 - HYPH I-NP O
5 407 411 2273650 test NN I-NP O
6 412 423 2273650 scopolamine NN I-NP B-Chemical
7 424 433 2273650 partially RB B-ADVP O
8 434 442 2273650 reversed VBD B-VP O
9 443 446 2273650 the DT B-NP O
10 447 458 2273650 scopolamine NN I-NP B-Chemical
11 458 459 2273650 - HYPH B-NP O
12 459 466 2273650 induced VBN I-NP O
13 467 474 2273650 amnesia NN I-NP B-Disease
14 474 475 2273650 , , O O
15 476 479 2273650 but CC O O
16 480 483 2273650 not RB O O
17 484 497 2273650 significantly RB B-ADVP O
18 497 498 2273650 ; : O O
19 499 502 2273650 and CC O O
20 503 506 2273650 pre AFX B-NP O
21 506 507 2273650 - HYPH I-NP O
22 507 511 2273650 test NN I-NP O
23 512 525 2273650 cycloheximide NN I-NP B-Chemical
24 526 532 2273650 failed VBD B-VP O
25 533 535 2273650 to TO I-VP O
26 536 543 2273650 reverse VB I-VP O
27 544 547 2273650 the DT B-NP O
28 548 561 2273650 cycloheximide NN I-NP B-Chemical
29 561 562 2273650 - HYPH B-NP O
30 562 569 2273650 induced VBN I-NP O
31 570 577 2273650 amnesia NN I-NP B-Disease
32 577 578 2273650 . . O O

1 579 584 2273650 These DT B-NP O
2 585 592 2273650 results NNS I-NP O
3 593 600 2273650 suggest VBP B-VP O
4 601 605 2273650 that IN B-SBAR O
5 606 609 2273650 the DT B-NP O
6 610 622 2273650 facilitation NN I-NP O
7 623 625 2273650 of IN B-PP O
8 626 632 2273650 memory NN B-NP O
9 633 642 2273650 retrieval NN I-NP O
10 643 645 2273650 by IN B-PP O
11 646 649 2273650 pre AFX B-NP O
12 649 650 2273650 - HYPH I-NP O
13 650 654 2273650 test NN I-NP O
14 655 663 2273650 morphine NN I-NP B-Chemical
15 664 669 2273650 might MD B-VP O
16 670 672 2273650 be VB I-VP O
17 673 676 2273650 the DT B-NP O
18 677 683 2273650 direct JJ I-NP O
19 684 690 2273650 action NN I-NP O
20 691 693 2273650 of IN B-PP O
21 694 702 2273650 morphine NN B-NP B-Chemical
22 703 709 2273650 rather RB B-CONJP O
23 710 714 2273650 than IN I-CONJP O
24 715 716 2273650 a DT B-NP O
25 717 722 2273650 state NN I-NP O
26 723 732 2273650 dependent JJ I-NP O
27 733 739 2273650 effect NN I-NP O
28 739 740 2273650 . . O O

1 0 0 16005948 -DOCSTART- -X- -X- O

1 0 10 16005948 Evaluation NN B-NP O
2 11 13 16005948 of IN B-PP O
3 14 17 16005948 the DT B-NP O
4 18 29 16005948 anticocaine NN I-NP O
5 30 40 16005948 monoclonal JJ I-NP O
6 41 49 16005948 antibody NN I-NP O
7 50 57 16005948 GNC92H2 NN I-NP B-Chemical
8 58 60 16005948 as IN B-PP O
9 61 63 16005948 an DT B-NP O
10 64 77 16005948 immunotherapy NN I-NP O
11 78 81 16005948 for IN B-PP O
12 82 89 16005948 cocaine NN B-NP B-Disease
13 90 98 16005948 overdose NN I-NP I-Disease
14 98 99 16005948 . . O O
15 100 103 16005948 The DT B-NP O
16 104 111 16005948 illicit JJ I-NP O
17 112 115 16005948 use NN I-NP O
18 116 118 16005948 of IN B-PP O
19 119 126 16005948 cocaine NN B-NP B-Chemical
20 127 136 16005948 continues VBZ B-VP O
21 137 139 16005948 in IN B-PP O
22 140 148 16005948 epidemic JJ B-NP O
23 149 160 16005948 proportions NNS I-NP O
24 161 164 16005948 and CC O O
25 165 174 16005948 treatment NN B-NP O
26 175 178 16005948 for IN B-PP O
27 179 186 16005948 cocaine NN B-NP B-Disease
28 187 195 16005948 overdose NN I-NP I-Disease
29 196 203 16005948 remains VBZ B-VP O
30 204 211 16005948 elusive JJ B-ADJP O
31 211 212 16005948 . . O O

1 213 220 16005948 Current JJ B-NP O
2 221 228 16005948 protein NN I-NP O
3 228 229 16005948 - HYPH B-NP O
4 229 234 16005948 based VBN I-NP O
5 235 245 16005948 technology NN I-NP O
6 246 252 16005948 offers VBZ B-VP O
7 253 254 16005948 a DT B-NP O
8 255 258 16005948 new JJ I-NP O
9 259 270 16005948 therapeutic JJ I-NP O
10 271 276 16005948 venue NN I-NP O
11 277 279 16005948 by IN B-PP O
12 280 285 16005948 which WDT B-NP O
13 286 296 16005948 antibodies NNS B-NP O
14 297 301 16005948 bind VBP B-VP O
15 302 305 16005948 the DT B-NP O
16 306 310 16005948 drug NN I-NP O
17 311 313 16005948 in IN B-PP O
18 314 317 16005948 the DT B-NP O
19 318 323 16005948 blood NN I-NP O
20 324 330 16005948 stream NN I-NP O
21 330 331 16005948 , , O O
22 332 344 16005948 inactivating VBG B-VP O
23 345 348 16005948 its PRP$ B-NP O
24 349 354 16005948 toxic JJ I-NP O
25 355 362 16005948 effects NNS I-NP O
26 362 363 16005948 . . O O

1 364 367 16005948 The DT B-NP O
2 368 379 16005948 therapeutic JJ I-NP O
3 380 389 16005948 potential NN I-NP O
4 390 392 16005948 of IN B-PP O
5 393 396 16005948 the DT B-NP O
6 397 408 16005948 anticocaine NN I-NP O
7 409 417 16005948 antibody NN I-NP O
8 418 425 16005948 GNC92H2 NN I-NP B-Chemical
9 426 429 16005948 was VBD B-VP O
10 430 438 16005948 examined VBN I-VP O
11 439 444 16005948 using VBG B-VP O
12 445 446 16005948 a DT B-NP O
13 447 452 16005948 model NN I-NP O
14 453 455 16005948 of IN B-PP O
15 456 463 16005948 cocaine NN B-NP B-Disease
16 464 472 16005948 overdose NN I-NP I-Disease
17 472 473 16005948 . . O O

1 474 479 16005948 Swiss JJ B-NP O
2 480 486 16005948 albino NN I-NP O
3 487 491 16005948 mice NNS I-NP O
4 492 500 16005948 prepared VBN B-VP O
5 501 505 16005948 with IN B-PP O
6 506 518 16005948 intrajugular JJ B-NP O
7 519 528 16005948 catheters NNS I-NP O
8 529 533 16005948 were VBD B-VP O
9 534 540 16005948 tested VBN I-VP O
10 541 543 16005948 in IN B-PP O
11 544 553 16005948 photocell NN B-NP O
12 554 559 16005948 cages NNS I-NP O
13 560 565 16005948 after IN B-PP O
14 566 580 16005948 administration NN B-NP O
15 581 583 16005948 of IN B-PP O
16 584 586 16005948 93 CD B-NP O
17 587 589 16005948 mg NN I-NP O
18 589 590 16005948 / SYM B-NP O
19 590 592 16005948 kg NN B-NP O
20 593 594 16005948 ( ( O O
21 594 598 16005948 LD50 NN B-NP O
22 598 599 16005948 ) ) O O
23 600 602 16005948 of IN B-PP O
24 603 610 16005948 cocaine NN B-NP B-Chemical
25 611 614 16005948 and CC I-NP O
26 615 622 16005948 GNC92H2 NN I-NP B-Chemical
27 623 632 16005948 infusions NNS I-NP O
28 633 640 16005948 ranging VBG B-VP O
29 641 645 16005948 from IN B-PP O
30 646 648 16005948 30 CD B-NP O
31 649 651 16005948 to TO I-NP O
32 652 655 16005948 190 CD I-NP O
33 656 658 16005948 mg NN I-NP O
34 658 659 16005948 / SYM B-NP O
35 659 661 16005948 kg NN I-NP O
36 661 662 16005948 . . O O

1 663 670 16005948 GNC92H2 NN B-NP B-Chemical
2 671 674 16005948 was VBD B-VP O
3 675 684 16005948 delivered VBN I-VP O
4 685 687 16005948 30 CD B-NP O
5 688 691 16005948 min NN I-NP O
6 692 698 16005948 before IN B-ADVP O
7 698 699 16005948 , , O O
8 700 713 16005948 concomitantly RB B-ADVP O
9 714 716 16005948 or CC O O
10 717 718 16005948 3 CD B-NP O
11 719 722 16005948 min NN I-NP O
12 723 728 16005948 after IN B-PP O
13 729 736 16005948 cocaine NN B-NP B-Chemical
14 737 746 16005948 treatment NN I-NP O
15 746 747 16005948 . . O O

1 748 759 16005948 Significant JJ B-NP O
2 760 768 16005948 blockade NN I-NP O
3 769 771 16005948 of IN B-PP O
4 772 779 16005948 cocaine NN B-NP B-Chemical
5 780 788 16005948 toxicity NN I-NP B-Disease
6 789 792 16005948 was VBD B-VP O
7 793 801 16005948 observed VBN I-VP O
8 802 806 16005948 with IN B-PP O
9 807 810 16005948 the DT B-NP O
10 811 817 16005948 higher JJR I-NP O
11 818 822 16005948 dose NN I-NP O
12 823 825 16005948 of IN B-PP O
13 826 833 16005948 GNC92H2 NN B-NP B-Chemical
14 834 835 16005948 ( ( O O
15 835 838 16005948 190 CD B-NP O
16 839 841 16005948 mg NN I-NP O
17 841 842 16005948 / SYM B-NP O
18 842 844 16005948 kg NN I-NP O
19 844 845 16005948 ) ) O O
20 845 846 16005948 , , O O
21 847 852 16005948 where WRB B-ADVP O
22 853 862 16005948 premorbid JJ B-NP O
23 863 872 16005948 behaviors NNS I-NP O
24 873 877 16005948 were VBD B-VP O
25 878 885 16005948 reduced VBN I-VP O
26 886 888 16005948 up RB B-ADVP O
27 889 891 16005948 to TO B-PP O
28 892 895 16005948 40% CD B-NP O
29 895 896 16005948 , , O O
30 897 905 16005948 seizures VBZ B-VP B-Disease
31 906 908 16005948 up RP B-PRT O
32 909 911 16005948 to TO B-PP O
33 912 915 16005948 77% NN B-NP O
34 916 919 16005948 and CC I-NP O
35 920 925 16005948 death NN I-NP B-Disease
36 926 928 16005948 by IN B-PP O
37 929 932 16005948 72% NN B-NP O
38 932 933 16005948 . . O O

1 934 945 16005948 Importantly RB B-ADVP O
2 945 946 16005948 , , O O
3 947 954 16005948 GNC92H2 NN B-NP B-Chemical
4 955 964 16005948 prevented VBD B-VP O
5 965 970 16005948 death NN B-NP B-Disease
6 971 975 16005948 even RB B-ADVP O
7 976 980 16005948 post AFX B-NP O
8 980 981 16005948 - HYPH I-NP O
9 981 988 16005948 cocaine NN B-NP B-Chemical
10 989 998 16005948 injection NN I-NP O
11 998 999 16005948 . . O O

1 1000 1003 16005948 The DT B-NP O
2 1004 1011 16005948 results NNS I-NP O
3 1012 1019 16005948 support VBP B-VP O
4 1020 1023 16005948 the DT B-NP O
5 1024 1033 16005948 important JJ I-NP O
6 1034 1043 16005948 potential NN I-NP O
7 1044 1046 16005948 of IN B-PP O
8 1047 1054 16005948 GNC92H2 NN B-NP B-Chemical
9 1055 1057 16005948 as IN B-PP O
10 1058 1059 16005948 a DT B-NP O
11 1060 1071 16005948 therapeutic JJ I-NP O
12 1072 1076 16005948 tool NN I-NP O
13 1077 1084 16005948 against IN B-PP O
14 1085 1092 16005948 cocaine NN B-NP B-Disease
15 1093 1101 16005948 overdose NN I-NP I-Disease
16 1101 1102 16005948 . . O O

1 0 0 2334618 -DOCSTART- -X- -X- O

1 0 10 2334618 Comparison NN B-NP O
2 11 13 2334618 of IN B-PP O
3 14 17 2334618 the DT B-NP O
4 18 29 2334618 respiratory JJ I-NP O
5 30 37 2334618 effects NNS I-NP O
6 38 40 2334618 of IN B-PP O
7 41 44 2334618 i.v NN B-NP O
8 44 45 2334618 . . O O

1 46 55 2334618 infusions NNS B-NP O
2 56 58 2334618 of IN B-PP O
3 59 67 2334618 morphine NN B-NP B-Chemical
4 68 71 2334618 and CC O O
5 72 80 2334618 regional JJ B-NP O
6 81 90 2334618 analgesia NN I-NP O
7 91 93 2334618 by IN B-PP O
8 94 104 2334618 extradural JJ B-NP O
9 105 110 2334618 block NN I-NP O
10 110 111 2334618 . . O O
11 112 115 2334618 The DT B-NP O
12 116 125 2334618 incidence NN I-NP O
13 126 128 2334618 of IN B-PP O
14 129 142 2334618 postoperative JJ B-NP O
15 143 154 2334618 respiratory JJ I-NP O
16 155 161 2334618 apnoea NN I-NP B-Disease
17 162 165 2334618 was VBD B-VP O
18 166 174 2334618 compared VBN I-VP O
19 175 182 2334618 between IN B-PP O
20 183 187 2334618 five CD B-NP O
21 188 196 2334618 patients NNS I-NP O
22 197 206 2334618 receiving VBG B-VP O
23 207 208 2334618 a DT B-NP O
24 209 219 2334618 continuous JJ I-NP O
25 220 223 2334618 i.v NN I-NP O
26 223 224 2334618 . . O O

1 225 233 2334618 infusion NN B-NP O
2 234 236 2334618 of IN B-PP O
3 237 245 2334618 morphine NN B-NP B-Chemical
4 246 247 2334618 ( ( O O
5 247 251 2334618 mean NN B-NP O
6 252 256 2334618 73.6 CD I-NP O
7 257 259 2334618 mg NN I-NP O
8 259 260 2334618 ) ) O O
9 261 264 2334618 and CC O O
10 265 269 2334618 five CD B-NP O
11 270 278 2334618 patients NNS I-NP O
12 279 288 2334618 receiving VBG B-VP O
13 289 290 2334618 a DT B-NP O
14 291 301 2334618 continuous JJ I-NP O
15 302 312 2334618 extradural JJ I-NP O
16 313 321 2334618 infusion NN I-NP O
17 322 324 2334618 of IN B-PP O
18 325 330 2334618 0.25% CD B-NP O
19 331 342 2334618 bupivacaine NN I-NP B-Chemical
20 343 344 2334618 ( ( O O
21 344 348 2334618 mean NN B-NP O
22 349 352 2334618 192 CD I-NP O
23 353 355 2334618 mg NN I-NP O
24 355 356 2334618 ) ) O O
25 357 359 2334618 in IN B-PP O
26 360 363 2334618 the DT B-NP O
27 364 366 2334618 24 CD I-NP O
28 366 367 2334618 - HYPH I-NP O
29 367 368 2334618 h NN I-NP O
30 369 375 2334618 period NN I-NP O
31 376 385 2334618 following VBG B-PP O
32 386 391 2334618 upper JJ B-NP O
33 392 401 2334618 abdominal JJ I-NP O
34 402 409 2334618 surgery NN I-NP O
35 409 410 2334618 . . O O

1 411 421 2334618 Monitoring NNP B-NP O
2 422 431 2334618 consisted VBD B-VP O
3 432 434 2334618 of IN B-PP O
4 435 442 2334618 airflow NN B-NP O
5 443 452 2334618 detection NN I-NP O
6 453 455 2334618 by IN B-PP O
7 456 457 2334618 a DT B-NP O
8 458 464 2334618 carbon NN I-NP B-Chemical
9 465 472 2334618 dioxide NN I-NP I-Chemical
10 473 481 2334618 analyser NN I-NP O
11 481 482 2334618 , , O O
12 483 488 2334618 chest NN B-NP O
13 489 493 2334618 wall NN I-NP O
14 494 502 2334618 movement NN I-NP O
15 503 511 2334618 detected VBN B-VP O
16 512 514 2334618 by IN B-PP O
17 515 524 2334618 pneumatic JJ B-NP O
18 525 533 2334618 capsules NNS I-NP O
19 533 534 2334618 , , O O
20 535 538 2334618 and CC O O
21 539 549 2334618 continuous JJ B-NP O
22 550 568 2334618 electrocardiograph NN I-NP O
23 569 577 2334618 recorded VBN B-VP O
24 578 582 2334618 with IN B-PP O
25 583 584 2334618 a DT B-NP O
26 585 591 2334618 Holter NNP I-NP O
27 592 602 2334618 ambulatory JJ I-NP O
28 603 610 2334618 monitor NN I-NP O
29 610 611 2334618 . . O O

1 612 616 2334618 Both CC O O
2 617 628 2334618 obstructive JJ O B-Disease
3 629 630 2334618 ( ( O I-Disease
4 630 631 2334618 P NN B-NP I-Disease
5 632 636 2334618 less JJR B-ADJP I-Disease
6 637 641 2334618 than IN B-PP I-Disease
7 642 646 2334618 0.05 CD B-NP I-Disease
8 646 647 2334618 ) ) O I-Disease
9 648 651 2334618 and CC O I-Disease
10 652 659 2334618 central JJ B-NP I-Disease
11 660 666 2334618 apnoea NN I-NP I-Disease
12 667 668 2334618 ( ( O O
13 668 669 2334618 P NN B-NP O
14 670 674 2334618 less JJR B-ADJP O
15 675 679 2334618 than IN B-PP O
16 680 684 2334618 0.05 CD B-NP O
17 684 685 2334618 ) ) O O
18 686 694 2334618 occurred VBD B-VP O
19 695 699 2334618 more RBR B-ADVP O
20 700 710 2334618 frequently RB I-ADVP O
21 711 713 2334618 in IN B-PP O
22 714 722 2334618 patients NNS B-NP O
23 723 726 2334618 who WP B-NP O
24 727 730 2334618 had VBD B-VP O
25 731 732 2334618 a DT B-NP O
26 733 741 2334618 morphine NN I-NP B-Chemical
27 742 750 2334618 infusion NN I-NP O
28 750 751 2334618 . . O O

1 752 757 2334618 There EX B-NP O
2 758 761 2334618 was VBD B-VP O
3 762 766 2334618 also RB B-ADVP O
4 767 768 2334618 a DT B-NP O
5 769 775 2334618 higher JJR I-NP O
6 776 785 2334618 incidence NN I-NP O
7 786 788 2334618 of IN B-PP O
8 789 805 2334618 tachyarrhythmias NNS B-NP B-Disease
9 806 807 2334618 ( ( O O
10 807 808 2334618 P NN B-NP O
11 809 813 2334618 less JJR B-ADJP O
12 814 818 2334618 than IN B-PP O
13 819 823 2334618 0.05 CD B-NP O
14 823 824 2334618 ) ) O O
15 825 828 2334618 and CC O O
16 829 840 2334618 ventricular JJ B-NP B-Disease
17 841 848 2334618 ectopic JJ I-NP I-Disease
18 849 854 2334618 beats NNS I-NP I-Disease
19 855 856 2334618 ( ( O O
20 856 857 2334618 P NN B-NP O
21 858 862 2334618 less JJR B-ADJP O
22 863 867 2334618 than IN B-PP O
23 868 872 2334618 0.05 CD B-NP O
24 872 873 2334618 ) ) O O
25 874 876 2334618 in IN B-PP O
26 877 880 2334618 the DT B-NP O
27 881 889 2334618 morphine NN I-NP B-Chemical
28 890 898 2334618 infusion NN I-NP O
29 899 904 2334618 group NN I-NP O
30 904 905 2334618 . . O O

1 0 0 8319760 -DOCSTART- -X- -X- O

1 0 3 8319760 Dup IN B-PP B-Chemical
2 4 7 8319760 753 CD B-NP I-Chemical
3 8 16 8319760 prevents NNS I-NP O
4 17 20 8319760 the DT B-NP O
5 21 32 8319760 development NN I-NP O
6 33 35 8319760 of IN B-PP O
7 36 45 8319760 puromycin NN B-NP B-Chemical
8 46 61 8319760 aminonucleoside NN I-NP I-Chemical
9 61 62 8319760 - HYPH B-NP O
10 62 69 8319760 induced VBN I-NP O
11 70 79 8319760 nephrosis NN I-NP B-Disease
12 79 80 8319760 . . O O
13 81 84 8319760 The DT B-NP O
14 85 95 8319760 appearance NN I-NP O
15 96 98 8319760 of IN B-PP O
16 99 108 8319760 nephrotic JJ B-NP B-Disease
17 109 118 8319760 syndromes NNS I-NP I-Disease
18 119 123 8319760 such JJ B-PP O
19 124 126 8319760 as IN I-PP O
20 127 138 8319760 proteinuria NN B-NP B-Disease
21 138 139 8319760 , , O O
22 140 155 8319760 hypoalbuminemia NN B-NP B-Disease
23 155 156 8319760 , , O O
24 157 177 8319760 hypercholesterolemia NN B-NP B-Disease
25 178 181 8319760 and CC I-NP O
26 182 190 8319760 increase NN I-NP O
27 191 193 8319760 in IN B-PP O
28 194 199 8319760 blood NN B-NP B-Chemical
29 200 208 8319760 nitrogen NN I-NP I-Chemical
30 209 213 8319760 urea NN I-NP I-Chemical
31 213 214 8319760 , , O O
32 215 222 8319760 induced VBN B-VP O
33 223 225 8319760 in IN B-PP O
34 226 230 8319760 rats NNS B-NP O
35 231 233 8319760 by IN B-PP O
36 234 243 8319760 injection NN B-NP O
37 244 246 8319760 of IN B-PP O
38 247 256 8319760 puromycin NN B-NP B-Chemical
39 257 272 8319760 aminonucleoside NN I-NP I-Chemical
40 273 276 8319760 was VBD B-VP O
41 277 285 8319760 markedly RB I-VP O
42 286 295 8319760 inhibited VBN I-VP O
43 296 298 8319760 by IN B-PP O
44 299 303 8319760 oral JJ B-NP O
45 304 318 8319760 administration NN I-NP O
46 319 321 8319760 of IN B-PP O
47 322 325 8319760 Dup NN B-NP B-Chemical
48 326 329 8319760 753 CD I-NP I-Chemical
49 330 331 8319760 ( ( O O
50 331 339 8319760 losartan NN B-NP B-Chemical
51 339 340 8319760 ) ) O O
52 340 341 8319760 , , O O
53 342 343 8319760 a DT B-NP O
54 344 349 8319760 novel JJ I-NP O
55 350 361 8319760 angiotensin NN I-NP B-Chemical
56 362 364 8319760 II CD I-NP I-Chemical
57 365 373 8319760 receptor NN I-NP O
58 374 384 8319760 antagonist NN I-NP O
59 384 385 8319760 , , O O
60 386 388 8319760 at IN B-PP O
61 389 390 8319760 a DT B-NP O
62 391 395 8319760 dose NN I-NP O
63 396 398 8319760 of IN B-PP O
64 399 400 8319760 1 CD B-NP O
65 401 403 8319760 or CC I-NP O
66 404 405 8319760 2 CD I-NP O
67 406 408 8319760 mg NN I-NP O
68 408 409 8319760 / SYM B-NP O
69 409 411 8319760 kg NN I-NP O
70 412 415 8319760 per IN B-PP O
71 416 419 8319760 day NN B-NP O
72 419 420 8319760 . . O O

1 421 424 8319760 The DT B-NP O
2 425 432 8319760 results NNS I-NP O
3 433 440 8319760 suggest VBP B-VP O
4 441 442 8319760 a DT B-NP O
5 443 451 8319760 possible JJ I-NP O
6 452 463 8319760 involvement NN I-NP O
7 464 466 8319760 of IN B-PP O
8 467 470 8319760 the DT B-NP O
9 471 476 8319760 renin NN I-NP O
10 476 477 8319760 - HYPH I-NP O
11 477 488 8319760 angiotensin NN I-NP B-Chemical
12 489 495 8319760 system NN I-NP O
13 496 498 8319760 in IN B-PP O
14 499 502 8319760 the DT B-NP O
15 503 514 8319760 development NN I-NP O
16 515 517 8319760 of IN B-PP O
17 518 527 8319760 puromycin NN B-NP B-Chemical
18 528 543 8319760 aminonucleoside NN I-NP I-Chemical
19 543 544 8319760 - HYPH B-NP O
20 544 551 8319760 induced VBN I-NP O
21 552 561 8319760 nephrosis NN I-NP B-Disease
22 561 562 8319760 . . O O

1 0 0 9199746 -DOCSTART- -X- -X- O

1 0 6 9199746 Macula NN B-NP O
2 7 15 9199746 toxicity NN I-NP B-Disease
3 16 21 9199746 after IN B-PP O
4 22 34 9199746 intravitreal JJ B-NP O
5 35 43 9199746 amikacin NN I-NP B-Chemical
6 43 44 9199746 . . I-NP O
7 45 55 9199746 BACKGROUND NN I-NP O
8 55 56 9199746 : : O O
9 57 65 9199746 Although IN B-SBAR O
10 66 78 9199746 intravitreal JJ B-NP O
11 79 94 9199746 aminoglycosides NNS I-NP B-Chemical
12 95 99 9199746 have VBP B-VP O
13 100 113 9199746 substantially RB I-VP O
14 114 122 9199746 improved VBN I-VP O
15 123 129 9199746 visual JJ B-NP O
16 130 139 9199746 prognosis NN I-NP O
17 140 142 9199746 in IN B-PP O
18 143 158 9199746 endophthalmitis NN B-NP B-Disease
19 158 159 9199746 , , O O
20 160 167 9199746 macular JJ B-NP O
21 168 178 9199746 infarction NN I-NP B-Disease
22 179 182 9199746 may MD B-VP O
23 183 189 9199746 impair VB I-VP O
24 190 194 9199746 full JJ B-NP O
25 195 201 9199746 visual JJ I-NP O
26 202 210 9199746 recovery NN I-NP O
27 210 211 9199746 . . O O

1 212 219 9199746 METHODS NNS B-NP O
2 219 220 9199746 : : O O
3 221 223 9199746 We PRP B-NP O
4 224 231 9199746 present VBP B-VP O
5 232 233 9199746 a DT B-NP O
6 234 238 9199746 case NN I-NP O
7 239 241 9199746 of IN B-PP O
8 242 250 9199746 presumed VBN B-NP O
9 251 259 9199746 amikacin NN I-NP B-Chemical
10 260 267 9199746 retinal NN I-NP B-Disease
11 268 276 9199746 toxicity NN I-NP I-Disease
12 277 286 9199746 following VBG B-PP O
13 287 296 9199746 treatment NN B-NP O
14 297 301 9199746 with IN B-PP O
15 302 310 9199746 amikacin NN B-NP B-Chemical
16 311 314 9199746 and CC I-NP O
17 315 325 9199746 vancomycin NN I-NP B-Chemical
18 326 329 9199746 for IN B-PP O
19 330 335 9199746 alpha SYM B-NP O
20 335 336 9199746 - HYPH B-NP O
21 336 346 9199746 haemolytic JJ I-NP O
22 347 360 9199746 streptococcal JJ I-NP B-Disease
23 361 376 9199746 endophthalmitis NN I-NP I-Disease
24 376 377 9199746 . . O O

1 378 385 9199746 RESULTS NNS B-NP O
2 385 386 9199746 : : O O
3 387 402 9199746 Endophthalmitis NN B-NP B-Disease
4 403 411 9199746 resolved VBN B-VP O
5 412 416 9199746 with IN B-PP O
6 417 428 9199746 improvement NN B-NP O
7 429 431 9199746 in IN B-PP O
8 432 438 9199746 visual JJ B-NP O
9 439 445 9199746 acuity NN I-NP O
10 446 448 9199746 to TO B-PP O
11 449 450 9199746 6 CD B-NP O
12 450 451 9199746 / SYM B-NP O
13 451 453 9199746 24 CD I-NP O
14 454 456 9199746 at IN B-PP O
15 457 462 9199746 three CD B-NP O
16 463 469 9199746 months NNS I-NP O
17 469 470 9199746 . . O O

1 471 477 9199746 Fundus NN B-NP O
2 478 489 9199746 fluorescein NN I-NP B-Chemical
3 490 501 9199746 angiography NN I-NP O
4 502 511 9199746 confirmed VBD B-VP O
5 512 519 9199746 macular JJ B-NP O
6 520 529 9199746 capillary JJ I-NP O
7 530 537 9199746 closure NN I-NP O
8 538 541 9199746 and CC I-NP O
9 542 556 9199746 telangiectasis NN I-NP B-Disease
10 556 557 9199746 . . O O

1 558 569 9199746 CONCLUSIONS NNS B-NP O
2 569 570 9199746 : : O O
3 571 580 9199746 Currently RB B-NP O
4 581 589 9199746 accepted VBN I-NP O
5 590 602 9199746 intravitreal JJ I-NP O
6 603 613 9199746 antibiotic JJ I-NP O
7 614 622 9199746 regimens NNS I-NP O
8 623 626 9199746 may MD B-VP O
9 627 632 9199746 cause VB I-VP O
10 633 640 9199746 retinal JJ B-NP B-Disease
11 641 649 9199746 toxicity NN I-NP I-Disease
12 650 653 9199746 and CC O O
13 654 661 9199746 macular JJ B-NP O
14 662 671 9199746 ischaemia NN I-NP B-Disease
15 671 672 9199746 . . O O

1 673 682 9199746 Treatment NN B-NP O
2 683 693 9199746 strategies NNS I-NP O
3 694 699 9199746 aimed VBN B-VP O
4 700 702 9199746 at IN B-PP O
5 703 711 9199746 avoiding VBG B-VP O
6 712 719 9199746 retinal JJ B-NP B-Disease
7 720 728 9199746 toxicity NN I-NP I-Disease
8 729 732 9199746 are VBP B-VP O
9 733 742 9199746 discussed VBN I-VP O
10 742 743 9199746 . . O O

1 0 0 19037603 -DOCSTART- -X- -X- O

1 0 12 19037603 Prophylactic JJ B-NP O
2 13 16 19037603 use NN I-NP O
3 17 19 19037603 of IN B-PP O
4 20 30 19037603 lamivudine NN B-NP B-Chemical
5 31 35 19037603 with IN B-PP O
6 36 43 19037603 chronic JJ B-NP O
7 44 61 19037603 immunosuppressive JJ I-NP O
8 62 69 19037603 therapy NN I-NP O
9 70 73 19037603 for IN B-PP O
10 74 87 19037603 rheumatologic JJ B-NP B-Disease
11 88 97 19037603 disorders NNS I-NP I-Disease
12 97 98 19037603 . . O O
13 99 102 19037603 The DT B-NP O
14 103 112 19037603 objective NN I-NP O
15 113 115 19037603 of IN B-PP O
16 116 120 19037603 this DT B-NP O
17 121 126 19037603 study NN I-NP O
18 127 130 19037603 was VBD B-VP O
19 131 133 19037603 to TO I-VP O
20 134 140 19037603 report VB I-VP O
21 141 144 19037603 our PRP$ B-NP O
22 145 155 19037603 experience NN I-NP O
23 156 166 19037603 concerning VBG B-VP O
24 167 170 19037603 the DT B-NP O
25 171 184 19037603 effectiveness NN I-NP O
26 185 187 19037603 of IN B-PP O
27 188 191 19037603 the DT B-NP O
28 192 204 19037603 prophylactic JJ I-NP O
29 205 219 19037603 administration NN I-NP O
30 220 222 19037603 of IN B-PP O
31 223 233 19037603 lamivudine NN B-NP B-Chemical
32 234 236 19037603 in IN B-PP O
33 237 246 19037603 hepatitis NN B-NP B-Chemical
34 247 248 19037603 B NN I-NP I-Chemical
35 249 254 19037603 virus NN I-NP I-Chemical
36 255 262 19037603 surface NN I-NP I-Chemical
37 263 270 19037603 antigen NN I-NP I-Chemical
38 271 272 19037603 ( ( O O
39 272 275 19037603 HBs NNS B-NP B-Chemical
40 276 278 19037603 Ag NN I-NP I-Chemical
41 278 279 19037603 ) ) O O
42 280 288 19037603 positive JJ B-NP O
43 289 297 19037603 patients NNS I-NP O
44 298 302 19037603 with IN B-PP O
45 303 316 19037603 rheumatologic JJ B-NP B-Disease
46 317 324 19037603 disease NN I-NP I-Disease
47 324 325 19037603 . . O O

1 326 330 19037603 From IN B-PP O
2 331 335 19037603 June NNP B-NP O
3 336 340 19037603 2004 CD I-NP O
4 341 343 19037603 to TO B-PP O
5 344 351 19037603 October NNP B-NP O
6 352 356 19037603 2006 CD I-NP O
7 356 357 19037603 , , I-NP O
8 358 360 19037603 11 CD I-NP O
9 361 364 19037603 HBs NNS I-NP B-Chemical
10 365 367 19037603 Ag NN I-NP I-Chemical
11 368 376 19037603 positive JJ B-NP O
12 377 385 19037603 patients NNS I-NP O
13 386 390 19037603 with IN B-PP O
14 391 404 19037603 rheumatologic JJ B-NP B-Disease
15 405 413 19037603 diseases NNS I-NP I-Disease
16 413 414 19037603 , , O O
17 415 418 19037603 who WP B-NP O
18 419 423 19037603 were VBD B-VP O
19 424 426 19037603 on IN B-PP O
20 427 431 19037603 both CC B-NP O
21 432 449 19037603 immunosuppressive JJ I-NP O
22 450 453 19037603 and CC I-NP O
23 454 466 19037603 prophylactic JJ I-NP O
24 467 477 19037603 lamivudine NN I-NP B-Chemical
25 478 487 19037603 therapies NNS I-NP O
26 487 488 19037603 , , O O
27 489 493 19037603 were VBD B-VP O
28 494 509 19037603 retrospectively RB I-VP O
29 510 518 19037603 assessed VBN I-VP O
30 518 519 19037603 . . O O

1 520 525 19037603 Liver NN B-NP O
2 526 534 19037603 function NN I-NP O
3 535 540 19037603 tests NNS I-NP O
4 540 541 19037603 , , O O
5 542 551 19037603 hepatitis NN B-NP B-Disease
6 552 553 19037603 B NN I-NP I-Disease
7 554 559 19037603 virus NN I-NP O
8 560 561 19037603 ( ( O O
9 561 564 19037603 HBV NN B-NP O
10 564 565 19037603 ) ) O O
11 566 575 19037603 serologic JJ B-NP O
12 576 583 19037603 markers NNS I-NP O
13 583 584 19037603 , , O O
14 585 588 19037603 and CC O O
15 589 592 19037603 HBV NN B-NP O
16 593 596 19037603 DNA NN I-NP O
17 597 603 19037603 levels NNS I-NP O
18 604 606 19037603 of IN B-PP O
19 607 610 19037603 the DT B-NP O
20 611 619 19037603 patients NNS I-NP O
21 620 626 19037603 during IN B-PP O
22 627 633 19037603 follow VB B-VP O
23 633 634 19037603 - HYPH B-PRT O
24 634 636 19037603 up RP B-PRT O
25 637 641 19037603 were VBD B-VP O
26 642 650 19037603 obtained VBN I-VP O
27 651 655 19037603 from IN B-PP O
28 656 664 19037603 hospital NN B-NP O
29 665 669 19037603 file NN I-NP O
30 670 677 19037603 records NNS I-NP O
31 677 678 19037603 . . O O

1 679 685 19037603 Eleven CD B-NP O
2 686 694 19037603 patients NNS I-NP O
3 695 696 19037603 ( ( O O
4 696 699 19037603 six CD B-NP O
5 700 704 19037603 male JJ I-NP O
6 704 705 19037603 ) ) O O
7 706 710 19037603 with IN B-PP O
8 711 717 19037603 median JJ B-NP O
9 718 721 19037603 age NN I-NP O
10 722 724 19037603 47 CD B-NP O
11 725 730 19037603 years NNS I-NP O
12 731 732 19037603 ( ( O O
13 732 737 19037603 range NN B-NP O
14 738 740 19037603 27 CD I-NP O
15 740 741 19037603 - HYPH B-NP O
16 741 743 19037603 73 CD I-NP O
17 743 744 19037603 ) ) O O
18 744 745 19037603 , , O O
19 746 752 19037603 median JJ B-NP O
20 753 760 19037603 disease NN I-NP O
21 761 769 19037603 duration NN I-NP O
22 770 772 19037603 50 CD B-NP O
23 773 779 19037603 months NNS I-NP O
24 780 781 19037603 ( ( O O
25 781 786 19037603 range NN B-NP O
26 787 788 19037603 9 CD I-NP O
27 788 789 19037603 - HYPH B-NP O
28 789 792 19037603 178 CD I-NP O
29 792 793 19037603 ) ) O O
30 794 797 19037603 and CC O O
31 798 804 19037603 median JJ B-VP O
32 805 811 19037603 follow VB I-VP O
33 811 812 19037603 - HYPH O O
34 812 814 19037603 up RP B-PRT O
35 815 821 19037603 period NN B-NP O
36 822 824 19037603 of IN B-PP O
37 825 833 19037603 patients NNS B-NP O
38 834 838 19037603 13.8 CD B-NP O
39 839 845 19037603 months NNS I-NP O
40 846 847 19037603 ( ( O O
41 847 852 19037603 range NN B-NP O
42 853 854 19037603 5 CD I-NP O
43 854 855 19037603 - HYPH B-NP O
44 855 857 19037603 27 CD I-NP O
45 857 858 19037603 ) ) O O
46 859 863 19037603 were VBD B-VP O
47 864 872 19037603 enrolled VBN I-VP O
48 873 875 19037603 in IN B-PP O
49 876 880 19037603 this DT B-NP O
50 881 886 19037603 study NN I-NP O
51 886 887 19037603 . . O O

1 888 898 19037603 Lamivudine NN B-NP B-Chemical
2 899 906 19037603 therapy NN I-NP O
3 907 910 19037603 was VBD B-VP O
4 911 918 19037603 started VBN I-VP O
5 919 920 19037603 3 CD B-NP O
6 920 921 19037603 - HYPH I-NP O
7 921 922 19037603 7 CD I-NP O
8 923 927 19037603 days NNS I-NP O
9 928 933 19037603 prior RB B-ADVP O
10 934 936 19037603 to TO B-PP O
11 937 954 19037603 immunosuppressive JJ B-NP O
12 955 962 19037603 therapy NN I-NP O
13 963 965 19037603 in IN B-PP O
14 966 969 19037603 all DT B-NP O
15 970 978 19037603 patients NNS I-NP O
16 978 979 19037603 . . O O

1 980 988 19037603 Baseline NN B-NP O
2 988 989 19037603 , , O O
3 990 995 19037603 liver NN B-NP O
4 996 1004 19037603 function NN I-NP O
5 1005 1010 19037603 tests NNS I-NP O
6 1011 1015 19037603 were VBD B-VP O
7 1016 1024 19037603 elevated VBN I-VP O
8 1025 1027 19037603 in IN B-PP O
9 1028 1031 19037603 two CD B-NP O
10 1032 1040 19037603 patients NNS I-NP O
11 1041 1042 19037603 ( ( O O
12 1042 1048 19037603 fourth JJ B-NP O
13 1049 1056 19037603 patient NN I-NP O
14 1056 1057 19037603 : : O O
15 1058 1061 19037603 ALT NN B-NP O
16 1061 1062 19037603 : : O O
17 1062 1065 19037603 122 CD B-NP O
18 1066 1068 19037603 IU NN I-NP O
19 1068 1069 19037603 / SYM B-NP O
20 1069 1070 19037603 l NN I-NP O
21 1070 1071 19037603 , , O O
22 1072 1075 19037603 AST NN B-NP O
23 1075 1076 19037603 : : O O
24 1076 1079 19037603 111 CD B-NP O
25 1080 1082 19037603 IU NN I-NP O
26 1082 1083 19037603 / SYM B-NP O
27 1083 1084 19037603 l NN I-NP O
28 1084 1085 19037603 , , O O
29 1086 1091 19037603 tenth NN B-NP O
30 1092 1099 19037603 patient NN I-NP O
31 1099 1100 19037603 : : O O
32 1100 1103 19037603 ALT NN B-NP O
33 1103 1104 19037603 : : O O
34 1104 1107 19037603 294 CD B-NP O
35 1108 1110 19037603 IU NN I-NP O
36 1110 1111 19037603 / SYM B-NP O
37 1111 1112 19037603 l NN I-NP O
38 1112 1113 19037603 , , O O
39 1114 1117 19037603 AST NN B-NP O
40 1117 1118 19037603 : : O O
41 1118 1121 19037603 274 CD B-NP O
42 1122 1124 19037603 IU NN I-NP O
43 1124 1125 19037603 / SYM B-NP O
44 1125 1126 19037603 l NN I-NP O
45 1126 1127 19037603 , , O O
46 1128 1132 19037603 with IN B-PP O
47 1133 1140 19037603 minimal JJ B-NP O
48 1141 1148 19037603 changes NNS I-NP O
49 1149 1151 19037603 in IN B-PP O
50 1152 1155 19037603 the DT B-NP O
51 1156 1161 19037603 liver NN I-NP O
52 1162 1168 19037603 biopsy NN I-NP O
53 1169 1171 19037603 in IN B-PP O
54 1172 1176 19037603 both DT B-NP O
55 1176 1177 19037603 ) ) O O
56 1177 1178 19037603 . . O O

1 1179 1186 19037603 Shortly RB B-ADVP O
2 1187 1192 19037603 after IN B-PP O
3 1193 1202 19037603 treatment NN B-NP O
4 1203 1208 19037603 their PRP$ B-NP O
5 1209 1214 19037603 tests NNS I-NP O
6 1215 1225 19037603 normalized VBN B-VP O
7 1226 1229 19037603 and CC O O
8 1230 1236 19037603 during IN B-VP O
9 1237 1243 19037603 follow VB I-VP O
10 1243 1244 19037603 - HYPH O O
11 1244 1246 19037603 up RP B-PRT O
12 1247 1253 19037603 period NN B-NP O
13 1254 1258 19037603 none NN I-NP O
14 1259 1261 19037603 of IN B-PP O
15 1262 1265 19037603 the DT B-NP O
16 1266 1274 19037603 patients NNS I-NP O
17 1275 1278 19037603 had VBD B-VP O
18 1279 1287 19037603 abnormal JJ B-NP B-Disease
19 1288 1293 19037603 liver NN I-NP I-Disease
20 1294 1302 19037603 function NN I-NP I-Disease
21 1303 1308 19037603 tests NNS I-NP O
22 1308 1309 19037603 . . O O

1 1310 1312 19037603 In IN B-PP O
2 1313 1317 19037603 four CD B-NP O
3 1318 1326 19037603 patients NNS I-NP O
4 1327 1330 19037603 HBV NN I-NP O
5 1331 1334 19037603 DNA NN I-NP O
6 1335 1341 19037603 levels NNS I-NP O
7 1342 1346 19037603 were VBD B-VP O
8 1347 1353 19037603 higher JJR B-ADJP O
9 1354 1358 19037603 than IN B-PP O
10 1359 1365 19037603 normal JJ B-ADJP O
11 1366 1368 19037603 at IN B-PP O
12 1369 1377 19037603 baseline NN B-NP O
13 1377 1378 19037603 . . O O

1 1379 1382 19037603 Two CD B-NP O
2 1383 1385 19037603 of IN B-PP O
3 1386 1391 19037603 these DT B-NP O
4 1392 1402 19037603 normalized VBN I-NP O
5 1403 1406 19037603 and CC O O
6 1407 1410 19037603 the DT B-NP O
7 1411 1417 19037603 others NNS I-NP O
8 1418 1427 19037603 increased VBD B-VP O
9 1428 1433 19037603 later RB B-ADVP O
10 1433 1434 19037603 . . O O

1 1435 1437 19037603 In IN B-PP O
2 1438 1443 19037603 three CD B-NP O
3 1444 1454 19037603 additional JJ I-NP O
4 1455 1463 19037603 patients NNS I-NP O
5 1463 1464 19037603 , , O O
6 1465 1468 19037603 HBV NN B-NP O
7 1469 1472 19037603 DNA NN I-NP O
8 1473 1479 19037603 levels NNS I-NP O
9 1480 1484 19037603 were VBD B-VP O
10 1485 1494 19037603 increased VBN I-VP O
11 1495 1501 19037603 during IN B-PP O
12 1502 1508 19037603 follow VB B-VP O
13 1508 1509 19037603 - HYPH O O
14 1509 1511 19037603 up RP B-PRT O
15 1511 1512 19037603 . . O O

1 1513 1517 19037603 None NN B-NP O
2 1518 1520 19037603 of IN B-PP O
3 1521 1524 19037603 the DT B-NP O
4 1525 1533 19037603 patients NNS I-NP O
5 1534 1537 19037603 had VBD B-VP O
6 1538 1549 19037603 significant JJ B-NP O
7 1550 1558 19037603 clinical JJ I-NP O
8 1559 1564 19037603 sings NNS I-NP O
9 1565 1567 19037603 of IN B-PP O
10 1568 1571 19037603 HBV NN B-NP O
11 1572 1582 19037603 activation NN I-NP O
12 1582 1583 19037603 . . O O

1 1584 1594 19037603 Lamivudine NN B-NP B-Chemical
2 1595 1598 19037603 was VBD B-VP O
3 1599 1603 19037603 well RB I-VP O
4 1604 1613 19037603 tolerated VBN I-VP O
5 1614 1617 19037603 and CC O O
6 1618 1621 19037603 was VBD B-VP O
7 1622 1631 19037603 continued VBN I-VP O
8 1632 1634 19037603 in IN B-PP O
9 1635 1638 19037603 all DT B-NP O
10 1639 1647 19037603 patients NNS I-NP O
11 1647 1648 19037603 . . O O

1 1649 1661 19037603 Prophylactic JJ B-NP O
2 1662 1676 19037603 administration NN I-NP O
3 1677 1679 19037603 of IN B-PP O
4 1680 1690 19037603 lamivudine NN B-NP B-Chemical
5 1691 1693 19037603 in IN B-PP O
6 1694 1702 19037603 patients NNS B-NP O
7 1703 1706 19037603 who WP B-NP O
8 1707 1715 19037603 required VBD B-VP O
9 1716 1733 19037603 immunosuppressive JJ B-NP O
10 1734 1741 19037603 therapy NN I-NP O
11 1742 1747 19037603 seems VBZ B-VP O
12 1748 1750 19037603 to TO I-VP O
13 1751 1753 19037603 be VB I-VP O
14 1754 1758 19037603 safe JJ B-ADJP O
15 1758 1759 19037603 , , O O
16 1760 1764 19037603 well RB B-ADJP O
17 1765 1774 19037603 tolerated VBN I-ADJP O
18 1775 1778 19037603 and CC O O
19 1779 1788 19037603 effective JJ B-ADJP O
20 1789 1791 19037603 in IN B-PP O
21 1792 1802 19037603 preventing VBG B-VP O
22 1803 1806 19037603 HBV NN B-NP O
23 1807 1819 19037603 reactivation NN I-NP O
24 1819 1820 19037603 . . O O

1 0 0 19631624 -DOCSTART- -X- -X- O

1 0 8 19631624 Learning NN B-NP B-Disease
2 9 12 19631624 and CC I-NP I-Disease
3 13 19 19631624 memory NN I-NP I-Disease
4 20 28 19631624 deficits NNS I-NP I-Disease
5 29 31 19631624 in IN B-PP O
6 32 39 19631624 ecstasy JJ B-NP B-Chemical
7 40 45 19631624 users NNS I-NP O
8 46 49 19631624 and CC O O
9 50 55 19631624 their PRP$ B-NP O
10 56 62 19631624 neural JJ I-NP O
11 63 73 19631624 correlates NNS I-NP O
12 74 80 19631624 during IN B-PP O
13 81 82 19631624 a DT B-NP O
14 83 87 19631624 face NN I-NP O
15 87 88 19631624 - HYPH O O
16 88 96 19631624 learning VBG B-VP O
17 97 101 19631624 task NN B-NP O
18 101 102 19631624 . . O O
19 103 105 19631624 It PRP B-NP O
20 106 109 19631624 has VBZ B-VP O
21 110 114 19631624 been VBN I-VP O
22 115 127 19631624 consistently RB I-VP O
23 128 133 19631624 shown VBN I-VP O
24 134 138 19631624 that IN B-SBAR O
25 139 146 19631624 ecstasy JJ B-NP B-Chemical
26 147 152 19631624 users NNS I-NP O
27 153 160 19631624 display VBP B-VP O
28 161 172 19631624 impairments NNS B-NP B-Disease
29 173 175 19631624 in IN B-PP I-Disease
30 176 184 19631624 learning NN B-NP I-Disease
31 185 188 19631624 and CC I-NP I-Disease
32 189 195 19631624 memory NN I-NP I-Disease
33 196 207 19631624 performance NN I-NP O
34 207 208 19631624 . . O O

1 209 211 19631624 In IN B-PP O
2 212 220 19631624 addition NN B-NP O
3 220 221 19631624 , , O O
4 222 229 19631624 working VBG B-VP O
5 230 236 19631624 memory NN B-NP O
6 237 247 19631624 processing NN I-NP O
7 248 250 19631624 in IN B-PP O
8 251 258 19631624 ecstasy JJ B-NP B-Chemical
9 259 264 19631624 users NNS I-NP O
10 265 268 19631624 has VBZ B-VP O
11 269 273 19631624 been VBN I-VP O
12 274 279 19631624 shown VBN I-VP O
13 280 282 19631624 to TO I-VP O
14 283 285 19631624 be VB I-VP O
15 286 296 19631624 associated VBN I-VP O
16 297 301 19631624 with IN B-PP O
17 302 308 19631624 neural JJ B-NP O
18 309 320 19631624 alterations NNS I-NP O
19 321 323 19631624 in IN B-PP O
20 324 335 19631624 hippocampal JJ O O
21 336 339 19631624 and CC O O
22 339 340 19631624 / SYM B-NP O
23 340 342 19631624 or CC O O
24 343 351 19631624 cortical JJ B-NP O
25 352 359 19631624 regions NNS I-NP O
26 360 362 19631624 as IN B-SBAR O
27 363 371 19631624 measured VBN B-VP O
28 372 374 19631624 by IN B-PP O
29 375 385 19631624 functional JJ B-NP O
30 386 394 19631624 magnetic JJ I-NP O
31 395 404 19631624 resonance NN I-NP O
32 405 412 19631624 imaging NN I-NP O
33 413 414 19631624 ( ( O O
34 414 418 19631624 fMRI NN B-NP O
35 418 419 19631624 ) ) O O
36 419 420 19631624 . . O O

1 421 426 19631624 Using VBG B-VP O
2 427 437 19631624 functional JJ B-NP O
3 438 445 19631624 imaging NN I-NP O
4 446 449 19631624 and CC O O
5 450 451 19631624 a DT B-NP O
6 452 456 19631624 face NN I-NP O
7 456 457 19631624 - HYPH O O
8 457 465 19631624 learning VBG B-VP O
9 466 470 19631624 task NN B-NP O
10 470 471 19631624 , , O O
11 472 474 19631624 we PRP B-NP O
12 475 487 19631624 investigated VBD B-VP O
13 488 494 19631624 neural JJ B-NP O
14 495 505 19631624 correlates NNS I-NP O
15 506 508 19631624 of IN B-PP O
16 509 517 19631624 encoding VBG B-VP O
17 518 521 19631624 and CC I-VP O
18 522 531 19631624 recalling VBG I-VP O
19 532 536 19631624 face NN B-NP O
20 536 537 19631624 - HYPH B-NP O
21 537 541 19631624 name NN I-NP O
22 542 554 19631624 associations NNS I-NP O
23 555 557 19631624 in IN B-PP O
24 558 560 19631624 20 CD B-NP O
25 561 573 19631624 recreational JJ I-NP O
26 574 578 19631624 drug NN I-NP O
27 579 584 19631624 users NNS I-NP O
28 585 590 19631624 whose WP$ B-NP O
29 591 602 19631624 predominant JJ I-NP O
30 603 607 19631624 drug NN I-NP O
31 608 611 19631624 use NN I-NP O
32 612 615 19631624 was VBD B-VP O
33 616 623 19631624 ecstasy JJ B-ADJP B-Chemical
34 624 627 19631624 and CC O O
35 628 630 19631624 20 CD B-NP O
36 631 639 19631624 controls NNS I-NP O
37 639 640 19631624 . . O O

1 641 643 19631624 To TO B-VP O
2 644 651 19631624 address VB I-VP O
3 652 655 19631624 the DT B-NP O
4 656 665 19631624 potential JJ I-NP O
5 666 677 19631624 confounding JJ I-NP O
6 678 685 19631624 effects NNS I-NP O
7 686 688 19631624 of IN B-PP O
8 689 692 19631624 the DT B-NP O
9 693 701 19631624 cannabis NN I-NP B-Chemical
10 702 705 19631624 use NN I-NP O
11 706 708 19631624 of IN B-PP O
12 709 712 19631624 the DT B-NP O
13 713 720 19631624 ecstasy NN I-NP B-Chemical
14 721 726 19631624 using VBG B-VP O
15 727 732 19631624 group NN B-NP O
16 732 733 19631624 , , O O
17 734 735 19631624 a DT B-NP O
18 736 742 19631624 second JJ I-NP O
19 743 751 19631624 analysis NN I-NP O
20 752 760 19631624 included VBD B-VP O
21 761 763 19631624 14 CD B-NP O
22 764 774 19631624 previously RB I-NP O
23 775 781 19631624 tested VBN I-NP O
24 782 790 19631624 cannabis NN I-NP B-Chemical
25 791 796 19631624 users NNS I-NP O
26 797 798 19631624 ( ( O O
27 798 804 19631624 Nestor NN B-NP O
28 804 805 19631624 , , O O
29 806 807 19631624 L NN B-NP O
30 807 808 19631624 . . O O
31 808 809 19631624 , , O O
32 810 817 19631624 Roberts NNP B-NP O
33 817 818 19631624 , , O O
34 819 820 19631624 G NNP B-NP O
35 820 821 19631624 . NNP I-NP O
36 821 822 19631624 , , O O
37 823 830 19631624 Garavan NNP B-NP O
38 830 831 19631624 , , O O
39 832 833 19631624 H NNP B-NP O
40 833 834 19631624 . VBD B-VP O
41 834 835 19631624 , , O O
42 836 842 19631624 Hester NNP B-NP O
43 842 843 19631624 , , O O
44 844 845 19631624 R NNP B-NP O
45 845 846 19631624 . . O O
46 846 847 19631624 , , O O
47 848 852 19631624 2008 CD B-NP O
48 852 853 19631624 . . O O

1 854 862 19631624 Deficits NNS B-NP B-Disease
2 863 865 19631624 in IN B-PP I-Disease
3 866 874 19631624 learning NN B-NP I-Disease
4 875 878 19631624 and CC I-NP I-Disease
5 879 885 19631624 memory NN I-NP I-Disease
6 885 886 19631624 : : O O
7 887 902 19631624 parahippocampal JJ B-NP O
8 903 916 19631624 hyperactivity NN I-NP B-Disease
9 917 920 19631624 and CC O O
10 921 935 19631624 frontocortical JJ B-NP O
11 936 948 19631624 hypoactivity NN I-NP O
12 949 951 19631624 in IN B-PP O
13 952 960 19631624 cannabis NN B-NP B-Chemical
14 961 966 19631624 users NNS I-NP O
15 966 967 19631624 . . O O

1 968 978 19631624 Neuroimage NN B-NP O
2 979 981 19631624 40 CD I-NP O
3 981 982 19631624 , , I-NP O
4 983 987 19631624 1328 CD I-NP O
5 987 988 19631624 - HYPH I-NP O
6 988 992 19631624 1339 CD I-NP O
7 992 993 19631624 ) ) O O
8 993 994 19631624 . . O O

1 995 1002 19631624 Ecstasy JJ B-NP B-Chemical
2 1003 1008 19631624 users NNS I-NP O
3 1009 1018 19631624 performed VBD B-VP O
4 1019 1032 19631624 significantly RB B-ADJP O
5 1033 1038 19631624 worse JJR I-ADJP O
6 1039 1041 19631624 in IN B-PP O
7 1042 1050 19631624 learning NN B-NP O
8 1051 1054 19631624 and CC I-NP O
9 1055 1061 19631624 memory NN I-NP O
10 1062 1070 19631624 compared VBN B-PP O
11 1071 1073 19631624 to TO B-PP O
12 1074 1082 19631624 controls NNS B-NP O
13 1083 1086 19631624 and CC O O
14 1087 1095 19631624 cannabis NN B-NP B-Chemical
15 1096 1101 19631624 users NNS I-NP O
16 1101 1102 19631624 . . O O

1 1103 1104 19631624 A DT B-NP O
2 1105 1116 19631624 conjunction NN I-NP O
3 1117 1125 19631624 analysis NN I-NP O
4 1126 1128 19631624 of IN B-PP O
5 1129 1132 19631624 the DT B-NP O
6 1133 1139 19631624 encode NN I-NP O
7 1140 1143 19631624 and CC I-NP O
8 1144 1150 19631624 recall NN I-NP O
9 1151 1157 19631624 phases NNS I-NP O
10 1158 1160 19631624 of IN B-PP O
11 1161 1164 19631624 the DT B-NP O
12 1165 1169 19631624 task NN I-NP O
13 1170 1178 19631624 revealed VBD B-VP O
14 1179 1186 19631624 ecstasy JJ B-NP B-Chemical
15 1186 1187 19631624 - HYPH I-NP O
16 1187 1195 19631624 specific JJ I-NP O
17 1196 1209 19631624 hyperactivity NN I-NP B-Disease
18 1210 1212 19631624 in IN B-PP O
19 1213 1222 19631624 bilateral JJ B-NP O
20 1223 1230 19631624 frontal JJ I-NP O
21 1231 1238 19631624 regions NNS I-NP O
22 1238 1239 19631624 , , O O
23 1240 1244 19631624 left VBD B-VP O
24 1245 1253 19631624 temporal JJ B-NP O
25 1253 1254 19631624 , , I-NP O
26 1255 1260 19631624 right JJ I-NP O
27 1261 1269 19631624 parietal JJ I-NP O
28 1269 1270 19631624 , , I-NP O
29 1271 1280 19631624 bilateral JJ I-NP O
30 1281 1289 19631624 temporal JJ I-NP O
31 1289 1290 19631624 , , O O
32 1291 1294 19631624 and CC O O
33 1295 1304 19631624 bilateral JJ B-NP O
34 1305 1314 19631624 occipital NN I-NP O
35 1315 1320 19631624 brain NN I-NP O
36 1321 1328 19631624 regions NNS I-NP O
37 1328 1329 19631624 . . O O

1 1330 1337 19631624 Ecstasy NN B-NP B-Chemical
2 1337 1338 19631624 - HYPH I-NP O
3 1338 1346 19631624 specific JJ I-NP O
4 1347 1359 19631624 hypoactivity NN I-NP O
5 1360 1363 19631624 was VBD B-VP O
6 1364 1371 19631624 evident JJ B-ADJP O
7 1372 1374 19631624 in IN B-PP O
8 1375 1378 19631624 the DT B-NP O
9 1379 1384 19631624 right JJ I-NP O
10 1385 1391 19631624 dorsal JJ I-NP O
11 1392 1400 19631624 anterior JJ I-NP O
12 1401 1411 19631624 cingulated VBN I-NP O
13 1412 1418 19631624 cortex NN I-NP O
14 1419 1420 19631624 ( ( O O
15 1420 1423 19631624 ACC NN B-NP O
16 1423 1424 19631624 ) ) O O
17 1425 1428 19631624 and CC O O
18 1429 1433 19631624 left VBD B-VP O
19 1434 1443 19631624 posterior JJ B-NP O
20 1444 1454 19631624 cingulated VBN I-NP O
21 1455 1461 19631624 cortex NN I-NP O
22 1461 1462 19631624 . . O O

1 1463 1465 19631624 In IN B-PP O
2 1466 1470 19631624 both CC O O
3 1471 1478 19631624 ecstasy JJ B-NP B-Chemical
4 1479 1482 19631624 and CC I-NP O
5 1483 1491 19631624 cannabis NN I-NP B-Chemical
6 1492 1498 19631624 groups NNS I-NP O
7 1499 1504 19631624 brain NN I-NP O
8 1505 1515 19631624 activation NN I-NP O
9 1516 1519 19631624 was VBD B-VP O
10 1520 1529 19631624 decreased VBN I-VP O
11 1530 1532 19631624 in IN B-PP O
12 1533 1536 19631624 the DT B-NP O
13 1537 1542 19631624 right JJ I-NP O
14 1543 1549 19631624 medial JJ I-NP O
15 1550 1557 19631624 frontal JJ I-NP O
16 1558 1563 19631624 gyrus NN I-NP O
17 1563 1564 19631624 , , O O
18 1565 1569 19631624 left VBD B-VP O
19 1570 1585 19631624 parahippocampal JJ B-NP O
20 1586 1591 19631624 gyrus NN I-NP O
21 1591 1592 19631624 , , O O
22 1593 1597 19631624 left VBD B-VP O
23 1598 1604 19631624 dorsal JJ B-NP O
24 1605 1614 19631624 cingulate NN I-NP O
25 1615 1620 19631624 gyrus NN I-NP O
26 1620 1621 19631624 , , O O
27 1622 1625 19631624 and CC O O
28 1626 1630 19631624 left VBD B-VP O
29 1631 1638 19631624 caudate NN B-NP O
30 1638 1639 19631624 . . O O

1 1640 1645 19631624 These DT B-NP O
2 1646 1653 19631624 results NNS I-NP O
3 1654 1664 19631624 elucidated VBD B-VP O
4 1665 1672 19631624 ecstasy NN B-NP B-Chemical
5 1672 1673 19631624 - HYPH B-NP O
6 1673 1680 19631624 related VBN I-NP O
7 1681 1689 19631624 deficits NNS I-NP O
8 1689 1690 19631624 , , O O
9 1691 1695 19631624 only RB B-NP O
10 1696 1700 19631624 some DT I-NP O
11 1701 1703 19631624 of IN B-PP O
12 1704 1709 19631624 which WDT B-NP O
13 1710 1715 19631624 might MD B-VP O
14 1716 1718 19631624 be VB I-VP O
15 1719 1729 19631624 attributed VBN I-VP O
16 1730 1732 19631624 to TO B-PP O
17 1733 1741 19631624 cannabis NN B-NP B-Chemical
18 1742 1745 19631624 use NN I-NP O
19 1745 1746 19631624 . . O O

1 1747 1752 19631624 These DT B-NP O
2 1753 1760 19631624 ecstasy AFX I-NP B-Chemical
3 1760 1761 19631624 - HYPH I-NP O
4 1761 1769 19631624 specific JJ I-NP O
5 1770 1777 19631624 effects NNS I-NP O
6 1778 1781 19631624 may MD B-VP O
7 1782 1784 19631624 be VB I-VP O
8 1785 1792 19631624 related JJ B-ADJP O
9 1793 1795 19631624 to TO B-PP O
10 1796 1799 19631624 the DT B-NP O
11 1800 1813 19631624 vulnerability NN I-NP O
12 1814 1816 19631624 of IN B-PP O
13 1817 1828 19631624 isocortical JJ B-NP O
14 1829 1832 19631624 and CC I-NP O
15 1833 1845 19631624 allocortical JJ I-NP O
16 1846 1853 19631624 regions NNS I-NP O
17 1854 1856 19631624 to TO B-PP O
18 1857 1860 19631624 the DT B-NP O
19 1861 1871 19631624 neurotoxic JJ I-NP B-Disease
20 1872 1879 19631624 effects NNS I-NP O
21 1880 1882 19631624 of IN B-PP O
22 1883 1890 19631624 ecstasy NN B-NP B-Chemical
23 1890 1891 19631624 . . O O

1 0 0 10791295 -DOCSTART- -X- -X- O

1 0 11 10791295 Development NN B-NP O
2 12 14 10791295 of IN B-PP O
3 15 26 10791295 apomorphine NN B-NP B-Chemical
4 26 27 10791295 - HYPH B-NP O
5 27 34 10791295 induced VBN I-NP O
6 35 45 10791295 aggressive JJ I-NP B-Disease
7 46 54 10791295 behavior NN I-NP I-Disease
8 54 55 10791295 : : O O
9 56 66 10791295 comparison NN B-NP O
10 67 69 10791295 of IN B-PP O
11 70 75 10791295 adult JJ B-NP O
12 76 80 10791295 male JJ I-NP O
13 81 84 10791295 and CC I-NP O
14 85 91 10791295 female JJ I-NP O
15 92 98 10791295 Wistar NNP I-NP O
16 99 103 10791295 rats NNS I-NP O
17 103 104 10791295 . . O O
18 105 108 10791295 The DT B-NP O
19 109 120 10791295 development NN I-NP O
20 121 123 10791295 of IN B-PP O
21 124 135 10791295 apomorphine NN B-NP B-Chemical
22 135 136 10791295 - HYPH O O
23 136 143 10791295 induced VBN B-VP O
24 144 145 10791295 ( ( O O
25 145 148 10791295 1.0 CD B-NP O
26 149 151 10791295 mg NN I-NP O
27 151 152 10791295 / SYM B-NP O
28 152 154 10791295 kg NN I-NP O
29 155 158 10791295 s.c NN I-NP O
30 158 159 10791295 . . O O

1 160 164 10791295 once RB B-ADVP O
2 165 170 10791295 daily RB I-ADVP O
3 170 171 10791295 ) ) O O
4 172 182 10791295 aggressive JJ B-NP B-Disease
5 183 191 10791295 behavior NN I-NP I-Disease
6 192 194 10791295 of IN B-PP O
7 195 200 10791295 adult JJ B-NP O
8 201 205 10791295 male JJ I-NP O
9 206 209 10791295 and CC I-NP O
10 210 216 10791295 female JJ I-NP O
11 217 223 10791295 Wistar NNP I-NP O
12 224 228 10791295 rats NNS I-NP O
13 229 237 10791295 obtained VBN B-VP O
14 238 242 10791295 from IN B-PP O
15 243 246 10791295 the DT B-NP O
16 247 251 10791295 same JJ I-NP O
17 252 259 10791295 breeder NN I-NP O
18 260 263 10791295 was VBD B-VP O
19 264 271 10791295 studied VBN I-VP O
20 272 274 10791295 in IN B-PP O
21 275 278 10791295 two CD B-NP O
22 279 290 10791295 consecutive JJ I-NP O
23 291 295 10791295 sets NNS I-NP O
24 295 296 10791295 . . O O

1 297 299 10791295 In IN B-PP O
2 300 304 10791295 male JJ B-NP O
3 305 312 10791295 animals NNS I-NP O
4 312 313 10791295 , , O O
5 314 322 10791295 repeated VBN B-NP O
6 323 334 10791295 apomorphine NN I-NP B-Chemical
7 335 344 10791295 treatment NN I-NP O
8 345 352 10791295 induced VBD B-VP O
9 353 354 10791295 a DT B-NP O
10 355 362 10791295 gradual JJ I-NP O
11 363 374 10791295 development NN I-NP O
12 375 377 10791295 of IN B-PP O
13 378 388 10791295 aggressive JJ B-NP B-Disease
14 389 397 10791295 behavior NN I-NP I-Disease
15 398 400 10791295 as IN B-SBAR O
16 401 410 10791295 evidenced VBN B-VP O
17 411 413 10791295 by IN B-PP O
18 414 417 10791295 the DT B-NP O
19 418 427 10791295 increased VBN I-NP O
20 428 437 10791295 intensity NN I-NP O
21 438 440 10791295 of IN B-PP O
22 441 455 10791295 aggressiveness NN B-NP B-Disease
23 456 459 10791295 and CC O O
24 460 469 10791295 shortened VBD B-VP O
25 470 477 10791295 latency NN B-NP O
26 478 484 10791295 before IN B-PP O
27 485 488 10791295 the DT B-NP O
28 489 494 10791295 first JJ I-NP O
29 495 501 10791295 attack NN I-NP O
30 502 508 10791295 toward IN B-PP O
31 509 512 10791295 the DT B-NP O
32 513 521 10791295 opponent NN I-NP O
33 521 522 10791295 . . O O

1 523 525 10791295 In IN B-PP O
2 526 532 10791295 female JJ B-NP O
3 533 537 10791295 rats NNS I-NP O
4 537 538 10791295 , , O O
5 539 543 10791295 only RB B-NP O
6 544 545 10791295 a DT I-NP O
7 546 550 10791295 weak JJ I-NP O
8 551 559 10791295 tendency NN I-NP O
9 560 566 10791295 toward IN B-PP O
10 567 581 10791295 aggressiveness NN B-NP B-Disease
11 582 585 10791295 was VBD B-VP O
12 586 591 10791295 found VBN I-VP O
13 591 592 10791295 . . O O

1 593 595 10791295 In IN B-PP O
2 596 606 10791295 conclusion NN B-NP O
3 606 607 10791295 , , O O
4 608 611 10791295 the DT B-NP O
5 612 619 10791295 present JJ I-NP O
6 620 625 10791295 study NN I-NP O
7 626 638 10791295 demonstrates VBZ B-VP O
8 639 645 10791295 gender NN B-NP O
9 646 657 10791295 differences NNS I-NP O
10 658 660 10791295 in IN B-PP O
11 661 664 10791295 the DT B-NP O
12 665 676 10791295 development NN I-NP O
13 677 679 10791295 of IN B-PP O
14 680 683 10791295 the DT B-NP O
15 684 695 10791295 apomorphine NN I-NP B-Chemical
16 695 696 10791295 - HYPH O O
17 696 703 10791295 induced VBN B-NP O
18 704 714 10791295 aggressive JJ I-NP B-Disease
19 715 723 10791295 behavior NN I-NP I-Disease
20 724 727 10791295 and CC O O
21 728 737 10791295 indicates VBZ B-VP O
22 738 742 10791295 that IN B-SBAR O
23 743 746 10791295 the DT B-NP O
24 747 753 10791295 female JJ I-NP O
25 754 758 10791295 rats NNS I-NP O
26 759 761 10791295 do VBP B-VP O
27 762 765 10791295 not RB I-VP O
28 766 770 10791295 fill VB I-VP O
29 771 774 10791295 the DT B-NP O
30 775 785 10791295 validation NN I-NP O
31 786 794 10791295 criteria NNS I-NP O
32 795 798 10791295 for IN B-PP O
33 799 802 10791295 use NN B-NP O
34 803 805 10791295 in IN B-PP O
35 806 810 10791295 this DT B-NP O
36 811 817 10791295 method NN I-NP O
37 817 818 10791295 . . O O

1 0 0 12789195 -DOCSTART- -X- -X- O

1 0 16 12789195 Pseudoacromegaly RB B-ADVP B-Disease
2 17 24 12789195 induced VBN B-VP O
3 25 27 12789195 by IN B-PP O
4 28 31 12789195 the DT B-NP O
5 32 36 12789195 long JJ I-NP O
6 36 37 12789195 - HYPH I-NP O
7 37 41 12789195 term NN I-NP O
8 42 45 12789195 use NN I-NP O
9 46 48 12789195 of IN B-PP O
10 49 58 12789195 minoxidil NN B-NP B-Chemical
11 58 59 12789195 . . O O
12 60 70 12789195 Acromegaly NNP B-NP B-Disease
13 71 73 12789195 is VBZ B-VP O
14 74 76 12789195 an DT B-NP O
15 77 86 12789195 endocrine JJ I-NP B-Disease
16 87 95 12789195 disorder NN I-NP I-Disease
17 96 102 12789195 caused VBN B-VP O
18 103 105 12789195 by IN B-PP O
19 106 113 12789195 chronic JJ B-NP O
20 114 123 12789195 excessive JJ I-NP O
21 124 130 12789195 growth NN I-NP O
22 131 138 12789195 hormone NN I-NP O
23 139 148 12789195 secretion NN I-NP O
24 149 153 12789195 from IN B-PP O
25 154 157 12789195 the DT B-NP O
26 158 166 12789195 anterior JJ I-NP O
27 167 176 12789195 pituitary JJ I-NP O
28 177 182 12789195 gland NN I-NP O
29 182 183 12789195 . . O O

1 184 195 12789195 Significant JJ B-NP O
2 196 207 12789195 disfiguring NN I-NP O
3 208 215 12789195 changes NNS I-NP O
4 216 221 12789195 occur VBP B-VP O
5 222 224 12789195 as IN B-PP O
6 225 226 12789195 a DT B-NP O
7 227 233 12789195 result NN I-NP O
8 234 236 12789195 of IN B-PP O
9 237 241 12789195 bone NN B-NP O
10 241 242 12789195 , , O O
11 243 252 12789195 cartilage NN B-NP O
12 252 253 12789195 , , O O
13 254 257 12789195 and CC O O
14 258 262 12789195 soft JJ B-NP O
15 263 269 12789195 tissue NN I-NP O
16 270 281 12789195 hypertrophy NN I-NP B-Disease
17 281 282 12789195 , , O O
18 283 292 12789195 including VBG B-PP O
19 293 296 12789195 the DT B-NP O
20 297 307 12789195 thickening NN I-NP O
21 308 310 12789195 of IN B-PP O
22 311 314 12789195 the DT B-NP O
23 315 319 12789195 skin NN I-NP O
24 319 320 12789195 , , O O
25 321 331 12789195 coarsening NN B-NP O
26 332 334 12789195 of IN B-PP O
27 335 341 12789195 facial JJ B-NP O
28 342 350 12789195 features NNS I-NP O
29 350 351 12789195 , , O O
30 352 355 12789195 and CC O O
31 356 361 12789195 cutis NN B-NP B-Disease
32 362 370 12789195 verticis NN I-NP I-Disease
33 371 377 12789195 gyrata NNS I-NP I-Disease
34 377 378 12789195 . . O O

1 379 395 12789195 Pseudoacromegaly RB B-ADVP B-Disease
2 395 396 12789195 , , O O
3 397 399 12789195 on IN B-PP O
4 400 403 12789195 the DT B-NP O
5 404 409 12789195 other JJ I-NP O
6 410 414 12789195 hand NN I-NP O
7 414 415 12789195 , , O O
8 416 418 12789195 is VBZ B-VP O
9 419 422 12789195 the DT B-NP O
10 423 431 12789195 presence NN I-NP O
11 432 434 12789195 of IN B-PP O
12 435 442 12789195 similar JJ B-NP O
13 443 455 12789195 acromegaloid JJ I-NP O
14 456 464 12789195 features NNS I-NP O
15 465 467 12789195 in IN B-PP O
16 468 471 12789195 the DT B-NP O
17 472 479 12789195 absence NN I-NP O
18 480 482 12789195 of IN B-PP O
19 483 491 12789195 elevated JJ B-NP O
20 492 498 12789195 growth NN I-NP O
21 499 506 12789195 hormone NN I-NP O
22 507 509 12789195 or CC I-NP O
23 510 517 12789195 insulin NN I-NP O
24 517 518 12789195 - HYPH O O
25 518 522 12789195 like JJ B-NP O
26 523 529 12789195 growth NN I-NP O
27 530 536 12789195 factor NN I-NP O
28 537 543 12789195 levels NNS I-NP O
29 543 544 12789195 . . O O

1 545 547 12789195 We PRP B-NP O
2 548 555 12789195 present VBP B-VP O
3 556 557 12789195 a DT B-NP O
4 558 565 12789195 patient NN I-NP O
5 566 570 12789195 with IN B-PP O
6 571 587 12789195 pseudoacromegaly NN B-NP B-Disease
7 588 592 12789195 that WDT B-NP O
8 593 601 12789195 resulted VBD B-VP O
9 602 606 12789195 from IN B-PP O
10 607 610 12789195 the DT B-NP O
11 611 615 12789195 long JJ I-NP O
12 615 616 12789195 - HYPH I-NP O
13 616 620 12789195 term NN I-NP O
14 621 624 12789195 use NN I-NP O
15 625 627 12789195 of IN B-PP O
16 628 637 12789195 minoxidil NN B-NP B-Chemical
17 638 640 12789195 at IN B-PP O
18 641 643 12789195 an DT B-NP O
19 644 653 12789195 unusually RB I-NP O
20 654 658 12789195 high JJ I-NP O
21 659 663 12789195 dose NN I-NP O
22 663 664 12789195 . . O O

1 665 669 12789195 This DT B-NP O
2 670 672 12789195 is VBZ B-VP O
3 673 676 12789195 the DT B-NP O
4 677 682 12789195 first JJ I-NP O
5 683 687 12789195 case NN I-NP O
6 688 694 12789195 report NN I-NP O
7 695 697 12789195 of IN B-PP O
8 698 714 12789195 pseudoacromegaly RB B-ADVP B-Disease
9 715 717 12789195 as IN B-PP O
10 718 719 12789195 a DT B-NP O
11 720 724 12789195 side NN I-NP O
12 725 731 12789195 effect NN I-NP O
13 732 734 12789195 of IN B-PP O
14 735 744 12789195 minoxidil NN B-NP B-Chemical
15 745 748 12789195 use NN I-NP O
16 748 749 12789195 . . O O

1 0 0 11745184 -DOCSTART- -X- -X- O

1 0 1 11745184 A DT B-NP O
2 2 7 11745184 Phase NN I-NP O
3 8 10 11745184 II CD I-NP O
4 11 16 11745184 trial NN I-NP O
5 17 19 11745184 of IN B-PP O
6 20 29 11745184 cisplatin NN B-NP B-Chemical
7 30 34 11745184 plus CC I-NP O
8 35 37 11745184 WR NN I-NP B-Chemical
9 37 38 11745184 - HYPH O I-Chemical
10 38 42 11745184 2721 CD B-NP I-Chemical
11 43 44 11745184 ( ( O O
12 44 54 11745184 amifostine NN B-NP B-Chemical
13 54 55 11745184 ) ) O O
14 56 59 11745184 for IN B-PP O
15 60 70 11745184 metastatic JJ B-NP O
16 71 77 11745184 breast NN I-NP B-Disease
17 78 87 11745184 carcinoma NN I-NP I-Disease
18 87 88 11745184 : : O O
19 89 91 11745184 an DT B-NP O
20 92 99 11745184 Eastern NNP I-NP O
21 100 111 11745184 Cooperative NNP I-NP O
22 112 120 11745184 Oncology NNP I-NP O
23 121 126 11745184 Group NNP I-NP O
24 127 132 11745184 Study NNP I-NP O
25 133 134 11745184 ( ( O O
26 134 139 11745184 E8188 NN B-NP O
27 139 140 11745184 ) ) O O
28 140 141 11745184 . . O O
29 142 152 11745184 BACKGROUND NN B-NP O
30 152 153 11745184 : : O O
31 154 163 11745184 Cisplatin NN B-NP B-Chemical
32 164 167 11745184 has VBZ B-VP O
33 168 175 11745184 minimal JJ B-NP O
34 176 185 11745184 antitumor JJ I-NP O
35 186 194 11745184 activity NN I-NP O
36 195 199 11745184 when WRB B-ADVP O
37 200 204 11745184 used VBN B-VP O
38 205 207 11745184 as IN B-PP O
39 208 214 11745184 second JJ B-NP O
40 214 215 11745184 - HYPH I-NP O
41 216 218 11745184 or CC I-NP O
42 219 224 11745184 third JJ I-NP O
43 224 225 11745184 - HYPH I-NP O
44 225 229 11745184 line NN I-NP O
45 230 239 11745184 treatment NN I-NP O
46 240 242 11745184 of IN B-PP O
47 243 253 11745184 metastatic JJ B-NP O
48 254 260 11745184 breast NN I-NP B-Disease
49 261 270 11745184 carcinoma NN I-NP I-Disease
50 270 271 11745184 . . O O

1 272 277 11745184 Older JJR B-NP O
2 278 285 11745184 reports NNS I-NP O
3 286 293 11745184 suggest VBP B-VP O
4 294 296 11745184 an DT B-NP O
5 297 306 11745184 objective JJ I-NP O
6 307 315 11745184 response NN I-NP O
7 316 320 11745184 rate NN I-NP O
8 321 323 11745184 of IN B-PP O
9 324 326 11745184 8% CD B-NP O
10 327 331 11745184 when WRB B-ADVP O
11 332 334 11745184 60 CD B-NP O
12 334 335 11745184 - HYPH I-NP O
13 335 338 11745184 120 CD I-NP O
14 339 341 11745184 mg NN I-NP O
15 341 342 11745184 / SYM B-NP O
16 342 344 11745184 m2 NN I-NP O
17 345 347 11745184 of IN B-PP O
18 348 357 11745184 cisplatin NN B-NP B-Chemical
19 358 360 11745184 is VBZ B-VP O
20 361 373 11745184 administered VBN I-VP O
21 374 379 11745184 every DT B-NP O
22 380 381 11745184 3 CD I-NP O
23 381 382 11745184 - HYPH I-NP O
24 382 383 11745184 4 CD I-NP O
25 384 389 11745184 weeks NNS I-NP O
26 389 390 11745184 . . O O

1 391 399 11745184 Although IN B-SBAR O
2 400 401 11745184 a DT B-NP O
3 402 406 11745184 dose NN I-NP O
4 406 407 11745184 - HYPH B-NP O
5 407 415 11745184 response NN I-NP O
6 416 422 11745184 effect NN I-NP O
7 423 426 11745184 has VBZ B-VP O
8 427 431 11745184 been VBN I-VP O
9 432 440 11745184 observed VBN I-VP O
10 441 445 11745184 with IN B-PP O
11 446 455 11745184 cisplatin NN B-NP B-Chemical
12 455 456 11745184 , , O O
13 457 460 11745184 the DT B-NP O
14 461 465 11745184 dose NN I-NP O
15 465 466 11745184 - HYPH O O
16 466 474 11745184 limiting VBG B-VP O
17 475 485 11745184 toxicities NNS B-NP B-Disease
18 486 496 11745184 associated VBN B-VP O
19 497 501 11745184 with IN B-PP O
20 502 511 11745184 cisplatin NN B-NP B-Chemical
21 512 513 11745184 ( ( O O
22 513 517 11745184 e.g. FW B-NP O
23 517 518 11745184 , , O O
24 519 533 11745184 nephrotoxicity NN B-NP B-Disease
25 533 534 11745184 , , O O
26 535 546 11745184 ototoxicity NN B-NP B-Disease
27 546 547 11745184 , , O O
28 548 551 11745184 and CC O O
29 552 565 11745184 neurotoxicity NN B-NP B-Disease
30 565 566 11745184 ) ) O O
31 567 571 11745184 have VBP B-VP O
32 572 579 11745184 limited VBN I-VP O
33 580 583 11745184 its PRP$ B-NP O
34 584 587 11745184 use NN I-NP O
35 588 590 11745184 as IN B-PP O
36 591 592 11745184 a DT B-NP O
37 593 602 11745184 treatment NN I-NP O
38 603 606 11745184 for IN B-PP O
39 607 613 11745184 breast NN B-NP B-Disease
40 614 623 11745184 carcinoma NN I-NP I-Disease
41 623 624 11745184 . . O O

1 625 627 11745184 WR NN B-NP B-Chemical
2 627 628 11745184 - HYPH O I-Chemical
3 628 632 11745184 2721 CD B-NP I-Chemical
4 633 635 11745184 or CC O O
5 636 646 11745184 amifostine NN B-NP B-Chemical
6 647 656 11745184 initially RB B-ADVP O
7 657 660 11745184 was VBD B-VP O
8 661 670 11745184 developed VBN I-VP O
9 671 673 11745184 to TO I-VP O
10 674 681 11745184 protect VB I-VP O
11 682 690 11745184 military JJ B-NP O
12 691 700 11745184 personnel NNS I-NP O
13 701 703 11745184 in IN B-PP O
14 704 707 11745184 the DT B-NP O
15 708 713 11745184 event NN I-NP O
16 714 716 11745184 of IN B-PP O
17 717 724 11745184 nuclear JJ B-NP O
18 725 728 11745184 war NN I-NP O
19 728 729 11745184 . . O O

1 730 740 11745184 Amifostine NN B-NP B-Chemical
2 741 753 11745184 subsequently RB B-ADVP O
3 754 757 11745184 was VBD B-VP O
4 758 763 11745184 shown VBN I-VP O
5 764 766 11745184 to TO I-VP O
6 767 774 11745184 protect VB I-VP O
7 775 781 11745184 normal JJ B-NP O
8 782 789 11745184 tissues NNS I-NP O
9 790 794 11745184 from IN B-PP O
10 795 798 11745184 the DT B-NP O
11 799 804 11745184 toxic JJ I-NP O
12 805 812 11745184 effects NNS I-NP O
13 813 815 11745184 of IN B-PP O
14 816 826 11745184 alkylating VBG B-NP B-Chemical
15 827 833 11745184 agents NNS I-NP I-Chemical
16 834 837 11745184 and CC O O
17 838 847 11745184 cisplatin NN B-NP B-Chemical
18 848 855 11745184 without IN B-PP O
19 856 866 11745184 decreasing VBG B-VP O
20 867 870 11745184 the DT B-NP O
21 871 880 11745184 antitumor JJ I-NP O
22 881 887 11745184 effect NN I-NP O
23 888 890 11745184 of IN B-PP O
24 891 894 11745184 the DT B-NP O
25 895 907 11745184 chemotherapy NN I-NP O
26 907 908 11745184 . . O O

1 909 914 11745184 Early JJ B-NP O
2 915 921 11745184 trials NNS I-NP O
3 922 924 11745184 of IN B-PP O
4 925 934 11745184 cisplatin NN B-NP B-Chemical
5 935 938 11745184 and CC I-NP O
6 939 949 11745184 amifostine NN I-NP B-Chemical
7 950 954 11745184 also RB B-ADVP O
8 955 964 11745184 suggested VBD B-VP O
9 965 969 11745184 that IN B-SBAR O
10 970 973 11745184 the DT B-NP O
11 974 983 11745184 incidence NN I-NP O
12 984 987 11745184 and CC I-NP O
13 988 996 11745184 severity NN I-NP O
14 997 999 11745184 of IN B-PP O
15 1000 1009 11745184 cisplatin NN B-NP B-Chemical
16 1009 1010 11745184 - HYPH B-NP O
17 1010 1017 11745184 induced VBN I-NP O
18 1018 1032 11745184 nephrotoxicity NN I-NP B-Disease
19 1032 1033 11745184 , , O O
20 1034 1045 11745184 ototoxicity NN B-NP B-Disease
21 1045 1046 11745184 , , O O
22 1047 1050 11745184 and CC O O
23 1051 1061 11745184 neuropathy NN B-NP B-Disease
24 1062 1066 11745184 were VBD B-VP O
25 1067 1074 11745184 reduced VBN I-VP O
26 1074 1075 11745184 . . O O

1 1076 1083 11745184 METHODS NNS B-NP O
2 1083 1084 11745184 : : O O
3 1085 1086 11745184 A DT B-NP O
4 1087 1092 11745184 Phase NN I-NP O
5 1093 1095 11745184 II CD I-NP O
6 1096 1101 11745184 study NN I-NP O
7 1102 1104 11745184 of IN B-PP O
8 1105 1108 11745184 the DT B-NP O
9 1109 1120 11745184 combination NN I-NP O
10 1121 1123 11745184 of IN B-PP O
11 1124 1133 11745184 cisplatin NN B-NP B-Chemical
12 1134 1138 11745184 plus CC I-NP O
13 1139 1149 11745184 amifostine NN I-NP B-Chemical
14 1150 1153 11745184 was VBD B-VP O
15 1154 1163 11745184 conducted VBN I-VP O
16 1164 1166 11745184 in IN B-PP O
17 1167 1175 11745184 patients NNS B-NP O
18 1176 1180 11745184 with IN B-PP O
19 1181 1192 11745184 progressive JJ B-NP O
20 1193 1203 11745184 metastatic JJ I-NP O
21 1204 1210 11745184 breast NN I-NP B-Disease
22 1211 1220 11745184 carcinoma NN I-NP I-Disease
23 1221 1224 11745184 who WP B-NP O
24 1225 1228 11745184 had VBD B-VP O
25 1229 1237 11745184 received VBN I-VP O
26 1238 1241 11745184 one CD B-NP O
27 1241 1242 11745184 , , O O
28 1243 1246 11745184 but CC O O
29 1247 1250 11745184 not RB O O
30 1251 1255 11745184 more JJR B-NP O
31 1256 1260 11745184 than IN I-NP O
32 1261 1264 11745184 one CD I-NP O
33 1264 1265 11745184 , , I-NP O
34 1266 1278 11745184 chemotherapy NN I-NP O
35 1279 1286 11745184 regimen NN I-NP O
36 1287 1290 11745184 for IN B-PP O
37 1291 1301 11745184 metastatic JJ B-NP O
38 1302 1309 11745184 disease NN I-NP O
39 1309 1310 11745184 . . O O

1 1311 1319 11745184 Patients NNS B-NP O
2 1320 1328 11745184 received VBD B-VP O
3 1329 1339 11745184 amifostine NN B-NP B-Chemical
4 1339 1340 11745184 , , O O
5 1341 1344 11745184 910 CD B-NP O
6 1345 1347 11745184 mg NN I-NP O
7 1347 1348 11745184 / SYM B-NP O
8 1348 1350 11745184 m2 NN I-NP O
9 1351 1364 11745184 intravenously RB B-NP O
10 1365 1369 11745184 over IN I-NP O
11 1370 1372 11745184 15 CD I-NP O
12 1373 1380 11745184 minutes NNS I-NP O
13 1380 1381 11745184 . . O O

1 1382 1387 11745184 After IN B-PP O
2 1388 1398 11745184 completion NN B-NP O
3 1399 1401 11745184 of IN B-PP O
4 1402 1405 11745184 the DT B-NP O
5 1406 1416 11745184 amifostine NN I-NP B-Chemical
6 1417 1425 11745184 infusion NN I-NP O
7 1425 1426 11745184 , , O O
8 1427 1436 11745184 cisplatin NN B-NP B-Chemical
9 1437 1440 11745184 120 CD I-NP O
10 1441 1443 11745184 mg NN I-NP O
11 1443 1444 11745184 / SYM B-NP O
12 1444 1446 11745184 m2 NN I-NP O
13 1447 1450 11745184 was VBD B-VP O
14 1451 1463 11745184 administered VBN I-VP O
15 1464 1468 11745184 over IN B-NP O
16 1469 1471 11745184 30 CD I-NP O
17 1472 1479 11745184 minutes NNS I-NP O
18 1479 1480 11745184 . . O O

1 1481 1492 11745184 Intravenous JJ B-NP O
2 1493 1502 11745184 hydration NN I-NP O
3 1503 1506 11745184 and CC I-NP O
4 1507 1515 11745184 mannitol NN I-NP B-Chemical
5 1516 1519 11745184 was VBD B-VP O
6 1520 1532 11745184 administered VBN I-VP O
7 1533 1539 11745184 before IN B-PP O
8 1540 1543 11745184 and CC I-PP O
9 1544 1549 11745184 after IN I-PP O
10 1550 1559 11745184 cisplatin NN B-NP B-Chemical
11 1559 1560 11745184 . . O O

1 1561 1570 11745184 Treatment NN B-NP O
2 1571 1574 11745184 was VBD B-VP O
3 1575 1587 11745184 administered VBN I-VP O
4 1588 1593 11745184 every DT B-NP O
5 1594 1595 11745184 3 CD I-NP O
6 1596 1601 11745184 weeks NNS I-NP O
7 1602 1607 11745184 until IN B-PP O
8 1608 1615 11745184 disease NN B-NP O
9 1616 1627 11745184 progression NN I-NP O
10 1627 1628 11745184 . . O O

1 1629 1636 11745184 RESULTS NNS B-NP O
2 1636 1637 11745184 : : O O
3 1638 1643 11745184 Forty CD B-NP O
4 1643 1644 11745184 - HYPH I-NP O
5 1644 1648 11745184 four CD I-NP O
6 1649 1657 11745184 patients NNS I-NP O
7 1658 1662 11745184 were VBD B-VP O
8 1663 1671 11745184 enrolled VBN I-VP O
9 1672 1674 11745184 in IN B-PP O
10 1675 1678 11745184 the DT B-NP O
11 1679 1684 11745184 study NN I-NP O
12 1685 1687 11745184 of IN B-PP O
13 1688 1693 11745184 which WDT B-NP O
14 1694 1695 11745184 7 CD B-NP O
15 1696 1697 11745184 ( ( O O
16 1697 1700 11745184 16% NN B-NP O
17 1700 1701 11745184 ) ) O O
18 1702 1706 11745184 were VBD B-VP O
19 1707 1717 11745184 ineligible JJ B-ADJP O
20 1717 1718 11745184 . . O O

1 1719 1720 11745184 A DT B-NP O
2 1721 1727 11745184 median NN I-NP O
3 1728 1730 11745184 of IN B-PP O
4 1731 1732 11745184 2 CD B-NP O
5 1733 1739 11745184 cycles NNS I-NP O
6 1740 1742 11745184 of IN B-PP O
7 1743 1750 11745184 therapy NN B-NP O
8 1751 1754 11745184 was VBD B-VP O
9 1755 1767 11745184 administered VBN I-VP O
10 1768 1770 11745184 to TO B-PP O
11 1771 1774 11745184 the DT B-NP O
12 1775 1777 11745184 37 CD I-NP O
13 1778 1786 11745184 eligible JJ I-NP O
14 1787 1795 11745184 patients NNS I-NP O
15 1795 1796 11745184 . . O O

1 1797 1800 11745184 Six CD B-NP O
2 1801 1808 11745184 partial JJ I-NP O
3 1809 1818 11745184 responses NNS I-NP O
4 1819 1823 11745184 were VBD B-VP O
5 1824 1832 11745184 observed VBN I-VP O
6 1833 1836 11745184 for IN B-PP O
7 1837 1839 11745184 an DT B-NP O
8 1840 1847 11745184 overall JJ I-NP O
9 1848 1856 11745184 response NN I-NP O
10 1857 1861 11745184 rate NN I-NP O
11 1862 1864 11745184 of IN B-PP O
12 1865 1868 11745184 16% NN B-NP O
13 1868 1869 11745184 . . O O

1 1870 1874 11745184 Most JJS B-NP O
2 1875 1883 11745184 patients NNS I-NP O
3 1884 1885 11745184 ( ( O O
4 1885 1888 11745184 57% NN B-NP O
5 1888 1889 11745184 ) ) O O
6 1890 1897 11745184 stopped VBD B-VP O
7 1898 1907 11745184 treatment NN B-NP O
8 1908 1915 11745184 because IN B-PP O
9 1916 1918 11745184 of IN I-PP O
10 1919 1926 11745184 disease NN B-NP O
11 1927 1938 11745184 progression NN I-NP O
12 1938 1939 11745184 . . O O

1 1940 1950 11745184 Neurologic JJ B-NP B-Disease
2 1951 1959 11745184 toxicity NN I-NP I-Disease
3 1960 1963 11745184 was VBD B-VP O
4 1964 1972 11745184 reported VBN I-VP O
5 1973 1975 11745184 in IN B-PP O
6 1976 1979 11745184 52% NN B-NP O
7 1980 1982 11745184 of IN B-PP O
8 1983 1991 11745184 patients NNS B-NP O
9 1991 1992 11745184 . . O O

1 1993 1998 11745184 Seven CD B-NP O
2 1999 2008 11745184 different JJ I-NP O
3 2009 2013 11745184 life NN I-NP O
4 2013 2014 11745184 - HYPH B-VP O
5 2014 2025 11745184 threatening VBG B-NP O
6 2026 2036 11745184 toxicities NNS I-NP B-Disease
7 2037 2041 11745184 were VBD B-VP O
8 2042 2050 11745184 observed VBN I-VP O
9 2051 2053 11745184 in IN B-PP O
10 2054 2062 11745184 patients NNS B-NP O
11 2063 2068 11745184 while IN B-SBAR O
12 2069 2078 11745184 receiving VBG B-VP O
13 2079 2088 11745184 treatment NN B-NP O
14 2088 2089 11745184 . . O O

1 2090 2101 11745184 CONCLUSIONS NNS B-NP O
2 2101 2102 11745184 : : O O
3 2103 2106 11745184 The DT B-NP O
4 2107 2118 11745184 combination NN I-NP O
5 2119 2121 11745184 of IN B-PP O
6 2122 2131 11745184 cisplatin NN B-NP B-Chemical
7 2132 2135 11745184 and CC I-NP O
8 2136 2146 11745184 amifostine NN I-NP B-Chemical
9 2147 2149 11745184 in IN B-PP O
10 2150 2154 11745184 this DT B-NP O
11 2155 2160 11745184 study NN I-NP O
12 2161 2169 11745184 resulted VBD B-VP O
13 2170 2172 11745184 in IN B-PP O
14 2173 2175 11745184 an DT B-NP O
15 2176 2183 11745184 overall JJ I-NP O
16 2184 2192 11745184 response NN I-NP O
17 2193 2197 11745184 rate NN I-NP O
18 2198 2200 11745184 of IN B-PP O
19 2201 2204 11745184 16% NN B-NP O
20 2204 2205 11745184 . . O O

1 2206 2213 11745184 Neither CC O O
2 2214 2215 11745184 a DT B-NP O
3 2216 2221 11745184 tumor NN I-NP B-Disease
4 2221 2222 11745184 - HYPH B-NP O
5 2222 2232 11745184 protective JJ I-NP O
6 2233 2239 11745184 effect NN I-NP O
7 2240 2243 11745184 nor CC O O
8 2244 2251 11745184 reduced JJ B-NP O
9 2252 2260 11745184 toxicity NN I-NP B-Disease
10 2261 2263 11745184 to TO B-PP O
11 2264 2270 11745184 normal JJ B-NP O
12 2271 2278 11745184 tissues NNS I-NP O
13 2279 2282 11745184 was VBD B-VP O
14 2283 2291 11745184 observed VBN I-VP O
15 2292 2296 11745184 with IN B-PP O
16 2297 2300 11745184 the DT B-NP O
17 2301 2309 11745184 addition NN I-NP O
18 2310 2312 11745184 of IN B-PP O
19 2313 2323 11745184 amifostine NN B-NP B-Chemical
20 2324 2326 11745184 to TO B-PP O
21 2327 2336 11745184 cisplatin NN B-NP B-Chemical
22 2337 2339 11745184 in IN B-PP O
23 2340 2344 11745184 this DT B-NP O
24 2345 2350 11745184 trial NN I-NP O
25 2350 2351 11745184 . . O O

1 0 0 2396046 -DOCSTART- -X- -X- O

1 0 2 2396046 No DT B-NP O
2 3 14 2396046 enhancement NN I-NP O
3 15 17 2396046 by IN B-PP O
4 18 31 2396046 phenobarbital NN B-NP B-Chemical
5 32 34 2396046 of IN B-PP O
6 35 38 2396046 the DT B-NP O
7 39 60 2396046 hepatocarcinogenicity NN I-NP O
8 61 63 2396046 of IN B-PP O
9 64 65 2396046 a DT B-NP O
10 66 73 2396046 choline NN I-NP B-Chemical
11 73 74 2396046 - HYPH B-NP O
12 74 80 2396046 devoid JJ I-NP O
13 81 85 2396046 diet NN I-NP O
14 86 88 2396046 in IN B-PP O
15 89 92 2396046 the DT B-NP O
16 93 96 2396046 rat NN I-NP O
17 96 97 2396046 . . O O
18 98 100 2396046 An DT B-NP O
19 101 111 2396046 experiment NN I-NP O
20 112 115 2396046 was VBD B-VP O
21 116 125 2396046 performed VBN I-VP O
22 126 128 2396046 to TO I-VP O
23 129 133 2396046 test VB I-VP O
24 134 141 2396046 whether IN B-SBAR O
25 142 151 2396046 inclusion NN B-NP O
26 152 154 2396046 of IN B-PP O
27 155 168 2396046 phenobarbital NN B-NP B-Chemical
28 169 171 2396046 in IN B-PP O
29 172 173 2396046 a DT B-NP O
30 174 181 2396046 choline NN I-NP B-Chemical
31 181 182 2396046 - HYPH B-NP O
32 182 188 2396046 devoid JJ I-NP O
33 189 193 2396046 diet NN I-NP O
34 194 199 2396046 would MD B-VP O
35 200 208 2396046 increase VB I-VP O
36 209 212 2396046 the DT B-NP O
37 213 234 2396046 hepatocarcinogenicity NN I-NP O
38 235 237 2396046 of IN B-PP O
39 238 241 2396046 the DT B-NP O
40 242 246 2396046 diet NN I-NP O
41 246 247 2396046 . . O O

1 248 254 2396046 Groups NNS B-NP O
2 255 257 2396046 of IN B-PP O
3 258 259 2396046 5 CD B-NP O
4 259 260 2396046 - HYPH I-NP O
5 260 264 2396046 week NN I-NP O
6 265 268 2396046 old JJ I-NP O
7 269 273 2396046 male JJ I-NP O
8 274 281 2396046 Fischer NNP I-NP O
9 281 282 2396046 - HYPH I-NP O
10 282 285 2396046 344 CD I-NP O
11 286 290 2396046 rats NNS I-NP O
12 291 295 2396046 were VBD B-VP O
13 296 299 2396046 fed VBN I-VP O
14 300 303 2396046 for IN B-PP O
15 304 305 2396046 7 CD B-NP O
16 305 306 2396046 - HYPH I-NP O
17 306 308 2396046 25 CD I-NP O
18 309 315 2396046 months NNS I-NP O
19 316 328 2396046 semipurified VBD B-VP O
20 329 336 2396046 choline NN B-NP B-Chemical
21 336 337 2396046 - HYPH B-NP O
22 337 343 2396046 devoid JJ I-NP O
23 344 346 2396046 or CC I-NP O
24 347 354 2396046 choline NN I-NP B-Chemical
25 354 355 2396046 - HYPH B-NP O
26 355 367 2396046 supplemented VBN I-NP O
27 368 373 2396046 diets NNS I-NP O
28 373 374 2396046 , , O O
29 375 385 2396046 containing VBG B-VP O
30 386 388 2396046 or CC O O
31 389 392 2396046 not RB O O
32 393 398 2396046 0.06% CD B-NP O
33 399 412 2396046 phenobarbital NN I-NP B-Chemical
34 412 413 2396046 . . O O

1 414 416 2396046 No DT B-NP O
2 417 424 2396046 hepatic JJ I-NP O
3 425 438 2396046 preneoplastic JJ I-NP O
4 439 446 2396046 nodules NNS I-NP O
5 447 449 2396046 or CC O O
6 450 464 2396046 hepatocellular JJ B-NP B-Disease
7 465 475 2396046 carcinomas NNS I-NP I-Disease
8 476 485 2396046 developed VBN B-VP O
9 486 488 2396046 in IN B-PP O
10 489 493 2396046 rats NNS B-NP O
11 494 497 2396046 fed VBN B-VP O
12 498 501 2396046 the DT B-NP O
13 502 507 2396046 plain JJ I-NP O
14 508 515 2396046 choline NN I-NP B-Chemical
15 515 516 2396046 - HYPH B-VP O
16 516 528 2396046 supplemented VBN B-NP O
17 529 533 2396046 diet NN I-NP O
18 533 534 2396046 , , O O
19 535 540 2396046 while IN B-SBAR O
20 541 544 2396046 one CD B-NP O
21 545 558 2396046 preneoplastic JJ I-NP O
22 559 565 2396046 nodule NN I-NP O
23 566 569 2396046 and CC O O
24 570 573 2396046 one CD B-NP O
25 574 588 2396046 hepatocellular JJ I-NP B-Disease
26 589 598 2396046 carcinoma NN I-NP I-Disease
27 599 608 2396046 developed VBN B-VP O
28 609 611 2396046 in IN B-PP O
29 612 615 2396046 two CD B-NP O
30 616 620 2396046 rats NNS I-NP O
31 621 624 2396046 fed VBN B-VP O
32 625 628 2396046 the DT B-NP O
33 629 633 2396046 same JJ I-NP O
34 634 638 2396046 diet NN I-NP O
35 639 649 2396046 containing VBG B-VP O
36 650 663 2396046 phenobarbital NN B-NP B-Chemical
37 663 664 2396046 . . O O

1 665 668 2396046 The DT B-NP O
2 669 678 2396046 incidence NN I-NP O
3 679 681 2396046 of IN B-PP O
4 682 695 2396046 preneoplastic JJ B-NP O
5 696 703 2396046 nodules NNS I-NP O
6 704 707 2396046 and CC B-PP O
7 708 710 2396046 of IN B-PP O
8 711 725 2396046 hepatocellular JJ B-NP B-Disease
9 726 736 2396046 carcinomas NNS I-NP I-Disease
10 737 740 2396046 was VBD B-VP O
11 741 744 2396046 10% CD B-NP O
12 745 748 2396046 and CC I-NP O
13 749 752 2396046 37% CD I-NP O
14 752 753 2396046 , , O O
15 754 766 2396046 respectively RB B-ADVP O
16 766 767 2396046 , , O O
17 768 770 2396046 in IN B-PP O
18 771 775 2396046 rats NNS B-NP O
19 776 779 2396046 fed VBN B-VP O
20 780 783 2396046 the DT B-NP O
21 784 789 2396046 plain JJ I-NP O
22 790 797 2396046 choline NN I-NP B-Chemical
23 797 798 2396046 - HYPH B-NP O
24 798 804 2396046 devoid JJ I-NP O
25 805 809 2396046 diet NN I-NP O
26 809 810 2396046 , , O O
27 811 814 2396046 and CC O O
28 815 818 2396046 17% NN B-NP O
29 819 822 2396046 and CC O O
30 823 826 2396046 30% CD B-NP O
31 826 827 2396046 , , O O
32 828 830 2396046 in IN B-PP O
33 831 835 2396046 rats NNS B-NP O
34 836 839 2396046 fed VBN B-VP O
35 840 843 2396046 the DT B-NP O
36 844 857 2396046 phenobarbital NN I-NP B-Chemical
37 857 858 2396046 - HYPH O O
38 858 868 2396046 containing VBG B-VP O
39 869 876 2396046 choline NN B-NP B-Chemical
40 876 877 2396046 - HYPH B-NP O
41 877 883 2396046 devoid JJ I-NP O
42 884 888 2396046 diet NN I-NP O
43 888 889 2396046 . . O O

1 890 893 2396046 The DT B-NP O
2 894 901 2396046 results NNS I-NP O
3 902 909 2396046 evinced VBD B-VP O
4 910 912 2396046 no DT B-NP O
5 913 924 2396046 enhancement NN I-NP O
6 925 927 2396046 of IN B-PP O
7 928 931 2396046 the DT B-NP O
8 932 953 2396046 hepatocarcinogenicity NN I-NP O
9 954 956 2396046 of IN B-PP O
10 957 960 2396046 the DT B-NP O
11 961 968 2396046 choline NN I-NP B-Chemical
12 968 969 2396046 - HYPH B-NP O
13 969 975 2396046 devoid JJ I-NP O
14 976 980 2396046 diet NN I-NP O
15 981 983 2396046 by IN B-PP O
16 984 997 2396046 phenobarbital NN B-NP B-Chemical
17 997 998 2396046 . . O O

1 999 1007 2396046 Sporadic JJ B-NP O
2 1008 1018 2396046 neoplastic JJ I-NP O
3 1019 1026 2396046 lesions NNS I-NP O
4 1027 1031 2396046 were VBD B-VP O
5 1032 1040 2396046 observed VBN I-VP O
6 1041 1043 2396046 in IN B-PP O
7 1044 1050 2396046 organs NNS B-NP O
8 1051 1056 2396046 other JJ B-ADJP O
9 1057 1061 2396046 than IN B-PP O
10 1062 1065 2396046 the DT B-NP O
11 1066 1071 2396046 liver NN I-NP O
12 1072 1074 2396046 of IN B-PP O
13 1075 1079 2396046 some DT B-NP O
14 1080 1082 2396046 of IN B-PP O
15 1083 1086 2396046 the DT B-NP O
16 1087 1094 2396046 animals NNS I-NP O
17 1094 1095 2396046 , , O O
18 1096 1108 2396046 irrespective JJ B-ADJP O
19 1109 1111 2396046 of IN B-PP O
20 1112 1115 2396046 the DT B-NP O
21 1116 1120 2396046 diet NN I-NP O
22 1121 1124 2396046 fed VBN B-VP O
23 1124 1125 2396046 . . O O

1 0 0 1147734 -DOCSTART- -X- -X- O

1 0 5 1147734 Liver NN B-NP B-Disease
2 6 13 1147734 disease NN I-NP I-Disease
3 14 20 1147734 caused VBN B-VP O
4 21 23 1147734 by IN B-PP O
5 24 40 1147734 propylthiouracil NN B-NP B-Chemical
6 40 41 1147734 . . O O
7 42 46 1147734 This DT B-NP O
8 47 53 1147734 report NN I-NP O
9 54 62 1147734 presents VBZ B-VP O
10 63 66 1147734 the DT B-NP O
11 67 75 1147734 clinical JJ I-NP O
12 75 76 1147734 , , I-NP O
13 77 87 1147734 laboratory NN I-NP O
14 87 88 1147734 , , O O
15 89 92 1147734 and CC O O
16 93 98 1147734 light NN B-NP O
17 99 102 1147734 and CC I-NP O
18 103 111 1147734 electron NN I-NP O
19 112 123 1147734 microscopic JJ I-NP O
20 124 136 1147734 observations NNS I-NP O
21 137 139 1147734 on IN B-PP O
22 140 141 1147734 a DT B-NP O
23 142 149 1147734 patient NN I-NP O
24 150 154 1147734 with IN B-PP O
25 155 162 1147734 chronic JJ B-NP B-Disease
26 163 169 1147734 active JJ I-NP I-Disease
27 170 171 1147734 ( ( O I-Disease
28 171 181 1147734 aggressive JJ B-ADJP I-Disease
29 181 182 1147734 ) ) O I-Disease
30 183 192 1147734 hepatitis NN B-NP I-Disease
31 193 199 1147734 caused VBN B-VP O
32 200 202 1147734 by IN B-PP O
33 203 206 1147734 the DT B-NP O
34 207 221 1147734 administration NN I-NP O
35 222 224 1147734 of IN B-PP O
36 225 241 1147734 propylthiouracil NN B-NP B-Chemical
37 241 242 1147734 . . O O

1 243 247 1147734 This DT B-NP O
2 248 250 1147734 is VBZ B-VP O
3 251 253 1147734 an DT B-NP O
4 254 262 1147734 addition NN I-NP O
5 263 265 1147734 to TO B-PP O
6 266 269 1147734 the DT B-NP O
7 270 274 1147734 list NN I-NP O
8 275 277 1147734 of IN B-PP O
9 278 283 1147734 drugs NNS B-NP O
10 284 288 1147734 that WDT B-NP O
11 289 293 1147734 must MD B-VP O
12 294 296 1147734 be VB I-VP O
13 297 307 1147734 considered VBN I-VP O
14 308 310 1147734 in IN B-PP O
15 311 314 1147734 the DT B-NP O
16 315 325 1147734 evaluation NN I-NP O
17 326 328 1147734 of IN B-PP O
18 329 336 1147734 chronic JJ B-NP O
19 337 342 1147734 liver NN I-NP B-Disease
20 343 350 1147734 disease NN I-NP I-Disease
21 350 351 1147734 . . O O

1 0 0 6386793 -DOCSTART- -X- -X- O

1 0 1 6386793 A DT B-NP O
2 2 8 6386793 double JJ I-NP O
3 8 9 6386793 - HYPH I-NP O
4 9 14 6386793 blind JJ I-NP O
5 15 20 6386793 study NN I-NP O
6 21 23 6386793 of IN B-PP O
7 24 27 6386793 the DT B-NP O
8 28 36 6386793 efficacy NN I-NP O
9 37 40 6386793 and CC I-NP O
10 41 47 6386793 safety NN I-NP O
11 48 50 6386793 of IN B-PP O
12 51 60 6386793 dothiepin NN B-NP B-Chemical
13 61 74 6386793 hydrochloride NN I-NP I-Chemical
14 75 77 6386793 in IN B-PP O
15 78 81 6386793 the DT B-NP O
16 82 91 6386793 treatment NN I-NP O
17 92 94 6386793 of IN B-PP O
18 95 100 6386793 major JJ B-NP O
19 101 111 6386793 depressive JJ I-NP B-Disease
20 112 120 6386793 disorder NN I-NP I-Disease
21 120 121 6386793 . . O O
22 122 124 6386793 In IN B-PP O
23 125 126 6386793 a DT B-NP O
24 127 128 6386793 6 CD I-NP O
25 128 129 6386793 - HYPH I-NP O
26 129 133 6386793 week NN I-NP O
27 134 140 6386793 double JJ I-NP O
28 140 141 6386793 - HYPH I-NP O
29 141 146 6386793 blind JJ I-NP O
30 147 155 6386793 parallel JJ I-NP O
31 156 165 6386793 treatment NN I-NP O
32 166 171 6386793 study NN I-NP O
33 171 172 6386793 , , O O
34 173 182 6386793 dothiepin NN B-NP B-Chemical
35 183 186 6386793 and CC I-NP O
36 187 200 6386793 amitriptyline NN I-NP B-Chemical
37 201 205 6386793 were VBD B-VP O
38 206 214 6386793 compared VBN I-VP O
39 215 217 6386793 to TO B-PP O
40 218 225 6386793 placebo NN B-NP O
41 226 228 6386793 in IN B-PP O
42 229 232 6386793 the DT B-NP O
43 233 242 6386793 treatment NN I-NP O
44 243 245 6386793 of IN B-PP O
45 246 248 6386793 33 CD B-NP O
46 249 258 6386793 depressed JJ I-NP B-Disease
47 259 270 6386793 outpatients NNS I-NP O
48 270 271 6386793 . . O O

1 272 281 6386793 Dothiepin NN B-NP B-Chemical
2 282 285 6386793 and CC I-NP O
3 286 299 6386793 amitriptyline NN I-NP B-Chemical
4 300 304 6386793 were VBD B-VP O
5 305 312 6386793 equally RB B-ADJP O
6 313 322 6386793 effective JJ I-ADJP O
7 323 325 6386793 in IN B-PP O
8 326 337 6386793 alleviating VBG B-VP O
9 338 341 6386793 the DT B-NP O
10 342 350 6386793 symptoms NNS I-NP O
11 351 353 6386793 of IN B-PP O
12 354 364 6386793 depressive JJ B-NP B-Disease
13 365 372 6386793 illness NN I-NP I-Disease
14 372 373 6386793 , , O O
15 374 377 6386793 and CC O O
16 378 382 6386793 both DT B-NP O
17 383 387 6386793 were VBD B-VP O
18 388 401 6386793 significantly RB B-ADJP O
19 402 410 6386793 superior JJ I-ADJP O
20 411 413 6386793 to TO B-PP O
21 414 421 6386793 placebo NN B-NP O
22 421 422 6386793 . . O O

1 423 426 6386793 The DT B-NP O
2 427 434 6386793 overall JJ I-NP O
3 435 444 6386793 incidence NN I-NP O
4 445 447 6386793 of IN B-PP O
5 448 452 6386793 side JJ B-NP O
6 453 460 6386793 effects NNS I-NP O
7 461 464 6386793 and CC O O
8 465 468 6386793 the DT B-NP O
9 469 478 6386793 frequency NN I-NP O
10 479 482 6386793 and CC I-NP O
11 483 491 6386793 severity NN I-NP O
12 492 494 6386793 of IN B-PP O
13 495 502 6386793 blurred JJ B-NP B-Disease
14 503 509 6386793 vision NN I-NP I-Disease
15 509 510 6386793 , , O O
16 511 514 6386793 dry JJ B-NP B-Disease
17 515 520 6386793 mouth NN I-NP I-Disease
18 520 521 6386793 , , O O
19 522 525 6386793 and CC O O
20 526 536 6386793 drowsiness NN B-NP O
21 537 541 6386793 were VBD B-VP O
22 542 555 6386793 significantly RB B-ADJP O
23 556 560 6386793 less JJR I-ADJP O
24 561 565 6386793 with IN B-PP O
25 566 575 6386793 dothiepin NN B-NP B-Chemical
26 576 580 6386793 than IN B-PP O
27 581 585 6386793 with IN B-PP O
28 586 599 6386793 amitriptyline NN B-NP B-Chemical
29 599 600 6386793 . . O O

1 601 610 6386793 Dothiepin NNP B-NP B-Chemical
2 611 615 6386793 also RB B-ADVP O
3 616 624 6386793 produced VBD B-VP O
4 625 630 6386793 fewer JJR B-NP O
5 631 634 6386793 CNS NN I-NP O
6 635 638 6386793 and CC I-NP O
7 639 653 6386793 cardiovascular JJ I-NP O
8 654 661 6386793 effects NNS I-NP O
9 661 662 6386793 . . O O

1 663 668 6386793 There EX B-NP O
2 669 673 6386793 were VBD B-VP O
3 674 676 6386793 no DT B-NP O
4 677 687 6386793 clinically RB I-NP O
5 688 697 6386793 important JJ I-NP O
6 698 705 6386793 changes NNS I-NP O
7 706 708 6386793 in IN B-PP O
8 709 719 6386793 laboratory NN B-NP O
9 720 730 6386793 parameters NNS I-NP O
10 730 731 6386793 . . O O

1 732 741 6386793 Dothiepin NNP B-NP B-Chemical
2 742 746 6386793 thus RB B-ADVP O
3 747 750 6386793 was VBD B-VP O
4 751 756 6386793 found VBN I-VP O
5 757 759 6386793 to TO I-VP O
6 760 762 6386793 be VB I-VP O
7 763 765 6386793 an DT B-NP O
8 766 775 6386793 effective JJ I-NP O
9 776 790 6386793 antidepressant NN I-NP B-Chemical
10 791 795 6386793 drug NN I-NP O
11 796 806 6386793 associated VBN B-VP O
12 807 811 6386793 with IN B-PP O
13 812 817 6386793 fewer JJR B-NP O
14 818 822 6386793 side NN I-NP O
15 823 830 6386793 effects NNS I-NP O
16 831 835 6386793 than IN B-PP O
17 836 849 6386793 amitriptyline NN B-NP B-Chemical
18 850 852 6386793 in IN B-PP O
19 853 856 6386793 the DT B-NP O
20 857 866 6386793 treatment NN I-NP O
21 867 869 6386793 of IN B-PP O
22 870 879 6386793 depressed JJ B-NP B-Disease
23 880 891 6386793 outpatients NNS I-NP O
24 891 892 6386793 . . O O

1 0 0 12536034 -DOCSTART- -X- -X- O

1 0 4 12536034 Anti AFX B-NP O
2 4 5 12536034 - HYPH I-NP O
3 5 14 12536034 epileptic JJ B-NP B-Disease
4 15 20 12536034 drugs NNS I-NP O
5 20 21 12536034 - HYPH B-VP O
6 21 28 12536034 induced VBN B-NP O
7 29 31 12536034 de FW I-NP O
8 32 36 12536034 novo FW I-NP O
9 37 44 12536034 absence NN I-NP B-Disease
10 45 53 12536034 seizures NNS I-NP I-Disease
11 53 54 12536034 . . O O
12 55 58 12536034 The DT B-NP O
13 59 66 12536034 authors NNS I-NP O
14 67 74 12536034 present VBP B-VP O
15 75 80 12536034 three CD B-NP O
16 81 89 12536034 patients NNS I-NP O
17 90 94 12536034 with IN B-PP O
18 95 97 12536034 de FW B-NP O
19 98 102 12536034 novo FW I-NP O
20 103 110 12536034 absence NN I-NP B-Disease
21 111 119 12536034 epilepsy NN I-NP I-Disease
22 120 125 12536034 after IN B-PP O
23 126 140 12536034 administration NN B-NP O
24 141 143 12536034 of IN B-PP O
25 144 157 12536034 carbamazepine NN B-NP B-Chemical
26 158 161 12536034 and CC I-NP O
27 162 172 12536034 vigabatrin NN I-NP B-Chemical
28 172 173 12536034 . . O O

1 174 181 12536034 Despite IN B-PP O
2 182 185 12536034 the DT B-NP O
3 186 196 12536034 underlying VBG I-NP O
4 197 205 12536034 diseases NNS I-NP O
5 205 206 12536034 , , O O
6 207 210 12536034 the DT B-NP O
7 211 220 12536034 prognosis NN I-NP O
8 221 224 12536034 for IN B-PP O
9 225 229 12536034 drug NN B-NP O
10 229 230 12536034 - HYPH B-VP O
11 230 237 12536034 induced VBN B-NP O
12 238 240 12536034 de FW I-NP O
13 241 245 12536034 novo FW I-NP O
14 246 253 12536034 absence NN I-NP B-Disease
15 254 261 12536034 seizure NN I-NP I-Disease
16 262 264 12536034 is VBZ B-VP O
17 265 269 12536034 good JJ B-ADJP O
18 270 277 12536034 because IN B-SBAR O
19 278 280 12536034 it PRP B-NP O
20 281 289 12536034 subsides VBZ B-VP O
21 290 297 12536034 rapidly RB B-ADVP O
22 298 303 12536034 after IN B-PP O
23 304 317 12536034 discontinuing VBG B-VP O
24 318 321 12536034 the DT B-NP O
25 322 325 12536034 use NN I-NP O
26 326 328 12536034 of IN B-PP O
27 329 332 12536034 the DT B-NP O
28 333 342 12536034 offending VBG I-NP O
29 343 348 12536034 drugs NNS I-NP O
30 348 349 12536034 . . O O

1 350 353 12536034 The DT B-NP O
2 354 359 12536034 gamma NN I-NP B-Chemical
3 359 360 12536034 - HYPH O I-Chemical
4 360 372 12536034 aminobutyric JJ B-NP I-Chemical
5 373 377 12536034 acid NN I-NP I-Chemical
6 377 378 12536034 - HYPH O O
7 378 389 12536034 transmitted VBN B-VP O
8 390 405 12536034 thalamocortical JJ B-NP O
9 406 415 12536034 circuitry NN I-NP O
10 416 424 12536034 accounts VBZ B-VP O
11 425 428 12536034 for IN B-PP O
12 429 430 12536034 a DT B-NP O
13 431 436 12536034 major JJ I-NP O
14 437 441 12536034 part NN I-NP O
15 442 444 12536034 of IN B-PP O
16 445 448 12536034 the DT B-NP O
17 449 459 12536034 underlying VBG I-NP O
18 460 475 12536034 neurophysiology NN I-NP O
19 476 478 12536034 of IN B-PP O
20 479 482 12536034 the DT B-NP O
21 483 490 12536034 absence NN I-NP B-Disease
22 491 499 12536034 epilepsy NN I-NP I-Disease
23 499 500 12536034 . . O O

1 501 508 12536034 Because IN B-SBAR O
2 509 513 12536034 drug NN B-NP O
3 513 514 12536034 - HYPH B-VP O
4 514 521 12536034 induced VBN B-NP O
5 522 524 12536034 de FW I-NP O
6 525 529 12536034 novo FW I-NP O
7 530 537 12536034 absence NN I-NP B-Disease
8 538 545 12536034 seizure NN I-NP I-Disease
9 546 548 12536034 is VBZ B-VP O
10 549 553 12536034 rare JJ B-ADJP O
11 553 554 12536034 , , O O
12 555 558 12536034 pro AFX O O
13 558 559 12536034 - HYPH O O
14 559 566 12536034 absence NN B-NP O
15 567 572 12536034 drugs NNS I-NP O
16 573 576 12536034 can MD B-VP O
17 577 581 12536034 only RB I-VP O
18 582 584 12536034 be VB I-VP O
19 585 595 12536034 considered VBN I-VP O
20 596 597 12536034 a DT B-NP O
21 598 607 12536034 promoting VBG I-NP O
22 608 614 12536034 factor NN I-NP O
23 614 615 12536034 . . O O

1 616 619 12536034 The DT B-NP O
2 620 630 12536034 underlying VBG I-NP O
3 631 647 12536034 epileptogenecity NN I-NP O
4 648 650 12536034 of IN B-PP O
5 651 654 12536034 the DT B-NP O
6 655 663 12536034 patients NNS I-NP O
7 664 666 12536034 or CC O O
8 667 670 12536034 the DT B-NP O
9 671 682 12536034 synergistic JJ I-NP O
10 683 690 12536034 effects NNS I-NP O
11 691 693 12536034 of IN B-PP O
12 694 697 12536034 the DT B-NP O
13 698 710 12536034 accompanying VBG I-NP O
14 711 716 12536034 drugs NNS I-NP O
15 717 719 12536034 is VBZ B-VP O
16 720 728 12536034 required VBN I-VP O
17 729 731 12536034 to TO I-VP O
18 732 739 12536034 trigger VB I-VP O
19 740 743 12536034 the DT B-NP O
20 744 746 12536034 de FW I-NP O
21 747 751 12536034 novo FW I-NP O
22 752 759 12536034 absence NN I-NP B-Disease
23 760 767 12536034 seizure NN I-NP I-Disease
24 767 768 12536034 . . O O

1 769 772 12536034 The DT B-NP O
2 773 784 12536034 possibility NN I-NP O
3 785 787 12536034 of IN B-PP O
4 788 792 12536034 drug NN B-NP O
5 792 793 12536034 - HYPH B-NP O
6 793 800 12536034 induced VBN I-NP O
7 801 812 12536034 aggravation NN I-NP O
8 813 819 12536034 should MD B-VP O
9 820 822 12536034 be VB I-VP O
10 823 833 12536034 considered VBN I-VP O
11 834 842 12536034 whenever WRB B-ADVP O
12 843 845 12536034 an DT B-NP O
13 846 856 12536034 unexpected JJ I-NP O
14 857 865 12536034 increase NN I-NP O
15 866 868 12536034 in IN B-PP O
16 869 876 12536034 seizure NN B-NP B-Disease
17 877 886 12536034 frequency NN I-NP O
18 887 890 12536034 and CC O O
19 890 891 12536034 / SYM B-NP O
20 891 893 12536034 or CC O O
21 894 897 12536034 new JJ B-NP O
22 898 905 12536034 seizure NN I-NP B-Disease
23 906 911 12536034 types NNS I-NP O
24 912 918 12536034 appear VBP B-VP O
25 919 928 12536034 following VBG I-VP O
26 929 930 12536034 a DT B-NP O
27 931 937 12536034 change NN I-NP O
28 938 940 12536034 in IN B-PP O
29 941 945 12536034 drug NN B-NP O
30 946 955 12536034 treatment NN I-NP O
31 955 956 12536034 . . O O

1 957 959 12536034 By IN B-PP O
2 960 973 12536034 understanding VBG B-VP O
3 974 977 12536034 the DT B-NP O
4 978 988 12536034 underlying VBG I-NP O
5 989 998 12536034 mechanism NN I-NP O
6 999 1001 12536034 of IN B-PP O
7 1002 1009 12536034 absence NN B-NP B-Disease
8 1010 1018 12536034 epilepsy NN I-NP I-Disease
9 1018 1019 12536034 , , O O
10 1020 1022 12536034 we PRP B-NP O
11 1023 1026 12536034 can MD B-VP O
12 1027 1032 12536034 avoid VB I-VP O
13 1033 1036 12536034 the DT B-NP O
14 1037 1050 12536034 inappropriate JJ I-NP O
15 1051 1054 12536034 use NN I-NP O
16 1055 1057 12536034 of IN B-PP O
17 1058 1073 12536034 anticonvulsants NNS B-NP O
18 1074 1076 12536034 in IN B-PP O
19 1077 1085 12536034 children NNS B-NP O
20 1086 1090 12536034 with IN B-PP O
21 1091 1099 12536034 epilepsy NN B-NP B-Disease
22 1100 1103 12536034 and CC O O
23 1104 1111 12536034 prevent VBP B-VP O
24 1112 1116 12536034 drug NN B-NP O
25 1116 1117 12536034 - HYPH B-NP O
26 1117 1124 12536034 induced VBN I-NP O
27 1125 1132 12536034 absence NN I-NP B-Disease
28 1133 1141 12536034 seizures NNS I-NP I-Disease
29 1141 1142 12536034 . . O O

1 0 0 7352670 -DOCSTART- -X- -X- O

1 0 7 7352670 Rebound VB B-VP O
2 8 20 7352670 hypertensive JJ B-ADJP B-Disease
3 21 26 7352670 after IN B-PP O
4 27 33 7352670 sodium NN B-NP B-Chemical
5 34 47 7352670 nitroprusside NN I-NP I-Chemical
6 48 57 7352670 prevented VBN B-VP O
7 58 60 7352670 by IN B-PP O
8 61 70 7352670 saralasin NN B-NP B-Chemical
9 71 73 7352670 in IN B-PP O
10 74 78 7352670 rats NNS B-NP O
11 78 79 7352670 . . O O
12 80 83 7352670 The DT B-NP O
13 84 88 7352670 role NN I-NP O
14 89 91 7352670 of IN B-PP O
15 92 95 7352670 the DT B-NP O
16 96 101 7352670 renin NN I-NP O
17 101 102 7352670 - HYPH O O
18 102 103 7352670 - HYPH B-NP O
19 103 114 7352670 angiotensin NN I-NP B-Chemical
20 115 121 7352670 system NN I-NP O
21 122 124 7352670 in IN B-PP O
22 125 128 7352670 the DT B-NP O
23 129 140 7352670 maintenance NN I-NP O
24 141 143 7352670 of IN B-PP O
25 144 149 7352670 blood NN B-NP O
26 150 158 7352670 pressure NN I-NP O
27 159 165 7352670 during IN B-PP O
28 166 175 7352670 halothane NN B-NP B-Chemical
29 176 186 7352670 anesthesia NN I-NP O
30 187 190 7352670 and CC O O
31 191 197 7352670 sodium NN B-NP B-Chemical
32 198 211 7352670 nitroprusside NN I-NP I-Chemical
33 212 213 7352670 ( ( O O
34 213 216 7352670 SNP NN B-NP B-Chemical
35 216 217 7352670 ) ) O O
36 217 218 7352670 - HYPH B-NP O
37 218 225 7352670 induced VBN I-NP O
38 226 237 7352670 hypotension NN I-NP B-Disease
39 238 241 7352670 was VBD B-VP O
40 242 251 7352670 evaluated VBN I-VP O
41 251 252 7352670 . . O O

1 253 260 7352670 Control NN B-NP O
2 261 265 7352670 rats NNS I-NP O
3 266 274 7352670 received VBD B-VP O
4 275 284 7352670 halothane NN B-NP B-Chemical
5 285 295 7352670 anesthesia NN I-NP O
6 296 297 7352670 ( ( O O
7 297 298 7352670 1 CD B-NP O
8 299 302 7352670 MAC NN I-NP O
9 302 303 7352670 ) ) O O
10 304 307 7352670 for IN B-PP O
11 308 311 7352670 one CD B-NP O
12 312 316 7352670 hour NN I-NP O
13 316 317 7352670 , , O O
14 318 326 7352670 followed VBN B-VP O
15 327 329 7352670 by IN B-PP O
16 330 333 7352670 SNP NN B-NP B-Chemical
17 334 342 7352670 infusion NN I-NP O
18 342 343 7352670 , , O O
19 344 346 7352670 40 CD B-NP O
20 347 356 7352670 microgram NN I-NP O
21 356 357 7352670 / SYM B-NP O
22 357 359 7352670 kg NN I-NP O
23 359 360 7352670 / SYM I-NP O
24 360 363 7352670 min NN I-NP O
25 363 364 7352670 , , O O
26 365 368 7352670 for IN B-PP O
27 369 371 7352670 30 CD B-NP O
28 372 375 7352670 min NN I-NP O
29 375 376 7352670 , , O O
30 377 385 7352670 followed VBN B-VP O
31 386 388 7352670 by IN B-PP O
32 389 390 7352670 a DT B-NP O
33 391 393 7352670 30 CD I-NP O
34 393 394 7352670 - HYPH I-NP O
35 394 397 7352670 min NN I-NP O
36 398 406 7352670 recovery NN I-NP O
37 407 413 7352670 period NN I-NP O
38 413 414 7352670 . . O O

1 415 416 7352670 A DT B-NP O
2 417 423 7352670 second JJ I-NP O
3 424 429 7352670 group NN I-NP O
4 430 432 7352670 of IN B-PP O
5 433 437 7352670 rats NNS B-NP O
6 438 441 7352670 was VBD B-VP O
7 442 449 7352670 treated VBN I-VP O
8 450 461 7352670 identically RB B-ADVP O
9 462 465 7352670 and CC O O
10 465 466 7352670 , , O O
11 467 469 7352670 in IN B-PP O
12 470 478 7352670 addition NN B-NP O
13 478 479 7352670 , , O O
14 480 488 7352670 received VBD B-VP O
15 489 491 7352670 an DT B-NP O
16 492 500 7352670 infusion NN I-NP O
17 501 503 7352670 of IN B-PP O
18 504 513 7352670 saralasin NN B-NP B-Chemical
19 514 515 7352670 ( ( O O
20 515 516 7352670 a DT B-NP O
21 517 528 7352670 competitive JJ I-NP O
22 529 538 7352670 inhibitor NN I-NP O
23 539 541 7352670 of IN B-PP O
24 542 553 7352670 angiotensin NN B-NP B-Chemical
25 554 556 7352670 II CD I-NP I-Chemical
26 556 557 7352670 ) ) O O
27 558 568 7352670 throughout IN B-PP O
28 569 572 7352670 the DT B-NP O
29 573 585 7352670 experimental JJ I-NP O
30 586 592 7352670 period NN I-NP O
31 592 593 7352670 . . O O

1 594 596 7352670 In IN B-PP O
2 597 601 7352670 each DT B-NP O
3 602 607 7352670 group NN I-NP O
4 607 608 7352670 , , O O
5 609 612 7352670 SNP NN B-NP B-Chemical
6 613 621 7352670 infusion NN I-NP O
7 622 630 7352670 resulted VBD B-VP O
8 631 633 7352670 in IN B-PP O
9 634 636 7352670 an DT B-NP O
10 637 644 7352670 initial JJ I-NP O
11 645 653 7352670 decrease NN I-NP O
12 654 656 7352670 in IN B-PP O
13 657 662 7352670 blood NN B-NP O
14 663 671 7352670 pressure NN I-NP O
15 672 676 7352670 from IN B-PP O
16 677 679 7352670 86 CD B-NP O
17 680 684 7352670 torr NN I-NP O
18 685 688 7352670 and CC O O
19 689 691 7352670 83 CD B-NP O
20 692 696 7352670 torr NN I-NP O
21 696 697 7352670 , , O O
22 698 710 7352670 respectively RB B-ADVP O
23 710 711 7352670 , , O O
24 712 714 7352670 to TO B-PP O
25 715 717 7352670 48 CD B-NP O
26 718 722 7352670 torr NN I-NP O
27 722 723 7352670 . . O O

1 724 730 7352670 During IN B-PP O
2 731 734 7352670 the DT B-NP O
3 735 738 7352670 SNP NN I-NP B-Chemical
4 739 747 7352670 infusion NN I-NP O
5 748 751 7352670 the DT B-NP O
6 752 759 7352670 control NN I-NP O
7 760 767 7352670 animals NNS I-NP O
8 768 780 7352670 demonstrated VBD B-VP O
9 781 782 7352670 a DT B-NP O
10 783 794 7352670 progressive JJ I-NP O
11 795 803 7352670 increase NN I-NP B-Disease
12 804 806 7352670 in IN B-PP I-Disease
13 807 812 7352670 blood NN B-NP I-Disease
14 813 821 7352670 pressure NN I-NP I-Disease
15 822 824 7352670 to TO B-PP O
16 825 827 7352670 61 CD B-NP O
17 828 832 7352670 torr NN I-NP O
18 832 833 7352670 , , O O
19 834 841 7352670 whereas IN O O
20 842 845 7352670 the DT B-NP O
21 846 855 7352670 saralasin NN I-NP B-Chemical
22 855 856 7352670 - HYPH B-NP O
23 856 863 7352670 treated VBN I-NP O
24 864 871 7352670 animals NNS I-NP O
25 872 878 7352670 showed VBD B-VP O
26 879 881 7352670 no DT B-NP O
27 882 888 7352670 change NN I-NP O
28 888 889 7352670 . . O O

1 890 899 7352670 Following VBG B-PP O
2 900 915 7352670 discontinuation NN B-NP O
3 916 918 7352670 of IN B-PP O
4 919 922 7352670 SNP NN B-NP B-Chemical
5 922 923 7352670 , , O O
6 924 929 7352670 blood NN B-NP O
7 930 938 7352670 pressure NN I-NP O
8 939 941 7352670 in IN B-PP O
9 942 945 7352670 the DT B-NP O
10 946 953 7352670 control NN I-NP O
11 954 961 7352670 animals NNS I-NP O
12 962 971 7352670 rebounded VBD B-VP O
13 972 974 7352670 to TO B-PP O
14 975 977 7352670 94 CD B-NP O
15 978 982 7352670 torr NN I-NP O
16 982 983 7352670 , , O O
17 984 986 7352670 as IN B-SBAR O
18 987 995 7352670 compared VBN B-PP O
19 996 1000 7352670 with IN B-PP O
20 1001 1003 7352670 78 CD B-NP O
21 1004 1008 7352670 torr NN I-NP O
22 1009 1011 7352670 in IN B-PP O
23 1012 1015 7352670 the DT B-NP O
24 1016 1025 7352670 saralasin NN I-NP B-Chemical
25 1025 1026 7352670 - HYPH B-NP O
26 1026 1033 7352670 treated VBN I-NP O
27 1034 1038 7352670 rats NNS I-NP O
28 1038 1039 7352670 . . O O

1 1040 1044 7352670 This DT B-NP O
2 1045 1050 7352670 study NN I-NP O
3 1051 1060 7352670 indicates VBZ B-VP O
4 1061 1065 7352670 that IN B-SBAR O
5 1066 1070 7352670 with IN B-PP O
6 1071 1077 7352670 stable JJ B-NP O
7 1078 1087 7352670 halothane NN I-NP B-Chemical
8 1088 1098 7352670 anesthesia NN I-NP O
9 1098 1099 7352670 , , O O
10 1100 1103 7352670 the DT B-NP O
11 1104 1111 7352670 partial JJ I-NP O
12 1112 1120 7352670 recovery NN I-NP O
13 1121 1123 7352670 of IN B-PP O
14 1124 1129 7352670 blood NN B-NP O
15 1130 1138 7352670 pressure NN I-NP O
16 1139 1145 7352670 during IN B-PP O
17 1146 1149 7352670 SNP NN B-NP B-Chemical
18 1150 1158 7352670 infusion NN I-NP O
19 1159 1162 7352670 and CC O O
20 1163 1166 7352670 the DT B-NP O
21 1167 1171 7352670 post AFX I-NP O
22 1171 1172 7352670 - HYPH I-NP O
23 1172 1175 7352670 SNP NN I-NP B-Chemical
24 1176 1183 7352670 rebound NN I-NP O
25 1184 1186 7352670 of IN B-PP O
26 1187 1192 7352670 blood NN B-NP O
27 1193 1201 7352670 pressure NN I-NP O
28 1202 1205 7352670 can MD B-VP O
29 1206 1208 7352670 be VB I-VP O
30 1209 1219 7352670 completely RB I-VP O
31 1220 1227 7352670 blocked VBN I-VP O
32 1228 1230 7352670 by IN B-PP O
33 1231 1240 7352670 saralasin NN B-NP B-Chemical
34 1240 1241 7352670 . . O O

1 1242 1246 7352670 This DT B-NP O
2 1247 1259 7352670 demonstrates VBZ B-VP O
3 1260 1263 7352670 the DT B-NP O
4 1264 1277 7352670 participation NN I-NP O
5 1278 1280 7352670 of IN B-PP O
6 1281 1284 7352670 the DT B-NP O
7 1285 1290 7352670 renin NN I-NP O
8 1290 1291 7352670 - HYPH O O
9 1291 1292 7352670 - HYPH B-NP O
10 1292 1303 7352670 angiotensin NN I-NP B-Chemical
11 1304 1310 7352670 system NN I-NP O
12 1311 1313 7352670 in IN B-PP O
13 1314 1326 7352670 antagonizing VBG B-VP O
14 1327 1330 7352670 the DT B-NP O
15 1331 1339 7352670 combined JJ I-NP O
16 1340 1351 7352670 hypotensive JJ I-NP B-Disease
17 1352 1359 7352670 effects NNS I-NP O
18 1360 1362 7352670 of IN B-PP O
19 1363 1372 7352670 halothane NN B-NP B-Chemical
20 1373 1376 7352670 and CC I-NP O
21 1377 1380 7352670 SNP NN I-NP B-Chemical
22 1380 1381 7352670 . . O O

1 0 0 18544179 -DOCSTART- -X- -X- O

1 0 8 18544179 Omitting VBG B-VP O
2 9 17 18544179 fentanyl NN B-NP B-Chemical
3 18 25 18544179 reduces VBZ B-VP O
4 26 32 18544179 nausea NN B-NP B-Disease
5 33 36 18544179 and CC I-NP O
6 37 45 18544179 vomiting NN I-NP B-Disease
7 45 46 18544179 , , O O
8 47 54 18544179 without IN B-PP O
9 55 65 18544179 increasing VBG B-VP O
10 66 70 18544179 pain NN B-NP B-Disease
11 70 71 18544179 , , O O
12 72 77 18544179 after IN B-PP O
13 78 89 18544179 sevoflurane NN B-NP B-Chemical
14 90 93 18544179 for IN B-PP O
15 94 97 18544179 day NN B-NP O
16 98 105 18544179 surgery NN I-NP O
17 105 106 18544179 . . O O
18 107 117 18544179 BACKGROUND NN B-NP O
19 118 121 18544179 AND CC I-NP O
20 122 131 18544179 OBJECTIVE NN I-NP O
21 131 132 18544179 : : O O
22 133 140 18544179 Despite IN B-PP O
23 141 151 18544179 advantages NNS B-NP O
24 152 154 18544179 of IN B-PP O
25 155 164 18544179 induction NN B-NP O
26 165 168 18544179 and CC I-NP O
27 169 180 18544179 maintenance NN I-NP O
28 181 183 18544179 of IN B-PP O
29 184 195 18544179 anaesthesia NN B-NP O
30 196 200 18544179 with IN B-PP O
31 201 212 18544179 sevoflurane NN B-NP B-Chemical
32 212 213 18544179 , , O O
33 214 227 18544179 postoperative JJ B-NP B-Disease
34 228 234 18544179 nausea NN I-NP I-Disease
35 235 238 18544179 and CC I-NP I-Disease
36 239 247 18544179 vomiting NN I-NP I-Disease
37 248 254 18544179 occurs VBZ B-VP O
38 255 265 18544179 frequently RB B-ADVP O
39 265 266 18544179 . . O O

1 267 275 18544179 Fentanyl NN B-NP B-Chemical
2 276 278 18544179 is VBZ B-VP O
3 279 280 18544179 a DT B-NP O
4 281 289 18544179 commonly RB I-NP O
5 290 294 18544179 used VBN I-NP O
6 295 305 18544179 supplement NN I-NP O
7 306 310 18544179 that WDT B-NP O
8 311 314 18544179 may MD B-VP O
9 315 325 18544179 contribute VB I-VP O
10 326 328 18544179 to TO B-PP O
11 329 333 18544179 this DT B-NP O
12 333 334 18544179 , , O O
13 335 343 18544179 although IN B-SBAR O
14 344 346 18544179 it PRP B-NP O
15 347 350 18544179 may MD B-VP O
16 351 355 18544179 also RB I-VP O
17 356 363 18544179 improve VB I-VP O
18 364 373 18544179 analgesia NN B-NP O
19 373 374 18544179 . . O O

1 375 382 18544179 METHODS NNS B-NP O
2 382 383 18544179 : : O O
3 384 388 18544179 This DT B-NP O
4 389 395 18544179 double JJ I-NP O
5 395 396 18544179 - HYPH I-NP O
6 396 401 18544179 blind JJ I-NP O
7 402 407 18544179 study NN I-NP O
8 408 416 18544179 examined VBD B-VP O
9 417 420 18544179 the DT B-NP O
10 421 430 18544179 incidence NN I-NP O
11 431 434 18544179 and CC I-NP O
12 435 443 18544179 severity NN I-NP O
13 444 446 18544179 of IN B-PP O
14 447 460 18544179 postoperative JJ B-NP B-Disease
15 461 467 18544179 nausea NN I-NP I-Disease
16 468 471 18544179 and CC I-NP I-Disease
17 472 480 18544179 vomiting NN I-NP I-Disease
18 481 484 18544179 and CC I-NP O
19 485 489 18544179 pain NN I-NP B-Disease
20 490 492 18544179 in IN B-PP O
21 493 496 18544179 the DT B-NP O
22 497 502 18544179 first JJ I-NP O
23 503 505 18544179 24 CD I-NP O
24 506 507 18544179 h NN I-NP O
25 508 513 18544179 after IN B-PP O
26 514 525 18544179 sevoflurane NN B-NP B-Chemical
27 526 537 18544179 anaesthesia NN I-NP O
28 538 540 18544179 in IN B-PP O
29 541 544 18544179 216 CD B-NP O
30 545 550 18544179 adult JJ I-NP O
31 551 554 18544179 day NN I-NP O
32 555 562 18544179 surgery NN I-NP O
33 563 571 18544179 patients NNS I-NP O
34 571 572 18544179 . . O O

1 573 581 18544179 Patients NNS B-NP O
2 582 586 18544179 were VBD B-VP O
3 587 595 18544179 randomly RB I-VP O
4 596 605 18544179 allocated VBN I-VP O
5 606 608 18544179 to TO B-PP O
6 609 615 18544179 either CC O O
7 616 623 18544179 receive VB B-VP O
8 624 626 18544179 or CC O O
9 627 630 18544179 not RB B-VP O
10 631 638 18544179 receive VB I-VP O
11 639 640 18544179 1 CD B-NP O
12 641 642 18544179 1 CD I-NP O
13 643 651 18544179 fentanyl NN I-NP B-Chemical
14 651 652 18544179 , , O O
15 653 658 18544179 while IN B-SBAR O
16 659 660 18544179 a DT B-NP O
17 661 666 18544179 third JJ I-NP O
18 667 672 18544179 group NN I-NP O
19 673 681 18544179 received VBD B-VP O
20 682 695 18544179 dexamethasone NN B-NP B-Chemical
21 696 698 18544179 in IN B-PP O
22 699 707 18544179 addition NN B-NP O
23 708 710 18544179 to TO B-PP O
24 711 719 18544179 fentanyl NN B-NP B-Chemical
25 719 720 18544179 . . O O

1 721 728 18544179 RESULTS NNS B-NP O
2 728 729 18544179 : : O O
3 730 738 18544179 Omission NN B-NP O
4 739 741 18544179 of IN B-PP O
5 742 750 18544179 fentanyl NN B-NP B-Chemical
6 751 754 18544179 did VBD B-VP O
7 755 758 18544179 not RB I-VP O
8 759 765 18544179 reduce VB I-VP O
9 766 769 18544179 the DT B-NP O
10 770 777 18544179 overall JJ I-NP O
11 778 787 18544179 incidence NN I-NP O
12 788 790 18544179 of IN B-PP O
13 791 804 18544179 postoperative JJ B-NP B-Disease
14 805 811 18544179 nausea NN I-NP I-Disease
15 812 815 18544179 and CC I-NP I-Disease
16 816 824 18544179 vomiting NN I-NP I-Disease
17 824 825 18544179 , , O O
18 826 829 18544179 but CC O O
19 830 833 18544179 did VBD B-VP O
20 834 840 18544179 reduce VB I-VP O
21 841 844 18544179 the DT B-NP O
22 845 854 18544179 incidence NN I-NP O
23 855 857 18544179 of IN B-PP O
24 858 866 18544179 vomiting VBG B-VP B-Disease
25 867 870 18544179 and CC O O
26 870 871 18544179 / SYM B-NP O
27 871 873 18544179 or CC O O
28 874 882 18544179 moderate JJ B-ADJP O
29 883 885 18544179 to TO B-PP O
30 886 892 18544179 severe JJ B-NP O
31 893 899 18544179 nausea NN I-NP B-Disease
32 900 905 18544179 prior JJ B-ADJP O
33 906 908 18544179 to TO B-VP O
34 909 918 18544179 discharge VB I-VP O
35 919 923 18544179 from IN B-PP O
36 924 927 18544179 20% NN B-NP O
37 928 931 18544179 and CC I-NP O
38 932 935 18544179 17% NN I-NP O
39 936 940 18544179 with IN B-PP O
40 941 949 18544179 fentanyl NN B-NP B-Chemical
41 950 953 18544179 and CC I-NP O
42 954 962 18544179 fentanyl NN I-NP B-Chemical
43 962 963 18544179 - HYPH O O
44 963 976 18544179 dexamethasone NN B-NP B-Chemical
45 976 977 18544179 , , O O
46 978 990 18544179 respectively RB B-ADVP O
47 990 991 18544179 , , O O
48 992 994 18544179 to TO B-PP O
49 995 997 18544179 5% CD B-NP O
50 998 999 18544179 ( ( O O
51 999 1000 18544179 P NN B-NP O
52 1001 1002 18544179 = SYM B-VP O
53 1003 1008 18544179 0.013 CD B-NP O
54 1008 1009 18544179 ) ) O O
55 1009 1010 18544179 . . O O

1 1011 1021 18544179 Antiemetic JJ B-NP O
2 1022 1034 18544179 requirements NNS I-NP O
3 1035 1039 18544179 were VBD B-VP O
4 1040 1047 18544179 reduced VBN I-VP O
5 1048 1052 18544179 from IN B-PP O
6 1053 1056 18544179 24% NN B-NP O
7 1057 1060 18544179 and CC O O
8 1061 1064 18544179 31% CD B-NP O
9 1065 1067 18544179 to TO B-PP O
10 1068 1070 18544179 7% CD B-NP O
11 1071 1072 18544179 ( ( O O
12 1072 1073 18544179 P NN B-NP O
13 1074 1075 18544179 = SYM B-VP O
14 1076 1082 18544179 0.0012 CD B-NP O
15 1082 1083 18544179 ) ) O O
16 1083 1084 18544179 . . O O

1 1085 1098 18544179 Dexamethasone NN B-NP B-Chemical
2 1099 1102 18544179 had VBD B-VP O
3 1103 1105 18544179 no DT B-NP O
4 1106 1117 18544179 significant JJ I-NP O
5 1118 1124 18544179 effect NN I-NP O
6 1125 1127 18544179 on IN B-PP O
7 1128 1131 18544179 the DT B-NP O
8 1132 1141 18544179 incidence NN I-NP O
9 1142 1144 18544179 or CC I-NP O
10 1145 1153 18544179 severity NN I-NP O
11 1154 1156 18544179 of IN B-PP O
12 1157 1170 18544179 postoperative JJ B-NP B-Disease
13 1171 1177 18544179 nausea NN I-NP I-Disease
14 1178 1181 18544179 and CC I-NP I-Disease
15 1182 1190 18544179 vomiting NN I-NP I-Disease
16 1190 1191 18544179 . . O O

1 1192 1201 18544179 Combining VBG B-VP O
2 1202 1205 18544179 the DT B-NP O
3 1206 1209 18544179 two CD I-NP O
4 1210 1218 18544179 fentanyl NN I-NP B-Chemical
5 1219 1225 18544179 groups NNS I-NP O
6 1226 1234 18544179 revealed VBD B-VP O
7 1235 1242 18544179 further JJ B-NP O
8 1243 1254 18544179 significant JJ I-NP O
9 1255 1263 18544179 benefits NNS I-NP O
10 1264 1268 18544179 from IN B-PP O
11 1269 1272 18544179 the DT B-NP O
12 1273 1282 18544179 avoidance NN I-NP O
13 1283 1285 18544179 of IN B-PP O
14 1286 1293 18544179 opioids NNS B-NP O
15 1293 1294 18544179 , , O O
16 1295 1303 18544179 reducing VBG B-VP O
17 1304 1317 18544179 postoperative JJ B-NP B-Disease
18 1318 1324 18544179 nausea NN I-NP I-Disease
19 1325 1328 18544179 and CC I-NP I-Disease
20 1329 1337 18544179 vomiting NN I-NP I-Disease
21 1338 1341 18544179 and CC I-NP O
22 1342 1348 18544179 nausea NN I-NP B-Disease
23 1349 1354 18544179 prior JJ B-ADJP O
24 1355 1357 18544179 to TO B-VP O
25 1358 1367 18544179 discharge VB I-VP O
26 1368 1372 18544179 from IN B-PP O
27 1373 1376 18544179 35% CD B-NP O
28 1377 1380 18544179 and CC I-NP O
29 1381 1384 18544179 33% CD I-NP O
30 1385 1387 18544179 to TO I-NP O
31 1388 1391 18544179 22% CD I-NP O
32 1392 1395 18544179 and CC I-NP O
33 1396 1399 18544179 19% CD I-NP O
34 1400 1401 18544179 ( ( O O
35 1401 1402 18544179 P NN B-NP O
36 1403 1404 18544179 = SYM B-VP O
37 1405 1410 18544179 0.049 CD B-NP O
38 1411 1414 18544179 and CC O O
39 1415 1416 18544179 P NN B-NP O
40 1417 1418 18544179 = SYM B-VP O
41 1419 1424 18544179 0.035 CD B-NP O
42 1424 1425 18544179 ) ) O O
43 1425 1426 18544179 , , O O
44 1427 1439 18544179 respectively RB B-ADVP O
45 1439 1440 18544179 , , O O
46 1441 1446 18544179 while IN B-SBAR O
47 1447 1453 18544179 nausea NN B-NP B-Disease
48 1454 1456 18544179 in IN B-PP O
49 1457 1460 18544179 the DT B-NP O
50 1461 1466 18544179 first JJ I-NP O
51 1467 1469 18544179 24 CD I-NP O
52 1470 1471 18544179 h NN I-NP O
53 1472 1475 18544179 was VBD B-VP O
54 1476 1485 18544179 decreased VBN I-VP O
55 1486 1490 18544179 from IN B-PP O
56 1491 1494 18544179 42% CD B-NP O
57 1495 1497 18544179 to TO B-PP O
58 1498 1501 18544179 27% CD B-NP O
59 1502 1503 18544179 ( ( O O
60 1503 1504 18544179 P NN B-NP O
61 1505 1506 18544179 = SYM B-VP O
62 1507 1512 18544179 0.034 CD B-NP O
63 1512 1513 18544179 ) ) O O
64 1513 1514 18544179 . . O O

1 1515 1519 18544179 Pain NN B-NP B-Disease
2 1520 1528 18544179 severity NN I-NP O
3 1529 1532 18544179 and CC O O
4 1533 1542 18544179 analgesic JJ B-NP O
5 1543 1555 18544179 requirements NNS I-NP O
6 1556 1560 18544179 were VBD B-VP O
7 1561 1571 18544179 unaffected JJ B-ADJP O
8 1572 1574 18544179 by IN B-PP O
9 1575 1578 18544179 the DT B-NP O
10 1579 1587 18544179 omission NN I-NP O
11 1588 1590 18544179 of IN B-PP O
12 1591 1599 18544179 fentanyl NN B-NP B-Chemical
13 1599 1600 18544179 . . O O

1 1601 1609 18544179 Fentanyl NN B-NP B-Chemical
2 1610 1613 18544179 did VBD B-VP O
3 1614 1620 18544179 reduce VB I-VP O
4 1621 1626 18544179 minor JJ B-NP O
5 1627 1641 18544179 intraoperative JJ I-NP O
6 1642 1650 18544179 movement NN I-NP O
7 1651 1654 18544179 but CC O O
8 1655 1658 18544179 had VBD B-VP O
9 1659 1661 18544179 no DT B-NP O
10 1662 1673 18544179 sevoflurane NN I-NP B-Chemical
11 1673 1674 18544179 - HYPH O O
12 1674 1681 18544179 sparing VBG B-VP O
13 1682 1688 18544179 effect NN B-NP O
14 1689 1692 18544179 and CC O O
15 1693 1702 18544179 increased VBD B-VP O
16 1703 1714 18544179 respiratory JJ B-NP B-Disease
17 1715 1725 18544179 depression NN I-NP I-Disease
18 1725 1726 18544179 , , O O
19 1727 1738 18544179 hypotension NN B-NP B-Disease
20 1739 1742 18544179 and CC I-NP O
21 1743 1754 18544179 bradycardia NN I-NP B-Disease
22 1754 1755 18544179 . . O O

1 1756 1766 18544179 CONCLUSION NN B-NP O
2 1766 1767 18544179 : : O O
3 1768 1770 18544179 As IN B-SBAR O
4 1771 1779 18544179 fentanyl NN B-NP B-Chemical
5 1780 1791 18544179 exacerbated JJ I-NP O
6 1792 1805 18544179 postoperative JJ I-NP B-Disease
7 1806 1812 18544179 nausea NN I-NP I-Disease
8 1813 1816 18544179 and CC I-NP I-Disease
9 1817 1825 18544179 vomiting NN I-NP I-Disease
10 1826 1833 18544179 without IN B-PP O
11 1834 1836 18544179 an DT B-NP O
12 1837 1848 18544179 improvement NN I-NP O
13 1849 1851 18544179 in IN B-PP O
14 1852 1865 18544179 postoperative JJ B-NP B-Disease
15 1866 1870 18544179 pain NN I-NP I-Disease
16 1871 1874 18544179 and CC O O
17 1875 1879 18544179 also RB B-ADVP O
18 1880 1883 18544179 had VBD B-VP O
19 1884 1891 18544179 adverse JJ B-NP O
20 1892 1909 18544179 cardiorespiratory JJ I-NP O
21 1910 1917 18544179 effects NNS I-NP O
22 1917 1918 18544179 , , O O
23 1919 1921 18544179 it PRP B-NP O
24 1922 1929 18544179 appears VBZ B-VP O
25 1930 1932 18544179 to TO I-VP O
26 1933 1935 18544179 be VB I-VP O
27 1936 1938 18544179 an DT B-NP O
28 1939 1950 18544179 unnecessary JJ I-NP O
29 1951 1954 18544179 and CC I-NP O
30 1955 1963 18544179 possibly RB I-NP O
31 1964 1975 18544179 detrimental JJ I-NP O
32 1976 1986 18544179 supplement NN I-NP O
33 1987 1989 18544179 to TO B-PP O
34 1990 2001 18544179 sevoflurane NN B-NP B-Chemical
35 2002 2004 18544179 in IN B-PP O
36 2005 2008 18544179 day NN B-NP O
37 2009 2016 18544179 surgery NN I-NP O
38 2016 2017 18544179 . . O O

1 0 0 20196116 -DOCSTART- -X- -X- O

1 0 16 20196116 Antituberculosis NN B-NP B-Chemical
2 17 24 20196116 therapy NN I-NP O
3 24 25 20196116 - HYPH O O
4 25 32 20196116 induced VBN B-NP O
5 33 38 20196116 acute JJ I-NP B-Disease
6 39 44 20196116 liver NN I-NP I-Disease
7 45 52 20196116 failure NN I-NP I-Disease
8 52 53 20196116 : : O O
9 54 63 20196116 magnitude NN B-NP O
10 63 64 20196116 , , O O
11 65 72 20196116 profile NN B-NP O
12 72 73 20196116 , , O O
13 74 83 20196116 prognosis NN B-NP O
14 83 84 20196116 , , O O
15 85 88 20196116 and CC O O
16 89 99 20196116 predictors NNS B-NP O
17 100 102 20196116 of IN B-PP O
18 103 110 20196116 outcome NN B-NP O
19 110 111 20196116 . . O O
20 112 128 20196116 Antituberculosis NN B-NP B-Chemical
21 129 136 20196116 therapy NN I-NP O
22 137 138 20196116 ( ( O O
23 138 141 20196116 ATT NN B-NP O
24 141 142 20196116 ) ) O O
25 142 143 20196116 - HYPH O O
26 143 153 20196116 associated VBN B-VP O
27 154 159 20196116 acute JJ B-NP B-Disease
28 160 165 20196116 liver NN I-NP I-Disease
29 166 173 20196116 failure NN I-NP I-Disease
30 174 175 20196116 ( ( O O
31 175 178 20196116 ATT NN B-NP O
32 178 179 20196116 - HYPH B-NP O
33 179 182 20196116 ALF NN I-NP B-Disease
34 182 183 20196116 ) ) O O
35 184 186 20196116 is VBZ B-VP O
36 187 190 20196116 the DT B-NP O
37 191 200 20196116 commonest JJS I-NP O
38 201 205 20196116 drug NN I-NP O
39 205 206 20196116 - HYPH B-NP O
40 206 213 20196116 induced VBN I-NP O
41 214 217 20196116 ALF NN I-NP B-Disease
42 218 220 20196116 in IN B-PP O
43 221 226 20196116 South NNP B-NP O
44 227 231 20196116 Asia NNP I-NP O
45 231 232 20196116 . . O O

1 233 244 20196116 Prospective JJ B-NP O
2 245 252 20196116 studies NNS I-NP O
3 253 255 20196116 on IN B-PP O
4 256 259 20196116 ATT NN B-NP O
5 259 260 20196116 - HYPH I-NP O
6 260 263 20196116 ALF NN I-NP B-Disease
7 264 267 20196116 are VBP B-VP O
8 268 275 20196116 lacking VBG I-VP O
9 275 276 20196116 . . O O

1 277 280 20196116 The DT B-NP O
2 281 288 20196116 current JJ I-NP O
3 289 294 20196116 study NN I-NP O
4 295 308 20196116 prospectively RB B-ADVP O
5 309 318 20196116 evaluated VBD B-VP O
6 319 322 20196116 the DT B-NP O
7 323 332 20196116 magnitude NN I-NP O
8 332 333 20196116 , , O O
9 334 342 20196116 clinical JJ B-NP O
10 343 349 20196116 course NN I-NP O
11 349 350 20196116 , , O O
12 351 358 20196116 outcome NN B-NP O
13 358 359 20196116 , , O O
14 360 363 20196116 and CC O O
15 364 374 20196116 prognostic JJ B-NP O
16 375 382 20196116 factors NNS I-NP O
17 383 385 20196116 in IN B-PP O
18 386 389 20196116 ATT NN B-NP O
19 389 390 20196116 - HYPH B-NP O
20 390 393 20196116 ALF NN I-NP B-Disease
21 393 394 20196116 . . O O

1 395 399 20196116 From IN B-PP O
2 400 407 20196116 January NNP B-NP O
3 408 412 20196116 1986 CD I-NP O
4 413 415 20196116 to TO B-PP O
5 416 423 20196116 January NNP B-NP O
6 424 428 20196116 2009 CD I-NP O
7 428 429 20196116 , , I-NP O
8 430 434 20196116 1223 CD I-NP O
9 435 446 20196116 consecutive JJ I-NP O
10 447 450 20196116 ALF NN I-NP B-Disease
11 451 459 20196116 patients NNS I-NP O
12 460 464 20196116 were VBD B-VP O
13 465 474 20196116 evaluated VBN I-VP O
14 474 475 20196116 : : O O
15 476 479 20196116 ATT NN B-NP O
16 480 485 20196116 alone RB B-ADVP O
17 486 489 20196116 was VBD B-VP O
18 490 493 20196116 the DT B-NP O
19 494 499 20196116 cause NN I-NP O
20 500 502 20196116 in IN B-PP O
21 503 505 20196116 70 CD B-NP O
22 506 507 20196116 ( ( O O
23 507 511 20196116 5.7% CD B-NP O
24 511 512 20196116 ) ) O O
25 513 521 20196116 patients NNS B-NP O
26 521 522 20196116 . . O O

1 523 530 20196116 Another DT B-NP O
2 531 533 20196116 15 CD I-NP O
3 534 535 20196116 ( ( O O
4 535 539 20196116 1.2% NN B-NP O
5 539 540 20196116 ) ) O O
6 541 544 20196116 had VBD B-VP O
7 545 548 20196116 ATT NN B-NP O
8 549 552 20196116 and CC O O
9 553 565 20196116 simultaneous JJ B-NP O
10 566 575 20196116 hepatitis NN I-NP B-Disease
11 576 581 20196116 virus NN I-NP I-Disease
12 582 591 20196116 infection NN I-NP I-Disease
13 591 592 20196116 . . O O

1 593 595 20196116 In IN B-PP O
2 596 598 20196116 44 CD B-NP O
3 599 600 20196116 ( ( O O
4 600 605 20196116 62.8% CD B-NP O
5 605 606 20196116 ) ) O O
6 607 615 20196116 patients NNS B-NP O
7 615 616 20196116 , , O O
8 617 620 20196116 ATT NN B-NP O
9 621 624 20196116 was VBD B-VP O
10 625 635 20196116 prescribed VBN I-VP O
11 636 647 20196116 empirically RB B-ADVP O
12 648 655 20196116 without IN B-PP O
13 656 666 20196116 definitive JJ B-NP O
14 667 675 20196116 evidence NN I-NP O
15 676 678 20196116 of IN B-PP O
16 679 691 20196116 tuberculosis NN B-NP B-Disease
17 691 692 20196116 . . O O

1 693 696 20196116 ATT NN B-NP O
2 696 697 20196116 - HYPH O O
3 697 700 20196116 ALF NN B-NP B-Disease
4 701 709 20196116 patients NNS I-NP O
5 710 714 20196116 were VBD B-VP O
6 715 722 20196116 younger JJR B-ADJP O
7 723 724 20196116 ( ( O O
8 724 729 20196116 32.87 CD B-NP O
9 730 731 20196116 [ ( O O
10 731 732 20196116 + SYM O O
11 732 733 20196116 / SYM B-NP O
12 733 734 20196116 - SYM I-NP O
13 734 738 20196116 15.8 CD I-NP O
14 738 739 20196116 ] ) I-NP O
15 740 745 20196116 years NNS I-NP O
16 745 746 20196116 ) ) O O
17 746 747 20196116 , , O O
18 748 751 20196116 and CC O O
19 752 754 20196116 49 CD B-NP O
20 755 756 20196116 ( ( O O
21 756 759 20196116 70% NN B-NP O
22 759 760 20196116 ) ) O O
23 761 763 20196116 of IN B-PP O
24 764 768 20196116 them PRP B-NP O
25 769 773 20196116 were VBD B-VP O
26 774 779 20196116 women NNS B-NP O
27 779 780 20196116 . . O O

1 781 785 20196116 Most JJS B-NP O
2 786 789 20196116 had VBD B-VP O
3 790 800 20196116 hyperacute JJ B-NP O
4 801 813 20196116 presentation NN I-NP O
5 813 814 20196116 ; : O O
6 815 818 20196116 the DT B-NP O
7 819 825 20196116 median JJ I-NP O
8 826 833 20196116 icterus NN I-NP B-Disease
9 834 848 20196116 encephalopathy NN I-NP B-Disease
10 849 857 20196116 interval NN I-NP O
11 858 861 20196116 was VBD B-VP O
12 862 865 20196116 4.5 CD B-NP O
13 866 867 20196116 ( ( O O
14 867 868 20196116 0 CD B-NP O
15 868 869 20196116 - HYPH B-NP O
16 869 871 20196116 30 CD I-NP O
17 871 872 20196116 ) ) I-NP O
18 873 877 20196116 days NNS I-NP O
19 877 878 20196116 . . O O

1 879 882 20196116 The DT B-NP O
2 883 889 20196116 median JJ I-NP O
3 890 898 20196116 duration NN I-NP O
4 899 901 20196116 of IN B-PP O
5 902 905 20196116 ATT NN B-NP O
6 906 912 20196116 before IN B-PP O
7 913 916 20196116 ALF NN B-NP B-Disease
8 917 920 20196116 was VBD B-VP O
9 921 923 20196116 30 CD B-NP O
10 924 925 20196116 ( ( O O
11 925 926 20196116 7 CD B-NP O
12 926 927 20196116 - HYPH B-NP O
13 927 930 20196116 350 CD I-NP O
14 930 931 20196116 ) ) I-NP O
15 932 936 20196116 days NNS I-NP O
16 936 937 20196116 . . O O

1 938 940 20196116 At IN B-PP O
2 941 953 20196116 presentation NN B-NP O
3 953 954 20196116 , , O O
4 955 963 20196116 advanced VBD B-VP O
5 964 978 20196116 encephalopathy NN B-NP B-Disease
6 979 982 20196116 and CC O O
7 983 991 20196116 cerebral JJ B-NP B-Disease
8 992 997 20196116 edema NN I-NP I-Disease
9 998 1002 20196116 were VBD B-VP O
10 1003 1010 20196116 present JJ B-ADJP O
11 1011 1013 20196116 in IN B-PP O
12 1014 1016 20196116 51 CD B-NP O
13 1017 1018 20196116 ( ( O O
14 1018 1021 20196116 76% CD B-NP O
15 1021 1022 20196116 ) ) O O
16 1023 1026 20196116 and CC O O
17 1027 1029 20196116 29 CD B-NP O
18 1030 1031 20196116 ( ( O O
19 1031 1036 20196116 41.4% CD B-NP O
20 1036 1037 20196116 ) ) O O
21 1038 1046 20196116 patients NNS B-NP O
22 1046 1047 20196116 , , O O
23 1048 1060 20196116 respectively RB B-ADVP O
24 1060 1061 20196116 . . O O

1 1062 1078 20196116 Gastrointestinal JJ B-NP B-Disease
2 1079 1084 20196116 bleed NN I-NP I-Disease
3 1084 1085 20196116 , , O O
4 1086 1094 20196116 seizures NNS B-NP B-Disease
5 1094 1095 20196116 , , O O
6 1096 1105 20196116 infection NN B-NP B-Disease
7 1105 1106 20196116 , , O O
8 1107 1110 20196116 and CC O O
9 1111 1116 20196116 acute JJ B-NP B-Disease
10 1117 1122 20196116 renal JJ I-NP I-Disease
11 1123 1130 20196116 failure NN I-NP I-Disease
12 1131 1135 20196116 were VBD B-VP O
13 1136 1146 20196116 documented VBN I-VP O
14 1147 1149 20196116 in IN B-PP O
15 1150 1155 20196116 seven CD B-NP O
16 1156 1157 20196116 ( ( O O
17 1157 1160 20196116 10% NN B-NP O
18 1160 1161 20196116 ) ) O O
19 1161 1162 20196116 , , O O
20 1163 1167 20196116 five CD B-NP O
21 1168 1169 20196116 ( ( O O
22 1169 1173 20196116 7.1% NN B-NP O
23 1173 1174 20196116 ) ) O O
24 1174 1175 20196116 , , O O
25 1176 1178 20196116 26 CD B-NP O
26 1179 1180 20196116 ( ( O O
27 1180 1185 20196116 37.1% NN B-NP O
28 1185 1186 20196116 ) ) O O
29 1186 1187 20196116 , , O O
30 1188 1191 20196116 and CC O O
31 1192 1197 20196116 seven CD B-NP O
32 1198 1199 20196116 ( ( O O
33 1199 1202 20196116 10% CD B-NP O
34 1202 1203 20196116 ) ) O O
35 1204 1212 20196116 patients NNS B-NP O
36 1212 1213 20196116 , , O O
37 1214 1226 20196116 respectively RB B-ADVP O
38 1226 1227 20196116 . . O O

1 1228 1236 20196116 Compared VBN B-PP O
2 1237 1241 20196116 with IN B-PP O
3 1242 1251 20196116 hepatitis NN B-NP B-Disease
4 1252 1253 20196116 E NN I-NP I-Disease
5 1254 1259 20196116 virus NN I-NP O
6 1260 1261 20196116 ( ( O O
7 1261 1264 20196116 HEV NN B-NP O
8 1264 1265 20196116 ) ) O O
9 1266 1269 20196116 and CC O O
10 1270 1273 20196116 non AFX B-NP O
11 1273 1274 20196116 - HYPH I-NP O
12 1274 1275 20196116 A NN I-NP O
13 1276 1279 20196116 non AFX I-NP O
14 1279 1280 20196116 - HYPH I-NP O
15 1280 1281 20196116 E NN I-NP O
16 1281 1282 20196116 - HYPH B-NP O
17 1282 1289 20196116 induced VBN I-NP O
18 1290 1293 20196116 ALF NN I-NP B-Disease
19 1293 1294 20196116 , , O O
20 1295 1298 20196116 ATT NN B-NP O
21 1298 1299 20196116 - HYPH O O
22 1299 1302 20196116 ALF NN B-NP B-Disease
23 1303 1311 20196116 patients NNS I-NP O
24 1312 1315 20196116 had VBD B-VP O
25 1316 1322 20196116 nearly RB B-NP O
26 1323 1330 20196116 similar JJ I-NP O
27 1331 1344 20196116 presentations NNS I-NP O
28 1345 1351 20196116 except IN B-PP O
29 1352 1355 20196116 for IN B-PP O
30 1356 1361 20196116 older JJR B-NP O
31 1362 1365 20196116 age NN I-NP O
32 1366 1369 20196116 and CC O O
33 1370 1374 20196116 less JJR B-NP O
34 1375 1384 20196116 elevation NN I-NP O
35 1385 1387 20196116 of IN B-PP O
36 1388 1393 20196116 liver NN B-NP O
37 1394 1401 20196116 enzymes NNS I-NP O
38 1401 1402 20196116 . . O O

1 1403 1406 20196116 The DT B-NP O
2 1407 1416 20196116 mortality NN I-NP O
3 1417 1421 20196116 rate NN I-NP O
4 1422 1427 20196116 among IN B-PP O
5 1428 1436 20196116 patients NNS B-NP O
6 1437 1441 20196116 with IN B-PP O
7 1442 1445 20196116 ATT NN B-NP O
8 1445 1446 20196116 - HYPH B-NP O
9 1446 1449 20196116 ALF NN I-NP B-Disease
10 1450 1453 20196116 was VBD B-VP O
11 1454 1458 20196116 high JJ B-ADJP O
12 1459 1460 20196116 ( ( O O
13 1460 1465 20196116 67.1% NN B-NP O
14 1465 1466 20196116 , , O O
15 1467 1468 20196116 n NN B-NP O
16 1469 1470 20196116 = SYM B-VP O
17 1471 1473 20196116 47 CD B-NP O
18 1473 1474 20196116 ) ) O O
19 1474 1475 20196116 , , O O
20 1476 1479 20196116 and CC O O
21 1480 1484 20196116 only RB B-NP O
22 1485 1487 20196116 23 CD I-NP O
23 1488 1489 20196116 ( ( O O
24 1489 1494 20196116 32.9% CD B-NP O
25 1494 1495 20196116 ) ) O O
26 1496 1504 20196116 patients NNS B-NP O
27 1505 1514 20196116 recovered VBN B-VP O
28 1515 1519 20196116 with IN B-PP O
29 1520 1527 20196116 medical JJ B-NP O
30 1528 1537 20196116 treatment NN I-NP O
31 1537 1538 20196116 . . O O

1 1539 1541 20196116 In IN B-PP O
2 1542 1554 20196116 multivariate JJ B-NP O
3 1555 1563 20196116 analysis NN I-NP O
4 1563 1564 20196116 , , O O
5 1565 1570 20196116 three CD B-NP O
6 1571 1578 20196116 factors NNS I-NP O
7 1579 1592 20196116 independently RB B-ADVP O
8 1593 1602 20196116 predicted VBD B-VP O
9 1603 1612 20196116 mortality NN B-NP O
10 1612 1613 20196116 : : O O
11 1614 1619 20196116 serum NN B-NP O
12 1620 1629 20196116 bilirubin NN I-NP B-Chemical
13 1630 1631 20196116 ( ( O O
14 1631 1632 20196116 > SYM B-NP O
15 1632 1634 20196116 or CC O O
16 1634 1635 20196116 = SYM B-VP O
17 1635 1639 20196116 10.8 CD B-NP O
18 1640 1642 20196116 mg NN I-NP O
19 1642 1643 20196116 / SYM B-NP O
20 1643 1645 20196116 dL NN I-NP O
21 1645 1646 20196116 ) ) O O
22 1646 1647 20196116 , , O O
23 1648 1659 20196116 prothrombin NN B-NP O
24 1660 1664 20196116 time NN I-NP O
25 1665 1666 20196116 ( ( O O
26 1666 1668 20196116 PT NN B-NP O
27 1668 1669 20196116 ) ) O O
28 1670 1682 20196116 prolongation NN B-NP O
29 1683 1684 20196116 ( ( O O
30 1684 1685 20196116 > SYM B-NP O
31 1685 1687 20196116 or CC O O
32 1687 1688 20196116 = SYM B-VP O
33 1688 1690 20196116 26 CD B-NP O
34 1691 1698 20196116 seconds NNS I-NP O
35 1698 1699 20196116 ) ) O O
36 1699 1700 20196116 , , O O
37 1701 1704 20196116 and CC O O
38 1705 1710 20196116 grade NN B-NP O
39 1711 1714 20196116 III CD I-NP O
40 1714 1715 20196116 / SYM I-NP O
41 1715 1717 20196116 IV CD I-NP O
42 1718 1732 20196116 encephalopathy NN I-NP B-Disease
43 1733 1735 20196116 at IN B-PP O
44 1736 1748 20196116 presentation NN B-NP O
45 1748 1749 20196116 . . O O

1 1750 1760 20196116 CONCLUSION NN B-NP O
2 1760 1761 20196116 : : O O
3 1762 1765 20196116 ATT NN B-NP O
4 1765 1766 20196116 - HYPH B-NP O
5 1766 1769 20196116 ALF NN I-NP B-Disease
6 1770 1781 20196116 constituted VBD B-VP O
7 1782 1786 20196116 5.7% NN B-NP O
8 1787 1789 20196116 of IN B-PP O
9 1790 1793 20196116 ALF NN B-NP B-Disease
10 1794 1796 20196116 at IN B-PP O
11 1797 1800 20196116 our PRP$ B-NP O
12 1801 1807 20196116 center NN I-NP O
13 1808 1811 20196116 and CC O O
14 1812 1815 20196116 had VBD B-VP O
15 1816 1817 20196116 a DT B-NP O
16 1818 1822 20196116 high JJ I-NP O
17 1823 1832 20196116 mortality NN I-NP O
18 1833 1837 20196116 rate NN I-NP O
19 1837 1838 20196116 . . O O

1 1839 1846 20196116 Because IN B-SBAR O
2 1847 1850 20196116 the DT B-NP O
3 1851 1860 20196116 mortality NN I-NP O
4 1861 1865 20196116 rate NN I-NP O
5 1866 1868 20196116 is VBZ B-VP O
6 1869 1871 20196116 so RB B-ADJP O
7 1872 1876 20196116 high JJ I-ADJP O
8 1876 1877 20196116 , , O O
9 1878 1889 20196116 determining VBG B-VP O
10 1890 1895 20196116 which WDT B-NP O
11 1896 1903 20196116 factors NNS B-NP O
12 1904 1907 20196116 are VBP B-VP O
13 1908 1918 20196116 predictors NNS B-NP O
14 1919 1921 20196116 is VBZ B-VP O
15 1922 1926 20196116 less RBR B-ADJP O
16 1927 1936 20196116 important JJ I-ADJP O
17 1936 1937 20196116 . . O O

1 1938 1939 20196116 A DT B-NP O
2 1940 1944 20196116 high JJ I-NP O
3 1945 1955 20196116 proportion NN I-NP O
4 1956 1958 20196116 of IN B-PP O
5 1959 1967 20196116 patients NNS B-NP O
6 1968 1971 20196116 had VBD B-VP O
7 1972 1980 20196116 consumed VBN I-VP O
8 1981 1984 20196116 ATT NNP B-NP O
9 1985 1996 20196116 empirically RB B-ADVP O
10 1996 1997 20196116 , , O O
11 1998 2003 20196116 which WDT B-NP O
12 2004 2009 20196116 could MD B-VP O
13 2010 2014 20196116 have VB I-VP O
14 2015 2019 20196116 been VBN I-VP O
15 2020 2029 20196116 prevented VBN I-VP O
16 2029 2030 20196116 . . O O

1 0 0 17931375 -DOCSTART- -X- -X- O

1 0 1 17931375 A DT B-NP O
2 2 7 17931375 study NN I-NP O
3 8 10 17931375 on IN B-PP O
4 11 14 17931375 the DT B-NP O
5 15 21 17931375 effect NN I-NP O
6 22 24 17931375 of IN B-PP O
7 25 28 17931375 the DT B-NP O
8 29 37 17931375 duration NN I-NP O
9 38 40 17931375 of IN B-PP O
10 41 53 17931375 subcutaneous JJ B-NP O
11 54 61 17931375 heparin NN I-NP B-Chemical
12 62 71 17931375 injection NN I-NP O
13 72 74 17931375 on IN B-PP O
14 75 83 17931375 bruising NN B-NP B-Disease
15 84 87 17931375 and CC I-NP O
16 88 92 17931375 pain NN I-NP B-Disease
17 92 93 17931375 . . I-NP O
18 94 97 17931375 AIM NN I-NP O
19 97 98 17931375 : : O O
20 99 103 17931375 This DT B-NP O
21 104 109 17931375 study NN I-NP O
22 110 113 17931375 was VBD B-VP O
23 114 121 17931375 carried VBN I-VP O
24 122 125 17931375 out RP B-PRT O
25 126 128 17931375 to TO B-VP O
26 129 138 17931375 determine VB I-VP O
27 139 142 17931375 the DT B-NP O
28 143 149 17931375 effect NN I-NP O
29 150 152 17931375 of IN B-PP O
30 153 162 17931375 injection NN B-NP O
31 163 171 17931375 duration NN I-NP O
32 172 174 17931375 on IN B-PP O
33 175 183 17931375 bruising VBG B-NP B-Disease
34 184 187 17931375 and CC I-NP O
35 188 192 17931375 pain NN I-NP B-Disease
36 193 202 17931375 following VBG B-PP O
37 203 206 17931375 the DT B-NP O
38 207 221 17931375 administration NN I-NP O
39 222 224 17931375 of IN B-PP O
40 225 228 17931375 the DT B-NP O
41 229 241 17931375 subcutaneous JJ I-NP O
42 242 251 17931375 injection NN I-NP O
43 252 254 17931375 of IN B-PP O
44 255 262 17931375 heparin NN B-NP B-Chemical
45 262 263 17931375 . . O O

1 264 274 17931375 BACKGROUND NN B-NP O
2 274 275 17931375 : : O O
3 276 284 17931375 Although IN B-SBAR O
4 285 294 17931375 different JJ B-NP O
5 295 302 17931375 methods NNS I-NP O
6 303 305 17931375 to TO B-VP O
7 306 313 17931375 prevent VB I-VP O
8 314 322 17931375 bruising NN B-NP B-Disease
9 323 326 17931375 and CC I-NP O
10 327 331 17931375 pain NN I-NP B-Disease
11 332 341 17931375 following VBG B-PP O
12 342 345 17931375 the DT B-NP O
13 346 358 17931375 subcutaneous JJ I-NP O
14 359 368 17931375 injection NN I-NP O
15 369 371 17931375 of IN B-PP O
16 372 379 17931375 heparin NN B-NP B-Chemical
17 380 384 17931375 have VBP B-VP O
18 385 389 17931375 been VBN I-VP O
19 390 396 17931375 widely RB I-VP O
20 397 404 17931375 studied VBN I-VP O
21 405 408 17931375 and CC I-VP O
22 409 418 17931375 described VBN I-VP O
23 418 419 17931375 , , O O
24 420 423 17931375 the DT B-NP O
25 424 430 17931375 effect NN I-NP O
26 431 433 17931375 of IN B-PP O
27 434 443 17931375 injection NN B-NP O
28 444 452 17931375 duration NN I-NP O
29 453 455 17931375 on IN B-PP O
30 456 459 17931375 the DT B-NP O
31 460 470 17931375 occurrence NN I-NP O
32 471 473 17931375 of IN B-PP O
33 474 482 17931375 bruising NN B-NP B-Disease
34 483 486 17931375 and CC I-NP O
35 487 491 17931375 pain NN I-NP B-Disease
36 492 494 17931375 is VBZ B-VP O
37 495 501 17931375 little JJ B-ADJP O
38 502 512 17931375 documented VBN B-VP O
39 512 513 17931375 . . O O

1 514 520 17931375 DESIGN NN B-NP O
2 520 521 17931375 : : O O
3 522 526 17931375 This DT B-NP O
4 527 532 17931375 study NN I-NP O
5 533 536 17931375 was VBD B-VP O
6 537 545 17931375 designed VBN I-VP O
7 546 548 17931375 as IN B-PP O
8 549 555 17931375 within IN B-PP O
9 555 556 17931375 - HYPH B-NP O
10 556 563 17931375 subject NN I-NP O
11 563 564 17931375 , , O O
12 565 570 17931375 quasi AFX B-NP O
13 570 571 17931375 - HYPH I-NP O
14 571 583 17931375 experimental JJ B-NP O
15 584 592 17931375 research NN I-NP O
16 592 593 17931375 . . O O

1 594 600 17931375 METHOD NN B-NP O
2 600 601 17931375 : : O O
3 602 605 17931375 The DT B-NP O
4 606 612 17931375 sample NN I-NP O
5 613 616 17931375 for IN B-PP O
6 617 620 17931375 the DT B-NP O
7 621 626 17931375 study NN I-NP O
8 627 636 17931375 consisted VBD B-VP O
9 637 639 17931375 of IN B-PP O
10 640 642 17931375 50 CD B-NP O
11 643 651 17931375 patients NNS I-NP O
12 652 654 17931375 to TO B-PP O
13 655 659 17931375 whom WP B-NP O
14 660 672 17931375 subcutaneous JJ B-NP O
15 673 680 17931375 heparin NN I-NP B-Chemical
16 681 684 17931375 was VBD B-VP O
17 685 697 17931375 administered VBN I-VP O
18 697 698 17931375 . . O O

1 699 706 17931375 Heparin NN B-NP B-Chemical
2 707 710 17931375 was VBD B-VP O
3 711 719 17931375 injected VBN I-VP O
4 720 724 17931375 over IN B-PP O
5 725 727 17931375 10 CD B-NP O
6 728 735 17931375 seconds NNS I-NP O
7 736 738 17931375 on IN B-PP O
8 739 742 17931375 the DT B-NP O
9 743 748 17931375 right JJ I-NP O
10 749 758 17931375 abdominal JJ I-NP O
11 759 763 17931375 site NN I-NP O
12 764 767 17931375 and CC O O
13 768 770 17931375 30 CD B-NP O
14 771 778 17931375 seconds NNS I-NP O
15 779 781 17931375 on IN B-PP O
16 782 785 17931375 the DT B-NP O
17 786 790 17931375 left JJ I-NP O
18 791 800 17931375 abdominal JJ I-NP O
19 801 805 17931375 site NN I-NP O
20 805 806 17931375 . . O O

1 807 817 17931375 Injections NNS B-NP O
2 818 823 17931375 areas NNS I-NP O
3 824 828 17931375 were VBD B-VP O
4 829 837 17931375 assessed VBN I-VP O
5 838 841 17931375 for IN B-PP O
6 842 845 17931375 the DT B-NP O
7 846 854 17931375 presence NN I-NP O
8 855 857 17931375 of IN B-PP O
9 858 866 17931375 bruising VBG B-VP B-Disease
10 867 869 17931375 at IN B-PP O
11 870 872 17931375 48 CD B-NP O
12 873 876 17931375 and CC I-NP O
13 877 879 17931375 72 CD I-NP O
14 880 885 17931375 hours NNS I-NP O
15 886 891 17931375 after IN B-PP O
16 892 896 17931375 each DT B-NP O
17 897 906 17931375 injection NN I-NP O
18 906 907 17931375 . . O O

1 908 918 17931375 Dimensions NNS B-NP O
2 919 921 17931375 of IN B-PP O
3 922 925 17931375 the DT B-NP O
4 926 934 17931375 bruising NN I-NP B-Disease
5 935 937 17931375 on IN B-PP O
6 938 941 17931375 the DT B-NP O
7 942 949 17931375 heparin NN I-NP B-Chemical
8 950 957 17931375 applied VBD B-VP O
9 958 963 17931375 areas NNS B-NP O
10 964 968 17931375 were VBD B-VP O
11 969 977 17931375 measured VBN I-VP O
12 978 983 17931375 using VBG B-VP O
13 984 995 17931375 transparent JJ B-NP O
14 996 1007 17931375 millimetric JJ I-NP O
15 1008 1017 17931375 measuring NN I-NP O
16 1018 1023 17931375 paper NN I-NP O
17 1023 1024 17931375 . . O O

1 1025 1028 17931375 The DT B-NP O
2 1029 1035 17931375 visual JJ I-NP O
3 1036 1042 17931375 analog NN I-NP O
4 1043 1048 17931375 scale NN I-NP O
5 1049 1050 17931375 ( ( O O
6 1050 1053 17931375 VAS NN B-NP O
7 1053 1054 17931375 ) ) O O
8 1055 1058 17931375 was VBD B-VP O
9 1059 1063 17931375 used VBN I-VP O
10 1064 1066 17931375 to TO B-VP O
11 1067 1074 17931375 measure VB I-VP O
12 1075 1079 17931375 pain NN B-NP B-Disease
13 1080 1089 17931375 intensity NN I-NP O
14 1090 1093 17931375 and CC O O
15 1094 1095 17931375 a DT B-NP O
16 1096 1100 17931375 stop NN I-NP O
17 1100 1101 17931375 - HYPH O O
18 1101 1106 17931375 watch NN B-NP O
19 1107 1110 17931375 was VBD B-VP O
20 1111 1115 17931375 used VBN I-VP O
21 1116 1118 17931375 to TO B-VP O
22 1119 1123 17931375 time VB I-VP O
23 1124 1127 17931375 the DT B-NP O
24 1128 1132 17931375 pain NN I-NP B-Disease
25 1133 1139 17931375 period NN I-NP O
26 1139 1140 17931375 . . O O

1 1141 1145 17931375 Data NNS B-NP O
2 1146 1150 17931375 were VBD B-VP O
3 1151 1159 17931375 analysed VBN I-VP O
4 1160 1165 17931375 using VBG B-VP O
5 1166 1169 17931375 chi AFX B-NP O
6 1169 1170 17931375 - HYPH I-NP O
7 1170 1176 17931375 square JJ I-NP O
8 1177 1181 17931375 test NN I-NP O
9 1181 1182 17931375 , , O O
10 1183 1187 17931375 Mann NNP B-NP O
11 1187 1188 17931375 - HYPH I-NP O
12 1188 1195 17931375 Whitney NNP I-NP O
13 1196 1197 17931375 U NNP I-NP O
14 1197 1198 17931375 , , O O
15 1199 1207 17931375 Wilcoxon NNP B-NP O
16 1208 1214 17931375 signed VBD B-VP O
17 1215 1220 17931375 ranks NNS B-NP O
18 1221 1226 17931375 tests NNS I-NP O
19 1227 1230 17931375 and CC O O
20 1231 1242 17931375 correlation NN B-NP O
21 1242 1243 17931375 . . O O

1 1244 1251 17931375 RESULTS NNS B-NP O
2 1251 1252 17931375 : : O O
3 1253 1256 17931375 The DT B-NP O
4 1257 1267 17931375 percentage NN I-NP O
5 1268 1270 17931375 of IN B-PP O
6 1271 1279 17931375 bruising VBG B-VP B-Disease
7 1280 1290 17931375 occurrence NN B-NP O
8 1291 1294 17931375 was VBD B-VP O
9 1295 1298 17931375 64% CD B-NP O
10 1299 1303 17931375 with IN B-PP O
11 1304 1307 17931375 the DT B-NP O
12 1308 1317 17931375 injection NN I-NP O
13 1318 1320 17931375 of IN B-PP O
14 1321 1323 17931375 10 CD B-NP O
15 1324 1331 17931375 seconds NNS I-NP O
16 1332 1340 17931375 duration NN I-NP O
17 1341 1344 17931375 and CC I-NP O
18 1345 1348 17931375 42% NN I-NP O
19 1349 1351 17931375 in IN B-PP O
20 1352 1355 17931375 the DT B-NP O
21 1356 1358 17931375 30 CD I-NP O
22 1358 1359 17931375 - HYPH I-NP O
23 1359 1365 17931375 second JJ I-NP O
24 1366 1375 17931375 injection NN I-NP O
25 1375 1376 17931375 . . O O

1 1377 1379 17931375 It PRP B-NP O
2 1380 1383 17931375 was VBD B-VP O
3 1384 1394 17931375 determined VBN I-VP O
4 1395 1399 17931375 that IN B-SBAR O
5 1400 1403 17931375 the DT B-NP O
6 1404 1408 17931375 size NN I-NP O
7 1409 1411 17931375 of IN B-PP O
8 1412 1415 17931375 the DT B-NP O
9 1416 1424 17931375 bruising NN I-NP B-Disease
10 1425 1428 17931375 was VBD B-VP O
11 1429 1436 17931375 smaller JJR B-ADJP O
12 1437 1439 17931375 in IN B-PP O
13 1440 1443 17931375 the DT B-NP O
14 1444 1446 17931375 30 CD I-NP O
15 1446 1447 17931375 - HYPH I-NP O
16 1447 1453 17931375 second JJ I-NP O
17 1454 1463 17931375 injection NN I-NP O
18 1463 1464 17931375 . . O O

1 1465 1469 17931375 Pain NN B-NP B-Disease
2 1470 1479 17931375 intensity NN I-NP O
3 1480 1483 17931375 and CC I-NP O
4 1484 1488 17931375 pain NN I-NP B-Disease
5 1489 1495 17931375 period NN I-NP O
6 1496 1500 17931375 were VBD B-VP O
7 1501 1514 17931375 statistically RB B-ADVP O
8 1515 1528 17931375 significantly RB B-ADJP O
9 1529 1534 17931375 lower JJR I-ADJP O
10 1535 1538 17931375 for IN B-PP O
11 1539 1542 17931375 the DT B-NP O
12 1543 1545 17931375 30 CD I-NP O
13 1545 1546 17931375 - HYPH I-NP O
14 1546 1552 17931375 second JJ I-NP O
15 1553 1562 17931375 injection NN I-NP O
16 1563 1567 17931375 than IN B-PP O
17 1568 1571 17931375 for IN B-PP O
18 1572 1575 17931375 the DT B-NP O
19 1576 1578 17931375 10 CD I-NP O
20 1578 1579 17931375 - HYPH I-NP O
21 1579 1585 17931375 second JJ I-NP O
22 1586 1595 17931375 injection NN I-NP O
23 1595 1596 17931375 . . O O

1 1597 1608 17931375 CONCLUSIONS NNS B-NP O
2 1608 1609 17931375 : : O O
3 1610 1612 17931375 It PRP B-NP O
4 1613 1616 17931375 was VBD B-VP O
5 1617 1627 17931375 determined VBN I-VP O
6 1628 1632 17931375 that IN B-SBAR O
7 1633 1642 17931375 injection NN B-NP O
8 1643 1651 17931375 duration NN I-NP O
9 1652 1655 17931375 had VBD B-VP O
10 1656 1658 17931375 an DT B-NP O
11 1659 1665 17931375 effect NN I-NP O
12 1666 1668 17931375 on IN B-PP O
13 1669 1677 17931375 bruising VBG B-NP B-Disease
14 1678 1681 17931375 and CC I-NP O
15 1682 1686 17931375 pain NN I-NP B-Disease
16 1687 1696 17931375 following VBG B-PP O
17 1697 1700 17931375 the DT B-NP O
18 1701 1713 17931375 subcutaneous JJ I-NP O
19 1714 1728 17931375 administration NN I-NP O
20 1729 1731 17931375 of IN B-PP O
21 1732 1739 17931375 heparin NN B-NP B-Chemical
22 1739 1740 17931375 . . O O

1 1741 1745 17931375 This DT B-NP O
2 1746 1751 17931375 study NN I-NP O
3 1752 1758 17931375 should MD B-VP O
4 1759 1761 17931375 be VB I-VP O
5 1762 1770 17931375 repeated VBN I-VP O
6 1771 1773 17931375 on IN B-PP O
7 1774 1775 17931375 a DT B-NP O
8 1776 1782 17931375 larger JJR I-NP O
9 1783 1789 17931375 sample NN I-NP O
10 1789 1790 17931375 . . O O

1 1791 1800 17931375 RELEVANCE NN B-NP O
2 1801 1803 17931375 TO TO B-PP O
3 1804 1812 17931375 CLINICAL NN B-NP O
4 1813 1821 17931375 PRACTICE NN I-NP O
5 1821 1822 17931375 : : O O
6 1823 1827 17931375 When WRB B-ADVP O
7 1828 1841 17931375 administering VBG B-VP O
8 1842 1854 17931375 subcutaneous JJ B-NP O
9 1855 1862 17931375 heparin NN I-NP B-Chemical
10 1863 1873 17931375 injections NNS I-NP O
11 1873 1874 17931375 , , O O
12 1875 1877 17931375 it PRP B-NP O
13 1878 1880 17931375 is VBZ B-VP O
14 1881 1890 17931375 important JJ B-ADJP O
15 1891 1893 17931375 to TO B-VP O
16 1894 1900 17931375 extend VB I-VP O
17 1901 1904 17931375 the DT B-NP O
18 1905 1913 17931375 duration NN I-NP O
19 1914 1916 17931375 of IN B-PP O
20 1917 1920 17931375 the DT B-NP O
21 1921 1930 17931375 injection NN I-NP O
22 1930 1931 17931375 . . O O

1 0 0 17562951 -DOCSTART- -X- -X- O

1 0 7 17562951 Cardiac JJ B-NP O
2 8 19 17562951 Angiography NN I-NP O
3 20 22 17562951 in IN B-PP O
4 23 30 17562951 Renally RB B-NP O
5 31 39 17562951 Impaired JJ I-NP O
6 40 48 17562951 Patients NNS I-NP O
7 49 50 17562951 ( ( O O
8 50 54 17562951 CARE NN B-NP O
9 54 55 17562951 ) ) O O
10 56 61 17562951 study NN B-NP O
11 61 62 17562951 : : O O
12 63 64 17562951 a DT B-NP O
13 65 75 17562951 randomized VBN I-NP O
14 76 82 17562951 double JJ I-NP O
15 82 83 17562951 - HYPH I-NP O
16 83 88 17562951 blind JJ I-NP O
17 89 94 17562951 trial NN I-NP O
18 95 97 17562951 of IN B-PP O
19 98 106 17562951 contrast NN B-NP O
20 106 107 17562951 - HYPH B-NP O
21 107 114 17562951 induced VBN I-NP O
22 115 126 17562951 nephropathy NN I-NP B-Disease
23 127 129 17562951 in IN B-PP O
24 130 138 17562951 patients NNS B-NP O
25 139 143 17562951 with IN B-PP O
26 144 151 17562951 chronic JJ B-NP B-Disease
27 152 158 17562951 kidney NN I-NP I-Disease
28 159 166 17562951 disease NN I-NP I-Disease
29 166 167 17562951 . . O O
30 168 178 17562951 BACKGROUND NN B-NP O
31 178 179 17562951 : : O O
32 180 182 17562951 No DT B-NP O
33 183 189 17562951 direct JJ I-NP O
34 190 201 17562951 comparisons NNS I-NP O
35 202 207 17562951 exist VBP B-VP O
36 208 210 17562951 of IN B-PP O
37 211 214 17562951 the DT B-NP O
38 215 220 17562951 renal JJ I-NP O
39 221 233 17562951 tolerability NN I-NP O
40 234 236 17562951 of IN B-PP O
41 237 240 17562951 the DT B-NP O
42 241 244 17562951 low JJ I-NP O
43 244 245 17562951 - HYPH I-NP O
44 245 255 17562951 osmolality NN I-NP O
45 256 264 17562951 contrast NN I-NP B-Chemical
46 265 271 17562951 medium NN I-NP I-Chemical
47 272 281 17562951 iopamidol NN I-NP B-Chemical
48 282 286 17562951 with IN B-PP O
49 287 291 17562951 that DT B-NP O
50 292 294 17562951 of IN B-PP O
51 295 298 17562951 the DT B-NP O
52 299 302 17562951 iso AFX I-NP O
53 302 303 17562951 - HYPH I-NP O
54 303 313 17562951 osmolality NN I-NP O
55 314 322 17562951 contrast NN I-NP B-Chemical
56 323 329 17562951 medium NN I-NP I-Chemical
57 330 339 17562951 iodixanol NN I-NP B-Chemical
58 340 342 17562951 in IN B-PP O
59 343 347 17562951 high JJ B-NP O
60 347 348 17562951 - HYPH I-NP O
61 348 352 17562951 risk NN B-NP O
62 353 361 17562951 patients NNS I-NP O
63 361 362 17562951 . . O O

1 363 370 17562951 METHODS NNS B-NP O
2 371 374 17562951 AND CC I-NP O
3 375 382 17562951 RESULTS NNS I-NP O
4 382 383 17562951 : : O O
5 384 387 17562951 The DT B-NP O
6 388 395 17562951 present JJ I-NP O
7 396 401 17562951 study NN I-NP O
8 402 404 17562951 is VBZ B-VP O
9 405 406 17562951 a DT B-NP O
10 407 418 17562951 multicenter NN I-NP O
11 418 419 17562951 , , O O
12 420 430 17562951 randomized VBN B-NP O
13 430 431 17562951 , , I-NP O
14 432 438 17562951 double JJ I-NP O
15 438 439 17562951 - HYPH I-NP O
16 439 444 17562951 blind JJ I-NP O
17 445 455 17562951 comparison NN I-NP O
18 456 458 17562951 of IN B-PP O
19 459 468 17562951 iopamidol NN B-NP B-Chemical
20 469 472 17562951 and CC I-NP O
21 473 482 17562951 iodixanol NN I-NP B-Chemical
22 483 485 17562951 in IN B-PP O
23 486 494 17562951 patients NNS B-NP O
24 495 499 17562951 with IN B-PP O
25 500 507 17562951 chronic JJ B-NP B-Disease
26 508 514 17562951 kidney NN I-NP I-Disease
27 515 522 17562951 disease NN I-NP I-Disease
28 523 524 17562951 ( ( O O
29 524 533 17562951 estimated VBN B-NP O
30 534 544 17562951 glomerular JJ I-NP O
31 545 555 17562951 filtration NN I-NP O
32 556 560 17562951 rate NN I-NP O
33 560 561 17562951 , , O O
34 562 564 17562951 20 CD B-NP O
35 565 567 17562951 to TO I-NP O
36 568 570 17562951 59 CD I-NP O
37 571 573 17562951 mL NN I-NP O
38 573 574 17562951 / SYM I-NP O
39 574 577 17562951 min NN I-NP O
40 577 578 17562951 ) ) O O
41 579 582 17562951 who WP B-NP O
42 583 592 17562951 underwent VBD B-VP O
43 593 600 17562951 cardiac JJ B-NP O
44 601 612 17562951 angiography NN I-NP O
45 613 615 17562951 or CC O O
46 616 628 17562951 percutaneous JJ B-NP O
47 629 637 17562951 coronary JJ I-NP O
48 638 651 17562951 interventions NNS I-NP O
49 651 652 17562951 . . O O

1 653 658 17562951 Serum NN B-NP O
2 659 669 17562951 creatinine NN I-NP B-Chemical
3 670 671 17562951 ( ( O O
4 671 674 17562951 SCr NN B-NP O
5 674 675 17562951 ) ) O O
6 676 682 17562951 levels NNS B-NP O
7 683 686 17562951 and CC O O
8 687 696 17562951 estimated VBN B-NP O
9 697 707 17562951 glomerular JJ I-NP O
10 708 718 17562951 filtration NN I-NP O
11 719 723 17562951 rate NN I-NP O
12 724 728 17562951 were VBD B-VP O
13 729 737 17562951 assessed VBN I-VP O
14 738 740 17562951 at IN B-PP O
15 741 749 17562951 baseline NN B-NP O
16 750 753 17562951 and CC O O
17 754 755 17562951 2 CD B-NP O
18 756 758 17562951 to TO I-NP O
19 759 760 17562951 5 CD I-NP O
20 761 765 17562951 days NNS I-NP O
21 766 771 17562951 after IN B-PP O
22 772 781 17562951 receiving VBG B-VP O
23 782 793 17562951 medications NNS B-NP O
24 793 794 17562951 . . O O

1 795 798 17562951 The DT B-NP O
2 799 806 17562951 primary JJ I-NP O
3 807 814 17562951 outcome NN I-NP O
4 815 818 17562951 was VBD B-VP O
5 819 820 17562951 a DT B-NP O
6 821 829 17562951 postdose JJ I-NP O
7 830 833 17562951 SCr NN I-NP O
8 834 842 17562951 increase NN I-NP O
9 843 844 17562951 > SYM B-VP O
10 845 847 17562951 or CC O O
11 848 849 17562951 = SYM B-VP O
12 850 853 17562951 0.5 CD B-NP O
13 854 856 17562951 mg NN I-NP O
14 856 857 17562951 / SYM B-NP O
15 857 859 17562951 dL NN B-NP O
16 860 861 17562951 ( ( O O
17 861 865 17562951 44.2 CD B-NP O
18 866 874 17562951 micromol NN I-NP O
19 874 875 17562951 / SYM B-NP O
20 875 876 17562951 L NN I-NP O
21 876 877 17562951 ) ) O O
22 878 882 17562951 over IN B-PP O
23 883 891 17562951 baseline NN B-NP O
24 891 892 17562951 . . O O

1 893 902 17562951 Secondary JJ B-NP O
2 903 911 17562951 outcomes NNS I-NP O
3 912 916 17562951 were VBD B-VP O
4 917 918 17562951 a DT B-NP O
5 919 927 17562951 postdose JJ I-NP O
6 928 931 17562951 SCr NN I-NP O
7 932 940 17562951 increase NN I-NP O
8 941 942 17562951 > SYM B-VP O
9 943 945 17562951 or CC O O
10 946 947 17562951 = SYM B-VP O
11 948 951 17562951 25% CD B-NP O
12 951 952 17562951 , , O O
13 953 954 17562951 a DT B-NP O
14 955 963 17562951 postdose JJ I-NP O
15 964 973 17562951 estimated VBN I-NP O
16 974 984 17562951 glomerular JJ I-NP O
17 985 995 17562951 filtration NN I-NP O
18 996 1000 17562951 rate NN I-NP O
19 1001 1009 17562951 decrease NN I-NP O
20 1010 1012 17562951 of IN B-PP O
21 1013 1014 17562951 > SYM B-NP O
22 1015 1017 17562951 or CC O O
23 1018 1019 17562951 = SYM B-VP O
24 1020 1023 17562951 25% CD B-NP O
25 1023 1024 17562951 , , O O
26 1025 1028 17562951 and CC O O
27 1029 1032 17562951 the DT B-NP O
28 1033 1037 17562951 mean JJ I-NP O
29 1038 1042 17562951 peak JJ I-NP O
30 1043 1049 17562951 change NN I-NP O
31 1050 1052 17562951 in IN B-PP O
32 1053 1056 17562951 SCr NN B-NP O
33 1056 1057 17562951 . . O O

1 1058 1060 17562951 In IN B-PP O
2 1061 1064 17562951 414 CD B-NP O
3 1065 1073 17562951 patients NNS I-NP O
4 1073 1074 17562951 , , O O
5 1075 1083 17562951 contrast NN B-NP O
6 1084 1090 17562951 volume NN I-NP O
7 1090 1091 17562951 , , O O
8 1092 1100 17562951 presence NN B-NP O
9 1101 1103 17562951 of IN B-PP O
10 1104 1112 17562951 diabetes NN B-NP B-Disease
11 1113 1121 17562951 mellitus NN I-NP I-Disease
12 1121 1122 17562951 , , O O
13 1123 1126 17562951 use NN B-NP O
14 1127 1129 17562951 of IN B-PP O
15 1130 1131 17562951 N NN B-NP B-Chemical
16 1131 1132 17562951 - HYPH B-NP I-Chemical
17 1132 1146 17562951 acetylcysteine NN I-NP I-Chemical
18 1146 1147 17562951 , , O O
19 1148 1152 17562951 mean JJ B-NP O
20 1153 1161 17562951 baseline NN I-NP O
21 1162 1165 17562951 SCr NN I-NP O
22 1165 1166 17562951 , , O O
23 1167 1170 17562951 and CC O O
24 1171 1180 17562951 estimated VBN B-NP O
25 1181 1191 17562951 glomerular JJ I-NP O
26 1192 1202 17562951 filtration NN I-NP O
27 1203 1207 17562951 rate NN I-NP O
28 1208 1212 17562951 were VBD B-VP O
29 1213 1223 17562951 comparable JJ B-ADJP O
30 1224 1226 17562951 in IN B-PP O
31 1227 1230 17562951 the DT B-NP O
32 1231 1232 17562951 2 CD I-NP O
33 1233 1239 17562951 groups NNS I-NP O
34 1239 1240 17562951 . . O O

1 1241 1244 17562951 SCr NN B-NP O
2 1245 1254 17562951 increases VBZ B-VP O
3 1255 1256 17562951 > SYM B-NP O
4 1257 1259 17562951 or CC O O
5 1260 1261 17562951 = SYM B-VP O
6 1262 1265 17562951 0.5 CD B-NP O
7 1266 1268 17562951 mg NN I-NP O
8 1268 1269 17562951 / SYM B-NP O
9 1269 1271 17562951 dL NN I-NP O
10 1272 1280 17562951 occurred VBD B-VP O
11 1281 1283 17562951 in IN B-PP O
12 1284 1288 17562951 4.4% CD B-NP O
13 1289 1290 17562951 ( ( O O
14 1290 1291 17562951 9 CD B-NP O
15 1292 1294 17562951 of IN B-PP O
16 1295 1298 17562951 204 CD B-NP O
17 1299 1307 17562951 patients NNS I-NP O
18 1307 1308 17562951 ) ) O O
19 1309 1314 17562951 after IN B-PP O
20 1315 1324 17562951 iopamidol NN B-NP B-Chemical
21 1325 1328 17562951 and CC I-NP O
22 1329 1333 17562951 6.7% NN I-NP O
23 1334 1335 17562951 ( ( O O
24 1335 1337 17562951 14 CD B-NP O
25 1338 1340 17562951 of IN B-PP O
26 1341 1344 17562951 210 CD B-NP O
27 1345 1353 17562951 patients NNS I-NP O
28 1353 1354 17562951 ) ) O O
29 1355 1360 17562951 after IN B-PP O
30 1361 1370 17562951 iodixanol NN B-NP B-Chemical
31 1371 1372 17562951 ( ( O O
32 1372 1373 17562951 P NN B-NP O
33 1373 1374 17562951 = SYM B-VP O
34 1374 1378 17562951 0.39 CD B-NP O
35 1378 1379 17562951 ) ) O O
36 1379 1380 17562951 , , O O
37 1381 1388 17562951 whereas IN O O
38 1389 1394 17562951 rates NNS B-NP O
39 1395 1397 17562951 of IN B-PP O
40 1398 1401 17562951 SCr NN B-NP O
41 1402 1411 17562951 increases VBZ B-VP O
42 1412 1413 17562951 > SYM B-NP O
43 1414 1416 17562951 or CC O O
44 1417 1418 17562951 = SYM B-NP O
45 1419 1422 17562951 25% CD B-NP O
46 1423 1427 17562951 were VBD B-VP O
47 1428 1432 17562951 9.8% CD B-NP O
48 1433 1436 17562951 and CC I-NP O
49 1437 1442 17562951 12.4% CD I-NP O
50 1442 1443 17562951 , , O O
51 1444 1456 17562951 respectively RB B-ADVP O
52 1457 1458 17562951 ( ( O O
53 1458 1459 17562951 P NN B-NP O
54 1459 1460 17562951 = SYM B-VP O
55 1460 1464 17562951 0.44 CD B-NP O
56 1464 1465 17562951 ) ) O O
57 1465 1466 17562951 . . O O

1 1467 1469 17562951 In IN B-PP O
2 1470 1478 17562951 patients NNS B-NP O
3 1479 1483 17562951 with IN B-PP O
4 1484 1492 17562951 diabetes NN B-NP B-Disease
5 1492 1493 17562951 , , O O
6 1494 1497 17562951 SCr NN B-NP O
7 1498 1507 17562951 increases VBZ B-VP O
8 1508 1509 17562951 > SYM B-NP O
9 1510 1512 17562951 or CC O O
10 1513 1514 17562951 = SYM B-VP O
11 1515 1518 17562951 0.5 CD B-NP O
12 1519 1521 17562951 mg NN I-NP O
13 1521 1522 17562951 / SYM B-NP O
14 1522 1524 17562951 dL NN I-NP O
15 1525 1529 17562951 were VBD B-VP O
16 1530 1534 17562951 5.1% CD B-NP O
17 1535 1536 17562951 ( ( O O
18 1536 1537 17562951 4 CD B-NP O
19 1538 1540 17562951 of IN B-PP O
20 1541 1543 17562951 78 CD B-NP O
21 1544 1552 17562951 patients NNS I-NP O
22 1552 1553 17562951 ) ) O O
23 1554 1558 17562951 with IN B-PP O
24 1559 1568 17562951 iopamidol NN B-NP B-Chemical
25 1569 1572 17562951 and CC I-NP O
26 1573 1578 17562951 13.0% NN I-NP O
27 1579 1580 17562951 ( ( O O
28 1580 1582 17562951 12 CD B-NP O
29 1583 1585 17562951 of IN B-PP O
30 1586 1588 17562951 92 CD B-NP O
31 1589 1597 17562951 patients NNS I-NP O
32 1597 1598 17562951 ) ) O O
33 1599 1603 17562951 with IN B-PP O
34 1604 1613 17562951 iodixanol NN B-NP B-Chemical
35 1614 1615 17562951 ( ( O O
36 1615 1616 17562951 P NN B-NP O
37 1616 1617 17562951 = SYM B-VP O
38 1617 1621 17562951 0.11 CD B-NP O
39 1621 1622 17562951 ) ) O O
40 1622 1623 17562951 , , O O
41 1624 1631 17562951 whereas IN O O
42 1632 1635 17562951 SCr NN B-NP O
43 1636 1645 17562951 increases VBZ B-VP O
44 1646 1647 17562951 > SYM B-NP O
45 1648 1650 17562951 or CC O O
46 1651 1652 17562951 = SYM B-NP O
47 1653 1656 17562951 25% CD B-NP O
48 1657 1661 17562951 were VBD B-VP O
49 1662 1667 17562951 10.3% CD B-NP O
50 1668 1671 17562951 and CC I-NP O
51 1672 1677 17562951 15.2% CD I-NP O
52 1677 1678 17562951 , , O O
53 1679 1691 17562951 respectively RB B-ADVP O
54 1692 1693 17562951 ( ( O O
55 1693 1694 17562951 P NN B-NP O
56 1694 1695 17562951 = SYM B-VP O
57 1695 1699 17562951 0.37 CD B-NP O
58 1699 1700 17562951 ) ) O O
59 1700 1701 17562951 . . O O

1 1702 1706 17562951 Mean JJ B-NP O
2 1707 1711 17562951 post AFX I-NP O
3 1711 1712 17562951 - HYPH I-NP O
4 1712 1715 17562951 SCr NN I-NP O
5 1716 1725 17562951 increases NNS I-NP O
6 1726 1730 17562951 were VBD B-VP O
7 1731 1744 17562951 significantly RB B-ADJP O
8 1745 1749 17562951 less JJR I-ADJP O
9 1750 1754 17562951 with IN B-PP O
10 1755 1764 17562951 iopamidol NN B-NP B-Chemical
11 1765 1766 17562951 ( ( O O
12 1766 1769 17562951 all DT B-NP O
13 1770 1778 17562951 patients NNS I-NP O
14 1778 1779 17562951 : : O O
15 1780 1784 17562951 0.07 CD B-NP O
16 1785 1791 17562951 versus IN I-NP O
17 1792 1796 17562951 0.12 CD I-NP O
18 1797 1799 17562951 mg NN I-NP O
19 1799 1800 17562951 / SYM B-NP O
20 1800 1802 17562951 dL NN I-NP O
21 1802 1803 17562951 , , O O
22 1804 1807 17562951 6.2 CD B-NP O
23 1808 1814 17562951 versus IN I-NP O
24 1815 1819 17562951 10.6 CD I-NP O
25 1820 1828 17562951 micromol NN I-NP O
26 1828 1829 17562951 / SYM O O
27 1829 1830 17562951 L NN B-NP O
28 1830 1831 17562951 , , O O
29 1832 1833 17562951 P NN B-NP O
30 1833 1834 17562951 = SYM B-VP O
31 1834 1838 17562951 0.03 CD B-NP O
32 1838 1839 17562951 ; : O O
33 1840 1848 17562951 patients NNS B-NP O
34 1849 1853 17562951 with IN B-PP O
35 1854 1862 17562951 diabetes NNS B-NP B-Disease
36 1862 1863 17562951 : : O O
37 1864 1868 17562951 0.07 CD B-NP O
38 1869 1875 17562951 versus IN I-NP O
39 1876 1880 17562951 0.16 CD I-NP O
40 1881 1883 17562951 mg NN I-NP O
41 1883 1884 17562951 / SYM B-NP O
42 1884 1886 17562951 dL NN I-NP O
43 1886 1887 17562951 , , O O
44 1888 1891 17562951 6.2 CD B-NP O
45 1892 1898 17562951 versus IN I-NP O
46 1899 1903 17562951 14.1 CD I-NP O
47 1904 1912 17562951 micromol NN I-NP O
48 1912 1913 17562951 / SYM O O
49 1913 1914 17562951 L NN B-NP O
50 1914 1915 17562951 , , O O
51 1916 1917 17562951 P NN B-NP O
52 1917 1918 17562951 = SYM B-VP O
53 1918 1922 17562951 0.01 CD B-NP O
54 1922 1923 17562951 ) ) O O
55 1923 1924 17562951 . . O O

1 1925 1936 17562951 CONCLUSIONS NNS B-NP O
2 1936 1937 17562951 : : O O
3 1938 1941 17562951 The DT B-NP O
4 1942 1946 17562951 rate NN I-NP O
5 1947 1949 17562951 of IN B-PP O
6 1950 1958 17562951 contrast NN B-NP O
7 1958 1959 17562951 - HYPH B-NP O
8 1959 1966 17562951 induced VBN I-NP O
9 1967 1978 17562951 nephropathy NN I-NP B-Disease
10 1978 1979 17562951 , , O O
11 1980 1987 17562951 defined VBN B-VP O
12 1988 1990 17562951 by IN B-PP O
13 1991 1999 17562951 multiple JJ B-NP O
14 2000 2003 17562951 end NN I-NP O
15 2004 2010 17562951 points NNS I-NP O
16 2010 2011 17562951 , , O O
17 2012 2014 17562951 is VBZ B-VP O
18 2015 2018 17562951 not RB O O
19 2019 2032 17562951 statistically RB B-ADJP O
20 2033 2042 17562951 different JJ I-ADJP O
21 2043 2048 17562951 after IN B-PP O
22 2049 2052 17562951 the DT B-NP O
23 2053 2066 17562951 intraarterial JJ I-NP O
24 2067 2081 17562951 administration NN I-NP O
25 2082 2084 17562951 of IN B-PP O
26 2085 2094 17562951 iopamidol NN B-NP B-Chemical
27 2095 2097 17562951 or CC I-NP O
28 2098 2107 17562951 iodixanol NN I-NP B-Chemical
29 2108 2110 17562951 to TO B-PP O
30 2111 2115 17562951 high JJ B-NP O
31 2115 2116 17562951 - HYPH I-NP O
32 2116 2120 17562951 risk NN I-NP O
33 2121 2129 17562951 patients NNS I-NP O
34 2129 2130 17562951 , , O O
35 2131 2135 17562951 with IN B-PP O
36 2136 2138 17562951 or CC B-PP O
37 2139 2146 17562951 without IN B-PP O
38 2147 2155 17562951 diabetes NN B-NP B-Disease
39 2156 2164 17562951 mellitus NN I-NP I-Disease
40 2164 2165 17562951 . . O O

1 2166 2169 17562951 Any DT B-NP O
2 2170 2174 17562951 true JJ I-NP O
3 2175 2185 17562951 difference NN I-NP O
4 2186 2193 17562951 between IN B-PP O
5 2194 2197 17562951 the DT B-NP O
6 2198 2204 17562951 agents NNS I-NP O
7 2205 2207 17562951 is VBZ B-VP O
8 2208 2213 17562951 small JJ B-ADJP O
9 2214 2217 17562951 and CC O O
10 2218 2221 17562951 not RB B-ADJP O
11 2222 2228 17562951 likely JJ I-ADJP O
12 2229 2231 17562951 to TO B-VP O
13 2232 2234 17562951 be VB I-VP O
14 2235 2245 17562951 clinically RB B-ADJP O
15 2246 2257 17562951 significant JJ I-ADJP O
16 2257 2258 17562951 . . O O

1 0 0 3856631 -DOCSTART- -X- -X- O

1 0 9 3856631 Remission NN B-NP O
2 10 19 3856631 induction NN I-NP O
3 20 22 3856631 of IN B-PP O
4 23 32 3856631 meningeal JJ B-NP B-Disease
5 33 41 3856631 leukemia NN I-NP I-Disease
6 42 46 3856631 with IN B-PP O
7 47 51 3856631 high JJ B-NP O
8 51 52 3856631 - HYPH I-NP O
9 52 56 3856631 dose NN I-NP O
10 57 68 3856631 intravenous JJ I-NP O
11 69 81 3856631 methotrexate NN I-NP B-Chemical
12 81 82 3856631 . . O O
13 83 89 3856631 Twenty CD B-NP O
14 90 98 3856631 children NNS I-NP O
15 99 103 3856631 with IN B-PP O
16 104 109 3856631 acute JJ B-NP B-Disease
17 110 123 3856631 lymphoblastic JJ I-NP I-Disease
18 124 132 3856631 leukemia NN I-NP I-Disease
19 133 136 3856631 who WP B-NP O
20 137 146 3856631 developed VBD B-VP O
21 147 156 3856631 meningeal JJ B-NP B-Disease
22 157 164 3856631 disease NN I-NP I-Disease
23 165 169 3856631 were VBD B-VP O
24 170 177 3856631 treated VBN I-VP O
25 178 182 3856631 with IN B-PP O
26 183 184 3856631 a DT B-NP O
27 185 189 3856631 high JJ I-NP O
28 189 190 3856631 - HYPH I-NP O
29 190 194 3856631 dose NN I-NP O
30 195 206 3856631 intravenous JJ I-NP O
31 207 219 3856631 methotrexate NN I-NP B-Chemical
32 220 227 3856631 regimen NN I-NP O
33 228 232 3856631 that WDT B-NP O
34 233 236 3856631 was VBD B-VP O
35 237 245 3856631 designed VBN I-VP O
36 246 248 3856631 to TO B-VP O
37 249 256 3856631 achieve VB I-VP O
38 257 260 3856631 and CC I-VP O
39 261 269 3856631 maintain VB I-VP O
40 270 273 3856631 CSF NN B-NP O
41 274 286 3856631 methotrexate NN I-NP B-Chemical
42 287 301 3856631 concentrations NNS I-NP O
43 302 304 3856631 of IN B-PP O
44 305 308 3856631 10( CD B-NP O
45 308 309 3856631 - HYPH I-NP O
46 309 311 3856631 5) CD I-NP O
47 312 315 3856631 mol NN I-NP O
48 315 316 3856631 / SYM B-NP O
49 316 317 3856631 L NN I-NP O
50 318 325 3856631 without IN B-PP O
51 326 329 3856631 the DT B-NP O
52 330 334 3856631 need NN I-NP O
53 335 338 3856631 for IN B-PP O
54 339 350 3856631 concomitant JJ B-NP O
55 351 362 3856631 intrathecal JJ I-NP O
56 363 369 3856631 dosing NN I-NP O
57 369 370 3856631 . . O O

1 371 374 3856631 The DT B-NP O
2 375 387 3856631 methotrexate NN I-NP B-Chemical
3 388 391 3856631 was VBD B-VP O
4 392 404 3856631 administered VBN I-VP O
5 405 407 3856631 as IN B-PP O
6 408 409 3856631 a DT B-NP O
7 410 417 3856631 loading NN I-NP O
8 418 422 3856631 dose NN I-NP O
9 423 425 3856631 of IN B-PP O
10 426 431 3856631 6,000 CD B-NP O
11 432 434 3856631 mg NN I-NP O
12 434 435 3856631 / SYM B-NP O
13 435 437 3856631 m2 NN I-NP O
14 438 441 3856631 for IN B-PP O
15 442 443 3856631 a DT B-NP O
16 444 450 3856631 period NN I-NP O
17 451 453 3856631 of IN B-PP O
18 454 457 3856631 one CD B-NP O
19 458 462 3856631 hour NN I-NP O
20 463 471 3856631 followed VBN B-VP O
21 472 474 3856631 by IN B-PP O
22 475 477 3856631 an DT B-NP O
23 478 486 3856631 infusion NN I-NP O
24 487 489 3856631 of IN B-PP O
25 490 495 3856631 1,200 CD B-NP O
26 496 498 3856631 mg NN I-NP O
27 498 499 3856631 / SYM B-NP O
28 499 501 3856631 m2 NN I-NP O
29 501 502 3856631 / SYM B-NP O
30 502 503 3856631 h NN I-NP O
31 504 507 3856631 for IN B-PP O
32 508 510 3856631 23 CD B-NP O
33 511 516 3856631 hours NNS I-NP O
34 516 517 3856631 . . O O

1 518 528 3856631 Leucovorin NN B-NP B-Chemical
2 529 535 3856631 rescue NN I-NP O
3 536 539 3856631 was VBD B-VP O
4 540 549 3856631 initiated VBN I-VP O
5 550 552 3856631 12 CD B-NP O
6 553 558 3856631 hours NNS I-NP O
7 559 564 3856631 after IN B-PP O
8 565 568 3856631 the DT B-NP O
9 569 572 3856631 end NN I-NP O
10 573 575 3856631 of IN B-PP O
11 576 579 3856631 the DT B-NP O
12 580 588 3856631 infusion NN I-NP O
13 589 593 3856631 with IN B-PP O
14 594 595 3856631 a DT B-NP O
15 596 603 3856631 loading NN I-NP O
16 604 608 3856631 dose NN I-NP O
17 609 611 3856631 of IN B-PP O
18 612 615 3856631 200 CD B-NP O
19 616 618 3856631 mg NN I-NP O
20 618 619 3856631 / SYM B-NP O
21 619 621 3856631 m2 NN I-NP O
22 622 630 3856631 followed VBN B-VP O
23 631 633 3856631 by IN B-PP O
24 634 636 3856631 12 CD B-NP O
25 637 639 3856631 mg NN I-NP O
26 639 640 3856631 / SYM B-NP O
27 640 642 3856631 m2 NN I-NP O
28 643 648 3856631 every DT B-NP O
29 649 654 3856631 three CD I-NP O
30 655 660 3856631 hours NNS I-NP O
31 661 664 3856631 for IN B-PP O
32 665 668 3856631 six CD B-NP O
33 669 674 3856631 doses NNS I-NP O
34 675 678 3856631 and CC O O
35 679 683 3856631 then RB B-ADVP O
36 684 689 3856631 every DT B-NP O
37 690 693 3856631 six CD I-NP O
38 694 699 3856631 hours NNS I-NP O
39 700 705 3856631 until IN B-PP O
40 706 709 3856631 the DT B-NP O
41 710 716 3856631 plasma NN I-NP O
42 717 729 3856631 methotrexate NN I-NP B-Chemical
43 730 735 3856631 level NN I-NP O
44 736 745 3856631 decreased VBD B-VP O
45 746 748 3856631 to TO B-PP O
46 749 753 3856631 less JJR B-NP O
47 754 758 3856631 than IN I-NP O
48 759 760 3856631 1 CD I-NP O
49 761 762 3856631 X SYM I-NP O
50 763 766 3856631 10( CD I-NP O
51 766 767 3856631 - HYPH I-NP O
52 767 769 3856631 7) CD I-NP O
53 770 773 3856631 mol NN I-NP O
54 773 774 3856631 / SYM B-NP O
55 774 775 3856631 L NN I-NP O
56 775 776 3856631 . . O O

1 777 780 3856631 The DT B-NP O
2 781 785 3856631 mean JJ I-NP O
3 786 792 3856631 steady JJ I-NP O
4 792 793 3856631 - HYPH I-NP O
5 793 798 3856631 state NN I-NP O
6 799 805 3856631 plasma NN I-NP O
7 806 809 3856631 and CC I-NP O
8 810 813 3856631 CSF NN I-NP O
9 814 826 3856631 methotrexate NN I-NP B-Chemical
10 827 841 3856631 concentrations NNS I-NP O
11 842 850 3856631 achieved VBN B-VP O
12 851 855 3856631 were VBD B-VP O
13 856 859 3856631 1.1 CD B-NP O
14 860 861 3856631 X SYM B-NP O
15 862 865 3856631 10( CD I-NP O
16 865 866 3856631 - HYPH I-NP O
17 866 868 3856631 3) CD I-NP O
18 869 872 3856631 mol NN I-NP O
19 872 873 3856631 / SYM B-NP O
20 873 874 3856631 L NN I-NP O
21 875 878 3856631 and CC O O
22 879 882 3856631 3.6 CD B-NP O
23 883 884 3856631 X SYM I-NP O
24 885 888 3856631 10( CD I-NP O
25 888 889 3856631 - HYPH I-NP O
26 889 891 3856631 5) CD I-NP O
27 892 895 3856631 mol NN I-NP O
28 895 896 3856631 / SYM O O
29 896 897 3856631 L NN B-NP O
30 897 898 3856631 , , O O
31 899 911 3856631 respectively RB B-ADVP O
32 911 912 3856631 . . O O

1 913 916 3856631 All DT B-NP O
2 917 919 3856631 20 CD I-NP O
3 920 928 3856631 patients NNS I-NP O
4 929 938 3856631 responded VBD B-VP O
5 939 941 3856631 to TO B-PP O
6 942 946 3856631 this DT B-NP O
7 947 954 3856631 regimen NN I-NP O
8 954 955 3856631 , , O O
9 956 958 3856631 16 CD B-NP O
10 958 959 3856631 / SYM I-NP O
11 959 961 3856631 20 CD I-NP O
12 962 963 3856631 ( ( O O
13 963 966 3856631 80% NN B-NP O
14 966 967 3856631 ) ) O O
15 968 976 3856631 achieved VBD B-VP O
16 977 978 3856631 a DT B-NP O
17 979 987 3856631 complete JJ I-NP O
18 988 997 3856631 remission NN I-NP O
19 997 998 3856631 , , O O
20 999 1002 3856631 and CC O O
21 1003 1006 3856631 20% CD B-NP O
22 1007 1015 3856631 obtained VBD B-VP O
23 1016 1017 3856631 a DT B-NP O
24 1018 1025 3856631 partial JJ I-NP O
25 1026 1035 3856631 remission NN I-NP O
26 1035 1036 3856631 . . O O

1 1037 1040 3856631 The DT B-NP O
2 1041 1045 3856631 most RBS I-NP O
3 1046 1052 3856631 common JJ I-NP O
4 1053 1063 3856631 toxicities NNS I-NP B-Disease
5 1064 1075 3856631 encountered VBN B-VP O
6 1076 1080 3856631 were VBD B-VP O
7 1081 1090 3856631 transient JJ B-NP O
8 1091 1096 3856631 serum NN I-NP O
9 1097 1109 3856631 transaminase NN I-NP O
10 1110 1113 3856631 and CC I-NP O
11 1114 1123 3856631 bilirubin NN I-NP B-Chemical
12 1124 1134 3856631 elevations NNS I-NP O
13 1134 1135 3856631 , , O O
14 1136 1147 3856631 neutropenia NN B-NP B-Disease
15 1147 1148 3856631 , , O O
16 1149 1152 3856631 and CC O O
17 1153 1162 3856631 mucositis NN B-NP B-Disease
18 1162 1163 3856631 . . O O

1 1164 1167 3856631 One CD B-NP O
2 1168 1175 3856631 patient NN I-NP O
3 1176 1179 3856631 had VBD B-VP O
4 1180 1185 3856631 focal JJ B-NP O
5 1186 1194 3856631 seizures NNS I-NP B-Disease
6 1195 1198 3856631 and CC O O
7 1199 1208 3856631 transient JJ B-NP B-Disease
8 1209 1220 3856631 hemiparesis NN I-NP I-Disease
9 1221 1224 3856631 but CC O O
10 1225 1234 3856631 recovered VBD B-VP O
11 1235 1245 3856631 completely RB B-ADVP O
12 1245 1246 3856631 . . O O

1 1247 1251 3856631 High JJ B-NP O
2 1251 1252 3856631 - HYPH I-NP O
3 1252 1256 3856631 dose NN I-NP O
4 1257 1268 3856631 intravenous JJ I-NP O
5 1269 1281 3856631 methotrexate NN I-NP B-Chemical
6 1282 1284 3856631 is VBZ B-VP O
7 1285 1287 3856631 an DT B-NP O
8 1288 1297 3856631 effective JJ I-NP O
9 1298 1307 3856631 treatment NN I-NP O
10 1308 1311 3856631 for IN B-PP O
11 1312 1315 3856631 the DT B-NP O
12 1316 1325 3856631 induction NN I-NP O
13 1326 1328 3856631 of IN B-PP O
14 1329 1338 3856631 remission NN B-NP O
15 1339 1344 3856631 after IN B-PP O
16 1345 1354 3856631 meningeal JJ B-NP O
17 1355 1362 3856631 relapse NN I-NP O
18 1363 1365 3856631 in IN B-PP O
19 1366 1371 3856631 acute JJ B-NP B-Disease
20 1372 1385 3856631 lymphoblastic JJ I-NP I-Disease
21 1386 1394 3856631 leukemia NN I-NP I-Disease
22 1394 1395 3856631 . . O O